cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	FDR	beta	r	Traits	SNP_position	Gene_position
TGCT	cis	rs1577917	0.655	rs1059307	ENSG00000203875.9	SNHG5	16.39	8.1e-33	9.7e-26	0.94	0.83	Response to antipsychotic treatment;	chr6:85678170	chr6:85660950~85678736:-
TGCT	cis	rs4691139	0.524	rs28548593	ENSG00000250227.1	TRIM60P14	15.61	4.77e-31	1.35e-24	0.92	0.81	Ovarian cancer in BRCA1 mutation carriers;	chr4:164965160	chr4:164915565~164916983:+
TGCT	cis	rs4691139	0.588	rs6814756	ENSG00000250227.1	TRIM60P14	15.61	4.77e-31	1.35e-24	0.92	0.81	Ovarian cancer in BRCA1 mutation carriers;	chr4:164965772	chr4:164915565~164916983:+
TGCT	cis	rs4691139	0.549	rs10001548	ENSG00000250227.1	TRIM60P14	15.57	5.99e-31	1.53e-24	0.93	0.81	Ovarian cancer in BRCA1 mutation carriers;	chr4:164958229	chr4:164915565~164916983:+
TGCT	cis	rs4691139	0.588	rs6848637	ENSG00000250227.1	TRIM60P14	15.56	6.13e-31	1.53e-24	0.95	0.81	Ovarian cancer in BRCA1 mutation carriers;	chr4:164956811	chr4:164915565~164916983:+
TGCT	cis	rs4691139	0.524	rs4349559	ENSG00000250227.1	TRIM60P14	15.54	6.81e-31	1.61e-24	0.92	0.81	Ovarian cancer in BRCA1 mutation carriers;	chr4:164968795	chr4:164915565~164916983:+
TGCT	cis	rs4691139	0.588	rs6827270	ENSG00000250227.1	TRIM60P14	15.47	9.71e-31	2.17e-24	0.92	0.81	Ovarian cancer in BRCA1 mutation carriers;	chr4:164967275	chr4:164915565~164916983:+
TGCT	cis	rs2739330	0.929	rs5751777	ENSG00000273295.1	AP000350.5	15.45	1.12e-30	2.26e-24	0.94	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23901432~23907068:-
TGCT	cis	rs2739330	0.892	rs5751776	ENSG00000273295.1	AP000350.5	15.31	2.29e-30	4.06e-24	0.93	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23901432~23907068:-
TGCT	cis	rs4691139	0.588	rs28475532	ENSG00000250227.1	TRIM60P14	15.17	4.86e-30	7.65e-24	0.92	0.81	Ovarian cancer in BRCA1 mutation carriers;	chr4:164974076	chr4:164915565~164916983:+
TGCT	cis	rs4691139	0.549	rs28633542	ENSG00000250227.1	TRIM60P14	15.17	4.86e-30	7.65e-24	0.92	0.81	Ovarian cancer in BRCA1 mutation carriers;	chr4:164974792	chr4:164915565~164916983:+
TGCT	cis	rs1577917	0.561	rs3087978	ENSG00000203875.9	SNHG5	15.08	7.86e-30	1.13e-23	0.93	0.8	Response to antipsychotic treatment;	chr6:85678505	chr6:85660950~85678736:-
TGCT	cis	rs4691139	0.588	rs7680569	ENSG00000250227.1	TRIM60P14	15.08	7.95e-30	1.13e-23	0.92	0.8	Ovarian cancer in BRCA1 mutation carriers;	chr4:164978073	chr4:164915565~164916983:+
TGCT	cis	rs1577917	0.727	rs9344539	ENSG00000203875.9	SNHG5	-14.97	1.4e-29	1.65e-23	-0.92	-0.8	Response to antipsychotic treatment;	chr6:85643903	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.771	rs9362232	ENSG00000203875.9	SNHG5	-14.97	1.4e-29	1.65e-23	-0.92	-0.8	Response to antipsychotic treatment;	chr6:85643904	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.655	rs9450311	ENSG00000203875.9	SNHG5	14.97	1.4e-29	1.65e-23	0.92	0.8	Response to antipsychotic treatment;	chr6:85666868	chr6:85660950~85678736:-
TGCT	cis	rs4691139	0.505	rs10034083	ENSG00000250227.1	TRIM60P14	14.87	2.5e-29	2.8e-23	0.94	0.8	Ovarian cancer in BRCA1 mutation carriers;	chr4:164957855	chr4:164915565~164916983:+
TGCT	cis	rs1577917	0.655	rs2758849	ENSG00000203875.9	SNHG5	-14.86	2.6e-29	2.83e-23	-0.93	-0.8	Response to antipsychotic treatment;	chr6:85634578	chr6:85660950~85678736:-
TGCT	cis	rs2739330	0.892	rs4822455	ENSG00000273295.1	AP000350.5	14.81	3.29e-29	3.49e-23	0.9	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23901432~23907068:-
TGCT	cis	rs4691139	0.588	rs72697954	ENSG00000250227.1	TRIM60P14	14.8	3.62e-29	3.67e-23	0.91	0.8	Ovarian cancer in BRCA1 mutation carriers;	chr4:164982890	chr4:164915565~164916983:+
TGCT	cis	rs1577917	0.56	rs12193777	ENSG00000203875.9	SNHG5	14.72	5.5e-29	4.5e-23	0.92	0.8	Response to antipsychotic treatment;	chr6:85536991	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.655	rs9444351	ENSG00000203875.9	SNHG5	14.72	5.5e-29	4.5e-23	0.92	0.8	Response to antipsychotic treatment;	chr6:85538081	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.655	rs7766485	ENSG00000203875.9	SNHG5	14.72	5.5e-29	4.5e-23	0.92	0.8	Response to antipsychotic treatment;	chr6:85553837	chr6:85660950~85678736:-
TGCT	cis	rs4691139	0.545	rs6828659	ENSG00000250227.1	TRIM60P14	14.7	6.02e-29	4.83e-23	0.92	0.8	Ovarian cancer in BRCA1 mutation carriers;	chr4:164960882	chr4:164915565~164916983:+
TGCT	cis	rs1577917	0.655	rs9342045	ENSG00000203875.9	SNHG5	14.62	9.58e-29	7.28e-23	0.92	0.8	Response to antipsychotic treatment;	chr6:85715430	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.655	rs2842605	ENSG00000203875.9	SNHG5	-14.6	1.03e-28	7.28e-23	-0.92	-0.8	Response to antipsychotic treatment;	chr6:85625432	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.655	rs2758848	ENSG00000203875.9	SNHG5	-14.6	1.03e-28	7.28e-23	-0.92	-0.8	Response to antipsychotic treatment;	chr6:85637887	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.655	rs9444352	ENSG00000203875.9	SNHG5	14.58	1.15e-28	8.04e-23	0.92	0.79	Response to antipsychotic treatment;	chr6:85547817	chr6:85660950~85678736:-
TGCT	cis	rs4691139	0.545	rs28631315	ENSG00000250227.1	TRIM60P14	14.56	1.3e-28	8.94e-23	0.92	0.79	Ovarian cancer in BRCA1 mutation carriers;	chr4:164971104	chr4:164915565~164916983:+
TGCT	cis	rs1577917	0.629	rs6927475	ENSG00000203875.9	SNHG5	14.49	1.91e-28	1.21e-22	0.93	0.79	Response to antipsychotic treatment;	chr6:85497055	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.629	rs9450285	ENSG00000203875.9	SNHG5	14.49	1.91e-28	1.21e-22	0.93	0.79	Response to antipsychotic treatment;	chr6:85498378	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.655	rs12203963	ENSG00000203875.9	SNHG5	14.49	1.91e-28	1.21e-22	0.93	0.79	Response to antipsychotic treatment;	chr6:85513598	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.654	rs9450284	ENSG00000203875.9	SNHG5	14.48	1.98e-28	1.24e-22	0.98	0.79	Response to antipsychotic treatment;	chr6:85489611	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.681	rs4707211	ENSG00000203875.9	SNHG5	14.45	2.34e-28	1.38e-22	0.93	0.79	Response to antipsychotic treatment;	chr6:85522992	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.655	rs9444354	ENSG00000203875.9	SNHG5	14.41	2.99e-28	1.69e-22	0.92	0.79	Response to antipsychotic treatment;	chr6:85582217	chr6:85660950~85678736:-
TGCT	cis	rs858239	0.6	rs1115941	ENSG00000230658.1	KLHL7-AS1	14.34	4.16e-28	2.13e-22	0.84	0.79	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23101228~23105703:-
TGCT	cis	rs1577917	0.566	rs2842611	ENSG00000203875.9	SNHG5	-14.34	4.29e-28	2.15e-22	-0.92	-0.79	Response to antipsychotic treatment;	chr6:85592316	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.655	rs2842600	ENSG00000203875.9	SNHG5	-14.34	4.29e-28	2.15e-22	-0.92	-0.79	Response to antipsychotic treatment;	chr6:85615914	chr6:85660950~85678736:-
TGCT	cis	rs2739330	0.964	rs2739338	ENSG00000273295.1	AP000350.5	14.25	6.85e-28	3.07e-22	0.91	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23954943	chr22:23901432~23907068:-
TGCT	cis	rs2739330	0.615	rs2858911	ENSG00000273295.1	AP000350.5	14.25	6.85e-28	3.07e-22	0.91	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23955008	chr22:23901432~23907068:-
TGCT	cis	rs2739330	0.576	rs2858912	ENSG00000273295.1	AP000350.5	14.25	6.85e-28	3.07e-22	0.91	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23955010	chr22:23901432~23907068:-
TGCT	cis	rs858239	0.6	rs13438188	ENSG00000230658.1	KLHL7-AS1	-14.24	7.15e-28	3.16e-22	-0.8	-0.79	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23101228~23105703:-
TGCT	cis	rs4691139	0.545	rs11100586	ENSG00000250227.1	TRIM60P14	-14.19	9.49e-28	3.94e-22	-0.91	-0.79	Ovarian cancer in BRCA1 mutation carriers;	chr4:164974607	chr4:164915565~164916983:+
TGCT	cis	rs4691139	0.545	rs28581275	ENSG00000250227.1	TRIM60P14	14.19	9.49e-28	3.94e-22	0.91	0.79	Ovarian cancer in BRCA1 mutation carriers;	chr4:164974454	chr4:164915565~164916983:+
TGCT	cis	rs4691139	0.504	rs56231925	ENSG00000250227.1	TRIM60P14	14.19	9.49e-28	3.94e-22	0.91	0.79	Ovarian cancer in BRCA1 mutation carriers;	chr4:164977350	chr4:164915565~164916983:+
TGCT	cis	rs2739330	1	rs2739330	ENSG00000273295.1	AP000350.5	14.19	9.57e-28	3.94e-22	0.9	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23953099	chr22:23901432~23907068:-
TGCT	cis	rs1577917	0.655	rs6454472	ENSG00000203875.9	SNHG5	14.19	9.64e-28	3.94e-22	0.92	0.79	Response to antipsychotic treatment;	chr6:85514335	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.681	rs4348284	ENSG00000203875.9	SNHG5	-14.18	1.01e-27	4.09e-22	-0.92	-0.79	Response to antipsychotic treatment;	chr6:85640676	chr6:85660950~85678736:-
TGCT	cis	rs858239	0.6	rs7785842	ENSG00000230658.1	KLHL7-AS1	14.06	1.91e-27	7.12e-22	0.83	0.78	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs7456915	ENSG00000230658.1	KLHL7-AS1	14.06	1.91e-27	7.12e-22	0.83	0.78	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs13438179	ENSG00000230658.1	KLHL7-AS1	14.06	1.91e-27	7.12e-22	0.83	0.78	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23101228~23105703:-
TGCT	cis	rs1577917	0.61	rs11752795	ENSG00000203875.9	SNHG5	14	2.7e-27	7.67e-22	0.93	0.78	Response to antipsychotic treatment;	chr6:85577411	chr6:85660950~85678736:-
TGCT	cis	rs858239	0.6	rs10235786	ENSG00000230658.1	KLHL7-AS1	13.99	2.9e-27	7.75e-22	0.84	0.78	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs10233039	ENSG00000230658.1	KLHL7-AS1	13.99	2.9e-27	7.75e-22	0.84	0.78	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs2072368	ENSG00000230658.1	KLHL7-AS1	13.98	3.05e-27	7.75e-22	0.83	0.78	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs10256524	ENSG00000230658.1	KLHL7-AS1	13.97	3.26e-27	8.15e-22	0.83	0.78	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs2072369	ENSG00000230658.1	KLHL7-AS1	13.97	3.26e-27	8.15e-22	0.83	0.78	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs9691762	ENSG00000230658.1	KLHL7-AS1	13.93	4e-27	9.22e-22	0.83	0.78	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs10266123	ENSG00000230658.1	KLHL7-AS1	13.91	4.35e-27	9.22e-22	0.85	0.78	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs2014768	ENSG00000230658.1	KLHL7-AS1	13.91	4.48e-27	9.22e-22	0.83	0.78	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs6978827	ENSG00000230658.1	KLHL7-AS1	13.91	4.48e-27	9.22e-22	0.83	0.78	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs7790157	ENSG00000230658.1	KLHL7-AS1	13.91	4.48e-27	9.22e-22	0.83	0.78	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs6960001	ENSG00000230658.1	KLHL7-AS1	13.91	4.48e-27	9.22e-22	0.83	0.78	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs10237755	ENSG00000230658.1	KLHL7-AS1	13.91	4.48e-27	9.22e-22	0.83	0.78	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs6961131	ENSG00000230658.1	KLHL7-AS1	13.91	4.48e-27	9.22e-22	0.83	0.78	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23101228~23105703:-
TGCT	cis	rs4691139	0.524	rs4350966	ENSG00000250227.1	TRIM60P14	13.88	5.22e-27	9.9e-22	0.9	0.78	Ovarian cancer in BRCA1 mutation carriers;	chr4:164981127	chr4:164915565~164916983:+
TGCT	cis	rs9326248	0.906	rs171052	ENSG00000254851.1	RP11-109L13.1	13.88	5.27e-27	9.94e-22	1.09	0.78	Blood protein levels;	chr11:117211047	chr11:117135528~117138582:+
TGCT	cis	rs9326248	0.817	rs1242127	ENSG00000254851.1	RP11-109L13.1	13.88	5.33e-27	9.98e-22	1.02	0.78	Blood protein levels;	chr11:117205848	chr11:117135528~117138582:+
TGCT	cis	rs2739330	0.753	rs4822452	ENSG00000273295.1	AP000350.5	13.87	5.58e-27	1.04e-21	0.9	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23901432~23907068:-
TGCT	cis	rs858239	0.6	rs6461691	ENSG00000230658.1	KLHL7-AS1	13.8	8e-27	1.21e-21	0.84	0.78	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs10488077	ENSG00000230658.1	KLHL7-AS1	13.8	8e-27	1.21e-21	0.84	0.78	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs10241208	ENSG00000230658.1	KLHL7-AS1	13.8	8e-27	1.21e-21	0.84	0.78	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs28646184	ENSG00000230658.1	KLHL7-AS1	13.78	8.84e-27	1.31e-21	0.83	0.78	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs4628176	ENSG00000230658.1	KLHL7-AS1	13.72	1.23e-26	1.79e-21	0.84	0.78	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs10256361	ENSG00000230658.1	KLHL7-AS1	13.71	1.34e-26	1.94e-21	0.83	0.78	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23101228~23105703:-
TGCT	cis	rs1577917	0.629	rs7761762	ENSG00000203875.9	SNHG5	13.68	1.53e-26	2.2e-21	0.96	0.78	Response to antipsychotic treatment;	chr6:85496250	chr6:85660950~85678736:-
TGCT	cis	rs2739330	0.828	rs4822454	ENSG00000273295.1	AP000350.5	13.68	1.58e-26	2.26e-21	0.9	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23901432~23907068:-
TGCT	cis	rs2739330	0.828	rs5760108	ENSG00000273295.1	AP000350.5	13.64	1.98e-26	2.77e-21	0.89	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23901432~23907068:-
TGCT	cis	rs2739330	0.828	rs2877178	ENSG00000273295.1	AP000350.5	13.61	2.23e-26	3.08e-21	0.89	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23901432~23907068:-
TGCT	cis	rs2739330	0.828	rs2154593	ENSG00000273295.1	AP000350.5	13.61	2.23e-26	3.08e-21	0.89	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23901432~23907068:-
TGCT	cis	rs858239	0.632	rs7811903	ENSG00000230658.1	KLHL7-AS1	13.61	2.24e-26	3.08e-21	0.82	0.77	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs7776649	ENSG00000230658.1	KLHL7-AS1	13.59	2.51e-26	3.44e-21	0.82	0.77	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23101228~23105703:-
TGCT	cis	rs2739330	0.796	rs2154594	ENSG00000273295.1	AP000350.5	-13.59	2.53e-26	3.46e-21	-0.89	-0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23901432~23907068:-
TGCT	cis	rs858239	0.6	rs4409314	ENSG00000230658.1	KLHL7-AS1	13.58	2.76e-26	3.67e-21	0.82	0.77	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23101228~23105703:-
TGCT	cis	rs2739330	0.828	rs5760107	ENSG00000273295.1	AP000350.5	13.57	2.88e-26	3.77e-21	0.9	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23901432~23907068:-
TGCT	cis	rs2739330	0.789	rs5760109	ENSG00000273295.1	AP000350.5	13.57	2.88e-26	3.77e-21	0.9	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23901432~23907068:-
TGCT	cis	rs2739330	0.796	rs5760106	ENSG00000273295.1	AP000350.5	-13.57	2.88e-26	3.77e-21	-0.9	-0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23901432~23907068:-
TGCT	cis	rs2739330	0.828	rs2186366	ENSG00000273295.1	AP000350.5	-13.57	2.88e-26	3.77e-21	-0.9	-0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23901432~23907068:-
TGCT	cis	rs2739330	0.828	rs2330635	ENSG00000273295.1	AP000350.5	13.54	3.28e-26	4.28e-21	0.9	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23901432~23907068:-
TGCT	cis	rs858239	0.6	rs7787110	ENSG00000230658.1	KLHL7-AS1	13.53	3.57e-26	4.64e-21	0.79	0.77	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23101228~23105703:-
TGCT	cis	rs2739330	0.828	rs5751770	ENSG00000273295.1	AP000350.5	13.42	6.32e-26	6.82e-21	0.88	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23901432~23907068:-
TGCT	cis	rs1577917	0.559	rs1173418	ENSG00000203875.9	SNHG5	13.4	7.17e-26	7.7e-21	0.89	0.77	Response to antipsychotic treatment;	chr6:85693198	chr6:85660950~85678736:-
TGCT	cis	rs4691139	0.588	rs6818620	ENSG00000250227.1	TRIM60P14	13.39	7.51e-26	7.94e-21	0.89	0.77	Ovarian cancer in BRCA1 mutation carriers;	chr4:164992407	chr4:164915565~164916983:+
TGCT	cis	rs4691139	0.588	rs6842101	ENSG00000250227.1	TRIM60P14	13.39	7.51e-26	7.94e-21	0.89	0.77	Ovarian cancer in BRCA1 mutation carriers;	chr4:164992602	chr4:164915565~164916983:+
TGCT	cis	rs4691139	0.549	rs28728214	ENSG00000250227.1	TRIM60P14	13.39	7.51e-26	7.94e-21	0.89	0.77	Ovarian cancer in BRCA1 mutation carriers;	chr4:164993866	chr4:164915565~164916983:+
TGCT	cis	rs2739330	0.828	rs5760102	ENSG00000273295.1	AP000350.5	13.37	8.66e-26	8.89e-21	0.89	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23901432~23907068:-
TGCT	cis	rs2739330	0.796	rs5760097	ENSG00000273295.1	AP000350.5	13.35	9.32e-26	9.46e-21	0.89	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23901432~23907068:-
TGCT	cis	rs2739330	0.828	rs4822451	ENSG00000273295.1	AP000350.5	13.35	9.32e-26	9.46e-21	0.89	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23901432~23907068:-
TGCT	cis	rs2739330	0.828	rs5760098	ENSG00000273295.1	AP000350.5	13.35	9.32e-26	9.46e-21	0.89	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23901432~23907068:-
TGCT	cis	rs2739330	0.828	rs5760099	ENSG00000273295.1	AP000350.5	13.35	9.32e-26	9.46e-21	0.89	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23901432~23907068:-
TGCT	cis	rs858239	0.6	rs1468592	ENSG00000230658.1	KLHL7-AS1	-13.29	1.29e-25	1.29e-20	-0.8	-0.77	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23101228~23105703:-
TGCT	cis	rs2739330	0.752	rs2330634	ENSG00000273295.1	AP000350.5	13.29	1.35e-25	1.33e-20	0.87	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23901432~23907068:-
TGCT	cis	rs2739330	0.828	rs4820572	ENSG00000273295.1	AP000350.5	13.29	1.35e-25	1.33e-20	0.89	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23901432~23907068:-
TGCT	cis	rs2739330	0.796	rs1006771	ENSG00000273295.1	AP000350.5	13.26	1.59e-25	1.55e-20	0.85	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23901432~23907068:-
TGCT	cis	rs9326248	0.953	rs488962	ENSG00000254851.1	RP11-109L13.1	13.19	2.28e-25	2.19e-20	1.06	0.76	Blood protein levels;	chr11:117201809	chr11:117135528~117138582:+
TGCT	cis	rs858239	0.632	rs1985769	ENSG00000230658.1	KLHL7-AS1	13.17	2.53e-25	2.39e-20	0.8	0.76	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs28499396	ENSG00000230658.1	KLHL7-AS1	13.17	2.53e-25	2.39e-20	0.8	0.76	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs7789237	ENSG00000230658.1	KLHL7-AS1	13.17	2.53e-25	2.39e-20	0.8	0.76	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.632	rs6952947	ENSG00000230658.1	KLHL7-AS1	-13.17	2.53e-25	2.39e-20	-0.8	-0.76	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs6461692	ENSG00000230658.1	KLHL7-AS1	13.16	2.77e-25	2.6e-20	0.79	0.76	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs7341483	ENSG00000230658.1	KLHL7-AS1	-13.15	2.88e-25	2.63e-20	-0.8	-0.76	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs2003555	ENSG00000230658.1	KLHL7-AS1	13.15	2.88e-25	2.63e-20	0.8	0.76	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs7784929	ENSG00000230658.1	KLHL7-AS1	13.15	2.88e-25	2.63e-20	0.8	0.76	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs7799422	ENSG00000230658.1	KLHL7-AS1	13.15	2.88e-25	2.63e-20	0.8	0.76	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs28483572	ENSG00000230658.1	KLHL7-AS1	13.15	2.88e-25	2.63e-20	0.8	0.76	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs6961406	ENSG00000230658.1	KLHL7-AS1	13.15	2.88e-25	2.63e-20	0.8	0.76	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs6461690	ENSG00000230658.1	KLHL7-AS1	13.15	2.88e-25	2.63e-20	0.8	0.76	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs6967419	ENSG00000230658.1	KLHL7-AS1	13.15	2.88e-25	2.63e-20	0.8	0.76	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs4321896	ENSG00000230658.1	KLHL7-AS1	13.02	5.82e-25	5.21e-20	0.79	0.76	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs61292332	ENSG00000230658.1	KLHL7-AS1	13.02	5.82e-25	5.21e-20	0.79	0.76	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs59073109	ENSG00000230658.1	KLHL7-AS1	13.02	5.82e-25	5.21e-20	0.79	0.76	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs7788821	ENSG00000230658.1	KLHL7-AS1	13.02	5.82e-25	5.21e-20	0.79	0.76	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs6956595	ENSG00000230658.1	KLHL7-AS1	13.02	5.82e-25	5.21e-20	0.79	0.76	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23101228~23105703:-
TGCT	cis	rs1577917	0.56	rs9450288	ENSG00000203875.9	SNHG5	13.02	5.92e-25	5.29e-20	0.89	0.76	Response to antipsychotic treatment;	chr6:85511868	chr6:85660950~85678736:-
TGCT	cis	rs858239	0.6	rs10256359	ENSG00000230658.1	KLHL7-AS1	12.97	7.57e-25	6.73e-20	0.8	0.76	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23101228~23105703:-
TGCT	cis	rs6538678	0.746	rs4762630	ENSG00000258343.1	RP11-536G4.2	-12.93	9.68e-25	8.59e-20	-1.41	-0.76	Lupus nephritis in systemic lupus erythematosus;	chr12:95850631	chr12:95795345~95858839:-
TGCT	cis	rs858239	0.6	rs7776644	ENSG00000230658.1	KLHL7-AS1	12.92	1.01e-24	8.98e-20	0.8	0.76	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.601	rs987257	ENSG00000230658.1	KLHL7-AS1	12.87	1.33e-24	1.16e-19	0.8	0.76	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.601	rs1034963	ENSG00000230658.1	KLHL7-AS1	12.87	1.33e-24	1.16e-19	0.8	0.76	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.57	rs10235467	ENSG00000230658.1	KLHL7-AS1	12.87	1.33e-24	1.16e-19	0.8	0.76	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.669	rs12539467	ENSG00000230658.1	KLHL7-AS1	12.85	1.5e-24	1.3e-19	0.83	0.76	Cerebrospinal fluid biomarker levels;	chr7:23076240	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.601	rs6461693	ENSG00000230658.1	KLHL7-AS1	-12.83	1.71e-24	1.46e-19	-0.8	-0.76	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.601	rs6980224	ENSG00000230658.1	KLHL7-AS1	12.81	1.93e-24	1.65e-19	0.8	0.75	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.601	rs73272048	ENSG00000230658.1	KLHL7-AS1	12.8	1.99e-24	1.69e-19	0.8	0.75	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23101228~23105703:-
TGCT	cis	rs2739330	0.892	rs5751776	ENSG00000225282.1	AP000350.6	12.78	2.18e-24	1.84e-19	0.89	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23926900~23929574:+
TGCT	cis	rs6538678	0.824	rs1436120	ENSG00000258343.1	RP11-536G4.2	12.77	2.32e-24	1.96e-19	1.4	0.75	Lupus nephritis in systemic lupus erythematosus;	chr12:95826872	chr12:95795345~95858839:-
TGCT	cis	rs858239	0.601	rs10239760	ENSG00000230658.1	KLHL7-AS1	12.76	2.52e-24	2.12e-19	0.81	0.75	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.601	rs10255228	ENSG00000230658.1	KLHL7-AS1	12.73	2.92e-24	2.44e-19	0.8	0.75	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.601	rs1558313	ENSG00000230658.1	KLHL7-AS1	12.71	3.29e-24	2.71e-19	0.8	0.75	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.601	rs6962526	ENSG00000230658.1	KLHL7-AS1	12.71	3.29e-24	2.71e-19	0.8	0.75	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.539	rs6971673	ENSG00000230658.1	KLHL7-AS1	12.71	3.29e-24	2.71e-19	0.8	0.75	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.601	rs10278700	ENSG00000230658.1	KLHL7-AS1	12.71	3.29e-24	2.71e-19	0.8	0.75	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.601	rs10263110	ENSG00000230658.1	KLHL7-AS1	12.71	3.29e-24	2.71e-19	0.8	0.75	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.57	rs10271613	ENSG00000230658.1	KLHL7-AS1	12.71	3.29e-24	2.71e-19	0.8	0.75	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.57	rs10242166	ENSG00000230658.1	KLHL7-AS1	12.71	3.29e-24	2.71e-19	0.8	0.75	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.601	rs11982002	ENSG00000230658.1	KLHL7-AS1	12.71	3.29e-24	2.71e-19	0.8	0.75	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.601	rs15775	ENSG00000230658.1	KLHL7-AS1	12.71	3.29e-24	2.71e-19	0.8	0.75	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23101228~23105703:-
TGCT	cis	rs6538678	0.857	rs4762626	ENSG00000258343.1	RP11-536G4.2	-12.71	3.36e-24	2.74e-19	-1.4	-0.75	Lupus nephritis in systemic lupus erythematosus;	chr12:95811383	chr12:95795345~95858839:-
TGCT	cis	rs6538678	0.824	rs7299632	ENSG00000258343.1	RP11-536G4.2	-12.71	3.36e-24	2.74e-19	-1.4	-0.75	Lupus nephritis in systemic lupus erythematosus;	chr12:95838376	chr12:95795345~95858839:-
TGCT	cis	rs6538678	0.784	rs7297403	ENSG00000258343.1	RP11-536G4.2	-12.71	3.36e-24	2.74e-19	-1.4	-0.75	Lupus nephritis in systemic lupus erythematosus;	chr12:95846683	chr12:95795345~95858839:-
TGCT	cis	rs858239	0.601	rs12539331	ENSG00000230658.1	KLHL7-AS1	12.66	4.26e-24	3.45e-19	0.81	0.75	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.601	rs7805206	ENSG00000230658.1	KLHL7-AS1	12.62	5.41e-24	4.26e-19	0.74	0.75	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.601	rs764534	ENSG00000230658.1	KLHL7-AS1	12.56	7.72e-24	5.99e-19	0.81	0.75	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.601	rs2068459	ENSG00000230658.1	KLHL7-AS1	12.56	7.72e-24	5.99e-19	0.81	0.75	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.601	rs73272053	ENSG00000230658.1	KLHL7-AS1	12.56	7.72e-24	5.99e-19	0.81	0.75	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23101228~23105703:-
TGCT	cis	rs9326248	1	rs10790175	ENSG00000254851.1	RP11-109L13.1	-12.55	8.11e-24	6.28e-19	-0.99	-0.75	Blood protein levels;	chr11:117164013	chr11:117135528~117138582:+
TGCT	cis	rs2739330	0.929	rs5751777	ENSG00000225282.1	AP000350.6	12.54	8.45e-24	6.5e-19	0.89	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23926900~23929574:+
TGCT	cis	rs858239	0.601	rs929507	ENSG00000230658.1	KLHL7-AS1	12.54	8.53e-24	6.5e-19	0.79	0.75	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.601	rs929508	ENSG00000230658.1	KLHL7-AS1	12.54	8.53e-24	6.5e-19	0.79	0.75	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.57	rs6968242	ENSG00000230658.1	KLHL7-AS1	12.54	8.53e-24	6.5e-19	0.79	0.75	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.601	rs1981665	ENSG00000230658.1	KLHL7-AS1	12.54	8.53e-24	6.5e-19	0.79	0.75	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.601	rs4599714	ENSG00000230658.1	KLHL7-AS1	12.54	8.53e-24	6.5e-19	0.79	0.75	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.541	rs4624924	ENSG00000230658.1	KLHL7-AS1	12.54	8.53e-24	6.5e-19	0.79	0.75	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.601	rs10278776	ENSG00000230658.1	KLHL7-AS1	12.54	8.53e-24	6.5e-19	0.79	0.75	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23101228~23105703:-
TGCT	cis	rs9326248	0.954	rs4938349	ENSG00000254851.1	RP11-109L13.1	-12.51	1.01e-23	7.65e-19	-1.02	-0.75	Blood protein levels;	chr11:117151207	chr11:117135528~117138582:+
TGCT	cis	rs9326248	1	rs3736120	ENSG00000254851.1	RP11-109L13.1	-12.49	1.09e-23	8.27e-19	-1.02	-0.75	Blood protein levels;	chr11:117161409	chr11:117135528~117138582:+
TGCT	cis	rs6538678	0.824	rs2887026	ENSG00000258343.1	RP11-536G4.2	-12.48	1.2e-23	9.01e-19	-1.39	-0.75	Lupus nephritis in systemic lupus erythematosus;	chr12:95854713	chr12:95795345~95858839:-
TGCT	cis	rs6538678	0.824	rs4762631	ENSG00000258343.1	RP11-536G4.2	-12.48	1.2e-23	9.01e-19	-1.39	-0.75	Lupus nephritis in systemic lupus erythematosus;	chr12:95855698	chr12:95795345~95858839:-
TGCT	cis	rs6538678	0.824	rs2367583	ENSG00000258343.1	RP11-536G4.2	-12.48	1.2e-23	9.01e-19	-1.39	-0.75	Lupus nephritis in systemic lupus erythematosus;	chr12:95856582	chr12:95795345~95858839:-
TGCT	cis	rs2882667	0.69	rs288016	ENSG00000253404.1	AC034243.1	-12.45	1.37e-23	1.02e-18	-0.85	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859299	chr5:138744434~138753309:-
TGCT	cis	rs943437	0.542	rs9487748	ENSG00000227012.2	RP1-97J1.2	12.4	1.8e-23	1.32e-18	0.93	0.74	Parkinson's disease;	chr6:111911715	chr6:111900489~111901851:-
TGCT	cis	rs6538678	0.746	rs1865736	ENSG00000258343.1	RP11-536G4.2	-12.3	3.16e-23	2.28e-18	-1.39	-0.74	Lupus nephritis in systemic lupus erythematosus;	chr12:95854051	chr12:95795345~95858839:-
TGCT	cis	rs858239	0.601	rs11984129	ENSG00000230658.1	KLHL7-AS1	12.24	4.46e-23	3.2e-18	0.77	0.74	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23101228~23105703:-
TGCT	cis	rs8013143	1	rs11846575	ENSG00000279656.1	RP11-298I3.6	-12.24	4.55e-23	3.26e-18	-1.08	-0.74	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23022075	chr14:23023083~23024217:-
TGCT	cis	rs858239	0.601	rs10224327	ENSG00000230658.1	KLHL7-AS1	12.2	5.7e-23	4.05e-18	0.79	0.74	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.601	rs764533	ENSG00000230658.1	KLHL7-AS1	12.16	7.21e-23	5.08e-18	0.77	0.74	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23101228~23105703:-
TGCT	cis	rs943437	0.542	rs9320385	ENSG00000227012.2	RP1-97J1.2	12.13	8.28e-23	5.76e-18	0.92	0.74	Parkinson's disease;	chr6:111911148	chr6:111900489~111901851:-
TGCT	cis	rs916888	0.697	rs199516	ENSG00000262539.1	RP11-259G18.3	-12.11	9.33e-23	6.46e-18	-1.2	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46259551~46260606:-
TGCT	cis	rs9326248	0.911	rs11216284	ENSG00000254851.1	RP11-109L13.1	-12.09	1.02e-22	6.82e-18	-1.05	-0.74	Blood protein levels;	chr11:117132344	chr11:117135528~117138582:+
TGCT	cis	rs9326248	1	rs664922	ENSG00000254851.1	RP11-109L13.1	-12.09	1.07e-22	7.09e-18	-1	-0.74	Blood protein levels;	chr11:117200179	chr11:117135528~117138582:+
TGCT	cis	rs9326248	1	rs664082	ENSG00000254851.1	RP11-109L13.1	-12.09	1.07e-22	7.09e-18	-1	-0.74	Blood protein levels;	chr11:117200354	chr11:117135528~117138582:+
TGCT	cis	rs8013143	1	rs8013143	ENSG00000279656.1	RP11-298I3.6	-12.08	1.09e-22	7.2e-18	-1.08	-0.74	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23025068	chr14:23023083~23024217:-
TGCT	cis	rs8013143	1	rs941718	ENSG00000279656.1	RP11-298I3.6	-12.08	1.09e-22	7.2e-18	-1.08	-0.74	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23025839	chr14:23023083~23024217:-
TGCT	cis	rs858239	0.601	rs6969733	ENSG00000230658.1	KLHL7-AS1	12	1.7e-22	1.11e-17	0.77	0.73	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.601	rs4440529	ENSG00000230658.1	KLHL7-AS1	12	1.7e-22	1.11e-17	0.77	0.73	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23101228~23105703:-
TGCT	cis	rs2882667	0.69	rs7714455	ENSG00000253404.1	AC034243.1	-12	1.74e-22	1.14e-17	-0.84	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818281	chr5:138744434~138753309:-
TGCT	cis	rs7757969	0.5	rs1327194	ENSG00000227012.2	RP1-97J1.2	11.96	2.11e-22	1.36e-17	1	0.73	Schizophrenia;	chr6:111847935	chr6:111900489~111901851:-
TGCT	cis	rs7757969	0.5	rs6568708	ENSG00000227012.2	RP1-97J1.2	11.96	2.11e-22	1.36e-17	1	0.73	Schizophrenia;	chr6:111849019	chr6:111900489~111901851:-
TGCT	cis	rs9326248	1	rs585849	ENSG00000254851.1	RP11-109L13.1	-11.94	2.36e-22	1.52e-17	-1.02	-0.73	Blood protein levels;	chr11:117198345	chr11:117135528~117138582:+
TGCT	cis	rs113525195	1	rs113525195	ENSG00000279656.1	RP11-298I3.6	-11.94	2.43e-22	1.57e-17	-1.07	-0.73	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Mean corpuscular hemoglobin;	chr14:23030112	chr14:23023083~23024217:-
TGCT	cis	rs2882667	0.69	rs274119	ENSG00000253404.1	AC034243.1	11.93	2.47e-22	1.57e-17	0.83	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138728530	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs274118	ENSG00000253404.1	AC034243.1	11.93	2.47e-22	1.57e-17	0.83	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729198	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs274117	ENSG00000253404.1	AC034243.1	11.93	2.47e-22	1.57e-17	0.83	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729359	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs1725335	ENSG00000253404.1	AC034243.1	-11.93	2.54e-22	1.61e-17	-0.83	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745541	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs13181762	ENSG00000253404.1	AC034243.1	11.93	2.54e-22	1.61e-17	0.83	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914417	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.598	rs10078179	ENSG00000253404.1	AC034243.1	11.93	2.54e-22	1.61e-17	0.83	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920410	chr5:138744434~138753309:-
TGCT	cis	rs916888	0.773	rs199448	ENSG00000262539.1	RP11-259G18.3	11.93	2.58e-22	1.63e-17	1.19	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46259551~46260606:-
TGCT	cis	rs916888	0.821	rs199514	ENSG00000262539.1	RP11-259G18.3	-11.9	2.96e-22	1.86e-17	-1.2	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46259551~46260606:-
TGCT	cis	rs8013143	0.961	rs7147308	ENSG00000279656.1	RP11-298I3.6	-11.9	3.02e-22	1.88e-17	-1.07	-0.73	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23028420	chr14:23023083~23024217:-
TGCT	cis	rs9326248	0.954	rs10790177	ENSG00000254851.1	RP11-109L13.1	-11.89	3.16e-22	1.94e-17	-0.98	-0.73	Blood protein levels;	chr11:117177701	chr11:117135528~117138582:+
TGCT	cis	rs7757969	0.5	rs9487731	ENSG00000227012.2	RP1-97J1.2	11.89	3.16e-22	1.94e-17	0.99	0.73	Schizophrenia;	chr6:111833645	chr6:111900489~111901851:-
TGCT	cis	rs2739330	0.964	rs2739338	ENSG00000218537.1	MIF-AS1	11.89	3.16e-22	1.94e-17	0.92	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23954943	chr22:23894426~23898930:-
TGCT	cis	rs2739330	0.615	rs2858911	ENSG00000218537.1	MIF-AS1	11.89	3.16e-22	1.94e-17	0.92	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23955008	chr22:23894426~23898930:-
TGCT	cis	rs2739330	0.576	rs2858912	ENSG00000218537.1	MIF-AS1	11.89	3.16e-22	1.94e-17	0.92	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23955010	chr22:23894426~23898930:-
TGCT	cis	rs2882667	0.69	rs160399	ENSG00000253404.1	AC034243.1	11.88	3.28e-22	2.01e-17	0.83	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727552	chr5:138744434~138753309:-
TGCT	cis	rs1577917	0.696	rs2842617	ENSG00000203875.9	SNHG5	-11.88	3.3e-22	2.01e-17	-0.88	-0.73	Response to antipsychotic treatment;	chr6:85599980	chr6:85660950~85678736:-
TGCT	cis	rs916888	0.773	rs199447	ENSG00000262539.1	RP11-259G18.3	11.85	4.01e-22	2.34e-17	1.22	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46259551~46260606:-
TGCT	cis	rs916888	0.773	rs199445	ENSG00000262539.1	RP11-259G18.3	11.85	4.01e-22	2.34e-17	1.22	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46259551~46260606:-
TGCT	cis	rs916888	0.773	rs199443	ENSG00000262539.1	RP11-259G18.3	11.85	4.01e-22	2.34e-17	1.22	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46259551~46260606:-
TGCT	cis	rs916888	0.773	rs199534	ENSG00000262539.1	RP11-259G18.3	11.85	4.01e-22	2.34e-17	1.22	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46259551~46260606:-
TGCT	cis	rs2739330	1	rs2739330	ENSG00000218537.1	MIF-AS1	11.83	4.32e-22	2.4e-17	0.92	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23953099	chr22:23894426~23898930:-
TGCT	cis	rs2882667	0.654	rs1703211	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138740587	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs1627698	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138741777	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.654	rs160406	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748032	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs6873425	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819556	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.654	rs884470	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820236	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs6860780	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138824367	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs4835705	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827887	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs6884198	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138828618	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs4835706	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138829037	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs1039789	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835734	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs1039788	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835812	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs1828188	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836307	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs4835707	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138838831	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs6887841	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840221	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs12656942	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840769	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.686	rs62381196	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841000	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.72	rs56044552	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841265	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs7710288	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844049	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.621	rs55901834	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844094	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs1976568	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844627	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs6880786	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138845874	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs9327826	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846318	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.654	rs1972072	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849604	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.654	rs6863054	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853166	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.654	rs288019	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138855704	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.587	rs288015	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859528	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs288013	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860128	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs176381	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138861042	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs288011	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864250	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs288010	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864340	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs495638	ENSG00000253404.1	AC034243.1	-11.83	4.46e-22	2.4e-17	-0.82	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138865253	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs10043478	ENSG00000253404.1	AC034243.1	11.83	4.46e-22	2.4e-17	0.82	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853022	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs288042	ENSG00000253404.1	AC034243.1	11.83	4.46e-22	2.4e-17	0.82	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138867345	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs288041	ENSG00000253404.1	AC034243.1	11.83	4.46e-22	2.4e-17	0.82	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138868322	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs288039	ENSG00000253404.1	AC034243.1	11.83	4.46e-22	2.4e-17	0.82	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138870511	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs288038	ENSG00000253404.1	AC034243.1	11.83	4.46e-22	2.4e-17	0.82	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138871844	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs288031	ENSG00000253404.1	AC034243.1	11.83	4.46e-22	2.4e-17	0.82	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880377	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs288030	ENSG00000253404.1	AC034243.1	11.83	4.46e-22	2.4e-17	0.82	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880594	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs288025	ENSG00000253404.1	AC034243.1	11.83	4.46e-22	2.4e-17	0.82	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887944	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs288023	ENSG00000253404.1	AC034243.1	11.83	4.46e-22	2.4e-17	0.82	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888359	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.599	rs288008	ENSG00000253404.1	AC034243.1	11.83	4.46e-22	2.4e-17	0.82	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138893632	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs288004	ENSG00000253404.1	AC034243.1	11.83	4.46e-22	2.4e-17	0.82	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138895956	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs2662543	ENSG00000253404.1	AC034243.1	11.83	4.46e-22	2.4e-17	0.82	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898441	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs17207772	ENSG00000253404.1	AC034243.1	11.83	4.46e-22	2.4e-17	0.82	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138906131	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs13172507	ENSG00000253404.1	AC034243.1	11.83	4.46e-22	2.4e-17	0.82	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138907409	chr5:138744434~138753309:-
TGCT	cis	rs858239	0.601	rs6971002	ENSG00000230658.1	KLHL7-AS1	11.82	4.78e-22	2.57e-17	0.77	0.73	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23101228~23105703:-
TGCT	cis	rs916888	0.773	rs199448	ENSG00000214401.4	KANSL1-AS1	11.8	5.17e-22	2.77e-17	1.06	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46193576~46196723:+
TGCT	cis	rs2882667	0.69	rs176382	ENSG00000253404.1	AC034243.1	11.78	5.9e-22	3.14e-17	0.83	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891078	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs2351463	ENSG00000253404.1	AC034243.1	11.77	6.23e-22	3.29e-17	0.83	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923113	chr5:138744434~138753309:-
TGCT	cis	rs858239	0.601	rs3735228	ENSG00000230658.1	KLHL7-AS1	11.75	7.12e-22	3.69e-17	0.76	0.73	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.601	rs4140959	ENSG00000230658.1	KLHL7-AS1	11.75	7.12e-22	3.69e-17	0.76	0.73	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.632	rs13438452	ENSG00000230658.1	KLHL7-AS1	11.75	7.12e-22	3.69e-17	0.76	0.73	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.601	rs6948469	ENSG00000230658.1	KLHL7-AS1	11.75	7.12e-22	3.69e-17	0.76	0.73	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.6	rs6967475	ENSG00000230658.1	KLHL7-AS1	11.74	7.15e-22	3.7e-17	0.78	0.73	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23101228~23105703:-
TGCT	cis	rs2882667	0.69	rs10038162	ENSG00000253404.1	AC034243.1	-11.74	7.24e-22	3.74e-17	-0.83	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901066	chr5:138744434~138753309:-
TGCT	cis	rs9326248	1	rs4938344	ENSG00000254851.1	RP11-109L13.1	-11.71	8.47e-22	4.34e-17	-1.03	-0.72	Blood protein levels;	chr11:117133033	chr11:117135528~117138582:+
TGCT	cis	rs916888	0.687	rs199456	ENSG00000262539.1	RP11-259G18.3	11.71	8.86e-22	4.52e-17	1.22	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46259551~46260606:-
TGCT	cis	rs2882667	0.654	rs12517514	ENSG00000253404.1	AC034243.1	-11.7	8.94e-22	4.55e-17	-0.82	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138814430	chr5:138744434~138753309:-
TGCT	cis	rs9326248	1	rs9326248	ENSG00000254851.1	RP11-109L13.1	-11.7	9.29e-22	4.71e-17	-1.02	-0.72	Blood protein levels;	chr11:117128509	chr11:117135528~117138582:+
TGCT	cis	rs2882667	0.69	rs288033	ENSG00000253404.1	AC034243.1	11.7	9.36e-22	4.74e-17	0.83	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138878405	chr5:138744434~138753309:-
TGCT	cis	rs916888	0.773	rs9896243	ENSG00000214401.4	KANSL1-AS1	11.69	9.67e-22	4.86e-17	1.08	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46193576~46196723:+
TGCT	cis	rs2882667	0.69	rs1703212	ENSG00000253404.1	AC034243.1	-11.69	9.77e-22	4.86e-17	-0.82	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138742863	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs1651032	ENSG00000253404.1	AC034243.1	-11.69	9.77e-22	4.86e-17	-0.82	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138743151	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.654	rs884469	ENSG00000253404.1	AC034243.1	-11.69	9.77e-22	4.86e-17	-0.82	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820270	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs6877187	ENSG00000253404.1	AC034243.1	-11.69	9.77e-22	4.86e-17	-0.82	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138823655	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs3804199	ENSG00000253404.1	AC034243.1	-11.69	9.77e-22	4.86e-17	-0.82	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138826440	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.722	rs2011462	ENSG00000253404.1	AC034243.1	-11.69	9.77e-22	4.86e-17	-0.82	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827083	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs4835708	ENSG00000253404.1	AC034243.1	-11.69	9.77e-22	4.86e-17	-0.82	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844204	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.587	rs1848506	ENSG00000253404.1	AC034243.1	-11.69	9.77e-22	4.86e-17	-0.82	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846768	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs1848505	ENSG00000253404.1	AC034243.1	-11.69	9.77e-22	4.86e-17	-0.82	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846841	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.659	rs311595	ENSG00000253404.1	AC034243.1	11.69	9.77e-22	4.86e-17	0.82	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736183	chr5:138744434~138753309:-
TGCT	cis	rs916888	0.773	rs199447	ENSG00000214401.4	KANSL1-AS1	11.69	9.95e-22	4.93e-17	1.09	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46193576~46196723:+
TGCT	cis	rs916888	0.773	rs199445	ENSG00000214401.4	KANSL1-AS1	11.69	9.95e-22	4.93e-17	1.09	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46193576~46196723:+
TGCT	cis	rs916888	0.773	rs199443	ENSG00000214401.4	KANSL1-AS1	11.69	9.95e-22	4.93e-17	1.09	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46193576~46196723:+
TGCT	cis	rs916888	0.773	rs199534	ENSG00000214401.4	KANSL1-AS1	11.69	9.95e-22	4.93e-17	1.09	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46193576~46196723:+
TGCT	cis	rs9326248	1	rs4938354	ENSG00000254851.1	RP11-109L13.1	-11.68	1.01e-21	4.98e-17	-0.97	-0.72	Blood protein levels;	chr11:117180449	chr11:117135528~117138582:+
TGCT	cis	rs9326248	1	rs7946257	ENSG00000254851.1	RP11-109L13.1	-11.67	1.11e-21	5.47e-17	-0.97	-0.72	Blood protein levels;	chr11:117182449	chr11:117135528~117138582:+
TGCT	cis	rs2882667	0.659	rs10056014	ENSG00000253404.1	AC034243.1	11.64	1.28e-21	6.25e-17	0.82	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920329	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs160405	ENSG00000253404.1	AC034243.1	11.64	1.31e-21	6.35e-17	0.83	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748387	chr5:138744434~138753309:-
TGCT	cis	rs916888	0.821	rs70600	ENSG00000262539.1	RP11-259G18.3	11.63	1.36e-21	6.53e-17	1.19	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46259551~46260606:-
TGCT	cis	rs916888	0.821	rs199512	ENSG00000262539.1	RP11-259G18.3	-11.63	1.36e-21	6.53e-17	-1.19	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46259551~46260606:-
TGCT	cis	rs916888	0.821	rs199509	ENSG00000262539.1	RP11-259G18.3	-11.63	1.36e-21	6.53e-17	-1.19	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46259551~46260606:-
TGCT	cis	rs916888	0.821	rs199507	ENSG00000262539.1	RP11-259G18.3	-11.63	1.36e-21	6.53e-17	-1.19	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46259551~46260606:-
TGCT	cis	rs916888	0.821	rs199506	ENSG00000262539.1	RP11-259G18.3	-11.63	1.36e-21	6.53e-17	-1.19	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46259551~46260606:-
TGCT	cis	rs916888	0.821	rs415430	ENSG00000262539.1	RP11-259G18.3	-11.63	1.36e-21	6.53e-17	-1.19	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46259551~46260606:-
TGCT	cis	rs916888	0.779	rs430685	ENSG00000262539.1	RP11-259G18.3	-11.63	1.36e-21	6.53e-17	-1.19	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46259551~46260606:-
TGCT	cis	rs916888	0.821	rs199505	ENSG00000262539.1	RP11-259G18.3	-11.63	1.36e-21	6.53e-17	-1.19	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46259551~46260606:-
TGCT	cis	rs916888	0.821	rs70602	ENSG00000262539.1	RP11-259G18.3	-11.63	1.36e-21	6.53e-17	-1.19	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46259551~46260606:-
TGCT	cis	rs916888	0.773	rs199533	ENSG00000262539.1	RP11-259G18.3	11.63	1.39e-21	6.62e-17	1.22	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46259551~46260606:-
TGCT	cis	rs2882667	0.69	rs6421921	ENSG00000253404.1	AC034243.1	-11.63	1.39e-21	6.62e-17	-0.83	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831581	chr5:138744434~138753309:-
TGCT	cis	rs7757969	0.5	rs9387042	ENSG00000227012.2	RP1-97J1.2	11.62	1.45e-21	6.9e-17	0.96	0.72	Schizophrenia;	chr6:111834467	chr6:111900489~111901851:-
TGCT	cis	rs916888	0.773	rs199451	ENSG00000262539.1	RP11-259G18.3	11.6	1.6e-21	7.57e-17	1.21	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46259551~46260606:-
TGCT	cis	rs9326248	0.911	rs474339	ENSG00000254851.1	RP11-109L13.1	-11.58	1.78e-21	8.4e-17	-0.95	-0.72	Blood protein levels;	chr11:117188836	chr11:117135528~117138582:+
TGCT	cis	rs1577917	0.74	rs7752502	ENSG00000203875.9	SNHG5	11.54	2.21e-21	1.03e-16	0.85	0.72	Response to antipsychotic treatment;	chr6:85700933	chr6:85660950~85678736:-
TGCT	cis	rs2882667	0.69	rs7446631	ENSG00000253404.1	AC034243.1	11.54	2.22e-21	1.03e-16	0.81	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891376	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.659	rs12719515	ENSG00000253404.1	AC034243.1	11.54	2.22e-21	1.03e-16	0.81	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905629	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs288014	ENSG00000253404.1	AC034243.1	-11.54	2.22e-21	1.03e-16	-0.81	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860104	chr5:138744434~138753309:-
TGCT	cis	rs2739330	0.892	rs4822455	ENSG00000225282.1	AP000350.6	11.53	2.4e-21	1.11e-16	0.84	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23926900~23929574:+
TGCT	cis	rs2882667	0.69	rs160398	ENSG00000253404.1	AC034243.1	11.53	2.41e-21	1.11e-16	0.84	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727750	chr5:138744434~138753309:-
TGCT	cis	rs916888	0.773	rs199533	ENSG00000214401.4	KANSL1-AS1	11.52	2.51e-21	1.15e-16	1.1	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46193576~46196723:+
TGCT	cis	rs7757969	0.5	rs10440852	ENSG00000227012.2	RP1-97J1.2	11.52	2.52e-21	1.16e-16	0.96	0.72	Schizophrenia;	chr6:111835817	chr6:111900489~111901851:-
TGCT	cis	rs2882667	0.69	rs13177415	ENSG00000253404.1	AC034243.1	11.5	2.83e-21	1.3e-16	0.82	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914251	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs13174008	ENSG00000253404.1	AC034243.1	11.5	2.87e-21	1.31e-16	0.82	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922220	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs13158360	ENSG00000253404.1	AC034243.1	11.5	2.87e-21	1.31e-16	0.82	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922488	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs6596456	ENSG00000253404.1	AC034243.1	-11.49	2.96e-21	1.35e-16	-0.82	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831808	chr5:138744434~138753309:-
TGCT	cis	rs7757969	0.5	rs9320378	ENSG00000227012.2	RP1-97J1.2	11.49	3.05e-21	1.38e-16	0.99	0.72	Schizophrenia;	chr6:111851543	chr6:111900489~111901851:-
TGCT	cis	rs916888	0.773	rs199535	ENSG00000214401.4	KANSL1-AS1	11.48	3.16e-21	1.43e-16	1.08	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46193576~46196723:+
TGCT	cis	rs2882667	0.69	rs825669	ENSG00000253404.1	AC034243.1	-11.48	3.18e-21	1.43e-16	-0.83	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138731258	chr5:138744434~138753309:-
TGCT	cis	rs9326248	0.954	rs521171	ENSG00000254851.1	RP11-109L13.1	-11.47	3.25e-21	1.47e-16	-0.97	-0.72	Blood protein levels;	chr11:117193977	chr11:117135528~117138582:+
TGCT	cis	rs7757969	0.5	rs9487733	ENSG00000227012.2	RP1-97J1.2	11.47	3.32e-21	1.5e-16	0.96	0.72	Schizophrenia;	chr6:111837012	chr6:111900489~111901851:-
TGCT	cis	rs7757969	0.5	rs58691769	ENSG00000227012.2	RP1-97J1.2	11.47	3.32e-21	1.5e-16	0.96	0.72	Schizophrenia;	chr6:111837865	chr6:111900489~111901851:-
TGCT	cis	rs1577917	0.74	rs9353327	ENSG00000203875.9	SNHG5	-11.47	3.39e-21	1.52e-16	-0.83	-0.72	Response to antipsychotic treatment;	chr6:85684348	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.74	rs9344542	ENSG00000203875.9	SNHG5	11.47	3.39e-21	1.52e-16	0.83	0.72	Response to antipsychotic treatment;	chr6:85684187	chr6:85660950~85678736:-
TGCT	cis	rs9326248	0.798	rs10892079	ENSG00000254851.1	RP11-109L13.1	-11.46	3.59e-21	1.61e-16	-1.03	-0.72	Blood protein levels;	chr11:117146108	chr11:117135528~117138582:+
TGCT	cis	rs916888	0.779	rs199528	ENSG00000262539.1	RP11-259G18.3	11.45	3.66e-21	1.64e-16	1.16	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46259551~46260606:-
TGCT	cis	rs916888	0.821	rs199525	ENSG00000262539.1	RP11-259G18.3	11.45	3.66e-21	1.64e-16	1.16	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46259551~46260606:-
TGCT	cis	rs2882667	0.69	rs1828187	ENSG00000253404.1	AC034243.1	11.43	4.17e-21	1.85e-16	0.81	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836531	chr5:138744434~138753309:-
TGCT	cis	rs916888	0.773	rs9896243	ENSG00000262539.1	RP11-259G18.3	11.42	4.5e-21	2e-16	1.18	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46259551~46260606:-
TGCT	cis	rs2882667	0.69	rs6872423	ENSG00000253404.1	AC034243.1	11.41	4.62e-21	2.05e-16	0.82	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138911089	chr5:138744434~138753309:-
TGCT	cis	rs7757969	0.5	rs7746529	ENSG00000227012.2	RP1-97J1.2	11.4	4.89e-21	2.15e-16	0.97	0.72	Schizophrenia;	chr6:111855036	chr6:111900489~111901851:-
TGCT	cis	rs2882667	0.69	rs423469	ENSG00000253404.1	AC034243.1	11.4	4.92e-21	2.16e-16	0.81	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898427	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs288012	ENSG00000253404.1	AC034243.1	-11.4	4.92e-21	2.16e-16	-0.81	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860584	chr5:138744434~138753309:-
TGCT	cis	rs916888	0.773	rs199457	ENSG00000262539.1	RP11-259G18.3	11.4	5.02e-21	2.2e-16	1.21	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46259551~46260606:-
TGCT	cis	rs916888	0.821	rs199504	ENSG00000262539.1	RP11-259G18.3	-11.4	5.04e-21	2.2e-16	-1.18	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46259551~46260606:-
TGCT	cis	rs2882667	0.69	rs311596	ENSG00000253404.1	AC034243.1	-11.39	5.11e-21	2.23e-16	-0.83	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736393	chr5:138744434~138753309:-
TGCT	cis	rs2739330	0.685	rs4822453	ENSG00000273295.1	AP000350.5	11.39	5.19e-21	2.26e-16	0.79	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23901432~23907068:-
TGCT	cis	rs916888	0.738	rs199515	ENSG00000214401.4	KANSL1-AS1	-11.35	6.42e-21	2.76e-16	-1.08	-0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46193576~46196723:+
TGCT	cis	rs2882667	0.591	rs56322405	ENSG00000253404.1	AC034243.1	-11.34	7.06e-21	3.03e-16	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138837693	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs160401	ENSG00000253404.1	AC034243.1	-11.32	7.78e-21	3.34e-16	-0.86	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138725652	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.628	rs311605	ENSG00000253404.1	AC034243.1	11.32	7.92e-21	3.39e-16	0.86	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138710150	chr5:138744434~138753309:-
TGCT	cis	rs2906856	0.848	rs3015001	ENSG00000255733.4	IFNG-AS1	-11.31	8.15e-21	3.48e-16	-0.69	-0.71	Mosquito bite size;	chr12:68003593	chr12:67989445~68234686:+
TGCT	cis	rs2882667	0.69	rs160402	ENSG00000253404.1	AC034243.1	11.31	8.36e-21	3.56e-16	0.87	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138723599	chr5:138744434~138753309:-
TGCT	cis	rs3814244	0.528	rs2906854	ENSG00000255733.4	IFNG-AS1	-11.3	8.49e-21	3.6e-16	-0.7	-0.71	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993566	chr12:67989445~68234686:+
TGCT	cis	rs2739330	1	rs2739330	ENSG00000225282.1	AP000350.6	11.3	8.57e-21	3.61e-16	0.84	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23953099	chr22:23926900~23929574:+
TGCT	cis	rs2739330	0.964	rs2739338	ENSG00000225282.1	AP000350.6	11.3	8.58e-21	3.61e-16	0.84	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23954943	chr22:23926900~23929574:+
TGCT	cis	rs2739330	0.615	rs2858911	ENSG00000225282.1	AP000350.6	11.3	8.58e-21	3.61e-16	0.84	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23955008	chr22:23926900~23929574:+
TGCT	cis	rs2739330	0.576	rs2858912	ENSG00000225282.1	AP000350.6	11.3	8.58e-21	3.61e-16	0.84	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23955010	chr22:23926900~23929574:+
TGCT	cis	rs2882667	0.69	rs1651358	ENSG00000253404.1	AC034243.1	-11.3	8.81e-21	3.69e-16	-0.81	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745318	chr5:138744434~138753309:-
TGCT	cis	rs858239	0.571	rs6953020	ENSG00000230658.1	KLHL7-AS1	11.28	9.82e-21	4.08e-16	0.74	0.71	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23101228~23105703:-
TGCT	cis	rs1577917	0.793	rs9362245	ENSG00000203875.9	SNHG5	-11.27	9.99e-21	4.12e-16	-0.92	-0.71	Response to antipsychotic treatment;	chr6:85786602	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.839	rs6929514	ENSG00000203875.9	SNHG5	-11.27	9.99e-21	4.12e-16	-0.92	-0.71	Response to antipsychotic treatment;	chr6:85816050	chr6:85660950~85678736:-
TGCT	cis	rs3814244	0.528	rs12228471	ENSG00000255733.4	IFNG-AS1	11.27	1e-20	4.13e-16	0.7	0.71	Itch intensity from mosquito bite adjusted by bite size;	chr12:68027842	chr12:67989445~68234686:+
TGCT	cis	rs3814244	0.528	rs2906859	ENSG00000255733.4	IFNG-AS1	11.27	1.04e-20	4.26e-16	0.69	0.71	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002355	chr12:67989445~68234686:+
TGCT	cis	rs3814244	0.528	rs1468487	ENSG00000255733.4	IFNG-AS1	-11.27	1.04e-20	4.26e-16	-0.69	-0.71	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996602	chr12:67989445~68234686:+
TGCT	cis	rs3814244	0.528	rs2860609	ENSG00000255733.4	IFNG-AS1	-11.27	1.04e-20	4.26e-16	-0.69	-0.71	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997215	chr12:67989445~68234686:+
TGCT	cis	rs2882667	0.628	rs311607	ENSG00000253404.1	AC034243.1	11.25	1.11e-20	4.57e-16	0.85	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709231	chr5:138744434~138753309:-
TGCT	cis	rs916888	0.687	rs199456	ENSG00000214401.4	KANSL1-AS1	11.22	1.33e-20	5.41e-16	1.07	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46193576~46196723:+
TGCT	cis	rs3814244	0.569	rs11177008	ENSG00000255733.4	IFNG-AS1	11.22	1.37e-20	5.58e-16	0.7	0.71	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021024	chr12:67989445~68234686:+
TGCT	cis	rs916888	0.738	rs199515	ENSG00000262539.1	RP11-259G18.3	-11.22	1.37e-20	5.59e-16	-1.19	-0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46259551~46260606:-
TGCT	cis	rs2739330	0.929	rs5751777	ENSG00000218537.1	MIF-AS1	11.21	1.42e-20	5.76e-16	0.9	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23894426~23898930:-
TGCT	cis	rs2882667	0.69	rs311597	ENSG00000253404.1	AC034243.1	11.2	1.49e-20	6.05e-16	0.86	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720212	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.658	rs311592	ENSG00000253404.1	AC034243.1	11.19	1.56e-20	6.27e-16	0.82	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138734506	chr5:138744434~138753309:-
TGCT	cis	rs1577917	0.883	rs12214536	ENSG00000203875.9	SNHG5	-11.19	1.57e-20	6.32e-16	-0.89	-0.71	Response to antipsychotic treatment;	chr6:86080592	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.883	rs9450375	ENSG00000203875.9	SNHG5	11.17	1.75e-20	6.95e-16	0.9	0.71	Response to antipsychotic treatment;	chr6:86046911	chr6:85660950~85678736:-
TGCT	cis	rs3814244	0.528	rs7306466	ENSG00000255733.4	IFNG-AS1	11.17	1.77e-20	7.03e-16	0.7	0.71	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014942	chr12:67989445~68234686:+
TGCT	cis	rs3814244	0.569	rs2051993	ENSG00000255733.4	IFNG-AS1	11.15	1.96e-20	7.71e-16	0.7	0.71	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019898	chr12:67989445~68234686:+
TGCT	cis	rs1577917	0.883	rs1415749	ENSG00000203875.9	SNHG5	11.15	1.98e-20	7.78e-16	0.9	0.71	Response to antipsychotic treatment;	chr6:86069366	chr6:85660950~85678736:-
TGCT	cis	rs77437330	0.504	rs9481202	ENSG00000227012.2	RP1-97J1.2	11.15	2.03e-20	7.99e-16	0.95	0.71	Skin pigmentation;	chr6:111908723	chr6:111900489~111901851:-
TGCT	cis	rs2882667	0.628	rs3749663	ENSG00000253404.1	AC034243.1	11.14	2.13e-20	8.26e-16	0.81	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935498	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs3749664	ENSG00000253404.1	AC034243.1	11.14	2.13e-20	8.26e-16	0.81	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935732	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs160400	ENSG00000253404.1	AC034243.1	-11.13	2.25e-20	8.68e-16	-0.83	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727330	chr5:138744434~138753309:-
TGCT	cis	rs2739330	0.828	rs5751770	ENSG00000225282.1	AP000350.6	11.13	2.26e-20	8.71e-16	0.83	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23926900~23929574:+
TGCT	cis	rs2882667	0.69	rs6890932	ENSG00000253404.1	AC034243.1	11.12	2.38e-20	9.16e-16	0.81	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138910639	chr5:138744434~138753309:-
TGCT	cis	rs2739330	0.892	rs5751776	ENSG00000218537.1	MIF-AS1	11.11	2.45e-20	9.39e-16	0.89	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23894426~23898930:-
TGCT	cis	rs3814244	0.528	rs17104682	ENSG00000255733.4	IFNG-AS1	-11.11	2.57e-20	9.82e-16	-0.77	-0.71	Itch intensity from mosquito bite adjusted by bite size;	chr12:68033256	chr12:67989445~68234686:+
TGCT	cis	rs916888	0.773	rs199457	ENSG00000214401.4	KANSL1-AS1	11.1	2.71e-20	1.03e-15	1.08	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46193576~46196723:+
TGCT	cis	rs916888	0.773	rs199535	ENSG00000262539.1	RP11-259G18.3	11.09	2.74e-20	1.04e-15	1.18	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46259551~46260606:-
TGCT	cis	rs2882667	0.69	rs700616	ENSG00000253404.1	AC034243.1	-11.09	2.8e-20	1.06e-15	-0.81	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752184	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.654	rs700617	ENSG00000253404.1	AC034243.1	-11.09	2.8e-20	1.06e-15	-0.81	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752290	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs700618	ENSG00000253404.1	AC034243.1	-11.09	2.8e-20	1.06e-15	-0.81	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752429	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs311599	ENSG00000253404.1	AC034243.1	11.07	3.13e-20	1.18e-15	0.86	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138718994	chr5:138744434~138753309:-
TGCT	cis	rs916888	0.821	rs199514	ENSG00000214401.4	KANSL1-AS1	-11.07	3.22e-20	1.21e-15	-1.05	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46193576~46196723:+
TGCT	cis	rs2739330	0.796	rs2154594	ENSG00000225282.1	AP000350.6	-11.06	3.25e-20	1.22e-15	-0.84	-0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23926900~23929574:+
TGCT	cis	rs2882667	0.69	rs1059110	ENSG00000253404.1	AC034243.1	11.06	3.35e-20	1.25e-15	0.82	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138930857	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs10068280	ENSG00000253404.1	AC034243.1	11.06	3.35e-20	1.25e-15	0.82	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931394	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs13178601	ENSG00000253404.1	AC034243.1	11.06	3.35e-20	1.25e-15	0.82	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931688	chr5:138744434~138753309:-
TGCT	cis	rs2739330	0.753	rs4822452	ENSG00000225282.1	AP000350.6	11.05	3.56e-20	1.33e-15	0.84	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23926900~23929574:+
TGCT	cis	rs3734266	0.702	rs451603	ENSG00000186328.4	RP11-140K17.2	-11.04	3.69e-20	1.38e-15	-1.03	-0.7	Systemic lupus erythematosus;	chr6:34581330	chr6:34715613~34715940:+
TGCT	cis	rs9326248	0.954	rs8521	ENSG00000254851.1	RP11-109L13.1	-11.04	3.7e-20	1.38e-15	-0.96	-0.7	Blood protein levels;	chr11:117196983	chr11:117135528~117138582:+
TGCT	cis	rs1577917	0.796	rs12661231	ENSG00000203875.9	SNHG5	-11.04	3.72e-20	1.38e-15	-0.91	-0.7	Response to antipsychotic treatment;	chr6:85834753	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.839	rs12664634	ENSG00000203875.9	SNHG5	-11.04	3.72e-20	1.38e-15	-0.91	-0.7	Response to antipsychotic treatment;	chr6:85869696	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.883	rs2166664	ENSG00000203875.9	SNHG5	-11.04	3.72e-20	1.38e-15	-0.91	-0.7	Response to antipsychotic treatment;	chr6:85886904	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.883	rs9450348	ENSG00000203875.9	SNHG5	-11.04	3.72e-20	1.38e-15	-0.91	-0.7	Response to antipsychotic treatment;	chr6:85888318	chr6:85660950~85678736:-
TGCT	cis	rs2882667	0.69	rs2016720	ENSG00000253404.1	AC034243.1	11.02	4.13e-20	1.53e-15	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138928369	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs891996	ENSG00000253404.1	AC034243.1	11.02	4.13e-20	1.53e-15	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138932127	chr5:138744434~138753309:-
TGCT	cis	rs1577917	0.771	rs2484355	ENSG00000203875.9	SNHG5	-11.02	4.24e-20	1.56e-15	-0.86	-0.7	Response to antipsychotic treatment;	chr6:85684685	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.839	rs6454504	ENSG00000203875.9	SNHG5	-11.01	4.31e-20	1.59e-15	-0.92	-0.7	Response to antipsychotic treatment;	chr6:85870612	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.785	rs1885607	ENSG00000203875.9	SNHG5	11.01	4.45e-20	1.63e-15	0.86	0.7	Response to antipsychotic treatment;	chr6:85685187	chr6:85660950~85678736:-
TGCT	cis	rs2882667	0.69	rs7709789	ENSG00000253404.1	AC034243.1	11.01	4.46e-20	1.64e-15	0.82	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138938762	chr5:138744434~138753309:-
TGCT	cis	rs943437	0.542	rs9487749	ENSG00000227012.2	RP1-97J1.2	-11	4.66e-20	1.7e-15	-0.87	-0.7	Parkinson's disease;	chr6:111911783	chr6:111900489~111901851:-
TGCT	cis	rs1577917	0.74	rs9344533	ENSG00000203875.9	SNHG5	10.99	4.87e-20	1.77e-15	0.83	0.7	Response to antipsychotic treatment;	chr6:85526470	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.74	rs9353320	ENSG00000203875.9	SNHG5	10.99	4.87e-20	1.77e-15	0.83	0.7	Response to antipsychotic treatment;	chr6:85535130	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.74	rs7775864	ENSG00000203875.9	SNHG5	10.99	4.87e-20	1.77e-15	0.83	0.7	Response to antipsychotic treatment;	chr6:85538041	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.74	rs7771612	ENSG00000203875.9	SNHG5	10.99	4.87e-20	1.77e-15	0.83	0.7	Response to antipsychotic treatment;	chr6:85554656	chr6:85660950~85678736:-
TGCT	cis	rs916888	0.779	rs199528	ENSG00000214401.4	KANSL1-AS1	10.99	4.91e-20	1.78e-15	1.03	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46193576~46196723:+
TGCT	cis	rs916888	0.821	rs199525	ENSG00000214401.4	KANSL1-AS1	10.99	4.91e-20	1.78e-15	1.03	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46193576~46196723:+
TGCT	cis	rs2882667	0.658	rs172664	ENSG00000253404.1	AC034243.1	10.99	5.01e-20	1.81e-15	0.84	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720617	chr5:138744434~138753309:-
TGCT	cis	rs1577917	0.883	rs2660575	ENSG00000203875.9	SNHG5	-10.97	5.38e-20	1.93e-15	-0.89	-0.7	Response to antipsychotic treatment;	chr6:85975277	chr6:85660950~85678736:-
TGCT	cis	rs916888	0.697	rs199516	ENSG00000214401.4	KANSL1-AS1	-10.97	5.5e-20	1.95e-15	-1.03	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46193576~46196723:+
TGCT	cis	rs2882667	0.69	rs700624	ENSG00000253404.1	AC034243.1	-10.97	5.55e-20	1.95e-15	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763332	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs700625	ENSG00000253404.1	AC034243.1	-10.97	5.55e-20	1.95e-15	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763908	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.654	rs2940595	ENSG00000253404.1	AC034243.1	-10.97	5.55e-20	1.95e-15	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138765348	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.587	rs2174972	ENSG00000253404.1	AC034243.1	-10.97	5.55e-20	1.95e-15	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138766229	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs851278	ENSG00000253404.1	AC034243.1	-10.97	5.55e-20	1.95e-15	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767577	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs2693963	ENSG00000253404.1	AC034243.1	-10.97	5.55e-20	1.95e-15	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138770637	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs1567313	ENSG00000253404.1	AC034243.1	-10.97	5.55e-20	1.95e-15	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138775013	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.589	rs825770	ENSG00000253404.1	AC034243.1	-10.97	5.55e-20	1.95e-15	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779530	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs825769	ENSG00000253404.1	AC034243.1	-10.97	5.55e-20	1.95e-15	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779666	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs700627	ENSG00000253404.1	AC034243.1	-10.97	5.55e-20	1.95e-15	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138783711	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs825758	ENSG00000253404.1	AC034243.1	-10.97	5.55e-20	1.95e-15	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138791288	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs825754	ENSG00000253404.1	AC034243.1	-10.97	5.55e-20	1.95e-15	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138796200	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.722	rs825751	ENSG00000253404.1	AC034243.1	-10.97	5.55e-20	1.95e-15	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138798180	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.62	rs3789151	ENSG00000253404.1	AC034243.1	-10.97	5.55e-20	1.95e-15	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138809771	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.722	rs4835649	ENSG00000253404.1	AC034243.1	-10.97	5.55e-20	1.95e-15	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810534	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.587	rs6596450	ENSG00000253404.1	AC034243.1	-10.97	5.55e-20	1.95e-15	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810831	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs288028	ENSG00000253404.1	AC034243.1	10.97	5.57e-20	1.96e-15	0.85	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886300	chr5:138744434~138753309:-
TGCT	cis	rs916888	0.821	rs199512	ENSG00000214401.4	KANSL1-AS1	-10.96	5.91e-20	2.03e-15	-1.04	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46193576~46196723:+
TGCT	cis	rs916888	0.821	rs199509	ENSG00000214401.4	KANSL1-AS1	-10.96	5.91e-20	2.03e-15	-1.04	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46193576~46196723:+
TGCT	cis	rs916888	0.821	rs199507	ENSG00000214401.4	KANSL1-AS1	-10.96	5.91e-20	2.03e-15	-1.04	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46193576~46196723:+
TGCT	cis	rs916888	0.821	rs199506	ENSG00000214401.4	KANSL1-AS1	-10.96	5.91e-20	2.03e-15	-1.04	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46193576~46196723:+
TGCT	cis	rs916888	0.821	rs415430	ENSG00000214401.4	KANSL1-AS1	-10.96	5.91e-20	2.03e-15	-1.04	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46193576~46196723:+
TGCT	cis	rs916888	0.779	rs430685	ENSG00000214401.4	KANSL1-AS1	-10.96	5.91e-20	2.03e-15	-1.04	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46193576~46196723:+
TGCT	cis	rs916888	0.821	rs199505	ENSG00000214401.4	KANSL1-AS1	-10.96	5.91e-20	2.03e-15	-1.04	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46193576~46196723:+
TGCT	cis	rs916888	0.821	rs70602	ENSG00000214401.4	KANSL1-AS1	-10.96	5.91e-20	2.03e-15	-1.04	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46193576~46196723:+
TGCT	cis	rs916888	0.821	rs70600	ENSG00000214401.4	KANSL1-AS1	10.96	5.91e-20	2.03e-15	1.04	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46193576~46196723:+
TGCT	cis	rs1577917	0.883	rs1337854	ENSG00000203875.9	SNHG5	10.96	5.91e-20	2.03e-15	0.9	0.7	Response to antipsychotic treatment;	chr6:86014297	chr6:85660950~85678736:-
TGCT	cis	rs2882667	0.69	rs9327829	ENSG00000253404.1	AC034243.1	-10.94	6.38e-20	2.18e-15	-0.83	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925982	chr5:138744434~138753309:-
TGCT	cis	rs1577917	0.816	rs1838952	ENSG00000203875.9	SNHG5	-10.94	6.47e-20	2.21e-15	-0.91	-0.7	Response to antipsychotic treatment;	chr6:85891426	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.839	rs12055653	ENSG00000203875.9	SNHG5	-10.93	6.72e-20	2.29e-15	-0.91	-0.7	Response to antipsychotic treatment;	chr6:85836945	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.682	rs6909767	ENSG00000203875.9	SNHG5	10.93	6.9e-20	2.36e-15	0.83	0.7	Response to antipsychotic treatment;	chr6:85518391	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.74	rs2475792	ENSG00000203875.9	SNHG5	10.93	7.04e-20	2.4e-15	0.81	0.7	Response to antipsychotic treatment;	chr6:85682384	chr6:85660950~85678736:-
TGCT	cis	rs2882667	0.69	rs9327830	ENSG00000253404.1	AC034243.1	10.93	7.08e-20	2.41e-15	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936560	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs9327831	ENSG00000253404.1	AC034243.1	10.93	7.08e-20	2.41e-15	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936597	chr5:138744434~138753309:-
TGCT	cis	rs2739330	0.828	rs5760108	ENSG00000225282.1	AP000350.6	10.91	7.52e-20	2.54e-15	0.83	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23926900~23929574:+
TGCT	cis	rs2739330	0.828	rs2877178	ENSG00000225282.1	AP000350.6	10.91	7.63e-20	2.57e-15	0.83	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23926900~23929574:+
TGCT	cis	rs2739330	0.828	rs2154593	ENSG00000225282.1	AP000350.6	10.91	7.63e-20	2.57e-15	0.83	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23926900~23929574:+
TGCT	cis	rs2882667	0.658	rs10076442	ENSG00000253404.1	AC034243.1	10.9	8.08e-20	2.72e-15	0.83	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941090	chr5:138744434~138753309:-
TGCT	cis	rs1577917	0.839	rs1596990	ENSG00000203875.9	SNHG5	-10.9	8.22e-20	2.75e-15	-0.91	-0.7	Response to antipsychotic treatment;	chr6:85840974	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.916	rs12661611	ENSG00000203875.9	SNHG5	-10.9	8.22e-20	2.75e-15	-0.91	-0.7	Response to antipsychotic treatment;	chr6:85844117	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.637	rs1838957	ENSG00000203875.9	SNHG5	-10.9	8.22e-20	2.75e-15	-0.91	-0.7	Response to antipsychotic treatment;	chr6:85855338	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.839	rs1838956	ENSG00000203875.9	SNHG5	-10.9	8.22e-20	2.75e-15	-0.91	-0.7	Response to antipsychotic treatment;	chr6:85855545	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.839	rs12216103	ENSG00000203875.9	SNHG5	-10.9	8.22e-20	2.75e-15	-0.91	-0.7	Response to antipsychotic treatment;	chr6:85861410	chr6:85660950~85678736:-
TGCT	cis	rs2882667	0.69	rs3763016	ENSG00000253404.1	AC034243.1	10.89	8.5e-20	2.81e-15	0.8	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935043	chr5:138744434~138753309:-
TGCT	cis	rs1577917	0.804	rs2786854	ENSG00000203875.9	SNHG5	-10.87	9.47e-20	3.1e-15	-0.89	-0.7	Response to antipsychotic treatment;	chr6:85959022	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.92	rs1337842	ENSG00000203875.9	SNHG5	-10.87	9.47e-20	3.1e-15	-0.89	-0.7	Response to antipsychotic treatment;	chr6:85965379	chr6:85660950~85678736:-
TGCT	cis	rs2882667	0.69	rs311602	ENSG00000253404.1	AC034243.1	10.86	1.01e-19	3.28e-15	0.84	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717370	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs930063	ENSG00000253404.1	AC034243.1	10.86	1.01e-19	3.28e-15	0.84	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717929	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs930062	ENSG00000253404.1	AC034243.1	10.86	1.01e-19	3.28e-15	0.84	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717934	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.654	rs6862845	ENSG00000253404.1	AC034243.1	10.86	1.02e-19	3.3e-15	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937456	chr5:138744434~138753309:-
TGCT	cis	rs1577917	0.74	rs9450302	ENSG00000203875.9	SNHG5	10.86	1.05e-19	3.4e-15	0.83	0.7	Response to antipsychotic treatment;	chr6:85579955	chr6:85660950~85678736:-
TGCT	cis	rs2739330	0.892	rs4822455	ENSG00000218537.1	MIF-AS1	10.85	1.06e-19	3.41e-15	0.87	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23894426~23898930:-
TGCT	cis	rs1577917	0.74	rs2842614	ENSG00000203875.9	SNHG5	-10.85	1.06e-19	3.43e-15	-0.83	-0.7	Response to antipsychotic treatment;	chr6:85596351	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.74	rs2758843	ENSG00000203875.9	SNHG5	-10.85	1.06e-19	3.43e-15	-0.83	-0.7	Response to antipsychotic treatment;	chr6:85618713	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.74	rs12212560	ENSG00000203875.9	SNHG5	-10.85	1.06e-19	3.43e-15	-0.83	-0.7	Response to antipsychotic treatment;	chr6:85632961	chr6:85660950~85678736:-
TGCT	cis	rs858239	0.601	rs2141307	ENSG00000230658.1	KLHL7-AS1	10.85	1.08e-19	3.47e-15	0.76	0.7	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.602	rs6953996	ENSG00000230658.1	KLHL7-AS1	10.85	1.09e-19	3.47e-15	0.75	0.7	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23101228~23105703:-
TGCT	cis	rs2882667	0.654	rs1095374	ENSG00000253404.1	AC034243.1	-10.85	1.09e-19	3.47e-15	-0.8	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759517	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs700620	ENSG00000253404.1	AC034243.1	-10.85	1.09e-19	3.47e-15	-0.8	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762247	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.659	rs700621	ENSG00000253404.1	AC034243.1	-10.85	1.09e-19	3.47e-15	-0.8	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762741	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs700623	ENSG00000253404.1	AC034243.1	-10.85	1.09e-19	3.47e-15	-0.8	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762993	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs700629	ENSG00000253404.1	AC034243.1	-10.85	1.09e-19	3.47e-15	-0.8	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138788305	chr5:138744434~138753309:-
TGCT	cis	rs1577917	0.771	rs4441928	ENSG00000203875.9	SNHG5	10.84	1.12e-19	3.55e-15	0.88	0.7	Response to antipsychotic treatment;	chr6:85532176	chr6:85660950~85678736:-
TGCT	cis	rs9326248	1	rs7107152	ENSG00000254851.1	RP11-109L13.1	10.83	1.19e-19	3.76e-15	0.88	0.7	Blood protein levels;	chr11:117185364	chr11:117135528~117138582:+
TGCT	cis	rs2882667	0.69	rs906695	ENSG00000253404.1	AC034243.1	10.82	1.26e-19	3.99e-15	0.83	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138803588	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.654	rs700626	ENSG00000253404.1	AC034243.1	-10.82	1.29e-19	4.05e-15	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138782249	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs10515504	ENSG00000253404.1	AC034243.1	-10.82	1.3e-19	4.09e-15	-0.83	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887305	chr5:138744434~138753309:-
TGCT	cis	rs1577917	0.959	rs2816822	ENSG00000203875.9	SNHG5	-10.81	1.39e-19	4.36e-15	-0.9	-0.7	Response to antipsychotic treatment;	chr6:85948574	chr6:85660950~85678736:-
TGCT	cis	rs2739330	0.828	rs5760107	ENSG00000225282.1	AP000350.6	10.79	1.5e-19	4.67e-15	0.83	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23926900~23929574:+
TGCT	cis	rs2739330	0.789	rs5760109	ENSG00000225282.1	AP000350.6	10.79	1.5e-19	4.67e-15	0.83	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23926900~23929574:+
TGCT	cis	rs2739330	0.796	rs5760106	ENSG00000225282.1	AP000350.6	-10.79	1.5e-19	4.67e-15	-0.83	-0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23926900~23929574:+
TGCT	cis	rs2739330	0.828	rs2186366	ENSG00000225282.1	AP000350.6	-10.79	1.5e-19	4.67e-15	-0.83	-0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23926900~23929574:+
TGCT	cis	rs2739330	0.828	rs2330635	ENSG00000225282.1	AP000350.6	10.79	1.52e-19	4.73e-15	0.83	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23926900~23929574:+
TGCT	cis	rs2739330	0.796	rs5760097	ENSG00000225282.1	AP000350.6	10.79	1.53e-19	4.73e-15	0.83	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23926900~23929574:+
TGCT	cis	rs2739330	0.828	rs4822451	ENSG00000225282.1	AP000350.6	10.79	1.53e-19	4.73e-15	0.83	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23926900~23929574:+
TGCT	cis	rs2739330	0.828	rs5760098	ENSG00000225282.1	AP000350.6	10.79	1.53e-19	4.73e-15	0.83	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23926900~23929574:+
TGCT	cis	rs2739330	0.828	rs5760099	ENSG00000225282.1	AP000350.6	10.79	1.53e-19	4.73e-15	0.83	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23926900~23929574:+
TGCT	cis	rs2739330	0.828	rs5760102	ENSG00000225282.1	AP000350.6	10.79	1.54e-19	4.78e-15	0.83	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23926900~23929574:+
TGCT	cis	rs2739330	0.828	rs4822454	ENSG00000225282.1	AP000350.6	10.78	1.64e-19	5.08e-15	0.83	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23926900~23929574:+
TGCT	cis	rs1577917	0.771	rs12199873	ENSG00000203875.9	SNHG5	-10.77	1.68e-19	5.1e-15	-0.86	-0.7	Response to antipsychotic treatment;	chr6:85585229	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.771	rs2842609	ENSG00000203875.9	SNHG5	-10.77	1.68e-19	5.1e-15	-0.86	-0.7	Response to antipsychotic treatment;	chr6:85587070	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.771	rs2842612	ENSG00000203875.9	SNHG5	-10.77	1.68e-19	5.1e-15	-0.86	-0.7	Response to antipsychotic treatment;	chr6:85593373	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.727	rs2758840	ENSG00000203875.9	SNHG5	-10.77	1.68e-19	5.1e-15	-0.86	-0.7	Response to antipsychotic treatment;	chr6:85594907	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.771	rs9362230	ENSG00000203875.9	SNHG5	-10.77	1.68e-19	5.1e-15	-0.86	-0.7	Response to antipsychotic treatment;	chr6:85595295	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.771	rs2758844	ENSG00000203875.9	SNHG5	-10.77	1.68e-19	5.1e-15	-0.86	-0.7	Response to antipsychotic treatment;	chr6:85620397	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.771	rs2842601	ENSG00000203875.9	SNHG5	-10.77	1.68e-19	5.1e-15	-0.86	-0.7	Response to antipsychotic treatment;	chr6:85620415	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.771	rs12205013	ENSG00000203875.9	SNHG5	-10.77	1.68e-19	5.1e-15	-0.86	-0.7	Response to antipsychotic treatment;	chr6:85623311	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.74	rs2842604	ENSG00000203875.9	SNHG5	-10.77	1.68e-19	5.1e-15	-0.86	-0.7	Response to antipsychotic treatment;	chr6:85626582	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.771	rs2842607	ENSG00000203875.9	SNHG5	-10.77	1.68e-19	5.1e-15	-0.86	-0.7	Response to antipsychotic treatment;	chr6:85635321	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.771	rs2758847	ENSG00000203875.9	SNHG5	-10.77	1.68e-19	5.1e-15	-0.86	-0.7	Response to antipsychotic treatment;	chr6:85639385	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.771	rs4145082	ENSG00000203875.9	SNHG5	-10.77	1.68e-19	5.1e-15	-0.86	-0.7	Response to antipsychotic treatment;	chr6:85642298	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.771	rs9362233	ENSG00000203875.9	SNHG5	-10.77	1.68e-19	5.1e-15	-0.86	-0.7	Response to antipsychotic treatment;	chr6:85648529	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.771	rs10944133	ENSG00000203875.9	SNHG5	-10.77	1.68e-19	5.1e-15	-0.86	-0.7	Response to antipsychotic treatment;	chr6:85649266	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.727	rs9351065	ENSG00000203875.9	SNHG5	-10.77	1.68e-19	5.1e-15	-0.86	-0.7	Response to antipsychotic treatment;	chr6:85650710	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.771	rs2475790	ENSG00000203875.9	SNHG5	-10.77	1.68e-19	5.1e-15	-0.86	-0.7	Response to antipsychotic treatment;	chr6:85658350	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.771	rs2475791	ENSG00000203875.9	SNHG5	-10.77	1.68e-19	5.1e-15	-0.86	-0.7	Response to antipsychotic treatment;	chr6:85658446	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.771	rs2842613	ENSG00000203875.9	SNHG5	10.77	1.68e-19	5.1e-15	0.86	0.7	Response to antipsychotic treatment;	chr6:85595984	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.771	rs2783171	ENSG00000203875.9	SNHG5	10.77	1.68e-19	5.1e-15	0.86	0.7	Response to antipsychotic treatment;	chr6:85673047	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.71	rs1059306	ENSG00000203875.9	SNHG5	10.77	1.68e-19	5.1e-15	0.86	0.7	Response to antipsychotic treatment;	chr6:85678391	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.771	rs9362237	ENSG00000203875.9	SNHG5	10.77	1.68e-19	5.1e-15	0.86	0.7	Response to antipsychotic treatment;	chr6:85699346	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.739	rs9450318	ENSG00000203875.9	SNHG5	10.77	1.7e-19	5.14e-15	0.86	0.7	Response to antipsychotic treatment;	chr6:85717459	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.771	rs9450319	ENSG00000203875.9	SNHG5	10.77	1.7e-19	5.14e-15	0.86	0.7	Response to antipsychotic treatment;	chr6:85717607	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.771	rs9362239	ENSG00000203875.9	SNHG5	10.77	1.7e-19	5.14e-15	0.86	0.7	Response to antipsychotic treatment;	chr6:85719545	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.771	rs4383777	ENSG00000203875.9	SNHG5	10.77	1.72e-19	5.19e-15	0.88	0.7	Response to antipsychotic treatment;	chr6:85726242	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.771	rs7762321	ENSG00000203875.9	SNHG5	10.75	1.85e-19	5.56e-15	0.82	0.69	Response to antipsychotic treatment;	chr6:85702428	chr6:85660950~85678736:-
TGCT	cis	rs2882667	0.69	rs825748	ENSG00000253404.1	AC034243.1	-10.75	1.87e-19	5.56e-15	-0.81	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800378	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs825746	ENSG00000253404.1	AC034243.1	-10.75	1.87e-19	5.56e-15	-0.81	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800930	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs825762	ENSG00000253404.1	AC034243.1	-10.75	1.87e-19	5.56e-15	-0.81	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138801981	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs825761	ENSG00000253404.1	AC034243.1	-10.75	1.87e-19	5.56e-15	-0.81	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138802318	chr5:138744434~138753309:-
TGCT	cis	rs2739330	0.796	rs1006771	ENSG00000225282.1	AP000350.6	10.75	1.89e-19	5.61e-15	0.8	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23926900~23929574:+
TGCT	cis	rs916888	0.773	rs199451	ENSG00000214401.4	KANSL1-AS1	10.75	1.92e-19	5.67e-15	1.05	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46193576~46196723:+
TGCT	cis	rs1577917	0.839	rs6454492	ENSG00000203875.9	SNHG5	-10.75	1.94e-19	5.74e-15	-0.9	-0.69	Response to antipsychotic treatment;	chr6:85773496	chr6:85660950~85678736:-
TGCT	cis	rs916888	0.821	rs199513	ENSG00000262539.1	RP11-259G18.3	-10.74	2e-19	5.91e-15	-1.09	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46259551~46260606:-
TGCT	cis	rs858239	0.539	rs4559148	ENSG00000230658.1	KLHL7-AS1	10.74	2.05e-19	6.03e-15	0.77	0.69	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.539	rs4377861	ENSG00000230658.1	KLHL7-AS1	10.74	2.05e-19	6.03e-15	0.77	0.69	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.539	rs10247268	ENSG00000230658.1	KLHL7-AS1	10.74	2.05e-19	6.03e-15	0.77	0.69	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.539	rs6461694	ENSG00000230658.1	KLHL7-AS1	10.74	2.05e-19	6.03e-15	0.77	0.69	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.508	rs7805071	ENSG00000230658.1	KLHL7-AS1	10.74	2.05e-19	6.03e-15	0.77	0.69	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.508	rs7805085	ENSG00000230658.1	KLHL7-AS1	10.74	2.05e-19	6.03e-15	0.77	0.69	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23101228~23105703:-
TGCT	cis	rs172166	0.516	rs1225715	ENSG00000216901.1	AL022393.7	-10.74	2.05e-19	6.03e-15	-0.75	-0.69	Cardiac Troponin-T levels;	chr6:28145595	chr6:28176188~28176674:+
TGCT	cis	rs2882667	0.69	rs160403	ENSG00000253404.1	AC034243.1	10.73	2.1e-19	6.17e-15	0.83	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138722793	chr5:138744434~138753309:-
TGCT	cis	rs858239	0.539	rs7791200	ENSG00000230658.1	KLHL7-AS1	10.72	2.18e-19	6.33e-15	0.75	0.69	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.539	rs57864591	ENSG00000230658.1	KLHL7-AS1	10.72	2.18e-19	6.33e-15	0.75	0.69	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.539	rs4294098	ENSG00000230658.1	KLHL7-AS1	10.72	2.18e-19	6.33e-15	0.75	0.69	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.539	rs4504540	ENSG00000230658.1	KLHL7-AS1	10.72	2.18e-19	6.33e-15	0.75	0.69	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.509	rs6975524	ENSG00000230658.1	KLHL7-AS1	10.72	2.18e-19	6.33e-15	0.75	0.69	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.539	rs6955726	ENSG00000230658.1	KLHL7-AS1	10.72	2.18e-19	6.33e-15	0.75	0.69	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.539	rs6976957	ENSG00000230658.1	KLHL7-AS1	10.72	2.18e-19	6.33e-15	0.75	0.69	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.539	rs6956828	ENSG00000230658.1	KLHL7-AS1	10.72	2.18e-19	6.33e-15	0.75	0.69	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.539	rs10280815	ENSG00000230658.1	KLHL7-AS1	10.72	2.18e-19	6.33e-15	0.75	0.69	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.539	rs10225608	ENSG00000230658.1	KLHL7-AS1	10.72	2.18e-19	6.33e-15	0.75	0.69	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.539	rs28624974	ENSG00000230658.1	KLHL7-AS1	10.72	2.18e-19	6.33e-15	0.75	0.69	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23101228~23105703:-
TGCT	cis	rs5850	0.557	rs10270788	ENSG00000230658.1	KLHL7-AS1	10.72	2.18e-19	6.33e-15	0.75	0.69	Blood protein levels;	chr7:23149381	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.539	rs28716381	ENSG00000230658.1	KLHL7-AS1	10.72	2.18e-19	6.33e-15	0.75	0.69	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.539	rs1358442	ENSG00000230658.1	KLHL7-AS1	10.72	2.18e-19	6.33e-15	0.75	0.69	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23101228~23105703:-
TGCT	cis	rs3734266	0.702	rs36032186	ENSG00000186328.4	RP11-140K17.2	10.72	2.24e-19	6.5e-15	1.12	0.69	Systemic lupus erythematosus;	chr6:34606163	chr6:34715613~34715940:+
TGCT	cis	rs9326248	0.817	rs6589598	ENSG00000254851.1	RP11-109L13.1	-10.71	2.32e-19	6.67e-15	-1.07	-0.69	Blood protein levels;	chr11:117131687	chr11:117135528~117138582:+
TGCT	cis	rs1577917	0.883	rs13212415	ENSG00000203875.9	SNHG5	-10.71	2.33e-19	6.69e-15	-0.9	-0.69	Response to antipsychotic treatment;	chr6:85898365	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.633	rs7770835	ENSG00000203875.9	SNHG5	-10.71	2.33e-19	6.69e-15	-0.9	-0.69	Response to antipsychotic treatment;	chr6:85899189	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.839	rs1447159	ENSG00000203875.9	SNHG5	-10.71	2.33e-19	6.69e-15	-0.9	-0.69	Response to antipsychotic treatment;	chr6:85899531	chr6:85660950~85678736:-
TGCT	cis	rs2283792	0.633	rs240068	ENSG00000228050.1	TOP3BP1	10.69	2.65e-19	7.56e-15	0.8	0.69	Multiple sclerosis;	chr22:21936031	chr22:22223187~22224566:-
TGCT	cis	rs858239	0.509	rs57611130	ENSG00000230658.1	KLHL7-AS1	10.69	2.67e-19	7.61e-15	0.75	0.69	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23101228~23105703:-
TGCT	cis	rs1577917	0.771	rs2842608	ENSG00000203875.9	SNHG5	-10.69	2.69e-19	7.66e-15	-0.85	-0.69	Response to antipsychotic treatment;	chr6:85586140	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.771	rs2842602	ENSG00000203875.9	SNHG5	-10.69	2.69e-19	7.66e-15	-0.85	-0.69	Response to antipsychotic treatment;	chr6:85622169	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.739	rs2758846	ENSG00000203875.9	SNHG5	-10.69	2.69e-19	7.66e-15	-0.85	-0.69	Response to antipsychotic treatment;	chr6:85639852	chr6:85660950~85678736:-
TGCT	cis	rs858239	0.539	rs6975852	ENSG00000230658.1	KLHL7-AS1	10.69	2.71e-19	7.71e-15	0.77	0.69	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23101228~23105703:-
TGCT	cis	rs2882667	0.69	rs9942422	ENSG00000253404.1	AC034243.1	10.69	2.72e-19	7.72e-15	0.8	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936847	chr5:138744434~138753309:-
TGCT	cis	rs2739330	0.828	rs4820572	ENSG00000225282.1	AP000350.6	10.67	2.98e-19	8.4e-15	0.83	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23926900~23929574:+
TGCT	cis	rs9326248	1	rs664971	ENSG00000254851.1	RP11-109L13.1	10.66	3.07e-19	8.64e-15	1.05	0.69	Blood protein levels;	chr11:117200141	chr11:117135528~117138582:+
TGCT	cis	rs3814244	0.528	rs7962511	ENSG00000255733.4	IFNG-AS1	10.66	3.08e-19	8.66e-15	0.68	0.69	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002854	chr12:67989445~68234686:+
TGCT	cis	rs1577917	0.655	rs9359658	ENSG00000203875.9	SNHG5	10.66	3.14e-19	8.82e-15	0.81	0.69	Response to antipsychotic treatment;	chr6:85596051	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.696	rs2842603	ENSG00000203875.9	SNHG5	-10.66	3.19e-19	8.96e-15	-0.81	-0.69	Response to antipsychotic treatment;	chr6:85626619	chr6:85660950~85678736:-
TGCT	cis	rs1150668	0.835	rs1233696	ENSG00000216901.1	AL022393.7	10.66	3.21e-19	8.97e-15	0.74	0.69	Pubertal anthropometrics;	chr6:28175232	chr6:28176188~28176674:+
TGCT	cis	rs2882667	0.69	rs311601	ENSG00000253404.1	AC034243.1	10.65	3.33e-19	9.26e-15	0.87	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717697	chr5:138744434~138753309:-
TGCT	cis	rs1155848	0.892	rs9574424	ENSG00000227354.5	RBM26-AS1	-10.65	3.36e-19	9.35e-15	-1.07	-0.69	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79448541	chr13:79406309~79424328:+
TGCT	cis	rs1577917	0.771	rs7742201	ENSG00000203875.9	SNHG5	-10.65	3.4e-19	9.45e-15	-0.84	-0.69	Response to antipsychotic treatment;	chr6:85723212	chr6:85660950~85678736:-
TGCT	cis	rs172166	0.56	rs203878	ENSG00000216901.1	AL022393.7	10.64	3.44e-19	9.53e-15	0.74	0.69	Cardiac Troponin-T levels;	chr6:28081218	chr6:28176188~28176674:+
TGCT	cis	rs172166	0.516	rs1150670	ENSG00000216901.1	AL022393.7	10.64	3.44e-19	9.53e-15	0.74	0.69	Cardiac Troponin-T levels;	chr6:28162781	chr6:28176188~28176674:+
TGCT	cis	rs172166	0.516	rs2021826	ENSG00000216901.1	AL022393.7	10.64	3.44e-19	9.53e-15	0.74	0.69	Cardiac Troponin-T levels;	chr6:28164978	chr6:28176188~28176674:+
TGCT	cis	rs172166	0.538	rs1150686	ENSG00000216901.1	AL022393.7	10.64	3.44e-19	9.53e-15	0.74	0.69	Cardiac Troponin-T levels;	chr6:28193493	chr6:28176188~28176674:+
TGCT	cis	rs1150688	1	rs1150688	ENSG00000216901.1	AL022393.7	10.64	3.44e-19	9.53e-15	0.74	0.69	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28176188~28176674:+
TGCT	cis	rs1577917	0.739	rs9344532	ENSG00000203875.9	SNHG5	10.64	3.56e-19	9.82e-15	0.86	0.69	Response to antipsychotic treatment;	chr6:85524352	chr6:85660950~85678736:-
TGCT	cis	rs2882667	0.69	rs825749	ENSG00000253404.1	AC034243.1	-10.63	3.65e-19	1e-14	-0.8	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800232	chr5:138744434~138753309:-
TGCT	cis	rs1577917	0.74	rs2758842	ENSG00000203875.9	SNHG5	-10.63	3.7e-19	1.02e-14	-0.81	-0.69	Response to antipsychotic treatment;	chr6:85599013	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.572	rs911927	ENSG00000203875.9	SNHG5	-10.63	3.7e-19	1.02e-14	-0.81	-0.69	Response to antipsychotic treatment;	chr6:85618142	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.74	rs2758845	ENSG00000203875.9	SNHG5	-10.63	3.7e-19	1.02e-14	-0.81	-0.69	Response to antipsychotic treatment;	chr6:85625130	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.655	rs7742691	ENSG00000203875.9	SNHG5	10.63	3.7e-19	1.02e-14	0.81	0.69	Response to antipsychotic treatment;	chr6:85568973	chr6:85660950~85678736:-
TGCT	cis	rs2739330	0.752	rs2330634	ENSG00000218537.1	MIF-AS1	10.62	4e-19	1.1e-14	0.86	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23894426~23898930:-
TGCT	cis	rs916888	0.821	rs199504	ENSG00000214401.4	KANSL1-AS1	-10.61	4.09e-19	1.12e-14	-1.03	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46193576~46196723:+
TGCT	cis	rs1150668	0.799	rs1736891	ENSG00000216901.1	AL022393.7	10.59	4.59e-19	1.25e-14	0.75	0.69	Pubertal anthropometrics;	chr6:28219323	chr6:28176188~28176674:+
TGCT	cis	rs858239	0.539	rs10270695	ENSG00000230658.1	KLHL7-AS1	-10.57	5.18e-19	1.4e-14	-0.73	-0.69	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23101228~23105703:-
TGCT	cis	rs801193	0.66	rs2659897	ENSG00000226824.5	RP4-756H11.3	10.56	5.49e-19	1.48e-14	0.78	0.69	Aortic root size;	chr7:66722728	chr7:66654538~66669855:+
TGCT	cis	rs2882667	0.69	rs9327827	ENSG00000253404.1	AC034243.1	10.53	6.48e-19	1.73e-14	1	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846639	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.728	rs10037071	ENSG00000253404.1	AC034243.1	10.53	6.67e-19	1.78e-14	0.81	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942158	chr5:138744434~138753309:-
TGCT	cis	rs916888	0.61	rs199529	ENSG00000214401.4	KANSL1-AS1	10.52	6.81e-19	1.81e-14	1.02	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46193576~46196723:+
TGCT	cis	rs1577917	0.771	rs4351223	ENSG00000203875.9	SNHG5	10.52	6.99e-19	1.85e-14	0.85	0.69	Response to antipsychotic treatment;	chr6:85528079	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.771	rs7452605	ENSG00000203875.9	SNHG5	10.52	6.99e-19	1.85e-14	0.85	0.69	Response to antipsychotic treatment;	chr6:85531233	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.771	rs9294337	ENSG00000203875.9	SNHG5	10.52	6.99e-19	1.85e-14	0.85	0.69	Response to antipsychotic treatment;	chr6:85538742	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.74	rs6926049	ENSG00000203875.9	SNHG5	10.52	6.99e-19	1.85e-14	0.85	0.69	Response to antipsychotic treatment;	chr6:85556415	chr6:85660950~85678736:-
TGCT	cis	rs2739330	0.752	rs2330634	ENSG00000225282.1	AP000350.6	10.49	8.26e-19	2.12e-14	0.8	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23926900~23929574:+
TGCT	cis	rs858239	0.665	rs6964665	ENSG00000230658.1	KLHL7-AS1	10.48	8.47e-19	2.17e-14	0.76	0.69	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.699	rs858260	ENSG00000230658.1	KLHL7-AS1	10.48	8.47e-19	2.17e-14	0.76	0.69	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23101228~23105703:-
TGCT	cis	rs3814244	0.528	rs61923060	ENSG00000255733.4	IFNG-AS1	10.47	8.97e-19	2.28e-14	0.67	0.69	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997341	chr12:67989445~68234686:+
TGCT	cis	rs3814244	0.528	rs11177002	ENSG00000255733.4	IFNG-AS1	10.47	8.97e-19	2.28e-14	0.67	0.69	Itch intensity from mosquito bite adjusted by bite size;	chr12:68003377	chr12:67989445~68234686:+
TGCT	cis	rs3814244	0.528	rs10878723	ENSG00000255733.4	IFNG-AS1	10.47	8.97e-19	2.28e-14	0.67	0.69	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005493	chr12:67989445~68234686:+
TGCT	cis	rs3814244	0.528	rs12582272	ENSG00000255733.4	IFNG-AS1	10.47	8.97e-19	2.28e-14	0.67	0.69	Itch intensity from mosquito bite adjusted by bite size;	chr12:68006298	chr12:67989445~68234686:+
TGCT	cis	rs916888	0.61	rs199529	ENSG00000262539.1	RP11-259G18.3	10.47	9.23e-19	2.33e-14	1.13	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46259551~46260606:-
TGCT	cis	rs858239	0.511	rs10256996	ENSG00000230658.1	KLHL7-AS1	-10.47	9.28e-19	2.34e-14	-0.7	-0.68	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.539	rs6955969	ENSG00000230658.1	KLHL7-AS1	10.46	9.65e-19	2.43e-14	0.74	0.68	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.867	rs10250602	ENSG00000230658.1	KLHL7-AS1	10.46	9.8e-19	2.47e-14	0.78	0.68	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23101228~23105703:-
TGCT	cis	rs172166	0.516	rs1225710	ENSG00000216901.1	AL022393.7	-10.44	1.08e-18	2.69e-14	-0.74	-0.68	Cardiac Troponin-T levels;	chr6:28132862	chr6:28176188~28176674:+
TGCT	cis	rs2882667	0.728	rs13181830	ENSG00000253404.1	AC034243.1	-10.44	1.1e-18	2.73e-14	-0.81	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944727	chr5:138744434~138753309:-
TGCT	cis	rs3734266	0.646	rs79139175	ENSG00000186328.4	RP11-140K17.2	10.43	1.11e-18	2.76e-14	1.08	0.68	Systemic lupus erythematosus;	chr6:34601709	chr6:34715613~34715940:+
TGCT	cis	rs2882667	0.69	rs160404	ENSG00000253404.1	AC034243.1	10.42	1.21e-18	2.95e-14	0.8	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748580	chr5:138744434~138753309:-
TGCT	cis	rs1150668	0.799	rs1150705	ENSG00000216901.1	AL022393.7	10.41	1.24e-18	3.02e-14	0.74	0.68	Pubertal anthropometrics;	chr6:28226008	chr6:28176188~28176674:+
TGCT	cis	rs1150668	0.799	rs1150707	ENSG00000216901.1	AL022393.7	10.41	1.24e-18	3.02e-14	0.74	0.68	Pubertal anthropometrics;	chr6:28229827	chr6:28176188~28176674:+
TGCT	cis	rs1150668	0.768	rs1233713	ENSG00000216901.1	AL022393.7	10.41	1.24e-18	3.02e-14	0.74	0.68	Pubertal anthropometrics;	chr6:28230503	chr6:28176188~28176674:+
TGCT	cis	rs1150668	0.799	rs7206	ENSG00000216901.1	AL022393.7	10.41	1.24e-18	3.02e-14	0.74	0.68	Pubertal anthropometrics;	chr6:28233360	chr6:28176188~28176674:+
TGCT	cis	rs3814244	0.528	rs7952790	ENSG00000255733.4	IFNG-AS1	10.41	1.27e-18	3.03e-14	0.73	0.68	Itch intensity from mosquito bite adjusted by bite size;	chr12:68012672	chr12:67989445~68234686:+
TGCT	cis	rs1577917	0.771	rs4419647	ENSG00000203875.9	SNHG5	10.4	1.36e-18	3.22e-14	0.85	0.68	Response to antipsychotic treatment;	chr6:85516021	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.771	rs9353318	ENSG00000203875.9	SNHG5	10.4	1.36e-18	3.22e-14	0.85	0.68	Response to antipsychotic treatment;	chr6:85522003	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.771	rs9450290	ENSG00000203875.9	SNHG5	10.4	1.36e-18	3.22e-14	0.85	0.68	Response to antipsychotic treatment;	chr6:85523679	chr6:85660950~85678736:-
TGCT	cis	rs2283792	0.622	rs2266979	ENSG00000228050.1	TOP3BP1	10.4	1.36e-18	3.23e-14	0.79	0.68	Multiple sclerosis;	chr22:21977447	chr22:22223187~22224566:-
TGCT	cis	rs916888	0.773	rs538628	ENSG00000262539.1	RP11-259G18.3	10.4	1.38e-18	3.27e-14	1.18	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46259551~46260606:-
TGCT	cis	rs916888	0.773	rs169201	ENSG00000262539.1	RP11-259G18.3	10.4	1.38e-18	3.27e-14	1.18	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46259551~46260606:-
TGCT	cis	rs916888	0.773	rs199439	ENSG00000262539.1	RP11-259G18.3	10.4	1.38e-18	3.27e-14	1.18	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46259551~46260606:-
TGCT	cis	rs172166	0.516	rs1225618	ENSG00000216901.1	AL022393.7	10.38	1.49e-18	3.5e-14	0.74	0.68	Cardiac Troponin-T levels;	chr6:28161935	chr6:28176188~28176674:+
TGCT	cis	rs1150668	0.835	rs203869	ENSG00000216901.1	AL022393.7	10.38	1.55e-18	3.62e-14	0.73	0.68	Pubertal anthropometrics;	chr6:28073041	chr6:28176188~28176674:+
TGCT	cis	rs6538678	0.824	rs4762633	ENSG00000258343.1	RP11-536G4.2	-10.37	1.57e-18	3.66e-14	-1.17	-0.68	Lupus nephritis in systemic lupus erythematosus;	chr12:95860295	chr12:95795345~95858839:-
TGCT	cis	rs1577917	0.696	rs10806334	ENSG00000203875.9	SNHG5	-10.37	1.57e-18	3.66e-14	-0.81	-0.68	Response to antipsychotic treatment;	chr6:85729611	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.839	rs9450333	ENSG00000203875.9	SNHG5	-10.37	1.61e-18	3.74e-14	-0.82	-0.68	Response to antipsychotic treatment;	chr6:85810037	chr6:85660950~85678736:-
TGCT	cis	rs875971	1	rs4718307	ENSG00000226824.5	RP4-756H11.3	10.37	1.61e-18	3.75e-14	0.76	0.68	Aortic root size;	chr7:66146001	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs7801282	ENSG00000226824.5	RP4-756H11.3	10.37	1.61e-18	3.75e-14	0.76	0.68	Aortic root size;	chr7:66148700	chr7:66654538~66669855:+
TGCT	cis	rs3814244	0.528	rs56393928	ENSG00000255733.4	IFNG-AS1	10.37	1.63e-18	3.79e-14	0.69	0.68	Itch intensity from mosquito bite adjusted by bite size;	chr12:68029927	chr12:67989445~68234686:+
TGCT	cis	rs916888	0.773	rs1378358	ENSG00000262539.1	RP11-259G18.3	10.36	1.65e-18	3.82e-14	1.18	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46259551~46260606:-
TGCT	cis	rs6538678	0.824	rs7307510	ENSG00000258343.1	RP11-536G4.2	-10.36	1.7e-18	3.91e-14	-1.23	-0.68	Lupus nephritis in systemic lupus erythematosus;	chr12:95843792	chr12:95795345~95858839:-
TGCT	cis	rs2283792	0.622	rs381523	ENSG00000228050.1	TOP3BP1	10.36	1.73e-18	3.97e-14	0.79	0.68	Multiple sclerosis;	chr22:21951257	chr22:22223187~22224566:-
TGCT	cis	rs172166	0.585	rs149963	ENSG00000216901.1	AL022393.7	10.35	1.81e-18	4.16e-14	0.73	0.68	Cardiac Troponin-T levels;	chr6:28049354	chr6:28176188~28176674:+
TGCT	cis	rs2487048	0.725	rs2246293	ENSG00000226334.1	RP11-217B7.2	10.34	1.89e-18	4.32e-14	0.7	0.68	Intraocular pressure;	chr9:104928557	chr9:104927553~104928892:+
TGCT	cis	rs1577917	0.682	rs6935918	ENSG00000203875.9	SNHG5	10.32	2.09e-18	4.76e-14	0.81	0.68	Response to antipsychotic treatment;	chr6:85573857	chr6:85660950~85678736:-
TGCT	cis	rs2487048	0.725	rs2422493	ENSG00000226334.1	RP11-217B7.2	-10.32	2.14e-18	4.87e-14	-0.69	-0.68	Intraocular pressure;	chr9:104928714	chr9:104927553~104928892:+
TGCT	cis	rs172166	0.561	rs149971	ENSG00000216901.1	AL022393.7	10.31	2.28e-18	5.18e-14	0.76	0.68	Cardiac Troponin-T levels;	chr6:28014374	chr6:28176188~28176674:+
TGCT	cis	rs875971	1	rs11974219	ENSG00000226824.5	RP4-756H11.3	10.31	2.29e-18	5.18e-14	0.76	0.68	Aortic root size;	chr7:66182423	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs11974264	ENSG00000226824.5	RP4-756H11.3	10.31	2.29e-18	5.18e-14	0.76	0.68	Aortic root size;	chr7:66182595	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs1540651	ENSG00000226824.5	RP4-756H11.3	10.31	2.29e-18	5.18e-14	0.76	0.68	Aortic root size;	chr7:66185134	chr7:66654538~66669855:+
TGCT	cis	rs858239	0.509	rs6962213	ENSG00000230658.1	KLHL7-AS1	10.29	2.5e-18	5.63e-14	0.72	0.68	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23101228~23105703:-
TGCT	cis	rs172166	0.538	rs149956	ENSG00000216901.1	AL022393.7	10.29	2.52e-18	5.67e-14	0.73	0.68	Cardiac Troponin-T levels;	chr6:28068473	chr6:28176188~28176674:+
TGCT	cis	rs1150668	0.768	rs1150716	ENSG00000216901.1	AL022393.7	10.28	2.58e-18	5.8e-14	0.72	0.68	Pubertal anthropometrics;	chr6:28294921	chr6:28176188~28176674:+
TGCT	cis	rs1150668	0.799	rs2142730	ENSG00000216901.1	AL022393.7	10.28	2.58e-18	5.8e-14	0.72	0.68	Pubertal anthropometrics;	chr6:28298372	chr6:28176188~28176674:+
TGCT	cis	rs2283792	0.542	rs9610500	ENSG00000228050.1	TOP3BP1	10.28	2.62e-18	5.86e-14	0.77	0.68	Multiple sclerosis;	chr22:21866877	chr22:22223187~22224566:-
TGCT	cis	rs916888	0.773	rs538628	ENSG00000214401.4	KANSL1-AS1	10.28	2.66e-18	5.91e-14	1.06	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46193576~46196723:+
TGCT	cis	rs916888	0.773	rs169201	ENSG00000214401.4	KANSL1-AS1	10.28	2.66e-18	5.91e-14	1.06	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46193576~46196723:+
TGCT	cis	rs916888	0.773	rs199439	ENSG00000214401.4	KANSL1-AS1	10.28	2.66e-18	5.91e-14	1.06	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46193576~46196723:+
TGCT	cis	rs801193	0.591	rs2707839	ENSG00000226824.5	RP4-756H11.3	-10.27	2.76e-18	6.15e-14	-0.77	-0.68	Aortic root size;	chr7:66728097	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs55962648	ENSG00000226824.5	RP4-756H11.3	10.26	2.88e-18	6.38e-14	0.76	0.68	Aortic root size;	chr7:66160764	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs11971949	ENSG00000226824.5	RP4-756H11.3	10.26	2.88e-18	6.38e-14	0.76	0.68	Aortic root size;	chr7:66161027	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs2420168	ENSG00000226824.5	RP4-756H11.3	10.26	2.88e-18	6.38e-14	0.76	0.68	Aortic root size;	chr7:66165644	chr7:66654538~66669855:+
TGCT	cis	rs11098499	0.866	rs12501602	ENSG00000245958.5	RP11-33B1.1	-10.25	3.07e-18	6.77e-14	-0.7	-0.68	Corneal astigmatism;	chr4:119366780	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.691	rs17009144	ENSG00000245958.5	RP11-33B1.1	10.25	3.08e-18	6.77e-14	0.67	0.68	Corneal astigmatism;	chr4:119349640	chr4:119454791~119552025:+
TGCT	cis	rs916888	0.773	rs1378358	ENSG00000214401.4	KANSL1-AS1	10.25	3.19e-18	7.01e-14	1.06	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46193576~46196723:+
TGCT	cis	rs1577917	0.682	rs1173419	ENSG00000203875.9	SNHG5	-10.25	3.19e-18	7.02e-14	-0.8	-0.68	Response to antipsychotic treatment;	chr6:85692445	chr6:85660950~85678736:-
TGCT	cis	rs3814244	0.528	rs2870960	ENSG00000255733.4	IFNG-AS1	10.24	3.28e-18	7.19e-14	0.68	0.68	Itch intensity from mosquito bite adjusted by bite size;	chr12:68032848	chr12:67989445~68234686:+
TGCT	cis	rs801193	0.66	rs2659914	ENSG00000226824.5	RP4-756H11.3	-10.23	3.43e-18	7.5e-14	-0.77	-0.68	Aortic root size;	chr7:66691927	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.636	rs2659895	ENSG00000226824.5	RP4-756H11.3	-10.23	3.43e-18	7.5e-14	-0.77	-0.68	Aortic root size;	chr7:66731484	chr7:66654538~66669855:+
TGCT	cis	rs858239	0.669	rs1006709	ENSG00000230658.1	KLHL7-AS1	10.23	3.44e-18	7.52e-14	0.71	0.68	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23101228~23105703:-
TGCT	cis	rs875971	1	rs1544549	ENSG00000226824.5	RP4-756H11.3	10.22	3.67e-18	7.96e-14	0.76	0.68	Aortic root size;	chr7:66625676	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs2420820	ENSG00000226824.5	RP4-756H11.3	10.22	3.67e-18	7.96e-14	0.76	0.68	Aortic root size;	chr7:66626920	chr7:66654538~66669855:+
TGCT	cis	rs2739330	0.734	rs2000467	ENSG00000273295.1	AP000350.5	-10.22	3.68e-18	7.97e-14	-0.84	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23901432~23907068:-
TGCT	cis	rs11098499	0.564	rs11098507	ENSG00000245958.5	RP11-33B1.1	-10.21	3.82e-18	8.22e-14	-0.69	-0.68	Corneal astigmatism;	chr4:119367131	chr4:119454791~119552025:+
TGCT	cis	rs3734266	0.702	rs205264	ENSG00000186328.4	RP11-140K17.2	10.21	3.82e-18	8.22e-14	1.1	0.68	Systemic lupus erythematosus;	chr6:34594419	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs205263	ENSG00000186328.4	RP11-140K17.2	10.21	3.82e-18	8.22e-14	1.1	0.68	Systemic lupus erythematosus;	chr6:34594746	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs205261	ENSG00000186328.4	RP11-140K17.2	10.21	3.82e-18	8.22e-14	1.1	0.68	Systemic lupus erythematosus;	chr6:34596110	chr6:34715613~34715940:+
TGCT	cis	rs801193	0.613	rs2659900	ENSG00000226824.5	RP4-756H11.3	-10.21	3.87e-18	8.32e-14	-0.77	-0.68	Aortic root size;	chr7:66719456	chr7:66654538~66669855:+
TGCT	cis	rs1577917	0.538	rs6454483	ENSG00000203875.9	SNHG5	10.21	3.96e-18	8.48e-14	0.8	0.68	Response to antipsychotic treatment;	chr6:85708565	chr6:85660950~85678736:-
TGCT	cis	rs2882667	0.69	rs17031	ENSG00000253404.1	AC034243.1	10.2	4.1e-18	8.76e-14	0.82	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138934853	chr5:138744434~138753309:-
TGCT	cis	rs7847628	0.587	rs4837796	ENSG00000226752.6	PSMD5-AS1	10.2	4.14e-18	8.85e-14	0.8	0.68	Birth weight;	chr9:120848010	chr9:120824828~120854385:+
TGCT	cis	rs3734266	0.646	rs205266	ENSG00000186328.4	RP11-140K17.2	10.2	4.2e-18	8.95e-14	1.11	0.68	Systemic lupus erythematosus;	chr6:34592516	chr6:34715613~34715940:+
TGCT	cis	rs2283792	0.622	rs239917	ENSG00000228050.1	TOP3BP1	10.19	4.45e-18	9.48e-14	0.78	0.67	Multiple sclerosis;	chr22:21960091	chr22:22223187~22224566:-
TGCT	cis	rs1577917	0.71	rs9342041	ENSG00000203875.9	SNHG5	10.18	4.51e-18	9.58e-14	0.81	0.67	Response to antipsychotic treatment;	chr6:85571157	chr6:85660950~85678736:-
TGCT	cis	rs7188445	0.556	rs7203910	ENSG00000261390.4	RP11-345M22.2	-10.18	4.57e-18	9.71e-14	-0.67	-0.67	Urate levels;	chr16:79711722	chr16:79715232~79770563:-
TGCT	cis	rs1150668	0.699	rs2394049	ENSG00000216901.1	AL022393.7	10.18	4.57e-18	9.71e-14	0.73	0.67	Pubertal anthropometrics;	chr6:28271903	chr6:28176188~28176674:+
TGCT	cis	rs2882667	0.69	rs10071381	ENSG00000253404.1	AC034243.1	10.18	4.6e-18	9.76e-14	0.8	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937159	chr5:138744434~138753309:-
TGCT	cis	rs2487048	0.761	rs1800976	ENSG00000226334.1	RP11-217B7.2	-10.18	4.64e-18	9.83e-14	-0.69	-0.67	Intraocular pressure;	chr9:104928428	chr9:104927553~104928892:+
TGCT	cis	rs7188445	0.615	rs4340340	ENSG00000261390.4	RP11-345M22.2	-10.18	4.66e-18	9.89e-14	-0.66	-0.67	Urate levels;	chr16:79716720	chr16:79715232~79770563:-
TGCT	cis	rs858239	0.539	rs6965833	ENSG00000230658.1	KLHL7-AS1	10.17	4.97e-18	1.05e-13	0.74	0.67	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.539	rs6949363	ENSG00000230658.1	KLHL7-AS1	10.17	4.97e-18	1.05e-13	0.74	0.67	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23101228~23105703:-
TGCT	cis	rs3734266	0.702	rs9469814	ENSG00000186328.4	RP11-140K17.2	-10.17	4.99e-18	1.05e-13	-1.07	-0.67	Systemic lupus erythematosus;	chr6:34603868	chr6:34715613~34715940:+
TGCT	cis	rs4713118	0.505	rs156740	ENSG00000216901.1	AL022393.7	10.16	5.21e-18	1.09e-13	0.73	0.67	Parkinson's disease;	chr6:27992657	chr6:28176188~28176674:+
TGCT	cis	rs801193	0.66	rs974239	ENSG00000226824.5	RP4-756H11.3	-10.15	5.33e-18	1.11e-13	-0.77	-0.67	Aortic root size;	chr7:66748504	chr7:66654538~66669855:+
TGCT	cis	rs858239	0.571	rs2390755	ENSG00000230658.1	KLHL7-AS1	10.15	5.47e-18	1.13e-13	0.74	0.67	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.539	rs4365988	ENSG00000230658.1	KLHL7-AS1	10.15	5.47e-18	1.13e-13	0.74	0.67	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.539	rs4295546	ENSG00000230658.1	KLHL7-AS1	10.15	5.47e-18	1.13e-13	0.74	0.67	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.539	rs10279194	ENSG00000230658.1	KLHL7-AS1	10.15	5.47e-18	1.13e-13	0.74	0.67	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.539	rs3950345	ENSG00000230658.1	KLHL7-AS1	10.15	5.47e-18	1.13e-13	0.74	0.67	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.539	rs2178140	ENSG00000230658.1	KLHL7-AS1	10.15	5.47e-18	1.13e-13	0.74	0.67	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.539	rs2178139	ENSG00000230658.1	KLHL7-AS1	10.15	5.47e-18	1.13e-13	0.74	0.67	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.539	rs2141306	ENSG00000230658.1	KLHL7-AS1	10.15	5.47e-18	1.13e-13	0.74	0.67	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.539	rs2141305	ENSG00000230658.1	KLHL7-AS1	10.15	5.47e-18	1.13e-13	0.74	0.67	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23101228~23105703:-
TGCT	cis	rs1150668	0.83	rs2023493	ENSG00000216901.1	AL022393.7	10.14	5.72e-18	1.18e-13	0.74	0.67	Pubertal anthropometrics;	chr6:28432385	chr6:28176188~28176674:+
TGCT	cis	rs7188445	0.556	rs7194711	ENSG00000261390.4	RP11-345M22.2	-10.13	6.11e-18	1.25e-13	-0.66	-0.67	Urate levels;	chr16:79715134	chr16:79715232~79770563:-
TGCT	cis	rs2882667	0.69	rs288022	ENSG00000253404.1	AC034243.1	10.13	6.27e-18	1.29e-13	0.78	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888586	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.598	rs288020	ENSG00000253404.1	AC034243.1	10.13	6.27e-18	1.29e-13	0.78	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888609	chr5:138744434~138753309:-
TGCT	cis	rs875971	0.66	rs801193	ENSG00000226824.5	RP4-756H11.3	10.11	6.84e-18	1.4e-13	0.79	0.67	Aortic root size;	chr7:66565625	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs2659909	ENSG00000226824.5	RP4-756H11.3	-10.11	6.89e-18	1.41e-13	-0.76	-0.67	Aortic root size;	chr7:66695292	chr7:66654538~66669855:+
TGCT	cis	rs172166	0.561	rs149973	ENSG00000216901.1	AL022393.7	10.11	6.97e-18	1.42e-13	0.74	0.67	Cardiac Troponin-T levels;	chr6:28015835	chr6:28176188~28176674:+
TGCT	cis	rs172166	0.561	rs149974	ENSG00000216901.1	AL022393.7	10.11	6.97e-18	1.42e-13	0.74	0.67	Cardiac Troponin-T levels;	chr6:28017318	chr6:28176188~28176674:+
TGCT	cis	rs801193	1	rs2420824	ENSG00000226824.5	RP4-756H11.3	10.1	7.03e-18	1.43e-13	0.76	0.67	Aortic root size;	chr7:66666129	chr7:66654538~66669855:+
TGCT	cis	rs172166	0.516	rs2622322	ENSG00000216901.1	AL022393.7	10.1	7.14e-18	1.45e-13	0.72	0.67	Cardiac Troponin-T levels;	chr6:28149665	chr6:28176188~28176674:+
TGCT	cis	rs858239	0.539	rs6945510	ENSG00000230658.1	KLHL7-AS1	10.09	7.48e-18	1.51e-13	0.74	0.67	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23101228~23105703:-
TGCT	cis	rs3734266	0.702	rs115531193	ENSG00000186328.4	RP11-140K17.2	10.09	7.49e-18	1.51e-13	1.03	0.67	Systemic lupus erythematosus;	chr6:34683534	chr6:34715613~34715940:+
TGCT	cis	rs1577917	0.739	rs6922	ENSG00000203875.9	SNHG5	10.09	7.79e-18	1.57e-13	0.83	0.67	Response to antipsychotic treatment;	chr6:85495605	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.666	rs6454471	ENSG00000203875.9	SNHG5	10.09	7.79e-18	1.57e-13	0.83	0.67	Response to antipsychotic treatment;	chr6:85504738	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.665	rs4304137	ENSG00000203875.9	SNHG5	10.09	7.79e-18	1.57e-13	0.83	0.67	Response to antipsychotic treatment;	chr6:85507730	chr6:85660950~85678736:-
TGCT	cis	rs2739330	0.652	rs2000469	ENSG00000273295.1	AP000350.5	10.08	7.93e-18	1.59e-13	0.81	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23901432~23907068:-
TGCT	cis	rs3734266	0.702	rs7764921	ENSG00000186328.4	RP11-140K17.2	10.08	7.99e-18	1.59e-13	1.02	0.67	Systemic lupus erythematosus;	chr6:34636558	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs9461994	ENSG00000186328.4	RP11-140K17.2	10.08	7.99e-18	1.59e-13	1.02	0.67	Systemic lupus erythematosus;	chr6:34643408	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs6909637	ENSG00000186328.4	RP11-140K17.2	10.08	7.99e-18	1.59e-13	1.02	0.67	Systemic lupus erythematosus;	chr6:34645853	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs9469837	ENSG00000186328.4	RP11-140K17.2	10.08	7.99e-18	1.59e-13	1.02	0.67	Systemic lupus erythematosus;	chr6:34647755	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs6937428	ENSG00000186328.4	RP11-140K17.2	10.08	7.99e-18	1.59e-13	1.02	0.67	Systemic lupus erythematosus;	chr6:34662468	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs7765969	ENSG00000186328.4	RP11-140K17.2	10.08	7.99e-18	1.59e-13	1.02	0.67	Systemic lupus erythematosus;	chr6:34667078	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs35286877	ENSG00000186328.4	RP11-140K17.2	10.08	7.99e-18	1.59e-13	1.02	0.67	Systemic lupus erythematosus;	chr6:34673301	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs35987776	ENSG00000186328.4	RP11-140K17.2	10.08	7.99e-18	1.59e-13	1.02	0.67	Systemic lupus erythematosus;	chr6:34673447	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.639	rs9469842	ENSG00000186328.4	RP11-140K17.2	10.08	7.99e-18	1.59e-13	1.02	0.67	Systemic lupus erythematosus;	chr6:34676304	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs9462002	ENSG00000186328.4	RP11-140K17.2	10.08	7.99e-18	1.59e-13	1.02	0.67	Systemic lupus erythematosus;	chr6:34691457	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs9462003	ENSG00000186328.4	RP11-140K17.2	10.08	7.99e-18	1.59e-13	1.02	0.67	Systemic lupus erythematosus;	chr6:34692161	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs72910111	ENSG00000186328.4	RP11-140K17.2	10.08	7.99e-18	1.59e-13	1.02	0.67	Systemic lupus erythematosus;	chr6:34699627	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs7759985	ENSG00000186328.4	RP11-140K17.2	10.08	7.99e-18	1.59e-13	1.02	0.67	Systemic lupus erythematosus;	chr6:34703009	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs6909393	ENSG00000186328.4	RP11-140K17.2	10.08	7.99e-18	1.59e-13	1.02	0.67	Systemic lupus erythematosus;	chr6:34705719	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.591	rs7749750	ENSG00000186328.4	RP11-140K17.2	10.08	7.99e-18	1.59e-13	1.02	0.67	Systemic lupus erythematosus;	chr6:34709268	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs9469852	ENSG00000186328.4	RP11-140K17.2	10.08	7.99e-18	1.59e-13	1.02	0.67	Systemic lupus erythematosus;	chr6:34709999	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs9469836	ENSG00000186328.4	RP11-140K17.2	-10.08	7.99e-18	1.59e-13	-1.02	-0.67	Systemic lupus erythematosus;	chr6:34647002	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs6900426	ENSG00000186328.4	RP11-140K17.2	-10.08	7.99e-18	1.59e-13	-1.02	-0.67	Systemic lupus erythematosus;	chr6:34656371	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs6908462	ENSG00000186328.4	RP11-140K17.2	-10.08	7.99e-18	1.59e-13	-1.02	-0.67	Systemic lupus erythematosus;	chr6:34705372	chr6:34715613~34715940:+
TGCT	cis	rs11098499	0.691	rs10028773	ENSG00000245958.5	RP11-33B1.1	10.08	8.29e-18	1.64e-13	0.67	0.67	Corneal astigmatism;	chr4:119344104	chr4:119454791~119552025:+
TGCT	cis	rs875971	1	rs3981131	ENSG00000226824.5	RP4-756H11.3	-10.07	8.41e-18	1.66e-13	-0.73	-0.67	Aortic root size;	chr7:66486690	chr7:66654538~66669855:+
TGCT	cis	rs7188445	0.592	rs17767281	ENSG00000261390.4	RP11-345M22.2	-10.07	8.43e-18	1.66e-13	-0.65	-0.67	Urate levels;	chr16:79708544	chr16:79715232~79770563:-
TGCT	cis	rs875971	1	rs2077593	ENSG00000226824.5	RP4-756H11.3	-10.06	8.9e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66427543	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs4717292	ENSG00000226824.5	RP4-756H11.3	-10.06	8.9e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66430611	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs2420591	ENSG00000226824.5	RP4-756H11.3	-10.06	8.9e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66447394	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.895	rs10755833	ENSG00000226824.5	RP4-756H11.3	-10.06	8.9e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66448930	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.964	rs12668936	ENSG00000226824.5	RP4-756H11.3	-10.06	8.9e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66449417	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.895	rs7788984	ENSG00000226824.5	RP4-756H11.3	-10.06	8.9e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66450629	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.895	rs1833495	ENSG00000226824.5	RP4-756H11.3	-10.06	8.9e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66456608	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.964	rs6945019	ENSG00000226824.5	RP4-756H11.3	-10.06	8.9e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66457471	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.964	rs6945032	ENSG00000226824.5	RP4-756H11.3	-10.06	8.9e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66457499	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.929	rs12673810	ENSG00000226824.5	RP4-756H11.3	-10.06	8.9e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66458866	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs35149210	ENSG00000226824.5	RP4-756H11.3	-10.06	8.9e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66464938	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.929	rs34406470	ENSG00000226824.5	RP4-756H11.3	-10.06	8.9e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66464969	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs6961155	ENSG00000226824.5	RP4-756H11.3	-10.06	8.9e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66468308	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs7789768	ENSG00000226824.5	RP4-756H11.3	-10.06	8.9e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66473993	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs1363055	ENSG00000226824.5	RP4-756H11.3	-10.06	8.9e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66478288	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.964	rs9691480	ENSG00000226824.5	RP4-756H11.3	-10.06	8.9e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66479319	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs7789554	ENSG00000226824.5	RP4-756H11.3	-10.06	8.9e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66481051	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs4717300	ENSG00000226824.5	RP4-756H11.3	-10.06	8.9e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66482393	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.895	rs1974769	ENSG00000226824.5	RP4-756H11.3	-10.06	8.9e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66485627	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.895	rs6460300	ENSG00000226824.5	RP4-756H11.3	-10.06	8.9e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66487937	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs7803416	ENSG00000226824.5	RP4-756H11.3	-10.06	8.9e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66489212	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs1981798	ENSG00000226824.5	RP4-756H11.3	-10.06	8.9e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66489916	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs1981799	ENSG00000226824.5	RP4-756H11.3	-10.06	8.9e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66490572	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.964	rs2277911	ENSG00000226824.5	RP4-756H11.3	-10.06	8.9e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66493638	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.964	rs1643388	ENSG00000226824.5	RP4-756H11.3	-10.06	8.92e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66379575	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs778722	ENSG00000226824.5	RP4-756H11.3	-10.06	8.92e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66379841	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.964	rs778721	ENSG00000226824.5	RP4-756H11.3	-10.06	8.92e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66380410	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs778706	ENSG00000226824.5	RP4-756H11.3	-10.06	8.92e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66395437	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.895	rs778700	ENSG00000226824.5	RP4-756H11.3	-10.06	8.92e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66401463	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs778699	ENSG00000226824.5	RP4-756H11.3	-10.06	8.92e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66403303	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.929	rs778692	ENSG00000226824.5	RP4-756H11.3	-10.06	8.92e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66407462	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs4718343	ENSG00000226824.5	RP4-756H11.3	-10.06	8.92e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66409301	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs1968225	ENSG00000226824.5	RP4-756H11.3	-10.06	8.92e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66409786	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs6460295	ENSG00000226824.5	RP4-756H11.3	-10.06	8.92e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66417741	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.964	rs6978721	ENSG00000226824.5	RP4-756H11.3	-10.06	8.92e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66418217	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs6979382	ENSG00000226824.5	RP4-756H11.3	-10.06	8.92e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66421388	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs6961990	ENSG00000226824.5	RP4-756H11.3	-10.06	8.92e-18	1.72e-13	-0.75	-0.67	Aortic root size;	chr7:66423583	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs7782320	ENSG00000226824.5	RP4-756H11.3	-10.06	9.07e-18	1.75e-13	-0.77	-0.67	Aortic root size;	chr7:66712111	chr7:66654538~66669855:+
TGCT	cis	rs858239	0.508	rs2390754	ENSG00000230658.1	KLHL7-AS1	10.05	9.43e-18	1.81e-13	0.75	0.67	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23101228~23105703:-
TGCT	cis	rs1150668	0.799	rs9301	ENSG00000216901.1	AL022393.7	10.05	9.53e-18	1.82e-13	0.72	0.67	Pubertal anthropometrics;	chr6:28324929	chr6:28176188~28176674:+
TGCT	cis	rs1150668	0.799	rs853684	ENSG00000216901.1	AL022393.7	10.05	9.53e-18	1.82e-13	0.72	0.67	Pubertal anthropometrics;	chr6:28326773	chr6:28176188~28176674:+
TGCT	cis	rs875971	0.964	rs6978429	ENSG00000226824.5	RP4-756H11.3	-10.05	9.54e-18	1.82e-13	-0.75	-0.67	Aortic root size;	chr7:66494889	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.929	rs12535036	ENSG00000226824.5	RP4-756H11.3	-10.05	9.54e-18	1.82e-13	-0.75	-0.67	Aortic root size;	chr7:66499076	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs12532998	ENSG00000226824.5	RP4-756H11.3	-10.05	9.54e-18	1.82e-13	-0.75	-0.67	Aortic root size;	chr7:66502472	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs12698523	ENSG00000226824.5	RP4-756H11.3	-10.05	9.54e-18	1.82e-13	-0.75	-0.67	Aortic root size;	chr7:66503126	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs6970030	ENSG00000226824.5	RP4-756H11.3	-10.05	9.54e-18	1.82e-13	-0.75	-0.67	Aortic root size;	chr7:66503692	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.928	rs6970357	ENSG00000226824.5	RP4-756H11.3	-10.05	9.54e-18	1.82e-13	-0.75	-0.67	Aortic root size;	chr7:66503891	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs3735148	ENSG00000226824.5	RP4-756H11.3	-10.05	9.54e-18	1.82e-13	-0.75	-0.67	Aortic root size;	chr7:66506022	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.929	rs6970860	ENSG00000226824.5	RP4-756H11.3	-10.05	9.54e-18	1.82e-13	-0.75	-0.67	Aortic root size;	chr7:66511647	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs6957199	ENSG00000226824.5	RP4-756H11.3	-10.05	9.54e-18	1.82e-13	-0.75	-0.67	Aortic root size;	chr7:66513532	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs6958271	ENSG00000226824.5	RP4-756H11.3	-10.05	9.54e-18	1.82e-13	-0.75	-0.67	Aortic root size;	chr7:66514344	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs6958277	ENSG00000226824.5	RP4-756H11.3	-10.05	9.54e-18	1.82e-13	-0.75	-0.67	Aortic root size;	chr7:66514362	chr7:66654538~66669855:+
TGCT	cis	rs2739330	0.76	rs5751761	ENSG00000273295.1	AP000350.5	-10.05	9.57e-18	1.82e-13	-0.73	-0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23901432~23907068:-
TGCT	cis	rs875971	0.895	rs12698520	ENSG00000226824.5	RP4-756H11.3	-10.05	9.58e-18	1.83e-13	-0.75	-0.67	Aortic root size;	chr7:66453720	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.967	rs2707841	ENSG00000226824.5	RP4-756H11.3	-10.05	9.72e-18	1.85e-13	-0.77	-0.67	Aortic root size;	chr7:66692033	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs4717310	ENSG00000226824.5	RP4-756H11.3	-10.05	9.72e-18	1.85e-13	-0.77	-0.67	Aortic root size;	chr7:66696020	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs7785213	ENSG00000226824.5	RP4-756H11.3	10.05	9.72e-18	1.85e-13	0.77	0.67	Aortic root size;	chr7:66673991	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.935	rs3800820	ENSG00000226824.5	RP4-756H11.3	10.05	9.72e-18	1.85e-13	0.77	0.67	Aortic root size;	chr7:66682191	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs2003301	ENSG00000226824.5	RP4-756H11.3	10.05	9.72e-18	1.85e-13	0.77	0.67	Aortic root size;	chr7:66682669	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.83	rs4718358	ENSG00000226824.5	RP4-756H11.3	-10.04	1e-17	1.9e-13	-0.75	-0.67	Aortic root size;	chr7:66508681	chr7:66654538~66669855:+
TGCT	cis	rs2739330	0.76	rs5751760	ENSG00000273295.1	AP000350.5	10.04	1.02e-17	1.93e-13	0.73	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23901432~23907068:-
TGCT	cis	rs1577917	0.771	rs3812133	ENSG00000203875.9	SNHG5	-10.03	1.04e-17	1.97e-13	-0.85	-0.67	Response to antipsychotic treatment;	chr6:85644693	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.682	rs1173417	ENSG00000203875.9	SNHG5	10.02	1.1e-17	2.08e-13	0.79	0.67	Response to antipsychotic treatment;	chr6:85694223	chr6:85660950~85678736:-
TGCT	cis	rs3734266	0.702	rs13196983	ENSG00000186328.4	RP11-140K17.2	10.02	1.12e-17	2.1e-13	1.02	0.67	Systemic lupus erythematosus;	chr6:34712698	chr6:34715613~34715940:+
TGCT	cis	rs2739330	0.76	rs1002286	ENSG00000273295.1	AP000350.5	-10.02	1.15e-17	2.1e-13	-0.73	-0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23901432~23907068:-
TGCT	cis	rs847845	0.535	rs72892238	ENSG00000186328.4	RP11-140K17.2	10.01	1.2e-17	2.2e-13	1.21	0.67	Non-small cell lung cancer;	chr6:34755359	chr6:34715613~34715940:+
TGCT	cis	rs875971	0.66	rs10272357	ENSG00000226824.5	RP4-756H11.3	10.01	1.2e-17	2.2e-13	0.77	0.67	Aortic root size;	chr7:66598087	chr7:66654538~66669855:+
TGCT	cis	rs1155848	0.892	rs3759438	ENSG00000227354.5	RBM26-AS1	10	1.25e-17	2.28e-13	1.06	0.67	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79566863	chr13:79406309~79424328:+
TGCT	cis	rs875971	1	rs6956179	ENSG00000226824.5	RP4-756H11.3	10	1.26e-17	2.3e-13	0.74	0.67	Aortic root size;	chr7:66341672	chr7:66654538~66669855:+
TGCT	cis	rs858239	0.539	rs2103281	ENSG00000230658.1	KLHL7-AS1	10	1.27e-17	2.33e-13	0.75	0.67	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23101228~23105703:-
TGCT	cis	rs875971	0.929	rs4122249	ENSG00000226824.5	RP4-756H11.3	-10	1.29e-17	2.35e-13	-0.75	-0.67	Aortic root size;	chr7:66455949	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs10234018	ENSG00000226824.5	RP4-756H11.3	10	1.3e-17	2.36e-13	0.77	0.67	Aortic root size;	chr7:66681297	chr7:66654538~66669855:+
TGCT	cis	rs858239	0.539	rs2390757	ENSG00000230658.1	KLHL7-AS1	9.99	1.36e-17	2.46e-13	0.75	0.67	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23101228~23105703:-
TGCT	cis	rs875971	0.66	rs2013222	ENSG00000226824.5	RP4-756H11.3	9.98	1.41e-17	2.54e-13	0.76	0.67	Aortic root size;	chr7:66570949	chr7:66654538~66669855:+
TGCT	cis	rs1150668	0.796	rs2531832	ENSG00000216901.1	AL022393.7	9.98	1.44e-17	2.59e-13	0.72	0.67	Pubertal anthropometrics;	chr6:28421445	chr6:28176188~28176674:+
TGCT	cis	rs2882667	0.69	rs11750163	ENSG00000253404.1	AC034243.1	9.97	1.47e-17	2.64e-13	0.74	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138705920	chr5:138744434~138753309:-
TGCT	cis	rs1150668	0.796	rs1124132	ENSG00000216901.1	AL022393.7	9.97	1.49e-17	2.67e-13	0.72	0.67	Pubertal anthropometrics;	chr6:28412544	chr6:28176188~28176674:+
TGCT	cis	rs875971	1	rs7792762	ENSG00000226824.5	RP4-756H11.3	-9.96	1.56e-17	2.78e-13	-0.74	-0.67	Aortic root size;	chr7:66539151	chr7:66654538~66669855:+
TGCT	cis	rs4713118	0.505	rs276371	ENSG00000216901.1	AL022393.7	9.96	1.56e-17	2.79e-13	0.72	0.67	Parkinson's disease;	chr6:27942930	chr6:28176188~28176674:+
TGCT	cis	rs2882667	0.728	rs10068766	ENSG00000253404.1	AC034243.1	9.96	1.61e-17	2.87e-13	0.83	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941095	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.728	rs7722413	ENSG00000253404.1	AC034243.1	9.95	1.68e-17	2.98e-13	0.8	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942562	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs825672	ENSG00000253404.1	AC034243.1	-9.95	1.71e-17	3.01e-13	-0.81	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759954	chr5:138744434~138753309:-
TGCT	cis	rs3734266	0.639	rs6914714	ENSG00000186328.4	RP11-140K17.2	9.95	1.71e-17	3.01e-13	1.02	0.67	Systemic lupus erythematosus;	chr6:34676442	chr6:34715613~34715940:+
TGCT	cis	rs875971	1	rs10215948	ENSG00000226824.5	RP4-756H11.3	9.95	1.72e-17	3.01e-13	0.76	0.67	Aortic root size;	chr7:66282799	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.838	rs2173570	ENSG00000226824.5	RP4-756H11.3	9.95	1.72e-17	3.01e-13	0.76	0.67	Aortic root size;	chr7:66297976	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.964	rs55748098	ENSG00000226824.5	RP4-756H11.3	9.95	1.72e-17	3.01e-13	0.76	0.67	Aortic root size;	chr7:66298631	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs6945843	ENSG00000226824.5	RP4-756H11.3	9.93	1.87e-17	3.24e-13	0.76	0.67	Aortic root size;	chr7:66269796	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.965	rs10267430	ENSG00000226824.5	RP4-756H11.3	9.93	1.87e-17	3.24e-13	0.76	0.67	Aortic root size;	chr7:66278036	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs10257427	ENSG00000226824.5	RP4-756H11.3	9.93	1.87e-17	3.24e-13	0.76	0.67	Aortic root size;	chr7:66278221	chr7:66654538~66669855:+
TGCT	cis	rs11098499	0.554	rs2175381	ENSG00000245958.5	RP11-33B1.1	-9.93	1.9e-17	3.28e-13	-0.66	-0.67	Corneal astigmatism;	chr4:119344812	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.599	rs3864142	ENSG00000245958.5	RP11-33B1.1	-9.93	1.9e-17	3.28e-13	-0.66	-0.67	Corneal astigmatism;	chr4:119345036	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.605	rs6833140	ENSG00000245958.5	RP11-33B1.1	-9.93	1.9e-17	3.28e-13	-0.66	-0.67	Corneal astigmatism;	chr4:119345667	chr4:119454791~119552025:+
TGCT	cis	rs875971	1	rs6961717	ENSG00000226824.5	RP4-756H11.3	9.93	1.9e-17	3.28e-13	0.74	0.67	Aortic root size;	chr7:66122550	chr7:66654538~66669855:+
TGCT	cis	rs2882667	0.69	rs288040	ENSG00000253404.1	AC034243.1	9.92	1.92e-17	3.29e-13	0.81	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138869205	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.659	rs288037	ENSG00000253404.1	AC034243.1	9.92	1.92e-17	3.29e-13	0.81	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138872752	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs288036	ENSG00000253404.1	AC034243.1	9.92	1.92e-17	3.29e-13	0.81	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138875206	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs288035	ENSG00000253404.1	AC034243.1	9.92	1.92e-17	3.29e-13	0.81	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138876728	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs288032	ENSG00000253404.1	AC034243.1	9.92	1.92e-17	3.29e-13	0.81	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138879639	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs288026	ENSG00000253404.1	AC034243.1	9.92	1.92e-17	3.29e-13	0.81	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886905	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs288024	ENSG00000253404.1	AC034243.1	9.92	1.92e-17	3.29e-13	0.81	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888103	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs288009	ENSG00000253404.1	AC034243.1	9.92	1.92e-17	3.29e-13	0.81	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138892973	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs185956	ENSG00000253404.1	AC034243.1	9.92	1.92e-17	3.29e-13	0.81	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894574	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs288007	ENSG00000253404.1	AC034243.1	9.92	1.92e-17	3.29e-13	0.81	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894939	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.658	rs288003	ENSG00000253404.1	AC034243.1	9.92	1.92e-17	3.29e-13	0.81	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896266	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs288002	ENSG00000253404.1	AC034243.1	9.92	1.92e-17	3.29e-13	0.81	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896398	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs10044401	ENSG00000253404.1	AC034243.1	9.92	1.92e-17	3.29e-13	0.81	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901868	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs10067361	ENSG00000253404.1	AC034243.1	9.92	1.92e-17	3.29e-13	0.81	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905185	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs12186373	ENSG00000253404.1	AC034243.1	9.92	1.92e-17	3.29e-13	0.81	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138912885	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.628	rs10076629	ENSG00000253404.1	AC034243.1	9.92	1.92e-17	3.29e-13	0.81	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920272	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs10078079	ENSG00000253404.1	AC034243.1	9.92	1.92e-17	3.29e-13	0.81	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920450	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.659	rs11750067	ENSG00000253404.1	AC034243.1	9.92	1.92e-17	3.29e-13	0.81	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920589	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs10054682	ENSG00000253404.1	AC034243.1	9.92	1.92e-17	3.29e-13	0.81	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923754	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs11953339	ENSG00000253404.1	AC034243.1	9.92	1.92e-17	3.29e-13	0.81	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923853	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs9327828	ENSG00000253404.1	AC034243.1	9.92	1.92e-17	3.29e-13	0.81	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925859	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs288018	ENSG00000253404.1	AC034243.1	-9.92	1.92e-17	3.29e-13	-0.81	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138856727	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs288017	ENSG00000253404.1	AC034243.1	-9.92	1.92e-17	3.29e-13	-0.81	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138857826	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs167009	ENSG00000253404.1	AC034243.1	-9.92	1.92e-17	3.29e-13	-0.81	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864768	chr5:138744434~138753309:-
TGCT	cis	rs7188445	0.592	rs7196490	ENSG00000261390.4	RP11-345M22.2	-9.92	1.93e-17	3.29e-13	-0.66	-0.67	Urate levels;	chr16:79718572	chr16:79715232~79770563:-
TGCT	cis	rs2739330	0.76	rs1007888	ENSG00000273295.1	AP000350.5	9.91	2.09e-17	3.56e-13	0.74	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23901432~23907068:-
TGCT	cis	rs801193	1	rs2707856	ENSG00000226824.5	RP4-756H11.3	-9.91	2.11e-17	3.58e-13	-0.77	-0.66	Aortic root size;	chr7:66746023	chr7:66654538~66669855:+
TGCT	cis	rs2882667	0.69	rs11954103	ENSG00000253404.1	AC034243.1	9.9	2.17e-17	3.67e-13	0.81	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138933459	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs10045605	ENSG00000253404.1	AC034243.1	9.9	2.17e-17	3.67e-13	0.81	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936458	chr5:138744434~138753309:-
TGCT	cis	rs801193	1	rs2707845	ENSG00000226824.5	RP4-756H11.3	-9.9	2.17e-17	3.67e-13	-0.77	-0.66	Aortic root size;	chr7:66733811	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs2707850	ENSG00000226824.5	RP4-756H11.3	-9.9	2.17e-17	3.67e-13	-0.77	-0.66	Aortic root size;	chr7:66738883	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.967	rs1110414	ENSG00000226824.5	RP4-756H11.3	-9.9	2.17e-17	3.67e-13	-0.77	-0.66	Aortic root size;	chr7:66740595	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs7783924	ENSG00000226824.5	RP4-756H11.3	-9.9	2.17e-17	3.67e-13	-0.77	-0.66	Aortic root size;	chr7:66744070	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs7789184	ENSG00000226824.5	RP4-756H11.3	-9.9	2.17e-17	3.67e-13	-0.77	-0.66	Aortic root size;	chr7:66745208	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs2707854	ENSG00000226824.5	RP4-756H11.3	-9.9	2.17e-17	3.67e-13	-0.77	-0.66	Aortic root size;	chr7:66747610	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.66	rs6460308	ENSG00000226824.5	RP4-756H11.3	9.9	2.17e-17	3.67e-13	0.77	0.66	Aortic root size;	chr7:66619753	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs2087647	ENSG00000226824.5	RP4-756H11.3	9.9	2.2e-17	3.71e-13	0.74	0.66	Aortic root size;	chr7:66128201	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs6958484	ENSG00000226824.5	RP4-756H11.3	9.9	2.2e-17	3.71e-13	0.74	0.66	Aortic root size;	chr7:66134459	chr7:66654538~66669855:+
TGCT	cis	rs3734266	0.702	rs16892384	ENSG00000186328.4	RP11-140K17.2	9.9	2.26e-17	3.8e-13	1.03	0.66	Systemic lupus erythematosus;	chr6:34651226	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs16892386	ENSG00000186328.4	RP11-140K17.2	9.9	2.26e-17	3.8e-13	1.03	0.66	Systemic lupus erythematosus;	chr6:34651615	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs9469838	ENSG00000186328.4	RP11-140K17.2	9.9	2.26e-17	3.8e-13	1.03	0.66	Systemic lupus erythematosus;	chr6:34655592	chr6:34715613~34715940:+
TGCT	cis	rs875971	0.66	rs12698534	ENSG00000226824.5	RP4-756H11.3	-9.89	2.31e-17	3.83e-13	-0.77	-0.66	Aortic root size;	chr7:66521858	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.66	rs62465434	ENSG00000226824.5	RP4-756H11.3	-9.89	2.31e-17	3.83e-13	-0.77	-0.66	Aortic root size;	chr7:66540165	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.66	rs13224319	ENSG00000226824.5	RP4-756H11.3	-9.89	2.31e-17	3.83e-13	-0.77	-0.66	Aortic root size;	chr7:66542376	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.66	rs801217	ENSG00000226824.5	RP4-756H11.3	9.89	2.31e-17	3.83e-13	0.77	0.66	Aortic root size;	chr7:66545590	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.638	rs801216	ENSG00000226824.5	RP4-756H11.3	9.89	2.31e-17	3.83e-13	0.77	0.66	Aortic root size;	chr7:66546680	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.66	rs801211	ENSG00000226824.5	RP4-756H11.3	9.89	2.31e-17	3.83e-13	0.77	0.66	Aortic root size;	chr7:66550702	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.638	rs801205	ENSG00000226824.5	RP4-756H11.3	9.89	2.31e-17	3.83e-13	0.77	0.66	Aortic root size;	chr7:66557157	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.617	rs810400	ENSG00000226824.5	RP4-756H11.3	9.89	2.31e-17	3.83e-13	0.77	0.66	Aortic root size;	chr7:66557902	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.638	rs3898855	ENSG00000226824.5	RP4-756H11.3	9.89	2.31e-17	3.83e-13	0.77	0.66	Aortic root size;	chr7:66571411	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.638	rs10278816	ENSG00000226824.5	RP4-756H11.3	9.89	2.31e-17	3.83e-13	0.77	0.66	Aortic root size;	chr7:66572000	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.66	rs10281080	ENSG00000226824.5	RP4-756H11.3	9.89	2.31e-17	3.83e-13	0.77	0.66	Aortic root size;	chr7:66577454	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.66	rs10950044	ENSG00000226824.5	RP4-756H11.3	9.89	2.31e-17	3.83e-13	0.77	0.66	Aortic root size;	chr7:66577989	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.638	rs10249404	ENSG00000226824.5	RP4-756H11.3	9.89	2.31e-17	3.83e-13	0.77	0.66	Aortic root size;	chr7:66581737	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.619	rs10278371	ENSG00000226824.5	RP4-756H11.3	9.89	2.31e-17	3.83e-13	0.77	0.66	Aortic root size;	chr7:66586553	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.522	rs1968127	ENSG00000226824.5	RP4-756H11.3	9.89	2.31e-17	3.83e-13	0.77	0.66	Aortic root size;	chr7:66591816	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.66	rs79009421	ENSG00000226824.5	RP4-756H11.3	9.89	2.31e-17	3.83e-13	0.77	0.66	Aortic root size;	chr7:66603522	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.66	rs7807930	ENSG00000226824.5	RP4-756H11.3	9.89	2.31e-17	3.83e-13	0.77	0.66	Aortic root size;	chr7:66622178	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.66	rs7807944	ENSG00000226824.5	RP4-756H11.3	9.89	2.31e-17	3.83e-13	0.77	0.66	Aortic root size;	chr7:66622208	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.638	rs35986979	ENSG00000226824.5	RP4-756H11.3	9.89	2.31e-17	3.83e-13	0.77	0.66	Aortic root size;	chr7:66624003	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.642	rs35526611	ENSG00000226824.5	RP4-756H11.3	9.89	2.31e-17	3.83e-13	0.77	0.66	Aortic root size;	chr7:66629021	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.66	rs3764903	ENSG00000226824.5	RP4-756H11.3	9.89	2.31e-17	3.83e-13	0.77	0.66	Aortic root size;	chr7:66633495	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.66	rs1860470	ENSG00000226824.5	RP4-756H11.3	9.89	2.31e-17	3.83e-13	0.77	0.66	Aortic root size;	chr7:66638707	chr7:66654538~66669855:+
TGCT	cis	rs858239	0.899	rs28635122	ENSG00000230658.1	KLHL7-AS1	9.89	2.33e-17	3.85e-13	0.75	0.66	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.899	rs7794684	ENSG00000230658.1	KLHL7-AS1	9.89	2.33e-17	3.85e-13	0.75	0.66	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23101228~23105703:-
TGCT	cis	rs10028773	0.6	rs4001390	ENSG00000245958.5	RP11-33B1.1	-9.89	2.38e-17	3.92e-13	-0.66	-0.66	Educational attainment;	chr4:119344628	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.691	rs2136911	ENSG00000245958.5	RP11-33B1.1	-9.89	2.38e-17	3.92e-13	-0.66	-0.66	Corneal astigmatism;	chr4:119344704	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.779	rs6815934	ENSG00000245958.5	RP11-33B1.1	-9.89	2.38e-17	3.92e-13	-0.66	-0.66	Corneal astigmatism;	chr4:119346155	chr4:119454791~119552025:+
TGCT	cis	rs10028773	0.568	rs6838457	ENSG00000245958.5	RP11-33B1.1	-9.89	2.38e-17	3.92e-13	-0.66	-0.66	Educational attainment;	chr4:119346212	chr4:119454791~119552025:+
TGCT	cis	rs172166	0.516	rs2791333	ENSG00000216901.1	AL022393.7	9.89	2.38e-17	3.92e-13	0.71	0.66	Cardiac Troponin-T levels;	chr6:28143336	chr6:28176188~28176674:+
TGCT	cis	rs875971	0.66	rs10215132	ENSG00000226824.5	RP4-756H11.3	9.89	2.38e-17	3.92e-13	0.77	0.66	Aortic root size;	chr7:66589419	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs2055682	ENSG00000226824.5	RP4-756H11.3	-9.88	2.42e-17	3.99e-13	-0.76	-0.66	Aortic root size;	chr7:66795302	chr7:66654538~66669855:+
TGCT	cis	rs1577917	0.727	rs9444361	ENSG00000203875.9	SNHG5	9.88	2.43e-17	4e-13	0.81	0.66	Response to antipsychotic treatment;	chr6:85691182	chr6:85660950~85678736:-
TGCT	cis	rs12439619	0.768	rs28694364	ENSG00000278603.1	RP13-608F4.5	9.88	2.44e-17	4.02e-13	1.03	0.66	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472203~82472426:+
TGCT	cis	rs1577917	0.883	rs6454505	ENSG00000203875.9	SNHG5	-9.88	2.52e-17	4.14e-13	-0.86	-0.66	Response to antipsychotic treatment;	chr6:85882644	chr6:85660950~85678736:-
TGCT	cis	rs2739330	0.753	rs4822452	ENSG00000218537.1	MIF-AS1	9.88	2.54e-17	4.15e-13	0.85	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23894426~23898930:-
TGCT	cis	rs2487048	0.761	rs2980083	ENSG00000226334.1	RP11-217B7.2	-9.87	2.56e-17	4.2e-13	-0.68	-0.66	Intraocular pressure;	chr9:104929081	chr9:104927553~104928892:+
TGCT	cis	rs801193	0.967	rs2707853	ENSG00000226824.5	RP4-756H11.3	-9.87	2.62e-17	4.26e-13	-0.77	-0.66	Aortic root size;	chr7:66749023	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs2659889	ENSG00000226824.5	RP4-756H11.3	-9.87	2.62e-17	4.26e-13	-0.77	-0.66	Aortic root size;	chr7:66752125	chr7:66654538~66669855:+
TGCT	cis	rs858239	0.539	rs6461695	ENSG00000230658.1	KLHL7-AS1	9.87	2.65e-17	4.3e-13	0.77	0.66	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23101228~23105703:-
TGCT	cis	rs12439619	0.693	rs9944185	ENSG00000278603.1	RP13-608F4.5	9.87	2.66e-17	4.31e-13	0.97	0.66	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472203~82472426:+
TGCT	cis	rs858239	0.899	rs2268747	ENSG00000230658.1	KLHL7-AS1	9.86	2.72e-17	4.41e-13	0.75	0.66	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23101228~23105703:-
TGCT	cis	rs875971	1	rs1565531	ENSG00000226824.5	RP4-756H11.3	9.85	2.89e-17	4.67e-13	0.76	0.66	Aortic root size;	chr7:66198126	chr7:66654538~66669855:+
TGCT	cis	rs12439619	0.81	rs28876157	ENSG00000278603.1	RP13-608F4.5	9.85	2.9e-17	4.68e-13	1.03	0.66	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472203~82472426:+
TGCT	cis	rs853679	0.506	rs1150711	ENSG00000216901.1	AL022393.7	9.85	3e-17	4.83e-13	0.72	0.66	Depression;	chr6:28240757	chr6:28176188~28176674:+
TGCT	cis	rs875971	1	rs4718357	ENSG00000226824.5	RP4-756H11.3	-9.83	3.19e-17	5.14e-13	-0.74	-0.66	Aortic root size;	chr7:66495891	chr7:66654538~66669855:+
TGCT	cis	rs916888	0.821	rs199513	ENSG00000214401.4	KANSL1-AS1	-9.83	3.23e-17	5.19e-13	-0.94	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46193576~46196723:+
TGCT	cis	rs801193	0.636	rs10233806	ENSG00000226824.5	RP4-756H11.3	9.83	3.25e-17	5.23e-13	0.75	0.66	Aortic root size;	chr7:66653261	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs17566701	ENSG00000226824.5	RP4-756H11.3	-9.83	3.32e-17	5.33e-13	-0.76	-0.66	Aortic root size;	chr7:66728196	chr7:66654538~66669855:+
TGCT	cis	rs2739330	0.76	rs5760095	ENSG00000273295.1	AP000350.5	9.83	3.33e-17	5.34e-13	0.72	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23901432~23907068:-
TGCT	cis	rs875971	1	rs875971	ENSG00000226824.5	RP4-756H11.3	9.82	3.4e-17	5.45e-13	0.74	0.66	Aortic root size;	chr7:66152608	chr7:66654538~66669855:+
TGCT	cis	rs12439619	0.846	rs62013464	ENSG00000278603.1	RP13-608F4.5	9.82	3.43e-17	5.47e-13	1.04	0.66	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472203~82472426:+
TGCT	cis	rs12439619	0.846	rs62010071	ENSG00000278603.1	RP13-608F4.5	9.82	3.43e-17	5.47e-13	1.04	0.66	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472203~82472426:+
TGCT	cis	rs11098499	0.866	rs7665125	ENSG00000245958.5	RP11-33B1.1	-9.82	3.48e-17	5.47e-13	-0.69	-0.66	Corneal astigmatism;	chr4:119480924	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.738	rs28687057	ENSG00000245958.5	RP11-33B1.1	-9.82	3.5e-17	5.47e-13	-0.67	-0.66	Corneal astigmatism;	chr4:119359657	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.775	rs67281037	ENSG00000245958.5	RP11-33B1.1	-9.82	3.5e-17	5.47e-13	-0.67	-0.66	Corneal astigmatism;	chr4:119360002	chr4:119454791~119552025:+
TGCT	cis	rs10028773	0.506	rs12374346	ENSG00000245958.5	RP11-33B1.1	-9.82	3.5e-17	5.47e-13	-0.67	-0.66	Educational attainment;	chr4:119360550	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.866	rs12374244	ENSG00000245958.5	RP11-33B1.1	-9.82	3.5e-17	5.47e-13	-0.67	-0.66	Corneal astigmatism;	chr4:119360817	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.866	rs12374352	ENSG00000245958.5	RP11-33B1.1	-9.82	3.5e-17	5.47e-13	-0.67	-0.66	Corneal astigmatism;	chr4:119360822	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.775	rs10021601	ENSG00000245958.5	RP11-33B1.1	-9.82	3.5e-17	5.47e-13	-0.67	-0.66	Corneal astigmatism;	chr4:119361408	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.866	rs6857892	ENSG00000245958.5	RP11-33B1.1	-9.82	3.5e-17	5.47e-13	-0.67	-0.66	Corneal astigmatism;	chr4:119361541	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.909	rs28581362	ENSG00000245958.5	RP11-33B1.1	-9.82	3.5e-17	5.47e-13	-0.67	-0.66	Corneal astigmatism;	chr4:119362393	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.82	rs12503082	ENSG00000245958.5	RP11-33B1.1	-9.82	3.5e-17	5.47e-13	-0.67	-0.66	Corneal astigmatism;	chr4:119363162	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.866	rs12499602	ENSG00000245958.5	RP11-33B1.1	-9.82	3.5e-17	5.47e-13	-0.67	-0.66	Corneal astigmatism;	chr4:119363232	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.774	rs11098505	ENSG00000245958.5	RP11-33B1.1	-9.82	3.5e-17	5.47e-13	-0.67	-0.66	Corneal astigmatism;	chr4:119363472	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.866	rs11098506	ENSG00000245958.5	RP11-33B1.1	-9.82	3.5e-17	5.47e-13	-0.67	-0.66	Corneal astigmatism;	chr4:119363816	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.866	rs13105020	ENSG00000245958.5	RP11-33B1.1	-9.82	3.5e-17	5.47e-13	-0.67	-0.66	Corneal astigmatism;	chr4:119364533	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.866	rs6824111	ENSG00000245958.5	RP11-33B1.1	-9.82	3.5e-17	5.47e-13	-0.67	-0.66	Corneal astigmatism;	chr4:119364813	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.779	rs10857066	ENSG00000245958.5	RP11-33B1.1	-9.82	3.5e-17	5.47e-13	-0.67	-0.66	Corneal astigmatism;	chr4:119365441	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.775	rs10029303	ENSG00000245958.5	RP11-33B1.1	-9.82	3.5e-17	5.47e-13	-0.67	-0.66	Corneal astigmatism;	chr4:119365600	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.866	rs9995136	ENSG00000245958.5	RP11-33B1.1	-9.82	3.5e-17	5.47e-13	-0.67	-0.66	Corneal astigmatism;	chr4:119365690	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.866	rs13125526	ENSG00000245958.5	RP11-33B1.1	-9.82	3.5e-17	5.47e-13	-0.67	-0.66	Corneal astigmatism;	chr4:119366864	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.866	rs12513310	ENSG00000245958.5	RP11-33B1.1	-9.82	3.5e-17	5.47e-13	-0.67	-0.66	Corneal astigmatism;	chr4:119366884	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.866	rs12510451	ENSG00000245958.5	RP11-33B1.1	-9.82	3.5e-17	5.47e-13	-0.67	-0.66	Corneal astigmatism;	chr4:119367988	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.774	rs73842616	ENSG00000245958.5	RP11-33B1.1	-9.82	3.5e-17	5.47e-13	-0.67	-0.66	Corneal astigmatism;	chr4:119369528	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.645	rs72676059	ENSG00000245958.5	RP11-33B1.1	-9.82	3.5e-17	5.47e-13	-0.67	-0.66	Corneal astigmatism;	chr4:119369673	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.569	rs55845118	ENSG00000245958.5	RP11-33B1.1	-9.82	3.5e-17	5.47e-13	-0.67	-0.66	Corneal astigmatism;	chr4:119369758	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.866	rs7677068	ENSG00000245958.5	RP11-33B1.1	-9.82	3.5e-17	5.47e-13	-0.67	-0.66	Corneal astigmatism;	chr4:119370549	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.866	rs9991221	ENSG00000245958.5	RP11-33B1.1	-9.82	3.5e-17	5.47e-13	-0.67	-0.66	Corneal astigmatism;	chr4:119370952	chr4:119454791~119552025:+
TGCT	cis	rs858239	0.699	rs1881201	ENSG00000230658.1	KLHL7-AS1	-9.82	3.52e-17	5.5e-13	-0.68	-0.66	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23101228~23105703:-
TGCT	cis	rs875971	0.619	rs2302918	ENSG00000226824.5	RP4-756H11.3	-9.81	3.57e-17	5.56e-13	-0.77	-0.66	Aortic root size;	chr7:66535945	chr7:66654538~66669855:+
TGCT	cis	rs858239	0.899	rs5850	ENSG00000230658.1	KLHL7-AS1	9.81	3.65e-17	5.69e-13	0.75	0.66	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.899	rs2268745	ENSG00000230658.1	KLHL7-AS1	9.81	3.66e-17	5.71e-13	0.74	0.66	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23101228~23105703:-
TGCT	cis	rs12439619	0.846	rs7496227	ENSG00000278603.1	RP13-608F4.5	9.81	3.67e-17	5.71e-13	1.04	0.66	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472203~82472426:+
TGCT	cis	rs801193	0.967	rs2420827	ENSG00000226824.5	RP4-756H11.3	9.8	3.78e-17	5.85e-13	0.76	0.66	Aortic root size;	chr7:66682114	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.967	rs3800823	ENSG00000226824.5	RP4-756H11.3	9.8	3.78e-17	5.85e-13	0.76	0.66	Aortic root size;	chr7:66682123	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.901	rs4273746	ENSG00000226824.5	RP4-756H11.3	9.8	3.79e-17	5.85e-13	0.76	0.66	Aortic root size;	chr7:66836124	chr7:66654538~66669855:+
TGCT	cis	rs2739330	0.703	rs5760112	ENSG00000273295.1	AP000350.5	9.8	3.79e-17	5.85e-13	0.72	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23901432~23907068:-
TGCT	cis	rs2882667	0.654	rs10044432	ENSG00000253404.1	AC034243.1	9.8	3.91e-17	6.03e-13	0.81	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138939207	chr5:138744434~138753309:-
TGCT	cis	rs1150668	0.796	rs1052215	ENSG00000216901.1	AL022393.7	-9.8	3.94e-17	6.06e-13	-0.72	-0.66	Pubertal anthropometrics;	chr6:28380381	chr6:28176188~28176674:+
TGCT	cis	rs1150668	0.699	rs1531681	ENSG00000216901.1	AL022393.7	9.79	4.07e-17	6.23e-13	0.71	0.66	Pubertal anthropometrics;	chr6:28259100	chr6:28176188~28176674:+
TGCT	cis	rs875971	0.862	rs7786892	ENSG00000226824.5	RP4-756H11.3	9.79	4.12e-17	6.27e-13	0.73	0.66	Aortic root size;	chr7:66163889	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs2420174	ENSG00000226824.5	RP4-756H11.3	9.79	4.12e-17	6.27e-13	0.73	0.66	Aortic root size;	chr7:66180374	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs2420173	ENSG00000226824.5	RP4-756H11.3	9.79	4.12e-17	6.27e-13	0.73	0.66	Aortic root size;	chr7:66180412	chr7:66654538~66669855:+
TGCT	cis	rs2739330	0.731	rs2000468	ENSG00000273295.1	AP000350.5	9.79	4.14e-17	6.29e-13	0.72	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23901432~23907068:-
TGCT	cis	rs2882667	0.69	rs288029	ENSG00000253404.1	AC034243.1	9.79	4.18e-17	6.34e-13	0.82	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138881616	chr5:138744434~138753309:-
TGCT	cis	rs2739330	0.828	rs5760102	ENSG00000218537.1	MIF-AS1	9.78	4.24e-17	6.43e-13	0.84	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23894426~23898930:-
TGCT	cis	rs1150668	0.764	rs9368565	ENSG00000216901.1	AL022393.7	-9.78	4.25e-17	6.44e-13	-0.72	-0.66	Pubertal anthropometrics;	chr6:28377433	chr6:28176188~28176674:+
TGCT	cis	rs3734266	0.527	rs9462001	ENSG00000186328.4	RP11-140K17.2	9.78	4.43e-17	6.7e-13	1	0.66	Systemic lupus erythematosus;	chr6:34687786	chr6:34715613~34715940:+
TGCT	cis	rs2739330	0.828	rs2877178	ENSG00000218537.1	MIF-AS1	9.77	4.65e-17	7.02e-13	0.84	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23894426~23898930:-
TGCT	cis	rs2739330	0.828	rs2154593	ENSG00000218537.1	MIF-AS1	9.77	4.65e-17	7.02e-13	0.84	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23894426~23898930:-
TGCT	cis	rs1150668	0.796	rs1005125	ENSG00000216901.1	AL022393.7	9.76	4.71e-17	7.12e-13	0.71	0.66	Pubertal anthropometrics;	chr6:28399578	chr6:28176188~28176674:+
TGCT	cis	rs7188445	0.592	rs4404082	ENSG00000261390.4	RP11-345M22.2	9.76	4.73e-17	7.14e-13	0.66	0.66	Urate levels;	chr16:79716615	chr16:79715232~79770563:-
TGCT	cis	rs3814244	0.515	rs3015002	ENSG00000255733.4	IFNG-AS1	-9.76	4.74e-17	7.16e-13	-0.65	-0.66	Itch intensity from mosquito bite adjusted by bite size;	chr12:68010853	chr12:67989445~68234686:+
TGCT	cis	rs875971	0.862	rs4368860	ENSG00000226824.5	RP4-756H11.3	9.76	4.76e-17	7.16e-13	0.72	0.66	Aortic root size;	chr7:66143495	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs1983372	ENSG00000226824.5	RP4-756H11.3	9.76	4.76e-17	7.16e-13	0.72	0.66	Aortic root size;	chr7:66146364	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs908915	ENSG00000226824.5	RP4-756H11.3	9.76	4.76e-17	7.16e-13	0.72	0.66	Aortic root size;	chr7:66149664	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs7809814	ENSG00000226824.5	RP4-756H11.3	9.76	4.76e-17	7.16e-13	0.72	0.66	Aortic root size;	chr7:66150410	chr7:66654538~66669855:+
TGCT	cis	rs2739330	0.796	rs5760097	ENSG00000218537.1	MIF-AS1	9.76	4.87e-17	7.33e-13	0.84	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23894426~23898930:-
TGCT	cis	rs2739330	0.828	rs4822451	ENSG00000218537.1	MIF-AS1	9.76	4.87e-17	7.33e-13	0.84	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23894426~23898930:-
TGCT	cis	rs2739330	0.828	rs5760098	ENSG00000218537.1	MIF-AS1	9.76	4.87e-17	7.33e-13	0.84	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23894426~23898930:-
TGCT	cis	rs2739330	0.828	rs5760099	ENSG00000218537.1	MIF-AS1	9.76	4.87e-17	7.33e-13	0.84	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23894426~23898930:-
TGCT	cis	rs1577917	0.958	rs13207173	ENSG00000203875.9	SNHG5	-9.76	4.92e-17	7.37e-13	-0.9	-0.66	Response to antipsychotic treatment;	chr6:85747804	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.917	rs4098044	ENSG00000203875.9	SNHG5	-9.76	4.92e-17	7.37e-13	-0.9	-0.66	Response to antipsychotic treatment;	chr6:85752348	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs2324817	ENSG00000203875.9	SNHG5	-9.76	4.92e-17	7.37e-13	-0.9	-0.66	Response to antipsychotic treatment;	chr6:85752936	chr6:85660950~85678736:-
TGCT	cis	rs875971	0.577	rs35072105	ENSG00000226824.5	RP4-756H11.3	9.76	4.95e-17	7.41e-13	0.76	0.66	Aortic root size;	chr7:66144830	chr7:66654538~66669855:+
TGCT	cis	rs12439619	0.739	rs62012046	ENSG00000278603.1	RP13-608F4.5	9.75	5.07e-17	7.57e-13	1.02	0.66	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472203~82472426:+
TGCT	cis	rs12439619	0.774	rs62012047	ENSG00000278603.1	RP13-608F4.5	9.75	5.07e-17	7.57e-13	1.02	0.66	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472203~82472426:+
TGCT	cis	rs12439619	0.81	rs62012049	ENSG00000278603.1	RP13-608F4.5	9.75	5.07e-17	7.57e-13	1.02	0.66	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472203~82472426:+
TGCT	cis	rs12439619	0.846	rs62012059	ENSG00000278603.1	RP13-608F4.5	9.75	5.07e-17	7.57e-13	1.02	0.66	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472203~82472426:+
TGCT	cis	rs12439619	0.774	rs2867649	ENSG00000278603.1	RP13-608F4.5	9.75	5.07e-17	7.57e-13	1.02	0.66	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472203~82472426:+
TGCT	cis	rs12439619	0.846	rs28697264	ENSG00000278603.1	RP13-608F4.5	9.75	5.07e-17	7.57e-13	1.02	0.66	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472203~82472426:+
TGCT	cis	rs801193	0.66	rs1016265	ENSG00000226824.5	RP4-756H11.3	-9.75	5.14e-17	7.66e-13	-0.75	-0.66	Aortic root size;	chr7:66749580	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.66	rs4610622	ENSG00000226824.5	RP4-756H11.3	-9.75	5.14e-17	7.66e-13	-0.75	-0.66	Aortic root size;	chr7:66759510	chr7:66654538~66669855:+
TGCT	cis	rs853679	0.527	rs1997660	ENSG00000216901.1	AL022393.7	9.75	5.22e-17	7.76e-13	0.71	0.66	Depression;	chr6:28301886	chr6:28176188~28176674:+
TGCT	cis	rs853679	0.527	rs9468333	ENSG00000216901.1	AL022393.7	9.75	5.22e-17	7.76e-13	0.71	0.66	Depression;	chr6:28303421	chr6:28176188~28176674:+
TGCT	cis	rs6903823	0.527	rs4713158	ENSG00000216901.1	AL022393.7	9.75	5.22e-17	7.76e-13	0.71	0.66	Pulmonary function;	chr6:28309994	chr6:28176188~28176674:+
TGCT	cis	rs2739330	0.828	rs2330635	ENSG00000218537.1	MIF-AS1	9.75	5.23e-17	7.77e-13	0.84	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23894426~23898930:-
TGCT	cis	rs2739330	0.828	rs5760108	ENSG00000218537.1	MIF-AS1	9.74	5.27e-17	7.83e-13	0.84	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23894426~23898930:-
TGCT	cis	rs2882667	0.69	rs700619	ENSG00000253404.1	AC034243.1	-9.74	5.36e-17	7.85e-13	-0.8	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138753060	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.652	rs700622	ENSG00000253404.1	AC034243.1	-9.74	5.36e-17	7.85e-13	-0.8	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762862	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs7722965	ENSG00000253404.1	AC034243.1	-9.74	5.36e-17	7.85e-13	-0.8	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138764766	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.587	rs825674	ENSG00000253404.1	AC034243.1	-9.74	5.36e-17	7.85e-13	-0.8	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767031	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs825677	ENSG00000253404.1	AC034243.1	-9.74	5.36e-17	7.85e-13	-0.8	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138769081	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs1976562	ENSG00000253404.1	AC034243.1	-9.74	5.36e-17	7.85e-13	-0.8	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138774905	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs825759	ENSG00000253404.1	AC034243.1	-9.74	5.36e-17	7.85e-13	-0.8	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138790250	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.654	rs7709770	ENSG00000253404.1	AC034243.1	-9.74	5.36e-17	7.85e-13	-0.8	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138813650	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs4835703	ENSG00000253404.1	AC034243.1	-9.74	5.36e-17	7.85e-13	-0.8	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815048	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.654	rs4835704	ENSG00000253404.1	AC034243.1	-9.74	5.36e-17	7.85e-13	-0.8	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815636	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs6596453	ENSG00000253404.1	AC034243.1	-9.74	5.36e-17	7.85e-13	-0.8	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816202	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.622	rs34645817	ENSG00000253404.1	AC034243.1	-9.74	5.36e-17	7.85e-13	-0.8	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816944	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs7736925	ENSG00000253404.1	AC034243.1	-9.74	5.36e-17	7.85e-13	-0.8	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818841	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.654	rs883333	ENSG00000253404.1	AC034243.1	-9.74	5.36e-17	7.85e-13	-0.8	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819781	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs6596455	ENSG00000253404.1	AC034243.1	-9.74	5.36e-17	7.85e-13	-0.8	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831416	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs995177	ENSG00000253404.1	AC034243.1	-9.74	5.36e-17	7.85e-13	-0.8	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138833874	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.654	rs7710300	ENSG00000253404.1	AC034243.1	-9.74	5.36e-17	7.85e-13	-0.8	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138834793	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.654	rs2351247	ENSG00000253404.1	AC034243.1	-9.74	5.36e-17	7.85e-13	-0.8	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849456	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.619	rs6861556	ENSG00000253404.1	AC034243.1	-9.74	5.36e-17	7.85e-13	-0.8	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138852351	chr5:138744434~138753309:-
TGCT	cis	rs1150668	0.699	rs12214383	ENSG00000216901.1	AL022393.7	-9.74	5.46e-17	7.98e-13	-0.71	-0.66	Pubertal anthropometrics;	chr6:28255953	chr6:28176188~28176674:+
TGCT	cis	rs1150668	0.699	rs1736895	ENSG00000216901.1	AL022393.7	9.74	5.46e-17	7.98e-13	0.71	0.66	Pubertal anthropometrics;	chr6:28252048	chr6:28176188~28176674:+
TGCT	cis	rs2739330	0.828	rs4820572	ENSG00000218537.1	MIF-AS1	9.74	5.51e-17	8.05e-13	0.84	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23894426~23898930:-
TGCT	cis	rs11098499	0.722	rs10025925	ENSG00000245958.5	RP11-33B1.1	-9.74	5.54e-17	8.08e-13	-0.65	-0.66	Corneal astigmatism;	chr4:119350589	chr4:119454791~119552025:+
TGCT	cis	rs2739330	0.828	rs4822454	ENSG00000218537.1	MIF-AS1	9.73	5.7e-17	8.29e-13	0.84	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23894426~23898930:-
TGCT	cis	rs2739330	0.796	rs5760106	ENSG00000218537.1	MIF-AS1	-9.72	5.97e-17	8.65e-13	-0.84	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23894426~23898930:-
TGCT	cis	rs2739330	0.828	rs2186366	ENSG00000218537.1	MIF-AS1	-9.72	5.97e-17	8.65e-13	-0.84	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23894426~23898930:-
TGCT	cis	rs2739330	0.828	rs5760107	ENSG00000218537.1	MIF-AS1	9.72	5.97e-17	8.65e-13	0.84	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23894426~23898930:-
TGCT	cis	rs2739330	0.789	rs5760109	ENSG00000218537.1	MIF-AS1	9.72	5.97e-17	8.65e-13	0.84	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23894426~23898930:-
TGCT	cis	rs1577917	0.958	rs12192033	ENSG00000203875.9	SNHG5	-9.72	6.03e-17	8.73e-13	-0.9	-0.66	Response to antipsychotic treatment;	chr6:85762841	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs12190603	ENSG00000203875.9	SNHG5	-9.72	6.03e-17	8.73e-13	-0.9	-0.66	Response to antipsychotic treatment;	chr6:85766000	chr6:85660950~85678736:-
TGCT	cis	rs875971	1	rs10244498	ENSG00000226824.5	RP4-756H11.3	-9.72	6.08e-17	8.8e-13	-0.75	-0.66	Aortic root size;	chr7:66651069	chr7:66654538~66669855:+
TGCT	cis	rs11098499	0.731	rs6846966	ENSG00000245958.5	RP11-33B1.1	-9.71	6.3e-17	9.1e-13	-0.68	-0.66	Corneal astigmatism;	chr4:119372053	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.866	rs6847778	ENSG00000245958.5	RP11-33B1.1	-9.71	6.3e-17	9.1e-13	-0.68	-0.66	Corneal astigmatism;	chr4:119372427	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.78	rs10013652	ENSG00000245958.5	RP11-33B1.1	-9.71	6.33e-17	9.13e-13	-0.66	-0.66	Corneal astigmatism;	chr4:119371101	chr4:119454791~119552025:+
TGCT	cis	rs875971	1	rs7781698	ENSG00000226824.5	RP4-756H11.3	-9.71	6.46e-17	9.28e-13	-0.74	-0.66	Aortic root size;	chr7:66431325	chr7:66654538~66669855:+
TGCT	cis	rs12439619	0.846	rs62012056	ENSG00000278603.1	RP13-608F4.5	9.7	6.63e-17	9.47e-13	1.02	0.66	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472203~82472426:+
TGCT	cis	rs11098499	0.954	rs6820115	ENSG00000245958.5	RP11-33B1.1	-9.7	6.65e-17	9.5e-13	-0.7	-0.66	Corneal astigmatism;	chr4:119477027	chr4:119454791~119552025:+
TGCT	cis	rs200367988	1	rs200367988	ENSG00000271670.1	RP11-95I16.4	-9.7	6.77e-17	9.65e-13	-0.65	-0.66	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;	chr10:120915337	chr10:120879256~120880667:-
TGCT	cis	rs801193	1	rs3800812	ENSG00000226824.5	RP4-756H11.3	-9.7	6.77e-17	9.65e-13	-0.76	-0.66	Aortic root size;	chr7:66758474	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs4279493	ENSG00000226824.5	RP4-756H11.3	-9.7	6.77e-17	9.65e-13	-0.76	-0.66	Aortic root size;	chr7:66761633	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.761	rs2659888	ENSG00000226824.5	RP4-756H11.3	-9.7	6.77e-17	9.65e-13	-0.76	-0.66	Aortic root size;	chr7:66765184	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.904	rs4718403	ENSG00000226824.5	RP4-756H11.3	-9.7	6.77e-17	9.65e-13	-0.76	-0.66	Aortic root size;	chr7:66777742	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs3778909	ENSG00000226824.5	RP4-756H11.3	-9.7	6.77e-17	9.65e-13	-0.76	-0.66	Aortic root size;	chr7:66790659	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs6460296	ENSG00000226824.5	RP4-756H11.3	-9.69	7.04e-17	9.98e-13	-0.73	-0.66	Aortic root size;	chr7:66430152	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.895	rs4718349	ENSG00000226824.5	RP4-756H11.3	-9.69	7.04e-17	9.98e-13	-0.73	-0.66	Aortic root size;	chr7:66444024	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs2042133	ENSG00000226824.5	RP4-756H11.3	-9.69	7.04e-17	9.98e-13	-0.73	-0.66	Aortic root size;	chr7:66466935	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.964	rs2161065	ENSG00000226824.5	RP4-756H11.3	-9.69	7.04e-17	9.98e-13	-0.73	-0.66	Aortic root size;	chr7:66467918	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs12698521	ENSG00000226824.5	RP4-756H11.3	-9.69	7.04e-17	9.98e-13	-0.73	-0.66	Aortic root size;	chr7:66474502	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.929	rs778712	ENSG00000226824.5	RP4-756H11.3	-9.69	7.06e-17	9.98e-13	-0.73	-0.66	Aortic root size;	chr7:66384991	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs778710	ENSG00000226824.5	RP4-756H11.3	-9.69	7.06e-17	9.98e-13	-0.73	-0.66	Aortic root size;	chr7:66389847	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.964	rs778708	ENSG00000226824.5	RP4-756H11.3	-9.69	7.06e-17	9.98e-13	-0.73	-0.66	Aortic root size;	chr7:66391332	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs778696	ENSG00000226824.5	RP4-756H11.3	-9.69	7.06e-17	9.98e-13	-0.73	-0.66	Aortic root size;	chr7:66405826	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs778694	ENSG00000226824.5	RP4-756H11.3	-9.69	7.06e-17	9.98e-13	-0.73	-0.66	Aortic root size;	chr7:66406571	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs4718344	ENSG00000226824.5	RP4-756H11.3	-9.69	7.06e-17	9.98e-13	-0.73	-0.66	Aortic root size;	chr7:66409394	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.737	rs7803424	ENSG00000226824.5	RP4-756H11.3	-9.69	7.06e-17	9.98e-13	-0.73	-0.66	Aortic root size;	chr7:66415618	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.83	rs7799834	ENSG00000226824.5	RP4-756H11.3	-9.69	7.06e-17	9.98e-13	-0.73	-0.66	Aortic root size;	chr7:66415707	chr7:66654538~66669855:+
TGCT	cis	rs3734266	0.702	rs205265	ENSG00000186328.4	RP11-140K17.2	9.69	7.07e-17	9.99e-13	1.06	0.66	Systemic lupus erythematosus;	chr6:34593808	chr6:34715613~34715940:+
TGCT	cis	rs172166	0.561	rs149976	ENSG00000216901.1	AL022393.7	-9.69	7.09e-17	1e-12	-0.71	-0.66	Cardiac Troponin-T levels;	chr6:28019998	chr6:28176188~28176674:+
TGCT	cis	rs875971	1	rs6963646	ENSG00000226824.5	RP4-756H11.3	9.69	7.17e-17	1.01e-12	0.74	0.66	Aortic root size;	chr7:66220780	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.965	rs28682868	ENSG00000226824.5	RP4-756H11.3	9.69	7.17e-17	1.01e-12	0.74	0.66	Aortic root size;	chr7:66224822	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.898	rs6977501	ENSG00000226824.5	RP4-756H11.3	9.69	7.17e-17	1.01e-12	0.74	0.66	Aortic root size;	chr7:66228355	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.965	rs6971509	ENSG00000226824.5	RP4-756H11.3	9.69	7.17e-17	1.01e-12	0.74	0.66	Aortic root size;	chr7:66249983	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs937495	ENSG00000226824.5	RP4-756H11.3	9.69	7.17e-17	1.01e-12	0.74	0.66	Aortic root size;	chr7:66314811	chr7:66654538~66669855:+
TGCT	cis	rs858239	0.829	rs2268744	ENSG00000230658.1	KLHL7-AS1	9.69	7.2e-17	1.01e-12	0.75	0.66	Cerebrospinal fluid biomarker levels;	chr7:23292661	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.539	rs870476	ENSG00000230658.1	KLHL7-AS1	9.68	7.35e-17	1.03e-12	0.7	0.66	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23101228~23105703:-
TGCT	cis	rs12439619	0.693	rs17269819	ENSG00000278603.1	RP13-608F4.5	9.68	7.49e-17	1.05e-12	0.95	0.66	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472203~82472426:+
TGCT	cis	rs875971	0.895	rs3857684	ENSG00000226824.5	RP4-756H11.3	-9.68	7.56e-17	1.06e-12	-0.73	-0.66	Aortic root size;	chr7:66473171	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs12533997	ENSG00000226824.5	RP4-756H11.3	-9.68	7.56e-17	1.06e-12	-0.73	-0.66	Aortic root size;	chr7:66500390	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.964	rs60193905	ENSG00000226824.5	RP4-756H11.3	-9.68	7.56e-17	1.06e-12	-0.73	-0.66	Aortic root size;	chr7:66506273	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.929	rs10950041	ENSG00000226824.5	RP4-756H11.3	-9.68	7.56e-17	1.06e-12	-0.73	-0.66	Aortic root size;	chr7:66508888	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.935	rs11772264	ENSG00000226824.5	RP4-756H11.3	-9.68	7.59e-17	1.06e-12	-0.76	-0.66	Aortic root size;	chr7:66711400	chr7:66654538~66669855:+
TGCT	cis	rs11098499	0.731	rs10015579	ENSG00000245958.5	RP11-33B1.1	-9.68	7.63e-17	1.07e-12	-0.65	-0.66	Corneal astigmatism;	chr4:119350647	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.866	rs10518329	ENSG00000245958.5	RP11-33B1.1	-9.67	7.77e-17	1.08e-12	-0.69	-0.66	Corneal astigmatism;	chr4:119480680	chr4:119454791~119552025:+
TGCT	cis	rs2739330	0.731	rs4822450	ENSG00000273295.1	AP000350.5	9.67	7.84e-17	1.09e-12	0.72	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23901432~23907068:-
TGCT	cis	rs801193	1	rs11773829	ENSG00000226824.5	RP4-756H11.3	9.66	8.24e-17	1.14e-12	0.76	0.66	Aortic root size;	chr7:66676087	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs7788576	ENSG00000226824.5	RP4-756H11.3	9.66	8.24e-17	1.14e-12	0.76	0.66	Aortic root size;	chr7:66683315	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.935	rs2659916	ENSG00000226824.5	RP4-756H11.3	-9.66	8.24e-17	1.14e-12	-0.76	-0.66	Aortic root size;	chr7:66686365	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs6958520	ENSG00000226824.5	RP4-756H11.3	-9.66	8.24e-17	1.14e-12	-0.76	-0.66	Aortic root size;	chr7:66686466	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.967	rs2707849	ENSG00000226824.5	RP4-756H11.3	-9.66	8.24e-17	1.14e-12	-0.76	-0.66	Aortic root size;	chr7:66687725	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs2707836	ENSG00000226824.5	RP4-756H11.3	-9.66	8.24e-17	1.14e-12	-0.76	-0.66	Aortic root size;	chr7:66695448	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.844	rs7779971	ENSG00000226824.5	RP4-756H11.3	-9.66	8.24e-17	1.14e-12	-0.76	-0.66	Aortic root size;	chr7:66696803	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs2659906	ENSG00000226824.5	RP4-756H11.3	-9.66	8.24e-17	1.14e-12	-0.76	-0.66	Aortic root size;	chr7:66700323	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.935	rs2659899	ENSG00000226824.5	RP4-756H11.3	-9.66	8.24e-17	1.14e-12	-0.76	-0.66	Aortic root size;	chr7:66721734	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs62466793	ENSG00000226824.5	RP4-756H11.3	-9.66	8.24e-17	1.14e-12	-0.76	-0.66	Aortic root size;	chr7:66726530	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs62466794	ENSG00000226824.5	RP4-756H11.3	-9.66	8.24e-17	1.14e-12	-0.76	-0.66	Aortic root size;	chr7:66726592	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs1553609	ENSG00000226824.5	RP4-756H11.3	-9.66	8.24e-17	1.14e-12	-0.76	-0.66	Aortic root size;	chr7:66732152	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs1553610	ENSG00000226824.5	RP4-756H11.3	-9.66	8.24e-17	1.14e-12	-0.76	-0.66	Aortic root size;	chr7:66732246	chr7:66654538~66669855:+
TGCT	cis	rs1150668	0.796	rs728122	ENSG00000216901.1	AL022393.7	9.66	8.36e-17	1.15e-12	0.73	0.66	Pubertal anthropometrics;	chr6:28431347	chr6:28176188~28176674:+
TGCT	cis	rs875971	0.638	rs7793569	ENSG00000226824.5	RP4-756H11.3	9.66	8.4e-17	1.15e-12	0.76	0.66	Aortic root size;	chr7:66651646	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs6975195	ENSG00000226824.5	RP4-756H11.3	9.66	8.4e-17	1.15e-12	0.76	0.66	Aortic root size;	chr7:66659787	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs3857688	ENSG00000226824.5	RP4-756H11.3	9.66	8.4e-17	1.15e-12	0.76	0.66	Aortic root size;	chr7:66662819	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs2286684	ENSG00000226824.5	RP4-756H11.3	9.66	8.4e-17	1.15e-12	0.76	0.66	Aortic root size;	chr7:66664843	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.935	rs2286683	ENSG00000226824.5	RP4-756H11.3	9.66	8.4e-17	1.15e-12	0.76	0.66	Aortic root size;	chr7:66664856	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs10274773	ENSG00000226824.5	RP4-756H11.3	9.66	8.4e-17	1.15e-12	0.76	0.66	Aortic root size;	chr7:66668591	chr7:66654538~66669855:+
TGCT	cis	rs1150668	0.796	rs2247002	ENSG00000216901.1	AL022393.7	9.66	8.53e-17	1.17e-12	0.73	0.66	Pubertal anthropometrics;	chr6:28430174	chr6:28176188~28176674:+
TGCT	cis	rs875971	1	rs709597	ENSG00000226824.5	RP4-756H11.3	9.66	8.56e-17	1.17e-12	0.73	0.66	Aortic root size;	chr7:66360996	chr7:66654538~66669855:+
TGCT	cis	rs2882667	0.69	rs11749163	ENSG00000253404.1	AC034243.1	9.66	8.61e-17	1.18e-12	0.77	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926981	chr5:138744434~138753309:-
TGCT	cis	rs875971	1	rs9986696	ENSG00000226824.5	RP4-756H11.3	9.66	8.67e-17	1.18e-12	0.74	0.66	Aortic root size;	chr7:66239589	chr7:66654538~66669855:+
TGCT	cis	rs7301826	0.651	rs1554807	ENSG00000256250.1	RP11-989F5.1	9.64	9.19e-17	1.24e-12	0.78	0.65	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.651	rs7132657	ENSG00000256250.1	RP11-989F5.1	-9.64	9.19e-17	1.24e-12	-0.78	-0.65	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.651	rs10734979	ENSG00000256250.1	RP11-989F5.1	-9.64	9.19e-17	1.24e-12	-0.78	-0.65	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.627	rs10773823	ENSG00000256250.1	RP11-989F5.1	-9.64	9.19e-17	1.24e-12	-0.78	-0.65	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.61	rs4759791	ENSG00000256250.1	RP11-989F5.1	-9.64	9.19e-17	1.24e-12	-0.78	-0.65	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.61	rs9668291	ENSG00000256250.1	RP11-989F5.1	-9.64	9.19e-17	1.24e-12	-0.78	-0.65	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.651	rs4759521	ENSG00000256250.1	RP11-989F5.1	-9.64	9.19e-17	1.24e-12	-0.78	-0.65	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.651	rs4759794	ENSG00000256250.1	RP11-989F5.1	-9.64	9.19e-17	1.24e-12	-0.78	-0.65	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.651	rs10734981	ENSG00000256250.1	RP11-989F5.1	-9.64	9.19e-17	1.24e-12	-0.78	-0.65	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.651	rs10744483	ENSG00000256250.1	RP11-989F5.1	-9.64	9.19e-17	1.24e-12	-0.78	-0.65	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.651	rs10744484	ENSG00000256250.1	RP11-989F5.1	-9.64	9.19e-17	1.24e-12	-0.78	-0.65	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.651	rs10744485	ENSG00000256250.1	RP11-989F5.1	-9.64	9.19e-17	1.24e-12	-0.78	-0.65	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.651	rs10773824	ENSG00000256250.1	RP11-989F5.1	-9.64	9.19e-17	1.24e-12	-0.78	-0.65	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.651	rs10773825	ENSG00000256250.1	RP11-989F5.1	-9.64	9.19e-17	1.24e-12	-0.78	-0.65	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.651	rs7295705	ENSG00000256250.1	RP11-989F5.1	-9.64	9.19e-17	1.24e-12	-0.78	-0.65	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.651	rs10848209	ENSG00000256250.1	RP11-989F5.1	-9.64	9.19e-17	1.24e-12	-0.78	-0.65	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.651	rs10848210	ENSG00000256250.1	RP11-989F5.1	-9.64	9.19e-17	1.24e-12	-0.78	-0.65	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.627	rs4325342	ENSG00000256250.1	RP11-989F5.1	-9.64	9.19e-17	1.24e-12	-0.78	-0.65	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.627	rs1077317	ENSG00000256250.1	RP11-989F5.1	-9.64	9.19e-17	1.24e-12	-0.78	-0.65	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.651	rs4759525	ENSG00000256250.1	RP11-989F5.1	-9.64	9.19e-17	1.24e-12	-0.78	-0.65	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810606~130812438:+
TGCT	cis	rs1577917	0.837	rs806529	ENSG00000203875.9	SNHG5	-9.64	9.51e-17	1.28e-12	-0.9	-0.65	Response to antipsychotic treatment;	chr6:85757403	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs6921315	ENSG00000203875.9	SNHG5	-9.64	9.51e-17	1.28e-12	-0.9	-0.65	Response to antipsychotic treatment;	chr6:85761950	chr6:85660950~85678736:-
TGCT	cis	rs11098499	0.722	rs10006192	ENSG00000245958.5	RP11-33B1.1	-9.64	9.59e-17	1.28e-12	-0.66	-0.65	Corneal astigmatism;	chr4:119341867	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.615	rs28551750	ENSG00000245958.5	RP11-33B1.1	-9.64	9.59e-17	1.28e-12	-0.66	-0.65	Corneal astigmatism;	chr4:119343746	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.691	rs9995716	ENSG00000245958.5	RP11-33B1.1	-9.64	9.59e-17	1.28e-12	-0.66	-0.65	Corneal astigmatism;	chr4:119343841	chr4:119454791~119552025:+
TGCT	cis	rs875971	0.862	rs11773628	ENSG00000226824.5	RP4-756H11.3	9.64	9.69e-17	1.3e-12	0.7	0.65	Aortic root size;	chr7:66517644	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs778726	ENSG00000226824.5	RP4-756H11.3	-9.63	9.72e-17	1.3e-12	-0.74	-0.65	Aortic root size;	chr7:66363744	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.767	rs1695815	ENSG00000226824.5	RP4-756H11.3	-9.63	9.72e-17	1.3e-12	-0.74	-0.65	Aortic root size;	chr7:66366357	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs778685	ENSG00000226824.5	RP4-756H11.3	-9.63	9.72e-17	1.3e-12	-0.74	-0.65	Aortic root size;	chr7:66371189	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.929	rs778682	ENSG00000226824.5	RP4-756H11.3	-9.63	9.72e-17	1.3e-12	-0.74	-0.65	Aortic root size;	chr7:66372947	chr7:66654538~66669855:+
TGCT	cis	rs943437	0.627	rs9374302	ENSG00000227012.2	RP1-97J1.2	9.63	9.74e-17	1.3e-12	0.72	0.65	Parkinson's disease;	chr6:111919129	chr6:111900489~111901851:-
TGCT	cis	rs2739330	0.828	rs5751770	ENSG00000218537.1	MIF-AS1	9.63	9.8e-17	1.31e-12	0.82	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23894426~23898930:-
TGCT	cis	rs875971	0.66	rs10229345	ENSG00000226824.5	RP4-756H11.3	-9.63	9.85e-17	1.31e-12	-0.76	-0.65	Aortic root size;	chr7:66517181	chr7:66654538~66669855:+
TGCT	cis	rs172166	0.61	rs156737	ENSG00000216901.1	AL022393.7	9.63	9.87e-17	1.32e-12	0.72	0.65	Cardiac Troponin-T levels;	chr6:27927435	chr6:28176188~28176674:+
TGCT	cis	rs801193	1	rs4717319	ENSG00000226824.5	RP4-756H11.3	-9.63	9.98e-17	1.33e-12	-0.76	-0.65	Aortic root size;	chr7:66777606	chr7:66654538~66669855:+
TGCT	cis	rs2283792	0.566	rs1005579	ENSG00000228050.1	TOP3BP1	9.63	1.01e-16	1.34e-12	0.77	0.65	Multiple sclerosis;	chr22:21946569	chr22:22223187~22224566:-
TGCT	cis	rs875971	0.964	rs778735	ENSG00000226824.5	RP4-756H11.3	-9.62	1.03e-16	1.37e-12	-0.74	-0.65	Aortic root size;	chr7:66349822	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs709595	ENSG00000226824.5	RP4-756H11.3	-9.62	1.03e-16	1.37e-12	-0.74	-0.65	Aortic root size;	chr7:66352346	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs811880	ENSG00000226824.5	RP4-756H11.3	-9.62	1.03e-16	1.37e-12	-0.74	-0.65	Aortic root size;	chr7:66353659	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.706	rs1643374	ENSG00000226824.5	RP4-756H11.3	-9.62	1.03e-16	1.38e-12	-0.76	-0.65	Aortic root size;	chr7:66407695	chr7:66654538~66669855:+
TGCT	cis	rs853679	0.527	rs853683	ENSG00000216901.1	AL022393.7	9.62	1.04e-16	1.39e-12	0.71	0.65	Depression;	chr6:28327262	chr6:28176188~28176674:+
TGCT	cis	rs172166	0.61	rs276369	ENSG00000216901.1	AL022393.7	9.62	1.05e-16	1.39e-12	0.72	0.65	Cardiac Troponin-T levels;	chr6:27951465	chr6:28176188~28176674:+
TGCT	cis	rs801193	0.904	rs4718405	ENSG00000226824.5	RP4-756H11.3	-9.61	1.1e-16	1.46e-12	-0.75	-0.65	Aortic root size;	chr7:66789659	chr7:66654538~66669855:+
TGCT	cis	rs12439619	0.693	rs28689861	ENSG00000278603.1	RP13-608F4.5	9.61	1.1e-16	1.46e-12	0.98	0.65	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472203~82472426:+
TGCT	cis	rs875971	0.558	rs4433015	ENSG00000226824.5	RP4-756H11.3	9.61	1.11e-16	1.47e-12	0.76	0.65	Aortic root size;	chr7:66174736	chr7:66654538~66669855:+
TGCT	cis	rs2882667	0.69	rs10155636	ENSG00000253404.1	AC034243.1	9.61	1.13e-16	1.49e-12	0.79	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926301	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.69	rs10463975	ENSG00000253404.1	AC034243.1	9.61	1.13e-16	1.49e-12	0.79	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138927560	chr5:138744434~138753309:-
TGCT	cis	rs875971	0.965	rs9969301	ENSG00000226824.5	RP4-756H11.3	9.6	1.15e-16	1.51e-12	0.74	0.65	Aortic root size;	chr7:66316668	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.867	rs1002053	ENSG00000226824.5	RP4-756H11.3	9.6	1.15e-16	1.51e-12	0.74	0.65	Aortic root size;	chr7:66333558	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs2036264	ENSG00000226824.5	RP4-756H11.3	9.6	1.15e-16	1.51e-12	0.74	0.65	Aortic root size;	chr7:66334917	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs7783613	ENSG00000226824.5	RP4-756H11.3	9.6	1.15e-16	1.51e-12	0.74	0.65	Aortic root size;	chr7:66340274	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs6460292	ENSG00000226824.5	RP4-756H11.3	9.6	1.15e-16	1.51e-12	0.74	0.65	Aortic root size;	chr7:66345088	chr7:66654538~66669855:+
TGCT	cis	rs7188445	0.614	rs62043313	ENSG00000261390.4	RP11-345M22.2	-9.6	1.17e-16	1.54e-12	-0.65	-0.65	Urate levels;	chr16:79710237	chr16:79715232~79770563:-
TGCT	cis	rs7301826	0.571	rs4759788	ENSG00000256250.1	RP11-989F5.1	-9.6	1.2e-16	1.57e-12	-0.78	-0.65	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.61	rs4759789	ENSG00000256250.1	RP11-989F5.1	-9.6	1.2e-16	1.57e-12	-0.78	-0.65	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810606~130812438:+
TGCT	cis	rs2739330	0.796	rs2154594	ENSG00000218537.1	MIF-AS1	-9.59	1.23e-16	1.62e-12	-0.83	-0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23894426~23898930:-
TGCT	cis	rs875971	0.666	rs13242072	ENSG00000226824.5	RP4-756H11.3	9.59	1.25e-16	1.64e-12	0.76	0.65	Aortic root size;	chr7:66301001	chr7:66654538~66669855:+
TGCT	cis	rs6538678	0.746	rs703693	ENSG00000258343.1	RP11-536G4.2	-9.59	1.27e-16	1.67e-12	-1.09	-0.65	Lupus nephritis in systemic lupus erythematosus;	chr12:95866214	chr12:95795345~95858839:-
TGCT	cis	rs853679	0.527	rs853690	ENSG00000216901.1	AL022393.7	9.58	1.29e-16	1.68e-12	0.7	0.65	Depression;	chr6:28317705	chr6:28176188~28176674:+
TGCT	cis	rs3734266	0.646	rs111567516	ENSG00000186328.4	RP11-140K17.2	9.57	1.38e-16	1.79e-12	0.98	0.65	Systemic lupus erythematosus;	chr6:34720937	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs34261333	ENSG00000186328.4	RP11-140K17.2	9.57	1.38e-16	1.79e-12	0.98	0.65	Systemic lupus erythematosus;	chr6:34721763	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs4438945	ENSG00000186328.4	RP11-140K17.2	9.57	1.38e-16	1.79e-12	0.98	0.65	Systemic lupus erythematosus;	chr6:34722238	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs66926909	ENSG00000186328.4	RP11-140K17.2	9.57	1.38e-16	1.79e-12	0.98	0.65	Systemic lupus erythematosus;	chr6:34722933	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs72910167	ENSG00000186328.4	RP11-140K17.2	9.57	1.38e-16	1.79e-12	0.98	0.65	Systemic lupus erythematosus;	chr6:34728388	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs77208116	ENSG00000186328.4	RP11-140K17.2	9.57	1.38e-16	1.79e-12	0.98	0.65	Systemic lupus erythematosus;	chr6:34729376	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs34377413	ENSG00000186328.4	RP11-140K17.2	9.57	1.38e-16	1.79e-12	0.98	0.65	Systemic lupus erythematosus;	chr6:34730524	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.646	rs35369977	ENSG00000186328.4	RP11-140K17.2	9.57	1.38e-16	1.79e-12	0.98	0.65	Systemic lupus erythematosus;	chr6:34731564	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.591	rs35744142	ENSG00000186328.4	RP11-140K17.2	9.57	1.38e-16	1.79e-12	0.98	0.65	Systemic lupus erythematosus;	chr6:34737265	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.639	rs66672772	ENSG00000186328.4	RP11-140K17.2	9.57	1.38e-16	1.79e-12	0.98	0.65	Systemic lupus erythematosus;	chr6:34738160	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs71542490	ENSG00000186328.4	RP11-140K17.2	9.57	1.38e-16	1.79e-12	0.98	0.65	Systemic lupus erythematosus;	chr6:34740699	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs35195182	ENSG00000186328.4	RP11-140K17.2	9.57	1.38e-16	1.79e-12	0.98	0.65	Systemic lupus erythematosus;	chr6:34741909	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs11961041	ENSG00000186328.4	RP11-140K17.2	9.57	1.38e-16	1.79e-12	0.98	0.65	Systemic lupus erythematosus;	chr6:34742132	chr6:34715613~34715940:+
TGCT	cis	rs11098499	0.687	rs71610270	ENSG00000245958.5	RP11-33B1.1	-9.57	1.39e-16	1.81e-12	-0.68	-0.65	Corneal astigmatism;	chr4:119366281	chr4:119454791~119552025:+
TGCT	cis	rs853679	0.527	rs707907	ENSG00000216901.1	AL022393.7	9.57	1.4e-16	1.81e-12	0.71	0.65	Depression;	chr6:28323463	chr6:28176188~28176674:+
TGCT	cis	rs875971	0.964	rs11765965	ENSG00000226824.5	RP4-756H11.3	-9.57	1.41e-16	1.82e-12	-0.74	-0.65	Aortic root size;	chr7:66377234	chr7:66654538~66669855:+
TGCT	cis	rs2882667	0.728	rs10068786	ENSG00000253404.1	AC034243.1	9.56	1.46e-16	1.89e-12	0.82	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941255	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.654	rs825760	ENSG00000253404.1	AC034243.1	-9.56	1.49e-16	1.92e-12	-0.8	-0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804285	chr5:138744434~138753309:-
TGCT	cis	rs875971	0.862	rs6971059	ENSG00000226824.5	RP4-756H11.3	9.56	1.49e-16	1.92e-12	0.71	0.65	Aortic root size;	chr7:66602045	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.789	rs7808013	ENSG00000226824.5	RP4-756H11.3	9.56	1.49e-16	1.92e-12	0.71	0.65	Aortic root size;	chr7:66606209	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.825	rs7384021	ENSG00000226824.5	RP4-756H11.3	9.56	1.49e-16	1.92e-12	0.71	0.65	Aortic root size;	chr7:66612917	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.825	rs66981195	ENSG00000226824.5	RP4-756H11.3	9.56	1.49e-16	1.92e-12	0.71	0.65	Aortic root size;	chr7:66614048	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs3926380	ENSG00000226824.5	RP4-756H11.3	9.56	1.49e-16	1.92e-12	0.71	0.65	Aortic root size;	chr7:66615658	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.825	rs1860472	ENSG00000226824.5	RP4-756H11.3	9.56	1.49e-16	1.92e-12	0.71	0.65	Aortic root size;	chr7:66617736	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.83	rs6976714	ENSG00000226824.5	RP4-756H11.3	-9.55	1.52e-16	1.96e-12	-0.71	-0.65	Aortic root size;	chr7:66426474	chr7:66654538~66669855:+
TGCT	cis	rs1577917	0.958	rs12213343	ENSG00000203875.9	SNHG5	-9.55	1.53e-16	1.97e-12	-0.88	-0.65	Response to antipsychotic treatment;	chr6:85733301	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs12215265	ENSG00000203875.9	SNHG5	-9.55	1.53e-16	1.97e-12	-0.88	-0.65	Response to antipsychotic treatment;	chr6:85734251	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs12197463	ENSG00000203875.9	SNHG5	-9.55	1.53e-16	1.97e-12	-0.88	-0.65	Response to antipsychotic treatment;	chr6:85735524	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs6454488	ENSG00000203875.9	SNHG5	-9.55	1.53e-16	1.97e-12	-0.88	-0.65	Response to antipsychotic treatment;	chr6:85741124	chr6:85660950~85678736:-
TGCT	cis	rs11098499	0.691	rs10010355	ENSG00000245958.5	RP11-33B1.1	-9.55	1.53e-16	1.97e-12	-0.65	-0.65	Corneal astigmatism;	chr4:119339888	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.691	rs9307471	ENSG00000245958.5	RP11-33B1.1	-9.55	1.53e-16	1.97e-12	-0.65	-0.65	Corneal astigmatism;	chr4:119340107	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.644	rs17517414	ENSG00000245958.5	RP11-33B1.1	-9.55	1.53e-16	1.97e-12	-0.65	-0.65	Corneal astigmatism;	chr4:119340946	chr4:119454791~119552025:+
TGCT	cis	rs2283792	0.622	rs5756323	ENSG00000228050.1	TOP3BP1	-9.55	1.55e-16	1.99e-12	-0.77	-0.65	Multiple sclerosis;	chr22:21980398	chr22:22223187~22224566:-
TGCT	cis	rs11673344	0.642	rs11083420	ENSG00000226686.6	LINC01535	9.55	1.58e-16	2.02e-12	0.72	0.65	Obesity-related traits;	chr19:37317901	chr19:37251912~37265535:+
TGCT	cis	rs6952407	1	rs6952407	ENSG00000226824.5	RP4-756H11.3	9.54	1.62e-16	2.07e-12	0.76	0.65	Cotinine glucuronidation;	chr7:66580525	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.66	rs801192	ENSG00000226824.5	RP4-756H11.3	9.54	1.64e-16	2.09e-12	0.76	0.65	Aortic root size;	chr7:66566965	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.66	rs801190	ENSG00000226824.5	RP4-756H11.3	9.54	1.64e-16	2.09e-12	0.76	0.65	Aortic root size;	chr7:66568046	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.66	rs3857686	ENSG00000226824.5	RP4-756H11.3	9.54	1.64e-16	2.09e-12	0.76	0.65	Aortic root size;	chr7:66571204	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.638	rs6460305	ENSG00000226824.5	RP4-756H11.3	9.54	1.64e-16	2.09e-12	0.76	0.65	Aortic root size;	chr7:66595421	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.638	rs6960778	ENSG00000226824.5	RP4-756H11.3	9.54	1.64e-16	2.09e-12	0.76	0.65	Aortic root size;	chr7:66606610	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.66	rs1860468	ENSG00000226824.5	RP4-756H11.3	9.54	1.64e-16	2.09e-12	0.76	0.65	Aortic root size;	chr7:66642265	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.619	rs12533585	ENSG00000226824.5	RP4-756H11.3	-9.54	1.64e-16	2.09e-12	-0.76	-0.65	Aortic root size;	chr7:66519618	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.66	rs28698552	ENSG00000226824.5	RP4-756H11.3	-9.54	1.64e-16	2.09e-12	-0.76	-0.65	Aortic root size;	chr7:66540031	chr7:66654538~66669855:+
TGCT	cis	rs7301826	0.651	rs4759517	ENSG00000256250.1	RP11-989F5.1	-9.53	1.69e-16	2.14e-12	-0.78	-0.65	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.651	rs7971046	ENSG00000256250.1	RP11-989F5.1	-9.53	1.69e-16	2.14e-12	-0.78	-0.65	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.651	rs4759519	ENSG00000256250.1	RP11-989F5.1	-9.53	1.69e-16	2.14e-12	-0.78	-0.65	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.651	rs12228957	ENSG00000256250.1	RP11-989F5.1	-9.53	1.69e-16	2.14e-12	-0.78	-0.65	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.651	rs12228959	ENSG00000256250.1	RP11-989F5.1	-9.53	1.69e-16	2.14e-12	-0.78	-0.65	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810606~130812438:+
TGCT	cis	rs875971	0.651	rs2420596	ENSG00000226824.5	RP4-756H11.3	-9.53	1.7e-16	2.15e-12	-0.71	-0.65	Aortic root size;	chr7:66450996	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.52	rs2420597	ENSG00000226824.5	RP4-756H11.3	-9.53	1.7e-16	2.15e-12	-0.71	-0.65	Aortic root size;	chr7:66450999	chr7:66654538~66669855:+
TGCT	cis	rs858239	0.699	rs955187	ENSG00000230658.1	KLHL7-AS1	-9.53	1.73e-16	2.18e-12	-0.68	-0.65	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23101228~23105703:-
TGCT	cis	rs875971	0.798	rs6460304	ENSG00000226824.5	RP4-756H11.3	-9.52	1.83e-16	2.29e-12	-0.7	-0.65	Aortic root size;	chr7:66499741	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs6945775	ENSG00000226824.5	RP4-756H11.3	-9.52	1.83e-16	2.29e-12	-0.7	-0.65	Aortic root size;	chr7:66503987	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.798	rs57739047	ENSG00000226824.5	RP4-756H11.3	-9.52	1.83e-16	2.29e-12	-0.7	-0.65	Aortic root size;	chr7:66507579	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.83	rs6950137	ENSG00000226824.5	RP4-756H11.3	-9.52	1.83e-16	2.29e-12	-0.7	-0.65	Aortic root size;	chr7:66511623	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs11763189	ENSG00000226824.5	RP4-756H11.3	-9.52	1.83e-16	2.29e-12	-0.7	-0.65	Aortic root size;	chr7:66518542	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.66	rs10950049	ENSG00000226824.5	RP4-756H11.3	-9.52	1.84e-16	2.31e-12	-0.75	-0.65	Aortic root size;	chr7:66765873	chr7:66654538~66669855:+
TGCT	cis	rs1150668	0.83	rs2859365	ENSG00000216901.1	AL022393.7	-9.52	1.88e-16	2.35e-12	-0.71	-0.65	Pubertal anthropometrics;	chr6:28423688	chr6:28176188~28176674:+
TGCT	cis	rs11673344	0.642	rs73025481	ENSG00000226686.6	LINC01535	9.51	1.91e-16	2.39e-12	0.72	0.65	Obesity-related traits;	chr19:37346437	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.642	rs55755939	ENSG00000226686.6	LINC01535	9.51	1.91e-16	2.39e-12	0.72	0.65	Obesity-related traits;	chr19:37353723	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.555	rs502546	ENSG00000226686.6	LINC01535	-9.51	1.91e-16	2.39e-12	-0.72	-0.65	Obesity-related traits;	chr19:37361788	chr19:37251912~37265535:+
TGCT	cis	rs11098499	0.661	rs10015965	ENSG00000245958.5	RP11-33B1.1	-9.51	1.93e-16	2.4e-12	-0.64	-0.65	Corneal astigmatism;	chr4:119347082	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.535	rs10005542	ENSG00000245958.5	RP11-33B1.1	-9.51	1.93e-16	2.4e-12	-0.64	-0.65	Corneal astigmatism;	chr4:119347147	chr4:119454791~119552025:+
TGCT	cis	rs875971	0.862	rs1695820	ENSG00000226824.5	RP4-756H11.3	-9.51	1.95e-16	2.43e-12	-0.7	-0.65	Aortic root size;	chr7:66379576	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.83	rs778715	ENSG00000226824.5	RP4-756H11.3	-9.51	1.95e-16	2.43e-12	-0.7	-0.65	Aortic root size;	chr7:66384222	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.83	rs809025	ENSG00000226824.5	RP4-756H11.3	-9.51	1.95e-16	2.43e-12	-0.7	-0.65	Aortic root size;	chr7:66384832	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs778702	ENSG00000226824.5	RP4-756H11.3	-9.51	1.95e-16	2.43e-12	-0.7	-0.65	Aortic root size;	chr7:66399848	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs1643375	ENSG00000226824.5	RP4-756H11.3	-9.51	1.95e-16	2.43e-12	-0.7	-0.65	Aortic root size;	chr7:66407690	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs6962717	ENSG00000226824.5	RP4-756H11.3	-9.51	1.95e-16	2.43e-12	-0.7	-0.65	Aortic root size;	chr7:66418748	chr7:66654538~66669855:+
TGCT	cis	rs11673344	0.642	rs55926714	ENSG00000226686.6	LINC01535	9.5	2.01e-16	2.49e-12	0.71	0.65	Obesity-related traits;	chr19:37307974	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.642	rs12462487	ENSG00000226686.6	LINC01535	9.5	2.01e-16	2.49e-12	0.71	0.65	Obesity-related traits;	chr19:37311211	chr19:37251912~37265535:+
TGCT	cis	rs801193	0.548	rs2659904	ENSG00000226824.5	RP4-756H11.3	-9.5	2.03e-16	2.52e-12	-0.74	-0.65	Aortic root size;	chr7:66713615	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs13239306	ENSG00000226824.5	RP4-756H11.3	9.5	2.05e-16	2.55e-12	0.76	0.65	Aortic root size;	chr7:66671030	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs6946143	ENSG00000226824.5	RP4-756H11.3	-9.5	2.1e-16	2.61e-12	-0.69	-0.65	Aortic root size;	chr7:66114735	chr7:66654538~66669855:+
TGCT	cis	rs3734266	0.639	rs9469813	ENSG00000186328.4	RP11-140K17.2	9.49	2.13e-16	2.64e-12	0.93	0.65	Systemic lupus erythematosus;	chr6:34602037	chr6:34715613~34715940:+
TGCT	cis	rs6903823	0.508	rs1778484	ENSG00000216901.1	AL022393.7	9.49	2.14e-16	2.64e-12	0.7	0.65	Pulmonary function;	chr6:28273021	chr6:28176188~28176674:+
TGCT	cis	rs12439619	0.705	rs4778665	ENSG00000278603.1	RP13-608F4.5	9.49	2.15e-16	2.66e-12	1.06	0.65	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472203~82472426:+
TGCT	cis	rs2882667	0.652	rs874115	ENSG00000253404.1	AC034243.1	9.49	2.18e-16	2.69e-12	0.77	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944367	chr5:138744434~138753309:-
TGCT	cis	rs3734266	0.702	rs34374374	ENSG00000186328.4	RP11-140K17.2	9.47	2.38e-16	2.93e-12	1.02	0.65	Systemic lupus erythematosus;	chr6:34600259	chr6:34715613~34715940:+
TGCT	cis	rs858239	0.899	rs10262243	ENSG00000230658.1	KLHL7-AS1	9.47	2.44e-16	3.01e-12	0.73	0.65	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.899	rs28458177	ENSG00000230658.1	KLHL7-AS1	9.47	2.44e-16	3.01e-12	0.73	0.65	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23101228~23105703:-
TGCT	cis	rs875971	0.893	rs62465470	ENSG00000226824.5	RP4-756H11.3	9.47	2.45e-16	3.01e-12	0.71	0.65	Aortic root size;	chr7:66136231	chr7:66654538~66669855:+
TGCT	cis	rs12439619	0.846	rs28470877	ENSG00000278603.1	RP13-608F4.5	9.47	2.47e-16	3.04e-12	1.01	0.65	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472203~82472426:+
TGCT	cis	rs7301826	0.557	rs7953184	ENSG00000256250.1	RP11-989F5.1	9.46	2.51e-16	3.08e-12	0.78	0.65	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810606~130812438:+
TGCT	cis	rs858239	0.699	rs1881200	ENSG00000230658.1	KLHL7-AS1	-9.46	2.53e-16	3.11e-12	-0.7	-0.65	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23101228~23105703:-
TGCT	cis	rs12439619	0.846	rs62011975	ENSG00000278603.1	RP13-608F4.5	9.46	2.54e-16	3.12e-12	1.01	0.65	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472203~82472426:+
TGCT	cis	rs12439619	0.846	rs62012003	ENSG00000278603.1	RP13-608F4.5	9.46	2.54e-16	3.12e-12	1.01	0.65	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472203~82472426:+
TGCT	cis	rs12439619	0.846	rs62012004	ENSG00000278603.1	RP13-608F4.5	9.46	2.54e-16	3.12e-12	1.01	0.65	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472203~82472426:+
TGCT	cis	rs875971	0.965	rs7794930	ENSG00000226824.5	RP4-756H11.3	9.46	2.54e-16	3.12e-12	0.74	0.65	Aortic root size;	chr7:66313559	chr7:66654538~66669855:+
TGCT	cis	rs1150668	0.83	rs213240	ENSG00000216901.1	AL022393.7	9.46	2.56e-16	3.14e-12	0.7	0.65	Pubertal anthropometrics;	chr6:28348098	chr6:28176188~28176674:+
TGCT	cis	rs6903823	0.508	rs1150724	ENSG00000216901.1	AL022393.7	9.46	2.61e-16	3.2e-12	0.7	0.65	Pulmonary function;	chr6:28282459	chr6:28176188~28176674:+
TGCT	cis	rs875971	0.825	rs1129531	ENSG00000226824.5	RP4-756H11.3	9.46	2.63e-16	3.22e-12	0.72	0.65	Aortic root size;	chr7:66154117	chr7:66654538~66669855:+
TGCT	cis	rs3734266	0.702	rs13209544	ENSG00000186328.4	RP11-140K17.2	9.45	2.68e-16	3.27e-12	1.1	0.65	Systemic lupus erythematosus;	chr6:34620190	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs9461992	ENSG00000186328.4	RP11-140K17.2	9.45	2.68e-16	3.27e-12	1.1	0.65	Systemic lupus erythematosus;	chr6:34621183	chr6:34715613~34715940:+
TGCT	cis	rs1577917	0.958	rs34795473	ENSG00000203875.9	SNHG5	-9.45	2.71e-16	3.31e-12	-0.88	-0.65	Response to antipsychotic treatment;	chr6:85752081	chr6:85660950~85678736:-
TGCT	cis	rs858239	0.899	rs10085838	ENSG00000230658.1	KLHL7-AS1	9.45	2.71e-16	3.31e-12	0.75	0.65	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23101228~23105703:-
TGCT	cis	rs11098499	0.691	rs12510133	ENSG00000245958.5	RP11-33B1.1	-9.45	2.74e-16	3.32e-12	-0.65	-0.65	Corneal astigmatism;	chr4:119350189	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs12506487	ENSG00000245958.5	RP11-33B1.1	-9.45	2.74e-16	3.32e-12	-0.65	-0.65	Corneal astigmatism;	chr4:119350206	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.691	rs12502524	ENSG00000245958.5	RP11-33B1.1	-9.45	2.74e-16	3.32e-12	-0.65	-0.65	Corneal astigmatism;	chr4:119350259	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.691	rs28396837	ENSG00000245958.5	RP11-33B1.1	-9.45	2.74e-16	3.32e-12	-0.65	-0.65	Corneal astigmatism;	chr4:119350386	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.629	rs28369518	ENSG00000245958.5	RP11-33B1.1	-9.45	2.74e-16	3.32e-12	-0.65	-0.65	Corneal astigmatism;	chr4:119350475	chr4:119454791~119552025:+
TGCT	cis	rs7301826	0.651	rs2037789	ENSG00000256250.1	RP11-989F5.1	9.45	2.74e-16	3.33e-12	0.77	0.65	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810606~130812438:+
TGCT	cis	rs875971	0.862	rs10274883	ENSG00000226824.5	RP4-756H11.3	9.45	2.76e-16	3.34e-12	0.71	0.65	Aortic root size;	chr7:66651104	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.569	rs881285	ENSG00000226824.5	RP4-756H11.3	9.45	2.76e-16	3.34e-12	0.71	0.65	Aortic root size;	chr7:66654433	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.569	rs3846973	ENSG00000226824.5	RP4-756H11.3	9.45	2.76e-16	3.34e-12	0.71	0.65	Aortic root size;	chr7:66655048	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.569	rs2013908	ENSG00000226824.5	RP4-756H11.3	9.45	2.76e-16	3.34e-12	0.71	0.65	Aortic root size;	chr7:66656082	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.569	rs13242290	ENSG00000226824.5	RP4-756H11.3	9.45	2.76e-16	3.34e-12	0.71	0.65	Aortic root size;	chr7:66656898	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.548	rs2109297	ENSG00000226824.5	RP4-756H11.3	9.45	2.76e-16	3.34e-12	0.71	0.65	Aortic root size;	chr7:66657397	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.569	rs6978178	ENSG00000226824.5	RP4-756H11.3	9.45	2.76e-16	3.34e-12	0.71	0.65	Aortic root size;	chr7:66658097	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.591	rs721717	ENSG00000226824.5	RP4-756H11.3	9.45	2.76e-16	3.34e-12	0.71	0.65	Aortic root size;	chr7:66665305	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.569	rs6951302	ENSG00000226824.5	RP4-756H11.3	9.45	2.76e-16	3.34e-12	0.71	0.65	Aortic root size;	chr7:66667525	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.508	rs10258739	ENSG00000226824.5	RP4-756H11.3	9.44	2.81e-16	3.4e-12	0.71	0.65	Aortic root size;	chr7:66597948	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs4236208	ENSG00000226824.5	RP4-756H11.3	9.44	2.82e-16	3.41e-12	0.72	0.65	Aortic root size;	chr7:66284091	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs10261398	ENSG00000226824.5	RP4-756H11.3	9.44	2.82e-16	3.41e-12	0.72	0.65	Aortic root size;	chr7:66285177	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs10224872	ENSG00000226824.5	RP4-756H11.3	9.44	2.82e-16	3.41e-12	0.72	0.65	Aortic root size;	chr7:66294786	chr7:66654538~66669855:+
TGCT	cis	rs6903823	0.508	rs1150726	ENSG00000216901.1	AL022393.7	9.44	2.84e-16	3.42e-12	0.7	0.65	Pulmonary function;	chr6:28275265	chr6:28176188~28176674:+
TGCT	cis	rs875971	0.862	rs28470208	ENSG00000226824.5	RP4-756H11.3	9.44	2.84e-16	3.42e-12	0.71	0.65	Aortic root size;	chr7:66119713	chr7:66654538~66669855:+
TGCT	cis	rs1577917	0.518	rs2475787	ENSG00000203875.9	SNHG5	9.44	2.85e-16	3.43e-12	0.77	0.65	Response to antipsychotic treatment;	chr6:85705518	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.518	rs6454482	ENSG00000203875.9	SNHG5	9.44	2.85e-16	3.43e-12	0.77	0.65	Response to antipsychotic treatment;	chr6:85708470	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs6454487	ENSG00000203875.9	SNHG5	9.44	2.87e-16	3.45e-12	0.88	0.65	Response to antipsychotic treatment;	chr6:85737150	chr6:85660950~85678736:-
TGCT	cis	rs801193	0.569	rs2659908	ENSG00000226824.5	RP4-756H11.3	-9.44	2.89e-16	3.47e-12	-0.71	-0.65	Aortic root size;	chr7:66695835	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.569	rs2659907	ENSG00000226824.5	RP4-756H11.3	-9.44	2.89e-16	3.47e-12	-0.71	-0.65	Aortic root size;	chr7:66699045	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.569	rs7782587	ENSG00000226824.5	RP4-756H11.3	-9.44	2.89e-16	3.47e-12	-0.71	-0.65	Aortic root size;	chr7:66701485	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.569	rs4717315	ENSG00000226824.5	RP4-756H11.3	-9.44	2.89e-16	3.47e-12	-0.71	-0.65	Aortic root size;	chr7:66713338	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.527	rs2707837	ENSG00000226824.5	RP4-756H11.3	-9.44	2.89e-16	3.47e-12	-0.71	-0.65	Aortic root size;	chr7:66716086	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.569	rs2707824	ENSG00000226824.5	RP4-756H11.3	-9.44	2.89e-16	3.47e-12	-0.71	-0.65	Aortic root size;	chr7:66724256	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.591	rs4506088	ENSG00000226824.5	RP4-756H11.3	9.44	2.89e-16	3.47e-12	0.71	0.65	Aortic root size;	chr7:66670470	chr7:66654538~66669855:+
TGCT	cis	rs6903823	0.508	rs1150721	ENSG00000216901.1	AL022393.7	9.44	2.92e-16	3.5e-12	0.7	0.65	Pulmonary function;	chr6:28287263	chr6:28176188~28176674:+
TGCT	cis	rs6903823	0.508	rs1150718	ENSG00000216901.1	AL022393.7	9.44	2.92e-16	3.5e-12	0.7	0.65	Pulmonary function;	chr6:28289170	chr6:28176188~28176674:+
TGCT	cis	rs6903823	0.508	rs1233660	ENSG00000216901.1	AL022393.7	9.44	2.92e-16	3.5e-12	0.7	0.65	Pulmonary function;	chr6:28292472	chr6:28176188~28176674:+
TGCT	cis	rs10028773	0.666	rs12498657	ENSG00000245958.5	RP11-33B1.1	-9.43	3e-16	3.59e-12	-0.66	-0.65	Educational attainment;	chr4:119341711	chr4:119454791~119552025:+
TGCT	cis	rs12439619	0.693	rs4778989	ENSG00000278603.1	RP13-608F4.5	9.42	3.13e-16	3.74e-12	0.97	0.65	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472203~82472426:+
TGCT	cis	rs3734266	0.591	rs35684630	ENSG00000186328.4	RP11-140K17.2	9.42	3.22e-16	3.83e-12	0.96	0.65	Systemic lupus erythematosus;	chr6:34702567	chr6:34715613~34715940:+
TGCT	cis	rs875971	0.862	rs10282433	ENSG00000226824.5	RP4-756H11.3	9.42	3.22e-16	3.83e-12	0.72	0.65	Aortic root size;	chr7:66256452	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs10276077	ENSG00000226824.5	RP4-756H11.3	9.42	3.22e-16	3.83e-12	0.72	0.65	Aortic root size;	chr7:66263424	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.825	rs4587224	ENSG00000226824.5	RP4-756H11.3	9.42	3.22e-16	3.83e-12	0.72	0.65	Aortic root size;	chr7:66271195	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.792	rs6971752	ENSG00000226824.5	RP4-756H11.3	9.42	3.22e-16	3.83e-12	0.72	0.65	Aortic root size;	chr7:66272999	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs10950033	ENSG00000226824.5	RP4-756H11.3	9.42	3.22e-16	3.83e-12	0.72	0.65	Aortic root size;	chr7:66274686	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs11760844	ENSG00000226824.5	RP4-756H11.3	9.42	3.22e-16	3.83e-12	0.72	0.65	Aortic root size;	chr7:66274896	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs4149461	ENSG00000226824.5	RP4-756H11.3	9.42	3.22e-16	3.83e-12	0.72	0.65	Aortic root size;	chr7:66279745	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs12537823	ENSG00000226824.5	RP4-756H11.3	-9.42	3.22e-16	3.83e-12	-0.72	-0.65	Aortic root size;	chr7:66255897	chr7:66654538~66669855:+
TGCT	cis	rs11673344	0.563	rs256744	ENSG00000226686.6	LINC01535	-9.41	3.4e-16	4.03e-12	-0.72	-0.65	Obesity-related traits;	chr19:37364586	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.562	rs256740	ENSG00000226686.6	LINC01535	-9.41	3.4e-16	4.03e-12	-0.72	-0.65	Obesity-related traits;	chr19:37365451	chr19:37251912~37265535:+
TGCT	cis	rs3734266	0.702	rs9469820	ENSG00000186328.4	RP11-140K17.2	9.4	3.59e-16	4.26e-12	1.09	0.65	Systemic lupus erythematosus;	chr6:34618986	chr6:34715613~34715940:+
TGCT	cis	rs858239	0.539	rs10254544	ENSG00000230658.1	KLHL7-AS1	9.4	3.61e-16	4.28e-12	0.74	0.64	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23101228~23105703:-
TGCT	cis	rs11098499	0.698	rs4422403	ENSG00000245958.5	RP11-33B1.1	-9.39	3.72e-16	4.4e-12	-0.66	-0.64	Corneal astigmatism;	chr4:119337039	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.569	rs10023641	ENSG00000245958.5	RP11-33B1.1	-9.39	3.72e-16	4.4e-12	-0.66	-0.64	Corneal astigmatism;	chr4:119337255	chr4:119454791~119552025:+
TGCT	cis	rs11673344	0.58	rs320881	ENSG00000226686.6	LINC01535	9.39	3.75e-16	4.43e-12	0.72	0.64	Obesity-related traits;	chr19:37246948	chr19:37251912~37265535:+
TGCT	cis	rs875971	0.862	rs1612452	ENSG00000226824.5	RP4-756H11.3	9.39	3.88e-16	4.58e-12	0.71	0.64	Aortic root size;	chr7:66108909	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs1167390	ENSG00000226824.5	RP4-756H11.3	9.39	3.88e-16	4.58e-12	0.71	0.64	Aortic root size;	chr7:66110906	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs35034167	ENSG00000226824.5	RP4-756H11.3	9.39	3.88e-16	4.58e-12	0.71	0.64	Aortic root size;	chr7:66115179	chr7:66654538~66669855:+
TGCT	cis	rs7301826	0.651	rs7968675	ENSG00000256250.1	RP11-989F5.1	-9.38	3.94e-16	4.66e-12	-0.77	-0.64	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810606~130812438:+
TGCT	cis	rs1150668	0.796	rs213237	ENSG00000216901.1	AL022393.7	9.38	4.05e-16	4.78e-12	0.7	0.64	Pubertal anthropometrics;	chr6:28356161	chr6:28176188~28176674:+
TGCT	cis	rs1150668	0.796	rs213236	ENSG00000216901.1	AL022393.7	9.38	4.05e-16	4.78e-12	0.7	0.64	Pubertal anthropometrics;	chr6:28356620	chr6:28176188~28176674:+
TGCT	cis	rs7301826	0.651	rs4514465	ENSG00000256250.1	RP11-989F5.1	-9.37	4.15e-16	4.9e-12	-0.76	-0.64	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810606~130812438:+
TGCT	cis	rs801193	1	rs2659912	ENSG00000226824.5	RP4-756H11.3	-9.37	4.17e-16	4.92e-12	-0.75	-0.64	Aortic root size;	chr7:66693012	chr7:66654538~66669855:+
TGCT	cis	rs801193	1	rs10252765	ENSG00000226824.5	RP4-756H11.3	-9.36	4.45e-16	5.24e-12	-0.74	-0.64	Aortic root size;	chr7:66763745	chr7:66654538~66669855:+
TGCT	cis	rs6452524	0.618	rs6452506	ENSG00000249664.1	CTD-2227C6.2	9.36	4.54e-16	5.33e-12	0.66	0.64	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:83012285~83013109:-
TGCT	cis	rs1155848	0.892	rs1023293	ENSG00000227354.5	RBM26-AS1	9.35	4.85e-16	5.68e-12	1.07	0.64	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480285	chr13:79406309~79424328:+
TGCT	cis	rs11098499	0.722	rs1814814	ENSG00000245958.5	RP11-33B1.1	-9.34	4.86e-16	5.7e-12	-0.64	-0.64	Corneal astigmatism;	chr4:119336969	chr4:119454791~119552025:+
TGCT	cis	rs3814244	0.515	rs2906856	ENSG00000255733.4	IFNG-AS1	-9.34	4.96e-16	5.8e-12	-0.63	-0.64	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996421	chr12:67989445~68234686:+
TGCT	cis	rs2906856	0.921	rs1019076	ENSG00000255733.4	IFNG-AS1	-9.34	4.96e-16	5.8e-12	-0.63	-0.64	Mosquito bite size;	chr12:68004338	chr12:67989445~68234686:+
TGCT	cis	rs3814244	0.515	rs2906862	ENSG00000255733.4	IFNG-AS1	-9.34	4.96e-16	5.8e-12	-0.63	-0.64	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005371	chr12:67989445~68234686:+
TGCT	cis	rs11673344	0.642	rs12462708	ENSG00000226686.6	LINC01535	-9.34	5.03e-16	5.87e-12	-0.7	-0.64	Obesity-related traits;	chr19:37306676	chr19:37251912~37265535:+
TGCT	cis	rs1577917	0.883	rs2782263	ENSG00000203875.9	SNHG5	-9.34	5.1e-16	5.95e-12	-0.78	-0.64	Response to antipsychotic treatment;	chr6:86081589	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.916	rs7759727	ENSG00000203875.9	SNHG5	-9.33	5.28e-16	6.14e-12	-0.88	-0.64	Response to antipsychotic treatment;	chr6:85809160	chr6:85660950~85678736:-
TGCT	cis	rs801193	0.569	rs2659893	ENSG00000226824.5	RP4-756H11.3	-9.33	5.28e-16	6.14e-12	-0.7	-0.64	Aortic root size;	chr7:66735006	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.569	rs2659892	ENSG00000226824.5	RP4-756H11.3	-9.33	5.28e-16	6.14e-12	-0.7	-0.64	Aortic root size;	chr7:66735318	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.548	rs2659891	ENSG00000226824.5	RP4-756H11.3	-9.33	5.28e-16	6.14e-12	-0.7	-0.64	Aortic root size;	chr7:66736127	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.569	rs2707847	ENSG00000226824.5	RP4-756H11.3	-9.33	5.28e-16	6.14e-12	-0.7	-0.64	Aortic root size;	chr7:66737884	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.548	rs7805152	ENSG00000226824.5	RP4-756H11.3	-9.33	5.28e-16	6.14e-12	-0.7	-0.64	Aortic root size;	chr7:66744266	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.569	rs11761542	ENSG00000226824.5	RP4-756H11.3	-9.33	5.28e-16	6.14e-12	-0.7	-0.64	Aortic root size;	chr7:66753209	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs1167612	ENSG00000226824.5	RP4-756H11.3	9.33	5.37e-16	6.24e-12	0.71	0.64	Aortic root size;	chr7:66102989	chr7:66654538~66669855:+
TGCT	cis	rs1577917	0.538	rs7755996	ENSG00000203875.9	SNHG5	9.32	5.59e-16	6.49e-12	0.76	0.64	Response to antipsychotic treatment;	chr6:85714002	chr6:85660950~85678736:-
TGCT	cis	rs858239	0.537	rs10279691	ENSG00000230658.1	KLHL7-AS1	9.31	5.86e-16	6.8e-12	0.75	0.64	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23101228~23105703:-
TGCT	cis	rs3734266	1	rs3734266	ENSG00000186328.4	RP11-140K17.2	9.31	5.92e-16	6.86e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34855410	chr6:34715613~34715940:+
TGCT	cis	rs875971	0.767	rs12668005	ENSG00000226824.5	RP4-756H11.3	-9.31	6.01e-16	6.87e-12	-0.69	-0.64	Aortic root size;	chr7:66444034	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs11765791	ENSG00000226824.5	RP4-756H11.3	-9.31	6.01e-16	6.87e-12	-0.69	-0.64	Aortic root size;	chr7:66471587	chr7:66654538~66669855:+
TGCT	cis	rs6538678	0.746	rs12820313	ENSG00000258343.1	RP11-536G4.2	-9.31	6.02e-16	6.87e-12	-1.02	-0.64	Lupus nephritis in systemic lupus erythematosus;	chr12:95861926	chr12:95795345~95858839:-
TGCT	cis	rs875971	0.862	rs4718319	ENSG00000226824.5	RP4-756H11.3	9.3	6.14e-16	7e-12	0.71	0.64	Aortic root size;	chr7:66187797	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.723	rs28391294	ENSG00000226824.5	RP4-756H11.3	9.3	6.14e-16	7e-12	0.71	0.64	Aortic root size;	chr7:66189328	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.83	rs6967708	ENSG00000226824.5	RP4-756H11.3	9.3	6.14e-16	7e-12	0.71	0.64	Aortic root size;	chr7:66192326	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.895	rs7782806	ENSG00000226824.5	RP4-756H11.3	9.3	6.14e-16	7e-12	0.71	0.64	Aortic root size;	chr7:66192910	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.66	rs10263935	ENSG00000226824.5	RP4-756H11.3	-9.3	6.23e-16	7.11e-12	-0.74	-0.64	Aortic root size;	chr7:66631041	chr7:66654538~66669855:+
TGCT	cis	rs12439619	0.693	rs7165536	ENSG00000278603.1	RP13-608F4.5	9.29	6.49e-16	7.39e-12	0.97	0.64	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472203~82472426:+
TGCT	cis	rs875971	0.756	rs2901210	ENSG00000226824.5	RP4-756H11.3	9.29	6.49e-16	7.39e-12	0.69	0.64	Aortic root size;	chr7:66552518	chr7:66654538~66669855:+
TGCT	cis	rs3734266	0.702	rs7775947	ENSG00000186328.4	RP11-140K17.2	9.29	6.62e-16	7.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34747380	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs7776439	ENSG00000186328.4	RP11-140K17.2	9.29	6.62e-16	7.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34747671	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs71567467	ENSG00000186328.4	RP11-140K17.2	9.29	6.62e-16	7.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34822832	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs6926373	ENSG00000186328.4	RP11-140K17.2	9.29	6.62e-16	7.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34833557	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs13210470	ENSG00000186328.4	RP11-140K17.2	9.29	6.62e-16	7.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34834001	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs2296362	ENSG00000186328.4	RP11-140K17.2	9.29	6.62e-16	7.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34835222	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs7743949	ENSG00000186328.4	RP11-140K17.2	9.29	6.62e-16	7.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34836738	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs35940001	ENSG00000186328.4	RP11-140K17.2	9.29	6.62e-16	7.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34838763	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs11966100	ENSG00000186328.4	RP11-140K17.2	9.29	6.62e-16	7.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34839740	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs34480956	ENSG00000186328.4	RP11-140K17.2	9.29	6.62e-16	7.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34840324	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs13196785	ENSG00000186328.4	RP11-140K17.2	9.29	6.62e-16	7.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34841044	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs13213288	ENSG00000186328.4	RP11-140K17.2	9.29	6.62e-16	7.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34844683	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs13213604	ENSG00000186328.4	RP11-140K17.2	9.29	6.62e-16	7.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34844764	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs34840245	ENSG00000186328.4	RP11-140K17.2	9.29	6.62e-16	7.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34844924	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs34355573	ENSG00000186328.4	RP11-140K17.2	9.29	6.62e-16	7.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34849619	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs6904996	ENSG00000186328.4	RP11-140K17.2	9.29	6.62e-16	7.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34852743	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs35203657	ENSG00000186328.4	RP11-140K17.2	9.29	6.62e-16	7.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34853513	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs13205210	ENSG00000186328.4	RP11-140K17.2	9.29	6.62e-16	7.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34864079	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.536	rs6925175	ENSG00000186328.4	RP11-140K17.2	9.29	6.62e-16	7.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34864518	chr6:34715613~34715940:+
TGCT	cis	rs875971	0.798	rs12698522	ENSG00000226824.5	RP4-756H11.3	-9.29	6.62e-16	7.4e-12	-0.69	-0.64	Aortic root size;	chr7:66502354	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.83	rs28714531	ENSG00000226824.5	RP4-756H11.3	-9.29	6.62e-16	7.4e-12	-0.69	-0.64	Aortic root size;	chr7:66503250	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs12698526	ENSG00000226824.5	RP4-756H11.3	-9.29	6.62e-16	7.4e-12	-0.69	-0.64	Aortic root size;	chr7:66504118	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs13232191	ENSG00000226824.5	RP4-756H11.3	-9.29	6.62e-16	7.4e-12	-0.69	-0.64	Aortic root size;	chr7:66521661	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs35378740	ENSG00000226824.5	RP4-756H11.3	-9.29	6.62e-16	7.4e-12	-0.69	-0.64	Aortic root size;	chr7:66522725	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs10950043	ENSG00000226824.5	RP4-756H11.3	-9.29	6.62e-16	7.4e-12	-0.69	-0.64	Aortic root size;	chr7:66523623	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs17747530	ENSG00000226824.5	RP4-756H11.3	-9.29	6.62e-16	7.4e-12	-0.69	-0.64	Aortic root size;	chr7:66529742	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs13226170	ENSG00000226824.5	RP4-756H11.3	-9.29	6.62e-16	7.4e-12	-0.69	-0.64	Aortic root size;	chr7:66534311	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs2420611	ENSG00000226824.5	RP4-756H11.3	-9.29	6.62e-16	7.4e-12	-0.69	-0.64	Aortic root size;	chr7:66534333	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.767	rs61348003	ENSG00000226824.5	RP4-756H11.3	-9.29	6.62e-16	7.4e-12	-0.69	-0.64	Aortic root size;	chr7:66540947	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.861	rs801215	ENSG00000226824.5	RP4-756H11.3	9.29	6.62e-16	7.4e-12	0.69	0.64	Aortic root size;	chr7:66546951	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs13536	ENSG00000226824.5	RP4-756H11.3	9.29	6.62e-16	7.4e-12	0.69	0.64	Aortic root size;	chr7:66554203	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs801209	ENSG00000226824.5	RP4-756H11.3	9.29	6.62e-16	7.4e-12	0.69	0.64	Aortic root size;	chr7:66554403	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs801206	ENSG00000226824.5	RP4-756H11.3	9.29	6.62e-16	7.4e-12	0.69	0.64	Aortic root size;	chr7:66556979	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs801204	ENSG00000226824.5	RP4-756H11.3	9.29	6.62e-16	7.4e-12	0.69	0.64	Aortic root size;	chr7:66557934	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs801203	ENSG00000226824.5	RP4-756H11.3	9.29	6.62e-16	7.4e-12	0.69	0.64	Aortic root size;	chr7:66558025	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.825	rs801202	ENSG00000226824.5	RP4-756H11.3	9.29	6.62e-16	7.4e-12	0.69	0.64	Aortic root size;	chr7:66558942	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs801195	ENSG00000226824.5	RP4-756H11.3	9.29	6.62e-16	7.4e-12	0.69	0.64	Aortic root size;	chr7:66561128	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs801194	ENSG00000226824.5	RP4-756H11.3	9.29	6.62e-16	7.4e-12	0.69	0.64	Aortic root size;	chr7:66563508	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs2024192	ENSG00000226824.5	RP4-756H11.3	9.29	6.62e-16	7.4e-12	0.69	0.64	Aortic root size;	chr7:66576460	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs6955837	ENSG00000226824.5	RP4-756H11.3	9.29	6.62e-16	7.4e-12	0.69	0.64	Aortic root size;	chr7:66578155	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.825	rs10281499	ENSG00000226824.5	RP4-756H11.3	9.29	6.62e-16	7.4e-12	0.69	0.64	Aortic root size;	chr7:66583979	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs4718377	ENSG00000226824.5	RP4-756H11.3	9.29	6.62e-16	7.4e-12	0.69	0.64	Aortic root size;	chr7:66584691	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs10278014	ENSG00000226824.5	RP4-756H11.3	9.29	6.62e-16	7.4e-12	0.69	0.64	Aortic root size;	chr7:66586277	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs1968126	ENSG00000226824.5	RP4-756H11.3	9.29	6.62e-16	7.4e-12	0.69	0.64	Aortic root size;	chr7:66592017	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs6460306	ENSG00000226824.5	RP4-756H11.3	9.29	6.62e-16	7.4e-12	0.69	0.64	Aortic root size;	chr7:66595806	chr7:66654538~66669855:+
TGCT	cis	rs2739330	0.796	rs1006771	ENSG00000218537.1	MIF-AS1	9.29	6.62e-16	7.4e-12	0.78	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23894426~23898930:-
TGCT	cis	rs875971	0.862	rs7783779	ENSG00000226824.5	RP4-756H11.3	9.29	6.74e-16	7.5e-12	0.69	0.64	Aortic root size;	chr7:66331639	chr7:66654538~66669855:+
TGCT	cis	rs1577917	0.958	rs12196230	ENSG00000203875.9	SNHG5	-9.28	6.88e-16	7.65e-12	-0.88	-0.64	Response to antipsychotic treatment;	chr6:85810242	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs34994386	ENSG00000203875.9	SNHG5	-9.28	6.88e-16	7.65e-12	-0.88	-0.64	Response to antipsychotic treatment;	chr6:85814417	chr6:85660950~85678736:-
TGCT	cis	rs875971	0.964	rs778723	ENSG00000226824.5	RP4-756H11.3	-9.28	6.9e-16	7.67e-12	-0.72	-0.64	Aortic root size;	chr7:66364510	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.83	rs778711	ENSG00000226824.5	RP4-756H11.3	-9.28	6.93e-16	7.68e-12	-0.69	-0.64	Aortic root size;	chr7:66386670	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs1083554	ENSG00000226824.5	RP4-756H11.3	-9.28	6.93e-16	7.68e-12	-0.69	-0.64	Aortic root size;	chr7:66387354	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs778707	ENSG00000226824.5	RP4-756H11.3	-9.28	6.93e-16	7.68e-12	-0.69	-0.64	Aortic root size;	chr7:66392040	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs778705	ENSG00000226824.5	RP4-756H11.3	-9.28	6.93e-16	7.68e-12	-0.69	-0.64	Aortic root size;	chr7:66396128	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs778697	ENSG00000226824.5	RP4-756H11.3	-9.28	6.93e-16	7.68e-12	-0.69	-0.64	Aortic root size;	chr7:66405439	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.798	rs7789615	ENSG00000226824.5	RP4-756H11.3	-9.28	6.93e-16	7.68e-12	-0.69	-0.64	Aortic root size;	chr7:66413674	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs6978028	ENSG00000226824.5	RP4-756H11.3	-9.28	6.93e-16	7.68e-12	-0.69	-0.64	Aortic root size;	chr7:66421313	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs6947339	ENSG00000226824.5	RP4-756H11.3	-9.28	6.93e-16	7.68e-12	-0.69	-0.64	Aortic root size;	chr7:66423483	chr7:66654538~66669855:+
TGCT	cis	rs1577917	0.958	rs4707223	ENSG00000203875.9	SNHG5	-9.28	6.95e-16	7.69e-12	-0.87	-0.64	Response to antipsychotic treatment;	chr6:85800084	chr6:85660950~85678736:-
TGCT	cis	rs853679	0.527	rs213228	ENSG00000216901.1	AL022393.7	9.28	7.06e-16	7.81e-12	0.73	0.64	Depression;	chr6:28363475	chr6:28176188~28176674:+
TGCT	cis	rs11098499	0.821	rs56155624	ENSG00000245958.5	RP11-33B1.1	-9.27	7.26e-16	8.03e-12	-0.66	-0.64	Corneal astigmatism;	chr4:119369871	chr4:119454791~119552025:+
TGCT	cis	rs875971	0.577	rs34888281	ENSG00000226824.5	RP4-756H11.3	9.27	7.42e-16	8.2e-12	0.74	0.64	Aortic root size;	chr7:66120784	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.628	rs6974355	ENSG00000226824.5	RP4-756H11.3	-9.26	7.78e-16	8.58e-12	-0.75	-0.64	Aortic root size;	chr7:66376994	chr7:66654538~66669855:+
TGCT	cis	rs6452524	0.618	rs1993948	ENSG00000249664.1	CTD-2227C6.2	9.26	7.95e-16	8.76e-12	0.66	0.64	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:83012285~83013109:-
TGCT	cis	rs801193	1	rs2659915	ENSG00000226824.5	RP4-756H11.3	-9.25	8.01e-16	8.83e-12	-0.7	-0.64	Aortic root size;	chr7:66688114	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.54	rs35510581	ENSG00000226824.5	RP4-756H11.3	9.25	8.18e-16	9e-12	0.73	0.64	Aortic root size;	chr7:66113790	chr7:66654538~66669855:+
TGCT	cis	rs3734266	0.702	rs36026951	ENSG00000186328.4	RP11-140K17.2	9.24	8.62e-16	9.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34754984	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs6941453	ENSG00000186328.4	RP11-140K17.2	9.24	8.62e-16	9.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34756118	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.639	rs7743724	ENSG00000186328.4	RP11-140K17.2	9.24	8.62e-16	9.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34757701	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs6934741	ENSG00000186328.4	RP11-140K17.2	9.24	8.62e-16	9.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34762272	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs35141641	ENSG00000186328.4	RP11-140K17.2	9.24	8.62e-16	9.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34769175	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.639	rs9968782	ENSG00000186328.4	RP11-140K17.2	9.24	8.62e-16	9.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34769177	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs11968954	ENSG00000186328.4	RP11-140K17.2	9.24	8.62e-16	9.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34773397	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs35081279	ENSG00000186328.4	RP11-140K17.2	9.24	8.62e-16	9.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34776999	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs67622212	ENSG00000186328.4	RP11-140K17.2	9.24	8.62e-16	9.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34782255	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs72892286	ENSG00000186328.4	RP11-140K17.2	9.24	8.62e-16	9.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34794400	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs13213239	ENSG00000186328.4	RP11-140K17.2	9.24	8.62e-16	9.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34809715	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.646	rs2395605	ENSG00000186328.4	RP11-140K17.2	9.24	8.62e-16	9.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34810716	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs7755354	ENSG00000186328.4	RP11-140K17.2	9.24	8.62e-16	9.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34814467	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs6910824	ENSG00000186328.4	RP11-140K17.2	9.24	8.62e-16	9.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34818729	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs1018622	ENSG00000186328.4	RP11-140K17.2	9.24	8.62e-16	9.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34820454	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.646	rs912717	ENSG00000186328.4	RP11-140K17.2	9.24	8.62e-16	9.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34820790	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs7764126	ENSG00000186328.4	RP11-140K17.2	9.24	8.62e-16	9.4e-12	0.98	0.64	Systemic lupus erythematosus;	chr6:34821285	chr6:34715613~34715940:+
TGCT	cis	rs1150668	0.796	rs2531825	ENSG00000216901.1	AL022393.7	9.24	8.64e-16	9.42e-12	0.7	0.64	Pubertal anthropometrics;	chr6:28381487	chr6:28176188~28176674:+
TGCT	cis	rs858239	0.899	rs1881203	ENSG00000230658.1	KLHL7-AS1	9.24	8.71e-16	9.49e-12	0.71	0.64	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23101228~23105703:-
TGCT	cis	rs12439619	0.693	rs8034801	ENSG00000278603.1	RP13-608F4.5	9.24	8.72e-16	9.5e-12	0.95	0.64	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472203~82472426:+
TGCT	cis	rs853679	0.527	rs853693	ENSG00000216901.1	AL022393.7	9.24	8.91e-16	9.7e-12	0.68	0.64	Depression;	chr6:28314871	chr6:28176188~28176674:+
TGCT	cis	rs6538678	0.895	rs7137751	ENSG00000258343.1	RP11-536G4.2	-9.24	8.92e-16	9.71e-12	-1.01	-0.64	Lupus nephritis in systemic lupus erythematosus;	chr12:95861806	chr12:95795345~95858839:-
TGCT	cis	rs1577917	0.958	rs28442244	ENSG00000203875.9	SNHG5	9.23	8.95e-16	9.74e-12	0.87	0.64	Response to antipsychotic treatment;	chr6:85991518	chr6:85660950~85678736:-
TGCT	cis	rs801193	0.967	rs34356500	ENSG00000226824.5	RP4-756H11.3	-9.23	8.99e-16	9.78e-12	-0.75	-0.64	Aortic root size;	chr7:66771620	chr7:66654538~66669855:+
TGCT	cis	rs2882667	0.628	rs13171173	ENSG00000253404.1	AC034243.1	-9.23	9.18e-16	9.98e-12	-0.75	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138706775	chr5:138744434~138753309:-
TGCT	cis	rs875971	0.862	rs2901152	ENSG00000226824.5	RP4-756H11.3	9.21	1e-15	1.09e-11	0.7	0.64	Aortic root size;	chr7:66300017	chr7:66654538~66669855:+
TGCT	cis	rs11098499	0.644	rs3986377	ENSG00000245958.5	RP11-33B1.1	-9.21	1.01e-15	1.09e-11	-0.65	-0.64	Corneal astigmatism;	chr4:119339115	chr4:119454791~119552025:+
TGCT	cis	rs10028773	0.556	rs4473640	ENSG00000245958.5	RP11-33B1.1	-9.21	1.01e-15	1.09e-11	-0.65	-0.64	Educational attainment;	chr4:119339282	chr4:119454791~119552025:+
TGCT	cis	rs7301826	0.61	rs7957899	ENSG00000256250.1	RP11-989F5.1	-9.21	1.04e-15	1.12e-11	-0.75	-0.64	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.651	rs1973834	ENSG00000256250.1	RP11-989F5.1	-9.21	1.04e-15	1.12e-11	-0.75	-0.64	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810606~130812438:+
TGCT	cis	rs2882667	0.69	rs288021	ENSG00000253404.1	AC034243.1	9.2	1.06e-15	1.14e-11	0.78	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888594	chr5:138744434~138753309:-
TGCT	cis	rs875971	0.965	rs697968	ENSG00000226824.5	RP4-756H11.3	9.2	1.08e-15	1.17e-11	0.71	0.64	Aortic root size;	chr7:66070046	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs1167411	ENSG00000226824.5	RP4-756H11.3	9.2	1.08e-15	1.17e-11	0.71	0.64	Aortic root size;	chr7:66074277	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs1183245	ENSG00000226824.5	RP4-756H11.3	9.2	1.08e-15	1.17e-11	0.71	0.64	Aortic root size;	chr7:66076198	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs1144895	ENSG00000226824.5	RP4-756H11.3	9.2	1.08e-15	1.17e-11	0.71	0.64	Aortic root size;	chr7:66076320	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs1144894	ENSG00000226824.5	RP4-756H11.3	9.2	1.08e-15	1.17e-11	0.71	0.64	Aortic root size;	chr7:66077907	chr7:66654538~66669855:+
TGCT	cis	rs6452524	0.935	rs7703318	ENSG00000249664.1	CTD-2227C6.2	9.2	1.11e-15	1.19e-11	0.65	0.64	Hypertension (SNP x SNP interaction);	chr5:83118234	chr5:83012285~83013109:-
TGCT	cis	rs977987	0.735	rs11149831	ENSG00000261783.1	RP11-252K23.2	-9.19	1.12e-15	1.21e-11	-0.92	-0.64	Dupuytren's disease;	chr16:75417563	chr16:75379818~75381260:-
TGCT	cis	rs875971	0.862	rs1875057	ENSG00000226824.5	RP4-756H11.3	9.19	1.14e-15	1.23e-11	0.7	0.64	Aortic root size;	chr7:66266868	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs6960446	ENSG00000226824.5	RP4-756H11.3	9.19	1.14e-15	1.23e-11	0.7	0.64	Aortic root size;	chr7:66268272	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.789	rs10260426	ENSG00000226824.5	RP4-756H11.3	9.19	1.14e-15	1.23e-11	0.7	0.64	Aortic root size;	chr7:66271055	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs7796162	ENSG00000226824.5	RP4-756H11.3	9.19	1.14e-15	1.23e-11	0.7	0.64	Aortic root size;	chr7:66280771	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.756	rs4718328	ENSG00000226824.5	RP4-756H11.3	9.19	1.15e-15	1.23e-11	0.7	0.64	Aortic root size;	chr7:66228350	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs4718330	ENSG00000226824.5	RP4-756H11.3	9.19	1.15e-15	1.23e-11	0.7	0.64	Aortic root size;	chr7:66250256	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs949930	ENSG00000226824.5	RP4-756H11.3	9.19	1.15e-15	1.23e-11	0.7	0.64	Aortic root size;	chr7:66301835	chr7:66654538~66669855:+
TGCT	cis	rs11098499	0.73	rs78971550	ENSG00000245958.5	RP11-33B1.1	-9.18	1.19e-15	1.27e-11	-0.66	-0.64	Corneal astigmatism;	chr4:119359886	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.645	rs78422072	ENSG00000245958.5	RP11-33B1.1	-9.18	1.19e-15	1.27e-11	-0.66	-0.64	Corneal astigmatism;	chr4:119359887	chr4:119454791~119552025:+
TGCT	cis	rs2283792	0.812	rs240064	ENSG00000228050.1	TOP3BP1	-9.18	1.21e-15	1.29e-11	-0.7	-0.64	Multiple sclerosis;	chr22:21927265	chr22:22223187~22224566:-
TGCT	cis	rs875971	0.825	rs6951503	ENSG00000226824.5	RP4-756H11.3	9.17	1.28e-15	1.37e-11	0.71	0.64	Aortic root size;	chr7:66253949	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.844	rs732465	ENSG00000226824.5	RP4-756H11.3	-9.17	1.29e-15	1.37e-11	-0.71	-0.64	Aortic root size;	chr7:66533463	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.773	rs801207	ENSG00000226824.5	RP4-756H11.3	9.17	1.29e-15	1.37e-11	0.71	0.64	Aortic root size;	chr7:66555603	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.543	rs801191	ENSG00000226824.5	RP4-756H11.3	9.17	1.29e-15	1.37e-11	0.71	0.64	Aortic root size;	chr7:66567968	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.508	rs6947808	ENSG00000226824.5	RP4-756H11.3	9.17	1.29e-15	1.37e-11	0.71	0.64	Aortic root size;	chr7:66580095	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.508	rs10242423	ENSG00000226824.5	RP4-756H11.3	9.17	1.29e-15	1.37e-11	0.71	0.64	Aortic root size;	chr7:66594188	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.508	rs10253883	ENSG00000226824.5	RP4-756H11.3	9.17	1.29e-15	1.37e-11	0.71	0.64	Aortic root size;	chr7:66596151	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.508	rs10950045	ENSG00000226824.5	RP4-756H11.3	9.17	1.29e-15	1.37e-11	0.71	0.64	Aortic root size;	chr7:66601386	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.839	rs6968619	ENSG00000226824.5	RP4-756H11.3	9.17	1.29e-15	1.37e-11	0.71	0.64	Aortic root size;	chr7:66603880	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.839	rs12534943	ENSG00000226824.5	RP4-756H11.3	9.17	1.29e-15	1.37e-11	0.71	0.64	Aortic root size;	chr7:66605533	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.805	rs12532355	ENSG00000226824.5	RP4-756H11.3	9.17	1.29e-15	1.37e-11	0.71	0.64	Aortic root size;	chr7:66605597	chr7:66654538~66669855:+
TGCT	cis	rs7301826	0.651	rs34749116	ENSG00000256250.1	RP11-989F5.1	9.17	1.3e-15	1.38e-11	0.76	0.64	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.627	rs7978987	ENSG00000256250.1	RP11-989F5.1	9.17	1.3e-15	1.38e-11	0.76	0.64	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.651	rs2277336	ENSG00000256250.1	RP11-989F5.1	9.17	1.3e-15	1.38e-11	0.76	0.64	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.627	rs34103763	ENSG00000256250.1	RP11-989F5.1	9.17	1.3e-15	1.38e-11	0.76	0.64	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.61	rs36051740	ENSG00000256250.1	RP11-989F5.1	9.17	1.3e-15	1.38e-11	0.76	0.64	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.61	rs7961690	ENSG00000256250.1	RP11-989F5.1	9.17	1.3e-15	1.38e-11	0.76	0.64	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.651	rs6486601	ENSG00000256250.1	RP11-989F5.1	9.17	1.3e-15	1.38e-11	0.76	0.64	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.627	rs61937256	ENSG00000256250.1	RP11-989F5.1	9.17	1.3e-15	1.38e-11	0.76	0.64	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.651	rs7299281	ENSG00000256250.1	RP11-989F5.1	9.17	1.3e-15	1.38e-11	0.76	0.64	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.56	rs12829294	ENSG00000256250.1	RP11-989F5.1	9.17	1.3e-15	1.38e-11	0.76	0.64	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.58	rs61938969	ENSG00000256250.1	RP11-989F5.1	9.17	1.3e-15	1.38e-11	0.76	0.64	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.585	rs6486600	ENSG00000256250.1	RP11-989F5.1	-9.17	1.3e-15	1.38e-11	-0.76	-0.64	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.627	rs4334059	ENSG00000256250.1	RP11-989F5.1	-9.17	1.3e-15	1.38e-11	-0.76	-0.64	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810606~130812438:+
TGCT	cis	rs1577917	0.958	rs34622605	ENSG00000203875.9	SNHG5	-9.15	1.42e-15	1.5e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85746801	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs12212480	ENSG00000203875.9	SNHG5	-9.15	1.42e-15	1.5e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85749059	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs66807489	ENSG00000203875.9	SNHG5	-9.15	1.42e-15	1.5e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85730984	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs10944136	ENSG00000203875.9	SNHG5	-9.15	1.42e-15	1.5e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85738781	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs9647601	ENSG00000203875.9	SNHG5	-9.15	1.42e-15	1.5e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85740109	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.837	rs10944157	ENSG00000203875.9	SNHG5	-9.15	1.42e-15	1.51e-11	-0.88	-0.63	Response to antipsychotic treatment;	chr6:85867481	chr6:85660950~85678736:-
TGCT	cis	rs6921919	0.515	rs1339898	ENSG00000216901.1	AL022393.7	9.15	1.43e-15	1.51e-11	0.71	0.63	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28176188~28176674:+
TGCT	cis	rs2487048	0.905	rs2437812	ENSG00000226334.1	RP11-217B7.2	-9.15	1.46e-15	1.54e-11	-0.64	-0.63	Intraocular pressure;	chr9:104930920	chr9:104927553~104928892:+
TGCT	cis	rs1577917	0.958	rs7739241	ENSG00000203875.9	SNHG5	-9.14	1.48e-15	1.56e-11	-0.87	-0.63	Response to antipsychotic treatment;	chr6:85866078	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs12202712	ENSG00000203875.9	SNHG5	-9.14	1.48e-15	1.56e-11	-0.87	-0.63	Response to antipsychotic treatment;	chr6:85868823	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs4707236	ENSG00000203875.9	SNHG5	-9.14	1.48e-15	1.56e-11	-0.87	-0.63	Response to antipsychotic treatment;	chr6:85874249	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs16876529	ENSG00000203875.9	SNHG5	-9.14	1.48e-15	1.56e-11	-0.87	-0.63	Response to antipsychotic treatment;	chr6:85881484	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs16876530	ENSG00000203875.9	SNHG5	-9.14	1.48e-15	1.56e-11	-0.87	-0.63	Response to antipsychotic treatment;	chr6:85885923	chr6:85660950~85678736:-
TGCT	cis	rs801193	0.844	rs2244022	ENSG00000226824.5	RP4-756H11.3	-9.14	1.5e-15	1.58e-11	-0.71	-0.63	Aortic root size;	chr7:66737443	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs6460302	ENSG00000226824.5	RP4-756H11.3	-9.14	1.52e-15	1.6e-11	-0.71	-0.63	Aortic root size;	chr7:66495270	chr7:66654538~66669855:+
TGCT	cis	rs1577917	0.816	rs12664099	ENSG00000203875.9	SNHG5	-9.13	1.56e-15	1.64e-11	-0.82	-0.63	Response to antipsychotic treatment;	chr6:85938854	chr6:85660950~85678736:-
TGCT	cis	rs7301826	0.627	rs73162873	ENSG00000256250.1	RP11-989F5.1	-9.13	1.58e-15	1.66e-11	-0.77	-0.63	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810606~130812438:+
TGCT	cis	rs6538678	1	rs6538678	ENSG00000258343.1	RP11-536G4.2	-9.13	1.62e-15	1.7e-11	-1.01	-0.63	Lupus nephritis in systemic lupus erythematosus;	chr12:95867790	chr12:95795345~95858839:-
TGCT	cis	rs7301826	0.651	rs10848206	ENSG00000256250.1	RP11-989F5.1	-9.12	1.65e-15	1.73e-11	-0.75	-0.63	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810606~130812438:+
TGCT	cis	rs847845	0.535	rs1201872	ENSG00000186328.4	RP11-140K17.2	-9.12	1.7e-15	1.78e-11	-1.01	-0.63	Non-small cell lung cancer;	chr6:34587932	chr6:34715613~34715940:+
TGCT	cis	rs2486288	0.554	rs1719235	ENSG00000259520.4	CTD-2651B20.3	9.11	1.81e-15	1.89e-11	0.51	0.63	Glomerular filtration rate;	chr15:45283910	chr15:45251580~45279251:-
TGCT	cis	rs1577917	0.958	rs11755642	ENSG00000203875.9	SNHG5	-9.1	1.9e-15	1.98e-11	-0.85	-0.63	Response to antipsychotic treatment;	chr6:85740348	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs13213899	ENSG00000203875.9	SNHG5	-9.1	1.9e-15	1.98e-11	-0.85	-0.63	Response to antipsychotic treatment;	chr6:85763422	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs10806337	ENSG00000203875.9	SNHG5	-9.1	1.9e-15	1.98e-11	-0.85	-0.63	Response to antipsychotic treatment;	chr6:85764531	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs12205492	ENSG00000203875.9	SNHG5	-9.1	1.9e-15	1.98e-11	-0.85	-0.63	Response to antipsychotic treatment;	chr6:85766258	chr6:85660950~85678736:-
TGCT	cis	rs1150668	0.745	rs213238	ENSG00000216901.1	AL022393.7	9.1	1.93e-15	2.01e-11	0.69	0.63	Pubertal anthropometrics;	chr6:28354216	chr6:28176188~28176674:+
TGCT	cis	rs1577917	1	rs2166663	ENSG00000203875.9	SNHG5	-9.09	1.98e-15	2.06e-11	-0.87	-0.63	Response to antipsychotic treatment;	chr6:85884178	chr6:85660950~85678736:-
TGCT	cis	rs1150668	0.796	rs9468372	ENSG00000216901.1	AL022393.7	9.09	1.99e-15	2.07e-11	0.7	0.63	Pubertal anthropometrics;	chr6:28411584	chr6:28176188~28176674:+
TGCT	cis	rs858239	0.67	rs6967526	ENSG00000230658.1	KLHL7-AS1	9.09	2.03e-15	2.1e-11	0.66	0.63	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23101228~23105703:-
TGCT	cis	rs875971	0.862	rs778734	ENSG00000226824.5	RP4-756H11.3	-9.08	2.12e-15	2.2e-11	-0.7	-0.63	Aortic root size;	chr7:66349862	chr7:66654538~66669855:+
TGCT	cis	rs858239	0.669	rs1618339	ENSG00000230658.1	KLHL7-AS1	9.08	2.16e-15	2.23e-11	0.66	0.63	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23101228~23105703:-
TGCT	cis	rs1577917	0.958	rs2100109	ENSG00000203875.9	SNHG5	-9.07	2.2e-15	2.25e-11	-0.87	-0.63	Response to antipsychotic treatment;	chr6:85835208	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs1447160	ENSG00000203875.9	SNHG5	-9.07	2.2e-15	2.25e-11	-0.87	-0.63	Response to antipsychotic treatment;	chr6:85836405	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs4707229	ENSG00000203875.9	SNHG5	-9.07	2.2e-15	2.25e-11	-0.87	-0.63	Response to antipsychotic treatment;	chr6:85836519	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs12198061	ENSG00000203875.9	SNHG5	-9.07	2.2e-15	2.25e-11	-0.87	-0.63	Response to antipsychotic treatment;	chr6:85841267	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.57	rs114854865	ENSG00000203875.9	SNHG5	-9.07	2.2e-15	2.25e-11	-0.87	-0.63	Response to antipsychotic treatment;	chr6:85844518	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.916	rs4706252	ENSG00000203875.9	SNHG5	-9.07	2.2e-15	2.25e-11	-0.87	-0.63	Response to antipsychotic treatment;	chr6:85845462	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.917	rs1838959	ENSG00000203875.9	SNHG5	-9.07	2.2e-15	2.25e-11	-0.87	-0.63	Response to antipsychotic treatment;	chr6:85847086	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.917	rs1579886	ENSG00000203875.9	SNHG5	-9.07	2.2e-15	2.25e-11	-0.87	-0.63	Response to antipsychotic treatment;	chr6:85847473	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs1816937	ENSG00000203875.9	SNHG5	-9.07	2.2e-15	2.25e-11	-0.87	-0.63	Response to antipsychotic treatment;	chr6:85847533	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs2324840	ENSG00000203875.9	SNHG5	-9.07	2.2e-15	2.25e-11	-0.87	-0.63	Response to antipsychotic treatment;	chr6:85847902	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs7382798	ENSG00000203875.9	SNHG5	-9.07	2.2e-15	2.25e-11	-0.87	-0.63	Response to antipsychotic treatment;	chr6:85850116	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs12202188	ENSG00000203875.9	SNHG5	-9.07	2.2e-15	2.25e-11	-0.87	-0.63	Response to antipsychotic treatment;	chr6:85852982	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs36035797	ENSG00000203875.9	SNHG5	-9.07	2.2e-15	2.25e-11	-0.87	-0.63	Response to antipsychotic treatment;	chr6:85853162	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs1838958	ENSG00000203875.9	SNHG5	-9.07	2.2e-15	2.25e-11	-0.87	-0.63	Response to antipsychotic treatment;	chr6:85854250	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs1838955	ENSG00000203875.9	SNHG5	-9.07	2.2e-15	2.25e-11	-0.87	-0.63	Response to antipsychotic treatment;	chr6:85855731	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.874	rs1838954	ENSG00000203875.9	SNHG5	-9.07	2.2e-15	2.25e-11	-0.87	-0.63	Response to antipsychotic treatment;	chr6:85855760	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs2084294	ENSG00000203875.9	SNHG5	-9.07	2.2e-15	2.25e-11	-0.87	-0.63	Response to antipsychotic treatment;	chr6:85856225	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.917	rs2084293	ENSG00000203875.9	SNHG5	-9.07	2.2e-15	2.25e-11	-0.87	-0.63	Response to antipsychotic treatment;	chr6:85856284	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs12209668	ENSG00000203875.9	SNHG5	-9.07	2.2e-15	2.25e-11	-0.87	-0.63	Response to antipsychotic treatment;	chr6:85856799	chr6:85660950~85678736:-
TGCT	cis	rs801193	0.66	rs1962050	ENSG00000226824.5	RP4-756H11.3	9.07	2.23e-15	2.27e-11	0.7	0.63	Aortic root size;	chr7:66775021	chr7:66654538~66669855:+
TGCT	cis	rs62388641	1	rs62388641	ENSG00000272279.1	RP11-157J24.2	9.06	2.3e-15	2.29e-11	0.82	0.63	Daytime sleep phenotypes;	chr6:1539849	chr6:1528364~1528911:-
TGCT	cis	rs875971	0.862	rs880166	ENSG00000226824.5	RP4-756H11.3	9.06	2.34e-15	2.31e-11	0.69	0.63	Aortic root size;	chr7:66205775	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.928	rs2036263	ENSG00000226824.5	RP4-756H11.3	9.06	2.34e-15	2.31e-11	0.69	0.63	Aortic root size;	chr7:66335210	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs10240949	ENSG00000226824.5	RP4-756H11.3	9.06	2.34e-15	2.31e-11	0.69	0.63	Aortic root size;	chr7:66339430	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs7782704	ENSG00000226824.5	RP4-756H11.3	9.06	2.34e-15	2.31e-11	0.69	0.63	Aortic root size;	chr7:66340379	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs6460290	ENSG00000226824.5	RP4-756H11.3	9.06	2.34e-15	2.31e-11	0.69	0.63	Aortic root size;	chr7:66344119	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs6959268	ENSG00000226824.5	RP4-756H11.3	9.06	2.34e-15	2.31e-11	0.69	0.63	Aortic root size;	chr7:66347979	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.825	rs28480509	ENSG00000226824.5	RP4-756H11.3	9.06	2.37e-15	2.34e-11	0.69	0.63	Aortic root size;	chr7:66634237	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs9791712	ENSG00000226824.5	RP4-756H11.3	9.06	2.37e-15	2.34e-11	0.69	0.63	Aortic root size;	chr7:66640176	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs9791713	ENSG00000226824.5	RP4-756H11.3	9.06	2.37e-15	2.34e-11	0.69	0.63	Aortic root size;	chr7:66640211	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs1860469	ENSG00000226824.5	RP4-756H11.3	9.06	2.37e-15	2.34e-11	0.69	0.63	Aortic root size;	chr7:66641888	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs4718383	ENSG00000226824.5	RP4-756H11.3	9.06	2.37e-15	2.34e-11	0.69	0.63	Aortic root size;	chr7:66643422	chr7:66654538~66669855:+
TGCT	cis	rs1577917	1	rs6454513	ENSG00000203875.9	SNHG5	9.06	2.37e-15	2.34e-11	0.86	0.63	Response to antipsychotic treatment;	chr6:86010331	chr6:85660950~85678736:-
TGCT	cis	rs62388641	0.802	rs13202504	ENSG00000272279.1	RP11-157J24.2	9.06	2.41e-15	2.37e-11	0.81	0.63	Daytime sleep phenotypes;	chr6:1537640	chr6:1528364~1528911:-
TGCT	cis	rs875971	0.895	rs6460278	ENSG00000226824.5	RP4-756H11.3	9.06	2.41e-15	2.37e-11	0.7	0.63	Aortic root size;	chr7:66197749	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs6460279	ENSG00000226824.5	RP4-756H11.3	9.06	2.41e-15	2.37e-11	0.7	0.63	Aortic root size;	chr7:66197774	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs28491091	ENSG00000226824.5	RP4-756H11.3	9.06	2.41e-15	2.37e-11	0.7	0.63	Aortic root size;	chr7:66204077	chr7:66654538~66669855:+
TGCT	cis	rs858239	0.537	rs2286272	ENSG00000230658.1	KLHL7-AS1	9.05	2.45e-15	2.41e-11	0.73	0.63	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.537	rs6955115	ENSG00000230658.1	KLHL7-AS1	9.05	2.45e-15	2.41e-11	0.73	0.63	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23101228~23105703:-
TGCT	cis	rs875971	0.862	rs778724	ENSG00000226824.5	RP4-756H11.3	-9.05	2.45e-15	2.41e-11	-0.69	-0.63	Aortic root size;	chr7:66364304	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs778686	ENSG00000226824.5	RP4-756H11.3	-9.05	2.45e-15	2.41e-11	-0.69	-0.63	Aortic root size;	chr7:66370923	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.767	rs1643394	ENSG00000226824.5	RP4-756H11.3	-9.05	2.45e-15	2.41e-11	-0.69	-0.63	Aortic root size;	chr7:66371107	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs778684	ENSG00000226824.5	RP4-756H11.3	-9.05	2.45e-15	2.41e-11	-0.69	-0.63	Aortic root size;	chr7:66371416	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs778680	ENSG00000226824.5	RP4-756H11.3	-9.05	2.45e-15	2.41e-11	-0.69	-0.63	Aortic root size;	chr7:66375427	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs11769079	ENSG00000226824.5	RP4-756H11.3	-9.05	2.45e-15	2.41e-11	-0.69	-0.63	Aortic root size;	chr7:66377141	chr7:66654538~66669855:+
TGCT	cis	rs1577917	1	rs6923148	ENSG00000203875.9	SNHG5	9.05	2.51e-15	2.46e-11	0.86	0.63	Response to antipsychotic treatment;	chr6:86058068	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.876	rs4618490	ENSG00000203875.9	SNHG5	-9.04	2.57e-15	2.51e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85808685	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.816	rs9353349	ENSG00000203875.9	SNHG5	9.04	2.61e-15	2.55e-11	0.86	0.63	Response to antipsychotic treatment;	chr6:85998007	chr6:85660950~85678736:-
TGCT	cis	rs6452524	0.618	rs6452504	ENSG00000249664.1	CTD-2227C6.2	9.04	2.61e-15	2.56e-11	0.64	0.63	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:83012285~83013109:-
TGCT	cis	rs2739330	0.685	rs4822453	ENSG00000225282.1	AP000350.6	9.04	2.62e-15	2.56e-11	0.72	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23926900~23929574:+
TGCT	cis	rs11098499	0.722	rs17595727	ENSG00000245958.5	RP11-33B1.1	9.04	2.63e-15	2.57e-11	0.64	0.63	Corneal astigmatism;	chr4:119340919	chr4:119454791~119552025:+
TGCT	cis	rs3734266	0.702	rs2296361	ENSG00000186328.4	RP11-140K17.2	-9.04	2.65e-15	2.59e-11	-0.89	-0.63	Systemic lupus erythematosus;	chr6:34835590	chr6:34715613~34715940:+
TGCT	cis	rs1355223	0.902	rs2185700	ENSG00000271369.1	RP11-350D17.3	-9.04	2.66e-15	2.6e-11	-0.6	-0.63	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34702657	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.902	rs34610590	ENSG00000271369.1	RP11-350D17.3	-9.04	2.66e-15	2.6e-11	-0.6	-0.63	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34703893	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.902	rs4465347	ENSG00000271369.1	RP11-350D17.3	-9.04	2.66e-15	2.6e-11	-0.6	-0.63	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34705786	chr11:34709600~34710161:+
TGCT	cis	rs875971	1	rs2220626	ENSG00000226824.5	RP4-756H11.3	9.04	2.68e-15	2.61e-11	0.7	0.63	Aortic root size;	chr7:66081075	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.964	rs697969	ENSG00000226824.5	RP4-756H11.3	9.04	2.68e-15	2.61e-11	0.7	0.63	Aortic root size;	chr7:66093491	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs697970	ENSG00000226824.5	RP4-756H11.3	9.04	2.68e-15	2.61e-11	0.7	0.63	Aortic root size;	chr7:66095065	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs1182882	ENSG00000226824.5	RP4-756H11.3	9.04	2.68e-15	2.61e-11	0.7	0.63	Aortic root size;	chr7:66097076	chr7:66654538~66669855:+
TGCT	cis	rs1355223	0.902	rs34875830	ENSG00000271369.1	RP11-350D17.3	-9.03	2.71e-15	2.64e-11	-0.6	-0.63	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34700658	chr11:34709600~34710161:+
TGCT	cis	rs2739330	0.761	rs5760176	ENSG00000273295.1	AP000350.5	-9.03	2.72e-15	2.65e-11	-0.7	-0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23901432~23907068:-
TGCT	cis	rs1355223	0.902	rs1901831	ENSG00000271369.1	RP11-350D17.3	-9.03	2.77e-15	2.7e-11	-0.6	-0.63	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34703628	chr11:34709600~34710161:+
TGCT	cis	rs1577917	1	rs4706254	ENSG00000203875.9	SNHG5	-9.03	2.8e-15	2.73e-11	-0.87	-0.63	Response to antipsychotic treatment;	chr6:85893095	chr6:85660950~85678736:-
TGCT	cis	rs1355223	0.902	rs1588353	ENSG00000271369.1	RP11-350D17.3	-9.03	2.82e-15	2.74e-11	-0.6	-0.63	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34709267	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.902	rs1258464	ENSG00000271369.1	RP11-350D17.3	-9.03	2.82e-15	2.74e-11	-0.6	-0.63	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34709949	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.902	rs836467	ENSG00000271369.1	RP11-350D17.3	-9.03	2.82e-15	2.74e-11	-0.6	-0.63	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34715885	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.902	rs865070	ENSG00000271369.1	RP11-350D17.3	-9.03	2.82e-15	2.74e-11	-0.6	-0.63	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34720950	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.902	rs1361645	ENSG00000271369.1	RP11-350D17.3	-9.03	2.82e-15	2.74e-11	-0.6	-0.63	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34724838	chr11:34709600~34710161:+
TGCT	cis	rs1577917	0.958	rs72907388	ENSG00000203875.9	SNHG5	-9.03	2.82e-15	2.74e-11	-0.85	-0.63	Response to antipsychotic treatment;	chr6:85730489	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs12193904	ENSG00000203875.9	SNHG5	-9.03	2.82e-15	2.74e-11	-0.85	-0.63	Response to antipsychotic treatment;	chr6:85742985	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs10944137	ENSG00000203875.9	SNHG5	-9.03	2.82e-15	2.74e-11	-0.85	-0.63	Response to antipsychotic treatment;	chr6:85744596	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs11754330	ENSG00000203875.9	SNHG5	-9.03	2.82e-15	2.74e-11	-0.85	-0.63	Response to antipsychotic treatment;	chr6:85745352	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs1335442	ENSG00000203875.9	SNHG5	-9.03	2.82e-15	2.74e-11	-0.85	-0.63	Response to antipsychotic treatment;	chr6:85756974	chr6:85660950~85678736:-
TGCT	cis	rs801193	0.569	rs11772819	ENSG00000226824.5	RP4-756H11.3	-9.02	2.86e-15	2.77e-11	-0.69	-0.63	Aortic root size;	chr7:66752983	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.569	rs7800620	ENSG00000226824.5	RP4-756H11.3	-9.02	2.86e-15	2.77e-11	-0.69	-0.63	Aortic root size;	chr7:66758701	chr7:66654538~66669855:+
TGCT	cis	rs1150668	0.83	rs2531831	ENSG00000216901.1	AL022393.7	9.02	2.87e-15	2.78e-11	0.68	0.63	Pubertal anthropometrics;	chr6:28420988	chr6:28176188~28176674:+
TGCT	cis	rs2882667	0.69	rs825747	ENSG00000253404.1	AC034243.1	-9.02	2.88e-15	2.79e-11	-0.79	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800896	chr5:138744434~138753309:-
TGCT	cis	rs858239	1	rs156425	ENSG00000230658.1	KLHL7-AS1	-9.02	2.92e-15	2.82e-11	-0.65	-0.63	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23101228~23105703:-
TGCT	cis	rs1577917	0.958	rs12213431	ENSG00000203875.9	SNHG5	-9.02	3e-15	2.89e-11	-0.84	-0.63	Response to antipsychotic treatment;	chr6:85791238	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs2816815	ENSG00000203875.9	SNHG5	-9.01	3.04e-15	2.92e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85981938	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs791856	ENSG00000203875.9	SNHG5	9.01	3.04e-15	2.92e-11	0.86	0.63	Response to antipsychotic treatment;	chr6:85972123	chr6:85660950~85678736:-
TGCT	cis	rs2283792	0.812	rs94194	ENSG00000228050.1	TOP3BP1	9.01	3.06e-15	2.94e-11	0.71	0.63	Multiple sclerosis;	chr22:21933937	chr22:22223187~22224566:-
TGCT	cis	rs2283792	0.812	rs5995269	ENSG00000228050.1	TOP3BP1	9.01	3.06e-15	2.94e-11	0.71	0.63	Multiple sclerosis;	chr22:21935025	chr22:22223187~22224566:-
TGCT	cis	rs6538678	0.833	rs10859966	ENSG00000258343.1	RP11-536G4.2	9.01	3.08e-15	2.96e-11	0.97	0.63	Lupus nephritis in systemic lupus erythematosus;	chr12:95859597	chr12:95795345~95858839:-
TGCT	cis	rs858239	0.636	rs28706766	ENSG00000230658.1	KLHL7-AS1	9	3.18e-15	3.05e-11	0.65	0.63	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23101228~23105703:-
TGCT	cis	rs1577917	0.916	rs12206726	ENSG00000203875.9	SNHG5	-9	3.33e-15	3.16e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85789998	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.917	rs1414201	ENSG00000203875.9	SNHG5	-9	3.33e-15	3.16e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85790598	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs7453105	ENSG00000203875.9	SNHG5	-9	3.33e-15	3.16e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85791043	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs12209259	ENSG00000203875.9	SNHG5	-9	3.33e-15	3.16e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85792630	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.916	rs4142546	ENSG00000203875.9	SNHG5	-9	3.33e-15	3.16e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85795593	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs6900436	ENSG00000203875.9	SNHG5	-9	3.33e-15	3.16e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85796570	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.687	rs1470531	ENSG00000203875.9	SNHG5	-9	3.33e-15	3.16e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85797651	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs12216074	ENSG00000203875.9	SNHG5	-9	3.33e-15	3.16e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85810284	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs12191340	ENSG00000203875.9	SNHG5	-9	3.33e-15	3.16e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85811682	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs1414199	ENSG00000203875.9	SNHG5	-9	3.33e-15	3.16e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85812652	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs36042496	ENSG00000203875.9	SNHG5	-9	3.33e-15	3.16e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85814496	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.917	rs1584273	ENSG00000203875.9	SNHG5	-9	3.33e-15	3.16e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85814859	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs12198971	ENSG00000203875.9	SNHG5	-9	3.33e-15	3.16e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85815727	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs34230196	ENSG00000203875.9	SNHG5	-9	3.33e-15	3.16e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85816304	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.917	rs4707226	ENSG00000203875.9	SNHG5	-9	3.33e-15	3.16e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85818110	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs10455448	ENSG00000203875.9	SNHG5	-9	3.33e-15	3.16e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85823893	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.876	rs12212808	ENSG00000203875.9	SNHG5	-9	3.33e-15	3.16e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85824254	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.917	rs13196576	ENSG00000203875.9	SNHG5	-9	3.33e-15	3.16e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85824348	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.917	rs13213603	ENSG00000203875.9	SNHG5	-9	3.33e-15	3.16e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85825040	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs3857480	ENSG00000203875.9	SNHG5	-9	3.33e-15	3.16e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85825431	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs2324839	ENSG00000203875.9	SNHG5	-9	3.33e-15	3.16e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85827224	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs3900313	ENSG00000203875.9	SNHG5	-9	3.33e-15	3.16e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85827436	chr6:85660950~85678736:-
TGCT	cis	rs858239	1	rs156421	ENSG00000230658.1	KLHL7-AS1	8.99	3.36e-15	3.19e-11	0.66	0.63	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23101228~23105703:-
TGCT	cis	rs1355223	0.872	rs12785367	ENSG00000271369.1	RP11-350D17.3	-8.99	3.37e-15	3.19e-11	-0.59	-0.63	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34693722	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.902	rs11819839	ENSG00000271369.1	RP11-350D17.3	-8.99	3.37e-15	3.19e-11	-0.59	-0.63	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34694231	chr11:34709600~34710161:+
TGCT	cis	rs6538678	0.929	rs10745733	ENSG00000258343.1	RP11-536G4.2	-8.99	3.42e-15	3.24e-11	-0.98	-0.63	Lupus nephritis in systemic lupus erythematosus;	chr12:95868728	chr12:95795345~95858839:-
TGCT	cis	rs6538678	0.926	rs10745734	ENSG00000258343.1	RP11-536G4.2	-8.99	3.42e-15	3.24e-11	-0.98	-0.63	Lupus nephritis in systemic lupus erythematosus;	chr12:95868936	chr12:95795345~95858839:-
TGCT	cis	rs858239	0.669	rs10950940	ENSG00000230658.1	KLHL7-AS1	-8.99	3.45e-15	3.27e-11	-0.65	-0.63	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.704	rs199657	ENSG00000230658.1	KLHL7-AS1	-8.98	3.56e-15	3.38e-11	-0.72	-0.63	Cerebrospinal fluid biomarker levels;	chr7:23297888	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.704	rs199656	ENSG00000230658.1	KLHL7-AS1	-8.98	3.56e-15	3.38e-11	-0.72	-0.63	Cerebrospinal fluid biomarker levels;	chr7:23297996	chr7:23101228~23105703:-
TGCT	cis	rs6538678	0.818	rs7976294	ENSG00000258343.1	RP11-536G4.2	-8.98	3.57e-15	3.38e-11	-1.06	-0.63	Lupus nephritis in systemic lupus erythematosus;	chr12:95876868	chr12:95795345~95858839:-
TGCT	cis	rs6538678	0.818	rs1036429	ENSG00000258343.1	RP11-536G4.2	-8.98	3.57e-15	3.38e-11	-1.06	-0.63	Lupus nephritis in systemic lupus erythematosus;	chr12:95877650	chr12:95795345~95858839:-
TGCT	cis	rs1355223	0.902	rs1597962	ENSG00000271369.1	RP11-350D17.3	-8.98	3.57e-15	3.38e-11	-0.6	-0.63	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34705625	chr11:34709600~34710161:+
TGCT	cis	rs6921919	0.515	rs1558205	ENSG00000216901.1	AL022393.7	-8.98	3.63e-15	3.44e-11	-0.69	-0.63	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28176188~28176674:+
TGCT	cis	rs2739330	0.76	rs5751761	ENSG00000225282.1	AP000350.6	-8.98	3.7e-15	3.5e-11	-0.7	-0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23926900~23929574:+
TGCT	cis	rs875971	0.862	rs10263690	ENSG00000226824.5	RP4-756H11.3	8.97	3.83e-15	3.62e-11	0.68	0.63	Aortic root size;	chr7:66301466	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs10250544	ENSG00000226824.5	RP4-756H11.3	8.97	3.83e-15	3.62e-11	0.68	0.63	Aortic root size;	chr7:66301574	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.895	rs12531677	ENSG00000226824.5	RP4-756H11.3	8.97	3.83e-15	3.62e-11	0.68	0.63	Aortic root size;	chr7:66304099	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs7798630	ENSG00000226824.5	RP4-756H11.3	8.97	3.83e-15	3.62e-11	0.68	0.63	Aortic root size;	chr7:66306492	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs11984115	ENSG00000226824.5	RP4-756H11.3	8.97	3.83e-15	3.62e-11	0.68	0.63	Aortic root size;	chr7:66308872	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.755	rs10228885	ENSG00000226824.5	RP4-756H11.3	8.97	3.83e-15	3.62e-11	0.68	0.63	Aortic root size;	chr7:66315542	chr7:66654538~66669855:+
TGCT	cis	rs858239	0.508	rs10242104	ENSG00000230658.1	KLHL7-AS1	8.96	4.14e-15	3.89e-11	0.72	0.63	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23101228~23105703:-
TGCT	cis	rs875971	0.862	rs6952182	ENSG00000226824.5	RP4-756H11.3	8.95	4.23e-15	3.96e-11	0.69	0.63	Aortic root size;	chr7:66218330	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs6964437	ENSG00000226824.5	RP4-756H11.3	8.95	4.23e-15	3.96e-11	0.69	0.63	Aortic root size;	chr7:66221457	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs6460282	ENSG00000226824.5	RP4-756H11.3	8.95	4.23e-15	3.96e-11	0.69	0.63	Aortic root size;	chr7:66226259	chr7:66654538~66669855:+
TGCT	cis	rs6538678	0.929	rs10777744	ENSG00000258343.1	RP11-536G4.2	-8.95	4.3e-15	4.02e-11	-0.98	-0.63	Lupus nephritis in systemic lupus erythematosus;	chr12:95864561	chr12:95795345~95858839:-
TGCT	cis	rs1577917	1	rs12201741	ENSG00000203875.9	SNHG5	-8.94	4.47e-15	4.16e-11	-0.86	-0.63	Response to antipsychotic treatment;	chr6:85892901	chr6:85660950~85678736:-
TGCT	cis	rs6452524	0.618	rs6452503	ENSG00000249664.1	CTD-2227C6.2	8.94	4.53e-15	4.22e-11	0.64	0.63	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:83012285~83013109:-
TGCT	cis	rs6538678	0.929	rs10735336	ENSG00000258343.1	RP11-536G4.2	-8.93	4.83e-15	4.49e-11	-0.98	-0.63	Lupus nephritis in systemic lupus erythematosus;	chr12:95869661	chr12:95795345~95858839:-
TGCT	cis	rs875971	0.79	rs10257911	ENSG00000226824.5	RP4-756H11.3	8.93	4.88e-15	4.52e-11	0.7	0.63	Aortic root size;	chr7:66278783	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.755	rs76288834	ENSG00000226824.5	RP4-756H11.3	8.93	4.89e-15	4.52e-11	0.68	0.63	Aortic root size;	chr7:66604815	chr7:66654538~66669855:+
TGCT	cis	rs858239	0.669	rs6461687	ENSG00000230658.1	KLHL7-AS1	8.91	5.4e-15	4.98e-11	0.66	0.62	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.669	rs6461688	ENSG00000230658.1	KLHL7-AS1	8.91	5.4e-15	4.98e-11	0.66	0.62	Cerebrospinal fluid biomarker levels;	chr7:23076996	chr7:23101228~23105703:-
TGCT	cis	rs2729354	0.768	rs2729384	ENSG00000265566.2	RN7SL605P	-8.91	5.49e-15	5.05e-11	-0.79	-0.62	Blood protein levels;	chr11:57491144	chr11:57528085~57528365:-
TGCT	cis	rs875971	0.862	rs6944374	ENSG00000226824.5	RP4-756H11.3	8.9	5.61e-15	5.15e-11	0.67	0.62	Aortic root size;	chr7:66221942	chr7:66654538~66669855:+
TGCT	cis	rs2729354	0.768	rs2848640	ENSG00000265566.2	RN7SL605P	-8.9	5.64e-15	5.18e-11	-0.8	-0.62	Blood protein levels;	chr11:57495207	chr11:57528085~57528365:-
TGCT	cis	rs1577917	1	rs13199006	ENSG00000203875.9	SNHG5	-8.9	5.67e-15	5.18e-11	-0.86	-0.62	Response to antipsychotic treatment;	chr6:85898990	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs4707239	ENSG00000203875.9	SNHG5	-8.9	5.67e-15	5.18e-11	-0.86	-0.62	Response to antipsychotic treatment;	chr6:85900999	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs7766645	ENSG00000203875.9	SNHG5	-8.9	5.67e-15	5.18e-11	-0.86	-0.62	Response to antipsychotic treatment;	chr6:85912520	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs1911552	ENSG00000203875.9	SNHG5	-8.9	5.67e-15	5.18e-11	-0.86	-0.62	Response to antipsychotic treatment;	chr6:85928306	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs9647603	ENSG00000203875.9	SNHG5	-8.9	5.67e-15	5.18e-11	-0.86	-0.62	Response to antipsychotic treatment;	chr6:85929623	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs7747824	ENSG00000203875.9	SNHG5	-8.9	5.67e-15	5.18e-11	-0.86	-0.62	Response to antipsychotic treatment;	chr6:85937388	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs35385043	ENSG00000203875.9	SNHG5	-8.9	5.67e-15	5.18e-11	-0.86	-0.62	Response to antipsychotic treatment;	chr6:85938828	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs35760725	ENSG00000203875.9	SNHG5	-8.9	5.67e-15	5.18e-11	-0.86	-0.62	Response to antipsychotic treatment;	chr6:85939267	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs2660576	ENSG00000203875.9	SNHG5	-8.9	5.67e-15	5.18e-11	-0.86	-0.62	Response to antipsychotic treatment;	chr6:85941885	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs6914463	ENSG00000203875.9	SNHG5	-8.9	5.67e-15	5.18e-11	-0.86	-0.62	Response to antipsychotic treatment;	chr6:85943697	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs2816821	ENSG00000203875.9	SNHG5	-8.9	5.67e-15	5.18e-11	-0.86	-0.62	Response to antipsychotic treatment;	chr6:85947366	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs2812972	ENSG00000203875.9	SNHG5	-8.9	5.67e-15	5.18e-11	-0.86	-0.62	Response to antipsychotic treatment;	chr6:85960162	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs1337843	ENSG00000203875.9	SNHG5	-8.9	5.67e-15	5.18e-11	-0.86	-0.62	Response to antipsychotic treatment;	chr6:85965827	chr6:85660950~85678736:-
TGCT	cis	rs1355223	0.902	rs1578622	ENSG00000271369.1	RP11-350D17.3	-8.9	5.72e-15	5.22e-11	-0.59	-0.62	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34704368	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.902	rs11603774	ENSG00000271369.1	RP11-350D17.3	-8.9	5.8e-15	5.3e-11	-0.59	-0.62	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34711344	chr11:34709600~34710161:+
TGCT	cis	rs1577917	0.876	rs1582127	ENSG00000203875.9	SNHG5	-8.89	5.95e-15	5.43e-11	-0.85	-0.62	Response to antipsychotic treatment;	chr6:85987486	chr6:85660950~85678736:-
TGCT	cis	rs2729354	0.768	rs2584856	ENSG00000265566.2	RN7SL605P	-8.89	5.96e-15	5.43e-11	-0.78	-0.62	Blood protein levels;	chr11:57499839	chr11:57528085~57528365:-
TGCT	cis	rs5769707	0.967	rs5769698	ENSG00000188511.11	C22orf34	8.89	6.01e-15	5.48e-11	0.6	0.62	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49414524~49657542:-
TGCT	cis	rs2729354	0.768	rs1001956	ENSG00000265566.2	RN7SL605P	-8.89	6.12e-15	5.58e-11	-0.78	-0.62	Blood protein levels;	chr11:57499476	chr11:57528085~57528365:-
TGCT	cis	rs3734266	0.702	rs9469832	ENSG00000186328.4	RP11-140K17.2	8.89	6.14e-15	5.59e-11	1	0.62	Systemic lupus erythematosus;	chr6:34635384	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs4646933	ENSG00000186328.4	RP11-140K17.2	8.88	6.22e-15	5.66e-11	1	0.62	Systemic lupus erythematosus;	chr6:34882883	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs1051115	ENSG00000186328.4	RP11-140K17.2	8.88	6.22e-15	5.66e-11	1	0.62	Systemic lupus erythematosus;	chr6:34887971	chr6:34715613~34715940:+
TGCT	cis	rs916888	0.697	rs199516	ENSG00000262500.1	RP11-259G18.2	-8.88	6.31e-15	5.75e-11	-0.92	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46243606~46245044:+
TGCT	cis	rs1167827	1	rs1167827	ENSG00000127957.15	PMS2P3	-8.88	6.41e-15	5.83e-11	-0.72	-0.62	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75502930~75528148:-
TGCT	cis	rs1577917	0.958	rs2225754	ENSG00000203875.9	SNHG5	-8.88	6.42e-15	5.84e-11	-0.83	-0.62	Response to antipsychotic treatment;	chr6:85739980	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.916	rs12198730	ENSG00000203875.9	SNHG5	-8.87	6.53e-15	5.93e-11	-0.85	-0.62	Response to antipsychotic treatment;	chr6:85845420	chr6:85660950~85678736:-
TGCT	cis	rs9326248	0.861	rs7120309	ENSG00000254851.1	RP11-109L13.1	-8.87	6.56e-15	5.96e-11	-0.92	-0.62	Blood protein levels;	chr11:117172100	chr11:117135528~117138582:+
TGCT	cis	rs9326248	0.861	rs7120449	ENSG00000254851.1	RP11-109L13.1	-8.87	6.56e-15	5.96e-11	-0.92	-0.62	Blood protein levels;	chr11:117172183	chr11:117135528~117138582:+
TGCT	cis	rs1577917	0.917	rs2218594	ENSG00000203875.9	SNHG5	-8.87	6.61e-15	5.99e-11	-0.85	-0.62	Response to antipsychotic treatment;	chr6:85834048	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs2197648	ENSG00000203875.9	SNHG5	-8.87	6.61e-15	5.99e-11	-0.85	-0.62	Response to antipsychotic treatment;	chr6:85834169	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs11752180	ENSG00000203875.9	SNHG5	-8.87	6.61e-15	5.99e-11	-0.85	-0.62	Response to antipsychotic treatment;	chr6:85863447	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.876	rs11752223	ENSG00000203875.9	SNHG5	-8.87	6.61e-15	5.99e-11	-0.85	-0.62	Response to antipsychotic treatment;	chr6:85863676	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs12660846	ENSG00000203875.9	SNHG5	-8.87	6.61e-15	5.99e-11	-0.85	-0.62	Response to antipsychotic treatment;	chr6:85864091	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.917	rs12665464	ENSG00000203875.9	SNHG5	-8.87	6.61e-15	5.99e-11	-0.85	-0.62	Response to antipsychotic treatment;	chr6:85864415	chr6:85660950~85678736:-
TGCT	cis	rs858239	0.537	rs6942981	ENSG00000230658.1	KLHL7-AS1	8.87	6.67e-15	6.03e-11	0.73	0.62	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23101228~23105703:-
TGCT	cis	rs3734266	0.639	rs11968972	ENSG00000186328.4	RP11-140K17.2	8.86	6.95e-15	6.28e-11	0.94	0.62	Systemic lupus erythematosus;	chr6:34773317	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.697	rs67895864	ENSG00000186328.4	RP11-140K17.2	8.86	6.95e-15	6.28e-11	0.94	0.62	Systemic lupus erythematosus;	chr6:34774996	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.639	rs11967912	ENSG00000186328.4	RP11-140K17.2	8.86	6.95e-15	6.28e-11	0.94	0.62	Systemic lupus erythematosus;	chr6:34790076	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.536	rs35143960	ENSG00000186328.4	RP11-140K17.2	8.86	6.95e-15	6.28e-11	0.94	0.62	Systemic lupus erythematosus;	chr6:34793898	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.584	rs12111129	ENSG00000186328.4	RP11-140K17.2	8.86	6.95e-15	6.28e-11	0.94	0.62	Systemic lupus erythematosus;	chr6:34806671	chr6:34715613~34715940:+
TGCT	cis	rs1930961	0.85	rs5996945	ENSG00000272977.1	CTA-390C10.10	8.86	7.2e-15	6.49e-11	0.83	0.62	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25476218~25479971:+
TGCT	cis	rs6538678	0.929	rs7962359	ENSG00000258343.1	RP11-536G4.2	-8.85	7.35e-15	6.63e-11	-0.97	-0.62	Lupus nephritis in systemic lupus erythematosus;	chr12:95862566	chr12:95795345~95858839:-
TGCT	cis	rs6538678	0.963	rs11108310	ENSG00000258343.1	RP11-536G4.2	-8.85	7.35e-15	6.63e-11	-0.97	-0.62	Lupus nephritis in systemic lupus erythematosus;	chr12:95864164	chr12:95795345~95858839:-
TGCT	cis	rs1355223	0.867	rs2281908	ENSG00000271369.1	RP11-350D17.3	-8.85	7.65e-15	6.9e-11	-0.59	-0.62	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34662031	chr11:34709600~34710161:+
TGCT	cis	rs7301826	0.651	rs7956851	ENSG00000256250.1	RP11-989F5.1	-8.84	7.67e-15	6.91e-11	-0.73	-0.62	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810606~130812438:+
TGCT	cis	rs2882667	0.628	rs13162420	ENSG00000253404.1	AC034243.1	8.84	7.75e-15	6.97e-11	0.83	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138839070	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.628	rs13167462	ENSG00000253404.1	AC034243.1	8.84	7.75e-15	6.97e-11	0.83	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841572	chr5:138744434~138753309:-
TGCT	cis	rs875971	0.862	rs3893216	ENSG00000226824.5	RP4-756H11.3	8.84	7.76e-15	6.97e-11	0.68	0.62	Aortic root size;	chr7:66325720	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs6958294	ENSG00000226824.5	RP4-756H11.3	8.84	7.76e-15	6.97e-11	0.68	0.62	Aortic root size;	chr7:66329809	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs2088655	ENSG00000226824.5	RP4-756H11.3	8.84	7.76e-15	6.97e-11	0.68	0.62	Aortic root size;	chr7:66330724	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.895	rs10447522	ENSG00000226824.5	RP4-756H11.3	8.84	7.76e-15	6.97e-11	0.68	0.62	Aortic root size;	chr7:66331087	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs2088653	ENSG00000226824.5	RP4-756H11.3	8.84	7.76e-15	6.97e-11	0.68	0.62	Aortic root size;	chr7:66343621	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs6460293	ENSG00000226824.5	RP4-756H11.3	8.84	7.76e-15	6.97e-11	0.68	0.62	Aortic root size;	chr7:66345205	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs778736	ENSG00000226824.5	RP4-756H11.3	-8.84	7.76e-15	6.97e-11	-0.68	-0.62	Aortic root size;	chr7:66348861	chr7:66654538~66669855:+
TGCT	cis	rs3734266	0.639	rs7739385	ENSG00000186328.4	RP11-140K17.2	8.84	7.99e-15	7.16e-11	0.99	0.62	Systemic lupus erythematosus;	chr6:34899701	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs16895659	ENSG00000186328.4	RP11-140K17.2	8.84	7.99e-15	7.16e-11	0.99	0.62	Systemic lupus erythematosus;	chr6:34923091	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs28360525	ENSG00000186328.4	RP11-140K17.2	8.84	7.99e-15	7.16e-11	0.99	0.62	Systemic lupus erythematosus;	chr6:34923261	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs6457797	ENSG00000186328.4	RP11-140K17.2	8.84	7.99e-15	7.16e-11	0.99	0.62	Systemic lupus erythematosus;	chr6:34929397	chr6:34715613~34715940:+
TGCT	cis	rs3734266	0.702	rs6457798	ENSG00000186328.4	RP11-140K17.2	8.84	7.99e-15	7.16e-11	0.99	0.62	Systemic lupus erythematosus;	chr6:34929422	chr6:34715613~34715940:+
TGCT	cis	rs11098499	0.754	rs1814813	ENSG00000245958.5	RP11-33B1.1	8.82	8.62e-15	7.7e-11	0.62	0.62	Corneal astigmatism;	chr4:119337052	chr4:119454791~119552025:+
TGCT	cis	rs7301826	0.603	rs7975825	ENSG00000256250.1	RP11-989F5.1	-8.82	8.66e-15	7.74e-11	-0.72	-0.62	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810606~130812438:+
TGCT	cis	rs6452524	0.618	rs3899556	ENSG00000249664.1	CTD-2227C6.2	8.82	8.73e-15	7.8e-11	0.62	0.62	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.56	rs6895174	ENSG00000249664.1	CTD-2227C6.2	8.82	8.76e-15	7.83e-11	0.62	0.62	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:83012285~83013109:-
TGCT	cis	rs1355223	0.902	rs7102625	ENSG00000271369.1	RP11-350D17.3	8.82	8.99e-15	8.03e-11	0.58	0.62	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34718170	chr11:34709600~34710161:+
TGCT	cis	rs1577917	1	rs12663690	ENSG00000203875.9	SNHG5	8.81	9.22e-15	8.19e-11	0.84	0.62	Response to antipsychotic treatment;	chr6:85930444	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs13213551	ENSG00000203875.9	SNHG5	-8.81	9.22e-15	8.19e-11	-0.84	-0.62	Response to antipsychotic treatment;	chr6:85898983	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs34622557	ENSG00000203875.9	SNHG5	-8.81	9.22e-15	8.19e-11	-0.84	-0.62	Response to antipsychotic treatment;	chr6:85921134	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs1911553	ENSG00000203875.9	SNHG5	-8.81	9.22e-15	8.19e-11	-0.84	-0.62	Response to antipsychotic treatment;	chr6:85921174	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs1995688	ENSG00000203875.9	SNHG5	-8.81	9.22e-15	8.19e-11	-0.84	-0.62	Response to antipsychotic treatment;	chr6:85922601	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs6940458	ENSG00000203875.9	SNHG5	-8.81	9.22e-15	8.19e-11	-0.84	-0.62	Response to antipsychotic treatment;	chr6:85935274	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs12213740	ENSG00000203875.9	SNHG5	-8.81	9.22e-15	8.19e-11	-0.84	-0.62	Response to antipsychotic treatment;	chr6:85947015	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs12207610	ENSG00000203875.9	SNHG5	-8.81	9.22e-15	8.19e-11	-0.84	-0.62	Response to antipsychotic treatment;	chr6:85978298	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs12203457	ENSG00000203875.9	SNHG5	-8.81	9.22e-15	8.19e-11	-0.84	-0.62	Response to antipsychotic treatment;	chr6:85979559	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs34852683	ENSG00000203875.9	SNHG5	-8.81	9.22e-15	8.19e-11	-0.84	-0.62	Response to antipsychotic treatment;	chr6:85992612	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.917	rs35038582	ENSG00000203875.9	SNHG5	-8.81	9.22e-15	8.19e-11	-0.84	-0.62	Response to antipsychotic treatment;	chr6:86011587	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs7760207	ENSG00000203875.9	SNHG5	-8.81	9.22e-15	8.19e-11	-0.84	-0.62	Response to antipsychotic treatment;	chr6:86011982	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs12207305	ENSG00000203875.9	SNHG5	-8.81	9.22e-15	8.19e-11	-0.84	-0.62	Response to antipsychotic treatment;	chr6:86013784	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs12199784	ENSG00000203875.9	SNHG5	-8.81	9.22e-15	8.19e-11	-0.84	-0.62	Response to antipsychotic treatment;	chr6:86017090	chr6:85660950~85678736:-
TGCT	cis	rs2729354	0.768	rs2581922	ENSG00000265566.2	RN7SL605P	-8.81	9.23e-15	8.19e-11	-0.77	-0.62	Blood protein levels;	chr11:57497927	chr11:57528085~57528365:-
TGCT	cis	rs2729354	0.817	rs2250673	ENSG00000265566.2	RN7SL605P	-8.81	9.25e-15	8.21e-11	-0.78	-0.62	Blood protein levels;	chr11:57500697	chr11:57528085~57528365:-
TGCT	cis	rs916888	0.821	rs199514	ENSG00000262500.1	RP11-259G18.2	-8.81	9.42e-15	8.35e-11	-0.92	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46243606~46245044:+
TGCT	cis	rs875971	0.862	rs10256544	ENSG00000226824.5	RP4-756H11.3	-8.81	9.5e-15	8.42e-11	-0.68	-0.62	Aortic root size;	chr7:66210141	chr7:66654538~66669855:+
TGCT	cis	rs858239	1	rs166663	ENSG00000230658.1	KLHL7-AS1	8.8	9.56e-15	8.47e-11	0.66	0.62	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23101228~23105703:-
TGCT	cis	rs1355223	0.902	rs1258470	ENSG00000271369.1	RP11-350D17.3	8.8	9.77e-15	8.65e-11	0.58	0.62	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34707718	chr11:34709600~34710161:+
TGCT	cis	rs847845	0.535	rs3734261	ENSG00000186328.4	RP11-140K17.2	-8.8	1e-14	8.88e-11	-1.13	-0.62	Non-small cell lung cancer;	chr6:34872621	chr6:34715613~34715940:+
TGCT	cis	rs2283792	0.792	rs151680	ENSG00000228050.1	TOP3BP1	8.79	1.01e-14	8.93e-11	0.7	0.62	Multiple sclerosis;	chr22:21918869	chr22:22223187~22224566:-
TGCT	cis	rs11098499	0.78	rs7692994	ENSG00000245958.5	RP11-33B1.1	-8.79	1.02e-14	8.98e-11	-0.66	-0.62	Corneal astigmatism;	chr4:119506334	chr4:119454791~119552025:+
TGCT	cis	rs801193	0.569	rs13226966	ENSG00000226824.5	RP4-756H11.3	-8.79	1.05e-14	9.25e-11	-0.69	-0.62	Aortic root size;	chr7:66768636	chr7:66654538~66669855:+
TGCT	cis	rs2283792	0.846	rs240051	ENSG00000228050.1	TOP3BP1	8.79	1.05e-14	9.25e-11	0.71	0.62	Multiple sclerosis;	chr22:21909763	chr22:22223187~22224566:-
TGCT	cis	rs2283792	0.846	rs240053	ENSG00000228050.1	TOP3BP1	8.79	1.05e-14	9.25e-11	0.71	0.62	Multiple sclerosis;	chr22:21911000	chr22:22223187~22224566:-
TGCT	cis	rs875971	0.862	rs2909688	ENSG00000226824.5	RP4-756H11.3	-8.79	1.05e-14	9.26e-11	-0.67	-0.62	Aortic root size;	chr7:66376625	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs709596	ENSG00000226824.5	RP4-756H11.3	-8.78	1.11e-14	9.73e-11	-0.68	-0.62	Aortic root size;	chr7:66360926	chr7:66654538~66669855:+
TGCT	cis	rs6452524	0.618	rs6452501	ENSG00000249664.1	CTD-2227C6.2	8.78	1.12e-14	9.83e-11	0.63	0.62	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:83012285~83013109:-
TGCT	cis	rs847845	0.535	rs205284	ENSG00000186328.4	RP11-140K17.2	8.78	1.12e-14	9.9e-11	1.09	0.62	Non-small cell lung cancer;	chr6:34584135	chr6:34715613~34715940:+
TGCT	cis	rs858239	0.636	rs7808488	ENSG00000230658.1	KLHL7-AS1	8.77	1.15e-14	1.01e-10	0.65	0.62	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23101228~23105703:-
TGCT	cis	rs7301826	0.651	rs12820597	ENSG00000256250.1	RP11-989F5.1	8.77	1.16e-14	1.02e-10	0.73	0.62	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810606~130812438:+
TGCT	cis	rs2739330	0.734	rs2000467	ENSG00000225282.1	AP000350.6	-8.77	1.16e-14	1.02e-10	-0.79	-0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23926900~23929574:+
TGCT	cis	rs1577917	0.958	rs13219504	ENSG00000203875.9	SNHG5	-8.77	1.17e-14	1.03e-10	-0.84	-0.62	Response to antipsychotic treatment;	chr6:85847199	chr6:85660950~85678736:-
TGCT	cis	rs1355223	0.902	rs1453387	ENSG00000271369.1	RP11-350D17.3	-8.77	1.18e-14	1.03e-10	-0.58	-0.62	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34686351	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.902	rs1258468	ENSG00000271369.1	RP11-350D17.3	-8.76	1.19e-14	1.04e-10	-0.58	-0.62	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34708184	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.872	rs1258466	ENSG00000271369.1	RP11-350D17.3	-8.76	1.19e-14	1.04e-10	-0.58	-0.62	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34708519	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.902	rs704744	ENSG00000271369.1	RP11-350D17.3	-8.76	1.19e-14	1.04e-10	-0.58	-0.62	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34715014	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.902	rs836466	ENSG00000271369.1	RP11-350D17.3	-8.76	1.19e-14	1.04e-10	-0.58	-0.62	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34715819	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.902	rs1773910	ENSG00000271369.1	RP11-350D17.3	-8.76	1.19e-14	1.04e-10	-0.58	-0.62	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34719706	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.902	rs1539251	ENSG00000271369.1	RP11-350D17.3	-8.76	1.19e-14	1.04e-10	-0.58	-0.62	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34721225	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.902	rs1539250	ENSG00000271369.1	RP11-350D17.3	-8.76	1.19e-14	1.04e-10	-0.58	-0.62	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34721228	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.902	rs836462	ENSG00000271369.1	RP11-350D17.3	-8.76	1.19e-14	1.04e-10	-0.58	-0.62	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34721716	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.902	rs1773908	ENSG00000271369.1	RP11-350D17.3	-8.76	1.19e-14	1.04e-10	-0.58	-0.62	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34721833	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.902	rs860712	ENSG00000271369.1	RP11-350D17.3	-8.76	1.19e-14	1.04e-10	-0.58	-0.62	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34721947	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.902	rs2226113	ENSG00000271369.1	RP11-350D17.3	-8.76	1.19e-14	1.04e-10	-0.58	-0.62	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34724742	chr11:34709600~34710161:+
TGCT	cis	rs2882667	0.628	rs13154573	ENSG00000253404.1	AC034243.1	8.76	1.2e-14	1.05e-10	0.82	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138812375	chr5:138744434~138753309:-
TGCT	cis	rs2283792	0.687	rs381849	ENSG00000228050.1	TOP3BP1	8.76	1.24e-14	1.08e-10	0.69	0.62	Multiple sclerosis;	chr22:21951341	chr22:22223187~22224566:-
TGCT	cis	rs2283792	0.718	rs239918	ENSG00000228050.1	TOP3BP1	8.76	1.24e-14	1.08e-10	0.69	0.62	Multiple sclerosis;	chr22:21959457	chr22:22223187~22224566:-
TGCT	cis	rs1577917	1	rs12204015	ENSG00000203875.9	SNHG5	-8.75	1.26e-14	1.09e-10	-0.84	-0.62	Response to antipsychotic treatment;	chr6:85888616	chr6:85660950~85678736:-
TGCT	cis	rs858239	0.669	rs1990365	ENSG00000230658.1	KLHL7-AS1	8.75	1.3e-14	1.12e-10	0.64	0.62	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23101228~23105703:-
TGCT	cis	rs1775715	0.87	rs1755085	ENSG00000239731.3	RN7SL825P	-8.74	1.37e-14	1.19e-10	-0.63	-0.62	Bipolar disorder with mood-incongruent psychosis;	chr10:31962003	chr10:31992087~31992381:-
TGCT	cis	rs3814244	0.868	rs10878726	ENSG00000255733.4	IFNG-AS1	8.74	1.39e-14	1.2e-10	0.56	0.62	Itch intensity from mosquito bite adjusted by bite size;	chr12:68022865	chr12:67989445~68234686:+
TGCT	cis	rs1577917	0.958	rs12192546	ENSG00000203875.9	SNHG5	8.74	1.4e-14	1.21e-10	0.84	0.62	Response to antipsychotic treatment;	chr6:85766766	chr6:85660950~85678736:-
TGCT	cis	rs943437	0.509	rs2148711	ENSG00000227012.2	RP1-97J1.2	8.72	1.49e-14	1.29e-10	0.98	0.62	Parkinson's disease;	chr6:111836531	chr6:111900489~111901851:-
TGCT	cis	rs875971	0.862	rs2460432	ENSG00000226824.5	RP4-756H11.3	8.72	1.5e-14	1.3e-10	0.68	0.62	Aortic root size;	chr7:66089398	chr7:66654538~66669855:+
TGCT	cis	rs17507216	0.958	rs72751643	ENSG00000278603.1	RP13-608F4.5	8.72	1.53e-14	1.32e-10	0.97	0.62	Excessive daytime sleepiness;	chr15:82559444	chr15:82472203~82472426:+
TGCT	cis	rs1355223	0.902	rs680727	ENSG00000271369.1	RP11-350D17.3	8.72	1.54e-14	1.33e-10	0.57	0.62	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34682899	chr11:34709600~34710161:+
TGCT	cis	rs2729354	0.729	rs2729353	ENSG00000265566.2	RN7SL605P	-8.72	1.55e-14	1.34e-10	-0.79	-0.62	Blood protein levels;	chr11:57480530	chr11:57528085~57528365:-
TGCT	cis	rs2729354	0.52	rs2729377	ENSG00000265566.2	RN7SL605P	-8.72	1.55e-14	1.34e-10	-0.79	-0.62	Blood protein levels;	chr11:57482611	chr11:57528085~57528365:-
TGCT	cis	rs2729354	0.768	rs2848635	ENSG00000265566.2	RN7SL605P	-8.72	1.55e-14	1.34e-10	-0.79	-0.62	Blood protein levels;	chr11:57486458	chr11:57528085~57528365:-
TGCT	cis	rs858239	1	rs156407	ENSG00000230658.1	KLHL7-AS1	8.71	1.62e-14	1.39e-10	0.65	0.62	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23101228~23105703:-
TGCT	cis	rs9326248	0.861	rs7931335	ENSG00000254851.1	RP11-109L13.1	-8.71	1.62e-14	1.39e-10	-0.92	-0.62	Blood protein levels;	chr11:117166089	chr11:117135528~117138582:+
TGCT	cis	rs1577917	1	rs34106666	ENSG00000203875.9	SNHG5	-8.7	1.68e-14	1.44e-10	-0.84	-0.62	Response to antipsychotic treatment;	chr6:85966540	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs1337844	ENSG00000203875.9	SNHG5	-8.7	1.68e-14	1.44e-10	-0.84	-0.62	Response to antipsychotic treatment;	chr6:85967555	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs884842	ENSG00000203875.9	SNHG5	-8.7	1.68e-14	1.44e-10	-0.84	-0.62	Response to antipsychotic treatment;	chr6:85970679	chr6:85660950~85678736:-
TGCT	cis	rs1355223	0.902	rs286862	ENSG00000271369.1	RP11-350D17.3	8.7	1.68e-14	1.44e-10	0.57	0.62	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34697232	chr11:34709600~34710161:+
TGCT	cis	rs5769707	0.933	rs2157444	ENSG00000188511.11	C22orf34	8.7	1.71e-14	1.46e-10	0.59	0.62	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49414524~49657542:-
TGCT	cis	rs1577917	0.958	rs2121594	ENSG00000203875.9	SNHG5	-8.7	1.72e-14	1.47e-10	-0.84	-0.62	Response to antipsychotic treatment;	chr6:85867136	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.916	rs12203358	ENSG00000203875.9	SNHG5	-8.7	1.72e-14	1.47e-10	-0.84	-0.62	Response to antipsychotic treatment;	chr6:85893506	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs34765423	ENSG00000203875.9	SNHG5	-8.7	1.72e-14	1.47e-10	-0.83	-0.62	Response to antipsychotic treatment;	chr6:85774730	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.917	rs2197651	ENSG00000203875.9	SNHG5	-8.7	1.72e-14	1.47e-10	-0.83	-0.62	Response to antipsychotic treatment;	chr6:85785724	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs12198876	ENSG00000203875.9	SNHG5	-8.7	1.72e-14	1.47e-10	-0.83	-0.62	Response to antipsychotic treatment;	chr6:85815758	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.876	rs66986937	ENSG00000203875.9	SNHG5	-8.7	1.72e-14	1.47e-10	-0.83	-0.62	Response to antipsychotic treatment;	chr6:85822473	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs10944144	ENSG00000203875.9	SNHG5	-8.7	1.72e-14	1.47e-10	-0.83	-0.62	Response to antipsychotic treatment;	chr6:85828037	chr6:85660950~85678736:-
TGCT	cis	rs858239	0.965	rs156429	ENSG00000230658.1	KLHL7-AS1	8.7	1.73e-14	1.48e-10	0.65	0.62	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23101228~23105703:-
TGCT	cis	rs875971	0.862	rs1167408	ENSG00000226824.5	RP4-756H11.3	8.69	1.76e-14	1.5e-10	0.68	0.62	Aortic root size;	chr7:66091121	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.83	rs1167406	ENSG00000226824.5	RP4-756H11.3	8.69	1.76e-14	1.5e-10	0.68	0.62	Aortic root size;	chr7:66091949	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs709609	ENSG00000226824.5	RP4-756H11.3	8.69	1.76e-14	1.5e-10	0.68	0.62	Aortic root size;	chr7:66095574	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs1167399	ENSG00000226824.5	RP4-756H11.3	8.69	1.76e-14	1.5e-10	0.68	0.62	Aortic root size;	chr7:66096890	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs57866200	ENSG00000226824.5	RP4-756H11.3	8.69	1.76e-14	1.5e-10	0.68	0.62	Aortic root size;	chr7:66100405	chr7:66654538~66669855:+
TGCT	cis	rs2729354	0.729	rs2581923	ENSG00000265566.2	RN7SL605P	-8.69	1.83e-14	1.55e-10	-0.79	-0.62	Blood protein levels;	chr11:57482518	chr11:57528085~57528365:-
TGCT	cis	rs1355223	0.902	rs1453380	ENSG00000271369.1	RP11-350D17.3	-8.68	1.85e-14	1.57e-10	-0.58	-0.61	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34682135	chr11:34709600~34710161:+
TGCT	cis	rs1775715	0.87	rs1775737	ENSG00000239731.3	RN7SL825P	-8.68	1.87e-14	1.59e-10	-0.62	-0.61	Bipolar disorder with mood-incongruent psychosis;	chr10:31967943	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.835	rs1419169	ENSG00000239731.3	RN7SL825P	-8.68	1.87e-14	1.59e-10	-0.62	-0.61	Bipolar disorder with mood-incongruent psychosis;	chr10:31968276	chr10:31992087~31992381:-
TGCT	cis	rs875971	0.825	rs1000464	ENSG00000226824.5	RP4-756H11.3	8.68	1.88e-14	1.59e-10	0.67	0.61	Aortic root size;	chr7:66312922	chr7:66654538~66669855:+
TGCT	cis	rs5769707	0.967	rs2187891	ENSG00000188511.11	C22orf34	8.68	1.88e-14	1.59e-10	0.58	0.61	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49414524~49657542:-
TGCT	cis	rs4423214	1	rs12792306	ENSG00000254682.1	RP11-660L16.2	8.68	1.92e-14	1.61e-10	0.81	0.61	Vitamin D levels;	chr11:71455946	chr11:71448674~71452157:+
TGCT	cis	rs6452524	1	rs9293332	ENSG00000249664.1	CTD-2227C6.2	8.68	1.94e-14	1.62e-10	0.61	0.61	Hypertension (SNP x SNP interaction);	chr5:83141546	chr5:83012285~83013109:-
TGCT	cis	rs916888	0.821	rs70600	ENSG00000262500.1	RP11-259G18.2	8.67	1.97e-14	1.64e-10	0.92	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46243606~46245044:+
TGCT	cis	rs916888	0.821	rs199512	ENSG00000262500.1	RP11-259G18.2	-8.67	1.97e-14	1.64e-10	-0.92	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46243606~46245044:+
TGCT	cis	rs916888	0.821	rs199509	ENSG00000262500.1	RP11-259G18.2	-8.67	1.97e-14	1.64e-10	-0.92	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46243606~46245044:+
TGCT	cis	rs916888	0.821	rs199507	ENSG00000262500.1	RP11-259G18.2	-8.67	1.97e-14	1.64e-10	-0.92	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46243606~46245044:+
TGCT	cis	rs916888	0.821	rs199506	ENSG00000262500.1	RP11-259G18.2	-8.67	1.97e-14	1.64e-10	-0.92	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46243606~46245044:+
TGCT	cis	rs916888	0.821	rs415430	ENSG00000262500.1	RP11-259G18.2	-8.67	1.97e-14	1.64e-10	-0.92	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46243606~46245044:+
TGCT	cis	rs916888	0.779	rs430685	ENSG00000262500.1	RP11-259G18.2	-8.67	1.97e-14	1.64e-10	-0.92	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46243606~46245044:+
TGCT	cis	rs916888	0.821	rs199505	ENSG00000262500.1	RP11-259G18.2	-8.67	1.97e-14	1.64e-10	-0.92	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46243606~46245044:+
TGCT	cis	rs916888	0.821	rs70602	ENSG00000262500.1	RP11-259G18.2	-8.67	1.97e-14	1.64e-10	-0.92	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46243606~46245044:+
TGCT	cis	rs1355223	0.902	rs35032224	ENSG00000271369.1	RP11-350D17.3	-8.67	1.98e-14	1.65e-10	-0.57	-0.61	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34676607	chr11:34709600~34710161:+
TGCT	cis	rs6452524	0.618	rs10051445	ENSG00000249664.1	CTD-2227C6.2	8.67	1.99e-14	1.65e-10	0.62	0.61	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:83012285~83013109:-
TGCT	cis	rs1577917	0.958	rs12195776	ENSG00000203875.9	SNHG5	-8.67	2e-14	1.67e-10	-0.84	-0.61	Response to antipsychotic treatment;	chr6:85778881	chr6:85660950~85678736:-
TGCT	cis	rs2487048	0.773	rs2472494	ENSG00000226334.1	RP11-217B7.2	-8.67	2.02e-14	1.68e-10	-0.6	-0.61	Intraocular pressure;	chr9:104933258	chr9:104927553~104928892:+
TGCT	cis	rs4423214	1	rs2002063	ENSG00000254682.1	RP11-660L16.2	8.67	2.03e-14	1.68e-10	0.82	0.61	Vitamin D levels;	chr11:71452430	chr11:71448674~71452157:+
TGCT	cis	rs4423214	1	rs11600860	ENSG00000254682.1	RP11-660L16.2	8.67	2.03e-14	1.68e-10	0.82	0.61	Vitamin D levels;	chr11:71452973	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.959	rs11606611	ENSG00000254682.1	RP11-660L16.2	8.67	2.03e-14	1.68e-10	0.82	0.61	Vitamin D levels;	chr11:71453000	chr11:71448674~71452157:+
TGCT	cis	rs4423214	1	rs11606612	ENSG00000254682.1	RP11-660L16.2	8.67	2.03e-14	1.68e-10	0.82	0.61	Vitamin D levels;	chr11:71453001	chr11:71448674~71452157:+
TGCT	cis	rs4423214	1	rs11606631	ENSG00000254682.1	RP11-660L16.2	8.67	2.03e-14	1.68e-10	0.82	0.61	Vitamin D levels;	chr11:71453075	chr11:71448674~71452157:+
TGCT	cis	rs4423214	1	rs12789751	ENSG00000254682.1	RP11-660L16.2	8.67	2.03e-14	1.68e-10	0.82	0.61	Vitamin D levels;	chr11:71453425	chr11:71448674~71452157:+
TGCT	cis	rs4423214	1	rs12791871	ENSG00000254682.1	RP11-660L16.2	8.67	2.03e-14	1.68e-10	0.82	0.61	Vitamin D levels;	chr11:71453498	chr11:71448674~71452157:+
TGCT	cis	rs4423214	1	rs7944926	ENSG00000254682.1	RP11-660L16.2	8.67	2.03e-14	1.68e-10	0.82	0.61	Vitamin D levels;	chr11:71454579	chr11:71448674~71452157:+
TGCT	cis	rs977987	0.868	rs10871313	ENSG00000261783.1	RP11-252K23.2	-8.66	2.08e-14	1.73e-10	-0.92	-0.61	Dupuytren's disease;	chr16:75473196	chr16:75379818~75381260:-
TGCT	cis	rs1355223	0.902	rs448016	ENSG00000271369.1	RP11-350D17.3	8.66	2.12e-14	1.76e-10	0.56	0.61	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34685046	chr11:34709600~34710161:+
TGCT	cis	rs2729354	0.729	rs2848634	ENSG00000265566.2	RN7SL605P	-8.66	2.13e-14	1.76e-10	-0.79	-0.61	Blood protein levels;	chr11:57484855	chr11:57528085~57528365:-
TGCT	cis	rs17507216	1	rs17507216	ENSG00000278603.1	RP13-608F4.5	-8.66	2.15e-14	1.78e-10	-0.96	-0.61	Excessive daytime sleepiness;	chr15:82558175	chr15:82472203~82472426:+
TGCT	cis	rs1355223	0.902	rs286858	ENSG00000271369.1	RP11-350D17.3	8.66	2.15e-14	1.78e-10	0.57	0.61	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34695810	chr11:34709600~34710161:+
TGCT	cis	rs7188445	0.592	rs7199794	ENSG00000261390.4	RP11-345M22.2	8.65	2.19e-14	1.82e-10	0.62	0.61	Urate levels;	chr16:79708296	chr16:79715232~79770563:-
TGCT	cis	rs7188445	0.736	rs11642757	ENSG00000261390.4	RP11-345M22.2	-8.65	2.2e-14	1.82e-10	-0.62	-0.61	Urate levels;	chr16:79719570	chr16:79715232~79770563:-
TGCT	cis	rs875971	0.825	rs59466412	ENSG00000226824.5	RP4-756H11.3	8.65	2.2e-14	1.82e-10	0.68	0.61	Aortic root size;	chr7:66100371	chr7:66654538~66669855:+
TGCT	cis	rs5769707	0.967	rs17182154	ENSG00000188511.11	C22orf34	8.65	2.27e-14	1.87e-10	0.58	0.61	Monocyte percentage of white cells;Monocyte count;	chr22:49596822	chr22:49414524~49657542:-
TGCT	cis	rs6452524	0.618	rs6452502	ENSG00000249664.1	CTD-2227C6.2	8.65	2.27e-14	1.87e-10	0.63	0.61	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:83012285~83013109:-
TGCT	cis	rs875971	0.83	rs12673450	ENSG00000226824.5	RP4-756H11.3	-8.65	2.28e-14	1.88e-10	-0.67	-0.61	Aortic root size;	chr7:66544233	chr7:66654538~66669855:+
TGCT	cis	rs2486288	0.656	rs1706770	ENSG00000259520.4	CTD-2651B20.3	8.64	2.32e-14	1.91e-10	0.5	0.61	Glomerular filtration rate;	chr15:45282864	chr15:45251580~45279251:-
TGCT	cis	rs1355223	0.902	rs12800220	ENSG00000271369.1	RP11-350D17.3	-8.64	2.35e-14	1.93e-10	-0.58	-0.61	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34680070	chr11:34709600~34710161:+
TGCT	cis	rs6452524	0.935	rs11750799	ENSG00000249664.1	CTD-2227C6.2	8.64	2.42e-14	1.98e-10	0.61	0.61	Hypertension (SNP x SNP interaction);	chr5:83082983	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs10942321	ENSG00000249664.1	CTD-2227C6.2	8.64	2.42e-14	1.98e-10	0.61	0.61	Hypertension (SNP x SNP interaction);	chr5:83083200	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs6868416	ENSG00000249664.1	CTD-2227C6.2	8.64	2.42e-14	1.98e-10	0.61	0.61	Hypertension (SNP x SNP interaction);	chr5:83084320	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs1478485	ENSG00000249664.1	CTD-2227C6.2	8.64	2.42e-14	1.98e-10	0.61	0.61	Hypertension (SNP x SNP interaction);	chr5:83084708	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.836	rs1478484	ENSG00000249664.1	CTD-2227C6.2	8.64	2.42e-14	1.98e-10	0.61	0.61	Hypertension (SNP x SNP interaction);	chr5:83085055	chr5:83012285~83013109:-
TGCT	cis	rs1775715	0.87	rs1775735	ENSG00000239731.3	RN7SL825P	-8.63	2.43e-14	2e-10	-0.62	-0.61	Bipolar disorder with mood-incongruent psychosis;	chr10:31966918	chr10:31992087~31992381:-
TGCT	cis	rs1577917	0.958	rs1545376	ENSG00000203875.9	SNHG5	8.63	2.46e-14	2.02e-10	0.85	0.61	Response to antipsychotic treatment;	chr6:85794864	chr6:85660950~85678736:-
TGCT	cis	rs916888	0.773	rs199447	ENSG00000262500.1	RP11-259G18.2	8.63	2.48e-14	2.03e-10	0.93	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46243606~46245044:+
TGCT	cis	rs916888	0.773	rs199445	ENSG00000262500.1	RP11-259G18.2	8.63	2.48e-14	2.03e-10	0.93	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46243606~46245044:+
TGCT	cis	rs916888	0.773	rs199443	ENSG00000262500.1	RP11-259G18.2	8.63	2.48e-14	2.03e-10	0.93	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46243606~46245044:+
TGCT	cis	rs916888	0.773	rs199534	ENSG00000262500.1	RP11-259G18.2	8.63	2.48e-14	2.03e-10	0.93	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46243606~46245044:+
TGCT	cis	rs2739330	0.731	rs5751792	ENSG00000273295.1	AP000350.5	8.63	2.49e-14	2.05e-10	0.68	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23901432~23907068:-
TGCT	cis	rs6452524	0.905	rs7736289	ENSG00000249664.1	CTD-2227C6.2	8.62	2.62e-14	2.15e-10	0.61	0.61	Hypertension (SNP x SNP interaction);	chr5:83082401	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs7718472	ENSG00000249664.1	CTD-2227C6.2	8.62	2.62e-14	2.15e-10	0.61	0.61	Hypertension (SNP x SNP interaction);	chr5:83082603	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.901	rs10079680	ENSG00000249664.1	CTD-2227C6.2	8.62	2.62e-14	2.15e-10	0.61	0.61	Hypertension (SNP x SNP interaction);	chr5:83082746	chr5:83012285~83013109:-
TGCT	cis	rs1355223	0.902	rs11607035	ENSG00000271369.1	RP11-350D17.3	-8.61	2.72e-14	2.22e-10	-0.59	-0.61	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34697364	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.902	rs61881050	ENSG00000271369.1	RP11-350D17.3	-8.61	2.72e-14	2.22e-10	-0.59	-0.61	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34698202	chr11:34709600~34710161:+
TGCT	cis	rs3734266	0.639	rs7761391	ENSG00000186328.4	RP11-140K17.2	-8.61	2.82e-14	2.29e-10	-0.91	-0.61	Systemic lupus erythematosus;	chr6:34836427	chr6:34715613~34715940:+
TGCT	cis	rs1775715	0.87	rs1775731	ENSG00000239731.3	RN7SL825P	-8.61	2.83e-14	2.3e-10	-0.62	-0.61	Bipolar disorder with mood-incongruent psychosis;	chr10:31964584	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.87	rs1615256	ENSG00000239731.3	RN7SL825P	-8.61	2.83e-14	2.3e-10	-0.62	-0.61	Bipolar disorder with mood-incongruent psychosis;	chr10:31965173	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.87	rs1755080	ENSG00000239731.3	RN7SL825P	-8.61	2.83e-14	2.3e-10	-0.62	-0.61	Bipolar disorder with mood-incongruent psychosis;	chr10:31966267	chr10:31992087~31992381:-
TGCT	cis	rs4423214	1	rs7928249	ENSG00000254682.1	RP11-660L16.2	8.61	2.85e-14	2.32e-10	0.83	0.61	Vitamin D levels;	chr11:71450017	chr11:71448674~71452157:+
TGCT	cis	rs6452524	1	rs6452520	ENSG00000249664.1	CTD-2227C6.2	8.6	2.92e-14	2.37e-10	0.61	0.61	Hypertension (SNP x SNP interaction);	chr5:83133452	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs6452521	ENSG00000249664.1	CTD-2227C6.2	8.6	2.92e-14	2.37e-10	0.61	0.61	Hypertension (SNP x SNP interaction);	chr5:83133453	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs6452522	ENSG00000249664.1	CTD-2227C6.2	8.6	2.92e-14	2.37e-10	0.61	0.61	Hypertension (SNP x SNP interaction);	chr5:83133471	chr5:83012285~83013109:-
TGCT	cis	rs1577917	0.958	rs67024565	ENSG00000203875.9	SNHG5	-8.6	2.95e-14	2.39e-10	-0.82	-0.61	Response to antipsychotic treatment;	chr6:85844279	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs36053156	ENSG00000203875.9	SNHG5	-8.6	2.95e-14	2.39e-10	-0.82	-0.61	Response to antipsychotic treatment;	chr6:85865791	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.917	rs12202170	ENSG00000203875.9	SNHG5	-8.6	2.95e-14	2.39e-10	-0.82	-0.61	Response to antipsychotic treatment;	chr6:85880668	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs10455449	ENSG00000203875.9	SNHG5	-8.6	2.95e-14	2.39e-10	-0.82	-0.61	Response to antipsychotic treatment;	chr6:85882508	chr6:85660950~85678736:-
TGCT	cis	rs2882667	0.628	rs13173618	ENSG00000253404.1	AC034243.1	8.6	2.97e-14	2.4e-10	0.82	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804091	chr5:138744434~138753309:-
TGCT	cis	rs6452524	0.618	rs255561	ENSG00000249664.1	CTD-2227C6.2	8.59	3.05e-14	2.47e-10	0.61	0.61	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.618	rs1871203	ENSG00000249664.1	CTD-2227C6.2	8.59	3.06e-14	2.47e-10	0.61	0.61	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.618	rs7722924	ENSG00000249664.1	CTD-2227C6.2	8.59	3.06e-14	2.47e-10	0.61	0.61	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.618	rs6867727	ENSG00000249664.1	CTD-2227C6.2	8.59	3.06e-14	2.47e-10	0.61	0.61	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.618	rs7723639	ENSG00000249664.1	CTD-2227C6.2	8.59	3.06e-14	2.47e-10	0.61	0.61	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.618	rs2306336	ENSG00000249664.1	CTD-2227C6.2	8.59	3.06e-14	2.47e-10	0.61	0.61	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.589	rs6882386	ENSG00000249664.1	CTD-2227C6.2	8.59	3.06e-14	2.47e-10	0.61	0.61	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.618	rs6860752	ENSG00000249664.1	CTD-2227C6.2	8.59	3.06e-14	2.47e-10	0.61	0.61	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:83012285~83013109:-
TGCT	cis	rs1577917	1	rs2324843	ENSG00000203875.9	SNHG5	-8.59	3.09e-14	2.5e-10	-0.82	-0.61	Response to antipsychotic treatment;	chr6:85907783	chr6:85660950~85678736:-
TGCT	cis	rs6452524	1	rs7716962	ENSG00000249664.1	CTD-2227C6.2	8.59	3.11e-14	2.51e-10	0.63	0.61	Hypertension (SNP x SNP interaction);	chr5:83138913	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs6882179	ENSG00000249664.1	CTD-2227C6.2	8.59	3.11e-14	2.51e-10	0.63	0.61	Hypertension (SNP x SNP interaction);	chr5:83139582	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs6863300	ENSG00000249664.1	CTD-2227C6.2	8.59	3.11e-14	2.51e-10	0.63	0.61	Hypertension (SNP x SNP interaction);	chr5:83139629	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs7732092	ENSG00000249664.1	CTD-2227C6.2	8.59	3.11e-14	2.51e-10	0.63	0.61	Hypertension (SNP x SNP interaction);	chr5:83141110	chr5:83012285~83013109:-
TGCT	cis	rs11673344	0.615	rs2921561	ENSG00000226686.6	LINC01535	8.59	3.18e-14	2.56e-10	0.67	0.61	Obesity-related traits;	chr19:37348969	chr19:37251912~37265535:+
TGCT	cis	rs2486288	0.656	rs6493144	ENSG00000259520.4	CTD-2651B20.3	-8.58	3.24e-14	2.6e-10	-0.5	-0.61	Glomerular filtration rate;	chr15:45281291	chr15:45251580~45279251:-
TGCT	cis	rs1355223	0.872	rs913204	ENSG00000271369.1	RP11-350D17.3	8.58	3.26e-14	2.62e-10	0.58	0.61	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34684677	chr11:34709600~34710161:+
TGCT	cis	rs858239	0.568	rs6970694	ENSG00000230658.1	KLHL7-AS1	8.58	3.3e-14	2.64e-10	0.71	0.61	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23101228~23105703:-
TGCT	cis	rs1577917	1	rs12201571	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85900032	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs11759855	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85901123	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.876	rs12201992	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85908501	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs12201880	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85917289	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs7756203	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85917989	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs10944161	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85920658	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs1857965	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85921058	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs7771342	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85922218	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs12154056	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85924376	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs1857964	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85926276	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.798	rs7772384	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85929962	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs13194429	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85936987	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs7747897	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85937631	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs12199832	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85943030	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs12207374	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85946927	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs12201735	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85947221	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs10455456	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85960604	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs10944170	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85975751	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.917	rs35283633	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85981069	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs36096931	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85983416	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs13207354	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85990545	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs12204365	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85990814	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs12663651	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85991937	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs34281561	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85992154	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs35419329	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85992573	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs6936048	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85992890	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs12216328	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85993700	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs1999852	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85996020	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs34581302	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85996230	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs35797755	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85996836	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs12190604	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:86006497	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.652	rs75593931	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:86009821	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.959	rs12201739	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:86011021	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs12212733	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:86016295	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs12199516	ENSG00000203875.9	SNHG5	-8.57	3.4e-14	2.69e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:86016503	chr6:85660950~85678736:-
TGCT	cis	rs11098499	0.562	rs58583086	ENSG00000245958.5	RP11-33B1.1	8.57	3.41e-14	2.69e-10	0.63	0.61	Corneal astigmatism;	chr4:119635207	chr4:119454791~119552025:+
TGCT	cis	rs6452524	1	rs6887846	ENSG00000249664.1	CTD-2227C6.2	-8.57	3.45e-14	2.71e-10	-0.6	-0.61	Hypertension (SNP x SNP interaction);	chr5:83140542	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs62374373	ENSG00000249664.1	CTD-2227C6.2	8.57	3.45e-14	2.71e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83137389	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs10043018	ENSG00000249664.1	CTD-2227C6.2	8.57	3.45e-14	2.71e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83138498	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs10037501	ENSG00000249664.1	CTD-2227C6.2	8.57	3.45e-14	2.71e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83138722	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.904	rs6452525	ENSG00000249664.1	CTD-2227C6.2	8.57	3.45e-14	2.71e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83138752	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs7716931	ENSG00000249664.1	CTD-2227C6.2	8.57	3.45e-14	2.71e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83138856	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs7721416	ENSG00000249664.1	CTD-2227C6.2	8.57	3.45e-14	2.71e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83139174	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs6882220	ENSG00000249664.1	CTD-2227C6.2	8.57	3.45e-14	2.71e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83139715	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs6452526	ENSG00000249664.1	CTD-2227C6.2	8.57	3.45e-14	2.71e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83140992	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs6452527	ENSG00000249664.1	CTD-2227C6.2	8.57	3.45e-14	2.71e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83141021	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs10055844	ENSG00000249664.1	CTD-2227C6.2	8.57	3.45e-14	2.71e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83141276	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs10077862	ENSG00000249664.1	CTD-2227C6.2	8.57	3.45e-14	2.71e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83141322	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs10474093	ENSG00000249664.1	CTD-2227C6.2	8.57	3.45e-14	2.71e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83141612	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs10473868	ENSG00000249664.1	CTD-2227C6.2	8.57	3.45e-14	2.71e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83141628	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs6868817	ENSG00000249664.1	CTD-2227C6.2	8.57	3.45e-14	2.71e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83142287	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs10042018	ENSG00000249664.1	CTD-2227C6.2	8.57	3.45e-14	2.71e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83142490	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs10036418	ENSG00000249664.1	CTD-2227C6.2	8.57	3.45e-14	2.71e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83142493	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs10055948	ENSG00000249664.1	CTD-2227C6.2	8.57	3.45e-14	2.71e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83143437	chr5:83012285~83013109:-
TGCT	cis	rs977987	0.654	rs8054194	ENSG00000261783.1	RP11-252K23.2	-8.57	3.47e-14	2.73e-10	-0.91	-0.61	Dupuytren's disease;	chr16:75463262	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.581	rs8056141	ENSG00000261783.1	RP11-252K23.2	-8.57	3.47e-14	2.73e-10	-0.91	-0.61	Dupuytren's disease;	chr16:75463264	chr16:75379818~75381260:-
TGCT	cis	rs4423214	1	rs12785878	ENSG00000254682.1	RP11-660L16.2	8.56	3.55e-14	2.79e-10	0.8	0.61	Vitamin D levels;	chr11:71456403	chr11:71448674~71452157:+
TGCT	cis	rs2739330	0.76	rs5751760	ENSG00000225282.1	AP000350.6	8.56	3.58e-14	2.81e-10	0.69	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23926900~23929574:+
TGCT	cis	rs2486288	0.656	rs8039352	ENSG00000259520.4	CTD-2651B20.3	8.56	3.58e-14	2.81e-10	0.5	0.61	Glomerular filtration rate;	chr15:45259592	chr15:45251580~45279251:-
TGCT	cis	rs916888	0.773	rs199535	ENSG00000262500.1	RP11-259G18.2	8.56	3.73e-14	2.93e-10	0.92	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46243606~46245044:+
TGCT	cis	rs916888	0.821	rs199504	ENSG00000262500.1	RP11-259G18.2	-8.55	3.77e-14	2.95e-10	-0.91	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46243606~46245044:+
TGCT	cis	rs1577917	0.876	rs1582126	ENSG00000203875.9	SNHG5	-8.55	3.78e-14	2.96e-10	-0.82	-0.61	Response to antipsychotic treatment;	chr6:85987487	chr6:85660950~85678736:-
TGCT	cis	rs2739330	0.703	rs5760112	ENSG00000225282.1	AP000350.6	8.55	3.81e-14	2.98e-10	0.69	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23926900~23929574:+
TGCT	cis	rs858239	0.932	rs1637190	ENSG00000230658.1	KLHL7-AS1	8.55	3.94e-14	3.08e-10	0.65	0.61	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23101228~23105703:-
TGCT	cis	rs6452524	1	rs10474094	ENSG00000249664.1	CTD-2227C6.2	8.54	3.96e-14	3.09e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83154678	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs1382368	ENSG00000249664.1	CTD-2227C6.2	8.54	3.96e-14	3.09e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83155256	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs1382364	ENSG00000249664.1	CTD-2227C6.2	8.54	3.96e-14	3.09e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83156677	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs1382363	ENSG00000249664.1	CTD-2227C6.2	8.54	3.96e-14	3.09e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83156753	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs11741897	ENSG00000249664.1	CTD-2227C6.2	8.54	3.96e-14	3.09e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83157246	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs13358361	ENSG00000249664.1	CTD-2227C6.2	8.54	3.96e-14	3.09e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83160237	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs10076000	ENSG00000249664.1	CTD-2227C6.2	8.54	3.96e-14	3.09e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83161629	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs6452528	ENSG00000249664.1	CTD-2227C6.2	8.54	3.96e-14	3.09e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83162560	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs6864479	ENSG00000249664.1	CTD-2227C6.2	8.54	3.96e-14	3.09e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83166421	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs13436667	ENSG00000249664.1	CTD-2227C6.2	8.54	3.96e-14	3.09e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83168948	chr5:83012285~83013109:-
TGCT	cis	rs2486288	0.656	rs1719236	ENSG00000259520.4	CTD-2651B20.3	8.54	3.97e-14	3.09e-10	0.51	0.61	Glomerular filtration rate;	chr15:45285585	chr15:45251580~45279251:-
TGCT	cis	rs916888	0.687	rs199456	ENSG00000262500.1	RP11-259G18.2	8.54	3.99e-14	3.11e-10	0.92	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46243606~46245044:+
TGCT	cis	rs2283792	0.745	rs5756306	ENSG00000228050.1	TOP3BP1	-8.54	4.12e-14	3.2e-10	-0.69	-0.61	Multiple sclerosis;	chr22:21978846	chr22:22223187~22224566:-
TGCT	cis	rs6452524	1	rs6452524	ENSG00000249664.1	CTD-2227C6.2	-8.54	4.15e-14	3.22e-10	-0.6	-0.61	Hypertension (SNP x SNP interaction);	chr5:83137962	chr5:83012285~83013109:-
TGCT	cis	rs11098499	0.865	rs11722183	ENSG00000245958.5	RP11-33B1.1	-8.53	4.32e-14	3.34e-10	-0.61	-0.61	Corneal astigmatism;	chr4:119359442	chr4:119454791~119552025:+
TGCT	cis	rs801193	0.548	rs6975044	ENSG00000226824.5	RP4-756H11.3	-8.53	4.33e-14	3.35e-10	-0.68	-0.61	Aortic root size;	chr7:66762495	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.569	rs35070132	ENSG00000226824.5	RP4-756H11.3	-8.53	4.33e-14	3.35e-10	-0.68	-0.61	Aortic root size;	chr7:66773096	chr7:66654538~66669855:+
TGCT	cis	rs2739330	0.76	rs1002286	ENSG00000225282.1	AP000350.6	-8.53	4.38e-14	3.39e-10	-0.68	-0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23926900~23929574:+
TGCT	cis	rs2486288	0.656	rs1719232	ENSG00000259520.4	CTD-2651B20.3	8.53	4.39e-14	3.4e-10	0.51	0.61	Glomerular filtration rate;	chr15:45279874	chr15:45251580~45279251:-
TGCT	cis	rs6452524	1	rs1382366	ENSG00000249664.1	CTD-2227C6.2	8.53	4.4e-14	3.4e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83156352	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs9293334	ENSG00000249664.1	CTD-2227C6.2	8.53	4.4e-14	3.4e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83156984	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs2126990	ENSG00000249664.1	CTD-2227C6.2	8.53	4.4e-14	3.4e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83161351	chr5:83012285~83013109:-
TGCT	cis	rs858239	0.862	rs1728292	ENSG00000230658.1	KLHL7-AS1	8.52	4.44e-14	3.43e-10	0.67	0.61	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23101228~23105703:-
TGCT	cis	rs5769707	0.935	rs1109320	ENSG00000188511.11	C22orf34	8.52	4.45e-14	3.44e-10	0.57	0.61	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49414524~49657542:-
TGCT	cis	rs858239	0.932	rs858275	ENSG00000230658.1	KLHL7-AS1	8.52	4.56e-14	3.53e-10	0.64	0.61	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23101228~23105703:-
TGCT	cis	rs2729354	0.817	rs2848626	ENSG00000265566.2	RN7SL605P	-8.52	4.64e-14	3.58e-10	-0.76	-0.61	Blood protein levels;	chr11:57516515	chr11:57528085~57528365:-
TGCT	cis	rs11098499	0.908	rs28499576	ENSG00000245958.5	RP11-33B1.1	-8.52	4.65e-14	3.58e-10	-0.64	-0.61	Corneal astigmatism;	chr4:119465522	chr4:119454791~119552025:+
TGCT	cis	rs1577917	0.958	rs10944147	ENSG00000203875.9	SNHG5	-8.51	4.74e-14	3.65e-10	-0.82	-0.61	Response to antipsychotic treatment;	chr6:85841068	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs13201730	ENSG00000203875.9	SNHG5	-8.51	4.74e-14	3.65e-10	-0.82	-0.61	Response to antipsychotic treatment;	chr6:85846929	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs12196377	ENSG00000203875.9	SNHG5	-8.51	4.74e-14	3.65e-10	-0.82	-0.61	Response to antipsychotic treatment;	chr6:85857057	chr6:85660950~85678736:-
TGCT	cis	rs6452524	0.618	rs4266384	ENSG00000249664.1	CTD-2227C6.2	8.51	4.74e-14	3.65e-10	0.63	0.61	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:83012285~83013109:-
TGCT	cis	rs916888	0.773	rs199451	ENSG00000262500.1	RP11-259G18.2	8.51	4.74e-14	3.65e-10	0.92	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46243606~46245044:+
TGCT	cis	rs858239	0.536	rs6956974	ENSG00000230658.1	KLHL7-AS1	-8.51	4.79e-14	3.69e-10	-0.66	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23101228~23105703:-
TGCT	cis	rs5769707	0.935	rs5770594	ENSG00000188511.11	C22orf34	8.51	4.88e-14	3.75e-10	0.57	0.61	Monocyte percentage of white cells;Monocyte count;	chr22:49624849	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.967	rs4524218	ENSG00000188511.11	C22orf34	8.51	4.88e-14	3.75e-10	0.57	0.61	Monocyte percentage of white cells;Monocyte count;	chr22:49624991	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.967	rs763126	ENSG00000188511.11	C22orf34	-8.51	4.88e-14	3.75e-10	-0.57	-0.61	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49414524~49657542:-
TGCT	cis	rs858239	1	rs199351	ENSG00000230658.1	KLHL7-AS1	8.51	4.89e-14	3.76e-10	0.65	0.61	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23101228~23105703:-
TGCT	cis	rs1577917	1	rs884841	ENSG00000203875.9	SNHG5	-8.5	5.02e-14	3.85e-10	-0.83	-0.61	Response to antipsychotic treatment;	chr6:85970582	chr6:85660950~85678736:-
TGCT	cis	rs6452524	1	rs7726564	ENSG00000249664.1	CTD-2227C6.2	8.5	5.12e-14	3.92e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83170274	chr5:83012285~83013109:-
TGCT	cis	rs858239	0.67	rs3807452	ENSG00000230658.1	KLHL7-AS1	-8.5	5.14e-14	3.93e-10	-0.62	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23101228~23105703:-
TGCT	cis	rs17507216	1	rs17356118	ENSG00000278603.1	RP13-608F4.5	8.5	5.17e-14	3.95e-10	0.95	0.61	Excessive daytime sleepiness;	chr15:82569149	chr15:82472203~82472426:+
TGCT	cis	rs11098499	0.954	rs10034623	ENSG00000245958.5	RP11-33B1.1	-8.49	5.24e-14	4.01e-10	-0.64	-0.61	Corneal astigmatism;	chr4:119476674	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs6849171	ENSG00000245958.5	RP11-33B1.1	-8.49	5.24e-14	4.01e-10	-0.64	-0.61	Corneal astigmatism;	chr4:119488394	chr4:119454791~119552025:+
TGCT	cis	rs858239	0.665	rs858306	ENSG00000230658.1	KLHL7-AS1	8.49	5.36e-14	4.1e-10	0.64	0.61	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.698	rs858295	ENSG00000230658.1	KLHL7-AS1	8.49	5.36e-14	4.1e-10	0.64	0.61	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23101228~23105703:-
TGCT	cis	rs11098499	0.865	rs4001305	ENSG00000245958.5	RP11-33B1.1	-8.48	5.56e-14	4.23e-10	-0.63	-0.61	Corneal astigmatism;	chr4:119438081	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.738	rs28408407	ENSG00000245958.5	RP11-33B1.1	-8.48	5.56e-14	4.23e-10	-0.63	-0.61	Corneal astigmatism;	chr4:119454875	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.909	rs1809406	ENSG00000245958.5	RP11-33B1.1	-8.48	5.56e-14	4.23e-10	-0.63	-0.61	Corneal astigmatism;	chr4:119455967	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.865	rs2389809	ENSG00000245958.5	RP11-33B1.1	-8.48	5.56e-14	4.23e-10	-0.63	-0.61	Corneal astigmatism;	chr4:119456244	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.909	rs9994810	ENSG00000245958.5	RP11-33B1.1	-8.48	5.56e-14	4.23e-10	-0.63	-0.61	Corneal astigmatism;	chr4:119460435	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.697	rs10020027	ENSG00000245958.5	RP11-33B1.1	-8.48	5.56e-14	4.23e-10	-0.63	-0.61	Corneal astigmatism;	chr4:119460724	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.779	rs7356491	ENSG00000245958.5	RP11-33B1.1	-8.48	5.56e-14	4.23e-10	-0.63	-0.61	Corneal astigmatism;	chr4:119460819	chr4:119454791~119552025:+
TGCT	cis	rs1577917	1	rs12190598	ENSG00000203875.9	SNHG5	-8.48	5.58e-14	4.24e-10	-0.84	-0.61	Response to antipsychotic treatment;	chr6:85976356	chr6:85660950~85678736:-
TGCT	cis	rs6452524	1	rs4590162	ENSG00000249664.1	CTD-2227C6.2	8.48	5.61e-14	4.27e-10	0.62	0.61	Hypertension (SNP x SNP interaction);	chr5:83145621	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs10037872	ENSG00000249664.1	CTD-2227C6.2	8.48	5.62e-14	4.27e-10	0.6	0.61	Hypertension (SNP x SNP interaction);	chr5:83144101	chr5:83012285~83013109:-
TGCT	cis	rs916888	0.61	rs142167	ENSG00000262539.1	RP11-259G18.3	-8.48	5.63e-14	4.28e-10	-0.88	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46259551~46260606:-
TGCT	cis	rs1577917	1	rs35761942	ENSG00000203875.9	SNHG5	-8.48	5.66e-14	4.28e-10	-0.81	-0.61	Response to antipsychotic treatment;	chr6:85919786	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs955227	ENSG00000203875.9	SNHG5	-8.48	5.66e-14	4.28e-10	-0.81	-0.61	Response to antipsychotic treatment;	chr6:85941314	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs13196930	ENSG00000203875.9	SNHG5	-8.48	5.66e-14	4.28e-10	-0.81	-0.61	Response to antipsychotic treatment;	chr6:85942527	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs10944163	ENSG00000203875.9	SNHG5	-8.48	5.66e-14	4.28e-10	-0.81	-0.61	Response to antipsychotic treatment;	chr6:85948975	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs10455455	ENSG00000203875.9	SNHG5	-8.48	5.66e-14	4.28e-10	-0.81	-0.61	Response to antipsychotic treatment;	chr6:85960496	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs12196037	ENSG00000203875.9	SNHG5	-8.48	5.66e-14	4.28e-10	-0.81	-0.61	Response to antipsychotic treatment;	chr6:85984913	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs12215037	ENSG00000203875.9	SNHG5	-8.48	5.66e-14	4.28e-10	-0.81	-0.61	Response to antipsychotic treatment;	chr6:86017913	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs10498958	ENSG00000203875.9	SNHG5	8.48	5.66e-14	4.28e-10	0.81	0.61	Response to antipsychotic treatment;	chr6:85939987	chr6:85660950~85678736:-
TGCT	cis	rs2739330	0.76	rs1007888	ENSG00000225282.1	AP000350.6	8.48	5.73e-14	4.33e-10	0.69	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23926900~23929574:+
TGCT	cis	rs5769707	0.935	rs739239	ENSG00000188511.11	C22orf34	8.48	5.74e-14	4.34e-10	0.57	0.61	Monocyte percentage of white cells;Monocyte count;	chr22:49656820	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.874	rs9616714	ENSG00000188511.11	C22orf34	8.48	5.74e-14	4.34e-10	0.57	0.61	Monocyte percentage of white cells;Monocyte count;	chr22:49657211	chr22:49414524~49657542:-
TGCT	cis	rs12439619	0.705	rs17354185	ENSG00000278603.1	RP13-608F4.5	-8.47	5.8e-14	4.38e-10	-1.08	-0.61	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472203~82472426:+
TGCT	cis	rs17507216	0.958	rs28648832	ENSG00000278603.1	RP13-608F4.5	8.47	5.82e-14	4.39e-10	0.96	0.61	Excessive daytime sleepiness;	chr15:82567642	chr15:82472203~82472426:+
TGCT	cis	rs11098499	0.69	rs34818745	ENSG00000245958.5	RP11-33B1.1	-8.47	5.87e-14	4.42e-10	-0.62	-0.61	Corneal astigmatism;	chr4:119335900	chr4:119454791~119552025:+
TGCT	cis	rs1577917	1	rs11758849	ENSG00000203875.9	SNHG5	-8.47	5.87e-14	4.43e-10	-0.81	-0.61	Response to antipsychotic treatment;	chr6:85998544	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs10455158	ENSG00000203875.9	SNHG5	-8.46	6.17e-14	4.64e-10	-0.82	-0.61	Response to antipsychotic treatment;	chr6:85963107	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs12215903	ENSG00000203875.9	SNHG5	-8.46	6.17e-14	4.64e-10	-0.82	-0.61	Response to antipsychotic treatment;	chr6:85965310	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs12216203	ENSG00000203875.9	SNHG5	-8.46	6.17e-14	4.64e-10	-0.82	-0.61	Response to antipsychotic treatment;	chr6:85965583	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.959	rs34258068	ENSG00000203875.9	SNHG5	-8.46	6.17e-14	4.64e-10	-0.82	-0.61	Response to antipsychotic treatment;	chr6:85969731	chr6:85660950~85678736:-
TGCT	cis	rs916888	0.647	rs199524	ENSG00000262539.1	RP11-259G18.3	-8.46	6.21e-14	4.67e-10	-0.87	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46259551~46260606:-
TGCT	cis	rs916888	0.647	rs199523	ENSG00000262539.1	RP11-259G18.3	-8.46	6.21e-14	4.67e-10	-0.87	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46259551~46260606:-
TGCT	cis	rs11098499	0.618	rs35265692	ENSG00000245958.5	RP11-33B1.1	-8.46	6.27e-14	4.7e-10	-0.64	-0.6	Corneal astigmatism;	chr4:119403980	chr4:119454791~119552025:+
TGCT	cis	rs7188445	0.932	rs3813582	ENSG00000261390.4	RP11-345M22.2	-8.46	6.28e-14	4.72e-10	-0.62	-0.6	Urate levels;	chr16:79715456	chr16:79715232~79770563:-
TGCT	cis	rs858239	0.806	rs10268610	ENSG00000230658.1	KLHL7-AS1	8.46	6.34e-14	4.76e-10	0.7	0.6	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23101228~23105703:-
TGCT	cis	rs2283792	0.812	rs240066	ENSG00000228050.1	TOP3BP1	-8.46	6.37e-14	4.78e-10	-0.66	-0.6	Multiple sclerosis;	chr22:21938623	chr22:22223187~22224566:-
TGCT	cis	rs6452524	1	rs62374374	ENSG00000249664.1	CTD-2227C6.2	8.46	6.41e-14	4.8e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83144838	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs1382372	ENSG00000249664.1	CTD-2227C6.2	8.46	6.41e-14	4.8e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83145237	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs1382371	ENSG00000249664.1	CTD-2227C6.2	8.46	6.41e-14	4.8e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83145300	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs1382369	ENSG00000249664.1	CTD-2227C6.2	8.46	6.41e-14	4.8e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83145610	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs2126988	ENSG00000249664.1	CTD-2227C6.2	8.46	6.41e-14	4.8e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83146496	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs2386240	ENSG00000249664.1	CTD-2227C6.2	8.46	6.41e-14	4.8e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83147192	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs17284288	ENSG00000249664.1	CTD-2227C6.2	8.46	6.41e-14	4.8e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83148997	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs9986131	ENSG00000249664.1	CTD-2227C6.2	8.46	6.41e-14	4.8e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83149037	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs11740478	ENSG00000249664.1	CTD-2227C6.2	8.46	6.41e-14	4.8e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83150567	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs4591730	ENSG00000249664.1	CTD-2227C6.2	8.46	6.41e-14	4.8e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83151983	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs1031902	ENSG00000249664.1	CTD-2227C6.2	8.46	6.41e-14	4.8e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83152308	chr5:83012285~83013109:-
TGCT	cis	rs2729354	0.817	rs2649667	ENSG00000265566.2	RN7SL605P	-8.45	6.52e-14	4.88e-10	-0.75	-0.6	Blood protein levels;	chr11:57503036	chr11:57528085~57528365:-
TGCT	cis	rs858239	0.863	rs466225	ENSG00000230658.1	KLHL7-AS1	8.45	6.71e-14	5.02e-10	0.65	0.6	Cerebrospinal fluid biomarker levels;	chr7:23292784	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.738	rs13225593	ENSG00000230658.1	KLHL7-AS1	8.45	6.73e-14	5.03e-10	0.69	0.6	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.738	rs7807879	ENSG00000230658.1	KLHL7-AS1	8.45	6.73e-14	5.03e-10	0.69	0.6	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23101228~23105703:-
TGCT	cis	rs11098499	0.738	rs72918577	ENSG00000245958.5	RP11-33B1.1	-8.45	6.75e-14	5.04e-10	-0.64	-0.6	Corneal astigmatism;	chr4:119405546	chr4:119454791~119552025:+
TGCT	cis	rs916888	0.647	rs199524	ENSG00000214401.4	KANSL1-AS1	-8.45	6.76e-14	5.05e-10	-0.79	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46193576~46196723:+
TGCT	cis	rs916888	0.647	rs199523	ENSG00000214401.4	KANSL1-AS1	-8.45	6.76e-14	5.05e-10	-0.79	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46193576~46196723:+
TGCT	cis	rs1577917	0.958	rs12213331	ENSG00000203875.9	SNHG5	-8.44	6.82e-14	5.09e-10	-0.82	-0.6	Response to antipsychotic treatment;	chr6:85795079	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs1591438	ENSG00000203875.9	SNHG5	-8.44	6.82e-14	5.09e-10	-0.82	-0.6	Response to antipsychotic treatment;	chr6:85815496	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs1591437	ENSG00000203875.9	SNHG5	-8.44	6.82e-14	5.09e-10	-0.82	-0.6	Response to antipsychotic treatment;	chr6:85815587	chr6:85660950~85678736:-
TGCT	cis	rs5769707	0.839	rs73176988	ENSG00000188511.11	C22orf34	8.44	6.91e-14	5.15e-10	0.57	0.6	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49414524~49657542:-
TGCT	cis	rs916888	0.779	rs199528	ENSG00000262500.1	RP11-259G18.2	8.44	7.01e-14	5.22e-10	0.89	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46243606~46245044:+
TGCT	cis	rs916888	0.821	rs199525	ENSG00000262500.1	RP11-259G18.2	8.44	7.01e-14	5.22e-10	0.89	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46243606~46245044:+
TGCT	cis	rs858239	1	rs199347	ENSG00000230658.1	KLHL7-AS1	8.44	7.1e-14	5.28e-10	0.64	0.6	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23101228~23105703:-
TGCT	cis	rs2487048	0.804	rs2472496	ENSG00000226334.1	RP11-217B7.2	-8.44	7.15e-14	5.31e-10	-0.58	-0.6	Intraocular pressure;	chr9:104933072	chr9:104927553~104928892:+
TGCT	cis	rs1775715	0.87	rs1755084	ENSG00000239731.3	RN7SL825P	-8.43	7.38e-14	5.48e-10	-0.61	-0.6	Bipolar disorder with mood-incongruent psychosis;	chr10:31964781	chr10:31992087~31992381:-
TGCT	cis	rs1577917	0.958	rs12208227	ENSG00000203875.9	SNHG5	-8.43	7.51e-14	5.57e-10	-0.81	-0.6	Response to antipsychotic treatment;	chr6:85961226	chr6:85660950~85678736:-
TGCT	cis	rs916888	0.61	rs199442	ENSG00000262539.1	RP11-259G18.3	8.43	7.59e-14	5.63e-10	0.88	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46259551~46260606:-
TGCT	cis	rs6452524	0.935	rs1017794	ENSG00000249664.1	CTD-2227C6.2	8.43	7.6e-14	5.63e-10	0.6	0.6	Hypertension (SNP x SNP interaction);	chr5:83086236	chr5:83012285~83013109:-
TGCT	cis	rs2739330	0.731	rs2000468	ENSG00000225282.1	AP000350.6	8.42	7.7e-14	5.71e-10	0.68	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23926900~23929574:+
TGCT	cis	rs916888	0.61	rs199444	ENSG00000262539.1	RP11-259G18.3	8.42	7.77e-14	5.75e-10	0.89	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46259551~46260606:-
TGCT	cis	rs6921919	0.583	rs1054372	ENSG00000216901.1	AL022393.7	8.42	7.77e-14	5.75e-10	0.72	0.6	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs9468354	ENSG00000216901.1	AL022393.7	8.42	7.77e-14	5.75e-10	0.72	0.6	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs7773051	ENSG00000216901.1	AL022393.7	8.42	7.77e-14	5.75e-10	0.72	0.6	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs12697938	ENSG00000216901.1	AL022393.7	8.42	7.77e-14	5.75e-10	0.72	0.6	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs13437294	ENSG00000216901.1	AL022393.7	8.42	7.77e-14	5.75e-10	0.72	0.6	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.609	rs9468357	ENSG00000216901.1	AL022393.7	8.42	7.77e-14	5.75e-10	0.72	0.6	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28176188~28176674:+
TGCT	cis	rs916888	0.647	rs199449	ENSG00000262539.1	RP11-259G18.3	8.42	7.93e-14	5.86e-10	0.88	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46259551~46260606:-
TGCT	cis	rs2486288	0.656	rs11631021	ENSG00000259520.4	CTD-2651B20.3	8.42	7.97e-14	5.89e-10	0.49	0.6	Glomerular filtration rate;	chr15:45264631	chr15:45251580~45279251:-
TGCT	cis	rs3096299	0.509	rs4785691	ENSG00000274627.1	RP11-104N10.2	8.41	8.25e-14	6.1e-10	0.62	0.6	Multiple myeloma (IgH translocation);	chr16:89530813	chr16:89516797~89522217:+
TGCT	cis	rs2739330	0.652	rs2000469	ENSG00000225282.1	AP000350.6	8.41	8.32e-14	6.15e-10	0.75	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23926900~23929574:+
TGCT	cis	rs916888	0.61	rs199436	ENSG00000262539.1	RP11-259G18.3	-8.4	8.52e-14	6.28e-10	-0.84	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46259551~46260606:-
TGCT	cis	rs1577917	0.874	rs11756621	ENSG00000203875.9	SNHG5	-8.4	8.52e-14	6.28e-10	-0.81	-0.6	Response to antipsychotic treatment;	chr6:86030345	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs12205548	ENSG00000203875.9	SNHG5	-8.4	8.52e-14	6.28e-10	-0.81	-0.6	Response to antipsychotic treatment;	chr6:86050052	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs12665321	ENSG00000203875.9	SNHG5	-8.4	8.52e-14	6.28e-10	-0.81	-0.6	Response to antipsychotic treatment;	chr6:86059571	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs12196175	ENSG00000203875.9	SNHG5	-8.4	8.52e-14	6.28e-10	-0.81	-0.6	Response to antipsychotic treatment;	chr6:86069652	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs12196411	ENSG00000203875.9	SNHG5	-8.4	8.52e-14	6.28e-10	-0.81	-0.6	Response to antipsychotic treatment;	chr6:86070044	chr6:85660950~85678736:-
TGCT	cis	rs858239	0.896	rs1637193	ENSG00000230658.1	KLHL7-AS1	8.4	8.56e-14	6.29e-10	0.63	0.6	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23101228~23105703:-
TGCT	cis	rs1355223	0.768	rs11032806	ENSG00000271369.1	RP11-350D17.3	-8.4	8.56e-14	6.3e-10	-0.56	-0.6	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34670758	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.867	rs1377495	ENSG00000271369.1	RP11-350D17.3	8.4	8.59e-14	6.31e-10	0.6	0.6	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34661415	chr11:34709600~34710161:+
TGCT	cis	rs9326248	0.773	rs1060211	ENSG00000254851.1	RP11-109L13.1	-8.4	8.59e-14	6.31e-10	-0.9	-0.6	Blood protein levels;	chr11:117169081	chr11:117135528~117138582:+
TGCT	cis	rs9326248	0.813	rs474488	ENSG00000254851.1	RP11-109L13.1	-8.4	8.69e-14	6.38e-10	-0.91	-0.6	Blood protein levels;	chr11:117198261	chr11:117135528~117138582:+
TGCT	cis	rs2486288	0.656	rs6493145	ENSG00000259520.4	CTD-2651B20.3	8.4	8.7e-14	6.39e-10	0.5	0.6	Glomerular filtration rate;	chr15:45281664	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs8024620	ENSG00000259520.4	CTD-2651B20.3	8.4	8.7e-14	6.39e-10	0.5	0.6	Glomerular filtration rate;	chr15:45282131	chr15:45251580~45279251:-
TGCT	cis	rs858239	1	rs199348	ENSG00000230658.1	KLHL7-AS1	8.4	8.7e-14	6.39e-10	0.65	0.6	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23101228~23105703:-
TGCT	cis	rs916888	0.773	rs9896243	ENSG00000262500.1	RP11-259G18.2	8.4	8.87e-14	6.51e-10	0.9	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46243606~46245044:+
TGCT	cis	rs1355223	0.872	rs12802798	ENSG00000271369.1	RP11-350D17.3	-8.39	8.97e-14	6.58e-10	-0.57	-0.6	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34725887	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.872	rs7116409	ENSG00000271369.1	RP11-350D17.3	-8.39	8.97e-14	6.58e-10	-0.57	-0.6	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34729460	chr11:34709600~34710161:+
TGCT	cis	rs2487048	0.773	rs2472493	ENSG00000226334.1	RP11-217B7.2	-8.39	9.01e-14	6.61e-10	-0.6	-0.6	Intraocular pressure;	chr9:104933567	chr9:104927553~104928892:+
TGCT	cis	rs916888	0.773	rs199533	ENSG00000262500.1	RP11-259G18.2	8.39	9.06e-14	6.64e-10	0.92	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46243606~46245044:+
TGCT	cis	rs1355223	0.867	rs7943363	ENSG00000271369.1	RP11-350D17.3	-8.39	9.07e-14	6.65e-10	-0.57	-0.6	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34669587	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.867	rs7944030	ENSG00000271369.1	RP11-350D17.3	-8.39	9.07e-14	6.65e-10	-0.57	-0.6	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34670191	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.837	rs11600402	ENSG00000271369.1	RP11-350D17.3	-8.39	9.07e-14	6.65e-10	-0.57	-0.6	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34670204	chr11:34709600~34710161:+
TGCT	cis	rs11098499	0.662	rs13108589	ENSG00000245958.5	RP11-33B1.1	-8.39	9.15e-14	6.7e-10	-0.6	-0.6	Corneal astigmatism;	chr4:119346947	chr4:119454791~119552025:+
TGCT	cis	rs6538678	0.895	rs4762637	ENSG00000258343.1	RP11-536G4.2	-8.39	9.21e-14	6.75e-10	-0.94	-0.6	Lupus nephritis in systemic lupus erythematosus;	chr12:95888877	chr12:95795345~95858839:-
TGCT	cis	rs5769707	0.967	rs763127	ENSG00000188511.11	C22orf34	8.39	9.27e-14	6.78e-10	0.57	0.6	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49414524~49657542:-
TGCT	cis	rs6452524	0.935	rs7714710	ENSG00000249664.1	CTD-2227C6.2	8.39	9.29e-14	6.8e-10	0.6	0.6	Hypertension (SNP x SNP interaction);	chr5:83085750	chr5:83012285~83013109:-
TGCT	cis	rs950027	0.549	rs1719250	ENSG00000259520.4	CTD-2651B20.3	-8.39	9.31e-14	6.81e-10	-0.48	-0.6	Response to fenofibrate (adiponectin levels);	chr15:45317575	chr15:45251580~45279251:-
TGCT	cis	rs1577917	0.959	rs16876540	ENSG00000203875.9	SNHG5	-8.39	9.32e-14	6.82e-10	-0.81	-0.6	Response to antipsychotic treatment;	chr6:85902801	chr6:85660950~85678736:-
TGCT	cis	rs5850	0.602	rs1005786	ENSG00000230658.1	KLHL7-AS1	8.38	9.56e-14	6.98e-10	0.62	0.6	Blood protein levels;	chr7:23106218	chr7:23101228~23105703:-
TGCT	cis	rs801193	0.569	rs10950050	ENSG00000226824.5	RP4-756H11.3	-8.38	9.62e-14	7.02e-10	-0.62	-0.6	Aortic root size;	chr7:66774601	chr7:66654538~66669855:+
TGCT	cis	rs858239	0.601	rs6461702	ENSG00000230658.1	KLHL7-AS1	8.38	9.7e-14	7.08e-10	0.7	0.6	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.932	rs1624451	ENSG00000230658.1	KLHL7-AS1	-8.38	9.75e-14	7.11e-10	-0.64	-0.6	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23101228~23105703:-
TGCT	cis	rs6452524	0.967	rs1564211	ENSG00000249664.1	CTD-2227C6.2	8.38	9.75e-14	7.11e-10	0.6	0.6	Hypertension (SNP x SNP interaction);	chr5:83117014	chr5:83012285~83013109:-
TGCT	cis	rs1577917	0.958	rs12215232	ENSG00000203875.9	SNHG5	-8.38	9.83e-14	7.16e-10	-0.81	-0.6	Response to antipsychotic treatment;	chr6:86075712	chr6:85660950~85678736:-
TGCT	cis	rs6452524	0.71	rs7708124	ENSG00000249664.1	CTD-2227C6.2	8.37	1.01e-13	7.31e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83132035	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs11958314	ENSG00000249664.1	CTD-2227C6.2	8.37	1.01e-13	7.31e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83132929	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.686	rs6452517	ENSG00000249664.1	CTD-2227C6.2	8.37	1.01e-13	7.31e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83133041	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.686	rs6452518	ENSG00000249664.1	CTD-2227C6.2	8.37	1.01e-13	7.31e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83133043	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs10069402	ENSG00000249664.1	CTD-2227C6.2	8.37	1.01e-13	7.31e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83133776	chr5:83012285~83013109:-
TGCT	cis	rs858239	0.831	rs7796541	ENSG00000230658.1	KLHL7-AS1	8.37	1.04e-13	7.53e-10	0.6	0.6	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23101228~23105703:-
TGCT	cis	rs1577917	1	rs12661204	ENSG00000203875.9	SNHG5	-8.36	1.06e-13	7.69e-10	-0.81	-0.6	Response to antipsychotic treatment;	chr6:85968868	chr6:85660950~85678736:-
TGCT	cis	rs6452524	0.967	rs62372752	ENSG00000249664.1	CTD-2227C6.2	8.35	1.13e-13	8.21e-10	0.62	0.6	Hypertension (SNP x SNP interaction);	chr5:83134239	chr5:83012285~83013109:-
TGCT	cis	rs1577917	0.958	rs12665542	ENSG00000203875.9	SNHG5	-8.35	1.17e-13	8.42e-10	-0.81	-0.6	Response to antipsychotic treatment;	chr6:85834725	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs2875456	ENSG00000203875.9	SNHG5	-8.35	1.17e-13	8.42e-10	-0.81	-0.6	Response to antipsychotic treatment;	chr6:85892566	chr6:85660950~85678736:-
TGCT	cis	rs3734266	0.702	rs11963234	ENSG00000186328.4	RP11-140K17.2	8.35	1.17e-13	8.44e-10	0.88	0.6	Systemic lupus erythematosus;	chr6:34754646	chr6:34715613~34715940:+
TGCT	cis	rs1891275	0.513	rs1539041	ENSG00000228701.1	TNKS2-AS1	-8.35	1.17e-13	8.45e-10	-0.76	-0.6	Intelligence (multi-trait analysis);	chr10:91817384	chr10:91782839~91798291:-
TGCT	cis	rs4423214	1	rs4944955	ENSG00000254682.1	RP11-660L16.2	8.34	1.19e-13	8.6e-10	0.79	0.6	Vitamin D levels;	chr11:71456631	chr11:71448674~71452157:+
TGCT	cis	rs4423214	1	rs4944956	ENSG00000254682.1	RP11-660L16.2	8.34	1.19e-13	8.6e-10	0.79	0.6	Vitamin D levels;	chr11:71456719	chr11:71448674~71452157:+
TGCT	cis	rs2729354	0.953	rs2848625	ENSG00000265566.2	RN7SL605P	-8.34	1.2e-13	8.62e-10	-0.74	-0.6	Blood protein levels;	chr11:57563177	chr11:57528085~57528365:-
TGCT	cis	rs2486288	0.656	rs2413771	ENSG00000259520.4	CTD-2651B20.3	8.34	1.2e-13	8.65e-10	0.49	0.6	Glomerular filtration rate;	chr15:45260942	chr15:45251580~45279251:-
TGCT	cis	rs858239	0.932	rs199355	ENSG00000230658.1	KLHL7-AS1	8.34	1.2e-13	8.67e-10	0.65	0.6	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23101228~23105703:-
TGCT	cis	rs6452524	0.935	rs9293330	ENSG00000249664.1	CTD-2227C6.2	8.34	1.23e-13	8.85e-10	0.6	0.6	Hypertension (SNP x SNP interaction);	chr5:83102299	chr5:83012285~83013109:-
TGCT	cis	rs1775715	0.87	rs10827003	ENSG00000239731.3	RN7SL825P	-8.33	1.24e-13	8.92e-10	-0.6	-0.6	Bipolar disorder with mood-incongruent psychosis;	chr10:31977288	chr10:31992087~31992381:-
TGCT	cis	rs6452524	1	rs10076271	ENSG00000249664.1	CTD-2227C6.2	8.33	1.25e-13	8.94e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83133875	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs10076274	ENSG00000249664.1	CTD-2227C6.2	8.33	1.25e-13	8.94e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83133908	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs10061521	ENSG00000249664.1	CTD-2227C6.2	8.33	1.25e-13	8.94e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83133936	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs7733151	ENSG00000249664.1	CTD-2227C6.2	8.33	1.25e-13	8.94e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83134655	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs7733330	ENSG00000249664.1	CTD-2227C6.2	8.33	1.25e-13	8.94e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83134774	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs7733354	ENSG00000249664.1	CTD-2227C6.2	8.33	1.25e-13	8.94e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83134859	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs4634330	ENSG00000249664.1	CTD-2227C6.2	8.33	1.25e-13	8.94e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83134963	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs2386238	ENSG00000249664.1	CTD-2227C6.2	8.33	1.25e-13	8.94e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83135266	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs2386239	ENSG00000249664.1	CTD-2227C6.2	8.33	1.25e-13	8.94e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83135339	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.934	rs7700253	ENSG00000249664.1	CTD-2227C6.2	8.33	1.25e-13	8.94e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83135510	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs10067439	ENSG00000249664.1	CTD-2227C6.2	8.33	1.25e-13	8.94e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83136274	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs7710900	ENSG00000249664.1	CTD-2227C6.2	8.33	1.25e-13	8.94e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83137201	chr5:83012285~83013109:-
TGCT	cis	rs5769707	0.967	rs739248	ENSG00000188511.11	C22orf34	8.33	1.25e-13	8.95e-10	0.56	0.6	Monocyte percentage of white cells;Monocyte count;	chr22:49631557	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.967	rs9616701	ENSG00000188511.11	C22orf34	8.33	1.25e-13	8.95e-10	0.56	0.6	Monocyte percentage of white cells;Monocyte count;	chr22:49631898	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.967	rs2071904	ENSG00000188511.11	C22orf34	8.33	1.25e-13	8.95e-10	0.56	0.6	Monocyte percentage of white cells;Monocyte count;	chr22:49640829	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.846	rs5770610	ENSG00000188511.11	C22orf34	8.33	1.25e-13	8.95e-10	0.56	0.6	Monocyte percentage of white cells;Monocyte count;	chr22:49643249	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.967	rs8141807	ENSG00000188511.11	C22orf34	8.33	1.25e-13	8.95e-10	0.56	0.6	Monocyte percentage of white cells;Monocyte count;	chr22:49650090	chr22:49414524~49657542:-
TGCT	cis	rs2739330	0.731	rs4822450	ENSG00000225282.1	AP000350.6	8.33	1.25e-13	8.95e-10	0.68	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23926900~23929574:+
TGCT	cis	rs1355223	0.872	rs7112608	ENSG00000271369.1	RP11-350D17.3	-8.33	1.25e-13	8.97e-10	-0.57	-0.6	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34677722	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.902	rs7129089	ENSG00000271369.1	RP11-350D17.3	-8.33	1.25e-13	8.97e-10	-0.57	-0.6	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34678152	chr11:34709600~34710161:+
TGCT	cis	rs11098499	0.697	rs35280960	ENSG00000245958.5	RP11-33B1.1	-8.33	1.25e-13	8.97e-10	-0.61	-0.6	Corneal astigmatism;	chr4:119335904	chr4:119454791~119552025:+
TGCT	cis	rs2486288	0.656	rs1706768	ENSG00000259520.4	CTD-2651B20.3	8.33	1.28e-13	9.15e-10	0.52	0.6	Glomerular filtration rate;	chr15:45277245	chr15:45251580~45279251:-
TGCT	cis	rs11098499	0.754	rs10212714	ENSG00000245958.5	RP11-33B1.1	-8.33	1.3e-13	9.32e-10	-0.61	-0.6	Corneal astigmatism;	chr4:119333147	chr4:119454791~119552025:+
TGCT	cis	rs1577917	1	rs1577917	ENSG00000203875.9	SNHG5	-8.33	1.31e-13	9.34e-10	-0.79	-0.6	Response to antipsychotic treatment;	chr6:85982222	chr6:85660950~85678736:-
TGCT	cis	rs916888	0.773	rs199457	ENSG00000262500.1	RP11-259G18.2	8.32	1.31e-13	9.36e-10	0.92	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46243606~46245044:+
TGCT	cis	rs7301826	0.557	rs7953184	ENSG00000256299.1	RP11-989F5.3	8.32	1.33e-13	9.46e-10	0.72	0.6	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810821~130812622:-
TGCT	cis	rs916888	0.821	rs199513	ENSG00000262500.1	RP11-259G18.2	-8.32	1.33e-13	9.49e-10	-0.85	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46243606~46245044:+
TGCT	cis	rs6921919	0.609	rs9461455	ENSG00000216901.1	AL022393.7	8.32	1.34e-13	9.55e-10	0.73	0.6	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28176188~28176674:+
TGCT	cis	rs1355223	0.902	rs34751755	ENSG00000271369.1	RP11-350D17.3	-8.32	1.34e-13	9.55e-10	-0.57	-0.6	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34672696	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.934	rs11602669	ENSG00000271369.1	RP11-350D17.3	-8.32	1.34e-13	9.55e-10	-0.57	-0.6	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34673567	chr11:34709600~34710161:+
TGCT	cis	rs6452524	0.868	rs10071617	ENSG00000249664.1	CTD-2227C6.2	8.31	1.38e-13	9.84e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83103207	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs10076059	ENSG00000249664.1	CTD-2227C6.2	8.31	1.38e-13	9.84e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83105698	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs7736783	ENSG00000249664.1	CTD-2227C6.2	8.31	1.38e-13	9.84e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83107050	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs11951257	ENSG00000249664.1	CTD-2227C6.2	8.31	1.38e-13	9.84e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83107492	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs767771	ENSG00000249664.1	CTD-2227C6.2	8.31	1.38e-13	9.84e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83108117	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs10045744	ENSG00000249664.1	CTD-2227C6.2	8.31	1.38e-13	9.84e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83113688	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs1542539	ENSG00000249664.1	CTD-2227C6.2	8.31	1.38e-13	9.84e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83116033	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs1543847	ENSG00000249664.1	CTD-2227C6.2	8.31	1.38e-13	9.84e-10	0.59	0.6	Hypertension (SNP x SNP interaction);	chr5:83116044	chr5:83012285~83013109:-
TGCT	cis	rs2882667	0.964	rs67296915	ENSG00000253404.1	AC034243.1	8.31	1.42e-13	1.01e-09	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138965910	chr5:138744434~138753309:-
TGCT	cis	rs7899628	1	rs7899628	ENSG00000226864.1	ATE1-AS1	-8.31	1.44e-13	1.02e-09	-0.75	-0.6	Breast cancer;	chr10:121904429	chr10:121928312~121951965:+
TGCT	cis	rs5769707	0.967	rs5770585	ENSG00000188511.11	C22orf34	8.31	1.45e-13	1.03e-09	0.57	0.6	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49414524~49657542:-
TGCT	cis	rs2486288	0.656	rs7166580	ENSG00000259520.4	CTD-2651B20.3	8.3	1.46e-13	1.03e-09	0.51	0.6	Glomerular filtration rate;	chr15:45279011	chr15:45251580~45279251:-
TGCT	cis	rs4423214	1	rs4944958	ENSG00000254682.1	RP11-660L16.2	8.3	1.49e-13	1.05e-09	0.79	0.6	Vitamin D levels;	chr11:71457027	chr11:71448674~71452157:+
TGCT	cis	rs1062177	1	rs62394155	ENSG00000253921.1	CTB-113P19.3	-8.3	1.49e-13	1.06e-09	-0.67	-0.6	Preschool internalizing problems;	chr5:151868508	chr5:151753992~151767247:+
TGCT	cis	rs6452524	0.648	rs27364	ENSG00000249664.1	CTD-2227C6.2	8.3	1.52e-13	1.07e-09	0.61	0.6	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:83012285~83013109:-
TGCT	cis	rs11098499	0.954	rs13107475	ENSG00000245958.5	RP11-33B1.1	-8.29	1.54e-13	1.09e-09	-0.64	-0.6	Corneal astigmatism;	chr4:119471856	chr4:119454791~119552025:+
TGCT	cis	rs1355223	0.902	rs12802120	ENSG00000271369.1	RP11-350D17.3	-8.29	1.54e-13	1.09e-09	-0.56	-0.6	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34726103	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.902	rs12802323	ENSG00000271369.1	RP11-350D17.3	-8.29	1.54e-13	1.09e-09	-0.56	-0.6	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34726192	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.902	rs7121272	ENSG00000271369.1	RP11-350D17.3	-8.29	1.54e-13	1.09e-09	-0.56	-0.6	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34731015	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.902	rs286861	ENSG00000271369.1	RP11-350D17.3	-8.29	1.58e-13	1.11e-09	-0.56	-0.6	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34696877	chr11:34709600~34710161:+
TGCT	cis	rs6538678	0.895	rs1436124	ENSG00000258343.1	RP11-536G4.2	-8.29	1.59e-13	1.12e-09	-0.91	-0.6	Lupus nephritis in systemic lupus erythematosus;	chr12:95889654	chr12:95795345~95858839:-
TGCT	cis	rs916888	0.738	rs199515	ENSG00000262500.1	RP11-259G18.2	-8.28	1.62e-13	1.14e-09	-0.9	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46243606~46245044:+
TGCT	cis	rs2729354	0.909	rs2729374	ENSG00000265566.2	RN7SL605P	-8.28	1.63e-13	1.15e-09	-0.73	-0.6	Blood protein levels;	chr11:57559454	chr11:57528085~57528365:-
TGCT	cis	rs2729354	0.953	rs2649650	ENSG00000265566.2	RN7SL605P	-8.28	1.63e-13	1.15e-09	-0.73	-0.6	Blood protein levels;	chr11:57560094	chr11:57528085~57528365:-
TGCT	cis	rs1577917	1	rs12203924	ENSG00000203875.9	SNHG5	-8.28	1.64e-13	1.16e-09	-0.81	-0.6	Response to antipsychotic treatment;	chr6:86066694	chr6:85660950~85678736:-
TGCT	cis	rs1062177	1	rs12653926	ENSG00000253921.1	CTB-113P19.3	-8.28	1.67e-13	1.17e-09	-0.67	-0.6	Preschool internalizing problems;	chr5:151870687	chr5:151753992~151767247:+
TGCT	cis	rs6921919	0.551	rs13201753	ENSG00000216901.1	AL022393.7	8.28	1.69e-13	1.19e-09	0.72	0.6	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28176188~28176674:+
TGCT	cis	rs7188445	0.787	rs7189954	ENSG00000261390.4	RP11-345M22.2	8.28	1.7e-13	1.19e-09	0.59	0.6	Urate levels;	chr16:79701150	chr16:79715232~79770563:-
TGCT	cis	rs2739330	0.76	rs5760095	ENSG00000225282.1	AP000350.6	8.28	1.71e-13	1.2e-09	0.67	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23926900~23929574:+
TGCT	cis	rs3734266	0.702	rs205267	ENSG00000186328.4	RP11-140K17.2	8.28	1.71e-13	1.2e-09	0.91	0.6	Systemic lupus erythematosus;	chr6:34591986	chr6:34715613~34715940:+
TGCT	cis	rs6452524	0.618	rs10462394	ENSG00000249664.1	CTD-2227C6.2	8.27	1.72e-13	1.21e-09	0.6	0.6	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:83012285~83013109:-
TGCT	cis	rs11098499	0.754	rs17049949	ENSG00000245958.5	RP11-33B1.1	-8.27	1.73e-13	1.21e-09	-0.61	-0.6	Corneal astigmatism;	chr4:119334135	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.865	rs10213221	ENSG00000245958.5	RP11-33B1.1	-8.27	1.73e-13	1.21e-09	-0.61	-0.6	Corneal astigmatism;	chr4:119334771	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs7689729	ENSG00000245958.5	RP11-33B1.1	-8.27	1.73e-13	1.21e-09	-0.61	-0.6	Corneal astigmatism;	chr4:119335037	chr4:119454791~119552025:+
TGCT	cis	rs10028773	0.7	rs7690338	ENSG00000245958.5	RP11-33B1.1	-8.27	1.73e-13	1.21e-09	-0.61	-0.6	Educational attainment;	chr4:119335313	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.865	rs3956464	ENSG00000245958.5	RP11-33B1.1	-8.27	1.73e-13	1.21e-09	-0.61	-0.6	Corneal astigmatism;	chr4:119335609	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.619	rs28502463	ENSG00000245958.5	RP11-33B1.1	-8.27	1.73e-13	1.21e-09	-0.61	-0.6	Corneal astigmatism;	chr4:119335868	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.648	rs2002047	ENSG00000245958.5	RP11-33B1.1	-8.27	1.73e-13	1.21e-09	-0.61	-0.6	Corneal astigmatism;	chr4:119336073	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.775	rs2002049	ENSG00000245958.5	RP11-33B1.1	-8.27	1.73e-13	1.21e-09	-0.61	-0.6	Corneal astigmatism;	chr4:119336262	chr4:119454791~119552025:+
TGCT	cis	rs5769707	0.967	rs9616327	ENSG00000188511.11	C22orf34	8.27	1.73e-13	1.21e-09	0.57	0.6	Monocyte percentage of white cells;Monocyte count;	chr22:49617243	chr22:49414524~49657542:-
TGCT	cis	rs11098499	0.866	rs72676074	ENSG00000245958.5	RP11-33B1.1	-8.27	1.74e-13	1.22e-09	-0.63	-0.6	Corneal astigmatism;	chr4:119438686	chr4:119454791~119552025:+
TGCT	cis	rs6921919	0.525	rs11760133	ENSG00000216901.1	AL022393.7	8.27	1.76e-13	1.23e-09	0.69	0.6	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28176188~28176674:+
TGCT	cis	rs2729354	0.953	rs2649663	ENSG00000265566.2	RN7SL605P	-8.27	1.78e-13	1.24e-09	-0.72	-0.6	Blood protein levels;	chr11:57589832	chr11:57528085~57528365:-
TGCT	cis	rs2486288	0.586	rs12909625	ENSG00000259520.4	CTD-2651B20.3	8.27	1.81e-13	1.26e-09	0.51	0.6	Glomerular filtration rate;	chr15:45279855	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.586	rs12909883	ENSG00000259520.4	CTD-2651B20.3	8.27	1.81e-13	1.26e-09	0.51	0.6	Glomerular filtration rate;	chr15:45279856	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs12910009	ENSG00000259520.4	CTD-2651B20.3	8.27	1.81e-13	1.26e-09	0.51	0.6	Glomerular filtration rate;	chr15:45280210	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs11637364	ENSG00000259520.4	CTD-2651B20.3	8.26	1.82e-13	1.28e-09	0.5	0.6	Glomerular filtration rate;	chr15:45287040	chr15:45251580~45279251:-
TGCT	cis	rs1355223	0.867	rs11821793	ENSG00000271369.1	RP11-350D17.3	-8.25	1.91e-13	1.33e-09	-0.57	-0.6	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34659915	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.867	rs7925421	ENSG00000271369.1	RP11-350D17.3	-8.25	1.91e-13	1.33e-09	-0.57	-0.6	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34660130	chr11:34709600~34710161:+
TGCT	cis	rs11098499	0.789	rs10212719	ENSG00000245958.5	RP11-33B1.1	-8.25	1.96e-13	1.36e-09	-0.61	-0.6	Corneal astigmatism;	chr4:119333282	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.691	rs9996644	ENSG00000245958.5	RP11-33B1.1	-8.25	2e-13	1.38e-09	-0.6	-0.6	Corneal astigmatism;	chr4:119317722	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.691	rs9996494	ENSG00000245958.5	RP11-33B1.1	-8.25	2e-13	1.38e-09	-0.6	-0.6	Corneal astigmatism;	chr4:119317725	chr4:119454791~119552025:+
TGCT	cis	rs916888	0.61	rs199453	ENSG00000262539.1	RP11-259G18.3	8.25	2.01e-13	1.39e-09	0.85	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46259551~46260606:-
TGCT	cis	rs916888	0.61	rs199452	ENSG00000262539.1	RP11-259G18.3	8.25	2.01e-13	1.39e-09	0.85	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46259551~46260606:-
TGCT	cis	rs6452524	0.935	rs6896953	ENSG00000249664.1	CTD-2227C6.2	-8.24	2.04e-13	1.41e-09	-0.59	-0.59	Hypertension (SNP x SNP interaction);	chr5:83089284	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.901	rs1039786	ENSG00000249664.1	CTD-2227C6.2	8.24	2.04e-13	1.41e-09	0.6	0.59	Hypertension (SNP x SNP interaction);	chr5:83204222	chr5:83012285~83013109:-
TGCT	cis	rs1577917	1	rs13217384	ENSG00000203875.9	SNHG5	-8.24	2.07e-13	1.43e-09	-0.75	-0.59	Response to antipsychotic treatment;	chr6:86010282	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs11755864	ENSG00000203875.9	SNHG5	-8.24	2.12e-13	1.46e-09	-0.8	-0.59	Response to antipsychotic treatment;	chr6:85982073	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs10944169	ENSG00000203875.9	SNHG5	-8.23	2.16e-13	1.49e-09	-0.82	-0.59	Response to antipsychotic treatment;	chr6:85973318	chr6:85660950~85678736:-
TGCT	cis	rs875971	0.862	rs6460307	ENSG00000226824.5	RP4-756H11.3	-8.23	2.16e-13	1.49e-09	-0.62	-0.59	Aortic root size;	chr7:66595884	chr7:66654538~66669855:+
TGCT	cis	rs1577917	1	rs12192992	ENSG00000203875.9	SNHG5	-8.23	2.16e-13	1.49e-09	-0.8	-0.59	Response to antipsychotic treatment;	chr6:85900197	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.917	rs35738006	ENSG00000203875.9	SNHG5	-8.23	2.16e-13	1.49e-09	-0.8	-0.59	Response to antipsychotic treatment;	chr6:85936591	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs12200330	ENSG00000203875.9	SNHG5	-8.23	2.16e-13	1.49e-09	-0.8	-0.59	Response to antipsychotic treatment;	chr6:85946935	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs12208493	ENSG00000203875.9	SNHG5	-8.23	2.16e-13	1.49e-09	-0.8	-0.59	Response to antipsychotic treatment;	chr6:85952549	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs12213149	ENSG00000203875.9	SNHG5	-8.23	2.16e-13	1.49e-09	-0.8	-0.59	Response to antipsychotic treatment;	chr6:85958926	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs11756510	ENSG00000203875.9	SNHG5	-8.23	2.16e-13	1.49e-09	-0.8	-0.59	Response to antipsychotic treatment;	chr6:85990076	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs68171315	ENSG00000203875.9	SNHG5	-8.23	2.16e-13	1.49e-09	-0.8	-0.59	Response to antipsychotic treatment;	chr6:85997682	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs12205336	ENSG00000203875.9	SNHG5	-8.23	2.16e-13	1.49e-09	-0.8	-0.59	Response to antipsychotic treatment;	chr6:86012649	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs12209127	ENSG00000203875.9	SNHG5	-8.23	2.16e-13	1.49e-09	-0.8	-0.59	Response to antipsychotic treatment;	chr6:86014709	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs1337850	ENSG00000203875.9	SNHG5	-8.23	2.16e-13	1.49e-09	-0.8	-0.59	Response to antipsychotic treatment;	chr6:86019385	chr6:85660950~85678736:-
TGCT	cis	rs875971	0.862	rs778720	ENSG00000226824.5	RP4-756H11.3	8.23	2.2e-13	1.51e-09	0.63	0.59	Aortic root size;	chr7:66381288	chr7:66654538~66669855:+
TGCT	cis	rs5769707	0.967	rs2051626	ENSG00000188511.11	C22orf34	8.23	2.21e-13	1.52e-09	0.57	0.59	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.967	rs1018812	ENSG00000188511.11	C22orf34	8.23	2.21e-13	1.52e-09	0.57	0.59	Monocyte percentage of white cells;Monocyte count;	chr22:49616425	chr22:49414524~49657542:-
TGCT	cis	rs858239	0.73	rs858279	ENSG00000230658.1	KLHL7-AS1	8.22	2.25e-13	1.54e-09	0.62	0.59	Cerebrospinal fluid biomarker levels;	chr7:23211386	chr7:23101228~23105703:-
TGCT	cis	rs2486288	0.656	rs12908818	ENSG00000259520.4	CTD-2651B20.3	8.22	2.27e-13	1.55e-09	0.5	0.59	Glomerular filtration rate;	chr15:45279470	chr15:45251580~45279251:-
TGCT	cis	rs7301826	0.58	rs12821464	ENSG00000256250.1	RP11-989F5.1	8.22	2.27e-13	1.56e-09	0.7	0.59	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810606~130812438:+
TGCT	cis	rs5769707	0.935	rs9616332	ENSG00000188511.11	C22orf34	8.22	2.28e-13	1.56e-09	0.56	0.59	Monocyte percentage of white cells;Monocyte count;	chr22:49654030	chr22:49414524~49657542:-
TGCT	cis	rs11098499	0.754	rs1546503	ENSG00000245958.5	RP11-33B1.1	-8.22	2.28e-13	1.56e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119320012	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.708	rs1546506	ENSG00000245958.5	RP11-33B1.1	-8.22	2.28e-13	1.56e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119320085	chr4:119454791~119552025:+
TGCT	cis	rs1355223	0.867	rs3818514	ENSG00000271369.1	RP11-350D17.3	-8.22	2.3e-13	1.57e-09	-0.57	-0.59	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34658506	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.833	rs11032804	ENSG00000271369.1	RP11-350D17.3	-8.22	2.3e-13	1.57e-09	-0.57	-0.59	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34659051	chr11:34709600~34710161:+
TGCT	cis	rs1775715	0.87	rs1251407	ENSG00000239731.3	RN7SL825P	-8.22	2.35e-13	1.61e-09	-0.59	-0.59	Bipolar disorder with mood-incongruent psychosis;	chr10:31949397	chr10:31992087~31992381:-
TGCT	cis	rs6452524	1	rs10080123	ENSG00000249664.1	CTD-2227C6.2	-8.22	2.35e-13	1.61e-09	-0.61	-0.59	Hypertension (SNP x SNP interaction);	chr5:83165447	chr5:83012285~83013109:-
TGCT	cis	rs5769707	0.967	rs9616333	ENSG00000188511.11	C22orf34	8.22	2.36e-13	1.61e-09	0.56	0.59	Monocyte percentage of white cells;Monocyte count;	chr22:49657199	chr22:49414524~49657542:-
TGCT	cis	rs1775715	0.87	rs1755072	ENSG00000239731.3	RN7SL825P	8.21	2.38e-13	1.62e-09	0.6	0.59	Bipolar disorder with mood-incongruent psychosis;	chr10:31977714	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.811	rs1775741	ENSG00000239731.3	RN7SL825P	8.21	2.38e-13	1.62e-09	0.6	0.59	Bipolar disorder with mood-incongruent psychosis;	chr10:31978356	chr10:31992087~31992381:-
TGCT	cis	rs916888	0.61	rs199454	ENSG00000262539.1	RP11-259G18.3	-8.21	2.39e-13	1.63e-09	-0.85	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46259551~46260606:-
TGCT	cis	rs11098499	0.575	rs907204	ENSG00000245958.5	RP11-33B1.1	-8.21	2.45e-13	1.67e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119317499	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.575	rs907205	ENSG00000245958.5	RP11-33B1.1	-8.21	2.45e-13	1.67e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119317509	chr4:119454791~119552025:+
TGCT	cis	rs2729354	1	rs2511983	ENSG00000265566.2	RN7SL605P	-8.21	2.47e-13	1.69e-09	-0.73	-0.59	Blood protein levels;	chr11:57579401	chr11:57528085~57528365:-
TGCT	cis	rs2729354	1	rs2729355	ENSG00000265566.2	RN7SL605P	-8.21	2.47e-13	1.69e-09	-0.73	-0.59	Blood protein levels;	chr11:57586510	chr11:57528085~57528365:-
TGCT	cis	rs2729354	1	rs2729354	ENSG00000265566.2	RN7SL605P	-8.21	2.47e-13	1.69e-09	-0.73	-0.59	Blood protein levels;	chr11:57588497	chr11:57528085~57528365:-
TGCT	cis	rs2729354	1	rs2848630	ENSG00000265566.2	RN7SL605P	-8.21	2.47e-13	1.69e-09	-0.73	-0.59	Blood protein levels;	chr11:57589434	chr11:57528085~57528365:-
TGCT	cis	rs916888	0.61	rs199446	ENSG00000262539.1	RP11-259G18.3	-8.21	2.48e-13	1.69e-09	-0.86	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46259551~46260606:-
TGCT	cis	rs916888	0.61	rs199536	ENSG00000262539.1	RP11-259G18.3	-8.21	2.48e-13	1.69e-09	-0.86	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46259551~46260606:-
TGCT	cis	rs11763147	1	rs11763147	ENSG00000226824.5	RP4-756H11.3	8.21	2.49e-13	1.7e-09	0.65	0.59	Corneal structure;	chr7:65861834	chr7:66654538~66669855:+
TGCT	cis	rs11098499	0.754	rs7672372	ENSG00000245958.5	RP11-33B1.1	-8.2	2.5e-13	1.7e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119327251	chr4:119454791~119552025:+
TGCT	cis	rs977987	0.864	rs37592	ENSG00000261783.1	RP11-252K23.2	8.2	2.51e-13	1.71e-09	0.88	0.59	Dupuytren's disease;	chr16:75462893	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.864	rs37595	ENSG00000261783.1	RP11-252K23.2	8.2	2.51e-13	1.71e-09	0.88	0.59	Dupuytren's disease;	chr16:75463065	chr16:75379818~75381260:-
TGCT	cis	rs11098499	0.754	rs12711071	ENSG00000245958.5	RP11-33B1.1	-8.2	2.52e-13	1.72e-09	-0.59	-0.59	Corneal astigmatism;	chr4:119319779	chr4:119454791~119552025:+
TGCT	cis	rs858239	0.665	rs858305	ENSG00000230658.1	KLHL7-AS1	-8.2	2.53e-13	1.72e-09	-0.62	-0.59	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23101228~23105703:-
TGCT	cis	rs6921919	0.583	rs9468370	ENSG00000216901.1	AL022393.7	8.2	2.54e-13	1.73e-09	0.7	0.59	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28176188~28176674:+
TGCT	cis	rs2486288	0.656	rs8039153	ENSG00000259520.4	CTD-2651B20.3	8.2	2.54e-13	1.73e-09	0.49	0.59	Glomerular filtration rate;	chr15:45287615	chr15:45251580~45279251:-
TGCT	cis	rs6452524	0.934	rs6452512	ENSG00000249664.1	CTD-2227C6.2	8.2	2.58e-13	1.75e-09	0.59	0.59	Hypertension (SNP x SNP interaction);	chr5:83127523	chr5:83012285~83013109:-
TGCT	cis	rs7188445	0.932	rs17767491	ENSG00000261390.4	RP11-345M22.2	-8.2	2.59e-13	1.75e-09	-0.6	-0.59	Urate levels;	chr16:79711590	chr16:79715232~79770563:-
TGCT	cis	rs11098499	0.789	rs9991166	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119316696	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.708	rs10005237	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119316742	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs878372	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119317625	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs10213267	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119317919	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs10212775	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119318089	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs9999724	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119318789	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs2964	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119318976	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs1511025	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119319083	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs12506610	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119320504	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.743	rs10003567	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119320519	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs10006259	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119320990	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs28652763	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119321157	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs714899	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119321880	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs7672594	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119327388	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs7672778	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119327430	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs2036860	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119327779	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs2036857	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119328085	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs2036856	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119328133	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs4443261	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119328146	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs66900435	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119328270	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs12513083	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119328457	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs12509621	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119328505	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs17595608	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119329351	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs1511017	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119329650	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.789	rs12498994	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119329663	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs12507565	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119329966	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.826	rs12511640	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119330093	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs1980027	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119330422	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs1980026	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119330488	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.722	rs28713555	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119330840	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.743	rs11098501	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119330862	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs11098502	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119330908	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.708	rs11732686	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119331175	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs11724409	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119331206	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.789	rs1980024	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119331892	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs34425882	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119332022	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs4107728	ENSG00000245958.5	RP11-33B1.1	-8.2	2.6e-13	1.75e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119332755	chr4:119454791~119552025:+
TGCT	cis	rs6452524	0.934	rs12153440	ENSG00000249664.1	CTD-2227C6.2	8.2	2.62e-13	1.76e-09	0.62	0.59	Hypertension (SNP x SNP interaction);	chr5:83125097	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.901	rs1842020	ENSG00000249664.1	CTD-2227C6.2	8.2	2.62e-13	1.76e-09	0.62	0.59	Hypertension (SNP x SNP interaction);	chr5:83125814	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs7718278	ENSG00000249664.1	CTD-2227C6.2	8.2	2.62e-13	1.76e-09	0.62	0.59	Hypertension (SNP x SNP interaction);	chr5:83126600	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.934	rs1120476	ENSG00000249664.1	CTD-2227C6.2	8.2	2.62e-13	1.76e-09	0.62	0.59	Hypertension (SNP x SNP interaction);	chr5:83126824	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.934	rs6452510	ENSG00000249664.1	CTD-2227C6.2	8.2	2.62e-13	1.76e-09	0.62	0.59	Hypertension (SNP x SNP interaction);	chr5:83127401	chr5:83012285~83013109:-
TGCT	cis	rs4423214	1	rs28364617	ENSG00000254682.1	RP11-660L16.2	8.2	2.63e-13	1.77e-09	0.79	0.59	Vitamin D levels;	chr11:71448718	chr11:71448674~71452157:+
TGCT	cis	rs1577917	1	rs955197	ENSG00000203875.9	SNHG5	-8.19	2.66e-13	1.79e-09	-0.8	-0.59	Response to antipsychotic treatment;	chr6:86019957	chr6:85660950~85678736:-
TGCT	cis	rs2729354	0.779	rs2511984	ENSG00000265566.2	RN7SL605P	-8.19	2.77e-13	1.86e-09	-0.74	-0.59	Blood protein levels;	chr11:57511260	chr11:57528085~57528365:-
TGCT	cis	rs2729354	0.817	rs2467327	ENSG00000265566.2	RN7SL605P	-8.18	2.8e-13	1.87e-09	-0.74	-0.59	Blood protein levels;	chr11:57511755	chr11:57528085~57528365:-
TGCT	cis	rs875971	0.793	rs460678	ENSG00000226824.5	RP4-756H11.3	-8.18	2.85e-13	1.9e-09	-0.65	-0.59	Aortic root size;	chr7:66062213	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.964	rs160635	ENSG00000226824.5	RP4-756H11.3	-8.18	2.85e-13	1.9e-09	-0.65	-0.59	Aortic root size;	chr7:66063931	chr7:66654538~66669855:+
TGCT	cis	rs977987	0.832	rs37597	ENSG00000261783.1	RP11-252K23.2	8.18	2.86e-13	1.91e-09	0.88	0.59	Dupuytren's disease;	chr16:75466377	chr16:75379818~75381260:-
TGCT	cis	rs5769707	0.967	rs739241	ENSG00000188511.11	C22orf34	8.18	2.86e-13	1.91e-09	0.56	0.59	Monocyte percentage of white cells;Monocyte count;	chr22:49659273	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.967	rs12485195	ENSG00000188511.11	C22orf34	8.18	2.86e-13	1.91e-09	0.56	0.59	Monocyte percentage of white cells;Monocyte count;	chr22:49660223	chr22:49414524~49657542:-
TGCT	cis	rs6452524	0.934	rs10473870	ENSG00000249664.1	CTD-2227C6.2	8.18	2.9e-13	1.93e-09	0.59	0.59	Hypertension (SNP x SNP interaction);	chr5:83199768	chr5:83012285~83013109:-
TGCT	cis	rs11098499	0.954	rs3733520	ENSG00000245958.5	RP11-33B1.1	-8.18	2.91e-13	1.94e-09	-0.63	-0.59	Corneal astigmatism;	chr4:119502325	chr4:119454791~119552025:+
TGCT	cis	rs858239	0.601	rs28673077	ENSG00000230658.1	KLHL7-AS1	8.17	2.94e-13	1.96e-09	0.69	0.59	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23101228~23105703:-
TGCT	cis	rs6597981	0.592	rs10902218	ENSG00000279672.1	CMB9-55F22.1	-8.17	2.96e-13	1.97e-09	-0.65	-0.59	Breast cancer;	chr11:743813	chr11:779617~780755:+
TGCT	cis	rs858239	0.536	rs6961109	ENSG00000230658.1	KLHL7-AS1	8.17	2.97e-13	1.98e-09	0.68	0.59	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23101228~23105703:-
TGCT	cis	rs6538678	0.712	rs10777748	ENSG00000258343.1	RP11-536G4.2	-8.17	2.98e-13	1.98e-09	-0.95	-0.59	Lupus nephritis in systemic lupus erythematosus;	chr12:95880227	chr12:95795345~95858839:-
TGCT	cis	rs6452524	0.967	rs6897075	ENSG00000249664.1	CTD-2227C6.2	8.17	2.99e-13	1.99e-09	0.59	0.59	Hypertension (SNP x SNP interaction);	chr5:83122959	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs10065973	ENSG00000249664.1	CTD-2227C6.2	8.17	2.99e-13	1.99e-09	0.59	0.59	Hypertension (SNP x SNP interaction);	chr5:83123181	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.934	rs12153179	ENSG00000249664.1	CTD-2227C6.2	8.17	2.99e-13	1.99e-09	0.59	0.59	Hypertension (SNP x SNP interaction);	chr5:83125109	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs12153441	ENSG00000249664.1	CTD-2227C6.2	8.17	2.99e-13	1.99e-09	0.59	0.59	Hypertension (SNP x SNP interaction);	chr5:83125181	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs12152891	ENSG00000249664.1	CTD-2227C6.2	8.17	2.99e-13	1.99e-09	0.59	0.59	Hypertension (SNP x SNP interaction);	chr5:83125217	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs6452507	ENSG00000249664.1	CTD-2227C6.2	8.17	2.99e-13	1.99e-09	0.59	0.59	Hypertension (SNP x SNP interaction);	chr5:83125537	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs6452508	ENSG00000249664.1	CTD-2227C6.2	8.17	2.99e-13	1.99e-09	0.59	0.59	Hypertension (SNP x SNP interaction);	chr5:83125546	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs7717964	ENSG00000249664.1	CTD-2227C6.2	8.17	2.99e-13	1.99e-09	0.59	0.59	Hypertension (SNP x SNP interaction);	chr5:83126323	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.934	rs1120477	ENSG00000249664.1	CTD-2227C6.2	8.17	2.99e-13	1.99e-09	0.59	0.59	Hypertension (SNP x SNP interaction);	chr5:83127062	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.934	rs1120478	ENSG00000249664.1	CTD-2227C6.2	8.17	2.99e-13	1.99e-09	0.59	0.59	Hypertension (SNP x SNP interaction);	chr5:83127072	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs6452514	ENSG00000249664.1	CTD-2227C6.2	8.17	2.99e-13	1.99e-09	0.59	0.59	Hypertension (SNP x SNP interaction);	chr5:83127627	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs6884543	ENSG00000249664.1	CTD-2227C6.2	8.17	2.99e-13	1.99e-09	0.59	0.59	Hypertension (SNP x SNP interaction);	chr5:83127939	chr5:83012285~83013109:-
TGCT	cis	rs10028773	0.7	rs7671797	ENSG00000245958.5	RP11-33B1.1	-8.17	3.02e-13	2e-09	-0.6	-0.59	Educational attainment;	chr4:119327002	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.909	rs10020034	ENSG00000245958.5	RP11-33B1.1	-8.17	3.05e-13	2.02e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119373176	chr4:119454791~119552025:+
TGCT	cis	rs4423214	1	rs12797951	ENSG00000254682.1	RP11-660L16.2	-8.17	3.07e-13	2.03e-09	-0.78	-0.59	Vitamin D levels;	chr11:71432220	chr11:71448674~71452157:+
TGCT	cis	rs6452524	1	rs6452531	ENSG00000249664.1	CTD-2227C6.2	8.17	3.09e-13	2.04e-09	0.57	0.59	Hypertension (SNP x SNP interaction);	chr5:83170355	chr5:83012285~83013109:-
TGCT	cis	rs11098499	0.754	rs28643450	ENSG00000245958.5	RP11-33B1.1	-8.16	3.13e-13	2.07e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119324087	chr4:119454791~119552025:+
TGCT	cis	rs6452524	0.905	rs1478482	ENSG00000249664.1	CTD-2227C6.2	8.16	3.13e-13	2.07e-09	0.59	0.59	Hypertension (SNP x SNP interaction);	chr5:83111279	chr5:83012285~83013109:-
TGCT	cis	rs11098499	0.588	rs6534149	ENSG00000245958.5	RP11-33B1.1	8.16	3.18e-13	2.1e-09	0.63	0.59	Corneal astigmatism;	chr4:119638137	chr4:119454791~119552025:+
TGCT	cis	rs1062177	1	rs2915882	ENSG00000253921.1	CTB-113P19.3	-8.16	3.24e-13	2.14e-09	-0.64	-0.59	Preschool internalizing problems;	chr5:151765875	chr5:151753992~151767247:+
TGCT	cis	rs1062177	1	rs2915880	ENSG00000253921.1	CTB-113P19.3	-8.16	3.24e-13	2.14e-09	-0.64	-0.59	Preschool internalizing problems;	chr5:151767773	chr5:151753992~151767247:+
TGCT	cis	rs1062177	1	rs2915878	ENSG00000253921.1	CTB-113P19.3	-8.16	3.24e-13	2.14e-09	-0.64	-0.59	Preschool internalizing problems;	chr5:151770101	chr5:151753992~151767247:+
TGCT	cis	rs6452524	0.967	rs2974448	ENSG00000249664.1	CTD-2227C6.2	8.15	3.29e-13	2.17e-09	0.59	0.59	Hypertension (SNP x SNP interaction);	chr5:83190937	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs6880566	ENSG00000249664.1	CTD-2227C6.2	8.15	3.31e-13	2.18e-09	0.59	0.59	Hypertension (SNP x SNP interaction);	chr5:83086909	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.905	rs6896548	ENSG00000249664.1	CTD-2227C6.2	8.15	3.32e-13	2.18e-09	0.58	0.59	Hypertension (SNP x SNP interaction);	chr5:83089247	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.901	rs1600362	ENSG00000249664.1	CTD-2227C6.2	8.15	3.32e-13	2.18e-09	0.58	0.59	Hypertension (SNP x SNP interaction);	chr5:83091354	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs1580311	ENSG00000249664.1	CTD-2227C6.2	8.15	3.32e-13	2.18e-09	0.58	0.59	Hypertension (SNP x SNP interaction);	chr5:83091667	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs1580310	ENSG00000249664.1	CTD-2227C6.2	8.15	3.32e-13	2.18e-09	0.58	0.59	Hypertension (SNP x SNP interaction);	chr5:83091792	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs1382376	ENSG00000249664.1	CTD-2227C6.2	8.15	3.32e-13	2.18e-09	0.58	0.59	Hypertension (SNP x SNP interaction);	chr5:83095418	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs12109517	ENSG00000249664.1	CTD-2227C6.2	8.15	3.32e-13	2.18e-09	0.58	0.59	Hypertension (SNP x SNP interaction);	chr5:83095947	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs12109514	ENSG00000249664.1	CTD-2227C6.2	8.15	3.32e-13	2.18e-09	0.58	0.59	Hypertension (SNP x SNP interaction);	chr5:83095965	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs1011979	ENSG00000249664.1	CTD-2227C6.2	8.15	3.32e-13	2.18e-09	0.58	0.59	Hypertension (SNP x SNP interaction);	chr5:83097431	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.901	rs17284211	ENSG00000249664.1	CTD-2227C6.2	8.15	3.32e-13	2.18e-09	0.58	0.59	Hypertension (SNP x SNP interaction);	chr5:83098706	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs1382374	ENSG00000249664.1	CTD-2227C6.2	8.15	3.32e-13	2.18e-09	0.58	0.59	Hypertension (SNP x SNP interaction);	chr5:83101010	chr5:83012285~83013109:-
TGCT	cis	rs5769707	1	rs5769707	ENSG00000188511.11	C22orf34	8.15	3.34e-13	2.19e-09	0.56	0.59	Monocyte percentage of white cells;Monocyte count;	chr22:49619754	chr22:49414524~49657542:-
TGCT	cis	rs4423214	1	rs4944946	ENSG00000254682.1	RP11-660L16.2	8.15	3.34e-13	2.19e-09	0.79	0.59	Vitamin D levels;	chr11:71448383	chr11:71448674~71452157:+
TGCT	cis	rs1577917	1	rs1415753	ENSG00000203875.9	SNHG5	-8.15	3.36e-13	2.2e-09	-0.79	-0.59	Response to antipsychotic treatment;	chr6:86043356	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs1577919	ENSG00000203875.9	SNHG5	-8.15	3.36e-13	2.2e-09	-0.79	-0.59	Response to antipsychotic treatment;	chr6:86047578	chr6:85660950~85678736:-
TGCT	cis	rs1577917	1	rs12203493	ENSG00000203875.9	SNHG5	-8.15	3.36e-13	2.2e-09	-0.79	-0.59	Response to antipsychotic treatment;	chr6:86048924	chr6:85660950~85678736:-
TGCT	cis	rs7301826	0.627	rs73162873	ENSG00000256299.1	RP11-989F5.3	-8.15	3.37e-13	2.21e-09	-0.72	-0.59	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810821~130812622:-
TGCT	cis	rs1775715	0.87	rs1251400	ENSG00000239731.3	RN7SL825P	-8.15	3.44e-13	2.25e-09	-0.58	-0.59	Bipolar disorder with mood-incongruent psychosis;	chr10:31946217	chr10:31992087~31992381:-
TGCT	cis	rs9326248	0.861	rs4938353	ENSG00000254851.1	RP11-109L13.1	-8.14	3.45e-13	2.26e-09	-0.85	-0.59	Blood protein levels;	chr11:117175481	chr11:117135528~117138582:+
TGCT	cis	rs6452524	0.967	rs4290995	ENSG00000249664.1	CTD-2227C6.2	8.14	3.49e-13	2.28e-09	0.59	0.59	Hypertension (SNP x SNP interaction);	chr5:83182177	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs2974443	ENSG00000249664.1	CTD-2227C6.2	8.14	3.49e-13	2.28e-09	0.59	0.59	Hypertension (SNP x SNP interaction);	chr5:83184595	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs965674	ENSG00000249664.1	CTD-2227C6.2	8.14	3.49e-13	2.28e-09	0.59	0.59	Hypertension (SNP x SNP interaction);	chr5:83186765	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs2662242	ENSG00000249664.1	CTD-2227C6.2	8.14	3.49e-13	2.28e-09	0.59	0.59	Hypertension (SNP x SNP interaction);	chr5:83189066	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs2731844	ENSG00000249664.1	CTD-2227C6.2	8.14	3.49e-13	2.28e-09	0.59	0.59	Hypertension (SNP x SNP interaction);	chr5:83192627	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.901	rs2940540	ENSG00000249664.1	CTD-2227C6.2	8.14	3.49e-13	2.28e-09	0.59	0.59	Hypertension (SNP x SNP interaction);	chr5:83193004	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs2974441	ENSG00000249664.1	CTD-2227C6.2	8.14	3.49e-13	2.28e-09	0.59	0.59	Hypertension (SNP x SNP interaction);	chr5:83193330	chr5:83012285~83013109:-
TGCT	cis	rs1062177	1	rs2016409	ENSG00000253921.1	CTB-113P19.3	8.14	3.5e-13	2.28e-09	0.64	0.59	Preschool internalizing problems;	chr5:151746763	chr5:151753992~151767247:+
TGCT	cis	rs1062177	1	rs17741826	ENSG00000253921.1	CTB-113P19.3	8.14	3.5e-13	2.28e-09	0.64	0.59	Preschool internalizing problems;	chr5:151769701	chr5:151753992~151767247:+
TGCT	cis	rs1062177	1	rs2964585	ENSG00000253921.1	CTB-113P19.3	-8.14	3.5e-13	2.28e-09	-0.64	-0.59	Preschool internalizing problems;	chr5:151762334	chr5:151753992~151767247:+
TGCT	cis	rs1062177	1	rs2964578	ENSG00000253921.1	CTB-113P19.3	-8.14	3.5e-13	2.28e-09	-0.64	-0.59	Preschool internalizing problems;	chr5:151767637	chr5:151753992~151767247:+
TGCT	cis	rs67383717	0.777	rs591486	ENSG00000175611.10	LINC00476	-8.14	3.5e-13	2.28e-09	-0.5	-0.59	Parkinson's disease (pesticide exposure interaction);	chr9:95887764	chr9:95759231~95875977:-
TGCT	cis	rs2486288	0.656	rs8037583	ENSG00000259520.4	CTD-2651B20.3	8.14	3.52e-13	2.29e-09	0.48	0.59	Glomerular filtration rate;	chr15:45254180	chr15:45251580~45279251:-
TGCT	cis	rs11098499	0.754	rs10213554	ENSG00000245958.5	RP11-33B1.1	8.14	3.56e-13	2.32e-09	0.58	0.59	Corneal astigmatism;	chr4:119339630	chr4:119454791~119552025:+
TGCT	cis	rs6921919	0.583	rs7740351	ENSG00000216901.1	AL022393.7	8.14	3.61e-13	2.35e-09	0.71	0.59	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs16894108	ENSG00000216901.1	AL022393.7	8.14	3.61e-13	2.35e-09	0.71	0.59	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28176188~28176674:+
TGCT	cis	rs11098499	0.909	rs11723757	ENSG00000245958.5	RP11-33B1.1	-8.13	3.68e-13	2.39e-09	-0.61	-0.59	Corneal astigmatism;	chr4:119378514	chr4:119454791~119552025:+
TGCT	cis	rs6921919	0.583	rs34513104	ENSG00000216901.1	AL022393.7	8.13	3.69e-13	2.4e-09	0.7	0.59	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs9461456	ENSG00000216901.1	AL022393.7	8.13	3.69e-13	2.4e-09	0.7	0.59	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.525	rs9468360	ENSG00000216901.1	AL022393.7	8.13	3.69e-13	2.4e-09	0.7	0.59	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs16894021	ENSG00000216901.1	AL022393.7	8.13	3.69e-13	2.4e-09	0.7	0.59	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs11751693	ENSG00000216901.1	AL022393.7	8.13	3.69e-13	2.4e-09	0.7	0.59	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs7749736	ENSG00000216901.1	AL022393.7	8.13	3.69e-13	2.4e-09	0.7	0.59	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.525	rs9468361	ENSG00000216901.1	AL022393.7	8.13	3.69e-13	2.4e-09	0.7	0.59	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs7775132	ENSG00000216901.1	AL022393.7	8.13	3.69e-13	2.4e-09	0.7	0.59	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28176188~28176674:+
TGCT	cis	rs7188445	0.932	rs7203756	ENSG00000261390.4	RP11-345M22.2	8.13	3.7e-13	2.4e-09	0.59	0.59	Urate levels;	chr16:79711709	chr16:79715232~79770563:-
TGCT	cis	rs7188445	0.932	rs17767383	ENSG00000261390.4	RP11-345M22.2	-8.13	3.7e-13	2.4e-09	-0.59	-0.59	Urate levels;	chr16:79710504	chr16:79715232~79770563:-
TGCT	cis	rs7188445	0.932	rs73575079	ENSG00000261390.4	RP11-345M22.2	-8.13	3.7e-13	2.4e-09	-0.59	-0.59	Urate levels;	chr16:79711344	chr16:79715232~79770563:-
TGCT	cis	rs9399137	0.507	rs4896128	ENSG00000232876.1	CTA-212D2.2	8.13	3.74e-13	2.42e-09	0.53	0.59	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028618	chr6:135055033~135060550:+
TGCT	cis	rs1577917	0.958	rs11755048	ENSG00000203875.9	SNHG5	-8.13	3.75e-13	2.43e-09	-0.79	-0.59	Response to antipsychotic treatment;	chr6:85804616	chr6:85660950~85678736:-
TGCT	cis	rs6452524	1	rs10068099	ENSG00000249664.1	CTD-2227C6.2	8.13	3.76e-13	2.43e-09	0.6	0.59	Hypertension (SNP x SNP interaction);	chr5:83161373	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs7349753	ENSG00000249664.1	CTD-2227C6.2	8.13	3.76e-13	2.43e-09	0.6	0.59	Hypertension (SNP x SNP interaction);	chr5:83165632	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs67683443	ENSG00000249664.1	CTD-2227C6.2	8.13	3.76e-13	2.43e-09	0.6	0.59	Hypertension (SNP x SNP interaction);	chr5:83167884	chr5:83012285~83013109:-
TGCT	cis	rs875971	0.522	rs1880556	ENSG00000226824.5	RP4-756H11.3	-8.13	3.82e-13	2.47e-09	-0.66	-0.59	Aortic root size;	chr7:65967557	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.522	rs781144	ENSG00000226824.5	RP4-756H11.3	-8.13	3.82e-13	2.47e-09	-0.66	-0.59	Aortic root size;	chr7:65975357	chr7:66654538~66669855:+
TGCT	cis	rs1062177	1	rs2964584	ENSG00000253921.1	CTB-113P19.3	-8.12	3.87e-13	2.5e-09	-0.64	-0.59	Preschool internalizing problems;	chr5:151763317	chr5:151753992~151767247:+
TGCT	cis	rs1577917	0.958	rs11756615	ENSG00000203875.9	SNHG5	-8.12	3.88e-13	2.51e-09	-0.8	-0.59	Response to antipsychotic treatment;	chr6:85970117	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs10944168	ENSG00000203875.9	SNHG5	-8.12	3.88e-13	2.51e-09	-0.8	-0.59	Response to antipsychotic treatment;	chr6:85970438	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.958	rs11758508	ENSG00000203875.9	SNHG5	8.12	3.89e-13	2.51e-09	0.76	0.59	Response to antipsychotic treatment;	chr6:85797160	chr6:85660950~85678736:-
TGCT	cis	rs1930961	1	rs6004669	ENSG00000272977.1	CTA-390C10.10	-8.12	3.92e-13	2.53e-09	-0.77	-0.59	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25476218~25479971:+
TGCT	cis	rs6921919	0.583	rs740622	ENSG00000216901.1	AL022393.7	8.12	3.92e-13	2.53e-09	0.7	0.59	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28176188~28176674:+
TGCT	cis	rs1930961	0.702	rs8141065	ENSG00000272977.1	CTA-390C10.10	8.12	3.93e-13	2.54e-09	0.82	0.59	Bipolar disorder with mood-incongruent psychosis;	chr22:25489221	chr22:25476218~25479971:+
TGCT	cis	rs916888	0.61	rs199442	ENSG00000214401.4	KANSL1-AS1	8.12	4.01e-13	2.59e-09	0.78	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46193576~46196723:+
TGCT	cis	rs1062177	1	rs12653926	ENSG00000213433.5	RPLP1P6	-8.12	4.03e-13	2.6e-09	-0.65	-0.59	Preschool internalizing problems;	chr5:151870687	chr5:151765859~151766378:-
TGCT	cis	rs7188445	0.932	rs17689455	ENSG00000261390.4	RP11-345M22.2	-8.11	4.07e-13	2.62e-09	-0.6	-0.59	Urate levels;	chr16:79712438	chr16:79715232~79770563:-
TGCT	cis	rs6452524	0.905	rs6884981	ENSG00000249664.1	CTD-2227C6.2	8.11	4.08e-13	2.63e-09	0.58	0.59	Hypertension (SNP x SNP interaction);	chr5:83087339	chr5:83012285~83013109:-
TGCT	cis	rs2799081	1	rs2799081	ENSG00000216901.1	AL022393.7	8.11	4.11e-13	2.65e-09	0.66	0.59	Myopia;	chr6:28302807	chr6:28176188~28176674:+
TGCT	cis	rs977987	0.671	rs9922008	ENSG00000261783.1	RP11-252K23.2	-8.11	4.13e-13	2.66e-09	-0.89	-0.59	Dupuytren's disease;	chr16:75301508	chr16:75379818~75381260:-
TGCT	cis	rs1355223	0.902	rs6484726	ENSG00000271369.1	RP11-350D17.3	-8.11	4.21e-13	2.71e-09	-0.55	-0.59	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34676011	chr11:34709600~34710161:+
TGCT	cis	rs916888	0.647	rs199449	ENSG00000214401.4	KANSL1-AS1	8.11	4.22e-13	2.72e-09	0.78	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46193576~46196723:+
TGCT	cis	rs11098499	0.954	rs7437420	ENSG00000245958.5	RP11-33B1.1	-8.1	4.3e-13	2.76e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119391748	chr4:119454791~119552025:+
TGCT	cis	rs1775715	0.87	rs1419168	ENSG00000239731.3	RN7SL825P	-8.1	4.33e-13	2.79e-09	-0.59	-0.59	Bipolar disorder with mood-incongruent psychosis;	chr10:31968404	chr10:31992087~31992381:-
TGCT	cis	rs2486288	0.656	rs12440356	ENSG00000259520.4	CTD-2651B20.3	-8.1	4.37e-13	2.81e-09	-0.51	-0.59	Glomerular filtration rate;	chr15:45275331	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs11639349	ENSG00000259520.4	CTD-2651B20.3	8.1	4.37e-13	2.81e-09	0.51	0.59	Glomerular filtration rate;	chr15:45276062	chr15:45251580~45279251:-
TGCT	cis	rs7195287	0.826	rs9925824	ENSG00000276791.1	CTD-2270P14.5	-8.1	4.4e-13	2.83e-09	-0.74	-0.59	Eosinophil counts;	chr16:2777972	chr16:2777319~2780568:+
TGCT	cis	rs1155848	0.892	rs953005	ENSG00000227354.5	RBM26-AS1	8.1	4.42e-13	2.84e-09	0.98	0.59	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480544	chr13:79406309~79424328:+
TGCT	cis	rs11098499	0.754	rs11732087	ENSG00000245958.5	RP11-33B1.1	-8.1	4.43e-13	2.84e-09	-0.59	-0.59	Corneal astigmatism;	chr4:119318676	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs12510269	ENSG00000245958.5	RP11-33B1.1	-8.1	4.48e-13	2.87e-09	-0.59	-0.59	Corneal astigmatism;	chr4:119320491	chr4:119454791~119552025:+
TGCT	cis	rs858239	0.633	rs858300	ENSG00000230658.1	KLHL7-AS1	8.09	4.59e-13	2.94e-09	0.62	0.59	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23101228~23105703:-
TGCT	cis	rs6452524	0.967	rs62374400	ENSG00000249664.1	CTD-2227C6.2	8.09	4.59e-13	2.94e-09	0.58	0.59	Hypertension (SNP x SNP interaction);	chr5:83177053	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs10040363	ENSG00000249664.1	CTD-2227C6.2	8.09	4.59e-13	2.94e-09	0.58	0.59	Hypertension (SNP x SNP interaction);	chr5:83177826	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs10051542	ENSG00000249664.1	CTD-2227C6.2	8.09	4.59e-13	2.94e-09	0.58	0.59	Hypertension (SNP x SNP interaction);	chr5:83178268	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs10051557	ENSG00000249664.1	CTD-2227C6.2	8.09	4.59e-13	2.94e-09	0.58	0.59	Hypertension (SNP x SNP interaction);	chr5:83178307	chr5:83012285~83013109:-
TGCT	cis	rs11098499	0.562	rs13101722	ENSG00000245958.5	RP11-33B1.1	8.09	4.65e-13	2.98e-09	0.62	0.59	Corneal astigmatism;	chr4:119634820	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.615	rs59867181	ENSG00000245958.5	RP11-33B1.1	8.09	4.65e-13	2.98e-09	0.62	0.59	Corneal astigmatism;	chr4:119635312	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.562	rs2389879	ENSG00000245958.5	RP11-33B1.1	8.09	4.65e-13	2.98e-09	0.62	0.59	Corneal astigmatism;	chr4:119636529	chr4:119454791~119552025:+
TGCT	cis	rs62388641	0.813	rs34779492	ENSG00000272279.1	RP11-157J24.2	8.09	4.65e-13	2.98e-09	0.67	0.59	Daytime sleep phenotypes;	chr6:1547737	chr6:1528364~1528911:-
TGCT	cis	rs916888	0.773	rs199448	ENSG00000262500.1	RP11-259G18.2	8.09	4.66e-13	2.98e-09	0.86	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46243606~46245044:+
TGCT	cis	rs7188445	0.932	rs17689159	ENSG00000261390.4	RP11-345M22.2	-8.09	4.66e-13	2.98e-09	-0.59	-0.59	Urate levels;	chr16:79708493	chr16:79715232~79770563:-
TGCT	cis	rs1775715	0.87	rs7095322	ENSG00000239731.3	RN7SL825P	8.09	4.71e-13	3.01e-09	0.58	0.59	Bipolar disorder with mood-incongruent psychosis;	chr10:31959563	chr10:31992087~31992381:-
TGCT	cis	rs9326248	0.652	rs7128382	ENSG00000254851.1	RP11-109L13.1	-8.09	4.72e-13	3.02e-09	-0.89	-0.59	Blood protein levels;	chr11:117152771	chr11:117135528~117138582:+
TGCT	cis	rs7301826	0.571	rs4759788	ENSG00000256299.1	RP11-989F5.3	-8.09	4.74e-13	3.03e-09	-0.7	-0.59	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.61	rs4759789	ENSG00000256299.1	RP11-989F5.3	-8.09	4.74e-13	3.03e-09	-0.7	-0.59	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810821~130812622:-
TGCT	cis	rs2739330	0.761	rs5760176	ENSG00000225282.1	AP000350.6	-8.08	4.77e-13	3.05e-09	-0.67	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23926900~23929574:+
TGCT	cis	rs858239	0.72	rs10227559	ENSG00000230658.1	KLHL7-AS1	8.08	4.79e-13	3.06e-09	0.68	0.59	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23101228~23105703:-
TGCT	cis	rs3734266	0.591	rs9469812	ENSG00000186328.4	RP11-140K17.2	8.08	4.81e-13	3.07e-09	0.99	0.59	Systemic lupus erythematosus;	chr6:34599754	chr6:34715613~34715940:+
TGCT	cis	rs6452524	0.618	rs1478487	ENSG00000249664.1	CTD-2227C6.2	8.08	4.84e-13	3.08e-09	0.61	0.59	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:83012285~83013109:-
TGCT	cis	rs11098499	0.535	rs7671759	ENSG00000245958.5	RP11-33B1.1	-8.08	4.88e-13	3.1e-09	-0.62	-0.59	Corneal astigmatism;	chr4:119326939	chr4:119454791~119552025:+
TGCT	cis	rs7188445	0.932	rs73575076	ENSG00000261390.4	RP11-345M22.2	-8.08	4.89e-13	3.11e-09	-0.59	-0.59	Urate levels;	chr16:79710251	chr16:79715232~79770563:-
TGCT	cis	rs11098499	0.954	rs59394118	ENSG00000245958.5	RP11-33B1.1	-8.08	4.92e-13	3.12e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119374396	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.865	rs9996417	ENSG00000245958.5	RP11-33B1.1	-8.08	4.92e-13	3.12e-09	-0.6	-0.59	Corneal astigmatism;	chr4:119374707	chr4:119454791~119552025:+
TGCT	cis	rs2486288	0.656	rs62026703	ENSG00000259520.4	CTD-2651B20.3	8.08	4.96e-13	3.15e-09	0.51	0.59	Glomerular filtration rate;	chr15:45277731	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs7171312	ENSG00000259520.4	CTD-2651B20.3	8.08	4.96e-13	3.15e-09	0.51	0.59	Glomerular filtration rate;	chr15:45278027	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs7165039	ENSG00000259520.4	CTD-2651B20.3	8.08	4.96e-13	3.15e-09	0.51	0.59	Glomerular filtration rate;	chr15:45278215	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs6493143	ENSG00000259520.4	CTD-2651B20.3	8.08	4.96e-13	3.15e-09	0.51	0.59	Glomerular filtration rate;	chr15:45278583	chr15:45251580~45279251:-
TGCT	cis	rs916888	0.61	rs199444	ENSG00000214401.4	KANSL1-AS1	8.07	5.13e-13	3.25e-09	0.78	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46193576~46196723:+
TGCT	cis	rs6921919	0.583	rs35560946	ENSG00000216901.1	AL022393.7	8.07	5.17e-13	3.27e-09	0.7	0.59	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28176188~28176674:+
TGCT	cis	rs7188445	0.932	rs17767419	ENSG00000261390.4	RP11-345M22.2	-8.07	5.19e-13	3.29e-09	-0.59	-0.59	Urate levels;	chr16:79710651	chr16:79715232~79770563:-
TGCT	cis	rs858239	0.73	rs858290	ENSG00000230658.1	KLHL7-AS1	8.07	5.23e-13	3.31e-09	0.62	0.59	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.73	rs858289	ENSG00000230658.1	KLHL7-AS1	8.07	5.23e-13	3.31e-09	0.62	0.59	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23101228~23105703:-
TGCT	cis	rs2486288	0.656	rs2413772	ENSG00000259520.4	CTD-2651B20.3	8.07	5.29e-13	3.35e-09	0.48	0.59	Glomerular filtration rate;	chr15:45257664	chr15:45251580~45279251:-
TGCT	cis	rs1355223	1	rs35365094	ENSG00000271369.1	RP11-350D17.3	-8.06	5.33e-13	3.36e-09	-0.57	-0.59	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34746243	chr11:34709600~34710161:+
TGCT	cis	rs7301826	0.651	rs7132657	ENSG00000256299.1	RP11-989F5.3	-8.06	5.34e-13	3.36e-09	-0.7	-0.59	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.651	rs10734979	ENSG00000256299.1	RP11-989F5.3	-8.06	5.34e-13	3.36e-09	-0.7	-0.59	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.627	rs10773823	ENSG00000256299.1	RP11-989F5.3	-8.06	5.34e-13	3.36e-09	-0.7	-0.59	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.61	rs4759791	ENSG00000256299.1	RP11-989F5.3	-8.06	5.34e-13	3.36e-09	-0.7	-0.59	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.61	rs9668291	ENSG00000256299.1	RP11-989F5.3	-8.06	5.34e-13	3.36e-09	-0.7	-0.59	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.651	rs4759521	ENSG00000256299.1	RP11-989F5.3	-8.06	5.34e-13	3.36e-09	-0.7	-0.59	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.651	rs4759794	ENSG00000256299.1	RP11-989F5.3	-8.06	5.34e-13	3.36e-09	-0.7	-0.59	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.651	rs10734981	ENSG00000256299.1	RP11-989F5.3	-8.06	5.34e-13	3.36e-09	-0.7	-0.59	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.651	rs10744483	ENSG00000256299.1	RP11-989F5.3	-8.06	5.34e-13	3.36e-09	-0.7	-0.59	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.651	rs10744484	ENSG00000256299.1	RP11-989F5.3	-8.06	5.34e-13	3.36e-09	-0.7	-0.59	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.651	rs10744485	ENSG00000256299.1	RP11-989F5.3	-8.06	5.34e-13	3.36e-09	-0.7	-0.59	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.651	rs10773824	ENSG00000256299.1	RP11-989F5.3	-8.06	5.34e-13	3.36e-09	-0.7	-0.59	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.651	rs10773825	ENSG00000256299.1	RP11-989F5.3	-8.06	5.34e-13	3.36e-09	-0.7	-0.59	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.651	rs7295705	ENSG00000256299.1	RP11-989F5.3	-8.06	5.34e-13	3.36e-09	-0.7	-0.59	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.651	rs10848209	ENSG00000256299.1	RP11-989F5.3	-8.06	5.34e-13	3.36e-09	-0.7	-0.59	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.651	rs10848210	ENSG00000256299.1	RP11-989F5.3	-8.06	5.34e-13	3.36e-09	-0.7	-0.59	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.627	rs4325342	ENSG00000256299.1	RP11-989F5.3	-8.06	5.34e-13	3.36e-09	-0.7	-0.59	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.627	rs1077317	ENSG00000256299.1	RP11-989F5.3	-8.06	5.34e-13	3.36e-09	-0.7	-0.59	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.651	rs4759525	ENSG00000256299.1	RP11-989F5.3	-8.06	5.34e-13	3.36e-09	-0.7	-0.59	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.651	rs1554807	ENSG00000256299.1	RP11-989F5.3	8.06	5.34e-13	3.36e-09	0.7	0.59	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810821~130812622:-
TGCT	cis	rs858239	0.932	rs1728313	ENSG00000230658.1	KLHL7-AS1	8.06	5.34e-13	3.36e-09	0.61	0.59	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23101228~23105703:-
TGCT	cis	rs7301826	0.651	rs4759517	ENSG00000256299.1	RP11-989F5.3	-8.06	5.36e-13	3.37e-09	-0.7	-0.59	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.651	rs7971046	ENSG00000256299.1	RP11-989F5.3	-8.06	5.36e-13	3.37e-09	-0.7	-0.59	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.651	rs4759519	ENSG00000256299.1	RP11-989F5.3	-8.06	5.36e-13	3.37e-09	-0.7	-0.59	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.651	rs12228957	ENSG00000256299.1	RP11-989F5.3	-8.06	5.36e-13	3.37e-09	-0.7	-0.59	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.651	rs12228959	ENSG00000256299.1	RP11-989F5.3	-8.06	5.36e-13	3.37e-09	-0.7	-0.59	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810821~130812622:-
TGCT	cis	rs875971	0.522	rs1917563	ENSG00000226824.5	RP4-756H11.3	8.06	5.48e-13	3.42e-09	0.65	0.59	Aortic root size;	chr7:65950660	chr7:66654538~66669855:+
TGCT	cis	rs6452524	0.967	rs11741420	ENSG00000249664.1	CTD-2227C6.2	8.06	5.52e-13	3.44e-09	0.58	0.59	Hypertension (SNP x SNP interaction);	chr5:83174913	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs4401555	ENSG00000249664.1	CTD-2227C6.2	8.06	5.52e-13	3.44e-09	0.58	0.59	Hypertension (SNP x SNP interaction);	chr5:83175267	chr5:83012285~83013109:-
TGCT	cis	rs6921919	0.525	rs16894095	ENSG00000216901.1	AL022393.7	8.05	5.61e-13	3.48e-09	0.68	0.59	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28176188~28176674:+
TGCT	cis	rs2929278	0.589	rs11638972	ENSG00000205771.5	CATSPER2P1	8.05	5.67e-13	3.48e-09	0.64	0.59	Schizophrenia;	chr15:43782493	chr15:43726918~43747094:-
TGCT	cis	rs6921919	0.583	rs2071965	ENSG00000216901.1	AL022393.7	8.05	5.68e-13	3.48e-09	0.69	0.59	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28176188~28176674:+
TGCT	cis	rs2929278	0.617	rs4617832	ENSG00000205771.5	CATSPER2P1	8.05	5.74e-13	3.5e-09	0.65	0.59	Schizophrenia;	chr15:43738381	chr15:43726918~43747094:-
TGCT	cis	rs2929278	0.589	rs2411284	ENSG00000205771.5	CATSPER2P1	8.05	5.74e-13	3.5e-09	0.65	0.59	Schizophrenia;	chr15:43746701	chr15:43726918~43747094:-
TGCT	cis	rs6452524	0.901	rs2662238	ENSG00000249664.1	CTD-2227C6.2	8.05	5.84e-13	3.56e-09	0.59	0.59	Hypertension (SNP x SNP interaction);	chr5:83203488	chr5:83012285~83013109:-
TGCT	cis	rs11098499	0.954	rs4309825	ENSG00000245958.5	RP11-33B1.1	8.05	5.9e-13	3.59e-09	0.61	0.59	Corneal astigmatism;	chr4:119393726	chr4:119454791~119552025:+
TGCT	cis	rs875971	0.516	rs6945322	ENSG00000226824.5	RP4-756H11.3	-8.04	5.94e-13	3.61e-09	-0.65	-0.59	Aortic root size;	chr7:65871069	chr7:66654538~66669855:+
TGCT	cis	rs17711722	0.701	rs55773927	ENSG00000226824.5	RP4-756H11.3	-8.04	5.94e-13	3.61e-09	-0.65	-0.59	Calcium levels;	chr7:65872915	chr7:66654538~66669855:+
TGCT	cis	rs17711722	0.727	rs35850374	ENSG00000226824.5	RP4-756H11.3	-8.04	5.94e-13	3.61e-09	-0.65	-0.59	Calcium levels;	chr7:65892789	chr7:66654538~66669855:+
TGCT	cis	rs6921919	0.583	rs4642462	ENSG00000216901.1	AL022393.7	8.04	5.99e-13	3.64e-09	0.69	0.59	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28176188~28176674:+
TGCT	cis	rs875971	0.54	rs4717275	ENSG00000226824.5	RP4-756H11.3	8.04	6.01e-13	3.65e-09	0.65	0.59	Aortic root size;	chr7:65800193	chr7:66654538~66669855:+
TGCT	cis	rs17711722	0.701	rs4467826	ENSG00000226824.5	RP4-756H11.3	-8.04	6.01e-13	3.65e-09	-0.65	-0.59	Calcium levels;	chr7:65903721	chr7:66654538~66669855:+
TGCT	cis	rs17711722	1	rs17711722	ENSG00000226824.5	RP4-756H11.3	8.04	6.08e-13	3.69e-09	0.65	0.59	Calcium levels;	chr7:65806210	chr7:66654538~66669855:+
TGCT	cis	rs17711722	0.675	rs6947132	ENSG00000226824.5	RP4-756H11.3	8.04	6.08e-13	3.69e-09	0.65	0.59	Calcium levels;	chr7:65808508	chr7:66654538~66669855:+
TGCT	cis	rs6921919	0.583	rs3800328	ENSG00000216901.1	AL022393.7	8.04	6.11e-13	3.7e-09	0.69	0.59	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.609	rs67211468	ENSG00000216901.1	AL022393.7	8.04	6.11e-13	3.7e-09	0.69	0.59	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28176188~28176674:+
TGCT	cis	rs3814244	1	rs3814244	ENSG00000255733.4	IFNG-AS1	-8.04	6.15e-13	3.73e-09	-0.56	-0.59	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019691	chr12:67989445~68234686:+
TGCT	cis	rs858239	1	rs858239	ENSG00000230658.1	KLHL7-AS1	8.04	6.16e-13	3.73e-09	0.61	0.59	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23101228~23105703:-
TGCT	cis	rs7301826	0.651	rs2037789	ENSG00000256299.1	RP11-989F5.3	8.04	6.23e-13	3.77e-09	0.7	0.59	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810821~130812622:-
TGCT	cis	rs858239	0.896	rs1637192	ENSG00000230658.1	KLHL7-AS1	8.03	6.26e-13	3.79e-09	0.62	0.59	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23101228~23105703:-
TGCT	cis	rs1062177	1	rs2915877	ENSG00000253921.1	CTB-113P19.3	-8.03	6.28e-13	3.79e-09	-0.63	-0.59	Preschool internalizing problems;	chr5:151771040	chr5:151753992~151767247:+
TGCT	cis	rs1062177	1	rs2964576	ENSG00000253921.1	CTB-113P19.3	-8.03	6.28e-13	3.79e-09	-0.63	-0.59	Preschool internalizing problems;	chr5:151771041	chr5:151753992~151767247:+
TGCT	cis	rs1062177	1	rs6890099	ENSG00000253921.1	CTB-113P19.3	-8.03	6.28e-13	3.79e-09	-0.63	-0.59	Preschool internalizing problems;	chr5:151772401	chr5:151753992~151767247:+
TGCT	cis	rs1062177	0.906	rs2964573	ENSG00000253921.1	CTB-113P19.3	-8.03	6.28e-13	3.79e-09	-0.63	-0.59	Preschool internalizing problems;	chr5:151780561	chr5:151753992~151767247:+
TGCT	cis	rs1062177	1	rs2964571	ENSG00000253921.1	CTB-113P19.3	-8.03	6.28e-13	3.79e-09	-0.63	-0.59	Preschool internalizing problems;	chr5:151791695	chr5:151753992~151767247:+
TGCT	cis	rs1062177	1	rs2915869	ENSG00000253921.1	CTB-113P19.3	-8.03	6.28e-13	3.79e-09	-0.63	-0.59	Preschool internalizing problems;	chr5:151791948	chr5:151753992~151767247:+
TGCT	cis	rs7188445	0.932	rs73575083	ENSG00000261390.4	RP11-345M22.2	-8.03	6.34e-13	3.83e-09	-0.6	-0.58	Urate levels;	chr16:79713958	chr16:79715232~79770563:-
TGCT	cis	rs7188445	0.932	rs73575085	ENSG00000261390.4	RP11-345M22.2	-8.03	6.34e-13	3.83e-09	-0.6	-0.58	Urate levels;	chr16:79714179	chr16:79715232~79770563:-
TGCT	cis	rs7188445	0.932	rs73575086	ENSG00000261390.4	RP11-345M22.2	-8.03	6.34e-13	3.83e-09	-0.6	-0.58	Urate levels;	chr16:79714588	chr16:79715232~79770563:-
TGCT	cis	rs7188445	0.932	rs17689625	ENSG00000261390.4	RP11-345M22.2	-8.03	6.34e-13	3.83e-09	-0.6	-0.58	Urate levels;	chr16:79715065	chr16:79715232~79770563:-
TGCT	cis	rs7188445	0.836	rs3813580	ENSG00000261390.4	RP11-345M22.2	-8.03	6.34e-13	3.83e-09	-0.6	-0.58	Urate levels;	chr16:79715383	chr16:79715232~79770563:-
TGCT	cis	rs9326248	0.813	rs7115562	ENSG00000254851.1	RP11-109L13.1	-8.03	6.46e-13	3.89e-09	-0.87	-0.58	Blood protein levels;	chr11:117149754	chr11:117135528~117138582:+
TGCT	cis	rs847845	0.541	rs61732793	ENSG00000186328.4	RP11-140K17.2	8.03	6.46e-13	3.89e-09	1.23	0.58	Non-small cell lung cancer;	chr6:34859144	chr6:34715613~34715940:+
TGCT	cis	rs847845	0.614	rs17703197	ENSG00000186328.4	RP11-140K17.2	8.03	6.46e-13	3.89e-09	1.23	0.58	Non-small cell lung cancer;	chr6:34875173	chr6:34715613~34715940:+
TGCT	cis	rs847845	0.614	rs4646947	ENSG00000186328.4	RP11-140K17.2	8.03	6.46e-13	3.89e-09	1.23	0.58	Non-small cell lung cancer;	chr6:34878500	chr6:34715613~34715940:+
TGCT	cis	rs847845	0.614	rs17647222	ENSG00000186328.4	RP11-140K17.2	8.03	6.46e-13	3.89e-09	1.23	0.58	Non-small cell lung cancer;	chr6:34912692	chr6:34715613~34715940:+
TGCT	cis	rs847845	0.614	rs72894076	ENSG00000186328.4	RP11-140K17.2	8.03	6.46e-13	3.89e-09	1.23	0.58	Non-small cell lung cancer;	chr6:34921058	chr6:34715613~34715940:+
TGCT	cis	rs2739330	0.964	rs2739338	ENSG00000272787.1	KB-226F1.2	-8.03	6.47e-13	3.89e-09	-0.67	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23954943	chr22:23969211~23969873:+
TGCT	cis	rs2739330	0.615	rs2858911	ENSG00000272787.1	KB-226F1.2	-8.03	6.47e-13	3.89e-09	-0.67	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23955008	chr22:23969211~23969873:+
TGCT	cis	rs2739330	0.576	rs2858912	ENSG00000272787.1	KB-226F1.2	-8.03	6.47e-13	3.89e-09	-0.67	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23955010	chr22:23969211~23969873:+
TGCT	cis	rs916888	0.61	rs199436	ENSG00000214401.4	KANSL1-AS1	-8.03	6.49e-13	3.91e-09	-0.74	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46193576~46196723:+
TGCT	cis	rs6921919	0.583	rs4254981	ENSG00000216901.1	AL022393.7	8.03	6.51e-13	3.91e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.525	rs6929825	ENSG00000216901.1	AL022393.7	8.03	6.51e-13	3.91e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs35599905	ENSG00000216901.1	AL022393.7	8.03	6.51e-13	3.91e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs1124131	ENSG00000216901.1	AL022393.7	8.03	6.51e-13	3.91e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs6899389	ENSG00000216901.1	AL022393.7	8.03	6.51e-13	3.91e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs6922374	ENSG00000216901.1	AL022393.7	8.03	6.51e-13	3.91e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs6899603	ENSG00000216901.1	AL022393.7	8.03	6.51e-13	3.91e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs6922429	ENSG00000216901.1	AL022393.7	8.03	6.51e-13	3.91e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs6922169	ENSG00000216901.1	AL022393.7	8.03	6.51e-13	3.91e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.559	rs13210866	ENSG00000216901.1	AL022393.7	8.03	6.51e-13	3.91e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.609	rs36018474	ENSG00000216901.1	AL022393.7	8.03	6.51e-13	3.91e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs13201726	ENSG00000216901.1	AL022393.7	8.03	6.51e-13	3.91e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs2027361	ENSG00000216901.1	AL022393.7	8.03	6.51e-13	3.91e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28176188~28176674:+
TGCT	cis	rs2486288	0.656	rs2461705	ENSG00000259520.4	CTD-2651B20.3	8.03	6.53e-13	3.92e-09	0.5	0.58	Glomerular filtration rate;	chr15:45278043	chr15:45251580~45279251:-
TGCT	cis	rs1062177	0.951	rs2915876	ENSG00000253921.1	CTB-113P19.3	-8.03	6.56e-13	3.93e-09	-0.64	-0.58	Preschool internalizing problems;	chr5:151771184	chr5:151753992~151767247:+
TGCT	cis	rs2739330	1	rs2739330	ENSG00000272787.1	KB-226F1.2	-8.02	6.61e-13	3.96e-09	-0.67	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23953099	chr22:23969211~23969873:+
TGCT	cis	rs916888	0.779	rs199498	ENSG00000262539.1	RP11-259G18.3	8.02	6.67e-13	3.99e-09	0.9	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46259551~46260606:-
TGCT	cis	rs11098499	0.618	rs28491261	ENSG00000245958.5	RP11-33B1.1	-8.02	6.67e-13	3.99e-09	-0.6	-0.58	Corneal astigmatism;	chr4:119373745	chr4:119454791~119552025:+
TGCT	cis	rs7301826	0.61	rs7957899	ENSG00000256299.1	RP11-989F5.3	-8.02	6.68e-13	4e-09	-0.69	-0.58	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.651	rs1973834	ENSG00000256299.1	RP11-989F5.3	-8.02	6.68e-13	4e-09	-0.69	-0.58	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810821~130812622:-
TGCT	cis	rs6452524	0.967	rs2974445	ENSG00000249664.1	CTD-2227C6.2	-8.02	6.71e-13	4.01e-09	-0.57	-0.58	Hypertension (SNP x SNP interaction);	chr5:83185561	chr5:83012285~83013109:-
TGCT	cis	rs17361889	0.711	rs17358277	ENSG00000224683.1	RPL36AP29	8.02	6.74e-13	4.03e-09	0.69	0.58	Pediatric bone mineral content (hip);	chr7:16093695	chr7:16208945~16209265:+
TGCT	cis	rs17361889	0.596	rs17286418	ENSG00000224683.1	RPL36AP29	8.02	6.74e-13	4.03e-09	0.69	0.58	Pediatric bone mineral content (hip);	chr7:16097894	chr7:16208945~16209265:+
TGCT	cis	rs17361889	0.711	rs3857709	ENSG00000224683.1	RPL36AP29	8.02	6.74e-13	4.03e-09	0.69	0.58	Pediatric bone mineral content (hip);	chr7:16100477	chr7:16208945~16209265:+
TGCT	cis	rs17361889	0.685	rs62442360	ENSG00000224683.1	RPL36AP29	8.02	6.74e-13	4.03e-09	0.69	0.58	Pediatric bone mineral content (hip);	chr7:16103664	chr7:16208945~16209265:+
TGCT	cis	rs6452524	0.935	rs7736296	ENSG00000249664.1	CTD-2227C6.2	-8.02	6.8e-13	4.06e-09	-0.58	-0.58	Hypertension (SNP x SNP interaction);	chr5:83082421	chr5:83012285~83013109:-
TGCT	cis	rs858239	0.932	rs858272	ENSG00000230658.1	KLHL7-AS1	8.02	6.9e-13	4.12e-09	0.61	0.58	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23101228~23105703:-
TGCT	cis	rs6538678	0.864	rs10777749	ENSG00000258343.1	RP11-536G4.2	-8.02	6.94e-13	4.14e-09	-0.89	-0.58	Lupus nephritis in systemic lupus erythematosus;	chr12:95883182	chr12:95795345~95858839:-
TGCT	cis	rs11098499	0.754	rs9991959	ENSG00000245958.5	RP11-33B1.1	8.01	6.96e-13	4.15e-09	0.59	0.58	Corneal astigmatism;	chr4:119332618	chr4:119454791~119552025:+
TGCT	cis	rs2929278	0.617	rs12908467	ENSG00000205771.5	CATSPER2P1	8.01	7.02e-13	4.18e-09	0.65	0.58	Schizophrenia;	chr15:43755232	chr15:43726918~43747094:-
TGCT	cis	rs2882667	0.964	rs12108892	ENSG00000253404.1	AC034243.1	8.01	7.1e-13	4.22e-09	0.67	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138963941	chr5:138744434~138753309:-
TGCT	cis	rs5769707	0.749	rs8137251	ENSG00000188511.11	C22orf34	8.01	7.16e-13	4.26e-09	0.61	0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49643021	chr22:49414524~49657542:-
TGCT	cis	rs977987	0.705	rs4888377	ENSG00000261783.1	RP11-252K23.2	-8.01	7.21e-13	4.28e-09	-0.86	-0.58	Dupuytren's disease;	chr16:75291788	chr16:75379818~75381260:-
TGCT	cis	rs4423214	1	rs3794060	ENSG00000254682.1	RP11-660L16.2	8.01	7.22e-13	4.29e-09	0.78	0.58	Vitamin D levels;	chr11:71476633	chr11:71448674~71452157:+
TGCT	cis	rs11098499	0.863	rs9997631	ENSG00000245958.5	RP11-33B1.1	-8	7.42e-13	4.4e-09	-0.62	-0.58	Corneal astigmatism;	chr4:119548840	chr4:119454791~119552025:+
TGCT	cis	rs1355223	0.902	rs12801509	ENSG00000271369.1	RP11-350D17.3	-8	7.44e-13	4.41e-09	-0.56	-0.58	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34725789	chr11:34709600~34710161:+
TGCT	cis	rs2486288	0.656	rs9921025	ENSG00000259520.4	CTD-2651B20.3	8	7.49e-13	4.42e-09	0.48	0.58	Glomerular filtration rate;	chr15:45254404	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs11629807	ENSG00000259520.4	CTD-2651B20.3	8	7.49e-13	4.42e-09	0.48	0.58	Glomerular filtration rate;	chr15:45254839	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.587	rs12899942	ENSG00000259520.4	CTD-2651B20.3	8	7.49e-13	4.42e-09	0.48	0.58	Glomerular filtration rate;	chr15:45255082	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs12899058	ENSG00000259520.4	CTD-2651B20.3	8	7.49e-13	4.42e-09	0.48	0.58	Glomerular filtration rate;	chr15:45255126	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs12904150	ENSG00000259520.4	CTD-2651B20.3	8	7.49e-13	4.42e-09	0.48	0.58	Glomerular filtration rate;	chr15:45255407	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs9920290	ENSG00000259520.4	CTD-2651B20.3	8	7.49e-13	4.42e-09	0.48	0.58	Glomerular filtration rate;	chr15:45255837	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs11854325	ENSG00000259520.4	CTD-2651B20.3	8	7.49e-13	4.42e-09	0.48	0.58	Glomerular filtration rate;	chr15:45256761	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs2413774	ENSG00000259520.4	CTD-2651B20.3	8	7.49e-13	4.42e-09	0.48	0.58	Glomerular filtration rate;	chr15:45257225	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs2413773	ENSG00000259520.4	CTD-2651B20.3	8	7.49e-13	4.42e-09	0.48	0.58	Glomerular filtration rate;	chr15:45257244	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs11632724	ENSG00000259520.4	CTD-2651B20.3	8	7.49e-13	4.42e-09	0.48	0.58	Glomerular filtration rate;	chr15:45258593	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs11632651	ENSG00000259520.4	CTD-2651B20.3	8	7.49e-13	4.42e-09	0.48	0.58	Glomerular filtration rate;	chr15:45258640	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs11637920	ENSG00000259520.4	CTD-2651B20.3	8	7.49e-13	4.42e-09	0.48	0.58	Glomerular filtration rate;	chr15:45258707	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs11632777	ENSG00000259520.4	CTD-2651B20.3	8	7.49e-13	4.42e-09	0.48	0.58	Glomerular filtration rate;	chr15:45258847	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs11632778	ENSG00000259520.4	CTD-2651B20.3	8	7.49e-13	4.42e-09	0.48	0.58	Glomerular filtration rate;	chr15:45258858	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs11632752	ENSG00000259520.4	CTD-2651B20.3	8	7.49e-13	4.42e-09	0.48	0.58	Glomerular filtration rate;	chr15:45258942	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs12911186	ENSG00000259520.4	CTD-2651B20.3	8	7.49e-13	4.42e-09	0.48	0.58	Glomerular filtration rate;	chr15:45259225	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs12915314	ENSG00000259520.4	CTD-2651B20.3	8	7.49e-13	4.42e-09	0.48	0.58	Glomerular filtration rate;	chr15:45259293	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs8039138	ENSG00000259520.4	CTD-2651B20.3	8	7.49e-13	4.42e-09	0.48	0.58	Glomerular filtration rate;	chr15:45259394	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs8039540	ENSG00000259520.4	CTD-2651B20.3	8	7.49e-13	4.42e-09	0.48	0.58	Glomerular filtration rate;	chr15:45259644	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs8040185	ENSG00000259520.4	CTD-2651B20.3	8	7.49e-13	4.42e-09	0.48	0.58	Glomerular filtration rate;	chr15:45259883	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs8039354	ENSG00000259520.4	CTD-2651B20.3	-8	7.49e-13	4.42e-09	-0.48	-0.58	Glomerular filtration rate;	chr15:45259558	chr15:45251580~45279251:-
TGCT	cis	rs1062177	1	rs1062177	ENSG00000253921.1	CTB-113P19.3	-8	7.53e-13	4.45e-09	-0.64	-0.58	Preschool internalizing problems;	chr5:151805140	chr5:151753992~151767247:+
TGCT	cis	rs7188445	0.932	rs17767904	ENSG00000261390.4	RP11-345M22.2	-8	7.58e-13	4.47e-09	-0.59	-0.58	Urate levels;	chr16:79716078	chr16:79715232~79770563:-
TGCT	cis	rs7188445	0.932	rs73575095	ENSG00000261390.4	RP11-345M22.2	-8	7.58e-13	4.47e-09	-0.59	-0.58	Urate levels;	chr16:79716435	chr16:79715232~79770563:-
TGCT	cis	rs1355223	0.816	rs2136506	ENSG00000271369.1	RP11-350D17.3	-8	7.68e-13	4.53e-09	-0.56	-0.58	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34726713	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.902	rs10501134	ENSG00000271369.1	RP11-350D17.3	-8	7.68e-13	4.53e-09	-0.56	-0.58	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34727590	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.902	rs7130325	ENSG00000271369.1	RP11-350D17.3	-8	7.68e-13	4.53e-09	-0.56	-0.58	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34729412	chr11:34709600~34710161:+
TGCT	cis	rs1062177	0.826	rs2915822	ENSG00000253921.1	CTB-113P19.3	8	7.69e-13	4.54e-09	0.62	0.58	Preschool internalizing problems;	chr5:151751340	chr5:151753992~151767247:+
TGCT	cis	rs1062177	0.756	rs2915815	ENSG00000253921.1	CTB-113P19.3	7.99	7.8e-13	4.6e-09	0.64	0.58	Preschool internalizing problems;	chr5:151736322	chr5:151753992~151767247:+
TGCT	cis	rs1355223	0.867	rs7943755	ENSG00000271369.1	RP11-350D17.3	-7.99	7.85e-13	4.62e-09	-0.55	-0.58	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34669904	chr11:34709600~34710161:+
TGCT	cis	rs7174755	0.961	rs12148843	ENSG00000260657.2	RP11-315D16.4	7.99	7.95e-13	4.68e-09	0.6	0.58	Major depressive disorder;	chr15:68302184	chr15:68267792~68277994:-
TGCT	cis	rs7174755	0.961	rs1122247	ENSG00000260657.2	RP11-315D16.4	7.99	7.95e-13	4.68e-09	0.6	0.58	Major depressive disorder;	chr15:68302523	chr15:68267792~68277994:-
TGCT	cis	rs7174755	0.961	rs11631030	ENSG00000260657.2	RP11-315D16.4	7.99	7.95e-13	4.68e-09	0.6	0.58	Major depressive disorder;	chr15:68303463	chr15:68267792~68277994:-
TGCT	cis	rs6921919	0.583	rs9461459	ENSG00000216901.1	AL022393.7	7.99	7.99e-13	4.69e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs28360638	ENSG00000216901.1	AL022393.7	7.99	7.99e-13	4.69e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs16894060	ENSG00000216901.1	AL022393.7	7.99	7.99e-13	4.69e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs9468368	ENSG00000216901.1	AL022393.7	7.99	7.99e-13	4.69e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.609	rs1005127	ENSG00000216901.1	AL022393.7	7.99	7.99e-13	4.69e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28176188~28176674:+
TGCT	cis	rs853679	0.515	rs4580862	ENSG00000216901.1	AL022393.7	7.99	7.99e-13	4.69e-09	0.69	0.58	Depression;	chr6:28399886	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs4357130	ENSG00000216901.1	AL022393.7	7.99	7.99e-13	4.69e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs11755942	ENSG00000216901.1	AL022393.7	7.99	7.99e-13	4.69e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs6907950	ENSG00000216901.1	AL022393.7	7.99	7.99e-13	4.69e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28176188~28176674:+
TGCT	cis	rs916888	0.61	rs142167	ENSG00000214401.4	KANSL1-AS1	-7.99	8.09e-13	4.75e-09	-0.76	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46193576~46196723:+
TGCT	cis	rs6921919	0.583	rs3734563	ENSG00000216901.1	AL022393.7	7.98	8.24e-13	4.83e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs1591913	ENSG00000216901.1	AL022393.7	7.98	8.24e-13	4.83e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs6928771	ENSG00000216901.1	AL022393.7	7.98	8.33e-13	4.88e-09	0.68	0.58	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs6928773	ENSG00000216901.1	AL022393.7	7.98	8.33e-13	4.88e-09	0.68	0.58	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28176188~28176674:+
TGCT	cis	rs11098499	0.663	rs9996501	ENSG00000245958.5	RP11-33B1.1	-7.98	8.46e-13	4.95e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119317763	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.697	rs28458294	ENSG00000245958.5	RP11-33B1.1	-7.98	8.46e-13	4.95e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119317769	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.663	rs28369503	ENSG00000245958.5	RP11-33B1.1	-7.98	8.46e-13	4.95e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119317770	chr4:119454791~119552025:+
TGCT	cis	rs7188445	0.899	rs17689024	ENSG00000261390.4	RP11-345M22.2	-7.98	8.51e-13	4.98e-09	-0.6	-0.58	Urate levels;	chr16:79706081	chr16:79715232~79770563:-
TGCT	cis	rs2729354	0.953	rs1846567	ENSG00000265566.2	RN7SL605P	-7.98	8.52e-13	4.98e-09	-0.74	-0.58	Blood protein levels;	chr11:57590120	chr11:57528085~57528365:-
TGCT	cis	rs62388641	0.813	rs62390562	ENSG00000272279.1	RP11-157J24.2	7.98	8.6e-13	5.02e-09	0.67	0.58	Daytime sleep phenotypes;	chr6:1551467	chr6:1528364~1528911:-
TGCT	cis	rs62388641	0.813	rs34114087	ENSG00000272279.1	RP11-157J24.2	7.97	8.71e-13	5.08e-09	0.65	0.58	Daytime sleep phenotypes;	chr6:1553203	chr6:1528364~1528911:-
TGCT	cis	rs1355223	0.833	rs286885	ENSG00000271369.1	RP11-350D17.3	7.97	8.78e-13	5.12e-09	0.57	0.58	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34665799	chr11:34709600~34710161:+
TGCT	cis	rs1062177	1	rs62394155	ENSG00000213433.5	RPLP1P6	-7.97	8.78e-13	5.12e-09	-0.64	-0.58	Preschool internalizing problems;	chr5:151868508	chr5:151765859~151766378:-
TGCT	cis	rs2929278	0.617	rs663214	ENSG00000205771.5	CATSPER2P1	7.97	8.84e-13	5.15e-09	0.65	0.58	Schizophrenia;	chr15:43821584	chr15:43726918~43747094:-
TGCT	cis	rs1775715	0.87	rs11008700	ENSG00000239731.3	RN7SL825P	-7.97	8.86e-13	5.15e-09	-0.58	-0.58	Bipolar disorder with mood-incongruent psychosis;	chr10:31948009	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.835	rs11008701	ENSG00000239731.3	RN7SL825P	-7.97	8.86e-13	5.15e-09	-0.58	-0.58	Bipolar disorder with mood-incongruent psychosis;	chr10:31952168	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.87	rs11008702	ENSG00000239731.3	RN7SL825P	-7.97	8.86e-13	5.15e-09	-0.58	-0.58	Bipolar disorder with mood-incongruent psychosis;	chr10:31955890	chr10:31992087~31992381:-
TGCT	cis	rs977987	0.931	rs11641430	ENSG00000261783.1	RP11-252K23.2	-7.97	8.94e-13	5.2e-09	-0.83	-0.58	Dupuytren's disease;	chr16:75461378	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.931	rs7195161	ENSG00000261783.1	RP11-252K23.2	-7.97	8.94e-13	5.2e-09	-0.83	-0.58	Dupuytren's disease;	chr16:75461674	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.931	rs1424013	ENSG00000261783.1	RP11-252K23.2	-7.97	8.94e-13	5.2e-09	-0.83	-0.58	Dupuytren's disease;	chr16:75462088	chr16:75379818~75381260:-
TGCT	cis	rs11098499	0.754	rs1849457	ENSG00000245958.5	RP11-33B1.1	-7.97	9.02e-13	5.24e-09	-0.6	-0.58	Corneal astigmatism;	chr4:119333200	chr4:119454791~119552025:+
TGCT	cis	rs1577917	1	rs1962716	ENSG00000203875.9	SNHG5	-7.97	9.06e-13	5.26e-09	-0.79	-0.58	Response to antipsychotic treatment;	chr6:85938718	chr6:85660950~85678736:-
TGCT	cis	rs6921919	0.583	rs7759191	ENSG00000216901.1	AL022393.7	7.96	9.13e-13	5.3e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs7764737	ENSG00000216901.1	AL022393.7	7.96	9.13e-13	5.3e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs9461458	ENSG00000216901.1	AL022393.7	7.96	9.13e-13	5.3e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.609	rs9468365	ENSG00000216901.1	AL022393.7	7.96	9.13e-13	5.3e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs1361385	ENSG00000216901.1	AL022393.7	7.96	9.13e-13	5.3e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs1416918	ENSG00000216901.1	AL022393.7	7.96	9.13e-13	5.3e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.583	rs9468367	ENSG00000216901.1	AL022393.7	7.96	9.13e-13	5.3e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28176188~28176674:+
TGCT	cis	rs977987	0.864	rs40446	ENSG00000261783.1	RP11-252K23.2	7.96	9.17e-13	5.31e-09	0.87	0.58	Dupuytren's disease;	chr16:75462760	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.864	rs37593	ENSG00000261783.1	RP11-252K23.2	7.96	9.17e-13	5.31e-09	0.87	0.58	Dupuytren's disease;	chr16:75463009	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.864	rs37594	ENSG00000261783.1	RP11-252K23.2	7.96	9.17e-13	5.31e-09	0.87	0.58	Dupuytren's disease;	chr16:75463045	chr16:75379818~75381260:-
TGCT	cis	rs17361889	0.698	rs1528136	ENSG00000224683.1	RPL36AP29	-7.96	9.23e-13	5.35e-09	-0.68	-0.58	Pediatric bone mineral content (hip);	chr7:16090018	chr7:16208945~16209265:+
TGCT	cis	rs2486288	0.656	rs12911861	ENSG00000259520.4	CTD-2651B20.3	7.96	9.37e-13	5.43e-09	0.51	0.58	Glomerular filtration rate;	chr15:45274520	chr15:45251580~45279251:-
TGCT	cis	rs875971	0.54	rs781152	ENSG00000226824.5	RP4-756H11.3	-7.96	9.44e-13	5.46e-09	-0.66	-0.58	Aortic root size;	chr7:66014585	chr7:66654538~66669855:+
TGCT	cis	rs17711722	0.727	rs781151	ENSG00000226824.5	RP4-756H11.3	-7.96	9.44e-13	5.46e-09	-0.66	-0.58	Calcium levels;	chr7:66014891	chr7:66654538~66669855:+
TGCT	cis	rs5769707	0.967	rs9616713	ENSG00000188511.11	C22orf34	7.96	9.5e-13	5.49e-09	0.55	0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49655461	chr22:49414524~49657542:-
TGCT	cis	rs7188445	0.899	rs57652769	ENSG00000261390.4	RP11-345M22.2	-7.96	9.52e-13	5.5e-09	-0.59	-0.58	Urate levels;	chr16:79720079	chr16:79715232~79770563:-
TGCT	cis	rs7188445	0.932	rs4575545	ENSG00000261390.4	RP11-345M22.2	-7.96	9.52e-13	5.5e-09	-0.59	-0.58	Urate levels;	chr16:79721549	chr16:79715232~79770563:-
TGCT	cis	rs5769707	0.749	rs7286706	ENSG00000188511.11	C22orf34	7.96	9.57e-13	5.53e-09	0.56	0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49664698	chr22:49414524~49657542:-
TGCT	cis	rs4423214	1	rs909217	ENSG00000254682.1	RP11-660L16.2	7.95	9.83e-13	5.67e-09	0.78	0.58	Vitamin D levels;	chr11:71435531	chr11:71448674~71452157:+
TGCT	cis	rs2283792	0.935	rs5750113	ENSG00000228050.1	TOP3BP1	7.95	9.9e-13	5.71e-09	0.68	0.58	Multiple sclerosis;	chr22:21865784	chr22:22223187~22224566:-
TGCT	cis	rs1355223	0.867	rs1869360	ENSG00000271369.1	RP11-350D17.3	-7.95	1e-12	5.77e-09	-0.55	-0.58	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34677043	chr11:34709600~34710161:+
TGCT	cis	rs11098499	0.863	rs10018280	ENSG00000245958.5	RP11-33B1.1	-7.94	1.01e-12	5.81e-09	-0.61	-0.58	Corneal astigmatism;	chr4:119556984	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs6534141	ENSG00000245958.5	RP11-33B1.1	-7.94	1.01e-12	5.81e-09	-0.61	-0.58	Corneal astigmatism;	chr4:119564068	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs2127823	ENSG00000245958.5	RP11-33B1.1	-7.94	1.01e-12	5.81e-09	-0.61	-0.58	Corneal astigmatism;	chr4:119564515	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs3775858	ENSG00000245958.5	RP11-33B1.1	-7.94	1.01e-12	5.81e-09	-0.61	-0.58	Corneal astigmatism;	chr4:119564873	chr4:119454791~119552025:+
TGCT	cis	rs4423214	1	rs12790010	ENSG00000254682.1	RP11-660L16.2	7.94	1.02e-12	5.85e-09	0.78	0.58	Vitamin D levels;	chr11:71459607	chr11:71448674~71452157:+
TGCT	cis	rs4423214	1	rs12806844	ENSG00000254682.1	RP11-660L16.2	7.94	1.02e-12	5.85e-09	0.78	0.58	Vitamin D levels;	chr11:71459724	chr11:71448674~71452157:+
TGCT	cis	rs4423214	1	rs12808368	ENSG00000254682.1	RP11-660L16.2	7.94	1.02e-12	5.85e-09	0.78	0.58	Vitamin D levels;	chr11:71459771	chr11:71448674~71452157:+
TGCT	cis	rs4423214	1	rs12790558	ENSG00000254682.1	RP11-660L16.2	7.94	1.02e-12	5.85e-09	0.78	0.58	Vitamin D levels;	chr11:71459859	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.959	rs11233747	ENSG00000254682.1	RP11-660L16.2	7.94	1.02e-12	5.85e-09	0.78	0.58	Vitamin D levels;	chr11:71460596	chr11:71448674~71452157:+
TGCT	cis	rs4423214	1	rs11600569	ENSG00000254682.1	RP11-660L16.2	7.94	1.02e-12	5.85e-09	0.78	0.58	Vitamin D levels;	chr11:71462701	chr11:71448674~71452157:+
TGCT	cis	rs1062177	1	rs41494545	ENSG00000253921.1	CTB-113P19.3	7.94	1.05e-12	6.03e-09	0.63	0.58	Preschool internalizing problems;	chr5:151855533	chr5:151753992~151767247:+
TGCT	cis	rs7301826	0.651	rs4514465	ENSG00000256299.1	RP11-989F5.3	-7.94	1.06e-12	6.08e-09	-0.69	-0.58	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810821~130812622:-
TGCT	cis	rs2729354	0.903	rs1846568	ENSG00000265566.2	RN7SL605P	-7.93	1.07e-12	6.13e-09	-0.7	-0.58	Blood protein levels;	chr11:57590241	chr11:57528085~57528365:-
TGCT	cis	rs858239	0.899	rs858271	ENSG00000230658.1	KLHL7-AS1	7.93	1.07e-12	6.16e-09	0.6	0.58	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23101228~23105703:-
TGCT	cis	rs858239	1	rs858240	ENSG00000230658.1	KLHL7-AS1	7.93	1.07e-12	6.16e-09	0.6	0.58	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23101228~23105703:-
TGCT	cis	rs1062177	1	rs17804178	ENSG00000253921.1	CTB-113P19.3	-7.93	1.08e-12	6.18e-09	-0.63	-0.58	Preschool internalizing problems;	chr5:151818168	chr5:151753992~151767247:+
TGCT	cis	rs1062177	1	rs2964612	ENSG00000253921.1	CTB-113P19.3	-7.93	1.08e-12	6.18e-09	-0.63	-0.58	Preschool internalizing problems;	chr5:151819189	chr5:151753992~151767247:+
TGCT	cis	rs1062177	1	rs12518722	ENSG00000253921.1	CTB-113P19.3	-7.93	1.08e-12	6.18e-09	-0.63	-0.58	Preschool internalizing problems;	chr5:151851899	chr5:151753992~151767247:+
TGCT	cis	rs1062177	1	rs72802204	ENSG00000253921.1	CTB-113P19.3	-7.93	1.09e-12	6.21e-09	-0.63	-0.58	Preschool internalizing problems;	chr5:151803622	chr5:151753992~151767247:+
TGCT	cis	rs2929278	0.617	rs533143	ENSG00000205771.5	CATSPER2P1	-7.93	1.1e-12	6.31e-09	-0.65	-0.58	Schizophrenia;	chr15:43896656	chr15:43726918~43747094:-
TGCT	cis	rs6538678	0.864	rs10777747	ENSG00000258343.1	RP11-536G4.2	-7.92	1.14e-12	6.49e-09	-0.88	-0.58	Lupus nephritis in systemic lupus erythematosus;	chr12:95870192	chr12:95795345~95858839:-
TGCT	cis	rs11098499	0.954	rs59866101	ENSG00000245958.5	RP11-33B1.1	-7.92	1.14e-12	6.49e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119375436	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.618	rs6858383	ENSG00000245958.5	RP11-33B1.1	-7.92	1.14e-12	6.49e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119375617	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.697	rs6832410	ENSG00000245958.5	RP11-33B1.1	-7.92	1.14e-12	6.49e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119375645	chr4:119454791~119552025:+
TGCT	cis	rs1355223	0.623	rs286878	ENSG00000271369.1	RP11-350D17.3	-7.92	1.14e-12	6.5e-09	-0.58	-0.58	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34673309	chr11:34709600~34710161:+
TGCT	cis	rs1930961	1	rs1930961	ENSG00000272977.1	CTA-390C10.10	-7.92	1.14e-12	6.51e-09	-0.73	-0.58	Bipolar disorder with mood-incongruent psychosis;	chr22:25479298	chr22:25476218~25479971:+
TGCT	cis	rs17711722	0.74	rs7809991	ENSG00000226824.5	RP4-756H11.3	-7.92	1.14e-12	6.52e-09	-0.65	-0.58	Calcium levels;	chr7:65941231	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.522	rs6960048	ENSG00000226824.5	RP4-756H11.3	-7.92	1.14e-12	6.52e-09	-0.65	-0.58	Aortic root size;	chr7:65943052	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.522	rs10807697	ENSG00000226824.5	RP4-756H11.3	-7.92	1.14e-12	6.52e-09	-0.65	-0.58	Aortic root size;	chr7:65951183	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.522	rs4718285	ENSG00000226824.5	RP4-756H11.3	-7.92	1.15e-12	6.55e-09	-0.64	-0.58	Aortic root size;	chr7:65827018	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.522	rs4718286	ENSG00000226824.5	RP4-756H11.3	-7.92	1.15e-12	6.55e-09	-0.64	-0.58	Aortic root size;	chr7:65827777	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.522	rs4502988	ENSG00000226824.5	RP4-756H11.3	-7.92	1.15e-12	6.55e-09	-0.64	-0.58	Aortic root size;	chr7:65832759	chr7:66654538~66669855:+
TGCT	cis	rs17711722	0.585	rs6942660	ENSG00000226824.5	RP4-756H11.3	-7.92	1.15e-12	6.55e-09	-0.64	-0.58	Calcium levels;	chr7:65837419	chr7:66654538~66669855:+
TGCT	cis	rs17711722	0.64	rs13237956	ENSG00000226824.5	RP4-756H11.3	-7.92	1.15e-12	6.55e-09	-0.64	-0.58	Calcium levels;	chr7:65853042	chr7:66654538~66669855:+
TGCT	cis	rs977987	0.966	rs6564261	ENSG00000261783.1	RP11-252K23.2	-7.92	1.15e-12	6.57e-09	-0.82	-0.58	Dupuytren's disease;	chr16:75458344	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.902	rs34539062	ENSG00000261783.1	RP11-252K23.2	-7.92	1.17e-12	6.63e-09	-0.83	-0.58	Dupuytren's disease;	chr16:75459381	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.866	rs17696831	ENSG00000261783.1	RP11-252K23.2	-7.92	1.17e-12	6.63e-09	-0.83	-0.58	Dupuytren's disease;	chr16:75459400	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.898	rs12918797	ENSG00000261783.1	RP11-252K23.2	-7.92	1.17e-12	6.63e-09	-0.83	-0.58	Dupuytren's disease;	chr16:75459912	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.898	rs12918974	ENSG00000261783.1	RP11-252K23.2	-7.92	1.17e-12	6.63e-09	-0.83	-0.58	Dupuytren's disease;	chr16:75460045	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.866	rs12932606	ENSG00000261783.1	RP11-252K23.2	-7.92	1.17e-12	6.63e-09	-0.83	-0.58	Dupuytren's disease;	chr16:75460046	chr16:75379818~75381260:-
TGCT	cis	rs6597981	0.675	rs4963120	ENSG00000279672.1	CMB9-55F22.1	-7.92	1.17e-12	6.67e-09	-0.64	-0.58	Breast cancer;	chr11:825777	chr11:779617~780755:+
TGCT	cis	rs7301826	0.651	rs7968675	ENSG00000256299.1	RP11-989F5.3	-7.92	1.18e-12	6.71e-09	-0.7	-0.58	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810821~130812622:-
TGCT	cis	rs6921919	0.583	rs6908137	ENSG00000216901.1	AL022393.7	7.91	1.2e-12	6.76e-09	0.69	0.58	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28176188~28176674:+
TGCT	cis	rs11098499	0.865	rs1112817	ENSG00000245958.5	RP11-33B1.1	-7.91	1.21e-12	6.76e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119376645	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.779	rs10016060	ENSG00000245958.5	RP11-33B1.1	-7.91	1.21e-12	6.76e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119377257	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs10005644	ENSG00000245958.5	RP11-33B1.1	-7.91	1.21e-12	6.76e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119377322	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.697	rs10016448	ENSG00000245958.5	RP11-33B1.1	-7.91	1.21e-12	6.76e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119377690	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.657	rs9996569	ENSG00000245958.5	RP11-33B1.1	-7.91	1.21e-12	6.76e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119377849	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.908	rs11729050	ENSG00000245958.5	RP11-33B1.1	-7.91	1.21e-12	6.76e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119378911	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs28429722	ENSG00000245958.5	RP11-33B1.1	-7.91	1.21e-12	6.76e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119378938	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs10014845	ENSG00000245958.5	RP11-33B1.1	-7.91	1.21e-12	6.76e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119379922	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.779	rs7674500	ENSG00000245958.5	RP11-33B1.1	-7.91	1.21e-12	6.76e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119382438	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.909	rs28884220	ENSG00000245958.5	RP11-33B1.1	-7.91	1.21e-12	6.76e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119386056	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.909	rs28793658	ENSG00000245958.5	RP11-33B1.1	-7.91	1.21e-12	6.76e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119386059	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.865	rs4507344	ENSG00000245958.5	RP11-33B1.1	-7.91	1.21e-12	6.76e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119386330	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.697	rs4373140	ENSG00000245958.5	RP11-33B1.1	-7.91	1.21e-12	6.76e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119386543	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs13113483	ENSG00000245958.5	RP11-33B1.1	-7.91	1.21e-12	6.76e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119387884	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.542	rs10440343	ENSG00000245958.5	RP11-33B1.1	-7.91	1.21e-12	6.76e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119388632	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.909	rs28668716	ENSG00000245958.5	RP11-33B1.1	-7.91	1.21e-12	6.76e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119388720	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.779	rs10011097	ENSG00000245958.5	RP11-33B1.1	-7.91	1.21e-12	6.76e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119389204	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.542	rs7677836	ENSG00000245958.5	RP11-33B1.1	-7.91	1.21e-12	6.76e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119389483	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.909	rs10002083	ENSG00000245958.5	RP11-33B1.1	-7.91	1.21e-12	6.76e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119389997	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs10024844	ENSG00000245958.5	RP11-33B1.1	-7.91	1.21e-12	6.76e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119390373	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs4345162	ENSG00000245958.5	RP11-33B1.1	-7.91	1.21e-12	6.76e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119391804	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.657	rs4463052	ENSG00000245958.5	RP11-33B1.1	-7.91	1.21e-12	6.76e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119392103	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.697	rs4560394	ENSG00000245958.5	RP11-33B1.1	-7.91	1.21e-12	6.76e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119392280	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs13151285	ENSG00000245958.5	RP11-33B1.1	-7.91	1.21e-12	6.76e-09	-0.59	-0.58	Corneal astigmatism;	chr4:119393586	chr4:119454791~119552025:+
TGCT	cis	rs2470135	1	rs2470135	ENSG00000205771.5	CATSPER2P1	-7.91	1.22e-12	6.84e-09	-0.66	-0.58	Diastolic blood pressure;	chr15:43703591	chr15:43726918~43747094:-
TGCT	cis	rs7301826	0.603	rs7975825	ENSG00000256299.1	RP11-989F5.3	-7.91	1.25e-12	6.96e-09	-0.68	-0.58	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810821~130812622:-
TGCT	cis	rs875971	0.522	rs7784623	ENSG00000226824.5	RP4-756H11.3	-7.91	1.25e-12	6.98e-09	-0.65	-0.58	Aortic root size;	chr7:65930047	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.522	rs34973832	ENSG00000226824.5	RP4-756H11.3	-7.91	1.25e-12	6.98e-09	-0.65	-0.58	Aortic root size;	chr7:65931217	chr7:66654538~66669855:+
TGCT	cis	rs950027	0.549	rs12909409	ENSG00000259520.4	CTD-2651B20.3	7.9	1.25e-12	7e-09	0.48	0.58	Response to fenofibrate (adiponectin levels);	chr15:45316384	chr15:45251580~45279251:-
TGCT	cis	rs950027	0.572	rs12910764	ENSG00000259520.4	CTD-2651B20.3	7.9	1.25e-12	7e-09	0.48	0.58	Response to fenofibrate (adiponectin levels);	chr15:45317162	chr15:45251580~45279251:-
TGCT	cis	rs2929278	0.588	rs1975364	ENSG00000205771.5	CATSPER2P1	-7.9	1.28e-12	7.15e-09	-0.65	-0.58	Schizophrenia;	chr15:43857991	chr15:43726918~43747094:-
TGCT	cis	rs2929278	0.546	rs686666	ENSG00000205771.5	CATSPER2P1	-7.9	1.28e-12	7.15e-09	-0.65	-0.58	Schizophrenia;	chr15:43869352	chr15:43726918~43747094:-
TGCT	cis	rs1062177	1	rs2915887	ENSG00000253921.1	CTB-113P19.3	-7.9	1.3e-12	7.22e-09	-0.63	-0.58	Preschool internalizing problems;	chr5:151825943	chr5:151753992~151767247:+
TGCT	cis	rs1062177	1	rs62377945	ENSG00000253921.1	CTB-113P19.3	-7.9	1.3e-12	7.22e-09	-0.63	-0.58	Preschool internalizing problems;	chr5:151828443	chr5:151753992~151767247:+
TGCT	cis	rs1062177	1	rs12515762	ENSG00000253921.1	CTB-113P19.3	-7.9	1.3e-12	7.22e-09	-0.63	-0.58	Preschool internalizing problems;	chr5:151830361	chr5:151753992~151767247:+
TGCT	cis	rs17711722	0.727	rs2658585	ENSG00000226824.5	RP4-756H11.3	-7.89	1.32e-12	7.34e-09	-0.66	-0.58	Calcium levels;	chr7:65996954	chr7:66654538~66669855:+
TGCT	cis	rs7188445	1	rs11150190	ENSG00000261390.4	RP11-345M22.2	-7.89	1.34e-12	7.45e-09	-0.57	-0.58	Urate levels;	chr16:79700352	chr16:79715232~79770563:-
TGCT	cis	rs5769707	0.904	rs7288869	ENSG00000188511.11	C22orf34	7.89	1.35e-12	7.53e-09	0.55	0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49621679	chr22:49414524~49657542:-
TGCT	cis	rs1062177	0.826	rs2915879	ENSG00000253921.1	CTB-113P19.3	-7.89	1.37e-12	7.63e-09	-0.61	-0.58	Preschool internalizing problems;	chr5:151767881	chr5:151753992~151767247:+
TGCT	cis	rs875971	0.522	rs2008188	ENSG00000226824.5	RP4-756H11.3	-7.88	1.4e-12	7.73e-09	-0.66	-0.58	Aortic root size;	chr7:65964026	chr7:66654538~66669855:+
TGCT	cis	rs17711722	0.727	rs1880555	ENSG00000226824.5	RP4-756H11.3	-7.88	1.4e-12	7.73e-09	-0.66	-0.58	Calcium levels;	chr7:65967580	chr7:66654538~66669855:+
TGCT	cis	rs17711722	0.701	rs781143	ENSG00000226824.5	RP4-756H11.3	-7.88	1.4e-12	7.73e-09	-0.66	-0.58	Calcium levels;	chr7:65974892	chr7:66654538~66669855:+
TGCT	cis	rs17711722	0.701	rs781145	ENSG00000226824.5	RP4-756H11.3	-7.88	1.4e-12	7.73e-09	-0.66	-0.58	Calcium levels;	chr7:65975383	chr7:66654538~66669855:+
TGCT	cis	rs1155848	0.892	rs9565508	ENSG00000227354.5	RBM26-AS1	7.88	1.4e-12	7.76e-09	0.96	0.58	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79482451	chr13:79406309~79424328:+
TGCT	cis	rs6700559	1	rs6700559	ENSG00000260088.1	RP11-92G12.3	7.88	1.4e-12	7.76e-09	0.68	0.58	Coronary artery disease;	chr1:200676945	chr1:200669507~200694250:+
TGCT	cis	rs875971	0.522	rs2949690	ENSG00000226824.5	RP4-756H11.3	7.88	1.4e-12	7.77e-09	0.66	0.58	Aortic root size;	chr7:66018255	chr7:66654538~66669855:+
TGCT	cis	rs7246967	0.673	rs62122382	ENSG00000269509.1	BNIP3P34	7.88	1.41e-12	7.8e-09	1.16	0.58	Bronchopulmonary dysplasia;	chr19:22798046	chr19:22773853~22774424:+
TGCT	cis	rs4423214	0.959	rs12793224	ENSG00000254682.1	RP11-660L16.2	7.88	1.41e-12	7.8e-09	0.78	0.58	Vitamin D levels;	chr11:71457664	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.959	rs12794668	ENSG00000254682.1	RP11-660L16.2	7.88	1.41e-12	7.8e-09	0.78	0.58	Vitamin D levels;	chr11:71457669	chr11:71448674~71452157:+
TGCT	cis	rs1062177	1	rs2347596	ENSG00000253921.1	CTB-113P19.3	-7.88	1.42e-12	7.82e-09	-0.62	-0.58	Preschool internalizing problems;	chr5:151799638	chr5:151753992~151767247:+
TGCT	cis	rs1062177	0.95	rs892005	ENSG00000253921.1	CTB-113P19.3	-7.88	1.42e-12	7.82e-09	-0.63	-0.58	Preschool internalizing problems;	chr5:151801060	chr5:151753992~151767247:+
TGCT	cis	rs1062177	1	rs892006	ENSG00000253921.1	CTB-113P19.3	-7.88	1.42e-12	7.85e-09	-0.63	-0.58	Preschool internalizing problems;	chr5:151801329	chr5:151753992~151767247:+
TGCT	cis	rs2486288	0.656	rs8041702	ENSG00000259520.4	CTD-2651B20.3	7.88	1.43e-12	7.87e-09	0.49	0.58	Glomerular filtration rate;	chr15:45254895	chr15:45251580~45279251:-
TGCT	cis	rs2283792	0.967	rs5999823	ENSG00000228050.1	TOP3BP1	7.88	1.44e-12	7.93e-09	0.68	0.58	Multiple sclerosis;	chr22:21856587	chr22:22223187~22224566:-
TGCT	cis	rs2486288	0.656	rs11637838	ENSG00000259520.4	CTD-2651B20.3	7.88	1.45e-12	7.98e-09	0.48	0.58	Glomerular filtration rate;	chr15:45258459	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs11632419	ENSG00000259520.4	CTD-2651B20.3	7.88	1.45e-12	7.98e-09	0.48	0.58	Glomerular filtration rate;	chr15:45265258	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs2271438	ENSG00000259520.4	CTD-2651B20.3	7.88	1.45e-12	7.98e-09	0.48	0.58	Glomerular filtration rate;	chr15:45265270	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs11854365	ENSG00000259520.4	CTD-2651B20.3	7.88	1.45e-12	7.98e-09	0.48	0.58	Glomerular filtration rate;	chr15:45265885	chr15:45251580~45279251:-
TGCT	cis	rs11098499	0.863	rs10004484	ENSG00000245958.5	RP11-33B1.1	-7.88	1.45e-12	7.98e-09	-0.61	-0.58	Corneal astigmatism;	chr4:119521273	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs1155576	ENSG00000245958.5	RP11-33B1.1	-7.88	1.45e-12	7.98e-09	-0.61	-0.58	Corneal astigmatism;	chr4:119529004	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs6858592	ENSG00000245958.5	RP11-33B1.1	-7.88	1.45e-12	7.98e-09	-0.61	-0.58	Corneal astigmatism;	chr4:119537537	chr4:119454791~119552025:+
TGCT	cis	rs801193	0.875	rs13227951	ENSG00000226824.5	RP4-756H11.3	7.88	1.45e-12	8.01e-09	0.65	0.58	Aortic root size;	chr7:66748121	chr7:66654538~66669855:+
TGCT	cis	rs11098499	0.588	rs2389874	ENSG00000245958.5	RP11-33B1.1	7.88	1.46e-12	8.02e-09	0.61	0.58	Corneal astigmatism;	chr4:119633836	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.865	rs11098513	ENSG00000245958.5	RP11-33B1.1	-7.88	1.46e-12	8.05e-09	-0.6	-0.58	Corneal astigmatism;	chr4:119394920	chr4:119454791~119552025:+
TGCT	cis	rs1062177	0.724	rs2915828	ENSG00000253921.1	CTB-113P19.3	7.88	1.47e-12	8.07e-09	0.62	0.58	Preschool internalizing problems;	chr5:151738560	chr5:151753992~151767247:+
TGCT	cis	rs1062177	0.724	rs2964590	ENSG00000253921.1	CTB-113P19.3	7.88	1.47e-12	8.07e-09	0.62	0.58	Preschool internalizing problems;	chr5:151738585	chr5:151753992~151767247:+
TGCT	cis	rs1062177	0.756	rs2964588	ENSG00000253921.1	CTB-113P19.3	7.88	1.47e-12	8.07e-09	0.62	0.58	Preschool internalizing problems;	chr5:151738825	chr5:151753992~151767247:+
TGCT	cis	rs1062177	0.756	rs2915827	ENSG00000253921.1	CTB-113P19.3	7.88	1.47e-12	8.07e-09	0.62	0.58	Preschool internalizing problems;	chr5:151740144	chr5:151753992~151767247:+
TGCT	cis	rs1062177	0.756	rs2915826	ENSG00000253921.1	CTB-113P19.3	7.88	1.47e-12	8.07e-09	0.62	0.58	Preschool internalizing problems;	chr5:151740402	chr5:151753992~151767247:+
TGCT	cis	rs1062177	0.756	rs2964587	ENSG00000253921.1	CTB-113P19.3	7.88	1.47e-12	8.07e-09	0.62	0.58	Preschool internalizing problems;	chr5:151740411	chr5:151753992~151767247:+
TGCT	cis	rs1062177	1	rs12654573	ENSG00000253921.1	CTB-113P19.3	-7.87	1.5e-12	8.23e-09	-0.63	-0.58	Preschool internalizing problems;	chr5:151827912	chr5:151753992~151767247:+
TGCT	cis	rs2283792	0.935	rs2283794	ENSG00000228050.1	TOP3BP1	7.87	1.5e-12	8.23e-09	0.68	0.58	Multiple sclerosis;	chr22:21858180	chr22:22223187~22224566:-
TGCT	cis	rs11098499	0.722	rs7673476	ENSG00000245958.5	RP11-33B1.1	-7.87	1.53e-12	8.39e-09	-0.58	-0.58	Corneal astigmatism;	chr4:119327528	chr4:119454791~119552025:+
TGCT	cis	rs1062177	1	rs973529	ENSG00000253921.1	CTB-113P19.3	-7.86	1.56e-12	8.53e-09	-0.63	-0.58	Preschool internalizing problems;	chr5:151808597	chr5:151753992~151767247:+
TGCT	cis	rs1355223	0.683	rs12803316	ENSG00000271369.1	RP11-350D17.3	-7.86	1.56e-12	8.53e-09	-0.56	-0.58	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34655964	chr11:34709600~34710161:+
TGCT	cis	rs1930961	0.702	rs1930966	ENSG00000272977.1	CTA-390C10.10	-7.86	1.56e-12	8.54e-09	-0.83	-0.58	Bipolar disorder with mood-incongruent psychosis;	chr22:25489737	chr22:25476218~25479971:+
TGCT	cis	rs4423214	0.921	rs12807827	ENSG00000254682.1	RP11-660L16.2	7.86	1.58e-12	8.62e-09	0.79	0.58	Vitamin D levels;	chr11:71492744	chr11:71448674~71452157:+
TGCT	cis	rs9326248	0.768	rs4936366	ENSG00000254851.1	RP11-109L13.1	-7.86	1.59e-12	8.68e-09	-0.87	-0.58	Blood protein levels;	chr11:117156169	chr11:117135528~117138582:+
TGCT	cis	rs9326248	0.861	rs4938352	ENSG00000254851.1	RP11-109L13.1	-7.86	1.59e-12	8.68e-09	-0.87	-0.58	Blood protein levels;	chr11:117156765	chr11:117135528~117138582:+
TGCT	cis	rs4423214	1	rs3750997	ENSG00000254682.1	RP11-660L16.2	7.86	1.6e-12	8.76e-09	0.76	0.58	Vitamin D levels;	chr11:71447795	chr11:71448674~71452157:+
TGCT	cis	rs916888	0.61	rs199454	ENSG00000214401.4	KANSL1-AS1	-7.86	1.61e-12	8.79e-09	-0.75	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46193576~46196723:+
TGCT	cis	rs6452524	0.967	rs2974444	ENSG00000249664.1	CTD-2227C6.2	7.86	1.62e-12	8.81e-09	0.56	0.58	Hypertension (SNP x SNP interaction);	chr5:83185174	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs2940542	ENSG00000249664.1	CTD-2227C6.2	7.86	1.62e-12	8.81e-09	0.56	0.58	Hypertension (SNP x SNP interaction);	chr5:83185734	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.934	rs2940543	ENSG00000249664.1	CTD-2227C6.2	7.86	1.62e-12	8.81e-09	0.56	0.58	Hypertension (SNP x SNP interaction);	chr5:83187297	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs2974450	ENSG00000249664.1	CTD-2227C6.2	7.86	1.62e-12	8.81e-09	0.56	0.58	Hypertension (SNP x SNP interaction);	chr5:83187323	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs2974449	ENSG00000249664.1	CTD-2227C6.2	7.86	1.62e-12	8.81e-09	0.56	0.58	Hypertension (SNP x SNP interaction);	chr5:83187465	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs2662241	ENSG00000249664.1	CTD-2227C6.2	7.86	1.62e-12	8.81e-09	0.56	0.58	Hypertension (SNP x SNP interaction);	chr5:83188774	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs2731861	ENSG00000249664.1	CTD-2227C6.2	7.86	1.62e-12	8.81e-09	0.56	0.58	Hypertension (SNP x SNP interaction);	chr5:83189445	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs2940544	ENSG00000249664.1	CTD-2227C6.2	7.86	1.62e-12	8.81e-09	0.56	0.58	Hypertension (SNP x SNP interaction);	chr5:83189785	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs2731865	ENSG00000249664.1	CTD-2227C6.2	7.86	1.62e-12	8.81e-09	0.56	0.58	Hypertension (SNP x SNP interaction);	chr5:83190570	chr5:83012285~83013109:-
TGCT	cis	rs1775715	0.87	rs11008696	ENSG00000239731.3	RN7SL825P	-7.86	1.62e-12	8.84e-09	-0.58	-0.58	Bipolar disorder with mood-incongruent psychosis;	chr10:31929686	chr10:31992087~31992381:-
TGCT	cis	rs977987	0.645	rs34904236	ENSG00000261783.1	RP11-252K23.2	-7.85	1.63e-12	8.9e-09	-0.83	-0.58	Dupuytren's disease;	chr16:75464355	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.933	rs1834014	ENSG00000261783.1	RP11-252K23.2	-7.85	1.63e-12	8.9e-09	-0.83	-0.58	Dupuytren's disease;	chr16:75467376	chr16:75379818~75381260:-
TGCT	cis	rs916888	0.61	rs199529	ENSG00000262500.1	RP11-259G18.2	7.85	1.65e-12	8.96e-09	0.86	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46243606~46245044:+
TGCT	cis	rs9326248	0.813	rs4938350	ENSG00000254851.1	RP11-109L13.1	-7.85	1.65e-12	8.96e-09	-0.86	-0.58	Blood protein levels;	chr11:117151560	chr11:117135528~117138582:+
TGCT	cis	rs916888	0.61	rs199453	ENSG00000214401.4	KANSL1-AS1	7.85	1.69e-12	9.14e-09	0.74	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46193576~46196723:+
TGCT	cis	rs916888	0.61	rs199452	ENSG00000214401.4	KANSL1-AS1	7.85	1.69e-12	9.14e-09	0.74	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46193576~46196723:+
TGCT	cis	rs977987	0.902	rs4888430	ENSG00000261783.1	RP11-252K23.2	-7.85	1.69e-12	9.17e-09	-0.82	-0.58	Dupuytren's disease;	chr16:75460526	chr16:75379818~75381260:-
TGCT	cis	rs1355223	0.966	rs11602318	ENSG00000271369.1	RP11-350D17.3	7.85	1.7e-12	9.19e-09	0.56	0.58	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34745436	chr11:34709600~34710161:+
TGCT	cis	rs1355223	1	rs1355222	ENSG00000271369.1	RP11-350D17.3	-7.85	1.7e-12	9.19e-09	-0.56	-0.58	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34737169	chr11:34709600~34710161:+
TGCT	cis	rs1355223	1	rs11601923	ENSG00000271369.1	RP11-350D17.3	-7.85	1.7e-12	9.19e-09	-0.56	-0.58	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34742807	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.934	rs5010670	ENSG00000271369.1	RP11-350D17.3	-7.85	1.7e-12	9.19e-09	-0.56	-0.58	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34745102	chr11:34709600~34710161:+
TGCT	cis	rs1355223	1	rs1396879	ENSG00000271369.1	RP11-350D17.3	-7.85	1.7e-12	9.19e-09	-0.56	-0.58	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34745106	chr11:34709600~34710161:+
TGCT	cis	rs1355223	1	rs11602909	ENSG00000271369.1	RP11-350D17.3	-7.85	1.7e-12	9.19e-09	-0.56	-0.58	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34746456	chr11:34709600~34710161:+
TGCT	cis	rs6452524	0.901	rs1580309	ENSG00000249664.1	CTD-2227C6.2	7.85	1.71e-12	9.24e-09	0.59	0.58	Hypertension (SNP x SNP interaction);	chr5:83091948	chr5:83012285~83013109:-
TGCT	cis	rs2283792	1	rs5999515	ENSG00000228050.1	TOP3BP1	-7.85	1.72e-12	9.29e-09	-0.67	-0.58	Multiple sclerosis;	chr22:21790812	chr22:22223187~22224566:-
TGCT	cis	rs1775715	0.87	rs10827001	ENSG00000239731.3	RN7SL825P	-7.84	1.73e-12	9.35e-09	-0.58	-0.58	Bipolar disorder with mood-incongruent psychosis;	chr10:31940806	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.835	rs12266771	ENSG00000239731.3	RN7SL825P	-7.84	1.73e-12	9.35e-09	-0.58	-0.58	Bipolar disorder with mood-incongruent psychosis;	chr10:31942452	chr10:31992087~31992381:-
TGCT	cis	rs875971	0.505	rs1167386	ENSG00000226824.5	RP4-756H11.3	7.84	1.73e-12	9.36e-09	0.65	0.58	Aortic root size;	chr7:66048109	chr7:66654538~66669855:+
TGCT	cis	rs1155848	0.571	rs6563127	ENSG00000227354.5	RBM26-AS1	7.84	1.75e-12	9.45e-09	0.88	0.58	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79642012	chr13:79406309~79424328:+
TGCT	cis	rs11098499	0.954	rs28572238	ENSG00000245958.5	RP11-33B1.1	-7.84	1.78e-12	9.64e-09	-0.6	-0.58	Corneal astigmatism;	chr4:119395531	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.909	rs28714195	ENSG00000245958.5	RP11-33B1.1	-7.84	1.78e-12	9.64e-09	-0.6	-0.58	Corneal astigmatism;	chr4:119395795	chr4:119454791~119552025:+
TGCT	cis	rs2980436	1	rs2980436	ENSG00000173295.6	FAM86B3P	-7.84	1.81e-12	9.77e-09	-0.69	-0.58	Schizophrenia;	chr8:8234503	chr8:8228595~8244865:+
TGCT	cis	rs2486288	0.656	rs1060896	ENSG00000259520.4	CTD-2651B20.3	7.83	1.82e-12	9.8e-09	0.47	0.58	Glomerular filtration rate;	chr15:45262069	chr15:45251580~45279251:-
TGCT	cis	rs1930961	1	rs7285549	ENSG00000272977.1	CTA-390C10.10	-7.83	1.85e-12	9.99e-09	-0.75	-0.58	Bipolar disorder with mood-incongruent psychosis;	chr22:25478613	chr22:25476218~25479971:+
TGCT	cis	rs8040855	0.794	rs4843024	ENSG00000259295.5	CSPG4P12	-7.83	1.86e-12	1e-08	-0.78	-0.58	Bulimia nervosa;	chr15:85162669	chr15:85191438~85213905:+
TGCT	cis	rs9326248	0.727	rs4938347	ENSG00000254851.1	RP11-109L13.1	-7.83	1.87e-12	1.01e-08	-0.86	-0.58	Blood protein levels;	chr11:117151043	chr11:117135528~117138582:+
TGCT	cis	rs950027	0.549	rs9920634	ENSG00000259520.4	CTD-2651B20.3	7.83	1.87e-12	1.01e-08	0.48	0.58	Response to fenofibrate (adiponectin levels);	chr15:45304348	chr15:45251580~45279251:-
TGCT	cis	rs6452524	1	rs10042854	ENSG00000249664.1	CTD-2227C6.2	-7.83	1.9e-12	1.02e-08	-0.58	-0.57	Hypertension (SNP x SNP interaction);	chr5:83143876	chr5:83012285~83013109:-
TGCT	cis	rs11098499	0.954	rs2389803	ENSG00000245958.5	RP11-33B1.1	7.82	1.95e-12	1.05e-08	0.64	0.57	Corneal astigmatism;	chr4:119472356	chr4:119454791~119552025:+
TGCT	cis	rs1155848	0.571	rs6563125	ENSG00000227354.5	RBM26-AS1	7.82	1.96e-12	1.05e-08	0.87	0.57	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79630618	chr13:79406309~79424328:+
TGCT	cis	rs875971	0.83	rs427973	ENSG00000226824.5	RP4-756H11.3	-7.82	1.97e-12	1.05e-08	-0.64	-0.57	Aortic root size;	chr7:66061661	chr7:66654538~66669855:+
TGCT	cis	rs7174755	0.961	rs58175526	ENSG00000260657.2	RP11-315D16.4	7.82	1.99e-12	1.05e-08	0.59	0.57	Major depressive disorder;	chr15:68300789	chr15:68267792~68277994:-
TGCT	cis	rs7174755	1	rs68069953	ENSG00000260657.2	RP11-315D16.4	7.82	1.99e-12	1.05e-08	0.59	0.57	Major depressive disorder;	chr15:68304235	chr15:68267792~68277994:-
TGCT	cis	rs7174755	0.924	rs8035431	ENSG00000260657.2	RP11-315D16.4	7.82	1.99e-12	1.05e-08	0.59	0.57	Major depressive disorder;	chr15:68305012	chr15:68267792~68277994:-
TGCT	cis	rs7246967	0.551	rs62118775	ENSG00000269509.1	BNIP3P34	7.82	2e-12	1.05e-08	1.15	0.57	Bronchopulmonary dysplasia;	chr19:22644376	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs62120273	ENSG00000269509.1	BNIP3P34	7.82	2e-12	1.05e-08	1.15	0.57	Bronchopulmonary dysplasia;	chr19:22679518	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.551	rs62121805	ENSG00000269509.1	BNIP3P34	7.82	2e-12	1.05e-08	1.15	0.57	Bronchopulmonary dysplasia;	chr19:22726178	chr19:22773853~22774424:+
TGCT	cis	rs5769707	0.732	rs135865	ENSG00000188511.11	C22orf34	7.82	2.01e-12	1.05e-08	0.6	0.57	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49414524~49657542:-
TGCT	cis	rs2882667	0.931	rs3749665	ENSG00000253404.1	AC034243.1	7.82	2.01e-12	1.05e-08	0.63	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021522	chr5:138744434~138753309:-
TGCT	cis	rs7188445	0.932	rs17767742	ENSG00000261390.4	RP11-345M22.2	-7.82	2.01e-12	1.05e-08	-0.58	-0.57	Urate levels;	chr16:79715108	chr16:79715232~79770563:-
TGCT	cis	rs7246967	0.673	rs62119090	ENSG00000269509.1	BNIP3P34	7.81	2.02e-12	1.06e-08	1.15	0.57	Bronchopulmonary dysplasia;	chr19:22741112	chr19:22773853~22774424:+
TGCT	cis	rs6921919	0.583	rs2041230	ENSG00000216901.1	AL022393.7	7.81	2.05e-12	1.07e-08	0.67	0.57	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28176188~28176674:+
TGCT	cis	rs11098499	0.754	rs1980025	ENSG00000245958.5	RP11-33B1.1	7.81	2.1e-12	1.1e-08	0.59	0.57	Corneal astigmatism;	chr4:119331651	chr4:119454791~119552025:+
TGCT	cis	rs1062177	0.826	rs1549920	ENSG00000253921.1	CTB-113P19.3	-7.8	2.15e-12	1.12e-08	-0.63	-0.57	Preschool internalizing problems;	chr5:151761283	chr5:151753992~151767247:+
TGCT	cis	rs1930961	1	rs5996946	ENSG00000272977.1	CTA-390C10.10	-7.8	2.16e-12	1.13e-08	-0.75	-0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25480021	chr22:25476218~25479971:+
TGCT	cis	rs1930961	1	rs997873	ENSG00000272977.1	CTA-390C10.10	-7.8	2.16e-12	1.13e-08	-0.75	-0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25482315	chr22:25476218~25479971:+
TGCT	cis	rs1930961	1	rs997872	ENSG00000272977.1	CTA-390C10.10	-7.8	2.16e-12	1.13e-08	-0.75	-0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25482647	chr22:25476218~25479971:+
TGCT	cis	rs1930961	1	rs6004671	ENSG00000272977.1	CTA-390C10.10	-7.8	2.16e-12	1.13e-08	-0.75	-0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25483507	chr22:25476218~25479971:+
TGCT	cis	rs950027	0.549	rs11070452	ENSG00000259520.4	CTD-2651B20.3	7.8	2.16e-12	1.13e-08	0.47	0.57	Response to fenofibrate (adiponectin levels);	chr15:45302638	chr15:45251580~45279251:-
TGCT	cis	rs875971	0.564	rs313804	ENSG00000226824.5	RP4-756H11.3	-7.79	2.26e-12	1.17e-08	-0.63	-0.57	Aortic root size;	chr7:66049635	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.662	rs448725	ENSG00000226824.5	RP4-756H11.3	-7.79	2.26e-12	1.17e-08	-0.63	-0.57	Aortic root size;	chr7:66049641	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.658	rs432667	ENSG00000226824.5	RP4-756H11.3	-7.79	2.26e-12	1.17e-08	-0.63	-0.57	Aortic root size;	chr7:66049646	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.8	rs427557	ENSG00000226824.5	RP4-756H11.3	-7.79	2.26e-12	1.17e-08	-0.63	-0.57	Aortic root size;	chr7:66054263	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.83	rs587360	ENSG00000226824.5	RP4-756H11.3	-7.79	2.26e-12	1.17e-08	-0.63	-0.57	Aortic root size;	chr7:66057711	chr7:66654538~66669855:+
TGCT	cis	rs9326248	0.581	rs7106437	ENSG00000254851.1	RP11-109L13.1	-7.79	2.27e-12	1.18e-08	-0.7	-0.57	Blood protein levels;	chr11:117121360	chr11:117135528~117138582:+
TGCT	cis	rs916888	0.531	rs183211	ENSG00000262539.1	RP11-259G18.3	7.79	2.29e-12	1.19e-08	0.82	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46259551~46260606:-
TGCT	cis	rs6452524	0.967	rs11949474	ENSG00000249664.1	CTD-2227C6.2	7.79	2.29e-12	1.19e-08	0.56	0.57	Hypertension (SNP x SNP interaction);	chr5:83179759	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs4541638	ENSG00000249664.1	CTD-2227C6.2	7.79	2.29e-12	1.19e-08	0.56	0.57	Hypertension (SNP x SNP interaction);	chr5:83181325	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs28360104	ENSG00000249664.1	CTD-2227C6.2	7.79	2.29e-12	1.19e-08	0.56	0.57	Hypertension (SNP x SNP interaction);	chr5:83181525	chr5:83012285~83013109:-
TGCT	cis	rs1062177	0.756	rs2915817	ENSG00000253921.1	CTB-113P19.3	7.79	2.32e-12	1.2e-08	0.61	0.57	Preschool internalizing problems;	chr5:151735956	chr5:151753992~151767247:+
TGCT	cis	rs2729354	1	rs2649662	ENSG00000265566.2	RN7SL605P	7.79	2.32e-12	1.2e-08	0.71	0.57	Blood protein levels;	chr11:57585089	chr11:57528085~57528365:-
TGCT	cis	rs11098499	0.71	rs4145952	ENSG00000245958.5	RP11-33B1.1	-7.79	2.33e-12	1.21e-08	-0.59	-0.57	Corneal astigmatism;	chr4:119234651	chr4:119454791~119552025:+
TGCT	cis	rs1355223	1	rs1355221	ENSG00000271369.1	RP11-350D17.3	-7.79	2.33e-12	1.21e-08	-0.53	-0.57	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34737062	chr11:34709600~34710161:+
TGCT	cis	rs1155848	0.571	rs58739959	ENSG00000227354.5	RBM26-AS1	7.79	2.33e-12	1.21e-08	0.86	0.57	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79633468	chr13:79406309~79424328:+
TGCT	cis	rs1355223	1	rs1396883	ENSG00000271369.1	RP11-350D17.3	-7.79	2.36e-12	1.22e-08	-0.56	-0.57	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34735900	chr11:34709600~34710161:+
TGCT	cis	rs9326248	0.861	rs4938348	ENSG00000254851.1	RP11-109L13.1	-7.78	2.41e-12	1.24e-08	-0.86	-0.57	Blood protein levels;	chr11:117151161	chr11:117135528~117138582:+
TGCT	cis	rs2739330	0.731	rs5751792	ENSG00000225282.1	AP000350.6	7.78	2.42e-12	1.25e-08	0.65	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23926900~23929574:+
TGCT	cis	rs916888	0.779	rs199498	ENSG00000214401.4	KANSL1-AS1	7.78	2.45e-12	1.26e-08	0.79	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46193576~46196723:+
TGCT	cis	rs2882667	0.893	rs10044672	ENSG00000253404.1	AC034243.1	7.78	2.45e-12	1.27e-08	0.66	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954790	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.893	rs13180851	ENSG00000253404.1	AC034243.1	7.78	2.45e-12	1.27e-08	0.66	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954918	chr5:138744434~138753309:-
TGCT	cis	rs6452524	1	rs6452519	ENSG00000249664.1	CTD-2227C6.2	7.78	2.47e-12	1.27e-08	0.56	0.57	Hypertension (SNP x SNP interaction);	chr5:83133429	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs6452509	ENSG00000249664.1	CTD-2227C6.2	7.78	2.47e-12	1.28e-08	0.6	0.57	Hypertension (SNP x SNP interaction);	chr5:83125564	chr5:83012285~83013109:-
TGCT	cis	rs7188445	0.932	rs56738967	ENSG00000261390.4	RP11-345M22.2	-7.78	2.48e-12	1.28e-08	-0.59	-0.57	Urate levels;	chr16:79706644	chr16:79715232~79770563:-
TGCT	cis	rs7301826	0.651	rs34749116	ENSG00000256299.1	RP11-989F5.3	7.77	2.51e-12	1.29e-08	0.68	0.57	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.627	rs7978987	ENSG00000256299.1	RP11-989F5.3	7.77	2.51e-12	1.29e-08	0.68	0.57	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.651	rs2277336	ENSG00000256299.1	RP11-989F5.3	7.77	2.51e-12	1.29e-08	0.68	0.57	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.627	rs34103763	ENSG00000256299.1	RP11-989F5.3	7.77	2.51e-12	1.29e-08	0.68	0.57	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.61	rs36051740	ENSG00000256299.1	RP11-989F5.3	7.77	2.51e-12	1.29e-08	0.68	0.57	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.61	rs7961690	ENSG00000256299.1	RP11-989F5.3	7.77	2.51e-12	1.29e-08	0.68	0.57	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.651	rs6486601	ENSG00000256299.1	RP11-989F5.3	7.77	2.51e-12	1.29e-08	0.68	0.57	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.627	rs61937256	ENSG00000256299.1	RP11-989F5.3	7.77	2.51e-12	1.29e-08	0.68	0.57	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.651	rs7299281	ENSG00000256299.1	RP11-989F5.3	7.77	2.51e-12	1.29e-08	0.68	0.57	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.56	rs12829294	ENSG00000256299.1	RP11-989F5.3	7.77	2.51e-12	1.29e-08	0.68	0.57	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.58	rs61938969	ENSG00000256299.1	RP11-989F5.3	7.77	2.51e-12	1.29e-08	0.68	0.57	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.585	rs6486600	ENSG00000256299.1	RP11-989F5.3	-7.77	2.51e-12	1.29e-08	-0.68	-0.57	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.627	rs4334059	ENSG00000256299.1	RP11-989F5.3	-7.77	2.51e-12	1.29e-08	-0.68	-0.57	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810821~130812622:-
TGCT	cis	rs1062177	0.774	rs2964574	ENSG00000253921.1	CTB-113P19.3	-7.77	2.53e-12	1.3e-08	-0.61	-0.57	Preschool internalizing problems;	chr5:151776150	chr5:151753992~151767247:+
TGCT	cis	rs1062177	0.826	rs2053063	ENSG00000253921.1	CTB-113P19.3	-7.77	2.53e-12	1.3e-08	-0.61	-0.57	Preschool internalizing problems;	chr5:151787203	chr5:151753992~151767247:+
TGCT	cis	rs950027	0.549	rs11636114	ENSG00000259520.4	CTD-2651B20.3	-7.77	2.56e-12	1.32e-08	-0.48	-0.57	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:45251580~45279251:-
TGCT	cis	rs6538678	0.833	rs1898178	ENSG00000258343.1	RP11-536G4.2	-7.77	2.58e-12	1.33e-08	-0.86	-0.57	Lupus nephritis in systemic lupus erythematosus;	chr12:95887554	chr12:95795345~95858839:-
TGCT	cis	rs6538678	0.833	rs1898177	ENSG00000258343.1	RP11-536G4.2	-7.77	2.58e-12	1.33e-08	-0.86	-0.57	Lupus nephritis in systemic lupus erythematosus;	chr12:95887568	chr12:95795345~95858839:-
TGCT	cis	rs916888	0.61	rs199446	ENSG00000214401.4	KANSL1-AS1	-7.77	2.59e-12	1.33e-08	-0.74	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46193576~46196723:+
TGCT	cis	rs916888	0.61	rs199536	ENSG00000214401.4	KANSL1-AS1	-7.77	2.59e-12	1.33e-08	-0.74	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46193576~46196723:+
TGCT	cis	rs7188445	1	rs11150189	ENSG00000261390.4	RP11-345M22.2	-7.77	2.61e-12	1.34e-08	-0.58	-0.57	Urate levels;	chr16:79700330	chr16:79715232~79770563:-
TGCT	cis	rs1062177	0.826	rs2915873	ENSG00000253921.1	CTB-113P19.3	-7.77	2.63e-12	1.35e-08	-0.61	-0.57	Preschool internalizing problems;	chr5:151777097	chr5:151753992~151767247:+
TGCT	cis	rs1062177	0.756	rs2964592	ENSG00000253921.1	CTB-113P19.3	7.76	2.67e-12	1.37e-08	0.61	0.57	Preschool internalizing problems;	chr5:151736127	chr5:151753992~151767247:+
TGCT	cis	rs17361889	0.671	rs1527201	ENSG00000224683.1	RPL36AP29	-7.76	2.67e-12	1.37e-08	-0.66	-0.57	Pediatric bone mineral content (hip);	chr7:16111403	chr7:16208945~16209265:+
TGCT	cis	rs6452524	0.967	rs4616871	ENSG00000249664.1	CTD-2227C6.2	7.76	2.68e-12	1.37e-08	0.56	0.57	Hypertension (SNP x SNP interaction);	chr5:83175271	chr5:83012285~83013109:-
TGCT	cis	rs17361889	0.738	rs17288304	ENSG00000224683.1	RPL36AP29	7.76	2.68e-12	1.37e-08	0.66	0.57	Pediatric bone mineral content (hip);	chr7:16153112	chr7:16208945~16209265:+
TGCT	cis	rs17361889	0.671	rs987932	ENSG00000224683.1	RPL36AP29	7.75	2.79e-12	1.43e-08	0.67	0.57	Pediatric bone mineral content (hip);	chr7:16114696	chr7:16208945~16209265:+
TGCT	cis	rs17361889	0.632	rs987934	ENSG00000224683.1	RPL36AP29	7.75	2.79e-12	1.43e-08	0.67	0.57	Pediatric bone mineral content (hip);	chr7:16115124	chr7:16208945~16209265:+
TGCT	cis	rs6700559	1	rs10494821	ENSG00000260088.1	RP11-92G12.3	-7.75	2.84e-12	1.45e-08	-0.68	-0.57	Coronary artery disease;	chr1:200673357	chr1:200669507~200694250:+
TGCT	cis	rs6700559	1	rs4311922	ENSG00000260088.1	RP11-92G12.3	-7.75	2.84e-12	1.45e-08	-0.68	-0.57	Coronary artery disease;	chr1:200674257	chr1:200669507~200694250:+
TGCT	cis	rs6700559	0.967	rs4447009	ENSG00000260088.1	RP11-92G12.3	-7.75	2.84e-12	1.45e-08	-0.68	-0.57	Coronary artery disease;	chr1:200674278	chr1:200669507~200694250:+
TGCT	cis	rs6700559	1	rs4265457	ENSG00000260088.1	RP11-92G12.3	-7.75	2.84e-12	1.45e-08	-0.68	-0.57	Coronary artery disease;	chr1:200674326	chr1:200669507~200694250:+
TGCT	cis	rs6700559	1	rs6667172	ENSG00000260088.1	RP11-92G12.3	-7.75	2.84e-12	1.45e-08	-0.68	-0.57	Coronary artery disease;	chr1:200674710	chr1:200669507~200694250:+
TGCT	cis	rs6700559	1	rs7527499	ENSG00000260088.1	RP11-92G12.3	-7.75	2.84e-12	1.45e-08	-0.68	-0.57	Coronary artery disease;	chr1:200676217	chr1:200669507~200694250:+
TGCT	cis	rs6700559	1	rs6427838	ENSG00000260088.1	RP11-92G12.3	-7.75	2.84e-12	1.45e-08	-0.68	-0.57	Coronary artery disease;	chr1:200676519	chr1:200669507~200694250:+
TGCT	cis	rs6700559	1	rs12061346	ENSG00000260088.1	RP11-92G12.3	-7.75	2.84e-12	1.45e-08	-0.68	-0.57	Coronary artery disease;	chr1:200677648	chr1:200669507~200694250:+
TGCT	cis	rs6700559	1	rs7533971	ENSG00000260088.1	RP11-92G12.3	-7.75	2.84e-12	1.45e-08	-0.68	-0.57	Coronary artery disease;	chr1:200678243	chr1:200669507~200694250:+
TGCT	cis	rs6700559	1	rs10919998	ENSG00000260088.1	RP11-92G12.3	-7.75	2.84e-12	1.45e-08	-0.68	-0.57	Coronary artery disease;	chr1:200679182	chr1:200669507~200694250:+
TGCT	cis	rs6700559	0.967	rs4072552	ENSG00000260088.1	RP11-92G12.3	-7.75	2.84e-12	1.45e-08	-0.68	-0.57	Coronary artery disease;	chr1:200680003	chr1:200669507~200694250:+
TGCT	cis	rs1155848	0.892	rs9565509	ENSG00000227354.5	RBM26-AS1	7.75	2.86e-12	1.46e-08	0.96	0.57	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79483696	chr13:79406309~79424328:+
TGCT	cis	rs1155848	0.892	rs28546558	ENSG00000227354.5	RBM26-AS1	7.75	2.86e-12	1.46e-08	0.96	0.57	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79516024	chr13:79406309~79424328:+
TGCT	cis	rs7301826	0.651	rs12820597	ENSG00000256299.1	RP11-989F5.3	7.75	2.92e-12	1.49e-08	0.68	0.57	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810821~130812622:-
TGCT	cis	rs2929278	0.617	rs524908	ENSG00000205771.5	CATSPER2P1	7.74	2.93e-12	1.49e-08	0.63	0.57	Schizophrenia;	chr15:43895793	chr15:43726918~43747094:-
TGCT	cis	rs875971	0.505	rs2462573	ENSG00000226824.5	RP4-756H11.3	7.74	2.94e-12	1.5e-08	0.64	0.57	Aortic root size;	chr7:66042405	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.505	rs1167385	ENSG00000226824.5	RP4-756H11.3	7.74	2.94e-12	1.5e-08	0.64	0.57	Aortic root size;	chr7:66048321	chr7:66654538~66669855:+
TGCT	cis	rs7301826	0.651	rs10848206	ENSG00000256299.1	RP11-989F5.3	-7.74	2.98e-12	1.51e-08	-0.68	-0.57	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810821~130812622:-
TGCT	cis	rs748404	0.518	rs2927085	ENSG00000205771.5	CATSPER2P1	-7.74	2.98e-12	1.52e-08	-0.65	-0.57	Lung cancer;	chr15:43697332	chr15:43726918~43747094:-
TGCT	cis	rs8040855	0.86	rs6496775	ENSG00000259295.5	CSPG4P12	-7.74	3e-12	1.53e-08	-0.77	-0.57	Bulimia nervosa;	chr15:85164910	chr15:85191438~85213905:+
TGCT	cis	rs2486288	0.656	rs10519018	ENSG00000259520.4	CTD-2651B20.3	7.74	3.07e-12	1.55e-08	0.47	0.57	Glomerular filtration rate;	chr15:45257067	chr15:45251580~45279251:-
TGCT	cis	rs977987	0.966	rs8055490	ENSG00000261783.1	RP11-252K23.2	-7.74	3.08e-12	1.56e-08	-0.82	-0.57	Dupuytren's disease;	chr16:75463237	chr16:75379818~75381260:-
TGCT	cis	rs1355223	1	rs11607300	ENSG00000271369.1	RP11-350D17.3	-7.74	3.09e-12	1.56e-08	-0.55	-0.57	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34737772	chr11:34709600~34710161:+
TGCT	cis	rs1355223	1	rs1355223	ENSG00000271369.1	RP11-350D17.3	-7.74	3.09e-12	1.56e-08	-0.55	-0.57	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34742932	chr11:34709600~34710161:+
TGCT	cis	rs1355223	1	rs12792532	ENSG00000271369.1	RP11-350D17.3	-7.74	3.09e-12	1.56e-08	-0.55	-0.57	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34744235	chr11:34709600~34710161:+
TGCT	cis	rs172166	0.543	rs1150691	ENSG00000216901.1	AL022393.7	7.73	3.09e-12	1.56e-08	0.62	0.57	Cardiac Troponin-T levels;	chr6:28200255	chr6:28176188~28176674:+
TGCT	cis	rs17361889	0.711	rs73056339	ENSG00000224683.1	RPL36AP29	7.73	3.12e-12	1.58e-08	0.66	0.57	Pediatric bone mineral content (hip);	chr7:16131751	chr7:16208945~16209265:+
TGCT	cis	rs6921919	0.583	rs740621	ENSG00000216901.1	AL022393.7	7.73	3.14e-12	1.59e-08	0.69	0.57	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28176188~28176674:+
TGCT	cis	rs4423214	1	rs2852853	ENSG00000254682.1	RP11-660L16.2	7.73	3.19e-12	1.61e-08	0.77	0.57	Vitamin D levels;	chr11:71439171	chr11:71448674~71452157:+
TGCT	cis	rs950027	0.549	rs2899375	ENSG00000259520.4	CTD-2651B20.3	7.73	3.21e-12	1.62e-08	0.47	0.57	Response to fenofibrate (adiponectin levels);	chr15:45306137	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs2413768	ENSG00000259520.4	CTD-2651B20.3	7.73	3.23e-12	1.63e-08	0.49	0.57	Glomerular filtration rate;	chr15:45269786	chr15:45251580~45279251:-
TGCT	cis	rs1775715	0.87	rs3847414	ENSG00000239731.3	RN7SL825P	-7.72	3.32e-12	1.67e-08	-0.58	-0.57	Bipolar disorder with mood-incongruent psychosis;	chr10:31930248	chr10:31992087~31992381:-
TGCT	cis	rs2980439	0.846	rs2980437	ENSG00000173295.6	FAM86B3P	-7.72	3.41e-12	1.72e-08	-0.66	-0.57	Neuroticism;	chr8:8237241	chr8:8228595~8244865:+
TGCT	cis	rs1355223	0.902	rs11605785	ENSG00000271369.1	RP11-350D17.3	-7.71	3.44e-12	1.73e-08	-0.56	-0.57	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34729840	chr11:34709600~34710161:+
TGCT	cis	rs858239	0.73	rs10255155	ENSG00000230658.1	KLHL7-AS1	-7.71	3.45e-12	1.73e-08	-0.6	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23101228~23105703:-
TGCT	cis	rs62388641	0.813	rs55821127	ENSG00000272279.1	RP11-157J24.2	7.71	3.47e-12	1.74e-08	0.63	0.57	Daytime sleep phenotypes;	chr6:1550635	chr6:1528364~1528911:-
TGCT	cis	rs1577917	1	rs6933377	ENSG00000203875.9	SNHG5	7.71	3.52e-12	1.76e-08	0.73	0.57	Response to antipsychotic treatment;	chr6:85995537	chr6:85660950~85678736:-
TGCT	cis	rs977987	0.931	rs1834013	ENSG00000261783.1	RP11-252K23.2	-7.71	3.52e-12	1.77e-08	-0.82	-0.57	Dupuytren's disease;	chr16:75462265	chr16:75379818~75381260:-
TGCT	cis	rs1355223	0.844	rs12809046	ENSG00000271369.1	RP11-350D17.3	-7.71	3.56e-12	1.78e-08	-0.56	-0.57	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34726714	chr11:34709600~34710161:+
TGCT	cis	rs875971	0.54	rs736270	ENSG00000226824.5	RP4-756H11.3	-7.71	3.56e-12	1.78e-08	-0.65	-0.57	Aortic root size;	chr7:65963835	chr7:66654538~66669855:+
TGCT	cis	rs3814244	0.897	rs4141135	ENSG00000255733.4	IFNG-AS1	7.71	3.59e-12	1.8e-08	0.53	0.57	Itch intensity from mosquito bite adjusted by bite size;	chr12:68025050	chr12:67989445~68234686:+
TGCT	cis	rs66887589	0.807	rs13134517	ENSG00000245958.5	RP11-33B1.1	-7.7	3.62e-12	1.81e-08	-0.56	-0.57	Diastolic blood pressure;	chr4:119484107	chr4:119454791~119552025:+
TGCT	cis	rs66887589	0.837	rs6534135	ENSG00000245958.5	RP11-33B1.1	-7.7	3.62e-12	1.81e-08	-0.56	-0.57	Diastolic blood pressure;	chr4:119485147	chr4:119454791~119552025:+
TGCT	cis	rs66887589	0.837	rs7661498	ENSG00000245958.5	RP11-33B1.1	-7.7	3.62e-12	1.81e-08	-0.56	-0.57	Diastolic blood pressure;	chr4:119486953	chr4:119454791~119552025:+
TGCT	cis	rs2486288	0.656	rs11639420	ENSG00000259520.4	CTD-2651B20.3	7.7	3.71e-12	1.85e-08	0.47	0.57	Glomerular filtration rate;	chr15:45267070	chr15:45251580~45279251:-
TGCT	cis	rs17361889	0.671	rs73071825	ENSG00000224683.1	RPL36AP29	7.7	3.71e-12	1.85e-08	0.67	0.57	Pediatric bone mineral content (hip);	chr7:16109442	chr7:16208945~16209265:+
TGCT	cis	rs17361889	0.685	rs111795100	ENSG00000224683.1	RPL36AP29	7.7	3.71e-12	1.85e-08	0.67	0.57	Pediatric bone mineral content (hip);	chr7:16112093	chr7:16208945~16209265:+
TGCT	cis	rs524281	0.731	rs11227439	ENSG00000255320.1	RP11-755F10.1	7.7	3.73e-12	1.86e-08	0.79	0.57	Electroencephalogram traits;	chr11:66258208	chr11:66244840~66246239:-
TGCT	cis	rs5769707	0.777	rs8138399	ENSG00000188511.11	C22orf34	7.7	3.77e-12	1.88e-08	0.56	0.57	Monocyte percentage of white cells;Monocyte count;	chr22:49651176	chr22:49414524~49657542:-
TGCT	cis	rs875971	0.54	rs1723268	ENSG00000226824.5	RP4-756H11.3	-7.7	3.81e-12	1.9e-08	-0.65	-0.57	Aortic root size;	chr7:66008093	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.522	rs1701760	ENSG00000226824.5	RP4-756H11.3	-7.7	3.81e-12	1.9e-08	-0.65	-0.57	Aortic root size;	chr7:66008701	chr7:66654538~66669855:+
TGCT	cis	rs1930961	1	rs760554	ENSG00000272977.1	CTA-390C10.10	-7.69	3.83e-12	1.91e-08	-0.74	-0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25476625	chr22:25476218~25479971:+
TGCT	cis	rs3814244	0.54	rs2159064	ENSG00000255733.4	IFNG-AS1	-7.69	3.88e-12	1.93e-08	-0.54	-0.57	Itch intensity from mosquito bite adjusted by bite size;	chr12:68017126	chr12:67989445~68234686:+
TGCT	cis	rs1355223	1	rs2221720	ENSG00000271369.1	RP11-350D17.3	7.69	3.89e-12	1.94e-08	0.55	0.57	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34733374	chr11:34709600~34710161:+
TGCT	cis	rs1930961	1	rs6004668	ENSG00000272977.1	CTA-390C10.10	7.69	3.93e-12	1.95e-08	0.74	0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25476218~25479971:+
TGCT	cis	rs875971	0.522	rs709604	ENSG00000226824.5	RP4-756H11.3	7.69	3.93e-12	1.95e-08	0.65	0.57	Aortic root size;	chr7:66032447	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.505	rs1723275	ENSG00000226824.5	RP4-756H11.3	7.69	3.93e-12	1.95e-08	0.65	0.57	Aortic root size;	chr7:66039646	chr7:66654538~66669855:+
TGCT	cis	rs4423214	1	rs4944062	ENSG00000254682.1	RP11-660L16.2	7.69	3.99e-12	1.98e-08	0.76	0.57	Vitamin D levels;	chr11:71476248	chr11:71448674~71452157:+
TGCT	cis	rs9399137	0.507	rs6923512	ENSG00000232876.1	CTA-212D2.2	7.69	4.02e-12	2e-08	0.52	0.57	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135014130	chr6:135055033~135060550:+
TGCT	cis	rs2283792	1	rs6518986	ENSG00000228050.1	TOP3BP1	7.68	4.08e-12	2.02e-08	0.66	0.57	Multiple sclerosis;	chr22:21831058	chr22:22223187~22224566:-
TGCT	cis	rs2283792	1	rs1892846	ENSG00000228050.1	TOP3BP1	7.68	4.08e-12	2.02e-08	0.66	0.57	Multiple sclerosis;	chr22:21832190	chr22:22223187~22224566:-
TGCT	cis	rs2283792	1	rs1892848	ENSG00000228050.1	TOP3BP1	7.68	4.08e-12	2.02e-08	0.66	0.57	Multiple sclerosis;	chr22:21832273	chr22:22223187~22224566:-
TGCT	cis	rs2283792	1	rs5999750	ENSG00000228050.1	TOP3BP1	7.68	4.08e-12	2.02e-08	0.66	0.57	Multiple sclerosis;	chr22:21833720	chr22:22223187~22224566:-
TGCT	cis	rs1775715	0.87	rs7912121	ENSG00000239731.3	RN7SL825P	-7.68	4.08e-12	2.02e-08	-0.57	-0.57	Bipolar disorder with mood-incongruent psychosis;	chr10:31940067	chr10:31992087~31992381:-
TGCT	cis	rs9399135	1	rs9399135	ENSG00000232876.1	CTA-212D2.2	-7.68	4.09e-12	2.03e-08	-0.52	-0.57	Red blood cell count;	chr6:135047176	chr6:135055033~135060550:+
TGCT	cis	rs6538678	0.864	rs4762249	ENSG00000258343.1	RP11-536G4.2	7.68	4.09e-12	2.03e-08	0.86	0.57	Lupus nephritis in systemic lupus erythematosus;	chr12:95884183	chr12:95795345~95858839:-
TGCT	cis	rs6921919	0.583	rs7764722	ENSG00000216901.1	AL022393.7	7.68	4.09e-12	2.03e-08	0.66	0.57	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28176188~28176674:+
TGCT	cis	rs875971	0.522	rs1617484	ENSG00000226824.5	RP4-756H11.3	-7.68	4.11e-12	2.04e-08	-0.63	-0.57	Aortic root size;	chr7:65998108	chr7:66654538~66669855:+
TGCT	cis	rs9399135	1	rs4896130	ENSG00000232876.1	CTA-212D2.2	-7.68	4.15e-12	2.06e-08	-0.52	-0.57	Red blood cell count;	chr6:135033980	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs6909975	ENSG00000232876.1	CTA-212D2.2	-7.68	4.17e-12	2.06e-08	-0.52	-0.57	Red blood cell count;	chr6:134994432	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs7773126	ENSG00000232876.1	CTA-212D2.2	-7.68	4.17e-12	2.06e-08	-0.52	-0.57	Red blood cell count;	chr6:134997252	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs6923827	ENSG00000232876.1	CTA-212D2.2	-7.68	4.17e-12	2.06e-08	-0.52	-0.57	Red blood cell count;	chr6:135014244	chr6:135055033~135060550:+
TGCT	cis	rs9399135	1	rs11754265	ENSG00000232876.1	CTA-212D2.2	-7.68	4.17e-12	2.06e-08	-0.52	-0.57	Red blood cell count;	chr6:135035078	chr6:135055033~135060550:+
TGCT	cis	rs1355223	1	rs11601205	ENSG00000271369.1	RP11-350D17.3	-7.67	4.29e-12	2.12e-08	-0.56	-0.57	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34746932	chr11:34709600~34710161:+
TGCT	cis	rs977987	1	rs977985	ENSG00000261783.1	RP11-252K23.2	-7.67	4.36e-12	2.16e-08	-0.81	-0.57	Dupuytren's disease;	chr16:75473049	chr16:75379818~75381260:-
TGCT	cis	rs1155848	0.571	rs7983556	ENSG00000227354.5	RBM26-AS1	7.67	4.38e-12	2.17e-08	0.86	0.57	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79608777	chr13:79406309~79424328:+
TGCT	cis	rs524281	0.773	rs10791863	ENSG00000255320.1	RP11-755F10.1	7.67	4.47e-12	2.19e-08	0.79	0.57	Electroencephalogram traits;	chr11:66259887	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.773	rs2155030	ENSG00000255320.1	RP11-755F10.1	7.67	4.47e-12	2.19e-08	0.79	0.57	Electroencephalogram traits;	chr11:66263216	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.773	rs2155031	ENSG00000255320.1	RP11-755F10.1	7.67	4.47e-12	2.19e-08	0.79	0.57	Electroencephalogram traits;	chr11:66263456	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.731	rs2276036	ENSG00000255320.1	RP11-755F10.1	7.67	4.47e-12	2.19e-08	0.79	0.57	Electroencephalogram traits;	chr11:66265959	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.773	rs10750781	ENSG00000255320.1	RP11-755F10.1	7.67	4.47e-12	2.19e-08	0.79	0.57	Electroencephalogram traits;	chr11:66269799	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.773	rs2017969	ENSG00000255320.1	RP11-755F10.1	7.67	4.47e-12	2.19e-08	0.79	0.57	Electroencephalogram traits;	chr11:66271561	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.773	rs2298468	ENSG00000255320.1	RP11-755F10.1	7.67	4.47e-12	2.19e-08	0.79	0.57	Electroencephalogram traits;	chr11:66275491	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.773	rs79770412	ENSG00000255320.1	RP11-755F10.1	7.67	4.47e-12	2.19e-08	0.79	0.57	Electroencephalogram traits;	chr11:66277873	chr11:66244840~66246239:-
TGCT	cis	rs17361889	0.633	rs17359183	ENSG00000224683.1	RPL36AP29	7.66	4.54e-12	2.21e-08	0.66	0.57	Pediatric bone mineral content (hip);	chr7:16123149	chr7:16208945~16209265:+
TGCT	cis	rs17361889	0.711	rs17359294	ENSG00000224683.1	RPL36AP29	7.66	4.54e-12	2.21e-08	0.66	0.57	Pediatric bone mineral content (hip);	chr7:16124889	chr7:16208945~16209265:+
TGCT	cis	rs9326248	0.861	rs4938343	ENSG00000254851.1	RP11-109L13.1	-7.66	4.58e-12	2.23e-08	-0.87	-0.57	Blood protein levels;	chr11:117132812	chr11:117135528~117138582:+
TGCT	cis	rs1930961	1	rs6004672	ENSG00000272977.1	CTA-390C10.10	-7.66	4.58e-12	2.23e-08	-0.74	-0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25485046	chr22:25476218~25479971:+
TGCT	cis	rs8040855	0.825	rs4843021	ENSG00000259295.5	CSPG4P12	-7.66	4.61e-12	2.24e-08	-0.76	-0.57	Bulimia nervosa;	chr15:85151317	chr15:85191438~85213905:+
TGCT	cis	rs17361889	0.711	rs17287882	ENSG00000224683.1	RPL36AP29	7.65	4.75e-12	2.31e-08	0.66	0.57	Pediatric bone mineral content (hip);	chr7:16139249	chr7:16208945~16209265:+
TGCT	cis	rs916888	0.61	rs199530	ENSG00000262539.1	RP11-259G18.3	-7.65	4.81e-12	2.34e-08	-0.8	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46259551~46260606:-
TGCT	cis	rs9326248	0.813	rs588534	ENSG00000254851.1	RP11-109L13.1	-7.64	5e-12	2.43e-08	-0.84	-0.57	Blood protein levels;	chr11:117197788	chr11:117135528~117138582:+
TGCT	cis	rs977987	0.872	rs4243111	ENSG00000261783.1	RP11-252K23.2	-7.64	5e-12	2.43e-08	-0.8	-0.57	Dupuytren's disease;	chr16:75286929	chr16:75379818~75381260:-
TGCT	cis	rs853679	0.657	rs1778483	ENSG00000216901.1	AL022393.7	7.64	5.11e-12	2.48e-08	0.66	0.57	Depression;	chr6:28273214	chr6:28176188~28176674:+
TGCT	cis	rs853679	0.657	rs1778482	ENSG00000216901.1	AL022393.7	7.64	5.11e-12	2.48e-08	0.66	0.57	Depression;	chr6:28273215	chr6:28176188~28176674:+
TGCT	cis	rs9399135	1	rs6569988	ENSG00000232876.1	CTA-212D2.2	-7.64	5.13e-12	2.48e-08	-0.53	-0.57	Red blood cell count;	chr6:135031165	chr6:135055033~135060550:+
TGCT	cis	rs7188445	1	rs7188445	ENSG00000261390.4	RP11-345M22.2	-7.64	5.15e-12	2.5e-08	-0.56	-0.57	Urate levels;	chr16:79701090	chr16:79715232~79770563:-
TGCT	cis	rs4423214	1	rs2276360	ENSG00000254682.1	RP11-660L16.2	7.64	5.22e-12	2.53e-08	0.75	0.57	Vitamin D levels;	chr11:71458501	chr11:71448674~71452157:+
TGCT	cis	rs1355223	0.752	rs17293467	ENSG00000271369.1	RP11-350D17.3	-7.63	5.26e-12	2.55e-08	-0.54	-0.57	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34655813	chr11:34709600~34710161:+
TGCT	cis	rs7188445	0.899	rs7195321	ENSG00000261390.4	RP11-345M22.2	-7.63	5.28e-12	2.56e-08	-0.57	-0.57	Urate levels;	chr16:79701065	chr16:79715232~79770563:-
TGCT	cis	rs7188445	0.871	rs11150187	ENSG00000261390.4	RP11-345M22.2	7.63	5.3e-12	2.56e-08	0.56	0.57	Urate levels;	chr16:79670515	chr16:79715232~79770563:-
TGCT	cis	rs9399135	0.636	rs4646871	ENSG00000232876.1	CTA-212D2.2	7.63	5.32e-12	2.58e-08	0.49	0.57	Red blood cell count;	chr6:134944479	chr6:135055033~135060550:+
TGCT	cis	rs1355223	0.752	rs896856	ENSG00000271369.1	RP11-350D17.3	-7.63	5.36e-12	2.6e-08	-0.54	-0.57	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34655295	chr11:34709600~34710161:+
TGCT	cis	rs9326248	0.861	rs1871757	ENSG00000254851.1	RP11-109L13.1	-7.63	5.4e-12	2.61e-08	-0.89	-0.57	Blood protein levels;	chr11:117159865	chr11:117135528~117138582:+
TGCT	cis	rs2486288	0.656	rs9921035	ENSG00000259520.4	CTD-2651B20.3	7.63	5.45e-12	2.64e-08	0.45	0.57	Glomerular filtration rate;	chr15:45254462	chr15:45251580~45279251:-
TGCT	cis	rs1577917	1	rs955196	ENSG00000203875.9	SNHG5	7.62	5.61e-12	2.71e-08	0.76	0.56	Response to antipsychotic treatment;	chr6:86020233	chr6:85660950~85678736:-
TGCT	cis	rs916888	0.61	rs199438	ENSG00000262539.1	RP11-259G18.3	7.62	5.61e-12	2.71e-08	0.82	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46259551~46260606:-
TGCT	cis	rs5769707	0.777	rs739243	ENSG00000188511.11	C22orf34	7.62	5.64e-12	2.72e-08	0.54	0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49663563	chr22:49414524~49657542:-
TGCT	cis	rs2283792	0.846	rs240049	ENSG00000228050.1	TOP3BP1	7.62	5.66e-12	2.73e-08	0.68	0.56	Multiple sclerosis;	chr22:21906236	chr22:22223187~22224566:-
TGCT	cis	rs524281	0.773	rs11227447	ENSG00000255320.1	RP11-755F10.1	7.62	5.77e-12	2.78e-08	0.78	0.56	Electroencephalogram traits;	chr11:66280809	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.773	rs11227448	ENSG00000255320.1	RP11-755F10.1	7.62	5.77e-12	2.78e-08	0.78	0.56	Electroencephalogram traits;	chr11:66281020	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.773	rs2282568	ENSG00000255320.1	RP11-755F10.1	7.62	5.77e-12	2.78e-08	0.78	0.56	Electroencephalogram traits;	chr11:66285361	chr11:66244840~66246239:-
TGCT	cis	rs4423214	1	rs2276361	ENSG00000254682.1	RP11-660L16.2	7.61	5.88e-12	2.83e-08	0.76	0.56	Vitamin D levels;	chr11:71458602	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.819	rs7938885	ENSG00000254682.1	RP11-660L16.2	7.61	5.88e-12	2.83e-08	0.76	0.56	Vitamin D levels;	chr11:71458997	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.959	rs12800438	ENSG00000254682.1	RP11-660L16.2	7.61	5.88e-12	2.83e-08	0.76	0.56	Vitamin D levels;	chr11:71459957	chr11:71448674~71452157:+
TGCT	cis	rs4423214	1	rs12807718	ENSG00000254682.1	RP11-660L16.2	7.61	5.88e-12	2.83e-08	0.76	0.56	Vitamin D levels;	chr11:71460124	chr11:71448674~71452157:+
TGCT	cis	rs4423214	1	rs4423214	ENSG00000254682.1	RP11-660L16.2	7.61	5.88e-12	2.83e-08	0.76	0.56	Vitamin D levels;	chr11:71462208	chr11:71448674~71452157:+
TGCT	cis	rs4423214	1	rs2276362	ENSG00000254682.1	RP11-660L16.2	7.61	5.88e-12	2.83e-08	0.76	0.56	Vitamin D levels;	chr11:71463406	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.879	rs4945008	ENSG00000254682.1	RP11-660L16.2	7.61	5.94e-12	2.85e-08	0.78	0.56	Vitamin D levels;	chr11:71510202	chr11:71448674~71452157:+
TGCT	cis	rs875971	0.505	rs6955582	ENSG00000226824.5	RP4-756H11.3	-7.61	6e-12	2.88e-08	-0.64	-0.56	Aortic root size;	chr7:65966699	chr7:66654538~66669855:+
TGCT	cis	rs6452524	0.967	rs62374399	ENSG00000249664.1	CTD-2227C6.2	7.61	6.02e-12	2.89e-08	0.58	0.56	Hypertension (SNP x SNP interaction);	chr5:83176051	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs62374401	ENSG00000249664.1	CTD-2227C6.2	7.61	6.02e-12	2.89e-08	0.58	0.56	Hypertension (SNP x SNP interaction);	chr5:83177159	chr5:83012285~83013109:-
TGCT	cis	rs2486288	0.656	rs7162022	ENSG00000259520.4	CTD-2651B20.3	7.61	6.07e-12	2.91e-08	0.49	0.56	Glomerular filtration rate;	chr15:45273055	chr15:45251580~45279251:-
TGCT	cis	rs2739330	0.685	rs4822453	ENSG00000218537.1	MIF-AS1	7.61	6.1e-12	2.92e-08	0.69	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23894426~23898930:-
TGCT	cis	rs1577917	1	rs12664335	ENSG00000203875.9	SNHG5	7.6	6.2e-12	2.97e-08	0.74	0.56	Response to antipsychotic treatment;	chr6:85888056	chr6:85660950~85678736:-
TGCT	cis	rs1775715	0.678	rs7096139	ENSG00000239731.3	RN7SL825P	-7.6	6.27e-12	3e-08	-0.57	-0.56	Bipolar disorder with mood-incongruent psychosis;	chr10:31928476	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.87	rs3847415	ENSG00000239731.3	RN7SL825P	-7.6	6.27e-12	3e-08	-0.57	-0.56	Bipolar disorder with mood-incongruent psychosis;	chr10:31930528	chr10:31992087~31992381:-
TGCT	cis	rs7188445	1	rs7190187	ENSG00000261390.4	RP11-345M22.2	-7.6	6.31e-12	3.02e-08	-0.57	-0.56	Urate levels;	chr16:79701281	chr16:79715232~79770563:-
TGCT	cis	rs7188445	0.932	rs11150191	ENSG00000261390.4	RP11-345M22.2	-7.59	6.48e-12	3.1e-08	-0.57	-0.56	Urate levels;	chr16:79700390	chr16:79715232~79770563:-
TGCT	cis	rs62388641	0.539	rs56304710	ENSG00000272279.1	RP11-157J24.2	7.59	6.49e-12	3.1e-08	0.64	0.56	Daytime sleep phenotypes;	chr6:1542341	chr6:1528364~1528911:-
TGCT	cis	rs11098499	0.863	rs17050695	ENSG00000245958.5	RP11-33B1.1	-7.59	6.6e-12	3.15e-08	-0.59	-0.56	Corneal astigmatism;	chr4:119568372	chr4:119454791~119552025:+
TGCT	cis	rs17361889	0.711	rs1120230	ENSG00000224683.1	RPL36AP29	7.59	6.68e-12	3.19e-08	0.67	0.56	Pediatric bone mineral content (hip);	chr7:16110992	chr7:16208945~16209265:+
TGCT	cis	rs17361889	0.671	rs4282466	ENSG00000224683.1	RPL36AP29	7.59	6.68e-12	3.19e-08	0.67	0.56	Pediatric bone mineral content (hip);	chr7:16111878	chr7:16208945~16209265:+
TGCT	cis	rs2486288	0.656	rs11632920	ENSG00000259520.4	CTD-2651B20.3	7.59	6.72e-12	3.2e-08	0.46	0.56	Glomerular filtration rate;	chr15:45259066	chr15:45251580~45279251:-
TGCT	cis	rs1930961	1	rs6004675	ENSG00000272977.1	CTA-390C10.10	-7.58	6.83e-12	3.26e-08	-0.75	-0.56	Bipolar disorder with mood-incongruent psychosis;	chr22:25493418	chr22:25476218~25479971:+
TGCT	cis	rs2929278	0.617	rs694461	ENSG00000205771.5	CATSPER2P1	7.58	6.85e-12	3.26e-08	0.63	0.56	Schizophrenia;	chr15:43803865	chr15:43726918~43747094:-
TGCT	cis	rs858239	1	rs199357	ENSG00000230658.1	KLHL7-AS1	-7.58	6.98e-12	3.32e-08	-0.58	-0.56	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23101228~23105703:-
TGCT	cis	rs2283792	0.935	rs8141851	ENSG00000228050.1	TOP3BP1	7.58	7.12e-12	3.38e-08	0.66	0.56	Multiple sclerosis;	chr22:21812161	chr22:22223187~22224566:-
TGCT	cis	rs4423214	1	rs7935125	ENSG00000254682.1	RP11-660L16.2	7.57	7.25e-12	3.44e-08	0.76	0.56	Vitamin D levels;	chr11:71473144	chr11:71448674~71452157:+
TGCT	cis	rs4423214	1	rs732934	ENSG00000254682.1	RP11-660L16.2	7.57	7.25e-12	3.44e-08	0.76	0.56	Vitamin D levels;	chr11:71475430	chr11:71448674~71452157:+
TGCT	cis	rs943437	0.557	rs9487736	ENSG00000227012.2	RP1-97J1.2	7.57	7.36e-12	3.49e-08	0.88	0.56	Parkinson's disease;	chr6:111847106	chr6:111900489~111901851:-
TGCT	cis	rs943437	0.557	rs17072993	ENSG00000227012.2	RP1-97J1.2	7.57	7.36e-12	3.49e-08	0.88	0.56	Parkinson's disease;	chr6:111849927	chr6:111900489~111901851:-
TGCT	cis	rs9399135	1	rs4475342	ENSG00000232876.1	CTA-212D2.2	-7.57	7.43e-12	3.53e-08	-0.52	-0.56	Red blood cell count;	chr6:134962210	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.507	rs11757723	ENSG00000232876.1	CTA-212D2.2	-7.57	7.45e-12	3.53e-08	-0.52	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134970155	chr6:135055033~135060550:+
TGCT	cis	rs9389248	0.737	rs56358308	ENSG00000232876.1	CTA-212D2.2	-7.57	7.45e-12	3.53e-08	-0.52	-0.56	High light scatter reticulocyte percentage of red cells;	chr6:134985842	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.507	rs11754021	ENSG00000232876.1	CTA-212D2.2	-7.57	7.45e-12	3.53e-08	-0.52	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134987237	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs12526055	ENSG00000232876.1	CTA-212D2.2	-7.57	7.47e-12	3.54e-08	-0.51	-0.56	Red blood cell count;	chr6:135004780	chr6:135055033~135060550:+
TGCT	cis	rs7246967	0.611	rs2617780	ENSG00000269509.1	BNIP3P34	7.57	7.49e-12	3.55e-08	1.06	0.56	Bronchopulmonary dysplasia;	chr19:22809388	chr19:22773853~22774424:+
TGCT	cis	rs9399135	0.967	rs4895434	ENSG00000232876.1	CTA-212D2.2	-7.56	7.6e-12	3.58e-08	-0.52	-0.56	Red blood cell count;	chr6:134972227	chr6:135055033~135060550:+
TGCT	cis	rs9399135	1	rs4895435	ENSG00000232876.1	CTA-212D2.2	-7.56	7.6e-12	3.58e-08	-0.52	-0.56	Red blood cell count;	chr6:134972325	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs4896120	ENSG00000232876.1	CTA-212D2.2	-7.56	7.6e-12	3.58e-08	-0.52	-0.56	Red blood cell count;	chr6:134972374	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs4896123	ENSG00000232876.1	CTA-212D2.2	-7.56	7.6e-12	3.58e-08	-0.52	-0.56	Red blood cell count;	chr6:134974272	chr6:135055033~135060550:+
TGCT	cis	rs9399135	1	rs35123050	ENSG00000232876.1	CTA-212D2.2	-7.56	7.6e-12	3.58e-08	-0.52	-0.56	Red blood cell count;	chr6:134981602	chr6:135055033~135060550:+
TGCT	cis	rs4423214	1	rs12419334	ENSG00000254682.1	RP11-660L16.2	7.56	7.68e-12	3.61e-08	0.76	0.56	Vitamin D levels;	chr11:71428426	chr11:71448674~71452157:+
TGCT	cis	rs916888	0.531	rs183211	ENSG00000214401.4	KANSL1-AS1	7.56	7.71e-12	3.62e-08	0.73	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46193576~46196723:+
TGCT	cis	rs2929278	0.562	rs8033846	ENSG00000205771.5	CATSPER2P1	7.56	7.92e-12	3.72e-08	0.62	0.56	Schizophrenia;	chr15:43743165	chr15:43726918~43747094:-
TGCT	cis	rs2929278	0.589	rs7174732	ENSG00000205771.5	CATSPER2P1	7.56	7.92e-12	3.72e-08	0.62	0.56	Schizophrenia;	chr15:43746265	chr15:43726918~43747094:-
TGCT	cis	rs17361889	0.778	rs56033714	ENSG00000224683.1	RPL36AP29	7.55	8.01e-12	3.75e-08	0.64	0.56	Pediatric bone mineral content (hip);	chr7:16171442	chr7:16208945~16209265:+
TGCT	cis	rs17361889	0.752	rs62440374	ENSG00000224683.1	RPL36AP29	7.55	8.01e-12	3.75e-08	0.64	0.56	Pediatric bone mineral content (hip);	chr7:16172290	chr7:16208945~16209265:+
TGCT	cis	rs17361889	0.738	rs35150436	ENSG00000224683.1	RPL36AP29	7.55	8.02e-12	3.75e-08	0.66	0.56	Pediatric bone mineral content (hip);	chr7:16147313	chr7:16208945~16209265:+
TGCT	cis	rs17361889	0.711	rs1978253	ENSG00000224683.1	RPL36AP29	7.55	8.02e-12	3.75e-08	0.66	0.56	Pediatric bone mineral content (hip);	chr7:16151114	chr7:16208945~16209265:+
TGCT	cis	rs11098499	0.575	rs9996586	ENSG00000245958.5	RP11-33B1.1	-7.55	8.07e-12	3.78e-08	-0.56	-0.56	Corneal astigmatism;	chr4:119405787	chr4:119454791~119552025:+
TGCT	cis	rs66887589	0.627	rs3872807	ENSG00000245958.5	RP11-33B1.1	-7.55	8.2e-12	3.83e-08	-0.56	-0.56	Diastolic blood pressure;	chr4:119439096	chr4:119454791~119552025:+
TGCT	cis	rs66887589	0.56	rs9684327	ENSG00000245958.5	RP11-33B1.1	-7.55	8.2e-12	3.83e-08	-0.56	-0.56	Diastolic blood pressure;	chr4:119444286	chr4:119454791~119552025:+
TGCT	cis	rs977987	0.966	rs11643207	ENSG00000261783.1	RP11-252K23.2	-7.55	8.41e-12	3.9e-08	-0.82	-0.56	Dupuytren's disease;	chr16:75464895	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.933	rs4888431	ENSG00000261783.1	RP11-252K23.2	-7.55	8.41e-12	3.9e-08	-0.82	-0.56	Dupuytren's disease;	chr16:75466801	chr16:75379818~75381260:-
TGCT	cis	rs977987	1	rs62060550	ENSG00000261783.1	RP11-252K23.2	-7.55	8.41e-12	3.9e-08	-0.82	-0.56	Dupuytren's disease;	chr16:75468354	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.966	rs62060551	ENSG00000261783.1	RP11-252K23.2	-7.55	8.41e-12	3.9e-08	-0.82	-0.56	Dupuytren's disease;	chr16:75468414	chr16:75379818~75381260:-
TGCT	cis	rs2929278	0.617	rs575082	ENSG00000205771.5	CATSPER2P1	7.54	8.61e-12	3.99e-08	0.63	0.56	Schizophrenia;	chr15:43817944	chr15:43726918~43747094:-
TGCT	cis	rs2929278	0.617	rs2955969	ENSG00000205771.5	CATSPER2P1	7.54	8.61e-12	3.99e-08	0.63	0.56	Schizophrenia;	chr15:43822329	chr15:43726918~43747094:-
TGCT	cis	rs2283792	1	rs5999521	ENSG00000228050.1	TOP3BP1	7.54	8.65e-12	4.01e-08	0.66	0.56	Multiple sclerosis;	chr22:21792110	chr22:22223187~22224566:-
TGCT	cis	rs2283792	1	rs5749986	ENSG00000228050.1	TOP3BP1	-7.54	8.65e-12	4.01e-08	-0.66	-0.56	Multiple sclerosis;	chr22:21803372	chr22:22223187~22224566:-
TGCT	cis	rs524281	0.773	rs7925123	ENSG00000255320.1	RP11-755F10.1	7.54	8.66e-12	4.01e-08	0.77	0.56	Electroencephalogram traits;	chr11:66225742	chr11:66244840~66246239:-
TGCT	cis	rs2882667	0.898	rs10058347	ENSG00000253404.1	AC034243.1	7.54	8.71e-12	4.03e-08	0.62	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025669	chr5:138744434~138753309:-
TGCT	cis	rs6700559	0.683	rs4915450	ENSG00000260088.1	RP11-92G12.3	-7.54	8.74e-12	4.04e-08	-0.68	-0.56	Coronary artery disease;	chr1:200672461	chr1:200669507~200694250:+
TGCT	cis	rs943437	0.778	rs997368	ENSG00000227012.2	RP1-97J1.2	7.53	8.94e-12	4.13e-08	0.76	0.56	Parkinson's disease;	chr6:111922088	chr6:111900489~111901851:-
TGCT	cis	rs2929278	0.617	rs11070410	ENSG00000205771.5	CATSPER2P1	7.53	8.95e-12	4.13e-08	0.62	0.56	Schizophrenia;	chr15:43764847	chr15:43726918~43747094:-
TGCT	cis	rs9399137	0.507	rs4289677	ENSG00000232876.1	CTA-212D2.2	-7.53	9.1e-12	4.2e-08	-0.53	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954347	chr6:135055033~135060550:+
TGCT	cis	rs997154	0.579	rs12889177	ENSG00000279656.1	RP11-298I3.6	-7.53	9.11e-12	4.2e-08	-0.99	-0.56	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23022120	chr14:23023083~23024217:-
TGCT	cis	rs524281	0.773	rs2155201	ENSG00000255320.1	RP11-755F10.1	7.53	9.14e-12	4.21e-08	0.76	0.56	Electroencephalogram traits;	chr11:66224873	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.773	rs2236651	ENSG00000255320.1	RP11-755F10.1	7.53	9.14e-12	4.21e-08	0.76	0.56	Electroencephalogram traits;	chr11:66233947	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.773	rs4393319	ENSG00000255320.1	RP11-755F10.1	7.53	9.14e-12	4.21e-08	0.76	0.56	Electroencephalogram traits;	chr11:66234407	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.773	rs10896105	ENSG00000255320.1	RP11-755F10.1	7.53	9.14e-12	4.21e-08	0.76	0.56	Electroencephalogram traits;	chr11:66234789	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.773	rs2236652	ENSG00000255320.1	RP11-755F10.1	7.53	9.14e-12	4.21e-08	0.76	0.56	Electroencephalogram traits;	chr11:66235210	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.731	rs11227433	ENSG00000255320.1	RP11-755F10.1	7.53	9.14e-12	4.21e-08	0.76	0.56	Electroencephalogram traits;	chr11:66237222	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.731	rs476551	ENSG00000255320.1	RP11-755F10.1	7.53	9.14e-12	4.21e-08	0.76	0.56	Electroencephalogram traits;	chr11:66238852	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.773	rs10791861	ENSG00000255320.1	RP11-755F10.1	7.53	9.14e-12	4.21e-08	0.76	0.56	Electroencephalogram traits;	chr11:66240999	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.773	rs10791862	ENSG00000255320.1	RP11-755F10.1	7.53	9.14e-12	4.21e-08	0.76	0.56	Electroencephalogram traits;	chr11:66246193	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.773	rs2155198	ENSG00000255320.1	RP11-755F10.1	7.53	9.14e-12	4.21e-08	0.76	0.56	Electroencephalogram traits;	chr11:66246829	chr11:66244840~66246239:-
TGCT	cis	rs1062177	0.694	rs2915816	ENSG00000253921.1	CTB-113P19.3	7.53	9.15e-12	4.21e-08	0.61	0.56	Preschool internalizing problems;	chr5:151736296	chr5:151753992~151767247:+
TGCT	cis	rs6700559	0.804	rs11588318	ENSG00000260088.1	RP11-92G12.3	-7.53	9.18e-12	4.23e-08	-0.67	-0.56	Coronary artery disease;	chr1:200669534	chr1:200669507~200694250:+
TGCT	cis	rs6700559	0.903	rs6661240	ENSG00000260088.1	RP11-92G12.3	-7.53	9.18e-12	4.23e-08	-0.67	-0.56	Coronary artery disease;	chr1:200669719	chr1:200669507~200694250:+
TGCT	cis	rs6700559	0.967	rs6688581	ENSG00000260088.1	RP11-92G12.3	-7.53	9.18e-12	4.23e-08	-0.67	-0.56	Coronary artery disease;	chr1:200670028	chr1:200669507~200694250:+
TGCT	cis	rs6700559	1	rs3806358	ENSG00000260088.1	RP11-92G12.3	-7.53	9.18e-12	4.23e-08	-0.67	-0.56	Coronary artery disease;	chr1:200670555	chr1:200669507~200694250:+
TGCT	cis	rs1062177	1	rs72802204	ENSG00000213433.5	RPLP1P6	-7.52	9.57e-12	4.4e-08	-0.6	-0.56	Preschool internalizing problems;	chr5:151803622	chr5:151765859~151766378:-
TGCT	cis	rs875971	0.83	rs427575	ENSG00000226824.5	RP4-756H11.3	-7.52	9.72e-12	4.46e-08	-0.62	-0.56	Aortic root size;	chr7:66054232	chr7:66654538~66669855:+
TGCT	cis	rs2882667	0.964	rs2288824	ENSG00000253404.1	AC034243.1	7.51	9.95e-12	4.57e-08	0.65	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138962707	chr5:138744434~138753309:-
TGCT	cis	rs9399137	0.507	rs4520025	ENSG00000232876.1	CTA-212D2.2	-7.51	1.02e-11	4.64e-08	-0.52	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957481	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.507	rs4451150	ENSG00000232876.1	CTA-212D2.2	-7.51	1.02e-11	4.64e-08	-0.52	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957925	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.561	rs11753985	ENSG00000232876.1	CTA-212D2.2	-7.51	1.02e-11	4.64e-08	-0.52	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134959300	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.529	rs7739722	ENSG00000232876.1	CTA-212D2.2	-7.51	1.02e-11	4.64e-08	-0.52	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961087	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.507	rs13196486	ENSG00000232876.1	CTA-212D2.2	-7.51	1.02e-11	4.64e-08	-0.52	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134962736	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.507	rs6918512	ENSG00000232876.1	CTA-212D2.2	-7.51	1.02e-11	4.64e-08	-0.52	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134963701	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.507	rs4594969	ENSG00000232876.1	CTA-212D2.2	-7.51	1.02e-11	4.64e-08	-0.52	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134964448	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.507	rs13064	ENSG00000232876.1	CTA-212D2.2	-7.51	1.02e-11	4.64e-08	-0.52	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134966395	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.507	rs12664898	ENSG00000232876.1	CTA-212D2.2	-7.51	1.02e-11	4.64e-08	-0.52	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967525	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.507	rs56164974	ENSG00000232876.1	CTA-212D2.2	-7.51	1.02e-11	4.64e-08	-0.52	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967578	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.507	rs12663810	ENSG00000232876.1	CTA-212D2.2	-7.51	1.02e-11	4.64e-08	-0.52	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134968644	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.507	rs35571217	ENSG00000232876.1	CTA-212D2.2	-7.51	1.02e-11	4.64e-08	-0.52	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134969217	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.507	rs4580893	ENSG00000232876.1	CTA-212D2.2	-7.51	1.02e-11	4.64e-08	-0.52	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134976524	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.507	rs6569986	ENSG00000232876.1	CTA-212D2.2	-7.51	1.02e-11	4.64e-08	-0.52	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134990503	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.507	rs13197750	ENSG00000232876.1	CTA-212D2.2	-7.51	1.02e-11	4.64e-08	-0.52	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134991242	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.507	rs7761964	ENSG00000232876.1	CTA-212D2.2	-7.51	1.02e-11	4.64e-08	-0.52	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134993127	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.507	rs11753673	ENSG00000232876.1	CTA-212D2.2	-7.51	1.02e-11	4.64e-08	-0.52	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995338	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.507	rs12663447	ENSG00000232876.1	CTA-212D2.2	-7.51	1.02e-11	4.64e-08	-0.52	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995888	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.507	rs4895437	ENSG00000232876.1	CTA-212D2.2	-7.51	1.02e-11	4.64e-08	-0.52	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134996216	chr6:135055033~135060550:+
TGCT	cis	rs1930961	1	rs760555	ENSG00000272977.1	CTA-390C10.10	-7.51	1.02e-11	4.65e-08	-0.73	-0.56	Bipolar disorder with mood-incongruent psychosis;	chr22:25476870	chr22:25476218~25479971:+
TGCT	cis	rs2882667	0.964	rs12055237	ENSG00000253404.1	AC034243.1	7.51	1.04e-11	4.73e-08	0.66	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138971617	chr5:138744434~138753309:-
TGCT	cis	rs2283792	0.967	rs3810609	ENSG00000228050.1	TOP3BP1	7.5	1.04e-11	4.75e-08	0.66	0.56	Multiple sclerosis;	chr22:21758513	chr22:22223187~22224566:-
TGCT	cis	rs9399135	1	rs1014021	ENSG00000232876.1	CTA-212D2.2	7.5	1.04e-11	4.75e-08	0.51	0.56	Red blood cell count;	chr6:135013462	chr6:135055033~135060550:+
TGCT	cis	rs2283792	1	rs3810610	ENSG00000228050.1	TOP3BP1	7.5	1.04e-11	4.76e-08	0.66	0.56	Multiple sclerosis;	chr22:21761209	chr22:22223187~22224566:-
TGCT	cis	rs2283792	1	rs13943	ENSG00000228050.1	TOP3BP1	7.5	1.04e-11	4.76e-08	0.66	0.56	Multiple sclerosis;	chr22:21761913	chr22:22223187~22224566:-
TGCT	cis	rs2283792	0.967	rs11704205	ENSG00000228050.1	TOP3BP1	7.5	1.05e-11	4.78e-08	0.66	0.56	Multiple sclerosis;	chr22:21790964	chr22:22223187~22224566:-
TGCT	cis	rs2929278	0.561	rs62018952	ENSG00000205771.5	CATSPER2P1	7.5	1.06e-11	4.84e-08	0.63	0.56	Schizophrenia;	chr15:43788539	chr15:43726918~43747094:-
TGCT	cis	rs9399135	0.967	rs6569990	ENSG00000232876.1	CTA-212D2.2	-7.5	1.06e-11	4.84e-08	-0.51	-0.56	Red blood cell count;	chr6:135044680	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs13191501	ENSG00000232876.1	CTA-212D2.2	-7.5	1.06e-11	4.84e-08	-0.51	-0.56	Red blood cell count;	chr6:135045742	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs6908512	ENSG00000232876.1	CTA-212D2.2	-7.5	1.06e-11	4.84e-08	-0.51	-0.56	Red blood cell count;	chr6:135046619	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs34546690	ENSG00000232876.1	CTA-212D2.2	-7.5	1.06e-11	4.84e-08	-0.51	-0.56	Red blood cell count;	chr6:135048571	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs11755229	ENSG00000232876.1	CTA-212D2.2	-7.5	1.06e-11	4.84e-08	-0.51	-0.56	Red blood cell count;	chr6:135048775	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs9389261	ENSG00000232876.1	CTA-212D2.2	-7.5	1.06e-11	4.84e-08	-0.51	-0.56	Red blood cell count;	chr6:135050010	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs9376085	ENSG00000232876.1	CTA-212D2.2	-7.5	1.06e-11	4.84e-08	-0.51	-0.56	Red blood cell count;	chr6:135050086	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs9373122	ENSG00000232876.1	CTA-212D2.2	-7.5	1.06e-11	4.84e-08	-0.51	-0.56	Red blood cell count;	chr6:135052396	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.933	rs28384512	ENSG00000232876.1	CTA-212D2.2	-7.5	1.06e-11	4.84e-08	-0.51	-0.56	Red blood cell count;	chr6:135055094	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.933	rs41294852	ENSG00000232876.1	CTA-212D2.2	-7.5	1.06e-11	4.84e-08	-0.51	-0.56	Red blood cell count;	chr6:135055241	chr6:135055033~135060550:+
TGCT	cis	rs9326248	0.581	rs7120515	ENSG00000254851.1	RP11-109L13.1	-7.5	1.06e-11	4.85e-08	-0.67	-0.56	Blood protein levels;	chr11:117121210	chr11:117135528~117138582:+
TGCT	cis	rs9399135	0.967	rs7763836	ENSG00000232876.1	CTA-212D2.2	-7.5	1.07e-11	4.86e-08	-0.51	-0.56	Red blood cell count;	chr6:135041240	chr6:135055033~135060550:+
TGCT	cis	rs2882667	0.893	rs7717375	ENSG00000253404.1	AC034243.1	7.5	1.07e-11	4.88e-08	0.65	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138955716	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.893	rs10054796	ENSG00000253404.1	AC034243.1	7.5	1.07e-11	4.88e-08	0.65	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958655	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.893	rs10069961	ENSG00000253404.1	AC034243.1	7.5	1.07e-11	4.88e-08	0.65	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958879	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.964	rs11958050	ENSG00000253404.1	AC034243.1	7.5	1.07e-11	4.89e-08	0.62	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138966139	chr5:138744434~138753309:-
TGCT	cis	rs9399135	0.967	rs1854865	ENSG00000232876.1	CTA-212D2.2	-7.5	1.08e-11	4.9e-08	-0.51	-0.56	Red blood cell count;	chr6:135039162	chr6:135055033~135060550:+
TGCT	cis	rs2283792	0.967	rs5999550	ENSG00000228050.1	TOP3BP1	7.5	1.08e-11	4.91e-08	0.66	0.56	Multiple sclerosis;	chr22:21796997	chr22:22223187~22224566:-
TGCT	cis	rs8040855	0.791	rs8042888	ENSG00000259295.5	CSPG4P12	-7.5	1.08e-11	4.92e-08	-0.76	-0.56	Bulimia nervosa;	chr15:85152360	chr15:85191438~85213905:+
TGCT	cis	rs1577917	0.876	rs12190735	ENSG00000203875.9	SNHG5	-7.5	1.09e-11	4.96e-08	-0.75	-0.56	Response to antipsychotic treatment;	chr6:85976749	chr6:85660950~85678736:-
TGCT	cis	rs858239	0.614	rs10229956	ENSG00000230658.1	KLHL7-AS1	-7.49	1.1e-11	5.02e-08	-0.55	-0.56	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23101228~23105703:-
TGCT	cis	rs2283792	1	rs2266967	ENSG00000228050.1	TOP3BP1	7.49	1.12e-11	5.08e-08	0.66	0.56	Multiple sclerosis;	chr22:21802500	chr22:22223187~22224566:-
TGCT	cis	rs916888	0.773	rs1378358	ENSG00000262500.1	RP11-259G18.2	7.49	1.13e-11	5.12e-08	0.87	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46243606~46245044:+
TGCT	cis	rs17361889	0.766	rs17672493	ENSG00000224683.1	RPL36AP29	-7.49	1.13e-11	5.14e-08	-0.62	-0.56	Pediatric bone mineral content (hip);	chr7:16196559	chr7:16208945~16209265:+
TGCT	cis	rs950027	0.62	rs1145076	ENSG00000259520.4	CTD-2651B20.3	-7.49	1.15e-11	5.21e-08	-0.45	-0.56	Response to fenofibrate (adiponectin levels);	chr15:45392310	chr15:45251580~45279251:-
TGCT	cis	rs66887589	0.807	rs9799664	ENSG00000245958.5	RP11-33B1.1	-7.48	1.19e-11	5.4e-08	-0.56	-0.56	Diastolic blood pressure;	chr4:119405523	chr4:119454791~119552025:+
TGCT	cis	rs4423214	1	rs4944959	ENSG00000254682.1	RP11-660L16.2	-7.48	1.2e-11	5.45e-08	-0.75	-0.56	Vitamin D levels;	chr11:71457188	chr11:71448674~71452157:+
TGCT	cis	rs7188445	0.899	rs58722186	ENSG00000261390.4	RP11-345M22.2	-7.47	1.22e-11	5.51e-08	-0.58	-0.56	Urate levels;	chr16:79717694	chr16:79715232~79770563:-
TGCT	cis	rs977987	0.931	rs8057084	ENSG00000261783.1	RP11-252K23.2	7.47	1.22e-11	5.52e-08	0.79	0.56	Dupuytren's disease;	chr16:75458808	chr16:75379818~75381260:-
TGCT	cis	rs977987	1	rs977987	ENSG00000261783.1	RP11-252K23.2	-7.47	1.23e-11	5.56e-08	-0.8	-0.56	Dupuytren's disease;	chr16:75472695	chr16:75379818~75381260:-
TGCT	cis	rs2929278	0.588	rs688009	ENSG00000205771.5	CATSPER2P1	-7.47	1.23e-11	5.57e-08	-0.63	-0.56	Schizophrenia;	chr15:43864104	chr15:43726918~43747094:-
TGCT	cis	rs9399135	0.967	rs6923765	ENSG00000232876.1	CTA-212D2.2	7.47	1.26e-11	5.7e-08	0.51	0.56	Red blood cell count;	chr6:135014038	chr6:135055033~135060550:+
TGCT	cis	rs67383717	0.689	rs1836404	ENSG00000175611.10	LINC00476	-7.47	1.26e-11	5.7e-08	-0.46	-0.56	Parkinson's disease (pesticide exposure interaction);	chr9:95787982	chr9:95759231~95875977:-
TGCT	cis	rs6538678	0.864	rs7308921	ENSG00000258343.1	RP11-536G4.2	7.46	1.3e-11	5.85e-08	0.8	0.56	Lupus nephritis in systemic lupus erythematosus;	chr12:95870757	chr12:95795345~95858839:-
TGCT	cis	rs943437	0.557	rs7775711	ENSG00000227012.2	RP1-97J1.2	7.46	1.3e-11	5.86e-08	0.87	0.56	Parkinson's disease;	chr6:111840583	chr6:111900489~111901851:-
TGCT	cis	rs943437	0.557	rs7749147	ENSG00000227012.2	RP1-97J1.2	7.46	1.3e-11	5.86e-08	0.87	0.56	Parkinson's disease;	chr6:111843110	chr6:111900489~111901851:-
TGCT	cis	rs943437	0.557	rs59856565	ENSG00000227012.2	RP1-97J1.2	7.46	1.3e-11	5.86e-08	0.87	0.56	Parkinson's disease;	chr6:111843238	chr6:111900489~111901851:-
TGCT	cis	rs2882667	0.861	rs7703288	ENSG00000253404.1	AC034243.1	7.46	1.3e-11	5.88e-08	0.6	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139030850	chr5:138744434~138753309:-
TGCT	cis	rs11098499	0.954	rs11098524	ENSG00000245958.5	RP11-33B1.1	-7.46	1.31e-11	5.89e-08	-0.66	-0.56	Corneal astigmatism;	chr4:119468877	chr4:119454791~119552025:+
TGCT	cis	rs4423214	0.921	rs11603330	ENSG00000254682.1	RP11-660L16.2	7.46	1.32e-11	5.93e-08	0.72	0.56	Vitamin D levels;	chr11:71442413	chr11:71448674~71452157:+
TGCT	cis	rs2283792	1	rs3788332	ENSG00000228050.1	TOP3BP1	7.46	1.32e-11	5.93e-08	0.64	0.56	Multiple sclerosis;	chr22:21817278	chr22:22223187~22224566:-
TGCT	cis	rs2283792	0.967	rs5749998	ENSG00000228050.1	TOP3BP1	7.46	1.32e-11	5.95e-08	0.64	0.56	Multiple sclerosis;	chr22:21808085	chr22:22223187~22224566:-
TGCT	cis	rs2283792	1	rs9607287	ENSG00000228050.1	TOP3BP1	7.46	1.32e-11	5.95e-08	0.64	0.56	Multiple sclerosis;	chr22:21809136	chr22:22223187~22224566:-
TGCT	cis	rs2283792	0.567	rs2027789	ENSG00000228050.1	TOP3BP1	7.45	1.35e-11	6.08e-08	0.68	0.56	Multiple sclerosis;	chr22:21933490	chr22:22223187~22224566:-
TGCT	cis	rs9399137	0.507	rs13209780	ENSG00000232876.1	CTA-212D2.2	-7.45	1.36e-11	6.13e-08	-0.52	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135023657	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.507	rs4896129	ENSG00000232876.1	CTA-212D2.2	-7.45	1.36e-11	6.13e-08	-0.52	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028707	chr6:135055033~135060550:+
TGCT	cis	rs67383717	0.689	rs62559007	ENSG00000175611.10	LINC00476	-7.45	1.37e-11	6.15e-08	-0.46	-0.56	Parkinson's disease (pesticide exposure interaction);	chr9:95790981	chr9:95759231~95875977:-
TGCT	cis	rs875971	0.597	rs11771318	ENSG00000226824.5	RP4-756H11.3	7.45	1.38e-11	6.18e-08	0.62	0.56	Aortic root size;	chr7:66597493	chr7:66654538~66669855:+
TGCT	cis	rs8040855	0.627	rs11632658	ENSG00000259295.5	CSPG4P12	-7.45	1.4e-11	6.26e-08	-0.72	-0.56	Bulimia nervosa;	chr15:85062982	chr15:85191438~85213905:+
TGCT	cis	rs9399135	0.967	rs2150681	ENSG00000232876.1	CTA-212D2.2	7.45	1.4e-11	6.27e-08	0.51	0.56	Red blood cell count;	chr6:135054094	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs1590975	ENSG00000232876.1	CTA-212D2.2	-7.45	1.4e-11	6.27e-08	-0.51	-0.56	Red blood cell count;	chr6:135030950	chr6:135055033~135060550:+
TGCT	cis	rs2739330	0.76	rs5751761	ENSG00000218537.1	MIF-AS1	-7.45	1.4e-11	6.29e-08	-0.67	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23894426~23898930:-
TGCT	cis	rs4691139	1	rs10517825	ENSG00000250227.1	TRIM60P14	-7.44	1.43e-11	6.38e-08	-0.61	-0.56	Ovarian cancer in BRCA1 mutation carriers;	chr4:164972334	chr4:164915565~164916983:+
TGCT	cis	rs1062177	1	rs2915877	ENSG00000213433.5	RPLP1P6	-7.44	1.43e-11	6.38e-08	-0.59	-0.56	Preschool internalizing problems;	chr5:151771040	chr5:151765859~151766378:-
TGCT	cis	rs1062177	1	rs2964576	ENSG00000213433.5	RPLP1P6	-7.44	1.43e-11	6.38e-08	-0.59	-0.56	Preschool internalizing problems;	chr5:151771041	chr5:151765859~151766378:-
TGCT	cis	rs1062177	1	rs6890099	ENSG00000213433.5	RPLP1P6	-7.44	1.43e-11	6.38e-08	-0.59	-0.56	Preschool internalizing problems;	chr5:151772401	chr5:151765859~151766378:-
TGCT	cis	rs1062177	0.906	rs2964573	ENSG00000213433.5	RPLP1P6	-7.44	1.43e-11	6.38e-08	-0.59	-0.56	Preschool internalizing problems;	chr5:151780561	chr5:151765859~151766378:-
TGCT	cis	rs1062177	1	rs2964571	ENSG00000213433.5	RPLP1P6	-7.44	1.43e-11	6.38e-08	-0.59	-0.56	Preschool internalizing problems;	chr5:151791695	chr5:151765859~151766378:-
TGCT	cis	rs1062177	1	rs2915869	ENSG00000213433.5	RPLP1P6	-7.44	1.43e-11	6.38e-08	-0.59	-0.56	Preschool internalizing problems;	chr5:151791948	chr5:151765859~151766378:-
TGCT	cis	rs11098499	0.908	rs1002152	ENSG00000245958.5	RP11-33B1.1	-7.44	1.43e-11	6.4e-08	-0.56	-0.56	Corneal astigmatism;	chr4:119352232	chr4:119454791~119552025:+
TGCT	cis	rs66887589	0.774	rs9307477	ENSG00000245958.5	RP11-33B1.1	-7.44	1.43e-11	6.41e-08	-0.55	-0.56	Diastolic blood pressure;	chr4:119500654	chr4:119454791~119552025:+
TGCT	cis	rs1062177	1	rs2915882	ENSG00000213433.5	RPLP1P6	-7.44	1.44e-11	6.44e-08	-0.59	-0.56	Preschool internalizing problems;	chr5:151765875	chr5:151765859~151766378:-
TGCT	cis	rs1062177	1	rs2915880	ENSG00000213433.5	RPLP1P6	-7.44	1.44e-11	6.44e-08	-0.59	-0.56	Preschool internalizing problems;	chr5:151767773	chr5:151765859~151766378:-
TGCT	cis	rs1062177	1	rs2915878	ENSG00000213433.5	RPLP1P6	-7.44	1.44e-11	6.44e-08	-0.59	-0.56	Preschool internalizing problems;	chr5:151770101	chr5:151765859~151766378:-
TGCT	cis	rs9399137	0.507	rs10484496	ENSG00000232876.1	CTA-212D2.2	-7.44	1.46e-11	6.52e-08	-0.51	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978544	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.507	rs13214669	ENSG00000232876.1	CTA-212D2.2	-7.44	1.46e-11	6.52e-08	-0.51	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978821	chr6:135055033~135060550:+
TGCT	cis	rs4423214	1	rs1981412	ENSG00000254682.1	RP11-660L16.2	7.44	1.46e-11	6.52e-08	0.76	0.56	Vitamin D levels;	chr11:71427664	chr11:71448674~71452157:+
TGCT	cis	rs4423214	1	rs12419279	ENSG00000254682.1	RP11-660L16.2	7.44	1.46e-11	6.52e-08	0.76	0.56	Vitamin D levels;	chr11:71428015	chr11:71448674~71452157:+
TGCT	cis	rs1062177	1	rs892006	ENSG00000213433.5	RPLP1P6	-7.44	1.49e-11	6.63e-08	-0.6	-0.56	Preschool internalizing problems;	chr5:151801329	chr5:151765859~151766378:-
TGCT	cis	rs977987	0.836	rs34673655	ENSG00000261783.1	RP11-252K23.2	-7.43	1.5e-11	6.67e-08	-0.81	-0.56	Dupuytren's disease;	chr16:75289661	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.836	rs17685540	ENSG00000261783.1	RP11-252K23.2	-7.43	1.5e-11	6.67e-08	-0.81	-0.56	Dupuytren's disease;	chr16:75289942	chr16:75379818~75381260:-
TGCT	cis	rs1062177	0.826	rs1549920	ENSG00000213433.5	RPLP1P6	-7.43	1.51e-11	6.7e-08	-0.6	-0.56	Preschool internalizing problems;	chr5:151761283	chr5:151765859~151766378:-
TGCT	cis	rs977987	0.872	rs4887816	ENSG00000261783.1	RP11-252K23.2	-7.43	1.51e-11	6.72e-08	-0.81	-0.56	Dupuytren's disease;	chr16:75285818	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.778	rs4243112	ENSG00000261783.1	RP11-252K23.2	-7.43	1.51e-11	6.72e-08	-0.81	-0.56	Dupuytren's disease;	chr16:75287133	chr16:75379818~75381260:-
TGCT	cis	rs11673344	0.566	rs2385181	ENSG00000226686.6	LINC01535	-7.43	1.52e-11	6.75e-08	-0.6	-0.56	Obesity-related traits;	chr19:37395428	chr19:37251912~37265535:+
TGCT	cis	rs524281	0.682	rs4483592	ENSG00000255320.1	RP11-755F10.1	7.43	1.54e-11	6.83e-08	0.76	0.56	Electroencephalogram traits;	chr11:66222968	chr11:66244840~66246239:-
TGCT	cis	rs916888	0.773	rs538628	ENSG00000262500.1	RP11-259G18.2	7.43	1.57e-11	6.94e-08	0.87	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46243606~46245044:+
TGCT	cis	rs916888	0.773	rs169201	ENSG00000262500.1	RP11-259G18.2	7.43	1.57e-11	6.94e-08	0.87	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46243606~46245044:+
TGCT	cis	rs916888	0.773	rs199439	ENSG00000262500.1	RP11-259G18.2	7.43	1.57e-11	6.94e-08	0.87	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46243606~46245044:+
TGCT	cis	rs11673344	0.566	rs256735	ENSG00000226686.6	LINC01535	-7.43	1.57e-11	6.97e-08	-0.6	-0.55	Obesity-related traits;	chr19:37375141	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.566	rs185369	ENSG00000226686.6	LINC01535	-7.43	1.57e-11	6.97e-08	-0.6	-0.55	Obesity-related traits;	chr19:37376137	chr19:37251912~37265535:+
TGCT	cis	rs977987	0.836	rs4888376	ENSG00000261783.1	RP11-252K23.2	-7.43	1.58e-11	6.98e-08	-0.81	-0.55	Dupuytren's disease;	chr16:75288675	chr16:75379818~75381260:-
TGCT	cis	rs2929278	0.617	rs3087657	ENSG00000205771.5	CATSPER2P1	-7.43	1.58e-11	6.98e-08	-0.6	-0.55	Schizophrenia;	chr15:43771661	chr15:43726918~43747094:-
TGCT	cis	rs1062177	1	rs2964584	ENSG00000213433.5	RPLP1P6	-7.42	1.59e-11	7.03e-08	-0.59	-0.55	Preschool internalizing problems;	chr5:151763317	chr5:151765859~151766378:-
TGCT	cis	rs4423214	0.918	rs11233789	ENSG00000254682.1	RP11-660L16.2	7.42	1.61e-11	7.1e-08	0.74	0.55	Vitamin D levels;	chr11:71470039	chr11:71448674~71452157:+
TGCT	cis	rs7188445	1	rs61221126	ENSG00000261390.4	RP11-345M22.2	-7.42	1.63e-11	7.19e-08	-0.57	-0.55	Urate levels;	chr16:79699377	chr16:79715232~79770563:-
TGCT	cis	rs11673344	0.566	rs185368	ENSG00000226686.6	LINC01535	-7.42	1.64e-11	7.24e-08	-0.6	-0.55	Obesity-related traits;	chr19:37381827	chr19:37251912~37265535:+
TGCT	cis	rs1062177	0.774	rs2964574	ENSG00000213433.5	RPLP1P6	-7.42	1.64e-11	7.24e-08	-0.58	-0.55	Preschool internalizing problems;	chr5:151776150	chr5:151765859~151766378:-
TGCT	cis	rs1062177	0.826	rs2053063	ENSG00000213433.5	RPLP1P6	-7.42	1.64e-11	7.24e-08	-0.58	-0.55	Preschool internalizing problems;	chr5:151787203	chr5:151765859~151766378:-
TGCT	cis	rs2283792	1	rs2283792	ENSG00000228050.1	TOP3BP1	7.42	1.65e-11	7.27e-08	0.65	0.55	Multiple sclerosis;	chr22:21776836	chr22:22223187~22224566:-
TGCT	cis	rs6452524	0.905	rs10040244	ENSG00000249664.1	CTD-2227C6.2	7.42	1.65e-11	7.28e-08	0.55	0.55	Hypertension (SNP x SNP interaction);	chr5:83089242	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs10474081	ENSG00000249664.1	CTD-2227C6.2	7.42	1.65e-11	7.28e-08	0.55	0.55	Hypertension (SNP x SNP interaction);	chr5:83095064	chr5:83012285~83013109:-
TGCT	cis	rs1062177	0.826	rs2915879	ENSG00000213433.5	RPLP1P6	-7.42	1.66e-11	7.34e-08	-0.58	-0.55	Preschool internalizing problems;	chr5:151767881	chr5:151765859~151766378:-
TGCT	cis	rs524281	0.773	rs7945723	ENSG00000255320.1	RP11-755F10.1	7.41	1.67e-11	7.37e-08	0.78	0.55	Electroencephalogram traits;	chr11:66288986	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.725	rs3132851	ENSG00000255320.1	RP11-755F10.1	-7.41	1.67e-11	7.37e-08	-0.78	-0.55	Electroencephalogram traits;	chr11:66288671	chr11:66244840~66246239:-
TGCT	cis	rs950027	0.62	rs1346267	ENSG00000259520.4	CTD-2651B20.3	-7.41	1.68e-11	7.41e-08	-0.45	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:45251580~45279251:-
TGCT	cis	rs2882667	0.898	rs6882583	ENSG00000253404.1	AC034243.1	7.41	1.69e-11	7.43e-08	0.61	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139050107	chr5:138744434~138753309:-
TGCT	cis	rs1062177	1	rs2347596	ENSG00000213433.5	RPLP1P6	-7.41	1.72e-11	7.56e-08	-0.59	-0.55	Preschool internalizing problems;	chr5:151799638	chr5:151765859~151766378:-
TGCT	cis	rs9549367	0.636	rs486407	ENSG00000269125.1	RP11-98F14.11	7.41	1.73e-11	7.61e-08	0.68	0.55	Platelet distribution width;	chr13:113179185	chr13:113165002~113165183:-
TGCT	cis	rs7246967	0.611	rs56944174	ENSG00000269509.1	BNIP3P34	7.41	1.73e-11	7.63e-08	1.13	0.55	Bronchopulmonary dysplasia;	chr19:22738872	chr19:22773853~22774424:+
TGCT	cis	rs67383717	0.713	rs1369156	ENSG00000175611.10	LINC00476	-7.4	1.77e-11	7.79e-08	-0.45	-0.55	Parkinson's disease (pesticide exposure interaction);	chr9:95794612	chr9:95759231~95875977:-
TGCT	cis	rs1933112	1	rs10918925	ENSG00000227777.1	RP4-738P11.3	7.4	1.77e-11	7.8e-08	0.58	0.55	Blood protein levels;	chr1:168556009	chr1:168542737~168543354:+
TGCT	cis	rs9399137	0.507	rs61738647	ENSG00000232876.1	CTA-212D2.2	-7.4	1.78e-11	7.81e-08	-0.51	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961597	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs9399129	ENSG00000232876.1	CTA-212D2.2	-7.4	1.81e-11	7.95e-08	-0.51	-0.55	Red blood cell count;	chr6:134964010	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs13199205	ENSG00000232876.1	CTA-212D2.2	-7.4	1.81e-11	7.95e-08	-0.51	-0.55	Red blood cell count;	chr6:134965367	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs9376077	ENSG00000232876.1	CTA-212D2.2	-7.4	1.82e-11	8e-08	-0.51	-0.55	Red blood cell count;	chr6:134978575	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs9389258	ENSG00000232876.1	CTA-212D2.2	-7.4	1.84e-11	8.08e-08	-0.51	-0.55	Red blood cell count;	chr6:135040002	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs4896119	ENSG00000232876.1	CTA-212D2.2	-7.4	1.85e-11	8.08e-08	-0.51	-0.55	Red blood cell count;	chr6:134972253	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs4896121	ENSG00000232876.1	CTA-212D2.2	-7.4	1.85e-11	8.08e-08	-0.51	-0.55	Red blood cell count;	chr6:134972507	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs4376365	ENSG00000232876.1	CTA-212D2.2	-7.4	1.85e-11	8.08e-08	-0.51	-0.55	Red blood cell count;	chr6:134986602	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.935	rs4445070	ENSG00000232876.1	CTA-212D2.2	-7.4	1.85e-11	8.08e-08	-0.51	-0.55	Red blood cell count;	chr6:134988074	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs13218642	ENSG00000232876.1	CTA-212D2.2	-7.4	1.85e-11	8.08e-08	-0.51	-0.55	Red blood cell count;	chr6:134988802	chr6:135055033~135060550:+
TGCT	cis	rs4691139	1	rs7693977	ENSG00000250227.1	TRIM60P14	7.39	1.85e-11	8.11e-08	0.59	0.55	Ovarian cancer in BRCA1 mutation carriers;	chr4:164981898	chr4:164915565~164916983:+
TGCT	cis	rs9399135	0.967	rs2327580	ENSG00000232876.1	CTA-212D2.2	-7.39	1.86e-11	8.15e-08	-0.51	-0.55	Red blood cell count;	chr6:135043279	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.844	rs13209789	ENSG00000232876.1	CTA-212D2.2	-7.39	1.86e-11	8.15e-08	-0.51	-0.55	Red blood cell count;	chr6:135046778	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs6915770	ENSG00000232876.1	CTA-212D2.2	-7.39	1.86e-11	8.15e-08	-0.51	-0.55	Red blood cell count;	chr6:135048076	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.935	rs9376086	ENSG00000232876.1	CTA-212D2.2	-7.39	1.86e-11	8.15e-08	-0.51	-0.55	Red blood cell count;	chr6:135050191	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs1041480	ENSG00000232876.1	CTA-212D2.2	-7.39	1.86e-11	8.15e-08	-0.51	-0.55	Red blood cell count;	chr6:135051938	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs2297338	ENSG00000232876.1	CTA-212D2.2	-7.39	1.86e-11	8.15e-08	-0.51	-0.55	Red blood cell count;	chr6:135054624	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs2297340	ENSG00000232876.1	CTA-212D2.2	-7.39	1.86e-11	8.15e-08	-0.51	-0.55	Red blood cell count;	chr6:135054920	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.933	rs9389262	ENSG00000232876.1	CTA-212D2.2	-7.39	1.86e-11	8.15e-08	-0.51	-0.55	Red blood cell count;	chr6:135055271	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs2183709	ENSG00000232876.1	CTA-212D2.2	-7.39	1.86e-11	8.15e-08	-0.51	-0.55	Red blood cell count;	chr6:135055953	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs4142299	ENSG00000232876.1	CTA-212D2.2	-7.39	1.86e-11	8.15e-08	-0.51	-0.55	Red blood cell count;	chr6:135056048	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.935	rs11759999	ENSG00000232876.1	CTA-212D2.2	-7.39	1.86e-11	8.15e-08	-0.51	-0.55	Red blood cell count;	chr6:135049357	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.935	rs11760000	ENSG00000232876.1	CTA-212D2.2	-7.39	1.86e-11	8.15e-08	-0.51	-0.55	Red blood cell count;	chr6:135049358	chr6:135055033~135060550:+
TGCT	cis	rs2882667	0.931	rs11955952	ENSG00000253404.1	AC034243.1	7.39	1.87e-11	8.18e-08	0.63	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138993430	chr5:138744434~138753309:-
TGCT	cis	rs9389248	0.5	rs116273677	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	High light scatter reticulocyte percentage of red cells;	chr6:135017997	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs6919862	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:135031305	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs10872427	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:135032314	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs7766189	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:135032713	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.816	rs4134030	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:135032956	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs9402676	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:135034369	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.933	rs7755680	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:134973121	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs4895436	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:134973863	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs4896122	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:134973943	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs9376075	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:134975825	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.935	rs4273704	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:134976382	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs4637662	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:134977020	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs4388304	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:134988459	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs4451151	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:134989408	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs6925424	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:134992810	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs6902954	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:134992856	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs7741626	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:134993044	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.904	rs4895438	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:134996527	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs4895439	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:134997716	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs17638970	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:134998925	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.935	rs11754504	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:135000371	chr6:135055033~135060550:+
TGCT	cis	rs9402673	0.558	rs9688342	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	High light scatter reticulocyte count;Reticulocyte count;	chr6:135001888	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs45544135	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:135002913	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.933	rs4559100	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:135002947	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs12527707	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:135003373	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs9389251	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:135004579	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.869	rs9402675	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:135004656	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs6929661	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:135007654	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs9389253	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:135008617	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs2327578	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:135008831	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs9389254	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:135009571	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs9389256	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:135010116	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs6910530	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:135011632	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs1014020	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:135013288	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs1041481	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:135013925	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs6902438	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:135015449	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.935	rs6908681	ENSG00000232876.1	CTA-212D2.2	-7.39	1.88e-11	8.18e-08	-0.51	-0.55	Red blood cell count;	chr6:135016595	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs12527683	ENSG00000232876.1	CTA-212D2.2	-7.39	1.89e-11	8.2e-08	-0.51	-0.55	Red blood cell count;	chr6:135003396	chr6:135055033~135060550:+
TGCT	cis	rs7188445	0.966	rs8053589	ENSG00000261390.4	RP11-345M22.2	-7.39	1.9e-11	8.25e-08	-0.57	-0.55	Urate levels;	chr16:79693093	chr16:79715232~79770563:-
TGCT	cis	rs7188445	1	rs11864901	ENSG00000261390.4	RP11-345M22.2	-7.39	1.9e-11	8.25e-08	-0.57	-0.55	Urate levels;	chr16:79697908	chr16:79715232~79770563:-
TGCT	cis	rs11098499	0.954	rs12508504	ENSG00000245958.5	RP11-33B1.1	-7.39	1.91e-11	8.3e-08	-0.57	-0.55	Corneal astigmatism;	chr4:119489452	chr4:119454791~119552025:+
TGCT	cis	rs6452524	0.935	rs7718284	ENSG00000249664.1	CTD-2227C6.2	-7.38	1.98e-11	8.58e-08	-0.57	-0.55	Hypertension (SNP x SNP interaction);	chr5:83082488	chr5:83012285~83013109:-
TGCT	cis	rs2980439	0.818	rs2945249	ENSG00000173295.6	FAM86B3P	7.38	1.99e-11	8.58e-08	0.66	0.55	Neuroticism;	chr8:8237204	chr8:8228595~8244865:+
TGCT	cis	rs5769707	0.777	rs8141219	ENSG00000188511.11	C22orf34	7.38	2.01e-11	8.67e-08	0.58	0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49650898	chr22:49414524~49657542:-
TGCT	cis	rs1062177	0.756	rs2964589	ENSG00000253921.1	CTB-113P19.3	7.38	2.02e-11	8.72e-08	0.61	0.55	Preschool internalizing problems;	chr5:151738628	chr5:151753992~151767247:+
TGCT	cis	rs17361889	0.806	rs1918259	ENSG00000224683.1	RPL36AP29	7.38	2.04e-11	8.81e-08	0.64	0.55	Pediatric bone mineral content (hip);	chr7:16205732	chr7:16208945~16209265:+
TGCT	cis	rs2739330	0.929	rs5751777	ENSG00000272787.1	KB-226F1.2	-7.37	2.07e-11	8.9e-08	-0.63	-0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23969211~23969873:+
TGCT	cis	rs1062177	1	rs12654573	ENSG00000213433.5	RPLP1P6	-7.37	2.08e-11	8.94e-08	-0.59	-0.55	Preschool internalizing problems;	chr5:151827912	chr5:151765859~151766378:-
TGCT	cis	rs2882667	0.867	rs11749045	ENSG00000253404.1	AC034243.1	7.37	2.08e-11	8.95e-08	0.6	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085271	chr5:138744434~138753309:-
TGCT	cis	rs4423214	0.959	rs11606033	ENSG00000254682.1	RP11-660L16.2	7.37	2.09e-11	8.99e-08	0.73	0.55	Vitamin D levels;	chr11:71443158	chr11:71448674~71452157:+
TGCT	cis	rs4423214	1	rs1044482	ENSG00000254682.1	RP11-660L16.2	7.37	2.09e-11	8.99e-08	0.73	0.55	Vitamin D levels;	chr11:71444125	chr11:71448674~71452157:+
TGCT	cis	rs17361889	0.645	rs17285792	ENSG00000224683.1	RPL36AP29	7.37	2.09e-11	9e-08	0.65	0.55	Pediatric bone mineral content (hip);	chr7:16086578	chr7:16208945~16209265:+
TGCT	cis	rs1062177	1	rs41494545	ENSG00000213433.5	RPLP1P6	7.37	2.13e-11	9.15e-08	0.59	0.55	Preschool internalizing problems;	chr5:151855533	chr5:151765859~151766378:-
TGCT	cis	rs11673344	0.566	rs11666708	ENSG00000226686.6	LINC01535	-7.37	2.13e-11	9.16e-08	-0.6	-0.55	Obesity-related traits;	chr19:37396208	chr19:37251912~37265535:+
TGCT	cis	rs2980439	0.818	rs2948300	ENSG00000173295.6	FAM86B3P	7.36	2.18e-11	9.34e-08	0.66	0.55	Neuroticism;	chr8:8248986	chr8:8228595~8244865:+
TGCT	cis	rs9399137	0.507	rs6940258	ENSG00000232876.1	CTA-212D2.2	-7.36	2.19e-11	9.38e-08	-0.51	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135044994	chr6:135055033~135060550:+
TGCT	cis	rs11098499	0.908	rs28559989	ENSG00000245958.5	RP11-33B1.1	-7.36	2.22e-11	9.53e-08	-0.58	-0.55	Corneal astigmatism;	chr4:119465472	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.909	rs28632018	ENSG00000245958.5	RP11-33B1.1	-7.36	2.22e-11	9.53e-08	-0.58	-0.55	Corneal astigmatism;	chr4:119465575	chr4:119454791~119552025:+
TGCT	cis	rs62388641	0.539	rs56016631	ENSG00000272279.1	RP11-157J24.2	7.36	2.24e-11	9.6e-08	0.63	0.55	Daytime sleep phenotypes;	chr6:1542340	chr6:1528364~1528911:-
TGCT	cis	rs11098499	0.532	rs4833624	ENSG00000245958.5	RP11-33B1.1	-7.35	2.29e-11	9.79e-08	-0.58	-0.55	Corneal astigmatism;	chr4:119664342	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.532	rs12512646	ENSG00000245958.5	RP11-33B1.1	-7.35	2.29e-11	9.79e-08	-0.58	-0.55	Corneal astigmatism;	chr4:119664578	chr4:119454791~119552025:+
TGCT	cis	rs11673344	0.566	rs1545755	ENSG00000226686.6	LINC01535	7.35	2.34e-11	9.99e-08	0.61	0.55	Obesity-related traits;	chr19:37490607	chr19:37251912~37265535:+
TGCT	cis	rs9326248	0.689	rs4516002	ENSG00000254851.1	RP11-109L13.1	-7.35	2.34e-11	1e-07	-0.96	-0.55	Blood protein levels;	chr11:117128343	chr11:117135528~117138582:+
TGCT	cis	rs2283792	0.967	rs4821402	ENSG00000228050.1	TOP3BP1	7.35	2.36e-11	1.01e-07	0.65	0.55	Multiple sclerosis;	chr22:21860457	chr22:22223187~22224566:-
TGCT	cis	rs858239	0.704	rs466240	ENSG00000230658.1	KLHL7-AS1	-7.35	2.37e-11	1.01e-07	-0.58	-0.55	Cerebrospinal fluid biomarker levels;	chr7:23299155	chr7:23101228~23105703:-
TGCT	cis	rs11098499	0.532	rs4504231	ENSG00000245958.5	RP11-33B1.1	-7.35	2.39e-11	1.02e-07	-0.59	-0.55	Corneal astigmatism;	chr4:119665736	chr4:119454791~119552025:+
TGCT	cis	rs9399135	0.967	rs59329760	ENSG00000232876.1	CTA-212D2.2	-7.35	2.39e-11	1.02e-07	-0.51	-0.55	Red blood cell count;	chr6:135021299	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs4896125	ENSG00000232876.1	CTA-212D2.2	-7.35	2.39e-11	1.02e-07	-0.51	-0.55	Red blood cell count;	chr6:135021431	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.838	rs4896126	ENSG00000232876.1	CTA-212D2.2	-7.35	2.39e-11	1.02e-07	-0.51	-0.55	Red blood cell count;	chr6:135021648	chr6:135055033~135060550:+
TGCT	cis	rs9402673	0.517	rs978036	ENSG00000232876.1	CTA-212D2.2	-7.35	2.39e-11	1.02e-07	-0.51	-0.55	High light scatter reticulocyte count;Reticulocyte count;	chr6:135021765	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.935	rs949547	ENSG00000232876.1	CTA-212D2.2	-7.35	2.39e-11	1.02e-07	-0.51	-0.55	Red blood cell count;	chr6:135022361	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs1023179	ENSG00000232876.1	CTA-212D2.2	-7.35	2.39e-11	1.02e-07	-0.51	-0.55	Red blood cell count;	chr6:135022691	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs9376082	ENSG00000232876.1	CTA-212D2.2	-7.35	2.39e-11	1.02e-07	-0.51	-0.55	Red blood cell count;	chr6:135025251	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.935	rs2150680	ENSG00000232876.1	CTA-212D2.2	-7.35	2.39e-11	1.02e-07	-0.51	-0.55	Red blood cell count;	chr6:135025993	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs11756988	ENSG00000232876.1	CTA-212D2.2	-7.35	2.39e-11	1.02e-07	-0.51	-0.55	Red blood cell count;	chr6:135026457	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs11754783	ENSG00000232876.1	CTA-212D2.2	-7.35	2.39e-11	1.02e-07	-0.51	-0.55	Red blood cell count;	chr6:135026523	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.967	rs952674	ENSG00000232876.1	CTA-212D2.2	-7.35	2.39e-11	1.02e-07	-0.51	-0.55	Red blood cell count;	chr6:135028019	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.935	rs987690	ENSG00000232876.1	CTA-212D2.2	-7.35	2.39e-11	1.02e-07	-0.51	-0.55	Red blood cell count;	chr6:135029241	chr6:135055033~135060550:+
TGCT	cis	rs2486288	0.656	rs11629858	ENSG00000259520.4	CTD-2651B20.3	7.35	2.4e-11	1.02e-07	0.47	0.55	Glomerular filtration rate;	chr15:45254916	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.656	rs11629859	ENSG00000259520.4	CTD-2651B20.3	7.35	2.4e-11	1.02e-07	0.47	0.55	Glomerular filtration rate;	chr15:45254923	chr15:45251580~45279251:-
TGCT	cis	rs9389248	0.708	rs7750574	ENSG00000232876.1	CTA-212D2.2	-7.34	2.41e-11	1.03e-07	-0.51	-0.55	High light scatter reticulocyte percentage of red cells;	chr6:135029794	chr6:135055033~135060550:+
TGCT	cis	rs8040855	0.627	rs4843019	ENSG00000259295.5	CSPG4P12	-7.34	2.43e-11	1.03e-07	-0.74	-0.55	Bulimia nervosa;	chr15:85101228	chr15:85191438~85213905:+
TGCT	cis	rs9399137	0.507	rs28384513	ENSG00000232876.1	CTA-212D2.2	-7.34	2.44e-11	1.04e-07	-0.5	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135055071	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.507	rs11154791	ENSG00000232876.1	CTA-212D2.2	-7.34	2.44e-11	1.04e-07	-0.5	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135058010	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.507	rs7745289	ENSG00000232876.1	CTA-212D2.2	-7.34	2.44e-11	1.04e-07	-0.5	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135059189	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.507	rs11759062	ENSG00000232876.1	CTA-212D2.2	-7.34	2.44e-11	1.04e-07	-0.5	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060110	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.507	rs11759077	ENSG00000232876.1	CTA-212D2.2	-7.34	2.44e-11	1.04e-07	-0.5	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060213	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.507	rs6904897	ENSG00000232876.1	CTA-212D2.2	-7.34	2.44e-11	1.04e-07	-0.5	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135061842	chr6:135055033~135060550:+
TGCT	cis	rs1062177	1	rs973529	ENSG00000213433.5	RPLP1P6	-7.34	2.44e-11	1.04e-07	-0.59	-0.55	Preschool internalizing problems;	chr5:151808597	chr5:151765859~151766378:-
TGCT	cis	rs5760092	0.755	rs5760096	ENSG00000273295.1	AP000350.5	7.34	2.45e-11	1.04e-07	0.67	0.55	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23905123	chr22:23901432~23907068:-
TGCT	cis	rs977987	0.835	rs1010630	ENSG00000261783.1	RP11-252K23.2	-7.34	2.45e-11	1.04e-07	-0.79	-0.55	Dupuytren's disease;	chr16:75294693	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.835	rs11641532	ENSG00000261783.1	RP11-252K23.2	-7.34	2.45e-11	1.04e-07	-0.79	-0.55	Dupuytren's disease;	chr16:75295582	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs35937717	ENSG00000261783.1	RP11-252K23.2	-7.34	2.45e-11	1.04e-07	-0.79	-0.55	Dupuytren's disease;	chr16:75297669	chr16:75379818~75381260:-
TGCT	cis	rs11098499	0.909	rs9759478	ENSG00000245958.5	RP11-33B1.1	-7.34	2.5e-11	1.06e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119446843	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.909	rs1546504	ENSG00000245958.5	RP11-33B1.1	-7.33	2.53e-11	1.07e-07	-0.57	-0.55	Corneal astigmatism;	chr4:119320024	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs9998585	ENSG00000245958.5	RP11-33B1.1	-7.33	2.54e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119475647	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.909	rs6842762	ENSG00000245958.5	RP11-33B1.1	-7.33	2.54e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119477081	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.908	rs11098527	ENSG00000245958.5	RP11-33B1.1	-7.33	2.54e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119478751	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs10518328	ENSG00000245958.5	RP11-33B1.1	-7.33	2.54e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119480624	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs6822679	ENSG00000245958.5	RP11-33B1.1	-7.33	2.54e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119481547	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs4577559	ENSG00000245958.5	RP11-33B1.1	-7.33	2.54e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119482888	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs7656252	ENSG00000245958.5	RP11-33B1.1	-7.33	2.54e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119483113	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.865	rs28845498	ENSG00000245958.5	RP11-33B1.1	-7.33	2.54e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119484031	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.865	rs28753180	ENSG00000245958.5	RP11-33B1.1	-7.33	2.54e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119484212	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs56270433	ENSG00000245958.5	RP11-33B1.1	-7.33	2.54e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119484875	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs10006525	ENSG00000245958.5	RP11-33B1.1	-7.33	2.54e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119487776	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs7681544	ENSG00000245958.5	RP11-33B1.1	-7.33	2.54e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119490100	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs17005535	ENSG00000245958.5	RP11-33B1.1	-7.33	2.54e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119490407	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs11940028	ENSG00000245958.5	RP11-33B1.1	-7.33	2.54e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119490752	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs11935596	ENSG00000245958.5	RP11-33B1.1	-7.33	2.54e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119491302	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs12507964	ENSG00000245958.5	RP11-33B1.1	-7.33	2.54e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119491906	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.909	rs11098530	ENSG00000245958.5	RP11-33B1.1	-7.33	2.54e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119491999	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs6834796	ENSG00000245958.5	RP11-33B1.1	-7.33	2.54e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119493538	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs11729521	ENSG00000245958.5	RP11-33B1.1	-7.33	2.54e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119495633	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs11734241	ENSG00000245958.5	RP11-33B1.1	-7.33	2.54e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119495717	chr4:119454791~119552025:+
TGCT	cis	rs2283792	1	rs2006893	ENSG00000228050.1	TOP3BP1	7.33	2.55e-11	1.07e-07	0.64	0.55	Multiple sclerosis;	chr22:21774389	chr22:22223187~22224566:-
TGCT	cis	rs11098499	0.954	rs10518331	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119402440	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs13133522	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119403269	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs35091806	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119404374	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.909	rs35165976	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119404475	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs2389802	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119404577	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs3890049	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119405128	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs6846442	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119405168	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs67265404	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119438115	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.909	rs71614422	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119438185	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.738	rs34566984	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119440115	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.738	rs34965784	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119440431	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs17009122	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119441248	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.505	rs75122014	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119441271	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs9685777	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119444810	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs71614438	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119450097	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs66506550	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119450290	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.909	rs7659501	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119450397	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs71629403	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119451412	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.697	rs28655325	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119451844	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.779	rs80242894	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119454597	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.865	rs28634456	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119454623	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.909	rs78332141	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119454627	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.779	rs28495013	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119454676	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.909	rs28571712	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119454825	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.657	rs71614442	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119458191	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs2892848	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119460186	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.865	rs9994730	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119460409	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.697	rs11941899	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119461603	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.909	rs7681978	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119462620	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.821	rs28665282	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119463031	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.738	rs10026493	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119463039	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.909	rs7681214	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119464165	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.908	rs71614449	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119465900	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs35063680	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119465947	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs34858317	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119465955	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs17046116	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119466104	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.909	rs17046118	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119466341	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs7654587	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119467251	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs11098525	ENSG00000245958.5	RP11-33B1.1	-7.33	2.55e-11	1.07e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119468997	chr4:119454791~119552025:+
TGCT	cis	rs7188445	0.871	rs7202770	ENSG00000261390.4	RP11-345M22.2	-7.33	2.59e-11	1.08e-07	-0.54	-0.55	Urate levels;	chr16:79672643	chr16:79715232~79770563:-
TGCT	cis	rs7188445	0.835	rs1424231	ENSG00000261390.4	RP11-345M22.2	-7.33	2.59e-11	1.08e-07	-0.54	-0.55	Urate levels;	chr16:79672854	chr16:79715232~79770563:-
TGCT	cis	rs1062177	1	rs17804178	ENSG00000213433.5	RPLP1P6	-7.33	2.6e-11	1.08e-07	-0.59	-0.55	Preschool internalizing problems;	chr5:151818168	chr5:151765859~151766378:-
TGCT	cis	rs1062177	1	rs2964612	ENSG00000213433.5	RPLP1P6	-7.33	2.6e-11	1.08e-07	-0.59	-0.55	Preschool internalizing problems;	chr5:151819189	chr5:151765859~151766378:-
TGCT	cis	rs1062177	1	rs12518722	ENSG00000213433.5	RPLP1P6	-7.33	2.6e-11	1.08e-07	-0.59	-0.55	Preschool internalizing problems;	chr5:151851899	chr5:151765859~151766378:-
TGCT	cis	rs17361889	0.766	rs1527220	ENSG00000224683.1	RPL36AP29	7.33	2.61e-11	1.09e-07	0.63	0.55	Pediatric bone mineral content (hip);	chr7:16206354	chr7:16208945~16209265:+
TGCT	cis	rs17361889	0.806	rs6961874	ENSG00000224683.1	RPL36AP29	7.33	2.61e-11	1.09e-07	0.63	0.55	Pediatric bone mineral content (hip);	chr7:16207299	chr7:16208945~16209265:+
TGCT	cis	rs17361889	0.766	rs1527221	ENSG00000224683.1	RPL36AP29	7.33	2.61e-11	1.09e-07	0.63	0.55	Pediatric bone mineral content (hip);	chr7:16207470	chr7:16208945~16209265:+
TGCT	cis	rs17361889	0.766	rs1918260	ENSG00000224683.1	RPL36AP29	7.33	2.61e-11	1.09e-07	0.63	0.55	Pediatric bone mineral content (hip);	chr7:16205510	chr7:16208945~16209265:+
TGCT	cis	rs7188445	0.871	rs8047723	ENSG00000261390.4	RP11-345M22.2	7.33	2.62e-11	1.09e-07	0.55	0.55	Urate levels;	chr16:79671018	chr16:79715232~79770563:-
TGCT	cis	rs7188445	0.871	rs8048928	ENSG00000261390.4	RP11-345M22.2	-7.33	2.62e-11	1.09e-07	-0.55	-0.55	Urate levels;	chr16:79671039	chr16:79715232~79770563:-
TGCT	cis	rs6452524	0.967	rs1031901	ENSG00000249664.1	CTD-2227C6.2	7.32	2.67e-11	1.11e-07	0.55	0.55	Hypertension (SNP x SNP interaction);	chr5:83147904	chr5:83012285~83013109:-
TGCT	cis	rs66887589	0.775	rs6843229	ENSG00000245958.5	RP11-33B1.1	-7.32	2.7e-11	1.12e-07	-0.54	-0.55	Diastolic blood pressure;	chr4:119502932	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs13145352	ENSG00000245958.5	RP11-33B1.1	7.32	2.7e-11	1.12e-07	0.6	0.55	Corneal astigmatism;	chr4:119488808	chr4:119454791~119552025:+
TGCT	cis	rs2283792	0.967	rs5755099	ENSG00000228050.1	TOP3BP1	7.32	2.77e-11	1.15e-07	0.64	0.55	Multiple sclerosis;	chr22:21770751	chr22:22223187~22224566:-
TGCT	cis	rs9399135	0.527	rs61738492	ENSG00000232876.1	CTA-212D2.2	-7.32	2.79e-11	1.16e-07	-0.51	-0.55	Red blood cell count;	chr6:134961633	chr6:135055033~135060550:+
TGCT	cis	rs2283792	1	rs6928	ENSG00000228050.1	TOP3BP1	7.31	2.83e-11	1.17e-07	0.64	0.55	Multiple sclerosis;	chr22:21760715	chr22:22223187~22224566:-
TGCT	cis	rs853679	0.567	rs6905380	ENSG00000216901.1	AL022393.7	7.31	2.88e-11	1.19e-07	0.66	0.55	Depression;	chr6:28407125	chr6:28176188~28176674:+
TGCT	cis	rs950027	0.62	rs1617634	ENSG00000259520.4	CTD-2651B20.3	-7.31	2.88e-11	1.19e-07	-0.46	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45323380	chr15:45251580~45279251:-
TGCT	cis	rs11098499	0.954	rs878373	ENSG00000245958.5	RP11-33B1.1	-7.31	2.91e-11	1.2e-07	-0.57	-0.55	Corneal astigmatism;	chr4:119316329	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs10006877	ENSG00000245958.5	RP11-33B1.1	-7.31	2.91e-11	1.2e-07	-0.57	-0.55	Corneal astigmatism;	chr4:119321638	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs12505469	ENSG00000245958.5	RP11-33B1.1	-7.31	2.91e-11	1.2e-07	-0.57	-0.55	Corneal astigmatism;	chr4:119328430	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.908	rs2017057	ENSG00000245958.5	RP11-33B1.1	-7.31	2.91e-11	1.2e-07	-0.57	-0.55	Corneal astigmatism;	chr4:119336556	chr4:119454791~119552025:+
TGCT	cis	rs11673344	0.544	rs6508721	ENSG00000226686.6	LINC01535	-7.31	2.93e-11	1.2e-07	-0.6	-0.55	Obesity-related traits;	chr19:37419119	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.566	rs7254009	ENSG00000226686.6	LINC01535	-7.31	2.93e-11	1.2e-07	-0.6	-0.55	Obesity-related traits;	chr19:37427707	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.566	rs2385180	ENSG00000226686.6	LINC01535	-7.31	2.93e-11	1.2e-07	-0.6	-0.55	Obesity-related traits;	chr19:37431454	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.566	rs1968251	ENSG00000226686.6	LINC01535	-7.31	2.93e-11	1.2e-07	-0.6	-0.55	Obesity-related traits;	chr19:37457005	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.566	rs10419281	ENSG00000226686.6	LINC01535	-7.31	2.93e-11	1.2e-07	-0.6	-0.55	Obesity-related traits;	chr19:37459351	chr19:37251912~37265535:+
TGCT	cis	rs11098499	0.954	rs17006190	ENSG00000245958.5	RP11-33B1.1	-7.3	2.96e-11	1.22e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119497683	chr4:119454791~119552025:+
TGCT	cis	rs17361889	0.806	rs17367660	ENSG00000224683.1	RPL36AP29	7.3	2.98e-11	1.22e-07	0.64	0.55	Pediatric bone mineral content (hip);	chr7:16179008	chr7:16208945~16209265:+
TGCT	cis	rs1933112	0.808	rs55863344	ENSG00000227777.1	RP4-738P11.3	-7.3	3.03e-11	1.24e-07	-0.6	-0.55	Blood protein levels;	chr1:168542884	chr1:168542737~168543354:+
TGCT	cis	rs524281	0.637	rs7126075	ENSG00000255320.1	RP11-755F10.1	7.3	3.09e-11	1.26e-07	0.69	0.55	Electroencephalogram traits;	chr11:66173092	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.861	rs2177054	ENSG00000255320.1	RP11-755F10.1	7.3	3.09e-11	1.26e-07	0.69	0.55	Electroencephalogram traits;	chr11:66177141	chr11:66244840~66246239:-
TGCT	cis	rs2882667	0.931	rs6596457	ENSG00000253404.1	AC034243.1	7.3	3.11e-11	1.27e-07	0.61	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138987690	chr5:138744434~138753309:-
TGCT	cis	rs11098499	0.863	rs1010740	ENSG00000245958.5	RP11-33B1.1	7.29	3.13e-11	1.28e-07	0.57	0.55	Corneal astigmatism;	chr4:119542254	chr4:119454791~119552025:+
TGCT	cis	rs950027	0.62	rs1153862	ENSG00000259520.4	CTD-2651B20.3	-7.29	3.15e-11	1.29e-07	-0.45	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45339670	chr15:45251580~45279251:-
TGCT	cis	rs950027	0.62	rs35861938	ENSG00000259520.4	CTD-2651B20.3	-7.29	3.15e-11	1.29e-07	-0.45	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45345145	chr15:45251580~45279251:-
TGCT	cis	rs950027	0.596	rs2467865	ENSG00000259520.4	CTD-2651B20.3	-7.29	3.15e-11	1.29e-07	-0.45	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45346109	chr15:45251580~45279251:-
TGCT	cis	rs950027	0.62	rs2467862	ENSG00000259520.4	CTD-2651B20.3	-7.29	3.15e-11	1.29e-07	-0.45	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45351645	chr15:45251580~45279251:-
TGCT	cis	rs950027	0.62	rs1145093	ENSG00000259520.4	CTD-2651B20.3	-7.29	3.15e-11	1.29e-07	-0.45	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45357615	chr15:45251580~45279251:-
TGCT	cis	rs950027	0.62	rs1145089	ENSG00000259520.4	CTD-2651B20.3	-7.29	3.15e-11	1.29e-07	-0.45	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45359856	chr15:45251580~45279251:-
TGCT	cis	rs950027	0.62	rs1049518	ENSG00000259520.4	CTD-2651B20.3	-7.29	3.15e-11	1.29e-07	-0.45	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45361169	chr15:45251580~45279251:-
TGCT	cis	rs950027	0.584	rs1145086	ENSG00000259520.4	CTD-2651B20.3	-7.29	3.15e-11	1.29e-07	-0.45	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45362129	chr15:45251580~45279251:-
TGCT	cis	rs950027	0.62	rs1153857	ENSG00000259520.4	CTD-2651B20.3	-7.29	3.15e-11	1.29e-07	-0.45	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45366897	chr15:45251580~45279251:-
TGCT	cis	rs950027	0.62	rs1153855	ENSG00000259520.4	CTD-2651B20.3	-7.29	3.15e-11	1.29e-07	-0.45	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45368560	chr15:45251580~45279251:-
TGCT	cis	rs950027	0.62	rs1145080	ENSG00000259520.4	CTD-2651B20.3	-7.29	3.15e-11	1.29e-07	-0.45	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45389140	chr15:45251580~45279251:-
TGCT	cis	rs943437	0.557	rs13340407	ENSG00000227012.2	RP1-97J1.2	7.29	3.2e-11	1.3e-07	0.84	0.55	Parkinson's disease;	chr6:111836412	chr6:111900489~111901851:-
TGCT	cis	rs524281	0.861	rs10896081	ENSG00000255320.1	RP11-755F10.1	7.29	3.27e-11	1.33e-07	0.65	0.55	Electroencephalogram traits;	chr11:66112883	chr11:66244840~66246239:-
TGCT	cis	rs2739330	0.76	rs1002286	ENSG00000218537.1	MIF-AS1	-7.29	3.27e-11	1.33e-07	-0.66	-0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23894426~23898930:-
TGCT	cis	rs7174755	1	rs7174755	ENSG00000260657.2	RP11-315D16.4	-7.28	3.3e-11	1.34e-07	-0.55	-0.55	Major depressive disorder;	chr15:68304789	chr15:68267792~68277994:-
TGCT	cis	rs1062177	1	rs1062177	ENSG00000213433.5	RPLP1P6	-7.28	3.33e-11	1.35e-07	-0.59	-0.55	Preschool internalizing problems;	chr5:151805140	chr5:151765859~151766378:-
TGCT	cis	rs950027	0.62	rs2461700	ENSG00000259520.4	CTD-2651B20.3	-7.28	3.35e-11	1.36e-07	-0.45	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45348429	chr15:45251580~45279251:-
TGCT	cis	rs950027	0.62	rs2453533	ENSG00000259520.4	CTD-2651B20.3	-7.28	3.35e-11	1.36e-07	-0.45	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45349027	chr15:45251580~45279251:-
TGCT	cis	rs17361889	0.806	rs7778438	ENSG00000224683.1	RPL36AP29	7.28	3.35e-11	1.36e-07	0.63	0.55	Pediatric bone mineral content (hip);	chr7:16207624	chr7:16208945~16209265:+
TGCT	cis	rs1355223	0.752	rs286893	ENSG00000271369.1	RP11-350D17.3	7.28	3.44e-11	1.4e-07	0.51	0.55	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34653335	chr11:34709600~34710161:+
TGCT	cis	rs1933112	1	rs1323534	ENSG00000227777.1	RP4-738P11.3	-7.28	3.44e-11	1.4e-07	-0.6	-0.55	Blood protein levels;	chr1:168534039	chr1:168542737~168543354:+
TGCT	cis	rs1933112	0.9	rs7519937	ENSG00000227777.1	RP4-738P11.3	-7.28	3.44e-11	1.4e-07	-0.6	-0.55	Blood protein levels;	chr1:168535403	chr1:168542737~168543354:+
TGCT	cis	rs1933112	1	rs2223582	ENSG00000227777.1	RP4-738P11.3	-7.28	3.44e-11	1.4e-07	-0.6	-0.55	Blood protein levels;	chr1:168537297	chr1:168542737~168543354:+
TGCT	cis	rs11098499	0.954	rs12510138	ENSG00000245958.5	RP11-33B1.1	-7.28	3.45e-11	1.4e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119502780	chr4:119454791~119552025:+
TGCT	cis	rs1062177	0.951	rs2915876	ENSG00000213433.5	RPLP1P6	-7.27	3.45e-11	1.4e-07	-0.58	-0.55	Preschool internalizing problems;	chr5:151771184	chr5:151765859~151766378:-
TGCT	cis	rs11098499	0.954	rs1480931	ENSG00000245958.5	RP11-33B1.1	-7.27	3.48e-11	1.41e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119474654	chr4:119454791~119552025:+
TGCT	cis	rs2882667	0.931	rs10038799	ENSG00000253404.1	AC034243.1	7.27	3.49e-11	1.41e-07	0.61	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139026594	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.898	rs2351465	ENSG00000253404.1	AC034243.1	7.27	3.49e-11	1.41e-07	0.61	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028162	chr5:138744434~138753309:-
TGCT	cis	rs977987	0.735	rs166013	ENSG00000261783.1	RP11-252K23.2	7.27	3.5e-11	1.42e-07	0.82	0.55	Dupuytren's disease;	chr16:75400248	chr16:75379818~75381260:-
TGCT	cis	rs9549367	0.713	rs2476328	ENSG00000269125.1	RP11-98F14.11	7.27	3.6e-11	1.46e-07	0.68	0.55	Platelet distribution width;	chr13:113175036	chr13:113165002~113165183:-
TGCT	cis	rs2882667	0.861	rs10037106	ENSG00000253404.1	AC034243.1	7.27	3.6e-11	1.46e-07	0.6	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029801	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.898	rs3925110	ENSG00000253404.1	AC034243.1	7.27	3.6e-11	1.46e-07	0.6	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035676	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.898	rs13163536	ENSG00000253404.1	AC034243.1	7.27	3.6e-11	1.46e-07	0.6	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041530	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.898	rs13182437	ENSG00000253404.1	AC034243.1	7.27	3.6e-11	1.46e-07	0.6	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051460	chr5:138744434~138753309:-
TGCT	cis	rs1062177	1	rs2016409	ENSG00000213433.5	RPLP1P6	7.27	3.61e-11	1.46e-07	0.58	0.55	Preschool internalizing problems;	chr5:151746763	chr5:151765859~151766378:-
TGCT	cis	rs1062177	1	rs17741826	ENSG00000213433.5	RPLP1P6	7.27	3.61e-11	1.46e-07	0.58	0.55	Preschool internalizing problems;	chr5:151769701	chr5:151765859~151766378:-
TGCT	cis	rs1062177	1	rs2964585	ENSG00000213433.5	RPLP1P6	-7.27	3.61e-11	1.46e-07	-0.58	-0.55	Preschool internalizing problems;	chr5:151762334	chr5:151765859~151766378:-
TGCT	cis	rs1062177	1	rs2964578	ENSG00000213433.5	RPLP1P6	-7.27	3.61e-11	1.46e-07	-0.58	-0.55	Preschool internalizing problems;	chr5:151767637	chr5:151765859~151766378:-
TGCT	cis	rs9399135	0.967	rs9321481	ENSG00000232876.1	CTA-212D2.2	7.27	3.62e-11	1.47e-07	0.49	0.55	Red blood cell count;	chr6:135031510	chr6:135055033~135060550:+
TGCT	cis	rs950027	0.62	rs872192	ENSG00000259520.4	CTD-2651B20.3	-7.26	3.64e-11	1.47e-07	-0.46	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45322304	chr15:45251580~45279251:-
TGCT	cis	rs9549367	0.713	rs1755690	ENSG00000269125.1	RP11-98F14.11	7.26	3.65e-11	1.48e-07	0.67	0.55	Platelet distribution width;	chr13:113169952	chr13:113165002~113165183:-
TGCT	cis	rs11098499	0.954	rs6848389	ENSG00000245958.5	RP11-33B1.1	-7.26	3.68e-11	1.49e-07	-0.59	-0.55	Corneal astigmatism;	chr4:119481467	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.908	rs7695996	ENSG00000245958.5	RP11-33B1.1	-7.26	3.71e-11	1.5e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119400878	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.908	rs7696649	ENSG00000245958.5	RP11-33B1.1	-7.26	3.71e-11	1.5e-07	-0.58	-0.55	Corneal astigmatism;	chr4:119401022	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.909	rs73842633	ENSG00000245958.5	RP11-33B1.1	-7.26	3.78e-11	1.52e-07	-0.59	-0.55	Corneal astigmatism;	chr4:119454309	chr4:119454791~119552025:+
TGCT	cis	rs2882667	0.931	rs10070021	ENSG00000253404.1	AC034243.1	7.26	3.81e-11	1.53e-07	0.6	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138989017	chr5:138744434~138753309:-
TGCT	cis	rs7301826	0.651	rs7956851	ENSG00000256299.1	RP11-989F5.3	-7.25	3.85e-11	1.55e-07	-0.64	-0.55	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810821~130812622:-
TGCT	cis	rs1062177	0.826	rs2915873	ENSG00000213433.5	RPLP1P6	-7.25	3.87e-11	1.56e-07	-0.57	-0.55	Preschool internalizing problems;	chr5:151777097	chr5:151765859~151766378:-
TGCT	cis	rs9399137	0.507	rs6940878	ENSG00000232876.1	CTA-212D2.2	-7.25	3.89e-11	1.57e-07	-0.51	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135045171	chr6:135055033~135060550:+
TGCT	cis	rs2739330	0.76	rs5751760	ENSG00000218537.1	MIF-AS1	7.25	3.9e-11	1.57e-07	0.66	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23894426~23898930:-
TGCT	cis	rs1062177	0.95	rs892005	ENSG00000213433.5	RPLP1P6	-7.25	4e-11	1.61e-07	-0.58	-0.55	Preschool internalizing problems;	chr5:151801060	chr5:151765859~151766378:-
TGCT	cis	rs9549367	0.713	rs9577211	ENSG00000269125.1	RP11-98F14.11	-7.25	4.01e-11	1.61e-07	-0.67	-0.55	Platelet distribution width;	chr13:113176404	chr13:113165002~113165183:-
TGCT	cis	rs2929278	0.617	rs693919	ENSG00000205771.5	CATSPER2P1	7.25	4.03e-11	1.62e-07	0.6	0.55	Schizophrenia;	chr15:43810130	chr15:43726918~43747094:-
TGCT	cis	rs2929278	0.561	rs3099045	ENSG00000205771.5	CATSPER2P1	-7.24	4.03e-11	1.62e-07	-0.61	-0.55	Schizophrenia;	chr15:43631757	chr15:43726918~43747094:-
TGCT	cis	rs2412819	0.599	rs2470120	ENSG00000205771.5	CATSPER2P1	-7.24	4.03e-11	1.62e-07	-0.61	-0.55	Lung cancer;	chr15:43636872	chr15:43726918~43747094:-
TGCT	cis	rs1062177	0.724	rs2915828	ENSG00000213433.5	RPLP1P6	7.24	4.04e-11	1.62e-07	0.57	0.55	Preschool internalizing problems;	chr5:151738560	chr5:151765859~151766378:-
TGCT	cis	rs1062177	0.724	rs2964590	ENSG00000213433.5	RPLP1P6	7.24	4.04e-11	1.62e-07	0.57	0.55	Preschool internalizing problems;	chr5:151738585	chr5:151765859~151766378:-
TGCT	cis	rs1062177	0.756	rs2964588	ENSG00000213433.5	RPLP1P6	7.24	4.04e-11	1.62e-07	0.57	0.55	Preschool internalizing problems;	chr5:151738825	chr5:151765859~151766378:-
TGCT	cis	rs1062177	0.756	rs2915827	ENSG00000213433.5	RPLP1P6	7.24	4.04e-11	1.62e-07	0.57	0.55	Preschool internalizing problems;	chr5:151740144	chr5:151765859~151766378:-
TGCT	cis	rs1062177	0.756	rs2915826	ENSG00000213433.5	RPLP1P6	7.24	4.04e-11	1.62e-07	0.57	0.55	Preschool internalizing problems;	chr5:151740402	chr5:151765859~151766378:-
TGCT	cis	rs1062177	0.756	rs2964587	ENSG00000213433.5	RPLP1P6	7.24	4.04e-11	1.62e-07	0.57	0.55	Preschool internalizing problems;	chr5:151740411	chr5:151765859~151766378:-
TGCT	cis	rs4423214	1	rs11233746	ENSG00000254682.1	RP11-660L16.2	7.24	4.05e-11	1.62e-07	0.72	0.55	Vitamin D levels;	chr11:71460394	chr11:71448674~71452157:+
TGCT	cis	rs4423214	1	rs2040323	ENSG00000254682.1	RP11-660L16.2	7.24	4.05e-11	1.62e-07	0.72	0.55	Vitamin D levels;	chr11:71461737	chr11:71448674~71452157:+
TGCT	cis	rs11098499	0.754	rs938056	ENSG00000245958.5	RP11-33B1.1	-7.24	4.11e-11	1.64e-07	-0.55	-0.55	Corneal astigmatism;	chr4:119316298	chr4:119454791~119552025:+
TGCT	cis	rs1933112	1	rs1040509	ENSG00000227777.1	RP4-738P11.3	-7.24	4.16e-11	1.66e-07	-0.57	-0.55	Blood protein levels;	chr1:168531746	chr1:168542737~168543354:+
TGCT	cis	rs1062177	0.756	rs2964592	ENSG00000213433.5	RPLP1P6	7.24	4.2e-11	1.68e-07	0.57	0.54	Preschool internalizing problems;	chr5:151736127	chr5:151765859~151766378:-
TGCT	cis	rs66887589	0.748	rs28439855	ENSG00000245958.5	RP11-33B1.1	-7.24	4.2e-11	1.68e-07	-0.54	-0.54	Diastolic blood pressure;	chr4:119341101	chr4:119454791~119552025:+
TGCT	cis	rs7188445	0.871	rs16950997	ENSG00000261390.4	RP11-345M22.2	-7.24	4.22e-11	1.69e-07	-0.54	-0.54	Urate levels;	chr16:79673733	chr16:79715232~79770563:-
TGCT	cis	rs1062177	0.855	rs62395861	ENSG00000213433.5	RPLP1P6	-7.23	4.3e-11	1.72e-07	-0.6	-0.54	Preschool internalizing problems;	chr5:151889709	chr5:151765859~151766378:-
TGCT	cis	rs1062177	0.95	rs59580263	ENSG00000213433.5	RPLP1P6	-7.23	4.3e-11	1.72e-07	-0.6	-0.54	Preschool internalizing problems;	chr5:151890016	chr5:151765859~151766378:-
TGCT	cis	rs9326248	0.689	rs236916	ENSG00000254851.1	RP11-109L13.1	7.23	4.33e-11	1.73e-07	0.93	0.54	Blood protein levels;	chr11:117218912	chr11:117135528~117138582:+
TGCT	cis	rs524281	0.861	rs6591207	ENSG00000255320.1	RP11-755F10.1	7.23	4.36e-11	1.74e-07	0.67	0.54	Electroencephalogram traits;	chr11:66182203	chr11:66244840~66246239:-
TGCT	cis	rs11098499	0.863	rs7699064	ENSG00000245958.5	RP11-33B1.1	7.23	4.38e-11	1.75e-07	0.57	0.54	Corneal astigmatism;	chr4:119507154	chr4:119454791~119552025:+
TGCT	cis	rs10028773	0.515	rs9994651	ENSG00000245958.5	RP11-33B1.1	-7.23	4.39e-11	1.75e-07	-0.58	-0.54	Educational attainment;	chr4:119666648	chr4:119454791~119552025:+
TGCT	cis	rs2739330	0.892	rs5751776	ENSG00000272787.1	KB-226F1.2	-7.23	4.4e-11	1.75e-07	-0.62	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23969211~23969873:+
TGCT	cis	rs1062177	1	rs2915887	ENSG00000213433.5	RPLP1P6	-7.23	4.44e-11	1.77e-07	-0.58	-0.54	Preschool internalizing problems;	chr5:151825943	chr5:151765859~151766378:-
TGCT	cis	rs1062177	1	rs62377945	ENSG00000213433.5	RPLP1P6	-7.23	4.44e-11	1.77e-07	-0.58	-0.54	Preschool internalizing problems;	chr5:151828443	chr5:151765859~151766378:-
TGCT	cis	rs1062177	1	rs12515762	ENSG00000213433.5	RPLP1P6	-7.23	4.44e-11	1.77e-07	-0.58	-0.54	Preschool internalizing problems;	chr5:151830361	chr5:151765859~151766378:-
TGCT	cis	rs11098499	0.908	rs9995234	ENSG00000245958.5	RP11-33B1.1	-7.23	4.46e-11	1.77e-07	-0.57	-0.54	Corneal astigmatism;	chr4:119400672	chr4:119454791~119552025:+
TGCT	cis	rs853679	0.567	rs16894091	ENSG00000216901.1	AL022393.7	-7.22	4.5e-11	1.79e-07	-0.67	-0.54	Depression;	chr6:28422360	chr6:28176188~28176674:+
TGCT	cis	rs853679	0.567	rs13209596	ENSG00000216901.1	AL022393.7	7.22	4.5e-11	1.79e-07	0.67	0.54	Depression;	chr6:28428413	chr6:28176188~28176674:+
TGCT	cis	rs1930961	1	rs9624836	ENSG00000272977.1	CTA-390C10.10	-7.22	4.51e-11	1.79e-07	-0.75	-0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25450120	chr22:25476218~25479971:+
TGCT	cis	rs1930961	0.867	rs6423498	ENSG00000272977.1	CTA-390C10.10	-7.22	4.51e-11	1.79e-07	-0.75	-0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25457401	chr22:25476218~25479971:+
TGCT	cis	rs1930961	1	rs6004654	ENSG00000272977.1	CTA-390C10.10	-7.22	4.51e-11	1.79e-07	-0.75	-0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25459237	chr22:25476218~25479971:+
TGCT	cis	rs7786410	1	rs7786410	ENSG00000226278.1	PSPHP1	7.22	4.52e-11	1.8e-07	0.97	0.54	Age-related hearing impairment;	chr7:55854630	chr7:55764797~55773288:+
TGCT	cis	rs6452524	1	rs7738033	ENSG00000249664.1	CTD-2227C6.2	7.22	4.57e-11	1.81e-07	0.55	0.54	Hypertension (SNP x SNP interaction);	chr5:83135470	chr5:83012285~83013109:-
TGCT	cis	rs6452524	1	rs6860239	ENSG00000249664.1	CTD-2227C6.2	7.22	4.57e-11	1.81e-07	0.55	0.54	Hypertension (SNP x SNP interaction);	chr5:83136022	chr5:83012285~83013109:-
TGCT	cis	rs997154	0.544	rs60950807	ENSG00000279656.1	RP11-298I3.6	-7.22	4.58e-11	1.82e-07	-0.98	-0.54	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23013195	chr14:23023083~23024217:-
TGCT	cis	rs2882667	0.931	rs10075039	ENSG00000253404.1	AC034243.1	7.22	4.64e-11	1.84e-07	0.61	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002165	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.931	rs12719518	ENSG00000253404.1	AC034243.1	7.22	4.64e-11	1.84e-07	0.61	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139005287	chr5:138744434~138753309:-
TGCT	cis	rs977987	0.8	rs1011121	ENSG00000261783.1	RP11-252K23.2	-7.22	4.69e-11	1.86e-07	-0.79	-0.54	Dupuytren's disease;	chr16:75292035	chr16:75379818~75381260:-
TGCT	cis	rs7174755	0.884	rs11634026	ENSG00000260657.2	RP11-315D16.4	7.22	4.7e-11	1.86e-07	0.58	0.54	Major depressive disorder;	chr15:68305668	chr15:68267792~68277994:-
TGCT	cis	rs7174755	0.923	rs11634149	ENSG00000260657.2	RP11-315D16.4	7.22	4.7e-11	1.86e-07	0.58	0.54	Major depressive disorder;	chr15:68306072	chr15:68267792~68277994:-
TGCT	cis	rs7174755	0.962	rs1020842	ENSG00000260657.2	RP11-315D16.4	-7.22	4.7e-11	1.86e-07	-0.58	-0.54	Major depressive disorder;	chr15:68309840	chr15:68267792~68277994:-
TGCT	cis	rs916888	0.61	rs199530	ENSG00000214401.4	KANSL1-AS1	-7.21	4.78e-11	1.89e-07	-0.69	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46193576~46196723:+
TGCT	cis	rs950027	0.62	rs1426932	ENSG00000259520.4	CTD-2651B20.3	-7.21	4.87e-11	1.92e-07	-0.44	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45395058	chr15:45251580~45279251:-
TGCT	cis	rs950027	0.596	rs2467853	ENSG00000259520.4	CTD-2651B20.3	-7.21	4.87e-11	1.92e-07	-0.44	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45406595	chr15:45251580~45279251:-
TGCT	cis	rs950027	0.595	rs2486288	ENSG00000259520.4	CTD-2651B20.3	-7.21	4.87e-11	1.92e-07	-0.44	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45420141	chr15:45251580~45279251:-
TGCT	cis	rs2486288	0.539	rs2433601	ENSG00000259520.4	CTD-2651B20.3	-7.21	4.87e-11	1.92e-07	-0.44	-0.54	Glomerular filtration rate;	chr15:45424227	chr15:45251580~45279251:-
TGCT	cis	rs853679	0.567	rs9969098	ENSG00000216901.1	AL022393.7	7.21	4.88e-11	1.93e-07	0.67	0.54	Depression;	chr6:28430971	chr6:28176188~28176674:+
TGCT	cis	rs853679	0.567	rs7740429	ENSG00000216901.1	AL022393.7	7.21	4.88e-11	1.93e-07	0.67	0.54	Depression;	chr6:28431469	chr6:28176188~28176674:+
TGCT	cis	rs853679	0.567	rs16894106	ENSG00000216901.1	AL022393.7	7.21	4.88e-11	1.93e-07	0.67	0.54	Depression;	chr6:28432562	chr6:28176188~28176674:+
TGCT	cis	rs2283792	0.776	rs9610458	ENSG00000228050.1	TOP3BP1	7.21	4.88e-11	1.93e-07	0.66	0.54	Multiple sclerosis;	chr22:21851064	chr22:22223187~22224566:-
TGCT	cis	rs2882667	0.627	rs1549203	ENSG00000253404.1	AC034243.1	-7.21	4.9e-11	1.93e-07	-0.62	-0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139132655	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.867	rs6868085	ENSG00000253404.1	AC034243.1	7.21	4.91e-11	1.94e-07	0.58	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139096757	chr5:138744434~138753309:-
TGCT	cis	rs200972	1	rs200972	ENSG00000216901.1	AL022393.7	7.21	4.93e-11	1.95e-07	0.62	0.54	Urinary tract infection frequency;	chr6:27891059	chr6:28176188~28176674:+
TGCT	cis	rs9399135	0.967	rs3756799	ENSG00000232876.1	CTA-212D2.2	-7.21	4.95e-11	1.95e-07	-0.5	-0.54	Red blood cell count;	chr6:135019873	chr6:135055033~135060550:+
TGCT	cis	rs977987	0.806	rs11643209	ENSG00000261783.1	RP11-252K23.2	-7.2	4.98e-11	1.96e-07	-0.79	-0.54	Dupuytren's disease;	chr16:75297146	chr16:75379818~75381260:-
TGCT	cis	rs11098499	0.78	rs12504773	ENSG00000245958.5	RP11-33B1.1	-7.2	5.03e-11	1.98e-07	-0.6	-0.54	Corneal astigmatism;	chr4:119640994	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.78	rs7680914	ENSG00000245958.5	RP11-33B1.1	-7.2	5.03e-11	1.98e-07	-0.6	-0.54	Corneal astigmatism;	chr4:119641898	chr4:119454791~119552025:+
TGCT	cis	rs1930961	1	rs6519611	ENSG00000272977.1	CTA-390C10.10	-7.2	5.05e-11	1.99e-07	-0.74	-0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25449888	chr22:25476218~25479971:+
TGCT	cis	rs11098499	0.954	rs6849561	ENSG00000245958.5	RP11-33B1.1	7.2	5.2e-11	2.04e-07	0.59	0.54	Corneal astigmatism;	chr4:119488539	chr4:119454791~119552025:+
TGCT	cis	rs2739330	0.76	rs5760095	ENSG00000218537.1	MIF-AS1	7.2	5.21e-11	2.05e-07	0.65	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23894426~23898930:-
TGCT	cis	rs4691139	0.967	rs4588418	ENSG00000250227.1	TRIM60P14	7.2	5.21e-11	2.05e-07	0.58	0.54	Ovarian cancer in BRCA1 mutation carriers;	chr4:164981136	chr4:164915565~164916983:+
TGCT	cis	rs4691139	1	rs7692919	ENSG00000250227.1	TRIM60P14	7.2	5.21e-11	2.05e-07	0.58	0.54	Ovarian cancer in BRCA1 mutation carriers;	chr4:164981629	chr4:164915565~164916983:+
TGCT	cis	rs4691139	1	rs1914859	ENSG00000250227.1	TRIM60P14	7.2	5.21e-11	2.05e-07	0.58	0.54	Ovarian cancer in BRCA1 mutation carriers;	chr4:164984989	chr4:164915565~164916983:+
TGCT	cis	rs4691139	1	rs6855591	ENSG00000250227.1	TRIM60P14	7.2	5.21e-11	2.05e-07	0.58	0.54	Ovarian cancer in BRCA1 mutation carriers;	chr4:164985571	chr4:164915565~164916983:+
TGCT	cis	rs4691139	1	rs12498808	ENSG00000250227.1	TRIM60P14	7.2	5.21e-11	2.05e-07	0.58	0.54	Ovarian cancer in BRCA1 mutation carriers;	chr4:164985753	chr4:164915565~164916983:+
TGCT	cis	rs524281	0.861	rs10896090	ENSG00000255320.1	RP11-755F10.1	7.2	5.22e-11	2.05e-07	0.7	0.54	Electroencephalogram traits;	chr11:66177715	chr11:66244840~66246239:-
TGCT	cis	rs2882667	0.898	rs12719519	ENSG00000253404.1	AC034243.1	7.19	5.25e-11	2.06e-07	0.61	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139039998	chr5:138744434~138753309:-
TGCT	cis	rs4691139	0.873	rs12509081	ENSG00000250227.1	TRIM60P14	7.19	5.4e-11	2.12e-07	0.58	0.54	Ovarian cancer in BRCA1 mutation carriers;	chr4:164971812	chr4:164915565~164916983:+
TGCT	cis	rs1062177	0.855	rs62395861	ENSG00000253921.1	CTB-113P19.3	-7.19	5.46e-11	2.14e-07	-0.61	-0.54	Preschool internalizing problems;	chr5:151889709	chr5:151753992~151767247:+
TGCT	cis	rs1062177	0.95	rs59580263	ENSG00000253921.1	CTB-113P19.3	-7.19	5.46e-11	2.14e-07	-0.61	-0.54	Preschool internalizing problems;	chr5:151890016	chr5:151753992~151767247:+
TGCT	cis	rs11098499	0.909	rs1546502	ENSG00000245958.5	RP11-33B1.1	-7.19	5.48e-11	2.15e-07	-0.56	-0.54	Corneal astigmatism;	chr4:119314743	chr4:119454791~119552025:+
TGCT	cis	rs2858942	0.602	rs1211375	ENSG00000268836.1	LA16c-OS12.2	-7.18	5.53e-11	2.17e-07	-0.56	-0.54	Mean corpuscular hemoglobin;	chr16:190281	chr16:185748~186294:-
TGCT	cis	rs943437	0.778	rs9400515	ENSG00000227012.2	RP1-97J1.2	7.18	5.54e-11	2.17e-07	0.73	0.54	Parkinson's disease;	chr6:111928907	chr6:111900489~111901851:-
TGCT	cis	rs10028773	0.515	rs9994488	ENSG00000245958.5	RP11-33B1.1	-7.18	5.55e-11	2.17e-07	-0.58	-0.54	Educational attainment;	chr4:119666626	chr4:119454791~119552025:+
TGCT	cis	rs2929278	0.561	rs2927071	ENSG00000205771.5	CATSPER2P1	-7.18	5.59e-11	2.19e-07	-0.62	-0.54	Schizophrenia;	chr15:43626883	chr15:43726918~43747094:-
TGCT	cis	rs7174755	0.923	rs4777033	ENSG00000260657.2	RP11-315D16.4	-7.18	5.63e-11	2.2e-07	-0.58	-0.54	Major depressive disorder;	chr15:68308010	chr15:68267792~68277994:-
TGCT	cis	rs7174755	0.962	rs4777034	ENSG00000260657.2	RP11-315D16.4	-7.18	5.63e-11	2.2e-07	-0.58	-0.54	Major depressive disorder;	chr15:68309546	chr15:68267792~68277994:-
TGCT	cis	rs2486288	0.656	rs7167146	ENSG00000259520.4	CTD-2651B20.3	-7.18	5.63e-11	2.2e-07	-0.45	-0.54	Glomerular filtration rate;	chr15:45279188	chr15:45251580~45279251:-
TGCT	cis	rs7044106	0.791	rs10985009	ENSG00000226752.6	PSMD5-AS1	7.18	5.64e-11	2.21e-07	0.68	0.54	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120824828~120854385:+
TGCT	cis	rs7208859	0.673	rs11657270	ENSG00000263531.1	RP13-753N3.1	7.18	5.68e-11	2.22e-07	0.92	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30863921~30864940:-
TGCT	cis	rs6921919	0.697	rs12180820	ENSG00000216901.1	AL022393.7	-7.18	5.68e-11	2.22e-07	-0.62	-0.54	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28176188~28176674:+
TGCT	cis	rs2882667	0.931	rs10074461	ENSG00000253404.1	AC034243.1	7.17	5.81e-11	2.27e-07	0.63	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138984126	chr5:138744434~138753309:-
TGCT	cis	rs9399137	0.507	rs4896118	ENSG00000232876.1	CTA-212D2.2	7.17	5.89e-11	2.3e-07	0.5	0.54	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954927	chr6:135055033~135060550:+
TGCT	cis	rs7714584	1	rs12656600	ENSG00000197083.10	ZNF300P1	7.17	5.92e-11	2.31e-07	1.03	0.54	Crohn's disease;	chr5:150932310	chr5:150930645~150946289:-
TGCT	cis	rs11098499	0.909	rs10026736	ENSG00000245958.5	RP11-33B1.1	-7.17	5.94e-11	2.32e-07	-0.57	-0.54	Corneal astigmatism;	chr4:119463167	chr4:119454791~119552025:+
TGCT	cis	rs1062177	0.826	rs2915822	ENSG00000213433.5	RPLP1P6	7.17	6.06e-11	2.36e-07	0.56	0.54	Preschool internalizing problems;	chr5:151751340	chr5:151765859~151766378:-
TGCT	cis	rs7208859	0.614	rs73265646	ENSG00000263531.1	RP13-753N3.1	7.17	6.07e-11	2.37e-07	0.94	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs58908911	ENSG00000263531.1	RP13-753N3.1	7.17	6.07e-11	2.37e-07	0.94	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30863921~30864940:-
TGCT	cis	rs524281	0.648	rs10896089	ENSG00000255320.1	RP11-755F10.1	7.17	6.09e-11	2.37e-07	0.67	0.54	Electroencephalogram traits;	chr11:66168821	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.861	rs7943911	ENSG00000255320.1	RP11-755F10.1	7.17	6.09e-11	2.37e-07	0.67	0.54	Electroencephalogram traits;	chr11:66175583	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.861	rs10750778	ENSG00000255320.1	RP11-755F10.1	7.17	6.09e-11	2.37e-07	0.67	0.54	Electroencephalogram traits;	chr11:66181177	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.861	rs6591208	ENSG00000255320.1	RP11-755F10.1	7.17	6.09e-11	2.37e-07	0.67	0.54	Electroencephalogram traits;	chr11:66182218	chr11:66244840~66246239:-
TGCT	cis	rs977987	0.806	rs766521	ENSG00000261783.1	RP11-252K23.2	7.16	6.19e-11	2.41e-07	0.77	0.54	Dupuytren's disease;	chr16:75390256	chr16:75379818~75381260:-
TGCT	cis	rs2882667	0.898	rs4380651	ENSG00000253404.1	AC034243.1	7.16	6.22e-11	2.42e-07	0.6	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139055383	chr5:138744434~138753309:-
TGCT	cis	rs2283792	0.967	rs743409	ENSG00000228050.1	TOP3BP1	7.16	6.23e-11	2.42e-07	0.63	0.54	Multiple sclerosis;	chr22:21774926	chr22:22223187~22224566:-
TGCT	cis	rs11098499	0.874	rs13139045	ENSG00000245958.5	RP11-33B1.1	-7.16	6.25e-11	2.43e-07	-0.55	-0.54	Corneal astigmatism;	chr4:119247433	chr4:119454791~119552025:+
TGCT	cis	rs916888	0.61	rs199438	ENSG00000214401.4	KANSL1-AS1	7.16	6.26e-11	2.44e-07	0.7	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46193576~46196723:+
TGCT	cis	rs11098499	0.826	rs4472123	ENSG00000245958.5	RP11-33B1.1	-7.16	6.28e-11	2.44e-07	-0.55	-0.54	Corneal astigmatism;	chr4:119315475	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.754	rs878376	ENSG00000245958.5	RP11-33B1.1	-7.16	6.28e-11	2.44e-07	-0.55	-0.54	Corneal astigmatism;	chr4:119316547	chr4:119454791~119552025:+
TGCT	cis	rs9399137	0.507	rs7768278	ENSG00000232876.1	CTA-212D2.2	-7.16	6.37e-11	2.47e-07	-0.5	-0.54	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134953819	chr6:135055033~135060550:+
TGCT	cis	rs9399137	0.507	rs7748708	ENSG00000232876.1	CTA-212D2.2	-7.16	6.37e-11	2.47e-07	-0.5	-0.54	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954004	chr6:135055033~135060550:+
TGCT	cis	rs7044106	0.5	rs56725168	ENSG00000226752.6	PSMD5-AS1	-7.15	6.42e-11	2.49e-07	-0.68	-0.54	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120824828~120854385:+
TGCT	cis	rs7044106	0.791	rs10985008	ENSG00000226752.6	PSMD5-AS1	-7.15	6.42e-11	2.49e-07	-0.68	-0.54	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120824828~120854385:+
TGCT	cis	rs7188445	0.966	rs11150188	ENSG00000261390.4	RP11-345M22.2	-7.15	6.46e-11	2.51e-07	-0.55	-0.54	Urate levels;	chr16:79673401	chr16:79715232~79770563:-
TGCT	cis	rs11098499	0.954	rs9993199	ENSG00000245958.5	RP11-33B1.1	7.15	6.49e-11	2.52e-07	0.58	0.54	Corneal astigmatism;	chr4:119471718	chr4:119454791~119552025:+
TGCT	cis	rs4691139	1	rs9917978	ENSG00000250227.1	TRIM60P14	7.15	6.51e-11	2.53e-07	0.58	0.54	Ovarian cancer in BRCA1 mutation carriers;	chr4:164963991	chr4:164915565~164916983:+
TGCT	cis	rs4691139	1	rs13134489	ENSG00000250227.1	TRIM60P14	7.15	6.51e-11	2.53e-07	0.58	0.54	Ovarian cancer in BRCA1 mutation carriers;	chr4:164968285	chr4:164915565~164916983:+
TGCT	cis	rs4691139	1	rs10007789	ENSG00000250227.1	TRIM60P14	7.15	6.51e-11	2.53e-07	0.58	0.54	Ovarian cancer in BRCA1 mutation carriers;	chr4:164969225	chr4:164915565~164916983:+
TGCT	cis	rs6452524	0.508	rs40214	ENSG00000249664.1	CTD-2227C6.2	-7.15	6.53e-11	2.53e-07	-0.57	-0.54	Hypertension (SNP x SNP interaction);	chr5:83000359	chr5:83012285~83013109:-
TGCT	cis	rs858239	0.698	rs4265084	ENSG00000230658.1	KLHL7-AS1	7.15	6.54e-11	2.54e-07	0.58	0.54	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23101228~23105703:-
TGCT	cis	rs2283792	0.871	rs8136867	ENSG00000228050.1	TOP3BP1	7.15	6.61e-11	2.56e-07	0.66	0.54	Multiple sclerosis;	chr22:21850504	chr22:22223187~22224566:-
TGCT	cis	rs2882667	0.898	rs6862393	ENSG00000253404.1	AC034243.1	7.15	6.65e-11	2.57e-07	0.6	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029009	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.858	rs4643949	ENSG00000253404.1	AC034243.1	7.15	6.65e-11	2.57e-07	0.6	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139036656	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.898	rs6867343	ENSG00000253404.1	AC034243.1	7.15	6.65e-11	2.57e-07	0.6	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038739	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.898	rs2882792	ENSG00000253404.1	AC034243.1	7.15	6.65e-11	2.57e-07	0.6	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044791	chr5:138744434~138753309:-
TGCT	cis	rs6452524	0.711	rs1478486	ENSG00000249664.1	CTD-2227C6.2	7.15	6.67e-11	2.58e-07	0.54	0.54	Hypertension (SNP x SNP interaction);	chr5:83081185	chr5:83012285~83013109:-
TGCT	cis	rs17301013	0.581	rs6685499	ENSG00000227373.4	RP11-160H22.5	7.15	6.72e-11	2.59e-07	0.64	0.54	Systemic lupus erythematosus;	chr1:174144237	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs4652193	ENSG00000227373.4	RP11-160H22.5	7.15	6.72e-11	2.59e-07	0.64	0.54	Systemic lupus erythematosus;	chr1:174144554	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.632	rs12079214	ENSG00000227373.4	RP11-160H22.5	7.15	6.72e-11	2.59e-07	0.64	0.54	Systemic lupus erythematosus;	chr1:174149572	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs12065785	ENSG00000227373.4	RP11-160H22.5	7.15	6.72e-11	2.59e-07	0.64	0.54	Systemic lupus erythematosus;	chr1:174151296	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs16846717	ENSG00000227373.4	RP11-160H22.5	7.15	6.72e-11	2.59e-07	0.64	0.54	Systemic lupus erythematosus;	chr1:174152180	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs16846718	ENSG00000227373.4	RP11-160H22.5	7.15	6.72e-11	2.59e-07	0.64	0.54	Systemic lupus erythematosus;	chr1:174152782	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs10912735	ENSG00000227373.4	RP11-160H22.5	7.15	6.72e-11	2.59e-07	0.64	0.54	Systemic lupus erythematosus;	chr1:174159002	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs12354141	ENSG00000227373.4	RP11-160H22.5	7.15	6.72e-11	2.59e-07	0.64	0.54	Systemic lupus erythematosus;	chr1:174166078	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs3086	ENSG00000227373.4	RP11-160H22.5	7.15	6.72e-11	2.59e-07	0.64	0.54	Systemic lupus erythematosus;	chr1:174167236	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs12082461	ENSG00000227373.4	RP11-160H22.5	7.15	6.72e-11	2.59e-07	0.64	0.54	Systemic lupus erythematosus;	chr1:174169876	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs10912737	ENSG00000227373.4	RP11-160H22.5	7.15	6.72e-11	2.59e-07	0.64	0.54	Systemic lupus erythematosus;	chr1:174172999	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.531	rs12079687	ENSG00000227373.4	RP11-160H22.5	7.15	6.72e-11	2.59e-07	0.64	0.54	Systemic lupus erythematosus;	chr1:174175545	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs12087808	ENSG00000227373.4	RP11-160H22.5	7.15	6.72e-11	2.59e-07	0.64	0.54	Systemic lupus erythematosus;	chr1:174178848	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs10912740	ENSG00000227373.4	RP11-160H22.5	7.15	6.72e-11	2.59e-07	0.64	0.54	Systemic lupus erythematosus;	chr1:174180224	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs724888	ENSG00000227373.4	RP11-160H22.5	7.15	6.72e-11	2.59e-07	0.64	0.54	Systemic lupus erythematosus;	chr1:174180403	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs7547766	ENSG00000227373.4	RP11-160H22.5	7.15	6.72e-11	2.59e-07	0.64	0.54	Systemic lupus erythematosus;	chr1:174180977	chr1:174115300~174160004:-
TGCT	cis	rs66887589	0.967	rs6844263	ENSG00000245958.5	RP11-33B1.1	-7.14	6.78e-11	2.61e-07	-0.54	-0.54	Diastolic blood pressure;	chr4:119512652	chr4:119454791~119552025:+
TGCT	cis	rs66887589	0.967	rs13104219	ENSG00000245958.5	RP11-33B1.1	-7.14	6.78e-11	2.61e-07	-0.54	-0.54	Diastolic blood pressure;	chr4:119517019	chr4:119454791~119552025:+
TGCT	cis	rs524281	0.861	rs7937281	ENSG00000255320.1	RP11-755F10.1	7.14	6.83e-11	2.63e-07	0.66	0.54	Electroencephalogram traits;	chr11:66182603	chr11:66244840~66246239:-
TGCT	cis	rs7617773	0.817	rs11130162	ENSG00000229759.1	MRPS18AP1	7.14	6.84e-11	2.63e-07	0.43	0.54	Coronary artery disease;	chr3:48256121	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.817	rs6787500	ENSG00000229759.1	MRPS18AP1	7.14	6.84e-11	2.63e-07	0.43	0.54	Coronary artery disease;	chr3:48257949	chr3:48256350~48256938:-
TGCT	cis	rs7208859	0.623	rs9914242	ENSG00000263531.1	RP13-753N3.1	7.14	6.84e-11	2.63e-07	0.95	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30863921~30864940:-
TGCT	cis	rs2729354	0.903	rs2729371	ENSG00000265566.2	RN7SL605P	-7.14	6.94e-11	2.67e-07	-0.68	-0.54	Blood protein levels;	chr11:57553849	chr11:57528085~57528365:-
TGCT	cis	rs1933112	1	rs7529824	ENSG00000227777.1	RP4-738P11.3	-7.14	6.97e-11	2.68e-07	-0.59	-0.54	Blood protein levels;	chr1:168531220	chr1:168542737~168543354:+
TGCT	cis	rs8040855	0.627	rs12900012	ENSG00000259295.5	CSPG4P12	7.14	7e-11	2.69e-07	0.71	0.54	Bulimia nervosa;	chr15:85046955	chr15:85191438~85213905:+
TGCT	cis	rs8040855	0.627	rs12909130	ENSG00000259295.5	CSPG4P12	7.14	7e-11	2.69e-07	0.71	0.54	Bulimia nervosa;	chr15:85047270	chr15:85191438~85213905:+
TGCT	cis	rs8040855	0.627	rs72757059	ENSG00000259295.5	CSPG4P12	7.14	7e-11	2.69e-07	0.71	0.54	Bulimia nervosa;	chr15:85059918	chr15:85191438~85213905:+
TGCT	cis	rs8040855	0.627	rs11630697	ENSG00000259295.5	CSPG4P12	7.14	7e-11	2.69e-07	0.71	0.54	Bulimia nervosa;	chr15:85063214	chr15:85191438~85213905:+
TGCT	cis	rs8040855	0.627	rs11634975	ENSG00000259295.5	CSPG4P12	7.14	7e-11	2.69e-07	0.71	0.54	Bulimia nervosa;	chr15:85063247	chr15:85191438~85213905:+
TGCT	cis	rs8040855	0.627	rs4980357	ENSG00000259295.5	CSPG4P12	7.14	7e-11	2.69e-07	0.71	0.54	Bulimia nervosa;	chr15:85064878	chr15:85191438~85213905:+
TGCT	cis	rs8040855	0.627	rs4980356	ENSG00000259295.5	CSPG4P12	7.14	7e-11	2.69e-07	0.71	0.54	Bulimia nervosa;	chr15:85064901	chr15:85191438~85213905:+
TGCT	cis	rs11098499	0.909	rs10014719	ENSG00000245958.5	RP11-33B1.1	-7.14	7.06e-11	2.71e-07	-0.57	-0.54	Corneal astigmatism;	chr4:119399560	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs10017543	ENSG00000245958.5	RP11-33B1.1	-7.14	7.06e-11	2.71e-07	-0.57	-0.54	Corneal astigmatism;	chr4:119400265	chr4:119454791~119552025:+
TGCT	cis	rs66887589	0.777	rs4643791	ENSG00000245958.5	RP11-33B1.1	7.14	7.09e-11	2.72e-07	0.53	0.54	Diastolic blood pressure;	chr4:119344464	chr4:119454791~119552025:+
TGCT	cis	rs2882667	0.898	rs11749944	ENSG00000253404.1	AC034243.1	7.13	7.21e-11	2.76e-07	0.59	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077090	chr5:138744434~138753309:-
TGCT	cis	rs11098499	0.954	rs10006706	ENSG00000245958.5	RP11-33B1.1	-7.13	7.24e-11	2.77e-07	-0.57	-0.54	Corneal astigmatism;	chr4:119487997	chr4:119454791~119552025:+
TGCT	cis	rs977987	0.835	rs8046109	ENSG00000261783.1	RP11-252K23.2	-7.13	7.35e-11	2.81e-07	-0.78	-0.54	Dupuytren's disease;	chr16:75326198	chr16:75379818~75381260:-
TGCT	cis	rs11098499	0.954	rs1546505	ENSG00000245958.5	RP11-33B1.1	-7.13	7.43e-11	2.84e-07	-0.57	-0.54	Corneal astigmatism;	chr4:119320069	chr4:119454791~119552025:+
TGCT	cis	rs6452524	0.935	rs3901654	ENSG00000249664.1	CTD-2227C6.2	7.13	7.45e-11	2.84e-07	0.54	0.54	Hypertension (SNP x SNP interaction);	chr5:83110519	chr5:83012285~83013109:-
TGCT	cis	rs858239	0.799	rs10279941	ENSG00000230658.1	KLHL7-AS1	7.12	7.52e-11	2.87e-07	0.59	0.54	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23101228~23105703:-
TGCT	cis	rs4423214	1	rs12278461	ENSG00000254682.1	RP11-660L16.2	7.12	7.53e-11	2.87e-07	0.72	0.54	Vitamin D levels;	chr11:71471139	chr11:71448674~71452157:+
TGCT	cis	rs4423214	1	rs2282621	ENSG00000254682.1	RP11-660L16.2	7.12	7.53e-11	2.87e-07	0.72	0.54	Vitamin D levels;	chr11:71472428	chr11:71448674~71452157:+
TGCT	cis	rs4423214	1	rs2282620	ENSG00000254682.1	RP11-660L16.2	7.12	7.53e-11	2.87e-07	0.72	0.54	Vitamin D levels;	chr11:71472431	chr11:71448674~71452157:+
TGCT	cis	rs8040855	0.597	rs12902942	ENSG00000259295.5	CSPG4P12	7.12	7.53e-11	2.87e-07	0.71	0.54	Bulimia nervosa;	chr15:85041573	chr15:85191438~85213905:+
TGCT	cis	rs8040855	0.547	rs17611171	ENSG00000259295.5	CSPG4P12	7.12	7.56e-11	2.88e-07	0.71	0.54	Bulimia nervosa;	chr15:85029468	chr15:85191438~85213905:+
TGCT	cis	rs8040855	0.575	rs12912860	ENSG00000259295.5	CSPG4P12	7.12	7.56e-11	2.88e-07	0.71	0.54	Bulimia nervosa;	chr15:85030267	chr15:85191438~85213905:+
TGCT	cis	rs7208859	0.673	rs9895684	ENSG00000263531.1	RP13-753N3.1	7.12	7.59e-11	2.89e-07	0.94	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30863921~30864940:-
TGCT	cis	rs9399137	0.507	rs7772031	ENSG00000232876.1	CTA-212D2.2	7.12	7.6e-11	2.89e-07	0.5	0.54	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134938596	chr6:135055033~135060550:+
TGCT	cis	rs7208859	0.673	rs79541516	ENSG00000263531.1	RP13-753N3.1	7.12	7.68e-11	2.92e-07	0.94	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30863921~30864940:-
TGCT	cis	rs4691139	1	rs4691139	ENSG00000250227.1	TRIM60P14	7.12	7.77e-11	2.95e-07	0.58	0.54	Ovarian cancer in BRCA1 mutation carriers;	chr4:164987569	chr4:164915565~164916983:+
TGCT	cis	rs4691139	1	rs6536882	ENSG00000250227.1	TRIM60P14	7.11	7.94e-11	3.02e-07	0.58	0.54	Ovarian cancer in BRCA1 mutation carriers;	chr4:164979528	chr4:164915565~164916983:+
TGCT	cis	rs4691139	1	rs6536883	ENSG00000250227.1	TRIM60P14	7.11	7.94e-11	3.02e-07	0.58	0.54	Ovarian cancer in BRCA1 mutation carriers;	chr4:164979552	chr4:164915565~164916983:+
TGCT	cis	rs853679	0.567	rs1005126	ENSG00000216901.1	AL022393.7	7.11	7.97e-11	3.03e-07	0.66	0.54	Depression;	chr6:28399846	chr6:28176188~28176674:+
TGCT	cis	rs853679	0.567	rs13196606	ENSG00000216901.1	AL022393.7	7.11	7.97e-11	3.03e-07	0.66	0.54	Depression;	chr6:28402301	chr6:28176188~28176674:+
TGCT	cis	rs853679	0.567	rs7774981	ENSG00000216901.1	AL022393.7	7.11	8.03e-11	3.05e-07	0.67	0.54	Depression;	chr6:28379133	chr6:28176188~28176674:+
TGCT	cis	rs853679	0.567	rs7754960	ENSG00000216901.1	AL022393.7	7.11	8.03e-11	3.05e-07	0.67	0.54	Depression;	chr6:28379168	chr6:28176188~28176674:+
TGCT	cis	rs9549367	0.713	rs11620600	ENSG00000269125.1	RP11-98F14.11	-7.11	8.27e-11	3.13e-07	-0.68	-0.54	Platelet distribution width;	chr13:113174776	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.713	rs9549681	ENSG00000269125.1	RP11-98F14.11	-7.11	8.27e-11	3.13e-07	-0.68	-0.54	Platelet distribution width;	chr13:113175559	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.713	rs9549682	ENSG00000269125.1	RP11-98F14.11	-7.11	8.27e-11	3.13e-07	-0.68	-0.54	Platelet distribution width;	chr13:113175867	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.713	rs56002882	ENSG00000269125.1	RP11-98F14.11	-7.11	8.27e-11	3.13e-07	-0.68	-0.54	Platelet distribution width;	chr13:113176380	chr13:113165002~113165183:-
TGCT	cis	rs7174755	0.923	rs9672383	ENSG00000260657.2	RP11-315D16.4	7.1	8.33e-11	3.15e-07	0.57	0.54	Major depressive disorder;	chr15:68306731	chr15:68267792~68277994:-
TGCT	cis	rs9399135	0.967	rs7750300	ENSG00000232876.1	CTA-212D2.2	-7.1	8.36e-11	3.17e-07	-0.49	-0.54	Red blood cell count;	chr6:135029812	chr6:135055033~135060550:+
TGCT	cis	rs2283792	1	rs5749806	ENSG00000228050.1	TOP3BP1	7.1	8.39e-11	3.18e-07	0.63	0.54	Multiple sclerosis;	chr22:21752329	chr22:22223187~22224566:-
TGCT	cis	rs11098499	0.644	rs10009566	ENSG00000245958.5	RP11-33B1.1	-7.1	8.43e-11	3.19e-07	-0.58	-0.54	Corneal astigmatism;	chr4:119637453	chr4:119454791~119552025:+
TGCT	cis	rs9399135	0.967	rs12661423	ENSG00000232876.1	CTA-212D2.2	-7.1	8.52e-11	3.22e-07	-0.49	-0.54	Red blood cell count;	chr6:135028432	chr6:135055033~135060550:+
TGCT	cis	rs8040855	0.658	rs11634877	ENSG00000259295.5	CSPG4P12	7.1	8.55e-11	3.23e-07	0.71	0.54	Bulimia nervosa;	chr15:85068246	chr15:85191438~85213905:+
TGCT	cis	rs8040855	0.627	rs11632175	ENSG00000259295.5	CSPG4P12	7.1	8.55e-11	3.23e-07	0.71	0.54	Bulimia nervosa;	chr15:85068449	chr15:85191438~85213905:+
TGCT	cis	rs8040855	0.627	rs62019482	ENSG00000259295.5	CSPG4P12	7.1	8.55e-11	3.23e-07	0.71	0.54	Bulimia nervosa;	chr15:85071796	chr15:85191438~85213905:+
TGCT	cis	rs9399137	0.507	rs7771310	ENSG00000232876.1	CTA-212D2.2	-7.1	8.58e-11	3.24e-07	-0.5	-0.54	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134951397	chr6:135055033~135060550:+
TGCT	cis	rs950027	0.62	rs1719246	ENSG00000259520.4	CTD-2651B20.3	-7.1	8.59e-11	3.25e-07	-0.44	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45333281	chr15:45251580~45279251:-
TGCT	cis	rs950027	0.62	rs2486274	ENSG00000259520.4	CTD-2651B20.3	-7.1	8.59e-11	3.25e-07	-0.44	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45374030	chr15:45251580~45279251:-
TGCT	cis	rs1577917	0.687	rs34618171	ENSG00000203875.9	SNHG5	-7.1	8.62e-11	3.26e-07	-0.77	-0.54	Response to antipsychotic treatment;	chr6:86101447	chr6:85660950~85678736:-
TGCT	cis	rs9399135	0.66	rs9376072	ENSG00000232876.1	CTA-212D2.2	-7.1	8.68e-11	3.27e-07	-0.49	-0.54	Red blood cell count;	chr6:134959381	chr6:135055033~135060550:+
TGCT	cis	rs853679	0.567	rs3799499	ENSG00000216901.1	AL022393.7	7.09	8.78e-11	3.31e-07	0.66	0.54	Depression;	chr6:28386473	chr6:28176188~28176674:+
TGCT	cis	rs853679	0.567	rs2232427	ENSG00000216901.1	AL022393.7	7.09	8.78e-11	3.31e-07	0.66	0.54	Depression;	chr6:28391932	chr6:28176188~28176674:+
TGCT	cis	rs7829975	0.536	rs2980439	ENSG00000173295.6	FAM86B3P	7.09	8.92e-11	3.36e-07	0.66	0.54	Mood instability;	chr8:8237348	chr8:8228595~8244865:+
TGCT	cis	rs2882667	0.931	rs10075951	ENSG00000253404.1	AC034243.1	7.09	9e-11	3.39e-07	0.6	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020274	chr5:138744434~138753309:-
TGCT	cis	rs8040855	0.627	rs3816105	ENSG00000259295.5	CSPG4P12	7.09	9.06e-11	3.41e-07	0.72	0.54	Bulimia nervosa;	chr15:85097680	chr15:85191438~85213905:+
TGCT	cis	rs8040855	0.627	rs2304418	ENSG00000259295.5	CSPG4P12	7.09	9.06e-11	3.41e-07	0.72	0.54	Bulimia nervosa;	chr15:85097752	chr15:85191438~85213905:+
TGCT	cis	rs8040855	0.627	rs11637512	ENSG00000259295.5	CSPG4P12	7.09	9.06e-11	3.41e-07	0.72	0.54	Bulimia nervosa;	chr15:85105528	chr15:85191438~85213905:+
TGCT	cis	rs8040855	0.627	rs17541051	ENSG00000259295.5	CSPG4P12	7.09	9.06e-11	3.41e-07	0.72	0.54	Bulimia nervosa;	chr15:85106122	chr15:85191438~85213905:+
TGCT	cis	rs8040855	0.627	rs35668291	ENSG00000259295.5	CSPG4P12	7.09	9.06e-11	3.41e-07	0.72	0.54	Bulimia nervosa;	chr15:85109582	chr15:85191438~85213905:+
TGCT	cis	rs7208859	0.673	rs999797	ENSG00000263531.1	RP13-753N3.1	7.09	9.19e-11	3.46e-07	0.94	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30863921~30864940:-
TGCT	cis	rs11098499	0.954	rs10017371	ENSG00000245958.5	RP11-33B1.1	-7.09	9.2e-11	3.46e-07	-0.55	-0.54	Corneal astigmatism;	chr4:119372621	chr4:119454791~119552025:+
TGCT	cis	rs524281	0.861	rs10896091	ENSG00000255320.1	RP11-755F10.1	7.08	9.25e-11	3.48e-07	0.67	0.54	Electroencephalogram traits;	chr11:66183354	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.861	rs7929909	ENSG00000255320.1	RP11-755F10.1	7.08	9.25e-11	3.48e-07	0.67	0.54	Electroencephalogram traits;	chr11:66184227	chr11:66244840~66246239:-
TGCT	cis	rs1355223	1	rs11604069	ENSG00000271369.1	RP11-350D17.3	-7.08	9.37e-11	3.52e-07	-0.53	-0.54	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34742704	chr11:34709600~34710161:+
TGCT	cis	rs2739330	0.703	rs5760112	ENSG00000218537.1	MIF-AS1	7.08	9.37e-11	3.52e-07	0.65	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23894426~23898930:-
TGCT	cis	rs2882667	0.931	rs10068237	ENSG00000253404.1	AC034243.1	7.08	9.38e-11	3.52e-07	0.59	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002271	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.898	rs3828600	ENSG00000253404.1	AC034243.1	7.08	9.39e-11	3.52e-07	0.6	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051170	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.861	rs10043676	ENSG00000253404.1	AC034243.1	7.08	9.39e-11	3.52e-07	0.6	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053872	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.898	rs10038121	ENSG00000253404.1	AC034243.1	7.08	9.39e-11	3.52e-07	0.6	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053913	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.861	rs10075541	ENSG00000253404.1	AC034243.1	7.08	9.39e-11	3.52e-07	0.6	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054629	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.898	rs2043272	ENSG00000253404.1	AC034243.1	7.08	9.39e-11	3.52e-07	0.6	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054942	chr5:138744434~138753309:-
TGCT	cis	rs2739330	0.734	rs2000467	ENSG00000218537.1	MIF-AS1	-7.08	9.61e-11	3.61e-07	-0.73	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23894426~23898930:-
TGCT	cis	rs17301013	0.606	rs1853321	ENSG00000227373.4	RP11-160H22.5	7.07	9.71e-11	3.64e-07	0.63	0.54	Systemic lupus erythematosus;	chr1:174125295	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs6694208	ENSG00000227373.4	RP11-160H22.5	7.07	9.71e-11	3.64e-07	0.63	0.54	Systemic lupus erythematosus;	chr1:174127631	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs727912	ENSG00000227373.4	RP11-160H22.5	7.07	9.71e-11	3.64e-07	0.63	0.54	Systemic lupus erythematosus;	chr1:174132729	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs4650951	ENSG00000227373.4	RP11-160H22.5	7.07	9.71e-11	3.64e-07	0.63	0.54	Systemic lupus erythematosus;	chr1:174134368	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs4652191	ENSG00000227373.4	RP11-160H22.5	7.07	9.71e-11	3.64e-07	0.63	0.54	Systemic lupus erythematosus;	chr1:174135473	chr1:174115300~174160004:-
TGCT	cis	rs950027	0.62	rs1153860	ENSG00000259520.4	CTD-2651B20.3	7.07	9.84e-11	3.69e-07	0.44	0.54	Response to fenofibrate (adiponectin levels);	chr15:45344386	chr15:45251580~45279251:-
TGCT	cis	rs977987	0.835	rs4888380	ENSG00000261783.1	RP11-252K23.2	-7.07	9.88e-11	3.7e-07	-0.77	-0.54	Dupuytren's disease;	chr16:75313792	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.835	rs8057535	ENSG00000261783.1	RP11-252K23.2	-7.07	9.88e-11	3.7e-07	-0.77	-0.54	Dupuytren's disease;	chr16:75314043	chr16:75379818~75381260:-
TGCT	cis	rs2283792	0.905	rs5755694	ENSG00000228050.1	TOP3BP1	7.07	1e-10	3.74e-07	0.65	0.54	Multiple sclerosis;	chr22:21846241	chr22:22223187~22224566:-
TGCT	cis	rs8040855	0.825	rs3964197	ENSG00000259295.5	CSPG4P12	7.07	1.02e-10	3.79e-07	0.7	0.54	Bulimia nervosa;	chr15:85178681	chr15:85191438~85213905:+
TGCT	cis	rs9549367	0.789	rs2287244	ENSG00000269125.1	RP11-98F14.11	7.06	1.02e-10	3.82e-07	0.63	0.54	Platelet distribution width;	chr13:113232859	chr13:113165002~113165183:-
TGCT	cis	rs2882667	1	rs10515505	ENSG00000253404.1	AC034243.1	7.06	1.03e-10	3.84e-07	0.61	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138977457	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.858	rs11957633	ENSG00000253404.1	AC034243.1	7.06	1.03e-10	3.84e-07	0.64	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028705	chr5:138744434~138753309:-
TGCT	cis	rs11098499	0.954	rs11098526	ENSG00000245958.5	RP11-33B1.1	-7.06	1.04e-10	3.88e-07	-0.57	-0.54	Corneal astigmatism;	chr4:119469204	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.821	rs10032151	ENSG00000245958.5	RP11-33B1.1	-7.06	1.04e-10	3.88e-07	-0.57	-0.54	Corneal astigmatism;	chr4:119470473	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.865	rs10032158	ENSG00000245958.5	RP11-33B1.1	-7.06	1.04e-10	3.88e-07	-0.57	-0.54	Corneal astigmatism;	chr4:119470477	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs6838814	ENSG00000245958.5	RP11-33B1.1	-7.06	1.04e-10	3.88e-07	-0.57	-0.54	Corneal astigmatism;	chr4:119471288	chr4:119454791~119552025:+
TGCT	cis	rs8040855	0.627	rs12913859	ENSG00000259295.5	CSPG4P12	7.06	1.04e-10	3.89e-07	0.72	0.54	Bulimia nervosa;	chr15:85095187	chr15:85191438~85213905:+
TGCT	cis	rs7044106	0.791	rs10739572	ENSG00000226752.6	PSMD5-AS1	-7.06	1.05e-10	3.92e-07	-0.66	-0.54	Hip circumference adjusted for BMI;	chr9:120727537	chr9:120824828~120854385:+
TGCT	cis	rs9389248	0.728	rs1022491	ENSG00000232876.1	CTA-212D2.2	7.06	1.05e-10	3.93e-07	0.5	0.54	High light scatter reticulocyte percentage of red cells;	chr6:134938228	chr6:135055033~135060550:+
TGCT	cis	rs17301013	0.606	rs11802158	ENSG00000227373.4	RP11-160H22.5	7.06	1.07e-10	3.98e-07	0.63	0.54	Systemic lupus erythematosus;	chr1:174223973	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.581	rs12081445	ENSG00000227373.4	RP11-160H22.5	7.06	1.07e-10	3.98e-07	0.63	0.54	Systemic lupus erythematosus;	chr1:174226923	chr1:174115300~174160004:-
TGCT	cis	rs7714584	1	rs76433514	ENSG00000197083.10	ZNF300P1	7.06	1.07e-10	3.98e-07	1.02	0.54	Crohn's disease;	chr5:150926970	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs17800886	ENSG00000197083.10	ZNF300P1	7.06	1.07e-10	3.98e-07	1.02	0.54	Crohn's disease;	chr5:150929977	chr5:150930645~150946289:-
TGCT	cis	rs1062177	0.756	rs2915817	ENSG00000213433.5	RPLP1P6	7.05	1.07e-10	3.99e-07	0.56	0.54	Preschool internalizing problems;	chr5:151735956	chr5:151765859~151766378:-
TGCT	cis	rs11098499	0.754	rs10518300	ENSG00000245958.5	RP11-33B1.1	7.05	1.08e-10	4.01e-07	0.59	0.54	Corneal astigmatism;	chr4:119328344	chr4:119454791~119552025:+
TGCT	cis	rs524281	0.773	rs7951079	ENSG00000255320.1	RP11-755F10.1	7.05	1.08e-10	4.03e-07	0.74	0.54	Electroencephalogram traits;	chr11:66213079	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.861	rs7120326	ENSG00000255320.1	RP11-755F10.1	7.05	1.09e-10	4.03e-07	0.67	0.54	Electroencephalogram traits;	chr11:66081785	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.861	rs918299	ENSG00000255320.1	RP11-755F10.1	7.05	1.09e-10	4.03e-07	0.67	0.54	Electroencephalogram traits;	chr11:66160136	chr11:66244840~66246239:-
TGCT	cis	rs11098499	0.954	rs7436506	ENSG00000245958.5	RP11-33B1.1	-7.05	1.09e-10	4.05e-07	-0.58	-0.53	Corneal astigmatism;	chr4:119472614	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs12499324	ENSG00000245958.5	RP11-33B1.1	-7.05	1.09e-10	4.05e-07	-0.58	-0.53	Corneal astigmatism;	chr4:119472631	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs10008459	ENSG00000245958.5	RP11-33B1.1	-7.05	1.09e-10	4.05e-07	-0.58	-0.53	Corneal astigmatism;	chr4:119473076	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.909	rs2127821	ENSG00000245958.5	RP11-33B1.1	-7.05	1.09e-10	4.05e-07	-0.58	-0.53	Corneal astigmatism;	chr4:119473380	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs28685688	ENSG00000245958.5	RP11-33B1.1	-7.05	1.09e-10	4.05e-07	-0.58	-0.53	Corneal astigmatism;	chr4:119499179	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs7687843	ENSG00000245958.5	RP11-33B1.1	-7.05	1.09e-10	4.05e-07	-0.58	-0.53	Corneal astigmatism;	chr4:119500056	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs2306455	ENSG00000245958.5	RP11-33B1.1	-7.05	1.09e-10	4.05e-07	-0.58	-0.53	Corneal astigmatism;	chr4:119500814	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs10031483	ENSG00000245958.5	RP11-33B1.1	-7.05	1.09e-10	4.05e-07	-0.58	-0.53	Corneal astigmatism;	chr4:119501481	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs10031665	ENSG00000245958.5	RP11-33B1.1	-7.05	1.09e-10	4.05e-07	-0.58	-0.53	Corneal astigmatism;	chr4:119501697	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs3733523	ENSG00000245958.5	RP11-33B1.1	-7.05	1.09e-10	4.05e-07	-0.58	-0.53	Corneal astigmatism;	chr4:119502564	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs12502423	ENSG00000245958.5	RP11-33B1.1	-7.05	1.09e-10	4.05e-07	-0.58	-0.53	Corneal astigmatism;	chr4:119503017	chr4:119454791~119552025:+
TGCT	cis	rs17301013	0.606	rs2103640	ENSG00000227373.4	RP11-160H22.5	7.05	1.09e-10	4.05e-07	0.62	0.53	Systemic lupus erythematosus;	chr1:174219147	chr1:174115300~174160004:-
TGCT	cis	rs1062177	0.901	rs1549622	ENSG00000253921.1	CTB-113P19.3	-7.05	1.1e-10	4.07e-07	-0.6	-0.53	Preschool internalizing problems;	chr5:151886488	chr5:151753992~151767247:+
TGCT	cis	rs858239	0.796	rs433395	ENSG00000230658.1	KLHL7-AS1	7.05	1.12e-10	4.14e-07	0.55	0.53	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23101228~23105703:-
TGCT	cis	rs12891047	0.834	rs7159982	ENSG00000258759.1	RP11-1012A1.7	-7.05	1.13e-10	4.16e-07	-0.48	-0.53	Amyotrophic lateral sclerosis (sporadic);	chr14:67798899	chr14:67799004~67799609:+
TGCT	cis	rs7617773	0.817	rs11130163	ENSG00000229759.1	MRPS18AP1	7.04	1.13e-10	4.18e-07	0.43	0.53	Coronary artery disease;	chr3:48271168	chr3:48256350~48256938:-
TGCT	cis	rs6452524	0.935	rs1478480	ENSG00000249664.1	CTD-2227C6.2	7.04	1.13e-10	4.18e-07	0.53	0.53	Hypertension (SNP x SNP interaction);	chr5:83112117	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.967	rs12186460	ENSG00000249664.1	CTD-2227C6.2	7.04	1.14e-10	4.19e-07	0.54	0.53	Hypertension (SNP x SNP interaction);	chr5:83123950	chr5:83012285~83013109:-
TGCT	cis	rs7208859	0.673	rs11651802	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs17826219	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs61223749	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs3764421	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs11651858	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs36056619	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs9909497	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs11080135	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs9894876	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs73277967	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs60020217	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.573	rs73277974	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs73277978	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs11657391	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs58089675	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs73263755	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs9899349	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs11652358	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs11656845	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs9891179	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs9891413	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs73263776	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs11650271	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs73263785	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs78799101	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs55904046	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs9889968	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs61348930	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.614	rs28758251	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs9899943	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs11080138	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs73265612	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs2433	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs11658435	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs73265624	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs2269915	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs2269916	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs11649765	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs12103759	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs59029591	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs73265633	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs9913782	ENSG00000263531.1	RP13-753N3.1	7.04	1.14e-10	4.19e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30863921~30864940:-
TGCT	cis	rs9399135	0.967	rs7741515	ENSG00000232876.1	CTA-212D2.2	7.04	1.16e-10	4.24e-07	0.48	0.53	Red blood cell count;	chr6:135053230	chr6:135055033~135060550:+
TGCT	cis	rs12891047	0.901	rs11621019	ENSG00000258759.1	RP11-1012A1.7	-7.03	1.2e-10	4.39e-07	-0.48	-0.53	Amyotrophic lateral sclerosis (sporadic);	chr14:67802718	chr14:67799004~67799609:+
TGCT	cis	rs9549367	0.713	rs2476319	ENSG00000269125.1	RP11-98F14.11	7.03	1.2e-10	4.41e-07	0.64	0.53	Platelet distribution width;	chr13:113182205	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.673	rs575453	ENSG00000269125.1	RP11-98F14.11	7.03	1.2e-10	4.41e-07	0.64	0.53	Platelet distribution width;	chr13:113183557	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.713	rs553316	ENSG00000269125.1	RP11-98F14.11	7.03	1.2e-10	4.41e-07	0.64	0.53	Platelet distribution width;	chr13:113183701	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.713	rs556990	ENSG00000269125.1	RP11-98F14.11	7.03	1.2e-10	4.41e-07	0.64	0.53	Platelet distribution width;	chr13:113190745	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.713	rs576463	ENSG00000269125.1	RP11-98F14.11	7.03	1.2e-10	4.41e-07	0.64	0.53	Platelet distribution width;	chr13:113192300	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.601	rs558869	ENSG00000269125.1	RP11-98F14.11	7.03	1.2e-10	4.41e-07	0.64	0.53	Platelet distribution width;	chr13:113195618	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.713	rs2480949	ENSG00000269125.1	RP11-98F14.11	7.03	1.2e-10	4.41e-07	0.64	0.53	Platelet distribution width;	chr13:113198835	chr13:113165002~113165183:-
TGCT	cis	rs17301013	0.606	rs724889	ENSG00000227373.4	RP11-160H22.5	-7.03	1.21e-10	4.42e-07	-0.64	-0.53	Systemic lupus erythematosus;	chr1:174180326	chr1:174115300~174160004:-
TGCT	cis	rs8040855	0.627	rs12905036	ENSG00000259295.5	CSPG4P12	7.03	1.22e-10	4.46e-07	0.71	0.53	Bulimia nervosa;	chr15:85094557	chr15:85191438~85213905:+
TGCT	cis	rs1775715	0.707	rs2808073	ENSG00000239731.3	RN7SL825P	-7.03	1.24e-10	4.53e-07	-0.52	-0.53	Bipolar disorder with mood-incongruent psychosis;	chr10:31890347	chr10:31992087~31992381:-
TGCT	cis	rs9399137	0.507	rs7754722	ENSG00000232876.1	CTA-212D2.2	7.03	1.25e-10	4.55e-07	0.5	0.53	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134939165	chr6:135055033~135060550:+
TGCT	cis	rs977987	0.741	rs10514393	ENSG00000261783.1	RP11-252K23.2	-7.03	1.25e-10	4.55e-07	-0.77	-0.53	Dupuytren's disease;	chr16:75310578	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs11864102	ENSG00000261783.1	RP11-252K23.2	-7.03	1.25e-10	4.56e-07	-0.77	-0.53	Dupuytren's disease;	chr16:75408462	chr16:75379818~75381260:-
TGCT	cis	rs950027	0.62	rs1719245	ENSG00000259520.4	CTD-2651B20.3	-7.03	1.25e-10	4.56e-07	-0.44	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45331584	chr15:45251580~45279251:-
TGCT	cis	rs8040855	0.657	rs6496733	ENSG00000259295.5	CSPG4P12	-7.02	1.26e-10	4.6e-07	-0.7	-0.53	Bulimia nervosa;	chr15:85129945	chr15:85191438~85213905:+
TGCT	cis	rs977987	0.806	rs4888405	ENSG00000261783.1	RP11-252K23.2	-7.02	1.27e-10	4.63e-07	-0.76	-0.53	Dupuytren's disease;	chr16:75394298	chr16:75379818~75381260:-
TGCT	cis	rs11098499	0.954	rs3733519	ENSG00000245958.5	RP11-33B1.1	-7.02	1.29e-10	4.71e-07	-0.57	-0.53	Corneal astigmatism;	chr4:119502293	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.954	rs3733524	ENSG00000245958.5	RP11-33B1.1	-7.02	1.29e-10	4.71e-07	-0.57	-0.53	Corneal astigmatism;	chr4:119502574	chr4:119454791~119552025:+
TGCT	cis	rs7617773	0.817	rs11720622	ENSG00000229759.1	MRPS18AP1	7.02	1.29e-10	4.71e-07	0.43	0.53	Coronary artery disease;	chr3:48205189	chr3:48256350~48256938:-
TGCT	cis	rs524281	0.861	rs471484	ENSG00000255320.1	RP11-755F10.1	7.02	1.3e-10	4.73e-07	0.64	0.53	Electroencephalogram traits;	chr11:66187673	chr11:66244840~66246239:-
TGCT	cis	rs1062177	0.756	rs2915815	ENSG00000213433.5	RPLP1P6	7.02	1.3e-10	4.74e-07	0.57	0.53	Preschool internalizing problems;	chr5:151736322	chr5:151765859~151766378:-
TGCT	cis	rs11098499	0.863	rs6835635	ENSG00000245958.5	RP11-33B1.1	-7.02	1.31e-10	4.76e-07	-0.56	-0.53	Corneal astigmatism;	chr4:119537712	chr4:119454791~119552025:+
TGCT	cis	rs2882667	0.929	rs34846849	ENSG00000253404.1	AC034243.1	7.01	1.34e-10	4.86e-07	0.64	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139024889	chr5:138744434~138753309:-
TGCT	cis	rs977987	0.778	rs11149825	ENSG00000261783.1	RP11-252K23.2	-7.01	1.36e-10	4.94e-07	-0.76	-0.53	Dupuytren's disease;	chr16:75400980	chr16:75379818~75381260:-
TGCT	cis	rs2882667	0.898	rs6890272	ENSG00000253404.1	AC034243.1	7.01	1.36e-10	4.94e-07	0.59	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035427	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.898	rs6882330	ENSG00000253404.1	AC034243.1	7.01	1.36e-10	4.94e-07	0.59	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046493	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.898	rs6882526	ENSG00000253404.1	AC034243.1	7.01	1.36e-10	4.94e-07	0.59	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046679	chr5:138744434~138753309:-
TGCT	cis	rs9549367	0.713	rs9549352	ENSG00000269125.1	RP11-98F14.11	-7.01	1.37e-10	4.97e-07	-0.67	-0.53	Platelet distribution width;	chr13:113178907	chr13:113165002~113165183:-
TGCT	cis	rs17361889	0.806	rs1949952	ENSG00000224683.1	RPL36AP29	-7.01	1.38e-10	5.01e-07	-0.62	-0.53	Pediatric bone mineral content (hip);	chr7:16189503	chr7:16208945~16209265:+
TGCT	cis	rs8040855	0.603	rs10520585	ENSG00000259295.5	CSPG4P12	-7	1.41e-10	5.09e-07	-0.75	-0.53	Bulimia nervosa;	chr15:85118275	chr15:85191438~85213905:+
TGCT	cis	rs9326248	0.648	rs11216257	ENSG00000254851.1	RP11-109L13.1	-7	1.44e-10	5.21e-07	-0.88	-0.53	Blood protein levels;	chr11:117061845	chr11:117135528~117138582:+
TGCT	cis	rs977987	0.527	rs62059844	ENSG00000261783.1	RP11-252K23.2	-6.99	1.47e-10	5.32e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75395839	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.585	rs62059845	ENSG00000261783.1	RP11-252K23.2	-6.99	1.47e-10	5.32e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75396815	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.778	rs62059846	ENSG00000261783.1	RP11-252K23.2	-6.99	1.47e-10	5.32e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75396911	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs11862582	ENSG00000261783.1	RP11-252K23.2	-6.99	1.47e-10	5.32e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75397397	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.778	rs11862719	ENSG00000261783.1	RP11-252K23.2	-6.99	1.47e-10	5.32e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75397810	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.843	rs11149824	ENSG00000261783.1	RP11-252K23.2	-6.99	1.47e-10	5.32e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75397932	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs4887823	ENSG00000261783.1	RP11-252K23.2	-6.99	1.47e-10	5.32e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75399176	chr16:75379818~75381260:-
TGCT	cis	rs8040855	0.627	rs17540307	ENSG00000259295.5	CSPG4P12	6.99	1.48e-10	5.33e-07	0.71	0.53	Bulimia nervosa;	chr15:85090614	chr15:85191438~85213905:+
TGCT	cis	rs950027	0.62	rs1145077	ENSG00000259520.4	CTD-2651B20.3	6.99	1.48e-10	5.35e-07	0.44	0.53	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:45251580~45279251:-
TGCT	cis	rs66887589	0.777	rs2017058	ENSG00000245958.5	RP11-33B1.1	-6.99	1.48e-10	5.35e-07	-0.53	-0.53	Diastolic blood pressure;	chr4:119336584	chr4:119454791~119552025:+
TGCT	cis	rs66887589	0.777	rs1814815	ENSG00000245958.5	RP11-33B1.1	-6.99	1.48e-10	5.35e-07	-0.53	-0.53	Diastolic blood pressure;	chr4:119336936	chr4:119454791~119552025:+
TGCT	cis	rs66887589	0.967	rs59516282	ENSG00000245958.5	RP11-33B1.1	6.99	1.49e-10	5.36e-07	0.53	0.53	Diastolic blood pressure;	chr4:119580861	chr4:119454791~119552025:+
TGCT	cis	rs66887589	0.934	rs12648182	ENSG00000245958.5	RP11-33B1.1	6.99	1.49e-10	5.36e-07	0.53	0.53	Diastolic blood pressure;	chr4:119582736	chr4:119454791~119552025:+
TGCT	cis	rs66887589	0.967	rs56173225	ENSG00000245958.5	RP11-33B1.1	6.99	1.49e-10	5.36e-07	0.53	0.53	Diastolic blood pressure;	chr4:119588817	chr4:119454791~119552025:+
TGCT	cis	rs66887589	0.967	rs7678973	ENSG00000245958.5	RP11-33B1.1	6.99	1.49e-10	5.36e-07	0.53	0.53	Diastolic blood pressure;	chr4:119590662	chr4:119454791~119552025:+
TGCT	cis	rs66887589	0.934	rs56843000	ENSG00000245958.5	RP11-33B1.1	6.99	1.49e-10	5.36e-07	0.53	0.53	Diastolic blood pressure;	chr4:119595442	chr4:119454791~119552025:+
TGCT	cis	rs9399135	0.684	rs1135205	ENSG00000232876.1	CTA-212D2.2	-6.99	1.49e-10	5.36e-07	-0.49	-0.53	Red blood cell count;	chr6:134960657	chr6:135055033~135060550:+
TGCT	cis	rs11098499	0.954	rs11722872	ENSG00000245958.5	RP11-33B1.1	-6.99	1.49e-10	5.36e-07	-0.56	-0.53	Corneal astigmatism;	chr4:119311875	chr4:119454791~119552025:+
TGCT	cis	rs11673344	0.583	rs10421436	ENSG00000226686.6	LINC01535	-6.99	1.49e-10	5.37e-07	-0.58	-0.53	Obesity-related traits;	chr19:37394601	chr19:37251912~37265535:+
TGCT	cis	rs7174755	0.923	rs9672310	ENSG00000260657.2	RP11-315D16.4	6.99	1.49e-10	5.38e-07	0.56	0.53	Major depressive disorder;	chr15:68306578	chr15:68267792~68277994:-
TGCT	cis	rs2882667	0.898	rs10079634	ENSG00000253404.1	AC034243.1	6.99	1.49e-10	5.38e-07	0.58	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077364	chr5:138744434~138753309:-
TGCT	cis	rs10028773	0.546	rs13117947	ENSG00000245958.5	RP11-33B1.1	-6.99	1.49e-10	5.38e-07	-0.53	-0.53	Educational attainment;	chr4:119335905	chr4:119454791~119552025:+
TGCT	cis	rs17826219	0.706	rs9905827	ENSG00000263531.1	RP13-753N3.1	6.99	1.5e-10	5.41e-07	0.93	0.53	Body mass index;	chr17:30865150	chr17:30863921~30864940:-
TGCT	cis	rs2980439	0.783	rs2948305	ENSG00000173295.6	FAM86B3P	6.99	1.51e-10	5.42e-07	0.64	0.53	Neuroticism;	chr8:8241055	chr8:8228595~8244865:+
TGCT	cis	rs2882667	0.931	rs10077796	ENSG00000253404.1	AC034243.1	-6.99	1.51e-10	5.42e-07	-0.59	-0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021086	chr5:138744434~138753309:-
TGCT	cis	rs1062177	0.756	rs2964589	ENSG00000213433.5	RPLP1P6	6.99	1.51e-10	5.44e-07	0.58	0.53	Preschool internalizing problems;	chr5:151738628	chr5:151765859~151766378:-
TGCT	cis	rs1775715	0.835	rs113450267	ENSG00000239731.3	RN7SL825P	-6.99	1.52e-10	5.46e-07	-0.54	-0.53	Bipolar disorder with mood-incongruent psychosis;	chr10:31934800	chr10:31992087~31992381:-
TGCT	cis	rs66887589	0.967	rs1155577	ENSG00000245958.5	RP11-33B1.1	6.99	1.53e-10	5.49e-07	0.52	0.53	Diastolic blood pressure;	chr4:119528655	chr4:119454791~119552025:+
TGCT	cis	rs66887589	0.967	rs2892869	ENSG00000245958.5	RP11-33B1.1	6.99	1.53e-10	5.5e-07	0.53	0.53	Diastolic blood pressure;	chr4:119600142	chr4:119454791~119552025:+
TGCT	cis	rs853679	0.538	rs13199081	ENSG00000216901.1	AL022393.7	6.98	1.55e-10	5.57e-07	0.67	0.53	Depression;	chr6:28364057	chr6:28176188~28176674:+
TGCT	cis	rs17301013	0.606	rs6670425	ENSG00000227373.4	RP11-160H22.5	6.98	1.56e-10	5.6e-07	0.63	0.53	Systemic lupus erythematosus;	chr1:174144204	chr1:174115300~174160004:-
TGCT	cis	rs9549367	0.789	rs6577031	ENSG00000269125.1	RP11-98F14.11	6.98	1.56e-10	5.61e-07	0.62	0.53	Platelet distribution width;	chr13:113223868	chr13:113165002~113165183:-
TGCT	cis	rs6700559	1	rs6656619	ENSG00000260088.1	RP11-92G12.3	6.98	1.58e-10	5.67e-07	0.62	0.53	Coronary artery disease;	chr1:200671664	chr1:200669507~200694250:+
TGCT	cis	rs7617773	0.817	rs6806112	ENSG00000229759.1	MRPS18AP1	6.98	1.59e-10	5.7e-07	0.42	0.53	Coronary artery disease;	chr3:48234587	chr3:48256350~48256938:-
TGCT	cis	rs2739330	0.587	rs4820571	ENSG00000273295.1	AP000350.5	6.98	1.6e-10	5.74e-07	0.6	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23901432~23907068:-
TGCT	cis	rs977987	0.835	rs4888379	ENSG00000261783.1	RP11-252K23.2	-6.97	1.62e-10	5.8e-07	-0.77	-0.53	Dupuytren's disease;	chr16:75306333	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.8	rs12922951	ENSG00000261783.1	RP11-252K23.2	-6.97	1.62e-10	5.8e-07	-0.77	-0.53	Dupuytren's disease;	chr16:75321198	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs4887818	ENSG00000261783.1	RP11-252K23.2	-6.97	1.62e-10	5.8e-07	-0.77	-0.53	Dupuytren's disease;	chr16:75328097	chr16:75379818~75381260:-
TGCT	cis	rs858239	0.676	rs3807459	ENSG00000230658.1	KLHL7-AS1	6.97	1.63e-10	5.83e-07	0.57	0.53	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23101228~23105703:-
TGCT	cis	rs9399135	0.66	rs9389248	ENSG00000232876.1	CTA-212D2.2	-6.97	1.63e-10	5.85e-07	-0.49	-0.53	Red blood cell count;	chr6:134961518	chr6:135055033~135060550:+
TGCT	cis	rs977987	0.843	rs4888415	ENSG00000261783.1	RP11-252K23.2	-6.97	1.66e-10	5.94e-07	-0.76	-0.53	Dupuytren's disease;	chr16:75415023	chr16:75379818~75381260:-
TGCT	cis	rs11098499	0.82	rs28578366	ENSG00000245958.5	RP11-33B1.1	6.97	1.66e-10	5.95e-07	0.56	0.53	Corneal astigmatism;	chr4:119615750	chr4:119454791~119552025:+
TGCT	cis	rs3814244	0.933	rs10878725	ENSG00000255733.4	IFNG-AS1	-6.97	1.68e-10	5.99e-07	-0.51	-0.53	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020930	chr12:67989445~68234686:+
TGCT	cis	rs3814244	0.966	rs10784666	ENSG00000255733.4	IFNG-AS1	-6.97	1.68e-10	5.99e-07	-0.51	-0.53	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021923	chr12:67989445~68234686:+
TGCT	cis	rs3814244	0.966	rs10784667	ENSG00000255733.4	IFNG-AS1	-6.97	1.68e-10	5.99e-07	-0.51	-0.53	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021996	chr12:67989445~68234686:+
TGCT	cis	rs2739330	0.652	rs2000469	ENSG00000218537.1	MIF-AS1	6.97	1.69e-10	6.02e-07	0.71	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23894426~23898930:-
TGCT	cis	rs11098499	1	rs7659194	ENSG00000245958.5	RP11-33B1.1	-6.97	1.69e-10	6.03e-07	-0.54	-0.53	Corneal astigmatism;	chr4:119285992	chr4:119454791~119552025:+
TGCT	cis	rs977987	0.75	rs4888414	ENSG00000261783.1	RP11-252K23.2	-6.97	1.69e-10	6.04e-07	-0.76	-0.53	Dupuytren's disease;	chr16:75413335	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs6564258	ENSG00000261783.1	RP11-252K23.2	-6.97	1.69e-10	6.04e-07	-0.76	-0.53	Dupuytren's disease;	chr16:75413465	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.843	rs6564259	ENSG00000261783.1	RP11-252K23.2	-6.97	1.69e-10	6.04e-07	-0.76	-0.53	Dupuytren's disease;	chr16:75413495	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.843	rs6564260	ENSG00000261783.1	RP11-252K23.2	-6.97	1.69e-10	6.04e-07	-0.76	-0.53	Dupuytren's disease;	chr16:75413528	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs8056236	ENSG00000261783.1	RP11-252K23.2	-6.97	1.69e-10	6.04e-07	-0.76	-0.53	Dupuytren's disease;	chr16:75414375	chr16:75379818~75381260:-
TGCT	cis	rs524281	0.814	rs1055615	ENSG00000255320.1	RP11-755F10.1	6.97	1.7e-10	6.06e-07	0.66	0.53	Electroencephalogram traits;	chr11:66079451	chr11:66244840~66246239:-
TGCT	cis	rs11098499	0.863	rs3775841	ENSG00000245958.5	RP11-33B1.1	-6.97	1.7e-10	6.07e-07	-0.57	-0.53	Corneal astigmatism;	chr4:119504622	chr4:119454791~119552025:+
TGCT	cis	rs5769707	0.837	rs5769709	ENSG00000188511.11	C22orf34	6.96	1.71e-10	6.09e-07	0.51	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49628109	chr22:49414524~49657542:-
TGCT	cis	rs2882667	0.964	rs11739351	ENSG00000253404.1	AC034243.1	6.96	1.73e-10	6.15e-07	0.61	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:138976053	chr5:138744434~138753309:-
TGCT	cis	rs950027	0.62	rs1145084	ENSG00000259520.4	CTD-2651B20.3	-6.96	1.73e-10	6.17e-07	-0.44	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45383242	chr15:45251580~45279251:-
TGCT	cis	rs2980439	0.818	rs2948294	ENSG00000173295.6	FAM86B3P	6.96	1.75e-10	6.22e-07	0.64	0.53	Neuroticism;	chr8:8237439	chr8:8228595~8244865:+
TGCT	cis	rs2980439	0.783	rs2955587	ENSG00000173295.6	FAM86B3P	6.96	1.75e-10	6.22e-07	0.64	0.53	Neuroticism;	chr8:8240557	chr8:8228595~8244865:+
TGCT	cis	rs2882667	0.861	rs13176902	ENSG00000253404.1	AC034243.1	6.96	1.75e-10	6.22e-07	0.59	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139057640	chr5:138744434~138753309:-
TGCT	cis	rs748404	0.588	rs2255410	ENSG00000205771.5	CATSPER2P1	-6.96	1.75e-10	6.24e-07	-0.61	-0.53	Lung cancer;	chr15:43538899	chr15:43726918~43747094:-
TGCT	cis	rs1933112	1	rs2179500	ENSG00000227777.1	RP4-738P11.3	-6.96	1.76e-10	6.27e-07	-0.59	-0.53	Blood protein levels;	chr1:168546589	chr1:168542737~168543354:+
TGCT	cis	rs2882667	0.894	rs1433008	ENSG00000253404.1	AC034243.1	6.96	1.76e-10	6.27e-07	0.6	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:138997975	chr5:138744434~138753309:-
TGCT	cis	rs7208859	0.673	rs9911989	ENSG00000263531.1	RP13-753N3.1	-6.96	1.76e-10	6.27e-07	-0.92	-0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30863921~30864940:-
TGCT	cis	rs11098499	1	rs11098500	ENSG00000245958.5	RP11-33B1.1	-6.96	1.78e-10	6.32e-07	-0.54	-0.53	Corneal astigmatism;	chr4:119298084	chr4:119454791~119552025:+
TGCT	cis	rs694739	0.628	rs475032	ENSG00000236935.1	AP003774.1	-6.96	1.78e-10	6.33e-07	-0.4	-0.53	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373265	chr11:64325050~64329504:-
TGCT	cis	rs694739	0.657	rs11231770	ENSG00000236935.1	AP003774.1	6.96	1.78e-10	6.33e-07	0.4	0.53	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373153	chr11:64325050~64329504:-
TGCT	cis	rs694739	0.687	rs11231771	ENSG00000236935.1	AP003774.1	6.96	1.78e-10	6.33e-07	0.4	0.53	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373170	chr11:64325050~64329504:-
TGCT	cis	rs694739	0.628	rs10897487	ENSG00000236935.1	AP003774.1	6.96	1.78e-10	6.33e-07	0.4	0.53	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373232	chr11:64325050~64329504:-
TGCT	cis	rs694739	0.654	rs10897488	ENSG00000236935.1	AP003774.1	6.96	1.78e-10	6.33e-07	0.4	0.53	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373334	chr11:64325050~64329504:-
TGCT	cis	rs1577917	1	rs1018184	ENSG00000203875.9	SNHG5	6.96	1.79e-10	6.36e-07	0.76	0.53	Response to antipsychotic treatment;	chr6:85938757	chr6:85660950~85678736:-
TGCT	cis	rs7208859	0.673	rs3764420	ENSG00000263531.1	RP13-753N3.1	6.95	1.81e-10	6.43e-07	0.93	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30863921~30864940:-
TGCT	cis	rs17301013	0.606	rs4650950	ENSG00000227373.4	RP11-160H22.5	6.95	1.81e-10	6.43e-07	0.63	0.53	Systemic lupus erythematosus;	chr1:174134264	chr1:174115300~174160004:-
TGCT	cis	rs2882667	0.931	rs10069528	ENSG00000253404.1	AC034243.1	6.95	1.83e-10	6.48e-07	0.59	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018338	chr5:138744434~138753309:-
TGCT	cis	rs524281	0.861	rs3953856	ENSG00000255320.1	RP11-755F10.1	6.95	1.83e-10	6.48e-07	0.66	0.53	Electroencephalogram traits;	chr11:66198437	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.861	rs2889313	ENSG00000255320.1	RP11-755F10.1	6.95	1.83e-10	6.48e-07	0.66	0.53	Electroencephalogram traits;	chr11:66198595	chr11:66244840~66246239:-
TGCT	cis	rs12891047	0.901	rs12433710	ENSG00000258759.1	RP11-1012A1.7	-6.95	1.83e-10	6.5e-07	-0.47	-0.53	Amyotrophic lateral sclerosis (sporadic);	chr14:67801840	chr14:67799004~67799609:+
TGCT	cis	rs1933112	1	rs10753777	ENSG00000227777.1	RP4-738P11.3	-6.95	1.83e-10	6.5e-07	-0.58	-0.53	Blood protein levels;	chr1:168558549	chr1:168542737~168543354:+
TGCT	cis	rs977987	0.806	rs4888404	ENSG00000261783.1	RP11-252K23.2	-6.95	1.86e-10	6.58e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75394199	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs2285225	ENSG00000261783.1	RP11-252K23.2	-6.95	1.86e-10	6.58e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75395354	chr16:75379818~75381260:-
TGCT	cis	rs11098499	0.863	rs12508173	ENSG00000245958.5	RP11-33B1.1	-6.95	1.86e-10	6.6e-07	-0.56	-0.53	Corneal astigmatism;	chr4:119397371	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.908	rs12504149	ENSG00000245958.5	RP11-33B1.1	-6.95	1.86e-10	6.6e-07	-0.56	-0.53	Corneal astigmatism;	chr4:119397422	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.58	rs12509234	ENSG00000245958.5	RP11-33B1.1	-6.95	1.86e-10	6.6e-07	-0.56	-0.53	Corneal astigmatism;	chr4:119398279	chr4:119454791~119552025:+
TGCT	cis	rs977987	0.872	rs1559339	ENSG00000261783.1	RP11-252K23.2	-6.95	1.88e-10	6.62e-07	-0.76	-0.53	Dupuytren's disease;	chr16:75284748	chr16:75379818~75381260:-
TGCT	cis	rs9549367	0.789	rs2287250	ENSG00000269125.1	RP11-98F14.11	6.94	1.9e-10	6.68e-07	0.61	0.53	Platelet distribution width;	chr13:113235160	chr13:113165002~113165183:-
TGCT	cis	rs11098499	0.863	rs11098531	ENSG00000245958.5	RP11-33B1.1	-6.94	1.91e-10	6.7e-07	-0.57	-0.53	Corneal astigmatism;	chr4:119543846	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs28718422	ENSG00000245958.5	RP11-33B1.1	-6.94	1.91e-10	6.7e-07	-0.57	-0.53	Corneal astigmatism;	chr4:119545149	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs12498539	ENSG00000245958.5	RP11-33B1.1	-6.94	1.91e-10	6.7e-07	-0.57	-0.53	Corneal astigmatism;	chr4:119547215	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.818	rs12498599	ENSG00000245958.5	RP11-33B1.1	-6.94	1.91e-10	6.7e-07	-0.57	-0.53	Corneal astigmatism;	chr4:119547348	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs10009626	ENSG00000245958.5	RP11-33B1.1	-6.94	1.91e-10	6.7e-07	-0.57	-0.53	Corneal astigmatism;	chr4:119548850	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs3822194	ENSG00000245958.5	RP11-33B1.1	-6.94	1.91e-10	6.7e-07	-0.57	-0.53	Corneal astigmatism;	chr4:119550493	chr4:119454791~119552025:+
TGCT	cis	rs977987	0.806	rs8051407	ENSG00000261783.1	RP11-252K23.2	-6.94	1.91e-10	6.7e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75414761	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs4888416	ENSG00000261783.1	RP11-252K23.2	-6.94	1.91e-10	6.7e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75415278	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs7199132	ENSG00000261783.1	RP11-252K23.2	-6.94	1.91e-10	6.7e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75416141	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs7188604	ENSG00000261783.1	RP11-252K23.2	-6.94	1.91e-10	6.7e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75417272	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.843	rs12149063	ENSG00000261783.1	RP11-252K23.2	-6.94	1.91e-10	6.7e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75417860	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs11642572	ENSG00000261783.1	RP11-252K23.2	-6.94	1.91e-10	6.7e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75418884	chr16:75379818~75381260:-
TGCT	cis	rs12891047	0.804	rs17783094	ENSG00000258759.1	RP11-1012A1.7	-6.94	1.91e-10	6.71e-07	-0.48	-0.53	Amyotrophic lateral sclerosis (sporadic);	chr14:67816203	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.804	rs72723196	ENSG00000258759.1	RP11-1012A1.7	-6.94	1.91e-10	6.71e-07	-0.48	-0.53	Amyotrophic lateral sclerosis (sporadic);	chr14:67816980	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.804	rs7149482	ENSG00000258759.1	RP11-1012A1.7	-6.94	1.91e-10	6.71e-07	-0.48	-0.53	Amyotrophic lateral sclerosis (sporadic);	chr14:67819578	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.804	rs11626769	ENSG00000258759.1	RP11-1012A1.7	-6.94	1.91e-10	6.71e-07	-0.48	-0.53	Amyotrophic lateral sclerosis (sporadic);	chr14:67824750	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.84	rs72725103	ENSG00000258759.1	RP11-1012A1.7	-6.94	1.91e-10	6.71e-07	-0.48	-0.53	Amyotrophic lateral sclerosis (sporadic);	chr14:67830383	chr14:67799004~67799609:+
TGCT	cis	rs6452524	0.836	rs10041617	ENSG00000249664.1	CTD-2227C6.2	6.94	1.92e-10	6.75e-07	0.52	0.53	Hypertension (SNP x SNP interaction);	chr5:83096535	chr5:83012285~83013109:-
TGCT	cis	rs17361889	0.778	rs1527198	ENSG00000224683.1	RPL36AP29	-6.94	1.94e-10	6.8e-07	-0.6	-0.53	Pediatric bone mineral content (hip);	chr7:16176520	chr7:16208945~16209265:+
TGCT	cis	rs11098499	0.73	rs12505735	ENSG00000245958.5	RP11-33B1.1	-6.94	1.96e-10	6.81e-07	-0.58	-0.53	Corneal astigmatism;	chr4:119611801	chr4:119454791~119552025:+
TGCT	cis	rs7397814	0.558	rs4764447	ENSG00000278635.1	CTD-2318O12.1	6.94	1.96e-10	6.81e-07	0.42	0.53	IgG glycosylation;	chr12:9426513	chr12:9415641~9416718:+
TGCT	cis	rs11673344	0.566	rs256733	ENSG00000226686.6	LINC01535	6.94	1.96e-10	6.83e-07	0.58	0.53	Obesity-related traits;	chr19:37384729	chr19:37251912~37265535:+
TGCT	cis	rs2412819	0.597	rs472385	ENSG00000205771.5	CATSPER2P1	-6.94	1.97e-10	6.85e-07	-0.62	-0.53	Lung cancer;	chr15:43894646	chr15:43726918~43747094:-
TGCT	cis	rs6921919	0.697	rs758398	ENSG00000216901.1	AL022393.7	6.93	2e-10	6.95e-07	0.61	0.53	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28176188~28176674:+
TGCT	cis	rs1775715	0.737	rs12256714	ENSG00000239731.3	RN7SL825P	6.93	2.01e-10	6.99e-07	0.53	0.53	Bipolar disorder with mood-incongruent psychosis;	chr10:31927334	chr10:31992087~31992381:-
TGCT	cis	rs977987	0.778	rs2865528	ENSG00000261783.1	RP11-252K23.2	-6.93	2.03e-10	7.02e-07	-0.76	-0.53	Dupuytren's disease;	chr16:75422044	chr16:75379818~75381260:-
TGCT	cis	rs9549367	0.673	rs3751413	ENSG00000269125.1	RP11-98F14.11	6.93	2.03e-10	7.02e-07	0.64	0.53	Platelet distribution width;	chr13:113200401	chr13:113165002~113165183:-
TGCT	cis	rs4423214	1	rs4944957	ENSG00000254682.1	RP11-660L16.2	-6.93	2.03e-10	7.04e-07	-0.68	-0.53	Vitamin D levels;	chr11:71456989	chr11:71448674~71452157:+
TGCT	cis	rs977987	0.843	rs60730309	ENSG00000261783.1	RP11-252K23.2	-6.93	2.03e-10	7.04e-07	-0.74	-0.53	Dupuytren's disease;	chr16:75397871	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.75	rs4888406	ENSG00000261783.1	RP11-252K23.2	-6.93	2.03e-10	7.04e-07	-0.74	-0.53	Dupuytren's disease;	chr16:75398436	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.75	rs4888407	ENSG00000261783.1	RP11-252K23.2	-6.93	2.03e-10	7.04e-07	-0.74	-0.53	Dupuytren's disease;	chr16:75398492	chr16:75379818~75381260:-
TGCT	cis	rs524281	0.861	rs10896077	ENSG00000255320.1	RP11-755F10.1	6.93	2.04e-10	7.05e-07	0.66	0.53	Electroencephalogram traits;	chr11:66084262	chr11:66244840~66246239:-
TGCT	cis	rs7757969	0.938	rs1887315	ENSG00000227012.2	RP1-97J1.2	6.93	2.04e-10	7.07e-07	0.86	0.53	Schizophrenia;	chr6:111830241	chr6:111900489~111901851:-
TGCT	cis	rs524281	0.861	rs11227411	ENSG00000255320.1	RP11-755F10.1	6.93	2.04e-10	7.07e-07	0.66	0.53	Electroencephalogram traits;	chr11:66112007	chr11:66244840~66246239:-
TGCT	cis	rs17301013	0.606	rs56338048	ENSG00000227373.4	RP11-160H22.5	6.93	2.06e-10	7.12e-07	0.62	0.53	Systemic lupus erythematosus;	chr1:174220266	chr1:174115300~174160004:-
TGCT	cis	rs2929278	0.638	rs2016840	ENSG00000205771.5	CATSPER2P1	6.93	2.06e-10	7.13e-07	0.62	0.53	Schizophrenia;	chr15:43919670	chr15:43726918~43747094:-
TGCT	cis	rs977987	0.806	rs12599361	ENSG00000261783.1	RP11-252K23.2	-6.93	2.07e-10	7.13e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75401075	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.843	rs10431974	ENSG00000261783.1	RP11-252K23.2	-6.93	2.07e-10	7.13e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75401563	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs12051136	ENSG00000261783.1	RP11-252K23.2	-6.93	2.07e-10	7.13e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75401833	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.778	rs4888409	ENSG00000261783.1	RP11-252K23.2	-6.93	2.07e-10	7.13e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75402333	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.778	rs7206541	ENSG00000261783.1	RP11-252K23.2	-6.93	2.07e-10	7.13e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75402815	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.788	rs7184525	ENSG00000261783.1	RP11-252K23.2	-6.93	2.07e-10	7.13e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75403288	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs12051326	ENSG00000261783.1	RP11-252K23.2	-6.93	2.07e-10	7.13e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75403989	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.843	rs12443834	ENSG00000261783.1	RP11-252K23.2	-6.93	2.07e-10	7.13e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75404571	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs12924920	ENSG00000261783.1	RP11-252K23.2	-6.93	2.07e-10	7.13e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75406235	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs4887824	ENSG00000261783.1	RP11-252K23.2	-6.93	2.07e-10	7.13e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75407715	chr16:75379818~75381260:-
TGCT	cis	rs2739330	0.76	rs1007888	ENSG00000218537.1	MIF-AS1	6.93	2.07e-10	7.14e-07	0.64	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23894426~23898930:-
TGCT	cis	rs11673344	0.583	rs10425719	ENSG00000226686.6	LINC01535	-6.93	2.07e-10	7.14e-07	-0.58	-0.53	Obesity-related traits;	chr19:37459896	chr19:37251912~37265535:+
TGCT	cis	rs6921919	0.697	rs6942030	ENSG00000216901.1	AL022393.7	6.93	2.08e-10	7.18e-07	0.6	0.53	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28176188~28176674:+
TGCT	cis	rs11098499	1	rs58601355	ENSG00000245958.5	RP11-33B1.1	-6.92	2.1e-10	7.25e-07	-0.55	-0.53	Corneal astigmatism;	chr4:119265212	chr4:119454791~119552025:+
TGCT	cis	rs8040855	0.627	rs11631548	ENSG00000259295.5	CSPG4P12	6.92	2.1e-10	7.25e-07	0.71	0.53	Bulimia nervosa;	chr15:85076017	chr15:85191438~85213905:+
TGCT	cis	rs8040855	0.627	rs1532776	ENSG00000259295.5	CSPG4P12	6.92	2.1e-10	7.25e-07	0.71	0.53	Bulimia nervosa;	chr15:85081383	chr15:85191438~85213905:+
TGCT	cis	rs977987	0.806	rs4888411	ENSG00000261783.1	RP11-252K23.2	-6.92	2.11e-10	7.26e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75409285	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.778	rs4888412	ENSG00000261783.1	RP11-252K23.2	-6.92	2.11e-10	7.26e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75409298	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.778	rs4888413	ENSG00000261783.1	RP11-252K23.2	-6.92	2.11e-10	7.26e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75409325	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.778	rs8057849	ENSG00000261783.1	RP11-252K23.2	-6.92	2.11e-10	7.26e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75409918	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs72787160	ENSG00000261783.1	RP11-252K23.2	-6.92	2.11e-10	7.26e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75411264	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.778	rs1109341	ENSG00000261783.1	RP11-252K23.2	-6.92	2.11e-10	7.26e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75411707	chr16:75379818~75381260:-
TGCT	cis	rs9898641	1	rs9898641	ENSG00000266992.1	DHX40P1	6.92	2.11e-10	7.27e-07	0.57	0.53	Interleukin-1-beta levels;	chr17:59493672	chr17:59976009~60002384:-
TGCT	cis	rs9326248	0.53	rs236918	ENSG00000254851.1	RP11-109L13.1	6.92	2.19e-10	7.5e-07	1.02	0.53	Blood protein levels;	chr11:117220893	chr11:117135528~117138582:+
TGCT	cis	rs11673344	0.566	rs8109103	ENSG00000226686.6	LINC01535	6.91	2.2e-10	7.54e-07	0.58	0.53	Obesity-related traits;	chr19:37503209	chr19:37251912~37265535:+
TGCT	cis	rs748404	0.516	rs523156	ENSG00000205771.5	CATSPER2P1	6.91	2.22e-10	7.58e-07	0.6	0.53	Lung cancer;	chr15:43519645	chr15:43726918~43747094:-
TGCT	cis	rs9549367	0.789	rs9577218	ENSG00000269125.1	RP11-98F14.11	-6.91	2.23e-10	7.61e-07	-0.61	-0.53	Platelet distribution width;	chr13:113240597	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.865	rs9549366	ENSG00000269125.1	RP11-98F14.11	-6.91	2.23e-10	7.61e-07	-0.61	-0.53	Platelet distribution width;	chr13:113253330	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.789	rs9577220	ENSG00000269125.1	RP11-98F14.11	-6.91	2.23e-10	7.61e-07	-0.61	-0.53	Platelet distribution width;	chr13:113253980	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.789	rs9549716	ENSG00000269125.1	RP11-98F14.11	-6.91	2.23e-10	7.61e-07	-0.61	-0.53	Platelet distribution width;	chr13:113254164	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.773	rs9549717	ENSG00000269125.1	RP11-98F14.11	-6.91	2.23e-10	7.61e-07	-0.61	-0.53	Platelet distribution width;	chr13:113254512	chr13:113165002~113165183:-
TGCT	cis	rs6452524	0.868	rs1564379	ENSG00000249664.1	CTD-2227C6.2	6.91	2.26e-10	7.7e-07	0.57	0.53	Hypertension (SNP x SNP interaction);	chr5:83082143	chr5:83012285~83013109:-
TGCT	cis	rs9399135	0.636	rs7749106	ENSG00000232876.1	CTA-212D2.2	-6.91	2.27e-10	7.73e-07	-0.48	-0.53	Red blood cell count;	chr6:134947004	chr6:135055033~135060550:+
TGCT	cis	rs8040855	0.576	rs62022528	ENSG00000259295.5	CSPG4P12	6.91	2.28e-10	7.75e-07	0.74	0.53	Bulimia nervosa;	chr15:84992030	chr15:85191438~85213905:+
TGCT	cis	rs11295209	1	rs11295209	ENSG00000245958.5	RP11-33B1.1	6.91	2.28e-10	7.76e-07	0.52	0.53	Plateletcrit;	chr4:119559079	chr4:119454791~119552025:+
TGCT	cis	rs2745572	0.538	rs4587210	ENSG00000272279.1	RP11-157J24.2	6.91	2.29e-10	7.8e-07	0.56	0.53	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1542956	chr6:1528364~1528911:-
TGCT	cis	rs8040855	0.597	rs994989	ENSG00000259295.5	CSPG4P12	6.91	2.3e-10	7.81e-07	0.72	0.53	Bulimia nervosa;	chr15:85117485	chr15:85191438~85213905:+
TGCT	cis	rs9326248	0.52	rs6589602	ENSG00000254851.1	RP11-109L13.1	-6.91	2.3e-10	7.81e-07	-0.64	-0.53	Blood protein levels;	chr11:117166349	chr11:117135528~117138582:+
TGCT	cis	rs977987	0.835	rs3863445	ENSG00000261783.1	RP11-252K23.2	-6.91	2.3e-10	7.82e-07	-0.76	-0.53	Dupuytren's disease;	chr16:75337846	chr16:75379818~75381260:-
TGCT	cis	rs2739330	0.892	rs4822455	ENSG00000272787.1	KB-226F1.2	-6.9	2.31e-10	7.86e-07	-0.59	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23969211~23969873:+
TGCT	cis	rs9399135	0.622	rs3817776	ENSG00000232876.1	CTA-212D2.2	6.9	2.33e-10	7.91e-07	0.47	0.53	Red blood cell count;	chr6:134935618	chr6:135055033~135060550:+
TGCT	cis	rs950027	0.62	rs1617984	ENSG00000259520.4	CTD-2651B20.3	-6.9	2.37e-10	8.04e-07	-0.44	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45330464	chr15:45251580~45279251:-
TGCT	cis	rs977987	0.843	rs11641801	ENSG00000261783.1	RP11-252K23.2	-6.9	2.37e-10	8.04e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75421550	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs11648176	ENSG00000261783.1	RP11-252K23.2	-6.9	2.37e-10	8.04e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75422525	chr16:75379818~75381260:-
TGCT	cis	rs17361889	0.806	rs10487915	ENSG00000224683.1	RPL36AP29	6.9	2.39e-10	8.11e-07	0.61	0.53	Pediatric bone mineral content (hip);	chr7:16189396	chr7:16208945~16209265:+
TGCT	cis	rs66887589	0.777	rs10015883	ENSG00000245958.5	RP11-33B1.1	-6.9	2.41e-10	8.15e-07	-0.51	-0.53	Diastolic blood pressure;	chr4:119346991	chr4:119454791~119552025:+
TGCT	cis	rs524281	0.861	rs7946917	ENSG00000255320.1	RP11-755F10.1	6.9	2.41e-10	8.17e-07	0.65	0.53	Electroencephalogram traits;	chr11:66189106	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.814	rs10896093	ENSG00000255320.1	RP11-755F10.1	6.9	2.41e-10	8.17e-07	0.65	0.53	Electroencephalogram traits;	chr11:66190940	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.861	rs10896094	ENSG00000255320.1	RP11-755F10.1	6.9	2.41e-10	8.17e-07	0.65	0.53	Electroencephalogram traits;	chr11:66191735	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.817	rs10896092	ENSG00000255320.1	RP11-755F10.1	6.9	2.42e-10	8.19e-07	0.64	0.53	Electroencephalogram traits;	chr11:66190575	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.861	rs485857	ENSG00000255320.1	RP11-755F10.1	6.9	2.42e-10	8.19e-07	0.64	0.53	Electroencephalogram traits;	chr11:66192048	chr11:66244840~66246239:-
TGCT	cis	rs12906542	0.516	rs76398134	ENSG00000259792.1	RP11-114H24.6	-6.9	2.43e-10	8.21e-07	-0.57	-0.53	Breast cancer;	chr15:77996385	chr15:77993405~77995289:+
TGCT	cis	rs1062177	0.901	rs1549622	ENSG00000213433.5	RPLP1P6	-6.89	2.46e-10	8.31e-07	-0.57	-0.53	Preschool internalizing problems;	chr5:151886488	chr5:151765859~151766378:-
TGCT	cis	rs875971	0.54	rs736270	ENSG00000222364.1	RNU6-96P	-6.89	2.48e-10	8.36e-07	-0.62	-0.53	Aortic root size;	chr7:65963835	chr7:66395191~66395286:+
TGCT	cis	rs10875976	0.525	rs10783323	ENSG00000257253.2	RP11-70F11.7	6.89	2.49e-10	8.42e-07	0.49	0.53	Obesity;	chr12:49860365	chr12:49861207~49865802:+
TGCT	cis	rs524281	0.861	rs3825067	ENSG00000255320.1	RP11-755F10.1	-6.89	2.5e-10	8.44e-07	-0.65	-0.53	Electroencephalogram traits;	chr11:66110948	chr11:66244840~66246239:-
TGCT	cis	rs11098499	0.863	rs3822195	ENSG00000245958.5	RP11-33B1.1	-6.89	2.51e-10	8.47e-07	-0.56	-0.53	Corneal astigmatism;	chr4:119550505	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs3775854	ENSG00000245958.5	RP11-33B1.1	-6.89	2.51e-10	8.47e-07	-0.56	-0.53	Corneal astigmatism;	chr4:119550816	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs2306456	ENSG00000245958.5	RP11-33B1.1	-6.89	2.51e-10	8.47e-07	-0.56	-0.53	Corneal astigmatism;	chr4:119551267	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs2306457	ENSG00000245958.5	RP11-33B1.1	-6.89	2.51e-10	8.47e-07	-0.56	-0.53	Corneal astigmatism;	chr4:119551684	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs11947234	ENSG00000245958.5	RP11-33B1.1	-6.89	2.51e-10	8.47e-07	-0.56	-0.53	Corneal astigmatism;	chr4:119553704	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs6853998	ENSG00000245958.5	RP11-33B1.1	-6.89	2.51e-10	8.47e-07	-0.56	-0.53	Corneal astigmatism;	chr4:119554705	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs6858777	ENSG00000245958.5	RP11-33B1.1	-6.89	2.51e-10	8.47e-07	-0.56	-0.53	Corneal astigmatism;	chr4:119554811	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs11933966	ENSG00000245958.5	RP11-33B1.1	-6.89	2.51e-10	8.47e-07	-0.56	-0.53	Corneal astigmatism;	chr4:119555560	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs36040693	ENSG00000245958.5	RP11-33B1.1	-6.89	2.51e-10	8.47e-07	-0.56	-0.53	Corneal astigmatism;	chr4:119556461	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs11731756	ENSG00000245958.5	RP11-33B1.1	-6.89	2.51e-10	8.47e-07	-0.56	-0.53	Corneal astigmatism;	chr4:119557541	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs34308924	ENSG00000245958.5	RP11-33B1.1	-6.89	2.51e-10	8.47e-07	-0.56	-0.53	Corneal astigmatism;	chr4:119560276	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs2170276	ENSG00000245958.5	RP11-33B1.1	-6.89	2.51e-10	8.47e-07	-0.56	-0.53	Corneal astigmatism;	chr4:119564669	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs1552092	ENSG00000245958.5	RP11-33B1.1	-6.89	2.51e-10	8.47e-07	-0.56	-0.53	Corneal astigmatism;	chr4:119567341	chr4:119454791~119552025:+
TGCT	cis	rs977987	0.762	rs1364079	ENSG00000261783.1	RP11-252K23.2	-6.89	2.52e-10	8.49e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75359233	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.843	rs17696749	ENSG00000261783.1	RP11-252K23.2	-6.89	2.52e-10	8.49e-07	-0.75	-0.53	Dupuytren's disease;	chr16:75369164	chr16:75379818~75381260:-
TGCT	cis	rs4423214	1	rs12422045	ENSG00000254682.1	RP11-660L16.2	6.89	2.54e-10	8.57e-07	0.69	0.53	Vitamin D levels;	chr11:71443774	chr11:71448674~71452157:+
TGCT	cis	rs977987	0.806	rs12444589	ENSG00000261783.1	RP11-252K23.2	6.89	2.55e-10	8.58e-07	0.75	0.53	Dupuytren's disease;	chr16:75420506	chr16:75379818~75381260:-
TGCT	cis	rs8040855	0.52	rs67613323	ENSG00000259295.5	CSPG4P12	6.89	2.55e-10	8.58e-07	0.75	0.53	Bulimia nervosa;	chr15:84986541	chr15:85191438~85213905:+
TGCT	cis	rs8040855	0.52	rs11629962	ENSG00000259295.5	CSPG4P12	6.89	2.55e-10	8.58e-07	0.75	0.53	Bulimia nervosa;	chr15:84986797	chr15:85191438~85213905:+
TGCT	cis	rs9399135	0.66	rs4440481	ENSG00000232876.1	CTA-212D2.2	-6.89	2.56e-10	8.62e-07	-0.48	-0.53	Red blood cell count;	chr6:134955558	chr6:135055033~135060550:+
TGCT	cis	rs11098499	1	rs1011054	ENSG00000245958.5	RP11-33B1.1	6.88	2.58e-10	8.68e-07	0.55	0.53	Corneal astigmatism;	chr4:119281232	chr4:119454791~119552025:+
TGCT	cis	rs62388641	0.547	rs2745610	ENSG00000272279.1	RP11-157J24.2	-6.88	2.58e-10	8.68e-07	-0.59	-0.53	Daytime sleep phenotypes;	chr6:1553741	chr6:1528364~1528911:-
TGCT	cis	rs8040855	0.576	rs62022527	ENSG00000259295.5	CSPG4P12	6.88	2.59e-10	8.72e-07	0.74	0.53	Bulimia nervosa;	chr15:84988022	chr15:85191438~85213905:+
TGCT	cis	rs17301013	0.606	rs72711443	ENSG00000227373.4	RP11-160H22.5	6.88	2.65e-10	8.91e-07	0.62	0.53	Systemic lupus erythematosus;	chr1:174090876	chr1:174115300~174160004:-
TGCT	cis	rs2739330	0.731	rs4822450	ENSG00000218537.1	MIF-AS1	6.88	2.66e-10	8.95e-07	0.64	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23894426~23898930:-
TGCT	cis	rs7044106	0.791	rs747819	ENSG00000226752.6	PSMD5-AS1	-6.87	2.69e-10	9.04e-07	-0.66	-0.53	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120824828~120854385:+
TGCT	cis	rs7044106	0.791	rs735110	ENSG00000226752.6	PSMD5-AS1	-6.87	2.69e-10	9.04e-07	-0.66	-0.53	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120824828~120854385:+
TGCT	cis	rs11098499	0.82	rs28394116	ENSG00000245958.5	RP11-33B1.1	-6.87	2.7e-10	9.07e-07	-0.57	-0.53	Corneal astigmatism;	chr4:119603128	chr4:119454791~119552025:+
TGCT	cis	rs6452524	0.508	rs256795	ENSG00000249664.1	CTD-2227C6.2	-6.87	2.72e-10	9.13e-07	-0.55	-0.53	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:83012285~83013109:-
TGCT	cis	rs11098499	1	rs6849889	ENSG00000245958.5	RP11-33B1.1	-6.87	2.76e-10	9.24e-07	-0.54	-0.53	Corneal astigmatism;	chr4:119265193	chr4:119454791~119552025:+
TGCT	cis	rs1933112	1	rs2223583	ENSG00000227777.1	RP4-738P11.3	-6.87	2.77e-10	9.27e-07	-0.56	-0.53	Blood protein levels;	chr1:168556178	chr1:168542737~168543354:+
TGCT	cis	rs1933112	0.966	rs4656605	ENSG00000227777.1	RP4-738P11.3	-6.87	2.77e-10	9.27e-07	-0.56	-0.53	Blood protein levels;	chr1:168556659	chr1:168542737~168543354:+
TGCT	cis	rs1933112	1	rs1024176	ENSG00000227777.1	RP4-738P11.3	-6.87	2.77e-10	9.27e-07	-0.56	-0.53	Blood protein levels;	chr1:168556865	chr1:168542737~168543354:+
TGCT	cis	rs11098499	0.644	rs3806808	ENSG00000245958.5	RP11-33B1.1	-6.87	2.79e-10	9.35e-07	-0.56	-0.52	Corneal astigmatism;	chr4:119629930	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.644	rs10012252	ENSG00000245958.5	RP11-33B1.1	-6.87	2.79e-10	9.35e-07	-0.56	-0.52	Corneal astigmatism;	chr4:119637984	chr4:119454791~119552025:+
TGCT	cis	rs977987	0.835	rs3851734	ENSG00000261783.1	RP11-252K23.2	-6.87	2.8e-10	9.37e-07	-0.76	-0.52	Dupuytren's disease;	chr16:75338022	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs7188231	ENSG00000261783.1	RP11-252K23.2	-6.87	2.82e-10	9.42e-07	-0.74	-0.52	Dupuytren's disease;	chr16:75402663	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.843	rs12443904	ENSG00000261783.1	RP11-252K23.2	-6.87	2.82e-10	9.42e-07	-0.74	-0.52	Dupuytren's disease;	chr16:75404872	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.843	rs35737321	ENSG00000261783.1	RP11-252K23.2	-6.87	2.82e-10	9.42e-07	-0.74	-0.52	Dupuytren's disease;	chr16:75405287	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.843	rs62062564	ENSG00000261783.1	RP11-252K23.2	-6.87	2.82e-10	9.42e-07	-0.74	-0.52	Dupuytren's disease;	chr16:75408724	chr16:75379818~75381260:-
TGCT	cis	rs11098499	0.954	rs1022145	ENSG00000245958.5	RP11-33B1.1	-6.87	2.83e-10	9.44e-07	-0.55	-0.52	Corneal astigmatism;	chr4:119309824	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.818	rs55825515	ENSG00000245958.5	RP11-33B1.1	-6.87	2.83e-10	9.45e-07	-0.56	-0.52	Corneal astigmatism;	chr4:119565247	chr4:119454791~119552025:+
TGCT	cis	rs10875976	0.525	rs7954572	ENSG00000257253.2	RP11-70F11.7	6.86	2.83e-10	9.46e-07	0.48	0.52	Obesity;	chr12:49859132	chr12:49861207~49865802:+
TGCT	cis	rs977987	0.843	rs62062568	ENSG00000261783.1	RP11-252K23.2	-6.86	2.86e-10	9.55e-07	-0.74	-0.52	Dupuytren's disease;	chr16:75411426	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.835	rs7200616	ENSG00000261783.1	RP11-252K23.2	-6.86	2.88e-10	9.59e-07	-0.75	-0.52	Dupuytren's disease;	chr16:75332191	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.835	rs3851733	ENSG00000261783.1	RP11-252K23.2	-6.86	2.88e-10	9.59e-07	-0.75	-0.52	Dupuytren's disease;	chr16:75336365	chr16:75379818~75381260:-
TGCT	cis	rs524281	0.861	rs10791855	ENSG00000255320.1	RP11-755F10.1	6.86	2.89e-10	9.64e-07	0.63	0.52	Electroencephalogram traits;	chr11:66196266	chr11:66244840~66246239:-
TGCT	cis	rs4423214	0.879	rs12803256	ENSG00000254682.1	RP11-660L16.2	6.86	2.89e-10	9.64e-07	0.7	0.52	Vitamin D levels;	chr11:71421822	chr11:71448674~71452157:+
TGCT	cis	rs17301013	0.606	rs6676161	ENSG00000227373.4	RP11-160H22.5	6.86	2.9e-10	9.64e-07	0.63	0.52	Systemic lupus erythematosus;	chr1:174138555	chr1:174115300~174160004:-
TGCT	cis	rs1933112	1	rs1933112	ENSG00000227777.1	RP4-738P11.3	-6.86	2.92e-10	9.67e-07	-0.57	-0.52	Blood protein levels;	chr1:168552179	chr1:168542737~168543354:+
TGCT	cis	rs7714584	1	rs4579248	ENSG00000197083.10	ZNF300P1	6.86	2.94e-10	9.73e-07	1.01	0.52	Crohn's disease;	chr5:150888589	chr5:150930645~150946289:-
TGCT	cis	rs11673344	0.583	rs7247090	ENSG00000226686.6	LINC01535	6.86	2.94e-10	9.73e-07	0.58	0.52	Obesity-related traits;	chr19:37522509	chr19:37251912~37265535:+
TGCT	cis	rs6452524	0.967	rs2662243	ENSG00000249664.1	CTD-2227C6.2	6.86	2.94e-10	9.73e-07	0.53	0.52	Hypertension (SNP x SNP interaction);	chr5:83192630	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs2731846	ENSG00000249664.1	CTD-2227C6.2	6.86	2.94e-10	9.73e-07	0.53	0.52	Hypertension (SNP x SNP interaction);	chr5:83193781	chr5:83012285~83013109:-
TGCT	cis	rs9549367	0.789	rs9549365	ENSG00000269125.1	RP11-98F14.11	6.85	2.98e-10	9.85e-07	0.61	0.52	Platelet distribution width;	chr13:113253077	chr13:113165002~113165183:-
TGCT	cis	rs524281	0.817	rs7115081	ENSG00000255320.1	RP11-755F10.1	6.85	3.02e-10	9.97e-07	0.66	0.52	Electroencephalogram traits;	chr11:66086070	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.861	rs11227403	ENSG00000255320.1	RP11-755F10.1	6.85	3.02e-10	9.97e-07	0.66	0.52	Electroencephalogram traits;	chr11:66090957	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.861	rs1862005	ENSG00000255320.1	RP11-755F10.1	6.85	3.02e-10	9.97e-07	0.66	0.52	Electroencephalogram traits;	chr11:66095931	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.861	rs7935336	ENSG00000255320.1	RP11-755F10.1	6.85	3.02e-10	9.97e-07	0.66	0.52	Electroencephalogram traits;	chr11:66097854	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.861	rs11227409	ENSG00000255320.1	RP11-755F10.1	6.85	3.02e-10	9.97e-07	0.66	0.52	Electroencephalogram traits;	chr11:66103467	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.861	rs11227410	ENSG00000255320.1	RP11-755F10.1	6.85	3.02e-10	9.97e-07	0.66	0.52	Electroencephalogram traits;	chr11:66105925	chr11:66244840~66246239:-
TGCT	cis	rs5769707	0.872	rs5770604	ENSG00000188511.11	C22orf34	6.85	3.06e-10	1.01e-06	0.51	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49637024	chr22:49414524~49657542:-
TGCT	cis	rs524281	0.861	rs10896086	ENSG00000255320.1	RP11-755F10.1	6.85	3.06e-10	1.01e-06	0.67	0.52	Electroencephalogram traits;	chr11:66147293	chr11:66244840~66246239:-
TGCT	cis	rs11098499	0.909	rs11723839	ENSG00000245958.5	RP11-33B1.1	-6.85	3.07e-10	1.01e-06	-0.54	-0.52	Corneal astigmatism;	chr4:119378518	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.779	rs7699346	ENSG00000245958.5	RP11-33B1.1	-6.85	3.07e-10	1.01e-06	-0.54	-0.52	Corneal astigmatism;	chr4:119389387	chr4:119454791~119552025:+
TGCT	cis	rs1933112	1	rs1933104	ENSG00000227777.1	RP4-738P11.3	-6.85	3.09e-10	1.02e-06	-0.57	-0.52	Blood protein levels;	chr1:168559648	chr1:168542737~168543354:+
TGCT	cis	rs977987	0.843	rs2059256	ENSG00000261783.1	RP11-252K23.2	-6.85	3.1e-10	1.02e-06	-0.75	-0.52	Dupuytren's disease;	chr16:75361937	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.815	rs1364078	ENSG00000261783.1	RP11-252K23.2	-6.85	3.1e-10	1.02e-06	-0.75	-0.52	Dupuytren's disease;	chr16:75362983	chr16:75379818~75381260:-
TGCT	cis	rs11098499	0.954	rs10008392	ENSG00000245958.5	RP11-33B1.1	-6.85	3.1e-10	1.02e-06	-0.55	-0.52	Corneal astigmatism;	chr4:119397684	chr4:119454791~119552025:+
TGCT	cis	rs17301013	0.606	rs4233169	ENSG00000227373.4	RP11-160H22.5	6.85	3.12e-10	1.02e-06	0.62	0.52	Systemic lupus erythematosus;	chr1:174118986	chr1:174115300~174160004:-
TGCT	cis	rs66887589	0.967	rs3775842	ENSG00000245958.5	RP11-33B1.1	-6.84	3.14e-10	1.03e-06	-0.53	-0.52	Diastolic blood pressure;	chr4:119506577	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.866	rs3756156	ENSG00000245958.5	RP11-33B1.1	-6.84	3.15e-10	1.03e-06	-0.57	-0.52	Corneal astigmatism;	chr4:119603686	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs13136462	ENSG00000245958.5	RP11-33B1.1	-6.84	3.15e-10	1.03e-06	-0.57	-0.52	Corneal astigmatism;	chr4:119622018	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.82	rs13122709	ENSG00000245958.5	RP11-33B1.1	-6.84	3.15e-10	1.03e-06	-0.57	-0.52	Corneal astigmatism;	chr4:119634201	chr4:119454791~119552025:+
TGCT	cis	rs17301013	0.606	rs72711487	ENSG00000227373.4	RP11-160H22.5	6.84	3.17e-10	1.04e-06	0.6	0.52	Systemic lupus erythematosus;	chr1:174189002	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs10912746	ENSG00000227373.4	RP11-160H22.5	6.84	3.17e-10	1.04e-06	0.6	0.52	Systemic lupus erythematosus;	chr1:174210205	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs6692437	ENSG00000227373.4	RP11-160H22.5	6.84	3.17e-10	1.04e-06	0.6	0.52	Systemic lupus erythematosus;	chr1:174213771	chr1:174115300~174160004:-
TGCT	cis	rs2882667	0.931	rs10044736	ENSG00000253404.1	AC034243.1	-6.84	3.19e-10	1.05e-06	-0.59	-0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:138985120	chr5:138744434~138753309:-
TGCT	cis	rs8040855	0.756	rs2342118	ENSG00000259295.5	CSPG4P12	-6.84	3.21e-10	1.05e-06	-0.68	-0.52	Bulimia nervosa;	chr15:85149785	chr15:85191438~85213905:+
TGCT	cis	rs2882667	0.964	rs12719517	ENSG00000253404.1	AC034243.1	6.84	3.22e-10	1.05e-06	0.62	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:138969813	chr5:138744434~138753309:-
TGCT	cis	rs5769707	0.837	rs1573726	ENSG00000188511.11	C22orf34	6.84	3.22e-10	1.05e-06	0.51	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49639224	chr22:49414524~49657542:-
TGCT	cis	rs7714584	1	rs11741861	ENSG00000197083.10	ZNF300P1	-6.84	3.23e-10	1.06e-06	-1.01	-0.52	Crohn's disease;	chr5:150898347	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs4958426	ENSG00000197083.10	ZNF300P1	6.84	3.23e-10	1.06e-06	1.01	0.52	Crohn's disease;	chr5:150898784	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs11743488	ENSG00000197083.10	ZNF300P1	6.84	3.23e-10	1.06e-06	1.01	0.52	Crohn's disease;	chr5:150899656	chr5:150930645~150946289:-
TGCT	cis	rs7301826	0.58	rs12821464	ENSG00000256299.1	RP11-989F5.3	6.84	3.23e-10	1.06e-06	0.62	0.52	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810821~130812622:-
TGCT	cis	rs1930961	1	rs9624834	ENSG00000272977.1	CTA-390C10.10	-6.84	3.25e-10	1.06e-06	-0.73	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25450048	chr22:25476218~25479971:+
TGCT	cis	rs1930961	1	rs9624835	ENSG00000272977.1	CTA-390C10.10	-6.84	3.25e-10	1.06e-06	-0.73	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25450054	chr22:25476218~25479971:+
TGCT	cis	rs1930961	1	rs6004658	ENSG00000272977.1	CTA-390C10.10	-6.84	3.25e-10	1.06e-06	-0.73	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25460264	chr22:25476218~25479971:+
TGCT	cis	rs1930961	1	rs6004659	ENSG00000272977.1	CTA-390C10.10	-6.84	3.25e-10	1.06e-06	-0.73	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25460444	chr22:25476218~25479971:+
TGCT	cis	rs1930961	1	rs6004662	ENSG00000272977.1	CTA-390C10.10	-6.84	3.25e-10	1.06e-06	-0.73	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25466157	chr22:25476218~25479971:+
TGCT	cis	rs9549367	0.664	rs3794419	ENSG00000269125.1	RP11-98F14.11	-6.84	3.26e-10	1.07e-06	-0.65	-0.52	Platelet distribution width;	chr13:113197560	chr13:113165002~113165183:-
TGCT	cis	rs524281	0.861	rs10896095	ENSG00000255320.1	RP11-755F10.1	6.84	3.27e-10	1.07e-06	0.64	0.52	Electroencephalogram traits;	chr11:66195089	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.861	rs2293121	ENSG00000255320.1	RP11-755F10.1	6.84	3.27e-10	1.07e-06	0.64	0.52	Electroencephalogram traits;	chr11:66193876	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.861	rs10791854	ENSG00000255320.1	RP11-755F10.1	6.84	3.27e-10	1.07e-06	0.64	0.52	Electroencephalogram traits;	chr11:66196072	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.861	rs2177053	ENSG00000255320.1	RP11-755F10.1	6.84	3.27e-10	1.07e-06	0.64	0.52	Electroencephalogram traits;	chr11:66198674	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.814	rs10896098	ENSG00000255320.1	RP11-755F10.1	6.84	3.27e-10	1.07e-06	0.64	0.52	Electroencephalogram traits;	chr11:66200945	chr11:66244840~66246239:-
TGCT	cis	rs11098499	0.863	rs3775845	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119511292	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs1383533	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119513421	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs2291185	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119513678	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs10030660	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119515549	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs13149407	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119516670	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.909	rs79026312	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119519522	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.909	rs35111518	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119519527	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs34868248	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119521275	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs3733525	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119525893	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs3775847	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119526487	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs3775848	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119526569	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs10013305	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119529269	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs3775849	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119529753	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.818	rs7688802	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119530513	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs7695620	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119531621	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs12502389	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119533036	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.821	rs3775852	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119533401	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.82	rs6534140	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119534156	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs7657849	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119534339	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs10034450	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119534494	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs1480939	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119535772	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs1480940	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119536527	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs9884402	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119568827	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.731	rs9995026	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119569344	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs11098532	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119569571	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs13140391	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119582282	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs13140409	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119582305	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.82	rs6829903	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119585729	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs7669520	ENSG00000245958.5	RP11-33B1.1	-6.84	3.29e-10	1.07e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119594123	chr4:119454791~119552025:+
TGCT	cis	rs4691139	1	rs9991678	ENSG00000250227.1	TRIM60P14	6.83	3.31e-10	1.08e-06	0.57	0.52	Ovarian cancer in BRCA1 mutation carriers;	chr4:164963887	chr4:164915565~164916983:+
TGCT	cis	rs1933112	1	rs1933110	ENSG00000227777.1	RP4-738P11.3	-6.83	3.31e-10	1.08e-06	-0.57	-0.52	Blood protein levels;	chr1:168554217	chr1:168542737~168543354:+
TGCT	cis	rs1933112	1	rs1933109	ENSG00000227777.1	RP4-738P11.3	-6.83	3.31e-10	1.08e-06	-0.57	-0.52	Blood protein levels;	chr1:168554386	chr1:168542737~168543354:+
TGCT	cis	rs11098499	0.644	rs2389880	ENSG00000245958.5	RP11-33B1.1	-6.83	3.32e-10	1.08e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119638715	chr4:119454791~119552025:+
TGCT	cis	rs2882667	0.931	rs10077896	ENSG00000253404.1	AC034243.1	6.83	3.32e-10	1.08e-06	0.59	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021067	chr5:138744434~138753309:-
TGCT	cis	rs11098499	0.82	rs2389885	ENSG00000245958.5	RP11-33B1.1	-6.83	3.33e-10	1.08e-06	-0.57	-0.52	Corneal astigmatism;	chr4:119612776	chr4:119454791~119552025:+
TGCT	cis	rs9549367	0.789	rs6577034	ENSG00000269125.1	RP11-98F14.11	-6.83	3.34e-10	1.09e-06	-0.61	-0.52	Platelet distribution width;	chr13:113225586	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.756	rs9549702	ENSG00000269125.1	RP11-98F14.11	-6.83	3.34e-10	1.09e-06	-0.61	-0.52	Platelet distribution width;	chr13:113227630	chr13:113165002~113165183:-
TGCT	cis	rs11098499	0.82	rs28535956	ENSG00000245958.5	RP11-33B1.1	6.83	3.37e-10	1.1e-06	0.57	0.52	Corneal astigmatism;	chr4:119615703	chr4:119454791~119552025:+
TGCT	cis	rs7714584	1	rs58717741	ENSG00000197083.10	ZNF300P1	6.83	3.37e-10	1.1e-06	0.97	0.52	Crohn's disease;	chr5:150905374	chr5:150930645~150946289:-
TGCT	cis	rs2745572	0.557	rs2816299	ENSG00000272279.1	RP11-157J24.2	-6.83	3.38e-10	1.1e-06	-0.56	-0.52	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1548451	chr6:1528364~1528911:-
TGCT	cis	rs12891047	0.901	rs2235967	ENSG00000258759.1	RP11-1012A1.7	-6.83	3.4e-10	1.11e-06	-0.47	-0.52	Amyotrophic lateral sclerosis (sporadic);	chr14:67782782	chr14:67799004~67799609:+
TGCT	cis	rs2739330	0.731	rs2000468	ENSG00000218537.1	MIF-AS1	6.83	3.42e-10	1.11e-06	0.63	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23894426~23898930:-
TGCT	cis	rs9549367	0.789	rs7317558	ENSG00000269125.1	RP11-98F14.11	-6.82	3.47e-10	1.12e-06	-0.6	-0.52	Platelet distribution width;	chr13:113239311	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.826	rs1885688	ENSG00000269125.1	RP11-98F14.11	-6.82	3.47e-10	1.12e-06	-0.6	-0.52	Platelet distribution width;	chr13:113239922	chr13:113165002~113165183:-
TGCT	cis	rs2948294	0.588	rs4840913	ENSG00000173295.6	FAM86B3P	6.82	3.48e-10	1.12e-06	0.64	0.52	Red cell distribution width;	chr8:8259384	chr8:8228595~8244865:+
TGCT	cis	rs7714584	0.826	rs12655654	ENSG00000197083.10	ZNF300P1	6.82	3.49e-10	1.12e-06	1	0.52	Crohn's disease;	chr5:150794733	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs74955473	ENSG00000197083.10	ZNF300P1	6.82	3.49e-10	1.12e-06	1	0.52	Crohn's disease;	chr5:150794996	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs79780973	ENSG00000197083.10	ZNF300P1	6.82	3.49e-10	1.12e-06	1	0.52	Crohn's disease;	chr5:150795248	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs6874560	ENSG00000197083.10	ZNF300P1	6.82	3.49e-10	1.12e-06	1	0.52	Crohn's disease;	chr5:150803151	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs11748553	ENSG00000197083.10	ZNF300P1	6.82	3.49e-10	1.12e-06	1	0.52	Crohn's disease;	chr5:150804991	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs11746560	ENSG00000197083.10	ZNF300P1	6.82	3.49e-10	1.12e-06	1	0.52	Crohn's disease;	chr5:150806363	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs4958422	ENSG00000197083.10	ZNF300P1	6.82	3.49e-10	1.12e-06	1	0.52	Crohn's disease;	chr5:150807172	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs59715748	ENSG00000197083.10	ZNF300P1	6.82	3.49e-10	1.12e-06	1	0.52	Crohn's disease;	chr5:150809725	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs17727568	ENSG00000197083.10	ZNF300P1	6.82	3.49e-10	1.12e-06	1	0.52	Crohn's disease;	chr5:150865126	chr5:150930645~150946289:-
TGCT	cis	rs943437	1	rs943437	ENSG00000227012.2	RP1-97J1.2	6.82	3.5e-10	1.13e-06	0.71	0.52	Parkinson's disease;	chr6:111921050	chr6:111900489~111901851:-
TGCT	cis	rs1062177	0.855	rs6892117	ENSG00000253921.1	CTB-113P19.3	6.82	3.51e-10	1.13e-06	0.56	0.52	Preschool internalizing problems;	chr5:151885424	chr5:151753992~151767247:+
TGCT	cis	rs11098499	0.954	rs12506546	ENSG00000245958.5	RP11-33B1.1	-6.82	3.53e-10	1.14e-06	-0.54	-0.52	Corneal astigmatism;	chr4:119380463	chr4:119454791~119552025:+
TGCT	cis	rs9660180	0.62	rs34298494	ENSG00000268575.1	RP1-283E3.8	6.82	3.57e-10	1.15e-06	0.46	0.52	Body mass index;	chr1:1731963	chr1:1702736~1737688:-
TGCT	cis	rs1933112	1	rs1024177	ENSG00000227777.1	RP4-738P11.3	-6.82	3.6e-10	1.15e-06	-0.56	-0.52	Blood protein levels;	chr1:168557477	chr1:168542737~168543354:+
TGCT	cis	rs11098499	0.954	rs6847248	ENSG00000245958.5	RP11-33B1.1	-6.82	3.62e-10	1.16e-06	-0.55	-0.52	Corneal astigmatism;	chr4:119304800	chr4:119454791~119552025:+
TGCT	cis	rs524281	0.861	rs7931544	ENSG00000255320.1	RP11-755F10.1	6.81	3.67e-10	1.18e-06	0.65	0.52	Electroencephalogram traits;	chr11:66149563	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.861	rs9736673	ENSG00000255320.1	RP11-755F10.1	6.81	3.67e-10	1.18e-06	0.65	0.52	Electroencephalogram traits;	chr11:66156553	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.861	rs10896087	ENSG00000255320.1	RP11-755F10.1	6.81	3.67e-10	1.18e-06	0.65	0.52	Electroencephalogram traits;	chr11:66157078	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.861	rs4013917	ENSG00000255320.1	RP11-755F10.1	6.81	3.67e-10	1.18e-06	0.65	0.52	Electroencephalogram traits;	chr11:66158714	chr11:66244840~66246239:-
TGCT	cis	rs2882667	0.898	rs11950819	ENSG00000253404.1	AC034243.1	6.81	3.7e-10	1.19e-06	0.57	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061411	chr5:138744434~138753309:-
TGCT	cis	rs8040855	0.627	rs4842863	ENSG00000259295.5	CSPG4P12	6.81	3.77e-10	1.21e-06	0.68	0.52	Bulimia nervosa;	chr15:85098974	chr15:85191438~85213905:+
TGCT	cis	rs12891047	0.804	rs10135927	ENSG00000258759.1	RP11-1012A1.7	-6.81	3.79e-10	1.21e-06	-0.47	-0.52	Amyotrophic lateral sclerosis (sporadic);	chr14:67846492	chr14:67799004~67799609:+
TGCT	cis	rs977987	0.586	rs12920883	ENSG00000261783.1	RP11-252K23.2	-6.81	3.83e-10	1.23e-06	-0.75	-0.52	Dupuytren's disease;	chr16:75398783	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.624	rs59867374	ENSG00000261783.1	RP11-252K23.2	-6.81	3.83e-10	1.23e-06	-0.75	-0.52	Dupuytren's disease;	chr16:75398784	chr16:75379818~75381260:-
TGCT	cis	rs11098499	0.863	rs3822192	ENSG00000245958.5	RP11-33B1.1	-6.8	3.89e-10	1.24e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119524565	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs59732491	ENSG00000245958.5	RP11-33B1.1	-6.8	3.89e-10	1.24e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119568433	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs11723090	ENSG00000245958.5	RP11-33B1.1	-6.8	3.89e-10	1.24e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119569437	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs6833334	ENSG00000245958.5	RP11-33B1.1	-6.8	3.89e-10	1.24e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119583072	chr4:119454791~119552025:+
TGCT	cis	rs17301013	0.606	rs10912751	ENSG00000227373.4	RP11-160H22.5	6.8	3.96e-10	1.26e-06	0.6	0.52	Systemic lupus erythematosus;	chr1:174262992	chr1:174115300~174160004:-
TGCT	cis	rs189798	0.807	rs12785	ENSG00000254340.1	RP11-10A14.3	6.8	3.98e-10	1.27e-06	0.6	0.52	Myopia (pathological);	chr8:9137426	chr8:9141424~9145435:+
TGCT	cis	rs17301013	0.606	rs10912728	ENSG00000227373.4	RP11-160H22.5	6.8	3.99e-10	1.27e-06	0.61	0.52	Systemic lupus erythematosus;	chr1:174093234	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs4652168	ENSG00000227373.4	RP11-160H22.5	6.8	3.99e-10	1.27e-06	0.61	0.52	Systemic lupus erythematosus;	chr1:174095077	chr1:174115300~174160004:-
TGCT	cis	rs9660180	0.62	rs3817856	ENSG00000268575.1	RP1-283E3.8	6.8	4.02e-10	1.28e-06	0.45	0.52	Body mass index;	chr1:1732392	chr1:1702736~1737688:-
TGCT	cis	rs17507216	0.718	rs4779034	ENSG00000278603.1	RP13-608F4.5	6.8	4.02e-10	1.28e-06	0.88	0.52	Excessive daytime sleepiness;	chr15:82576799	chr15:82472203~82472426:+
TGCT	cis	rs9549367	0.713	rs9549357	ENSG00000269125.1	RP11-98F14.11	-6.79	4.09e-10	1.3e-06	-0.62	-0.52	Platelet distribution width;	chr13:113205807	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.756	rs9603814	ENSG00000269125.1	RP11-98F14.11	6.79	4.1e-10	1.3e-06	0.6	0.52	Platelet distribution width;	chr13:113246468	chr13:113165002~113165183:-
TGCT	cis	rs2882667	0.652	rs6596463	ENSG00000253404.1	AC034243.1	6.79	4.11e-10	1.31e-06	0.58	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139109237	chr5:138744434~138753309:-
TGCT	cis	rs11098499	1	rs6837898	ENSG00000245958.5	RP11-33B1.1	-6.79	4.17e-10	1.32e-06	-0.54	-0.52	Corneal astigmatism;	chr4:119257999	chr4:119454791~119552025:+
TGCT	cis	rs11098499	1	rs11098499	ENSG00000245958.5	RP11-33B1.1	-6.79	4.17e-10	1.32e-06	-0.54	-0.52	Corneal astigmatism;	chr4:119266456	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.909	rs28555550	ENSG00000245958.5	RP11-33B1.1	-6.79	4.18e-10	1.33e-06	-0.53	-0.52	Corneal astigmatism;	chr4:119289885	chr4:119454791~119552025:+
TGCT	cis	rs11098499	1	rs28419773	ENSG00000245958.5	RP11-33B1.1	-6.79	4.18e-10	1.33e-06	-0.53	-0.52	Corneal astigmatism;	chr4:119289906	chr4:119454791~119552025:+
TGCT	cis	rs11098499	1	rs11726229	ENSG00000245958.5	RP11-33B1.1	-6.79	4.18e-10	1.33e-06	-0.53	-0.52	Corneal astigmatism;	chr4:119290425	chr4:119454791~119552025:+
TGCT	cis	rs11098499	1	rs3749591	ENSG00000245958.5	RP11-33B1.1	-6.79	4.18e-10	1.33e-06	-0.53	-0.52	Corneal astigmatism;	chr4:119292875	chr4:119454791~119552025:+
TGCT	cis	rs7208859	0.673	rs28588622	ENSG00000263531.1	RP13-753N3.1	6.79	4.19e-10	1.33e-06	0.91	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30863921~30864940:-
TGCT	cis	rs748404	0.56	rs2255663	ENSG00000205771.5	CATSPER2P1	6.79	4.21e-10	1.34e-06	0.6	0.52	Lung cancer;	chr15:43536810	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.518	rs480108	ENSG00000205771.5	CATSPER2P1	-6.78	4.27e-10	1.35e-06	-0.6	-0.52	Lung cancer;	chr15:43525208	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.56	rs572837	ENSG00000205771.5	CATSPER2P1	-6.78	4.27e-10	1.35e-06	-0.6	-0.52	Lung cancer;	chr15:43531615	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.56	rs570933	ENSG00000205771.5	CATSPER2P1	-6.78	4.27e-10	1.35e-06	-0.6	-0.52	Lung cancer;	chr15:43531832	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.56	rs689797	ENSG00000205771.5	CATSPER2P1	-6.78	4.27e-10	1.35e-06	-0.6	-0.52	Lung cancer;	chr15:43534359	chr15:43726918~43747094:-
TGCT	cis	rs524281	0.861	rs580891	ENSG00000255320.1	RP11-755F10.1	6.78	4.27e-10	1.35e-06	0.65	0.52	Electroencephalogram traits;	chr11:66187210	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.861	rs11607393	ENSG00000255320.1	RP11-755F10.1	6.78	4.31e-10	1.36e-06	0.65	0.52	Electroencephalogram traits;	chr11:66107678	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.861	rs10896080	ENSG00000255320.1	RP11-755F10.1	6.78	4.31e-10	1.36e-06	0.65	0.52	Electroencephalogram traits;	chr11:66109325	chr11:66244840~66246239:-
TGCT	cis	rs977987	0.8	rs3784935	ENSG00000261783.1	RP11-252K23.2	-6.78	4.33e-10	1.37e-06	-0.77	-0.52	Dupuytren's disease;	chr16:75302532	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.8	rs11645329	ENSG00000261783.1	RP11-252K23.2	-6.78	4.33e-10	1.37e-06	-0.77	-0.52	Dupuytren's disease;	chr16:75302781	chr16:75379818~75381260:-
TGCT	cis	rs6452524	0.534	rs10061690	ENSG00000249664.1	CTD-2227C6.2	6.78	4.35e-10	1.38e-06	0.57	0.52	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:83012285~83013109:-
TGCT	cis	rs5769707	0.837	rs5770599	ENSG00000188511.11	C22orf34	6.78	4.37e-10	1.38e-06	0.51	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49626333	chr22:49414524~49657542:-
TGCT	cis	rs9399135	0.66	rs4267967	ENSG00000232876.1	CTA-212D2.2	-6.78	4.38e-10	1.39e-06	-0.48	-0.52	Red blood cell count;	chr6:134951339	chr6:135055033~135060550:+
TGCT	cis	rs858239	0.863	rs274054	ENSG00000230658.1	KLHL7-AS1	6.78	4.44e-10	1.4e-06	0.53	0.52	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23101228~23105703:-
TGCT	cis	rs858239	0.863	rs274058	ENSG00000230658.1	KLHL7-AS1	6.78	4.44e-10	1.4e-06	0.53	0.52	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23101228~23105703:-
TGCT	cis	rs2412819	0.597	rs602370	ENSG00000205771.5	CATSPER2P1	-6.78	4.45e-10	1.4e-06	-0.61	-0.52	Lung cancer;	chr15:43895671	chr15:43726918~43747094:-
TGCT	cis	rs6452524	0.836	rs1015440	ENSG00000249664.1	CTD-2227C6.2	6.77	4.48e-10	1.41e-06	0.55	0.52	Hypertension (SNP x SNP interaction);	chr5:83202986	chr5:83012285~83013109:-
TGCT	cis	rs1062177	0.855	rs6896664	ENSG00000253921.1	CTB-113P19.3	-6.77	4.52e-10	1.42e-06	-0.58	-0.52	Preschool internalizing problems;	chr5:151885713	chr5:151753992~151767247:+
TGCT	cis	rs1775715	0.707	rs2808094	ENSG00000239731.3	RN7SL825P	-6.77	4.56e-10	1.43e-06	-0.51	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr10:31844828	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.644	rs2799022	ENSG00000239731.3	RN7SL825P	-6.77	4.56e-10	1.43e-06	-0.51	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr10:31848270	chr10:31992087~31992381:-
TGCT	cis	rs9399135	0.66	rs4646868	ENSG00000232876.1	CTA-212D2.2	-6.77	4.57e-10	1.43e-06	-0.48	-0.52	Red blood cell count;	chr6:134950808	chr6:135055033~135060550:+
TGCT	cis	rs977987	0.736	rs4888392	ENSG00000261783.1	RP11-252K23.2	-6.77	4.58e-10	1.43e-06	-0.77	-0.52	Dupuytren's disease;	chr16:75378364	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs11860284	ENSG00000261783.1	RP11-252K23.2	-6.77	4.58e-10	1.43e-06	-0.77	-0.52	Dupuytren's disease;	chr16:75379009	chr16:75379818~75381260:-
TGCT	cis	rs17507216	1	rs3850610	ENSG00000278603.1	RP13-608F4.5	-6.77	4.59e-10	1.44e-06	-0.8	-0.52	Excessive daytime sleepiness;	chr15:82552642	chr15:82472203~82472426:+
TGCT	cis	rs17301013	0.606	rs28831202	ENSG00000227373.4	RP11-160H22.5	6.77	4.6e-10	1.44e-06	0.61	0.52	Systemic lupus erythematosus;	chr1:174099231	chr1:174115300~174160004:-
TGCT	cis	rs9389248	0.69	rs6569982	ENSG00000232876.1	CTA-212D2.2	-6.77	4.61e-10	1.44e-06	-0.48	-0.52	High light scatter reticulocyte percentage of red cells;	chr6:134935357	chr6:135055033~135060550:+
TGCT	cis	rs6921919	0.638	rs1416920	ENSG00000216901.1	AL022393.7	6.77	4.62e-10	1.45e-06	0.58	0.52	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28176188~28176674:+
TGCT	cis	rs8040855	0.659	rs8037886	ENSG00000259295.5	CSPG4P12	-6.77	4.63e-10	1.45e-06	-0.69	-0.52	Bulimia nervosa;	chr15:85143533	chr15:85191438~85213905:+
TGCT	cis	rs9326248	0.501	rs4938351	ENSG00000254851.1	RP11-109L13.1	-6.77	4.63e-10	1.45e-06	-0.63	-0.52	Blood protein levels;	chr11:117151636	chr11:117135528~117138582:+
TGCT	cis	rs16828019	0.852	rs12048187	ENSG00000235358.1	RP11-399E6.1	6.77	4.64e-10	1.45e-06	0.89	0.52	Intelligence (multi-trait analysis);	chr1:41150511	chr1:41242373~41284861:+
TGCT	cis	rs1933112	0.9	rs1040508	ENSG00000227777.1	RP4-738P11.3	-6.77	4.64e-10	1.45e-06	-0.59	-0.52	Blood protein levels;	chr1:168531512	chr1:168542737~168543354:+
TGCT	cis	rs2882667	0.931	rs10075893	ENSG00000253404.1	AC034243.1	-6.77	4.64e-10	1.45e-06	-0.59	-0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020182	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.898	rs10045761	ENSG00000253404.1	AC034243.1	6.77	4.65e-10	1.45e-06	0.57	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061600	chr5:138744434~138753309:-
TGCT	cis	rs12906542	0.516	rs10444863	ENSG00000259792.1	RP11-114H24.6	-6.77	4.69e-10	1.46e-06	-0.56	-0.52	Breast cancer;	chr15:78066495	chr15:77993405~77995289:+
TGCT	cis	rs977987	0.843	rs10459859	ENSG00000261783.1	RP11-252K23.2	-6.76	4.74e-10	1.48e-06	-0.74	-0.52	Dupuytren's disease;	chr16:75348052	chr16:75379818~75381260:-
TGCT	cis	rs6921919	0.525	rs1361386	ENSG00000216901.1	AL022393.7	6.76	4.75e-10	1.48e-06	0.58	0.52	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.638	rs6456815	ENSG00000216901.1	AL022393.7	6.76	4.75e-10	1.48e-06	0.58	0.52	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.638	rs2108926	ENSG00000216901.1	AL022393.7	6.76	4.75e-10	1.48e-06	0.58	0.52	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28176188~28176674:+
TGCT	cis	rs1775715	0.707	rs2799019	ENSG00000239731.3	RN7SL825P	-6.76	4.76e-10	1.48e-06	-0.51	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr10:31853922	chr10:31992087~31992381:-
TGCT	cis	rs1062177	0.547	rs2915818	ENSG00000253921.1	CTB-113P19.3	6.76	4.76e-10	1.48e-06	0.53	0.52	Preschool internalizing problems;	chr5:151735729	chr5:151753992~151767247:+
TGCT	cis	rs11098499	0.863	rs1552095	ENSG00000245958.5	RP11-33B1.1	-6.76	4.78e-10	1.49e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119539151	chr4:119454791~119552025:+
TGCT	cis	rs2739330	0.761	rs5760176	ENSG00000218537.1	MIF-AS1	-6.76	4.79e-10	1.49e-06	-0.63	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23894426~23898930:-
TGCT	cis	rs1775715	0.675	rs2808085	ENSG00000239731.3	RN7SL825P	-6.76	4.82e-10	1.5e-06	-0.51	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr10:31859671	chr10:31992087~31992381:-
TGCT	cis	rs524281	0.861	rs12226649	ENSG00000255320.1	RP11-755F10.1	6.76	4.9e-10	1.52e-06	0.64	0.52	Electroencephalogram traits;	chr11:66074576	chr11:66244840~66246239:-
TGCT	cis	rs12906542	0.516	rs4886992	ENSG00000259792.1	RP11-114H24.6	-6.76	4.92e-10	1.53e-06	-0.56	-0.52	Breast cancer;	chr15:78032887	chr15:77993405~77995289:+
TGCT	cis	rs12891047	0.866	rs181562	ENSG00000258759.1	RP11-1012A1.7	-6.76	4.93e-10	1.53e-06	-0.46	-0.52	Amyotrophic lateral sclerosis (sporadic);	chr14:67814585	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.866	rs181561	ENSG00000258759.1	RP11-1012A1.7	-6.76	4.93e-10	1.53e-06	-0.46	-0.52	Amyotrophic lateral sclerosis (sporadic);	chr14:67814902	chr14:67799004~67799609:+
TGCT	cis	rs17301013	0.606	rs10912750	ENSG00000227373.4	RP11-160H22.5	6.75	4.97e-10	1.54e-06	0.6	0.52	Systemic lupus erythematosus;	chr1:174253637	chr1:174115300~174160004:-
TGCT	cis	rs12891047	0.804	rs72725114	ENSG00000258759.1	RP11-1012A1.7	-6.75	5.04e-10	1.56e-06	-0.47	-0.52	Amyotrophic lateral sclerosis (sporadic);	chr14:67851137	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.804	rs35272075	ENSG00000258759.1	RP11-1012A1.7	-6.75	5.04e-10	1.56e-06	-0.47	-0.52	Amyotrophic lateral sclerosis (sporadic);	chr14:67851282	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.804	rs10141638	ENSG00000258759.1	RP11-1012A1.7	-6.75	5.04e-10	1.56e-06	-0.47	-0.52	Amyotrophic lateral sclerosis (sporadic);	chr14:67851876	chr14:67799004~67799609:+
TGCT	cis	rs977987	0.806	rs1109342	ENSG00000261783.1	RP11-252K23.2	6.75	5.05e-10	1.57e-06	0.75	0.52	Dupuytren's disease;	chr16:75411777	chr16:75379818~75381260:-
TGCT	cis	rs9549367	0.756	rs2302756	ENSG00000269125.1	RP11-98F14.11	6.75	5.08e-10	1.58e-06	0.61	0.52	Platelet distribution width;	chr13:113245883	chr13:113165002~113165183:-
TGCT	cis	rs11098499	1	rs13116504	ENSG00000245958.5	RP11-33B1.1	-6.75	5.08e-10	1.58e-06	-0.52	-0.52	Corneal astigmatism;	chr4:119288257	chr4:119454791~119552025:+
TGCT	cis	rs7714584	1	rs73282209	ENSG00000197083.10	ZNF300P1	6.75	5.09e-10	1.58e-06	0.98	0.52	Crohn's disease;	chr5:150795397	chr5:150930645~150946289:-
TGCT	cis	rs7714584	0.793	rs2161363	ENSG00000197083.10	ZNF300P1	6.75	5.09e-10	1.58e-06	0.98	0.52	Crohn's disease;	chr5:150802517	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs6875011	ENSG00000197083.10	ZNF300P1	6.75	5.09e-10	1.58e-06	0.98	0.52	Crohn's disease;	chr5:150803148	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs73282234	ENSG00000197083.10	ZNF300P1	6.75	5.09e-10	1.58e-06	0.98	0.52	Crohn's disease;	chr5:150816362	chr5:150930645~150946289:-
TGCT	cis	rs8046696	1	rs8046696	ENSG00000261783.1	RP11-252K23.2	-6.75	5.1e-10	1.58e-06	-0.74	-0.52	Coronary artery disease;	chr16:75408245	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.737	rs8046697	ENSG00000261783.1	RP11-252K23.2	-6.75	5.1e-10	1.58e-06	-0.74	-0.52	Dupuytren's disease;	chr16:75408246	chr16:75379818~75381260:-
TGCT	cis	rs1062177	0.756	rs2964591	ENSG00000253921.1	CTB-113P19.3	6.75	5.15e-10	1.59e-06	0.6	0.52	Preschool internalizing problems;	chr5:151737836	chr5:151753992~151767247:+
TGCT	cis	rs17301013	0.581	rs7551605	ENSG00000227373.4	RP11-160H22.5	6.75	5.18e-10	1.6e-06	0.6	0.52	Systemic lupus erythematosus;	chr1:174245718	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.581	rs12080977	ENSG00000227373.4	RP11-160H22.5	6.75	5.18e-10	1.6e-06	0.6	0.52	Systemic lupus erythematosus;	chr1:174247026	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs72713503	ENSG00000227373.4	RP11-160H22.5	6.75	5.18e-10	1.6e-06	0.6	0.52	Systemic lupus erythematosus;	chr1:174247553	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs16846816	ENSG00000227373.4	RP11-160H22.5	6.75	5.18e-10	1.6e-06	0.6	0.52	Systemic lupus erythematosus;	chr1:174251602	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.581	rs12083540	ENSG00000227373.4	RP11-160H22.5	6.75	5.18e-10	1.6e-06	0.6	0.52	Systemic lupus erythematosus;	chr1:174254096	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs12085311	ENSG00000227373.4	RP11-160H22.5	6.75	5.18e-10	1.6e-06	0.6	0.52	Systemic lupus erythematosus;	chr1:174256097	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.531	rs6678286	ENSG00000227373.4	RP11-160H22.5	6.75	5.19e-10	1.6e-06	0.6	0.52	Systemic lupus erythematosus;	chr1:174200481	chr1:174115300~174160004:-
TGCT	cis	rs5769707	0.521	rs5769719	ENSG00000188511.11	C22orf34	6.74	5.2e-10	1.61e-06	0.58	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49668453	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.521	rs5769720	ENSG00000188511.11	C22orf34	6.74	5.2e-10	1.61e-06	0.58	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49668485	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.521	rs5770633	ENSG00000188511.11	C22orf34	6.74	5.2e-10	1.61e-06	0.58	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49668779	chr22:49414524~49657542:-
TGCT	cis	rs12908161	0.959	rs11637728	ENSG00000225151.9	GOLGA2P7	-6.74	5.22e-10	1.61e-06	-0.59	-0.52	Schizophrenia;	chr15:84660161	chr15:84199311~84230136:-
TGCT	cis	rs10875976	0.525	rs7969178	ENSG00000257253.2	RP11-70F11.7	6.74	5.22e-10	1.61e-06	0.47	0.52	Obesity;	chr12:49859019	chr12:49861207~49865802:+
TGCT	cis	rs8040855	0.52	rs11629963	ENSG00000259295.5	CSPG4P12	-6.74	5.27e-10	1.63e-06	-0.79	-0.52	Bulimia nervosa;	chr15:84986808	chr15:85191438~85213905:+
TGCT	cis	rs11098499	1	rs28374891	ENSG00000245958.5	RP11-33B1.1	-6.74	5.27e-10	1.63e-06	-0.53	-0.52	Corneal astigmatism;	chr4:119262395	chr4:119454791~119552025:+
TGCT	cis	rs11098499	1	rs35643470	ENSG00000245958.5	RP11-33B1.1	-6.74	5.27e-10	1.63e-06	-0.53	-0.52	Corneal astigmatism;	chr4:119263793	chr4:119454791~119552025:+
TGCT	cis	rs11098499	1	rs12506395	ENSG00000245958.5	RP11-33B1.1	-6.74	5.27e-10	1.63e-06	-0.53	-0.52	Corneal astigmatism;	chr4:119263939	chr4:119454791~119552025:+
TGCT	cis	rs748404	0.56	rs1060939	ENSG00000205771.5	CATSPER2P1	-6.74	5.31e-10	1.64e-06	-0.6	-0.52	Lung cancer;	chr15:43524719	chr15:43726918~43747094:-
TGCT	cis	rs977987	0.806	rs2865531	ENSG00000261783.1	RP11-252K23.2	-6.74	5.32e-10	1.64e-06	-0.76	-0.52	Dupuytren's disease;	chr16:75356418	chr16:75379818~75381260:-
TGCT	cis	rs7714584	1	rs59531858	ENSG00000197083.10	ZNF300P1	6.74	5.33e-10	1.64e-06	0.98	0.52	Crohn's disease;	chr5:150867501	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs12656538	ENSG00000197083.10	ZNF300P1	6.74	5.33e-10	1.64e-06	0.98	0.52	Crohn's disease;	chr5:150871818	chr5:150930645~150946289:-
TGCT	cis	rs11098499	0.863	rs13134665	ENSG00000245958.5	RP11-33B1.1	-6.74	5.33e-10	1.64e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119505275	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs3775843	ENSG00000245958.5	RP11-33B1.1	-6.74	5.33e-10	1.64e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119506689	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs3775844	ENSG00000245958.5	RP11-33B1.1	-6.74	5.33e-10	1.64e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119506878	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs7664986	ENSG00000245958.5	RP11-33B1.1	-6.74	5.33e-10	1.64e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119508797	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.818	rs10008791	ENSG00000245958.5	RP11-33B1.1	-6.74	5.33e-10	1.64e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119510314	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs11736416	ENSG00000245958.5	RP11-33B1.1	-6.74	5.33e-10	1.64e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119510506	chr4:119454791~119552025:+
TGCT	cis	rs7684253	0.565	rs7697176	ENSG00000269949.1	RP11-738E22.3	-6.74	5.38e-10	1.66e-06	-0.53	-0.52	Migraine;	chr4:56956882	chr4:56960927~56961373:-
TGCT	cis	rs7684253	0.565	rs7680140	ENSG00000269949.1	RP11-738E22.3	-6.74	5.38e-10	1.66e-06	-0.53	-0.52	Migraine;	chr4:56957291	chr4:56960927~56961373:-
TGCT	cis	rs694739	0.734	rs663743	ENSG00000236935.1	AP003774.1	6.74	5.42e-10	1.67e-06	0.4	0.52	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64340263	chr11:64325050~64329504:-
TGCT	cis	rs2882667	0.858	rs13174479	ENSG00000253404.1	AC034243.1	6.74	5.42e-10	1.67e-06	0.6	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139108481	chr5:138744434~138753309:-
TGCT	cis	rs9326248	0.539	rs7120565	ENSG00000254851.1	RP11-109L13.1	-6.74	5.44e-10	1.67e-06	-0.62	-0.52	Blood protein levels;	chr11:117172233	chr11:117135528~117138582:+
TGCT	cis	rs9549367	0.774	rs9549696	ENSG00000269125.1	RP11-98F14.11	-6.73	5.52e-10	1.7e-06	-0.59	-0.52	Platelet distribution width;	chr13:113220748	chr13:113165002~113165183:-
TGCT	cis	rs10875976	0.525	rs3741558	ENSG00000257253.2	RP11-70F11.7	6.73	5.53e-10	1.7e-06	0.47	0.52	Obesity;	chr12:49864422	chr12:49861207~49865802:+
TGCT	cis	rs10875976	0.525	rs3741557	ENSG00000257253.2	RP11-70F11.7	6.73	5.53e-10	1.7e-06	0.47	0.52	Obesity;	chr12:49864542	chr12:49861207~49865802:+
TGCT	cis	rs977987	0.843	rs11649638	ENSG00000261783.1	RP11-252K23.2	-6.73	5.67e-10	1.74e-06	-0.75	-0.52	Dupuytren's disease;	chr16:75454387	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.815	rs4887829	ENSG00000261783.1	RP11-252K23.2	-6.73	5.67e-10	1.74e-06	-0.75	-0.52	Dupuytren's disease;	chr16:75455037	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.843	rs28558946	ENSG00000261783.1	RP11-252K23.2	-6.73	5.67e-10	1.74e-06	-0.75	-0.52	Dupuytren's disease;	chr16:75455424	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.843	rs28655617	ENSG00000261783.1	RP11-252K23.2	-6.73	5.67e-10	1.74e-06	-0.75	-0.52	Dupuytren's disease;	chr16:75455744	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs11644306	ENSG00000261783.1	RP11-252K23.2	-6.73	5.67e-10	1.74e-06	-0.75	-0.52	Dupuytren's disease;	chr16:75456155	chr16:75379818~75381260:-
TGCT	cis	rs9549367	0.713	rs3024776	ENSG00000269125.1	RP11-98F14.11	6.73	5.71e-10	1.75e-06	0.66	0.52	Platelet distribution width;	chr13:113172761	chr13:113165002~113165183:-
TGCT	cis	rs7044106	0.791	rs10760116	ENSG00000226752.6	PSMD5-AS1	-6.73	5.73e-10	1.76e-06	-0.65	-0.52	Hip circumference adjusted for BMI;	chr9:120732403	chr9:120824828~120854385:+
TGCT	cis	rs524281	0.861	rs10896085	ENSG00000255320.1	RP11-755F10.1	6.72	5.75e-10	1.77e-06	0.65	0.52	Electroencephalogram traits;	chr11:66146361	chr11:66244840~66246239:-
TGCT	cis	rs875971	1	rs1565531	ENSG00000222364.1	RNU6-96P	6.72	5.82e-10	1.78e-06	0.6	0.52	Aortic root size;	chr7:66198126	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.895	rs6460278	ENSG00000222364.1	RNU6-96P	6.72	5.84e-10	1.79e-06	0.59	0.52	Aortic root size;	chr7:66197749	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs6460279	ENSG00000222364.1	RNU6-96P	6.72	5.84e-10	1.79e-06	0.59	0.52	Aortic root size;	chr7:66197774	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs28491091	ENSG00000222364.1	RNU6-96P	6.72	5.84e-10	1.79e-06	0.59	0.52	Aortic root size;	chr7:66204077	chr7:66395191~66395286:+
TGCT	cis	rs7208859	0.623	rs80355557	ENSG00000263531.1	RP13-753N3.1	6.72	5.85e-10	1.79e-06	0.87	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs9911173	ENSG00000263531.1	RP13-753N3.1	6.72	5.85e-10	1.79e-06	0.87	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs73271887	ENSG00000263531.1	RP13-753N3.1	6.72	5.85e-10	1.79e-06	0.87	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs9898858	ENSG00000263531.1	RP13-753N3.1	6.72	5.85e-10	1.79e-06	0.87	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs55658077	ENSG00000263531.1	RP13-753N3.1	6.72	5.85e-10	1.79e-06	0.87	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs9899692	ENSG00000263531.1	RP13-753N3.1	6.72	5.85e-10	1.79e-06	0.87	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs9906957	ENSG00000263531.1	RP13-753N3.1	6.72	5.85e-10	1.79e-06	0.87	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs9915139	ENSG00000263531.1	RP13-753N3.1	6.72	5.85e-10	1.79e-06	0.87	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30863921~30864940:-
TGCT	cis	rs9326248	0.569	rs10892082	ENSG00000254851.1	RP11-109L13.1	-6.72	5.85e-10	1.79e-06	-0.95	-0.52	Blood protein levels;	chr11:117168609	chr11:117135528~117138582:+
TGCT	cis	rs4423214	0.57	rs7118246	ENSG00000254682.1	RP11-660L16.2	6.72	5.86e-10	1.79e-06	0.77	0.52	Vitamin D levels;	chr11:71520078	chr11:71448674~71452157:+
TGCT	cis	rs12906542	0.516	rs12593545	ENSG00000259792.1	RP11-114H24.6	-6.72	5.91e-10	1.81e-06	-0.56	-0.52	Breast cancer;	chr15:78045597	chr15:77993405~77995289:+
TGCT	cis	rs524281	0.773	rs7127808	ENSG00000255320.1	RP11-755F10.1	6.72	5.92e-10	1.81e-06	0.66	0.52	Electroencephalogram traits;	chr11:66164448	chr11:66244840~66246239:-
TGCT	cis	rs2745572	0.557	rs2745569	ENSG00000272279.1	RP11-157J24.2	-6.72	5.93e-10	1.81e-06	-0.55	-0.52	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1547396	chr6:1528364~1528911:-
TGCT	cis	rs17507216	0.681	rs28877110	ENSG00000278603.1	RP13-608F4.5	6.72	5.94e-10	1.82e-06	0.88	0.52	Excessive daytime sleepiness;	chr15:82672111	chr15:82472203~82472426:+
TGCT	cis	rs17507216	0.609	rs1431716	ENSG00000278603.1	RP13-608F4.5	6.72	5.94e-10	1.82e-06	0.88	0.52	Excessive daytime sleepiness;	chr15:82676180	chr15:82472203~82472426:+
TGCT	cis	rs7684253	0.565	rs12641030	ENSG00000269949.1	RP11-738E22.3	-6.72	5.95e-10	1.82e-06	-0.52	-0.52	Migraine;	chr4:56937339	chr4:56960927~56961373:-
TGCT	cis	rs7684253	0.565	rs13130605	ENSG00000269949.1	RP11-738E22.3	-6.72	5.95e-10	1.82e-06	-0.52	-0.52	Migraine;	chr4:56943905	chr4:56960927~56961373:-
TGCT	cis	rs7684253	0.565	rs6830774	ENSG00000269949.1	RP11-738E22.3	-6.72	5.95e-10	1.82e-06	-0.52	-0.52	Migraine;	chr4:56950140	chr4:56960927~56961373:-
TGCT	cis	rs875971	1	rs10215948	ENSG00000222364.1	RNU6-96P	6.72	5.97e-10	1.82e-06	0.6	0.52	Aortic root size;	chr7:66282799	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.838	rs2173570	ENSG00000222364.1	RNU6-96P	6.72	5.97e-10	1.82e-06	0.6	0.52	Aortic root size;	chr7:66297976	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.964	rs55748098	ENSG00000222364.1	RNU6-96P	6.72	5.97e-10	1.82e-06	0.6	0.52	Aortic root size;	chr7:66298631	chr7:66395191~66395286:+
TGCT	cis	rs977987	0.778	rs4888400	ENSG00000261783.1	RP11-252K23.2	-6.72	5.98e-10	1.82e-06	-0.74	-0.52	Dupuytren's disease;	chr16:75391698	chr16:75379818~75381260:-
TGCT	cis	rs17507216	0.718	rs7161977	ENSG00000278603.1	RP13-608F4.5	6.72	5.98e-10	1.83e-06	0.88	0.52	Excessive daytime sleepiness;	chr15:82646782	chr15:82472203~82472426:+
TGCT	cis	rs8040855	0.627	rs12904238	ENSG00000259295.5	CSPG4P12	6.72	5.99e-10	1.83e-06	0.73	0.52	Bulimia nervosa;	chr15:85096610	chr15:85191438~85213905:+
TGCT	cis	rs9549367	0.713	rs1323315	ENSG00000269125.1	RP11-98F14.11	6.72	6.03e-10	1.84e-06	0.61	0.52	Platelet distribution width;	chr13:113205344	chr13:113165002~113165183:-
TGCT	cis	rs1775715	0.513	rs2808089	ENSG00000239731.3	RN7SL825P	-6.71	6.05e-10	1.85e-06	-0.51	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr10:31856184	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.707	rs2808088	ENSG00000239731.3	RN7SL825P	-6.71	6.05e-10	1.85e-06	-0.51	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr10:31857222	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.707	rs2808087	ENSG00000239731.3	RN7SL825P	-6.71	6.05e-10	1.85e-06	-0.51	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr10:31857516	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.678	rs2778649	ENSG00000239731.3	RN7SL825P	-6.71	6.05e-10	1.85e-06	-0.51	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr10:31857875	chr10:31992087~31992381:-
TGCT	cis	rs4691139	1	rs12512283	ENSG00000250227.1	TRIM60P14	6.71	6.07e-10	1.85e-06	0.56	0.52	Ovarian cancer in BRCA1 mutation carriers;	chr4:164987775	chr4:164915565~164916983:+
TGCT	cis	rs12906542	0.516	rs894301	ENSG00000259792.1	RP11-114H24.6	-6.71	6.16e-10	1.88e-06	-0.56	-0.52	Breast cancer;	chr15:78005183	chr15:77993405~77995289:+
TGCT	cis	rs12906542	0.516	rs4886989	ENSG00000259792.1	RP11-114H24.6	-6.71	6.16e-10	1.88e-06	-0.56	-0.52	Breast cancer;	chr15:78011406	chr15:77993405~77995289:+
TGCT	cis	rs12906542	0.516	rs56357772	ENSG00000259792.1	RP11-114H24.6	-6.71	6.16e-10	1.88e-06	-0.56	-0.52	Breast cancer;	chr15:78020699	chr15:77993405~77995289:+
TGCT	cis	rs12906542	0.516	rs16969422	ENSG00000259792.1	RP11-114H24.6	-6.71	6.16e-10	1.88e-06	-0.56	-0.52	Breast cancer;	chr15:78033857	chr15:77993405~77995289:+
TGCT	cis	rs8040855	0.627	rs12909971	ENSG00000259295.5	CSPG4P12	6.71	6.18e-10	1.88e-06	0.66	0.52	Bulimia nervosa;	chr15:85045767	chr15:85191438~85213905:+
TGCT	cis	rs4691139	1	rs6821283	ENSG00000250227.1	TRIM60P14	6.71	6.22e-10	1.89e-06	0.56	0.52	Ovarian cancer in BRCA1 mutation carriers;	chr4:164980493	chr4:164915565~164916983:+
TGCT	cis	rs6452524	0.561	rs4331874	ENSG00000249664.1	CTD-2227C6.2	6.71	6.22e-10	1.89e-06	0.56	0.52	Hypertension (SNP x SNP interaction);	chr5:83068253	chr5:83012285~83013109:-
TGCT	cis	rs8040855	0.756	rs12909477	ENSG00000259295.5	CSPG4P12	-6.71	6.3e-10	1.91e-06	-0.69	-0.52	Bulimia nervosa;	chr15:85146644	chr15:85191438~85213905:+
TGCT	cis	rs17507216	0.718	rs17158403	ENSG00000278603.1	RP13-608F4.5	6.71	6.3e-10	1.91e-06	0.87	0.52	Excessive daytime sleepiness;	chr15:82572478	chr15:82472203~82472426:+
TGCT	cis	rs17507216	0.671	rs4779035	ENSG00000278603.1	RP13-608F4.5	6.71	6.3e-10	1.91e-06	0.87	0.52	Excessive daytime sleepiness;	chr15:82591686	chr15:82472203~82472426:+
TGCT	cis	rs11098499	1	rs13435802	ENSG00000245958.5	RP11-33B1.1	6.71	6.3e-10	1.91e-06	0.52	0.52	Corneal astigmatism;	chr4:119256805	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.909	rs10017335	ENSG00000245958.5	RP11-33B1.1	6.71	6.3e-10	1.92e-06	0.56	0.52	Corneal astigmatism;	chr4:119460368	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs58452170	ENSG00000245958.5	RP11-33B1.1	-6.71	6.31e-10	1.92e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119538519	chr4:119454791~119552025:+
TGCT	cis	rs7412746	0.503	rs72704639	ENSG00000206931.1	RNU6-1042P	6.71	6.34e-10	1.93e-06	0.41	0.52	Melanoma;	chr1:150825859	chr1:150701866~150701972:+
TGCT	cis	rs67383717	0.527	rs12004422	ENSG00000175611.10	LINC00476	6.7	6.41e-10	1.95e-06	0.45	0.52	Parkinson's disease (pesticide exposure interaction);	chr9:95873393	chr9:95759231~95875977:-
TGCT	cis	rs2882667	0.931	rs13153618	ENSG00000253404.1	AC034243.1	6.7	6.48e-10	1.97e-06	0.58	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139017087	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.894	rs10054478	ENSG00000253404.1	AC034243.1	6.7	6.48e-10	1.97e-06	0.58	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018386	chr5:138744434~138753309:-
TGCT	cis	rs10875976	0.525	rs67723963	ENSG00000257253.2	RP11-70F11.7	6.7	6.51e-10	1.98e-06	0.47	0.52	Obesity;	chr12:49864759	chr12:49861207~49865802:+
TGCT	cis	rs875971	0.862	rs4718319	ENSG00000222364.1	RNU6-96P	6.7	6.53e-10	1.98e-06	0.59	0.52	Aortic root size;	chr7:66187797	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.723	rs28391294	ENSG00000222364.1	RNU6-96P	6.7	6.53e-10	1.98e-06	0.59	0.52	Aortic root size;	chr7:66189328	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.83	rs6967708	ENSG00000222364.1	RNU6-96P	6.7	6.53e-10	1.98e-06	0.59	0.52	Aortic root size;	chr7:66192326	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.895	rs7782806	ENSG00000222364.1	RNU6-96P	6.7	6.53e-10	1.98e-06	0.59	0.52	Aortic root size;	chr7:66192910	chr7:66395191~66395286:+
TGCT	cis	rs11098499	0.82	rs11737395	ENSG00000245958.5	RP11-33B1.1	-6.7	6.61e-10	2e-06	-0.56	-0.52	Corneal astigmatism;	chr4:119599549	chr4:119454791~119552025:+
TGCT	cis	rs16828019	0.777	rs67460888	ENSG00000235358.1	RP11-399E6.1	6.7	6.62e-10	2.01e-06	0.86	0.52	Intelligence (multi-trait analysis);	chr1:41003665	chr1:41242373~41284861:+
TGCT	cis	rs17507216	0.718	rs28587782	ENSG00000278603.1	RP13-608F4.5	6.7	6.63e-10	2.01e-06	0.87	0.52	Excessive daytime sleepiness;	chr15:82576881	chr15:82472203~82472426:+
TGCT	cis	rs17507216	0.718	rs72751657	ENSG00000278603.1	RP13-608F4.5	6.7	6.63e-10	2.01e-06	0.87	0.52	Excessive daytime sleepiness;	chr15:82581259	chr15:82472203~82472426:+
TGCT	cis	rs17507216	0.718	rs72751662	ENSG00000278603.1	RP13-608F4.5	6.7	6.63e-10	2.01e-06	0.87	0.52	Excessive daytime sleepiness;	chr15:82594705	chr15:82472203~82472426:+
TGCT	cis	rs17507216	0.718	rs72751675	ENSG00000278603.1	RP13-608F4.5	6.7	6.63e-10	2.01e-06	0.87	0.52	Excessive daytime sleepiness;	chr15:82630452	chr15:82472203~82472426:+
TGCT	cis	rs17507216	0.718	rs7165690	ENSG00000278603.1	RP13-608F4.5	6.7	6.63e-10	2.01e-06	0.87	0.52	Excessive daytime sleepiness;	chr15:82654804	chr15:82472203~82472426:+
TGCT	cis	rs875971	0.862	rs4236208	ENSG00000222364.1	RNU6-96P	6.69	6.69e-10	2.02e-06	0.59	0.52	Aortic root size;	chr7:66284091	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs10261398	ENSG00000222364.1	RNU6-96P	6.69	6.69e-10	2.02e-06	0.59	0.52	Aortic root size;	chr7:66285177	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs10224872	ENSG00000222364.1	RNU6-96P	6.69	6.69e-10	2.02e-06	0.59	0.52	Aortic root size;	chr7:66294786	chr7:66395191~66395286:+
TGCT	cis	rs9389248	0.69	rs2064101	ENSG00000232876.1	CTA-212D2.2	6.69	6.7e-10	2.03e-06	0.48	0.52	High light scatter reticulocyte percentage of red cells;	chr6:134929392	chr6:135055033~135060550:+
TGCT	cis	rs9389248	0.69	rs2294321	ENSG00000232876.1	CTA-212D2.2	6.69	6.7e-10	2.03e-06	0.48	0.52	High light scatter reticulocyte percentage of red cells;	chr6:134931910	chr6:135055033~135060550:+
TGCT	cis	rs9399135	0.507	rs2072825	ENSG00000232876.1	CTA-212D2.2	6.69	6.7e-10	2.03e-06	0.48	0.52	Red blood cell count;	chr6:134932313	chr6:135055033~135060550:+
TGCT	cis	rs9389248	0.69	rs2072826	ENSG00000232876.1	CTA-212D2.2	6.69	6.7e-10	2.03e-06	0.48	0.52	High light scatter reticulocyte percentage of red cells;	chr6:134932420	chr6:135055033~135060550:+
TGCT	cis	rs7684253	0.565	rs13108570	ENSG00000269949.1	RP11-738E22.3	-6.69	6.71e-10	2.03e-06	-0.53	-0.52	Migraine;	chr4:56940917	chr4:56960927~56961373:-
TGCT	cis	rs2745572	0.515	rs2250686	ENSG00000272279.1	RP11-157J24.2	-6.69	6.73e-10	2.03e-06	-0.55	-0.52	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1548909	chr6:1528364~1528911:-
TGCT	cis	rs2745572	0.557	rs2745574	ENSG00000272279.1	RP11-157J24.2	-6.69	6.73e-10	2.03e-06	-0.55	-0.52	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1548990	chr6:1528364~1528911:-
TGCT	cis	rs2745572	0.557	rs2745576	ENSG00000272279.1	RP11-157J24.2	-6.69	6.73e-10	2.03e-06	-0.55	-0.52	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1549211	chr6:1528364~1528911:-
TGCT	cis	rs977987	0.843	rs67409275	ENSG00000261783.1	RP11-252K23.2	-6.69	6.76e-10	2.04e-06	-0.74	-0.52	Dupuytren's disease;	chr16:75423314	chr16:75379818~75381260:-
TGCT	cis	rs6452524	0.534	rs7727691	ENSG00000249664.1	CTD-2227C6.2	6.69	6.78e-10	2.05e-06	0.57	0.52	Hypertension (SNP x SNP interaction);	chr5:83075876	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.562	rs10474080	ENSG00000249664.1	CTD-2227C6.2	6.69	6.78e-10	2.05e-06	0.57	0.52	Hypertension (SNP x SNP interaction);	chr5:83078300	chr5:83012285~83013109:-
TGCT	cis	rs977987	0.771	rs8048527	ENSG00000261783.1	RP11-252K23.2	-6.69	6.78e-10	2.05e-06	-0.73	-0.52	Dupuytren's disease;	chr16:75388156	chr16:75379818~75381260:-
TGCT	cis	rs2945232	1	rs2945232	ENSG00000173295.6	FAM86B3P	6.69	6.81e-10	2.06e-06	0.63	0.52	Schizophrenia;	chr8:8240516	chr8:8228595~8244865:+
TGCT	cis	rs6921919	0.638	rs9468344	ENSG00000216901.1	AL022393.7	6.69	6.87e-10	2.07e-06	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28176188~28176674:+
TGCT	cis	rs17301013	0.581	rs4652204	ENSG00000227373.4	RP11-160H22.5	6.69	6.87e-10	2.07e-06	0.62	0.51	Systemic lupus erythematosus;	chr1:174150682	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.581	rs56158362	ENSG00000227373.4	RP11-160H22.5	6.69	6.87e-10	2.07e-06	0.62	0.51	Systemic lupus erythematosus;	chr1:174166437	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs77379897	ENSG00000227373.4	RP11-160H22.5	6.69	6.87e-10	2.07e-06	0.62	0.51	Systemic lupus erythematosus;	chr1:174169373	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs56375942	ENSG00000227373.4	RP11-160H22.5	6.69	6.87e-10	2.07e-06	0.62	0.51	Systemic lupus erythematosus;	chr1:174176206	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs56404641	ENSG00000227373.4	RP11-160H22.5	6.69	6.87e-10	2.07e-06	0.62	0.51	Systemic lupus erythematosus;	chr1:174176323	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs56239105	ENSG00000227373.4	RP11-160H22.5	6.69	6.87e-10	2.07e-06	0.62	0.51	Systemic lupus erythematosus;	chr1:174179346	chr1:174115300~174160004:-
TGCT	cis	rs7044106	0.791	rs735109	ENSG00000226752.6	PSMD5-AS1	-6.69	6.88e-10	2.07e-06	-0.64	-0.51	Hip circumference adjusted for BMI;	chr9:120726601	chr9:120824828~120854385:+
TGCT	cis	rs7714584	1	rs12659118	ENSG00000197083.10	ZNF300P1	6.69	6.9e-10	2.08e-06	1.06	0.51	Crohn's disease;	chr5:150945060	chr5:150930645~150946289:-
TGCT	cis	rs875971	0.522	rs2008188	ENSG00000222364.1	RNU6-96P	-6.69	6.91e-10	2.08e-06	-0.6	-0.51	Aortic root size;	chr7:65964026	chr7:66395191~66395286:+
TGCT	cis	rs17711722	0.727	rs1880555	ENSG00000222364.1	RNU6-96P	-6.69	6.91e-10	2.08e-06	-0.6	-0.51	Calcium levels;	chr7:65967580	chr7:66395191~66395286:+
TGCT	cis	rs17711722	0.701	rs781143	ENSG00000222364.1	RNU6-96P	-6.69	6.91e-10	2.08e-06	-0.6	-0.51	Calcium levels;	chr7:65974892	chr7:66395191~66395286:+
TGCT	cis	rs17711722	0.701	rs781145	ENSG00000222364.1	RNU6-96P	-6.69	6.91e-10	2.08e-06	-0.6	-0.51	Calcium levels;	chr7:65975383	chr7:66395191~66395286:+
TGCT	cis	rs1775715	0.737	rs2778661	ENSG00000239731.3	RN7SL825P	-6.69	6.93e-10	2.08e-06	-0.51	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr10:31870263	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.707	rs2065443	ENSG00000239731.3	RN7SL825P	-6.69	6.93e-10	2.08e-06	-0.51	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr10:31875308	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.707	rs2808079	ENSG00000239731.3	RN7SL825P	-6.69	6.93e-10	2.08e-06	-0.51	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr10:31878457	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.769	rs2799030	ENSG00000239731.3	RN7SL825P	-6.69	6.93e-10	2.08e-06	-0.51	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr10:31884007	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.677	rs2799034	ENSG00000239731.3	RN7SL825P	-6.69	6.93e-10	2.08e-06	-0.51	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr10:31886968	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.677	rs2808074	ENSG00000239731.3	RN7SL825P	-6.69	6.93e-10	2.08e-06	-0.51	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr10:31890256	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.707	rs1541262	ENSG00000239731.3	RN7SL825P	-6.69	6.93e-10	2.08e-06	-0.51	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr10:31890843	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.677	rs2491272	ENSG00000239731.3	RN7SL825P	-6.69	6.93e-10	2.08e-06	-0.51	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr10:31897855	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.737	rs2799018	ENSG00000239731.3	RN7SL825P	-6.69	6.93e-10	2.08e-06	-0.51	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr10:31913141	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.737	rs2808072	ENSG00000239731.3	RN7SL825P	-6.69	6.93e-10	2.08e-06	-0.51	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr10:31916576	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.737	rs11817598	ENSG00000239731.3	RN7SL825P	-6.69	6.93e-10	2.08e-06	-0.51	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr10:31917331	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.678	rs2105360	ENSG00000239731.3	RN7SL825P	-6.69	6.93e-10	2.08e-06	-0.51	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr10:31921270	chr10:31992087~31992381:-
TGCT	cis	rs6452524	0.806	rs10078084	ENSG00000249664.1	CTD-2227C6.2	6.69	6.93e-10	2.09e-06	0.57	0.51	Hypertension (SNP x SNP interaction);	chr5:83106588	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.868	rs11750836	ENSG00000249664.1	CTD-2227C6.2	6.69	6.93e-10	2.09e-06	0.57	0.51	Hypertension (SNP x SNP interaction);	chr5:83107368	chr5:83012285~83013109:-
TGCT	cis	rs9389248	0.69	rs6939543	ENSG00000232876.1	CTA-212D2.2	6.69	6.94e-10	2.09e-06	0.48	0.51	High light scatter reticulocyte percentage of red cells;	chr6:134934005	chr6:135055033~135060550:+
TGCT	cis	rs9389248	0.69	rs1028314	ENSG00000232876.1	CTA-212D2.2	6.69	6.94e-10	2.09e-06	0.48	0.51	High light scatter reticulocyte percentage of red cells;	chr6:134934572	chr6:135055033~135060550:+
TGCT	cis	rs6452524	0.87	rs2174976	ENSG00000249664.1	CTD-2227C6.2	6.69	6.94e-10	2.09e-06	0.55	0.51	Hypertension (SNP x SNP interaction);	chr5:83197136	chr5:83012285~83013109:-
TGCT	cis	rs977987	0.815	rs11646677	ENSG00000261783.1	RP11-252K23.2	-6.69	6.95e-10	2.09e-06	-0.75	-0.51	Dupuytren's disease;	chr16:75375083	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.843	rs8056080	ENSG00000261783.1	RP11-252K23.2	-6.69	6.95e-10	2.09e-06	-0.75	-0.51	Dupuytren's disease;	chr16:75376900	chr16:75379818~75381260:-
TGCT	cis	rs1775715	0.737	rs2808090	ENSG00000239731.3	RN7SL825P	-6.69	6.98e-10	2.1e-06	-0.5	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr10:31854280	chr10:31992087~31992381:-
TGCT	cis	rs1062177	0.855	rs919262	ENSG00000253921.1	CTB-113P19.3	6.69	7e-10	2.1e-06	0.58	0.51	Preschool internalizing problems;	chr5:151886523	chr5:151753992~151767247:+
TGCT	cis	rs7044106	0.791	rs7043969	ENSG00000226752.6	PSMD5-AS1	-6.68	7.03e-10	2.11e-06	-0.65	-0.51	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120824828~120854385:+
TGCT	cis	rs2882667	0.931	rs1433009	ENSG00000253404.1	AC034243.1	6.68	7.1e-10	2.13e-06	0.59	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998095	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.931	rs7720150	ENSG00000253404.1	AC034243.1	6.68	7.1e-10	2.13e-06	0.59	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998380	chr5:138744434~138753309:-
TGCT	cis	rs524281	0.684	rs7946447	ENSG00000255320.1	RP11-755F10.1	6.68	7.11e-10	2.13e-06	0.65	0.51	Electroencephalogram traits;	chr11:66096867	chr11:66244840~66246239:-
TGCT	cis	rs2882667	0.898	rs2116789	ENSG00000253404.1	AC034243.1	6.68	7.15e-10	2.14e-06	0.58	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058573	chr5:138744434~138753309:-
TGCT	cis	rs1775715	0.737	rs1419171	ENSG00000239731.3	RN7SL825P	-6.68	7.19e-10	2.15e-06	-0.51	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr10:31925903	chr10:31992087~31992381:-
TGCT	cis	rs11098499	0.644	rs10050092	ENSG00000245958.5	RP11-33B1.1	-6.68	7.3e-10	2.18e-06	-0.55	-0.51	Corneal astigmatism;	chr4:119610930	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.644	rs7693919	ENSG00000245958.5	RP11-33B1.1	-6.68	7.3e-10	2.18e-06	-0.55	-0.51	Corneal astigmatism;	chr4:119619416	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.57	rs6832740	ENSG00000245958.5	RP11-33B1.1	-6.68	7.3e-10	2.18e-06	-0.55	-0.51	Corneal astigmatism;	chr4:119624981	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.644	rs6855918	ENSG00000245958.5	RP11-33B1.1	-6.68	7.3e-10	2.18e-06	-0.55	-0.51	Corneal astigmatism;	chr4:119625144	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.644	rs34835603	ENSG00000245958.5	RP11-33B1.1	-6.68	7.3e-10	2.18e-06	-0.55	-0.51	Corneal astigmatism;	chr4:119632273	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.615	rs28850368	ENSG00000245958.5	RP11-33B1.1	-6.68	7.3e-10	2.18e-06	-0.55	-0.51	Corneal astigmatism;	chr4:119633158	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.644	rs7676296	ENSG00000245958.5	RP11-33B1.1	-6.68	7.3e-10	2.18e-06	-0.55	-0.51	Corneal astigmatism;	chr4:119634532	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.675	rs11098534	ENSG00000245958.5	RP11-33B1.1	-6.68	7.3e-10	2.18e-06	-0.55	-0.51	Corneal astigmatism;	chr4:119635617	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs3736115	ENSG00000245958.5	RP11-33B1.1	6.68	7.35e-10	2.19e-06	0.59	0.51	Corneal astigmatism;	chr4:119567548	chr4:119454791~119552025:+
TGCT	cis	rs977987	0.742	rs34624768	ENSG00000261783.1	RP11-252K23.2	-6.68	7.36e-10	2.19e-06	-0.76	-0.51	Dupuytren's disease;	chr16:75297674	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.8	rs4888378	ENSG00000261783.1	RP11-252K23.2	-6.68	7.36e-10	2.19e-06	-0.76	-0.51	Dupuytren's disease;	chr16:75298143	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.8	rs12935787	ENSG00000261783.1	RP11-252K23.2	-6.68	7.36e-10	2.19e-06	-0.76	-0.51	Dupuytren's disease;	chr16:75298437	chr16:75379818~75381260:-
TGCT	cis	rs9549367	0.789	rs12869947	ENSG00000269125.1	RP11-98F14.11	-6.67	7.38e-10	2.2e-06	-0.6	-0.51	Platelet distribution width;	chr13:113241842	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.789	rs9549718	ENSG00000269125.1	RP11-98F14.11	-6.67	7.47e-10	2.22e-06	-0.6	-0.51	Platelet distribution width;	chr13:113255508	chr13:113165002~113165183:-
TGCT	cis	rs17361889	0.806	rs62440376	ENSG00000224683.1	RPL36AP29	6.67	7.48e-10	2.23e-06	0.6	0.51	Pediatric bone mineral content (hip);	chr7:16193307	chr7:16208945~16209265:+
TGCT	cis	rs875971	1	rs6945843	ENSG00000222364.1	RNU6-96P	6.67	7.52e-10	2.24e-06	0.6	0.51	Aortic root size;	chr7:66269796	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.965	rs10267430	ENSG00000222364.1	RNU6-96P	6.67	7.52e-10	2.24e-06	0.6	0.51	Aortic root size;	chr7:66278036	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs10257427	ENSG00000222364.1	RNU6-96P	6.67	7.52e-10	2.24e-06	0.6	0.51	Aortic root size;	chr7:66278221	chr7:66395191~66395286:+
TGCT	cis	rs17507216	0.718	rs72753931	ENSG00000278603.1	RP13-608F4.5	6.67	7.54e-10	2.24e-06	0.87	0.51	Excessive daytime sleepiness;	chr15:82721485	chr15:82472203~82472426:+
TGCT	cis	rs2882667	0.898	rs11952020	ENSG00000253404.1	AC034243.1	6.67	7.55e-10	2.25e-06	0.57	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059467	chr5:138744434~138753309:-
TGCT	cis	rs17507216	0.628	rs28607761	ENSG00000278603.1	RP13-608F4.5	6.67	7.58e-10	2.25e-06	0.86	0.51	Excessive daytime sleepiness;	chr15:82715317	chr15:82472203~82472426:+
TGCT	cis	rs7208859	0.623	rs3752019	ENSG00000263531.1	RP13-753N3.1	6.67	7.59e-10	2.26e-06	0.86	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs73271869	ENSG00000263531.1	RP13-753N3.1	6.67	7.59e-10	2.26e-06	0.86	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs73271872	ENSG00000263531.1	RP13-753N3.1	6.67	7.59e-10	2.26e-06	0.86	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs55724095	ENSG00000263531.1	RP13-753N3.1	6.67	7.59e-10	2.26e-06	0.86	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs56146117	ENSG00000263531.1	RP13-753N3.1	6.67	7.59e-10	2.26e-06	0.86	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30863921~30864940:-
TGCT	cis	rs17826219	0.568	rs9903854	ENSG00000263531.1	RP13-753N3.1	6.67	7.59e-10	2.26e-06	0.86	0.51	Body mass index;	chr17:30826980	chr17:30863921~30864940:-
TGCT	cis	rs17826219	0.568	rs9907834	ENSG00000263531.1	RP13-753N3.1	6.67	7.59e-10	2.26e-06	0.86	0.51	Body mass index;	chr17:30826995	chr17:30863921~30864940:-
TGCT	cis	rs2882667	0.824	rs1560656	ENSG00000253404.1	AC034243.1	-6.67	7.6e-10	2.26e-06	-0.61	-0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135100	chr5:138744434~138753309:-
TGCT	cis	rs9549367	0.789	rs34989271	ENSG00000269125.1	RP11-98F14.11	-6.67	7.72e-10	2.29e-06	-0.6	-0.51	Platelet distribution width;	chr13:113240452	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.789	rs71446679	ENSG00000269125.1	RP11-98F14.11	-6.67	7.72e-10	2.29e-06	-0.6	-0.51	Platelet distribution width;	chr13:113240507	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.737	rs71446680	ENSG00000269125.1	RP11-98F14.11	-6.67	7.72e-10	2.29e-06	-0.6	-0.51	Platelet distribution width;	chr13:113240532	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.789	rs71446682	ENSG00000269125.1	RP11-98F14.11	-6.67	7.72e-10	2.29e-06	-0.6	-0.51	Platelet distribution width;	chr13:113240594	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.826	rs9549710	ENSG00000269125.1	RP11-98F14.11	-6.67	7.72e-10	2.29e-06	-0.6	-0.51	Platelet distribution width;	chr13:113243750	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.789	rs9549711	ENSG00000269125.1	RP11-98F14.11	-6.67	7.72e-10	2.29e-06	-0.6	-0.51	Platelet distribution width;	chr13:113246243	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.737	rs9549712	ENSG00000269125.1	RP11-98F14.11	-6.67	7.72e-10	2.29e-06	-0.6	-0.51	Platelet distribution width;	chr13:113248041	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.774	rs9549364	ENSG00000269125.1	RP11-98F14.11	-6.67	7.72e-10	2.29e-06	-0.6	-0.51	Platelet distribution width;	chr13:113249431	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.737	rs11619691	ENSG00000269125.1	RP11-98F14.11	-6.67	7.72e-10	2.29e-06	-0.6	-0.51	Platelet distribution width;	chr13:113250322	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.826	rs9549713	ENSG00000269125.1	RP11-98F14.11	-6.67	7.72e-10	2.29e-06	-0.6	-0.51	Platelet distribution width;	chr13:113250994	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.789	rs3850451	ENSG00000269125.1	RP11-98F14.11	-6.67	7.72e-10	2.29e-06	-0.6	-0.51	Platelet distribution width;	chr13:113251498	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.789	rs3861720	ENSG00000269125.1	RP11-98F14.11	-6.67	7.72e-10	2.29e-06	-0.6	-0.51	Platelet distribution width;	chr13:113251783	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.865	rs3861721	ENSG00000269125.1	RP11-98F14.11	-6.67	7.72e-10	2.29e-06	-0.6	-0.51	Platelet distribution width;	chr13:113251994	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.789	rs7994324	ENSG00000269125.1	RP11-98F14.11	-6.67	7.72e-10	2.29e-06	-0.6	-0.51	Platelet distribution width;	chr13:113252183	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.789	rs9549715	ENSG00000269125.1	RP11-98F14.11	-6.67	7.72e-10	2.29e-06	-0.6	-0.51	Platelet distribution width;	chr13:113253926	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.789	rs2302757	ENSG00000269125.1	RP11-98F14.11	-6.67	7.72e-10	2.29e-06	-0.6	-0.51	Platelet distribution width;	chr13:113255025	chr13:113165002~113165183:-
TGCT	cis	rs977987	0.806	rs4888418	ENSG00000261783.1	RP11-252K23.2	-6.66	7.78e-10	2.31e-06	-0.73	-0.51	Dupuytren's disease;	chr16:75426408	chr16:75379818~75381260:-
TGCT	cis	rs11098499	0.863	rs7678400	ENSG00000245958.5	RP11-33B1.1	-6.66	7.81e-10	2.31e-06	-0.56	-0.51	Corneal astigmatism;	chr4:119540802	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs1480936	ENSG00000245958.5	RP11-33B1.1	-6.66	7.81e-10	2.31e-06	-0.56	-0.51	Corneal astigmatism;	chr4:119541706	chr4:119454791~119552025:+
TGCT	cis	rs2882667	0.858	rs11948429	ENSG00000253404.1	AC034243.1	6.66	7.92e-10	2.35e-06	0.6	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139122895	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.858	rs2043271	ENSG00000253404.1	AC034243.1	6.66	7.92e-10	2.35e-06	0.6	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139123419	chr5:138744434~138753309:-
TGCT	cis	rs977987	0.806	rs4638613	ENSG00000261783.1	RP11-252K23.2	-6.66	7.94e-10	2.35e-06	-0.72	-0.51	Dupuytren's disease;	chr16:75391655	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.843	rs7499872	ENSG00000261783.1	RP11-252K23.2	-6.66	7.94e-10	2.35e-06	-0.72	-0.51	Dupuytren's disease;	chr16:75392631	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.778	rs7203157	ENSG00000261783.1	RP11-252K23.2	-6.65	8.23e-10	2.43e-06	-0.73	-0.51	Dupuytren's disease;	chr16:75384022	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.815	rs11149821	ENSG00000261783.1	RP11-252K23.2	-6.65	8.23e-10	2.43e-06	-0.73	-0.51	Dupuytren's disease;	chr16:75388919	chr16:75379818~75381260:-
TGCT	cis	rs17711722	0.727	rs2658585	ENSG00000222364.1	RNU6-96P	-6.65	8.25e-10	2.44e-06	-0.6	-0.51	Calcium levels;	chr7:65996954	chr7:66395191~66395286:+
TGCT	cis	rs1775715	0.737	rs11008695	ENSG00000239731.3	RN7SL825P	-6.65	8.26e-10	2.44e-06	-0.52	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr10:31927959	chr10:31992087~31992381:-
TGCT	cis	rs977987	0.645	rs10871311	ENSG00000261783.1	RP11-252K23.2	-6.65	8.29e-10	2.45e-06	-0.74	-0.51	Dupuytren's disease;	chr16:75417014	chr16:75379818~75381260:-
TGCT	cis	rs2882667	0.858	rs11951899	ENSG00000253404.1	AC034243.1	6.65	8.29e-10	2.45e-06	0.61	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038621	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.858	rs35812969	ENSG00000253404.1	AC034243.1	6.65	8.29e-10	2.45e-06	0.61	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041861	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.858	rs11242442	ENSG00000253404.1	AC034243.1	6.65	8.29e-10	2.45e-06	0.61	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044800	chr5:138744434~138753309:-
TGCT	cis	rs6538678	0.777	rs10745736	ENSG00000258343.1	RP11-536G4.2	-6.65	8.29e-10	2.45e-06	-0.69	-0.51	Lupus nephritis in systemic lupus erythematosus;	chr12:95889308	chr12:95795345~95858839:-
TGCT	cis	rs12891047	0.832	rs181565	ENSG00000258759.1	RP11-1012A1.7	6.65	8.29e-10	2.45e-06	0.46	0.51	Amyotrophic lateral sclerosis (sporadic);	chr14:67810698	chr14:67799004~67799609:+
TGCT	cis	rs17507216	0.718	rs4779033	ENSG00000278603.1	RP13-608F4.5	-6.65	8.3e-10	2.45e-06	-0.84	-0.51	Excessive daytime sleepiness;	chr15:82576634	chr15:82472203~82472426:+
TGCT	cis	rs977987	0.806	rs1895490	ENSG00000261783.1	RP11-252K23.2	-6.65	8.33e-10	2.45e-06	-0.74	-0.51	Dupuytren's disease;	chr16:75358908	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs4888388	ENSG00000261783.1	RP11-252K23.2	-6.65	8.33e-10	2.45e-06	-0.74	-0.51	Dupuytren's disease;	chr16:75360250	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs1364077	ENSG00000261783.1	RP11-252K23.2	-6.65	8.33e-10	2.45e-06	-0.74	-0.51	Dupuytren's disease;	chr16:75363093	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.843	rs4887820	ENSG00000261783.1	RP11-252K23.2	-6.65	8.33e-10	2.45e-06	-0.74	-0.51	Dupuytren's disease;	chr16:75363389	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.778	rs34222958	ENSG00000261783.1	RP11-252K23.2	-6.65	8.33e-10	2.45e-06	-0.74	-0.51	Dupuytren's disease;	chr16:75364354	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.778	rs4887821	ENSG00000261783.1	RP11-252K23.2	-6.65	8.33e-10	2.45e-06	-0.74	-0.51	Dupuytren's disease;	chr16:75364676	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs4888390	ENSG00000261783.1	RP11-252K23.2	-6.65	8.33e-10	2.45e-06	-0.74	-0.51	Dupuytren's disease;	chr16:75366422	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs4888391	ENSG00000261783.1	RP11-252K23.2	-6.65	8.33e-10	2.45e-06	-0.74	-0.51	Dupuytren's disease;	chr16:75366848	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs8054769	ENSG00000261783.1	RP11-252K23.2	-6.65	8.33e-10	2.45e-06	-0.74	-0.51	Dupuytren's disease;	chr16:75367215	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs11640473	ENSG00000261783.1	RP11-252K23.2	-6.65	8.33e-10	2.45e-06	-0.74	-0.51	Dupuytren's disease;	chr16:75369391	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs8057203	ENSG00000261783.1	RP11-252K23.2	-6.65	8.33e-10	2.45e-06	-0.74	-0.51	Dupuytren's disease;	chr16:75371076	chr16:75379818~75381260:-
TGCT	cis	rs12891047	0.901	rs2874132	ENSG00000258759.1	RP11-1012A1.7	-6.65	8.52e-10	2.5e-06	-0.45	-0.51	Amyotrophic lateral sclerosis (sporadic);	chr14:67779006	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.866	rs181570	ENSG00000258759.1	RP11-1012A1.7	-6.65	8.52e-10	2.5e-06	-0.45	-0.51	Amyotrophic lateral sclerosis (sporadic);	chr14:67808625	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.8	rs11158694	ENSG00000258759.1	RP11-1012A1.7	6.65	8.52e-10	2.5e-06	0.45	0.51	Amyotrophic lateral sclerosis (sporadic);	chr14:67774628	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.832	rs12893157	ENSG00000258759.1	RP11-1012A1.7	6.65	8.52e-10	2.5e-06	0.45	0.51	Amyotrophic lateral sclerosis (sporadic);	chr14:67776901	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.832	rs2295106	ENSG00000258759.1	RP11-1012A1.7	6.65	8.52e-10	2.5e-06	0.45	0.51	Amyotrophic lateral sclerosis (sporadic);	chr14:67780138	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.901	rs2295107	ENSG00000258759.1	RP11-1012A1.7	6.65	8.52e-10	2.5e-06	0.45	0.51	Amyotrophic lateral sclerosis (sporadic);	chr14:67780159	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.901	rs4143685	ENSG00000258759.1	RP11-1012A1.7	6.65	8.52e-10	2.5e-06	0.45	0.51	Amyotrophic lateral sclerosis (sporadic);	chr14:67780851	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.865	rs8011120	ENSG00000258759.1	RP11-1012A1.7	6.65	8.52e-10	2.5e-06	0.45	0.51	Amyotrophic lateral sclerosis (sporadic);	chr14:67791521	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.901	rs1040598	ENSG00000258759.1	RP11-1012A1.7	6.65	8.52e-10	2.5e-06	0.45	0.51	Amyotrophic lateral sclerosis (sporadic);	chr14:67792265	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.901	rs12891164	ENSG00000258759.1	RP11-1012A1.7	6.65	8.52e-10	2.5e-06	0.45	0.51	Amyotrophic lateral sclerosis (sporadic);	chr14:67798150	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.901	rs7159622	ENSG00000258759.1	RP11-1012A1.7	6.65	8.52e-10	2.5e-06	0.45	0.51	Amyotrophic lateral sclerosis (sporadic);	chr14:67798799	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.901	rs7142433	ENSG00000258759.1	RP11-1012A1.7	6.65	8.52e-10	2.5e-06	0.45	0.51	Amyotrophic lateral sclerosis (sporadic);	chr14:67802921	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.866	rs181576	ENSG00000258759.1	RP11-1012A1.7	6.65	8.52e-10	2.5e-06	0.45	0.51	Amyotrophic lateral sclerosis (sporadic);	chr14:67806713	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.866	rs181574	ENSG00000258759.1	RP11-1012A1.7	6.65	8.52e-10	2.5e-06	0.45	0.51	Amyotrophic lateral sclerosis (sporadic);	chr14:67807095	chr14:67799004~67799609:+
TGCT	cis	rs9549367	0.707	rs9549353	ENSG00000269125.1	RP11-98F14.11	-6.65	8.56e-10	2.51e-06	-0.63	-0.51	Platelet distribution width;	chr13:113189113	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.664	rs9549689	ENSG00000269125.1	RP11-98F14.11	-6.65	8.56e-10	2.51e-06	-0.63	-0.51	Platelet distribution width;	chr13:113194073	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.713	rs9549356	ENSG00000269125.1	RP11-98F14.11	-6.65	8.56e-10	2.51e-06	-0.63	-0.51	Platelet distribution width;	chr13:113197319	chr13:113165002~113165183:-
TGCT	cis	rs950169	0.544	rs2036949	ENSG00000225151.9	GOLGA2P7	-6.65	8.57e-10	2.52e-06	-0.58	-0.51	Schizophrenia;	chr15:84620374	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.58	rs11635597	ENSG00000225151.9	GOLGA2P7	-6.65	8.57e-10	2.52e-06	-0.58	-0.51	Schizophrenia;	chr15:84622468	chr15:84199311~84230136:-
TGCT	cis	rs2739330	0.752	rs2330634	ENSG00000272787.1	KB-226F1.2	-6.64	8.59e-10	2.52e-06	-0.58	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23969211~23969873:+
TGCT	cis	rs7412746	0.611	rs11204747	ENSG00000206931.1	RNU6-1042P	-6.64	8.62e-10	2.53e-06	-0.42	-0.51	Melanoma;	chr1:150954676	chr1:150701866~150701972:+
TGCT	cis	rs875971	0.522	rs2949690	ENSG00000222364.1	RNU6-96P	6.64	8.64e-10	2.53e-06	0.6	0.51	Aortic root size;	chr7:66018255	chr7:66395191~66395286:+
TGCT	cis	rs73086581	0.741	rs17212649	ENSG00000229539.1	RP11-119B16.2	6.64	8.69e-10	2.55e-06	0.78	0.51	Response to antidepressants in depression;	chr20:3872446	chr20:3888239~3888868:-
TGCT	cis	rs2882667	0.838	rs11958529	ENSG00000253404.1	AC034243.1	6.64	8.69e-10	2.55e-06	0.57	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059379	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.861	rs11959727	ENSG00000253404.1	AC034243.1	6.64	8.69e-10	2.55e-06	0.57	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061276	chr5:138744434~138753309:-
TGCT	cis	rs7208859	0.623	rs56325146	ENSG00000263531.1	RP13-753N3.1	6.64	8.71e-10	2.55e-06	0.86	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30863921~30864940:-
TGCT	cis	rs977987	0.806	rs2865530	ENSG00000261783.1	RP11-252K23.2	-6.64	8.72e-10	2.56e-06	-0.75	-0.51	Dupuytren's disease;	chr16:75380478	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.843	rs4888427	ENSG00000261783.1	RP11-252K23.2	-6.64	8.73e-10	2.56e-06	-0.75	-0.51	Dupuytren's disease;	chr16:75444549	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs35683383	ENSG00000261783.1	RP11-252K23.2	-6.64	8.73e-10	2.56e-06	-0.75	-0.51	Dupuytren's disease;	chr16:75445379	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.843	rs12928036	ENSG00000261783.1	RP11-252K23.2	-6.64	8.73e-10	2.56e-06	-0.75	-0.51	Dupuytren's disease;	chr16:75449234	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.843	rs59465235	ENSG00000261783.1	RP11-252K23.2	-6.64	8.73e-10	2.56e-06	-0.75	-0.51	Dupuytren's disease;	chr16:75449912	chr16:75379818~75381260:-
TGCT	cis	rs950169	0.519	rs7237	ENSG00000225151.9	GOLGA2P7	-6.64	8.74e-10	2.56e-06	-0.57	-0.51	Schizophrenia;	chr15:84643346	chr15:84199311~84230136:-
TGCT	cis	rs16828019	0.852	rs16827876	ENSG00000235358.1	RP11-399E6.1	6.64	8.74e-10	2.56e-06	0.89	0.51	Intelligence (multi-trait analysis);	chr1:41073864	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.852	rs34979067	ENSG00000235358.1	RP11-399E6.1	6.64	8.74e-10	2.56e-06	0.89	0.51	Intelligence (multi-trait analysis);	chr1:41077412	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.852	rs35190461	ENSG00000235358.1	RP11-399E6.1	6.64	8.74e-10	2.56e-06	0.89	0.51	Intelligence (multi-trait analysis);	chr1:41077463	chr1:41242373~41284861:+
TGCT	cis	rs7412746	0.658	rs10305714	ENSG00000206931.1	RNU6-1042P	-6.64	8.77e-10	2.57e-06	-0.39	-0.51	Melanoma;	chr1:150828179	chr1:150701866~150701972:+
TGCT	cis	rs1775715	0.707	rs2799024	ENSG00000239731.3	RN7SL825P	-6.64	8.78e-10	2.57e-06	-0.52	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr10:31877994	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.707	rs1541261	ENSG00000239731.3	RN7SL825P	-6.64	8.78e-10	2.57e-06	-0.52	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr10:31890595	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.651	rs2808033	ENSG00000239731.3	RN7SL825P	-6.64	8.78e-10	2.57e-06	-0.52	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr10:31905199	chr10:31992087~31992381:-
TGCT	cis	rs977987	0.806	rs8050059	ENSG00000261783.1	RP11-252K23.2	-6.64	8.81e-10	2.58e-06	-0.75	-0.51	Dupuytren's disease;	chr16:75354833	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs1549306	ENSG00000261783.1	RP11-252K23.2	-6.64	8.81e-10	2.58e-06	-0.75	-0.51	Dupuytren's disease;	chr16:75381443	chr16:75379818~75381260:-
TGCT	cis	rs11098499	0.644	rs28787668	ENSG00000245958.5	RP11-33B1.1	-6.64	8.81e-10	2.58e-06	-0.54	-0.51	Corneal astigmatism;	chr4:119633532	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.82	rs13128602	ENSG00000245958.5	RP11-33B1.1	6.64	8.83e-10	2.58e-06	0.55	0.51	Corneal astigmatism;	chr4:119538211	chr4:119454791~119552025:+
TGCT	cis	rs17301013	0.606	rs4650969	ENSG00000227373.4	RP11-160H22.5	6.64	8.89e-10	2.6e-06	0.61	0.51	Systemic lupus erythematosus;	chr1:174229622	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.581	rs72711501	ENSG00000227373.4	RP11-160H22.5	6.64	8.89e-10	2.6e-06	0.61	0.51	Systemic lupus erythematosus;	chr1:174233081	chr1:174115300~174160004:-
TGCT	cis	rs977987	0.815	rs11149818	ENSG00000261783.1	RP11-252K23.2	-6.64	8.93e-10	2.61e-06	-0.72	-0.51	Dupuytren's disease;	chr16:75385475	chr16:75379818~75381260:-
TGCT	cis	rs524281	0.861	rs10791856	ENSG00000255320.1	RP11-755F10.1	6.64	8.94e-10	2.61e-06	0.63	0.51	Electroencephalogram traits;	chr11:66197179	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.817	rs10896097	ENSG00000255320.1	RP11-755F10.1	6.64	8.94e-10	2.61e-06	0.63	0.51	Electroencephalogram traits;	chr11:66200482	chr11:66244840~66246239:-
TGCT	cis	rs17301013	0.606	rs6668008	ENSG00000227373.4	RP11-160H22.5	6.63	9.04e-10	2.64e-06	0.61	0.51	Systemic lupus erythematosus;	chr1:174138752	chr1:174115300~174160004:-
TGCT	cis	rs12908161	0.96	rs17599989	ENSG00000225151.9	GOLGA2P7	-6.63	9.15e-10	2.67e-06	-0.57	-0.51	Schizophrenia;	chr15:84742305	chr15:84199311~84230136:-
TGCT	cis	rs10875976	0.525	rs7137210	ENSG00000257253.2	RP11-70F11.7	6.63	9.16e-10	2.67e-06	0.46	0.51	Obesity;	chr12:49856660	chr12:49861207~49865802:+
TGCT	cis	rs7208859	0.673	rs75142521	ENSG00000263531.1	RP13-753N3.1	6.63	9.2e-10	2.68e-06	0.89	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30863921~30864940:-
TGCT	cis	rs7044106	0.664	rs7861679	ENSG00000226752.6	PSMD5-AS1	6.63	9.23e-10	2.69e-06	0.65	0.51	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120824828~120854385:+
TGCT	cis	rs2882667	0.898	rs6863347	ENSG00000253404.1	AC034243.1	6.63	9.24e-10	2.69e-06	0.53	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025446	chr5:138744434~138753309:-
TGCT	cis	rs189798	0.807	rs330905	ENSG00000254340.1	RP11-10A14.3	6.63	9.25e-10	2.7e-06	0.58	0.51	Myopia (pathological);	chr8:9136041	chr8:9141424~9145435:+
TGCT	cis	rs73086581	0.687	rs16989002	ENSG00000229539.1	RP11-119B16.2	6.63	9.25e-10	2.7e-06	0.78	0.51	Response to antidepressants in depression;	chr20:3870056	chr20:3888239~3888868:-
TGCT	cis	rs73086581	0.787	rs73084505	ENSG00000229539.1	RP11-119B16.2	6.63	9.25e-10	2.7e-06	0.78	0.51	Response to antidepressants in depression;	chr20:3876227	chr20:3888239~3888868:-
TGCT	cis	rs11098499	0.863	rs3822190	ENSG00000245958.5	RP11-33B1.1	-6.63	9.26e-10	2.7e-06	-0.55	-0.51	Corneal astigmatism;	chr4:119506943	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.863	rs3822191	ENSG00000245958.5	RP11-33B1.1	-6.63	9.26e-10	2.7e-06	-0.55	-0.51	Corneal astigmatism;	chr4:119506946	chr4:119454791~119552025:+
TGCT	cis	rs3096299	0.685	rs12446145	ENSG00000274627.1	RP11-104N10.2	6.63	9.37e-10	2.73e-06	0.51	0.51	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:89516797~89522217:+
TGCT	cis	rs524281	0.817	rs10791849	ENSG00000255320.1	RP11-755F10.1	6.63	9.38e-10	2.73e-06	0.66	0.51	Electroencephalogram traits;	chr11:66123126	chr11:66244840~66246239:-
TGCT	cis	rs7188445	1	rs16950982	ENSG00000261390.4	RP11-345M22.2	-6.63	9.44e-10	2.75e-06	-0.52	-0.51	Urate levels;	chr16:79668474	chr16:79715232~79770563:-
TGCT	cis	rs11673344	0.526	rs17303902	ENSG00000226686.6	LINC01535	6.63	9.44e-10	2.75e-06	0.59	0.51	Obesity-related traits;	chr19:37551912	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.526	rs55754546	ENSG00000226686.6	LINC01535	6.63	9.44e-10	2.75e-06	0.59	0.51	Obesity-related traits;	chr19:37552860	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.526	rs17244713	ENSG00000226686.6	LINC01535	6.63	9.44e-10	2.75e-06	0.59	0.51	Obesity-related traits;	chr19:37559938	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.526	rs17244769	ENSG00000226686.6	LINC01535	6.63	9.44e-10	2.75e-06	0.59	0.51	Obesity-related traits;	chr19:37562031	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.526	rs8111790	ENSG00000226686.6	LINC01535	6.63	9.44e-10	2.75e-06	0.59	0.51	Obesity-related traits;	chr19:37565861	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.526	rs8101610	ENSG00000226686.6	LINC01535	-6.63	9.44e-10	2.75e-06	-0.59	-0.51	Obesity-related traits;	chr19:37566604	chr19:37251912~37265535:+
TGCT	cis	rs10875976	0.525	rs7967564	ENSG00000257253.2	RP11-70F11.7	6.62	9.53e-10	2.77e-06	0.47	0.51	Obesity;	chr12:49855748	chr12:49861207~49865802:+
TGCT	cis	rs10875976	0.525	rs10783321	ENSG00000257253.2	RP11-70F11.7	6.62	9.53e-10	2.77e-06	0.47	0.51	Obesity;	chr12:49855820	chr12:49861207~49865802:+
TGCT	cis	rs10875976	0.545	rs7309919	ENSG00000257253.2	RP11-70F11.7	6.62	9.53e-10	2.77e-06	0.47	0.51	Obesity;	chr12:49857032	chr12:49861207~49865802:+
TGCT	cis	rs875971	0.862	rs10282433	ENSG00000222364.1	RNU6-96P	6.62	9.57e-10	2.78e-06	0.58	0.51	Aortic root size;	chr7:66256452	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs10276077	ENSG00000222364.1	RNU6-96P	6.62	9.57e-10	2.78e-06	0.58	0.51	Aortic root size;	chr7:66263424	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.825	rs4587224	ENSG00000222364.1	RNU6-96P	6.62	9.57e-10	2.78e-06	0.58	0.51	Aortic root size;	chr7:66271195	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.792	rs6971752	ENSG00000222364.1	RNU6-96P	6.62	9.57e-10	2.78e-06	0.58	0.51	Aortic root size;	chr7:66272999	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs10950033	ENSG00000222364.1	RNU6-96P	6.62	9.57e-10	2.78e-06	0.58	0.51	Aortic root size;	chr7:66274686	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs11760844	ENSG00000222364.1	RNU6-96P	6.62	9.57e-10	2.78e-06	0.58	0.51	Aortic root size;	chr7:66274896	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs4149461	ENSG00000222364.1	RNU6-96P	6.62	9.57e-10	2.78e-06	0.58	0.51	Aortic root size;	chr7:66279745	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs12537823	ENSG00000222364.1	RNU6-96P	-6.62	9.57e-10	2.78e-06	-0.58	-0.51	Aortic root size;	chr7:66255897	chr7:66395191~66395286:+
TGCT	cis	rs17301013	0.606	rs6656491	ENSG00000227373.4	RP11-160H22.5	6.62	9.57e-10	2.78e-06	0.61	0.51	Systemic lupus erythematosus;	chr1:174127524	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.581	rs72711457	ENSG00000227373.4	RP11-160H22.5	6.62	9.57e-10	2.78e-06	0.61	0.51	Systemic lupus erythematosus;	chr1:174135385	chr1:174115300~174160004:-
TGCT	cis	rs66887589	0.807	rs7694483	ENSG00000245958.5	RP11-33B1.1	-6.62	9.58e-10	2.78e-06	-0.5	-0.51	Diastolic blood pressure;	chr4:119484774	chr4:119454791~119552025:+
TGCT	cis	rs11098499	1	rs10029750	ENSG00000245958.5	RP11-33B1.1	-6.62	9.62e-10	2.79e-06	-0.52	-0.51	Corneal astigmatism;	chr4:119251388	chr4:119454791~119552025:+
TGCT	cis	rs1211375	0.606	rs1203977	ENSG00000268836.1	LA16c-OS12.2	-6.62	9.69e-10	2.81e-06	-0.49	-0.51	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:206279	chr16:185748~186294:-
TGCT	cis	rs16828019	0.64	rs1140227	ENSG00000235358.1	RP11-399E6.1	6.62	9.83e-10	2.85e-06	0.87	0.51	Intelligence (multi-trait analysis);	chr1:41028139	chr1:41242373~41284861:+
TGCT	cis	rs7617773	0.694	rs13099560	ENSG00000229759.1	MRPS18AP1	-6.62	9.84e-10	2.85e-06	-0.4	-0.51	Coronary artery disease;	chr3:48163278	chr3:48256350~48256938:-
TGCT	cis	rs17301013	0.606	rs12079689	ENSG00000227373.4	RP11-160H22.5	6.62	9.88e-10	2.86e-06	0.6	0.51	Systemic lupus erythematosus;	chr1:174240514	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs7535987	ENSG00000227373.4	RP11-160H22.5	6.62	9.88e-10	2.86e-06	0.6	0.51	Systemic lupus erythematosus;	chr1:174240840	chr1:174115300~174160004:-
TGCT	cis	rs11098499	0.955	rs1511018	ENSG00000245958.5	RP11-33B1.1	-6.62	9.93e-10	2.88e-06	-0.52	-0.51	Corneal astigmatism;	chr4:119240425	chr4:119454791~119552025:+
TGCT	cis	rs17507216	0.671	rs28582623	ENSG00000278603.1	RP13-608F4.5	6.62	9.94e-10	2.88e-06	0.87	0.51	Excessive daytime sleepiness;	chr15:82577381	chr15:82472203~82472426:+
TGCT	cis	rs6452524	0.904	rs10076056	ENSG00000249664.1	CTD-2227C6.2	-6.61	9.97e-10	2.89e-06	-0.54	-0.51	Hypertension (SNP x SNP interaction);	chr5:83161702	chr5:83012285~83013109:-
TGCT	cis	rs977987	0.843	rs11860231	ENSG00000261783.1	RP11-252K23.2	-6.61	1.02e-09	2.93e-06	-0.74	-0.51	Dupuytren's disease;	chr16:75351261	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs4888383	ENSG00000261783.1	RP11-252K23.2	-6.61	1.02e-09	2.93e-06	-0.74	-0.51	Dupuytren's disease;	chr16:75352451	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs8050769	ENSG00000261783.1	RP11-252K23.2	-6.61	1.02e-09	2.93e-06	-0.74	-0.51	Dupuytren's disease;	chr16:75354536	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs6564252	ENSG00000261783.1	RP11-252K23.2	-6.61	1.02e-09	2.93e-06	-0.74	-0.51	Dupuytren's disease;	chr16:75355042	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs2903033	ENSG00000261783.1	RP11-252K23.2	-6.61	1.02e-09	2.93e-06	-0.74	-0.51	Dupuytren's disease;	chr16:75355708	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.771	rs4888387	ENSG00000261783.1	RP11-252K23.2	-6.61	1.02e-09	2.93e-06	-0.74	-0.51	Dupuytren's disease;	chr16:75355857	chr16:75379818~75381260:-
TGCT	cis	rs875971	0.862	rs2901152	ENSG00000222364.1	RNU6-96P	6.61	1.02e-09	2.94e-06	0.57	0.51	Aortic root size;	chr7:66300017	chr7:66395191~66395286:+
TGCT	cis	rs4423214	0.65	rs2186777	ENSG00000254682.1	RP11-660L16.2	6.61	1.02e-09	2.94e-06	0.77	0.51	Vitamin D levels;	chr11:71508757	chr11:71448674~71452157:+
TGCT	cis	rs73086581	0.787	rs67633417	ENSG00000229539.1	RP11-119B16.2	6.61	1.03e-09	2.97e-06	0.77	0.51	Response to antidepressants in depression;	chr20:3887610	chr20:3888239~3888868:-
TGCT	cis	rs73086581	0.787	rs68127408	ENSG00000229539.1	RP11-119B16.2	6.61	1.03e-09	2.97e-06	0.77	0.51	Response to antidepressants in depression;	chr20:3887800	chr20:3888239~3888868:-
TGCT	cis	rs73086581	0.787	rs67724338	ENSG00000229539.1	RP11-119B16.2	6.61	1.03e-09	2.97e-06	0.77	0.51	Response to antidepressants in depression;	chr20:3888410	chr20:3888239~3888868:-
TGCT	cis	rs73086581	0.787	rs67202952	ENSG00000229539.1	RP11-119B16.2	6.61	1.03e-09	2.97e-06	0.77	0.51	Response to antidepressants in depression;	chr20:3888452	chr20:3888239~3888868:-
TGCT	cis	rs2739330	0.791	rs4822458	ENSG00000225282.1	AP000350.6	6.61	1.04e-09	2.98e-06	0.59	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23926900~23929574:+
TGCT	cis	rs1775715	0.737	rs2151047	ENSG00000239731.3	RN7SL825P	-6.61	1.04e-09	2.99e-06	-0.5	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr10:31813182	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.705	rs2778651	ENSG00000239731.3	RN7SL825P	-6.61	1.04e-09	2.99e-06	-0.5	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr10:31817647	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.737	rs2799015	ENSG00000239731.3	RN7SL825P	-6.61	1.04e-09	2.99e-06	-0.5	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr10:31818784	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.769	rs2808102	ENSG00000239731.3	RN7SL825P	-6.61	1.04e-09	2.99e-06	-0.5	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr10:31828821	chr10:31992087~31992381:-
TGCT	cis	rs977987	0.806	rs2161684	ENSG00000261783.1	RP11-252K23.2	-6.61	1.04e-09	3e-06	-0.74	-0.51	Dupuytren's disease;	chr16:75445255	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs34996006	ENSG00000261783.1	RP11-252K23.2	-6.61	1.04e-09	3e-06	-0.74	-0.51	Dupuytren's disease;	chr16:75445536	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.843	rs12927562	ENSG00000261783.1	RP11-252K23.2	-6.61	1.04e-09	3e-06	-0.74	-0.51	Dupuytren's disease;	chr16:75448962	chr16:75379818~75381260:-
TGCT	cis	rs11098499	0.955	rs13113112	ENSG00000245958.5	RP11-33B1.1	-6.61	1.05e-09	3.01e-06	-0.52	-0.51	Corneal astigmatism;	chr4:119234885	chr4:119454791~119552025:+
TGCT	cis	rs524281	0.861	rs3862386	ENSG00000255320.1	RP11-755F10.1	6.6	1.05e-09	3.02e-06	0.67	0.51	Electroencephalogram traits;	chr11:66126953	chr11:66244840~66246239:-
TGCT	cis	rs10875976	0.526	rs7307673	ENSG00000257253.2	RP11-70F11.7	6.6	1.05e-09	3.02e-06	0.48	0.51	Obesity;	chr12:49844421	chr12:49861207~49865802:+
TGCT	cis	rs6700559	0.873	rs7542210	ENSG00000260088.1	RP11-92G12.3	-6.6	1.05e-09	3.03e-06	-0.6	-0.51	Coronary artery disease;	chr1:200693087	chr1:200669507~200694250:+
TGCT	cis	rs9549367	0.789	rs3794422	ENSG00000269125.1	RP11-98F14.11	-6.6	1.06e-09	3.05e-06	-0.6	-0.51	Platelet distribution width;	chr13:113239415	chr13:113165002~113165183:-
TGCT	cis	rs11098499	0.955	rs1511019	ENSG00000245958.5	RP11-33B1.1	-6.6	1.06e-09	3.05e-06	-0.52	-0.51	Corneal astigmatism;	chr4:119244852	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.955	rs35434465	ENSG00000245958.5	RP11-33B1.1	-6.6	1.06e-09	3.05e-06	-0.52	-0.51	Corneal astigmatism;	chr4:119248223	chr4:119454791~119552025:+
TGCT	cis	rs875971	1	rs11974219	ENSG00000222364.1	RNU6-96P	6.6	1.06e-09	3.05e-06	0.59	0.51	Aortic root size;	chr7:66182423	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs11974264	ENSG00000222364.1	RNU6-96P	6.6	1.06e-09	3.05e-06	0.59	0.51	Aortic root size;	chr7:66182595	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs1540651	ENSG00000222364.1	RNU6-96P	6.6	1.06e-09	3.05e-06	0.59	0.51	Aortic root size;	chr7:66185134	chr7:66395191~66395286:+
TGCT	cis	rs524281	0.861	rs11227415	ENSG00000255320.1	RP11-755F10.1	-6.6	1.07e-09	3.06e-06	-0.64	-0.51	Electroencephalogram traits;	chr11:66117988	chr11:66244840~66246239:-
TGCT	cis	rs66887589	0.934	rs7681980	ENSG00000245958.5	RP11-33B1.1	6.6	1.07e-09	3.06e-06	0.5	0.51	Diastolic blood pressure;	chr4:119612068	chr4:119454791~119552025:+
TGCT	cis	rs66887589	0.87	rs59590064	ENSG00000245958.5	RP11-33B1.1	6.6	1.07e-09	3.06e-06	0.5	0.51	Diastolic blood pressure;	chr4:119618598	chr4:119454791~119552025:+
TGCT	cis	rs66887589	0.934	rs6817317	ENSG00000245958.5	RP11-33B1.1	6.6	1.07e-09	3.06e-06	0.5	0.51	Diastolic blood pressure;	chr4:119621672	chr4:119454791~119552025:+
TGCT	cis	rs66887589	0.934	rs7672519	ENSG00000245958.5	RP11-33B1.1	6.6	1.07e-09	3.06e-06	0.5	0.51	Diastolic blood pressure;	chr4:119622957	chr4:119454791~119552025:+
TGCT	cis	rs66887589	0.934	rs2389873	ENSG00000245958.5	RP11-33B1.1	6.6	1.07e-09	3.06e-06	0.5	0.51	Diastolic blood pressure;	chr4:119633559	chr4:119454791~119552025:+
TGCT	cis	rs66887589	0.934	rs4834792	ENSG00000245958.5	RP11-33B1.1	6.6	1.07e-09	3.06e-06	0.5	0.51	Diastolic blood pressure;	chr4:119634541	chr4:119454791~119552025:+
TGCT	cis	rs4889009	0.533	rs12596569	ENSG00000261390.4	RP11-345M22.2	6.6	1.07e-09	3.08e-06	0.49	0.51	Thyroid peroxidase antibody positivity;	chr16:79701354	chr16:79715232~79770563:-
TGCT	cis	rs977987	0.843	rs11149820	ENSG00000261783.1	RP11-252K23.2	-6.6	1.08e-09	3.09e-06	-0.72	-0.51	Dupuytren's disease;	chr16:75388862	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.843	rs10514396	ENSG00000261783.1	RP11-252K23.2	-6.6	1.08e-09	3.09e-06	-0.72	-0.51	Dupuytren's disease;	chr16:75389005	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs34021527	ENSG00000261783.1	RP11-252K23.2	-6.6	1.08e-09	3.09e-06	-0.73	-0.51	Dupuytren's disease;	chr16:75440192	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.751	rs56004344	ENSG00000261783.1	RP11-252K23.2	-6.6	1.08e-09	3.09e-06	-0.73	-0.51	Dupuytren's disease;	chr16:75440291	chr16:75379818~75381260:-
TGCT	cis	rs7714584	1	rs75294883	ENSG00000197083.10	ZNF300P1	6.6	1.08e-09	3.1e-06	0.99	0.51	Crohn's disease;	chr5:150816941	chr5:150930645~150946289:-
TGCT	cis	rs6904897	0.563	rs6569976	ENSG00000232876.1	CTA-212D2.2	-6.6	1.08e-09	3.11e-06	-0.46	-0.51	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903615	chr6:135055033~135060550:+
TGCT	cis	rs748404	0.66	rs690367	ENSG00000205771.5	CATSPER2P1	6.6	1.09e-09	3.11e-06	0.58	0.51	Lung cancer;	chr15:43456106	chr15:43726918~43747094:-
TGCT	cis	rs875971	1	rs55962648	ENSG00000222364.1	RNU6-96P	6.6	1.09e-09	3.12e-06	0.59	0.51	Aortic root size;	chr7:66160764	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs11971949	ENSG00000222364.1	RNU6-96P	6.6	1.09e-09	3.12e-06	0.59	0.51	Aortic root size;	chr7:66161027	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs2420168	ENSG00000222364.1	RNU6-96P	6.6	1.09e-09	3.12e-06	0.59	0.51	Aortic root size;	chr7:66165644	chr7:66395191~66395286:+
TGCT	cis	rs694739	1	rs694739	ENSG00000236935.1	AP003774.1	6.6	1.09e-09	3.12e-06	0.39	0.51	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64329761	chr11:64325050~64329504:-
TGCT	cis	rs7208859	0.673	rs73277964	ENSG00000263531.1	RP13-753N3.1	6.6	1.1e-09	3.14e-06	0.88	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs11652409	ENSG00000263531.1	RP13-753N3.1	6.6	1.1e-09	3.14e-06	0.88	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs9896095	ENSG00000263531.1	RP13-753N3.1	6.6	1.1e-09	3.14e-06	0.88	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.573	rs58920731	ENSG00000263531.1	RP13-753N3.1	6.6	1.1e-09	3.14e-06	0.88	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs73277984	ENSG00000263531.1	RP13-753N3.1	6.6	1.1e-09	3.14e-06	0.88	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs73277986	ENSG00000263531.1	RP13-753N3.1	6.6	1.1e-09	3.14e-06	0.88	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs12103588	ENSG00000263531.1	RP13-753N3.1	6.6	1.1e-09	3.14e-06	0.88	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.614	rs9914534	ENSG00000263531.1	RP13-753N3.1	6.6	1.1e-09	3.14e-06	0.88	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs4131618	ENSG00000263531.1	RP13-753N3.1	6.6	1.1e-09	3.14e-06	0.88	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs11658344	ENSG00000263531.1	RP13-753N3.1	6.6	1.1e-09	3.14e-06	0.88	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs9900144	ENSG00000263531.1	RP13-753N3.1	6.6	1.1e-09	3.14e-06	0.88	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.573	rs11656121	ENSG00000263531.1	RP13-753N3.1	6.6	1.1e-09	3.14e-06	0.88	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs11650973	ENSG00000263531.1	RP13-753N3.1	6.6	1.1e-09	3.14e-06	0.88	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs56085216	ENSG00000263531.1	RP13-753N3.1	6.6	1.1e-09	3.14e-06	0.88	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs11650305	ENSG00000263531.1	RP13-753N3.1	6.6	1.1e-09	3.14e-06	0.88	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs11654914	ENSG00000263531.1	RP13-753N3.1	6.6	1.1e-09	3.14e-06	0.88	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs9914271	ENSG00000263531.1	RP13-753N3.1	6.6	1.1e-09	3.14e-06	0.88	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs11656462	ENSG00000263531.1	RP13-753N3.1	6.6	1.1e-09	3.14e-06	0.88	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30863921~30864940:-
TGCT	cis	rs16828019	0.852	rs12022978	ENSG00000235358.1	RP11-399E6.1	6.59	1.1e-09	3.15e-06	0.88	0.51	Intelligence (multi-trait analysis);	chr1:41088416	chr1:41242373~41284861:+
TGCT	cis	rs7714584	1	rs59321715	ENSG00000197083.10	ZNF300P1	6.59	1.1e-09	3.15e-06	1	0.51	Crohn's disease;	chr5:150933918	chr5:150930645~150946289:-
TGCT	cis	rs7044106	0.708	rs991121	ENSG00000226752.6	PSMD5-AS1	-6.59	1.1e-09	3.15e-06	-0.64	-0.51	Hip circumference adjusted for BMI;	chr9:120608067	chr9:120824828~120854385:+
TGCT	cis	rs5760092	0.755	rs5760096	ENSG00000218537.1	MIF-AS1	6.59	1.11e-09	3.17e-06	0.69	0.51	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23905123	chr22:23894426~23898930:-
TGCT	cis	rs875971	0.862	rs7786892	ENSG00000222364.1	RNU6-96P	6.59	1.13e-09	3.23e-06	0.57	0.51	Aortic root size;	chr7:66163889	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs2420174	ENSG00000222364.1	RNU6-96P	6.59	1.13e-09	3.23e-06	0.57	0.51	Aortic root size;	chr7:66180374	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs2420173	ENSG00000222364.1	RNU6-96P	6.59	1.13e-09	3.23e-06	0.57	0.51	Aortic root size;	chr7:66180412	chr7:66395191~66395286:+
TGCT	cis	rs7829975	0.623	rs10087493	ENSG00000173295.6	FAM86B3P	-6.59	1.14e-09	3.25e-06	-0.61	-0.51	Mood instability;	chr8:8516047	chr8:8228595~8244865:+
TGCT	cis	rs7412746	0.658	rs10305711	ENSG00000206931.1	RNU6-1042P	6.59	1.14e-09	3.25e-06	0.4	0.51	Melanoma;	chr1:150830520	chr1:150701866~150701972:+
TGCT	cis	rs916888	0.647	rs199524	ENSG00000262500.1	RP11-259G18.2	-6.59	1.15e-09	3.25e-06	-0.66	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46243606~46245044:+
TGCT	cis	rs916888	0.647	rs199523	ENSG00000262500.1	RP11-259G18.2	-6.59	1.15e-09	3.25e-06	-0.66	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46243606~46245044:+
TGCT	cis	rs11098499	0.955	rs11944880	ENSG00000245958.5	RP11-33B1.1	6.58	1.16e-09	3.29e-06	0.51	0.51	Corneal astigmatism;	chr4:119238179	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.955	rs6815725	ENSG00000245958.5	RP11-33B1.1	-6.58	1.16e-09	3.29e-06	-0.51	-0.51	Corneal astigmatism;	chr4:119237255	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.955	rs1551	ENSG00000245958.5	RP11-33B1.1	-6.58	1.16e-09	3.29e-06	-0.51	-0.51	Corneal astigmatism;	chr4:119237345	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.955	rs11931312	ENSG00000245958.5	RP11-33B1.1	-6.58	1.16e-09	3.29e-06	-0.51	-0.51	Corneal astigmatism;	chr4:119237868	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.955	rs1397608	ENSG00000245958.5	RP11-33B1.1	-6.58	1.16e-09	3.29e-06	-0.51	-0.51	Corneal astigmatism;	chr4:119240589	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.955	rs7685268	ENSG00000245958.5	RP11-33B1.1	-6.58	1.16e-09	3.29e-06	-0.51	-0.51	Corneal astigmatism;	chr4:119241033	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.955	rs7684942	ENSG00000245958.5	RP11-33B1.1	-6.58	1.16e-09	3.29e-06	-0.51	-0.51	Corneal astigmatism;	chr4:119241046	chr4:119454791~119552025:+
TGCT	cis	rs6700559	0.654	rs2809345	ENSG00000260088.1	RP11-92G12.3	6.58	1.16e-09	3.29e-06	0.6	0.51	Coronary artery disease;	chr1:200627135	chr1:200669507~200694250:+
TGCT	cis	rs977987	0.836	rs7199062	ENSG00000261783.1	RP11-252K23.2	-6.58	1.16e-09	3.3e-06	-0.72	-0.51	Dupuytren's disease;	chr16:75440929	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.872	rs7206665	ENSG00000261783.1	RP11-252K23.2	-6.58	1.16e-09	3.3e-06	-0.72	-0.51	Dupuytren's disease;	chr16:75441389	chr16:75379818~75381260:-
TGCT	cis	rs12891047	0.899	rs10141589	ENSG00000258759.1	RP11-1012A1.7	-6.58	1.17e-09	3.32e-06	-0.46	-0.51	Amyotrophic lateral sclerosis (sporadic);	chr14:67844626	chr14:67799004~67799609:+
TGCT	cis	rs16828019	0.777	rs2300658	ENSG00000235358.1	RP11-399E6.1	6.58	1.18e-09	3.34e-06	0.87	0.51	Intelligence (multi-trait analysis);	chr1:41039350	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.852	rs12729448	ENSG00000235358.1	RP11-399E6.1	6.58	1.18e-09	3.34e-06	0.87	0.51	Intelligence (multi-trait analysis);	chr1:41044162	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.852	rs2268678	ENSG00000235358.1	RP11-399E6.1	6.58	1.18e-09	3.34e-06	0.87	0.51	Intelligence (multi-trait analysis);	chr1:41045381	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.852	rs10489520	ENSG00000235358.1	RP11-399E6.1	6.58	1.18e-09	3.34e-06	0.87	0.51	Intelligence (multi-trait analysis);	chr1:41046083	chr1:41242373~41284861:+
TGCT	cis	rs2882667	0.824	rs11748097	ENSG00000253404.1	AC034243.1	6.58	1.18e-09	3.34e-06	0.62	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144198	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.824	rs12173085	ENSG00000253404.1	AC034243.1	6.58	1.18e-09	3.34e-06	0.62	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144336	chr5:138744434~138753309:-
TGCT	cis	rs1930961	1	rs6004667	ENSG00000272977.1	CTA-390C10.10	6.58	1.18e-09	3.35e-06	0.68	0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25476218~25479971:+
TGCT	cis	rs16828019	0.777	rs16911	ENSG00000235358.1	RP11-399E6.1	6.58	1.2e-09	3.38e-06	0.87	0.51	Intelligence (multi-trait analysis);	chr1:41032349	chr1:41242373~41284861:+
TGCT	cis	rs1062177	0.855	rs1346489	ENSG00000253921.1	CTB-113P19.3	-6.58	1.2e-09	3.41e-06	-0.57	-0.51	Preschool internalizing problems;	chr5:151886973	chr5:151753992~151767247:+
TGCT	cis	rs17361889	0.778	rs6963052	ENSG00000224683.1	RPL36AP29	6.58	1.21e-09	3.43e-06	0.57	0.51	Pediatric bone mineral content (hip);	chr7:16171904	chr7:16208945~16209265:+
TGCT	cis	rs7617773	0.817	rs936427	ENSG00000229759.1	MRPS18AP1	-6.58	1.21e-09	3.43e-06	-0.43	-0.51	Coronary artery disease;	chr3:48259584	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.817	rs13068265	ENSG00000229759.1	MRPS18AP1	6.58	1.21e-09	3.43e-06	0.43	0.51	Coronary artery disease;	chr3:48260124	chr3:48256350~48256938:-
TGCT	cis	rs7757969	1	rs1022649	ENSG00000227012.2	RP1-97J1.2	6.57	1.22e-09	3.44e-06	0.78	0.51	Schizophrenia;	chr6:111798778	chr6:111900489~111901851:-
TGCT	cis	rs11098499	0.863	rs10019674	ENSG00000245958.5	RP11-33B1.1	6.57	1.22e-09	3.45e-06	0.55	0.51	Corneal astigmatism;	chr4:119522334	chr4:119454791~119552025:+
TGCT	cis	rs6452524	0.935	rs2386241	ENSG00000249664.1	CTD-2227C6.2	-6.57	1.23e-09	3.47e-06	-0.57	-0.51	Hypertension (SNP x SNP interaction);	chr5:83149872	chr5:83012285~83013109:-
TGCT	cis	rs1775715	0.737	rs2799000	ENSG00000239731.3	RN7SL825P	-6.57	1.23e-09	3.48e-06	-0.5	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr10:31835966	chr10:31992087~31992381:-
TGCT	cis	rs11098499	0.913	rs11098496	ENSG00000245958.5	RP11-33B1.1	-6.57	1.24e-09	3.5e-06	-0.51	-0.51	Corneal astigmatism;	chr4:119246311	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.955	rs35197422	ENSG00000245958.5	RP11-33B1.1	-6.57	1.24e-09	3.5e-06	-0.51	-0.51	Corneal astigmatism;	chr4:119248159	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.955	rs1511015	ENSG00000245958.5	RP11-33B1.1	-6.57	1.24e-09	3.5e-06	-0.51	-0.51	Corneal astigmatism;	chr4:119249318	chr4:119454791~119552025:+
TGCT	cis	rs748404	0.66	rs690446	ENSG00000205771.5	CATSPER2P1	-6.57	1.24e-09	3.5e-06	-0.57	-0.51	Lung cancer;	chr15:43469066	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.66	rs518288	ENSG00000205771.5	CATSPER2P1	-6.57	1.24e-09	3.5e-06	-0.57	-0.51	Lung cancer;	chr15:43471801	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.66	rs690472	ENSG00000205771.5	CATSPER2P1	-6.57	1.24e-09	3.5e-06	-0.57	-0.51	Lung cancer;	chr15:43472170	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.631	rs560191	ENSG00000205771.5	CATSPER2P1	-6.57	1.24e-09	3.5e-06	-0.57	-0.51	Lung cancer;	chr15:43475576	chr15:43726918~43747094:-
TGCT	cis	rs9549367	0.789	rs9549708	ENSG00000269125.1	RP11-98F14.11	-6.57	1.24e-09	3.5e-06	-0.59	-0.51	Platelet distribution width;	chr13:113237573	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.789	rs34568744	ENSG00000269125.1	RP11-98F14.11	-6.57	1.24e-09	3.5e-06	-0.59	-0.51	Platelet distribution width;	chr13:113240250	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.789	rs57747440	ENSG00000269125.1	RP11-98F14.11	-6.57	1.24e-09	3.5e-06	-0.59	-0.51	Platelet distribution width;	chr13:113240436	chr13:113165002~113165183:-
TGCT	cis	rs11098499	0.913	rs10010696	ENSG00000245958.5	RP11-33B1.1	-6.57	1.25e-09	3.51e-06	-0.51	-0.51	Corneal astigmatism;	chr4:119243148	chr4:119454791~119552025:+
TGCT	cis	rs7044106	0.791	rs10985004	ENSG00000226752.6	PSMD5-AS1	-6.57	1.25e-09	3.51e-06	-0.64	-0.51	Hip circumference adjusted for BMI;	chr9:120722659	chr9:120824828~120854385:+
TGCT	cis	rs1062177	0.694	rs2915816	ENSG00000213433.5	RPLP1P6	6.57	1.25e-09	3.52e-06	0.54	0.51	Preschool internalizing problems;	chr5:151736296	chr5:151765859~151766378:-
TGCT	cis	rs17507216	0.588	rs4778687	ENSG00000278603.1	RP13-608F4.5	6.57	1.26e-09	3.54e-06	0.85	0.51	Excessive daytime sleepiness;	chr15:82649085	chr15:82472203~82472426:+
TGCT	cis	rs16828019	0.852	rs12406620	ENSG00000235358.1	RP11-399E6.1	6.57	1.26e-09	3.54e-06	0.87	0.51	Intelligence (multi-trait analysis);	chr1:41046992	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.852	rs12729586	ENSG00000235358.1	RP11-399E6.1	6.57	1.26e-09	3.54e-06	0.87	0.51	Intelligence (multi-trait analysis);	chr1:41056705	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.704	rs34486565	ENSG00000235358.1	RP11-399E6.1	6.57	1.26e-09	3.54e-06	0.87	0.51	Intelligence (multi-trait analysis);	chr1:41056838	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.852	rs12742379	ENSG00000235358.1	RP11-399E6.1	6.57	1.26e-09	3.54e-06	0.87	0.51	Intelligence (multi-trait analysis);	chr1:41060709	chr1:41242373~41284861:+
TGCT	cis	rs875971	0.825	rs6951503	ENSG00000222364.1	RNU6-96P	6.57	1.26e-09	3.55e-06	0.58	0.51	Aortic root size;	chr7:66253949	chr7:66395191~66395286:+
TGCT	cis	rs977987	0.836	rs7200053	ENSG00000261783.1	RP11-252K23.2	-6.57	1.26e-09	3.55e-06	-0.72	-0.51	Dupuytren's disease;	chr16:75440720	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs7204984	ENSG00000261783.1	RP11-252K23.2	-6.57	1.26e-09	3.55e-06	-0.72	-0.51	Dupuytren's disease;	chr16:75441622	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.778	rs35214308	ENSG00000261783.1	RP11-252K23.2	-6.57	1.26e-09	3.55e-06	-0.72	-0.51	Dupuytren's disease;	chr16:75442190	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.778	rs4888426	ENSG00000261783.1	RP11-252K23.2	-6.57	1.26e-09	3.55e-06	-0.72	-0.51	Dupuytren's disease;	chr16:75442553	chr16:75379818~75381260:-
TGCT	cis	rs9549367	0.789	rs9549705	ENSG00000269125.1	RP11-98F14.11	-6.57	1.26e-09	3.55e-06	-0.59	-0.51	Platelet distribution width;	chr13:113234111	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.774	rs2287246	ENSG00000269125.1	RP11-98F14.11	-6.57	1.26e-09	3.55e-06	-0.59	-0.51	Platelet distribution width;	chr13:113234813	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.789	rs2287247	ENSG00000269125.1	RP11-98F14.11	-6.57	1.26e-09	3.55e-06	-0.59	-0.51	Platelet distribution width;	chr13:113234898	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.789	rs2287248	ENSG00000269125.1	RP11-98F14.11	-6.57	1.26e-09	3.55e-06	-0.59	-0.51	Platelet distribution width;	chr13:113234912	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.826	rs2287249	ENSG00000269125.1	RP11-98F14.11	-6.57	1.26e-09	3.55e-06	-0.59	-0.51	Platelet distribution width;	chr13:113235041	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.789	rs2287251	ENSG00000269125.1	RP11-98F14.11	-6.57	1.26e-09	3.55e-06	-0.59	-0.51	Platelet distribution width;	chr13:113235185	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.756	rs2316463	ENSG00000269125.1	RP11-98F14.11	-6.57	1.27e-09	3.57e-06	-0.59	-0.51	Platelet distribution width;	chr13:113247092	chr13:113165002~113165183:-
TGCT	cis	rs7714584	1	rs11739677	ENSG00000197083.10	ZNF300P1	6.57	1.27e-09	3.58e-06	0.95	0.51	Crohn's disease;	chr5:150915321	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs11747065	ENSG00000197083.10	ZNF300P1	6.57	1.27e-09	3.58e-06	0.95	0.51	Crohn's disease;	chr5:150915924	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs11740172	ENSG00000197083.10	ZNF300P1	6.57	1.27e-09	3.58e-06	0.95	0.51	Crohn's disease;	chr5:150920716	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs11746807	ENSG00000197083.10	ZNF300P1	6.57	1.27e-09	3.58e-06	0.95	0.51	Crohn's disease;	chr5:150920857	chr5:150930645~150946289:-
TGCT	cis	rs189798	0.738	rs330908	ENSG00000254340.1	RP11-10A14.3	6.57	1.27e-09	3.58e-06	0.57	0.51	Myopia (pathological);	chr8:9137656	chr8:9141424~9145435:+
TGCT	cis	rs9549367	0.662	rs3818334	ENSG00000269125.1	RP11-98F14.11	-6.57	1.27e-09	3.59e-06	-0.63	-0.51	Platelet distribution width;	chr13:113170860	chr13:113165002~113165183:-
TGCT	cis	rs7412746	0.658	rs17660092	ENSG00000206931.1	RNU6-1042P	6.56	1.28e-09	3.6e-06	0.4	0.51	Melanoma;	chr1:150825272	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs2089082	ENSG00000206931.1	RNU6-1042P	6.56	1.28e-09	3.6e-06	0.4	0.51	Melanoma;	chr1:150827614	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs10305704	ENSG00000206931.1	RNU6-1042P	6.56	1.28e-09	3.6e-06	0.4	0.51	Melanoma;	chr1:150831953	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs3768016	ENSG00000206931.1	RNU6-1042P	6.56	1.28e-09	3.6e-06	0.4	0.51	Melanoma;	chr1:150837443	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs1027699	ENSG00000206931.1	RNU6-1042P	6.56	1.28e-09	3.6e-06	0.4	0.51	Melanoma;	chr1:150839236	chr1:150701866~150701972:+
TGCT	cis	rs2882667	1	rs10064130	ENSG00000253404.1	AC034243.1	6.56	1.29e-09	3.63e-06	0.6	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973618	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.931	rs7706391	ENSG00000253404.1	AC034243.1	6.56	1.29e-09	3.63e-06	0.58	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139013475	chr5:138744434~138753309:-
TGCT	cis	rs943437	0.866	rs7356805	ENSG00000227012.2	RP1-97J1.2	-6.56	1.3e-09	3.65e-06	-0.78	-0.51	Parkinson's disease;	chr6:111945144	chr6:111900489~111901851:-
TGCT	cis	rs9549367	0.713	rs3024764	ENSG00000269125.1	RP11-98F14.11	-6.56	1.3e-09	3.66e-06	-0.61	-0.51	Platelet distribution width;	chr13:113170000	chr13:113165002~113165183:-
TGCT	cis	rs66887589	1	rs66887589	ENSG00000245958.5	RP11-33B1.1	6.56	1.31e-09	3.67e-06	0.51	0.51	Diastolic blood pressure;	chr4:119588124	chr4:119454791~119552025:+
TGCT	cis	rs6452524	0.839	rs28745307	ENSG00000249664.1	CTD-2227C6.2	6.56	1.33e-09	3.73e-06	0.55	0.51	Hypertension (SNP x SNP interaction);	chr5:83122099	chr5:83012285~83013109:-
TGCT	cis	rs7829975	0.624	rs7823056	ENSG00000173295.6	FAM86B3P	6.56	1.33e-09	3.73e-06	0.61	0.51	Mood instability;	chr8:8525195	chr8:8228595~8244865:+
TGCT	cis	rs7412746	0.658	rs897815	ENSG00000206931.1	RNU6-1042P	-6.55	1.37e-09	3.82e-06	-0.4	-0.51	Melanoma;	chr1:150906625	chr1:150701866~150701972:+
TGCT	cis	rs748404	0.646	rs2253268	ENSG00000205771.5	CATSPER2P1	-6.55	1.37e-09	3.83e-06	-0.58	-0.51	Lung cancer;	chr15:43508770	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.588	rs506120	ENSG00000205771.5	CATSPER2P1	-6.55	1.37e-09	3.83e-06	-0.58	-0.51	Lung cancer;	chr15:43509826	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.56	rs1869258	ENSG00000205771.5	CATSPER2P1	-6.55	1.37e-09	3.83e-06	-0.58	-0.51	Lung cancer;	chr15:43511423	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.56	rs529611	ENSG00000205771.5	CATSPER2P1	-6.55	1.37e-09	3.83e-06	-0.58	-0.51	Lung cancer;	chr15:43513790	chr15:43726918~43747094:-
TGCT	cis	rs950169	0.58	rs11636189	ENSG00000225151.9	GOLGA2P7	-6.55	1.37e-09	3.83e-06	-0.57	-0.51	Schizophrenia;	chr15:84650323	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.58	rs35516100	ENSG00000225151.9	GOLGA2P7	-6.55	1.37e-09	3.83e-06	-0.57	-0.51	Schizophrenia;	chr15:84652199	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.58	rs62021208	ENSG00000225151.9	GOLGA2P7	-6.55	1.37e-09	3.83e-06	-0.57	-0.51	Schizophrenia;	chr15:84653013	chr15:84199311~84230136:-
TGCT	cis	rs694739	1	rs499425	ENSG00000236935.1	AP003774.1	-6.55	1.38e-09	3.85e-06	-0.39	-0.51	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338457	chr11:64325050~64329504:-
TGCT	cis	rs977987	0.806	rs11862095	ENSG00000261783.1	RP11-252K23.2	-6.55	1.38e-09	3.86e-06	-0.73	-0.51	Dupuytren's disease;	chr16:75351520	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs4888386	ENSG00000261783.1	RP11-252K23.2	-6.55	1.38e-09	3.86e-06	-0.73	-0.51	Dupuytren's disease;	chr16:75355842	chr16:75379818~75381260:-
TGCT	cis	rs2882667	0.858	rs17207870	ENSG00000253404.1	AC034243.1	6.55	1.39e-09	3.87e-06	0.61	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139052048	chr5:138744434~138753309:-
TGCT	cis	rs977987	0.806	rs4888425	ENSG00000261783.1	RP11-252K23.2	-6.55	1.39e-09	3.87e-06	-0.72	-0.51	Dupuytren's disease;	chr16:75442465	chr16:75379818~75381260:-
TGCT	cis	rs875971	0.862	rs6460302	ENSG00000222364.1	RNU6-96P	-6.55	1.39e-09	3.88e-06	-0.58	-0.51	Aortic root size;	chr7:66495270	chr7:66395191~66395286:+
TGCT	cis	rs172166	0.637	rs1233708	ENSG00000216901.1	AL022393.7	6.55	1.4e-09	3.89e-06	0.6	0.51	Cardiac Troponin-T levels;	chr6:28205441	chr6:28176188~28176674:+
TGCT	cis	rs17507216	0.588	rs28864981	ENSG00000278603.1	RP13-608F4.5	6.55	1.4e-09	3.89e-06	0.85	0.51	Excessive daytime sleepiness;	chr15:82695420	chr15:82472203~82472426:+
TGCT	cis	rs17507216	0.628	rs8032321	ENSG00000278603.1	RP13-608F4.5	6.55	1.4e-09	3.89e-06	0.85	0.51	Excessive daytime sleepiness;	chr15:82698956	chr15:82472203~82472426:+
TGCT	cis	rs17507216	0.628	rs8040488	ENSG00000278603.1	RP13-608F4.5	6.55	1.4e-09	3.89e-06	0.85	0.51	Excessive daytime sleepiness;	chr15:82699081	chr15:82472203~82472426:+
TGCT	cis	rs17507216	0.628	rs4627310	ENSG00000278603.1	RP13-608F4.5	6.55	1.4e-09	3.89e-06	0.85	0.51	Excessive daytime sleepiness;	chr15:82708330	chr15:82472203~82472426:+
TGCT	cis	rs17507216	0.628	rs28371837	ENSG00000278603.1	RP13-608F4.5	6.55	1.4e-09	3.89e-06	0.85	0.51	Excessive daytime sleepiness;	chr15:82714435	chr15:82472203~82472426:+
TGCT	cis	rs11098499	0.863	rs6534139	ENSG00000245958.5	RP11-33B1.1	6.55	1.4e-09	3.9e-06	0.56	0.51	Corneal astigmatism;	chr4:119528301	chr4:119454791~119552025:+
TGCT	cis	rs2739330	0.731	rs5751792	ENSG00000218537.1	MIF-AS1	6.55	1.41e-09	3.91e-06	0.62	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23894426~23898930:-
TGCT	cis	rs3814244	0.902	rs2870961	ENSG00000255733.4	IFNG-AS1	-6.55	1.41e-09	3.92e-06	-0.47	-0.51	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024262	chr12:67989445~68234686:+
TGCT	cis	rs3814244	0.933	rs10748093	ENSG00000255733.4	IFNG-AS1	-6.55	1.41e-09	3.92e-06	-0.47	-0.51	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024469	chr12:67989445~68234686:+
TGCT	cis	rs3814244	0.933	rs11610126	ENSG00000255733.4	IFNG-AS1	-6.55	1.41e-09	3.92e-06	-0.47	-0.51	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026493	chr12:67989445~68234686:+
TGCT	cis	rs12908161	1	rs12905057	ENSG00000225151.9	GOLGA2P7	-6.55	1.41e-09	3.92e-06	-0.59	-0.51	Schizophrenia;	chr15:84667534	chr15:84199311~84230136:-
TGCT	cis	rs7044106	0.708	rs959558	ENSG00000226752.6	PSMD5-AS1	-6.54	1.41e-09	3.93e-06	-0.64	-0.51	Hip circumference adjusted for BMI;	chr9:120606633	chr9:120824828~120854385:+
TGCT	cis	rs12908161	1	rs12908161	ENSG00000225151.9	GOLGA2P7	-6.54	1.42e-09	3.95e-06	-0.58	-0.51	Schizophrenia;	chr15:84664594	chr15:84199311~84230136:-
TGCT	cis	rs12908161	0.96	rs34452033	ENSG00000225151.9	GOLGA2P7	-6.54	1.42e-09	3.95e-06	-0.58	-0.51	Schizophrenia;	chr15:84678762	chr15:84199311~84230136:-
TGCT	cis	rs12908161	1	rs11638290	ENSG00000225151.9	GOLGA2P7	-6.54	1.42e-09	3.95e-06	-0.58	-0.51	Schizophrenia;	chr15:84684405	chr15:84199311~84230136:-
TGCT	cis	rs12908161	0.959	rs34028043	ENSG00000225151.9	GOLGA2P7	-6.54	1.42e-09	3.95e-06	-0.58	-0.51	Schizophrenia;	chr15:84688354	chr15:84199311~84230136:-
TGCT	cis	rs12908161	0.959	rs34784022	ENSG00000225151.9	GOLGA2P7	-6.54	1.42e-09	3.95e-06	-0.58	-0.51	Schizophrenia;	chr15:84688675	chr15:84199311~84230136:-
TGCT	cis	rs12908161	1	rs12911736	ENSG00000225151.9	GOLGA2P7	-6.54	1.42e-09	3.95e-06	-0.58	-0.51	Schizophrenia;	chr15:84696777	chr15:84199311~84230136:-
TGCT	cis	rs12908161	0.959	rs12908699	ENSG00000225151.9	GOLGA2P7	-6.54	1.42e-09	3.95e-06	-0.58	-0.51	Schizophrenia;	chr15:84697172	chr15:84199311~84230136:-
TGCT	cis	rs17301013	0.606	rs4650939	ENSG00000227373.4	RP11-160H22.5	6.54	1.43e-09	3.97e-06	0.6	0.51	Systemic lupus erythematosus;	chr1:174096823	chr1:174115300~174160004:-
TGCT	cis	rs875971	0.965	rs7794930	ENSG00000222364.1	RNU6-96P	6.54	1.44e-09	4e-06	0.59	0.51	Aortic root size;	chr7:66313559	chr7:66395191~66395286:+
TGCT	cis	rs5769707	0.542	rs739242	ENSG00000188511.11	C22orf34	6.54	1.45e-09	4.04e-06	0.57	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49663468	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.521	rs7285764	ENSG00000188511.11	C22orf34	6.54	1.45e-09	4.04e-06	0.57	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49664913	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.521	rs9616715	ENSG00000188511.11	C22orf34	6.54	1.45e-09	4.04e-06	0.57	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49664934	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.521	rs6009805	ENSG00000188511.11	C22orf34	6.54	1.45e-09	4.04e-06	0.57	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49665067	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.521	rs6009807	ENSG00000188511.11	C22orf34	6.54	1.45e-09	4.04e-06	0.57	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49665274	chr22:49414524~49657542:-
TGCT	cis	rs16828019	0.777	rs12023079	ENSG00000235358.1	RP11-399E6.1	6.54	1.46e-09	4.05e-06	0.85	0.51	Intelligence (multi-trait analysis);	chr1:41004439	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.789	rs36084778	ENSG00000235358.1	RP11-399E6.1	6.54	1.46e-09	4.05e-06	0.85	0.51	Intelligence (multi-trait analysis);	chr1:41013866	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.777	rs11209363	ENSG00000235358.1	RP11-399E6.1	6.54	1.46e-09	4.05e-06	0.85	0.51	Intelligence (multi-trait analysis);	chr1:41019405	chr1:41242373~41284861:+
TGCT	cis	rs875971	0.862	rs1875057	ENSG00000222364.1	RNU6-96P	6.54	1.47e-09	4.08e-06	0.57	0.51	Aortic root size;	chr7:66266868	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs6960446	ENSG00000222364.1	RNU6-96P	6.54	1.47e-09	4.08e-06	0.57	0.51	Aortic root size;	chr7:66268272	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.789	rs10260426	ENSG00000222364.1	RNU6-96P	6.54	1.47e-09	4.08e-06	0.57	0.51	Aortic root size;	chr7:66271055	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs7796162	ENSG00000222364.1	RNU6-96P	6.54	1.47e-09	4.08e-06	0.57	0.51	Aortic root size;	chr7:66280771	chr7:66395191~66395286:+
TGCT	cis	rs17301013	0.507	rs2142864	ENSG00000227373.4	RP11-160H22.5	6.54	1.48e-09	4.1e-06	0.58	0.51	Systemic lupus erythematosus;	chr1:174304924	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs2860909	ENSG00000227373.4	RP11-160H22.5	6.54	1.48e-09	4.1e-06	0.58	0.51	Systemic lupus erythematosus;	chr1:174305211	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs6700482	ENSG00000227373.4	RP11-160H22.5	6.54	1.48e-09	4.1e-06	0.58	0.51	Systemic lupus erythematosus;	chr1:174306699	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs7553317	ENSG00000227373.4	RP11-160H22.5	6.54	1.48e-09	4.1e-06	0.58	0.51	Systemic lupus erythematosus;	chr1:174307182	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs10912759	ENSG00000227373.4	RP11-160H22.5	6.54	1.48e-09	4.1e-06	0.58	0.51	Systemic lupus erythematosus;	chr1:174312178	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs6425278	ENSG00000227373.4	RP11-160H22.5	6.54	1.48e-09	4.1e-06	0.58	0.51	Systemic lupus erythematosus;	chr1:174313148	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12083548	ENSG00000227373.4	RP11-160H22.5	6.54	1.48e-09	4.1e-06	0.58	0.51	Systemic lupus erythematosus;	chr1:174319134	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12083814	ENSG00000227373.4	RP11-160H22.5	6.54	1.48e-09	4.1e-06	0.58	0.51	Systemic lupus erythematosus;	chr1:174319917	chr1:174115300~174160004:-
TGCT	cis	rs9326248	0.52	rs236919	ENSG00000254851.1	RP11-109L13.1	-6.54	1.48e-09	4.1e-06	-0.61	-0.51	Blood protein levels;	chr11:117224645	chr11:117135528~117138582:+
TGCT	cis	rs950169	0.544	rs62021193	ENSG00000225151.9	GOLGA2P7	-6.54	1.48e-09	4.1e-06	-0.58	-0.51	Schizophrenia;	chr15:84627352	chr15:84199311~84230136:-
TGCT	cis	rs11098499	0.955	rs4145951	ENSG00000245958.5	RP11-33B1.1	-6.53	1.5e-09	4.14e-06	-0.51	-0.51	Corneal astigmatism;	chr4:119234662	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.955	rs35916640	ENSG00000245958.5	RP11-33B1.1	-6.53	1.5e-09	4.14e-06	-0.51	-0.51	Corneal astigmatism;	chr4:119234697	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.955	rs13114751	ENSG00000245958.5	RP11-33B1.1	-6.53	1.5e-09	4.14e-06	-0.51	-0.51	Corneal astigmatism;	chr4:119235462	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.913	rs35271032	ENSG00000245958.5	RP11-33B1.1	-6.53	1.5e-09	4.14e-06	-0.51	-0.51	Corneal astigmatism;	chr4:119235504	chr4:119454791~119552025:+
TGCT	cis	rs12908161	1	rs12903134	ENSG00000225151.9	GOLGA2P7	-6.53	1.5e-09	4.14e-06	-0.57	-0.51	Schizophrenia;	chr15:84794468	chr15:84199311~84230136:-
TGCT	cis	rs12908161	1	rs35726233	ENSG00000225151.9	GOLGA2P7	-6.53	1.5e-09	4.14e-06	-0.57	-0.51	Schizophrenia;	chr15:84794569	chr15:84199311~84230136:-
TGCT	cis	rs12908161	1	rs35960805	ENSG00000225151.9	GOLGA2P7	-6.53	1.5e-09	4.14e-06	-0.57	-0.51	Schizophrenia;	chr15:84800749	chr15:84199311~84230136:-
TGCT	cis	rs12908161	1	rs12912388	ENSG00000225151.9	GOLGA2P7	-6.53	1.5e-09	4.14e-06	-0.57	-0.51	Schizophrenia;	chr15:84801319	chr15:84199311~84230136:-
TGCT	cis	rs12908161	1	rs35630683	ENSG00000225151.9	GOLGA2P7	-6.53	1.5e-09	4.14e-06	-0.57	-0.51	Schizophrenia;	chr15:84806000	chr15:84199311~84230136:-
TGCT	cis	rs11098499	0.566	rs17051356	ENSG00000245958.5	RP11-33B1.1	-6.53	1.5e-09	4.15e-06	-0.55	-0.51	Corneal astigmatism;	chr4:119664153	chr4:119454791~119552025:+
TGCT	cis	rs1211375	0.607	rs1203978	ENSG00000268836.1	LA16c-OS12.2	-6.53	1.51e-09	4.16e-06	-0.48	-0.51	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:207212	chr16:185748~186294:-
TGCT	cis	rs7829975	0.688	rs6995407	ENSG00000173295.6	FAM86B3P	6.53	1.52e-09	4.21e-06	0.62	0.51	Mood instability;	chr8:8527137	chr8:8228595~8244865:+
TGCT	cis	rs12908161	0.92	rs35738019	ENSG00000225151.9	GOLGA2P7	-6.53	1.54e-09	4.26e-06	-0.58	-0.51	Schizophrenia;	chr15:84736979	chr15:84199311~84230136:-
TGCT	cis	rs12908161	1	rs34570071	ENSG00000225151.9	GOLGA2P7	-6.53	1.54e-09	4.26e-06	-0.58	-0.51	Schizophrenia;	chr15:84736981	chr15:84199311~84230136:-
TGCT	cis	rs6452524	0.507	rs28592576	ENSG00000249664.1	CTD-2227C6.2	6.53	1.54e-09	4.26e-06	0.56	0.51	Hypertension (SNP x SNP interaction);	chr5:83074772	chr5:83012285~83013109:-
TGCT	cis	rs73086581	1	rs3746665	ENSG00000229539.1	RP11-119B16.2	-6.53	1.55e-09	4.27e-06	-0.71	-0.51	Response to antidepressants in depression;	chr20:3929759	chr20:3888239~3888868:-
TGCT	cis	rs16828019	0.777	rs13376450	ENSG00000235358.1	RP11-399E6.1	6.53	1.56e-09	4.29e-06	0.85	0.51	Intelligence (multi-trait analysis);	chr1:41003371	chr1:41242373~41284861:+
TGCT	cis	rs9549367	0.789	rs34448227	ENSG00000269125.1	RP11-98F14.11	-6.53	1.56e-09	4.3e-06	-0.59	-0.51	Platelet distribution width;	chr13:113230440	chr13:113165002~113165183:-
TGCT	cis	rs1528149	0.856	rs6952865	ENSG00000224683.1	RPL36AP29	6.53	1.56e-09	4.3e-06	0.62	0.51	Sitting height ratio;	chr7:16082239	chr7:16208945~16209265:+
TGCT	cis	rs2134046	0.555	rs11854483	ENSG00000278603.1	RP13-608F4.5	6.52	1.56e-09	4.31e-06	0.65	0.51	Cognitive ability;	chr15:82267217	chr15:82472203~82472426:+
TGCT	cis	rs7829975	0.623	rs10092965	ENSG00000173295.6	FAM86B3P	6.52	1.57e-09	4.33e-06	0.61	0.51	Mood instability;	chr8:8515975	chr8:8228595~8244865:+
TGCT	cis	rs7829975	0.623	rs7010753	ENSG00000173295.6	FAM86B3P	6.52	1.57e-09	4.33e-06	0.61	0.51	Mood instability;	chr8:8516446	chr8:8228595~8244865:+
TGCT	cis	rs5769707	0.681	rs9616329	ENSG00000188511.11	C22orf34	6.52	1.58e-09	4.35e-06	0.55	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49632666	chr22:49414524~49657542:-
TGCT	cis	rs9549367	0.789	rs7338235	ENSG00000269125.1	RP11-98F14.11	-6.52	1.59e-09	4.38e-06	-0.58	-0.51	Platelet distribution width;	chr13:113234373	chr13:113165002~113165183:-
TGCT	cis	rs6452524	0.904	rs10473867	ENSG00000249664.1	CTD-2227C6.2	6.52	1.59e-09	4.39e-06	0.54	0.51	Hypertension (SNP x SNP interaction);	chr5:83141613	chr5:83012285~83013109:-
TGCT	cis	rs875971	0.862	rs4368860	ENSG00000222364.1	RNU6-96P	6.52	1.6e-09	4.39e-06	0.57	0.51	Aortic root size;	chr7:66143495	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs1983372	ENSG00000222364.1	RNU6-96P	6.52	1.6e-09	4.39e-06	0.57	0.51	Aortic root size;	chr7:66146364	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs908915	ENSG00000222364.1	RNU6-96P	6.52	1.6e-09	4.39e-06	0.57	0.51	Aortic root size;	chr7:66149664	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs7809814	ENSG00000222364.1	RNU6-96P	6.52	1.6e-09	4.39e-06	0.57	0.51	Aortic root size;	chr7:66150410	chr7:66395191~66395286:+
TGCT	cis	rs7044106	0.734	rs12553070	ENSG00000226752.6	PSMD5-AS1	-6.52	1.6e-09	4.39e-06	-0.63	-0.51	Hip circumference adjusted for BMI;	chr9:120722988	chr9:120824828~120854385:+
TGCT	cis	rs524281	0.861	rs9645684	ENSG00000255320.1	RP11-755F10.1	6.52	1.6e-09	4.39e-06	0.63	0.51	Electroencephalogram traits;	chr11:66140493	chr11:66244840~66246239:-
TGCT	cis	rs9326248	0.53	rs11216316	ENSG00000254851.1	RP11-109L13.1	6.52	1.6e-09	4.4e-06	0.99	0.51	Blood protein levels;	chr11:117210784	chr11:117135528~117138582:+
TGCT	cis	rs7174755	0.772	rs75395345	ENSG00000260657.2	RP11-315D16.4	6.52	1.6e-09	4.4e-06	0.56	0.51	Major depressive disorder;	chr15:68081380	chr15:68267792~68277994:-
TGCT	cis	rs694739	0.93	rs574087	ENSG00000236935.1	AP003774.1	6.52	1.61e-09	4.41e-06	0.39	0.51	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64335476	chr11:64325050~64329504:-
TGCT	cis	rs9399135	0.66	rs4472368	ENSG00000232876.1	CTA-212D2.2	-6.52	1.61e-09	4.42e-06	-0.47	-0.51	Red blood cell count;	chr6:134953094	chr6:135055033~135060550:+
TGCT	cis	rs12891047	0.899	rs8018709	ENSG00000258759.1	RP11-1012A1.7	-6.52	1.61e-09	4.42e-06	-0.45	-0.51	Amyotrophic lateral sclerosis (sporadic);	chr14:67821166	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.899	rs28604984	ENSG00000258759.1	RP11-1012A1.7	-6.52	1.61e-09	4.42e-06	-0.45	-0.51	Amyotrophic lateral sclerosis (sporadic);	chr14:67823709	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.899	rs28623567	ENSG00000258759.1	RP11-1012A1.7	-6.52	1.61e-09	4.42e-06	-0.45	-0.51	Amyotrophic lateral sclerosis (sporadic);	chr14:67823747	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.865	rs11626778	ENSG00000258759.1	RP11-1012A1.7	-6.52	1.61e-09	4.42e-06	-0.45	-0.51	Amyotrophic lateral sclerosis (sporadic);	chr14:67824801	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.833	rs8011393	ENSG00000258759.1	RP11-1012A1.7	-6.52	1.61e-09	4.42e-06	-0.45	-0.51	Amyotrophic lateral sclerosis (sporadic);	chr14:67825181	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.833	rs7154635	ENSG00000258759.1	RP11-1012A1.7	-6.52	1.61e-09	4.42e-06	-0.45	-0.51	Amyotrophic lateral sclerosis (sporadic);	chr14:67825981	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.866	rs28373844	ENSG00000258759.1	RP11-1012A1.7	-6.52	1.61e-09	4.42e-06	-0.45	-0.51	Amyotrophic lateral sclerosis (sporadic);	chr14:67826773	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.866	rs932555	ENSG00000258759.1	RP11-1012A1.7	-6.52	1.61e-09	4.42e-06	-0.45	-0.51	Amyotrophic lateral sclerosis (sporadic);	chr14:67827067	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.865	rs11623756	ENSG00000258759.1	RP11-1012A1.7	-6.52	1.61e-09	4.42e-06	-0.45	-0.51	Amyotrophic lateral sclerosis (sporadic);	chr14:67832880	chr14:67799004~67799609:+
TGCT	cis	rs950169	0.656	rs748455	ENSG00000225151.9	GOLGA2P7	-6.52	1.63e-09	4.47e-06	-0.58	-0.51	Schizophrenia;	chr15:84606344	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.544	rs12913702	ENSG00000225151.9	GOLGA2P7	-6.52	1.63e-09	4.47e-06	-0.58	-0.51	Schizophrenia;	chr15:84609953	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.509	rs71395455	ENSG00000225151.9	GOLGA2P7	-6.52	1.63e-09	4.47e-06	-0.58	-0.51	Schizophrenia;	chr15:84610573	chr15:84199311~84230136:-
TGCT	cis	rs875971	1	rs4718307	ENSG00000222364.1	RNU6-96P	6.52	1.63e-09	4.48e-06	0.57	0.51	Aortic root size;	chr7:66146001	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs7801282	ENSG00000222364.1	RNU6-96P	6.52	1.63e-09	4.48e-06	0.57	0.51	Aortic root size;	chr7:66148700	chr7:66395191~66395286:+
TGCT	cis	rs524281	0.861	rs7941469	ENSG00000255320.1	RP11-755F10.1	-6.52	1.64e-09	4.49e-06	-0.64	-0.51	Electroencephalogram traits;	chr11:66132681	chr11:66244840~66246239:-
TGCT	cis	rs5769707	0.521	rs739244	ENSG00000188511.11	C22orf34	6.51	1.64e-09	4.5e-06	0.56	0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49666510	chr22:49414524~49657542:-
TGCT	cis	rs9322193	0.923	rs1889471	ENSG00000216906.2	RP11-350J20.9	6.51	1.66e-09	4.55e-06	0.57	0.5	Lung cancer;	chr6:149864388	chr6:149904243~149906418:+
TGCT	cis	rs10875976	0.525	rs7306374	ENSG00000257253.2	RP11-70F11.7	6.51	1.66e-09	4.56e-06	0.46	0.5	Obesity;	chr12:49856606	chr12:49861207~49865802:+
TGCT	cis	rs1775715	0.707	rs2778669	ENSG00000239731.3	RN7SL825P	-6.51	1.67e-09	4.56e-06	-0.5	-0.5	Bipolar disorder with mood-incongruent psychosis;	chr10:31872613	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.674	rs2778670	ENSG00000239731.3	RN7SL825P	-6.51	1.67e-09	4.56e-06	-0.5	-0.5	Bipolar disorder with mood-incongruent psychosis;	chr10:31872748	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.737	rs2808078	ENSG00000239731.3	RN7SL825P	-6.51	1.67e-09	4.56e-06	-0.5	-0.5	Bipolar disorder with mood-incongruent psychosis;	chr10:31883624	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.737	rs2799031	ENSG00000239731.3	RN7SL825P	-6.51	1.67e-09	4.56e-06	-0.5	-0.5	Bipolar disorder with mood-incongruent psychosis;	chr10:31884240	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.737	rs55859032	ENSG00000239731.3	RN7SL825P	-6.51	1.67e-09	4.56e-06	-0.5	-0.5	Bipolar disorder with mood-incongruent psychosis;	chr10:31924311	chr10:31992087~31992381:-
TGCT	cis	rs6452524	0.868	rs10079372	ENSG00000249664.1	CTD-2227C6.2	6.51	1.67e-09	4.57e-06	0.55	0.5	Hypertension (SNP x SNP interaction);	chr5:83117113	chr5:83012285~83013109:-
TGCT	cis	rs9549367	0.713	rs4907599	ENSG00000269125.1	RP11-98F14.11	6.51	1.67e-09	4.58e-06	0.59	0.5	Platelet distribution width;	chr13:113207127	chr13:113165002~113165183:-
TGCT	cis	rs950169	0.595	rs11631921	ENSG00000225151.9	GOLGA2P7	-6.51	1.67e-09	4.58e-06	-0.58	-0.5	Schizophrenia;	chr15:84600046	chr15:84199311~84230136:-
TGCT	cis	rs977987	0.806	rs1030262	ENSG00000261783.1	RP11-252K23.2	-6.51	1.69e-09	4.61e-06	-0.73	-0.5	Dupuytren's disease;	chr16:75457429	chr16:75379818~75381260:-
TGCT	cis	rs748404	0.66	rs2467742	ENSG00000205771.5	CATSPER2P1	-6.51	1.69e-09	4.61e-06	-0.57	-0.5	Lung cancer;	chr15:43458039	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.69	rs2244981	ENSG00000205771.5	CATSPER2P1	-6.51	1.69e-09	4.61e-06	-0.57	-0.5	Lung cancer;	chr15:43460553	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.66	rs694725	ENSG00000205771.5	CATSPER2P1	-6.51	1.69e-09	4.61e-06	-0.57	-0.5	Lung cancer;	chr15:43464012	chr15:43726918~43747094:-
TGCT	cis	rs7208859	0.673	rs11654331	ENSG00000263531.1	RP13-753N3.1	6.51	1.69e-09	4.63e-06	0.88	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.573	rs73277960	ENSG00000263531.1	RP13-753N3.1	6.51	1.69e-09	4.63e-06	0.88	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30863921~30864940:-
TGCT	cis	rs2134046	0.587	rs11854289	ENSG00000278603.1	RP13-608F4.5	-6.51	1.7e-09	4.64e-06	-0.65	-0.5	Cognitive ability;	chr15:82266461	chr15:82472203~82472426:+
TGCT	cis	rs9549367	0.789	rs2302754	ENSG00000269125.1	RP11-98F14.11	6.51	1.71e-09	4.67e-06	0.6	0.5	Platelet distribution width;	chr13:113244071	chr13:113165002~113165183:-
TGCT	cis	rs17301013	0.606	rs1793315	ENSG00000227373.4	RP11-160H22.5	-6.51	1.71e-09	4.68e-06	-0.58	-0.5	Systemic lupus erythematosus;	chr1:174808923	chr1:174115300~174160004:-
TGCT	cis	rs16828019	0.852	rs3766324	ENSG00000235358.1	RP11-399E6.1	6.51	1.72e-09	4.68e-06	0.85	0.5	Intelligence (multi-trait analysis);	chr1:41122981	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.852	rs12759023	ENSG00000235358.1	RP11-399E6.1	6.51	1.72e-09	4.68e-06	0.85	0.5	Intelligence (multi-trait analysis);	chr1:41138306	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.852	rs34286980	ENSG00000235358.1	RP11-399E6.1	6.51	1.72e-09	4.68e-06	0.85	0.5	Intelligence (multi-trait analysis);	chr1:41142717	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.852	rs71648534	ENSG00000235358.1	RP11-399E6.1	6.51	1.72e-09	4.68e-06	0.85	0.5	Intelligence (multi-trait analysis);	chr1:41148075	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.852	rs71648535	ENSG00000235358.1	RP11-399E6.1	6.51	1.72e-09	4.68e-06	0.85	0.5	Intelligence (multi-trait analysis);	chr1:41148078	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.852	rs71648536	ENSG00000235358.1	RP11-399E6.1	6.51	1.72e-09	4.68e-06	0.85	0.5	Intelligence (multi-trait analysis);	chr1:41166336	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.852	rs12742803	ENSG00000235358.1	RP11-399E6.1	6.51	1.72e-09	4.68e-06	0.85	0.5	Intelligence (multi-trait analysis);	chr1:41182459	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.852	rs12408956	ENSG00000235358.1	RP11-399E6.1	6.51	1.72e-09	4.68e-06	0.85	0.5	Intelligence (multi-trait analysis);	chr1:41186280	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.852	rs35992757	ENSG00000235358.1	RP11-399E6.1	6.51	1.72e-09	4.68e-06	0.85	0.5	Intelligence (multi-trait analysis);	chr1:41187190	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.852	rs12044539	ENSG00000235358.1	RP11-399E6.1	6.51	1.72e-09	4.68e-06	0.85	0.5	Intelligence (multi-trait analysis);	chr1:41196060	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.852	rs12759050	ENSG00000235358.1	RP11-399E6.1	6.51	1.72e-09	4.68e-06	0.85	0.5	Intelligence (multi-trait analysis);	chr1:41198532	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.789	rs34216154	ENSG00000235358.1	RP11-399E6.1	6.51	1.72e-09	4.68e-06	0.85	0.5	Intelligence (multi-trait analysis);	chr1:41205235	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.929	rs1032728	ENSG00000235358.1	RP11-399E6.1	6.51	1.72e-09	4.68e-06	0.85	0.5	Intelligence (multi-trait analysis);	chr1:41213894	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.929	rs12029321	ENSG00000235358.1	RP11-399E6.1	6.51	1.72e-09	4.68e-06	0.85	0.5	Intelligence (multi-trait analysis);	chr1:41216858	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.929	rs35286837	ENSG00000235358.1	RP11-399E6.1	6.51	1.72e-09	4.68e-06	0.85	0.5	Intelligence (multi-trait analysis);	chr1:41217326	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.929	rs11209734	ENSG00000235358.1	RP11-399E6.1	6.51	1.72e-09	4.68e-06	0.85	0.5	Intelligence (multi-trait analysis);	chr1:41232402	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.929	rs12037037	ENSG00000235358.1	RP11-399E6.1	6.51	1.72e-09	4.68e-06	0.85	0.5	Intelligence (multi-trait analysis);	chr1:41232584	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.929	rs8179465	ENSG00000235358.1	RP11-399E6.1	6.51	1.72e-09	4.68e-06	0.85	0.5	Intelligence (multi-trait analysis);	chr1:41236075	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.929	rs2363805	ENSG00000235358.1	RP11-399E6.1	6.51	1.72e-09	4.68e-06	0.85	0.5	Intelligence (multi-trait analysis);	chr1:41253762	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.852	rs71648540	ENSG00000235358.1	RP11-399E6.1	6.51	1.72e-09	4.68e-06	0.85	0.5	Intelligence (multi-trait analysis);	chr1:41256623	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.929	rs10524	ENSG00000235358.1	RP11-399E6.1	6.51	1.72e-09	4.68e-06	0.85	0.5	Intelligence (multi-trait analysis);	chr1:41260801	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.929	rs111309254	ENSG00000235358.1	RP11-399E6.1	6.51	1.72e-09	4.68e-06	0.85	0.5	Intelligence (multi-trait analysis);	chr1:41270328	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.929	rs4131949	ENSG00000235358.1	RP11-399E6.1	6.51	1.72e-09	4.68e-06	0.85	0.5	Intelligence (multi-trait analysis);	chr1:41272965	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.929	rs35813191	ENSG00000235358.1	RP11-399E6.1	6.51	1.72e-09	4.68e-06	0.85	0.5	Intelligence (multi-trait analysis);	chr1:41277128	chr1:41242373~41284861:+
TGCT	cis	rs9549367	0.789	rs3764124	ENSG00000269125.1	RP11-98F14.11	-6.51	1.72e-09	4.69e-06	-0.59	-0.5	Platelet distribution width;	chr13:113243006	chr13:113165002~113165183:-
TGCT	cis	rs6700559	0.654	rs66717951	ENSG00000260088.1	RP11-92G12.3	6.51	1.72e-09	4.69e-06	0.61	0.5	Coronary artery disease;	chr1:200626437	chr1:200669507~200694250:+
TGCT	cis	rs6700559	0.654	rs2809346	ENSG00000260088.1	RP11-92G12.3	6.51	1.72e-09	4.69e-06	0.61	0.5	Coronary artery disease;	chr1:200627089	chr1:200669507~200694250:+
TGCT	cis	rs17301013	0.606	rs1417186	ENSG00000227373.4	RP11-160H22.5	-6.5	1.73e-09	4.7e-06	-0.58	-0.5	Systemic lupus erythematosus;	chr1:174171090	chr1:174115300~174160004:-
TGCT	cis	rs9322193	0.923	rs9322225	ENSG00000216906.2	RP11-350J20.9	6.5	1.74e-09	4.73e-06	0.57	0.5	Lung cancer;	chr6:149863746	chr6:149904243~149906418:+
TGCT	cis	rs875971	0.66	rs801193	ENSG00000222364.1	RNU6-96P	6.5	1.75e-09	4.75e-06	0.6	0.5	Aortic root size;	chr7:66565625	chr7:66395191~66395286:+
TGCT	cis	rs977987	0.806	rs17696696	ENSG00000261783.1	RP11-252K23.2	6.5	1.75e-09	4.77e-06	0.72	0.5	Dupuytren's disease;	chr16:75359454	chr16:75379818~75381260:-
TGCT	cis	rs3096299	0.658	rs12443705	ENSG00000274627.1	RP11-104N10.2	6.5	1.76e-09	4.78e-06	0.52	0.5	Multiple myeloma (IgH translocation);	chr16:89480646	chr16:89516797~89522217:+
TGCT	cis	rs17301013	0.507	rs10912757	ENSG00000227373.4	RP11-160H22.5	6.5	1.76e-09	4.78e-06	0.58	0.5	Systemic lupus erythematosus;	chr1:174299064	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs10912758	ENSG00000227373.4	RP11-160H22.5	6.5	1.76e-09	4.78e-06	0.58	0.5	Systemic lupus erythematosus;	chr1:174300822	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs6693198	ENSG00000227373.4	RP11-160H22.5	6.5	1.76e-09	4.78e-06	0.58	0.5	Systemic lupus erythematosus;	chr1:174304301	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs1121537	ENSG00000227373.4	RP11-160H22.5	6.5	1.76e-09	4.78e-06	0.58	0.5	Systemic lupus erythematosus;	chr1:174307568	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs10912762	ENSG00000227373.4	RP11-160H22.5	6.5	1.76e-09	4.78e-06	0.58	0.5	Systemic lupus erythematosus;	chr1:174312477	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs10912763	ENSG00000227373.4	RP11-160H22.5	6.5	1.76e-09	4.78e-06	0.58	0.5	Systemic lupus erythematosus;	chr1:174316083	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs10912764	ENSG00000227373.4	RP11-160H22.5	6.5	1.76e-09	4.78e-06	0.58	0.5	Systemic lupus erythematosus;	chr1:174316085	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12097252	ENSG00000227373.4	RP11-160H22.5	6.5	1.76e-09	4.78e-06	0.58	0.5	Systemic lupus erythematosus;	chr1:174318374	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs10912765	ENSG00000227373.4	RP11-160H22.5	6.5	1.76e-09	4.78e-06	0.58	0.5	Systemic lupus erythematosus;	chr1:174322812	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs4651008	ENSG00000227373.4	RP11-160H22.5	6.5	1.76e-09	4.78e-06	0.58	0.5	Systemic lupus erythematosus;	chr1:174342681	chr1:174115300~174160004:-
TGCT	cis	rs977987	0.806	rs7202596	ENSG00000261783.1	RP11-252K23.2	-6.5	1.78e-09	4.83e-06	-0.73	-0.5	Dupuytren's disease;	chr16:75457174	chr16:75379818~75381260:-
TGCT	cis	rs9549367	0.789	rs12584981	ENSG00000269125.1	RP11-98F14.11	-6.5	1.79e-09	4.85e-06	-0.59	-0.5	Platelet distribution width;	chr13:113226871	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.789	rs12584008	ENSG00000269125.1	RP11-98F14.11	-6.5	1.79e-09	4.85e-06	-0.59	-0.5	Platelet distribution width;	chr13:113226914	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.789	rs9549701	ENSG00000269125.1	RP11-98F14.11	-6.5	1.79e-09	4.85e-06	-0.59	-0.5	Platelet distribution width;	chr13:113227438	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.789	rs2025247	ENSG00000269125.1	RP11-98F14.11	-6.5	1.79e-09	4.85e-06	-0.59	-0.5	Platelet distribution width;	chr13:113228250	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.789	rs912012	ENSG00000269125.1	RP11-98F14.11	-6.5	1.79e-09	4.85e-06	-0.59	-0.5	Platelet distribution width;	chr13:113231838	chr13:113165002~113165183:-
TGCT	cis	rs12891047	0.866	rs8006089	ENSG00000258759.1	RP11-1012A1.7	6.5	1.79e-09	4.85e-06	0.44	0.5	Amyotrophic lateral sclerosis (sporadic);	chr14:67823803	chr14:67799004~67799609:+
TGCT	cis	rs916888	0.61	rs199444	ENSG00000262500.1	RP11-259G18.2	6.5	1.8e-09	4.89e-06	0.67	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46243606~46245044:+
TGCT	cis	rs916888	0.61	rs199442	ENSG00000262500.1	RP11-259G18.2	6.5	1.8e-09	4.89e-06	0.67	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46243606~46245044:+
TGCT	cis	rs9549367	0.713	rs3024769	ENSG00000269125.1	RP11-98F14.11	6.5	1.8e-09	4.9e-06	0.6	0.5	Platelet distribution width;	chr13:113171287	chr13:113165002~113165183:-
TGCT	cis	rs11098499	0.955	rs56386062	ENSG00000245958.5	RP11-33B1.1	-6.5	1.81e-09	4.9e-06	-0.51	-0.5	Corneal astigmatism;	chr4:119233980	chr4:119454791~119552025:+
TGCT	cis	rs7412746	0.634	rs7521592	ENSG00000206931.1	RNU6-1042P	6.5	1.81e-09	4.9e-06	0.4	0.5	Melanoma;	chr1:150849215	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.634	rs72704658	ENSG00000206931.1	RNU6-1042P	6.5	1.81e-09	4.9e-06	0.4	0.5	Melanoma;	chr1:150860534	chr1:150701866~150701972:+
TGCT	cis	rs12908161	1	rs35316992	ENSG00000225151.9	GOLGA2P7	-6.49	1.81e-09	4.92e-06	-0.57	-0.5	Schizophrenia;	chr15:84704902	chr15:84199311~84230136:-
TGCT	cis	rs12908161	1	rs4643294	ENSG00000225151.9	GOLGA2P7	-6.49	1.81e-09	4.92e-06	-0.57	-0.5	Schizophrenia;	chr15:84707022	chr15:84199311~84230136:-
TGCT	cis	rs12908161	1	rs62021219	ENSG00000225151.9	GOLGA2P7	-6.49	1.81e-09	4.92e-06	-0.57	-0.5	Schizophrenia;	chr15:84712928	chr15:84199311~84230136:-
TGCT	cis	rs12908161	1	rs34900908	ENSG00000225151.9	GOLGA2P7	-6.49	1.81e-09	4.92e-06	-0.57	-0.5	Schizophrenia;	chr15:84714368	chr15:84199311~84230136:-
TGCT	cis	rs12908161	1	rs35524990	ENSG00000225151.9	GOLGA2P7	-6.49	1.81e-09	4.92e-06	-0.57	-0.5	Schizophrenia;	chr15:84714972	chr15:84199311~84230136:-
TGCT	cis	rs12908161	1	rs58416181	ENSG00000225151.9	GOLGA2P7	-6.49	1.81e-09	4.92e-06	-0.57	-0.5	Schizophrenia;	chr15:84721230	chr15:84199311~84230136:-
TGCT	cis	rs875971	0.54	rs1723268	ENSG00000222364.1	RNU6-96P	-6.49	1.82e-09	4.92e-06	-0.58	-0.5	Aortic root size;	chr7:66008093	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.522	rs1701760	ENSG00000222364.1	RNU6-96P	-6.49	1.82e-09	4.92e-06	-0.58	-0.5	Aortic root size;	chr7:66008701	chr7:66395191~66395286:+
TGCT	cis	rs977987	0.778	rs2113232	ENSG00000261783.1	RP11-252K23.2	-6.49	1.83e-09	4.96e-06	-0.73	-0.5	Dupuytren's disease;	chr16:75357287	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs35263058	ENSG00000261783.1	RP11-252K23.2	-6.49	1.83e-09	4.96e-06	-0.73	-0.5	Dupuytren's disease;	chr16:75358039	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs7185640	ENSG00000261783.1	RP11-252K23.2	-6.49	1.83e-09	4.96e-06	-0.73	-0.5	Dupuytren's disease;	chr16:75360501	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs11640674	ENSG00000261783.1	RP11-252K23.2	-6.49	1.83e-09	4.96e-06	-0.73	-0.5	Dupuytren's disease;	chr16:75361046	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs4888389	ENSG00000261783.1	RP11-252K23.2	-6.49	1.83e-09	4.96e-06	-0.73	-0.5	Dupuytren's disease;	chr16:75361330	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs11865004	ENSG00000261783.1	RP11-252K23.2	-6.49	1.83e-09	4.96e-06	-0.73	-0.5	Dupuytren's disease;	chr16:75361879	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.778	rs35415181	ENSG00000261783.1	RP11-252K23.2	-6.49	1.83e-09	4.96e-06	-0.73	-0.5	Dupuytren's disease;	chr16:75369226	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs35552529	ENSG00000261783.1	RP11-252K23.2	-6.49	1.83e-09	4.96e-06	-0.73	-0.5	Dupuytren's disease;	chr16:75371981	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs56343285	ENSG00000261783.1	RP11-252K23.2	-6.49	1.83e-09	4.96e-06	-0.73	-0.5	Dupuytren's disease;	chr16:75375899	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs1544810	ENSG00000261783.1	RP11-252K23.2	-6.49	1.83e-09	4.96e-06	-0.73	-0.5	Dupuytren's disease;	chr16:75377265	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.778	rs11858992	ENSG00000261783.1	RP11-252K23.2	-6.49	1.83e-09	4.96e-06	-0.73	-0.5	Dupuytren's disease;	chr16:75377547	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs4993970	ENSG00000261783.1	RP11-252K23.2	-6.49	1.83e-09	4.96e-06	-0.73	-0.5	Dupuytren's disease;	chr16:75377721	chr16:75379818~75381260:-
TGCT	cis	rs2882667	0.858	rs66839813	ENSG00000253404.1	AC034243.1	6.49	1.84e-09	4.98e-06	0.57	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106633	chr5:138744434~138753309:-
TGCT	cis	rs8040855	0.93	rs6496767	ENSG00000259295.5	CSPG4P12	-6.49	1.85e-09	5.01e-06	-0.66	-0.5	Bulimia nervosa;	chr15:85159522	chr15:85191438~85213905:+
TGCT	cis	rs524281	0.861	rs7124165	ENSG00000255320.1	RP11-755F10.1	6.49	1.86e-09	5.04e-06	0.64	0.5	Electroencephalogram traits;	chr11:66133747	chr11:66244840~66246239:-
TGCT	cis	rs5769707	0.609	rs2071890	ENSG00000188511.11	C22orf34	6.49	1.87e-09	5.05e-06	0.56	0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49607643	chr22:49414524~49657542:-
TGCT	cis	rs7617773	0.817	rs13100815	ENSG00000229759.1	MRPS18AP1	6.49	1.89e-09	5.1e-06	0.43	0.5	Coronary artery disease;	chr3:48245959	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.817	rs13059037	ENSG00000229759.1	MRPS18AP1	6.49	1.89e-09	5.1e-06	0.43	0.5	Coronary artery disease;	chr3:48246389	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.817	rs35414021	ENSG00000229759.1	MRPS18AP1	6.49	1.89e-09	5.1e-06	0.43	0.5	Coronary artery disease;	chr3:48252034	chr3:48256350~48256938:-
TGCT	cis	rs943437	0.511	rs9400505	ENSG00000227012.2	RP1-97J1.2	6.49	1.9e-09	5.12e-06	0.79	0.5	Parkinson's disease;	chr6:111789325	chr6:111900489~111901851:-
TGCT	cis	rs7757969	1	rs9374289	ENSG00000227012.2	RP1-97J1.2	6.49	1.9e-09	5.12e-06	0.79	0.5	Schizophrenia;	chr6:111790191	chr6:111900489~111901851:-
TGCT	cis	rs875971	0.862	rs28470208	ENSG00000222364.1	RNU6-96P	6.48	1.91e-09	5.15e-06	0.56	0.5	Aortic root size;	chr7:66119713	chr7:66395191~66395286:+
TGCT	cis	rs17361889	0.752	rs1918266	ENSG00000224683.1	RPL36AP29	-6.48	1.94e-09	5.22e-06	-0.58	-0.5	Pediatric bone mineral content (hip);	chr7:16231996	chr7:16208945~16209265:+
TGCT	cis	rs9322193	0.676	rs1889472	ENSG00000216906.2	RP11-350J20.9	6.48	1.94e-09	5.23e-06	0.57	0.5	Lung cancer;	chr6:149864373	chr6:149904243~149906418:+
TGCT	cis	rs6452524	0.904	rs10474095	ENSG00000249664.1	CTD-2227C6.2	6.48	1.96e-09	5.27e-06	0.54	0.5	Hypertension (SNP x SNP interaction);	chr5:83154887	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.869	rs10051155	ENSG00000249664.1	CTD-2227C6.2	6.48	1.96e-09	5.27e-06	0.54	0.5	Hypertension (SNP x SNP interaction);	chr5:83160851	chr5:83012285~83013109:-
TGCT	cis	rs7412746	0.658	rs10888397	ENSG00000206931.1	RNU6-1042P	-6.48	1.98e-09	5.32e-06	-0.39	-0.5	Melanoma;	chr1:150914276	chr1:150701866~150701972:+
TGCT	cis	rs2929278	0.736	rs2412823	ENSG00000205771.5	CATSPER2P1	6.48	1.99e-09	5.34e-06	0.59	0.5	Schizophrenia;	chr15:43935072	chr15:43726918~43747094:-
TGCT	cis	rs16828019	0.852	rs34386859	ENSG00000235358.1	RP11-399E6.1	6.48	1.99e-09	5.36e-06	0.86	0.5	Intelligence (multi-trait analysis);	chr1:41098352	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.852	rs2300649	ENSG00000235358.1	RP11-399E6.1	6.48	1.99e-09	5.36e-06	0.86	0.5	Intelligence (multi-trait analysis);	chr1:41103531	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.852	rs3904243	ENSG00000235358.1	RP11-399E6.1	6.48	1.99e-09	5.36e-06	0.86	0.5	Intelligence (multi-trait analysis);	chr1:41109180	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.852	rs11209545	ENSG00000235358.1	RP11-399E6.1	6.48	1.99e-09	5.36e-06	0.86	0.5	Intelligence (multi-trait analysis);	chr1:41110685	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.852	rs11209576	ENSG00000235358.1	RP11-399E6.1	6.48	1.99e-09	5.36e-06	0.86	0.5	Intelligence (multi-trait analysis);	chr1:41120357	chr1:41242373~41284861:+
TGCT	cis	rs1062177	0.855	rs919263	ENSG00000253921.1	CTB-113P19.3	-6.47	2e-09	5.38e-06	-0.57	-0.5	Preschool internalizing problems;	chr5:151886292	chr5:151753992~151767247:+
TGCT	cis	rs7412746	0.658	rs72704652	ENSG00000206931.1	RNU6-1042P	6.47	2.01e-09	5.39e-06	0.4	0.5	Melanoma;	chr1:150846994	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.622	rs72704654	ENSG00000206931.1	RNU6-1042P	6.47	2.01e-09	5.39e-06	0.4	0.5	Melanoma;	chr1:150853934	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs11582281	ENSG00000206931.1	RNU6-1042P	6.47	2.01e-09	5.39e-06	0.4	0.5	Melanoma;	chr1:150854355	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.621	rs72704656	ENSG00000206931.1	RNU6-1042P	6.47	2.01e-09	5.39e-06	0.4	0.5	Melanoma;	chr1:150855831	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.524	rs58304714	ENSG00000206931.1	RNU6-1042P	6.47	2.01e-09	5.39e-06	0.4	0.5	Melanoma;	chr1:150859085	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.588	rs10305664	ENSG00000206931.1	RNU6-1042P	6.47	2.01e-09	5.39e-06	0.4	0.5	Melanoma;	chr1:150867210	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs6660845	ENSG00000206931.1	RNU6-1042P	6.47	2.01e-09	5.39e-06	0.4	0.5	Melanoma;	chr1:150868590	chr1:150701866~150701972:+
TGCT	cis	rs8040855	0.894	rs6496770	ENSG00000259295.5	CSPG4P12	-6.47	2.02e-09	5.42e-06	-0.66	-0.5	Bulimia nervosa;	chr15:85161890	chr15:85191438~85213905:+
TGCT	cis	rs6452524	0.935	rs72767160	ENSG00000249664.1	CTD-2227C6.2	6.47	2.03e-09	5.44e-06	0.54	0.5	Hypertension (SNP x SNP interaction);	chr5:83161102	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs5000997	ENSG00000249664.1	CTD-2227C6.2	6.47	2.03e-09	5.44e-06	0.54	0.5	Hypertension (SNP x SNP interaction);	chr5:83164248	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.935	rs10043698	ENSG00000249664.1	CTD-2227C6.2	6.47	2.03e-09	5.44e-06	0.54	0.5	Hypertension (SNP x SNP interaction);	chr5:83169100	chr5:83012285~83013109:-
TGCT	cis	rs875971	0.522	rs709604	ENSG00000222364.1	RNU6-96P	6.47	2.03e-09	5.45e-06	0.58	0.5	Aortic root size;	chr7:66032447	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.505	rs1723275	ENSG00000222364.1	RNU6-96P	6.47	2.03e-09	5.45e-06	0.58	0.5	Aortic root size;	chr7:66039646	chr7:66395191~66395286:+
TGCT	cis	rs6904897	0.563	rs4896117	ENSG00000232876.1	CTA-212D2.2	6.47	2.04e-09	5.46e-06	0.45	0.5	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134908262	chr6:135055033~135060550:+
TGCT	cis	rs17301013	0.606	rs55698100	ENSG00000227373.4	RP11-160H22.5	6.47	2.04e-09	5.47e-06	0.59	0.5	Systemic lupus erythematosus;	chr1:174258295	chr1:174115300~174160004:-
TGCT	cis	rs7044106	0.791	rs12554440	ENSG00000226752.6	PSMD5-AS1	-6.47	2.04e-09	5.47e-06	-0.64	-0.5	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120824828~120854385:+
TGCT	cis	rs1528149	0.93	rs62440849	ENSG00000224683.1	RPL36AP29	6.47	2.06e-09	5.52e-06	0.61	0.5	Sitting height ratio;	chr7:16072349	chr7:16208945~16209265:+
TGCT	cis	rs1528149	0.866	rs1528147	ENSG00000224683.1	RPL36AP29	6.47	2.06e-09	5.52e-06	0.61	0.5	Sitting height ratio;	chr7:16073898	chr7:16208945~16209265:+
TGCT	cis	rs1528149	0.93	rs17357253	ENSG00000224683.1	RPL36AP29	6.47	2.06e-09	5.52e-06	0.61	0.5	Sitting height ratio;	chr7:16074339	chr7:16208945~16209265:+
TGCT	cis	rs977987	0.736	rs11865296	ENSG00000261783.1	RP11-252K23.2	-6.47	2.08e-09	5.56e-06	-0.71	-0.5	Dupuytren's disease;	chr16:75439795	chr16:75379818~75381260:-
TGCT	cis	rs7412746	0.658	rs3768015	ENSG00000206931.1	RNU6-1042P	6.47	2.08e-09	5.56e-06	0.4	0.5	Melanoma;	chr1:150840478	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.611	rs2864873	ENSG00000206931.1	RNU6-1042P	6.47	2.08e-09	5.56e-06	0.4	0.5	Melanoma;	chr1:150841698	chr1:150701866~150701972:+
TGCT	cis	rs7044106	0.791	rs4617229	ENSG00000226752.6	PSMD5-AS1	-6.47	2.08e-09	5.58e-06	-0.64	-0.5	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120824828~120854385:+
TGCT	cis	rs875971	0.862	rs1612452	ENSG00000222364.1	RNU6-96P	6.47	2.09e-09	5.6e-06	0.56	0.5	Aortic root size;	chr7:66108909	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs1167390	ENSG00000222364.1	RNU6-96P	6.47	2.09e-09	5.6e-06	0.56	0.5	Aortic root size;	chr7:66110906	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs35034167	ENSG00000222364.1	RNU6-96P	6.47	2.09e-09	5.6e-06	0.56	0.5	Aortic root size;	chr7:66115179	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.522	rs1880556	ENSG00000236529.1	RP13-254B10.1	6.46	2.1e-09	5.63e-06	0.38	0.5	Aortic root size;	chr7:65967557	chr7:65840212~65840596:+
TGCT	cis	rs875971	0.522	rs781144	ENSG00000236529.1	RP13-254B10.1	6.46	2.1e-09	5.63e-06	0.38	0.5	Aortic root size;	chr7:65975357	chr7:65840212~65840596:+
TGCT	cis	rs8040855	0.69	rs8041189	ENSG00000259295.5	CSPG4P12	-6.46	2.11e-09	5.65e-06	-0.68	-0.5	Bulimia nervosa;	chr15:85143096	chr15:85191438~85213905:+
TGCT	cis	rs7617773	0.817	rs11709691	ENSG00000229759.1	MRPS18AP1	6.46	2.12e-09	5.66e-06	0.43	0.5	Coronary artery disease;	chr3:48262179	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.817	rs17647717	ENSG00000229759.1	MRPS18AP1	6.46	2.12e-09	5.66e-06	0.43	0.5	Coronary artery disease;	chr3:48263966	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.817	rs34225441	ENSG00000229759.1	MRPS18AP1	6.46	2.12e-09	5.66e-06	0.43	0.5	Coronary artery disease;	chr3:48267401	chr3:48256350~48256938:-
TGCT	cis	rs6964833	1	rs4717906	ENSG00000123965.13	PMS2P5	6.46	2.13e-09	5.69e-06	0.64	0.5	Menarche (age at onset);	chr7:74671923	chr7:74894116~74897835:+
TGCT	cis	rs11098499	0.955	rs13129661	ENSG00000245958.5	RP11-33B1.1	-6.46	2.14e-09	5.71e-06	-0.51	-0.5	Corneal astigmatism;	chr4:119231754	chr4:119454791~119552025:+
TGCT	cis	rs977987	0.806	rs12933281	ENSG00000261783.1	RP11-252K23.2	-6.46	2.14e-09	5.71e-06	-0.72	-0.5	Dupuytren's disease;	chr16:75449166	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.843	rs59155720	ENSG00000261783.1	RP11-252K23.2	-6.46	2.14e-09	5.71e-06	-0.72	-0.5	Dupuytren's disease;	chr16:75449908	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.843	rs10871312	ENSG00000261783.1	RP11-252K23.2	-6.46	2.14e-09	5.71e-06	-0.72	-0.5	Dupuytren's disease;	chr16:75452304	chr16:75379818~75381260:-
TGCT	cis	rs7617773	0.817	rs6796490	ENSG00000229759.1	MRPS18AP1	6.46	2.14e-09	5.72e-06	0.4	0.5	Coronary artery disease;	chr3:48195614	chr3:48256350~48256938:-
TGCT	cis	rs7412746	0.622	rs11552229	ENSG00000206931.1	RNU6-1042P	6.46	2.15e-09	5.75e-06	0.4	0.5	Melanoma;	chr1:150811509	chr1:150701866~150701972:+
TGCT	cis	rs67383717	0.672	rs589458	ENSG00000175611.10	LINC00476	6.46	2.16e-09	5.77e-06	0.41	0.5	Parkinson's disease (pesticide exposure interaction);	chr9:95878389	chr9:95759231~95875977:-
TGCT	cis	rs694739	1	rs646153	ENSG00000236935.1	AP003774.1	6.46	2.18e-09	5.81e-06	0.39	0.5	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64322116	chr11:64325050~64329504:-
TGCT	cis	rs12908161	1	rs60957376	ENSG00000225151.9	GOLGA2P7	-6.46	2.19e-09	5.84e-06	-0.57	-0.5	Schizophrenia;	chr15:84737561	chr15:84199311~84230136:-
TGCT	cis	rs12908161	1	rs11632465	ENSG00000225151.9	GOLGA2P7	-6.46	2.19e-09	5.84e-06	-0.57	-0.5	Schizophrenia;	chr15:84738814	chr15:84199311~84230136:-
TGCT	cis	rs12908161	0.96	rs62019463	ENSG00000225151.9	GOLGA2P7	-6.46	2.19e-09	5.84e-06	-0.57	-0.5	Schizophrenia;	chr15:84744856	chr15:84199311~84230136:-
TGCT	cis	rs1528149	0.93	rs62440852	ENSG00000224683.1	RPL36AP29	6.46	2.2e-09	5.87e-06	0.62	0.5	Sitting height ratio;	chr7:16077294	chr7:16208945~16209265:+
TGCT	cis	rs1528149	0.93	rs17357511	ENSG00000224683.1	RPL36AP29	6.46	2.2e-09	5.87e-06	0.62	0.5	Sitting height ratio;	chr7:16077339	chr7:16208945~16209265:+
TGCT	cis	rs1528149	0.93	rs2389581	ENSG00000224683.1	RPL36AP29	6.46	2.2e-09	5.87e-06	0.62	0.5	Sitting height ratio;	chr7:16078546	chr7:16208945~16209265:+
TGCT	cis	rs1775715	0.707	rs2808081	ENSG00000239731.3	RN7SL825P	6.46	2.21e-09	5.88e-06	0.51	0.5	Bipolar disorder with mood-incongruent psychosis;	chr10:31873414	chr10:31992087~31992381:-
TGCT	cis	rs16828019	0.777	rs34502739	ENSG00000235358.1	RP11-399E6.1	6.45	2.22e-09	5.92e-06	0.87	0.5	Intelligence (multi-trait analysis);	chr1:40993474	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.777	rs67450703	ENSG00000235358.1	RP11-399E6.1	6.45	2.22e-09	5.92e-06	0.87	0.5	Intelligence (multi-trait analysis);	chr1:40994457	chr1:41242373~41284861:+
TGCT	cis	rs748404	0.66	rs2444251	ENSG00000205771.5	CATSPER2P1	-6.45	2.23e-09	5.94e-06	-0.56	-0.5	Lung cancer;	chr15:43496397	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.66	rs548704	ENSG00000205771.5	CATSPER2P1	-6.45	2.23e-09	5.94e-06	-0.56	-0.5	Lung cancer;	chr15:43499508	chr15:43726918~43747094:-
TGCT	cis	rs11098499	0.863	rs1383532	ENSG00000245958.5	RP11-33B1.1	6.45	2.23e-09	5.95e-06	0.56	0.5	Corneal astigmatism;	chr4:119513249	chr4:119454791~119552025:+
TGCT	cis	rs2882667	1	rs2882667	ENSG00000253404.1	AC034243.1	6.45	2.24e-09	5.97e-06	0.58	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138978417	chr5:138744434~138753309:-
TGCT	cis	rs9549367	0.789	rs9549699	ENSG00000269125.1	RP11-98F14.11	-6.45	2.24e-09	5.97e-06	-0.58	-0.5	Platelet distribution width;	chr13:113223949	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.789	rs7999579	ENSG00000269125.1	RP11-98F14.11	-6.45	2.24e-09	5.97e-06	-0.58	-0.5	Platelet distribution width;	chr13:113225043	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.789	rs6577035	ENSG00000269125.1	RP11-98F14.11	-6.45	2.24e-09	5.97e-06	-0.58	-0.5	Platelet distribution width;	chr13:113225683	chr13:113165002~113165183:-
TGCT	cis	rs943437	0.877	rs571871	ENSG00000227012.2	RP1-97J1.2	6.45	2.24e-09	5.97e-06	0.66	0.5	Parkinson's disease;	chr6:111952657	chr6:111900489~111901851:-
TGCT	cis	rs10875976	0.525	rs9805137	ENSG00000257253.2	RP11-70F11.7	6.45	2.25e-09	5.98e-06	0.46	0.5	Obesity;	chr12:49865279	chr12:49861207~49865802:+
TGCT	cis	rs9549367	0.789	rs2316442	ENSG00000269125.1	RP11-98F14.11	-6.45	2.26e-09	6e-06	-0.58	-0.5	Platelet distribution width;	chr13:113223173	chr13:113165002~113165183:-
TGCT	cis	rs9326248	0.861	rs494356	ENSG00000254851.1	RP11-109L13.1	-6.45	2.26e-09	6.02e-06	-0.84	-0.5	Blood protein levels;	chr11:117201254	chr11:117135528~117138582:+
TGCT	cis	rs6003958	1	rs6003958	ENSG00000273295.1	AP000350.5	-6.45	2.3e-09	6.11e-06	-0.68	-0.5	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23901432~23907068:-
TGCT	cis	rs5760092	0.755	rs6003959	ENSG00000273295.1	AP000350.5	-6.45	2.3e-09	6.11e-06	-0.68	-0.5	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23901432~23907068:-
TGCT	cis	rs950169	0.58	rs11633762	ENSG00000225151.9	GOLGA2P7	-6.45	2.32e-09	6.15e-06	-0.57	-0.5	Schizophrenia;	chr15:84643921	chr15:84199311~84230136:-
TGCT	cis	rs1062177	0.855	rs6884630	ENSG00000253921.1	CTB-113P19.3	-6.44	2.32e-09	6.16e-06	-0.57	-0.5	Preschool internalizing problems;	chr5:151889436	chr5:151753992~151767247:+
TGCT	cis	rs9549367	0.789	rs9549361	ENSG00000269125.1	RP11-98F14.11	6.44	2.35e-09	6.24e-06	0.58	0.5	Platelet distribution width;	chr13:113244015	chr13:113165002~113165183:-
TGCT	cis	rs1062177	0.756	rs2964591	ENSG00000213433.5	RPLP1P6	6.44	2.36e-09	6.27e-06	0.56	0.5	Preschool internalizing problems;	chr5:151737836	chr5:151765859~151766378:-
TGCT	cis	rs12908161	1	rs12910012	ENSG00000225151.9	GOLGA2P7	-6.44	2.39e-09	6.33e-06	-0.57	-0.5	Schizophrenia;	chr15:84755431	chr15:84199311~84230136:-
TGCT	cis	rs12908161	1	rs12899981	ENSG00000225151.9	GOLGA2P7	-6.44	2.39e-09	6.33e-06	-0.57	-0.5	Schizophrenia;	chr15:84759142	chr15:84199311~84230136:-
TGCT	cis	rs875971	0.893	rs62465470	ENSG00000222364.1	RNU6-96P	6.44	2.4e-09	6.34e-06	0.56	0.5	Aortic root size;	chr7:66136231	chr7:66395191~66395286:+
TGCT	cis	rs9549367	0.762	rs9549694	ENSG00000269125.1	RP11-98F14.11	-6.44	2.4e-09	6.36e-06	-0.58	-0.5	Platelet distribution width;	chr13:113216196	chr13:113165002~113165183:-
TGCT	cis	rs7412746	0.611	rs2256355	ENSG00000206931.1	RNU6-1042P	6.44	2.4e-09	6.36e-06	0.39	0.5	Melanoma;	chr1:150839318	chr1:150701866~150701972:+
TGCT	cis	rs875971	0.505	rs1167386	ENSG00000222364.1	RNU6-96P	6.44	2.41e-09	6.37e-06	0.58	0.5	Aortic root size;	chr7:66048109	chr7:66395191~66395286:+
TGCT	cis	rs3096299	0.685	rs12935112	ENSG00000274627.1	RP11-104N10.2	-6.44	2.43e-09	6.43e-06	-0.5	-0.5	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:89516797~89522217:+
TGCT	cis	rs977987	0.806	rs4146809	ENSG00000261783.1	RP11-252K23.2	6.44	2.43e-09	6.43e-06	0.72	0.5	Dupuytren's disease;	chr16:75381877	chr16:75379818~75381260:-
TGCT	cis	rs1775715	0.737	rs2799017	ENSG00000239731.3	RN7SL825P	-6.43	2.46e-09	6.49e-06	-0.51	-0.5	Bipolar disorder with mood-incongruent psychosis;	chr10:31914532	chr10:31992087~31992381:-
TGCT	cis	rs17301013	0.606	rs1407127	ENSG00000227373.4	RP11-160H22.5	-6.43	2.47e-09	6.52e-06	-0.58	-0.5	Systemic lupus erythematosus;	chr1:174119548	chr1:174115300~174160004:-
TGCT	cis	rs3096299	0.632	rs8051537	ENSG00000274627.1	RP11-104N10.2	6.43	2.48e-09	6.55e-06	0.51	0.5	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:89516797~89522217:+
TGCT	cis	rs16828019	0.852	rs11209531	ENSG00000235358.1	RP11-399E6.1	6.43	2.49e-09	6.56e-06	0.88	0.5	Intelligence (multi-trait analysis);	chr1:41105349	chr1:41242373~41284861:+
TGCT	cis	rs875971	0.545	rs73378304	ENSG00000226824.5	RP4-756H11.3	-6.43	2.5e-09	6.58e-06	-0.61	-0.5	Aortic root size;	chr7:66175760	chr7:66654538~66669855:+
TGCT	cis	rs17301013	0.581	rs1591944	ENSG00000227373.4	RP11-160H22.5	6.43	2.5e-09	6.58e-06	0.58	0.5	Systemic lupus erythematosus;	chr1:174204917	chr1:174115300~174160004:-
TGCT	cis	rs1775715	0.737	rs1023207	ENSG00000239731.3	RN7SL825P	-6.43	2.5e-09	6.59e-06	-0.49	-0.5	Bipolar disorder with mood-incongruent psychosis;	chr10:31805962	chr10:31992087~31992381:-
TGCT	cis	rs875971	1	rs875971	ENSG00000222364.1	RNU6-96P	6.43	2.51e-09	6.61e-06	0.57	0.5	Aortic root size;	chr7:66152608	chr7:66395191~66395286:+
TGCT	cis	rs7757969	1	rs1409839	ENSG00000227012.2	RP1-97J1.2	6.43	2.51e-09	6.62e-06	0.78	0.5	Schizophrenia;	chr6:111794152	chr6:111900489~111901851:-
TGCT	cis	rs1775715	0.737	rs2808028	ENSG00000239731.3	RN7SL825P	-6.43	2.52e-09	6.63e-06	-0.49	-0.5	Bipolar disorder with mood-incongruent psychosis;	chr10:31812261	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.737	rs2799012	ENSG00000239731.3	RN7SL825P	-6.43	2.52e-09	6.63e-06	-0.49	-0.5	Bipolar disorder with mood-incongruent psychosis;	chr10:31814149	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.737	rs1541260	ENSG00000239731.3	RN7SL825P	-6.43	2.52e-09	6.63e-06	-0.49	-0.5	Bipolar disorder with mood-incongruent psychosis;	chr10:31816642	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.737	rs2778650	ENSG00000239731.3	RN7SL825P	-6.43	2.52e-09	6.63e-06	-0.49	-0.5	Bipolar disorder with mood-incongruent psychosis;	chr10:31817923	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.677	rs2808105	ENSG00000239731.3	RN7SL825P	-6.43	2.52e-09	6.63e-06	-0.49	-0.5	Bipolar disorder with mood-incongruent psychosis;	chr10:31821979	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.737	rs2778672	ENSG00000239731.3	RN7SL825P	-6.43	2.52e-09	6.63e-06	-0.49	-0.5	Bipolar disorder with mood-incongruent psychosis;	chr10:31833491	chr10:31992087~31992381:-
TGCT	cis	rs16828019	0.852	rs12045171	ENSG00000235358.1	RP11-399E6.1	6.43	2.52e-09	6.64e-06	0.84	0.5	Intelligence (multi-trait analysis);	chr1:41063133	chr1:41242373~41284861:+
TGCT	cis	rs916888	0.647	rs199449	ENSG00000262500.1	RP11-259G18.2	6.43	2.52e-09	6.65e-06	0.66	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46243606~46245044:+
TGCT	cis	rs977987	0.806	rs11643410	ENSG00000261783.1	RP11-252K23.2	-6.43	2.54e-09	6.68e-06	-0.72	-0.5	Dupuytren's disease;	chr16:75394408	chr16:75379818~75381260:-
TGCT	cis	rs875971	0.558	rs4433015	ENSG00000222364.1	RNU6-96P	6.42	2.56e-09	6.73e-06	0.59	0.5	Aortic root size;	chr7:66174736	chr7:66395191~66395286:+
TGCT	cis	rs2882667	1	rs2060222	ENSG00000253404.1	AC034243.1	6.42	2.59e-09	6.79e-06	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138972777	chr5:138744434~138753309:-
TGCT	cis	rs2882667	1	rs10064201	ENSG00000253404.1	AC034243.1	6.42	2.59e-09	6.79e-06	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973716	chr5:138744434~138753309:-
TGCT	cis	rs6904897	0.538	rs4639353	ENSG00000232876.1	CTA-212D2.2	6.42	2.59e-09	6.8e-06	0.44	0.5	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903190	chr6:135055033~135060550:+
TGCT	cis	rs950169	0.58	rs11630887	ENSG00000225151.9	GOLGA2P7	-6.42	2.61e-09	6.85e-06	-0.57	-0.5	Schizophrenia;	chr15:84649784	chr15:84199311~84230136:-
TGCT	cis	rs694739	1	rs11231757	ENSG00000236935.1	AP003774.1	6.42	2.62e-09	6.87e-06	0.38	0.5	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338845	chr11:64325050~64329504:-
TGCT	cis	rs524281	0.773	rs11227413	ENSG00000255320.1	RP11-755F10.1	6.42	2.63e-09	6.91e-06	0.63	0.5	Electroencephalogram traits;	chr11:66116225	chr11:66244840~66246239:-
TGCT	cis	rs7757969	1	rs9481189	ENSG00000227012.2	RP1-97J1.2	6.42	2.64e-09	6.91e-06	0.77	0.5	Schizophrenia;	chr6:111792735	chr6:111900489~111901851:-
TGCT	cis	rs7757969	1	rs6939727	ENSG00000227012.2	RP1-97J1.2	6.42	2.64e-09	6.91e-06	0.77	0.5	Schizophrenia;	chr6:111795248	chr6:111900489~111901851:-
TGCT	cis	rs7757969	1	rs6908866	ENSG00000227012.2	RP1-97J1.2	6.42	2.64e-09	6.91e-06	0.77	0.5	Schizophrenia;	chr6:111797302	chr6:111900489~111901851:-
TGCT	cis	rs7757969	1	rs6919306	ENSG00000227012.2	RP1-97J1.2	6.42	2.64e-09	6.91e-06	0.77	0.5	Schizophrenia;	chr6:111798416	chr6:111900489~111901851:-
TGCT	cis	rs7757969	1	rs2148709	ENSG00000227012.2	RP1-97J1.2	6.42	2.64e-09	6.91e-06	0.77	0.5	Schizophrenia;	chr6:111800025	chr6:111900489~111901851:-
TGCT	cis	rs7757969	0.941	rs9487723	ENSG00000227012.2	RP1-97J1.2	6.42	2.64e-09	6.91e-06	0.77	0.5	Schizophrenia;	chr6:111803237	chr6:111900489~111901851:-
TGCT	cis	rs7757969	1	rs9387038	ENSG00000227012.2	RP1-97J1.2	6.42	2.64e-09	6.91e-06	0.77	0.5	Schizophrenia;	chr6:111804132	chr6:111900489~111901851:-
TGCT	cis	rs7757969	1	rs9481192	ENSG00000227012.2	RP1-97J1.2	6.42	2.64e-09	6.91e-06	0.77	0.5	Schizophrenia;	chr6:111809275	chr6:111900489~111901851:-
TGCT	cis	rs7757969	1	rs9387040	ENSG00000227012.2	RP1-97J1.2	6.42	2.64e-09	6.91e-06	0.77	0.5	Schizophrenia;	chr6:111810375	chr6:111900489~111901851:-
TGCT	cis	rs7757969	1	rs7757969	ENSG00000227012.2	RP1-97J1.2	6.42	2.64e-09	6.91e-06	0.77	0.5	Schizophrenia;	chr6:111810829	chr6:111900489~111901851:-
TGCT	cis	rs875971	0.522	rs1880556	ENSG00000222364.1	RNU6-96P	-6.42	2.65e-09	6.94e-06	-0.57	-0.5	Aortic root size;	chr7:65967557	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.522	rs781144	ENSG00000222364.1	RNU6-96P	-6.42	2.65e-09	6.94e-06	-0.57	-0.5	Aortic root size;	chr7:65975357	chr7:66395191~66395286:+
TGCT	cis	rs3814244	0.751	rs12832728	ENSG00000255733.4	IFNG-AS1	-6.42	2.65e-09	6.95e-06	-0.47	-0.5	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026623	chr12:67989445~68234686:+
TGCT	cis	rs12891047	0.866	rs1956346	ENSG00000258759.1	RP11-1012A1.7	-6.42	2.67e-09	6.98e-06	-0.44	-0.5	Amyotrophic lateral sclerosis (sporadic);	chr14:67836857	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.865	rs11620947	ENSG00000258759.1	RP11-1012A1.7	-6.42	2.67e-09	6.98e-06	-0.44	-0.5	Amyotrophic lateral sclerosis (sporadic);	chr14:67839245	chr14:67799004~67799609:+
TGCT	cis	rs5769707	0.521	rs6009810	ENSG00000188511.11	C22orf34	6.42	2.68e-09	7.02e-06	0.56	0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49665892	chr22:49414524~49657542:-
TGCT	cis	rs748404	0.66	rs2467741	ENSG00000205771.5	CATSPER2P1	-6.41	2.69e-09	7.05e-06	-0.56	-0.5	Lung cancer;	chr15:43450428	chr15:43726918~43747094:-
TGCT	cis	rs943437	0.808	rs9487770	ENSG00000227012.2	RP1-97J1.2	6.41	2.7e-09	7.06e-06	0.68	0.5	Parkinson's disease;	chr6:111959953	chr6:111900489~111901851:-
TGCT	cis	rs943437	0.866	rs9487771	ENSG00000227012.2	RP1-97J1.2	6.41	2.7e-09	7.06e-06	0.68	0.5	Parkinson's disease;	chr6:111960074	chr6:111900489~111901851:-
TGCT	cis	rs875971	0.577	rs35072105	ENSG00000222364.1	RNU6-96P	6.41	2.7e-09	7.07e-06	0.59	0.5	Aortic root size;	chr7:66144830	chr7:66395191~66395286:+
TGCT	cis	rs7412746	0.658	rs3843843	ENSG00000206931.1	RNU6-1042P	6.41	2.72e-09	7.1e-06	0.4	0.5	Melanoma;	chr1:150945608	chr1:150701866~150701972:+
TGCT	cis	rs9549367	0.789	rs9549698	ENSG00000269125.1	RP11-98F14.11	-6.41	2.72e-09	7.1e-06	-0.59	-0.5	Platelet distribution width;	chr13:113223387	chr13:113165002~113165183:-
TGCT	cis	rs172166	0.637	rs1071893	ENSG00000216901.1	AL022393.7	6.41	2.73e-09	7.12e-06	0.62	0.5	Cardiac Troponin-T levels;	chr6:28199857	chr6:28176188~28176674:+
TGCT	cis	rs9326248	0.731	rs90192	ENSG00000254851.1	RP11-109L13.1	-6.41	2.75e-09	7.18e-06	-0.83	-0.5	Blood protein levels;	chr11:117188631	chr11:117135528~117138582:+
TGCT	cis	rs17301013	0.606	rs17300775	ENSG00000227373.4	RP11-160H22.5	6.41	2.76e-09	7.19e-06	0.58	0.5	Systemic lupus erythematosus;	chr1:174191901	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.566	rs72711492	ENSG00000227373.4	RP11-160H22.5	6.41	2.76e-09	7.19e-06	0.58	0.5	Systemic lupus erythematosus;	chr1:174195464	chr1:174115300~174160004:-
TGCT	cis	rs875971	0.545	rs4441996	ENSG00000226824.5	RP4-756H11.3	6.41	2.77e-09	7.2e-06	0.62	0.5	Aortic root size;	chr7:66123233	chr7:66654538~66669855:+
TGCT	cis	rs12891047	0.899	rs8017013	ENSG00000258759.1	RP11-1012A1.7	-6.41	2.79e-09	7.26e-06	-0.44	-0.5	Amyotrophic lateral sclerosis (sporadic);	chr14:67834688	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.865	rs17783160	ENSG00000258759.1	RP11-1012A1.7	-6.41	2.79e-09	7.26e-06	-0.44	-0.5	Amyotrophic lateral sclerosis (sporadic);	chr14:67835410	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.899	rs1956348	ENSG00000258759.1	RP11-1012A1.7	-6.41	2.79e-09	7.26e-06	-0.44	-0.5	Amyotrophic lateral sclerosis (sporadic);	chr14:67836612	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.866	rs1956345	ENSG00000258759.1	RP11-1012A1.7	-6.41	2.79e-09	7.26e-06	-0.44	-0.5	Amyotrophic lateral sclerosis (sporadic);	chr14:67837208	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.866	rs10146380	ENSG00000258759.1	RP11-1012A1.7	-6.41	2.79e-09	7.26e-06	-0.44	-0.5	Amyotrophic lateral sclerosis (sporadic);	chr14:67837306	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.899	rs11627417	ENSG00000258759.1	RP11-1012A1.7	-6.41	2.79e-09	7.26e-06	-0.44	-0.5	Amyotrophic lateral sclerosis (sporadic);	chr14:67837628	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.865	rs55999745	ENSG00000258759.1	RP11-1012A1.7	-6.41	2.79e-09	7.26e-06	-0.44	-0.5	Amyotrophic lateral sclerosis (sporadic);	chr14:67839144	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.899	rs11844492	ENSG00000258759.1	RP11-1012A1.7	-6.41	2.79e-09	7.26e-06	-0.44	-0.5	Amyotrophic lateral sclerosis (sporadic);	chr14:67839813	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.866	rs11158697	ENSG00000258759.1	RP11-1012A1.7	-6.41	2.79e-09	7.26e-06	-0.44	-0.5	Amyotrophic lateral sclerosis (sporadic);	chr14:67840665	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.933	rs11622535	ENSG00000258759.1	RP11-1012A1.7	-6.41	2.79e-09	7.26e-06	-0.44	-0.5	Amyotrophic lateral sclerosis (sporadic);	chr14:67841216	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.898	rs10873208	ENSG00000258759.1	RP11-1012A1.7	-6.41	2.79e-09	7.26e-06	-0.44	-0.5	Amyotrophic lateral sclerosis (sporadic);	chr14:67841777	chr14:67799004~67799609:+
TGCT	cis	rs9326248	0.53	rs1242229	ENSG00000254851.1	RP11-109L13.1	-6.41	2.79e-09	7.27e-06	-0.91	-0.5	Blood protein levels;	chr11:117191654	chr11:117135528~117138582:+
TGCT	cis	rs1930961	1	rs6004673	ENSG00000272977.1	CTA-390C10.10	-6.41	2.8e-09	7.27e-06	-0.65	-0.5	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25476218~25479971:+
TGCT	cis	rs3096299	0.658	rs34590044	ENSG00000274627.1	RP11-104N10.2	6.41	2.81e-09	7.29e-06	0.5	0.5	Multiple myeloma (IgH translocation);	chr16:89476749	chr16:89516797~89522217:+
TGCT	cis	rs17301013	0.606	rs56152378	ENSG00000227373.4	RP11-160H22.5	6.41	2.81e-09	7.3e-06	0.6	0.5	Systemic lupus erythematosus;	chr1:174106480	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs4652179	ENSG00000227373.4	RP11-160H22.5	6.41	2.81e-09	7.3e-06	0.6	0.5	Systemic lupus erythematosus;	chr1:174107185	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.581	rs17353198	ENSG00000227373.4	RP11-160H22.5	6.41	2.81e-09	7.3e-06	0.6	0.5	Systemic lupus erythematosus;	chr1:174107439	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs17350991	ENSG00000227373.4	RP11-160H22.5	6.41	2.81e-09	7.3e-06	0.6	0.5	Systemic lupus erythematosus;	chr1:174114330	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs57407575	ENSG00000227373.4	RP11-160H22.5	6.41	2.81e-09	7.3e-06	0.6	0.5	Systemic lupus erythematosus;	chr1:174115504	chr1:174115300~174160004:-
TGCT	cis	rs524281	0.861	rs12049852	ENSG00000255320.1	RP11-755F10.1	6.4	2.83e-09	7.35e-06	0.62	0.5	Electroencephalogram traits;	chr11:66117231	chr11:66244840~66246239:-
TGCT	cis	rs694739	0.628	rs538147	ENSG00000236935.1	AP003774.1	6.4	2.84e-09	7.38e-06	0.37	0.5	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64362250	chr11:64325050~64329504:-
TGCT	cis	rs2283792	0.765	rs34550586	ENSG00000228050.1	TOP3BP1	6.4	2.84e-09	7.38e-06	0.59	0.5	Multiple sclerosis;	chr22:21791345	chr22:22223187~22224566:-
TGCT	cis	rs17301013	0.507	rs10912753	ENSG00000227373.4	RP11-160H22.5	6.4	2.85e-09	7.4e-06	0.59	0.5	Systemic lupus erythematosus;	chr1:174265226	chr1:174115300~174160004:-
TGCT	cis	rs9549367	0.713	rs510160	ENSG00000269125.1	RP11-98F14.11	6.4	2.85e-09	7.4e-06	0.61	0.5	Platelet distribution width;	chr13:113168167	chr13:113165002~113165183:-
TGCT	cis	rs7617773	0.817	rs3731534	ENSG00000229759.1	MRPS18AP1	6.4	2.86e-09	7.4e-06	0.43	0.5	Coronary artery disease;	chr3:48170287	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.817	rs3731513	ENSG00000229759.1	MRPS18AP1	6.4	2.86e-09	7.4e-06	0.43	0.5	Coronary artery disease;	chr3:48178047	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.817	rs3729577	ENSG00000229759.1	MRPS18AP1	6.4	2.86e-09	7.4e-06	0.43	0.5	Coronary artery disease;	chr3:48187504	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.779	rs3731487	ENSG00000229759.1	MRPS18AP1	6.4	2.86e-09	7.4e-06	0.43	0.5	Coronary artery disease;	chr3:48188134	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.851	rs7647817	ENSG00000229759.1	MRPS18AP1	6.4	2.86e-09	7.4e-06	0.43	0.5	Coronary artery disease;	chr3:48195017	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.817	rs11707606	ENSG00000229759.1	MRPS18AP1	6.4	2.86e-09	7.4e-06	0.43	0.5	Coronary artery disease;	chr3:48195597	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.817	rs17786132	ENSG00000229759.1	MRPS18AP1	6.4	2.86e-09	7.4e-06	0.43	0.5	Coronary artery disease;	chr3:48207930	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.817	rs35456569	ENSG00000229759.1	MRPS18AP1	6.4	2.86e-09	7.4e-06	0.43	0.5	Coronary artery disease;	chr3:48209409	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.784	rs11715799	ENSG00000229759.1	MRPS18AP1	6.4	2.86e-09	7.4e-06	0.43	0.5	Coronary artery disease;	chr3:48213730	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.817	rs34728236	ENSG00000229759.1	MRPS18AP1	6.4	2.86e-09	7.4e-06	0.43	0.5	Coronary artery disease;	chr3:48217618	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.817	rs79310258	ENSG00000229759.1	MRPS18AP1	6.4	2.86e-09	7.4e-06	0.43	0.5	Coronary artery disease;	chr3:48218177	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.746	rs6796343	ENSG00000229759.1	MRPS18AP1	6.4	2.86e-09	7.4e-06	0.43	0.5	Coronary artery disease;	chr3:48240531	chr3:48256350~48256938:-
TGCT	cis	rs6700559	0.873	rs7526031	ENSG00000260088.1	RP11-92G12.3	-6.4	2.86e-09	7.41e-06	-0.6	-0.5	Coronary artery disease;	chr1:200695174	chr1:200669507~200694250:+
TGCT	cis	rs875971	1	rs6961717	ENSG00000222364.1	RNU6-96P	6.4	2.88e-09	7.46e-06	0.57	0.5	Aortic root size;	chr7:66122550	chr7:66395191~66395286:+
TGCT	cis	rs7757969	1	rs6921229	ENSG00000227012.2	RP1-97J1.2	6.4	2.88e-09	7.47e-06	0.8	0.5	Schizophrenia;	chr6:111827090	chr6:111900489~111901851:-
TGCT	cis	rs7412746	0.611	rs111905669	ENSG00000206931.1	RNU6-1042P	6.4	2.89e-09	7.48e-06	0.39	0.5	Melanoma;	chr1:150805089	chr1:150701866~150701972:+
TGCT	cis	rs2882667	0.858	rs6882112	ENSG00000253404.1	AC034243.1	-6.4	2.92e-09	7.55e-06	-0.58	-0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078046	chr5:138744434~138753309:-
TGCT	cis	rs7617773	0.78	rs3731489	ENSG00000229759.1	MRPS18AP1	6.4	2.97e-09	7.67e-06	0.43	0.5	Coronary artery disease;	chr3:48187416	chr3:48256350~48256938:-
TGCT	cis	rs875971	0.571	rs160641	ENSG00000226824.5	RP4-756H11.3	6.39	2.97e-09	7.69e-06	0.62	0.5	Aortic root size;	chr7:66112359	chr7:66654538~66669855:+
TGCT	cis	rs17301013	0.581	rs11801385	ENSG00000227373.4	RP11-160H22.5	6.39	2.99e-09	7.72e-06	0.61	0.5	Systemic lupus erythematosus;	chr1:174089454	chr1:174115300~174160004:-
TGCT	cis	rs10875976	0.525	rs2271688	ENSG00000257253.2	RP11-70F11.7	6.39	3.01e-09	7.77e-06	0.42	0.5	Obesity;	chr12:49865746	chr12:49861207~49865802:+
TGCT	cis	rs4691139	0.903	rs13127188	ENSG00000250227.1	TRIM60P14	6.39	3.02e-09	7.8e-06	0.55	0.5	Ovarian cancer in BRCA1 mutation carriers;	chr4:164997524	chr4:164915565~164916983:+
TGCT	cis	rs4691139	0.903	rs6835415	ENSG00000250227.1	TRIM60P14	6.39	3.02e-09	7.8e-06	0.55	0.5	Ovarian cancer in BRCA1 mutation carriers;	chr4:164998932	chr4:164915565~164916983:+
TGCT	cis	rs4691139	0.903	rs6812591	ENSG00000250227.1	TRIM60P14	6.39	3.02e-09	7.8e-06	0.55	0.5	Ovarian cancer in BRCA1 mutation carriers;	chr4:164999023	chr4:164915565~164916983:+
TGCT	cis	rs4691139	0.903	rs6812776	ENSG00000250227.1	TRIM60P14	6.39	3.02e-09	7.8e-06	0.55	0.5	Ovarian cancer in BRCA1 mutation carriers;	chr4:164999097	chr4:164915565~164916983:+
TGCT	cis	rs2283792	0.73	rs738858	ENSG00000228050.1	TOP3BP1	6.39	3.03e-09	7.83e-06	0.57	0.5	Multiple sclerosis;	chr22:21926544	chr22:22223187~22224566:-
TGCT	cis	rs189798	0.807	rs330909	ENSG00000254340.1	RP11-10A14.3	6.39	3.04e-09	7.85e-06	0.57	0.5	Myopia (pathological);	chr8:9137877	chr8:9141424~9145435:+
TGCT	cis	rs6597981	0.604	rs7945912	ENSG00000279672.1	CMB9-55F22.1	6.39	3.05e-09	7.86e-06	0.74	0.5	Breast cancer;	chr11:750849	chr11:779617~780755:+
TGCT	cis	rs875971	1	rs2087647	ENSG00000222364.1	RNU6-96P	6.39	3.07e-09	7.92e-06	0.57	0.5	Aortic root size;	chr7:66128201	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs6958484	ENSG00000222364.1	RNU6-96P	6.39	3.07e-09	7.92e-06	0.57	0.5	Aortic root size;	chr7:66134459	chr7:66395191~66395286:+
TGCT	cis	rs4691139	0.901	rs9762579	ENSG00000250227.1	TRIM60P14	6.39	3.08e-09	7.93e-06	0.54	0.5	Ovarian cancer in BRCA1 mutation carriers;	chr4:164956838	chr4:164915565~164916983:+
TGCT	cis	rs950169	0.58	rs17598114	ENSG00000225151.9	GOLGA2P7	-6.39	3.09e-09	7.96e-06	-0.56	-0.5	Schizophrenia;	chr15:84628086	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.58	rs17532346	ENSG00000225151.9	GOLGA2P7	-6.39	3.09e-09	7.96e-06	-0.56	-0.5	Schizophrenia;	chr15:84628264	chr15:84199311~84230136:-
TGCT	cis	rs35828350	1	rs35828350	ENSG00000225151.9	GOLGA2P7	-6.39	3.11e-09	8e-06	-0.57	-0.5	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.58	rs11634322	ENSG00000225151.9	GOLGA2P7	-6.38	3.15e-09	8.11e-06	-0.56	-0.5	Schizophrenia;	chr15:84628978	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.58	rs4603535	ENSG00000225151.9	GOLGA2P7	-6.38	3.15e-09	8.11e-06	-0.56	-0.5	Schizophrenia;	chr15:84630641	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.541	rs10795	ENSG00000225151.9	GOLGA2P7	-6.38	3.15e-09	8.11e-06	-0.56	-0.5	Schizophrenia;	chr15:84634066	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.58	rs36126054	ENSG00000225151.9	GOLGA2P7	-6.38	3.15e-09	8.11e-06	-0.56	-0.5	Schizophrenia;	chr15:84634492	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.58	rs1061737	ENSG00000225151.9	GOLGA2P7	-6.38	3.15e-09	8.11e-06	-0.56	-0.5	Schizophrenia;	chr15:84640559	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.58	rs11634320	ENSG00000225151.9	GOLGA2P7	6.38	3.15e-09	8.11e-06	0.56	0.5	Schizophrenia;	chr15:84628952	chr15:84199311~84230136:-
TGCT	cis	rs875971	1	rs1544549	ENSG00000222364.1	RNU6-96P	6.38	3.16e-09	8.12e-06	0.57	0.5	Aortic root size;	chr7:66625676	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs2420820	ENSG00000222364.1	RNU6-96P	6.38	3.16e-09	8.12e-06	0.57	0.5	Aortic root size;	chr7:66626920	chr7:66395191~66395286:+
TGCT	cis	rs694739	1	rs1783521	ENSG00000236935.1	AP003774.1	6.38	3.17e-09	8.14e-06	0.38	0.5	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338819	chr11:64325050~64329504:-
TGCT	cis	rs977987	0.843	rs4146810	ENSG00000261783.1	RP11-252K23.2	-6.38	3.19e-09	8.14e-06	-0.71	-0.5	Dupuytren's disease;	chr16:75381933	chr16:75379818~75381260:-
TGCT	cis	rs12908161	0.92	rs35758837	ENSG00000225151.9	GOLGA2P7	-6.38	3.2e-09	8.14e-06	-0.56	-0.5	Schizophrenia;	chr15:84768151	chr15:84199311~84230136:-
TGCT	cis	rs12908161	1	rs17600551	ENSG00000225151.9	GOLGA2P7	-6.38	3.2e-09	8.14e-06	-0.56	-0.5	Schizophrenia;	chr15:84776027	chr15:84199311~84230136:-
TGCT	cis	rs12908161	1	rs36033486	ENSG00000225151.9	GOLGA2P7	-6.38	3.2e-09	8.14e-06	-0.56	-0.5	Schizophrenia;	chr15:84776461	chr15:84199311~84230136:-
TGCT	cis	rs12908161	1	rs62019469	ENSG00000225151.9	GOLGA2P7	-6.38	3.2e-09	8.14e-06	-0.56	-0.5	Schizophrenia;	chr15:84777989	chr15:84199311~84230136:-
TGCT	cis	rs12908161	1	rs12908549	ENSG00000225151.9	GOLGA2P7	-6.38	3.2e-09	8.14e-06	-0.56	-0.5	Schizophrenia;	chr15:84779120	chr15:84199311~84230136:-
TGCT	cis	rs76878669	0.793	rs7924580	ENSG00000254510.1	RP11-867G23.10	-6.38	3.21e-09	8.17e-06	-0.73	-0.5	Educational attainment (years of education);	chr11:66313299	chr11:66409158~66417137:+
TGCT	cis	rs12891047	0.901	rs7143496	ENSG00000258759.1	RP11-1012A1.7	6.38	3.23e-09	8.22e-06	0.44	0.5	Amyotrophic lateral sclerosis (sporadic);	chr14:67783797	chr14:67799004~67799609:+
TGCT	cis	rs9549367	0.756	rs3861723	ENSG00000269125.1	RP11-98F14.11	-6.38	3.23e-09	8.22e-06	-0.57	-0.5	Platelet distribution width;	chr13:113256612	chr13:113165002~113165183:-
TGCT	cis	rs189798	0.807	rs9949	ENSG00000254340.1	RP11-10A14.3	6.38	3.23e-09	8.22e-06	0.54	0.5	Myopia (pathological);	chr8:9137002	chr8:9141424~9145435:+
TGCT	cis	rs11098499	0.604	rs2389886	ENSG00000245958.5	RP11-33B1.1	-6.38	3.24e-09	8.23e-06	-0.53	-0.5	Corneal astigmatism;	chr4:119649267	chr4:119454791~119552025:+
TGCT	cis	rs1528149	0.856	rs60333130	ENSG00000224683.1	RPL36AP29	6.37	3.28e-09	8.28e-06	0.6	0.5	Sitting height ratio;	chr7:16059809	chr7:16208945~16209265:+
TGCT	cis	rs6452524	0.836	rs2731849	ENSG00000249664.1	CTD-2227C6.2	-6.37	3.28e-09	8.28e-06	-0.55	-0.5	Hypertension (SNP x SNP interaction);	chr5:83214060	chr5:83012285~83013109:-
TGCT	cis	rs524281	0.861	rs535395	ENSG00000255320.1	RP11-755F10.1	-6.37	3.28e-09	8.3e-06	-0.62	-0.5	Electroencephalogram traits;	chr11:66139063	chr11:66244840~66246239:-
TGCT	cis	rs6452524	0.713	rs2386245	ENSG00000249664.1	CTD-2227C6.2	-6.37	3.3e-09	8.32e-06	-0.55	-0.5	Hypertension (SNP x SNP interaction);	chr5:83214866	chr5:83012285~83013109:-
TGCT	cis	rs12891047	0.966	rs181563	ENSG00000258759.1	RP11-1012A1.7	-6.37	3.31e-09	8.35e-06	-0.43	-0.5	Amyotrophic lateral sclerosis (sporadic);	chr14:67814131	chr14:67799004~67799609:+
TGCT	cis	rs7412746	0.611	rs12410869	ENSG00000206931.1	RNU6-1042P	6.37	3.33e-09	8.39e-06	0.4	0.5	Melanoma;	chr1:150883677	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.611	rs36008098	ENSG00000206931.1	RNU6-1042P	6.37	3.33e-09	8.39e-06	0.4	0.5	Melanoma;	chr1:150884330	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.634	rs12409208	ENSG00000206931.1	RNU6-1042P	6.37	3.33e-09	8.39e-06	0.4	0.5	Melanoma;	chr1:150887579	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs12410394	ENSG00000206931.1	RNU6-1042P	6.37	3.33e-09	8.39e-06	0.4	0.5	Melanoma;	chr1:150887710	chr1:150701866~150701972:+
TGCT	cis	rs17301013	0.606	rs4650968	ENSG00000227373.4	RP11-160H22.5	6.37	3.37e-09	8.49e-06	0.59	0.5	Systemic lupus erythematosus;	chr1:174223322	chr1:174115300~174160004:-
TGCT	cis	rs12891047	0.901	rs1543391	ENSG00000258759.1	RP11-1012A1.7	-6.37	3.37e-09	8.49e-06	-0.43	-0.5	Amyotrophic lateral sclerosis (sporadic);	chr14:67801533	chr14:67799004~67799609:+
TGCT	cis	rs2882667	0.822	rs11738376	ENSG00000253404.1	AC034243.1	6.37	3.4e-09	8.57e-06	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139062483	chr5:138744434~138753309:-
TGCT	cis	rs7044106	0.762	rs3903886	ENSG00000226752.6	PSMD5-AS1	6.36	3.48e-09	8.75e-06	0.61	0.5	Hip circumference adjusted for BMI;	chr9:120621368	chr9:120824828~120854385:+
TGCT	cis	rs11155671	0.53	rs9371215	ENSG00000216906.2	RP11-350J20.9	6.36	3.51e-09	8.82e-06	0.55	0.5	Testicular germ cell tumor;	chr6:149873162	chr6:149904243~149906418:+
TGCT	cis	rs875971	0.825	rs28480509	ENSG00000222364.1	RNU6-96P	6.36	3.53e-09	8.85e-06	0.56	0.5	Aortic root size;	chr7:66634237	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs9791712	ENSG00000222364.1	RNU6-96P	6.36	3.53e-09	8.85e-06	0.56	0.5	Aortic root size;	chr7:66640176	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs9791713	ENSG00000222364.1	RNU6-96P	6.36	3.53e-09	8.85e-06	0.56	0.5	Aortic root size;	chr7:66640211	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs1860469	ENSG00000222364.1	RNU6-96P	6.36	3.53e-09	8.85e-06	0.56	0.5	Aortic root size;	chr7:66641888	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs4718383	ENSG00000222364.1	RNU6-96P	6.36	3.53e-09	8.85e-06	0.56	0.5	Aortic root size;	chr7:66643422	chr7:66395191~66395286:+
TGCT	cis	rs3096299	0.754	rs2965816	ENSG00000274627.1	RP11-104N10.2	-6.36	3.54e-09	8.87e-06	-0.5	-0.5	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89516797~89522217:+
TGCT	cis	rs17301013	0.507	rs6701911	ENSG00000227373.4	RP11-160H22.5	6.36	3.54e-09	8.89e-06	0.57	0.5	Systemic lupus erythematosus;	chr1:174364755	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs56148594	ENSG00000227373.4	RP11-160H22.5	6.36	3.54e-09	8.89e-06	0.57	0.5	Systemic lupus erythematosus;	chr1:174383932	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12091056	ENSG00000227373.4	RP11-160H22.5	6.36	3.54e-09	8.89e-06	0.57	0.5	Systemic lupus erythematosus;	chr1:174384470	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs57953555	ENSG00000227373.4	RP11-160H22.5	6.36	3.54e-09	8.89e-06	0.57	0.5	Systemic lupus erythematosus;	chr1:174384958	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs4651019	ENSG00000227373.4	RP11-160H22.5	6.36	3.54e-09	8.89e-06	0.57	0.5	Systemic lupus erythematosus;	chr1:174385079	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs10912775	ENSG00000227373.4	RP11-160H22.5	6.36	3.54e-09	8.89e-06	0.57	0.5	Systemic lupus erythematosus;	chr1:174388034	chr1:174115300~174160004:-
TGCT	cis	rs172166	0.637	rs1225597	ENSG00000216901.1	AL022393.7	6.36	3.54e-09	8.89e-06	0.62	0.5	Cardiac Troponin-T levels;	chr6:28194309	chr6:28176188~28176674:+
TGCT	cis	rs7617773	0.817	rs11928691	ENSG00000229759.1	MRPS18AP1	6.36	3.55e-09	8.91e-06	0.42	0.5	Coronary artery disease;	chr3:48245275	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.817	rs9311421	ENSG00000229759.1	MRPS18AP1	6.36	3.55e-09	8.91e-06	0.42	0.5	Coronary artery disease;	chr3:48251588	chr3:48256350~48256938:-
TGCT	cis	rs9389248	0.69	rs728030	ENSG00000232876.1	CTA-212D2.2	6.36	3.56e-09	8.92e-06	0.45	0.5	High light scatter reticulocyte percentage of red cells;	chr6:134925156	chr6:135055033~135060550:+
TGCT	cis	rs875971	0.54	rs781152	ENSG00000236529.1	RP13-254B10.1	6.36	3.57e-09	8.95e-06	0.37	0.5	Aortic root size;	chr7:66014585	chr7:65840212~65840596:+
TGCT	cis	rs17711722	0.727	rs781151	ENSG00000236529.1	RP13-254B10.1	6.36	3.57e-09	8.95e-06	0.37	0.5	Calcium levels;	chr7:66014891	chr7:65840212~65840596:+
TGCT	cis	rs7412746	0.646	rs10399947	ENSG00000206931.1	RNU6-1042P	6.36	3.57e-09	8.95e-06	0.4	0.5	Melanoma;	chr1:150889484	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.634	rs12096831	ENSG00000206931.1	RNU6-1042P	6.36	3.57e-09	8.95e-06	0.4	0.5	Melanoma;	chr1:150891637	chr1:150701866~150701972:+
TGCT	cis	rs1528149	1	rs1528149	ENSG00000224683.1	RPL36AP29	6.36	3.61e-09	9.03e-06	0.6	0.5	Sitting height ratio;	chr7:16067733	chr7:16208945~16209265:+
TGCT	cis	rs875971	0.545	rs7783889	ENSG00000226824.5	RP4-756H11.3	-6.35	3.62e-09	9.05e-06	-0.6	-0.5	Aortic root size;	chr7:66283366	chr7:66654538~66669855:+
TGCT	cis	rs17301013	0.507	rs61218633	ENSG00000227373.4	RP11-160H22.5	6.35	3.62e-09	9.07e-06	0.57	0.5	Systemic lupus erythematosus;	chr1:174375955	chr1:174115300~174160004:-
TGCT	cis	rs9326248	0.52	rs2735183	ENSG00000254851.1	RP11-109L13.1	-6.35	3.63e-09	9.1e-06	-0.61	-0.5	Blood protein levels;	chr11:117144479	chr11:117135528~117138582:+
TGCT	cis	rs5769707	0.706	rs2071903	ENSG00000188511.11	C22orf34	6.35	3.67e-09	9.19e-06	0.54	0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49640869	chr22:49414524~49657542:-
TGCT	cis	rs748404	0.66	rs2467738	ENSG00000205771.5	CATSPER2P1	-6.35	3.68e-09	9.2e-06	-0.55	-0.5	Lung cancer;	chr15:43447738	chr15:43726918~43747094:-
TGCT	cis	rs6452524	0.935	rs6887915	ENSG00000249664.1	CTD-2227C6.2	6.35	3.7e-09	9.25e-06	0.53	0.5	Hypertension (SNP x SNP interaction);	chr5:83170837	chr5:83012285~83013109:-
TGCT	cis	rs875971	0.522	rs1617484	ENSG00000222364.1	RNU6-96P	-6.35	3.71e-09	9.25e-06	-0.57	-0.5	Aortic root size;	chr7:65998108	chr7:66395191~66395286:+
TGCT	cis	rs7757969	1	rs7758660	ENSG00000227012.2	RP1-97J1.2	6.35	3.73e-09	9.29e-06	0.76	0.5	Schizophrenia;	chr6:111807744	chr6:111900489~111901851:-
TGCT	cis	rs2882667	0.861	rs11242445	ENSG00000253404.1	AC034243.1	6.35	3.74e-09	9.3e-06	0.55	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139081365	chr5:138744434~138753309:-
TGCT	cis	rs9890032	0.52	rs2321926	ENSG00000266490.1	CTD-2349P21.9	6.35	3.75e-09	9.34e-06	0.39	0.5	Hip circumference adjusted for BMI;	chr17:30714534	chr17:30792372~30792833:+
TGCT	cis	rs801193	0.66	rs2659897	ENSG00000222364.1	RNU6-96P	6.35	3.76e-09	9.36e-06	0.57	0.5	Aortic root size;	chr7:66722728	chr7:66395191~66395286:+
TGCT	cis	rs1891275	0.551	rs4933687	ENSG00000228701.1	TNKS2-AS1	-6.35	3.77e-09	9.39e-06	-0.57	-0.5	Intelligence (multi-trait analysis);	chr10:91650642	chr10:91782839~91798291:-
TGCT	cis	rs875971	0.52	rs12666485	ENSG00000226824.5	RP4-756H11.3	-6.35	3.78e-09	9.39e-06	-0.61	-0.5	Aortic root size;	chr7:66160135	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs67688847	ENSG00000226824.5	RP4-756H11.3	-6.35	3.78e-09	9.39e-06	-0.61	-0.5	Aortic root size;	chr7:66161064	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs7787063	ENSG00000226824.5	RP4-756H11.3	-6.35	3.78e-09	9.39e-06	-0.61	-0.5	Aortic root size;	chr7:66164012	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs12673308	ENSG00000226824.5	RP4-756H11.3	-6.35	3.78e-09	9.39e-06	-0.61	-0.5	Aortic root size;	chr7:66166374	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs67397473	ENSG00000226824.5	RP4-756H11.3	-6.35	3.78e-09	9.39e-06	-0.61	-0.5	Aortic root size;	chr7:66168318	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs10950027	ENSG00000226824.5	RP4-756H11.3	-6.35	3.78e-09	9.39e-06	-0.61	-0.5	Aortic root size;	chr7:66169164	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs73376401	ENSG00000226824.5	RP4-756H11.3	-6.35	3.78e-09	9.39e-06	-0.61	-0.5	Aortic root size;	chr7:66174841	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs6460276	ENSG00000226824.5	RP4-756H11.3	-6.35	3.78e-09	9.39e-06	-0.61	-0.5	Aortic root size;	chr7:66182290	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs67775320	ENSG00000226824.5	RP4-756H11.3	-6.35	3.78e-09	9.39e-06	-0.61	-0.5	Aortic root size;	chr7:66193792	chr7:66654538~66669855:+
TGCT	cis	rs2283792	0.73	rs2329884	ENSG00000228050.1	TOP3BP1	6.35	3.78e-09	9.39e-06	0.57	0.5	Multiple sclerosis;	chr22:21927890	chr22:22223187~22224566:-
TGCT	cis	rs943437	0.74	rs626007	ENSG00000227012.2	RP1-97J1.2	6.35	3.78e-09	9.39e-06	0.66	0.5	Parkinson's disease;	chr6:111936824	chr6:111900489~111901851:-
TGCT	cis	rs875971	0.965	rs9969301	ENSG00000222364.1	RNU6-96P	6.34	3.8e-09	9.43e-06	0.57	0.5	Aortic root size;	chr7:66316668	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.867	rs1002053	ENSG00000222364.1	RNU6-96P	6.34	3.8e-09	9.43e-06	0.57	0.5	Aortic root size;	chr7:66333558	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs2036264	ENSG00000222364.1	RNU6-96P	6.34	3.8e-09	9.43e-06	0.57	0.5	Aortic root size;	chr7:66334917	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs7783613	ENSG00000222364.1	RNU6-96P	6.34	3.8e-09	9.43e-06	0.57	0.5	Aortic root size;	chr7:66340274	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs6460292	ENSG00000222364.1	RNU6-96P	6.34	3.8e-09	9.43e-06	0.57	0.5	Aortic root size;	chr7:66345088	chr7:66395191~66395286:+
TGCT	cis	rs17507216	0.628	rs4513065	ENSG00000278603.1	RP13-608F4.5	6.34	3.8e-09	9.43e-06	0.84	0.5	Excessive daytime sleepiness;	chr15:82712096	chr15:82472203~82472426:+
TGCT	cis	rs10875976	0.525	rs10783326	ENSG00000257253.2	RP11-70F11.7	6.34	3.8e-09	9.43e-06	0.44	0.5	Obesity;	chr12:49865361	chr12:49861207~49865802:+
TGCT	cis	rs2882667	0.756	rs11957953	ENSG00000253404.1	AC034243.1	6.34	3.81e-09	9.46e-06	0.61	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139143688	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.788	rs11959691	ENSG00000253404.1	AC034243.1	6.34	3.81e-09	9.46e-06	0.61	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139145399	chr5:138744434~138753309:-
TGCT	cis	rs875971	0.66	rs10272357	ENSG00000222364.1	RNU6-96P	6.34	3.82e-09	9.49e-06	0.58	0.49	Aortic root size;	chr7:66598087	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs9986696	ENSG00000222364.1	RNU6-96P	6.34	3.83e-09	9.49e-06	0.57	0.49	Aortic root size;	chr7:66239589	chr7:66395191~66395286:+
TGCT	cis	rs9549367	0.569	rs3024738	ENSG00000269125.1	RP11-98F14.11	6.34	3.83e-09	9.5e-06	0.6	0.49	Platelet distribution width;	chr13:113165607	chr13:113165002~113165183:-
TGCT	cis	rs1891275	0.601	rs1970506	ENSG00000228701.1	TNKS2-AS1	-6.34	3.84e-09	9.53e-06	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91668529	chr10:91782839~91798291:-
TGCT	cis	rs6452524	0.836	rs2089565	ENSG00000249664.1	CTD-2227C6.2	-6.34	3.87e-09	9.6e-06	-0.55	-0.49	Hypertension (SNP x SNP interaction);	chr5:83214410	chr5:83012285~83013109:-
TGCT	cis	rs875971	1	rs6963646	ENSG00000222364.1	RNU6-96P	6.34	3.89e-09	9.63e-06	0.57	0.49	Aortic root size;	chr7:66220780	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.965	rs28682868	ENSG00000222364.1	RNU6-96P	6.34	3.89e-09	9.63e-06	0.57	0.49	Aortic root size;	chr7:66224822	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.898	rs6977501	ENSG00000222364.1	RNU6-96P	6.34	3.89e-09	9.63e-06	0.57	0.49	Aortic root size;	chr7:66228355	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.965	rs6971509	ENSG00000222364.1	RNU6-96P	6.34	3.89e-09	9.63e-06	0.57	0.49	Aortic root size;	chr7:66249983	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs937495	ENSG00000222364.1	RNU6-96P	6.34	3.89e-09	9.63e-06	0.57	0.49	Aortic root size;	chr7:66314811	chr7:66395191~66395286:+
TGCT	cis	rs7757969	1	rs9384810	ENSG00000227012.2	RP1-97J1.2	6.34	3.9e-09	9.66e-06	0.8	0.49	Schizophrenia;	chr6:111828170	chr6:111900489~111901851:-
TGCT	cis	rs875971	0.545	rs1796226	ENSG00000226824.5	RP4-756H11.3	-6.34	3.9e-09	9.66e-06	-0.6	-0.49	Aortic root size;	chr7:66622723	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs2707851	ENSG00000226824.5	RP4-756H11.3	6.34	3.9e-09	9.66e-06	0.6	0.49	Aortic root size;	chr7:66624178	chr7:66654538~66669855:+
TGCT	cis	rs6700559	0.81	rs7529962	ENSG00000260088.1	RP11-92G12.3	-6.34	3.91e-09	9.67e-06	-0.58	-0.49	Coronary artery disease;	chr1:200627849	chr1:200669507~200694250:+
TGCT	cis	rs875971	0.54	rs35510581	ENSG00000222364.1	RNU6-96P	6.34	3.94e-09	9.74e-06	0.58	0.49	Aortic root size;	chr7:66113790	chr7:66395191~66395286:+
TGCT	cis	rs6452524	0.836	rs62374402	ENSG00000249664.1	CTD-2227C6.2	6.34	3.96e-09	9.79e-06	0.54	0.49	Hypertension (SNP x SNP interaction);	chr5:83207343	chr5:83012285~83013109:-
TGCT	cis	rs875971	0.505	rs2462573	ENSG00000222364.1	RNU6-96P	6.34	3.97e-09	9.79e-06	0.57	0.49	Aortic root size;	chr7:66042405	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.505	rs1167385	ENSG00000222364.1	RNU6-96P	6.34	3.97e-09	9.79e-06	0.57	0.49	Aortic root size;	chr7:66048321	chr7:66395191~66395286:+
TGCT	cis	rs7412746	0.658	rs11589458	ENSG00000206931.1	RNU6-1042P	6.34	3.97e-09	9.81e-06	0.39	0.49	Melanoma;	chr1:150820140	chr1:150701866~150701972:+
TGCT	cis	rs9549367	1	rs9549367	ENSG00000269125.1	RP11-98F14.11	-6.33	4.01e-09	9.88e-06	-0.59	-0.49	Platelet distribution width;	chr13:113257218	chr13:113165002~113165183:-
TGCT	cis	rs875971	0.545	rs2420456	ENSG00000226824.5	RP4-756H11.3	-6.33	4.02e-09	9.92e-06	-0.6	-0.49	Aortic root size;	chr7:66280619	chr7:66654538~66669855:+
TGCT	cis	rs7412746	0.658	rs2272214	ENSG00000206931.1	RNU6-1042P	6.33	4.05e-09	9.99e-06	0.39	0.49	Melanoma;	chr1:150958986	chr1:150701866~150701972:+
TGCT	cis	rs875971	0.862	rs6971059	ENSG00000222364.1	RNU6-96P	6.33	4.06e-09	1e-05	0.55	0.49	Aortic root size;	chr7:66602045	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.789	rs7808013	ENSG00000222364.1	RNU6-96P	6.33	4.06e-09	1e-05	0.55	0.49	Aortic root size;	chr7:66606209	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.825	rs7384021	ENSG00000222364.1	RNU6-96P	6.33	4.06e-09	1e-05	0.55	0.49	Aortic root size;	chr7:66612917	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.825	rs66981195	ENSG00000222364.1	RNU6-96P	6.33	4.06e-09	1e-05	0.55	0.49	Aortic root size;	chr7:66614048	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs3926380	ENSG00000222364.1	RNU6-96P	6.33	4.06e-09	1e-05	0.55	0.49	Aortic root size;	chr7:66615658	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.825	rs1860472	ENSG00000222364.1	RNU6-96P	6.33	4.06e-09	1e-05	0.55	0.49	Aortic root size;	chr7:66617736	chr7:66395191~66395286:+
TGCT	cis	rs6452524	0.805	rs2731850	ENSG00000249664.1	CTD-2227C6.2	-6.33	4.06e-09	1e-05	-0.55	-0.49	Hypertension (SNP x SNP interaction);	chr5:83213024	chr5:83012285~83013109:-
TGCT	cis	rs3096299	0.642	rs12934829	ENSG00000274627.1	RP11-104N10.2	6.33	4.07e-09	1e-05	0.5	0.49	Multiple myeloma (IgH translocation);	chr16:89456941	chr16:89516797~89522217:+
TGCT	cis	rs9549367	0.713	rs4907598	ENSG00000269125.1	RP11-98F14.11	6.33	4.1e-09	1.01e-05	0.61	0.49	Platelet distribution width;	chr13:113207071	chr13:113165002~113165183:-
TGCT	cis	rs11673344	0.526	rs35153242	ENSG00000226686.6	LINC01535	-6.33	4.1e-09	1.01e-05	-0.57	-0.49	Obesity-related traits;	chr19:37660841	chr19:37251912~37265535:+
TGCT	cis	rs7412746	0.658	rs6669855	ENSG00000206931.1	RNU6-1042P	6.33	4.11e-09	1.01e-05	0.39	0.49	Melanoma;	chr1:150888753	chr1:150701866~150701972:+
TGCT	cis	rs7714584	1	rs931058	ENSG00000197083.10	ZNF300P1	6.33	4.12e-09	1.01e-05	1.13	0.49	Crohn's disease;	chr5:150954136	chr5:150930645~150946289:-
TGCT	cis	rs5760092	0.618	rs4461358	ENSG00000273295.1	AP000350.5	-6.33	4.17e-09	1.02e-05	-0.64	-0.49	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23901432~23907068:-
TGCT	cis	rs17301013	0.606	rs17350956	ENSG00000227373.4	RP11-160H22.5	6.32	4.18e-09	1.03e-05	0.6	0.49	Systemic lupus erythematosus;	chr1:174093863	chr1:174115300~174160004:-
TGCT	cis	rs3814244	0.933	rs12423194	ENSG00000255733.4	IFNG-AS1	6.32	4.19e-09	1.03e-05	0.47	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020387	chr12:67989445~68234686:+
TGCT	cis	rs875971	0.545	rs10950025	ENSG00000226824.5	RP4-756H11.3	-6.32	4.2e-09	1.03e-05	-0.61	-0.49	Aortic root size;	chr7:66158946	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs1547529	ENSG00000226824.5	RP4-756H11.3	-6.32	4.2e-09	1.03e-05	-0.61	-0.49	Aortic root size;	chr7:66258859	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs316324	ENSG00000226824.5	RP4-756H11.3	6.32	4.2e-09	1.03e-05	0.61	0.49	Aortic root size;	chr7:66145627	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs316323	ENSG00000226824.5	RP4-756H11.3	6.32	4.2e-09	1.03e-05	0.61	0.49	Aortic root size;	chr7:66146002	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs316316	ENSG00000226824.5	RP4-756H11.3	6.32	4.2e-09	1.03e-05	0.61	0.49	Aortic root size;	chr7:66149270	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs2460427	ENSG00000226824.5	RP4-756H11.3	6.32	4.2e-09	1.03e-05	0.61	0.49	Aortic root size;	chr7:66154218	chr7:66654538~66669855:+
TGCT	cis	rs6452524	0.804	rs2048215	ENSG00000249664.1	CTD-2227C6.2	-6.32	4.21e-09	1.03e-05	-0.54	-0.49	Hypertension (SNP x SNP interaction);	chr5:83208589	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.836	rs11949301	ENSG00000249664.1	CTD-2227C6.2	-6.32	4.21e-09	1.03e-05	-0.54	-0.49	Hypertension (SNP x SNP interaction);	chr5:83209334	chr5:83012285~83013109:-
TGCT	cis	rs875971	0.964	rs778735	ENSG00000222364.1	RNU6-96P	-6.32	4.22e-09	1.04e-05	-0.57	-0.49	Aortic root size;	chr7:66349822	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs709595	ENSG00000222364.1	RNU6-96P	-6.32	4.22e-09	1.04e-05	-0.57	-0.49	Aortic root size;	chr7:66352346	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs811880	ENSG00000222364.1	RNU6-96P	-6.32	4.22e-09	1.04e-05	-0.57	-0.49	Aortic root size;	chr7:66353659	chr7:66395191~66395286:+
TGCT	cis	rs17301013	0.606	rs6666588	ENSG00000227373.4	RP11-160H22.5	6.32	4.26e-09	1.04e-05	0.58	0.49	Systemic lupus erythematosus;	chr1:174248972	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs72713504	ENSG00000227373.4	RP11-160H22.5	6.32	4.26e-09	1.04e-05	0.58	0.49	Systemic lupus erythematosus;	chr1:174251916	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs72713505	ENSG00000227373.4	RP11-160H22.5	6.32	4.26e-09	1.04e-05	0.58	0.49	Systemic lupus erythematosus;	chr1:174255911	chr1:174115300~174160004:-
TGCT	cis	rs9549367	0.713	rs3024756	ENSG00000269125.1	RP11-98F14.11	-6.32	4.26e-09	1.04e-05	-0.61	-0.49	Platelet distribution width;	chr13:113168636	chr13:113165002~113165183:-
TGCT	cis	rs7174755	0.772	rs80187654	ENSG00000260657.2	RP11-315D16.4	6.32	4.29e-09	1.05e-05	0.56	0.49	Major depressive disorder;	chr15:68082833	chr15:68267792~68277994:-
TGCT	cis	rs6452524	0.836	rs2731852	ENSG00000249664.1	CTD-2227C6.2	-6.32	4.31e-09	1.05e-05	-0.55	-0.49	Hypertension (SNP x SNP interaction);	chr5:83212591	chr5:83012285~83013109:-
TGCT	cis	rs9326248	0.52	rs74830	ENSG00000254851.1	RP11-109L13.1	6.32	4.31e-09	1.06e-05	0.6	0.49	Blood protein levels;	chr11:117219842	chr11:117135528~117138582:+
TGCT	cis	rs17301013	0.507	rs12091076	ENSG00000227373.4	RP11-160H22.5	6.32	4.32e-09	1.06e-05	0.57	0.49	Systemic lupus erythematosus;	chr1:174321545	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs16846861	ENSG00000227373.4	RP11-160H22.5	6.32	4.32e-09	1.06e-05	0.57	0.49	Systemic lupus erythematosus;	chr1:174338731	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs2860954	ENSG00000227373.4	RP11-160H22.5	6.32	4.32e-09	1.06e-05	0.57	0.49	Systemic lupus erythematosus;	chr1:174344313	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs60864659	ENSG00000227373.4	RP11-160H22.5	6.32	4.32e-09	1.06e-05	0.57	0.49	Systemic lupus erythematosus;	chr1:174344641	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs332764	ENSG00000227373.4	RP11-160H22.5	6.32	4.35e-09	1.06e-05	0.56	0.49	Systemic lupus erythematosus;	chr1:174693056	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs332763	ENSG00000227373.4	RP11-160H22.5	6.32	4.35e-09	1.06e-05	0.56	0.49	Systemic lupus erythematosus;	chr1:174693482	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.581	rs332772	ENSG00000227373.4	RP11-160H22.5	6.32	4.35e-09	1.06e-05	0.56	0.49	Systemic lupus erythematosus;	chr1:174695740	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs333471	ENSG00000227373.4	RP11-160H22.5	6.32	4.35e-09	1.06e-05	0.56	0.49	Systemic lupus erythematosus;	chr1:174705062	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs332784	ENSG00000227373.4	RP11-160H22.5	6.32	4.35e-09	1.06e-05	0.56	0.49	Systemic lupus erythematosus;	chr1:174719927	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs332798	ENSG00000227373.4	RP11-160H22.5	6.32	4.35e-09	1.06e-05	0.56	0.49	Systemic lupus erythematosus;	chr1:174729096	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs459078	ENSG00000227373.4	RP11-160H22.5	6.32	4.35e-09	1.06e-05	0.56	0.49	Systemic lupus erythematosus;	chr1:174733772	chr1:174115300~174160004:-
TGCT	cis	rs16828019	0.85	rs12027691	ENSG00000235358.1	RP11-399E6.1	6.32	4.36e-09	1.07e-05	0.85	0.49	Intelligence (multi-trait analysis);	chr1:40996360	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.777	rs12047078	ENSG00000235358.1	RP11-399E6.1	6.32	4.36e-09	1.07e-05	0.85	0.49	Intelligence (multi-trait analysis);	chr1:40997314	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.777	rs12739052	ENSG00000235358.1	RP11-399E6.1	6.32	4.36e-09	1.07e-05	0.85	0.49	Intelligence (multi-trait analysis);	chr1:40998783	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.777	rs12748235	ENSG00000235358.1	RP11-399E6.1	6.32	4.36e-09	1.07e-05	0.85	0.49	Intelligence (multi-trait analysis);	chr1:41000549	chr1:41242373~41284861:+
TGCT	cis	rs694739	0.628	rs508168	ENSG00000236935.1	AP003774.1	6.32	4.38e-09	1.07e-05	0.37	0.49	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64367963	chr11:64325050~64329504:-
TGCT	cis	rs694739	0.595	rs11606015	ENSG00000236935.1	AP003774.1	6.32	4.38e-09	1.07e-05	0.37	0.49	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64369405	chr11:64325050~64329504:-
TGCT	cis	rs694739	0.628	rs11606081	ENSG00000236935.1	AP003774.1	6.32	4.38e-09	1.07e-05	0.37	0.49	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64370403	chr11:64325050~64329504:-
TGCT	cis	rs5769707	0.681	rs2319346	ENSG00000188511.11	C22orf34	6.31	4.41e-09	1.08e-05	0.54	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49635992	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.681	rs135879	ENSG00000188511.11	C22orf34	6.31	4.42e-09	1.08e-05	0.54	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49625003	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.642	rs135880	ENSG00000188511.11	C22orf34	6.31	4.42e-09	1.08e-05	0.54	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49625006	chr22:49414524~49657542:-
TGCT	cis	rs875971	0.505	rs6955582	ENSG00000222364.1	RNU6-96P	-6.31	4.43e-09	1.08e-05	-0.57	-0.49	Aortic root size;	chr7:65966699	chr7:66395191~66395286:+
TGCT	cis	rs801193	1	rs2659915	ENSG00000222364.1	RNU6-96P	-6.31	4.45e-09	1.09e-05	-0.55	-0.49	Aortic root size;	chr7:66688114	chr7:66395191~66395286:+
TGCT	cis	rs3096299	0.658	rs4291902	ENSG00000274627.1	RP11-104N10.2	6.31	4.46e-09	1.09e-05	0.51	0.49	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:89516797~89522217:+
TGCT	cis	rs76878669	0.793	rs10791867	ENSG00000254510.1	RP11-867G23.10	-6.31	4.46e-09	1.09e-05	-0.72	-0.49	Educational attainment (years of education);	chr11:66313740	chr11:66409158~66417137:+
TGCT	cis	rs977987	0.815	rs11861810	ENSG00000261783.1	RP11-252K23.2	-6.31	4.48e-09	1.09e-05	-0.72	-0.49	Dupuytren's disease;	chr16:75427931	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.778	rs12930452	ENSG00000261783.1	RP11-252K23.2	-6.31	4.48e-09	1.09e-05	-0.72	-0.49	Dupuytren's disease;	chr16:75428157	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.778	rs12929908	ENSG00000261783.1	RP11-252K23.2	-6.31	4.48e-09	1.09e-05	-0.72	-0.49	Dupuytren's disease;	chr16:75428173	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.742	rs12928898	ENSG00000261783.1	RP11-252K23.2	-6.31	4.48e-09	1.09e-05	-0.72	-0.49	Dupuytren's disease;	chr16:75428183	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs11149832	ENSG00000261783.1	RP11-252K23.2	-6.31	4.48e-09	1.09e-05	-0.72	-0.49	Dupuytren's disease;	chr16:75428815	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs12448947	ENSG00000261783.1	RP11-252K23.2	-6.31	4.48e-09	1.09e-05	-0.72	-0.49	Dupuytren's disease;	chr16:75429056	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs4888420	ENSG00000261783.1	RP11-252K23.2	-6.31	4.48e-09	1.09e-05	-0.72	-0.49	Dupuytren's disease;	chr16:75429100	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs12449170	ENSG00000261783.1	RP11-252K23.2	-6.31	4.48e-09	1.09e-05	-0.72	-0.49	Dupuytren's disease;	chr16:75429114	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs11149833	ENSG00000261783.1	RP11-252K23.2	-6.31	4.48e-09	1.09e-05	-0.72	-0.49	Dupuytren's disease;	chr16:75430104	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs11641587	ENSG00000261783.1	RP11-252K23.2	-6.31	4.48e-09	1.09e-05	-0.72	-0.49	Dupuytren's disease;	chr16:75430521	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs12930768	ENSG00000261783.1	RP11-252K23.2	-6.31	4.48e-09	1.09e-05	-0.72	-0.49	Dupuytren's disease;	chr16:75430602	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.778	rs12445726	ENSG00000261783.1	RP11-252K23.2	-6.31	4.48e-09	1.09e-05	-0.72	-0.49	Dupuytren's disease;	chr16:75431677	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.843	rs11644741	ENSG00000261783.1	RP11-252K23.2	-6.31	4.48e-09	1.09e-05	-0.72	-0.49	Dupuytren's disease;	chr16:75432535	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs12917651	ENSG00000261783.1	RP11-252K23.2	-6.31	4.48e-09	1.09e-05	-0.72	-0.49	Dupuytren's disease;	chr16:75432798	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.806	rs35787595	ENSG00000261783.1	RP11-252K23.2	-6.31	4.48e-09	1.09e-05	-0.72	-0.49	Dupuytren's disease;	chr16:75432949	chr16:75379818~75381260:-
TGCT	cis	rs524281	0.861	rs10750779	ENSG00000255320.1	RP11-755F10.1	6.31	4.48e-09	1.09e-05	0.63	0.49	Electroencephalogram traits;	chr11:66207120	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.861	rs10750780	ENSG00000255320.1	RP11-755F10.1	6.31	4.48e-09	1.09e-05	0.63	0.49	Electroencephalogram traits;	chr11:66207121	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.861	rs10791858	ENSG00000255320.1	RP11-755F10.1	6.31	4.48e-09	1.09e-05	0.63	0.49	Electroencephalogram traits;	chr11:66210925	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.817	rs10791859	ENSG00000255320.1	RP11-755F10.1	6.31	4.48e-09	1.09e-05	0.63	0.49	Electroencephalogram traits;	chr11:66210982	chr11:66244840~66246239:-
TGCT	cis	rs10875976	0.525	rs2271687	ENSG00000257253.2	RP11-70F11.7	6.31	4.49e-09	1.09e-05	0.44	0.49	Obesity;	chr12:49865732	chr12:49861207~49865802:+
TGCT	cis	rs2882667	0.929	rs17207828	ENSG00000253404.1	AC034243.1	6.31	4.49e-09	1.09e-05	0.59	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:138964146	chr5:138744434~138753309:-
TGCT	cis	rs875971	0.545	rs1638735	ENSG00000226824.5	RP4-756H11.3	-6.31	4.51e-09	1.1e-05	-0.58	-0.49	Aortic root size;	chr7:66630751	chr7:66654538~66669855:+
TGCT	cis	rs5760092	0.618	rs5996631	ENSG00000273295.1	AP000350.5	-6.31	4.51e-09	1.1e-05	-0.64	-0.49	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23901432~23907068:-
TGCT	cis	rs5769707	0.706	rs763128	ENSG00000188511.11	C22orf34	6.31	4.51e-09	1.1e-05	0.54	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49624397	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.568	rs2011097	ENSG00000188511.11	C22orf34	6.31	4.51e-09	1.1e-05	0.54	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49624421	chr22:49414524~49657542:-
TGCT	cis	rs875971	0.619	rs2302918	ENSG00000222364.1	RNU6-96P	-6.31	4.52e-09	1.1e-05	-0.59	-0.49	Aortic root size;	chr7:66535945	chr7:66395191~66395286:+
TGCT	cis	rs748404	0.66	rs693510	ENSG00000205771.5	CATSPER2P1	-6.31	4.53e-09	1.1e-05	-0.55	-0.49	Lung cancer;	chr15:43422427	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.66	rs509306	ENSG00000205771.5	CATSPER2P1	-6.31	4.53e-09	1.1e-05	-0.55	-0.49	Lung cancer;	chr15:43422973	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.66	rs690512	ENSG00000205771.5	CATSPER2P1	-6.31	4.53e-09	1.1e-05	-0.55	-0.49	Lung cancer;	chr15:43425480	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.66	rs542898	ENSG00000205771.5	CATSPER2P1	-6.31	4.53e-09	1.1e-05	-0.55	-0.49	Lung cancer;	chr15:43427194	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.66	rs690012	ENSG00000205771.5	CATSPER2P1	-6.31	4.53e-09	1.1e-05	-0.55	-0.49	Lung cancer;	chr15:43427557	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.66	rs2249952	ENSG00000205771.5	CATSPER2P1	-6.31	4.53e-09	1.1e-05	-0.55	-0.49	Lung cancer;	chr15:43428335	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.66	rs689767	ENSG00000205771.5	CATSPER2P1	-6.31	4.53e-09	1.1e-05	-0.55	-0.49	Lung cancer;	chr15:43429879	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.66	rs2439845	ENSG00000205771.5	CATSPER2P1	-6.31	4.53e-09	1.1e-05	-0.55	-0.49	Lung cancer;	chr15:43430412	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.631	rs2467745	ENSG00000205771.5	CATSPER2P1	-6.31	4.53e-09	1.1e-05	-0.55	-0.49	Lung cancer;	chr15:43430544	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.69	rs2467737	ENSG00000205771.5	CATSPER2P1	-6.31	4.53e-09	1.1e-05	-0.55	-0.49	Lung cancer;	chr15:43444990	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.66	rs2439846	ENSG00000205771.5	CATSPER2P1	-6.31	4.53e-09	1.1e-05	-0.55	-0.49	Lung cancer;	chr15:43448772	chr15:43726918~43747094:-
TGCT	cis	rs875971	0.862	rs6952182	ENSG00000222364.1	RNU6-96P	6.31	4.54e-09	1.1e-05	0.55	0.49	Aortic root size;	chr7:66218330	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs6964437	ENSG00000222364.1	RNU6-96P	6.31	4.54e-09	1.1e-05	0.55	0.49	Aortic root size;	chr7:66221457	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs6460282	ENSG00000222364.1	RNU6-96P	6.31	4.54e-09	1.1e-05	0.55	0.49	Aortic root size;	chr7:66226259	chr7:66395191~66395286:+
TGCT	cis	rs7617773	0.817	rs3731555	ENSG00000229759.1	MRPS18AP1	6.31	4.55e-09	1.1e-05	0.42	0.49	Coronary artery disease;	chr3:48164612	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs3731550	ENSG00000229759.1	MRPS18AP1	6.31	4.55e-09	1.1e-05	0.42	0.49	Coronary artery disease;	chr3:48165093	chr3:48256350~48256938:-
TGCT	cis	rs7044106	0.762	rs10739570	ENSG00000226752.6	PSMD5-AS1	-6.31	4.55e-09	1.11e-05	-0.61	-0.49	Hip circumference adjusted for BMI;	chr9:120618944	chr9:120824828~120854385:+
TGCT	cis	rs875971	1	rs6946143	ENSG00000222364.1	RNU6-96P	-6.31	4.58e-09	1.11e-05	-0.54	-0.49	Aortic root size;	chr7:66114735	chr7:66395191~66395286:+
TGCT	cis	rs17301013	0.507	rs12067852	ENSG00000227373.4	RP11-160H22.5	-6.31	4.59e-09	1.11e-05	-0.56	-0.49	Systemic lupus erythematosus;	chr1:174302481	chr1:174115300~174160004:-
TGCT	cis	rs9549367	0.789	rs9604040	ENSG00000269125.1	RP11-98F14.11	6.31	4.61e-09	1.12e-05	0.58	0.49	Platelet distribution width;	chr13:113256297	chr13:113165002~113165183:-
TGCT	cis	rs7174755	0.772	rs8025474	ENSG00000260657.2	RP11-315D16.4	6.3	4.63e-09	1.12e-05	0.56	0.49	Major depressive disorder;	chr15:68094185	chr15:68267792~68277994:-
TGCT	cis	rs5769707	0.681	rs4824068	ENSG00000188511.11	C22orf34	6.3	4.65e-09	1.13e-05	0.53	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49631153	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.605	rs6009791	ENSG00000188511.11	C22orf34	6.3	4.65e-09	1.13e-05	0.53	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49631617	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.667	rs4824069	ENSG00000188511.11	C22orf34	6.3	4.65e-09	1.13e-05	0.53	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49636677	chr22:49414524~49657542:-
TGCT	cis	rs7115242	0.8	rs7131536	ENSG00000254851.1	RP11-109L13.1	-6.3	4.69e-09	1.14e-05	-0.95	-0.49	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117135528~117138582:+
TGCT	cis	rs6452524	0.534	rs11746747	ENSG00000249664.1	CTD-2227C6.2	6.3	4.7e-09	1.14e-05	0.54	0.49	Hypertension (SNP x SNP interaction);	chr5:83067666	chr5:83012285~83013109:-
TGCT	cis	rs6921919	0.638	rs7772827	ENSG00000216901.1	AL022393.7	6.3	4.71e-09	1.14e-05	0.57	0.49	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28176188~28176674:+
TGCT	cis	rs12891047	0.899	rs17783124	ENSG00000258759.1	RP11-1012A1.7	6.3	4.72e-09	1.14e-05	0.43	0.49	Amyotrophic lateral sclerosis (sporadic);	chr14:67823655	chr14:67799004~67799609:+
TGCT	cis	rs8040855	0.557	rs9744503	ENSG00000259295.5	CSPG4P12	-6.3	4.74e-09	1.15e-05	-0.63	-0.49	Bulimia nervosa;	chr15:85180986	chr15:85191438~85213905:+
TGCT	cis	rs8040855	0.599	rs8037195	ENSG00000259295.5	CSPG4P12	-6.3	4.74e-09	1.15e-05	-0.63	-0.49	Bulimia nervosa;	chr15:85181455	chr15:85191438~85213905:+
TGCT	cis	rs875971	0.862	rs880166	ENSG00000222364.1	RNU6-96P	6.3	4.75e-09	1.15e-05	0.55	0.49	Aortic root size;	chr7:66205775	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.928	rs2036263	ENSG00000222364.1	RNU6-96P	6.3	4.75e-09	1.15e-05	0.55	0.49	Aortic root size;	chr7:66335210	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs10240949	ENSG00000222364.1	RNU6-96P	6.3	4.75e-09	1.15e-05	0.55	0.49	Aortic root size;	chr7:66339430	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs7782704	ENSG00000222364.1	RNU6-96P	6.3	4.75e-09	1.15e-05	0.55	0.49	Aortic root size;	chr7:66340379	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs6460290	ENSG00000222364.1	RNU6-96P	6.3	4.75e-09	1.15e-05	0.55	0.49	Aortic root size;	chr7:66344119	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs6959268	ENSG00000222364.1	RNU6-96P	6.3	4.75e-09	1.15e-05	0.55	0.49	Aortic root size;	chr7:66347979	chr7:66395191~66395286:+
TGCT	cis	rs16828019	0.704	rs12024115	ENSG00000235358.1	RP11-399E6.1	6.3	4.75e-09	1.15e-05	0.83	0.49	Intelligence (multi-trait analysis);	chr1:41068685	chr1:41242373~41284861:+
TGCT	cis	rs5760092	0.755	rs11090298	ENSG00000273295.1	AP000350.5	-6.3	4.77e-09	1.15e-05	-0.67	-0.49	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23901432~23907068:-
TGCT	cis	rs3096299	0.563	rs4600467	ENSG00000274627.1	RP11-104N10.2	6.3	4.79e-09	1.16e-05	0.51	0.49	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:89516797~89522217:+
TGCT	cis	rs9326248	0.53	rs7112513	ENSG00000254851.1	RP11-109L13.1	-6.3	4.81e-09	1.16e-05	-0.93	-0.49	Blood protein levels;	chr11:117166645	chr11:117135528~117138582:+
TGCT	cis	rs6452524	0.532	rs27363	ENSG00000249664.1	CTD-2227C6.2	6.3	4.83e-09	1.17e-05	0.54	0.49	Hypertension (SNP x SNP interaction);	chr5:83040943	chr5:83012285~83013109:-
TGCT	cis	rs4691139	0.903	rs13127378	ENSG00000250227.1	TRIM60P14	6.3	4.84e-09	1.17e-05	0.55	0.49	Ovarian cancer in BRCA1 mutation carriers;	chr4:164997485	chr4:164915565~164916983:+
TGCT	cis	rs7412746	0.634	rs3754212	ENSG00000206931.1	RNU6-1042P	6.29	4.85e-09	1.17e-05	0.39	0.49	Melanoma;	chr1:150765724	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.611	rs11204726	ENSG00000206931.1	RNU6-1042P	6.29	4.85e-09	1.17e-05	0.39	0.49	Melanoma;	chr1:150771016	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.553	rs59337856	ENSG00000206931.1	RNU6-1042P	6.29	4.85e-09	1.17e-05	0.39	0.49	Melanoma;	chr1:150773930	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs6657388	ENSG00000206931.1	RNU6-1042P	6.29	4.85e-09	1.17e-05	0.39	0.49	Melanoma;	chr1:150776310	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.611	rs6660084	ENSG00000206931.1	RNU6-1042P	6.29	4.85e-09	1.17e-05	0.39	0.49	Melanoma;	chr1:150776327	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.611	rs10888394	ENSG00000206931.1	RNU6-1042P	6.29	4.85e-09	1.17e-05	0.39	0.49	Melanoma;	chr1:150777437	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.611	rs10888395	ENSG00000206931.1	RNU6-1042P	6.29	4.85e-09	1.17e-05	0.39	0.49	Melanoma;	chr1:150789695	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs57818453	ENSG00000206931.1	RNU6-1042P	6.29	4.85e-09	1.17e-05	0.39	0.49	Melanoma;	chr1:150790663	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.566	rs2864871	ENSG00000206931.1	RNU6-1042P	6.29	4.85e-09	1.17e-05	0.39	0.49	Melanoma;	chr1:150794488	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.611	rs4509581	ENSG00000206931.1	RNU6-1042P	6.29	4.85e-09	1.17e-05	0.39	0.49	Melanoma;	chr1:150801989	chr1:150701866~150701972:+
TGCT	cis	rs875971	0.756	rs4718328	ENSG00000222364.1	RNU6-96P	6.29	4.86e-09	1.17e-05	0.55	0.49	Aortic root size;	chr7:66228350	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs4718330	ENSG00000222364.1	RNU6-96P	6.29	4.86e-09	1.17e-05	0.55	0.49	Aortic root size;	chr7:66250256	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs949930	ENSG00000222364.1	RNU6-96P	6.29	4.86e-09	1.17e-05	0.55	0.49	Aortic root size;	chr7:66301835	chr7:66395191~66395286:+
TGCT	cis	rs17301013	0.507	rs34409674	ENSG00000227373.4	RP11-160H22.5	-6.29	4.9e-09	1.18e-05	-0.59	-0.49	Systemic lupus erythematosus;	chr1:174560246	chr1:174115300~174160004:-
TGCT	cis	rs17507216	1	rs17158413	ENSG00000278603.1	RP13-608F4.5	6.29	4.91e-09	1.18e-05	0.77	0.49	Excessive daytime sleepiness;	chr15:82566658	chr15:82472203~82472426:+
TGCT	cis	rs875971	0.825	rs1129531	ENSG00000222364.1	RNU6-96P	6.29	4.93e-09	1.18e-05	0.56	0.49	Aortic root size;	chr7:66154117	chr7:66395191~66395286:+
TGCT	cis	rs12908161	1	rs62019464	ENSG00000225151.9	GOLGA2P7	-6.29	4.93e-09	1.19e-05	-0.56	-0.49	Schizophrenia;	chr15:84751238	chr15:84199311~84230136:-
TGCT	cis	rs12908161	1	rs56864281	ENSG00000225151.9	GOLGA2P7	-6.29	4.94e-09	1.19e-05	-0.56	-0.49	Schizophrenia;	chr15:84814418	chr15:84199311~84230136:-
TGCT	cis	rs6700559	0.742	rs10399790	ENSG00000260088.1	RP11-92G12.3	-6.29	4.94e-09	1.19e-05	-0.58	-0.49	Coronary artery disease;	chr1:200626241	chr1:200669507~200694250:+
TGCT	cis	rs6700559	0.81	rs10919990	ENSG00000260088.1	RP11-92G12.3	-6.29	4.94e-09	1.19e-05	-0.58	-0.49	Coronary artery disease;	chr1:200627076	chr1:200669507~200694250:+
TGCT	cis	rs6700559	0.81	rs10919991	ENSG00000260088.1	RP11-92G12.3	-6.29	4.94e-09	1.19e-05	-0.58	-0.49	Coronary artery disease;	chr1:200627217	chr1:200669507~200694250:+
TGCT	cis	rs6700559	0.81	rs10399615	ENSG00000260088.1	RP11-92G12.3	6.29	4.94e-09	1.19e-05	0.58	0.49	Coronary artery disease;	chr1:200626145	chr1:200669507~200694250:+
TGCT	cis	rs5769707	0.681	rs6009803	ENSG00000188511.11	C22orf34	6.29	4.96e-09	1.19e-05	0.54	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49657359	chr22:49414524~49657542:-
TGCT	cis	rs17711722	0.653	rs2460421	ENSG00000226824.5	RP4-756H11.3	6.29	4.99e-09	1.2e-05	0.54	0.49	Calcium levels;	chr7:66026136	chr7:66654538~66669855:+
TGCT	cis	rs3096299	0.685	rs8050512	ENSG00000274627.1	RP11-104N10.2	6.29	5e-09	1.2e-05	0.51	0.49	Multiple myeloma (IgH translocation);	chr16:89485912	chr16:89516797~89522217:+
TGCT	cis	rs7412746	0.611	rs10888398	ENSG00000206931.1	RNU6-1042P	-6.29	5.02e-09	1.2e-05	-0.4	-0.49	Melanoma;	chr1:150914306	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.552	rs4970980	ENSG00000206931.1	RNU6-1042P	6.29	5.02e-09	1.2e-05	0.4	0.49	Melanoma;	chr1:150892516	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs4970982	ENSG00000206931.1	RNU6-1042P	6.29	5.02e-09	1.2e-05	0.4	0.49	Melanoma;	chr1:150892608	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.611	rs1889741	ENSG00000206931.1	RNU6-1042P	6.29	5.02e-09	1.2e-05	0.4	0.49	Melanoma;	chr1:150896569	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs12097963	ENSG00000206931.1	RNU6-1042P	6.29	5.02e-09	1.2e-05	0.4	0.49	Melanoma;	chr1:150897974	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.611	rs66847267	ENSG00000206931.1	RNU6-1042P	6.29	5.02e-09	1.2e-05	0.4	0.49	Melanoma;	chr1:150902697	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.586	rs2864882	ENSG00000206931.1	RNU6-1042P	6.29	5.02e-09	1.2e-05	0.4	0.49	Melanoma;	chr1:150910561	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.611	rs4970984	ENSG00000206931.1	RNU6-1042P	6.29	5.02e-09	1.2e-05	0.4	0.49	Melanoma;	chr1:150914901	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.611	rs7556661	ENSG00000206931.1	RNU6-1042P	6.29	5.02e-09	1.2e-05	0.4	0.49	Melanoma;	chr1:150919533	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs12090215	ENSG00000206931.1	RNU6-1042P	6.29	5.02e-09	1.2e-05	0.4	0.49	Melanoma;	chr1:150921184	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.611	rs72704679	ENSG00000206931.1	RNU6-1042P	6.29	5.02e-09	1.2e-05	0.4	0.49	Melanoma;	chr1:150925001	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs72704682	ENSG00000206931.1	RNU6-1042P	6.29	5.02e-09	1.2e-05	0.4	0.49	Melanoma;	chr1:150925201	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs72704685	ENSG00000206931.1	RNU6-1042P	6.29	5.02e-09	1.2e-05	0.4	0.49	Melanoma;	chr1:150925211	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.526	rs6587542	ENSG00000206931.1	RNU6-1042P	6.29	5.02e-09	1.2e-05	0.4	0.49	Tonsillectomy;	chr1:150935225	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs4970986	ENSG00000206931.1	RNU6-1042P	6.29	5.02e-09	1.2e-05	0.4	0.49	Melanoma;	chr1:150935479	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs59024312	ENSG00000206931.1	RNU6-1042P	6.29	5.02e-09	1.2e-05	0.4	0.49	Melanoma;	chr1:150936529	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.611	rs4970931	ENSG00000206931.1	RNU6-1042P	6.29	5.02e-09	1.2e-05	0.4	0.49	Melanoma;	chr1:150938251	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.611	rs9661876	ENSG00000206931.1	RNU6-1042P	6.29	5.02e-09	1.2e-05	0.4	0.49	Melanoma;	chr1:150938435	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs7521719	ENSG00000206931.1	RNU6-1042P	6.29	5.02e-09	1.2e-05	0.4	0.49	Melanoma;	chr1:150940658	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.503	rs7556451	ENSG00000206931.1	RNU6-1042P	6.29	5.02e-09	1.2e-05	0.4	0.49	Tonsillectomy;	chr1:150940666	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs7528773	ENSG00000206931.1	RNU6-1042P	6.29	5.02e-09	1.2e-05	0.4	0.49	Melanoma;	chr1:150943399	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.611	rs2271076	ENSG00000206931.1	RNU6-1042P	6.29	5.02e-09	1.2e-05	0.4	0.49	Melanoma;	chr1:150944181	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs6658066	ENSG00000206931.1	RNU6-1042P	6.29	5.02e-09	1.2e-05	0.4	0.49	Melanoma;	chr1:150946461	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.634	rs2124952	ENSG00000206931.1	RNU6-1042P	6.29	5.02e-09	1.2e-05	0.4	0.49	Melanoma;	chr1:150951298	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.611	rs11204748	ENSG00000206931.1	RNU6-1042P	6.29	5.02e-09	1.2e-05	0.4	0.49	Melanoma;	chr1:150954893	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.621	rs11204749	ENSG00000206931.1	RNU6-1042P	6.29	5.02e-09	1.2e-05	0.4	0.49	Melanoma;	chr1:150957087	chr1:150701866~150701972:+
TGCT	cis	rs3091242	0.9	rs669063	ENSG00000224183.1	SDHDP6	-6.29	5.05e-09	1.21e-05	-0.53	-0.49	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25294164~25294643:-
TGCT	cis	rs7412746	0.621	rs7518156	ENSG00000206931.1	RNU6-1042P	6.28	5.09e-09	1.21e-05	0.4	0.49	Melanoma;	chr1:150973318	chr1:150701866~150701972:+
TGCT	cis	rs17301013	0.507	rs2064150	ENSG00000227373.4	RP11-160H22.5	-6.28	5.11e-09	1.22e-05	-0.58	-0.49	Systemic lupus erythematosus;	chr1:174339289	chr1:174115300~174160004:-
TGCT	cis	rs875971	0.522	rs1617484	ENSG00000236529.1	RP13-254B10.1	6.28	5.15e-09	1.23e-05	0.37	0.49	Aortic root size;	chr7:65998108	chr7:65840212~65840596:+
TGCT	cis	rs17361889	0.752	rs56161298	ENSG00000224683.1	RPL36AP29	6.28	5.21e-09	1.24e-05	0.55	0.49	Pediatric bone mineral content (hip);	chr7:16215537	chr7:16208945~16209265:+
TGCT	cis	rs17361889	0.633	rs1918267	ENSG00000224683.1	RPL36AP29	6.28	5.21e-09	1.24e-05	0.55	0.49	Pediatric bone mineral content (hip);	chr7:16231700	chr7:16208945~16209265:+
TGCT	cis	rs710913	0.738	rs755247	ENSG00000182109.6	RP11-69E11.4	-6.28	5.22e-09	1.24e-05	-0.48	-0.49	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39528873	chr1:39522280~39546187:-
TGCT	cis	rs748404	0.578	rs4547312	ENSG00000205771.5	CATSPER2P1	-6.28	5.22e-09	1.24e-05	-0.54	-0.49	Lung cancer;	chr15:43339940	chr15:43726918~43747094:-
TGCT	cis	rs11673344	0.526	rs73035160	ENSG00000226686.6	LINC01535	6.28	5.24e-09	1.25e-05	0.57	0.49	Obesity-related traits;	chr19:37655135	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.526	rs1871196	ENSG00000226686.6	LINC01535	6.28	5.24e-09	1.25e-05	0.57	0.49	Obesity-related traits;	chr19:37656022	chr19:37251912~37265535:+
TGCT	cis	rs7044106	0.708	rs2416760	ENSG00000226752.6	PSMD5-AS1	-6.28	5.26e-09	1.25e-05	-0.61	-0.49	Hip circumference adjusted for BMI;	chr9:120612361	chr9:120824828~120854385:+
TGCT	cis	rs7412746	0.658	rs8444	ENSG00000206931.1	RNU6-1042P	6.28	5.27e-09	1.25e-05	0.4	0.49	Melanoma;	chr1:150966095	chr1:150701866~150701972:+
TGCT	cis	rs6452524	0.534	rs10037377	ENSG00000249664.1	CTD-2227C6.2	6.28	5.28e-09	1.25e-05	0.54	0.49	Hypertension (SNP x SNP interaction);	chr5:83071150	chr5:83012285~83013109:-
TGCT	cis	rs12891047	0.966	rs181566	ENSG00000258759.1	RP11-1012A1.7	6.28	5.3e-09	1.26e-05	0.43	0.49	Amyotrophic lateral sclerosis (sporadic);	chr14:67810492	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.899	rs10130919	ENSG00000258759.1	RP11-1012A1.7	6.28	5.3e-09	1.26e-05	0.43	0.49	Amyotrophic lateral sclerosis (sporadic);	chr14:67840070	chr14:67799004~67799609:+
TGCT	cis	rs875971	0.862	rs2460432	ENSG00000222364.1	RNU6-96P	6.27	5.35e-09	1.27e-05	0.56	0.49	Aortic root size;	chr7:66089398	chr7:66395191~66395286:+
TGCT	cis	rs11098499	0.604	rs17051352	ENSG00000245958.5	RP11-33B1.1	-6.27	5.36e-09	1.27e-05	-0.54	-0.49	Corneal astigmatism;	chr4:119660272	chr4:119454791~119552025:+
TGCT	cis	rs12908161	1	rs11637142	ENSG00000225151.9	GOLGA2P7	-6.27	5.43e-09	1.29e-05	-0.56	-0.49	Schizophrenia;	chr15:84752696	chr15:84199311~84230136:-
TGCT	cis	rs6452524	0.569	rs7720588	ENSG00000249664.1	CTD-2227C6.2	6.27	5.44e-09	1.29e-05	0.54	0.49	Hypertension (SNP x SNP interaction);	chr5:83081107	chr5:83012285~83013109:-
TGCT	cis	rs3096299	0.632	rs4399533	ENSG00000274627.1	RP11-104N10.2	6.27	5.44e-09	1.29e-05	0.5	0.49	Multiple myeloma (IgH translocation);	chr16:89472974	chr16:89516797~89522217:+
TGCT	cis	rs875971	0.577	rs34888281	ENSG00000222364.1	RNU6-96P	6.27	5.44e-09	1.29e-05	0.58	0.49	Aortic root size;	chr7:66120784	chr7:66395191~66395286:+
TGCT	cis	rs6700559	0.81	rs2809344	ENSG00000260088.1	RP11-92G12.3	6.27	5.45e-09	1.29e-05	0.59	0.49	Coronary artery disease;	chr1:200627478	chr1:200669507~200694250:+
TGCT	cis	rs1062177	0.855	rs919262	ENSG00000213433.5	RPLP1P6	6.27	5.45e-09	1.29e-05	0.54	0.49	Preschool internalizing problems;	chr5:151886523	chr5:151765859~151766378:-
TGCT	cis	rs172166	0.637	rs1225592	ENSG00000216901.1	AL022393.7	6.27	5.47e-09	1.3e-05	0.61	0.49	Cardiac Troponin-T levels;	chr6:28182464	chr6:28176188~28176674:+
TGCT	cis	rs172166	0.637	rs1225595	ENSG00000216901.1	AL022393.7	6.27	5.47e-09	1.3e-05	0.61	0.49	Cardiac Troponin-T levels;	chr6:28183562	chr6:28176188~28176674:+
TGCT	cis	rs172166	0.637	rs1233691	ENSG00000216901.1	AL022393.7	6.27	5.47e-09	1.3e-05	0.61	0.49	Cardiac Troponin-T levels;	chr6:28186119	chr6:28176188~28176674:+
TGCT	cis	rs9549367	0.713	rs9549691	ENSG00000269125.1	RP11-98F14.11	-6.27	5.5e-09	1.3e-05	-0.62	-0.49	Platelet distribution width;	chr13:113207292	chr13:113165002~113165183:-
TGCT	cis	rs6700559	0.81	rs7521550	ENSG00000260088.1	RP11-92G12.3	-6.27	5.56e-09	1.31e-05	-0.58	-0.49	Coronary artery disease;	chr1:200623235	chr1:200669507~200694250:+
TGCT	cis	rs2006771	0.713	rs9606878	ENSG00000236132.1	CTA-440B3.1	-6.27	5.57e-09	1.31e-05	-0.5	-0.49	Nonsyndromic cleft lip with cleft palate;	chr22:31824694	chr22:31816379~31817491:-
TGCT	cis	rs748404	0.631	rs28702649	ENSG00000205771.5	CATSPER2P1	-6.27	5.58e-09	1.31e-05	-0.55	-0.49	Lung cancer;	chr15:43356431	chr15:43726918~43747094:-
TGCT	cis	rs16828019	0.704	rs12743340	ENSG00000235358.1	RP11-399E6.1	6.27	5.59e-09	1.31e-05	0.85	0.49	Intelligence (multi-trait analysis);	chr1:40990360	chr1:41242373~41284861:+
TGCT	cis	rs710913	0.816	rs1727098	ENSG00000182109.6	RP11-69E11.4	-6.26	5.61e-09	1.31e-05	-0.47	-0.49	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39523655	chr1:39522280~39546187:-
TGCT	cis	rs12908161	0.959	rs2175567	ENSG00000225151.9	GOLGA2P7	-6.26	5.69e-09	1.33e-05	-0.56	-0.49	Schizophrenia;	chr15:84657715	chr15:84199311~84230136:-
TGCT	cis	rs12908161	0.92	rs12904605	ENSG00000225151.9	GOLGA2P7	-6.26	5.69e-09	1.33e-05	-0.56	-0.49	Schizophrenia;	chr15:84658188	chr15:84199311~84230136:-
TGCT	cis	rs694739	0.541	rs61886926	ENSG00000236935.1	AP003774.1	6.26	5.71e-09	1.33e-05	0.37	0.49	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64366080	chr11:64325050~64329504:-
TGCT	cis	rs694739	0.628	rs617051	ENSG00000236935.1	AP003774.1	6.26	5.71e-09	1.33e-05	0.37	0.49	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64366166	chr11:64325050~64329504:-
TGCT	cis	rs11098499	0.566	rs7664440	ENSG00000245958.5	RP11-33B1.1	-6.26	5.72e-09	1.34e-05	-0.53	-0.49	Corneal astigmatism;	chr4:119657385	chr4:119454791~119552025:+
TGCT	cis	rs7208859	0.673	rs9889755	ENSG00000263531.1	RP13-753N3.1	-6.26	5.73e-09	1.34e-05	-0.84	-0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30863921~30864940:-
TGCT	cis	rs977987	0.806	rs11862684	ENSG00000261783.1	RP11-252K23.2	-6.26	5.74e-09	1.34e-05	-0.72	-0.49	Dupuytren's disease;	chr16:75427848	chr16:75379818~75381260:-
TGCT	cis	rs875971	0.862	rs778734	ENSG00000222364.1	RNU6-96P	-6.26	5.75e-09	1.34e-05	-0.55	-0.49	Aortic root size;	chr7:66349862	chr7:66395191~66395286:+
TGCT	cis	rs7757969	1	rs1327201	ENSG00000227012.2	RP1-97J1.2	6.26	5.77e-09	1.35e-05	0.8	0.49	Schizophrenia;	chr6:111820529	chr6:111900489~111901851:-
TGCT	cis	rs7757969	1	rs2064700	ENSG00000227012.2	RP1-97J1.2	6.26	5.77e-09	1.35e-05	0.8	0.49	Schizophrenia;	chr6:111820705	chr6:111900489~111901851:-
TGCT	cis	rs977987	0.872	rs3743609	ENSG00000261783.1	RP11-252K23.2	-6.26	5.79e-09	1.35e-05	-0.71	-0.49	Dupuytren's disease;	chr16:75433123	chr16:75379818~75381260:-
TGCT	cis	rs7412746	0.611	rs2280627	ENSG00000206931.1	RNU6-1042P	6.26	5.87e-09	1.37e-05	0.4	0.49	Melanoma;	chr1:150963396	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.646	rs1972060	ENSG00000206931.1	RNU6-1042P	6.26	5.87e-09	1.37e-05	0.4	0.49	Melanoma;	chr1:150965118	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs1546376	ENSG00000206931.1	RNU6-1042P	6.26	5.87e-09	1.37e-05	0.4	0.49	Melanoma;	chr1:150965185	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.611	rs752376	ENSG00000206931.1	RNU6-1042P	6.26	5.87e-09	1.37e-05	0.4	0.49	Melanoma;	chr1:150968905	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.587	rs3849279	ENSG00000206931.1	RNU6-1042P	6.26	5.87e-09	1.37e-05	0.4	0.49	Melanoma;	chr1:150972231	chr1:150701866~150701972:+
TGCT	cis	rs11098499	0.604	rs10022185	ENSG00000245958.5	RP11-33B1.1	-6.25	5.9e-09	1.37e-05	-0.53	-0.49	Corneal astigmatism;	chr4:119650610	chr4:119454791~119552025:+
TGCT	cis	rs7412746	0.611	rs1889740	ENSG00000206931.1	RNU6-1042P	6.25	5.92e-09	1.38e-05	0.39	0.49	Melanoma;	chr1:150827279	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.519	rs11800855	ENSG00000206931.1	RNU6-1042P	6.25	5.92e-09	1.38e-05	0.39	0.49	Tonsillectomy;	chr1:150828519	chr1:150701866~150701972:+
TGCT	cis	rs748404	0.578	rs2278856	ENSG00000205771.5	CATSPER2P1	-6.25	5.95e-09	1.38e-05	-0.55	-0.49	Lung cancer;	chr15:43339158	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.604	rs2278857	ENSG00000205771.5	CATSPER2P1	-6.25	5.95e-09	1.38e-05	-0.55	-0.49	Lung cancer;	chr15:43340351	chr15:43726918~43747094:-
TGCT	cis	rs977987	0.771	rs12929673	ENSG00000261783.1	RP11-252K23.2	-6.25	5.95e-09	1.38e-05	-0.72	-0.49	Dupuytren's disease;	chr16:75436397	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.836	rs35209155	ENSG00000261783.1	RP11-252K23.2	-6.25	5.95e-09	1.38e-05	-0.72	-0.49	Dupuytren's disease;	chr16:75436598	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.836	rs8055974	ENSG00000261783.1	RP11-252K23.2	-6.25	5.95e-09	1.38e-05	-0.72	-0.49	Dupuytren's disease;	chr16:75437088	chr16:75379818~75381260:-
TGCT	cis	rs977987	0.872	rs4887825	ENSG00000261783.1	RP11-252K23.2	-6.25	5.95e-09	1.38e-05	-0.72	-0.49	Dupuytren's disease;	chr16:75438524	chr16:75379818~75381260:-
TGCT	cis	rs7186831	1	rs7186831	ENSG00000261783.1	RP11-252K23.2	-6.25	5.95e-09	1.38e-05	-0.72	-0.49	Chronic obstructive pulmonary disease;	chr16:75439257	chr16:75379818~75381260:-
TGCT	cis	rs1891275	0.54	rs10732773	ENSG00000228701.1	TNKS2-AS1	-6.25	5.99e-09	1.39e-05	-0.57	-0.49	Intelligence (multi-trait analysis);	chr10:91656468	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.551	rs2421624	ENSG00000228701.1	TNKS2-AS1	-6.25	5.99e-09	1.39e-05	-0.57	-0.49	Intelligence (multi-trait analysis);	chr10:91656659	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.551	rs2421625	ENSG00000228701.1	TNKS2-AS1	-6.25	5.99e-09	1.39e-05	-0.57	-0.49	Intelligence (multi-trait analysis);	chr10:91656744	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.576	rs7900117	ENSG00000228701.1	TNKS2-AS1	-6.25	5.99e-09	1.39e-05	-0.57	-0.49	Intelligence (multi-trait analysis);	chr10:91657530	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.551	rs4933213	ENSG00000228701.1	TNKS2-AS1	-6.25	5.99e-09	1.39e-05	-0.57	-0.49	Intelligence (multi-trait analysis);	chr10:91657947	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.515	rs7358148	ENSG00000228701.1	TNKS2-AS1	-6.25	5.99e-09	1.39e-05	-0.57	-0.49	Intelligence (multi-trait analysis);	chr10:91658775	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.551	rs7908547	ENSG00000228701.1	TNKS2-AS1	-6.25	5.99e-09	1.39e-05	-0.57	-0.49	Intelligence (multi-trait analysis);	chr10:91659230	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.515	rs7908980	ENSG00000228701.1	TNKS2-AS1	-6.25	5.99e-09	1.39e-05	-0.57	-0.49	Intelligence (multi-trait analysis);	chr10:91659545	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.551	rs4933690	ENSG00000228701.1	TNKS2-AS1	-6.25	5.99e-09	1.39e-05	-0.57	-0.49	Intelligence (multi-trait analysis);	chr10:91659810	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.576	rs4933216	ENSG00000228701.1	TNKS2-AS1	-6.25	5.99e-09	1.39e-05	-0.57	-0.49	Intelligence (multi-trait analysis);	chr10:91659825	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.551	rs4933691	ENSG00000228701.1	TNKS2-AS1	-6.25	5.99e-09	1.39e-05	-0.57	-0.49	Intelligence (multi-trait analysis);	chr10:91660200	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.551	rs2421626	ENSG00000228701.1	TNKS2-AS1	-6.25	5.99e-09	1.39e-05	-0.57	-0.49	Intelligence (multi-trait analysis);	chr10:91661177	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.551	rs2421627	ENSG00000228701.1	TNKS2-AS1	-6.25	5.99e-09	1.39e-05	-0.57	-0.49	Intelligence (multi-trait analysis);	chr10:91662226	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.551	rs2421628	ENSG00000228701.1	TNKS2-AS1	-6.25	5.99e-09	1.39e-05	-0.57	-0.49	Intelligence (multi-trait analysis);	chr10:91662412	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.515	rs10881945	ENSG00000228701.1	TNKS2-AS1	-6.25	5.99e-09	1.39e-05	-0.57	-0.49	Intelligence (multi-trait analysis);	chr10:91663826	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.551	rs2421629	ENSG00000228701.1	TNKS2-AS1	-6.25	5.99e-09	1.39e-05	-0.57	-0.49	Intelligence (multi-trait analysis);	chr10:91664018	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.551	rs4933692	ENSG00000228701.1	TNKS2-AS1	-6.25	5.99e-09	1.39e-05	-0.57	-0.49	Intelligence (multi-trait analysis);	chr10:91664876	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.551	rs7900863	ENSG00000228701.1	TNKS2-AS1	-6.25	5.99e-09	1.39e-05	-0.57	-0.49	Intelligence (multi-trait analysis);	chr10:91665737	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.588	rs6583782	ENSG00000228701.1	TNKS2-AS1	-6.25	5.99e-09	1.39e-05	-0.57	-0.49	Intelligence (multi-trait analysis);	chr10:91666022	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.551	rs1891271	ENSG00000228701.1	TNKS2-AS1	-6.25	5.99e-09	1.39e-05	-0.57	-0.49	Intelligence (multi-trait analysis);	chr10:91666566	chr10:91782839~91798291:-
TGCT	cis	rs5769707	0.605	rs9616702	ENSG00000188511.11	C22orf34	6.25	6e-09	1.39e-05	0.54	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49632290	chr22:49414524~49657542:-
TGCT	cis	rs11098499	0.739	rs10031033	ENSG00000245958.5	RP11-33B1.1	-6.25	6.04e-09	1.4e-05	-0.48	-0.49	Corneal astigmatism;	chr4:119230297	chr4:119454791~119552025:+
TGCT	cis	rs3096299	0.685	rs3803682	ENSG00000274627.1	RP11-104N10.2	6.25	6.05e-09	1.4e-05	0.5	0.49	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:89516797~89522217:+
TGCT	cis	rs1153858	0.621	rs1719237	ENSG00000259520.4	CTD-2651B20.3	-6.25	6.06e-09	1.41e-05	-0.44	-0.49	Homoarginine levels;	chr15:45287624	chr15:45251580~45279251:-
TGCT	cis	rs1153858	0.621	rs1706824	ENSG00000259520.4	CTD-2651B20.3	-6.25	6.06e-09	1.41e-05	-0.44	-0.49	Homoarginine levels;	chr15:45287750	chr15:45251580~45279251:-
TGCT	cis	rs1153858	0.621	rs12913645	ENSG00000259520.4	CTD-2651B20.3	6.25	6.06e-09	1.41e-05	0.44	0.49	Homoarginine levels;	chr15:45262868	chr15:45251580~45279251:-
TGCT	cis	rs12891047	0.804	rs8004611	ENSG00000258759.1	RP11-1012A1.7	-6.25	6.06e-09	1.41e-05	-0.45	-0.49	Amyotrophic lateral sclerosis (sporadic);	chr14:67821795	chr14:67799004~67799609:+
TGCT	cis	rs5760092	0.755	rs4585126	ENSG00000273295.1	AP000350.5	-6.25	6.07e-09	1.41e-05	-0.66	-0.49	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23901432~23907068:-
TGCT	cis	rs17301013	0.606	rs333423	ENSG00000227373.4	RP11-160H22.5	6.25	6.09e-09	1.41e-05	0.56	0.49	Systemic lupus erythematosus;	chr1:174666557	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs333437	ENSG00000227373.4	RP11-160H22.5	6.25	6.09e-09	1.41e-05	0.56	0.49	Systemic lupus erythematosus;	chr1:174672224	chr1:174115300~174160004:-
TGCT	cis	rs7208859	0.623	rs73263788	ENSG00000263531.1	RP13-753N3.1	6.25	6.13e-09	1.42e-05	0.85	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs12949860	ENSG00000263531.1	RP13-753N3.1	6.25	6.13e-09	1.42e-05	0.85	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs3816780	ENSG00000263531.1	RP13-753N3.1	6.25	6.14e-09	1.42e-05	0.93	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30863921~30864940:-
TGCT	cis	rs7412746	0.611	rs2228099	ENSG00000206931.1	RNU6-1042P	6.25	6.17e-09	1.43e-05	0.37	0.49	Melanoma;	chr1:150836413	chr1:150701866~150701972:+
TGCT	cis	rs9549367	0.713	rs3024761	ENSG00000269125.1	RP11-98F14.11	6.25	6.18e-09	1.43e-05	0.61	0.49	Platelet distribution width;	chr13:113169776	chr13:113165002~113165183:-
TGCT	cis	rs801193	1	rs13239306	ENSG00000222364.1	RNU6-96P	6.24	6.19e-09	1.43e-05	0.59	0.49	Aortic root size;	chr7:66671030	chr7:66395191~66395286:+
TGCT	cis	rs1062177	0.855	rs919263	ENSG00000213433.5	RPLP1P6	-6.24	6.24e-09	1.44e-05	-0.55	-0.49	Preschool internalizing problems;	chr5:151886292	chr5:151765859~151766378:-
TGCT	cis	rs9549367	0.713	rs3024757	ENSG00000269125.1	RP11-98F14.11	-6.24	6.24e-09	1.44e-05	-0.63	-0.49	Platelet distribution width;	chr13:113168872	chr13:113165002~113165183:-
TGCT	cis	rs7849270	0.879	rs10760587	ENSG00000268707.1	RP11-247A12.7	6.24	6.26e-09	1.45e-05	0.54	0.49	Blood metabolite ratios;	chr9:129083737	chr9:129170434~129170940:+
TGCT	cis	rs6452524	0.868	rs10045104	ENSG00000249664.1	CTD-2227C6.2	6.24	6.27e-09	1.45e-05	0.53	0.49	Hypertension (SNP x SNP interaction);	chr5:83116543	chr5:83012285~83013109:-
TGCT	cis	rs875971	0.862	rs1167408	ENSG00000222364.1	RNU6-96P	6.24	6.3e-09	1.45e-05	0.55	0.49	Aortic root size;	chr7:66091121	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.83	rs1167406	ENSG00000222364.1	RNU6-96P	6.24	6.3e-09	1.45e-05	0.55	0.49	Aortic root size;	chr7:66091949	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs709609	ENSG00000222364.1	RNU6-96P	6.24	6.3e-09	1.45e-05	0.55	0.49	Aortic root size;	chr7:66095574	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs1167399	ENSG00000222364.1	RNU6-96P	6.24	6.3e-09	1.45e-05	0.55	0.49	Aortic root size;	chr7:66096890	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs57866200	ENSG00000222364.1	RNU6-96P	6.24	6.3e-09	1.45e-05	0.55	0.49	Aortic root size;	chr7:66100405	chr7:66395191~66395286:+
TGCT	cis	rs943437	0.877	rs547076	ENSG00000227012.2	RP1-97J1.2	6.24	6.31e-09	1.46e-05	0.65	0.49	Parkinson's disease;	chr6:111952274	chr6:111900489~111901851:-
TGCT	cis	rs17301013	0.531	rs4650958	ENSG00000227373.4	RP11-160H22.5	6.24	6.31e-09	1.46e-05	0.58	0.49	Systemic lupus erythematosus;	chr1:174178378	chr1:174115300~174160004:-
TGCT	cis	rs2882667	0.898	rs11956089	ENSG00000253404.1	AC034243.1	-6.24	6.32e-09	1.46e-05	-0.59	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058915	chr5:138744434~138753309:-
TGCT	cis	rs977987	0.806	rs4993969	ENSG00000261783.1	RP11-252K23.2	-6.24	6.32e-09	1.46e-05	-0.72	-0.49	Dupuytren's disease;	chr16:75377623	chr16:75379818~75381260:-
TGCT	cis	rs3096299	0.658	rs3934737	ENSG00000274627.1	RP11-104N10.2	6.24	6.33e-09	1.46e-05	0.51	0.49	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89516797~89522217:+
TGCT	cis	rs6700559	0.81	rs2808248	ENSG00000260088.1	RP11-92G12.3	6.24	6.38e-09	1.47e-05	0.58	0.49	Coronary artery disease;	chr1:200623147	chr1:200669507~200694250:+
TGCT	cis	rs875971	0.54	rs781152	ENSG00000222364.1	RNU6-96P	-6.24	6.4e-09	1.47e-05	-0.56	-0.49	Aortic root size;	chr7:66014585	chr7:66395191~66395286:+
TGCT	cis	rs17711722	0.727	rs781151	ENSG00000222364.1	RNU6-96P	-6.24	6.4e-09	1.47e-05	-0.56	-0.49	Calcium levels;	chr7:66014891	chr7:66395191~66395286:+
TGCT	cis	rs7412746	0.658	rs11204739	ENSG00000206931.1	RNU6-1042P	6.24	6.4e-09	1.47e-05	0.39	0.49	Melanoma;	chr1:150893284	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs11581757	ENSG00000206931.1	RNU6-1042P	6.24	6.4e-09	1.47e-05	0.39	0.49	Melanoma;	chr1:150919768	chr1:150701866~150701972:+
TGCT	cis	rs6452524	0.78	rs2386237	ENSG00000249664.1	CTD-2227C6.2	6.24	6.41e-09	1.48e-05	0.53	0.49	Hypertension (SNP x SNP interaction);	chr5:83101852	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.804	rs1478481	ENSG00000249664.1	CTD-2227C6.2	6.24	6.41e-09	1.48e-05	0.53	0.49	Hypertension (SNP x SNP interaction);	chr5:83111286	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.775	rs10071579	ENSG00000249664.1	CTD-2227C6.2	6.24	6.41e-09	1.48e-05	0.53	0.49	Hypertension (SNP x SNP interaction);	chr5:83113925	chr5:83012285~83013109:-
TGCT	cis	rs7412746	0.611	rs12085336	ENSG00000206931.1	RNU6-1042P	6.24	6.44e-09	1.48e-05	0.38	0.49	Melanoma;	chr1:150803304	chr1:150701866~150701972:+
TGCT	cis	rs875971	0.964	rs11765965	ENSG00000222364.1	RNU6-96P	-6.24	6.45e-09	1.48e-05	-0.57	-0.49	Aortic root size;	chr7:66377234	chr7:66395191~66395286:+
TGCT	cis	rs2739330	0.796	rs2154594	ENSG00000272787.1	KB-226F1.2	6.24	6.46e-09	1.49e-05	0.56	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23969211~23969873:+
TGCT	cis	rs950169	0.58	rs2271431	ENSG00000225151.9	GOLGA2P7	-6.23	6.49e-09	1.49e-05	-0.55	-0.49	Schizophrenia;	chr15:84646233	chr15:84199311~84230136:-
TGCT	cis	rs11098499	0.604	rs2389887	ENSG00000245958.5	RP11-33B1.1	-6.23	6.51e-09	1.49e-05	-0.53	-0.49	Corneal astigmatism;	chr4:119649489	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.604	rs34278750	ENSG00000245958.5	RP11-33B1.1	-6.23	6.51e-09	1.49e-05	-0.53	-0.49	Corneal astigmatism;	chr4:119649981	chr4:119454791~119552025:+
TGCT	cis	rs73086581	0.687	rs73082600	ENSG00000229539.1	RP11-119B16.2	6.23	6.51e-09	1.49e-05	0.77	0.49	Response to antidepressants in depression;	chr20:3863718	chr20:3888239~3888868:-
TGCT	cis	rs11098499	0.604	rs12642411	ENSG00000245958.5	RP11-33B1.1	-6.23	6.53e-09	1.5e-05	-0.52	-0.49	Corneal astigmatism;	chr4:119659370	chr4:119454791~119552025:+
TGCT	cis	rs875971	0.545	rs13311962	ENSG00000226824.5	RP4-756H11.3	6.23	6.63e-09	1.52e-05	0.59	0.49	Aortic root size;	chr7:66603142	chr7:66654538~66669855:+
TGCT	cis	rs1062177	0.855	rs1346489	ENSG00000213433.5	RPLP1P6	-6.23	6.69e-09	1.53e-05	-0.54	-0.49	Preschool internalizing problems;	chr5:151886973	chr5:151765859~151766378:-
TGCT	cis	rs4713118	0.715	rs200480	ENSG00000216901.1	AL022393.7	6.23	6.75e-09	1.55e-05	0.54	0.49	Parkinson's disease;	chr6:27805886	chr6:28176188~28176674:+
TGCT	cis	rs9549367	0.826	rs2302755	ENSG00000269125.1	RP11-98F14.11	-6.23	6.76e-09	1.55e-05	-0.57	-0.49	Platelet distribution width;	chr13:113244104	chr13:113165002~113165183:-
TGCT	cis	rs11155671	0.53	rs2342770	ENSG00000216906.2	RP11-350J20.9	6.23	6.8e-09	1.56e-05	0.53	0.49	Testicular germ cell tumor;	chr6:149895549	chr6:149904243~149906418:+
TGCT	cis	rs1891275	0.506	rs4933214	ENSG00000228701.1	TNKS2-AS1	-6.22	6.82e-09	1.56e-05	-0.57	-0.49	Intelligence (multi-trait analysis);	chr10:91658004	chr10:91782839~91798291:-
TGCT	cis	rs16828019	0.777	rs35044078	ENSG00000235358.1	RP11-399E6.1	6.22	6.85e-09	1.57e-05	0.82	0.49	Intelligence (multi-trait analysis);	chr1:41008728	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.704	rs4996176	ENSG00000235358.1	RP11-399E6.1	6.22	6.85e-09	1.57e-05	0.82	0.49	Intelligence (multi-trait analysis);	chr1:41022496	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.777	rs35496942	ENSG00000235358.1	RP11-399E6.1	6.22	6.85e-09	1.57e-05	0.82	0.49	Intelligence (multi-trait analysis);	chr1:41023232	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.704	rs12031277	ENSG00000235358.1	RP11-399E6.1	6.22	6.85e-09	1.57e-05	0.82	0.49	Intelligence (multi-trait analysis);	chr1:41026129	chr1:41242373~41284861:+
TGCT	cis	rs748404	0.631	rs8042688	ENSG00000205771.5	CATSPER2P1	-6.22	6.87e-09	1.57e-05	-0.55	-0.49	Lung cancer;	chr15:43346327	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.587	rs9920879	ENSG00000205771.5	CATSPER2P1	-6.22	6.87e-09	1.57e-05	-0.55	-0.49	Lung cancer;	chr15:43347572	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.631	rs7166812	ENSG00000205771.5	CATSPER2P1	-6.22	6.87e-09	1.57e-05	-0.55	-0.49	Lung cancer;	chr15:43352562	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.631	rs4296223	ENSG00000205771.5	CATSPER2P1	-6.22	6.87e-09	1.57e-05	-0.55	-0.49	Lung cancer;	chr15:43353048	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.631	rs11070399	ENSG00000205771.5	CATSPER2P1	-6.22	6.87e-09	1.57e-05	-0.55	-0.49	Lung cancer;	chr15:43354149	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.631	rs6493084	ENSG00000205771.5	CATSPER2P1	-6.22	6.87e-09	1.57e-05	-0.55	-0.49	Lung cancer;	chr15:43355429	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.631	rs12905772	ENSG00000205771.5	CATSPER2P1	-6.22	6.87e-09	1.57e-05	-0.55	-0.49	Lung cancer;	chr15:43356246	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.676	rs4401024	ENSG00000205771.5	CATSPER2P1	-6.22	6.87e-09	1.57e-05	-0.55	-0.49	Lung cancer;	chr15:43358137	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.631	rs1133395	ENSG00000205771.5	CATSPER2P1	-6.22	6.87e-09	1.57e-05	-0.55	-0.49	Lung cancer;	chr15:43358186	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.631	rs6493086	ENSG00000205771.5	CATSPER2P1	-6.22	6.87e-09	1.57e-05	-0.55	-0.49	Lung cancer;	chr15:43363196	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.631	rs3809482	ENSG00000205771.5	CATSPER2P1	-6.22	6.87e-09	1.57e-05	-0.55	-0.49	Lung cancer;	chr15:43369604	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.631	rs2412781	ENSG00000205771.5	CATSPER2P1	6.22	6.87e-09	1.57e-05	0.55	0.49	Lung cancer;	chr15:43375702	chr15:43726918~43747094:-
TGCT	cis	rs17301013	0.606	rs10912747	ENSG00000227373.4	RP11-160H22.5	-6.22	6.92e-09	1.58e-05	-0.55	-0.49	Systemic lupus erythematosus;	chr1:174224564	chr1:174115300~174160004:-
TGCT	cis	rs7714584	0.793	rs12653039	ENSG00000197083.10	ZNF300P1	6.22	6.93e-09	1.58e-05	0.89	0.49	Crohn's disease;	chr5:150873069	chr5:150930645~150946289:-
TGCT	cis	rs6452524	0.901	rs12188673	ENSG00000249664.1	CTD-2227C6.2	6.22	6.94e-09	1.58e-05	0.54	0.49	Hypertension (SNP x SNP interaction);	chr5:83126268	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.87	rs6452511	ENSG00000249664.1	CTD-2227C6.2	6.22	6.94e-09	1.58e-05	0.54	0.49	Hypertension (SNP x SNP interaction);	chr5:83127403	chr5:83012285~83013109:-
TGCT	cis	rs875971	0.862	rs778736	ENSG00000222364.1	RNU6-96P	-6.22	6.95e-09	1.58e-05	-0.54	-0.49	Aortic root size;	chr7:66348861	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs3893216	ENSG00000222364.1	RNU6-96P	6.22	6.95e-09	1.58e-05	0.54	0.49	Aortic root size;	chr7:66325720	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs6958294	ENSG00000222364.1	RNU6-96P	6.22	6.95e-09	1.58e-05	0.54	0.49	Aortic root size;	chr7:66329809	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs2088655	ENSG00000222364.1	RNU6-96P	6.22	6.95e-09	1.58e-05	0.54	0.49	Aortic root size;	chr7:66330724	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.895	rs10447522	ENSG00000222364.1	RNU6-96P	6.22	6.95e-09	1.58e-05	0.54	0.49	Aortic root size;	chr7:66331087	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs2088653	ENSG00000222364.1	RNU6-96P	6.22	6.95e-09	1.58e-05	0.54	0.49	Aortic root size;	chr7:66343621	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs6460293	ENSG00000222364.1	RNU6-96P	6.22	6.95e-09	1.58e-05	0.54	0.49	Aortic root size;	chr7:66345205	chr7:66395191~66395286:+
TGCT	cis	rs7714584	1	rs61530785	ENSG00000197083.10	ZNF300P1	6.22	7e-09	1.59e-05	0.93	0.49	Crohn's disease;	chr5:150881802	chr5:150930645~150946289:-
TGCT	cis	rs801193	0.66	rs974239	ENSG00000222364.1	RNU6-96P	-6.22	7.01e-09	1.59e-05	-0.57	-0.49	Aortic root size;	chr7:66748504	chr7:66395191~66395286:+
TGCT	cis	rs17301013	0.606	rs913687	ENSG00000227373.4	RP11-160H22.5	6.22	7.05e-09	1.6e-05	0.57	0.49	Systemic lupus erythematosus;	chr1:174805993	chr1:174115300~174160004:-
TGCT	cis	rs6452524	0.746	rs28745311	ENSG00000249664.1	CTD-2227C6.2	6.22	7.09e-09	1.61e-05	0.53	0.49	Hypertension (SNP x SNP interaction);	chr5:83123030	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.87	rs12152892	ENSG00000249664.1	CTD-2227C6.2	6.22	7.09e-09	1.61e-05	0.53	0.49	Hypertension (SNP x SNP interaction);	chr5:83125110	chr5:83012285~83013109:-
TGCT	cis	rs694739	0.892	rs647152	ENSG00000236935.1	AP003774.1	6.22	7.1e-09	1.61e-05	0.37	0.49	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64341646	chr11:64325050~64329504:-
TGCT	cis	rs2882667	0.858	rs11959851	ENSG00000253404.1	AC034243.1	6.22	7.1e-09	1.61e-05	0.56	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085716	chr5:138744434~138753309:-
TGCT	cis	rs875971	0.862	rs10263690	ENSG00000222364.1	RNU6-96P	6.22	7.13e-09	1.61e-05	0.54	0.49	Aortic root size;	chr7:66301466	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs10250544	ENSG00000222364.1	RNU6-96P	6.22	7.13e-09	1.61e-05	0.54	0.49	Aortic root size;	chr7:66301574	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.895	rs12531677	ENSG00000222364.1	RNU6-96P	6.22	7.13e-09	1.61e-05	0.54	0.49	Aortic root size;	chr7:66304099	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs7798630	ENSG00000222364.1	RNU6-96P	6.22	7.13e-09	1.61e-05	0.54	0.49	Aortic root size;	chr7:66306492	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs11984115	ENSG00000222364.1	RNU6-96P	6.22	7.13e-09	1.61e-05	0.54	0.49	Aortic root size;	chr7:66308872	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.755	rs10228885	ENSG00000222364.1	RNU6-96P	6.22	7.13e-09	1.61e-05	0.54	0.49	Aortic root size;	chr7:66315542	chr7:66395191~66395286:+
TGCT	cis	rs7826238	0.566	rs2945886	ENSG00000173295.6	FAM86B3P	6.22	7.15e-09	1.61e-05	0.59	0.49	Systolic blood pressure;	chr8:8290748	chr8:8228595~8244865:+
TGCT	cis	rs7757969	0.877	rs4427030	ENSG00000227012.2	RP1-97J1.2	6.22	7.15e-09	1.61e-05	0.74	0.49	Schizophrenia;	chr6:111793046	chr6:111900489~111901851:-
TGCT	cis	rs7757969	1	rs2881040	ENSG00000227012.2	RP1-97J1.2	6.22	7.15e-09	1.61e-05	0.74	0.49	Schizophrenia;	chr6:111793105	chr6:111900489~111901851:-
TGCT	cis	rs7757969	1	rs9374291	ENSG00000227012.2	RP1-97J1.2	6.22	7.15e-09	1.61e-05	0.74	0.49	Schizophrenia;	chr6:111793588	chr6:111900489~111901851:-
TGCT	cis	rs7757969	1	rs2182643	ENSG00000227012.2	RP1-97J1.2	6.22	7.15e-09	1.61e-05	0.74	0.49	Schizophrenia;	chr6:111799893	chr6:111900489~111901851:-
TGCT	cis	rs7757969	1	rs9487722	ENSG00000227012.2	RP1-97J1.2	6.22	7.15e-09	1.61e-05	0.74	0.49	Schizophrenia;	chr6:111800563	chr6:111900489~111901851:-
TGCT	cis	rs7757969	1	rs2148710	ENSG00000227012.2	RP1-97J1.2	6.22	7.15e-09	1.61e-05	0.74	0.49	Schizophrenia;	chr6:111801023	chr6:111900489~111901851:-
TGCT	cis	rs7757969	0.941	rs9481191	ENSG00000227012.2	RP1-97J1.2	6.22	7.15e-09	1.61e-05	0.74	0.49	Schizophrenia;	chr6:111803235	chr6:111900489~111901851:-
TGCT	cis	rs1211375	0.563	rs1203980	ENSG00000268836.1	LA16c-OS12.2	-6.21	7.17e-09	1.62e-05	-0.47	-0.49	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:214643	chr16:185748~186294:-
TGCT	cis	rs6452524	0.534	rs17284134	ENSG00000249664.1	CTD-2227C6.2	-6.21	7.22e-09	1.63e-05	-0.53	-0.49	Hypertension (SNP x SNP interaction);	chr5:83068325	chr5:83012285~83013109:-
TGCT	cis	rs12908161	1	rs17601029	ENSG00000225151.9	GOLGA2P7	-6.21	7.23e-09	1.63e-05	-0.55	-0.49	Schizophrenia;	chr15:84804478	chr15:84199311~84230136:-
TGCT	cis	rs8072100	1	rs4794048	ENSG00000228782.6	CTD-2026D20.3	6.21	7.24e-09	1.64e-05	0.57	0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685707	chr17:47450568~47492492:-
TGCT	cis	rs55794721	0.543	rs1293260	ENSG00000224183.1	SDHDP6	-6.21	7.27e-09	1.64e-05	-0.52	-0.49	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25294164~25294643:-
TGCT	cis	rs5769707	0.681	rs4622843	ENSG00000188511.11	C22orf34	6.21	7.28e-09	1.64e-05	0.53	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49643268	chr22:49414524~49657542:-
TGCT	cis	rs7044106	0.791	rs4837792	ENSG00000226752.6	PSMD5-AS1	-6.21	7.28e-09	1.64e-05	-0.62	-0.49	Hip circumference adjusted for BMI;	chr9:120721281	chr9:120824828~120854385:+
TGCT	cis	rs875971	1	rs709597	ENSG00000222364.1	RNU6-96P	6.21	7.28e-09	1.64e-05	0.56	0.49	Aortic root size;	chr7:66360996	chr7:66395191~66395286:+
TGCT	cis	rs11673344	0.526	rs55909413	ENSG00000226686.6	LINC01535	6.21	7.28e-09	1.64e-05	0.57	0.49	Obesity-related traits;	chr19:37578663	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.526	rs55865869	ENSG00000226686.6	LINC01535	6.21	7.28e-09	1.64e-05	0.57	0.49	Obesity-related traits;	chr19:37578683	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.502	rs17304703	ENSG00000226686.6	LINC01535	6.21	7.28e-09	1.64e-05	0.57	0.49	Obesity-related traits;	chr19:37582646	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.526	rs73033122	ENSG00000226686.6	LINC01535	6.21	7.28e-09	1.64e-05	0.57	0.49	Obesity-related traits;	chr19:37586006	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.526	rs2306201	ENSG00000226686.6	LINC01535	6.21	7.28e-09	1.64e-05	0.57	0.49	Obesity-related traits;	chr19:37586573	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.526	rs2291001	ENSG00000226686.6	LINC01535	6.21	7.28e-09	1.64e-05	0.57	0.49	Obesity-related traits;	chr19:37594431	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.518	rs73033134	ENSG00000226686.6	LINC01535	6.21	7.28e-09	1.64e-05	0.57	0.49	Obesity-related traits;	chr19:37596046	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.526	rs17305193	ENSG00000226686.6	LINC01535	6.21	7.28e-09	1.64e-05	0.57	0.49	Obesity-related traits;	chr19:37598764	chr19:37251912~37265535:+
TGCT	cis	rs6452524	0.78	rs10078661	ENSG00000249664.1	CTD-2227C6.2	6.21	7.29e-09	1.64e-05	0.56	0.49	Hypertension (SNP x SNP interaction);	chr5:83182136	chr5:83012285~83013109:-
TGCT	cis	rs8040855	0.599	rs2342123	ENSG00000259295.5	CSPG4P12	6.21	7.33e-09	1.65e-05	0.61	0.49	Bulimia nervosa;	chr15:85181918	chr15:85191438~85213905:+
TGCT	cis	rs73086581	1	rs3746666	ENSG00000229539.1	RP11-119B16.2	6.21	7.34e-09	1.65e-05	0.73	0.49	Response to antidepressants in depression;	chr20:3930214	chr20:3888239~3888868:-
TGCT	cis	rs875971	0.79	rs10257911	ENSG00000222364.1	RNU6-96P	6.21	7.34e-09	1.65e-05	0.55	0.49	Aortic root size;	chr7:66278783	chr7:66395191~66395286:+
TGCT	cis	rs7617773	0.817	rs3731497	ENSG00000229759.1	MRPS18AP1	6.21	7.36e-09	1.66e-05	0.42	0.49	Coronary artery disease;	chr3:48185063	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.71	rs36064160	ENSG00000229759.1	MRPS18AP1	6.21	7.36e-09	1.66e-05	0.42	0.49	Coronary artery disease;	chr3:48201611	chr3:48256350~48256938:-
TGCT	cis	rs875971	0.545	rs1909508	ENSG00000226824.5	RP4-756H11.3	-6.21	7.36e-09	1.66e-05	-0.58	-0.49	Aortic root size;	chr7:66301366	chr7:66654538~66669855:+
TGCT	cis	rs5769707	0.632	rs5770601	ENSG00000188511.11	C22orf34	6.21	7.39e-09	1.66e-05	0.54	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49628255	chr22:49414524~49657542:-
TGCT	cis	rs875971	0.545	rs316305	ENSG00000226824.5	RP4-756H11.3	6.21	7.45e-09	1.68e-05	0.6	0.49	Aortic root size;	chr7:66152984	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs316306	ENSG00000226824.5	RP4-756H11.3	6.21	7.45e-09	1.68e-05	0.6	0.49	Aortic root size;	chr7:66153687	chr7:66654538~66669855:+
TGCT	cis	rs7412746	0.611	rs7532045	ENSG00000206931.1	RNU6-1042P	6.21	7.45e-09	1.68e-05	0.39	0.49	Melanoma;	chr1:150849371	chr1:150701866~150701972:+
TGCT	cis	rs3096299	0.685	rs4785675	ENSG00000274627.1	RP11-104N10.2	6.21	7.45e-09	1.68e-05	0.5	0.49	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:89516797~89522217:+
TGCT	cis	rs3096299	0.685	rs4238830	ENSG00000274627.1	RP11-104N10.2	6.21	7.45e-09	1.68e-05	0.5	0.49	Multiple myeloma (IgH translocation);	chr16:89473833	chr16:89516797~89522217:+
TGCT	cis	rs7412746	0.658	rs2275235	ENSG00000206931.1	RNU6-1042P	6.2	7.51e-09	1.69e-05	0.39	0.49	Melanoma;	chr1:150757803	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs11204723	ENSG00000206931.1	RNU6-1042P	6.2	7.51e-09	1.69e-05	0.39	0.49	Melanoma;	chr1:150759142	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs4537557	ENSG00000206931.1	RNU6-1042P	6.2	7.51e-09	1.69e-05	0.39	0.49	Melanoma;	chr1:150761960	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs2864869	ENSG00000206931.1	RNU6-1042P	6.2	7.51e-09	1.69e-05	0.39	0.49	Melanoma;	chr1:150762179	chr1:150701866~150701972:+
TGCT	cis	rs1891275	0.576	rs1891272	ENSG00000228701.1	TNKS2-AS1	-6.2	7.52e-09	1.69e-05	-0.57	-0.49	Intelligence (multi-trait analysis);	chr10:91666306	chr10:91782839~91798291:-
TGCT	cis	rs977987	0.872	rs1542864	ENSG00000261783.1	RP11-252K23.2	-6.2	7.55e-09	1.7e-05	-0.71	-0.49	Dupuytren's disease;	chr16:75437480	chr16:75379818~75381260:-
TGCT	cis	rs7412746	0.658	rs11204750	ENSG00000206931.1	RNU6-1042P	6.2	7.55e-09	1.7e-05	0.39	0.49	Melanoma;	chr1:150967268	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs6656535	ENSG00000206931.1	RNU6-1042P	6.2	7.55e-09	1.7e-05	0.39	0.49	Melanoma;	chr1:150967881	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs6677420	ENSG00000206931.1	RNU6-1042P	6.2	7.55e-09	1.7e-05	0.39	0.49	Melanoma;	chr1:150974014	chr1:150701866~150701972:+
TGCT	cis	rs875971	0.66	rs10215132	ENSG00000222364.1	RNU6-96P	6.2	7.57e-09	1.7e-05	0.58	0.49	Aortic root size;	chr7:66589419	chr7:66395191~66395286:+
TGCT	cis	rs7412746	0.634	rs12562939	ENSG00000206931.1	RNU6-1042P	6.2	7.57e-09	1.7e-05	0.39	0.49	Melanoma;	chr1:150978976	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs12067685	ENSG00000206931.1	RNU6-1042P	6.2	7.57e-09	1.7e-05	0.39	0.49	Melanoma;	chr1:150980441	chr1:150701866~150701972:+
TGCT	cis	rs2948294	0.588	rs12544596	ENSG00000173295.6	FAM86B3P	6.2	7.58e-09	1.7e-05	0.62	0.49	Red cell distribution width;	chr8:8258824	chr8:8228595~8244865:+
TGCT	cis	rs7829975	0.514	rs2979151	ENSG00000173295.6	FAM86B3P	-6.2	7.62e-09	1.71e-05	-0.58	-0.49	Mood instability;	chr8:8400509	chr8:8228595~8244865:+
TGCT	cis	rs875971	0.545	rs10950036	ENSG00000226824.5	RP4-756H11.3	-6.2	7.65e-09	1.72e-05	-0.58	-0.49	Aortic root size;	chr7:66353241	chr7:66654538~66669855:+
TGCT	cis	rs524281	0.861	rs11227426	ENSG00000255320.1	RP11-755F10.1	6.2	7.66e-09	1.72e-05	0.6	0.49	Electroencephalogram traits;	chr11:66204480	chr11:66244840~66246239:-
TGCT	cis	rs801193	0.591	rs2707839	ENSG00000222364.1	RNU6-96P	-6.2	7.71e-09	1.73e-05	-0.57	-0.49	Aortic root size;	chr7:66728097	chr7:66395191~66395286:+
TGCT	cis	rs3091242	0.935	rs3093632	ENSG00000224183.1	SDHDP6	-6.2	7.71e-09	1.73e-05	-0.52	-0.49	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25294164~25294643:-
TGCT	cis	rs73086581	1	rs73084575	ENSG00000229539.1	RP11-119B16.2	6.2	7.71e-09	1.73e-05	0.71	0.49	Response to antidepressants in depression;	chr20:3926121	chr20:3888239~3888868:-
TGCT	cis	rs3091242	1	rs3091242	ENSG00000224183.1	SDHDP6	-6.2	7.72e-09	1.73e-05	-0.52	-0.49	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25294164~25294643:-
TGCT	cis	rs3091242	0.967	rs3091240	ENSG00000224183.1	SDHDP6	-6.2	7.72e-09	1.73e-05	-0.52	-0.49	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25294164~25294643:-
TGCT	cis	rs12908161	0.959	rs17534709	ENSG00000225151.9	GOLGA2P7	-6.2	7.74e-09	1.73e-05	-0.56	-0.49	Schizophrenia;	chr15:84771166	chr15:84199311~84230136:-
TGCT	cis	rs9549367	0.713	rs3024746	ENSG00000269125.1	RP11-98F14.11	-6.2	7.87e-09	1.76e-05	-0.59	-0.49	Platelet distribution width;	chr13:113167463	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.713	rs3024747	ENSG00000269125.1	RP11-98F14.11	-6.2	7.87e-09	1.76e-05	-0.59	-0.49	Platelet distribution width;	chr13:113167473	chr13:113165002~113165183:-
TGCT	cis	rs748404	0.69	rs1079309	ENSG00000205771.5	CATSPER2P1	-6.19	7.88e-09	1.76e-05	-0.55	-0.49	Lung cancer;	chr15:43490966	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.69	rs2924369	ENSG00000205771.5	CATSPER2P1	6.19	7.88e-09	1.76e-05	0.55	0.49	Lung cancer;	chr15:43485787	chr15:43726918~43747094:-
TGCT	cis	rs9549367	0.789	rs2287253	ENSG00000269125.1	RP11-98F14.11	6.19	8.02e-09	1.79e-05	0.58	0.49	Platelet distribution width;	chr13:113236761	chr13:113165002~113165183:-
TGCT	cis	rs875971	1	rs2220626	ENSG00000222364.1	RNU6-96P	6.19	8.07e-09	1.8e-05	0.56	0.49	Aortic root size;	chr7:66081075	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.964	rs697969	ENSG00000222364.1	RNU6-96P	6.19	8.07e-09	1.8e-05	0.56	0.49	Aortic root size;	chr7:66093491	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs697970	ENSG00000222364.1	RNU6-96P	6.19	8.07e-09	1.8e-05	0.56	0.49	Aortic root size;	chr7:66095065	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs1182882	ENSG00000222364.1	RNU6-96P	6.19	8.07e-09	1.8e-05	0.56	0.49	Aortic root size;	chr7:66097076	chr7:66395191~66395286:+
TGCT	cis	rs16828019	0.852	rs3820090	ENSG00000235358.1	RP11-399E6.1	6.19	8.09e-09	1.81e-05	0.88	0.49	Intelligence (multi-trait analysis);	chr1:41107980	chr1:41242373~41284861:+
TGCT	cis	rs875971	0.66	rs10263935	ENSG00000222364.1	RNU6-96P	-6.19	8.09e-09	1.81e-05	-0.57	-0.49	Aortic root size;	chr7:66631041	chr7:66395191~66395286:+
TGCT	cis	rs17301013	0.606	rs6425277	ENSG00000227373.4	RP11-160H22.5	6.19	8.12e-09	1.81e-05	0.54	0.49	Systemic lupus erythematosus;	chr1:174296153	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs12074276	ENSG00000227373.4	RP11-160H22.5	6.19	8.12e-09	1.81e-05	0.54	0.49	Systemic lupus erythematosus;	chr1:174302167	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.659	rs59649440	ENSG00000227373.4	RP11-160H22.5	6.19	8.12e-09	1.81e-05	0.54	0.49	Systemic lupus erythematosus;	chr1:174332024	chr1:174115300~174160004:-
TGCT	cis	rs875971	0.66	rs12698534	ENSG00000222364.1	RNU6-96P	-6.19	8.14e-09	1.81e-05	-0.58	-0.49	Aortic root size;	chr7:66521858	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.66	rs62465434	ENSG00000222364.1	RNU6-96P	-6.19	8.14e-09	1.81e-05	-0.58	-0.49	Aortic root size;	chr7:66540165	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.66	rs13224319	ENSG00000222364.1	RNU6-96P	-6.19	8.14e-09	1.81e-05	-0.58	-0.49	Aortic root size;	chr7:66542376	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.66	rs801217	ENSG00000222364.1	RNU6-96P	6.19	8.14e-09	1.81e-05	0.58	0.49	Aortic root size;	chr7:66545590	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.638	rs801216	ENSG00000222364.1	RNU6-96P	6.19	8.14e-09	1.81e-05	0.58	0.49	Aortic root size;	chr7:66546680	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.66	rs801211	ENSG00000222364.1	RNU6-96P	6.19	8.14e-09	1.81e-05	0.58	0.49	Aortic root size;	chr7:66550702	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.638	rs801205	ENSG00000222364.1	RNU6-96P	6.19	8.14e-09	1.81e-05	0.58	0.49	Aortic root size;	chr7:66557157	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.617	rs810400	ENSG00000222364.1	RNU6-96P	6.19	8.14e-09	1.81e-05	0.58	0.49	Aortic root size;	chr7:66557902	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.638	rs3898855	ENSG00000222364.1	RNU6-96P	6.19	8.14e-09	1.81e-05	0.58	0.49	Aortic root size;	chr7:66571411	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.638	rs10278816	ENSG00000222364.1	RNU6-96P	6.19	8.14e-09	1.81e-05	0.58	0.49	Aortic root size;	chr7:66572000	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.66	rs10281080	ENSG00000222364.1	RNU6-96P	6.19	8.14e-09	1.81e-05	0.58	0.49	Aortic root size;	chr7:66577454	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.66	rs10950044	ENSG00000222364.1	RNU6-96P	6.19	8.14e-09	1.81e-05	0.58	0.49	Aortic root size;	chr7:66577989	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.638	rs10249404	ENSG00000222364.1	RNU6-96P	6.19	8.14e-09	1.81e-05	0.58	0.49	Aortic root size;	chr7:66581737	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.619	rs10278371	ENSG00000222364.1	RNU6-96P	6.19	8.14e-09	1.81e-05	0.58	0.49	Aortic root size;	chr7:66586553	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.522	rs1968127	ENSG00000222364.1	RNU6-96P	6.19	8.14e-09	1.81e-05	0.58	0.49	Aortic root size;	chr7:66591816	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.66	rs79009421	ENSG00000222364.1	RNU6-96P	6.19	8.14e-09	1.81e-05	0.58	0.49	Aortic root size;	chr7:66603522	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.66	rs7807930	ENSG00000222364.1	RNU6-96P	6.19	8.14e-09	1.81e-05	0.58	0.49	Aortic root size;	chr7:66622178	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.66	rs7807944	ENSG00000222364.1	RNU6-96P	6.19	8.14e-09	1.81e-05	0.58	0.49	Aortic root size;	chr7:66622208	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.638	rs35986979	ENSG00000222364.1	RNU6-96P	6.19	8.14e-09	1.81e-05	0.58	0.49	Aortic root size;	chr7:66624003	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.642	rs35526611	ENSG00000222364.1	RNU6-96P	6.19	8.14e-09	1.81e-05	0.58	0.49	Aortic root size;	chr7:66629021	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.66	rs3764903	ENSG00000222364.1	RNU6-96P	6.19	8.14e-09	1.81e-05	0.58	0.49	Aortic root size;	chr7:66633495	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.66	rs1860470	ENSG00000222364.1	RNU6-96P	6.19	8.14e-09	1.81e-05	0.58	0.49	Aortic root size;	chr7:66638707	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.528	rs801213	ENSG00000226824.5	RP4-756H11.3	6.19	8.15e-09	1.81e-05	0.58	0.49	Aortic root size;	chr7:66549931	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs801212	ENSG00000226824.5	RP4-756H11.3	6.19	8.15e-09	1.81e-05	0.58	0.49	Aortic root size;	chr7:66550643	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs801199	ENSG00000226824.5	RP4-756H11.3	6.19	8.15e-09	1.81e-05	0.58	0.49	Aortic root size;	chr7:66560286	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs1638724	ENSG00000226824.5	RP4-756H11.3	6.19	8.15e-09	1.81e-05	0.58	0.49	Aortic root size;	chr7:66575494	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs1267814	ENSG00000226824.5	RP4-756H11.3	6.19	8.15e-09	1.81e-05	0.58	0.49	Aortic root size;	chr7:66579422	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs75840613	ENSG00000226824.5	RP4-756H11.3	-6.19	8.15e-09	1.81e-05	-0.58	-0.49	Aortic root size;	chr7:66376399	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs73148639	ENSG00000226824.5	RP4-756H11.3	-6.19	8.15e-09	1.81e-05	-0.58	-0.49	Aortic root size;	chr7:66390342	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs6460298	ENSG00000226824.5	RP4-756H11.3	-6.19	8.15e-09	1.81e-05	-0.58	-0.49	Aortic root size;	chr7:66442783	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs35459055	ENSG00000226824.5	RP4-756H11.3	-6.19	8.15e-09	1.81e-05	-0.58	-0.49	Aortic root size;	chr7:66479399	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs75577046	ENSG00000226824.5	RP4-756H11.3	-6.19	8.15e-09	1.81e-05	-0.58	-0.49	Aortic root size;	chr7:66493729	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs3735147	ENSG00000226824.5	RP4-756H11.3	-6.19	8.15e-09	1.81e-05	-0.58	-0.49	Aortic root size;	chr7:66505541	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs6950988	ENSG00000226824.5	RP4-756H11.3	-6.19	8.15e-09	1.81e-05	-0.58	-0.49	Aortic root size;	chr7:66511428	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs73152714	ENSG00000226824.5	RP4-756H11.3	-6.19	8.15e-09	1.81e-05	-0.58	-0.49	Aortic root size;	chr7:66534641	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs4718364	ENSG00000226824.5	RP4-756H11.3	-6.19	8.15e-09	1.81e-05	-0.58	-0.49	Aortic root size;	chr7:66536353	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs6961853	ENSG00000226824.5	RP4-756H11.3	-6.19	8.15e-09	1.81e-05	-0.58	-0.49	Aortic root size;	chr7:66537035	chr7:66654538~66669855:+
TGCT	cis	rs2283792	0.73	rs2083565	ENSG00000228050.1	TOP3BP1	6.19	8.25e-09	1.83e-05	0.57	0.49	Multiple sclerosis;	chr22:21929985	chr22:22223187~22224566:-
TGCT	cis	rs2283792	0.73	rs2027790	ENSG00000228050.1	TOP3BP1	6.19	8.25e-09	1.83e-05	0.57	0.49	Multiple sclerosis;	chr22:21933592	chr22:22223187~22224566:-
TGCT	cis	rs7044106	0.791	rs4836830	ENSG00000226752.6	PSMD5-AS1	-6.19	8.25e-09	1.83e-05	-0.63	-0.49	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120824828~120854385:+
TGCT	cis	rs875971	1	rs1167612	ENSG00000222364.1	RNU6-96P	6.19	8.26e-09	1.84e-05	0.55	0.49	Aortic root size;	chr7:66102989	chr7:66395191~66395286:+
TGCT	cis	rs17301013	0.507	rs7517516	ENSG00000227373.4	RP11-160H22.5	6.18	8.32e-09	1.85e-05	0.56	0.49	Systemic lupus erythematosus;	chr1:174346187	chr1:174115300~174160004:-
TGCT	cis	rs7829975	0.659	rs4382480	ENSG00000173295.6	FAM86B3P	6.18	8.34e-09	1.85e-05	0.56	0.49	Mood instability;	chr8:8863963	chr8:8228595~8244865:+
TGCT	cis	rs1891275	0.551	rs7088831	ENSG00000228701.1	TNKS2-AS1	-6.18	8.35e-09	1.85e-05	-0.56	-0.49	Intelligence (multi-trait analysis);	chr10:91652695	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.551	rs2000177	ENSG00000228701.1	TNKS2-AS1	-6.18	8.35e-09	1.85e-05	-0.56	-0.49	Intelligence (multi-trait analysis);	chr10:91653237	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.576	rs2000178	ENSG00000228701.1	TNKS2-AS1	-6.18	8.35e-09	1.85e-05	-0.56	-0.49	Intelligence (multi-trait analysis);	chr10:91653287	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.551	rs2027486	ENSG00000228701.1	TNKS2-AS1	-6.18	8.35e-09	1.85e-05	-0.56	-0.49	Intelligence (multi-trait analysis);	chr10:91654229	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.551	rs2421623	ENSG00000228701.1	TNKS2-AS1	-6.18	8.35e-09	1.85e-05	-0.56	-0.49	Intelligence (multi-trait analysis);	chr10:91654700	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.551	rs10881941	ENSG00000228701.1	TNKS2-AS1	-6.18	8.35e-09	1.85e-05	-0.56	-0.49	Intelligence (multi-trait analysis);	chr10:91655154	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.576	rs10881942	ENSG00000228701.1	TNKS2-AS1	-6.18	8.35e-09	1.85e-05	-0.56	-0.49	Intelligence (multi-trait analysis);	chr10:91655263	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.516	rs10881943	ENSG00000228701.1	TNKS2-AS1	-6.18	8.35e-09	1.85e-05	-0.56	-0.49	Intelligence (multi-trait analysis);	chr10:91655373	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.551	rs7087959	ENSG00000228701.1	TNKS2-AS1	-6.18	8.35e-09	1.85e-05	-0.56	-0.49	Intelligence (multi-trait analysis);	chr10:91656160	chr10:91782839~91798291:-
TGCT	cis	rs875971	0.545	rs11767262	ENSG00000226824.5	RP4-756H11.3	-6.18	8.36e-09	1.85e-05	-0.58	-0.49	Aortic root size;	chr7:66302237	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs66594357	ENSG00000226824.5	RP4-756H11.3	-6.18	8.36e-09	1.85e-05	-0.58	-0.49	Aortic root size;	chr7:66327797	chr7:66654538~66669855:+
TGCT	cis	rs73086581	1	rs73086588	ENSG00000229539.1	RP11-119B16.2	6.18	8.51e-09	1.88e-05	0.73	0.49	Response to antidepressants in depression;	chr20:4001577	chr20:3888239~3888868:-
TGCT	cis	rs73086581	1	rs73086595	ENSG00000229539.1	RP11-119B16.2	6.18	8.51e-09	1.88e-05	0.73	0.49	Response to antidepressants in depression;	chr20:4002801	chr20:3888239~3888868:-
TGCT	cis	rs73086581	1	rs73086597	ENSG00000229539.1	RP11-119B16.2	6.18	8.51e-09	1.88e-05	0.73	0.49	Response to antidepressants in depression;	chr20:4002924	chr20:3888239~3888868:-
TGCT	cis	rs73086581	1	rs34640283	ENSG00000229539.1	RP11-119B16.2	6.18	8.51e-09	1.88e-05	0.73	0.49	Response to antidepressants in depression;	chr20:4008929	chr20:3888239~3888868:-
TGCT	cis	rs875971	1	rs778726	ENSG00000222364.1	RNU6-96P	-6.18	8.52e-09	1.88e-05	-0.56	-0.49	Aortic root size;	chr7:66363744	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.767	rs1695815	ENSG00000222364.1	RNU6-96P	-6.18	8.52e-09	1.88e-05	-0.56	-0.49	Aortic root size;	chr7:66366357	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs778685	ENSG00000222364.1	RNU6-96P	-6.18	8.52e-09	1.88e-05	-0.56	-0.49	Aortic root size;	chr7:66371189	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.929	rs778682	ENSG00000222364.1	RNU6-96P	-6.18	8.52e-09	1.88e-05	-0.56	-0.49	Aortic root size;	chr7:66372947	chr7:66395191~66395286:+
TGCT	cis	rs6921919	0.848	rs9468350	ENSG00000216901.1	AL022393.7	6.18	8.54e-09	1.89e-05	0.59	0.49	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28176188~28176674:+
TGCT	cis	rs17301013	0.606	rs12064743	ENSG00000227373.4	RP11-160H22.5	6.18	8.54e-09	1.89e-05	0.57	0.49	Systemic lupus erythematosus;	chr1:174496646	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs7536102	ENSG00000227373.4	RP11-160H22.5	6.18	8.54e-09	1.89e-05	0.57	0.49	Systemic lupus erythematosus;	chr1:174496801	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs7522253	ENSG00000227373.4	RP11-160H22.5	6.18	8.54e-09	1.89e-05	0.57	0.49	Systemic lupus erythematosus;	chr1:174496980	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs4652500	ENSG00000227373.4	RP11-160H22.5	6.18	8.54e-09	1.89e-05	0.57	0.49	Systemic lupus erythematosus;	chr1:174500656	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12071794	ENSG00000227373.4	RP11-160H22.5	6.18	8.54e-09	1.89e-05	0.57	0.49	Systemic lupus erythematosus;	chr1:174500767	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.556	rs7535845	ENSG00000227373.4	RP11-160H22.5	6.18	8.54e-09	1.89e-05	0.57	0.49	Systemic lupus erythematosus;	chr1:174502672	chr1:174115300~174160004:-
TGCT	cis	rs6964833	0.786	rs35633336	ENSG00000123965.13	PMS2P5	6.18	8.55e-09	1.89e-05	0.64	0.49	Menarche (age at onset);	chr7:74643961	chr7:74894116~74897835:+
TGCT	cis	rs6964833	0.935	rs35735900	ENSG00000123965.13	PMS2P5	6.18	8.55e-09	1.89e-05	0.64	0.49	Menarche (age at onset);	chr7:74651887	chr7:74894116~74897835:+
TGCT	cis	rs6964833	0.872	rs4717903	ENSG00000123965.13	PMS2P5	6.18	8.55e-09	1.89e-05	0.64	0.49	Menarche (age at onset);	chr7:74653827	chr7:74894116~74897835:+
TGCT	cis	rs875971	0.545	rs10950029	ENSG00000226824.5	RP4-756H11.3	-6.18	8.56e-09	1.89e-05	-0.57	-0.49	Aortic root size;	chr7:66169334	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.66	rs6460308	ENSG00000222364.1	RNU6-96P	6.18	8.65e-09	1.91e-05	0.57	0.49	Aortic root size;	chr7:66619753	chr7:66395191~66395286:+
TGCT	cis	rs12891047	0.866	rs181564	ENSG00000258759.1	RP11-1012A1.7	6.18	8.66e-09	1.91e-05	0.42	0.48	Amyotrophic lateral sclerosis (sporadic);	chr14:67812639	chr14:67799004~67799609:+
TGCT	cis	rs73086581	1	rs17286349	ENSG00000229539.1	RP11-119B16.2	6.17	8.71e-09	1.92e-05	0.72	0.48	Response to antidepressants in depression;	chr20:3933655	chr20:3888239~3888868:-
TGCT	cis	rs5769707	0.681	rs2071902	ENSG00000188511.11	C22orf34	6.17	8.71e-09	1.92e-05	0.53	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49640890	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.604	rs1018814	ENSG00000188511.11	C22orf34	6.17	8.71e-09	1.92e-05	0.53	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49643252	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.681	rs8137111	ENSG00000188511.11	C22orf34	6.17	8.71e-09	1.92e-05	0.53	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49650102	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.681	rs8140095	ENSG00000188511.11	C22orf34	6.17	8.71e-09	1.92e-05	0.53	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49650147	chr22:49414524~49657542:-
TGCT	cis	rs12908161	0.959	rs1051168	ENSG00000225151.9	GOLGA2P7	-6.17	8.73e-09	1.92e-05	-0.55	-0.48	Schizophrenia;	chr15:84657289	chr15:84199311~84230136:-
TGCT	cis	rs748404	0.66	rs493377	ENSG00000205771.5	CATSPER2P1	-6.17	8.73e-09	1.92e-05	-0.55	-0.48	Lung cancer;	chr15:43481269	chr15:43726918~43747094:-
TGCT	cis	rs7617773	0.746	rs7619865	ENSG00000229759.1	MRPS18AP1	6.17	8.76e-09	1.93e-05	0.39	0.48	Coronary artery disease;	chr3:48329090	chr3:48256350~48256938:-
TGCT	cis	rs6964833	1	rs4717907	ENSG00000123965.13	PMS2P5	6.17	8.79e-09	1.94e-05	0.61	0.48	Menarche (age at onset);	chr7:74672169	chr7:74894116~74897835:+
TGCT	cis	rs801193	0.613	rs2659900	ENSG00000222364.1	RNU6-96P	-6.17	8.8e-09	1.94e-05	-0.57	-0.48	Aortic root size;	chr7:66719456	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.545	rs17138149	ENSG00000226824.5	RP4-756H11.3	-6.17	8.84e-09	1.95e-05	-0.58	-0.48	Aortic root size;	chr7:66228193	chr7:66654538~66669855:+
TGCT	cis	rs9326248	0.581	rs10790167	ENSG00000254851.1	RP11-109L13.1	-6.17	8.85e-09	1.95e-05	-0.57	-0.48	Blood protein levels;	chr11:116930227	chr11:117135528~117138582:+
TGCT	cis	rs2882667	0.858	rs7724108	ENSG00000253404.1	AC034243.1	-6.17	8.86e-09	1.95e-05	-0.55	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139075233	chr5:138744434~138753309:-
TGCT	cis	rs801193	0.66	rs2659914	ENSG00000222364.1	RNU6-96P	-6.17	8.89e-09	1.95e-05	-0.56	-0.48	Aortic root size;	chr7:66691927	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.636	rs2659895	ENSG00000222364.1	RNU6-96P	-6.17	8.89e-09	1.95e-05	-0.56	-0.48	Aortic root size;	chr7:66731484	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.545	rs6460281	ENSG00000226824.5	RP4-756H11.3	-6.17	8.91e-09	1.96e-05	-0.59	-0.48	Aortic root size;	chr7:66216128	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs17138156	ENSG00000226824.5	RP4-756H11.3	-6.17	8.91e-09	1.96e-05	-0.59	-0.48	Aortic root size;	chr7:66249708	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.502	rs2465121	ENSG00000226824.5	RP4-756H11.3	6.17	8.91e-09	1.96e-05	0.6	0.48	Aortic root size;	chr7:66156017	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.502	rs11769702	ENSG00000226824.5	RP4-756H11.3	-6.17	8.91e-09	1.96e-05	-0.6	-0.48	Aortic root size;	chr7:66255529	chr7:66654538~66669855:+
TGCT	cis	rs1891275	0.551	rs11186640	ENSG00000228701.1	TNKS2-AS1	-6.17	8.91e-09	1.96e-05	-0.56	-0.48	Intelligence (multi-trait analysis);	chr10:91640674	chr10:91782839~91798291:-
TGCT	cis	rs7246967	0.866	rs62120785	ENSG00000269509.1	BNIP3P34	6.17	8.97e-09	1.97e-05	0.84	0.48	Bronchopulmonary dysplasia;	chr19:22861997	chr19:22773853~22774424:+
TGCT	cis	rs7044106	0.791	rs10985000	ENSG00000226752.6	PSMD5-AS1	-6.17	8.98e-09	1.97e-05	-0.61	-0.48	Hip circumference adjusted for BMI;	chr9:120721837	chr9:120824828~120854385:+
TGCT	cis	rs7044106	0.791	rs10985001	ENSG00000226752.6	PSMD5-AS1	-6.17	8.98e-09	1.97e-05	-0.61	-0.48	Hip circumference adjusted for BMI;	chr9:120721954	chr9:120824828~120854385:+
TGCT	cis	rs9326248	0.769	rs499910	ENSG00000254851.1	RP11-109L13.1	-6.17	9e-09	1.98e-05	-0.67	-0.48	Blood protein levels;	chr11:116892318	chr11:117135528~117138582:+
TGCT	cis	rs875971	0.522	rs7784623	ENSG00000222364.1	RNU6-96P	-6.17	9e-09	1.98e-05	-0.56	-0.48	Aortic root size;	chr7:65930047	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.522	rs34973832	ENSG00000222364.1	RNU6-96P	-6.17	9e-09	1.98e-05	-0.56	-0.48	Aortic root size;	chr7:65931217	chr7:66395191~66395286:+
TGCT	cis	rs7412746	0.611	rs4970985	ENSG00000206931.1	RNU6-1042P	-6.17	9.03e-09	1.98e-05	-0.39	-0.48	Melanoma;	chr1:150914966	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs4970987	ENSG00000206931.1	RNU6-1042P	6.17	9.04e-09	1.98e-05	0.39	0.48	Melanoma;	chr1:150977206	chr1:150701866~150701972:+
TGCT	cis	rs9326248	0.581	rs10892048	ENSG00000254851.1	RP11-109L13.1	-6.17	9.08e-09	1.99e-05	-0.56	-0.48	Blood protein levels;	chr11:116943880	chr11:117135528~117138582:+
TGCT	cis	rs9549367	0.713	rs3024743	ENSG00000269125.1	RP11-98F14.11	-6.16	9.13e-09	2e-05	-0.59	-0.48	Platelet distribution width;	chr13:113167116	chr13:113165002~113165183:-
TGCT	cis	rs9549367	0.713	rs3024744	ENSG00000269125.1	RP11-98F14.11	-6.16	9.13e-09	2e-05	-0.59	-0.48	Platelet distribution width;	chr13:113167163	chr13:113165002~113165183:-
TGCT	cis	rs875971	0.545	rs6970498	ENSG00000226824.5	RP4-756H11.3	-6.16	9.17e-09	2.01e-05	-0.59	-0.48	Aortic root size;	chr7:66275908	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs6979636	ENSG00000226824.5	RP4-756H11.3	-6.16	9.17e-09	2.01e-05	-0.59	-0.48	Aortic root size;	chr7:66276638	chr7:66654538~66669855:+
TGCT	cis	rs9549367	0.673	rs3024735	ENSG00000269125.1	RP11-98F14.11	-6.16	9.17e-09	2.01e-05	-0.6	-0.48	Platelet distribution width;	chr13:113165199	chr13:113165002~113165183:-
TGCT	cis	rs875971	0.502	rs1796227	ENSG00000226824.5	RP4-756H11.3	6.16	9.21e-09	2.02e-05	0.59	0.48	Aortic root size;	chr7:66622032	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs1796219	ENSG00000226824.5	RP4-756H11.3	6.16	9.21e-09	2.02e-05	0.59	0.48	Aortic root size;	chr7:66645977	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.502	rs6460311	ENSG00000226824.5	RP4-756H11.3	6.16	9.21e-09	2.02e-05	0.59	0.48	Aortic root size;	chr7:66646886	chr7:66654538~66669855:+
TGCT	cis	rs17711722	0.74	rs7809991	ENSG00000222364.1	RNU6-96P	-6.16	9.21e-09	2.02e-05	-0.56	-0.48	Calcium levels;	chr7:65941231	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.522	rs6960048	ENSG00000222364.1	RNU6-96P	-6.16	9.21e-09	2.02e-05	-0.56	-0.48	Aortic root size;	chr7:65943052	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.522	rs10807697	ENSG00000222364.1	RNU6-96P	-6.16	9.21e-09	2.02e-05	-0.56	-0.48	Aortic root size;	chr7:65951183	chr7:66395191~66395286:+
TGCT	cis	rs17264034	0.821	rs60322708	ENSG00000250786.1	SNHG18	6.16	9.23e-09	2.02e-05	0.52	0.48	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9555837	chr5:9546200~9550609:+
TGCT	cis	rs748404	0.631	rs7163288	ENSG00000205771.5	CATSPER2P1	-6.16	9.25e-09	2.03e-05	-0.53	-0.48	Lung cancer;	chr15:43379157	chr15:43726918~43747094:-
TGCT	cis	rs9326248	0.581	rs7121898	ENSG00000254851.1	RP11-109L13.1	-6.16	9.3e-09	2.04e-05	-0.57	-0.48	Blood protein levels;	chr11:116926130	chr11:117135528~117138582:+
TGCT	cis	rs9326248	0.52	rs1446105	ENSG00000254851.1	RP11-109L13.1	-6.16	9.3e-09	2.04e-05	-0.57	-0.48	Blood protein levels;	chr11:116927828	chr11:117135528~117138582:+
TGCT	cis	rs7412746	0.658	rs7526489	ENSG00000206931.1	RNU6-1042P	6.16	9.34e-09	2.04e-05	0.39	0.48	Melanoma;	chr1:150753762	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs12068264	ENSG00000206931.1	RNU6-1042P	6.16	9.34e-09	2.04e-05	0.39	0.48	Melanoma;	chr1:150754853	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.658	rs2230061	ENSG00000206931.1	RNU6-1042P	6.16	9.34e-09	2.04e-05	0.39	0.48	Melanoma;	chr1:150755063	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.611	rs10788794	ENSG00000206931.1	RNU6-1042P	6.16	9.34e-09	2.04e-05	0.39	0.48	Melanoma;	chr1:150756200	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.611	rs10888391	ENSG00000206931.1	RNU6-1042P	6.16	9.34e-09	2.04e-05	0.39	0.48	Melanoma;	chr1:150757507	chr1:150701866~150701972:+
TGCT	cis	rs875971	0.545	rs73376394	ENSG00000226824.5	RP4-756H11.3	-6.16	9.38e-09	2.05e-05	-0.6	-0.48	Aortic root size;	chr7:66172694	chr7:66654538~66669855:+
TGCT	cis	rs1775715	1	rs1251355	ENSG00000239731.3	RN7SL825P	-6.16	9.38e-09	2.05e-05	-0.5	-0.48	Bipolar disorder with mood-incongruent psychosis;	chr10:32001218	chr10:31992087~31992381:-
TGCT	cis	rs1891275	0.551	rs7071844	ENSG00000228701.1	TNKS2-AS1	-6.16	9.46e-09	2.07e-05	-0.56	-0.48	Intelligence (multi-trait analysis);	chr10:91644092	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.551	rs4933684	ENSG00000228701.1	TNKS2-AS1	-6.16	9.46e-09	2.07e-05	-0.56	-0.48	Intelligence (multi-trait analysis);	chr10:91647805	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.516	rs10881935	ENSG00000228701.1	TNKS2-AS1	-6.16	9.48e-09	2.07e-05	-0.56	-0.48	Intelligence (multi-trait analysis);	chr10:91637944	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.551	rs2421621	ENSG00000228701.1	TNKS2-AS1	-6.16	9.48e-09	2.07e-05	-0.56	-0.48	Intelligence (multi-trait analysis);	chr10:91640344	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.527	rs35812291	ENSG00000228701.1	TNKS2-AS1	-6.16	9.48e-09	2.07e-05	-0.56	-0.48	Intelligence (multi-trait analysis);	chr10:91642584	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.551	rs4933681	ENSG00000228701.1	TNKS2-AS1	-6.16	9.48e-09	2.07e-05	-0.56	-0.48	Intelligence (multi-trait analysis);	chr10:91643365	chr10:91782839~91798291:-
TGCT	cis	rs17301013	0.507	rs6678209	ENSG00000227373.4	RP11-160H22.5	-6.16	9.5e-09	2.07e-05	-0.54	-0.48	Systemic lupus erythematosus;	chr1:174325607	chr1:174115300~174160004:-
TGCT	cis	rs1062177	0.855	rs6884630	ENSG00000213433.5	RPLP1P6	-6.16	9.52e-09	2.08e-05	-0.54	-0.48	Preschool internalizing problems;	chr5:151889436	chr5:151765859~151766378:-
TGCT	cis	rs748404	0.631	rs6493083	ENSG00000205771.5	CATSPER2P1	-6.15	9.59e-09	2.09e-05	-0.53	-0.48	Lung cancer;	chr15:43345787	chr15:43726918~43747094:-
TGCT	cis	rs1062177	0.855	rs6892117	ENSG00000213433.5	RPLP1P6	6.15	9.61e-09	2.09e-05	0.51	0.48	Preschool internalizing problems;	chr5:151885424	chr5:151765859~151766378:-
TGCT	cis	rs524281	0.692	rs10896076	ENSG00000255320.1	RP11-755F10.1	6.15	9.69e-09	2.11e-05	0.58	0.48	Electroencephalogram traits;	chr11:66073197	chr11:66244840~66246239:-
TGCT	cis	rs11155671	0.53	rs4458704	ENSG00000216906.2	RP11-350J20.9	6.15	9.71e-09	2.11e-05	0.51	0.48	Testicular germ cell tumor;	chr6:149911743	chr6:149904243~149906418:+
TGCT	cis	rs748404	0.66	rs2602141	ENSG00000205771.5	CATSPER2P1	-6.15	9.73e-09	2.11e-05	-0.54	-0.48	Lung cancer;	chr15:43432448	chr15:43726918~43747094:-
TGCT	cis	rs7104764	1	rs6598060	ENSG00000277290.1	RP11-326C3.16	-6.15	9.79e-09	2.13e-05	-0.47	-0.48	Menarche (age at onset);	chr11:243987	chr11:243099~243483:-
TGCT	cis	rs9549367	0.826	rs35306827	ENSG00000269125.1	RP11-98F14.11	-6.15	9.8e-09	2.13e-05	-0.57	-0.48	Platelet distribution width;	chr13:113214731	chr13:113165002~113165183:-
TGCT	cis	rs9890032	0.532	rs1808257	ENSG00000266490.1	CTD-2349P21.9	6.15	9.87e-09	2.14e-05	0.39	0.48	Hip circumference adjusted for BMI;	chr17:30712948	chr17:30792372~30792833:+
TGCT	cis	rs7899628	1	rs7899628	ENSG00000276742.1	RP11-500G22.4	-6.15	9.91e-09	2.15e-05	-0.56	-0.48	Breast cancer;	chr10:121904429	chr10:121956782~121957098:+
TGCT	cis	rs972540	0.662	rs7592852	ENSG00000279220.1	GPR1-AS	6.15	9.99e-09	2.17e-05	0.45	0.48	Body mass index;	chr2:206343839	chr2:206203376~206266243:+
TGCT	cis	rs321358	1	rs321368	ENSG00000271584.1	RP11-89C3.4	6.15	1e-08	2.17e-05	0.63	0.48	Body mass index;	chr11:111129033	chr11:111091932~111097357:-
TGCT	cis	rs321358	1	rs321369	ENSG00000271584.1	RP11-89C3.4	6.15	1e-08	2.17e-05	0.63	0.48	Body mass index;	chr11:111129797	chr11:111091932~111097357:-
TGCT	cis	rs321358	1	rs321370	ENSG00000271584.1	RP11-89C3.4	6.15	1e-08	2.17e-05	0.63	0.48	Body mass index;	chr11:111129959	chr11:111091932~111097357:-
TGCT	cis	rs321358	1	rs419633	ENSG00000271584.1	RP11-89C3.4	6.15	1e-08	2.17e-05	0.63	0.48	Body mass index;	chr11:111132187	chr11:111091932~111097357:-
TGCT	cis	rs321358	1	rs429803	ENSG00000271584.1	RP11-89C3.4	6.15	1e-08	2.17e-05	0.63	0.48	Body mass index;	chr11:111132263	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.943	rs402820	ENSG00000271584.1	RP11-89C3.4	6.15	1e-08	2.17e-05	0.63	0.48	Body mass index;	chr11:111132480	chr11:111091932~111097357:-
TGCT	cis	rs9326248	0.581	rs10892053	ENSG00000254851.1	RP11-109L13.1	-6.14	1e-08	2.18e-05	-0.57	-0.48	Blood protein levels;	chr11:116986287	chr11:117135528~117138582:+
TGCT	cis	rs7246967	0.673	rs56209802	ENSG00000269509.1	BNIP3P34	6.14	1e-08	2.18e-05	0.83	0.48	Bronchopulmonary dysplasia;	chr19:22842750	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.8	rs8108944	ENSG00000269509.1	BNIP3P34	6.14	1e-08	2.18e-05	0.83	0.48	Bronchopulmonary dysplasia;	chr19:22855641	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs117679583	ENSG00000269509.1	BNIP3P34	6.14	1e-08	2.18e-05	0.83	0.48	Bronchopulmonary dysplasia;	chr19:22862775	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs7258098	ENSG00000269509.1	BNIP3P34	6.14	1e-08	2.18e-05	0.83	0.48	Bronchopulmonary dysplasia;	chr19:22873927	chr19:22773853~22774424:+
TGCT	cis	rs11098499	0.913	rs56122576	ENSG00000245958.5	RP11-33B1.1	-6.14	1.01e-08	2.18e-05	-0.49	-0.48	Corneal astigmatism;	chr4:119208181	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.913	rs68128210	ENSG00000245958.5	RP11-33B1.1	-6.14	1.01e-08	2.18e-05	-0.49	-0.48	Corneal astigmatism;	chr4:119216664	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.913	rs13126596	ENSG00000245958.5	RP11-33B1.1	-6.14	1.01e-08	2.18e-05	-0.49	-0.48	Corneal astigmatism;	chr4:119219574	chr4:119454791~119552025:+
TGCT	cis	rs7714584	1	rs4958842	ENSG00000197083.10	ZNF300P1	6.14	1.01e-08	2.19e-05	0.91	0.48	Crohn's disease;	chr5:150845315	chr5:150930645~150946289:-
TGCT	cis	rs321358	1	rs321365	ENSG00000271584.1	RP11-89C3.4	6.14	1.01e-08	2.19e-05	0.6	0.48	Body mass index;	chr11:111126676	chr11:111091932~111097357:-
TGCT	cis	rs17301013	0.606	rs162815	ENSG00000227373.4	RP11-160H22.5	6.14	1.01e-08	2.19e-05	0.56	0.48	Systemic lupus erythematosus;	chr1:174738792	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs1793307	ENSG00000227373.4	RP11-160H22.5	-6.14	1.01e-08	2.19e-05	-0.56	-0.48	Systemic lupus erythematosus;	chr1:174758716	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.632	rs1653636	ENSG00000227373.4	RP11-160H22.5	-6.14	1.01e-08	2.19e-05	-0.56	-0.48	Systemic lupus erythematosus;	chr1:174767739	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.62	rs1793310	ENSG00000227373.4	RP11-160H22.5	-6.14	1.01e-08	2.19e-05	-0.56	-0.48	Systemic lupus erythematosus;	chr1:174770786	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs1754360	ENSG00000227373.4	RP11-160H22.5	-6.14	1.01e-08	2.19e-05	-0.56	-0.48	Systemic lupus erythematosus;	chr1:174775825	chr1:174115300~174160004:-
TGCT	cis	rs4927850	0.881	rs7624638	ENSG00000242086.7	LINC00969	6.14	1.02e-08	2.2e-05	0.53	0.48	Pancreatic cancer;	chr3:196021858	chr3:195658062~195739964:+
TGCT	cis	rs4927850	1	rs10881564	ENSG00000242086.7	LINC00969	6.14	1.02e-08	2.2e-05	0.53	0.48	Pancreatic cancer;	chr3:196023455	chr3:195658062~195739964:+
TGCT	cis	rs2948294	0.524	rs13270062	ENSG00000173295.6	FAM86B3P	6.14	1.02e-08	2.2e-05	0.62	0.48	Red cell distribution width;	chr8:8255128	chr8:8228595~8244865:+
TGCT	cis	rs2948294	0.545	rs11776397	ENSG00000173295.6	FAM86B3P	6.14	1.02e-08	2.2e-05	0.62	0.48	Red cell distribution width;	chr8:8257639	chr8:8228595~8244865:+
TGCT	cis	rs6452524	0.868	rs1011981	ENSG00000249664.1	CTD-2227C6.2	6.14	1.02e-08	2.2e-05	0.52	0.48	Hypertension (SNP x SNP interaction);	chr5:83097869	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.868	rs17284218	ENSG00000249664.1	CTD-2227C6.2	6.14	1.02e-08	2.2e-05	0.52	0.48	Hypertension (SNP x SNP interaction);	chr5:83099530	chr5:83012285~83013109:-
TGCT	cis	rs8113308	0.515	rs68124997	ENSG00000269235.1	ZNF350-AS1	6.14	1.02e-08	2.2e-05	0.9	0.48	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51949276	chr19:51949134~51981367:+
TGCT	cis	rs17301013	0.606	rs12067463	ENSG00000227373.4	RP11-160H22.5	6.14	1.02e-08	2.21e-05	0.56	0.48	Systemic lupus erythematosus;	chr1:174625437	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs10912823	ENSG00000227373.4	RP11-160H22.5	6.14	1.02e-08	2.21e-05	0.56	0.48	Systemic lupus erythematosus;	chr1:174625602	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs6677874	ENSG00000227373.4	RP11-160H22.5	6.14	1.02e-08	2.21e-05	0.56	0.48	Systemic lupus erythematosus;	chr1:174628410	chr1:174115300~174160004:-
TGCT	cis	rs16828019	0.632	rs12749196	ENSG00000235358.1	RP11-399E6.1	6.14	1.03e-08	2.23e-05	0.84	0.48	Intelligence (multi-trait analysis);	chr1:40995111	chr1:41242373~41284861:+
TGCT	cis	rs16828019	0.777	rs12047657	ENSG00000235358.1	RP11-399E6.1	6.14	1.03e-08	2.23e-05	0.84	0.48	Intelligence (multi-trait analysis);	chr1:40995841	chr1:41242373~41284861:+
TGCT	cis	rs9326248	0.581	rs6589590	ENSG00000254851.1	RP11-109L13.1	-6.14	1.04e-08	2.23e-05	-0.58	-0.48	Blood protein levels;	chr11:117065365	chr11:117135528~117138582:+
TGCT	cis	rs17301013	0.507	rs72715204	ENSG00000227373.4	RP11-160H22.5	6.14	1.04e-08	2.24e-05	0.59	0.48	Systemic lupus erythematosus;	chr1:174492787	chr1:174115300~174160004:-
TGCT	cis	rs6452524	0.506	rs7891	ENSG00000249664.1	CTD-2227C6.2	6.14	1.04e-08	2.25e-05	0.53	0.48	Hypertension (SNP x SNP interaction);	chr5:83053558	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.534	rs7724935	ENSG00000249664.1	CTD-2227C6.2	6.14	1.04e-08	2.25e-05	0.53	0.48	Hypertension (SNP x SNP interaction);	chr5:83057264	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.506	rs7707143	ENSG00000249664.1	CTD-2227C6.2	6.14	1.04e-08	2.25e-05	0.53	0.48	Hypertension (SNP x SNP interaction);	chr5:83057268	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.563	rs10473863	ENSG00000249664.1	CTD-2227C6.2	6.14	1.04e-08	2.25e-05	0.53	0.48	Hypertension (SNP x SNP interaction);	chr5:83057500	chr5:83012285~83013109:-
TGCT	cis	rs12891047	0.833	rs8011690	ENSG00000258759.1	RP11-1012A1.7	-6.14	1.05e-08	2.25e-05	-0.42	-0.48	Amyotrophic lateral sclerosis (sporadic);	chr14:67825190	chr14:67799004~67799609:+
TGCT	cis	rs875971	0.965	rs697968	ENSG00000222364.1	RNU6-96P	6.14	1.05e-08	2.26e-05	0.55	0.48	Aortic root size;	chr7:66070046	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs1167411	ENSG00000222364.1	RNU6-96P	6.14	1.05e-08	2.26e-05	0.55	0.48	Aortic root size;	chr7:66074277	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs1183245	ENSG00000222364.1	RNU6-96P	6.14	1.05e-08	2.26e-05	0.55	0.48	Aortic root size;	chr7:66076198	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs1144895	ENSG00000222364.1	RNU6-96P	6.14	1.05e-08	2.26e-05	0.55	0.48	Aortic root size;	chr7:66076320	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs1144894	ENSG00000222364.1	RNU6-96P	6.14	1.05e-08	2.26e-05	0.55	0.48	Aortic root size;	chr7:66077907	chr7:66395191~66395286:+
TGCT	cis	rs7044106	0.791	rs4837793	ENSG00000226752.6	PSMD5-AS1	-6.13	1.06e-08	2.27e-05	-0.62	-0.48	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120824828~120854385:+
TGCT	cis	rs3096299	0.685	rs4785676	ENSG00000274627.1	RP11-104N10.2	6.13	1.06e-08	2.28e-05	0.5	0.48	Multiple myeloma (IgH translocation);	chr16:89487216	chr16:89516797~89522217:+
TGCT	cis	rs5760092	0.755	rs915589	ENSG00000273295.1	AP000350.5	-6.13	1.06e-08	2.28e-05	-0.65	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23901432~23907068:-
TGCT	cis	rs5760092	0.627	rs6519489	ENSG00000273295.1	AP000350.5	-6.13	1.06e-08	2.28e-05	-0.65	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23901432~23907068:-
TGCT	cis	rs6061231	0.624	rs8668	ENSG00000273619.1	RP5-908M14.9	6.13	1.07e-08	2.3e-05	0.54	0.48	Colorectal cancer;	chr20:62389008	chr20:62386303~62386970:-
TGCT	cis	rs977987	0.836	rs7198873	ENSG00000261783.1	RP11-252K23.2	-6.13	1.07e-08	2.3e-05	-0.69	-0.48	Dupuytren's disease;	chr16:75440856	chr16:75379818~75381260:-
TGCT	cis	rs9322193	0.847	rs880246	ENSG00000216906.2	RP11-350J20.9	6.13	1.08e-08	2.31e-05	0.56	0.48	Lung cancer;	chr6:149845972	chr6:149904243~149906418:+
TGCT	cis	rs7115242	0.514	rs4936367	ENSG00000254851.1	RP11-109L13.1	-6.13	1.08e-08	2.31e-05	-0.91	-0.48	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117171661	chr11:117135528~117138582:+
TGCT	cis	rs9326248	0.53	rs4604928	ENSG00000254851.1	RP11-109L13.1	-6.13	1.08e-08	2.31e-05	-0.91	-0.48	Blood protein levels;	chr11:117173487	chr11:117135528~117138582:+
TGCT	cis	rs8062405	1	rs12325113	ENSG00000259982.1	CDC37P1	6.13	1.08e-08	2.31e-05	0.66	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28700294~28701540:-
TGCT	cis	rs56163509	1	rs56163509	ENSG00000259982.1	CDC37P1	6.13	1.08e-08	2.31e-05	0.66	0.48	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.964	rs7187333	ENSG00000259982.1	CDC37P1	6.13	1.08e-08	2.31e-05	0.66	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs12446589	ENSG00000259982.1	CDC37P1	6.13	1.08e-08	2.31e-05	0.66	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs62037369	ENSG00000259982.1	CDC37P1	6.13	1.08e-08	2.31e-05	0.66	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.965	rs7359397	ENSG00000259982.1	CDC37P1	6.13	1.08e-08	2.31e-05	0.66	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28700294~28701540:-
TGCT	cis	rs7044106	0.537	rs10818474	ENSG00000226752.6	PSMD5-AS1	-6.13	1.08e-08	2.31e-05	-0.6	-0.48	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120824828~120854385:+
TGCT	cis	rs2739330	0.796	rs1006771	ENSG00000272787.1	KB-226F1.2	-6.13	1.08e-08	2.31e-05	-0.53	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23969211~23969873:+
TGCT	cis	rs875971	0.545	rs6969224	ENSG00000226824.5	RP4-756H11.3	-6.13	1.09e-08	2.33e-05	-0.58	-0.48	Aortic root size;	chr7:66370011	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs1796217	ENSG00000226824.5	RP4-756H11.3	6.13	1.1e-08	2.34e-05	0.59	0.48	Aortic root size;	chr7:66620931	chr7:66654538~66669855:+
TGCT	cis	rs6565180	0.507	rs4471699	ENSG00000183604.13	SMG1P5	-6.13	1.1e-08	2.35e-05	-0.32	-0.48	Tonsillectomy;	chr16:30308986	chr16:30267553~30335374:-
TGCT	cis	rs1799949	1	rs8070085	ENSG00000198496.9	NBR2	6.12	1.11e-08	2.37e-05	0.65	0.48	Menopause (age at onset);	chr17:43189967	chr17:43125610~43153671:+
TGCT	cis	rs694739	0.964	rs2510066	ENSG00000236935.1	AP003774.1	6.12	1.11e-08	2.37e-05	0.36	0.48	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64284975	chr11:64325050~64329504:-
TGCT	cis	rs694739	0.894	rs887314	ENSG00000236935.1	AP003774.1	6.12	1.11e-08	2.37e-05	0.36	0.48	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64285685	chr11:64325050~64329504:-
TGCT	cis	rs875971	0.83	rs4718358	ENSG00000222364.1	RNU6-96P	-6.12	1.12e-08	2.38e-05	-0.55	-0.48	Aortic root size;	chr7:66508681	chr7:66395191~66395286:+
TGCT	cis	rs17301013	0.507	rs41472847	ENSG00000227373.4	RP11-160H22.5	-6.12	1.12e-08	2.39e-05	-0.57	-0.48	Systemic lupus erythematosus;	chr1:174475342	chr1:174115300~174160004:-
TGCT	cis	rs8062405	0.698	rs8046545	ENSG00000259982.1	CDC37P1	-6.12	1.13e-08	2.4e-05	-0.7	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.698	rs10499	ENSG00000259982.1	CDC37P1	-6.12	1.13e-08	2.4e-05	-0.7	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28700294~28701540:-
TGCT	cis	rs875971	0.862	rs7783779	ENSG00000222364.1	RNU6-96P	6.12	1.13e-08	2.4e-05	0.53	0.48	Aortic root size;	chr7:66331639	chr7:66395191~66395286:+
TGCT	cis	rs2283792	0.73	rs894095	ENSG00000228050.1	TOP3BP1	6.12	1.13e-08	2.41e-05	0.56	0.48	Multiple sclerosis;	chr22:21928404	chr22:22223187~22224566:-
TGCT	cis	rs1528149	0.836	rs740823	ENSG00000224683.1	RPL36AP29	6.12	1.13e-08	2.41e-05	0.58	0.48	Sitting height ratio;	chr7:16062778	chr7:16208945~16209265:+
TGCT	cis	rs6952407	1	rs6952407	ENSG00000222364.1	RNU6-96P	6.12	1.14e-08	2.42e-05	0.57	0.48	Cotinine glucuronidation;	chr7:66580525	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs778724	ENSG00000222364.1	RNU6-96P	-6.12	1.14e-08	2.43e-05	-0.54	-0.48	Aortic root size;	chr7:66364304	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs778686	ENSG00000222364.1	RNU6-96P	-6.12	1.14e-08	2.43e-05	-0.54	-0.48	Aortic root size;	chr7:66370923	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.767	rs1643394	ENSG00000222364.1	RNU6-96P	-6.12	1.14e-08	2.43e-05	-0.54	-0.48	Aortic root size;	chr7:66371107	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs778684	ENSG00000222364.1	RNU6-96P	-6.12	1.14e-08	2.43e-05	-0.54	-0.48	Aortic root size;	chr7:66371416	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs778680	ENSG00000222364.1	RNU6-96P	-6.12	1.14e-08	2.43e-05	-0.54	-0.48	Aortic root size;	chr7:66375427	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs11769079	ENSG00000222364.1	RNU6-96P	-6.12	1.14e-08	2.43e-05	-0.54	-0.48	Aortic root size;	chr7:66377141	chr7:66395191~66395286:+
TGCT	cis	rs1062177	0.855	rs6896664	ENSG00000213433.5	RPLP1P6	-6.12	1.14e-08	2.43e-05	-0.52	-0.48	Preschool internalizing problems;	chr5:151885713	chr5:151765859~151766378:-
TGCT	cis	rs9326248	0.581	rs10502222	ENSG00000254851.1	RP11-109L13.1	-6.12	1.15e-08	2.44e-05	-0.56	-0.48	Blood protein levels;	chr11:116963014	chr11:117135528~117138582:+
TGCT	cis	rs9326248	0.559	rs10892052	ENSG00000254851.1	RP11-109L13.1	-6.12	1.15e-08	2.44e-05	-0.56	-0.48	Blood protein levels;	chr11:116963597	chr11:117135528~117138582:+
TGCT	cis	rs875971	0.619	rs12533585	ENSG00000222364.1	RNU6-96P	-6.12	1.16e-08	2.46e-05	-0.57	-0.48	Aortic root size;	chr7:66519618	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.66	rs28698552	ENSG00000222364.1	RNU6-96P	-6.12	1.16e-08	2.46e-05	-0.57	-0.48	Aortic root size;	chr7:66540031	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.66	rs801192	ENSG00000222364.1	RNU6-96P	6.12	1.16e-08	2.46e-05	0.57	0.48	Aortic root size;	chr7:66566965	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.66	rs801190	ENSG00000222364.1	RNU6-96P	6.12	1.16e-08	2.46e-05	0.57	0.48	Aortic root size;	chr7:66568046	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.66	rs3857686	ENSG00000222364.1	RNU6-96P	6.12	1.16e-08	2.46e-05	0.57	0.48	Aortic root size;	chr7:66571204	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.638	rs6460305	ENSG00000222364.1	RNU6-96P	6.12	1.16e-08	2.46e-05	0.57	0.48	Aortic root size;	chr7:66595421	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.638	rs6960778	ENSG00000222364.1	RNU6-96P	6.12	1.16e-08	2.46e-05	0.57	0.48	Aortic root size;	chr7:66606610	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.66	rs1860468	ENSG00000222364.1	RNU6-96P	6.12	1.16e-08	2.46e-05	0.57	0.48	Aortic root size;	chr7:66642265	chr7:66395191~66395286:+
TGCT	cis	rs35955747	0.539	rs738685	ENSG00000236132.1	CTA-440B3.1	6.12	1.16e-08	2.46e-05	0.47	0.48	Neutrophil count;Sum basophil neutrophil counts;	chr22:31636292	chr22:31816379~31817491:-
TGCT	cis	rs12908161	0.959	rs3748376	ENSG00000225151.9	GOLGA2P7	-6.11	1.16e-08	2.47e-05	-0.55	-0.48	Schizophrenia;	chr15:84785121	chr15:84199311~84230136:-
TGCT	cis	rs9549367	0.789	rs3764125	ENSG00000269125.1	RP11-98F14.11	6.11	1.16e-08	2.47e-05	0.55	0.48	Platelet distribution width;	chr13:113243334	chr13:113165002~113165183:-
TGCT	cis	rs5760092	0.755	rs3884794	ENSG00000273295.1	AP000350.5	6.11	1.17e-08	2.47e-05	0.63	0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23909579	chr22:23901432~23907068:-
TGCT	cis	rs9326248	0.581	rs10892061	ENSG00000254851.1	RP11-109L13.1	-6.11	1.17e-08	2.48e-05	-0.57	-0.48	Blood protein levels;	chr11:117015398	chr11:117135528~117138582:+
TGCT	cis	rs875971	0.929	rs4122249	ENSG00000222364.1	RNU6-96P	-6.11	1.17e-08	2.49e-05	-0.55	-0.48	Aortic root size;	chr7:66455949	chr7:66395191~66395286:+
TGCT	cis	rs2739330	0.753	rs4822452	ENSG00000272787.1	KB-226F1.2	-6.11	1.17e-08	2.49e-05	-0.55	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23969211~23969873:+
TGCT	cis	rs12908161	0.959	rs34342559	ENSG00000225151.9	GOLGA2P7	-6.11	1.17e-08	2.49e-05	-0.55	-0.48	Schizophrenia;	chr15:84788040	chr15:84199311~84230136:-
TGCT	cis	rs12908161	0.959	rs62019472	ENSG00000225151.9	GOLGA2P7	-6.11	1.17e-08	2.49e-05	-0.55	-0.48	Schizophrenia;	chr15:84788262	chr15:84199311~84230136:-
TGCT	cis	rs12908161	0.959	rs35557864	ENSG00000225151.9	GOLGA2P7	-6.11	1.17e-08	2.49e-05	-0.55	-0.48	Schizophrenia;	chr15:84788398	chr15:84199311~84230136:-
TGCT	cis	rs694739	0.796	rs479777	ENSG00000236935.1	AP003774.1	6.11	1.18e-08	2.5e-05	0.36	0.48	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64340005	chr11:64325050~64329504:-
TGCT	cis	rs7044106	0.791	rs10984997	ENSG00000226752.6	PSMD5-AS1	-6.11	1.18e-08	2.5e-05	-0.62	-0.48	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120824828~120854385:+
TGCT	cis	rs4713118	0.513	rs149878	ENSG00000216901.1	AL022393.7	6.11	1.19e-08	2.52e-05	0.6	0.48	Parkinson's disease;	chr6:27910960	chr6:28176188~28176674:+
TGCT	cis	rs875971	0.825	rs59466412	ENSG00000222364.1	RNU6-96P	6.11	1.19e-08	2.52e-05	0.55	0.48	Aortic root size;	chr7:66100371	chr7:66395191~66395286:+
TGCT	cis	rs2948294	0.588	rs7011221	ENSG00000173295.6	FAM86B3P	6.11	1.2e-08	2.53e-05	0.61	0.48	Red cell distribution width;	chr8:8256724	chr8:8228595~8244865:+
TGCT	cis	rs875971	0.862	rs11773628	ENSG00000222364.1	RNU6-96P	6.11	1.2e-08	2.54e-05	0.53	0.48	Aortic root size;	chr7:66517644	chr7:66395191~66395286:+
TGCT	cis	rs7044106	0.791	rs10984995	ENSG00000226752.6	PSMD5-AS1	-6.11	1.2e-08	2.54e-05	-0.61	-0.48	Hip circumference adjusted for BMI;	chr9:120716932	chr9:120824828~120854385:+
TGCT	cis	rs66887589	0.776	rs10518337	ENSG00000245958.5	RP11-33B1.1	6.11	1.2e-08	2.54e-05	0.47	0.48	Diastolic blood pressure;	chr4:119653719	chr4:119454791~119552025:+
TGCT	cis	rs9549367	0.789	rs12866090	ENSG00000269125.1	RP11-98F14.11	-6.11	1.21e-08	2.55e-05	-0.56	-0.48	Platelet distribution width;	chr13:113215096	chr13:113165002~113165183:-
TGCT	cis	rs17301013	0.606	rs10912798	ENSG00000227373.4	RP11-160H22.5	6.11	1.21e-08	2.56e-05	0.56	0.48	Systemic lupus erythematosus;	chr1:174511420	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.581	rs10912799	ENSG00000227373.4	RP11-160H22.5	6.11	1.21e-08	2.56e-05	0.56	0.48	Systemic lupus erythematosus;	chr1:174511422	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.556	rs10912800	ENSG00000227373.4	RP11-160H22.5	6.11	1.21e-08	2.56e-05	0.56	0.48	Systemic lupus erythematosus;	chr1:174513939	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs56213002	ENSG00000227373.4	RP11-160H22.5	6.11	1.21e-08	2.56e-05	0.56	0.48	Systemic lupus erythematosus;	chr1:174516512	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.541	rs10798319	ENSG00000227373.4	RP11-160H22.5	6.11	1.21e-08	2.56e-05	0.56	0.48	Systemic lupus erythematosus;	chr1:174516983	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs9730220	ENSG00000227373.4	RP11-160H22.5	6.11	1.21e-08	2.56e-05	0.56	0.48	Systemic lupus erythematosus;	chr1:174519092	chr1:174115300~174160004:-
TGCT	cis	rs12429206	0.512	rs9535530	ENSG00000233672.5	RNASEH2B-AS1	-6.11	1.21e-08	2.56e-05	-0.54	-0.48	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50925136	chr13:50862172~50910764:-
TGCT	cis	rs5758659	0.652	rs4822084	ENSG00000270083.1	RP1-257I20.14	-6.11	1.21e-08	2.56e-05	-0.45	-0.48	Cognitive function;	chr22:42039864	chr22:42089630~42090028:-
TGCT	cis	rs9326248	0.603	rs7396061	ENSG00000254851.1	RP11-109L13.1	-6.11	1.21e-08	2.56e-05	-0.58	-0.48	Blood protein levels;	chr11:116880158	chr11:117135528~117138582:+
TGCT	cis	rs875971	0.862	rs6944374	ENSG00000222364.1	RNU6-96P	6.11	1.22e-08	2.56e-05	0.53	0.48	Aortic root size;	chr7:66221942	chr7:66395191~66395286:+
TGCT	cis	rs12891047	1	rs7160196	ENSG00000258759.1	RP11-1012A1.7	6.1	1.22e-08	2.57e-05	0.42	0.48	Amyotrophic lateral sclerosis (sporadic);	chr14:67799027	chr14:67799004~67799609:+
TGCT	cis	rs11673344	0.526	rs57654288	ENSG00000226686.6	LINC01535	6.1	1.22e-08	2.57e-05	0.56	0.48	Obesity-related traits;	chr19:37587870	chr19:37251912~37265535:+
TGCT	cis	rs11155671	0.53	rs9383940	ENSG00000216906.2	RP11-350J20.9	6.1	1.22e-08	2.58e-05	0.52	0.48	Testicular germ cell tumor;	chr6:149904923	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.887	rs4870139	ENSG00000216906.2	RP11-350J20.9	6.1	1.22e-08	2.58e-05	0.56	0.48	Lung cancer;	chr6:149575182	chr6:149904243~149906418:+
TGCT	cis	rs801193	0.66	rs1016265	ENSG00000222364.1	RNU6-96P	-6.1	1.23e-08	2.59e-05	-0.56	-0.48	Aortic root size;	chr7:66749580	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.66	rs4610622	ENSG00000222364.1	RNU6-96P	-6.1	1.23e-08	2.59e-05	-0.56	-0.48	Aortic root size;	chr7:66759510	chr7:66395191~66395286:+
TGCT	cis	rs7412746	0.563	rs3768013	ENSG00000206931.1	RNU6-1042P	6.1	1.23e-08	2.59e-05	0.38	0.48	Melanoma;	chr1:150842935	chr1:150701866~150701972:+
TGCT	cis	rs2882667	0.858	rs11949916	ENSG00000253404.1	AC034243.1	6.1	1.24e-08	2.62e-05	0.57	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139060588	chr5:138744434~138753309:-
TGCT	cis	rs8040855	0.627	rs11632899	ENSG00000259295.5	CSPG4P12	6.1	1.24e-08	2.62e-05	0.61	0.48	Bulimia nervosa;	chr15:85057609	chr15:85191438~85213905:+
TGCT	cis	rs8040855	0.658	rs12909111	ENSG00000259295.5	CSPG4P12	6.1	1.24e-08	2.62e-05	0.61	0.48	Bulimia nervosa;	chr15:85061095	chr15:85191438~85213905:+
TGCT	cis	rs17301013	0.507	rs6697959	ENSG00000227373.4	RP11-160H22.5	6.1	1.26e-08	2.66e-05	0.57	0.48	Systemic lupus erythematosus;	chr1:174285450	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12066504	ENSG00000227373.4	RP11-160H22.5	6.1	1.26e-08	2.66e-05	0.57	0.48	Systemic lupus erythematosus;	chr1:174288695	chr1:174115300~174160004:-
TGCT	cis	rs916888	0.779	rs199498	ENSG00000262500.1	RP11-259G18.2	6.1	1.27e-08	2.66e-05	0.67	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46243606~46245044:+
TGCT	cis	rs9326248	0.53	rs10732856	ENSG00000254851.1	RP11-109L13.1	-6.1	1.27e-08	2.66e-05	-0.8	-0.48	Blood protein levels;	chr11:117036397	chr11:117135528~117138582:+
TGCT	cis	rs10793273	1	rs10793273	ENSG00000246174.6	KCTD21-AS1	-6.1	1.27e-08	2.66e-05	-0.54	-0.48	Pelvic organ prolapse;	chr11:78031549	chr11:78139771~78175323:+
TGCT	cis	rs2739330	0.828	rs4822454	ENSG00000272787.1	KB-226F1.2	-6.1	1.27e-08	2.66e-05	-0.55	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23969211~23969873:+
TGCT	cis	rs7044106	0.791	rs10818473	ENSG00000226752.6	PSMD5-AS1	-6.09	1.28e-08	2.68e-05	-0.61	-0.48	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120824828~120854385:+
TGCT	cis	rs7104764	0.879	rs6598072	ENSG00000277290.1	RP11-326C3.16	-6.09	1.28e-08	2.69e-05	-0.47	-0.48	Menarche (age at onset);	chr11:219793	chr11:243099~243483:-
TGCT	cis	rs7104764	0.957	rs6598071	ENSG00000277290.1	RP11-326C3.16	-6.09	1.28e-08	2.69e-05	-0.47	-0.48	Menarche (age at onset);	chr11:219800	chr11:243099~243483:-
TGCT	cis	rs7104764	0.957	rs10794301	ENSG00000277290.1	RP11-326C3.16	-6.09	1.28e-08	2.69e-05	-0.47	-0.48	Menarche (age at onset);	chr11:220401	chr11:243099~243483:-
TGCT	cis	rs7104764	0.879	rs6421986	ENSG00000277290.1	RP11-326C3.16	-6.09	1.28e-08	2.69e-05	-0.47	-0.48	Menarche (age at onset);	chr11:221659	chr11:243099~243483:-
TGCT	cis	rs6452524	0.901	rs4571449	ENSG00000249664.1	CTD-2227C6.2	6.09	1.29e-08	2.69e-05	0.53	0.48	Hypertension (SNP x SNP interaction);	chr5:83175392	chr5:83012285~83013109:-
TGCT	cis	rs17301013	0.507	rs2060158	ENSG00000227373.4	RP11-160H22.5	6.09	1.29e-08	2.69e-05	0.57	0.48	Systemic lupus erythematosus;	chr1:174667379	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs16847335	ENSG00000227373.4	RP11-160H22.5	6.09	1.29e-08	2.69e-05	0.57	0.48	Systemic lupus erythematosus;	chr1:174682746	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs3862941	ENSG00000227373.4	RP11-160H22.5	6.09	1.29e-08	2.69e-05	0.57	0.48	Systemic lupus erythematosus;	chr1:174689418	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.531	rs55688014	ENSG00000227373.4	RP11-160H22.5	6.09	1.29e-08	2.69e-05	0.57	0.48	Systemic lupus erythematosus;	chr1:174693321	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs55667039	ENSG00000227373.4	RP11-160H22.5	6.09	1.29e-08	2.69e-05	0.57	0.48	Systemic lupus erythematosus;	chr1:174698699	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs72715281	ENSG00000227373.4	RP11-160H22.5	6.09	1.29e-08	2.69e-05	0.57	0.48	Systemic lupus erythematosus;	chr1:174711533	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs2861005	ENSG00000227373.4	RP11-160H22.5	6.09	1.29e-08	2.69e-05	0.57	0.48	Systemic lupus erythematosus;	chr1:174711832	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs17842156	ENSG00000227373.4	RP11-160H22.5	6.09	1.29e-08	2.69e-05	0.57	0.48	Systemic lupus erythematosus;	chr1:174715050	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs2146564	ENSG00000227373.4	RP11-160H22.5	6.09	1.29e-08	2.69e-05	0.57	0.48	Systemic lupus erythematosus;	chr1:174716214	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs17842157	ENSG00000227373.4	RP11-160H22.5	6.09	1.29e-08	2.69e-05	0.57	0.48	Systemic lupus erythematosus;	chr1:174719442	chr1:174115300~174160004:-
TGCT	cis	rs6452524	0.534	rs10514246	ENSG00000249664.1	CTD-2227C6.2	6.09	1.3e-08	2.71e-05	0.52	0.48	Hypertension (SNP x SNP interaction);	chr5:83069979	chr5:83012285~83013109:-
TGCT	cis	rs916888	0.61	rs199454	ENSG00000262500.1	RP11-259G18.2	-6.09	1.3e-08	2.73e-05	-0.62	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46243606~46245044:+
TGCT	cis	rs7757969	1	rs7752620	ENSG00000227012.2	RP1-97J1.2	-6.09	1.31e-08	2.73e-05	-0.73	-0.48	Schizophrenia;	chr6:111817091	chr6:111900489~111901851:-
TGCT	cis	rs943437	0.866	rs1887313	ENSG00000227012.2	RP1-97J1.2	6.09	1.31e-08	2.73e-05	0.67	0.48	Parkinson's disease;	chr6:111946030	chr6:111900489~111901851:-
TGCT	cis	rs7044106	0.791	rs2416797	ENSG00000226752.6	PSMD5-AS1	-6.09	1.31e-08	2.73e-05	-0.62	-0.48	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120824828~120854385:+
TGCT	cis	rs7044106	0.791	rs2416798	ENSG00000226752.6	PSMD5-AS1	-6.09	1.31e-08	2.73e-05	-0.62	-0.48	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120824828~120854385:+
TGCT	cis	rs8062405	1	rs7498555	ENSG00000259982.1	CDC37P1	6.09	1.32e-08	2.75e-05	0.65	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28700294~28701540:-
TGCT	cis	rs6921919	0.848	rs56131013	ENSG00000216901.1	AL022393.7	6.09	1.32e-08	2.75e-05	0.59	0.48	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28176188~28176674:+
TGCT	cis	rs8040855	0.579	rs28521166	ENSG00000259295.5	CSPG4P12	-6.09	1.33e-08	2.76e-05	-0.64	-0.48	Bulimia nervosa;	chr15:85184801	chr15:85191438~85213905:+
TGCT	cis	rs801193	0.636	rs10233806	ENSG00000222364.1	RNU6-96P	6.09	1.33e-08	2.77e-05	0.56	0.48	Aortic root size;	chr7:66653261	chr7:66395191~66395286:+
TGCT	cis	rs524281	0.861	rs7942894	ENSG00000255320.1	RP11-755F10.1	6.09	1.33e-08	2.77e-05	0.61	0.48	Electroencephalogram traits;	chr11:66209054	chr11:66244840~66246239:-
TGCT	cis	rs7811142	0.72	rs112622797	ENSG00000242294.5	STAG3L5P	6.09	1.33e-08	2.78e-05	0.46	0.48	Platelet count;	chr7:100319793	chr7:100336079~100351900:+
TGCT	cis	rs524281	0.814	rs2270448	ENSG00000255320.1	RP11-755F10.1	6.08	1.34e-08	2.79e-05	0.61	0.48	Electroencephalogram traits;	chr11:66068460	chr11:66244840~66246239:-
TGCT	cis	rs9733	0.596	rs3087960	ENSG00000206931.1	RNU6-1042P	6.08	1.35e-08	2.8e-05	0.38	0.48	Tonsillectomy;	chr1:150648093	chr1:150701866~150701972:+
TGCT	cis	rs4927850	1	rs7625570	ENSG00000242086.7	LINC00969	6.08	1.35e-08	2.81e-05	0.53	0.48	Pancreatic cancer;	chr3:196020527	chr3:195658062~195739964:+
TGCT	cis	rs801193	0.569	rs2659893	ENSG00000222364.1	RNU6-96P	-6.08	1.36e-08	2.81e-05	-0.54	-0.48	Aortic root size;	chr7:66735006	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.569	rs2659892	ENSG00000222364.1	RNU6-96P	-6.08	1.36e-08	2.81e-05	-0.54	-0.48	Aortic root size;	chr7:66735318	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.548	rs2659891	ENSG00000222364.1	RNU6-96P	-6.08	1.36e-08	2.81e-05	-0.54	-0.48	Aortic root size;	chr7:66736127	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.569	rs2707847	ENSG00000222364.1	RNU6-96P	-6.08	1.36e-08	2.81e-05	-0.54	-0.48	Aortic root size;	chr7:66737884	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.548	rs7805152	ENSG00000222364.1	RNU6-96P	-6.08	1.36e-08	2.81e-05	-0.54	-0.48	Aortic root size;	chr7:66744266	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.569	rs11761542	ENSG00000222364.1	RNU6-96P	-6.08	1.36e-08	2.81e-05	-0.54	-0.48	Aortic root size;	chr7:66753209	chr7:66395191~66395286:+
TGCT	cis	rs2882667	0.858	rs13176497	ENSG00000253404.1	AC034243.1	6.08	1.36e-08	2.81e-05	0.56	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139110385	chr5:138744434~138753309:-
TGCT	cis	rs916888	0.61	rs199446	ENSG00000262500.1	RP11-259G18.2	-6.08	1.36e-08	2.82e-05	-0.62	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46243606~46245044:+
TGCT	cis	rs916888	0.61	rs199536	ENSG00000262500.1	RP11-259G18.2	-6.08	1.36e-08	2.82e-05	-0.62	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46243606~46245044:+
TGCT	cis	rs2739330	0.828	rs2330635	ENSG00000272787.1	KB-226F1.2	-6.08	1.37e-08	2.83e-05	-0.55	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23969211~23969873:+
TGCT	cis	rs2739330	0.828	rs2877178	ENSG00000272787.1	KB-226F1.2	-6.08	1.38e-08	2.84e-05	-0.55	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23969211~23969873:+
TGCT	cis	rs2739330	0.828	rs2154593	ENSG00000272787.1	KB-226F1.2	-6.08	1.38e-08	2.84e-05	-0.55	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23969211~23969873:+
TGCT	cis	rs943437	0.877	rs539756	ENSG00000227012.2	RP1-97J1.2	6.08	1.38e-08	2.84e-05	0.65	0.48	Parkinson's disease;	chr6:111951435	chr6:111900489~111901851:-
TGCT	cis	rs943437	0.877	rs633640	ENSG00000227012.2	RP1-97J1.2	6.08	1.38e-08	2.84e-05	0.65	0.48	Parkinson's disease;	chr6:111951602	chr6:111900489~111901851:-
TGCT	cis	rs943437	0.877	rs632914	ENSG00000227012.2	RP1-97J1.2	-6.08	1.38e-08	2.84e-05	-0.65	-0.48	Parkinson's disease;	chr6:111945946	chr6:111900489~111901851:-
TGCT	cis	rs2739330	0.828	rs5760107	ENSG00000272787.1	KB-226F1.2	-6.08	1.38e-08	2.85e-05	-0.55	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23969211~23969873:+
TGCT	cis	rs2739330	0.789	rs5760109	ENSG00000272787.1	KB-226F1.2	-6.08	1.38e-08	2.85e-05	-0.55	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23969211~23969873:+
TGCT	cis	rs2739330	0.796	rs5760106	ENSG00000272787.1	KB-226F1.2	6.08	1.38e-08	2.85e-05	0.55	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23969211~23969873:+
TGCT	cis	rs2739330	0.828	rs2186366	ENSG00000272787.1	KB-226F1.2	6.08	1.38e-08	2.85e-05	0.55	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23969211~23969873:+
TGCT	cis	rs2739330	0.828	rs5760108	ENSG00000272787.1	KB-226F1.2	-6.08	1.39e-08	2.87e-05	-0.55	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23969211~23969873:+
TGCT	cis	rs875971	0.964	rs778723	ENSG00000222364.1	RNU6-96P	-6.08	1.4e-08	2.87e-05	-0.55	-0.48	Aortic root size;	chr7:66364510	chr7:66395191~66395286:+
TGCT	cis	rs6700559	1	rs12076877	ENSG00000260088.1	RP11-92G12.3	-6.08	1.4e-08	2.88e-05	-0.58	-0.48	Coronary artery disease;	chr1:200674277	chr1:200669507~200694250:+
TGCT	cis	rs6700559	1	rs10800720	ENSG00000260088.1	RP11-92G12.3	-6.08	1.4e-08	2.88e-05	-0.58	-0.48	Coronary artery disease;	chr1:200679441	chr1:200669507~200694250:+
TGCT	cis	rs6700559	0.935	rs4072553	ENSG00000260088.1	RP11-92G12.3	-6.08	1.4e-08	2.88e-05	-0.58	-0.48	Coronary artery disease;	chr1:200680036	chr1:200669507~200694250:+
TGCT	cis	rs6452524	0.534	rs9293328	ENSG00000249664.1	CTD-2227C6.2	6.07	1.41e-08	2.9e-05	0.53	0.48	Hypertension (SNP x SNP interaction);	chr5:83066855	chr5:83012285~83013109:-
TGCT	cis	rs7412746	0.611	rs4319334	ENSG00000206931.1	RNU6-1042P	6.07	1.42e-08	2.91e-05	0.38	0.48	Melanoma;	chr1:150794346	chr1:150701866~150701972:+
TGCT	cis	rs875971	0.964	rs1643388	ENSG00000222364.1	RNU6-96P	-6.07	1.43e-08	2.94e-05	-0.55	-0.48	Aortic root size;	chr7:66379575	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs778722	ENSG00000222364.1	RNU6-96P	-6.07	1.43e-08	2.94e-05	-0.55	-0.48	Aortic root size;	chr7:66379841	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.964	rs778721	ENSG00000222364.1	RNU6-96P	-6.07	1.43e-08	2.94e-05	-0.55	-0.48	Aortic root size;	chr7:66380410	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs778706	ENSG00000222364.1	RNU6-96P	-6.07	1.43e-08	2.94e-05	-0.55	-0.48	Aortic root size;	chr7:66395437	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.895	rs778700	ENSG00000222364.1	RNU6-96P	-6.07	1.43e-08	2.94e-05	-0.55	-0.48	Aortic root size;	chr7:66401463	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs778699	ENSG00000222364.1	RNU6-96P	-6.07	1.43e-08	2.94e-05	-0.55	-0.48	Aortic root size;	chr7:66403303	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.929	rs778692	ENSG00000222364.1	RNU6-96P	-6.07	1.43e-08	2.94e-05	-0.55	-0.48	Aortic root size;	chr7:66407462	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs4718343	ENSG00000222364.1	RNU6-96P	-6.07	1.43e-08	2.94e-05	-0.55	-0.48	Aortic root size;	chr7:66409301	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs1968225	ENSG00000222364.1	RNU6-96P	-6.07	1.43e-08	2.94e-05	-0.55	-0.48	Aortic root size;	chr7:66409786	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs6460295	ENSG00000222364.1	RNU6-96P	-6.07	1.43e-08	2.94e-05	-0.55	-0.48	Aortic root size;	chr7:66417741	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.964	rs6978721	ENSG00000222364.1	RNU6-96P	-6.07	1.43e-08	2.94e-05	-0.55	-0.48	Aortic root size;	chr7:66418217	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs6979382	ENSG00000222364.1	RNU6-96P	-6.07	1.43e-08	2.94e-05	-0.55	-0.48	Aortic root size;	chr7:66421388	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs6961990	ENSG00000222364.1	RNU6-96P	-6.07	1.43e-08	2.94e-05	-0.55	-0.48	Aortic root size;	chr7:66423583	chr7:66395191~66395286:+
TGCT	cis	rs6921919	0.806	rs213230	ENSG00000216901.1	AL022393.7	6.07	1.43e-08	2.94e-05	0.58	0.48	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28176188~28176674:+
TGCT	cis	rs1153858	0.621	rs2687512	ENSG00000259520.4	CTD-2651B20.3	6.07	1.44e-08	2.95e-05	0.43	0.48	Homoarginine levels;	chr15:45289297	chr15:45251580~45279251:-
TGCT	cis	rs875971	0.545	rs12670811	ENSG00000226824.5	RP4-756H11.3	-6.07	1.44e-08	2.96e-05	-0.57	-0.48	Aortic root size;	chr7:66358032	chr7:66654538~66669855:+
TGCT	cis	rs524281	0.861	rs7941431	ENSG00000255320.1	RP11-755F10.1	6.07	1.45e-08	2.97e-05	0.63	0.48	Electroencephalogram traits;	chr11:66192686	chr11:66244840~66246239:-
TGCT	cis	rs9326248	0.53	rs7122944	ENSG00000254851.1	RP11-109L13.1	-6.07	1.46e-08	2.99e-05	-0.91	-0.48	Blood protein levels;	chr11:117163903	chr11:117135528~117138582:+
TGCT	cis	rs17301013	0.507	rs72713528	ENSG00000227373.4	RP11-160H22.5	6.07	1.46e-08	2.99e-05	0.56	0.48	Systemic lupus erythematosus;	chr1:174319862	chr1:174115300~174160004:-
TGCT	cis	rs6700559	0.967	rs12041320	ENSG00000260088.1	RP11-92G12.3	-6.07	1.46e-08	2.99e-05	-0.58	-0.48	Coronary artery disease;	chr1:200652107	chr1:200669507~200694250:+
TGCT	cis	rs17301013	0.54	rs72713601	ENSG00000227373.4	RP11-160H22.5	6.07	1.46e-08	3e-05	0.56	0.48	Systemic lupus erythematosus;	chr1:174482987	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs9729907	ENSG00000227373.4	RP11-160H22.5	6.07	1.46e-08	3e-05	0.56	0.48	Systemic lupus erythematosus;	chr1:174483607	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.581	rs2901818	ENSG00000227373.4	RP11-160H22.5	6.07	1.46e-08	3e-05	0.56	0.48	Systemic lupus erythematosus;	chr1:174486239	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs6658315	ENSG00000227373.4	RP11-160H22.5	6.07	1.46e-08	3e-05	0.56	0.48	Systemic lupus erythematosus;	chr1:174489961	chr1:174115300~174160004:-
TGCT	cis	rs8040855	0.694	rs12908400	ENSG00000259295.5	CSPG4P12	6.07	1.46e-08	3e-05	0.61	0.48	Bulimia nervosa;	chr15:85029945	chr15:85191438~85213905:+
TGCT	cis	rs875971	0.964	rs6978429	ENSG00000222364.1	RNU6-96P	-6.07	1.47e-08	3.01e-05	-0.54	-0.48	Aortic root size;	chr7:66494889	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.929	rs12535036	ENSG00000222364.1	RNU6-96P	-6.07	1.47e-08	3.01e-05	-0.54	-0.48	Aortic root size;	chr7:66499076	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs12532998	ENSG00000222364.1	RNU6-96P	-6.07	1.47e-08	3.01e-05	-0.54	-0.48	Aortic root size;	chr7:66502472	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs12698523	ENSG00000222364.1	RNU6-96P	-6.07	1.47e-08	3.01e-05	-0.54	-0.48	Aortic root size;	chr7:66503126	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs6970030	ENSG00000222364.1	RNU6-96P	-6.07	1.47e-08	3.01e-05	-0.54	-0.48	Aortic root size;	chr7:66503692	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.928	rs6970357	ENSG00000222364.1	RNU6-96P	-6.07	1.47e-08	3.01e-05	-0.54	-0.48	Aortic root size;	chr7:66503891	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs3735148	ENSG00000222364.1	RNU6-96P	-6.07	1.47e-08	3.01e-05	-0.54	-0.48	Aortic root size;	chr7:66506022	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.929	rs6970860	ENSG00000222364.1	RNU6-96P	-6.07	1.47e-08	3.01e-05	-0.54	-0.48	Aortic root size;	chr7:66511647	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs6957199	ENSG00000222364.1	RNU6-96P	-6.07	1.47e-08	3.01e-05	-0.54	-0.48	Aortic root size;	chr7:66513532	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs6958271	ENSG00000222364.1	RNU6-96P	-6.07	1.47e-08	3.01e-05	-0.54	-0.48	Aortic root size;	chr7:66514344	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs6958277	ENSG00000222364.1	RNU6-96P	-6.07	1.47e-08	3.01e-05	-0.54	-0.48	Aortic root size;	chr7:66514362	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs7792762	ENSG00000222364.1	RNU6-96P	-6.07	1.47e-08	3.01e-05	-0.54	-0.48	Aortic root size;	chr7:66539151	chr7:66395191~66395286:+
TGCT	cis	rs76878669	0.917	rs10219183	ENSG00000254510.1	RP11-867G23.10	6.07	1.47e-08	3.02e-05	0.67	0.48	Educational attainment (years of education);	chr11:66322561	chr11:66409158~66417137:+
TGCT	cis	rs7412746	0.587	rs11204722	ENSG00000206931.1	RNU6-1042P	-6.06	1.49e-08	3.05e-05	-0.38	-0.48	Melanoma;	chr1:150757708	chr1:150701866~150701972:+
TGCT	cis	rs875971	0.545	rs316328	ENSG00000226824.5	RP4-756H11.3	6.06	1.49e-08	3.05e-05	0.55	0.48	Aortic root size;	chr7:66143851	chr7:66654538~66669855:+
TGCT	cis	rs9326248	0.581	rs10892063	ENSG00000254851.1	RP11-109L13.1	-6.06	1.5e-08	3.06e-05	-0.56	-0.48	Blood protein levels;	chr11:117025439	chr11:117135528~117138582:+
TGCT	cis	rs9326248	0.559	rs10892064	ENSG00000254851.1	RP11-109L13.1	-6.06	1.5e-08	3.06e-05	-0.56	-0.48	Blood protein levels;	chr11:117025837	chr11:117135528~117138582:+
TGCT	cis	rs9326248	0.539	rs10892065	ENSG00000254851.1	RP11-109L13.1	-6.06	1.5e-08	3.06e-05	-0.56	-0.48	Blood protein levels;	chr11:117026308	chr11:117135528~117138582:+
TGCT	cis	rs9326248	0.581	rs11216242	ENSG00000254851.1	RP11-109L13.1	-6.06	1.5e-08	3.06e-05	-0.56	-0.48	Blood protein levels;	chr11:117030833	chr11:117135528~117138582:+
TGCT	cis	rs9326248	0.581	rs12804122	ENSG00000254851.1	RP11-109L13.1	-6.06	1.5e-08	3.06e-05	-0.56	-0.48	Blood protein levels;	chr11:117031900	chr11:117135528~117138582:+
TGCT	cis	rs9326248	0.581	rs7120963	ENSG00000254851.1	RP11-109L13.1	6.06	1.51e-08	3.07e-05	0.55	0.48	Blood protein levels;	chr11:116959545	chr11:117135528~117138582:+
TGCT	cis	rs11098499	0.604	rs2389882	ENSG00000245958.5	RP11-33B1.1	-6.06	1.51e-08	3.08e-05	-0.51	-0.48	Corneal astigmatism;	chr4:119645578	chr4:119454791~119552025:+
TGCT	cis	rs17301013	0.507	rs2142863	ENSG00000227373.4	RP11-160H22.5	6.06	1.51e-08	3.08e-05	0.56	0.48	Systemic lupus erythematosus;	chr1:174301582	chr1:174115300~174160004:-
TGCT	cis	rs66887589	0.87	rs2389875	ENSG00000245958.5	RP11-33B1.1	6.06	1.51e-08	3.09e-05	0.48	0.48	Diastolic blood pressure;	chr4:119635859	chr4:119454791~119552025:+
TGCT	cis	rs9322193	0.884	rs880245	ENSG00000216906.2	RP11-350J20.9	-6.06	1.52e-08	3.1e-05	-0.55	-0.48	Lung cancer;	chr6:149846262	chr6:149904243~149906418:+
TGCT	cis	rs6452524	0.534	rs72765386	ENSG00000249664.1	CTD-2227C6.2	6.06	1.52e-08	3.1e-05	0.53	0.48	Hypertension (SNP x SNP interaction);	chr5:83061502	chr5:83012285~83013109:-
TGCT	cis	rs3096299	0.754	rs2965942	ENSG00000274627.1	RP11-104N10.2	6.06	1.53e-08	3.1e-05	0.5	0.48	Multiple myeloma (IgH translocation);	chr16:89443919	chr16:89516797~89522217:+
TGCT	cis	rs12908161	1	rs35808647	ENSG00000225151.9	GOLGA2P7	-6.06	1.53e-08	3.1e-05	-0.57	-0.48	Schizophrenia;	chr15:84834210	chr15:84199311~84230136:-
TGCT	cis	rs4927850	0.958	rs1975582	ENSG00000242086.7	LINC00969	6.06	1.54e-08	3.12e-05	0.53	0.48	Pancreatic cancer;	chr3:196024568	chr3:195658062~195739964:+
TGCT	cis	rs4927850	0.957	rs4927851	ENSG00000242086.7	LINC00969	6.06	1.54e-08	3.12e-05	0.53	0.48	Pancreatic cancer;	chr3:196024982	chr3:195658062~195739964:+
TGCT	cis	rs4927850	0.918	rs4361313	ENSG00000242086.7	LINC00969	6.06	1.54e-08	3.12e-05	0.53	0.48	Pancreatic cancer;	chr3:196025389	chr3:195658062~195739964:+
TGCT	cis	rs4927850	1	rs7627706	ENSG00000242086.7	LINC00969	6.06	1.54e-08	3.12e-05	0.53	0.48	Pancreatic cancer;	chr3:196026482	chr3:195658062~195739964:+
TGCT	cis	rs4927850	0.881	rs7630489	ENSG00000242086.7	LINC00969	6.06	1.54e-08	3.12e-05	0.53	0.48	Pancreatic cancer;	chr3:196026530	chr3:195658062~195739964:+
TGCT	cis	rs4927850	1	rs7627868	ENSG00000242086.7	LINC00969	6.06	1.54e-08	3.12e-05	0.53	0.48	Pancreatic cancer;	chr3:196026602	chr3:195658062~195739964:+
TGCT	cis	rs3096299	0.685	rs3803681	ENSG00000274627.1	RP11-104N10.2	6.06	1.54e-08	3.12e-05	0.5	0.48	Multiple myeloma (IgH translocation);	chr16:89478348	chr16:89516797~89522217:+
TGCT	cis	rs875971	0.862	rs10274883	ENSG00000222364.1	RNU6-96P	6.06	1.54e-08	3.12e-05	0.53	0.48	Aortic root size;	chr7:66651104	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.569	rs881285	ENSG00000222364.1	RNU6-96P	6.06	1.54e-08	3.12e-05	0.53	0.48	Aortic root size;	chr7:66654433	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.569	rs3846973	ENSG00000222364.1	RNU6-96P	6.06	1.54e-08	3.12e-05	0.53	0.48	Aortic root size;	chr7:66655048	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.569	rs2013908	ENSG00000222364.1	RNU6-96P	6.06	1.54e-08	3.12e-05	0.53	0.48	Aortic root size;	chr7:66656082	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.569	rs13242290	ENSG00000222364.1	RNU6-96P	6.06	1.54e-08	3.12e-05	0.53	0.48	Aortic root size;	chr7:66656898	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.548	rs2109297	ENSG00000222364.1	RNU6-96P	6.06	1.54e-08	3.12e-05	0.53	0.48	Aortic root size;	chr7:66657397	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.569	rs6978178	ENSG00000222364.1	RNU6-96P	6.06	1.54e-08	3.12e-05	0.53	0.48	Aortic root size;	chr7:66658097	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.591	rs721717	ENSG00000222364.1	RNU6-96P	6.06	1.54e-08	3.12e-05	0.53	0.48	Aortic root size;	chr7:66665305	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.569	rs6951302	ENSG00000222364.1	RNU6-96P	6.06	1.54e-08	3.12e-05	0.53	0.48	Aortic root size;	chr7:66667525	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs2077593	ENSG00000222364.1	RNU6-96P	-6.06	1.54e-08	3.12e-05	-0.54	-0.48	Aortic root size;	chr7:66427543	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs4717292	ENSG00000222364.1	RNU6-96P	-6.06	1.54e-08	3.12e-05	-0.54	-0.48	Aortic root size;	chr7:66430611	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs2420591	ENSG00000222364.1	RNU6-96P	-6.06	1.54e-08	3.12e-05	-0.54	-0.48	Aortic root size;	chr7:66447394	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.895	rs10755833	ENSG00000222364.1	RNU6-96P	-6.06	1.54e-08	3.12e-05	-0.54	-0.48	Aortic root size;	chr7:66448930	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.964	rs12668936	ENSG00000222364.1	RNU6-96P	-6.06	1.54e-08	3.12e-05	-0.54	-0.48	Aortic root size;	chr7:66449417	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.895	rs7788984	ENSG00000222364.1	RNU6-96P	-6.06	1.54e-08	3.12e-05	-0.54	-0.48	Aortic root size;	chr7:66450629	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.895	rs1833495	ENSG00000222364.1	RNU6-96P	-6.06	1.54e-08	3.12e-05	-0.54	-0.48	Aortic root size;	chr7:66456608	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.964	rs6945019	ENSG00000222364.1	RNU6-96P	-6.06	1.54e-08	3.12e-05	-0.54	-0.48	Aortic root size;	chr7:66457471	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.964	rs6945032	ENSG00000222364.1	RNU6-96P	-6.06	1.54e-08	3.12e-05	-0.54	-0.48	Aortic root size;	chr7:66457499	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.929	rs12673810	ENSG00000222364.1	RNU6-96P	-6.06	1.54e-08	3.12e-05	-0.54	-0.48	Aortic root size;	chr7:66458866	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs35149210	ENSG00000222364.1	RNU6-96P	-6.06	1.54e-08	3.12e-05	-0.54	-0.48	Aortic root size;	chr7:66464938	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.929	rs34406470	ENSG00000222364.1	RNU6-96P	-6.06	1.54e-08	3.12e-05	-0.54	-0.48	Aortic root size;	chr7:66464969	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs6961155	ENSG00000222364.1	RNU6-96P	-6.06	1.54e-08	3.12e-05	-0.54	-0.48	Aortic root size;	chr7:66468308	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs7789768	ENSG00000222364.1	RNU6-96P	-6.06	1.54e-08	3.12e-05	-0.54	-0.48	Aortic root size;	chr7:66473993	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs1363055	ENSG00000222364.1	RNU6-96P	-6.06	1.54e-08	3.12e-05	-0.54	-0.48	Aortic root size;	chr7:66478288	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.964	rs9691480	ENSG00000222364.1	RNU6-96P	-6.06	1.54e-08	3.12e-05	-0.54	-0.48	Aortic root size;	chr7:66479319	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs7789554	ENSG00000222364.1	RNU6-96P	-6.06	1.54e-08	3.12e-05	-0.54	-0.48	Aortic root size;	chr7:66481051	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs4717300	ENSG00000222364.1	RNU6-96P	-6.06	1.54e-08	3.12e-05	-0.54	-0.48	Aortic root size;	chr7:66482393	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.895	rs1974769	ENSG00000222364.1	RNU6-96P	-6.06	1.54e-08	3.12e-05	-0.54	-0.48	Aortic root size;	chr7:66485627	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.895	rs6460300	ENSG00000222364.1	RNU6-96P	-6.06	1.54e-08	3.12e-05	-0.54	-0.48	Aortic root size;	chr7:66487937	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs7803416	ENSG00000222364.1	RNU6-96P	-6.06	1.54e-08	3.12e-05	-0.54	-0.48	Aortic root size;	chr7:66489212	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs1981798	ENSG00000222364.1	RNU6-96P	-6.06	1.54e-08	3.12e-05	-0.54	-0.48	Aortic root size;	chr7:66489916	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs1981799	ENSG00000222364.1	RNU6-96P	-6.06	1.54e-08	3.12e-05	-0.54	-0.48	Aortic root size;	chr7:66490572	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.964	rs2277911	ENSG00000222364.1	RNU6-96P	-6.06	1.54e-08	3.12e-05	-0.54	-0.48	Aortic root size;	chr7:66493638	chr7:66395191~66395286:+
TGCT	cis	rs2739330	0.828	rs5760102	ENSG00000272787.1	KB-226F1.2	-6.05	1.55e-08	3.13e-05	-0.55	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23969211~23969873:+
TGCT	cis	rs8062405	0.965	rs8049439	ENSG00000259982.1	CDC37P1	6.05	1.55e-08	3.14e-05	0.63	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28700294~28701540:-
TGCT	cis	rs440932	0.887	rs398801	ENSG00000254340.1	RP11-10A14.3	-6.05	1.56e-08	3.15e-05	-0.51	-0.48	High light scatter reticulocyte percentage of red cells;	chr8:9174194	chr8:9141424~9145435:+
TGCT	cis	rs17301013	0.507	rs1653630	ENSG00000227373.4	RP11-160H22.5	-6.05	1.56e-08	3.16e-05	-0.55	-0.48	Systemic lupus erythematosus;	chr1:174791810	chr1:174115300~174160004:-
TGCT	cis	rs875971	0.862	rs2909688	ENSG00000222364.1	RNU6-96P	-6.05	1.57e-08	3.17e-05	-0.53	-0.48	Aortic root size;	chr7:66376625	chr7:66395191~66395286:+
TGCT	cis	rs11723261	0.546	rs57839456	ENSG00000275426.1	CH17-262A2.1	6.05	1.57e-08	3.18e-05	0.91	0.48	Immune response to smallpox vaccine (IL-6);	chr4:154494	chr4:149738~150317:+
TGCT	cis	rs8062405	0.964	rs62036614	ENSG00000259982.1	CDC37P1	6.05	1.58e-08	3.19e-05	0.64	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28700294~28701540:-
TGCT	cis	rs6921919	0.848	rs6903652	ENSG00000216901.1	AL022393.7	6.05	1.58e-08	3.19e-05	0.59	0.48	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.848	rs6903823	ENSG00000216901.1	AL022393.7	6.05	1.58e-08	3.19e-05	0.59	0.48	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28176188~28176674:+
TGCT	cis	rs801193	1	rs10252765	ENSG00000222364.1	RNU6-96P	-6.05	1.58e-08	3.19e-05	-0.56	-0.48	Aortic root size;	chr7:66763745	chr7:66395191~66395286:+
TGCT	cis	rs17711722	0.653	rs2460421	ENSG00000222364.1	RNU6-96P	6.05	1.58e-08	3.2e-05	0.54	0.48	Calcium levels;	chr7:66026136	chr7:66395191~66395286:+
TGCT	cis	rs17507216	0.591	rs7163848	ENSG00000278603.1	RP13-608F4.5	6.05	1.59e-08	3.21e-05	0.77	0.48	Excessive daytime sleepiness;	chr15:82729563	chr15:82472203~82472426:+
TGCT	cis	rs321358	1	rs12419222	ENSG00000271584.1	RP11-89C3.4	6.05	1.59e-08	3.22e-05	0.63	0.48	Body mass index;	chr11:111128439	chr11:111091932~111097357:-
TGCT	cis	rs321358	1	rs73019214	ENSG00000271584.1	RP11-89C3.4	6.05	1.59e-08	3.22e-05	0.63	0.48	Body mass index;	chr11:111131680	chr11:111091932~111097357:-
TGCT	cis	rs2882667	0.858	rs6596460	ENSG00000253404.1	AC034243.1	6.05	1.6e-08	3.23e-05	0.56	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078491	chr5:138744434~138753309:-
TGCT	cis	rs7044106	0.762	rs10760107	ENSG00000226752.6	PSMD5-AS1	-6.05	1.6e-08	3.24e-05	-0.59	-0.48	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120824828~120854385:+
TGCT	cis	rs7714584	1	rs11957134	ENSG00000197083.10	ZNF300P1	-6.05	1.6e-08	3.24e-05	-0.89	-0.48	Crohn's disease;	chr5:150851388	chr5:150930645~150946289:-
TGCT	cis	rs5769707	0.681	rs739236	ENSG00000188511.11	C22orf34	6.05	1.61e-08	3.24e-05	0.53	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49647954	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.681	rs916360	ENSG00000188511.11	C22orf34	6.05	1.61e-08	3.24e-05	0.53	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49648324	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.681	rs1107514	ENSG00000188511.11	C22orf34	6.05	1.61e-08	3.24e-05	0.53	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49648735	chr22:49414524~49657542:-
TGCT	cis	rs801193	0.773	rs801207	ENSG00000222364.1	RNU6-96P	6.05	1.61e-08	3.24e-05	0.54	0.48	Aortic root size;	chr7:66555603	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.543	rs801191	ENSG00000222364.1	RNU6-96P	6.05	1.61e-08	3.24e-05	0.54	0.48	Aortic root size;	chr7:66567968	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.508	rs6947808	ENSG00000222364.1	RNU6-96P	6.05	1.61e-08	3.24e-05	0.54	0.48	Aortic root size;	chr7:66580095	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.508	rs10242423	ENSG00000222364.1	RNU6-96P	6.05	1.61e-08	3.24e-05	0.54	0.48	Aortic root size;	chr7:66594188	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.508	rs10253883	ENSG00000222364.1	RNU6-96P	6.05	1.61e-08	3.24e-05	0.54	0.48	Aortic root size;	chr7:66596151	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.508	rs10950045	ENSG00000222364.1	RNU6-96P	6.05	1.61e-08	3.24e-05	0.54	0.48	Aortic root size;	chr7:66601386	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.839	rs6968619	ENSG00000222364.1	RNU6-96P	6.05	1.61e-08	3.24e-05	0.54	0.48	Aortic root size;	chr7:66603880	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.839	rs12534943	ENSG00000222364.1	RNU6-96P	6.05	1.61e-08	3.24e-05	0.54	0.48	Aortic root size;	chr7:66605533	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.805	rs12532355	ENSG00000222364.1	RNU6-96P	6.05	1.61e-08	3.24e-05	0.54	0.48	Aortic root size;	chr7:66605597	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.844	rs732465	ENSG00000222364.1	RNU6-96P	-6.05	1.61e-08	3.24e-05	-0.54	-0.48	Aortic root size;	chr7:66533463	chr7:66395191~66395286:+
TGCT	cis	rs8040855	0.658	rs4842864	ENSG00000259295.5	CSPG4P12	6.05	1.61e-08	3.24e-05	0.62	0.48	Bulimia nervosa;	chr15:85101315	chr15:85191438~85213905:+
TGCT	cis	rs875971	0.508	rs10258739	ENSG00000222364.1	RNU6-96P	6.05	1.61e-08	3.25e-05	0.53	0.48	Aortic root size;	chr7:66597948	chr7:66395191~66395286:+
TGCT	cis	rs11673344	0.526	rs17305823	ENSG00000226686.6	LINC01535	-6.05	1.62e-08	3.27e-05	-0.56	-0.48	Obesity-related traits;	chr19:37644145	chr19:37251912~37265535:+
TGCT	cis	rs2739330	0.828	rs4820572	ENSG00000272787.1	KB-226F1.2	-6.05	1.62e-08	3.27e-05	-0.55	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23969211~23969873:+
TGCT	cis	rs2739330	0.796	rs5760097	ENSG00000272787.1	KB-226F1.2	-6.04	1.62e-08	3.27e-05	-0.55	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23969211~23969873:+
TGCT	cis	rs2739330	0.828	rs4822451	ENSG00000272787.1	KB-226F1.2	-6.04	1.62e-08	3.27e-05	-0.55	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23969211~23969873:+
TGCT	cis	rs2739330	0.828	rs5760098	ENSG00000272787.1	KB-226F1.2	-6.04	1.62e-08	3.27e-05	-0.55	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23969211~23969873:+
TGCT	cis	rs2739330	0.828	rs5760099	ENSG00000272787.1	KB-226F1.2	-6.04	1.62e-08	3.27e-05	-0.55	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23969211~23969873:+
TGCT	cis	rs66887589	0.967	rs1480933	ENSG00000245958.5	RP11-33B1.1	-6.04	1.62e-08	3.27e-05	-0.53	-0.48	Diastolic blood pressure;	chr4:119512093	chr4:119454791~119552025:+
TGCT	cis	rs7044106	0.791	rs2416799	ENSG00000226752.6	PSMD5-AS1	-6.04	1.65e-08	3.32e-05	-0.61	-0.48	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120824828~120854385:+
TGCT	cis	rs7044106	0.791	rs10984998	ENSG00000226752.6	PSMD5-AS1	-6.04	1.65e-08	3.32e-05	-0.61	-0.48	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120824828~120854385:+
TGCT	cis	rs694739	0.628	rs645078	ENSG00000236935.1	AP003774.1	6.04	1.65e-08	3.32e-05	0.36	0.48	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64367826	chr11:64325050~64329504:-
TGCT	cis	rs2882667	0.755	rs55650316	ENSG00000253404.1	AC034243.1	6.04	1.65e-08	3.33e-05	0.57	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139131603	chr5:138744434~138753309:-
TGCT	cis	rs858239	0.712	rs200717	ENSG00000230658.1	KLHL7-AS1	6.04	1.66e-08	3.34e-05	0.47	0.48	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23101228~23105703:-
TGCT	cis	rs6452524	0.901	rs72767146	ENSG00000249664.1	CTD-2227C6.2	6.04	1.67e-08	3.35e-05	0.52	0.48	Hypertension (SNP x SNP interaction);	chr5:83126365	chr5:83012285~83013109:-
TGCT	cis	rs875971	0.895	rs12698520	ENSG00000222364.1	RNU6-96P	-6.04	1.67e-08	3.35e-05	-0.54	-0.48	Aortic root size;	chr7:66453720	chr7:66395191~66395286:+
TGCT	cis	rs3096299	0.658	rs4785679	ENSG00000274627.1	RP11-104N10.2	6.04	1.67e-08	3.36e-05	0.49	0.48	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89516797~89522217:+
TGCT	cis	rs6700559	0.967	rs10919992	ENSG00000260088.1	RP11-92G12.3	-6.04	1.68e-08	3.38e-05	-0.56	-0.48	Coronary artery disease;	chr1:200638338	chr1:200669507~200694250:+
TGCT	cis	rs17711722	1	rs17711722	ENSG00000222364.1	RNU6-96P	6.04	1.68e-08	3.38e-05	0.54	0.48	Calcium levels;	chr7:65806210	chr7:66395191~66395286:+
TGCT	cis	rs17711722	0.675	rs6947132	ENSG00000222364.1	RNU6-96P	6.04	1.68e-08	3.38e-05	0.54	0.48	Calcium levels;	chr7:65808508	chr7:66395191~66395286:+
TGCT	cis	rs11763147	1	rs11763147	ENSG00000222364.1	RNU6-96P	6.04	1.69e-08	3.39e-05	0.54	0.48	Corneal structure;	chr7:65861834	chr7:66395191~66395286:+
TGCT	cis	rs73086581	0.947	rs73084523	ENSG00000229539.1	RP11-119B16.2	6.04	1.69e-08	3.39e-05	0.72	0.48	Response to antidepressants in depression;	chr20:3894979	chr20:3888239~3888868:-
TGCT	cis	rs73086581	0.947	rs56123574	ENSG00000229539.1	RP11-119B16.2	6.04	1.69e-08	3.39e-05	0.72	0.48	Response to antidepressants in depression;	chr20:3897434	chr20:3888239~3888868:-
TGCT	cis	rs875971	0.862	rs709596	ENSG00000222364.1	RNU6-96P	-6.04	1.7e-08	3.42e-05	-0.53	-0.48	Aortic root size;	chr7:66360926	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.516	rs6945322	ENSG00000222364.1	RNU6-96P	-6.03	1.71e-08	3.43e-05	-0.54	-0.48	Aortic root size;	chr7:65871069	chr7:66395191~66395286:+
TGCT	cis	rs17711722	0.701	rs55773927	ENSG00000222364.1	RNU6-96P	-6.03	1.71e-08	3.43e-05	-0.54	-0.48	Calcium levels;	chr7:65872915	chr7:66395191~66395286:+
TGCT	cis	rs17711722	0.727	rs35850374	ENSG00000222364.1	RNU6-96P	-6.03	1.71e-08	3.43e-05	-0.54	-0.48	Calcium levels;	chr7:65892789	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.54	rs4717275	ENSG00000222364.1	RNU6-96P	6.03	1.72e-08	3.44e-05	0.54	0.48	Aortic root size;	chr7:65800193	chr7:66395191~66395286:+
TGCT	cis	rs17711722	0.701	rs4467826	ENSG00000222364.1	RNU6-96P	-6.03	1.72e-08	3.44e-05	-0.54	-0.48	Calcium levels;	chr7:65903721	chr7:66395191~66395286:+
TGCT	cis	rs7044106	0.791	rs4836829	ENSG00000226752.6	PSMD5-AS1	-6.03	1.74e-08	3.48e-05	-0.61	-0.48	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120824828~120854385:+
TGCT	cis	rs9733	0.596	rs7418501	ENSG00000206931.1	RNU6-1042P	6.03	1.74e-08	3.48e-05	0.35	0.48	Tonsillectomy;	chr1:150739420	chr1:150701866~150701972:+
TGCT	cis	rs9322193	0.651	rs9322188	ENSG00000216906.2	RP11-350J20.9	-6.03	1.75e-08	3.5e-05	-0.53	-0.48	Lung cancer;	chr6:149588355	chr6:149904243~149906418:+
TGCT	cis	rs17301013	0.606	rs12086693	ENSG00000227373.4	RP11-160H22.5	6.03	1.75e-08	3.51e-05	0.56	0.48	Systemic lupus erythematosus;	chr1:174527651	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs12062170	ENSG00000227373.4	RP11-160H22.5	6.03	1.75e-08	3.51e-05	0.56	0.48	Systemic lupus erythematosus;	chr1:174528420	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs12062483	ENSG00000227373.4	RP11-160H22.5	6.03	1.75e-08	3.51e-05	0.56	0.48	Systemic lupus erythematosus;	chr1:174529089	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs6681970	ENSG00000227373.4	RP11-160H22.5	6.03	1.75e-08	3.51e-05	0.56	0.48	Systemic lupus erythematosus;	chr1:174532698	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs6668096	ENSG00000227373.4	RP11-160H22.5	6.03	1.75e-08	3.51e-05	0.56	0.48	Systemic lupus erythematosus;	chr1:174537343	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs6692173	ENSG00000227373.4	RP11-160H22.5	6.03	1.75e-08	3.51e-05	0.56	0.48	Systemic lupus erythematosus;	chr1:174544474	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs10494492	ENSG00000227373.4	RP11-160H22.5	-6.03	1.76e-08	3.52e-05	-0.54	-0.48	Systemic lupus erythematosus;	chr1:174723499	chr1:174115300~174160004:-
TGCT	cis	rs11155671	0.53	rs9371504	ENSG00000216906.2	RP11-350J20.9	6.03	1.77e-08	3.54e-05	0.53	0.48	Testicular germ cell tumor;	chr6:149862944	chr6:149904243~149906418:+
TGCT	cis	rs11155671	0.53	rs9371505	ENSG00000216906.2	RP11-350J20.9	6.03	1.77e-08	3.54e-05	0.53	0.48	Testicular germ cell tumor;	chr6:149863012	chr6:149904243~149906418:+
TGCT	cis	rs17301013	0.507	rs2901820	ENSG00000227373.4	RP11-160H22.5	6.03	1.78e-08	3.55e-05	0.59	0.48	Systemic lupus erythematosus;	chr1:174505201	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs4652512	ENSG00000227373.4	RP11-160H22.5	6.03	1.78e-08	3.55e-05	0.59	0.48	Systemic lupus erythematosus;	chr1:174515519	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs57512497	ENSG00000227373.4	RP11-160H22.5	6.03	1.78e-08	3.55e-05	0.59	0.48	Systemic lupus erythematosus;	chr1:174518346	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs11807229	ENSG00000227373.4	RP11-160H22.5	6.03	1.78e-08	3.55e-05	0.59	0.48	Systemic lupus erythematosus;	chr1:174519456	chr1:174115300~174160004:-
TGCT	cis	rs748404	0.578	rs512628	ENSG00000205771.5	CATSPER2P1	-6.03	1.78e-08	3.55e-05	-0.53	-0.48	Lung cancer;	chr15:43326536	chr15:43726918~43747094:-
TGCT	cis	rs2882667	0.858	rs11744972	ENSG00000253404.1	AC034243.1	6.03	1.78e-08	3.56e-05	0.54	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139093100	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.858	rs11741150	ENSG00000253404.1	AC034243.1	6.03	1.78e-08	3.56e-05	0.54	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095768	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.858	rs13177503	ENSG00000253404.1	AC034243.1	6.03	1.78e-08	3.56e-05	0.54	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139097070	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.858	rs13170388	ENSG00000253404.1	AC034243.1	6.03	1.78e-08	3.56e-05	0.54	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139101176	chr5:138744434~138753309:-
TGCT	cis	rs875971	0.798	rs6460304	ENSG00000222364.1	RNU6-96P	-6.02	1.79e-08	3.57e-05	-0.53	-0.48	Aortic root size;	chr7:66499741	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs6945775	ENSG00000222364.1	RNU6-96P	-6.02	1.79e-08	3.57e-05	-0.53	-0.48	Aortic root size;	chr7:66503987	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.798	rs57739047	ENSG00000222364.1	RNU6-96P	-6.02	1.79e-08	3.57e-05	-0.53	-0.48	Aortic root size;	chr7:66507579	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.83	rs6950137	ENSG00000222364.1	RNU6-96P	-6.02	1.79e-08	3.57e-05	-0.53	-0.48	Aortic root size;	chr7:66511623	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs11763189	ENSG00000222364.1	RNU6-96P	-6.02	1.79e-08	3.57e-05	-0.53	-0.48	Aortic root size;	chr7:66518542	chr7:66395191~66395286:+
TGCT	cis	rs3091242	1	rs3091242	ENSG00000261349.1	RP3-465N24.5	-6.02	1.79e-08	3.57e-05	-0.48	-0.48	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25266102~25267136:-
TGCT	cis	rs3091242	0.967	rs3091240	ENSG00000261349.1	RP3-465N24.5	-6.02	1.79e-08	3.57e-05	-0.48	-0.48	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25266102~25267136:-
TGCT	cis	rs875971	1	rs10244498	ENSG00000222364.1	RNU6-96P	-6.02	1.79e-08	3.58e-05	-0.55	-0.48	Aortic root size;	chr7:66651069	chr7:66395191~66395286:+
TGCT	cis	rs7104764	1	rs1128322	ENSG00000277290.1	RP11-326C3.16	6.02	1.8e-08	3.58e-05	0.46	0.48	Menarche (age at onset);	chr11:244197	chr11:243099~243483:-
TGCT	cis	rs7104764	1	rs7395328	ENSG00000277290.1	RP11-326C3.16	-6.02	1.8e-08	3.58e-05	-0.46	-0.48	Menarche (age at onset);	chr11:242624	chr11:243099~243483:-
TGCT	cis	rs7104764	0.917	rs6598068	ENSG00000277290.1	RP11-326C3.16	-6.02	1.8e-08	3.58e-05	-0.46	-0.48	Menarche (age at onset);	chr11:243092	chr11:243099~243483:-
TGCT	cis	rs7104764	0.917	rs6598067	ENSG00000277290.1	RP11-326C3.16	-6.02	1.8e-08	3.58e-05	-0.46	-0.48	Menarche (age at onset);	chr11:243093	chr11:243099~243483:-
TGCT	cis	rs7104764	1	rs6598065	ENSG00000277290.1	RP11-326C3.16	-6.02	1.8e-08	3.58e-05	-0.46	-0.48	Menarche (age at onset);	chr11:243211	chr11:243099~243483:-
TGCT	cis	rs7104764	0.957	rs6598064	ENSG00000277290.1	RP11-326C3.16	-6.02	1.8e-08	3.58e-05	-0.46	-0.48	Menarche (age at onset);	chr11:243557	chr11:243099~243483:-
TGCT	cis	rs7104764	1	rs6598063	ENSG00000277290.1	RP11-326C3.16	-6.02	1.8e-08	3.58e-05	-0.46	-0.48	Menarche (age at onset);	chr11:243672	chr11:243099~243483:-
TGCT	cis	rs7104764	1	rs6598062	ENSG00000277290.1	RP11-326C3.16	-6.02	1.8e-08	3.58e-05	-0.46	-0.48	Menarche (age at onset);	chr11:243712	chr11:243099~243483:-
TGCT	cis	rs7104764	1	rs6598061	ENSG00000277290.1	RP11-326C3.16	-6.02	1.8e-08	3.58e-05	-0.46	-0.48	Menarche (age at onset);	chr11:243853	chr11:243099~243483:-
TGCT	cis	rs7104764	1	rs10902112	ENSG00000277290.1	RP11-326C3.16	-6.02	1.8e-08	3.58e-05	-0.46	-0.48	Menarche (age at onset);	chr11:244106	chr11:243099~243483:-
TGCT	cis	rs7104764	0.917	rs7107362	ENSG00000277290.1	RP11-326C3.16	-6.02	1.8e-08	3.58e-05	-0.46	-0.48	Menarche (age at onset);	chr11:244108	chr11:243099~243483:-
TGCT	cis	rs7104764	1	rs7128044	ENSG00000277290.1	RP11-326C3.16	-6.02	1.8e-08	3.58e-05	-0.46	-0.48	Menarche (age at onset);	chr11:244115	chr11:243099~243483:-
TGCT	cis	rs7104764	0.957	rs7116130	ENSG00000277290.1	RP11-326C3.16	-6.02	1.8e-08	3.58e-05	-0.46	-0.48	Menarche (age at onset);	chr11:244129	chr11:243099~243483:-
TGCT	cis	rs7104764	1	rs7128029	ENSG00000277290.1	RP11-326C3.16	-6.02	1.8e-08	3.58e-05	-0.46	-0.48	Menarche (age at onset);	chr11:244141	chr11:243099~243483:-
TGCT	cis	rs7104764	1	rs1128320	ENSG00000277290.1	RP11-326C3.16	-6.02	1.8e-08	3.58e-05	-0.46	-0.48	Menarche (age at onset);	chr11:244167	chr11:243099~243483:-
TGCT	cis	rs7104764	0.957	rs1128321	ENSG00000277290.1	RP11-326C3.16	-6.02	1.8e-08	3.58e-05	-0.46	-0.48	Menarche (age at onset);	chr11:244171	chr11:243099~243483:-
TGCT	cis	rs7104764	1	rs2272565	ENSG00000277290.1	RP11-326C3.16	-6.02	1.8e-08	3.58e-05	-0.46	-0.48	Menarche (age at onset);	chr11:244414	chr11:243099~243483:-
TGCT	cis	rs7104764	1	rs10902113	ENSG00000277290.1	RP11-326C3.16	-6.02	1.8e-08	3.58e-05	-0.46	-0.48	Menarche (age at onset);	chr11:245523	chr11:243099~243483:-
TGCT	cis	rs7104764	1	rs7482591	ENSG00000277290.1	RP11-326C3.16	-6.02	1.8e-08	3.58e-05	-0.46	-0.48	Menarche (age at onset);	chr11:245861	chr11:243099~243483:-
TGCT	cis	rs7104764	1	rs10902114	ENSG00000277290.1	RP11-326C3.16	-6.02	1.8e-08	3.58e-05	-0.46	-0.48	Menarche (age at onset);	chr11:246234	chr11:243099~243483:-
TGCT	cis	rs7104764	1	rs10400248	ENSG00000277290.1	RP11-326C3.16	-6.02	1.8e-08	3.58e-05	-0.46	-0.48	Menarche (age at onset);	chr11:247029	chr11:243099~243483:-
TGCT	cis	rs11155671	0.53	rs6935829	ENSG00000216906.2	RP11-350J20.9	6.02	1.8e-08	3.59e-05	0.52	0.48	Testicular germ cell tumor;	chr6:149896675	chr6:149904243~149906418:+
TGCT	cis	rs2732480	0.577	rs2732457	ENSG00000258273.1	RP11-370I10.4	6.02	1.8e-08	3.59e-05	0.57	0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48333755~48333901:-
TGCT	cis	rs3091242	0.935	rs3093632	ENSG00000261349.1	RP3-465N24.5	-6.02	1.8e-08	3.59e-05	-0.48	-0.48	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25266102~25267136:-
TGCT	cis	rs321358	1	rs321358	ENSG00000271584.1	RP11-89C3.4	6.02	1.81e-08	3.6e-05	0.59	0.48	Body mass index;	chr11:111125247	chr11:111091932~111097357:-
TGCT	cis	rs10875976	0.507	rs4898539	ENSG00000257253.2	RP11-70F11.7	6.02	1.81e-08	3.6e-05	0.4	0.48	Obesity;	chr12:49858127	chr12:49861207~49865802:+
TGCT	cis	rs7811142	0.83	rs28495773	ENSG00000242294.5	STAG3L5P	6.02	1.81e-08	3.61e-05	0.46	0.48	Platelet count;	chr7:100345960	chr7:100336079~100351900:+
TGCT	cis	rs875971	0.862	rs1695820	ENSG00000222364.1	RNU6-96P	-6.02	1.82e-08	3.61e-05	-0.53	-0.48	Aortic root size;	chr7:66379576	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.83	rs778715	ENSG00000222364.1	RNU6-96P	-6.02	1.82e-08	3.61e-05	-0.53	-0.48	Aortic root size;	chr7:66384222	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.83	rs809025	ENSG00000222364.1	RNU6-96P	-6.02	1.82e-08	3.61e-05	-0.53	-0.48	Aortic root size;	chr7:66384832	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs778702	ENSG00000222364.1	RNU6-96P	-6.02	1.82e-08	3.61e-05	-0.53	-0.48	Aortic root size;	chr7:66399848	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs1643375	ENSG00000222364.1	RNU6-96P	-6.02	1.82e-08	3.61e-05	-0.53	-0.48	Aortic root size;	chr7:66407690	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs6962717	ENSG00000222364.1	RNU6-96P	-6.02	1.82e-08	3.61e-05	-0.53	-0.48	Aortic root size;	chr7:66418748	chr7:66395191~66395286:+
TGCT	cis	rs748404	0.578	rs552701	ENSG00000205771.5	CATSPER2P1	-6.02	1.82e-08	3.62e-05	-0.54	-0.48	Lung cancer;	chr15:43321612	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.578	rs573615	ENSG00000205771.5	CATSPER2P1	-6.02	1.82e-08	3.62e-05	-0.54	-0.48	Lung cancer;	chr15:43322083	chr15:43726918~43747094:-
TGCT	cis	rs7208859	0.673	rs11655623	ENSG00000263531.1	RP13-753N3.1	6.02	1.82e-08	3.63e-05	0.83	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30863921~30864940:-
TGCT	cis	rs55794721	0.543	rs1293260	ENSG00000261349.1	RP3-465N24.5	-6.02	1.82e-08	3.63e-05	-0.48	-0.48	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25266102~25267136:-
TGCT	cis	rs17301013	0.606	rs12077529	ENSG00000227373.4	RP11-160H22.5	6.02	1.83e-08	3.63e-05	0.52	0.48	Systemic lupus erythematosus;	chr1:174549874	chr1:174115300~174160004:-
TGCT	cis	rs6452524	0.537	rs1583	ENSG00000249664.1	CTD-2227C6.2	6.02	1.85e-08	3.67e-05	0.53	0.48	Hypertension (SNP x SNP interaction);	chr5:83052403	chr5:83012285~83013109:-
TGCT	cis	rs875971	0.83	rs6976714	ENSG00000222364.1	RNU6-96P	-6.02	1.85e-08	3.67e-05	-0.53	-0.48	Aortic root size;	chr7:66426474	chr7:66395191~66395286:+
TGCT	cis	rs1832871	0.599	rs661857	ENSG00000188451.8	SRP72P2	6.02	1.85e-08	3.68e-05	0.4	0.48	Height;	chr6:158237756	chr6:158237336~158242797:-
TGCT	cis	rs875971	1	rs6956179	ENSG00000222364.1	RNU6-96P	6.02	1.86e-08	3.69e-05	0.54	0.48	Aortic root size;	chr7:66341672	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.545	rs221986	ENSG00000226824.5	RP4-756H11.3	6.02	1.86e-08	3.69e-05	0.59	0.48	Aortic root size;	chr7:66105323	chr7:66654538~66669855:+
TGCT	cis	rs7412746	0.611	rs16827671	ENSG00000206931.1	RNU6-1042P	6.02	1.87e-08	3.69e-05	0.38	0.48	Melanoma;	chr1:150766283	chr1:150701866~150701972:+
TGCT	cis	rs3091242	0.866	rs11249249	ENSG00000224183.1	SDHDP6	-6.02	1.87e-08	3.7e-05	-0.5	-0.48	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25294164~25294643:-
TGCT	cis	rs972540	0.64	rs17304002	ENSG00000279220.1	GPR1-AS	-6.02	1.87e-08	3.7e-05	-0.46	-0.48	Body mass index;	chr2:206342413	chr2:206203376~206266243:+
TGCT	cis	rs16828019	0.777	rs3738369	ENSG00000235358.1	RP11-399E6.1	6.02	1.87e-08	3.71e-05	0.81	0.48	Intelligence (multi-trait analysis);	chr1:41020736	chr1:41242373~41284861:+
TGCT	cis	rs875971	0.545	rs73142233	ENSG00000226824.5	RP4-756H11.3	-6.01	1.88e-08	3.72e-05	-0.58	-0.48	Aortic root size;	chr7:66221293	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs73142245	ENSG00000226824.5	RP4-756H11.3	-6.01	1.88e-08	3.72e-05	-0.58	-0.48	Aortic root size;	chr7:66226662	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs73142265	ENSG00000226824.5	RP4-756H11.3	-6.01	1.88e-08	3.72e-05	-0.58	-0.48	Aortic root size;	chr7:66234510	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs73146609	ENSG00000226824.5	RP4-756H11.3	-6.01	1.89e-08	3.73e-05	-0.57	-0.48	Aortic root size;	chr7:66302477	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs2173571	ENSG00000226824.5	RP4-756H11.3	-6.01	1.89e-08	3.73e-05	-0.57	-0.48	Aortic root size;	chr7:66305392	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs11770063	ENSG00000226824.5	RP4-756H11.3	-6.01	1.89e-08	3.73e-05	-0.57	-0.48	Aortic root size;	chr7:66318029	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs3936065	ENSG00000226824.5	RP4-756H11.3	-6.01	1.89e-08	3.73e-05	-0.57	-0.48	Aortic root size;	chr7:66325577	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs4718335	ENSG00000226824.5	RP4-756H11.3	-6.01	1.89e-08	3.73e-05	-0.57	-0.48	Aortic root size;	chr7:66339619	chr7:66654538~66669855:+
TGCT	cis	rs801193	0.569	rs2659908	ENSG00000222364.1	RNU6-96P	-6.01	1.89e-08	3.73e-05	-0.53	-0.48	Aortic root size;	chr7:66695835	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.569	rs2659907	ENSG00000222364.1	RNU6-96P	-6.01	1.89e-08	3.73e-05	-0.53	-0.48	Aortic root size;	chr7:66699045	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.569	rs7782587	ENSG00000222364.1	RNU6-96P	-6.01	1.89e-08	3.73e-05	-0.53	-0.48	Aortic root size;	chr7:66701485	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.569	rs4717315	ENSG00000222364.1	RNU6-96P	-6.01	1.89e-08	3.73e-05	-0.53	-0.48	Aortic root size;	chr7:66713338	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.527	rs2707837	ENSG00000222364.1	RNU6-96P	-6.01	1.89e-08	3.73e-05	-0.53	-0.48	Aortic root size;	chr7:66716086	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.569	rs2707824	ENSG00000222364.1	RNU6-96P	-6.01	1.89e-08	3.73e-05	-0.53	-0.48	Aortic root size;	chr7:66724256	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.591	rs4506088	ENSG00000222364.1	RNU6-96P	6.01	1.89e-08	3.73e-05	0.53	0.48	Aortic root size;	chr7:66670470	chr7:66395191~66395286:+
TGCT	cis	rs8062405	1	rs62036616	ENSG00000259982.1	CDC37P1	6.01	1.9e-08	3.74e-05	0.64	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28700294~28701540:-
TGCT	cis	rs875971	0.545	rs2279757	ENSG00000226824.5	RP4-756H11.3	-6.01	1.9e-08	3.75e-05	-0.57	-0.48	Aortic root size;	chr7:66363676	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs11766183	ENSG00000226824.5	RP4-756H11.3	-6.01	1.9e-08	3.75e-05	-0.57	-0.48	Aortic root size;	chr7:66374173	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs1065265	ENSG00000226824.5	RP4-756H11.3	-6.01	1.9e-08	3.75e-05	-0.57	-0.48	Aortic root size;	chr7:66376216	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs7811204	ENSG00000226824.5	RP4-756H11.3	-6.01	1.9e-08	3.75e-05	-0.57	-0.48	Aortic root size;	chr7:66387213	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.571	rs78668714	ENSG00000226824.5	RP4-756H11.3	-6.01	1.9e-08	3.75e-05	-0.57	-0.48	Aortic root size;	chr7:66474464	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs73150604	ENSG00000226824.5	RP4-756H11.3	-6.01	1.9e-08	3.75e-05	-0.57	-0.48	Aortic root size;	chr7:66480545	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs7810213	ENSG00000226824.5	RP4-756H11.3	-6.01	1.9e-08	3.75e-05	-0.57	-0.48	Aortic root size;	chr7:66481592	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs2420612	ENSG00000226824.5	RP4-756H11.3	-6.01	1.9e-08	3.75e-05	-0.57	-0.48	Aortic root size;	chr7:66536825	chr7:66654538~66669855:+
TGCT	cis	rs916888	0.61	rs199453	ENSG00000262500.1	RP11-259G18.2	6.01	1.91e-08	3.76e-05	0.61	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46243606~46245044:+
TGCT	cis	rs916888	0.61	rs199452	ENSG00000262500.1	RP11-259G18.2	6.01	1.91e-08	3.76e-05	0.61	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46243606~46245044:+
TGCT	cis	rs7714584	1	rs11167515	ENSG00000197083.10	ZNF300P1	6.01	1.91e-08	3.77e-05	0.89	0.47	Crohn's disease;	chr5:150859909	chr5:150930645~150946289:-
TGCT	cis	rs11098499	0.739	rs9996382	ENSG00000245958.5	RP11-33B1.1	-6.01	1.91e-08	3.77e-05	-0.47	-0.47	Corneal astigmatism;	chr4:119229857	chr4:119454791~119552025:+
TGCT	cis	rs875971	0.651	rs2420596	ENSG00000222364.1	RNU6-96P	-6.01	1.94e-08	3.81e-05	-0.53	-0.47	Aortic root size;	chr7:66450996	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.52	rs2420597	ENSG00000222364.1	RNU6-96P	-6.01	1.94e-08	3.81e-05	-0.53	-0.47	Aortic root size;	chr7:66450999	chr7:66395191~66395286:+
TGCT	cis	rs1153858	0.668	rs63603561	ENSG00000259520.4	CTD-2651B20.3	6.01	1.95e-08	3.83e-05	0.43	0.47	Homoarginine levels;	chr15:45301125	chr15:45251580~45279251:-
TGCT	cis	rs3091242	0.9	rs1811832	ENSG00000224183.1	SDHDP6	-6.01	1.95e-08	3.84e-05	-0.5	-0.47	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25294164~25294643:-
TGCT	cis	rs7104764	1	rs7104764	ENSG00000277290.1	RP11-326C3.16	-6.01	1.95e-08	3.84e-05	-0.46	-0.47	Menarche (age at onset);	chr11:229977	chr11:243099~243483:-
TGCT	cis	rs7104764	0.957	rs3829998	ENSG00000277290.1	RP11-326C3.16	-6.01	1.95e-08	3.84e-05	-0.46	-0.47	Menarche (age at onset);	chr11:230751	chr11:243099~243483:-
TGCT	cis	rs5769707	0.609	rs739247	ENSG00000188511.11	C22orf34	6.01	1.96e-08	3.85e-05	0.52	0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49603009	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.609	rs135861	ENSG00000188511.11	C22orf34	6.01	1.96e-08	3.85e-05	0.52	0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49414524~49657542:-
TGCT	cis	rs801193	1	rs2707856	ENSG00000222364.1	RNU6-96P	-6	1.97e-08	3.87e-05	-0.56	-0.47	Aortic root size;	chr7:66746023	chr7:66395191~66395286:+
TGCT	cis	rs7044106	0.762	rs3904197	ENSG00000226752.6	PSMD5-AS1	-6	1.98e-08	3.88e-05	-0.6	-0.47	Hip circumference adjusted for BMI;	chr9:120718100	chr9:120824828~120854385:+
TGCT	cis	rs7174755	0.923	rs4777036	ENSG00000260657.2	RP11-315D16.4	-6	2e-08	3.92e-05	-0.49	-0.47	Major depressive disorder;	chr15:68313230	chr15:68267792~68277994:-
TGCT	cis	rs9322193	0.847	rs56103941	ENSG00000216906.2	RP11-350J20.9	6	2e-08	3.92e-05	0.55	0.47	Lung cancer;	chr6:149816095	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.847	rs12210605	ENSG00000216906.2	RP11-350J20.9	6	2e-08	3.92e-05	0.55	0.47	Lung cancer;	chr6:149817267	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9371199	ENSG00000216906.2	RP11-350J20.9	6	2e-08	3.92e-05	0.55	0.47	Lung cancer;	chr6:149817526	chr6:149904243~149906418:+
TGCT	cis	rs73086581	1	rs73086581	ENSG00000229539.1	RP11-119B16.2	6	2.02e-08	3.95e-05	0.72	0.47	Response to antidepressants in depression;	chr20:3996678	chr20:3888239~3888868:-
TGCT	cis	rs5769707	0.632	rs6009782	ENSG00000188511.11	C22orf34	6	2.02e-08	3.95e-05	0.53	0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49617164	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.592	rs6009783	ENSG00000188511.11	C22orf34	6	2.02e-08	3.95e-05	0.53	0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49617353	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.656	rs135875	ENSG00000188511.11	C22orf34	6	2.02e-08	3.95e-05	0.53	0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49618771	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.616	rs6009786	ENSG00000188511.11	C22orf34	6	2.02e-08	3.95e-05	0.53	0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49621497	chr22:49414524~49657542:-
TGCT	cis	rs9322193	0.884	rs1108889	ENSG00000216906.2	RP11-350J20.9	6	2.02e-08	3.96e-05	0.57	0.47	Lung cancer;	chr6:149845433	chr6:149904243~149906418:+
TGCT	cis	rs7044106	0.762	rs1324473	ENSG00000226752.6	PSMD5-AS1	6	2.03e-08	3.96e-05	0.6	0.47	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120824828~120854385:+
TGCT	cis	rs4970988	0.787	rs1532770	ENSG00000206931.1	RNU6-1042P	6	2.03e-08	3.98e-05	0.38	0.47	Urate levels;	chr1:150752859	chr1:150701866~150701972:+
TGCT	cis	rs977987	0.872	rs4888422	ENSG00000261783.1	RP11-252K23.2	-6	2.04e-08	3.99e-05	-0.68	-0.47	Dupuytren's disease;	chr16:75436678	chr16:75379818~75381260:-
TGCT	cis	rs5758659	0.652	rs133349	ENSG00000270083.1	RP1-257I20.14	6	2.05e-08	4.01e-05	0.44	0.47	Cognitive function;	chr22:42032723	chr22:42089630~42090028:-
TGCT	cis	rs5758659	0.652	rs5758553	ENSG00000270083.1	RP1-257I20.14	6	2.05e-08	4.01e-05	0.44	0.47	Cognitive function;	chr22:42035425	chr22:42089630~42090028:-
TGCT	cis	rs7174755	0.608	rs62004789	ENSG00000260657.2	RP11-315D16.4	6	2.05e-08	4.01e-05	0.51	0.47	Major depressive disorder;	chr15:68148268	chr15:68267792~68277994:-
TGCT	cis	rs943437	0.877	rs671271	ENSG00000227012.2	RP1-97J1.2	6	2.05e-08	4.01e-05	0.64	0.47	Parkinson's disease;	chr6:111940182	chr6:111900489~111901851:-
TGCT	cis	rs5769707	0.632	rs135871	ENSG00000188511.11	C22orf34	6	2.05e-08	4.02e-05	0.53	0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49615321	chr22:49414524~49657542:-
TGCT	cis	rs5769707	0.632	rs135872	ENSG00000188511.11	C22orf34	6	2.05e-08	4.02e-05	0.53	0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49615652	chr22:49414524~49657542:-
TGCT	cis	rs6700559	0.935	rs10920001	ENSG00000260088.1	RP11-92G12.3	-6	2.06e-08	4.02e-05	-0.57	-0.47	Coronary artery disease;	chr1:200682420	chr1:200669507~200694250:+
TGCT	cis	rs7811142	0.83	rs11771936	ENSG00000242294.5	STAG3L5P	6	2.06e-08	4.02e-05	0.45	0.47	Platelet count;	chr7:100345660	chr7:100336079~100351900:+
TGCT	cis	rs875971	0.825	rs1000464	ENSG00000222364.1	RNU6-96P	5.99	2.07e-08	4.05e-05	0.53	0.47	Aortic root size;	chr7:66312922	chr7:66395191~66395286:+
TGCT	cis	rs7044106	0.718	rs1981021	ENSG00000226752.6	PSMD5-AS1	-5.99	2.08e-08	4.06e-05	-0.6	-0.47	Hip circumference adjusted for BMI;	chr9:120626115	chr9:120824828~120854385:+
TGCT	cis	rs7044106	0.734	rs1981020	ENSG00000226752.6	PSMD5-AS1	-5.99	2.08e-08	4.06e-05	-0.6	-0.47	Hip circumference adjusted for BMI;	chr9:120626186	chr9:120824828~120854385:+
TGCT	cis	rs7044106	0.762	rs13291660	ENSG00000226752.6	PSMD5-AS1	-5.99	2.08e-08	4.06e-05	-0.6	-0.47	Hip circumference adjusted for BMI;	chr9:120630470	chr9:120824828~120854385:+
TGCT	cis	rs7301826	1	rs7301826	ENSG00000256250.1	RP11-989F5.1	-5.99	2.09e-08	4.07e-05	-0.51	-0.47	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810606~130812438:+
TGCT	cis	rs1167827	0.68	rs1167796	ENSG00000127957.15	PMS2P3	5.99	2.09e-08	4.08e-05	0.55	0.47	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75502930~75528148:-
TGCT	cis	rs1061377	1	rs13182	ENSG00000249207.1	RP11-360F5.1	-5.99	2.09e-08	4.09e-05	-0.51	-0.47	Uric acid levels;	chr4:39121293	chr4:39112677~39126818:-
TGCT	cis	rs2729354	0.502	rs2848641	ENSG00000265566.2	RN7SL605P	-5.99	2.09e-08	4.09e-05	-0.58	-0.47	Blood protein levels;	chr11:57495595	chr11:57528085~57528365:-
TGCT	cis	rs6061231	0.793	rs2427320	ENSG00000273619.1	RP5-908M14.9	-5.99	2.09e-08	4.09e-05	-0.56	-0.47	Colorectal cancer;	chr20:62401667	chr20:62386303~62386970:-
TGCT	cis	rs6061231	0.793	rs6061512	ENSG00000273619.1	RP5-908M14.9	-5.99	2.09e-08	4.09e-05	-0.56	-0.47	Colorectal cancer;	chr20:62401873	chr20:62386303~62386970:-
TGCT	cis	rs6061231	0.837	rs6061235	ENSG00000273619.1	RP5-908M14.9	-5.99	2.09e-08	4.09e-05	-0.56	-0.47	Colorectal cancer;	chr20:62403468	chr20:62386303~62386970:-
TGCT	cis	rs5758659	0.652	rs133358	ENSG00000270083.1	RP1-257I20.14	5.99	2.09e-08	4.09e-05	0.44	0.47	Cognitive function;	chr22:42046535	chr22:42089630~42090028:-
TGCT	cis	rs786425	0.77	rs7138503	ENSG00000278112.1	RP11-972P1.11	5.99	2.11e-08	4.11e-05	0.55	0.47	Pubertal anthropometrics;	chr12:123699280	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.711	rs12819746	ENSG00000278112.1	RP11-972P1.11	5.99	2.11e-08	4.11e-05	0.55	0.47	Pubertal anthropometrics;	chr12:123709027	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.77	rs12825800	ENSG00000278112.1	RP11-972P1.11	5.99	2.11e-08	4.11e-05	0.55	0.47	Pubertal anthropometrics;	chr12:123709119	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.77	rs6488897	ENSG00000278112.1	RP11-972P1.11	5.99	2.11e-08	4.11e-05	0.55	0.47	Pubertal anthropometrics;	chr12:123710936	chr12:123519390~123519856:-
TGCT	cis	rs9733	0.519	rs7529194	ENSG00000206931.1	RNU6-1042P	5.99	2.12e-08	4.13e-05	0.37	0.47	Tonsillectomy;	chr1:150650144	chr1:150701866~150701972:+
TGCT	cis	rs5769707	0.609	rs2007024	ENSG00000188511.11	C22orf34	5.99	2.12e-08	4.14e-05	0.51	0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49595167	chr22:49414524~49657542:-
TGCT	cis	rs9549367	0.789	rs9549695	ENSG00000269125.1	RP11-98F14.11	5.99	2.13e-08	4.15e-05	0.51	0.47	Platelet distribution width;	chr13:113220500	chr13:113165002~113165183:-
TGCT	cis	rs801193	1	rs2707845	ENSG00000222364.1	RNU6-96P	-5.99	2.13e-08	4.15e-05	-0.56	-0.47	Aortic root size;	chr7:66733811	chr7:66395191~66395286:+
TGCT	cis	rs801193	1	rs2707850	ENSG00000222364.1	RNU6-96P	-5.99	2.13e-08	4.15e-05	-0.56	-0.47	Aortic root size;	chr7:66738883	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.967	rs1110414	ENSG00000222364.1	RNU6-96P	-5.99	2.13e-08	4.15e-05	-0.56	-0.47	Aortic root size;	chr7:66740595	chr7:66395191~66395286:+
TGCT	cis	rs801193	1	rs7783924	ENSG00000222364.1	RNU6-96P	-5.99	2.13e-08	4.15e-05	-0.56	-0.47	Aortic root size;	chr7:66744070	chr7:66395191~66395286:+
TGCT	cis	rs801193	1	rs7789184	ENSG00000222364.1	RNU6-96P	-5.99	2.13e-08	4.15e-05	-0.56	-0.47	Aortic root size;	chr7:66745208	chr7:66395191~66395286:+
TGCT	cis	rs801193	1	rs2707854	ENSG00000222364.1	RNU6-96P	-5.99	2.13e-08	4.15e-05	-0.56	-0.47	Aortic root size;	chr7:66747610	chr7:66395191~66395286:+
TGCT	cis	rs5758659	0.652	rs133347	ENSG00000270083.1	RP1-257I20.14	5.99	2.13e-08	4.15e-05	0.44	0.47	Cognitive function;	chr22:42027641	chr22:42089630~42090028:-
TGCT	cis	rs7412746	0.658	rs4970988	ENSG00000206931.1	RNU6-1042P	-5.99	2.13e-08	4.15e-05	-0.38	-0.47	Melanoma;	chr1:150977586	chr1:150701866~150701972:+
TGCT	cis	rs801193	0.569	rs11772819	ENSG00000222364.1	RNU6-96P	-5.99	2.14e-08	4.15e-05	-0.53	-0.47	Aortic root size;	chr7:66752983	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.569	rs7800620	ENSG00000222364.1	RNU6-96P	-5.99	2.14e-08	4.15e-05	-0.53	-0.47	Aortic root size;	chr7:66758701	chr7:66395191~66395286:+
TGCT	cis	rs9733	0.596	rs12403255	ENSG00000206931.1	RNU6-1042P	5.99	2.14e-08	4.16e-05	0.36	0.47	Tonsillectomy;	chr1:150687936	chr1:150701866~150701972:+
TGCT	cis	rs17301013	0.606	rs2860907	ENSG00000227373.4	RP11-160H22.5	5.99	2.14e-08	4.17e-05	0.55	0.47	Systemic lupus erythematosus;	chr1:174203246	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs4607949	ENSG00000227373.4	RP11-160H22.5	5.99	2.14e-08	4.17e-05	0.55	0.47	Systemic lupus erythematosus;	chr1:174212218	chr1:174115300~174160004:-
TGCT	cis	rs73086581	1	rs73088416	ENSG00000229539.1	RP11-119B16.2	5.99	2.14e-08	4.17e-05	0.72	0.47	Response to antidepressants in depression;	chr20:4014629	chr20:3888239~3888868:-
TGCT	cis	rs5769707	0.554	rs10854876	ENSG00000188511.11	C22orf34	5.99	2.15e-08	4.18e-05	0.53	0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49616922	chr22:49414524~49657542:-
TGCT	cis	rs17301013	0.507	rs72717617	ENSG00000227373.4	RP11-160H22.5	5.99	2.15e-08	4.19e-05	0.57	0.47	Systemic lupus erythematosus;	chr1:174815514	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs72717618	ENSG00000227373.4	RP11-160H22.5	5.99	2.15e-08	4.19e-05	0.57	0.47	Systemic lupus erythematosus;	chr1:174816839	chr1:174115300~174160004:-
TGCT	cis	rs7617773	0.817	rs13072018	ENSG00000229759.1	MRPS18AP1	5.98	2.16e-08	4.2e-05	0.41	0.47	Coronary artery disease;	chr3:48278842	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.817	rs13094727	ENSG00000229759.1	MRPS18AP1	5.98	2.16e-08	4.2e-05	0.41	0.47	Coronary artery disease;	chr3:48281999	chr3:48256350~48256938:-
TGCT	cis	rs875971	0.756	rs2901210	ENSG00000222364.1	RNU6-96P	5.98	2.17e-08	4.21e-05	0.52	0.47	Aortic root size;	chr7:66552518	chr7:66395191~66395286:+
TGCT	cis	rs7044106	0.762	rs1158554	ENSG00000226752.6	PSMD5-AS1	-5.98	2.17e-08	4.22e-05	-0.61	-0.47	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120824828~120854385:+
TGCT	cis	rs6964833	0.935	rs34630792	ENSG00000123965.13	PMS2P5	5.98	2.18e-08	4.23e-05	0.63	0.47	Menarche (age at onset);	chr7:74646869	chr7:74894116~74897835:+
TGCT	cis	rs17301013	0.606	rs1618408	ENSG00000227373.4	RP11-160H22.5	-5.98	2.18e-08	4.23e-05	-0.56	-0.47	Systemic lupus erythematosus;	chr1:174777402	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs4652797	ENSG00000227373.4	RP11-160H22.5	5.98	2.18e-08	4.23e-05	0.57	0.47	Systemic lupus erythematosus;	chr1:174791236	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs7521109	ENSG00000227373.4	RP11-160H22.5	5.98	2.18e-08	4.23e-05	0.57	0.47	Systemic lupus erythematosus;	chr1:174802629	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs72717616	ENSG00000227373.4	RP11-160H22.5	5.98	2.18e-08	4.23e-05	0.57	0.47	Systemic lupus erythematosus;	chr1:174812711	chr1:174115300~174160004:-
TGCT	cis	rs17264034	0.861	rs55713652	ENSG00000250786.1	SNHG18	5.98	2.2e-08	4.26e-05	0.53	0.47	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9557010	chr5:9546200~9550609:+
TGCT	cis	rs17361889	0.778	rs1527219	ENSG00000224683.1	RPL36AP29	5.98	2.21e-08	4.28e-05	0.54	0.47	Pediatric bone mineral content (hip);	chr7:16206127	chr7:16208945~16209265:+
TGCT	cis	rs5769707	0.616	rs135869	ENSG00000188511.11	C22orf34	5.98	2.21e-08	4.28e-05	0.53	0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49614718	chr22:49414524~49657542:-
TGCT	cis	rs73086581	0.947	rs73084531	ENSG00000229539.1	RP11-119B16.2	5.98	2.21e-08	4.29e-05	0.72	0.47	Response to antidepressants in depression;	chr20:3897782	chr20:3888239~3888868:-
TGCT	cis	rs9733	0.519	rs1336900	ENSG00000206931.1	RNU6-1042P	5.98	2.22e-08	4.3e-05	0.35	0.47	Tonsillectomy;	chr1:150706557	chr1:150701866~150701972:+
TGCT	cis	rs801193	0.967	rs2707853	ENSG00000222364.1	RNU6-96P	-5.98	2.23e-08	4.31e-05	-0.56	-0.47	Aortic root size;	chr7:66749023	chr7:66395191~66395286:+
TGCT	cis	rs801193	1	rs2659889	ENSG00000222364.1	RNU6-96P	-5.98	2.23e-08	4.31e-05	-0.56	-0.47	Aortic root size;	chr7:66752125	chr7:66395191~66395286:+
TGCT	cis	rs7849270	0.879	rs2229419	ENSG00000268707.1	RP11-247A12.7	5.98	2.23e-08	4.31e-05	0.54	0.47	Blood metabolite ratios;	chr9:129095351	chr9:129170434~129170940:+
TGCT	cis	rs4774565	0.762	rs7164848	ENSG00000244879.4	GABPB1-AS1	5.98	2.23e-08	4.32e-05	0.38	0.47	Breast cancer;	chr15:50370833	chr15:50354959~50372202:+
TGCT	cis	rs7826238	0.539	rs2945891	ENSG00000173295.6	FAM86B3P	5.98	2.24e-08	4.34e-05	0.57	0.47	Systolic blood pressure;	chr8:8297953	chr8:8228595~8244865:+
TGCT	cis	rs76878669	0.754	rs10896113	ENSG00000254510.1	RP11-867G23.10	-5.98	2.25e-08	4.34e-05	-0.67	-0.47	Educational attainment (years of education);	chr11:66349640	chr11:66409158~66417137:+
TGCT	cis	rs17264034	0.861	rs1508798	ENSG00000250786.1	SNHG18	-5.98	2.25e-08	4.35e-05	-0.51	-0.47	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9556582	chr5:9546200~9550609:+
TGCT	cis	rs943437	0.866	rs9320387	ENSG00000227012.2	RP1-97J1.2	5.98	2.26e-08	4.37e-05	0.67	0.47	Parkinson's disease;	chr6:111951522	chr6:111900489~111901851:-
TGCT	cis	rs321358	1	rs321359	ENSG00000271584.1	RP11-89C3.4	5.98	2.26e-08	4.37e-05	0.6	0.47	Body mass index;	chr11:111125257	chr11:111091932~111097357:-
TGCT	cis	rs321358	1	rs321360	ENSG00000271584.1	RP11-89C3.4	5.98	2.26e-08	4.37e-05	0.6	0.47	Body mass index;	chr11:111125346	chr11:111091932~111097357:-
TGCT	cis	rs321358	1	rs321361	ENSG00000271584.1	RP11-89C3.4	5.98	2.26e-08	4.37e-05	0.6	0.47	Body mass index;	chr11:111125495	chr11:111091932~111097357:-
TGCT	cis	rs321358	1	rs321362	ENSG00000271584.1	RP11-89C3.4	5.98	2.26e-08	4.37e-05	0.6	0.47	Body mass index;	chr11:111125754	chr11:111091932~111097357:-
TGCT	cis	rs321358	1	rs321363	ENSG00000271584.1	RP11-89C3.4	5.98	2.26e-08	4.37e-05	0.6	0.47	Body mass index;	chr11:111125929	chr11:111091932~111097357:-
TGCT	cis	rs556990	0.76	rs3024739	ENSG00000269125.1	RP11-98F14.11	-5.97	2.27e-08	4.39e-05	-0.6	-0.47	Blood protein levels;	chr13:113165634	chr13:113165002~113165183:-
TGCT	cis	rs2882667	0.822	rs13187096	ENSG00000253404.1	AC034243.1	5.97	2.29e-08	4.41e-05	0.55	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139068399	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.858	rs11957527	ENSG00000253404.1	AC034243.1	5.97	2.29e-08	4.41e-05	0.55	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139069206	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.858	rs11242444	ENSG00000253404.1	AC034243.1	5.97	2.29e-08	4.41e-05	0.55	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070690	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.858	rs11956159	ENSG00000253404.1	AC034243.1	5.97	2.29e-08	4.41e-05	0.55	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139072879	chr5:138744434~138753309:-
TGCT	cis	rs875971	0.929	rs778712	ENSG00000222364.1	RNU6-96P	-5.97	2.29e-08	4.42e-05	-0.54	-0.47	Aortic root size;	chr7:66384991	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs778710	ENSG00000222364.1	RNU6-96P	-5.97	2.29e-08	4.42e-05	-0.54	-0.47	Aortic root size;	chr7:66389847	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.964	rs778708	ENSG00000222364.1	RNU6-96P	-5.97	2.29e-08	4.42e-05	-0.54	-0.47	Aortic root size;	chr7:66391332	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs778696	ENSG00000222364.1	RNU6-96P	-5.97	2.29e-08	4.42e-05	-0.54	-0.47	Aortic root size;	chr7:66405826	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs778694	ENSG00000222364.1	RNU6-96P	-5.97	2.29e-08	4.42e-05	-0.54	-0.47	Aortic root size;	chr7:66406571	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs4718344	ENSG00000222364.1	RNU6-96P	-5.97	2.29e-08	4.42e-05	-0.54	-0.47	Aortic root size;	chr7:66409394	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.737	rs7803424	ENSG00000222364.1	RNU6-96P	-5.97	2.29e-08	4.42e-05	-0.54	-0.47	Aortic root size;	chr7:66415618	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.83	rs7799834	ENSG00000222364.1	RNU6-96P	-5.97	2.29e-08	4.42e-05	-0.54	-0.47	Aortic root size;	chr7:66415707	chr7:66395191~66395286:+
TGCT	cis	rs17301013	0.606	rs11487399	ENSG00000227373.4	RP11-160H22.5	5.97	2.31e-08	4.45e-05	0.55	0.47	Systemic lupus erythematosus;	chr1:174527129	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs7530265	ENSG00000227373.4	RP11-160H22.5	5.97	2.32e-08	4.47e-05	0.55	0.47	Systemic lupus erythematosus;	chr1:174564603	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs12080535	ENSG00000227373.4	RP11-160H22.5	5.97	2.32e-08	4.47e-05	0.55	0.47	Systemic lupus erythematosus;	chr1:174569832	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs12083628	ENSG00000227373.4	RP11-160H22.5	5.97	2.32e-08	4.47e-05	0.55	0.47	Systemic lupus erythematosus;	chr1:174572097	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs6691118	ENSG00000227373.4	RP11-160H22.5	5.97	2.32e-08	4.47e-05	0.55	0.47	Systemic lupus erythematosus;	chr1:174577798	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.54	rs61624206	ENSG00000227373.4	RP11-160H22.5	5.97	2.32e-08	4.47e-05	0.55	0.47	Systemic lupus erythematosus;	chr1:174578374	chr1:174115300~174160004:-
TGCT	cis	rs7849270	0.959	rs10739742	ENSG00000268707.1	RP11-247A12.7	-5.97	2.33e-08	4.48e-05	-0.51	-0.47	Blood metabolite ratios;	chr9:129159389	chr9:129170434~129170940:+
TGCT	cis	rs3096299	0.685	rs4329923	ENSG00000274627.1	RP11-104N10.2	5.97	2.33e-08	4.48e-05	0.49	0.47	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89516797~89522217:+
TGCT	cis	rs73086581	1	rs14047	ENSG00000229539.1	RP11-119B16.2	5.97	2.33e-08	4.49e-05	0.71	0.47	Response to antidepressants in depression;	chr20:3933568	chr20:3888239~3888868:-
TGCT	cis	rs9733	0.596	rs11204704	ENSG00000206931.1	RNU6-1042P	5.97	2.34e-08	4.5e-05	0.36	0.47	Tonsillectomy;	chr1:150699154	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs12077833	ENSG00000206931.1	RNU6-1042P	5.97	2.34e-08	4.5e-05	0.36	0.47	Tonsillectomy;	chr1:150701857	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.519	rs2184833	ENSG00000206931.1	RNU6-1042P	5.97	2.34e-08	4.5e-05	0.36	0.47	Tonsillectomy;	chr1:150703007	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.566	rs112967224	ENSG00000206931.1	RNU6-1042P	5.97	2.34e-08	4.5e-05	0.36	0.47	Tonsillectomy;	chr1:150704787	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs72702552	ENSG00000206931.1	RNU6-1042P	5.97	2.34e-08	4.5e-05	0.36	0.47	Tonsillectomy;	chr1:150704986	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.566	rs72702554	ENSG00000206931.1	RNU6-1042P	5.97	2.34e-08	4.5e-05	0.36	0.47	Tonsillectomy;	chr1:150705758	chr1:150701866~150701972:+
TGCT	cis	rs9326248	0.581	rs6589582	ENSG00000254851.1	RP11-109L13.1	-5.97	2.35e-08	4.52e-05	-0.54	-0.47	Blood protein levels;	chr11:116958484	chr11:117135528~117138582:+
TGCT	cis	rs1061377	1	rs1897136	ENSG00000249207.1	RP11-360F5.1	-5.97	2.35e-08	4.52e-05	-0.5	-0.47	Uric acid levels;	chr4:39131242	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs1897137	ENSG00000249207.1	RP11-360F5.1	-5.97	2.35e-08	4.52e-05	-0.5	-0.47	Uric acid levels;	chr4:39131387	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs35437629	ENSG00000249207.1	RP11-360F5.1	-5.97	2.35e-08	4.52e-05	-0.5	-0.47	Uric acid levels;	chr4:39131712	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs7657926	ENSG00000249207.1	RP11-360F5.1	-5.97	2.35e-08	4.52e-05	-0.5	-0.47	Uric acid levels;	chr4:39132443	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs7681116	ENSG00000249207.1	RP11-360F5.1	-5.97	2.35e-08	4.52e-05	-0.5	-0.47	Uric acid levels;	chr4:39133015	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs11096982	ENSG00000249207.1	RP11-360F5.1	-5.97	2.35e-08	4.52e-05	-0.5	-0.47	Uric acid levels;	chr4:39133247	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs11727875	ENSG00000249207.1	RP11-360F5.1	-5.97	2.35e-08	4.52e-05	-0.5	-0.47	Uric acid levels;	chr4:39133699	chr4:39112677~39126818:-
TGCT	cis	rs1061377	0.965	rs10018622	ENSG00000249207.1	RP11-360F5.1	-5.97	2.35e-08	4.52e-05	-0.5	-0.47	Uric acid levels;	chr4:39133944	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs28607301	ENSG00000249207.1	RP11-360F5.1	-5.97	2.35e-08	4.52e-05	-0.5	-0.47	Uric acid levels;	chr4:39136460	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs36090629	ENSG00000249207.1	RP11-360F5.1	-5.97	2.35e-08	4.52e-05	-0.5	-0.47	Uric acid levels;	chr4:39137195	chr4:39112677~39126818:-
TGCT	cis	rs1061377	0.87	rs73238544	ENSG00000249207.1	RP11-360F5.1	-5.97	2.35e-08	4.52e-05	-0.5	-0.47	Uric acid levels;	chr4:39137343	chr4:39112677~39126818:-
TGCT	cis	rs875971	0.895	rs3857684	ENSG00000222364.1	RNU6-96P	-5.97	2.36e-08	4.52e-05	-0.54	-0.47	Aortic root size;	chr7:66473171	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs12533997	ENSG00000222364.1	RNU6-96P	-5.97	2.36e-08	4.52e-05	-0.54	-0.47	Aortic root size;	chr7:66500390	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.964	rs60193905	ENSG00000222364.1	RNU6-96P	-5.97	2.36e-08	4.52e-05	-0.54	-0.47	Aortic root size;	chr7:66506273	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.929	rs10950041	ENSG00000222364.1	RNU6-96P	-5.97	2.36e-08	4.52e-05	-0.54	-0.47	Aortic root size;	chr7:66508888	chr7:66395191~66395286:+
TGCT	cis	rs66887589	0.72	rs11724758	ENSG00000245958.5	RP11-33B1.1	-5.97	2.36e-08	4.53e-05	-0.45	-0.47	Diastolic blood pressure;	chr4:119318723	chr4:119454791~119552025:+
TGCT	cis	rs5769707	0.632	rs1476037	ENSG00000188511.11	C22orf34	5.97	2.36e-08	4.54e-05	0.52	0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49597729	chr22:49414524~49657542:-
TGCT	cis	rs6921919	0.789	rs1119211	ENSG00000216901.1	AL022393.7	-5.97	2.37e-08	4.54e-05	-0.57	-0.47	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28176188~28176674:+
TGCT	cis	rs11155671	0.53	rs9397398	ENSG00000216906.2	RP11-350J20.9	5.97	2.37e-08	4.54e-05	0.52	0.47	Testicular germ cell tumor;	chr6:149872467	chr6:149904243~149906418:+
TGCT	cis	rs55794721	0.509	rs873308	ENSG00000261349.1	RP3-465N24.5	5.97	2.37e-08	4.54e-05	0.46	0.47	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25266102~25267136:-
TGCT	cis	rs943437	0.866	rs481262	ENSG00000227012.2	RP1-97J1.2	5.96	2.39e-08	4.58e-05	0.64	0.47	Parkinson's disease;	chr6:111940286	chr6:111900489~111901851:-
TGCT	cis	rs1891275	0.601	rs7358034	ENSG00000228701.1	TNKS2-AS1	-5.96	2.41e-08	4.62e-05	-0.54	-0.47	Intelligence (multi-trait analysis);	chr10:91659007	chr10:91782839~91798291:-
TGCT	cis	rs2948294	0.566	rs13261997	ENSG00000173295.6	FAM86B3P	5.96	2.41e-08	4.62e-05	0.6	0.47	Red cell distribution width;	chr8:8254773	chr8:8228595~8244865:+
TGCT	cis	rs8062405	0.895	rs62036658	ENSG00000259982.1	CDC37P1	5.96	2.41e-08	4.62e-05	0.65	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28700294~28701540:-
TGCT	cis	rs55794721	0.509	rs2375313	ENSG00000224183.1	SDHDP6	-5.96	2.42e-08	4.64e-05	-0.5	-0.47	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25294164~25294643:-
TGCT	cis	rs66887589	0.72	rs2036858	ENSG00000245958.5	RP11-33B1.1	-5.96	2.43e-08	4.64e-05	-0.45	-0.47	Diastolic blood pressure;	chr4:119328082	chr4:119454791~119552025:+
TGCT	cis	rs7811142	0.779	rs111312383	ENSG00000242294.5	STAG3L5P	5.96	2.43e-08	4.65e-05	0.44	0.47	Platelet count;	chr7:100307702	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.83	rs1063945	ENSG00000242294.5	STAG3L5P	5.96	2.43e-08	4.65e-05	0.44	0.47	Platelet count;	chr7:100332824	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.83	rs11761253	ENSG00000242294.5	STAG3L5P	5.96	2.43e-08	4.65e-05	0.44	0.47	Platelet count;	chr7:100341698	chr7:100336079~100351900:+
TGCT	cis	rs6921919	0.789	rs6456814	ENSG00000216901.1	AL022393.7	5.96	2.43e-08	4.65e-05	0.57	0.47	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.789	rs13210258	ENSG00000216901.1	AL022393.7	5.96	2.43e-08	4.65e-05	0.57	0.47	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28176188~28176674:+
TGCT	cis	rs12891047	0.966	rs181572	ENSG00000258759.1	RP11-1012A1.7	5.96	2.44e-08	4.67e-05	0.41	0.47	Amyotrophic lateral sclerosis (sporadic);	chr14:67807303	chr14:67799004~67799609:+
TGCT	cis	rs875971	0.522	rs4718285	ENSG00000222364.1	RNU6-96P	-5.96	2.46e-08	4.69e-05	-0.53	-0.47	Aortic root size;	chr7:65827018	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.522	rs4718286	ENSG00000222364.1	RNU6-96P	-5.96	2.46e-08	4.69e-05	-0.53	-0.47	Aortic root size;	chr7:65827777	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.522	rs4502988	ENSG00000222364.1	RNU6-96P	-5.96	2.46e-08	4.69e-05	-0.53	-0.47	Aortic root size;	chr7:65832759	chr7:66395191~66395286:+
TGCT	cis	rs17711722	0.585	rs6942660	ENSG00000222364.1	RNU6-96P	-5.96	2.46e-08	4.69e-05	-0.53	-0.47	Calcium levels;	chr7:65837419	chr7:66395191~66395286:+
TGCT	cis	rs17711722	0.64	rs13237956	ENSG00000222364.1	RNU6-96P	-5.96	2.46e-08	4.69e-05	-0.53	-0.47	Calcium levels;	chr7:65853042	chr7:66395191~66395286:+
TGCT	cis	rs17301013	0.581	rs12082139	ENSG00000227373.4	RP11-160H22.5	5.96	2.46e-08	4.69e-05	0.55	0.47	Systemic lupus erythematosus;	chr1:174589043	chr1:174115300~174160004:-
TGCT	cis	rs875971	1	rs6460296	ENSG00000222364.1	RNU6-96P	-5.96	2.46e-08	4.69e-05	-0.54	-0.47	Aortic root size;	chr7:66430152	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.895	rs4718349	ENSG00000222364.1	RNU6-96P	-5.96	2.46e-08	4.69e-05	-0.54	-0.47	Aortic root size;	chr7:66444024	chr7:66395191~66395286:+
TGCT	cis	rs875971	1	rs2042133	ENSG00000222364.1	RNU6-96P	-5.96	2.46e-08	4.69e-05	-0.54	-0.47	Aortic root size;	chr7:66466935	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.964	rs2161065	ENSG00000222364.1	RNU6-96P	-5.96	2.46e-08	4.69e-05	-0.54	-0.47	Aortic root size;	chr7:66467918	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs12698521	ENSG00000222364.1	RNU6-96P	-5.96	2.46e-08	4.69e-05	-0.54	-0.47	Aortic root size;	chr7:66474502	chr7:66395191~66395286:+
TGCT	cis	rs755249	0.509	rs710913	ENSG00000182109.6	RP11-69E11.4	-5.96	2.46e-08	4.7e-05	-0.42	-0.47	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39524254	chr1:39522280~39546187:-
TGCT	cis	rs12908161	0.959	rs61074241	ENSG00000225151.9	GOLGA2P7	-5.96	2.46e-08	4.7e-05	-0.55	-0.47	Schizophrenia;	chr15:84790165	chr15:84199311~84230136:-
TGCT	cis	rs6452524	0.837	rs1479569	ENSG00000249664.1	CTD-2227C6.2	5.96	2.46e-08	4.7e-05	0.53	0.47	Hypertension (SNP x SNP interaction);	chr5:83081747	chr5:83012285~83013109:-
TGCT	cis	rs7397814	0.558	rs4764447	ENSG00000256673.1	RP11-599J14.2	5.96	2.48e-08	4.72e-05	0.45	0.47	IgG glycosylation;	chr12:9426513	chr12:9398355~9414851:-
TGCT	cis	rs17507216	0.628	rs8028130	ENSG00000278603.1	RP13-608F4.5	5.96	2.48e-08	4.73e-05	0.78	0.47	Excessive daytime sleepiness;	chr15:82734974	chr15:82472203~82472426:+
TGCT	cis	rs7208859	0.725	rs9897673	ENSG00000263531.1	RP13-753N3.1	5.96	2.49e-08	4.74e-05	0.79	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916348	chr17:30863921~30864940:-
TGCT	cis	rs34217772	0.68	rs17181636	ENSG00000258536.1	RP11-1053O12.1	-5.96	2.49e-08	4.75e-05	-0.39	-0.47	Myopia;	chr14:41727772	chr14:41742639~41742963:+
TGCT	cis	rs6452524	0.532	rs26263	ENSG00000249664.1	CTD-2227C6.2	5.95	2.51e-08	4.79e-05	0.52	0.47	Hypertension (SNP x SNP interaction);	chr5:83044465	chr5:83012285~83013109:-
TGCT	cis	rs12908161	0.959	rs12906348	ENSG00000225151.9	GOLGA2P7	-5.95	2.52e-08	4.8e-05	-0.54	-0.47	Schizophrenia;	chr15:84786190	chr15:84199311~84230136:-
TGCT	cis	rs2739330	0.76	rs5751761	ENSG00000272787.1	KB-226F1.2	5.95	2.52e-08	4.8e-05	0.51	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23969211~23969873:+
TGCT	cis	rs8062405	1	rs8055982	ENSG00000259982.1	CDC37P1	5.95	2.54e-08	4.81e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs7498665	ENSG00000259982.1	CDC37P1	5.95	2.54e-08	4.81e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.964	rs11864107	ENSG00000259982.1	CDC37P1	5.95	2.54e-08	4.81e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs62037371	ENSG00000259982.1	CDC37P1	5.95	2.54e-08	4.81e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs8055138	ENSG00000259982.1	CDC37P1	5.95	2.54e-08	4.81e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28700294~28701540:-
TGCT	cis	rs7104764	1	rs7483951	ENSG00000277290.1	RP11-326C3.16	-5.95	2.54e-08	4.81e-05	-0.46	-0.47	Menarche (age at onset);	chr11:231758	chr11:243099~243483:-
TGCT	cis	rs7104764	1	rs10794302	ENSG00000277290.1	RP11-326C3.16	-5.95	2.54e-08	4.81e-05	-0.46	-0.47	Menarche (age at onset);	chr11:234102	chr11:243099~243483:-
TGCT	cis	rs7104764	1	rs9795476	ENSG00000277290.1	RP11-326C3.16	-5.95	2.54e-08	4.81e-05	-0.46	-0.47	Menarche (age at onset);	chr11:235894	chr11:243099~243483:-
TGCT	cis	rs7104764	1	rs2272563	ENSG00000277290.1	RP11-326C3.16	-5.95	2.54e-08	4.81e-05	-0.46	-0.47	Menarche (age at onset);	chr11:236871	chr11:243099~243483:-
TGCT	cis	rs7104764	0.917	rs1045288	ENSG00000277290.1	RP11-326C3.16	-5.95	2.54e-08	4.81e-05	-0.46	-0.47	Menarche (age at onset);	chr11:237087	chr11:243099~243483:-
TGCT	cis	rs7104764	0.957	rs3817629	ENSG00000277290.1	RP11-326C3.16	-5.95	2.54e-08	4.81e-05	-0.46	-0.47	Menarche (age at onset);	chr11:237312	chr11:243099~243483:-
TGCT	cis	rs7104764	1	rs10902110	ENSG00000277290.1	RP11-326C3.16	-5.95	2.54e-08	4.81e-05	-0.46	-0.47	Menarche (age at onset);	chr11:237648	chr11:243099~243483:-
TGCT	cis	rs7104764	1	rs7481993	ENSG00000277290.1	RP11-326C3.16	-5.95	2.54e-08	4.81e-05	-0.46	-0.47	Menarche (age at onset);	chr11:237875	chr11:243099~243483:-
TGCT	cis	rs7104764	1	rs6598069	ENSG00000277290.1	RP11-326C3.16	-5.95	2.54e-08	4.81e-05	-0.46	-0.47	Menarche (age at onset);	chr11:240664	chr11:243099~243483:-
TGCT	cis	rs875971	0.522	rs1917563	ENSG00000222364.1	RNU6-96P	5.95	2.54e-08	4.81e-05	0.54	0.47	Aortic root size;	chr7:65950660	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.861	rs801215	ENSG00000222364.1	RNU6-96P	5.95	2.54e-08	4.81e-05	0.52	0.47	Aortic root size;	chr7:66546951	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs13536	ENSG00000222364.1	RNU6-96P	5.95	2.54e-08	4.81e-05	0.52	0.47	Aortic root size;	chr7:66554203	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs801209	ENSG00000222364.1	RNU6-96P	5.95	2.54e-08	4.81e-05	0.52	0.47	Aortic root size;	chr7:66554403	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs801206	ENSG00000222364.1	RNU6-96P	5.95	2.54e-08	4.81e-05	0.52	0.47	Aortic root size;	chr7:66556979	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs801204	ENSG00000222364.1	RNU6-96P	5.95	2.54e-08	4.81e-05	0.52	0.47	Aortic root size;	chr7:66557934	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs801203	ENSG00000222364.1	RNU6-96P	5.95	2.54e-08	4.81e-05	0.52	0.47	Aortic root size;	chr7:66558025	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.825	rs801202	ENSG00000222364.1	RNU6-96P	5.95	2.54e-08	4.81e-05	0.52	0.47	Aortic root size;	chr7:66558942	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs801195	ENSG00000222364.1	RNU6-96P	5.95	2.54e-08	4.81e-05	0.52	0.47	Aortic root size;	chr7:66561128	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs801194	ENSG00000222364.1	RNU6-96P	5.95	2.54e-08	4.81e-05	0.52	0.47	Aortic root size;	chr7:66563508	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs2024192	ENSG00000222364.1	RNU6-96P	5.95	2.54e-08	4.81e-05	0.52	0.47	Aortic root size;	chr7:66576460	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs6955837	ENSG00000222364.1	RNU6-96P	5.95	2.54e-08	4.81e-05	0.52	0.47	Aortic root size;	chr7:66578155	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.825	rs10281499	ENSG00000222364.1	RNU6-96P	5.95	2.54e-08	4.81e-05	0.52	0.47	Aortic root size;	chr7:66583979	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs4718377	ENSG00000222364.1	RNU6-96P	5.95	2.54e-08	4.81e-05	0.52	0.47	Aortic root size;	chr7:66584691	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs10278014	ENSG00000222364.1	RNU6-96P	5.95	2.54e-08	4.81e-05	0.52	0.47	Aortic root size;	chr7:66586277	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs1968126	ENSG00000222364.1	RNU6-96P	5.95	2.54e-08	4.81e-05	0.52	0.47	Aortic root size;	chr7:66592017	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs6460306	ENSG00000222364.1	RNU6-96P	5.95	2.54e-08	4.81e-05	0.52	0.47	Aortic root size;	chr7:66595806	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.798	rs12698522	ENSG00000222364.1	RNU6-96P	-5.95	2.54e-08	4.81e-05	-0.52	-0.47	Aortic root size;	chr7:66502354	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.83	rs28714531	ENSG00000222364.1	RNU6-96P	-5.95	2.54e-08	4.81e-05	-0.52	-0.47	Aortic root size;	chr7:66503250	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs12698526	ENSG00000222364.1	RNU6-96P	-5.95	2.54e-08	4.81e-05	-0.52	-0.47	Aortic root size;	chr7:66504118	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs13232191	ENSG00000222364.1	RNU6-96P	-5.95	2.54e-08	4.81e-05	-0.52	-0.47	Aortic root size;	chr7:66521661	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs35378740	ENSG00000222364.1	RNU6-96P	-5.95	2.54e-08	4.81e-05	-0.52	-0.47	Aortic root size;	chr7:66522725	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs10950043	ENSG00000222364.1	RNU6-96P	-5.95	2.54e-08	4.81e-05	-0.52	-0.47	Aortic root size;	chr7:66523623	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs17747530	ENSG00000222364.1	RNU6-96P	-5.95	2.54e-08	4.81e-05	-0.52	-0.47	Aortic root size;	chr7:66529742	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs13226170	ENSG00000222364.1	RNU6-96P	-5.95	2.54e-08	4.81e-05	-0.52	-0.47	Aortic root size;	chr7:66534311	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs2420611	ENSG00000222364.1	RNU6-96P	-5.95	2.54e-08	4.81e-05	-0.52	-0.47	Aortic root size;	chr7:66534333	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.767	rs61348003	ENSG00000222364.1	RNU6-96P	-5.95	2.54e-08	4.81e-05	-0.52	-0.47	Aortic root size;	chr7:66540947	chr7:66395191~66395286:+
TGCT	cis	rs4927850	1	rs7630875	ENSG00000242086.7	LINC00969	5.95	2.55e-08	4.81e-05	0.53	0.47	Pancreatic cancer;	chr3:196026895	chr3:195658062~195739964:+
TGCT	cis	rs5760092	0.842	rs5760103	ENSG00000273295.1	AP000350.5	5.95	2.56e-08	4.84e-05	0.66	0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23906594	chr22:23901432~23907068:-
TGCT	cis	rs17301013	0.507	rs72715218	ENSG00000227373.4	RP11-160H22.5	5.95	2.56e-08	4.84e-05	0.58	0.47	Systemic lupus erythematosus;	chr1:174529056	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs55748748	ENSG00000227373.4	RP11-160H22.5	5.95	2.56e-08	4.84e-05	0.58	0.47	Systemic lupus erythematosus;	chr1:174546252	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs41266050	ENSG00000227373.4	RP11-160H22.5	5.95	2.56e-08	4.84e-05	0.58	0.47	Systemic lupus erythematosus;	chr1:174547861	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs72715237	ENSG00000227373.4	RP11-160H22.5	5.95	2.56e-08	4.84e-05	0.58	0.47	Systemic lupus erythematosus;	chr1:174550527	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs72715240	ENSG00000227373.4	RP11-160H22.5	5.95	2.56e-08	4.84e-05	0.58	0.47	Systemic lupus erythematosus;	chr1:174560838	chr1:174115300~174160004:-
TGCT	cis	rs875971	0.83	rs778711	ENSG00000222364.1	RNU6-96P	-5.95	2.57e-08	4.85e-05	-0.52	-0.47	Aortic root size;	chr7:66386670	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs1083554	ENSG00000222364.1	RNU6-96P	-5.95	2.57e-08	4.85e-05	-0.52	-0.47	Aortic root size;	chr7:66387354	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs778707	ENSG00000222364.1	RNU6-96P	-5.95	2.57e-08	4.85e-05	-0.52	-0.47	Aortic root size;	chr7:66392040	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs778705	ENSG00000222364.1	RNU6-96P	-5.95	2.57e-08	4.85e-05	-0.52	-0.47	Aortic root size;	chr7:66396128	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs778697	ENSG00000222364.1	RNU6-96P	-5.95	2.57e-08	4.85e-05	-0.52	-0.47	Aortic root size;	chr7:66405439	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.798	rs7789615	ENSG00000222364.1	RNU6-96P	-5.95	2.57e-08	4.85e-05	-0.52	-0.47	Aortic root size;	chr7:66413674	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs6978028	ENSG00000222364.1	RNU6-96P	-5.95	2.57e-08	4.85e-05	-0.52	-0.47	Aortic root size;	chr7:66421313	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs6947339	ENSG00000222364.1	RNU6-96P	-5.95	2.57e-08	4.85e-05	-0.52	-0.47	Aortic root size;	chr7:66423483	chr7:66395191~66395286:+
TGCT	cis	rs2882667	0.858	rs10900856	ENSG00000253404.1	AC034243.1	-5.95	2.57e-08	4.85e-05	-0.55	-0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139082057	chr5:138744434~138753309:-
TGCT	cis	rs5769707	0.632	rs135876	ENSG00000188511.11	C22orf34	5.95	2.58e-08	4.87e-05	0.53	0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49619925	chr22:49414524~49657542:-
TGCT	cis	rs1061377	1	rs1061377	ENSG00000249207.1	RP11-360F5.1	-5.95	2.6e-08	4.89e-05	-0.5	-0.47	Uric acid levels;	chr4:39123130	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs1982009	ENSG00000249207.1	RP11-360F5.1	-5.95	2.6e-08	4.89e-05	-0.5	-0.47	Uric acid levels;	chr4:39123253	chr4:39112677~39126818:-
TGCT	cis	rs1061377	0.965	rs1138494	ENSG00000249207.1	RP11-360F5.1	-5.95	2.6e-08	4.89e-05	-0.5	-0.47	Uric acid levels;	chr4:39123315	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs13109200	ENSG00000249207.1	RP11-360F5.1	-5.95	2.6e-08	4.89e-05	-0.5	-0.47	Uric acid levels;	chr4:39124396	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs2890659	ENSG00000249207.1	RP11-360F5.1	-5.95	2.6e-08	4.89e-05	-0.5	-0.47	Uric acid levels;	chr4:39125401	chr4:39112677~39126818:-
TGCT	cis	rs1061377	0.965	rs1046655	ENSG00000249207.1	RP11-360F5.1	-5.95	2.6e-08	4.89e-05	-0.5	-0.47	Uric acid levels;	chr4:39126127	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs7694760	ENSG00000249207.1	RP11-360F5.1	-5.95	2.6e-08	4.89e-05	-0.5	-0.47	Uric acid levels;	chr4:39126481	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs35116118	ENSG00000249207.1	RP11-360F5.1	-5.95	2.6e-08	4.89e-05	-0.5	-0.47	Uric acid levels;	chr4:39127293	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs34771104	ENSG00000249207.1	RP11-360F5.1	-5.95	2.6e-08	4.89e-05	-0.5	-0.47	Uric acid levels;	chr4:39127432	chr4:39112677~39126818:-
TGCT	cis	rs1061377	0.932	rs35464499	ENSG00000249207.1	RP11-360F5.1	-5.95	2.6e-08	4.89e-05	-0.5	-0.47	Uric acid levels;	chr4:39127670	chr4:39112677~39126818:-
TGCT	cis	rs1061377	0.965	rs11728058	ENSG00000249207.1	RP11-360F5.1	-5.95	2.6e-08	4.89e-05	-0.5	-0.47	Uric acid levels;	chr4:39128224	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs13144374	ENSG00000249207.1	RP11-360F5.1	-5.95	2.6e-08	4.89e-05	-0.5	-0.47	Uric acid levels;	chr4:39128859	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs17508864	ENSG00000249207.1	RP11-360F5.1	-5.95	2.6e-08	4.89e-05	-0.5	-0.47	Uric acid levels;	chr4:39129025	chr4:39112677~39126818:-
TGCT	cis	rs8062405	1	rs3888190	ENSG00000259982.1	CDC37P1	5.95	2.6e-08	4.89e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28700294~28701540:-
TGCT	cis	rs7849270	0.879	rs10988197	ENSG00000268707.1	RP11-247A12.7	-5.94	2.62e-08	4.94e-05	-0.53	-0.47	Blood metabolite ratios;	chr9:129078980	chr9:129170434~129170940:+
TGCT	cis	rs875971	0.54	rs4717275	ENSG00000236529.1	RP13-254B10.1	-5.94	2.64e-08	4.97e-05	-0.35	-0.47	Aortic root size;	chr7:65800193	chr7:65840212~65840596:+
TGCT	cis	rs17711722	0.701	rs4467826	ENSG00000236529.1	RP13-254B10.1	5.94	2.64e-08	4.97e-05	0.35	0.47	Calcium levels;	chr7:65903721	chr7:65840212~65840596:+
TGCT	cis	rs858239	0.712	rs199650	ENSG00000230658.1	KLHL7-AS1	-5.94	2.64e-08	4.97e-05	-0.47	-0.47	Cerebrospinal fluid biomarker levels;	chr7:23327570	chr7:23101228~23105703:-
TGCT	cis	rs875971	0.545	rs4718325	ENSG00000226824.5	RP4-756H11.3	-5.94	2.64e-08	4.98e-05	-0.58	-0.47	Aortic root size;	chr7:66215323	chr7:66654538~66669855:+
TGCT	cis	rs17301013	0.507	rs2860725	ENSG00000227373.4	RP11-160H22.5	-5.94	2.64e-08	4.98e-05	-0.54	-0.47	Systemic lupus erythematosus;	chr1:174815447	chr1:174115300~174160004:-
TGCT	cis	rs7829975	0.511	rs2980426	ENSG00000173295.6	FAM86B3P	5.94	2.65e-08	4.99e-05	0.57	0.47	Mood instability;	chr8:8288087	chr8:8228595~8244865:+
TGCT	cis	rs875971	0.516	rs6945322	ENSG00000236529.1	RP13-254B10.1	5.94	2.65e-08	4.99e-05	0.35	0.47	Aortic root size;	chr7:65871069	chr7:65840212~65840596:+
TGCT	cis	rs17711722	0.701	rs55773927	ENSG00000236529.1	RP13-254B10.1	5.94	2.65e-08	4.99e-05	0.35	0.47	Calcium levels;	chr7:65872915	chr7:65840212~65840596:+
TGCT	cis	rs17711722	0.727	rs35850374	ENSG00000236529.1	RP13-254B10.1	5.94	2.65e-08	4.99e-05	0.35	0.47	Calcium levels;	chr7:65892789	chr7:65840212~65840596:+
TGCT	cis	rs17301013	0.507	rs1793320	ENSG00000227373.4	RP11-160H22.5	5.94	2.66e-08	5.01e-05	0.54	0.47	Systemic lupus erythematosus;	chr1:174796308	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs913688	ENSG00000227373.4	RP11-160H22.5	-5.94	2.66e-08	5.01e-05	-0.54	-0.47	Systemic lupus erythematosus;	chr1:174805080	chr1:174115300~174160004:-
TGCT	cis	rs9549367	0.713	rs3024745	ENSG00000269125.1	RP11-98F14.11	-5.94	2.67e-08	5.02e-05	-0.59	-0.47	Platelet distribution width;	chr13:113167284	chr13:113165002~113165183:-
TGCT	cis	rs2739330	0.734	rs2000467	ENSG00000272787.1	KB-226F1.2	5.94	2.68e-08	5.03e-05	0.58	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23969211~23969873:+
TGCT	cis	rs17711722	1	rs17711722	ENSG00000236529.1	RP13-254B10.1	-5.94	2.68e-08	5.04e-05	-0.35	-0.47	Calcium levels;	chr7:65806210	chr7:65840212~65840596:+
TGCT	cis	rs17711722	0.675	rs6947132	ENSG00000236529.1	RP13-254B10.1	-5.94	2.68e-08	5.04e-05	-0.35	-0.47	Calcium levels;	chr7:65808508	chr7:65840212~65840596:+
TGCT	cis	rs8062405	1	rs3088215	ENSG00000259982.1	CDC37P1	5.94	2.69e-08	5.05e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs28403629	ENSG00000259982.1	CDC37P1	5.94	2.69e-08	5.05e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs61737565	ENSG00000259982.1	CDC37P1	5.94	2.69e-08	5.05e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs4788099	ENSG00000259982.1	CDC37P1	5.94	2.69e-08	5.05e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs9972693	ENSG00000259982.1	CDC37P1	5.94	2.69e-08	5.05e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.964	rs9972768	ENSG00000259982.1	CDC37P1	5.94	2.69e-08	5.05e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.965	rs56040780	ENSG00000259982.1	CDC37P1	5.94	2.69e-08	5.05e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.965	rs62037363	ENSG00000259982.1	CDC37P1	5.94	2.69e-08	5.05e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs7205323	ENSG00000259982.1	CDC37P1	5.94	2.69e-08	5.05e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs4788101	ENSG00000259982.1	CDC37P1	5.94	2.69e-08	5.05e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs62037364	ENSG00000259982.1	CDC37P1	5.94	2.69e-08	5.05e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs62037365	ENSG00000259982.1	CDC37P1	5.94	2.69e-08	5.05e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.929	rs11150609	ENSG00000259982.1	CDC37P1	5.94	2.69e-08	5.05e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.737	rs11861132	ENSG00000259982.1	CDC37P1	5.94	2.69e-08	5.05e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs11861174	ENSG00000259982.1	CDC37P1	5.94	2.69e-08	5.05e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs4788102	ENSG00000259982.1	CDC37P1	5.94	2.69e-08	5.05e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs62037367	ENSG00000259982.1	CDC37P1	5.94	2.69e-08	5.05e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs7198606	ENSG00000259982.1	CDC37P1	5.94	2.69e-08	5.05e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.929	rs11864750	ENSG00000259982.1	CDC37P1	5.94	2.69e-08	5.05e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.964	rs7193733	ENSG00000259982.1	CDC37P1	5.94	2.69e-08	5.05e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28700294~28701540:-
TGCT	cis	rs875971	0.666	rs13242072	ENSG00000222364.1	RNU6-96P	5.94	2.69e-08	5.05e-05	0.56	0.47	Aortic root size;	chr7:66301001	chr7:66395191~66395286:+
TGCT	cis	rs4423214	0.65	rs4245442	ENSG00000254682.1	RP11-660L16.2	5.94	2.71e-08	5.07e-05	0.68	0.47	Vitamin D levels;	chr11:71509863	chr11:71448674~71452157:+
TGCT	cis	rs12908161	0.959	rs17598603	ENSG00000225151.9	GOLGA2P7	5.94	2.71e-08	5.08e-05	0.53	0.47	Schizophrenia;	chr15:84656980	chr15:84199311~84230136:-
TGCT	cis	rs10256972	0.706	rs12701970	ENSG00000226291.1	AC091729.8	-5.94	2.71e-08	5.08e-05	-0.5	-0.47	Endometriosis;Longevity;	chr7:1082322	chr7:1080863~1082178:+
TGCT	cis	rs12906542	0.507	rs4395040	ENSG00000259792.1	RP11-114H24.6	-5.94	2.73e-08	5.11e-05	-0.49	-0.47	Breast cancer;	chr15:77990191	chr15:77993405~77995289:+
TGCT	cis	rs875971	0.767	rs12668005	ENSG00000222364.1	RNU6-96P	-5.94	2.74e-08	5.12e-05	-0.52	-0.47	Aortic root size;	chr7:66444034	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.862	rs11765791	ENSG00000222364.1	RNU6-96P	-5.94	2.74e-08	5.12e-05	-0.52	-0.47	Aortic root size;	chr7:66471587	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.755	rs76288834	ENSG00000222364.1	RNU6-96P	5.93	2.76e-08	5.17e-05	0.52	0.47	Aortic root size;	chr7:66604815	chr7:66395191~66395286:+
TGCT	cis	rs5769707	0.632	rs135877	ENSG00000188511.11	C22orf34	5.93	2.77e-08	5.18e-05	0.53	0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49620354	chr22:49414524~49657542:-
TGCT	cis	rs972540	0.505	rs56023087	ENSG00000279220.1	GPR1-AS	5.93	2.77e-08	5.18e-05	0.46	0.47	Body mass index;	chr2:206283393	chr2:206203376~206266243:+
TGCT	cis	rs5769707	0.872	rs5770604	ENSG00000235111.1	RP1-29C18.8	-5.93	2.77e-08	5.18e-05	-0.39	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49637024	chr22:49612657~49615716:-
TGCT	cis	rs801193	0.548	rs2659904	ENSG00000222364.1	RNU6-96P	-5.93	2.77e-08	5.19e-05	-0.55	-0.47	Aortic root size;	chr7:66713615	chr7:66395191~66395286:+
TGCT	cis	rs9733	0.519	rs11204717	ENSG00000206931.1	RNU6-1042P	5.93	2.78e-08	5.19e-05	0.36	0.47	Tonsillectomy;	chr1:150736653	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.611	rs111842513	ENSG00000206931.1	RNU6-1042P	5.93	2.78e-08	5.19e-05	0.36	0.47	Melanoma;	chr1:150740450	chr1:150701866~150701972:+
TGCT	cis	rs2729354	0.514	rs1967179	ENSG00000265566.2	RN7SL605P	-5.93	2.81e-08	5.26e-05	-0.55	-0.47	Blood protein levels;	chr11:57581010	chr11:57528085~57528365:-
TGCT	cis	rs453301	0.592	rs4841084	ENSG00000173295.6	FAM86B3P	5.93	2.82e-08	5.27e-05	0.57	0.47	Joint mobility (Beighton score);	chr8:9026395	chr8:8228595~8244865:+
TGCT	cis	rs453301	0.653	rs2956244	ENSG00000173295.6	FAM86B3P	5.93	2.82e-08	5.27e-05	0.57	0.47	Joint mobility (Beighton score);	chr8:9027656	chr8:8228595~8244865:+
TGCT	cis	rs5769707	0.656	rs135878	ENSG00000188511.11	C22orf34	5.93	2.82e-08	5.27e-05	0.53	0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49620721	chr22:49414524~49657542:-
TGCT	cis	rs7412746	0.658	rs12405726	ENSG00000206931.1	RNU6-1042P	5.93	2.82e-08	5.27e-05	0.38	0.47	Melanoma;	chr1:150983652	chr1:150701866~150701972:+
TGCT	cis	rs17301013	0.507	rs12074107	ENSG00000227373.4	RP11-160H22.5	-5.93	2.83e-08	5.29e-05	-0.55	-0.47	Systemic lupus erythematosus;	chr1:174307926	chr1:174115300~174160004:-
TGCT	cis	rs76878669	0.561	rs905770	ENSG00000254510.1	RP11-867G23.10	5.93	2.84e-08	5.29e-05	0.63	0.47	Educational attainment (years of education);	chr11:66389294	chr11:66409158~66417137:+
TGCT	cis	rs76878669	0.561	rs7117630	ENSG00000254510.1	RP11-867G23.10	-5.93	2.84e-08	5.29e-05	-0.63	-0.47	Educational attainment (years of education);	chr11:66387306	chr11:66409158~66417137:+
TGCT	cis	rs7301826	0.967	rs4759792	ENSG00000256250.1	RP11-989F5.1	-5.93	2.85e-08	5.31e-05	-0.51	-0.47	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810606~130812438:+
TGCT	cis	rs524281	1	rs565198	ENSG00000255320.1	RP11-755F10.1	-5.93	2.85e-08	5.32e-05	-0.56	-0.47	Electroencephalogram traits;	chr11:66146037	chr11:66244840~66246239:-
TGCT	cis	rs9326248	0.53	rs2471884	ENSG00000254851.1	RP11-109L13.1	-5.93	2.86e-08	5.33e-05	-0.92	-0.47	Blood protein levels;	chr11:117139604	chr11:117135528~117138582:+
TGCT	cis	rs1153858	0.723	rs4580098	ENSG00000259520.4	CTD-2651B20.3	-5.92	2.88e-08	5.37e-05	-0.43	-0.47	Homoarginine levels;	chr15:45304711	chr15:45251580~45279251:-
TGCT	cis	rs1153858	0.723	rs1719238	ENSG00000259520.4	CTD-2651B20.3	5.92	2.88e-08	5.37e-05	0.43	0.47	Homoarginine levels;	chr15:45302568	chr15:45251580~45279251:-
TGCT	cis	rs9549367	0.789	rs12584813	ENSG00000269125.1	RP11-98F14.11	-5.92	2.88e-08	5.37e-05	-0.66	-0.47	Platelet distribution width;	chr13:113241129	chr13:113165002~113165183:-
TGCT	cis	rs916888	0.61	rs199530	ENSG00000262500.1	RP11-259G18.2	-5.92	2.88e-08	5.38e-05	-0.6	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46243606~46245044:+
TGCT	cis	rs8062405	0.679	rs72793818	ENSG00000259982.1	CDC37P1	5.92	2.91e-08	5.42e-05	0.63	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28700294~28701540:-
TGCT	cis	rs11098499	0.71	rs6851130	ENSG00000245958.5	RP11-33B1.1	5.92	2.91e-08	5.42e-05	0.47	0.47	Corneal astigmatism;	chr4:119212557	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.739	rs4833612	ENSG00000245958.5	RP11-33B1.1	5.92	2.91e-08	5.42e-05	0.47	0.47	Corneal astigmatism;	chr4:119226441	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.739	rs10013032	ENSG00000245958.5	RP11-33B1.1	5.92	2.91e-08	5.42e-05	0.47	0.47	Corneal astigmatism;	chr4:119228264	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.739	rs951570	ENSG00000245958.5	RP11-33B1.1	5.92	2.91e-08	5.42e-05	0.47	0.47	Corneal astigmatism;	chr4:119229312	chr4:119454791~119552025:+
TGCT	cis	rs5760092	0.618	rs4461358	ENSG00000218537.1	MIF-AS1	-5.92	2.91e-08	5.43e-05	-0.67	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23894426~23898930:-
TGCT	cis	rs6452524	0.868	rs17205699	ENSG00000249664.1	CTD-2227C6.2	5.92	2.92e-08	5.45e-05	0.51	0.47	Hypertension (SNP x SNP interaction);	chr5:83098479	chr5:83012285~83013109:-
TGCT	cis	rs8062405	1	rs62036622	ENSG00000259982.1	CDC37P1	5.92	2.94e-08	5.47e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs72793812	ENSG00000259982.1	CDC37P1	5.92	2.94e-08	5.47e-05	0.64	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28700294~28701540:-
TGCT	cis	rs6700559	0.81	rs2808250	ENSG00000260088.1	RP11-92G12.3	-5.92	2.94e-08	5.47e-05	-0.53	-0.47	Coronary artery disease;	chr1:200623419	chr1:200669507~200694250:+
TGCT	cis	rs17264034	0.861	rs56344213	ENSG00000250786.1	SNHG18	5.92	2.95e-08	5.48e-05	0.51	0.47	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9553756	chr5:9546200~9550609:+
TGCT	cis	rs11155671	0.53	rs7756850	ENSG00000216906.2	RP11-350J20.9	5.92	2.97e-08	5.51e-05	0.51	0.47	Testicular germ cell tumor;	chr6:149891460	chr6:149904243~149906418:+
TGCT	cis	rs11155671	0.53	rs9371223	ENSG00000216906.2	RP11-350J20.9	5.92	2.97e-08	5.51e-05	0.51	0.47	Testicular germ cell tumor;	chr6:149893670	chr6:149904243~149906418:+
TGCT	cis	rs11155671	0.53	rs2342769	ENSG00000216906.2	RP11-350J20.9	5.92	2.97e-08	5.51e-05	0.51	0.47	Testicular germ cell tumor;	chr6:149895371	chr6:149904243~149906418:+
TGCT	cis	rs875971	0.545	rs10261710	ENSG00000226824.5	RP4-756H11.3	-5.92	2.99e-08	5.54e-05	-0.59	-0.47	Aortic root size;	chr7:66249202	chr7:66654538~66669855:+
TGCT	cis	rs9890032	0.57	rs8068504	ENSG00000266490.1	CTD-2349P21.9	5.92	2.99e-08	5.54e-05	0.38	0.47	Hip circumference adjusted for BMI;	chr17:30785052	chr17:30792372~30792833:+
TGCT	cis	rs9890032	0.618	rs1979507	ENSG00000266490.1	CTD-2349P21.9	5.92	2.99e-08	5.54e-05	0.38	0.47	Hip circumference adjusted for BMI;	chr17:30811002	chr17:30792372~30792833:+
TGCT	cis	rs6452524	0.836	rs62372713	ENSG00000249664.1	CTD-2227C6.2	5.92	3e-08	5.56e-05	0.51	0.47	Hypertension (SNP x SNP interaction);	chr5:83090635	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.868	rs62372714	ENSG00000249664.1	CTD-2227C6.2	5.92	3e-08	5.56e-05	0.51	0.47	Hypertension (SNP x SNP interaction);	chr5:83095449	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.868	rs10057303	ENSG00000249664.1	CTD-2227C6.2	5.92	3e-08	5.56e-05	0.51	0.47	Hypertension (SNP x SNP interaction);	chr5:83098564	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.868	rs2386235	ENSG00000249664.1	CTD-2227C6.2	5.92	3e-08	5.56e-05	0.51	0.47	Hypertension (SNP x SNP interaction);	chr5:83101452	chr5:83012285~83013109:-
TGCT	cis	rs9326248	0.559	rs4938334	ENSG00000254851.1	RP11-109L13.1	-5.92	3e-08	5.56e-05	-0.57	-0.47	Blood protein levels;	chr11:117060326	chr11:117135528~117138582:+
TGCT	cis	rs7617773	0.638	rs7644414	ENSG00000229759.1	MRPS18AP1	5.91	3.02e-08	5.59e-05	0.41	0.47	Coronary artery disease;	chr3:48257589	chr3:48256350~48256938:-
TGCT	cis	rs7044106	0.708	rs1324472	ENSG00000226752.6	PSMD5-AS1	-5.91	3.02e-08	5.59e-05	-0.58	-0.47	Hip circumference adjusted for BMI;	chr9:120612832	chr9:120824828~120854385:+
TGCT	cis	rs7617773	0.784	rs9850672	ENSG00000229759.1	MRPS18AP1	5.91	3.03e-08	5.6e-05	0.4	0.47	Coronary artery disease;	chr3:48259682	chr3:48256350~48256938:-
TGCT	cis	rs5760092	0.842	rs5751763	ENSG00000273295.1	AP000350.5	5.91	3.06e-08	5.65e-05	0.65	0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23905606	chr22:23901432~23907068:-
TGCT	cis	rs7044106	0.791	rs7036196	ENSG00000226752.6	PSMD5-AS1	-5.91	3.06e-08	5.65e-05	-0.6	-0.47	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120824828~120854385:+
TGCT	cis	rs7044106	0.791	rs7036766	ENSG00000226752.6	PSMD5-AS1	-5.91	3.06e-08	5.65e-05	-0.6	-0.47	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120824828~120854385:+
TGCT	cis	rs7044106	0.791	rs3904196	ENSG00000226752.6	PSMD5-AS1	-5.91	3.06e-08	5.65e-05	-0.6	-0.47	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120824828~120854385:+
TGCT	cis	rs7849270	0.959	rs10760591	ENSG00000268707.1	RP11-247A12.7	-5.91	3.06e-08	5.65e-05	-0.51	-0.47	Blood metabolite ratios;	chr9:129152749	chr9:129170434~129170940:+
TGCT	cis	rs7849270	1	rs10988232	ENSG00000268707.1	RP11-247A12.7	-5.91	3.06e-08	5.65e-05	-0.51	-0.47	Blood metabolite ratios;	chr9:129153069	chr9:129170434~129170940:+
TGCT	cis	rs7849270	0.959	rs10988233	ENSG00000268707.1	RP11-247A12.7	-5.91	3.06e-08	5.65e-05	-0.51	-0.47	Blood metabolite ratios;	chr9:129153647	chr9:129170434~129170940:+
TGCT	cis	rs7849270	1	rs1009242	ENSG00000268707.1	RP11-247A12.7	-5.91	3.06e-08	5.65e-05	-0.51	-0.47	Blood metabolite ratios;	chr9:129154553	chr9:129170434~129170940:+
TGCT	cis	rs7849270	0.959	rs913276	ENSG00000268707.1	RP11-247A12.7	-5.91	3.06e-08	5.65e-05	-0.51	-0.47	Blood metabolite ratios;	chr9:129154885	chr9:129170434~129170940:+
TGCT	cis	rs7849270	1	rs7868408	ENSG00000268707.1	RP11-247A12.7	-5.91	3.06e-08	5.65e-05	-0.51	-0.47	Blood metabolite ratios;	chr9:129155585	chr9:129170434~129170940:+
TGCT	cis	rs9733	0.519	rs1336899	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Tonsillectomy;	chr1:150706434	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs11586422	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Tonsillectomy;	chr1:150706882	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs72702556	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Tonsillectomy;	chr1:150707639	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs72702557	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Tonsillectomy;	chr1:150707654	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs17606613	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Tonsillectomy;	chr1:150710539	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.543	rs72702558	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Tonsillectomy;	chr1:150710775	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.628	rs11807409	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Tonsillectomy;	chr1:150710947	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.565	rs11804276	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Tonsillectomy;	chr1:150713285	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.611	rs11803940	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Melanoma;	chr1:150713359	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs12072339	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Tonsillectomy;	chr1:150713623	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs34600506	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Tonsillectomy;	chr1:150715332	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs72702570	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Tonsillectomy;	chr1:150715720	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs11582840	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Tonsillectomy;	chr1:150716011	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.569	rs11588404	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Tonsillectomy;	chr1:150716053	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs72702573	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Tonsillectomy;	chr1:150716574	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs72702580	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Tonsillectomy;	chr1:150718809	chr1:150701866~150701972:+
TGCT	cis	rs4970988	0.501	rs11204713	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Urate levels;	chr1:150722147	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.525	rs11584184	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Tonsillectomy;	chr1:150723213	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs6669369	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Tonsillectomy;	chr1:150723416	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs6681990	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Tonsillectomy;	chr1:150723453	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs6692960	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Tonsillectomy;	chr1:150723489	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs72702585	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Tonsillectomy;	chr1:150723951	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs12086472	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Tonsillectomy;	chr1:150725234	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.628	rs7540874	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Tonsillectomy;	chr1:150730187	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs1136808	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Tonsillectomy;	chr1:150730241	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs1415148	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Tonsillectomy;	chr1:150733279	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.519	rs7521898	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Tonsillectomy;	chr1:150735120	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.519	rs7511673	ENSG00000206931.1	RNU6-1042P	5.91	3.06e-08	5.65e-05	0.36	0.47	Tonsillectomy;	chr1:150735160	chr1:150701866~150701972:+
TGCT	cis	rs76878669	0.516	rs7104570	ENSG00000254510.1	RP11-867G23.10	5.91	3.07e-08	5.65e-05	0.63	0.47	Educational attainment (years of education);	chr11:66391627	chr11:66409158~66417137:+
TGCT	cis	rs76878669	0.561	rs7105015	ENSG00000254510.1	RP11-867G23.10	5.91	3.07e-08	5.65e-05	0.63	0.47	Educational attainment (years of education);	chr11:66391919	chr11:66409158~66417137:+
TGCT	cis	rs2732480	0.538	rs2468943	ENSG00000258273.1	RP11-370I10.4	5.91	3.07e-08	5.65e-05	0.55	0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48333755~48333901:-
TGCT	cis	rs17301013	0.507	rs61528155	ENSG00000227373.4	RP11-160H22.5	5.91	3.07e-08	5.65e-05	0.55	0.47	Systemic lupus erythematosus;	chr1:174276140	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12066700	ENSG00000227373.4	RP11-160H22.5	5.91	3.07e-08	5.65e-05	0.55	0.47	Systemic lupus erythematosus;	chr1:174282054	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12060460	ENSG00000227373.4	RP11-160H22.5	5.91	3.07e-08	5.65e-05	0.55	0.47	Systemic lupus erythematosus;	chr1:174284513	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs11806996	ENSG00000227373.4	RP11-160H22.5	5.91	3.08e-08	5.67e-05	0.58	0.47	Systemic lupus erythematosus;	chr1:174654784	chr1:174115300~174160004:-
TGCT	cis	rs9733	0.596	rs2867300	ENSG00000206931.1	RNU6-1042P	5.91	3.1e-08	5.7e-05	0.36	0.47	Tonsillectomy;	chr1:150694514	chr1:150701866~150701972:+
TGCT	cis	rs1832871	0.578	rs262820	ENSG00000188451.8	SRP72P2	5.91	3.1e-08	5.71e-05	0.4	0.47	Height;	chr6:158242069	chr6:158237336~158242797:-
TGCT	cis	rs1832871	0.619	rs262821	ENSG00000188451.8	SRP72P2	5.91	3.1e-08	5.71e-05	0.4	0.47	Height;	chr6:158244165	chr6:158237336~158242797:-
TGCT	cis	rs1832871	0.619	rs262823	ENSG00000188451.8	SRP72P2	5.91	3.1e-08	5.71e-05	0.4	0.47	Height;	chr6:158255117	chr6:158237336~158242797:-
TGCT	cis	rs858239	0.676	rs274032	ENSG00000230658.1	KLHL7-AS1	5.91	3.1e-08	5.71e-05	0.47	0.47	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23101228~23105703:-
TGCT	cis	rs6452524	0.868	rs11746977	ENSG00000249664.1	CTD-2227C6.2	5.91	3.1e-08	5.71e-05	0.51	0.47	Hypertension (SNP x SNP interaction);	chr5:83085581	chr5:83012285~83013109:-
TGCT	cis	rs6003958	1	rs6003958	ENSG00000225282.1	AP000350.6	-5.91	3.12e-08	5.73e-05	-0.66	-0.47	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23926900~23929574:+
TGCT	cis	rs5760092	0.755	rs6003959	ENSG00000225282.1	AP000350.6	-5.91	3.12e-08	5.73e-05	-0.66	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23926900~23929574:+
TGCT	cis	rs875971	0.545	rs12671152	ENSG00000226824.5	RP4-756H11.3	-5.91	3.13e-08	5.75e-05	-0.58	-0.47	Aortic root size;	chr7:66311140	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.522	rs4718285	ENSG00000236529.1	RP13-254B10.1	5.91	3.14e-08	5.77e-05	0.35	0.47	Aortic root size;	chr7:65827018	chr7:65840212~65840596:+
TGCT	cis	rs875971	0.522	rs4718286	ENSG00000236529.1	RP13-254B10.1	5.91	3.14e-08	5.77e-05	0.35	0.47	Aortic root size;	chr7:65827777	chr7:65840212~65840596:+
TGCT	cis	rs875971	0.522	rs4502988	ENSG00000236529.1	RP13-254B10.1	5.91	3.14e-08	5.77e-05	0.35	0.47	Aortic root size;	chr7:65832759	chr7:65840212~65840596:+
TGCT	cis	rs17711722	0.585	rs6942660	ENSG00000236529.1	RP13-254B10.1	5.91	3.14e-08	5.77e-05	0.35	0.47	Calcium levels;	chr7:65837419	chr7:65840212~65840596:+
TGCT	cis	rs17711722	0.64	rs13237956	ENSG00000236529.1	RP13-254B10.1	5.91	3.14e-08	5.77e-05	0.35	0.47	Calcium levels;	chr7:65853042	chr7:65840212~65840596:+
TGCT	cis	rs8040855	0.77	rs8023774	ENSG00000259295.5	CSPG4P12	-5.91	3.16e-08	5.8e-05	-0.65	-0.47	Bulimia nervosa;	chr15:85155685	chr15:85191438~85213905:+
TGCT	cis	rs786425	0.77	rs7313032	ENSG00000278112.1	RP11-972P1.11	5.9	3.17e-08	5.82e-05	0.53	0.47	Pubertal anthropometrics;	chr12:123688184	chr12:123519390~123519856:-
TGCT	cis	rs5758659	0.652	rs1063392	ENSG00000270083.1	RP1-257I20.14	-5.9	3.17e-08	5.82e-05	-0.44	-0.47	Cognitive function;	chr22:42058946	chr22:42089630~42090028:-
TGCT	cis	rs786425	0.77	rs7306549	ENSG00000278112.1	RP11-972P1.11	5.9	3.18e-08	5.83e-05	0.54	0.47	Pubertal anthropometrics;	chr12:123672350	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.77	rs7313140	ENSG00000278112.1	RP11-972P1.11	5.9	3.18e-08	5.83e-05	0.54	0.47	Pubertal anthropometrics;	chr12:123672641	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.77	rs7133199	ENSG00000278112.1	RP11-972P1.11	5.9	3.18e-08	5.83e-05	0.54	0.47	Pubertal anthropometrics;	chr12:123674638	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.77	rs7134074	ENSG00000278112.1	RP11-972P1.11	5.9	3.18e-08	5.83e-05	0.54	0.47	Pubertal anthropometrics;	chr12:123675338	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.77	rs35158437	ENSG00000278112.1	RP11-972P1.11	5.9	3.18e-08	5.83e-05	0.54	0.47	Pubertal anthropometrics;	chr12:123676217	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.77	rs7960951	ENSG00000278112.1	RP11-972P1.11	5.9	3.18e-08	5.83e-05	0.54	0.47	Pubertal anthropometrics;	chr12:123681282	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.77	rs7974279	ENSG00000278112.1	RP11-972P1.11	5.9	3.18e-08	5.83e-05	0.54	0.47	Pubertal anthropometrics;	chr12:123681864	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.77	rs7964443	ENSG00000278112.1	RP11-972P1.11	5.9	3.18e-08	5.83e-05	0.54	0.47	Pubertal anthropometrics;	chr12:123681953	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.77	rs7313261	ENSG00000278112.1	RP11-972P1.11	5.9	3.18e-08	5.83e-05	0.54	0.47	Pubertal anthropometrics;	chr12:123682390	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.77	rs7308862	ENSG00000278112.1	RP11-972P1.11	5.9	3.18e-08	5.83e-05	0.54	0.47	Pubertal anthropometrics;	chr12:123686604	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.77	rs7297576	ENSG00000278112.1	RP11-972P1.11	5.9	3.18e-08	5.83e-05	0.54	0.47	Pubertal anthropometrics;	chr12:123686776	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.77	rs7298831	ENSG00000278112.1	RP11-972P1.11	5.9	3.18e-08	5.83e-05	0.54	0.47	Pubertal anthropometrics;	chr12:123688008	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.77	rs11829958	ENSG00000278112.1	RP11-972P1.11	5.9	3.18e-08	5.83e-05	0.54	0.47	Pubertal anthropometrics;	chr12:123688458	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.77	rs11609591	ENSG00000278112.1	RP11-972P1.11	5.9	3.18e-08	5.83e-05	0.54	0.47	Pubertal anthropometrics;	chr12:123689518	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.77	rs35114195	ENSG00000278112.1	RP11-972P1.11	5.9	3.18e-08	5.83e-05	0.54	0.47	Pubertal anthropometrics;	chr12:123691466	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.77	rs12828633	ENSG00000278112.1	RP11-972P1.11	5.9	3.18e-08	5.83e-05	0.54	0.47	Pubertal anthropometrics;	chr12:123695073	chr12:123519390~123519856:-
TGCT	cis	rs9322193	0.962	rs7740784	ENSG00000216906.2	RP11-350J20.9	5.9	3.19e-08	5.84e-05	0.54	0.47	Lung cancer;	chr6:149833364	chr6:149904243~149906418:+
TGCT	cis	rs7174755	0.743	rs4777035	ENSG00000260657.2	RP11-315D16.4	-5.9	3.19e-08	5.84e-05	-0.44	-0.47	Major depressive disorder;	chr15:68312831	chr15:68267792~68277994:-
TGCT	cis	rs17264034	0.861	rs1614229	ENSG00000250786.1	SNHG18	5.9	3.19e-08	5.85e-05	0.52	0.47	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9546883	chr5:9546200~9550609:+
TGCT	cis	rs17264034	0.861	rs1651285	ENSG00000250786.1	SNHG18	5.9	3.19e-08	5.85e-05	0.52	0.47	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9547829	chr5:9546200~9550609:+
TGCT	cis	rs17264034	0.808	rs1706987	ENSG00000250786.1	SNHG18	5.9	3.19e-08	5.85e-05	0.52	0.47	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9547853	chr5:9546200~9550609:+
TGCT	cis	rs17264034	0.861	rs1398337	ENSG00000250786.1	SNHG18	5.9	3.19e-08	5.85e-05	0.52	0.47	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9547986	chr5:9546200~9550609:+
TGCT	cis	rs17264034	0.821	rs374218	ENSG00000250786.1	SNHG18	5.9	3.19e-08	5.85e-05	0.52	0.47	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9548331	chr5:9546200~9550609:+
TGCT	cis	rs17264034	0.861	rs431288	ENSG00000250786.1	SNHG18	5.9	3.19e-08	5.85e-05	0.52	0.47	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9549347	chr5:9546200~9550609:+
TGCT	cis	rs7617773	0.746	rs4130995	ENSG00000229759.1	MRPS18AP1	5.9	3.2e-08	5.86e-05	0.38	0.47	Coronary artery disease;	chr3:48316765	chr3:48256350~48256938:-
TGCT	cis	rs1832871	0.619	rs262826	ENSG00000188451.8	SRP72P2	5.9	3.21e-08	5.88e-05	0.4	0.47	Height;	chr6:158259535	chr6:158237336~158242797:-
TGCT	cis	rs4691139	0.903	rs6812176	ENSG00000250227.1	TRIM60P14	5.9	3.22e-08	5.9e-05	0.52	0.47	Ovarian cancer in BRCA1 mutation carriers;	chr4:164998820	chr4:164915565~164916983:+
TGCT	cis	rs5760092	0.618	rs5996631	ENSG00000218537.1	MIF-AS1	-5.9	3.23e-08	5.91e-05	-0.66	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23894426~23898930:-
TGCT	cis	rs2739330	0.587	rs4820571	ENSG00000225282.1	AP000350.6	5.9	3.24e-08	5.92e-05	0.54	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23926900~23929574:+
TGCT	cis	rs6921919	0.789	rs6912584	ENSG00000216901.1	AL022393.7	5.9	3.26e-08	5.94e-05	0.58	0.47	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28176188~28176674:+
TGCT	cis	rs943437	0.611	rs58526762	ENSG00000227012.2	RP1-97J1.2	5.9	3.26e-08	5.94e-05	0.89	0.47	Parkinson's disease;	chr6:111874771	chr6:111900489~111901851:-
TGCT	cis	rs943437	0.673	rs12663341	ENSG00000227012.2	RP1-97J1.2	5.9	3.26e-08	5.94e-05	0.89	0.47	Parkinson's disease;	chr6:111884414	chr6:111900489~111901851:-
TGCT	cis	rs943437	0.673	rs11153321	ENSG00000227012.2	RP1-97J1.2	5.9	3.26e-08	5.94e-05	0.89	0.47	Parkinson's disease;	chr6:111885764	chr6:111900489~111901851:-
TGCT	cis	rs943437	0.673	rs9384814	ENSG00000227012.2	RP1-97J1.2	5.9	3.26e-08	5.94e-05	0.89	0.47	Parkinson's disease;	chr6:111885992	chr6:111900489~111901851:-
TGCT	cis	rs9733	0.596	rs56058687	ENSG00000206931.1	RNU6-1042P	5.9	3.26e-08	5.95e-05	0.37	0.47	Tonsillectomy;	chr1:150662590	chr1:150701866~150701972:+
TGCT	cis	rs17301013	0.606	rs7536987	ENSG00000227373.4	RP11-160H22.5	5.9	3.27e-08	5.97e-05	0.53	0.47	Systemic lupus erythematosus;	chr1:174367978	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.556	rs10912774	ENSG00000227373.4	RP11-160H22.5	5.9	3.27e-08	5.97e-05	0.53	0.47	Systemic lupus erythematosus;	chr1:174387706	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.606	rs16846938	ENSG00000227373.4	RP11-160H22.5	5.9	3.27e-08	5.97e-05	0.53	0.47	Systemic lupus erythematosus;	chr1:174400537	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.632	rs10912782	ENSG00000227373.4	RP11-160H22.5	5.9	3.27e-08	5.97e-05	0.53	0.47	Systemic lupus erythematosus;	chr1:174418758	chr1:174115300~174160004:-
TGCT	cis	rs3091242	0.9	rs669063	ENSG00000261349.1	RP3-465N24.5	-5.9	3.28e-08	5.98e-05	-0.48	-0.47	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25266102~25267136:-
TGCT	cis	rs9326248	0.581	rs12225187	ENSG00000254851.1	RP11-109L13.1	-5.9	3.28e-08	5.98e-05	-0.55	-0.47	Blood protein levels;	chr11:116922515	chr11:117135528~117138582:+
TGCT	cis	rs17264034	0.861	rs414396	ENSG00000250786.1	SNHG18	5.9	3.29e-08	5.99e-05	0.52	0.47	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9550596	chr5:9546200~9550609:+
TGCT	cis	rs875971	0.597	rs11763224	ENSG00000226824.5	RP4-756H11.3	-5.9	3.3e-08	6.01e-05	-0.57	-0.47	Aortic root size;	chr7:66518628	chr7:66654538~66669855:+
TGCT	cis	rs17301013	0.507	rs72715294	ENSG00000227373.4	RP11-160H22.5	5.9	3.3e-08	6.01e-05	0.57	0.47	Systemic lupus erythematosus;	chr1:174754922	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs1813136	ENSG00000227373.4	RP11-160H22.5	5.9	3.3e-08	6.01e-05	0.57	0.47	Systemic lupus erythematosus;	chr1:174756656	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs60811893	ENSG00000227373.4	RP11-160H22.5	5.9	3.3e-08	6.01e-05	0.57	0.47	Systemic lupus erythematosus;	chr1:174765968	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs72715300	ENSG00000227373.4	RP11-160H22.5	5.9	3.3e-08	6.01e-05	0.57	0.47	Systemic lupus erythematosus;	chr1:174768405	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs55844798	ENSG00000227373.4	RP11-160H22.5	5.9	3.3e-08	6.01e-05	0.57	0.47	Systemic lupus erythematosus;	chr1:174768973	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs72717608	ENSG00000227373.4	RP11-160H22.5	5.9	3.3e-08	6.01e-05	0.57	0.47	Systemic lupus erythematosus;	chr1:174788316	chr1:174115300~174160004:-
TGCT	cis	rs66887589	0.592	rs28580295	ENSG00000245958.5	RP11-33B1.1	-5.9	3.31e-08	6.03e-05	-0.44	-0.47	Diastolic blood pressure;	chr4:119357718	chr4:119454791~119552025:+
TGCT	cis	rs66887589	0.592	rs62320740	ENSG00000245958.5	RP11-33B1.1	-5.9	3.31e-08	6.03e-05	-0.44	-0.47	Diastolic blood pressure;	chr4:119358331	chr4:119454791~119552025:+
TGCT	cis	rs6964833	1	rs6964833	ENSG00000123965.13	PMS2P5	5.89	3.34e-08	6.07e-05	0.61	0.47	Menarche (age at onset);	chr7:74687575	chr7:74894116~74897835:+
TGCT	cis	rs34217772	0.68	rs61990345	ENSG00000258536.1	RP11-1053O12.1	5.89	3.35e-08	6.09e-05	0.4	0.47	Myopia;	chr14:41725446	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.64	rs61990347	ENSG00000258536.1	RP11-1053O12.1	5.89	3.35e-08	6.09e-05	0.4	0.47	Myopia;	chr14:41729996	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.563	rs1597049	ENSG00000258536.1	RP11-1053O12.1	5.89	3.35e-08	6.09e-05	0.4	0.47	Myopia;	chr14:41730116	chr14:41742639~41742963:+
TGCT	cis	rs1320333	0.772	rs35181861	ENSG00000233296.1	AC092159.2	5.89	3.36e-08	6.09e-05	0.66	0.47	Obesity-related traits;	chr2:679483	chr2:677186~697371:+
TGCT	cis	rs7412746	0.571	rs12402939	ENSG00000206931.1	RNU6-1042P	5.89	3.36e-08	6.1e-05	0.38	0.47	Melanoma;	chr1:150642618	chr1:150701866~150701972:+
TGCT	cis	rs748404	0.587	rs690276	ENSG00000205771.5	CATSPER2P1	-5.89	3.36e-08	6.1e-05	-0.53	-0.47	Lung cancer;	chr15:43412360	chr15:43726918~43747094:-
TGCT	cis	rs8072100	0.967	rs9894905	ENSG00000228782.6	CTD-2026D20.3	5.89	3.37e-08	6.11e-05	0.58	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408616	chr17:47450568~47492492:-
TGCT	cis	rs8072100	0.967	rs4338849	ENSG00000228782.6	CTD-2026D20.3	5.89	3.37e-08	6.11e-05	0.58	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435117	chr17:47450568~47492492:-
TGCT	cis	rs17301013	0.507	rs10489256	ENSG00000227373.4	RP11-160H22.5	5.89	3.38e-08	6.12e-05	0.55	0.47	Systemic lupus erythematosus;	chr1:174359663	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs4651016	ENSG00000227373.4	RP11-160H22.5	5.89	3.38e-08	6.12e-05	0.55	0.47	Systemic lupus erythematosus;	chr1:174375146	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs16846949	ENSG00000227373.4	RP11-160H22.5	5.89	3.38e-08	6.12e-05	0.55	0.47	Systemic lupus erythematosus;	chr1:174402071	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs7413513	ENSG00000227373.4	RP11-160H22.5	5.89	3.38e-08	6.12e-05	0.55	0.47	Systemic lupus erythematosus;	chr1:174403163	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs74128393	ENSG00000227373.4	RP11-160H22.5	5.89	3.38e-08	6.12e-05	0.55	0.47	Systemic lupus erythematosus;	chr1:174407961	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs11799535	ENSG00000227373.4	RP11-160H22.5	5.89	3.38e-08	6.12e-05	0.55	0.47	Systemic lupus erythematosus;	chr1:174415790	chr1:174115300~174160004:-
TGCT	cis	rs73086581	1	rs73088421	ENSG00000229539.1	RP11-119B16.2	5.89	3.39e-08	6.15e-05	0.72	0.47	Response to antidepressants in depression;	chr20:4017224	chr20:3888239~3888868:-
TGCT	cis	rs748404	0.578	rs510108	ENSG00000205771.5	CATSPER2P1	-5.89	3.4e-08	6.16e-05	-0.53	-0.47	Lung cancer;	chr15:43313241	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.578	rs507178	ENSG00000205771.5	CATSPER2P1	-5.89	3.4e-08	6.16e-05	-0.53	-0.47	Lung cancer;	chr15:43317937	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.578	rs478028	ENSG00000205771.5	CATSPER2P1	-5.89	3.4e-08	6.16e-05	-0.53	-0.47	Lung cancer;	chr15:43318574	chr15:43726918~43747094:-
TGCT	cis	rs17301013	0.507	rs3118990	ENSG00000227373.4	RP11-160H22.5	-5.89	3.4e-08	6.17e-05	-0.55	-0.47	Systemic lupus erythematosus;	chr1:174818586	chr1:174115300~174160004:-
TGCT	cis	rs34217772	0.68	rs61990339	ENSG00000258536.1	RP11-1053O12.1	5.89	3.4e-08	6.17e-05	0.4	0.47	Myopia;	chr14:41716441	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.622	rs61990342	ENSG00000258536.1	RP11-1053O12.1	5.89	3.4e-08	6.17e-05	0.4	0.47	Myopia;	chr14:41719148	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.68	rs17181615	ENSG00000258536.1	RP11-1053O12.1	5.89	3.4e-08	6.17e-05	0.4	0.47	Myopia;	chr14:41719296	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.68	rs72686528	ENSG00000258536.1	RP11-1053O12.1	5.89	3.4e-08	6.17e-05	0.4	0.47	Myopia;	chr14:41721738	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.57	rs113771571	ENSG00000258536.1	RP11-1053O12.1	5.89	3.4e-08	6.17e-05	0.4	0.47	Myopia;	chr14:41722561	chr14:41742639~41742963:+
TGCT	cis	rs875971	0.571	rs160647	ENSG00000226824.5	RP4-756H11.3	5.89	3.42e-08	6.19e-05	0.59	0.47	Aortic root size;	chr7:66089365	chr7:66654538~66669855:+
TGCT	cis	rs950027	0.787	rs1153845	ENSG00000259520.4	CTD-2651B20.3	5.89	3.43e-08	6.21e-05	0.36	0.47	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45251580~45279251:-
TGCT	cis	rs4713118	0.513	rs149972	ENSG00000216901.1	AL022393.7	5.89	3.46e-08	6.26e-05	0.6	0.47	Parkinson's disease;	chr6:28015449	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.513	rs149975	ENSG00000216901.1	AL022393.7	5.89	3.46e-08	6.26e-05	0.6	0.47	Parkinson's disease;	chr6:28018562	chr6:28176188~28176674:+
TGCT	cis	rs17301013	0.507	rs464635	ENSG00000227373.4	RP11-160H22.5	5.89	3.46e-08	6.26e-05	0.53	0.47	Systemic lupus erythematosus;	chr1:174732730	chr1:174115300~174160004:-
TGCT	cis	rs2948294	0.566	rs13274039	ENSG00000173295.6	FAM86B3P	5.89	3.47e-08	6.27e-05	0.6	0.47	Red cell distribution width;	chr8:8254137	chr8:8228595~8244865:+
TGCT	cis	rs12891047	1	rs10131048	ENSG00000258759.1	RP11-1012A1.7	5.89	3.47e-08	6.27e-05	0.41	0.47	Amyotrophic lateral sclerosis (sporadic);	chr14:67790366	chr14:67799004~67799609:+
TGCT	cis	rs1832871	0.538	rs6924801	ENSG00000188451.8	SRP72P2	-5.88	3.51e-08	6.33e-05	-0.4	-0.47	Height;	chr6:158297773	chr6:158237336~158242797:-
TGCT	cis	rs7714584	1	rs12652003	ENSG00000197083.10	ZNF300P1	5.88	3.52e-08	6.34e-05	0.88	0.47	Crohn's disease;	chr5:150852383	chr5:150930645~150946289:-
TGCT	cis	rs2906856	0.526	rs2906852	ENSG00000255733.4	IFNG-AS1	5.88	3.52e-08	6.36e-05	0.48	0.47	Mosquito bite size;	chr12:67985701	chr12:67989445~68234686:+
TGCT	cis	rs797680	0.576	rs55838267	ENSG00000223745.6	RP4-717I23.3	5.88	3.58e-08	6.45e-05	0.44	0.47	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93338159	chr1:93262186~93346025:-
TGCT	cis	rs11155671	0.53	rs7758033	ENSG00000216906.2	RP11-350J20.9	5.88	3.62e-08	6.52e-05	0.51	0.47	Testicular germ cell tumor;	chr6:149886999	chr6:149904243~149906418:+
TGCT	cis	rs1775715	1	rs1251363	ENSG00000239731.3	RN7SL825P	5.87	3.67e-08	6.61e-05	0.49	0.47	Bipolar disorder with mood-incongruent psychosis;	chr10:32039598	chr10:31992087~31992381:-
TGCT	cis	rs17301013	0.606	rs10798307	ENSG00000227373.4	RP11-160H22.5	5.87	3.68e-08	6.61e-05	0.54	0.47	Systemic lupus erythematosus;	chr1:174264172	chr1:174115300~174160004:-
TGCT	cis	rs904251	0.861	rs1776456	ENSG00000279942.1	RP1-153P14.7	-5.87	3.7e-08	6.64e-05	-0.52	-0.47	Cognitive performance;	chr6:37516922	chr6:37567716~37571460:+
TGCT	cis	rs9494142	0.592	rs1547247	ENSG00000232876.1	CTA-212D2.2	-5.87	3.7e-08	6.64e-05	-0.44	-0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;Lymphocyte counts;	chr6:135069698	chr6:135055033~135060550:+
TGCT	cis	rs7811142	1	rs68116612	ENSG00000242294.5	STAG3L5P	5.87	3.72e-08	6.67e-05	0.43	0.47	Platelet count;	chr7:100408870	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs67040465	ENSG00000242294.5	STAG3L5P	5.87	3.72e-08	6.67e-05	0.43	0.47	Platelet count;	chr7:100485455	chr7:100336079~100351900:+
TGCT	cis	rs3096299	0.692	rs4785565	ENSG00000274627.1	RP11-104N10.2	5.87	3.72e-08	6.67e-05	0.47	0.47	Multiple myeloma (IgH translocation);	chr16:89449351	chr16:89516797~89522217:+
TGCT	cis	rs748404	0.586	rs2584700	ENSG00000205771.5	CATSPER2P1	-5.87	3.73e-08	6.69e-05	-0.52	-0.47	Lung cancer;	chr15:43393134	chr15:43726918~43747094:-
TGCT	cis	rs2276314	0.857	rs4799408	ENSG00000278986.1	RP11-723J4.3	5.87	3.73e-08	6.7e-05	0.53	0.47	Endometriosis;Drug-induced torsades de pointes;	chr18:36009019	chr18:35972151~35973916:+
TGCT	cis	rs875971	0.628	rs6974355	ENSG00000222364.1	RNU6-96P	-5.87	3.73e-08	6.7e-05	-0.56	-0.47	Aortic root size;	chr7:66376994	chr7:66395191~66395286:+
TGCT	cis	rs10875976	0.647	rs4391887	ENSG00000257253.2	RP11-70F11.7	5.87	3.74e-08	6.71e-05	0.44	0.47	Obesity;	chr12:49831467	chr12:49861207~49865802:+
TGCT	cis	rs2739330	0.828	rs5751770	ENSG00000272787.1	KB-226F1.2	-5.87	3.74e-08	6.71e-05	-0.53	-0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23969211~23969873:+
TGCT	cis	rs748404	0.631	rs7167882	ENSG00000205771.5	CATSPER2P1	-5.87	3.76e-08	6.74e-05	-0.52	-0.47	Lung cancer;	chr15:43386465	chr15:43726918~43747094:-
TGCT	cis	rs11098499	0.913	rs10006304	ENSG00000245958.5	RP11-33B1.1	-5.87	3.77e-08	6.75e-05	-0.48	-0.47	Corneal astigmatism;	chr4:119203150	chr4:119454791~119552025:+
TGCT	cis	rs17711722	0.74	rs7809991	ENSG00000236529.1	RP13-254B10.1	5.87	3.77e-08	6.75e-05	0.35	0.47	Calcium levels;	chr7:65941231	chr7:65840212~65840596:+
TGCT	cis	rs875971	0.522	rs6960048	ENSG00000236529.1	RP13-254B10.1	5.87	3.77e-08	6.75e-05	0.35	0.47	Aortic root size;	chr7:65943052	chr7:65840212~65840596:+
TGCT	cis	rs875971	0.522	rs10807697	ENSG00000236529.1	RP13-254B10.1	5.87	3.77e-08	6.75e-05	0.35	0.47	Aortic root size;	chr7:65951183	chr7:65840212~65840596:+
TGCT	cis	rs7208859	0.673	rs999796	ENSG00000263531.1	RP13-753N3.1	5.87	3.77e-08	6.76e-05	0.79	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832386	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.725	rs9910051	ENSG00000263531.1	RP13-753N3.1	5.87	3.77e-08	6.76e-05	0.79	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834184	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.725	rs7210904	ENSG00000263531.1	RP13-753N3.1	5.87	3.77e-08	6.76e-05	0.79	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843187	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.725	rs9915802	ENSG00000263531.1	RP13-753N3.1	5.87	3.77e-08	6.76e-05	0.79	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846040	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.725	rs7342938	ENSG00000263531.1	RP13-753N3.1	5.87	3.77e-08	6.76e-05	0.79	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862812	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.725	rs6505215	ENSG00000263531.1	RP13-753N3.1	5.87	3.77e-08	6.76e-05	0.79	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862885	chr17:30863921~30864940:-
TGCT	cis	rs2882667	0.858	rs11242447	ENSG00000253404.1	AC034243.1	5.87	3.78e-08	6.76e-05	0.54	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139090484	chr5:138744434~138753309:-
TGCT	cis	rs3096299	0.667	rs2965947	ENSG00000274627.1	RP11-104N10.2	5.87	3.78e-08	6.77e-05	0.48	0.47	Multiple myeloma (IgH translocation);	chr16:89452262	chr16:89516797~89522217:+
TGCT	cis	rs524281	0.954	rs549187	ENSG00000255320.1	RP11-755F10.1	5.87	3.8e-08	6.8e-05	0.55	0.47	Electroencephalogram traits;	chr11:66131160	chr11:66244840~66246239:-
TGCT	cis	rs6061231	0.544	rs2427314	ENSG00000273619.1	RP5-908M14.9	-5.87	3.82e-08	6.83e-05	-0.53	-0.47	Colorectal cancer;	chr20:62398610	chr20:62386303~62386970:-
TGCT	cis	rs7849270	1	rs10760589	ENSG00000268707.1	RP11-247A12.7	-5.86	3.82e-08	6.84e-05	-0.5	-0.47	Blood metabolite ratios;	chr9:129144014	chr9:129170434~129170940:+
TGCT	cis	rs7849270	1	rs1360172	ENSG00000268707.1	RP11-247A12.7	-5.86	3.82e-08	6.84e-05	-0.5	-0.47	Blood metabolite ratios;	chr9:129145701	chr9:129170434~129170940:+
TGCT	cis	rs7849270	0.851	rs1819381	ENSG00000268707.1	RP11-247A12.7	-5.86	3.82e-08	6.84e-05	-0.5	-0.47	Blood metabolite ratios;	chr9:129145728	chr9:129170434~129170940:+
TGCT	cis	rs7849270	1	rs746489	ENSG00000268707.1	RP11-247A12.7	-5.86	3.82e-08	6.84e-05	-0.5	-0.47	Blood metabolite ratios;	chr9:129147814	chr9:129170434~129170940:+
TGCT	cis	rs7849270	0.959	rs913275	ENSG00000268707.1	RP11-247A12.7	-5.86	3.82e-08	6.84e-05	-0.5	-0.47	Blood metabolite ratios;	chr9:129148365	chr9:129170434~129170940:+
TGCT	cis	rs7849270	1	rs7869804	ENSG00000268707.1	RP11-247A12.7	-5.86	3.82e-08	6.84e-05	-0.5	-0.47	Blood metabolite ratios;	chr9:129150865	chr9:129170434~129170940:+
TGCT	cis	rs7849270	0.959	rs1410017	ENSG00000268707.1	RP11-247A12.7	-5.86	3.82e-08	6.84e-05	-0.5	-0.47	Blood metabolite ratios;	chr9:129151151	chr9:129170434~129170940:+
TGCT	cis	rs7849270	1	rs1571229	ENSG00000268707.1	RP11-247A12.7	-5.86	3.82e-08	6.84e-05	-0.5	-0.47	Blood metabolite ratios;	chr9:129151432	chr9:129170434~129170940:+
TGCT	cis	rs3096299	0.719	rs2965945	ENSG00000274627.1	RP11-104N10.2	5.86	3.88e-08	6.93e-05	0.47	0.47	Multiple myeloma (IgH translocation);	chr16:89447609	chr16:89516797~89522217:+
TGCT	cis	rs9890032	0.618	rs55872374	ENSG00000266490.1	CTD-2349P21.9	5.86	3.88e-08	6.93e-05	0.37	0.47	Hip circumference adjusted for BMI;	chr17:30822863	chr17:30792372~30792833:+
TGCT	cis	rs9326248	0.581	rs7120706	ENSG00000254851.1	RP11-109L13.1	5.86	3.91e-08	6.98e-05	0.53	0.47	Blood protein levels;	chr11:116959371	chr11:117135528~117138582:+
TGCT	cis	rs6964833	1	rs6967152	ENSG00000123965.13	PMS2P5	5.86	3.93e-08	7.01e-05	0.61	0.47	Menarche (age at onset);	chr7:74684983	chr7:74894116~74897835:+
TGCT	cis	rs875971	1	rs4718357	ENSG00000222364.1	RNU6-96P	-5.86	3.94e-08	7.03e-05	-0.53	-0.47	Aortic root size;	chr7:66495891	chr7:66395191~66395286:+
TGCT	cis	rs916888	0.61	rs142167	ENSG00000262500.1	RP11-259G18.2	-5.86	3.95e-08	7.04e-05	-0.61	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46243606~46245044:+
TGCT	cis	rs6964833	1	rs17515241	ENSG00000123965.13	PMS2P5	-5.86	3.96e-08	7.05e-05	-0.68	-0.47	Menarche (age at onset);	chr7:74717695	chr7:74894116~74897835:+
TGCT	cis	rs875971	0.522	rs7784623	ENSG00000236529.1	RP13-254B10.1	5.86	3.96e-08	7.05e-05	0.35	0.47	Aortic root size;	chr7:65930047	chr7:65840212~65840596:+
TGCT	cis	rs875971	0.522	rs34973832	ENSG00000236529.1	RP13-254B10.1	5.86	3.96e-08	7.05e-05	0.35	0.47	Aortic root size;	chr7:65931217	chr7:65840212~65840596:+
TGCT	cis	rs76878669	0.561	rs4930362	ENSG00000254510.1	RP11-867G23.10	5.86	3.96e-08	7.05e-05	0.62	0.47	Educational attainment (years of education);	chr11:66386889	chr11:66409158~66417137:+
TGCT	cis	rs76878669	0.561	rs4930179	ENSG00000254510.1	RP11-867G23.10	5.86	3.96e-08	7.05e-05	0.62	0.47	Educational attainment (years of education);	chr11:66389961	chr11:66409158~66417137:+
TGCT	cis	rs3096299	0.719	rs2965817	ENSG00000274627.1	RP11-104N10.2	5.86	3.97e-08	7.07e-05	0.47	0.47	Multiple myeloma (IgH translocation);	chr16:89446826	chr16:89516797~89522217:+
TGCT	cis	rs76878669	0.561	rs2236679	ENSG00000254510.1	RP11-867G23.10	-5.86	3.97e-08	7.07e-05	-0.62	-0.47	Educational attainment (years of education);	chr11:66341423	chr11:66409158~66417137:+
TGCT	cis	rs801193	0.844	rs2244022	ENSG00000222364.1	RNU6-96P	-5.86	3.98e-08	7.08e-05	-0.53	-0.47	Aortic root size;	chr7:66737443	chr7:66395191~66395286:+
TGCT	cis	rs10256972	0.706	rs4285396	ENSG00000226291.1	AC091729.8	-5.86	3.99e-08	7.09e-05	-0.49	-0.47	Endometriosis;Longevity;	chr7:1084102	chr7:1080863~1082178:+
TGCT	cis	rs5769707	0.837	rs1573726	ENSG00000235111.1	RP1-29C18.8	-5.85	4.04e-08	7.17e-05	-0.38	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49639224	chr22:49612657~49615716:-
TGCT	cis	rs76878669	0.561	rs7948058	ENSG00000254510.1	RP11-867G23.10	-5.85	4.04e-08	7.18e-05	-0.63	-0.47	Educational attainment (years of education);	chr11:66380640	chr11:66409158~66417137:+
TGCT	cis	rs786425	0.77	rs7958693	ENSG00000278112.1	RP11-972P1.11	5.85	4.06e-08	7.21e-05	0.52	0.47	Pubertal anthropometrics;	chr12:123678203	chr12:123519390~123519856:-
TGCT	cis	rs904251	0.861	rs2776877	ENSG00000279942.1	RP1-153P14.7	-5.85	4.06e-08	7.21e-05	-0.53	-0.47	Cognitive performance;	chr6:37519359	chr6:37567716~37571460:+
TGCT	cis	rs904251	0.864	rs2797801	ENSG00000279942.1	RP1-153P14.7	-5.85	4.06e-08	7.21e-05	-0.53	-0.47	Cognitive performance;	chr6:37519385	chr6:37567716~37571460:+
TGCT	cis	rs904251	0.797	rs2776878	ENSG00000279942.1	RP1-153P14.7	-5.85	4.06e-08	7.21e-05	-0.53	-0.47	Cognitive performance;	chr6:37519497	chr6:37567716~37571460:+
TGCT	cis	rs904251	0.828	rs2797803	ENSG00000279942.1	RP1-153P14.7	-5.85	4.06e-08	7.21e-05	-0.53	-0.47	Cognitive performance;	chr6:37519564	chr6:37567716~37571460:+
TGCT	cis	rs7301826	1	rs1106369	ENSG00000256250.1	RP11-989F5.1	-5.85	4.07e-08	7.22e-05	-0.5	-0.47	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810606~130812438:+
TGCT	cis	rs1450985	0.864	rs17344417	ENSG00000239653.1	PSMD6-AS2	5.85	4.07e-08	7.22e-05	0.43	0.47	Breast cancer;	chr3:64026861	chr3:64004022~64012148:+
TGCT	cis	rs796364	0.762	rs13030712	ENSG00000232732.8	AC073043.1	-5.85	4.07e-08	7.22e-05	-0.6	-0.47	Schizophrenia;	chr2:200108846	chr2:199867396~199911159:-
TGCT	cis	rs5769707	0.642	rs4824070	ENSG00000188511.11	C22orf34	5.85	4.07e-08	7.23e-05	0.51	0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49637873	chr22:49414524~49657542:-
TGCT	cis	rs3096299	0.728	rs1011749	ENSG00000274627.1	RP11-104N10.2	5.85	4.07e-08	7.23e-05	0.47	0.47	Multiple myeloma (IgH translocation);	chr16:89444461	chr16:89516797~89522217:+
TGCT	cis	rs55794721	0.509	rs6699896	ENSG00000224183.1	SDHDP6	-5.85	4.08e-08	7.24e-05	-0.5	-0.47	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25294164~25294643:-
TGCT	cis	rs3091242	0.933	rs35148262	ENSG00000224183.1	SDHDP6	-5.85	4.08e-08	7.24e-05	-0.5	-0.47	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25294164~25294643:-
TGCT	cis	rs3096299	0.719	rs2353581	ENSG00000274627.1	RP11-104N10.2	5.85	4.11e-08	7.29e-05	0.48	0.47	Multiple myeloma (IgH translocation);	chr16:89452500	chr16:89516797~89522217:+
TGCT	cis	rs3096299	0.719	rs12934708	ENSG00000274627.1	RP11-104N10.2	5.85	4.11e-08	7.29e-05	0.48	0.47	Multiple myeloma (IgH translocation);	chr16:89457382	chr16:89516797~89522217:+
TGCT	cis	rs875971	0.862	rs10256544	ENSG00000222364.1	RNU6-96P	-5.85	4.12e-08	7.29e-05	-0.52	-0.47	Aortic root size;	chr7:66210141	chr7:66395191~66395286:+
TGCT	cis	rs11155671	0.53	rs9371542	ENSG00000216906.2	RP11-350J20.9	5.85	4.13e-08	7.32e-05	0.5	0.46	Testicular germ cell tumor;	chr6:149891949	chr6:149904243~149906418:+
TGCT	cis	rs7811142	0.83	rs6948685	ENSG00000242294.5	STAG3L5P	5.85	4.15e-08	7.35e-05	0.43	0.46	Platelet count;	chr7:100372565	chr7:100336079~100351900:+
TGCT	cis	rs9326248	0.581	rs4938331	ENSG00000254851.1	RP11-109L13.1	-5.85	4.17e-08	7.38e-05	-0.56	-0.46	Blood protein levels;	chr11:117059966	chr11:117135528~117138582:+
TGCT	cis	rs9326248	0.51	rs4938332	ENSG00000254851.1	RP11-109L13.1	-5.85	4.17e-08	7.38e-05	-0.56	-0.46	Blood protein levels;	chr11:117060082	chr11:117135528~117138582:+
TGCT	cis	rs55794721	0.509	rs2375313	ENSG00000261349.1	RP3-465N24.5	-5.85	4.18e-08	7.38e-05	-0.46	-0.46	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25266102~25267136:-
TGCT	cis	rs17264034	1	rs414829	ENSG00000250786.1	SNHG18	5.85	4.18e-08	7.39e-05	0.51	0.46	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9552413	chr5:9546200~9550609:+
TGCT	cis	rs17264034	0.861	rs11749803	ENSG00000250786.1	SNHG18	5.85	4.18e-08	7.39e-05	0.51	0.46	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9553456	chr5:9546200~9550609:+
TGCT	cis	rs73086581	0.947	rs11906612	ENSG00000229539.1	RP11-119B16.2	5.84	4.2e-08	7.42e-05	0.7	0.46	Response to antidepressants in depression;	chr20:3922987	chr20:3888239~3888868:-
TGCT	cis	rs875971	0.83	rs427973	ENSG00000222364.1	RNU6-96P	-5.84	4.2e-08	7.43e-05	-0.53	-0.46	Aortic root size;	chr7:66061661	chr7:66395191~66395286:+
TGCT	cis	rs7811142	0.83	rs75636500	ENSG00000242294.5	STAG3L5P	5.84	4.21e-08	7.43e-05	0.43	0.46	Platelet count;	chr7:100350034	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.779	rs77370288	ENSG00000242294.5	STAG3L5P	5.84	4.21e-08	7.43e-05	0.43	0.46	Platelet count;	chr7:100350274	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.83	rs7341507	ENSG00000242294.5	STAG3L5P	5.84	4.21e-08	7.43e-05	0.43	0.46	Platelet count;	chr7:100353692	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.83	rs76798830	ENSG00000242294.5	STAG3L5P	5.84	4.21e-08	7.43e-05	0.43	0.46	Platelet count;	chr7:100355205	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.83	rs78256546	ENSG00000242294.5	STAG3L5P	5.84	4.21e-08	7.43e-05	0.43	0.46	Platelet count;	chr7:100355347	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.775	rs6946768	ENSG00000242294.5	STAG3L5P	5.84	4.21e-08	7.43e-05	0.43	0.46	Platelet count;	chr7:100356770	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.83	rs41280971	ENSG00000242294.5	STAG3L5P	5.84	4.21e-08	7.43e-05	0.43	0.46	Platelet count;	chr7:100356834	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.83	rs3087502	ENSG00000242294.5	STAG3L5P	5.84	4.21e-08	7.43e-05	0.43	0.46	Platelet count;	chr7:100357741	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.83	rs61735533	ENSG00000242294.5	STAG3L5P	5.84	4.21e-08	7.43e-05	0.43	0.46	Platelet count;	chr7:100358243	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.83	rs11761426	ENSG00000242294.5	STAG3L5P	5.84	4.21e-08	7.43e-05	0.43	0.46	Platelet count;	chr7:100359270	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.83	rs77861211	ENSG00000242294.5	STAG3L5P	5.84	4.21e-08	7.43e-05	0.43	0.46	Platelet count;	chr7:100364473	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.83	rs11769057	ENSG00000242294.5	STAG3L5P	5.84	4.21e-08	7.43e-05	0.43	0.46	Platelet count;	chr7:100367038	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.83	rs11765869	ENSG00000242294.5	STAG3L5P	5.84	4.21e-08	7.43e-05	0.43	0.46	Platelet count;	chr7:100367166	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.83	rs705866	ENSG00000242294.5	STAG3L5P	5.84	4.21e-08	7.43e-05	0.43	0.46	Platelet count;	chr7:100367662	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.83	rs6965458	ENSG00000242294.5	STAG3L5P	5.84	4.21e-08	7.43e-05	0.43	0.46	Platelet count;	chr7:100375779	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.83	rs73401450	ENSG00000242294.5	STAG3L5P	5.84	4.21e-08	7.43e-05	0.43	0.46	Platelet count;	chr7:100384236	chr7:100336079~100351900:+
TGCT	cis	rs1528149	0.504	rs7795348	ENSG00000224683.1	RPL36AP29	5.84	4.22e-08	7.44e-05	0.49	0.46	Sitting height ratio;	chr7:16110647	chr7:16208945~16209265:+
TGCT	cis	rs7849270	1	rs10819464	ENSG00000268707.1	RP11-247A12.7	-5.84	4.22e-08	7.45e-05	-0.51	-0.46	Blood metabolite ratios;	chr9:129113998	chr9:129170434~129170940:+
TGCT	cis	rs7849270	0.885	rs10760588	ENSG00000268707.1	RP11-247A12.7	-5.84	4.22e-08	7.45e-05	-0.51	-0.46	Blood metabolite ratios;	chr9:129115195	chr9:129170434~129170940:+
TGCT	cis	rs7849270	0.921	rs6478864	ENSG00000268707.1	RP11-247A12.7	-5.84	4.22e-08	7.45e-05	-0.51	-0.46	Blood metabolite ratios;	chr9:129118351	chr9:129170434~129170940:+
TGCT	cis	rs7849270	0.851	rs7861663	ENSG00000268707.1	RP11-247A12.7	-5.84	4.22e-08	7.45e-05	-0.51	-0.46	Blood metabolite ratios;	chr9:129118667	chr9:129170434~129170940:+
TGCT	cis	rs7849270	1	rs10819466	ENSG00000268707.1	RP11-247A12.7	-5.84	4.22e-08	7.45e-05	-0.51	-0.46	Blood metabolite ratios;	chr9:129119213	chr9:129170434~129170940:+
TGCT	cis	rs7849270	1	rs3739843	ENSG00000268707.1	RP11-247A12.7	-5.84	4.22e-08	7.45e-05	-0.51	-0.46	Blood metabolite ratios;	chr9:129120682	chr9:129170434~129170940:+
TGCT	cis	rs7849270	1	rs10988214	ENSG00000268707.1	RP11-247A12.7	-5.84	4.22e-08	7.45e-05	-0.51	-0.46	Blood metabolite ratios;	chr9:129121473	chr9:129170434~129170940:+
TGCT	cis	rs7849270	1	rs932833	ENSG00000268707.1	RP11-247A12.7	-5.84	4.22e-08	7.45e-05	-0.51	-0.46	Blood metabolite ratios;	chr9:129121762	chr9:129170434~129170940:+
TGCT	cis	rs7849270	1	rs7020708	ENSG00000268707.1	RP11-247A12.7	-5.84	4.22e-08	7.45e-05	-0.51	-0.46	Blood metabolite ratios;	chr9:129122852	chr9:129170434~129170940:+
TGCT	cis	rs7044106	0.762	rs10984972	ENSG00000226752.6	PSMD5-AS1	-5.84	4.23e-08	7.45e-05	-0.59	-0.46	Hip circumference adjusted for BMI;	chr9:120647586	chr9:120824828~120854385:+
TGCT	cis	rs1832871	0.599	rs7752547	ENSG00000188451.8	SRP72P2	-5.84	4.23e-08	7.46e-05	-0.39	-0.46	Height;	chr6:158330131	chr6:158237336~158242797:-
TGCT	cis	rs9733	0.596	rs12063547	ENSG00000206931.1	RNU6-1042P	-5.84	4.24e-08	7.47e-05	-0.35	-0.46	Tonsillectomy;	chr1:150701577	chr1:150701866~150701972:+
TGCT	cis	rs6964833	1	rs3846966	ENSG00000123965.13	PMS2P5	5.84	4.24e-08	7.47e-05	0.62	0.46	Menarche (age at onset);	chr7:74698811	chr7:74894116~74897835:+
TGCT	cis	rs6964833	1	rs2301907	ENSG00000123965.13	PMS2P5	5.84	4.24e-08	7.47e-05	0.62	0.46	Menarche (age at onset);	chr7:74700517	chr7:74894116~74897835:+
TGCT	cis	rs6964833	0.935	rs7795282	ENSG00000123965.13	PMS2P5	5.84	4.24e-08	7.47e-05	0.62	0.46	Menarche (age at onset);	chr7:74708526	chr7:74894116~74897835:+
TGCT	cis	rs9733	0.519	rs11807450	ENSG00000206931.1	RNU6-1042P	5.84	4.27e-08	7.52e-05	0.35	0.46	Tonsillectomy;	chr1:150705243	chr1:150701866~150701972:+
TGCT	cis	rs7301826	1	rs10773822	ENSG00000256250.1	RP11-989F5.1	-5.84	4.28e-08	7.53e-05	-0.5	-0.46	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810606~130812438:+
TGCT	cis	rs7301826	1	rs4759793	ENSG00000256250.1	RP11-989F5.1	-5.84	4.28e-08	7.53e-05	-0.5	-0.46	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810606~130812438:+
TGCT	cis	rs7301826	1	rs4759523	ENSG00000256250.1	RP11-989F5.1	-5.84	4.28e-08	7.53e-05	-0.5	-0.46	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810606~130812438:+
TGCT	cis	rs7301826	1	rs4759524	ENSG00000256250.1	RP11-989F5.1	-5.84	4.28e-08	7.53e-05	-0.5	-0.46	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810606~130812438:+
TGCT	cis	rs4927850	1	rs4927850	ENSG00000242086.7	LINC00969	-5.84	4.29e-08	7.55e-05	-0.51	-0.46	Pancreatic cancer;	chr3:196024759	chr3:195658062~195739964:+
TGCT	cis	rs17711722	0.565	rs4275112	ENSG00000164669.11	INTS4P1	5.84	4.3e-08	7.56e-05	0.46	0.46	Calcium levels;	chr7:65733651	chr7:65141225~65234216:+
TGCT	cis	rs875971	0.545	rs4718348	ENSG00000226824.5	RP4-756H11.3	-5.84	4.3e-08	7.56e-05	-0.57	-0.46	Aortic root size;	chr7:66441589	chr7:66654538~66669855:+
TGCT	cis	rs7412746	0.611	rs3768018	ENSG00000206931.1	RNU6-1042P	5.84	4.3e-08	7.57e-05	0.38	0.46	Melanoma;	chr1:150751271	chr1:150701866~150701972:+
TGCT	cis	rs3814244	0.788	rs3741649	ENSG00000255733.4	IFNG-AS1	-5.84	4.32e-08	7.6e-05	-0.43	-0.46	Itch intensity from mosquito bite adjusted by bite size;	chr12:68028351	chr12:67989445~68234686:+
TGCT	cis	rs3814244	0.788	rs11177014	ENSG00000255733.4	IFNG-AS1	-5.84	4.32e-08	7.6e-05	-0.43	-0.46	Itch intensity from mosquito bite adjusted by bite size;	chr12:68031871	chr12:67989445~68234686:+
TGCT	cis	rs17301013	0.502	rs6703836	ENSG00000227373.4	RP11-160H22.5	5.84	4.32e-08	7.6e-05	0.57	0.46	Systemic lupus erythematosus;	chr1:174099675	chr1:174115300~174160004:-
TGCT	cis	rs8062405	1	rs72793811	ENSG00000259982.1	CDC37P1	5.84	4.36e-08	7.67e-05	0.63	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs12443881	ENSG00000259982.1	CDC37P1	5.84	4.36e-08	7.67e-05	0.63	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28700294~28701540:-
TGCT	cis	rs6061231	0.724	rs1570027	ENSG00000273619.1	RP5-908M14.9	-5.83	4.43e-08	7.76e-05	-0.55	-0.46	Colorectal cancer;	chr20:62393540	chr20:62386303~62386970:-
TGCT	cis	rs6061231	0.798	rs2427308	ENSG00000273619.1	RP5-908M14.9	-5.83	4.43e-08	7.76e-05	-0.55	-0.46	Colorectal cancer;	chr20:62394395	chr20:62386303~62386970:-
TGCT	cis	rs875971	0.545	rs1796222	ENSG00000226824.5	RP4-756H11.3	5.83	4.44e-08	7.77e-05	0.56	0.46	Aortic root size;	chr7:66592167	chr7:66654538~66669855:+
TGCT	cis	rs2921073	0.509	rs2976931	ENSG00000173295.6	FAM86B3P	5.83	4.44e-08	7.78e-05	0.57	0.46	Parkinson's disease;	chr8:8399807	chr8:8228595~8244865:+
TGCT	cis	rs7829975	0.514	rs2976929	ENSG00000173295.6	FAM86B3P	5.83	4.44e-08	7.78e-05	0.57	0.46	Mood instability;	chr8:8401202	chr8:8228595~8244865:+
TGCT	cis	rs7829975	0.514	rs2920991	ENSG00000173295.6	FAM86B3P	5.83	4.44e-08	7.78e-05	0.57	0.46	Mood instability;	chr8:8401607	chr8:8228595~8244865:+
TGCT	cis	rs7617773	0.817	rs11710861	ENSG00000229759.1	MRPS18AP1	5.83	4.47e-08	7.82e-05	0.39	0.46	Coronary artery disease;	chr3:48256070	chr3:48256350~48256938:-
TGCT	cis	rs7714584	1	rs57406211	ENSG00000197083.10	ZNF300P1	5.83	4.47e-08	7.83e-05	0.96	0.46	Crohn's disease;	chr5:150791404	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs79442859	ENSG00000197083.10	ZNF300P1	5.83	4.47e-08	7.83e-05	0.96	0.46	Crohn's disease;	chr5:150791648	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs76872831	ENSG00000197083.10	ZNF300P1	5.83	4.47e-08	7.83e-05	0.96	0.46	Crohn's disease;	chr5:150791997	chr5:150930645~150946289:-
TGCT	cis	rs7044106	0.537	rs4434680	ENSG00000226752.6	PSMD5-AS1	-5.83	4.48e-08	7.84e-05	-0.58	-0.46	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120824828~120854385:+
TGCT	cis	rs7044106	0.537	rs10739573	ENSG00000226752.6	PSMD5-AS1	-5.83	4.48e-08	7.84e-05	-0.58	-0.46	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120824828~120854385:+
TGCT	cis	rs17301013	0.507	rs11805578	ENSG00000227373.4	RP11-160H22.5	5.83	4.49e-08	7.86e-05	0.57	0.46	Systemic lupus erythematosus;	chr1:174573174	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs4652652	ENSG00000227373.4	RP11-160H22.5	5.83	4.49e-08	7.86e-05	0.57	0.46	Systemic lupus erythematosus;	chr1:174596582	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs4651103	ENSG00000227373.4	RP11-160H22.5	5.83	4.49e-08	7.86e-05	0.57	0.46	Systemic lupus erythematosus;	chr1:174596750	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs72715262	ENSG00000227373.4	RP11-160H22.5	5.83	4.49e-08	7.86e-05	0.57	0.46	Systemic lupus erythematosus;	chr1:174607088	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs4615901	ENSG00000227373.4	RP11-160H22.5	5.83	4.49e-08	7.86e-05	0.57	0.46	Systemic lupus erythematosus;	chr1:174609432	chr1:174115300~174160004:-
TGCT	cis	rs4713118	0.513	rs149897	ENSG00000216901.1	AL022393.7	5.83	4.49e-08	7.86e-05	0.61	0.46	Parkinson's disease;	chr6:28038872	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.513	rs156734	ENSG00000216901.1	AL022393.7	5.83	4.49e-08	7.86e-05	0.61	0.46	Parkinson's disease;	chr6:28039579	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.513	rs202908	ENSG00000216901.1	AL022393.7	5.83	4.49e-08	7.86e-05	0.61	0.46	Parkinson's disease;	chr6:28043773	chr6:28176188~28176674:+
TGCT	cis	rs7301826	0.967	rs4759790	ENSG00000256250.1	RP11-989F5.1	-5.83	4.51e-08	7.89e-05	-0.5	-0.46	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810606~130812438:+
TGCT	cis	rs17301013	0.861	rs332770	ENSG00000227373.4	RP11-160H22.5	5.83	4.52e-08	7.9e-05	0.49	0.46	Systemic lupus erythematosus;	chr1:174681511	chr1:174115300~174160004:-
TGCT	cis	rs7104764	1	rs6598074	ENSG00000277290.1	RP11-326C3.16	-5.83	4.53e-08	7.92e-05	-0.47	-0.46	Menarche (age at onset);	chr11:219398	chr11:243099~243483:-
TGCT	cis	rs8072100	0.967	rs12452315	ENSG00000228782.6	CTD-2026D20.3	-5.83	4.54e-08	7.93e-05	-0.56	-0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402080	chr17:47450568~47492492:-
TGCT	cis	rs17301013	0.606	rs1894198	ENSG00000227373.4	RP11-160H22.5	-5.83	4.58e-08	7.99e-05	-0.55	-0.46	Systemic lupus erythematosus;	chr1:174835393	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.659	rs1894199	ENSG00000227373.4	RP11-160H22.5	-5.83	4.58e-08	7.99e-05	-0.55	-0.46	Systemic lupus erythematosus;	chr1:174835545	chr1:174115300~174160004:-
TGCT	cis	rs76878669	0.561	rs55998145	ENSG00000254510.1	RP11-867G23.10	5.83	4.6e-08	8.02e-05	0.62	0.46	Educational attainment (years of education);	chr11:66385115	chr11:66409158~66417137:+
TGCT	cis	rs9733	0.596	rs7412396	ENSG00000206931.1	RNU6-1042P	5.83	4.6e-08	8.02e-05	0.34	0.46	Tonsillectomy;	chr1:150694321	chr1:150701866~150701972:+
TGCT	cis	rs9322193	0.567	rs7747457	ENSG00000216906.2	RP11-350J20.9	5.83	4.61e-08	8.04e-05	0.5	0.46	Lung cancer;	chr6:149892366	chr6:149904243~149906418:+
TGCT	cis	rs7714584	1	rs17800987	ENSG00000197083.10	ZNF300P1	5.82	4.62e-08	8.05e-05	0.93	0.46	Crohn's disease;	chr5:150943866	chr5:150930645~150946289:-
TGCT	cis	rs73086581	0.898	rs11906452	ENSG00000229539.1	RP11-119B16.2	5.82	4.63e-08	8.07e-05	0.66	0.46	Response to antidepressants in depression;	chr20:4000912	chr20:3888239~3888868:-
TGCT	cis	rs801193	0.66	rs10950049	ENSG00000222364.1	RNU6-96P	-5.82	4.64e-08	8.08e-05	-0.55	-0.46	Aortic root size;	chr7:66765873	chr7:66395191~66395286:+
TGCT	cis	rs73086581	1	rs56324992	ENSG00000229539.1	RP11-119B16.2	5.82	4.64e-08	8.09e-05	0.69	0.46	Response to antidepressants in depression;	chr20:3997506	chr20:3888239~3888868:-
TGCT	cis	rs73086581	1	rs73084594	ENSG00000229539.1	RP11-119B16.2	5.82	4.66e-08	8.12e-05	0.7	0.46	Response to antidepressants in depression;	chr20:3935733	chr20:3888239~3888868:-
TGCT	cis	rs7617773	0.779	rs77957078	ENSG00000229759.1	MRPS18AP1	5.82	4.67e-08	8.13e-05	0.4	0.46	Coronary artery disease;	chr3:48289796	chr3:48256350~48256938:-
TGCT	cis	rs9733	0.596	rs6587516	ENSG00000206931.1	RNU6-1042P	5.82	4.7e-08	8.13e-05	0.36	0.46	Tonsillectomy;	chr1:150650745	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs6678013	ENSG00000206931.1	RNU6-1042P	5.82	4.7e-08	8.13e-05	0.36	0.46	Tonsillectomy;	chr1:150650809	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs2175615	ENSG00000206931.1	RNU6-1042P	5.82	4.7e-08	8.13e-05	0.36	0.46	Tonsillectomy;	chr1:150651625	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.628	rs72700895	ENSG00000206931.1	RNU6-1042P	5.82	4.7e-08	8.13e-05	0.36	0.46	Tonsillectomy;	chr1:150653553	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs72700897	ENSG00000206931.1	RNU6-1042P	5.82	4.7e-08	8.13e-05	0.36	0.46	Tonsillectomy;	chr1:150653562	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs6661872	ENSG00000206931.1	RNU6-1042P	5.82	4.7e-08	8.13e-05	0.36	0.46	Tonsillectomy;	chr1:150655881	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs11204687	ENSG00000206931.1	RNU6-1042P	5.82	4.7e-08	8.13e-05	0.36	0.46	Tonsillectomy;	chr1:150657404	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs2867304	ENSG00000206931.1	RNU6-1042P	5.82	4.7e-08	8.13e-05	0.36	0.46	Tonsillectomy;	chr1:150658519	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs6690725	ENSG00000206931.1	RNU6-1042P	5.82	4.7e-08	8.13e-05	0.36	0.46	Tonsillectomy;	chr1:150659846	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.544	rs72700902	ENSG00000206931.1	RNU6-1042P	5.82	4.7e-08	8.13e-05	0.36	0.46	Tonsillectomy;	chr1:150660871	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs72702504	ENSG00000206931.1	RNU6-1042P	5.82	4.7e-08	8.13e-05	0.36	0.46	Tonsillectomy;	chr1:150662898	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs6686525	ENSG00000206931.1	RNU6-1042P	5.82	4.7e-08	8.13e-05	0.36	0.46	Tonsillectomy;	chr1:150663335	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.536	rs6661415	ENSG00000206931.1	RNU6-1042P	5.82	4.7e-08	8.13e-05	0.36	0.46	Tonsillectomy;	chr1:150663393	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.519	rs10788792	ENSG00000206931.1	RNU6-1042P	5.82	4.7e-08	8.13e-05	0.36	0.46	Tonsillectomy;	chr1:150666096	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs11807058	ENSG00000206931.1	RNU6-1042P	5.82	4.7e-08	8.13e-05	0.36	0.46	Tonsillectomy;	chr1:150667999	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs34140753	ENSG00000206931.1	RNU6-1042P	5.82	4.7e-08	8.13e-05	0.36	0.46	Tonsillectomy;	chr1:150670107	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.569	rs11204691	ENSG00000206931.1	RNU6-1042P	5.82	4.7e-08	8.13e-05	0.36	0.46	Tonsillectomy;	chr1:150671863	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs12089731	ENSG00000206931.1	RNU6-1042P	5.82	4.7e-08	8.13e-05	0.36	0.46	Tonsillectomy;	chr1:150675322	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.526	rs11204696	ENSG00000206931.1	RNU6-1042P	5.82	4.7e-08	8.13e-05	0.36	0.46	Tonsillectomy;	chr1:150686245	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs11204697	ENSG00000206931.1	RNU6-1042P	5.82	4.7e-08	8.13e-05	0.36	0.46	Tonsillectomy;	chr1:150686495	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.526	rs11204698	ENSG00000206931.1	RNU6-1042P	5.82	4.7e-08	8.13e-05	0.36	0.46	Tonsillectomy;	chr1:150687069	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs7529998	ENSG00000206931.1	RNU6-1042P	5.82	4.7e-08	8.13e-05	0.36	0.46	Tonsillectomy;	chr1:150690055	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs11803569	ENSG00000206931.1	RNU6-1042P	5.82	4.7e-08	8.13e-05	0.36	0.46	Tonsillectomy;	chr1:150691601	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs1336898	ENSG00000206931.1	RNU6-1042P	5.82	4.7e-08	8.13e-05	0.36	0.46	Tonsillectomy;	chr1:150692574	chr1:150701866~150701972:+
TGCT	cis	rs7412746	0.597	rs868751	ENSG00000206931.1	RNU6-1042P	5.82	4.7e-08	8.13e-05	0.36	0.46	Melanoma;	chr1:150696938	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs2275236	ENSG00000206931.1	RNU6-1042P	-5.82	4.7e-08	8.13e-05	-0.36	-0.46	Tonsillectomy;	chr1:150697476	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs17658705	ENSG00000206931.1	RNU6-1042P	-5.82	4.7e-08	8.13e-05	-0.36	-0.46	Tonsillectomy;	chr1:150705595	chr1:150701866~150701972:+
TGCT	cis	rs2739330	0.76	rs5751761	ENSG00000250470.1	AP000351.3	-5.82	4.71e-08	8.15e-05	-0.45	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23976904~23977585:-
TGCT	cis	rs972540	0.64	rs35382888	ENSG00000279220.1	GPR1-AS	5.82	4.72e-08	8.17e-05	0.45	0.46	Body mass index;	chr2:206325964	chr2:206203376~206266243:+
TGCT	cis	rs972540	0.64	rs34427052	ENSG00000279220.1	GPR1-AS	5.82	4.72e-08	8.17e-05	0.45	0.46	Body mass index;	chr2:206326497	chr2:206203376~206266243:+
TGCT	cis	rs972540	0.64	rs12989476	ENSG00000279220.1	GPR1-AS	5.82	4.72e-08	8.17e-05	0.45	0.46	Body mass index;	chr2:206332431	chr2:206203376~206266243:+
TGCT	cis	rs972540	0.64	rs12994992	ENSG00000279220.1	GPR1-AS	5.82	4.72e-08	8.17e-05	0.45	0.46	Body mass index;	chr2:206338462	chr2:206203376~206266243:+
TGCT	cis	rs950027	0.787	rs1547487	ENSG00000259520.4	CTD-2651B20.3	-5.82	4.73e-08	8.19e-05	-0.36	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45431785	chr15:45251580~45279251:-
TGCT	cis	rs7301826	1	rs4759787	ENSG00000256250.1	RP11-989F5.1	-5.82	4.77e-08	8.26e-05	-0.5	-0.46	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810606~130812438:+
TGCT	cis	rs875971	0.66	rs2013222	ENSG00000222364.1	RNU6-96P	5.82	4.78e-08	8.28e-05	0.54	0.46	Aortic root size;	chr7:66570949	chr7:66395191~66395286:+
TGCT	cis	rs5769707	0.837	rs5769709	ENSG00000235111.1	RP1-29C18.8	-5.82	4.82e-08	8.33e-05	-0.38	-0.46	Monocyte percentage of white cells;Monocyte count;	chr22:49628109	chr22:49612657~49615716:-
TGCT	cis	rs76878669	0.561	rs10896112	ENSG00000254510.1	RP11-867G23.10	-5.82	4.83e-08	8.35e-05	-0.62	-0.46	Educational attainment (years of education);	chr11:66349365	chr11:66409158~66417137:+
TGCT	cis	rs76878669	0.519	rs10791869	ENSG00000254510.1	RP11-867G23.10	-5.82	4.83e-08	8.35e-05	-0.62	-0.46	Educational attainment (years of education);	chr11:66349642	chr11:66409158~66417137:+
TGCT	cis	rs76878669	0.561	rs7110944	ENSG00000254510.1	RP11-867G23.10	-5.82	4.83e-08	8.35e-05	-0.62	-0.46	Educational attainment (years of education);	chr11:66350746	chr11:66409158~66417137:+
TGCT	cis	rs76878669	0.561	rs4930177	ENSG00000254510.1	RP11-867G23.10	5.82	4.83e-08	8.35e-05	0.62	0.46	Educational attainment (years of education);	chr11:66353313	chr11:66409158~66417137:+
TGCT	cis	rs76878669	0.561	rs12794121	ENSG00000254510.1	RP11-867G23.10	5.82	4.83e-08	8.35e-05	0.62	0.46	Educational attainment (years of education);	chr11:66358698	chr11:66409158~66417137:+
TGCT	cis	rs76878669	0.538	rs73489638	ENSG00000254510.1	RP11-867G23.10	-5.82	4.83e-08	8.35e-05	-0.62	-0.46	Educational attainment (years of education);	chr11:66360168	chr11:66409158~66417137:+
TGCT	cis	rs76878669	0.561	rs4930178	ENSG00000254510.1	RP11-867G23.10	5.82	4.83e-08	8.35e-05	0.62	0.46	Educational attainment (years of education);	chr11:66361971	chr11:66409158~66417137:+
TGCT	cis	rs76878669	0.561	rs4244813	ENSG00000254510.1	RP11-867G23.10	5.82	4.83e-08	8.35e-05	0.62	0.46	Educational attainment (years of education);	chr11:66362017	chr11:66409158~66417137:+
TGCT	cis	rs76878669	0.515	rs12576299	ENSG00000254510.1	RP11-867G23.10	5.82	4.83e-08	8.35e-05	0.62	0.46	Educational attainment (years of education);	chr11:66364815	chr11:66409158~66417137:+
TGCT	cis	rs76878669	0.561	rs2279861	ENSG00000254510.1	RP11-867G23.10	5.82	4.83e-08	8.35e-05	0.62	0.46	Educational attainment (years of education);	chr11:66365865	chr11:66409158~66417137:+
TGCT	cis	rs2276314	1	rs62101367	ENSG00000278986.1	RP11-723J4.3	-5.82	4.83e-08	8.35e-05	-0.51	-0.46	Endometriosis;Drug-induced torsades de pointes;	chr18:35970921	chr18:35972151~35973916:+
TGCT	cis	rs847845	0.535	rs67385931	ENSG00000186328.4	RP11-140K17.2	5.81	4.86e-08	8.39e-05	0.73	0.46	Non-small cell lung cancer;	chr6:35018729	chr6:34715613~34715940:+
TGCT	cis	rs7044106	0.791	rs10984994	ENSG00000226752.6	PSMD5-AS1	5.81	4.88e-08	8.43e-05	0.59	0.46	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120824828~120854385:+
TGCT	cis	rs7617773	0.78	rs6442111	ENSG00000229759.1	MRPS18AP1	5.81	4.89e-08	8.43e-05	0.39	0.46	Coronary artery disease;	chr3:48270570	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.817	rs3937	ENSG00000229759.1	MRPS18AP1	5.81	4.89e-08	8.43e-05	0.39	0.46	Coronary artery disease;	chr3:48270912	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.851	rs6775179	ENSG00000229759.1	MRPS18AP1	5.81	4.89e-08	8.43e-05	0.39	0.46	Coronary artery disease;	chr3:48271928	chr3:48256350~48256938:-
TGCT	cis	rs875971	0.706	rs1643374	ENSG00000222364.1	RNU6-96P	-5.81	4.89e-08	8.43e-05	-0.55	-0.46	Aortic root size;	chr7:66407695	chr7:66395191~66395286:+
TGCT	cis	rs524281	1	rs475805	ENSG00000255320.1	RP11-755F10.1	-5.81	4.9e-08	8.44e-05	-0.55	-0.46	Electroencephalogram traits;	chr11:66081267	chr11:66244840~66246239:-
TGCT	cis	rs76878669	0.561	rs7125752	ENSG00000254510.1	RP11-867G23.10	-5.81	4.9e-08	8.45e-05	-0.62	-0.46	Educational attainment (years of education);	chr11:66394948	chr11:66409158~66417137:+
TGCT	cis	rs2732480	0.577	rs2634680	ENSG00000258273.1	RP11-370I10.4	-5.81	4.9e-08	8.45e-05	-0.54	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48333755~48333901:-
TGCT	cis	rs2732480	0.577	rs2634678	ENSG00000258273.1	RP11-370I10.4	-5.81	4.9e-08	8.45e-05	-0.54	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48333755~48333901:-
TGCT	cis	rs2732480	0.577	rs2732479	ENSG00000258273.1	RP11-370I10.4	-5.81	4.9e-08	8.45e-05	-0.54	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48333755~48333901:-
TGCT	cis	rs2732480	0.537	rs1061986	ENSG00000258273.1	RP11-370I10.4	-5.81	4.9e-08	8.45e-05	-0.54	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48333755~48333901:-
TGCT	cis	rs9733	0.519	rs1134067	ENSG00000206931.1	RNU6-1042P	5.81	4.91e-08	8.46e-05	0.36	0.46	Tonsillectomy;	chr1:150748699	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.519	rs11587444	ENSG00000206931.1	RNU6-1042P	5.81	4.91e-08	8.46e-05	0.36	0.46	Tonsillectomy;	chr1:150750368	chr1:150701866~150701972:+
TGCT	cis	rs7617773	0.963	rs12493256	ENSG00000229759.1	MRPS18AP1	-5.81	4.91e-08	8.46e-05	-0.36	-0.46	Coronary artery disease;	chr3:48135257	chr3:48256350~48256938:-
TGCT	cis	rs9326248	0.581	rs10892072	ENSG00000254851.1	RP11-109L13.1	-5.81	4.91e-08	8.46e-05	-0.57	-0.46	Blood protein levels;	chr11:117089597	chr11:117135528~117138582:+
TGCT	cis	rs73086581	1	rs6107391	ENSG00000229539.1	RP11-119B16.2	5.81	4.92e-08	8.47e-05	0.69	0.46	Response to antidepressants in depression;	chr20:4002436	chr20:3888239~3888868:-
TGCT	cis	rs73086581	1	rs6107393	ENSG00000229539.1	RP11-119B16.2	5.81	4.92e-08	8.47e-05	0.69	0.46	Response to antidepressants in depression;	chr20:4007091	chr20:3888239~3888868:-
TGCT	cis	rs6061231	0.74	rs11698650	ENSG00000273619.1	RP5-908M14.9	-5.81	4.93e-08	8.48e-05	-0.5	-0.46	Colorectal cancer;	chr20:62383318	chr20:62386303~62386970:-
TGCT	cis	rs6061231	0.755	rs11699160	ENSG00000273619.1	RP5-908M14.9	-5.81	4.93e-08	8.48e-05	-0.5	-0.46	Colorectal cancer;	chr20:62383595	chr20:62386303~62386970:-
TGCT	cis	rs875971	0.564	rs313804	ENSG00000222364.1	RNU6-96P	-5.81	4.96e-08	8.53e-05	-0.52	-0.46	Aortic root size;	chr7:66049635	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.662	rs448725	ENSG00000222364.1	RNU6-96P	-5.81	4.96e-08	8.53e-05	-0.52	-0.46	Aortic root size;	chr7:66049641	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.658	rs432667	ENSG00000222364.1	RNU6-96P	-5.81	4.96e-08	8.53e-05	-0.52	-0.46	Aortic root size;	chr7:66049646	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.8	rs427557	ENSG00000222364.1	RNU6-96P	-5.81	4.96e-08	8.53e-05	-0.52	-0.46	Aortic root size;	chr7:66054263	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.83	rs587360	ENSG00000222364.1	RNU6-96P	-5.81	4.96e-08	8.53e-05	-0.52	-0.46	Aortic root size;	chr7:66057711	chr7:66395191~66395286:+
TGCT	cis	rs7849270	0.959	rs7032712	ENSG00000268707.1	RP11-247A12.7	-5.81	4.97e-08	8.55e-05	-0.51	-0.46	Blood metabolite ratios;	chr9:129130808	chr9:129170434~129170940:+
TGCT	cis	rs17361889	0.517	rs62440455	ENSG00000224683.1	RPL36AP29	5.81	5e-08	8.6e-05	0.59	0.46	Pediatric bone mineral content (hip);	chr7:16285646	chr7:16208945~16209265:+
TGCT	cis	rs7188445	0.736	rs7500666	ENSG00000261390.4	RP11-345M22.2	5.81	5.01e-08	8.62e-05	0.44	0.46	Urate levels;	chr16:79672509	chr16:79715232~79770563:-
TGCT	cis	rs3096299	0.719	rs2965818	ENSG00000274627.1	RP11-104N10.2	5.81	5.03e-08	8.63e-05	0.47	0.46	Multiple myeloma (IgH translocation);	chr16:89444086	chr16:89516797~89522217:+
TGCT	cis	rs17361889	0.727	rs1295129	ENSG00000224683.1	RPL36AP29	-5.81	5.05e-08	8.67e-05	-0.47	-0.46	Pediatric bone mineral content (hip);	chr7:16277030	chr7:16208945~16209265:+
TGCT	cis	rs76878669	0.561	rs11227465	ENSG00000254510.1	RP11-867G23.10	-5.81	5.06e-08	8.68e-05	-0.63	-0.46	Educational attainment (years of education);	chr11:66348408	chr11:66409158~66417137:+
TGCT	cis	rs12906542	0.544	rs35472584	ENSG00000259792.1	RP11-114H24.6	-5.81	5.06e-08	8.69e-05	-0.46	-0.46	Breast cancer;	chr15:77974385	chr15:77993405~77995289:+
TGCT	cis	rs6061231	0.556	rs6121571	ENSG00000273619.1	RP5-908M14.9	-5.8	5.08e-08	8.71e-05	-0.53	-0.46	Colorectal cancer;	chr20:62402267	chr20:62386303~62386970:-
TGCT	cis	rs2276314	1	rs2298715	ENSG00000278986.1	RP11-723J4.3	-5.8	5.08e-08	8.72e-05	-0.51	-0.46	Endometriosis;Drug-induced torsades de pointes;	chr18:35972462	chr18:35972151~35973916:+
TGCT	cis	rs2276314	1	rs4573997	ENSG00000278986.1	RP11-723J4.3	-5.8	5.08e-08	8.72e-05	-0.51	-0.46	Endometriosis;Drug-induced torsades de pointes;	chr18:35972605	chr18:35972151~35973916:+
TGCT	cis	rs2276314	1	rs2276314	ENSG00000278986.1	RP11-723J4.3	5.8	5.08e-08	8.72e-05	0.51	0.46	Endometriosis;Drug-induced torsades de pointes;	chr18:35977503	chr18:35972151~35973916:+
TGCT	cis	rs524281	0.692	rs2452681	ENSG00000255320.1	RP11-755F10.1	-5.8	5.09e-08	8.73e-05	-0.55	-0.46	Electroencephalogram traits;	chr11:66047371	chr11:66244840~66246239:-
TGCT	cis	rs76878669	0.538	rs1785633	ENSG00000254510.1	RP11-867G23.10	5.8	5.15e-08	8.82e-05	0.62	0.46	Educational attainment (years of education);	chr11:66340056	chr11:66409158~66417137:+
TGCT	cis	rs76878669	0.515	rs947978	ENSG00000254510.1	RP11-867G23.10	5.8	5.15e-08	8.82e-05	0.62	0.46	Educational attainment (years of education);	chr11:66341189	chr11:66409158~66417137:+
TGCT	cis	rs2980439	0.525	rs2945238	ENSG00000173295.6	FAM86B3P	5.8	5.16e-08	8.83e-05	0.56	0.46	Neuroticism;	chr8:8312614	chr8:8228595~8244865:+
TGCT	cis	rs875971	0.522	rs1917563	ENSG00000236529.1	RP13-254B10.1	-5.8	5.17e-08	8.85e-05	-0.34	-0.46	Aortic root size;	chr7:65950660	chr7:65840212~65840596:+
TGCT	cis	rs9733	0.519	rs12095002	ENSG00000206931.1	RNU6-1042P	5.8	5.17e-08	8.85e-05	0.36	0.46	Tonsillectomy;	chr1:150676773	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs12085275	ENSG00000206931.1	RNU6-1042P	5.8	5.17e-08	8.85e-05	0.36	0.46	Tonsillectomy;	chr1:150677789	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs12086630	ENSG00000206931.1	RNU6-1042P	5.8	5.17e-08	8.85e-05	0.36	0.46	Tonsillectomy;	chr1:150678479	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs2065900	ENSG00000206931.1	RNU6-1042P	5.8	5.17e-08	8.85e-05	0.36	0.46	Tonsillectomy;	chr1:150679726	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.544	rs2867302	ENSG00000206931.1	RNU6-1042P	5.8	5.17e-08	8.85e-05	0.36	0.46	Tonsillectomy;	chr1:150681174	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs2867301	ENSG00000206931.1	RNU6-1042P	5.8	5.17e-08	8.85e-05	0.36	0.46	Tonsillectomy;	chr1:150681319	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs7538493	ENSG00000206931.1	RNU6-1042P	5.8	5.17e-08	8.85e-05	0.36	0.46	Tonsillectomy;	chr1:150682945	chr1:150701866~150701972:+
TGCT	cis	rs4970988	0.64	rs7524734	ENSG00000206931.1	RNU6-1042P	5.8	5.17e-08	8.85e-05	0.36	0.46	Urate levels;	chr1:150683210	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.596	rs7549795	ENSG00000206931.1	RNU6-1042P	5.8	5.17e-08	8.85e-05	0.36	0.46	Tonsillectomy;	chr1:150684397	chr1:150701866~150701972:+
TGCT	cis	rs1061377	1	rs12646251	ENSG00000249207.1	RP11-360F5.1	-5.8	5.18e-08	8.86e-05	-0.49	-0.46	Uric acid levels;	chr4:39132751	chr4:39112677~39126818:-
TGCT	cis	rs3096299	0.719	rs2911265	ENSG00000274627.1	RP11-104N10.2	5.8	5.2e-08	8.88e-05	0.47	0.46	Multiple myeloma (IgH translocation);	chr16:89444920	chr16:89516797~89522217:+
TGCT	cis	rs5760092	0.755	rs4585126	ENSG00000225282.1	AP000350.6	-5.8	5.2e-08	8.88e-05	-0.65	-0.46	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23926900~23929574:+
TGCT	cis	rs2739330	0.791	rs4822458	ENSG00000273295.1	AP000350.5	5.8	5.21e-08	8.89e-05	0.52	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23901432~23907068:-
TGCT	cis	rs875971	0.651	rs313829	ENSG00000226824.5	RP4-756H11.3	5.8	5.21e-08	8.9e-05	0.55	0.46	Aortic root size;	chr7:66087510	chr7:66654538~66669855:+
TGCT	cis	rs7617773	0.78	rs9846818	ENSG00000229759.1	MRPS18AP1	5.8	5.23e-08	8.92e-05	0.38	0.46	Coronary artery disease;	chr3:48334195	chr3:48256350~48256938:-
TGCT	cis	rs801193	1	rs7782320	ENSG00000222364.1	RNU6-96P	-5.8	5.23e-08	8.92e-05	-0.54	-0.46	Aortic root size;	chr7:66712111	chr7:66395191~66395286:+
TGCT	cis	rs950169	0.922	rs4586394	ENSG00000225151.9	GOLGA2P7	5.8	5.23e-08	8.93e-05	0.54	0.46	Schizophrenia;	chr15:84153633	chr15:84199311~84230136:-
TGCT	cis	rs17301013	0.861	rs7538650	ENSG00000227373.4	RP11-160H22.5	-5.8	5.28e-08	9.01e-05	-0.52	-0.46	Systemic lupus erythematosus;	chr1:174788821	chr1:174115300~174160004:-
TGCT	cis	rs9322193	0.923	rs4870050	ENSG00000216906.2	RP11-350J20.9	5.8	5.29e-08	9.03e-05	0.53	0.46	Lung cancer;	chr6:149838917	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs7752089	ENSG00000216906.2	RP11-350J20.9	5.8	5.29e-08	9.03e-05	0.53	0.46	Lung cancer;	chr6:149839298	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs4242279	ENSG00000216906.2	RP11-350J20.9	5.8	5.29e-08	9.03e-05	0.53	0.46	Lung cancer;	chr6:149839815	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs2275045	ENSG00000216906.2	RP11-350J20.9	5.8	5.29e-08	9.03e-05	0.53	0.46	Lung cancer;	chr6:149842775	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs2184370	ENSG00000216906.2	RP11-350J20.9	5.8	5.29e-08	9.03e-05	0.53	0.46	Lung cancer;	chr6:149843242	chr6:149904243~149906418:+
TGCT	cis	rs1799949	1	rs2037075	ENSG00000198496.9	NBR2	-5.8	5.3e-08	9.04e-05	-0.67	-0.46	Menopause (age at onset);	chr17:43153809	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.55	rs2343818	ENSG00000198496.9	NBR2	-5.8	5.3e-08	9.04e-05	-0.67	-0.46	Menopause (age at onset);	chr17:43332406	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.526	rs4352088	ENSG00000198496.9	NBR2	-5.8	5.3e-08	9.04e-05	-0.67	-0.46	Menopause (age at onset);	chr17:43337311	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.965	rs34633610	ENSG00000198496.9	NBR2	-5.8	5.3e-08	9.04e-05	-0.67	-0.46	Menopause (age at onset);	chr17:43342017	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.965	rs11654051	ENSG00000198496.9	NBR2	-5.8	5.3e-08	9.04e-05	-0.67	-0.46	Menopause (age at onset);	chr17:43342288	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.93	rs56729776	ENSG00000198496.9	NBR2	-5.8	5.3e-08	9.04e-05	-0.67	-0.46	Menopause (age at onset);	chr17:43344763	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs9646417	ENSG00000198496.9	NBR2	-5.8	5.3e-08	9.04e-05	-0.67	-0.46	Menopause (age at onset);	chr17:43346885	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs1545764	ENSG00000198496.9	NBR2	-5.8	5.3e-08	9.04e-05	-0.67	-0.46	Menopause (age at onset);	chr17:43347197	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs9646412	ENSG00000198496.9	NBR2	-5.8	5.3e-08	9.04e-05	-0.67	-0.46	Menopause (age at onset);	chr17:43348525	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs4793231	ENSG00000198496.9	NBR2	-5.8	5.3e-08	9.04e-05	-0.67	-0.46	Menopause (age at onset);	chr17:43350101	chr17:43125610~43153671:+
TGCT	cis	rs11155671	0.53	rs1334510	ENSG00000216906.2	RP11-350J20.9	5.79	5.32e-08	9.06e-05	0.5	0.46	Testicular germ cell tumor;	chr6:149880043	chr6:149904243~149906418:+
TGCT	cis	rs6061231	0.837	rs6121558	ENSG00000273619.1	RP5-908M14.9	-5.79	5.33e-08	9.08e-05	-0.52	-0.46	Colorectal cancer;	chr20:62386309	chr20:62386303~62386970:-
TGCT	cis	rs36052053	0.521	rs13200680	ENSG00000219700.1	PTCHD3P3	5.79	5.35e-08	9.1e-05	0.97	0.46	Red cell distribution width;	chr6:109192842	chr6:109288571~109290503:-
TGCT	cis	rs36052053	0.521	rs71558350	ENSG00000219700.1	PTCHD3P3	5.79	5.35e-08	9.1e-05	0.97	0.46	Red cell distribution width;	chr6:109193340	chr6:109288571~109290503:-
TGCT	cis	rs36052053	0.521	rs71558353	ENSG00000219700.1	PTCHD3P3	5.79	5.35e-08	9.1e-05	0.97	0.46	Red cell distribution width;	chr6:109201315	chr6:109288571~109290503:-
TGCT	cis	rs36052053	0.521	rs35370422	ENSG00000219700.1	PTCHD3P3	5.79	5.35e-08	9.1e-05	0.97	0.46	Red cell distribution width;	chr6:109210537	chr6:109288571~109290503:-
TGCT	cis	rs36052053	0.521	rs36085386	ENSG00000219700.1	PTCHD3P3	5.79	5.35e-08	9.1e-05	0.97	0.46	Red cell distribution width;	chr6:109223182	chr6:109288571~109290503:-
TGCT	cis	rs36052053	0.521	rs71558357	ENSG00000219700.1	PTCHD3P3	5.79	5.35e-08	9.1e-05	0.97	0.46	Red cell distribution width;	chr6:109238166	chr6:109288571~109290503:-
TGCT	cis	rs36052053	0.521	rs13219774	ENSG00000219700.1	PTCHD3P3	5.79	5.35e-08	9.1e-05	0.97	0.46	Red cell distribution width;	chr6:109243023	chr6:109288571~109290503:-
TGCT	cis	rs17301013	0.507	rs398350	ENSG00000227373.4	RP11-160H22.5	5.79	5.35e-08	9.1e-05	0.53	0.46	Systemic lupus erythematosus;	chr1:174706168	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs3117843	ENSG00000227373.4	RP11-160H22.5	5.79	5.35e-08	9.1e-05	0.53	0.46	Systemic lupus erythematosus;	chr1:174711581	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs332786	ENSG00000227373.4	RP11-160H22.5	5.79	5.35e-08	9.1e-05	0.53	0.46	Systemic lupus erythematosus;	chr1:174713584	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs332779	ENSG00000227373.4	RP11-160H22.5	5.79	5.35e-08	9.1e-05	0.53	0.46	Systemic lupus erythematosus;	chr1:174716623	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs332781	ENSG00000227373.4	RP11-160H22.5	5.79	5.35e-08	9.1e-05	0.53	0.46	Systemic lupus erythematosus;	chr1:174718483	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs193082	ENSG00000227373.4	RP11-160H22.5	5.79	5.35e-08	9.1e-05	0.53	0.46	Systemic lupus erythematosus;	chr1:174725439	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs460878	ENSG00000227373.4	RP11-160H22.5	5.79	5.35e-08	9.1e-05	0.53	0.46	Systemic lupus erythematosus;	chr1:174732645	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs2568096	ENSG00000227373.4	RP11-160H22.5	5.79	5.35e-08	9.1e-05	0.53	0.46	Systemic lupus erythematosus;	chr1:174735463	chr1:174115300~174160004:-
TGCT	cis	rs524281	1	rs472518	ENSG00000255320.1	RP11-755F10.1	-5.79	5.38e-08	9.14e-05	-0.55	-0.46	Electroencephalogram traits;	chr11:66084431	chr11:66244840~66246239:-
TGCT	cis	rs7804306	1	rs13222718	ENSG00000233264.2	AC006042.8	5.79	5.39e-08	9.15e-05	0.94	0.46	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7974690	chr7:7980312~7982228:+
TGCT	cis	rs7804306	1	rs34438930	ENSG00000233264.2	AC006042.8	5.79	5.39e-08	9.15e-05	0.94	0.46	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7974740	chr7:7980312~7982228:+
TGCT	cis	rs7804306	1	rs35425218	ENSG00000233264.2	AC006042.8	5.79	5.39e-08	9.15e-05	0.94	0.46	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7977124	chr7:7980312~7982228:+
TGCT	cis	rs7829975	0.514	rs2976926	ENSG00000173295.6	FAM86B3P	5.79	5.41e-08	9.18e-05	0.56	0.46	Mood instability;	chr8:8404114	chr8:8228595~8244865:+
TGCT	cis	rs801193	1	rs4717319	ENSG00000222364.1	RNU6-96P	-5.79	5.43e-08	9.22e-05	-0.55	-0.46	Aortic root size;	chr7:66777606	chr7:66395191~66395286:+
TGCT	cis	rs7811142	1	rs6979335	ENSG00000242294.5	STAG3L5P	5.79	5.45e-08	9.25e-05	0.43	0.46	Platelet count;	chr7:100492237	chr7:100336079~100351900:+
TGCT	cis	rs12891047	0.966	rs12588401	ENSG00000258759.1	RP11-1012A1.7	5.79	5.45e-08	9.25e-05	0.39	0.46	Amyotrophic lateral sclerosis (sporadic);	chr14:67774231	chr14:67799004~67799609:+
TGCT	cis	rs7208859	0.623	rs7220999	ENSG00000263531.1	RP13-753N3.1	5.79	5.47e-08	9.29e-05	0.88	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs55638872	ENSG00000263531.1	RP13-753N3.1	5.79	5.47e-08	9.29e-05	0.88	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs9899268	ENSG00000263531.1	RP13-753N3.1	5.79	5.47e-08	9.29e-05	0.88	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30863921~30864940:-
TGCT	cis	rs7605378	0.528	rs1704191	ENSG00000232732.8	AC073043.1	-5.79	5.49e-08	9.32e-05	-0.53	-0.46	Osteoporosis;	chr2:199951670	chr2:199867396~199911159:-
TGCT	cis	rs875971	0.66	rs10229345	ENSG00000222364.1	RNU6-96P	-5.79	5.52e-08	9.36e-05	-0.54	-0.46	Aortic root size;	chr7:66517181	chr7:66395191~66395286:+
TGCT	cis	rs950169	0.922	rs11635505	ENSG00000225151.9	GOLGA2P7	5.79	5.53e-08	9.38e-05	0.52	0.46	Schizophrenia;	chr15:84553803	chr15:84199311~84230136:-
TGCT	cis	rs2276314	1	rs56050783	ENSG00000278986.1	RP11-723J4.3	-5.79	5.54e-08	9.38e-05	-0.5	-0.46	Endometriosis;Drug-induced torsades de pointes;	chr18:35973828	chr18:35972151~35973916:+
TGCT	cis	rs2276314	1	rs58054756	ENSG00000278986.1	RP11-723J4.3	-5.79	5.54e-08	9.38e-05	-0.5	-0.46	Endometriosis;Drug-induced torsades de pointes;	chr18:35974090	chr18:35972151~35973916:+
TGCT	cis	rs2276314	0.947	rs4799831	ENSG00000278986.1	RP11-723J4.3	-5.79	5.54e-08	9.38e-05	-0.5	-0.46	Endometriosis;Drug-induced torsades de pointes;	chr18:35974812	chr18:35972151~35973916:+
TGCT	cis	rs8062405	1	rs4788095	ENSG00000259982.1	CDC37P1	5.79	5.55e-08	9.41e-05	0.63	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.964	rs72793809	ENSG00000259982.1	CDC37P1	5.79	5.55e-08	9.41e-05	0.63	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs62036620	ENSG00000259982.1	CDC37P1	5.79	5.55e-08	9.41e-05	0.63	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs62036621	ENSG00000259982.1	CDC37P1	5.79	5.55e-08	9.41e-05	0.63	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28700294~28701540:-
TGCT	cis	rs801193	1	rs7785213	ENSG00000222364.1	RNU6-96P	5.78	5.58e-08	9.45e-05	0.54	0.46	Aortic root size;	chr7:66673991	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.935	rs3800820	ENSG00000222364.1	RNU6-96P	5.78	5.58e-08	9.45e-05	0.54	0.46	Aortic root size;	chr7:66682191	chr7:66395191~66395286:+
TGCT	cis	rs801193	1	rs2003301	ENSG00000222364.1	RNU6-96P	5.78	5.58e-08	9.45e-05	0.54	0.46	Aortic root size;	chr7:66682669	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.967	rs2707841	ENSG00000222364.1	RNU6-96P	-5.78	5.58e-08	9.45e-05	-0.54	-0.46	Aortic root size;	chr7:66692033	chr7:66395191~66395286:+
TGCT	cis	rs801193	1	rs4717310	ENSG00000222364.1	RNU6-96P	-5.78	5.58e-08	9.45e-05	-0.54	-0.46	Aortic root size;	chr7:66696020	chr7:66395191~66395286:+
TGCT	cis	rs1891275	0.551	rs7908678	ENSG00000228701.1	TNKS2-AS1	5.78	5.58e-08	9.45e-05	0.53	0.46	Intelligence (multi-trait analysis);	chr10:91659253	chr10:91782839~91798291:-
TGCT	cis	rs9733	0.519	rs3768005	ENSG00000206931.1	RNU6-1042P	5.78	5.59e-08	9.46e-05	0.35	0.46	Tonsillectomy;	chr1:150708512	chr1:150701866~150701972:+
TGCT	cis	rs9733	0.519	rs72704603	ENSG00000206931.1	RNU6-1042P	5.78	5.59e-08	9.46e-05	0.35	0.46	Tonsillectomy;	chr1:150735516	chr1:150701866~150701972:+
TGCT	cis	rs76878669	0.538	rs4930360	ENSG00000254510.1	RP11-867G23.10	5.78	5.6e-08	9.48e-05	0.62	0.46	Educational attainment (years of education);	chr11:66375776	chr11:66409158~66417137:+
TGCT	cis	rs17301013	0.507	rs2183202	ENSG00000227373.4	RP11-160H22.5	5.78	5.63e-08	9.53e-05	0.56	0.46	Systemic lupus erythematosus;	chr1:174824553	chr1:174115300~174160004:-
TGCT	cis	rs8040855	0.579	rs4843029	ENSG00000259295.5	CSPG4P12	-5.78	5.64e-08	9.54e-05	-0.58	-0.46	Bulimia nervosa;	chr15:85182164	chr15:85191438~85213905:+
TGCT	cis	rs2276314	0.857	rs62101376	ENSG00000278986.1	RP11-723J4.3	-5.78	5.65e-08	9.55e-05	-0.53	-0.46	Endometriosis;Drug-induced torsades de pointes;	chr18:36002992	chr18:35972151~35973916:+
TGCT	cis	rs7829975	0.514	rs2920983	ENSG00000173295.6	FAM86B3P	5.78	5.69e-08	9.62e-05	0.56	0.46	Mood instability;	chr8:8410553	chr8:8228595~8244865:+
TGCT	cis	rs7044106	0.762	rs1158553	ENSG00000226752.6	PSMD5-AS1	-5.78	5.69e-08	9.62e-05	-0.59	-0.46	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120824828~120854385:+
TGCT	cis	rs17301013	0.507	rs1613634	ENSG00000227373.4	RP11-160H22.5	-5.78	5.71e-08	9.64e-05	-0.51	-0.46	Systemic lupus erythematosus;	chr1:174803184	chr1:174115300~174160004:-
TGCT	cis	rs3091242	1	rs9689	ENSG00000261349.1	RP3-465N24.5	-5.78	5.73e-08	9.69e-05	-0.46	-0.46	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25266102~25267136:-
TGCT	cis	rs76878669	0.561	rs10896111	ENSG00000254510.1	RP11-867G23.10	-5.78	5.77e-08	9.73e-05	-0.62	-0.46	Educational attainment (years of education);	chr11:66348219	chr11:66409158~66417137:+
TGCT	cis	rs1832871	0.64	rs262831	ENSG00000188451.8	SRP72P2	5.78	5.77e-08	9.74e-05	0.39	0.46	Height;	chr6:158270137	chr6:158237336~158242797:-
TGCT	cis	rs4713118	0.513	rs149989	ENSG00000216901.1	AL022393.7	5.78	5.77e-08	9.74e-05	0.59	0.46	Parkinson's disease;	chr6:28030406	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.513	rs149941	ENSG00000216901.1	AL022393.7	5.78	5.77e-08	9.74e-05	0.59	0.46	Parkinson's disease;	chr6:28033255	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.513	rs149942	ENSG00000216901.1	AL022393.7	5.78	5.77e-08	9.74e-05	0.59	0.46	Parkinson's disease;	chr6:28033832	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.513	rs149944	ENSG00000216901.1	AL022393.7	5.78	5.77e-08	9.74e-05	0.59	0.46	Parkinson's disease;	chr6:28035040	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.513	rs149945	ENSG00000216901.1	AL022393.7	5.78	5.77e-08	9.74e-05	0.59	0.46	Parkinson's disease;	chr6:28035075	chr6:28176188~28176674:+
TGCT	cis	rs12891047	0.866	rs1810523	ENSG00000258759.1	RP11-1012A1.7	-5.78	5.77e-08	9.75e-05	-0.4	-0.46	Amyotrophic lateral sclerosis (sporadic);	chr14:67799991	chr14:67799004~67799609:+
TGCT	cis	rs710913	0.816	rs1180341	ENSG00000182109.6	RP11-69E11.4	-5.78	5.8e-08	9.8e-05	-0.45	-0.46	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527136	chr1:39522280~39546187:-
TGCT	cis	rs17361889	0.752	rs10264415	ENSG00000224683.1	RPL36AP29	-5.78	5.81e-08	9.8e-05	-0.49	-0.46	Pediatric bone mineral content (hip);	chr7:16258087	chr7:16208945~16209265:+
TGCT	cis	rs7811142	1	rs73405353	ENSG00000242294.5	STAG3L5P	5.78	5.82e-08	9.81e-05	0.43	0.46	Platelet count;	chr7:100493592	chr7:100336079~100351900:+
TGCT	cis	rs7849270	0.921	rs7019373	ENSG00000268707.1	RP11-247A12.7	-5.77	5.85e-08	9.85e-05	-0.5	-0.46	Blood metabolite ratios;	chr9:129134942	chr9:129170434~129170940:+
TGCT	cis	rs7849270	1	rs7036236	ENSG00000268707.1	RP11-247A12.7	-5.77	5.85e-08	9.85e-05	-0.5	-0.46	Blood metabolite ratios;	chr9:129137020	chr9:129170434~129170940:+
TGCT	cis	rs7849270	0.959	rs7039031	ENSG00000268707.1	RP11-247A12.7	-5.77	5.85e-08	9.85e-05	-0.5	-0.46	Blood metabolite ratios;	chr9:129137116	chr9:129170434~129170940:+
TGCT	cis	rs7849270	1	rs2297112	ENSG00000268707.1	RP11-247A12.7	-5.77	5.85e-08	9.85e-05	-0.5	-0.46	Blood metabolite ratios;	chr9:129137901	chr9:129170434~129170940:+
TGCT	cis	rs7849270	0.959	rs713218	ENSG00000268707.1	RP11-247A12.7	-5.77	5.85e-08	9.85e-05	-0.5	-0.46	Blood metabolite ratios;	chr9:129138491	chr9:129170434~129170940:+
TGCT	cis	rs7617773	0.779	rs11718329	ENSG00000229759.1	MRPS18AP1	5.77	5.87e-08	9.88e-05	0.39	0.46	Coronary artery disease;	chr3:48268338	chr3:48256350~48256938:-
TGCT	cis	rs11673344	0.9	rs11671112	ENSG00000226686.6	LINC01535	5.77	5.87e-08	9.88e-05	0.54	0.46	Obesity-related traits;	chr19:37169384	chr19:37251912~37265535:+
TGCT	cis	rs875971	0.505	rs2462573	ENSG00000236529.1	RP13-254B10.1	-5.77	5.87e-08	9.88e-05	-0.35	-0.46	Aortic root size;	chr7:66042405	chr7:65840212~65840596:+
TGCT	cis	rs875971	0.505	rs1167385	ENSG00000236529.1	RP13-254B10.1	-5.77	5.87e-08	9.88e-05	-0.35	-0.46	Aortic root size;	chr7:66048321	chr7:65840212~65840596:+
TGCT	cis	rs17301013	0.896	rs3118980	ENSG00000227373.4	RP11-160H22.5	-5.77	5.87e-08	9.89e-05	-0.49	-0.46	Systemic lupus erythematosus;	chr1:174793701	chr1:174115300~174160004:-
TGCT	cis	rs801193	0.548	rs6975044	ENSG00000222364.1	RNU6-96P	-5.77	5.88e-08	9.9e-05	-0.52	-0.46	Aortic root size;	chr7:66762495	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.569	rs35070132	ENSG00000222364.1	RNU6-96P	-5.77	5.88e-08	9.9e-05	-0.52	-0.46	Aortic root size;	chr7:66773096	chr7:66395191~66395286:+
TGCT	cis	rs7849270	0.959	rs2297111	ENSG00000268707.1	RP11-247A12.7	-5.77	5.88e-08	9.91e-05	-0.5	-0.46	Blood metabolite ratios;	chr9:129142015	chr9:129170434~129170940:+
TGCT	cis	rs4774565	0.762	rs11634585	ENSG00000244879.4	GABPB1-AS1	5.77	5.92e-08	9.96e-05	0.38	0.46	Breast cancer;	chr15:50364252	chr15:50354959~50372202:+
TGCT	cis	rs17301013	0.507	rs72715260	ENSG00000227373.4	RP11-160H22.5	5.77	5.98e-08	1e-04	0.57	0.46	Systemic lupus erythematosus;	chr1:174604995	chr1:174115300~174160004:-
TGCT	cis	rs17361889	0.517	rs62440456	ENSG00000224683.1	RPL36AP29	5.77	5.99e-08	0.000101	0.59	0.46	Pediatric bone mineral content (hip);	chr7:16285655	chr7:16208945~16209265:+
TGCT	cis	rs950169	0.922	rs17531523	ENSG00000225151.9	GOLGA2P7	-5.77	6.01e-08	0.000101	-0.51	-0.46	Schizophrenia;	chr15:84589218	chr15:84199311~84230136:-
TGCT	cis	rs875971	0.522	rs709604	ENSG00000236529.1	RP13-254B10.1	-5.77	6.04e-08	0.000101	-0.35	-0.46	Aortic root size;	chr7:66032447	chr7:65840212~65840596:+
TGCT	cis	rs875971	0.505	rs1723275	ENSG00000236529.1	RP13-254B10.1	-5.77	6.04e-08	0.000101	-0.35	-0.46	Aortic root size;	chr7:66039646	chr7:65840212~65840596:+
TGCT	cis	rs17301013	0.606	rs12089182	ENSG00000227373.4	RP11-160H22.5	5.77	6.04e-08	0.000101	0.53	0.46	Systemic lupus erythematosus;	chr1:174463816	chr1:174115300~174160004:-
TGCT	cis	rs7811142	0.666	rs28401739	ENSG00000242294.5	STAG3L5P	5.77	6.06e-08	0.000102	0.43	0.46	Platelet count;	chr7:100308061	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.775	rs1059129	ENSG00000242294.5	STAG3L5P	5.77	6.06e-08	0.000102	0.43	0.46	Platelet count;	chr7:100328899	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.562	rs7786844	ENSG00000242294.5	STAG3L5P	5.77	6.06e-08	0.000102	0.43	0.46	Platelet count;	chr7:100336385	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.83	rs6979910	ENSG00000242294.5	STAG3L5P	5.77	6.06e-08	0.000102	0.43	0.46	Platelet count;	chr7:100343007	chr7:100336079~100351900:+
TGCT	cis	rs1832871	0.619	rs262825	ENSG00000188451.8	SRP72P2	-5.77	6.07e-08	0.000102	-0.39	-0.46	Height;	chr6:158257599	chr6:158237336~158242797:-
TGCT	cis	rs11723261	0.582	rs11248006	ENSG00000275426.1	CH17-262A2.1	5.77	6.07e-08	0.000102	0.93	0.46	Immune response to smallpox vaccine (IL-6);	chr4:172914	chr4:149738~150317:+
TGCT	cis	rs1062177	0.547	rs2915818	ENSG00000213433.5	RPLP1P6	5.76	6.11e-08	0.000102	0.46	0.46	Preschool internalizing problems;	chr5:151735729	chr5:151765859~151766378:-
TGCT	cis	rs11723261	0.582	rs7679573	ENSG00000275426.1	CH17-262A2.1	5.76	6.13e-08	0.000103	0.86	0.46	Immune response to smallpox vaccine (IL-6);	chr4:157810	chr4:149738~150317:+
TGCT	cis	rs7104764	1	rs6598066	ENSG00000277290.1	RP11-326C3.16	-5.76	6.14e-08	0.000103	-0.47	-0.46	Menarche (age at onset);	chr11:243185	chr11:243099~243483:-
TGCT	cis	rs11723261	0.582	rs6599293	ENSG00000275426.1	CH17-262A2.1	5.76	6.14e-08	0.000103	0.84	0.46	Immune response to smallpox vaccine (IL-6);	chr4:139246	chr4:149738~150317:+
TGCT	cis	rs11723261	0.582	rs4634177	ENSG00000275426.1	CH17-262A2.1	5.76	6.14e-08	0.000103	0.84	0.46	Immune response to smallpox vaccine (IL-6);	chr4:143055	chr4:149738~150317:+
TGCT	cis	rs62388641	0.547	rs9391923	ENSG00000272279.1	RP11-157J24.2	-5.76	6.16e-08	0.000103	-0.5	-0.46	Daytime sleep phenotypes;	chr6:1554089	chr6:1528364~1528911:-
TGCT	cis	rs36052053	0.908	rs13203020	ENSG00000219700.1	PTCHD3P3	5.76	6.17e-08	0.000103	0.79	0.46	Red cell distribution width;	chr6:109263442	chr6:109288571~109290503:-
TGCT	cis	rs36052053	0.908	rs13203987	ENSG00000219700.1	PTCHD3P3	5.76	6.17e-08	0.000103	0.79	0.46	Red cell distribution width;	chr6:109264037	chr6:109288571~109290503:-
TGCT	cis	rs36052053	0.908	rs1812230	ENSG00000219700.1	PTCHD3P3	5.76	6.17e-08	0.000103	0.79	0.46	Red cell distribution width;	chr6:109268132	chr6:109288571~109290503:-
TGCT	cis	rs36052053	0.908	rs34352435	ENSG00000219700.1	PTCHD3P3	5.76	6.17e-08	0.000103	0.79	0.46	Red cell distribution width;	chr6:109272401	chr6:109288571~109290503:-
TGCT	cis	rs36052053	0.908	rs34854922	ENSG00000219700.1	PTCHD3P3	5.76	6.17e-08	0.000103	0.79	0.46	Red cell distribution width;	chr6:109272953	chr6:109288571~109290503:-
TGCT	cis	rs36052053	0.908	rs36094641	ENSG00000219700.1	PTCHD3P3	5.76	6.17e-08	0.000103	0.79	0.46	Red cell distribution width;	chr6:109282652	chr6:109288571~109290503:-
TGCT	cis	rs5760092	0.755	rs5760096	ENSG00000225282.1	AP000350.6	5.76	6.18e-08	0.000103	0.58	0.46	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23905123	chr22:23926900~23929574:+
TGCT	cis	rs76878669	0.561	rs3177514	ENSG00000254510.1	RP11-867G23.10	5.76	6.22e-08	0.000104	0.62	0.46	Educational attainment (years of education);	chr11:66362887	chr11:66409158~66417137:+
TGCT	cis	rs7617773	0.817	rs745116	ENSG00000229759.1	MRPS18AP1	5.76	6.25e-08	0.000104	0.39	0.46	Coronary artery disease;	chr3:48231046	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.817	rs9847953	ENSG00000229759.1	MRPS18AP1	5.76	6.25e-08	0.000104	0.39	0.46	Coronary artery disease;	chr3:48241205	chr3:48256350~48256938:-
TGCT	cis	rs2882667	0.824	rs13189485	ENSG00000253404.1	AC034243.1	5.76	6.25e-08	0.000104	0.56	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139139712	chr5:138744434~138753309:-
TGCT	cis	rs8062405	1	rs4451951	ENSG00000259982.1	CDC37P1	5.76	6.28e-08	0.000105	0.62	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28700294~28701540:-
TGCT	cis	rs9890032	0.581	rs62070592	ENSG00000266490.1	CTD-2349P21.9	5.76	6.32e-08	0.000105	0.36	0.46	Hip circumference adjusted for BMI;	chr17:30695531	chr17:30792372~30792833:+
TGCT	cis	rs875971	0.793	rs460678	ENSG00000222364.1	RNU6-96P	-5.76	6.32e-08	0.000105	-0.51	-0.46	Aortic root size;	chr7:66062213	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.964	rs160635	ENSG00000222364.1	RNU6-96P	-5.76	6.32e-08	0.000105	-0.51	-0.46	Aortic root size;	chr7:66063931	chr7:66395191~66395286:+
TGCT	cis	rs1832871	0.619	rs827861	ENSG00000188451.8	SRP72P2	5.76	6.33e-08	0.000105	0.39	0.46	Height;	chr6:158289042	chr6:158237336~158242797:-
TGCT	cis	rs17507216	0.628	rs28737193	ENSG00000278603.1	RP13-608F4.5	5.76	6.35e-08	0.000106	0.76	0.46	Excessive daytime sleepiness;	chr15:82701318	chr15:82472203~82472426:+
TGCT	cis	rs950169	0.922	rs11633534	ENSG00000225151.9	GOLGA2P7	-5.76	6.36e-08	0.000106	-0.51	-0.46	Schizophrenia;	chr15:84581411	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.65	rs12902052	ENSG00000225151.9	GOLGA2P7	-5.76	6.36e-08	0.000106	-0.51	-0.46	Schizophrenia;	chr15:84582607	chr15:84199311~84230136:-
TGCT	cis	rs9733	0.596	rs12089989	ENSG00000206931.1	RNU6-1042P	5.76	6.36e-08	0.000106	0.36	0.46	Tonsillectomy;	chr1:150743306	chr1:150701866~150701972:+
TGCT	cis	rs904251	0.766	rs1757175	ENSG00000279942.1	RP1-153P14.7	-5.76	6.37e-08	0.000106	-0.52	-0.46	Cognitive performance;	chr6:37518918	chr6:37567716~37571460:+
TGCT	cis	rs904251	0.828	rs1757174	ENSG00000279942.1	RP1-153P14.7	-5.76	6.37e-08	0.000106	-0.52	-0.46	Cognitive performance;	chr6:37518919	chr6:37567716~37571460:+
TGCT	cis	rs3096299	0.503	rs9940093	ENSG00000274627.1	RP11-104N10.2	5.76	6.37e-08	0.000106	0.47	0.46	Multiple myeloma (IgH translocation);	chr16:89492297	chr16:89516797~89522217:+
TGCT	cis	rs17361889	0.517	rs12699776	ENSG00000224683.1	RPL36AP29	5.76	6.38e-08	0.000106	0.59	0.46	Pediatric bone mineral content (hip);	chr7:16286676	chr7:16208945~16209265:+
TGCT	cis	rs875971	0.545	rs73136346	ENSG00000226824.5	RP4-756H11.3	5.76	6.39e-08	0.000106	0.58	0.46	Aortic root size;	chr7:66101095	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.54	rs1723268	ENSG00000236529.1	RP13-254B10.1	5.75	6.4e-08	0.000106	0.35	0.46	Aortic root size;	chr7:66008093	chr7:65840212~65840596:+
TGCT	cis	rs875971	0.522	rs1701760	ENSG00000236529.1	RP13-254B10.1	5.75	6.4e-08	0.000106	0.35	0.46	Aortic root size;	chr7:66008701	chr7:65840212~65840596:+
TGCT	cis	rs3091242	0.9	rs1811832	ENSG00000261349.1	RP3-465N24.5	-5.75	6.41e-08	0.000107	-0.45	-0.46	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25266102~25267136:-
TGCT	cis	rs17301013	0.507	rs12072050	ENSG00000227373.4	RP11-160H22.5	5.75	6.43e-08	0.000107	0.56	0.46	Systemic lupus erythematosus;	chr1:174269648	chr1:174115300~174160004:-
TGCT	cis	rs9322193	0.886	rs4870049	ENSG00000216906.2	RP11-350J20.9	5.75	6.44e-08	0.000107	0.54	0.46	Lung cancer;	chr6:149837058	chr6:149904243~149906418:+
TGCT	cis	rs17301013	0.507	rs10798324	ENSG00000227373.4	RP11-160H22.5	-5.75	6.47e-08	0.000107	-0.54	-0.46	Systemic lupus erythematosus;	chr1:174787485	chr1:174115300~174160004:-
TGCT	cis	rs7044106	0.762	rs10818471	ENSG00000226752.6	PSMD5-AS1	-5.75	6.47e-08	0.000107	-0.58	-0.46	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120824828~120854385:+
TGCT	cis	rs904251	0.861	rs2776875	ENSG00000279942.1	RP1-153P14.7	-5.75	6.49e-08	0.000108	-0.52	-0.46	Cognitive performance;	chr6:37519020	chr6:37567716~37571460:+
TGCT	cis	rs904251	0.861	rs1757173	ENSG00000279942.1	RP1-153P14.7	-5.75	6.49e-08	0.000108	-0.52	-0.46	Cognitive performance;	chr6:37519176	chr6:37567716~37571460:+
TGCT	cis	rs904251	0.861	rs1757169	ENSG00000279942.1	RP1-153P14.7	-5.75	6.49e-08	0.000108	-0.52	-0.46	Cognitive performance;	chr6:37519300	chr6:37567716~37571460:+
TGCT	cis	rs2276314	1	rs2298716	ENSG00000278986.1	RP11-723J4.3	-5.75	6.49e-08	0.000108	-0.5	-0.46	Endometriosis;Drug-induced torsades de pointes;	chr18:35972635	chr18:35972151~35973916:+
TGCT	cis	rs11763147	1	rs11763147	ENSG00000236529.1	RP13-254B10.1	-5.75	6.5e-08	0.000108	-0.34	-0.46	Corneal structure;	chr7:65861834	chr7:65840212~65840596:+
TGCT	cis	rs17301013	0.932	rs2987874	ENSG00000227373.4	RP11-160H22.5	-5.75	6.5e-08	0.000108	-0.49	-0.46	Systemic lupus erythematosus;	chr1:174801053	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.932	rs1754355	ENSG00000227373.4	RP11-160H22.5	-5.75	6.5e-08	0.000108	-0.49	-0.46	Systemic lupus erythematosus;	chr1:174807407	chr1:174115300~174160004:-
TGCT	cis	rs4713118	0.513	rs1225591	ENSG00000216901.1	AL022393.7	5.75	6.51e-08	0.000108	0.6	0.46	Parkinson's disease;	chr6:28180974	chr6:28176188~28176674:+
TGCT	cis	rs34217772	1	rs35963043	ENSG00000258536.1	RP11-1053O12.1	5.75	6.52e-08	0.000108	0.41	0.46	Myopia;	chr14:41787813	chr14:41742639~41742963:+
TGCT	cis	rs73086581	1	rs6052220	ENSG00000229539.1	RP11-119B16.2	5.75	6.53e-08	0.000108	0.67	0.46	Response to antidepressants in depression;	chr20:3989947	chr20:3888239~3888868:-
TGCT	cis	rs1061377	1	rs56119980	ENSG00000249207.1	RP11-360F5.1	-5.75	6.56e-08	0.000109	-0.51	-0.46	Uric acid levels;	chr4:39139390	chr4:39112677~39126818:-
TGCT	cis	rs916888	0.61	rs199436	ENSG00000262500.1	RP11-259G18.2	-5.75	6.59e-08	0.000109	-0.58	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46243606~46245044:+
TGCT	cis	rs17301013	0.606	rs10912754	ENSG00000227373.4	RP11-160H22.5	5.75	6.59e-08	0.000109	0.53	0.46	Systemic lupus erythematosus;	chr1:174273667	chr1:174115300~174160004:-
TGCT	cis	rs11168618	0.509	rs2731108	ENSG00000240399.1	RP1-228P16.1	-5.75	6.6e-08	0.000109	-0.44	-0.46	Adiponectin levels;	chr12:48493578	chr12:48054813~48055591:-
TGCT	cis	rs3091242	0.866	rs11249249	ENSG00000261349.1	RP3-465N24.5	-5.75	6.61e-08	0.000109	-0.45	-0.46	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25266102~25267136:-
TGCT	cis	rs977987	0.843	rs4888372	ENSG00000261783.1	RP11-252K23.2	-5.75	6.62e-08	0.000109	-0.67	-0.46	Dupuytren's disease;	chr16:75279587	chr16:75379818~75381260:-
TGCT	cis	rs7849270	1	rs10988224	ENSG00000268707.1	RP11-247A12.7	-5.75	6.64e-08	0.00011	-0.5	-0.46	Blood metabolite ratios;	chr9:129141055	chr9:129170434~129170940:+
TGCT	cis	rs2882667	0.858	rs11959803	ENSG00000253404.1	AC034243.1	5.75	6.65e-08	0.00011	0.54	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139115626	chr5:138744434~138753309:-
TGCT	cis	rs875971	0.789	rs28815324	ENSG00000226824.5	RP4-756H11.3	5.75	6.67e-08	0.00011	0.58	0.46	Aortic root size;	chr7:66100789	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.862	rs6460307	ENSG00000222364.1	RNU6-96P	-5.75	6.67e-08	0.00011	-0.49	-0.46	Aortic root size;	chr7:66595884	chr7:66395191~66395286:+
TGCT	cis	rs1757171	0.542	rs3818985	ENSG00000279942.1	RP1-153P14.7	-5.74	6.71e-08	0.000111	-0.47	-0.46	Cognitive performance;	chr6:37516438	chr6:37567716~37571460:+
TGCT	cis	rs76878669	0.561	rs56321771	ENSG00000254510.1	RP11-867G23.10	5.74	6.74e-08	0.000111	0.61	0.46	Educational attainment (years of education);	chr11:66393601	chr11:66409158~66417137:+
TGCT	cis	rs76878669	0.561	rs4630308	ENSG00000254510.1	RP11-867G23.10	5.74	6.74e-08	0.000111	0.61	0.46	Educational attainment (years of education);	chr11:66395116	chr11:66409158~66417137:+
TGCT	cis	rs76878669	0.561	rs12420203	ENSG00000254510.1	RP11-867G23.10	5.74	6.74e-08	0.000111	0.61	0.46	Educational attainment (years of education);	chr11:66396323	chr11:66409158~66417137:+
TGCT	cis	rs7617773	0.817	rs936426	ENSG00000229759.1	MRPS18AP1	5.74	6.75e-08	0.000112	0.39	0.46	Coronary artery disease;	chr3:48173763	chr3:48256350~48256938:-
TGCT	cis	rs321358	0.943	rs17537987	ENSG00000271584.1	RP11-89C3.4	5.74	6.79e-08	0.000112	0.61	0.46	Body mass index;	chr11:111134144	chr11:111091932~111097357:-
TGCT	cis	rs875971	0.545	rs313830	ENSG00000226824.5	RP4-756H11.3	5.74	6.83e-08	0.000113	0.57	0.46	Aortic root size;	chr7:66086944	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.545	rs313828	ENSG00000226824.5	RP4-756H11.3	5.74	6.83e-08	0.000113	0.57	0.46	Aortic root size;	chr7:66087627	chr7:66654538~66669855:+
TGCT	cis	rs875971	0.52	rs160645	ENSG00000226824.5	RP4-756H11.3	5.74	6.83e-08	0.000113	0.57	0.46	Aortic root size;	chr7:66091320	chr7:66654538~66669855:+
TGCT	cis	rs875971	1	rs7781698	ENSG00000222364.1	RNU6-96P	-5.74	6.83e-08	0.000113	-0.52	-0.46	Aortic root size;	chr7:66431325	chr7:66395191~66395286:+
TGCT	cis	rs7044106	0.762	rs7357638	ENSG00000226752.6	PSMD5-AS1	-5.74	6.87e-08	0.000113	-0.59	-0.46	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120824828~120854385:+
TGCT	cis	rs7044106	0.718	rs1960421	ENSG00000226752.6	PSMD5-AS1	-5.74	6.87e-08	0.000113	-0.59	-0.46	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120824828~120854385:+
TGCT	cis	rs875971	0.502	rs2946580	ENSG00000226824.5	RP4-756H11.3	5.74	6.92e-08	0.000113	0.58	0.46	Aortic root size;	chr7:66066855	chr7:66654538~66669855:+
TGCT	cis	rs3096299	0.503	rs4785677	ENSG00000274627.1	RP11-104N10.2	5.74	6.92e-08	0.000113	0.47	0.46	Multiple myeloma (IgH translocation);	chr16:89488693	chr16:89516797~89522217:+
TGCT	cis	rs4774565	0.762	rs8041193	ENSG00000244879.4	GABPB1-AS1	-5.74	6.92e-08	0.000113	-0.37	-0.46	Breast cancer;	chr15:50369960	chr15:50354959~50372202:+
TGCT	cis	rs4774565	0.762	rs34565064	ENSG00000244879.4	GABPB1-AS1	-5.74	6.92e-08	0.000113	-0.37	-0.46	Breast cancer;	chr15:50371706	chr15:50354959~50372202:+
TGCT	cis	rs1775715	1	rs1775715	ENSG00000239731.3	RN7SL825P	5.74	6.92e-08	0.000113	0.49	0.46	Bipolar disorder with mood-incongruent psychosis;	chr10:32020077	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.966	rs1755066	ENSG00000239731.3	RN7SL825P	5.74	6.92e-08	0.000113	0.49	0.46	Bipolar disorder with mood-incongruent psychosis;	chr10:32020232	chr10:31992087~31992381:-
TGCT	cis	rs1775715	0.966	rs1251386	ENSG00000239731.3	RN7SL825P	5.74	6.92e-08	0.000113	0.49	0.46	Bipolar disorder with mood-incongruent psychosis;	chr10:32030186	chr10:31992087~31992381:-
TGCT	cis	rs4834770	0.718	rs4833618	ENSG00000245958.5	RP11-33B1.1	5.74	6.93e-08	0.000113	0.45	0.46	Blood protein levels;	chr4:119388345	chr4:119454791~119552025:+
TGCT	cis	rs710913	0.717	rs1180352	ENSG00000182109.6	RP11-69E11.4	-5.74	6.96e-08	0.000114	-0.46	-0.46	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39542157	chr1:39522280~39546187:-
TGCT	cis	rs172166	0.694	rs203876	ENSG00000216901.1	AL022393.7	5.74	6.96e-08	0.000114	0.58	0.46	Cardiac Troponin-T levels;	chr6:28078895	chr6:28176188~28176674:+
TGCT	cis	rs172166	0.694	rs203877	ENSG00000216901.1	AL022393.7	5.74	6.96e-08	0.000114	0.58	0.46	Cardiac Troponin-T levels;	chr6:28080846	chr6:28176188~28176674:+
TGCT	cis	rs172166	0.694	rs203893	ENSG00000216901.1	AL022393.7	5.74	6.96e-08	0.000114	0.58	0.46	Cardiac Troponin-T levels;	chr6:28094288	chr6:28176188~28176674:+
TGCT	cis	rs172166	0.652	rs476167	ENSG00000216901.1	AL022393.7	5.74	6.96e-08	0.000114	0.58	0.46	Cardiac Troponin-T levels;	chr6:28098110	chr6:28176188~28176674:+
TGCT	cis	rs172166	0.694	rs203892	ENSG00000216901.1	AL022393.7	5.74	6.96e-08	0.000114	0.58	0.46	Cardiac Troponin-T levels;	chr6:28099418	chr6:28176188~28176674:+
TGCT	cis	rs172166	0.694	rs188105	ENSG00000216901.1	AL022393.7	5.74	6.96e-08	0.000114	0.58	0.46	Cardiac Troponin-T levels;	chr6:28103615	chr6:28176188~28176674:+
TGCT	cis	rs76878669	0.561	rs10791872	ENSG00000254510.1	RP11-867G23.10	-5.74	6.97e-08	0.000114	-0.61	-0.46	Educational attainment (years of education);	chr11:66370963	chr11:66409158~66417137:+
TGCT	cis	rs76878669	0.561	rs2279862	ENSG00000254510.1	RP11-867G23.10	5.74	6.97e-08	0.000114	0.61	0.46	Educational attainment (years of education);	chr11:66367708	chr11:66409158~66417137:+
TGCT	cis	rs76878669	0.561	rs12416747	ENSG00000254510.1	RP11-867G23.10	5.74	6.97e-08	0.000114	0.61	0.46	Educational attainment (years of education);	chr11:66368143	chr11:66409158~66417137:+
TGCT	cis	rs76878669	0.561	rs7107191	ENSG00000254510.1	RP11-867G23.10	5.74	6.97e-08	0.000114	0.61	0.46	Educational attainment (years of education);	chr11:66372926	chr11:66409158~66417137:+
TGCT	cis	rs7714584	1	rs1000113	ENSG00000197083.10	ZNF300P1	5.74	7.02e-08	0.000114	0.86	0.46	Crohn's disease;	chr5:150860514	chr5:150930645~150946289:-
TGCT	cis	rs4927850	1	rs10881563	ENSG00000242086.7	LINC00969	5.73	7.13e-08	0.000116	0.52	0.46	Pancreatic cancer;	chr3:196023354	chr3:195658062~195739964:+
TGCT	cis	rs2006771	0.742	rs5749334	ENSG00000236132.1	CTA-440B3.1	-5.73	7.13e-08	0.000116	-0.47	-0.46	Nonsyndromic cleft lip with cleft palate;	chr22:31815426	chr22:31816379~31817491:-
TGCT	cis	rs524281	1	rs489337	ENSG00000255320.1	RP11-755F10.1	-5.73	7.14e-08	0.000116	-0.57	-0.46	Electroencephalogram traits;	chr11:66087090	chr11:66244840~66246239:-
TGCT	cis	rs4835473	0.897	rs17693780	ENSG00000251600.4	RP11-673E1.1	-5.73	7.15e-08	0.000116	-0.45	-0.46	Immature fraction of reticulocytes;	chr4:143737563	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs35556180	ENSG00000251600.4	RP11-673E1.1	-5.73	7.15e-08	0.000116	-0.45	-0.46	Immature fraction of reticulocytes;	chr4:143737595	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs35377051	ENSG00000251600.4	RP11-673E1.1	-5.73	7.15e-08	0.000116	-0.45	-0.46	Immature fraction of reticulocytes;	chr4:143737627	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.864	rs17018131	ENSG00000251600.4	RP11-673E1.1	-5.73	7.15e-08	0.000116	-0.45	-0.46	Immature fraction of reticulocytes;	chr4:143737647	chr4:143912331~143982454:+
TGCT	cis	rs7104764	0.879	rs6598070	ENSG00000277290.1	RP11-326C3.16	-5.73	7.15e-08	0.000116	-0.46	-0.46	Menarche (age at onset);	chr11:225466	chr11:243099~243483:-
TGCT	cis	rs3091242	1	rs9689	ENSG00000224183.1	SDHDP6	-5.73	7.16e-08	0.000116	-0.49	-0.46	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25294164~25294643:-
TGCT	cis	rs12891047	0.866	rs11627100	ENSG00000258759.1	RP11-1012A1.7	-5.73	7.17e-08	0.000117	-0.41	-0.46	Amyotrophic lateral sclerosis (sporadic);	chr14:67840799	chr14:67799004~67799609:+
TGCT	cis	rs6921919	0.789	rs11970439	ENSG00000216901.1	AL022393.7	5.73	7.18e-08	0.000117	0.56	0.46	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28176188~28176674:+
TGCT	cis	rs11155671	0.53	rs9383912	ENSG00000216906.2	RP11-350J20.9	5.73	7.24e-08	0.000118	0.49	0.46	Testicular germ cell tumor;	chr6:149885479	chr6:149904243~149906418:+
TGCT	cis	rs11155671	0.53	rs9383577	ENSG00000216906.2	RP11-350J20.9	5.73	7.24e-08	0.000118	0.49	0.46	Testicular germ cell tumor;	chr6:149886059	chr6:149904243~149906418:+
TGCT	cis	rs11155671	0.53	rs9383914	ENSG00000216906.2	RP11-350J20.9	5.73	7.24e-08	0.000118	0.49	0.46	Testicular germ cell tumor;	chr6:149886098	chr6:149904243~149906418:+
TGCT	cis	rs11155671	0.517	rs9397058	ENSG00000216906.2	RP11-350J20.9	5.73	7.24e-08	0.000118	0.49	0.46	Testicular germ cell tumor;	chr6:149886113	chr6:149904243~149906418:+
TGCT	cis	rs11155671	0.53	rs7768626	ENSG00000216906.2	RP11-350J20.9	5.73	7.24e-08	0.000118	0.49	0.46	Testicular germ cell tumor;	chr6:149886826	chr6:149904243~149906418:+
TGCT	cis	rs11155671	0.53	rs7768665	ENSG00000216906.2	RP11-350J20.9	5.73	7.24e-08	0.000118	0.49	0.46	Testicular germ cell tumor;	chr6:149886888	chr6:149904243~149906418:+
TGCT	cis	rs11155671	0.53	rs7758020	ENSG00000216906.2	RP11-350J20.9	5.73	7.24e-08	0.000118	0.49	0.46	Testicular germ cell tumor;	chr6:149886975	chr6:149904243~149906418:+
TGCT	cis	rs11155671	0.53	rs9322228	ENSG00000216906.2	RP11-350J20.9	5.73	7.24e-08	0.000118	0.49	0.46	Testicular germ cell tumor;	chr6:149888173	chr6:149904243~149906418:+
TGCT	cis	rs11155671	0.53	rs7774787	ENSG00000216906.2	RP11-350J20.9	5.73	7.24e-08	0.000118	0.49	0.46	Testicular germ cell tumor;	chr6:149888296	chr6:149904243~149906418:+
TGCT	cis	rs11155671	0.53	rs2342767	ENSG00000216906.2	RP11-350J20.9	5.73	7.24e-08	0.000118	0.49	0.46	Testicular germ cell tumor;	chr6:149888581	chr6:149904243~149906418:+
TGCT	cis	rs11155671	0.53	rs7764376	ENSG00000216906.2	RP11-350J20.9	5.73	7.24e-08	0.000118	0.49	0.46	Testicular germ cell tumor;	chr6:149889208	chr6:149904243~149906418:+
TGCT	cis	rs11155671	0.53	rs6933882	ENSG00000216906.2	RP11-350J20.9	5.73	7.24e-08	0.000118	0.49	0.46	Testicular germ cell tumor;	chr6:149889666	chr6:149904243~149906418:+
TGCT	cis	rs11155671	0.53	rs6939761	ENSG00000216906.2	RP11-350J20.9	5.73	7.24e-08	0.000118	0.49	0.46	Testicular germ cell tumor;	chr6:149889858	chr6:149904243~149906418:+
TGCT	cis	rs11155671	0.53	rs3823021	ENSG00000216906.2	RP11-350J20.9	5.73	7.24e-08	0.000118	0.49	0.46	Testicular germ cell tumor;	chr6:149889863	chr6:149904243~149906418:+
TGCT	cis	rs11155671	0.53	rs4869763	ENSG00000216906.2	RP11-350J20.9	5.73	7.24e-08	0.000118	0.49	0.46	Testicular germ cell tumor;	chr6:149890548	chr6:149904243~149906418:+
TGCT	cis	rs11155671	0.53	rs4869764	ENSG00000216906.2	RP11-350J20.9	5.73	7.24e-08	0.000118	0.49	0.46	Testicular germ cell tumor;	chr6:149890692	chr6:149904243~149906418:+
TGCT	cis	rs17301013	0.606	rs5015737	ENSG00000227373.4	RP11-160H22.5	5.73	7.24e-08	0.000118	0.52	0.46	Systemic lupus erythematosus;	chr1:174452857	chr1:174115300~174160004:-
TGCT	cis	rs7811142	1	rs7803454	ENSG00000242294.5	STAG3L5P	5.73	7.26e-08	0.000118	0.43	0.46	Platelet count;	chr7:100393925	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs11771241	ENSG00000242294.5	STAG3L5P	5.73	7.26e-08	0.000118	0.43	0.46	Platelet count;	chr7:100397162	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.943	rs11769886	ENSG00000242294.5	STAG3L5P	5.73	7.26e-08	0.000118	0.43	0.46	Platelet count;	chr7:100400984	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.887	rs35111986	ENSG00000242294.5	STAG3L5P	5.73	7.26e-08	0.000118	0.43	0.46	Platelet count;	chr7:100402651	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs67315960	ENSG00000242294.5	STAG3L5P	5.73	7.26e-08	0.000118	0.43	0.46	Platelet count;	chr7:100417501	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs11763414	ENSG00000242294.5	STAG3L5P	5.73	7.26e-08	0.000118	0.43	0.46	Platelet count;	chr7:100419221	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs7783159	ENSG00000242294.5	STAG3L5P	5.73	7.26e-08	0.000118	0.43	0.46	Platelet count;	chr7:100419831	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs67163493	ENSG00000242294.5	STAG3L5P	5.73	7.26e-08	0.000118	0.43	0.46	Platelet count;	chr7:100426215	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs6975729	ENSG00000242294.5	STAG3L5P	5.73	7.26e-08	0.000118	0.43	0.46	Platelet count;	chr7:100430564	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs1073	ENSG00000242294.5	STAG3L5P	5.73	7.26e-08	0.000118	0.43	0.46	Platelet count;	chr7:100433989	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.887	rs4074838	ENSG00000242294.5	STAG3L5P	5.73	7.26e-08	0.000118	0.43	0.46	Platelet count;	chr7:100435042	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs11761725	ENSG00000242294.5	STAG3L5P	5.73	7.26e-08	0.000118	0.43	0.46	Platelet count;	chr7:100442192	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs11764818	ENSG00000242294.5	STAG3L5P	5.73	7.26e-08	0.000118	0.43	0.46	Platelet count;	chr7:100445432	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs2406255	ENSG00000242294.5	STAG3L5P	5.73	7.26e-08	0.000118	0.43	0.46	Platelet count;	chr7:100456067	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.945	rs6955362	ENSG00000242294.5	STAG3L5P	5.73	7.26e-08	0.000118	0.43	0.46	Platelet count;	chr7:100458543	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs6975514	ENSG00000242294.5	STAG3L5P	5.73	7.26e-08	0.000118	0.43	0.46	Platelet count;	chr7:100458597	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs7811142	ENSG00000242294.5	STAG3L5P	5.73	7.26e-08	0.000118	0.43	0.46	Platelet count;	chr7:100467820	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs7794485	ENSG00000242294.5	STAG3L5P	5.73	7.26e-08	0.000118	0.43	0.46	Platelet count;	chr7:100471313	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs11773661	ENSG00000242294.5	STAG3L5P	5.73	7.26e-08	0.000118	0.43	0.46	Platelet count;	chr7:100475446	chr7:100336079~100351900:+
TGCT	cis	rs801193	0.569	rs13226966	ENSG00000222364.1	RNU6-96P	-5.73	7.28e-08	0.000118	-0.52	-0.46	Aortic root size;	chr7:66768636	chr7:66395191~66395286:+
TGCT	cis	rs7104764	1	rs2293167	ENSG00000277290.1	RP11-326C3.16	5.73	7.3e-08	0.000118	0.44	0.46	Menarche (age at onset);	chr11:211644	chr11:243099~243483:-
TGCT	cis	rs7104764	1	rs76552490	ENSG00000277290.1	RP11-326C3.16	5.73	7.3e-08	0.000118	0.44	0.46	Menarche (age at onset);	chr11:212015	chr11:243099~243483:-
TGCT	cis	rs7104764	1	rs1533825	ENSG00000277290.1	RP11-326C3.16	5.73	7.3e-08	0.000118	0.44	0.46	Menarche (age at onset);	chr11:214163	chr11:243099~243483:-
TGCT	cis	rs36052053	0.908	rs71558363	ENSG00000219700.1	PTCHD3P3	5.73	7.32e-08	0.000119	0.78	0.46	Red cell distribution width;	chr6:109283778	chr6:109288571~109290503:-
TGCT	cis	rs36052053	0.808	rs78799897	ENSG00000219700.1	PTCHD3P3	5.73	7.32e-08	0.000119	0.78	0.46	Red cell distribution width;	chr6:109285941	chr6:109288571~109290503:-
TGCT	cis	rs1061377	0.76	rs7678457	ENSG00000249207.1	RP11-360F5.1	-5.73	7.32e-08	0.000119	-0.49	-0.46	Uric acid levels;	chr4:39136041	chr4:39112677~39126818:-
TGCT	cis	rs17826219	0.5	rs117560728	ENSG00000263531.1	RP13-753N3.1	5.73	7.35e-08	0.000119	0.95	0.46	Body mass index;	chr17:30743920	chr17:30863921~30864940:-
TGCT	cis	rs12891047	1	rs11158695	ENSG00000258759.1	RP11-1012A1.7	5.72	7.37e-08	0.000119	0.39	0.46	Amyotrophic lateral sclerosis (sporadic);	chr14:67774894	chr14:67799004~67799609:+
TGCT	cis	rs12891047	1	rs12886915	ENSG00000258759.1	RP11-1012A1.7	5.72	7.37e-08	0.000119	0.39	0.46	Amyotrophic lateral sclerosis (sporadic);	chr14:67776181	chr14:67799004~67799609:+
TGCT	cis	rs12891047	1	rs12891047	ENSG00000258759.1	RP11-1012A1.7	5.72	7.37e-08	0.000119	0.39	0.46	Amyotrophic lateral sclerosis (sporadic);	chr14:67776358	chr14:67799004~67799609:+
TGCT	cis	rs12891047	1	rs12892221	ENSG00000258759.1	RP11-1012A1.7	5.72	7.37e-08	0.000119	0.39	0.46	Amyotrophic lateral sclerosis (sporadic);	chr14:67776871	chr14:67799004~67799609:+
TGCT	cis	rs12891047	1	rs4902517	ENSG00000258759.1	RP11-1012A1.7	5.72	7.37e-08	0.000119	0.39	0.46	Amyotrophic lateral sclerosis (sporadic);	chr14:67777038	chr14:67799004~67799609:+
TGCT	cis	rs12891047	1	rs767972	ENSG00000258759.1	RP11-1012A1.7	5.72	7.37e-08	0.000119	0.39	0.46	Amyotrophic lateral sclerosis (sporadic);	chr14:67777485	chr14:67799004~67799609:+
TGCT	cis	rs12891047	1	rs10132318	ENSG00000258759.1	RP11-1012A1.7	5.72	7.37e-08	0.000119	0.39	0.46	Amyotrophic lateral sclerosis (sporadic);	chr14:67787544	chr14:67799004~67799609:+
TGCT	cis	rs12891047	1	rs4902519	ENSG00000258759.1	RP11-1012A1.7	5.72	7.37e-08	0.000119	0.39	0.46	Amyotrophic lateral sclerosis (sporadic);	chr14:67787886	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.738	rs764088	ENSG00000258759.1	RP11-1012A1.7	-5.72	7.37e-08	0.000119	-0.39	-0.46	Amyotrophic lateral sclerosis (sporadic);	chr14:67863189	chr14:67799004~67799609:+
TGCT	cis	rs17361889	0.727	rs1527209	ENSG00000224683.1	RPL36AP29	5.72	7.41e-08	0.00012	0.48	0.46	Pediatric bone mineral content (hip);	chr7:16241462	chr7:16208945~16209265:+
TGCT	cis	rs7301826	0.932	rs1007246	ENSG00000256250.1	RP11-989F5.1	-5.72	7.42e-08	0.00012	-0.5	-0.46	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810606~130812438:+
TGCT	cis	rs5760092	0.755	rs11090298	ENSG00000225282.1	AP000350.6	-5.72	7.42e-08	0.00012	-0.64	-0.46	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23926900~23929574:+
TGCT	cis	rs1799949	0.965	rs1842147	ENSG00000198496.9	NBR2	-5.72	7.48e-08	0.000121	-0.67	-0.46	Menopause (age at onset);	chr17:43357824	chr17:43125610~43153671:+
TGCT	cis	rs34217772	0.68	rs17181622	ENSG00000258536.1	RP11-1053O12.1	-5.72	7.53e-08	0.000122	-0.37	-0.46	Myopia;	chr14:41724366	chr14:41742639~41742963:+
TGCT	cis	rs950169	0.922	rs62021167	ENSG00000225151.9	GOLGA2P7	-5.72	7.54e-08	0.000122	-0.51	-0.46	Schizophrenia;	chr15:84574820	chr15:84199311~84230136:-
TGCT	cis	rs73086581	1	rs17214949	ENSG00000229539.1	RP11-119B16.2	5.72	7.56e-08	0.000122	0.69	0.46	Response to antidepressants in depression;	chr20:3960305	chr20:3888239~3888868:-
TGCT	cis	rs73086581	1	rs73086535	ENSG00000229539.1	RP11-119B16.2	5.72	7.56e-08	0.000122	0.69	0.46	Response to antidepressants in depression;	chr20:3963503	chr20:3888239~3888868:-
TGCT	cis	rs73086581	1	rs17215054	ENSG00000229539.1	RP11-119B16.2	5.72	7.56e-08	0.000122	0.69	0.46	Response to antidepressants in depression;	chr20:3964132	chr20:3888239~3888868:-
TGCT	cis	rs73086581	1	rs17287486	ENSG00000229539.1	RP11-119B16.2	5.72	7.56e-08	0.000122	0.69	0.46	Response to antidepressants in depression;	chr20:3965620	chr20:3888239~3888868:-
TGCT	cis	rs73086581	1	rs73086540	ENSG00000229539.1	RP11-119B16.2	5.72	7.56e-08	0.000122	0.69	0.46	Response to antidepressants in depression;	chr20:3970203	chr20:3888239~3888868:-
TGCT	cis	rs73086581	1	rs73086544	ENSG00000229539.1	RP11-119B16.2	5.72	7.56e-08	0.000122	0.69	0.46	Response to antidepressants in depression;	chr20:3970281	chr20:3888239~3888868:-
TGCT	cis	rs73086581	1	rs2326289	ENSG00000229539.1	RP11-119B16.2	5.72	7.56e-08	0.000122	0.69	0.46	Response to antidepressants in depression;	chr20:3971653	chr20:3888239~3888868:-
TGCT	cis	rs73086581	1	rs73086549	ENSG00000229539.1	RP11-119B16.2	5.72	7.56e-08	0.000122	0.69	0.46	Response to antidepressants in depression;	chr20:3974015	chr20:3888239~3888868:-
TGCT	cis	rs73086581	0.947	rs55794220	ENSG00000229539.1	RP11-119B16.2	5.72	7.56e-08	0.000122	0.69	0.46	Response to antidepressants in depression;	chr20:3975755	chr20:3888239~3888868:-
TGCT	cis	rs73086581	1	rs113812453	ENSG00000229539.1	RP11-119B16.2	5.72	7.56e-08	0.000122	0.69	0.46	Response to antidepressants in depression;	chr20:3982546	chr20:3888239~3888868:-
TGCT	cis	rs73086581	0.891	rs55871214	ENSG00000229539.1	RP11-119B16.2	5.72	7.56e-08	0.000122	0.69	0.46	Response to antidepressants in depression;	chr20:3985059	chr20:3888239~3888868:-
TGCT	cis	rs73086581	1	rs56069856	ENSG00000229539.1	RP11-119B16.2	5.72	7.56e-08	0.000122	0.69	0.46	Response to antidepressants in depression;	chr20:3985062	chr20:3888239~3888868:-
TGCT	cis	rs73086581	0.947	rs17287577	ENSG00000229539.1	RP11-119B16.2	5.72	7.56e-08	0.000122	0.69	0.46	Response to antidepressants in depression;	chr20:3985607	chr20:3888239~3888868:-
TGCT	cis	rs12891047	0.738	rs7151495	ENSG00000258759.1	RP11-1012A1.7	-5.72	7.56e-08	0.000122	-0.39	-0.46	Amyotrophic lateral sclerosis (sporadic);	chr14:67859162	chr14:67799004~67799609:+
TGCT	cis	rs801193	0.935	rs11772264	ENSG00000222364.1	RNU6-96P	-5.72	7.58e-08	0.000122	-0.54	-0.46	Aortic root size;	chr7:66711400	chr7:66395191~66395286:+
TGCT	cis	rs34217772	1	rs10483523	ENSG00000258536.1	RP11-1053O12.1	-5.72	7.58e-08	0.000122	-0.43	-0.46	Myopia;	chr14:41794890	chr14:41742639~41742963:+
TGCT	cis	rs9733	0.565	rs7524620	ENSG00000206931.1	RNU6-1042P	-5.72	7.6e-08	0.000122	-0.36	-0.46	Tonsillectomy;	chr1:150644223	chr1:150701866~150701972:+
TGCT	cis	rs875971	0.505	rs6955582	ENSG00000236529.1	RP13-254B10.1	5.72	7.62e-08	0.000123	0.34	0.46	Aortic root size;	chr7:65966699	chr7:65840212~65840596:+
TGCT	cis	rs11723261	0.582	rs11248005	ENSG00000275426.1	CH17-262A2.1	5.72	7.63e-08	0.000123	0.88	0.46	Immune response to smallpox vaccine (IL-6);	chr4:172826	chr4:149738~150317:+
TGCT	cis	rs11723261	0.582	rs11733927	ENSG00000275426.1	CH17-262A2.1	5.72	7.63e-08	0.000123	0.88	0.46	Immune response to smallpox vaccine (IL-6);	chr4:173039	chr4:149738~150317:+
TGCT	cis	rs12908161	0.96	rs11633450	ENSG00000225151.9	GOLGA2P7	-5.72	7.64e-08	0.000123	-0.56	-0.46	Schizophrenia;	chr15:84764056	chr15:84199311~84230136:-
TGCT	cis	rs9326248	0.559	rs12808524	ENSG00000254851.1	RP11-109L13.1	-5.71	7.73e-08	0.000124	-0.54	-0.46	Blood protein levels;	chr11:117020277	chr11:117135528~117138582:+
TGCT	cis	rs786425	0.77	rs66647364	ENSG00000278112.1	RP11-972P1.11	5.71	7.76e-08	0.000125	0.54	0.46	Pubertal anthropometrics;	chr12:123712733	chr12:123519390~123519856:-
TGCT	cis	rs801193	1	rs3800812	ENSG00000222364.1	RNU6-96P	-5.71	7.81e-08	0.000125	-0.54	-0.46	Aortic root size;	chr7:66758474	chr7:66395191~66395286:+
TGCT	cis	rs801193	1	rs4279493	ENSG00000222364.1	RNU6-96P	-5.71	7.81e-08	0.000125	-0.54	-0.46	Aortic root size;	chr7:66761633	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.761	rs2659888	ENSG00000222364.1	RNU6-96P	-5.71	7.81e-08	0.000125	-0.54	-0.46	Aortic root size;	chr7:66765184	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.904	rs4718403	ENSG00000222364.1	RNU6-96P	-5.71	7.81e-08	0.000125	-0.54	-0.46	Aortic root size;	chr7:66777742	chr7:66395191~66395286:+
TGCT	cis	rs801193	1	rs3778909	ENSG00000222364.1	RNU6-96P	-5.71	7.81e-08	0.000125	-0.54	-0.46	Aortic root size;	chr7:66790659	chr7:66395191~66395286:+
TGCT	cis	rs1832871	0.599	rs1754413	ENSG00000188451.8	SRP72P2	-5.71	7.82e-08	0.000126	-0.39	-0.46	Height;	chr6:158343709	chr6:158237336~158242797:-
TGCT	cis	rs7301826	1	rs1609985	ENSG00000256250.1	RP11-989F5.1	-5.71	7.83e-08	0.000126	-0.49	-0.46	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810606~130812438:+
TGCT	cis	rs7811142	1	rs73161762	ENSG00000242294.5	STAG3L5P	5.71	7.84e-08	0.000126	0.43	0.46	Platelet count;	chr7:100417223	chr7:100336079~100351900:+
TGCT	cis	rs950169	0.922	rs6603022	ENSG00000225151.9	GOLGA2P7	5.71	7.85e-08	0.000126	0.53	0.46	Schizophrenia;	chr15:84161418	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.922	rs11639244	ENSG00000225151.9	GOLGA2P7	-5.71	7.85e-08	0.000126	-0.53	-0.46	Schizophrenia;	chr15:84163898	chr15:84199311~84230136:-
TGCT	cis	rs801193	0.967	rs34356500	ENSG00000222364.1	RNU6-96P	-5.71	7.89e-08	0.000127	-0.55	-0.46	Aortic root size;	chr7:66771620	chr7:66395191~66395286:+
TGCT	cis	rs7849270	0.879	rs7042928	ENSG00000268707.1	RP11-247A12.7	5.71	7.92e-08	0.000127	0.52	0.46	Blood metabolite ratios;	chr9:129092996	chr9:129170434~129170940:+
TGCT	cis	rs7811142	1	rs60257855	ENSG00000242294.5	STAG3L5P	5.71	7.92e-08	0.000127	0.43	0.46	Platelet count;	chr7:100429157	chr7:100336079~100351900:+
TGCT	cis	rs1832871	0.599	rs1539312	ENSG00000188451.8	SRP72P2	-5.71	7.98e-08	0.000128	-0.39	-0.46	Height;	chr6:158322156	chr6:158237336~158242797:-
TGCT	cis	rs7849270	0.837	rs4642748	ENSG00000268707.1	RP11-247A12.7	-5.71	7.99e-08	0.000128	-0.52	-0.46	Blood metabolite ratios;	chr9:129092668	chr9:129170434~129170940:+
TGCT	cis	rs7849270	0.692	rs4397510	ENSG00000268707.1	RP11-247A12.7	-5.71	7.99e-08	0.000128	-0.52	-0.46	Blood metabolite ratios;	chr9:129092671	chr9:129170434~129170940:+
TGCT	cis	rs7849270	0.879	rs10739741	ENSG00000268707.1	RP11-247A12.7	-5.71	7.99e-08	0.000128	-0.52	-0.46	Blood metabolite ratios;	chr9:129092881	chr9:129170434~129170940:+
TGCT	cis	rs7849270	0.879	rs7046990	ENSG00000268707.1	RP11-247A12.7	-5.71	7.99e-08	0.000128	-0.52	-0.46	Blood metabolite ratios;	chr9:129093859	chr9:129170434~129170940:+
TGCT	cis	rs7849270	0.837	rs10819463	ENSG00000268707.1	RP11-247A12.7	-5.71	7.99e-08	0.000128	-0.52	-0.46	Blood metabolite ratios;	chr9:129100958	chr9:129170434~129170940:+
TGCT	cis	rs8062405	1	rs56404918	ENSG00000259982.1	CDC37P1	5.71	8e-08	0.000128	0.62	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs55719896	ENSG00000259982.1	CDC37P1	5.71	8e-08	0.000128	0.62	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs55830740	ENSG00000259982.1	CDC37P1	5.71	8e-08	0.000128	0.62	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28700294~28701540:-
TGCT	cis	rs1528149	0.504	rs10227232	ENSG00000224683.1	RPL36AP29	-5.71	8.03e-08	0.000129	-0.5	-0.46	Sitting height ratio;	chr7:16138475	chr7:16208945~16209265:+
TGCT	cis	rs7811142	0.667	rs3873746	ENSG00000242294.5	STAG3L5P	5.71	8.05e-08	0.000129	0.43	0.46	Platelet count;	chr7:100337474	chr7:100336079~100351900:+
TGCT	cis	rs9733	0.596	rs6685702	ENSG00000206931.1	RNU6-1042P	5.71	8.05e-08	0.000129	0.35	0.46	Tonsillectomy;	chr1:150683831	chr1:150701866~150701972:+
TGCT	cis	rs17301013	0.507	rs72713591	ENSG00000227373.4	RP11-160H22.5	5.7	8.09e-08	0.00013	0.55	0.46	Systemic lupus erythematosus;	chr1:174442956	chr1:174115300~174160004:-
TGCT	cis	rs7804306	0.826	rs17566854	ENSG00000233264.2	AC006042.8	5.7	8.13e-08	0.00013	1.08	0.46	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7993887	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.826	rs56017154	ENSG00000233264.2	AC006042.8	5.7	8.13e-08	0.00013	1.08	0.46	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7995282	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.826	rs73049293	ENSG00000233264.2	AC006042.8	5.7	8.13e-08	0.00013	1.08	0.46	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7999017	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.826	rs73049297	ENSG00000233264.2	AC006042.8	5.7	8.13e-08	0.00013	1.08	0.46	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7999429	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.826	rs73049300	ENSG00000233264.2	AC006042.8	5.7	8.13e-08	0.00013	1.08	0.46	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8002315	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.826	rs58348680	ENSG00000233264.2	AC006042.8	5.7	8.13e-08	0.00013	1.08	0.46	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8005655	chr7:7980312~7982228:+
TGCT	cis	rs7804306	1	rs73050915	ENSG00000233264.2	AC006042.8	5.7	8.13e-08	0.00013	1.08	0.46	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8010614	chr7:7980312~7982228:+
TGCT	cis	rs7804306	1	rs73050929	ENSG00000233264.2	AC006042.8	5.7	8.13e-08	0.00013	1.08	0.46	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8019638	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.826	rs73050940	ENSG00000233264.2	AC006042.8	5.7	8.13e-08	0.00013	1.08	0.46	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8027882	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.826	rs56142807	ENSG00000233264.2	AC006042.8	5.7	8.13e-08	0.00013	1.08	0.46	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8028562	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.826	rs73050951	ENSG00000233264.2	AC006042.8	5.7	8.13e-08	0.00013	1.08	0.46	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8032762	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.826	rs73050956	ENSG00000233264.2	AC006042.8	5.7	8.13e-08	0.00013	1.08	0.46	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8036076	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.826	rs73050958	ENSG00000233264.2	AC006042.8	5.7	8.13e-08	0.00013	1.08	0.46	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8036162	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.826	rs73050959	ENSG00000233264.2	AC006042.8	5.7	8.13e-08	0.00013	1.08	0.46	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8037069	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.826	rs77672302	ENSG00000233264.2	AC006042.8	5.7	8.13e-08	0.00013	1.08	0.46	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8048681	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.826	rs55832940	ENSG00000233264.2	AC006042.8	5.7	8.13e-08	0.00013	1.08	0.46	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8054449	chr7:7980312~7982228:+
TGCT	cis	rs950027	0.787	rs2433616	ENSG00000259520.4	CTD-2651B20.3	-5.7	8.14e-08	0.00013	-0.36	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45436401	chr15:45251580~45279251:-
TGCT	cis	rs801193	1	rs11773829	ENSG00000222364.1	RNU6-96P	5.7	8.17e-08	0.00013	0.54	0.46	Aortic root size;	chr7:66676087	chr7:66395191~66395286:+
TGCT	cis	rs801193	1	rs7788576	ENSG00000222364.1	RNU6-96P	5.7	8.17e-08	0.00013	0.54	0.46	Aortic root size;	chr7:66683315	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.935	rs2659916	ENSG00000222364.1	RNU6-96P	-5.7	8.17e-08	0.00013	-0.54	-0.46	Aortic root size;	chr7:66686365	chr7:66395191~66395286:+
TGCT	cis	rs801193	1	rs6958520	ENSG00000222364.1	RNU6-96P	-5.7	8.17e-08	0.00013	-0.54	-0.46	Aortic root size;	chr7:66686466	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.967	rs2707849	ENSG00000222364.1	RNU6-96P	-5.7	8.17e-08	0.00013	-0.54	-0.46	Aortic root size;	chr7:66687725	chr7:66395191~66395286:+
TGCT	cis	rs801193	1	rs2707836	ENSG00000222364.1	RNU6-96P	-5.7	8.17e-08	0.00013	-0.54	-0.46	Aortic root size;	chr7:66695448	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.844	rs7779971	ENSG00000222364.1	RNU6-96P	-5.7	8.17e-08	0.00013	-0.54	-0.46	Aortic root size;	chr7:66696803	chr7:66395191~66395286:+
TGCT	cis	rs801193	1	rs2659906	ENSG00000222364.1	RNU6-96P	-5.7	8.17e-08	0.00013	-0.54	-0.46	Aortic root size;	chr7:66700323	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.935	rs2659899	ENSG00000222364.1	RNU6-96P	-5.7	8.17e-08	0.00013	-0.54	-0.46	Aortic root size;	chr7:66721734	chr7:66395191~66395286:+
TGCT	cis	rs801193	1	rs62466793	ENSG00000222364.1	RNU6-96P	-5.7	8.17e-08	0.00013	-0.54	-0.46	Aortic root size;	chr7:66726530	chr7:66395191~66395286:+
TGCT	cis	rs801193	1	rs62466794	ENSG00000222364.1	RNU6-96P	-5.7	8.17e-08	0.00013	-0.54	-0.46	Aortic root size;	chr7:66726592	chr7:66395191~66395286:+
TGCT	cis	rs801193	1	rs1553609	ENSG00000222364.1	RNU6-96P	-5.7	8.17e-08	0.00013	-0.54	-0.46	Aortic root size;	chr7:66732152	chr7:66395191~66395286:+
TGCT	cis	rs801193	1	rs1553610	ENSG00000222364.1	RNU6-96P	-5.7	8.17e-08	0.00013	-0.54	-0.46	Aortic root size;	chr7:66732246	chr7:66395191~66395286:+
TGCT	cis	rs12891047	1	rs12896666	ENSG00000258759.1	RP11-1012A1.7	-5.7	8.18e-08	0.000131	-0.38	-0.46	Amyotrophic lateral sclerosis (sporadic);	chr14:67774212	chr14:67799004~67799609:+
TGCT	cis	rs1528149	0.504	rs1527215	ENSG00000224683.1	RPL36AP29	-5.7	8.19e-08	0.000131	-0.5	-0.46	Sitting height ratio;	chr7:16127184	chr7:16208945~16209265:+
TGCT	cis	rs3091242	0.933	rs9645452	ENSG00000261349.1	RP3-465N24.5	5.7	8.22e-08	0.000131	0.45	0.46	Erythrocyte sedimentation rate;	chr1:25341835	chr1:25266102~25267136:-
TGCT	cis	rs9326248	0.581	rs11216267	ENSG00000254851.1	RP11-109L13.1	-5.7	8.23e-08	0.000131	-0.56	-0.46	Blood protein levels;	chr11:117081676	chr11:117135528~117138582:+
TGCT	cis	rs916888	0.531	rs183211	ENSG00000262500.1	RP11-259G18.2	5.7	8.24e-08	0.000131	0.59	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46243606~46245044:+
TGCT	cis	rs9733	0.519	rs6700022	ENSG00000206931.1	RNU6-1042P	-5.7	8.29e-08	0.000132	-0.34	-0.46	Tonsillectomy;	chr1:150698008	chr1:150701866~150701972:+
TGCT	cis	rs1153858	0.621	rs2413769	ENSG00000259520.4	CTD-2651B20.3	-5.7	8.32e-08	0.000133	-0.43	-0.46	Homoarginine levels;	chr15:45269670	chr15:45251580~45279251:-
TGCT	cis	rs8062405	1	rs62036626	ENSG00000259982.1	CDC37P1	5.7	8.33e-08	0.000133	0.62	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs62036657	ENSG00000259982.1	CDC37P1	5.7	8.33e-08	0.000133	0.62	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs12444171	ENSG00000259982.1	CDC37P1	5.7	8.33e-08	0.000133	0.62	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28700294~28701540:-
TGCT	cis	rs9462027	0.959	rs205262	ENSG00000186328.4	RP11-140K17.2	5.7	8.34e-08	0.000133	0.48	0.46	Systemic lupus erythematosus;	chr6:34595387	chr6:34715613~34715940:+
TGCT	cis	rs7301826	0.966	rs10734980	ENSG00000256250.1	RP11-989F5.1	-5.7	8.36e-08	0.000133	-0.49	-0.46	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810606~130812438:+
TGCT	cis	rs7849270	0.879	rs3124495	ENSG00000268707.1	RP11-247A12.7	5.7	8.38e-08	0.000134	0.53	0.46	Blood metabolite ratios;	chr9:129093731	chr9:129170434~129170940:+
TGCT	cis	rs7849270	0.879	rs3124496	ENSG00000268707.1	RP11-247A12.7	5.7	8.38e-08	0.000134	0.53	0.46	Blood metabolite ratios;	chr9:129094583	chr9:129170434~129170940:+
TGCT	cis	rs7849270	0.798	rs7865337	ENSG00000268707.1	RP11-247A12.7	-5.7	8.38e-08	0.000134	-0.53	-0.46	Blood metabolite ratios;	chr9:129091799	chr9:129170434~129170940:+
TGCT	cis	rs9322193	0.962	rs2342764	ENSG00000216906.2	RP11-350J20.9	5.7	8.4e-08	0.000134	0.54	0.46	Lung cancer;	chr6:149835068	chr6:149904243~149906418:+
TGCT	cis	rs5760092	0.755	rs3884794	ENSG00000218537.1	MIF-AS1	5.7	8.42e-08	0.000134	0.66	0.46	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23909579	chr22:23894426~23898930:-
TGCT	cis	rs66887589	0.66	rs4833613	ENSG00000245958.5	RP11-33B1.1	5.7	8.42e-08	0.000134	0.45	0.46	Diastolic blood pressure;	chr4:119229001	chr4:119454791~119552025:+
TGCT	cis	rs73086581	1	rs73086512	ENSG00000229539.1	RP11-119B16.2	5.7	8.45e-08	0.000134	0.69	0.46	Response to antidepressants in depression;	chr20:3942125	chr20:3888239~3888868:-
TGCT	cis	rs875971	0.522	rs2949690	ENSG00000236529.1	RP13-254B10.1	-5.7	8.46e-08	0.000135	-0.34	-0.46	Aortic root size;	chr7:66018255	chr7:65840212~65840596:+
TGCT	cis	rs1426063	0.614	rs17199632	ENSG00000260265.1	RP11-44F21.5	5.69	8.48e-08	0.000135	0.61	0.46	QT interval;	chr4:75103663	chr4:75081702~75084717:-
TGCT	cis	rs1426063	0.614	rs76931926	ENSG00000260265.1	RP11-44F21.5	5.69	8.48e-08	0.000135	0.61	0.46	QT interval;	chr4:75106902	chr4:75081702~75084717:-
TGCT	cis	rs1426063	0.614	rs114761716	ENSG00000260265.1	RP11-44F21.5	5.69	8.48e-08	0.000135	0.61	0.46	QT interval;	chr4:75107209	chr4:75081702~75084717:-
TGCT	cis	rs1426063	0.614	rs115279737	ENSG00000260265.1	RP11-44F21.5	5.69	8.48e-08	0.000135	0.61	0.46	QT interval;	chr4:75107557	chr4:75081702~75084717:-
TGCT	cis	rs1426063	0.614	rs78784058	ENSG00000260265.1	RP11-44F21.5	5.69	8.48e-08	0.000135	0.61	0.46	QT interval;	chr4:75108738	chr4:75081702~75084717:-
TGCT	cis	rs1426063	0.614	rs17000261	ENSG00000260265.1	RP11-44F21.5	5.69	8.48e-08	0.000135	0.61	0.46	QT interval;	chr4:75108766	chr4:75081702~75084717:-
TGCT	cis	rs1426063	0.614	rs17000262	ENSG00000260265.1	RP11-44F21.5	5.69	8.48e-08	0.000135	0.61	0.46	QT interval;	chr4:75108836	chr4:75081702~75084717:-
TGCT	cis	rs1426063	0.614	rs17000264	ENSG00000260265.1	RP11-44F21.5	5.69	8.48e-08	0.000135	0.61	0.46	QT interval;	chr4:75108962	chr4:75081702~75084717:-
TGCT	cis	rs1426063	0.614	rs74949513	ENSG00000260265.1	RP11-44F21.5	5.69	8.48e-08	0.000135	0.61	0.46	QT interval;	chr4:75124631	chr4:75081702~75084717:-
TGCT	cis	rs1426063	0.614	rs77982391	ENSG00000260265.1	RP11-44F21.5	5.69	8.48e-08	0.000135	0.61	0.46	QT interval;	chr4:75125224	chr4:75081702~75084717:-
TGCT	cis	rs1426063	0.541	rs116664844	ENSG00000260265.1	RP11-44F21.5	5.69	8.48e-08	0.000135	0.61	0.46	QT interval;	chr4:75125677	chr4:75081702~75084717:-
TGCT	cis	rs1426063	0.541	rs114162294	ENSG00000260265.1	RP11-44F21.5	5.69	8.48e-08	0.000135	0.61	0.46	QT interval;	chr4:75125682	chr4:75081702~75084717:-
TGCT	cis	rs1426063	0.614	rs76087197	ENSG00000260265.1	RP11-44F21.5	5.69	8.48e-08	0.000135	0.61	0.46	QT interval;	chr4:75134108	chr4:75081702~75084717:-
TGCT	cis	rs1426063	0.614	rs17199779	ENSG00000260265.1	RP11-44F21.5	-5.69	8.48e-08	0.000135	-0.61	-0.46	QT interval;	chr4:75105647	chr4:75081702~75084717:-
TGCT	cis	rs7044106	0.708	rs10984992	ENSG00000226752.6	PSMD5-AS1	-5.69	8.52e-08	0.000135	-0.58	-0.46	Hip circumference adjusted for BMI;	chr9:120711138	chr9:120824828~120854385:+
TGCT	cis	rs7044106	0.708	rs10760113	ENSG00000226752.6	PSMD5-AS1	-5.69	8.52e-08	0.000135	-0.58	-0.46	Hip circumference adjusted for BMI;	chr9:120711772	chr9:120824828~120854385:+
TGCT	cis	rs7044106	0.762	rs10760115	ENSG00000226752.6	PSMD5-AS1	-5.69	8.52e-08	0.000135	-0.58	-0.46	Hip circumference adjusted for BMI;	chr9:120714674	chr9:120824828~120854385:+
TGCT	cis	rs7605378	0.528	rs281791	ENSG00000232732.8	AC073043.1	5.69	8.55e-08	0.000136	0.51	0.46	Osteoporosis;	chr2:199985679	chr2:199867396~199911159:-
TGCT	cis	rs11673344	0.801	rs56343212	ENSG00000226686.6	LINC01535	5.69	8.57e-08	0.000136	0.54	0.46	Obesity-related traits;	chr19:37167684	chr19:37251912~37265535:+
TGCT	cis	rs1799949	1	rs4793229	ENSG00000198496.9	NBR2	5.69	8.58e-08	0.000136	0.66	0.46	Menopause (age at onset);	chr17:43340966	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.501	rs2343819	ENSG00000198496.9	NBR2	-5.69	8.58e-08	0.000136	-0.66	-0.46	Menopause (age at onset);	chr17:43332285	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.501	rs35399157	ENSG00000198496.9	NBR2	-5.69	8.58e-08	0.000136	-0.66	-0.46	Menopause (age at onset);	chr17:43334234	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.602	rs4600503	ENSG00000198496.9	NBR2	-5.69	8.58e-08	0.000136	-0.66	-0.46	Menopause (age at onset);	chr17:43336956	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.501	rs9675035	ENSG00000198496.9	NBR2	-5.69	8.58e-08	0.000136	-0.66	-0.46	Menopause (age at onset);	chr17:43337648	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs11649954	ENSG00000198496.9	NBR2	-5.69	8.58e-08	0.000136	-0.66	-0.46	Menopause (age at onset);	chr17:43342667	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs1824889	ENSG00000198496.9	NBR2	-5.69	8.58e-08	0.000136	-0.66	-0.46	Menopause (age at onset);	chr17:43344508	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs35956818	ENSG00000198496.9	NBR2	-5.69	8.58e-08	0.000136	-0.66	-0.46	Menopause (age at onset);	chr17:43345617	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.93	rs4584865	ENSG00000198496.9	NBR2	-5.69	8.58e-08	0.000136	-0.66	-0.46	Menopause (age at onset);	chr17:43347551	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs11651341	ENSG00000198496.9	NBR2	-5.69	8.58e-08	0.000136	-0.66	-0.46	Menopause (age at onset);	chr17:43350693	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs34572725	ENSG00000198496.9	NBR2	-5.69	8.58e-08	0.000136	-0.66	-0.46	Menopause (age at onset);	chr17:43351298	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs4534897	ENSG00000198496.9	NBR2	-5.69	8.58e-08	0.000136	-0.66	-0.46	Menopause (age at onset);	chr17:43354440	chr17:43125610~43153671:+
TGCT	cis	rs11723261	0.582	rs6830247	ENSG00000275426.1	CH17-262A2.1	5.69	8.58e-08	0.000136	0.85	0.46	Immune response to smallpox vaccine (IL-6);	chr4:156885	chr4:149738~150317:+
TGCT	cis	rs9322193	0.923	rs9766037	ENSG00000216906.2	RP11-350J20.9	5.69	8.58e-08	0.000136	0.5	0.46	Lung cancer;	chr6:149616921	chr6:149904243~149906418:+
TGCT	cis	rs2882667	0.522	rs7731574	ENSG00000253404.1	AC034243.1	-5.69	8.59e-08	0.000136	-0.5	-0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139118503	chr5:138744434~138753309:-
TGCT	cis	rs8062405	1	rs8062405	ENSG00000259982.1	CDC37P1	-5.69	8.6e-08	0.000136	-0.62	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28700294~28701540:-
TGCT	cis	rs11168618	0.509	rs2731099	ENSG00000240399.1	RP1-228P16.1	-5.69	8.61e-08	0.000136	-0.43	-0.46	Adiponectin levels;	chr12:48490143	chr12:48054813~48055591:-
TGCT	cis	rs11168618	0.509	rs2731100	ENSG00000240399.1	RP1-228P16.1	-5.69	8.61e-08	0.000136	-0.43	-0.46	Adiponectin levels;	chr12:48490375	chr12:48054813~48055591:-
TGCT	cis	rs11168618	0.509	rs2731103	ENSG00000240399.1	RP1-228P16.1	-5.69	8.61e-08	0.000136	-0.43	-0.46	Adiponectin levels;	chr12:48490973	chr12:48054813~48055591:-
TGCT	cis	rs875971	0.638	rs7793569	ENSG00000222364.1	RNU6-96P	5.69	8.64e-08	0.000137	0.54	0.46	Aortic root size;	chr7:66651646	chr7:66395191~66395286:+
TGCT	cis	rs801193	1	rs6975195	ENSG00000222364.1	RNU6-96P	5.69	8.64e-08	0.000137	0.54	0.46	Aortic root size;	chr7:66659787	chr7:66395191~66395286:+
TGCT	cis	rs801193	1	rs3857688	ENSG00000222364.1	RNU6-96P	5.69	8.64e-08	0.000137	0.54	0.46	Aortic root size;	chr7:66662819	chr7:66395191~66395286:+
TGCT	cis	rs801193	1	rs2286684	ENSG00000222364.1	RNU6-96P	5.69	8.64e-08	0.000137	0.54	0.46	Aortic root size;	chr7:66664843	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.935	rs2286683	ENSG00000222364.1	RNU6-96P	5.69	8.64e-08	0.000137	0.54	0.46	Aortic root size;	chr7:66664856	chr7:66395191~66395286:+
TGCT	cis	rs801193	1	rs10274773	ENSG00000222364.1	RNU6-96P	5.69	8.64e-08	0.000137	0.54	0.46	Aortic root size;	chr7:66668591	chr7:66395191~66395286:+
TGCT	cis	rs76878669	0.561	rs1039594	ENSG00000254510.1	RP11-867G23.10	5.69	8.64e-08	0.000137	0.61	0.46	Educational attainment (years of education);	chr11:66363678	chr11:66409158~66417137:+
TGCT	cis	rs9733	0.596	rs72702523	ENSG00000206931.1	RNU6-1042P	5.69	8.67e-08	0.000137	0.35	0.46	Tonsillectomy;	chr1:150677949	chr1:150701866~150701972:+
TGCT	cis	rs8062405	0.656	rs7189927	ENSG00000259982.1	CDC37P1	-5.69	8.7e-08	0.000138	-0.66	-0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28902466	chr16:28700294~28701540:-
TGCT	cis	rs12891047	0.738	rs11158700	ENSG00000258759.1	RP11-1012A1.7	-5.69	8.72e-08	0.000138	-0.39	-0.45	Amyotrophic lateral sclerosis (sporadic);	chr14:67874465	chr14:67799004~67799609:+
TGCT	cis	rs950169	1	rs11638297	ENSG00000225151.9	GOLGA2P7	-5.69	8.73e-08	0.000138	-0.49	-0.45	Schizophrenia;	chr15:84113665	chr15:84199311~84230136:-
TGCT	cis	rs7811142	1	rs7783550	ENSG00000242294.5	STAG3L5P	-5.69	8.75e-08	0.000139	-0.43	-0.45	Platelet count;	chr7:100390182	chr7:100336079~100351900:+
TGCT	cis	rs17301013	0.507	rs1754354	ENSG00000227373.4	RP11-160H22.5	-5.69	8.77e-08	0.000139	-0.53	-0.45	Systemic lupus erythematosus;	chr1:174817196	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs10912791	ENSG00000227373.4	RP11-160H22.5	5.69	8.77e-08	0.000139	0.54	0.45	Systemic lupus erythematosus;	chr1:174479298	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12079334	ENSG00000227373.4	RP11-160H22.5	5.69	8.77e-08	0.000139	0.54	0.45	Systemic lupus erythematosus;	chr1:174480815	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs4652494	ENSG00000227373.4	RP11-160H22.5	5.69	8.77e-08	0.000139	0.54	0.45	Systemic lupus erythematosus;	chr1:174495861	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs7537823	ENSG00000227373.4	RP11-160H22.5	5.69	8.77e-08	0.000139	0.54	0.45	Systemic lupus erythematosus;	chr1:174502222	chr1:174115300~174160004:-
TGCT	cis	rs17711722	0.727	rs2658585	ENSG00000236529.1	RP13-254B10.1	5.69	8.81e-08	0.000139	0.34	0.45	Calcium levels;	chr7:65996954	chr7:65840212~65840596:+
TGCT	cis	rs9425766	0.679	rs2901785	ENSG00000227373.4	RP11-160H22.5	5.69	8.81e-08	0.000139	0.49	0.45	Life satisfaction;	chr1:174135605	chr1:174115300~174160004:-
TGCT	cis	rs7826238	0.509	rs2948288	ENSG00000173295.6	FAM86B3P	5.69	8.84e-08	0.00014	0.55	0.45	Systolic blood pressure;	chr8:8257782	chr8:8228595~8244865:+
TGCT	cis	rs9733	0.596	rs72702536	ENSG00000206931.1	RNU6-1042P	5.69	8.85e-08	0.00014	0.35	0.45	Tonsillectomy;	chr1:150690098	chr1:150701866~150701972:+
TGCT	cis	rs853679	0.628	rs9368560	ENSG00000187763.3	OR2B7P	5.69	8.85e-08	0.00014	0.47	0.45	Depression;	chr6:28192182	chr6:28046434~28047367:+
TGCT	cis	rs17301013	0.507	rs333422	ENSG00000227373.4	RP11-160H22.5	-5.68	8.87e-08	0.00014	-0.52	-0.45	Systemic lupus erythematosus;	chr1:174664167	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs333438	ENSG00000227373.4	RP11-160H22.5	5.68	8.87e-08	0.00014	0.52	0.45	Systemic lupus erythematosus;	chr1:174672782	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs2771401	ENSG00000227373.4	RP11-160H22.5	5.68	8.87e-08	0.00014	0.52	0.45	Systemic lupus erythematosus;	chr1:174678302	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs464540	ENSG00000227373.4	RP11-160H22.5	5.68	8.87e-08	0.00014	0.52	0.45	Systemic lupus erythematosus;	chr1:174679250	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs467437	ENSG00000227373.4	RP11-160H22.5	5.68	8.87e-08	0.00014	0.52	0.45	Systemic lupus erythematosus;	chr1:174679861	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs2568098	ENSG00000227373.4	RP11-160H22.5	5.68	8.87e-08	0.00014	0.52	0.45	Systemic lupus erythematosus;	chr1:174732183	chr1:174115300~174160004:-
TGCT	cis	rs7412746	0.566	rs11204743	ENSG00000206931.1	RNU6-1042P	5.68	8.92e-08	0.000141	0.39	0.45	Melanoma;	chr1:150917930	chr1:150701866~150701972:+
TGCT	cis	rs4423214	0.879	rs1792284	ENSG00000254682.1	RP11-660L16.2	5.68	8.94e-08	0.000141	0.68	0.45	Vitamin D levels;	chr11:71423920	chr11:71448674~71452157:+
TGCT	cis	rs1832871	0.579	rs828006	ENSG00000188451.8	SRP72P2	-5.68	8.94e-08	0.000141	-0.39	-0.45	Height;	chr6:158353982	chr6:158237336~158242797:-
TGCT	cis	rs11723261	0.582	rs11735742	ENSG00000275426.1	CH17-262A2.1	-5.68	8.96e-08	0.000141	-0.84	-0.45	Immune response to smallpox vaccine (IL-6);	chr4:148766	chr4:149738~150317:+
TGCT	cis	rs6061231	0.761	rs2427312	ENSG00000273619.1	RP5-908M14.9	-5.68	8.97e-08	0.000142	-0.59	-0.45	Colorectal cancer;	chr20:62395535	chr20:62386303~62386970:-
TGCT	cis	rs2117029	0.767	rs11614738	ENSG00000258017.1	RP11-386G11.10	-5.68	9.05e-08	0.000143	-0.59	-0.45	Intelligence (multi-trait analysis);	chr12:49030833	chr12:49127782~49147869:+
TGCT	cis	rs507080	0.733	rs4486664	ENSG00000255422.1	AP002954.4	-5.68	9.07e-08	0.000143	-0.54	-0.45	Serum metabolite levels;	chr11:118698358	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.733	rs7108144	ENSG00000255422.1	AP002954.4	-5.68	9.07e-08	0.000143	-0.54	-0.45	Serum metabolite levels;	chr11:118698985	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.663	rs523793	ENSG00000255422.1	AP002954.4	-5.68	9.07e-08	0.000143	-0.54	-0.45	Serum metabolite levels;	chr11:118699988	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.736	rs659564	ENSG00000255422.1	AP002954.4	-5.68	9.07e-08	0.000143	-0.54	-0.45	Serum metabolite levels;	chr11:118700205	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.736	rs642224	ENSG00000255422.1	AP002954.4	-5.68	9.07e-08	0.000143	-0.54	-0.45	Serum metabolite levels;	chr11:118700210	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.733	rs541631	ENSG00000255422.1	AP002954.4	-5.68	9.07e-08	0.000143	-0.54	-0.45	Serum metabolite levels;	chr11:118700314	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.736	rs658676	ENSG00000255422.1	AP002954.4	-5.68	9.07e-08	0.000143	-0.54	-0.45	Serum metabolite levels;	chr11:118700414	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.733	rs488141	ENSG00000255422.1	AP002954.4	-5.68	9.07e-08	0.000143	-0.54	-0.45	Serum metabolite levels;	chr11:118700459	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.733	rs657769	ENSG00000255422.1	AP002954.4	-5.68	9.07e-08	0.000143	-0.54	-0.45	Serum metabolite levels;	chr11:118700607	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.733	rs544452	ENSG00000255422.1	AP002954.4	-5.68	9.07e-08	0.000143	-0.54	-0.45	Serum metabolite levels;	chr11:118700648	chr11:118704607~118750263:+
TGCT	cis	rs3091242	0.934	rs666686	ENSG00000224183.1	SDHDP6	-5.68	9.13e-08	0.000144	-0.48	-0.45	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25294164~25294643:-
TGCT	cis	rs172166	0.694	rs1225716	ENSG00000216901.1	AL022393.7	5.68	9.16e-08	0.000144	0.58	0.45	Cardiac Troponin-T levels;	chr6:28145968	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.512	rs2622319	ENSG00000216901.1	AL022393.7	5.68	9.16e-08	0.000144	0.58	0.45	Parkinson's disease;	chr6:28152623	chr6:28176188~28176674:+
TGCT	cis	rs172166	0.694	rs1150666	ENSG00000216901.1	AL022393.7	5.68	9.16e-08	0.000144	0.58	0.45	Cardiac Troponin-T levels;	chr6:28156150	chr6:28176188~28176674:+
TGCT	cis	rs172166	0.694	rs9295760	ENSG00000216901.1	AL022393.7	5.68	9.16e-08	0.000144	0.58	0.45	Cardiac Troponin-T levels;	chr6:28179607	chr6:28176188~28176674:+
TGCT	cis	rs2739330	0.76	rs1007888	ENSG00000272787.1	KB-226F1.2	-5.68	9.16e-08	0.000144	-0.5	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23969211~23969873:+
TGCT	cis	rs17301013	0.507	rs332767	ENSG00000227373.4	RP11-160H22.5	5.68	9.19e-08	0.000145	0.53	0.45	Systemic lupus erythematosus;	chr1:174686386	chr1:174115300~174160004:-
TGCT	cis	rs9733	0.527	rs11204694	ENSG00000206931.1	RNU6-1042P	5.68	9.2e-08	0.000145	0.35	0.45	Tonsillectomy;	chr1:150680915	chr1:150701866~150701972:+
TGCT	cis	rs4713118	0.513	rs156739	ENSG00000216901.1	AL022393.7	5.68	9.26e-08	0.000146	0.58	0.45	Parkinson's disease;	chr6:28045632	chr6:28176188~28176674:+
TGCT	cis	rs6964833	1	rs13227433	ENSG00000123965.13	PMS2P5	5.67	9.29e-08	0.000146	0.6	0.45	Menarche (age at onset);	chr7:74680386	chr7:74894116~74897835:+
TGCT	cis	rs17301013	0.507	rs11810824	ENSG00000227373.4	RP11-160H22.5	-5.67	9.31e-08	0.000146	-0.52	-0.45	Systemic lupus erythematosus;	chr1:174408223	chr1:174115300~174160004:-
TGCT	cis	rs9322193	0.923	rs9371207	ENSG00000216906.2	RP11-350J20.9	5.67	9.32e-08	0.000146	0.54	0.45	Lung cancer;	chr6:149858087	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs2880436	ENSG00000216906.2	RP11-350J20.9	5.67	9.32e-08	0.000146	0.54	0.45	Lung cancer;	chr6:149859123	chr6:149904243~149906418:+
TGCT	cis	rs17711722	0.565	rs73372653	ENSG00000164669.11	INTS4P1	-5.67	9.47e-08	0.000149	-0.45	-0.45	Calcium levels;	chr7:65977808	chr7:65141225~65234216:+
TGCT	cis	rs11098499	0.739	rs9884728	ENSG00000245958.5	RP11-33B1.1	5.67	9.49e-08	0.000149	0.46	0.45	Corneal astigmatism;	chr4:119205924	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.739	rs2203039	ENSG00000245958.5	RP11-33B1.1	5.67	9.49e-08	0.000149	0.46	0.45	Corneal astigmatism;	chr4:119211192	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.739	rs7441137	ENSG00000245958.5	RP11-33B1.1	5.67	9.49e-08	0.000149	0.46	0.45	Corneal astigmatism;	chr4:119212066	chr4:119454791~119552025:+
TGCT	cis	rs1799949	0.931	rs34410138	ENSG00000198496.9	NBR2	-5.67	9.5e-08	0.000149	-0.66	-0.45	Menopause (age at onset);	chr17:43127753	chr17:43125610~43153671:+
TGCT	cis	rs9733	0.596	rs6587518	ENSG00000206931.1	RNU6-1042P	5.67	9.54e-08	0.00015	0.36	0.45	Tonsillectomy;	chr1:150689311	chr1:150701866~150701972:+
TGCT	cis	rs2006771	0.81	rs2006648	ENSG00000236132.1	CTA-440B3.1	5.67	9.57e-08	0.00015	0.44	0.45	Nonsyndromic cleft lip with cleft palate;	chr22:31685943	chr22:31816379~31817491:-
TGCT	cis	rs17301013	0.507	rs72713532	ENSG00000227373.4	RP11-160H22.5	5.67	9.58e-08	0.00015	0.51	0.45	Systemic lupus erythematosus;	chr1:174337826	chr1:174115300~174160004:-
TGCT	cis	rs507080	0.845	rs481903	ENSG00000255422.1	AP002954.4	-5.67	9.6e-08	0.000151	-0.54	-0.45	Serum metabolite levels;	chr11:118697024	chr11:118704607~118750263:+
TGCT	cis	rs875971	0.522	rs2008188	ENSG00000236529.1	RP13-254B10.1	5.67	9.65e-08	0.000151	0.34	0.45	Aortic root size;	chr7:65964026	chr7:65840212~65840596:+
TGCT	cis	rs17711722	0.727	rs1880555	ENSG00000236529.1	RP13-254B10.1	5.67	9.65e-08	0.000151	0.34	0.45	Calcium levels;	chr7:65967580	chr7:65840212~65840596:+
TGCT	cis	rs17711722	0.701	rs781143	ENSG00000236529.1	RP13-254B10.1	5.67	9.65e-08	0.000151	0.34	0.45	Calcium levels;	chr7:65974892	chr7:65840212~65840596:+
TGCT	cis	rs17711722	0.701	rs781145	ENSG00000236529.1	RP13-254B10.1	5.67	9.65e-08	0.000151	0.34	0.45	Calcium levels;	chr7:65975383	chr7:65840212~65840596:+
TGCT	cis	rs875971	1	rs3981131	ENSG00000222364.1	RNU6-96P	-5.67	9.68e-08	0.000152	-0.51	-0.45	Aortic root size;	chr7:66486690	chr7:66395191~66395286:+
TGCT	cis	rs7829975	0.688	rs7837587	ENSG00000173295.6	FAM86B3P	5.67	9.71e-08	0.000152	0.54	0.45	Mood instability;	chr8:8521482	chr8:8228595~8244865:+
TGCT	cis	rs7829975	0.688	rs7826654	ENSG00000173295.6	FAM86B3P	5.67	9.71e-08	0.000152	0.54	0.45	Mood instability;	chr8:8521596	chr8:8228595~8244865:+
TGCT	cis	rs7829975	0.688	rs7826660	ENSG00000173295.6	FAM86B3P	5.67	9.71e-08	0.000152	0.54	0.45	Mood instability;	chr8:8521597	chr8:8228595~8244865:+
TGCT	cis	rs7829975	0.688	rs6601703	ENSG00000173295.6	FAM86B3P	5.67	9.71e-08	0.000152	0.54	0.45	Mood instability;	chr8:8522714	chr8:8228595~8244865:+
TGCT	cis	rs2006771	0.846	rs6518754	ENSG00000236132.1	CTA-440B3.1	-5.66	9.79e-08	0.000153	-0.44	-0.45	Nonsyndromic cleft lip with cleft palate;	chr22:31701789	chr22:31816379~31817491:-
TGCT	cis	rs55794721	0.509	rs873308	ENSG00000224183.1	SDHDP6	5.66	9.8e-08	0.000153	0.48	0.45	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25294164~25294643:-
TGCT	cis	rs7811142	0.83	rs6955367	ENSG00000242294.5	STAG3L5P	5.66	9.81e-08	0.000153	0.42	0.45	Platelet count;	chr7:100363571	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.83	rs11768967	ENSG00000242294.5	STAG3L5P	5.66	9.81e-08	0.000153	0.42	0.45	Platelet count;	chr7:100370021	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.83	rs7792959	ENSG00000242294.5	STAG3L5P	5.66	9.81e-08	0.000153	0.42	0.45	Platelet count;	chr7:100374780	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.83	rs6975660	ENSG00000242294.5	STAG3L5P	5.66	9.81e-08	0.000153	0.42	0.45	Platelet count;	chr7:100377643	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.83	rs73401443	ENSG00000242294.5	STAG3L5P	5.66	9.81e-08	0.000153	0.42	0.45	Platelet count;	chr7:100379959	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.83	rs10085549	ENSG00000242294.5	STAG3L5P	5.66	9.81e-08	0.000153	0.42	0.45	Platelet count;	chr7:100385512	chr7:100336079~100351900:+
TGCT	cis	rs34217772	1	rs72668845	ENSG00000258536.1	RP11-1053O12.1	5.66	9.83e-08	0.000154	0.4	0.45	Myopia;	chr14:41788844	chr14:41742639~41742963:+
TGCT	cis	rs34217772	1	rs17181699	ENSG00000258536.1	RP11-1053O12.1	5.66	9.83e-08	0.000154	0.4	0.45	Myopia;	chr14:41791465	chr14:41742639~41742963:+
TGCT	cis	rs34217772	1	rs10483522	ENSG00000258536.1	RP11-1053O12.1	5.66	9.84e-08	0.000154	0.4	0.45	Myopia;	chr14:41806761	chr14:41742639~41742963:+
TGCT	cis	rs7829975	0.688	rs7827182	ENSG00000173295.6	FAM86B3P	5.66	9.85e-08	0.000154	0.54	0.45	Mood instability;	chr8:8522961	chr8:8228595~8244865:+
TGCT	cis	rs7829975	0.688	rs7817376	ENSG00000173295.6	FAM86B3P	-5.66	9.85e-08	0.000154	-0.54	-0.45	Mood instability;	chr8:8523020	chr8:8228595~8244865:+
TGCT	cis	rs7804306	0.655	rs17508185	ENSG00000233264.2	AC006042.8	5.66	9.87e-08	0.000154	1.12	0.45	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8015622	chr7:7980312~7982228:+
TGCT	cis	rs11155671	0.53	rs7757984	ENSG00000216906.2	RP11-350J20.9	5.66	9.92e-08	0.000154	0.5	0.45	Testicular germ cell tumor;	chr6:149887515	chr6:149904243~149906418:+
TGCT	cis	rs1799949	1	rs8176126	ENSG00000198496.9	NBR2	5.66	9.92e-08	0.000155	0.66	0.45	Menopause (age at onset);	chr17:43107032	chr17:43125610~43153671:+
TGCT	cis	rs17264034	0.821	rs460234	ENSG00000250786.1	SNHG18	5.66	9.93e-08	0.000155	0.52	0.45	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9543022	chr5:9546200~9550609:+
TGCT	cis	rs17264034	0.821	rs422309	ENSG00000250786.1	SNHG18	5.66	9.93e-08	0.000155	0.52	0.45	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9544284	chr5:9546200~9550609:+
TGCT	cis	rs1823913	0.927	rs13013390	ENSG00000227542.1	AC092614.2	5.66	9.98e-08	0.000155	0.47	0.45	Obesity-related traits;	chr2:191262001	chr2:191229165~191246172:-
TGCT	cis	rs7044106	0.708	rs920745	ENSG00000226752.6	PSMD5-AS1	-5.66	1e-07	0.000156	-0.58	-0.45	Hip circumference adjusted for BMI;	chr9:120667665	chr9:120824828~120854385:+
TGCT	cis	rs7044106	0.734	rs10491784	ENSG00000226752.6	PSMD5-AS1	-5.66	1e-07	0.000156	-0.58	-0.45	Hip circumference adjusted for BMI;	chr9:120670011	chr9:120824828~120854385:+
TGCT	cis	rs7044106	0.762	rs1886337	ENSG00000226752.6	PSMD5-AS1	-5.66	1e-07	0.000156	-0.58	-0.45	Hip circumference adjusted for BMI;	chr9:120681498	chr9:120824828~120854385:+
TGCT	cis	rs7044106	0.762	rs1411158	ENSG00000226752.6	PSMD5-AS1	-5.66	1e-07	0.000156	-0.58	-0.45	Hip circumference adjusted for BMI;	chr9:120702526	chr9:120824828~120854385:+
TGCT	cis	rs6964833	0.935	rs13238996	ENSG00000123965.13	PMS2P5	5.66	1e-07	0.000156	0.67	0.45	Menarche (age at onset);	chr7:74655318	chr7:74894116~74897835:+
TGCT	cis	rs950169	1	rs79318564	ENSG00000225151.9	GOLGA2P7	-5.66	1e-07	0.000156	-0.5	-0.45	Schizophrenia;	chr15:84117398	chr15:84199311~84230136:-
TGCT	cis	rs950169	1	rs1911155	ENSG00000225151.9	GOLGA2P7	-5.66	1e-07	0.000156	-0.5	-0.45	Schizophrenia;	chr15:84118883	chr15:84199311~84230136:-
TGCT	cis	rs10256972	0.681	rs6979076	ENSG00000226291.1	AC091729.8	5.66	1e-07	0.000156	0.48	0.45	Endometriosis;Longevity;	chr7:1076611	chr7:1080863~1082178:+
TGCT	cis	rs17361889	0.727	rs62440406	ENSG00000224683.1	RPL36AP29	5.66	1e-07	0.000156	0.48	0.45	Pediatric bone mineral content (hip);	chr7:16245394	chr7:16208945~16209265:+
TGCT	cis	rs9322193	0.772	rs7738696	ENSG00000216906.2	RP11-350J20.9	5.66	1.01e-07	0.000157	0.51	0.45	Lung cancer;	chr6:149848985	chr6:149904243~149906418:+
TGCT	cis	rs12891047	0.705	rs11626332	ENSG00000258759.1	RP11-1012A1.7	-5.66	1.01e-07	0.000157	-0.38	-0.45	Amyotrophic lateral sclerosis (sporadic);	chr14:67867102	chr14:67799004~67799609:+
TGCT	cis	rs8062405	0.964	rs78613234	ENSG00000259982.1	CDC37P1	5.66	1.01e-07	0.000157	0.62	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs62036624	ENSG00000259982.1	CDC37P1	5.66	1.01e-07	0.000157	0.62	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs55991577	ENSG00000259982.1	CDC37P1	5.66	1.01e-07	0.000157	0.62	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs56358680	ENSG00000259982.1	CDC37P1	5.66	1.01e-07	0.000157	0.62	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28700294~28701540:-
TGCT	cis	rs7188445	0.736	rs8048539	ENSG00000261390.4	RP11-345M22.2	5.66	1.02e-07	0.000158	0.44	0.45	Urate levels;	chr16:79670255	chr16:79715232~79770563:-
TGCT	cis	rs950169	0.84	rs62019457	ENSG00000225151.9	GOLGA2P7	-5.65	1.03e-07	0.000159	-0.52	-0.45	Schizophrenia;	chr15:84558911	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.922	rs67804993	ENSG00000225151.9	GOLGA2P7	-5.65	1.03e-07	0.000159	-0.52	-0.45	Schizophrenia;	chr15:84560799	chr15:84199311~84230136:-
TGCT	cis	rs73086581	0.947	rs67356712	ENSG00000229539.1	RP11-119B16.2	5.65	1.03e-07	0.000159	0.68	0.45	Response to antidepressants in depression;	chr20:3912239	chr20:3888239~3888868:-
TGCT	cis	rs2117029	0.767	rs3741622	ENSG00000258017.1	RP11-386G11.10	-5.65	1.03e-07	0.000159	-0.57	-0.45	Intelligence (multi-trait analysis);	chr12:49032195	chr12:49127782~49147869:+
TGCT	cis	rs7104764	0.957	rs519592	ENSG00000277290.1	RP11-326C3.16	-5.65	1.03e-07	0.000159	-0.43	-0.45	Menarche (age at onset);	chr11:236811	chr11:243099~243483:-
TGCT	cis	rs7208859	0.673	rs999798	ENSG00000263531.1	RP13-753N3.1	5.65	1.04e-07	0.000161	0.74	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30863921~30864940:-
TGCT	cis	rs11723261	0.582	rs6814287	ENSG00000275426.1	CH17-262A2.1	5.65	1.04e-07	0.000161	0.86	0.45	Immune response to smallpox vaccine (IL-6);	chr4:122443	chr4:149738~150317:+
TGCT	cis	rs950169	0.922	rs11630760	ENSG00000225151.9	GOLGA2P7	-5.65	1.04e-07	0.000162	-0.51	-0.45	Schizophrenia;	chr15:84570106	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.887	rs71395453	ENSG00000225151.9	GOLGA2P7	-5.65	1.04e-07	0.000162	-0.51	-0.45	Schizophrenia;	chr15:84570259	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.922	rs11633075	ENSG00000225151.9	GOLGA2P7	-5.65	1.04e-07	0.000162	-0.51	-0.45	Schizophrenia;	chr15:84570741	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.84	rs12905223	ENSG00000225151.9	GOLGA2P7	-5.65	1.04e-07	0.000162	-0.51	-0.45	Schizophrenia;	chr15:84571037	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.922	rs12912934	ENSG00000225151.9	GOLGA2P7	-5.65	1.04e-07	0.000162	-0.51	-0.45	Schizophrenia;	chr15:84571216	chr15:84199311~84230136:-
TGCT	cis	rs7208859	0.573	rs216443	ENSG00000263531.1	RP13-753N3.1	5.65	1.04e-07	0.000162	0.85	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30863921~30864940:-
TGCT	cis	rs172166	0.611	rs203882	ENSG00000216901.1	AL022393.7	5.65	1.05e-07	0.000162	0.58	0.45	Cardiac Troponin-T levels;	chr6:28110724	chr6:28176188~28176674:+
TGCT	cis	rs172166	0.694	rs1770131	ENSG00000216901.1	AL022393.7	5.65	1.05e-07	0.000162	0.58	0.45	Cardiac Troponin-T levels;	chr6:28118635	chr6:28176188~28176674:+
TGCT	cis	rs172166	0.694	rs1631552	ENSG00000216901.1	AL022393.7	5.65	1.05e-07	0.000162	0.58	0.45	Cardiac Troponin-T levels;	chr6:28121921	chr6:28176188~28176674:+
TGCT	cis	rs172166	0.694	rs536704	ENSG00000216901.1	AL022393.7	5.65	1.05e-07	0.000162	0.58	0.45	Cardiac Troponin-T levels;	chr6:28124825	chr6:28176188~28176674:+
TGCT	cis	rs950169	0.922	rs2033284	ENSG00000225151.9	GOLGA2P7	-5.65	1.05e-07	0.000162	-0.53	-0.45	Schizophrenia;	chr15:84391575	chr15:84199311~84230136:-
TGCT	cis	rs11723261	0.582	rs11732336	ENSG00000275426.1	CH17-262A2.1	5.65	1.05e-07	0.000162	0.85	0.45	Immune response to smallpox vaccine (IL-6);	chr4:146728	chr4:149738~150317:+
TGCT	cis	rs9322193	0.923	rs7769101	ENSG00000216906.2	RP11-350J20.9	5.65	1.05e-07	0.000163	0.51	0.45	Lung cancer;	chr6:149848768	chr6:149904243~149906418:+
TGCT	cis	rs7605378	0.528	rs281787	ENSG00000232732.8	AC073043.1	5.65	1.06e-07	0.000164	0.51	0.45	Osteoporosis;	chr2:199919515	chr2:199867396~199911159:-
TGCT	cis	rs7605378	0.528	rs281767	ENSG00000232732.8	AC073043.1	-5.65	1.06e-07	0.000164	-0.51	-0.45	Osteoporosis;	chr2:199958558	chr2:199867396~199911159:-
TGCT	cis	rs875971	0.505	rs1167386	ENSG00000236529.1	RP13-254B10.1	-5.65	1.06e-07	0.000164	-0.34	-0.45	Aortic root size;	chr7:66048109	chr7:65840212~65840596:+
TGCT	cis	rs1799949	0.864	rs60309406	ENSG00000198496.9	NBR2	-5.65	1.06e-07	0.000164	-0.66	-0.45	Menopause (age at onset);	chr17:43358297	chr17:43125610~43153671:+
TGCT	cis	rs2739330	0.791	rs4822458	ENSG00000218537.1	MIF-AS1	5.65	1.06e-07	0.000164	0.56	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23894426~23898930:-
TGCT	cis	rs786425	0.707	rs1051793	ENSG00000278112.1	RP11-972P1.11	5.65	1.06e-07	0.000164	0.53	0.45	Pubertal anthropometrics;	chr12:123659848	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.676	rs4930708	ENSG00000278112.1	RP11-972P1.11	5.65	1.06e-07	0.000164	0.53	0.45	Pubertal anthropometrics;	chr12:123661150	chr12:123519390~123519856:-
TGCT	cis	rs7044106	0.762	rs4837790	ENSG00000226752.6	PSMD5-AS1	-5.64	1.07e-07	0.000165	-0.58	-0.45	Hip circumference adjusted for BMI;	chr9:120684047	chr9:120824828~120854385:+
TGCT	cis	rs7044106	0.762	rs10491783	ENSG00000226752.6	PSMD5-AS1	-5.64	1.07e-07	0.000165	-0.58	-0.45	Hip circumference adjusted for BMI;	chr9:120687877	chr9:120824828~120854385:+
TGCT	cis	rs7044106	0.762	rs966397	ENSG00000226752.6	PSMD5-AS1	-5.64	1.07e-07	0.000165	-0.58	-0.45	Hip circumference adjusted for BMI;	chr9:120691034	chr9:120824828~120854385:+
TGCT	cis	rs17301013	0.932	rs3737651	ENSG00000227373.4	RP11-160H22.5	-5.64	1.08e-07	0.000166	-0.47	-0.45	Systemic lupus erythematosus;	chr1:174475414	chr1:174115300~174160004:-
TGCT	cis	rs9322193	0.567	rs7742692	ENSG00000216906.2	RP11-350J20.9	5.64	1.08e-07	0.000166	0.49	0.45	Lung cancer;	chr6:149892363	chr6:149904243~149906418:+
TGCT	cis	rs950169	1	rs1818950	ENSG00000225151.9	GOLGA2P7	-5.64	1.08e-07	0.000167	-0.5	-0.45	Schizophrenia;	chr15:84053769	chr15:84199311~84230136:-
TGCT	cis	rs7804306	0.826	rs74761423	ENSG00000233264.2	AC006042.8	5.64	1.08e-07	0.000167	1.07	0.45	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8059693	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.655	rs73053544	ENSG00000233264.2	AC006042.8	5.64	1.08e-07	0.000167	1.07	0.45	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8059883	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.826	rs73053556	ENSG00000233264.2	AC006042.8	5.64	1.08e-07	0.000167	1.07	0.45	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8066180	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.826	rs73053562	ENSG00000233264.2	AC006042.8	5.64	1.08e-07	0.000167	1.07	0.45	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8068527	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.826	rs55746128	ENSG00000233264.2	AC006042.8	5.64	1.08e-07	0.000167	1.07	0.45	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8070757	chr7:7980312~7982228:+
TGCT	cis	rs950169	0.887	rs220333	ENSG00000225151.9	GOLGA2P7	-5.64	1.09e-07	0.000168	-0.51	-0.45	Schizophrenia;	chr15:84547902	chr15:84199311~84230136:-
TGCT	cis	rs8072100	0.875	rs62073966	ENSG00000228782.6	CTD-2026D20.3	-5.64	1.09e-07	0.000168	-0.55	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47522647	chr17:47450568~47492492:-
TGCT	cis	rs12906542	0.529	rs62008651	ENSG00000259792.1	RP11-114H24.6	-5.64	1.09e-07	0.000168	-0.48	-0.45	Breast cancer;	chr15:77984075	chr15:77993405~77995289:+
TGCT	cis	rs801193	0.569	rs10950050	ENSG00000222364.1	RNU6-96P	-5.64	1.09e-07	0.000168	-0.48	-0.45	Aortic root size;	chr7:66774601	chr7:66395191~66395286:+
TGCT	cis	rs9549367	0.569	rs3024719	ENSG00000269125.1	RP11-98F14.11	-5.64	1.09e-07	0.000168	-0.6	-0.45	Platelet distribution width;	chr13:113159911	chr13:113165002~113165183:-
TGCT	cis	rs7044106	0.762	rs1547268	ENSG00000226752.6	PSMD5-AS1	-5.64	1.09e-07	0.000168	-0.57	-0.45	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120824828~120854385:+
TGCT	cis	rs7044106	0.762	rs1547267	ENSG00000226752.6	PSMD5-AS1	-5.64	1.09e-07	0.000168	-0.57	-0.45	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120824828~120854385:+
TGCT	cis	rs7044106	0.762	rs4142158	ENSG00000226752.6	PSMD5-AS1	-5.64	1.09e-07	0.000168	-0.57	-0.45	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120824828~120854385:+
TGCT	cis	rs8072100	1	rs4375701	ENSG00000228782.6	CTD-2026D20.3	5.64	1.1e-07	0.000169	0.54	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47634852	chr17:47450568~47492492:-
TGCT	cis	rs8072100	1	rs8065437	ENSG00000228782.6	CTD-2026D20.3	5.64	1.1e-07	0.000169	0.54	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644287	chr17:47450568~47492492:-
TGCT	cis	rs8072100	1	rs11650372	ENSG00000228782.6	CTD-2026D20.3	5.64	1.1e-07	0.000169	0.54	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644429	chr17:47450568~47492492:-
TGCT	cis	rs8072100	1	rs8065669	ENSG00000228782.6	CTD-2026D20.3	5.64	1.1e-07	0.000169	0.54	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47647630	chr17:47450568~47492492:-
TGCT	cis	rs8072100	0.967	rs4580230	ENSG00000228782.6	CTD-2026D20.3	5.64	1.1e-07	0.000169	0.54	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47661495	chr17:47450568~47492492:-
TGCT	cis	rs8072100	0.934	rs9905583	ENSG00000228782.6	CTD-2026D20.3	5.64	1.1e-07	0.000169	0.54	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47663650	chr17:47450568~47492492:-
TGCT	cis	rs2732480	0.538	rs1387259	ENSG00000258273.1	RP11-370I10.4	5.64	1.1e-07	0.000169	0.53	0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48333755~48333901:-
TGCT	cis	rs3091242	0.9	rs1883427	ENSG00000224183.1	SDHDP6	-5.64	1.1e-07	0.000169	-0.48	-0.45	Erythrocyte sedimentation rate;	chr1:25417977	chr1:25294164~25294643:-
TGCT	cis	rs977987	0.8	rs11149815	ENSG00000261783.1	RP11-252K23.2	-5.64	1.1e-07	0.00017	-0.67	-0.45	Dupuytren's disease;	chr16:75302275	chr16:75379818~75381260:-
TGCT	cis	rs5760092	0.755	rs915589	ENSG00000218537.1	MIF-AS1	-5.64	1.1e-07	0.00017	-0.67	-0.45	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23894426~23898930:-
TGCT	cis	rs5760092	0.627	rs6519489	ENSG00000218537.1	MIF-AS1	-5.64	1.1e-07	0.00017	-0.67	-0.45	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23894426~23898930:-
TGCT	cis	rs76878669	0.561	rs4930363	ENSG00000254510.1	RP11-867G23.10	5.64	1.11e-07	0.00017	0.59	0.45	Educational attainment (years of education);	chr11:66402205	chr11:66409158~66417137:+
TGCT	cis	rs7188445	0.736	rs4243177	ENSG00000261390.4	RP11-345M22.2	5.64	1.11e-07	0.000171	0.42	0.45	Urate levels;	chr16:79669932	chr16:79715232~79770563:-
TGCT	cis	rs11155671	0.53	rs7742993	ENSG00000216906.2	RP11-350J20.9	5.64	1.11e-07	0.000171	0.49	0.45	Testicular germ cell tumor;	chr6:149883959	chr6:149904243~149906418:+
TGCT	cis	rs2732480	0.557	rs2732454	ENSG00000258273.1	RP11-370I10.4	-5.64	1.11e-07	0.000171	-0.52	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48333755~48333901:-
TGCT	cis	rs2732480	0.557	rs923397	ENSG00000258273.1	RP11-370I10.4	-5.64	1.11e-07	0.000171	-0.52	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48333755~48333901:-
TGCT	cis	rs2732480	0.557	rs2409004	ENSG00000258273.1	RP11-370I10.4	-5.64	1.11e-07	0.000171	-0.52	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48333755~48333901:-
TGCT	cis	rs2732480	0.577	rs2450994	ENSG00000258273.1	RP11-370I10.4	-5.64	1.11e-07	0.000171	-0.52	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48333755~48333901:-
TGCT	cis	rs524281	1	rs547087	ENSG00000255320.1	RP11-755F10.1	-5.64	1.12e-07	0.000172	-0.55	-0.45	Electroencephalogram traits;	chr11:66078793	chr11:66244840~66246239:-
TGCT	cis	rs2906856	0.524	rs56236103	ENSG00000255733.4	IFNG-AS1	5.63	1.13e-07	0.000173	0.52	0.45	Mosquito bite size;	chr12:67937437	chr12:67989445~68234686:+
TGCT	cis	rs904251	0.797	rs1757177	ENSG00000279942.1	RP1-153P14.7	-5.63	1.13e-07	0.000173	-0.53	-0.45	Cognitive performance;	chr6:37518594	chr6:37567716~37571460:+
TGCT	cis	rs6061231	0.561	rs67072353	ENSG00000273619.1	RP5-908M14.9	-5.63	1.14e-07	0.000174	-0.55	-0.45	Colorectal cancer;	chr20:62365646	chr20:62386303~62386970:-
TGCT	cis	rs2427308	0.607	rs1741635	ENSG00000273619.1	RP5-908M14.9	5.63	1.14e-07	0.000175	0.54	0.45	Colorectal cancer;	chr20:62363141	chr20:62386303~62386970:-
TGCT	cis	rs11723261	0.621	rs3829	ENSG00000275426.1	CH17-262A2.1	5.63	1.14e-07	0.000175	0.92	0.45	Immune response to smallpox vaccine (IL-6);	chr4:141070	chr4:149738~150317:+
TGCT	cis	rs11723261	0.621	rs57013142	ENSG00000275426.1	CH17-262A2.1	5.63	1.14e-07	0.000175	0.92	0.45	Immune response to smallpox vaccine (IL-6);	chr4:141956	chr4:149738~150317:+
TGCT	cis	rs11723261	0.564	rs61792258	ENSG00000275426.1	CH17-262A2.1	5.63	1.14e-07	0.000175	0.92	0.45	Immune response to smallpox vaccine (IL-6);	chr4:143482	chr4:149738~150317:+
TGCT	cis	rs7811142	0.887	rs111972532	ENSG00000242294.5	STAG3L5P	5.63	1.14e-07	0.000175	0.42	0.45	Platelet count;	chr7:100471465	chr7:100336079~100351900:+
TGCT	cis	rs4713118	0.513	rs149958	ENSG00000216901.1	AL022393.7	5.63	1.14e-07	0.000175	0.58	0.45	Parkinson's disease;	chr6:28045839	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.513	rs149959	ENSG00000216901.1	AL022393.7	5.63	1.14e-07	0.000175	0.58	0.45	Parkinson's disease;	chr6:28046076	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.513	rs156738	ENSG00000216901.1	AL022393.7	5.63	1.14e-07	0.000175	0.58	0.45	Parkinson's disease;	chr6:28046247	chr6:28176188~28176674:+
TGCT	cis	rs8072100	0.967	rs2317826	ENSG00000228782.6	CTD-2026D20.3	5.63	1.15e-07	0.000176	0.54	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47653533	chr17:47450568~47492492:-
TGCT	cis	rs8072100	0.688	rs12602134	ENSG00000228782.6	CTD-2026D20.3	-5.63	1.15e-07	0.000176	-0.55	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47504770	chr17:47450568~47492492:-
TGCT	cis	rs17361889	0.517	rs62441879	ENSG00000224683.1	RPL36AP29	5.63	1.16e-07	0.000177	0.59	0.45	Pediatric bone mineral content (hip);	chr7:16290195	chr7:16208945~16209265:+
TGCT	cis	rs2739330	0.76	rs5760095	ENSG00000250470.1	AP000351.3	5.63	1.16e-07	0.000178	0.44	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23976904~23977585:-
TGCT	cis	rs7412746	0.634	rs4451553	ENSG00000206931.1	RNU6-1042P	5.63	1.16e-07	0.000178	0.37	0.45	Melanoma;	chr1:150964853	chr1:150701866~150701972:+
TGCT	cis	rs1062177	0.502	rs10463321	ENSG00000213433.5	RPLP1P6	-5.63	1.16e-07	0.000178	-0.51	-0.45	Preschool internalizing problems;	chr5:151944344	chr5:151765859~151766378:-
TGCT	cis	rs2739330	0.731	rs4822450	ENSG00000272787.1	KB-226F1.2	-5.63	1.16e-07	0.000178	-0.5	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23969211~23969873:+
TGCT	cis	rs9549367	0.789	rs8001506	ENSG00000269125.1	RP11-98F14.11	-5.63	1.16e-07	0.000178	-0.52	-0.45	Platelet distribution width;	chr13:113212839	chr13:113165002~113165183:-
TGCT	cis	rs9326248	0.53	rs2127905	ENSG00000254851.1	RP11-109L13.1	-5.63	1.16e-07	0.000178	-0.89	-0.45	Blood protein levels;	chr11:117155658	chr11:117135528~117138582:+
TGCT	cis	rs9326248	0.53	rs7123517	ENSG00000254851.1	RP11-109L13.1	-5.63	1.16e-07	0.000178	-0.89	-0.45	Blood protein levels;	chr11:117157039	chr11:117135528~117138582:+
TGCT	cis	rs9326248	0.53	rs7940310	ENSG00000254851.1	RP11-109L13.1	-5.63	1.17e-07	0.000179	-0.88	-0.45	Blood protein levels;	chr11:117153765	chr11:117135528~117138582:+
TGCT	cis	rs76878669	0.917	rs10896110	ENSG00000254510.1	RP11-867G23.10	-5.63	1.17e-07	0.000179	-0.66	-0.45	Educational attainment (years of education);	chr11:66334507	chr11:66409158~66417137:+
TGCT	cis	rs76878669	0.917	rs10444359	ENSG00000254510.1	RP11-867G23.10	-5.63	1.17e-07	0.000179	-0.66	-0.45	Educational attainment (years of education);	chr11:66335336	chr11:66409158~66417137:+
TGCT	cis	rs4713118	0.539	rs200951	ENSG00000216901.1	AL022393.7	5.62	1.18e-07	0.00018	0.6	0.45	Parkinson's disease;	chr6:27868152	chr6:28176188~28176674:+
TGCT	cis	rs7617773	0.817	rs9819094	ENSG00000229759.1	MRPS18AP1	5.62	1.18e-07	0.00018	0.38	0.45	Coronary artery disease;	chr3:48278068	chr3:48256350~48256938:-
TGCT	cis	rs9322193	0.923	rs12205092	ENSG00000216906.2	RP11-350J20.9	5.62	1.18e-07	0.000181	0.51	0.45	Lung cancer;	chr6:149761375	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs10872651	ENSG00000216906.2	RP11-350J20.9	5.62	1.18e-07	0.000181	0.51	0.45	Lung cancer;	chr6:149768273	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs3805749	ENSG00000216906.2	RP11-350J20.9	5.62	1.18e-07	0.000181	0.51	0.45	Lung cancer;	chr6:149772546	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.847	rs9505972	ENSG00000216906.2	RP11-350J20.9	5.62	1.18e-07	0.000181	0.51	0.45	Lung cancer;	chr6:149775255	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs3805752	ENSG00000216906.2	RP11-350J20.9	5.62	1.18e-07	0.000181	0.51	0.45	Lung cancer;	chr6:149795490	chr6:149904243~149906418:+
TGCT	cis	rs17301013	0.507	rs1793316	ENSG00000227373.4	RP11-160H22.5	5.62	1.19e-07	0.000181	0.53	0.45	Systemic lupus erythematosus;	chr1:174825006	chr1:174115300~174160004:-
TGCT	cis	rs1153858	1	rs7402650	ENSG00000259520.4	CTD-2651B20.3	-5.62	1.19e-07	0.000182	-0.39	-0.45	Homoarginine levels;	chr15:45409697	chr15:45251580~45279251:-
TGCT	cis	rs1153858	0.943	rs7402632	ENSG00000259520.4	CTD-2651B20.3	-5.62	1.19e-07	0.000182	-0.39	-0.45	Homoarginine levels;	chr15:45409715	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs8042786	ENSG00000259520.4	CTD-2651B20.3	-5.62	1.19e-07	0.000182	-0.39	-0.45	Homoarginine levels;	chr15:45411341	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs12440038	ENSG00000259520.4	CTD-2651B20.3	-5.62	1.19e-07	0.000182	-0.39	-0.45	Homoarginine levels;	chr15:45414541	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs60476496	ENSG00000259520.4	CTD-2651B20.3	-5.62	1.19e-07	0.000182	-0.39	-0.45	Homoarginine levels;	chr15:45421603	chr15:45251580~45279251:-
TGCT	cis	rs6061231	1	rs11696991	ENSG00000273619.1	RP5-908M14.9	-5.62	1.19e-07	0.000182	-0.49	-0.45	Colorectal cancer;	chr20:62384638	chr20:62386303~62386970:-
TGCT	cis	rs1799949	0.965	rs4793233	ENSG00000198496.9	NBR2	-5.62	1.19e-07	0.000182	-0.66	-0.45	Menopause (age at onset);	chr17:43358069	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.965	rs4793234	ENSG00000198496.9	NBR2	-5.62	1.19e-07	0.000182	-0.66	-0.45	Menopause (age at onset);	chr17:43358815	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs4793236	ENSG00000198496.9	NBR2	-5.62	1.19e-07	0.000182	-0.66	-0.45	Menopause (age at onset);	chr17:43359072	chr17:43125610~43153671:+
TGCT	cis	rs1061377	1	rs9996285	ENSG00000249207.1	RP11-360F5.1	-5.62	1.19e-07	0.000182	-0.49	-0.45	Uric acid levels;	chr4:39130556	chr4:39112677~39126818:-
TGCT	cis	rs2732480	0.577	rs2634693	ENSG00000258273.1	RP11-370I10.4	-5.62	1.2e-07	0.000183	-0.52	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48312715	chr12:48333755~48333901:-
TGCT	cis	rs2732480	0.577	rs2634691	ENSG00000258273.1	RP11-370I10.4	-5.62	1.2e-07	0.000183	-0.52	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48314476	chr12:48333755~48333901:-
TGCT	cis	rs2732480	0.557	rs2732441	ENSG00000258273.1	RP11-370I10.4	-5.62	1.2e-07	0.000183	-0.52	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48333755~48333901:-
TGCT	cis	rs2732480	0.577	rs2732448	ENSG00000258273.1	RP11-370I10.4	-5.62	1.2e-07	0.000183	-0.52	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48333755~48333901:-
TGCT	cis	rs2732480	0.577	rs2732466	ENSG00000258273.1	RP11-370I10.4	-5.62	1.2e-07	0.000183	-0.52	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48333755~48333901:-
TGCT	cis	rs2732480	0.557	rs2634682	ENSG00000258273.1	RP11-370I10.4	-5.62	1.2e-07	0.000183	-0.52	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48333755~48333901:-
TGCT	cis	rs6964833	1	rs35203738	ENSG00000123965.13	PMS2P5	5.62	1.2e-07	0.000183	0.62	0.45	Menarche (age at onset);	chr7:74690864	chr7:74894116~74897835:+
TGCT	cis	rs6964833	0.935	rs7795281	ENSG00000123965.13	PMS2P5	5.62	1.2e-07	0.000183	0.62	0.45	Menarche (age at onset);	chr7:74708523	chr7:74894116~74897835:+
TGCT	cis	rs12891047	0.899	rs11847628	ENSG00000258759.1	RP11-1012A1.7	-5.62	1.2e-07	0.000183	-0.39	-0.45	Amyotrophic lateral sclerosis (sporadic);	chr14:67817358	chr14:67799004~67799609:+
TGCT	cis	rs916888	0.61	rs199438	ENSG00000262500.1	RP11-259G18.2	5.62	1.2e-07	0.000183	0.59	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46243606~46245044:+
TGCT	cis	rs8072100	0.905	rs8077106	ENSG00000228782.6	CTD-2026D20.3	-5.62	1.2e-07	0.000183	-0.54	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575925	chr17:47450568~47492492:-
TGCT	cis	rs8072100	0.754	rs8081717	ENSG00000228782.6	CTD-2026D20.3	-5.62	1.2e-07	0.000183	-0.54	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47576555	chr17:47450568~47492492:-
TGCT	cis	rs8072100	1	rs8072100	ENSG00000228782.6	CTD-2026D20.3	-5.62	1.2e-07	0.000183	-0.54	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597321	chr17:47450568~47492492:-
TGCT	cis	rs8072100	0.935	rs12150231	ENSG00000228782.6	CTD-2026D20.3	-5.62	1.2e-07	0.000183	-0.54	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47639725	chr17:47450568~47492492:-
TGCT	cis	rs8072100	1	rs3809868	ENSG00000228782.6	CTD-2026D20.3	-5.62	1.2e-07	0.000183	-0.54	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47673230	chr17:47450568~47492492:-
TGCT	cis	rs8072100	1	rs7210738	ENSG00000228782.6	CTD-2026D20.3	-5.62	1.2e-07	0.000183	-0.54	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47680232	chr17:47450568~47492492:-
TGCT	cis	rs3091242	0.934	rs666686	ENSG00000261349.1	RP3-465N24.5	-5.62	1.21e-07	0.000184	-0.45	-0.45	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25266102~25267136:-
TGCT	cis	rs2882667	0.754	rs11746434	ENSG00000253404.1	AC034243.1	5.62	1.21e-07	0.000184	0.52	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139099614	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.858	rs11242448	ENSG00000253404.1	AC034243.1	5.62	1.21e-07	0.000184	0.52	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139107465	chr5:138744434~138753309:-
TGCT	cis	rs34217772	0.68	rs60030517	ENSG00000258536.1	RP11-1053O12.1	5.62	1.21e-07	0.000184	0.4	0.45	Myopia;	chr14:41733863	chr14:41742639~41742963:+
TGCT	cis	rs8040855	0.86	rs7172266	ENSG00000259295.5	CSPG4P12	-5.62	1.22e-07	0.000185	-0.62	-0.45	Bulimia nervosa;	chr15:85172982	chr15:85191438~85213905:+
TGCT	cis	rs17301013	0.507	rs333436	ENSG00000227373.4	RP11-160H22.5	5.62	1.22e-07	0.000185	0.53	0.45	Systemic lupus erythematosus;	chr1:174739069	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs392307	ENSG00000227373.4	RP11-160H22.5	5.62	1.22e-07	0.000185	0.53	0.45	Systemic lupus erythematosus;	chr1:174744243	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs3117838	ENSG00000227373.4	RP11-160H22.5	5.62	1.22e-07	0.000185	0.53	0.45	Systemic lupus erythematosus;	chr1:174749205	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs1923818	ENSG00000227373.4	RP11-160H22.5	5.62	1.22e-07	0.000185	0.53	0.45	Systemic lupus erythematosus;	chr1:174749737	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs332801	ENSG00000227373.4	RP11-160H22.5	5.62	1.22e-07	0.000185	0.53	0.45	Systemic lupus erythematosus;	chr1:174753192	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs332800	ENSG00000227373.4	RP11-160H22.5	5.62	1.22e-07	0.000185	0.53	0.45	Systemic lupus erythematosus;	chr1:174753467	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs1622802	ENSG00000227373.4	RP11-160H22.5	-5.62	1.22e-07	0.000185	-0.53	-0.45	Systemic lupus erythematosus;	chr1:174766066	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs1329281	ENSG00000227373.4	RP11-160H22.5	-5.62	1.22e-07	0.000185	-0.53	-0.45	Systemic lupus erythematosus;	chr1:174766432	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs6696465	ENSG00000227373.4	RP11-160H22.5	-5.62	1.22e-07	0.000185	-0.53	-0.45	Systemic lupus erythematosus;	chr1:174769700	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs1793292	ENSG00000227373.4	RP11-160H22.5	-5.62	1.22e-07	0.000185	-0.53	-0.45	Systemic lupus erythematosus;	chr1:174778185	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.531	rs1653634	ENSG00000227373.4	RP11-160H22.5	-5.62	1.22e-07	0.000185	-0.53	-0.45	Systemic lupus erythematosus;	chr1:174783348	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs1793298	ENSG00000227373.4	RP11-160H22.5	-5.62	1.22e-07	0.000185	-0.53	-0.45	Systemic lupus erythematosus;	chr1:174784601	chr1:174115300~174160004:-
TGCT	cis	rs34217772	0.68	rs61990349	ENSG00000258536.1	RP11-1053O12.1	5.62	1.22e-07	0.000185	0.4	0.45	Myopia;	chr14:41733468	chr14:41742639~41742963:+
TGCT	cis	rs5758659	0.714	rs133373	ENSG00000270083.1	RP1-257I20.14	5.62	1.22e-07	0.000185	0.43	0.45	Cognitive function;	chr22:42069784	chr22:42089630~42090028:-
TGCT	cis	rs2732480	0.577	rs2732481	ENSG00000258273.1	RP11-370I10.4	-5.62	1.22e-07	0.000186	-0.53	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48333755~48333901:-
TGCT	cis	rs2732480	0.557	rs2732484	ENSG00000258273.1	RP11-370I10.4	-5.62	1.22e-07	0.000186	-0.53	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48333755~48333901:-
TGCT	cis	rs2732480	0.577	rs2732486	ENSG00000258273.1	RP11-370I10.4	-5.62	1.22e-07	0.000186	-0.53	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48333755~48333901:-
TGCT	cis	rs2732480	0.517	rs2634676	ENSG00000258273.1	RP11-370I10.4	-5.62	1.22e-07	0.000186	-0.53	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48333755~48333901:-
TGCT	cis	rs2732480	0.577	rs1489109	ENSG00000258273.1	RP11-370I10.4	-5.62	1.22e-07	0.000186	-0.53	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48333755~48333901:-
TGCT	cis	rs2732480	0.577	rs1489108	ENSG00000258273.1	RP11-370I10.4	-5.62	1.22e-07	0.000186	-0.53	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48333755~48333901:-
TGCT	cis	rs7044106	0.762	rs1470307	ENSG00000226752.6	PSMD5-AS1	-5.62	1.22e-07	0.000186	-0.57	-0.45	Hip circumference adjusted for BMI;	chr9:120670761	chr9:120824828~120854385:+
TGCT	cis	rs8072100	0.934	rs8067286	ENSG00000228782.6	CTD-2026D20.3	-5.62	1.22e-07	0.000186	-0.54	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47517224	chr17:47450568~47492492:-
TGCT	cis	rs8072100	0.935	rs78551919	ENSG00000228782.6	CTD-2026D20.3	-5.62	1.22e-07	0.000186	-0.54	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47548636	chr17:47450568~47492492:-
TGCT	cis	rs8062405	1	rs1987472	ENSG00000259982.1	CDC37P1	5.62	1.23e-07	0.000186	0.6	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.895	rs56186137	ENSG00000259982.1	CDC37P1	5.62	1.23e-07	0.000186	0.6	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28700294~28701540:-
TGCT	cis	rs8062405	1	rs2008514	ENSG00000259982.1	CDC37P1	-5.61	1.23e-07	0.000187	-0.6	-0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28700294~28701540:-
TGCT	cis	rs66887589	0.934	rs41464847	ENSG00000245958.5	RP11-33B1.1	5.61	1.23e-07	0.000187	0.52	0.45	Diastolic blood pressure;	chr4:119611246	chr4:119454791~119552025:+
TGCT	cis	rs17361889	0.752	rs62440450	ENSG00000224683.1	RPL36AP29	5.61	1.23e-07	0.000187	0.47	0.45	Pediatric bone mineral content (hip);	chr7:16257771	chr7:16208945~16209265:+
TGCT	cis	rs2732480	0.538	rs1387260	ENSG00000258273.1	RP11-370I10.4	-5.61	1.23e-07	0.000187	-0.53	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48333755~48333901:-
TGCT	cis	rs950169	0.881	rs34117475	ENSG00000225151.9	GOLGA2P7	-5.61	1.23e-07	0.000187	-0.5	-0.45	Schizophrenia;	chr15:84565212	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.81	rs2879976	ENSG00000225151.9	GOLGA2P7	-5.61	1.23e-07	0.000187	-0.5	-0.45	Schizophrenia;	chr15:84566347	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.8	rs34302901	ENSG00000225151.9	GOLGA2P7	-5.61	1.23e-07	0.000187	-0.5	-0.45	Schizophrenia;	chr15:84567712	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.922	rs12915832	ENSG00000225151.9	GOLGA2P7	-5.61	1.23e-07	0.000187	-0.5	-0.45	Schizophrenia;	chr15:84568226	chr15:84199311~84230136:-
TGCT	cis	rs3091242	0.9	rs1883427	ENSG00000261349.1	RP3-465N24.5	-5.61	1.24e-07	0.000188	-0.45	-0.45	Erythrocyte sedimentation rate;	chr1:25417977	chr1:25266102~25267136:-
TGCT	cis	rs8040855	0.931	rs11855471	ENSG00000259295.5	CSPG4P12	-5.61	1.24e-07	0.000188	-0.58	-0.45	Bulimia nervosa;	chr15:85175976	chr15:85191438~85213905:+
TGCT	cis	rs17301013	0.507	rs6677243	ENSG00000227373.4	RP11-160H22.5	5.61	1.24e-07	0.000188	0.52	0.45	Systemic lupus erythematosus;	chr1:174339471	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs10912766	ENSG00000227373.4	RP11-160H22.5	5.61	1.24e-07	0.000188	0.52	0.45	Systemic lupus erythematosus;	chr1:174341129	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12059307	ENSG00000227373.4	RP11-160H22.5	5.61	1.24e-07	0.000188	0.52	0.45	Systemic lupus erythematosus;	chr1:174342105	chr1:174115300~174160004:-
TGCT	cis	rs7174755	0.608	rs10162905	ENSG00000260657.2	RP11-315D16.4	5.61	1.24e-07	0.000189	0.48	0.45	Major depressive disorder;	chr15:68103709	chr15:68267792~68277994:-
TGCT	cis	rs7115242	0.8	rs6589597	ENSG00000254851.1	RP11-109L13.1	5.61	1.26e-07	0.00019	0.78	0.45	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117127082	chr11:117135528~117138582:+
TGCT	cis	rs8072100	1	rs4794016	ENSG00000228782.6	CTD-2026D20.3	-5.61	1.26e-07	0.000191	-0.54	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47648565	chr17:47450568~47492492:-
TGCT	cis	rs8072100	1	rs11870935	ENSG00000228782.6	CTD-2026D20.3	-5.61	1.26e-07	0.000191	-0.54	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655239	chr17:47450568~47492492:-
TGCT	cis	rs8062405	1	rs7187776	ENSG00000259982.1	CDC37P1	5.61	1.26e-07	0.000191	0.6	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28700294~28701540:-
TGCT	cis	rs7811142	0.779	rs28680963	ENSG00000242294.5	STAG3L5P	5.61	1.26e-07	0.000192	0.42	0.45	Platelet count;	chr7:100307852	chr7:100336079~100351900:+
TGCT	cis	rs7849270	1	rs1107328	ENSG00000268707.1	RP11-247A12.7	5.61	1.27e-07	0.000192	0.5	0.45	Blood metabolite ratios;	chr9:129155255	chr9:129170434~129170940:+
TGCT	cis	rs17361889	0.656	rs2058269	ENSG00000224683.1	RPL36AP29	5.61	1.27e-07	0.000193	0.51	0.45	Pediatric bone mineral content (hip);	chr7:16193629	chr7:16208945~16209265:+
TGCT	cis	rs12891047	1	rs2235963	ENSG00000258759.1	RP11-1012A1.7	5.61	1.27e-07	0.000193	0.38	0.45	Amyotrophic lateral sclerosis (sporadic);	chr14:67782228	chr14:67799004~67799609:+
TGCT	cis	rs34217772	1	rs2023562	ENSG00000258536.1	RP11-1053O12.1	5.61	1.28e-07	0.000193	0.38	0.45	Myopia;	chr14:41801713	chr14:41742639~41742963:+
TGCT	cis	rs7829975	0.533	rs35900578	ENSG00000173295.6	FAM86B3P	5.61	1.28e-07	0.000193	0.55	0.45	Mood instability;	chr8:8862003	chr8:8228595~8244865:+
TGCT	cis	rs1153858	1	rs2056493	ENSG00000259520.4	CTD-2651B20.3	-5.61	1.28e-07	0.000194	-0.39	-0.45	Homoarginine levels;	chr15:45356074	chr15:45251580~45279251:-
TGCT	cis	rs55794721	0.509	rs12027110	ENSG00000261349.1	RP3-465N24.5	-5.6	1.29e-07	0.000194	-0.44	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25266102~25267136:-
TGCT	cis	rs2276314	0.857	rs9304155	ENSG00000278986.1	RP11-723J4.3	-5.6	1.29e-07	0.000195	-0.5	-0.45	Endometriosis;Drug-induced torsades de pointes;	chr18:36005747	chr18:35972151~35973916:+
TGCT	cis	rs6061231	0.583	rs2427313	ENSG00000273619.1	RP5-908M14.9	-5.6	1.29e-07	0.000195	-0.52	-0.45	Colorectal cancer;	chr20:62395619	chr20:62386303~62386970:-
TGCT	cis	rs9322193	0.961	rs9767713	ENSG00000216906.2	RP11-350J20.9	5.6	1.29e-07	0.000195	0.51	0.45	Lung cancer;	chr6:149588241	chr6:149904243~149906418:+
TGCT	cis	rs17711722	0.522	rs4642526	ENSG00000164669.11	INTS4P1	-5.6	1.29e-07	0.000195	-0.44	-0.45	Calcium levels;	chr7:65751755	chr7:65141225~65234216:+
TGCT	cis	rs2732480	0.577	rs2634681	ENSG00000258273.1	RP11-370I10.4	5.6	1.29e-07	0.000195	0.52	0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48333755~48333901:-
TGCT	cis	rs8062405	0.655	rs7184597	ENSG00000259982.1	CDC37P1	-5.6	1.3e-07	0.000196	-0.66	-0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28700294~28701540:-
TGCT	cis	rs7849270	1	rs3739847	ENSG00000268707.1	RP11-247A12.7	5.6	1.3e-07	0.000196	0.5	0.45	Blood metabolite ratios;	chr9:129149295	chr9:129170434~129170940:+
TGCT	cis	rs17301013	0.507	rs12076548	ENSG00000227373.4	RP11-160H22.5	-5.6	1.3e-07	0.000196	-0.53	-0.45	Systemic lupus erythematosus;	chr1:174479005	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs2281011	ENSG00000227373.4	RP11-160H22.5	5.6	1.3e-07	0.000196	0.53	0.45	Systemic lupus erythematosus;	chr1:174509890	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs2072759	ENSG00000227373.4	RP11-160H22.5	5.6	1.3e-07	0.000196	0.53	0.45	Systemic lupus erythematosus;	chr1:174510189	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs4652511	ENSG00000227373.4	RP11-160H22.5	5.6	1.3e-07	0.000196	0.53	0.45	Systemic lupus erythematosus;	chr1:174515500	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs4652513	ENSG00000227373.4	RP11-160H22.5	5.6	1.3e-07	0.000196	0.53	0.45	Systemic lupus erythematosus;	chr1:174515794	chr1:174115300~174160004:-
TGCT	cis	rs1799949	1	rs1973646	ENSG00000198496.9	NBR2	-5.6	1.3e-07	0.000196	-0.65	-0.45	Menopause (age at onset);	chr17:43158478	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.965	rs11650132	ENSG00000198496.9	NBR2	-5.6	1.3e-07	0.000196	-0.65	-0.45	Menopause (age at onset);	chr17:43174070	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs11654731	ENSG00000198496.9	NBR2	-5.6	1.3e-07	0.000196	-0.65	-0.45	Menopause (age at onset);	chr17:43174923	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.965	rs11651623	ENSG00000198496.9	NBR2	-5.6	1.3e-07	0.000196	-0.65	-0.45	Menopause (age at onset);	chr17:43177830	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.965	rs11657883	ENSG00000198496.9	NBR2	-5.6	1.3e-07	0.000196	-0.65	-0.45	Menopause (age at onset);	chr17:43178007	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.965	rs11656945	ENSG00000198496.9	NBR2	-5.6	1.3e-07	0.000196	-0.65	-0.45	Menopause (age at onset);	chr17:43178248	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs11653460	ENSG00000198496.9	NBR2	-5.6	1.3e-07	0.000196	-0.65	-0.45	Menopause (age at onset);	chr17:43179289	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.965	rs11650913	ENSG00000198496.9	NBR2	-5.6	1.3e-07	0.000196	-0.65	-0.45	Menopause (age at onset);	chr17:43179580	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs12936831	ENSG00000198496.9	NBR2	-5.6	1.3e-07	0.000196	-0.65	-0.45	Menopause (age at onset);	chr17:43179799	chr17:43125610~43153671:+
TGCT	cis	rs7804306	0.655	rs117620902	ENSG00000233264.2	AC006042.8	5.6	1.3e-07	0.000196	1.11	0.45	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8061518	chr7:7980312~7982228:+
TGCT	cis	rs7044106	0.762	rs10984974	ENSG00000226752.6	PSMD5-AS1	-5.6	1.31e-07	0.000198	-0.58	-0.45	Hip circumference adjusted for BMI;	chr9:120659278	chr9:120824828~120854385:+
TGCT	cis	rs7804306	1	rs35149843	ENSG00000233264.2	AC006042.8	5.6	1.31e-07	0.000198	1.05	0.45	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7972860	chr7:7980312~7982228:+
TGCT	cis	rs2919917	1	rs3736169	ENSG00000254352.1	RP11-578O24.2	5.6	1.31e-07	0.000198	0.5	0.45	Lymphocyte counts;	chr8:78675620	chr8:78723796~78724136:-
TGCT	cis	rs2919917	1	rs10093127	ENSG00000254352.1	RP11-578O24.2	5.6	1.31e-07	0.000198	0.5	0.45	Lymphocyte counts;	chr8:78686869	chr8:78723796~78724136:-
TGCT	cis	rs2919917	1	rs1872072	ENSG00000254352.1	RP11-578O24.2	5.6	1.31e-07	0.000198	0.5	0.45	Lymphocyte counts;	chr8:78689185	chr8:78723796~78724136:-
TGCT	cis	rs5769707	0.837	rs5770599	ENSG00000235111.1	RP1-29C18.8	-5.6	1.31e-07	0.000198	-0.37	-0.45	Monocyte percentage of white cells;Monocyte count;	chr22:49626333	chr22:49612657~49615716:-
TGCT	cis	rs2115630	0.645	rs1107179	ENSG00000225151.9	GOLGA2P7	-5.6	1.32e-07	0.000199	-0.46	-0.45	P wave terminal force;	chr15:84655131	chr15:84199311~84230136:-
TGCT	cis	rs8072100	0.846	rs4264433	ENSG00000228782.6	CTD-2026D20.3	-5.6	1.32e-07	0.000199	-0.54	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47659909	chr17:47450568~47492492:-
TGCT	cis	rs4713118	0.513	rs149962	ENSG00000216901.1	AL022393.7	5.6	1.32e-07	0.000199	0.57	0.45	Parkinson's disease;	chr6:28048140	chr6:28176188~28176674:+
TGCT	cis	rs172166	0.769	rs149965	ENSG00000216901.1	AL022393.7	5.6	1.32e-07	0.000199	0.57	0.45	Cardiac Troponin-T levels;	chr6:28050911	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.513	rs9368547	ENSG00000216901.1	AL022393.7	5.6	1.32e-07	0.000199	0.57	0.45	Parkinson's disease;	chr6:28060289	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.513	rs183244	ENSG00000216901.1	AL022393.7	5.6	1.32e-07	0.000199	0.57	0.45	Parkinson's disease;	chr6:28064060	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.513	rs149950	ENSG00000216901.1	AL022393.7	5.6	1.32e-07	0.000199	0.57	0.45	Parkinson's disease;	chr6:28065261	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.513	rs149951	ENSG00000216901.1	AL022393.7	5.6	1.32e-07	0.000199	0.57	0.45	Parkinson's disease;	chr6:28065309	chr6:28176188~28176674:+
TGCT	cis	rs2117029	0.727	rs10875910	ENSG00000258017.1	RP11-386G11.10	-5.6	1.33e-07	2e-04	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49008610	chr12:49127782~49147869:+
TGCT	cis	rs76878669	0.561	rs1784029	ENSG00000254510.1	RP11-867G23.10	5.6	1.33e-07	2e-04	0.6	0.45	Educational attainment (years of education);	chr11:66332516	chr11:66409158~66417137:+
TGCT	cis	rs380904	0.926	rs7842979	ENSG00000254859.1	RP11-661A12.5	-5.6	1.33e-07	2e-04	-0.67	-0.45	Venous thromboembolism (SNP x SNP interaction);	chr8:143519726	chr8:143541973~143549729:-
TGCT	cis	rs7301826	1	rs2001483	ENSG00000256250.1	RP11-989F5.1	-5.6	1.33e-07	2e-04	-0.48	-0.45	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810606~130812438:+
TGCT	cis	rs321358	1	rs73019218	ENSG00000271584.1	RP11-89C3.4	5.6	1.33e-07	0.000201	0.6	0.45	Body mass index;	chr11:111134521	chr11:111091932~111097357:-
TGCT	cis	rs1061377	1	rs7685468	ENSG00000249207.1	RP11-360F5.1	-5.6	1.33e-07	0.000201	-0.48	-0.45	Uric acid levels;	chr4:39116649	chr4:39112677~39126818:-
TGCT	cis	rs11155671	0.53	rs9397420	ENSG00000216906.2	RP11-350J20.9	-5.6	1.34e-07	0.000201	-0.48	-0.45	Testicular germ cell tumor;	chr6:149885645	chr6:149904243~149906418:+
TGCT	cis	rs1528149	0.504	rs6968537	ENSG00000224683.1	RPL36AP29	-5.6	1.34e-07	0.000202	-0.49	-0.45	Sitting height ratio;	chr7:16129083	chr7:16208945~16209265:+
TGCT	cis	rs321358	0.945	rs17458235	ENSG00000271584.1	RP11-89C3.4	-5.6	1.34e-07	0.000202	-0.59	-0.45	Body mass index;	chr11:111106114	chr11:111091932~111097357:-
TGCT	cis	rs7688540	0.511	rs61794965	ENSG00000275426.1	CH17-262A2.1	5.59	1.34e-07	0.000202	0.94	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:177880	chr4:149738~150317:+
TGCT	cis	rs7688540	0.511	rs11731927	ENSG00000275426.1	CH17-262A2.1	5.59	1.34e-07	0.000202	0.94	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:180316	chr4:149738~150317:+
TGCT	cis	rs440932	0.565	rs19334	ENSG00000254340.1	RP11-10A14.3	5.59	1.35e-07	0.000203	0.44	0.45	High light scatter reticulocyte percentage of red cells;	chr8:9152396	chr8:9141424~9145435:+
TGCT	cis	rs7208859	0.623	rs73269923	ENSG00000263531.1	RP13-753N3.1	5.59	1.35e-07	0.000203	0.85	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30863921~30864940:-
TGCT	cis	rs7617773	0.78	rs3197223	ENSG00000229759.1	MRPS18AP1	5.59	1.35e-07	0.000203	0.39	0.45	Coronary artery disease;	chr3:48294367	chr3:48256350~48256938:-
TGCT	cis	rs76878669	0.606	rs2282531	ENSG00000254510.1	RP11-867G23.10	-5.59	1.36e-07	0.000204	-0.6	-0.45	Educational attainment (years of education);	chr11:66332023	chr11:66409158~66417137:+
TGCT	cis	rs17301013	0.531	rs1793318	ENSG00000227373.4	RP11-160H22.5	-5.59	1.36e-07	0.000204	-0.53	-0.45	Systemic lupus erythematosus;	chr1:174824678	chr1:174115300~174160004:-
TGCT	cis	rs1799949	0.794	rs116409325	ENSG00000198496.9	NBR2	-5.59	1.37e-07	0.000205	-0.66	-0.45	Menopause (age at onset);	chr17:43368092	chr17:43125610~43153671:+
TGCT	cis	rs7044106	0.762	rs12003646	ENSG00000226752.6	PSMD5-AS1	-5.59	1.37e-07	0.000205	-0.58	-0.45	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120824828~120854385:+
TGCT	cis	rs7617773	1	rs12496784	ENSG00000229759.1	MRPS18AP1	-5.59	1.37e-07	0.000206	-0.35	-0.45	Coronary artery disease;	chr3:48144777	chr3:48256350~48256938:-
TGCT	cis	rs34217772	1	rs17181692	ENSG00000258536.1	RP11-1053O12.1	5.59	1.38e-07	0.000208	0.4	0.45	Myopia;	chr14:41791135	chr14:41742639~41742963:+
TGCT	cis	rs1387259	0.931	rs11168474	ENSG00000258273.1	RP11-370I10.4	-5.59	1.38e-07	0.000208	-0.53	-0.45	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48333755~48333901:-
TGCT	cis	rs17459044	1	rs17459044	ENSG00000268707.1	RP11-247A12.7	-5.59	1.39e-07	0.000208	-0.51	-0.45	Pelvic organ prolapse (moderate/severe);	chr9:129091345	chr9:129170434~129170940:+
TGCT	cis	rs76878669	0.561	rs10791876	ENSG00000254510.1	RP11-867G23.10	-5.59	1.39e-07	0.000209	-0.6	-0.45	Educational attainment (years of education);	chr11:66402175	chr11:66409158~66417137:+
TGCT	cis	rs2919917	1	rs13269243	ENSG00000254352.1	RP11-578O24.2	5.59	1.39e-07	0.000209	0.51	0.45	Lymphocyte counts;	chr8:78669501	chr8:78723796~78724136:-
TGCT	cis	rs2919917	1	rs7839152	ENSG00000254352.1	RP11-578O24.2	5.59	1.39e-07	0.000209	0.51	0.45	Lymphocyte counts;	chr8:78677777	chr8:78723796~78724136:-
TGCT	cis	rs2919917	1	rs28429528	ENSG00000254352.1	RP11-578O24.2	5.59	1.39e-07	0.000209	0.51	0.45	Lymphocyte counts;	chr8:78678782	chr8:78723796~78724136:-
TGCT	cis	rs2919917	1	rs9298316	ENSG00000254352.1	RP11-578O24.2	5.59	1.39e-07	0.000209	0.51	0.45	Lymphocyte counts;	chr8:78680191	chr8:78723796~78724136:-
TGCT	cis	rs2919917	1	rs7842142	ENSG00000254352.1	RP11-578O24.2	5.59	1.39e-07	0.000209	0.51	0.45	Lymphocyte counts;	chr8:78681501	chr8:78723796~78724136:-
TGCT	cis	rs2919917	1	rs11785966	ENSG00000254352.1	RP11-578O24.2	5.59	1.39e-07	0.000209	0.51	0.45	Lymphocyte counts;	chr8:78681851	chr8:78723796~78724136:-
TGCT	cis	rs2919917	1	rs10092335	ENSG00000254352.1	RP11-578O24.2	5.59	1.39e-07	0.000209	0.51	0.45	Lymphocyte counts;	chr8:78686218	chr8:78723796~78724136:-
TGCT	cis	rs2919917	0.956	rs10112388	ENSG00000254352.1	RP11-578O24.2	5.59	1.39e-07	0.000209	0.51	0.45	Lymphocyte counts;	chr8:78691512	chr8:78723796~78724136:-
TGCT	cis	rs2919917	1	rs6980663	ENSG00000254352.1	RP11-578O24.2	5.59	1.39e-07	0.000209	0.51	0.45	Lymphocyte counts;	chr8:78691589	chr8:78723796~78724136:-
TGCT	cis	rs2919917	1	rs7001074	ENSG00000254352.1	RP11-578O24.2	5.59	1.39e-07	0.000209	0.51	0.45	Lymphocyte counts;	chr8:78691689	chr8:78723796~78724136:-
TGCT	cis	rs7829975	0.633	rs2979181	ENSG00000173295.6	FAM86B3P	5.59	1.39e-07	0.000209	0.52	0.45	Mood instability;	chr8:8465578	chr8:8228595~8244865:+
TGCT	cis	rs710913	0.966	rs3738676	ENSG00000182109.6	RP11-69E11.4	5.59	1.4e-07	0.000209	0.41	0.45	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39525916	chr1:39522280~39546187:-
TGCT	cis	rs9549367	0.577	rs513479	ENSG00000269125.1	RP11-98F14.11	-5.59	1.4e-07	0.000209	-0.57	-0.45	Platelet distribution width;	chr13:113160886	chr13:113165002~113165183:-
TGCT	cis	rs172166	0.694	rs2791332	ENSG00000216901.1	AL022393.7	5.59	1.4e-07	0.00021	0.58	0.45	Cardiac Troponin-T levels;	chr6:28141010	chr6:28176188~28176674:+
TGCT	cis	rs2276314	0.857	rs59649576	ENSG00000278986.1	RP11-723J4.3	-5.59	1.4e-07	0.00021	-0.5	-0.45	Endometriosis;Drug-induced torsades de pointes;	chr18:36036112	chr18:35972151~35973916:+
TGCT	cis	rs904251	0.523	rs9369005	ENSG00000279942.1	RP1-153P14.7	-5.59	1.4e-07	0.00021	-0.46	-0.45	Cognitive performance;	chr6:37515333	chr6:37567716~37571460:+
TGCT	cis	rs17301013	0.507	rs10912822	ENSG00000227373.4	RP11-160H22.5	5.59	1.4e-07	0.00021	0.53	0.45	Systemic lupus erythematosus;	chr1:174624490	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12065527	ENSG00000227373.4	RP11-160H22.5	5.59	1.4e-07	0.00021	0.53	0.45	Systemic lupus erythematosus;	chr1:174627066	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12064403	ENSG00000227373.4	RP11-160H22.5	5.59	1.4e-07	0.00021	0.53	0.45	Systemic lupus erythematosus;	chr1:174627067	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12065825	ENSG00000227373.4	RP11-160H22.5	5.59	1.4e-07	0.00021	0.53	0.45	Systemic lupus erythematosus;	chr1:174627902	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs6667107	ENSG00000227373.4	RP11-160H22.5	5.59	1.4e-07	0.00021	0.53	0.45	Systemic lupus erythematosus;	chr1:174628667	chr1:174115300~174160004:-
TGCT	cis	rs172166	0.611	rs203883	ENSG00000216901.1	AL022393.7	5.59	1.4e-07	0.00021	0.58	0.45	Cardiac Troponin-T levels;	chr6:28110578	chr6:28176188~28176674:+
TGCT	cis	rs73086581	0.68	rs11908158	ENSG00000229539.1	RP11-119B16.2	5.59	1.41e-07	0.00021	0.64	0.45	Response to antidepressants in depression;	chr20:3956025	chr20:3888239~3888868:-
TGCT	cis	rs950169	0.84	rs72748702	ENSG00000225151.9	GOLGA2P7	-5.58	1.41e-07	0.000211	-0.52	-0.45	Schizophrenia;	chr15:84246494	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.922	rs4338765	ENSG00000225151.9	GOLGA2P7	-5.58	1.41e-07	0.000211	-0.52	-0.45	Schizophrenia;	chr15:84248084	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.922	rs62028133	ENSG00000225151.9	GOLGA2P7	-5.58	1.41e-07	0.000211	-0.52	-0.45	Schizophrenia;	chr15:84250623	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.723	rs17589320	ENSG00000225151.9	GOLGA2P7	-5.58	1.41e-07	0.000211	-0.52	-0.45	Schizophrenia;	chr15:84251244	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.845	rs4502182	ENSG00000225151.9	GOLGA2P7	-5.58	1.41e-07	0.000211	-0.52	-0.45	Schizophrenia;	chr15:84254768	chr15:84199311~84230136:-
TGCT	cis	rs17361889	0.752	rs6956986	ENSG00000224683.1	RPL36AP29	-5.58	1.41e-07	0.000211	-0.46	-0.45	Pediatric bone mineral content (hip);	chr7:16230707	chr7:16208945~16209265:+
TGCT	cis	rs2276314	0.857	rs16967327	ENSG00000278986.1	RP11-723J4.3	-5.58	1.41e-07	0.000211	-0.5	-0.45	Endometriosis;Drug-induced torsades de pointes;	chr18:36007073	chr18:35972151~35973916:+
TGCT	cis	rs2276314	0.857	rs62101393	ENSG00000278986.1	RP11-723J4.3	-5.58	1.41e-07	0.000211	-0.5	-0.45	Endometriosis;Drug-induced torsades de pointes;	chr18:36012205	chr18:35972151~35973916:+
TGCT	cis	rs2276314	0.857	rs62101394	ENSG00000278986.1	RP11-723J4.3	-5.58	1.41e-07	0.000211	-0.5	-0.45	Endometriosis;Drug-induced torsades de pointes;	chr18:36012336	chr18:35972151~35973916:+
TGCT	cis	rs2276314	0.857	rs4799409	ENSG00000278986.1	RP11-723J4.3	-5.58	1.41e-07	0.000211	-0.5	-0.45	Endometriosis;Drug-induced torsades de pointes;	chr18:36012639	chr18:35972151~35973916:+
TGCT	cis	rs2276314	0.762	rs3826600	ENSG00000278986.1	RP11-723J4.3	-5.58	1.41e-07	0.000211	-0.5	-0.45	Endometriosis;Drug-induced torsades de pointes;	chr18:36029090	chr18:35972151~35973916:+
TGCT	cis	rs2276314	0.857	rs72883058	ENSG00000278986.1	RP11-723J4.3	-5.58	1.41e-07	0.000211	-0.5	-0.45	Endometriosis;Drug-induced torsades de pointes;	chr18:36032954	chr18:35972151~35973916:+
TGCT	cis	rs7208859	0.623	rs11651857	ENSG00000263531.1	RP13-753N3.1	5.58	1.41e-07	0.000211	0.85	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs216439	ENSG00000263531.1	RP13-753N3.1	5.58	1.41e-07	0.000211	0.85	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.573	rs216442	ENSG00000263531.1	RP13-753N3.1	5.58	1.41e-07	0.000211	0.85	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs216445	ENSG00000263531.1	RP13-753N3.1	5.58	1.41e-07	0.000211	0.85	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs216446	ENSG00000263531.1	RP13-753N3.1	5.58	1.41e-07	0.000211	0.85	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs79607958	ENSG00000263531.1	RP13-753N3.1	5.58	1.41e-07	0.000211	0.85	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs75136574	ENSG00000263531.1	RP13-753N3.1	5.58	1.41e-07	0.000211	0.85	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs77544470	ENSG00000263531.1	RP13-753N3.1	5.58	1.41e-07	0.000211	0.85	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs609063	ENSG00000263531.1	RP13-753N3.1	5.58	1.41e-07	0.000211	0.85	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs383436	ENSG00000263531.1	RP13-753N3.1	5.58	1.41e-07	0.000211	0.85	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30863921~30864940:-
TGCT	cis	rs17826219	0.714	rs11650821	ENSG00000263531.1	RP13-753N3.1	5.58	1.41e-07	0.000211	0.85	0.45	Body mass index;	chr17:30641132	chr17:30863921~30864940:-
TGCT	cis	rs1528149	0.504	rs12537888	ENSG00000224683.1	RPL36AP29	-5.58	1.42e-07	0.000211	-0.49	-0.45	Sitting height ratio;	chr7:16127873	chr7:16208945~16209265:+
TGCT	cis	rs2739330	0.76	rs5751760	ENSG00000272787.1	KB-226F1.2	-5.58	1.42e-07	0.000212	-0.49	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23969211~23969873:+
TGCT	cis	rs4927850	1	rs7614767	ENSG00000242086.7	LINC00969	5.58	1.42e-07	0.000213	0.49	0.45	Pancreatic cancer;	chr3:196026580	chr3:195658062~195739964:+
TGCT	cis	rs2115630	0.691	rs2292462	ENSG00000225151.9	GOLGA2P7	5.58	1.43e-07	0.000213	0.46	0.45	P wave terminal force;	chr15:84657523	chr15:84199311~84230136:-
TGCT	cis	rs4927850	0.752	rs7618864	ENSG00000207650.1	MIR570	5.58	1.43e-07	0.000213	0.56	0.45	Pancreatic cancer;	chr3:196022690	chr3:195699401~195699497:+
TGCT	cis	rs2980439	0.607	rs2980419	ENSG00000173295.6	FAM86B3P	5.58	1.43e-07	0.000213	0.55	0.45	Neuroticism;	chr8:8256619	chr8:8228595~8244865:+
TGCT	cis	rs9322193	0.961	rs9285521	ENSG00000216906.2	RP11-350J20.9	5.58	1.44e-07	0.000215	0.5	0.45	Lung cancer;	chr6:149585576	chr6:149904243~149906418:+
TGCT	cis	rs2882667	0.66	rs11951084	ENSG00000253404.1	AC034243.1	5.58	1.45e-07	0.000216	0.49	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139125858	chr5:138744434~138753309:-
TGCT	cis	rs7208859	0.573	rs55661352	ENSG00000263531.1	RP13-753N3.1	5.58	1.45e-07	0.000217	0.84	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30863921~30864940:-
TGCT	cis	rs7829975	0.514	rs2945873	ENSG00000173295.6	FAM86B3P	5.58	1.45e-07	0.000217	0.55	0.45	Mood instability;	chr8:8402935	chr8:8228595~8244865:+
TGCT	cis	rs9322193	0.961	rs4870144	ENSG00000216906.2	RP11-350J20.9	5.58	1.45e-07	0.000217	0.51	0.45	Lung cancer;	chr6:149575540	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.884	rs7744105	ENSG00000216906.2	RP11-350J20.9	5.58	1.46e-07	0.000217	0.51	0.45	Lung cancer;	chr6:149849308	chr6:149904243~149906418:+
TGCT	cis	rs2919917	0.915	rs2953477	ENSG00000254352.1	RP11-578O24.2	5.58	1.46e-07	0.000217	0.5	0.45	Lymphocyte counts;	chr8:78712370	chr8:78723796~78724136:-
TGCT	cis	rs17264034	0.821	rs605126	ENSG00000250786.1	SNHG18	5.58	1.46e-07	0.000217	0.51	0.45	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9541754	chr5:9546200~9550609:+
TGCT	cis	rs55794721	0.509	rs12027110	ENSG00000224183.1	SDHDP6	-5.58	1.46e-07	0.000218	-0.47	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25294164~25294643:-
TGCT	cis	rs1799955	0.608	rs11571579	ENSG00000215515.2	IFIT1P1	-5.58	1.47e-07	0.000219	-0.57	-0.45	LDL cholesterol levels;	chr13:32317661	chr13:32384660~32386108:+
TGCT	cis	rs528808	1	rs528808	ENSG00000219755.1	RP1-199J3.5	5.58	1.47e-07	0.000219	0.64	0.45	Age-related hearing impairment;	chr6:99656413	chr6:99575712~99576456:+
TGCT	cis	rs7621025	0.5	rs16844241	ENSG00000239213.4	NCK1-AS1	-5.57	1.48e-07	0.00022	-0.47	-0.45	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136916329	chr3:136841726~136862054:-
TGCT	cis	rs9322193	0.923	rs10782318	ENSG00000216906.2	RP11-350J20.9	5.57	1.49e-07	0.000221	0.51	0.45	Lung cancer;	chr6:149754137	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.886	rs2065663	ENSG00000216906.2	RP11-350J20.9	5.57	1.49e-07	0.000221	0.51	0.45	Lung cancer;	chr6:149760331	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs12176034	ENSG00000216906.2	RP11-350J20.9	5.57	1.49e-07	0.000221	0.51	0.45	Lung cancer;	chr6:149800557	chr6:149904243~149906418:+
TGCT	cis	rs8062405	0.964	rs11860513	ENSG00000259982.1	CDC37P1	5.57	1.49e-07	0.000221	0.6	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28700294~28701540:-
TGCT	cis	rs943437	0.808	rs9487766	ENSG00000227012.2	RP1-97J1.2	5.57	1.49e-07	0.000221	0.61	0.45	Parkinson's disease;	chr6:111952521	chr6:111900489~111901851:-
TGCT	cis	rs943437	0.866	rs9487768	ENSG00000227012.2	RP1-97J1.2	5.57	1.49e-07	0.000221	0.61	0.45	Parkinson's disease;	chr6:111956682	chr6:111900489~111901851:-
TGCT	cis	rs2976388	0.524	rs7012804	ENSG00000253196.1	RP11-706C16.7	5.57	1.5e-07	0.000222	0.44	0.45	Urinary tract infection frequency;	chr8:142763232	chr8:142763116~142766427:+
TGCT	cis	rs2333021	0.78	rs12886469	ENSG00000259015.1	RP11-109N23.6	5.57	1.5e-07	0.000222	0.24	0.45	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72985979	chr14:72960595~72961993:+
TGCT	cis	rs17837474	0.656	rs17273	ENSG00000276597.1	TRBV11-3	5.57	1.5e-07	0.000222	0.52	0.45	Cancer;	chr7:142407435	chr7:142554836~142555318:+
TGCT	cis	rs76878669	0.561	rs1892940	ENSG00000254510.1	RP11-867G23.10	-5.57	1.5e-07	0.000223	-0.6	-0.45	Educational attainment (years of education);	chr11:66343780	chr11:66409158~66417137:+
TGCT	cis	rs7208859	0.623	rs170051	ENSG00000263531.1	RP13-753N3.1	5.57	1.5e-07	0.000223	0.85	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs216434	ENSG00000263531.1	RP13-753N3.1	5.57	1.5e-07	0.000223	0.85	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs216436	ENSG00000263531.1	RP13-753N3.1	5.57	1.5e-07	0.000223	0.85	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30863921~30864940:-
TGCT	cis	rs17301013	0.507	rs10489255	ENSG00000227373.4	RP11-160H22.5	5.57	1.5e-07	0.000223	0.51	0.45	Systemic lupus erythematosus;	chr1:174341985	chr1:174115300~174160004:-
TGCT	cis	rs8062405	1	rs80275162	ENSG00000259982.1	CDC37P1	5.57	1.51e-07	0.000224	0.61	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28700294~28701540:-
TGCT	cis	rs7829975	0.511	rs2948286	ENSG00000173295.6	FAM86B3P	5.57	1.51e-07	0.000224	0.55	0.45	Mood instability;	chr8:8272638	chr8:8228595~8244865:+
TGCT	cis	rs3931020	0.772	rs1409785	ENSG00000272864.1	RP11-17E13.2	-5.57	1.51e-07	0.000224	-0.51	-0.45	Resistin levels;	chr1:74782438	chr1:74698769~74699333:-
TGCT	cis	rs1426063	0.614	rs75345649	ENSG00000260265.1	RP11-44F21.5	5.57	1.51e-07	0.000224	0.65	0.45	QT interval;	chr4:75100963	chr4:75081702~75084717:-
TGCT	cis	rs1426063	0.614	rs77333523	ENSG00000260265.1	RP11-44F21.5	5.57	1.51e-07	0.000224	0.65	0.45	QT interval;	chr4:75101024	chr4:75081702~75084717:-
TGCT	cis	rs2919917	1	rs2046338	ENSG00000254352.1	RP11-578O24.2	5.57	1.51e-07	0.000224	0.5	0.45	Lymphocyte counts;	chr8:78723734	chr8:78723796~78724136:-
TGCT	cis	rs2882667	0.505	rs6596465	ENSG00000253404.1	AC034243.1	-5.57	1.52e-07	0.000225	-0.49	-0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139147337	chr5:138744434~138753309:-
TGCT	cis	rs2919917	1	rs13280202	ENSG00000254352.1	RP11-578O24.2	-5.57	1.52e-07	0.000225	-0.5	-0.45	Lymphocyte counts;	chr8:78700238	chr8:78723796~78724136:-
TGCT	cis	rs1799949	1	rs33946455	ENSG00000198496.9	NBR2	-5.57	1.53e-07	0.000226	-0.65	-0.45	Menopause (age at onset);	chr17:43169829	chr17:43125610~43153671:+
TGCT	cis	rs6964833	1	rs34324835	ENSG00000123965.13	PMS2P5	5.57	1.53e-07	0.000226	0.67	0.45	Menarche (age at onset);	chr7:74717986	chr7:74894116~74897835:+
TGCT	cis	rs3931020	0.705	rs28482086	ENSG00000272864.1	RP11-17E13.2	-5.57	1.53e-07	0.000227	-0.51	-0.45	Resistin levels;	chr1:74760568	chr1:74698769~74699333:-
TGCT	cis	rs7208859	0.524	rs8065744	ENSG00000263531.1	RP13-753N3.1	5.57	1.54e-07	0.000227	0.85	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30863921~30864940:-
TGCT	cis	rs17826219	0.706	rs8071236	ENSG00000263531.1	RP13-753N3.1	5.57	1.54e-07	0.000227	0.85	0.45	Body mass index;	chr17:30772984	chr17:30863921~30864940:-
TGCT	cis	rs17826219	0.636	rs2449770	ENSG00000263531.1	RP13-753N3.1	5.57	1.54e-07	0.000227	0.85	0.45	Body mass index;	chr17:30774046	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.524	rs59913838	ENSG00000263531.1	RP13-753N3.1	5.57	1.54e-07	0.000227	0.85	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs56163556	ENSG00000263531.1	RP13-753N3.1	5.57	1.54e-07	0.000227	0.85	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs8067035	ENSG00000263531.1	RP13-753N3.1	5.57	1.54e-07	0.000227	0.85	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs8067338	ENSG00000263531.1	RP13-753N3.1	5.57	1.54e-07	0.000227	0.85	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.573	rs4055105	ENSG00000263531.1	RP13-753N3.1	5.57	1.54e-07	0.000227	0.85	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30863921~30864940:-
TGCT	cis	rs9326248	0.59	rs2542063	ENSG00000254851.1	RP11-109L13.1	-5.57	1.54e-07	0.000227	-0.56	-0.45	Blood protein levels;	chr11:116814051	chr11:117135528~117138582:+
TGCT	cis	rs17301013	0.932	rs4233195	ENSG00000227373.4	RP11-160H22.5	-5.57	1.54e-07	0.000227	-0.47	-0.45	Systemic lupus erythematosus;	chr1:174806736	chr1:174115300~174160004:-
TGCT	cis	rs35160687	0.862	rs13023154	ENSG00000273080.1	RP11-301O19.1	-5.57	1.54e-07	0.000228	-0.47	-0.45	Night sleep phenotypes;	chr2:86289861	chr2:86195590~86196049:+
TGCT	cis	rs3096299	0.719	rs2911262	ENSG00000274627.1	RP11-104N10.2	5.56	1.54e-07	0.000228	0.46	0.45	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:89516797~89522217:+
TGCT	cis	rs9322193	0.543	rs9371533	ENSG00000216906.2	RP11-350J20.9	5.56	1.54e-07	0.000228	0.48	0.45	Lung cancer;	chr6:149889545	chr6:149904243~149906418:+
TGCT	cis	rs453301	0.598	rs10104303	ENSG00000173295.6	FAM86B3P	5.56	1.54e-07	0.000228	0.53	0.45	Joint mobility (Beighton score);	chr8:8977018	chr8:8228595~8244865:+
TGCT	cis	rs950169	1	rs12915234	ENSG00000225151.9	GOLGA2P7	-5.56	1.55e-07	0.000229	-0.48	-0.45	Schizophrenia;	chr15:84089549	chr15:84199311~84230136:-
TGCT	cis	rs1799949	1	rs8176242	ENSG00000198496.9	NBR2	-5.56	1.55e-07	0.000229	-0.65	-0.45	Menopause (age at onset);	chr17:43065857	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.93	rs3092987	ENSG00000198496.9	NBR2	-5.56	1.55e-07	0.000229	-0.65	-0.45	Menopause (age at onset);	chr17:43070706	chr17:43125610~43153671:+
TGCT	cis	rs7826238	0.594	rs2948285	ENSG00000173295.6	FAM86B3P	5.56	1.55e-07	0.000229	0.55	0.45	Systolic blood pressure;	chr8:8273016	chr8:8228595~8244865:+
TGCT	cis	rs950169	0.922	rs11630507	ENSG00000225151.9	GOLGA2P7	-5.56	1.55e-07	0.000229	-0.51	-0.45	Schizophrenia;	chr15:84552494	chr15:84199311~84230136:-
TGCT	cis	rs2333021	0.745	rs12323848	ENSG00000259015.1	RP11-109N23.6	5.56	1.56e-07	0.00023	0.24	0.45	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72986502	chr14:72960595~72961993:+
TGCT	cis	rs2919917	1	rs2919936	ENSG00000254352.1	RP11-578O24.2	5.56	1.56e-07	0.00023	0.5	0.45	Lymphocyte counts;	chr8:78721772	chr8:78723796~78724136:-
TGCT	cis	rs2739330	0.731	rs2000468	ENSG00000250470.1	AP000351.3	5.56	1.56e-07	0.00023	0.43	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23976904~23977585:-
TGCT	cis	rs1799949	1	rs8176083	ENSG00000198496.9	NBR2	-5.56	1.56e-07	0.00023	-0.65	-0.45	Menopause (age at onset);	chr17:43123134	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.965	rs33961729	ENSG00000198496.9	NBR2	-5.56	1.56e-07	0.00023	-0.65	-0.45	Menopause (age at onset);	chr17:43135907	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs11657835	ENSG00000198496.9	NBR2	-5.56	1.56e-07	0.00023	-0.65	-0.45	Menopause (age at onset);	chr17:43139936	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs1135214	ENSG00000198496.9	NBR2	-5.56	1.56e-07	0.00023	-0.65	-0.45	Menopause (age at onset);	chr17:43140306	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs11652332	ENSG00000198496.9	NBR2	-5.56	1.56e-07	0.00023	-0.65	-0.45	Menopause (age at onset);	chr17:43143472	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs4793212	ENSG00000198496.9	NBR2	-5.56	1.56e-07	0.00023	-0.65	-0.45	Menopause (age at onset);	chr17:43150733	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs34534709	ENSG00000198496.9	NBR2	-5.56	1.56e-07	0.00023	-0.65	-0.45	Menopause (age at onset);	chr17:43150923	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs34059614	ENSG00000198496.9	NBR2	-5.56	1.56e-07	0.00023	-0.65	-0.45	Menopause (age at onset);	chr17:43151054	chr17:43125610~43153671:+
TGCT	cis	rs1707322	0.686	rs3014251	ENSG00000280836.1	AL355480.1	5.56	1.56e-07	0.00023	0.62	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.686	rs2230658	ENSG00000280836.1	AL355480.1	5.56	1.56e-07	0.00023	0.62	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.686	rs2230659	ENSG00000280836.1	AL355480.1	5.56	1.56e-07	0.00023	0.62	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.686	rs2991987	ENSG00000280836.1	AL355480.1	5.56	1.56e-07	0.00023	0.62	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.686	rs1547924	ENSG00000280836.1	AL355480.1	-5.56	1.56e-07	0.00023	-0.62	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr1:45581219~45581321:-
TGCT	cis	rs1799949	0.965	rs11658499	ENSG00000198496.9	NBR2	-5.56	1.56e-07	0.00023	-0.65	-0.45	Menopause (age at onset);	chr17:43182732	chr17:43125610~43153671:+
TGCT	cis	rs950169	0.845	rs4106951	ENSG00000225151.9	GOLGA2P7	-5.56	1.56e-07	0.00023	-0.52	-0.45	Schizophrenia;	chr15:84164642	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.922	rs8037078	ENSG00000225151.9	GOLGA2P7	5.56	1.56e-07	0.00023	0.52	0.45	Schizophrenia;	chr15:84150119	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.922	rs4842941	ENSG00000225151.9	GOLGA2P7	5.56	1.56e-07	0.00023	0.52	0.45	Schizophrenia;	chr15:84162560	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.922	rs12911223	ENSG00000225151.9	GOLGA2P7	5.56	1.56e-07	0.00023	0.52	0.45	Schizophrenia;	chr15:84162919	chr15:84199311~84230136:-
TGCT	cis	rs3814244	0.788	rs3741647	ENSG00000255733.4	IFNG-AS1	-5.56	1.57e-07	0.000231	-0.41	-0.45	Itch intensity from mosquito bite adjusted by bite size;	chr12:68028249	chr12:67989445~68234686:+
TGCT	cis	rs200986	1	rs200986	ENSG00000216901.1	AL022393.7	5.56	1.57e-07	0.000231	0.59	0.45	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28176188~28176674:+
TGCT	cis	rs1799949	1	rs2271573	ENSG00000198496.9	NBR2	-5.56	1.57e-07	0.000231	-0.65	-0.45	Menopause (age at onset);	chr17:43175604	chr17:43125610~43153671:+
TGCT	cis	rs7208859	0.623	rs11658022	ENSG00000263531.1	RP13-753N3.1	5.56	1.57e-07	0.000231	0.84	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs3794796	ENSG00000263531.1	RP13-753N3.1	5.56	1.57e-07	0.000231	0.84	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.573	rs11654035	ENSG00000263531.1	RP13-753N3.1	5.56	1.57e-07	0.000231	0.84	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs11657662	ENSG00000263531.1	RP13-753N3.1	-5.56	1.57e-07	0.000231	-0.84	-0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30863921~30864940:-
TGCT	cis	rs2015599	0.623	rs2288128	ENSG00000257176.2	RP11-996F15.2	5.56	1.58e-07	0.000232	0.48	0.45	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29280418~29317848:-
TGCT	cis	rs2015599	0.584	rs2288129	ENSG00000257176.2	RP11-996F15.2	5.56	1.58e-07	0.000232	0.48	0.45	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29280418~29317848:-
TGCT	cis	rs2919917	1	rs1054283	ENSG00000254352.1	RP11-578O24.2	5.56	1.58e-07	0.000232	0.5	0.45	Lymphocyte counts;	chr8:78698475	chr8:78723796~78724136:-
TGCT	cis	rs2919917	1	rs7010897	ENSG00000254352.1	RP11-578O24.2	5.56	1.58e-07	0.000232	0.5	0.45	Lymphocyte counts;	chr8:78708119	chr8:78723796~78724136:-
TGCT	cis	rs2919917	1	rs11986947	ENSG00000254352.1	RP11-578O24.2	5.56	1.58e-07	0.000232	0.5	0.45	Lymphocyte counts;	chr8:78708957	chr8:78723796~78724136:-
TGCT	cis	rs2919917	1	rs2717539	ENSG00000254352.1	RP11-578O24.2	5.56	1.58e-07	0.000232	0.5	0.45	Lymphocyte counts;	chr8:78716804	chr8:78723796~78724136:-
TGCT	cis	rs2919917	0.793	rs2625664	ENSG00000254352.1	RP11-578O24.2	5.56	1.58e-07	0.000232	0.5	0.45	Lymphocyte counts;	chr8:78718373	chr8:78723796~78724136:-
TGCT	cis	rs2919917	1	rs1026920	ENSG00000254352.1	RP11-578O24.2	5.56	1.58e-07	0.000232	0.5	0.45	Lymphocyte counts;	chr8:78719775	chr8:78723796~78724136:-
TGCT	cis	rs2919917	1	rs2717538	ENSG00000254352.1	RP11-578O24.2	5.56	1.58e-07	0.000232	0.5	0.45	Lymphocyte counts;	chr8:78720914	chr8:78723796~78724136:-
TGCT	cis	rs17301013	0.507	rs12065454	ENSG00000227373.4	RP11-160H22.5	5.56	1.59e-07	0.000234	0.54	0.45	Systemic lupus erythematosus;	chr1:174492226	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs11802092	ENSG00000227373.4	RP11-160H22.5	5.56	1.59e-07	0.000234	0.53	0.45	Systemic lupus erythematosus;	chr1:174601773	chr1:174115300~174160004:-
TGCT	cis	rs7301826	1	rs10848205	ENSG00000256250.1	RP11-989F5.1	-5.56	1.59e-07	0.000234	-0.46	-0.45	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810606~130812438:+
TGCT	cis	rs8072100	0.905	rs9895274	ENSG00000228782.6	CTD-2026D20.3	5.56	1.6e-07	0.000235	0.55	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47461751	chr17:47450568~47492492:-
TGCT	cis	rs17301013	0.507	rs2281010	ENSG00000227373.4	RP11-160H22.5	5.56	1.6e-07	0.000235	0.54	0.45	Systemic lupus erythematosus;	chr1:174509917	chr1:174115300~174160004:-
TGCT	cis	rs7849270	1	rs7849160	ENSG00000268707.1	RP11-247A12.7	-5.56	1.61e-07	0.000236	-0.49	-0.45	Blood metabolite ratios;	chr9:129112273	chr9:129170434~129170940:+
TGCT	cis	rs7208859	0.51	rs216402	ENSG00000263531.1	RP13-753N3.1	5.56	1.61e-07	0.000237	0.86	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30863921~30864940:-
TGCT	cis	rs2880765	0.566	rs17553790	ENSG00000259295.5	CSPG4P12	-5.55	1.62e-07	0.000237	-0.56	-0.45	Coronary artery disease;	chr15:85470434	chr15:85191438~85213905:+
TGCT	cis	rs1061377	1	rs9997089	ENSG00000249207.1	RP11-360F5.1	-5.55	1.62e-07	0.000238	-0.46	-0.45	Uric acid levels;	chr4:39119263	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs28465556	ENSG00000249207.1	RP11-360F5.1	-5.55	1.62e-07	0.000238	-0.46	-0.45	Uric acid levels;	chr4:39119569	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs10027813	ENSG00000249207.1	RP11-360F5.1	-5.55	1.62e-07	0.000238	-0.46	-0.45	Uric acid levels;	chr4:39119818	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs9990755	ENSG00000249207.1	RP11-360F5.1	-5.55	1.62e-07	0.000238	-0.46	-0.45	Uric acid levels;	chr4:39119819	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs7675782	ENSG00000249207.1	RP11-360F5.1	-5.55	1.62e-07	0.000238	-0.46	-0.45	Uric acid levels;	chr4:39120048	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs7676008	ENSG00000249207.1	RP11-360F5.1	-5.55	1.62e-07	0.000238	-0.46	-0.45	Uric acid levels;	chr4:39120154	chr4:39112677~39126818:-
TGCT	cis	rs1061377	0.965	rs7677729	ENSG00000249207.1	RP11-360F5.1	-5.55	1.62e-07	0.000238	-0.46	-0.45	Uric acid levels;	chr4:39120370	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs7655122	ENSG00000249207.1	RP11-360F5.1	-5.55	1.62e-07	0.000238	-0.46	-0.45	Uric acid levels;	chr4:39120396	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs3796511	ENSG00000249207.1	RP11-360F5.1	-5.55	1.62e-07	0.000238	-0.46	-0.45	Uric acid levels;	chr4:39120586	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs3733274	ENSG00000249207.1	RP11-360F5.1	-5.55	1.62e-07	0.000238	-0.46	-0.45	Uric acid levels;	chr4:39120957	chr4:39112677~39126818:-
TGCT	cis	rs1061377	0.965	rs3733275	ENSG00000249207.1	RP11-360F5.1	-5.55	1.62e-07	0.000238	-0.46	-0.45	Uric acid levels;	chr4:39121077	chr4:39112677~39126818:-
TGCT	cis	rs2333021	0.78	rs28619241	ENSG00000259015.1	RP11-109N23.6	5.55	1.62e-07	0.000238	0.24	0.45	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72972902	chr14:72960595~72961993:+
TGCT	cis	rs2333021	0.78	rs12931	ENSG00000259015.1	RP11-109N23.6	5.55	1.62e-07	0.000238	0.24	0.45	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72974156	chr14:72960595~72961993:+
TGCT	cis	rs2333021	0.78	rs12887074	ENSG00000259015.1	RP11-109N23.6	5.55	1.62e-07	0.000238	0.24	0.45	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72981132	chr14:72960595~72961993:+
TGCT	cis	rs9326248	0.559	rs482371	ENSG00000254851.1	RP11-109L13.1	-5.55	1.62e-07	0.000238	-0.53	-0.45	Blood protein levels;	chr11:116881447	chr11:117135528~117138582:+
TGCT	cis	rs9326248	0.559	rs1269329	ENSG00000254851.1	RP11-109L13.1	-5.55	1.62e-07	0.000238	-0.53	-0.45	Blood protein levels;	chr11:116884325	chr11:117135528~117138582:+
TGCT	cis	rs11673344	0.838	rs55856280	ENSG00000226686.6	LINC01535	5.55	1.62e-07	0.000238	0.53	0.45	Obesity-related traits;	chr19:37150747	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.838	rs112401881	ENSG00000226686.6	LINC01535	5.55	1.62e-07	0.000238	0.53	0.45	Obesity-related traits;	chr19:37156092	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.75	rs78241494	ENSG00000226686.6	LINC01535	5.55	1.62e-07	0.000238	0.53	0.45	Obesity-related traits;	chr19:37158846	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.838	rs111827672	ENSG00000226686.6	LINC01535	5.55	1.62e-07	0.000238	0.53	0.45	Obesity-related traits;	chr19:37158964	chr19:37251912~37265535:+
TGCT	cis	rs3931020	0.745	rs10874274	ENSG00000272864.1	RP11-17E13.2	-5.55	1.62e-07	0.000238	-0.51	-0.45	Resistin levels;	chr1:74786450	chr1:74698769~74699333:-
TGCT	cis	rs2015599	0.623	rs12581107	ENSG00000257176.2	RP11-996F15.2	-5.55	1.63e-07	0.000238	-0.51	-0.45	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29280418~29317848:-
TGCT	cis	rs2919917	1	rs2953475	ENSG00000254352.1	RP11-578O24.2	-5.55	1.63e-07	0.000239	-0.5	-0.45	Lymphocyte counts;	chr8:78725903	chr8:78723796~78724136:-
TGCT	cis	rs2919917	1	rs1021156	ENSG00000254352.1	RP11-578O24.2	5.55	1.63e-07	0.000239	0.49	0.45	Lymphocyte counts;	chr8:78663569	chr8:78723796~78724136:-
TGCT	cis	rs7688540	0.511	rs61794991	ENSG00000275426.1	CH17-262A2.1	5.55	1.64e-07	0.000239	0.94	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:204418	chr4:149738~150317:+
TGCT	cis	rs3931020	0.772	rs11485555	ENSG00000272864.1	RP11-17E13.2	-5.55	1.64e-07	0.00024	-0.5	-0.45	Resistin levels;	chr1:74720825	chr1:74698769~74699333:-
TGCT	cis	rs17711722	0.522	rs62469933	ENSG00000164669.11	INTS4P1	-5.55	1.64e-07	0.00024	-0.44	-0.45	Calcium levels;	chr7:65800652	chr7:65141225~65234216:+
TGCT	cis	rs3091242	0.904	rs6661533	ENSG00000261349.1	RP3-465N24.5	-5.55	1.64e-07	0.00024	-0.44	-0.45	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25266102~25267136:-
TGCT	cis	rs55794721	0.509	rs6699113	ENSG00000261349.1	RP3-465N24.5	-5.55	1.64e-07	0.00024	-0.44	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25266102~25267136:-
TGCT	cis	rs55794721	0.509	rs7554255	ENSG00000261349.1	RP3-465N24.5	-5.55	1.64e-07	0.00024	-0.44	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25266102~25267136:-
TGCT	cis	rs55794721	0.509	rs4649085	ENSG00000261349.1	RP3-465N24.5	-5.55	1.64e-07	0.00024	-0.44	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25266102~25267136:-
TGCT	cis	rs7174755	0.637	rs113002386	ENSG00000260657.2	RP11-315D16.4	5.55	1.64e-07	0.00024	0.48	0.45	Major depressive disorder;	chr15:68172375	chr15:68267792~68277994:-
TGCT	cis	rs7849270	1	rs3124510	ENSG00000268707.1	RP11-247A12.7	5.55	1.65e-07	0.000241	0.5	0.45	Blood metabolite ratios;	chr9:129137411	chr9:129170434~129170940:+
TGCT	cis	rs1799949	1	rs12944430	ENSG00000198496.9	NBR2	-5.55	1.65e-07	0.000241	-0.65	-0.45	Menopause (age at onset);	chr17:43178803	chr17:43125610~43153671:+
TGCT	cis	rs7688540	0.511	rs77815676	ENSG00000275426.1	CH17-262A2.1	5.55	1.65e-07	0.000241	0.93	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:196080	chr4:149738~150317:+
TGCT	cis	rs7688540	0.547	rs11728864	ENSG00000275426.1	CH17-262A2.1	5.55	1.65e-07	0.000241	0.93	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:197518	chr4:149738~150317:+
TGCT	cis	rs7688540	0.511	rs76125013	ENSG00000275426.1	CH17-262A2.1	5.55	1.65e-07	0.000241	0.93	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:201493	chr4:149738~150317:+
TGCT	cis	rs11723261	0.545	rs6812799	ENSG00000275426.1	CH17-262A2.1	5.55	1.65e-07	0.000241	0.93	0.45	Immune response to smallpox vaccine (IL-6);	chr4:203545	chr4:149738~150317:+
TGCT	cis	rs7688540	0.511	rs11735723	ENSG00000275426.1	CH17-262A2.1	5.55	1.65e-07	0.000241	0.93	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:205848	chr4:149738~150317:+
TGCT	cis	rs7688540	0.511	rs6845131	ENSG00000275426.1	CH17-262A2.1	5.55	1.65e-07	0.000241	0.93	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:206358	chr4:149738~150317:+
TGCT	cis	rs7688540	0.511	rs11731623	ENSG00000275426.1	CH17-262A2.1	5.55	1.65e-07	0.000241	0.93	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:207221	chr4:149738~150317:+
TGCT	cis	rs2732480	0.577	rs2634684	ENSG00000258273.1	RP11-370I10.4	5.55	1.65e-07	0.000241	0.51	0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48333755~48333901:-
TGCT	cis	rs11155671	0.53	rs9968871	ENSG00000216906.2	RP11-350J20.9	5.55	1.65e-07	0.000241	0.48	0.45	Testicular germ cell tumor;	chr6:149888060	chr6:149904243~149906418:+
TGCT	cis	rs11155671	0.53	rs9969044	ENSG00000216906.2	RP11-350J20.9	5.55	1.65e-07	0.000241	0.48	0.45	Testicular germ cell tumor;	chr6:149888068	chr6:149904243~149906418:+
TGCT	cis	rs5758659	0.714	rs2413668	ENSG00000270083.1	RP1-257I20.14	-5.55	1.66e-07	0.000242	-0.43	-0.45	Cognitive function;	chr22:42109837	chr22:42089630~42090028:-
TGCT	cis	rs5758659	0.714	rs5751216	ENSG00000270083.1	RP1-257I20.14	-5.55	1.66e-07	0.000242	-0.43	-0.45	Cognitive function;	chr22:42112933	chr22:42089630~42090028:-
TGCT	cis	rs5758659	0.657	rs5758587	ENSG00000270083.1	RP1-257I20.14	-5.55	1.66e-07	0.000242	-0.43	-0.45	Cognitive function;	chr22:42121632	chr22:42089630~42090028:-
TGCT	cis	rs17826219	0.706	rs8075357	ENSG00000263531.1	RP13-753N3.1	5.55	1.66e-07	0.000242	0.84	0.45	Body mass index;	chr17:30730179	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs59447372	ENSG00000263531.1	RP13-753N3.1	5.55	1.66e-07	0.000242	0.84	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30863921~30864940:-
TGCT	cis	rs17826219	0.706	rs61643715	ENSG00000263531.1	RP13-753N3.1	5.55	1.66e-07	0.000242	0.84	0.45	Body mass index;	chr17:30730744	chr17:30863921~30864940:-
TGCT	cis	rs17826219	0.636	rs8080829	ENSG00000263531.1	RP13-753N3.1	5.55	1.66e-07	0.000242	0.84	0.45	Body mass index;	chr17:30731712	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs8079891	ENSG00000263531.1	RP13-753N3.1	5.55	1.66e-07	0.000242	0.84	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs73267858	ENSG00000263531.1	RP13-753N3.1	5.55	1.66e-07	0.000242	0.84	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs56018041	ENSG00000263531.1	RP13-753N3.1	5.55	1.66e-07	0.000242	0.84	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs56095789	ENSG00000263531.1	RP13-753N3.1	5.55	1.66e-07	0.000242	0.84	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs11656844	ENSG00000263531.1	RP13-753N3.1	5.55	1.66e-07	0.000242	0.84	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs11652533	ENSG00000263531.1	RP13-753N3.1	5.55	1.66e-07	0.000242	0.84	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs11652631	ENSG00000263531.1	RP13-753N3.1	5.55	1.66e-07	0.000242	0.84	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30863921~30864940:-
TGCT	cis	rs7104764	0.957	rs1045454	ENSG00000277290.1	RP11-326C3.16	5.55	1.66e-07	0.000242	0.42	0.45	Menarche (age at onset);	chr11:204228	chr11:243099~243483:-
TGCT	cis	rs7104764	0.957	rs56357554	ENSG00000277290.1	RP11-326C3.16	5.55	1.66e-07	0.000242	0.42	0.45	Menarche (age at onset);	chr11:204715	chr11:243099~243483:-
TGCT	cis	rs7104764	0.957	rs3782120	ENSG00000277290.1	RP11-326C3.16	5.55	1.66e-07	0.000242	0.42	0.45	Menarche (age at onset);	chr11:206089	chr11:243099~243483:-
TGCT	cis	rs1336900	0.641	rs6587756	ENSG00000206931.1	RNU6-1042P	-5.55	1.66e-07	0.000243	-0.36	-0.45	Blood protein levels;	chr1:150574389	chr1:150701866~150701972:+
TGCT	cis	rs1336900	0.637	rs35967040	ENSG00000206931.1	RNU6-1042P	-5.55	1.66e-07	0.000243	-0.36	-0.45	Blood protein levels;	chr1:150583112	chr1:150701866~150701972:+
TGCT	cis	rs17361889	0.752	rs62440451	ENSG00000224683.1	RPL36AP29	5.55	1.67e-07	0.000243	0.46	0.45	Pediatric bone mineral content (hip);	chr7:16259676	chr7:16208945~16209265:+
TGCT	cis	rs3091242	0.904	rs6661533	ENSG00000224183.1	SDHDP6	-5.55	1.67e-07	0.000244	-0.47	-0.45	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25294164~25294643:-
TGCT	cis	rs55794721	0.509	rs6699113	ENSG00000224183.1	SDHDP6	-5.55	1.67e-07	0.000244	-0.47	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25294164~25294643:-
TGCT	cis	rs55794721	0.509	rs7554255	ENSG00000224183.1	SDHDP6	-5.55	1.67e-07	0.000244	-0.47	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25294164~25294643:-
TGCT	cis	rs55794721	0.509	rs4649085	ENSG00000224183.1	SDHDP6	-5.55	1.67e-07	0.000244	-0.47	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25294164~25294643:-
TGCT	cis	rs10256972	0.568	rs1133043	ENSG00000226291.1	AC091729.8	-5.55	1.67e-07	0.000244	-0.48	-0.45	Endometriosis;Longevity;	chr7:1093669	chr7:1080863~1082178:+
TGCT	cis	rs2115630	0.645	rs4842978	ENSG00000225151.9	GOLGA2P7	5.55	1.68e-07	0.000244	0.46	0.45	P wave terminal force;	chr15:84654022	chr15:84199311~84230136:-
TGCT	cis	rs17301013	0.507	rs6687616	ENSG00000227373.4	RP11-160H22.5	5.55	1.68e-07	0.000244	0.55	0.45	Systemic lupus erythematosus;	chr1:174840322	chr1:174115300~174160004:-
TGCT	cis	rs8072100	0.905	rs8078686	ENSG00000228782.6	CTD-2026D20.3	-5.55	1.68e-07	0.000244	-0.53	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47658340	chr17:47450568~47492492:-
TGCT	cis	rs4835473	0.9	rs13137885	ENSG00000251600.4	RP11-673E1.1	-5.55	1.68e-07	0.000245	-0.43	-0.45	Immature fraction of reticulocytes;	chr4:143734212	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs13105550	ENSG00000251600.4	RP11-673E1.1	-5.55	1.68e-07	0.000245	-0.43	-0.45	Immature fraction of reticulocytes;	chr4:143734220	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs13105571	ENSG00000251600.4	RP11-673E1.1	-5.55	1.68e-07	0.000245	-0.43	-0.45	Immature fraction of reticulocytes;	chr4:143734241	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs36083417	ENSG00000251600.4	RP11-673E1.1	-5.55	1.68e-07	0.000245	-0.43	-0.45	Immature fraction of reticulocytes;	chr4:143734253	chr4:143912331~143982454:+
TGCT	cis	rs2919917	0.915	rs2046339	ENSG00000254352.1	RP11-578O24.2	5.55	1.68e-07	0.000245	0.5	0.45	Lymphocyte counts;	chr8:78724283	chr8:78723796~78724136:-
TGCT	cis	rs748404	0.578	rs576557	ENSG00000205771.5	CATSPER2P1	-5.55	1.68e-07	0.000245	-0.51	-0.45	Lung cancer;	chr15:43305539	chr15:43726918~43747094:-
TGCT	cis	rs2019137	0.56	rs11123172	ENSG00000189223.12	PAX8-AS1	5.55	1.68e-07	0.000245	0.59	0.45	Lymphocyte counts;	chr2:113226726	chr2:113211522~113276581:+
TGCT	cis	rs7829975	0.564	rs2921060	ENSG00000173295.6	FAM86B3P	-5.55	1.68e-07	0.000245	-0.5	-0.45	Mood instability;	chr8:8460307	chr8:8228595~8244865:+
TGCT	cis	rs4835473	0.897	rs17693768	ENSG00000251600.4	RP11-673E1.1	-5.55	1.68e-07	0.000245	-0.44	-0.45	Immature fraction of reticulocytes;	chr4:143737503	chr4:143912331~143982454:+
TGCT	cis	rs9322193	0.923	rs4870052	ENSG00000216906.2	RP11-350J20.9	5.55	1.69e-07	0.000246	0.53	0.45	Lung cancer;	chr6:149839978	chr6:149904243~149906418:+
TGCT	cis	rs950169	0.8	rs4842847	ENSG00000225151.9	GOLGA2P7	-5.55	1.69e-07	0.000246	-0.52	-0.45	Schizophrenia;	chr15:84262447	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.763	rs35372971	ENSG00000225151.9	GOLGA2P7	-5.55	1.69e-07	0.000246	-0.52	-0.45	Schizophrenia;	chr15:84387097	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.881	rs4842852	ENSG00000225151.9	GOLGA2P7	-5.55	1.69e-07	0.000246	-0.52	-0.45	Schizophrenia;	chr15:84387263	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.84	rs4842853	ENSG00000225151.9	GOLGA2P7	-5.55	1.69e-07	0.000246	-0.52	-0.45	Schizophrenia;	chr15:84387606	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.922	rs4842946	ENSG00000225151.9	GOLGA2P7	-5.55	1.69e-07	0.000246	-0.52	-0.45	Schizophrenia;	chr15:84387633	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.84	rs4842854	ENSG00000225151.9	GOLGA2P7	-5.55	1.69e-07	0.000246	-0.52	-0.45	Schizophrenia;	chr15:84387641	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.84	rs2896002	ENSG00000225151.9	GOLGA2P7	-5.55	1.69e-07	0.000246	-0.52	-0.45	Schizophrenia;	chr15:84390423	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.887	rs3860265	ENSG00000225151.9	GOLGA2P7	-5.55	1.69e-07	0.000246	-0.52	-0.45	Schizophrenia;	chr15:84390487	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.724	rs11632668	ENSG00000225151.9	GOLGA2P7	-5.55	1.69e-07	0.000246	-0.52	-0.45	Schizophrenia;	chr15:84393989	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.881	rs34591918	ENSG00000225151.9	GOLGA2P7	-5.55	1.69e-07	0.000246	-0.52	-0.45	Schizophrenia;	chr15:84396135	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.887	rs12903946	ENSG00000225151.9	GOLGA2P7	-5.55	1.69e-07	0.000246	-0.52	-0.45	Schizophrenia;	chr15:84399732	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.887	rs62029593	ENSG00000225151.9	GOLGA2P7	-5.55	1.69e-07	0.000246	-0.52	-0.45	Schizophrenia;	chr15:84400482	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.81	rs62029594	ENSG00000225151.9	GOLGA2P7	-5.55	1.69e-07	0.000246	-0.52	-0.45	Schizophrenia;	chr15:84400554	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.84	rs62029595	ENSG00000225151.9	GOLGA2P7	-5.55	1.69e-07	0.000246	-0.52	-0.45	Schizophrenia;	chr15:84400603	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.881	rs62029596	ENSG00000225151.9	GOLGA2P7	-5.55	1.69e-07	0.000246	-0.52	-0.45	Schizophrenia;	chr15:84400736	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.881	rs4081123	ENSG00000225151.9	GOLGA2P7	-5.55	1.69e-07	0.000246	-0.52	-0.45	Schizophrenia;	chr15:84401537	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.881	rs62029599	ENSG00000225151.9	GOLGA2P7	-5.55	1.69e-07	0.000246	-0.52	-0.45	Schizophrenia;	chr15:84401867	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.8	rs4099846	ENSG00000225151.9	GOLGA2P7	-5.55	1.69e-07	0.000246	-0.52	-0.45	Schizophrenia;	chr15:84402196	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.922	rs12910334	ENSG00000225151.9	GOLGA2P7	-5.55	1.69e-07	0.000246	-0.52	-0.45	Schizophrenia;	chr15:84403620	chr15:84199311~84230136:-
TGCT	cis	rs12130219	1	rs12130219	ENSG00000237975.5	FLG-AS1	5.55	1.69e-07	0.000246	0.6	0.45	Inflammatory skin disease;	chr1:152189630	chr1:152168125~152445456:+
TGCT	cis	rs12130219	1	rs1552994	ENSG00000237975.5	FLG-AS1	5.55	1.69e-07	0.000246	0.6	0.45	Inflammatory skin disease;	chr1:152198985	chr1:152168125~152445456:+
TGCT	cis	rs12130219	1	rs12733173	ENSG00000237975.5	FLG-AS1	5.55	1.69e-07	0.000246	0.6	0.45	Inflammatory skin disease;	chr1:152201496	chr1:152168125~152445456:+
TGCT	cis	rs1153858	1	rs59889118	ENSG00000259520.4	CTD-2651B20.3	-5.54	1.69e-07	0.000246	-0.38	-0.45	Homoarginine levels;	chr15:45326532	chr15:45251580~45279251:-
TGCT	cis	rs4853012	0.838	rs6707729	ENSG00000217702.2	RP11-287D1.4	5.54	1.69e-07	0.000246	0.62	0.45	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74130583~74135395:+
TGCT	cis	rs2739330	0.76	rs5751760	ENSG00000250470.1	AP000351.3	5.54	1.7e-07	0.000247	0.43	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23976904~23977585:-
TGCT	cis	rs2276314	1	rs4799835	ENSG00000278986.1	RP11-723J4.3	-5.54	1.7e-07	0.000247	-0.5	-0.45	Endometriosis;Drug-induced torsades de pointes;	chr18:35991305	chr18:35972151~35973916:+
TGCT	cis	rs8062405	1	rs62036617	ENSG00000259982.1	CDC37P1	5.54	1.7e-07	0.000248	0.6	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28700294~28701540:-
TGCT	cis	rs10875746	0.556	rs4760619	ENSG00000240399.1	RP1-228P16.1	-5.54	1.71e-07	0.000248	-0.61	-0.45	Longevity (90 years and older);	chr12:48106148	chr12:48054813~48055591:-
TGCT	cis	rs950169	1	rs12903820	ENSG00000225151.9	GOLGA2P7	-5.54	1.71e-07	0.000248	-0.48	-0.45	Schizophrenia;	chr15:84055068	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.919	rs12915589	ENSG00000225151.9	GOLGA2P7	-5.54	1.71e-07	0.000248	-0.48	-0.45	Schizophrenia;	chr15:84065712	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.959	rs66801143	ENSG00000225151.9	GOLGA2P7	-5.54	1.71e-07	0.000248	-0.48	-0.45	Schizophrenia;	chr15:84067905	chr15:84199311~84230136:-
TGCT	cis	rs950169	1	rs35648189	ENSG00000225151.9	GOLGA2P7	-5.54	1.71e-07	0.000248	-0.48	-0.45	Schizophrenia;	chr15:84071996	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.92	rs17300048	ENSG00000225151.9	GOLGA2P7	-5.54	1.71e-07	0.000248	-0.48	-0.45	Schizophrenia;	chr15:84080725	chr15:84199311~84230136:-
TGCT	cis	rs950169	1	rs1848093	ENSG00000225151.9	GOLGA2P7	-5.54	1.71e-07	0.000248	-0.48	-0.45	Schizophrenia;	chr15:84086775	chr15:84199311~84230136:-
TGCT	cis	rs1426063	0.614	rs76512224	ENSG00000260265.1	RP11-44F21.5	5.54	1.71e-07	0.000248	0.59	0.45	QT interval;	chr4:75144808	chr4:75081702~75084717:-
TGCT	cis	rs8072100	0.934	rs6504872	ENSG00000228782.6	CTD-2026D20.3	5.54	1.71e-07	0.000248	0.54	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47361586	chr17:47450568~47492492:-
TGCT	cis	rs9326248	0.53	rs7124741	ENSG00000254851.1	RP11-109L13.1	-5.54	1.71e-07	0.000249	-0.83	-0.45	Blood protein levels;	chr11:116881503	chr11:117135528~117138582:+
TGCT	cis	rs7849270	1	rs7849270	ENSG00000268707.1	RP11-247A12.7	-5.54	1.72e-07	0.000249	-0.5	-0.45	Blood metabolite ratios;	chr9:129112362	chr9:129170434~129170940:+
TGCT	cis	rs7804306	0.826	rs112270482	ENSG00000233264.2	AC006042.8	5.54	1.72e-07	0.000249	0.99	0.45	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7981281	chr7:7980312~7982228:+
TGCT	cis	rs8059260	0.604	rs9652600	ENSG00000274038.1	RP11-66H6.4	-5.54	1.72e-07	0.000249	-0.62	-0.45	Alcohol consumption over the past year;	chr16:11080157	chr16:11056556~11057034:+
TGCT	cis	rs1153858	1	rs1554521	ENSG00000259520.4	CTD-2651B20.3	5.54	1.72e-07	0.000249	0.39	0.45	Homoarginine levels;	chr15:45371991	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs4395020	ENSG00000259520.4	CTD-2651B20.3	-5.54	1.72e-07	0.000249	-0.39	-0.45	Homoarginine levels;	chr15:45360691	chr15:45251580~45279251:-
TGCT	cis	rs55794721	0.509	rs909834	ENSG00000224183.1	SDHDP6	-5.54	1.72e-07	0.00025	-0.46	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25294164~25294643:-
TGCT	cis	rs7811142	0.775	rs1636980	ENSG00000242294.5	STAG3L5P	-5.54	1.72e-07	0.00025	-0.42	-0.45	Platelet count;	chr7:100341241	chr7:100336079~100351900:+
TGCT	cis	rs17711722	0.565	rs73372653	ENSG00000236529.1	RP13-254B10.1	5.54	1.72e-07	0.00025	0.32	0.45	Calcium levels;	chr7:65977808	chr7:65840212~65840596:+
TGCT	cis	rs2919917	1	rs3808619	ENSG00000254352.1	RP11-578O24.2	5.54	1.72e-07	0.00025	0.5	0.45	Lymphocyte counts;	chr8:78665491	chr8:78723796~78724136:-
TGCT	cis	rs2732480	0.5	rs11168468	ENSG00000258273.1	RP11-370I10.4	-5.54	1.72e-07	0.00025	-0.52	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48333755~48333901:-
TGCT	cis	rs2882667	0.858	rs11750382	ENSG00000253404.1	AC034243.1	-5.54	1.73e-07	0.000251	-0.52	-0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121305	chr5:138744434~138753309:-
TGCT	cis	rs4970988	0.556	rs6681426	ENSG00000206931.1	RNU6-1042P	-5.54	1.73e-07	0.000251	-0.36	-0.45	Urate levels;	chr1:150614495	chr1:150701866~150701972:+
TGCT	cis	rs7208859	0.623	rs122898	ENSG00000263531.1	RP13-753N3.1	-5.54	1.73e-07	0.000251	-0.82	-0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30863921~30864940:-
TGCT	cis	rs11651753	0.561	rs35336840	ENSG00000264920.1	RP11-6N17.4	-5.54	1.73e-07	0.000251	-0.42	-0.45	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47888742	chr17:47891255~47895812:-
TGCT	cis	rs11651753	0.561	rs60580012	ENSG00000264920.1	RP11-6N17.4	-5.54	1.73e-07	0.000251	-0.42	-0.45	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47892442	chr17:47891255~47895812:-
TGCT	cis	rs11651753	0.561	rs61422354	ENSG00000264920.1	RP11-6N17.4	-5.54	1.73e-07	0.000251	-0.42	-0.45	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47892443	chr17:47891255~47895812:-
TGCT	cis	rs875971	0.577	rs34888281	ENSG00000236529.1	RP13-254B10.1	-5.54	1.73e-07	0.000252	-0.34	-0.45	Aortic root size;	chr7:66120784	chr7:65840212~65840596:+
TGCT	cis	rs7829975	0.688	rs13270194	ENSG00000173295.6	FAM86B3P	5.54	1.73e-07	0.000252	0.53	0.45	Mood instability;	chr8:8520592	chr8:8228595~8244865:+
TGCT	cis	rs7829975	0.533	rs1039917	ENSG00000173295.6	FAM86B3P	5.54	1.74e-07	0.000252	0.53	0.45	Mood instability;	chr8:8861340	chr8:8228595~8244865:+
TGCT	cis	rs950169	1	rs34751999	ENSG00000225151.9	GOLGA2P7	-5.54	1.74e-07	0.000252	-0.48	-0.45	Schizophrenia;	chr15:84089667	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.919	rs17300292	ENSG00000225151.9	GOLGA2P7	-5.54	1.74e-07	0.000252	-0.48	-0.45	Schizophrenia;	chr15:84093816	chr15:84199311~84230136:-
TGCT	cis	rs950169	1	rs12916348	ENSG00000225151.9	GOLGA2P7	-5.54	1.74e-07	0.000252	-0.48	-0.45	Schizophrenia;	chr15:84096775	chr15:84199311~84230136:-
TGCT	cis	rs950169	1	rs35297609	ENSG00000225151.9	GOLGA2P7	-5.54	1.74e-07	0.000252	-0.48	-0.45	Schizophrenia;	chr15:84104144	chr15:84199311~84230136:-
TGCT	cis	rs950169	1	rs62026530	ENSG00000225151.9	GOLGA2P7	-5.54	1.74e-07	0.000252	-0.48	-0.45	Schizophrenia;	chr15:84107088	chr15:84199311~84230136:-
TGCT	cis	rs950169	1	rs11638394	ENSG00000225151.9	GOLGA2P7	-5.54	1.74e-07	0.000252	-0.48	-0.45	Schizophrenia;	chr15:84110176	chr15:84199311~84230136:-
TGCT	cis	rs950169	1	rs35658069	ENSG00000225151.9	GOLGA2P7	-5.54	1.74e-07	0.000252	-0.48	-0.45	Schizophrenia;	chr15:84111394	chr15:84199311~84230136:-
TGCT	cis	rs2919917	0.915	rs3899796	ENSG00000254352.1	RP11-578O24.2	5.54	1.74e-07	0.000252	0.5	0.45	Lymphocyte counts;	chr8:78655847	chr8:78723796~78724136:-
TGCT	cis	rs3091242	0.933	rs3093584	ENSG00000261349.1	RP3-465N24.5	5.54	1.74e-07	0.000252	0.44	0.45	Erythrocyte sedimentation rate;	chr1:25342223	chr1:25266102~25267136:-
TGCT	cis	rs8040855	0.579	rs6496797	ENSG00000259295.5	CSPG4P12	-5.54	1.75e-07	0.000253	-0.59	-0.45	Bulimia nervosa;	chr15:85183624	chr15:85191438~85213905:+
TGCT	cis	rs8040855	0.599	rs6496800	ENSG00000259295.5	CSPG4P12	-5.54	1.75e-07	0.000253	-0.59	-0.45	Bulimia nervosa;	chr15:85185055	chr15:85191438~85213905:+
TGCT	cis	rs1799949	0.859	rs11657004	ENSG00000198496.9	NBR2	-5.54	1.75e-07	0.000254	-0.64	-0.45	Menopause (age at onset);	chr17:43365383	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.931	rs34474989	ENSG00000198496.9	NBR2	-5.54	1.75e-07	0.000254	-0.64	-0.45	Menopause (age at onset);	chr17:43368042	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.931	rs9912203	ENSG00000198496.9	NBR2	5.54	1.75e-07	0.000254	0.64	0.45	Menopause (age at onset);	chr17:43367777	chr17:43125610~43153671:+
TGCT	cis	rs4713118	0.513	rs149954	ENSG00000216901.1	AL022393.7	5.54	1.76e-07	0.000255	0.56	0.45	Parkinson's disease;	chr6:28067468	chr6:28176188~28176674:+
TGCT	cis	rs1799949	0.965	rs9646413	ENSG00000198496.9	NBR2	-5.54	1.76e-07	0.000255	-0.61	-0.45	Menopause (age at onset);	chr17:43348789	chr17:43125610~43153671:+
TGCT	cis	rs3091242	0.933	rs28633797	ENSG00000261349.1	RP3-465N24.5	-5.53	1.77e-07	0.000256	-0.44	-0.45	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25266102~25267136:-
TGCT	cis	rs55794721	0.509	rs2982358	ENSG00000261349.1	RP3-465N24.5	-5.53	1.77e-07	0.000256	-0.44	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25266102~25267136:-
TGCT	cis	rs2919917	0.666	rs10957898	ENSG00000254352.1	RP11-578O24.2	-5.53	1.78e-07	0.000257	-0.53	-0.45	Lymphocyte counts;	chr8:78705078	chr8:78723796~78724136:-
TGCT	cis	rs524281	1	rs524281	ENSG00000255320.1	RP11-755F10.1	-5.53	1.78e-07	0.000257	-0.54	-0.45	Electroencephalogram traits;	chr11:66119191	chr11:66244840~66246239:-
TGCT	cis	rs2483374	1	rs7331734	ENSG00000253771.4	TPTE2P1	5.53	1.78e-07	0.000257	0.43	0.45	Obesity-related traits;	chr13:24957117	chr13:24924677~24968487:-
TGCT	cis	rs1707322	0.686	rs3014242	ENSG00000280836.1	AL355480.1	5.53	1.79e-07	0.000258	0.62	0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.686	rs3014239	ENSG00000280836.1	AL355480.1	5.53	1.79e-07	0.000258	0.62	0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.686	rs3014236	ENSG00000280836.1	AL355480.1	5.53	1.79e-07	0.000258	0.62	0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45581219~45581321:-
TGCT	cis	rs7208859	0.524	rs77498725	ENSG00000263531.1	RP13-753N3.1	5.53	1.79e-07	0.000258	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.573	rs73267865	ENSG00000263531.1	RP13-753N3.1	5.53	1.79e-07	0.000258	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30863921~30864940:-
TGCT	cis	rs17826219	0.706	rs57698184	ENSG00000263531.1	RP13-753N3.1	5.53	1.79e-07	0.000258	0.84	0.44	Body mass index;	chr17:30737900	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.524	rs59923796	ENSG00000263531.1	RP13-753N3.1	5.53	1.79e-07	0.000258	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30863921~30864940:-
TGCT	cis	rs17826219	0.5	rs57005940	ENSG00000263531.1	RP13-753N3.1	5.53	1.79e-07	0.000258	0.84	0.44	Body mass index;	chr17:30739311	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.573	rs73267872	ENSG00000263531.1	RP13-753N3.1	5.53	1.79e-07	0.000258	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30863921~30864940:-
TGCT	cis	rs17826219	0.706	rs9893922	ENSG00000263531.1	RP13-753N3.1	5.53	1.79e-07	0.000258	0.84	0.44	Body mass index;	chr17:30741407	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs56812022	ENSG00000263531.1	RP13-753N3.1	5.53	1.79e-07	0.000258	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.524	rs57670615	ENSG00000263531.1	RP13-753N3.1	5.53	1.79e-07	0.000258	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30863921~30864940:-
TGCT	cis	rs1150668	0.768	rs1150709	ENSG00000216901.1	AL022393.7	-5.53	1.79e-07	0.000258	-0.57	-0.44	Pubertal anthropometrics;	chr6:28239585	chr6:28176188~28176674:+
TGCT	cis	rs76878669	0.606	rs1785639	ENSG00000254510.1	RP11-867G23.10	5.53	1.79e-07	0.000258	0.59	0.44	Educational attainment (years of education);	chr11:66332959	chr11:66409158~66417137:+
TGCT	cis	rs2117029	0.767	rs10875912	ENSG00000258017.1	RP11-386G11.10	-5.53	1.79e-07	0.000258	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49023161	chr12:49127782~49147869:+
TGCT	cis	rs5758659	0.714	rs2284087	ENSG00000270083.1	RP1-257I20.14	-5.53	1.79e-07	0.000258	-0.43	-0.44	Cognitive function;	chr22:42089667	chr22:42089630~42090028:-
TGCT	cis	rs5758659	0.714	rs5758578	ENSG00000270083.1	RP1-257I20.14	-5.53	1.79e-07	0.000258	-0.43	-0.44	Cognitive function;	chr22:42094288	chr22:42089630~42090028:-
TGCT	cis	rs5758659	0.714	rs5758589	ENSG00000270083.1	RP1-257I20.14	-5.53	1.79e-07	0.000258	-0.43	-0.44	Cognitive function;	chr22:42122378	chr22:42089630~42090028:-
TGCT	cis	rs34217772	0.941	rs12893555	ENSG00000258536.1	RP11-1053O12.1	5.53	1.79e-07	0.000258	0.39	0.44	Myopia;	chr14:41801166	chr14:41742639~41742963:+
TGCT	cis	rs34217772	1	rs17781427	ENSG00000258536.1	RP11-1053O12.1	5.53	1.79e-07	0.000258	0.39	0.44	Myopia;	chr14:41802022	chr14:41742639~41742963:+
TGCT	cis	rs34217772	1	rs12884531	ENSG00000258536.1	RP11-1053O12.1	5.53	1.79e-07	0.000258	0.39	0.44	Myopia;	chr14:41803413	chr14:41742639~41742963:+
TGCT	cis	rs34217772	1	rs34217772	ENSG00000258536.1	RP11-1053O12.1	5.53	1.79e-07	0.000258	0.39	0.44	Myopia;	chr14:41804367	chr14:41742639~41742963:+
TGCT	cis	rs1387259	0.929	rs11168460	ENSG00000258273.1	RP11-370I10.4	-5.53	1.8e-07	0.000259	-0.52	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48333755~48333901:-
TGCT	cis	rs2732480	0.5	rs7297824	ENSG00000258273.1	RP11-370I10.4	-5.53	1.8e-07	0.000259	-0.52	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48333755~48333901:-
TGCT	cis	rs2732480	0.5	rs7315820	ENSG00000258273.1	RP11-370I10.4	-5.53	1.8e-07	0.000259	-0.52	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48333755~48333901:-
TGCT	cis	rs2732480	0.5	rs11168464	ENSG00000258273.1	RP11-370I10.4	-5.53	1.8e-07	0.000259	-0.52	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48333755~48333901:-
TGCT	cis	rs1387259	0.899	rs7307566	ENSG00000258273.1	RP11-370I10.4	-5.53	1.8e-07	0.000259	-0.52	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48333755~48333901:-
TGCT	cis	rs2732480	0.5	rs1387257	ENSG00000258273.1	RP11-370I10.4	-5.53	1.8e-07	0.000259	-0.52	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48333755~48333901:-
TGCT	cis	rs2732480	0.5	rs12828309	ENSG00000258273.1	RP11-370I10.4	-5.53	1.8e-07	0.000259	-0.52	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48333755~48333901:-
TGCT	cis	rs2732480	0.5	rs1552550	ENSG00000258273.1	RP11-370I10.4	-5.53	1.8e-07	0.000259	-0.52	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48333755~48333901:-
TGCT	cis	rs2732480	0.5	rs2450991	ENSG00000258273.1	RP11-370I10.4	-5.53	1.8e-07	0.000259	-0.52	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48333755~48333901:-
TGCT	cis	rs2732480	0.5	rs2450989	ENSG00000258273.1	RP11-370I10.4	5.53	1.8e-07	0.000259	0.52	0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48333755~48333901:-
TGCT	cis	rs904251	0.861	rs1757171	ENSG00000279942.1	RP1-153P14.7	-5.53	1.81e-07	0.00026	-0.5	-0.44	Cognitive performance;	chr6:37519268	chr6:37567716~37571460:+
TGCT	cis	rs1707322	0.656	rs3014210	ENSG00000280836.1	AL355480.1	5.53	1.81e-07	0.00026	0.62	0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45581219~45581321:-
TGCT	cis	rs904251	0.861	rs1757183	ENSG00000279942.1	RP1-153P14.7	5.53	1.82e-07	0.000261	0.48	0.44	Cognitive performance;	chr6:37517014	chr6:37567716~37571460:+
TGCT	cis	rs2919917	1	rs1441438	ENSG00000254352.1	RP11-578O24.2	-5.53	1.82e-07	0.000262	-0.5	-0.44	Lymphocyte counts;	chr8:78729534	chr8:78723796~78724136:-
TGCT	cis	rs2919917	1	rs894221	ENSG00000254352.1	RP11-578O24.2	-5.53	1.82e-07	0.000262	-0.5	-0.44	Lymphocyte counts;	chr8:78736822	chr8:78723796~78724136:-
TGCT	cis	rs3096299	0.781	rs2965819	ENSG00000274627.1	RP11-104N10.2	-5.53	1.82e-07	0.000262	-0.45	-0.44	Multiple myeloma (IgH translocation);	chr16:89434622	chr16:89516797~89522217:+
TGCT	cis	rs7829975	0.593	rs2921051	ENSG00000173295.6	FAM86B3P	5.53	1.83e-07	0.000263	0.52	0.44	Mood instability;	chr8:8462594	chr8:8228595~8244865:+
TGCT	cis	rs5769707	0.706	rs763128	ENSG00000235111.1	RP1-29C18.8	-5.53	1.85e-07	0.000266	-0.41	-0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49624397	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.568	rs2011097	ENSG00000235111.1	RP1-29C18.8	-5.53	1.85e-07	0.000266	-0.41	-0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49624421	chr22:49612657~49615716:-
TGCT	cis	rs1799949	1	rs4793194	ENSG00000198496.9	NBR2	-5.52	1.85e-07	0.000266	-0.65	-0.44	Menopause (age at onset);	chr17:43066316	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs8176234	ENSG00000198496.9	NBR2	-5.52	1.85e-07	0.000266	-0.65	-0.44	Menopause (age at onset);	chr17:43067763	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs8176233	ENSG00000198496.9	NBR2	-5.52	1.85e-07	0.000266	-0.65	-0.44	Menopause (age at onset);	chr17:43067787	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs8176220	ENSG00000198496.9	NBR2	-5.52	1.85e-07	0.000266	-0.65	-0.44	Menopause (age at onset);	chr17:43070445	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs1799966	ENSG00000198496.9	NBR2	-5.52	1.85e-07	0.000266	-0.65	-0.44	Menopause (age at onset);	chr17:43071077	chr17:43125610~43153671:+
TGCT	cis	rs7849270	0.959	rs3124509	ENSG00000268707.1	RP11-247A12.7	5.52	1.86e-07	0.000266	0.5	0.44	Blood metabolite ratios;	chr9:129134720	chr9:129170434~129170940:+
TGCT	cis	rs7849270	1	rs3118632	ENSG00000268707.1	RP11-247A12.7	5.52	1.86e-07	0.000266	0.5	0.44	Blood metabolite ratios;	chr9:129139005	chr9:129170434~129170940:+
TGCT	cis	rs7684253	1	rs7684253	ENSG00000269949.1	RP11-738E22.3	5.52	1.86e-07	0.000267	0.41	0.44	Migraine;	chr4:56861145	chr4:56960927~56961373:-
TGCT	cis	rs6061231	0.631	rs2427317	ENSG00000273619.1	RP5-908M14.9	-5.52	1.86e-07	0.000267	-0.48	-0.44	Colorectal cancer;	chr20:62400669	chr20:62386303~62386970:-
TGCT	cis	rs6061231	0.631	rs2427318	ENSG00000273619.1	RP5-908M14.9	-5.52	1.86e-07	0.000267	-0.48	-0.44	Colorectal cancer;	chr20:62400671	chr20:62386303~62386970:-
TGCT	cis	rs904251	1	rs12212090	ENSG00000279942.1	RP1-153P14.7	-5.52	1.86e-07	0.000267	-0.51	-0.44	Cognitive performance;	chr6:37464032	chr6:37567716~37571460:+
TGCT	cis	rs904251	0.965	rs62406516	ENSG00000279942.1	RP1-153P14.7	-5.52	1.86e-07	0.000267	-0.51	-0.44	Cognitive performance;	chr6:37471588	chr6:37567716~37571460:+
TGCT	cis	rs904251	1	rs10947673	ENSG00000279942.1	RP1-153P14.7	-5.52	1.86e-07	0.000267	-0.51	-0.44	Cognitive performance;	chr6:37477303	chr6:37567716~37571460:+
TGCT	cis	rs904251	1	rs904251	ENSG00000279942.1	RP1-153P14.7	-5.52	1.86e-07	0.000267	-0.51	-0.44	Cognitive performance;	chr6:37483920	chr6:37567716~37571460:+
TGCT	cis	rs801193	0.66	rs1962050	ENSG00000222364.1	RNU6-96P	5.52	1.86e-07	0.000267	0.5	0.44	Aortic root size;	chr7:66775021	chr7:66395191~66395286:+
TGCT	cis	rs10083777	0.551	rs111889995	ENSG00000261061.1	RP11-303E16.2	-5.52	1.87e-07	0.000268	-0.89	-0.44	Metabolite levels (small molecules and protein measures);	chr16:81000166	chr16:81030770~81031485:+
TGCT	cis	rs3091242	0.804	rs631133	ENSG00000224183.1	SDHDP6	-5.52	1.87e-07	0.000268	-0.48	-0.44	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25294164~25294643:-
TGCT	cis	rs7804306	1	rs7804306	ENSG00000233264.2	AC006042.8	5.52	1.87e-07	0.000268	0.89	0.44	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7978549	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.826	rs67343471	ENSG00000233264.2	AC006042.8	5.52	1.87e-07	0.000268	0.89	0.44	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7979532	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.826	rs56073406	ENSG00000233264.2	AC006042.8	5.52	1.87e-07	0.000268	0.89	0.44	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7981025	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.826	rs6975218	ENSG00000233264.2	AC006042.8	5.52	1.87e-07	0.000268	0.89	0.44	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7981982	chr7:7980312~7982228:+
TGCT	cis	rs7829975	0.514	rs2979139	ENSG00000173295.6	FAM86B3P	5.52	1.87e-07	0.000268	0.55	0.44	Mood instability;	chr8:8410803	chr8:8228595~8244865:+
TGCT	cis	rs4774565	0.724	rs606118	ENSG00000244879.4	GABPB1-AS1	-5.52	1.87e-07	0.000268	-0.37	-0.44	Breast cancer;	chr15:50362974	chr15:50354959~50372202:+
TGCT	cis	rs950169	0.887	rs35986397	ENSG00000225151.9	GOLGA2P7	-5.52	1.88e-07	0.000269	-0.52	-0.44	Schizophrenia;	chr15:84400409	chr15:84199311~84230136:-
TGCT	cis	rs1153858	1	rs4774577	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45352487	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs11070453	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45352956	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs4774578	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45353853	chr15:45251580~45279251:-
TGCT	cis	rs61524473	1	rs61524473	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Metabolite levels (small molecules and protein measures);	chr15:45354085	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs12593230	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45354770	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs10444821	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45355038	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs72623915	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45355235	chr15:45251580~45279251:-
TGCT	cis	rs1153858	0.725	rs74572151	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45355328	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs66714503	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45355840	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs67831559	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45357109	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs2066090	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45357820	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs61365925	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45358113	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs16952714	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45358160	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs12101539	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45358468	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs8032904	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45359111	chr15:45251580~45279251:-
TGCT	cis	rs1153858	0.943	rs8038342	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45359339	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs4774579	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45359605	chr15:45251580~45279251:-
TGCT	cis	rs1153858	0.943	rs4774580	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45359888	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs4271549	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45360532	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs4627277	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45360570	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs4625670	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45360728	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs4534782	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45360735	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs1049503	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45361509	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs12595087	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45363034	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs3759899	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45363705	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs1890565	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45371101	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs12594857	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45374980	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs7164602	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45379127	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs12441971	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45379759	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs1346268	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45380831	chr15:45251580~45279251:-
TGCT	cis	rs1153858	0.943	rs67045941	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45384813	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs67744121	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45385039	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs16942568	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45385192	chr15:45251580~45279251:-
TGCT	cis	rs1153858	0.943	rs11070454	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45388054	chr15:45251580~45279251:-
TGCT	cis	rs1153858	0.943	rs12439575	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45392618	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs9788780	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45393289	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs7181167	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45394038	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs11070456	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45394637	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs11070457	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45394745	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs3809472	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45402120	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs1820518	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45402381	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs1365610	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.88e-07	0.000269	-0.39	-0.44	Homoarginine levels;	chr15:45402412	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs4775911	ENSG00000259520.4	CTD-2651B20.3	5.52	1.88e-07	0.000269	0.39	0.44	Homoarginine levels;	chr15:45357589	chr15:45251580~45279251:-
TGCT	cis	rs17301013	0.507	rs12084948	ENSG00000227373.4	RP11-160H22.5	5.52	1.88e-07	0.000269	0.53	0.44	Systemic lupus erythematosus;	chr1:174525776	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs11809482	ENSG00000227373.4	RP11-160H22.5	5.52	1.88e-07	0.000269	0.53	0.44	Systemic lupus erythematosus;	chr1:174530269	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs909533	ENSG00000227373.4	RP11-160H22.5	5.52	1.88e-07	0.000269	0.53	0.44	Systemic lupus erythematosus;	chr1:174531428	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12093966	ENSG00000227373.4	RP11-160H22.5	5.52	1.88e-07	0.000269	0.53	0.44	Systemic lupus erythematosus;	chr1:174535120	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs7550472	ENSG00000227373.4	RP11-160H22.5	5.52	1.88e-07	0.000269	0.53	0.44	Systemic lupus erythematosus;	chr1:174536442	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs11484645	ENSG00000227373.4	RP11-160H22.5	5.52	1.88e-07	0.000269	0.53	0.44	Systemic lupus erythematosus;	chr1:174542993	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12063545	ENSG00000227373.4	RP11-160H22.5	5.52	1.88e-07	0.000269	0.53	0.44	Systemic lupus erythematosus;	chr1:174552863	chr1:174115300~174160004:-
TGCT	cis	rs11098499	0.874	rs13123591	ENSG00000245958.5	RP11-33B1.1	-5.52	1.89e-07	0.00027	-0.46	-0.44	Corneal astigmatism;	chr4:119184835	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.874	rs7661020	ENSG00000245958.5	RP11-33B1.1	-5.52	1.89e-07	0.00027	-0.46	-0.44	Corneal astigmatism;	chr4:119185827	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.874	rs17839089	ENSG00000245958.5	RP11-33B1.1	-5.52	1.89e-07	0.00027	-0.46	-0.44	Corneal astigmatism;	chr4:119189914	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.874	rs6826823	ENSG00000245958.5	RP11-33B1.1	-5.52	1.89e-07	0.00027	-0.46	-0.44	Corneal astigmatism;	chr4:119190943	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.874	rs12509054	ENSG00000245958.5	RP11-33B1.1	-5.52	1.89e-07	0.00027	-0.46	-0.44	Corneal astigmatism;	chr4:119193920	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.874	rs10022508	ENSG00000245958.5	RP11-33B1.1	-5.52	1.89e-07	0.00027	-0.46	-0.44	Corneal astigmatism;	chr4:119194073	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.874	rs12502503	ENSG00000245958.5	RP11-33B1.1	-5.52	1.89e-07	0.00027	-0.46	-0.44	Corneal astigmatism;	chr4:119195100	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.874	rs6851169	ENSG00000245958.5	RP11-33B1.1	-5.52	1.89e-07	0.00027	-0.46	-0.44	Corneal astigmatism;	chr4:119196355	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.874	rs6832670	ENSG00000245958.5	RP11-33B1.1	-5.52	1.89e-07	0.00027	-0.46	-0.44	Corneal astigmatism;	chr4:119197637	chr4:119454791~119552025:+
TGCT	cis	rs11098499	0.874	rs6822498	ENSG00000245958.5	RP11-33B1.1	-5.52	1.89e-07	0.00027	-0.46	-0.44	Corneal astigmatism;	chr4:119199028	chr4:119454791~119552025:+
TGCT	cis	rs321358	1	rs321353	ENSG00000271584.1	RP11-89C3.4	-5.52	1.89e-07	0.00027	-0.54	-0.44	Body mass index;	chr11:111123841	chr11:111091932~111097357:-
TGCT	cis	rs2005	0.582	rs9394287	ENSG00000186328.4	RP11-140K17.2	5.52	1.89e-07	0.00027	0.68	0.44	Obesity-related traits;	chr6:35248963	chr6:34715613~34715940:+
TGCT	cis	rs2276314	1	rs1540042	ENSG00000278986.1	RP11-723J4.3	-5.52	1.89e-07	0.00027	-0.48	-0.44	Endometriosis;Drug-induced torsades de pointes;	chr18:35975273	chr18:35972151~35973916:+
TGCT	cis	rs12130219	1	rs34428306	ENSG00000237975.5	FLG-AS1	5.52	1.89e-07	0.00027	0.59	0.44	Inflammatory skin disease;	chr1:152211840	chr1:152168125~152445456:+
TGCT	cis	rs2276314	0.857	rs62101379	ENSG00000278986.1	RP11-723J4.3	-5.52	1.89e-07	0.00027	-0.51	-0.44	Endometriosis;Drug-induced torsades de pointes;	chr18:36004939	chr18:35972151~35973916:+
TGCT	cis	rs2276314	0.802	rs9963714	ENSG00000278986.1	RP11-723J4.3	-5.52	1.89e-07	0.00027	-0.51	-0.44	Endometriosis;Drug-induced torsades de pointes;	chr18:36012093	chr18:35972151~35973916:+
TGCT	cis	rs2276314	0.802	rs4799838	ENSG00000278986.1	RP11-723J4.3	-5.52	1.89e-07	0.00027	-0.51	-0.44	Endometriosis;Drug-induced torsades de pointes;	chr18:36017567	chr18:35972151~35973916:+
TGCT	cis	rs2276314	0.748	rs4799839	ENSG00000278986.1	RP11-723J4.3	-5.52	1.89e-07	0.00027	-0.51	-0.44	Endometriosis;Drug-induced torsades de pointes;	chr18:36017568	chr18:35972151~35973916:+
TGCT	cis	rs2276314	0.857	rs28375959	ENSG00000278986.1	RP11-723J4.3	-5.52	1.89e-07	0.00027	-0.51	-0.44	Endometriosis;Drug-induced torsades de pointes;	chr18:36021571	chr18:35972151~35973916:+
TGCT	cis	rs2276314	0.857	rs28379448	ENSG00000278986.1	RP11-723J4.3	-5.52	1.89e-07	0.00027	-0.51	-0.44	Endometriosis;Drug-induced torsades de pointes;	chr18:36024401	chr18:35972151~35973916:+
TGCT	cis	rs2276314	0.857	rs3737474	ENSG00000278986.1	RP11-723J4.3	-5.52	1.89e-07	0.00027	-0.51	-0.44	Endometriosis;Drug-induced torsades de pointes;	chr18:36033632	chr18:35972151~35973916:+
TGCT	cis	rs8113308	0.81	rs11881650	ENSG00000269235.1	ZNF350-AS1	-5.52	1.9e-07	0.00027	-0.73	-0.44	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946886	chr19:51949134~51981367:+
TGCT	cis	rs8113308	0.81	rs11880193	ENSG00000269235.1	ZNF350-AS1	5.52	1.9e-07	0.00027	0.73	0.44	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51945416	chr19:51949134~51981367:+
TGCT	cis	rs8113308	0.81	rs16983256	ENSG00000269235.1	ZNF350-AS1	5.52	1.9e-07	0.00027	0.73	0.44	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946228	chr19:51949134~51981367:+
TGCT	cis	rs8113308	0.81	rs8100521	ENSG00000269235.1	ZNF350-AS1	5.52	1.9e-07	0.00027	0.73	0.44	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946390	chr19:51949134~51981367:+
TGCT	cis	rs8113308	0.81	rs8100541	ENSG00000269235.1	ZNF350-AS1	5.52	1.9e-07	0.00027	0.73	0.44	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946442	chr19:51949134~51981367:+
TGCT	cis	rs8113308	0.81	rs11879040	ENSG00000269235.1	ZNF350-AS1	5.52	1.9e-07	0.00027	0.73	0.44	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946856	chr19:51949134~51981367:+
TGCT	cis	rs8113308	0.81	rs55810059	ENSG00000269235.1	ZNF350-AS1	5.52	1.9e-07	0.00027	0.73	0.44	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51947475	chr19:51949134~51981367:+
TGCT	cis	rs8113308	0.81	rs7255377	ENSG00000269235.1	ZNF350-AS1	5.52	1.9e-07	0.00027	0.73	0.44	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51948085	chr19:51949134~51981367:+
TGCT	cis	rs8113308	0.81	rs7254930	ENSG00000269235.1	ZNF350-AS1	5.52	1.9e-07	0.00027	0.73	0.44	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51948274	chr19:51949134~51981367:+
TGCT	cis	rs7849270	1	rs3124513	ENSG00000268707.1	RP11-247A12.7	5.52	1.9e-07	0.000271	0.5	0.44	Blood metabolite ratios;	chr9:129142314	chr9:129170434~129170940:+
TGCT	cis	rs7849270	1	rs3124514	ENSG00000268707.1	RP11-247A12.7	5.52	1.9e-07	0.000271	0.5	0.44	Blood metabolite ratios;	chr9:129142329	chr9:129170434~129170940:+
TGCT	cis	rs2732480	0.5	rs12829841	ENSG00000258273.1	RP11-370I10.4	-5.52	1.91e-07	0.000271	-0.53	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48333755~48333901:-
TGCT	cis	rs2732480	0.523	rs34286639	ENSG00000258273.1	RP11-370I10.4	-5.52	1.91e-07	0.000271	-0.53	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48333755~48333901:-
TGCT	cis	rs1387259	0.929	rs11168484	ENSG00000258273.1	RP11-370I10.4	-5.52	1.91e-07	0.000271	-0.53	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48333755~48333901:-
TGCT	cis	rs1387259	0.79	rs2732445	ENSG00000258273.1	RP11-370I10.4	-5.52	1.91e-07	0.000271	-0.53	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48333755~48333901:-
TGCT	cis	rs7617773	0.963	rs6800730	ENSG00000229759.1	MRPS18AP1	5.52	1.91e-07	0.000272	0.35	0.44	Coronary artery disease;	chr3:48132720	chr3:48256350~48256938:-
TGCT	cis	rs950169	0.959	rs12911210	ENSG00000225151.9	GOLGA2P7	-5.52	1.92e-07	0.000273	-0.49	-0.44	Schizophrenia;	chr15:84123331	chr15:84199311~84230136:-
TGCT	cis	rs35160687	0.829	rs13017143	ENSG00000273080.1	RP11-301O19.1	-5.52	1.92e-07	0.000273	-0.52	-0.44	Night sleep phenotypes;	chr2:86239426	chr2:86195590~86196049:+
TGCT	cis	rs5758659	0.714	rs6002626	ENSG00000270083.1	RP1-257I20.14	-5.52	1.92e-07	0.000273	-0.43	-0.44	Cognitive function;	chr22:42121985	chr22:42089630~42090028:-
TGCT	cis	rs7301826	1	rs10744482	ENSG00000256250.1	RP11-989F5.1	-5.52	1.93e-07	0.000275	-0.47	-0.44	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810606~130812438:+
TGCT	cis	rs7301826	0.966	rs4759795	ENSG00000256250.1	RP11-989F5.1	-5.52	1.93e-07	0.000275	-0.47	-0.44	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810606~130812438:+
TGCT	cis	rs11098499	0.874	rs9995277	ENSG00000245958.5	RP11-33B1.1	-5.52	1.93e-07	0.000275	-0.46	-0.44	Corneal astigmatism;	chr4:119187448	chr4:119454791~119552025:+
TGCT	cis	rs950169	0.922	rs4842940	ENSG00000225151.9	GOLGA2P7	5.52	1.94e-07	0.000275	0.51	0.44	Schizophrenia;	chr15:84162473	chr15:84199311~84230136:-
TGCT	cis	rs1010254	0.51	rs1363418	ENSG00000213433.5	RPLP1P6	5.52	1.94e-07	0.000275	0.59	0.44	Optic nerve measurement (cup area);	chr5:152320273	chr5:151765859~151766378:-
TGCT	cis	rs17361889	0.778	rs2214626	ENSG00000224683.1	RPL36AP29	5.52	1.94e-07	0.000275	0.46	0.44	Pediatric bone mineral content (hip);	chr7:16276027	chr7:16208945~16209265:+
TGCT	cis	rs2919917	1	rs1384804	ENSG00000254352.1	RP11-578O24.2	5.52	1.94e-07	0.000275	0.49	0.44	Lymphocyte counts;	chr8:78659987	chr8:78723796~78724136:-
TGCT	cis	rs2919917	1	rs10093654	ENSG00000254352.1	RP11-578O24.2	5.52	1.94e-07	0.000275	0.49	0.44	Lymphocyte counts;	chr8:78660360	chr8:78723796~78724136:-
TGCT	cis	rs2919917	1	rs10093797	ENSG00000254352.1	RP11-578O24.2	5.52	1.94e-07	0.000275	0.49	0.44	Lymphocyte counts;	chr8:78660478	chr8:78723796~78724136:-
TGCT	cis	rs3931020	0.745	rs1969111	ENSG00000272864.1	RP11-17E13.2	5.51	1.94e-07	0.000276	0.51	0.44	Resistin levels;	chr1:74797801	chr1:74698769~74699333:-
TGCT	cis	rs1775715	0.966	rs1755067	ENSG00000239731.3	RN7SL825P	5.51	1.94e-07	0.000276	0.47	0.44	Bipolar disorder with mood-incongruent psychosis;	chr10:32007267	chr10:31992087~31992381:-
TGCT	cis	rs7208859	0.725	rs9891656	ENSG00000263531.1	RP13-753N3.1	5.51	1.94e-07	0.000276	0.71	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916337	chr17:30863921~30864940:-
TGCT	cis	rs3931020	0.72	rs1327090	ENSG00000272864.1	RP11-17E13.2	-5.51	1.94e-07	0.000276	-0.51	-0.44	Resistin levels;	chr1:74800795	chr1:74698769~74699333:-
TGCT	cis	rs11723261	0.509	rs61792240	ENSG00000275426.1	CH17-262A2.1	5.51	1.94e-07	0.000276	0.91	0.44	Immune response to smallpox vaccine (IL-6);	chr4:134876	chr4:149738~150317:+
TGCT	cis	rs801193	1	rs2659912	ENSG00000222364.1	RNU6-96P	-5.51	1.94e-07	0.000276	-0.53	-0.44	Aortic root size;	chr7:66693012	chr7:66395191~66395286:+
TGCT	cis	rs36052053	0.908	rs13205489	ENSG00000219700.1	PTCHD3P3	-5.51	1.95e-07	0.000276	-0.74	-0.44	Red cell distribution width;	chr6:109282207	chr6:109288571~109290503:-
TGCT	cis	rs36052053	0.908	rs28360564	ENSG00000219700.1	PTCHD3P3	5.51	1.95e-07	0.000276	0.74	0.44	Red cell distribution width;	chr6:109297186	chr6:109288571~109290503:-
TGCT	cis	rs36052053	0.908	rs13220206	ENSG00000219700.1	PTCHD3P3	5.51	1.95e-07	0.000276	0.74	0.44	Red cell distribution width;	chr6:109303278	chr6:109288571~109290503:-
TGCT	cis	rs36052053	0.908	rs34780834	ENSG00000219700.1	PTCHD3P3	5.51	1.95e-07	0.000276	0.74	0.44	Red cell distribution width;	chr6:109303563	chr6:109288571~109290503:-
TGCT	cis	rs11651753	0.561	rs17616603	ENSG00000264920.1	RP11-6N17.4	-5.51	1.95e-07	0.000276	-0.42	-0.44	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47882254	chr17:47891255~47895812:-
TGCT	cis	rs11651753	0.561	rs11654010	ENSG00000264920.1	RP11-6N17.4	5.51	1.95e-07	0.000276	0.42	0.44	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47883499	chr17:47891255~47895812:-
TGCT	cis	rs875971	0.862	rs778720	ENSG00000222364.1	RNU6-96P	5.51	1.95e-07	0.000276	0.48	0.44	Aortic root size;	chr7:66381288	chr7:66395191~66395286:+
TGCT	cis	rs8072100	0.84	rs12452796	ENSG00000228782.6	CTD-2026D20.3	-5.51	1.95e-07	0.000276	-0.54	-0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402367	chr17:47450568~47492492:-
TGCT	cis	rs8072100	0.84	rs11079774	ENSG00000228782.6	CTD-2026D20.3	5.51	1.96e-07	0.000277	0.54	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402340	chr17:47450568~47492492:-
TGCT	cis	rs5758659	0.714	rs5758574	ENSG00000270083.1	RP1-257I20.14	-5.51	1.96e-07	0.000277	-0.43	-0.44	Cognitive function;	chr22:42085396	chr22:42089630~42090028:-
TGCT	cis	rs9322193	0.884	rs9397036	ENSG00000216906.2	RP11-350J20.9	5.51	1.96e-07	0.000277	0.52	0.44	Lung cancer;	chr6:149851787	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.884	rs9383864	ENSG00000216906.2	RP11-350J20.9	5.51	1.96e-07	0.000277	0.52	0.44	Lung cancer;	chr6:149851969	chr6:149904243~149906418:+
TGCT	cis	rs8072100	0.807	rs2175290	ENSG00000228782.6	CTD-2026D20.3	5.51	1.96e-07	0.000278	0.54	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402551	chr17:47450568~47492492:-
TGCT	cis	rs6061231	0.631	rs927133	ENSG00000273619.1	RP5-908M14.9	-5.51	1.97e-07	0.000278	-0.48	-0.44	Colorectal cancer;	chr20:62397053	chr20:62386303~62386970:-
TGCT	cis	rs7811142	1	rs1000215	ENSG00000242294.5	STAG3L5P	5.51	1.97e-07	0.000278	0.41	0.44	Platelet count;	chr7:100406920	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.943	rs111757992	ENSG00000242294.5	STAG3L5P	5.51	1.97e-07	0.000278	0.41	0.44	Platelet count;	chr7:100418731	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs28490152	ENSG00000242294.5	STAG3L5P	5.51	1.97e-07	0.000278	0.41	0.44	Platelet count;	chr7:100423359	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.943	rs28660238	ENSG00000242294.5	STAG3L5P	5.51	1.97e-07	0.000278	0.41	0.44	Platelet count;	chr7:100425685	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.943	rs67196635	ENSG00000242294.5	STAG3L5P	5.51	1.97e-07	0.000278	0.41	0.44	Platelet count;	chr7:100427941	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs6962151	ENSG00000242294.5	STAG3L5P	5.51	1.97e-07	0.000278	0.41	0.44	Platelet count;	chr7:100430861	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.943	rs67483801	ENSG00000242294.5	STAG3L5P	5.51	1.97e-07	0.000278	0.41	0.44	Platelet count;	chr7:100434135	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs11761784	ENSG00000242294.5	STAG3L5P	5.51	1.97e-07	0.000278	0.41	0.44	Platelet count;	chr7:100442347	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs112317829	ENSG00000242294.5	STAG3L5P	5.51	1.97e-07	0.000278	0.41	0.44	Platelet count;	chr7:100445550	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.943	rs28578163	ENSG00000242294.5	STAG3L5P	5.51	1.97e-07	0.000278	0.41	0.44	Platelet count;	chr7:100447131	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs67239991	ENSG00000242294.5	STAG3L5P	5.51	1.97e-07	0.000278	0.41	0.44	Platelet count;	chr7:100448881	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.943	rs111493473	ENSG00000242294.5	STAG3L5P	5.51	1.97e-07	0.000278	0.41	0.44	Platelet count;	chr7:100452119	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs4472444	ENSG00000242294.5	STAG3L5P	5.51	1.97e-07	0.000278	0.41	0.44	Platelet count;	chr7:100473135	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs7809801	ENSG00000242294.5	STAG3L5P	5.51	1.97e-07	0.000278	0.41	0.44	Platelet count;	chr7:100474408	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs11766752	ENSG00000242294.5	STAG3L5P	5.51	1.97e-07	0.000278	0.41	0.44	Platelet count;	chr7:100475669	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs11559117	ENSG00000242294.5	STAG3L5P	5.51	1.97e-07	0.000278	0.41	0.44	Platelet count;	chr7:100478991	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs2406253	ENSG00000242294.5	STAG3L5P	5.51	1.97e-07	0.000278	0.41	0.44	Platelet count;	chr7:100479650	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs4463351	ENSG00000242294.5	STAG3L5P	5.51	1.97e-07	0.000278	0.41	0.44	Platelet count;	chr7:100480603	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs60844404	ENSG00000242294.5	STAG3L5P	5.51	1.97e-07	0.000278	0.41	0.44	Platelet count;	chr7:100482851	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs113738841	ENSG00000242294.5	STAG3L5P	5.51	1.97e-07	0.000278	0.41	0.44	Platelet count;	chr7:100483683	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs11763511	ENSG00000242294.5	STAG3L5P	5.51	1.97e-07	0.000278	0.41	0.44	Platelet count;	chr7:100484321	chr7:100336079~100351900:+
TGCT	cis	rs524281	0.692	rs11227395	ENSG00000255320.1	RP11-755F10.1	5.51	1.97e-07	0.000279	0.53	0.44	Electroencephalogram traits;	chr11:66062166	chr11:66244840~66246239:-
TGCT	cis	rs7804306	0.826	rs73049252	ENSG00000233264.2	AC006042.8	5.51	1.97e-07	0.000279	1.02	0.44	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7976971	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.826	rs73049256	ENSG00000233264.2	AC006042.8	5.51	1.97e-07	0.000279	1.02	0.44	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7978858	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.826	rs73049270	ENSG00000233264.2	AC006042.8	5.51	1.97e-07	0.000279	1.02	0.44	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7982015	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.826	rs73049276	ENSG00000233264.2	AC006042.8	5.51	1.97e-07	0.000279	1.02	0.44	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7982385	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.826	rs113537684	ENSG00000233264.2	AC006042.8	5.51	1.97e-07	0.000279	1.02	0.44	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7985192	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.826	rs73049290	ENSG00000233264.2	AC006042.8	5.51	1.97e-07	0.000279	1.02	0.44	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7992584	chr7:7980312~7982228:+
TGCT	cis	rs7688540	0.511	rs4522818	ENSG00000275426.1	CH17-262A2.1	5.51	1.97e-07	0.000279	0.93	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:187973	chr4:149738~150317:+
TGCT	cis	rs7688540	0.511	rs61794969	ENSG00000275426.1	CH17-262A2.1	5.51	1.97e-07	0.000279	0.93	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:194242	chr4:149738~150317:+
TGCT	cis	rs7208859	0.573	rs79505916	ENSG00000263531.1	RP13-753N3.1	5.51	1.98e-07	0.000279	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30863921~30864940:-
TGCT	cis	rs3091242	0.809	rs660129	ENSG00000261349.1	RP3-465N24.5	-5.51	1.98e-07	0.000279	-0.45	-0.44	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25266102~25267136:-
TGCT	cis	rs3091242	0.728	rs706845	ENSG00000261349.1	RP3-465N24.5	-5.51	1.98e-07	0.000279	-0.45	-0.44	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25266102~25267136:-
TGCT	cis	rs1707322	0.686	rs2991986	ENSG00000280836.1	AL355480.1	5.51	1.98e-07	0.000279	0.62	0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45581219~45581321:-
TGCT	cis	rs5760092	0.618	rs4461358	ENSG00000225282.1	AP000350.6	-5.51	1.98e-07	0.000279	-0.59	-0.44	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23926900~23929574:+
TGCT	cis	rs950169	0.881	rs150965	ENSG00000225151.9	GOLGA2P7	-5.51	1.98e-07	0.00028	-0.51	-0.44	Schizophrenia;	chr15:84537296	chr15:84199311~84230136:-
TGCT	cis	rs36052053	0.908	rs34739891	ENSG00000219700.1	PTCHD3P3	5.51	1.99e-07	0.000281	0.74	0.44	Red cell distribution width;	chr6:109290264	chr6:109288571~109290503:-
TGCT	cis	rs36052053	0.908	rs71558364	ENSG00000219700.1	PTCHD3P3	5.51	1.99e-07	0.000281	0.74	0.44	Red cell distribution width;	chr6:109295036	chr6:109288571~109290503:-
TGCT	cis	rs8072100	0.84	rs9900360	ENSG00000228782.6	CTD-2026D20.3	5.51	2e-07	0.000281	0.54	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47414613	chr17:47450568~47492492:-
TGCT	cis	rs8072100	0.84	rs56952963	ENSG00000228782.6	CTD-2026D20.3	5.51	2e-07	0.000281	0.54	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416460	chr17:47450568~47492492:-
TGCT	cis	rs1153858	1	rs4775909	ENSG00000259520.4	CTD-2651B20.3	-5.51	2e-07	0.000282	-0.39	-0.44	Homoarginine levels;	chr15:45350844	chr15:45251580~45279251:-
TGCT	cis	rs7849270	0.959	rs2900271	ENSG00000268707.1	RP11-247A12.7	5.51	2.01e-07	0.000283	0.5	0.44	Blood metabolite ratios;	chr9:129132655	chr9:129170434~129170940:+
TGCT	cis	rs7923609	0.756	rs12768534	ENSG00000232075.1	MRPL35P2	-5.51	2.01e-07	0.000283	-0.43	-0.44	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63581137	chr10:63634317~63634827:-
TGCT	cis	rs3931020	0.53	rs6668736	ENSG00000272864.1	RP11-17E13.2	-5.51	2.01e-07	0.000283	-0.49	-0.44	Resistin levels;	chr1:74768866	chr1:74698769~74699333:-
TGCT	cis	rs5758659	0.714	rs6002607	ENSG00000270083.1	RP1-257I20.14	-5.51	2.01e-07	0.000283	-0.43	-0.44	Cognitive function;	chr22:42100502	chr22:42089630~42090028:-
TGCT	cis	rs5758659	0.714	rs133376	ENSG00000270083.1	RP1-257I20.14	5.51	2.01e-07	0.000283	0.43	0.44	Cognitive function;	chr22:42070901	chr22:42089630~42090028:-
TGCT	cis	rs5758659	0.653	rs133383	ENSG00000270083.1	RP1-257I20.14	5.51	2.01e-07	0.000283	0.43	0.44	Cognitive function;	chr22:42077599	chr22:42089630~42090028:-
TGCT	cis	rs3091242	0.804	rs631133	ENSG00000261349.1	RP3-465N24.5	-5.51	2.01e-07	0.000284	-0.44	-0.44	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25266102~25267136:-
TGCT	cis	rs5758659	0.714	rs7245	ENSG00000270083.1	RP1-257I20.14	-5.51	2.03e-07	0.000285	-0.43	-0.44	Cognitive function;	chr22:42085845	chr22:42089630~42090028:-
TGCT	cis	rs3091242	0.867	rs602052	ENSG00000261349.1	RP3-465N24.5	-5.5	2.03e-07	0.000285	-0.45	-0.44	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25266102~25267136:-
TGCT	cis	rs17301013	0.556	rs1754353	ENSG00000227373.4	RP11-160H22.5	-5.5	2.03e-07	0.000286	-0.53	-0.44	Systemic lupus erythematosus;	chr1:174822229	chr1:174115300~174160004:-
TGCT	cis	rs17711722	0.523	rs365896	ENSG00000236529.1	RP13-254B10.1	-5.5	2.03e-07	0.000286	-0.32	-0.44	Calcium levels;	chr7:66045710	chr7:65840212~65840596:+
TGCT	cis	rs3931020	0.679	rs28671241	ENSG00000272864.1	RP11-17E13.2	-5.5	2.04e-07	0.000287	-0.51	-0.44	Resistin levels;	chr1:74716197	chr1:74698769~74699333:-
TGCT	cis	rs7104764	0.701	rs3782115	ENSG00000277290.1	RP11-326C3.16	-5.5	2.04e-07	0.000287	-0.43	-0.44	Menarche (age at onset);	chr11:223272	chr11:243099~243483:-
TGCT	cis	rs10256972	0.63	rs13235747	ENSG00000226291.1	AC091729.8	-5.5	2.05e-07	0.000288	-0.47	-0.44	Endometriosis;Longevity;	chr7:1089487	chr7:1080863~1082178:+
TGCT	cis	rs10256972	0.681	rs12702016	ENSG00000226291.1	AC091729.8	-5.5	2.05e-07	0.000288	-0.47	-0.44	Endometriosis;Longevity;	chr7:1089756	chr7:1080863~1082178:+
TGCT	cis	rs10256972	0.641	rs12702017	ENSG00000226291.1	AC091729.8	-5.5	2.05e-07	0.000288	-0.47	-0.44	Endometriosis;Longevity;	chr7:1089777	chr7:1080863~1082178:+
TGCT	cis	rs5758659	0.714	rs5751220	ENSG00000270083.1	RP1-257I20.14	-5.5	2.05e-07	0.000288	-0.43	-0.44	Cognitive function;	chr22:42120201	chr22:42089630~42090028:-
TGCT	cis	rs7829975	0.626	rs907183	ENSG00000173295.6	FAM86B3P	-5.5	2.05e-07	0.000288	-0.51	-0.44	Mood instability;	chr8:8872251	chr8:8228595~8244865:+
TGCT	cis	rs1775715	0.966	rs1639132	ENSG00000239731.3	RN7SL825P	5.5	2.05e-07	0.000289	0.47	0.44	Bipolar disorder with mood-incongruent psychosis;	chr10:32012332	chr10:31992087~31992381:-
TGCT	cis	rs73086581	1	rs73086505	ENSG00000229539.1	RP11-119B16.2	5.5	2.06e-07	0.000289	0.68	0.44	Response to antidepressants in depression;	chr20:3940924	chr20:3888239~3888868:-
TGCT	cis	rs73086581	1	rs73086508	ENSG00000229539.1	RP11-119B16.2	5.5	2.06e-07	0.000289	0.68	0.44	Response to antidepressants in depression;	chr20:3941068	chr20:3888239~3888868:-
TGCT	cis	rs73086581	1	rs73086510	ENSG00000229539.1	RP11-119B16.2	5.5	2.06e-07	0.000289	0.68	0.44	Response to antidepressants in depression;	chr20:3941484	chr20:3888239~3888868:-
TGCT	cis	rs73086581	1	rs17286768	ENSG00000229539.1	RP11-119B16.2	5.5	2.06e-07	0.000289	0.68	0.44	Response to antidepressants in depression;	chr20:3943922	chr20:3888239~3888868:-
TGCT	cis	rs73086581	1	rs17214621	ENSG00000229539.1	RP11-119B16.2	5.5	2.06e-07	0.000289	0.68	0.44	Response to antidepressants in depression;	chr20:3945277	chr20:3888239~3888868:-
TGCT	cis	rs7811142	0.72	rs7795656	ENSG00000242294.5	STAG3L5P	5.5	2.07e-07	0.00029	0.41	0.44	Platelet count;	chr7:100352674	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.83	rs7792525	ENSG00000242294.5	STAG3L5P	5.5	2.07e-07	0.00029	0.41	0.44	Platelet count;	chr7:100374499	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.83	rs6945952	ENSG00000242294.5	STAG3L5P	5.5	2.07e-07	0.00029	0.41	0.44	Platelet count;	chr7:100384152	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.83	rs73401451	ENSG00000242294.5	STAG3L5P	5.5	2.07e-07	0.00029	0.41	0.44	Platelet count;	chr7:100384272	chr7:100336079~100351900:+
TGCT	cis	rs17301013	0.507	rs10912828	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.52	0.44	Systemic lupus erythematosus;	chr1:174635701	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs10912829	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.52	0.44	Systemic lupus erythematosus;	chr1:174635894	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs6689153	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.52	0.44	Systemic lupus erythematosus;	chr1:174639550	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs395109	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.52	0.44	Systemic lupus erythematosus;	chr1:174641233	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs2760058	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.52	0.44	Systemic lupus erythematosus;	chr1:174641320	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs333454	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.52	0.44	Systemic lupus erythematosus;	chr1:174653939	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs333452	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.52	0.44	Systemic lupus erythematosus;	chr1:174654718	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs411665	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.52	0.44	Systemic lupus erythematosus;	chr1:174656563	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs2860955	ENSG00000227373.4	RP11-160H22.5	-5.5	2.07e-07	0.00029	-0.5	-0.44	Systemic lupus erythematosus;	chr1:174391380	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs6684688	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.5	0.44	Systemic lupus erythematosus;	chr1:174357180	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs926349	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.5	0.44	Systemic lupus erythematosus;	chr1:174368408	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs28628056	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.5	0.44	Systemic lupus erythematosus;	chr1:174369545	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs10912772	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.5	0.44	Systemic lupus erythematosus;	chr1:174370832	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12073751	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.5	0.44	Systemic lupus erythematosus;	chr1:174373177	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs10912777	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.5	0.44	Systemic lupus erythematosus;	chr1:174393764	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs10912778	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.5	0.44	Systemic lupus erythematosus;	chr1:174393827	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs2205937	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.5	0.44	Systemic lupus erythematosus;	chr1:174394440	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12084291	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.5	0.44	Systemic lupus erythematosus;	chr1:174395721	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs2901815	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.5	0.44	Systemic lupus erythematosus;	chr1:174397404	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs1883262	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.5	0.44	Systemic lupus erythematosus;	chr1:174401104	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs2860959	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.5	0.44	Systemic lupus erythematosus;	chr1:174403704	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs10912779	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.5	0.44	Systemic lupus erythematosus;	chr1:174404311	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12090860	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.5	0.44	Systemic lupus erythematosus;	chr1:174405166	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12064126	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.5	0.44	Systemic lupus erythematosus;	chr1:174405312	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs10798310	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.5	0.44	Systemic lupus erythematosus;	chr1:174408581	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs11799704	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.5	0.44	Systemic lupus erythematosus;	chr1:174413640	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs2901817	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.5	0.44	Systemic lupus erythematosus;	chr1:174414479	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs6701534	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.5	0.44	Systemic lupus erythematosus;	chr1:174418612	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs10798312	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.5	0.44	Systemic lupus erythematosus;	chr1:174419089	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs4652422	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.5	0.44	Systemic lupus erythematosus;	chr1:174419501	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs4233181	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.5	0.44	Systemic lupus erythematosus;	chr1:174419697	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs10489258	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.5	0.44	Systemic lupus erythematosus;	chr1:174420447	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs10798313	ENSG00000227373.4	RP11-160H22.5	5.5	2.07e-07	0.00029	0.5	0.44	Systemic lupus erythematosus;	chr1:174420995	chr1:174115300~174160004:-
TGCT	cis	rs950169	0.922	rs4842939	ENSG00000225151.9	GOLGA2P7	5.5	2.07e-07	0.00029	0.49	0.44	Schizophrenia;	chr15:84159214	chr15:84199311~84230136:-
TGCT	cis	rs1799949	1	rs33926631	ENSG00000198496.9	NBR2	-5.5	2.08e-07	0.000291	-0.64	-0.44	Menopause (age at onset);	chr17:43152446	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs1960605	ENSG00000198496.9	NBR2	-5.5	2.08e-07	0.000291	-0.64	-0.44	Menopause (age at onset);	chr17:43153380	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs2037076	ENSG00000198496.9	NBR2	-5.5	2.08e-07	0.000291	-0.64	-0.44	Menopause (age at onset);	chr17:43153866	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.965	rs12950779	ENSG00000198496.9	NBR2	-5.5	2.08e-07	0.000291	-0.64	-0.44	Menopause (age at onset);	chr17:43154506	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.929	rs12937015	ENSG00000198496.9	NBR2	-5.5	2.08e-07	0.000291	-0.64	-0.44	Menopause (age at onset);	chr17:43155456	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs4340367	ENSG00000198496.9	NBR2	-5.5	2.08e-07	0.000291	-0.64	-0.44	Menopause (age at onset);	chr17:43155755	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs4792981	ENSG00000198496.9	NBR2	-5.5	2.08e-07	0.000291	-0.64	-0.44	Menopause (age at onset);	chr17:43156257	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.965	rs35521261	ENSG00000198496.9	NBR2	-5.5	2.08e-07	0.000291	-0.64	-0.44	Menopause (age at onset);	chr17:43161595	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.896	rs33933393	ENSG00000198496.9	NBR2	-5.5	2.08e-07	0.000291	-0.64	-0.44	Menopause (age at onset);	chr17:43165415	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs2271574	ENSG00000198496.9	NBR2	-5.5	2.08e-07	0.000291	-0.64	-0.44	Menopause (age at onset);	chr17:43175631	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs33994002	ENSG00000198496.9	NBR2	-5.5	2.08e-07	0.000291	-0.64	-0.44	Menopause (age at onset);	chr17:43176801	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs33920795	ENSG00000198496.9	NBR2	-5.5	2.08e-07	0.000291	-0.64	-0.44	Menopause (age at onset);	chr17:43176993	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs33918839	ENSG00000198496.9	NBR2	-5.5	2.08e-07	0.000291	-0.64	-0.44	Menopause (age at onset);	chr17:43177155	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs11653231	ENSG00000198496.9	NBR2	-5.5	2.08e-07	0.000291	-0.64	-0.44	Menopause (age at onset);	chr17:43179443	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs1399323	ENSG00000198496.9	NBR2	-5.5	2.08e-07	0.000291	-0.64	-0.44	Menopause (age at onset);	chr17:43180313	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.965	rs35954893	ENSG00000198496.9	NBR2	-5.5	2.08e-07	0.000291	-0.64	-0.44	Menopause (age at onset);	chr17:43181769	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.93	rs4445938	ENSG00000198496.9	NBR2	-5.5	2.08e-07	0.000291	-0.64	-0.44	Menopause (age at onset);	chr17:43185883	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs8074136	ENSG00000198496.9	NBR2	-5.5	2.08e-07	0.000291	-0.64	-0.44	Menopause (age at onset);	chr17:43190296	chr17:43125610~43153671:+
TGCT	cis	rs4970988	0.556	rs6695123	ENSG00000206931.1	RNU6-1042P	-5.5	2.08e-07	0.000291	-0.37	-0.44	Urate levels;	chr1:150591007	chr1:150701866~150701972:+
TGCT	cis	rs4835473	0.932	rs17018238	ENSG00000251600.4	RP11-673E1.1	-5.5	2.08e-07	0.000291	-0.43	-0.44	Immature fraction of reticulocytes;	chr4:143782737	chr4:143912331~143982454:+
TGCT	cis	rs7849270	1	rs10819469	ENSG00000268707.1	RP11-247A12.7	-5.5	2.08e-07	0.000291	-0.49	-0.44	Blood metabolite ratios;	chr9:129119788	chr9:129170434~129170940:+
TGCT	cis	rs8040855	0.965	rs4843027	ENSG00000259295.5	CSPG4P12	-5.5	2.09e-07	0.000292	-0.57	-0.44	Bulimia nervosa;	chr15:85171892	chr15:85191438~85213905:+
TGCT	cis	rs5760092	0.755	rs11090298	ENSG00000218537.1	MIF-AS1	-5.5	2.09e-07	0.000292	-0.66	-0.44	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23894426~23898930:-
TGCT	cis	rs2333021	0.78	rs2243596	ENSG00000259015.1	RP11-109N23.6	-5.5	2.1e-07	0.000293	-0.23	-0.44	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72961952	chr14:72960595~72961993:+
TGCT	cis	rs10256972	0.516	rs12702081	ENSG00000226291.1	AC091729.8	-5.5	2.1e-07	0.000293	-0.46	-0.44	Endometriosis;Longevity;	chr7:1101892	chr7:1080863~1082178:+
TGCT	cis	rs2276314	0.857	rs6507158	ENSG00000278986.1	RP11-723J4.3	-5.5	2.1e-07	0.000293	-0.51	-0.44	Endometriosis;Drug-induced torsades de pointes;	chr18:36056103	chr18:35972151~35973916:+
TGCT	cis	rs55794721	0.509	rs909834	ENSG00000261349.1	RP3-465N24.5	-5.5	2.1e-07	0.000294	-0.43	-0.44	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25266102~25267136:-
TGCT	cis	rs17361889	0.727	rs1527208	ENSG00000224683.1	RPL36AP29	5.5	2.11e-07	0.000295	0.5	0.44	Pediatric bone mineral content (hip);	chr7:16241218	chr7:16208945~16209265:+
TGCT	cis	rs17361889	0.752	rs4721485	ENSG00000224683.1	RPL36AP29	5.5	2.11e-07	0.000295	0.5	0.44	Pediatric bone mineral content (hip);	chr7:16242848	chr7:16208945~16209265:+
TGCT	cis	rs4835473	0.832	rs35398499	ENSG00000251600.4	RP11-673E1.1	-5.5	2.11e-07	0.000295	-0.44	-0.44	Immature fraction of reticulocytes;	chr4:143737715	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.832	rs35763177	ENSG00000251600.4	RP11-673E1.1	-5.5	2.11e-07	0.000295	-0.44	-0.44	Immature fraction of reticulocytes;	chr4:143737717	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.864	rs5015762	ENSG00000251600.4	RP11-673E1.1	-5.5	2.11e-07	0.000295	-0.44	-0.44	Immature fraction of reticulocytes;	chr4:143737773	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.864	rs5015761	ENSG00000251600.4	RP11-673E1.1	-5.5	2.11e-07	0.000295	-0.44	-0.44	Immature fraction of reticulocytes;	chr4:143737791	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs7356305	ENSG00000251600.4	RP11-673E1.1	5.5	2.11e-07	0.000295	0.44	0.44	Immature fraction of reticulocytes;	chr4:143737850	chr4:143912331~143982454:+
TGCT	cis	rs1799949	1	rs4793197	ENSG00000198496.9	NBR2	-5.5	2.11e-07	0.000295	-0.64	-0.44	Menopause (age at onset);	chr17:43079885	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs1060915	ENSG00000198496.9	NBR2	-5.5	2.11e-07	0.000295	-0.64	-0.44	Menopause (age at onset);	chr17:43082453	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs16941	ENSG00000198496.9	NBR2	-5.5	2.11e-07	0.000295	-0.64	-0.44	Menopause (age at onset);	chr17:43092418	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs67060599	ENSG00000198496.9	NBR2	-5.5	2.11e-07	0.000295	-0.64	-0.44	Menopause (age at onset);	chr17:43103085	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs8176133	ENSG00000198496.9	NBR2	-5.5	2.11e-07	0.000295	-0.64	-0.44	Menopause (age at onset);	chr17:43105441	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.965	rs8176087	ENSG00000198496.9	NBR2	-5.5	2.11e-07	0.000295	-0.64	-0.44	Menopause (age at onset);	chr17:43118649	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs34942571	ENSG00000198496.9	NBR2	-5.5	2.11e-07	0.000295	-0.64	-0.44	Menopause (age at onset);	chr17:43121362	chr17:43125610~43153671:+
TGCT	cis	rs8062405	0.755	rs56209193	ENSG00000259982.1	CDC37P1	5.5	2.12e-07	0.000295	0.63	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28700294~28701540:-
TGCT	cis	rs4774565	0.762	rs7182201	ENSG00000244879.4	GABPB1-AS1	-5.5	2.12e-07	0.000296	-0.37	-0.44	Breast cancer;	chr15:50364377	chr15:50354959~50372202:+
TGCT	cis	rs4774565	0.724	rs2555486	ENSG00000244879.4	GABPB1-AS1	5.5	2.12e-07	0.000296	0.37	0.44	Breast cancer;	chr15:50363924	chr15:50354959~50372202:+
TGCT	cis	rs9326248	0.559	rs609177	ENSG00000254851.1	RP11-109L13.1	-5.5	2.12e-07	0.000296	-0.53	-0.44	Blood protein levels;	chr11:116899801	chr11:117135528~117138582:+
TGCT	cis	rs7044106	0.648	rs2031369	ENSG00000226752.6	PSMD5-AS1	-5.49	2.13e-07	0.000297	-0.57	-0.44	Hip circumference adjusted for BMI;	chr9:120598016	chr9:120824828~120854385:+
TGCT	cis	rs8113308	0.688	rs7259507	ENSG00000269235.1	ZNF350-AS1	5.49	2.13e-07	0.000297	0.72	0.44	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942475	chr19:51949134~51981367:+
TGCT	cis	rs8113308	0.81	rs7259622	ENSG00000269235.1	ZNF350-AS1	5.49	2.13e-07	0.000297	0.72	0.44	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942484	chr19:51949134~51981367:+
TGCT	cis	rs8113308	0.81	rs73582180	ENSG00000269235.1	ZNF350-AS1	5.49	2.13e-07	0.000297	0.72	0.44	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51943284	chr19:51949134~51981367:+
TGCT	cis	rs8113308	0.81	rs8105910	ENSG00000269235.1	ZNF350-AS1	5.49	2.13e-07	0.000297	0.72	0.44	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51943815	chr19:51949134~51981367:+
TGCT	cis	rs12891047	0.738	rs11158701	ENSG00000258759.1	RP11-1012A1.7	-5.49	2.14e-07	0.000298	-0.39	-0.44	Amyotrophic lateral sclerosis (sporadic);	chr14:67877397	chr14:67799004~67799609:+
TGCT	cis	rs7714584	1	rs7724558	ENSG00000197083.10	ZNF300P1	5.49	2.14e-07	0.000298	0.95	0.44	Crohn's disease;	chr5:150949304	chr5:150930645~150946289:-
TGCT	cis	rs2732480	0.5	rs2932093	ENSG00000258273.1	RP11-370I10.4	-5.49	2.14e-07	0.000298	-0.52	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48333755~48333901:-
TGCT	cis	rs875971	0.83	rs427575	ENSG00000222364.1	RNU6-96P	-5.49	2.14e-07	0.000298	-0.5	-0.44	Aortic root size;	chr7:66054232	chr7:66395191~66395286:+
TGCT	cis	rs12439619	0.921	rs4778672	ENSG00000278603.1	RP13-608F4.5	-5.49	2.14e-07	0.000298	-0.62	-0.44	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472203~82472426:+
TGCT	cis	rs2015599	0.623	rs10843385	ENSG00000257176.2	RP11-996F15.2	-5.49	2.14e-07	0.000298	-0.49	-0.44	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29280418~29317848:-
TGCT	cis	rs2015599	0.601	rs17715086	ENSG00000257176.2	RP11-996F15.2	-5.49	2.14e-07	0.000298	-0.49	-0.44	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29280418~29317848:-
TGCT	cis	rs2980439	0.807	rs2980438	ENSG00000173295.6	FAM86B3P	5.49	2.15e-07	3e-04	0.53	0.44	Neuroticism;	chr8:8237303	chr8:8228595~8244865:+
TGCT	cis	rs4423214	0.65	rs7940244	ENSG00000254682.1	RP11-660L16.2	-5.49	2.15e-07	3e-04	-0.63	-0.44	Vitamin D levels;	chr11:71510528	chr11:71448674~71452157:+
TGCT	cis	rs801193	1	rs10234018	ENSG00000222364.1	RNU6-96P	5.49	2.15e-07	3e-04	0.52	0.44	Aortic root size;	chr7:66681297	chr7:66395191~66395286:+
TGCT	cis	rs4713118	0.513	rs149955	ENSG00000216901.1	AL022393.7	5.49	2.15e-07	3e-04	0.56	0.44	Parkinson's disease;	chr6:28068447	chr6:28176188~28176674:+
TGCT	cis	rs4927850	1	rs4927850	ENSG00000207650.1	MIR570	-5.49	2.16e-07	3e-04	-0.54	-0.44	Pancreatic cancer;	chr3:196024759	chr3:195699401~195699497:+
TGCT	cis	rs11673344	0.864	rs1533736	ENSG00000226686.6	LINC01535	5.49	2.16e-07	0.000301	0.52	0.44	Obesity-related traits;	chr19:37164074	chr19:37251912~37265535:+
TGCT	cis	rs7849270	1	rs10819471	ENSG00000268707.1	RP11-247A12.7	-5.49	2.16e-07	0.000301	-0.49	-0.44	Blood metabolite ratios;	chr9:129134046	chr9:129170434~129170940:+
TGCT	cis	rs853679	0.517	rs16893666	ENSG00000219392.1	RP1-265C24.5	5.49	2.17e-07	0.000302	0.57	0.44	Depression;	chr6:28086929	chr6:28115628~28116551:+
TGCT	cis	rs2739330	0.76	rs1002286	ENSG00000272787.1	KB-226F1.2	5.49	2.18e-07	0.000303	0.48	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23969211~23969873:+
TGCT	cis	rs1426063	0.614	rs79750906	ENSG00000260265.1	RP11-44F21.5	5.49	2.18e-07	0.000303	0.59	0.44	QT interval;	chr4:75139193	chr4:75081702~75084717:-
TGCT	cis	rs943437	0.877	rs633177	ENSG00000227012.2	RP1-97J1.2	5.49	2.18e-07	0.000303	0.61	0.44	Parkinson's disease;	chr6:111951736	chr6:111900489~111901851:-
TGCT	cis	rs17711722	0.523	rs313812	ENSG00000164669.11	INTS4P1	5.49	2.19e-07	0.000304	0.43	0.44	Calcium levels;	chr7:66040056	chr7:65141225~65234216:+
TGCT	cis	rs11671005	0.735	rs12977592	ENSG00000268912.1	CTD-2619J13.17	-5.49	2.2e-07	0.000304	-0.49	-0.44	Mean platelet volume;	chr19:58449689	chr19:58428632~58431148:-
TGCT	cis	rs321358	1	rs321352	ENSG00000271584.1	RP11-89C3.4	5.49	2.2e-07	0.000305	0.56	0.44	Body mass index;	chr11:111123001	chr11:111091932~111097357:-
TGCT	cis	rs321358	1	rs167683	ENSG00000271584.1	RP11-89C3.4	5.49	2.2e-07	0.000305	0.56	0.44	Body mass index;	chr11:111123131	chr11:111091932~111097357:-
TGCT	cis	rs321358	1	rs321355	ENSG00000271584.1	RP11-89C3.4	5.49	2.2e-07	0.000305	0.56	0.44	Body mass index;	chr11:111124273	chr11:111091932~111097357:-
TGCT	cis	rs9322193	0.923	rs9800686	ENSG00000216906.2	RP11-350J20.9	5.49	2.2e-07	0.000305	0.51	0.44	Lung cancer;	chr6:149634464	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs55849538	ENSG00000216906.2	RP11-350J20.9	5.49	2.2e-07	0.000305	0.51	0.44	Lung cancer;	chr6:149635330	chr6:149904243~149906418:+
TGCT	cis	rs7849270	1	rs2541161	ENSG00000268707.1	RP11-247A12.7	5.49	2.2e-07	0.000305	0.5	0.44	Blood metabolite ratios;	chr9:129122523	chr9:129170434~129170940:+
TGCT	cis	rs710913	0.745	rs1180334	ENSG00000182109.6	RP11-69E11.4	-5.49	2.21e-07	0.000305	-0.44	-0.44	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39555972	chr1:39522280~39546187:-
TGCT	cis	rs710913	0.691	rs1180351	ENSG00000182109.6	RP11-69E11.4	-5.49	2.21e-07	0.000305	-0.44	-0.44	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39541605	chr1:39522280~39546187:-
TGCT	cis	rs950169	1	rs950169	ENSG00000225151.9	GOLGA2P7	-5.49	2.21e-07	0.000306	-0.48	-0.44	Schizophrenia;	chr15:84037709	chr15:84199311~84230136:-
TGCT	cis	rs2739330	0.703	rs5760112	ENSG00000250470.1	AP000351.3	5.49	2.21e-07	0.000306	0.43	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23976904~23977585:-
TGCT	cis	rs7829975	0.511	rs1401390	ENSG00000173295.6	FAM86B3P	5.49	2.21e-07	0.000306	0.54	0.44	Mood instability;	chr8:8278888	chr8:8228595~8244865:+
TGCT	cis	rs950169	0.84	rs35522895	ENSG00000225151.9	GOLGA2P7	-5.49	2.21e-07	0.000306	-0.52	-0.44	Schizophrenia;	chr15:84259297	chr15:84199311~84230136:-
TGCT	cis	rs7617773	0.78	rs7645425	ENSG00000229759.1	MRPS18AP1	5.49	2.22e-07	0.000306	0.39	0.44	Coronary artery disease;	chr3:48320879	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.743	rs11716371	ENSG00000229759.1	MRPS18AP1	5.49	2.22e-07	0.000306	0.39	0.44	Coronary artery disease;	chr3:48321260	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs6793223	ENSG00000229759.1	MRPS18AP1	5.49	2.22e-07	0.000306	0.39	0.44	Coronary artery disease;	chr3:48322611	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs4541431	ENSG00000229759.1	MRPS18AP1	5.49	2.22e-07	0.000306	0.39	0.44	Coronary artery disease;	chr3:48323728	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs11714944	ENSG00000229759.1	MRPS18AP1	5.49	2.22e-07	0.000306	0.39	0.44	Coronary artery disease;	chr3:48325481	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.743	rs13071960	ENSG00000229759.1	MRPS18AP1	5.49	2.22e-07	0.000306	0.39	0.44	Coronary artery disease;	chr3:48326047	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.743	rs4632568	ENSG00000229759.1	MRPS18AP1	5.49	2.22e-07	0.000306	0.39	0.44	Coronary artery disease;	chr3:48326329	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs11130164	ENSG00000229759.1	MRPS18AP1	5.49	2.22e-07	0.000306	0.39	0.44	Coronary artery disease;	chr3:48327544	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs7653336	ENSG00000229759.1	MRPS18AP1	5.49	2.22e-07	0.000306	0.39	0.44	Coronary artery disease;	chr3:48327974	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.747	rs34076262	ENSG00000229759.1	MRPS18AP1	5.49	2.22e-07	0.000306	0.39	0.44	Coronary artery disease;	chr3:48328926	chr3:48256350~48256938:-
TGCT	cis	rs801193	0.591	rs9986881	ENSG00000226824.5	RP4-756H11.3	-5.49	2.22e-07	0.000307	-0.48	-0.44	Aortic root size;	chr7:66708053	chr7:66654538~66669855:+
TGCT	cis	rs7044106	0.762	rs10760110	ENSG00000226752.6	PSMD5-AS1	5.49	2.22e-07	0.000307	0.56	0.44	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120824828~120854385:+
TGCT	cis	rs9322193	0.81	rs62439811	ENSG00000216906.2	RP11-350J20.9	5.48	2.22e-07	0.000307	0.51	0.44	Lung cancer;	chr6:149640416	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs57938011	ENSG00000216906.2	RP11-350J20.9	5.48	2.22e-07	0.000307	0.51	0.44	Lung cancer;	chr6:149642969	chr6:149904243~149906418:+
TGCT	cis	rs3091242	0.933	rs12402120	ENSG00000261349.1	RP3-465N24.5	-5.48	2.22e-07	0.000307	-0.44	-0.44	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25266102~25267136:-
TGCT	cis	rs7688540	0.511	rs6841415	ENSG00000275426.1	CH17-262A2.1	5.48	2.23e-07	0.000308	0.92	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:203594	chr4:149738~150317:+
TGCT	cis	rs5769707	0.681	rs135879	ENSG00000235111.1	RP1-29C18.8	-5.48	2.23e-07	0.000308	-0.41	-0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49625003	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.642	rs135880	ENSG00000235111.1	RP1-29C18.8	-5.48	2.23e-07	0.000308	-0.41	-0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49625006	chr22:49612657~49615716:-
TGCT	cis	rs17361889	0.752	rs34750529	ENSG00000224683.1	RPL36AP29	5.48	2.24e-07	0.000309	0.48	0.44	Pediatric bone mineral content (hip);	chr7:16236950	chr7:16208945~16209265:+
TGCT	cis	rs7188445	0.736	rs4888043	ENSG00000261390.4	RP11-345M22.2	5.48	2.24e-07	0.000309	0.42	0.44	Urate levels;	chr16:79668744	chr16:79715232~79770563:-
TGCT	cis	rs11168618	0.545	rs1807757	ENSG00000240399.1	RP1-228P16.1	-5.48	2.25e-07	0.00031	-0.42	-0.44	Adiponectin levels;	chr12:48560257	chr12:48054813~48055591:-
TGCT	cis	rs2115630	0.645	rs6496284	ENSG00000225151.9	GOLGA2P7	5.48	2.26e-07	0.000311	0.45	0.44	P wave terminal force;	chr15:84635039	chr15:84199311~84230136:-
TGCT	cis	rs6061231	0.631	rs2427310	ENSG00000273619.1	RP5-908M14.9	-5.48	2.26e-07	0.000311	-0.48	-0.44	Colorectal cancer;	chr20:62394873	chr20:62386303~62386970:-
TGCT	cis	rs867371	0.656	rs2665103	ENSG00000255769.6	GOLGA2P10	5.48	2.26e-07	0.000312	0.46	0.44	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:82472993~82513950:-
TGCT	cis	rs2115630	0.645	rs2292463	ENSG00000225151.9	GOLGA2P7	5.48	2.29e-07	0.000315	0.45	0.44	P wave terminal force;	chr15:84632519	chr15:84199311~84230136:-
TGCT	cis	rs1799949	1	rs4793215	ENSG00000198496.9	NBR2	-5.48	2.29e-07	0.000315	-0.64	-0.44	Menopause (age at onset);	chr17:43166915	chr17:43125610~43153671:+
TGCT	cis	rs9425766	0.541	rs4652274	ENSG00000227373.4	RP11-160H22.5	5.48	2.29e-07	0.000316	0.48	0.44	Life satisfaction;	chr1:174249434	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.566	rs56188862	ENSG00000227373.4	RP11-160H22.5	5.48	2.29e-07	0.000316	0.49	0.44	Life satisfaction;	chr1:174220131	chr1:174115300~174160004:-
TGCT	cis	rs66887589	0.616	rs13113885	ENSG00000245958.5	RP11-33B1.1	-5.48	2.3e-07	0.000316	-0.43	-0.44	Diastolic blood pressure;	chr4:119300021	chr4:119454791~119552025:+
TGCT	cis	rs1528149	0.504	rs1990364	ENSG00000224683.1	RPL36AP29	5.48	2.3e-07	0.000317	0.49	0.44	Sitting height ratio;	chr7:16129300	chr7:16208945~16209265:+
TGCT	cis	rs786425	0.77	rs7306549	ENSG00000247373.3	RP11-486O12.2	5.48	2.31e-07	0.000317	0.54	0.44	Pubertal anthropometrics;	chr12:123672350	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.77	rs7313140	ENSG00000247373.3	RP11-486O12.2	5.48	2.31e-07	0.000317	0.54	0.44	Pubertal anthropometrics;	chr12:123672641	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.77	rs7133199	ENSG00000247373.3	RP11-486O12.2	5.48	2.31e-07	0.000317	0.54	0.44	Pubertal anthropometrics;	chr12:123674638	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.77	rs7134074	ENSG00000247373.3	RP11-486O12.2	5.48	2.31e-07	0.000317	0.54	0.44	Pubertal anthropometrics;	chr12:123675338	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.77	rs35158437	ENSG00000247373.3	RP11-486O12.2	5.48	2.31e-07	0.000317	0.54	0.44	Pubertal anthropometrics;	chr12:123676217	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.77	rs7960951	ENSG00000247373.3	RP11-486O12.2	5.48	2.31e-07	0.000317	0.54	0.44	Pubertal anthropometrics;	chr12:123681282	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.77	rs7974279	ENSG00000247373.3	RP11-486O12.2	5.48	2.31e-07	0.000317	0.54	0.44	Pubertal anthropometrics;	chr12:123681864	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.77	rs7964443	ENSG00000247373.3	RP11-486O12.2	5.48	2.31e-07	0.000317	0.54	0.44	Pubertal anthropometrics;	chr12:123681953	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.77	rs7313261	ENSG00000247373.3	RP11-486O12.2	5.48	2.31e-07	0.000317	0.54	0.44	Pubertal anthropometrics;	chr12:123682390	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.77	rs7308862	ENSG00000247373.3	RP11-486O12.2	5.48	2.31e-07	0.000317	0.54	0.44	Pubertal anthropometrics;	chr12:123686604	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.77	rs7297576	ENSG00000247373.3	RP11-486O12.2	5.48	2.31e-07	0.000317	0.54	0.44	Pubertal anthropometrics;	chr12:123686776	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.77	rs7298831	ENSG00000247373.3	RP11-486O12.2	5.48	2.31e-07	0.000317	0.54	0.44	Pubertal anthropometrics;	chr12:123688008	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.77	rs11829958	ENSG00000247373.3	RP11-486O12.2	5.48	2.31e-07	0.000317	0.54	0.44	Pubertal anthropometrics;	chr12:123688458	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.77	rs11609591	ENSG00000247373.3	RP11-486O12.2	5.48	2.31e-07	0.000317	0.54	0.44	Pubertal anthropometrics;	chr12:123689518	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.77	rs35114195	ENSG00000247373.3	RP11-486O12.2	5.48	2.31e-07	0.000317	0.54	0.44	Pubertal anthropometrics;	chr12:123691466	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.77	rs12828633	ENSG00000247373.3	RP11-486O12.2	5.48	2.31e-07	0.000317	0.54	0.44	Pubertal anthropometrics;	chr12:123695073	chr12:123575891~123585115:-
TGCT	cis	rs3091242	0.933	rs932372	ENSG00000261349.1	RP3-465N24.5	-5.48	2.31e-07	0.000318	-0.43	-0.44	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25266102~25267136:-
TGCT	cis	rs6061231	1	rs6061231	ENSG00000273619.1	RP5-908M14.9	-5.48	2.32e-07	0.000319	-0.47	-0.44	Colorectal cancer;	chr20:62381861	chr20:62386303~62386970:-
TGCT	cis	rs11155671	0.53	rs9371544	ENSG00000216906.2	RP11-350J20.9	5.48	2.32e-07	0.000319	0.47	0.44	Testicular germ cell tumor;	chr6:149896224	chr6:149904243~149906418:+
TGCT	cis	rs11155671	0.53	rs7763849	ENSG00000216906.2	RP11-350J20.9	5.48	2.32e-07	0.000319	0.47	0.44	Testicular germ cell tumor;	chr6:149885244	chr6:149904243~149906418:+
TGCT	cis	rs3091242	0.967	rs665372	ENSG00000261349.1	RP3-465N24.5	-5.47	2.33e-07	0.00032	-0.44	-0.44	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25266102~25267136:-
TGCT	cis	rs507080	0.922	rs525485	ENSG00000255422.1	AP002954.4	-5.47	2.33e-07	0.000321	-0.51	-0.44	Serum metabolite levels;	chr11:118685045	chr11:118704607~118750263:+
TGCT	cis	rs9322193	0.923	rs11155677	ENSG00000216906.2	RP11-350J20.9	5.47	2.34e-07	0.000321	0.49	0.44	Lung cancer;	chr6:149756953	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.884	rs9480009	ENSG00000216906.2	RP11-350J20.9	5.47	2.34e-07	0.000321	0.49	0.44	Lung cancer;	chr6:149758502	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs10747276	ENSG00000216906.2	RP11-350J20.9	5.47	2.34e-07	0.000321	0.49	0.44	Lung cancer;	chr6:149758739	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9480031	ENSG00000216906.2	RP11-350J20.9	5.47	2.34e-07	0.000321	0.49	0.44	Lung cancer;	chr6:149758875	chr6:149904243~149906418:+
TGCT	cis	rs943437	0.673	rs910684	ENSG00000227012.2	RP1-97J1.2	5.47	2.34e-07	0.000321	0.84	0.44	Parkinson's disease;	chr6:111862255	chr6:111900489~111901851:-
TGCT	cis	rs3931020	0.772	rs1475396	ENSG00000272864.1	RP11-17E13.2	-5.47	2.34e-07	0.000321	-0.5	-0.44	Resistin levels;	chr1:74776712	chr1:74698769~74699333:-
TGCT	cis	rs2739330	0.703	rs5760112	ENSG00000272787.1	KB-226F1.2	-5.47	2.34e-07	0.000321	-0.48	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23969211~23969873:+
TGCT	cis	rs75422866	0.867	rs73111258	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47597313	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs117388682	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47599713	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs79113930	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47600628	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs35044089	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47610881	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs78912815	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47612065	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs73113117	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47617299	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs73113139	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47622826	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs73113143	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47623060	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.717	rs73113159	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47631318	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.717	rs73113161	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47632361	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs117022227	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47633282	chr12:47706085~47742294:+
TGCT	cis	rs75422866	1	rs73102120	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47637280	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs73102125	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47637869	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs12426849	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47638975	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs117950951	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47639794	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs7954764	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47641136	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs12422974	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47644559	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs73102127	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47645341	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs73102140	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47647497	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs73102148	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47648013	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs73102151	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47648023	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs75568526	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47649718	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs116302411	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47649788	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs73102166	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47653769	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs73102168	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47654010	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs73102171	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47656077	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs76100981	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47660092	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs73102188	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47662993	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs73102195	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47666309	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs73102201	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47669269	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs73104103	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47669604	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs73104104	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47671986	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs73104111	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47673994	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs73104115	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47684843	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs73104116	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47685023	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs73104138	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47692302	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.717	rs73104143	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47693449	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs73104144	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47694390	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs73104148	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47696732	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs73104152	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47699091	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs73104155	ENSG00000257433.4	RP1-197B17.3	5.47	2.34e-07	0.000321	0.85	0.44	Pneumonia;	chr12:47700790	chr12:47706085~47742294:+
TGCT	cis	rs7246967	0.932	rs8101067	ENSG00000269509.1	BNIP3P34	5.47	2.35e-07	0.000322	0.78	0.44	Bronchopulmonary dysplasia;	chr19:22882375	chr19:22773853~22774424:+
TGCT	cis	rs977987	0.872	rs10781976	ENSG00000261783.1	RP11-252K23.2	-5.47	2.35e-07	0.000322	-0.69	-0.44	Dupuytren's disease;	chr16:75280940	chr16:75379818~75381260:-
TGCT	cis	rs2880765	0.566	rs11630381	ENSG00000259295.5	CSPG4P12	5.47	2.35e-07	0.000323	0.56	0.44	Coronary artery disease;	chr15:85469272	chr15:85191438~85213905:+
TGCT	cis	rs7044106	0.762	rs10760112	ENSG00000226752.6	PSMD5-AS1	-5.47	2.36e-07	0.000324	-0.57	-0.44	Hip circumference adjusted for BMI;	chr9:120705292	chr9:120824828~120854385:+
TGCT	cis	rs1528149	0.504	rs6943936	ENSG00000224683.1	RPL36AP29	-5.47	2.36e-07	0.000324	-0.49	-0.44	Sitting height ratio;	chr7:16128648	chr7:16208945~16209265:+
TGCT	cis	rs9584850	0.834	rs2031239	ENSG00000231194.1	FARP1-AS1	5.47	2.38e-07	0.000326	0.58	0.44	Neuroticism;	chr13:98459306	chr13:98435405~98435840:-
TGCT	cis	rs9462027	0.597	rs6940215	ENSG00000186328.4	RP11-140K17.2	5.47	2.38e-07	0.000326	0.46	0.44	Systemic lupus erythematosus;	chr6:34738581	chr6:34715613~34715940:+
TGCT	cis	rs875971	0.83	rs12673450	ENSG00000222364.1	RNU6-96P	-5.47	2.38e-07	0.000326	-0.49	-0.44	Aortic root size;	chr7:66544233	chr7:66395191~66395286:+
TGCT	cis	rs55794721	0.509	rs6699896	ENSG00000261349.1	RP3-465N24.5	-5.47	2.39e-07	0.000328	-0.44	-0.44	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25266102~25267136:-
TGCT	cis	rs3091242	0.933	rs35148262	ENSG00000261349.1	RP3-465N24.5	-5.47	2.39e-07	0.000328	-0.44	-0.44	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25266102~25267136:-
TGCT	cis	rs380904	1	rs380904	ENSG00000254859.1	RP11-661A12.5	-5.47	2.4e-07	0.000328	-0.64	-0.44	Venous thromboembolism (SNP x SNP interaction);	chr8:143483735	chr8:143541973~143549729:-
TGCT	cis	rs1153858	0.895	rs12593402	ENSG00000259520.4	CTD-2651B20.3	-5.47	2.41e-07	0.000329	-0.38	-0.44	Homoarginine levels;	chr15:45325194	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs12593370	ENSG00000259520.4	CTD-2651B20.3	-5.47	2.41e-07	0.000329	-0.38	-0.44	Homoarginine levels;	chr15:45325219	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs4775895	ENSG00000259520.4	CTD-2651B20.3	-5.47	2.41e-07	0.000329	-0.38	-0.44	Homoarginine levels;	chr15:45325759	chr15:45251580~45279251:-
TGCT	cis	rs17711722	0.565	rs4717276	ENSG00000164669.11	INTS4P1	-5.47	2.41e-07	0.000329	-0.43	-0.44	Calcium levels;	chr7:65829754	chr7:65141225~65234216:+
TGCT	cis	rs904251	0.6	rs4714068	ENSG00000279942.1	RP1-153P14.7	-5.47	2.41e-07	0.000329	-0.45	-0.44	Cognitive performance;	chr6:37487866	chr6:37567716~37571460:+
TGCT	cis	rs7849270	1	rs3124511	ENSG00000268707.1	RP11-247A12.7	5.47	2.41e-07	0.000329	0.5	0.44	Blood metabolite ratios;	chr9:129139179	chr9:129170434~129170940:+
TGCT	cis	rs9322193	0.887	rs3734295	ENSG00000216906.2	RP11-350J20.9	5.47	2.41e-07	0.00033	0.51	0.44	Lung cancer;	chr6:149593917	chr6:149904243~149906418:+
TGCT	cis	rs2177312	0.596	rs13108845	ENSG00000251129.1	RP11-734I18.1	-5.47	2.41e-07	0.00033	-0.51	-0.44	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31995660	chr4:31997397~32155406:+
TGCT	cis	rs4774565	0.762	rs17431150	ENSG00000244879.4	GABPB1-AS1	-5.47	2.41e-07	0.00033	-0.36	-0.44	Breast cancer;	chr15:50371385	chr15:50354959~50372202:+
TGCT	cis	rs4774565	0.762	rs17431171	ENSG00000244879.4	GABPB1-AS1	-5.47	2.41e-07	0.00033	-0.36	-0.44	Breast cancer;	chr15:50371424	chr15:50354959~50372202:+
TGCT	cis	rs4774565	0.762	rs720599	ENSG00000244879.4	GABPB1-AS1	-5.47	2.41e-07	0.00033	-0.36	-0.44	Breast cancer;	chr15:50372318	chr15:50354959~50372202:+
TGCT	cis	rs2882667	0.66	rs3088052	ENSG00000253404.1	AC034243.1	5.47	2.41e-07	0.00033	0.48	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121126	chr5:138744434~138753309:-
TGCT	cis	rs9322193	0.961	rs2064520	ENSG00000216906.2	RP11-350J20.9	5.47	2.43e-07	0.000332	0.49	0.44	Lung cancer;	chr6:149603650	chr6:149904243~149906418:+
TGCT	cis	rs17301013	0.507	rs72715224	ENSG00000227373.4	RP11-160H22.5	5.47	2.43e-07	0.000333	0.53	0.44	Systemic lupus erythematosus;	chr1:174534256	chr1:174115300~174160004:-
TGCT	cis	rs7849270	1	rs2254230	ENSG00000268707.1	RP11-247A12.7	5.46	2.43e-07	0.000333	0.5	0.44	Blood metabolite ratios;	chr9:129142898	chr9:129170434~129170940:+
TGCT	cis	rs9322193	0.884	rs7450246	ENSG00000216906.2	RP11-350J20.9	5.46	2.44e-07	0.000333	0.5	0.44	Lung cancer;	chr6:149702517	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9383812	ENSG00000216906.2	RP11-350J20.9	5.46	2.44e-07	0.000333	0.5	0.44	Lung cancer;	chr6:149712355	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.847	rs9383844	ENSG00000216906.2	RP11-350J20.9	5.46	2.44e-07	0.000333	0.5	0.44	Lung cancer;	chr6:149716268	chr6:149904243~149906418:+
TGCT	cis	rs1799949	1	rs8176202	ENSG00000198496.9	NBR2	-5.46	2.44e-07	0.000333	-0.64	-0.44	Menopause (age at onset);	chr17:43078211	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.93	rs8176194	ENSG00000198496.9	NBR2	-5.46	2.44e-07	0.000333	-0.64	-0.44	Menopause (age at onset);	chr17:43079204	chr17:43125610~43153671:+
TGCT	cis	rs7826238	0.564	rs2921053	ENSG00000173295.6	FAM86B3P	5.46	2.44e-07	0.000333	0.52	0.44	Systolic blood pressure;	chr8:8462453	chr8:8228595~8244865:+
TGCT	cis	rs2732480	0.5	rs2450986	ENSG00000258273.1	RP11-370I10.4	-5.46	2.44e-07	0.000333	-0.52	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48333755~48333901:-
TGCT	cis	rs1387259	0.929	rs2634666	ENSG00000258273.1	RP11-370I10.4	-5.46	2.44e-07	0.000333	-0.52	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48333755~48333901:-
TGCT	cis	rs1387259	0.929	rs2956703	ENSG00000258273.1	RP11-370I10.4	-5.46	2.44e-07	0.000333	-0.52	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48333755~48333901:-
TGCT	cis	rs1387259	0.931	rs1107654	ENSG00000258273.1	RP11-370I10.4	-5.46	2.44e-07	0.000333	-0.52	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48333755~48333901:-
TGCT	cis	rs1387259	0.859	rs2054905	ENSG00000258273.1	RP11-370I10.4	-5.46	2.44e-07	0.000333	-0.52	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48333755~48333901:-
TGCT	cis	rs2732480	0.5	rs2732461	ENSG00000258273.1	RP11-370I10.4	-5.46	2.44e-07	0.000333	-0.52	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48333755~48333901:-
TGCT	cis	rs950169	0.92	rs2135551	ENSG00000225151.9	GOLGA2P7	-5.46	2.45e-07	0.000334	-0.47	-0.44	Schizophrenia;	chr15:84039099	chr15:84199311~84230136:-
TGCT	cis	rs950169	1	rs12902672	ENSG00000225151.9	GOLGA2P7	-5.46	2.45e-07	0.000334	-0.47	-0.44	Schizophrenia;	chr15:84048234	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.922	rs11631096	ENSG00000225151.9	GOLGA2P7	-5.46	2.45e-07	0.000335	-0.52	-0.44	Schizophrenia;	chr15:84557698	chr15:84199311~84230136:-
TGCT	cis	rs17301013	0.896	rs332773	ENSG00000227373.4	RP11-160H22.5	5.46	2.46e-07	0.000336	0.46	0.44	Systemic lupus erythematosus;	chr1:174695711	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.932	rs332771	ENSG00000227373.4	RP11-160H22.5	5.46	2.46e-07	0.000336	0.46	0.44	Systemic lupus erythematosus;	chr1:174704141	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.932	rs444678	ENSG00000227373.4	RP11-160H22.5	5.46	2.46e-07	0.000336	0.46	0.44	Systemic lupus erythematosus;	chr1:174706080	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.896	rs332791	ENSG00000227373.4	RP11-160H22.5	5.46	2.46e-07	0.000336	0.46	0.44	Systemic lupus erythematosus;	chr1:174709784	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.861	rs332789	ENSG00000227373.4	RP11-160H22.5	5.46	2.46e-07	0.000336	0.46	0.44	Systemic lupus erythematosus;	chr1:174735754	chr1:174115300~174160004:-
TGCT	cis	rs7923609	0.841	rs10761786	ENSG00000232075.1	MRPL35P2	-5.46	2.46e-07	0.000336	-0.42	-0.44	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576447	chr10:63634317~63634827:-
TGCT	cis	rs3091242	0.967	rs3093614	ENSG00000261349.1	RP3-465N24.5	5.46	2.47e-07	0.000337	0.43	0.44	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25266102~25267136:-
TGCT	cis	rs2882667	0.638	rs6895690	ENSG00000253404.1	AC034243.1	5.46	2.48e-07	0.000338	0.47	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139130162	chr5:138744434~138753309:-
TGCT	cis	rs3091242	0.809	rs660129	ENSG00000224183.1	SDHDP6	-5.46	2.48e-07	0.000338	-0.47	-0.44	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25294164~25294643:-
TGCT	cis	rs3091242	0.728	rs706845	ENSG00000224183.1	SDHDP6	-5.46	2.48e-07	0.000338	-0.47	-0.44	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25294164~25294643:-
TGCT	cis	rs950169	0.92	rs12915390	ENSG00000225151.9	GOLGA2P7	-5.46	2.48e-07	0.000338	-0.48	-0.44	Schizophrenia;	chr15:84123317	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.959	rs12902070	ENSG00000225151.9	GOLGA2P7	-5.46	2.48e-07	0.000338	-0.48	-0.44	Schizophrenia;	chr15:84124806	chr15:84199311~84230136:-
TGCT	cis	rs1707322	0.686	rs2275085	ENSG00000280836.1	AL355480.1	5.46	2.48e-07	0.000338	0.61	0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr1:45581219~45581321:-
TGCT	cis	rs1799949	0.896	rs8176086	ENSG00000198496.9	NBR2	-5.46	2.48e-07	0.000338	-0.64	-0.44	Menopause (age at onset);	chr17:43122761	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.93	rs3765640	ENSG00000198496.9	NBR2	-5.46	2.48e-07	0.000338	-0.64	-0.44	Menopause (age at onset);	chr17:43124230	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs8176077	ENSG00000198496.9	NBR2	-5.46	2.48e-07	0.000338	-0.64	-0.44	Menopause (age at onset);	chr17:43124331	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs11655505	ENSG00000198496.9	NBR2	-5.46	2.48e-07	0.000338	-0.64	-0.44	Menopause (age at onset);	chr17:43126360	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.965	rs4793204	ENSG00000198496.9	NBR2	-5.46	2.48e-07	0.000338	-0.64	-0.44	Menopause (age at onset);	chr17:43127281	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.965	rs12947782	ENSG00000198496.9	NBR2	-5.46	2.48e-07	0.000338	-0.64	-0.44	Menopause (age at onset);	chr17:43127865	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs33945274	ENSG00000198496.9	NBR2	-5.46	2.48e-07	0.000338	-0.64	-0.44	Menopause (age at onset);	chr17:43128056	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.965	rs33925201	ENSG00000198496.9	NBR2	-5.46	2.48e-07	0.000338	-0.64	-0.44	Menopause (age at onset);	chr17:43128665	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs11653069	ENSG00000198496.9	NBR2	-5.46	2.48e-07	0.000338	-0.64	-0.44	Menopause (age at onset);	chr17:43131360	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.965	rs33988650	ENSG00000198496.9	NBR2	-5.46	2.48e-07	0.000338	-0.64	-0.44	Menopause (age at onset);	chr17:43135863	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs11656097	ENSG00000198496.9	NBR2	-5.46	2.48e-07	0.000338	-0.64	-0.44	Menopause (age at onset);	chr17:43138596	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs2292595	ENSG00000198496.9	NBR2	-5.46	2.48e-07	0.000338	-0.64	-0.44	Menopause (age at onset);	chr17:43138657	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs11658754	ENSG00000198496.9	NBR2	-5.46	2.48e-07	0.000338	-0.64	-0.44	Menopause (age at onset);	chr17:43140722	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.93	rs33968979	ENSG00000198496.9	NBR2	-5.46	2.48e-07	0.000338	-0.64	-0.44	Menopause (age at onset);	chr17:43145975	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs12952790	ENSG00000198496.9	NBR2	-5.46	2.48e-07	0.000338	-0.64	-0.44	Menopause (age at onset);	chr17:43147590	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs12950607	ENSG00000198496.9	NBR2	-5.46	2.48e-07	0.000338	-0.64	-0.44	Menopause (age at onset);	chr17:43147911	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs11079056	ENSG00000198496.9	NBR2	-5.46	2.48e-07	0.000338	-0.64	-0.44	Menopause (age at onset);	chr17:43148782	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs12936816	ENSG00000198496.9	NBR2	-5.46	2.48e-07	0.000338	-0.64	-0.44	Menopause (age at onset);	chr17:43149692	chr17:43125610~43153671:+
TGCT	cis	rs4835473	0.9	rs35311036	ENSG00000251600.4	RP11-673E1.1	-5.46	2.48e-07	0.000338	-0.43	-0.44	Immature fraction of reticulocytes;	chr4:143734397	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs35906127	ENSG00000251600.4	RP11-673E1.1	-5.46	2.48e-07	0.000338	-0.43	-0.44	Immature fraction of reticulocytes;	chr4:143734400	chr4:143912331~143982454:+
TGCT	cis	rs3091242	0.967	rs1053438	ENSG00000261349.1	RP3-465N24.5	5.46	2.5e-07	0.00034	0.43	0.44	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25266102~25267136:-
TGCT	cis	rs17301013	0.507	rs72715259	ENSG00000227373.4	RP11-160H22.5	5.46	2.5e-07	0.00034	0.54	0.44	Systemic lupus erythematosus;	chr1:174604590	chr1:174115300~174160004:-
TGCT	cis	rs76878669	0.561	rs7940980	ENSG00000254510.1	RP11-867G23.10	-5.46	2.5e-07	0.00034	-0.59	-0.44	Educational attainment (years of education);	chr11:66405439	chr11:66409158~66417137:+
TGCT	cis	rs875971	0.54	rs35510581	ENSG00000236529.1	RP13-254B10.1	-5.46	2.51e-07	0.000341	-0.34	-0.44	Aortic root size;	chr7:66113790	chr7:65840212~65840596:+
TGCT	cis	rs2524005	1	rs2524005	ENSG00000227766.1	HCG4P5	-5.46	2.53e-07	0.000343	-0.62	-0.44	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29942075~29943067:-
TGCT	cis	rs7617773	0.963	rs12494304	ENSG00000229759.1	MRPS18AP1	-5.46	2.53e-07	0.000343	-0.34	-0.44	Coronary artery disease;	chr3:48136539	chr3:48256350~48256938:-
TGCT	cis	rs2115630	0.645	rs3825877	ENSG00000225151.9	GOLGA2P7	5.46	2.53e-07	0.000343	0.45	0.44	P wave terminal force;	chr15:84631400	chr15:84199311~84230136:-
TGCT	cis	rs2115630	0.645	rs3825878	ENSG00000225151.9	GOLGA2P7	5.46	2.53e-07	0.000343	0.45	0.44	P wave terminal force;	chr15:84631524	chr15:84199311~84230136:-
TGCT	cis	rs34217772	1	rs12434724	ENSG00000258536.1	RP11-1053O12.1	-5.46	2.53e-07	0.000343	-0.37	-0.44	Myopia;	chr14:41801994	chr14:41742639~41742963:+
TGCT	cis	rs8072100	0.84	rs4968319	ENSG00000228782.6	CTD-2026D20.3	5.46	2.53e-07	0.000343	0.51	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47387601	chr17:47450568~47492492:-
TGCT	cis	rs12891047	0.899	rs8003431	ENSG00000258759.1	RP11-1012A1.7	-5.46	2.54e-07	0.000344	-0.42	-0.44	Amyotrophic lateral sclerosis (sporadic);	chr14:67821863	chr14:67799004~67799609:+
TGCT	cis	rs3091242	0.933	rs932372	ENSG00000224183.1	SDHDP6	-5.46	2.55e-07	0.000345	-0.46	-0.44	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25294164~25294643:-
TGCT	cis	rs6003958	1	rs6003958	ENSG00000218537.1	MIF-AS1	-5.45	2.55e-07	0.000345	-0.66	-0.44	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23894426~23898930:-
TGCT	cis	rs5760092	0.755	rs6003959	ENSG00000218537.1	MIF-AS1	-5.45	2.55e-07	0.000345	-0.66	-0.44	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23894426~23898930:-
TGCT	cis	rs3091242	0.867	rs602052	ENSG00000224183.1	SDHDP6	-5.45	2.56e-07	0.000346	-0.47	-0.44	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25294164~25294643:-
TGCT	cis	rs2739330	0.731	rs4822450	ENSG00000250470.1	AP000351.3	5.45	2.56e-07	0.000347	0.43	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23976904~23977585:-
TGCT	cis	rs2019137	0.56	rs7578633	ENSG00000189223.12	PAX8-AS1	-5.45	2.57e-07	0.000347	-0.59	-0.44	Lymphocyte counts;	chr2:113221073	chr2:113211522~113276581:+
TGCT	cis	rs2019137	0.539	rs11123170	ENSG00000189223.12	PAX8-AS1	-5.45	2.57e-07	0.000347	-0.59	-0.44	Lymphocyte counts;	chr2:113221363	chr2:113211522~113276581:+
TGCT	cis	rs3091242	1	rs646867	ENSG00000261349.1	RP3-465N24.5	-5.45	2.57e-07	0.000348	-0.43	-0.44	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25266102~25267136:-
TGCT	cis	rs9322193	0.923	rs55993747	ENSG00000216906.2	RP11-350J20.9	5.45	2.58e-07	0.000348	0.51	0.44	Lung cancer;	chr6:149622016	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.847	rs12191643	ENSG00000216906.2	RP11-350J20.9	5.45	2.58e-07	0.000348	0.51	0.44	Lung cancer;	chr6:149628912	chr6:149904243~149906418:+
TGCT	cis	rs3091242	0.933	rs12402120	ENSG00000224183.1	SDHDP6	-5.45	2.58e-07	0.000348	-0.46	-0.44	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25294164~25294643:-
TGCT	cis	rs9322193	0.923	rs12529698	ENSG00000216906.2	RP11-350J20.9	5.45	2.58e-07	0.000349	0.51	0.44	Lung cancer;	chr6:149650951	chr6:149904243~149906418:+
TGCT	cis	rs4927850	1	rs7614767	ENSG00000231464.1	AC024937.4	5.45	2.59e-07	0.00035	0.43	0.44	Pancreatic cancer;	chr3:196026580	chr3:195996738~195998233:+
TGCT	cis	rs12891047	1	rs2295108	ENSG00000258759.1	RP11-1012A1.7	5.45	2.59e-07	0.00035	0.37	0.44	Amyotrophic lateral sclerosis (sporadic);	chr14:67783905	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.934	rs10483805	ENSG00000258759.1	RP11-1012A1.7	5.45	2.59e-07	0.00035	0.37	0.44	Amyotrophic lateral sclerosis (sporadic);	chr14:67788934	chr14:67799004~67799609:+
TGCT	cis	rs7811142	0.83	rs118119933	ENSG00000242294.5	STAG3L5P	5.45	2.6e-07	0.00035	0.46	0.44	Platelet count;	chr7:100341427	chr7:100336079~100351900:+
TGCT	cis	rs5769707	0.681	rs4622843	ENSG00000235111.1	RP1-29C18.8	-5.45	2.6e-07	0.000351	-0.41	-0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49643268	chr22:49612657~49615716:-
TGCT	cis	rs17301013	0.861	rs333418	ENSG00000227373.4	RP11-160H22.5	5.45	2.6e-07	0.000351	0.47	0.44	Systemic lupus erythematosus;	chr1:174707294	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.828	rs332783	ENSG00000227373.4	RP11-160H22.5	5.45	2.6e-07	0.000351	0.47	0.44	Systemic lupus erythematosus;	chr1:174719260	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.861	rs170768	ENSG00000227373.4	RP11-160H22.5	5.45	2.6e-07	0.000351	0.47	0.44	Systemic lupus erythematosus;	chr1:174720787	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.861	rs332796	ENSG00000227373.4	RP11-160H22.5	5.45	2.6e-07	0.000351	0.47	0.44	Systemic lupus erythematosus;	chr1:174727142	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.861	rs332799	ENSG00000227373.4	RP11-160H22.5	5.45	2.6e-07	0.000351	0.47	0.44	Systemic lupus erythematosus;	chr1:174731110	chr1:174115300~174160004:-
TGCT	cis	rs8113308	0.81	rs8105110	ENSG00000269235.1	ZNF350-AS1	5.45	2.63e-07	0.000354	0.71	0.44	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51948863	chr19:51949134~51981367:+
TGCT	cis	rs7688540	0.511	rs75433628	ENSG00000275426.1	CH17-262A2.1	5.45	2.63e-07	0.000355	0.92	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:184563	chr4:149738~150317:+
TGCT	cis	rs9462027	1	rs6457796	ENSG00000186328.4	RP11-140K17.2	5.45	2.65e-07	0.000356	0.46	0.44	Systemic lupus erythematosus;	chr6:34860776	chr6:34715613~34715940:+
TGCT	cis	rs5769707	0.681	rs9616329	ENSG00000235111.1	RP1-29C18.8	-5.45	2.66e-07	0.000357	-0.41	-0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49632666	chr22:49612657~49615716:-
TGCT	cis	rs4835473	0.897	rs13145976	ENSG00000251600.4	RP11-673E1.1	-5.45	2.66e-07	0.000357	-0.43	-0.44	Immature fraction of reticulocytes;	chr4:143735710	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs13114071	ENSG00000251600.4	RP11-673E1.1	-5.45	2.66e-07	0.000357	-0.43	-0.44	Immature fraction of reticulocytes;	chr4:143735728	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs13140654	ENSG00000251600.4	RP11-673E1.1	-5.45	2.66e-07	0.000357	-0.43	-0.44	Immature fraction of reticulocytes;	chr4:143735733	chr4:143912331~143982454:+
TGCT	cis	rs7617773	0.817	rs9837228	ENSG00000229759.1	MRPS18AP1	-5.45	2.66e-07	0.000358	-0.38	-0.44	Coronary artery disease;	chr3:48282976	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.817	rs9818937	ENSG00000229759.1	MRPS18AP1	5.45	2.66e-07	0.000358	0.38	0.44	Coronary artery disease;	chr3:48283791	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.817	rs6801801	ENSG00000229759.1	MRPS18AP1	5.45	2.66e-07	0.000358	0.38	0.44	Coronary artery disease;	chr3:48284943	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.743	rs6804986	ENSG00000229759.1	MRPS18AP1	5.44	2.67e-07	0.000359	0.38	0.44	Coronary artery disease;	chr3:48322105	chr3:48256350~48256938:-
TGCT	cis	rs7829975	0.564	rs2976855	ENSG00000173295.6	FAM86B3P	5.44	2.67e-07	0.00036	0.5	0.44	Mood instability;	chr8:8444284	chr8:8228595~8244865:+
TGCT	cis	rs2739330	0.76	rs1002286	ENSG00000250470.1	AP000351.3	-5.44	2.68e-07	0.000361	-0.43	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23976904~23977585:-
TGCT	cis	rs9322193	0.923	rs9689716	ENSG00000216906.2	RP11-350J20.9	5.44	2.69e-07	0.000362	0.49	0.44	Lung cancer;	chr6:149655662	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9689723	ENSG00000216906.2	RP11-350J20.9	5.44	2.69e-07	0.000362	0.49	0.44	Lung cancer;	chr6:149655935	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9322207	ENSG00000216906.2	RP11-350J20.9	5.44	2.69e-07	0.000362	0.49	0.44	Lung cancer;	chr6:149657185	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9968911	ENSG00000216906.2	RP11-350J20.9	5.44	2.69e-07	0.000362	0.49	0.44	Lung cancer;	chr6:149657419	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9322208	ENSG00000216906.2	RP11-350J20.9	5.44	2.69e-07	0.000362	0.49	0.44	Lung cancer;	chr6:149658547	chr6:149904243~149906418:+
TGCT	cis	rs11723261	0.621	rs6599306	ENSG00000275426.1	CH17-262A2.1	-5.44	2.69e-07	0.000362	-0.87	-0.44	Immune response to smallpox vaccine (IL-6);	chr4:149655	chr4:149738~150317:+
TGCT	cis	rs17301013	0.507	rs16828481	ENSG00000227373.4	RP11-160H22.5	5.44	2.7e-07	0.000363	0.51	0.44	Systemic lupus erythematosus;	chr1:174415979	chr1:174115300~174160004:-
TGCT	cis	rs11723261	0.582	rs61792238	ENSG00000275426.1	CH17-262A2.1	5.44	2.71e-07	0.000363	0.9	0.44	Immune response to smallpox vaccine (IL-6);	chr4:112398	chr4:149738~150317:+
TGCT	cis	rs440932	0.717	rs330944	ENSG00000254340.1	RP11-10A14.3	5.44	2.71e-07	0.000364	0.46	0.44	High light scatter reticulocyte percentage of red cells;	chr8:9163783	chr8:9141424~9145435:+
TGCT	cis	rs950169	0.686	rs12906474	ENSG00000225151.9	GOLGA2P7	-5.44	2.71e-07	0.000364	-0.5	-0.44	Schizophrenia;	chr15:84566006	chr15:84199311~84230136:-
TGCT	cis	rs9595066	0.564	rs12869383	ENSG00000227258.4	SMIM2-AS1	-5.44	2.73e-07	0.000367	-0.51	-0.44	Schizophrenia;	chr13:44131305	chr13:44110451~44240517:+
TGCT	cis	rs1707322	0.686	rs1541131	ENSG00000280836.1	AL355480.1	5.44	2.74e-07	0.000367	0.6	0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45581219~45581321:-
TGCT	cis	rs11673344	0.502	rs62108306	ENSG00000226686.6	LINC01535	5.44	2.75e-07	0.000368	0.49	0.44	Obesity-related traits;	chr19:37691789	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.536	rs7259272	ENSG00000226686.6	LINC01535	5.44	2.75e-07	0.000368	0.49	0.44	Obesity-related traits;	chr19:37692214	chr19:37251912~37265535:+
TGCT	cis	rs17301013	0.507	rs1754352	ENSG00000227373.4	RP11-160H22.5	5.44	2.75e-07	0.000368	0.53	0.44	Systemic lupus erythematosus;	chr1:174835984	chr1:174115300~174160004:-
TGCT	cis	rs11651753	0.561	rs4794261	ENSG00000264920.1	RP11-6N17.4	-5.44	2.75e-07	0.000369	-0.42	-0.44	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47904980	chr17:47891255~47895812:-
TGCT	cis	rs11651753	0.561	rs1108833	ENSG00000264920.1	RP11-6N17.4	-5.44	2.75e-07	0.000369	-0.42	-0.44	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47905431	chr17:47891255~47895812:-
TGCT	cis	rs11651753	0.561	rs7211859	ENSG00000264920.1	RP11-6N17.4	-5.44	2.75e-07	0.000369	-0.42	-0.44	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47908916	chr17:47891255~47895812:-
TGCT	cis	rs11651753	0.598	rs4794286	ENSG00000264920.1	RP11-6N17.4	-5.44	2.75e-07	0.000369	-0.42	-0.44	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47913231	chr17:47891255~47895812:-
TGCT	cis	rs950169	0.881	rs72750843	ENSG00000225151.9	GOLGA2P7	-5.44	2.76e-07	0.00037	-0.49	-0.44	Schizophrenia;	chr15:84592552	chr15:84199311~84230136:-
TGCT	cis	rs17301013	0.507	rs116545832	ENSG00000227373.4	RP11-160H22.5	5.44	2.76e-07	0.00037	0.51	0.44	Systemic lupus erythematosus;	chr1:174438725	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs10912789	ENSG00000227373.4	RP11-160H22.5	5.44	2.76e-07	0.00037	0.51	0.44	Systemic lupus erythematosus;	chr1:174465616	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs6684141	ENSG00000227373.4	RP11-160H22.5	5.44	2.76e-07	0.00037	0.51	0.44	Systemic lupus erythematosus;	chr1:174467305	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12058377	ENSG00000227373.4	RP11-160H22.5	5.44	2.76e-07	0.00037	0.51	0.44	Systemic lupus erythematosus;	chr1:174470971	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs6656925	ENSG00000227373.4	RP11-160H22.5	5.44	2.76e-07	0.00037	0.51	0.44	Systemic lupus erythematosus;	chr1:174474161	chr1:174115300~174160004:-
TGCT	cis	rs1153858	1	rs9783731	ENSG00000259520.4	CTD-2651B20.3	5.44	2.76e-07	0.00037	0.38	0.44	Homoarginine levels;	chr15:45350686	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs7171577	ENSG00000259520.4	CTD-2651B20.3	-5.44	2.76e-07	0.00037	-0.38	-0.44	Homoarginine levels;	chr15:45335781	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs10519021	ENSG00000259520.4	CTD-2651B20.3	-5.44	2.76e-07	0.00037	-0.38	-0.44	Homoarginine levels;	chr15:45339597	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs16942000	ENSG00000259520.4	CTD-2651B20.3	-5.44	2.76e-07	0.00037	-0.38	-0.44	Homoarginine levels;	chr15:45340805	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs56850226	ENSG00000259520.4	CTD-2651B20.3	-5.44	2.76e-07	0.00037	-0.38	-0.44	Homoarginine levels;	chr15:45340920	chr15:45251580~45279251:-
TGCT	cis	rs1153858	0.945	rs7182300	ENSG00000259520.4	CTD-2651B20.3	-5.44	2.76e-07	0.00037	-0.38	-0.44	Homoarginine levels;	chr15:45342730	chr15:45251580~45279251:-
TGCT	cis	rs1153858	0.887	rs7171163	ENSG00000259520.4	CTD-2651B20.3	-5.44	2.76e-07	0.00037	-0.38	-0.44	Homoarginine levels;	chr15:45344197	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs56669689	ENSG00000259520.4	CTD-2651B20.3	-5.44	2.76e-07	0.00037	-0.38	-0.44	Homoarginine levels;	chr15:45345531	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs56806728	ENSG00000259520.4	CTD-2651B20.3	-5.44	2.76e-07	0.00037	-0.38	-0.44	Homoarginine levels;	chr15:45345616	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs4775906	ENSG00000259520.4	CTD-2651B20.3	-5.44	2.76e-07	0.00037	-0.38	-0.44	Homoarginine levels;	chr15:45346096	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs7179743	ENSG00000259520.4	CTD-2651B20.3	-5.44	2.76e-07	0.00037	-0.38	-0.44	Homoarginine levels;	chr15:45346133	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs4775907	ENSG00000259520.4	CTD-2651B20.3	-5.44	2.76e-07	0.00037	-0.38	-0.44	Homoarginine levels;	chr15:45346449	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs7163720	ENSG00000259520.4	CTD-2651B20.3	-5.44	2.76e-07	0.00037	-0.38	-0.44	Homoarginine levels;	chr15:45347176	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs7167900	ENSG00000259520.4	CTD-2651B20.3	-5.44	2.76e-07	0.00037	-0.38	-0.44	Homoarginine levels;	chr15:45347273	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs12591058	ENSG00000259520.4	CTD-2651B20.3	-5.44	2.76e-07	0.00037	-0.38	-0.44	Homoarginine levels;	chr15:45347974	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs7169587	ENSG00000259520.4	CTD-2651B20.3	-5.44	2.76e-07	0.00037	-0.38	-0.44	Homoarginine levels;	chr15:45348181	chr15:45251580~45279251:-
TGCT	cis	rs1153858	0.943	rs28605551	ENSG00000259520.4	CTD-2651B20.3	-5.44	2.76e-07	0.00037	-0.38	-0.44	Homoarginine levels;	chr15:45349522	chr15:45251580~45279251:-
TGCT	cis	rs7829975	0.54	rs2976909	ENSG00000173295.6	FAM86B3P	-5.44	2.76e-07	0.00037	-0.48	-0.44	Mood instability;	chr8:8489180	chr8:8228595~8244865:+
TGCT	cis	rs7849270	1	rs2768630	ENSG00000268707.1	RP11-247A12.7	5.44	2.77e-07	0.000371	0.5	0.44	Blood metabolite ratios;	chr9:129104109	chr9:129170434~129170940:+
TGCT	cis	rs7849270	1	rs1977447	ENSG00000268707.1	RP11-247A12.7	5.44	2.77e-07	0.000371	0.5	0.44	Blood metabolite ratios;	chr9:129105917	chr9:129170434~129170940:+
TGCT	cis	rs7849270	1	rs3118625	ENSG00000268707.1	RP11-247A12.7	5.44	2.77e-07	0.000371	0.5	0.44	Blood metabolite ratios;	chr9:129110977	chr9:129170434~129170940:+
TGCT	cis	rs7811142	1	rs2897358	ENSG00000242294.5	STAG3L5P	5.44	2.78e-07	0.000371	0.41	0.44	Platelet count;	chr7:100491017	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs60478351	ENSG00000242294.5	STAG3L5P	5.44	2.78e-07	0.000371	0.41	0.44	Platelet count;	chr7:100491394	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs7787620	ENSG00000242294.5	STAG3L5P	5.44	2.78e-07	0.000371	0.41	0.44	Platelet count;	chr7:100491611	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs11769700	ENSG00000242294.5	STAG3L5P	5.44	2.78e-07	0.000371	0.41	0.44	Platelet count;	chr7:100492426	chr7:100336079~100351900:+
TGCT	cis	rs7849270	1	rs9697030	ENSG00000268707.1	RP11-247A12.7	-5.44	2.78e-07	0.000372	-0.48	-0.44	Blood metabolite ratios;	chr9:129157902	chr9:129170434~129170940:+
TGCT	cis	rs8072100	0.539	rs36043200	ENSG00000228782.6	CTD-2026D20.3	-5.44	2.78e-07	0.000372	-0.52	-0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47552040	chr17:47450568~47492492:-
TGCT	cis	rs7617773	0.78	rs13084616	ENSG00000229759.1	MRPS18AP1	-5.44	2.79e-07	0.000373	-0.38	-0.44	Coronary artery disease;	chr3:48298209	chr3:48256350~48256938:-
TGCT	cis	rs453301	0.653	rs1045529	ENSG00000173295.6	FAM86B3P	-5.44	2.79e-07	0.000373	-0.52	-0.44	Joint mobility (Beighton score);	chr8:9032588	chr8:8228595~8244865:+
TGCT	cis	rs2739330	0.652	rs2000469	ENSG00000272787.1	KB-226F1.2	-5.43	2.81e-07	0.000375	-0.53	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23969211~23969873:+
TGCT	cis	rs786425	0.677	rs10846537	ENSG00000278112.1	RP11-972P1.11	5.43	2.81e-07	0.000376	0.51	0.44	Pubertal anthropometrics;	chr12:123653799	chr12:123519390~123519856:-
TGCT	cis	rs1153858	1	rs66528868	ENSG00000259520.4	CTD-2651B20.3	-5.43	2.82e-07	0.000377	-0.38	-0.44	Homoarginine levels;	chr15:45376349	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs7494956	ENSG00000259520.4	CTD-2651B20.3	-5.43	2.82e-07	0.000377	-0.38	-0.44	Homoarginine levels;	chr15:45376367	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs12437840	ENSG00000259520.4	CTD-2651B20.3	-5.43	2.82e-07	0.000377	-0.38	-0.44	Homoarginine levels;	chr15:45376857	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs12437887	ENSG00000259520.4	CTD-2651B20.3	-5.43	2.82e-07	0.000377	-0.38	-0.44	Homoarginine levels;	chr15:45376896	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs2114501	ENSG00000259520.4	CTD-2651B20.3	-5.43	2.82e-07	0.000377	-0.38	-0.44	Homoarginine levels;	chr15:45378118	chr15:45251580~45279251:-
TGCT	cis	rs1153858	0.887	rs7164139	ENSG00000259520.4	CTD-2651B20.3	-5.43	2.82e-07	0.000377	-0.38	-0.44	Homoarginine levels;	chr15:45378653	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs67461176	ENSG00000259520.4	CTD-2651B20.3	-5.43	2.82e-07	0.000377	-0.38	-0.44	Homoarginine levels;	chr15:45384621	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs66939267	ENSG00000259520.4	CTD-2651B20.3	-5.43	2.82e-07	0.000377	-0.38	-0.44	Homoarginine levels;	chr15:45384704	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs4775937	ENSG00000259520.4	CTD-2651B20.3	-5.43	2.82e-07	0.000377	-0.38	-0.44	Homoarginine levels;	chr15:45386416	chr15:45251580~45279251:-
TGCT	cis	rs4927850	0.723	rs7630825	ENSG00000207650.1	MIR570	5.43	2.82e-07	0.000377	0.56	0.44	Pancreatic cancer;	chr3:196026869	chr3:195699401~195699497:+
TGCT	cis	rs11098499	0.739	rs6534130	ENSG00000245958.5	RP11-33B1.1	5.43	2.82e-07	0.000377	0.45	0.44	Corneal astigmatism;	chr4:119210184	chr4:119454791~119552025:+
TGCT	cis	rs7849270	0.921	rs7868476	ENSG00000268707.1	RP11-247A12.7	-5.43	2.83e-07	0.000378	-0.48	-0.44	Blood metabolite ratios;	chr9:129155854	chr9:129170434~129170940:+
TGCT	cis	rs7849270	0.959	rs2094704	ENSG00000268707.1	RP11-247A12.7	-5.43	2.83e-07	0.000378	-0.48	-0.44	Blood metabolite ratios;	chr9:129156015	chr9:129170434~129170940:+
TGCT	cis	rs55794721	0.509	rs11249248	ENSG00000261349.1	RP3-465N24.5	-5.43	2.84e-07	0.000379	-0.43	-0.44	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25266102~25267136:-
TGCT	cis	rs3091242	0.933	rs909833	ENSG00000261349.1	RP3-465N24.5	-5.43	2.84e-07	0.000379	-0.43	-0.44	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25266102~25267136:-
TGCT	cis	rs2739330	0.76	rs5760095	ENSG00000272787.1	KB-226F1.2	-5.43	2.84e-07	0.000379	-0.47	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23969211~23969873:+
TGCT	cis	rs4835473	0.897	rs35598237	ENSG00000251600.4	RP11-673E1.1	-5.43	2.85e-07	0.00038	-0.43	-0.44	Immature fraction of reticulocytes;	chr4:143735961	chr4:143912331~143982454:+
TGCT	cis	rs2882667	0.505	rs7721110	ENSG00000253404.1	AC034243.1	5.43	2.86e-07	0.000381	0.49	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139146817	chr5:138744434~138753309:-
TGCT	cis	rs73086581	1	rs17287822	ENSG00000229539.1	RP11-119B16.2	5.43	2.86e-07	0.000382	0.65	0.44	Response to antidepressants in depression;	chr20:3997889	chr20:3888239~3888868:-
TGCT	cis	rs17301013	0.932	rs6425282	ENSG00000227373.4	RP11-160H22.5	5.43	2.87e-07	0.000383	0.46	0.44	Systemic lupus erythematosus;	chr1:174493387	chr1:174115300~174160004:-
TGCT	cis	rs950169	0.922	rs11638445	ENSG00000225151.9	GOLGA2P7	-5.43	2.87e-07	0.000383	-0.49	-0.44	Schizophrenia;	chr15:84594463	chr15:84199311~84230136:-
TGCT	cis	rs801193	1	rs2659909	ENSG00000222364.1	RNU6-96P	-5.43	2.87e-07	0.000383	-0.51	-0.44	Aortic root size;	chr7:66695292	chr7:66395191~66395286:+
TGCT	cis	rs11098499	0.874	rs28452522	ENSG00000245958.5	RP11-33B1.1	-5.43	2.88e-07	0.000384	-0.45	-0.44	Corneal astigmatism;	chr4:119189629	chr4:119454791~119552025:+
TGCT	cis	rs172166	0.694	rs203884	ENSG00000216901.1	AL022393.7	5.43	2.89e-07	0.000385	0.54	0.44	Cardiac Troponin-T levels;	chr6:28109596	chr6:28176188~28176674:+
TGCT	cis	rs1799949	0.965	rs8176193	ENSG00000198496.9	NBR2	-5.43	2.89e-07	0.000386	-0.64	-0.44	Menopause (age at onset);	chr17:43079499	chr17:43125610~43153671:+
TGCT	cis	rs34779708	0.868	rs2384352	ENSG00000230534.5	RP11-297A16.2	5.43	2.9e-07	0.000387	0.52	0.44	Inflammatory bowel disease;Crohn's disease;	chr10:35203904	chr10:35098006~35127020:-
TGCT	cis	rs12891047	1	rs11158693	ENSG00000258759.1	RP11-1012A1.7	-5.43	2.91e-07	0.000388	-0.37	-0.44	Amyotrophic lateral sclerosis (sporadic);	chr14:67774544	chr14:67799004~67799609:+
TGCT	cis	rs5760092	0.618	rs5996631	ENSG00000225282.1	AP000350.6	-5.43	2.91e-07	0.000388	-0.58	-0.44	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23926900~23929574:+
TGCT	cis	rs3091242	0.933	rs4649084	ENSG00000261349.1	RP3-465N24.5	-5.42	2.92e-07	0.000389	-0.43	-0.44	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25266102~25267136:-
TGCT	cis	rs17301013	0.507	rs3920486	ENSG00000227373.4	RP11-160H22.5	5.42	2.92e-07	0.000389	0.52	0.44	Systemic lupus erythematosus;	chr1:174567714	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12079118	ENSG00000227373.4	RP11-160H22.5	5.42	2.92e-07	0.000389	0.52	0.44	Systemic lupus erythematosus;	chr1:174568885	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs7414200	ENSG00000227373.4	RP11-160H22.5	5.42	2.92e-07	0.000389	0.52	0.44	Systemic lupus erythematosus;	chr1:174569820	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12079879	ENSG00000227373.4	RP11-160H22.5	5.42	2.92e-07	0.000389	0.52	0.44	Systemic lupus erythematosus;	chr1:174571877	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs2092084	ENSG00000227373.4	RP11-160H22.5	5.42	2.92e-07	0.000389	0.52	0.44	Systemic lupus erythematosus;	chr1:174581547	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs10489264	ENSG00000227373.4	RP11-160H22.5	5.42	2.92e-07	0.000389	0.52	0.44	Systemic lupus erythematosus;	chr1:174584310	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12082012	ENSG00000227373.4	RP11-160H22.5	5.42	2.92e-07	0.000389	0.52	0.44	Systemic lupus erythematosus;	chr1:174588729	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12085652	ENSG00000227373.4	RP11-160H22.5	5.42	2.92e-07	0.000389	0.52	0.44	Systemic lupus erythematosus;	chr1:174588864	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs4451598	ENSG00000227373.4	RP11-160H22.5	5.42	2.92e-07	0.000389	0.52	0.44	Systemic lupus erythematosus;	chr1:174606576	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs10912817	ENSG00000227373.4	RP11-160H22.5	5.42	2.92e-07	0.000389	0.52	0.44	Systemic lupus erythematosus;	chr1:174615581	chr1:174115300~174160004:-
TGCT	cis	rs875971	0.54	rs736270	ENSG00000236529.1	RP13-254B10.1	5.42	2.92e-07	0.000389	0.33	0.44	Aortic root size;	chr7:65963835	chr7:65840212~65840596:+
TGCT	cis	rs9322193	0.887	rs11155662	ENSG00000216906.2	RP11-350J20.9	5.42	2.94e-07	0.000392	0.51	0.44	Lung cancer;	chr6:149592731	chr6:149904243~149906418:+
TGCT	cis	rs453301	0.571	rs2929456	ENSG00000173295.6	FAM86B3P	-5.42	2.94e-07	0.000392	-0.49	-0.44	Joint mobility (Beighton score);	chr8:9225906	chr8:8228595~8244865:+
TGCT	cis	rs453301	0.571	rs2929454	ENSG00000173295.6	FAM86B3P	-5.42	2.94e-07	0.000392	-0.49	-0.44	Joint mobility (Beighton score);	chr8:9226344	chr8:8228595~8244865:+
TGCT	cis	rs453301	0.571	rs2929452	ENSG00000173295.6	FAM86B3P	-5.42	2.94e-07	0.000392	-0.49	-0.44	Joint mobility (Beighton score);	chr8:9226955	chr8:8228595~8244865:+
TGCT	cis	rs453301	0.571	rs2929305	ENSG00000173295.6	FAM86B3P	-5.42	2.94e-07	0.000392	-0.49	-0.44	Joint mobility (Beighton score);	chr8:9227707	chr8:8228595~8244865:+
TGCT	cis	rs7208859	0.623	rs7220289	ENSG00000263531.1	RP13-753N3.1	5.42	2.95e-07	0.000392	0.83	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30863921~30864940:-
TGCT	cis	rs66887589	0.592	rs11731571	ENSG00000245958.5	RP11-33B1.1	-5.42	2.95e-07	0.000392	-0.42	-0.44	Diastolic blood pressure;	chr4:119300030	chr4:119454791~119552025:+
TGCT	cis	rs7621025	0.5	rs71630059	ENSG00000239213.4	NCK1-AS1	-5.42	2.95e-07	0.000393	-0.49	-0.44	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136862769	chr3:136841726~136862054:-
TGCT	cis	rs7811142	1	rs6953107	ENSG00000242294.5	STAG3L5P	5.42	2.95e-07	0.000393	0.41	0.44	Platelet count;	chr7:100498041	chr7:100336079~100351900:+
TGCT	cis	rs453301	0.538	rs7830804	ENSG00000254340.1	RP11-10A14.3	-5.42	2.96e-07	0.000394	-0.47	-0.44	Joint mobility (Beighton score);	chr8:9113252	chr8:9141424~9145435:+
TGCT	cis	rs3091242	0.933	rs9438904	ENSG00000261349.1	RP3-465N24.5	-5.42	2.97e-07	0.000395	-0.43	-0.44	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25266102~25267136:-
TGCT	cis	rs4927850	0.521	rs4927679	ENSG00000242086.7	LINC00969	-5.42	2.97e-07	0.000395	-0.49	-0.44	Pancreatic cancer;	chr3:195931489	chr3:195658062~195739964:+
TGCT	cis	rs801193	1	rs17566701	ENSG00000222364.1	RNU6-96P	-5.42	2.97e-07	0.000395	-0.51	-0.44	Aortic root size;	chr7:66728196	chr7:66395191~66395286:+
TGCT	cis	rs507080	0.733	rs4393358	ENSG00000255422.1	AP002954.4	-5.42	2.98e-07	0.000396	-0.52	-0.44	Serum metabolite levels;	chr11:118698388	chr11:118704607~118750263:+
TGCT	cis	rs7044106	0.762	rs966396	ENSG00000226752.6	PSMD5-AS1	-5.42	2.98e-07	0.000396	-0.56	-0.44	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120824828~120854385:+
TGCT	cis	rs7044106	0.762	rs7044226	ENSG00000226752.6	PSMD5-AS1	-5.42	2.98e-07	0.000396	-0.56	-0.44	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120824828~120854385:+
TGCT	cis	rs76878669	0.917	rs3116068	ENSG00000254510.1	RP11-867G23.10	-5.42	2.98e-07	0.000396	-0.66	-0.44	Educational attainment (years of education);	chr11:66337522	chr11:66409158~66417137:+
TGCT	cis	rs7617773	0.78	rs13090538	ENSG00000229759.1	MRPS18AP1	5.42	2.99e-07	0.000397	0.37	0.44	Coronary artery disease;	chr3:48329279	chr3:48256350~48256938:-
TGCT	cis	rs9322193	0.923	rs62439840	ENSG00000216906.2	RP11-350J20.9	5.42	2.99e-07	0.000398	0.51	0.44	Lung cancer;	chr6:149674639	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs9393175	ENSG00000216906.2	RP11-350J20.9	5.42	2.99e-07	0.000398	0.51	0.44	Lung cancer;	chr6:149677587	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs4870509	ENSG00000216906.2	RP11-350J20.9	5.42	2.99e-07	0.000398	0.51	0.44	Lung cancer;	chr6:149702212	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9322214	ENSG00000216906.2	RP11-350J20.9	5.42	2.99e-07	0.000398	0.51	0.44	Lung cancer;	chr6:149703986	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.887	rs9767113	ENSG00000216906.2	RP11-350J20.9	5.42	2.99e-07	0.000398	0.51	0.44	Lung cancer;	chr6:149718157	chr6:149904243~149906418:+
TGCT	cis	rs2919917	0.915	rs10957897	ENSG00000254352.1	RP11-578O24.2	5.42	3e-07	0.000398	0.5	0.44	Lymphocyte counts;	chr8:78695658	chr8:78723796~78724136:-
TGCT	cis	rs4835473	0.932	rs12509642	ENSG00000251600.4	RP11-673E1.1	-5.42	3e-07	0.000398	-0.43	-0.44	Immature fraction of reticulocytes;	chr4:143737080	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs5015759	ENSG00000251600.4	RP11-673E1.1	-5.42	3e-07	0.000398	-0.43	-0.44	Immature fraction of reticulocytes;	chr4:143738050	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs5015758	ENSG00000251600.4	RP11-673E1.1	-5.42	3e-07	0.000398	-0.43	-0.44	Immature fraction of reticulocytes;	chr4:143738052	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs34569841	ENSG00000251600.4	RP11-673E1.1	-5.42	3e-07	0.000398	-0.43	-0.44	Immature fraction of reticulocytes;	chr4:143738060	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs34950821	ENSG00000251600.4	RP11-673E1.1	-5.42	3e-07	0.000398	-0.43	-0.44	Immature fraction of reticulocytes;	chr4:143738174	chr4:143912331~143982454:+
TGCT	cis	rs9322193	0.884	rs7769115	ENSG00000216906.2	RP11-350J20.9	5.42	3.01e-07	4e-04	0.51	0.44	Lung cancer;	chr6:149848796	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.884	rs7743823	ENSG00000216906.2	RP11-350J20.9	5.42	3.01e-07	4e-04	0.51	0.44	Lung cancer;	chr6:149849744	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.884	rs9383865	ENSG00000216906.2	RP11-350J20.9	5.42	3.01e-07	4e-04	0.51	0.44	Lung cancer;	chr6:149852043	chr6:149904243~149906418:+
TGCT	cis	rs36052053	0.908	rs932222	ENSG00000219700.1	PTCHD3P3	-5.42	3.03e-07	0.000401	-0.7	-0.44	Red cell distribution width;	chr6:109265475	chr6:109288571~109290503:-
TGCT	cis	rs8072100	0.84	rs9893901	ENSG00000228782.6	CTD-2026D20.3	5.42	3.03e-07	0.000402	0.54	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47429316	chr17:47450568~47492492:-
TGCT	cis	rs4774565	0.762	rs1056682	ENSG00000244879.4	GABPB1-AS1	-5.42	3.03e-07	0.000402	-0.36	-0.44	Breast cancer;	chr15:50368004	chr15:50354959~50372202:+
TGCT	cis	rs4774565	0.762	rs17431095	ENSG00000244879.4	GABPB1-AS1	-5.42	3.03e-07	0.000402	-0.36	-0.44	Breast cancer;	chr15:50369252	chr15:50354959~50372202:+
TGCT	cis	rs9322193	0.923	rs11155671	ENSG00000216906.2	RP11-350J20.9	5.42	3.04e-07	0.000404	0.5	0.44	Lung cancer;	chr6:149650996	chr6:149904243~149906418:+
TGCT	cis	rs11992186	0.505	rs7845203	ENSG00000173295.6	FAM86B3P	5.42	3.05e-07	0.000405	0.52	0.44	Neuroticism;	chr8:8287918	chr8:8228595~8244865:+
TGCT	cis	rs2976388	0.507	rs7813604	ENSG00000253196.1	RP11-706C16.7	5.41	3.06e-07	0.000405	0.44	0.44	Urinary tract infection frequency;	chr8:142756644	chr8:142763116~142766427:+
TGCT	cis	rs9549367	0.577	rs3024713	ENSG00000269125.1	RP11-98F14.11	-5.41	3.06e-07	0.000405	-0.57	-0.44	Platelet distribution width;	chr13:113159007	chr13:113165002~113165183:-
TGCT	cis	rs8072100	0.875	rs4794047	ENSG00000228782.6	CTD-2026D20.3	-5.41	3.07e-07	0.000406	-0.54	-0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685639	chr17:47450568~47492492:-
TGCT	cis	rs7923609	0.871	rs10761787	ENSG00000232075.1	MRPL35P2	-5.41	3.07e-07	0.000407	-0.42	-0.44	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63593995	chr10:63634317~63634827:-
TGCT	cis	rs507080	0.922	rs533646	ENSG00000255422.1	AP002954.4	-5.41	3.09e-07	0.000409	-0.52	-0.44	Serum metabolite levels;	chr11:118696037	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.922	rs642662	ENSG00000255422.1	AP002954.4	-5.41	3.09e-07	0.000409	-0.52	-0.44	Serum metabolite levels;	chr11:118696311	chr11:118704607~118750263:+
TGCT	cis	rs801193	1	rs2420824	ENSG00000222364.1	RNU6-96P	5.41	3.11e-07	0.000411	0.51	0.44	Aortic root size;	chr7:66666129	chr7:66395191~66395286:+
TGCT	cis	rs7208859	0.623	rs1054400	ENSG00000263531.1	RP13-753N3.1	5.41	3.11e-07	0.000412	0.82	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30863921~30864940:-
TGCT	cis	rs748404	0.534	rs489509	ENSG00000205771.5	CATSPER2P1	-5.41	3.12e-07	0.000413	-0.5	-0.44	Lung cancer;	chr15:43294709	chr15:43726918~43747094:-
TGCT	cis	rs1823913	1	rs12623832	ENSG00000227542.1	AC092614.2	-5.41	3.12e-07	0.000413	-0.46	-0.44	Obesity-related traits;	chr2:191260918	chr2:191229165~191246172:-
TGCT	cis	rs453301	0.653	rs7853	ENSG00000173295.6	FAM86B3P	5.41	3.13e-07	0.000414	0.52	0.44	Joint mobility (Beighton score);	chr8:9033304	chr8:8228595~8244865:+
TGCT	cis	rs36052053	0.521	rs13219673	ENSG00000219700.1	PTCHD3P3	5.41	3.13e-07	0.000415	0.91	0.44	Red cell distribution width;	chr6:109233713	chr6:109288571~109290503:-
TGCT	cis	rs7044106	0.762	rs7024046	ENSG00000226752.6	PSMD5-AS1	-5.41	3.14e-07	0.000416	-0.56	-0.44	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120824828~120854385:+
TGCT	cis	rs7044106	0.762	rs1530370	ENSG00000226752.6	PSMD5-AS1	-5.41	3.14e-07	0.000416	-0.56	-0.44	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120824828~120854385:+
TGCT	cis	rs7044106	0.762	rs4837789	ENSG00000226752.6	PSMD5-AS1	-5.41	3.14e-07	0.000416	-0.56	-0.44	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120824828~120854385:+
TGCT	cis	rs7044106	0.762	rs1867254	ENSG00000226752.6	PSMD5-AS1	-5.41	3.14e-07	0.000416	-0.56	-0.44	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120824828~120854385:+
TGCT	cis	rs2732480	0.538	rs2732462	ENSG00000258273.1	RP11-370I10.4	-5.41	3.14e-07	0.000416	-0.51	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48333755~48333901:-
TGCT	cis	rs6061231	1	rs67941642	ENSG00000273619.1	RP5-908M14.9	-5.41	3.14e-07	0.000416	-0.47	-0.44	Colorectal cancer;	chr20:62383052	chr20:62386303~62386970:-
TGCT	cis	rs367615	0.537	rs10463600	ENSG00000249476.1	CTD-2587M2.1	5.41	3.15e-07	0.000416	0.46	0.44	Colorectal cancer (SNP x SNP interaction);	chr5:109327935	chr5:109237120~109326369:-
TGCT	cis	rs4835473	0.801	rs76574827	ENSG00000251600.4	RP11-673E1.1	-5.41	3.15e-07	0.000417	-0.43	-0.44	Immature fraction of reticulocytes;	chr4:143737303	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.832	rs62337616	ENSG00000251600.4	RP11-673E1.1	-5.41	3.15e-07	0.000417	-0.43	-0.44	Immature fraction of reticulocytes;	chr4:143737307	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.832	rs66717029	ENSG00000251600.4	RP11-673E1.1	-5.41	3.15e-07	0.000417	-0.43	-0.44	Immature fraction of reticulocytes;	chr4:143737318	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.864	rs17750354	ENSG00000251600.4	RP11-673E1.1	-5.41	3.15e-07	0.000417	-0.43	-0.44	Immature fraction of reticulocytes;	chr4:143737352	chr4:143912331~143982454:+
TGCT	cis	rs2276314	1	rs1789513	ENSG00000278986.1	RP11-723J4.3	5.41	3.16e-07	0.000418	0.47	0.44	Endometriosis;Drug-induced torsades de pointes;	chr18:35965667	chr18:35972151~35973916:+
TGCT	cis	rs17301013	0.507	rs969472	ENSG00000227373.4	RP11-160H22.5	5.41	3.17e-07	0.000419	0.51	0.44	Systemic lupus erythematosus;	chr1:174458562	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs10798314	ENSG00000227373.4	RP11-160H22.5	5.41	3.17e-07	0.000419	0.51	0.44	Systemic lupus erythematosus;	chr1:174458958	chr1:174115300~174160004:-
TGCT	cis	rs801193	1	rs2055682	ENSG00000222364.1	RNU6-96P	-5.41	3.17e-07	0.000419	-0.51	-0.44	Aortic root size;	chr7:66795302	chr7:66395191~66395286:+
TGCT	cis	rs9322193	0.504	rs7771014	ENSG00000216906.2	RP11-350J20.9	5.41	3.19e-07	0.000421	0.48	0.44	Lung cancer;	chr6:149884310	chr6:149904243~149906418:+
TGCT	cis	rs524281	0.692	rs10791845	ENSG00000255320.1	RP11-755F10.1	-5.4	3.19e-07	0.000422	-0.52	-0.44	Electroencephalogram traits;	chr11:66066869	chr11:66244840~66246239:-
TGCT	cis	rs17301013	0.861	rs7521870	ENSG00000227373.4	RP11-160H22.5	-5.4	3.19e-07	0.000422	-0.47	-0.44	Systemic lupus erythematosus;	chr1:174497239	chr1:174115300~174160004:-
TGCT	cis	rs34217772	0.83	rs36024104	ENSG00000258536.1	RP11-1053O12.1	5.4	3.2e-07	0.000422	0.38	0.44	Myopia;	chr14:41825790	chr14:41742639~41742963:+
TGCT	cis	rs4835473	0.932	rs13135034	ENSG00000251600.4	RP11-673E1.1	5.4	3.21e-07	0.000423	0.43	0.44	Immature fraction of reticulocytes;	chr4:143738247	chr4:143912331~143982454:+
TGCT	cis	rs12935418	0.733	rs12448615	ENSG00000261061.1	RP11-303E16.2	-5.4	3.21e-07	0.000423	-0.68	-0.44	Mean corpuscular volume;	chr16:80947132	chr16:81030770~81031485:+
TGCT	cis	rs7208859	0.623	rs1054397	ENSG00000263531.1	RP13-753N3.1	5.4	3.22e-07	0.000424	0.82	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30863921~30864940:-
TGCT	cis	rs17711722	0.522	rs6957759	ENSG00000164669.11	INTS4P1	-5.4	3.22e-07	0.000424	-0.43	-0.44	Calcium levels;	chr7:65806798	chr7:65141225~65234216:+
TGCT	cis	rs17361889	0.514	rs10251171	ENSG00000224683.1	RPL36AP29	5.4	3.25e-07	0.000428	0.58	0.44	Pediatric bone mineral content (hip);	chr7:16353495	chr7:16208945~16209265:+
TGCT	cis	rs1061377	1	rs12499266	ENSG00000249207.1	RP11-360F5.1	5.4	3.25e-07	0.000429	0.45	0.44	Uric acid levels;	chr4:39118133	chr4:39112677~39126818:-
TGCT	cis	rs7301826	0.934	rs10773826	ENSG00000256250.1	RP11-989F5.1	-5.4	3.25e-07	0.000429	-0.48	-0.44	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810606~130812438:+
TGCT	cis	rs2283792	0.764	rs2298432	ENSG00000228050.1	TOP3BP1	5.4	3.25e-07	0.000429	0.53	0.44	Multiple sclerosis;	chr22:21768900	chr22:22223187~22224566:-
TGCT	cis	rs7605378	0.528	rs7592587	ENSG00000232732.8	AC073043.1	-5.4	3.26e-07	0.00043	-0.49	-0.44	Osteoporosis;	chr2:199921793	chr2:199867396~199911159:-
TGCT	cis	rs17711722	0.523	rs313812	ENSG00000236529.1	RP13-254B10.1	-5.4	3.28e-07	0.000432	-0.31	-0.44	Calcium levels;	chr7:66040056	chr7:65840212~65840596:+
TGCT	cis	rs5769707	0.632	rs1476037	ENSG00000235111.1	RP1-29C18.8	-5.4	3.29e-07	0.000433	-0.41	-0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49597729	chr22:49612657~49615716:-
TGCT	cis	rs35160687	0.901	rs6713456	ENSG00000273080.1	RP11-301O19.1	5.4	3.31e-07	0.000435	0.49	0.44	Night sleep phenotypes;	chr2:86280530	chr2:86195590~86196049:+
TGCT	cis	rs9322193	0.923	rs9766004	ENSG00000216906.2	RP11-350J20.9	5.4	3.31e-07	0.000435	0.48	0.44	Lung cancer;	chr6:149754363	chr6:149904243~149906418:+
TGCT	cis	rs5769707	0.609	rs739247	ENSG00000235111.1	RP1-29C18.8	-5.4	3.31e-07	0.000436	-0.41	-0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49603009	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.609	rs135861	ENSG00000235111.1	RP1-29C18.8	-5.4	3.31e-07	0.000436	-0.41	-0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49612657~49615716:-
TGCT	cis	rs17361889	0.711	rs7782485	ENSG00000224683.1	RPL36AP29	5.4	3.32e-07	0.000436	0.44	0.44	Pediatric bone mineral content (hip);	chr7:16272940	chr7:16208945~16209265:+
TGCT	cis	rs7301826	1	rs10773819	ENSG00000256250.1	RP11-989F5.1	-5.4	3.32e-07	0.000436	-0.47	-0.44	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810606~130812438:+
TGCT	cis	rs7804306	0.85	rs7793278	ENSG00000233264.2	AC006042.8	5.4	3.32e-07	0.000437	0.91	0.44	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7973456	chr7:7980312~7982228:+
TGCT	cis	rs801193	0.904	rs4718405	ENSG00000222364.1	RNU6-96P	-5.4	3.33e-07	0.000437	-0.51	-0.44	Aortic root size;	chr7:66789659	chr7:66395191~66395286:+
TGCT	cis	rs9326248	0.539	rs518181	ENSG00000254851.1	RP11-109L13.1	-5.4	3.33e-07	0.000437	-0.52	-0.44	Blood protein levels;	chr11:116902071	chr11:117135528~117138582:+
TGCT	cis	rs1799949	0.965	rs8176161	ENSG00000198496.9	NBR2	-5.4	3.33e-07	0.000437	-0.63	-0.44	Menopause (age at onset);	chr17:43089373	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.894	rs8176160	ENSG00000198496.9	NBR2	-5.4	3.33e-07	0.000437	-0.63	-0.44	Menopause (age at onset);	chr17:43089486	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.896	rs35908185	ENSG00000198496.9	NBR2	-5.4	3.33e-07	0.000437	-0.63	-0.44	Menopause (age at onset);	chr17:43103094	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.965	rs8176130	ENSG00000198496.9	NBR2	-5.4	3.33e-07	0.000437	-0.63	-0.44	Menopause (age at onset);	chr17:43106026	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs8176120	ENSG00000198496.9	NBR2	-5.4	3.33e-07	0.000437	-0.63	-0.44	Menopause (age at onset);	chr17:43109216	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs8176109	ENSG00000198496.9	NBR2	-5.4	3.33e-07	0.000437	-0.63	-0.44	Menopause (age at onset);	chr17:43113759	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.896	rs8176098	ENSG00000198496.9	NBR2	-5.4	3.33e-07	0.000437	-0.63	-0.44	Menopause (age at onset);	chr17:43116189	chr17:43125610~43153671:+
TGCT	cis	rs801193	0.967	rs2420827	ENSG00000222364.1	RNU6-96P	5.4	3.34e-07	0.000439	0.51	0.44	Aortic root size;	chr7:66682114	chr7:66395191~66395286:+
TGCT	cis	rs801193	0.967	rs3800823	ENSG00000222364.1	RNU6-96P	5.4	3.34e-07	0.000439	0.51	0.44	Aortic root size;	chr7:66682123	chr7:66395191~66395286:+
TGCT	cis	rs1450985	0.832	rs12497119	ENSG00000239653.1	PSMD6-AS2	5.39	3.36e-07	0.000441	0.41	0.44	Breast cancer;	chr3:64028964	chr3:64004022~64012148:+
TGCT	cis	rs3096299	0.504	rs4785574	ENSG00000274627.1	RP11-104N10.2	5.39	3.36e-07	0.000441	0.44	0.44	Multiple myeloma (IgH translocation);	chr16:89502467	chr16:89516797~89522217:+
TGCT	cis	rs904251	0.861	rs1757180	ENSG00000279942.1	RP1-153P14.7	-5.39	3.36e-07	0.000441	-0.49	-0.44	Cognitive performance;	chr6:37518369	chr6:37567716~37571460:+
TGCT	cis	rs17301013	0.507	rs6665535	ENSG00000227373.4	RP11-160H22.5	5.39	3.38e-07	0.000444	0.52	0.44	Systemic lupus erythematosus;	chr1:174522480	chr1:174115300~174160004:-
TGCT	cis	rs1799955	0.58	rs12869544	ENSG00000215515.2	IFIT1P1	-5.39	3.38e-07	0.000444	-0.55	-0.44	LDL cholesterol levels;	chr13:32328257	chr13:32384660~32386108:+
TGCT	cis	rs1799955	0.554	rs1029304	ENSG00000215515.2	IFIT1P1	-5.39	3.38e-07	0.000444	-0.55	-0.44	LDL cholesterol levels;	chr13:32334492	chr13:32384660~32386108:+
TGCT	cis	rs786425	0.682	rs7307008	ENSG00000278112.1	RP11-972P1.11	-5.39	3.39e-07	0.000444	-0.53	-0.44	Pubertal anthropometrics;	chr12:123675474	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs7968029	ENSG00000278112.1	RP11-972P1.11	5.39	3.39e-07	0.000444	0.53	0.44	Pubertal anthropometrics;	chr12:123697573	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.637	rs7308234	ENSG00000278112.1	RP11-972P1.11	5.39	3.39e-07	0.000444	0.53	0.44	Pubertal anthropometrics;	chr12:123699257	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs11613632	ENSG00000278112.1	RP11-972P1.11	5.39	3.39e-07	0.000444	0.53	0.44	Pubertal anthropometrics;	chr12:123699518	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.575	rs73219037	ENSG00000278112.1	RP11-972P1.11	5.39	3.39e-07	0.000444	0.53	0.44	Pubertal anthropometrics;	chr12:123699935	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs7398152	ENSG00000278112.1	RP11-972P1.11	5.39	3.39e-07	0.000444	0.53	0.44	Pubertal anthropometrics;	chr12:123700092	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.655	rs7973155	ENSG00000278112.1	RP11-972P1.11	5.39	3.39e-07	0.000444	0.53	0.44	Pubertal anthropometrics;	chr12:123701401	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.655	rs11612030	ENSG00000278112.1	RP11-972P1.11	5.39	3.39e-07	0.000444	0.53	0.44	Pubertal anthropometrics;	chr12:123703517	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs12827074	ENSG00000278112.1	RP11-972P1.11	5.39	3.39e-07	0.000444	0.53	0.44	Pubertal anthropometrics;	chr12:123706289	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.655	rs7398298	ENSG00000278112.1	RP11-972P1.11	5.39	3.39e-07	0.000444	0.53	0.44	Pubertal anthropometrics;	chr12:123708181	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.654	rs7305838	ENSG00000278112.1	RP11-972P1.11	5.39	3.39e-07	0.000444	0.53	0.44	Pubertal anthropometrics;	chr12:123708924	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs7399224	ENSG00000278112.1	RP11-972P1.11	5.39	3.39e-07	0.000444	0.53	0.44	Pubertal anthropometrics;	chr12:123711309	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.74	rs7397160	ENSG00000278112.1	RP11-972P1.11	5.39	3.39e-07	0.000444	0.53	0.44	Pubertal anthropometrics;	chr12:123711672	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.601	rs67178535	ENSG00000278112.1	RP11-972P1.11	5.39	3.39e-07	0.000444	0.53	0.44	Pubertal anthropometrics;	chr12:123711752	chr12:123519390~123519856:-
TGCT	cis	rs17301013	0.507	rs72713537	ENSG00000227373.4	RP11-160H22.5	5.39	3.39e-07	0.000445	0.49	0.44	Systemic lupus erythematosus;	chr1:174354189	chr1:174115300~174160004:-
TGCT	cis	rs507080	0.922	rs625513	ENSG00000255422.1	AP002954.4	-5.39	3.39e-07	0.000445	-0.51	-0.44	Serum metabolite levels;	chr11:118685010	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.922	rs514143	ENSG00000255422.1	AP002954.4	-5.39	3.39e-07	0.000445	-0.51	-0.44	Serum metabolite levels;	chr11:118687740	chr11:118704607~118750263:+
TGCT	cis	rs786425	0.689	rs2222060	ENSG00000278112.1	RP11-972P1.11	5.39	3.4e-07	0.000445	0.54	0.44	Pubertal anthropometrics;	chr12:123709891	chr12:123519390~123519856:-
TGCT	cis	rs1061377	0.722	rs34803689	ENSG00000249207.1	RP11-360F5.1	-5.39	3.41e-07	0.000446	-0.45	-0.44	Uric acid levels;	chr4:39116665	chr4:39112677~39126818:-
TGCT	cis	rs1061377	0.965	rs7669376	ENSG00000249207.1	RP11-360F5.1	-5.39	3.41e-07	0.000446	-0.45	-0.44	Uric acid levels;	chr4:39116717	chr4:39112677~39126818:-
TGCT	cis	rs7208859	0.673	rs11653955	ENSG00000263531.1	RP13-753N3.1	5.39	3.41e-07	0.000447	0.81	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30863921~30864940:-
TGCT	cis	rs2921073	0.605	rs2976933	ENSG00000173295.6	FAM86B3P	5.39	3.41e-07	0.000447	0.51	0.44	Parkinson's disease;	chr8:8397365	chr8:8228595~8244865:+
TGCT	cis	rs11723261	0.621	rs11733385	ENSG00000275426.1	CH17-262A2.1	5.39	3.41e-07	0.000447	0.88	0.44	Immune response to smallpox vaccine (IL-6);	chr4:146677	chr4:149738~150317:+
TGCT	cis	rs11723261	0.546	rs4315728	ENSG00000275426.1	CH17-262A2.1	5.39	3.41e-07	0.000447	0.88	0.44	Immune response to smallpox vaccine (IL-6);	chr4:147237	chr4:149738~150317:+
TGCT	cis	rs710913	0.717	rs2243761	ENSG00000182109.6	RP11-69E11.4	-5.39	3.42e-07	0.000447	-0.44	-0.44	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39585944	chr1:39522280~39546187:-
TGCT	cis	rs7617773	0.78	rs13067450	ENSG00000229759.1	MRPS18AP1	5.39	3.42e-07	0.000448	0.38	0.44	Coronary artery disease;	chr3:48295716	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs4479622	ENSG00000229759.1	MRPS18AP1	5.39	3.42e-07	0.000448	0.38	0.44	Coronary artery disease;	chr3:48296683	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs34946886	ENSG00000229759.1	MRPS18AP1	5.39	3.42e-07	0.000448	0.38	0.44	Coronary artery disease;	chr3:48296997	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs13079728	ENSG00000229759.1	MRPS18AP1	5.39	3.42e-07	0.000448	0.38	0.44	Coronary artery disease;	chr3:48297870	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs34589064	ENSG00000229759.1	MRPS18AP1	5.39	3.42e-07	0.000448	0.38	0.44	Coronary artery disease;	chr3:48298059	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs2541	ENSG00000229759.1	MRPS18AP1	5.39	3.42e-07	0.000448	0.38	0.44	Coronary artery disease;	chr3:48298128	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs13085251	ENSG00000229759.1	MRPS18AP1	5.39	3.42e-07	0.000448	0.38	0.44	Coronary artery disease;	chr3:48298555	chr3:48256350~48256938:-
TGCT	cis	rs904251	0.861	rs914349	ENSG00000279942.1	RP1-153P14.7	-5.39	3.43e-07	0.000449	-0.48	-0.44	Cognitive performance;	chr6:37516939	chr6:37567716~37571460:+
TGCT	cis	rs11673344	0.864	rs79407399	ENSG00000226686.6	LINC01535	5.39	3.43e-07	0.000449	0.52	0.44	Obesity-related traits;	chr19:37000004	chr19:37251912~37265535:+
TGCT	cis	rs7617773	0.78	rs11706277	ENSG00000229759.1	MRPS18AP1	5.39	3.43e-07	0.000449	0.37	0.44	Coronary artery disease;	chr3:48318943	chr3:48256350~48256938:-
TGCT	cis	rs1061377	1	rs10030904	ENSG00000249207.1	RP11-360F5.1	-5.39	3.43e-07	0.000449	-0.45	-0.44	Uric acid levels;	chr4:39113603	chr4:39112677~39126818:-
TGCT	cis	rs189798	1	rs189798	ENSG00000254340.1	RP11-10A14.3	-5.39	3.44e-07	0.000449	-0.48	-0.44	Myopia (pathological);	chr8:9133067	chr8:9141424~9145435:+
TGCT	cis	rs1707322	0.506	rs2991983	ENSG00000280836.1	AL355480.1	5.39	3.44e-07	0.00045	0.61	0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.717	rs3014249	ENSG00000280836.1	AL355480.1	5.39	3.44e-07	0.00045	0.61	0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.717	rs2253862	ENSG00000280836.1	AL355480.1	5.39	3.44e-07	0.00045	0.61	0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.717	rs2991988	ENSG00000280836.1	AL355480.1	5.39	3.44e-07	0.00045	0.61	0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.717	rs2991989	ENSG00000280836.1	AL355480.1	5.39	3.44e-07	0.00045	0.61	0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr1:45581219~45581321:-
TGCT	cis	rs786425	0.682	rs7979528	ENSG00000278112.1	RP11-972P1.11	5.39	3.44e-07	0.00045	0.52	0.44	Pubertal anthropometrics;	chr12:123697273	chr12:123519390~123519856:-
TGCT	cis	rs2019137	0.56	rs6707386	ENSG00000189223.12	PAX8-AS1	-5.39	3.45e-07	0.000451	-0.58	-0.44	Lymphocyte counts;	chr2:113223445	chr2:113211522~113276581:+
TGCT	cis	rs11155671	0.53	rs4870080	ENSG00000216906.2	RP11-350J20.9	5.39	3.45e-07	0.000451	0.48	0.44	Testicular germ cell tumor;	chr6:149881508	chr6:149904243~149906418:+
TGCT	cis	rs11673344	0.77	rs34729406	ENSG00000226686.6	LINC01535	5.39	3.46e-07	0.000452	0.51	0.44	Obesity-related traits;	chr19:37012764	chr19:37251912~37265535:+
TGCT	cis	rs7115242	1	rs7115242	ENSG00000254851.1	RP11-109L13.1	5.39	3.47e-07	0.000453	0.9	0.44	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117135528~117138582:+
TGCT	cis	rs7208859	0.524	rs60114476	ENSG00000263531.1	RP13-753N3.1	5.39	3.47e-07	0.000453	0.82	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs9903862	ENSG00000263531.1	RP13-753N3.1	5.39	3.47e-07	0.000454	0.82	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879415	chr17:30863921~30864940:-
TGCT	cis	rs7923609	0.812	rs10822184	ENSG00000232075.1	MRPL35P2	5.39	3.48e-07	0.000454	0.42	0.44	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63577393	chr10:63634317~63634827:-
TGCT	cis	rs5758659	0.652	rs133335	ENSG00000270083.1	RP1-257I20.14	-5.39	3.48e-07	0.000454	-0.41	-0.44	Cognitive function;	chr22:42020052	chr22:42089630~42090028:-
TGCT	cis	rs9322193	0.923	rs9767123	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149660323	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs3924871	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149662080	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs35961297	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149667929	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs4870267	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149671572	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs35967444	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149675588	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs62439842	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149675847	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs4380763	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149678086	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs7767622	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149681766	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs4421206	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149682891	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs3798761	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149683643	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9322209	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149691226	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.884	rs9322210	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149695440	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs4354168	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149696642	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs11155674	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149711111	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs1934534	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149711896	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs2185352	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149714640	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs4870529	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149716436	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9767309	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149716807	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs12174349	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149718012	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs2297932	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149718225	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs2297930	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149718360	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs2297928	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149718584	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs17745062	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149721079	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs62441279	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149721194	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9479094	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149725083	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9478291	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149729434	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9479494	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149739108	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs56397000	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149739347	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9800806	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149740350	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9688517	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149740655	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.884	rs9689702	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149740720	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs10782315	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149743093	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs1572229	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149743841	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.884	rs10872646	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149746539	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.884	rs12528279	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149750892	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs62441284	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149751542	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs10782316	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149752755	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs10782317	ENSG00000216906.2	RP11-350J20.9	-5.39	3.48e-07	0.000454	-0.48	-0.44	Lung cancer;	chr6:149753911	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs10872649	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149759454	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs10872650	ENSG00000216906.2	RP11-350J20.9	5.39	3.48e-07	0.000454	0.48	0.44	Lung cancer;	chr6:149760959	chr6:149904243~149906418:+
TGCT	cis	rs11673344	0.536	rs62108291	ENSG00000226686.6	LINC01535	5.39	3.48e-07	0.000454	0.48	0.44	Obesity-related traits;	chr19:37659457	chr19:37251912~37265535:+
TGCT	cis	rs12935418	0.616	rs77336552	ENSG00000261061.1	RP11-303E16.2	-5.39	3.48e-07	0.000454	-0.68	-0.44	Mean corpuscular volume;	chr16:80942989	chr16:81030770~81031485:+
TGCT	cis	rs12935418	0.733	rs11150329	ENSG00000261061.1	RP11-303E16.2	-5.39	3.48e-07	0.000454	-0.68	-0.44	Mean corpuscular volume;	chr16:80945189	chr16:81030770~81031485:+
TGCT	cis	rs7829975	0.593	rs2921077	ENSG00000173295.6	FAM86B3P	5.38	3.5e-07	0.000456	0.49	0.44	Mood instability;	chr8:8446992	chr8:8228595~8244865:+
TGCT	cis	rs507080	0.885	rs693037	ENSG00000255422.1	AP002954.4	-5.38	3.5e-07	0.000456	-0.53	-0.44	Serum metabolite levels;	chr11:118682617	chr11:118704607~118750263:+
TGCT	cis	rs73086581	0.945	rs6037715	ENSG00000229539.1	RP11-119B16.2	5.38	3.51e-07	0.000457	0.65	0.44	Response to antidepressants in depression;	chr20:3991519	chr20:3888239~3888868:-
TGCT	cis	rs73086581	1	rs6107386	ENSG00000229539.1	RP11-119B16.2	5.38	3.51e-07	0.000457	0.65	0.44	Response to antidepressants in depression;	chr20:3992109	chr20:3888239~3888868:-
TGCT	cis	rs73086581	0.945	rs6052222	ENSG00000229539.1	RP11-119B16.2	5.38	3.51e-07	0.000457	0.65	0.44	Response to antidepressants in depression;	chr20:3992146	chr20:3888239~3888868:-
TGCT	cis	rs73086581	1	rs17215529	ENSG00000229539.1	RP11-119B16.2	5.38	3.51e-07	0.000457	0.65	0.44	Response to antidepressants in depression;	chr20:3994755	chr20:3888239~3888868:-
TGCT	cis	rs9660180	0.875	rs4648727	ENSG00000268575.1	RP1-283E3.8	5.38	3.52e-07	0.000459	0.38	0.44	Body mass index;	chr1:1844830	chr1:1702736~1737688:-
TGCT	cis	rs853679	0.517	rs9380047	ENSG00000219392.1	RP1-265C24.5	-5.38	3.52e-07	0.000459	-0.59	-0.44	Depression;	chr6:28070115	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs7755442	ENSG00000219392.1	RP1-265C24.5	-5.38	3.52e-07	0.000459	-0.59	-0.44	Depression;	chr6:28071237	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs4713135	ENSG00000219392.1	RP1-265C24.5	-5.38	3.52e-07	0.000459	-0.59	-0.44	Depression;	chr6:28071808	chr6:28115628~28116551:+
TGCT	cis	rs1061377	0.965	rs12511857	ENSG00000249207.1	RP11-360F5.1	-5.38	3.53e-07	0.000459	-0.47	-0.44	Uric acid levels;	chr4:39143252	chr4:39112677~39126818:-
TGCT	cis	rs7826238	0.72	rs12546760	ENSG00000173295.6	FAM86B3P	-5.38	3.53e-07	0.00046	-0.5	-0.44	Systolic blood pressure;	chr8:8517326	chr8:8228595~8244865:+
TGCT	cis	rs786425	0.77	rs7138503	ENSG00000247373.3	RP11-486O12.2	5.38	3.54e-07	0.000461	0.53	0.44	Pubertal anthropometrics;	chr12:123699280	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.711	rs12819746	ENSG00000247373.3	RP11-486O12.2	5.38	3.54e-07	0.000461	0.53	0.44	Pubertal anthropometrics;	chr12:123709027	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.77	rs12825800	ENSG00000247373.3	RP11-486O12.2	5.38	3.54e-07	0.000461	0.53	0.44	Pubertal anthropometrics;	chr12:123709119	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.77	rs6488897	ENSG00000247373.3	RP11-486O12.2	5.38	3.54e-07	0.000461	0.53	0.44	Pubertal anthropometrics;	chr12:123710936	chr12:123575891~123585115:-
TGCT	cis	rs2117029	0.52	rs876333	ENSG00000258017.1	RP11-386G11.10	-5.38	3.55e-07	0.000461	-0.59	-0.44	Intelligence (multi-trait analysis);	chr12:49029736	chr12:49127782~49147869:+
TGCT	cis	rs6921919	0.789	rs17301128	ENSG00000216901.1	AL022393.7	5.38	3.56e-07	0.000462	0.53	0.44	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28176188~28176674:+
TGCT	cis	rs7208859	0.623	rs73269916	ENSG00000263531.1	RP13-753N3.1	5.38	3.56e-07	0.000463	0.82	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30863921~30864940:-
TGCT	cis	rs904251	0.523	rs10807184	ENSG00000279942.1	RP1-153P14.7	-5.38	3.57e-07	0.000463	-0.45	-0.44	Cognitive performance;	chr6:37515937	chr6:37567716~37571460:+
TGCT	cis	rs904251	0.561	rs1757189	ENSG00000279942.1	RP1-153P14.7	-5.38	3.57e-07	0.000463	-0.45	-0.44	Cognitive performance;	chr6:37515951	chr6:37567716~37571460:+
TGCT	cis	rs321358	0.945	rs73015196	ENSG00000271584.1	RP11-89C3.4	5.38	3.58e-07	0.000465	0.58	0.43	Body mass index;	chr11:111104608	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.945	rs73015199	ENSG00000271584.1	RP11-89C3.4	5.38	3.58e-07	0.000465	0.58	0.43	Body mass index;	chr11:111104952	chr11:111091932~111097357:-
TGCT	cis	rs1061377	1	rs7664078	ENSG00000249207.1	RP11-360F5.1	-5.38	3.6e-07	0.000467	-0.45	-0.43	Uric acid levels;	chr4:39116583	chr4:39112677~39126818:-
TGCT	cis	rs2919917	0.614	rs10102877	ENSG00000254352.1	RP11-578O24.2	5.38	3.6e-07	0.000467	0.47	0.43	Lymphocyte counts;	chr8:78686127	chr8:78723796~78724136:-
TGCT	cis	rs8062405	0.823	rs7202948	ENSG00000259982.1	CDC37P1	5.38	3.61e-07	0.000468	0.55	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28700294~28701540:-
TGCT	cis	rs9462027	1	rs9462027	ENSG00000186328.4	RP11-140K17.2	5.38	3.61e-07	0.000469	0.45	0.43	Systemic lupus erythematosus;	chr6:34829464	chr6:34715613~34715940:+
TGCT	cis	rs17301013	0.531	rs332806	ENSG00000227373.4	RP11-160H22.5	5.38	3.62e-07	0.000469	0.51	0.43	Systemic lupus erythematosus;	chr1:174653645	chr1:174115300~174160004:-
TGCT	cis	rs9584850	0.834	rs3783005	ENSG00000231194.1	FARP1-AS1	-5.38	3.62e-07	0.00047	-0.55	-0.43	Neuroticism;	chr13:98459083	chr13:98435405~98435840:-
TGCT	cis	rs1799949	0.93	rs35292991	ENSG00000198496.9	NBR2	-5.38	3.62e-07	0.00047	-0.63	-0.43	Menopause (age at onset);	chr17:43181999	chr17:43125610~43153671:+
TGCT	cis	rs9584850	0.874	rs3742136	ENSG00000231194.1	FARP1-AS1	5.38	3.63e-07	0.000471	0.6	0.43	Neuroticism;	chr13:98450353	chr13:98435405~98435840:-
TGCT	cis	rs5769707	0.632	rs6009782	ENSG00000235111.1	RP1-29C18.8	-5.38	3.65e-07	0.000473	-0.41	-0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49617164	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.592	rs6009783	ENSG00000235111.1	RP1-29C18.8	-5.38	3.65e-07	0.000473	-0.41	-0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49617353	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.656	rs135875	ENSG00000235111.1	RP1-29C18.8	-5.38	3.65e-07	0.000473	-0.41	-0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49618771	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.616	rs6009786	ENSG00000235111.1	RP1-29C18.8	-5.38	3.65e-07	0.000473	-0.41	-0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49621497	chr22:49612657~49615716:-
TGCT	cis	rs4853012	0.838	rs4452177	ENSG00000217702.2	RP11-287D1.4	5.37	3.66e-07	0.000474	0.6	0.43	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74130583~74135395:+
TGCT	cis	rs4853012	0.838	rs60705299	ENSG00000217702.2	RP11-287D1.4	5.37	3.66e-07	0.000474	0.6	0.43	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74130583~74135395:+
TGCT	cis	rs73086581	1	rs56141565	ENSG00000229539.1	RP11-119B16.2	5.37	3.67e-07	0.000475	0.67	0.43	Response to antidepressants in depression;	chr20:4017956	chr20:3888239~3888868:-
TGCT	cis	rs9322193	0.847	rs4870054	ENSG00000216906.2	RP11-350J20.9	5.37	3.69e-07	0.000477	0.51	0.43	Lung cancer;	chr6:149848402	chr6:149904243~149906418:+
TGCT	cis	rs1061377	1	rs9999327	ENSG00000249207.1	RP11-360F5.1	-5.37	3.72e-07	0.00048	-0.45	-0.43	Uric acid levels;	chr4:39110111	chr4:39112677~39126818:-
TGCT	cis	rs1061377	0.965	rs6833654	ENSG00000249207.1	RP11-360F5.1	-5.37	3.72e-07	0.00048	-0.45	-0.43	Uric acid levels;	chr4:39110701	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs1036036	ENSG00000249207.1	RP11-360F5.1	-5.37	3.72e-07	0.00048	-0.45	-0.43	Uric acid levels;	chr4:39111104	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs1036038	ENSG00000249207.1	RP11-360F5.1	-5.37	3.72e-07	0.00048	-0.45	-0.43	Uric acid levels;	chr4:39111383	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs1560396	ENSG00000249207.1	RP11-360F5.1	-5.37	3.72e-07	0.00048	-0.45	-0.43	Uric acid levels;	chr4:39112092	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs1560397	ENSG00000249207.1	RP11-360F5.1	-5.37	3.72e-07	0.00048	-0.45	-0.43	Uric acid levels;	chr4:39112265	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs2381285	ENSG00000249207.1	RP11-360F5.1	-5.37	3.72e-07	0.00048	-0.45	-0.43	Uric acid levels;	chr4:39112775	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs2163272	ENSG00000249207.1	RP11-360F5.1	-5.37	3.72e-07	0.00048	-0.45	-0.43	Uric acid levels;	chr4:39112790	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs2163273	ENSG00000249207.1	RP11-360F5.1	-5.37	3.72e-07	0.00048	-0.45	-0.43	Uric acid levels;	chr4:39112835	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs62310332	ENSG00000249207.1	RP11-360F5.1	-5.37	3.72e-07	0.00048	-0.45	-0.43	Uric acid levels;	chr4:39112939	chr4:39112677~39126818:-
TGCT	cis	rs1061377	0.965	rs3796510	ENSG00000249207.1	RP11-360F5.1	-5.37	3.72e-07	0.00048	-0.45	-0.43	Uric acid levels;	chr4:39113309	chr4:39112677~39126818:-
TGCT	cis	rs1061377	0.932	rs6855118	ENSG00000249207.1	RP11-360F5.1	-5.37	3.72e-07	0.00048	-0.45	-0.43	Uric acid levels;	chr4:39114322	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs6829234	ENSG00000249207.1	RP11-360F5.1	-5.37	3.72e-07	0.00048	-0.45	-0.43	Uric acid levels;	chr4:39114586	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs6812540	ENSG00000249207.1	RP11-360F5.1	-5.37	3.72e-07	0.00048	-0.45	-0.43	Uric acid levels;	chr4:39114803	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs10026775	ENSG00000249207.1	RP11-360F5.1	-5.37	3.72e-07	0.00048	-0.45	-0.43	Uric acid levels;	chr4:39115155	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs3733276	ENSG00000249207.1	RP11-360F5.1	-5.37	3.72e-07	0.00048	-0.45	-0.43	Uric acid levels;	chr4:39115291	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs3733277	ENSG00000249207.1	RP11-360F5.1	-5.37	3.72e-07	0.00048	-0.45	-0.43	Uric acid levels;	chr4:39115483	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs3733278	ENSG00000249207.1	RP11-360F5.1	-5.37	3.72e-07	0.00048	-0.45	-0.43	Uric acid levels;	chr4:39115615	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs3733279	ENSG00000249207.1	RP11-360F5.1	-5.37	3.72e-07	0.00048	-0.45	-0.43	Uric acid levels;	chr4:39115625	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs10018049	ENSG00000249207.1	RP11-360F5.1	-5.37	3.72e-07	0.00048	-0.45	-0.43	Uric acid levels;	chr4:39115781	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs7685082	ENSG00000249207.1	RP11-360F5.1	-5.37	3.72e-07	0.00048	-0.45	-0.43	Uric acid levels;	chr4:39116472	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs9998481	ENSG00000249207.1	RP11-360F5.1	-5.37	3.72e-07	0.00048	-0.45	-0.43	Uric acid levels;	chr4:39117215	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs9998867	ENSG00000249207.1	RP11-360F5.1	-5.37	3.72e-07	0.00048	-0.45	-0.43	Uric acid levels;	chr4:39117542	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs2381284	ENSG00000249207.1	RP11-360F5.1	-5.37	3.72e-07	0.00048	-0.45	-0.43	Uric acid levels;	chr4:39117976	chr4:39112677~39126818:-
TGCT	cis	rs1061377	0.803	rs6857761	ENSG00000249207.1	RP11-360F5.1	-5.37	3.72e-07	0.00048	-0.45	-0.43	Uric acid levels;	chr4:39118353	chr4:39112677~39126818:-
TGCT	cis	rs10875746	0.855	rs10875728	ENSG00000240399.1	RP1-228P16.1	-5.37	3.73e-07	0.000482	-0.54	-0.43	Longevity (90 years and older);	chr12:48032609	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.855	rs10875729	ENSG00000240399.1	RP1-228P16.1	-5.37	3.73e-07	0.000482	-0.54	-0.43	Longevity (90 years and older);	chr12:48032943	chr12:48054813~48055591:-
TGCT	cis	rs2333021	0.727	rs1986616	ENSG00000259015.1	RP11-109N23.6	-5.37	3.74e-07	0.000483	-0.23	-0.43	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73074228	chr14:72960595~72961993:+
TGCT	cis	rs2333021	1	rs2333021	ENSG00000259015.1	RP11-109N23.6	5.37	3.75e-07	0.000484	0.23	0.43	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73017676	chr14:72960595~72961993:+
TGCT	cis	rs7605378	0.567	rs717915	ENSG00000232732.8	AC073043.1	-5.37	3.76e-07	0.000485	-0.5	-0.43	Osteoporosis;	chr2:199850043	chr2:199867396~199911159:-
TGCT	cis	rs2919917	1	rs1545228	ENSG00000254352.1	RP11-578O24.2	-5.37	3.78e-07	0.000487	-0.49	-0.43	Lymphocyte counts;	chr8:78732202	chr8:78723796~78724136:-
TGCT	cis	rs1799955	0.638	rs11571583	ENSG00000215515.2	IFIT1P1	-5.37	3.79e-07	0.000489	-0.54	-0.43	LDL cholesterol levels;	chr13:32318623	chr13:32384660~32386108:+
TGCT	cis	rs8059260	0.541	rs12917947	ENSG00000274038.1	RP11-66H6.4	-5.37	3.79e-07	0.000489	-0.58	-0.43	Alcohol consumption over the past year;	chr16:11116386	chr16:11056556~11057034:+
TGCT	cis	rs710913	0.717	rs2068473	ENSG00000182109.6	RP11-69E11.4	-5.37	3.8e-07	0.000489	-0.43	-0.43	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572925	chr1:39522280~39546187:-
TGCT	cis	rs12946454	0.696	rs4792819	ENSG00000267288.2	RP13-890H12.2	-5.37	3.8e-07	0.00049	-0.46	-0.43	Systolic blood pressure;	chr17:45170590	chr17:45168800~45171584:-
TGCT	cis	rs9322193	0.924	rs9322189	ENSG00000216906.2	RP11-350J20.9	5.37	3.81e-07	0.000491	0.48	0.43	Lung cancer;	chr6:149588797	chr6:149904243~149906418:+
TGCT	cis	rs9322193	1	rs9377228	ENSG00000216906.2	RP11-350J20.9	5.37	3.81e-07	0.000491	0.48	0.43	Lung cancer;	chr6:149600862	chr6:149904243~149906418:+
TGCT	cis	rs8062405	0.688	rs3924376	ENSG00000259982.1	CDC37P1	-5.37	3.81e-07	0.000491	-0.65	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28700294~28701540:-
TGCT	cis	rs321358	0.945	rs7111445	ENSG00000271584.1	RP11-89C3.4	-5.36	3.83e-07	0.000493	-0.56	-0.43	Body mass index;	chr11:111105787	chr11:111091932~111097357:-
TGCT	cis	rs6061231	1	rs11908473	ENSG00000273619.1	RP5-908M14.9	-5.36	3.83e-07	0.000494	-0.46	-0.43	Colorectal cancer;	chr20:62382714	chr20:62386303~62386970:-
TGCT	cis	rs4835473	0.9	rs71612420	ENSG00000251600.4	RP11-673E1.1	-5.36	3.84e-07	0.000494	-0.44	-0.43	Immature fraction of reticulocytes;	chr4:143779107	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs13134869	ENSG00000251600.4	RP11-673E1.1	-5.36	3.84e-07	0.000494	-0.44	-0.43	Immature fraction of reticulocytes;	chr4:143782301	chr4:143912331~143982454:+
TGCT	cis	rs7849270	1	rs3124512	ENSG00000268707.1	RP11-247A12.7	5.36	3.85e-07	0.000496	0.48	0.43	Blood metabolite ratios;	chr9:129141602	chr9:129170434~129170940:+
TGCT	cis	rs2921073	0.604	rs2979140	ENSG00000173295.6	FAM86B3P	5.36	3.87e-07	0.000497	0.52	0.43	Parkinson's disease;	chr8:8409692	chr8:8228595~8244865:+
TGCT	cis	rs73086581	1	rs11906274	ENSG00000229539.1	RP11-119B16.2	5.36	3.88e-07	0.000498	0.65	0.43	Response to antidepressants in depression;	chr20:3964889	chr20:3888239~3888868:-
TGCT	cis	rs73086581	1	rs6052196	ENSG00000229539.1	RP11-119B16.2	5.36	3.88e-07	0.000498	0.65	0.43	Response to antidepressants in depression;	chr20:3965177	chr20:3888239~3888868:-
TGCT	cis	rs73086581	1	rs6116130	ENSG00000229539.1	RP11-119B16.2	5.36	3.88e-07	0.000498	0.65	0.43	Response to antidepressants in depression;	chr20:3966379	chr20:3888239~3888868:-
TGCT	cis	rs73086581	0.786	rs6037705	ENSG00000229539.1	RP11-119B16.2	5.36	3.88e-07	0.000498	0.65	0.43	Response to antidepressants in depression;	chr20:3972183	chr20:3888239~3888868:-
TGCT	cis	rs73086581	1	rs6037708	ENSG00000229539.1	RP11-119B16.2	5.36	3.88e-07	0.000498	0.65	0.43	Response to antidepressants in depression;	chr20:3980606	chr20:3888239~3888868:-
TGCT	cis	rs73086581	1	rs6052209	ENSG00000229539.1	RP11-119B16.2	5.36	3.88e-07	0.000498	0.65	0.43	Response to antidepressants in depression;	chr20:3981100	chr20:3888239~3888868:-
TGCT	cis	rs73086581	1	rs6052217	ENSG00000229539.1	RP11-119B16.2	5.36	3.88e-07	0.000498	0.65	0.43	Response to antidepressants in depression;	chr20:3989564	chr20:3888239~3888868:-
TGCT	cis	rs73086581	1	rs6052218	ENSG00000229539.1	RP11-119B16.2	5.36	3.88e-07	0.000498	0.65	0.43	Response to antidepressants in depression;	chr20:3989565	chr20:3888239~3888868:-
TGCT	cis	rs73086581	0.945	rs6052219	ENSG00000229539.1	RP11-119B16.2	5.36	3.88e-07	0.000498	0.65	0.43	Response to antidepressants in depression;	chr20:3989660	chr20:3888239~3888868:-
TGCT	cis	rs7804306	0.655	rs34746652	ENSG00000233264.2	AC006042.8	5.36	3.89e-07	0.000499	1	0.43	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8012957	chr7:7980312~7982228:+
TGCT	cis	rs7804306	1	rs35143180	ENSG00000233264.2	AC006042.8	5.36	3.89e-07	0.000499	1	0.43	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8017141	chr7:7980312~7982228:+
TGCT	cis	rs7804306	1	rs34059590	ENSG00000233264.2	AC006042.8	5.36	3.89e-07	0.000499	1	0.43	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8026584	chr7:7980312~7982228:+
TGCT	cis	rs7804306	1	rs13225545	ENSG00000233264.2	AC006042.8	5.36	3.89e-07	0.000499	1	0.43	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8027509	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.826	rs35567393	ENSG00000233264.2	AC006042.8	5.36	3.89e-07	0.000499	1	0.43	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8033938	chr7:7980312~7982228:+
TGCT	cis	rs7804306	1	rs35009545	ENSG00000233264.2	AC006042.8	5.36	3.89e-07	0.000499	1	0.43	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8037223	chr7:7980312~7982228:+
TGCT	cis	rs7804306	1	rs34156160	ENSG00000233264.2	AC006042.8	5.36	3.89e-07	0.000499	1	0.43	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8043155	chr7:7980312~7982228:+
TGCT	cis	rs7804306	1	rs35641104	ENSG00000233264.2	AC006042.8	5.36	3.89e-07	0.000499	1	0.43	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8046289	chr7:7980312~7982228:+
TGCT	cis	rs7804306	1	rs12702689	ENSG00000233264.2	AC006042.8	5.36	3.89e-07	0.000499	1	0.43	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8046767	chr7:7980312~7982228:+
TGCT	cis	rs4835473	0.932	rs13133444	ENSG00000251600.4	RP11-673E1.1	5.36	3.89e-07	5e-04	0.42	0.43	Immature fraction of reticulocytes;	chr4:143738191	chr4:143912331~143982454:+
TGCT	cis	rs1061377	0.965	rs12504238	ENSG00000249207.1	RP11-360F5.1	-5.36	3.9e-07	0.000501	-0.47	-0.43	Uric acid levels;	chr4:39142824	chr4:39112677~39126818:-
TGCT	cis	rs7811142	1	rs11771419	ENSG00000242294.5	STAG3L5P	5.36	3.91e-07	0.000501	0.4	0.43	Platelet count;	chr7:100390780	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.943	rs10241492	ENSG00000242294.5	STAG3L5P	5.36	3.91e-07	0.000501	0.4	0.43	Platelet count;	chr7:100397190	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs76913697	ENSG00000242294.5	STAG3L5P	5.36	3.91e-07	0.000501	0.4	0.43	Platelet count;	chr7:100405149	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs67471932	ENSG00000242294.5	STAG3L5P	5.36	3.91e-07	0.000501	0.4	0.43	Platelet count;	chr7:100412362	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs73161759	ENSG00000242294.5	STAG3L5P	5.36	3.91e-07	0.000501	0.4	0.43	Platelet count;	chr7:100412371	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs66632384	ENSG00000242294.5	STAG3L5P	5.36	3.91e-07	0.000501	0.4	0.43	Platelet count;	chr7:100421281	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.943	rs73403312	ENSG00000242294.5	STAG3L5P	5.36	3.91e-07	0.000501	0.4	0.43	Platelet count;	chr7:100426530	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs74460138	ENSG00000242294.5	STAG3L5P	5.36	3.91e-07	0.000501	0.4	0.43	Platelet count;	chr7:100429716	chr7:100336079~100351900:+
TGCT	cis	rs7811142	1	rs4989959	ENSG00000242294.5	STAG3L5P	5.36	3.91e-07	0.000501	0.4	0.43	Platelet count;	chr7:100434665	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.943	rs66958101	ENSG00000242294.5	STAG3L5P	5.36	3.91e-07	0.000501	0.4	0.43	Platelet count;	chr7:100476397	chr7:100336079~100351900:+
TGCT	cis	rs2412819	0.571	rs514255	ENSG00000205771.5	CATSPER2P1	-5.36	3.92e-07	0.000501	-0.65	-0.43	Lung cancer;	chr15:43893134	chr15:43726918~43747094:-
TGCT	cis	rs7849270	1	rs932835	ENSG00000268707.1	RP11-247A12.7	-5.36	3.92e-07	0.000501	-0.48	-0.43	Blood metabolite ratios;	chr9:129124792	chr9:129170434~129170940:+
TGCT	cis	rs7849270	1	rs7023900	ENSG00000268707.1	RP11-247A12.7	-5.36	3.92e-07	0.000501	-0.48	-0.43	Blood metabolite ratios;	chr9:129128873	chr9:129170434~129170940:+
TGCT	cis	rs9322193	0.884	rs9371201	ENSG00000216906.2	RP11-350J20.9	5.36	3.92e-07	0.000501	0.49	0.43	Lung cancer;	chr6:149823865	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9371486	ENSG00000216906.2	RP11-350J20.9	5.36	3.92e-07	0.000501	0.49	0.43	Lung cancer;	chr6:149832090	chr6:149904243~149906418:+
TGCT	cis	rs3091242	0.933	rs9645452	ENSG00000224183.1	SDHDP6	5.36	3.92e-07	0.000501	0.46	0.43	Erythrocyte sedimentation rate;	chr1:25341835	chr1:25294164~25294643:-
TGCT	cis	rs1707322	0.717	rs3014246	ENSG00000280836.1	AL355480.1	5.36	3.93e-07	0.000501	0.6	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.717	rs3014245	ENSG00000280836.1	AL355480.1	5.36	3.93e-07	0.000501	0.6	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.655	rs3014240	ENSG00000280836.1	AL355480.1	5.36	3.93e-07	0.000501	0.6	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.717	rs3014237	ENSG00000280836.1	AL355480.1	5.36	3.93e-07	0.000501	0.6	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.686	rs3014235	ENSG00000280836.1	AL355480.1	5.36	3.93e-07	0.000501	0.6	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.717	rs1135850	ENSG00000280836.1	AL355480.1	-5.36	3.93e-07	0.000501	-0.6	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45581219~45581321:-
TGCT	cis	rs17826219	0.5	rs2874724	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Body mass index;	chr17:30745415	chr17:30863921~30864940:-
TGCT	cis	rs17826219	0.568	rs9898097	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Body mass index;	chr17:30745654	chr17:30863921~30864940:-
TGCT	cis	rs17826219	0.5	rs9891256	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Body mass index;	chr17:30745674	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs9911490	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs7503542	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs7503335	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.573	rs11656278	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.573	rs56031503	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs6505207	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.573	rs7223803	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30863921~30864940:-
TGCT	cis	rs17826219	0.568	rs2626985	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Body mass index;	chr17:30750419	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs55814012	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30863921~30864940:-
TGCT	cis	rs17826219	0.5	rs2449749	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Body mass index;	chr17:30751280	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs9894709	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs9896603	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs7219361	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs7219712	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.573	rs8078656	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs8080882	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs9898084	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs28556733	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30863921~30864940:-
TGCT	cis	rs17826219	0.5	rs28452421	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Body mass index;	chr17:30756962	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs28433704	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.573	rs28779471	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30863921~30864940:-
TGCT	cis	rs17826219	0.5	rs61685770	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Body mass index;	chr17:30758695	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs57486336	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30863921~30864940:-
TGCT	cis	rs17826219	0.706	rs55764512	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Body mass index;	chr17:30758740	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.524	rs73988172	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs12103440	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs12103508	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.524	rs11653605	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs11657777	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs73269913	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs7217984	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs55811708	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.562	rs8078897	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs8075163	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30863921~30864940:-
TGCT	cis	rs17826219	0.706	rs8075107	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Body mass index;	chr17:30779631	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs7223209	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs7223404	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs9916725	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs9916727	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs9914499	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs73269945	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs9897728	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs9890558	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs9912283	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs12006	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs3752021	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs3752020	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs9890855	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs9893422	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs9891166	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs73269974	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs34756112	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.573	rs60724269	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs76633166	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs1061346	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs1061343	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs1061342	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs55938328	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs73269988	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs55961983	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.573	rs7222803	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs9899525	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30863921~30864940:-
TGCT	cis	rs17826219	0.568	rs7213925	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Body mass index;	chr17:30794616	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.524	rs11653098	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs11658945	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs11657990	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs9911784	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs9911997	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs9890862	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs78071511	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs11650982	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs2035494	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs9915546	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs9915566	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.573	rs8064686	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs11657369	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs8075341	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs73271842	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs9895815	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.573	rs7214313	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs8077116	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.524	rs28760584	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30863921~30864940:-
TGCT	cis	rs17826219	0.706	rs73271850	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Body mass index;	chr17:30815122	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs7208088	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs7212991	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs7208441	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs28627615	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs9912440	ENSG00000263531.1	RP13-753N3.1	5.36	3.93e-07	0.000501	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30863921~30864940:-
TGCT	cis	rs11157436	0.958	rs2075494	ENSG00000211813.2	TRAV34	5.36	3.93e-07	0.000501	0.47	0.43	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22202564	chr14:22207522~22208129:+
TGCT	cis	rs11157436	0.958	rs2242542	ENSG00000211813.2	TRAV34	5.36	3.93e-07	0.000501	0.47	0.43	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22203081	chr14:22207522~22208129:+
TGCT	cis	rs11157436	0.958	rs61972231	ENSG00000211813.2	TRAV34	5.36	3.93e-07	0.000501	0.47	0.43	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22206508	chr14:22207522~22208129:+
TGCT	cis	rs11157436	0.958	rs17255537	ENSG00000211813.2	TRAV34	5.36	3.93e-07	0.000501	0.47	0.43	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22208225	chr14:22207522~22208129:+
TGCT	cis	rs9322193	0.923	rs4455682	ENSG00000216906.2	RP11-350J20.9	5.36	3.94e-07	0.000501	0.48	0.43	Lung cancer;	chr6:149700161	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.809	rs9479808	ENSG00000216906.2	RP11-350J20.9	5.36	3.94e-07	0.000502	0.48	0.43	Lung cancer;	chr6:149751328	chr6:149904243~149906418:+
TGCT	cis	rs943437	0.866	rs943436	ENSG00000227012.2	RP1-97J1.2	5.36	3.95e-07	0.000504	0.66	0.43	Parkinson's disease;	chr6:111920951	chr6:111900489~111901851:-
TGCT	cis	rs4853012	0.793	rs6707619	ENSG00000217702.2	RP11-287D1.4	5.36	3.96e-07	0.000504	0.59	0.43	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74130583~74135395:+
TGCT	cis	rs3931020	0.72	rs927904	ENSG00000272864.1	RP11-17E13.2	-5.36	3.96e-07	0.000504	-0.52	-0.43	Resistin levels;	chr1:74794644	chr1:74698769~74699333:-
TGCT	cis	rs4835473	0.897	rs55635947	ENSG00000251600.4	RP11-673E1.1	-5.36	3.96e-07	0.000504	-0.43	-0.43	Immature fraction of reticulocytes;	chr4:143736218	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs56334914	ENSG00000251600.4	RP11-673E1.1	-5.36	3.96e-07	0.000504	-0.43	-0.43	Immature fraction of reticulocytes;	chr4:143736291	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs56324738	ENSG00000251600.4	RP11-673E1.1	-5.36	3.96e-07	0.000504	-0.43	-0.43	Immature fraction of reticulocytes;	chr4:143736297	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs55862664	ENSG00000251600.4	RP11-673E1.1	-5.36	3.96e-07	0.000504	-0.43	-0.43	Immature fraction of reticulocytes;	chr4:143736311	chr4:143912331~143982454:+
TGCT	cis	rs853679	0.513	rs9468296	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28145952	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs4711164	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28147378	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs4711165	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28147406	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs4713148	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28148143	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9348794	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28149979	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9468297	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28151096	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9295758	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28152885	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs17774663	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28153120	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9468298	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28154567	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9295759	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28156691	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9348796	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28158424	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs11552219	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28159056	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9380058	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28159666	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9393896	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28159925	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9393897	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28159932	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9357065	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28161802	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9357066	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28162053	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9393898	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28162598	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9368556	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28163375	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9368557	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28163759	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9380059	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28164580	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9380060	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28164825	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs35227624	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28164948	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9380061	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28165025	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9368558	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28165528	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.587	rs9393899	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Parkinson's disease;	chr6:28165750	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs4713150	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28168434	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.527	rs4713151	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Parkinson's disease;	chr6:28168578	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9393901	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28169019	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs3173443	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28169249	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs4713152	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28169676	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9348797	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28169755	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9380062	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28169791	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.542	rs9380063	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28170075	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs12332979	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28173770	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs67878650	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28174809	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.569	rs9348798	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28175233	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9380065	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28176973	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9295761	ENSG00000219392.1	RP1-265C24.5	-5.36	3.97e-07	0.000505	-0.58	-0.43	Depression;	chr6:28180209	chr6:28115628~28116551:+
TGCT	cis	rs73086581	0.891	rs11907503	ENSG00000229539.1	RP11-119B16.2	5.36	3.99e-07	0.000507	0.65	0.43	Response to antidepressants in depression;	chr20:3906943	chr20:3888239~3888868:-
TGCT	cis	rs4835473	0.932	rs12512649	ENSG00000251600.4	RP11-673E1.1	-5.36	4e-07	0.000508	-0.43	-0.43	Immature fraction of reticulocytes;	chr4:143736745	chr4:143912331~143982454:+
TGCT	cis	rs8113308	0.81	rs8104281	ENSG00000269235.1	ZNF350-AS1	5.35	4.02e-07	0.000511	0.71	0.43	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939766	chr19:51949134~51981367:+
TGCT	cis	rs8113308	0.81	rs8104121	ENSG00000269235.1	ZNF350-AS1	5.35	4.02e-07	0.000511	0.71	0.43	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939810	chr19:51949134~51981367:+
TGCT	cis	rs8113308	0.81	rs8104323	ENSG00000269235.1	ZNF350-AS1	5.35	4.02e-07	0.000511	0.71	0.43	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939992	chr19:51949134~51981367:+
TGCT	cis	rs8113308	0.81	rs8108525	ENSG00000269235.1	ZNF350-AS1	5.35	4.02e-07	0.000511	0.71	0.43	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51940883	chr19:51949134~51981367:+
TGCT	cis	rs8113308	0.81	rs7258701	ENSG00000269235.1	ZNF350-AS1	5.35	4.02e-07	0.000511	0.71	0.43	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51941816	chr19:51949134~51981367:+
TGCT	cis	rs904251	0.737	rs914347	ENSG00000279942.1	RP1-153P14.7	-5.35	4.02e-07	0.000511	-0.48	-0.43	Cognitive performance;	chr6:37517194	chr6:37567716~37571460:+
TGCT	cis	rs7617773	0.78	rs7653152	ENSG00000229759.1	MRPS18AP1	5.35	4.02e-07	0.000511	0.38	0.43	Coronary artery disease;	chr3:48320607	chr3:48256350~48256938:-
TGCT	cis	rs7301826	1	rs4619189	ENSG00000256250.1	RP11-989F5.1	-5.35	4.02e-07	0.000511	-0.46	-0.43	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810606~130812438:+
TGCT	cis	rs875971	0.558	rs4433015	ENSG00000236529.1	RP13-254B10.1	-5.35	4.08e-07	0.000517	-0.34	-0.43	Aortic root size;	chr7:66174736	chr7:65840212~65840596:+
TGCT	cis	rs9584850	0.874	rs7988959	ENSG00000231194.1	FARP1-AS1	5.35	4.09e-07	0.000518	0.6	0.43	Neuroticism;	chr13:98451750	chr13:98435405~98435840:-
TGCT	cis	rs17301013	0.507	rs1474575	ENSG00000227373.4	RP11-160H22.5	-5.35	4.09e-07	0.000518	-0.51	-0.43	Systemic lupus erythematosus;	chr1:174569563	chr1:174115300~174160004:-
TGCT	cis	rs12891047	1	rs4569184	ENSG00000258759.1	RP11-1012A1.7	-5.35	4.1e-07	0.00052	-0.36	-0.43	Amyotrophic lateral sclerosis (sporadic);	chr14:67786581	chr14:67799004~67799609:+
TGCT	cis	rs786425	0.682	rs7302788	ENSG00000278112.1	RP11-972P1.11	5.35	4.11e-07	0.000521	0.52	0.43	Pubertal anthropometrics;	chr12:123682474	chr12:123519390~123519856:-
TGCT	cis	rs17301013	0.507	rs72713586	ENSG00000227373.4	RP11-160H22.5	5.35	4.13e-07	0.000522	0.52	0.43	Systemic lupus erythematosus;	chr1:174441265	chr1:174115300~174160004:-
TGCT	cis	rs1336900	0.513	rs56253522	ENSG00000206931.1	RNU6-1042P	5.35	4.13e-07	0.000523	0.35	0.43	Blood protein levels;	chr1:150642393	chr1:150701866~150701972:+
TGCT	cis	rs7617773	0.744	rs2125482	ENSG00000229759.1	MRPS18AP1	5.35	4.13e-07	0.000523	0.37	0.43	Coronary artery disease;	chr3:48281643	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.817	rs6800492	ENSG00000229759.1	MRPS18AP1	5.35	4.13e-07	0.000523	0.37	0.43	Coronary artery disease;	chr3:48282400	chr3:48256350~48256938:-
TGCT	cis	rs367615	0.512	rs246105	ENSG00000249476.1	CTD-2587M2.1	5.35	4.15e-07	0.000525	0.45	0.43	Colorectal cancer (SNP x SNP interaction);	chr5:109337245	chr5:109237120~109326369:-
TGCT	cis	rs7617773	0.817	rs9830016	ENSG00000229759.1	MRPS18AP1	5.35	4.16e-07	0.000526	0.37	0.43	Coronary artery disease;	chr3:48241004	chr3:48256350~48256938:-
TGCT	cis	rs17826219	0.636	rs7221463	ENSG00000263531.1	RP13-753N3.1	5.35	4.17e-07	0.000527	0.81	0.43	Body mass index;	chr17:30753533	chr17:30863921~30864940:-
TGCT	cis	rs801193	0.901	rs4273746	ENSG00000222364.1	RNU6-96P	5.34	4.19e-07	0.00053	0.51	0.43	Aortic root size;	chr7:66836124	chr7:66395191~66395286:+
TGCT	cis	rs7208859	0.562	rs11650923	ENSG00000263531.1	RP13-753N3.1	5.34	4.19e-07	0.00053	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs56378576	ENSG00000263531.1	RP13-753N3.1	5.34	4.19e-07	0.00053	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs35916850	ENSG00000263531.1	RP13-753N3.1	5.34	4.19e-07	0.00053	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30863921~30864940:-
TGCT	cis	rs5760092	0.755	rs915589	ENSG00000225282.1	AP000350.6	-5.34	4.19e-07	0.00053	-0.6	-0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23926900~23929574:+
TGCT	cis	rs5760092	0.627	rs6519489	ENSG00000225282.1	AP000350.6	-5.34	4.19e-07	0.00053	-0.6	-0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23926900~23929574:+
TGCT	cis	rs853679	0.517	rs12174753	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28074687	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs55747925	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28076559	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs56310871	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28076704	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs34716816	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28078391	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9393884	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28079011	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9380049	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28080757	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9380050	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28080760	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9393885	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28082231	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9393886	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28082261	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.515	rs9368549	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Parkinson's disease;	chr6:28082269	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs56364346	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28082984	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9357061	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28083994	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9368550	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28084025	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.542	rs2295594	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28085319	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs2273564	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28089816	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs1853097	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28090857	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9393887	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28091242	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9393888	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28091439	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9357063	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28092227	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs3823180	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28093966	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9368551	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28094014	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9393890	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28096077	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9366715	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28096855	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.598	rs9380054	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28099759	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.547	rs2116981	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Parkinson's disease;	chr6:28100173	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9368552	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28100648	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs2281588	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28104824	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.542	rs34131763	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28107222	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs35193936	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28108492	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs36078605	ENSG00000219392.1	RP1-265C24.5	-5.34	4.2e-07	0.00053	-0.58	-0.43	Depression;	chr6:28110254	chr6:28115628~28116551:+
TGCT	cis	rs2177312	0.596	rs6553983	ENSG00000251129.1	RP11-734I18.1	-5.34	4.2e-07	0.00053	-0.52	-0.43	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:32003817	chr4:31997397~32155406:+
TGCT	cis	rs524281	0.692	rs2302884	ENSG00000255320.1	RP11-755F10.1	5.34	4.2e-07	0.00053	0.53	0.43	Electroencephalogram traits;	chr11:66056613	chr11:66244840~66246239:-
TGCT	cis	rs76878669	0.561	rs11823140	ENSG00000254510.1	RP11-867G23.10	-5.34	4.22e-07	0.000533	-0.59	-0.43	Educational attainment (years of education);	chr11:66330851	chr11:66409158~66417137:+
TGCT	cis	rs2276314	1	rs16967317	ENSG00000278986.1	RP11-723J4.3	-5.34	4.23e-07	0.000533	-0.48	-0.43	Endometriosis;Drug-induced torsades de pointes;	chr18:35993437	chr18:35972151~35973916:+
TGCT	cis	rs7927592	0.717	rs7126451	ENSG00000212093.1	AP000807.1	-5.34	4.24e-07	0.000535	-0.41	-0.43	Total body bone mineral density;	chr11:68489918	chr11:68506083~68506166:-
TGCT	cis	rs3091242	0.933	rs11802413	ENSG00000261349.1	RP3-465N24.5	5.34	4.25e-07	0.000535	0.43	0.43	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25266102~25267136:-
TGCT	cis	rs189798	0.592	rs10111263	ENSG00000254340.1	RP11-10A14.3	-5.34	4.26e-07	0.000536	-0.44	-0.43	Myopia (pathological);	chr8:9111923	chr8:9141424~9145435:+
TGCT	cis	rs321358	0.945	rs10502129	ENSG00000271584.1	RP11-89C3.4	5.34	4.27e-07	0.000538	0.57	0.43	Body mass index;	chr11:111107405	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.945	rs10502130	ENSG00000271584.1	RP11-89C3.4	5.34	4.27e-07	0.000538	0.57	0.43	Body mass index;	chr11:111107437	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.945	rs73017109	ENSG00000271584.1	RP11-89C3.4	5.34	4.27e-07	0.000538	0.57	0.43	Body mass index;	chr11:111108484	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.887	rs1470537	ENSG00000271584.1	RP11-89C3.4	5.34	4.27e-07	0.000538	0.57	0.43	Body mass index;	chr11:111109328	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.945	rs12421769	ENSG00000271584.1	RP11-89C3.4	5.34	4.27e-07	0.000538	0.57	0.43	Body mass index;	chr11:111109500	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.945	rs73017114	ENSG00000271584.1	RP11-89C3.4	5.34	4.27e-07	0.000538	0.57	0.43	Body mass index;	chr11:111111582	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.945	rs17458493	ENSG00000271584.1	RP11-89C3.4	5.34	4.27e-07	0.000538	0.57	0.43	Body mass index;	chr11:111112156	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.945	rs17458541	ENSG00000271584.1	RP11-89C3.4	5.34	4.27e-07	0.000538	0.57	0.43	Body mass index;	chr11:111113182	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.836	rs17458597	ENSG00000271584.1	RP11-89C3.4	5.34	4.27e-07	0.000538	0.57	0.43	Body mass index;	chr11:111113599	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.945	rs73017176	ENSG00000271584.1	RP11-89C3.4	5.34	4.27e-07	0.000538	0.57	0.43	Body mass index;	chr11:111113879	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.887	rs80221187	ENSG00000271584.1	RP11-89C3.4	5.34	4.27e-07	0.000538	0.57	0.43	Body mass index;	chr11:111113977	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.945	rs73017177	ENSG00000271584.1	RP11-89C3.4	5.34	4.27e-07	0.000538	0.57	0.43	Body mass index;	chr11:111114034	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.895	rs73017179	ENSG00000271584.1	RP11-89C3.4	5.34	4.27e-07	0.000538	0.57	0.43	Body mass index;	chr11:111114037	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.945	rs1356411	ENSG00000271584.1	RP11-89C3.4	5.34	4.27e-07	0.000538	0.57	0.43	Body mass index;	chr11:111115371	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.945	rs12420595	ENSG00000271584.1	RP11-89C3.4	5.34	4.27e-07	0.000538	0.57	0.43	Body mass index;	chr11:111115871	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.945	rs17537360	ENSG00000271584.1	RP11-89C3.4	5.34	4.27e-07	0.000538	0.57	0.43	Body mass index;	chr11:111116921	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.945	rs17537367	ENSG00000271584.1	RP11-89C3.4	5.34	4.27e-07	0.000538	0.57	0.43	Body mass index;	chr11:111117008	chr11:111091932~111097357:-
TGCT	cis	rs17301013	0.897	rs1793291	ENSG00000227373.4	RP11-160H22.5	-5.34	4.28e-07	0.000539	-0.49	-0.43	Systemic lupus erythematosus;	chr1:174822675	chr1:174115300~174160004:-
TGCT	cis	rs2288073	0.965	rs10185445	ENSG00000223754.1	AC008073.9	-5.34	4.3e-07	0.000541	-0.53	-0.43	Venous thromboembolism (SNP x SNP interaction);	chr2:24188107	chr2:24199839~24201698:-
TGCT	cis	rs2288073	0.93	rs7604097	ENSG00000223754.1	AC008073.9	5.34	4.3e-07	0.000541	0.53	0.43	Venous thromboembolism (SNP x SNP interaction);	chr2:24178936	chr2:24199839~24201698:-
TGCT	cis	rs2288073	0.965	rs10173949	ENSG00000223754.1	AC008073.9	5.34	4.3e-07	0.000541	0.53	0.43	Venous thromboembolism (SNP x SNP interaction);	chr2:24187387	chr2:24199839~24201698:-
TGCT	cis	rs2288073	0.965	rs13395596	ENSG00000223754.1	AC008073.9	5.34	4.3e-07	0.000541	0.53	0.43	Venous thromboembolism (SNP x SNP interaction);	chr2:24187869	chr2:24199839~24201698:-
TGCT	cis	rs2288073	0.896	rs13404513	ENSG00000223754.1	AC008073.9	5.34	4.3e-07	0.000541	0.53	0.43	Venous thromboembolism (SNP x SNP interaction);	chr2:24187911	chr2:24199839~24201698:-
TGCT	cis	rs1153858	0.723	rs11855527	ENSG00000259520.4	CTD-2651B20.3	5.34	4.33e-07	0.000545	0.38	0.43	Homoarginine levels;	chr15:45314487	chr15:45251580~45279251:-
TGCT	cis	rs440932	1	rs378974	ENSG00000254340.1	RP11-10A14.3	5.34	4.33e-07	0.000545	0.47	0.43	High light scatter reticulocyte percentage of red cells;	chr8:9169129	chr8:9141424~9145435:+
TGCT	cis	rs5769707	0.681	rs2071902	ENSG00000235111.1	RP1-29C18.8	-5.34	4.34e-07	0.000546	-0.4	-0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49640890	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.604	rs1018814	ENSG00000235111.1	RP1-29C18.8	-5.34	4.34e-07	0.000546	-0.4	-0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49643252	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.681	rs8137111	ENSG00000235111.1	RP1-29C18.8	-5.34	4.34e-07	0.000546	-0.4	-0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49650102	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.681	rs8140095	ENSG00000235111.1	RP1-29C18.8	-5.34	4.34e-07	0.000546	-0.4	-0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49650147	chr22:49612657~49615716:-
TGCT	cis	rs10875746	0.855	rs2269936	ENSG00000240399.1	RP1-228P16.1	-5.34	4.34e-07	0.000546	-0.53	-0.43	Longevity (90 years and older);	chr12:48031452	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.855	rs10875730	ENSG00000240399.1	RP1-228P16.1	-5.34	4.34e-07	0.000546	-0.53	-0.43	Longevity (90 years and older);	chr12:48034092	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.855	rs11168369	ENSG00000240399.1	RP1-228P16.1	-5.34	4.34e-07	0.000546	-0.53	-0.43	Longevity (90 years and older);	chr12:48037385	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.855	rs10875731	ENSG00000240399.1	RP1-228P16.1	-5.34	4.34e-07	0.000546	-0.53	-0.43	Longevity (90 years and older);	chr12:48038960	chr12:48054813~48055591:-
TGCT	cis	rs9322193	0.884	rs62439837	ENSG00000216906.2	RP11-350J20.9	5.34	4.34e-07	0.000546	0.5	0.43	Lung cancer;	chr6:149670380	chr6:149904243~149906418:+
TGCT	cis	rs2019137	0.539	rs6755040	ENSG00000189223.12	PAX8-AS1	-5.34	4.36e-07	0.000548	-0.57	-0.43	Lymphocyte counts;	chr2:113223560	chr2:113211522~113276581:+
TGCT	cis	rs2019137	0.539	rs4849177	ENSG00000189223.12	PAX8-AS1	-5.34	4.36e-07	0.000548	-0.57	-0.43	Lymphocyte counts;	chr2:113225007	chr2:113211522~113276581:+
TGCT	cis	rs2019137	0.56	rs4849179	ENSG00000189223.12	PAX8-AS1	-5.34	4.36e-07	0.000548	-0.57	-0.43	Lymphocyte counts;	chr2:113227593	chr2:113211522~113276581:+
TGCT	cis	rs2019137	0.56	rs10175462	ENSG00000189223.12	PAX8-AS1	-5.34	4.36e-07	0.000548	-0.57	-0.43	Lymphocyte counts;	chr2:113230915	chr2:113211522~113276581:+
TGCT	cis	rs1450985	0.931	rs6785145	ENSG00000239653.1	PSMD6-AS2	5.34	4.36e-07	0.000548	0.4	0.43	Breast cancer;	chr3:64033530	chr3:64004022~64012148:+
TGCT	cis	rs929843	1	rs929843	ENSG00000226232.7	RP11-419C5.2	-5.34	4.36e-07	0.000548	-0.52	-0.43	Menarche (age at onset);	chr16:70011845	chr16:69976388~69996188:-
TGCT	cis	rs7208859	0.623	rs9895785	ENSG00000263531.1	RP13-753N3.1	-5.34	4.36e-07	0.000548	-0.81	-0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30863921~30864940:-
TGCT	cis	rs3091242	0.967	rs665372	ENSG00000224183.1	SDHDP6	-5.34	4.37e-07	0.000549	-0.46	-0.43	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25294164~25294643:-
TGCT	cis	rs7208859	0.673	rs216411	ENSG00000280069.1	CTD-2349P21.3	5.33	4.39e-07	0.000552	0.59	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576475	chr17:30738182~30740275:+
TGCT	cis	rs3091242	0.933	rs3093584	ENSG00000224183.1	SDHDP6	5.33	4.41e-07	0.000553	0.46	0.43	Erythrocyte sedimentation rate;	chr1:25342223	chr1:25294164~25294643:-
TGCT	cis	rs853679	0.517	rs3734573	ENSG00000219392.1	RP1-265C24.5	-5.33	4.42e-07	0.000554	-0.58	-0.43	Depression;	chr6:28091659	chr6:28115628~28116551:+
TGCT	cis	rs7849270	0.879	rs6478866	ENSG00000268707.1	RP11-247A12.7	-5.33	4.43e-07	0.000556	-0.5	-0.43	Blood metabolite ratios;	chr9:129133585	chr9:129170434~129170940:+
TGCT	cis	rs17301013	0.827	rs1793309	ENSG00000227373.4	RP11-160H22.5	-5.33	4.44e-07	0.000558	-0.47	-0.43	Systemic lupus erythematosus;	chr1:174826199	chr1:174115300~174160004:-
TGCT	cis	rs7849270	1	rs7036114	ENSG00000268707.1	RP11-247A12.7	-5.33	4.44e-07	0.000558	-0.48	-0.43	Blood metabolite ratios;	chr9:129131127	chr9:129170434~129170940:+
TGCT	cis	rs7849270	1	rs34055941	ENSG00000268707.1	RP11-247A12.7	-5.33	4.44e-07	0.000558	-0.48	-0.43	Blood metabolite ratios;	chr9:129132797	chr9:129170434~129170940:+
TGCT	cis	rs9322193	0.923	rs9767652	ENSG00000216906.2	RP11-350J20.9	5.33	4.45e-07	0.000558	0.49	0.43	Lung cancer;	chr6:149734502	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs10782314	ENSG00000216906.2	RP11-350J20.9	5.33	4.45e-07	0.000558	0.49	0.43	Lung cancer;	chr6:149735527	chr6:149904243~149906418:+
TGCT	cis	rs11671005	0.735	rs34873624	ENSG00000268912.1	CTD-2619J13.17	-5.33	4.46e-07	0.000559	-0.5	-0.43	Mean platelet volume;	chr19:58432035	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.693	rs34230465	ENSG00000268912.1	CTD-2619J13.17	-5.33	4.46e-07	0.000559	-0.5	-0.43	Mean platelet volume;	chr19:58432209	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.735	rs3764529	ENSG00000268912.1	CTD-2619J13.17	-5.33	4.46e-07	0.000559	-0.5	-0.43	Mean platelet volume;	chr19:58433722	chr19:58428632~58431148:-
TGCT	cis	rs7617773	0.963	rs9822496	ENSG00000229759.1	MRPS18AP1	5.33	4.46e-07	0.000559	0.33	0.43	Coronary artery disease;	chr3:48139843	chr3:48256350~48256938:-
TGCT	cis	rs440932	0.757	rs330943	ENSG00000254340.1	RP11-10A14.3	5.33	4.49e-07	0.000563	0.48	0.43	High light scatter reticulocyte percentage of red cells;	chr8:9163516	chr8:9141424~9145435:+
TGCT	cis	rs9322193	0.923	rs1080670	ENSG00000216906.2	RP11-350J20.9	5.33	4.5e-07	0.000564	0.49	0.43	Lung cancer;	chr6:149620161	chr6:149904243~149906418:+
TGCT	cis	rs7923609	0.756	rs7077256	ENSG00000232075.1	MRPL35P2	5.33	4.5e-07	0.000564	0.42	0.43	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576425	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.729	rs7902616	ENSG00000232075.1	MRPL35P2	5.33	4.5e-07	0.000564	0.42	0.43	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576613	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.756	rs10822183	ENSG00000232075.1	MRPL35P2	5.33	4.5e-07	0.000564	0.42	0.43	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63577381	chr10:63634317~63634827:-
TGCT	cis	rs7301826	1	rs7301826	ENSG00000256299.1	RP11-989F5.3	-5.33	4.51e-07	0.000565	-0.47	-0.43	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810821~130812622:-
TGCT	cis	rs8072100	0.871	rs7206971	ENSG00000228782.6	CTD-2026D20.3	-5.33	4.51e-07	0.000565	-0.52	-0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347749	chr17:47450568~47492492:-
TGCT	cis	rs17361889	0.752	rs6974124	ENSG00000224683.1	RPL36AP29	5.33	4.51e-07	0.000565	0.47	0.43	Pediatric bone mineral content (hip);	chr7:16234495	chr7:16208945~16209265:+
TGCT	cis	rs7301826	1	rs1106369	ENSG00000256299.1	RP11-989F5.3	-5.33	4.52e-07	0.000565	-0.47	-0.43	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810821~130812622:-
TGCT	cis	rs4835473	0.932	rs5015760	ENSG00000251600.4	RP11-673E1.1	-5.33	4.52e-07	0.000566	-0.43	-0.43	Immature fraction of reticulocytes;	chr4:143737955	chr4:143912331~143982454:+
TGCT	cis	rs3091242	0.933	rs11249250	ENSG00000261349.1	RP3-465N24.5	-5.33	4.53e-07	0.000567	-0.42	-0.43	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25266102~25267136:-
TGCT	cis	rs4713118	0.513	rs200971	ENSG00000216901.1	AL022393.7	5.33	4.54e-07	0.000569	0.55	0.43	Parkinson's disease;	chr6:27891126	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.539	rs200967	ENSG00000216901.1	AL022393.7	5.33	4.54e-07	0.000569	0.55	0.43	Parkinson's disease;	chr6:27894349	chr6:28176188~28176674:+
TGCT	cis	rs9425766	0.566	rs12079820	ENSG00000227373.4	RP11-160H22.5	5.33	4.55e-07	0.000569	0.47	0.43	Life satisfaction;	chr1:174240771	chr1:174115300~174160004:-
TGCT	cis	rs1823913	1	rs1840377	ENSG00000227542.1	AC092614.2	-5.33	4.56e-07	0.00057	-0.46	-0.43	Obesity-related traits;	chr2:191257992	chr2:191229165~191246172:-
TGCT	cis	rs1823913	1	rs4853564	ENSG00000227542.1	AC092614.2	-5.33	4.56e-07	0.00057	-0.46	-0.43	Obesity-related traits;	chr2:191258939	chr2:191229165~191246172:-
TGCT	cis	rs1823913	1	rs4853565	ENSG00000227542.1	AC092614.2	-5.33	4.56e-07	0.00057	-0.46	-0.43	Obesity-related traits;	chr2:191259020	chr2:191229165~191246172:-
TGCT	cis	rs1823913	1	rs4853462	ENSG00000227542.1	AC092614.2	-5.33	4.56e-07	0.00057	-0.46	-0.43	Obesity-related traits;	chr2:191259078	chr2:191229165~191246172:-
TGCT	cis	rs17361889	0.727	rs62440394	ENSG00000224683.1	RPL36AP29	5.33	4.56e-07	0.00057	0.47	0.43	Pediatric bone mineral content (hip);	chr7:16215008	chr7:16208945~16209265:+
TGCT	cis	rs17301013	0.507	rs10912786	ENSG00000227373.4	RP11-160H22.5	5.33	4.57e-07	0.000571	0.5	0.43	Systemic lupus erythematosus;	chr1:174427609	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12074416	ENSG00000227373.4	RP11-160H22.5	5.33	4.57e-07	0.000571	0.5	0.43	Systemic lupus erythematosus;	chr1:174430109	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12069134	ENSG00000227373.4	RP11-160H22.5	5.33	4.57e-07	0.000571	0.5	0.43	Systemic lupus erythematosus;	chr1:174434287	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs6677262	ENSG00000227373.4	RP11-160H22.5	5.33	4.57e-07	0.000571	0.5	0.43	Systemic lupus erythematosus;	chr1:174434539	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs60409344	ENSG00000227373.4	RP11-160H22.5	5.33	4.57e-07	0.000571	0.5	0.43	Systemic lupus erythematosus;	chr1:174438724	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs72713584	ENSG00000227373.4	RP11-160H22.5	5.33	4.57e-07	0.000571	0.5	0.43	Systemic lupus erythematosus;	chr1:174439129	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12077381	ENSG00000227373.4	RP11-160H22.5	5.33	4.57e-07	0.000571	0.5	0.43	Systemic lupus erythematosus;	chr1:174439566	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs74126805	ENSG00000227373.4	RP11-160H22.5	5.33	4.57e-07	0.000571	0.5	0.43	Systemic lupus erythematosus;	chr1:174440226	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12078960	ENSG00000227373.4	RP11-160H22.5	5.33	4.57e-07	0.000571	0.5	0.43	Systemic lupus erythematosus;	chr1:174440891	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12079011	ENSG00000227373.4	RP11-160H22.5	5.33	4.57e-07	0.000571	0.5	0.43	Systemic lupus erythematosus;	chr1:174441055	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12080407	ENSG00000227373.4	RP11-160H22.5	5.33	4.57e-07	0.000571	0.5	0.43	Systemic lupus erythematosus;	chr1:174441964	chr1:174115300~174160004:-
TGCT	cis	rs9462027	1	rs9296133	ENSG00000186328.4	RP11-140K17.2	5.32	4.58e-07	0.000572	0.45	0.43	Systemic lupus erythematosus;	chr6:34809756	chr6:34715613~34715940:+
TGCT	cis	rs8059260	0.604	rs35715760	ENSG00000274038.1	RP11-66H6.4	-5.32	4.58e-07	0.000573	-0.58	-0.43	Alcohol consumption over the past year;	chr16:11102091	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.544	rs34846673	ENSG00000274038.1	RP11-66H6.4	-5.32	4.58e-07	0.000573	-0.58	-0.43	Alcohol consumption over the past year;	chr16:11102829	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.604	rs12929596	ENSG00000274038.1	RP11-66H6.4	-5.32	4.58e-07	0.000573	-0.58	-0.43	Alcohol consumption over the past year;	chr16:11105495	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.604	rs12928945	ENSG00000274038.1	RP11-66H6.4	-5.32	4.58e-07	0.000573	-0.58	-0.43	Alcohol consumption over the past year;	chr16:11106309	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.604	rs34573672	ENSG00000274038.1	RP11-66H6.4	-5.32	4.58e-07	0.000573	-0.58	-0.43	Alcohol consumption over the past year;	chr16:11111882	chr16:11056556~11057034:+
TGCT	cis	rs904251	0.525	rs12200378	ENSG00000279942.1	RP1-153P14.7	-5.32	4.58e-07	0.000573	-0.45	-0.43	Cognitive performance;	chr6:37457528	chr6:37567716~37571460:+
TGCT	cis	rs8062405	0.755	rs4788076	ENSG00000259982.1	CDC37P1	5.32	4.59e-07	0.000573	0.6	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28700294~28701540:-
TGCT	cis	rs7301826	0.932	rs1007246	ENSG00000256299.1	RP11-989F5.3	-5.32	4.61e-07	0.000575	-0.47	-0.43	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810821~130812622:-
TGCT	cis	rs7044106	0.762	rs7849566	ENSG00000226752.6	PSMD5-AS1	-5.32	4.61e-07	0.000575	-0.56	-0.43	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120824828~120854385:+
TGCT	cis	rs9322193	0.886	rs9767555	ENSG00000216906.2	RP11-350J20.9	5.32	4.62e-07	0.000575	0.51	0.43	Lung cancer;	chr6:149647022	chr6:149904243~149906418:+
TGCT	cis	rs7811142	0.943	rs3900792	ENSG00000242294.5	STAG3L5P	5.32	4.64e-07	0.000578	0.4	0.43	Platelet count;	chr7:100406954	chr7:100336079~100351900:+
TGCT	cis	rs11671005	0.735	rs11670871	ENSG00000268912.1	CTD-2619J13.17	5.32	4.64e-07	0.000578	0.5	0.43	Mean platelet volume;	chr19:58429147	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.735	rs11667591	ENSG00000268912.1	CTD-2619J13.17	-5.32	4.64e-07	0.000578	-0.5	-0.43	Mean platelet volume;	chr19:58426270	chr19:58428632~58431148:-
TGCT	cis	rs8072100	0.84	rs12453233	ENSG00000228782.6	CTD-2026D20.3	5.32	4.66e-07	0.00058	0.53	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377204	chr17:47450568~47492492:-
TGCT	cis	rs17826219	0.636	rs4055314	ENSG00000263531.1	RP13-753N3.1	5.32	4.67e-07	0.000582	0.81	0.43	Body mass index;	chr17:30752751	chr17:30863921~30864940:-
TGCT	cis	rs17826219	0.636	rs79565452	ENSG00000263531.1	RP13-753N3.1	5.32	4.67e-07	0.000582	0.81	0.43	Body mass index;	chr17:30815823	chr17:30863921~30864940:-
TGCT	cis	rs11157436	0.958	rs17183308	ENSG00000211813.2	TRAV34	5.32	4.68e-07	0.000582	0.47	0.43	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22195090	chr14:22207522~22208129:+
TGCT	cis	rs35160687	0.64	rs13015186	ENSG00000273080.1	RP11-301O19.1	5.32	4.68e-07	0.000582	0.5	0.43	Night sleep phenotypes;	chr2:86258455	chr2:86195590~86196049:+
TGCT	cis	rs35160687	0.862	rs17737955	ENSG00000273080.1	RP11-301O19.1	5.32	4.68e-07	0.000582	0.5	0.43	Night sleep phenotypes;	chr2:86280891	chr2:86195590~86196049:+
TGCT	cis	rs899997	0.906	rs1809415	ENSG00000261143.1	ADAMTS7P3	-5.32	4.68e-07	0.000582	-0.55	-0.43	Coronary artery disease or large artery stroke;	chr15:78735859	chr15:77976042~77993057:+
TGCT	cis	rs7757969	0.536	rs706911	ENSG00000227012.2	RP1-97J1.2	5.32	4.69e-07	0.000584	0.74	0.43	Schizophrenia;	chr6:111728849	chr6:111900489~111901851:-
TGCT	cis	rs17826219	0.636	rs12946563	ENSG00000263531.1	RP13-753N3.1	5.32	4.71e-07	0.000586	0.82	0.43	Body mass index;	chr17:30776148	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs8081299	ENSG00000263531.1	RP13-753N3.1	5.32	4.71e-07	0.000586	0.82	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs8068645	ENSG00000263531.1	RP13-753N3.1	5.32	4.71e-07	0.000586	0.82	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30863921~30864940:-
TGCT	cis	rs11168618	0.509	rs4760729	ENSG00000240399.1	RP1-228P16.1	5.32	4.72e-07	0.000587	0.4	0.43	Adiponectin levels;	chr12:48546598	chr12:48054813~48055591:-
TGCT	cis	rs17301013	0.932	rs461910	ENSG00000227373.4	RP11-160H22.5	5.32	4.74e-07	0.000589	0.46	0.43	Systemic lupus erythematosus;	chr1:174736351	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.9	rs1754351	ENSG00000227373.4	RP11-160H22.5	-5.32	4.74e-07	0.000589	-0.46	-0.43	Systemic lupus erythematosus;	chr1:174762458	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.9	rs1793300	ENSG00000227373.4	RP11-160H22.5	-5.32	4.74e-07	0.000589	-0.46	-0.43	Systemic lupus erythematosus;	chr1:174768559	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.932	rs1653626	ENSG00000227373.4	RP11-160H22.5	-5.32	4.74e-07	0.000589	-0.46	-0.43	Systemic lupus erythematosus;	chr1:174770348	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.932	rs1653627	ENSG00000227373.4	RP11-160H22.5	-5.32	4.74e-07	0.000589	-0.46	-0.43	Systemic lupus erythematosus;	chr1:174771879	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.932	rs1793297	ENSG00000227373.4	RP11-160H22.5	-5.32	4.74e-07	0.000589	-0.46	-0.43	Systemic lupus erythematosus;	chr1:174784411	chr1:174115300~174160004:-
TGCT	cis	rs7208859	0.615	rs216462	ENSG00000263531.1	RP13-753N3.1	-5.32	4.74e-07	0.000589	-0.84	-0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30568879	chr17:30863921~30864940:-
TGCT	cis	rs5769707	0.632	rs135877	ENSG00000235111.1	RP1-29C18.8	-5.32	4.74e-07	0.000589	-0.41	-0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49620354	chr22:49612657~49615716:-
TGCT	cis	rs11671005	0.735	rs12986387	ENSG00000268912.1	CTD-2619J13.17	-5.32	4.75e-07	0.00059	-0.51	-0.43	Mean platelet volume;	chr19:58415848	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.735	rs11667723	ENSG00000268912.1	CTD-2619J13.17	-5.32	4.75e-07	0.00059	-0.51	-0.43	Mean platelet volume;	chr19:58416122	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.693	rs11668757	ENSG00000268912.1	CTD-2619J13.17	-5.32	4.75e-07	0.00059	-0.51	-0.43	Mean platelet volume;	chr19:58416932	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.735	rs11668789	ENSG00000268912.1	CTD-2619J13.17	-5.32	4.75e-07	0.00059	-0.51	-0.43	Mean platelet volume;	chr19:58416942	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.735	rs35652377	ENSG00000268912.1	CTD-2619J13.17	-5.32	4.75e-07	0.00059	-0.51	-0.43	Mean platelet volume;	chr19:58417833	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.735	rs3764532	ENSG00000268912.1	CTD-2619J13.17	-5.32	4.75e-07	0.00059	-0.51	-0.43	Mean platelet volume;	chr19:58417855	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.735	rs3088284	ENSG00000268912.1	CTD-2619J13.17	-5.32	4.75e-07	0.00059	-0.51	-0.43	Mean platelet volume;	chr19:58418060	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.735	rs12981649	ENSG00000268912.1	CTD-2619J13.17	-5.32	4.75e-07	0.00059	-0.51	-0.43	Mean platelet volume;	chr19:58418676	chr19:58428632~58431148:-
TGCT	cis	rs440932	1	rs440932	ENSG00000254340.1	RP11-10A14.3	5.32	4.77e-07	0.000592	0.47	0.43	High light scatter reticulocyte percentage of red cells;	chr8:9169419	chr8:9141424~9145435:+
TGCT	cis	rs440932	1	rs365309	ENSG00000254340.1	RP11-10A14.3	-5.32	4.77e-07	0.000592	-0.47	-0.43	High light scatter reticulocyte percentage of red cells;	chr8:9169430	chr8:9141424~9145435:+
TGCT	cis	rs8072100	0.84	rs1912482	ENSG00000228782.6	CTD-2026D20.3	5.32	4.77e-07	0.000592	0.53	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377517	chr17:47450568~47492492:-
TGCT	cis	rs8072100	0.84	rs2136751	ENSG00000228782.6	CTD-2026D20.3	5.32	4.77e-07	0.000592	0.53	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378727	chr17:47450568~47492492:-
TGCT	cis	rs453301	0.653	rs7005133	ENSG00000173295.6	FAM86B3P	5.32	4.77e-07	0.000593	0.52	0.43	Joint mobility (Beighton score);	chr8:9043712	chr8:8228595~8244865:+
TGCT	cis	rs875971	0.862	rs778720	ENSG00000232559.3	GS1-124K5.12	-5.31	4.78e-07	0.000594	-0.39	-0.43	Aortic root size;	chr7:66381288	chr7:66554588~66576923:-
TGCT	cis	rs1320333	0.772	rs2867116	ENSG00000233296.1	AC092159.2	5.31	4.79e-07	0.000595	0.6	0.43	Obesity-related traits;	chr2:682363	chr2:677186~697371:+
TGCT	cis	rs1320333	0.772	rs2903491	ENSG00000233296.1	AC092159.2	5.31	4.79e-07	0.000595	0.6	0.43	Obesity-related traits;	chr2:686688	chr2:677186~697371:+
TGCT	cis	rs1320333	0.772	rs111825088	ENSG00000233296.1	AC092159.2	5.31	4.79e-07	0.000595	0.6	0.43	Obesity-related traits;	chr2:695785	chr2:677186~697371:+
TGCT	cis	rs1799949	1	rs2175957	ENSG00000198496.9	NBR2	-5.31	4.79e-07	0.000595	-0.63	-0.43	Menopause (age at onset);	chr17:43134805	chr17:43125610~43153671:+
TGCT	cis	rs8072100	0.811	rs9889709	ENSG00000228782.6	CTD-2026D20.3	5.31	4.8e-07	0.000596	0.52	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47367863	chr17:47450568~47492492:-
TGCT	cis	rs17301013	0.507	rs16847337	ENSG00000227373.4	RP11-160H22.5	-5.31	4.82e-07	0.000597	-0.52	-0.43	Systemic lupus erythematosus;	chr1:174683121	chr1:174115300~174160004:-
TGCT	cis	rs9604529	0.759	rs73579379	ENSG00000269376.1	RP11-120K24.5	5.31	4.82e-07	0.000597	0.42	0.43	Response to tocilizumab in rheumatoid arthritis;	chr13:113917809	chr13:113009671~113010319:+
TGCT	cis	rs9604529	0.759	rs79693929	ENSG00000269376.1	RP11-120K24.5	5.31	4.82e-07	0.000597	0.42	0.43	Response to tocilizumab in rheumatoid arthritis;	chr13:113920290	chr13:113009671~113010319:+
TGCT	cis	rs9604529	0.759	rs79192570	ENSG00000269376.1	RP11-120K24.5	5.31	4.82e-07	0.000597	0.42	0.43	Response to tocilizumab in rheumatoid arthritis;	chr13:113922597	chr13:113009671~113010319:+
TGCT	cis	rs9326248	0.53	rs6589589	ENSG00000254851.1	RP11-109L13.1	-5.31	4.83e-07	0.000597	-0.83	-0.43	Blood protein levels;	chr11:117061712	chr11:117135528~117138582:+
TGCT	cis	rs321358	1	rs321357	ENSG00000271584.1	RP11-89C3.4	5.31	4.83e-07	0.000597	0.55	0.43	Body mass index;	chr11:111125002	chr11:111091932~111097357:-
TGCT	cis	rs4423214	0.535	rs1540129	ENSG00000254682.1	RP11-660L16.2	5.31	4.83e-07	0.000598	0.6	0.43	Vitamin D levels;	chr11:71418477	chr11:71448674~71452157:+
TGCT	cis	rs8072100	0.811	rs1912483	ENSG00000228782.6	CTD-2026D20.3	5.31	4.84e-07	0.000599	0.52	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366128	chr17:47450568~47492492:-
TGCT	cis	rs34779708	0.931	rs12268745	ENSG00000230534.5	RP11-297A16.2	5.31	4.84e-07	0.000599	0.5	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35017061	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs72789609	ENSG00000230534.5	RP11-297A16.2	5.31	4.84e-07	0.000599	0.5	0.43	Inflammatory bowel disease;Crohn's disease;	chr10:35017278	chr10:35098006~35127020:-
TGCT	cis	rs2115630	0.653	rs61394864	ENSG00000225151.9	GOLGA2P7	5.31	4.85e-07	6e-04	0.44	0.43	P wave terminal force;	chr15:84626943	chr15:84199311~84230136:-
TGCT	cis	rs7795991	1	rs10238619	ENSG00000224330.1	AC005019.3	-5.31	4.86e-07	0.000601	-0.45	-0.43	Type 2 diabetes;	chr7:13861391	chr7:13854355~13859025:-
TGCT	cis	rs11723261	0.582	rs3747693	ENSG00000275426.1	CH17-262A2.1	5.31	4.86e-07	0.000601	0.82	0.43	Immune response to smallpox vaccine (IL-6);	chr4:124493	chr4:149738~150317:+
TGCT	cis	rs6061231	0.834	rs2427307	ENSG00000273619.1	RP5-908M14.9	-5.31	4.86e-07	0.000601	-0.46	-0.43	Colorectal cancer;	chr20:62391630	chr20:62386303~62386970:-
TGCT	cis	rs7605378	0.528	rs812760	ENSG00000232732.8	AC073043.1	-5.31	4.86e-07	0.000602	-0.49	-0.43	Osteoporosis;	chr2:199859649	chr2:199867396~199911159:-
TGCT	cis	rs4835473	0.712	rs12498218	ENSG00000251600.4	RP11-673E1.1	-5.31	4.87e-07	0.000602	-0.43	-0.43	Immature fraction of reticulocytes;	chr4:143736900	chr4:143912331~143982454:+
TGCT	cis	rs5769707	0.609	rs2007024	ENSG00000235111.1	RP1-29C18.8	-5.31	4.88e-07	0.000604	-0.4	-0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49595167	chr22:49612657~49615716:-
TGCT	cis	rs7811142	0.945	rs34989573	ENSG00000242294.5	STAG3L5P	5.31	4.89e-07	0.000604	0.41	0.43	Platelet count;	chr7:100500272	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.945	rs6974282	ENSG00000242294.5	STAG3L5P	5.31	4.89e-07	0.000604	0.41	0.43	Platelet count;	chr7:100500672	chr7:100336079~100351900:+
TGCT	cis	rs7811142	0.945	rs6978739	ENSG00000242294.5	STAG3L5P	5.31	4.89e-07	0.000604	0.41	0.43	Platelet count;	chr7:100501057	chr7:100336079~100351900:+
TGCT	cis	rs904251	0.6	rs2270687	ENSG00000279942.1	RP1-153P14.7	-5.31	4.89e-07	0.000604	-0.45	-0.43	Cognitive performance;	chr6:37450487	chr6:37567716~37571460:+
TGCT	cis	rs3091242	0.933	rs1534954	ENSG00000224183.1	SDHDP6	-5.31	4.89e-07	0.000605	-0.46	-0.43	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25294164~25294643:-
TGCT	cis	rs453301	0.507	rs2929306	ENSG00000173295.6	FAM86B3P	-5.31	4.91e-07	0.000607	-0.47	-0.43	Joint mobility (Beighton score);	chr8:9227399	chr8:8228595~8244865:+
TGCT	cis	rs7714584	1	rs75774363	ENSG00000197083.10	ZNF300P1	5.31	4.94e-07	0.00061	0.75	0.43	Crohn's disease;	chr5:150844160	chr5:150930645~150946289:-
TGCT	cis	rs1823913	0.927	rs13025919	ENSG00000227542.1	AC092614.2	5.31	4.94e-07	0.00061	0.46	0.43	Obesity-related traits;	chr2:191260175	chr2:191229165~191246172:-
TGCT	cis	rs2117029	0.737	rs34436857	ENSG00000258017.1	RP11-386G11.10	-5.31	4.94e-07	0.00061	-0.54	-0.43	Intelligence (multi-trait analysis);	chr12:49045738	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.767	rs12580349	ENSG00000258017.1	RP11-386G11.10	5.31	4.94e-07	0.00061	0.54	0.43	Intelligence (multi-trait analysis);	chr12:49042941	chr12:49127782~49147869:+
TGCT	cis	rs12891047	0.966	rs181575	ENSG00000258759.1	RP11-1012A1.7	-5.31	4.95e-07	0.000611	-0.36	-0.43	Amyotrophic lateral sclerosis (sporadic);	chr14:67806862	chr14:67799004~67799609:+
TGCT	cis	rs17361889	0.778	rs56279207	ENSG00000224683.1	RPL36AP29	5.31	4.96e-07	0.000612	0.44	0.43	Pediatric bone mineral content (hip);	chr7:16275559	chr7:16208945~16209265:+
TGCT	cis	rs7617773	0.78	rs35297395	ENSG00000229759.1	MRPS18AP1	5.31	4.97e-07	0.000613	0.38	0.43	Coronary artery disease;	chr3:48301392	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs36075665	ENSG00000229759.1	MRPS18AP1	5.31	4.97e-07	0.000613	0.38	0.43	Coronary artery disease;	chr3:48301597	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs34630841	ENSG00000229759.1	MRPS18AP1	5.31	4.97e-07	0.000613	0.38	0.43	Coronary artery disease;	chr3:48301771	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs35190747	ENSG00000229759.1	MRPS18AP1	5.31	4.97e-07	0.000613	0.38	0.43	Coronary artery disease;	chr3:48301800	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.743	rs7621785	ENSG00000229759.1	MRPS18AP1	5.31	4.97e-07	0.000613	0.38	0.43	Coronary artery disease;	chr3:48302218	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs4511915	ENSG00000229759.1	MRPS18AP1	5.31	4.97e-07	0.000613	0.38	0.43	Coronary artery disease;	chr3:48302368	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs13066758	ENSG00000229759.1	MRPS18AP1	5.31	4.97e-07	0.000613	0.38	0.43	Coronary artery disease;	chr3:48302387	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs4392440	ENSG00000229759.1	MRPS18AP1	5.31	4.97e-07	0.000613	0.38	0.43	Coronary artery disease;	chr3:48302430	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs13082859	ENSG00000229759.1	MRPS18AP1	5.31	4.97e-07	0.000613	0.38	0.43	Coronary artery disease;	chr3:48303185	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs36121690	ENSG00000229759.1	MRPS18AP1	5.31	4.97e-07	0.000613	0.38	0.43	Coronary artery disease;	chr3:48304021	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs35778847	ENSG00000229759.1	MRPS18AP1	5.31	4.97e-07	0.000613	0.38	0.43	Coronary artery disease;	chr3:48305495	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs34749846	ENSG00000229759.1	MRPS18AP1	5.31	4.97e-07	0.000613	0.38	0.43	Coronary artery disease;	chr3:48305678	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs7632297	ENSG00000229759.1	MRPS18AP1	5.31	4.97e-07	0.000613	0.38	0.43	Coronary artery disease;	chr3:48306673	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs79089926	ENSG00000229759.1	MRPS18AP1	5.31	4.97e-07	0.000613	0.38	0.43	Coronary artery disease;	chr3:48307074	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.643	rs78159520	ENSG00000229759.1	MRPS18AP1	5.31	4.97e-07	0.000613	0.38	0.43	Coronary artery disease;	chr3:48307533	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs77044321	ENSG00000229759.1	MRPS18AP1	5.31	4.97e-07	0.000613	0.38	0.43	Coronary artery disease;	chr3:48307824	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs4511916	ENSG00000229759.1	MRPS18AP1	5.31	4.97e-07	0.000613	0.38	0.43	Coronary artery disease;	chr3:48308876	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.815	rs7624450	ENSG00000229759.1	MRPS18AP1	5.31	4.97e-07	0.000613	0.38	0.43	Coronary artery disease;	chr3:48308885	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.815	rs6793150	ENSG00000229759.1	MRPS18AP1	5.31	4.97e-07	0.000613	0.38	0.43	Coronary artery disease;	chr3:48310070	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs6793239	ENSG00000229759.1	MRPS18AP1	5.31	4.97e-07	0.000613	0.38	0.43	Coronary artery disease;	chr3:48310128	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs6782166	ENSG00000229759.1	MRPS18AP1	5.31	4.97e-07	0.000613	0.38	0.43	Coronary artery disease;	chr3:48310193	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs4130522	ENSG00000229759.1	MRPS18AP1	5.31	4.97e-07	0.000613	0.38	0.43	Coronary artery disease;	chr3:48310823	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.674	rs13069029	ENSG00000229759.1	MRPS18AP1	5.31	4.97e-07	0.000613	0.38	0.43	Coronary artery disease;	chr3:48313534	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs13081169	ENSG00000229759.1	MRPS18AP1	5.31	4.97e-07	0.000613	0.38	0.43	Coronary artery disease;	chr3:48315307	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.743	rs13081633	ENSG00000229759.1	MRPS18AP1	5.31	4.97e-07	0.000613	0.38	0.43	Coronary artery disease;	chr3:48315791	chr3:48256350~48256938:-
TGCT	cis	rs8059260	0.544	rs35347079	ENSG00000274038.1	RP11-66H6.4	-5.31	4.97e-07	0.000613	-0.59	-0.43	Alcohol consumption over the past year;	chr16:11099696	chr16:11056556~11057034:+
TGCT	cis	rs2880765	0.566	rs12911430	ENSG00000259295.5	CSPG4P12	5.31	4.97e-07	0.000613	0.55	0.43	Coronary artery disease;	chr15:85468033	chr15:85191438~85213905:+
TGCT	cis	rs35160687	0.862	rs12476706	ENSG00000273080.1	RP11-301O19.1	5.31	4.97e-07	0.000613	0.5	0.43	Night sleep phenotypes;	chr2:86301247	chr2:86195590~86196049:+
TGCT	cis	rs453301	0.522	rs2929309	ENSG00000173295.6	FAM86B3P	-5.31	4.97e-07	0.000613	-0.49	-0.43	Joint mobility (Beighton score);	chr8:9226261	chr8:8228595~8244865:+
TGCT	cis	rs17301013	0.869	rs3133270	ENSG00000227373.4	RP11-160H22.5	-5.31	5e-07	0.000616	-0.47	-0.43	Systemic lupus erythematosus;	chr1:174819547	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.932	rs2987869	ENSG00000227373.4	RP11-160H22.5	-5.31	5e-07	0.000616	-0.47	-0.43	Systemic lupus erythematosus;	chr1:174820269	chr1:174115300~174160004:-
TGCT	cis	rs3091242	0.9	rs35345536	ENSG00000224183.1	SDHDP6	-5.3	5.01e-07	0.000617	-0.46	-0.43	Erythrocyte sedimentation rate;	chr1:25439997	chr1:25294164~25294643:-
TGCT	cis	rs2880765	0.566	rs17553249	ENSG00000259295.5	CSPG4P12	5.3	5.01e-07	0.000618	0.55	0.43	Coronary artery disease;	chr15:85463463	chr15:85191438~85213905:+
TGCT	cis	rs9660180	0.837	rs915292	ENSG00000268575.1	RP1-283E3.8	-5.3	5.01e-07	0.000618	-0.35	-0.43	Body mass index;	chr1:1860718	chr1:1702736~1737688:-
TGCT	cis	rs8062405	0.755	rs1074631	ENSG00000259982.1	CDC37P1	-5.3	5.03e-07	0.000619	-0.6	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28700294~28701540:-
TGCT	cis	rs367615	0.512	rs414724	ENSG00000249476.1	CTD-2587M2.1	5.3	5.03e-07	0.000619	0.45	0.43	Colorectal cancer (SNP x SNP interaction);	chr5:109334720	chr5:109237120~109326369:-
TGCT	cis	rs9322193	0.923	rs9688350	ENSG00000216906.2	RP11-350J20.9	5.3	5.04e-07	0.00062	0.48	0.43	Lung cancer;	chr6:149730977	chr6:149904243~149906418:+
TGCT	cis	rs4423214	0.879	rs1790353	ENSG00000254682.1	RP11-660L16.2	-5.3	5.05e-07	0.000621	-0.66	-0.43	Vitamin D levels;	chr11:71425684	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.879	rs1792277	ENSG00000254682.1	RP11-660L16.2	-5.3	5.05e-07	0.000621	-0.66	-0.43	Vitamin D levels;	chr11:71427872	chr11:71448674~71452157:+
TGCT	cis	rs7208859	0.623	rs7214570	ENSG00000263531.1	RP13-753N3.1	5.3	5.05e-07	0.000621	0.75	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30863921~30864940:-
TGCT	cis	rs6964833	1	rs36044436	ENSG00000123965.13	PMS2P5	5.3	5.06e-07	0.000622	0.62	0.43	Menarche (age at onset);	chr7:74675495	chr7:74894116~74897835:+
TGCT	cis	rs875971	0.577	rs35072105	ENSG00000236529.1	RP13-254B10.1	-5.3	5.07e-07	0.000624	-0.33	-0.43	Aortic root size;	chr7:66144830	chr7:65840212~65840596:+
TGCT	cis	rs1153858	1	rs2467863	ENSG00000259520.4	CTD-2651B20.3	-5.3	5.07e-07	0.000624	-0.37	-0.43	Homoarginine levels;	chr15:45349682	chr15:45251580~45279251:-
TGCT	cis	rs4423214	0.625	rs78685409	ENSG00000254682.1	RP11-660L16.2	-5.3	5.08e-07	0.000624	-0.66	-0.43	Vitamin D levels;	chr11:71426337	chr11:71448674~71452157:+
TGCT	cis	rs6061231	1	rs13043313	ENSG00000273619.1	RP5-908M14.9	-5.3	5.1e-07	0.000626	-0.46	-0.43	Colorectal cancer;	chr20:62383213	chr20:62386303~62386970:-
TGCT	cis	rs11671005	0.735	rs1122955	ENSG00000268912.1	CTD-2619J13.17	-5.3	5.11e-07	0.000628	-0.5	-0.43	Mean platelet volume;	chr19:58434836	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.735	rs11668814	ENSG00000268912.1	CTD-2619J13.17	-5.3	5.11e-07	0.000628	-0.5	-0.43	Mean platelet volume;	chr19:58435466	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.735	rs45617039	ENSG00000268912.1	CTD-2619J13.17	-5.3	5.11e-07	0.000628	-0.5	-0.43	Mean platelet volume;	chr19:58439729	chr19:58428632~58431148:-
TGCT	cis	rs2115630	0.691	rs8040066	ENSG00000225151.9	GOLGA2P7	5.3	5.14e-07	0.000631	0.43	0.43	P wave terminal force;	chr15:84633234	chr15:84199311~84230136:-
TGCT	cis	rs9660180	0.967	rs6687065	ENSG00000268575.1	RP1-283E3.8	-5.3	5.15e-07	0.000632	-0.35	-0.43	Body mass index;	chr1:1847030	chr1:1702736~1737688:-
TGCT	cis	rs321358	0.945	rs17458885	ENSG00000271584.1	RP11-89C3.4	5.3	5.15e-07	0.000632	0.57	0.43	Body mass index;	chr11:111117222	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.945	rs7931995	ENSG00000271584.1	RP11-89C3.4	5.3	5.15e-07	0.000632	0.57	0.43	Body mass index;	chr11:111117691	chr11:111091932~111097357:-
TGCT	cis	rs17301013	0.507	rs2760057	ENSG00000227373.4	RP11-160H22.5	5.3	5.15e-07	0.000632	0.5	0.43	Systemic lupus erythematosus;	chr1:174743384	chr1:174115300~174160004:-
TGCT	cis	rs321358	0.945	rs7112932	ENSG00000271584.1	RP11-89C3.4	5.3	5.16e-07	0.000634	0.57	0.43	Body mass index;	chr11:111101099	chr11:111091932~111097357:-
TGCT	cis	rs453301	0.598	rs1025395	ENSG00000173295.6	FAM86B3P	5.3	5.16e-07	0.000634	0.52	0.43	Joint mobility (Beighton score);	chr8:8979093	chr8:8228595~8244865:+
TGCT	cis	rs3091242	0.933	rs926438	ENSG00000261349.1	RP3-465N24.5	-5.3	5.17e-07	0.000634	-0.42	-0.43	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25266102~25267136:-
TGCT	cis	rs4835473	0.669	rs75704080	ENSG00000251600.4	RP11-673E1.1	-5.3	5.17e-07	0.000634	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143779066	chr4:143912331~143982454:+
TGCT	cis	rs904251	0.504	rs1757188	ENSG00000279942.1	RP1-153P14.7	-5.3	5.18e-07	0.000636	-0.43	-0.43	Cognitive performance;	chr6:37516032	chr6:37567716~37571460:+
TGCT	cis	rs904251	0.522	rs882322	ENSG00000279942.1	RP1-153P14.7	-5.3	5.18e-07	0.000636	-0.43	-0.43	Cognitive performance;	chr6:37516327	chr6:37567716~37571460:+
TGCT	cis	rs1757171	0.542	rs1757186	ENSG00000279942.1	RP1-153P14.7	-5.3	5.18e-07	0.000636	-0.43	-0.43	Cognitive performance;	chr6:37516335	chr6:37567716~37571460:+
TGCT	cis	rs7849270	1	rs7021449	ENSG00000268707.1	RP11-247A12.7	-5.3	5.18e-07	0.000636	-0.48	-0.43	Blood metabolite ratios;	chr9:129137033	chr9:129170434~129170940:+
TGCT	cis	rs7849270	1	rs713219	ENSG00000268707.1	RP11-247A12.7	-5.3	5.18e-07	0.000636	-0.48	-0.43	Blood metabolite ratios;	chr9:129138641	chr9:129170434~129170940:+
TGCT	cis	rs8040855	0.965	rs6496766	ENSG00000259295.5	CSPG4P12	-5.3	5.2e-07	0.000637	-0.55	-0.43	Bulimia nervosa;	chr15:85159144	chr15:85191438~85213905:+
TGCT	cis	rs8040855	1	rs6496768	ENSG00000259295.5	CSPG4P12	-5.3	5.2e-07	0.000637	-0.55	-0.43	Bulimia nervosa;	chr15:85159701	chr15:85191438~85213905:+
TGCT	cis	rs4835473	0.932	rs28796049	ENSG00000251600.4	RP11-673E1.1	5.3	5.21e-07	0.000637	0.42	0.43	Immature fraction of reticulocytes;	chr4:143733990	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs13152209	ENSG00000251600.4	RP11-673E1.1	5.3	5.21e-07	0.000637	0.42	0.43	Immature fraction of reticulocytes;	chr4:143776088	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs10016223	ENSG00000251600.4	RP11-673E1.1	5.3	5.21e-07	0.000637	0.42	0.43	Immature fraction of reticulocytes;	chr4:143777429	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs13129702	ENSG00000251600.4	RP11-673E1.1	5.3	5.21e-07	0.000637	0.42	0.43	Immature fraction of reticulocytes;	chr4:143785132	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs4383567	ENSG00000251600.4	RP11-673E1.1	5.3	5.21e-07	0.000637	0.42	0.43	Immature fraction of reticulocytes;	chr4:143788873	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs35230778	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143734336	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs34772566	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143734355	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs35419968	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143734583	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.868	rs66634585	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143734608	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.868	rs35016507	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143734617	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs67600034	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143734670	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs35655934	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143734697	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs35515006	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143734705	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs34525847	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143734970	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs35277115	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143735001	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs34653324	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143735058	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs35947648	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143735092	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs66474962	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143735145	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.838	rs35800634	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143735199	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.838	rs34505330	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143735206	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs4597770	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143735239	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.868	rs4629390	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143735302	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.838	rs4583708	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143735610	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.864	rs13117932	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143735873	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs34257944	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143736443	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs5016158	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143738472	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs5016157	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143738587	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.808	rs13134564	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143738763	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.838	rs13134571	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143738771	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs13139738	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143738828	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs17018165	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143738849	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.808	rs2060652	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143739129	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.808	rs2060653	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143739132	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs2060654	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143739155	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs2060655	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143739159	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs7689374	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143769567	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs6537183	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143770441	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs12512202	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143771248	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs6843671	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143772041	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs35395070	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143772283	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs34614750	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143772369	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs35002497	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143772952	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs13119630	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143773901	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1450233	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143774710	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs4308330	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143774761	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs11725708	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143775683	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs17762299	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143777196	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs17694797	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143778812	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs35947975	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143778969	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.778	rs75562808	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143779065	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1375987	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143779622	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs7687151	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143781681	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1450236	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143783069	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs62339580	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143785090	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs62339581	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143785172	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs7666368	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143785372	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs7690428	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143785400	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs34781605	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143785486	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.808	rs4054643	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143787329	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.838	rs34819068	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143787330	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs11100810	ENSG00000251600.4	RP11-673E1.1	-5.3	5.21e-07	0.000637	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143787518	chr4:143912331~143982454:+
TGCT	cis	rs651907	0.737	rs9844218	ENSG00000244119.1	PDCL3P4	-5.3	5.21e-07	0.000638	-0.29	-0.43	Colorectal cancer;	chr3:101866139	chr3:101712472~101713191:+
TGCT	cis	rs35160687	0.862	rs13024964	ENSG00000273080.1	RP11-301O19.1	5.3	5.21e-07	0.000638	0.5	0.43	Night sleep phenotypes;	chr2:86284745	chr2:86195590~86196049:+
TGCT	cis	rs786425	0.682	rs11611354	ENSG00000278112.1	RP11-972P1.11	5.3	5.21e-07	0.000638	0.52	0.43	Pubertal anthropometrics;	chr12:123669092	chr12:123519390~123519856:-
TGCT	cis	rs7849270	1	rs7037163	ENSG00000268707.1	RP11-247A12.7	-5.3	5.22e-07	0.000638	-0.49	-0.43	Blood metabolite ratios;	chr9:129132061	chr9:129170434~129170940:+
TGCT	cis	rs507080	0.922	rs654792	ENSG00000255422.1	AP002954.4	5.3	5.22e-07	0.000638	0.5	0.43	Serum metabolite levels;	chr11:118682287	chr11:118704607~118750263:+
TGCT	cis	rs12891047	1	rs2235965	ENSG00000258759.1	RP11-1012A1.7	5.3	5.22e-07	0.000639	0.36	0.43	Amyotrophic lateral sclerosis (sporadic);	chr14:67782316	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.87	rs2235966	ENSG00000258759.1	RP11-1012A1.7	5.3	5.22e-07	0.000639	0.36	0.43	Amyotrophic lateral sclerosis (sporadic);	chr14:67782387	chr14:67799004~67799609:+
TGCT	cis	rs847845	0.614	rs56140217	ENSG00000186328.4	RP11-140K17.2	5.3	5.23e-07	0.000639	0.73	0.43	Non-small cell lung cancer;	chr6:34973241	chr6:34715613~34715940:+
TGCT	cis	rs17301013	0.794	rs1793293	ENSG00000227373.4	RP11-160H22.5	-5.3	5.23e-07	0.000639	-0.47	-0.43	Systemic lupus erythematosus;	chr1:174774451	chr1:174115300~174160004:-
TGCT	cis	rs1799949	1	rs16940	ENSG00000198496.9	NBR2	-5.29	5.23e-07	0.00064	-0.62	-0.43	Menopause (age at onset);	chr17:43093220	chr17:43125610~43153671:+
TGCT	cis	rs2115630	0.691	rs61322921	ENSG00000225151.9	GOLGA2P7	5.29	5.23e-07	0.00064	0.44	0.43	P wave terminal force;	chr15:84620407	chr15:84199311~84230136:-
TGCT	cis	rs11671005	0.695	rs8106061	ENSG00000268912.1	CTD-2619J13.17	-5.29	5.24e-07	0.000641	-0.5	-0.43	Mean platelet volume;	chr19:58406623	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.735	rs11084544	ENSG00000268912.1	CTD-2619J13.17	-5.29	5.24e-07	0.000641	-0.5	-0.43	Mean platelet volume;	chr19:58428760	chr19:58428632~58431148:-
TGCT	cis	rs4835473	0.932	rs13134327	ENSG00000251600.4	RP11-673E1.1	5.29	5.27e-07	0.000644	0.42	0.43	Immature fraction of reticulocytes;	chr4:143738642	chr4:143912331~143982454:+
TGCT	cis	rs10504229	0.775	rs56155911	ENSG00000253301.4	RP11-513O17.2	5.29	5.28e-07	0.000645	0.61	0.43	Developmental language disorder (linguistic errors);	chr8:57250688	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.775	rs56082079	ENSG00000253301.4	RP11-513O17.2	5.29	5.28e-07	0.000645	0.61	0.43	Developmental language disorder (linguistic errors);	chr8:57251173	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.815	rs55855654	ENSG00000253301.4	RP11-513O17.2	5.29	5.28e-07	0.000645	0.61	0.43	Developmental language disorder (linguistic errors);	chr8:57251740	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.815	rs72650877	ENSG00000253301.4	RP11-513O17.2	5.29	5.28e-07	0.000645	0.61	0.43	Developmental language disorder (linguistic errors);	chr8:57251951	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.815	rs72650879	ENSG00000253301.4	RP11-513O17.2	5.29	5.28e-07	0.000645	0.61	0.43	Developmental language disorder (linguistic errors);	chr8:57252089	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.774	rs72650880	ENSG00000253301.4	RP11-513O17.2	5.29	5.28e-07	0.000645	0.61	0.43	Developmental language disorder (linguistic errors);	chr8:57252168	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.863	rs75954631	ENSG00000253301.4	RP11-513O17.2	5.29	5.28e-07	0.000645	0.61	0.43	Developmental language disorder (linguistic errors);	chr8:57253635	chr8:57142689~57240298:+
TGCT	cis	rs507080	0.922	rs546890	ENSG00000255422.1	AP002954.4	-5.29	5.28e-07	0.000645	-0.5	-0.43	Serum metabolite levels;	chr11:118686489	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.922	rs555356	ENSG00000255422.1	AP002954.4	-5.29	5.28e-07	0.000645	-0.5	-0.43	Serum metabolite levels;	chr11:118687369	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.883	rs693306	ENSG00000255422.1	AP002954.4	-5.29	5.28e-07	0.000645	-0.5	-0.43	Serum metabolite levels;	chr11:118687624	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.922	rs558907	ENSG00000255422.1	AP002954.4	-5.29	5.28e-07	0.000645	-0.5	-0.43	Serum metabolite levels;	chr11:118687746	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.922	rs561845	ENSG00000255422.1	AP002954.4	-5.29	5.28e-07	0.000645	-0.5	-0.43	Serum metabolite levels;	chr11:118688118	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.922	rs638805	ENSG00000255422.1	AP002954.4	-5.29	5.28e-07	0.000645	-0.5	-0.43	Serum metabolite levels;	chr11:118688180	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.845	rs510408	ENSG00000255422.1	AP002954.4	-5.29	5.28e-07	0.000645	-0.5	-0.43	Serum metabolite levels;	chr11:118688192	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.845	rs509641	ENSG00000255422.1	AP002954.4	-5.29	5.28e-07	0.000645	-0.5	-0.43	Serum metabolite levels;	chr11:118688243	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.883	rs563549	ENSG00000255422.1	AP002954.4	-5.29	5.28e-07	0.000645	-0.5	-0.43	Serum metabolite levels;	chr11:118688244	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.885	rs533144	ENSG00000255422.1	AP002954.4	-5.29	5.28e-07	0.000645	-0.5	-0.43	Serum metabolite levels;	chr11:118688538	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.885	rs7926959	ENSG00000255422.1	AP002954.4	-5.29	5.28e-07	0.000645	-0.5	-0.43	Serum metabolite levels;	chr11:118689157	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.663	rs7926970	ENSG00000255422.1	AP002954.4	-5.29	5.28e-07	0.000645	-0.5	-0.43	Serum metabolite levels;	chr11:118689172	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.885	rs4938530	ENSG00000255422.1	AP002954.4	-5.29	5.28e-07	0.000645	-0.5	-0.43	Serum metabolite levels;	chr11:118689861	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.883	rs12798453	ENSG00000255422.1	AP002954.4	-5.29	5.28e-07	0.000645	-0.5	-0.43	Serum metabolite levels;	chr11:118690701	chr11:118704607~118750263:+
TGCT	cis	rs4970988	0.556	rs2280078	ENSG00000206931.1	RNU6-1042P	-5.29	5.29e-07	0.000645	-0.34	-0.43	Urate levels;	chr1:150627705	chr1:150701866~150701972:+
TGCT	cis	rs2739330	0.76	rs1007888	ENSG00000250470.1	AP000351.3	5.29	5.3e-07	0.000646	0.42	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23976904~23977585:-
TGCT	cis	rs4835473	0.897	rs34380794	ENSG00000251600.4	RP11-673E1.1	-5.29	5.3e-07	0.000647	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143735800	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.75	rs56372690	ENSG00000251600.4	RP11-673E1.1	-5.29	5.3e-07	0.000647	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143735816	chr4:143912331~143982454:+
TGCT	cis	rs950169	0.922	rs62029585	ENSG00000225151.9	GOLGA2P7	-5.29	5.3e-07	0.000647	-0.51	-0.43	Schizophrenia;	chr15:84397176	chr15:84199311~84230136:-
TGCT	cis	rs17826219	0.706	rs2322197	ENSG00000263531.1	RP13-753N3.1	5.29	5.31e-07	0.000647	0.8	0.43	Body mass index;	chr17:30778787	chr17:30863921~30864940:-
TGCT	cis	rs8072100	0.84	rs9895746	ENSG00000228782.6	CTD-2026D20.3	5.29	5.31e-07	0.000648	0.52	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47401733	chr17:47450568~47492492:-
TGCT	cis	rs1450985	0.966	rs6764606	ENSG00000239653.1	PSMD6-AS2	5.29	5.32e-07	0.000649	0.4	0.43	Breast cancer;	chr3:64034771	chr3:64004022~64012148:+
TGCT	cis	rs7617773	0.746	rs11713476	ENSG00000229759.1	MRPS18AP1	5.29	5.32e-07	0.000649	0.36	0.43	Coronary artery disease;	chr3:48333944	chr3:48256350~48256938:-
TGCT	cis	rs2921073	0.51	rs2976945	ENSG00000173295.6	FAM86B3P	5.29	5.32e-07	0.000649	0.53	0.43	Parkinson's disease;	chr8:8413361	chr8:8228595~8244865:+
TGCT	cis	rs3091242	0.836	rs34997029	ENSG00000261349.1	RP3-465N24.5	5.29	5.32e-07	0.000649	0.42	0.43	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25266102~25267136:-
TGCT	cis	rs55794721	0.509	rs12027135	ENSG00000261349.1	RP3-465N24.5	-5.29	5.32e-07	0.000649	-0.42	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25266102~25267136:-
TGCT	cis	rs11157436	0.958	rs1041859	ENSG00000211813.2	TRAV34	5.29	5.34e-07	0.000651	0.46	0.43	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22204878	chr14:22207522~22208129:+
TGCT	cis	rs11157436	0.958	rs1041860	ENSG00000211813.2	TRAV34	5.29	5.34e-07	0.000651	0.46	0.43	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22204897	chr14:22207522~22208129:+
TGCT	cis	rs904251	0.797	rs1776460	ENSG00000279942.1	RP1-153P14.7	-5.29	5.34e-07	0.000651	-0.47	-0.43	Cognitive performance;	chr6:37517708	chr6:37567716~37571460:+
TGCT	cis	rs5769707	0.632	rs135871	ENSG00000235111.1	RP1-29C18.8	-5.29	5.35e-07	0.000652	-0.41	-0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49615321	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.632	rs135872	ENSG00000235111.1	RP1-29C18.8	-5.29	5.35e-07	0.000652	-0.41	-0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49615652	chr22:49612657~49615716:-
TGCT	cis	rs453301	0.624	rs2979265	ENSG00000173295.6	FAM86B3P	5.29	5.36e-07	0.000653	0.51	0.43	Joint mobility (Beighton score);	chr8:9001207	chr8:8228595~8244865:+
TGCT	cis	rs8062405	0.755	rs12447461	ENSG00000259982.1	CDC37P1	5.29	5.36e-07	0.000653	0.6	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.755	rs111693583	ENSG00000259982.1	CDC37P1	5.29	5.36e-07	0.000653	0.6	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.755	rs7186573	ENSG00000259982.1	CDC37P1	5.29	5.36e-07	0.000653	0.6	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.755	rs4788073	ENSG00000259982.1	CDC37P1	5.29	5.36e-07	0.000653	0.6	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.755	rs55792032	ENSG00000259982.1	CDC37P1	5.29	5.36e-07	0.000653	0.6	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28700294~28701540:-
TGCT	cis	rs7104764	0.673	rs3782118	ENSG00000277290.1	RP11-326C3.16	-5.29	5.36e-07	0.000653	-0.4	-0.43	Menarche (age at onset);	chr11:222620	chr11:243099~243483:-
TGCT	cis	rs7849270	1	rs6478867	ENSG00000268707.1	RP11-247A12.7	5.29	5.37e-07	0.000654	0.48	0.43	Blood metabolite ratios;	chr9:129141644	chr9:129170434~129170940:+
TGCT	cis	rs5760092	0.572	rs738806	ENSG00000218537.1	MIF-AS1	5.29	5.39e-07	0.000657	0.6	0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23894426~23898930:-
TGCT	cis	rs3091242	0.806	rs35189848	ENSG00000224183.1	SDHDP6	5.29	5.4e-07	0.000658	0.46	0.43	Erythrocyte sedimentation rate;	chr1:25461931	chr1:25294164~25294643:-
TGCT	cis	rs3091242	0.836	rs35346083	ENSG00000224183.1	SDHDP6	5.29	5.4e-07	0.000658	0.46	0.43	Erythrocyte sedimentation rate;	chr1:25461934	chr1:25294164~25294643:-
TGCT	cis	rs950169	0.922	rs12906983	ENSG00000225151.9	GOLGA2P7	-5.29	5.42e-07	0.000659	-0.5	-0.43	Schizophrenia;	chr15:84262270	chr15:84199311~84230136:-
TGCT	cis	rs899997	1	rs12899940	ENSG00000261143.1	ADAMTS7P3	-5.29	5.42e-07	0.00066	-0.48	-0.43	Coronary artery disease or large artery stroke;	chr15:78709357	chr15:77976042~77993057:+
TGCT	cis	rs2739330	0.761	rs5760176	ENSG00000250470.1	AP000351.3	-5.29	5.43e-07	0.00066	-0.42	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23976904~23977585:-
TGCT	cis	rs7829975	0.902	rs777707	ENSG00000173295.6	FAM86B3P	5.29	5.43e-07	0.000661	0.51	0.43	Mood instability;	chr8:8726834	chr8:8228595~8244865:+
TGCT	cis	rs7849270	1	rs4713	ENSG00000268707.1	RP11-247A12.7	5.29	5.45e-07	0.000663	0.46	0.43	Blood metabolite ratios;	chr9:129148526	chr9:129170434~129170940:+
TGCT	cis	rs11157436	1	rs61972228	ENSG00000211813.2	TRAV34	5.29	5.47e-07	0.000665	0.47	0.43	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22179460	chr14:22207522~22208129:+
TGCT	cis	rs11157436	1	rs12587157	ENSG00000211813.2	TRAV34	5.29	5.47e-07	0.000665	0.47	0.43	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22181476	chr14:22207522~22208129:+
TGCT	cis	rs11157436	1	rs11157440	ENSG00000211813.2	TRAV34	5.29	5.47e-07	0.000665	0.47	0.43	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22181757	chr14:22207522~22208129:+
TGCT	cis	rs11157436	0.915	rs11622938	ENSG00000211813.2	TRAV34	5.29	5.47e-07	0.000665	0.47	0.43	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22183456	chr14:22207522~22208129:+
TGCT	cis	rs11157436	1	rs75648426	ENSG00000211813.2	TRAV34	5.29	5.47e-07	0.000665	0.47	0.43	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22184044	chr14:22207522~22208129:+
TGCT	cis	rs11157436	0.958	rs2204963	ENSG00000211813.2	TRAV34	5.29	5.47e-07	0.000665	0.47	0.43	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22187871	chr14:22207522~22208129:+
TGCT	cis	rs11157436	0.958	rs61972229	ENSG00000211813.2	TRAV34	5.29	5.47e-07	0.000665	0.47	0.43	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22189754	chr14:22207522~22208129:+
TGCT	cis	rs11157436	0.958	rs17183301	ENSG00000211813.2	TRAV34	5.29	5.47e-07	0.000665	0.47	0.43	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22190003	chr14:22207522~22208129:+
TGCT	cis	rs524281	0.647	rs2302883	ENSG00000255320.1	RP11-755F10.1	5.28	5.48e-07	0.000666	0.53	0.43	Electroencephalogram traits;	chr11:66057523	chr11:66244840~66246239:-
TGCT	cis	rs7246967	0.673	rs2361260	ENSG00000269509.1	BNIP3P34	-5.28	5.48e-07	0.000667	-0.68	-0.43	Bronchopulmonary dysplasia;	chr19:22731342	chr19:22773853~22774424:+
TGCT	cis	rs7115242	0.8	rs10736487	ENSG00000254851.1	RP11-109L13.1	-5.28	5.49e-07	0.000667	-0.82	-0.43	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117079516	chr11:117135528~117138582:+
TGCT	cis	rs8062405	0.723	rs4788077	ENSG00000259982.1	CDC37P1	5.28	5.49e-07	0.000667	0.6	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.755	rs56272201	ENSG00000259982.1	CDC37P1	5.28	5.49e-07	0.000667	0.6	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.755	rs62034355	ENSG00000259982.1	CDC37P1	5.28	5.49e-07	0.000667	0.6	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28700294~28701540:-
TGCT	cis	rs507080	0.922	rs7114458	ENSG00000255422.1	AP002954.4	-5.28	5.51e-07	0.000669	-0.5	-0.43	Serum metabolite levels;	chr11:118695466	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.922	rs7114216	ENSG00000255422.1	AP002954.4	-5.28	5.51e-07	0.000669	-0.5	-0.43	Serum metabolite levels;	chr11:118695525	chr11:118704607~118750263:+
TGCT	cis	rs5769707	0.632	rs135876	ENSG00000235111.1	RP1-29C18.8	-5.28	5.52e-07	0.000671	-0.41	-0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49619925	chr22:49612657~49615716:-
TGCT	cis	rs904251	0.6	rs11756241	ENSG00000279942.1	RP1-153P14.7	-5.28	5.53e-07	0.000671	-0.45	-0.43	Cognitive performance;	chr6:37477325	chr6:37567716~37571460:+
TGCT	cis	rs1061377	1	rs9990742	ENSG00000249207.1	RP11-360F5.1	-5.28	5.53e-07	0.000672	-0.45	-0.43	Uric acid levels;	chr4:39119794	chr4:39112677~39126818:-
TGCT	cis	rs17301013	0.507	rs2987872	ENSG00000227373.4	RP11-160H22.5	-5.28	5.53e-07	0.000672	-0.51	-0.43	Systemic lupus erythematosus;	chr1:174840935	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs1793305	ENSG00000227373.4	RP11-160H22.5	-5.28	5.53e-07	0.000672	-0.51	-0.43	Systemic lupus erythematosus;	chr1:174841124	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs1894201	ENSG00000227373.4	RP11-160H22.5	-5.28	5.53e-07	0.000672	-0.51	-0.43	Systemic lupus erythematosus;	chr1:174841452	chr1:174115300~174160004:-
TGCT	cis	rs710913	0.618	rs6587	ENSG00000182109.6	RP11-69E11.4	5.28	5.53e-07	0.000672	0.43	0.43	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39624273	chr1:39522280~39546187:-
TGCT	cis	rs7757969	1	rs28566870	ENSG00000227012.2	RP1-97J1.2	5.28	5.54e-07	0.000673	0.76	0.43	Schizophrenia;	chr6:111797729	chr6:111900489~111901851:-
TGCT	cis	rs17711722	0.522	rs62469933	ENSG00000236529.1	RP13-254B10.1	5.28	5.55e-07	0.000674	0.31	0.43	Calcium levels;	chr7:65800652	chr7:65840212~65840596:+
TGCT	cis	rs950169	0.526	rs698620	ENSG00000225151.9	GOLGA2P7	5.28	5.56e-07	0.000675	0.43	0.43	Schizophrenia;	chr15:84633977	chr15:84199311~84230136:-
TGCT	cis	rs9660180	0.967	rs6603803	ENSG00000268575.1	RP1-283E3.8	-5.28	5.57e-07	0.000675	-0.35	-0.43	Body mass index;	chr1:1881249	chr1:1702736~1737688:-
TGCT	cis	rs2015599	0.645	rs12578931	ENSG00000257176.2	RP11-996F15.2	-5.28	5.57e-07	0.000675	-0.5	-0.43	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29280418~29317848:-
TGCT	cis	rs2015599	0.623	rs4931174	ENSG00000257176.2	RP11-996F15.2	-5.28	5.57e-07	0.000675	-0.5	-0.43	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29280418~29317848:-
TGCT	cis	rs786425	0.682	rs11612479	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123670979	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.717	rs12817757	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123671940	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.601	rs7138209	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123672505	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs12822546	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123672700	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs7975119	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123673127	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs7975233	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123673198	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs7978447	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123673533	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs7953596	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123673903	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs7953599	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123673908	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs7963498	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123673955	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.74	rs7133543	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123674864	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs7302649	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123675219	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs34534928	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123676287	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs12820195	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123677500	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs7973695	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123677930	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs7959553	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123678158	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.711	rs66690784	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123681130	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.711	rs7963968	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123681494	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.628	rs118004082	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123684693	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.655	rs114208992	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123684695	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs35416308	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123684914	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs7309528	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123687111	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.69	rs6488892	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123687279	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs6488893	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123687356	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs12829984	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123687760	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs7135660	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123689687	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.654	rs7307343	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123689818	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.654	rs7310918	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123690109	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs11833604	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123691925	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs35946281	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123692469	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.655	rs12821242	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123693782	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.711	rs12831081	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123695192	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs7298440	ENSG00000278112.1	RP11-972P1.11	5.28	5.57e-07	0.000675	0.51	0.43	Pubertal anthropometrics;	chr12:123696502	chr12:123519390~123519856:-
TGCT	cis	rs17301013	0.932	rs332795	ENSG00000227373.4	RP11-160H22.5	5.28	5.61e-07	0.00068	0.45	0.43	Systemic lupus erythematosus;	chr1:174726785	chr1:174115300~174160004:-
TGCT	cis	rs8062405	0.69	rs762634	ENSG00000259982.1	CDC37P1	5.28	5.63e-07	0.000681	0.6	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28700294~28701540:-
TGCT	cis	rs62034325	0.697	rs710410	ENSG00000259982.1	CDC37P1	5.28	5.63e-07	0.000681	0.6	0.43	Body mass index;	chr16:28592021	chr16:28700294~28701540:-
TGCT	cis	rs11673344	0.801	rs17707446	ENSG00000226686.6	LINC01535	-5.28	5.63e-07	0.000682	-0.5	-0.43	Obesity-related traits;	chr19:37092140	chr19:37251912~37265535:+
TGCT	cis	rs1799955	0.529	rs1801406	ENSG00000215515.2	IFIT1P1	-5.28	5.64e-07	0.000682	-0.54	-0.43	LDL cholesterol levels;	chr13:32337751	chr13:32384660~32386108:+
TGCT	cis	rs2177312	0.53	rs7675353	ENSG00000251129.1	RP11-734I18.1	-5.28	5.64e-07	0.000683	-0.51	-0.43	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31999465	chr4:31997397~32155406:+
TGCT	cis	rs2117029	1	rs11168827	ENSG00000258017.1	RP11-386G11.10	5.28	5.64e-07	0.000683	0.53	0.43	Intelligence (multi-trait analysis);	chr12:49025894	chr12:49127782~49147869:+
TGCT	cis	rs507080	0.697	rs656287	ENSG00000255422.1	AP002954.4	-5.28	5.65e-07	0.000684	-0.52	-0.43	Serum metabolite levels;	chr11:118701081	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.733	rs570949	ENSG00000255422.1	AP002954.4	-5.28	5.65e-07	0.000684	-0.52	-0.43	Serum metabolite levels;	chr11:118701202	chr11:118704607~118750263:+
TGCT	cis	rs76878669	0.561	rs7115577	ENSG00000254510.1	RP11-867G23.10	-5.28	5.67e-07	0.000686	-0.57	-0.43	Educational attainment (years of education);	chr11:66404787	chr11:66409158~66417137:+
TGCT	cis	rs1153858	1	rs28679834	ENSG00000259520.4	CTD-2651B20.3	-5.28	5.67e-07	0.000686	-0.38	-0.43	Homoarginine levels;	chr15:45324008	chr15:45251580~45279251:-
TGCT	cis	rs9322193	0.923	rs10872644	ENSG00000216906.2	RP11-350J20.9	5.28	5.68e-07	0.000687	0.48	0.43	Lung cancer;	chr6:149741819	chr6:149904243~149906418:+
TGCT	cis	rs8040855	0.624	rs12903975	ENSG00000259295.5	CSPG4P12	5.28	5.7e-07	0.00069	0.57	0.43	Bulimia nervosa;	chr15:85006004	chr15:85191438~85213905:+
TGCT	cis	rs17711722	0.522	rs6957759	ENSG00000236529.1	RP13-254B10.1	5.28	5.71e-07	0.000691	0.31	0.43	Calcium levels;	chr7:65806798	chr7:65840212~65840596:+
TGCT	cis	rs710913	0.717	rs1180349	ENSG00000182109.6	RP11-69E11.4	-5.28	5.71e-07	0.000691	-0.43	-0.43	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39540380	chr1:39522280~39546187:-
TGCT	cis	rs453301	0.653	rs11784393	ENSG00000173295.6	FAM86B3P	5.27	5.73e-07	0.000692	0.52	0.43	Joint mobility (Beighton score);	chr8:9045624	chr8:8228595~8244865:+
TGCT	cis	rs8062405	0.755	rs62031607	ENSG00000259982.1	CDC37P1	5.27	5.74e-07	0.000693	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28700294~28701540:-
TGCT	cis	rs4841097	0.876	rs6601288	ENSG00000254340.1	RP11-10A14.3	5.27	5.74e-07	0.000693	0.45	0.43	Platelet distribution width;	chr8:9085920	chr8:9141424~9145435:+
TGCT	cis	rs7208859	0.573	rs73267829	ENSG00000263531.1	RP13-753N3.1	5.27	5.75e-07	0.000694	0.81	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30863921~30864940:-
TGCT	cis	rs12429206	0.52	rs1870839	ENSG00000233672.5	RNASEH2B-AS1	-5.27	5.75e-07	0.000694	-0.57	-0.43	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50899732	chr13:50862172~50910764:-
TGCT	cis	rs453301	0.653	rs1562211	ENSG00000173295.6	FAM86B3P	-5.27	5.76e-07	0.000695	-0.51	-0.43	Joint mobility (Beighton score);	chr8:9044914	chr8:8228595~8244865:+
TGCT	cis	rs4835473	0.808	rs62339607	ENSG00000251600.4	RP11-673E1.1	-5.27	5.82e-07	0.000702	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143791474	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.838	rs56033497	ENSG00000251600.4	RP11-673E1.1	-5.27	5.82e-07	0.000702	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143792341	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.801	rs35839125	ENSG00000251600.4	RP11-673E1.1	-5.27	5.82e-07	0.000702	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143792351	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.75	rs12498381	ENSG00000251600.4	RP11-673E1.1	-5.27	5.82e-07	0.000702	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143793928	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs11100812	ENSG00000251600.4	RP11-673E1.1	5.27	5.82e-07	0.000702	0.42	0.43	Immature fraction of reticulocytes;	chr4:143790400	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.545	rs10022856	ENSG00000251600.4	RP11-673E1.1	5.27	5.82e-07	0.000702	0.42	0.43	Immature fraction of reticulocytes;	chr4:143793157	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1842484	ENSG00000251600.4	RP11-673E1.1	5.27	5.82e-07	0.000702	0.42	0.43	Immature fraction of reticulocytes;	chr4:143793829	chr4:143912331~143982454:+
TGCT	cis	rs2117029	0.767	rs11168838	ENSG00000258017.1	RP11-386G11.10	-5.27	5.82e-07	0.000702	-0.55	-0.43	Intelligence (multi-trait analysis);	chr12:49061223	chr12:49127782~49147869:+
TGCT	cis	rs1799955	0.554	rs11571613	ENSG00000215515.2	IFIT1P1	-5.27	5.83e-07	0.000703	-0.53	-0.43	LDL cholesterol levels;	chr13:32325430	chr13:32384660~32386108:+
TGCT	cis	rs7829975	0.593	rs2979241	ENSG00000173295.6	FAM86B3P	5.27	5.84e-07	0.000705	0.49	0.43	Mood instability;	chr8:8445843	chr8:8228595~8244865:+
TGCT	cis	rs2276314	0.947	rs16967319	ENSG00000278986.1	RP11-723J4.3	-5.27	5.85e-07	0.000705	-0.48	-0.43	Endometriosis;Drug-induced torsades de pointes;	chr18:35993562	chr18:35972151~35973916:+
TGCT	cis	rs7849270	1	rs10988223	ENSG00000268707.1	RP11-247A12.7	-5.27	5.85e-07	0.000705	-0.48	-0.43	Blood metabolite ratios;	chr9:129140742	chr9:129170434~129170940:+
TGCT	cis	rs904251	0.523	rs10947675	ENSG00000279942.1	RP1-153P14.7	-5.27	5.86e-07	0.000707	-0.44	-0.43	Cognitive performance;	chr6:37512196	chr6:37567716~37571460:+
TGCT	cis	rs507080	0.922	rs558781	ENSG00000255422.1	AP002954.4	-5.27	5.87e-07	0.000707	-0.5	-0.43	Serum metabolite levels;	chr11:118693688	chr11:118704607~118750263:+
TGCT	cis	rs710913	0.717	rs11206377	ENSG00000182109.6	RP11-69E11.4	5.27	5.87e-07	0.000707	0.43	0.43	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583432	chr1:39522280~39546187:-
TGCT	cis	rs8040855	0.965	rs11073990	ENSG00000259295.5	CSPG4P12	5.27	5.87e-07	0.000708	0.54	0.43	Bulimia nervosa;	chr15:85168070	chr15:85191438~85213905:+
TGCT	cis	rs2117029	1	rs3782357	ENSG00000258017.1	RP11-386G11.10	-5.27	5.88e-07	0.000709	-0.53	-0.43	Intelligence (multi-trait analysis);	chr12:49033869	chr12:49127782~49147869:+
TGCT	cis	rs453301	0.653	rs7016139	ENSG00000173295.6	FAM86B3P	-5.27	5.88e-07	0.000709	-0.5	-0.43	Joint mobility (Beighton score);	chr8:9037960	chr8:8228595~8244865:+
TGCT	cis	rs367615	0.552	rs2963010	ENSG00000249476.1	CTD-2587M2.1	-5.27	5.9e-07	0.000711	-0.44	-0.43	Colorectal cancer (SNP x SNP interaction);	chr5:109401342	chr5:109237120~109326369:-
TGCT	cis	rs9660180	0.934	rs12729990	ENSG00000268575.1	RP1-283E3.8	-5.27	5.9e-07	0.000711	-0.35	-0.43	Body mass index;	chr1:1880596	chr1:1702736~1737688:-
TGCT	cis	rs7621025	0.5	rs9845460	ENSG00000239213.4	NCK1-AS1	5.27	5.91e-07	0.000712	0.45	0.43	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136868275	chr3:136841726~136862054:-
TGCT	cis	rs7621025	0.5	rs12629000	ENSG00000239213.4	NCK1-AS1	5.27	5.91e-07	0.000712	0.45	0.43	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136924729	chr3:136841726~136862054:-
TGCT	cis	rs7621025	0.5	rs1965107	ENSG00000239213.4	NCK1-AS1	5.27	5.91e-07	0.000712	0.45	0.43	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136929801	chr3:136841726~136862054:-
TGCT	cis	rs7208859	0.573	rs73267873	ENSG00000263531.1	RP13-753N3.1	5.27	5.92e-07	0.000713	0.8	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30863921~30864940:-
TGCT	cis	rs17826219	0.561	rs4085382	ENSG00000263531.1	RP13-753N3.1	5.27	5.92e-07	0.000713	0.8	0.43	Body mass index;	chr17:30744184	chr17:30863921~30864940:-
TGCT	cis	rs453301	0.571	rs2929453	ENSG00000173295.6	FAM86B3P	-5.27	5.92e-07	0.000713	-0.47	-0.43	Joint mobility (Beighton score);	chr8:9226831	chr8:8228595~8244865:+
TGCT	cis	rs904251	0.6	rs1874736	ENSG00000279942.1	RP1-153P14.7	-5.27	5.92e-07	0.000713	-0.45	-0.43	Cognitive performance;	chr6:37480218	chr6:37567716~37571460:+
TGCT	cis	rs9549367	0.577	rs3024711	ENSG00000269125.1	RP11-98F14.11	-5.27	5.93e-07	0.000714	-0.56	-0.43	Platelet distribution width;	chr13:113158954	chr13:113165002~113165183:-
TGCT	cis	rs1061377	1	rs1036037	ENSG00000249207.1	RP11-360F5.1	-5.27	5.94e-07	0.000715	-0.44	-0.43	Uric acid levels;	chr4:39111272	chr4:39112677~39126818:-
TGCT	cis	rs17301013	0.932	rs11804941	ENSG00000227373.4	RP11-160H22.5	-5.27	5.94e-07	0.000716	-0.45	-0.43	Systemic lupus erythematosus;	chr1:174624074	chr1:174115300~174160004:-
TGCT	cis	rs710913	0.587	rs6690413	ENSG00000182109.6	RP11-69E11.4	5.27	5.97e-07	0.000718	0.44	0.43	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39620620	chr1:39522280~39546187:-
TGCT	cis	rs5769707	0.681	rs4824068	ENSG00000235111.1	RP1-29C18.8	-5.27	5.97e-07	0.000718	-0.39	-0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49631153	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.605	rs6009791	ENSG00000235111.1	RP1-29C18.8	-5.27	5.97e-07	0.000718	-0.39	-0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49631617	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.667	rs4824069	ENSG00000235111.1	RP1-29C18.8	-5.27	5.97e-07	0.000718	-0.39	-0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49636677	chr22:49612657~49615716:-
TGCT	cis	rs10504229	0.906	rs114627636	ENSG00000253301.4	RP11-513O17.2	5.26	5.98e-07	0.00072	0.6	0.43	Developmental language disorder (linguistic errors);	chr8:57261173	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.817	rs78138632	ENSG00000253301.4	RP11-513O17.2	5.26	5.98e-07	0.00072	0.6	0.43	Developmental language disorder (linguistic errors);	chr8:57278782	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.773	rs1874374	ENSG00000253301.4	RP11-513O17.2	5.26	5.98e-07	0.00072	0.6	0.43	Developmental language disorder (linguistic errors);	chr8:57281863	chr8:57142689~57240298:+
TGCT	cis	rs5769707	0.706	rs2071903	ENSG00000235111.1	RP1-29C18.8	-5.26	5.98e-07	0.00072	-0.4	-0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49640869	chr22:49612657~49615716:-
TGCT	cis	rs4853012	0.838	rs4429500	ENSG00000217702.2	RP11-287D1.4	5.26	5.98e-07	0.00072	0.6	0.43	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74130583~74135395:+
TGCT	cis	rs2882667	0.537	rs10057545	ENSG00000253404.1	AC034243.1	5.26	6e-07	0.000721	0.48	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095319	chr5:138744434~138753309:-
TGCT	cis	rs7301826	0.967	rs4759792	ENSG00000256299.1	RP11-989F5.3	-5.26	6e-07	0.000722	-0.47	-0.43	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810821~130812622:-
TGCT	cis	rs9462027	1	rs6457792	ENSG00000186328.4	RP11-140K17.2	-5.26	6.02e-07	0.000724	-0.44	-0.43	Systemic lupus erythematosus;	chr6:34796666	chr6:34715613~34715940:+
TGCT	cis	rs9462027	1	rs9689160	ENSG00000186328.4	RP11-140K17.2	5.26	6.02e-07	0.000724	0.44	0.43	Systemic lupus erythematosus;	chr6:34782072	chr6:34715613~34715940:+
TGCT	cis	rs3091242	0.933	rs28633797	ENSG00000224183.1	SDHDP6	-5.26	6.04e-07	0.000726	-0.45	-0.43	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25294164~25294643:-
TGCT	cis	rs55794721	0.509	rs2982358	ENSG00000224183.1	SDHDP6	-5.26	6.04e-07	0.000726	-0.45	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25294164~25294643:-
TGCT	cis	rs2732480	0.5	rs7966829	ENSG00000258273.1	RP11-370I10.4	-5.26	6.04e-07	0.000726	-0.48	-0.43	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48333755~48333901:-
TGCT	cis	rs2333021	0.711	rs34518714	ENSG00000259015.1	RP11-109N23.6	5.26	6.04e-07	0.000726	0.22	0.43	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72992601	chr14:72960595~72961993:+
TGCT	cis	rs2333021	0.801	rs4903086	ENSG00000259015.1	RP11-109N23.6	5.26	6.04e-07	0.000726	0.22	0.43	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72995605	chr14:72960595~72961993:+
TGCT	cis	rs17301013	0.507	rs12065326	ENSG00000227373.4	RP11-160H22.5	5.26	6.04e-07	0.000726	0.5	0.43	Systemic lupus erythematosus;	chr1:174426892	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.507	rs12097931	ENSG00000227373.4	RP11-160H22.5	5.26	6.04e-07	0.000726	0.5	0.43	Systemic lupus erythematosus;	chr1:174454841	chr1:174115300~174160004:-
TGCT	cis	rs2739330	0.685	rs4822453	ENSG00000250470.1	AP000351.3	5.26	6.05e-07	0.000727	0.42	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23976904~23977585:-
TGCT	cis	rs1799949	1	rs8176103	ENSG00000198496.9	NBR2	-5.26	6.05e-07	0.000727	-0.61	-0.43	Menopause (age at onset);	chr17:43115033	chr17:43125610~43153671:+
TGCT	cis	rs12745968	0.652	rs1359490	ENSG00000223787.2	RP4-593M8.1	5.26	6.08e-07	0.00073	0.52	0.43	Bipolar disorder and schizophrenia;	chr1:92488298	chr1:92580476~92580821:-
TGCT	cis	rs4927850	0.666	rs4927853	ENSG00000242086.7	LINC00969	5.26	6.08e-07	0.00073	0.54	0.43	Pancreatic cancer;	chr3:196025182	chr3:195658062~195739964:+
TGCT	cis	rs2115630	0.875	rs8039472	ENSG00000225151.9	GOLGA2P7	5.26	6.09e-07	0.00073	0.46	0.43	P wave terminal force;	chr15:84818413	chr15:84199311~84230136:-
TGCT	cis	rs36052053	0.521	rs71558356	ENSG00000219700.1	PTCHD3P3	5.26	6.09e-07	0.000731	0.89	0.43	Red cell distribution width;	chr6:109224908	chr6:109288571~109290503:-
TGCT	cis	rs7847628	0.566	rs10739575	ENSG00000226752.6	PSMD5-AS1	5.26	6.1e-07	0.000732	0.72	0.43	Birth weight;	chr9:120843823	chr9:120824828~120854385:+
TGCT	cis	rs17301013	0.507	rs3118988	ENSG00000227373.4	RP11-160H22.5	-5.26	6.1e-07	0.000732	-0.51	-0.43	Systemic lupus erythematosus;	chr1:174819245	chr1:174115300~174160004:-
TGCT	cis	rs11673344	0.832	rs56210764	ENSG00000226686.6	LINC01535	5.26	6.1e-07	0.000732	0.51	0.43	Obesity-related traits;	chr19:37125970	chr19:37251912~37265535:+
TGCT	cis	rs507080	0.733	rs489126	ENSG00000255422.1	AP002954.4	-5.26	6.11e-07	0.000732	-0.51	-0.43	Serum metabolite levels;	chr11:118702038	chr11:118704607~118750263:+
TGCT	cis	rs1555322	0.53	rs2425049	ENSG00000126005.14	MMP24-AS1	-5.26	6.11e-07	0.000733	-0.5	-0.43	Attention deficit hyperactivity disorder;	chr20:35286917	chr20:35216462~35278131:-
TGCT	cis	rs7617773	0.78	rs34523942	ENSG00000229759.1	MRPS18AP1	5.26	6.12e-07	0.000734	0.37	0.43	Coronary artery disease;	chr3:48301179	chr3:48256350~48256938:-
TGCT	cis	rs8113308	0.81	rs10411484	ENSG00000269235.1	ZNF350-AS1	5.26	6.12e-07	0.000734	0.7	0.43	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51940152	chr19:51949134~51981367:+
TGCT	cis	rs8113308	0.81	rs17695737	ENSG00000269235.1	ZNF350-AS1	5.26	6.12e-07	0.000734	0.7	0.43	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942283	chr19:51949134~51981367:+
TGCT	cis	rs11157436	0.918	rs7159024	ENSG00000211813.2	TRAV34	5.26	6.13e-07	0.000735	0.47	0.43	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22228760	chr14:22207522~22208129:+
TGCT	cis	rs2276314	0.857	rs28651028	ENSG00000278986.1	RP11-723J4.3	-5.26	6.15e-07	0.000737	-0.48	-0.43	Endometriosis;Drug-induced torsades de pointes;	chr18:36058947	chr18:35972151~35973916:+
TGCT	cis	rs8062405	0.721	rs151181	ENSG00000259982.1	CDC37P1	5.26	6.16e-07	0.000738	0.56	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28700294~28701540:-
TGCT	cis	rs7923609	0.756	rs6479908	ENSG00000232075.1	MRPL35P2	5.26	6.16e-07	0.000738	0.42	0.43	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63573888	chr10:63634317~63634827:-
TGCT	cis	rs35160687	0.901	rs7571424	ENSG00000273080.1	RP11-301O19.1	5.26	6.17e-07	0.000739	0.47	0.43	Night sleep phenotypes;	chr2:86312037	chr2:86195590~86196049:+
TGCT	cis	rs8111998	0.826	rs4933008	ENSG00000269332.4	GOLGA2P9	5.26	6.18e-07	0.00074	0.74	0.43	Corneal structure;	chr19:22586966	chr19:22596257~22603550:+
TGCT	cis	rs7714584	1	rs4958852	ENSG00000197083.10	ZNF300P1	5.26	6.21e-07	0.000743	1.11	0.43	Crohn's disease;	chr5:150951069	chr5:150930645~150946289:-
TGCT	cis	rs786425	0.71	rs11057326	ENSG00000278112.1	RP11-972P1.11	5.26	6.22e-07	0.000745	0.5	0.43	Pubertal anthropometrics;	chr12:123663931	chr12:123519390~123519856:-
TGCT	cis	rs7849270	1	rs7855278	ENSG00000268707.1	RP11-247A12.7	5.26	6.24e-07	0.000746	0.47	0.43	Blood metabolite ratios;	chr9:129159086	chr9:129170434~129170940:+
TGCT	cis	rs9660180	0.846	rs10907195	ENSG00000268575.1	RP1-283E3.8	5.26	6.24e-07	0.000746	0.37	0.43	Body mass index;	chr1:1781909	chr1:1702736~1737688:-
TGCT	cis	rs4423214	0.879	rs1792281	ENSG00000254682.1	RP11-660L16.2	-5.26	6.24e-07	0.000747	-0.65	-0.43	Vitamin D levels;	chr11:71424450	chr11:71448674~71452157:+
TGCT	cis	rs1153858	1	rs12439274	ENSG00000259520.4	CTD-2651B20.3	-5.26	6.24e-07	0.000747	-0.38	-0.43	Homoarginine levels;	chr15:45344469	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs11852800	ENSG00000259520.4	CTD-2651B20.3	5.26	6.24e-07	0.000747	0.38	0.43	Homoarginine levels;	chr15:45346933	chr15:45251580~45279251:-
TGCT	cis	rs651907	0.535	rs9830943	ENSG00000244119.1	PDCL3P4	5.25	6.28e-07	0.00075	0.32	0.43	Colorectal cancer;	chr3:101710055	chr3:101712472~101713191:+
TGCT	cis	rs9322193	0.923	rs10782310	ENSG00000216906.2	RP11-350J20.9	5.25	6.29e-07	0.000752	0.48	0.43	Lung cancer;	chr6:149622458	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs10782311	ENSG00000216906.2	RP11-350J20.9	5.25	6.29e-07	0.000752	0.48	0.43	Lung cancer;	chr6:149622592	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.884	rs10782312	ENSG00000216906.2	RP11-350J20.9	5.25	6.29e-07	0.000752	0.48	0.43	Lung cancer;	chr6:149622669	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs10747275	ENSG00000216906.2	RP11-350J20.9	5.25	6.29e-07	0.000752	0.48	0.43	Lung cancer;	chr6:149622782	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.886	rs9322198	ENSG00000216906.2	RP11-350J20.9	5.25	6.29e-07	0.000752	0.48	0.43	Lung cancer;	chr6:149623772	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.847	rs12234128	ENSG00000216906.2	RP11-350J20.9	5.25	6.29e-07	0.000752	0.48	0.43	Lung cancer;	chr6:149627553	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs57012784	ENSG00000216906.2	RP11-350J20.9	5.25	6.29e-07	0.000752	0.48	0.43	Lung cancer;	chr6:149627691	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9322200	ENSG00000216906.2	RP11-350J20.9	5.25	6.29e-07	0.000752	0.48	0.43	Lung cancer;	chr6:149630078	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9689599	ENSG00000216906.2	RP11-350J20.9	5.25	6.29e-07	0.000752	0.48	0.43	Lung cancer;	chr6:149631973	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.884	rs9688794	ENSG00000216906.2	RP11-350J20.9	5.25	6.29e-07	0.000752	0.48	0.43	Lung cancer;	chr6:149632121	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9800580	ENSG00000216906.2	RP11-350J20.9	5.25	6.29e-07	0.000752	0.48	0.43	Lung cancer;	chr6:149632845	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.884	rs11155669	ENSG00000216906.2	RP11-350J20.9	5.25	6.29e-07	0.000752	0.48	0.43	Lung cancer;	chr6:149633501	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.887	rs9505824	ENSG00000216906.2	RP11-350J20.9	5.25	6.29e-07	0.000752	0.48	0.43	Lung cancer;	chr6:149633663	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9505826	ENSG00000216906.2	RP11-350J20.9	5.25	6.29e-07	0.000752	0.48	0.43	Lung cancer;	chr6:149633912	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9322204	ENSG00000216906.2	RP11-350J20.9	5.25	6.29e-07	0.000752	0.48	0.43	Lung cancer;	chr6:149636047	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9766886	ENSG00000216906.2	RP11-350J20.9	5.25	6.29e-07	0.000752	0.48	0.43	Lung cancer;	chr6:149637048	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9689084	ENSG00000216906.2	RP11-350J20.9	5.25	6.29e-07	0.000752	0.48	0.43	Lung cancer;	chr6:149639648	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs7740278	ENSG00000216906.2	RP11-350J20.9	5.25	6.29e-07	0.000752	0.48	0.43	Lung cancer;	chr6:149640116	chr6:149904243~149906418:+
TGCT	cis	rs4835473	0.9	rs35670120	ENSG00000251600.4	RP11-673E1.1	-5.25	6.3e-07	0.000753	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143787041	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs4054634	ENSG00000251600.4	RP11-673E1.1	-5.25	6.3e-07	0.000753	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143787045	chr4:143912331~143982454:+
TGCT	cis	rs11673344	0.832	rs112380313	ENSG00000226686.6	LINC01535	5.25	6.32e-07	0.000754	0.51	0.43	Obesity-related traits;	chr19:37027979	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.832	rs76470527	ENSG00000226686.6	LINC01535	5.25	6.32e-07	0.000754	0.51	0.43	Obesity-related traits;	chr19:37035981	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.74	rs113752815	ENSG00000226686.6	LINC01535	5.25	6.32e-07	0.000754	0.51	0.43	Obesity-related traits;	chr19:37043829	chr19:37251912~37265535:+
TGCT	cis	rs9322193	0.923	rs12174716	ENSG00000216906.2	RP11-350J20.9	5.25	6.33e-07	0.000755	0.48	0.43	Lung cancer;	chr6:149644487	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9800871	ENSG00000216906.2	RP11-350J20.9	5.25	6.33e-07	0.000755	0.48	0.43	Lung cancer;	chr6:149644540	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9800614	ENSG00000216906.2	RP11-350J20.9	5.25	6.33e-07	0.000755	0.48	0.43	Lung cancer;	chr6:149644604	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs11155670	ENSG00000216906.2	RP11-350J20.9	5.25	6.33e-07	0.000755	0.48	0.43	Lung cancer;	chr6:149644992	chr6:149904243~149906418:+
TGCT	cis	rs11085466	0.51	rs8108399	ENSG00000268278.1	RP11-420K14.1	5.25	6.34e-07	0.000756	0.36	0.43	Colorectal or endometrial cancer;	chr19:21618479	chr19:21637974~21656300:+
TGCT	cis	rs2739330	0.731	rs2000468	ENSG00000272787.1	KB-226F1.2	-5.25	6.34e-07	0.000756	-0.46	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23969211~23969873:+
TGCT	cis	rs2276314	1	rs9956938	ENSG00000278986.1	RP11-723J4.3	-5.25	6.35e-07	0.000757	-0.47	-0.43	Endometriosis;Drug-induced torsades de pointes;	chr18:35987098	chr18:35972151~35973916:+
TGCT	cis	rs4713118	0.662	rs149900	ENSG00000219891.2	ZSCAN12P1	5.25	6.37e-07	0.000759	0.55	0.43	Parkinson's disease;	chr6:28046819	chr6:28091154~28093664:+
TGCT	cis	rs7617773	0.78	rs13066044	ENSG00000229759.1	MRPS18AP1	5.25	6.38e-07	0.000761	0.38	0.43	Coronary artery disease;	chr3:48335786	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.778	rs11715776	ENSG00000229759.1	MRPS18AP1	5.25	6.38e-07	0.000761	0.38	0.43	Coronary artery disease;	chr3:48336121	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.778	rs11707997	ENSG00000229759.1	MRPS18AP1	5.25	6.38e-07	0.000761	0.38	0.43	Coronary artery disease;	chr3:48336385	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs11720026	ENSG00000229759.1	MRPS18AP1	5.25	6.38e-07	0.000761	0.38	0.43	Coronary artery disease;	chr3:48336431	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.743	rs11715876	ENSG00000229759.1	MRPS18AP1	5.25	6.38e-07	0.000761	0.38	0.43	Coronary artery disease;	chr3:48336432	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs35297486	ENSG00000229759.1	MRPS18AP1	5.25	6.38e-07	0.000761	0.38	0.43	Coronary artery disease;	chr3:48336657	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs11716848	ENSG00000229759.1	MRPS18AP1	5.25	6.38e-07	0.000761	0.38	0.43	Coronary artery disease;	chr3:48337010	chr3:48256350~48256938:-
TGCT	cis	rs17711722	0.522	rs4642526	ENSG00000236529.1	RP13-254B10.1	5.25	6.38e-07	0.000761	0.31	0.43	Calcium levels;	chr7:65751755	chr7:65840212~65840596:+
TGCT	cis	rs5758659	0.652	rs133303	ENSG00000270083.1	RP1-257I20.14	5.25	6.39e-07	0.000762	0.41	0.43	Cognitive function;	chr22:41999238	chr22:42089630~42090028:-
TGCT	cis	rs853679	0.517	rs17711344	ENSG00000219392.1	RP1-265C24.5	5.25	6.4e-07	0.000762	0.56	0.43	Depression;	chr6:28109824	chr6:28115628~28116551:+
TGCT	cis	rs321358	1	rs321366	ENSG00000271584.1	RP11-89C3.4	5.25	6.41e-07	0.000763	0.57	0.43	Body mass index;	chr11:111128003	chr11:111091932~111097357:-
TGCT	cis	rs6993244	1	rs6993244	ENSG00000173295.6	FAM86B3P	5.25	6.43e-07	0.000765	0.51	0.43	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8228595~8244865:+
TGCT	cis	rs7115242	0.567	rs10047462	ENSG00000254851.1	RP11-109L13.1	-5.25	6.44e-07	0.000767	-0.88	-0.43	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116851325	chr11:117135528~117138582:+
TGCT	cis	rs5760092	0.842	rs5760103	ENSG00000218537.1	MIF-AS1	5.25	6.46e-07	0.000769	0.65	0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23906594	chr22:23894426~23898930:-
TGCT	cis	rs76878669	0.561	rs10750784	ENSG00000254510.1	RP11-867G23.10	-5.25	6.47e-07	0.00077	-0.58	-0.43	Educational attainment (years of education);	chr11:66343195	chr11:66409158~66417137:+
TGCT	cis	rs35160687	1	rs35160687	ENSG00000273080.1	RP11-301O19.1	5.25	6.47e-07	0.00077	0.49	0.43	Night sleep phenotypes;	chr2:86244991	chr2:86195590~86196049:+
TGCT	cis	rs35160687	0.901	rs12620833	ENSG00000273080.1	RP11-301O19.1	5.25	6.47e-07	0.00077	0.49	0.43	Night sleep phenotypes;	chr2:86245747	chr2:86195590~86196049:+
TGCT	cis	rs8113308	0.515	rs55866828	ENSG00000269235.1	ZNF350-AS1	5.25	6.49e-07	0.000772	0.86	0.43	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51938332	chr19:51949134~51981367:+
TGCT	cis	rs8113308	0.515	rs73066981	ENSG00000269235.1	ZNF350-AS1	5.25	6.49e-07	0.000772	0.86	0.43	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51959146	chr19:51949134~51981367:+
TGCT	cis	rs8113308	0.515	rs56343029	ENSG00000269235.1	ZNF350-AS1	5.25	6.49e-07	0.000772	0.86	0.43	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51960184	chr19:51949134~51981367:+
TGCT	cis	rs17301013	0.932	rs727279	ENSG00000227373.4	RP11-160H22.5	5.25	6.52e-07	0.000775	0.45	0.43	Systemic lupus erythematosus;	chr1:174496026	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.794	rs6425283	ENSG00000227373.4	RP11-160H22.5	5.25	6.52e-07	0.000775	0.45	0.43	Systemic lupus erythematosus;	chr1:174499853	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.932	rs2072760	ENSG00000227373.4	RP11-160H22.5	5.25	6.52e-07	0.000775	0.45	0.43	Systemic lupus erythematosus;	chr1:174510186	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.932	rs10912797	ENSG00000227373.4	RP11-160H22.5	5.25	6.52e-07	0.000775	0.45	0.43	Systemic lupus erythematosus;	chr1:174511225	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.932	rs6668053	ENSG00000227373.4	RP11-160H22.5	5.25	6.52e-07	0.000775	0.45	0.43	Systemic lupus erythematosus;	chr1:174515139	chr1:174115300~174160004:-
TGCT	cis	rs7811142	1	rs6972167	ENSG00000242294.5	STAG3L5P	5.25	6.52e-07	0.000776	0.4	0.43	Platelet count;	chr7:100482390	chr7:100336079~100351900:+
TGCT	cis	rs972540	1	rs7422054	ENSG00000279220.1	GPR1-AS	5.25	6.53e-07	0.000776	0.44	0.43	Body mass index;	chr2:206383456	chr2:206203376~206266243:+
TGCT	cis	rs7923609	0.756	rs7090758	ENSG00000232075.1	MRPL35P2	5.24	6.55e-07	0.000778	0.41	0.43	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63575555	chr10:63634317~63634827:-
TGCT	cis	rs4835473	0.932	rs4835278	ENSG00000251600.4	RP11-673E1.1	-5.24	6.58e-07	0.00078	-0.42	-0.43	Immature fraction of reticulocytes;	chr4:143788433	chr4:143912331~143982454:+
TGCT	cis	rs17301013	0.932	rs6689170	ENSG00000227373.4	RP11-160H22.5	5.24	6.59e-07	0.00078	0.45	0.43	Systemic lupus erythematosus;	chr1:174639596	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.612	rs56199565	ENSG00000227373.4	RP11-160H22.5	5.24	6.59e-07	0.00078	0.45	0.43	Systemic lupus erythematosus;	chr1:174640992	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.761	rs332805	ENSG00000227373.4	RP11-160H22.5	5.24	6.59e-07	0.00078	0.45	0.43	Systemic lupus erythematosus;	chr1:174652487	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.861	rs34819375	ENSG00000227373.4	RP11-160H22.5	5.24	6.59e-07	0.00078	0.45	0.43	Systemic lupus erythematosus;	chr1:174654958	chr1:174115300~174160004:-
TGCT	cis	rs4835473	0.9	rs10032963	ENSG00000251600.4	RP11-673E1.1	5.24	6.59e-07	0.00078	0.41	0.43	Immature fraction of reticulocytes;	chr4:143733068	chr4:143912331~143982454:+
TGCT	cis	rs9322193	0.923	rs9767554	ENSG00000216906.2	RP11-350J20.9	5.24	6.62e-07	0.000784	0.5	0.43	Lung cancer;	chr6:149616860	chr6:149904243~149906418:+
TGCT	cis	rs36052053	0.908	rs34599673	ENSG00000219700.1	PTCHD3P3	5.24	6.63e-07	0.000785	0.78	0.43	Red cell distribution width;	chr6:109251799	chr6:109288571~109290503:-
TGCT	cis	rs36052053	0.908	rs13209450	ENSG00000219700.1	PTCHD3P3	5.24	6.63e-07	0.000785	0.78	0.43	Red cell distribution width;	chr6:109252804	chr6:109288571~109290503:-
TGCT	cis	rs36052053	0.908	rs75793323	ENSG00000219700.1	PTCHD3P3	5.24	6.63e-07	0.000785	0.78	0.43	Red cell distribution width;	chr6:109253508	chr6:109288571~109290503:-
TGCT	cis	rs36052053	0.908	rs71558360	ENSG00000219700.1	PTCHD3P3	5.24	6.63e-07	0.000785	0.78	0.43	Red cell distribution width;	chr6:109256780	chr6:109288571~109290503:-
TGCT	cis	rs36052053	0.908	rs71558361	ENSG00000219700.1	PTCHD3P3	5.24	6.63e-07	0.000785	0.78	0.43	Red cell distribution width;	chr6:109260045	chr6:109288571~109290503:-
TGCT	cis	rs36052053	0.908	rs13190802	ENSG00000219700.1	PTCHD3P3	5.24	6.63e-07	0.000785	0.78	0.43	Red cell distribution width;	chr6:109260601	chr6:109288571~109290503:-
TGCT	cis	rs367615	0.537	rs431669	ENSG00000249476.1	CTD-2587M2.1	5.24	6.64e-07	0.000786	0.45	0.43	Colorectal cancer (SNP x SNP interaction);	chr5:109327414	chr5:109237120~109326369:-
TGCT	cis	rs380904	0.963	rs410836	ENSG00000254859.1	RP11-661A12.5	-5.24	6.65e-07	0.000787	-0.63	-0.43	Venous thromboembolism (SNP x SNP interaction);	chr8:143494679	chr8:143541973~143549729:-
TGCT	cis	rs977987	0.528	rs9926933	ENSG00000261783.1	RP11-252K23.2	5.24	6.66e-07	0.000789	0.68	0.43	Dupuytren's disease;	chr16:75467669	chr16:75379818~75381260:-
TGCT	cis	rs2276314	0.857	rs9960670	ENSG00000278986.1	RP11-723J4.3	-5.24	6.67e-07	0.000789	-0.48	-0.43	Endometriosis;Drug-induced torsades de pointes;	chr18:35997749	chr18:35972151~35973916:+
TGCT	cis	rs2276314	0.857	rs28431958	ENSG00000278986.1	RP11-723J4.3	-5.24	6.67e-07	0.000789	-0.48	-0.43	Endometriosis;Drug-induced torsades de pointes;	chr18:35998438	chr18:35972151~35973916:+
TGCT	cis	rs7829975	0.509	rs2945269	ENSG00000173295.6	FAM86B3P	5.24	6.68e-07	0.00079	0.51	0.43	Mood instability;	chr8:8258056	chr8:8228595~8244865:+
TGCT	cis	rs12439619	0.883	rs62012045	ENSG00000278603.1	RP13-608F4.5	5.24	6.69e-07	0.000791	0.59	0.43	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472203~82472426:+
TGCT	cis	rs12439619	0.921	rs56042848	ENSG00000278603.1	RP13-608F4.5	5.24	6.69e-07	0.000791	0.59	0.43	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472203~82472426:+
TGCT	cis	rs5760092	0.755	rs3884794	ENSG00000225282.1	AP000350.6	5.24	6.69e-07	0.000792	0.58	0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23909579	chr22:23926900~23929574:+
TGCT	cis	rs7617773	0.709	rs4404473	ENSG00000229759.1	MRPS18AP1	5.24	6.72e-07	0.000795	0.37	0.43	Coronary artery disease;	chr3:48312136	chr3:48256350~48256938:-
TGCT	cis	rs36052053	1	rs36052053	ENSG00000219700.1	PTCHD3P3	5.24	6.73e-07	0.000796	0.78	0.43	Red cell distribution width;	chr6:109262596	chr6:109288571~109290503:-
TGCT	cis	rs7301826	0.967	rs4759790	ENSG00000256299.1	RP11-989F5.3	-5.24	6.73e-07	0.000796	-0.46	-0.43	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810821~130812622:-
TGCT	cis	rs4835473	0.932	rs1450250	ENSG00000251600.4	RP11-673E1.1	5.24	6.73e-07	0.000796	0.43	0.43	Immature fraction of reticulocytes;	chr4:143731873	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs7664248	ENSG00000251600.4	RP11-673E1.1	5.24	6.73e-07	0.000796	0.43	0.43	Immature fraction of reticulocytes;	chr4:143732554	chr4:143912331~143982454:+
TGCT	cis	rs1707322	0.682	rs3014241	ENSG00000280836.1	AL355480.1	5.24	6.77e-07	8e-04	0.6	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr1:45581219~45581321:-
TGCT	cis	rs8062405	0.69	rs62034351	ENSG00000259982.1	CDC37P1	5.24	6.79e-07	0.000802	0.59	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28700294~28701540:-
TGCT	cis	rs2880765	0.546	rs11637726	ENSG00000259295.5	CSPG4P12	-5.24	6.79e-07	0.000802	-0.52	-0.43	Coronary artery disease;	chr15:85516040	chr15:85191438~85213905:+
TGCT	cis	rs2283792	0.905	rs9610505	ENSG00000228050.1	TOP3BP1	5.23	6.84e-07	0.000807	0.52	0.43	Multiple sclerosis;	chr22:21867813	chr22:22223187~22224566:-
TGCT	cis	rs4835473	0.932	rs5016159	ENSG00000251600.4	RP11-673E1.1	5.23	6.85e-07	0.000807	0.41	0.43	Immature fraction of reticulocytes;	chr4:143738362	chr4:143912331~143982454:+
TGCT	cis	rs710913	0.745	rs67563067	ENSG00000182109.6	RP11-69E11.4	-5.23	6.85e-07	0.000808	-0.43	-0.43	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39581323	chr1:39522280~39546187:-
TGCT	cis	rs367615	0.537	rs17161729	ENSG00000249476.1	CTD-2587M2.1	-5.23	6.85e-07	0.000808	-0.44	-0.43	Colorectal cancer (SNP x SNP interaction);	chr5:109324827	chr5:109237120~109326369:-
TGCT	cis	rs7301826	1	rs4759787	ENSG00000256299.1	RP11-989F5.3	-5.23	6.85e-07	0.000808	-0.46	-0.43	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810821~130812622:-
TGCT	cis	rs2880765	0.545	rs11631739	ENSG00000259295.5	CSPG4P12	5.23	6.85e-07	0.000808	0.54	0.43	Coronary artery disease;	chr15:85469347	chr15:85191438~85213905:+
TGCT	cis	rs7605378	0.528	rs281780	ENSG00000232732.8	AC073043.1	-5.23	6.89e-07	0.000812	-0.49	-0.43	Osteoporosis;	chr2:199891608	chr2:199867396~199911159:-
TGCT	cis	rs7605378	0.528	rs1704190	ENSG00000232732.8	AC073043.1	-5.23	6.89e-07	0.000812	-0.49	-0.43	Osteoporosis;	chr2:199895906	chr2:199867396~199911159:-
TGCT	cis	rs3091242	0.933	rs34006994	ENSG00000261349.1	RP3-465N24.5	5.23	6.89e-07	0.000812	0.41	0.43	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25266102~25267136:-
TGCT	cis	rs3091242	0.933	rs61775167	ENSG00000261349.1	RP3-465N24.5	5.23	6.89e-07	0.000812	0.41	0.43	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25266102~25267136:-
TGCT	cis	rs3091242	0.902	rs36003018	ENSG00000261349.1	RP3-465N24.5	5.23	6.89e-07	0.000812	0.41	0.43	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25266102~25267136:-
TGCT	cis	rs3091242	0.933	rs35403885	ENSG00000261349.1	RP3-465N24.5	5.23	6.89e-07	0.000812	0.41	0.43	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25266102~25267136:-
TGCT	cis	rs3091242	0.933	rs10903130	ENSG00000261349.1	RP3-465N24.5	-5.23	6.89e-07	0.000812	-0.41	-0.43	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25266102~25267136:-
TGCT	cis	rs3091242	0.933	rs11249251	ENSG00000261349.1	RP3-465N24.5	-5.23	6.89e-07	0.000812	-0.41	-0.43	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25266102~25267136:-
TGCT	cis	rs3091242	0.9	rs4649086	ENSG00000261349.1	RP3-465N24.5	-5.23	6.89e-07	0.000812	-0.41	-0.43	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25266102~25267136:-
TGCT	cis	rs11168618	0.74	rs7299323	ENSG00000240399.1	RP1-228P16.1	5.23	6.91e-07	0.000814	0.41	0.43	Adiponectin levels;	chr12:48527750	chr12:48054813~48055591:-
TGCT	cis	rs9425766	0.566	rs4442420	ENSG00000227373.4	RP11-160H22.5	5.23	6.93e-07	0.000816	0.46	0.43	Life satisfaction;	chr1:174199667	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.566	rs4447042	ENSG00000227373.4	RP11-160H22.5	5.23	6.93e-07	0.000816	0.46	0.43	Life satisfaction;	chr1:174212747	chr1:174115300~174160004:-
TGCT	cis	rs5758659	0.652	rs133322	ENSG00000270083.1	RP1-257I20.14	5.23	6.93e-07	0.000816	0.41	0.43	Cognitive function;	chr22:42009655	chr22:42089630~42090028:-
TGCT	cis	rs10256972	0.567	rs2960850	ENSG00000226291.1	AC091729.8	-5.23	6.93e-07	0.000817	-0.46	-0.43	Endometriosis;Longevity;	chr7:1172013	chr7:1080863~1082178:+
TGCT	cis	rs12908161	0.65	rs306206	ENSG00000225151.9	GOLGA2P7	-5.23	6.95e-07	0.000818	-0.5	-0.43	Schizophrenia;	chr15:84845422	chr15:84199311~84230136:-
TGCT	cis	rs12908161	0.65	rs182517	ENSG00000225151.9	GOLGA2P7	-5.23	6.95e-07	0.000818	-0.5	-0.43	Schizophrenia;	chr15:84846400	chr15:84199311~84230136:-
TGCT	cis	rs7301826	1	rs10773822	ENSG00000256299.1	RP11-989F5.3	-5.23	6.95e-07	0.000818	-0.46	-0.43	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810821~130812622:-
TGCT	cis	rs7301826	1	rs4759793	ENSG00000256299.1	RP11-989F5.3	-5.23	6.95e-07	0.000818	-0.46	-0.43	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810821~130812622:-
TGCT	cis	rs7301826	1	rs4759523	ENSG00000256299.1	RP11-989F5.3	-5.23	6.95e-07	0.000818	-0.46	-0.43	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810821~130812622:-
TGCT	cis	rs7301826	1	rs4759524	ENSG00000256299.1	RP11-989F5.3	-5.23	6.95e-07	0.000818	-0.46	-0.43	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810821~130812622:-
TGCT	cis	rs5760092	0.755	rs4585126	ENSG00000218537.1	MIF-AS1	-5.23	6.95e-07	0.000819	-0.63	-0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23894426~23898930:-
TGCT	cis	rs76878669	0.538	rs1546358	ENSG00000254510.1	RP11-867G23.10	5.23	6.97e-07	0.000821	0.57	0.43	Educational attainment (years of education);	chr11:66407790	chr11:66409158~66417137:+
TGCT	cis	rs76878669	0.561	rs6591217	ENSG00000254510.1	RP11-867G23.10	-5.23	6.97e-07	0.000821	-0.57	-0.43	Educational attainment (years of education);	chr11:66407182	chr11:66409158~66417137:+
TGCT	cis	rs2919917	1	rs2717547	ENSG00000254352.1	RP11-578O24.2	-5.23	6.99e-07	0.000823	-0.51	-0.43	Lymphocyte counts;	chr8:78744754	chr8:78723796~78724136:-
TGCT	cis	rs2919917	1	rs2919917	ENSG00000254352.1	RP11-578O24.2	-5.23	6.99e-07	0.000823	-0.51	-0.43	Lymphocyte counts;	chr8:78745028	chr8:78723796~78724136:-
TGCT	cis	rs17301013	0.861	rs10218528	ENSG00000227373.4	RP11-160H22.5	5.23	7.01e-07	0.000825	0.46	0.43	Systemic lupus erythematosus;	chr1:174478450	chr1:174115300~174160004:-
TGCT	cis	rs904251	0.523	rs914348	ENSG00000279942.1	RP1-153P14.7	-5.23	7.01e-07	0.000825	-0.43	-0.43	Cognitive performance;	chr6:37516953	chr6:37567716~37571460:+
TGCT	cis	rs9660180	0.967	rs2272908	ENSG00000268575.1	RP1-283E3.8	5.23	7.02e-07	0.000825	0.34	0.43	Body mass index;	chr1:1790040	chr1:1702736~1737688:-
TGCT	cis	rs35160687	0.901	rs10520415	ENSG00000273080.1	RP11-301O19.1	-5.23	7.04e-07	0.000828	-0.48	-0.42	Night sleep phenotypes;	chr2:86271615	chr2:86195590~86196049:+
TGCT	cis	rs35160687	0.901	rs12472390	ENSG00000273080.1	RP11-301O19.1	5.23	7.04e-07	0.000828	0.48	0.42	Night sleep phenotypes;	chr2:86247960	chr2:86195590~86196049:+
TGCT	cis	rs35160687	0.865	rs10189492	ENSG00000273080.1	RP11-301O19.1	5.23	7.04e-07	0.000828	0.48	0.42	Night sleep phenotypes;	chr2:86251779	chr2:86195590~86196049:+
TGCT	cis	rs12429206	0.52	rs75594262	ENSG00000233672.5	RNASEH2B-AS1	-5.23	7.05e-07	0.000829	-0.57	-0.42	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50900249	chr13:50862172~50910764:-
TGCT	cis	rs4835473	0.932	rs13119602	ENSG00000251600.4	RP11-673E1.1	-5.23	7.06e-07	0.00083	-0.41	-0.42	Immature fraction of reticulocytes;	chr4:143736621	chr4:143912331~143982454:+
TGCT	cis	rs3091242	0.933	rs35497030	ENSG00000261349.1	RP3-465N24.5	5.23	7.06e-07	0.00083	0.41	0.42	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25266102~25267136:-
TGCT	cis	rs911555	0.662	rs4906322	ENSG00000244691.1	RPL10AP1	5.23	7.06e-07	0.00083	0.57	0.42	Intelligence (multi-trait analysis);	chr14:103412695	chr14:103412119~103412761:-
TGCT	cis	rs17711722	0.523	rs365896	ENSG00000164669.11	INTS4P1	5.23	7.07e-07	0.000831	0.41	0.42	Calcium levels;	chr7:66045710	chr7:65141225~65234216:+
TGCT	cis	rs2006771	0.81	rs4820988	ENSG00000236132.1	CTA-440B3.1	5.23	7.09e-07	0.000834	0.41	0.42	Nonsyndromic cleft lip with cleft palate;	chr22:31669821	chr22:31816379~31817491:-
TGCT	cis	rs34779708	0.931	rs7920095	ENSG00000230534.5	RP11-297A16.2	5.23	7.1e-07	0.000834	0.49	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35014406	chr10:35098006~35127020:-
TGCT	cis	rs1823913	1	rs6749232	ENSG00000227542.1	AC092614.2	-5.23	7.1e-07	0.000834	-0.45	-0.42	Obesity-related traits;	chr2:191250326	chr2:191229165~191246172:-
TGCT	cis	rs9584850	0.794	rs9630321	ENSG00000231194.1	FARP1-AS1	5.23	7.1e-07	0.000835	0.59	0.42	Neuroticism;	chr13:98454725	chr13:98435405~98435840:-
TGCT	cis	rs4660456	0.913	rs12743517	ENSG00000237899.1	RP4-739H11.3	5.23	7.11e-07	0.000836	0.57	0.42	Platelet count;	chr1:40759682	chr1:40669089~40687588:-
TGCT	cis	rs35343117	1	rs35343117	ENSG00000259295.5	CSPG4P12	5.23	7.12e-07	0.000836	0.53	0.42	Psoriasis;	chr15:85535884	chr15:85191438~85213905:+
TGCT	cis	rs12891047	0.966	rs1955470	ENSG00000258759.1	RP11-1012A1.7	5.23	7.14e-07	0.000838	0.35	0.42	Amyotrophic lateral sclerosis (sporadic);	chr14:67774035	chr14:67799004~67799609:+
TGCT	cis	rs4835473	0.932	rs13147386	ENSG00000251600.4	RP11-673E1.1	5.23	7.14e-07	0.000838	0.41	0.42	Immature fraction of reticulocytes;	chr4:143736586	chr4:143912331~143982454:+
TGCT	cis	rs7617773	0.78	rs35411187	ENSG00000229759.1	MRPS18AP1	5.22	7.15e-07	0.000839	0.37	0.42	Coronary artery disease;	chr3:48318527	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs11714176	ENSG00000229759.1	MRPS18AP1	5.22	7.15e-07	0.000839	0.37	0.42	Coronary artery disease;	chr3:48319372	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs11718350	ENSG00000229759.1	MRPS18AP1	5.22	7.15e-07	0.000839	0.37	0.42	Coronary artery disease;	chr3:48319502	chr3:48256350~48256938:-
TGCT	cis	rs11168618	0.561	rs4075258	ENSG00000240399.1	RP1-228P16.1	5.22	7.15e-07	0.00084	0.41	0.42	Adiponectin levels;	chr12:48525876	chr12:48054813~48055591:-
TGCT	cis	rs11168618	0.74	rs12425460	ENSG00000240399.1	RP1-228P16.1	5.22	7.15e-07	0.00084	0.41	0.42	Adiponectin levels;	chr12:48526013	chr12:48054813~48055591:-
TGCT	cis	rs11168618	0.74	rs10875826	ENSG00000240399.1	RP1-228P16.1	5.22	7.15e-07	0.00084	0.41	0.42	Adiponectin levels;	chr12:48527377	chr12:48054813~48055591:-
TGCT	cis	rs899997	1	rs9888691	ENSG00000261143.1	ADAMTS7P3	5.22	7.15e-07	0.00084	0.46	0.42	Coronary artery disease or large artery stroke;	chr15:78717704	chr15:77976042~77993057:+
TGCT	cis	rs899997	1	rs4887078	ENSG00000261143.1	ADAMTS7P3	5.22	7.15e-07	0.00084	0.46	0.42	Coronary artery disease or large artery stroke;	chr15:78718731	chr15:77976042~77993057:+
TGCT	cis	rs853679	0.517	rs9393895	ENSG00000219392.1	RP1-265C24.5	-5.22	7.16e-07	0.00084	-0.58	-0.42	Depression;	chr6:28159843	chr6:28115628~28116551:+
TGCT	cis	rs17711722	0.503	rs453835	ENSG00000236529.1	RP13-254B10.1	-5.22	7.18e-07	0.000842	-0.3	-0.42	Calcium levels;	chr7:66046172	chr7:65840212~65840596:+
TGCT	cis	rs1528149	0.576	rs1881242	ENSG00000224683.1	RPL36AP29	-5.22	7.21e-07	0.000845	-0.47	-0.42	Sitting height ratio;	chr7:16073822	chr7:16208945~16209265:+
TGCT	cis	rs11673344	0.832	rs11540540	ENSG00000226686.6	LINC01535	5.22	7.21e-07	0.000846	0.5	0.42	Obesity-related traits;	chr19:37129629	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.801	rs76806623	ENSG00000226686.6	LINC01535	5.22	7.21e-07	0.000846	0.5	0.42	Obesity-related traits;	chr19:37132525	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.77	rs74770693	ENSG00000226686.6	LINC01535	5.22	7.21e-07	0.000846	0.5	0.42	Obesity-related traits;	chr19:37135613	chr19:37251912~37265535:+
TGCT	cis	rs11671005	0.735	rs56292587	ENSG00000268912.1	CTD-2619J13.17	-5.22	7.25e-07	0.00085	-0.5	-0.42	Mean platelet volume;	chr19:58407699	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.735	rs56290606	ENSG00000268912.1	CTD-2619J13.17	-5.22	7.25e-07	0.00085	-0.5	-0.42	Mean platelet volume;	chr19:58407953	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.651	rs11878203	ENSG00000268912.1	CTD-2619J13.17	-5.22	7.25e-07	0.00085	-0.5	-0.42	Mean platelet volume;	chr19:58408683	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.735	rs11878198	ENSG00000268912.1	CTD-2619J13.17	-5.22	7.25e-07	0.00085	-0.5	-0.42	Mean platelet volume;	chr19:58408935	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.735	rs11666716	ENSG00000268912.1	CTD-2619J13.17	-5.22	7.25e-07	0.00085	-0.5	-0.42	Mean platelet volume;	chr19:58409585	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.735	rs34511020	ENSG00000268912.1	CTD-2619J13.17	-5.22	7.25e-07	0.00085	-0.5	-0.42	Mean platelet volume;	chr19:58409929	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.735	rs11666303	ENSG00000268912.1	CTD-2619J13.17	-5.22	7.25e-07	0.00085	-0.5	-0.42	Mean platelet volume;	chr19:58411135	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.735	rs34152946	ENSG00000268912.1	CTD-2619J13.17	-5.22	7.25e-07	0.00085	-0.5	-0.42	Mean platelet volume;	chr19:58411896	chr19:58428632~58431148:-
TGCT	cis	rs7621025	0.5	rs4678275	ENSG00000239213.4	NCK1-AS1	5.22	7.25e-07	0.00085	0.44	0.42	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136934841	chr3:136841726~136862054:-
TGCT	cis	rs12439619	0.508	rs17354842	ENSG00000278603.1	RP13-608F4.5	-5.22	7.26e-07	0.00085	-0.55	-0.42	Intelligence (multi-trait analysis);	chr15:82177259	chr15:82472203~82472426:+
TGCT	cis	rs367615	0.512	rs814153	ENSG00000249476.1	CTD-2587M2.1	5.22	7.26e-07	0.000851	0.44	0.42	Colorectal cancer (SNP x SNP interaction);	chr5:109332128	chr5:109237120~109326369:-
TGCT	cis	rs7617773	0.963	rs6766754	ENSG00000229759.1	MRPS18AP1	-5.22	7.27e-07	0.000852	-0.33	-0.42	Coronary artery disease;	chr3:48141099	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.832	rs6775114	ENSG00000229759.1	MRPS18AP1	-5.22	7.27e-07	0.000852	-0.33	-0.42	Coronary artery disease;	chr3:48141130	chr3:48256350~48256938:-
TGCT	cis	rs2117029	1	rs10783299	ENSG00000258017.1	RP11-386G11.10	-5.22	7.27e-07	0.000852	-0.53	-0.42	Intelligence (multi-trait analysis);	chr12:48996894	chr12:49127782~49147869:+
TGCT	cis	rs2880765	0.527	rs35184622	ENSG00000259295.5	CSPG4P12	5.22	7.33e-07	0.000858	0.53	0.42	Coronary artery disease;	chr15:85529804	chr15:85191438~85213905:+
TGCT	cis	rs2880765	0.527	rs1483578	ENSG00000259295.5	CSPG4P12	5.22	7.33e-07	0.000858	0.53	0.42	Coronary artery disease;	chr15:85532186	chr15:85191438~85213905:+
TGCT	cis	rs1153858	1	rs1980288	ENSG00000259520.4	CTD-2651B20.3	-5.22	7.33e-07	0.000858	-0.37	-0.42	Homoarginine levels;	chr15:45328414	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs12909158	ENSG00000259520.4	CTD-2651B20.3	-5.22	7.33e-07	0.000858	-0.37	-0.42	Homoarginine levels;	chr15:45328976	chr15:45251580~45279251:-
TGCT	cis	rs17301013	0.861	rs12568655	ENSG00000227373.4	RP11-160H22.5	5.22	7.34e-07	0.00086	0.46	0.42	Systemic lupus erythematosus;	chr1:174465194	chr1:174115300~174160004:-
TGCT	cis	rs2980436	1	rs2980436	ENSG00000253981.4	ALG1L13P	-5.22	7.36e-07	0.000862	-0.44	-0.42	Schizophrenia;	chr8:8234503	chr8:8236003~8244667:-
TGCT	cis	rs7208859	0.623	rs60890550	ENSG00000263531.1	RP13-753N3.1	5.22	7.39e-07	0.000864	0.78	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30863921~30864940:-
TGCT	cis	rs796364	0.587	rs7588746	ENSG00000232732.8	AC073043.1	-5.22	7.39e-07	0.000864	-0.58	-0.42	Schizophrenia;	chr2:200121622	chr2:199867396~199911159:-
TGCT	cis	rs2117029	0.862	rs10875915	ENSG00000258017.1	RP11-386G11.10	-5.22	7.41e-07	0.000867	-0.52	-0.42	Intelligence (multi-trait analysis);	chr12:49036311	chr12:49127782~49147869:+
TGCT	cis	rs3091242	0.9	rs35345536	ENSG00000261349.1	RP3-465N24.5	-5.22	7.42e-07	0.000868	-0.42	-0.42	Erythrocyte sedimentation rate;	chr1:25439997	chr1:25266102~25267136:-
TGCT	cis	rs10829156	0.945	rs10741131	ENSG00000240291.1	RP11-499P20.2	5.22	7.43e-07	0.000869	0.41	0.42	Sudden cardiac arrest;	chr10:18683130	chr10:18513115~18545651:-
TGCT	cis	rs3091242	0.933	rs1534954	ENSG00000261349.1	RP3-465N24.5	-5.22	7.45e-07	0.000871	-0.42	-0.42	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25266102~25267136:-
TGCT	cis	rs34217772	0.941	rs34543976	ENSG00000258536.1	RP11-1053O12.1	5.22	7.45e-07	0.000871	0.39	0.42	Myopia;	chr14:41782929	chr14:41742639~41742963:+
TGCT	cis	rs7301826	1	rs10848205	ENSG00000256299.1	RP11-989F5.3	-5.22	7.45e-07	0.000871	-0.44	-0.42	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810821~130812622:-
TGCT	cis	rs1707322	0.717	rs2275086	ENSG00000280836.1	AL355480.1	5.22	7.45e-07	0.000871	0.59	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45581219~45581321:-
TGCT	cis	rs3091242	0.933	rs10903129	ENSG00000261349.1	RP3-465N24.5	-5.21	7.47e-07	0.000873	-0.41	-0.42	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25266102~25267136:-
TGCT	cis	rs5758659	0.569	rs133294	ENSG00000270083.1	RP1-257I20.14	5.21	7.52e-07	0.000878	0.41	0.42	Cognitive function;	chr22:41986801	chr22:42089630~42090028:-
TGCT	cis	rs5758659	0.652	rs133300	ENSG00000270083.1	RP1-257I20.14	5.21	7.52e-07	0.000878	0.41	0.42	Cognitive function;	chr22:41993835	chr22:42089630~42090028:-
TGCT	cis	rs5758659	0.623	rs133328	ENSG00000270083.1	RP1-257I20.14	5.21	7.52e-07	0.000878	0.41	0.42	Cognitive function;	chr22:42012075	chr22:42089630~42090028:-
TGCT	cis	rs9660180	0.967	rs11260623	ENSG00000268575.1	RP1-283E3.8	-5.21	7.52e-07	0.000878	-0.35	-0.42	Body mass index;	chr1:1850017	chr1:1702736~1737688:-
TGCT	cis	rs9660180	0.967	rs9660106	ENSG00000268575.1	RP1-283E3.8	-5.21	7.55e-07	0.000881	-0.35	-0.42	Body mass index;	chr1:1866508	chr1:1702736~1737688:-
TGCT	cis	rs11098499	0.863	rs1010739	ENSG00000245958.5	RP11-33B1.1	-5.21	7.57e-07	0.000883	-0.46	-0.42	Corneal astigmatism;	chr4:119542316	chr4:119454791~119552025:+
TGCT	cis	rs8059260	0.544	rs7205916	ENSG00000274038.1	RP11-66H6.4	-5.21	7.59e-07	0.000885	-0.58	-0.42	Alcohol consumption over the past year;	chr16:11095399	chr16:11056556~11057034:+
TGCT	cis	rs2117029	1	rs10875913	ENSG00000258017.1	RP11-386G11.10	-5.21	7.61e-07	0.000887	-0.52	-0.42	Intelligence (multi-trait analysis);	chr12:49025525	chr12:49127782~49147869:+
TGCT	cis	rs17301013	0.861	rs1894200	ENSG00000227373.4	RP11-160H22.5	-5.21	7.61e-07	0.000887	-0.48	-0.42	Systemic lupus erythematosus;	chr1:174842039	chr1:174115300~174160004:-
TGCT	cis	rs899997	0.731	rs58717592	ENSG00000261143.1	ADAMTS7P3	-5.21	7.62e-07	0.000888	-0.55	-0.42	Coronary artery disease or large artery stroke;	chr15:78738075	chr15:77976042~77993057:+
TGCT	cis	rs9322193	0.923	rs4869750	ENSG00000216906.2	RP11-350J20.9	5.21	7.66e-07	0.000892	0.46	0.42	Lung cancer;	chr6:149855996	chr6:149904243~149906418:+
TGCT	cis	rs4835473	0.897	rs12508285	ENSG00000251600.4	RP11-673E1.1	-5.21	7.67e-07	0.000894	-0.43	-0.42	Immature fraction of reticulocytes;	chr4:143792642	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs7667544	ENSG00000251600.4	RP11-673E1.1	-5.21	7.67e-07	0.000894	-0.43	-0.42	Immature fraction of reticulocytes;	chr4:143793802	chr4:143912331~143982454:+
TGCT	cis	rs11671005	0.693	rs11668821	ENSG00000268912.1	CTD-2619J13.17	-5.21	7.67e-07	0.000894	-0.5	-0.42	Mean platelet volume;	chr19:58444446	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.616	rs12980907	ENSG00000268912.1	CTD-2619J13.17	-5.21	7.67e-07	0.000894	-0.5	-0.42	Mean platelet volume;	chr19:58444959	chr19:58428632~58431148:-
TGCT	cis	rs453301	0.624	rs6987558	ENSG00000173295.6	FAM86B3P	5.21	7.68e-07	0.000895	0.51	0.42	Joint mobility (Beighton score);	chr8:9005011	chr8:8228595~8244865:+
TGCT	cis	rs9584850	0.834	rs7339274	ENSG00000231194.1	FARP1-AS1	-5.21	7.69e-07	0.000895	-0.57	-0.42	Neuroticism;	chr13:98468018	chr13:98435405~98435840:-
TGCT	cis	rs10504229	0.817	rs58957714	ENSG00000253301.4	RP11-513O17.2	5.21	7.7e-07	0.000896	0.6	0.42	Developmental language disorder (linguistic errors);	chr8:57283305	chr8:57142689~57240298:+
TGCT	cis	rs11118620	0.81	rs1603047	ENSG00000272823.1	RP11-295M18.6	5.21	7.71e-07	0.000898	0.4	0.42	Heart failure;	chr1:220849953	chr1:220828676~220829211:-
TGCT	cis	rs2276314	0.793	rs77590522	ENSG00000278986.1	RP11-723J4.3	-5.21	7.72e-07	0.000899	-0.49	-0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:36049447	chr18:35972151~35973916:+
TGCT	cis	rs9584850	0.718	rs6491427	ENSG00000231194.1	FARP1-AS1	5.21	7.72e-07	0.000899	0.56	0.42	Neuroticism;	chr13:98460912	chr13:98435405~98435840:-
TGCT	cis	rs507080	0.733	rs611733	ENSG00000255422.1	AP002954.4	-5.21	7.74e-07	0.000901	-0.51	-0.42	Serum metabolite levels;	chr11:118702051	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.733	rs552079	ENSG00000255422.1	AP002954.4	-5.21	7.74e-07	0.000901	-0.51	-0.42	Serum metabolite levels;	chr11:118702313	chr11:118704607~118750263:+
TGCT	cis	rs17301013	0.803	rs2187562	ENSG00000227373.4	RP11-160H22.5	5.21	7.75e-07	0.000901	0.46	0.42	Systemic lupus erythematosus;	chr1:174842513	chr1:174115300~174160004:-
TGCT	cis	rs10256972	0.528	rs7784607	ENSG00000226291.1	AC091729.8	-5.21	7.75e-07	0.000902	-0.47	-0.42	Endometriosis;Longevity;	chr7:1139058	chr7:1080863~1082178:+
TGCT	cis	rs143626010	1	rs143626010	ENSG00000259982.1	CDC37P1	5.21	7.77e-07	0.000904	0.59	0.42	Mosquito bite size;	chr16:28528081	chr16:28700294~28701540:-
TGCT	cis	rs3091242	0.933	rs35530120	ENSG00000261349.1	RP3-465N24.5	5.21	7.78e-07	0.000905	0.41	0.42	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25266102~25267136:-
TGCT	cis	rs1707322	0.686	rs1250	ENSG00000280836.1	AL355480.1	-5.21	7.78e-07	0.000906	-0.58	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45581219~45581321:-
TGCT	cis	rs11673344	0.683	rs11668615	ENSG00000226686.6	LINC01535	5.21	7.79e-07	0.000906	0.5	0.42	Obesity-related traits;	chr19:37063632	chr19:37251912~37265535:+
TGCT	cis	rs1275600	0.677	rs56059557	ENSG00000271142.1	YWHAQP7	5.21	7.8e-07	0.000907	0.43	0.42	Non-glioblastoma glioma;	chr12:75860758	chr12:76619386~76620043:+
TGCT	cis	rs853679	0.723	rs1736904	ENSG00000216901.1	AL022393.7	5.2	7.82e-07	0.000909	0.58	0.42	Depression;	chr6:28251492	chr6:28176188~28176674:+
TGCT	cis	rs4563143	0.663	rs2218396	ENSG00000267243.4	AC005307.3	-5.2	7.87e-07	0.000914	-0.48	-0.42	Methadone dose in opioid dependence;	chr19:28745485	chr19:28435388~28727777:-
TGCT	cis	rs904251	0.797	rs1757181	ENSG00000279942.1	RP1-153P14.7	5.2	7.88e-07	0.000915	0.47	0.42	Cognitive performance;	chr6:37517952	chr6:37567716~37571460:+
TGCT	cis	rs2276314	0.857	rs7237599	ENSG00000278986.1	RP11-723J4.3	-5.2	7.88e-07	0.000915	-0.48	-0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:36059433	chr18:35972151~35973916:+
TGCT	cis	rs12745968	0.652	rs4970703	ENSG00000223787.2	RP4-593M8.1	-5.2	7.88e-07	0.000915	-0.54	-0.42	Bipolar disorder and schizophrenia;	chr1:92492298	chr1:92580476~92580821:-
TGCT	cis	rs12745968	0.62	rs7520630	ENSG00000223787.2	RP4-593M8.1	-5.2	7.88e-07	0.000915	-0.54	-0.42	Bipolar disorder and schizophrenia;	chr1:92493404	chr1:92580476~92580821:-
TGCT	cis	rs8062405	0.792	rs12446550	ENSG00000259982.1	CDC37P1	5.2	7.89e-07	0.000916	0.54	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.824	rs28698667	ENSG00000259982.1	CDC37P1	5.2	7.91e-07	0.000918	0.54	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.754	rs62034323	ENSG00000259982.1	CDC37P1	5.2	7.91e-07	0.000918	0.54	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.824	rs62034324	ENSG00000259982.1	CDC37P1	5.2	7.91e-07	0.000918	0.54	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.824	rs62034326	ENSG00000259982.1	CDC37P1	5.2	7.91e-07	0.000918	0.54	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.824	rs4788084	ENSG00000259982.1	CDC37P1	5.2	7.91e-07	0.000918	0.54	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28700294~28701540:-
TGCT	cis	rs3091242	1	rs646867	ENSG00000224183.1	SDHDP6	-5.2	7.92e-07	0.000919	-0.45	-0.42	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25294164~25294643:-
TGCT	cis	rs1799949	1	rs11659028	ENSG00000198496.9	NBR2	-5.2	7.96e-07	0.000923	-0.64	-0.42	Menopause (age at onset);	chr17:43043008	chr17:43125610~43153671:+
TGCT	cis	rs2919917	0.955	rs1441850	ENSG00000254352.1	RP11-578O24.2	-5.2	7.96e-07	0.000924	-0.5	-0.42	Lymphocyte counts;	chr8:78745431	chr8:78723796~78724136:-
TGCT	cis	rs3091242	0.967	rs1053438	ENSG00000224183.1	SDHDP6	5.2	7.96e-07	0.000924	0.45	0.42	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25294164~25294643:-
TGCT	cis	rs17301013	0.932	rs1653632	ENSG00000227373.4	RP11-160H22.5	-5.2	7.97e-07	0.000924	-0.45	-0.42	Systemic lupus erythematosus;	chr1:174786459	chr1:174115300~174160004:-
TGCT	cis	rs3091242	0.967	rs3093614	ENSG00000224183.1	SDHDP6	5.2	7.97e-07	0.000925	0.45	0.42	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25294164~25294643:-
TGCT	cis	rs2117029	0.898	rs10875914	ENSG00000258017.1	RP11-386G11.10	-5.2	7.98e-07	0.000925	-0.52	-0.42	Intelligence (multi-trait analysis);	chr12:49028311	chr12:49127782~49147869:+
TGCT	cis	rs67383717	0.527	rs10760718	ENSG00000175611.10	LINC00476	5.2	7.99e-07	0.000926	0.35	0.42	Parkinson's disease (pesticide exposure interaction);	chr9:96032397	chr9:95759231~95875977:-
TGCT	cis	rs4925386	0.84	rs6143034	ENSG00000273619.1	RP5-908M14.9	-5.2	7.99e-07	0.000927	-0.53	-0.42	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345489	chr20:62386303~62386970:-
TGCT	cis	rs4835473	0.932	rs11721523	ENSG00000251600.4	RP11-673E1.1	-5.2	8.07e-07	0.000935	-0.42	-0.42	Immature fraction of reticulocytes;	chr4:143767301	chr4:143912331~143982454:+
TGCT	cis	rs2276314	1	rs4799832	ENSG00000278986.1	RP11-723J4.3	-5.2	8.07e-07	0.000935	-0.47	-0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:35979683	chr18:35972151~35973916:+
TGCT	cis	rs2276314	1	rs8086395	ENSG00000278986.1	RP11-723J4.3	-5.2	8.07e-07	0.000935	-0.47	-0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:35984629	chr18:35972151~35973916:+
TGCT	cis	rs2276314	0.947	rs3898595	ENSG00000278986.1	RP11-723J4.3	-5.2	8.07e-07	0.000935	-0.47	-0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:35985922	chr18:35972151~35973916:+
TGCT	cis	rs2276314	1	rs4799834	ENSG00000278986.1	RP11-723J4.3	-5.2	8.07e-07	0.000935	-0.47	-0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:35986280	chr18:35972151~35973916:+
TGCT	cis	rs34779708	0.931	rs7923172	ENSG00000230534.5	RP11-297A16.2	5.2	8.08e-07	0.000936	0.49	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35020439	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs7908573	ENSG00000230534.5	RP11-297A16.2	5.2	8.08e-07	0.000936	0.49	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35020585	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs3740083	ENSG00000230534.5	RP11-297A16.2	5.2	8.08e-07	0.000936	0.49	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35031455	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs17583009	ENSG00000230534.5	RP11-297A16.2	5.2	8.08e-07	0.000936	0.49	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35031987	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs12261654	ENSG00000230534.5	RP11-297A16.2	5.2	8.08e-07	0.000936	0.49	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35033096	chr10:35098006~35127020:-
TGCT	cis	rs651907	0.557	rs7629753	ENSG00000244119.1	PDCL3P4	-5.2	8.09e-07	0.000937	-0.31	-0.42	Colorectal cancer;	chr3:101653078	chr3:101712472~101713191:+
TGCT	cis	rs11671005	0.693	rs11084542	ENSG00000268912.1	CTD-2619J13.17	-5.2	8.1e-07	0.000938	-0.5	-0.42	Mean platelet volume;	chr19:58420732	chr19:58428632~58431148:-
TGCT	cis	rs11723261	0.621	rs61794960	ENSG00000275426.1	CH17-262A2.1	5.2	8.1e-07	0.000938	0.86	0.42	Immune response to smallpox vaccine (IL-6);	chr4:156661	chr4:149738~150317:+
TGCT	cis	rs7208859	0.673	rs423151	ENSG00000266490.1	CTD-2349P21.9	5.2	8.11e-07	0.000939	0.44	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30792372~30792833:+
TGCT	cis	rs6061231	0.518	rs639836	ENSG00000273619.1	RP5-908M14.9	5.2	8.15e-07	0.000944	0.47	0.42	Colorectal cancer;	chr20:62351167	chr20:62386303~62386970:-
TGCT	cis	rs6061231	0.597	rs624313	ENSG00000273619.1	RP5-908M14.9	5.2	8.15e-07	0.000944	0.47	0.42	Colorectal cancer;	chr20:62352356	chr20:62386303~62386970:-
TGCT	cis	rs6061231	0.546	rs482220	ENSG00000273619.1	RP5-908M14.9	5.2	8.15e-07	0.000944	0.47	0.42	Colorectal cancer;	chr20:62352426	chr20:62386303~62386970:-
TGCT	cis	rs6061231	0.571	rs482010	ENSG00000273619.1	RP5-908M14.9	5.2	8.15e-07	0.000944	0.47	0.42	Colorectal cancer;	chr20:62352495	chr20:62386303~62386970:-
TGCT	cis	rs2276314	0.857	rs28396546	ENSG00000278986.1	RP11-723J4.3	-5.19	8.16e-07	0.000945	-0.48	-0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:36059061	chr18:35972151~35973916:+
TGCT	cis	rs10829156	0.699	rs10764584	ENSG00000240291.1	RP11-499P20.2	-5.19	8.16e-07	0.000945	-0.37	-0.42	Sudden cardiac arrest;	chr10:18546396	chr10:18513115~18545651:-
TGCT	cis	rs4835473	0.771	rs4835097	ENSG00000251600.4	RP11-673E1.1	5.19	8.16e-07	0.000945	0.44	0.42	Immature fraction of reticulocytes;	chr4:143960687	chr4:143912331~143982454:+
TGCT	cis	rs34217772	0.68	rs59082466	ENSG00000258536.1	RP11-1053O12.1	5.19	8.17e-07	0.000945	0.35	0.42	Myopia;	chr14:41718111	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.68	rs17181601	ENSG00000258536.1	RP11-1053O12.1	5.19	8.17e-07	0.000945	0.35	0.42	Myopia;	chr14:41718729	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.68	rs17181608	ENSG00000258536.1	RP11-1053O12.1	5.19	8.17e-07	0.000945	0.35	0.42	Myopia;	chr14:41719240	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.68	rs61990343	ENSG00000258536.1	RP11-1053O12.1	5.19	8.17e-07	0.000945	0.35	0.42	Myopia;	chr14:41720521	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.68	rs4603462	ENSG00000258536.1	RP11-1053O12.1	5.19	8.17e-07	0.000945	0.35	0.42	Myopia;	chr14:41721758	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.68	rs4624078	ENSG00000258536.1	RP11-1053O12.1	5.19	8.17e-07	0.000945	0.35	0.42	Myopia;	chr14:41721774	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.68	rs4586337	ENSG00000258536.1	RP11-1053O12.1	5.19	8.17e-07	0.000945	0.35	0.42	Myopia;	chr14:41721820	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.68	rs4584739	ENSG00000258536.1	RP11-1053O12.1	5.19	8.17e-07	0.000945	0.35	0.42	Myopia;	chr14:41721859	chr14:41742639~41742963:+
TGCT	cis	rs12429206	0.547	rs75419800	ENSG00000233672.5	RNASEH2B-AS1	-5.19	8.18e-07	0.000946	-0.57	-0.42	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50898897	chr13:50862172~50910764:-
TGCT	cis	rs4835473	0.932	rs12512652	ENSG00000251600.4	RP11-673E1.1	-5.19	8.18e-07	0.000946	-0.41	-0.42	Immature fraction of reticulocytes;	chr4:143736787	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs12509579	ENSG00000251600.4	RP11-673E1.1	-5.19	8.18e-07	0.000946	-0.41	-0.42	Immature fraction of reticulocytes;	chr4:143736821	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.712	rs12509607	ENSG00000251600.4	RP11-673E1.1	-5.19	8.18e-07	0.000946	-0.41	-0.42	Immature fraction of reticulocytes;	chr4:143736894	chr4:143912331~143982454:+
TGCT	cis	rs853679	0.517	rs9283884	ENSG00000219392.1	RP1-265C24.5	5.19	8.2e-07	0.000948	0.56	0.42	Depression;	chr6:28167882	chr6:28115628~28116551:+
TGCT	cis	rs12891047	1	rs2874131	ENSG00000258759.1	RP11-1012A1.7	5.19	8.2e-07	0.000948	0.36	0.42	Amyotrophic lateral sclerosis (sporadic);	chr14:67778982	chr14:67799004~67799609:+
TGCT	cis	rs8040855	1	rs8040855	ENSG00000259295.5	CSPG4P12	-5.19	8.23e-07	0.000951	-0.54	-0.42	Bulimia nervosa;	chr15:85155976	chr15:85191438~85213905:+
TGCT	cis	rs1799949	0.93	rs66499067	ENSG00000198496.9	NBR2	-5.19	8.24e-07	0.000953	-0.61	-0.42	Menopause (age at onset);	chr17:43096467	chr17:43125610~43153671:+
TGCT	cis	rs34217772	0.68	rs17781361	ENSG00000258536.1	RP11-1053O12.1	5.19	8.25e-07	0.000953	0.36	0.42	Myopia;	chr14:41726320	chr14:41742639~41742963:+
TGCT	cis	rs786425	0.677	rs11834141	ENSG00000278112.1	RP11-972P1.11	5.19	8.26e-07	0.000955	0.5	0.42	Pubertal anthropometrics;	chr12:123666149	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.59	rs7296804	ENSG00000278112.1	RP11-972P1.11	5.19	8.26e-07	0.000955	0.5	0.42	Pubertal anthropometrics;	chr12:123669316	chr12:123519390~123519856:-
TGCT	cis	rs2276314	0.857	rs4799843	ENSG00000278986.1	RP11-723J4.3	-5.19	8.29e-07	0.000957	-0.49	-0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:36065039	chr18:35972151~35973916:+
TGCT	cis	rs12946454	0.668	rs4792867	ENSG00000267288.2	RP13-890H12.2	-5.19	8.3e-07	0.000959	-0.46	-0.42	Systolic blood pressure;	chr17:45172077	chr17:45168800~45171584:-
TGCT	cis	rs17711722	0.528	rs73138179	ENSG00000164669.11	INTS4P1	-5.19	8.3e-07	0.000959	-0.41	-0.42	Calcium levels;	chr7:65829495	chr7:65141225~65234216:+
TGCT	cis	rs7923609	0.756	rs7910951	ENSG00000232075.1	MRPL35P2	5.19	8.31e-07	0.000959	0.41	0.42	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63578544	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.756	rs7911761	ENSG00000232075.1	MRPL35P2	5.19	8.31e-07	0.000959	0.41	0.42	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63578993	chr10:63634317~63634827:-
TGCT	cis	rs12891047	0.78	rs961700	ENSG00000258759.1	RP11-1012A1.7	-5.19	8.32e-07	0.00096	-0.35	-0.42	Amyotrophic lateral sclerosis (sporadic);	chr14:67864720	chr14:67799004~67799609:+
TGCT	cis	rs7617773	0.779	rs9833309	ENSG00000229759.1	MRPS18AP1	5.19	8.35e-07	0.000963	0.36	0.42	Coronary artery disease;	chr3:48285960	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.817	rs9853804	ENSG00000229759.1	MRPS18AP1	5.19	8.35e-07	0.000963	0.36	0.42	Coronary artery disease;	chr3:48286239	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.817	rs9834095	ENSG00000229759.1	MRPS18AP1	5.19	8.35e-07	0.000963	0.36	0.42	Coronary artery disease;	chr3:48286261	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.817	rs4131361	ENSG00000229759.1	MRPS18AP1	5.19	8.35e-07	0.000963	0.36	0.42	Coronary artery disease;	chr3:48287322	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.817	rs4131362	ENSG00000229759.1	MRPS18AP1	5.19	8.35e-07	0.000963	0.36	0.42	Coronary artery disease;	chr3:48287546	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.817	rs6791930	ENSG00000229759.1	MRPS18AP1	5.19	8.35e-07	0.000963	0.36	0.42	Coronary artery disease;	chr3:48288410	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.817	rs6794644	ENSG00000229759.1	MRPS18AP1	5.19	8.35e-07	0.000963	0.36	0.42	Coronary artery disease;	chr3:48288547	chr3:48256350~48256938:-
TGCT	cis	rs9918079	0.56	rs7438356	ENSG00000273133.1	RP11-799M12.2	-5.19	8.37e-07	0.000965	-0.61	-0.42	Obesity-related traits;	chr4:15623147	chr4:15563698~15564253:-
TGCT	cis	rs524281	1	rs527897	ENSG00000255320.1	RP11-755F10.1	5.19	8.38e-07	0.000966	0.51	0.42	Electroencephalogram traits;	chr11:66133306	chr11:66244840~66246239:-
TGCT	cis	rs1799949	0.536	rs4793227	ENSG00000198496.9	NBR2	-5.19	8.4e-07	0.000969	-0.6	-0.42	Menopause (age at onset);	chr17:43334882	chr17:43125610~43153671:+
TGCT	cis	rs8040855	0.894	rs4843023	ENSG00000259295.5	CSPG4P12	-5.19	8.4e-07	0.000969	-0.54	-0.42	Bulimia nervosa;	chr15:85162641	chr15:85191438~85213905:+
TGCT	cis	rs5758659	0.622	rs5758527	ENSG00000270083.1	RP1-257I20.14	5.19	8.44e-07	0.000973	0.4	0.42	Cognitive function;	chr22:41979757	chr22:42089630~42090028:-
TGCT	cis	rs2333021	0.866	rs10133784	ENSG00000259015.1	RP11-109N23.6	5.19	8.45e-07	0.000974	0.22	0.42	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73003328	chr14:72960595~72961993:+
TGCT	cis	rs8062405	0.755	rs62034325	ENSG00000259982.1	CDC37P1	5.19	8.46e-07	0.000975	0.59	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28700294~28701540:-
TGCT	cis	rs11157436	1	rs3811278	ENSG00000211813.2	TRAV34	5.19	8.46e-07	0.000976	0.46	0.42	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22186227	chr14:22207522~22208129:+
TGCT	cis	rs9322193	0.923	rs9800736	ENSG00000216906.2	RP11-350J20.9	5.19	8.47e-07	0.000976	0.48	0.42	Lung cancer;	chr6:149661281	chr6:149904243~149906418:+
TGCT	cis	rs4563143	0.663	rs10417671	ENSG00000267243.4	AC005307.3	-5.19	8.49e-07	0.000978	-0.48	-0.42	Methadone dose in opioid dependence;	chr19:28744428	chr19:28435388~28727777:-
TGCT	cis	rs9549367	0.712	rs2316443	ENSG00000269125.1	RP11-98F14.11	-5.19	8.49e-07	0.000978	-0.5	-0.42	Platelet distribution width;	chr13:113210523	chr13:113165002~113165183:-
TGCT	cis	rs1823913	1	rs4853562	ENSG00000280083.1	RP11-317J9.1	5.19	8.5e-07	0.000979	0.36	0.42	Obesity-related traits;	chr2:191253696	chr2:191154118~191156070:-
TGCT	cis	rs1823913	1	rs4853461	ENSG00000280083.1	RP11-317J9.1	5.19	8.5e-07	0.000979	0.36	0.42	Obesity-related traits;	chr2:191254572	chr2:191154118~191156070:-
TGCT	cis	rs1823913	1	rs4853563	ENSG00000280083.1	RP11-317J9.1	5.19	8.5e-07	0.000979	0.36	0.42	Obesity-related traits;	chr2:191254808	chr2:191154118~191156070:-
TGCT	cis	rs9322193	0.847	rs868375	ENSG00000216906.2	RP11-350J20.9	5.18	8.57e-07	0.000986	0.49	0.42	Lung cancer;	chr6:149844905	chr6:149904243~149906418:+
TGCT	cis	rs9425766	0.591	rs2049991	ENSG00000227373.4	RP11-160H22.5	5.18	8.57e-07	0.000987	0.45	0.42	Life satisfaction;	chr1:174356428	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.566	rs10912773	ENSG00000227373.4	RP11-160H22.5	5.18	8.57e-07	0.000987	0.45	0.42	Life satisfaction;	chr1:174374567	chr1:174115300~174160004:-
TGCT	cis	rs2333021	0.833	rs10141389	ENSG00000259015.1	RP11-109N23.6	5.18	8.59e-07	0.000989	0.22	0.42	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73000413	chr14:72960595~72961993:+
TGCT	cis	rs7104764	0.957	rs6598075	ENSG00000277290.1	RP11-326C3.16	5.18	8.6e-07	0.000989	0.4	0.42	Menarche (age at onset);	chr11:207275	chr11:243099~243483:-
TGCT	cis	rs7104764	0.957	rs58692051	ENSG00000277290.1	RP11-326C3.16	5.18	8.6e-07	0.000989	0.4	0.42	Menarche (age at onset);	chr11:207410	chr11:243099~243483:-
TGCT	cis	rs3091242	0.933	rs9438904	ENSG00000224183.1	SDHDP6	-5.18	8.61e-07	0.000991	-0.44	-0.42	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25294164~25294643:-
TGCT	cis	rs4835473	0.742	rs7695853	ENSG00000251600.4	RP11-673E1.1	5.18	8.62e-07	0.000991	0.44	0.42	Immature fraction of reticulocytes;	chr4:143883243	chr4:143912331~143982454:+
TGCT	cis	rs2019137	0.56	rs7421852	ENSG00000189223.12	PAX8-AS1	-5.18	8.62e-07	0.000991	-0.57	-0.42	Lymphocyte counts;	chr2:113232684	chr2:113211522~113276581:+
TGCT	cis	rs667920	0.573	rs9682783	ENSG00000239213.4	NCK1-AS1	5.18	8.62e-07	0.000991	0.43	0.42	Coronary artery disease;	chr3:136820847	chr3:136841726~136862054:-
TGCT	cis	rs5760092	0.842	rs5751763	ENSG00000218537.1	MIF-AS1	5.18	8.65e-07	0.000994	0.64	0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23905606	chr22:23894426~23898930:-
TGCT	cis	rs4713118	0.621	rs9295755	ENSG00000219392.1	RP1-265C24.5	5.18	8.65e-07	0.000995	0.54	0.42	Parkinson's disease;	chr6:28065396	chr6:28115628~28116551:+
TGCT	cis	rs9660180	0.935	rs9786942	ENSG00000268575.1	RP1-283E3.8	-5.18	8.69e-07	0.000999	-0.34	-0.42	Body mass index;	chr1:1827774	chr1:1702736~1737688:-
TGCT	cis	rs9660180	0.934	rs34849348	ENSG00000268575.1	RP1-283E3.8	-5.18	8.69e-07	0.000999	-0.34	-0.42	Body mass index;	chr1:1831318	chr1:1702736~1737688:-
TGCT	cis	rs2276314	0.857	rs28530656	ENSG00000278986.1	RP11-723J4.3	5.18	8.69e-07	0.000999	0.46	0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:36008737	chr18:35972151~35973916:+
TGCT	cis	rs1153858	1	rs11858495	ENSG00000259520.4	CTD-2651B20.3	5.18	8.72e-07	0.001	0.39	0.42	Homoarginine levels;	chr15:45345464	chr15:45251580~45279251:-
TGCT	cis	rs367615	0.537	rs1965670	ENSG00000249476.1	CTD-2587M2.1	-5.18	8.73e-07	0.001	-0.42	-0.42	Colorectal cancer (SNP x SNP interaction);	chr5:109314097	chr5:109237120~109326369:-
TGCT	cis	rs3091242	0.933	rs4649084	ENSG00000224183.1	SDHDP6	-5.18	8.73e-07	0.001	-0.44	-0.42	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25294164~25294643:-
TGCT	cis	rs55794721	0.509	rs11249248	ENSG00000224183.1	SDHDP6	-5.18	8.74e-07	0.001	-0.44	-0.42	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25294164~25294643:-
TGCT	cis	rs3091242	0.933	rs909833	ENSG00000224183.1	SDHDP6	-5.18	8.74e-07	0.001	-0.44	-0.42	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25294164~25294643:-
TGCT	cis	rs853679	0.517	rs6932109	ENSG00000219392.1	RP1-265C24.5	5.18	8.74e-07	0.001	0.56	0.42	Depression;	chr6:28110525	chr6:28115628~28116551:+
TGCT	cis	rs9322193	0.887	rs3777949	ENSG00000216906.2	RP11-350J20.9	5.18	8.79e-07	0.00101	0.48	0.42	Lung cancer;	chr6:149596021	chr6:149904243~149906418:+
TGCT	cis	rs911555	0.673	rs7144271	ENSG00000244691.1	RPL10AP1	-5.18	8.8e-07	0.00101	-0.58	-0.42	Intelligence (multi-trait analysis);	chr14:103424337	chr14:103412119~103412761:-
TGCT	cis	rs2412819	0.597	rs2412821	ENSG00000205771.5	CATSPER2P1	-5.18	8.82e-07	0.00101	-0.65	-0.42	Lung cancer;	chr15:43864966	chr15:43726918~43747094:-
TGCT	cis	rs8062405	0.72	rs9926245	ENSG00000259982.1	CDC37P1	5.18	8.82e-07	0.00101	0.53	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28700294~28701540:-
TGCT	cis	rs7927592	0.763	rs10896351	ENSG00000212093.1	AP000807.1	5.18	8.88e-07	0.00102	0.4	0.42	Total body bone mineral density;	chr11:68619428	chr11:68506083~68506166:-
TGCT	cis	rs8059260	0.544	rs16958051	ENSG00000274038.1	RP11-66H6.4	5.18	8.89e-07	0.00102	0.65	0.42	Alcohol consumption over the past year;	chr16:11097362	chr16:11056556~11057034:+
TGCT	cis	rs9322193	0.886	rs9718079	ENSG00000216906.2	RP11-350J20.9	5.17	8.91e-07	0.00102	0.48	0.42	Lung cancer;	chr6:149645947	chr6:149904243~149906418:+
TGCT	cis	rs911555	0.723	rs7144010	ENSG00000244691.1	RPL10AP1	5.17	8.93e-07	0.00102	0.57	0.42	Intelligence (multi-trait analysis);	chr14:103403532	chr14:103412119~103412761:-
TGCT	cis	rs1061377	0.722	rs34803689	ENSG00000249685.1	RP11-360F5.3	5.17	8.93e-07	0.00102	0.38	0.42	Uric acid levels;	chr4:39116665	chr4:39133913~39135608:+
TGCT	cis	rs1061377	0.965	rs7669376	ENSG00000249685.1	RP11-360F5.3	5.17	8.93e-07	0.00102	0.38	0.42	Uric acid levels;	chr4:39116717	chr4:39133913~39135608:+
TGCT	cis	rs7849270	0.959	rs1107329	ENSG00000268707.1	RP11-247A12.7	5.17	8.96e-07	0.00103	0.48	0.42	Blood metabolite ratios;	chr9:129155435	chr9:129170434~129170940:+
TGCT	cis	rs9462027	0.585	rs1201873	ENSG00000186328.4	RP11-140K17.2	5.17	8.97e-07	0.00103	0.4	0.42	Systemic lupus erythematosus;	chr6:34582880	chr6:34715613~34715940:+
TGCT	cis	rs950027	0.967	rs2643718	ENSG00000259520.4	CTD-2651B20.3	-5.17	8.98e-07	0.00103	-0.31	-0.42	Response to fenofibrate (adiponectin levels);	chr15:45502464	chr15:45251580~45279251:-
TGCT	cis	rs7795991	0.967	rs10282101	ENSG00000224330.1	AC005019.3	-5.17	9.01e-07	0.00103	-0.44	-0.42	Type 2 diabetes;	chr7:13861466	chr7:13854355~13859025:-
TGCT	cis	rs507080	0.807	rs7926944	ENSG00000255422.1	AP002954.4	-5.17	9.02e-07	0.00103	-0.49	-0.42	Serum metabolite levels;	chr11:118689119	chr11:118704607~118750263:+
TGCT	cis	rs875971	0.505	rs6955582	ENSG00000237310.1	GS1-124K5.4	5.17	9.02e-07	0.00103	0.47	0.42	Aortic root size;	chr7:65966699	chr7:66493706~66495474:+
TGCT	cis	rs17826219	0.706	rs28469200	ENSG00000263531.1	RP13-753N3.1	5.17	9.04e-07	0.00103	0.79	0.42	Body mass index;	chr17:30806554	chr17:30863921~30864940:-
TGCT	cis	rs11157436	0.958	rs17255510	ENSG00000211813.2	TRAV34	-5.17	9.04e-07	0.00104	-0.46	-0.42	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22194962	chr14:22207522~22208129:+
TGCT	cis	rs71281886	1	rs71281886	ENSG00000229759.1	MRPS18AP1	5.17	9.05e-07	0.00104	0.37	0.42	Breast cancer;	chr3:48311088	chr3:48256350~48256938:-
TGCT	cis	rs1061377	1	rs9990742	ENSG00000249685.1	RP11-360F5.3	5.17	9.08e-07	0.00104	0.39	0.42	Uric acid levels;	chr4:39119794	chr4:39133913~39135608:+
TGCT	cis	rs4835473	0.932	rs7683686	ENSG00000251600.4	RP11-673E1.1	-5.17	9.08e-07	0.00104	-0.39	-0.42	Immature fraction of reticulocytes;	chr4:143784352	chr4:143912331~143982454:+
TGCT	cis	rs2882667	0.537	rs6887866	ENSG00000253404.1	AC034243.1	5.17	9.08e-07	0.00104	0.47	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139102007	chr5:138744434~138753309:-
TGCT	cis	rs2177312	0.729	rs1403531	ENSG00000251129.1	RP11-734I18.1	-5.17	9.09e-07	0.00104	-0.5	-0.42	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31994525	chr4:31997397~32155406:+
TGCT	cis	rs2117029	0.965	rs1138908	ENSG00000258017.1	RP11-386G11.10	-5.17	9.09e-07	0.00104	-0.52	-0.42	Intelligence (multi-trait analysis);	chr12:49008516	chr12:49127782~49147869:+
TGCT	cis	rs2117029	1	rs2117029	ENSG00000258017.1	RP11-386G11.10	-5.17	9.09e-07	0.00104	-0.52	-0.42	Intelligence (multi-trait analysis);	chr12:49014657	chr12:49127782~49147869:+
TGCT	cis	rs8062405	0.754	rs149299	ENSG00000259982.1	CDC37P1	5.17	9.1e-07	0.00104	0.55	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28700294~28701540:-
TGCT	cis	rs17301013	0.507	rs4652460	ENSG00000227373.4	RP11-160H22.5	5.17	9.11e-07	0.00104	0.47	0.42	Systemic lupus erythematosus;	chr1:174459499	chr1:174115300~174160004:-
TGCT	cis	rs2739330	0.761	rs5760176	ENSG00000272787.1	KB-226F1.2	5.17	9.13e-07	0.00104	0.46	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23969211~23969873:+
TGCT	cis	rs2725220	0.521	rs12512476	ENSG00000202000.1	RNU1-36P	5.17	9.13e-07	0.00104	0.41	0.42	Renal function-related traits (urea);	chr4:88042450	chr4:88000237~88000401:+
TGCT	cis	rs507080	0.883	rs558593	ENSG00000255422.1	AP002954.4	-5.17	9.15e-07	0.00105	-0.49	-0.42	Serum metabolite levels;	chr11:118691811	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.922	rs582630	ENSG00000255422.1	AP002954.4	-5.17	9.15e-07	0.00105	-0.49	-0.42	Serum metabolite levels;	chr11:118692090	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.883	rs527475	ENSG00000255422.1	AP002954.4	-5.17	9.15e-07	0.00105	-0.49	-0.42	Serum metabolite levels;	chr11:118692530	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.922	rs585039	ENSG00000255422.1	AP002954.4	-5.17	9.15e-07	0.00105	-0.49	-0.42	Serum metabolite levels;	chr11:118692672	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.922	rs508640	ENSG00000255422.1	AP002954.4	-5.17	9.15e-07	0.00105	-0.49	-0.42	Serum metabolite levels;	chr11:118693704	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.922	rs471227	ENSG00000255422.1	AP002954.4	-5.17	9.15e-07	0.00105	-0.49	-0.42	Serum metabolite levels;	chr11:118693892	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.922	rs516153	ENSG00000255422.1	AP002954.4	-5.17	9.15e-07	0.00105	-0.49	-0.42	Serum metabolite levels;	chr11:118694053	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.922	rs518028	ENSG00000255422.1	AP002954.4	-5.17	9.15e-07	0.00105	-0.49	-0.42	Serum metabolite levels;	chr11:118694273	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.922	rs519982	ENSG00000255422.1	AP002954.4	-5.17	9.15e-07	0.00105	-0.49	-0.42	Serum metabolite levels;	chr11:118694522	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.922	rs478371	ENSG00000255422.1	AP002954.4	-5.17	9.15e-07	0.00105	-0.49	-0.42	Serum metabolite levels;	chr11:118694627	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.922	rs502601	ENSG00000255422.1	AP002954.4	-5.17	9.15e-07	0.00105	-0.49	-0.42	Serum metabolite levels;	chr11:118694970	chr11:118704607~118750263:+
TGCT	cis	rs4835473	0.932	rs35164917	ENSG00000251600.4	RP11-673E1.1	5.17	9.15e-07	0.00105	0.42	0.42	Immature fraction of reticulocytes;	chr4:143748891	chr4:143912331~143982454:+
TGCT	cis	rs8062405	0.721	rs151303	ENSG00000259982.1	CDC37P1	5.17	9.2e-07	0.00105	0.55	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28700294~28701540:-
TGCT	cis	rs1510272	0.515	rs6807235	ENSG00000243926.1	TIPARP-AS1	-5.17	9.2e-07	0.00105	-0.57	-0.42	Testicular germ cell tumor;	chr3:156623812	chr3:156671862~156674378:-
TGCT	cis	rs5769707	0.605	rs9616702	ENSG00000235111.1	RP1-29C18.8	-5.17	9.22e-07	0.00105	-0.39	-0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49632290	chr22:49612657~49615716:-
TGCT	cis	rs1010254	0.51	rs80091187	ENSG00000213433.5	RPLP1P6	-5.17	9.22e-07	0.00105	-0.51	-0.42	Optic nerve measurement (cup area);	chr5:152315294	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.51	rs1363419	ENSG00000213433.5	RPLP1P6	-5.17	9.22e-07	0.00105	-0.51	-0.42	Optic nerve measurement (cup area);	chr5:152316850	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.51	rs17446143	ENSG00000213433.5	RPLP1P6	-5.17	9.22e-07	0.00105	-0.51	-0.42	Optic nerve measurement (cup area);	chr5:152318089	chr5:151765859~151766378:-
TGCT	cis	rs10800713	0.954	rs4623737	ENSG00000260088.1	RP11-92G12.3	-5.17	9.26e-07	0.00106	-0.44	-0.42	Tandem gait;	chr1:200594578	chr1:200669507~200694250:+
TGCT	cis	rs9322193	0.923	rs9377230	ENSG00000216906.2	RP11-350J20.9	5.17	9.26e-07	0.00106	0.48	0.42	Lung cancer;	chr6:149613607	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9404048	ENSG00000216906.2	RP11-350J20.9	5.17	9.26e-07	0.00106	0.48	0.42	Lung cancer;	chr6:149616188	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9505982	ENSG00000216906.2	RP11-350J20.9	5.17	9.26e-07	0.00106	0.48	0.42	Lung cancer;	chr6:149618465	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.886	rs9485408	ENSG00000216906.2	RP11-350J20.9	5.17	9.26e-07	0.00106	0.48	0.42	Lung cancer;	chr6:149618888	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9322196	ENSG00000216906.2	RP11-350J20.9	5.17	9.26e-07	0.00106	0.48	0.42	Lung cancer;	chr6:149619645	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9505823	ENSG00000216906.2	RP11-350J20.9	5.17	9.26e-07	0.00106	0.48	0.42	Lung cancer;	chr6:149628899	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.847	rs62439808	ENSG00000216906.2	RP11-350J20.9	5.17	9.26e-07	0.00106	0.48	0.42	Lung cancer;	chr6:149629690	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9688861	ENSG00000216906.2	RP11-350J20.9	5.17	9.26e-07	0.00106	0.48	0.42	Lung cancer;	chr6:149637924	chr6:149904243~149906418:+
TGCT	cis	rs1799949	0.965	rs9897425	ENSG00000198496.9	NBR2	-5.17	9.27e-07	0.00106	-0.6	-0.42	Menopause (age at onset);	chr17:43352811	chr17:43125610~43153671:+
TGCT	cis	rs76878669	0.561	rs6591215	ENSG00000254510.1	RP11-867G23.10	-5.17	9.29e-07	0.00106	-0.56	-0.42	Educational attainment (years of education);	chr11:66403140	chr11:66409158~66417137:+
TGCT	cis	rs507080	0.733	rs673547	ENSG00000255422.1	AP002954.4	-5.16	9.35e-07	0.00107	-0.5	-0.42	Serum metabolite levels;	chr11:118702630	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.733	rs517445	ENSG00000255422.1	AP002954.4	-5.16	9.35e-07	0.00107	-0.5	-0.42	Serum metabolite levels;	chr11:118702826	chr11:118704607~118750263:+
TGCT	cis	rs4563143	0.663	rs5025682	ENSG00000267243.4	AC005307.3	-5.16	9.36e-07	0.00107	-0.48	-0.42	Methadone dose in opioid dependence;	chr19:28747763	chr19:28435388~28727777:-
TGCT	cis	rs10504229	0.728	rs56180705	ENSG00000253301.4	RP11-513O17.2	5.16	9.36e-07	0.00107	0.59	0.42	Developmental language disorder (linguistic errors);	chr8:57237175	chr8:57142689~57240298:+
TGCT	cis	rs11671005	0.57	rs73062110	ENSG00000268912.1	CTD-2619J13.17	-5.16	9.37e-07	0.00107	-0.49	-0.42	Mean platelet volume;	chr19:58425275	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.735	rs11668420	ENSG00000268912.1	CTD-2619J13.17	-5.16	9.37e-07	0.00107	-0.49	-0.42	Mean platelet volume;	chr19:58426469	chr19:58428632~58431148:-
TGCT	cis	rs911555	0.723	rs7149767	ENSG00000244691.1	RPL10AP1	5.16	9.4e-07	0.00107	0.57	0.42	Intelligence (multi-trait analysis);	chr14:103397208	chr14:103412119~103412761:-
TGCT	cis	rs5769707	0.609	rs2071890	ENSG00000235111.1	RP1-29C18.8	-5.16	9.4e-07	0.00107	-0.4	-0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49607643	chr22:49612657~49615716:-
TGCT	cis	rs899997	1	rs11629824	ENSG00000261143.1	ADAMTS7P3	5.16	9.4e-07	0.00107	0.46	0.42	Coronary artery disease or large artery stroke;	chr15:78713182	chr15:77976042~77993057:+
TGCT	cis	rs899997	1	rs11634628	ENSG00000261143.1	ADAMTS7P3	5.16	9.4e-07	0.00107	0.46	0.42	Coronary artery disease or large artery stroke;	chr15:78713237	chr15:77976042~77993057:+
TGCT	cis	rs12891047	0.78	rs7151091	ENSG00000258759.1	RP11-1012A1.7	5.16	9.41e-07	0.00107	0.35	0.42	Amyotrophic lateral sclerosis (sporadic);	chr14:67867432	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.78	rs7157288	ENSG00000258759.1	RP11-1012A1.7	-5.16	9.41e-07	0.00107	-0.35	-0.42	Amyotrophic lateral sclerosis (sporadic);	chr14:67859268	chr14:67799004~67799609:+
TGCT	cis	rs2980439	0.87	rs2945230	ENSG00000173295.6	FAM86B3P	5.16	9.44e-07	0.00107	0.52	0.42	Neuroticism;	chr8:8252414	chr8:8228595~8244865:+
TGCT	cis	rs7208859	0.614	rs216477	ENSG00000280069.1	CTD-2349P21.3	5.16	9.45e-07	0.00108	0.54	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30539726	chr17:30738182~30740275:+
TGCT	cis	rs34217772	0.941	rs34009991	ENSG00000258536.1	RP11-1053O12.1	5.16	9.5e-07	0.00108	0.38	0.42	Myopia;	chr14:41783923	chr14:41742639~41742963:+
TGCT	cis	rs3091242	0.933	rs9438905	ENSG00000261349.1	RP3-465N24.5	-5.16	9.51e-07	0.00108	-0.41	-0.42	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25266102~25267136:-
TGCT	cis	rs3091242	0.935	rs4233043	ENSG00000261349.1	RP3-465N24.5	-5.16	9.51e-07	0.00108	-0.41	-0.42	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25266102~25267136:-
TGCT	cis	rs10504229	0.728	rs17804822	ENSG00000253301.4	RP11-513O17.2	5.16	9.54e-07	0.00108	0.59	0.42	Developmental language disorder (linguistic errors);	chr8:57243717	chr8:57142689~57240298:+
TGCT	cis	rs2739330	0.731	rs5751792	ENSG00000250470.1	AP000351.3	5.16	9.54e-07	0.00108	0.41	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23976904~23977585:-
TGCT	cis	rs786425	0.682	rs12828408	ENSG00000278112.1	RP11-972P1.11	5.16	9.55e-07	0.00109	0.51	0.42	Pubertal anthropometrics;	chr12:123714171	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs3817309	ENSG00000278112.1	RP11-972P1.11	5.16	9.55e-07	0.00109	0.51	0.42	Pubertal anthropometrics;	chr12:123714174	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs66471742	ENSG00000278112.1	RP11-972P1.11	5.16	9.55e-07	0.00109	0.51	0.42	Pubertal anthropometrics;	chr12:123714459	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs7135267	ENSG00000278112.1	RP11-972P1.11	5.16	9.55e-07	0.00109	0.51	0.42	Pubertal anthropometrics;	chr12:123714573	chr12:123519390~123519856:-
TGCT	cis	rs2880765	0.545	rs17553734	ENSG00000259295.5	CSPG4P12	-5.16	9.56e-07	0.00109	-0.55	-0.42	Coronary artery disease;	chr15:85469828	chr15:85191438~85213905:+
TGCT	cis	rs4927850	0.958	rs1975582	ENSG00000207650.1	MIR570	5.16	9.56e-07	0.00109	0.52	0.42	Pancreatic cancer;	chr3:196024568	chr3:195699401~195699497:+
TGCT	cis	rs4927850	0.957	rs4927851	ENSG00000207650.1	MIR570	5.16	9.56e-07	0.00109	0.52	0.42	Pancreatic cancer;	chr3:196024982	chr3:195699401~195699497:+
TGCT	cis	rs4927850	0.918	rs4361313	ENSG00000207650.1	MIR570	5.16	9.56e-07	0.00109	0.52	0.42	Pancreatic cancer;	chr3:196025389	chr3:195699401~195699497:+
TGCT	cis	rs4927850	1	rs7627706	ENSG00000207650.1	MIR570	5.16	9.56e-07	0.00109	0.52	0.42	Pancreatic cancer;	chr3:196026482	chr3:195699401~195699497:+
TGCT	cis	rs4927850	0.881	rs7630489	ENSG00000207650.1	MIR570	5.16	9.56e-07	0.00109	0.52	0.42	Pancreatic cancer;	chr3:196026530	chr3:195699401~195699497:+
TGCT	cis	rs4927850	1	rs7627868	ENSG00000207650.1	MIR570	5.16	9.56e-07	0.00109	0.52	0.42	Pancreatic cancer;	chr3:196026602	chr3:195699401~195699497:+
TGCT	cis	rs7849270	1	rs2541164	ENSG00000268707.1	RP11-247A12.7	-5.16	9.57e-07	0.00109	-0.47	-0.42	Blood metabolite ratios;	chr9:129114629	chr9:129170434~129170940:+
TGCT	cis	rs453301	0.598	rs2921383	ENSG00000173295.6	FAM86B3P	5.16	9.58e-07	0.00109	0.5	0.42	Joint mobility (Beighton score);	chr8:9034711	chr8:8228595~8244865:+
TGCT	cis	rs8059260	0.611	rs34143079	ENSG00000274038.1	RP11-66H6.4	-5.16	9.58e-07	0.00109	-0.56	-0.42	Alcohol consumption over the past year;	chr16:11069069	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.541	rs7195452	ENSG00000274038.1	RP11-66H6.4	-5.16	9.58e-07	0.00109	-0.56	-0.42	Alcohol consumption over the past year;	chr16:11069469	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.604	rs16958021	ENSG00000274038.1	RP11-66H6.4	-5.16	9.58e-07	0.00109	-0.56	-0.42	Alcohol consumption over the past year;	chr16:11076190	chr16:11056556~11057034:+
TGCT	cis	rs6604026	0.602	rs11583778	ENSG00000223787.2	RP4-593M8.1	5.16	9.62e-07	0.00109	0.63	0.42	Multiple sclerosis;	chr1:92797917	chr1:92580476~92580821:-
TGCT	cis	rs8062405	0.691	rs11646653	ENSG00000259982.1	CDC37P1	-5.16	9.63e-07	0.00109	-0.61	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28700294~28701540:-
TGCT	cis	rs8113308	0.515	rs60581730	ENSG00000269235.1	ZNF350-AS1	5.16	9.64e-07	0.00109	0.85	0.42	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51937883	chr19:51949134~51981367:+
TGCT	cis	rs7115242	0.8	rs1320668	ENSG00000254851.1	RP11-109L13.1	-5.16	9.67e-07	0.0011	-0.81	-0.42	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117096950	chr11:117135528~117138582:+
TGCT	cis	rs2427308	0.643	rs477859	ENSG00000273619.1	RP5-908M14.9	5.16	9.68e-07	0.0011	0.49	0.42	Colorectal cancer;	chr20:62362541	chr20:62386303~62386970:-
TGCT	cis	rs17301013	0.896	rs13375788	ENSG00000227373.4	RP11-160H22.5	5.16	9.69e-07	0.0011	0.45	0.42	Systemic lupus erythematosus;	chr1:174524207	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.932	rs10912804	ENSG00000227373.4	RP11-160H22.5	5.16	9.69e-07	0.0011	0.45	0.42	Systemic lupus erythematosus;	chr1:174527412	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.9	rs12088073	ENSG00000227373.4	RP11-160H22.5	5.16	9.69e-07	0.0011	0.45	0.42	Systemic lupus erythematosus;	chr1:174528504	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.932	rs10912807	ENSG00000227373.4	RP11-160H22.5	5.16	9.69e-07	0.0011	0.45	0.42	Systemic lupus erythematosus;	chr1:174547228	chr1:174115300~174160004:-
TGCT	cis	rs786425	0.77	rs71458814	ENSG00000278112.1	RP11-972P1.11	5.16	9.7e-07	0.0011	0.51	0.42	Pubertal anthropometrics;	chr12:123712344	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.682	rs1139320	ENSG00000278112.1	RP11-972P1.11	5.16	9.7e-07	0.0011	0.51	0.42	Pubertal anthropometrics;	chr12:123712552	chr12:123519390~123519856:-
TGCT	cis	rs1799949	1	rs3950989	ENSG00000198496.9	NBR2	-5.16	9.7e-07	0.0011	-0.61	-0.42	Menopause (age at onset);	chr17:43085936	chr17:43125610~43153671:+
TGCT	cis	rs4927850	1	rs7625570	ENSG00000231464.1	AC024937.4	5.16	9.7e-07	0.0011	0.41	0.42	Pancreatic cancer;	chr3:196020527	chr3:195996738~195998233:+
TGCT	cis	rs853679	0.76	rs9468317	ENSG00000216901.1	AL022393.7	5.16	9.72e-07	0.0011	0.64	0.42	Depression;	chr6:28230678	chr6:28176188~28176674:+
TGCT	cis	rs853679	0.76	rs2299029	ENSG00000216901.1	AL022393.7	5.16	9.72e-07	0.0011	0.64	0.42	Depression;	chr6:28231053	chr6:28176188~28176674:+
TGCT	cis	rs853679	0.76	rs11962305	ENSG00000216901.1	AL022393.7	5.16	9.72e-07	0.0011	0.64	0.42	Depression;	chr6:28232159	chr6:28176188~28176674:+
TGCT	cis	rs12906542	1	rs12906542	ENSG00000259792.1	RP11-114H24.6	-5.16	9.72e-07	0.0011	-0.44	-0.42	Breast cancer;	chr15:77977130	chr15:77993405~77995289:+
TGCT	cis	rs5769707	0.554	rs10854876	ENSG00000235111.1	RP1-29C18.8	-5.15	9.75e-07	0.0011	-0.4	-0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49616922	chr22:49612657~49615716:-
TGCT	cis	rs11671005	0.735	rs11671591	ENSG00000268912.1	CTD-2619J13.17	5.15	9.76e-07	0.0011	0.49	0.42	Mean platelet volume;	chr19:58406970	chr19:58428632~58431148:-
TGCT	cis	rs17301013	0.932	rs1754349	ENSG00000227373.4	RP11-160H22.5	-5.15	9.78e-07	0.00111	-0.46	-0.42	Systemic lupus erythematosus;	chr1:174837663	chr1:174115300~174160004:-
TGCT	cis	rs11671005	0.693	rs11669665	ENSG00000268912.1	CTD-2619J13.17	-5.15	9.78e-07	0.00111	-0.49	-0.42	Mean platelet volume;	chr19:58420518	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.735	rs11084543	ENSG00000268912.1	CTD-2619J13.17	-5.15	9.78e-07	0.00111	-0.49	-0.42	Mean platelet volume;	chr19:58421334	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.735	rs11881000	ENSG00000268912.1	CTD-2619J13.17	-5.15	9.78e-07	0.00111	-0.49	-0.42	Mean platelet volume;	chr19:58421421	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.695	rs11673069	ENSG00000268912.1	CTD-2619J13.17	-5.15	9.78e-07	0.00111	-0.49	-0.42	Mean platelet volume;	chr19:58423551	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.735	rs12981875	ENSG00000268912.1	CTD-2619J13.17	-5.15	9.78e-07	0.00111	-0.49	-0.42	Mean platelet volume;	chr19:58423763	chr19:58428632~58431148:-
TGCT	cis	rs904251	0.6	rs12211110	ENSG00000279942.1	RP1-153P14.7	-5.15	9.82e-07	0.00111	-0.45	-0.42	Cognitive performance;	chr6:37498456	chr6:37567716~37571460:+
TGCT	cis	rs7208859	0.673	rs1347360	ENSG00000263531.1	RP13-753N3.1	5.15	9.86e-07	0.00111	0.77	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30863921~30864940:-
TGCT	cis	rs8062405	0.824	rs4788085	ENSG00000259982.1	CDC37P1	5.15	9.86e-07	0.00112	0.53	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.824	rs28772958	ENSG00000259982.1	CDC37P1	5.15	9.86e-07	0.00112	0.53	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.789	rs2106480	ENSG00000259982.1	CDC37P1	5.15	9.86e-07	0.00112	0.53	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28700294~28701540:-
TGCT	cis	rs8072100	0.967	rs8074149	ENSG00000228782.6	CTD-2026D20.3	-5.15	9.87e-07	0.00112	-0.51	-0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47506009	chr17:47450568~47492492:-
TGCT	cis	rs4563143	0.663	rs73025068	ENSG00000267243.4	AC005307.3	-5.15	9.89e-07	0.00112	-0.47	-0.42	Methadone dose in opioid dependence;	chr19:28748091	chr19:28435388~28727777:-
TGCT	cis	rs4563143	0.634	rs113736470	ENSG00000267243.4	AC005307.3	-5.15	9.89e-07	0.00112	-0.47	-0.42	Methadone dose in opioid dependence;	chr19:28749218	chr19:28435388~28727777:-
TGCT	cis	rs10875976	0.625	rs7133995	ENSG00000257253.2	RP11-70F11.7	5.15	9.89e-07	0.00112	0.37	0.42	Obesity;	chr12:49859732	chr12:49861207~49865802:+
TGCT	cis	rs9326248	0.954	rs10790177	ENSG00000280143.1	AP000892.6	5.15	9.92e-07	0.00112	0.55	0.42	Blood protein levels;	chr11:117177701	chr11:117204967~117210292:+
TGCT	cis	rs4423214	0.879	rs1792283	ENSG00000254682.1	RP11-660L16.2	-5.15	9.93e-07	0.00112	-0.64	-0.42	Vitamin D levels;	chr11:71424090	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.879	rs1792282	ENSG00000254682.1	RP11-660L16.2	-5.15	9.93e-07	0.00112	-0.64	-0.42	Vitamin D levels;	chr11:71424120	chr11:71448674~71452157:+
TGCT	cis	rs11118620	0.81	rs4587570	ENSG00000272823.1	RP11-295M18.6	5.15	9.95e-07	0.00112	0.4	0.42	Heart failure;	chr1:220860693	chr1:220828676~220829211:-
TGCT	cis	rs2115630	0.846	rs8024538	ENSG00000225151.9	GOLGA2P7	5.15	9.96e-07	0.00113	0.44	0.42	P wave terminal force;	chr15:84825188	chr15:84199311~84230136:-
TGCT	cis	rs7208859	0.614	rs7216394	ENSG00000280069.1	CTD-2349P21.3	5.15	9.97e-07	0.00113	0.54	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30498738	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.614	rs4794874	ENSG00000280069.1	CTD-2349P21.3	5.15	9.97e-07	0.00113	0.54	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30514300	chr17:30738182~30740275:+
TGCT	cis	rs853679	0.55	rs6901017	ENSG00000219392.1	RP1-265C24.5	-5.15	9.97e-07	0.00113	-0.56	-0.42	Depression;	chr6:28184805	chr6:28115628~28116551:+
TGCT	cis	rs1799949	1	rs3092988	ENSG00000198496.9	NBR2	-5.15	1e-06	0.00113	-0.63	-0.42	Menopause (age at onset);	chr17:43049685	chr17:43125610~43153671:+
TGCT	cis	rs9322193	0.924	rs9498382	ENSG00000216906.2	RP11-350J20.9	5.15	1e-06	0.00113	0.48	0.42	Lung cancer;	chr6:149610982	chr6:149904243~149906418:+
TGCT	cis	rs9322193	1	rs9399693	ENSG00000216906.2	RP11-350J20.9	5.15	1e-06	0.00113	0.48	0.42	Lung cancer;	chr6:149612718	chr6:149904243~149906418:+
TGCT	cis	rs17711722	0.51	rs11767457	ENSG00000164669.11	INTS4P1	-5.15	1e-06	0.00113	-0.41	-0.42	Calcium levels;	chr7:65825628	chr7:65141225~65234216:+
TGCT	cis	rs8062405	0.69	rs4787458	ENSG00000259982.1	CDC37P1	5.15	1.01e-06	0.00114	0.58	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28700294~28701540:-
TGCT	cis	rs3091242	0.933	rs7541095	ENSG00000261349.1	RP3-465N24.5	-5.15	1.01e-06	0.00114	-0.41	-0.42	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25266102~25267136:-
TGCT	cis	rs786425	0.77	rs7958693	ENSG00000247373.3	RP11-486O12.2	5.15	1.01e-06	0.00114	0.5	0.42	Pubertal anthropometrics;	chr12:123678203	chr12:123575891~123585115:-
TGCT	cis	rs2709736	0.631	rs2215855	ENSG00000232790.2	LINC01162	5.15	1.01e-06	0.00114	0.33	0.42	Bipolar I disorder;	chr7:20888405	chr7:20835431~21023148:+
TGCT	cis	rs11168854	0.656	rs7969963	ENSG00000258017.1	RP11-386G11.10	-5.15	1.01e-06	0.00114	-0.55	-0.42	Body mass index;	chr12:49118222	chr12:49127782~49147869:+
TGCT	cis	rs11157436	0.846	rs12435431	ENSG00000211813.2	TRAV34	5.15	1.01e-06	0.00114	0.44	0.42	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22230301	chr14:22207522~22208129:+
TGCT	cis	rs4713118	0.621	rs10484403	ENSG00000219392.1	RP1-265C24.5	-5.15	1.01e-06	0.00114	-0.55	-0.42	Parkinson's disease;	chr6:28065745	chr6:28115628~28116551:+
TGCT	cis	rs904251	0.828	rs1757178	ENSG00000279942.1	RP1-153P14.7	5.15	1.01e-06	0.00114	0.47	0.42	Cognitive performance;	chr6:37518534	chr6:37567716~37571460:+
TGCT	cis	rs8059260	0.604	rs71381192	ENSG00000274038.1	RP11-66H6.4	-5.15	1.01e-06	0.00114	-0.56	-0.42	Alcohol consumption over the past year;	chr16:11075528	chr16:11056556~11057034:+
TGCT	cis	rs2333021	0.934	rs12879195	ENSG00000259015.1	RP11-109N23.6	5.15	1.01e-06	0.00114	0.22	0.42	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73006248	chr14:72960595~72961993:+
TGCT	cis	rs10875746	0.951	rs2269935	ENSG00000240399.1	RP1-228P16.1	-5.14	1.02e-06	0.00114	-0.5	-0.42	Longevity (90 years and older);	chr12:48122681	chr12:48054813~48055591:-
TGCT	cis	rs2882667	0.638	rs2351905	ENSG00000253404.1	AC034243.1	5.14	1.02e-06	0.00115	0.5	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135641	chr5:138744434~138753309:-
TGCT	cis	rs4925386	0.681	rs2427295	ENSG00000273619.1	RP5-908M14.9	-5.14	1.02e-06	0.00115	-0.52	-0.42	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352375	chr20:62386303~62386970:-
TGCT	cis	rs4925386	0.681	rs2427296	ENSG00000273619.1	RP5-908M14.9	-5.14	1.02e-06	0.00115	-0.52	-0.42	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352419	chr20:62386303~62386970:-
TGCT	cis	rs3091242	0.806	rs35189848	ENSG00000261349.1	RP3-465N24.5	5.14	1.02e-06	0.00115	0.42	0.42	Erythrocyte sedimentation rate;	chr1:25461931	chr1:25266102~25267136:-
TGCT	cis	rs3091242	0.836	rs35346083	ENSG00000261349.1	RP3-465N24.5	5.14	1.02e-06	0.00115	0.42	0.42	Erythrocyte sedimentation rate;	chr1:25461934	chr1:25266102~25267136:-
TGCT	cis	rs2709736	0.596	rs116973	ENSG00000232790.2	LINC01162	-5.14	1.03e-06	0.00115	-0.33	-0.42	Bipolar I disorder;	chr7:20863923	chr7:20835431~21023148:+
TGCT	cis	rs7221109	0.601	rs2109223	ENSG00000278834.1	RP11-458J1.1	5.14	1.03e-06	0.00115	0.32	0.42	Type 1 diabetes;	chr17:40690602	chr17:40648300~40649718:+
TGCT	cis	rs11168854	0.656	rs7969967	ENSG00000258017.1	RP11-386G11.10	5.14	1.03e-06	0.00115	0.55	0.42	Body mass index;	chr12:49118234	chr12:49127782~49147869:+
TGCT	cis	rs12946454	0.621	rs11651809	ENSG00000267288.2	RP13-890H12.2	-5.14	1.03e-06	0.00115	-0.46	-0.42	Systolic blood pressure;	chr17:45178314	chr17:45168800~45171584:-
TGCT	cis	rs911555	0.755	rs10148970	ENSG00000244691.1	RPL10AP1	-5.14	1.03e-06	0.00115	-0.57	-0.42	Intelligence (multi-trait analysis);	chr14:103425663	chr14:103412119~103412761:-
TGCT	cis	rs2019137	0.56	rs10206269	ENSG00000189223.12	PAX8-AS1	-5.14	1.03e-06	0.00115	-0.56	-0.42	Lymphocyte counts;	chr2:113232816	chr2:113211522~113276581:+
TGCT	cis	rs4927850	0.881	rs7624638	ENSG00000207650.1	MIR570	5.14	1.03e-06	0.00116	0.51	0.42	Pancreatic cancer;	chr3:196021858	chr3:195699401~195699497:+
TGCT	cis	rs4927850	1	rs10881564	ENSG00000207650.1	MIR570	5.14	1.03e-06	0.00116	0.51	0.42	Pancreatic cancer;	chr3:196023455	chr3:195699401~195699497:+
TGCT	cis	rs4925386	0.84	rs6143036	ENSG00000273619.1	RP5-908M14.9	-5.14	1.03e-06	0.00116	-0.53	-0.42	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62346665	chr20:62386303~62386970:-
TGCT	cis	rs7829975	0.511	rs2921028	ENSG00000173295.6	FAM86B3P	5.14	1.03e-06	0.00116	0.48	0.42	Mood instability;	chr8:8482967	chr8:8228595~8244865:+
TGCT	cis	rs11671005	0.735	rs3826684	ENSG00000268912.1	CTD-2619J13.17	-5.14	1.04e-06	0.00116	-0.49	-0.42	Mean platelet volume;	chr19:58407338	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.735	rs3826683	ENSG00000268912.1	CTD-2619J13.17	-5.14	1.04e-06	0.00116	-0.49	-0.42	Mean platelet volume;	chr19:58407366	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.735	rs3826682	ENSG00000268912.1	CTD-2619J13.17	-5.14	1.04e-06	0.00116	-0.49	-0.42	Mean platelet volume;	chr19:58407381	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.735	rs3826681	ENSG00000268912.1	CTD-2619J13.17	-5.14	1.04e-06	0.00116	-0.49	-0.42	Mean platelet volume;	chr19:58407397	chr19:58428632~58431148:-
TGCT	cis	rs5769707	0.642	rs4824070	ENSG00000235111.1	RP1-29C18.8	-5.14	1.04e-06	0.00116	-0.39	-0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49637873	chr22:49612657~49615716:-
TGCT	cis	rs8113308	1	rs8104737	ENSG00000269235.1	ZNF350-AS1	5.14	1.04e-06	0.00116	0.65	0.42	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51938444	chr19:51949134~51981367:+
TGCT	cis	rs8072100	0.777	rs9914653	ENSG00000228782.6	CTD-2026D20.3	5.14	1.04e-06	0.00117	0.51	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47460029	chr17:47450568~47492492:-
TGCT	cis	rs8072100	0.84	rs9912311	ENSG00000228782.6	CTD-2026D20.3	5.14	1.04e-06	0.00117	0.51	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469766	chr17:47450568~47492492:-
TGCT	cis	rs2333021	0.934	rs7155380	ENSG00000259015.1	RP11-109N23.6	5.14	1.05e-06	0.00117	0.23	0.42	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73014626	chr14:72960595~72961993:+
TGCT	cis	rs11118620	1	rs11118620	ENSG00000272823.1	RP11-295M18.6	5.14	1.05e-06	0.00118	0.4	0.42	Heart failure;	chr1:220855166	chr1:220828676~220829211:-
TGCT	cis	rs10504229	0.775	rs17805074	ENSG00000253301.4	RP11-513O17.2	-5.14	1.05e-06	0.00118	-0.55	-0.42	Developmental language disorder (linguistic errors);	chr8:57248489	chr8:57142689~57240298:+
TGCT	cis	rs17711722	0.653	rs2460421	ENSG00000236529.1	RP13-254B10.1	-5.14	1.05e-06	0.00118	-0.31	-0.42	Calcium levels;	chr7:66026136	chr7:65840212~65840596:+
TGCT	cis	rs4835473	0.932	rs5015757	ENSG00000251600.4	RP11-673E1.1	5.14	1.05e-06	0.00118	0.42	0.42	Immature fraction of reticulocytes;	chr4:143738144	chr4:143912331~143982454:+
TGCT	cis	rs7208859	0.673	rs216424	ENSG00000266490.1	CTD-2349P21.9	5.14	1.06e-06	0.00118	0.45	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30792372~30792833:+
TGCT	cis	rs8059260	0.544	rs12925161	ENSG00000274038.1	RP11-66H6.4	-5.14	1.06e-06	0.00118	-0.56	-0.42	Alcohol consumption over the past year;	chr16:11112719	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.604	rs34215426	ENSG00000274038.1	RP11-66H6.4	-5.14	1.06e-06	0.00118	-0.56	-0.42	Alcohol consumption over the past year;	chr16:11113614	chr16:11056556~11057034:+
TGCT	cis	rs9322193	0.851	rs9322194	ENSG00000216906.2	RP11-350J20.9	5.14	1.06e-06	0.00119	0.48	0.42	Lung cancer;	chr6:149599113	chr6:149904243~149906418:+
TGCT	cis	rs9660180	0.935	rs2180311	ENSG00000268575.1	RP1-283E3.8	-5.14	1.06e-06	0.00119	-0.35	-0.42	Body mass index;	chr1:1817295	chr1:1702736~1737688:-
TGCT	cis	rs17301013	0.9	rs56347239	ENSG00000227373.4	RP11-160H22.5	5.14	1.06e-06	0.00119	0.45	0.42	Systemic lupus erythematosus;	chr1:174564476	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.932	rs12074753	ENSG00000227373.4	RP11-160H22.5	5.14	1.06e-06	0.00119	0.45	0.42	Systemic lupus erythematosus;	chr1:174565768	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.896	rs6425287	ENSG00000227373.4	RP11-160H22.5	5.14	1.06e-06	0.00119	0.45	0.42	Systemic lupus erythematosus;	chr1:174566264	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.932	rs1016466	ENSG00000227373.4	RP11-160H22.5	5.14	1.06e-06	0.00119	0.45	0.42	Systemic lupus erythematosus;	chr1:174570652	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.932	rs10753086	ENSG00000227373.4	RP11-160H22.5	5.14	1.06e-06	0.00119	0.45	0.42	Systemic lupus erythematosus;	chr1:174580802	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.541	rs12691474	ENSG00000227373.4	RP11-160H22.5	5.13	1.06e-06	0.00119	0.45	0.42	Life satisfaction;	chr1:174200867	chr1:174115300~174160004:-
TGCT	cis	rs8072100	0.744	rs34537623	ENSG00000228782.6	CTD-2026D20.3	5.13	1.06e-06	0.00119	0.51	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47452837	chr17:47450568~47492492:-
TGCT	cis	rs9322193	0.923	rs12526675	ENSG00000216906.2	RP11-350J20.9	-5.13	1.07e-06	0.00119	-0.48	-0.42	Lung cancer;	chr6:149729540	chr6:149904243~149906418:+
TGCT	cis	rs2976388	0.625	rs2257840	ENSG00000253196.1	RP11-706C16.7	5.13	1.07e-06	0.00119	0.42	0.42	Urinary tract infection frequency;	chr8:142727775	chr8:142763116~142766427:+
TGCT	cis	rs7208859	0.673	rs9907197	ENSG00000266490.1	CTD-2349P21.9	5.13	1.07e-06	0.0012	0.45	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs9915963	ENSG00000266490.1	CTD-2349P21.9	5.13	1.07e-06	0.0012	0.45	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30792372~30792833:+
TGCT	cis	rs1799949	0.965	rs4793237	ENSG00000198496.9	NBR2	-5.13	1.07e-06	0.0012	-0.59	-0.42	Menopause (age at onset);	chr17:43359227	chr17:43125610~43153671:+
TGCT	cis	rs9660180	0.967	rs10907191	ENSG00000268575.1	RP1-283E3.8	-5.13	1.08e-06	0.0012	-0.34	-0.42	Body mass index;	chr1:1843381	chr1:1702736~1737688:-
TGCT	cis	rs7115242	0.858	rs6589592	ENSG00000254851.1	RP11-109L13.1	-5.13	1.08e-06	0.0012	-0.94	-0.42	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117087191	chr11:117135528~117138582:+
TGCT	cis	rs4927850	0.958	rs1975582	ENSG00000231464.1	AC024937.4	5.13	1.08e-06	0.0012	0.41	0.42	Pancreatic cancer;	chr3:196024568	chr3:195996738~195998233:+
TGCT	cis	rs4927850	0.957	rs4927851	ENSG00000231464.1	AC024937.4	5.13	1.08e-06	0.0012	0.41	0.42	Pancreatic cancer;	chr3:196024982	chr3:195996738~195998233:+
TGCT	cis	rs4927850	0.918	rs4361313	ENSG00000231464.1	AC024937.4	5.13	1.08e-06	0.0012	0.41	0.42	Pancreatic cancer;	chr3:196025389	chr3:195996738~195998233:+
TGCT	cis	rs4927850	1	rs7627706	ENSG00000231464.1	AC024937.4	5.13	1.08e-06	0.0012	0.41	0.42	Pancreatic cancer;	chr3:196026482	chr3:195996738~195998233:+
TGCT	cis	rs4927850	0.881	rs7630489	ENSG00000231464.1	AC024937.4	5.13	1.08e-06	0.0012	0.41	0.42	Pancreatic cancer;	chr3:196026530	chr3:195996738~195998233:+
TGCT	cis	rs4927850	1	rs7627868	ENSG00000231464.1	AC024937.4	5.13	1.08e-06	0.0012	0.41	0.42	Pancreatic cancer;	chr3:196026602	chr3:195996738~195998233:+
TGCT	cis	rs853679	0.55	rs1225598	ENSG00000219392.1	RP1-265C24.5	-5.13	1.08e-06	0.0012	-0.56	-0.42	Depression;	chr6:28193021	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.55	rs1150689	ENSG00000219392.1	RP1-265C24.5	-5.13	1.08e-06	0.0012	-0.56	-0.42	Depression;	chr6:28197321	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.55	rs1225599	ENSG00000219392.1	RP1-265C24.5	-5.13	1.08e-06	0.0012	-0.56	-0.42	Depression;	chr6:28197412	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.574	rs1233705	ENSG00000219392.1	RP1-265C24.5	-5.13	1.08e-06	0.0012	-0.56	-0.42	Depression;	chr6:28198669	chr6:28115628~28116551:+
TGCT	cis	rs7795991	1	rs7795991	ENSG00000224330.1	AC005019.3	5.13	1.08e-06	0.00121	0.43	0.42	Type 2 diabetes;	chr7:13861106	chr7:13854355~13859025:-
TGCT	cis	rs453301	0.564	rs28649568	ENSG00000254340.1	RP11-10A14.3	-5.13	1.08e-06	0.00121	-0.44	-0.42	Joint mobility (Beighton score);	chr8:9102161	chr8:9141424~9145435:+
TGCT	cis	rs651907	0.557	rs3094297	ENSG00000244119.1	PDCL3P4	5.13	1.08e-06	0.00121	0.3	0.42	Colorectal cancer;	chr3:101680416	chr3:101712472~101713191:+
TGCT	cis	rs9425766	0.679	rs6681390	ENSG00000227373.4	RP11-160H22.5	5.13	1.09e-06	0.00121	0.44	0.42	Life satisfaction;	chr1:174261331	chr1:174115300~174160004:-
TGCT	cis	rs2745572	1	rs2745572	ENSG00000272279.1	RP11-157J24.2	-5.13	1.09e-06	0.00122	-0.5	-0.42	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1548134	chr6:1528364~1528911:-
TGCT	cis	rs1799949	0.894	rs71367985	ENSG00000198496.9	NBR2	-5.13	1.1e-06	0.00122	-0.6	-0.42	Menopause (age at onset);	chr17:43222443	chr17:43125610~43153671:+
TGCT	cis	rs10829156	0.699	rs10828879	ENSG00000240291.1	RP11-499P20.2	5.13	1.1e-06	0.00122	0.37	0.42	Sudden cardiac arrest;	chr10:18546425	chr10:18513115~18545651:-
TGCT	cis	rs2739330	0.685	rs4822453	ENSG00000272787.1	KB-226F1.2	-5.13	1.1e-06	0.00122	-0.46	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23969211~23969873:+
TGCT	cis	rs972540	1	rs13398243	ENSG00000279220.1	GPR1-AS	5.13	1.1e-06	0.00122	0.43	0.42	Body mass index;	chr2:206389507	chr2:206203376~206266243:+
TGCT	cis	rs972540	0.96	rs13427533	ENSG00000279220.1	GPR1-AS	5.13	1.1e-06	0.00122	0.43	0.42	Body mass index;	chr2:206390808	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs13427551	ENSG00000279220.1	GPR1-AS	5.13	1.1e-06	0.00122	0.43	0.42	Body mass index;	chr2:206390854	chr2:206203376~206266243:+
TGCT	cis	rs786425	0.682	rs7136939	ENSG00000278112.1	RP11-972P1.11	5.13	1.1e-06	0.00122	0.51	0.42	Pubertal anthropometrics;	chr12:123705110	chr12:123519390~123519856:-
TGCT	cis	rs7221109	0.56	rs2429549	ENSG00000278834.1	RP11-458J1.1	-5.13	1.1e-06	0.00122	-0.33	-0.42	Type 1 diabetes;	chr17:40698154	chr17:40648300~40649718:+
TGCT	cis	rs4927850	1	rs7630875	ENSG00000207650.1	MIR570	5.13	1.1e-06	0.00123	0.52	0.42	Pancreatic cancer;	chr3:196026895	chr3:195699401~195699497:+
TGCT	cis	rs7208859	0.614	rs216412	ENSG00000280069.1	CTD-2349P21.3	5.13	1.1e-06	0.00123	0.55	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30738182~30740275:+
TGCT	cis	rs11231017	0.507	rs11231027	ENSG00000254454.2	RCC2P6	-5.13	1.1e-06	0.00123	-0.29	-0.42	HIV-1 viral setpoint;	chr11:62312570	chr11:62371146~62373168:+
TGCT	cis	rs1823913	1	rs12623832	ENSG00000280083.1	RP11-317J9.1	5.13	1.1e-06	0.00123	0.35	0.42	Obesity-related traits;	chr2:191260918	chr2:191154118~191156070:-
TGCT	cis	rs9918079	0.56	rs4557256	ENSG00000273133.1	RP11-799M12.2	-5.13	1.11e-06	0.00123	-0.6	-0.42	Obesity-related traits;	chr4:15625024	chr4:15563698~15564253:-
TGCT	cis	rs1789	0.839	rs9997068	ENSG00000273133.1	RP11-799M12.2	-5.13	1.11e-06	0.00123	-0.6	-0.42	Blood protein levels;	chr4:15649367	chr4:15563698~15564253:-
TGCT	cis	rs9918079	0.56	rs6414767	ENSG00000273133.1	RP11-799M12.2	-5.13	1.11e-06	0.00123	-0.6	-0.42	Obesity-related traits;	chr4:15654098	chr4:15563698~15564253:-
TGCT	cis	rs4563143	0.675	rs56407818	ENSG00000267243.4	AC005307.3	-5.12	1.11e-06	0.00124	-0.52	-0.42	Methadone dose in opioid dependence;	chr19:28788472	chr19:28435388~28727777:-
TGCT	cis	rs4563143	0.675	rs55849754	ENSG00000267243.4	AC005307.3	-5.12	1.11e-06	0.00124	-0.52	-0.42	Methadone dose in opioid dependence;	chr19:28788758	chr19:28435388~28727777:-
TGCT	cis	rs4563143	0.675	rs17498203	ENSG00000267243.4	AC005307.3	-5.12	1.11e-06	0.00124	-0.52	-0.42	Methadone dose in opioid dependence;	chr19:28788827	chr19:28435388~28727777:-
TGCT	cis	rs4563143	0.592	rs12151001	ENSG00000267243.4	AC005307.3	-5.12	1.11e-06	0.00124	-0.52	-0.42	Methadone dose in opioid dependence;	chr19:28792479	chr19:28435388~28727777:-
TGCT	cis	rs4563143	0.502	rs73029061	ENSG00000267243.4	AC005307.3	-5.12	1.11e-06	0.00124	-0.52	-0.42	Methadone dose in opioid dependence;	chr19:28793073	chr19:28435388~28727777:-
TGCT	cis	rs9660180	0.967	rs6664664	ENSG00000268575.1	RP1-283E3.8	-5.12	1.11e-06	0.00124	-0.34	-0.42	Body mass index;	chr1:1819825	chr1:1702736~1737688:-
TGCT	cis	rs2709736	0.631	rs2539956	ENSG00000232790.2	LINC01162	5.12	1.11e-06	0.00124	0.34	0.42	Bipolar I disorder;	chr7:20891368	chr7:20835431~21023148:+
TGCT	cis	rs2882667	0.683	rs13188935	ENSG00000253404.1	AC034243.1	5.12	1.12e-06	0.00124	0.45	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139116536	chr5:138744434~138753309:-
TGCT	cis	rs12891047	0.738	rs72725127	ENSG00000258759.1	RP11-1012A1.7	-5.12	1.12e-06	0.00125	-0.35	-0.42	Amyotrophic lateral sclerosis (sporadic);	chr14:67881580	chr14:67799004~67799609:+
TGCT	cis	rs5769707	0.681	rs6009803	ENSG00000235111.1	RP1-29C18.8	-5.12	1.12e-06	0.00125	-0.39	-0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49657359	chr22:49612657~49615716:-
TGCT	cis	rs7804306	0.826	rs117300282	ENSG00000233264.2	AC006042.8	5.12	1.12e-06	0.00125	0.99	0.42	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7973661	chr7:7980312~7982228:+
TGCT	cis	rs3096299	0.933	rs2965824	ENSG00000274627.1	RP11-104N10.2	5.12	1.12e-06	0.00125	0.43	0.42	Multiple myeloma (IgH translocation);	chr16:89388898	chr16:89516797~89522217:+
TGCT	cis	rs200895692	1	rs200895692	ENSG00000227533.4	SLC2A1-AS1	5.12	1.12e-06	0.00125	0.58	0.42	Monocyte count;	chr1:42956299	chr1:42959049~42983358:+
TGCT	cis	rs2117029	1	rs2293445	ENSG00000258017.1	RP11-386G11.10	-5.12	1.13e-06	0.00126	-0.52	-0.42	Intelligence (multi-trait analysis);	chr12:49005079	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.965	rs2293446	ENSG00000258017.1	RP11-386G11.10	-5.12	1.13e-06	0.00126	-0.52	-0.42	Intelligence (multi-trait analysis);	chr12:49018926	chr12:49127782~49147869:+
TGCT	cis	rs5769707	0.632	rs5770601	ENSG00000235111.1	RP1-29C18.8	-5.12	1.13e-06	0.00126	-0.39	-0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49628255	chr22:49612657~49615716:-
TGCT	cis	rs17301013	0.861	rs2038025	ENSG00000227373.4	RP11-160H22.5	5.12	1.13e-06	0.00126	0.46	0.42	Systemic lupus erythematosus;	chr1:174574712	chr1:174115300~174160004:-
TGCT	cis	rs7927592	0.763	rs10791982	ENSG00000212093.1	AP000807.1	-5.12	1.13e-06	0.00126	-0.4	-0.42	Total body bone mineral density;	chr11:68570196	chr11:68506083~68506166:-
TGCT	cis	rs11155671	0.53	rs6557133	ENSG00000216906.2	RP11-350J20.9	5.12	1.13e-06	0.00126	0.48	0.42	Testicular germ cell tumor;	chr6:149874248	chr6:149904243~149906418:+
TGCT	cis	rs2948294	0.566	rs13274039	ENSG00000254340.1	RP11-10A14.3	5.12	1.14e-06	0.00126	0.45	0.42	Red cell distribution width;	chr8:8254137	chr8:9141424~9145435:+
TGCT	cis	rs67311347	0.868	rs10865895	ENSG00000223797.4	ENTPD3-AS1	5.12	1.14e-06	0.00126	0.44	0.42	Renal cell carcinoma;	chr3:40337186	chr3:40313802~40453329:-
TGCT	cis	rs1799949	1	rs3092994	ENSG00000198496.9	NBR2	-5.12	1.14e-06	0.00126	-0.63	-0.42	Menopause (age at onset);	chr17:43063808	chr17:43125610~43153671:+
TGCT	cis	rs1799955	0.554	rs11571662	ENSG00000215515.2	IFIT1P1	-5.12	1.14e-06	0.00126	-0.52	-0.42	LDL cholesterol levels;	chr13:32341387	chr13:32384660~32386108:+
TGCT	cis	rs2276314	1	rs9304153	ENSG00000278986.1	RP11-723J4.3	-5.12	1.14e-06	0.00126	-0.47	-0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:35982187	chr18:35972151~35973916:+
TGCT	cis	rs2276314	1	rs9304154	ENSG00000278986.1	RP11-723J4.3	-5.12	1.14e-06	0.00126	-0.47	-0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:35982264	chr18:35972151~35973916:+
TGCT	cis	rs10256972	0.553	rs4236381	ENSG00000226291.1	AC091729.8	-5.12	1.14e-06	0.00126	-0.45	-0.42	Endometriosis;Longevity;	chr7:1126087	chr7:1080863~1082178:+
TGCT	cis	rs10256972	0.591	rs6950319	ENSG00000226291.1	AC091729.8	-5.12	1.14e-06	0.00126	-0.44	-0.42	Endometriosis;Longevity;	chr7:1121688	chr7:1080863~1082178:+
TGCT	cis	rs2709736	0.545	rs2539957	ENSG00000232790.2	LINC01162	5.12	1.14e-06	0.00126	0.33	0.42	Bipolar I disorder;	chr7:20879788	chr7:20835431~21023148:+
TGCT	cis	rs1799949	1	rs8176273	ENSG00000198496.9	NBR2	-5.12	1.14e-06	0.00126	-0.63	-0.42	Menopause (age at onset);	chr17:43059636	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs8176269	ENSG00000198496.9	NBR2	-5.12	1.14e-06	0.00126	-0.63	-0.42	Menopause (age at onset);	chr17:43061609	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs8176265	ENSG00000198496.9	NBR2	-5.12	1.14e-06	0.00126	-0.63	-0.42	Menopause (age at onset);	chr17:43061979	chr17:43125610~43153671:+
TGCT	cis	rs380904	0.963	rs410822	ENSG00000254859.1	RP11-661A12.5	-5.12	1.14e-06	0.00126	-0.61	-0.42	Venous thromboembolism (SNP x SNP interaction);	chr8:143492441	chr8:143541973~143549729:-
TGCT	cis	rs10256972	0.527	rs28671326	ENSG00000226291.1	AC091729.8	-5.12	1.14e-06	0.00127	-0.45	-0.42	Endometriosis;Longevity;	chr7:1135337	chr7:1080863~1082178:+
TGCT	cis	rs2015599	0.525	rs10743656	ENSG00000257176.2	RP11-996F15.2	5.12	1.14e-06	0.00127	0.44	0.42	Platelet count;Mean platelet volume;	chr12:29332516	chr12:29280418~29317848:-
TGCT	cis	rs7829975	0.572	rs28730413	ENSG00000173295.6	FAM86B3P	-5.12	1.15e-06	0.00127	-0.48	-0.42	Mood instability;	chr8:8937937	chr8:8228595~8244865:+
TGCT	cis	rs911555	0.574	rs34251103	ENSG00000244691.1	RPL10AP1	5.12	1.15e-06	0.00127	0.56	0.42	Intelligence (multi-trait analysis);	chr14:103393726	chr14:103412119~103412761:-
TGCT	cis	rs911555	0.723	rs6575982	ENSG00000244691.1	RPL10AP1	5.12	1.15e-06	0.00127	0.56	0.42	Intelligence (multi-trait analysis);	chr14:103396344	chr14:103412119~103412761:-
TGCT	cis	rs651907	0.557	rs35850993	ENSG00000244119.1	PDCL3P4	5.12	1.15e-06	0.00127	0.3	0.42	Colorectal cancer;	chr3:101718589	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.557	rs62284198	ENSG00000244119.1	PDCL3P4	5.12	1.15e-06	0.00127	0.3	0.42	Colorectal cancer;	chr3:101755855	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.557	rs2318090	ENSG00000244119.1	PDCL3P4	5.12	1.15e-06	0.00127	0.3	0.42	Colorectal cancer;	chr3:101756089	chr3:101712472~101713191:+
TGCT	cis	rs9660180	0.836	rs72634845	ENSG00000268575.1	RP1-283E3.8	-5.12	1.15e-06	0.00127	-0.33	-0.42	Body mass index;	chr1:1773460	chr1:1702736~1737688:-
TGCT	cis	rs9660180	0.868	rs72634846	ENSG00000268575.1	RP1-283E3.8	-5.12	1.15e-06	0.00127	-0.33	-0.42	Body mass index;	chr1:1773476	chr1:1702736~1737688:-
TGCT	cis	rs9660180	0.839	rs12040826	ENSG00000268575.1	RP1-283E3.8	-5.12	1.15e-06	0.00127	-0.33	-0.42	Body mass index;	chr1:1773848	chr1:1702736~1737688:-
TGCT	cis	rs9660180	0.967	rs12044597	ENSG00000268575.1	RP1-283E3.8	-5.12	1.15e-06	0.00127	-0.33	-0.42	Body mass index;	chr1:1777362	chr1:1702736~1737688:-
TGCT	cis	rs10504229	0.775	rs55734109	ENSG00000253301.4	RP11-513O17.2	5.12	1.15e-06	0.00127	0.57	0.42	Developmental language disorder (linguistic errors);	chr8:57249763	chr8:57142689~57240298:+
TGCT	cis	rs4660456	0.913	rs556875	ENSG00000237899.1	RP4-739H11.3	-5.12	1.15e-06	0.00127	-0.55	-0.42	Platelet count;	chr1:40688571	chr1:40669089~40687588:-
TGCT	cis	rs1061377	1	rs3796509	ENSG00000249207.1	RP11-360F5.1	-5.12	1.15e-06	0.00127	-0.44	-0.42	Uric acid levels;	chr4:39108566	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs4974998	ENSG00000249207.1	RP11-360F5.1	-5.12	1.15e-06	0.00127	-0.44	-0.42	Uric acid levels;	chr4:39109129	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs7673299	ENSG00000249207.1	RP11-360F5.1	-5.12	1.15e-06	0.00127	-0.44	-0.42	Uric acid levels;	chr4:39109138	chr4:39112677~39126818:-
TGCT	cis	rs1061377	1	rs4974997	ENSG00000249207.1	RP11-360F5.1	-5.12	1.15e-06	0.00127	-0.44	-0.42	Uric acid levels;	chr4:39109151	chr4:39112677~39126818:-
TGCT	cis	rs899997	0.954	rs11856441	ENSG00000261143.1	ADAMTS7P3	5.12	1.16e-06	0.00128	0.48	0.42	Coronary artery disease or large artery stroke;	chr15:78738184	chr15:77976042~77993057:+
TGCT	cis	rs9326248	0.53	rs10750101	ENSG00000254851.1	RP11-109L13.1	-5.12	1.16e-06	0.00128	-0.8	-0.42	Blood protein levels;	chr11:117108973	chr11:117135528~117138582:+
TGCT	cis	rs11168618	0.703	rs4760721	ENSG00000240399.1	RP1-228P16.1	5.11	1.16e-06	0.00128	0.4	0.42	Adiponectin levels;	chr12:48531941	chr12:48054813~48055591:-
TGCT	cis	rs11168618	0.74	rs4760723	ENSG00000240399.1	RP1-228P16.1	5.11	1.16e-06	0.00128	0.4	0.42	Adiponectin levels;	chr12:48532079	chr12:48054813~48055591:-
TGCT	cis	rs11168618	0.765	rs7301368	ENSG00000240399.1	RP1-228P16.1	5.11	1.16e-06	0.00128	0.4	0.42	Adiponectin levels;	chr12:48533009	chr12:48054813~48055591:-
TGCT	cis	rs786425	0.538	rs786452	ENSG00000278112.1	RP11-972P1.11	-5.11	1.16e-06	0.00128	-0.48	-0.42	Pubertal anthropometrics;	chr12:123572622	chr12:123519390~123519856:-
TGCT	cis	rs2019137	0.56	rs11123172	ENSG00000274877.1	RP11-65I12.1	5.11	1.16e-06	0.00128	0.41	0.42	Lymphocyte counts;	chr2:113226726	chr2:113237595~113240825:+
TGCT	cis	rs4713118	0.539	rs200988	ENSG00000216901.1	AL022393.7	5.11	1.16e-06	0.00129	0.55	0.42	Parkinson's disease;	chr6:27851575	chr6:28176188~28176674:+
TGCT	cis	rs34217772	0.68	rs72686527	ENSG00000258536.1	RP11-1053O12.1	5.11	1.17e-06	0.00129	0.35	0.42	Myopia;	chr14:41721651	chr14:41742639~41742963:+
TGCT	cis	rs7617773	1	rs6771889	ENSG00000229759.1	MRPS18AP1	-5.11	1.17e-06	0.00129	-0.33	-0.42	Coronary artery disease;	chr3:48152836	chr3:48256350~48256938:-
TGCT	cis	rs1823913	1	rs4853568	ENSG00000280083.1	RP11-317J9.1	5.11	1.17e-06	0.00129	0.36	0.42	Obesity-related traits;	chr2:191261464	chr2:191154118~191156070:-
TGCT	cis	rs651907	0.554	rs10470501	ENSG00000244119.1	PDCL3P4	5.11	1.17e-06	0.00129	0.31	0.42	Colorectal cancer;	chr3:101911653	chr3:101712472~101713191:+
TGCT	cis	rs9918079	0.56	rs10008975	ENSG00000273133.1	RP11-799M12.2	-5.11	1.17e-06	0.00129	-0.6	-0.42	Obesity-related traits;	chr4:15622948	chr4:15563698~15564253:-
TGCT	cis	rs9918079	0.56	rs4698402	ENSG00000273133.1	RP11-799M12.2	-5.11	1.17e-06	0.00129	-0.6	-0.42	Obesity-related traits;	chr4:15628180	chr4:15563698~15564253:-
TGCT	cis	rs9918079	0.56	rs7662032	ENSG00000273133.1	RP11-799M12.2	-5.11	1.17e-06	0.00129	-0.6	-0.42	Obesity-related traits;	chr4:15633791	chr4:15563698~15564253:-
TGCT	cis	rs9918079	0.56	rs12651550	ENSG00000273133.1	RP11-799M12.2	-5.11	1.17e-06	0.00129	-0.6	-0.42	Obesity-related traits;	chr4:15639395	chr4:15563698~15564253:-
TGCT	cis	rs9918079	0.506	rs7696127	ENSG00000273133.1	RP11-799M12.2	-5.11	1.17e-06	0.00129	-0.6	-0.42	Obesity-related traits;	chr4:15641330	chr4:15563698~15564253:-
TGCT	cis	rs11723261	0.621	rs7692530	ENSG00000275426.1	CH17-262A2.1	5.11	1.17e-06	0.00129	0.76	0.42	Immune response to smallpox vaccine (IL-6);	chr4:123563	chr4:149738~150317:+
TGCT	cis	rs10256972	0.591	rs10229680	ENSG00000226291.1	AC091729.8	-5.11	1.17e-06	0.00129	-0.44	-0.42	Endometriosis;Longevity;	chr7:1118929	chr7:1080863~1082178:+
TGCT	cis	rs10256972	0.567	rs7782651	ENSG00000226291.1	AC091729.8	-5.11	1.17e-06	0.00129	-0.44	-0.42	Endometriosis;Longevity;	chr7:1120259	chr7:1080863~1082178:+
TGCT	cis	rs7849270	0.959	rs3118628	ENSG00000268707.1	RP11-247A12.7	5.11	1.18e-06	0.0013	0.48	0.42	Blood metabolite ratios;	chr9:129123000	chr9:129170434~129170940:+
TGCT	cis	rs7849270	0.959	rs9408986	ENSG00000268707.1	RP11-247A12.7	5.11	1.18e-06	0.0013	0.48	0.42	Blood metabolite ratios;	chr9:129126156	chr9:129170434~129170940:+
TGCT	cis	rs9322193	0.923	rs35830138	ENSG00000216906.2	RP11-350J20.9	5.11	1.18e-06	0.0013	0.47	0.42	Lung cancer;	chr6:149668635	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.884	rs62439836	ENSG00000216906.2	RP11-350J20.9	5.11	1.18e-06	0.0013	0.47	0.42	Lung cancer;	chr6:149669173	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs4869812	ENSG00000216906.2	RP11-350J20.9	5.11	1.18e-06	0.0013	0.47	0.42	Lung cancer;	chr6:149669447	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs66516768	ENSG00000216906.2	RP11-350J20.9	5.11	1.18e-06	0.0013	0.47	0.42	Lung cancer;	chr6:149671999	chr6:149904243~149906418:+
TGCT	cis	rs2948294	0.588	rs4840913	ENSG00000254340.1	RP11-10A14.3	5.11	1.18e-06	0.0013	0.43	0.42	Red cell distribution width;	chr8:8259384	chr8:9141424~9145435:+
TGCT	cis	rs2976388	0.609	rs2717605	ENSG00000253196.1	RP11-706C16.7	5.11	1.18e-06	0.0013	0.42	0.42	Urinary tract infection frequency;	chr8:142719597	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.609	rs2572907	ENSG00000253196.1	RP11-706C16.7	5.11	1.18e-06	0.0013	0.42	0.42	Urinary tract infection frequency;	chr8:142720520	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.609	rs2572908	ENSG00000253196.1	RP11-706C16.7	5.11	1.18e-06	0.0013	0.42	0.42	Urinary tract infection frequency;	chr8:142721218	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.609	rs2717602	ENSG00000253196.1	RP11-706C16.7	5.11	1.18e-06	0.0013	0.42	0.42	Urinary tract infection frequency;	chr8:142724265	chr8:142763116~142766427:+
TGCT	cis	rs2283792	0.715	rs55891647	ENSG00000228050.1	TOP3BP1	5.11	1.18e-06	0.0013	0.49	0.42	Multiple sclerosis;	chr22:21824198	chr22:22223187~22224566:-
TGCT	cis	rs67311347	0.955	rs11711994	ENSG00000223797.4	ENTPD3-AS1	5.11	1.18e-06	0.0013	0.44	0.42	Renal cell carcinoma;	chr3:40349595	chr3:40313802~40453329:-
TGCT	cis	rs34779708	0.931	rs4934700	ENSG00000230534.5	RP11-297A16.2	5.11	1.18e-06	0.0013	0.49	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35021914	chr10:35098006~35127020:-
TGCT	cis	rs524281	0.692	rs2254388	ENSG00000255320.1	RP11-755F10.1	-5.11	1.18e-06	0.0013	-0.49	-0.42	Electroencephalogram traits;	chr11:66070128	chr11:66244840~66246239:-
TGCT	cis	rs8062405	0.755	rs7193402	ENSG00000259982.1	CDC37P1	5.11	1.18e-06	0.0013	0.57	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28700294~28701540:-
TGCT	cis	rs1799949	0.965	rs8176323	ENSG00000198496.9	NBR2	-5.11	1.18e-06	0.0013	-0.63	-0.42	Menopause (age at onset);	chr17:43043694	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.965	rs8176322	ENSG00000198496.9	NBR2	-5.11	1.18e-06	0.0013	-0.63	-0.42	Menopause (age at onset);	chr17:43043756	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs12516	ENSG00000198496.9	NBR2	-5.11	1.18e-06	0.0013	-0.63	-0.42	Menopause (age at onset);	chr17:43044391	chr17:43125610~43153671:+
TGCT	cis	rs2880765	0.546	rs11639291	ENSG00000259295.5	CSPG4P12	5.11	1.18e-06	0.0013	0.53	0.42	Coronary artery disease;	chr15:85520899	chr15:85191438~85213905:+
TGCT	cis	rs2880765	0.546	rs35316253	ENSG00000259295.5	CSPG4P12	5.11	1.18e-06	0.0013	0.53	0.42	Coronary artery disease;	chr15:85522329	chr15:85191438~85213905:+
TGCT	cis	rs66887589	0.616	rs11732621	ENSG00000245958.5	RP11-33B1.1	-5.11	1.18e-06	0.0013	-0.4	-0.42	Diastolic blood pressure;	chr4:119291728	chr4:119454791~119552025:+
TGCT	cis	rs7829975	0.593	rs2921061	ENSG00000173295.6	FAM86B3P	5.11	1.18e-06	0.0013	0.49	0.42	Mood instability;	chr8:8460105	chr8:8228595~8244865:+
TGCT	cis	rs9322193	0.962	rs4870048	ENSG00000216906.2	RP11-350J20.9	5.11	1.18e-06	0.0013	0.47	0.42	Lung cancer;	chr6:149834324	chr6:149904243~149906418:+
TGCT	cis	rs2882667	0.518	rs10041986	ENSG00000253404.1	AC034243.1	5.11	1.18e-06	0.0013	0.48	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139088748	chr5:138744434~138753309:-
TGCT	cis	rs12891047	1	rs2235962	ENSG00000258759.1	RP11-1012A1.7	-5.11	1.19e-06	0.00131	-0.36	-0.42	Amyotrophic lateral sclerosis (sporadic);	chr14:67781564	chr14:67799004~67799609:+
TGCT	cis	rs8059260	0.736	rs7200623	ENSG00000274038.1	RP11-66H6.4	-5.11	1.19e-06	0.00131	-0.58	-0.42	Alcohol consumption over the past year;	chr16:11001188	chr16:11056556~11057034:+
TGCT	cis	rs9660180	0.967	rs61422524	ENSG00000268575.1	RP1-283E3.8	-5.11	1.19e-06	0.00131	-0.34	-0.42	Body mass index;	chr1:1836126	chr1:1702736~1737688:-
TGCT	cis	rs34217772	0.883	rs72668818	ENSG00000258536.1	RP11-1053O12.1	5.11	1.19e-06	0.00131	0.39	0.42	Myopia;	chr14:41761485	chr14:41742639~41742963:+
TGCT	cis	rs10829156	0.66	rs10828901	ENSG00000240291.1	RP11-499P20.2	5.11	1.19e-06	0.00131	0.36	0.42	Sudden cardiac arrest;	chr10:18552161	chr10:18513115~18545651:-
TGCT	cis	rs2276314	0.857	rs4799844	ENSG00000278986.1	RP11-723J4.3	-5.11	1.2e-06	0.00132	-0.49	-0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:36065181	chr18:35972151~35973916:+
TGCT	cis	rs899997	1	rs1814880	ENSG00000261143.1	ADAMTS7P3	5.11	1.2e-06	0.00132	0.47	0.42	Coronary artery disease or large artery stroke;	chr15:78728798	chr15:77976042~77993057:+
TGCT	cis	rs9326248	0.954	rs8521	ENSG00000280143.1	AP000892.6	5.11	1.2e-06	0.00132	0.55	0.42	Blood protein levels;	chr11:117196983	chr11:117204967~117210292:+
TGCT	cis	rs1799949	0.965	rs9646418	ENSG00000198496.9	NBR2	-5.11	1.2e-06	0.00132	-0.58	-0.42	Menopause (age at onset);	chr17:43348533	chr17:43125610~43153671:+
TGCT	cis	rs801193	0.613	rs2016325	ENSG00000226824.5	RP4-756H11.3	5.11	1.2e-06	0.00132	0.46	0.42	Aortic root size;	chr7:66858513	chr7:66654538~66669855:+
TGCT	cis	rs1618992	0.729	rs7229151	ENSG00000265994.1	RP11-510D21.1	-5.11	1.2e-06	0.00132	-0.42	-0.42	Gut microbiome composition (summer and winter);	chr18:28603958	chr18:28785068~28789260:+
TGCT	cis	rs9660180	0.78	rs12038111	ENSG00000268575.1	RP1-283E3.8	-5.11	1.2e-06	0.00132	-0.33	-0.42	Body mass index;	chr1:1772410	chr1:1702736~1737688:-
TGCT	cis	rs9660180	0.836	rs12038134	ENSG00000268575.1	RP1-283E3.8	-5.11	1.2e-06	0.00132	-0.33	-0.42	Body mass index;	chr1:1772426	chr1:1702736~1737688:-
TGCT	cis	rs972540	1	rs6757124	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206366510	chr2:206203376~206266243:+
TGCT	cis	rs972540	0.883	rs62195882	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206366803	chr2:206203376~206266243:+
TGCT	cis	rs972540	0.921	rs6757701	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206366818	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs7355776	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206367385	chr2:206203376~206266243:+
TGCT	cis	rs972540	0.846	rs7355777	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206367469	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs13396393	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206370968	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs13422132	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206371013	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs113426863	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206372073	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs972540	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206380059	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs972539	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206380103	chr2:206203376~206266243:+
TGCT	cis	rs972540	0.96	rs62195891	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206381845	chr2:206203376~206266243:+
TGCT	cis	rs972540	0.96	rs7355410	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206382705	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs2122121	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206383108	chr2:206203376~206266243:+
TGCT	cis	rs972540	0.96	rs7423990	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206383510	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs7424013	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206383643	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs7424014	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206383659	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs62195892	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206384061	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs62195893	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206384176	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs62195894	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206384191	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs12052703	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206385879	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs12053062	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206385896	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs12052727	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206386305	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs12052372	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206386517	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs62195895	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206387073	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs62195896	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206387216	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs12052545	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206387911	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs62195930	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206388588	chr2:206203376~206266243:+
TGCT	cis	rs972540	0.921	rs6715034	ENSG00000279220.1	GPR1-AS	5.11	1.2e-06	0.00132	0.43	0.42	Body mass index;	chr2:206366445	chr2:206203376~206266243:+
TGCT	cis	rs950169	0.96	rs35159785	ENSG00000225151.9	GOLGA2P7	-5.11	1.2e-06	0.00132	-0.47	-0.42	Schizophrenia;	chr15:84135262	chr15:84199311~84230136:-
TGCT	cis	rs66486766	1	rs66486766	ENSG00000225151.9	GOLGA2P7	-5.11	1.2e-06	0.00132	-0.47	-0.42	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84199311~84230136:-
TGCT	cis	rs5769707	0.904	rs7288869	ENSG00000235111.1	RP1-29C18.8	-5.11	1.2e-06	0.00132	-0.34	-0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49621679	chr22:49612657~49615716:-
TGCT	cis	rs34779708	0.931	rs35848945	ENSG00000230534.5	RP11-297A16.2	5.11	1.2e-06	0.00132	0.49	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:34998633	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs11597392	ENSG00000230534.5	RP11-297A16.2	5.11	1.2e-06	0.00132	0.49	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:34999647	chr10:35098006~35127020:-
TGCT	cis	rs1707322	0.656	rs9429172	ENSG00000280836.1	AL355480.1	5.11	1.21e-06	0.00132	0.58	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45581219~45581321:-
TGCT	cis	rs34779708	0.897	rs4934529	ENSG00000230534.5	RP11-297A16.2	5.11	1.21e-06	0.00132	0.49	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35013448	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.897	rs12830	ENSG00000230534.5	RP11-297A16.2	5.11	1.21e-06	0.00132	0.49	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35013777	chr10:35098006~35127020:-
TGCT	cis	rs10504229	0.554	rs17802082	ENSG00000253301.4	RP11-513O17.2	5.11	1.21e-06	0.00133	0.67	0.42	Developmental language disorder (linguistic errors);	chr8:57183308	chr8:57142689~57240298:+
TGCT	cis	rs17301013	0.932	rs7542389	ENSG00000227373.4	RP11-160H22.5	5.1	1.21e-06	0.00133	0.45	0.42	Systemic lupus erythematosus;	chr1:174565104	chr1:174115300~174160004:-
TGCT	cis	rs9326248	0.574	rs1263173	ENSG00000254851.1	RP11-109L13.1	-5.1	1.21e-06	0.00133	-0.53	-0.42	Blood protein levels;	chr11:116810292	chr11:117135528~117138582:+
TGCT	cis	rs1823913	1	rs4853562	ENSG00000227542.1	AC092614.2	-5.1	1.21e-06	0.00133	-0.44	-0.42	Obesity-related traits;	chr2:191253696	chr2:191229165~191246172:-
TGCT	cis	rs1823913	1	rs4853461	ENSG00000227542.1	AC092614.2	-5.1	1.21e-06	0.00133	-0.44	-0.42	Obesity-related traits;	chr2:191254572	chr2:191229165~191246172:-
TGCT	cis	rs1823913	1	rs4853563	ENSG00000227542.1	AC092614.2	-5.1	1.21e-06	0.00133	-0.44	-0.42	Obesity-related traits;	chr2:191254808	chr2:191229165~191246172:-
TGCT	cis	rs10829156	0.699	rs7911922	ENSG00000240291.1	RP11-499P20.2	5.1	1.21e-06	0.00133	0.36	0.42	Sudden cardiac arrest;	chr10:18542768	chr10:18513115~18545651:-
TGCT	cis	rs9660180	0.967	rs12040325	ENSG00000268575.1	RP1-283E3.8	-5.1	1.21e-06	0.00133	-0.33	-0.42	Body mass index;	chr1:1770997	chr1:1702736~1737688:-
TGCT	cis	rs2276314	0.857	rs8097597	ENSG00000278986.1	RP11-723J4.3	-5.1	1.21e-06	0.00133	-0.45	-0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:36039485	chr18:35972151~35973916:+
TGCT	cis	rs12439619	0.508	rs11856561	ENSG00000278603.1	RP13-608F4.5	5.1	1.22e-06	0.00133	0.54	0.42	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472203~82472426:+
TGCT	cis	rs673078	0.607	rs61943391	ENSG00000275759.1	RP11-131L12.3	-5.1	1.22e-06	0.00133	-0.76	-0.42	Glucose homeostasis traits;	chr12:118382603	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs61943392	ENSG00000275759.1	RP11-131L12.3	-5.1	1.22e-06	0.00133	-0.76	-0.42	Glucose homeostasis traits;	chr12:118382618	chr12:118428281~118428870:+
TGCT	cis	rs9322193	0.923	rs2342765	ENSG00000216906.2	RP11-350J20.9	5.1	1.22e-06	0.00133	0.45	0.42	Lung cancer;	chr6:149858873	chr6:149904243~149906418:+
TGCT	cis	rs4423214	0.879	rs1790345	ENSG00000254682.1	RP11-660L16.2	-5.1	1.22e-06	0.00133	-0.63	-0.42	Vitamin D levels;	chr11:71434895	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.879	rs1790330	ENSG00000254682.1	RP11-660L16.2	-5.1	1.22e-06	0.00133	-0.63	-0.42	Vitamin D levels;	chr11:71436779	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.84	rs1790328	ENSG00000254682.1	RP11-660L16.2	-5.1	1.22e-06	0.00133	-0.63	-0.42	Vitamin D levels;	chr11:71436992	chr11:71448674~71452157:+
TGCT	cis	rs7246967	0.866	rs111292710	ENSG00000269509.1	BNIP3P34	5.1	1.22e-06	0.00134	0.72	0.42	Bronchopulmonary dysplasia;	chr19:22884678	chr19:22773853~22774424:+
TGCT	cis	rs10829156	0.699	rs6482516	ENSG00000240291.1	RP11-499P20.2	5.1	1.22e-06	0.00134	0.36	0.42	Sudden cardiac arrest;	chr10:18550421	chr10:18513115~18545651:-
TGCT	cis	rs10829156	0.66	rs11014830	ENSG00000240291.1	RP11-499P20.2	5.1	1.22e-06	0.00134	0.36	0.42	Sudden cardiac arrest;	chr10:18551504	chr10:18513115~18545651:-
TGCT	cis	rs7927592	0.701	rs12226585	ENSG00000212093.1	AP000807.1	-5.1	1.22e-06	0.00134	-0.39	-0.42	Total body bone mineral density;	chr11:68490393	chr11:68506083~68506166:-
TGCT	cis	rs7849270	0.959	rs4836641	ENSG00000268707.1	RP11-247A12.7	5.1	1.22e-06	0.00134	0.48	0.42	Blood metabolite ratios;	chr9:129149953	chr9:129170434~129170940:+
TGCT	cis	rs35160687	0.871	rs2278105	ENSG00000273080.1	RP11-301O19.1	5.1	1.22e-06	0.00134	0.48	0.42	Night sleep phenotypes;	chr2:86239393	chr2:86195590~86196049:+
TGCT	cis	rs7714584	1	rs11167526	ENSG00000197083.10	ZNF300P1	5.1	1.23e-06	0.00134	1.08	0.42	Crohn's disease;	chr5:150952919	chr5:150930645~150946289:-
TGCT	cis	rs2948294	0.566	rs13261997	ENSG00000254340.1	RP11-10A14.3	5.1	1.23e-06	0.00135	0.45	0.42	Red cell distribution width;	chr8:8254773	chr8:9141424~9145435:+
TGCT	cis	rs2976388	0.647	rs2585136	ENSG00000253196.1	RP11-706C16.7	5.1	1.23e-06	0.00135	0.42	0.42	Urinary tract infection frequency;	chr8:142730723	chr8:142763116~142766427:+
TGCT	cis	rs2919917	0.688	rs6993386	ENSG00000254352.1	RP11-578O24.2	-5.1	1.23e-06	0.00135	-0.46	-0.42	Lymphocyte counts;	chr8:78741910	chr8:78723796~78724136:-
TGCT	cis	rs17301013	0.861	rs10912824	ENSG00000227373.4	RP11-160H22.5	5.1	1.24e-06	0.00135	0.45	0.42	Systemic lupus erythematosus;	chr1:174625846	chr1:174115300~174160004:-
TGCT	cis	rs1707322	0.682	rs12037459	ENSG00000280836.1	AL355480.1	-5.1	1.24e-06	0.00135	-0.59	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45581219~45581321:-
TGCT	cis	rs2117029	0.555	rs9788140	ENSG00000258017.1	RP11-386G11.10	-5.1	1.24e-06	0.00135	-0.55	-0.42	Intelligence (multi-trait analysis);	chr12:49126738	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.555	rs9788139	ENSG00000258017.1	RP11-386G11.10	-5.1	1.24e-06	0.00135	-0.55	-0.42	Intelligence (multi-trait analysis);	chr12:49126886	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.619	rs2241727	ENSG00000258017.1	RP11-386G11.10	-5.1	1.24e-06	0.00135	-0.55	-0.42	Intelligence (multi-trait analysis);	chr12:49131225	chr12:49127782~49147869:+
TGCT	cis	rs34779708	0.931	rs7079205	ENSG00000230534.5	RP11-297A16.2	5.1	1.24e-06	0.00136	0.5	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35035691	chr10:35098006~35127020:-
TGCT	cis	rs911555	0.692	rs7145753	ENSG00000244691.1	RPL10AP1	5.1	1.24e-06	0.00136	0.56	0.42	Intelligence (multi-trait analysis);	chr14:103399763	chr14:103412119~103412761:-
TGCT	cis	rs11157436	0.958	rs6572313	ENSG00000211813.2	TRAV34	5.1	1.25e-06	0.00136	0.44	0.42	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22214070	chr14:22207522~22208129:+
TGCT	cis	rs1799949	1	rs4793190	ENSG00000198496.9	NBR2	-5.1	1.25e-06	0.00136	-0.63	-0.42	Menopause (age at onset);	chr17:43048092	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs8176297	ENSG00000198496.9	NBR2	-5.1	1.25e-06	0.00136	-0.63	-0.42	Menopause (age at onset);	chr17:43051308	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs8176296	ENSG00000198496.9	NBR2	-5.1	1.25e-06	0.00136	-0.63	-0.42	Menopause (age at onset);	chr17:43051574	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs4793191	ENSG00000198496.9	NBR2	-5.1	1.25e-06	0.00136	-0.63	-0.42	Menopause (age at onset);	chr17:43052360	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs4793192	ENSG00000198496.9	NBR2	-5.1	1.25e-06	0.00136	-0.63	-0.42	Menopause (age at onset);	chr17:43052373	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs8176289	ENSG00000198496.9	NBR2	-5.1	1.25e-06	0.00136	-0.63	-0.42	Menopause (age at onset);	chr17:43054039	chr17:43125610~43153671:+
TGCT	cis	rs1061377	1	rs4974931	ENSG00000249207.1	RP11-360F5.1	-5.1	1.25e-06	0.00136	-0.44	-0.42	Uric acid levels;	chr4:39108896	chr4:39112677~39126818:-
TGCT	cis	rs710913	0.618	rs11206437	ENSG00000182109.6	RP11-69E11.4	5.1	1.25e-06	0.00136	0.44	0.42	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39613039	chr1:39522280~39546187:-
TGCT	cis	rs12935418	0.83	rs12928638	ENSG00000261061.1	RP11-303E16.2	-5.1	1.25e-06	0.00137	-0.57	-0.42	Mean corpuscular volume;	chr16:81016195	chr16:81030770~81031485:+
TGCT	cis	rs3091242	0.933	rs11802413	ENSG00000224183.1	SDHDP6	5.1	1.25e-06	0.00137	0.44	0.42	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25294164~25294643:-
TGCT	cis	rs1799949	1	rs2070834	ENSG00000198496.9	NBR2	-5.1	1.25e-06	0.00137	-0.6	-0.42	Menopause (age at onset);	chr17:43090268	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs16942	ENSG00000198496.9	NBR2	-5.1	1.25e-06	0.00137	-0.6	-0.42	Menopause (age at onset);	chr17:43091983	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs8176145	ENSG00000198496.9	NBR2	-5.1	1.25e-06	0.00137	-0.6	-0.42	Menopause (age at onset);	chr17:43097077	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.965	rs8176140	ENSG00000198496.9	NBR2	-5.1	1.25e-06	0.00137	-0.6	-0.42	Menopause (age at onset);	chr17:43099629	chr17:43125610~43153671:+
TGCT	cis	rs7301826	1	rs10773819	ENSG00000256299.1	RP11-989F5.3	-5.1	1.25e-06	0.00137	-0.45	-0.42	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810821~130812622:-
TGCT	cis	rs10504229	0.728	rs59266065	ENSG00000253301.4	RP11-513O17.2	5.1	1.25e-06	0.00137	0.59	0.42	Developmental language disorder (linguistic errors);	chr8:57243677	chr8:57142689~57240298:+
TGCT	cis	rs1933112	0.545	rs10429892	ENSG00000227777.1	RP4-738P11.3	-5.1	1.26e-06	0.00137	-0.44	-0.42	Blood protein levels;	chr1:168532215	chr1:168542737~168543354:+
TGCT	cis	rs9462027	0.606	rs412392	ENSG00000186328.4	RP11-140K17.2	5.1	1.26e-06	0.00137	0.39	0.42	Systemic lupus erythematosus;	chr6:34581922	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.606	rs1201874	ENSG00000186328.4	RP11-140K17.2	5.1	1.26e-06	0.00137	0.39	0.42	Systemic lupus erythematosus;	chr6:34582033	chr6:34715613~34715940:+
TGCT	cis	rs2288073	0.965	rs36101491	ENSG00000223754.1	AC008073.9	5.1	1.26e-06	0.00137	0.55	0.42	Venous thromboembolism (SNP x SNP interaction);	chr2:24164663	chr2:24199839~24201698:-
TGCT	cis	rs853679	0.76	rs9393910	ENSG00000216901.1	AL022393.7	5.1	1.26e-06	0.00137	0.62	0.42	Depression;	chr6:28240414	chr6:28176188~28176674:+
TGCT	cis	rs853679	0.76	rs9368563	ENSG00000216901.1	AL022393.7	5.1	1.26e-06	0.00137	0.62	0.42	Depression;	chr6:28240780	chr6:28176188~28176674:+
TGCT	cis	rs853679	0.76	rs9295768	ENSG00000216901.1	AL022393.7	5.1	1.26e-06	0.00137	0.62	0.42	Depression;	chr6:28241324	chr6:28176188~28176674:+
TGCT	cis	rs853679	0.699	rs9468318	ENSG00000216901.1	AL022393.7	5.1	1.26e-06	0.00137	0.62	0.42	Depression;	chr6:28241753	chr6:28176188~28176674:+
TGCT	cis	rs853679	0.76	rs9357067	ENSG00000216901.1	AL022393.7	5.1	1.26e-06	0.00137	0.62	0.42	Depression;	chr6:28242515	chr6:28176188~28176674:+
TGCT	cis	rs853679	0.76	rs967005	ENSG00000216901.1	AL022393.7	5.1	1.26e-06	0.00137	0.62	0.42	Depression;	chr6:28242910	chr6:28176188~28176674:+
TGCT	cis	rs786425	0.707	rs34996665	ENSG00000278112.1	RP11-972P1.11	5.1	1.26e-06	0.00138	0.48	0.42	Pubertal anthropometrics;	chr12:123650109	chr12:123519390~123519856:-
TGCT	cis	rs5769707	0.681	rs2319346	ENSG00000235111.1	RP1-29C18.8	-5.09	1.27e-06	0.00138	-0.38	-0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49635992	chr22:49612657~49615716:-
TGCT	cis	rs1933112	0.565	rs76400946	ENSG00000227777.1	RP4-738P11.3	-5.09	1.27e-06	0.00138	-0.46	-0.42	Blood protein levels;	chr1:168541917	chr1:168542737~168543354:+
TGCT	cis	rs6921919	0.945	rs16901847	ENSG00000216901.1	AL022393.7	5.09	1.27e-06	0.00138	0.54	0.42	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28176188~28176674:+
TGCT	cis	rs4835473	0.897	rs1553070	ENSG00000251600.4	RP11-673E1.1	5.09	1.27e-06	0.00138	0.42	0.42	Immature fraction of reticulocytes;	chr4:143715981	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs7678190	ENSG00000251600.4	RP11-673E1.1	5.09	1.27e-06	0.00138	0.42	0.42	Immature fraction of reticulocytes;	chr4:143722421	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs12505617	ENSG00000251600.4	RP11-673E1.1	5.09	1.27e-06	0.00138	0.42	0.42	Immature fraction of reticulocytes;	chr4:143723522	chr4:143912331~143982454:+
TGCT	cis	rs673078	0.607	rs17440942	ENSG00000275759.1	RP11-131L12.3	5.09	1.27e-06	0.00138	0.76	0.42	Glucose homeostasis traits;	chr12:118394030	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs7968011	ENSG00000275759.1	RP11-131L12.3	-5.09	1.27e-06	0.00138	-0.76	-0.42	Glucose homeostasis traits;	chr12:118382001	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs2055534	ENSG00000275759.1	RP11-131L12.3	-5.09	1.27e-06	0.00138	-0.76	-0.42	Glucose homeostasis traits;	chr12:118386527	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs56157623	ENSG00000275759.1	RP11-131L12.3	-5.09	1.27e-06	0.00138	-0.76	-0.42	Glucose homeostasis traits;	chr12:118388162	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs4767669	ENSG00000275759.1	RP11-131L12.3	-5.09	1.27e-06	0.00138	-0.76	-0.42	Glucose homeostasis traits;	chr12:118390651	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs4767670	ENSG00000275759.1	RP11-131L12.3	-5.09	1.27e-06	0.00138	-0.76	-0.42	Glucose homeostasis traits;	chr12:118390737	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs950288	ENSG00000275759.1	RP11-131L12.3	-5.09	1.27e-06	0.00138	-0.76	-0.42	Glucose homeostasis traits;	chr12:118392201	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs61943399	ENSG00000275759.1	RP11-131L12.3	-5.09	1.27e-06	0.00138	-0.76	-0.42	Glucose homeostasis traits;	chr12:118393628	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs7137055	ENSG00000275759.1	RP11-131L12.3	-5.09	1.27e-06	0.00138	-0.76	-0.42	Glucose homeostasis traits;	chr12:118395030	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs7137184	ENSG00000275759.1	RP11-131L12.3	-5.09	1.27e-06	0.00138	-0.76	-0.42	Glucose homeostasis traits;	chr12:118395163	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.562	rs4767672	ENSG00000275759.1	RP11-131L12.3	-5.09	1.27e-06	0.00138	-0.76	-0.42	Glucose homeostasis traits;	chr12:118397048	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs73205594	ENSG00000275759.1	RP11-131L12.3	-5.09	1.27e-06	0.00138	-0.76	-0.42	Glucose homeostasis traits;	chr12:118397168	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs61943400	ENSG00000275759.1	RP11-131L12.3	-5.09	1.27e-06	0.00138	-0.76	-0.42	Glucose homeostasis traits;	chr12:118398236	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs61943401	ENSG00000275759.1	RP11-131L12.3	-5.09	1.27e-06	0.00138	-0.76	-0.42	Glucose homeostasis traits;	chr12:118398527	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs61943402	ENSG00000275759.1	RP11-131L12.3	-5.09	1.27e-06	0.00138	-0.76	-0.42	Glucose homeostasis traits;	chr12:118398808	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs7309484	ENSG00000275759.1	RP11-131L12.3	-5.09	1.27e-06	0.00138	-0.76	-0.42	Glucose homeostasis traits;	chr12:118400833	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs17512763	ENSG00000275759.1	RP11-131L12.3	-5.09	1.27e-06	0.00138	-0.76	-0.42	Glucose homeostasis traits;	chr12:118400974	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs61943404	ENSG00000275759.1	RP11-131L12.3	-5.09	1.27e-06	0.00138	-0.76	-0.42	Glucose homeostasis traits;	chr12:118402062	chr12:118428281~118428870:+
TGCT	cis	rs8072100	0.745	rs7214410	ENSG00000228782.6	CTD-2026D20.3	5.09	1.27e-06	0.00138	0.5	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47345262	chr17:47450568~47492492:-
TGCT	cis	rs8062405	0.69	rs7187604	ENSG00000259982.1	CDC37P1	5.09	1.27e-06	0.00139	0.57	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28700294~28701540:-
TGCT	cis	rs2015599	0.525	rs10771514	ENSG00000257176.2	RP11-996F15.2	5.09	1.27e-06	0.00139	0.43	0.42	Platelet count;Mean platelet volume;	chr12:29315751	chr12:29280418~29317848:-
TGCT	cis	rs2015599	0.525	rs7298031	ENSG00000257176.2	RP11-996F15.2	5.09	1.27e-06	0.00139	0.43	0.42	Platelet count;Mean platelet volume;	chr12:29317333	chr12:29280418~29317848:-
TGCT	cis	rs2015599	0.525	rs2016832	ENSG00000257176.2	RP11-996F15.2	5.09	1.27e-06	0.00139	0.43	0.42	Platelet count;Mean platelet volume;	chr12:29318199	chr12:29280418~29317848:-
TGCT	cis	rs507080	0.771	rs687664	ENSG00000255422.1	AP002954.4	-5.09	1.28e-06	0.00139	-0.5	-0.42	Serum metabolite levels;	chr11:118703476	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.771	rs523715	ENSG00000255422.1	AP002954.4	-5.09	1.28e-06	0.00139	-0.5	-0.42	Serum metabolite levels;	chr11:118703479	chr11:118704607~118750263:+
TGCT	cis	rs853679	0.76	rs9393909	ENSG00000216901.1	AL022393.7	-5.09	1.28e-06	0.00139	-0.65	-0.42	Depression;	chr6:28239422	chr6:28176188~28176674:+
TGCT	cis	rs7829975	0.511	rs2976902	ENSG00000173295.6	FAM86B3P	5.09	1.28e-06	0.00139	0.47	0.42	Mood instability;	chr8:8483595	chr8:8228595~8244865:+
TGCT	cis	rs7829975	0.511	rs2976906	ENSG00000173295.6	FAM86B3P	5.09	1.28e-06	0.00139	0.47	0.42	Mood instability;	chr8:8484905	chr8:8228595~8244865:+
TGCT	cis	rs2412819	0.571	rs56226333	ENSG00000205771.5	CATSPER2P1	-5.09	1.28e-06	0.00139	-0.62	-0.42	Lung cancer;	chr15:43632410	chr15:43726918~43747094:-
TGCT	cis	rs6061231	0.834	rs2427311	ENSG00000273619.1	RP5-908M14.9	-5.09	1.29e-06	0.0014	-0.45	-0.42	Colorectal cancer;	chr20:62395067	chr20:62386303~62386970:-
TGCT	cis	rs9326248	0.569	rs4938315	ENSG00000254851.1	RP11-109L13.1	-5.09	1.29e-06	0.0014	-0.75	-0.42	Blood protein levels;	chr11:116860489	chr11:117135528~117138582:+
TGCT	cis	rs6921919	1	rs6922111	ENSG00000216901.1	AL022393.7	5.09	1.29e-06	0.0014	0.51	0.42	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28176188~28176674:+
TGCT	cis	rs1061377	1	rs7664078	ENSG00000249685.1	RP11-360F5.3	5.09	1.29e-06	0.00141	0.38	0.42	Uric acid levels;	chr4:39116583	chr4:39133913~39135608:+
TGCT	cis	rs17301013	0.861	rs61826916	ENSG00000227373.4	RP11-160H22.5	5.09	1.29e-06	0.00141	0.45	0.42	Systemic lupus erythematosus;	chr1:174616048	chr1:174115300~174160004:-
TGCT	cis	rs367615	0.512	rs246104	ENSG00000249476.1	CTD-2587M2.1	-5.09	1.3e-06	0.00141	-0.44	-0.42	Colorectal cancer (SNP x SNP interaction);	chr5:109365281	chr5:109237120~109326369:-
TGCT	cis	rs5742933	0.857	rs10931430	ENSG00000273240.1	RP11-455J20.3	5.09	1.3e-06	0.00141	0.39	0.42	Ferritin levels;	chr2:189677460	chr2:189763859~189764456:-
TGCT	cis	rs5742933	0.817	rs11679767	ENSG00000273240.1	RP11-455J20.3	5.09	1.3e-06	0.00141	0.39	0.42	Ferritin levels;	chr2:189681574	chr2:189763859~189764456:-
TGCT	cis	rs9322193	0.884	rs10872648	ENSG00000216906.2	RP11-350J20.9	5.09	1.3e-06	0.00141	0.47	0.42	Lung cancer;	chr6:149758699	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.884	rs11155679	ENSG00000216906.2	RP11-350J20.9	5.09	1.3e-06	0.00141	0.47	0.42	Lung cancer;	chr6:149758881	chr6:149904243~149906418:+
TGCT	cis	rs7795991	0.935	rs35282797	ENSG00000224330.1	AC005019.3	-5.09	1.3e-06	0.00142	-0.44	-0.42	Type 2 diabetes;	chr7:13861490	chr7:13854355~13859025:-
TGCT	cis	rs7795991	0.935	rs35636989	ENSG00000224330.1	AC005019.3	-5.09	1.3e-06	0.00142	-0.44	-0.42	Type 2 diabetes;	chr7:13861492	chr7:13854355~13859025:-
TGCT	cis	rs7795991	0.967	rs34116975	ENSG00000224330.1	AC005019.3	-5.09	1.3e-06	0.00142	-0.44	-0.42	Type 2 diabetes;	chr7:13861494	chr7:13854355~13859025:-
TGCT	cis	rs7927592	0.731	rs488381	ENSG00000212093.1	AP000807.1	-5.09	1.3e-06	0.00142	-0.4	-0.42	Total body bone mineral density;	chr11:68524225	chr11:68506083~68506166:-
TGCT	cis	rs4925386	1	rs4925386	ENSG00000273619.1	RP5-908M14.9	-5.09	1.31e-06	0.00142	-0.45	-0.42	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345988	chr20:62386303~62386970:-
TGCT	cis	rs35160687	0.901	rs12622200	ENSG00000273080.1	RP11-301O19.1	-5.09	1.31e-06	0.00142	-0.47	-0.42	Night sleep phenotypes;	chr2:86271472	chr2:86195590~86196049:+
TGCT	cis	rs35160687	0.901	rs13017338	ENSG00000273080.1	RP11-301O19.1	5.09	1.31e-06	0.00142	0.47	0.42	Night sleep phenotypes;	chr2:86274430	chr2:86195590~86196049:+
TGCT	cis	rs35160687	0.901	rs12999029	ENSG00000273080.1	RP11-301O19.1	5.09	1.31e-06	0.00142	0.47	0.42	Night sleep phenotypes;	chr2:86275790	chr2:86195590~86196049:+
TGCT	cis	rs1799949	1	rs2298862	ENSG00000198496.9	NBR2	-5.09	1.31e-06	0.00142	-0.62	-0.42	Menopause (age at onset);	chr17:43024671	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.93	rs2298861	ENSG00000198496.9	NBR2	-5.09	1.31e-06	0.00142	-0.62	-0.42	Menopause (age at onset);	chr17:43024814	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs915945	ENSG00000198496.9	NBR2	-5.09	1.31e-06	0.00142	-0.62	-0.42	Menopause (age at onset);	chr17:43027847	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs12944458	ENSG00000198496.9	NBR2	-5.09	1.31e-06	0.00142	-0.62	-0.42	Menopause (age at onset);	chr17:43028755	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs36036395	ENSG00000198496.9	NBR2	-5.09	1.31e-06	0.00142	-0.62	-0.42	Menopause (age at onset);	chr17:43029280	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs72829113	ENSG00000198496.9	NBR2	-5.09	1.31e-06	0.00142	-0.62	-0.42	Menopause (age at onset);	chr17:43029818	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs11653253	ENSG00000198496.9	NBR2	-5.09	1.31e-06	0.00142	-0.62	-0.42	Menopause (age at onset);	chr17:43030645	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs12951869	ENSG00000198496.9	NBR2	-5.09	1.31e-06	0.00142	-0.62	-0.42	Menopause (age at onset);	chr17:43035550	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs12944597	ENSG00000198496.9	NBR2	-5.09	1.31e-06	0.00142	-0.62	-0.42	Menopause (age at onset);	chr17:43035667	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs12942277	ENSG00000198496.9	NBR2	-5.09	1.31e-06	0.00142	-0.62	-0.42	Menopause (age at onset);	chr17:43035957	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.965	rs34616041	ENSG00000198496.9	NBR2	-5.09	1.31e-06	0.00142	-0.62	-0.42	Menopause (age at onset);	chr17:43036769	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs11654452	ENSG00000198496.9	NBR2	-5.09	1.31e-06	0.00142	-0.62	-0.42	Menopause (age at onset);	chr17:43037366	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs4793189	ENSG00000198496.9	NBR2	-5.09	1.31e-06	0.00142	-0.62	-0.42	Menopause (age at onset);	chr17:43038698	chr17:43125610~43153671:+
TGCT	cis	rs1799949	1	rs11657053	ENSG00000198496.9	NBR2	-5.09	1.31e-06	0.00142	-0.62	-0.42	Menopause (age at onset);	chr17:43039112	chr17:43125610~43153671:+
TGCT	cis	rs4925386	0.84	rs6143035	ENSG00000273619.1	RP5-908M14.9	5.09	1.31e-06	0.00142	0.52	0.42	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345644	chr20:62386303~62386970:-
TGCT	cis	rs17301013	0.932	rs7555533	ENSG00000227373.4	RP11-160H22.5	5.09	1.31e-06	0.00142	0.44	0.42	Systemic lupus erythematosus;	chr1:174589983	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.932	rs6671824	ENSG00000227373.4	RP11-160H22.5	5.09	1.31e-06	0.00142	0.44	0.42	Systemic lupus erythematosus;	chr1:174603721	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.861	rs6672148	ENSG00000227373.4	RP11-160H22.5	5.09	1.31e-06	0.00142	0.44	0.42	Systemic lupus erythematosus;	chr1:174604016	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.932	rs10912813	ENSG00000227373.4	RP11-160H22.5	5.09	1.31e-06	0.00142	0.44	0.42	Systemic lupus erythematosus;	chr1:174607342	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.932	rs67967476	ENSG00000227373.4	RP11-160H22.5	5.09	1.31e-06	0.00142	0.44	0.42	Systemic lupus erythematosus;	chr1:174616119	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.932	rs6683602	ENSG00000227373.4	RP11-160H22.5	5.09	1.31e-06	0.00142	0.44	0.42	Systemic lupus erythematosus;	chr1:174617615	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.932	rs6696197	ENSG00000227373.4	RP11-160H22.5	5.09	1.31e-06	0.00142	0.44	0.42	Systemic lupus erythematosus;	chr1:174617860	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.896	rs6425292	ENSG00000227373.4	RP11-160H22.5	5.09	1.31e-06	0.00142	0.44	0.42	Systemic lupus erythematosus;	chr1:174618364	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.73	rs12060177	ENSG00000227373.4	RP11-160H22.5	5.09	1.31e-06	0.00142	0.44	0.42	Systemic lupus erythematosus;	chr1:174618545	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.932	rs6664864	ENSG00000227373.4	RP11-160H22.5	5.09	1.31e-06	0.00142	0.44	0.42	Systemic lupus erythematosus;	chr1:174622912	chr1:174115300~174160004:-
TGCT	cis	rs9326248	0.53	rs1351452	ENSG00000254851.1	RP11-109L13.1	5.09	1.31e-06	0.00142	0.78	0.42	Blood protein levels;	chr11:117072638	chr11:117135528~117138582:+
TGCT	cis	rs12891047	0.738	rs12431490	ENSG00000258759.1	RP11-1012A1.7	-5.09	1.31e-06	0.00142	-0.35	-0.42	Amyotrophic lateral sclerosis (sporadic);	chr14:67882029	chr14:67799004~67799609:+
TGCT	cis	rs8062405	0.755	rs62034358	ENSG00000259982.1	CDC37P1	5.09	1.31e-06	0.00142	0.57	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.755	rs12445823	ENSG00000259982.1	CDC37P1	5.09	1.31e-06	0.00142	0.57	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.723	rs12445744	ENSG00000259982.1	CDC37P1	5.09	1.31e-06	0.00142	0.57	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.755	rs4787455	ENSG00000259982.1	CDC37P1	5.09	1.31e-06	0.00142	0.57	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.755	rs4788074	ENSG00000259982.1	CDC37P1	-5.09	1.31e-06	0.00142	-0.57	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28700294~28701540:-
TGCT	cis	rs7208859	0.673	rs57432042	ENSG00000263531.1	RP13-753N3.1	5.09	1.31e-06	0.00142	0.75	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30914020	chr17:30863921~30864940:-
TGCT	cis	rs3091242	0.933	rs926438	ENSG00000224183.1	SDHDP6	-5.09	1.32e-06	0.00142	-0.44	-0.42	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25294164~25294643:-
TGCT	cis	rs7221109	0.71	rs1048572	ENSG00000278834.1	RP11-458J1.1	-5.09	1.32e-06	0.00143	-0.29	-0.42	Type 1 diabetes;	chr17:40640990	chr17:40648300~40649718:+
TGCT	cis	rs11231017	0.507	rs11231025	ENSG00000254454.2	RCC2P6	-5.09	1.32e-06	0.00143	-0.29	-0.42	HIV-1 viral setpoint;	chr11:62305833	chr11:62371146~62373168:+
TGCT	cis	rs12821008	1	rs12821008	ENSG00000258017.1	RP11-386G11.10	-5.09	1.32e-06	0.00143	-0.52	-0.42	Bone mineral density;	chr12:49080822	chr12:49127782~49147869:+
TGCT	cis	rs786425	0.77	rs7313032	ENSG00000247373.3	RP11-486O12.2	5.08	1.33e-06	0.00144	0.5	0.42	Pubertal anthropometrics;	chr12:123688184	chr12:123575891~123585115:-
TGCT	cis	rs2919917	0.688	rs3780003	ENSG00000254352.1	RP11-578O24.2	5.08	1.33e-06	0.00144	0.45	0.42	Lymphocyte counts;	chr8:78696019	chr8:78723796~78724136:-
TGCT	cis	rs1075265	0.584	rs1833497	ENSG00000233266.1	HMGB1P31	5.08	1.33e-06	0.00144	0.46	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54052186	chr2:54051334~54051760:+
TGCT	cis	rs1075265	0.584	rs7558126	ENSG00000233266.1	HMGB1P31	5.08	1.33e-06	0.00144	0.46	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54053847	chr2:54051334~54051760:+
TGCT	cis	rs1075265	0.584	rs1862122	ENSG00000233266.1	HMGB1P31	-5.08	1.33e-06	0.00144	-0.46	-0.42	Chronotype;Morning vs. evening chronotype;	chr2:54052992	chr2:54051334~54051760:+
TGCT	cis	rs9399135	0.773	rs949895	ENSG00000232876.1	CTA-212D2.2	-5.08	1.33e-06	0.00144	-0.36	-0.42	Red blood cell count;	chr6:135084221	chr6:135055033~135060550:+
TGCT	cis	rs2412819	0.571	rs2930529	ENSG00000205771.5	CATSPER2P1	5.08	1.33e-06	0.00144	0.61	0.42	Lung cancer;	chr15:43819467	chr15:43726918~43747094:-
TGCT	cis	rs2412819	0.571	rs2930530	ENSG00000205771.5	CATSPER2P1	5.08	1.33e-06	0.00144	0.61	0.42	Lung cancer;	chr15:43823268	chr15:43726918~43747094:-
TGCT	cis	rs2880765	0.566	rs55899824	ENSG00000259295.5	CSPG4P12	5.08	1.33e-06	0.00144	0.53	0.42	Coronary artery disease;	chr15:85460860	chr15:85191438~85213905:+
TGCT	cis	rs2880765	0.631	rs55767890	ENSG00000259295.5	CSPG4P12	5.08	1.33e-06	0.00144	0.53	0.42	Coronary artery disease;	chr15:85460911	chr15:85191438~85213905:+
TGCT	cis	rs651907	0.557	rs59596156	ENSG00000244119.1	PDCL3P4	5.08	1.34e-06	0.00145	0.3	0.42	Colorectal cancer;	chr3:101675373	chr3:101712472~101713191:+
TGCT	cis	rs11168618	0.74	rs11168617	ENSG00000240399.1	RP1-228P16.1	5.08	1.34e-06	0.00145	0.4	0.42	Adiponectin levels;	chr12:48534925	chr12:48054813~48055591:-
TGCT	cis	rs11168618	0.703	rs11495272	ENSG00000240399.1	RP1-228P16.1	5.08	1.34e-06	0.00145	0.4	0.42	Adiponectin levels;	chr12:48535043	chr12:48054813~48055591:-
TGCT	cis	rs11168618	0.74	rs11495433	ENSG00000240399.1	RP1-228P16.1	5.08	1.34e-06	0.00145	0.4	0.42	Adiponectin levels;	chr12:48535289	chr12:48054813~48055591:-
TGCT	cis	rs11168618	0.74	rs4523733	ENSG00000240399.1	RP1-228P16.1	-5.08	1.34e-06	0.00145	-0.4	-0.42	Adiponectin levels;	chr12:48533731	chr12:48054813~48055591:-
TGCT	cis	rs6921919	0.945	rs7765989	ENSG00000216901.1	AL022393.7	5.08	1.35e-06	0.00145	0.54	0.42	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28176188~28176674:+
TGCT	cis	rs6921919	0.887	rs16894116	ENSG00000216901.1	AL022393.7	5.08	1.35e-06	0.00145	0.54	0.42	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28176188~28176674:+
TGCT	cis	rs34779708	0.931	rs17582416	ENSG00000230534.5	RP11-297A16.2	5.08	1.35e-06	0.00146	0.49	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:34998722	chr10:35098006~35127020:-
TGCT	cis	rs6921919	1	rs6921919	ENSG00000216901.1	AL022393.7	5.08	1.35e-06	0.00146	0.52	0.42	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28176188~28176674:+
TGCT	cis	rs2742234	0.59	rs2435337	ENSG00000273008.1	RP11-351D16.3	-5.08	1.35e-06	0.00146	-0.55	-0.42	Hirschsprung disease;	chr10:43166388	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.59	rs2505557	ENSG00000273008.1	RP11-351D16.3	-5.08	1.35e-06	0.00146	-0.55	-0.42	Hirschsprung disease;	chr10:43170568	chr10:43136824~43138334:-
TGCT	cis	rs2276314	0.857	rs28791905	ENSG00000278986.1	RP11-723J4.3	-5.08	1.35e-06	0.00146	-0.47	-0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:36022250	chr18:35972151~35973916:+
TGCT	cis	rs1061377	1	rs10030904	ENSG00000249685.1	RP11-360F5.3	5.08	1.35e-06	0.00146	0.38	0.42	Uric acid levels;	chr4:39113603	chr4:39133913~39135608:+
TGCT	cis	rs904251	0.523	rs2776874	ENSG00000279942.1	RP1-153P14.7	-5.08	1.35e-06	0.00146	-0.39	-0.42	Cognitive performance;	chr6:37515421	chr6:37567716~37571460:+
TGCT	cis	rs10504229	0.728	rs72650852	ENSG00000253301.4	RP11-513O17.2	5.08	1.35e-06	0.00146	0.58	0.42	Developmental language disorder (linguistic errors);	chr8:57237904	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.728	rs77197419	ENSG00000253301.4	RP11-513O17.2	5.08	1.35e-06	0.00146	0.58	0.42	Developmental language disorder (linguistic errors);	chr8:57238320	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.728	rs72650853	ENSG00000253301.4	RP11-513O17.2	5.08	1.35e-06	0.00146	0.58	0.42	Developmental language disorder (linguistic errors);	chr8:57238914	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.728	rs17804365	ENSG00000253301.4	RP11-513O17.2	5.08	1.35e-06	0.00146	0.58	0.42	Developmental language disorder (linguistic errors);	chr8:57238978	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.769	rs17804383	ENSG00000253301.4	RP11-513O17.2	5.08	1.35e-06	0.00146	0.58	0.42	Developmental language disorder (linguistic errors);	chr8:57239271	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.728	rs72650855	ENSG00000253301.4	RP11-513O17.2	5.08	1.35e-06	0.00146	0.58	0.42	Developmental language disorder (linguistic errors);	chr8:57240011	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.728	rs72650856	ENSG00000253301.4	RP11-513O17.2	5.08	1.35e-06	0.00146	0.58	0.42	Developmental language disorder (linguistic errors);	chr8:57240136	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.728	rs17215621	ENSG00000253301.4	RP11-513O17.2	5.08	1.35e-06	0.00146	0.58	0.42	Developmental language disorder (linguistic errors);	chr8:57240147	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.769	rs17215649	ENSG00000253301.4	RP11-513O17.2	5.08	1.35e-06	0.00146	0.58	0.42	Developmental language disorder (linguistic errors);	chr8:57240232	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.728	rs72650858	ENSG00000253301.4	RP11-513O17.2	5.08	1.35e-06	0.00146	0.58	0.42	Developmental language disorder (linguistic errors);	chr8:57240273	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.728	rs17215676	ENSG00000253301.4	RP11-513O17.2	5.08	1.35e-06	0.00146	0.58	0.42	Developmental language disorder (linguistic errors);	chr8:57240356	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.728	rs72650860	ENSG00000253301.4	RP11-513O17.2	5.08	1.35e-06	0.00146	0.58	0.42	Developmental language disorder (linguistic errors);	chr8:57240552	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.728	rs72650861	ENSG00000253301.4	RP11-513O17.2	5.08	1.35e-06	0.00146	0.58	0.42	Developmental language disorder (linguistic errors);	chr8:57240714	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.728	rs17215753	ENSG00000253301.4	RP11-513O17.2	5.08	1.35e-06	0.00146	0.58	0.42	Developmental language disorder (linguistic errors);	chr8:57241205	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.728	rs17215851	ENSG00000253301.4	RP11-513O17.2	5.08	1.35e-06	0.00146	0.58	0.42	Developmental language disorder (linguistic errors);	chr8:57241601	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.728	rs17804624	ENSG00000253301.4	RP11-513O17.2	5.08	1.35e-06	0.00146	0.58	0.42	Developmental language disorder (linguistic errors);	chr8:57241657	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.728	rs78765835	ENSG00000253301.4	RP11-513O17.2	5.08	1.35e-06	0.00146	0.58	0.42	Developmental language disorder (linguistic errors);	chr8:57241778	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.728	rs17804666	ENSG00000253301.4	RP11-513O17.2	5.08	1.35e-06	0.00146	0.58	0.42	Developmental language disorder (linguistic errors);	chr8:57241914	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.728	rs17804720	ENSG00000253301.4	RP11-513O17.2	5.08	1.35e-06	0.00146	0.58	0.42	Developmental language disorder (linguistic errors);	chr8:57242006	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.728	rs72650867	ENSG00000253301.4	RP11-513O17.2	5.08	1.35e-06	0.00146	0.58	0.42	Developmental language disorder (linguistic errors);	chr8:57242353	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.728	rs1495867	ENSG00000253301.4	RP11-513O17.2	5.08	1.35e-06	0.00146	0.58	0.42	Developmental language disorder (linguistic errors);	chr8:57242941	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.728	rs72650868	ENSG00000253301.4	RP11-513O17.2	5.08	1.35e-06	0.00146	0.58	0.42	Developmental language disorder (linguistic errors);	chr8:57243009	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.728	rs17804750	ENSG00000253301.4	RP11-513O17.2	5.08	1.35e-06	0.00146	0.58	0.42	Developmental language disorder (linguistic errors);	chr8:57243192	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.728	rs17804774	ENSG00000253301.4	RP11-513O17.2	5.08	1.35e-06	0.00146	0.58	0.42	Developmental language disorder (linguistic errors);	chr8:57243391	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.728	rs17804335	ENSG00000253301.4	RP11-513O17.2	-5.08	1.35e-06	0.00146	-0.58	-0.42	Developmental language disorder (linguistic errors);	chr8:57238869	chr8:57142689~57240298:+
TGCT	cis	rs7617773	0.746	rs4371540	ENSG00000229759.1	MRPS18AP1	5.08	1.35e-06	0.00146	0.36	0.42	Coronary artery disease;	chr3:48312053	chr3:48256350~48256938:-
TGCT	cis	rs2742234	0.541	rs10793422	ENSG00000273008.1	RP11-351D16.3	5.08	1.36e-06	0.00146	0.58	0.41	Hirschsprung disease;	chr10:43208426	chr10:43136824~43138334:-
TGCT	cis	rs4835473	0.868	rs11737787	ENSG00000251600.4	RP11-673E1.1	-5.08	1.36e-06	0.00146	-0.41	-0.41	Immature fraction of reticulocytes;	chr4:143826498	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs10857413	ENSG00000251600.4	RP11-673E1.1	5.08	1.36e-06	0.00146	0.41	0.41	Immature fraction of reticulocytes;	chr4:143827752	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs6828935	ENSG00000251600.4	RP11-673E1.1	5.08	1.36e-06	0.00146	0.41	0.41	Immature fraction of reticulocytes;	chr4:143829113	chr4:143912331~143982454:+
TGCT	cis	rs11231017	0.507	rs1009052	ENSG00000254454.2	RCC2P6	-5.08	1.36e-06	0.00146	-0.3	-0.41	HIV-1 viral setpoint;	chr11:62299679	chr11:62371146~62373168:+
TGCT	cis	rs4835473	0.932	rs4835279	ENSG00000251600.4	RP11-673E1.1	-5.08	1.36e-06	0.00146	-0.4	-0.41	Immature fraction of reticulocytes;	chr4:143788917	chr4:143912331~143982454:+
TGCT	cis	rs2276314	0.857	rs28435069	ENSG00000278986.1	RP11-723J4.3	-5.08	1.36e-06	0.00146	-0.47	-0.41	Endometriosis;Drug-induced torsades de pointes;	chr18:36048512	chr18:35972151~35973916:+
TGCT	cis	rs2276314	0.857	rs8087539	ENSG00000278986.1	RP11-723J4.3	-5.08	1.36e-06	0.00146	-0.47	-0.41	Endometriosis;Drug-induced torsades de pointes;	chr18:36051574	chr18:35972151~35973916:+
TGCT	cis	rs7829975	0.564	rs2921057	ENSG00000173295.6	FAM86B3P	5.08	1.36e-06	0.00147	0.49	0.41	Mood instability;	chr8:8461157	chr8:8228595~8244865:+
TGCT	cis	rs1757171	0.534	rs2797793	ENSG00000279942.1	RP1-153P14.7	5.08	1.36e-06	0.00147	0.42	0.41	Cognitive performance;	chr6:37509486	chr6:37567716~37571460:+
TGCT	cis	rs2882667	0.537	rs7701338	ENSG00000253404.1	AC034243.1	5.08	1.37e-06	0.00148	0.46	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070305	chr5:138744434~138753309:-
TGCT	cis	rs11168618	0.74	rs7307588	ENSG00000240399.1	RP1-228P16.1	5.08	1.37e-06	0.00148	0.4	0.41	Adiponectin levels;	chr12:48529449	chr12:48054813~48055591:-
TGCT	cis	rs367615	0.552	rs7720036	ENSG00000249476.1	CTD-2587M2.1	-5.08	1.37e-06	0.00148	-0.43	-0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109374998	chr5:109237120~109326369:-
TGCT	cis	rs1061377	1	rs9999327	ENSG00000249685.1	RP11-360F5.3	5.08	1.37e-06	0.00148	0.38	0.41	Uric acid levels;	chr4:39110111	chr4:39133913~39135608:+
TGCT	cis	rs1061377	0.965	rs6833654	ENSG00000249685.1	RP11-360F5.3	5.08	1.37e-06	0.00148	0.38	0.41	Uric acid levels;	chr4:39110701	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs1036036	ENSG00000249685.1	RP11-360F5.3	5.08	1.37e-06	0.00148	0.38	0.41	Uric acid levels;	chr4:39111104	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs1036038	ENSG00000249685.1	RP11-360F5.3	5.08	1.37e-06	0.00148	0.38	0.41	Uric acid levels;	chr4:39111383	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs1560396	ENSG00000249685.1	RP11-360F5.3	5.08	1.37e-06	0.00148	0.38	0.41	Uric acid levels;	chr4:39112092	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs1560397	ENSG00000249685.1	RP11-360F5.3	5.08	1.37e-06	0.00148	0.38	0.41	Uric acid levels;	chr4:39112265	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs2381285	ENSG00000249685.1	RP11-360F5.3	5.08	1.37e-06	0.00148	0.38	0.41	Uric acid levels;	chr4:39112775	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs2163272	ENSG00000249685.1	RP11-360F5.3	5.08	1.37e-06	0.00148	0.38	0.41	Uric acid levels;	chr4:39112790	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs2163273	ENSG00000249685.1	RP11-360F5.3	5.08	1.37e-06	0.00148	0.38	0.41	Uric acid levels;	chr4:39112835	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs62310332	ENSG00000249685.1	RP11-360F5.3	5.08	1.37e-06	0.00148	0.38	0.41	Uric acid levels;	chr4:39112939	chr4:39133913~39135608:+
TGCT	cis	rs1061377	0.965	rs3796510	ENSG00000249685.1	RP11-360F5.3	5.08	1.37e-06	0.00148	0.38	0.41	Uric acid levels;	chr4:39113309	chr4:39133913~39135608:+
TGCT	cis	rs1061377	0.932	rs6855118	ENSG00000249685.1	RP11-360F5.3	5.08	1.37e-06	0.00148	0.38	0.41	Uric acid levels;	chr4:39114322	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs6829234	ENSG00000249685.1	RP11-360F5.3	5.08	1.37e-06	0.00148	0.38	0.41	Uric acid levels;	chr4:39114586	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs6812540	ENSG00000249685.1	RP11-360F5.3	5.08	1.37e-06	0.00148	0.38	0.41	Uric acid levels;	chr4:39114803	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs10026775	ENSG00000249685.1	RP11-360F5.3	5.08	1.37e-06	0.00148	0.38	0.41	Uric acid levels;	chr4:39115155	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs3733276	ENSG00000249685.1	RP11-360F5.3	5.08	1.37e-06	0.00148	0.38	0.41	Uric acid levels;	chr4:39115291	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs3733277	ENSG00000249685.1	RP11-360F5.3	5.08	1.37e-06	0.00148	0.38	0.41	Uric acid levels;	chr4:39115483	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs3733278	ENSG00000249685.1	RP11-360F5.3	5.08	1.37e-06	0.00148	0.38	0.41	Uric acid levels;	chr4:39115615	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs3733279	ENSG00000249685.1	RP11-360F5.3	5.08	1.37e-06	0.00148	0.38	0.41	Uric acid levels;	chr4:39115625	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs10018049	ENSG00000249685.1	RP11-360F5.3	5.08	1.37e-06	0.00148	0.38	0.41	Uric acid levels;	chr4:39115781	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs7685082	ENSG00000249685.1	RP11-360F5.3	5.08	1.37e-06	0.00148	0.38	0.41	Uric acid levels;	chr4:39116472	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs9998481	ENSG00000249685.1	RP11-360F5.3	5.08	1.37e-06	0.00148	0.38	0.41	Uric acid levels;	chr4:39117215	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs9998867	ENSG00000249685.1	RP11-360F5.3	5.08	1.37e-06	0.00148	0.38	0.41	Uric acid levels;	chr4:39117542	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs2381284	ENSG00000249685.1	RP11-360F5.3	5.08	1.37e-06	0.00148	0.38	0.41	Uric acid levels;	chr4:39117976	chr4:39133913~39135608:+
TGCT	cis	rs1061377	0.803	rs6857761	ENSG00000249685.1	RP11-360F5.3	5.08	1.37e-06	0.00148	0.38	0.41	Uric acid levels;	chr4:39118353	chr4:39133913~39135608:+
TGCT	cis	rs972540	1	rs2084499	ENSG00000279220.1	GPR1-AS	5.08	1.37e-06	0.00148	0.43	0.41	Body mass index;	chr2:206385451	chr2:206203376~206266243:+
TGCT	cis	rs9368849	0.512	rs942373	ENSG00000186328.4	RP11-140K17.2	-5.08	1.38e-06	0.00148	-0.58	-0.41	Airway responsiveness in chronic obstructive pulmonary disease;	chr6:35185211	chr6:34715613~34715940:+
TGCT	cis	rs507080	0.922	rs519848	ENSG00000255422.1	AP002954.4	-5.07	1.38e-06	0.00148	-0.51	-0.41	Serum metabolite levels;	chr11:118682006	chr11:118704607~118750263:+
TGCT	cis	rs2882667	0.556	rs6873733	ENSG00000253404.1	AC034243.1	5.07	1.39e-06	0.00149	0.48	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139067628	chr5:138744434~138753309:-
TGCT	cis	rs34779708	0.931	rs10437420	ENSG00000230534.5	RP11-297A16.2	-5.07	1.39e-06	0.00149	-0.49	-0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35046116	chr10:35098006~35127020:-
TGCT	cis	rs911555	0.755	rs7148567	ENSG00000244691.1	RPL10AP1	-5.07	1.39e-06	0.00149	-0.56	-0.41	Intelligence (multi-trait analysis);	chr14:103415897	chr14:103412119~103412761:-
TGCT	cis	rs911555	0.755	rs10144051	ENSG00000244691.1	RPL10AP1	-5.07	1.39e-06	0.00149	-0.56	-0.41	Intelligence (multi-trait analysis);	chr14:103419594	chr14:103412119~103412761:-
TGCT	cis	rs911555	0.723	rs6575986	ENSG00000244691.1	RPL10AP1	-5.07	1.39e-06	0.00149	-0.56	-0.41	Intelligence (multi-trait analysis);	chr14:103420334	chr14:103412119~103412761:-
TGCT	cis	rs1010254	0.51	rs17543421	ENSG00000213433.5	RPLP1P6	-5.07	1.39e-06	0.00149	-0.5	-0.41	Optic nerve measurement (cup area);	chr5:152321789	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.51	rs72806379	ENSG00000213433.5	RPLP1P6	-5.07	1.39e-06	0.00149	-0.5	-0.41	Optic nerve measurement (cup area);	chr5:152322381	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.51	rs72806384	ENSG00000213433.5	RPLP1P6	-5.07	1.39e-06	0.00149	-0.5	-0.41	Optic nerve measurement (cup area);	chr5:152324397	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.51	rs72806385	ENSG00000213433.5	RPLP1P6	-5.07	1.39e-06	0.00149	-0.5	-0.41	Optic nerve measurement (cup area);	chr5:152324446	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.51	rs72806389	ENSG00000213433.5	RPLP1P6	-5.07	1.39e-06	0.00149	-0.5	-0.41	Optic nerve measurement (cup area);	chr5:152325372	chr5:151765859~151766378:-
TGCT	cis	rs8020912	0.504	rs3759577	ENSG00000244691.1	RPL10AP1	5.07	1.39e-06	0.0015	0.61	0.41	Granulocyte percentage of myeloid white cells;	chr14:103384626	chr14:103412119~103412761:-
TGCT	cis	rs7208859	0.614	rs216474	ENSG00000280069.1	CTD-2349P21.3	5.07	1.39e-06	0.0015	0.54	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30538073	chr17:30738182~30740275:+
TGCT	cis	rs35160687	0.901	rs12472676	ENSG00000273080.1	RP11-301O19.1	5.07	1.39e-06	0.0015	0.47	0.41	Night sleep phenotypes;	chr2:86283692	chr2:86195590~86196049:+
TGCT	cis	rs2117029	0.586	rs11168874	ENSG00000258017.1	RP11-386G11.10	-5.07	1.4e-06	0.0015	-0.55	-0.41	Intelligence (multi-trait analysis);	chr12:49133753	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.523	rs12227296	ENSG00000258017.1	RP11-386G11.10	-5.07	1.4e-06	0.0015	-0.55	-0.41	Intelligence (multi-trait analysis);	chr12:49136712	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.521	rs10875925	ENSG00000258017.1	RP11-386G11.10	-5.07	1.4e-06	0.0015	-0.55	-0.41	Intelligence (multi-trait analysis);	chr12:49142575	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.586	rs11168882	ENSG00000258017.1	RP11-386G11.10	-5.07	1.4e-06	0.0015	-0.55	-0.41	Intelligence (multi-trait analysis);	chr12:49143560	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.521	rs12227610	ENSG00000258017.1	RP11-386G11.10	-5.07	1.4e-06	0.0015	-0.55	-0.41	Intelligence (multi-trait analysis);	chr12:49146153	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.521	rs11168885	ENSG00000258017.1	RP11-386G11.10	-5.07	1.4e-06	0.0015	-0.55	-0.41	Intelligence (multi-trait analysis);	chr12:49146204	chr12:49127782~49147869:+
TGCT	cis	rs7617773	0.78	rs13082158	ENSG00000229759.1	MRPS18AP1	5.07	1.4e-06	0.0015	0.37	0.41	Coronary artery disease;	chr3:48330980	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.676	rs13060020	ENSG00000229759.1	MRPS18AP1	5.07	1.4e-06	0.0015	0.37	0.41	Coronary artery disease;	chr3:48331156	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs11710257	ENSG00000229759.1	MRPS18AP1	5.07	1.4e-06	0.0015	0.37	0.41	Coronary artery disease;	chr3:48331724	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.707	rs13061269	ENSG00000229759.1	MRPS18AP1	5.07	1.4e-06	0.0015	0.37	0.41	Coronary artery disease;	chr3:48331853	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs71323395	ENSG00000229759.1	MRPS18AP1	5.07	1.4e-06	0.0015	0.37	0.41	Coronary artery disease;	chr3:48332587	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.78	rs71323396	ENSG00000229759.1	MRPS18AP1	5.07	1.4e-06	0.0015	0.37	0.41	Coronary artery disease;	chr3:48333244	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.743	rs71323397	ENSG00000229759.1	MRPS18AP1	5.07	1.4e-06	0.0015	0.37	0.41	Coronary artery disease;	chr3:48333384	chr3:48256350~48256938:-
TGCT	cis	rs4563143	0.675	rs73029050	ENSG00000267243.4	AC005307.3	-5.07	1.4e-06	0.0015	-0.51	-0.41	Methadone dose in opioid dependence;	chr19:28785647	chr19:28435388~28727777:-
TGCT	cis	rs2117029	0.521	rs12229524	ENSG00000258017.1	RP11-386G11.10	-5.07	1.4e-06	0.00151	-0.56	-0.41	Intelligence (multi-trait analysis);	chr12:49191570	chr12:49127782~49147869:+
TGCT	cis	rs7927592	0.763	rs3740628	ENSG00000212093.1	AP000807.1	5.07	1.4e-06	0.00151	0.39	0.41	Total body bone mineral density;	chr11:68613947	chr11:68506083~68506166:-
TGCT	cis	rs7927592	0.731	rs10896350	ENSG00000212093.1	AP000807.1	5.07	1.4e-06	0.00151	0.39	0.41	Total body bone mineral density;	chr11:68618905	chr11:68506083~68506166:-
TGCT	cis	rs7829975	0.606	rs11776838	ENSG00000173295.6	FAM86B3P	-5.07	1.41e-06	0.00151	-0.48	-0.41	Mood instability;	chr8:8937291	chr8:8228595~8244865:+
TGCT	cis	rs1799949	1	rs35330014	ENSG00000198496.9	NBR2	-5.07	1.41e-06	0.00151	-0.63	-0.41	Menopause (age at onset);	chr17:43060530	chr17:43125610~43153671:+
TGCT	cis	rs1823913	0.599	rs17412094	ENSG00000227542.1	AC092614.2	5.07	1.41e-06	0.00151	0.43	0.41	Obesity-related traits;	chr2:191284202	chr2:191229165~191246172:-
TGCT	cis	rs4713118	0.539	rs510987	ENSG00000216901.1	AL022393.7	5.07	1.41e-06	0.00151	0.54	0.41	Parkinson's disease;	chr6:27879739	chr6:28176188~28176674:+
TGCT	cis	rs28735056	0.592	rs10853392	ENSG00000261126.6	RP11-795F19.1	-5.07	1.41e-06	0.00152	-0.35	-0.41	Schizophrenia;	chr18:79948781	chr18:80046900~80095482:+
TGCT	cis	rs7221109	0.677	rs4890092	ENSG00000278834.1	RP11-458J1.1	5.07	1.42e-06	0.00152	0.3	0.41	Type 1 diabetes;	chr17:40630199	chr17:40648300~40649718:+
TGCT	cis	rs7221109	0.633	rs9915135	ENSG00000278834.1	RP11-458J1.1	5.07	1.42e-06	0.00152	0.3	0.41	Type 1 diabetes;	chr17:40634823	chr17:40648300~40649718:+
TGCT	cis	rs4835473	0.932	rs9997931	ENSG00000251600.4	RP11-673E1.1	5.07	1.42e-06	0.00152	0.41	0.41	Immature fraction of reticulocytes;	chr4:143904601	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs2036880	ENSG00000251600.4	RP11-673E1.1	5.07	1.42e-06	0.00152	0.41	0.41	Immature fraction of reticulocytes;	chr4:143907834	chr4:143912331~143982454:+
TGCT	cis	rs1010254	0.51	rs72806351	ENSG00000213433.5	RPLP1P6	-5.07	1.42e-06	0.00152	-0.5	-0.41	Optic nerve measurement (cup area);	chr5:152301549	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.51	rs72806363	ENSG00000213433.5	RPLP1P6	-5.07	1.42e-06	0.00152	-0.5	-0.41	Optic nerve measurement (cup area);	chr5:152307408	chr5:151765859~151766378:-
TGCT	cis	rs9326248	0.53	rs2000615	ENSG00000254851.1	RP11-109L13.1	-5.07	1.42e-06	0.00152	-0.82	-0.41	Blood protein levels;	chr11:117045103	chr11:117135528~117138582:+
TGCT	cis	rs10256972	0.591	rs11766651	ENSG00000226291.1	AC091729.8	-5.07	1.43e-06	0.00153	-0.44	-0.41	Endometriosis;Longevity;	chr7:1122010	chr7:1080863~1082178:+
TGCT	cis	rs801193	0.844	rs732465	ENSG00000237310.1	GS1-124K5.4	5.07	1.43e-06	0.00153	0.45	0.41	Aortic root size;	chr7:66533463	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.773	rs801207	ENSG00000237310.1	GS1-124K5.4	-5.07	1.43e-06	0.00153	-0.45	-0.41	Aortic root size;	chr7:66555603	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.543	rs801191	ENSG00000237310.1	GS1-124K5.4	-5.07	1.43e-06	0.00153	-0.45	-0.41	Aortic root size;	chr7:66567968	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.508	rs6947808	ENSG00000237310.1	GS1-124K5.4	-5.07	1.43e-06	0.00153	-0.45	-0.41	Aortic root size;	chr7:66580095	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.508	rs10242423	ENSG00000237310.1	GS1-124K5.4	-5.07	1.43e-06	0.00153	-0.45	-0.41	Aortic root size;	chr7:66594188	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.508	rs10253883	ENSG00000237310.1	GS1-124K5.4	-5.07	1.43e-06	0.00153	-0.45	-0.41	Aortic root size;	chr7:66596151	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.508	rs10950045	ENSG00000237310.1	GS1-124K5.4	-5.07	1.43e-06	0.00153	-0.45	-0.41	Aortic root size;	chr7:66601386	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.839	rs6968619	ENSG00000237310.1	GS1-124K5.4	-5.07	1.43e-06	0.00153	-0.45	-0.41	Aortic root size;	chr7:66603880	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.839	rs12534943	ENSG00000237310.1	GS1-124K5.4	-5.07	1.43e-06	0.00153	-0.45	-0.41	Aortic root size;	chr7:66605533	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.805	rs12532355	ENSG00000237310.1	GS1-124K5.4	-5.07	1.43e-06	0.00153	-0.45	-0.41	Aortic root size;	chr7:66605597	chr7:66493706~66495474:+
TGCT	cis	rs1799949	0.628	rs4474733	ENSG00000198496.9	NBR2	-5.07	1.43e-06	0.00153	-0.67	-0.41	Menopause (age at onset);	chr17:43356292	chr17:43125610~43153671:+
TGCT	cis	rs9660180	0.783	rs1107910	ENSG00000268575.1	RP1-283E3.8	-5.07	1.43e-06	0.00153	-0.34	-0.41	Body mass index;	chr1:1760882	chr1:1702736~1737688:-
TGCT	cis	rs2015599	0.525	rs7959145	ENSG00000257176.2	RP11-996F15.2	5.07	1.43e-06	0.00153	0.44	0.41	Platelet count;Mean platelet volume;	chr12:29330850	chr12:29280418~29317848:-
TGCT	cis	rs2015599	0.525	rs7961943	ENSG00000257176.2	RP11-996F15.2	5.07	1.43e-06	0.00153	0.44	0.41	Platelet count;Mean platelet volume;	chr12:29331146	chr12:29280418~29317848:-
TGCT	cis	rs2276314	0.857	rs62101402	ENSG00000278986.1	RP11-723J4.3	-5.07	1.44e-06	0.00154	-0.47	-0.41	Endometriosis;Drug-induced torsades de pointes;	chr18:36049472	chr18:35972151~35973916:+
TGCT	cis	rs8111998	1	rs10403617	ENSG00000269332.4	GOLGA2P9	5.07	1.44e-06	0.00154	0.8	0.41	Corneal structure;	chr19:22572536	chr19:22596257~22603550:+
TGCT	cis	rs4835473	0.932	rs9685306	ENSG00000251600.4	RP11-673E1.1	-5.07	1.44e-06	0.00154	-0.43	-0.41	Immature fraction of reticulocytes;	chr4:143748843	chr4:143912331~143982454:+
TGCT	cis	rs1010254	0.51	rs1035401	ENSG00000213433.5	RPLP1P6	-5.06	1.44e-06	0.00154	-0.5	-0.41	Optic nerve measurement (cup area);	chr5:152330117	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.51	rs2112538	ENSG00000213433.5	RPLP1P6	-5.06	1.44e-06	0.00154	-0.5	-0.41	Optic nerve measurement (cup area);	chr5:152331831	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.51	rs17113105	ENSG00000213433.5	RPLP1P6	-5.06	1.44e-06	0.00154	-0.5	-0.41	Optic nerve measurement (cup area);	chr5:152332726	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.51	rs2348648	ENSG00000213433.5	RPLP1P6	-5.06	1.44e-06	0.00154	-0.5	-0.41	Optic nerve measurement (cup area);	chr5:152335009	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.51	rs72808305	ENSG00000213433.5	RPLP1P6	-5.06	1.44e-06	0.00154	-0.5	-0.41	Optic nerve measurement (cup area);	chr5:152339960	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.559	rs72808307	ENSG00000213433.5	RPLP1P6	-5.06	1.44e-06	0.00154	-0.5	-0.41	Optic nerve measurement (cup area);	chr5:152349046	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.559	rs114133296	ENSG00000213433.5	RPLP1P6	-5.06	1.44e-06	0.00154	-0.5	-0.41	Optic nerve measurement (cup area);	chr5:152350694	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.559	rs114626875	ENSG00000213433.5	RPLP1P6	-5.06	1.44e-06	0.00154	-0.5	-0.41	Optic nerve measurement (cup area);	chr5:152361378	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.559	rs55920366	ENSG00000213433.5	RPLP1P6	-5.06	1.44e-06	0.00154	-0.5	-0.41	Optic nerve measurement (cup area);	chr5:152361476	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.559	rs72808322	ENSG00000213433.5	RPLP1P6	-5.06	1.44e-06	0.00154	-0.5	-0.41	Optic nerve measurement (cup area);	chr5:152363175	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.559	rs72808324	ENSG00000213433.5	RPLP1P6	-5.06	1.44e-06	0.00154	-0.5	-0.41	Optic nerve measurement (cup area);	chr5:152363434	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.559	rs114309942	ENSG00000213433.5	RPLP1P6	-5.06	1.44e-06	0.00154	-0.5	-0.41	Optic nerve measurement (cup area);	chr5:152364354	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.559	rs1592896	ENSG00000213433.5	RPLP1P6	-5.06	1.44e-06	0.00154	-0.5	-0.41	Optic nerve measurement (cup area);	chr5:152366524	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.559	rs72808328	ENSG00000213433.5	RPLP1P6	-5.06	1.44e-06	0.00154	-0.5	-0.41	Optic nerve measurement (cup area);	chr5:152366749	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.559	rs72808330	ENSG00000213433.5	RPLP1P6	-5.06	1.44e-06	0.00154	-0.5	-0.41	Optic nerve measurement (cup area);	chr5:152367008	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.559	rs991637	ENSG00000213433.5	RPLP1P6	-5.06	1.44e-06	0.00154	-0.5	-0.41	Optic nerve measurement (cup area);	chr5:152369247	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.559	rs991635	ENSG00000213433.5	RPLP1P6	-5.06	1.44e-06	0.00154	-0.5	-0.41	Optic nerve measurement (cup area);	chr5:152369360	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.559	rs115672114	ENSG00000213433.5	RPLP1P6	-5.06	1.44e-06	0.00154	-0.5	-0.41	Optic nerve measurement (cup area);	chr5:152370213	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.559	rs56261934	ENSG00000213433.5	RPLP1P6	-5.06	1.44e-06	0.00154	-0.5	-0.41	Optic nerve measurement (cup area);	chr5:152370870	chr5:151765859~151766378:-
TGCT	cis	rs10829156	0.699	rs1917209	ENSG00000240291.1	RP11-499P20.2	5.06	1.44e-06	0.00154	0.37	0.41	Sudden cardiac arrest;	chr10:18543631	chr10:18513115~18545651:-
TGCT	cis	rs10829156	0.66	rs10764587	ENSG00000240291.1	RP11-499P20.2	5.06	1.44e-06	0.00154	0.37	0.41	Sudden cardiac arrest;	chr10:18548901	chr10:18513115~18545651:-
TGCT	cis	rs710913	0.618	rs12030495	ENSG00000182109.6	RP11-69E11.4	5.06	1.44e-06	0.00154	0.43	0.41	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39623923	chr1:39522280~39546187:-
TGCT	cis	rs2333021	0.78	rs2806042	ENSG00000259015.1	RP11-109N23.6	-5.06	1.44e-06	0.00154	-0.22	-0.41	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72947939	chr14:72960595~72961993:+
TGCT	cis	rs10829156	0.625	rs7082235	ENSG00000240291.1	RP11-499P20.2	5.06	1.45e-06	0.00155	0.36	0.41	Sudden cardiac arrest;	chr10:18536765	chr10:18513115~18545651:-
TGCT	cis	rs17301013	0.932	rs6425280	ENSG00000227373.4	RP11-160H22.5	5.06	1.45e-06	0.00155	0.43	0.41	Systemic lupus erythematosus;	chr1:174422186	chr1:174115300~174160004:-
TGCT	cis	rs875971	0.505	rs1167386	ENSG00000237310.1	GS1-124K5.4	-5.06	1.45e-06	0.00155	-0.46	-0.41	Aortic root size;	chr7:66048109	chr7:66493706~66495474:+
TGCT	cis	rs5769707	0.616	rs135869	ENSG00000235111.1	RP1-29C18.8	-5.06	1.45e-06	0.00155	-0.4	-0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49614718	chr22:49612657~49615716:-
TGCT	cis	rs2019137	0.56	rs7578633	ENSG00000274877.1	RP11-65I12.1	-5.06	1.46e-06	0.00155	-0.41	-0.41	Lymphocyte counts;	chr2:113221073	chr2:113237595~113240825:+
TGCT	cis	rs2019137	0.539	rs11123170	ENSG00000274877.1	RP11-65I12.1	-5.06	1.46e-06	0.00155	-0.41	-0.41	Lymphocyte counts;	chr2:113221363	chr2:113237595~113240825:+
TGCT	cis	rs17361889	0.502	rs10807780	ENSG00000224683.1	RPL36AP29	-5.06	1.46e-06	0.00156	-0.45	-0.41	Pediatric bone mineral content (hip);	chr7:16179743	chr7:16208945~16209265:+
TGCT	cis	rs35160687	0.901	rs10200186	ENSG00000273080.1	RP11-301O19.1	5.06	1.46e-06	0.00156	0.47	0.41	Night sleep phenotypes;	chr2:86300300	chr2:86195590~86196049:+
TGCT	cis	rs35160687	0.842	rs10200526	ENSG00000273080.1	RP11-301O19.1	5.06	1.46e-06	0.00156	0.47	0.41	Night sleep phenotypes;	chr2:86300476	chr2:86195590~86196049:+
TGCT	cis	rs35160687	0.901	rs34048420	ENSG00000273080.1	RP11-301O19.1	5.06	1.46e-06	0.00156	0.47	0.41	Night sleep phenotypes;	chr2:86302625	chr2:86195590~86196049:+
TGCT	cis	rs35160687	0.901	rs34069316	ENSG00000273080.1	RP11-301O19.1	5.06	1.46e-06	0.00156	0.47	0.41	Night sleep phenotypes;	chr2:86302669	chr2:86195590~86196049:+
TGCT	cis	rs35160687	0.901	rs11127026	ENSG00000273080.1	RP11-301O19.1	5.06	1.46e-06	0.00156	0.47	0.41	Night sleep phenotypes;	chr2:86304625	chr2:86195590~86196049:+
TGCT	cis	rs35160687	0.901	rs12478575	ENSG00000273080.1	RP11-301O19.1	5.06	1.46e-06	0.00156	0.47	0.41	Night sleep phenotypes;	chr2:86308191	chr2:86195590~86196049:+
TGCT	cis	rs35160687	0.871	rs11127028	ENSG00000273080.1	RP11-301O19.1	5.06	1.46e-06	0.00156	0.47	0.41	Night sleep phenotypes;	chr2:86310386	chr2:86195590~86196049:+
TGCT	cis	rs853679	0.517	rs9380052	ENSG00000219392.1	RP1-265C24.5	-5.06	1.46e-06	0.00156	-0.56	-0.41	Depression;	chr6:28096845	chr6:28115628~28116551:+
TGCT	cis	rs4927850	1	rs7625570	ENSG00000207650.1	MIR570	5.06	1.46e-06	0.00156	0.51	0.41	Pancreatic cancer;	chr3:196020527	chr3:195699401~195699497:+
TGCT	cis	rs10246939	0.579	rs13240104	ENSG00000228775.6	WEE2-AS1	5.06	1.46e-06	0.00156	0.36	0.41	Bitter taste perception;	chr7:141913405	chr7:141704338~141738346:-
TGCT	cis	rs10246939	0.579	rs34588922	ENSG00000228775.6	WEE2-AS1	5.06	1.46e-06	0.00156	0.36	0.41	Bitter taste perception;	chr7:141913448	chr7:141704338~141738346:-
TGCT	cis	rs4713118	0.516	rs6931858	ENSG00000219392.1	RP1-265C24.5	-5.06	1.46e-06	0.00156	-0.57	-0.41	Parkinson's disease;	chr6:28110633	chr6:28115628~28116551:+
TGCT	cis	rs786425	0.707	rs2250026	ENSG00000278112.1	RP11-972P1.11	5.06	1.47e-06	0.00156	0.46	0.41	Pubertal anthropometrics;	chr12:123713858	chr12:123519390~123519856:-
TGCT	cis	rs12891047	0.709	rs7150705	ENSG00000258759.1	RP11-1012A1.7	-5.06	1.47e-06	0.00156	-0.35	-0.41	Amyotrophic lateral sclerosis (sporadic);	chr14:67897310	chr14:67799004~67799609:+
TGCT	cis	rs1387259	0.723	rs2732488	ENSG00000258273.1	RP11-370I10.4	-5.06	1.47e-06	0.00157	-0.49	-0.41	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48333755~48333901:-
TGCT	cis	rs1387259	0.758	rs2634670	ENSG00000258273.1	RP11-370I10.4	-5.06	1.47e-06	0.00157	-0.49	-0.41	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48333755~48333901:-
TGCT	cis	rs16975963	0.644	rs12459013	ENSG00000276846.1	CTD-3220F14.3	-5.06	1.47e-06	0.00157	-0.41	-0.41	Longevity;	chr19:37638596	chr19:37314868~37315620:-
TGCT	cis	rs9584850	0.794	rs17574433	ENSG00000231194.1	FARP1-AS1	-5.06	1.47e-06	0.00157	-0.56	-0.41	Neuroticism;	chr13:98485803	chr13:98435405~98435840:-
TGCT	cis	rs911555	0.723	rs4906320	ENSG00000244691.1	RPL10AP1	5.06	1.47e-06	0.00157	0.55	0.41	Intelligence (multi-trait analysis);	chr14:103410588	chr14:103412119~103412761:-
TGCT	cis	rs1061377	0.965	rs7690465	ENSG00000249207.1	RP11-360F5.1	-5.06	1.47e-06	0.00157	-0.45	-0.41	Uric acid levels;	chr4:39147015	chr4:39112677~39126818:-
TGCT	cis	rs13118159	0.55	rs11941200	ENSG00000254094.1	AC078852.1	-5.06	1.47e-06	0.00157	-0.52	-0.41	Longevity;	chr4:1375305	chr4:1356581~1358075:+
TGCT	cis	rs13118159	0.55	rs11946956	ENSG00000254094.1	AC078852.1	-5.06	1.47e-06	0.00157	-0.52	-0.41	Longevity;	chr4:1375306	chr4:1356581~1358075:+
TGCT	cis	rs9326248	1	rs4938354	ENSG00000280143.1	AP000892.6	5.06	1.47e-06	0.00157	0.54	0.41	Blood protein levels;	chr11:117180449	chr11:117204967~117210292:+
TGCT	cis	rs453301	0.624	rs2288673	ENSG00000173295.6	FAM86B3P	5.06	1.47e-06	0.00157	0.49	0.41	Joint mobility (Beighton score);	chr8:9002766	chr8:8228595~8244865:+
TGCT	cis	rs1823913	1	rs11691372	ENSG00000227542.1	AC092614.2	-5.06	1.48e-06	0.00157	-0.43	-0.41	Obesity-related traits;	chr2:191249952	chr2:191229165~191246172:-
TGCT	cis	rs34779708	0.931	rs34954932	ENSG00000230534.5	RP11-297A16.2	5.06	1.48e-06	0.00157	0.49	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35121879	chr10:35098006~35127020:-
TGCT	cis	rs1799949	0.965	rs4793230	ENSG00000198496.9	NBR2	-5.06	1.48e-06	0.00157	-0.58	-0.41	Menopause (age at onset);	chr17:43350035	chr17:43125610~43153671:+
TGCT	cis	rs4835473	0.932	rs6858195	ENSG00000251600.4	RP11-673E1.1	-5.06	1.48e-06	0.00158	-0.41	-0.41	Immature fraction of reticulocytes;	chr4:143768444	chr4:143912331~143982454:+
TGCT	cis	rs651907	0.557	rs11712748	ENSG00000244119.1	PDCL3P4	5.06	1.48e-06	0.00158	0.3	0.41	Colorectal cancer;	chr3:101664718	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.557	rs7651406	ENSG00000244119.1	PDCL3P4	5.06	1.48e-06	0.00158	0.3	0.41	Colorectal cancer;	chr3:101674452	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.557	rs3806654	ENSG00000244119.1	PDCL3P4	5.06	1.48e-06	0.00158	0.3	0.41	Colorectal cancer;	chr3:101677685	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.557	rs3864012	ENSG00000244119.1	PDCL3P4	5.06	1.48e-06	0.00158	0.3	0.41	Colorectal cancer;	chr3:101678779	chr3:101712472~101713191:+
TGCT	cis	rs2412819	0.571	rs28410121	ENSG00000205771.5	CATSPER2P1	5.06	1.48e-06	0.00158	0.56	0.41	Lung cancer;	chr15:43777831	chr15:43726918~43747094:-
TGCT	cis	rs9322193	0.884	rs9688699	ENSG00000216906.2	RP11-350J20.9	5.06	1.49e-06	0.00159	0.47	0.41	Lung cancer;	chr6:149733680	chr6:149904243~149906418:+
TGCT	cis	rs1061377	1	rs7685468	ENSG00000249685.1	RP11-360F5.3	5.06	1.49e-06	0.00159	0.38	0.41	Uric acid levels;	chr4:39116649	chr4:39133913~39135608:+
TGCT	cis	rs2288073	0.965	rs10199334	ENSG00000223754.1	AC008073.9	5.06	1.49e-06	0.00159	0.53	0.41	Venous thromboembolism (SNP x SNP interaction);	chr2:24169749	chr2:24199839~24201698:-
TGCT	cis	rs2288073	0.965	rs72789923	ENSG00000223754.1	AC008073.9	5.06	1.49e-06	0.00159	0.53	0.41	Venous thromboembolism (SNP x SNP interaction);	chr2:24171635	chr2:24199839~24201698:-
TGCT	cis	rs2288073	0.965	rs10192600	ENSG00000223754.1	AC008073.9	5.06	1.49e-06	0.00159	0.53	0.41	Venous thromboembolism (SNP x SNP interaction);	chr2:24173811	chr2:24199839~24201698:-
TGCT	cis	rs2239557	0.608	rs2041186	ENSG00000259065.1	RP5-1021I20.1	-5.06	1.5e-06	0.00159	-0.38	-0.41	Common traits (Other);	chr14:73815334	chr14:73787360~73803270:+
TGCT	cis	rs801193	1	rs4717319	ENSG00000237310.1	GS1-124K5.4	5.06	1.5e-06	0.00159	0.48	0.41	Aortic root size;	chr7:66777606	chr7:66493706~66495474:+
TGCT	cis	rs7301826	0.934	rs10848212	ENSG00000256250.1	RP11-989F5.1	5.06	1.5e-06	0.0016	0.44	0.41	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810606~130812438:+
TGCT	cis	rs10829156	0.699	rs4747353	ENSG00000240291.1	RP11-499P20.2	5.06	1.5e-06	0.0016	0.36	0.41	Sudden cardiac arrest;	chr10:18548028	chr10:18513115~18545651:-
TGCT	cis	rs2015599	0.549	rs7956305	ENSG00000257176.2	RP11-996F15.2	5.05	1.51e-06	0.0016	0.43	0.41	Platelet count;Mean platelet volume;	chr12:29308639	chr12:29280418~29317848:-
TGCT	cis	rs2015599	0.543	rs6487807	ENSG00000257176.2	RP11-996F15.2	5.05	1.51e-06	0.0016	0.43	0.41	Platelet count;Mean platelet volume;	chr12:29309291	chr12:29280418~29317848:-
TGCT	cis	rs34217772	0.68	rs61990336	ENSG00000258536.1	RP11-1053O12.1	5.05	1.51e-06	0.0016	0.35	0.41	Myopia;	chr14:41712728	chr14:41742639~41742963:+
TGCT	cis	rs5769707	0.656	rs135878	ENSG00000235111.1	RP1-29C18.8	-5.05	1.51e-06	0.00161	-0.4	-0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49620721	chr22:49612657~49615716:-
TGCT	cis	rs9425766	0.679	rs6667267	ENSG00000227373.4	RP11-160H22.5	5.05	1.52e-06	0.00161	0.44	0.41	Life satisfaction;	chr1:174243623	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.679	rs2064149	ENSG00000227373.4	RP11-160H22.5	5.05	1.52e-06	0.00161	0.44	0.41	Life satisfaction;	chr1:174255856	chr1:174115300~174160004:-
TGCT	cis	rs8072100	0.817	rs9912101	ENSG00000228782.6	CTD-2026D20.3	5.05	1.52e-06	0.00161	0.48	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469712	chr17:47450568~47492492:-
TGCT	cis	rs7829975	0.626	rs332040	ENSG00000173295.6	FAM86B3P	5.05	1.52e-06	0.00162	0.48	0.41	Mood instability;	chr8:8872978	chr8:8228595~8244865:+
TGCT	cis	rs2117029	0.521	rs58336603	ENSG00000258017.1	RP11-386G11.10	-5.05	1.52e-06	0.00162	-0.55	-0.41	Intelligence (multi-trait analysis);	chr12:49163105	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.553	rs1991427	ENSG00000258017.1	RP11-386G11.10	-5.05	1.52e-06	0.00162	-0.55	-0.41	Intelligence (multi-trait analysis);	chr12:49164175	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.521	rs2114845	ENSG00000258017.1	RP11-386G11.10	-5.05	1.52e-06	0.00162	-0.55	-0.41	Intelligence (multi-trait analysis);	chr12:49164750	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.521	rs6580702	ENSG00000258017.1	RP11-386G11.10	-5.05	1.52e-06	0.00162	-0.55	-0.41	Intelligence (multi-trait analysis);	chr12:49169483	chr12:49127782~49147869:+
TGCT	cis	rs11168854	0.651	rs12227770	ENSG00000258017.1	RP11-386G11.10	-5.05	1.52e-06	0.00162	-0.55	-0.41	Body mass index;	chr12:49183065	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.521	rs7953169	ENSG00000258017.1	RP11-386G11.10	-5.05	1.52e-06	0.00162	-0.55	-0.41	Intelligence (multi-trait analysis);	chr12:49184389	chr12:49127782~49147869:+
TGCT	cis	rs1823913	1	rs4853568	ENSG00000227542.1	AC092614.2	-5.05	1.52e-06	0.00162	-0.44	-0.41	Obesity-related traits;	chr2:191261464	chr2:191229165~191246172:-
TGCT	cis	rs1010254	0.559	rs17447016	ENSG00000213433.5	RPLP1P6	-5.05	1.53e-06	0.00162	-0.53	-0.41	Optic nerve measurement (cup area);	chr5:152357998	chr5:151765859~151766378:-
TGCT	cis	rs4835473	0.838	rs6838981	ENSG00000251600.4	RP11-673E1.1	-5.05	1.53e-06	0.00162	-0.42	-0.41	Immature fraction of reticulocytes;	chr4:143826484	chr4:143912331~143982454:+
TGCT	cis	rs1153858	1	rs1153849	ENSG00000259520.4	CTD-2651B20.3	-5.05	1.53e-06	0.00162	-0.35	-0.41	Homoarginine levels;	chr15:45403497	chr15:45251580~45279251:-
TGCT	cis	rs1153858	0.945	rs2467854	ENSG00000259520.4	CTD-2651B20.3	-5.05	1.53e-06	0.00162	-0.35	-0.41	Homoarginine levels;	chr15:45409399	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs2461701	ENSG00000259520.4	CTD-2651B20.3	-5.05	1.53e-06	0.00162	-0.35	-0.41	Homoarginine levels;	chr15:45411193	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs2467858	ENSG00000259520.4	CTD-2651B20.3	-5.05	1.53e-06	0.00162	-0.35	-0.41	Homoarginine levels;	chr15:45419294	chr15:45251580~45279251:-
TGCT	cis	rs34217772	0.83	rs1951877	ENSG00000258536.1	RP11-1053O12.1	5.05	1.53e-06	0.00163	0.35	0.41	Myopia;	chr14:41824579	chr14:41742639~41742963:+
TGCT	cis	rs67311347	1	rs12488805	ENSG00000223797.4	ENTPD3-AS1	5.05	1.54e-06	0.00163	0.43	0.41	Renal cell carcinoma;	chr3:40381378	chr3:40313802~40453329:-
TGCT	cis	rs1799949	1	rs8176318	ENSG00000198496.9	NBR2	-5.05	1.54e-06	0.00163	-0.62	-0.41	Menopause (age at onset);	chr17:43045257	chr17:43125610~43153671:+
TGCT	cis	rs7174755	0.637	rs10152713	ENSG00000260657.2	RP11-315D16.4	-5.05	1.54e-06	0.00164	-0.45	-0.41	Major depressive disorder;	chr15:68179553	chr15:68267792~68277994:-
TGCT	cis	rs28735056	0.565	rs12957336	ENSG00000261126.6	RP11-795F19.1	-5.05	1.54e-06	0.00164	-0.35	-0.41	Schizophrenia;	chr18:79956889	chr18:80046900~80095482:+
TGCT	cis	rs17826219	0.561	rs11655876	ENSG00000266490.1	CTD-2349P21.9	5.05	1.54e-06	0.00164	0.45	0.41	Body mass index;	chr17:30690132	chr17:30792372~30792833:+
TGCT	cis	rs1061377	1	rs12499266	ENSG00000249685.1	RP11-360F5.3	-5.05	1.54e-06	0.00164	-0.38	-0.41	Uric acid levels;	chr4:39118133	chr4:39133913~39135608:+
TGCT	cis	rs4927850	1	rs7630875	ENSG00000231464.1	AC024937.4	5.05	1.54e-06	0.00164	0.41	0.41	Pancreatic cancer;	chr3:196026895	chr3:195996738~195998233:+
TGCT	cis	rs4237845	0.611	rs10877036	ENSG00000257159.1	RP11-58A17.3	-5.05	1.54e-06	0.00164	-0.5	-0.41	Intelligence (multi-trait analysis);	chr12:57927867	chr12:57967058~57968399:+
TGCT	cis	rs5769707	0.681	rs739236	ENSG00000235111.1	RP1-29C18.8	-5.05	1.54e-06	0.00164	-0.39	-0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49647954	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.681	rs916360	ENSG00000235111.1	RP1-29C18.8	-5.05	1.54e-06	0.00164	-0.39	-0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49648324	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.681	rs1107514	ENSG00000235111.1	RP1-29C18.8	-5.05	1.54e-06	0.00164	-0.39	-0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49648735	chr22:49612657~49615716:-
TGCT	cis	rs7208859	0.623	rs122898	ENSG00000280069.1	CTD-2349P21.3	5.05	1.55e-06	0.00164	0.57	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30738182~30740275:+
TGCT	cis	rs7927592	0.731	rs11228275	ENSG00000212093.1	AP000807.1	-5.05	1.55e-06	0.00164	-0.38	-0.41	Total body bone mineral density;	chr11:68536512	chr11:68506083~68506166:-
TGCT	cis	rs877819	0.519	rs2671711	ENSG00000228403.1	RP11-563N6.6	5.05	1.56e-06	0.00165	0.42	0.41	Systemic lupus erythematosus;	chr10:48886741	chr10:48878022~48878649:+
TGCT	cis	rs2333021	1	rs4899453	ENSG00000259015.1	RP11-109N23.6	-5.05	1.56e-06	0.00165	-0.22	-0.41	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73021883	chr14:72960595~72961993:+
TGCT	cis	rs972540	1	rs41388648	ENSG00000279220.1	GPR1-AS	5.05	1.57e-06	0.00166	0.42	0.41	Body mass index;	chr2:206366636	chr2:206203376~206266243:+
TGCT	cis	rs2412819	0.571	rs4923964	ENSG00000205771.5	CATSPER2P1	5.05	1.57e-06	0.00166	0.58	0.41	Lung cancer;	chr15:43722882	chr15:43726918~43747094:-
TGCT	cis	rs2412819	0.571	rs12443084	ENSG00000205771.5	CATSPER2P1	5.05	1.57e-06	0.00166	0.58	0.41	Lung cancer;	chr15:43748767	chr15:43726918~43747094:-
TGCT	cis	rs2412819	0.571	rs10163069	ENSG00000205771.5	CATSPER2P1	5.05	1.57e-06	0.00166	0.58	0.41	Lung cancer;	chr15:43755372	chr15:43726918~43747094:-
TGCT	cis	rs2929278	0.617	rs3986209	ENSG00000205771.5	CATSPER2P1	5.05	1.57e-06	0.00166	0.58	0.41	Schizophrenia;	chr15:43758675	chr15:43726918~43747094:-
TGCT	cis	rs4927850	0.881	rs7624638	ENSG00000231464.1	AC024937.4	5.05	1.57e-06	0.00166	0.4	0.41	Pancreatic cancer;	chr3:196021858	chr3:195996738~195998233:+
TGCT	cis	rs4927850	1	rs10881564	ENSG00000231464.1	AC024937.4	5.05	1.57e-06	0.00166	0.4	0.41	Pancreatic cancer;	chr3:196023455	chr3:195996738~195998233:+
TGCT	cis	rs8062405	0.722	rs3785354	ENSG00000259982.1	CDC37P1	5.04	1.57e-06	0.00166	0.57	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.755	rs4787457	ENSG00000259982.1	CDC37P1	5.04	1.57e-06	0.00166	0.57	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.755	rs4788080	ENSG00000259982.1	CDC37P1	5.04	1.57e-06	0.00166	0.57	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.755	rs4787456	ENSG00000259982.1	CDC37P1	5.04	1.57e-06	0.00166	0.57	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.755	rs4788078	ENSG00000259982.1	CDC37P1	5.04	1.57e-06	0.00166	0.57	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.755	rs62034350	ENSG00000259982.1	CDC37P1	5.04	1.57e-06	0.00166	0.57	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28700294~28701540:-
TGCT	cis	rs9584850	0.834	rs17574378	ENSG00000231194.1	FARP1-AS1	5.04	1.57e-06	0.00166	0.54	0.41	Neuroticism;	chr13:98464130	chr13:98435405~98435840:-
TGCT	cis	rs321358	1	rs321356	ENSG00000271584.1	RP11-89C3.4	-5.04	1.58e-06	0.00167	-0.51	-0.41	Body mass index;	chr11:111124957	chr11:111091932~111097357:-
TGCT	cis	rs4835473	0.662	rs4340756	ENSG00000251600.4	RP11-673E1.1	5.04	1.58e-06	0.00167	0.43	0.41	Immature fraction of reticulocytes;	chr4:144017063	chr4:143912331~143982454:+
TGCT	cis	rs1372520	0.684	rs1837891	ENSG00000247775.2	SNCA-AS1	-5.04	1.59e-06	0.00168	-0.41	-0.41	Neuroticism;	chr4:89814980	chr4:89836408~89841978:+
TGCT	cis	rs2742234	0.59	rs2503848	ENSG00000273008.1	RP11-351D16.3	-5.04	1.59e-06	0.00168	-0.55	-0.41	Hirschsprung disease;	chr10:43177337	chr10:43136824~43138334:-
TGCT	cis	rs651907	0.557	rs13099674	ENSG00000244119.1	PDCL3P4	5.04	1.59e-06	0.00168	0.29	0.41	Colorectal cancer;	chr3:101770785	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.557	rs34181125	ENSG00000244119.1	PDCL3P4	5.04	1.59e-06	0.00168	0.29	0.41	Colorectal cancer;	chr3:101771434	chr3:101712472~101713191:+
TGCT	cis	rs8062405	0.723	rs4788079	ENSG00000259982.1	CDC37P1	5.04	1.59e-06	0.00168	0.57	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28700294~28701540:-
TGCT	cis	rs911555	0.723	rs56227024	ENSG00000244691.1	RPL10AP1	5.04	1.59e-06	0.00168	0.55	0.41	Intelligence (multi-trait analysis);	chr14:103395369	chr14:103412119~103412761:-
TGCT	cis	rs12935418	0.83	rs12448368	ENSG00000261061.1	RP11-303E16.2	5.04	1.6e-06	0.00168	0.57	0.41	Mean corpuscular volume;	chr16:81011342	chr16:81030770~81031485:+
TGCT	cis	rs3091242	0.933	rs7541095	ENSG00000224183.1	SDHDP6	-5.04	1.6e-06	0.00169	-0.43	-0.41	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25294164~25294643:-
TGCT	cis	rs1799949	0.929	rs4792988	ENSG00000198496.9	NBR2	-5.04	1.6e-06	0.00169	-0.61	-0.41	Menopause (age at onset);	chr17:43360179	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.965	rs4792989	ENSG00000198496.9	NBR2	-5.04	1.6e-06	0.00169	-0.61	-0.41	Menopause (age at onset);	chr17:43360184	chr17:43125610~43153671:+
TGCT	cis	rs10829156	0.945	rs8181345	ENSG00000240291.1	RP11-499P20.2	5.04	1.6e-06	0.00169	0.4	0.41	Sudden cardiac arrest;	chr10:18678689	chr10:18513115~18545651:-
TGCT	cis	rs10829156	0.945	rs10829199	ENSG00000240291.1	RP11-499P20.2	5.04	1.6e-06	0.00169	0.4	0.41	Sudden cardiac arrest;	chr10:18679012	chr10:18513115~18545651:-
TGCT	cis	rs911555	0.755	rs35233301	ENSG00000244691.1	RPL10AP1	5.04	1.6e-06	0.00169	0.56	0.41	Intelligence (multi-trait analysis);	chr14:103418954	chr14:103412119~103412761:-
TGCT	cis	rs7757969	0.536	rs697642	ENSG00000227012.2	RP1-97J1.2	-5.04	1.61e-06	0.0017	-0.64	-0.41	Schizophrenia;	chr6:111731902	chr6:111900489~111901851:-
TGCT	cis	rs9549367	0.577	rs3024718	ENSG00000269125.1	RP11-98F14.11	5.04	1.61e-06	0.0017	0.53	0.41	Platelet distribution width;	chr13:113159539	chr13:113165002~113165183:-
TGCT	cis	rs7804306	1	rs73049231	ENSG00000233264.2	AC006042.8	5.04	1.61e-06	0.0017	0.97	0.41	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7965829	chr7:7980312~7982228:+
TGCT	cis	rs7804306	1	rs73049238	ENSG00000233264.2	AC006042.8	5.04	1.61e-06	0.0017	0.97	0.41	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7967141	chr7:7980312~7982228:+
TGCT	cis	rs524281	0.731	rs2452682	ENSG00000255320.1	RP11-755F10.1	5.04	1.62e-06	0.0017	0.62	0.41	Electroencephalogram traits;	chr11:66045138	chr11:66244840~66246239:-
TGCT	cis	rs853679	0.55	rs1233699	ENSG00000219392.1	RP1-265C24.5	-5.04	1.62e-06	0.00171	-0.54	-0.41	Depression;	chr6:28201380	chr6:28115628~28116551:+
TGCT	cis	rs7208859	0.573	rs73267873	ENSG00000266490.1	CTD-2349P21.9	5.04	1.62e-06	0.00171	0.46	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30792372~30792833:+
TGCT	cis	rs17826219	0.561	rs4085382	ENSG00000266490.1	CTD-2349P21.9	5.04	1.62e-06	0.00171	0.46	0.41	Body mass index;	chr17:30744184	chr17:30792372~30792833:+
TGCT	cis	rs12891047	0.647	rs7150903	ENSG00000258759.1	RP11-1012A1.7	-5.04	1.62e-06	0.00171	-0.35	-0.41	Amyotrophic lateral sclerosis (sporadic);	chr14:67897442	chr14:67799004~67799609:+
TGCT	cis	rs10246939	0.579	rs6976028	ENSG00000228775.6	WEE2-AS1	5.04	1.62e-06	0.00171	0.36	0.41	Bitter taste perception;	chr7:141912917	chr7:141704338~141738346:-
TGCT	cis	rs2019137	0.56	rs6707386	ENSG00000274877.1	RP11-65I12.1	-5.04	1.62e-06	0.00171	-0.41	-0.41	Lymphocyte counts;	chr2:113223445	chr2:113237595~113240825:+
TGCT	cis	rs2283792	0.935	rs9610375	ENSG00000228050.1	TOP3BP1	5.04	1.63e-06	0.00172	0.49	0.41	Multiple sclerosis;	chr22:21832804	chr22:22223187~22224566:-
TGCT	cis	rs10256972	0.591	rs6968988	ENSG00000226291.1	AC091729.8	-5.04	1.63e-06	0.00172	-0.43	-0.41	Endometriosis;Longevity;	chr7:1129983	chr7:1080863~1082178:+
TGCT	cis	rs1707322	0.717	rs1972410	ENSG00000280836.1	AL355480.1	-5.04	1.64e-06	0.00173	-0.59	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr1:45581219~45581321:-
TGCT	cis	rs2980439	0.556	rs2921059	ENSG00000173295.6	FAM86B3P	5.03	1.64e-06	0.00173	0.5	0.41	Neuroticism;	chr8:8460377	chr8:8228595~8244865:+
TGCT	cis	rs34779708	0.966	rs1545757	ENSG00000230534.5	RP11-297A16.2	5.03	1.64e-06	0.00173	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35156660	chr10:35098006~35127020:-
TGCT	cis	rs992157	0.965	rs13427681	ENSG00000261338.2	RP11-378A13.1	5.03	1.65e-06	0.00174	0.33	0.41	Colorectal cancer;	chr2:218302840	chr2:218255319~218257366:+
TGCT	cis	rs12931792	0.875	rs58175255	ENSG00000183604.13	SMG1P5	5.03	1.65e-06	0.00174	0.29	0.41	Tonsillectomy;	chr16:30143969	chr16:30267553~30335374:-
TGCT	cis	rs10256972	0.616	rs4585652	ENSG00000226291.1	AC091729.8	-5.03	1.66e-06	0.00174	-0.43	-0.41	Endometriosis;Longevity;	chr7:1105760	chr7:1080863~1082178:+
TGCT	cis	rs7617773	0.963	rs12495221	ENSG00000229759.1	MRPS18AP1	-5.03	1.66e-06	0.00174	-0.32	-0.41	Coronary artery disease;	chr3:48137688	chr3:48256350~48256938:-
TGCT	cis	rs2555155	0.633	rs2303493	ENSG00000254595.1	CTD-2010I16.1	5.03	1.66e-06	0.00175	0.35	0.41	DNA methylation (variation);	chr11:6477985	chr11:6488186~6489377:-
TGCT	cis	rs17301013	0.829	rs2006197	ENSG00000227373.4	RP11-160H22.5	5.03	1.66e-06	0.00175	0.44	0.41	Systemic lupus erythematosus;	chr1:174432825	chr1:174115300~174160004:-
TGCT	cis	rs899997	0.906	rs1994018	ENSG00000261143.1	ADAMTS7P3	-5.03	1.67e-06	0.00175	-0.53	-0.41	Coronary artery disease or large artery stroke;	chr15:78733242	chr15:77976042~77993057:+
TGCT	cis	rs8062405	0.824	rs4788083	ENSG00000259982.1	CDC37P1	5.03	1.67e-06	0.00176	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28700294~28701540:-
TGCT	cis	rs1799949	0.931	rs9891977	ENSG00000198496.9	NBR2	-5.03	1.67e-06	0.00176	-0.59	-0.41	Menopause (age at onset);	chr17:43360030	chr17:43125610~43153671:+
TGCT	cis	rs34217772	0.509	rs61990509	ENSG00000258536.1	RP11-1053O12.1	5.03	1.68e-06	0.00176	0.36	0.41	Myopia;	chr14:41973482	chr14:41742639~41742963:+
TGCT	cis	rs7617773	0.815	rs9825637	ENSG00000229759.1	MRPS18AP1	5.03	1.68e-06	0.00176	0.37	0.41	Coronary artery disease;	chr3:48330792	chr3:48256350~48256938:-
TGCT	cis	rs4423214	0.879	rs1792264	ENSG00000254682.1	RP11-660L16.2	-5.03	1.68e-06	0.00176	-0.63	-0.41	Vitamin D levels;	chr11:71439201	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.879	rs1630498	ENSG00000254682.1	RP11-660L16.2	-5.03	1.68e-06	0.00176	-0.63	-0.41	Vitamin D levels;	chr11:71439739	chr11:71448674~71452157:+
TGCT	cis	rs507080	0.922	rs12788848	ENSG00000255239.1	AP002954.6	5.03	1.68e-06	0.00176	0.55	0.41	Serum metabolite levels;	chr11:118683079	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.922	rs4474473	ENSG00000255239.1	AP002954.6	5.03	1.68e-06	0.00176	0.55	0.41	Serum metabolite levels;	chr11:118683180	chr11:118688039~118690600:-
TGCT	cis	rs11231017	0.514	rs953169	ENSG00000254454.2	RCC2P6	5.03	1.68e-06	0.00176	0.29	0.41	HIV-1 viral setpoint;	chr11:62316070	chr11:62371146~62373168:+
TGCT	cis	rs1061377	1	rs6829450	ENSG00000249207.1	RP11-360F5.1	-5.03	1.68e-06	0.00176	-0.42	-0.41	Uric acid levels;	chr4:39114721	chr4:39112677~39126818:-
TGCT	cis	rs9918079	0.542	rs12499412	ENSG00000273133.1	RP11-799M12.2	5.03	1.68e-06	0.00176	0.6	0.41	Obesity-related traits;	chr4:15600629	chr4:15563698~15564253:-
TGCT	cis	rs2919917	0.662	rs1483572	ENSG00000254352.1	RP11-578O24.2	5.03	1.68e-06	0.00177	0.44	0.41	Lymphocyte counts;	chr8:78723008	chr8:78723796~78724136:-
TGCT	cis	rs3091242	0.933	rs9438905	ENSG00000224183.1	SDHDP6	-5.03	1.68e-06	0.00177	-0.43	-0.41	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25294164~25294643:-
TGCT	cis	rs3091242	0.935	rs4233043	ENSG00000224183.1	SDHDP6	-5.03	1.68e-06	0.00177	-0.43	-0.41	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25294164~25294643:-
TGCT	cis	rs796364	0.906	rs1658810	ENSG00000232732.8	AC073043.1	-5.03	1.68e-06	0.00177	-0.59	-0.41	Schizophrenia;	chr2:199951659	chr2:199867396~199911159:-
TGCT	cis	rs507080	0.883	rs692750	ENSG00000255422.1	AP002954.4	-5.03	1.68e-06	0.00177	-0.47	-0.41	Serum metabolite levels;	chr11:118667599	chr11:118704607~118750263:+
TGCT	cis	rs8062405	0.824	rs240702	ENSG00000259982.1	CDC37P1	5.03	1.69e-06	0.00177	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28700294~28701540:-
TGCT	cis	rs7927592	0.731	rs2840367	ENSG00000212093.1	AP000807.1	-5.03	1.69e-06	0.00177	-0.39	-0.41	Total body bone mineral density;	chr11:68534633	chr11:68506083~68506166:-
TGCT	cis	rs7927592	0.763	rs7120876	ENSG00000212093.1	AP000807.1	5.03	1.69e-06	0.00177	0.4	0.41	Total body bone mineral density;	chr11:68493930	chr11:68506083~68506166:-
TGCT	cis	rs7927592	0.763	rs7129248	ENSG00000212093.1	AP000807.1	5.03	1.69e-06	0.00177	0.4	0.41	Total body bone mineral density;	chr11:68495808	chr11:68506083~68506166:-
TGCT	cis	rs4835473	0.932	rs10857415	ENSG00000251600.4	RP11-673E1.1	5.03	1.7e-06	0.00178	0.42	0.41	Immature fraction of reticulocytes;	chr4:143908753	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.618	rs12499429	ENSG00000251600.4	RP11-673E1.1	-5.03	1.7e-06	0.00178	-0.42	-0.41	Immature fraction of reticulocytes;	chr4:143889914	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.801	rs28715976	ENSG00000251600.4	RP11-673E1.1	-5.03	1.7e-06	0.00178	-0.42	-0.41	Immature fraction of reticulocytes;	chr4:143891603	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.838	rs12507468	ENSG00000251600.4	RP11-673E1.1	-5.03	1.7e-06	0.00178	-0.42	-0.41	Immature fraction of reticulocytes;	chr4:143908061	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1849135	ENSG00000251600.4	RP11-673E1.1	-5.03	1.7e-06	0.00178	-0.42	-0.41	Immature fraction of reticulocytes;	chr4:143912279	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1849136	ENSG00000251600.4	RP11-673E1.1	-5.03	1.7e-06	0.00178	-0.42	-0.41	Immature fraction of reticulocytes;	chr4:143912380	chr4:143912331~143982454:+
TGCT	cis	rs786425	0.627	rs35804181	ENSG00000278112.1	RP11-972P1.11	5.03	1.7e-06	0.00178	0.5	0.41	Pubertal anthropometrics;	chr12:123677797	chr12:123519390~123519856:-
TGCT	cis	rs3096299	0.738	rs9929606	ENSG00000274627.1	RP11-104N10.2	5.03	1.7e-06	0.00178	0.43	0.41	Multiple myeloma (IgH translocation);	chr16:89461129	chr16:89516797~89522217:+
TGCT	cis	rs7208859	0.623	rs8082537	ENSG00000266490.1	CTD-2349P21.9	5.03	1.7e-06	0.00179	0.45	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30792372~30792833:+
TGCT	cis	rs2412819	0.597	rs514311	ENSG00000205771.5	CATSPER2P1	-5.03	1.71e-06	0.00179	-0.64	-0.41	Lung cancer;	chr15:43869376	chr15:43726918~43747094:-
TGCT	cis	rs2412819	0.571	rs678084	ENSG00000205771.5	CATSPER2P1	5.03	1.71e-06	0.00179	0.64	0.41	Lung cancer;	chr15:43828361	chr15:43726918~43747094:-
TGCT	cis	rs2412819	0.571	rs2729494	ENSG00000205771.5	CATSPER2P1	5.03	1.71e-06	0.00179	0.64	0.41	Lung cancer;	chr15:43837395	chr15:43726918~43747094:-
TGCT	cis	rs2412819	0.571	rs528764	ENSG00000205771.5	CATSPER2P1	5.03	1.71e-06	0.00179	0.64	0.41	Lung cancer;	chr15:43838650	chr15:43726918~43747094:-
TGCT	cis	rs2412819	0.571	rs495880	ENSG00000205771.5	CATSPER2P1	5.03	1.71e-06	0.00179	0.64	0.41	Lung cancer;	chr15:43855067	chr15:43726918~43747094:-
TGCT	cis	rs7826238	0.535	rs2979179	ENSG00000173295.6	FAM86B3P	5.03	1.71e-06	0.00179	0.5	0.41	Systolic blood pressure;	chr8:8462519	chr8:8228595~8244865:+
TGCT	cis	rs7849270	0.879	rs10819461	ENSG00000268707.1	RP11-247A12.7	-5.03	1.71e-06	0.00179	-0.5	-0.41	Blood metabolite ratios;	chr9:129079608	chr9:129170434~129170940:+
TGCT	cis	rs9322193	0.884	rs11155675	ENSG00000216906.2	RP11-350J20.9	5.03	1.71e-06	0.00179	0.46	0.41	Lung cancer;	chr6:149742883	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.884	rs10872647	ENSG00000216906.2	RP11-350J20.9	5.03	1.71e-06	0.00179	0.46	0.41	Lung cancer;	chr6:149758687	chr6:149904243~149906418:+
TGCT	cis	rs7605378	1	rs2346662	ENSG00000232732.8	AC073043.1	-5.02	1.72e-06	0.0018	-0.47	-0.41	Osteoporosis;	chr2:199814435	chr2:199867396~199911159:-
TGCT	cis	rs1010254	0.51	rs17543712	ENSG00000213433.5	RPLP1P6	-5.02	1.72e-06	0.0018	-0.49	-0.41	Optic nerve measurement (cup area);	chr5:152335965	chr5:151765859~151766378:-
TGCT	cis	rs899997	1	rs11072793	ENSG00000261143.1	ADAMTS7P3	5.02	1.72e-06	0.0018	0.45	0.41	Coronary artery disease or large artery stroke;	chr15:78714100	chr15:77976042~77993057:+
TGCT	cis	rs4835473	0.932	rs4835013	ENSG00000251600.4	RP11-673E1.1	5.02	1.73e-06	0.00181	0.43	0.41	Immature fraction of reticulocytes;	chr4:143748485	chr4:143912331~143982454:+
TGCT	cis	rs911555	0.692	rs7140647	ENSG00000244691.1	RPL10AP1	5.02	1.73e-06	0.00181	0.56	0.41	Intelligence (multi-trait analysis);	chr14:103427128	chr14:103412119~103412761:-
TGCT	cis	rs2980439	0.525	rs1850511	ENSG00000173295.6	FAM86B3P	5.02	1.73e-06	0.00181	0.49	0.41	Neuroticism;	chr8:8312807	chr8:8228595~8244865:+
TGCT	cis	rs34779708	0.931	rs4934697	ENSG00000230534.5	RP11-297A16.2	5.02	1.73e-06	0.00181	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:34998264	chr10:35098006~35127020:-
TGCT	cis	rs57502260	0.573	rs11228295	ENSG00000212093.1	AP000807.1	5.02	1.73e-06	0.00181	0.42	0.41	Total body bone mineral density (age 45-60);	chr11:68621120	chr11:68506083~68506166:-
TGCT	cis	rs11168618	0.692	rs4760707	ENSG00000240399.1	RP1-228P16.1	5.02	1.74e-06	0.00182	0.4	0.41	Adiponectin levels;	chr12:48454857	chr12:48054813~48055591:-
TGCT	cis	rs6474412	0.789	rs6987704	ENSG00000255101.1	RP11-412B14.1	5.02	1.74e-06	0.00182	0.44	0.41	Smoking behavior;	chr8:42692480	chr8:42705583~42721946:-
TGCT	cis	rs66887589	0.616	rs11098497	ENSG00000245958.5	RP11-33B1.1	-5.02	1.74e-06	0.00182	-0.4	-0.41	Diastolic blood pressure;	chr4:119265913	chr4:119454791~119552025:+
TGCT	cis	rs66887589	0.616	rs11098498	ENSG00000245958.5	RP11-33B1.1	-5.02	1.74e-06	0.00182	-0.4	-0.41	Diastolic blood pressure;	chr4:119265964	chr4:119454791~119552025:+
TGCT	cis	rs66887589	0.616	rs10032299	ENSG00000245958.5	RP11-33B1.1	-5.02	1.74e-06	0.00182	-0.4	-0.41	Diastolic blood pressure;	chr4:119285264	chr4:119454791~119552025:+
TGCT	cis	rs66887589	0.616	rs7659403	ENSG00000245958.5	RP11-33B1.1	-5.02	1.74e-06	0.00182	-0.4	-0.41	Diastolic blood pressure;	chr4:119286099	chr4:119454791~119552025:+
TGCT	cis	rs73086581	0.838	rs73088424	ENSG00000229539.1	RP11-119B16.2	5.02	1.74e-06	0.00182	0.6	0.41	Response to antidepressants in depression;	chr20:4020359	chr20:3888239~3888868:-
TGCT	cis	rs10875976	0.525	rs7954572	ENSG00000242041.1	RP11-70F11.2	5.02	1.74e-06	0.00182	0.39	0.41	Obesity;	chr12:49859132	chr12:49863173~49863503:+
TGCT	cis	rs3020264	0.627	rs2912064	ENSG00000271743.1	CTD-2541M15.3	5.02	1.75e-06	0.00182	0.37	0.41	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6631189	chr8:6615604~6617198:-
TGCT	cis	rs2980439	0.557	rs2976876	ENSG00000173295.6	FAM86B3P	5.02	1.75e-06	0.00183	0.5	0.41	Neuroticism;	chr8:8461340	chr8:8228595~8244865:+
TGCT	cis	rs2980439	0.557	rs2921056	ENSG00000173295.6	FAM86B3P	5.02	1.75e-06	0.00183	0.5	0.41	Neuroticism;	chr8:8461672	chr8:8228595~8244865:+
TGCT	cis	rs7826238	0.524	rs2921055	ENSG00000173295.6	FAM86B3P	5.02	1.75e-06	0.00183	0.5	0.41	Systolic blood pressure;	chr8:8461832	chr8:8228595~8244865:+
TGCT	cis	rs9399135	0.773	rs1331308	ENSG00000232876.1	CTA-212D2.2	5.02	1.75e-06	0.00183	0.35	0.41	Red blood cell count;	chr6:135083984	chr6:135055033~135060550:+
TGCT	cis	rs507080	0.961	rs4457789	ENSG00000255422.1	AP002954.4	-5.02	1.75e-06	0.00183	-0.47	-0.41	Serum metabolite levels;	chr11:118668461	chr11:118704607~118750263:+
TGCT	cis	rs55794721	0.509	rs12027135	ENSG00000224183.1	SDHDP6	-5.02	1.75e-06	0.00183	-0.43	-0.41	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25294164~25294643:-
TGCT	cis	rs3091242	0.836	rs34997029	ENSG00000224183.1	SDHDP6	5.02	1.75e-06	0.00183	0.43	0.41	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25294164~25294643:-
TGCT	cis	rs5758659	0.652	rs5751195	ENSG00000270083.1	RP1-257I20.14	5.02	1.75e-06	0.00183	0.39	0.41	Cognitive function;	chr22:41983997	chr22:42089630~42090028:-
TGCT	cis	rs5758659	0.569	rs133293	ENSG00000270083.1	RP1-257I20.14	5.02	1.75e-06	0.00183	0.39	0.41	Cognitive function;	chr22:41986793	chr22:42089630~42090028:-
TGCT	cis	rs5758659	0.652	rs133301	ENSG00000270083.1	RP1-257I20.14	5.02	1.75e-06	0.00183	0.39	0.41	Cognitive function;	chr22:41994089	chr22:42089630~42090028:-
TGCT	cis	rs5758659	0.652	rs133305	ENSG00000270083.1	RP1-257I20.14	5.02	1.75e-06	0.00183	0.39	0.41	Cognitive function;	chr22:41999956	chr22:42089630~42090028:-
TGCT	cis	rs5758659	0.682	rs133306	ENSG00000270083.1	RP1-257I20.14	5.02	1.75e-06	0.00183	0.39	0.41	Cognitive function;	chr22:42000146	chr22:42089630~42090028:-
TGCT	cis	rs5758659	0.519	rs133307	ENSG00000270083.1	RP1-257I20.14	5.02	1.75e-06	0.00183	0.39	0.41	Cognitive function;	chr22:42000564	chr22:42089630~42090028:-
TGCT	cis	rs5758659	0.652	rs5758537	ENSG00000270083.1	RP1-257I20.14	5.02	1.75e-06	0.00183	0.39	0.41	Cognitive function;	chr22:42001038	chr22:42089630~42090028:-
TGCT	cis	rs5758659	0.622	rs129856	ENSG00000270083.1	RP1-257I20.14	5.02	1.75e-06	0.00183	0.39	0.41	Cognitive function;	chr22:42003392	chr22:42089630~42090028:-
TGCT	cis	rs5758659	0.652	rs133313	ENSG00000270083.1	RP1-257I20.14	5.02	1.75e-06	0.00183	0.39	0.41	Cognitive function;	chr22:42005745	chr22:42089630~42090028:-
TGCT	cis	rs5758659	0.652	rs133314	ENSG00000270083.1	RP1-257I20.14	5.02	1.75e-06	0.00183	0.39	0.41	Cognitive function;	chr22:42005837	chr22:42089630~42090028:-
TGCT	cis	rs5758659	0.652	rs133321	ENSG00000270083.1	RP1-257I20.14	5.02	1.75e-06	0.00183	0.39	0.41	Cognitive function;	chr22:42009318	chr22:42089630~42090028:-
TGCT	cis	rs5758659	0.652	rs133323	ENSG00000270083.1	RP1-257I20.14	5.02	1.75e-06	0.00183	0.39	0.41	Cognitive function;	chr22:42009918	chr22:42089630~42090028:-
TGCT	cis	rs5758659	0.652	rs133324	ENSG00000270083.1	RP1-257I20.14	5.02	1.75e-06	0.00183	0.39	0.41	Cognitive function;	chr22:42010367	chr22:42089630~42090028:-
TGCT	cis	rs5758659	0.652	rs133327	ENSG00000270083.1	RP1-257I20.14	5.02	1.75e-06	0.00183	0.39	0.41	Cognitive function;	chr22:42011685	chr22:42089630~42090028:-
TGCT	cis	rs5758659	0.652	rs133330	ENSG00000270083.1	RP1-257I20.14	5.02	1.75e-06	0.00183	0.39	0.41	Cognitive function;	chr22:42013452	chr22:42089630~42090028:-
TGCT	cis	rs5758659	0.652	rs129857	ENSG00000270083.1	RP1-257I20.14	-5.02	1.75e-06	0.00183	-0.39	-0.41	Cognitive function;	chr22:42003682	chr22:42089630~42090028:-
TGCT	cis	rs7617773	0.925	rs6442105	ENSG00000229759.1	MRPS18AP1	-5.02	1.75e-06	0.00183	-0.32	-0.41	Coronary artery disease;	chr3:48140836	chr3:48256350~48256938:-
TGCT	cis	rs9755467	0.656	rs62262338	ENSG00000221413.1	AC023593.1	5.02	1.76e-06	0.00183	0.67	0.41	Educational attainment (years of education);	chr3:127460905	chr3:127664704~127664810:+
TGCT	cis	rs4925386	0.759	rs2427293	ENSG00000273619.1	RP5-908M14.9	5.02	1.76e-06	0.00184	0.51	0.41	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62350803	chr20:62386303~62386970:-
TGCT	cis	rs453301	0.624	rs2288671	ENSG00000173295.6	FAM86B3P	5.02	1.76e-06	0.00184	0.49	0.41	Joint mobility (Beighton score);	chr8:9003384	chr8:8228595~8244865:+
TGCT	cis	rs6600671	0.719	rs9728991	ENSG00000275131.1	CH17-472G23.4	-5.02	1.77e-06	0.00184	-0.26	-0.41	Hip geometry;	chr1:121522281	chr1:120489625~120579190:-
TGCT	cis	rs8062405	0.755	rs17640009	ENSG00000259982.1	CDC37P1	5.02	1.77e-06	0.00185	0.58	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28700294~28701540:-
TGCT	cis	rs507080	0.769	rs571001	ENSG00000255422.1	AP002954.4	-5.02	1.78e-06	0.00185	-0.48	-0.41	Serum metabolite levels;	chr11:118629457	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.769	rs570952	ENSG00000255422.1	AP002954.4	-5.02	1.78e-06	0.00185	-0.48	-0.41	Serum metabolite levels;	chr11:118629477	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.769	rs645637	ENSG00000255422.1	AP002954.4	-5.02	1.78e-06	0.00185	-0.48	-0.41	Serum metabolite levels;	chr11:118634373	chr11:118704607~118750263:+
TGCT	cis	rs853679	0.55	rs9295762	ENSG00000219392.1	RP1-265C24.5	5.02	1.78e-06	0.00185	0.52	0.41	Depression;	chr6:28187640	chr6:28115628~28116551:+
TGCT	cis	rs7301826	1	rs10744482	ENSG00000256299.1	RP11-989F5.3	-5.02	1.79e-06	0.00186	-0.44	-0.41	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810821~130812622:-
TGCT	cis	rs7301826	0.966	rs4759795	ENSG00000256299.1	RP11-989F5.3	-5.02	1.79e-06	0.00186	-0.44	-0.41	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810821~130812622:-
TGCT	cis	rs7301826	1	rs2001483	ENSG00000256299.1	RP11-989F5.3	-5.02	1.79e-06	0.00186	-0.44	-0.41	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810821~130812622:-
TGCT	cis	rs10875746	0.951	rs2228500	ENSG00000240399.1	RP1-228P16.1	5.02	1.79e-06	0.00186	0.5	0.41	Longevity (90 years and older);	chr12:48132929	chr12:48054813~48055591:-
TGCT	cis	rs904251	0.504	rs12202664	ENSG00000279942.1	RP1-153P14.7	-5.01	1.79e-06	0.00186	-0.42	-0.41	Cognitive performance;	chr6:37513422	chr6:37567716~37571460:+
TGCT	cis	rs7617773	0.539	rs35460860	ENSG00000229759.1	MRPS18AP1	5.01	1.79e-06	0.00187	0.34	0.41	Coronary artery disease;	chr3:48350595	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.563	rs13082269	ENSG00000229759.1	MRPS18AP1	5.01	1.79e-06	0.00187	0.34	0.41	Coronary artery disease;	chr3:48350784	chr3:48256350~48256938:-
TGCT	cis	rs67311347	0.955	rs4974067	ENSG00000223797.4	ENTPD3-AS1	5.01	1.8e-06	0.00187	0.42	0.41	Renal cell carcinoma;	chr3:40333060	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs9865348	ENSG00000223797.4	ENTPD3-AS1	5.01	1.8e-06	0.00187	0.42	0.41	Renal cell carcinoma;	chr3:40356167	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs9849992	ENSG00000223797.4	ENTPD3-AS1	5.01	1.8e-06	0.00187	0.42	0.41	Renal cell carcinoma;	chr3:40360649	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs11715214	ENSG00000223797.4	ENTPD3-AS1	5.01	1.8e-06	0.00187	0.42	0.41	Renal cell carcinoma;	chr3:40361513	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs9860162	ENSG00000223797.4	ENTPD3-AS1	5.01	1.8e-06	0.00187	0.42	0.41	Renal cell carcinoma;	chr3:40362384	chr3:40313802~40453329:-
TGCT	cis	rs877819	0.552	rs2671710	ENSG00000228403.1	RP11-563N6.6	5.01	1.8e-06	0.00187	0.42	0.41	Systemic lupus erythematosus;	chr10:48886672	chr10:48878022~48878649:+
TGCT	cis	rs1320333	0.772	rs17786120	ENSG00000233296.1	AC092159.2	5.01	1.81e-06	0.00188	0.57	0.41	Obesity-related traits;	chr2:700580	chr2:677186~697371:+
TGCT	cis	rs7208859	0.524	rs8069400	ENSG00000263531.1	RP13-753N3.1	5.01	1.81e-06	0.00189	0.79	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30863921~30864940:-
TGCT	cis	rs4925386	1	rs2151512	ENSG00000273619.1	RP5-908M14.9	5.01	1.82e-06	0.00189	0.46	0.41	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62338439	chr20:62386303~62386970:-
TGCT	cis	rs17301013	0.93	rs6425279	ENSG00000227373.4	RP11-160H22.5	-5.01	1.82e-06	0.00189	-0.43	-0.41	Systemic lupus erythematosus;	chr1:174418717	chr1:174115300~174160004:-
TGCT	cis	rs9918079	0.58	rs13120905	ENSG00000273133.1	RP11-799M12.2	5.01	1.82e-06	0.00189	0.6	0.41	Obesity-related traits;	chr4:15610665	chr4:15563698~15564253:-
TGCT	cis	rs4835473	0.932	rs2323191	ENSG00000251600.4	RP11-673E1.1	-5.01	1.82e-06	0.0019	-0.41	-0.41	Immature fraction of reticulocytes;	chr4:143744472	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs1375982	ENSG00000251600.4	RP11-673E1.1	-5.01	1.82e-06	0.0019	-0.41	-0.41	Immature fraction of reticulocytes;	chr4:143745764	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs4835237	ENSG00000251600.4	RP11-673E1.1	-5.01	1.82e-06	0.0019	-0.41	-0.41	Immature fraction of reticulocytes;	chr4:143746349	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs56084616	ENSG00000251600.4	RP11-673E1.1	-5.01	1.82e-06	0.0019	-0.41	-0.41	Immature fraction of reticulocytes;	chr4:143746697	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.966	rs11722639	ENSG00000251600.4	RP11-673E1.1	-5.01	1.82e-06	0.0019	-0.41	-0.41	Immature fraction of reticulocytes;	chr4:143746884	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.966	rs11722673	ENSG00000251600.4	RP11-673E1.1	-5.01	1.82e-06	0.0019	-0.41	-0.41	Immature fraction of reticulocytes;	chr4:143746946	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs6821979	ENSG00000251600.4	RP11-673E1.1	-5.01	1.82e-06	0.0019	-0.41	-0.41	Immature fraction of reticulocytes;	chr4:143748091	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs6838887	ENSG00000251600.4	RP11-673E1.1	-5.01	1.82e-06	0.0019	-0.41	-0.41	Immature fraction of reticulocytes;	chr4:143748130	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1982392	ENSG00000251600.4	RP11-673E1.1	-5.01	1.82e-06	0.0019	-0.41	-0.41	Immature fraction of reticulocytes;	chr4:143748604	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1982393	ENSG00000251600.4	RP11-673E1.1	-5.01	1.82e-06	0.0019	-0.41	-0.41	Immature fraction of reticulocytes;	chr4:143748736	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs9683880	ENSG00000251600.4	RP11-673E1.1	-5.01	1.82e-06	0.0019	-0.41	-0.41	Immature fraction of reticulocytes;	chr4:143748787	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs7687976	ENSG00000251600.4	RP11-673E1.1	-5.01	1.82e-06	0.0019	-0.41	-0.41	Immature fraction of reticulocytes;	chr4:143749171	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs7683287	ENSG00000251600.4	RP11-673E1.1	-5.01	1.82e-06	0.0019	-0.41	-0.41	Immature fraction of reticulocytes;	chr4:143749270	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.712	rs2198000	ENSG00000251600.4	RP11-673E1.1	-5.01	1.82e-06	0.0019	-0.41	-0.41	Immature fraction of reticulocytes;	chr4:143750005	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs2198002	ENSG00000251600.4	RP11-673E1.1	-5.01	1.82e-06	0.0019	-0.41	-0.41	Immature fraction of reticulocytes;	chr4:143750028	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs6853460	ENSG00000251600.4	RP11-673E1.1	-5.01	1.82e-06	0.0019	-0.41	-0.41	Immature fraction of reticulocytes;	chr4:143750392	chr4:143912331~143982454:+
TGCT	cis	rs1799949	1	rs35668327	ENSG00000198496.9	NBR2	-5.01	1.83e-06	0.0019	-0.6	-0.41	Menopause (age at onset);	chr17:43121078	chr17:43125610~43153671:+
TGCT	cis	rs10504229	0.775	rs17804888	ENSG00000253301.4	RP11-513O17.2	-5.01	1.84e-06	0.00191	-0.58	-0.41	Developmental language disorder (linguistic errors);	chr8:57245756	chr8:57142689~57240298:+
TGCT	cis	rs67311347	0.869	rs6790495	ENSG00000223797.4	ENTPD3-AS1	5.01	1.85e-06	0.00192	0.42	0.41	Renal cell carcinoma;	chr3:40325279	chr3:40313802~40453329:-
TGCT	cis	rs67311347	0.869	rs7646899	ENSG00000223797.4	ENTPD3-AS1	5.01	1.85e-06	0.00192	0.42	0.41	Renal cell carcinoma;	chr3:40325491	chr3:40313802~40453329:-
TGCT	cis	rs8059260	0.541	rs34361212	ENSG00000274038.1	RP11-66H6.4	-5.01	1.85e-06	0.00192	-0.57	-0.41	Alcohol consumption over the past year;	chr16:11145832	chr16:11056556~11057034:+
TGCT	cis	rs2412819	0.571	rs17727853	ENSG00000205771.5	CATSPER2P1	-5.01	1.85e-06	0.00192	-0.62	-0.41	Lung cancer;	chr15:43630299	chr15:43726918~43747094:-
TGCT	cis	rs2412819	0.571	rs62018900	ENSG00000205771.5	CATSPER2P1	-5.01	1.85e-06	0.00192	-0.62	-0.41	Lung cancer;	chr15:43633252	chr15:43726918~43747094:-
TGCT	cis	rs2412819	0.545	rs35333173	ENSG00000205771.5	CATSPER2P1	-5.01	1.85e-06	0.00192	-0.62	-0.41	Lung cancer;	chr15:43640818	chr15:43726918~43747094:-
TGCT	cis	rs2412819	0.571	rs112667279	ENSG00000205771.5	CATSPER2P1	-5.01	1.85e-06	0.00192	-0.62	-0.41	Lung cancer;	chr15:43649258	chr15:43726918~43747094:-
TGCT	cis	rs2764208	0.86	rs205286	ENSG00000186328.4	RP11-140K17.2	5.01	1.86e-06	0.00193	0.38	0.41	Systemic lupus erythematosus;	chr6:34583557	chr6:34715613~34715940:+
TGCT	cis	rs875971	0.505	rs2462573	ENSG00000237310.1	GS1-124K5.4	-5.01	1.86e-06	0.00193	-0.45	-0.41	Aortic root size;	chr7:66042405	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.505	rs1167385	ENSG00000237310.1	GS1-124K5.4	-5.01	1.86e-06	0.00193	-0.45	-0.41	Aortic root size;	chr7:66048321	chr7:66493706~66495474:+
TGCT	cis	rs17711722	0.565	rs4275112	ENSG00000236529.1	RP13-254B10.1	-5.01	1.86e-06	0.00193	-0.3	-0.41	Calcium levels;	chr7:65733651	chr7:65840212~65840596:+
TGCT	cis	rs1823913	0.927	rs13025919	ENSG00000280083.1	RP11-317J9.1	-5	1.87e-06	0.00194	-0.35	-0.41	Obesity-related traits;	chr2:191260175	chr2:191154118~191156070:-
TGCT	cis	rs847851	0.617	rs9368844	ENSG00000186328.4	RP11-140K17.2	5	1.87e-06	0.00194	0.57	0.41	Colonoscopy-negative controls vs population controls;	chr6:35010253	chr6:34715613~34715940:+
TGCT	cis	rs8062405	0.754	rs151179	ENSG00000259982.1	CDC37P1	5	1.88e-06	0.00194	0.54	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28700294~28701540:-
TGCT	cis	rs2976388	0.632	rs2585139	ENSG00000253196.1	RP11-706C16.7	5	1.88e-06	0.00194	0.41	0.41	Urinary tract infection frequency;	chr8:142726757	chr8:142763116~142766427:+
TGCT	cis	rs1387259	0.69	rs1601985	ENSG00000258273.1	RP11-370I10.4	-5	1.88e-06	0.00194	-0.49	-0.41	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48333755~48333901:-
TGCT	cis	rs1799949	0.965	rs799916	ENSG00000198496.9	NBR2	5	1.88e-06	0.00195	0.53	0.41	Menopause (age at onset);	chr17:43091173	chr17:43125610~43153671:+
TGCT	cis	rs1075265	0.584	rs1862121	ENSG00000233266.1	HMGB1P31	5	1.89e-06	0.00195	0.45	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54058102	chr2:54051334~54051760:+
TGCT	cis	rs7208859	0.623	rs9895785	ENSG00000280069.1	CTD-2349P21.3	5	1.89e-06	0.00196	0.58	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30738182~30740275:+
TGCT	cis	rs875971	0.83	rs778711	ENSG00000232559.3	GS1-124K5.12	5	1.9e-06	0.00196	0.37	0.41	Aortic root size;	chr7:66386670	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs1083554	ENSG00000232559.3	GS1-124K5.12	5	1.9e-06	0.00196	0.37	0.41	Aortic root size;	chr7:66387354	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs778707	ENSG00000232559.3	GS1-124K5.12	5	1.9e-06	0.00196	0.37	0.41	Aortic root size;	chr7:66392040	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs778705	ENSG00000232559.3	GS1-124K5.12	5	1.9e-06	0.00196	0.37	0.41	Aortic root size;	chr7:66396128	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs778697	ENSG00000232559.3	GS1-124K5.12	5	1.9e-06	0.00196	0.37	0.41	Aortic root size;	chr7:66405439	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.798	rs7789615	ENSG00000232559.3	GS1-124K5.12	5	1.9e-06	0.00196	0.37	0.41	Aortic root size;	chr7:66413674	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs6978028	ENSG00000232559.3	GS1-124K5.12	5	1.9e-06	0.00196	0.37	0.41	Aortic root size;	chr7:66421313	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs6947339	ENSG00000232559.3	GS1-124K5.12	5	1.9e-06	0.00196	0.37	0.41	Aortic root size;	chr7:66423483	chr7:66554588~66576923:-
TGCT	cis	rs8062405	0.789	rs240704	ENSG00000259982.1	CDC37P1	5	1.9e-06	0.00196	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28700294~28701540:-
TGCT	cis	rs507080	0.922	rs12796373	ENSG00000255422.1	AP002954.4	-5	1.9e-06	0.00197	-0.48	-0.41	Serum metabolite levels;	chr11:118684230	chr11:118704607~118750263:+
TGCT	cis	rs875971	0.862	rs7783779	ENSG00000232559.3	GS1-124K5.12	-5	1.9e-06	0.00197	-0.37	-0.41	Aortic root size;	chr7:66331639	chr7:66554588~66576923:-
TGCT	cis	rs9326248	1	rs3736120	ENSG00000280143.1	AP000892.6	5	1.9e-06	0.00197	0.54	0.41	Blood protein levels;	chr11:117161409	chr11:117204967~117210292:+
TGCT	cis	rs9326248	0.53	rs588918	ENSG00000254851.1	RP11-109L13.1	-5	1.91e-06	0.00198	-0.69	-0.41	Blood protein levels;	chr11:116985926	chr11:117135528~117138582:+
TGCT	cis	rs9326248	0.954	rs4938349	ENSG00000280143.1	AP000892.6	5	1.91e-06	0.00198	0.54	0.41	Blood protein levels;	chr11:117151207	chr11:117204967~117210292:+
TGCT	cis	rs6600671	0.899	rs2319971	ENSG00000275131.1	CH17-472G23.4	-5	1.92e-06	0.00198	-0.27	-0.41	Hip geometry;	chr1:121485184	chr1:120489625~120579190:-
TGCT	cis	rs4563143	0.675	rs56322221	ENSG00000267243.4	AC005307.3	-5	1.92e-06	0.00198	-0.51	-0.41	Methadone dose in opioid dependence;	chr19:28779442	chr19:28435388~28727777:-
TGCT	cis	rs4563143	0.675	rs56293553	ENSG00000267243.4	AC005307.3	-5	1.92e-06	0.00198	-0.51	-0.41	Methadone dose in opioid dependence;	chr19:28779548	chr19:28435388~28727777:-
TGCT	cis	rs4563143	0.675	rs34113156	ENSG00000267243.4	AC005307.3	-5	1.92e-06	0.00198	-0.51	-0.41	Methadone dose in opioid dependence;	chr19:28779915	chr19:28435388~28727777:-
TGCT	cis	rs4563143	0.675	rs73029049	ENSG00000267243.4	AC005307.3	-5	1.92e-06	0.00198	-0.51	-0.41	Methadone dose in opioid dependence;	chr19:28784627	chr19:28435388~28727777:-
TGCT	cis	rs507080	0.922	rs4938524	ENSG00000255422.1	AP002954.4	-5	1.92e-06	0.00199	-0.5	-0.41	Serum metabolite levels;	chr11:118681365	chr11:118704607~118750263:+
TGCT	cis	rs34779708	0.966	rs10827492	ENSG00000230534.5	RP11-297A16.2	-5	1.92e-06	0.00199	-0.48	-0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35140897	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs12761675	ENSG00000230534.5	RP11-297A16.2	-5	1.92e-06	0.00199	-0.48	-0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35149409	chr10:35098006~35127020:-
TGCT	cis	rs34217772	0.883	rs12435558	ENSG00000258536.1	RP11-1053O12.1	5	1.93e-06	0.00199	0.39	0.41	Myopia;	chr14:41759255	chr14:41742639~41742963:+
TGCT	cis	rs7115242	0.748	rs1035237	ENSG00000254851.1	RP11-109L13.1	-5	1.93e-06	0.00199	-0.72	-0.41	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116857134	chr11:117135528~117138582:+
TGCT	cis	rs7927592	0.731	rs643609	ENSG00000212093.1	AP000807.1	5	1.93e-06	0.002	0.4	0.41	Total body bone mineral density;	chr11:68474365	chr11:68506083~68506166:-
TGCT	cis	rs7927592	0.763	rs596494	ENSG00000212093.1	AP000807.1	5	1.93e-06	0.002	0.4	0.41	Total body bone mineral density;	chr11:68483586	chr11:68506083~68506166:-
TGCT	cis	rs6017291	1	rs6017291	ENSG00000223891.4	OSER1-AS1	5	1.94e-06	0.002	0.6	0.41	Cognitive performance;	chr20:44225494	chr20:44210960~44226027:+
TGCT	cis	rs853679	0.517	rs3757185	ENSG00000219392.1	RP1-265C24.5	-5	1.94e-06	0.002	-0.56	-0.41	Depression;	chr6:28139998	chr6:28115628~28116551:+
TGCT	cis	rs4835473	0.932	rs11724752	ENSG00000251600.4	RP11-673E1.1	-5	1.94e-06	0.002	-0.42	-0.41	Immature fraction of reticulocytes;	chr4:143769473	chr4:143912331~143982454:+
TGCT	cis	rs7804306	1	rs73049239	ENSG00000233264.2	AC006042.8	5	1.94e-06	0.00201	0.96	0.41	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7967322	chr7:7980312~7982228:+
TGCT	cis	rs9326248	1	rs7946257	ENSG00000280143.1	AP000892.6	5	1.95e-06	0.00201	0.53	0.41	Blood protein levels;	chr11:117182449	chr11:117204967~117210292:+
TGCT	cis	rs7684253	0.587	rs9685436	ENSG00000269949.1	RP11-738E22.3	-5	1.95e-06	0.00201	-0.4	-0.41	Migraine;	chr4:56881195	chr4:56960927~56961373:-
TGCT	cis	rs2492301	0.506	rs11264049	ENSG00000233621.1	LINC01137	5	1.95e-06	0.00201	0.34	0.41	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr1:37436534	chr1:37454879~37474411:-
TGCT	cis	rs2276314	0.802	rs58906216	ENSG00000278986.1	RP11-723J4.3	-4.99	1.95e-06	0.00201	-0.47	-0.41	Endometriosis;Drug-induced torsades de pointes;	chr18:36050334	chr18:35972151~35973916:+
TGCT	cis	rs2276314	0.857	rs6507157	ENSG00000278986.1	RP11-723J4.3	-4.99	1.95e-06	0.00201	-0.47	-0.41	Endometriosis;Drug-induced torsades de pointes;	chr18:36051740	chr18:35972151~35973916:+
TGCT	cis	rs904251	0.504	rs9380677	ENSG00000279942.1	RP1-153P14.7	-4.99	1.95e-06	0.00201	-0.42	-0.41	Cognitive performance;	chr6:37512590	chr6:37567716~37571460:+
TGCT	cis	rs35160687	0.901	rs6714362	ENSG00000273080.1	RP11-301O19.1	-4.99	1.96e-06	0.00202	-0.46	-0.41	Night sleep phenotypes;	chr2:86249465	chr2:86195590~86196049:+
TGCT	cis	rs17711722	0.565	rs4717276	ENSG00000236529.1	RP13-254B10.1	4.99	1.96e-06	0.00202	0.29	0.41	Calcium levels;	chr7:65829754	chr7:65840212~65840596:+
TGCT	cis	rs2015599	0.623	rs3782510	ENSG00000257176.2	RP11-996F15.2	4.99	1.96e-06	0.00202	0.44	0.41	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29280418~29317848:-
TGCT	cis	rs17361889	0.727	rs61282805	ENSG00000224683.1	RPL36AP29	4.99	1.96e-06	0.00202	0.44	0.41	Pediatric bone mineral content (hip);	chr7:16236981	chr7:16208945~16209265:+
TGCT	cis	rs34779708	0.897	rs4934716	ENSG00000230534.5	RP11-297A16.2	4.99	1.96e-06	0.00202	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35080371	chr10:35098006~35127020:-
TGCT	cis	rs7829975	0.711	rs12682352	ENSG00000173295.6	FAM86B3P	4.99	1.96e-06	0.00202	0.49	0.41	Mood instability;	chr8:8788736	chr8:8228595~8244865:+
TGCT	cis	rs66887589	0.87	rs10518336	ENSG00000245958.5	RP11-33B1.1	-4.99	1.96e-06	0.00202	-0.41	-0.41	Diastolic blood pressure;	chr4:119601779	chr4:119454791~119552025:+
TGCT	cis	rs7829975	0.501	rs2980769	ENSG00000173295.6	FAM86B3P	4.99	1.97e-06	0.00203	0.5	0.41	Mood instability;	chr8:8462781	chr8:8228595~8244865:+
TGCT	cis	rs801193	0.844	rs2244022	ENSG00000237310.1	GS1-124K5.4	4.99	1.97e-06	0.00203	0.45	0.41	Aortic root size;	chr7:66737443	chr7:66493706~66495474:+
TGCT	cis	rs1618992	0.729	rs17679153	ENSG00000265994.1	RP11-510D21.1	4.99	1.97e-06	0.00203	0.41	0.41	Gut microbiome composition (summer and winter);	chr18:28601429	chr18:28785068~28789260:+
TGCT	cis	rs1618992	0.703	rs8095028	ENSG00000265994.1	RP11-510D21.1	4.99	1.97e-06	0.00203	0.41	0.41	Gut microbiome composition (summer and winter);	chr18:28602541	chr18:28785068~28789260:+
TGCT	cis	rs67311347	1	rs73078164	ENSG00000223797.4	ENTPD3-AS1	4.99	1.97e-06	0.00203	0.44	0.41	Renal cell carcinoma;	chr3:40438798	chr3:40313802~40453329:-
TGCT	cis	rs5758659	0.652	rs133326	ENSG00000270083.1	RP1-257I20.14	4.99	1.98e-06	0.00204	0.4	0.41	Cognitive function;	chr22:42010881	chr22:42089630~42090028:-
TGCT	cis	rs5758659	0.652	rs133336	ENSG00000270083.1	RP1-257I20.14	4.99	1.98e-06	0.00204	0.4	0.41	Cognitive function;	chr22:42020299	chr22:42089630~42090028:-
TGCT	cis	rs5758659	0.652	rs133340	ENSG00000270083.1	RP1-257I20.14	-4.99	1.98e-06	0.00204	-0.4	-0.41	Cognitive function;	chr22:42021683	chr22:42089630~42090028:-
TGCT	cis	rs507080	0.922	rs12788848	ENSG00000255422.1	AP002954.4	-4.99	1.98e-06	0.00204	-0.5	-0.41	Serum metabolite levels;	chr11:118683079	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.922	rs4474473	ENSG00000255422.1	AP002954.4	-4.99	1.98e-06	0.00204	-0.5	-0.41	Serum metabolite levels;	chr11:118683180	chr11:118704607~118750263:+
TGCT	cis	rs7208859	0.673	rs1347360	ENSG00000280069.1	CTD-2349P21.3	-4.99	1.98e-06	0.00204	-0.56	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30738182~30740275:+
TGCT	cis	rs11157436	0.958	rs17183356	ENSG00000211813.2	TRAV34	4.99	1.98e-06	0.00204	0.44	0.41	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22219101	chr14:22207522~22208129:+
TGCT	cis	rs4835473	0.932	rs17018500	ENSG00000251600.4	RP11-673E1.1	-4.99	1.99e-06	0.00205	-0.4	-0.41	Immature fraction of reticulocytes;	chr4:143824849	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs2218791	ENSG00000251600.4	RP11-673E1.1	-4.99	1.99e-06	0.00205	-0.38	-0.41	Immature fraction of reticulocytes;	chr4:143749300	chr4:143912331~143982454:+
TGCT	cis	rs4423214	0.765	rs2002064	ENSG00000254682.1	RP11-660L16.2	-4.99	1.99e-06	0.00205	-0.62	-0.41	Vitamin D levels;	chr11:71452374	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.84	rs1792315	ENSG00000254682.1	RP11-660L16.2	-4.99	1.99e-06	0.00205	-0.62	-0.41	Vitamin D levels;	chr11:71454501	chr11:71448674~71452157:+
TGCT	cis	rs6604026	0.778	rs11164820	ENSG00000223787.2	RP4-593M8.1	-4.99	2.01e-06	0.00206	-0.61	-0.41	Multiple sclerosis;	chr1:92815231	chr1:92580476~92580821:-
TGCT	cis	rs4835473	0.778	rs6856553	ENSG00000251600.4	RP11-673E1.1	-4.99	2.01e-06	0.00207	-0.4	-0.41	Immature fraction of reticulocytes;	chr4:143825973	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.808	rs1984810	ENSG00000251600.4	RP11-673E1.1	4.99	2.01e-06	0.00207	0.4	0.41	Immature fraction of reticulocytes;	chr4:143824970	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.831	rs1984809	ENSG00000251600.4	RP11-673E1.1	4.99	2.01e-06	0.00207	0.4	0.41	Immature fraction of reticulocytes;	chr4:143825018	chr4:143912331~143982454:+
TGCT	cis	rs7208859	0.673	rs216411	ENSG00000266490.1	CTD-2349P21.9	-4.99	2.01e-06	0.00207	-0.45	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576475	chr17:30792372~30792833:+
TGCT	cis	rs4970988	0.607	rs7548516	ENSG00000206931.1	RNU6-1042P	-4.99	2.01e-06	0.00207	-0.36	-0.41	Urate levels;	chr1:151007805	chr1:150701866~150701972:+
TGCT	cis	rs673078	0.607	rs61943388	ENSG00000275759.1	RP11-131L12.3	-4.99	2.01e-06	0.00207	-0.75	-0.41	Glucose homeostasis traits;	chr12:118374590	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs61943389	ENSG00000275759.1	RP11-131L12.3	-4.99	2.01e-06	0.00207	-0.75	-0.41	Glucose homeostasis traits;	chr12:118377467	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs7299040	ENSG00000275759.1	RP11-131L12.3	-4.99	2.01e-06	0.00207	-0.75	-0.41	Glucose homeostasis traits;	chr12:118380660	chr12:118428281~118428870:+
TGCT	cis	rs1707322	0.627	rs3014213	ENSG00000280836.1	AL355480.1	4.99	2.02e-06	0.00208	0.58	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.686	rs2152078	ENSG00000280836.1	AL355480.1	4.99	2.02e-06	0.00208	0.58	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.686	rs2991979	ENSG00000280836.1	AL355480.1	4.99	2.02e-06	0.00208	0.58	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45581219~45581321:-
TGCT	cis	rs4835473	0.897	rs4835333	ENSG00000251600.4	RP11-673E1.1	-4.99	2.03e-06	0.00208	-0.41	-0.41	Immature fraction of reticulocytes;	chr4:143703174	chr4:143912331~143982454:+
TGCT	cis	rs651907	0.535	rs11919389	ENSG00000244119.1	PDCL3P4	4.99	2.03e-06	0.00208	0.3	0.41	Colorectal cancer;	chr3:101705614	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.514	rs55654108	ENSG00000244119.1	PDCL3P4	4.99	2.03e-06	0.00208	0.3	0.41	Colorectal cancer;	chr3:101706859	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.535	rs13059470	ENSG00000244119.1	PDCL3P4	-4.99	2.03e-06	0.00208	-0.3	-0.41	Colorectal cancer;	chr3:101705956	chr3:101712472~101713191:+
TGCT	cis	rs8059260	0.668	rs7199305	ENSG00000274038.1	RP11-66H6.4	4.99	2.03e-06	0.00209	0.59	0.41	Alcohol consumption over the past year;	chr16:11006476	chr16:11056556~11057034:+
TGCT	cis	rs17361889	0.634	rs6954901	ENSG00000224683.1	RPL36AP29	-4.99	2.03e-06	0.00209	-0.41	-0.41	Pediatric bone mineral content (hip);	chr7:16267078	chr7:16208945~16209265:+
TGCT	cis	rs7208859	0.673	rs73263981	ENSG00000266490.1	CTD-2349P21.9	4.99	2.03e-06	0.00209	0.44	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.524	rs73263982	ENSG00000266490.1	CTD-2349P21.9	4.99	2.03e-06	0.00209	0.44	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs216433	ENSG00000266490.1	CTD-2349P21.9	4.99	2.03e-06	0.00209	0.44	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs216435	ENSG00000266490.1	CTD-2349P21.9	4.99	2.03e-06	0.00209	0.44	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30792372~30792833:+
TGCT	cis	rs10875976	0.525	rs10783323	ENSG00000242041.1	RP11-70F11.2	4.99	2.03e-06	0.00209	0.4	0.41	Obesity;	chr12:49860365	chr12:49863173~49863503:+
TGCT	cis	rs7208859	0.562	rs216408	ENSG00000266490.1	CTD-2349P21.9	-4.99	2.03e-06	0.00209	-0.43	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs1347359	ENSG00000266490.1	CTD-2349P21.9	4.99	2.03e-06	0.00209	0.43	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30792372~30792833:+
TGCT	cis	rs853679	0.517	rs1904841	ENSG00000219392.1	RP1-265C24.5	-4.99	2.04e-06	0.00209	-0.56	-0.41	Depression;	chr6:28140307	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs1904840	ENSG00000219392.1	RP1-265C24.5	-4.99	2.04e-06	0.00209	-0.56	-0.41	Depression;	chr6:28140454	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9368555	ENSG00000219392.1	RP1-265C24.5	-4.99	2.04e-06	0.00209	-0.56	-0.41	Depression;	chr6:28141189	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9393893	ENSG00000219392.1	RP1-265C24.5	-4.99	2.04e-06	0.00209	-0.56	-0.41	Depression;	chr6:28141484	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs868987	ENSG00000219392.1	RP1-265C24.5	4.99	2.04e-06	0.00209	0.56	0.41	Depression;	chr6:28142370	chr6:28115628~28116551:+
TGCT	cis	rs972540	1	rs62195931	ENSG00000279220.1	GPR1-AS	4.98	2.04e-06	0.00209	0.42	0.41	Body mass index;	chr2:206389551	chr2:206203376~206266243:+
TGCT	cis	rs972540	0.961	rs59825268	ENSG00000279220.1	GPR1-AS	4.98	2.04e-06	0.00209	0.42	0.41	Body mass index;	chr2:206392509	chr2:206203376~206266243:+
TGCT	cis	rs34779708	0.931	rs4007289	ENSG00000230534.5	RP11-297A16.2	4.98	2.04e-06	0.00209	0.49	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:34980862	chr10:35098006~35127020:-
TGCT	cis	rs7617773	0.823	rs9839446	ENSG00000229759.1	MRPS18AP1	-4.98	2.04e-06	0.00209	-0.32	-0.41	Coronary artery disease;	chr3:48153176	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.823	rs9839447	ENSG00000229759.1	MRPS18AP1	-4.98	2.04e-06	0.00209	-0.32	-0.41	Coronary artery disease;	chr3:48153177	chr3:48256350~48256938:-
TGCT	cis	rs3096299	0.933	rs2965934	ENSG00000274627.1	RP11-104N10.2	4.98	2.04e-06	0.0021	0.42	0.41	Multiple myeloma (IgH translocation);	chr16:89414821	chr16:89516797~89522217:+
TGCT	cis	rs4835473	0.932	rs1973608	ENSG00000251600.4	RP11-673E1.1	4.98	2.05e-06	0.0021	0.42	0.41	Immature fraction of reticulocytes;	chr4:143913057	chr4:143912331~143982454:+
TGCT	cis	rs2483374	0.725	rs1981053	ENSG00000253771.4	TPTE2P1	-4.98	2.05e-06	0.0021	-0.42	-0.41	Obesity-related traits;	chr13:24958140	chr13:24924677~24968487:-
TGCT	cis	rs4841097	0.806	rs6992247	ENSG00000254340.1	RP11-10A14.3	4.98	2.05e-06	0.00211	0.48	0.41	Platelet distribution width;	chr8:9090959	chr8:9141424~9145435:+
TGCT	cis	rs9918079	0.56	rs7685083	ENSG00000273133.1	RP11-799M12.2	4.98	2.06e-06	0.00211	0.6	0.41	Obesity-related traits;	chr4:15609148	chr4:15563698~15564253:-
TGCT	cis	rs4835473	0.868	rs62337291	ENSG00000251600.4	RP11-673E1.1	-4.98	2.06e-06	0.00211	-0.41	-0.41	Immature fraction of reticulocytes;	chr4:143807903	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs13121861	ENSG00000251600.4	RP11-673E1.1	-4.98	2.06e-06	0.00211	-0.41	-0.41	Immature fraction of reticulocytes;	chr4:143814007	chr4:143912331~143982454:+
TGCT	cis	rs34779708	0.897	rs4934527	ENSG00000230534.5	RP11-297A16.2	4.98	2.07e-06	0.00212	0.49	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:34992190	chr10:35098006~35127020:-
TGCT	cis	rs972540	1	rs6751830	ENSG00000279220.1	GPR1-AS	4.98	2.07e-06	0.00212	0.4	0.41	Body mass index;	chr2:206396246	chr2:206203376~206266243:+
TGCT	cis	rs67311347	0.955	rs9821036	ENSG00000223797.4	ENTPD3-AS1	4.98	2.07e-06	0.00212	0.42	0.41	Renal cell carcinoma;	chr3:40337516	chr3:40313802~40453329:-
TGCT	cis	rs67311347	0.869	rs9832311	ENSG00000223797.4	ENTPD3-AS1	4.98	2.07e-06	0.00212	0.42	0.41	Renal cell carcinoma;	chr3:40339831	chr3:40313802~40453329:-
TGCT	cis	rs17301013	0.861	rs1793319	ENSG00000227373.4	RP11-160H22.5	4.98	2.08e-06	0.00213	0.47	0.41	Systemic lupus erythematosus;	chr1:174795470	chr1:174115300~174160004:-
TGCT	cis	rs8091660	0.929	rs12456253	ENSG00000278983.1	RP11-426J5.3	-4.98	2.08e-06	0.00213	-0.48	-0.41	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550603	chr18:48564795~48568342:+
TGCT	cis	rs4713118	0.621	rs4713132	ENSG00000219392.1	RP1-265C24.5	-4.98	2.08e-06	0.00213	-0.53	-0.41	Parkinson's disease;	chr6:28066257	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.621	rs4713133	ENSG00000219392.1	RP1-265C24.5	-4.98	2.08e-06	0.00213	-0.53	-0.41	Parkinson's disease;	chr6:28066263	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.621	rs4713134	ENSG00000219392.1	RP1-265C24.5	-4.98	2.08e-06	0.00213	-0.53	-0.41	Parkinson's disease;	chr6:28066343	chr6:28115628~28116551:+
TGCT	cis	rs728616	0.614	rs35193855	ENSG00000230091.5	TMEM254-AS1	4.98	2.09e-06	0.00213	0.71	0.41	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80028739	chr10:80046860~80078912:-
TGCT	cis	rs1061377	1	rs3796509	ENSG00000249685.1	RP11-360F5.3	4.98	2.09e-06	0.00213	0.38	0.41	Uric acid levels;	chr4:39108566	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs4974998	ENSG00000249685.1	RP11-360F5.3	4.98	2.09e-06	0.00213	0.38	0.41	Uric acid levels;	chr4:39109129	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs7673299	ENSG00000249685.1	RP11-360F5.3	4.98	2.09e-06	0.00213	0.38	0.41	Uric acid levels;	chr4:39109138	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs4974997	ENSG00000249685.1	RP11-360F5.3	4.98	2.09e-06	0.00213	0.38	0.41	Uric acid levels;	chr4:39109151	chr4:39133913~39135608:+
TGCT	cis	rs2412819	0.597	rs541871	ENSG00000205771.5	CATSPER2P1	-4.98	2.09e-06	0.00213	-0.64	-0.41	Lung cancer;	chr15:43868656	chr15:43726918~43747094:-
TGCT	cis	rs4563143	0.675	rs55884228	ENSG00000267243.4	AC005307.3	-4.98	2.09e-06	0.00213	-0.5	-0.41	Methadone dose in opioid dependence;	chr19:28752990	chr19:28435388~28727777:-
TGCT	cis	rs4563143	0.675	rs73025085	ENSG00000267243.4	AC005307.3	-4.98	2.09e-06	0.00213	-0.5	-0.41	Methadone dose in opioid dependence;	chr19:28756111	chr19:28435388~28727777:-
TGCT	cis	rs4563143	0.675	rs56123392	ENSG00000267243.4	AC005307.3	-4.98	2.09e-06	0.00213	-0.5	-0.41	Methadone dose in opioid dependence;	chr19:28764724	chr19:28435388~28727777:-
TGCT	cis	rs4563143	0.647	rs73029014	ENSG00000267243.4	AC005307.3	-4.98	2.09e-06	0.00213	-0.5	-0.41	Methadone dose in opioid dependence;	chr19:28766748	chr19:28435388~28727777:-
TGCT	cis	rs4563143	0.675	rs112383987	ENSG00000267243.4	AC005307.3	-4.98	2.09e-06	0.00213	-0.5	-0.41	Methadone dose in opioid dependence;	chr19:28770174	chr19:28435388~28727777:-
TGCT	cis	rs4563143	0.675	rs55976444	ENSG00000267243.4	AC005307.3	-4.98	2.09e-06	0.00213	-0.5	-0.41	Methadone dose in opioid dependence;	chr19:28774307	chr19:28435388~28727777:-
TGCT	cis	rs4563143	0.675	rs73029042	ENSG00000267243.4	AC005307.3	-4.98	2.09e-06	0.00213	-0.5	-0.41	Methadone dose in opioid dependence;	chr19:28777072	chr19:28435388~28727777:-
TGCT	cis	rs8022179	0.58	rs8013228	ENSG00000244691.1	RPL10AP1	-4.98	2.1e-06	0.00214	-0.58	-0.41	Monocyte count;	chr14:103376313	chr14:103412119~103412761:-
TGCT	cis	rs9326248	0.53	rs2155583	ENSG00000254851.1	RP11-109L13.1	-4.98	2.1e-06	0.00214	-0.81	-0.41	Blood protein levels;	chr11:117044501	chr11:117135528~117138582:+
TGCT	cis	rs853679	0.517	rs9393891	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Depression;	chr6:28111382	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9468286	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Depression;	chr6:28111650	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.516	rs7739216	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Parkinson's disease;	chr6:28112168	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs35512245	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Depression;	chr6:28112175	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.542	rs9393892	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Depression;	chr6:28113616	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9380055	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Depression;	chr6:28113851	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9368553	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Depression;	chr6:28114487	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9368554	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Depression;	chr6:28114933	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs4713137	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Depression;	chr6:28115743	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9348793	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Depression;	chr6:28116411	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.586	rs6905516	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Parkinson's disease;	chr6:28118700	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.586	rs6905522	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Parkinson's disease;	chr6:28118701	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.586	rs9468290	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Parkinson's disease;	chr6:28119896	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.542	rs6934769	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Depression;	chr6:28123153	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs17711801	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Depression;	chr6:28124529	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs6922063	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Depression;	chr6:28126588	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs2275508	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Depression;	chr6:28126953	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.527	rs9461433	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Parkinson's disease;	chr6:28127394	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9468292	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Depression;	chr6:28127577	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs1947863	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Depression;	chr6:28131566	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs4713141	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Depression;	chr6:28133900	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9380056	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Depression;	chr6:28136698	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9380057	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Depression;	chr6:28136856	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs1947862	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Depression;	chr6:28137418	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs6941992	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Depression;	chr6:28138363	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.516	rs4713142	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Parkinson's disease;	chr6:28138569	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs4713143	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Depression;	chr6:28138981	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs4713144	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Depression;	chr6:28139012	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs4713145	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Depression;	chr6:28139049	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs3757187	ENSG00000219392.1	RP1-265C24.5	-4.98	2.11e-06	0.00214	-0.56	-0.41	Depression;	chr6:28139876	chr6:28115628~28116551:+
TGCT	cis	rs34779708	0.931	rs4934724	ENSG00000230534.5	RP11-297A16.2	4.98	2.11e-06	0.00215	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35104741	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs4934725	ENSG00000230534.5	RP11-297A16.2	4.98	2.11e-06	0.00215	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35109308	chr10:35098006~35127020:-
TGCT	cis	rs34779708	1	rs12769189	ENSG00000230534.5	RP11-297A16.2	4.98	2.11e-06	0.00215	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35110740	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs12774834	ENSG00000230534.5	RP11-297A16.2	4.98	2.11e-06	0.00215	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35111142	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs12775759	ENSG00000230534.5	RP11-297A16.2	4.98	2.11e-06	0.00215	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35111255	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs34296409	ENSG00000230534.5	RP11-297A16.2	4.98	2.11e-06	0.00215	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35115685	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs11599606	ENSG00000230534.5	RP11-297A16.2	4.98	2.11e-06	0.00215	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35117698	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs10827487	ENSG00000230534.5	RP11-297A16.2	4.98	2.11e-06	0.00215	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35117950	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs35777088	ENSG00000230534.5	RP11-297A16.2	4.98	2.11e-06	0.00215	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35120120	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs11592567	ENSG00000230534.5	RP11-297A16.2	4.98	2.11e-06	0.00215	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35120441	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs11010101	ENSG00000230534.5	RP11-297A16.2	4.98	2.11e-06	0.00215	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35122117	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs11010102	ENSG00000230534.5	RP11-297A16.2	4.98	2.11e-06	0.00215	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35122138	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs34605125	ENSG00000230534.5	RP11-297A16.2	4.98	2.11e-06	0.00215	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35122318	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs12784482	ENSG00000230534.5	RP11-297A16.2	4.98	2.11e-06	0.00215	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35157937	chr10:35098006~35127020:-
TGCT	cis	rs73198271	0.562	rs964772	ENSG00000253893.2	FAM85B	4.98	2.11e-06	0.00215	0.64	0.41	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793796	chr8:8167819~8226614:-
TGCT	cis	rs73198271	0.562	rs964773	ENSG00000253893.2	FAM85B	4.98	2.11e-06	0.00215	0.64	0.41	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793804	chr8:8167819~8226614:-
TGCT	cis	rs8062405	0.824	rs153106	ENSG00000259982.1	CDC37P1	4.98	2.11e-06	0.00215	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28700294~28701540:-
TGCT	cis	rs2412819	0.571	rs8038068	ENSG00000205771.5	CATSPER2P1	-4.98	2.11e-06	0.00215	-0.63	-0.41	Lung cancer;	chr15:43622175	chr15:43726918~43747094:-
TGCT	cis	rs2412819	0.571	rs8030536	ENSG00000205771.5	CATSPER2P1	-4.98	2.11e-06	0.00215	-0.63	-0.41	Lung cancer;	chr15:43627365	chr15:43726918~43747094:-
TGCT	cis	rs2412819	0.571	rs56246169	ENSG00000205771.5	CATSPER2P1	-4.98	2.11e-06	0.00215	-0.63	-0.41	Lung cancer;	chr15:43628358	chr15:43726918~43747094:-
TGCT	cis	rs10246939	0.579	rs10464444	ENSG00000228775.6	WEE2-AS1	-4.98	2.11e-06	0.00215	-0.36	-0.41	Bitter taste perception;	chr7:141832387	chr7:141704338~141738346:-
TGCT	cis	rs2117029	0.554	rs12579015	ENSG00000258017.1	RP11-386G11.10	-4.98	2.11e-06	0.00215	-0.55	-0.41	Intelligence (multi-trait analysis);	chr12:49162648	chr12:49127782~49147869:+
TGCT	cis	rs2412819	0.571	rs66903736	ENSG00000205771.5	CATSPER2P1	-4.98	2.12e-06	0.00215	-0.63	-0.41	Lung cancer;	chr15:43619435	chr15:43726918~43747094:-
TGCT	cis	rs2412819	0.571	rs66749753	ENSG00000205771.5	CATSPER2P1	-4.98	2.12e-06	0.00215	-0.63	-0.41	Lung cancer;	chr15:43619601	chr15:43726918~43747094:-
TGCT	cis	rs853679	0.55	rs1233707	ENSG00000219392.1	RP1-265C24.5	-4.98	2.12e-06	0.00216	-0.54	-0.41	Depression;	chr6:28205175	chr6:28115628~28116551:+
TGCT	cis	rs1891275	0.515	rs7093728	ENSG00000228701.1	TNKS2-AS1	-4.98	2.12e-06	0.00216	-0.45	-0.41	Intelligence (multi-trait analysis);	chr10:91683860	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.515	rs10786010	ENSG00000228701.1	TNKS2-AS1	-4.98	2.12e-06	0.00216	-0.45	-0.41	Intelligence (multi-trait analysis);	chr10:91684016	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.515	rs1986941	ENSG00000228701.1	TNKS2-AS1	-4.98	2.12e-06	0.00216	-0.45	-0.41	Intelligence (multi-trait analysis);	chr10:91684586	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.515	rs7098763	ENSG00000228701.1	TNKS2-AS1	-4.98	2.12e-06	0.00216	-0.45	-0.41	Intelligence (multi-trait analysis);	chr10:91685070	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.508	rs7099557	ENSG00000228701.1	TNKS2-AS1	-4.98	2.12e-06	0.00216	-0.45	-0.41	Intelligence (multi-trait analysis);	chr10:91685607	chr10:91782839~91798291:-
TGCT	cis	rs507080	0.961	rs34413584	ENSG00000255422.1	AP002954.4	-4.97	2.13e-06	0.00216	-0.47	-0.41	Serum metabolite levels;	chr11:118675072	chr11:118704607~118750263:+
TGCT	cis	rs7927592	0.672	rs10501398	ENSG00000212093.1	AP000807.1	-4.97	2.13e-06	0.00216	-0.38	-0.41	Total body bone mineral density;	chr11:68564247	chr11:68506083~68506166:-
TGCT	cis	rs10875746	0.729	rs11168357	ENSG00000240399.1	RP1-228P16.1	-4.97	2.13e-06	0.00216	-0.48	-0.41	Longevity (90 years and older);	chr12:48018355	chr12:48054813~48055591:-
TGCT	cis	rs7044106	0.69	rs10739569	ENSG00000226752.6	PSMD5-AS1	-4.97	2.13e-06	0.00216	-0.51	-0.41	Hip circumference adjusted for BMI;	chr9:120598749	chr9:120824828~120854385:+
TGCT	cis	rs34779708	0.966	rs11010135	ENSG00000230534.5	RP11-297A16.2	4.97	2.14e-06	0.00217	0.49	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35229135	chr10:35098006~35127020:-
TGCT	cis	rs1707322	0.686	rs2991977	ENSG00000280836.1	AL355480.1	4.97	2.14e-06	0.00217	0.58	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.656	rs2991981	ENSG00000280836.1	AL355480.1	4.97	2.14e-06	0.00217	0.58	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45581219~45581321:-
TGCT	cis	rs17826219	0.568	rs59858012	ENSG00000280069.1	CTD-2349P21.3	-4.97	2.14e-06	0.00217	-0.65	-0.41	Body mass index;	chr17:30751564	chr17:30738182~30740275:+
TGCT	cis	rs875971	0.597	rs11771318	ENSG00000222364.1	RNU6-96P	4.97	2.14e-06	0.00217	0.47	0.41	Aortic root size;	chr7:66597493	chr7:66395191~66395286:+
TGCT	cis	rs34787248	1	rs34787248	ENSG00000216901.1	AL022393.7	4.97	2.15e-06	0.00218	0.64	0.41	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28176188~28176674:+
TGCT	cis	rs7795991	0.667	rs7787720	ENSG00000224330.1	AC005019.3	-4.97	2.15e-06	0.00218	-0.45	-0.41	Type 2 diabetes;	chr7:13847029	chr7:13854355~13859025:-
TGCT	cis	rs1823913	1	rs1823913	ENSG00000227542.1	AC092614.2	4.97	2.15e-06	0.00218	0.44	0.41	Obesity-related traits;	chr2:191253321	chr2:191229165~191246172:-
TGCT	cis	rs1823913	1	rs11691372	ENSG00000280083.1	RP11-317J9.1	4.97	2.16e-06	0.00219	0.34	0.41	Obesity-related traits;	chr2:191249952	chr2:191154118~191156070:-
TGCT	cis	rs1061377	1	rs4974931	ENSG00000249685.1	RP11-360F5.3	4.97	2.16e-06	0.00219	0.38	0.41	Uric acid levels;	chr4:39108896	chr4:39133913~39135608:+
TGCT	cis	rs7927592	0.626	rs11228279	ENSG00000212093.1	AP000807.1	-4.97	2.16e-06	0.00219	-0.39	-0.41	Total body bone mineral density;	chr11:68542212	chr11:68506083~68506166:-
TGCT	cis	rs7927592	0.763	rs10896340	ENSG00000212093.1	AP000807.1	-4.97	2.16e-06	0.00219	-0.39	-0.41	Total body bone mineral density;	chr11:68545177	chr11:68506083~68506166:-
TGCT	cis	rs7927592	0.763	rs11822059	ENSG00000212093.1	AP000807.1	4.97	2.16e-06	0.00219	0.39	0.41	Total body bone mineral density;	chr11:68533354	chr11:68506083~68506166:-
TGCT	cis	rs7829975	0.5	rs7841082	ENSG00000173295.6	FAM86B3P	-4.97	2.17e-06	0.0022	-0.47	-0.41	Mood instability;	chr8:8311465	chr8:8228595~8244865:+
TGCT	cis	rs34779708	0.898	rs11595898	ENSG00000230534.5	RP11-297A16.2	4.97	2.17e-06	0.0022	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35037335	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs4934704	ENSG00000230534.5	RP11-297A16.2	4.97	2.17e-06	0.0022	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35043236	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs35886556	ENSG00000230534.5	RP11-297A16.2	4.97	2.17e-06	0.0022	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35046057	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs1926556	ENSG00000230534.5	RP11-297A16.2	4.97	2.17e-06	0.0022	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35055979	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs1926554	ENSG00000230534.5	RP11-297A16.2	4.97	2.17e-06	0.0022	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35056041	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs7099036	ENSG00000230534.5	RP11-297A16.2	4.97	2.17e-06	0.0022	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35060646	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs4934710	ENSG00000230534.5	RP11-297A16.2	4.97	2.17e-06	0.0022	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35061488	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs11010083	ENSG00000230534.5	RP11-297A16.2	4.97	2.17e-06	0.0022	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35062603	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.897	rs35784065	ENSG00000230534.5	RP11-297A16.2	4.97	2.17e-06	0.0022	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35064646	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs4934711	ENSG00000230534.5	RP11-297A16.2	4.97	2.17e-06	0.0022	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35071382	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs34375045	ENSG00000230534.5	RP11-297A16.2	4.97	2.17e-06	0.0022	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35073428	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs34304999	ENSG00000230534.5	RP11-297A16.2	4.97	2.17e-06	0.0022	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35076777	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs12773169	ENSG00000230534.5	RP11-297A16.2	4.97	2.17e-06	0.0022	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35077534	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs7099593	ENSG00000230534.5	RP11-297A16.2	4.97	2.17e-06	0.0022	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35077950	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs7084196	ENSG00000230534.5	RP11-297A16.2	4.97	2.17e-06	0.0022	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35078233	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs13376871	ENSG00000230534.5	RP11-297A16.2	4.97	2.17e-06	0.0022	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35080128	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs13376801	ENSG00000230534.5	RP11-297A16.2	4.97	2.17e-06	0.0022	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35081515	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs7897457	ENSG00000230534.5	RP11-297A16.2	4.97	2.17e-06	0.0022	0.47	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35097112	chr10:35098006~35127020:-
TGCT	cis	rs853679	0.55	rs1150692	ENSG00000219392.1	RP1-265C24.5	-4.97	2.18e-06	0.0022	-0.54	-0.41	Depression;	chr6:28206179	chr6:28115628~28116551:+
TGCT	cis	rs8072100	0.537	rs9912450	ENSG00000228782.6	CTD-2026D20.3	4.97	2.19e-06	0.00221	0.54	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47324842	chr17:47450568~47492492:-
TGCT	cis	rs796364	1	rs281794	ENSG00000232732.8	AC073043.1	-4.97	2.19e-06	0.00221	-0.57	-0.41	Schizophrenia;	chr2:199981943	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.951	rs281793	ENSG00000232732.8	AC073043.1	-4.97	2.19e-06	0.00221	-0.57	-0.41	Schizophrenia;	chr2:199983267	chr2:199867396~199911159:-
TGCT	cis	rs972540	1	rs74809591	ENSG00000279220.1	GPR1-AS	4.97	2.19e-06	0.00221	0.42	0.41	Body mass index;	chr2:206383953	chr2:206203376~206266243:+
TGCT	cis	rs972540	0.961	rs79166192	ENSG00000279220.1	GPR1-AS	4.97	2.19e-06	0.00221	0.42	0.41	Body mass index;	chr2:206383963	chr2:206203376~206266243:+
TGCT	cis	rs972540	0.961	rs79767740	ENSG00000279220.1	GPR1-AS	4.97	2.19e-06	0.00221	0.42	0.41	Body mass index;	chr2:206383989	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs62195884	ENSG00000279220.1	GPR1-AS	4.97	2.19e-06	0.00221	0.42	0.41	Body mass index;	chr2:206367996	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs62195886	ENSG00000279220.1	GPR1-AS	4.97	2.19e-06	0.00221	0.42	0.41	Body mass index;	chr2:206368908	chr2:206203376~206266243:+
TGCT	cis	rs972540	0.883	rs2884693	ENSG00000279220.1	GPR1-AS	4.97	2.19e-06	0.00221	0.42	0.41	Body mass index;	chr2:206368923	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs56750678	ENSG00000279220.1	GPR1-AS	4.97	2.19e-06	0.00221	0.42	0.41	Body mass index;	chr2:206370570	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs113242332	ENSG00000279220.1	GPR1-AS	4.97	2.19e-06	0.00221	0.42	0.41	Body mass index;	chr2:206372126	chr2:206203376~206266243:+
TGCT	cis	rs972540	0.961	rs75388389	ENSG00000279220.1	GPR1-AS	4.97	2.19e-06	0.00221	0.42	0.41	Body mass index;	chr2:206378400	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs62195890	ENSG00000279220.1	GPR1-AS	4.97	2.19e-06	0.00221	0.42	0.41	Body mass index;	chr2:206379210	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs80109481	ENSG00000279220.1	GPR1-AS	4.97	2.19e-06	0.00221	0.42	0.41	Body mass index;	chr2:206382327	chr2:206203376~206266243:+
TGCT	cis	rs972540	1	rs1448901	ENSG00000279220.1	GPR1-AS	4.97	2.19e-06	0.00221	0.42	0.41	Body mass index;	chr2:206388916	chr2:206203376~206266243:+
TGCT	cis	rs34779708	0.966	rs4934735	ENSG00000230534.5	RP11-297A16.2	-4.97	2.19e-06	0.00221	-0.47	-0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35207802	chr10:35098006~35127020:-
TGCT	cis	rs4835473	0.897	rs6835827	ENSG00000251600.4	RP11-673E1.1	4.97	2.19e-06	0.00222	0.41	0.41	Immature fraction of reticulocytes;	chr4:143712803	chr4:143912331~143982454:+
TGCT	cis	rs2019137	0.868	rs6755639	ENSG00000189223.12	PAX8-AS1	-4.97	2.2e-06	0.00222	-0.5	-0.41	Lymphocyte counts;	chr2:113224233	chr2:113211522~113276581:+
TGCT	cis	rs2442825	0.693	rs2596916	ENSG00000206573.7	THUMPD3-AS1	4.97	2.2e-06	0.00222	0.36	0.41	Cerebrospinal fluid clusterin levels;	chr3:9380526	chr3:9349689~9398579:-
TGCT	cis	rs34779708	0.931	rs7923217	ENSG00000230534.5	RP11-297A16.2	4.97	2.2e-06	0.00222	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35020661	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.75	rs35032841	ENSG00000230534.5	RP11-297A16.2	4.97	2.2e-06	0.00222	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35023759	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.742	rs35912711	ENSG00000230534.5	RP11-297A16.2	4.97	2.2e-06	0.00222	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35024068	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs11010095	ENSG00000230534.5	RP11-297A16.2	4.97	2.2e-06	0.00222	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35107020	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs10466072	ENSG00000230534.5	RP11-297A16.2	4.97	2.2e-06	0.00222	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35113828	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs998658	ENSG00000230534.5	RP11-297A16.2	4.97	2.2e-06	0.00222	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35119726	chr10:35098006~35127020:-
TGCT	cis	rs992157	0.798	rs1017698	ENSG00000261338.2	RP11-378A13.1	-4.97	2.2e-06	0.00222	-0.34	-0.41	Colorectal cancer;	chr2:218305802	chr2:218255319~218257366:+
TGCT	cis	rs34779708	0.931	rs4934524	ENSG00000230534.5	RP11-297A16.2	4.97	2.2e-06	0.00222	0.49	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:34981993	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs4934693	ENSG00000230534.5	RP11-297A16.2	4.97	2.2e-06	0.00222	0.49	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:34982916	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs11592404	ENSG00000230534.5	RP11-297A16.2	4.97	2.2e-06	0.00222	0.49	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:34984548	chr10:35098006~35127020:-
TGCT	cis	rs1061377	1	rs1036037	ENSG00000249685.1	RP11-360F5.3	4.97	2.2e-06	0.00223	0.37	0.41	Uric acid levels;	chr4:39111272	chr4:39133913~39135608:+
TGCT	cis	rs1930961	1	rs59226697	ENSG00000272977.1	CTA-390C10.10	-4.97	2.2e-06	0.00223	-0.67	-0.41	Bipolar disorder with mood-incongruent psychosis;	chr22:25474070	chr22:25476218~25479971:+
TGCT	cis	rs4925386	0.84	rs8124907	ENSG00000273619.1	RP5-908M14.9	-4.97	2.21e-06	0.00223	-0.51	-0.41	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62338071	chr20:62386303~62386970:-
TGCT	cis	rs853679	0.76	rs11967137	ENSG00000216901.1	AL022393.7	4.97	2.21e-06	0.00223	0.61	0.41	Depression;	chr6:28231986	chr6:28176188~28176674:+
TGCT	cis	rs507080	0.845	rs613377	ENSG00000255422.1	AP002954.4	-4.97	2.21e-06	0.00223	-0.48	-0.41	Serum metabolite levels;	chr11:118685375	chr11:118704607~118750263:+
TGCT	cis	rs4835473	0.868	rs62337303	ENSG00000251600.4	RP11-673E1.1	-4.96	2.22e-06	0.00225	-0.42	-0.41	Immature fraction of reticulocytes;	chr4:143824967	chr4:143912331~143982454:+
TGCT	cis	rs1555322	0.53	rs2425047	ENSG00000126005.14	MMP24-AS1	4.96	2.23e-06	0.00225	0.48	0.41	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35216462~35278131:-
TGCT	cis	rs5758659	0.594	rs739292	ENSG00000270083.1	RP1-257I20.14	4.96	2.23e-06	0.00225	0.39	0.41	Cognitive function;	chr22:41972853	chr22:42089630~42090028:-
TGCT	cis	rs12745968	0.589	rs7540564	ENSG00000223787.2	RP4-593M8.1	-4.96	2.23e-06	0.00225	-0.51	-0.41	Bipolar disorder and schizophrenia;	chr1:92492269	chr1:92580476~92580821:-
TGCT	cis	rs2177312	0.718	rs1589656	ENSG00000251129.1	RP11-734I18.1	-4.96	2.24e-06	0.00226	-0.5	-0.41	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31983334	chr4:31997397~32155406:+
TGCT	cis	rs11231017	0.507	rs2178260	ENSG00000254454.2	RCC2P6	-4.96	2.25e-06	0.00227	-0.29	-0.41	HIV-1 viral setpoint;	chr11:62301893	chr11:62371146~62373168:+
TGCT	cis	rs11673344	0.832	rs56080874	ENSG00000226686.6	LINC01535	4.96	2.25e-06	0.00227	0.49	0.41	Obesity-related traits;	chr19:37085487	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.77	rs7257135	ENSG00000226686.6	LINC01535	4.96	2.25e-06	0.00227	0.49	0.41	Obesity-related traits;	chr19:37088726	chr19:37251912~37265535:+
TGCT	cis	rs11157436	0.871	rs8003190	ENSG00000211813.2	TRAV34	4.96	2.27e-06	0.00229	0.43	0.41	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22212096	chr14:22207522~22208129:+
TGCT	cis	rs1707322	0.717	rs1547925	ENSG00000280836.1	AL355480.1	4.96	2.27e-06	0.00229	0.56	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45581219~45581321:-
TGCT	cis	rs4853012	0.838	rs6715351	ENSG00000217702.2	RP11-287D1.4	4.96	2.27e-06	0.00229	0.56	0.41	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74130583~74135395:+
TGCT	cis	rs35160687	0.901	rs13020869	ENSG00000273080.1	RP11-301O19.1	4.96	2.27e-06	0.00229	0.46	0.41	Night sleep phenotypes;	chr2:86296237	chr2:86195590~86196049:+
TGCT	cis	rs35160687	0.901	rs12714180	ENSG00000273080.1	RP11-301O19.1	4.96	2.27e-06	0.00229	0.46	0.41	Night sleep phenotypes;	chr2:86298200	chr2:86195590~86196049:+
TGCT	cis	rs35160687	0.901	rs35281683	ENSG00000273080.1	RP11-301O19.1	4.96	2.27e-06	0.00229	0.46	0.41	Night sleep phenotypes;	chr2:86299249	chr2:86195590~86196049:+
TGCT	cis	rs786425	0.77	rs66647364	ENSG00000247373.3	RP11-486O12.2	4.96	2.27e-06	0.00229	0.51	0.41	Pubertal anthropometrics;	chr12:123712733	chr12:123575891~123585115:-
TGCT	cis	rs853679	1	rs853694	ENSG00000216901.1	AL022393.7	4.96	2.28e-06	0.00229	0.65	0.41	Depression;	chr6:28311323	chr6:28176188~28176674:+
TGCT	cis	rs853679	1	rs1936365	ENSG00000216901.1	AL022393.7	-4.96	2.28e-06	0.00229	-0.65	-0.41	Depression;	chr6:28300675	chr6:28176188~28176674:+
TGCT	cis	rs4380275	0.782	rs4854369	ENSG00000223751.1	AC116609.2	4.96	2.28e-06	0.00229	0.42	0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:752530	chr2:742488~747767:+
TGCT	cis	rs9326248	0.911	rs474339	ENSG00000280143.1	AP000892.6	4.96	2.28e-06	0.00229	0.52	0.41	Blood protein levels;	chr11:117188836	chr11:117204967~117210292:+
TGCT	cis	rs801193	1	rs10234018	ENSG00000272831.1	RP11-792A8.4	-4.96	2.28e-06	0.00229	-0.43	-0.41	Aortic root size;	chr7:66681297	chr7:66739829~66740385:-
TGCT	cis	rs847851	0.917	rs6912327	ENSG00000186328.4	RP11-140K17.2	4.96	2.28e-06	0.0023	0.45	0.41	Colonoscopy-negative controls vs population controls;	chr6:34797145	chr6:34715613~34715940:+
TGCT	cis	rs3096299	0.933	rs747485	ENSG00000274627.1	RP11-104N10.2	4.96	2.29e-06	0.0023	0.43	0.41	Multiple myeloma (IgH translocation);	chr16:89407686	chr16:89516797~89522217:+
TGCT	cis	rs6017291	1	rs8124430	ENSG00000223891.4	OSER1-AS1	4.96	2.29e-06	0.0023	0.6	0.41	Cognitive performance;	chr20:44269030	chr20:44210960~44226027:+
TGCT	cis	rs6017291	1	rs35182603	ENSG00000223891.4	OSER1-AS1	4.96	2.29e-06	0.0023	0.6	0.41	Cognitive performance;	chr20:44269910	chr20:44210960~44226027:+
TGCT	cis	rs6017291	1	rs12481568	ENSG00000223891.4	OSER1-AS1	4.96	2.29e-06	0.0023	0.6	0.41	Cognitive performance;	chr20:44272615	chr20:44210960~44226027:+
TGCT	cis	rs6017291	1	rs35767731	ENSG00000223891.4	OSER1-AS1	4.96	2.29e-06	0.0023	0.6	0.41	Cognitive performance;	chr20:44278297	chr20:44210960~44226027:+
TGCT	cis	rs2412819	0.571	rs11070411	ENSG00000205771.5	CATSPER2P1	4.96	2.29e-06	0.00231	0.59	0.41	Lung cancer;	chr15:43766436	chr15:43726918~43747094:-
TGCT	cis	rs2412819	0.597	rs7181912	ENSG00000205771.5	CATSPER2P1	4.96	2.29e-06	0.00231	0.59	0.41	Lung cancer;	chr15:43770676	chr15:43726918~43747094:-
TGCT	cis	rs2412819	0.545	rs3862143	ENSG00000205771.5	CATSPER2P1	4.96	2.29e-06	0.00231	0.59	0.41	Lung cancer;	chr15:43779282	chr15:43726918~43747094:-
TGCT	cis	rs13068223	0.562	rs346003	ENSG00000243926.1	TIPARP-AS1	-4.96	2.3e-06	0.00232	-0.44	-0.41	Age-related hearing impairment (SNP x SNP interaction);	chr3:156705283	chr3:156671862~156674378:-
TGCT	cis	rs1799955	0.554	rs9567578	ENSG00000215515.2	IFIT1P1	4.96	2.31e-06	0.00232	0.5	0.41	LDL cholesterol levels;	chr13:32347807	chr13:32384660~32386108:+
TGCT	cis	rs1320333	0.772	rs2867136	ENSG00000233296.1	AC092159.2	-4.96	2.31e-06	0.00232	-0.57	-0.41	Obesity-related traits;	chr2:701455	chr2:677186~697371:+
TGCT	cis	rs9660180	0.967	rs6603802	ENSG00000268575.1	RP1-283E3.8	-4.96	2.31e-06	0.00232	-0.34	-0.41	Body mass index;	chr1:1881082	chr1:1702736~1737688:-
TGCT	cis	rs2980439	0.846	rs2980437	ENSG00000253981.4	ALG1L13P	-4.96	2.31e-06	0.00232	-0.41	-0.41	Neuroticism;	chr8:8237241	chr8:8236003~8244667:-
TGCT	cis	rs5769707	0.967	rs9616333	ENSG00000235111.1	RP1-29C18.8	-4.96	2.31e-06	0.00232	-0.33	-0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49657199	chr22:49612657~49615716:-
TGCT	cis	rs67311347	1	rs11706148	ENSG00000223797.4	ENTPD3-AS1	4.96	2.31e-06	0.00232	0.43	0.41	Renal cell carcinoma;	chr3:40365752	chr3:40313802~40453329:-
TGCT	cis	rs2919917	0.628	rs12680932	ENSG00000254352.1	RP11-578O24.2	-4.96	2.31e-06	0.00232	-0.51	-0.41	Lymphocyte counts;	chr8:78685516	chr8:78723796~78724136:-
TGCT	cis	rs9326248	0.53	rs900012	ENSG00000254851.1	RP11-109L13.1	-4.96	2.31e-06	0.00233	-0.78	-0.41	Blood protein levels;	chr11:117095719	chr11:117135528~117138582:+
TGCT	cis	rs899997	1	rs11072794	ENSG00000261143.1	ADAMTS7P3	4.95	2.32e-06	0.00233	0.44	0.41	Coronary artery disease or large artery stroke;	chr15:78714240	chr15:77976042~77993057:+
TGCT	cis	rs6600671	0.693	rs1853731	ENSG00000275131.1	CH17-472G23.4	-4.95	2.32e-06	0.00233	-0.26	-0.41	Hip geometry;	chr1:121510262	chr1:120489625~120579190:-
TGCT	cis	rs904251	0.523	rs1776455	ENSG00000279942.1	RP1-153P14.7	-4.95	2.32e-06	0.00233	-0.39	-0.41	Cognitive performance;	chr6:37515147	chr6:37567716~37571460:+
TGCT	cis	rs36052053	0.908	rs13199388	ENSG00000219700.1	PTCHD3P3	4.95	2.33e-06	0.00234	0.76	0.41	Red cell distribution width;	chr6:109262897	chr6:109288571~109290503:-
TGCT	cis	rs8059260	0.668	rs16957855	ENSG00000274038.1	RP11-66H6.4	-4.95	2.33e-06	0.00234	-0.57	-0.41	Alcohol consumption over the past year;	chr16:10977116	chr16:11056556~11057034:+
TGCT	cis	rs507080	0.922	rs592280	ENSG00000255422.1	AP002954.4	-4.95	2.33e-06	0.00234	-0.5	-0.41	Serum metabolite levels;	chr11:118682509	chr11:118704607~118750263:+
TGCT	cis	rs2581828	0.646	rs2564923	ENSG00000242142.1	SERBP1P3	4.95	2.33e-06	0.00234	0.36	0.41	Crohn's disease;	chr3:53069246	chr3:53064283~53065091:-
TGCT	cis	rs7617773	1	rs11711766	ENSG00000229759.1	MRPS18AP1	-4.95	2.33e-06	0.00234	-0.32	-0.41	Coronary artery disease;	chr3:48151680	chr3:48256350~48256938:-
TGCT	cis	rs7617773	1	rs7617773	ENSG00000229759.1	MRPS18AP1	-4.95	2.33e-06	0.00234	-0.32	-0.41	Coronary artery disease;	chr3:48152025	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.963	rs6771787	ENSG00000229759.1	MRPS18AP1	-4.95	2.33e-06	0.00234	-0.32	-0.41	Coronary artery disease;	chr3:48152752	chr3:48256350~48256938:-
TGCT	cis	rs3096299	0.967	rs2911256	ENSG00000274627.1	RP11-104N10.2	4.95	2.34e-06	0.00234	0.42	0.41	Multiple myeloma (IgH translocation);	chr16:89418688	chr16:89516797~89522217:+
TGCT	cis	rs4835473	0.932	rs7670010	ENSG00000251600.4	RP11-673E1.1	4.95	2.34e-06	0.00234	0.42	0.41	Immature fraction of reticulocytes;	chr4:143821679	chr4:143912331~143982454:+
TGCT	cis	rs507080	0.769	rs2077173	ENSG00000255422.1	AP002954.4	-4.95	2.34e-06	0.00235	-0.48	-0.41	Serum metabolite levels;	chr11:118621876	chr11:118704607~118750263:+
TGCT	cis	rs1823913	0.895	rs10931491	ENSG00000227542.1	AC092614.2	-4.95	2.34e-06	0.00235	-0.44	-0.41	Obesity-related traits;	chr2:191256087	chr2:191229165~191246172:-
TGCT	cis	rs1823913	1	rs11681777	ENSG00000227542.1	AC092614.2	-4.95	2.34e-06	0.00235	-0.44	-0.41	Obesity-related traits;	chr2:191256741	chr2:191229165~191246172:-
TGCT	cis	rs9880211	0.8	rs13433683	ENSG00000239213.4	NCK1-AS1	-4.95	2.34e-06	0.00235	-0.43	-0.41	Height;Body mass index;	chr3:136799828	chr3:136841726~136862054:-
TGCT	cis	rs2412819	0.571	rs4923965	ENSG00000205771.5	CATSPER2P1	4.95	2.34e-06	0.00235	0.65	0.41	Lung cancer;	chr15:43790232	chr15:43726918~43747094:-
TGCT	cis	rs2412819	0.571	rs6493090	ENSG00000205771.5	CATSPER2P1	4.95	2.34e-06	0.00235	0.65	0.41	Lung cancer;	chr15:43792084	chr15:43726918~43747094:-
TGCT	cis	rs2412819	0.571	rs4644832	ENSG00000205771.5	CATSPER2P1	4.95	2.34e-06	0.00235	0.65	0.41	Lung cancer;	chr15:43792507	chr15:43726918~43747094:-
TGCT	cis	rs710913	0.604	rs1180343	ENSG00000182109.6	RP11-69E11.4	-4.95	2.35e-06	0.00236	-0.39	-0.41	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527760	chr1:39522280~39546187:-
TGCT	cis	rs2739330	0.731	rs5751792	ENSG00000272787.1	KB-226F1.2	-4.95	2.35e-06	0.00236	-0.45	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23969211~23969873:+
TGCT	cis	rs651907	0.557	rs2303474	ENSG00000244119.1	PDCL3P4	4.95	2.35e-06	0.00236	0.3	0.41	Colorectal cancer;	chr3:101653055	chr3:101712472~101713191:+
TGCT	cis	rs4927850	1	rs7614767	ENSG00000207650.1	MIR570	4.95	2.35e-06	0.00236	0.49	0.41	Pancreatic cancer;	chr3:196026580	chr3:195699401~195699497:+
TGCT	cis	rs34779708	0.966	rs7913615	ENSG00000230534.5	RP11-297A16.2	4.95	2.35e-06	0.00236	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35134029	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs34776628	ENSG00000230534.5	RP11-297A16.2	4.95	2.35e-06	0.00236	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35137396	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs17499247	ENSG00000230534.5	RP11-297A16.2	4.95	2.35e-06	0.00236	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35137827	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs10827491	ENSG00000230534.5	RP11-297A16.2	4.95	2.35e-06	0.00236	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35138467	chr10:35098006~35127020:-
TGCT	cis	rs2242073	0.733	rs62194805	ENSG00000232799.1	CRYGFP	-4.95	2.36e-06	0.00237	-0.59	-0.41	Attention deficit hyperactivity disorder;	chr2:208162554	chr2:209145241~209147687:+
TGCT	cis	rs35160687	0.901	rs67903513	ENSG00000273080.1	RP11-301O19.1	4.95	2.36e-06	0.00237	0.46	0.41	Night sleep phenotypes;	chr2:86284976	chr2:86195590~86196049:+
TGCT	cis	rs1010254	0.559	rs72808310	ENSG00000213433.5	RPLP1P6	-4.95	2.37e-06	0.00237	-0.48	-0.41	Optic nerve measurement (cup area);	chr5:152350746	chr5:151765859~151766378:-
TGCT	cis	rs673078	0.607	rs7136676	ENSG00000275759.1	RP11-131L12.3	-4.95	2.37e-06	0.00237	-0.75	-0.41	Glucose homeostasis traits;	chr12:118403605	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs17441033	ENSG00000275759.1	RP11-131L12.3	-4.95	2.37e-06	0.00237	-0.75	-0.41	Glucose homeostasis traits;	chr12:118404101	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.562	rs61943405	ENSG00000275759.1	RP11-131L12.3	-4.95	2.37e-06	0.00237	-0.75	-0.41	Glucose homeostasis traits;	chr12:118405030	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs61943406	ENSG00000275759.1	RP11-131L12.3	-4.95	2.37e-06	0.00237	-0.75	-0.41	Glucose homeostasis traits;	chr12:118405767	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs17441075	ENSG00000275759.1	RP11-131L12.3	-4.95	2.37e-06	0.00237	-0.75	-0.41	Glucose homeostasis traits;	chr12:118410542	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs965524	ENSG00000275759.1	RP11-131L12.3	-4.95	2.37e-06	0.00237	-0.75	-0.41	Glucose homeostasis traits;	chr12:118412361	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs74685643	ENSG00000275759.1	RP11-131L12.3	-4.95	2.37e-06	0.00237	-0.75	-0.41	Glucose homeostasis traits;	chr12:118412761	chr12:118428281~118428870:+
TGCT	cis	rs904251	0.523	rs9349039	ENSG00000204110.6	RP1-153P14.8	-4.95	2.37e-06	0.00237	-0.44	-0.41	Cognitive performance;	chr6:37512616	chr6:37507348~37535616:+
TGCT	cis	rs904251	0.523	rs9366935	ENSG00000204110.6	RP1-153P14.8	-4.95	2.37e-06	0.00237	-0.44	-0.41	Cognitive performance;	chr6:37512628	chr6:37507348~37535616:+
TGCT	cis	rs1075265	0.568	rs10865278	ENSG00000233266.1	HMGB1P31	4.95	2.37e-06	0.00237	0.42	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54074902	chr2:54051334~54051760:+
TGCT	cis	rs7208859	0.615	rs216462	ENSG00000280069.1	CTD-2349P21.3	4.95	2.37e-06	0.00238	0.6	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30568879	chr17:30738182~30740275:+
TGCT	cis	rs853679	1	rs6905391	ENSG00000216901.1	AL022393.7	4.95	2.37e-06	0.00238	0.65	0.41	Depression;	chr6:28294909	chr6:28176188~28176674:+
TGCT	cis	rs11723261	0.621	rs11721745	ENSG00000275426.1	CH17-262A2.1	4.95	2.37e-06	0.00238	0.83	0.41	Immune response to smallpox vaccine (IL-6);	chr4:115052	chr4:149738~150317:+
TGCT	cis	rs673078	0.607	rs17441061	ENSG00000275759.1	RP11-131L12.3	-4.95	2.38e-06	0.00238	-0.76	-0.41	Glucose homeostasis traits;	chr12:118409847	chr12:118428281~118428870:+
TGCT	cis	rs1153858	1	rs2453541	ENSG00000259520.4	CTD-2651B20.3	-4.95	2.38e-06	0.00238	-0.35	-0.41	Homoarginine levels;	chr15:45353180	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs2461702	ENSG00000259520.4	CTD-2651B20.3	-4.95	2.38e-06	0.00238	-0.35	-0.41	Homoarginine levels;	chr15:45355229	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs1145091	ENSG00000259520.4	CTD-2651B20.3	-4.95	2.38e-06	0.00238	-0.35	-0.41	Homoarginine levels;	chr15:45357798	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs1049508	ENSG00000259520.4	CTD-2651B20.3	-4.95	2.38e-06	0.00238	-0.35	-0.41	Homoarginine levels;	chr15:45361394	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs1145085	ENSG00000259520.4	CTD-2651B20.3	-4.95	2.38e-06	0.00238	-0.35	-0.41	Homoarginine levels;	chr15:45365606	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs1288775	ENSG00000259520.4	CTD-2651B20.3	-4.95	2.38e-06	0.00238	-0.35	-0.41	Homoarginine levels;	chr15:45369480	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs1145081	ENSG00000259520.4	CTD-2651B20.3	-4.95	2.38e-06	0.00238	-0.35	-0.41	Homoarginine levels;	chr15:45387469	chr15:45251580~45279251:-
TGCT	cis	rs1153858	0.943	rs1145079	ENSG00000259520.4	CTD-2651B20.3	-4.95	2.38e-06	0.00238	-0.35	-0.41	Homoarginine levels;	chr15:45389563	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs1346266	ENSG00000259520.4	CTD-2651B20.3	-4.95	2.38e-06	0.00238	-0.35	-0.41	Homoarginine levels;	chr15:45402318	chr15:45251580~45279251:-
TGCT	cis	rs4713118	0.587	rs61471148	ENSG00000219392.1	RP1-265C24.5	-4.95	2.38e-06	0.00239	-0.54	-0.41	Parkinson's disease;	chr6:28069254	chr6:28115628~28116551:+
TGCT	cis	rs2333021	0.934	rs4903092	ENSG00000259015.1	RP11-109N23.6	4.95	2.38e-06	0.00239	0.22	0.41	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73013017	chr14:72960595~72961993:+
TGCT	cis	rs67311347	1	rs9874499	ENSG00000223797.4	ENTPD3-AS1	4.95	2.38e-06	0.00239	0.42	0.41	Renal cell carcinoma;	chr3:40400417	chr3:40313802~40453329:-
TGCT	cis	rs4925386	0.559	rs2427291	ENSG00000273619.1	RP5-908M14.9	-4.95	2.39e-06	0.00239	-0.52	-0.41	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62346268	chr20:62386303~62386970:-
TGCT	cis	rs34779708	0.966	rs2045915	ENSG00000230534.5	RP11-297A16.2	4.95	2.39e-06	0.00239	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35129688	chr10:35098006~35127020:-
TGCT	cis	rs9918079	0.542	rs6414765	ENSG00000273133.1	RP11-799M12.2	-4.95	2.39e-06	0.00239	-0.59	-0.41	Obesity-related traits;	chr4:15624870	chr4:15563698~15564253:-
TGCT	cis	rs9322193	0.886	rs4870055	ENSG00000216906.2	RP11-350J20.9	4.95	2.39e-06	0.0024	0.45	0.41	Lung cancer;	chr6:149848433	chr6:149904243~149906418:+
TGCT	cis	rs57502260	0.573	rs12291008	ENSG00000212093.1	AP000807.1	4.95	2.4e-06	0.0024	0.42	0.41	Total body bone mineral density (age 45-60);	chr11:68621604	chr11:68506083~68506166:-
TGCT	cis	rs9584850	0.834	rs7985565	ENSG00000231194.1	FARP1-AS1	4.95	2.4e-06	0.0024	0.57	0.41	Neuroticism;	chr13:98461217	chr13:98435405~98435840:-
TGCT	cis	rs1799949	0.965	rs6503727	ENSG00000198496.9	NBR2	-4.95	2.4e-06	0.0024	-0.56	-0.41	Menopause (age at onset);	chr17:43160842	chr17:43125610~43153671:+
TGCT	cis	rs17826219	0.568	rs11658027	ENSG00000263531.1	RP13-753N3.1	-4.95	2.4e-06	0.0024	-0.79	-0.41	Body mass index;	chr17:30767864	chr17:30863921~30864940:-
TGCT	cis	rs10875976	0.525	rs7967564	ENSG00000242041.1	RP11-70F11.2	4.95	2.4e-06	0.0024	0.39	0.41	Obesity;	chr12:49855748	chr12:49863173~49863503:+
TGCT	cis	rs10875976	0.525	rs10783321	ENSG00000242041.1	RP11-70F11.2	4.95	2.4e-06	0.0024	0.39	0.41	Obesity;	chr12:49855820	chr12:49863173~49863503:+
TGCT	cis	rs10875976	0.545	rs7309919	ENSG00000242041.1	RP11-70F11.2	4.95	2.4e-06	0.0024	0.39	0.41	Obesity;	chr12:49857032	chr12:49863173~49863503:+
TGCT	cis	rs1372520	0.748	rs1471484	ENSG00000247775.2	SNCA-AS1	4.95	2.41e-06	0.00241	0.4	0.41	Neuroticism;	chr4:89833162	chr4:89836408~89841978:+
TGCT	cis	rs7927592	0.763	rs1193699	ENSG00000212093.1	AP000807.1	4.95	2.41e-06	0.00241	0.39	0.41	Total body bone mineral density;	chr11:68482012	chr11:68506083~68506166:-
TGCT	cis	rs7208859	0.623	rs426434	ENSG00000263531.1	RP13-753N3.1	4.95	2.41e-06	0.00241	0.77	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30863921~30864940:-
TGCT	cis	rs34779708	0.931	rs2001893	ENSG00000230534.5	RP11-297A16.2	4.95	2.42e-06	0.00242	0.48	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35011695	chr10:35098006~35127020:-
TGCT	cis	rs16975963	0.644	rs7248397	ENSG00000276846.1	CTD-3220F14.3	-4.95	2.42e-06	0.00242	-0.4	-0.41	Longevity;	chr19:37642310	chr19:37314868~37315620:-
TGCT	cis	rs2742234	0.541	rs12416428	ENSG00000273008.1	RP11-351D16.3	4.94	2.42e-06	0.00242	0.57	0.41	Hirschsprung disease;	chr10:43213550	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.541	rs11238476	ENSG00000273008.1	RP11-351D16.3	4.94	2.42e-06	0.00242	0.57	0.41	Hirschsprung disease;	chr10:43215988	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.541	rs7096500	ENSG00000273008.1	RP11-351D16.3	4.94	2.42e-06	0.00242	0.57	0.41	Hirschsprung disease;	chr10:43216647	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.541	rs4648313	ENSG00000273008.1	RP11-351D16.3	4.94	2.42e-06	0.00242	0.57	0.41	Hirschsprung disease;	chr10:43221291	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.541	rs10793424	ENSG00000273008.1	RP11-351D16.3	4.94	2.42e-06	0.00242	0.57	0.41	Hirschsprung disease;	chr10:43221668	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.541	rs11238479	ENSG00000273008.1	RP11-351D16.3	4.94	2.42e-06	0.00242	0.57	0.41	Hirschsprung disease;	chr10:43221975	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.541	rs10899778	ENSG00000273008.1	RP11-351D16.3	4.94	2.42e-06	0.00242	0.57	0.41	Hirschsprung disease;	chr10:43223061	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.541	rs11238481	ENSG00000273008.1	RP11-351D16.3	4.94	2.42e-06	0.00242	0.57	0.41	Hirschsprung disease;	chr10:43223838	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.541	rs61268333	ENSG00000273008.1	RP11-351D16.3	4.94	2.42e-06	0.00242	0.57	0.41	Hirschsprung disease;	chr10:43225922	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.541	rs60845448	ENSG00000273008.1	RP11-351D16.3	4.94	2.42e-06	0.00242	0.57	0.41	Hirschsprung disease;	chr10:43226014	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.541	rs10899779	ENSG00000273008.1	RP11-351D16.3	4.94	2.42e-06	0.00242	0.57	0.41	Hirschsprung disease;	chr10:43228528	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.504	rs10899780	ENSG00000273008.1	RP11-351D16.3	4.94	2.42e-06	0.00242	0.57	0.41	Hirschsprung disease;	chr10:43230348	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.541	rs11238483	ENSG00000273008.1	RP11-351D16.3	4.94	2.42e-06	0.00242	0.57	0.41	Hirschsprung disease;	chr10:43233332	chr10:43136824~43138334:-
TGCT	cis	rs9584850	0.834	rs7334078	ENSG00000231194.1	FARP1-AS1	-4.94	2.42e-06	0.00242	-0.54	-0.41	Neuroticism;	chr13:98468230	chr13:98435405~98435840:-
TGCT	cis	rs6604026	0.624	rs59864761	ENSG00000223787.2	RP4-593M8.1	4.94	2.42e-06	0.00242	0.59	0.41	Multiple sclerosis;	chr1:92791656	chr1:92580476~92580821:-
TGCT	cis	rs4835473	0.9	rs4835303	ENSG00000251600.4	RP11-673E1.1	-4.94	2.43e-06	0.00242	-0.4	-0.41	Immature fraction of reticulocytes;	chr4:143821533	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs4835034	ENSG00000251600.4	RP11-673E1.1	-4.94	2.43e-06	0.00242	-0.4	-0.41	Immature fraction of reticulocytes;	chr4:143821538	chr4:143912331~143982454:+
TGCT	cis	rs1075265	0.547	rs11125520	ENSG00000233266.1	HMGB1P31	4.94	2.44e-06	0.00244	0.44	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54076696	chr2:54051334~54051760:+
TGCT	cis	rs853679	0.527	rs9461443	ENSG00000216901.1	AL022393.7	4.94	2.44e-06	0.00244	0.54	0.41	Depression;	chr6:28226851	chr6:28176188~28176674:+
TGCT	cis	rs7208859	0.623	rs60890550	ENSG00000266490.1	CTD-2349P21.9	4.94	2.45e-06	0.00244	0.45	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30792372~30792833:+
TGCT	cis	rs1799955	0.529	rs9567576	ENSG00000215515.2	IFIT1P1	-4.94	2.45e-06	0.00244	-0.5	-0.41	LDL cholesterol levels;	chr13:32345500	chr13:32384660~32386108:+
TGCT	cis	rs10246939	0.579	rs12703413	ENSG00000228775.6	WEE2-AS1	-4.94	2.45e-06	0.00244	-0.36	-0.41	Bitter taste perception;	chr7:141847047	chr7:141704338~141738346:-
TGCT	cis	rs7849270	0.879	rs7859344	ENSG00000268707.1	RP11-247A12.7	-4.94	2.45e-06	0.00245	-0.47	-0.41	Blood metabolite ratios;	chr9:129086103	chr9:129170434~129170940:+
TGCT	cis	rs453301	0.564	rs28649568	ENSG00000173295.6	FAM86B3P	-4.94	2.46e-06	0.00245	-0.5	-0.41	Joint mobility (Beighton score);	chr8:9102161	chr8:8228595~8244865:+
TGCT	cis	rs7617773	1	rs9832957	ENSG00000229759.1	MRPS18AP1	-4.94	2.46e-06	0.00246	-0.31	-0.41	Coronary artery disease;	chr3:48143776	chr3:48256350~48256938:-
TGCT	cis	rs10256972	0.524	rs6945202	ENSG00000226291.1	AC091729.8	-4.94	2.47e-06	0.00246	-0.46	-0.41	Endometriosis;Longevity;	chr7:1076922	chr7:1080863~1082178:+
TGCT	cis	rs7301826	0.966	rs10734980	ENSG00000256299.1	RP11-989F5.3	-4.94	2.47e-06	0.00247	-0.44	-0.41	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810821~130812622:-
TGCT	cis	rs9326248	0.798	rs10892079	ENSG00000280143.1	AP000892.6	4.94	2.48e-06	0.00247	0.56	0.41	Blood protein levels;	chr11:117146108	chr11:117204967~117210292:+
TGCT	cis	rs6964833	0.554	rs112506907	ENSG00000123965.13	PMS2P5	4.94	2.48e-06	0.00247	0.47	0.41	Menarche (age at onset);	chr7:74654407	chr7:74894116~74897835:+
TGCT	cis	rs8059260	0.541	rs12927046	ENSG00000274038.1	RP11-66H6.4	-4.94	2.49e-06	0.00248	-0.57	-0.41	Alcohol consumption over the past year;	chr16:11148334	chr16:11056556~11057034:+
TGCT	cis	rs853679	0.517	rs1340004	ENSG00000219392.1	RP1-265C24.5	-4.94	2.49e-06	0.00248	-0.57	-0.41	Depression;	chr6:28135913	chr6:28115628~28116551:+
TGCT	cis	rs651907	0.557	rs11924013	ENSG00000244119.1	PDCL3P4	4.94	2.49e-06	0.00248	0.3	0.41	Colorectal cancer;	chr3:101647854	chr3:101712472~101713191:+
TGCT	cis	rs1707322	0.686	rs2050376	ENSG00000280836.1	AL355480.1	-4.94	2.49e-06	0.00248	-0.56	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45581219~45581321:-
TGCT	cis	rs2288073	1	rs2288073	ENSG00000223754.1	AC008073.9	-4.94	2.49e-06	0.00248	-0.5	-0.41	Venous thromboembolism (SNP x SNP interaction);	chr2:24190429	chr2:24199839~24201698:-
TGCT	cis	rs8062405	0.824	rs62034319	ENSG00000259982.1	CDC37P1	4.94	2.49e-06	0.00248	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28700294~28701540:-
TGCT	cis	rs528418	1	rs1415808	ENSG00000270638.1	RP3-466P17.1	4.94	2.49e-06	0.00248	0.41	0.41	Methadone dose in opioid dependence;	chr6:145266937	chr6:145735570~145737218:+
TGCT	cis	rs7927592	0.763	rs7119422	ENSG00000212093.1	AP000807.1	-4.94	2.5e-06	0.00249	-0.38	-0.41	Total body bone mineral density;	chr11:68563686	chr11:68506083~68506166:-
TGCT	cis	rs10875976	0.525	rs7969178	ENSG00000242041.1	RP11-70F11.2	4.94	2.5e-06	0.00249	0.39	0.41	Obesity;	chr12:49859019	chr12:49863173~49863503:+
TGCT	cis	rs1062177	0.502	rs10463321	ENSG00000253921.1	CTB-113P19.3	-4.94	2.5e-06	0.00249	-0.46	-0.41	Preschool internalizing problems;	chr5:151944344	chr5:151753992~151767247:+
TGCT	cis	rs2976388	0.609	rs2585148	ENSG00000253196.1	RP11-706C16.7	4.94	2.5e-06	0.00249	0.4	0.41	Urinary tract infection frequency;	chr8:142714775	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.565	rs2572905	ENSG00000253196.1	RP11-706C16.7	4.94	2.5e-06	0.00249	0.4	0.41	Urinary tract infection frequency;	chr8:142715686	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.647	rs2572906	ENSG00000253196.1	RP11-706C16.7	4.94	2.5e-06	0.00249	0.4	0.41	Urinary tract infection frequency;	chr8:142716851	chr8:142763116~142766427:+
TGCT	cis	rs7786410	1	rs7786410	ENSG00000275875.1	RP11-613E4.5	4.94	2.51e-06	0.00249	0.7	0.41	Age-related hearing impairment;	chr7:55854630	chr7:55741525~55741869:+
TGCT	cis	rs786425	0.682	rs34586028	ENSG00000278112.1	RP11-972P1.11	4.94	2.51e-06	0.00249	0.49	0.41	Pubertal anthropometrics;	chr12:123702535	chr12:123519390~123519856:-
TGCT	cis	rs9425766	0.679	rs57919173	ENSG00000227373.4	RP11-160H22.5	4.94	2.51e-06	0.0025	0.44	0.41	Life satisfaction;	chr1:174159856	chr1:174115300~174160004:-
TGCT	cis	rs4835473	0.932	rs2323190	ENSG00000251600.4	RP11-673E1.1	-4.94	2.51e-06	0.0025	-0.4	-0.41	Immature fraction of reticulocytes;	chr4:143744282	chr4:143912331~143982454:+
TGCT	cis	rs3931020	0.548	rs17618340	ENSG00000272864.1	RP11-17E13.2	-4.94	2.52e-06	0.0025	-0.44	-0.41	Resistin levels;	chr1:74781933	chr1:74698769~74699333:-
TGCT	cis	rs853679	1	rs853679	ENSG00000216901.1	AL022393.7	4.94	2.52e-06	0.00251	0.67	0.41	Depression;	chr6:28329086	chr6:28176188~28176674:+
TGCT	cis	rs853679	1	rs853678	ENSG00000216901.1	AL022393.7	4.94	2.52e-06	0.00251	0.67	0.41	Depression;	chr6:28329536	chr6:28176188~28176674:+
TGCT	cis	rs853679	1	rs853676	ENSG00000216901.1	AL022393.7	4.94	2.52e-06	0.00251	0.67	0.41	Depression;	chr6:28331910	chr6:28176188~28176674:+
TGCT	cis	rs10504229	0.775	rs17804840	ENSG00000253301.4	RP11-513O17.2	4.94	2.52e-06	0.00251	0.55	0.41	Developmental language disorder (linguistic errors);	chr8:57244486	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.728	rs55812114	ENSG00000253301.4	RP11-513O17.2	4.94	2.52e-06	0.00251	0.55	0.41	Developmental language disorder (linguistic errors);	chr8:57244894	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.775	rs55825382	ENSG00000253301.4	RP11-513O17.2	4.94	2.52e-06	0.00251	0.55	0.41	Developmental language disorder (linguistic errors);	chr8:57245046	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.775	rs72650869	ENSG00000253301.4	RP11-513O17.2	4.94	2.52e-06	0.00251	0.55	0.41	Developmental language disorder (linguistic errors);	chr8:57245364	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.775	rs55764517	ENSG00000253301.4	RP11-513O17.2	4.94	2.52e-06	0.00251	0.55	0.41	Developmental language disorder (linguistic errors);	chr8:57245679	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.728	rs17216187	ENSG00000253301.4	RP11-513O17.2	4.94	2.52e-06	0.00251	0.55	0.41	Developmental language disorder (linguistic errors);	chr8:57246219	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.775	rs17216236	ENSG00000253301.4	RP11-513O17.2	4.94	2.52e-06	0.00251	0.55	0.41	Developmental language disorder (linguistic errors);	chr8:57246793	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.775	rs17805026	ENSG00000253301.4	RP11-513O17.2	4.94	2.52e-06	0.00251	0.55	0.41	Developmental language disorder (linguistic errors);	chr8:57248078	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.775	rs17805146	ENSG00000253301.4	RP11-513O17.2	4.94	2.52e-06	0.00251	0.55	0.41	Developmental language disorder (linguistic errors);	chr8:57248925	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.775	rs72650876	ENSG00000253301.4	RP11-513O17.2	4.94	2.52e-06	0.00251	0.55	0.41	Developmental language disorder (linguistic errors);	chr8:57249079	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.775	rs10504228	ENSG00000253301.4	RP11-513O17.2	4.94	2.52e-06	0.00251	0.55	0.41	Developmental language disorder (linguistic errors);	chr8:57249494	chr8:57142689~57240298:+
TGCT	cis	rs9326248	0.53	rs6589576	ENSG00000254851.1	RP11-109L13.1	4.93	2.52e-06	0.00251	0.74	0.41	Blood protein levels;	chr11:116865072	chr11:117135528~117138582:+
TGCT	cis	rs2276314	0.857	rs28540805	ENSG00000278986.1	RP11-723J4.3	-4.93	2.53e-06	0.00251	-0.48	-0.41	Endometriosis;Drug-induced torsades de pointes;	chr18:36062012	chr18:35972151~35973916:+
TGCT	cis	rs9326248	0.53	rs10790172	ENSG00000254851.1	RP11-109L13.1	-4.93	2.53e-06	0.00252	-0.8	-0.41	Blood protein levels;	chr11:117057024	chr11:117135528~117138582:+
TGCT	cis	rs11822910	0.911	rs2250887	ENSG00000265566.2	RN7SL605P	4.93	2.54e-06	0.00252	0.51	0.41	Platelet distribution width;	chr11:57434711	chr11:57528085~57528365:-
TGCT	cis	rs1799949	0.965	rs11080034	ENSG00000198496.9	NBR2	-4.93	2.54e-06	0.00252	-0.57	-0.41	Menopause (age at onset);	chr17:43365646	chr17:43125610~43153671:+
TGCT	cis	rs2976388	0.647	rs2164307	ENSG00000253196.1	RP11-706C16.7	4.93	2.54e-06	0.00252	0.4	0.41	Urinary tract infection frequency;	chr8:142707413	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.573	rs1529865	ENSG00000253196.1	RP11-706C16.7	4.93	2.54e-06	0.00252	0.4	0.41	Urinary tract infection frequency;	chr8:142707753	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.609	rs1560986	ENSG00000253196.1	RP11-706C16.7	4.93	2.54e-06	0.00252	0.4	0.41	Urinary tract infection frequency;	chr8:142708357	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.609	rs2376491	ENSG00000253196.1	RP11-706C16.7	4.93	2.54e-06	0.00252	0.4	0.41	Urinary tract infection frequency;	chr8:142709516	chr8:142763116~142766427:+
TGCT	cis	rs2276314	0.857	rs56230698	ENSG00000278986.1	RP11-723J4.3	-4.93	2.54e-06	0.00252	-0.47	-0.41	Endometriosis;Drug-induced torsades de pointes;	chr18:36048922	chr18:35972151~35973916:+
TGCT	cis	rs1320333	0.772	rs17786111	ENSG00000233296.1	AC092159.2	4.93	2.54e-06	0.00252	0.57	0.41	Obesity-related traits;	chr2:700562	chr2:677186~697371:+
TGCT	cis	rs1320333	0.685	rs6710875	ENSG00000233296.1	AC092159.2	-4.93	2.54e-06	0.00252	-0.57	-0.41	Obesity-related traits;	chr2:699976	chr2:677186~697371:+
TGCT	cis	rs2709736	0.563	rs204597	ENSG00000232790.2	LINC01162	-4.93	2.55e-06	0.00253	-0.32	-0.41	Bipolar I disorder;	chr7:20872775	chr7:20835431~21023148:+
TGCT	cis	rs11231017	0.507	rs10897267	ENSG00000254454.2	RCC2P6	-4.93	2.55e-06	0.00253	-0.28	-0.41	HIV-1 viral setpoint;	chr11:62389946	chr11:62371146~62373168:+
TGCT	cis	rs853679	0.506	rs1150693	ENSG00000219392.1	RP1-265C24.5	-4.93	2.55e-06	0.00253	-0.54	-0.4	Depression;	chr6:28206812	chr6:28115628~28116551:+
TGCT	cis	rs3096299	0.9	rs2911258	ENSG00000274627.1	RP11-104N10.2	4.93	2.55e-06	0.00253	0.42	0.4	Multiple myeloma (IgH translocation);	chr16:89414352	chr16:89516797~89522217:+
TGCT	cis	rs796364	1	rs4263095	ENSG00000232732.8	AC073043.1	4.93	2.56e-06	0.00254	0.57	0.4	Schizophrenia;	chr2:199965414	chr2:199867396~199911159:-
TGCT	cis	rs796364	1	rs1704186	ENSG00000232732.8	AC073043.1	-4.93	2.56e-06	0.00254	-0.57	-0.4	Schizophrenia;	chr2:199904816	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.906	rs281789	ENSG00000232732.8	AC073043.1	-4.93	2.56e-06	0.00254	-0.57	-0.4	Schizophrenia;	chr2:199915975	chr2:199867396~199911159:-
TGCT	cis	rs796364	1	rs281788	ENSG00000232732.8	AC073043.1	-4.93	2.56e-06	0.00254	-0.57	-0.4	Schizophrenia;	chr2:199918982	chr2:199867396~199911159:-
TGCT	cis	rs796364	1	rs281759	ENSG00000232732.8	AC073043.1	-4.93	2.56e-06	0.00254	-0.57	-0.4	Schizophrenia;	chr2:199922996	chr2:199867396~199911159:-
TGCT	cis	rs796364	1	rs281760	ENSG00000232732.8	AC073043.1	-4.93	2.56e-06	0.00254	-0.57	-0.4	Schizophrenia;	chr2:199923081	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.951	rs3098341	ENSG00000232732.8	AC073043.1	-4.93	2.56e-06	0.00254	-0.57	-0.4	Schizophrenia;	chr2:199927775	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.951	rs971232	ENSG00000232732.8	AC073043.1	-4.93	2.56e-06	0.00254	-0.57	-0.4	Schizophrenia;	chr2:199928158	chr2:199867396~199911159:-
TGCT	cis	rs796364	1	rs281763	ENSG00000232732.8	AC073043.1	-4.93	2.56e-06	0.00254	-0.57	-0.4	Schizophrenia;	chr2:199930147	chr2:199867396~199911159:-
TGCT	cis	rs796364	1	rs281762	ENSG00000232732.8	AC073043.1	-4.93	2.56e-06	0.00254	-0.57	-0.4	Schizophrenia;	chr2:199934478	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.951	rs281769	ENSG00000232732.8	AC073043.1	-4.93	2.56e-06	0.00254	-0.57	-0.4	Schizophrenia;	chr2:199944986	chr2:199867396~199911159:-
TGCT	cis	rs796364	1	rs281774	ENSG00000232732.8	AC073043.1	-4.93	2.56e-06	0.00254	-0.57	-0.4	Schizophrenia;	chr2:199949849	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.789	rs176008	ENSG00000232732.8	AC073043.1	-4.93	2.56e-06	0.00254	-0.57	-0.4	Schizophrenia;	chr2:199949997	chr2:199867396~199911159:-
TGCT	cis	rs796364	1	rs4410273	ENSG00000232732.8	AC073043.1	-4.93	2.56e-06	0.00254	-0.57	-0.4	Schizophrenia;	chr2:199953535	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.906	rs281766	ENSG00000232732.8	AC073043.1	-4.93	2.56e-06	0.00254	-0.57	-0.4	Schizophrenia;	chr2:199955782	chr2:199867396~199911159:-
TGCT	cis	rs796364	1	rs166845	ENSG00000232732.8	AC073043.1	-4.93	2.56e-06	0.00254	-0.57	-0.4	Schizophrenia;	chr2:199958637	chr2:199867396~199911159:-
TGCT	cis	rs796364	1	rs10178177	ENSG00000232732.8	AC073043.1	-4.93	2.56e-06	0.00254	-0.57	-0.4	Schizophrenia;	chr2:199965270	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.951	rs281776	ENSG00000232732.8	AC073043.1	-4.93	2.56e-06	0.00254	-0.57	-0.4	Schizophrenia;	chr2:199969559	chr2:199867396~199911159:-
TGCT	cis	rs7301826	1	rs1609985	ENSG00000256299.1	RP11-989F5.3	-4.93	2.56e-06	0.00254	-0.44	-0.4	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810821~130812622:-
TGCT	cis	rs4835473	0.868	rs5025156	ENSG00000251600.4	RP11-673E1.1	-4.93	2.56e-06	0.00254	-0.42	-0.4	Immature fraction of reticulocytes;	chr4:143738025	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs13117421	ENSG00000251600.4	RP11-673E1.1	-4.93	2.56e-06	0.00254	-0.42	-0.4	Immature fraction of reticulocytes;	chr4:143769405	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.838	rs34521499	ENSG00000251600.4	RP11-673E1.1	-4.93	2.56e-06	0.00254	-0.42	-0.4	Immature fraction of reticulocytes;	chr4:143777628	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs34264936	ENSG00000251600.4	RP11-673E1.1	-4.93	2.56e-06	0.00254	-0.42	-0.4	Immature fraction of reticulocytes;	chr4:143780294	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs13140028	ENSG00000251600.4	RP11-673E1.1	-4.93	2.56e-06	0.00254	-0.42	-0.4	Immature fraction of reticulocytes;	chr4:143782195	chr4:143912331~143982454:+
TGCT	cis	rs2442825	0.693	rs2728924	ENSG00000206573.7	THUMPD3-AS1	4.93	2.56e-06	0.00254	0.36	0.4	Cerebrospinal fluid clusterin levels;	chr3:9381294	chr3:9349689~9398579:-
TGCT	cis	rs2442825	0.693	rs2600194	ENSG00000206573.7	THUMPD3-AS1	4.93	2.56e-06	0.00254	0.36	0.4	Cerebrospinal fluid clusterin levels;	chr3:9382941	chr3:9349689~9398579:-
TGCT	cis	rs7104764	0.719	rs3782116	ENSG00000277290.1	RP11-326C3.16	-4.93	2.57e-06	0.00254	-0.38	-0.4	Menarche (age at onset);	chr11:223119	chr11:243099~243483:-
TGCT	cis	rs16975963	0.644	rs12462505	ENSG00000276846.1	CTD-3220F14.3	-4.93	2.57e-06	0.00255	-0.4	-0.4	Longevity;	chr19:37647224	chr19:37314868~37315620:-
TGCT	cis	rs16975963	0.644	rs11083430	ENSG00000276846.1	CTD-3220F14.3	-4.93	2.57e-06	0.00255	-0.4	-0.4	Longevity;	chr19:37648587	chr19:37314868~37315620:-
TGCT	cis	rs16975963	0.644	rs73035158	ENSG00000276846.1	CTD-3220F14.3	-4.93	2.57e-06	0.00255	-0.4	-0.4	Longevity;	chr19:37650979	chr19:37314868~37315620:-
TGCT	cis	rs16975963	0.644	rs1478462	ENSG00000276846.1	CTD-3220F14.3	-4.93	2.57e-06	0.00255	-0.4	-0.4	Longevity;	chr19:37656124	chr19:37314868~37315620:-
TGCT	cis	rs73607972	0.778	rs55662133	ENSG00000275191.1	RP11-36I17.2	-4.93	2.57e-06	0.00255	-0.48	-0.4	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53612761	chr16:53628256~53628816:-
TGCT	cis	rs9462027	0.585	rs188190	ENSG00000186328.4	RP11-140K17.2	4.93	2.58e-06	0.00255	0.38	0.4	Systemic lupus erythematosus;	chr6:34583309	chr6:34715613~34715940:+
TGCT	cis	rs524281	0.731	rs2430979	ENSG00000255320.1	RP11-755F10.1	-4.93	2.58e-06	0.00255	-0.57	-0.4	Electroencephalogram traits;	chr11:66045912	chr11:66244840~66246239:-
TGCT	cis	rs8059260	0.604	rs76969865	ENSG00000274038.1	RP11-66H6.4	-4.93	2.58e-06	0.00256	-0.57	-0.4	Alcohol consumption over the past year;	chr16:11050092	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.604	rs16957984	ENSG00000274038.1	RP11-66H6.4	-4.93	2.58e-06	0.00256	-0.57	-0.4	Alcohol consumption over the past year;	chr16:11051105	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.604	rs78753859	ENSG00000274038.1	RP11-66H6.4	-4.93	2.58e-06	0.00256	-0.57	-0.4	Alcohol consumption over the past year;	chr16:11052774	chr16:11056556~11057034:+
TGCT	cis	rs7617773	0.925	rs7374376	ENSG00000229759.1	MRPS18AP1	-4.93	2.59e-06	0.00256	-0.32	-0.4	Coronary artery disease;	chr3:48131197	chr3:48256350~48256938:-
TGCT	cis	rs11673344	0.67	rs73039188	ENSG00000226686.6	LINC01535	4.93	2.59e-06	0.00256	0.46	0.4	Obesity-related traits;	chr19:36922449	chr19:37251912~37265535:+
TGCT	cis	rs1075265	0.568	rs7604357	ENSG00000233266.1	HMGB1P31	4.93	2.6e-06	0.00257	0.44	0.4	Chronotype;Morning vs. evening chronotype;	chr2:54074026	chr2:54051334~54051760:+
TGCT	cis	rs1075265	0.568	rs10865277	ENSG00000233266.1	HMGB1P31	4.93	2.6e-06	0.00257	0.44	0.4	Chronotype;Morning vs. evening chronotype;	chr2:54074865	chr2:54051334~54051760:+
TGCT	cis	rs7684446	1	rs7684446	ENSG00000273133.1	RP11-799M12.2	4.93	2.6e-06	0.00257	0.54	0.4	Red blood cell count;	chr4:15591241	chr4:15563698~15564253:-
TGCT	cis	rs1789	0.653	rs13142069	ENSG00000273133.1	RP11-799M12.2	4.93	2.6e-06	0.00257	0.54	0.4	Blood protein levels;	chr4:15592069	chr4:15563698~15564253:-
TGCT	cis	rs2742234	0.59	rs2293020	ENSG00000273008.1	RP11-351D16.3	4.93	2.6e-06	0.00257	0.53	0.4	Hirschsprung disease;	chr10:43197439	chr10:43136824~43138334:-
TGCT	cis	rs8022179	0.58	rs6575979	ENSG00000244691.1	RPL10AP1	-4.93	2.6e-06	0.00257	-0.57	-0.4	Monocyte count;	chr14:103374681	chr14:103412119~103412761:-
TGCT	cis	rs10246939	0.579	rs6969430	ENSG00000228775.6	WEE2-AS1	4.93	2.6e-06	0.00257	0.36	0.4	Bitter taste perception;	chr7:141831340	chr7:141704338~141738346:-
TGCT	cis	rs10246939	0.579	rs35647444	ENSG00000228775.6	WEE2-AS1	4.93	2.6e-06	0.00257	0.36	0.4	Bitter taste perception;	chr7:141833957	chr7:141704338~141738346:-
TGCT	cis	rs17123764	0.71	rs933738	ENSG00000257464.1	RP11-161H23.8	-4.93	2.6e-06	0.00257	-0.52	-0.4	Intelligence (multi-trait analysis);	chr12:49549339	chr12:49442424~49442652:-
TGCT	cis	rs2442825	0.693	rs2255558	ENSG00000206573.7	THUMPD3-AS1	4.93	2.6e-06	0.00257	0.37	0.4	Cerebrospinal fluid clusterin levels;	chr3:9375148	chr3:9349689~9398579:-
TGCT	cis	rs2442825	0.72	rs2648561	ENSG00000206573.7	THUMPD3-AS1	4.93	2.6e-06	0.00257	0.37	0.4	Cerebrospinal fluid clusterin levels;	chr3:9376399	chr3:9349689~9398579:-
TGCT	cis	rs3096299	0.967	rs2911255	ENSG00000274627.1	RP11-104N10.2	4.93	2.6e-06	0.00257	0.42	0.4	Multiple myeloma (IgH translocation);	chr16:89420729	chr16:89516797~89522217:+
TGCT	cis	rs67311347	1	rs9854493	ENSG00000223797.4	ENTPD3-AS1	4.93	2.61e-06	0.00258	0.43	0.4	Renal cell carcinoma;	chr3:40382131	chr3:40313802~40453329:-
TGCT	cis	rs10875976	0.525	rs9805137	ENSG00000242041.1	RP11-70F11.2	4.93	2.61e-06	0.00258	0.39	0.4	Obesity;	chr12:49865279	chr12:49863173~49863503:+
TGCT	cis	rs9326248	0.53	rs7114963	ENSG00000254851.1	RP11-109L13.1	-4.93	2.61e-06	0.00258	-0.69	-0.4	Blood protein levels;	chr11:117005267	chr11:117135528~117138582:+
TGCT	cis	rs7115242	0.72	rs10790169	ENSG00000254851.1	RP11-109L13.1	-4.93	2.61e-06	0.00258	-0.69	-0.4	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117006443	chr11:117135528~117138582:+
TGCT	cis	rs9326248	0.53	rs7950364	ENSG00000254851.1	RP11-109L13.1	-4.93	2.61e-06	0.00258	-0.69	-0.4	Blood protein levels;	chr11:117028170	chr11:117135528~117138582:+
TGCT	cis	rs12745968	0.652	rs10782912	ENSG00000223787.2	RP4-593M8.1	-4.93	2.62e-06	0.00259	-0.53	-0.4	Bipolar disorder and schizophrenia;	chr1:92491355	chr1:92580476~92580821:-
TGCT	cis	rs761746	0.739	rs5998086	ENSG00000236132.1	CTA-440B3.1	-4.93	2.62e-06	0.00259	-0.51	-0.4	Intelligence;	chr22:31684258	chr22:31816379~31817491:-
TGCT	cis	rs761746	0.739	rs140081	ENSG00000236132.1	CTA-440B3.1	-4.93	2.62e-06	0.00259	-0.51	-0.4	Intelligence;	chr22:31716475	chr22:31816379~31817491:-
TGCT	cis	rs761746	0.739	rs131225	ENSG00000236132.1	CTA-440B3.1	-4.93	2.62e-06	0.00259	-0.51	-0.4	Intelligence;	chr22:31717863	chr22:31816379~31817491:-
TGCT	cis	rs761746	0.695	rs3804087	ENSG00000236132.1	CTA-440B3.1	4.93	2.62e-06	0.00259	0.51	0.4	Intelligence;	chr22:31683317	chr22:31816379~31817491:-
TGCT	cis	rs35160687	0.901	rs35762338	ENSG00000273080.1	RP11-301O19.1	4.93	2.62e-06	0.00259	0.46	0.4	Night sleep phenotypes;	chr2:86286430	chr2:86195590~86196049:+
TGCT	cis	rs35160687	0.901	rs17738096	ENSG00000273080.1	RP11-301O19.1	4.93	2.62e-06	0.00259	0.46	0.4	Night sleep phenotypes;	chr2:86286770	chr2:86195590~86196049:+
TGCT	cis	rs35160687	0.901	rs12714179	ENSG00000273080.1	RP11-301O19.1	4.93	2.62e-06	0.00259	0.46	0.4	Night sleep phenotypes;	chr2:86287835	chr2:86195590~86196049:+
TGCT	cis	rs9584850	0.834	rs4294654	ENSG00000231194.1	FARP1-AS1	4.93	2.63e-06	0.00259	0.53	0.4	Neuroticism;	chr13:98467353	chr13:98435405~98435840:-
TGCT	cis	rs34779708	0.931	rs4934702	ENSG00000230534.5	RP11-297A16.2	4.93	2.63e-06	0.00259	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35034146	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs2244100	ENSG00000230534.5	RP11-297A16.2	-4.93	2.63e-06	0.00259	-0.48	-0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35034708	chr10:35098006~35127020:-
TGCT	cis	rs507080	0.961	rs520543	ENSG00000255422.1	AP002954.4	-4.93	2.63e-06	0.00259	-0.47	-0.4	Serum metabolite levels;	chr11:118667448	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.922	rs4589335	ENSG00000255422.1	AP002954.4	-4.93	2.63e-06	0.00259	-0.47	-0.4	Serum metabolite levels;	chr11:118668431	chr11:118704607~118750263:+
TGCT	cis	rs3096299	0.586	rs4572400	ENSG00000274627.1	RP11-104N10.2	4.93	2.63e-06	0.0026	0.43	0.4	Multiple myeloma (IgH translocation);	chr16:89467108	chr16:89516797~89522217:+
TGCT	cis	rs7182621	0.622	rs12904160	ENSG00000259363.4	CTD-2054N24.2	-4.92	2.64e-06	0.00261	-0.39	-0.4	Colonoscopy-negative controls vs population controls;	chr15:99869471	chr15:99807023~99877148:+
TGCT	cis	rs1336900	0.544	rs10888386	ENSG00000206931.1	RNU6-1042P	-4.92	2.65e-06	0.00262	-0.33	-0.4	Blood protein levels;	chr1:150639481	chr1:150701866~150701972:+
TGCT	cis	rs6600671	0.934	rs67718113	ENSG00000275131.1	CH17-472G23.4	4.92	2.65e-06	0.00262	0.27	0.4	Hip geometry;	chr1:121497112	chr1:120489625~120579190:-
TGCT	cis	rs1618992	0.729	rs8085050	ENSG00000265994.1	RP11-510D21.1	4.92	2.66e-06	0.00262	0.41	0.4	Gut microbiome composition (summer and winter);	chr18:28586327	chr18:28785068~28789260:+
TGCT	cis	rs67311347	1	rs11707673	ENSG00000223797.4	ENTPD3-AS1	4.92	2.66e-06	0.00262	0.42	0.4	Renal cell carcinoma;	chr3:40409113	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs4973993	ENSG00000223797.4	ENTPD3-AS1	4.92	2.66e-06	0.00262	0.42	0.4	Renal cell carcinoma;	chr3:40411469	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs4973994	ENSG00000223797.4	ENTPD3-AS1	4.92	2.66e-06	0.00262	0.42	0.4	Renal cell carcinoma;	chr3:40411533	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs9833430	ENSG00000223797.4	ENTPD3-AS1	4.92	2.66e-06	0.00262	0.42	0.4	Renal cell carcinoma;	chr3:40417552	chr3:40313802~40453329:-
TGCT	cis	rs67311347	0.784	rs13326389	ENSG00000223797.4	ENTPD3-AS1	4.92	2.66e-06	0.00262	0.42	0.4	Renal cell carcinoma;	chr3:40418233	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs12492035	ENSG00000223797.4	ENTPD3-AS1	4.92	2.66e-06	0.00262	0.42	0.4	Renal cell carcinoma;	chr3:40425619	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs11707278	ENSG00000223797.4	ENTPD3-AS1	4.92	2.66e-06	0.00262	0.42	0.4	Renal cell carcinoma;	chr3:40445584	chr3:40313802~40453329:-
TGCT	cis	rs8111998	0.826	rs7245541	ENSG00000269332.4	GOLGA2P9	-4.92	2.66e-06	0.00262	-0.65	-0.4	Corneal structure;	chr19:22585969	chr19:22596257~22603550:+
TGCT	cis	rs11673344	0.698	rs56161518	ENSG00000226686.6	LINC01535	4.92	2.66e-06	0.00262	0.46	0.4	Obesity-related traits;	chr19:36978555	chr19:37251912~37265535:+
TGCT	cis	rs10256972	0.552	rs2960837	ENSG00000226291.1	AC091729.8	-4.92	2.66e-06	0.00262	-0.43	-0.4	Endometriosis;Longevity;	chr7:1164321	chr7:1080863~1082178:+
TGCT	cis	rs4835473	0.932	rs6827971	ENSG00000251600.4	RP11-673E1.1	-4.92	2.66e-06	0.00262	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143822126	chr4:143912331~143982454:+
TGCT	cis	rs7829975	0.606	rs10112585	ENSG00000173295.6	FAM86B3P	-4.92	2.66e-06	0.00262	-0.47	-0.4	Mood instability;	chr8:8937520	chr8:8228595~8244865:+
TGCT	cis	rs7829975	0.572	rs7005000	ENSG00000173295.6	FAM86B3P	-4.92	2.66e-06	0.00262	-0.47	-0.4	Mood instability;	chr8:8939092	chr8:8228595~8244865:+
TGCT	cis	rs17301013	0.507	rs7515116	ENSG00000227373.4	RP11-160H22.5	-4.92	2.66e-06	0.00262	-0.56	-0.4	Systemic lupus erythematosus;	chr1:174474516	chr1:174115300~174160004:-
TGCT	cis	rs904251	0.6	rs9380673	ENSG00000279942.1	RP1-153P14.7	-4.92	2.67e-06	0.00263	-0.41	-0.4	Cognitive performance;	chr6:37447349	chr6:37567716~37571460:+
TGCT	cis	rs2015599	0.549	rs7134796	ENSG00000257176.2	RP11-996F15.2	4.92	2.67e-06	0.00263	0.43	0.4	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29280418~29317848:-
TGCT	cis	rs4835473	0.808	rs6831401	ENSG00000251600.4	RP11-673E1.1	-4.92	2.67e-06	0.00263	-0.42	-0.4	Immature fraction of reticulocytes;	chr4:143801038	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.778	rs6853798	ENSG00000251600.4	RP11-673E1.1	-4.92	2.67e-06	0.00263	-0.42	-0.4	Immature fraction of reticulocytes;	chr4:143801153	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs12502940	ENSG00000251600.4	RP11-673E1.1	-4.92	2.67e-06	0.00263	-0.42	-0.4	Immature fraction of reticulocytes;	chr4:143812117	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs12503074	ENSG00000251600.4	RP11-673E1.1	-4.92	2.67e-06	0.00263	-0.42	-0.4	Immature fraction of reticulocytes;	chr4:143812560	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.778	rs2622380	ENSG00000251600.4	RP11-673E1.1	-4.92	2.67e-06	0.00263	-0.42	-0.4	Immature fraction of reticulocytes;	chr4:143814571	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs35792820	ENSG00000251600.4	RP11-673E1.1	-4.92	2.67e-06	0.00263	-0.42	-0.4	Immature fraction of reticulocytes;	chr4:143814806	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.864	rs62337300	ENSG00000251600.4	RP11-673E1.1	-4.92	2.67e-06	0.00263	-0.42	-0.4	Immature fraction of reticulocytes;	chr4:143815897	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs7697498	ENSG00000251600.4	RP11-673E1.1	-4.92	2.67e-06	0.00263	-0.42	-0.4	Immature fraction of reticulocytes;	chr4:143816854	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs7656455	ENSG00000251600.4	RP11-673E1.1	-4.92	2.67e-06	0.00263	-0.42	-0.4	Immature fraction of reticulocytes;	chr4:143817005	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs13133239	ENSG00000251600.4	RP11-673E1.1	-4.92	2.67e-06	0.00263	-0.42	-0.4	Immature fraction of reticulocytes;	chr4:143818894	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs13106488	ENSG00000251600.4	RP11-673E1.1	-4.92	2.67e-06	0.00263	-0.42	-0.4	Immature fraction of reticulocytes;	chr4:143818969	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs13105102	ENSG00000251600.4	RP11-673E1.1	-4.92	2.67e-06	0.00263	-0.42	-0.4	Immature fraction of reticulocytes;	chr4:143819046	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.868	rs13105118	ENSG00000251600.4	RP11-673E1.1	-4.92	2.67e-06	0.00263	-0.42	-0.4	Immature fraction of reticulocytes;	chr4:143819077	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs35271123	ENSG00000251600.4	RP11-673E1.1	-4.92	2.67e-06	0.00263	-0.42	-0.4	Immature fraction of reticulocytes;	chr4:143819629	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1383443	ENSG00000251600.4	RP11-673E1.1	-4.92	2.67e-06	0.00263	-0.42	-0.4	Immature fraction of reticulocytes;	chr4:143819940	chr4:143912331~143982454:+
TGCT	cis	rs4927850	1	rs10881563	ENSG00000207650.1	MIR570	4.92	2.67e-06	0.00263	0.51	0.4	Pancreatic cancer;	chr3:196023354	chr3:195699401~195699497:+
TGCT	cis	rs867371	1	rs8042464	ENSG00000255769.6	GOLGA2P10	-4.92	2.67e-06	0.00263	-0.44	-0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173195	chr15:82472993~82513950:-
TGCT	cis	rs17301013	0.932	rs12077622	ENSG00000227373.4	RP11-160H22.5	4.92	2.67e-06	0.00263	0.42	0.4	Systemic lupus erythematosus;	chr1:174442507	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.932	rs6664764	ENSG00000227373.4	RP11-160H22.5	4.92	2.67e-06	0.00263	0.42	0.4	Systemic lupus erythematosus;	chr1:174443402	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.932	rs6425281	ENSG00000227373.4	RP11-160H22.5	4.92	2.67e-06	0.00263	0.42	0.4	Systemic lupus erythematosus;	chr1:174449784	chr1:174115300~174160004:-
TGCT	cis	rs9462027	0.606	rs2814981	ENSG00000186328.4	RP11-140K17.2	4.92	2.67e-06	0.00263	0.38	0.4	Systemic lupus erythematosus;	chr6:34613278	chr6:34715613~34715940:+
TGCT	cis	rs6600671	0.691	rs6600662	ENSG00000275131.1	CH17-472G23.4	-4.92	2.68e-06	0.00263	-0.24	-0.4	Hip geometry;	chr1:121488992	chr1:120489625~120579190:-
TGCT	cis	rs673078	0.607	rs7304342	ENSG00000275759.1	RP11-131L12.3	-4.92	2.68e-06	0.00264	-0.74	-0.4	Glucose homeostasis traits;	chr12:118390166	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.615	rs61943397	ENSG00000275759.1	RP11-131L12.3	-4.92	2.68e-06	0.00264	-0.74	-0.4	Glucose homeostasis traits;	chr12:118390996	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs61943398	ENSG00000275759.1	RP11-131L12.3	-4.92	2.68e-06	0.00264	-0.74	-0.4	Glucose homeostasis traits;	chr12:118393280	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs61943403	ENSG00000275759.1	RP11-131L12.3	-4.92	2.68e-06	0.00264	-0.74	-0.4	Glucose homeostasis traits;	chr12:118399887	chr12:118428281~118428870:+
TGCT	cis	rs8040855	0.965	rs1961276	ENSG00000259295.5	CSPG4P12	4.92	2.68e-06	0.00264	0.51	0.4	Bulimia nervosa;	chr15:85170986	chr15:85191438~85213905:+
TGCT	cis	rs12935418	0.733	rs35115578	ENSG00000261061.1	RP11-303E16.2	-4.92	2.68e-06	0.00264	-0.6	-0.4	Mean corpuscular volume;	chr16:80946392	chr16:81030770~81031485:+
TGCT	cis	rs7927592	0.731	rs7108376	ENSG00000212093.1	AP000807.1	-4.92	2.7e-06	0.00265	-0.39	-0.4	Total body bone mineral density;	chr11:68580402	chr11:68506083~68506166:-
TGCT	cis	rs7927592	0.731	rs11228288	ENSG00000212093.1	AP000807.1	4.92	2.7e-06	0.00265	0.39	0.4	Total body bone mineral density;	chr11:68586082	chr11:68506083~68506166:-
TGCT	cis	rs7927592	0.763	rs2513277	ENSG00000212093.1	AP000807.1	4.92	2.7e-06	0.00265	0.39	0.4	Total body bone mineral density;	chr11:68593419	chr11:68506083~68506166:-
TGCT	cis	rs7927592	0.763	rs4340059	ENSG00000212093.1	AP000807.1	4.92	2.7e-06	0.00265	0.39	0.4	Total body bone mineral density;	chr11:68594965	chr11:68506083~68506166:-
TGCT	cis	rs8105895	0.935	rs7259971	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22054517	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs6511316	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22054827	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs10406553	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22054999	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs10406653	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22055221	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs10407250	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22055349	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs10412953	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22055680	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs4510150	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22056867	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs4542784	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22056949	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs4257328	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22057288	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs10404669	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22058416	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.877	rs9973249	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22059358	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.877	rs2359833	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22059419	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.877	rs2163837	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22059434	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs2163835	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22059877	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs28857211	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22060302	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs28894669	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22060462	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs10406551	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22061718	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs10405613	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22061970	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs10405673	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22062088	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs10406485	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22062200	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs10406119	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22062207	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs10408150	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22062423	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs7251884	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22062728	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs7252023	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22062844	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs7253053	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22062883	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs7252550	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22063215	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs10413784	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22063389	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs10407173	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22063861	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs8104144	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22064111	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs8103518	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22064150	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs8104630	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22064475	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs9653157	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22066688	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs9653142	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22066794	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs7247041	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22066988	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs7247147	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22067056	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs7247228	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22067334	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.877	rs7248305	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22067469	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs7250905	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22067941	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs2043317	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22068294	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs2043316	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22068402	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs8108651	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22068662	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs8108976	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22068899	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs10420019	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22069103	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs10420042	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22069124	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs2043315	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22070021	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.778	rs10401922	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22070450	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs10422289	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22073258	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs78646027	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22074608	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs10411275	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22076667	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs10411943	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22076980	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs62110990	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22077639	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.799	rs10426159	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22084522	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.932	rs28600030	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22085641	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs6511321	ENSG00000269742.1	BNIP3P29	4.92	2.7e-06	0.00265	0.71	0.4	Body mass index (change over time);	chr19:22087266	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs6511314	ENSG00000269742.1	BNIP3P29	-4.92	2.7e-06	0.00265	-0.71	-0.4	Body mass index (change over time);	chr19:22053593	chr19:22065828~22066398:-
TGCT	cis	rs4835473	0.838	rs6832094	ENSG00000251600.4	RP11-673E1.1	-4.92	2.7e-06	0.00265	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143795388	chr4:143912331~143982454:+
TGCT	cis	rs9425766	0.64	rs10912734	ENSG00000227373.4	RP11-160H22.5	4.92	2.7e-06	0.00265	0.43	0.4	Life satisfaction;	chr1:174141977	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.628	rs6425274	ENSG00000227373.4	RP11-160H22.5	4.92	2.7e-06	0.00265	0.43	0.4	Life satisfaction;	chr1:174144270	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.566	rs6696076	ENSG00000227373.4	RP11-160H22.5	4.92	2.7e-06	0.00265	0.43	0.4	Life satisfaction;	chr1:174149900	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.679	rs4652234	ENSG00000227373.4	RP11-160H22.5	4.92	2.7e-06	0.00265	0.43	0.4	Life satisfaction;	chr1:174181712	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.732	rs6658543	ENSG00000227373.4	RP11-160H22.5	4.92	2.7e-06	0.00265	0.43	0.4	Life satisfaction;	chr1:174183338	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.679	rs6656188	ENSG00000227373.4	RP11-160H22.5	4.92	2.7e-06	0.00265	0.43	0.4	Life satisfaction;	chr1:174183550	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.679	rs12087441	ENSG00000227373.4	RP11-160H22.5	4.92	2.7e-06	0.00265	0.43	0.4	Life satisfaction;	chr1:174188696	chr1:174115300~174160004:-
TGCT	cis	rs801193	0.935	rs11772264	ENSG00000237310.1	GS1-124K5.4	4.92	2.7e-06	0.00265	0.46	0.4	Aortic root size;	chr7:66711400	chr7:66493706~66495474:+
TGCT	cis	rs3096299	0.967	rs2911257	ENSG00000274627.1	RP11-104N10.2	4.92	2.71e-06	0.00265	0.42	0.4	Multiple myeloma (IgH translocation);	chr16:89417726	chr16:89516797~89522217:+
TGCT	cis	rs4660456	0.913	rs569159	ENSG00000237899.1	RP4-739H11.3	-4.92	2.71e-06	0.00265	-0.53	-0.4	Platelet count;	chr1:40701862	chr1:40669089~40687588:-
TGCT	cis	rs10504229	0.815	rs16921955	ENSG00000253301.4	RP11-513O17.2	4.92	2.71e-06	0.00266	0.53	0.4	Developmental language disorder (linguistic errors);	chr8:57251994	chr8:57142689~57240298:+
TGCT	cis	rs3096299	0.967	rs2965932	ENSG00000274627.1	RP11-104N10.2	-4.92	2.71e-06	0.00266	-0.42	-0.4	Multiple myeloma (IgH translocation);	chr16:89410643	chr16:89516797~89522217:+
TGCT	cis	rs8091660	0.929	rs11082685	ENSG00000278983.1	RP11-426J5.3	4.92	2.72e-06	0.00266	0.48	0.4	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48566806	chr18:48564795~48568342:+
TGCT	cis	rs7221109	0.56	rs2469818	ENSG00000278834.1	RP11-458J1.1	-4.92	2.72e-06	0.00266	-0.31	-0.4	Type 1 diabetes;	chr17:40708479	chr17:40648300~40649718:+
TGCT	cis	rs1387259	0.839	rs7486941	ENSG00000258273.1	RP11-370I10.4	4.92	2.72e-06	0.00266	0.44	0.4	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48333755~48333901:-
TGCT	cis	rs1387259	0.839	rs7487682	ENSG00000258273.1	RP11-370I10.4	4.92	2.72e-06	0.00266	0.44	0.4	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48333755~48333901:-
TGCT	cis	rs10246939	0.553	rs34894166	ENSG00000228775.6	WEE2-AS1	4.92	2.73e-06	0.00268	0.35	0.4	Bitter taste perception;	chr7:141852158	chr7:141704338~141738346:-
TGCT	cis	rs10246939	0.579	rs17133534	ENSG00000228775.6	WEE2-AS1	4.92	2.73e-06	0.00268	0.35	0.4	Bitter taste perception;	chr7:141860855	chr7:141704338~141738346:-
TGCT	cis	rs10246939	0.579	rs13232651	ENSG00000228775.6	WEE2-AS1	4.92	2.73e-06	0.00268	0.35	0.4	Bitter taste perception;	chr7:141862624	chr7:141704338~141738346:-
TGCT	cis	rs9425766	0.679	rs60363188	ENSG00000227373.4	RP11-160H22.5	4.92	2.74e-06	0.00268	0.42	0.4	Life satisfaction;	chr1:174375959	chr1:174115300~174160004:-
TGCT	cis	rs9326248	0.53	rs2075292	ENSG00000254851.1	RP11-109L13.1	-4.92	2.74e-06	0.00268	-0.76	-0.4	Blood protein levels;	chr11:116861796	chr11:117135528~117138582:+
TGCT	cis	rs9326248	0.53	rs6589575	ENSG00000254851.1	RP11-109L13.1	-4.92	2.74e-06	0.00268	-0.76	-0.4	Blood protein levels;	chr11:116862594	chr11:117135528~117138582:+
TGCT	cis	rs9326248	0.53	rs718847	ENSG00000254851.1	RP11-109L13.1	-4.92	2.74e-06	0.00268	-0.76	-0.4	Blood protein levels;	chr11:116863430	chr11:117135528~117138582:+
TGCT	cis	rs7617773	0.925	rs34513961	ENSG00000229759.1	MRPS18AP1	4.92	2.75e-06	0.00269	0.35	0.4	Coronary artery disease;	chr3:48132163	chr3:48256350~48256938:-
TGCT	cis	rs5760092	0.572	rs738806	ENSG00000273295.1	AP000350.5	4.92	2.75e-06	0.00269	0.51	0.4	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23901432~23907068:-
TGCT	cis	rs7208859	0.673	rs450585	ENSG00000266490.1	CTD-2349P21.9	4.92	2.75e-06	0.00269	0.42	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30792372~30792833:+
TGCT	cis	rs5742933	0.857	rs7571089	ENSG00000273240.1	RP11-455J20.3	4.92	2.75e-06	0.00269	0.38	0.4	Ferritin levels;	chr2:189697067	chr2:189763859~189764456:-
TGCT	cis	rs875971	0.638	rs7793569	ENSG00000237310.1	GS1-124K5.4	-4.92	2.75e-06	0.00269	-0.46	-0.4	Aortic root size;	chr7:66651646	chr7:66493706~66495474:+
TGCT	cis	rs801193	1	rs6975195	ENSG00000237310.1	GS1-124K5.4	-4.92	2.75e-06	0.00269	-0.46	-0.4	Aortic root size;	chr7:66659787	chr7:66493706~66495474:+
TGCT	cis	rs801193	1	rs3857688	ENSG00000237310.1	GS1-124K5.4	-4.92	2.75e-06	0.00269	-0.46	-0.4	Aortic root size;	chr7:66662819	chr7:66493706~66495474:+
TGCT	cis	rs801193	1	rs2286684	ENSG00000237310.1	GS1-124K5.4	-4.92	2.75e-06	0.00269	-0.46	-0.4	Aortic root size;	chr7:66664843	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.935	rs2286683	ENSG00000237310.1	GS1-124K5.4	-4.92	2.75e-06	0.00269	-0.46	-0.4	Aortic root size;	chr7:66664856	chr7:66493706~66495474:+
TGCT	cis	rs801193	1	rs10274773	ENSG00000237310.1	GS1-124K5.4	-4.92	2.75e-06	0.00269	-0.46	-0.4	Aortic root size;	chr7:66668591	chr7:66493706~66495474:+
TGCT	cis	rs1707322	0.789	rs7540578	ENSG00000280836.1	AL355480.1	-4.91	2.75e-06	0.00269	-0.52	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:45581219~45581321:-
TGCT	cis	rs10875746	0.859	rs11558768	ENSG00000240399.1	RP1-228P16.1	-4.91	2.75e-06	0.00269	-0.47	-0.4	Longevity (90 years and older);	chr12:48184006	chr12:48054813~48055591:-
TGCT	cis	rs1372520	0.684	rs2619341	ENSG00000247775.2	SNCA-AS1	4.91	2.76e-06	0.00269	0.4	0.4	Neuroticism;	chr4:89820622	chr4:89836408~89841978:+
TGCT	cis	rs1372520	0.684	rs10008964	ENSG00000247775.2	SNCA-AS1	4.91	2.76e-06	0.00269	0.4	0.4	Neuroticism;	chr4:89823570	chr4:89836408~89841978:+
TGCT	cis	rs1372520	0.684	rs3113355	ENSG00000247775.2	SNCA-AS1	4.91	2.76e-06	0.00269	0.4	0.4	Neuroticism;	chr4:89824194	chr4:89836408~89841978:+
TGCT	cis	rs1372520	0.684	rs2583968	ENSG00000247775.2	SNCA-AS1	4.91	2.76e-06	0.00269	0.4	0.4	Neuroticism;	chr4:89824244	chr4:89836408~89841978:+
TGCT	cis	rs2019137	0.539	rs6755040	ENSG00000274877.1	RP11-65I12.1	-4.91	2.76e-06	0.00269	-0.39	-0.4	Lymphocyte counts;	chr2:113223560	chr2:113237595~113240825:+
TGCT	cis	rs2019137	0.539	rs4849177	ENSG00000274877.1	RP11-65I12.1	-4.91	2.76e-06	0.00269	-0.39	-0.4	Lymphocyte counts;	chr2:113225007	chr2:113237595~113240825:+
TGCT	cis	rs2019137	0.56	rs4849179	ENSG00000274877.1	RP11-65I12.1	-4.91	2.76e-06	0.00269	-0.39	-0.4	Lymphocyte counts;	chr2:113227593	chr2:113237595~113240825:+
TGCT	cis	rs2019137	0.56	rs10175462	ENSG00000274877.1	RP11-65I12.1	-4.91	2.76e-06	0.00269	-0.39	-0.4	Lymphocyte counts;	chr2:113230915	chr2:113237595~113240825:+
TGCT	cis	rs7221109	0.522	rs2462970	ENSG00000278834.1	RP11-458J1.1	-4.91	2.76e-06	0.0027	-0.32	-0.4	Type 1 diabetes;	chr17:40714797	chr17:40648300~40649718:+
TGCT	cis	rs9425766	0.679	rs9787001	ENSG00000227373.4	RP11-160H22.5	4.91	2.76e-06	0.0027	0.44	0.4	Life satisfaction;	chr1:174222556	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.679	rs972361	ENSG00000227373.4	RP11-160H22.5	4.91	2.76e-06	0.0027	0.44	0.4	Life satisfaction;	chr1:174228270	chr1:174115300~174160004:-
TGCT	cis	rs66887589	0.616	rs6822808	ENSG00000245958.5	RP11-33B1.1	-4.91	2.77e-06	0.00271	-0.39	-0.4	Diastolic blood pressure;	chr4:119296210	chr4:119454791~119552025:+
TGCT	cis	rs66887589	0.616	rs6843509	ENSG00000245958.5	RP11-33B1.1	-4.91	2.77e-06	0.00271	-0.39	-0.4	Diastolic blood pressure;	chr4:119299041	chr4:119454791~119552025:+
TGCT	cis	rs2980439	0.517	rs17594093	ENSG00000254340.1	RP11-10A14.3	-4.91	2.77e-06	0.00271	-0.43	-0.4	Neuroticism;	chr8:8248884	chr8:9141424~9145435:+
TGCT	cis	rs7174755	0.558	rs11071975	ENSG00000260657.2	RP11-315D16.4	-4.91	2.78e-06	0.00271	-0.46	-0.4	Major depressive disorder;	chr15:68037106	chr15:68267792~68277994:-
TGCT	cis	rs4142441	0.643	rs12625612	ENSG00000223891.4	OSER1-AS1	4.91	2.78e-06	0.00272	0.53	0.4	Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Monocyte count;	chr20:44217034	chr20:44210960~44226027:+
TGCT	cis	rs7208859	0.673	rs423151	ENSG00000263531.1	RP13-753N3.1	4.91	2.79e-06	0.00272	0.69	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30863921~30864940:-
TGCT	cis	rs6600671	0.899	rs6674392	ENSG00000275131.1	CH17-472G23.4	-4.91	2.79e-06	0.00272	-0.26	-0.4	Hip geometry;	chr1:121518864	chr1:120489625~120579190:-
TGCT	cis	rs6600671	0.934	rs7528274	ENSG00000275131.1	CH17-472G23.4	-4.91	2.79e-06	0.00272	-0.26	-0.4	Hip geometry;	chr1:121545103	chr1:120489625~120579190:-
TGCT	cis	rs34779708	0.931	rs7079498	ENSG00000230534.5	RP11-297A16.2	4.91	2.79e-06	0.00272	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35086416	chr10:35098006~35127020:-
TGCT	cis	rs4713118	0.629	rs203888	ENSG00000219891.2	ZSCAN12P1	4.91	2.79e-06	0.00272	0.5	0.4	Parkinson's disease;	chr6:28053811	chr6:28091154~28093664:+
TGCT	cis	rs9880211	0.8	rs1872239	ENSG00000239213.4	NCK1-AS1	4.91	2.79e-06	0.00273	0.42	0.4	Height;Body mass index;	chr3:136785069	chr3:136841726~136862054:-
TGCT	cis	rs2980439	0.818	rs2948300	ENSG00000254340.1	RP11-10A14.3	4.91	2.79e-06	0.00273	0.41	0.4	Neuroticism;	chr8:8248986	chr8:9141424~9145435:+
TGCT	cis	rs7829975	0.617	rs4841071	ENSG00000173295.6	FAM86B3P	4.91	2.8e-06	0.00273	0.46	0.4	Mood instability;	chr8:8933634	chr8:8228595~8244865:+
TGCT	cis	rs10246939	0.579	rs58093678	ENSG00000228775.6	WEE2-AS1	4.91	2.8e-06	0.00273	0.36	0.4	Bitter taste perception;	chr7:141856719	chr7:141704338~141738346:-
TGCT	cis	rs10246939	0.529	rs60165685	ENSG00000228775.6	WEE2-AS1	4.91	2.8e-06	0.00273	0.36	0.4	Bitter taste perception;	chr7:141861190	chr7:141704338~141738346:-
TGCT	cis	rs7208859	0.673	rs216418	ENSG00000266490.1	CTD-2349P21.9	4.91	2.8e-06	0.00273	0.43	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30609519	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs216420	ENSG00000266490.1	CTD-2349P21.9	4.91	2.8e-06	0.00273	0.43	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs216423	ENSG00000266490.1	CTD-2349P21.9	4.91	2.8e-06	0.00273	0.43	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30792372~30792833:+
TGCT	cis	rs61931739	0.544	rs6488163	ENSG00000259937.2	RP11-438D14.2	-4.91	2.8e-06	0.00274	-0.37	-0.4	Morning vs. evening chronotype;	chr12:33446192	chr12:33404872~33405896:-
TGCT	cis	rs2976388	0.647	rs2082801	ENSG00000253196.1	RP11-706C16.7	4.91	2.8e-06	0.00274	0.4	0.4	Urinary tract infection frequency;	chr8:142705043	chr8:142763116~142766427:+
TGCT	cis	rs7208859	0.673	rs56846352	ENSG00000280069.1	CTD-2349P21.3	-4.91	2.81e-06	0.00274	-0.53	-0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.673	rs7211776	ENSG00000280069.1	CTD-2349P21.3	-4.91	2.81e-06	0.00274	-0.53	-0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.673	rs9912122	ENSG00000280069.1	CTD-2349P21.3	-4.91	2.81e-06	0.00274	-0.53	-0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30738182~30740275:+
TGCT	cis	rs786425	0.711	rs1060639	ENSG00000278112.1	RP11-972P1.11	4.91	2.81e-06	0.00274	0.47	0.4	Pubertal anthropometrics;	chr12:123625441	chr12:123519390~123519856:-
TGCT	cis	rs5769707	0.935	rs9616332	ENSG00000235111.1	RP1-29C18.8	-4.91	2.81e-06	0.00274	-0.32	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49654030	chr22:49612657~49615716:-
TGCT	cis	rs801193	1	rs11773829	ENSG00000237310.1	GS1-124K5.4	-4.91	2.81e-06	0.00274	-0.46	-0.4	Aortic root size;	chr7:66676087	chr7:66493706~66495474:+
TGCT	cis	rs801193	1	rs7788576	ENSG00000237310.1	GS1-124K5.4	-4.91	2.81e-06	0.00274	-0.46	-0.4	Aortic root size;	chr7:66683315	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.935	rs2659916	ENSG00000237310.1	GS1-124K5.4	4.91	2.81e-06	0.00274	0.46	0.4	Aortic root size;	chr7:66686365	chr7:66493706~66495474:+
TGCT	cis	rs801193	1	rs6958520	ENSG00000237310.1	GS1-124K5.4	4.91	2.81e-06	0.00274	0.46	0.4	Aortic root size;	chr7:66686466	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.967	rs2707849	ENSG00000237310.1	GS1-124K5.4	4.91	2.81e-06	0.00274	0.46	0.4	Aortic root size;	chr7:66687725	chr7:66493706~66495474:+
TGCT	cis	rs801193	1	rs2707836	ENSG00000237310.1	GS1-124K5.4	4.91	2.81e-06	0.00274	0.46	0.4	Aortic root size;	chr7:66695448	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.844	rs7779971	ENSG00000237310.1	GS1-124K5.4	4.91	2.81e-06	0.00274	0.46	0.4	Aortic root size;	chr7:66696803	chr7:66493706~66495474:+
TGCT	cis	rs801193	1	rs2659906	ENSG00000237310.1	GS1-124K5.4	4.91	2.81e-06	0.00274	0.46	0.4	Aortic root size;	chr7:66700323	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.935	rs2659899	ENSG00000237310.1	GS1-124K5.4	4.91	2.81e-06	0.00274	0.46	0.4	Aortic root size;	chr7:66721734	chr7:66493706~66495474:+
TGCT	cis	rs801193	1	rs62466793	ENSG00000237310.1	GS1-124K5.4	4.91	2.81e-06	0.00274	0.46	0.4	Aortic root size;	chr7:66726530	chr7:66493706~66495474:+
TGCT	cis	rs801193	1	rs62466794	ENSG00000237310.1	GS1-124K5.4	4.91	2.81e-06	0.00274	0.46	0.4	Aortic root size;	chr7:66726592	chr7:66493706~66495474:+
TGCT	cis	rs801193	1	rs1553609	ENSG00000237310.1	GS1-124K5.4	4.91	2.81e-06	0.00274	0.46	0.4	Aortic root size;	chr7:66732152	chr7:66493706~66495474:+
TGCT	cis	rs801193	1	rs1553610	ENSG00000237310.1	GS1-124K5.4	4.91	2.81e-06	0.00274	0.46	0.4	Aortic root size;	chr7:66732246	chr7:66493706~66495474:+
TGCT	cis	rs972540	1	rs7568556	ENSG00000279220.1	GPR1-AS	4.91	2.82e-06	0.00275	0.42	0.4	Body mass index;	chr2:206365730	chr2:206203376~206266243:+
TGCT	cis	rs4835473	0.932	rs12503900	ENSG00000251600.4	RP11-673E1.1	-4.91	2.82e-06	0.00275	-0.42	-0.4	Immature fraction of reticulocytes;	chr4:143812459	chr4:143912331~143982454:+
TGCT	cis	rs992157	0.732	rs10932771	ENSG00000261338.2	RP11-378A13.1	4.91	2.82e-06	0.00275	0.34	0.4	Colorectal cancer;	chr2:218305513	chr2:218255319~218257366:+
TGCT	cis	rs992157	0.798	rs10932772	ENSG00000261338.2	RP11-378A13.1	4.91	2.82e-06	0.00275	0.34	0.4	Colorectal cancer;	chr2:218312425	chr2:218255319~218257366:+
TGCT	cis	rs1075265	0.584	rs4671178	ENSG00000233266.1	HMGB1P31	-4.91	2.82e-06	0.00275	-0.44	-0.4	Chronotype;Morning vs. evening chronotype;	chr2:54056356	chr2:54051334~54051760:+
TGCT	cis	rs57502260	0.573	rs11228294	ENSG00000212093.1	AP000807.1	4.91	2.82e-06	0.00275	0.41	0.4	Total body bone mineral density (age 45-60);	chr11:68621099	chr11:68506083~68506166:-
TGCT	cis	rs801193	1	rs3800812	ENSG00000237310.1	GS1-124K5.4	4.91	2.83e-06	0.00275	0.46	0.4	Aortic root size;	chr7:66758474	chr7:66493706~66495474:+
TGCT	cis	rs801193	1	rs4279493	ENSG00000237310.1	GS1-124K5.4	4.91	2.83e-06	0.00275	0.46	0.4	Aortic root size;	chr7:66761633	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.761	rs2659888	ENSG00000237310.1	GS1-124K5.4	4.91	2.83e-06	0.00275	0.46	0.4	Aortic root size;	chr7:66765184	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.904	rs4718403	ENSG00000237310.1	GS1-124K5.4	4.91	2.83e-06	0.00275	0.46	0.4	Aortic root size;	chr7:66777742	chr7:66493706~66495474:+
TGCT	cis	rs801193	1	rs3778909	ENSG00000237310.1	GS1-124K5.4	4.91	2.83e-06	0.00275	0.46	0.4	Aortic root size;	chr7:66790659	chr7:66493706~66495474:+
TGCT	cis	rs8059260	0.668	rs8055893	ENSG00000274038.1	RP11-66H6.4	-4.91	2.84e-06	0.00276	-0.58	-0.4	Alcohol consumption over the past year;	chr16:10977938	chr16:11056556~11057034:+
TGCT	cis	rs1023500	0.573	rs133378	ENSG00000270083.1	RP1-257I20.14	4.91	2.84e-06	0.00276	0.42	0.4	Schizophrenia;	chr22:42071691	chr22:42089630~42090028:-
TGCT	cis	rs10875746	0.951	rs58865997	ENSG00000240399.1	RP1-228P16.1	-4.91	2.84e-06	0.00276	-0.48	-0.4	Longevity (90 years and older);	chr12:48173090	chr12:48054813~48055591:-
TGCT	cis	rs877819	0.552	rs2943255	ENSG00000228403.1	RP11-563N6.6	4.91	2.85e-06	0.00277	0.42	0.4	Systemic lupus erythematosus;	chr10:48884349	chr10:48878022~48878649:+
TGCT	cis	rs10256972	0.567	rs2949185	ENSG00000226291.1	AC091729.8	-4.91	2.85e-06	0.00277	-0.42	-0.4	Endometriosis;Longevity;	chr7:1169377	chr7:1080863~1082178:+
TGCT	cis	rs2283792	0.819	rs2266965	ENSG00000228050.1	TOP3BP1	4.91	2.85e-06	0.00277	0.48	0.4	Multiple sclerosis;	chr22:21766866	chr22:22223187~22224566:-
TGCT	cis	rs9425766	0.679	rs10912761	ENSG00000227373.4	RP11-160H22.5	4.91	2.86e-06	0.00278	0.43	0.4	Life satisfaction;	chr1:174312466	chr1:174115300~174160004:-
TGCT	cis	rs651907	0.557	rs36002990	ENSG00000244119.1	PDCL3P4	4.91	2.86e-06	0.00278	0.29	0.4	Colorectal cancer;	chr3:101719018	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.557	rs11720745	ENSG00000244119.1	PDCL3P4	4.91	2.86e-06	0.00278	0.29	0.4	Colorectal cancer;	chr3:101722846	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.557	rs35117343	ENSG00000244119.1	PDCL3P4	4.91	2.86e-06	0.00278	0.29	0.4	Colorectal cancer;	chr3:101726282	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.557	rs11914318	ENSG00000244119.1	PDCL3P4	4.91	2.86e-06	0.00278	0.29	0.4	Colorectal cancer;	chr3:101735014	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.557	rs1031710	ENSG00000244119.1	PDCL3P4	4.91	2.86e-06	0.00278	0.29	0.4	Colorectal cancer;	chr3:101745051	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.535	rs13065944	ENSG00000244119.1	PDCL3P4	4.91	2.86e-06	0.00278	0.29	0.4	Colorectal cancer;	chr3:101754244	chr3:101712472~101713191:+
TGCT	cis	rs12891047	0.78	rs8009358	ENSG00000258759.1	RP11-1012A1.7	-4.91	2.86e-06	0.00278	-0.34	-0.4	Amyotrophic lateral sclerosis (sporadic);	chr14:67883127	chr14:67799004~67799609:+
TGCT	cis	rs16975963	0.644	rs73033139	ENSG00000276846.1	CTD-3220F14.3	-4.91	2.86e-06	0.00278	-0.41	-0.4	Longevity;	chr19:37600784	chr19:37314868~37315620:-
TGCT	cis	rs16975963	0.644	rs59426132	ENSG00000276846.1	CTD-3220F14.3	-4.91	2.86e-06	0.00278	-0.41	-0.4	Longevity;	chr19:37601869	chr19:37314868~37315620:-
TGCT	cis	rs16975963	0.644	rs73033145	ENSG00000276846.1	CTD-3220F14.3	-4.91	2.86e-06	0.00278	-0.41	-0.4	Longevity;	chr19:37606412	chr19:37314868~37315620:-
TGCT	cis	rs9918079	0.56	rs13147590	ENSG00000273133.1	RP11-799M12.2	4.91	2.86e-06	0.00278	0.59	0.4	Obesity-related traits;	chr4:15619565	chr4:15563698~15564253:-
TGCT	cis	rs507080	0.769	rs11603616	ENSG00000255422.1	AP002954.4	-4.91	2.86e-06	0.00278	-0.47	-0.4	Serum metabolite levels;	chr11:118625350	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.769	rs483283	ENSG00000255422.1	AP002954.4	-4.91	2.86e-06	0.00278	-0.47	-0.4	Serum metabolite levels;	chr11:118635684	chr11:118704607~118750263:+
TGCT	cis	rs66887589	0.616	rs1052633	ENSG00000245958.5	RP11-33B1.1	-4.91	2.87e-06	0.00279	-0.39	-0.4	Diastolic blood pressure;	chr4:119294159	chr4:119454791~119552025:+
TGCT	cis	rs66887589	0.592	rs2175383	ENSG00000245958.5	RP11-33B1.1	-4.91	2.87e-06	0.00279	-0.39	-0.4	Diastolic blood pressure;	chr4:119294681	chr4:119454791~119552025:+
TGCT	cis	rs7927592	0.763	rs624003	ENSG00000212093.1	AP000807.1	4.9	2.87e-06	0.00279	0.39	0.4	Total body bone mineral density;	chr11:68463772	chr11:68506083~68506166:-
TGCT	cis	rs7927592	0.763	rs10896326	ENSG00000212093.1	AP000807.1	4.9	2.87e-06	0.00279	0.39	0.4	Total body bone mineral density;	chr11:68467103	chr11:68506083~68506166:-
TGCT	cis	rs7927592	0.763	rs10896327	ENSG00000212093.1	AP000807.1	4.9	2.87e-06	0.00279	0.39	0.4	Total body bone mineral density;	chr11:68467807	chr11:68506083~68506166:-
TGCT	cis	rs4713118	0.662	rs175954	ENSG00000219392.1	RP1-265C24.5	-4.9	2.87e-06	0.00279	-0.53	-0.4	Parkinson's disease;	chr6:28043807	chr6:28115628~28116551:+
TGCT	cis	rs7829975	0.582	rs448231	ENSG00000173295.6	FAM86B3P	-4.9	2.88e-06	0.0028	-0.46	-0.4	Mood instability;	chr8:8932549	chr8:8228595~8244865:+
TGCT	cis	rs761746	0.739	rs131233	ENSG00000236132.1	CTA-440B3.1	-4.9	2.88e-06	0.0028	-0.51	-0.4	Intelligence;	chr22:31721114	chr22:31816379~31817491:-
TGCT	cis	rs9918079	0.56	rs4270584	ENSG00000273133.1	RP11-799M12.2	4.9	2.89e-06	0.0028	0.59	0.4	Obesity-related traits;	chr4:15599176	chr4:15563698~15564253:-
TGCT	cis	rs875971	0.862	rs1695820	ENSG00000232559.3	GS1-124K5.12	4.9	2.89e-06	0.0028	0.37	0.4	Aortic root size;	chr7:66379576	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.83	rs778715	ENSG00000232559.3	GS1-124K5.12	4.9	2.89e-06	0.0028	0.37	0.4	Aortic root size;	chr7:66384222	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.83	rs809025	ENSG00000232559.3	GS1-124K5.12	4.9	2.89e-06	0.0028	0.37	0.4	Aortic root size;	chr7:66384832	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs778702	ENSG00000232559.3	GS1-124K5.12	4.9	2.89e-06	0.0028	0.37	0.4	Aortic root size;	chr7:66399848	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs1643375	ENSG00000232559.3	GS1-124K5.12	4.9	2.89e-06	0.0028	0.37	0.4	Aortic root size;	chr7:66407690	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs6962717	ENSG00000232559.3	GS1-124K5.12	4.9	2.89e-06	0.0028	0.37	0.4	Aortic root size;	chr7:66418748	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.522	rs709604	ENSG00000237310.1	GS1-124K5.4	-4.9	2.89e-06	0.0028	-0.45	-0.4	Aortic root size;	chr7:66032447	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.505	rs1723275	ENSG00000237310.1	GS1-124K5.4	-4.9	2.89e-06	0.0028	-0.45	-0.4	Aortic root size;	chr7:66039646	chr7:66493706~66495474:+
TGCT	cis	rs9425766	0.679	rs7555067	ENSG00000227373.4	RP11-160H22.5	4.9	2.89e-06	0.0028	0.42	0.4	Life satisfaction;	chr1:174297504	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.679	rs6695636	ENSG00000227373.4	RP11-160H22.5	4.9	2.89e-06	0.0028	0.42	0.4	Life satisfaction;	chr1:174303087	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.64	rs7512930	ENSG00000227373.4	RP11-160H22.5	4.9	2.89e-06	0.0028	0.42	0.4	Life satisfaction;	chr1:174319464	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.679	rs7523460	ENSG00000227373.4	RP11-160H22.5	4.9	2.89e-06	0.0028	0.42	0.4	Life satisfaction;	chr1:174319664	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.679	rs7552830	ENSG00000227373.4	RP11-160H22.5	4.9	2.89e-06	0.0028	0.42	0.4	Life satisfaction;	chr1:174321643	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.679	rs7523938	ENSG00000227373.4	RP11-160H22.5	4.9	2.89e-06	0.0028	0.42	0.4	Life satisfaction;	chr1:174327373	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.64	rs6681780	ENSG00000227373.4	RP11-160H22.5	4.9	2.89e-06	0.0028	0.42	0.4	Life satisfaction;	chr1:174328980	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.55	rs57366619	ENSG00000227373.4	RP11-160H22.5	4.9	2.89e-06	0.0028	0.42	0.4	Life satisfaction;	chr1:174334929	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.64	rs17301013	ENSG00000227373.4	RP11-160H22.5	4.9	2.89e-06	0.0028	0.42	0.4	Life satisfaction;	chr1:174343675	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.655	rs6666767	ENSG00000227373.4	RP11-160H22.5	4.9	2.89e-06	0.0028	0.42	0.4	Life satisfaction;	chr1:174357564	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.64	rs6693423	ENSG00000227373.4	RP11-160H22.5	4.9	2.89e-06	0.0028	0.42	0.4	Life satisfaction;	chr1:174364680	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.679	rs12084119	ENSG00000227373.4	RP11-160H22.5	4.9	2.89e-06	0.0028	0.42	0.4	Life satisfaction;	chr1:174377138	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.965	rs7548540	ENSG00000227373.4	RP11-160H22.5	4.9	2.89e-06	0.0028	0.42	0.4	Systemic lupus erythematosus;	chr1:174411672	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.965	rs2179214	ENSG00000227373.4	RP11-160H22.5	4.9	2.89e-06	0.0028	0.42	0.4	Systemic lupus erythematosus;	chr1:174413954	chr1:174115300~174160004:-
TGCT	cis	rs17301013	0.93	rs7523263	ENSG00000227373.4	RP11-160H22.5	4.9	2.89e-06	0.0028	0.42	0.4	Systemic lupus erythematosus;	chr1:174414542	chr1:174115300~174160004:-
TGCT	cis	rs9326248	1	rs664922	ENSG00000280143.1	AP000892.6	4.9	2.89e-06	0.00281	0.53	0.4	Blood protein levels;	chr11:117200179	chr11:117204967~117210292:+
TGCT	cis	rs9326248	1	rs664082	ENSG00000280143.1	AP000892.6	4.9	2.89e-06	0.00281	0.53	0.4	Blood protein levels;	chr11:117200354	chr11:117204967~117210292:+
TGCT	cis	rs7208859	0.623	rs9895785	ENSG00000266490.1	CTD-2349P21.9	-4.9	2.9e-06	0.00281	-0.46	-0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30792372~30792833:+
TGCT	cis	rs877819	0.552	rs2671712	ENSG00000228403.1	RP11-563N6.6	4.9	2.91e-06	0.00282	0.41	0.4	Systemic lupus erythematosus;	chr10:48883000	chr10:48878022~48878649:+
TGCT	cis	rs321358	0.895	rs6589210	ENSG00000271584.1	RP11-89C3.4	4.9	2.91e-06	0.00282	0.48	0.4	Body mass index;	chr11:111088408	chr11:111091932~111097357:-
TGCT	cis	rs9462027	0.517	rs2744973	ENSG00000186328.4	RP11-140K17.2	4.9	2.91e-06	0.00282	0.4	0.4	Systemic lupus erythematosus;	chr6:34612444	chr6:34715613~34715940:+
TGCT	cis	rs2463822	0.925	rs72923272	ENSG00000254454.2	RCC2P6	4.9	2.92e-06	0.00283	0.45	0.4	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62399360	chr11:62371146~62373168:+
TGCT	cis	rs34779708	0.931	rs79749947	ENSG00000230534.5	RP11-297A16.2	4.9	2.92e-06	0.00283	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:34988153	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs9663401	ENSG00000230534.5	RP11-297A16.2	4.9	2.92e-06	0.00283	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:34989921	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.897	rs9787566	ENSG00000230534.5	RP11-297A16.2	4.9	2.92e-06	0.00283	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:34990527	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs4351760	ENSG00000230534.5	RP11-297A16.2	4.9	2.92e-06	0.00283	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:34991326	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.898	rs4934695	ENSG00000230534.5	RP11-297A16.2	4.9	2.92e-06	0.00283	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:34991677	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs11597483	ENSG00000230534.5	RP11-297A16.2	4.9	2.92e-06	0.00283	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:34996189	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs35317849	ENSG00000230534.5	RP11-297A16.2	4.9	2.92e-06	0.00283	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:34996793	chr10:35098006~35127020:-
TGCT	cis	rs2709736	0.631	rs2709720	ENSG00000232790.2	LINC01162	-4.9	2.92e-06	0.00283	-0.31	-0.4	Bipolar I disorder;	chr7:20882328	chr7:20835431~21023148:+
TGCT	cis	rs904251	0.704	rs2776873	ENSG00000279942.1	RP1-153P14.7	-4.9	2.93e-06	0.00284	-0.48	-0.4	Cognitive performance;	chr6:37515366	chr6:37567716~37571460:+
TGCT	cis	rs2742234	0.59	rs2505506	ENSG00000273008.1	RP11-351D16.3	-4.9	2.93e-06	0.00284	-0.53	-0.4	Hirschsprung disease;	chr10:43150406	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.59	rs2257767	ENSG00000273008.1	RP11-351D16.3	-4.9	2.93e-06	0.00284	-0.53	-0.4	Hirschsprung disease;	chr10:43162363	chr10:43136824~43138334:-
TGCT	cis	rs10875976	0.525	rs2271688	ENSG00000242041.1	RP11-70F11.2	4.9	2.94e-06	0.00285	0.36	0.4	Obesity;	chr12:49865746	chr12:49863173~49863503:+
TGCT	cis	rs904251	0.523	rs2797799	ENSG00000279942.1	RP1-153P14.7	-4.9	2.94e-06	0.00285	-0.4	-0.4	Cognitive performance;	chr6:37515844	chr6:37567716~37571460:+
TGCT	cis	rs761746	0.739	rs5994420	ENSG00000236132.1	CTA-440B3.1	-4.9	2.94e-06	0.00285	-0.51	-0.4	Intelligence;	chr22:31674765	chr22:31816379~31817491:-
TGCT	cis	rs2439831	0.702	rs8033995	ENSG00000205771.5	CATSPER2P1	-4.9	2.95e-06	0.00285	-0.7	-0.4	Lung cancer in ever smokers;	chr15:43721311	chr15:43726918~43747094:-
TGCT	cis	rs4835473	0.932	rs13152443	ENSG00000251600.4	RP11-673E1.1	-4.9	2.95e-06	0.00286	-0.42	-0.4	Immature fraction of reticulocytes;	chr4:143742492	chr4:143912331~143982454:+
TGCT	cis	rs8105895	0.877	rs28822164	ENSG00000269742.1	BNIP3P29	4.9	2.95e-06	0.00286	0.71	0.4	Body mass index (change over time);	chr19:22062306	chr19:22065828~22066398:-
TGCT	cis	rs453301	0.512	rs2921381	ENSG00000173295.6	FAM86B3P	4.9	2.96e-06	0.00286	0.47	0.4	Joint mobility (Beighton score);	chr8:9037891	chr8:8228595~8244865:+
TGCT	cis	rs66887589	0.616	rs11731675	ENSG00000245958.5	RP11-33B1.1	-4.9	2.96e-06	0.00286	-0.39	-0.4	Diastolic blood pressure;	chr4:119291359	chr4:119454791~119552025:+
TGCT	cis	rs2742234	0.578	rs2435354	ENSG00000273008.1	RP11-351D16.3	-4.9	2.96e-06	0.00286	-0.54	-0.4	Hirschsprung disease;	chr10:43156997	chr10:43136824~43138334:-
TGCT	cis	rs10246939	0.579	rs9640205	ENSG00000228775.6	WEE2-AS1	4.9	2.97e-06	0.00287	0.36	0.4	Bitter taste perception;	chr7:141844400	chr7:141704338~141738346:-
TGCT	cis	rs5769707	0.777	rs8138399	ENSG00000235111.1	RP1-29C18.8	-4.9	2.97e-06	0.00287	-0.33	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49651176	chr22:49612657~49615716:-
TGCT	cis	rs1823913	1	rs6749232	ENSG00000280083.1	RP11-317J9.1	4.9	2.98e-06	0.00287	0.34	0.4	Obesity-related traits;	chr2:191250326	chr2:191154118~191156070:-
TGCT	cis	rs2117029	0.965	rs2241726	ENSG00000258017.1	RP11-386G11.10	-4.9	2.98e-06	0.00287	-0.5	-0.4	Intelligence (multi-trait analysis);	chr12:49050762	chr12:49127782~49147869:+
TGCT	cis	rs875971	0.862	rs1695820	ENSG00000237310.1	GS1-124K5.4	4.9	2.98e-06	0.00288	0.43	0.4	Aortic root size;	chr7:66379576	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.83	rs778715	ENSG00000237310.1	GS1-124K5.4	4.9	2.98e-06	0.00288	0.43	0.4	Aortic root size;	chr7:66384222	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.83	rs809025	ENSG00000237310.1	GS1-124K5.4	4.9	2.98e-06	0.00288	0.43	0.4	Aortic root size;	chr7:66384832	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs778702	ENSG00000237310.1	GS1-124K5.4	4.9	2.98e-06	0.00288	0.43	0.4	Aortic root size;	chr7:66399848	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs1643375	ENSG00000237310.1	GS1-124K5.4	4.9	2.98e-06	0.00288	0.43	0.4	Aortic root size;	chr7:66407690	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs6962717	ENSG00000237310.1	GS1-124K5.4	4.9	2.98e-06	0.00288	0.43	0.4	Aortic root size;	chr7:66418748	chr7:66493706~66495474:+
TGCT	cis	rs2976388	0.609	rs2585149	ENSG00000253196.1	RP11-706C16.7	4.9	2.99e-06	0.00288	0.4	0.4	Urinary tract infection frequency;	chr8:142711902	chr8:142763116~142766427:+
TGCT	cis	rs786425	0.707	rs1051793	ENSG00000247373.3	RP11-486O12.2	4.9	2.99e-06	0.00288	0.5	0.4	Pubertal anthropometrics;	chr12:123659848	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.676	rs4930708	ENSG00000247373.3	RP11-486O12.2	4.9	2.99e-06	0.00288	0.5	0.4	Pubertal anthropometrics;	chr12:123661150	chr12:123575891~123585115:-
TGCT	cis	rs321358	0.895	rs7950087	ENSG00000271584.1	RP11-89C3.4	-4.9	2.99e-06	0.00289	-0.54	-0.4	Body mass index;	chr11:111082536	chr11:111091932~111097357:-
TGCT	cis	rs651907	0.557	rs34376498	ENSG00000244119.1	PDCL3P4	4.89	3e-06	0.00289	0.29	0.4	Colorectal cancer;	chr3:101761312	chr3:101712472~101713191:+
TGCT	cis	rs1372520	0.577	rs2737021	ENSG00000247775.2	SNCA-AS1	4.89	3.01e-06	0.00291	0.41	0.4	Neuroticism;	chr4:89818841	chr4:89836408~89841978:+
TGCT	cis	rs7208859	0.623	rs170051	ENSG00000280069.1	CTD-2349P21.3	-4.89	3.01e-06	0.00291	-0.58	-0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs216434	ENSG00000280069.1	CTD-2349P21.3	-4.89	3.01e-06	0.00291	-0.58	-0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs216436	ENSG00000280069.1	CTD-2349P21.3	-4.89	3.01e-06	0.00291	-0.58	-0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30738182~30740275:+
TGCT	cis	rs4835473	0.932	rs13129993	ENSG00000251600.4	RP11-673E1.1	-4.89	3.02e-06	0.00291	-0.43	-0.4	Immature fraction of reticulocytes;	chr4:143763076	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1580002	ENSG00000251600.4	RP11-673E1.1	-4.89	3.02e-06	0.00291	-0.43	-0.4	Immature fraction of reticulocytes;	chr4:143766507	chr4:143912331~143982454:+
TGCT	cis	rs2976388	0.609	rs2585152	ENSG00000253196.1	RP11-706C16.7	4.89	3.02e-06	0.00291	0.4	0.4	Urinary tract infection frequency;	chr8:142704796	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.609	rs2717550	ENSG00000253196.1	RP11-706C16.7	4.89	3.02e-06	0.00291	0.4	0.4	Urinary tract infection frequency;	chr8:142706390	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.609	rs2263092	ENSG00000253196.1	RP11-706C16.7	4.89	3.02e-06	0.00291	0.4	0.4	Urinary tract infection frequency;	chr8:142708548	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.609	rs1594999	ENSG00000253196.1	RP11-706C16.7	4.89	3.02e-06	0.00291	0.4	0.4	Urinary tract infection frequency;	chr8:142709156	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.506	rs2572902	ENSG00000253196.1	RP11-706C16.7	4.89	3.02e-06	0.00291	0.4	0.4	Urinary tract infection frequency;	chr8:142709969	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.609	rs2572904	ENSG00000253196.1	RP11-706C16.7	4.89	3.02e-06	0.00291	0.4	0.4	Urinary tract infection frequency;	chr8:142710775	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.609	rs2585150	ENSG00000253196.1	RP11-706C16.7	4.89	3.02e-06	0.00291	0.4	0.4	Urinary tract infection frequency;	chr8:142711251	chr8:142763116~142766427:+
TGCT	cis	rs2442825	0.526	rs6443237	ENSG00000206573.7	THUMPD3-AS1	-4.89	3.02e-06	0.00292	-0.37	-0.4	Cerebrospinal fluid clusterin levels;	chr3:9395777	chr3:9349689~9398579:-
TGCT	cis	rs7208859	0.51	rs216402	ENSG00000280069.1	CTD-2349P21.3	-4.89	3.02e-06	0.00292	-0.58	-0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30738182~30740275:+
TGCT	cis	rs4835473	0.643	rs34680080	ENSG00000251600.4	RP11-673E1.1	-4.89	3.03e-06	0.00292	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143797290	chr4:143912331~143982454:+
TGCT	cis	rs5742933	0.857	rs13021611	ENSG00000273240.1	RP11-455J20.3	4.89	3.03e-06	0.00292	0.38	0.4	Ferritin levels;	chr2:189700038	chr2:189763859~189764456:-
TGCT	cis	rs1823913	1	rs1840377	ENSG00000280083.1	RP11-317J9.1	4.89	3.03e-06	0.00292	0.34	0.4	Obesity-related traits;	chr2:191257992	chr2:191154118~191156070:-
TGCT	cis	rs1823913	1	rs4853564	ENSG00000280083.1	RP11-317J9.1	4.89	3.03e-06	0.00292	0.34	0.4	Obesity-related traits;	chr2:191258939	chr2:191154118~191156070:-
TGCT	cis	rs1823913	1	rs4853565	ENSG00000280083.1	RP11-317J9.1	4.89	3.03e-06	0.00292	0.34	0.4	Obesity-related traits;	chr2:191259020	chr2:191154118~191156070:-
TGCT	cis	rs1823913	1	rs4853462	ENSG00000280083.1	RP11-317J9.1	4.89	3.03e-06	0.00292	0.34	0.4	Obesity-related traits;	chr2:191259078	chr2:191154118~191156070:-
TGCT	cis	rs2439831	0.702	rs3784275	ENSG00000205771.5	CATSPER2P1	-4.89	3.03e-06	0.00292	-0.74	-0.4	Lung cancer in ever smokers;	chr15:43799188	chr15:43726918~43747094:-
TGCT	cis	rs8059260	0.736	rs78121798	ENSG00000274038.1	RP11-66H6.4	-4.89	3.03e-06	0.00292	-0.57	-0.4	Alcohol consumption over the past year;	chr16:10984224	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.736	rs16957872	ENSG00000274038.1	RP11-66H6.4	-4.89	3.03e-06	0.00292	-0.57	-0.4	Alcohol consumption over the past year;	chr16:10988835	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.736	rs113120936	ENSG00000274038.1	RP11-66H6.4	-4.89	3.03e-06	0.00292	-0.57	-0.4	Alcohol consumption over the past year;	chr16:10989474	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.736	rs12149904	ENSG00000274038.1	RP11-66H6.4	-4.89	3.03e-06	0.00292	-0.57	-0.4	Alcohol consumption over the past year;	chr16:10991789	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.736	rs16957883	ENSG00000274038.1	RP11-66H6.4	-4.89	3.03e-06	0.00292	-0.57	-0.4	Alcohol consumption over the past year;	chr16:10994788	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.668	rs16957894	ENSG00000274038.1	RP11-66H6.4	-4.89	3.03e-06	0.00292	-0.57	-0.4	Alcohol consumption over the past year;	chr16:10996501	chr16:11056556~11057034:+
TGCT	cis	rs67311347	0.955	rs4974068	ENSG00000223797.4	ENTPD3-AS1	4.89	3.04e-06	0.00293	0.42	0.4	Renal cell carcinoma;	chr3:40335438	chr3:40313802~40453329:-
TGCT	cis	rs4380275	0.782	rs4335978	ENSG00000223751.1	AC116609.2	4.89	3.04e-06	0.00293	0.42	0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:750078	chr2:742488~747767:+
TGCT	cis	rs6600671	0.692	rs11249430	ENSG00000275131.1	CH17-472G23.4	-4.89	3.04e-06	0.00293	-0.26	-0.4	Hip geometry;	chr1:121547115	chr1:120489625~120579190:-
TGCT	cis	rs9584850	0.789	rs7988345	ENSG00000231194.1	FARP1-AS1	4.89	3.05e-06	0.00294	0.53	0.4	Neuroticism;	chr13:98465431	chr13:98435405~98435840:-
TGCT	cis	rs9584850	0.834	rs9584854	ENSG00000231194.1	FARP1-AS1	4.89	3.05e-06	0.00294	0.53	0.4	Neuroticism;	chr13:98466336	chr13:98435405~98435840:-
TGCT	cis	rs1075265	0.633	rs4671190	ENSG00000233266.1	HMGB1P31	4.89	3.06e-06	0.00294	0.45	0.4	Chronotype;Morning vs. evening chronotype;	chr2:54085604	chr2:54051334~54051760:+
TGCT	cis	rs1075265	0.547	rs6741891	ENSG00000233266.1	HMGB1P31	4.89	3.06e-06	0.00294	0.45	0.4	Chronotype;Morning vs. evening chronotype;	chr2:54088529	chr2:54051334~54051760:+
TGCT	cis	rs904251	0.504	rs1757188	ENSG00000204110.6	RP1-153P14.8	-4.89	3.06e-06	0.00294	-0.42	-0.4	Cognitive performance;	chr6:37516032	chr6:37507348~37535616:+
TGCT	cis	rs904251	0.522	rs882322	ENSG00000204110.6	RP1-153P14.8	-4.89	3.06e-06	0.00294	-0.42	-0.4	Cognitive performance;	chr6:37516327	chr6:37507348~37535616:+
TGCT	cis	rs1757171	0.542	rs1757186	ENSG00000204110.6	RP1-153P14.8	-4.89	3.06e-06	0.00294	-0.42	-0.4	Cognitive performance;	chr6:37516335	chr6:37507348~37535616:+
TGCT	cis	rs904251	0.504	rs2797795	ENSG00000279942.1	RP1-153P14.7	-4.89	3.06e-06	0.00294	-0.4	-0.4	Cognitive performance;	chr6:37512907	chr6:37567716~37571460:+
TGCT	cis	rs904251	0.523	rs2797796	ENSG00000279942.1	RP1-153P14.7	-4.89	3.06e-06	0.00294	-0.4	-0.4	Cognitive performance;	chr6:37513110	chr6:37567716~37571460:+
TGCT	cis	rs904251	0.523	rs2776870	ENSG00000279942.1	RP1-153P14.7	-4.89	3.06e-06	0.00294	-0.4	-0.4	Cognitive performance;	chr6:37513588	chr6:37567716~37571460:+
TGCT	cis	rs904251	0.523	rs2797798	ENSG00000279942.1	RP1-153P14.7	-4.89	3.06e-06	0.00294	-0.4	-0.4	Cognitive performance;	chr6:37513661	chr6:37567716~37571460:+
TGCT	cis	rs904251	0.523	rs2776871	ENSG00000279942.1	RP1-153P14.7	-4.89	3.06e-06	0.00294	-0.4	-0.4	Cognitive performance;	chr6:37513983	chr6:37567716~37571460:+
TGCT	cis	rs904251	0.523	rs1776454	ENSG00000279942.1	RP1-153P14.7	-4.89	3.06e-06	0.00294	-0.4	-0.4	Cognitive performance;	chr6:37514323	chr6:37567716~37571460:+
TGCT	cis	rs524281	0.731	rs10791841	ENSG00000255320.1	RP11-755F10.1	4.89	3.06e-06	0.00294	0.57	0.4	Electroencephalogram traits;	chr11:66041116	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.731	rs3814744	ENSG00000255320.1	RP11-755F10.1	4.89	3.06e-06	0.00294	0.57	0.4	Electroencephalogram traits;	chr11:66042292	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.648	rs4565902	ENSG00000255320.1	RP11-755F10.1	4.89	3.06e-06	0.00294	0.57	0.4	Electroencephalogram traits;	chr11:66042574	chr11:66244840~66246239:-
TGCT	cis	rs34779708	0.966	rs17591857	ENSG00000230534.5	RP11-297A16.2	-4.89	3.06e-06	0.00294	-0.47	-0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35210115	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs2384283	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35037861	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs66887762	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35041649	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs34087268	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35057796	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs2148482	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35059982	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs58159560	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35062321	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.658	rs4934715	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35076064	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs67976880	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35083333	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs72789687	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35083561	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs35997236	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35087762	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs4934719	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35087841	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs4934720	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35087872	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs4934721	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35088787	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.897	rs34481177	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35091985	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs11593858	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35092445	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs4934723	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35092835	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs72789690	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35093889	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs68039650	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35096571	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs35136660	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35097045	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.897	rs7897827	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35097309	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.897	rs12764820	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35097393	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs67261877	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35097412	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs12768019	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35100915	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs12775548	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35190576	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs35079558	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35190958	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs1057108	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35196021	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs7070427	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35196761	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs12775799	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35199336	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs11010122	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35204590	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.9	rs73262807	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35207458	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs4934736	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35207940	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs17591781	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35209610	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs17500582	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35209860	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs11010125	ENSG00000230534.5	RP11-297A16.2	4.89	3.06e-06	0.00294	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35214025	chr10:35098006~35127020:-
TGCT	cis	rs9322193	0.962	rs7818	ENSG00000216906.2	RP11-350J20.9	4.89	3.07e-06	0.00295	0.45	0.4	Lung cancer;	chr6:149810956	chr6:149904243~149906418:+
TGCT	cis	rs3931020	1	rs10874122	ENSG00000272864.1	RP11-17E13.2	-4.89	3.07e-06	0.00295	-0.47	-0.4	Resistin levels;	chr1:74770182	chr1:74698769~74699333:-
TGCT	cis	rs453301	0.624	rs4841083	ENSG00000173295.6	FAM86B3P	4.89	3.07e-06	0.00295	0.49	0.4	Joint mobility (Beighton score);	chr8:9012918	chr8:8228595~8244865:+
TGCT	cis	rs453301	0.624	rs2979256	ENSG00000173295.6	FAM86B3P	4.89	3.07e-06	0.00295	0.49	0.4	Joint mobility (Beighton score);	chr8:9014200	chr8:8228595~8244865:+
TGCT	cis	rs4713118	0.629	rs203887	ENSG00000219891.2	ZSCAN12P1	4.89	3.08e-06	0.00295	0.51	0.4	Parkinson's disease;	chr6:28053491	chr6:28091154~28093664:+
TGCT	cis	rs651907	0.514	rs10936744	ENSG00000244119.1	PDCL3P4	4.89	3.08e-06	0.00296	0.29	0.4	Colorectal cancer;	chr3:101714596	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.514	rs12636046	ENSG00000244119.1	PDCL3P4	4.89	3.08e-06	0.00296	0.29	0.4	Colorectal cancer;	chr3:101715604	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.514	rs12636047	ENSG00000244119.1	PDCL3P4	4.89	3.08e-06	0.00296	0.29	0.4	Colorectal cancer;	chr3:101715605	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.557	rs7612283	ENSG00000244119.1	PDCL3P4	4.89	3.08e-06	0.00296	0.29	0.4	Colorectal cancer;	chr3:101716075	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.557	rs34457525	ENSG00000244119.1	PDCL3P4	4.89	3.08e-06	0.00296	0.29	0.4	Colorectal cancer;	chr3:101716381	chr3:101712472~101713191:+
TGCT	cis	rs9322193	0.923	rs9767105	ENSG00000216906.2	RP11-350J20.9	4.89	3.08e-06	0.00296	0.44	0.4	Lung cancer;	chr6:149659591	chr6:149904243~149906418:+
TGCT	cis	rs2442825	0.693	rs2596913	ENSG00000206573.7	THUMPD3-AS1	4.89	3.08e-06	0.00296	0.35	0.4	Cerebrospinal fluid clusterin levels;	chr3:9394788	chr3:9349689~9398579:-
TGCT	cis	rs34779708	0.897	rs16935880	ENSG00000230534.5	RP11-297A16.2	4.89	3.09e-06	0.00296	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35126540	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs4934730	ENSG00000230534.5	RP11-297A16.2	4.89	3.09e-06	0.00296	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35126627	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs12765038	ENSG00000230534.5	RP11-297A16.2	4.89	3.09e-06	0.00296	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35127585	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs2045918	ENSG00000230534.5	RP11-297A16.2	4.89	3.09e-06	0.00296	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35129589	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs2045917	ENSG00000230534.5	RP11-297A16.2	4.89	3.09e-06	0.00296	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35129598	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs4294520	ENSG00000230534.5	RP11-297A16.2	4.89	3.09e-06	0.00296	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35133578	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs34876468	ENSG00000230534.5	RP11-297A16.2	4.89	3.09e-06	0.00296	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35135522	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs35814343	ENSG00000230534.5	RP11-297A16.2	4.89	3.09e-06	0.00296	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35138786	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs4934732	ENSG00000230534.5	RP11-297A16.2	4.89	3.09e-06	0.00296	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35142756	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs4934535	ENSG00000230534.5	RP11-297A16.2	4.89	3.09e-06	0.00296	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35143793	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs4934734	ENSG00000230534.5	RP11-297A16.2	4.89	3.09e-06	0.00296	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35145445	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs12769575	ENSG00000230534.5	RP11-297A16.2	4.89	3.09e-06	0.00296	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35146999	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs12773647	ENSG00000230534.5	RP11-297A16.2	4.89	3.09e-06	0.00296	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35151399	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs878264	ENSG00000230534.5	RP11-297A16.2	4.89	3.09e-06	0.00296	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35151653	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs4934536	ENSG00000230534.5	RP11-297A16.2	4.89	3.09e-06	0.00296	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35152241	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs4934537	ENSG00000230534.5	RP11-297A16.2	4.89	3.09e-06	0.00296	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35152584	chr10:35098006~35127020:-
TGCT	cis	rs1061377	1	rs6829450	ENSG00000249685.1	RP11-360F5.3	4.89	3.09e-06	0.00296	0.36	0.4	Uric acid levels;	chr4:39114721	chr4:39133913~39135608:+
TGCT	cis	rs9880211	0.706	rs9289513	ENSG00000239213.4	NCK1-AS1	4.89	3.1e-06	0.00297	0.44	0.4	Height;Body mass index;	chr3:136732904	chr3:136841726~136862054:-
TGCT	cis	rs1426063	0.614	rs17000260	ENSG00000260265.1	RP11-44F21.5	4.89	3.11e-06	0.00298	0.58	0.4	QT interval;	chr4:75108576	chr4:75081702~75084717:-
TGCT	cis	rs507080	0.845	rs667982	ENSG00000255422.1	AP002954.4	-4.89	3.11e-06	0.00298	-0.48	-0.4	Serum metabolite levels;	chr11:118692058	chr11:118704607~118750263:+
TGCT	cis	rs10504229	0.683	rs2318147	ENSG00000253301.4	RP11-513O17.2	4.89	3.11e-06	0.00298	0.59	0.4	Developmental language disorder (linguistic errors);	chr8:57202372	chr8:57142689~57240298:+
TGCT	cis	rs875971	0.54	rs1723268	ENSG00000237310.1	GS1-124K5.4	4.89	3.11e-06	0.00298	0.45	0.4	Aortic root size;	chr7:66008093	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.522	rs1701760	ENSG00000237310.1	GS1-124K5.4	4.89	3.11e-06	0.00298	0.45	0.4	Aortic root size;	chr7:66008701	chr7:66493706~66495474:+
TGCT	cis	rs1023500	0.551	rs133355	ENSG00000270083.1	RP1-257I20.14	4.89	3.11e-06	0.00298	0.41	0.4	Schizophrenia;	chr22:42044281	chr22:42089630~42090028:-
TGCT	cis	rs380904	1	rs12543128	ENSG00000254859.1	RP11-661A12.5	-4.89	3.11e-06	0.00298	-0.58	-0.4	Venous thromboembolism (SNP x SNP interaction);	chr8:143512872	chr8:143541973~143549729:-
TGCT	cis	rs440932	0.798	rs330942	ENSG00000254340.1	RP11-10A14.3	4.89	3.11e-06	0.00298	0.43	0.4	High light scatter reticulocyte percentage of red cells;	chr8:9162929	chr8:9141424~9145435:+
TGCT	cis	rs2117029	1	rs10783301	ENSG00000258017.1	RP11-386G11.10	-4.89	3.12e-06	0.00298	-0.49	-0.4	Intelligence (multi-trait analysis);	chr12:49045593	chr12:49127782~49147869:+
TGCT	cis	rs2742234	0.518	rs2505514	ENSG00000273008.1	RP11-351D16.3	-4.88	3.13e-06	0.00299	-0.53	-0.4	Hirschsprung disease;	chr10:43137800	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.59	rs2435338	ENSG00000273008.1	RP11-351D16.3	-4.88	3.13e-06	0.00299	-0.53	-0.4	Hirschsprung disease;	chr10:43146667	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.59	rs2435339	ENSG00000273008.1	RP11-351D16.3	-4.88	3.13e-06	0.00299	-0.53	-0.4	Hirschsprung disease;	chr10:43146725	chr10:43136824~43138334:-
TGCT	cis	rs7829975	0.774	rs1703982	ENSG00000173295.6	FAM86B3P	-4.88	3.13e-06	0.003	-0.48	-0.4	Mood instability;	chr8:8740878	chr8:8228595~8244865:+
TGCT	cis	rs786425	0.627	rs7133734	ENSG00000278112.1	RP11-972P1.11	4.88	3.14e-06	0.003	0.5	0.4	Pubertal anthropometrics;	chr12:123712188	chr12:123519390~123519856:-
TGCT	cis	rs7729723	0.905	rs3813321	ENSG00000250159.5	RP11-381K20.2	-4.88	3.15e-06	0.00301	-0.43	-0.4	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);	chr5:138464335	chr5:137814333~137889336:-
TGCT	cis	rs651907	0.557	rs13069443	ENSG00000244119.1	PDCL3P4	4.88	3.15e-06	0.00301	0.29	0.4	Colorectal cancer;	chr3:101654461	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.557	rs11925001	ENSG00000244119.1	PDCL3P4	4.88	3.15e-06	0.00301	0.29	0.4	Colorectal cancer;	chr3:101655122	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.557	rs34624546	ENSG00000244119.1	PDCL3P4	4.88	3.15e-06	0.00301	0.29	0.4	Colorectal cancer;	chr3:101655382	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.557	rs56291106	ENSG00000244119.1	PDCL3P4	4.88	3.15e-06	0.00301	0.29	0.4	Colorectal cancer;	chr3:101658630	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.557	rs13081846	ENSG00000244119.1	PDCL3P4	4.88	3.15e-06	0.00301	0.29	0.4	Colorectal cancer;	chr3:101664477	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.557	rs11711079	ENSG00000244119.1	PDCL3P4	4.88	3.15e-06	0.00301	0.29	0.4	Colorectal cancer;	chr3:101668074	chr3:101712472~101713191:+
TGCT	cis	rs17345786	0.511	rs13061565	ENSG00000244119.1	PDCL3P4	4.88	3.15e-06	0.00301	0.29	0.4	Colonoscopy-negative controls vs population controls;	chr3:101673426	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.557	rs7651404	ENSG00000244119.1	PDCL3P4	4.88	3.15e-06	0.00301	0.29	0.4	Colorectal cancer;	chr3:101674450	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.557	rs7651721	ENSG00000244119.1	PDCL3P4	4.88	3.15e-06	0.00301	0.29	0.4	Colorectal cancer;	chr3:101674739	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.557	rs3806653	ENSG00000244119.1	PDCL3P4	4.88	3.15e-06	0.00301	0.29	0.4	Colorectal cancer;	chr3:101678128	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.557	rs1056579	ENSG00000244119.1	PDCL3P4	4.88	3.15e-06	0.00301	0.29	0.4	Colorectal cancer;	chr3:101679033	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.557	rs17411983	ENSG00000244119.1	PDCL3P4	-4.88	3.15e-06	0.00301	-0.29	-0.4	Colorectal cancer;	chr3:101680282	chr3:101712472~101713191:+
TGCT	cis	rs17345786	0.511	rs1138818	ENSG00000244119.1	PDCL3P4	4.88	3.15e-06	0.00301	0.29	0.4	Colonoscopy-negative controls vs population controls;	chr3:101680739	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.557	rs3094295	ENSG00000244119.1	PDCL3P4	4.88	3.15e-06	0.00301	0.29	0.4	Colorectal cancer;	chr3:101683151	chr3:101712472~101713191:+
TGCT	cis	rs4835473	0.897	rs924234	ENSG00000251600.4	RP11-673E1.1	4.88	3.15e-06	0.00301	0.42	0.4	Immature fraction of reticulocytes;	chr4:143706799	chr4:143912331~143982454:+
TGCT	cis	rs4713118	0.662	rs4713120	ENSG00000216901.1	AL022393.7	4.88	3.15e-06	0.00301	0.45	0.4	Parkinson's disease;	chr6:27754056	chr6:28176188~28176674:+
TGCT	cis	rs34779708	0.931	rs4934731	ENSG00000230534.5	RP11-297A16.2	4.88	3.15e-06	0.00301	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35142708	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs57081218	ENSG00000230534.5	RP11-297A16.2	4.88	3.15e-06	0.00301	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35145680	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs6481941	ENSG00000230534.5	RP11-297A16.2	4.88	3.15e-06	0.00301	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35151213	chr10:35098006~35127020:-
TGCT	cis	rs5742933	0.857	rs12471217	ENSG00000273240.1	RP11-455J20.3	4.88	3.16e-06	0.00302	0.38	0.4	Ferritin levels;	chr2:189707337	chr2:189763859~189764456:-
TGCT	cis	rs5742933	0.744	rs13002216	ENSG00000273240.1	RP11-455J20.3	4.88	3.16e-06	0.00302	0.38	0.4	Ferritin levels;	chr2:189746358	chr2:189763859~189764456:-
TGCT	cis	rs5742933	0.652	rs10210345	ENSG00000273240.1	RP11-455J20.3	4.88	3.16e-06	0.00302	0.38	0.4	Ferritin levels;	chr2:189754760	chr2:189763859~189764456:-
TGCT	cis	rs5742933	0.948	rs7592066	ENSG00000273240.1	RP11-455J20.3	4.88	3.16e-06	0.00302	0.38	0.4	Ferritin levels;	chr2:189778792	chr2:189763859~189764456:-
TGCT	cis	rs5742933	0.779	rs7595020	ENSG00000273240.1	RP11-455J20.3	4.88	3.16e-06	0.00302	0.38	0.4	Ferritin levels;	chr2:189778950	chr2:189763859~189764456:-
TGCT	cis	rs5742933	0.681	rs4525728	ENSG00000273240.1	RP11-455J20.3	4.88	3.16e-06	0.00302	0.38	0.4	Ferritin levels;	chr2:189780324	chr2:189763859~189764456:-
TGCT	cis	rs5742933	0.779	rs1899025	ENSG00000273240.1	RP11-455J20.3	4.88	3.16e-06	0.00302	0.38	0.4	Ferritin levels;	chr2:189784856	chr2:189763859~189764456:-
TGCT	cis	rs875971	0.66	rs2191268	ENSG00000272831.1	RP11-792A8.4	4.88	3.16e-06	0.00302	0.57	0.4	Aortic root size;	chr7:66645237	chr7:66739829~66740385:-
TGCT	cis	rs4925386	0.681	rs2427294	ENSG00000273619.1	RP5-908M14.9	-4.88	3.16e-06	0.00302	-0.51	-0.4	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352201	chr20:62386303~62386970:-
TGCT	cis	rs10875746	0.903	rs725454	ENSG00000240399.1	RP1-228P16.1	-4.88	3.16e-06	0.00302	-0.48	-0.4	Longevity (90 years and older);	chr12:48108317	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.903	rs17122666	ENSG00000240399.1	RP1-228P16.1	-4.88	3.16e-06	0.00302	-0.48	-0.4	Longevity (90 years and older);	chr12:48108791	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.903	rs4760681	ENSG00000240399.1	RP1-228P16.1	-4.88	3.16e-06	0.00302	-0.48	-0.4	Longevity (90 years and older);	chr12:48111447	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.903	rs11168414	ENSG00000240399.1	RP1-228P16.1	-4.88	3.16e-06	0.00302	-0.48	-0.4	Longevity (90 years and older);	chr12:48118548	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.903	rs11168418	ENSG00000240399.1	RP1-228P16.1	-4.88	3.16e-06	0.00302	-0.48	-0.4	Longevity (90 years and older);	chr12:48121971	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.903	rs11168427	ENSG00000240399.1	RP1-228P16.1	-4.88	3.16e-06	0.00302	-0.48	-0.4	Longevity (90 years and older);	chr12:48145196	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.951	rs61918826	ENSG00000240399.1	RP1-228P16.1	-4.88	3.16e-06	0.00302	-0.48	-0.4	Longevity (90 years and older);	chr12:48150195	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.904	rs10875750	ENSG00000240399.1	RP1-228P16.1	-4.88	3.16e-06	0.00302	-0.48	-0.4	Longevity (90 years and older);	chr12:48151847	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.951	rs7485355	ENSG00000240399.1	RP1-228P16.1	-4.88	3.16e-06	0.00302	-0.48	-0.4	Longevity (90 years and older);	chr12:48154559	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.951	rs10875756	ENSG00000240399.1	RP1-228P16.1	-4.88	3.16e-06	0.00302	-0.48	-0.4	Longevity (90 years and older);	chr12:48168521	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.951	rs4760689	ENSG00000240399.1	RP1-228P16.1	-4.88	3.16e-06	0.00302	-0.48	-0.4	Longevity (90 years and older);	chr12:48169861	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.951	rs4760690	ENSG00000240399.1	RP1-228P16.1	-4.88	3.16e-06	0.00302	-0.48	-0.4	Longevity (90 years and older);	chr12:48169870	chr12:48054813~48055591:-
TGCT	cis	rs7208859	0.623	rs73269916	ENSG00000266490.1	CTD-2349P21.9	4.88	3.17e-06	0.00303	0.46	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30792372~30792833:+
TGCT	cis	rs904251	0.504	rs2797795	ENSG00000204110.6	RP1-153P14.8	-4.88	3.17e-06	0.00303	-0.42	-0.4	Cognitive performance;	chr6:37512907	chr6:37507348~37535616:+
TGCT	cis	rs904251	0.523	rs2797796	ENSG00000204110.6	RP1-153P14.8	-4.88	3.17e-06	0.00303	-0.42	-0.4	Cognitive performance;	chr6:37513110	chr6:37507348~37535616:+
TGCT	cis	rs904251	0.523	rs2776870	ENSG00000204110.6	RP1-153P14.8	-4.88	3.17e-06	0.00303	-0.42	-0.4	Cognitive performance;	chr6:37513588	chr6:37507348~37535616:+
TGCT	cis	rs904251	0.523	rs2797798	ENSG00000204110.6	RP1-153P14.8	-4.88	3.17e-06	0.00303	-0.42	-0.4	Cognitive performance;	chr6:37513661	chr6:37507348~37535616:+
TGCT	cis	rs904251	0.523	rs2776871	ENSG00000204110.6	RP1-153P14.8	-4.88	3.17e-06	0.00303	-0.42	-0.4	Cognitive performance;	chr6:37513983	chr6:37507348~37535616:+
TGCT	cis	rs904251	0.523	rs1776454	ENSG00000204110.6	RP1-153P14.8	-4.88	3.17e-06	0.00303	-0.42	-0.4	Cognitive performance;	chr6:37514323	chr6:37507348~37535616:+
TGCT	cis	rs524281	0.731	rs9326365	ENSG00000255320.1	RP11-755F10.1	-4.88	3.17e-06	0.00303	-0.56	-0.4	Electroencephalogram traits;	chr11:66040414	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.731	rs1125078	ENSG00000255320.1	RP11-755F10.1	-4.88	3.17e-06	0.00303	-0.56	-0.4	Electroencephalogram traits;	chr11:66042404	chr11:66244840~66246239:-
TGCT	cis	rs453301	0.522	rs2929455	ENSG00000173295.6	FAM86B3P	-4.88	3.18e-06	0.00303	-0.45	-0.4	Joint mobility (Beighton score);	chr8:9225923	chr8:8228595~8244865:+
TGCT	cis	rs67311347	1	rs9822909	ENSG00000223797.4	ENTPD3-AS1	4.88	3.18e-06	0.00304	0.41	0.4	Renal cell carcinoma;	chr3:40415593	chr3:40313802~40453329:-
TGCT	cis	rs1372520	0.627	rs2737025	ENSG00000247775.2	SNCA-AS1	4.88	3.19e-06	0.00304	0.4	0.4	Neuroticism;	chr4:89798041	chr4:89836408~89841978:+
TGCT	cis	rs1372520	0.684	rs2583963	ENSG00000247775.2	SNCA-AS1	4.88	3.19e-06	0.00304	0.4	0.4	Neuroticism;	chr4:89805937	chr4:89836408~89841978:+
TGCT	cis	rs1372520	0.627	rs2583964	ENSG00000247775.2	SNCA-AS1	4.88	3.19e-06	0.00304	0.4	0.4	Neuroticism;	chr4:89806067	chr4:89836408~89841978:+
TGCT	cis	rs1372520	0.684	rs2197120	ENSG00000247775.2	SNCA-AS1	4.88	3.19e-06	0.00304	0.4	0.4	Neuroticism;	chr4:89808451	chr4:89836408~89841978:+
TGCT	cis	rs1372520	0.684	rs2619368	ENSG00000247775.2	SNCA-AS1	4.88	3.19e-06	0.00304	0.4	0.4	Neuroticism;	chr4:89808596	chr4:89836408~89841978:+
TGCT	cis	rs7927592	0.731	rs2156463	ENSG00000212093.1	AP000807.1	4.88	3.2e-06	0.00305	0.37	0.4	Total body bone mineral density;	chr11:68618843	chr11:68506083~68506166:-
TGCT	cis	rs796364	0.806	rs203766	ENSG00000232732.8	AC073043.1	4.88	3.2e-06	0.00305	0.57	0.4	Schizophrenia;	chr2:200037949	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs203765	ENSG00000232732.8	AC073043.1	4.88	3.2e-06	0.00305	0.57	0.4	Schizophrenia;	chr2:200038297	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs188102	ENSG00000232732.8	AC073043.1	4.88	3.2e-06	0.00305	0.57	0.4	Schizophrenia;	chr2:200038466	chr2:199867396~199911159:-
TGCT	cis	rs507080	0.769	rs570836	ENSG00000255422.1	AP002954.4	-4.88	3.2e-06	0.00306	-0.47	-0.4	Serum metabolite levels;	chr11:118641444	chr11:118704607~118750263:+
TGCT	cis	rs786425	0.707	rs1969272	ENSG00000247373.3	RP11-486O12.2	4.88	3.2e-06	0.00306	0.48	0.4	Pubertal anthropometrics;	chr12:123685746	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.866	rs7302449	ENSG00000247373.3	RP11-486O12.2	4.88	3.2e-06	0.00306	0.48	0.4	Pubertal anthropometrics;	chr12:123688199	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.576	rs10846541	ENSG00000247373.3	RP11-486O12.2	4.88	3.2e-06	0.00306	0.48	0.4	Pubertal anthropometrics;	chr12:123691739	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.866	rs7137946	ENSG00000247373.3	RP11-486O12.2	4.88	3.2e-06	0.00306	0.48	0.4	Pubertal anthropometrics;	chr12:123692742	chr12:123575891~123585115:-
TGCT	cis	rs9462027	0.606	rs2814979	ENSG00000186328.4	RP11-140K17.2	4.88	3.2e-06	0.00306	0.38	0.4	Systemic lupus erythematosus;	chr6:34610648	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.583	rs2744974	ENSG00000186328.4	RP11-140K17.2	4.88	3.2e-06	0.00306	0.38	0.4	Systemic lupus erythematosus;	chr6:34611654	chr6:34715613~34715940:+
TGCT	cis	rs507080	0.922	rs4938524	ENSG00000255239.1	AP002954.6	4.88	3.21e-06	0.00306	0.55	0.4	Serum metabolite levels;	chr11:118681365	chr11:118688039~118690600:-
TGCT	cis	rs2117029	0.619	rs2753	ENSG00000258017.1	RP11-386G11.10	-4.88	3.21e-06	0.00306	-0.53	-0.4	Intelligence (multi-trait analysis);	chr12:49127889	chr12:49127782~49147869:+
TGCT	cis	rs5769707	0.839	rs73176988	ENSG00000235111.1	RP1-29C18.8	-4.88	3.21e-06	0.00307	-0.32	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49612657~49615716:-
TGCT	cis	rs11231017	0.507	rs10792351	ENSG00000254454.2	RCC2P6	-4.88	3.22e-06	0.00307	-0.28	-0.4	HIV-1 viral setpoint;	chr11:62390000	chr11:62371146~62373168:+
TGCT	cis	rs796364	1	rs281771	ENSG00000232732.8	AC073043.1	4.88	3.22e-06	0.00307	0.56	0.4	Schizophrenia;	chr2:199947479	chr2:199867396~199911159:-
TGCT	cis	rs1799949	0.93	rs34210004	ENSG00000198496.9	NBR2	-4.88	3.22e-06	0.00307	-0.56	-0.4	Menopause (age at onset);	chr17:43218318	chr17:43125610~43153671:+
TGCT	cis	rs4563143	0.704	rs16961809	ENSG00000267243.4	AC005307.3	-4.88	3.22e-06	0.00307	-0.45	-0.4	Methadone dose in opioid dependence;	chr19:28735392	chr19:28435388~28727777:-
TGCT	cis	rs2015599	0.623	rs3782505	ENSG00000257176.2	RP11-996F15.2	4.88	3.22e-06	0.00307	0.43	0.4	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29280418~29317848:-
TGCT	cis	rs1153858	1	rs2467864	ENSG00000259520.4	CTD-2651B20.3	4.88	3.23e-06	0.00308	0.34	0.4	Homoarginine levels;	chr15:45348900	chr15:45251580~45279251:-
TGCT	cis	rs4835473	0.932	rs7356157	ENSG00000251600.4	RP11-673E1.1	4.88	3.23e-06	0.00308	0.4	0.4	Immature fraction of reticulocytes;	chr4:143739233	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs2060656	ENSG00000251600.4	RP11-673E1.1	-4.88	3.23e-06	0.00308	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143739330	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.864	rs67749935	ENSG00000251600.4	RP11-673E1.1	-4.88	3.23e-06	0.00308	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143739852	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs66934100	ENSG00000251600.4	RP11-673E1.1	-4.88	3.23e-06	0.00308	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143739872	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs4257605	ENSG00000251600.4	RP11-673E1.1	-4.88	3.23e-06	0.00308	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143740081	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs4498094	ENSG00000251600.4	RP11-673E1.1	-4.88	3.23e-06	0.00308	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143740097	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs4325971	ENSG00000251600.4	RP11-673E1.1	-4.88	3.23e-06	0.00308	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143740167	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs4443230	ENSG00000251600.4	RP11-673E1.1	-4.88	3.23e-06	0.00308	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143740372	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs4637344	ENSG00000251600.4	RP11-673E1.1	-4.88	3.23e-06	0.00308	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143740434	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs56277406	ENSG00000251600.4	RP11-673E1.1	-4.88	3.23e-06	0.00308	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143740620	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs13143879	ENSG00000251600.4	RP11-673E1.1	-4.88	3.23e-06	0.00308	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143740901	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs2127788	ENSG00000251600.4	RP11-673E1.1	4.88	3.23e-06	0.00308	0.4	0.4	Immature fraction of reticulocytes;	chr4:143741996	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs6851999	ENSG00000251600.4	RP11-673E1.1	4.88	3.23e-06	0.00308	0.4	0.4	Immature fraction of reticulocytes;	chr4:143742567	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs6852195	ENSG00000251600.4	RP11-673E1.1	4.88	3.23e-06	0.00308	0.4	0.4	Immature fraction of reticulocytes;	chr4:143742584	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs36086465	ENSG00000251600.4	RP11-673E1.1	-4.88	3.23e-06	0.00308	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143742738	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs873430	ENSG00000251600.4	RP11-673E1.1	-4.88	3.23e-06	0.00308	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143742953	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs873431	ENSG00000251600.4	RP11-673E1.1	-4.88	3.23e-06	0.00308	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143743035	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs899903	ENSG00000251600.4	RP11-673E1.1	-4.88	3.23e-06	0.00308	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143743551	chr4:143912331~143982454:+
TGCT	cis	rs7208859	0.524	rs60114476	ENSG00000266490.1	CTD-2349P21.9	4.88	3.23e-06	0.00308	0.46	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30792372~30792833:+
TGCT	cis	rs5769707	0.967	rs739248	ENSG00000235111.1	RP1-29C18.8	-4.88	3.23e-06	0.00308	-0.32	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49631557	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.967	rs9616701	ENSG00000235111.1	RP1-29C18.8	-4.88	3.23e-06	0.00308	-0.32	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49631898	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.967	rs2071904	ENSG00000235111.1	RP1-29C18.8	-4.88	3.23e-06	0.00308	-0.32	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49640829	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.846	rs5770610	ENSG00000235111.1	RP1-29C18.8	-4.88	3.23e-06	0.00308	-0.32	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49643249	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.967	rs8141807	ENSG00000235111.1	RP1-29C18.8	-4.88	3.23e-06	0.00308	-0.32	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49650090	chr22:49612657~49615716:-
TGCT	cis	rs4835473	0.932	rs7669198	ENSG00000251600.4	RP11-673E1.1	-4.88	3.24e-06	0.00308	-0.41	-0.4	Immature fraction of reticulocytes;	chr4:143821229	chr4:143912331~143982454:+
TGCT	cis	rs10875976	0.525	rs7137210	ENSG00000242041.1	RP11-70F11.2	4.88	3.24e-06	0.00309	0.38	0.4	Obesity;	chr12:49856660	chr12:49863173~49863503:+
TGCT	cis	rs5769707	0.521	rs6009810	ENSG00000235111.1	RP1-29C18.8	-4.88	3.24e-06	0.00309	-0.38	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49665892	chr22:49612657~49615716:-
TGCT	cis	rs10246939	0.544	rs6955562	ENSG00000228775.6	WEE2-AS1	4.88	3.24e-06	0.00309	0.36	0.4	Bitter taste perception;	chr7:141886641	chr7:141704338~141738346:-
TGCT	cis	rs875971	0.862	rs10256544	ENSG00000232559.3	GS1-124K5.12	4.88	3.26e-06	0.0031	0.37	0.4	Aortic root size;	chr7:66210141	chr7:66554588~66576923:-
TGCT	cis	rs3091242	0.933	rs34933589	ENSG00000261349.1	RP3-465N24.5	4.87	3.26e-06	0.0031	0.4	0.4	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25266102~25267136:-
TGCT	cis	rs12439619	0.846	rs7496227	ENSG00000255769.6	GOLGA2P10	-4.87	3.26e-06	0.0031	-0.49	-0.4	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472993~82513950:-
TGCT	cis	rs853679	0.723	rs9366718	ENSG00000216901.1	AL022393.7	4.87	3.26e-06	0.00311	0.61	0.4	Depression;	chr6:28237724	chr6:28176188~28176674:+
TGCT	cis	rs5742933	0.857	rs11685425	ENSG00000273240.1	RP11-455J20.3	4.87	3.27e-06	0.00311	0.38	0.4	Ferritin levels;	chr2:189747977	chr2:189763859~189764456:-
TGCT	cis	rs11168618	0.74	rs4409884	ENSG00000240399.1	RP1-228P16.1	4.87	3.28e-06	0.00312	0.39	0.4	Adiponectin levels;	chr12:48533758	chr12:48054813~48055591:-
TGCT	cis	rs904251	0.523	rs2797794	ENSG00000279942.1	RP1-153P14.7	-4.87	3.29e-06	0.00312	-0.4	-0.4	Cognitive performance;	chr6:37512828	chr6:37567716~37571460:+
TGCT	cis	rs904251	0.523	rs2776920	ENSG00000279942.1	RP1-153P14.7	-4.87	3.29e-06	0.00312	-0.4	-0.4	Cognitive performance;	chr6:37512829	chr6:37567716~37571460:+
TGCT	cis	rs5769707	0.935	rs1109320	ENSG00000235111.1	RP1-29C18.8	-4.87	3.29e-06	0.00312	-0.32	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49612657~49615716:-
TGCT	cis	rs2976388	0.609	rs1469811	ENSG00000253196.1	RP11-706C16.7	4.87	3.29e-06	0.00312	0.4	0.4	Urinary tract infection frequency;	chr8:142706581	chr8:142763116~142766427:+
TGCT	cis	rs16975963	0.644	rs78644049	ENSG00000276846.1	CTD-3220F14.3	-4.87	3.3e-06	0.00313	-0.4	-0.4	Longevity;	chr19:37622141	chr19:37314868~37315620:-
TGCT	cis	rs16975963	0.644	rs75499934	ENSG00000276846.1	CTD-3220F14.3	-4.87	3.3e-06	0.00313	-0.4	-0.4	Longevity;	chr19:37622142	chr19:37314868~37315620:-
TGCT	cis	rs16975963	0.604	rs17305326	ENSG00000276846.1	CTD-3220F14.3	-4.87	3.3e-06	0.00313	-0.4	-0.4	Longevity;	chr19:37628646	chr19:37314868~37315620:-
TGCT	cis	rs4660456	0.913	rs7551747	ENSG00000237899.1	RP4-739H11.3	4.87	3.3e-06	0.00313	0.52	0.4	Platelet count;	chr1:40699407	chr1:40669089~40687588:-
TGCT	cis	rs4835473	0.897	rs11727223	ENSG00000251600.4	RP11-673E1.1	4.87	3.31e-06	0.00314	0.41	0.4	Immature fraction of reticulocytes;	chr4:143707090	chr4:143912331~143982454:+
TGCT	cis	rs10875746	0.903	rs12313404	ENSG00000240399.1	RP1-228P16.1	-4.87	3.31e-06	0.00315	-0.48	-0.4	Longevity (90 years and older);	chr12:48098265	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.855	rs73102065	ENSG00000240399.1	RP1-228P16.1	-4.87	3.31e-06	0.00315	-0.48	-0.4	Longevity (90 years and older);	chr12:48098824	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.855	rs73102067	ENSG00000240399.1	RP1-228P16.1	-4.87	3.31e-06	0.00315	-0.48	-0.4	Longevity (90 years and older);	chr12:48100643	chr12:48054813~48055591:-
TGCT	cis	rs72772090	0.539	rs72773969	ENSG00000248734.2	CTD-2260A17.1	-4.87	3.32e-06	0.00315	-0.52	-0.4	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96809493	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs10515250	ENSG00000248734.2	CTD-2260A17.1	-4.87	3.32e-06	0.00315	-0.52	-0.4	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96814490	chr5:96784777~96785999:+
TGCT	cis	rs9322193	0.923	rs6913486	ENSG00000216906.2	RP11-350J20.9	-4.87	3.32e-06	0.00315	-0.47	-0.4	Lung cancer;	chr6:149705060	chr6:149904243~149906418:+
TGCT	cis	rs5769707	0.542	rs739242	ENSG00000235111.1	RP1-29C18.8	-4.87	3.32e-06	0.00315	-0.38	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49663468	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.521	rs7285764	ENSG00000235111.1	RP1-29C18.8	-4.87	3.32e-06	0.00315	-0.38	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49664913	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.521	rs9616715	ENSG00000235111.1	RP1-29C18.8	-4.87	3.32e-06	0.00315	-0.38	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49664934	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.521	rs6009805	ENSG00000235111.1	RP1-29C18.8	-4.87	3.32e-06	0.00315	-0.38	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49665067	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.521	rs6009807	ENSG00000235111.1	RP1-29C18.8	-4.87	3.32e-06	0.00315	-0.38	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49665274	chr22:49612657~49615716:-
TGCT	cis	rs67311347	1	rs17078511	ENSG00000223797.4	ENTPD3-AS1	4.87	3.33e-06	0.00316	0.41	0.4	Renal cell carcinoma;	chr3:40354763	chr3:40313802~40453329:-
TGCT	cis	rs2033711	0.936	rs893185	ENSG00000269473.1	CTD-2619J13.19	4.87	3.33e-06	0.00316	0.34	0.4	Uric acid clearance;	chr19:58478128	chr19:58440448~58445849:+
TGCT	cis	rs12439619	0.846	rs62013464	ENSG00000255769.6	GOLGA2P10	-4.87	3.33e-06	0.00316	-0.48	-0.4	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472993~82513950:-
TGCT	cis	rs12439619	0.846	rs62010071	ENSG00000255769.6	GOLGA2P10	-4.87	3.33e-06	0.00316	-0.48	-0.4	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472993~82513950:-
TGCT	cis	rs1153858	1	rs7169818	ENSG00000259520.4	CTD-2651B20.3	-4.87	3.34e-06	0.00316	-0.34	-0.4	Homoarginine levels;	chr15:45347993	chr15:45251580~45279251:-
TGCT	cis	rs67311347	0.955	rs73078170	ENSG00000223797.4	ENTPD3-AS1	4.87	3.34e-06	0.00317	0.45	0.4	Renal cell carcinoma;	chr3:40442456	chr3:40313802~40453329:-
TGCT	cis	rs17361889	0.613	rs62440449	ENSG00000224683.1	RPL36AP29	4.87	3.34e-06	0.00317	0.4	0.4	Pediatric bone mineral content (hip);	chr7:16257180	chr7:16208945~16209265:+
TGCT	cis	rs875971	0.522	rs1917563	ENSG00000237310.1	GS1-124K5.4	-4.87	3.34e-06	0.00317	-0.44	-0.4	Aortic root size;	chr7:65950660	chr7:66493706~66495474:+
TGCT	cis	rs77669868	0.929	rs76761091	ENSG00000256452.1	RP11-667M19.10	-4.87	3.35e-06	0.00318	-0.38	-0.4	Monocyte percentage of white cells;	chr11:114196336	chr11:113818077~113822458:+
TGCT	cis	rs875971	0.66	rs801192	ENSG00000237310.1	GS1-124K5.4	-4.87	3.36e-06	0.00318	-0.46	-0.4	Aortic root size;	chr7:66566965	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.66	rs801190	ENSG00000237310.1	GS1-124K5.4	-4.87	3.36e-06	0.00318	-0.46	-0.4	Aortic root size;	chr7:66568046	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.66	rs3857686	ENSG00000237310.1	GS1-124K5.4	-4.87	3.36e-06	0.00318	-0.46	-0.4	Aortic root size;	chr7:66571204	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.638	rs6460305	ENSG00000237310.1	GS1-124K5.4	-4.87	3.36e-06	0.00318	-0.46	-0.4	Aortic root size;	chr7:66595421	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.638	rs6960778	ENSG00000237310.1	GS1-124K5.4	-4.87	3.36e-06	0.00318	-0.46	-0.4	Aortic root size;	chr7:66606610	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.66	rs1860468	ENSG00000237310.1	GS1-124K5.4	-4.87	3.36e-06	0.00318	-0.46	-0.4	Aortic root size;	chr7:66642265	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.619	rs12533585	ENSG00000237310.1	GS1-124K5.4	4.87	3.36e-06	0.00318	0.46	0.4	Aortic root size;	chr7:66519618	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.66	rs28698552	ENSG00000237310.1	GS1-124K5.4	4.87	3.36e-06	0.00318	0.46	0.4	Aortic root size;	chr7:66540031	chr7:66493706~66495474:+
TGCT	cis	rs7044106	0.887	rs1359328	ENSG00000226752.6	PSMD5-AS1	-4.87	3.36e-06	0.00319	-0.56	-0.4	Hip circumference adjusted for BMI;	chr9:120608544	chr9:120824828~120854385:+
TGCT	cis	rs72772090	0.539	rs56319744	ENSG00000248734.2	CTD-2260A17.1	-4.87	3.37e-06	0.00319	-0.52	-0.4	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96806235	chr5:96784777~96785999:+
TGCT	cis	rs1372520	0.684	rs2619347	ENSG00000247775.2	SNCA-AS1	4.87	3.37e-06	0.00319	0.4	0.4	Neuroticism;	chr4:89824619	chr4:89836408~89841978:+
TGCT	cis	rs1372520	0.684	rs2737010	ENSG00000247775.2	SNCA-AS1	4.87	3.37e-06	0.00319	0.4	0.4	Neuroticism;	chr4:89825315	chr4:89836408~89841978:+
TGCT	cis	rs1372520	0.567	rs2619349	ENSG00000247775.2	SNCA-AS1	4.87	3.37e-06	0.00319	0.4	0.4	Neuroticism;	chr4:89825495	chr4:89836408~89841978:+
TGCT	cis	rs1372520	0.684	rs1811442	ENSG00000247775.2	SNCA-AS1	4.87	3.37e-06	0.00319	0.4	0.4	Neuroticism;	chr4:89826600	chr4:89836408~89841978:+
TGCT	cis	rs1372520	0.577	rs1811443	ENSG00000247775.2	SNCA-AS1	4.87	3.37e-06	0.00319	0.4	0.4	Neuroticism;	chr4:89826732	chr4:89836408~89841978:+
TGCT	cis	rs1372520	0.684	rs2619355	ENSG00000247775.2	SNCA-AS1	4.87	3.37e-06	0.00319	0.4	0.4	Neuroticism;	chr4:89827223	chr4:89836408~89841978:+
TGCT	cis	rs1372520	0.684	rs1442148	ENSG00000247775.2	SNCA-AS1	4.87	3.37e-06	0.00319	0.4	0.4	Neuroticism;	chr4:89827695	chr4:89836408~89841978:+
TGCT	cis	rs1372520	0.684	rs2583978	ENSG00000247775.2	SNCA-AS1	4.87	3.37e-06	0.00319	0.4	0.4	Neuroticism;	chr4:89829175	chr4:89836408~89841978:+
TGCT	cis	rs1372520	0.684	rs2583979	ENSG00000247775.2	SNCA-AS1	4.87	3.37e-06	0.00319	0.4	0.4	Neuroticism;	chr4:89829437	chr4:89836408~89841978:+
TGCT	cis	rs1372520	0.684	rs2619356	ENSG00000247775.2	SNCA-AS1	4.87	3.37e-06	0.00319	0.4	0.4	Neuroticism;	chr4:89829693	chr4:89836408~89841978:+
TGCT	cis	rs1372520	0.748	rs2737002	ENSG00000247775.2	SNCA-AS1	4.87	3.37e-06	0.00319	0.4	0.4	Neuroticism;	chr4:89832029	chr4:89836408~89841978:+
TGCT	cis	rs1372520	0.748	rs990085	ENSG00000247775.2	SNCA-AS1	4.87	3.37e-06	0.00319	0.4	0.4	Neuroticism;	chr4:89833620	chr4:89836408~89841978:+
TGCT	cis	rs8059260	0.542	rs6498148	ENSG00000274038.1	RP11-66H6.4	-4.87	3.37e-06	0.00319	-0.55	-0.4	Alcohol consumption over the past year;	chr16:11018374	chr16:11056556~11057034:+
TGCT	cis	rs786425	0.711	rs1515815	ENSG00000278112.1	RP11-972P1.11	4.87	3.37e-06	0.0032	0.47	0.4	Pubertal anthropometrics;	chr12:123627452	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.711	rs36018806	ENSG00000278112.1	RP11-972P1.11	4.87	3.37e-06	0.0032	0.47	0.4	Pubertal anthropometrics;	chr12:123630005	chr12:123519390~123519856:-
TGCT	cis	rs11118620	0.853	rs12037861	ENSG00000272823.1	RP11-295M18.6	4.87	3.38e-06	0.0032	0.37	0.4	Heart failure;	chr1:220864835	chr1:220828676~220829211:-
TGCT	cis	rs10875976	0.525	rs3741558	ENSG00000242041.1	RP11-70F11.2	4.87	3.38e-06	0.0032	0.38	0.4	Obesity;	chr12:49864422	chr12:49863173~49863503:+
TGCT	cis	rs10875976	0.525	rs3741557	ENSG00000242041.1	RP11-70F11.2	4.87	3.38e-06	0.0032	0.38	0.4	Obesity;	chr12:49864542	chr12:49863173~49863503:+
TGCT	cis	rs67311347	1	rs73078163	ENSG00000223797.4	ENTPD3-AS1	4.87	3.39e-06	0.00321	0.43	0.4	Renal cell carcinoma;	chr3:40438467	chr3:40313802~40453329:-
TGCT	cis	rs5742933	0.744	rs13009889	ENSG00000273240.1	RP11-455J20.3	4.87	3.39e-06	0.00321	0.37	0.4	Ferritin levels;	chr2:189763842	chr2:189763859~189764456:-
TGCT	cis	rs5742933	0.817	rs1055091	ENSG00000273240.1	RP11-455J20.3	4.87	3.39e-06	0.00321	0.37	0.4	Ferritin levels;	chr2:189770417	chr2:189763859~189764456:-
TGCT	cis	rs5742933	0.817	rs6942	ENSG00000273240.1	RP11-455J20.3	4.87	3.39e-06	0.00321	0.37	0.4	Ferritin levels;	chr2:189771685	chr2:189763859~189764456:-
TGCT	cis	rs5742933	0.817	rs3816196	ENSG00000273240.1	RP11-455J20.3	4.87	3.39e-06	0.00321	0.37	0.4	Ferritin levels;	chr2:189775749	chr2:189763859~189764456:-
TGCT	cis	rs5742933	0.817	rs6738042	ENSG00000273240.1	RP11-455J20.3	4.87	3.39e-06	0.00321	0.37	0.4	Ferritin levels;	chr2:189776958	chr2:189763859~189764456:-
TGCT	cis	rs9326248	0.515	rs2727793	ENSG00000254851.1	RP11-109L13.1	-4.87	3.39e-06	0.00321	-0.53	-0.4	Blood protein levels;	chr11:116812658	chr11:117135528~117138582:+
TGCT	cis	rs9918079	0.506	rs10214	ENSG00000273133.1	RP11-799M12.2	4.87	3.39e-06	0.00321	0.59	0.4	Obesity-related traits;	chr4:15604808	chr4:15563698~15564253:-
TGCT	cis	rs950169	0.614	rs765524	ENSG00000225151.9	GOLGA2P7	-4.87	3.4e-06	0.00321	-0.5	-0.4	Schizophrenia;	chr15:84013030	chr15:84199311~84230136:-
TGCT	cis	rs9322193	0.962	rs4869730	ENSG00000216906.2	RP11-350J20.9	4.87	3.4e-06	0.00321	0.45	0.4	Lung cancer;	chr6:149808187	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.884	rs11155689	ENSG00000216906.2	RP11-350J20.9	4.87	3.4e-06	0.00321	0.45	0.4	Lung cancer;	chr6:149808470	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs2151913	ENSG00000216906.2	RP11-350J20.9	4.87	3.4e-06	0.00321	0.45	0.4	Lung cancer;	chr6:149809506	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs2342857	ENSG00000216906.2	RP11-350J20.9	4.87	3.4e-06	0.00321	0.45	0.4	Lung cancer;	chr6:149809537	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.884	rs933055	ENSG00000216906.2	RP11-350J20.9	4.87	3.4e-06	0.00321	0.45	0.4	Lung cancer;	chr6:149809701	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs4869731	ENSG00000216906.2	RP11-350J20.9	4.87	3.4e-06	0.00321	0.45	0.4	Lung cancer;	chr6:149810072	chr6:149904243~149906418:+
TGCT	cis	rs34779708	0.931	rs35388511	ENSG00000230534.5	RP11-297A16.2	4.87	3.4e-06	0.00322	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35007688	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs34815241	ENSG00000230534.5	RP11-297A16.2	4.87	3.4e-06	0.00322	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35007748	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs2384275	ENSG00000230534.5	RP11-297A16.2	4.87	3.4e-06	0.00322	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35008214	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs11010067	ENSG00000230534.5	RP11-297A16.2	-4.87	3.4e-06	0.00322	-0.48	-0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35006503	chr10:35098006~35127020:-
TGCT	cis	rs796364	1	rs1509835	ENSG00000232732.8	AC073043.1	-4.87	3.4e-06	0.00322	-0.55	-0.4	Schizophrenia;	chr2:199950086	chr2:199867396~199911159:-
TGCT	cis	rs6600671	0.899	rs11249432	ENSG00000275131.1	CH17-472G23.4	-4.86	3.41e-06	0.00322	-0.26	-0.4	Hip geometry;	chr1:121541678	chr1:120489625~120579190:-
TGCT	cis	rs6600671	0.934	rs12131379	ENSG00000275131.1	CH17-472G23.4	-4.86	3.41e-06	0.00322	-0.26	-0.4	Hip geometry;	chr1:121551639	chr1:120489625~120579190:-
TGCT	cis	rs4835473	0.932	rs6813011	ENSG00000251600.4	RP11-673E1.1	4.86	3.41e-06	0.00322	0.41	0.4	Immature fraction of reticulocytes;	chr4:143914496	chr4:143912331~143982454:+
TGCT	cis	rs5769707	1	rs5769707	ENSG00000235111.1	RP1-29C18.8	-4.86	3.41e-06	0.00323	-0.32	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49619754	chr22:49612657~49615716:-
TGCT	cis	rs8022179	0.58	rs58153827	ENSG00000244691.1	RPL10AP1	4.86	3.41e-06	0.00323	0.58	0.4	Monocyte count;	chr14:103378293	chr14:103412119~103412761:-
TGCT	cis	rs2242073	0.733	rs6750890	ENSG00000232799.1	CRYGFP	4.86	3.43e-06	0.00324	0.59	0.4	Attention deficit hyperactivity disorder;	chr2:208146290	chr2:209145241~209147687:+
TGCT	cis	rs12143943	0.866	rs4252745	ENSG00000176754.11	LINC00303	-4.86	3.44e-06	0.00325	-0.37	-0.4	Cognitive performance;	chr1:204550059	chr1:204032447~204041265:-
TGCT	cis	rs7829975	0.659	rs4382480	ENSG00000254340.1	RP11-10A14.3	4.86	3.44e-06	0.00325	0.39	0.4	Mood instability;	chr8:8863963	chr8:9141424~9145435:+
TGCT	cis	rs875971	0.756	rs2901210	ENSG00000232559.3	GS1-124K5.12	-4.86	3.44e-06	0.00325	-0.36	-0.4	Aortic root size;	chr7:66552518	chr7:66554588~66576923:-
TGCT	cis	rs67311347	0.911	rs6776044	ENSG00000223797.4	ENTPD3-AS1	4.86	3.44e-06	0.00325	0.42	0.4	Renal cell carcinoma;	chr3:40336012	chr3:40313802~40453329:-
TGCT	cis	rs67311347	0.955	rs6764102	ENSG00000223797.4	ENTPD3-AS1	4.86	3.44e-06	0.00325	0.42	0.4	Renal cell carcinoma;	chr3:40336662	chr3:40313802~40453329:-
TGCT	cis	rs673078	0.607	rs61943443	ENSG00000275759.1	RP11-131L12.3	-4.86	3.44e-06	0.00325	-0.74	-0.4	Glucose homeostasis traits;	chr12:118416602	chr12:118428281~118428870:+
TGCT	cis	rs56080343	0.808	rs1045552	ENSG00000275759.1	RP11-131L12.3	-4.86	3.44e-06	0.00325	-0.74	-0.4	Neuroticism;	chr12:118417678	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs7305647	ENSG00000275759.1	RP11-131L12.3	-4.86	3.44e-06	0.00325	-0.74	-0.4	Glucose homeostasis traits;	chr12:118417761	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs61943444	ENSG00000275759.1	RP11-131L12.3	-4.86	3.44e-06	0.00325	-0.74	-0.4	Glucose homeostasis traits;	chr12:118421641	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs73207504	ENSG00000275759.1	RP11-131L12.3	-4.86	3.44e-06	0.00325	-0.74	-0.4	Glucose homeostasis traits;	chr12:118427914	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs73207564	ENSG00000275759.1	RP11-131L12.3	-4.86	3.44e-06	0.00325	-0.74	-0.4	Glucose homeostasis traits;	chr12:118429566	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs61943447	ENSG00000275759.1	RP11-131L12.3	-4.86	3.44e-06	0.00325	-0.74	-0.4	Glucose homeostasis traits;	chr12:118430598	chr12:118428281~118428870:+
TGCT	cis	rs67311347	1	rs9827461	ENSG00000223797.4	ENTPD3-AS1	4.86	3.44e-06	0.00325	0.43	0.4	Renal cell carcinoma;	chr3:40447860	chr3:40313802~40453329:-
TGCT	cis	rs1153858	0.832	rs1145078	ENSG00000259520.4	CTD-2651B20.3	-4.86	3.45e-06	0.00326	-0.34	-0.4	Homoarginine levels;	chr15:45390079	chr15:45251580~45279251:-
TGCT	cis	rs1799949	0.965	rs8067269	ENSG00000198496.9	NBR2	-4.86	3.45e-06	0.00326	-0.56	-0.4	Menopause (age at onset);	chr17:43083782	chr17:43125610~43153671:+
TGCT	cis	rs8091660	0.929	rs12606093	ENSG00000278983.1	RP11-426J5.3	4.86	3.46e-06	0.00326	0.47	0.4	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550924	chr18:48564795~48568342:+
TGCT	cis	rs67311347	1	rs9857824	ENSG00000223797.4	ENTPD3-AS1	4.86	3.46e-06	0.00326	0.43	0.4	Renal cell carcinoma;	chr3:40417921	chr3:40313802~40453329:-
TGCT	cis	rs9322193	0.962	rs7745915	ENSG00000216906.2	RP11-350J20.9	4.86	3.46e-06	0.00327	0.44	0.4	Lung cancer;	chr6:149834111	chr6:149904243~149906418:+
TGCT	cis	rs9326248	1	rs585849	ENSG00000280143.1	AP000892.6	4.86	3.47e-06	0.00327	0.54	0.4	Blood protein levels;	chr11:117198345	chr11:117204967~117210292:+
TGCT	cis	rs4563143	0.663	rs10406794	ENSG00000267243.4	AC005307.3	-4.86	3.47e-06	0.00328	-0.45	-0.4	Methadone dose in opioid dependence;	chr19:28737149	chr19:28435388~28727777:-
TGCT	cis	rs875971	0.522	rs2949690	ENSG00000237310.1	GS1-124K5.4	-4.86	3.48e-06	0.00328	-0.45	-0.4	Aortic root size;	chr7:66018255	chr7:66493706~66495474:+
TGCT	cis	rs2015599	0.623	rs7358667	ENSG00000257176.2	RP11-996F15.2	4.86	3.48e-06	0.00329	0.43	0.4	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29280418~29317848:-
TGCT	cis	rs6952407	1	rs6952407	ENSG00000237310.1	GS1-124K5.4	-4.86	3.49e-06	0.00329	-0.46	-0.4	Cotinine glucuronidation;	chr7:66580525	chr7:66493706~66495474:+
TGCT	cis	rs4835473	0.9	rs58106929	ENSG00000251600.4	RP11-673E1.1	4.86	3.49e-06	0.00329	0.39	0.4	Immature fraction of reticulocytes;	chr4:143733166	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs7698963	ENSG00000251600.4	RP11-673E1.1	4.86	3.49e-06	0.00329	0.39	0.4	Immature fraction of reticulocytes;	chr4:143733190	chr4:143912331~143982454:+
TGCT	cis	rs1075265	0.568	rs959286	ENSG00000233266.1	HMGB1P31	4.86	3.49e-06	0.00329	0.44	0.4	Chronotype;Morning vs. evening chronotype;	chr2:54078941	chr2:54051334~54051760:+
TGCT	cis	rs1075265	0.527	rs959285	ENSG00000233266.1	HMGB1P31	4.86	3.49e-06	0.00329	0.44	0.4	Chronotype;Morning vs. evening chronotype;	chr2:54078964	chr2:54051334~54051760:+
TGCT	cis	rs1075265	0.528	rs2018747	ENSG00000233266.1	HMGB1P31	4.86	3.49e-06	0.00329	0.44	0.4	Chronotype;Morning vs. evening chronotype;	chr2:54082487	chr2:54051334~54051760:+
TGCT	cis	rs1707322	0.721	rs4660883	ENSG00000280836.1	AL355480.1	-4.86	3.49e-06	0.00329	-0.53	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45581219~45581321:-
TGCT	cis	rs7301826	0.934	rs10773826	ENSG00000256299.1	RP11-989F5.3	-4.86	3.5e-06	0.00329	-0.44	-0.4	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810821~130812622:-
TGCT	cis	rs2976388	0.647	rs2585138	ENSG00000253196.1	RP11-706C16.7	4.86	3.5e-06	0.0033	0.4	0.4	Urinary tract infection frequency;	chr8:142727533	chr8:142763116~142766427:+
TGCT	cis	rs34217772	0.883	rs61992434	ENSG00000258536.1	RP11-1053O12.1	4.86	3.5e-06	0.0033	0.37	0.4	Myopia;	chr14:41762055	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.883	rs59348864	ENSG00000258536.1	RP11-1053O12.1	4.86	3.5e-06	0.0033	0.37	0.4	Myopia;	chr14:41768184	chr14:41742639~41742963:+
TGCT	cis	rs2412819	0.571	rs12900924	ENSG00000205771.5	CATSPER2P1	-4.86	3.5e-06	0.0033	-0.6	-0.4	Lung cancer;	chr15:43737329	chr15:43726918~43747094:-
TGCT	cis	rs2412819	0.571	rs7174260	ENSG00000205771.5	CATSPER2P1	-4.86	3.5e-06	0.0033	-0.6	-0.4	Lung cancer;	chr15:43751988	chr15:43726918~43747094:-
TGCT	cis	rs875971	0.522	rs2008188	ENSG00000237310.1	GS1-124K5.4	4.86	3.51e-06	0.0033	0.45	0.4	Aortic root size;	chr7:65964026	chr7:66493706~66495474:+
TGCT	cis	rs17711722	0.727	rs1880555	ENSG00000237310.1	GS1-124K5.4	4.86	3.51e-06	0.0033	0.45	0.4	Calcium levels;	chr7:65967580	chr7:66493706~66495474:+
TGCT	cis	rs17711722	0.701	rs781143	ENSG00000237310.1	GS1-124K5.4	4.86	3.51e-06	0.0033	0.45	0.4	Calcium levels;	chr7:65974892	chr7:66493706~66495474:+
TGCT	cis	rs17711722	0.701	rs781145	ENSG00000237310.1	GS1-124K5.4	4.86	3.51e-06	0.0033	0.45	0.4	Calcium levels;	chr7:65975383	chr7:66493706~66495474:+
TGCT	cis	rs524281	0.64	rs61895584	ENSG00000255320.1	RP11-755F10.1	-4.86	3.51e-06	0.0033	-0.63	-0.4	Electroencephalogram traits;	chr11:66042738	chr11:66244840~66246239:-
TGCT	cis	rs755249	0.565	rs3768320	ENSG00000182109.6	RP11-69E11.4	-4.86	3.52e-06	0.00331	-0.38	-0.4	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39566567	chr1:39522280~39546187:-
TGCT	cis	rs5769707	0.967	rs763127	ENSG00000235111.1	RP1-29C18.8	-4.86	3.52e-06	0.00331	-0.32	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49612657~49615716:-
TGCT	cis	rs1023500	0.596	rs133352	ENSG00000270083.1	RP1-257I20.14	4.86	3.52e-06	0.00331	0.41	0.4	Schizophrenia;	chr22:42038018	chr22:42089630~42090028:-
TGCT	cis	rs5769707	0.935	rs5770594	ENSG00000235111.1	RP1-29C18.8	-4.86	3.52e-06	0.00331	-0.32	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49624849	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.967	rs4524218	ENSG00000235111.1	RP1-29C18.8	-4.86	3.52e-06	0.00331	-0.32	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49624991	chr22:49612657~49615716:-
TGCT	cis	rs2463822	0.844	rs72923263	ENSG00000254454.2	RCC2P6	4.86	3.52e-06	0.00331	0.45	0.4	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62393698	chr11:62371146~62373168:+
TGCT	cis	rs2463822	0.614	rs117699706	ENSG00000254454.2	RCC2P6	4.86	3.52e-06	0.00331	0.45	0.4	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62394187	chr11:62371146~62373168:+
TGCT	cis	rs2463822	0.688	rs7121684	ENSG00000254454.2	RCC2P6	4.86	3.52e-06	0.00331	0.45	0.4	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62394917	chr11:62371146~62373168:+
TGCT	cis	rs34779708	0.733	rs11597184	ENSG00000230534.5	RP11-297A16.2	4.86	3.53e-06	0.00331	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35108468	chr10:35098006~35127020:-
TGCT	cis	rs7221109	0.56	rs2159430	ENSG00000278834.1	RP11-458J1.1	-4.86	3.53e-06	0.00332	-0.31	-0.4	Type 1 diabetes;	chr17:40704360	chr17:40648300~40649718:+
TGCT	cis	rs7221109	0.56	rs2462963	ENSG00000278834.1	RP11-458J1.1	-4.86	3.53e-06	0.00332	-0.31	-0.4	Type 1 diabetes;	chr17:40705505	chr17:40648300~40649718:+
TGCT	cis	rs507080	0.922	rs519848	ENSG00000255239.1	AP002954.6	4.86	3.53e-06	0.00332	0.55	0.4	Serum metabolite levels;	chr11:118682006	chr11:118688039~118690600:-
TGCT	cis	rs4835473	0.9	rs6834494	ENSG00000251600.4	RP11-673E1.1	-4.86	3.53e-06	0.00332	-0.41	-0.4	Immature fraction of reticulocytes;	chr4:143822257	chr4:143912331~143982454:+
TGCT	cis	rs7829975	0.774	rs11249893	ENSG00000173295.6	FAM86B3P	4.86	3.54e-06	0.00332	0.47	0.4	Mood instability;	chr8:8843341	chr8:8228595~8244865:+
TGCT	cis	rs2980439	0.818	rs2945249	ENSG00000253893.2	FAM85B	-4.86	3.54e-06	0.00333	-0.51	-0.4	Neuroticism;	chr8:8237204	chr8:8167819~8226614:-
TGCT	cis	rs1618992	0.729	rs11663444	ENSG00000265994.1	RP11-510D21.1	-4.86	3.55e-06	0.00333	-0.41	-0.4	Gut microbiome composition (summer and winter);	chr18:28592123	chr18:28785068~28789260:+
TGCT	cis	rs801193	1	rs7782320	ENSG00000237310.1	GS1-124K5.4	4.86	3.55e-06	0.00333	0.45	0.4	Aortic root size;	chr7:66712111	chr7:66493706~66495474:+
TGCT	cis	rs7208859	0.623	rs7220289	ENSG00000266490.1	CTD-2349P21.9	4.86	3.55e-06	0.00333	0.46	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30792372~30792833:+
TGCT	cis	rs67311347	1	rs11914297	ENSG00000223797.4	ENTPD3-AS1	4.85	3.55e-06	0.00333	0.42	0.4	Renal cell carcinoma;	chr3:40368579	chr3:40313802~40453329:-
TGCT	cis	rs67311347	0.955	rs12487955	ENSG00000223797.4	ENTPD3-AS1	4.85	3.55e-06	0.00333	0.42	0.4	Renal cell carcinoma;	chr3:40371362	chr3:40313802~40453329:-
TGCT	cis	rs67311347	0.911	rs58282210	ENSG00000223797.4	ENTPD3-AS1	4.85	3.55e-06	0.00333	0.42	0.4	Renal cell carcinoma;	chr3:40376452	chr3:40313802~40453329:-
TGCT	cis	rs17711722	0.727	rs2658585	ENSG00000237310.1	GS1-124K5.4	4.85	3.55e-06	0.00334	0.45	0.4	Calcium levels;	chr7:65996954	chr7:66493706~66495474:+
TGCT	cis	rs7182621	0.774	rs12101368	ENSG00000259363.4	CTD-2054N24.2	-4.85	3.55e-06	0.00334	-0.37	-0.4	Colonoscopy-negative controls vs population controls;	chr15:99872475	chr15:99807023~99877148:+
TGCT	cis	rs2919917	0.628	rs13267679	ENSG00000254352.1	RP11-578O24.2	-4.85	3.55e-06	0.00334	-0.5	-0.4	Lymphocyte counts;	chr8:78711603	chr8:78723796~78724136:-
TGCT	cis	rs867371	0.502	rs7176926	ENSG00000255769.6	GOLGA2P10	-4.85	3.55e-06	0.00334	-0.38	-0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82472993~82513950:-
TGCT	cis	rs2665103	0.632	rs3902959	ENSG00000255769.6	GOLGA2P10	-4.85	3.55e-06	0.00334	-0.38	-0.4	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82472993~82513950:-
TGCT	cis	rs67311347	1	rs1047855	ENSG00000223797.4	ENTPD3-AS1	-4.85	3.56e-06	0.00334	-0.43	-0.4	Renal cell carcinoma;	chr3:40427405	chr3:40313802~40453329:-
TGCT	cis	rs4835473	0.864	rs13145791	ENSG00000251600.4	RP11-673E1.1	-4.85	3.56e-06	0.00334	-0.39	-0.4	Immature fraction of reticulocytes;	chr4:143735688	chr4:143912331~143982454:+
TGCT	cis	rs7615952	0.932	rs11922218	ENSG00000171084.14	FAM86JP	4.85	3.57e-06	0.00335	0.67	0.4	Blood pressure (smoking interaction);	chr3:125912446	chr3:125916620~125930024:+
TGCT	cis	rs7615952	0.866	rs11922276	ENSG00000171084.14	FAM86JP	4.85	3.57e-06	0.00335	0.67	0.4	Blood pressure (smoking interaction);	chr3:125912483	chr3:125916620~125930024:+
TGCT	cis	rs2880765	0.525	rs2062234	ENSG00000259295.5	CSPG4P12	4.85	3.57e-06	0.00335	0.51	0.4	Coronary artery disease;	chr15:85511259	chr15:85191438~85213905:+
TGCT	cis	rs899997	0.814	rs28661610	ENSG00000261143.1	ADAMTS7P3	-4.85	3.57e-06	0.00335	-0.49	-0.4	Coronary artery disease or large artery stroke;	chr15:78692975	chr15:77976042~77993057:+
TGCT	cis	rs673078	0.607	rs59594854	ENSG00000275759.1	RP11-131L12.3	-4.85	3.59e-06	0.00336	-0.65	-0.4	Glucose homeostasis traits;	chr12:118374000	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs4766899	ENSG00000275759.1	RP11-131L12.3	-4.85	3.59e-06	0.00336	-0.65	-0.4	Glucose homeostasis traits;	chr12:118374888	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs10850967	ENSG00000275759.1	RP11-131L12.3	-4.85	3.59e-06	0.00336	-0.65	-0.4	Glucose homeostasis traits;	chr12:118380072	chr12:118428281~118428870:+
TGCT	cis	rs1023500	0.573	rs2413666	ENSG00000270083.1	RP1-257I20.14	4.85	3.59e-06	0.00337	0.41	0.4	Schizophrenia;	chr22:42063618	chr22:42089630~42090028:-
TGCT	cis	rs10875746	0.951	rs11168433	ENSG00000240399.1	RP1-228P16.1	-4.85	3.59e-06	0.00337	-0.47	-0.4	Longevity (90 years and older);	chr12:48164281	chr12:48054813~48055591:-
TGCT	cis	rs321358	0.895	rs73015151	ENSG00000271584.1	RP11-89C3.4	4.85	3.59e-06	0.00337	0.52	0.4	Body mass index;	chr11:111084669	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.895	rs17535886	ENSG00000271584.1	RP11-89C3.4	4.85	3.59e-06	0.00337	0.52	0.4	Body mass index;	chr11:111084852	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.895	rs17457375	ENSG00000271584.1	RP11-89C3.4	4.85	3.59e-06	0.00337	0.52	0.4	Body mass index;	chr11:111085100	chr11:111091932~111097357:-
TGCT	cis	rs10256972	0.552	rs2949192	ENSG00000226291.1	AC091729.8	-4.85	3.6e-06	0.00338	-0.42	-0.4	Endometriosis;Longevity;	chr7:1164205	chr7:1080863~1082178:+
TGCT	cis	rs10875746	1	rs10875746	ENSG00000240399.1	RP1-228P16.1	-4.85	3.62e-06	0.00339	-0.47	-0.4	Longevity (90 years and older);	chr12:48124481	chr12:48054813~48055591:-
TGCT	cis	rs877819	0.583	rs2663033	ENSG00000228403.1	RP11-563N6.6	-4.85	3.63e-06	0.0034	-0.41	-0.4	Systemic lupus erythematosus;	chr10:48876623	chr10:48878022~48878649:+
TGCT	cis	rs9880211	0.752	rs67145204	ENSG00000239213.4	NCK1-AS1	4.85	3.63e-06	0.0034	0.43	0.4	Height;Body mass index;	chr3:136609823	chr3:136841726~136862054:-
TGCT	cis	rs11671005	0.693	rs11668821	ENSG00000232098.3	CTD-2619J13.14	-4.85	3.63e-06	0.0034	-0.45	-0.4	Mean platelet volume;	chr19:58444446	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.616	rs12980907	ENSG00000232098.3	CTD-2619J13.14	-4.85	3.63e-06	0.0034	-0.45	-0.4	Mean platelet volume;	chr19:58444959	chr19:58404238~58408484:-
TGCT	cis	rs992157	1	rs6736362	ENSG00000261338.2	RP11-378A13.1	4.85	3.64e-06	0.0034	0.32	0.4	Colorectal cancer;	chr2:218250385	chr2:218255319~218257366:+
TGCT	cis	rs875971	0.508	rs10258739	ENSG00000237310.1	GS1-124K5.4	-4.85	3.64e-06	0.00341	-0.43	-0.4	Aortic root size;	chr7:66597948	chr7:66493706~66495474:+
TGCT	cis	rs755249	0.509	rs11206378	ENSG00000182109.6	RP11-69E11.4	-4.85	3.64e-06	0.00341	-0.37	-0.4	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583512	chr1:39522280~39546187:-
TGCT	cis	rs13118159	0.836	rs2276903	ENSG00000254094.1	AC078852.1	-4.85	3.64e-06	0.00341	-0.47	-0.4	Longevity;	chr4:1349617	chr4:1356581~1358075:+
TGCT	cis	rs875971	0.798	rs6460304	ENSG00000237310.1	GS1-124K5.4	4.85	3.64e-06	0.00341	0.43	0.4	Aortic root size;	chr7:66499741	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs6945775	ENSG00000237310.1	GS1-124K5.4	4.85	3.64e-06	0.00341	0.43	0.4	Aortic root size;	chr7:66503987	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.798	rs57739047	ENSG00000237310.1	GS1-124K5.4	4.85	3.64e-06	0.00341	0.43	0.4	Aortic root size;	chr7:66507579	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.83	rs6950137	ENSG00000237310.1	GS1-124K5.4	4.85	3.64e-06	0.00341	0.43	0.4	Aortic root size;	chr7:66511623	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs11763189	ENSG00000237310.1	GS1-124K5.4	4.85	3.64e-06	0.00341	0.43	0.4	Aortic root size;	chr7:66518542	chr7:66493706~66495474:+
TGCT	cis	rs16975963	0.644	rs73037036	ENSG00000276846.1	CTD-3220F14.3	-4.85	3.65e-06	0.00341	-0.38	-0.4	Longevity;	chr19:37670169	chr19:37314868~37315620:-
TGCT	cis	rs16975963	0.644	rs111319455	ENSG00000276846.1	CTD-3220F14.3	-4.85	3.65e-06	0.00341	-0.38	-0.4	Longevity;	chr19:37671746	chr19:37314868~37315620:-
TGCT	cis	rs5742933	0.857	rs1437891	ENSG00000273240.1	RP11-455J20.3	-4.85	3.65e-06	0.00341	-0.37	-0.4	Ferritin levels;	chr2:189697982	chr2:189763859~189764456:-
TGCT	cis	rs853679	1	rs853685	ENSG00000216901.1	AL022393.7	4.85	3.65e-06	0.00342	0.67	0.4	Depression;	chr6:28321008	chr6:28176188~28176674:+
TGCT	cis	rs904251	0.523	rs2797794	ENSG00000204110.6	RP1-153P14.8	-4.85	3.65e-06	0.00342	-0.42	-0.4	Cognitive performance;	chr6:37512828	chr6:37507348~37535616:+
TGCT	cis	rs904251	0.523	rs2776920	ENSG00000204110.6	RP1-153P14.8	-4.85	3.65e-06	0.00342	-0.42	-0.4	Cognitive performance;	chr6:37512829	chr6:37507348~37535616:+
TGCT	cis	rs9584850	0.834	rs3803253	ENSG00000231194.1	FARP1-AS1	4.85	3.66e-06	0.00343	0.52	0.4	Neuroticism;	chr13:98464895	chr13:98435405~98435840:-
TGCT	cis	rs1372520	0.577	rs2737028	ENSG00000247775.2	SNCA-AS1	4.85	3.66e-06	0.00343	0.4	0.4	Neuroticism;	chr4:89795865	chr4:89836408~89841978:+
TGCT	cis	rs7927592	0.673	rs498782	ENSG00000212093.1	AP000807.1	4.85	3.66e-06	0.00343	0.39	0.4	Total body bone mineral density;	chr11:68508383	chr11:68506083~68506166:-
TGCT	cis	rs4835473	0.932	rs6849896	ENSG00000251600.4	RP11-673E1.1	-4.85	3.66e-06	0.00343	-0.41	-0.4	Immature fraction of reticulocytes;	chr4:143794927	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs6826665	ENSG00000251600.4	RP11-673E1.1	-4.85	3.66e-06	0.00343	-0.41	-0.4	Immature fraction of reticulocytes;	chr4:143795140	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.838	rs35998817	ENSG00000251600.4	RP11-673E1.1	-4.85	3.66e-06	0.00343	-0.41	-0.4	Immature fraction of reticulocytes;	chr4:143795355	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs13134808	ENSG00000251600.4	RP11-673E1.1	-4.85	3.66e-06	0.00343	-0.41	-0.4	Immature fraction of reticulocytes;	chr4:143798339	chr4:143912331~143982454:+
TGCT	cis	rs801193	1	rs7785213	ENSG00000237310.1	GS1-124K5.4	-4.85	3.67e-06	0.00343	-0.45	-0.4	Aortic root size;	chr7:66673991	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.935	rs3800820	ENSG00000237310.1	GS1-124K5.4	-4.85	3.67e-06	0.00343	-0.45	-0.4	Aortic root size;	chr7:66682191	chr7:66493706~66495474:+
TGCT	cis	rs801193	1	rs2003301	ENSG00000237310.1	GS1-124K5.4	-4.85	3.67e-06	0.00343	-0.45	-0.4	Aortic root size;	chr7:66682669	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.967	rs2707841	ENSG00000237310.1	GS1-124K5.4	4.85	3.67e-06	0.00343	0.45	0.4	Aortic root size;	chr7:66692033	chr7:66493706~66495474:+
TGCT	cis	rs801193	1	rs4717310	ENSG00000237310.1	GS1-124K5.4	4.85	3.67e-06	0.00343	0.45	0.4	Aortic root size;	chr7:66696020	chr7:66493706~66495474:+
TGCT	cis	rs4835473	0.897	rs11723113	ENSG00000251600.4	RP11-673E1.1	4.85	3.67e-06	0.00343	0.4	0.4	Immature fraction of reticulocytes;	chr4:143707283	chr4:143912331~143982454:+
TGCT	cis	rs2742234	0.59	rs2435383	ENSG00000273008.1	RP11-351D16.3	-4.85	3.67e-06	0.00343	-0.53	-0.4	Hirschsprung disease;	chr10:43180223	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.541	rs1059484	ENSG00000273008.1	RP11-351D16.3	-4.85	3.67e-06	0.00343	-0.53	-0.4	Hirschsprung disease;	chr10:43184352	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.59	rs2435376	ENSG00000273008.1	RP11-351D16.3	-4.85	3.67e-06	0.00343	-0.53	-0.4	Hirschsprung disease;	chr10:43189515	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.579	rs2503881	ENSG00000273008.1	RP11-351D16.3	-4.85	3.67e-06	0.00343	-0.53	-0.4	Hirschsprung disease;	chr10:43190578	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.59	rs2115817	ENSG00000273008.1	RP11-351D16.3	-4.85	3.67e-06	0.00343	-0.53	-0.4	Hirschsprung disease;	chr10:43191104	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.59	rs1254965	ENSG00000273008.1	RP11-351D16.3	4.85	3.67e-06	0.00343	0.53	0.4	Hirschsprung disease;	chr10:43194405	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.518	rs1254967	ENSG00000273008.1	RP11-351D16.3	4.85	3.67e-06	0.00343	0.53	0.4	Hirschsprung disease;	chr10:43194943	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.503	rs1254968	ENSG00000273008.1	RP11-351D16.3	4.85	3.67e-06	0.00343	0.53	0.4	Hirschsprung disease;	chr10:43196243	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.554	rs1254963	ENSG00000273008.1	RP11-351D16.3	4.85	3.67e-06	0.00343	0.53	0.4	Hirschsprung disease;	chr10:43200638	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.59	rs1254962	ENSG00000273008.1	RP11-351D16.3	4.85	3.67e-06	0.00343	0.53	0.4	Hirschsprung disease;	chr10:43201544	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.554	rs1270015	ENSG00000273008.1	RP11-351D16.3	4.85	3.67e-06	0.00343	0.53	0.4	Hirschsprung disease;	chr10:43202792	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.59	rs1254960	ENSG00000273008.1	RP11-351D16.3	4.85	3.67e-06	0.00343	0.53	0.4	Hirschsprung disease;	chr10:43204209	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.541	rs1254959	ENSG00000273008.1	RP11-351D16.3	4.85	3.67e-06	0.00343	0.53	0.4	Hirschsprung disease;	chr10:43205531	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.541	rs1254958	ENSG00000273008.1	RP11-351D16.3	4.85	3.67e-06	0.00343	0.53	0.4	Hirschsprung disease;	chr10:43206695	chr10:43136824~43138334:-
TGCT	cis	rs875971	0.862	rs778720	ENSG00000237310.1	GS1-124K5.4	-4.85	3.68e-06	0.00343	-0.42	-0.4	Aortic root size;	chr7:66381288	chr7:66493706~66495474:+
TGCT	cis	rs7617773	0.539	rs6779517	ENSG00000229759.1	MRPS18AP1	4.85	3.68e-06	0.00344	0.33	0.4	Coronary artery disease;	chr3:48342898	chr3:48256350~48256938:-
TGCT	cis	rs8059260	0.668	rs4781029	ENSG00000274038.1	RP11-66H6.4	-4.85	3.68e-06	0.00344	-0.56	-0.4	Alcohol consumption over the past year;	chr16:10983717	chr16:11056556~11057034:+
TGCT	cis	rs1153858	1	rs2668747	ENSG00000259520.4	CTD-2651B20.3	-4.85	3.69e-06	0.00344	-0.34	-0.4	Homoarginine levels;	chr15:45325018	chr15:45251580~45279251:-
TGCT	cis	rs2463822	0.925	rs6863	ENSG00000254454.2	RCC2P6	4.85	3.69e-06	0.00344	0.44	0.4	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62393253	chr11:62371146~62373168:+
TGCT	cis	rs4927850	1	rs10881563	ENSG00000231464.1	AC024937.4	4.85	3.69e-06	0.00344	0.4	0.4	Pancreatic cancer;	chr3:196023354	chr3:195996738~195998233:+
TGCT	cis	rs4927850	1	rs4927850	ENSG00000231464.1	AC024937.4	-4.85	3.7e-06	0.00344	-0.39	-0.4	Pancreatic cancer;	chr3:196024759	chr3:195996738~195998233:+
TGCT	cis	rs17507216	0.591	rs7163848	ENSG00000255769.6	GOLGA2P10	-4.85	3.7e-06	0.00345	-0.5	-0.4	Excessive daytime sleepiness;	chr15:82729563	chr15:82472993~82513950:-
TGCT	cis	rs875971	0.619	rs2302918	ENSG00000237310.1	GS1-124K5.4	4.84	3.71e-06	0.00345	0.46	0.4	Aortic root size;	chr7:66535945	chr7:66493706~66495474:+
TGCT	cis	rs10875746	0.855	rs12296244	ENSG00000240399.1	RP1-228P16.1	-4.84	3.71e-06	0.00346	-0.47	-0.4	Longevity (90 years and older);	chr12:48047696	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.855	rs12310999	ENSG00000240399.1	RP1-228P16.1	-4.84	3.71e-06	0.00346	-0.47	-0.4	Longevity (90 years and older);	chr12:48053875	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.903	rs61918774	ENSG00000240399.1	RP1-228P16.1	-4.84	3.71e-06	0.00346	-0.47	-0.4	Longevity (90 years and older);	chr12:48054351	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.807	rs12297004	ENSG00000240399.1	RP1-228P16.1	-4.84	3.71e-06	0.00346	-0.47	-0.4	Longevity (90 years and older);	chr12:48060037	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.903	rs58952582	ENSG00000240399.1	RP1-228P16.1	-4.84	3.71e-06	0.00346	-0.47	-0.4	Longevity (90 years and older);	chr12:48064665	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.903	rs10875735	ENSG00000240399.1	RP1-228P16.1	-4.84	3.71e-06	0.00346	-0.47	-0.4	Longevity (90 years and older);	chr12:48070023	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.855	rs17122620	ENSG00000240399.1	RP1-228P16.1	-4.84	3.71e-06	0.00346	-0.47	-0.4	Longevity (90 years and older);	chr12:48070692	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.859	rs4760680	ENSG00000240399.1	RP1-228P16.1	-4.84	3.71e-06	0.00346	-0.47	-0.4	Longevity (90 years and older);	chr12:48072914	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.903	rs11168386	ENSG00000240399.1	RP1-228P16.1	-4.84	3.71e-06	0.00346	-0.47	-0.4	Longevity (90 years and older);	chr12:48074194	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.807	rs12313300	ENSG00000240399.1	RP1-228P16.1	-4.84	3.71e-06	0.00346	-0.47	-0.4	Longevity (90 years and older);	chr12:48076934	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.903	rs12315625	ENSG00000240399.1	RP1-228P16.1	-4.84	3.71e-06	0.00346	-0.47	-0.4	Longevity (90 years and older);	chr12:48078670	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.903	rs10875738	ENSG00000240399.1	RP1-228P16.1	-4.84	3.71e-06	0.00346	-0.47	-0.4	Longevity (90 years and older);	chr12:48079956	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.903	rs12301339	ENSG00000240399.1	RP1-228P16.1	-4.84	3.71e-06	0.00346	-0.47	-0.4	Longevity (90 years and older);	chr12:48081450	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.903	rs886588	ENSG00000240399.1	RP1-228P16.1	-4.84	3.71e-06	0.00346	-0.47	-0.4	Longevity (90 years and older);	chr12:48083639	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.903	rs11168401	ENSG00000240399.1	RP1-228P16.1	-4.84	3.71e-06	0.00346	-0.47	-0.4	Longevity (90 years and older);	chr12:48087736	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.903	rs12304476	ENSG00000240399.1	RP1-228P16.1	-4.84	3.71e-06	0.00346	-0.47	-0.4	Longevity (90 years and older);	chr12:48088370	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.903	rs12306451	ENSG00000240399.1	RP1-228P16.1	-4.84	3.71e-06	0.00346	-0.47	-0.4	Longevity (90 years and older);	chr12:48089458	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.903	rs3782911	ENSG00000240399.1	RP1-228P16.1	-4.84	3.71e-06	0.00346	-0.47	-0.4	Longevity (90 years and older);	chr12:48089709	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.859	rs3782910	ENSG00000240399.1	RP1-228P16.1	-4.84	3.71e-06	0.00346	-0.47	-0.4	Longevity (90 years and older);	chr12:48089724	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.903	rs989144	ENSG00000240399.1	RP1-228P16.1	-4.84	3.71e-06	0.00346	-0.47	-0.4	Longevity (90 years and older);	chr12:48090190	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.903	rs61918806	ENSG00000240399.1	RP1-228P16.1	-4.84	3.71e-06	0.00346	-0.47	-0.4	Longevity (90 years and older);	chr12:48090650	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.903	rs11168403	ENSG00000240399.1	RP1-228P16.1	-4.84	3.71e-06	0.00346	-0.47	-0.4	Longevity (90 years and older);	chr12:48091175	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.903	rs10875740	ENSG00000240399.1	RP1-228P16.1	-4.84	3.71e-06	0.00346	-0.47	-0.4	Longevity (90 years and older);	chr12:48095334	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.903	rs2158516	ENSG00000240399.1	RP1-228P16.1	-4.84	3.71e-06	0.00346	-0.47	-0.4	Longevity (90 years and older);	chr12:48097051	chr12:48054813~48055591:-
TGCT	cis	rs75422866	0.867	rs7304743	ENSG00000257433.4	RP1-197B17.3	-4.84	3.71e-06	0.00346	-0.72	-0.4	Pneumonia;	chr12:47683658	chr12:47706085~47742294:+
TGCT	cis	rs75422866	0.867	rs7303895	ENSG00000257433.4	RP1-197B17.3	4.84	3.71e-06	0.00346	0.72	0.4	Pneumonia;	chr12:47683290	chr12:47706085~47742294:+
TGCT	cis	rs11157436	0.914	rs7142794	ENSG00000211813.2	TRAV34	4.84	3.73e-06	0.00347	0.43	0.4	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22238175	chr14:22207522~22208129:+
TGCT	cis	rs673078	0.607	rs11068926	ENSG00000275759.1	RP11-131L12.3	-4.84	3.73e-06	0.00347	-0.66	-0.4	Glucose homeostasis traits;	chr12:118367320	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs4442583	ENSG00000275759.1	RP11-131L12.3	-4.84	3.73e-06	0.00347	-0.66	-0.4	Glucose homeostasis traits;	chr12:118367914	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs61943370	ENSG00000275759.1	RP11-131L12.3	-4.84	3.73e-06	0.00347	-0.66	-0.4	Glucose homeostasis traits;	chr12:118369469	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs61943371	ENSG00000275759.1	RP11-131L12.3	-4.84	3.73e-06	0.00347	-0.66	-0.4	Glucose homeostasis traits;	chr12:118369600	chr12:118428281~118428870:+
TGCT	cis	rs4237845	0.586	rs4760174	ENSG00000257159.1	RP11-58A17.3	4.84	3.73e-06	0.00347	0.5	0.4	Intelligence (multi-trait analysis);	chr12:57926653	chr12:57967058~57968399:+
TGCT	cis	rs10875976	0.525	rs67723963	ENSG00000242041.1	RP11-70F11.2	4.84	3.73e-06	0.00347	0.38	0.4	Obesity;	chr12:49864759	chr12:49863173~49863503:+
TGCT	cis	rs4380275	0.782	rs4468850	ENSG00000223751.1	AC116609.2	4.84	3.73e-06	0.00347	0.41	0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:749467	chr2:742488~747767:+
TGCT	cis	rs728616	0.764	rs79529820	ENSG00000230091.5	TMEM254-AS1	4.84	3.73e-06	0.00347	0.68	0.4	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80060773	chr10:80046860~80078912:-
TGCT	cis	rs35160687	0.814	rs6547673	ENSG00000273080.1	RP11-301O19.1	4.84	3.73e-06	0.00347	0.45	0.4	Night sleep phenotypes;	chr2:86301815	chr2:86195590~86196049:+
TGCT	cis	rs877819	0.519	rs7088194	ENSG00000228403.1	RP11-563N6.6	-4.84	3.74e-06	0.00347	-0.41	-0.4	Systemic lupus erythematosus;	chr10:48887887	chr10:48878022~48878649:+
TGCT	cis	rs8059260	0.736	rs80207136	ENSG00000274038.1	RP11-66H6.4	-4.84	3.75e-06	0.00349	-0.55	-0.4	Alcohol consumption over the past year;	chr16:11015480	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.668	rs78573173	ENSG00000274038.1	RP11-66H6.4	-4.84	3.75e-06	0.00349	-0.55	-0.4	Alcohol consumption over the past year;	chr16:11017642	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.668	rs75811377	ENSG00000274038.1	RP11-66H6.4	-4.84	3.75e-06	0.00349	-0.55	-0.4	Alcohol consumption over the past year;	chr16:11023451	chr16:11056556~11057034:+
TGCT	cis	rs911555	0.755	rs2756132	ENSG00000244691.1	RPL10AP1	4.84	3.75e-06	0.00349	0.53	0.4	Intelligence (multi-trait analysis);	chr14:103501483	chr14:103412119~103412761:-
TGCT	cis	rs8105895	0.935	rs7256462	ENSG00000269742.1	BNIP3P29	4.84	3.76e-06	0.00349	0.71	0.4	Body mass index (change over time);	chr19:22099191	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs10425828	ENSG00000269742.1	BNIP3P29	4.84	3.76e-06	0.00349	0.71	0.4	Body mass index (change over time);	chr19:22100275	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs8103374	ENSG00000269742.1	BNIP3P29	4.84	3.76e-06	0.00349	0.71	0.4	Body mass index (change over time);	chr19:22101517	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs8103279	ENSG00000269742.1	BNIP3P29	4.84	3.76e-06	0.00349	0.71	0.4	Body mass index (change over time);	chr19:22101538	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.867	rs8106762	ENSG00000269742.1	BNIP3P29	4.84	3.76e-06	0.00349	0.71	0.4	Body mass index (change over time);	chr19:22101934	chr19:22065828~22066398:-
TGCT	cis	rs7221109	0.744	rs1048573	ENSG00000278834.1	RP11-458J1.1	4.84	3.77e-06	0.0035	0.29	0.4	Type 1 diabetes;	chr17:40640950	chr17:40648300~40649718:+
TGCT	cis	rs7221109	0.71	rs9906785	ENSG00000278834.1	RP11-458J1.1	4.84	3.77e-06	0.0035	0.29	0.4	Type 1 diabetes;	chr17:40641157	chr17:40648300~40649718:+
TGCT	cis	rs2412819	0.545	rs17795279	ENSG00000205771.5	CATSPER2P1	4.84	3.77e-06	0.0035	0.59	0.4	Lung cancer;	chr15:43637180	chr15:43726918~43747094:-
TGCT	cis	rs7829975	0.84	rs572366	ENSG00000173295.6	FAM86B3P	4.84	3.79e-06	0.00351	0.49	0.4	Mood instability;	chr8:8721284	chr8:8228595~8244865:+
TGCT	cis	rs875971	0.893	rs62465470	ENSG00000232559.3	GS1-124K5.12	-4.84	3.79e-06	0.00351	-0.37	-0.4	Aortic root size;	chr7:66136231	chr7:66554588~66576923:-
TGCT	cis	rs7115242	0.8	rs519794	ENSG00000254851.1	RP11-109L13.1	-4.84	3.79e-06	0.00352	-0.67	-0.4	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116988737	chr11:117135528~117138582:+
TGCT	cis	rs321358	1	rs73021573	ENSG00000271584.1	RP11-89C3.4	4.84	3.79e-06	0.00352	0.54	0.4	Body mass index;	chr11:111155508	chr11:111091932~111097357:-
TGCT	cis	rs321358	1	rs73003503	ENSG00000271584.1	RP11-89C3.4	4.84	3.79e-06	0.00352	0.54	0.4	Body mass index;	chr11:111158360	chr11:111091932~111097357:-
TGCT	cis	rs321358	1	rs73003511	ENSG00000271584.1	RP11-89C3.4	4.84	3.79e-06	0.00352	0.54	0.4	Body mass index;	chr11:111160478	chr11:111091932~111097357:-
TGCT	cis	rs321358	1	rs73003514	ENSG00000271584.1	RP11-89C3.4	4.84	3.79e-06	0.00352	0.54	0.4	Body mass index;	chr11:111160605	chr11:111091932~111097357:-
TGCT	cis	rs8105895	0.666	rs62110991	ENSG00000269742.1	BNIP3P29	4.84	3.79e-06	0.00352	0.73	0.4	Body mass index (change over time);	chr19:22078040	chr19:22065828~22066398:-
TGCT	cis	rs12022452	0.63	rs3795346	ENSG00000238287.1	RP11-656D10.3	-4.84	3.79e-06	0.00352	-0.51	-0.4	Age-related hearing impairment (SNP x SNP interaction);	chr1:40508753	chr1:40493157~40508661:-
TGCT	cis	rs453301	0.653	rs7853	ENSG00000254340.1	RP11-10A14.3	4.84	3.8e-06	0.00352	0.4	0.4	Joint mobility (Beighton score);	chr8:9033304	chr8:9141424~9145435:+
TGCT	cis	rs10938353	0.68	rs73191059	ENSG00000273369.1	RP11-700J17.1	4.84	3.8e-06	0.00352	0.61	0.4	Body mass index;	chr4:44629998	chr4:44693946~44694386:-
TGCT	cis	rs8072100	0.817	rs9892497	ENSG00000228782.6	CTD-2026D20.3	4.84	3.8e-06	0.00352	0.47	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47468553	chr17:47450568~47492492:-
TGCT	cis	rs8072100	0.817	rs9905581	ENSG00000228782.6	CTD-2026D20.3	4.84	3.8e-06	0.00352	0.47	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469819	chr17:47450568~47492492:-
TGCT	cis	rs8072100	0.817	rs12449647	ENSG00000228782.6	CTD-2026D20.3	4.84	3.8e-06	0.00352	0.47	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47471592	chr17:47450568~47492492:-
TGCT	cis	rs1891275	0.515	rs7475294	ENSG00000228701.1	TNKS2-AS1	-4.84	3.8e-06	0.00353	-0.44	-0.4	Intelligence (multi-trait analysis);	chr10:91748442	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.515	rs2421694	ENSG00000228701.1	TNKS2-AS1	-4.84	3.8e-06	0.00353	-0.44	-0.4	Intelligence (multi-trait analysis);	chr10:91756347	chr10:91782839~91798291:-
TGCT	cis	rs10504229	0.683	rs17194487	ENSG00000253301.4	RP11-513O17.2	4.84	3.81e-06	0.00353	0.59	0.4	Developmental language disorder (linguistic errors);	chr8:57192353	chr8:57142689~57240298:+
TGCT	cis	rs9987353	0.518	rs4841110	ENSG00000173295.6	FAM86B3P	4.84	3.81e-06	0.00353	0.42	0.4	Recombination measurement;	chr8:9228513	chr8:8228595~8244865:+
TGCT	cis	rs9425766	0.64	rs6658769	ENSG00000227373.4	RP11-160H22.5	4.84	3.81e-06	0.00353	0.43	0.4	Life satisfaction;	chr1:174100843	chr1:174115300~174160004:-
TGCT	cis	rs10256972	0.552	rs7805591	ENSG00000226291.1	AC091729.8	-4.84	3.81e-06	0.00353	-0.42	-0.4	Endometriosis;Longevity;	chr7:1171109	chr7:1080863~1082178:+
TGCT	cis	rs10759883	0.563	rs657451	ENSG00000175611.10	LINC00476	-4.84	3.81e-06	0.00354	-0.35	-0.4	Nicotine dependence;	chr9:96003496	chr9:95759231~95875977:-
TGCT	cis	rs10256972	0.567	rs2960835	ENSG00000226291.1	AC091729.8	-4.84	3.82e-06	0.00354	-0.42	-0.4	Endometriosis;Longevity;	chr7:1163327	chr7:1080863~1082178:+
TGCT	cis	rs6921919	1	rs35875412	ENSG00000216901.1	AL022393.7	4.84	3.85e-06	0.00356	0.52	0.4	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28176188~28176674:+
TGCT	cis	rs9425766	0.54	rs2294492	ENSG00000227373.4	RP11-160H22.5	4.84	3.85e-06	0.00356	0.43	0.4	Life satisfaction;	chr1:174157884	chr1:174115300~174160004:-
TGCT	cis	rs4563143	0.647	rs34218744	ENSG00000267243.4	AC005307.3	-4.84	3.85e-06	0.00357	-0.49	-0.4	Methadone dose in opioid dependence;	chr19:28765914	chr19:28435388~28727777:-
TGCT	cis	rs4563143	0.647	rs117946634	ENSG00000267243.4	AC005307.3	-4.84	3.85e-06	0.00357	-0.49	-0.4	Methadone dose in opioid dependence;	chr19:28765915	chr19:28435388~28727777:-
TGCT	cis	rs4563143	0.647	rs117442062	ENSG00000267243.4	AC005307.3	-4.84	3.85e-06	0.00357	-0.49	-0.4	Methadone dose in opioid dependence;	chr19:28765916	chr19:28435388~28727777:-
TGCT	cis	rs10256972	0.577	rs4999286	ENSG00000226291.1	AC091729.8	-4.84	3.85e-06	0.00357	-0.42	-0.4	Endometriosis;Longevity;	chr7:1159870	chr7:1080863~1082178:+
TGCT	cis	rs7221109	0.614	rs8076587	ENSG00000278834.1	RP11-458J1.1	4.84	3.86e-06	0.00357	0.3	0.4	Type 1 diabetes;	chr17:40667949	chr17:40648300~40649718:+
TGCT	cis	rs7221109	0.601	rs7209404	ENSG00000278834.1	RP11-458J1.1	4.84	3.86e-06	0.00357	0.3	0.4	Type 1 diabetes;	chr17:40668150	chr17:40648300~40649718:+
TGCT	cis	rs7221109	0.645	rs7223332	ENSG00000278834.1	RP11-458J1.1	4.84	3.86e-06	0.00357	0.3	0.4	Type 1 diabetes;	chr17:40668384	chr17:40648300~40649718:+
TGCT	cis	rs7221109	0.645	rs9896791	ENSG00000278834.1	RP11-458J1.1	4.84	3.86e-06	0.00357	0.3	0.4	Type 1 diabetes;	chr17:40669305	chr17:40648300~40649718:+
TGCT	cis	rs7221109	0.633	rs7217237	ENSG00000278834.1	RP11-458J1.1	4.84	3.86e-06	0.00357	0.3	0.4	Type 1 diabetes;	chr17:40670810	chr17:40648300~40649718:+
TGCT	cis	rs7221109	0.56	rs2315020	ENSG00000278834.1	RP11-458J1.1	4.84	3.86e-06	0.00357	0.3	0.4	Type 1 diabetes;	chr17:40671414	chr17:40648300~40649718:+
TGCT	cis	rs7731657	0.569	rs17621454	ENSG00000279584.1	AC005593.2	-4.83	3.87e-06	0.00358	-0.67	-0.4	Fasting plasma glucose;	chr5:130869891	chr5:131797415~131797929:+
TGCT	cis	rs17826219	0.636	rs12946563	ENSG00000266490.1	CTD-2349P21.9	4.83	3.87e-06	0.00358	0.46	0.4	Body mass index;	chr17:30776148	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs8081299	ENSG00000266490.1	CTD-2349P21.9	4.83	3.87e-06	0.00358	0.46	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs8068645	ENSG00000266490.1	CTD-2349P21.9	4.83	3.87e-06	0.00358	0.46	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30792372~30792833:+
TGCT	cis	rs17826219	0.789	rs4794873	ENSG00000263531.1	RP13-753N3.1	4.83	3.88e-06	0.00359	0.71	0.4	Body mass index;	chr17:30421334	chr17:30863921~30864940:-
TGCT	cis	rs761746	0.739	rs9621317	ENSG00000236132.1	CTA-440B3.1	-4.83	3.88e-06	0.00359	-0.51	-0.4	Intelligence;	chr22:31698060	chr22:31816379~31817491:-
TGCT	cis	rs3931020	0.962	rs2185695	ENSG00000272864.1	RP11-17E13.2	-4.83	3.88e-06	0.00359	-0.47	-0.4	Resistin levels;	chr1:74792197	chr1:74698769~74699333:-
TGCT	cis	rs7221109	0.585	rs6503547	ENSG00000278834.1	RP11-458J1.1	4.83	3.89e-06	0.0036	0.3	0.4	Type 1 diabetes;	chr17:40662956	chr17:40648300~40649718:+
TGCT	cis	rs7221109	0.592	rs917595	ENSG00000278834.1	RP11-458J1.1	4.83	3.89e-06	0.0036	0.3	0.4	Type 1 diabetes;	chr17:40663246	chr17:40648300~40649718:+
TGCT	cis	rs7221109	0.677	rs7223354	ENSG00000278834.1	RP11-458J1.1	4.83	3.89e-06	0.0036	0.3	0.4	Type 1 diabetes;	chr17:40668420	chr17:40648300~40649718:+
TGCT	cis	rs7221109	0.677	rs6503549	ENSG00000278834.1	RP11-458J1.1	4.83	3.89e-06	0.0036	0.3	0.4	Type 1 diabetes;	chr17:40668492	chr17:40648300~40649718:+
TGCT	cis	rs7804306	0.826	rs12113109	ENSG00000233264.2	AC006042.8	4.83	3.89e-06	0.0036	0.75	0.4	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7979920	chr7:7980312~7982228:+
TGCT	cis	rs7804306	1	rs715377	ENSG00000233264.2	AC006042.8	4.83	3.89e-06	0.0036	0.75	0.4	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7980303	chr7:7980312~7982228:+
TGCT	cis	rs1891275	0.508	rs2096079	ENSG00000228701.1	TNKS2-AS1	-4.83	3.9e-06	0.0036	-0.44	-0.4	Intelligence (multi-trait analysis);	chr10:91736910	chr10:91782839~91798291:-
TGCT	cis	rs875971	0.862	rs28470208	ENSG00000232559.3	GS1-124K5.12	-4.83	3.9e-06	0.0036	-0.37	-0.4	Aortic root size;	chr7:66119713	chr7:66554588~66576923:-
TGCT	cis	rs321358	0.895	rs73015171	ENSG00000271584.1	RP11-89C3.4	4.83	3.9e-06	0.0036	0.5	0.4	Body mass index;	chr11:111087535	chr11:111091932~111097357:-
TGCT	cis	rs34217772	0.699	rs12432265	ENSG00000258536.1	RP11-1053O12.1	4.83	3.9e-06	0.0036	0.33	0.4	Myopia;	chr14:41843491	chr14:41742639~41742963:+
TGCT	cis	rs8105895	0.935	rs7260331	ENSG00000269742.1	BNIP3P29	4.83	3.92e-06	0.00362	0.73	0.4	Body mass index (change over time);	chr19:22108969	chr19:22065828~22066398:-
TGCT	cis	rs67311347	1	rs17078941	ENSG00000223797.4	ENTPD3-AS1	-4.83	3.92e-06	0.00362	-0.43	-0.4	Renal cell carcinoma;	chr3:40409397	chr3:40313802~40453329:-
TGCT	cis	rs453301	0.682	rs2929451	ENSG00000173295.6	FAM86B3P	4.83	3.93e-06	0.00363	0.46	0.4	Joint mobility (Beighton score);	chr8:9227785	chr8:8228595~8244865:+
TGCT	cis	rs453301	0.682	rs2929308	ENSG00000173295.6	FAM86B3P	-4.83	3.93e-06	0.00363	-0.46	-0.4	Joint mobility (Beighton score);	chr8:9226611	chr8:8228595~8244865:+
TGCT	cis	rs4835473	0.932	rs1993015	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143760202	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs1993016	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143760217	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1993017	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143760285	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs1375983	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143760423	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1375984	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143760510	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1375985	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143760556	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs17018200	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143760866	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs11100805	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143760979	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.868	rs56115009	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143761073	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs10857406	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143761216	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs10857407	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143761226	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs10857408	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143761333	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs10857409	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143761461	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs10857410	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143761566	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs10857411	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143761599	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1006406	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143761710	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1562776	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143761999	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs34697602	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143762499	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs34618381	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143762612	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs11100808	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143762728	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs7661407	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143762982	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs4285038	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143763637	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1562777	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143763676	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1562778	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143763816	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1562779	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143763999	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1597441	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143764158	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1597442	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143764359	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1597443	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143764406	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1597444	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143764547	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs60038202	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143764662	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs34886773	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143764678	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1450230	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143765118	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs34683160	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143765227	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs72946226	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143765238	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs34230433	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143765253	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs7696106	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143765454	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs7680045	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143765470	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs7696869	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143765855	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs7698287	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143765859	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs11721495	ENSG00000251600.4	RP11-673E1.1	-4.83	3.93e-06	0.00363	-0.4	-0.4	Immature fraction of reticulocytes;	chr4:143767216	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs11100806	ENSG00000251600.4	RP11-673E1.1	4.83	3.93e-06	0.00363	0.4	0.4	Immature fraction of reticulocytes;	chr4:143761006	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs2323200	ENSG00000251600.4	RP11-673E1.1	4.83	3.93e-06	0.00363	0.4	0.4	Immature fraction of reticulocytes;	chr4:143765448	chr4:143912331~143982454:+
TGCT	cis	rs7617773	1	rs6442108	ENSG00000229759.1	MRPS18AP1	-4.83	3.93e-06	0.00363	-0.31	-0.4	Coronary artery disease;	chr3:48151469	chr3:48256350~48256938:-
TGCT	cis	rs7617773	1	rs6442109	ENSG00000229759.1	MRPS18AP1	-4.83	3.93e-06	0.00363	-0.31	-0.4	Coronary artery disease;	chr3:48151491	chr3:48256350~48256938:-
TGCT	cis	rs2976388	0.647	rs2572898	ENSG00000253196.1	RP11-706C16.7	4.83	3.94e-06	0.00363	0.39	0.4	Urinary tract infection frequency;	chr8:142700856	chr8:142763116~142766427:+
TGCT	cis	rs7847628	0.765	rs7026635	ENSG00000226752.6	PSMD5-AS1	4.83	3.94e-06	0.00363	0.53	0.4	Birth weight;	chr9:120787749	chr9:120824828~120854385:+
TGCT	cis	rs599083	0.573	rs3018713	ENSG00000212093.1	AP000807.1	4.83	3.94e-06	0.00364	0.37	0.4	Bone mineral density (spine);	chr11:68623518	chr11:68506083~68506166:-
TGCT	cis	rs7927592	0.673	rs2510392	ENSG00000212093.1	AP000807.1	4.83	3.94e-06	0.00364	0.37	0.4	Total body bone mineral density;	chr11:68626989	chr11:68506083~68506166:-
TGCT	cis	rs651907	0.557	rs13077925	ENSG00000244119.1	PDCL3P4	4.83	3.94e-06	0.00364	0.28	0.4	Colorectal cancer;	chr3:101769337	chr3:101712472~101713191:+
TGCT	cis	rs3931020	1	rs12410060	ENSG00000272864.1	RP11-17E13.2	-4.83	3.94e-06	0.00364	-0.47	-0.4	Resistin levels;	chr1:74780164	chr1:74698769~74699333:-
TGCT	cis	rs4713118	0.629	rs203887	ENSG00000219392.1	RP1-265C24.5	-4.83	3.95e-06	0.00364	-0.52	-0.4	Parkinson's disease;	chr6:28053491	chr6:28115628~28116551:+
TGCT	cis	rs2739330	0.587	rs4820571	ENSG00000250470.1	AP000351.3	4.83	3.95e-06	0.00364	0.4	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23976904~23977585:-
TGCT	cis	rs853679	0.55	rs1233701	ENSG00000219392.1	RP1-265C24.5	4.83	3.96e-06	0.00364	0.52	0.4	Depression;	chr6:28200948	chr6:28115628~28116551:+
TGCT	cis	rs6017291	0.59	rs16988852	ENSG00000223891.4	OSER1-AS1	4.83	3.96e-06	0.00365	0.63	0.4	Cognitive performance;	chr20:44212989	chr20:44210960~44226027:+
TGCT	cis	rs6017291	0.59	rs73106287	ENSG00000223891.4	OSER1-AS1	4.83	3.96e-06	0.00365	0.63	0.4	Cognitive performance;	chr20:44213723	chr20:44210960~44226027:+
TGCT	cis	rs6017291	0.623	rs73106290	ENSG00000223891.4	OSER1-AS1	4.83	3.96e-06	0.00365	0.63	0.4	Cognitive performance;	chr20:44214631	chr20:44210960~44226027:+
TGCT	cis	rs6017291	0.793	rs73106293	ENSG00000223891.4	OSER1-AS1	4.83	3.96e-06	0.00365	0.63	0.4	Cognitive performance;	chr20:44215289	chr20:44210960~44226027:+
TGCT	cis	rs6017291	0.793	rs12624924	ENSG00000223891.4	OSER1-AS1	4.83	3.96e-06	0.00365	0.63	0.4	Cognitive performance;	chr20:44216629	chr20:44210960~44226027:+
TGCT	cis	rs6017291	0.793	rs45472797	ENSG00000223891.4	OSER1-AS1	4.83	3.96e-06	0.00365	0.63	0.4	Cognitive performance;	chr20:44217425	chr20:44210960~44226027:+
TGCT	cis	rs4268898	0.722	rs11691212	ENSG00000223754.1	AC008073.9	-4.83	3.97e-06	0.00365	-0.43	-0.4	Asthma;	chr2:24181864	chr2:24199839~24201698:-
TGCT	cis	rs4268898	0.697	rs10445892	ENSG00000223754.1	AC008073.9	-4.83	3.97e-06	0.00365	-0.43	-0.4	Asthma;	chr2:24184089	chr2:24199839~24201698:-
TGCT	cis	rs4268898	0.722	rs10445893	ENSG00000223754.1	AC008073.9	-4.83	3.97e-06	0.00365	-0.43	-0.4	Asthma;	chr2:24184259	chr2:24199839~24201698:-
TGCT	cis	rs651907	0.557	rs7645391	ENSG00000244119.1	PDCL3P4	4.83	3.97e-06	0.00365	0.29	0.4	Colorectal cancer;	chr3:101642662	chr3:101712472~101713191:+
TGCT	cis	rs786425	0.866	rs7139193	ENSG00000247373.3	RP11-486O12.2	4.83	3.97e-06	0.00366	0.48	0.4	Pubertal anthropometrics;	chr12:123686629	chr12:123575891~123585115:-
TGCT	cis	rs7301826	1	rs4619189	ENSG00000256299.1	RP11-989F5.3	-4.83	3.98e-06	0.00366	-0.42	-0.4	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810821~130812622:-
TGCT	cis	rs877819	0.583	rs1904595	ENSG00000228403.1	RP11-563N6.6	4.83	3.98e-06	0.00366	0.41	0.4	Systemic lupus erythematosus;	chr10:48877222	chr10:48878022~48878649:+
TGCT	cis	rs5758659	0.652	rs6519301	ENSG00000270083.1	RP1-257I20.14	4.83	3.98e-06	0.00366	0.38	0.4	Cognitive function;	chr22:41989963	chr22:42089630~42090028:-
TGCT	cis	rs9322193	1	rs58189451	ENSG00000216906.2	RP11-350J20.9	4.83	3.98e-06	0.00366	0.45	0.4	Lung cancer;	chr6:149600252	chr6:149904243~149906418:+
TGCT	cis	rs2919917	1	rs2369440	ENSG00000254352.1	RP11-578O24.2	4.83	3.98e-06	0.00366	0.4	0.4	Lymphocyte counts;	chr8:78709474	chr8:78723796~78724136:-
TGCT	cis	rs2288073	0.965	rs13387930	ENSG00000223754.1	AC008073.9	4.83	3.98e-06	0.00366	0.49	0.4	Venous thromboembolism (SNP x SNP interaction);	chr2:24191531	chr2:24199839~24201698:-
TGCT	cis	rs2288073	0.965	rs10469924	ENSG00000223754.1	AC008073.9	4.83	3.98e-06	0.00366	0.49	0.4	Venous thromboembolism (SNP x SNP interaction);	chr2:24193361	chr2:24199839~24201698:-
TGCT	cis	rs2288073	0.965	rs6545335	ENSG00000223754.1	AC008073.9	4.83	3.98e-06	0.00366	0.49	0.4	Venous thromboembolism (SNP x SNP interaction);	chr2:24199142	chr2:24199839~24201698:-
TGCT	cis	rs2288073	0.965	rs6545338	ENSG00000223754.1	AC008073.9	4.83	3.98e-06	0.00366	0.49	0.4	Venous thromboembolism (SNP x SNP interaction);	chr2:24199287	chr2:24199839~24201698:-
TGCT	cis	rs2288073	0.965	rs6545340	ENSG00000223754.1	AC008073.9	4.83	3.98e-06	0.00366	0.49	0.4	Venous thromboembolism (SNP x SNP interaction);	chr2:24199400	chr2:24199839~24201698:-
TGCT	cis	rs2288073	0.965	rs10173173	ENSG00000223754.1	AC008073.9	-4.83	3.98e-06	0.00366	-0.49	-0.4	Venous thromboembolism (SNP x SNP interaction);	chr2:24192592	chr2:24199839~24201698:-
TGCT	cis	rs875971	0.862	rs1612452	ENSG00000232559.3	GS1-124K5.12	-4.83	3.99e-06	0.00367	-0.37	-0.4	Aortic root size;	chr7:66108909	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs1167390	ENSG00000232559.3	GS1-124K5.12	-4.83	3.99e-06	0.00367	-0.37	-0.4	Aortic root size;	chr7:66110906	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs35034167	ENSG00000232559.3	GS1-124K5.12	-4.83	3.99e-06	0.00367	-0.37	-0.4	Aortic root size;	chr7:66115179	chr7:66554588~66576923:-
TGCT	cis	rs507080	0.807	rs7926944	ENSG00000255239.1	AP002954.6	4.83	3.99e-06	0.00367	0.52	0.4	Serum metabolite levels;	chr11:118689119	chr11:118688039~118690600:-
TGCT	cis	rs3091242	0.933	rs11249250	ENSG00000224183.1	SDHDP6	-4.83	3.99e-06	0.00367	-0.42	-0.4	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25294164~25294643:-
TGCT	cis	rs10256972	0.552	rs6978842	ENSG00000226291.1	AC091729.8	-4.83	4e-06	0.00367	-0.42	-0.4	Endometriosis;Longevity;	chr7:1164963	chr7:1080863~1082178:+
TGCT	cis	rs2980439	0.846	rs2980437	ENSG00000254340.1	RP11-10A14.3	-4.83	4.01e-06	0.00368	-0.39	-0.4	Neuroticism;	chr8:8237241	chr8:9141424~9145435:+
TGCT	cis	rs8059260	0.673	rs74985998	ENSG00000274038.1	RP11-66H6.4	-4.83	4.01e-06	0.00368	-0.57	-0.4	Alcohol consumption over the past year;	chr16:10967208	chr16:11056556~11057034:+
TGCT	cis	rs5742933	0.803	rs1233262	ENSG00000273240.1	RP11-455J20.3	-4.83	4.02e-06	0.00369	-0.37	-0.4	Ferritin levels;	chr2:189793107	chr2:189763859~189764456:-
TGCT	cis	rs5742933	0.817	rs1233265	ENSG00000273240.1	RP11-455J20.3	-4.83	4.02e-06	0.00369	-0.37	-0.4	Ferritin levels;	chr2:189796390	chr2:189763859~189764456:-
TGCT	cis	rs5742933	0.817	rs5742938	ENSG00000273240.1	RP11-455J20.3	4.83	4.02e-06	0.00369	0.37	0.4	Ferritin levels;	chr2:189785232	chr2:189763859~189764456:-
TGCT	cis	rs1372520	0.684	rs2737030	ENSG00000247775.2	SNCA-AS1	4.83	4.02e-06	0.00369	0.39	0.4	Neuroticism;	chr4:89788948	chr4:89836408~89841978:+
TGCT	cis	rs4835473	0.932	rs17750042	ENSG00000251600.4	RP11-673E1.1	-4.83	4.02e-06	0.00369	-0.41	-0.4	Immature fraction of reticulocytes;	chr4:143726691	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1375989	ENSG00000251600.4	RP11-673E1.1	-4.83	4.02e-06	0.00369	-0.41	-0.4	Immature fraction of reticulocytes;	chr4:143726893	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs35598827	ENSG00000251600.4	RP11-673E1.1	-4.83	4.02e-06	0.00369	-0.41	-0.4	Immature fraction of reticulocytes;	chr4:143729605	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs34570929	ENSG00000251600.4	RP11-673E1.1	-4.83	4.02e-06	0.00369	-0.41	-0.4	Immature fraction of reticulocytes;	chr4:143730766	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs17750172	ENSG00000251600.4	RP11-673E1.1	-4.83	4.02e-06	0.00369	-0.41	-0.4	Immature fraction of reticulocytes;	chr4:143731094	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs34324222	ENSG00000251600.4	RP11-673E1.1	-4.83	4.02e-06	0.00369	-0.41	-0.4	Immature fraction of reticulocytes;	chr4:143784572	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1813908	ENSG00000251600.4	RP11-673E1.1	4.83	4.02e-06	0.00369	0.41	0.4	Immature fraction of reticulocytes;	chr4:143728174	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs4835454	ENSG00000251600.4	RP11-673E1.1	4.83	4.02e-06	0.00369	0.41	0.4	Immature fraction of reticulocytes;	chr4:143730081	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1839449	ENSG00000251600.4	RP11-673E1.1	4.83	4.02e-06	0.00369	0.41	0.4	Immature fraction of reticulocytes;	chr4:143730222	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1450235	ENSG00000251600.4	RP11-673E1.1	4.83	4.02e-06	0.00369	0.41	0.4	Immature fraction of reticulocytes;	chr4:143782927	chr4:143912331~143982454:+
TGCT	cis	rs9326248	0.954	rs521171	ENSG00000280143.1	AP000892.6	4.83	4.03e-06	0.0037	0.52	0.4	Blood protein levels;	chr11:117193977	chr11:117204967~117210292:+
TGCT	cis	rs6700559	0.74	rs11582610	ENSG00000260088.1	RP11-92G12.3	4.82	4.03e-06	0.0037	0.48	0.4	Coronary artery disease;	chr1:200675973	chr1:200669507~200694250:+
TGCT	cis	rs12908161	0.515	rs12907646	ENSG00000225151.9	GOLGA2P7	-4.82	4.04e-06	0.0037	-0.5	-0.4	Schizophrenia;	chr15:84860265	chr15:84199311~84230136:-
TGCT	cis	rs904251	0.523	rs2776872	ENSG00000279942.1	RP1-153P14.7	-4.82	4.04e-06	0.0037	-0.39	-0.4	Cognitive performance;	chr6:37515011	chr6:37567716~37571460:+
TGCT	cis	rs904251	0.523	rs1757191	ENSG00000279942.1	RP1-153P14.7	-4.82	4.04e-06	0.0037	-0.39	-0.4	Cognitive performance;	chr6:37515095	chr6:37567716~37571460:+
TGCT	cis	rs4835473	0.932	rs13130345	ENSG00000251600.4	RP11-673E1.1	4.82	4.04e-06	0.0037	0.41	0.4	Immature fraction of reticulocytes;	chr4:143920939	chr4:143912331~143982454:+
TGCT	cis	rs7208859	0.673	rs2470251	ENSG00000280069.1	CTD-2349P21.3	-4.82	4.04e-06	0.00371	-0.53	-0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.673	rs11652370	ENSG00000280069.1	CTD-2349P21.3	-4.82	4.04e-06	0.00371	-0.53	-0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30738182~30740275:+
TGCT	cis	rs7731657	0.569	rs12522693	ENSG00000279584.1	AC005593.2	4.82	4.05e-06	0.00372	0.68	0.4	Fasting plasma glucose;	chr5:130860038	chr5:131797415~131797929:+
TGCT	cis	rs13068223	0.607	rs193197	ENSG00000243926.1	TIPARP-AS1	-4.82	4.07e-06	0.00373	-0.43	-0.4	Age-related hearing impairment (SNP x SNP interaction);	chr3:156693943	chr3:156671862~156674378:-
TGCT	cis	rs10875976	0.525	rs7306374	ENSG00000242041.1	RP11-70F11.2	4.82	4.07e-06	0.00373	0.38	0.4	Obesity;	chr12:49856606	chr12:49863173~49863503:+
TGCT	cis	rs5742933	0.725	rs1132360	ENSG00000273240.1	RP11-455J20.3	4.82	4.08e-06	0.00373	0.38	0.4	Ferritin levels;	chr2:189661498	chr2:189763859~189764456:-
TGCT	cis	rs2948294	0.524	rs13270062	ENSG00000254340.1	RP11-10A14.3	4.82	4.08e-06	0.00374	0.43	0.4	Red cell distribution width;	chr8:8255128	chr8:9141424~9145435:+
TGCT	cis	rs2948294	0.545	rs11776397	ENSG00000254340.1	RP11-10A14.3	4.82	4.08e-06	0.00374	0.43	0.4	Red cell distribution width;	chr8:8257639	chr8:9141424~9145435:+
TGCT	cis	rs901683	1	rs3764990	ENSG00000264204.2	AGAP7P	-4.82	4.09e-06	0.00374	-0.84	-0.4	Mean corpuscular volume;Red blood cell traits;	chr10:45461380	chr10:46109621~46131358:+
TGCT	cis	rs970548	0.954	rs2291429	ENSG00000264204.2	AGAP7P	-4.82	4.09e-06	0.00374	-0.84	-0.4	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45463433	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs12769244	ENSG00000264204.2	AGAP7P	-4.82	4.09e-06	0.00374	-0.84	-0.4	Mean corpuscular volume;Red blood cell traits;	chr10:45463937	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs12771275	ENSG00000264204.2	AGAP7P	-4.82	4.09e-06	0.00374	-0.84	-0.4	Mean corpuscular volume;Red blood cell traits;	chr10:45464204	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs901684	ENSG00000264204.2	AGAP7P	-4.82	4.09e-06	0.00374	-0.84	-0.4	Mean corpuscular volume;Red blood cell traits;	chr10:45471180	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs768673	ENSG00000264204.2	AGAP7P	-4.82	4.09e-06	0.00374	-0.84	-0.4	Mean corpuscular volume;Red blood cell traits;	chr10:45471301	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs10508895	ENSG00000264204.2	AGAP7P	-4.82	4.09e-06	0.00374	-0.84	-0.4	Mean corpuscular volume;Red blood cell traits;	chr10:45472320	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs17157852	ENSG00000264204.2	AGAP7P	-4.82	4.09e-06	0.00374	-0.84	-0.4	Mean corpuscular volume;Red blood cell traits;	chr10:45472353	chr10:46109621~46131358:+
TGCT	cis	rs728616	0.867	rs17886286	ENSG00000230091.5	TMEM254-AS1	4.82	4.09e-06	0.00374	0.73	0.4	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79944096	chr10:80046860~80078912:-
TGCT	cis	rs13108904	0.518	rs4974603	ENSG00000253399.1	AC078852.2	-4.82	4.09e-06	0.00374	-0.49	-0.4	Obesity-related traits;	chr4:1349380	chr4:1358479~1359461:+
TGCT	cis	rs2117029	0.555	rs7978448	ENSG00000258017.1	RP11-386G11.10	-4.82	4.09e-06	0.00375	-0.52	-0.4	Intelligence (multi-trait analysis);	chr12:49113157	chr12:49127782~49147869:+
TGCT	cis	rs3020736	0.5	rs6002601	ENSG00000270083.1	RP1-257I20.14	-4.82	4.1e-06	0.00375	-0.41	-0.4	Autism spectrum disorder or schizophrenia;	chr22:42093054	chr22:42089630~42090028:-
TGCT	cis	rs2919917	0.628	rs2717544	ENSG00000254352.1	RP11-578O24.2	-4.82	4.1e-06	0.00375	-0.46	-0.4	Lymphocyte counts;	chr8:78724307	chr8:78723796~78724136:-
TGCT	cis	rs1577917	0.545	rs9294338	ENSG00000203875.9	SNHG5	4.82	4.11e-06	0.00376	0.51	0.4	Response to antipsychotic treatment;	chr6:85764650	chr6:85660950~85678736:-
TGCT	cis	rs4970988	0.527	rs12067556	ENSG00000206931.1	RNU6-1042P	4.82	4.11e-06	0.00376	0.33	0.4	Urate levels;	chr1:150642059	chr1:150701866~150701972:+
TGCT	cis	rs3096299	1	rs3096299	ENSG00000274627.1	RP11-104N10.2	4.82	4.13e-06	0.00377	0.42	0.4	Multiple myeloma (IgH translocation);	chr16:89382255	chr16:89516797~89522217:+
TGCT	cis	rs34217772	0.824	rs61992433	ENSG00000258536.1	RP11-1053O12.1	4.82	4.14e-06	0.00378	0.38	0.4	Myopia;	chr14:41757997	chr14:41742639~41742963:+
TGCT	cis	rs5742933	0.817	rs4667297	ENSG00000273240.1	RP11-455J20.3	4.82	4.15e-06	0.00379	0.38	0.4	Ferritin levels;	chr2:189664270	chr2:189763859~189764456:-
TGCT	cis	rs5742933	0.711	rs12693551	ENSG00000273240.1	RP11-455J20.3	4.82	4.15e-06	0.00379	0.38	0.4	Ferritin levels;	chr2:189664505	chr2:189763859~189764456:-
TGCT	cis	rs12745968	0.652	rs4565725	ENSG00000223787.2	RP4-593M8.1	-4.82	4.15e-06	0.00379	-0.51	-0.4	Bipolar disorder and schizophrenia;	chr1:92485380	chr1:92580476~92580821:-
TGCT	cis	rs507080	0.922	rs592280	ENSG00000255239.1	AP002954.6	4.82	4.16e-06	0.0038	0.54	0.4	Serum metabolite levels;	chr11:118682509	chr11:118688039~118690600:-
TGCT	cis	rs10935480	1	rs10935480	ENSG00000239445.4	ST3GAL6-AS1	-4.82	4.17e-06	0.0038	-0.36	-0.4	Blood protein levels;	chr3:98713142	chr3:98714330~98732651:-
TGCT	cis	rs10935480	0.935	rs4857414	ENSG00000239445.4	ST3GAL6-AS1	-4.82	4.17e-06	0.0038	-0.36	-0.4	Blood protein levels;	chr3:98713715	chr3:98714330~98732651:-
TGCT	cis	rs673078	0.607	rs4766900	ENSG00000275759.1	RP11-131L12.3	-4.82	4.17e-06	0.0038	-0.73	-0.4	Glucose homeostasis traits;	chr12:118375139	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs884844	ENSG00000275759.1	RP11-131L12.3	-4.82	4.17e-06	0.0038	-0.73	-0.4	Glucose homeostasis traits;	chr12:118377033	chr12:118428281~118428870:+
TGCT	cis	rs3931020	1	rs3931020	ENSG00000272864.1	RP11-17E13.2	-4.82	4.17e-06	0.00381	-0.47	-0.4	Resistin levels;	chr1:74769633	chr1:74698769~74699333:-
TGCT	cis	rs9918079	0.56	rs10008376	ENSG00000273133.1	RP11-799M12.2	4.82	4.18e-06	0.00381	0.57	0.4	Obesity-related traits;	chr4:15622332	chr4:15563698~15564253:-
TGCT	cis	rs710913	0.557	rs1180320	ENSG00000182109.6	RP11-69E11.4	4.82	4.19e-06	0.00382	0.42	0.4	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39616330	chr1:39522280~39546187:-
TGCT	cis	rs972540	1	rs10497882	ENSG00000279220.1	GPR1-AS	4.82	4.19e-06	0.00382	0.47	0.4	Body mass index;	chr2:206368391	chr2:206203376~206266243:+
TGCT	cis	rs4268898	0.722	rs7564420	ENSG00000223754.1	AC008073.9	4.82	4.19e-06	0.00382	0.43	0.4	Asthma;	chr2:24191133	chr2:24199839~24201698:-
TGCT	cis	rs4660456	0.711	rs12409109	ENSG00000237899.1	RP4-739H11.3	-4.82	4.19e-06	0.00382	-0.53	-0.4	Platelet count;	chr1:40727216	chr1:40669089~40687588:-
TGCT	cis	rs12931792	0.846	rs9924308	ENSG00000183604.13	SMG1P5	-4.82	4.19e-06	0.00382	-0.28	-0.4	Tonsillectomy;	chr16:30143419	chr16:30267553~30335374:-
TGCT	cis	rs875971	0.798	rs12698522	ENSG00000232559.3	GS1-124K5.12	4.82	4.19e-06	0.00382	0.36	0.4	Aortic root size;	chr7:66502354	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.83	rs28714531	ENSG00000232559.3	GS1-124K5.12	4.82	4.19e-06	0.00382	0.36	0.4	Aortic root size;	chr7:66503250	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs12698526	ENSG00000232559.3	GS1-124K5.12	4.82	4.19e-06	0.00382	0.36	0.4	Aortic root size;	chr7:66504118	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs13232191	ENSG00000232559.3	GS1-124K5.12	4.82	4.19e-06	0.00382	0.36	0.4	Aortic root size;	chr7:66521661	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs35378740	ENSG00000232559.3	GS1-124K5.12	4.82	4.19e-06	0.00382	0.36	0.4	Aortic root size;	chr7:66522725	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs10950043	ENSG00000232559.3	GS1-124K5.12	4.82	4.19e-06	0.00382	0.36	0.4	Aortic root size;	chr7:66523623	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs17747530	ENSG00000232559.3	GS1-124K5.12	4.82	4.19e-06	0.00382	0.36	0.4	Aortic root size;	chr7:66529742	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs13226170	ENSG00000232559.3	GS1-124K5.12	4.82	4.19e-06	0.00382	0.36	0.4	Aortic root size;	chr7:66534311	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs2420611	ENSG00000232559.3	GS1-124K5.12	4.82	4.19e-06	0.00382	0.36	0.4	Aortic root size;	chr7:66534333	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.767	rs61348003	ENSG00000232559.3	GS1-124K5.12	4.82	4.19e-06	0.00382	0.36	0.4	Aortic root size;	chr7:66540947	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.861	rs801215	ENSG00000232559.3	GS1-124K5.12	-4.82	4.19e-06	0.00382	-0.36	-0.4	Aortic root size;	chr7:66546951	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs13536	ENSG00000232559.3	GS1-124K5.12	-4.82	4.19e-06	0.00382	-0.36	-0.4	Aortic root size;	chr7:66554203	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs801209	ENSG00000232559.3	GS1-124K5.12	-4.82	4.19e-06	0.00382	-0.36	-0.4	Aortic root size;	chr7:66554403	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs801206	ENSG00000232559.3	GS1-124K5.12	-4.82	4.19e-06	0.00382	-0.36	-0.4	Aortic root size;	chr7:66556979	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs801204	ENSG00000232559.3	GS1-124K5.12	-4.82	4.19e-06	0.00382	-0.36	-0.4	Aortic root size;	chr7:66557934	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs801203	ENSG00000232559.3	GS1-124K5.12	-4.82	4.19e-06	0.00382	-0.36	-0.4	Aortic root size;	chr7:66558025	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.825	rs801202	ENSG00000232559.3	GS1-124K5.12	-4.82	4.19e-06	0.00382	-0.36	-0.4	Aortic root size;	chr7:66558942	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs801195	ENSG00000232559.3	GS1-124K5.12	-4.82	4.19e-06	0.00382	-0.36	-0.4	Aortic root size;	chr7:66561128	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs801194	ENSG00000232559.3	GS1-124K5.12	-4.82	4.19e-06	0.00382	-0.36	-0.4	Aortic root size;	chr7:66563508	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs2024192	ENSG00000232559.3	GS1-124K5.12	-4.82	4.19e-06	0.00382	-0.36	-0.4	Aortic root size;	chr7:66576460	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs6955837	ENSG00000232559.3	GS1-124K5.12	-4.82	4.19e-06	0.00382	-0.36	-0.4	Aortic root size;	chr7:66578155	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.825	rs10281499	ENSG00000232559.3	GS1-124K5.12	-4.82	4.19e-06	0.00382	-0.36	-0.4	Aortic root size;	chr7:66583979	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs4718377	ENSG00000232559.3	GS1-124K5.12	-4.82	4.19e-06	0.00382	-0.36	-0.4	Aortic root size;	chr7:66584691	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs10278014	ENSG00000232559.3	GS1-124K5.12	-4.82	4.19e-06	0.00382	-0.36	-0.4	Aortic root size;	chr7:66586277	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs1968126	ENSG00000232559.3	GS1-124K5.12	-4.82	4.19e-06	0.00382	-0.36	-0.4	Aortic root size;	chr7:66592017	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs6460306	ENSG00000232559.3	GS1-124K5.12	-4.82	4.19e-06	0.00382	-0.36	-0.4	Aortic root size;	chr7:66595806	chr7:66554588~66576923:-
TGCT	cis	rs8105895	0.877	rs8100768	ENSG00000269742.1	BNIP3P29	4.82	4.19e-06	0.00382	0.71	0.4	Body mass index (change over time);	chr19:22087666	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs10417916	ENSG00000269742.1	BNIP3P29	4.82	4.19e-06	0.00382	0.71	0.4	Body mass index (change over time);	chr19:22089813	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs10418804	ENSG00000269742.1	BNIP3P29	4.82	4.19e-06	0.00382	0.71	0.4	Body mass index (change over time);	chr19:22090213	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs2043319	ENSG00000269742.1	BNIP3P29	4.82	4.19e-06	0.00382	0.71	0.4	Body mass index (change over time);	chr19:22091793	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs28374572	ENSG00000269742.1	BNIP3P29	4.82	4.19e-06	0.00382	0.71	0.4	Body mass index (change over time);	chr19:22093676	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs1968446	ENSG00000269742.1	BNIP3P29	4.82	4.19e-06	0.00382	0.71	0.4	Body mass index (change over time);	chr19:22096245	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.733	rs10423457	ENSG00000269742.1	BNIP3P29	4.82	4.19e-06	0.00382	0.71	0.4	Body mass index (change over time);	chr19:22096465	chr19:22065828~22066398:-
TGCT	cis	rs17373728	0.77	rs1949109	ENSG00000249395.2	CASC9	4.82	4.2e-06	0.00382	0.5	0.4	Diabetic kidney disease;	chr8:75311948	chr8:75223404~75324741:-
TGCT	cis	rs7221109	0.601	rs2462964	ENSG00000278834.1	RP11-458J1.1	-4.81	4.2e-06	0.00383	-0.31	-0.4	Type 1 diabetes;	chr17:40706276	chr17:40648300~40649718:+
TGCT	cis	rs875971	0.83	rs6976714	ENSG00000237310.1	GS1-124K5.4	4.81	4.21e-06	0.00383	0.42	0.4	Aortic root size;	chr7:66426474	chr7:66493706~66495474:+
TGCT	cis	rs1618992	0.694	rs28470293	ENSG00000265994.1	RP11-510D21.1	4.81	4.22e-06	0.00384	0.4	0.4	Gut microbiome composition (summer and winter);	chr18:28601706	chr18:28785068~28789260:+
TGCT	cis	rs1618992	0.703	rs8094710	ENSG00000265994.1	RP11-510D21.1	4.81	4.22e-06	0.00384	0.4	0.4	Gut microbiome composition (summer and winter);	chr18:28602725	chr18:28785068~28789260:+
TGCT	cis	rs1618992	0.729	rs6508554	ENSG00000265994.1	RP11-510D21.1	4.81	4.22e-06	0.00384	0.4	0.4	Gut microbiome composition (summer and winter);	chr18:28603373	chr18:28785068~28789260:+
TGCT	cis	rs9425766	0.679	rs2860846	ENSG00000227373.4	RP11-160H22.5	4.81	4.22e-06	0.00384	0.43	0.4	Life satisfaction;	chr1:174106786	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.679	rs2860847	ENSG00000227373.4	RP11-160H22.5	4.81	4.22e-06	0.00384	0.43	0.4	Life satisfaction;	chr1:174106787	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.679	rs6672986	ENSG00000227373.4	RP11-160H22.5	4.81	4.22e-06	0.00384	0.43	0.4	Life satisfaction;	chr1:174107726	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.679	rs7533430	ENSG00000227373.4	RP11-160H22.5	4.81	4.22e-06	0.00384	0.43	0.4	Life satisfaction;	chr1:174109279	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.679	rs7526024	ENSG00000227373.4	RP11-160H22.5	4.81	4.22e-06	0.00384	0.43	0.4	Life satisfaction;	chr1:174109722	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.679	rs12079062	ENSG00000227373.4	RP11-160H22.5	4.81	4.22e-06	0.00384	0.43	0.4	Life satisfaction;	chr1:174110446	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.679	rs12079063	ENSG00000227373.4	RP11-160H22.5	4.81	4.22e-06	0.00384	0.43	0.4	Life satisfaction;	chr1:174110447	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.679	rs12094341	ENSG00000227373.4	RP11-160H22.5	4.81	4.22e-06	0.00384	0.43	0.4	Life satisfaction;	chr1:174110562	chr1:174115300~174160004:-
TGCT	cis	rs801193	1	rs2659912	ENSG00000237310.1	GS1-124K5.4	4.81	4.23e-06	0.00384	0.45	0.4	Aortic root size;	chr7:66693012	chr7:66493706~66495474:+
TGCT	cis	rs8091660	0.929	rs3744827	ENSG00000278983.1	RP11-426J5.3	-4.81	4.23e-06	0.00384	-0.48	-0.4	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48569572	chr18:48564795~48568342:+
TGCT	cis	rs1263173	0.696	rs1263172	ENSG00000254851.1	RP11-109L13.1	-4.81	4.23e-06	0.00385	-0.57	-0.4	HDL cholesterol;	chr11:116810202	chr11:117135528~117138582:+
TGCT	cis	rs13108904	0.517	rs7671242	ENSG00000253399.1	AC078852.2	-4.81	4.23e-06	0.00385	-0.48	-0.4	Obesity-related traits;	chr4:1346087	chr4:1358479~1359461:+
TGCT	cis	rs10504229	0.815	rs17805008	ENSG00000253301.4	RP11-513O17.2	4.81	4.24e-06	0.00385	0.53	0.4	Developmental language disorder (linguistic errors);	chr8:57247626	chr8:57142689~57240298:+
TGCT	cis	rs11231017	0.507	rs2178258	ENSG00000254454.2	RCC2P6	-4.81	4.24e-06	0.00385	-0.28	-0.4	HIV-1 viral setpoint;	chr11:62302421	chr11:62371146~62373168:+
TGCT	cis	rs11231017	0.507	rs9633995	ENSG00000254454.2	RCC2P6	-4.81	4.24e-06	0.00385	-0.28	-0.4	HIV-1 viral setpoint;	chr11:62303743	chr11:62371146~62373168:+
TGCT	cis	rs1061377	1	rs9997089	ENSG00000249685.1	RP11-360F5.3	4.81	4.24e-06	0.00385	0.36	0.4	Uric acid levels;	chr4:39119263	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs28465556	ENSG00000249685.1	RP11-360F5.3	4.81	4.24e-06	0.00385	0.36	0.4	Uric acid levels;	chr4:39119569	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs10027813	ENSG00000249685.1	RP11-360F5.3	4.81	4.24e-06	0.00385	0.36	0.4	Uric acid levels;	chr4:39119818	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs9990755	ENSG00000249685.1	RP11-360F5.3	4.81	4.24e-06	0.00385	0.36	0.4	Uric acid levels;	chr4:39119819	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs7675782	ENSG00000249685.1	RP11-360F5.3	4.81	4.24e-06	0.00385	0.36	0.4	Uric acid levels;	chr4:39120048	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs7676008	ENSG00000249685.1	RP11-360F5.3	4.81	4.24e-06	0.00385	0.36	0.4	Uric acid levels;	chr4:39120154	chr4:39133913~39135608:+
TGCT	cis	rs1061377	0.965	rs7677729	ENSG00000249685.1	RP11-360F5.3	4.81	4.24e-06	0.00385	0.36	0.4	Uric acid levels;	chr4:39120370	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs7655122	ENSG00000249685.1	RP11-360F5.3	4.81	4.24e-06	0.00385	0.36	0.4	Uric acid levels;	chr4:39120396	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs3796511	ENSG00000249685.1	RP11-360F5.3	4.81	4.24e-06	0.00385	0.36	0.4	Uric acid levels;	chr4:39120586	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs3733274	ENSG00000249685.1	RP11-360F5.3	4.81	4.24e-06	0.00385	0.36	0.4	Uric acid levels;	chr4:39120957	chr4:39133913~39135608:+
TGCT	cis	rs1061377	0.965	rs3733275	ENSG00000249685.1	RP11-360F5.3	4.81	4.24e-06	0.00385	0.36	0.4	Uric acid levels;	chr4:39121077	chr4:39133913~39135608:+
TGCT	cis	rs7221109	0.56	rs2253717	ENSG00000278834.1	RP11-458J1.1	-4.81	4.24e-06	0.00385	-0.31	-0.4	Type 1 diabetes;	chr17:40711984	chr17:40648300~40649718:+
TGCT	cis	rs11673344	0.573	rs73039109	ENSG00000226686.6	LINC01535	4.81	4.25e-06	0.00386	0.44	0.4	Obesity-related traits;	chr19:36891073	chr19:37251912~37265535:+
TGCT	cis	rs10875746	0.81	rs10875732	ENSG00000240399.1	RP1-228P16.1	-4.81	4.26e-06	0.00387	-0.47	-0.4	Longevity (90 years and older);	chr12:48048322	chr12:48054813~48055591:-
TGCT	cis	rs16975963	0.644	rs112666969	ENSG00000276846.1	CTD-3220F14.3	-4.81	4.27e-06	0.00388	-0.38	-0.4	Longevity;	chr19:37556743	chr19:37314868~37315620:-
TGCT	cis	rs796364	0.756	rs2949006	ENSG00000232732.8	AC073043.1	-4.81	4.27e-06	0.00388	-0.57	-0.4	Schizophrenia;	chr2:199850665	chr2:199867396~199911159:-
TGCT	cis	rs7829975	0.902	rs485107	ENSG00000173295.6	FAM86B3P	-4.81	4.28e-06	0.00388	-0.48	-0.4	Mood instability;	chr8:8723898	chr8:8228595~8244865:+
TGCT	cis	rs7829975	0.871	rs777709	ENSG00000173295.6	FAM86B3P	-4.81	4.28e-06	0.00388	-0.48	-0.4	Mood instability;	chr8:8726362	chr8:8228595~8244865:+
TGCT	cis	rs17826219	0.706	rs28469200	ENSG00000266490.1	CTD-2349P21.9	4.81	4.28e-06	0.00389	0.45	0.4	Body mass index;	chr17:30806554	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.573	rs79505916	ENSG00000266490.1	CTD-2349P21.9	4.81	4.3e-06	0.0039	0.45	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30792372~30792833:+
TGCT	cis	rs9987353	0.566	rs6998368	ENSG00000173295.6	FAM86B3P	-4.81	4.3e-06	0.0039	-0.44	-0.4	Recombination measurement;	chr8:9212778	chr8:8228595~8244865:+
TGCT	cis	rs10829156	0.625	rs10828906	ENSG00000240291.1	RP11-499P20.2	4.81	4.3e-06	0.0039	0.36	0.4	Sudden cardiac arrest;	chr10:18552866	chr10:18513115~18545651:-
TGCT	cis	rs5769707	0.967	rs9616713	ENSG00000235111.1	RP1-29C18.8	-4.81	4.3e-06	0.0039	-0.32	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49655461	chr22:49612657~49615716:-
TGCT	cis	rs11168618	0.509	rs2731092	ENSG00000240399.1	RP1-228P16.1	-4.81	4.3e-06	0.0039	-0.39	-0.4	Adiponectin levels;	chr12:48486767	chr12:48054813~48055591:-
TGCT	cis	rs853679	0.55	rs34477097	ENSG00000216901.1	AL022393.7	4.81	4.34e-06	0.00393	0.53	0.4	Depression;	chr6:28229408	chr6:28176188~28176674:+
TGCT	cis	rs11822910	0.911	rs61886978	ENSG00000265566.2	RN7SL605P	4.81	4.34e-06	0.00393	0.48	0.4	Platelet distribution width;	chr11:57427375	chr11:57528085~57528365:-
TGCT	cis	rs732716	0.785	rs11085073	ENSG00000267769.1	CTB-50L17.9	4.81	4.34e-06	0.00393	0.44	0.4	Mean corpuscular volume;	chr19:4375165	chr19:4454014~4455286:+
TGCT	cis	rs9462027	0.628	rs9462030	ENSG00000186328.4	RP11-140K17.2	4.81	4.35e-06	0.00393	0.38	0.4	Systemic lupus erythematosus;	chr6:34863503	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs3734264	ENSG00000186328.4	RP11-140K17.2	4.81	4.35e-06	0.00393	0.38	0.4	Systemic lupus erythematosus;	chr6:34864089	chr6:34715613~34715940:+
TGCT	cis	rs4380275	0.782	rs11127506	ENSG00000223751.1	AC116609.2	-4.81	4.36e-06	0.00394	-0.4	-0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:751300	chr2:742488~747767:+
TGCT	cis	rs9987353	0.566	rs34491841	ENSG00000173295.6	FAM86B3P	-4.81	4.36e-06	0.00394	-0.43	-0.4	Recombination measurement;	chr8:9208000	chr8:8228595~8244865:+
TGCT	cis	rs9322193	0.962	rs4552	ENSG00000216906.2	RP11-350J20.9	4.81	4.37e-06	0.00394	0.44	0.4	Lung cancer;	chr6:149811183	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs9397022	ENSG00000216906.2	RP11-350J20.9	4.81	4.37e-06	0.00394	0.44	0.4	Lung cancer;	chr6:149812052	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs9397357	ENSG00000216906.2	RP11-350J20.9	4.81	4.37e-06	0.00394	0.44	0.4	Lung cancer;	chr6:149812465	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs17673294	ENSG00000216906.2	RP11-350J20.9	4.81	4.37e-06	0.00394	0.44	0.4	Lung cancer;	chr6:149813857	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs6899661	ENSG00000216906.2	RP11-350J20.9	4.81	4.37e-06	0.00394	0.44	0.4	Lung cancer;	chr6:149818093	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs3763163	ENSG00000216906.2	RP11-350J20.9	4.81	4.37e-06	0.00394	0.44	0.4	Lung cancer;	chr6:149819770	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs14314	ENSG00000216906.2	RP11-350J20.9	4.81	4.37e-06	0.00394	0.44	0.4	Lung cancer;	chr6:149820395	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs1413655	ENSG00000216906.2	RP11-350J20.9	4.81	4.37e-06	0.00394	0.44	0.4	Lung cancer;	chr6:149821815	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.926	rs9383546	ENSG00000216906.2	RP11-350J20.9	4.81	4.37e-06	0.00394	0.44	0.4	Lung cancer;	chr6:149822743	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs9478848	ENSG00000216906.2	RP11-350J20.9	4.81	4.37e-06	0.00394	0.44	0.4	Lung cancer;	chr6:149825080	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs1889473	ENSG00000216906.2	RP11-350J20.9	4.81	4.37e-06	0.00394	0.44	0.4	Lung cancer;	chr6:149825485	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs6903998	ENSG00000216906.2	RP11-350J20.9	4.81	4.37e-06	0.00394	0.44	0.4	Lung cancer;	chr6:149831357	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs1984111	ENSG00000216906.2	RP11-350J20.9	4.81	4.37e-06	0.00394	0.44	0.4	Lung cancer;	chr6:149831720	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs2151912	ENSG00000216906.2	RP11-350J20.9	4.81	4.37e-06	0.00394	0.44	0.4	Lung cancer;	chr6:149831772	chr6:149904243~149906418:+
TGCT	cis	rs10875976	0.525	rs2271687	ENSG00000242041.1	RP11-70F11.2	4.81	4.37e-06	0.00394	0.37	0.4	Obesity;	chr12:49865732	chr12:49863173~49863503:+
TGCT	cis	rs1618992	0.729	rs8097472	ENSG00000265994.1	RP11-510D21.1	4.81	4.37e-06	0.00394	0.4	0.4	Gut microbiome composition (summer and winter);	chr18:28593315	chr18:28785068~28789260:+
TGCT	cis	rs1618992	0.729	rs7229832	ENSG00000265994.1	RP11-510D21.1	4.81	4.37e-06	0.00394	0.4	0.4	Gut microbiome composition (summer and winter);	chr18:28594726	chr18:28785068~28789260:+
TGCT	cis	rs877819	0.583	rs2620887	ENSG00000228403.1	RP11-563N6.6	-4.81	4.37e-06	0.00394	-0.43	-0.4	Systemic lupus erythematosus;	chr10:48852457	chr10:48878022~48878649:+
TGCT	cis	rs7829975	0.711	rs4481596	ENSG00000173295.6	FAM86B3P	4.8	4.39e-06	0.00396	0.47	0.4	Mood instability;	chr8:8846820	chr8:8228595~8244865:+
TGCT	cis	rs36093924	0.646	rs7285557	ENSG00000182057.4	OGFRP1	-4.8	4.4e-06	0.00396	-0.29	-0.4	Intelligence;	chr22:41952786	chr22:42269753~42275196:+
TGCT	cis	rs877819	0.583	rs2663021	ENSG00000228403.1	RP11-563N6.6	-4.8	4.4e-06	0.00397	-0.41	-0.4	Systemic lupus erythematosus;	chr10:48870072	chr10:48878022~48878649:+
TGCT	cis	rs877819	0.552	rs2127586	ENSG00000228403.1	RP11-563N6.6	-4.8	4.4e-06	0.00397	-0.41	-0.4	Systemic lupus erythematosus;	chr10:48871605	chr10:48878022~48878649:+
TGCT	cis	rs67311347	1	rs73078158	ENSG00000223797.4	ENTPD3-AS1	4.8	4.4e-06	0.00397	0.42	0.4	Renal cell carcinoma;	chr3:40431076	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs73078169	ENSG00000223797.4	ENTPD3-AS1	4.8	4.4e-06	0.00397	0.42	0.4	Renal cell carcinoma;	chr3:40442307	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs1123019	ENSG00000223797.4	ENTPD3-AS1	4.8	4.4e-06	0.00397	0.42	0.4	Renal cell carcinoma;	chr3:40446789	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs2371186	ENSG00000223797.4	ENTPD3-AS1	4.8	4.4e-06	0.00397	0.42	0.4	Renal cell carcinoma;	chr3:40447222	chr3:40313802~40453329:-
TGCT	cis	rs9425766	0.679	rs4652237	ENSG00000227373.4	RP11-160H22.5	4.8	4.42e-06	0.00398	0.42	0.4	Life satisfaction;	chr1:174189718	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.679	rs6681618	ENSG00000227373.4	RP11-160H22.5	-4.8	4.42e-06	0.00398	-0.42	-0.4	Life satisfaction;	chr1:174201203	chr1:174115300~174160004:-
TGCT	cis	rs4713118	0.621	rs9295756	ENSG00000219392.1	RP1-265C24.5	-4.8	4.42e-06	0.00398	-0.52	-0.4	Parkinson's disease;	chr6:28065618	chr6:28115628~28116551:+
TGCT	cis	rs2742234	0.59	rs741968	ENSG00000273008.1	RP11-351D16.3	-4.8	4.43e-06	0.00399	-0.53	-0.4	Hirschsprung disease;	chr10:43116260	chr10:43136824~43138334:-
TGCT	cis	rs1707322	0.682	rs10890334	ENSG00000280836.1	AL355480.1	-4.8	4.43e-06	0.00399	-0.54	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.682	rs10890335	ENSG00000280836.1	AL355480.1	-4.8	4.43e-06	0.00399	-0.54	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45581219~45581321:-
TGCT	cis	rs5769707	0.967	rs763126	ENSG00000235111.1	RP1-29C18.8	4.8	4.43e-06	0.00399	0.32	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49612657~49615716:-
TGCT	cis	rs13118159	0.55	rs28733902	ENSG00000254094.1	AC078852.1	-4.8	4.43e-06	0.00399	-0.5	-0.4	Longevity;	chr4:1381001	chr4:1356581~1358075:+
TGCT	cis	rs1823913	1	rs1823913	ENSG00000280083.1	RP11-317J9.1	-4.8	4.44e-06	0.00399	-0.34	-0.4	Obesity-related traits;	chr2:191253321	chr2:191154118~191156070:-
TGCT	cis	rs4835473	0.932	rs17763107	ENSG00000251600.4	RP11-673E1.1	-4.8	4.45e-06	0.00401	-0.41	-0.4	Immature fraction of reticulocytes;	chr4:143828512	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs17695782	ENSG00000251600.4	RP11-673E1.1	-4.8	4.45e-06	0.00401	-0.41	-0.4	Immature fraction of reticulocytes;	chr4:143830311	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs34917094	ENSG00000251600.4	RP11-673E1.1	-4.8	4.45e-06	0.00401	-0.41	-0.4	Immature fraction of reticulocytes;	chr4:143832003	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs11736609	ENSG00000251600.4	RP11-673E1.1	-4.8	4.45e-06	0.00401	-0.41	-0.4	Immature fraction of reticulocytes;	chr4:143832876	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs11730929	ENSG00000251600.4	RP11-673E1.1	-4.8	4.45e-06	0.00401	-0.41	-0.4	Immature fraction of reticulocytes;	chr4:143834795	chr4:143912331~143982454:+
TGCT	cis	rs9987353	0.566	rs34389718	ENSG00000173295.6	FAM86B3P	-4.8	4.46e-06	0.00401	-0.44	-0.4	Recombination measurement;	chr8:9208015	chr8:8228595~8244865:+
TGCT	cis	rs6600671	0.934	rs11249429	ENSG00000275131.1	CH17-472G23.4	4.8	4.46e-06	0.00401	0.26	0.4	Hip geometry;	chr1:121549282	chr1:120489625~120579190:-
TGCT	cis	rs673078	0.607	rs7132753	ENSG00000275759.1	RP11-131L12.3	-4.8	4.46e-06	0.00401	-0.72	-0.4	Glucose homeostasis traits;	chr12:118420383	chr12:118428281~118428870:+
TGCT	cis	rs875971	0.66	rs10215132	ENSG00000237310.1	GS1-124K5.4	-4.8	4.46e-06	0.00401	-0.45	-0.4	Aortic root size;	chr7:66589419	chr7:66493706~66495474:+
TGCT	cis	rs11168618	0.74	rs4237859	ENSG00000240399.1	RP1-228P16.1	4.8	4.46e-06	0.00402	0.38	0.4	Adiponectin levels;	chr12:48530892	chr12:48054813~48055591:-
TGCT	cis	rs2463822	0.92	rs72923207	ENSG00000254454.2	RCC2P6	4.8	4.47e-06	0.00402	0.43	0.4	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62350487	chr11:62371146~62373168:+
TGCT	cis	rs5742933	0.744	rs12693557	ENSG00000273240.1	RP11-455J20.3	4.8	4.47e-06	0.00402	0.37	0.4	Ferritin levels;	chr2:189726211	chr2:189763859~189764456:-
TGCT	cis	rs5742933	0.817	rs13035966	ENSG00000273240.1	RP11-455J20.3	4.8	4.47e-06	0.00402	0.37	0.4	Ferritin levels;	chr2:189726507	chr2:189763859~189764456:-
TGCT	cis	rs5742933	0.762	rs2033746	ENSG00000273240.1	RP11-455J20.3	4.8	4.47e-06	0.00402	0.37	0.4	Ferritin levels;	chr2:189734726	chr2:189763859~189764456:-
TGCT	cis	rs5742933	0.762	rs12992061	ENSG00000273240.1	RP11-455J20.3	4.8	4.47e-06	0.00402	0.37	0.4	Ferritin levels;	chr2:189736026	chr2:189763859~189764456:-
TGCT	cis	rs12745968	0.652	rs11164608	ENSG00000223787.2	RP4-593M8.1	-4.8	4.47e-06	0.00402	-0.52	-0.4	Bipolar disorder and schizophrenia;	chr1:92481870	chr1:92580476~92580821:-
TGCT	cis	rs875971	0.66	rs12698534	ENSG00000237310.1	GS1-124K5.4	4.8	4.48e-06	0.00402	0.45	0.4	Aortic root size;	chr7:66521858	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.66	rs62465434	ENSG00000237310.1	GS1-124K5.4	4.8	4.48e-06	0.00402	0.45	0.4	Aortic root size;	chr7:66540165	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.66	rs13224319	ENSG00000237310.1	GS1-124K5.4	4.8	4.48e-06	0.00402	0.45	0.4	Aortic root size;	chr7:66542376	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.66	rs801217	ENSG00000237310.1	GS1-124K5.4	-4.8	4.48e-06	0.00402	-0.45	-0.4	Aortic root size;	chr7:66545590	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.638	rs801216	ENSG00000237310.1	GS1-124K5.4	-4.8	4.48e-06	0.00402	-0.45	-0.4	Aortic root size;	chr7:66546680	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.66	rs801211	ENSG00000237310.1	GS1-124K5.4	-4.8	4.48e-06	0.00402	-0.45	-0.4	Aortic root size;	chr7:66550702	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.638	rs801205	ENSG00000237310.1	GS1-124K5.4	-4.8	4.48e-06	0.00402	-0.45	-0.4	Aortic root size;	chr7:66557157	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.617	rs810400	ENSG00000237310.1	GS1-124K5.4	-4.8	4.48e-06	0.00402	-0.45	-0.4	Aortic root size;	chr7:66557902	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.638	rs3898855	ENSG00000237310.1	GS1-124K5.4	-4.8	4.48e-06	0.00402	-0.45	-0.4	Aortic root size;	chr7:66571411	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.638	rs10278816	ENSG00000237310.1	GS1-124K5.4	-4.8	4.48e-06	0.00402	-0.45	-0.4	Aortic root size;	chr7:66572000	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.66	rs10281080	ENSG00000237310.1	GS1-124K5.4	-4.8	4.48e-06	0.00402	-0.45	-0.4	Aortic root size;	chr7:66577454	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.66	rs10950044	ENSG00000237310.1	GS1-124K5.4	-4.8	4.48e-06	0.00402	-0.45	-0.4	Aortic root size;	chr7:66577989	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.638	rs10249404	ENSG00000237310.1	GS1-124K5.4	-4.8	4.48e-06	0.00402	-0.45	-0.4	Aortic root size;	chr7:66581737	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.619	rs10278371	ENSG00000237310.1	GS1-124K5.4	-4.8	4.48e-06	0.00402	-0.45	-0.4	Aortic root size;	chr7:66586553	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.522	rs1968127	ENSG00000237310.1	GS1-124K5.4	-4.8	4.48e-06	0.00402	-0.45	-0.4	Aortic root size;	chr7:66591816	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.66	rs79009421	ENSG00000237310.1	GS1-124K5.4	-4.8	4.48e-06	0.00402	-0.45	-0.4	Aortic root size;	chr7:66603522	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.66	rs7807930	ENSG00000237310.1	GS1-124K5.4	-4.8	4.48e-06	0.00402	-0.45	-0.4	Aortic root size;	chr7:66622178	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.66	rs7807944	ENSG00000237310.1	GS1-124K5.4	-4.8	4.48e-06	0.00402	-0.45	-0.4	Aortic root size;	chr7:66622208	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.638	rs35986979	ENSG00000237310.1	GS1-124K5.4	-4.8	4.48e-06	0.00402	-0.45	-0.4	Aortic root size;	chr7:66624003	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.642	rs35526611	ENSG00000237310.1	GS1-124K5.4	-4.8	4.48e-06	0.00402	-0.45	-0.4	Aortic root size;	chr7:66629021	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.66	rs3764903	ENSG00000237310.1	GS1-124K5.4	-4.8	4.48e-06	0.00402	-0.45	-0.4	Aortic root size;	chr7:66633495	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.66	rs1860470	ENSG00000237310.1	GS1-124K5.4	-4.8	4.48e-06	0.00402	-0.45	-0.4	Aortic root size;	chr7:66638707	chr7:66493706~66495474:+
TGCT	cis	rs8113308	0.515	rs113082012	ENSG00000269235.1	ZNF350-AS1	4.8	4.48e-06	0.00403	0.88	0.4	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51960980	chr19:51949134~51981367:+
TGCT	cis	rs16852403	0.519	rs421767	ENSG00000224687.1	RASAL2-AS1	-4.8	4.49e-06	0.00403	-0.52	-0.4	Childhood ear infection;	chr1:178127787	chr1:178091508~178093984:-
TGCT	cis	rs5742933	0.857	rs893784	ENSG00000273240.1	RP11-455J20.3	-4.8	4.49e-06	0.00403	-0.37	-0.4	Ferritin levels;	chr2:189671557	chr2:189763859~189764456:-
TGCT	cis	rs904251	0.523	rs2797799	ENSG00000204110.6	RP1-153P14.8	-4.8	4.49e-06	0.00403	-0.4	-0.4	Cognitive performance;	chr6:37515844	chr6:37507348~37535616:+
TGCT	cis	rs6700559	0.74	rs10919997	ENSG00000260088.1	RP11-92G12.3	4.8	4.5e-06	0.00404	0.48	0.4	Coronary artery disease;	chr1:200677522	chr1:200669507~200694250:+
TGCT	cis	rs6700559	0.74	rs4437908	ENSG00000260088.1	RP11-92G12.3	4.8	4.5e-06	0.00404	0.48	0.4	Coronary artery disease;	chr1:200679311	chr1:200669507~200694250:+
TGCT	cis	rs6700559	0.74	rs4072551	ENSG00000260088.1	RP11-92G12.3	4.8	4.5e-06	0.00404	0.48	0.4	Coronary artery disease;	chr1:200679993	chr1:200669507~200694250:+
TGCT	cis	rs6700559	0.74	rs4072554	ENSG00000260088.1	RP11-92G12.3	4.8	4.5e-06	0.00404	0.48	0.4	Coronary artery disease;	chr1:200680238	chr1:200669507~200694250:+
TGCT	cis	rs6700559	0.74	rs10919999	ENSG00000260088.1	RP11-92G12.3	4.8	4.5e-06	0.00404	0.48	0.4	Coronary artery disease;	chr1:200680631	chr1:200669507~200694250:+
TGCT	cis	rs73086581	0.838	rs73088426	ENSG00000229539.1	RP11-119B16.2	4.8	4.5e-06	0.00404	0.59	0.4	Response to antidepressants in depression;	chr20:4022636	chr20:3888239~3888868:-
TGCT	cis	rs4925386	0.84	rs6143024	ENSG00000273619.1	RP5-908M14.9	-4.8	4.5e-06	0.00404	-0.5	-0.4	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62339173	chr20:62386303~62386970:-
TGCT	cis	rs9326248	0.53	rs7121347	ENSG00000254851.1	RP11-109L13.1	-4.8	4.5e-06	0.00404	-0.68	-0.4	Blood protein levels;	chr11:116996493	chr11:117135528~117138582:+
TGCT	cis	rs16975963	0.644	rs73031326	ENSG00000276846.1	CTD-3220F14.3	-4.8	4.51e-06	0.00404	-0.38	-0.4	Longevity;	chr19:37552120	chr19:37314868~37315620:-
TGCT	cis	rs10246939	0.543	rs11765106	ENSG00000228775.6	WEE2-AS1	4.8	4.51e-06	0.00405	0.35	0.4	Bitter taste perception;	chr7:141902676	chr7:141704338~141738346:-
TGCT	cis	rs10246939	0.543	rs7786202	ENSG00000228775.6	WEE2-AS1	4.8	4.51e-06	0.00405	0.35	0.4	Bitter taste perception;	chr7:141906099	chr7:141704338~141738346:-
TGCT	cis	rs10246939	0.543	rs7802271	ENSG00000228775.6	WEE2-AS1	4.8	4.51e-06	0.00405	0.35	0.4	Bitter taste perception;	chr7:141909624	chr7:141704338~141738346:-
TGCT	cis	rs10246939	0.52	rs7782886	ENSG00000228775.6	WEE2-AS1	4.8	4.51e-06	0.00405	0.35	0.4	Bitter taste perception;	chr7:141909958	chr7:141704338~141738346:-
TGCT	cis	rs10246939	0.543	rs994808	ENSG00000228775.6	WEE2-AS1	4.8	4.51e-06	0.00405	0.35	0.4	Bitter taste perception;	chr7:141911091	chr7:141704338~141738346:-
TGCT	cis	rs10246939	0.543	rs7808421	ENSG00000228775.6	WEE2-AS1	4.8	4.51e-06	0.00405	0.35	0.4	Bitter taste perception;	chr7:141911592	chr7:141704338~141738346:-
TGCT	cis	rs10246939	0.543	rs7789123	ENSG00000228775.6	WEE2-AS1	4.8	4.51e-06	0.00405	0.35	0.4	Bitter taste perception;	chr7:141911699	chr7:141704338~141738346:-
TGCT	cis	rs10246939	0.543	rs11767119	ENSG00000228775.6	WEE2-AS1	4.8	4.51e-06	0.00405	0.35	0.4	Bitter taste perception;	chr7:141912316	chr7:141704338~141738346:-
TGCT	cis	rs10246939	0.543	rs11767947	ENSG00000228775.6	WEE2-AS1	4.8	4.51e-06	0.00405	0.35	0.4	Bitter taste perception;	chr7:141912821	chr7:141704338~141738346:-
TGCT	cis	rs875971	0.862	rs4368860	ENSG00000232559.3	GS1-124K5.12	-4.8	4.51e-06	0.00405	-0.37	-0.4	Aortic root size;	chr7:66143495	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs1983372	ENSG00000232559.3	GS1-124K5.12	-4.8	4.51e-06	0.00405	-0.37	-0.4	Aortic root size;	chr7:66146364	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs908915	ENSG00000232559.3	GS1-124K5.12	-4.8	4.51e-06	0.00405	-0.37	-0.4	Aortic root size;	chr7:66149664	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs7809814	ENSG00000232559.3	GS1-124K5.12	-4.8	4.51e-06	0.00405	-0.37	-0.4	Aortic root size;	chr7:66150410	chr7:66554588~66576923:-
TGCT	cis	rs4660456	0.913	rs12040422	ENSG00000237899.1	RP4-739H11.3	4.8	4.52e-06	0.00405	0.53	0.4	Platelet count;	chr1:40669239	chr1:40669089~40687588:-
TGCT	cis	rs4835473	0.932	rs4615131	ENSG00000251600.4	RP11-673E1.1	-4.8	4.52e-06	0.00405	-0.39	-0.4	Immature fraction of reticulocytes;	chr4:143740295	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs4499657	ENSG00000251600.4	RP11-673E1.1	-4.8	4.52e-06	0.00405	-0.39	-0.4	Immature fraction of reticulocytes;	chr4:143740316	chr4:143912331~143982454:+
TGCT	cis	rs11157436	0.958	rs3811277	ENSG00000211813.2	TRAV34	4.8	4.52e-06	0.00406	0.42	0.4	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22190419	chr14:22207522~22208129:+
TGCT	cis	rs786425	0.509	rs56176939	ENSG00000247373.3	RP11-486O12.2	4.8	4.52e-06	0.00406	0.47	0.4	Pubertal anthropometrics;	chr12:123700282	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.833	rs2222061	ENSG00000247373.3	RP11-486O12.2	4.8	4.52e-06	0.00406	0.47	0.4	Pubertal anthropometrics;	chr12:123710382	chr12:123575891~123585115:-
TGCT	cis	rs651907	0.557	rs2288272	ENSG00000244119.1	PDCL3P4	4.8	4.54e-06	0.00407	0.29	0.4	Colorectal cancer;	chr3:101659632	chr3:101712472~101713191:+
TGCT	cis	rs9425766	0.679	rs2143114	ENSG00000227373.4	RP11-160H22.5	4.8	4.54e-06	0.00407	0.42	0.4	Life satisfaction;	chr1:174192292	chr1:174115300~174160004:-
TGCT	cis	rs12745968	0.652	rs942753	ENSG00000223787.2	RP4-593M8.1	-4.8	4.54e-06	0.00407	-0.52	-0.4	Bipolar disorder and schizophrenia;	chr1:92476909	chr1:92580476~92580821:-
TGCT	cis	rs6452524	0.772	rs13156510	ENSG00000249664.1	CTD-2227C6.2	-4.8	4.54e-06	0.00407	-0.42	-0.4	Hypertension (SNP x SNP interaction);	chr5:83208668	chr5:83012285~83013109:-
TGCT	cis	rs6452524	0.836	rs10514249	ENSG00000249664.1	CTD-2227C6.2	-4.8	4.54e-06	0.00407	-0.42	-0.4	Hypertension (SNP x SNP interaction);	chr5:83209037	chr5:83012285~83013109:-
TGCT	cis	rs321358	0.895	rs7110930	ENSG00000271584.1	RP11-89C3.4	-4.8	4.54e-06	0.00407	-0.55	-0.4	Body mass index;	chr11:111088556	chr11:111091932~111097357:-
TGCT	cis	rs6504663	0.596	rs7208018	ENSG00000275897.1	RP11-94C24.13	-4.8	4.56e-06	0.00408	-0.55	-0.4	Visceral fat;	chr17:50480502	chr17:50475819~50478391:+
TGCT	cis	rs4985726	0.702	rs12603708	ENSG00000266651.1	RP11-138I1.3	-4.8	4.56e-06	0.00409	-0.46	-0.4	Non-albumin protein levels;	chr17:16943799	chr17:16440479~16440952:-
TGCT	cis	rs507080	0.769	rs745663	ENSG00000255422.1	AP002954.4	-4.8	4.56e-06	0.00409	-0.45	-0.4	Serum metabolite levels;	chr11:118658886	chr11:118704607~118750263:+
TGCT	cis	rs1799949	0.602	rs8176235	ENSG00000198496.9	NBR2	-4.79	4.58e-06	0.0041	-0.64	-0.4	Menopause (age at onset);	chr17:43067543	chr17:43125610~43153671:+
TGCT	cis	rs875971	0.651	rs2420596	ENSG00000237310.1	GS1-124K5.4	4.79	4.58e-06	0.0041	0.42	0.4	Aortic root size;	chr7:66450996	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.52	rs2420597	ENSG00000237310.1	GS1-124K5.4	4.79	4.58e-06	0.0041	0.42	0.4	Aortic root size;	chr7:66450999	chr7:66493706~66495474:+
TGCT	cis	rs16975963	0.644	rs73031309	ENSG00000276846.1	CTD-3220F14.3	-4.79	4.58e-06	0.0041	-0.38	-0.4	Longevity;	chr19:37541082	chr19:37314868~37315620:-
TGCT	cis	rs16975963	0.644	rs11665759	ENSG00000276846.1	CTD-3220F14.3	-4.79	4.58e-06	0.0041	-0.38	-0.4	Longevity;	chr19:37548773	chr19:37314868~37315620:-
TGCT	cis	rs16975963	0.644	rs73031321	ENSG00000276846.1	CTD-3220F14.3	-4.79	4.58e-06	0.0041	-0.38	-0.4	Longevity;	chr19:37549956	chr19:37314868~37315620:-
TGCT	cis	rs16975963	0.644	rs73031322	ENSG00000276846.1	CTD-3220F14.3	-4.79	4.58e-06	0.0041	-0.38	-0.4	Longevity;	chr19:37549977	chr19:37314868~37315620:-
TGCT	cis	rs16975963	0.644	rs111694872	ENSG00000276846.1	CTD-3220F14.3	-4.79	4.58e-06	0.0041	-0.38	-0.4	Longevity;	chr19:37555429	chr19:37314868~37315620:-
TGCT	cis	rs16975963	0.644	rs73033117	ENSG00000276846.1	CTD-3220F14.3	-4.79	4.58e-06	0.0041	-0.38	-0.4	Longevity;	chr19:37582245	chr19:37314868~37315620:-
TGCT	cis	rs16975963	0.644	rs11083427	ENSG00000276846.1	CTD-3220F14.3	-4.79	4.58e-06	0.0041	-0.38	-0.4	Longevity;	chr19:37583251	chr19:37314868~37315620:-
TGCT	cis	rs16975963	0.644	rs73033129	ENSG00000276846.1	CTD-3220F14.3	-4.79	4.58e-06	0.0041	-0.38	-0.4	Longevity;	chr19:37589634	chr19:37314868~37315620:-
TGCT	cis	rs16975963	0.644	rs12162238	ENSG00000276846.1	CTD-3220F14.3	-4.79	4.58e-06	0.0041	-0.38	-0.4	Longevity;	chr19:37591484	chr19:37314868~37315620:-
TGCT	cis	rs16975963	0.644	rs11083428	ENSG00000276846.1	CTD-3220F14.3	-4.79	4.58e-06	0.0041	-0.38	-0.4	Longevity;	chr19:37593066	chr19:37314868~37315620:-
TGCT	cis	rs4925386	1	rs6089351	ENSG00000273619.1	RP5-908M14.9	4.79	4.58e-06	0.0041	0.44	0.4	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62341097	chr20:62386303~62386970:-
TGCT	cis	rs10256972	0.577	rs6962809	ENSG00000226291.1	AC091729.8	-4.79	4.6e-06	0.00412	-0.41	-0.4	Endometriosis;Longevity;	chr7:1169253	chr7:1080863~1082178:+
TGCT	cis	rs7829975	0.777	rs560544	ENSG00000173295.6	FAM86B3P	-4.79	4.61e-06	0.00412	-0.48	-0.4	Mood instability;	chr8:8779919	chr8:8228595~8244865:+
TGCT	cis	rs11231017	0.507	rs10792346	ENSG00000254454.2	RCC2P6	4.79	4.61e-06	0.00413	0.27	0.4	HIV-1 viral setpoint;	chr11:62372597	chr11:62371146~62373168:+
TGCT	cis	rs875971	0.66	rs6460308	ENSG00000237310.1	GS1-124K5.4	-4.79	4.61e-06	0.00413	-0.45	-0.4	Aortic root size;	chr7:66619753	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs6460302	ENSG00000237310.1	GS1-124K5.4	4.79	4.62e-06	0.00413	0.44	0.4	Aortic root size;	chr7:66495270	chr7:66493706~66495474:+
TGCT	cis	rs6600671	1	rs12145080	ENSG00000275131.1	CH17-472G23.4	4.79	4.62e-06	0.00413	0.25	0.4	Hip geometry;	chr1:121443673	chr1:120489625~120579190:-
TGCT	cis	rs2709736	0.622	rs204598	ENSG00000232790.2	LINC01162	-4.79	4.62e-06	0.00414	-0.31	-0.4	Bipolar I disorder;	chr7:20875125	chr7:20835431~21023148:+
TGCT	cis	rs2709736	0.59	rs2709718	ENSG00000232790.2	LINC01162	4.79	4.63e-06	0.00414	0.31	0.4	Bipolar I disorder;	chr7:20878949	chr7:20835431~21023148:+
TGCT	cis	rs10504229	0.683	rs17194529	ENSG00000253301.4	RP11-513O17.2	4.79	4.63e-06	0.00414	0.6	0.4	Developmental language disorder (linguistic errors);	chr8:57193088	chr8:57142689~57240298:+
TGCT	cis	rs877819	0.552	rs2620878	ENSG00000228403.1	RP11-563N6.6	-4.79	4.63e-06	0.00414	-0.41	-0.4	Systemic lupus erythematosus;	chr10:48879727	chr10:48878022~48878649:+
TGCT	cis	rs1823913	0.895	rs10931491	ENSG00000280083.1	RP11-317J9.1	4.79	4.65e-06	0.00415	0.34	0.4	Obesity-related traits;	chr2:191256087	chr2:191154118~191156070:-
TGCT	cis	rs1823913	1	rs11681777	ENSG00000280083.1	RP11-317J9.1	4.79	4.65e-06	0.00415	0.34	0.4	Obesity-related traits;	chr2:191256741	chr2:191154118~191156070:-
TGCT	cis	rs7714584	0.793	rs35707106	ENSG00000197083.10	ZNF300P1	4.79	4.65e-06	0.00416	0.65	0.4	Crohn's disease;	chr5:150845815	chr5:150930645~150946289:-
TGCT	cis	rs1707322	0.752	rs4660313	ENSG00000280836.1	AL355480.1	4.79	4.65e-06	0.00416	0.53	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45581219~45581321:-
TGCT	cis	rs847851	0.617	rs9394267	ENSG00000186328.4	RP11-140K17.2	-4.79	4.65e-06	0.00416	-0.57	-0.4	Colonoscopy-negative controls vs population controls;	chr6:34992983	chr6:34715613~34715940:+
TGCT	cis	rs847851	0.617	rs3807051	ENSG00000186328.4	RP11-140K17.2	4.79	4.65e-06	0.00416	0.57	0.4	Colonoscopy-negative controls vs population controls;	chr6:34954662	chr6:34715613~34715940:+
TGCT	cis	rs12143943	0.738	rs11240750	ENSG00000176754.11	LINC00303	4.79	4.65e-06	0.00416	0.35	0.4	Cognitive performance;	chr1:204490658	chr1:204032447~204041265:-
TGCT	cis	rs5760092	0.842	rs5760103	ENSG00000225282.1	AP000350.6	4.79	4.66e-06	0.00416	0.57	0.4	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23906594	chr22:23926900~23929574:+
TGCT	cis	rs875971	0.706	rs1643374	ENSG00000236529.1	RP13-254B10.1	4.79	4.66e-06	0.00416	0.3	0.4	Aortic root size;	chr7:66407695	chr7:65840212~65840596:+
TGCT	cis	rs7208859	0.673	rs216409	ENSG00000280069.1	CTD-2349P21.3	4.79	4.66e-06	0.00417	0.52	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30738182~30740275:+
TGCT	cis	rs9584850	0.834	rs12869627	ENSG00000231194.1	FARP1-AS1	4.79	4.67e-06	0.00417	0.53	0.4	Neuroticism;	chr13:98468198	chr13:98435405~98435840:-
TGCT	cis	rs7208859	0.573	rs216443	ENSG00000266490.1	CTD-2349P21.9	4.79	4.67e-06	0.00417	0.45	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30792372~30792833:+
TGCT	cis	rs1555322	0.53	rs6060341	ENSG00000126005.14	MMP24-AS1	4.79	4.68e-06	0.00418	0.48	0.4	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35216462~35278131:-
TGCT	cis	rs9326248	0.53	rs17120139	ENSG00000254851.1	RP11-109L13.1	4.79	4.68e-06	0.00418	0.69	0.4	Blood protein levels;	chr11:116903485	chr11:117135528~117138582:+
TGCT	cis	rs1618992	0.703	rs1910561	ENSG00000265994.1	RP11-510D21.1	4.79	4.68e-06	0.00418	0.4	0.4	Gut microbiome composition (summer and winter);	chr18:28589700	chr18:28785068~28789260:+
TGCT	cis	rs801193	1	rs17566701	ENSG00000237310.1	GS1-124K5.4	4.79	4.68e-06	0.00418	0.45	0.4	Aortic root size;	chr7:66728196	chr7:66493706~66495474:+
TGCT	cis	rs9425766	0.679	rs12085290	ENSG00000227373.4	RP11-160H22.5	-4.79	4.69e-06	0.00418	-0.42	-0.4	Life satisfaction;	chr1:174124699	chr1:174115300~174160004:-
TGCT	cis	rs1023500	0.573	rs133370	ENSG00000270083.1	RP1-257I20.14	4.79	4.69e-06	0.00418	0.4	0.4	Schizophrenia;	chr22:42069256	chr22:42089630~42090028:-
TGCT	cis	rs1023500	0.551	rs133371	ENSG00000270083.1	RP1-257I20.14	4.79	4.69e-06	0.00418	0.4	0.4	Schizophrenia;	chr22:42069570	chr22:42089630~42090028:-
TGCT	cis	rs1023500	0.573	rs133374	ENSG00000270083.1	RP1-257I20.14	4.79	4.69e-06	0.00418	0.4	0.4	Schizophrenia;	chr22:42069937	chr22:42089630~42090028:-
TGCT	cis	rs7208859	0.623	rs8082537	ENSG00000263531.1	RP13-753N3.1	4.79	4.69e-06	0.00418	0.71	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30863921~30864940:-
TGCT	cis	rs7221109	0.56	rs758630	ENSG00000278834.1	RP11-458J1.1	-4.79	4.7e-06	0.00419	-0.31	-0.4	Type 1 diabetes;	chr17:40713053	chr17:40648300~40649718:+
TGCT	cis	rs7829975	0.572	rs28446104	ENSG00000173295.6	FAM86B3P	-4.79	4.7e-06	0.00419	-0.47	-0.4	Mood instability;	chr8:8938391	chr8:8228595~8244865:+
TGCT	cis	rs1799949	0.683	rs55737636	ENSG00000198496.9	NBR2	-4.79	4.71e-06	0.00419	-0.55	-0.4	Menopause (age at onset);	chr17:43112722	chr17:43125610~43153671:+
TGCT	cis	rs4423214	0.879	rs10898144	ENSG00000254682.1	RP11-660L16.2	-4.79	4.71e-06	0.0042	-0.57	-0.39	Vitamin D levels;	chr11:71440494	chr11:71448674~71452157:+
TGCT	cis	rs34217772	0.771	rs61992388	ENSG00000258536.1	RP11-1053O12.1	4.79	4.72e-06	0.0042	0.38	0.39	Myopia;	chr14:41740677	chr14:41742639~41742963:+
TGCT	cis	rs67311347	0.955	rs60554147	ENSG00000223797.4	ENTPD3-AS1	4.79	4.73e-06	0.00421	0.41	0.39	Renal cell carcinoma;	chr3:40431012	chr3:40313802~40453329:-
TGCT	cis	rs8059260	0.604	rs741176	ENSG00000274038.1	RP11-66H6.4	4.79	4.74e-06	0.00422	0.58	0.39	Alcohol consumption over the past year;	chr16:11051953	chr16:11056556~11057034:+
TGCT	cis	rs4423214	0.84	rs1792229	ENSG00000254682.1	RP11-660L16.2	-4.79	4.75e-06	0.00422	-0.6	-0.39	Vitamin D levels;	chr11:71468349	chr11:71448674~71452157:+
TGCT	cis	rs8059260	0.736	rs8049278	ENSG00000274038.1	RP11-66H6.4	-4.79	4.75e-06	0.00422	-0.56	-0.39	Alcohol consumption over the past year;	chr16:10968766	chr16:11056556~11057034:+
TGCT	cis	rs2980439	0.818	rs2945249	ENSG00000253981.4	ALG1L13P	4.79	4.75e-06	0.00423	0.41	0.39	Neuroticism;	chr8:8237204	chr8:8236003~8244667:-
TGCT	cis	rs6600671	1	rs11249350	ENSG00000275131.1	CH17-472G23.4	-4.79	4.76e-06	0.00423	-0.25	-0.39	Hip geometry;	chr1:121436587	chr1:120489625~120579190:-
TGCT	cis	rs6600671	1	rs10903161	ENSG00000275131.1	CH17-472G23.4	-4.79	4.76e-06	0.00423	-0.25	-0.39	Hip geometry;	chr1:121436882	chr1:120489625~120579190:-
TGCT	cis	rs6600671	1	rs10903159	ENSG00000275131.1	CH17-472G23.4	-4.79	4.76e-06	0.00423	-0.25	-0.39	Hip geometry;	chr1:121440138	chr1:120489625~120579190:-
TGCT	cis	rs7826238	0.653	rs2979202	ENSG00000173295.6	FAM86B3P	4.79	4.76e-06	0.00423	0.45	0.39	Systolic blood pressure;	chr8:8486617	chr8:8228595~8244865:+
TGCT	cis	rs853679	0.55	rs1233704	ENSG00000219392.1	RP1-265C24.5	4.79	4.76e-06	0.00423	0.53	0.39	Depression;	chr6:28199145	chr6:28115628~28116551:+
TGCT	cis	rs34217772	0.739	rs12432485	ENSG00000258536.1	RP11-1053O12.1	4.79	4.77e-06	0.00424	0.32	0.39	Myopia;	chr14:41838612	chr14:41742639~41742963:+
TGCT	cis	rs8062405	0.824	rs7191618	ENSG00000259982.1	CDC37P1	4.79	4.77e-06	0.00424	0.5	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.754	rs3859172	ENSG00000259982.1	CDC37P1	4.79	4.77e-06	0.00424	0.5	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28700294~28701540:-
TGCT	cis	rs4835473	0.932	rs13107719	ENSG00000251600.4	RP11-673E1.1	-4.78	4.77e-06	0.00424	-0.42	-0.39	Immature fraction of reticulocytes;	chr4:143752034	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs2323194	ENSG00000251600.4	RP11-673E1.1	-4.78	4.77e-06	0.00424	-0.42	-0.39	Immature fraction of reticulocytes;	chr4:143752879	chr4:143912331~143982454:+
TGCT	cis	rs11168618	0.509	rs2705127	ENSG00000240399.1	RP1-228P16.1	-4.78	4.77e-06	0.00425	-0.39	-0.39	Adiponectin levels;	chr12:48489229	chr12:48054813~48055591:-
TGCT	cis	rs2665103	0.687	rs11633000	ENSG00000278603.1	RP13-608F4.5	4.78	4.78e-06	0.00425	0.53	0.39	Intelligence (multi-trait analysis);	chr15:82269320	chr15:82472203~82472426:+
TGCT	cis	rs9987353	0.589	rs1053036	ENSG00000173295.6	FAM86B3P	-4.78	4.79e-06	0.00426	-0.42	-0.39	Recombination measurement;	chr8:9202567	chr8:8228595~8244865:+
TGCT	cis	rs10246939	0.543	rs994809	ENSG00000228775.6	WEE2-AS1	4.78	4.79e-06	0.00426	0.36	0.39	Bitter taste perception;	chr7:141911485	chr7:141704338~141738346:-
TGCT	cis	rs2188561	0.697	rs6956243	ENSG00000241764.3	AC002467.7	4.78	4.79e-06	0.00426	0.37	0.39	Alcohol consumption;	chr7:107748466	chr7:107742817~107744581:-
TGCT	cis	rs2188561	0.666	rs13231387	ENSG00000241764.3	AC002467.7	4.78	4.79e-06	0.00426	0.37	0.39	Alcohol consumption;	chr7:107749534	chr7:107742817~107744581:-
TGCT	cis	rs2188561	0.615	rs13226711	ENSG00000241764.3	AC002467.7	4.78	4.79e-06	0.00426	0.37	0.39	Alcohol consumption;	chr7:107754897	chr7:107742817~107744581:-
TGCT	cis	rs2188561	0.697	rs12705421	ENSG00000241764.3	AC002467.7	4.78	4.79e-06	0.00426	0.37	0.39	Alcohol consumption;	chr7:107760984	chr7:107742817~107744581:-
TGCT	cis	rs2188561	0.697	rs12539555	ENSG00000241764.3	AC002467.7	4.78	4.79e-06	0.00426	0.37	0.39	Alcohol consumption;	chr7:107764028	chr7:107742817~107744581:-
TGCT	cis	rs12439619	0.846	rs62012056	ENSG00000255769.6	GOLGA2P10	-4.78	4.79e-06	0.00426	-0.47	-0.39	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472993~82513950:-
TGCT	cis	rs761746	0.705	rs10154390	ENSG00000236132.1	CTA-440B3.1	-4.78	4.79e-06	0.00426	-0.49	-0.39	Intelligence;	chr22:31655103	chr22:31816379~31817491:-
TGCT	cis	rs853679	0.545	rs35949109	ENSG00000219891.2	ZSCAN12P1	4.78	4.81e-06	0.00427	0.64	0.39	Depression;	chr6:28058148	chr6:28091154~28093664:+
TGCT	cis	rs7208859	0.573	rs8078182	ENSG00000263531.1	RP13-753N3.1	4.78	4.82e-06	0.00428	0.73	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30863921~30864940:-
TGCT	cis	rs728616	0.614	rs35469841	ENSG00000230091.5	TMEM254-AS1	4.78	4.82e-06	0.00428	0.7	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80034436	chr10:80046860~80078912:-
TGCT	cis	rs847851	0.617	rs11970238	ENSG00000186328.4	RP11-140K17.2	4.78	4.83e-06	0.00429	0.58	0.39	Colonoscopy-negative controls vs population controls;	chr6:34977366	chr6:34715613~34715940:+
TGCT	cis	rs847851	0.617	rs9394265	ENSG00000186328.4	RP11-140K17.2	4.78	4.83e-06	0.00429	0.58	0.39	Colonoscopy-negative controls vs population controls;	chr6:34982497	chr6:34715613~34715940:+
TGCT	cis	rs728616	0.614	rs55720611	ENSG00000230091.5	TMEM254-AS1	4.78	4.83e-06	0.00429	0.67	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80030543	chr10:80046860~80078912:-
TGCT	cis	rs10504229	0.775	rs17805110	ENSG00000253301.4	RP11-513O17.2	-4.78	4.83e-06	0.00429	-0.54	-0.39	Developmental language disorder (linguistic errors);	chr8:57248880	chr8:57142689~57240298:+
TGCT	cis	rs10256972	0.577	rs2949179	ENSG00000226291.1	AC091729.8	-4.78	4.83e-06	0.00429	-0.42	-0.39	Endometriosis;Longevity;	chr7:1170249	chr7:1080863~1082178:+
TGCT	cis	rs10256972	0.504	rs2949178	ENSG00000226291.1	AC091729.8	-4.78	4.83e-06	0.00429	-0.42	-0.39	Endometriosis;Longevity;	chr7:1170289	chr7:1080863~1082178:+
TGCT	cis	rs7221109	0.533	rs7210983	ENSG00000278834.1	RP11-458J1.1	4.78	4.84e-06	0.0043	0.29	0.39	Type 1 diabetes;	chr17:40660862	chr17:40648300~40649718:+
TGCT	cis	rs4835473	0.932	rs5016160	ENSG00000251600.4	RP11-673E1.1	4.78	4.84e-06	0.0043	0.4	0.39	Immature fraction of reticulocytes;	chr4:143738305	chr4:143912331~143982454:+
TGCT	cis	rs884366	1	rs12191774	ENSG00000203799.9	CCDC162P	-4.78	4.85e-06	0.0043	-0.42	-0.39	HDL cholesterol;HDL cholesterol levels;	chr6:109327150	chr6:109285485~109355063:+
TGCT	cis	rs673078	0.607	rs882927	ENSG00000275759.1	RP11-131L12.3	-4.78	4.85e-06	0.00431	-0.73	-0.39	Glucose homeostasis traits;	chr12:118406737	chr12:118428281~118428870:+
TGCT	cis	rs9326248	0.53	rs2000614	ENSG00000254851.1	RP11-109L13.1	-4.78	4.86e-06	0.00431	-0.78	-0.39	Blood protein levels;	chr11:117045026	chr11:117135528~117138582:+
TGCT	cis	rs9326248	0.53	rs2000616	ENSG00000254851.1	RP11-109L13.1	-4.78	4.86e-06	0.00431	-0.78	-0.39	Blood protein levels;	chr11:117045813	chr11:117135528~117138582:+
TGCT	cis	rs9326248	0.53	rs10750100	ENSG00000254851.1	RP11-109L13.1	-4.78	4.86e-06	0.00431	-0.78	-0.39	Blood protein levels;	chr11:117046528	chr11:117135528~117138582:+
TGCT	cis	rs1075265	0.692	rs805361	ENSG00000233266.1	HMGB1P31	4.78	4.86e-06	0.00431	0.4	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53938709	chr2:54051334~54051760:+
TGCT	cis	rs7221109	0.677	rs8068721	ENSG00000278834.1	RP11-458J1.1	4.78	4.87e-06	0.00432	0.29	0.39	Type 1 diabetes;	chr17:40657572	chr17:40648300~40649718:+
TGCT	cis	rs7221109	0.625	rs2008469	ENSG00000278834.1	RP11-458J1.1	4.78	4.87e-06	0.00432	0.29	0.39	Type 1 diabetes;	chr17:40660343	chr17:40648300~40649718:+
TGCT	cis	rs7221109	0.677	rs12943859	ENSG00000278834.1	RP11-458J1.1	4.78	4.87e-06	0.00432	0.29	0.39	Type 1 diabetes;	chr17:40661128	chr17:40648300~40649718:+
TGCT	cis	rs7221109	0.633	rs7209735	ENSG00000278834.1	RP11-458J1.1	4.78	4.87e-06	0.00432	0.29	0.39	Type 1 diabetes;	chr17:40662346	chr17:40648300~40649718:+
TGCT	cis	rs8059260	0.668	rs79389789	ENSG00000274038.1	RP11-66H6.4	-4.78	4.88e-06	0.00433	-0.54	-0.39	Alcohol consumption over the past year;	chr16:11015168	chr16:11056556~11057034:+
TGCT	cis	rs11673344	0.668	rs7248693	ENSG00000226686.6	LINC01535	4.78	4.89e-06	0.00433	0.46	0.39	Obesity-related traits;	chr19:36991864	chr19:37251912~37265535:+
TGCT	cis	rs8059260	0.524	rs1122185	ENSG00000274038.1	RP11-66H6.4	-4.78	4.89e-06	0.00433	-0.41	-0.39	Alcohol consumption over the past year;	chr16:11104119	chr16:11056556~11057034:+
TGCT	cis	rs5760092	0.842	rs5751763	ENSG00000225282.1	AP000350.6	4.78	4.9e-06	0.00434	0.56	0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23905606	chr22:23926900~23929574:+
TGCT	cis	rs17826219	0.789	rs4794873	ENSG00000280069.1	CTD-2349P21.3	-4.78	4.9e-06	0.00434	-0.53	-0.39	Body mass index;	chr17:30421334	chr17:30738182~30740275:+
TGCT	cis	rs2976388	0.669	rs1836633	ENSG00000253196.1	RP11-706C16.7	4.78	4.9e-06	0.00434	0.39	0.39	Urinary tract infection frequency;	chr8:142693174	chr8:142763116~142766427:+
TGCT	cis	rs7221109	0.677	rs917593	ENSG00000278834.1	RP11-458J1.1	4.78	4.91e-06	0.00435	0.29	0.39	Type 1 diabetes;	chr17:40660274	chr17:40648300~40649718:+
TGCT	cis	rs875971	0.862	rs6460307	ENSG00000232559.3	GS1-124K5.12	4.78	4.91e-06	0.00435	0.35	0.39	Aortic root size;	chr7:66595884	chr7:66554588~66576923:-
TGCT	cis	rs651907	0.535	rs36060163	ENSG00000244119.1	PDCL3P4	4.78	4.92e-06	0.00435	0.29	0.39	Colorectal cancer;	chr3:101642119	chr3:101712472~101713191:+
TGCT	cis	rs4660214	0.724	rs3931300	ENSG00000182109.6	RP11-69E11.4	-4.78	4.92e-06	0.00435	-0.4	-0.39	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39195175	chr1:39522280~39546187:-
TGCT	cis	rs66823261	0.741	rs7841786	ENSG00000253166.2	RP11-585F1.6	-4.78	4.92e-06	0.00435	-0.51	-0.39	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:241746	chr8:202660~202897:-
TGCT	cis	rs12439619	1	rs12439619	ENSG00000255769.6	GOLGA2P10	-4.78	4.92e-06	0.00436	-0.39	-0.39	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472993~82513950:-
TGCT	cis	rs1891275	0.515	rs1080496	ENSG00000228701.1	TNKS2-AS1	4.78	4.92e-06	0.00436	0.45	0.39	Intelligence (multi-trait analysis);	chr10:91684505	chr10:91782839~91798291:-
TGCT	cis	rs8113308	0.81	rs56029016	ENSG00000269235.1	ZNF350-AS1	4.78	4.93e-06	0.00436	0.64	0.39	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51949209	chr19:51949134~51981367:+
TGCT	cis	rs2948294	0.588	rs12544596	ENSG00000254340.1	RP11-10A14.3	4.78	4.93e-06	0.00436	0.42	0.39	Red cell distribution width;	chr8:8258824	chr8:9141424~9145435:+
TGCT	cis	rs10129255	0.5	rs1974468	ENSG00000223648.3	IGHV3-64	4.78	4.94e-06	0.00437	0.34	0.39	Kawasaki disease;	chr14:106686149	chr14:106643132~106658258:-
TGCT	cis	rs5769707	0.967	rs5770585	ENSG00000235111.1	RP1-29C18.8	-4.78	4.94e-06	0.00437	-0.32	-0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49612657~49615716:-
TGCT	cis	rs2976388	0.609	rs2585145	ENSG00000253196.1	RP11-706C16.7	4.78	4.94e-06	0.00437	0.39	0.39	Urinary tract infection frequency;	chr8:142718039	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.587	rs2717606	ENSG00000253196.1	RP11-706C16.7	4.78	4.94e-06	0.00437	0.39	0.39	Urinary tract infection frequency;	chr8:142718078	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.609	rs2585144	ENSG00000253196.1	RP11-706C16.7	4.78	4.94e-06	0.00437	0.39	0.39	Urinary tract infection frequency;	chr8:142718851	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.609	rs2717603	ENSG00000253196.1	RP11-706C16.7	4.78	4.94e-06	0.00437	0.39	0.39	Urinary tract infection frequency;	chr8:142721775	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.609	rs2572909	ENSG00000253196.1	RP11-706C16.7	4.78	4.94e-06	0.00437	0.39	0.39	Urinary tract infection frequency;	chr8:142725046	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.609	rs2585140	ENSG00000253196.1	RP11-706C16.7	4.78	4.94e-06	0.00437	0.39	0.39	Urinary tract infection frequency;	chr8:142725478	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.609	rs2717601	ENSG00000253196.1	RP11-706C16.7	4.78	4.94e-06	0.00437	0.39	0.39	Urinary tract infection frequency;	chr8:142726506	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.609	rs2257796	ENSG00000253196.1	RP11-706C16.7	4.78	4.94e-06	0.00437	0.39	0.39	Urinary tract infection frequency;	chr8:142727249	chr8:142763116~142766427:+
TGCT	cis	rs875971	0.862	rs11773628	ENSG00000237310.1	GS1-124K5.4	-4.78	4.94e-06	0.00437	-0.42	-0.39	Aortic root size;	chr7:66517644	chr7:66493706~66495474:+
TGCT	cis	rs4323050	0.546	rs13124157	ENSG00000251600.4	RP11-673E1.1	4.78	4.95e-06	0.00438	0.42	0.39	High light scatter reticulocyte percentage of red cells;	chr4:143975741	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs13147170	ENSG00000251600.4	RP11-673E1.1	4.78	4.95e-06	0.00438	0.42	0.39	Immature fraction of reticulocytes;	chr4:143975848	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs13147184	ENSG00000251600.4	RP11-673E1.1	4.78	4.95e-06	0.00438	0.42	0.39	Immature fraction of reticulocytes;	chr4:143975873	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.8	rs13124170	ENSG00000251600.4	RP11-673E1.1	4.78	4.95e-06	0.00438	0.42	0.39	Immature fraction of reticulocytes;	chr4:143975951	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs4054616	ENSG00000251600.4	RP11-673E1.1	4.78	4.96e-06	0.00438	0.41	0.39	Immature fraction of reticulocytes;	chr4:143837472	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs2323325	ENSG00000251600.4	RP11-673E1.1	4.78	4.96e-06	0.00438	0.41	0.39	Immature fraction of reticulocytes;	chr4:143837561	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.8	rs4835330	ENSG00000251600.4	RP11-673E1.1	4.78	4.96e-06	0.00438	0.41	0.39	Immature fraction of reticulocytes;	chr4:143846303	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.736	rs6851661	ENSG00000251600.4	RP11-673E1.1	4.78	4.96e-06	0.00438	0.41	0.39	Immature fraction of reticulocytes;	chr4:143850587	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.864	rs4835343	ENSG00000251600.4	RP11-673E1.1	4.78	4.96e-06	0.00438	0.41	0.39	Immature fraction of reticulocytes;	chr4:143866038	chr4:143912331~143982454:+
TGCT	cis	rs7208859	0.524	rs8065744	ENSG00000266490.1	CTD-2349P21.9	4.78	4.96e-06	0.00438	0.45	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30792372~30792833:+
TGCT	cis	rs17826219	0.706	rs8071236	ENSG00000266490.1	CTD-2349P21.9	4.78	4.96e-06	0.00438	0.45	0.39	Body mass index;	chr17:30772984	chr17:30792372~30792833:+
TGCT	cis	rs17826219	0.636	rs2449770	ENSG00000266490.1	CTD-2349P21.9	4.78	4.96e-06	0.00438	0.45	0.39	Body mass index;	chr17:30774046	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.524	rs59913838	ENSG00000266490.1	CTD-2349P21.9	4.78	4.96e-06	0.00438	0.45	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs56163556	ENSG00000266490.1	CTD-2349P21.9	4.78	4.96e-06	0.00438	0.45	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs8067035	ENSG00000266490.1	CTD-2349P21.9	4.78	4.96e-06	0.00438	0.45	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs8067338	ENSG00000266490.1	CTD-2349P21.9	4.78	4.96e-06	0.00438	0.45	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.573	rs4055105	ENSG00000266490.1	CTD-2349P21.9	4.78	4.96e-06	0.00438	0.45	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30792372~30792833:+
TGCT	cis	rs34779708	0.931	rs11010132	ENSG00000230534.5	RP11-297A16.2	4.78	4.97e-06	0.00439	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35228337	chr10:35098006~35127020:-
TGCT	cis	rs877819	0.583	rs2620881	ENSG00000228403.1	RP11-563N6.6	-4.78	4.97e-06	0.00439	-0.41	-0.39	Systemic lupus erythematosus;	chr10:48875066	chr10:48878022~48878649:+
TGCT	cis	rs801193	0.967	rs2420827	ENSG00000237310.1	GS1-124K5.4	-4.77	4.99e-06	0.0044	-0.45	-0.39	Aortic root size;	chr7:66682114	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.967	rs3800823	ENSG00000237310.1	GS1-124K5.4	-4.77	4.99e-06	0.0044	-0.45	-0.39	Aortic root size;	chr7:66682123	chr7:66493706~66495474:+
TGCT	cis	rs9880211	0.699	rs34804893	ENSG00000239213.4	NCK1-AS1	4.77	4.99e-06	0.0044	0.43	0.39	Height;Body mass index;	chr3:136621128	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.752	rs9820717	ENSG00000239213.4	NCK1-AS1	4.77	4.99e-06	0.0044	0.43	0.39	Height;Body mass index;	chr3:136627771	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.8	rs28390205	ENSG00000239213.4	NCK1-AS1	4.77	4.99e-06	0.0044	0.43	0.39	Height;Body mass index;	chr3:136646008	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.752	rs35428413	ENSG00000239213.4	NCK1-AS1	4.77	4.99e-06	0.0044	0.43	0.39	Height;Body mass index;	chr3:136661856	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.699	rs13433688	ENSG00000239213.4	NCK1-AS1	4.77	4.99e-06	0.0044	0.43	0.39	Height;Body mass index;	chr3:136690329	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.752	rs13062352	ENSG00000239213.4	NCK1-AS1	4.77	4.99e-06	0.0044	0.43	0.39	Height;Body mass index;	chr3:136745920	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.8	rs35100027	ENSG00000239213.4	NCK1-AS1	4.77	4.99e-06	0.0044	0.43	0.39	Height;Body mass index;	chr3:136748719	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.8	rs9819856	ENSG00000239213.4	NCK1-AS1	4.77	4.99e-06	0.0044	0.43	0.39	Height;Body mass index;	chr3:136773307	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.8	rs36109616	ENSG00000239213.4	NCK1-AS1	4.77	4.99e-06	0.0044	0.43	0.39	Height;Body mass index;	chr3:136773561	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.8	rs35198484	ENSG00000239213.4	NCK1-AS1	4.77	4.99e-06	0.0044	0.43	0.39	Height;Body mass index;	chr3:136773795	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.66	rs9289514	ENSG00000239213.4	NCK1-AS1	4.77	4.99e-06	0.0044	0.43	0.39	Height;Body mass index;	chr3:136774361	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.8	rs79876804	ENSG00000239213.4	NCK1-AS1	4.77	4.99e-06	0.0044	0.43	0.39	Height;Body mass index;	chr3:136775308	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.8	rs75901823	ENSG00000239213.4	NCK1-AS1	4.77	4.99e-06	0.0044	0.43	0.39	Height;Body mass index;	chr3:136775309	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.706	rs35716521	ENSG00000239213.4	NCK1-AS1	4.77	4.99e-06	0.0044	0.43	0.39	Height;Body mass index;	chr3:136775828	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.8	rs35210994	ENSG00000239213.4	NCK1-AS1	4.77	4.99e-06	0.0044	0.43	0.39	Height;Body mass index;	chr3:136777294	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.8	rs17365792	ENSG00000239213.4	NCK1-AS1	4.77	4.99e-06	0.0044	0.43	0.39	Height;Body mass index;	chr3:136778550	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.8	rs66509730	ENSG00000239213.4	NCK1-AS1	4.77	4.99e-06	0.0044	0.43	0.39	Height;Body mass index;	chr3:136785416	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.8	rs35422852	ENSG00000239213.4	NCK1-AS1	4.77	4.99e-06	0.0044	0.43	0.39	Height;Body mass index;	chr3:136787073	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.8	rs35880395	ENSG00000239213.4	NCK1-AS1	4.77	4.99e-06	0.0044	0.43	0.39	Height;Body mass index;	chr3:136788248	chr3:136841726~136862054:-
TGCT	cis	rs7208859	0.623	rs1054397	ENSG00000266490.1	CTD-2349P21.9	4.77	4.99e-06	0.00441	0.45	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30792372~30792833:+
TGCT	cis	rs2117029	0.782	rs7969091	ENSG00000258017.1	RP11-386G11.10	-4.77	5e-06	0.00441	-0.47	-0.39	Intelligence (multi-trait analysis);	chr12:49070666	chr12:49127782~49147869:+
TGCT	cis	rs10459221	1	rs10459221	ENSG00000258017.1	RP11-386G11.10	-4.77	5e-06	0.00441	-0.47	-0.39	Bipolar disorder;	chr12:49073211	chr12:49127782~49147869:+
TGCT	cis	rs786425	0.707	rs2250026	ENSG00000247373.3	RP11-486O12.2	4.77	5e-06	0.00441	0.46	0.39	Pubertal anthropometrics;	chr12:123713858	chr12:123575891~123585115:-
TGCT	cis	rs972540	0.889	rs10186616	ENSG00000279220.1	GPR1-AS	4.77	5.02e-06	0.00442	0.41	0.39	Body mass index;	chr2:206352732	chr2:206203376~206266243:+
TGCT	cis	rs972540	0.855	rs62195876	ENSG00000279220.1	GPR1-AS	4.77	5.02e-06	0.00442	0.41	0.39	Body mass index;	chr2:206360643	chr2:206203376~206266243:+
TGCT	cis	rs972540	0.855	rs13419098	ENSG00000279220.1	GPR1-AS	4.77	5.02e-06	0.00442	0.41	0.39	Body mass index;	chr2:206361512	chr2:206203376~206266243:+
TGCT	cis	rs972540	0.768	rs77831502	ENSG00000279220.1	GPR1-AS	4.77	5.02e-06	0.00442	0.41	0.39	Body mass index;	chr2:206364284	chr2:206203376~206266243:+
TGCT	cis	rs972540	0.924	rs10196764	ENSG00000279220.1	GPR1-AS	-4.77	5.02e-06	0.00442	-0.41	-0.39	Body mass index;	chr2:206364804	chr2:206203376~206266243:+
TGCT	cis	rs875971	0.767	rs12668005	ENSG00000232559.3	GS1-124K5.12	4.77	5.02e-06	0.00442	0.36	0.39	Aortic root size;	chr7:66444034	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs11765791	ENSG00000232559.3	GS1-124K5.12	4.77	5.02e-06	0.00442	0.36	0.39	Aortic root size;	chr7:66471587	chr7:66554588~66576923:-
TGCT	cis	rs2236295	0.814	rs1848797	ENSG00000238280.1	RP11-436D10.3	-4.77	5.03e-06	0.00444	-0.51	-0.39	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62793174	chr10:62793562~62805887:-
TGCT	cis	rs17711722	0.51	rs11767457	ENSG00000236529.1	RP13-254B10.1	4.77	5.04e-06	0.00444	0.28	0.39	Calcium levels;	chr7:65825628	chr7:65840212~65840596:+
TGCT	cis	rs6504663	0.558	rs7627	ENSG00000275897.1	RP11-94C24.13	4.77	5.04e-06	0.00444	0.59	0.39	Visceral fat;	chr17:50474793	chr17:50475819~50478391:+
TGCT	cis	rs2581828	0.656	rs1864367	ENSG00000242142.1	SERBP1P3	4.77	5.04e-06	0.00444	0.35	0.39	Crohn's disease;	chr3:53077688	chr3:53064283~53065091:-
TGCT	cis	rs11157436	0.958	rs12432733	ENSG00000211813.2	TRAV34	4.77	5.04e-06	0.00444	0.42	0.39	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22230741	chr14:22207522~22208129:+
TGCT	cis	rs3742264	1	rs9526140	ENSG00000235903.6	CPB2-AS1	-4.77	5.05e-06	0.00444	-0.47	-0.39	Blood protein levels;	chr13:46070017	chr13:46052806~46113332:+
TGCT	cis	rs3742264	1	rs17844080	ENSG00000235903.6	CPB2-AS1	-4.77	5.05e-06	0.00444	-0.47	-0.39	Blood protein levels;	chr13:46070270	chr13:46052806~46113332:+
TGCT	cis	rs3742264	1	rs4942471	ENSG00000235903.6	CPB2-AS1	-4.77	5.05e-06	0.00444	-0.47	-0.39	Blood protein levels;	chr13:46070358	chr13:46052806~46113332:+
TGCT	cis	rs3742264	1	rs2404964	ENSG00000235903.6	CPB2-AS1	-4.77	5.05e-06	0.00444	-0.47	-0.39	Blood protein levels;	chr13:46070739	chr13:46052806~46113332:+
TGCT	cis	rs3742264	1	rs9316181	ENSG00000235903.6	CPB2-AS1	-4.77	5.05e-06	0.00444	-0.47	-0.39	Blood protein levels;	chr13:46071605	chr13:46052806~46113332:+
TGCT	cis	rs7849270	0.801	rs10819474	ENSG00000268707.1	RP11-247A12.7	-4.77	5.05e-06	0.00445	-0.42	-0.39	Blood metabolite ratios;	chr9:129168215	chr9:129170434~129170940:+
TGCT	cis	rs875971	0.522	rs7784623	ENSG00000237310.1	GS1-124K5.4	4.77	5.05e-06	0.00445	0.44	0.39	Aortic root size;	chr7:65930047	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.522	rs34973832	ENSG00000237310.1	GS1-124K5.4	4.77	5.05e-06	0.00445	0.44	0.39	Aortic root size;	chr7:65931217	chr7:66493706~66495474:+
TGCT	cis	rs5997397	0.72	rs132549	ENSG00000226471.5	CTA-292E10.6	4.77	5.06e-06	0.00445	0.41	0.39	Red cell distribution width;	chr22:28922736	chr22:28800683~28848559:+
TGCT	cis	rs11231017	0.507	rs11231058	ENSG00000254454.2	RCC2P6	-4.77	5.06e-06	0.00446	-0.27	-0.39	HIV-1 viral setpoint;	chr11:62371418	chr11:62371146~62373168:+
TGCT	cis	rs17826219	0.706	rs8075357	ENSG00000266490.1	CTD-2349P21.9	4.77	5.06e-06	0.00446	0.45	0.39	Body mass index;	chr17:30730179	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs59447372	ENSG00000266490.1	CTD-2349P21.9	4.77	5.06e-06	0.00446	0.45	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30792372~30792833:+
TGCT	cis	rs17826219	0.706	rs61643715	ENSG00000266490.1	CTD-2349P21.9	4.77	5.06e-06	0.00446	0.45	0.39	Body mass index;	chr17:30730744	chr17:30792372~30792833:+
TGCT	cis	rs17826219	0.636	rs8080829	ENSG00000266490.1	CTD-2349P21.9	4.77	5.06e-06	0.00446	0.45	0.39	Body mass index;	chr17:30731712	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs8079891	ENSG00000266490.1	CTD-2349P21.9	4.77	5.06e-06	0.00446	0.45	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs73267858	ENSG00000266490.1	CTD-2349P21.9	4.77	5.06e-06	0.00446	0.45	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs56018041	ENSG00000266490.1	CTD-2349P21.9	4.77	5.06e-06	0.00446	0.45	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs56095789	ENSG00000266490.1	CTD-2349P21.9	4.77	5.06e-06	0.00446	0.45	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs11656844	ENSG00000266490.1	CTD-2349P21.9	4.77	5.06e-06	0.00446	0.45	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs11652533	ENSG00000266490.1	CTD-2349P21.9	4.77	5.06e-06	0.00446	0.45	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs11652631	ENSG00000266490.1	CTD-2349P21.9	4.77	5.06e-06	0.00446	0.45	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30792372~30792833:+
TGCT	cis	rs875971	0.545	rs1909508	ENSG00000237310.1	GS1-124K5.4	4.77	5.07e-06	0.00446	0.46	0.39	Aortic root size;	chr7:66301366	chr7:66493706~66495474:+
TGCT	cis	rs1577917	0.545	rs9450325	ENSG00000203875.9	SNHG5	4.77	5.07e-06	0.00446	0.53	0.39	Response to antipsychotic treatment;	chr6:85766096	chr6:85660950~85678736:-
TGCT	cis	rs801193	1	rs2055682	ENSG00000237310.1	GS1-124K5.4	4.77	5.07e-06	0.00446	0.44	0.39	Aortic root size;	chr7:66795302	chr7:66493706~66495474:+
TGCT	cis	rs7246967	0.673	rs9676498	ENSG00000269509.1	BNIP3P34	4.77	5.08e-06	0.00446	0.59	0.39	Bronchopulmonary dysplasia;	chr19:22727708	chr19:22773853~22774424:+
TGCT	cis	rs17711722	0.74	rs7809991	ENSG00000237310.1	GS1-124K5.4	4.77	5.09e-06	0.00447	0.44	0.39	Calcium levels;	chr7:65941231	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.522	rs6960048	ENSG00000237310.1	GS1-124K5.4	4.77	5.09e-06	0.00447	0.44	0.39	Aortic root size;	chr7:65943052	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.522	rs10807697	ENSG00000237310.1	GS1-124K5.4	4.77	5.09e-06	0.00447	0.44	0.39	Aortic root size;	chr7:65951183	chr7:66493706~66495474:+
TGCT	cis	rs9462027	0.606	rs2814987	ENSG00000186328.4	RP11-140K17.2	4.77	5.09e-06	0.00447	0.37	0.39	Systemic lupus erythematosus;	chr6:34637368	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs2814991	ENSG00000186328.4	RP11-140K17.2	4.77	5.09e-06	0.00447	0.37	0.39	Systemic lupus erythematosus;	chr6:34647666	chr6:34715613~34715940:+
TGCT	cis	rs34779708	0.966	rs2126984	ENSG00000230534.5	RP11-297A16.2	4.77	5.09e-06	0.00448	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35121363	chr10:35098006~35127020:-
TGCT	cis	rs7714584	0.793	rs11949375	ENSG00000197083.10	ZNF300P1	4.77	5.1e-06	0.00448	0.65	0.39	Crohn's disease;	chr5:150823418	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs76548544	ENSG00000197083.10	ZNF300P1	4.77	5.1e-06	0.00448	0.65	0.39	Crohn's disease;	chr5:150843953	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs73282255	ENSG00000197083.10	ZNF300P1	4.77	5.1e-06	0.00448	0.65	0.39	Crohn's disease;	chr5:150844085	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs80075680	ENSG00000197083.10	ZNF300P1	4.77	5.1e-06	0.00448	0.65	0.39	Crohn's disease;	chr5:150844175	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs4958843	ENSG00000197083.10	ZNF300P1	4.77	5.1e-06	0.00448	0.65	0.39	Crohn's disease;	chr5:150845362	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs4958424	ENSG00000197083.10	ZNF300P1	4.77	5.1e-06	0.00448	0.65	0.39	Crohn's disease;	chr5:150845474	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs2004711	ENSG00000197083.10	ZNF300P1	4.77	5.1e-06	0.00448	0.65	0.39	Crohn's disease;	chr5:150845506	chr5:150930645~150946289:-
TGCT	cis	rs7714584	0.826	rs34005003	ENSG00000197083.10	ZNF300P1	4.77	5.1e-06	0.00448	0.65	0.39	Crohn's disease;	chr5:150845637	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs34156253	ENSG00000197083.10	ZNF300P1	4.77	5.1e-06	0.00448	0.65	0.39	Crohn's disease;	chr5:150846668	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs61270113	ENSG00000197083.10	ZNF300P1	4.77	5.1e-06	0.00448	0.65	0.39	Crohn's disease;	chr5:150846701	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs11748151	ENSG00000197083.10	ZNF300P1	4.77	5.1e-06	0.00448	0.65	0.39	Crohn's disease;	chr5:150846730	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs11748158	ENSG00000197083.10	ZNF300P1	4.77	5.1e-06	0.00448	0.65	0.39	Crohn's disease;	chr5:150846783	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs10058821	ENSG00000197083.10	ZNF300P1	4.77	5.1e-06	0.00448	0.65	0.39	Crohn's disease;	chr5:150846823	chr5:150930645~150946289:-
TGCT	cis	rs12439619	0.768	rs28694364	ENSG00000255769.6	GOLGA2P10	-4.77	5.11e-06	0.00448	-0.47	-0.39	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472993~82513950:-
TGCT	cis	rs1023500	0.529	rs133375	ENSG00000270083.1	RP1-257I20.14	4.77	5.11e-06	0.00448	0.41	0.39	Schizophrenia;	chr22:42070505	chr22:42089630~42090028:-
TGCT	cis	rs7208859	0.673	rs216409	ENSG00000266490.1	CTD-2349P21.9	-4.77	5.11e-06	0.00449	-0.42	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30792372~30792833:+
TGCT	cis	rs3096299	0.967	rs11648663	ENSG00000274627.1	RP11-104N10.2	4.77	5.12e-06	0.00449	0.42	0.39	Multiple myeloma (IgH translocation);	chr16:89399899	chr16:89516797~89522217:+
TGCT	cis	rs3096299	0.967	rs28644774	ENSG00000274627.1	RP11-104N10.2	4.77	5.12e-06	0.00449	0.42	0.39	Multiple myeloma (IgH translocation);	chr16:89405773	chr16:89516797~89522217:+
TGCT	cis	rs875971	0.66	rs10229345	ENSG00000236529.1	RP13-254B10.1	4.77	5.13e-06	0.0045	0.3	0.39	Aortic root size;	chr7:66517181	chr7:65840212~65840596:+
TGCT	cis	rs7208859	0.673	rs2470251	ENSG00000266490.1	CTD-2349P21.9	4.77	5.13e-06	0.0045	0.42	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs11652370	ENSG00000266490.1	CTD-2349P21.9	4.77	5.13e-06	0.0045	0.42	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30792372~30792833:+
TGCT	cis	rs5769707	0.967	rs9616327	ENSG00000235111.1	RP1-29C18.8	-4.77	5.13e-06	0.0045	-0.32	-0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49617243	chr22:49612657~49615716:-
TGCT	cis	rs17826219	0.585	rs8064302	ENSG00000280069.1	CTD-2349P21.3	4.77	5.14e-06	0.00451	0.52	0.39	Body mass index;	chr17:30397920	chr17:30738182~30740275:+
TGCT	cis	rs875971	0.862	rs10256544	ENSG00000237310.1	GS1-124K5.4	4.77	5.14e-06	0.00451	0.42	0.39	Aortic root size;	chr7:66210141	chr7:66493706~66495474:+
TGCT	cis	rs2709736	0.593	rs2709729	ENSG00000232790.2	LINC01162	4.77	5.15e-06	0.00452	0.32	0.39	Bipolar I disorder;	chr7:20886387	chr7:20835431~21023148:+
TGCT	cis	rs2709736	0.641	rs2192464	ENSG00000232790.2	LINC01162	4.77	5.15e-06	0.00452	0.32	0.39	Bipolar I disorder;	chr7:20888487	chr7:20835431~21023148:+
TGCT	cis	rs2709736	0.606	rs2465056	ENSG00000232790.2	LINC01162	4.77	5.15e-06	0.00452	0.32	0.39	Bipolar I disorder;	chr7:20889784	chr7:20835431~21023148:+
TGCT	cis	rs8059260	0.604	rs8052325	ENSG00000274038.1	RP11-66H6.4	-4.77	5.16e-06	0.00452	-0.55	-0.39	Alcohol consumption over the past year;	chr16:11044121	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.604	rs9302458	ENSG00000274038.1	RP11-66H6.4	-4.77	5.16e-06	0.00452	-0.55	-0.39	Alcohol consumption over the past year;	chr16:11050352	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.604	rs741177	ENSG00000274038.1	RP11-66H6.4	-4.77	5.16e-06	0.00452	-0.55	-0.39	Alcohol consumption over the past year;	chr16:11051791	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.604	rs12102345	ENSG00000274038.1	RP11-66H6.4	-4.77	5.16e-06	0.00452	-0.55	-0.39	Alcohol consumption over the past year;	chr16:11053863	chr16:11056556~11057034:+
TGCT	cis	rs2581828	0.656	rs2564940	ENSG00000242142.1	SERBP1P3	4.77	5.16e-06	0.00452	0.35	0.39	Crohn's disease;	chr3:53073553	chr3:53064283~53065091:-
TGCT	cis	rs786425	0.711	rs1060637	ENSG00000278112.1	RP11-972P1.11	4.77	5.16e-06	0.00452	0.47	0.39	Pubertal anthropometrics;	chr12:123625575	chr12:123519390~123519856:-
TGCT	cis	rs2742234	0.541	rs2742235	ENSG00000273008.1	RP11-351D16.3	-4.77	5.17e-06	0.00453	-0.53	-0.39	Hirschsprung disease;	chr10:43120877	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.666	rs715106	ENSG00000273008.1	RP11-351D16.3	-4.77	5.17e-06	0.00453	-0.53	-0.39	Hirschsprung disease;	chr10:43121303	chr10:43136824~43138334:-
TGCT	cis	rs11168618	0.74	rs10506281	ENSG00000240399.1	RP1-228P16.1	-4.77	5.18e-06	0.00453	-0.35	-0.39	Adiponectin levels;	chr12:48529991	chr12:48054813~48055591:-
TGCT	cis	rs801193	0.967	rs2707853	ENSG00000237310.1	GS1-124K5.4	4.77	5.18e-06	0.00454	0.45	0.39	Aortic root size;	chr7:66749023	chr7:66493706~66495474:+
TGCT	cis	rs801193	1	rs2659889	ENSG00000237310.1	GS1-124K5.4	4.77	5.18e-06	0.00454	0.45	0.39	Aortic root size;	chr7:66752125	chr7:66493706~66495474:+
TGCT	cis	rs34217772	0.766	rs61992404	ENSG00000258536.1	RP11-1053O12.1	4.77	5.18e-06	0.00454	0.38	0.39	Myopia;	chr14:41747596	chr14:41742639~41742963:+
TGCT	cis	rs2487048	0.519	rs2487032	ENSG00000226334.1	RP11-217B7.2	-4.77	5.19e-06	0.00454	-0.36	-0.39	Intraocular pressure;	chr9:104941653	chr9:104927553~104928892:+
TGCT	cis	rs12022452	0.591	rs4660415	ENSG00000238287.1	RP11-656D10.3	-4.77	5.19e-06	0.00454	-0.5	-0.39	Age-related hearing impairment (SNP x SNP interaction);	chr1:40512819	chr1:40493157~40508661:-
TGCT	cis	rs12022452	0.556	rs11208298	ENSG00000238287.1	RP11-656D10.3	-4.77	5.19e-06	0.00454	-0.5	-0.39	Age-related hearing impairment (SNP x SNP interaction);	chr1:40513206	chr1:40493157~40508661:-
TGCT	cis	rs12022452	0.591	rs61781641	ENSG00000238287.1	RP11-656D10.3	-4.77	5.19e-06	0.00454	-0.5	-0.39	Age-related hearing impairment (SNP x SNP interaction);	chr1:40517412	chr1:40493157~40508661:-
TGCT	cis	rs12022452	0.591	rs11208315	ENSG00000238287.1	RP11-656D10.3	-4.77	5.19e-06	0.00454	-0.5	-0.39	Age-related hearing impairment (SNP x SNP interaction);	chr1:40519730	chr1:40493157~40508661:-
TGCT	cis	rs12022452	0.591	rs12049435	ENSG00000238287.1	RP11-656D10.3	-4.77	5.19e-06	0.00454	-0.5	-0.39	Age-related hearing impairment (SNP x SNP interaction);	chr1:40524888	chr1:40493157~40508661:-
TGCT	cis	rs801193	1	rs2707845	ENSG00000237310.1	GS1-124K5.4	4.76	5.21e-06	0.00456	0.45	0.39	Aortic root size;	chr7:66733811	chr7:66493706~66495474:+
TGCT	cis	rs801193	1	rs2707850	ENSG00000237310.1	GS1-124K5.4	4.76	5.21e-06	0.00456	0.45	0.39	Aortic root size;	chr7:66738883	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.967	rs1110414	ENSG00000237310.1	GS1-124K5.4	4.76	5.21e-06	0.00456	0.45	0.39	Aortic root size;	chr7:66740595	chr7:66493706~66495474:+
TGCT	cis	rs801193	1	rs7783924	ENSG00000237310.1	GS1-124K5.4	4.76	5.21e-06	0.00456	0.45	0.39	Aortic root size;	chr7:66744070	chr7:66493706~66495474:+
TGCT	cis	rs801193	1	rs7789184	ENSG00000237310.1	GS1-124K5.4	4.76	5.21e-06	0.00456	0.45	0.39	Aortic root size;	chr7:66745208	chr7:66493706~66495474:+
TGCT	cis	rs801193	1	rs2707854	ENSG00000237310.1	GS1-124K5.4	4.76	5.21e-06	0.00456	0.45	0.39	Aortic root size;	chr7:66747610	chr7:66493706~66495474:+
TGCT	cis	rs5758659	0.622	rs6519298	ENSG00000270083.1	RP1-257I20.14	4.76	5.21e-06	0.00456	0.37	0.39	Cognitive function;	chr22:41968993	chr22:42089630~42090028:-
TGCT	cis	rs4423214	0.798	rs12224205	ENSG00000254682.1	RP11-660L16.2	-4.76	5.22e-06	0.00456	-0.6	-0.39	Vitamin D levels;	chr11:71469946	chr11:71448674~71452157:+
TGCT	cis	rs875971	0.545	rs2279757	ENSG00000237310.1	GS1-124K5.4	4.76	5.22e-06	0.00457	0.46	0.39	Aortic root size;	chr7:66363676	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs11766183	ENSG00000237310.1	GS1-124K5.4	4.76	5.22e-06	0.00457	0.46	0.39	Aortic root size;	chr7:66374173	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs1065265	ENSG00000237310.1	GS1-124K5.4	4.76	5.22e-06	0.00457	0.46	0.39	Aortic root size;	chr7:66376216	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs7811204	ENSG00000237310.1	GS1-124K5.4	4.76	5.22e-06	0.00457	0.46	0.39	Aortic root size;	chr7:66387213	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.571	rs78668714	ENSG00000237310.1	GS1-124K5.4	4.76	5.22e-06	0.00457	0.46	0.39	Aortic root size;	chr7:66474464	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs73150604	ENSG00000237310.1	GS1-124K5.4	4.76	5.22e-06	0.00457	0.46	0.39	Aortic root size;	chr7:66480545	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs7810213	ENSG00000237310.1	GS1-124K5.4	4.76	5.22e-06	0.00457	0.46	0.39	Aortic root size;	chr7:66481592	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs2420612	ENSG00000237310.1	GS1-124K5.4	4.76	5.22e-06	0.00457	0.46	0.39	Aortic root size;	chr7:66536825	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs6969224	ENSG00000237310.1	GS1-124K5.4	4.76	5.22e-06	0.00457	0.47	0.39	Aortic root size;	chr7:66370011	chr7:66493706~66495474:+
TGCT	cis	rs1023500	0.552	rs133368	ENSG00000270083.1	RP1-257I20.14	4.76	5.23e-06	0.00457	0.4	0.39	Schizophrenia;	chr22:42067685	chr22:42089630~42090028:-
TGCT	cis	rs1023500	0.596	rs133369	ENSG00000270083.1	RP1-257I20.14	4.76	5.23e-06	0.00457	0.4	0.39	Schizophrenia;	chr22:42067810	chr22:42089630~42090028:-
TGCT	cis	rs1618992	0.791	rs1504108	ENSG00000265994.1	RP11-510D21.1	4.76	5.23e-06	0.00457	0.39	0.39	Gut microbiome composition (summer and winter);	chr18:28645001	chr18:28785068~28789260:+
TGCT	cis	rs875971	0.862	rs709596	ENSG00000237310.1	GS1-124K5.4	4.76	5.23e-06	0.00457	0.42	0.39	Aortic root size;	chr7:66360926	chr7:66493706~66495474:+
TGCT	cis	rs1023500	0.573	rs1807494	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Schizophrenia;	chr22:42078134	chr22:42089630~42090028:-
TGCT	cis	rs1023500	0.573	rs8135801	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Schizophrenia;	chr22:42079564	chr22:42089630~42090028:-
TGCT	cis	rs1023500	0.573	rs2269524	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Schizophrenia;	chr22:42079699	chr22:42089630~42090028:-
TGCT	cis	rs1023500	0.573	rs6002592	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Schizophrenia;	chr22:42080750	chr22:42089630~42090028:-
TGCT	cis	rs3020736	0.5	rs4147641	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Autism spectrum disorder or schizophrenia;	chr22:42086498	chr22:42089630~42090028:-
TGCT	cis	rs3020736	0.5	rs4147640	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Autism spectrum disorder or schizophrenia;	chr22:42089288	chr22:42089630~42090028:-
TGCT	cis	rs3020736	0.5	rs1801311	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Autism spectrum disorder or schizophrenia;	chr22:42090719	chr22:42089630~42090028:-
TGCT	cis	rs3020736	0.5	rs4147638	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Autism spectrum disorder or schizophrenia;	chr22:42091896	chr22:42089630~42090028:-
TGCT	cis	rs1023500	0.507	rs6002600	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Schizophrenia;	chr22:42092902	chr22:42089630~42090028:-
TGCT	cis	rs3020736	0.5	rs6002604	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Autism spectrum disorder or schizophrenia;	chr22:42097077	chr22:42089630~42090028:-
TGCT	cis	rs3020736	0.5	rs5996109	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Autism spectrum disorder or schizophrenia;	chr22:42097094	chr22:42089630~42090028:-
TGCT	cis	rs3020736	0.5	rs5996110	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Autism spectrum disorder or schizophrenia;	chr22:42097763	chr22:42089630~42090028:-
TGCT	cis	rs3020736	0.5	rs6002605	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Autism spectrum disorder or schizophrenia;	chr22:42098331	chr22:42089630~42090028:-
TGCT	cis	rs3020736	0.5	rs9620026	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Autism spectrum disorder or schizophrenia;	chr22:42102574	chr22:42089630~42090028:-
TGCT	cis	rs3020736	0.5	rs28791586	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Autism spectrum disorder or schizophrenia;	chr22:42104479	chr22:42089630~42090028:-
TGCT	cis	rs3020736	0.5	rs2839708	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Autism spectrum disorder or schizophrenia;	chr22:42104741	chr22:42089630~42090028:-
TGCT	cis	rs3020736	0.5	rs6519306	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Autism spectrum disorder or schizophrenia;	chr22:42105213	chr22:42089630~42090028:-
TGCT	cis	rs3020736	0.5	rs6002614	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Autism spectrum disorder or schizophrenia;	chr22:42105798	chr22:42089630~42090028:-
TGCT	cis	rs3020736	0.5	rs6002616	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Autism spectrum disorder or schizophrenia;	chr22:42108675	chr22:42089630~42090028:-
TGCT	cis	rs3020736	0.5	rs7364293	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Autism spectrum disorder or schizophrenia;	chr22:42110366	chr22:42089630~42090028:-
TGCT	cis	rs3020736	0.5	rs2413669	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Autism spectrum disorder or schizophrenia;	chr22:42111744	chr22:42089630~42090028:-
TGCT	cis	rs3020736	0.5	rs6002618	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Autism spectrum disorder or schizophrenia;	chr22:42111855	chr22:42089630~42090028:-
TGCT	cis	rs1023500	0.551	rs61665536	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Schizophrenia;	chr22:42116609	chr22:42089630~42090028:-
TGCT	cis	rs3020736	0.5	rs2413672	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Autism spectrum disorder or schizophrenia;	chr22:42117257	chr22:42089630~42090028:-
TGCT	cis	rs3020736	0.5	rs6002623	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Autism spectrum disorder or schizophrenia;	chr22:42117757	chr22:42089630~42090028:-
TGCT	cis	rs3020736	0.5	rs11090076	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Autism spectrum disorder or schizophrenia;	chr22:42118186	chr22:42089630~42090028:-
TGCT	cis	rs3020736	0.5	rs8143153	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Autism spectrum disorder or schizophrenia;	chr22:42119633	chr22:42089630~42090028:-
TGCT	cis	rs3020736	0.5	rs8138678	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Autism spectrum disorder or schizophrenia;	chr22:42120225	chr22:42089630~42090028:-
TGCT	cis	rs3020736	0.519	rs5996116	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Autism spectrum disorder or schizophrenia;	chr22:42121488	chr22:42089630~42090028:-
TGCT	cis	rs3020736	0.5	rs764481	ENSG00000270083.1	RP1-257I20.14	-4.76	5.23e-06	0.00457	-0.41	-0.39	Autism spectrum disorder or schizophrenia;	chr22:42122422	chr22:42089630~42090028:-
TGCT	cis	rs1023500	0.573	rs133377	ENSG00000270083.1	RP1-257I20.14	4.76	5.23e-06	0.00457	0.41	0.39	Schizophrenia;	chr22:42070946	chr22:42089630~42090028:-
TGCT	cis	rs1023500	0.551	rs2859438	ENSG00000270083.1	RP1-257I20.14	4.76	5.23e-06	0.00457	0.41	0.39	Schizophrenia;	chr22:42070976	chr22:42089630~42090028:-
TGCT	cis	rs1023500	0.573	rs4822088	ENSG00000270083.1	RP1-257I20.14	4.76	5.23e-06	0.00457	0.41	0.39	Schizophrenia;	chr22:42074585	chr22:42089630~42090028:-
TGCT	cis	rs1023500	0.573	rs133382	ENSG00000270083.1	RP1-257I20.14	4.76	5.23e-06	0.00457	0.41	0.39	Schizophrenia;	chr22:42075770	chr22:42089630~42090028:-
TGCT	cis	rs1618992	0.729	rs12454506	ENSG00000265994.1	RP11-510D21.1	4.76	5.24e-06	0.00457	0.4	0.39	Gut microbiome composition (summer and winter);	chr18:28595653	chr18:28785068~28789260:+
TGCT	cis	rs1618992	0.729	rs4356550	ENSG00000265994.1	RP11-510D21.1	4.76	5.24e-06	0.00457	0.4	0.39	Gut microbiome composition (summer and winter);	chr18:28596485	chr18:28785068~28789260:+
TGCT	cis	rs1618992	0.729	rs1910558	ENSG00000265994.1	RP11-510D21.1	4.76	5.24e-06	0.00457	0.4	0.39	Gut microbiome composition (summer and winter);	chr18:28599543	chr18:28785068~28789260:+
TGCT	cis	rs1891275	0.515	rs2153653	ENSG00000228701.1	TNKS2-AS1	-4.76	5.25e-06	0.00458	-0.43	-0.39	Intelligence (multi-trait analysis);	chr10:91736169	chr10:91782839~91798291:-
TGCT	cis	rs11157436	0.958	rs764161	ENSG00000211813.2	TRAV34	4.76	5.25e-06	0.00458	0.42	0.39	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231182	chr14:22207522~22208129:+
TGCT	cis	rs11157436	0.958	rs12433649	ENSG00000211813.2	TRAV34	4.76	5.25e-06	0.00458	0.42	0.39	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231828	chr14:22207522~22208129:+
TGCT	cis	rs4713118	0.662	rs9393881	ENSG00000219891.2	ZSCAN12P1	4.76	5.25e-06	0.00458	0.49	0.39	Parkinson's disease;	chr6:28055973	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.621	rs9368548	ENSG00000219392.1	RP1-265C24.5	-4.76	5.26e-06	0.00459	-0.51	-0.39	Parkinson's disease;	chr6:28066959	chr6:28115628~28116551:+
TGCT	cis	rs2442825	0.693	rs2728928	ENSG00000206573.7	THUMPD3-AS1	-4.76	5.26e-06	0.00459	-0.35	-0.39	Cerebrospinal fluid clusterin levels;	chr3:9388275	chr3:9349689~9398579:-
TGCT	cis	rs801193	0.569	rs10950050	ENSG00000237310.1	GS1-124K5.4	4.76	5.27e-06	0.0046	0.4	0.39	Aortic root size;	chr7:66774601	chr7:66493706~66495474:+
TGCT	cis	rs1865760	1	rs6938233	ENSG00000217159.2	LARP1P1	-4.76	5.27e-06	0.0046	-0.46	-0.39	Height;	chr6:25913849	chr6:26164072~26164363:+
TGCT	cis	rs2288884	0.636	rs6509620	ENSG00000269235.1	ZNF350-AS1	4.76	5.27e-06	0.0046	0.48	0.39	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52077543	chr19:51949134~51981367:+
TGCT	cis	rs3096299	0.967	rs2965830	ENSG00000274627.1	RP11-104N10.2	4.76	5.27e-06	0.0046	0.42	0.39	Multiple myeloma (IgH translocation);	chr16:89393882	chr16:89516797~89522217:+
TGCT	cis	rs786425	0.801	rs12813346	ENSG00000247373.3	RP11-486O12.2	4.76	5.28e-06	0.0046	0.47	0.39	Pubertal anthropometrics;	chr12:123716567	chr12:123575891~123585115:-
TGCT	cis	rs4853012	0.793	rs6707619	ENSG00000257800.1	FNBP1P1	4.76	5.29e-06	0.00461	0.42	0.39	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74120680~74123218:+
TGCT	cis	rs6964833	0.554	rs2527366	ENSG00000123965.13	PMS2P5	-4.76	5.29e-06	0.00461	-0.45	-0.39	Menarche (age at onset);	chr7:74684615	chr7:74894116~74897835:+
TGCT	cis	rs6964833	0.554	rs2527367	ENSG00000123965.13	PMS2P5	-4.76	5.29e-06	0.00461	-0.45	-0.39	Menarche (age at onset);	chr7:74684804	chr7:74894116~74897835:+
TGCT	cis	rs2665103	0.715	rs11639440	ENSG00000278603.1	RP13-608F4.5	4.76	5.3e-06	0.00461	0.53	0.39	Intelligence (multi-trait analysis);	chr15:82278705	chr15:82472203~82472426:+
TGCT	cis	rs9987353	0.566	rs13260067	ENSG00000173295.6	FAM86B3P	-4.76	5.3e-06	0.00462	-0.43	-0.39	Recombination measurement;	chr8:9213523	chr8:8228595~8244865:+
TGCT	cis	rs8111998	0.826	rs60727766	ENSG00000269332.4	GOLGA2P9	4.76	5.31e-06	0.00462	0.67	0.39	Corneal structure;	chr19:22586931	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.826	rs9916997	ENSG00000269332.4	GOLGA2P9	4.76	5.31e-06	0.00462	0.67	0.39	Corneal structure;	chr19:22586948	chr19:22596257~22603550:+
TGCT	cis	rs7714584	1	rs10051804	ENSG00000197083.10	ZNF300P1	4.76	5.32e-06	0.00463	0.65	0.39	Crohn's disease;	chr5:150846862	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs10058943	ENSG00000197083.10	ZNF300P1	4.76	5.32e-06	0.00463	0.65	0.39	Crohn's disease;	chr5:150847024	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs10051924	ENSG00000197083.10	ZNF300P1	4.76	5.32e-06	0.00463	0.65	0.39	Crohn's disease;	chr5:150847077	chr5:150930645~150946289:-
TGCT	cis	rs4888378	0.535	rs9319483	ENSG00000261783.1	RP11-252K23.2	4.76	5.33e-06	0.00464	0.61	0.39	Coronary artery disease;	chr16:75311893	chr16:75379818~75381260:-
TGCT	cis	rs34779708	0.931	rs12776390	ENSG00000230534.5	RP11-297A16.2	4.76	5.33e-06	0.00464	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35102607	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs34630580	ENSG00000230534.5	RP11-297A16.2	4.76	5.33e-06	0.00464	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35160300	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs10827493	ENSG00000230534.5	RP11-297A16.2	4.76	5.33e-06	0.00464	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35166048	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs17499811	ENSG00000230534.5	RP11-297A16.2	4.76	5.33e-06	0.00464	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35167287	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs35146199	ENSG00000230534.5	RP11-297A16.2	4.76	5.33e-06	0.00464	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35172011	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.897	rs9665538	ENSG00000230534.5	RP11-297A16.2	4.76	5.33e-06	0.00464	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35172110	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs12260130	ENSG00000230534.5	RP11-297A16.2	4.76	5.33e-06	0.00464	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35178743	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs4934538	ENSG00000230534.5	RP11-297A16.2	4.76	5.33e-06	0.00464	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35183222	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs4934539	ENSG00000230534.5	RP11-297A16.2	4.76	5.33e-06	0.00464	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35183271	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs1478463	ENSG00000230534.5	RP11-297A16.2	4.76	5.33e-06	0.00464	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35184107	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.833	rs12777517	ENSG00000230534.5	RP11-297A16.2	4.76	5.33e-06	0.00464	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35184999	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs4934540	ENSG00000230534.5	RP11-297A16.2	4.76	5.33e-06	0.00464	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35185771	chr10:35098006~35127020:-
TGCT	cis	rs3096299	0.933	rs2965823	ENSG00000274627.1	RP11-104N10.2	4.76	5.33e-06	0.00464	0.41	0.39	Multiple myeloma (IgH translocation);	chr16:89388516	chr16:89516797~89522217:+
TGCT	cis	rs2976388	0.669	rs2976391	ENSG00000253196.1	RP11-706C16.7	4.76	5.33e-06	0.00464	0.39	0.39	Urinary tract infection frequency;	chr8:142681306	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.692	rs2978983	ENSG00000253196.1	RP11-706C16.7	4.76	5.33e-06	0.00464	0.39	0.39	Urinary tract infection frequency;	chr8:142684424	chr8:142763116~142766427:+
TGCT	cis	rs4423214	0.879	rs736894	ENSG00000254682.1	RP11-660L16.2	4.76	5.34e-06	0.00464	0.58	0.39	Vitamin D levels;	chr11:71441212	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.879	rs1790324	ENSG00000254682.1	RP11-660L16.2	-4.76	5.34e-06	0.00464	-0.58	-0.39	Vitamin D levels;	chr11:71439474	chr11:71448674~71452157:+
TGCT	cis	rs904251	0.504	rs9380677	ENSG00000204110.6	RP1-153P14.8	-4.76	5.34e-06	0.00465	-0.42	-0.39	Cognitive performance;	chr6:37512590	chr6:37507348~37535616:+
TGCT	cis	rs2117029	0.554	rs35884657	ENSG00000258017.1	RP11-386G11.10	-4.76	5.35e-06	0.00465	-0.52	-0.39	Intelligence (multi-trait analysis);	chr12:49137317	chr12:49127782~49147869:+
TGCT	cis	rs11168854	0.62	rs11168888	ENSG00000258017.1	RP11-386G11.10	-4.76	5.35e-06	0.00465	-0.52	-0.39	Body mass index;	chr12:49149614	chr12:49127782~49147869:+
TGCT	cis	rs16852403	0.517	rs10494512	ENSG00000224687.1	RASAL2-AS1	4.76	5.35e-06	0.00465	0.52	0.39	Childhood ear infection;	chr1:178282545	chr1:178091508~178093984:-
TGCT	cis	rs3091242	0.933	rs35497030	ENSG00000224183.1	SDHDP6	4.76	5.37e-06	0.00467	0.41	0.39	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25294164~25294643:-
TGCT	cis	rs1823913	0.892	rs35596292	ENSG00000227542.1	AC092614.2	4.76	5.37e-06	0.00467	0.42	0.39	Obesity-related traits;	chr2:191246890	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.927	rs35530564	ENSG00000227542.1	AC092614.2	4.76	5.37e-06	0.00467	0.42	0.39	Obesity-related traits;	chr2:191247324	chr2:191229165~191246172:-
TGCT	cis	rs6600671	1	rs4844616	ENSG00000275131.1	CH17-472G23.4	-4.76	5.37e-06	0.00467	-0.24	-0.39	Hip geometry;	chr1:121429348	chr1:120489625~120579190:-
TGCT	cis	rs2117029	0.555	rs10783304	ENSG00000258017.1	RP11-386G11.10	-4.76	5.37e-06	0.00467	-0.51	-0.39	Intelligence (multi-trait analysis);	chr12:49106615	chr12:49127782~49147869:+
TGCT	cis	rs3091242	0.933	rs34006994	ENSG00000224183.1	SDHDP6	4.76	5.37e-06	0.00467	0.41	0.39	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25294164~25294643:-
TGCT	cis	rs3091242	0.933	rs61775167	ENSG00000224183.1	SDHDP6	4.76	5.37e-06	0.00467	0.41	0.39	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25294164~25294643:-
TGCT	cis	rs3091242	0.902	rs36003018	ENSG00000224183.1	SDHDP6	4.76	5.37e-06	0.00467	0.41	0.39	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25294164~25294643:-
TGCT	cis	rs3091242	0.933	rs35403885	ENSG00000224183.1	SDHDP6	4.76	5.37e-06	0.00467	0.41	0.39	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25294164~25294643:-
TGCT	cis	rs3091242	0.933	rs10903130	ENSG00000224183.1	SDHDP6	-4.76	5.37e-06	0.00467	-0.41	-0.39	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25294164~25294643:-
TGCT	cis	rs3091242	0.933	rs11249251	ENSG00000224183.1	SDHDP6	-4.76	5.37e-06	0.00467	-0.41	-0.39	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25294164~25294643:-
TGCT	cis	rs3091242	0.9	rs4649086	ENSG00000224183.1	SDHDP6	-4.76	5.37e-06	0.00467	-0.41	-0.39	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25294164~25294643:-
TGCT	cis	rs4713118	0.662	rs149961	ENSG00000219392.1	RP1-265C24.5	-4.76	5.37e-06	0.00467	-0.51	-0.39	Parkinson's disease;	chr6:28047791	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.629	rs149899	ENSG00000219392.1	RP1-265C24.5	-4.76	5.37e-06	0.00467	-0.51	-0.39	Parkinson's disease;	chr6:28052201	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.629	rs172165	ENSG00000219392.1	RP1-265C24.5	-4.76	5.37e-06	0.00467	-0.51	-0.39	Parkinson's disease;	chr6:28053036	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.597	rs172166	ENSG00000219392.1	RP1-265C24.5	-4.76	5.37e-06	0.00467	-0.51	-0.39	Parkinson's disease;	chr6:28053042	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.629	rs203889	ENSG00000219392.1	RP1-265C24.5	-4.76	5.37e-06	0.00467	-0.51	-0.39	Parkinson's disease;	chr6:28053997	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.629	rs203890	ENSG00000219392.1	RP1-265C24.5	-4.76	5.37e-06	0.00467	-0.51	-0.39	Parkinson's disease;	chr6:28054470	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.662	rs9357060	ENSG00000219392.1	RP1-265C24.5	-4.76	5.37e-06	0.00467	-0.51	-0.39	Parkinson's disease;	chr6:28056708	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.662	rs9468271	ENSG00000219392.1	RP1-265C24.5	-4.76	5.37e-06	0.00467	-0.51	-0.39	Parkinson's disease;	chr6:28056792	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.662	rs9380045	ENSG00000219392.1	RP1-265C24.5	-4.76	5.37e-06	0.00467	-0.51	-0.39	Parkinson's disease;	chr6:28057501	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.616	rs9348789	ENSG00000219392.1	RP1-265C24.5	-4.76	5.37e-06	0.00467	-0.51	-0.39	Parkinson's disease;	chr6:28057708	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.662	rs9468274	ENSG00000219392.1	RP1-265C24.5	-4.76	5.37e-06	0.00467	-0.51	-0.39	Parkinson's disease;	chr6:28058299	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.662	rs9468275	ENSG00000219392.1	RP1-265C24.5	-4.76	5.37e-06	0.00467	-0.51	-0.39	Parkinson's disease;	chr6:28058358	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.662	rs9468276	ENSG00000219392.1	RP1-265C24.5	-4.76	5.37e-06	0.00467	-0.51	-0.39	Parkinson's disease;	chr6:28059910	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.662	rs9468277	ENSG00000219392.1	RP1-265C24.5	-4.76	5.37e-06	0.00467	-0.51	-0.39	Parkinson's disease;	chr6:28060612	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.662	rs9468278	ENSG00000219392.1	RP1-265C24.5	-4.76	5.37e-06	0.00467	-0.51	-0.39	Parkinson's disease;	chr6:28060704	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.662	rs13218430	ENSG00000219392.1	RP1-265C24.5	-4.76	5.37e-06	0.00467	-0.51	-0.39	Parkinson's disease;	chr6:28062059	chr6:28115628~28116551:+
TGCT	cis	rs875971	0.66	rs10263935	ENSG00000272831.1	RP11-792A8.4	4.76	5.37e-06	0.00467	0.42	0.39	Aortic root size;	chr7:66631041	chr7:66739829~66740385:-
TGCT	cis	rs6560039	1	rs6560039	ENSG00000214888.2	XXyac-YM21GA2.7	-4.76	5.38e-06	0.00467	-0.35	-0.39	Gait variability;	chr9:87860031	chr9:87857015~87859399:-
TGCT	cis	rs877819	0.583	rs2170133	ENSG00000228403.1	RP11-563N6.6	-4.76	5.39e-06	0.00468	-0.41	-0.39	Systemic lupus erythematosus;	chr10:48848166	chr10:48878022~48878649:+
TGCT	cis	rs2177312	0.83	rs6835697	ENSG00000251129.1	RP11-734I18.1	-4.76	5.39e-06	0.00468	-0.45	-0.39	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31981812	chr4:31997397~32155406:+
TGCT	cis	rs8072100	0.544	rs7214993	ENSG00000228782.6	CTD-2026D20.3	4.76	5.39e-06	0.00468	0.48	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309431	chr17:47450568~47492492:-
TGCT	cis	rs875971	0.862	rs7786892	ENSG00000232559.3	GS1-124K5.12	-4.76	5.4e-06	0.00469	-0.37	-0.39	Aortic root size;	chr7:66163889	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs2420174	ENSG00000232559.3	GS1-124K5.12	-4.76	5.4e-06	0.00469	-0.37	-0.39	Aortic root size;	chr7:66180374	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs2420173	ENSG00000232559.3	GS1-124K5.12	-4.76	5.4e-06	0.00469	-0.37	-0.39	Aortic root size;	chr7:66180412	chr7:66554588~66576923:-
TGCT	cis	rs17826219	0.636	rs4055314	ENSG00000266490.1	CTD-2349P21.9	4.76	5.4e-06	0.00469	0.44	0.39	Body mass index;	chr17:30752751	chr17:30792372~30792833:+
TGCT	cis	rs17826219	0.636	rs79565452	ENSG00000266490.1	CTD-2349P21.9	4.76	5.4e-06	0.00469	0.44	0.39	Body mass index;	chr17:30815823	chr17:30792372~30792833:+
TGCT	cis	rs801193	1	rs2659912	ENSG00000272831.1	RP11-792A8.4	4.75	5.41e-06	0.0047	0.42	0.39	Aortic root size;	chr7:66693012	chr7:66739829~66740385:-
TGCT	cis	rs2581828	0.656	rs2253209	ENSG00000242142.1	SERBP1P3	4.75	5.41e-06	0.0047	0.35	0.39	Crohn's disease;	chr3:53081144	chr3:53064283~53065091:-
TGCT	cis	rs67311347	0.956	rs9817233	ENSG00000223797.4	ENTPD3-AS1	4.75	5.42e-06	0.0047	0.42	0.39	Renal cell carcinoma;	chr3:40384127	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs9817142	ENSG00000223797.4	ENTPD3-AS1	4.75	5.42e-06	0.0047	0.42	0.39	Renal cell carcinoma;	chr3:40384283	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs9822644	ENSG00000223797.4	ENTPD3-AS1	4.75	5.42e-06	0.0047	0.42	0.39	Renal cell carcinoma;	chr3:40385118	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs12494022	ENSG00000223797.4	ENTPD3-AS1	4.75	5.42e-06	0.0047	0.42	0.39	Renal cell carcinoma;	chr3:40385161	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs11714032	ENSG00000223797.4	ENTPD3-AS1	4.75	5.42e-06	0.0047	0.42	0.39	Renal cell carcinoma;	chr3:40390114	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs7634375	ENSG00000223797.4	ENTPD3-AS1	4.75	5.42e-06	0.0047	0.42	0.39	Renal cell carcinoma;	chr3:40390455	chr3:40313802~40453329:-
TGCT	cis	rs67311347	0.826	rs9863679	ENSG00000223797.4	ENTPD3-AS1	4.75	5.42e-06	0.0047	0.42	0.39	Renal cell carcinoma;	chr3:40398123	chr3:40313802~40453329:-
TGCT	cis	rs67311347	0.911	rs9863737	ENSG00000223797.4	ENTPD3-AS1	4.75	5.42e-06	0.0047	0.42	0.39	Renal cell carcinoma;	chr3:40398345	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs73076035	ENSG00000223797.4	ENTPD3-AS1	4.75	5.42e-06	0.0047	0.42	0.39	Renal cell carcinoma;	chr3:40398390	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs9875245	ENSG00000223797.4	ENTPD3-AS1	4.75	5.42e-06	0.0047	0.42	0.39	Renal cell carcinoma;	chr3:40400789	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs954589	ENSG00000223797.4	ENTPD3-AS1	4.75	5.42e-06	0.0047	0.42	0.39	Renal cell carcinoma;	chr3:40403054	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs17078916	ENSG00000223797.4	ENTPD3-AS1	4.75	5.42e-06	0.0047	0.42	0.39	Renal cell carcinoma;	chr3:40403947	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs73076046	ENSG00000223797.4	ENTPD3-AS1	4.75	5.42e-06	0.0047	0.42	0.39	Renal cell carcinoma;	chr3:40406233	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs4973989	ENSG00000223797.4	ENTPD3-AS1	4.75	5.42e-06	0.0047	0.42	0.39	Renal cell carcinoma;	chr3:40410052	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs12634013	ENSG00000223797.4	ENTPD3-AS1	4.75	5.42e-06	0.0047	0.42	0.39	Renal cell carcinoma;	chr3:40410897	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs6793596	ENSG00000223797.4	ENTPD3-AS1	4.75	5.42e-06	0.0047	0.42	0.39	Renal cell carcinoma;	chr3:40416304	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs73078123	ENSG00000223797.4	ENTPD3-AS1	4.75	5.42e-06	0.0047	0.42	0.39	Renal cell carcinoma;	chr3:40417472	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs4973998	ENSG00000223797.4	ENTPD3-AS1	4.75	5.42e-06	0.0047	0.42	0.39	Renal cell carcinoma;	chr3:40418861	chr3:40313802~40453329:-
TGCT	cis	rs1153858	1	rs1153858	ENSG00000259520.4	CTD-2651B20.3	4.75	5.43e-06	0.00471	0.34	0.39	Homoarginine levels;	chr15:45360505	chr15:45251580~45279251:-
TGCT	cis	rs10875746	0.903	rs11168420	ENSG00000240399.1	RP1-228P16.1	-4.75	5.44e-06	0.00471	-0.45	-0.39	Longevity (90 years and older);	chr12:48122113	chr12:48054813~48055591:-
TGCT	cis	rs3096299	0.967	rs28575874	ENSG00000274627.1	RP11-104N10.2	4.75	5.44e-06	0.00472	0.42	0.39	Multiple myeloma (IgH translocation);	chr16:89403482	chr16:89516797~89522217:+
TGCT	cis	rs2117029	0.587	rs57853986	ENSG00000258017.1	RP11-386G11.10	-4.75	5.44e-06	0.00472	-0.52	-0.39	Intelligence (multi-trait analysis);	chr12:49124612	chr12:49127782~49147869:+
TGCT	cis	rs2948294	0.588	rs7011221	ENSG00000254340.1	RP11-10A14.3	4.75	5.47e-06	0.00474	0.42	0.39	Red cell distribution width;	chr8:8256724	chr8:9141424~9145435:+
TGCT	cis	rs1618992	0.791	rs2847403	ENSG00000265994.1	RP11-510D21.1	4.75	5.47e-06	0.00474	0.39	0.39	Gut microbiome composition (summer and winter);	chr18:28651552	chr18:28785068~28789260:+
TGCT	cis	rs67311347	1	rs12108041	ENSG00000223797.4	ENTPD3-AS1	4.75	5.47e-06	0.00474	0.42	0.39	Renal cell carcinoma;	chr3:40446044	chr3:40313802~40453329:-
TGCT	cis	rs7208859	0.623	rs1054400	ENSG00000280069.1	CTD-2349P21.3	-4.75	5.47e-06	0.00474	-0.55	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30738182~30740275:+
TGCT	cis	rs507080	0.769	rs7389	ENSG00000255422.1	AP002954.4	4.75	5.47e-06	0.00474	0.45	0.39	Serum metabolite levels;	chr11:118657756	chr11:118704607~118750263:+
TGCT	cis	rs321358	0.895	rs17535942	ENSG00000271584.1	RP11-89C3.4	4.75	5.48e-06	0.00475	0.51	0.39	Body mass index;	chr11:111085233	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.895	rs17457430	ENSG00000271584.1	RP11-89C3.4	4.75	5.48e-06	0.00475	0.51	0.39	Body mass index;	chr11:111085279	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.895	rs7101466	ENSG00000271584.1	RP11-89C3.4	4.75	5.48e-06	0.00475	0.51	0.39	Body mass index;	chr11:111085729	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.895	rs7101576	ENSG00000271584.1	RP11-89C3.4	4.75	5.48e-06	0.00475	0.51	0.39	Body mass index;	chr11:111085795	chr11:111091932~111097357:-
TGCT	cis	rs1618992	0.729	rs1910560	ENSG00000265994.1	RP11-510D21.1	4.75	5.48e-06	0.00475	0.4	0.39	Gut microbiome composition (summer and winter);	chr18:28589728	chr18:28785068~28789260:+
TGCT	cis	rs1618992	0.729	rs1827607	ENSG00000265994.1	RP11-510D21.1	4.75	5.48e-06	0.00475	0.4	0.39	Gut microbiome composition (summer and winter);	chr18:28590029	chr18:28785068~28789260:+
TGCT	cis	rs9462027	0.628	rs9368832	ENSG00000186328.4	RP11-140K17.2	-4.75	5.48e-06	0.00475	-0.37	-0.39	Systemic lupus erythematosus;	chr6:34711810	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.606	rs12201281	ENSG00000186328.4	RP11-140K17.2	-4.75	5.48e-06	0.00475	-0.37	-0.39	Systemic lupus erythematosus;	chr6:34713314	chr6:34715613~34715940:+
TGCT	cis	rs11054731	0.807	rs4763794	ENSG00000247498.8	RP11-392P7.6	4.75	5.48e-06	0.00475	0.37	0.39	Coronary artery calcification;	chr12:12284484	chr12:12927726~12984645:+
TGCT	cis	rs1618992	0.791	rs2655360	ENSG00000265994.1	RP11-510D21.1	4.75	5.49e-06	0.00475	0.39	0.39	Gut microbiome composition (summer and winter);	chr18:28651426	chr18:28785068~28789260:+
TGCT	cis	rs67311347	0.91	rs13089215	ENSG00000223797.4	ENTPD3-AS1	-4.75	5.49e-06	0.00475	-0.44	-0.39	Renal cell carcinoma;	chr3:40454403	chr3:40313802~40453329:-
TGCT	cis	rs36093924	0.646	rs5996092	ENSG00000182057.4	OGFRP1	-4.75	5.49e-06	0.00476	-0.28	-0.39	Intelligence;	chr22:41948404	chr22:42269753~42275196:+
TGCT	cis	rs904251	0.504	rs12202664	ENSG00000204110.6	RP1-153P14.8	-4.75	5.49e-06	0.00476	-0.41	-0.39	Cognitive performance;	chr6:37513422	chr6:37507348~37535616:+
TGCT	cis	rs1555322	0.53	rs2275275	ENSG00000126005.14	MMP24-AS1	-4.75	5.5e-06	0.00477	-0.47	-0.39	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35216462~35278131:-
TGCT	cis	rs10504229	0.683	rs2291765	ENSG00000253301.4	RP11-513O17.2	4.75	5.51e-06	0.00477	0.5	0.39	Developmental language disorder (linguistic errors);	chr8:57230315	chr8:57142689~57240298:+
TGCT	cis	rs801193	1	rs2707856	ENSG00000237310.1	GS1-124K5.4	4.75	5.51e-06	0.00477	0.45	0.39	Aortic root size;	chr7:66746023	chr7:66493706~66495474:+
TGCT	cis	rs1799949	0.86	rs8176279	ENSG00000198496.9	NBR2	-4.75	5.52e-06	0.00478	-0.57	-0.39	Menopause (age at onset);	chr17:43058379	chr17:43125610~43153671:+
TGCT	cis	rs6017291	0.793	rs41280254	ENSG00000223891.4	OSER1-AS1	4.75	5.52e-06	0.00478	0.63	0.39	Cognitive performance;	chr20:44223869	chr20:44210960~44226027:+
TGCT	cis	rs67311347	1	rs6801859	ENSG00000223797.4	ENTPD3-AS1	-4.75	5.53e-06	0.00478	-0.41	-0.39	Renal cell carcinoma;	chr3:40451727	chr3:40313802~40453329:-
TGCT	cis	rs2880765	0.546	rs36098649	ENSG00000259295.5	CSPG4P12	4.75	5.54e-06	0.00479	0.49	0.39	Coronary artery disease;	chr15:85513576	chr15:85191438~85213905:+
TGCT	cis	rs10129255	0.517	rs11625572	ENSG00000211970.3	IGHV4-61	-4.75	5.55e-06	0.0048	-0.42	-0.39	Kawasaki disease;	chr14:106656426	chr14:106639119~106639657:-
TGCT	cis	rs10875976	0.525	rs10783326	ENSG00000242041.1	RP11-70F11.2	4.75	5.55e-06	0.0048	0.37	0.39	Obesity;	chr12:49865361	chr12:49863173~49863503:+
TGCT	cis	rs4835473	0.831	rs7689328	ENSG00000251600.4	RP11-673E1.1	4.75	5.56e-06	0.00481	0.41	0.39	Immature fraction of reticulocytes;	chr4:143973768	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.831	rs7694353	ENSG00000251600.4	RP11-673E1.1	4.75	5.56e-06	0.00481	0.41	0.39	Immature fraction of reticulocytes;	chr4:143973787	chr4:143912331~143982454:+
TGCT	cis	rs2581828	0.656	rs2581782	ENSG00000242142.1	SERBP1P3	4.75	5.56e-06	0.00481	0.35	0.39	Crohn's disease;	chr3:53088241	chr3:53064283~53065091:-
TGCT	cis	rs2581828	0.656	rs11242	ENSG00000242142.1	SERBP1P3	-4.75	5.56e-06	0.00481	-0.35	-0.39	Crohn's disease;	chr3:53091906	chr3:53064283~53065091:-
TGCT	cis	rs9880211	0.752	rs9838884	ENSG00000239213.4	NCK1-AS1	4.75	5.56e-06	0.00481	0.44	0.39	Height;Body mass index;	chr3:136736862	chr3:136841726~136862054:-
TGCT	cis	rs1555322	0.53	rs932562	ENSG00000126005.14	MMP24-AS1	-4.75	5.56e-06	0.00481	-0.48	-0.39	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35216462~35278131:-
TGCT	cis	rs10246939	0.543	rs35836873	ENSG00000228775.6	WEE2-AS1	4.75	5.58e-06	0.00482	0.35	0.39	Bitter taste perception;	chr7:141844010	chr7:141704338~141738346:-
TGCT	cis	rs10246939	0.543	rs9640358	ENSG00000228775.6	WEE2-AS1	4.75	5.58e-06	0.00482	0.35	0.39	Bitter taste perception;	chr7:141844082	chr7:141704338~141738346:-
TGCT	cis	rs2136613	0.533	rs1571922	ENSG00000238280.1	RP11-436D10.3	-4.75	5.58e-06	0.00482	-0.44	-0.39	Selective IgA deficiency;	chr10:62851189	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs10822066	ENSG00000238280.1	RP11-436D10.3	-4.75	5.58e-06	0.00482	-0.44	-0.39	Selective IgA deficiency;	chr10:62851432	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs10740091	ENSG00000238280.1	RP11-436D10.3	-4.75	5.58e-06	0.00482	-0.44	-0.39	Selective IgA deficiency;	chr10:62851628	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs10822067	ENSG00000238280.1	RP11-436D10.3	-4.75	5.58e-06	0.00482	-0.44	-0.39	Selective IgA deficiency;	chr10:62851949	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs10761669	ENSG00000238280.1	RP11-436D10.3	-4.75	5.58e-06	0.00482	-0.44	-0.39	Selective IgA deficiency;	chr10:62852050	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs10509173	ENSG00000238280.1	RP11-436D10.3	-4.75	5.58e-06	0.00482	-0.44	-0.39	Selective IgA deficiency;	chr10:62852129	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs10822068	ENSG00000238280.1	RP11-436D10.3	-4.75	5.58e-06	0.00482	-0.44	-0.39	Selective IgA deficiency;	chr10:62852505	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs10822069	ENSG00000238280.1	RP11-436D10.3	-4.75	5.58e-06	0.00482	-0.44	-0.39	Selective IgA deficiency;	chr10:62853482	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs10995331	ENSG00000238280.1	RP11-436D10.3	-4.75	5.58e-06	0.00482	-0.44	-0.39	Selective IgA deficiency;	chr10:62853948	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs10822070	ENSG00000238280.1	RP11-436D10.3	-4.75	5.58e-06	0.00482	-0.44	-0.39	Selective IgA deficiency;	chr10:62854149	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs4141617	ENSG00000238280.1	RP11-436D10.3	-4.75	5.58e-06	0.00482	-0.44	-0.39	Selective IgA deficiency;	chr10:62854308	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs10761673	ENSG00000238280.1	RP11-436D10.3	-4.75	5.58e-06	0.00482	-0.44	-0.39	Selective IgA deficiency;	chr10:62855691	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs10822071	ENSG00000238280.1	RP11-436D10.3	-4.75	5.58e-06	0.00482	-0.44	-0.39	Selective IgA deficiency;	chr10:62855716	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs10822072	ENSG00000238280.1	RP11-436D10.3	-4.75	5.58e-06	0.00482	-0.44	-0.39	Selective IgA deficiency;	chr10:62856010	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs1509958	ENSG00000238280.1	RP11-436D10.3	-4.75	5.58e-06	0.00482	-0.44	-0.39	Selective IgA deficiency;	chr10:62856390	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs12258444	ENSG00000238280.1	RP11-436D10.3	-4.75	5.58e-06	0.00482	-0.44	-0.39	Selective IgA deficiency;	chr10:62856825	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs10995332	ENSG00000238280.1	RP11-436D10.3	-4.75	5.58e-06	0.00482	-0.44	-0.39	Selective IgA deficiency;	chr10:62857905	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs10995333	ENSG00000238280.1	RP11-436D10.3	-4.75	5.58e-06	0.00482	-0.44	-0.39	Selective IgA deficiency;	chr10:62858034	chr10:62793562~62805887:-
TGCT	cis	rs875971	0.66	rs801192	ENSG00000272831.1	RP11-792A8.4	-4.75	5.59e-06	0.00482	-0.42	-0.39	Aortic root size;	chr7:66566965	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.66	rs801190	ENSG00000272831.1	RP11-792A8.4	-4.75	5.59e-06	0.00482	-0.42	-0.39	Aortic root size;	chr7:66568046	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.66	rs3857686	ENSG00000272831.1	RP11-792A8.4	-4.75	5.59e-06	0.00482	-0.42	-0.39	Aortic root size;	chr7:66571204	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.638	rs6460305	ENSG00000272831.1	RP11-792A8.4	-4.75	5.59e-06	0.00482	-0.42	-0.39	Aortic root size;	chr7:66595421	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.638	rs6960778	ENSG00000272831.1	RP11-792A8.4	-4.75	5.59e-06	0.00482	-0.42	-0.39	Aortic root size;	chr7:66606610	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.66	rs1860468	ENSG00000272831.1	RP11-792A8.4	-4.75	5.59e-06	0.00482	-0.42	-0.39	Aortic root size;	chr7:66642265	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.619	rs12533585	ENSG00000272831.1	RP11-792A8.4	4.75	5.59e-06	0.00482	0.42	0.39	Aortic root size;	chr7:66519618	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.66	rs28698552	ENSG00000272831.1	RP11-792A8.4	4.75	5.59e-06	0.00482	0.42	0.39	Aortic root size;	chr7:66540031	chr7:66739829~66740385:-
TGCT	cis	rs10875746	0.903	rs11168370	ENSG00000240399.1	RP1-228P16.1	-4.75	5.59e-06	0.00483	-0.44	-0.39	Longevity (90 years and older);	chr12:48041497	chr12:48054813~48055591:-
TGCT	cis	rs8072100	0.807	rs4561509	ENSG00000228782.6	CTD-2026D20.3	4.75	5.6e-06	0.00483	0.45	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47704433	chr17:47450568~47492492:-
TGCT	cis	rs524281	0.731	rs78578425	ENSG00000255320.1	RP11-755F10.1	4.75	5.6e-06	0.00483	0.59	0.39	Electroencephalogram traits;	chr11:66042768	chr11:66244840~66246239:-
TGCT	cis	rs875971	0.862	rs6952182	ENSG00000232559.3	GS1-124K5.12	-4.75	5.61e-06	0.00484	-0.37	-0.39	Aortic root size;	chr7:66218330	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs6964437	ENSG00000232559.3	GS1-124K5.12	-4.75	5.61e-06	0.00484	-0.37	-0.39	Aortic root size;	chr7:66221457	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs6460282	ENSG00000232559.3	GS1-124K5.12	-4.75	5.61e-06	0.00484	-0.37	-0.39	Aortic root size;	chr7:66226259	chr7:66554588~66576923:-
TGCT	cis	rs761746	0.542	rs7290856	ENSG00000236132.1	CTA-440B3.1	-4.75	5.61e-06	0.00484	-0.48	-0.39	Intelligence;	chr22:31834930	chr22:31816379~31817491:-
TGCT	cis	rs9584850	0.834	rs9584855	ENSG00000231194.1	FARP1-AS1	-4.75	5.62e-06	0.00485	-0.5	-0.39	Neuroticism;	chr13:98466746	chr13:98435405~98435840:-
TGCT	cis	rs853679	0.517	rs4713146	ENSG00000219392.1	RP1-265C24.5	-4.75	5.62e-06	0.00485	-0.54	-0.39	Depression;	chr6:28143758	chr6:28115628~28116551:+
TGCT	cis	rs853679	0.517	rs9393894	ENSG00000219392.1	RP1-265C24.5	-4.75	5.62e-06	0.00485	-0.54	-0.39	Depression;	chr6:28144784	chr6:28115628~28116551:+
TGCT	cis	rs2136613	0.505	rs10761674	ENSG00000238280.1	RP11-436D10.3	-4.75	5.62e-06	0.00485	-0.44	-0.39	Selective IgA deficiency;	chr10:62858580	chr10:62793562~62805887:-
TGCT	cis	rs6474412	1	rs13277254	ENSG00000255101.1	RP11-412B14.1	4.75	5.62e-06	0.00485	0.4	0.39	Smoking behavior;	chr8:42694839	chr8:42705583~42721946:-
TGCT	cis	rs2239557	0.581	rs12100961	ENSG00000259065.1	RP5-1021I20.1	-4.75	5.62e-06	0.00485	-0.35	-0.39	Common traits (Other);	chr14:73815667	chr14:73787360~73803270:+
TGCT	cis	rs3096299	0.967	rs3102341	ENSG00000274627.1	RP11-104N10.2	4.75	5.63e-06	0.00485	0.42	0.39	Multiple myeloma (IgH translocation);	chr16:89384336	chr16:89516797~89522217:+
TGCT	cis	rs4237845	0.611	rs7298370	ENSG00000257159.1	RP11-58A17.3	4.75	5.64e-06	0.00486	0.49	0.39	Intelligence (multi-trait analysis);	chr12:57925114	chr12:57967058~57968399:+
TGCT	cis	rs8062405	0.69	rs6498089	ENSG00000259982.1	CDC37P1	-4.75	5.64e-06	0.00486	-0.48	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.754	rs28410083	ENSG00000259982.1	CDC37P1	-4.75	5.64e-06	0.00486	-0.48	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28700294~28701540:-
TGCT	cis	rs8062405	0.789	rs1968751	ENSG00000259982.1	CDC37P1	-4.75	5.64e-06	0.00486	-0.48	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28700294~28701540:-
TGCT	cis	rs6981523	0.532	rs1987190	ENSG00000255310.2	AF131215.2	-4.74	5.64e-06	0.00486	-0.33	-0.39	Neuroticism;	chr8:11196005	chr8:11107788~11109726:-
TGCT	cis	rs12439619	0.81	rs28876157	ENSG00000255769.6	GOLGA2P10	-4.74	5.65e-06	0.00487	-0.47	-0.39	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472993~82513950:-
TGCT	cis	rs875971	0.862	rs778724	ENSG00000237310.1	GS1-124K5.4	4.74	5.65e-06	0.00487	0.42	0.39	Aortic root size;	chr7:66364304	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs778686	ENSG00000237310.1	GS1-124K5.4	4.74	5.65e-06	0.00487	0.42	0.39	Aortic root size;	chr7:66370923	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.767	rs1643394	ENSG00000237310.1	GS1-124K5.4	4.74	5.65e-06	0.00487	0.42	0.39	Aortic root size;	chr7:66371107	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs778684	ENSG00000237310.1	GS1-124K5.4	4.74	5.65e-06	0.00487	0.42	0.39	Aortic root size;	chr7:66371416	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs778680	ENSG00000237310.1	GS1-124K5.4	4.74	5.65e-06	0.00487	0.42	0.39	Aortic root size;	chr7:66375427	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs11769079	ENSG00000237310.1	GS1-124K5.4	4.74	5.65e-06	0.00487	0.42	0.39	Aortic root size;	chr7:66377141	chr7:66493706~66495474:+
TGCT	cis	rs1251350	0.753	rs1775725	ENSG00000239731.3	RN7SL825P	4.74	5.66e-06	0.00487	0.51	0.39	Schizophrenia;	chr10:31975105	chr10:31992087~31992381:-
TGCT	cis	rs16852403	0.519	rs2791604	ENSG00000224687.1	RASAL2-AS1	-4.74	5.66e-06	0.00487	-0.55	-0.39	Childhood ear infection;	chr1:178089771	chr1:178091508~178093984:-
TGCT	cis	rs34217772	0.699	rs2147106	ENSG00000258536.1	RP11-1053O12.1	4.74	5.66e-06	0.00487	0.33	0.39	Myopia;	chr14:41832783	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.603	rs17781325	ENSG00000258536.1	RP11-1053O12.1	4.74	5.67e-06	0.00488	0.34	0.39	Myopia;	chr14:41713161	chr14:41742639~41742963:+
TGCT	cis	rs1891275	0.515	rs1361552	ENSG00000228701.1	TNKS2-AS1	-4.74	5.68e-06	0.00489	-0.44	-0.39	Intelligence (multi-trait analysis);	chr10:91774867	chr10:91782839~91798291:-
TGCT	cis	rs673078	0.607	rs2036489	ENSG00000275759.1	RP11-131L12.3	-4.74	5.69e-06	0.00489	-0.63	-0.39	Glucose homeostasis traits;	chr12:118364643	chr12:118428281~118428870:+
TGCT	cis	rs56080343	0.688	rs10083190	ENSG00000275759.1	RP11-131L12.3	-4.74	5.69e-06	0.00489	-0.63	-0.39	Neuroticism;	chr12:118365385	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs10082823	ENSG00000275759.1	RP11-131L12.3	-4.74	5.69e-06	0.00489	-0.63	-0.39	Glucose homeostasis traits;	chr12:118365386	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs2062519	ENSG00000275759.1	RP11-131L12.3	-4.74	5.69e-06	0.00489	-0.63	-0.39	Glucose homeostasis traits;	chr12:118367577	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.66	rs76842574	ENSG00000275759.1	RP11-131L12.3	-4.74	5.69e-06	0.00489	-0.63	-0.39	Glucose homeostasis traits;	chr12:118371789	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.615	rs56324376	ENSG00000275759.1	RP11-131L12.3	-4.74	5.69e-06	0.00489	-0.63	-0.39	Glucose homeostasis traits;	chr12:118372134	chr12:118428281~118428870:+
TGCT	cis	rs1372520	0.684	rs2572318	ENSG00000247775.2	SNCA-AS1	4.74	5.69e-06	0.0049	0.43	0.39	Neuroticism;	chr4:89797568	chr4:89836408~89841978:+
TGCT	cis	rs34779708	0.931	rs2490663	ENSG00000230534.5	RP11-297A16.2	-4.74	5.69e-06	0.0049	-0.46	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35040807	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs10508815	ENSG00000230534.5	RP11-297A16.2	4.74	5.69e-06	0.0049	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35043693	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs6481935	ENSG00000230534.5	RP11-297A16.2	4.74	5.69e-06	0.0049	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35054031	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs2384289	ENSG00000230534.5	RP11-297A16.2	4.74	5.69e-06	0.0049	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35054597	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs12242882	ENSG00000230534.5	RP11-297A16.2	4.74	5.69e-06	0.0049	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35058932	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs11010082	ENSG00000230534.5	RP11-297A16.2	4.74	5.69e-06	0.0049	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35062227	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs12240347	ENSG00000230534.5	RP11-297A16.2	4.74	5.69e-06	0.0049	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35070547	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs4934533	ENSG00000230534.5	RP11-297A16.2	4.74	5.69e-06	0.0049	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35070691	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs12248333	ENSG00000230534.5	RP11-297A16.2	4.74	5.69e-06	0.0049	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35074049	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs2505631	ENSG00000230534.5	RP11-297A16.2	-4.74	5.69e-06	0.0049	-0.46	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35079457	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs12767414	ENSG00000230534.5	RP11-297A16.2	4.74	5.69e-06	0.0049	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35101265	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs2505639	ENSG00000230534.5	RP11-297A16.2	-4.74	5.69e-06	0.0049	-0.46	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35185493	chr10:35098006~35127020:-
TGCT	cis	rs4925386	0.802	rs6142735	ENSG00000273619.1	RP5-908M14.9	-4.74	5.7e-06	0.0049	-0.48	-0.39	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62343031	chr20:62386303~62386970:-
TGCT	cis	rs4654783	1	rs4654783	ENSG00000218510.5	LINC00339	4.74	5.7e-06	0.0049	0.48	0.39	Endometriosis;	chr1:22113027	chr1:22025188~22031223:+
TGCT	cis	rs7115242	0.92	rs6589574	ENSG00000254851.1	RP11-109L13.1	-4.74	5.7e-06	0.0049	-0.83	-0.39	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116859922	chr11:117135528~117138582:+
TGCT	cis	rs8059260	0.541	rs16958028	ENSG00000274038.1	RP11-66H6.4	-4.74	5.7e-06	0.0049	-0.64	-0.39	Alcohol consumption over the past year;	chr16:11082811	chr16:11056556~11057034:+
TGCT	cis	rs2980439	0.607	rs2980419	ENSG00000254340.1	RP11-10A14.3	4.74	5.71e-06	0.00491	0.4	0.39	Neuroticism;	chr8:8256619	chr8:9141424~9145435:+
TGCT	cis	rs9322193	0.962	rs2275046	ENSG00000216906.2	RP11-350J20.9	4.74	5.71e-06	0.00491	0.44	0.39	Lung cancer;	chr6:149835865	chr6:149904243~149906418:+
TGCT	cis	rs8091660	0.893	rs1567656	ENSG00000278983.1	RP11-426J5.3	-4.74	5.71e-06	0.00491	-0.47	-0.39	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568420	chr18:48564795~48568342:+
TGCT	cis	rs7208859	0.562	rs11650923	ENSG00000266490.1	CTD-2349P21.9	4.74	5.71e-06	0.00491	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs56378576	ENSG00000266490.1	CTD-2349P21.9	4.74	5.71e-06	0.00491	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs35916850	ENSG00000266490.1	CTD-2349P21.9	4.74	5.71e-06	0.00491	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30792372~30792833:+
TGCT	cis	rs599083	0.744	rs603129	ENSG00000212093.1	AP000807.1	-4.74	5.71e-06	0.00491	-0.39	-0.39	Bone mineral density (spine);	chr11:68419201	chr11:68506083~68506166:-
TGCT	cis	rs4713118	0.662	rs9380046	ENSG00000219392.1	RP1-265C24.5	-4.74	5.72e-06	0.00492	-0.51	-0.39	Parkinson's disease;	chr6:28062721	chr6:28115628~28116551:+
TGCT	cis	rs904251	0.523	rs2776872	ENSG00000204110.6	RP1-153P14.8	-4.74	5.73e-06	0.00492	-0.4	-0.39	Cognitive performance;	chr6:37515011	chr6:37507348~37535616:+
TGCT	cis	rs904251	0.523	rs1757191	ENSG00000204110.6	RP1-153P14.8	-4.74	5.73e-06	0.00492	-0.4	-0.39	Cognitive performance;	chr6:37515095	chr6:37507348~37535616:+
TGCT	cis	rs4853012	0.838	rs61521879	ENSG00000217702.2	RP11-287D1.4	4.74	5.73e-06	0.00492	0.54	0.39	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74130583~74135395:+
TGCT	cis	rs8059260	0.545	rs2286972	ENSG00000274038.1	RP11-66H6.4	-4.74	5.74e-06	0.00493	-0.56	-0.39	Alcohol consumption over the past year;	chr16:11061141	chr16:11056556~11057034:+
TGCT	cis	rs7927592	0.546	rs497261	ENSG00000212093.1	AP000807.1	4.74	5.75e-06	0.00494	0.39	0.39	Total body bone mineral density;	chr11:68424776	chr11:68506083~68506166:-
TGCT	cis	rs7927592	0.546	rs599083	ENSG00000212093.1	AP000807.1	4.74	5.75e-06	0.00494	0.39	0.39	Total body bone mineral density;	chr11:68424878	chr11:68506083~68506166:-
TGCT	cis	rs7927592	0.546	rs683978	ENSG00000212093.1	AP000807.1	4.74	5.75e-06	0.00494	0.39	0.39	Total body bone mineral density;	chr11:68424953	chr11:68506083~68506166:-
TGCT	cis	rs7927592	0.546	rs554734	ENSG00000212093.1	AP000807.1	4.74	5.75e-06	0.00494	0.39	0.39	Total body bone mineral density;	chr11:68425050	chr11:68506083~68506166:-
TGCT	cis	rs875971	0.54	rs736270	ENSG00000237310.1	GS1-124K5.4	4.74	5.76e-06	0.00494	0.44	0.39	Aortic root size;	chr7:65963835	chr7:66493706~66495474:+
TGCT	cis	rs10246939	0.543	rs9640204	ENSG00000228775.6	WEE2-AS1	4.74	5.77e-06	0.00495	0.35	0.39	Bitter taste perception;	chr7:141844300	chr7:141704338~141738346:-
TGCT	cis	rs10246939	0.543	rs9640359	ENSG00000228775.6	WEE2-AS1	4.74	5.77e-06	0.00495	0.35	0.39	Bitter taste perception;	chr7:141844399	chr7:141704338~141738346:-
TGCT	cis	rs7208859	0.573	rs8070182	ENSG00000280069.1	CTD-2349P21.3	-4.74	5.77e-06	0.00495	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30738182~30740275:+
TGCT	cis	rs9462027	0.628	rs2744949	ENSG00000186328.4	RP11-140K17.2	4.74	5.78e-06	0.00495	0.37	0.39	Systemic lupus erythematosus;	chr6:34666085	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.606	rs2815001	ENSG00000186328.4	RP11-140K17.2	4.74	5.78e-06	0.00495	0.37	0.39	Systemic lupus erythematosus;	chr6:34666576	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs2815004	ENSG00000186328.4	RP11-140K17.2	4.74	5.78e-06	0.00495	0.37	0.39	Systemic lupus erythematosus;	chr6:34668491	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs2395598	ENSG00000186328.4	RP11-140K17.2	4.74	5.78e-06	0.00495	0.37	0.39	Systemic lupus erythematosus;	chr6:34672909	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.651	rs2395599	ENSG00000186328.4	RP11-140K17.2	4.74	5.78e-06	0.00495	0.37	0.39	Systemic lupus erythematosus;	chr6:34673638	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.63	rs2744943	ENSG00000186328.4	RP11-140K17.2	4.74	5.78e-06	0.00495	0.37	0.39	Systemic lupus erythematosus;	chr6:34675402	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.606	rs2744941	ENSG00000186328.4	RP11-140K17.2	4.74	5.78e-06	0.00495	0.37	0.39	Systemic lupus erythematosus;	chr6:34679140	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs2814945	ENSG00000186328.4	RP11-140K17.2	4.74	5.78e-06	0.00495	0.37	0.39	Systemic lupus erythematosus;	chr6:34680201	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.562	rs2814946	ENSG00000186328.4	RP11-140K17.2	4.74	5.78e-06	0.00495	0.37	0.39	Systemic lupus erythematosus;	chr6:34683403	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.583	rs2814947	ENSG00000186328.4	RP11-140K17.2	4.74	5.78e-06	0.00495	0.37	0.39	Systemic lupus erythematosus;	chr6:34685491	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs7771778	ENSG00000186328.4	RP11-140K17.2	-4.74	5.78e-06	0.00495	-0.37	-0.39	Systemic lupus erythematosus;	chr6:34692547	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs7742652	ENSG00000186328.4	RP11-140K17.2	-4.74	5.78e-06	0.00495	-0.37	-0.39	Systemic lupus erythematosus;	chr6:34699298	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs9348950	ENSG00000186328.4	RP11-140K17.2	-4.74	5.78e-06	0.00495	-0.37	-0.39	Systemic lupus erythematosus;	chr6:34705901	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs9357181	ENSG00000186328.4	RP11-140K17.2	-4.74	5.78e-06	0.00495	-0.37	-0.39	Systemic lupus erythematosus;	chr6:34706056	chr6:34715613~34715940:+
TGCT	cis	rs4835473	0.932	rs1839448	ENSG00000251600.4	RP11-673E1.1	4.74	5.78e-06	0.00495	0.39	0.39	Immature fraction of reticulocytes;	chr4:143752113	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs10021860	ENSG00000251600.4	RP11-673E1.1	4.74	5.78e-06	0.00495	0.39	0.39	Immature fraction of reticulocytes;	chr4:143754593	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs6853676	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143750495	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs6848393	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143750537	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs971390	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143751264	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.868	rs971391	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143751324	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs971392	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143751384	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.838	rs35978782	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143751713	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs34060266	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143751766	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs35300159	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143751768	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs13139419	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143751862	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.868	rs13106052	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143751995	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs13134401	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143752008	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs13106287	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143752091	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs13134679	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143752187	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs13108134	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143752213	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs34406317	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143752237	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs35863996	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143752260	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs6836896	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143752404	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs2874983	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143752589	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs2874984	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143752622	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs2323192	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143752646	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs2323193	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143752812	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs34152627	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143753205	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs35670108	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143753280	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs6832005	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143754284	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.838	rs55963933	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143755048	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.868	rs35243309	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143755116	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs34790336	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143755284	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs35740243	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143755395	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs4395452	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143755678	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.741	rs6537180	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143755984	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.741	rs6537181	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143755995	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs6814065	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143756233	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs6816347	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143756674	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.808	rs6847256	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143757032	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.868	rs57413073	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143757852	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs34732468	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143758009	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs12510395	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143758107	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs12513087	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143758551	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs12513119	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143758619	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs12513130	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143758666	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs935732	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143759164	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.868	rs7681891	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143759289	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs7681903	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143759326	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs7656753	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143759414	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs7656786	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143759455	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.771	rs34069296	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143759656	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs7687915	ENSG00000251600.4	RP11-673E1.1	-4.74	5.78e-06	0.00495	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143759801	chr4:143912331~143982454:+
TGCT	cis	rs34217772	0.699	rs34958394	ENSG00000258536.1	RP11-1053O12.1	4.74	5.78e-06	0.00495	0.33	0.39	Myopia;	chr14:41830201	chr14:41742639~41742963:+
TGCT	cis	rs17361889	0.634	rs7799150	ENSG00000224683.1	RPL36AP29	4.74	5.78e-06	0.00495	0.39	0.39	Pediatric bone mineral content (hip);	chr7:16258813	chr7:16208945~16209265:+
TGCT	cis	rs6952407	1	rs6952407	ENSG00000272831.1	RP11-792A8.4	-4.74	5.78e-06	0.00495	-0.42	-0.39	Cotinine glucuronidation;	chr7:66580525	chr7:66739829~66740385:-
TGCT	cis	rs761746	0.739	rs5998072	ENSG00000236132.1	CTA-440B3.1	-4.74	5.79e-06	0.00496	-0.5	-0.39	Intelligence;	chr22:31652388	chr22:31816379~31817491:-
TGCT	cis	rs7208859	0.673	rs73263981	ENSG00000280069.1	CTD-2349P21.3	-4.74	5.8e-06	0.00496	-0.52	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.524	rs73263982	ENSG00000280069.1	CTD-2349P21.3	-4.74	5.8e-06	0.00496	-0.52	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs216433	ENSG00000280069.1	CTD-2349P21.3	-4.74	5.8e-06	0.00496	-0.52	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.673	rs216435	ENSG00000280069.1	CTD-2349P21.3	-4.74	5.8e-06	0.00496	-0.52	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30738182~30740275:+
TGCT	cis	rs17608059	0.504	rs11656981	ENSG00000141028.6	CDRT15P1	-4.74	5.81e-06	0.00497	-0.44	-0.39	Temperament;	chr17:14075460	chr17:14024514~14025488:+
TGCT	cis	rs801193	0.901	rs4273746	ENSG00000237310.1	GS1-124K5.4	-4.74	5.81e-06	0.00497	-0.44	-0.39	Aortic root size;	chr7:66836124	chr7:66493706~66495474:+
TGCT	cis	rs35160687	0.787	rs10186289	ENSG00000273080.1	RP11-301O19.1	4.74	5.81e-06	0.00497	0.44	0.39	Night sleep phenotypes;	chr2:86285865	chr2:86195590~86196049:+
TGCT	cis	rs35160687	0.814	rs7563887	ENSG00000273080.1	RP11-301O19.1	4.74	5.81e-06	0.00497	0.44	0.39	Night sleep phenotypes;	chr2:86288998	chr2:86195590~86196049:+
TGCT	cis	rs8072100	0.676	rs7221345	ENSG00000228782.6	CTD-2026D20.3	4.74	5.82e-06	0.00498	0.5	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47327778	chr17:47450568~47492492:-
TGCT	cis	rs1510272	0.515	rs6762762	ENSG00000243926.1	TIPARP-AS1	-4.74	5.83e-06	0.00498	-0.52	-0.39	Testicular germ cell tumor;	chr3:156625194	chr3:156671862~156674378:-
TGCT	cis	rs10935480	0.904	rs13065271	ENSG00000239445.4	ST3GAL6-AS1	-4.74	5.84e-06	0.00498	-0.35	-0.39	Blood protein levels;	chr3:98715649	chr3:98714330~98732651:-
TGCT	cis	rs4986172	0.69	rs11657325	ENSG00000267288.2	RP13-890H12.2	-4.74	5.84e-06	0.00498	-0.46	-0.39	Height;	chr17:45165327	chr17:45168800~45171584:-
TGCT	cis	rs8059260	0.736	rs8059156	ENSG00000274038.1	RP11-66H6.4	-4.74	5.84e-06	0.00498	-0.56	-0.39	Alcohol consumption over the past year;	chr16:10952135	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.736	rs7192171	ENSG00000274038.1	RP11-66H6.4	-4.74	5.84e-06	0.00498	-0.56	-0.39	Alcohol consumption over the past year;	chr16:10955262	chr16:11056556~11057034:+
TGCT	cis	rs4423214	0.592	rs1790349	ENSG00000254682.1	RP11-660L16.2	-4.74	5.84e-06	0.00498	-0.71	-0.39	Vitamin D levels;	chr11:71431304	chr11:71448674~71452157:+
TGCT	cis	rs17826219	0.5	rs2874724	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Body mass index;	chr17:30745415	chr17:30792372~30792833:+
TGCT	cis	rs17826219	0.568	rs9898097	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Body mass index;	chr17:30745654	chr17:30792372~30792833:+
TGCT	cis	rs17826219	0.5	rs9891256	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Body mass index;	chr17:30745674	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs9911490	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs7503542	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs7503335	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.573	rs11656278	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.573	rs56031503	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs6505207	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.573	rs7223803	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30792372~30792833:+
TGCT	cis	rs17826219	0.568	rs2626985	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Body mass index;	chr17:30750419	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs55814012	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30792372~30792833:+
TGCT	cis	rs17826219	0.5	rs2449749	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Body mass index;	chr17:30751280	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs9894709	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs9896603	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs7219361	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs7219712	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.573	rs8078656	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs8080882	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs9898084	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs28556733	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30792372~30792833:+
TGCT	cis	rs17826219	0.5	rs28452421	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Body mass index;	chr17:30756962	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs28433704	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.573	rs28779471	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30792372~30792833:+
TGCT	cis	rs17826219	0.5	rs61685770	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Body mass index;	chr17:30758695	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs57486336	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30792372~30792833:+
TGCT	cis	rs17826219	0.706	rs55764512	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Body mass index;	chr17:30758740	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.524	rs73988172	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs12103440	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs12103508	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.524	rs11653605	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs11657777	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs73269913	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs7217984	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs55811708	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.562	rs8078897	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs8075163	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30792372~30792833:+
TGCT	cis	rs17826219	0.706	rs8075107	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Body mass index;	chr17:30779631	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs7223209	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs7223404	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs9916725	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs9916727	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs9914499	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs73269945	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs9897728	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs9890558	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs9912283	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs12006	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs3752021	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs3752020	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs9890855	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs9893422	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs9891166	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs73269974	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs34756112	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.573	rs60724269	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs76633166	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs1061346	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs1061343	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs1061342	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs55938328	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs73269988	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs55961983	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.573	rs7222803	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs9899525	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30792372~30792833:+
TGCT	cis	rs17826219	0.568	rs7213925	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Body mass index;	chr17:30794616	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.524	rs11653098	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs11658945	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs11657990	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs9911784	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs9911997	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs9890862	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs78071511	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs11650982	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs2035494	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs9915546	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs9915566	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.573	rs8064686	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs11657369	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs8075341	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs73271842	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs9895815	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.573	rs7214313	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs8077116	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.524	rs28760584	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30792372~30792833:+
TGCT	cis	rs17826219	0.706	rs73271850	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Body mass index;	chr17:30815122	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs7208088	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs7212991	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs7208441	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs28627615	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs9912440	ENSG00000266490.1	CTD-2349P21.9	4.74	5.85e-06	0.00498	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30792372~30792833:+
TGCT	cis	rs4660456	0.564	rs34320811	ENSG00000237899.1	RP4-739H11.3	-4.74	5.85e-06	0.00498	-0.52	-0.39	Platelet count;	chr1:40763288	chr1:40669089~40687588:-
TGCT	cis	rs11168854	0.719	rs11168902	ENSG00000258017.1	RP11-386G11.10	-4.74	5.85e-06	0.00498	-0.52	-0.39	Body mass index;	chr12:49174483	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.553	rs11168903	ENSG00000258017.1	RP11-386G11.10	-4.74	5.85e-06	0.00498	-0.52	-0.39	Intelligence (multi-trait analysis);	chr12:49174883	chr12:49127782~49147869:+
TGCT	cis	rs12439619	0.739	rs62012046	ENSG00000255769.6	GOLGA2P10	-4.74	5.86e-06	0.00498	-0.47	-0.39	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472993~82513950:-
TGCT	cis	rs12439619	0.774	rs62012047	ENSG00000255769.6	GOLGA2P10	-4.74	5.86e-06	0.00498	-0.47	-0.39	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472993~82513950:-
TGCT	cis	rs12439619	0.81	rs62012049	ENSG00000255769.6	GOLGA2P10	-4.74	5.86e-06	0.00498	-0.47	-0.39	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472993~82513950:-
TGCT	cis	rs12439619	0.846	rs62012059	ENSG00000255769.6	GOLGA2P10	-4.74	5.86e-06	0.00498	-0.47	-0.39	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472993~82513950:-
TGCT	cis	rs12439619	0.774	rs2867649	ENSG00000255769.6	GOLGA2P10	-4.74	5.86e-06	0.00498	-0.47	-0.39	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472993~82513950:-
TGCT	cis	rs12439619	0.846	rs28697264	ENSG00000255769.6	GOLGA2P10	-4.74	5.86e-06	0.00498	-0.47	-0.39	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472993~82513950:-
TGCT	cis	rs8059260	0.604	rs16957966	ENSG00000274038.1	RP11-66H6.4	-4.74	5.86e-06	0.00499	-0.55	-0.39	Alcohol consumption over the past year;	chr16:11046280	chr16:11056556~11057034:+
TGCT	cis	rs9462027	0.606	rs2814984	ENSG00000186328.4	RP11-140K17.2	4.74	5.87e-06	0.00499	0.37	0.39	Systemic lupus erythematosus;	chr6:34629736	chr6:34715613~34715940:+
TGCT	cis	rs12439619	0.693	rs7165536	ENSG00000255769.6	GOLGA2P10	-4.74	5.87e-06	0.00499	-0.45	-0.39	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472993~82513950:-
TGCT	cis	rs10829156	0.773	rs7909552	ENSG00000240291.1	RP11-499P20.2	4.74	5.87e-06	0.005	0.34	0.39	Sudden cardiac arrest;	chr10:18620407	chr10:18513115~18545651:-
TGCT	cis	rs1618992	0.791	rs17685777	ENSG00000265994.1	RP11-510D21.1	4.73	5.88e-06	0.005	0.39	0.39	Gut microbiome composition (summer and winter);	chr18:28644600	chr18:28785068~28789260:+
TGCT	cis	rs1618992	0.791	rs1504107	ENSG00000265994.1	RP11-510D21.1	4.73	5.88e-06	0.005	0.39	0.39	Gut microbiome composition (summer and winter);	chr18:28645120	chr18:28785068~28789260:+
TGCT	cis	rs875971	0.54	rs781152	ENSG00000237310.1	GS1-124K5.4	4.73	5.89e-06	0.00501	0.43	0.39	Aortic root size;	chr7:66014585	chr7:66493706~66495474:+
TGCT	cis	rs17711722	0.727	rs781151	ENSG00000237310.1	GS1-124K5.4	4.73	5.89e-06	0.00501	0.43	0.39	Calcium levels;	chr7:66014891	chr7:66493706~66495474:+
TGCT	cis	rs8059260	0.736	rs8044180	ENSG00000274038.1	RP11-66H6.4	-4.73	5.89e-06	0.00501	-0.56	-0.39	Alcohol consumption over the past year;	chr16:10952531	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.668	rs16957839	ENSG00000274038.1	RP11-66H6.4	-4.73	5.89e-06	0.00501	-0.56	-0.39	Alcohol consumption over the past year;	chr16:10962521	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.736	rs3871209	ENSG00000274038.1	RP11-66H6.4	-4.73	5.89e-06	0.00501	-0.56	-0.39	Alcohol consumption over the past year;	chr16:10962907	chr16:11056556~11057034:+
TGCT	cis	rs9462027	0.628	rs2477508	ENSG00000186328.4	RP11-140K17.2	-4.73	5.89e-06	0.00501	-0.36	-0.39	Systemic lupus erythematosus;	chr6:34735918	chr6:34715613~34715940:+
TGCT	cis	rs3742264	1	rs9526139	ENSG00000235903.6	CPB2-AS1	-4.73	5.9e-06	0.00502	-0.47	-0.39	Blood protein levels;	chr13:46069921	chr13:46052806~46113332:+
TGCT	cis	rs7923609	0.902	rs10740136	ENSG00000232075.1	MRPL35P2	-4.73	5.9e-06	0.00502	-0.38	-0.39	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63569862	chr10:63634317~63634827:-
TGCT	cis	rs673078	0.517	rs73205578	ENSG00000275759.1	RP11-131L12.3	-4.73	5.91e-06	0.00503	-0.73	-0.39	Glucose homeostasis traits;	chr12:118385113	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.66	rs73205579	ENSG00000275759.1	RP11-131L12.3	-4.73	5.91e-06	0.00503	-0.73	-0.39	Glucose homeostasis traits;	chr12:118385125	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs4767671	ENSG00000275759.1	RP11-131L12.3	-4.73	5.91e-06	0.00503	-0.73	-0.39	Glucose homeostasis traits;	chr12:118396038	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs17440956	ENSG00000275759.1	RP11-131L12.3	4.73	5.91e-06	0.00503	0.73	0.39	Glucose homeostasis traits;	chr12:118394639	chr12:118428281~118428870:+
TGCT	cis	rs2463822	1	rs72921501	ENSG00000254454.2	RCC2P6	4.73	5.91e-06	0.00503	0.42	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62348150	chr11:62371146~62373168:+
TGCT	cis	rs2581828	0.656	rs2163167	ENSG00000242142.1	SERBP1P3	4.73	5.91e-06	0.00503	0.35	0.39	Crohn's disease;	chr3:53097756	chr3:53064283~53065091:-
TGCT	cis	rs2581828	0.541	rs2115781	ENSG00000242142.1	SERBP1P3	4.73	5.91e-06	0.00503	0.35	0.39	Crohn's disease;	chr3:53097813	chr3:53064283~53065091:-
TGCT	cis	rs7617773	0.539	rs13087050	ENSG00000229759.1	MRPS18AP1	4.73	5.91e-06	0.00503	0.32	0.39	Coronary artery disease;	chr3:48351310	chr3:48256350~48256938:-
TGCT	cis	rs10829156	0.66	rs7918933	ENSG00000240291.1	RP11-499P20.2	4.73	5.92e-06	0.00503	0.34	0.39	Sudden cardiac arrest;	chr10:18517434	chr10:18513115~18545651:-
TGCT	cis	rs12745968	0.652	rs4970714	ENSG00000223787.2	RP4-593M8.1	-4.73	5.93e-06	0.00504	-0.52	-0.39	Bipolar disorder and schizophrenia;	chr1:92475800	chr1:92580476~92580821:-
TGCT	cis	rs4835473	0.838	rs4271960	ENSG00000251600.4	RP11-673E1.1	-4.73	5.93e-06	0.00504	-0.4	-0.39	Immature fraction of reticulocytes;	chr4:143763591	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.808	rs2323198	ENSG00000251600.4	RP11-673E1.1	-4.73	5.93e-06	0.00504	-0.4	-0.39	Immature fraction of reticulocytes;	chr4:143763595	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs2323199	ENSG00000251600.4	RP11-673E1.1	-4.73	5.93e-06	0.00504	-0.4	-0.39	Immature fraction of reticulocytes;	chr4:143763606	chr4:143912331~143982454:+
TGCT	cis	rs875971	0.83	rs6976714	ENSG00000232559.3	GS1-124K5.12	4.73	5.93e-06	0.00504	0.36	0.39	Aortic root size;	chr7:66426474	chr7:66554588~66576923:-
TGCT	cis	rs11822910	0.871	rs2581928	ENSG00000265566.2	RN7SL605P	-4.73	5.93e-06	0.00504	-0.49	-0.39	Platelet distribution width;	chr11:57435317	chr11:57528085~57528365:-
TGCT	cis	rs2463822	1	rs12279819	ENSG00000254454.2	RCC2P6	4.73	5.94e-06	0.00504	0.42	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62369773	chr11:62371146~62373168:+
TGCT	cis	rs2463822	0.92	rs28678254	ENSG00000254454.2	RCC2P6	4.73	5.94e-06	0.00504	0.42	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62384403	chr11:62371146~62373168:+
TGCT	cis	rs2463822	0.687	rs118012228	ENSG00000254454.2	RCC2P6	4.73	5.94e-06	0.00504	0.42	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62388442	chr11:62371146~62373168:+
TGCT	cis	rs2463822	0.925	rs12292586	ENSG00000254454.2	RCC2P6	4.73	5.94e-06	0.00504	0.42	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62388840	chr11:62371146~62373168:+
TGCT	cis	rs875971	0.756	rs4718328	ENSG00000237310.1	GS1-124K5.4	-4.73	5.94e-06	0.00504	-0.42	-0.39	Aortic root size;	chr7:66228350	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs4718330	ENSG00000237310.1	GS1-124K5.4	-4.73	5.94e-06	0.00504	-0.42	-0.39	Aortic root size;	chr7:66250256	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs949930	ENSG00000237310.1	GS1-124K5.4	-4.73	5.94e-06	0.00504	-0.42	-0.39	Aortic root size;	chr7:66301835	chr7:66493706~66495474:+
TGCT	cis	rs761746	0.739	rs140078	ENSG00000236132.1	CTA-440B3.1	4.73	5.95e-06	0.00506	0.5	0.39	Intelligence;	chr22:31714177	chr22:31816379~31817491:-
TGCT	cis	rs875971	0.522	rs1917563	ENSG00000272831.1	RP11-792A8.4	-4.73	5.96e-06	0.00506	-0.4	-0.39	Aortic root size;	chr7:65950660	chr7:66739829~66740385:-
TGCT	cis	rs7221109	0.677	rs1029792	ENSG00000278834.1	RP11-458J1.1	4.73	5.96e-06	0.00506	0.29	0.39	Type 1 diabetes;	chr17:40652689	chr17:40648300~40649718:+
TGCT	cis	rs1153858	1	rs1145074	ENSG00000259520.4	CTD-2651B20.3	-4.73	5.96e-06	0.00506	-0.33	-0.39	Homoarginine levels;	chr15:45411626	chr15:45251580~45279251:-
TGCT	cis	rs2581828	0.694	rs2336725	ENSG00000242142.1	SERBP1P3	4.73	5.97e-06	0.00506	0.35	0.39	Crohn's disease;	chr3:53084723	chr3:53064283~53065091:-
TGCT	cis	rs2581828	0.656	rs2253656	ENSG00000242142.1	SERBP1P3	4.73	5.97e-06	0.00506	0.35	0.39	Crohn's disease;	chr3:53085083	chr3:53064283~53065091:-
TGCT	cis	rs2581828	0.656	rs2253685	ENSG00000242142.1	SERBP1P3	4.73	5.97e-06	0.00506	0.35	0.39	Crohn's disease;	chr3:53085687	chr3:53064283~53065091:-
TGCT	cis	rs2581828	0.656	rs2253796	ENSG00000242142.1	SERBP1P3	4.73	5.97e-06	0.00506	0.35	0.39	Crohn's disease;	chr3:53086082	chr3:53064283~53065091:-
TGCT	cis	rs2581828	0.656	rs11130338	ENSG00000242142.1	SERBP1P3	4.73	5.97e-06	0.00506	0.35	0.39	Crohn's disease;	chr3:53086908	chr3:53064283~53065091:-
TGCT	cis	rs2581828	0.656	rs2581783	ENSG00000242142.1	SERBP1P3	4.73	5.97e-06	0.00506	0.35	0.39	Crohn's disease;	chr3:53088242	chr3:53064283~53065091:-
TGCT	cis	rs2581828	0.607	rs2581784	ENSG00000242142.1	SERBP1P3	4.73	5.97e-06	0.00506	0.35	0.39	Crohn's disease;	chr3:53088354	chr3:53064283~53065091:-
TGCT	cis	rs2581828	0.656	rs891368	ENSG00000242142.1	SERBP1P3	4.73	5.97e-06	0.00506	0.35	0.39	Crohn's disease;	chr3:53089257	chr3:53064283~53065091:-
TGCT	cis	rs2581828	0.656	rs1078968	ENSG00000242142.1	SERBP1P3	4.73	5.97e-06	0.00506	0.35	0.39	Crohn's disease;	chr3:53089470	chr3:53064283~53065091:-
TGCT	cis	rs2581828	0.656	rs2581786	ENSG00000242142.1	SERBP1P3	4.73	5.97e-06	0.00506	0.35	0.39	Crohn's disease;	chr3:53092127	chr3:53064283~53065091:-
TGCT	cis	rs875971	0.893	rs62465470	ENSG00000237310.1	GS1-124K5.4	-4.73	5.97e-06	0.00507	-0.42	-0.39	Aortic root size;	chr7:66136231	chr7:66493706~66495474:+
TGCT	cis	rs67311347	1	rs2276870	ENSG00000223797.4	ENTPD3-AS1	-4.73	5.97e-06	0.00507	-0.4	-0.39	Renal cell carcinoma;	chr3:40457691	chr3:40313802~40453329:-
TGCT	cis	rs8072100	0.748	rs9908016	ENSG00000228782.6	CTD-2026D20.3	4.73	5.97e-06	0.00507	0.47	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47473995	chr17:47450568~47492492:-
TGCT	cis	rs8072100	0.782	rs28507314	ENSG00000228782.6	CTD-2026D20.3	4.73	5.97e-06	0.00507	0.47	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47474036	chr17:47450568~47492492:-
TGCT	cis	rs1618992	0.791	rs2847402	ENSG00000265994.1	RP11-510D21.1	4.73	5.98e-06	0.00507	0.39	0.39	Gut microbiome composition (summer and winter);	chr18:28650097	chr18:28785068~28789260:+
TGCT	cis	rs1618992	0.791	rs2655362	ENSG00000265994.1	RP11-510D21.1	4.73	5.98e-06	0.00507	0.39	0.39	Gut microbiome composition (summer and winter);	chr18:28651261	chr18:28785068~28789260:+
TGCT	cis	rs1618992	0.791	rs2655361	ENSG00000265994.1	RP11-510D21.1	4.73	5.98e-06	0.00507	0.39	0.39	Gut microbiome composition (summer and winter);	chr18:28651414	chr18:28785068~28789260:+
TGCT	cis	rs5742933	0.857	rs2289226	ENSG00000273240.1	RP11-455J20.3	-4.73	5.98e-06	0.00507	-0.36	-0.39	Ferritin levels;	chr2:189661479	chr2:189763859~189764456:-
TGCT	cis	rs2463822	1	rs11231050	ENSG00000254454.2	RCC2P6	4.73	5.98e-06	0.00507	0.41	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62364188	chr11:62371146~62373168:+
TGCT	cis	rs6600671	1	rs11249351	ENSG00000275131.1	CH17-472G23.4	-4.73	5.98e-06	0.00507	-0.24	-0.39	Hip geometry;	chr1:121430082	chr1:120489625~120579190:-
TGCT	cis	rs6600671	0.967	rs12069545	ENSG00000275131.1	CH17-472G23.4	-4.73	5.98e-06	0.00507	-0.24	-0.39	Hip geometry;	chr1:121430343	chr1:120489625~120579190:-
TGCT	cis	rs796364	0.951	rs72932280	ENSG00000232732.8	AC073043.1	4.73	5.99e-06	0.00508	0.5	0.39	Schizophrenia;	chr2:200132128	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.951	rs1105964	ENSG00000232732.8	AC073043.1	4.73	5.99e-06	0.00508	0.5	0.39	Schizophrenia;	chr2:200136053	chr2:199867396~199911159:-
TGCT	cis	rs7208859	0.562	rs216408	ENSG00000280069.1	CTD-2349P21.3	4.73	5.99e-06	0.00508	0.51	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.673	rs1347359	ENSG00000280069.1	CTD-2349P21.3	-4.73	5.99e-06	0.00508	-0.51	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30738182~30740275:+
TGCT	cis	rs875971	0.825	rs1129531	ENSG00000232559.3	GS1-124K5.12	-4.73	5.99e-06	0.00508	-0.37	-0.39	Aortic root size;	chr7:66154117	chr7:66554588~66576923:-
TGCT	cis	rs9462027	0.54	rs9366863	ENSG00000186328.4	RP11-140K17.2	-4.73	6.01e-06	0.00509	-0.37	-0.39	Systemic lupus erythematosus;	chr6:34721169	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs10947521	ENSG00000186328.4	RP11-140K17.2	-4.73	6.01e-06	0.00509	-0.37	-0.39	Systemic lupus erythematosus;	chr6:34721600	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs6929567	ENSG00000186328.4	RP11-140K17.2	-4.73	6.01e-06	0.00509	-0.37	-0.39	Systemic lupus erythematosus;	chr6:34724958	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs10807141	ENSG00000186328.4	RP11-140K17.2	-4.73	6.01e-06	0.00509	-0.37	-0.39	Systemic lupus erythematosus;	chr6:34725334	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs10738078	ENSG00000186328.4	RP11-140K17.2	-4.73	6.01e-06	0.00509	-0.37	-0.39	Systemic lupus erythematosus;	chr6:34726140	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs2764211	ENSG00000186328.4	RP11-140K17.2	-4.73	6.01e-06	0.00509	-0.37	-0.39	Systemic lupus erythematosus;	chr6:34736836	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.606	rs4513788	ENSG00000186328.4	RP11-140K17.2	4.73	6.01e-06	0.00509	0.37	0.39	Systemic lupus erythematosus;	chr6:34727002	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.54	rs2814951	ENSG00000186328.4	RP11-140K17.2	4.73	6.01e-06	0.00509	0.37	0.39	Systemic lupus erythematosus;	chr6:34727304	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.675	rs13206387	ENSG00000186328.4	RP11-140K17.2	4.73	6.01e-06	0.00509	0.37	0.39	Systemic lupus erythematosus;	chr6:34729015	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs2814957	ENSG00000186328.4	RP11-140K17.2	4.73	6.01e-06	0.00509	0.37	0.39	Systemic lupus erythematosus;	chr6:34734912	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs2477507	ENSG00000186328.4	RP11-140K17.2	4.73	6.01e-06	0.00509	0.37	0.39	Systemic lupus erythematosus;	chr6:34735822	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs2764197	ENSG00000186328.4	RP11-140K17.2	4.73	6.01e-06	0.00509	0.37	0.39	Systemic lupus erythematosus;	chr6:34737278	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs2492860	ENSG00000186328.4	RP11-140K17.2	4.73	6.01e-06	0.00509	0.37	0.39	Systemic lupus erythematosus;	chr6:34737753	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs2814959	ENSG00000186328.4	RP11-140K17.2	4.73	6.01e-06	0.00509	0.37	0.39	Systemic lupus erythematosus;	chr6:34738170	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs2764198	ENSG00000186328.4	RP11-140K17.2	4.73	6.01e-06	0.00509	0.37	0.39	Systemic lupus erythematosus;	chr6:34738351	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs2814961	ENSG00000186328.4	RP11-140K17.2	4.73	6.01e-06	0.00509	0.37	0.39	Systemic lupus erythematosus;	chr6:34739174	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs9462006	ENSG00000186328.4	RP11-140K17.2	4.73	6.01e-06	0.00509	0.37	0.39	Systemic lupus erythematosus;	chr6:34742550	chr6:34715613~34715940:+
TGCT	cis	rs3091242	0.933	rs35530120	ENSG00000224183.1	SDHDP6	4.73	6.01e-06	0.00509	0.41	0.39	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25294164~25294643:-
TGCT	cis	rs1618992	0.729	rs9807801	ENSG00000265994.1	RP11-510D21.1	4.73	6.02e-06	0.0051	0.4	0.39	Gut microbiome composition (summer and winter);	chr18:28582646	chr18:28785068~28789260:+
TGCT	cis	rs1519814	0.592	rs4870969	ENSG00000254343.2	RP11-760H22.2	-4.73	6.03e-06	0.00511	-0.64	-0.39	Breast cancer;	chr8:119994309	chr8:120052180~120056201:+
TGCT	cis	rs1891275	0.509	rs34190234	ENSG00000228701.1	TNKS2-AS1	-4.73	6.04e-06	0.00511	-0.44	-0.39	Intelligence (multi-trait analysis);	chr10:91683317	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.509	rs76313529	ENSG00000228701.1	TNKS2-AS1	-4.73	6.04e-06	0.00511	-0.44	-0.39	Intelligence (multi-trait analysis);	chr10:91683319	chr10:91782839~91798291:-
TGCT	cis	rs7182621	0.793	rs12904168	ENSG00000259363.4	CTD-2054N24.2	-4.73	6.04e-06	0.00511	-0.37	-0.39	Colonoscopy-negative controls vs population controls;	chr15:99869495	chr15:99807023~99877148:+
TGCT	cis	rs6600671	0.967	rs4844613	ENSG00000275131.1	CH17-472G23.4	-4.73	6.04e-06	0.00511	-0.25	-0.39	Hip geometry;	chr1:121431913	chr1:120489625~120579190:-
TGCT	cis	rs7208859	0.623	rs73269923	ENSG00000266490.1	CTD-2349P21.9	4.73	6.04e-06	0.00511	0.45	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30792372~30792833:+
TGCT	cis	rs1618992	0.703	rs7228474	ENSG00000265994.1	RP11-510D21.1	4.73	6.05e-06	0.00512	0.4	0.39	Gut microbiome composition (summer and winter);	chr18:28607243	chr18:28785068~28789260:+
TGCT	cis	rs4835473	0.932	rs12505628	ENSG00000251600.4	RP11-673E1.1	-4.73	6.06e-06	0.00513	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143758468	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs12505663	ENSG00000251600.4	RP11-673E1.1	-4.73	6.06e-06	0.00513	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143758491	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.868	rs12513078	ENSG00000251600.4	RP11-673E1.1	-4.73	6.06e-06	0.00513	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143758494	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs12505665	ENSG00000251600.4	RP11-673E1.1	-4.73	6.06e-06	0.00513	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143758515	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs12509716	ENSG00000251600.4	RP11-673E1.1	-4.73	6.06e-06	0.00513	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143758520	chr4:143912331~143982454:+
TGCT	cis	rs12143943	0.934	rs17335392	ENSG00000176754.11	LINC00303	4.73	6.06e-06	0.00513	0.35	0.39	Cognitive performance;	chr1:204626771	chr1:204032447~204041265:-
TGCT	cis	rs9400467	0.506	rs12207616	ENSG00000272356.1	RP5-1112D6.8	-4.73	6.07e-06	0.00513	-0.5	-0.39	Amino acid levels;Blood metabolite levels;	chr6:111287594	chr6:111309203~111313517:+
TGCT	cis	rs17826219	0.585	rs8064302	ENSG00000263531.1	RP13-753N3.1	-4.73	6.07e-06	0.00514	-0.68	-0.39	Body mass index;	chr17:30397920	chr17:30863921~30864940:-
TGCT	cis	rs875971	0.505	rs2462573	ENSG00000272831.1	RP11-792A8.4	-4.73	6.07e-06	0.00514	-0.41	-0.39	Aortic root size;	chr7:66042405	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.505	rs1167385	ENSG00000272831.1	RP11-792A8.4	-4.73	6.07e-06	0.00514	-0.41	-0.39	Aortic root size;	chr7:66048321	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.706	rs1643374	ENSG00000237310.1	GS1-124K5.4	4.73	6.07e-06	0.00514	0.45	0.39	Aortic root size;	chr7:66407695	chr7:66493706~66495474:+
TGCT	cis	rs16928809	0.52	rs74050440	ENSG00000183562.3	CTC-343N3.1	4.73	6.08e-06	0.00514	0.6	0.39	Bilirubin levels;	chr11:2941213	chr11:2989863~2991344:+
TGCT	cis	rs72819454	0.522	rs72815793	ENSG00000266852.2	MIR4482	4.73	6.09e-06	0.00515	0.64	0.39	Interleukin-9 levels;	chr10:103723366	chr10:104268336~104268405:-
TGCT	cis	rs6474412	1	rs1955186	ENSG00000255101.1	RP11-412B14.1	4.73	6.1e-06	0.00515	0.38	0.39	Smoking behavior;	chr8:42694348	chr8:42705583~42721946:-
TGCT	cis	rs6474412	1	rs1955185	ENSG00000255101.1	RP11-412B14.1	4.73	6.1e-06	0.00515	0.38	0.39	Smoking behavior;	chr8:42694504	chr8:42705583~42721946:-
TGCT	cis	rs6474412	1	rs13277524	ENSG00000255101.1	RP11-412B14.1	4.73	6.1e-06	0.00515	0.38	0.39	Smoking behavior;	chr8:42694914	chr8:42705583~42721946:-
TGCT	cis	rs6474412	0.957	rs6474413	ENSG00000255101.1	RP11-412B14.1	4.73	6.1e-06	0.00515	0.38	0.39	Smoking behavior;	chr8:42695921	chr8:42705583~42721946:-
TGCT	cis	rs6474412	1	rs6985052	ENSG00000255101.1	RP11-412B14.1	4.73	6.1e-06	0.00515	0.38	0.39	Smoking behavior;	chr8:42696176	chr8:42705583~42721946:-
TGCT	cis	rs8105895	0.935	rs8111854	ENSG00000269742.1	BNIP3P29	4.73	6.1e-06	0.00516	0.68	0.39	Body mass index (change over time);	chr19:22057411	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs8110969	ENSG00000269742.1	BNIP3P29	4.73	6.1e-06	0.00516	0.68	0.39	Body mass index (change over time);	chr19:22057420	chr19:22065828~22066398:-
TGCT	cis	rs1799955	1	rs11571725	ENSG00000215515.2	IFIT1P1	4.73	6.1e-06	0.00516	0.54	0.39	LDL cholesterol levels;	chr13:32364744	chr13:32384660~32386108:+
TGCT	cis	rs796364	0.806	rs203769	ENSG00000232732.8	AC073043.1	4.73	6.11e-06	0.00516	0.55	0.39	Schizophrenia;	chr2:200036143	chr2:199867396~199911159:-
TGCT	cis	rs12022452	0.556	rs12037288	ENSG00000238287.1	RP11-656D10.3	-4.73	6.11e-06	0.00516	-0.5	-0.39	Age-related hearing impairment (SNP x SNP interaction);	chr1:40530625	chr1:40493157~40508661:-
TGCT	cis	rs12022452	0.591	rs1001400	ENSG00000238287.1	RP11-656D10.3	-4.73	6.11e-06	0.00516	-0.5	-0.39	Age-related hearing impairment (SNP x SNP interaction);	chr1:40533230	chr1:40493157~40508661:-
TGCT	cis	rs786425	0.618	rs7294984	ENSG00000278112.1	RP11-972P1.11	4.73	6.11e-06	0.00517	0.46	0.39	Pubertal anthropometrics;	chr12:123657202	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.594	rs6488888	ENSG00000278112.1	RP11-972P1.11	4.73	6.11e-06	0.00517	0.46	0.39	Pubertal anthropometrics;	chr12:123658044	chr12:123519390~123519856:-
TGCT	cis	rs1618992	0.791	rs2847400	ENSG00000265994.1	RP11-510D21.1	4.73	6.12e-06	0.00517	0.39	0.39	Gut microbiome composition (summer and winter);	chr18:28645865	chr18:28785068~28789260:+
TGCT	cis	rs1618992	0.818	rs1504105	ENSG00000265994.1	RP11-510D21.1	4.73	6.12e-06	0.00517	0.39	0.39	Gut microbiome composition (summer and winter);	chr18:28646167	chr18:28785068~28789260:+
TGCT	cis	rs10759883	0.627	rs700962	ENSG00000175611.10	LINC00476	-4.73	6.12e-06	0.00517	-0.35	-0.39	Nicotine dependence;	chr9:95815766	chr9:95759231~95875977:-
TGCT	cis	rs1372520	0.577	rs748849	ENSG00000247775.2	SNCA-AS1	4.73	6.12e-06	0.00517	0.39	0.39	Neuroticism;	chr4:89813810	chr4:89836408~89841978:+
TGCT	cis	rs1372520	0.684	rs1442144	ENSG00000247775.2	SNCA-AS1	4.73	6.12e-06	0.00517	0.39	0.39	Neuroticism;	chr4:89814962	chr4:89836408~89841978:+
TGCT	cis	rs2019137	0.56	rs10206269	ENSG00000274877.1	RP11-65I12.1	-4.73	6.13e-06	0.00518	-0.39	-0.39	Lymphocyte counts;	chr2:113232816	chr2:113237595~113240825:+
TGCT	cis	rs6600671	1	rs4844381	ENSG00000275131.1	CH17-472G23.4	-4.73	6.13e-06	0.00518	-0.25	-0.39	Hip geometry;	chr1:121443040	chr1:120489625~120579190:-
TGCT	cis	rs7208859	0.623	rs1054400	ENSG00000266490.1	CTD-2349P21.9	4.72	6.13e-06	0.00518	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30792372~30792833:+
TGCT	cis	rs9425766	0.679	rs4650989	ENSG00000227373.4	RP11-160H22.5	4.72	6.13e-06	0.00518	0.42	0.39	Life satisfaction;	chr1:174289739	chr1:174115300~174160004:-
TGCT	cis	rs6600671	1	rs12047116	ENSG00000275131.1	CH17-472G23.4	-4.72	6.14e-06	0.00518	-0.25	-0.39	Hip geometry;	chr1:121443912	chr1:120489625~120579190:-
TGCT	cis	rs6600671	0.934	rs11249348	ENSG00000275131.1	CH17-472G23.4	-4.72	6.14e-06	0.00518	-0.25	-0.39	Hip geometry;	chr1:121446444	chr1:120489625~120579190:-
TGCT	cis	rs6600671	0.967	rs11249347	ENSG00000275131.1	CH17-472G23.4	-4.72	6.14e-06	0.00518	-0.25	-0.39	Hip geometry;	chr1:121446489	chr1:120489625~120579190:-
TGCT	cis	rs5742933	0.857	rs1233291	ENSG00000273240.1	RP11-455J20.3	-4.72	6.14e-06	0.00518	-0.36	-0.39	Ferritin levels;	chr2:189826225	chr2:189763859~189764456:-
TGCT	cis	rs7208859	0.51	rs216402	ENSG00000266490.1	CTD-2349P21.9	4.72	6.14e-06	0.00518	0.45	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30792372~30792833:+
TGCT	cis	rs796364	0.806	rs203767	ENSG00000232732.8	AC073043.1	4.72	6.14e-06	0.00518	0.57	0.39	Schizophrenia;	chr2:200037688	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.755	rs203762	ENSG00000232732.8	AC073043.1	4.72	6.14e-06	0.00518	0.57	0.39	Schizophrenia;	chr2:200040413	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs12619136	ENSG00000232732.8	AC073043.1	4.72	6.14e-06	0.00518	0.57	0.39	Schizophrenia;	chr2:200045624	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.76	rs56225698	ENSG00000232732.8	AC073043.1	4.72	6.14e-06	0.00518	0.57	0.39	Schizophrenia;	chr2:200045930	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs78527234	ENSG00000232732.8	AC073043.1	4.72	6.14e-06	0.00518	0.57	0.39	Schizophrenia;	chr2:200048730	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs74771155	ENSG00000232732.8	AC073043.1	4.72	6.14e-06	0.00518	0.57	0.39	Schizophrenia;	chr2:200049020	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs79156935	ENSG00000232732.8	AC073043.1	4.72	6.14e-06	0.00518	0.57	0.39	Schizophrenia;	chr2:200049099	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs79333757	ENSG00000232732.8	AC073043.1	4.72	6.14e-06	0.00518	0.57	0.39	Schizophrenia;	chr2:200050993	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs11688168	ENSG00000232732.8	AC073043.1	4.72	6.14e-06	0.00518	0.57	0.39	Schizophrenia;	chr2:200051281	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs11694236	ENSG00000232732.8	AC073043.1	4.72	6.14e-06	0.00518	0.57	0.39	Schizophrenia;	chr2:200051507	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs11688194	ENSG00000232732.8	AC073043.1	4.72	6.14e-06	0.00518	0.57	0.39	Schizophrenia;	chr2:200051516	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs34381014	ENSG00000232732.8	AC073043.1	4.72	6.14e-06	0.00518	0.57	0.39	Schizophrenia;	chr2:200051680	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.76	rs56285751	ENSG00000232732.8	AC073043.1	4.72	6.14e-06	0.00518	0.57	0.39	Schizophrenia;	chr2:200055113	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs11679658	ENSG00000232732.8	AC073043.1	4.72	6.14e-06	0.00518	0.57	0.39	Schizophrenia;	chr2:200058358	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs76568708	ENSG00000232732.8	AC073043.1	4.72	6.14e-06	0.00518	0.57	0.39	Schizophrenia;	chr2:200064808	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs6743396	ENSG00000232732.8	AC073043.1	-4.72	6.14e-06	0.00518	-0.57	-0.39	Schizophrenia;	chr2:199995415	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs6435040	ENSG00000232732.8	AC073043.1	-4.72	6.14e-06	0.00518	-0.57	-0.39	Schizophrenia;	chr2:199996438	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs4673634	ENSG00000232732.8	AC073043.1	-4.72	6.14e-06	0.00518	-0.57	-0.39	Schizophrenia;	chr2:199998626	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs6435041	ENSG00000232732.8	AC073043.1	-4.72	6.14e-06	0.00518	-0.57	-0.39	Schizophrenia;	chr2:200002421	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs1605900	ENSG00000232732.8	AC073043.1	-4.72	6.14e-06	0.00518	-0.57	-0.39	Schizophrenia;	chr2:200005474	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs1509832	ENSG00000232732.8	AC073043.1	-4.72	6.14e-06	0.00518	-0.57	-0.39	Schizophrenia;	chr2:200009720	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.76	rs2202922	ENSG00000232732.8	AC073043.1	-4.72	6.14e-06	0.00518	-0.57	-0.39	Schizophrenia;	chr2:200017887	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.664	rs3106089	ENSG00000232732.8	AC073043.1	-4.72	6.14e-06	0.00518	-0.57	-0.39	Schizophrenia;	chr2:200019892	chr2:199867396~199911159:-
TGCT	cis	rs10875746	0.904	rs11168422	ENSG00000240399.1	RP1-228P16.1	-4.72	6.15e-06	0.00519	-0.47	-0.39	Longevity (90 years and older);	chr12:48125722	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.951	rs10875747	ENSG00000240399.1	RP1-228P16.1	-4.72	6.15e-06	0.00519	-0.47	-0.39	Longevity (90 years and older);	chr12:48132078	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.951	rs10875748	ENSG00000240399.1	RP1-228P16.1	-4.72	6.15e-06	0.00519	-0.47	-0.39	Longevity (90 years and older);	chr12:48132577	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.951	rs2286021	ENSG00000240399.1	RP1-228P16.1	-4.72	6.15e-06	0.00519	-0.47	-0.39	Longevity (90 years and older);	chr12:48134437	chr12:48054813~48055591:-
TGCT	cis	rs12439619	0.846	rs28470877	ENSG00000255769.6	GOLGA2P10	-4.72	6.16e-06	0.0052	-0.47	-0.39	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472993~82513950:-
TGCT	cis	rs5742933	0.817	rs2033870	ENSG00000273240.1	RP11-455J20.3	-4.72	6.17e-06	0.0052	-0.37	-0.39	Ferritin levels;	chr2:189739104	chr2:189763859~189764456:-
TGCT	cis	rs2739330	0.791	rs4822458	ENSG00000250470.1	AP000351.3	4.72	6.17e-06	0.0052	0.39	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23976904~23977585:-
TGCT	cis	rs12891047	0.726	rs986382	ENSG00000258759.1	RP11-1012A1.7	-4.72	6.17e-06	0.00521	-0.32	-0.39	Amyotrophic lateral sclerosis (sporadic);	chr14:67860736	chr14:67799004~67799609:+
TGCT	cis	rs7729723	1	rs7729723	ENSG00000250159.5	RP11-381K20.2	-4.72	6.17e-06	0.00521	-0.41	-0.39	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);	chr5:138461691	chr5:137814333~137889336:-
TGCT	cis	rs13134327	0.513	rs7679687	ENSG00000251600.4	RP11-673E1.1	-4.72	6.18e-06	0.00521	-0.41	-0.39	Glycated hemoglobin levels;	chr4:144024031	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.618	rs7685385	ENSG00000251600.4	RP11-673E1.1	-4.72	6.18e-06	0.00521	-0.41	-0.39	Immature fraction of reticulocytes;	chr4:144029851	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.838	rs10024263	ENSG00000251600.4	RP11-673E1.1	4.72	6.18e-06	0.00521	0.41	0.39	Immature fraction of reticulocytes;	chr4:144038174	chr4:143912331~143982454:+
TGCT	cis	rs7221109	0.677	rs7209467	ENSG00000278834.1	RP11-458J1.1	4.72	6.18e-06	0.00521	0.29	0.39	Type 1 diabetes;	chr17:40653033	chr17:40648300~40649718:+
TGCT	cis	rs9322193	0.923	rs12660304	ENSG00000216906.2	RP11-350J20.9	4.72	6.18e-06	0.00521	0.43	0.39	Lung cancer;	chr6:149739647	chr6:149904243~149906418:+
TGCT	cis	rs2117029	0.521	rs1039225	ENSG00000258017.1	RP11-386G11.10	-4.72	6.2e-06	0.00523	-0.52	-0.39	Intelligence (multi-trait analysis);	chr12:49188909	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.521	rs11168910	ENSG00000258017.1	RP11-386G11.10	-4.72	6.2e-06	0.00523	-0.52	-0.39	Intelligence (multi-trait analysis);	chr12:49192707	chr12:49127782~49147869:+
TGCT	cis	rs7221109	0.677	rs7219483	ENSG00000278834.1	RP11-458J1.1	4.72	6.21e-06	0.00523	0.29	0.39	Type 1 diabetes;	chr17:40651705	chr17:40648300~40649718:+
TGCT	cis	rs7221109	0.645	rs2014704	ENSG00000278834.1	RP11-458J1.1	4.72	6.21e-06	0.00523	0.29	0.39	Type 1 diabetes;	chr17:40651997	chr17:40648300~40649718:+
TGCT	cis	rs34779708	0.931	rs2384287	ENSG00000230534.5	RP11-297A16.2	4.72	6.21e-06	0.00524	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35051631	chr10:35098006~35127020:-
TGCT	cis	rs9462027	0.606	rs2744959	ENSG00000186328.4	RP11-140K17.2	4.72	6.22e-06	0.00524	0.37	0.39	Systemic lupus erythematosus;	chr6:34648877	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs2814992	ENSG00000186328.4	RP11-140K17.2	4.72	6.22e-06	0.00524	0.37	0.39	Systemic lupus erythematosus;	chr6:34649367	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs2744957	ENSG00000186328.4	RP11-140K17.2	4.72	6.22e-06	0.00524	0.37	0.39	Systemic lupus erythematosus;	chr6:34650739	chr6:34715613~34715940:+
TGCT	cis	rs7208859	0.573	rs55661352	ENSG00000266490.1	CTD-2349P21.9	4.72	6.22e-06	0.00524	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30792372~30792833:+
TGCT	cis	rs875971	0.628	rs6974355	ENSG00000236529.1	RP13-254B10.1	4.72	6.23e-06	0.00524	0.3	0.39	Aortic root size;	chr7:66376994	chr7:65840212~65840596:+
TGCT	cis	rs4925386	0.921	rs11204472	ENSG00000273619.1	RP5-908M14.9	4.72	6.24e-06	0.00525	0.43	0.39	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345831	chr20:62386303~62386970:-
TGCT	cis	rs7829975	0.51	rs332037	ENSG00000254340.1	RP11-10A14.3	4.72	6.24e-06	0.00525	0.4	0.39	Mood instability;	chr8:8865165	chr8:9141424~9145435:+
TGCT	cis	rs7044106	1	rs7044106	ENSG00000226752.6	PSMD5-AS1	-4.72	6.25e-06	0.00525	-0.54	-0.39	Hip circumference adjusted for BMI;	chr9:120731784	chr9:120824828~120854385:+
TGCT	cis	rs17826219	0.733	rs7221691	ENSG00000280069.1	CTD-2349P21.3	4.72	6.25e-06	0.00526	0.51	0.39	Body mass index;	chr17:30396601	chr17:30738182~30740275:+
TGCT	cis	rs4925386	1	rs4925389	ENSG00000273619.1	RP5-908M14.9	4.72	6.25e-06	0.00526	0.43	0.39	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62347456	chr20:62386303~62386970:-
TGCT	cis	rs67311347	1	rs4571217	ENSG00000223797.4	ENTPD3-AS1	4.72	6.26e-06	0.00526	0.43	0.39	Renal cell carcinoma;	chr3:40480482	chr3:40313802~40453329:-
TGCT	cis	rs4835473	0.9	rs10003922	ENSG00000251600.4	RP11-673E1.1	-4.72	6.26e-06	0.00527	-0.4	-0.39	Immature fraction of reticulocytes;	chr4:143921235	chr4:143912331~143982454:+
TGCT	cis	rs1799949	0.965	rs6503726	ENSG00000198496.9	NBR2	-4.72	6.27e-06	0.00527	-0.55	-0.39	Menopause (age at onset);	chr17:43132725	chr17:43125610~43153671:+
TGCT	cis	rs2117029	0.555	rs3741621	ENSG00000258017.1	RP11-386G11.10	-4.72	6.27e-06	0.00527	-0.51	-0.39	Intelligence (multi-trait analysis);	chr12:49100242	chr12:49127782~49147869:+
TGCT	cis	rs2976388	0.647	rs13272904	ENSG00000253196.1	RP11-706C16.7	4.72	6.28e-06	0.00528	0.39	0.39	Urinary tract infection frequency;	chr8:142701196	chr8:142763116~142766427:+
TGCT	cis	rs651907	0.557	rs13066768	ENSG00000244119.1	PDCL3P4	-4.72	6.28e-06	0.00528	-0.28	-0.39	Colorectal cancer;	chr3:101768076	chr3:101712472~101713191:+
TGCT	cis	rs73198271	0.53	rs11778326	ENSG00000253893.2	FAM85B	4.72	6.29e-06	0.00528	0.62	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794056	chr8:8167819~8226614:-
TGCT	cis	rs73198271	0.562	rs113730597	ENSG00000253893.2	FAM85B	4.72	6.29e-06	0.00528	0.62	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794063	chr8:8167819~8226614:-
TGCT	cis	rs73198271	0.562	rs11774860	ENSG00000253893.2	FAM85B	4.72	6.29e-06	0.00528	0.62	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794369	chr8:8167819~8226614:-
TGCT	cis	rs73198271	0.531	rs17154756	ENSG00000253893.2	FAM85B	4.72	6.29e-06	0.00528	0.62	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794884	chr8:8167819~8226614:-
TGCT	cis	rs73198271	0.531	rs11985640	ENSG00000253893.2	FAM85B	4.72	6.29e-06	0.00528	0.62	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794994	chr8:8167819~8226614:-
TGCT	cis	rs73198271	0.531	rs56100346	ENSG00000253893.2	FAM85B	4.72	6.29e-06	0.00528	0.62	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8795334	chr8:8167819~8226614:-
TGCT	cis	rs73198271	0.531	rs17154758	ENSG00000253893.2	FAM85B	4.72	6.29e-06	0.00528	0.62	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8795833	chr8:8167819~8226614:-
TGCT	cis	rs73198271	0.53	rs113160067	ENSG00000253893.2	FAM85B	4.72	6.29e-06	0.00528	0.62	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8797011	chr8:8167819~8226614:-
TGCT	cis	rs11671005	0.779	rs3794970	ENSG00000268912.1	CTD-2619J13.17	4.72	6.29e-06	0.00528	0.49	0.39	Mean platelet volume;	chr19:58474893	chr19:58428632~58431148:-
TGCT	cis	rs875971	0.798	rs6460304	ENSG00000232559.3	GS1-124K5.12	4.72	6.3e-06	0.00529	0.36	0.39	Aortic root size;	chr7:66499741	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs6945775	ENSG00000232559.3	GS1-124K5.12	4.72	6.3e-06	0.00529	0.36	0.39	Aortic root size;	chr7:66503987	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.798	rs57739047	ENSG00000232559.3	GS1-124K5.12	4.72	6.3e-06	0.00529	0.36	0.39	Aortic root size;	chr7:66507579	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.83	rs6950137	ENSG00000232559.3	GS1-124K5.12	4.72	6.3e-06	0.00529	0.36	0.39	Aortic root size;	chr7:66511623	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs11763189	ENSG00000232559.3	GS1-124K5.12	4.72	6.3e-06	0.00529	0.36	0.39	Aortic root size;	chr7:66518542	chr7:66554588~66576923:-
TGCT	cis	rs673078	0.66	rs17512609	ENSG00000275759.1	RP11-131L12.3	-4.72	6.3e-06	0.00529	-0.72	-0.39	Glucose homeostasis traits;	chr12:118354072	chr12:118428281~118428870:+
TGCT	cis	rs9880211	0.706	rs67382287	ENSG00000239213.4	NCK1-AS1	4.72	6.31e-06	0.00529	0.42	0.39	Height;Body mass index;	chr3:136661617	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.8	rs9813376	ENSG00000239213.4	NCK1-AS1	4.72	6.31e-06	0.00529	0.42	0.39	Height;Body mass index;	chr3:136756584	chr3:136841726~136862054:-
TGCT	cis	rs4660456	0.913	rs16827569	ENSG00000237899.1	RP4-739H11.3	-4.72	6.31e-06	0.00529	-0.51	-0.39	Platelet count;	chr1:40761655	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs2361650	ENSG00000237899.1	RP4-739H11.3	-4.72	6.31e-06	0.00529	-0.51	-0.39	Platelet count;	chr1:40764678	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs954654	ENSG00000237899.1	RP4-739H11.3	-4.72	6.31e-06	0.00529	-0.51	-0.39	Platelet count;	chr1:40764979	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.826	rs3767952	ENSG00000237899.1	RP4-739H11.3	-4.72	6.31e-06	0.00529	-0.51	-0.39	Platelet count;	chr1:40765360	chr1:40669089~40687588:-
TGCT	cis	rs9326248	1	rs9326248	ENSG00000280143.1	AP000892.6	4.72	6.31e-06	0.0053	0.53	0.39	Blood protein levels;	chr11:117128509	chr11:117204967~117210292:+
TGCT	cis	rs1153858	1	rs10519022	ENSG00000259520.4	CTD-2651B20.3	4.72	6.32e-06	0.0053	0.37	0.39	Homoarginine levels;	chr15:45371486	chr15:45251580~45279251:-
TGCT	cis	rs7221109	0.677	rs3752026	ENSG00000278834.1	RP11-458J1.1	4.72	6.32e-06	0.0053	0.29	0.39	Type 1 diabetes;	chr17:40648309	chr17:40648300~40649718:+
TGCT	cis	rs9462027	0.628	rs2814942	ENSG00000186328.4	RP11-140K17.2	4.72	6.33e-06	0.00531	0.37	0.39	Systemic lupus erythematosus;	chr6:34676484	chr6:34715613~34715940:+
TGCT	cis	rs9880211	0.8	rs9845862	ENSG00000239213.4	NCK1-AS1	4.72	6.33e-06	0.00531	0.42	0.39	Height;Body mass index;	chr3:136753731	chr3:136841726~136862054:-
TGCT	cis	rs2709736	0.596	rs204576	ENSG00000232790.2	LINC01162	-4.72	6.33e-06	0.00531	-0.31	-0.39	Bipolar I disorder;	chr7:20860040	chr7:20835431~21023148:+
TGCT	cis	rs2709736	0.596	rs204577	ENSG00000232790.2	LINC01162	-4.72	6.33e-06	0.00531	-0.31	-0.39	Bipolar I disorder;	chr7:20860063	chr7:20835431~21023148:+
TGCT	cis	rs2709736	0.596	rs204579	ENSG00000232790.2	LINC01162	-4.72	6.33e-06	0.00531	-0.31	-0.39	Bipolar I disorder;	chr7:20860945	chr7:20835431~21023148:+
TGCT	cis	rs2709736	0.596	rs204580	ENSG00000232790.2	LINC01162	-4.72	6.33e-06	0.00531	-0.31	-0.39	Bipolar I disorder;	chr7:20861264	chr7:20835431~21023148:+
TGCT	cis	rs2709736	0.596	rs204583	ENSG00000232790.2	LINC01162	-4.72	6.33e-06	0.00531	-0.31	-0.39	Bipolar I disorder;	chr7:20862294	chr7:20835431~21023148:+
TGCT	cis	rs2709736	0.596	rs204584	ENSG00000232790.2	LINC01162	-4.72	6.33e-06	0.00531	-0.31	-0.39	Bipolar I disorder;	chr7:20862425	chr7:20835431~21023148:+
TGCT	cis	rs2709736	0.596	rs204586	ENSG00000232790.2	LINC01162	-4.72	6.33e-06	0.00531	-0.31	-0.39	Bipolar I disorder;	chr7:20863343	chr7:20835431~21023148:+
TGCT	cis	rs2709736	0.562	rs204587	ENSG00000232790.2	LINC01162	-4.72	6.33e-06	0.00531	-0.31	-0.39	Bipolar I disorder;	chr7:20864651	chr7:20835431~21023148:+
TGCT	cis	rs2709736	0.563	rs204589	ENSG00000232790.2	LINC01162	-4.72	6.33e-06	0.00531	-0.31	-0.39	Bipolar I disorder;	chr7:20866409	chr7:20835431~21023148:+
TGCT	cis	rs9425766	0.64	rs6685314	ENSG00000227373.4	RP11-160H22.5	4.72	6.34e-06	0.00531	0.43	0.39	Life satisfaction;	chr1:174089905	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.679	rs12563301	ENSG00000227373.4	RP11-160H22.5	4.72	6.34e-06	0.00531	0.43	0.39	Life satisfaction;	chr1:174090924	chr1:174115300~174160004:-
TGCT	cis	rs728616	0.867	rs34870056	ENSG00000230091.5	TMEM254-AS1	4.72	6.34e-06	0.00531	0.71	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80188299	chr10:80046860~80078912:-
TGCT	cis	rs72819454	0.579	rs72815788	ENSG00000266852.2	MIR4482	4.72	6.34e-06	0.00532	0.62	0.39	Interleukin-9 levels;	chr10:103720257	chr10:104268336~104268405:-
TGCT	cis	rs4268898	0.686	rs2042468	ENSG00000223754.1	AC008073.9	-4.72	6.35e-06	0.00532	-0.43	-0.39	Asthma;	chr2:24175577	chr2:24199839~24201698:-
TGCT	cis	rs7847628	0.666	rs2031974	ENSG00000226752.6	PSMD5-AS1	-4.72	6.35e-06	0.00532	-0.53	-0.39	Birth weight;	chr9:120765243	chr9:120824828~120854385:+
TGCT	cis	rs9867325	0.778	rs9877089	ENSG00000239213.4	NCK1-AS1	4.72	6.35e-06	0.00532	0.45	0.39	Body mass index;	chr3:136937751	chr3:136841726~136862054:-
TGCT	cis	rs901683	1	rs2279433	ENSG00000264204.2	AGAP7P	-4.72	6.35e-06	0.00533	-0.83	-0.39	Mean corpuscular volume;Red blood cell traits;	chr10:45459359	chr10:46109621~46131358:+
TGCT	cis	rs2463822	0.925	rs1881535	ENSG00000254454.2	RCC2P6	-4.72	6.35e-06	0.00533	-0.41	-0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62354151	chr11:62371146~62373168:+
TGCT	cis	rs2463822	0.858	rs2463836	ENSG00000254454.2	RCC2P6	-4.72	6.35e-06	0.00533	-0.41	-0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62359022	chr11:62371146~62373168:+
TGCT	cis	rs2463822	1	rs7481995	ENSG00000254454.2	RCC2P6	-4.72	6.35e-06	0.00533	-0.41	-0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62361840	chr11:62371146~62373168:+
TGCT	cis	rs2463822	1	rs72921498	ENSG00000254454.2	RCC2P6	4.72	6.35e-06	0.00533	0.41	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62345618	chr11:62371146~62373168:+
TGCT	cis	rs1823913	0.599	rs17414109	ENSG00000227542.1	AC092614.2	4.72	6.35e-06	0.00533	0.42	0.39	Obesity-related traits;	chr2:191310675	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs13020656	ENSG00000227542.1	AC092614.2	4.72	6.35e-06	0.00533	0.42	0.39	Obesity-related traits;	chr2:191314197	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.538	rs35311234	ENSG00000227542.1	AC092614.2	4.72	6.35e-06	0.00533	0.42	0.39	Obesity-related traits;	chr2:191316952	chr2:191229165~191246172:-
TGCT	cis	rs7829975	0.522	rs6601689	ENSG00000173295.6	FAM86B3P	4.72	6.36e-06	0.00533	0.43	0.39	Mood instability;	chr8:8314761	chr8:8228595~8244865:+
TGCT	cis	rs8059260	0.604	rs11863415	ENSG00000274038.1	RP11-66H6.4	-4.72	6.37e-06	0.00534	-0.54	-0.39	Alcohol consumption over the past year;	chr16:11053237	chr16:11056556~11057034:+
TGCT	cis	rs17301013	0.507	rs6689327	ENSG00000227373.4	RP11-160H22.5	4.72	6.37e-06	0.00534	0.48	0.39	Systemic lupus erythematosus;	chr1:174464274	chr1:174115300~174160004:-
TGCT	cis	rs17826219	0.733	rs7221691	ENSG00000263531.1	RP13-753N3.1	-4.72	6.37e-06	0.00534	-0.68	-0.39	Body mass index;	chr17:30396601	chr17:30863921~30864940:-
TGCT	cis	rs2463822	1	rs2463821	ENSG00000254454.2	RCC2P6	-4.72	6.38e-06	0.00534	-0.44	-0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62344190	chr11:62371146~62373168:+
TGCT	cis	rs2463822	1	rs2463820	ENSG00000254454.2	RCC2P6	-4.72	6.38e-06	0.00534	-0.44	-0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62344818	chr11:62371146~62373168:+
TGCT	cis	rs321358	0.79	rs73015129	ENSG00000271584.1	RP11-89C3.4	4.72	6.39e-06	0.00535	0.5	0.39	Body mass index;	chr11:111076157	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.79	rs73015134	ENSG00000271584.1	RP11-89C3.4	4.72	6.39e-06	0.00535	0.5	0.39	Body mass index;	chr11:111076520	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.79	rs77820525	ENSG00000271584.1	RP11-89C3.4	4.72	6.39e-06	0.00535	0.5	0.39	Body mass index;	chr11:111076697	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.848	rs73015141	ENSG00000271584.1	RP11-89C3.4	4.72	6.39e-06	0.00535	0.5	0.39	Body mass index;	chr11:111077556	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.848	rs73015142	ENSG00000271584.1	RP11-89C3.4	4.72	6.39e-06	0.00535	0.5	0.39	Body mass index;	chr11:111078647	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.848	rs78087740	ENSG00000271584.1	RP11-89C3.4	4.72	6.39e-06	0.00535	0.5	0.39	Body mass index;	chr11:111079016	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.848	rs73015146	ENSG00000271584.1	RP11-89C3.4	4.72	6.39e-06	0.00535	0.5	0.39	Body mass index;	chr11:111079143	chr11:111091932~111097357:-
TGCT	cis	rs111321694	1	rs111321694	ENSG00000271584.1	RP11-89C3.4	4.72	6.39e-06	0.00535	0.5	0.39	Educational attainment (years of education);	chr11:111079662	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.895	rs17457076	ENSG00000271584.1	RP11-89C3.4	4.72	6.39e-06	0.00535	0.5	0.39	Body mass index;	chr11:111081030	chr11:111091932~111097357:-
TGCT	cis	rs651907	0.557	rs62284199	ENSG00000244119.1	PDCL3P4	4.71	6.4e-06	0.00536	0.28	0.39	Colorectal cancer;	chr3:101759687	chr3:101712472~101713191:+
TGCT	cis	rs5769707	0.935	rs739239	ENSG00000235111.1	RP1-29C18.8	-4.71	6.4e-06	0.00536	-0.31	-0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49656820	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.874	rs9616714	ENSG00000235111.1	RP1-29C18.8	-4.71	6.4e-06	0.00536	-0.31	-0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49657211	chr22:49612657~49615716:-
TGCT	cis	rs2463822	0.844	rs2513737	ENSG00000254454.2	RCC2P6	-4.71	6.41e-06	0.00536	-0.41	-0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62352023	chr11:62371146~62373168:+
TGCT	cis	rs2463822	0.925	rs74692811	ENSG00000254454.2	RCC2P6	4.71	6.41e-06	0.00536	0.41	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62389100	chr11:62371146~62373168:+
TGCT	cis	rs7208859	0.673	rs216409	ENSG00000263531.1	RP13-753N3.1	-4.71	6.41e-06	0.00537	-0.68	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs216424	ENSG00000280069.1	CTD-2349P21.3	-4.71	6.42e-06	0.00537	-0.52	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30738182~30740275:+
TGCT	cis	rs7617773	0.925	rs35942721	ENSG00000229759.1	MRPS18AP1	4.71	6.42e-06	0.00537	0.34	0.39	Coronary artery disease;	chr3:48131579	chr3:48256350~48256938:-
TGCT	cis	rs4660456	0.871	rs7549789	ENSG00000237899.1	RP4-739H11.3	-4.71	6.43e-06	0.00538	-0.51	-0.39	Platelet count;	chr1:40759362	chr1:40669089~40687588:-
TGCT	cis	rs911555	0.723	rs11160751	ENSG00000244691.1	RPL10AP1	-4.71	6.44e-06	0.00539	-0.52	-0.39	Intelligence (multi-trait analysis);	chr14:103459403	chr14:103412119~103412761:-
TGCT	cis	rs911555	0.713	rs10162425	ENSG00000244691.1	RPL10AP1	-4.71	6.44e-06	0.00539	-0.52	-0.39	Intelligence (multi-trait analysis);	chr14:103465284	chr14:103412119~103412761:-
TGCT	cis	rs911555	0.755	rs6575988	ENSG00000244691.1	RPL10AP1	4.71	6.44e-06	0.00539	0.52	0.39	Intelligence (multi-trait analysis);	chr14:103434490	chr14:103412119~103412761:-
TGCT	cis	rs10875746	0.729	rs11168355	ENSG00000240399.1	RP1-228P16.1	4.71	6.44e-06	0.00539	0.45	0.39	Longevity (90 years and older);	chr12:48017195	chr12:48054813~48055591:-
TGCT	cis	rs7208859	0.623	rs426434	ENSG00000280069.1	CTD-2349P21.3	-4.71	6.44e-06	0.00539	-0.55	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30738182~30740275:+
TGCT	cis	rs10256972	0.552	rs2949195	ENSG00000226291.1	AC091729.8	-4.71	6.44e-06	0.00539	-0.41	-0.39	Endometriosis;Longevity;	chr7:1163069	chr7:1080863~1082178:+
TGCT	cis	rs1707322	0.721	rs10890333	ENSG00000280836.1	AL355480.1	-4.71	6.44e-06	0.00539	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs12043945	ENSG00000280836.1	AL355480.1	-4.71	6.44e-06	0.00539	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs12091503	ENSG00000280836.1	AL355480.1	-4.71	6.44e-06	0.00539	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs10890336	ENSG00000280836.1	AL355480.1	-4.71	6.44e-06	0.00539	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs11211151	ENSG00000280836.1	AL355480.1	-4.71	6.44e-06	0.00539	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs12045096	ENSG00000280836.1	AL355480.1	-4.71	6.44e-06	0.00539	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs4609469	ENSG00000280836.1	AL355480.1	-4.71	6.44e-06	0.00539	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs12049027	ENSG00000280836.1	AL355480.1	-4.71	6.44e-06	0.00539	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.752	rs10789467	ENSG00000280836.1	AL355480.1	-4.71	6.44e-06	0.00539	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs10890337	ENSG00000280836.1	AL355480.1	-4.71	6.44e-06	0.00539	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.752	rs3811435	ENSG00000280836.1	AL355480.1	-4.71	6.44e-06	0.00539	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs9793568	ENSG00000280836.1	AL355480.1	-4.71	6.44e-06	0.00539	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs11211157	ENSG00000280836.1	AL355480.1	-4.71	6.44e-06	0.00539	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs11211158	ENSG00000280836.1	AL355480.1	-4.71	6.44e-06	0.00539	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs6429575	ENSG00000280836.1	AL355480.1	-4.71	6.44e-06	0.00539	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.685	rs6690926	ENSG00000280836.1	AL355480.1	-4.71	6.44e-06	0.00539	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.752	rs8179402	ENSG00000280836.1	AL355480.1	-4.71	6.44e-06	0.00539	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.752	rs8179296	ENSG00000280836.1	AL355480.1	-4.71	6.44e-06	0.00539	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45581219~45581321:-
TGCT	cis	rs1865760	1	rs2071299	ENSG00000217159.2	LARP1P1	-4.71	6.45e-06	0.00539	-0.46	-0.39	Height;	chr6:25914573	chr6:26164072~26164363:+
TGCT	cis	rs1865760	1	rs2071298	ENSG00000217159.2	LARP1P1	-4.71	6.45e-06	0.00539	-0.46	-0.39	Height;	chr6:25914673	chr6:26164072~26164363:+
TGCT	cis	rs1865760	0.964	rs1324084	ENSG00000217159.2	LARP1P1	-4.71	6.45e-06	0.00539	-0.46	-0.39	Height;	chr6:25914906	chr6:26164072~26164363:+
TGCT	cis	rs1865760	1	rs1865760	ENSG00000217159.2	LARP1P1	-4.71	6.45e-06	0.00539	-0.46	-0.39	Height;	chr6:25916751	chr6:26164072~26164363:+
TGCT	cis	rs12891047	0.726	rs11626594	ENSG00000258759.1	RP11-1012A1.7	-4.71	6.46e-06	0.0054	-0.32	-0.39	Amyotrophic lateral sclerosis (sporadic);	chr14:67884622	chr14:67799004~67799609:+
TGCT	cis	rs4925386	0.959	rs6121989	ENSG00000273619.1	RP5-908M14.9	4.71	6.46e-06	0.0054	0.43	0.39	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62341657	chr20:62386303~62386970:-
TGCT	cis	rs8072100	0.748	rs9912592	ENSG00000228782.6	CTD-2026D20.3	4.71	6.46e-06	0.0054	0.47	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47479579	chr17:47450568~47492492:-
TGCT	cis	rs8059260	0.541	rs8046052	ENSG00000274038.1	RP11-66H6.4	-4.71	6.46e-06	0.0054	-0.53	-0.39	Alcohol consumption over the past year;	chr16:11129464	chr16:11056556~11057034:+
TGCT	cis	rs10504229	0.953	rs2270610	ENSG00000253301.4	RP11-513O17.2	4.71	6.47e-06	0.0054	0.51	0.39	Developmental language disorder (linguistic errors);	chr8:57282110	chr8:57142689~57240298:+
TGCT	cis	rs12439619	0.693	rs4778989	ENSG00000255769.6	GOLGA2P10	-4.71	6.47e-06	0.00541	-0.45	-0.39	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472993~82513950:-
TGCT	cis	rs4835473	0.897	rs7662736	ENSG00000251600.4	RP11-673E1.1	4.71	6.48e-06	0.00541	0.41	0.39	Immature fraction of reticulocytes;	chr4:143958036	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.8	rs1849134	ENSG00000251600.4	RP11-673E1.1	4.71	6.48e-06	0.00541	0.41	0.39	Immature fraction of reticulocytes;	chr4:143958260	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.8	rs1849133	ENSG00000251600.4	RP11-673E1.1	4.71	6.48e-06	0.00541	0.41	0.39	Immature fraction of reticulocytes;	chr4:143958262	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.864	rs1849132	ENSG00000251600.4	RP11-673E1.1	4.71	6.48e-06	0.00541	0.41	0.39	Immature fraction of reticulocytes;	chr4:143958309	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs13123407	ENSG00000251600.4	RP11-673E1.1	4.71	6.48e-06	0.00541	0.41	0.39	Immature fraction of reticulocytes;	chr4:143958713	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs61611095	ENSG00000251600.4	RP11-673E1.1	4.71	6.48e-06	0.00541	0.41	0.39	Immature fraction of reticulocytes;	chr4:143958802	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs4835449	ENSG00000251600.4	RP11-673E1.1	4.71	6.48e-06	0.00541	0.41	0.39	Immature fraction of reticulocytes;	chr4:143958830	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.77	rs4835096	ENSG00000251600.4	RP11-673E1.1	4.71	6.48e-06	0.00541	0.41	0.39	Immature fraction of reticulocytes;	chr4:143960685	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1838516	ENSG00000251600.4	RP11-673E1.1	4.71	6.48e-06	0.00541	0.41	0.39	Immature fraction of reticulocytes;	chr4:143962082	chr4:143912331~143982454:+
TGCT	cis	rs2709736	0.571	rs7787115	ENSG00000232790.2	LINC01162	4.71	6.49e-06	0.00542	0.32	0.39	Bipolar I disorder;	chr7:20891706	chr7:20835431~21023148:+
TGCT	cis	rs875971	0.83	rs778711	ENSG00000237310.1	GS1-124K5.4	4.71	6.49e-06	0.00542	0.41	0.39	Aortic root size;	chr7:66386670	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs1083554	ENSG00000237310.1	GS1-124K5.4	4.71	6.49e-06	0.00542	0.41	0.39	Aortic root size;	chr7:66387354	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs778707	ENSG00000237310.1	GS1-124K5.4	4.71	6.49e-06	0.00542	0.41	0.39	Aortic root size;	chr7:66392040	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs778705	ENSG00000237310.1	GS1-124K5.4	4.71	6.49e-06	0.00542	0.41	0.39	Aortic root size;	chr7:66396128	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs778697	ENSG00000237310.1	GS1-124K5.4	4.71	6.49e-06	0.00542	0.41	0.39	Aortic root size;	chr7:66405439	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.798	rs7789615	ENSG00000237310.1	GS1-124K5.4	4.71	6.49e-06	0.00542	0.41	0.39	Aortic root size;	chr7:66413674	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs6978028	ENSG00000237310.1	GS1-124K5.4	4.71	6.49e-06	0.00542	0.41	0.39	Aortic root size;	chr7:66421313	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs6947339	ENSG00000237310.1	GS1-124K5.4	4.71	6.49e-06	0.00542	0.41	0.39	Aortic root size;	chr7:66423483	chr7:66493706~66495474:+
TGCT	cis	rs11671005	0.651	rs35117909	ENSG00000268912.1	CTD-2619J13.17	-4.71	6.49e-06	0.00542	-0.48	-0.39	Mean platelet volume;	chr19:58401539	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.693	rs34023391	ENSG00000268912.1	CTD-2619J13.17	-4.71	6.49e-06	0.00542	-0.48	-0.39	Mean platelet volume;	chr19:58402001	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.693	rs11666928	ENSG00000268912.1	CTD-2619J13.17	-4.71	6.49e-06	0.00542	-0.48	-0.39	Mean platelet volume;	chr19:58402864	chr19:58428632~58431148:-
TGCT	cis	rs875971	0.862	rs778734	ENSG00000237310.1	GS1-124K5.4	4.71	6.49e-06	0.00542	0.42	0.39	Aortic root size;	chr7:66349862	chr7:66493706~66495474:+
TGCT	cis	rs2019137	0.56	rs7421852	ENSG00000274877.1	RP11-65I12.1	-4.71	6.49e-06	0.00542	-0.39	-0.39	Lymphocyte counts;	chr2:113232684	chr2:113237595~113240825:+
TGCT	cis	rs10829156	1	rs10829156	ENSG00000240291.1	RP11-499P20.2	4.71	6.5e-06	0.00543	0.35	0.39	Sudden cardiac arrest;	chr10:18661626	chr10:18513115~18545651:-
TGCT	cis	rs7829975	0.681	rs2271342	ENSG00000173295.6	FAM86B3P	4.71	6.51e-06	0.00543	0.47	0.39	Mood instability;	chr8:8786428	chr8:8228595~8244865:+
TGCT	cis	rs7829975	0.591	rs12677543	ENSG00000173295.6	FAM86B3P	4.71	6.51e-06	0.00543	0.47	0.39	Mood instability;	chr8:8786764	chr8:8228595~8244865:+
TGCT	cis	rs786425	0.966	rs6488883	ENSG00000278112.1	RP11-972P1.11	4.71	6.51e-06	0.00544	0.44	0.39	Pubertal anthropometrics;	chr12:123616800	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.966	rs7134896	ENSG00000278112.1	RP11-972P1.11	4.71	6.51e-06	0.00544	0.44	0.39	Pubertal anthropometrics;	chr12:123617311	chr12:123519390~123519856:-
TGCT	cis	rs2882667	0.66	rs6894907	ENSG00000253404.1	AC034243.1	4.71	6.53e-06	0.00545	0.41	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106815	chr5:138744434~138753309:-
TGCT	cis	rs728616	0.867	rs55835350	ENSG00000230091.5	TMEM254-AS1	4.71	6.53e-06	0.00545	0.72	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80041972	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs2152548	ENSG00000230091.5	TMEM254-AS1	4.71	6.53e-06	0.00545	0.72	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80042911	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs79904324	ENSG00000230091.5	TMEM254-AS1	4.71	6.53e-06	0.00545	0.72	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80044932	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs17096197	ENSG00000230091.5	TMEM254-AS1	4.71	6.53e-06	0.00545	0.72	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80048428	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs56123058	ENSG00000230091.5	TMEM254-AS1	4.71	6.53e-06	0.00545	0.72	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80051316	chr10:80046860~80078912:-
TGCT	cis	rs875971	0.66	rs10229345	ENSG00000237310.1	GS1-124K5.4	4.71	6.53e-06	0.00545	0.44	0.39	Aortic root size;	chr7:66517181	chr7:66493706~66495474:+
TGCT	cis	rs9462027	0.583	rs2814995	ENSG00000186328.4	RP11-140K17.2	4.71	6.54e-06	0.00545	0.37	0.39	Systemic lupus erythematosus;	chr6:34653394	chr6:34715613~34715940:+
TGCT	cis	rs875971	0.862	rs4368860	ENSG00000237310.1	GS1-124K5.4	-4.71	6.55e-06	0.00546	-0.42	-0.39	Aortic root size;	chr7:66143495	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs1983372	ENSG00000237310.1	GS1-124K5.4	-4.71	6.55e-06	0.00546	-0.42	-0.39	Aortic root size;	chr7:66146364	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs908915	ENSG00000237310.1	GS1-124K5.4	-4.71	6.55e-06	0.00546	-0.42	-0.39	Aortic root size;	chr7:66149664	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs7809814	ENSG00000237310.1	GS1-124K5.4	-4.71	6.55e-06	0.00546	-0.42	-0.39	Aortic root size;	chr7:66150410	chr7:66493706~66495474:+
TGCT	cis	rs6921919	0.945	rs61289879	ENSG00000216901.1	AL022393.7	4.71	6.57e-06	0.00547	0.52	0.39	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28176188~28176674:+
TGCT	cis	rs972540	0.847	rs62195456	ENSG00000279220.1	GPR1-AS	4.71	6.57e-06	0.00547	0.41	0.39	Body mass index;	chr2:206344328	chr2:206203376~206266243:+
TGCT	cis	rs801193	0.875	rs13227951	ENSG00000222364.1	RNU6-96P	4.71	6.57e-06	0.00547	0.45	0.39	Aortic root size;	chr7:66748121	chr7:66395191~66395286:+
TGCT	cis	rs507080	0.961	rs642497	ENSG00000255422.1	AP002954.4	-4.71	6.58e-06	0.00548	-0.46	-0.39	Serum metabolite levels;	chr11:118680075	chr11:118704607~118750263:+
TGCT	cis	rs867371	0.896	rs6495647	ENSG00000255769.6	GOLGA2P10	-4.71	6.58e-06	0.00548	-0.41	-0.39	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82472993~82513950:-
TGCT	cis	rs7757969	0.536	rs1327203	ENSG00000227012.2	RP1-97J1.2	4.71	6.59e-06	0.00549	0.78	0.39	Schizophrenia;	chr6:111831291	chr6:111900489~111901851:-
TGCT	cis	rs7757969	0.536	rs9398288	ENSG00000227012.2	RP1-97J1.2	4.71	6.59e-06	0.00549	0.78	0.39	Schizophrenia;	chr6:111831565	chr6:111900489~111901851:-
TGCT	cis	rs7757969	0.536	rs7761265	ENSG00000227012.2	RP1-97J1.2	4.71	6.59e-06	0.00549	0.78	0.39	Schizophrenia;	chr6:111833041	chr6:111900489~111901851:-
TGCT	cis	rs7757969	0.536	rs11961774	ENSG00000227012.2	RP1-97J1.2	4.71	6.59e-06	0.00549	0.78	0.39	Schizophrenia;	chr6:111834270	chr6:111900489~111901851:-
TGCT	cis	rs7757969	0.536	rs1327204	ENSG00000227012.2	RP1-97J1.2	-4.71	6.59e-06	0.00549	-0.78	-0.39	Schizophrenia;	chr6:111831357	chr6:111900489~111901851:-
TGCT	cis	rs7757969	0.536	rs7761236	ENSG00000227012.2	RP1-97J1.2	-4.71	6.59e-06	0.00549	-0.78	-0.39	Schizophrenia;	chr6:111832997	chr6:111900489~111901851:-
TGCT	cis	rs8059260	0.604	rs9940096	ENSG00000274038.1	RP11-66H6.4	-4.71	6.59e-06	0.00549	-0.55	-0.39	Alcohol consumption over the past year;	chr16:11045737	chr16:11056556~11057034:+
TGCT	cis	rs786425	0.932	rs786443	ENSG00000278112.1	RP11-972P1.11	-4.71	6.61e-06	0.0055	-0.44	-0.39	Pubertal anthropometrics;	chr12:123579344	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.868	rs786447	ENSG00000278112.1	RP11-972P1.11	-4.71	6.61e-06	0.0055	-0.44	-0.39	Pubertal anthropometrics;	chr12:123585120	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.932	rs786448	ENSG00000278112.1	RP11-972P1.11	-4.71	6.61e-06	0.0055	-0.44	-0.39	Pubertal anthropometrics;	chr12:123585667	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.966	rs786449	ENSG00000278112.1	RP11-972P1.11	-4.71	6.61e-06	0.0055	-0.44	-0.39	Pubertal anthropometrics;	chr12:123587181	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.966	rs6551	ENSG00000278112.1	RP11-972P1.11	-4.71	6.61e-06	0.0055	-0.44	-0.39	Pubertal anthropometrics;	chr12:123597693	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.966	rs786422	ENSG00000278112.1	RP11-972P1.11	-4.71	6.61e-06	0.0055	-0.44	-0.39	Pubertal anthropometrics;	chr12:123599015	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.838	rs1543075	ENSG00000278112.1	RP11-972P1.11	-4.71	6.61e-06	0.0055	-0.44	-0.39	Pubertal anthropometrics;	chr12:123601901	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.966	rs4456350	ENSG00000278112.1	RP11-972P1.11	4.71	6.61e-06	0.0055	0.44	0.39	Pubertal anthropometrics;	chr12:123573942	chr12:123519390~123519856:-
TGCT	cis	rs1865760	1	rs2071297	ENSG00000217159.2	LARP1P1	4.71	6.61e-06	0.00551	0.46	0.39	Height;	chr6:25924285	chr6:26164072~26164363:+
TGCT	cis	rs1799949	1	rs35070007	ENSG00000198496.9	NBR2	4.71	6.62e-06	0.00551	0.55	0.39	Menopause (age at onset);	chr17:43164730	chr17:43125610~43153671:+
TGCT	cis	rs11231017	0.501	rs11231053	ENSG00000254454.2	RCC2P6	-4.71	6.62e-06	0.00551	-0.26	-0.39	HIV-1 viral setpoint;	chr11:62365748	chr11:62371146~62373168:+
TGCT	cis	rs11673344	0.665	rs74435359	ENSG00000226686.6	LINC01535	4.71	6.63e-06	0.00551	0.45	0.39	Obesity-related traits;	chr19:36955252	chr19:37251912~37265535:+
TGCT	cis	rs5742933	0.817	rs1233299	ENSG00000273240.1	RP11-455J20.3	-4.71	6.63e-06	0.00552	-0.36	-0.39	Ferritin levels;	chr2:189799912	chr2:189763859~189764456:-
TGCT	cis	rs7819412	0.645	rs4841508	ENSG00000255310.2	AF131215.2	-4.71	6.64e-06	0.00552	-0.33	-0.39	Triglycerides;	chr8:11207494	chr8:11107788~11109726:-
TGCT	cis	rs11129295	0.618	rs5012869	ENSG00000224237.1	MINOS1P3	4.71	6.65e-06	0.00553	0.43	0.39	Multiple sclerosis;	chr3:27769729	chr3:27214816~27215018:-
TGCT	cis	rs2717559	0.542	rs2585156	ENSG00000253196.1	RP11-706C16.7	-4.71	6.65e-06	0.00553	-0.41	-0.39	Urinary tract infection frequency;	chr8:142798379	chr8:142763116~142766427:+
TGCT	cis	rs875971	0.638	rs7793569	ENSG00000272831.1	RP11-792A8.4	-4.71	6.66e-06	0.00554	-0.41	-0.39	Aortic root size;	chr7:66651646	chr7:66739829~66740385:-
TGCT	cis	rs801193	1	rs6975195	ENSG00000272831.1	RP11-792A8.4	-4.71	6.66e-06	0.00554	-0.41	-0.39	Aortic root size;	chr7:66659787	chr7:66739829~66740385:-
TGCT	cis	rs801193	1	rs3857688	ENSG00000272831.1	RP11-792A8.4	-4.71	6.66e-06	0.00554	-0.41	-0.39	Aortic root size;	chr7:66662819	chr7:66739829~66740385:-
TGCT	cis	rs801193	1	rs2286684	ENSG00000272831.1	RP11-792A8.4	-4.71	6.66e-06	0.00554	-0.41	-0.39	Aortic root size;	chr7:66664843	chr7:66739829~66740385:-
TGCT	cis	rs801193	0.935	rs2286683	ENSG00000272831.1	RP11-792A8.4	-4.71	6.66e-06	0.00554	-0.41	-0.39	Aortic root size;	chr7:66664856	chr7:66739829~66740385:-
TGCT	cis	rs801193	1	rs10274773	ENSG00000272831.1	RP11-792A8.4	-4.71	6.66e-06	0.00554	-0.41	-0.39	Aortic root size;	chr7:66668591	chr7:66739829~66740385:-
TGCT	cis	rs4925386	1	rs4925382	ENSG00000273619.1	RP5-908M14.9	4.7	6.66e-06	0.00554	0.43	0.39	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62343486	chr20:62386303~62386970:-
TGCT	cis	rs4925386	1	rs6121990	ENSG00000273619.1	RP5-908M14.9	4.7	6.66e-06	0.00554	0.43	0.39	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344207	chr20:62386303~62386970:-
TGCT	cis	rs4925386	0.959	rs4925385	ENSG00000273619.1	RP5-908M14.9	4.7	6.66e-06	0.00554	0.43	0.39	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345568	chr20:62386303~62386970:-
TGCT	cis	rs62038064	1	rs62036257	ENSG00000278058.1	RP11-70D24.2	4.7	6.67e-06	0.00555	0.32	0.39	Post bronchodilator FEV1/FVC ratio;	chr16:78894780	chr16:79605802~79606605:+
TGCT	cis	rs62038064	1	rs62036258	ENSG00000278058.1	RP11-70D24.2	4.7	6.67e-06	0.00555	0.32	0.39	Post bronchodilator FEV1/FVC ratio;	chr16:78894789	chr16:79605802~79606605:+
TGCT	cis	rs3096299	0.935	rs3102387	ENSG00000274627.1	RP11-104N10.2	4.7	6.67e-06	0.00555	0.4	0.39	Multiple myeloma (IgH translocation);	chr16:89365868	chr16:89516797~89522217:+
TGCT	cis	rs875971	0.545	rs73146609	ENSG00000237310.1	GS1-124K5.4	4.7	6.67e-06	0.00555	0.46	0.39	Aortic root size;	chr7:66302477	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs2173571	ENSG00000237310.1	GS1-124K5.4	4.7	6.67e-06	0.00555	0.46	0.39	Aortic root size;	chr7:66305392	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs11770063	ENSG00000237310.1	GS1-124K5.4	4.7	6.67e-06	0.00555	0.46	0.39	Aortic root size;	chr7:66318029	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs3936065	ENSG00000237310.1	GS1-124K5.4	4.7	6.67e-06	0.00555	0.46	0.39	Aortic root size;	chr7:66325577	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs4718335	ENSG00000237310.1	GS1-124K5.4	4.7	6.67e-06	0.00555	0.46	0.39	Aortic root size;	chr7:66339619	chr7:66493706~66495474:+
TGCT	cis	rs9462027	0.628	rs9380455	ENSG00000186328.4	RP11-140K17.2	-4.7	6.67e-06	0.00555	-0.37	-0.39	Systemic lupus erythematosus;	chr6:34723001	chr6:34715613~34715940:+
TGCT	cis	rs10246939	0.543	rs9640357	ENSG00000228775.6	WEE2-AS1	4.7	6.68e-06	0.00555	0.35	0.39	Bitter taste perception;	chr7:141843298	chr7:141704338~141738346:-
TGCT	cis	rs4713118	0.662	rs149961	ENSG00000219891.2	ZSCAN12P1	4.7	6.68e-06	0.00555	0.49	0.39	Parkinson's disease;	chr6:28047791	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.629	rs149899	ENSG00000219891.2	ZSCAN12P1	4.7	6.68e-06	0.00555	0.49	0.39	Parkinson's disease;	chr6:28052201	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.629	rs172165	ENSG00000219891.2	ZSCAN12P1	4.7	6.68e-06	0.00555	0.49	0.39	Parkinson's disease;	chr6:28053036	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.597	rs172166	ENSG00000219891.2	ZSCAN12P1	4.7	6.68e-06	0.00555	0.49	0.39	Parkinson's disease;	chr6:28053042	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.629	rs203889	ENSG00000219891.2	ZSCAN12P1	4.7	6.68e-06	0.00555	0.49	0.39	Parkinson's disease;	chr6:28053997	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.629	rs203890	ENSG00000219891.2	ZSCAN12P1	4.7	6.68e-06	0.00555	0.49	0.39	Parkinson's disease;	chr6:28054470	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.662	rs9357060	ENSG00000219891.2	ZSCAN12P1	4.7	6.68e-06	0.00555	0.49	0.39	Parkinson's disease;	chr6:28056708	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.662	rs9468271	ENSG00000219891.2	ZSCAN12P1	4.7	6.68e-06	0.00555	0.49	0.39	Parkinson's disease;	chr6:28056792	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.662	rs9380045	ENSG00000219891.2	ZSCAN12P1	4.7	6.68e-06	0.00555	0.49	0.39	Parkinson's disease;	chr6:28057501	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.616	rs9348789	ENSG00000219891.2	ZSCAN12P1	4.7	6.68e-06	0.00555	0.49	0.39	Parkinson's disease;	chr6:28057708	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.662	rs9468274	ENSG00000219891.2	ZSCAN12P1	4.7	6.68e-06	0.00555	0.49	0.39	Parkinson's disease;	chr6:28058299	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.662	rs9468275	ENSG00000219891.2	ZSCAN12P1	4.7	6.68e-06	0.00555	0.49	0.39	Parkinson's disease;	chr6:28058358	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.662	rs9468276	ENSG00000219891.2	ZSCAN12P1	4.7	6.68e-06	0.00555	0.49	0.39	Parkinson's disease;	chr6:28059910	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.662	rs9468277	ENSG00000219891.2	ZSCAN12P1	4.7	6.68e-06	0.00555	0.49	0.39	Parkinson's disease;	chr6:28060612	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.662	rs9468278	ENSG00000219891.2	ZSCAN12P1	4.7	6.68e-06	0.00555	0.49	0.39	Parkinson's disease;	chr6:28060704	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.662	rs13218430	ENSG00000219891.2	ZSCAN12P1	4.7	6.68e-06	0.00555	0.49	0.39	Parkinson's disease;	chr6:28062059	chr6:28091154~28093664:+
TGCT	cis	rs6474412	1	rs7004381	ENSG00000255101.1	RP11-412B14.1	4.7	6.68e-06	0.00555	0.4	0.39	Smoking behavior;	chr8:42696018	chr8:42705583~42721946:-
TGCT	cis	rs16852403	0.517	rs316266	ENSG00000224687.1	RASAL2-AS1	-4.7	6.7e-06	0.00555	-0.51	-0.39	Childhood ear infection;	chr1:178133346	chr1:178091508~178093984:-
TGCT	cis	rs16852403	0.548	rs316269	ENSG00000224687.1	RASAL2-AS1	-4.7	6.7e-06	0.00555	-0.51	-0.39	Childhood ear infection;	chr1:178138727	chr1:178091508~178093984:-
TGCT	cis	rs6474412	1	rs6474412	ENSG00000255101.1	RP11-412B14.1	4.7	6.7e-06	0.00555	0.39	0.39	Smoking behavior;	chr8:42695355	chr8:42705583~42721946:-
TGCT	cis	rs16852403	0.548	rs387917	ENSG00000224687.1	RASAL2-AS1	-4.7	6.7e-06	0.00556	-0.53	-0.39	Childhood ear infection;	chr1:178148407	chr1:178091508~178093984:-
TGCT	cis	rs4423214	0.84	rs1629220	ENSG00000254682.1	RP11-660L16.2	-4.7	6.7e-06	0.00556	-0.59	-0.39	Vitamin D levels;	chr11:71463507	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.84	rs1792224	ENSG00000254682.1	RP11-660L16.2	-4.7	6.7e-06	0.00556	-0.59	-0.39	Vitamin D levels;	chr11:71465095	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.84	rs1792226	ENSG00000254682.1	RP11-660L16.2	-4.7	6.7e-06	0.00556	-0.59	-0.39	Vitamin D levels;	chr11:71465528	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.84	rs1790344	ENSG00000254682.1	RP11-660L16.2	-4.7	6.7e-06	0.00556	-0.59	-0.39	Vitamin D levels;	chr11:71465851	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.84	rs1790343	ENSG00000254682.1	RP11-660L16.2	-4.7	6.7e-06	0.00556	-0.59	-0.39	Vitamin D levels;	chr11:71466161	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.84	rs1792227	ENSG00000254682.1	RP11-660L16.2	-4.7	6.7e-06	0.00556	-0.59	-0.39	Vitamin D levels;	chr11:71466366	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.84	rs1790341	ENSG00000254682.1	RP11-660L16.2	-4.7	6.7e-06	0.00556	-0.59	-0.39	Vitamin D levels;	chr11:71466532	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.84	rs1540127	ENSG00000254682.1	RP11-660L16.2	-4.7	6.7e-06	0.00556	-0.59	-0.39	Vitamin D levels;	chr11:71467992	chr11:71448674~71452157:+
TGCT	cis	rs17826219	0.636	rs7221463	ENSG00000280069.1	CTD-2349P21.3	-4.7	6.71e-06	0.00556	-0.54	-0.39	Body mass index;	chr17:30753533	chr17:30738182~30740275:+
TGCT	cis	rs601999	1	rs601999	ENSG00000108785.7	HSD17B1P1	4.7	6.71e-06	0.00556	0.31	0.39	Parkinson's disease;	chr17:42546140	chr17:42546764~42548706:+
TGCT	cis	rs2455601	0.638	rs3815991	ENSG00000254860.4	TMEM9B-AS1	-4.7	6.72e-06	0.00557	-0.46	-0.39	Schizophrenia;	chr11:8986122	chr11:8964675~8977527:+
TGCT	cis	rs4423214	0.84	rs1792235	ENSG00000254682.1	RP11-660L16.2	-4.7	6.72e-06	0.00557	-0.59	-0.39	Vitamin D levels;	chr11:71470427	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.84	rs1619577	ENSG00000254682.1	RP11-660L16.2	-4.7	6.72e-06	0.00557	-0.59	-0.39	Vitamin D levels;	chr11:71470439	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.84	rs1792234	ENSG00000254682.1	RP11-660L16.2	-4.7	6.72e-06	0.00557	-0.59	-0.39	Vitamin D levels;	chr11:71470972	chr11:71448674~71452157:+
TGCT	cis	rs7115242	0.8	rs4245168	ENSG00000254851.1	RP11-109L13.1	-4.7	6.72e-06	0.00557	-0.66	-0.39	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117011922	chr11:117135528~117138582:+
TGCT	cis	rs9462027	0.583	rs6937784	ENSG00000186328.4	RP11-140K17.2	4.7	6.72e-06	0.00557	0.37	0.39	Systemic lupus erythematosus;	chr6:34676499	chr6:34715613~34715940:+
TGCT	cis	rs9880211	0.8	rs13314357	ENSG00000239213.4	NCK1-AS1	4.7	6.73e-06	0.00558	0.41	0.39	Height;Body mass index;	chr3:136768717	chr3:136841726~136862054:-
TGCT	cis	rs1799949	0.965	rs2236762	ENSG00000198496.9	NBR2	-4.7	6.74e-06	0.00558	-0.55	-0.39	Menopause (age at onset);	chr17:43074658	chr17:43125610~43153671:+
TGCT	cis	rs4713118	0.629	rs203888	ENSG00000219392.1	RP1-265C24.5	-4.7	6.75e-06	0.00559	-0.5	-0.39	Parkinson's disease;	chr6:28053811	chr6:28115628~28116551:+
TGCT	cis	rs2921036	0.529	rs2979192	ENSG00000173295.6	FAM86B3P	4.7	6.75e-06	0.00559	0.47	0.39	Neuroticism;	chr8:8480637	chr8:8228595~8244865:+
TGCT	cis	rs1618992	0.729	rs8095821	ENSG00000265994.1	RP11-510D21.1	4.7	6.75e-06	0.00559	0.39	0.39	Gut microbiome composition (summer and winter);	chr18:28597500	chr18:28785068~28789260:+
TGCT	cis	rs875971	0.862	rs10263690	ENSG00000232559.3	GS1-124K5.12	-4.7	6.76e-06	0.0056	-0.36	-0.39	Aortic root size;	chr7:66301466	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs10250544	ENSG00000232559.3	GS1-124K5.12	-4.7	6.76e-06	0.0056	-0.36	-0.39	Aortic root size;	chr7:66301574	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.895	rs12531677	ENSG00000232559.3	GS1-124K5.12	-4.7	6.76e-06	0.0056	-0.36	-0.39	Aortic root size;	chr7:66304099	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs7798630	ENSG00000232559.3	GS1-124K5.12	-4.7	6.76e-06	0.0056	-0.36	-0.39	Aortic root size;	chr7:66306492	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs11984115	ENSG00000232559.3	GS1-124K5.12	-4.7	6.76e-06	0.0056	-0.36	-0.39	Aortic root size;	chr7:66308872	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.755	rs10228885	ENSG00000232559.3	GS1-124K5.12	-4.7	6.76e-06	0.0056	-0.36	-0.39	Aortic root size;	chr7:66315542	chr7:66554588~66576923:-
TGCT	cis	rs867371	1	rs9944197	ENSG00000255769.6	GOLGA2P10	-4.7	6.77e-06	0.00561	-0.41	-0.39	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82472993~82513950:-
TGCT	cis	rs34779708	0.931	rs11596502	ENSG00000230534.5	RP11-297A16.2	4.7	6.77e-06	0.00561	0.45	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35098259	chr10:35098006~35127020:-
TGCT	cis	rs2117029	0.587	rs1865157	ENSG00000258017.1	RP11-386G11.10	-4.7	6.77e-06	0.00561	-0.51	-0.39	Intelligence (multi-trait analysis);	chr12:49129003	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.653	rs1476137	ENSG00000258017.1	RP11-386G11.10	-4.7	6.77e-06	0.00561	-0.51	-0.39	Intelligence (multi-trait analysis);	chr12:49129930	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.553	rs731350	ENSG00000258017.1	RP11-386G11.10	-4.7	6.77e-06	0.00561	-0.51	-0.39	Intelligence (multi-trait analysis);	chr12:49130804	chr12:49127782~49147869:+
TGCT	cis	rs11671005	0.571	rs56243535	ENSG00000232098.3	CTD-2619J13.14	-4.7	6.78e-06	0.00562	-0.45	-0.39	Mean platelet volume;	chr19:58494783	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.611	rs56026876	ENSG00000232098.3	CTD-2619J13.14	-4.7	6.78e-06	0.00562	-0.45	-0.39	Mean platelet volume;	chr19:58494790	chr19:58404238~58408484:-
TGCT	cis	rs2976388	0.692	rs1435453	ENSG00000253196.1	RP11-706C16.7	4.7	6.79e-06	0.00562	0.39	0.39	Urinary tract infection frequency;	chr8:142699357	chr8:142763116~142766427:+
TGCT	cis	rs34217772	0.524	rs41319550	ENSG00000258536.1	RP11-1053O12.1	-4.7	6.8e-06	0.00563	-0.32	-0.39	Myopia;	chr14:41731076	chr14:41742639~41742963:+
TGCT	cis	rs875971	0.54	rs4717275	ENSG00000237310.1	GS1-124K5.4	-4.7	6.8e-06	0.00563	-0.43	-0.39	Aortic root size;	chr7:65800193	chr7:66493706~66495474:+
TGCT	cis	rs17711722	0.701	rs4467826	ENSG00000237310.1	GS1-124K5.4	4.7	6.8e-06	0.00563	0.43	0.39	Calcium levels;	chr7:65903721	chr7:66493706~66495474:+
TGCT	cis	rs507080	0.885	rs693037	ENSG00000255239.1	AP002954.6	4.7	6.81e-06	0.00563	0.52	0.39	Serum metabolite levels;	chr11:118682617	chr11:118688039~118690600:-
TGCT	cis	rs13118159	0.509	rs9683830	ENSG00000254094.1	AC078852.1	-4.7	6.82e-06	0.00564	-0.49	-0.39	Longevity;	chr4:1384085	chr4:1356581~1358075:+
TGCT	cis	rs1075265	0.547	rs41385746	ENSG00000233266.1	HMGB1P31	-4.7	6.82e-06	0.00564	-0.41	-0.39	Chronotype;Morning vs. evening chronotype;	chr2:54077893	chr2:54051334~54051760:+
TGCT	cis	rs867371	0.519	rs1566560	ENSG00000255769.6	GOLGA2P10	-4.7	6.83e-06	0.00565	-0.38	-0.39	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82472993~82513950:-
TGCT	cis	rs867371	0.519	rs1566559	ENSG00000255769.6	GOLGA2P10	-4.7	6.83e-06	0.00565	-0.38	-0.39	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82472993~82513950:-
TGCT	cis	rs17711722	0.503	rs453835	ENSG00000164669.11	INTS4P1	4.7	6.83e-06	0.00565	0.37	0.39	Calcium levels;	chr7:66046172	chr7:65141225~65234216:+
TGCT	cis	rs67311347	1	rs2276871	ENSG00000223797.4	ENTPD3-AS1	4.7	6.83e-06	0.00565	0.4	0.39	Renal cell carcinoma;	chr3:40457782	chr3:40313802~40453329:-
TGCT	cis	rs16852403	0.519	rs11586307	ENSG00000224687.1	RASAL2-AS1	4.7	6.84e-06	0.00566	0.55	0.39	Childhood ear infection;	chr1:178088523	chr1:178091508~178093984:-
TGCT	cis	rs4835473	0.868	rs35809032	ENSG00000251600.4	RP11-673E1.1	-4.7	6.85e-06	0.00566	-0.4	-0.39	Immature fraction of reticulocytes;	chr4:143824797	chr4:143912331~143982454:+
TGCT	cis	rs6474412	0.505	rs1530850	ENSG00000255101.1	RP11-412B14.1	-4.7	6.86e-06	0.00567	-0.41	-0.39	Smoking behavior;	chr8:42649810	chr8:42705583~42721946:-
TGCT	cis	rs875971	0.516	rs6945322	ENSG00000237310.1	GS1-124K5.4	4.7	6.88e-06	0.00568	0.43	0.39	Aortic root size;	chr7:65871069	chr7:66493706~66495474:+
TGCT	cis	rs17711722	0.701	rs55773927	ENSG00000237310.1	GS1-124K5.4	4.7	6.88e-06	0.00568	0.43	0.39	Calcium levels;	chr7:65872915	chr7:66493706~66495474:+
TGCT	cis	rs17711722	0.727	rs35850374	ENSG00000237310.1	GS1-124K5.4	4.7	6.88e-06	0.00568	0.43	0.39	Calcium levels;	chr7:65892789	chr7:66493706~66495474:+
TGCT	cis	rs1891275	0.55	rs4933694	ENSG00000228701.1	TNKS2-AS1	-4.7	6.88e-06	0.00568	-0.43	-0.39	Intelligence (multi-trait analysis);	chr10:91739456	chr10:91782839~91798291:-
TGCT	cis	rs34375054	0.525	rs12316499	ENSG00000279233.1	RP11-158L12.4	4.7	6.88e-06	0.00568	0.4	0.39	Post bronchodilator FEV1/FVC ratio;	chr12:125108772	chr12:125138245~125141711:+
TGCT	cis	rs12143943	1	rs12143943	ENSG00000176754.11	LINC00303	4.7	6.88e-06	0.00569	0.35	0.39	Cognitive performance;	chr1:204602943	chr1:204032447~204041265:-
TGCT	cis	rs10129255	0.613	rs916546	ENSG00000211970.3	IGHV4-61	-4.7	6.88e-06	0.00569	-0.43	-0.39	Kawasaki disease;	chr14:106654441	chr14:106639119~106639657:-
TGCT	cis	rs10129255	0.642	rs11624918	ENSG00000211970.3	IGHV4-61	-4.7	6.88e-06	0.00569	-0.43	-0.39	Kawasaki disease;	chr14:106664672	chr14:106639119~106639657:-
TGCT	cis	rs4660456	0.913	rs12727412	ENSG00000237899.1	RP4-739H11.3	-4.7	6.9e-06	0.0057	-0.51	-0.39	Platelet count;	chr1:40723243	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs4660448	ENSG00000237899.1	RP4-739H11.3	-4.7	6.9e-06	0.0057	-0.51	-0.39	Platelet count;	chr1:40724682	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs7532802	ENSG00000237899.1	RP4-739H11.3	-4.7	6.9e-06	0.0057	-0.51	-0.39	Platelet count;	chr1:40725528	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs2361648	ENSG00000237899.1	RP4-739H11.3	-4.7	6.9e-06	0.0057	-0.51	-0.39	Platelet count;	chr1:40726825	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs6675886	ENSG00000237899.1	RP4-739H11.3	-4.7	6.9e-06	0.0057	-0.51	-0.39	Platelet count;	chr1:40727955	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.83	rs12742219	ENSG00000237899.1	RP4-739H11.3	-4.7	6.9e-06	0.0057	-0.51	-0.39	Platelet count;	chr1:40728665	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs6668453	ENSG00000237899.1	RP4-739H11.3	-4.7	6.9e-06	0.0057	-0.51	-0.39	Platelet count;	chr1:40733299	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs35881320	ENSG00000237899.1	RP4-739H11.3	-4.7	6.9e-06	0.0057	-0.51	-0.39	Platelet count;	chr1:40733893	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.871	rs34512220	ENSG00000237899.1	RP4-739H11.3	-4.7	6.9e-06	0.0057	-0.51	-0.39	Platelet count;	chr1:40733912	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs6664044	ENSG00000237899.1	RP4-739H11.3	-4.7	6.9e-06	0.0057	-0.51	-0.39	Platelet count;	chr1:40735089	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs6702983	ENSG00000237899.1	RP4-739H11.3	-4.7	6.9e-06	0.0057	-0.51	-0.39	Platelet count;	chr1:40735585	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs12566733	ENSG00000237899.1	RP4-739H11.3	-4.7	6.9e-06	0.0057	-0.51	-0.39	Platelet count;	chr1:40736067	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.871	rs2274957	ENSG00000237899.1	RP4-739H11.3	-4.7	6.9e-06	0.0057	-0.51	-0.39	Platelet count;	chr1:40747290	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs4660173	ENSG00000237899.1	RP4-739H11.3	-4.7	6.9e-06	0.0057	-0.51	-0.39	Platelet count;	chr1:40747876	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs4660452	ENSG00000237899.1	RP4-739H11.3	-4.7	6.9e-06	0.0057	-0.51	-0.39	Platelet count;	chr1:40748519	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs12567925	ENSG00000237899.1	RP4-739H11.3	-4.7	6.9e-06	0.0057	-0.51	-0.39	Platelet count;	chr1:40751428	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs12728776	ENSG00000237899.1	RP4-739H11.3	-4.7	6.9e-06	0.0057	-0.51	-0.39	Platelet count;	chr1:40751718	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs12567755	ENSG00000237899.1	RP4-739H11.3	-4.7	6.9e-06	0.0057	-0.51	-0.39	Platelet count;	chr1:40751813	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs16827532	ENSG00000237899.1	RP4-739H11.3	-4.7	6.9e-06	0.0057	-0.51	-0.39	Platelet count;	chr1:40755064	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs12729696	ENSG00000237899.1	RP4-739H11.3	-4.7	6.9e-06	0.0057	-0.51	-0.39	Platelet count;	chr1:40755099	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs16827552	ENSG00000237899.1	RP4-739H11.3	-4.7	6.9e-06	0.0057	-0.51	-0.39	Platelet count;	chr1:40758336	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.871	rs669072	ENSG00000237899.1	RP4-739H11.3	4.7	6.9e-06	0.0057	0.51	0.39	Platelet count;	chr1:40679946	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.912	rs658806	ENSG00000237899.1	RP4-739H11.3	4.7	6.9e-06	0.0057	0.51	0.39	Platelet count;	chr1:40683312	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs489222	ENSG00000237899.1	RP4-739H11.3	4.7	6.9e-06	0.0057	0.51	0.39	Platelet count;	chr1:40683422	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.871	rs671704	ENSG00000237899.1	RP4-739H11.3	4.7	6.9e-06	0.0057	0.51	0.39	Platelet count;	chr1:40683974	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.826	rs507914	ENSG00000237899.1	RP4-739H11.3	4.7	6.9e-06	0.0057	0.51	0.39	Platelet count;	chr1:40686529	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs2780950	ENSG00000237899.1	RP4-739H11.3	4.7	6.9e-06	0.0057	0.51	0.39	Platelet count;	chr1:40686937	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.826	rs2744802	ENSG00000237899.1	RP4-739H11.3	4.7	6.9e-06	0.0057	0.51	0.39	Platelet count;	chr1:40687577	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs2780952	ENSG00000237899.1	RP4-739H11.3	4.7	6.9e-06	0.0057	0.51	0.39	Platelet count;	chr1:40689711	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs656230	ENSG00000237899.1	RP4-739H11.3	4.7	6.9e-06	0.0057	0.51	0.39	Platelet count;	chr1:40692701	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs2780953	ENSG00000237899.1	RP4-739H11.3	4.7	6.9e-06	0.0057	0.51	0.39	Platelet count;	chr1:40694105	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs6661855	ENSG00000237899.1	RP4-739H11.3	4.7	6.9e-06	0.0057	0.51	0.39	Platelet count;	chr1:40703245	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs7542019	ENSG00000237899.1	RP4-739H11.3	4.7	6.9e-06	0.0057	0.51	0.39	Platelet count;	chr1:40704039	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs1494	ENSG00000237899.1	RP4-739H11.3	4.7	6.9e-06	0.0057	0.51	0.39	Platelet count;	chr1:40706176	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.869	rs7518344	ENSG00000237899.1	RP4-739H11.3	4.7	6.9e-06	0.0057	0.51	0.39	Platelet count;	chr1:40708327	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.827	rs10736404	ENSG00000237899.1	RP4-739H11.3	4.7	6.9e-06	0.0057	0.51	0.39	Platelet count;	chr1:40710331	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs2744799	ENSG00000237899.1	RP4-739H11.3	4.7	6.9e-06	0.0057	0.51	0.39	Platelet count;	chr1:40719862	chr1:40669089~40687588:-
TGCT	cis	rs17826219	0.706	rs2322197	ENSG00000280069.1	CTD-2349P21.3	-4.7	6.9e-06	0.0057	-0.54	-0.39	Body mass index;	chr17:30778787	chr17:30738182~30740275:+
TGCT	cis	rs875971	0.522	rs4718285	ENSG00000237310.1	GS1-124K5.4	4.7	6.92e-06	0.0057	0.42	0.39	Aortic root size;	chr7:65827018	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.522	rs4718286	ENSG00000237310.1	GS1-124K5.4	4.7	6.92e-06	0.0057	0.42	0.39	Aortic root size;	chr7:65827777	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.522	rs4502988	ENSG00000237310.1	GS1-124K5.4	4.7	6.92e-06	0.0057	0.42	0.39	Aortic root size;	chr7:65832759	chr7:66493706~66495474:+
TGCT	cis	rs17711722	0.585	rs6942660	ENSG00000237310.1	GS1-124K5.4	4.7	6.92e-06	0.0057	0.42	0.39	Calcium levels;	chr7:65837419	chr7:66493706~66495474:+
TGCT	cis	rs17711722	0.64	rs13237956	ENSG00000237310.1	GS1-124K5.4	4.7	6.92e-06	0.0057	0.42	0.39	Calcium levels;	chr7:65853042	chr7:66493706~66495474:+
TGCT	cis	rs17826219	0.706	rs2322197	ENSG00000266490.1	CTD-2349P21.9	4.7	6.93e-06	0.00572	0.44	0.39	Body mass index;	chr17:30778787	chr17:30792372~30792833:+
TGCT	cis	rs867371	0.892	rs4344697	ENSG00000255769.6	GOLGA2P10	-4.7	6.94e-06	0.00572	-0.41	-0.39	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82472993~82513950:-
TGCT	cis	rs801193	1	rs11773829	ENSG00000272831.1	RP11-792A8.4	-4.7	6.94e-06	0.00572	-0.41	-0.39	Aortic root size;	chr7:66676087	chr7:66739829~66740385:-
TGCT	cis	rs801193	1	rs7788576	ENSG00000272831.1	RP11-792A8.4	-4.7	6.94e-06	0.00572	-0.41	-0.39	Aortic root size;	chr7:66683315	chr7:66739829~66740385:-
TGCT	cis	rs801193	0.935	rs2659916	ENSG00000272831.1	RP11-792A8.4	4.7	6.94e-06	0.00572	0.41	0.39	Aortic root size;	chr7:66686365	chr7:66739829~66740385:-
TGCT	cis	rs801193	1	rs6958520	ENSG00000272831.1	RP11-792A8.4	4.7	6.94e-06	0.00572	0.41	0.39	Aortic root size;	chr7:66686466	chr7:66739829~66740385:-
TGCT	cis	rs801193	0.967	rs2707849	ENSG00000272831.1	RP11-792A8.4	4.7	6.94e-06	0.00572	0.41	0.39	Aortic root size;	chr7:66687725	chr7:66739829~66740385:-
TGCT	cis	rs801193	1	rs2707836	ENSG00000272831.1	RP11-792A8.4	4.7	6.94e-06	0.00572	0.41	0.39	Aortic root size;	chr7:66695448	chr7:66739829~66740385:-
TGCT	cis	rs801193	0.844	rs7779971	ENSG00000272831.1	RP11-792A8.4	4.7	6.94e-06	0.00572	0.41	0.39	Aortic root size;	chr7:66696803	chr7:66739829~66740385:-
TGCT	cis	rs801193	1	rs2659906	ENSG00000272831.1	RP11-792A8.4	4.7	6.94e-06	0.00572	0.41	0.39	Aortic root size;	chr7:66700323	chr7:66739829~66740385:-
TGCT	cis	rs801193	0.935	rs2659899	ENSG00000272831.1	RP11-792A8.4	4.7	6.94e-06	0.00572	0.41	0.39	Aortic root size;	chr7:66721734	chr7:66739829~66740385:-
TGCT	cis	rs801193	1	rs62466793	ENSG00000272831.1	RP11-792A8.4	4.7	6.94e-06	0.00572	0.41	0.39	Aortic root size;	chr7:66726530	chr7:66739829~66740385:-
TGCT	cis	rs801193	1	rs62466794	ENSG00000272831.1	RP11-792A8.4	4.7	6.94e-06	0.00572	0.41	0.39	Aortic root size;	chr7:66726592	chr7:66739829~66740385:-
TGCT	cis	rs801193	1	rs1553609	ENSG00000272831.1	RP11-792A8.4	4.7	6.94e-06	0.00572	0.41	0.39	Aortic root size;	chr7:66732152	chr7:66739829~66740385:-
TGCT	cis	rs801193	1	rs1553610	ENSG00000272831.1	RP11-792A8.4	4.7	6.94e-06	0.00572	0.41	0.39	Aortic root size;	chr7:66732246	chr7:66739829~66740385:-
TGCT	cis	rs4835473	0.897	rs4835095	ENSG00000251600.4	RP11-673E1.1	4.69	6.96e-06	0.00573	0.41	0.39	Immature fraction of reticulocytes;	chr4:143960431	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.831	rs2667353	ENSG00000251600.4	RP11-673E1.1	4.69	6.96e-06	0.00573	0.41	0.39	Immature fraction of reticulocytes;	chr4:143960462	chr4:143912331~143982454:+
TGCT	cis	rs10875746	0.951	rs8804	ENSG00000240399.1	RP1-228P16.1	-4.69	6.97e-06	0.00574	-0.45	-0.39	Longevity (90 years and older);	chr12:48147974	chr12:48054813~48055591:-
TGCT	cis	rs877819	0.583	rs2663030	ENSG00000228403.1	RP11-563N6.6	-4.69	6.97e-06	0.00574	-0.4	-0.39	Systemic lupus erythematosus;	chr10:48879413	chr10:48878022~48878649:+
TGCT	cis	rs2117029	0.782	rs10459232	ENSG00000258017.1	RP11-386G11.10	-4.69	6.99e-06	0.00575	-0.47	-0.39	Intelligence (multi-trait analysis);	chr12:49073293	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.782	rs11168850	ENSG00000258017.1	RP11-386G11.10	-4.69	6.99e-06	0.00575	-0.47	-0.39	Intelligence (multi-trait analysis);	chr12:49079182	chr12:49127782~49147869:+
TGCT	cis	rs2980439	0.517	rs712253	ENSG00000254340.1	RP11-10A14.3	-4.69	6.99e-06	0.00575	-0.42	-0.39	Neuroticism;	chr8:8246260	chr8:9141424~9145435:+
TGCT	cis	rs2980439	0.517	rs17594065	ENSG00000254340.1	RP11-10A14.3	-4.69	6.99e-06	0.00575	-0.42	-0.39	Neuroticism;	chr8:8247883	chr8:9141424~9145435:+
TGCT	cis	rs10875976	0.526	rs7307673	ENSG00000242041.1	RP11-70F11.2	4.69	6.99e-06	0.00576	0.38	0.39	Obesity;	chr12:49844421	chr12:49863173~49863503:+
TGCT	cis	rs2117029	0.555	rs2047101	ENSG00000258017.1	RP11-386G11.10	-4.69	6.99e-06	0.00576	-0.51	-0.39	Intelligence (multi-trait analysis);	chr12:49103860	chr12:49127782~49147869:+
TGCT	cis	rs2463822	0.925	rs17157227	ENSG00000254454.2	RCC2P6	-4.69	7e-06	0.00576	-0.42	-0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62402300	chr11:62371146~62373168:+
TGCT	cis	rs4660456	0.913	rs552147	ENSG00000237899.1	RP4-739H11.3	-4.69	7.02e-06	0.00578	-0.51	-0.39	Platelet count;	chr1:40689141	chr1:40669089~40687588:-
TGCT	cis	rs10504229	0.683	rs7820302	ENSG00000253301.4	RP11-513O17.2	4.69	7.03e-06	0.00578	0.57	0.39	Developmental language disorder (linguistic errors);	chr8:57229943	chr8:57142689~57240298:+
TGCT	cis	rs801193	0.935	rs11772264	ENSG00000272831.1	RP11-792A8.4	4.69	7.03e-06	0.00579	0.41	0.39	Aortic root size;	chr7:66711400	chr7:66739829~66740385:-
TGCT	cis	rs2919917	0.628	rs1384803	ENSG00000254352.1	RP11-578O24.2	-4.69	7.04e-06	0.00579	-0.47	-0.39	Lymphocyte counts;	chr8:78669393	chr8:78723796~78724136:-
TGCT	cis	rs2919917	0.617	rs4641056	ENSG00000254352.1	RP11-578O24.2	4.69	7.04e-06	0.00579	0.47	0.39	Lymphocyte counts;	chr8:78670261	chr8:78723796~78724136:-
TGCT	cis	rs5742933	0.857	rs1233282	ENSG00000273240.1	RP11-455J20.3	-4.69	7.04e-06	0.00579	-0.36	-0.39	Ferritin levels;	chr2:189823518	chr2:189763859~189764456:-
TGCT	cis	rs875971	0.862	rs28470208	ENSG00000237310.1	GS1-124K5.4	-4.69	7.05e-06	0.0058	-0.42	-0.39	Aortic root size;	chr7:66119713	chr7:66493706~66495474:+
TGCT	cis	rs853679	0.599	rs149949	ENSG00000219891.2	ZSCAN12P1	4.69	7.05e-06	0.0058	0.63	0.39	Depression;	chr6:28043738	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.599	rs202906	ENSG00000219891.2	ZSCAN12P1	-4.69	7.05e-06	0.0058	-0.63	-0.39	Depression;	chr6:28043874	chr6:28091154~28093664:+
TGCT	cis	rs34779708	0.966	rs7077242	ENSG00000230534.5	RP11-297A16.2	-4.69	7.07e-06	0.00581	-0.45	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35193037	chr10:35098006~35127020:-
TGCT	cis	rs7208859	0.614	rs216412	ENSG00000266490.1	CTD-2349P21.9	-4.69	7.07e-06	0.00581	-0.41	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30792372~30792833:+
TGCT	cis	rs507080	0.922	rs12796373	ENSG00000255239.1	AP002954.6	4.69	7.08e-06	0.00582	0.51	0.39	Serum metabolite levels;	chr11:118684230	chr11:118688039~118690600:-
TGCT	cis	rs2581828	0.656	rs34530577	ENSG00000242142.1	SERBP1P3	4.69	7.08e-06	0.00582	0.35	0.39	Crohn's disease;	chr3:53069780	chr3:53064283~53065091:-
TGCT	cis	rs12891047	0.664	rs10148527	ENSG00000258759.1	RP11-1012A1.7	-4.69	7.09e-06	0.00583	-0.32	-0.39	Amyotrophic lateral sclerosis (sporadic);	chr14:67901338	chr14:67799004~67799609:+
TGCT	cis	rs12439619	0.693	rs17269819	ENSG00000255769.6	GOLGA2P10	-4.69	7.1e-06	0.00583	-0.44	-0.39	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472993~82513950:-
TGCT	cis	rs875971	0.528	rs801213	ENSG00000237310.1	GS1-124K5.4	-4.69	7.1e-06	0.00583	-0.46	-0.39	Aortic root size;	chr7:66549931	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs801212	ENSG00000237310.1	GS1-124K5.4	-4.69	7.1e-06	0.00583	-0.46	-0.39	Aortic root size;	chr7:66550643	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs801199	ENSG00000237310.1	GS1-124K5.4	-4.69	7.1e-06	0.00583	-0.46	-0.39	Aortic root size;	chr7:66560286	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs1638724	ENSG00000237310.1	GS1-124K5.4	-4.69	7.1e-06	0.00583	-0.46	-0.39	Aortic root size;	chr7:66575494	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs1267814	ENSG00000237310.1	GS1-124K5.4	-4.69	7.1e-06	0.00583	-0.46	-0.39	Aortic root size;	chr7:66579422	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs75840613	ENSG00000237310.1	GS1-124K5.4	4.69	7.1e-06	0.00583	0.46	0.39	Aortic root size;	chr7:66376399	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs73148639	ENSG00000237310.1	GS1-124K5.4	4.69	7.1e-06	0.00583	0.46	0.39	Aortic root size;	chr7:66390342	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs6460298	ENSG00000237310.1	GS1-124K5.4	4.69	7.1e-06	0.00583	0.46	0.39	Aortic root size;	chr7:66442783	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs35459055	ENSG00000237310.1	GS1-124K5.4	4.69	7.1e-06	0.00583	0.46	0.39	Aortic root size;	chr7:66479399	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs75577046	ENSG00000237310.1	GS1-124K5.4	4.69	7.1e-06	0.00583	0.46	0.39	Aortic root size;	chr7:66493729	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs3735147	ENSG00000237310.1	GS1-124K5.4	4.69	7.1e-06	0.00583	0.46	0.39	Aortic root size;	chr7:66505541	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs6950988	ENSG00000237310.1	GS1-124K5.4	4.69	7.1e-06	0.00583	0.46	0.39	Aortic root size;	chr7:66511428	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs73152714	ENSG00000237310.1	GS1-124K5.4	4.69	7.1e-06	0.00583	0.46	0.39	Aortic root size;	chr7:66534641	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs4718364	ENSG00000237310.1	GS1-124K5.4	4.69	7.1e-06	0.00583	0.46	0.39	Aortic root size;	chr7:66536353	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs6961853	ENSG00000237310.1	GS1-124K5.4	4.69	7.1e-06	0.00583	0.46	0.39	Aortic root size;	chr7:66537035	chr7:66493706~66495474:+
TGCT	cis	rs2742234	0.59	rs2435377	ENSG00000273008.1	RP11-351D16.3	4.69	7.1e-06	0.00584	0.5	0.39	Hirschsprung disease;	chr10:43188152	chr10:43136824~43138334:-
TGCT	cis	rs507080	0.769	rs527290	ENSG00000255422.1	AP002954.4	-4.69	7.11e-06	0.00584	-0.44	-0.39	Serum metabolite levels;	chr11:118644898	chr11:118704607~118750263:+
TGCT	cis	rs67311347	1	rs17078813	ENSG00000223797.4	ENTPD3-AS1	4.69	7.11e-06	0.00584	0.42	0.39	Renal cell carcinoma;	chr3:40392671	chr3:40313802~40453329:-
TGCT	cis	rs4835473	0.571	rs1992656	ENSG00000251600.4	RP11-673E1.1	4.69	7.12e-06	0.00584	0.38	0.39	Immature fraction of reticulocytes;	chr4:143855286	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.571	rs1992655	ENSG00000251600.4	RP11-673E1.1	4.69	7.12e-06	0.00584	0.38	0.39	Immature fraction of reticulocytes;	chr4:143855290	chr4:143912331~143982454:+
TGCT	cis	rs904251	0.523	rs10807184	ENSG00000204110.6	RP1-153P14.8	-4.69	7.13e-06	0.00585	-0.41	-0.39	Cognitive performance;	chr6:37515937	chr6:37507348~37535616:+
TGCT	cis	rs904251	0.561	rs1757189	ENSG00000204110.6	RP1-153P14.8	-4.69	7.13e-06	0.00585	-0.41	-0.39	Cognitive performance;	chr6:37515951	chr6:37507348~37535616:+
TGCT	cis	rs875971	0.862	rs880166	ENSG00000237310.1	GS1-124K5.4	-4.69	7.13e-06	0.00585	-0.42	-0.39	Aortic root size;	chr7:66205775	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.928	rs2036263	ENSG00000237310.1	GS1-124K5.4	-4.69	7.13e-06	0.00585	-0.42	-0.39	Aortic root size;	chr7:66335210	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs10240949	ENSG00000237310.1	GS1-124K5.4	-4.69	7.13e-06	0.00585	-0.42	-0.39	Aortic root size;	chr7:66339430	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs7782704	ENSG00000237310.1	GS1-124K5.4	-4.69	7.13e-06	0.00585	-0.42	-0.39	Aortic root size;	chr7:66340379	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs6460290	ENSG00000237310.1	GS1-124K5.4	-4.69	7.13e-06	0.00585	-0.42	-0.39	Aortic root size;	chr7:66344119	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs6959268	ENSG00000237310.1	GS1-124K5.4	-4.69	7.13e-06	0.00585	-0.42	-0.39	Aortic root size;	chr7:66347979	chr7:66493706~66495474:+
TGCT	cis	rs2463822	0.925	rs1528730	ENSG00000254454.2	RCC2P6	-4.69	7.13e-06	0.00585	-0.43	-0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62313709	chr11:62371146~62373168:+
TGCT	cis	rs2463822	0.748	rs2513038	ENSG00000254454.2	RCC2P6	-4.69	7.13e-06	0.00585	-0.43	-0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62313857	chr11:62371146~62373168:+
TGCT	cis	rs2177312	0.868	rs1523167	ENSG00000251129.1	RP11-734I18.1	-4.69	7.13e-06	0.00585	-0.42	-0.39	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31944574	chr4:31997397~32155406:+
TGCT	cis	rs2136613	0.533	rs10995327	ENSG00000238280.1	RP11-436D10.3	-4.69	7.14e-06	0.00586	-0.43	-0.39	Selective IgA deficiency;	chr10:62842814	chr10:62793562~62805887:-
TGCT	cis	rs2033711	0.902	rs4801589	ENSG00000269473.1	CTD-2619J13.19	4.69	7.15e-06	0.00587	0.31	0.39	Uric acid clearance;	chr19:58442031	chr19:58440448~58445849:+
TGCT	cis	rs4925386	0.765	rs6142737	ENSG00000273619.1	RP5-908M14.9	-4.69	7.16e-06	0.00587	-0.48	-0.39	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344744	chr20:62386303~62386970:-
TGCT	cis	rs4925386	0.84	rs6142738	ENSG00000273619.1	RP5-908M14.9	4.69	7.16e-06	0.00587	0.48	0.39	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344904	chr20:62386303~62386970:-
TGCT	cis	rs4835473	0.932	rs10030428	ENSG00000251600.4	RP11-673E1.1	4.69	7.16e-06	0.00587	0.39	0.39	Immature fraction of reticulocytes;	chr4:143762699	chr4:143912331~143982454:+
TGCT	cis	rs67311347	1	rs73078162	ENSG00000223797.4	ENTPD3-AS1	4.69	7.16e-06	0.00587	0.42	0.39	Renal cell carcinoma;	chr3:40435618	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs1004655	ENSG00000223797.4	ENTPD3-AS1	4.69	7.16e-06	0.00587	0.42	0.39	Renal cell carcinoma;	chr3:40448518	chr3:40313802~40453329:-
TGCT	cis	rs11671005	0.737	rs11671033	ENSG00000268912.1	CTD-2619J13.17	-4.69	7.16e-06	0.00587	-0.5	-0.39	Mean platelet volume;	chr19:58452302	chr19:58428632~58431148:-
TGCT	cis	rs9309473	1	rs7598396	ENSG00000163016.8	ALMS1P	4.69	7.16e-06	0.00588	0.35	0.39	Metabolite levels;	chr2:73425500	chr2:73644919~73685576:+
TGCT	cis	rs7829975	0.626	rs907183	ENSG00000254340.1	RP11-10A14.3	-4.69	7.17e-06	0.00588	-0.38	-0.39	Mood instability;	chr8:8872251	chr8:9141424~9145435:+
TGCT	cis	rs28735056	0.591	rs62101204	ENSG00000261126.6	RP11-795F19.1	4.69	7.17e-06	0.00588	0.33	0.39	Schizophrenia;	chr18:79952832	chr18:80046900~80095482:+
TGCT	cis	rs36093924	0.646	rs5996094	ENSG00000182057.4	OGFRP1	-4.69	7.19e-06	0.00589	-0.28	-0.39	Intelligence;	chr22:41951056	chr22:42269753~42275196:+
TGCT	cis	rs2976388	0.647	rs2244163	ENSG00000253196.1	RP11-706C16.7	4.69	7.19e-06	0.0059	0.38	0.39	Urinary tract infection frequency;	chr8:142703082	chr8:142763116~142766427:+
TGCT	cis	rs11230394	0.601	rs12576721	ENSG00000255947.1	RP11-855O10.3	-4.69	7.2e-06	0.0059	-0.33	-0.39	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);	chr11:60674954	chr11:61654665~61655702:-
TGCT	cis	rs801193	1	rs3800812	ENSG00000272831.1	RP11-792A8.4	4.69	7.2e-06	0.0059	0.41	0.39	Aortic root size;	chr7:66758474	chr7:66739829~66740385:-
TGCT	cis	rs801193	1	rs4279493	ENSG00000272831.1	RP11-792A8.4	4.69	7.2e-06	0.0059	0.41	0.39	Aortic root size;	chr7:66761633	chr7:66739829~66740385:-
TGCT	cis	rs801193	0.761	rs2659888	ENSG00000272831.1	RP11-792A8.4	4.69	7.2e-06	0.0059	0.41	0.39	Aortic root size;	chr7:66765184	chr7:66739829~66740385:-
TGCT	cis	rs801193	0.904	rs4718403	ENSG00000272831.1	RP11-792A8.4	4.69	7.2e-06	0.0059	0.41	0.39	Aortic root size;	chr7:66777742	chr7:66739829~66740385:-
TGCT	cis	rs801193	1	rs3778909	ENSG00000272831.1	RP11-792A8.4	4.69	7.2e-06	0.0059	0.41	0.39	Aortic root size;	chr7:66790659	chr7:66739829~66740385:-
TGCT	cis	rs2717559	0.522	rs2572925	ENSG00000253196.1	RP11-706C16.7	4.69	7.21e-06	0.00591	0.41	0.39	Urinary tract infection frequency;	chr8:142786489	chr8:142763116~142766427:+
TGCT	cis	rs2717559	0.504	rs2585130	ENSG00000253196.1	RP11-706C16.7	4.69	7.21e-06	0.00591	0.41	0.39	Urinary tract infection frequency;	chr8:142787561	chr8:142763116~142766427:+
TGCT	cis	rs9584850	0.834	rs745639	ENSG00000231194.1	FARP1-AS1	4.69	7.21e-06	0.00591	0.53	0.39	Neuroticism;	chr13:98467025	chr13:98435405~98435840:-
TGCT	cis	rs17711722	1	rs17711722	ENSG00000237310.1	GS1-124K5.4	-4.69	7.21e-06	0.00591	-0.43	-0.39	Calcium levels;	chr7:65806210	chr7:66493706~66495474:+
TGCT	cis	rs17711722	0.675	rs6947132	ENSG00000237310.1	GS1-124K5.4	-4.69	7.21e-06	0.00591	-0.43	-0.39	Calcium levels;	chr7:65808508	chr7:66493706~66495474:+
TGCT	cis	rs17826219	0.636	rs7221463	ENSG00000266490.1	CTD-2349P21.9	4.69	7.21e-06	0.00591	0.44	0.39	Body mass index;	chr17:30753533	chr17:30792372~30792833:+
TGCT	cis	rs12439619	0.693	rs9944185	ENSG00000255769.6	GOLGA2P10	-4.69	7.22e-06	0.00592	-0.44	-0.39	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472993~82513950:-
TGCT	cis	rs321358	0.732	rs17535419	ENSG00000271584.1	RP11-89C3.4	4.69	7.22e-06	0.00592	0.5	0.39	Body mass index;	chr11:111075357	chr11:111091932~111097357:-
TGCT	cis	rs5769707	0.967	rs2051626	ENSG00000235111.1	RP1-29C18.8	-4.69	7.22e-06	0.00592	-0.32	-0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.967	rs1018812	ENSG00000235111.1	RP1-29C18.8	-4.69	7.22e-06	0.00592	-0.32	-0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49616425	chr22:49612657~49615716:-
TGCT	cis	rs2136613	0.533	rs1967747	ENSG00000238280.1	RP11-436D10.3	-4.68	7.24e-06	0.00593	-0.43	-0.39	Selective IgA deficiency;	chr10:62844205	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs10761663	ENSG00000238280.1	RP11-436D10.3	-4.68	7.24e-06	0.00593	-0.43	-0.39	Selective IgA deficiency;	chr10:62845239	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs1475082	ENSG00000238280.1	RP11-436D10.3	-4.68	7.24e-06	0.00593	-0.43	-0.39	Selective IgA deficiency;	chr10:62845621	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs1475083	ENSG00000238280.1	RP11-436D10.3	-4.68	7.24e-06	0.00593	-0.43	-0.39	Selective IgA deficiency;	chr10:62845638	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs1475084	ENSG00000238280.1	RP11-436D10.3	-4.68	7.24e-06	0.00593	-0.43	-0.39	Selective IgA deficiency;	chr10:62845974	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs7088066	ENSG00000238280.1	RP11-436D10.3	-4.68	7.24e-06	0.00593	-0.43	-0.39	Selective IgA deficiency;	chr10:62846097	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs7088601	ENSG00000238280.1	RP11-436D10.3	-4.68	7.24e-06	0.00593	-0.43	-0.39	Selective IgA deficiency;	chr10:62846627	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs7089121	ENSG00000238280.1	RP11-436D10.3	-4.68	7.24e-06	0.00593	-0.43	-0.39	Selective IgA deficiency;	chr10:62846850	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs10740087	ENSG00000238280.1	RP11-436D10.3	-4.68	7.24e-06	0.00593	-0.43	-0.39	Selective IgA deficiency;	chr10:62847511	chr10:62793562~62805887:-
TGCT	cis	rs7208859	0.673	rs11653955	ENSG00000266490.1	CTD-2349P21.9	4.68	7.25e-06	0.00594	0.44	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30792372~30792833:+
TGCT	cis	rs875971	0.825	rs1000464	ENSG00000237310.1	GS1-124K5.4	-4.68	7.25e-06	0.00594	-0.42	-0.39	Aortic root size;	chr7:66312922	chr7:66493706~66495474:+
TGCT	cis	rs2742234	0.656	rs1864400	ENSG00000273008.1	RP11-351D16.3	-4.68	7.25e-06	0.00594	-0.52	-0.39	Hirschsprung disease;	chr10:43114918	chr10:43136824~43138334:-
TGCT	cis	rs4835473	0.897	rs1817027	ENSG00000251600.4	RP11-673E1.1	-4.68	7.26e-06	0.00594	-0.4	-0.39	Immature fraction of reticulocytes;	chr4:143713336	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.801	rs999049	ENSG00000251600.4	RP11-673E1.1	-4.68	7.26e-06	0.00594	-0.4	-0.39	Immature fraction of reticulocytes;	chr4:143715440	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs11735341	ENSG00000251600.4	RP11-673E1.1	-4.68	7.26e-06	0.00594	-0.4	-0.39	Immature fraction of reticulocytes;	chr4:143716030	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs1450249	ENSG00000251600.4	RP11-673E1.1	4.68	7.26e-06	0.00594	0.4	0.39	Immature fraction of reticulocytes;	chr4:143724425	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs34425128	ENSG00000251600.4	RP11-673E1.1	-4.68	7.26e-06	0.00594	-0.4	-0.39	Immature fraction of reticulocytes;	chr4:143725191	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs62337587	ENSG00000251600.4	RP11-673E1.1	-4.68	7.26e-06	0.00594	-0.4	-0.39	Immature fraction of reticulocytes;	chr4:143725839	chr4:143912331~143982454:+
TGCT	cis	rs1075265	0.584	rs10164409	ENSG00000233266.1	HMGB1P31	4.68	7.27e-06	0.00595	0.39	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53940867	chr2:54051334~54051760:+
TGCT	cis	rs875971	0.505	rs1167386	ENSG00000272831.1	RP11-792A8.4	-4.68	7.28e-06	0.00596	-0.4	-0.39	Aortic root size;	chr7:66048109	chr7:66739829~66740385:-
TGCT	cis	rs67311347	0.955	rs2085114	ENSG00000223797.4	ENTPD3-AS1	4.68	7.29e-06	0.00596	0.42	0.39	Renal cell carcinoma;	chr3:40455946	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs2085115	ENSG00000223797.4	ENTPD3-AS1	4.68	7.29e-06	0.00596	0.42	0.39	Renal cell carcinoma;	chr3:40456049	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs28707772	ENSG00000223797.4	ENTPD3-AS1	4.68	7.29e-06	0.00596	0.42	0.39	Renal cell carcinoma;	chr3:40463175	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs73080126	ENSG00000223797.4	ENTPD3-AS1	4.68	7.29e-06	0.00596	0.42	0.39	Renal cell carcinoma;	chr3:40467662	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs28871903	ENSG00000223797.4	ENTPD3-AS1	4.68	7.29e-06	0.00596	0.42	0.39	Renal cell carcinoma;	chr3:40469603	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs56291770	ENSG00000223797.4	ENTPD3-AS1	4.68	7.29e-06	0.00596	0.42	0.39	Renal cell carcinoma;	chr3:40473879	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs12630072	ENSG00000223797.4	ENTPD3-AS1	4.68	7.29e-06	0.00596	0.42	0.39	Renal cell carcinoma;	chr3:40475699	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs4128740	ENSG00000223797.4	ENTPD3-AS1	4.68	7.29e-06	0.00596	0.42	0.39	Renal cell carcinoma;	chr3:40478041	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs56303661	ENSG00000223797.4	ENTPD3-AS1	4.68	7.29e-06	0.00596	0.42	0.39	Renal cell carcinoma;	chr3:40479287	chr3:40313802~40453329:-
TGCT	cis	rs16852403	0.548	rs615226	ENSG00000224687.1	RASAL2-AS1	4.68	7.3e-06	0.00597	0.52	0.39	Childhood ear infection;	chr1:178225389	chr1:178091508~178093984:-
TGCT	cis	rs786425	0.683	rs11572920	ENSG00000278112.1	RP11-972P1.11	4.68	7.31e-06	0.00597	0.46	0.39	Pubertal anthropometrics;	chr12:123635436	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.683	rs12830927	ENSG00000278112.1	RP11-972P1.11	4.68	7.31e-06	0.00597	0.46	0.39	Pubertal anthropometrics;	chr12:123636444	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.618	rs12817576	ENSG00000278112.1	RP11-972P1.11	4.68	7.31e-06	0.00597	0.46	0.39	Pubertal anthropometrics;	chr12:123641792	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.618	rs11572952	ENSG00000278112.1	RP11-972P1.11	4.68	7.31e-06	0.00597	0.46	0.39	Pubertal anthropometrics;	chr12:123645262	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.646	rs11612927	ENSG00000278112.1	RP11-972P1.11	4.68	7.31e-06	0.00597	0.46	0.39	Pubertal anthropometrics;	chr12:123647180	chr12:123519390~123519856:-
TGCT	cis	rs35160687	0.901	rs12478653	ENSG00000273080.1	RP11-301O19.1	-4.68	7.31e-06	0.00598	-0.43	-0.39	Night sleep phenotypes;	chr2:86308271	chr2:86195590~86196049:+
TGCT	cis	rs2117029	0.556	rs1057725	ENSG00000258017.1	RP11-386G11.10	-4.68	7.31e-06	0.00598	-0.51	-0.39	Intelligence (multi-trait analysis);	chr12:49128795	chr12:49127782~49147869:+
TGCT	cis	rs875971	0.545	rs1796222	ENSG00000237310.1	GS1-124K5.4	-4.68	7.32e-06	0.00598	-0.46	-0.39	Aortic root size;	chr7:66592167	chr7:66493706~66495474:+
TGCT	cis	rs1153858	1	rs1719247	ENSG00000259520.4	CTD-2651B20.3	-4.68	7.32e-06	0.00599	-0.33	-0.39	Homoarginine levels;	chr15:45328787	chr15:45251580~45279251:-
TGCT	cis	rs6604026	0.624	rs11164814	ENSG00000223787.2	RP4-593M8.1	4.68	7.34e-06	0.00599	0.57	0.39	Multiple sclerosis;	chr1:92795816	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.624	rs11164816	ENSG00000223787.2	RP4-593M8.1	4.68	7.34e-06	0.00599	0.57	0.39	Multiple sclerosis;	chr1:92795941	chr1:92580476~92580821:-
TGCT	cis	rs4834770	0.668	rs11737086	ENSG00000245958.5	RP11-33B1.1	4.68	7.34e-06	0.00599	0.43	0.39	Blood protein levels;	chr4:119205962	chr4:119454791~119552025:+
TGCT	cis	rs4834770	0.668	rs1397610	ENSG00000245958.5	RP11-33B1.1	4.68	7.34e-06	0.00599	0.43	0.39	Blood protein levels;	chr4:119206606	chr4:119454791~119552025:+
TGCT	cis	rs9322193	0.962	rs9322206	ENSG00000216906.2	RP11-350J20.9	4.68	7.35e-06	0.006	0.43	0.39	Lung cancer;	chr6:149641481	chr6:149904243~149906418:+
TGCT	cis	rs507080	0.961	rs642530	ENSG00000255422.1	AP002954.4	-4.68	7.36e-06	0.00601	-0.42	-0.39	Serum metabolite levels;	chr11:118680047	chr11:118704607~118750263:+
TGCT	cis	rs1799949	0.894	rs36062488	ENSG00000198496.9	NBR2	4.68	7.37e-06	0.00601	0.54	0.39	Menopause (age at onset);	chr17:43185455	chr17:43125610~43153671:+
TGCT	cis	rs6017291	1	rs2093007	ENSG00000223891.4	OSER1-AS1	4.68	7.37e-06	0.00601	0.58	0.39	Cognitive performance;	chr20:44285956	chr20:44210960~44226027:+
TGCT	cis	rs6017291	1	rs36172862	ENSG00000223891.4	OSER1-AS1	4.68	7.37e-06	0.00601	0.58	0.39	Cognitive performance;	chr20:44292642	chr20:44210960~44226027:+
TGCT	cis	rs6017291	1	rs1884609	ENSG00000223891.4	OSER1-AS1	4.68	7.37e-06	0.00601	0.58	0.39	Cognitive performance;	chr20:44293488	chr20:44210960~44226027:+
TGCT	cis	rs6017291	1	rs2004265	ENSG00000223891.4	OSER1-AS1	4.68	7.37e-06	0.00601	0.58	0.39	Cognitive performance;	chr20:44295776	chr20:44210960~44226027:+
TGCT	cis	rs6017291	0.59	rs36168717	ENSG00000223891.4	OSER1-AS1	4.68	7.37e-06	0.00601	0.58	0.39	Cognitive performance;	chr20:44296936	chr20:44210960~44226027:+
TGCT	cis	rs6017291	1	rs68169205	ENSG00000223891.4	OSER1-AS1	4.68	7.37e-06	0.00601	0.58	0.39	Cognitive performance;	chr20:44297374	chr20:44210960~44226027:+
TGCT	cis	rs6017291	1	rs56373343	ENSG00000223891.4	OSER1-AS1	4.68	7.37e-06	0.00601	0.58	0.39	Cognitive performance;	chr20:44301340	chr20:44210960~44226027:+
TGCT	cis	rs911555	0.755	rs975892	ENSG00000244691.1	RPL10AP1	-4.68	7.37e-06	0.00601	-0.52	-0.39	Intelligence (multi-trait analysis);	chr14:103417012	chr14:103412119~103412761:-
TGCT	cis	rs673078	0.607	rs61943367	ENSG00000275759.1	RP11-131L12.3	-4.68	7.38e-06	0.00601	-0.7	-0.39	Glucose homeostasis traits;	chr12:118366316	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs61943368	ENSG00000275759.1	RP11-131L12.3	-4.68	7.38e-06	0.00601	-0.7	-0.39	Glucose homeostasis traits;	chr12:118366568	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs61943385	ENSG00000275759.1	RP11-131L12.3	-4.68	7.38e-06	0.00601	-0.7	-0.39	Glucose homeostasis traits;	chr12:118370339	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs17512644	ENSG00000275759.1	RP11-131L12.3	-4.68	7.38e-06	0.00601	-0.7	-0.39	Glucose homeostasis traits;	chr12:118359963	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs17512652	ENSG00000275759.1	RP11-131L12.3	-4.68	7.38e-06	0.00601	-0.7	-0.39	Glucose homeostasis traits;	chr12:118361278	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs17440893	ENSG00000275759.1	RP11-131L12.3	-4.68	7.38e-06	0.00601	-0.7	-0.39	Glucose homeostasis traits;	chr12:118362532	chr12:118428281~118428870:+
TGCT	cis	rs875971	0.597	rs11771318	ENSG00000236529.1	RP13-254B10.1	-4.68	7.38e-06	0.00601	-0.29	-0.39	Aortic root size;	chr7:66597493	chr7:65840212~65840596:+
TGCT	cis	rs7829975	0.606	rs6422352	ENSG00000173295.6	FAM86B3P	-4.68	7.38e-06	0.00602	-0.46	-0.39	Mood instability;	chr8:8936683	chr8:8228595~8244865:+
TGCT	cis	rs7829975	0.606	rs891570	ENSG00000173295.6	FAM86B3P	-4.68	7.38e-06	0.00602	-0.46	-0.39	Mood instability;	chr8:8936944	chr8:8228595~8244865:+
TGCT	cis	rs2717559	0.561	rs7841267	ENSG00000253196.1	RP11-706C16.7	-4.68	7.39e-06	0.00602	-0.41	-0.39	Urinary tract infection frequency;	chr8:142800267	chr8:142763116~142766427:+
TGCT	cis	rs2717559	0.542	rs34147336	ENSG00000253196.1	RP11-706C16.7	-4.68	7.39e-06	0.00602	-0.41	-0.39	Urinary tract infection frequency;	chr8:142803453	chr8:142763116~142766427:+
TGCT	cis	rs2333021	0.77	rs12892806	ENSG00000259015.1	RP11-109N23.6	4.68	7.39e-06	0.00602	0.21	0.39	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72936225	chr14:72960595~72961993:+
TGCT	cis	rs1707322	0.827	rs6694302	ENSG00000280836.1	AL355480.1	-4.68	7.4e-06	0.00603	-0.51	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr1:45581219~45581321:-
TGCT	cis	rs4834770	0.792	rs6823331	ENSG00000245958.5	RP11-33B1.1	-4.68	7.4e-06	0.00603	-0.39	-0.39	Blood protein levels;	chr4:119259635	chr4:119454791~119552025:+
TGCT	cis	rs9462027	0.628	rs2814953	ENSG00000186328.4	RP11-140K17.2	4.68	7.4e-06	0.00603	0.37	0.39	Systemic lupus erythematosus;	chr6:34729990	chr6:34715613~34715940:+
TGCT	cis	rs875971	0.862	rs11773628	ENSG00000232559.3	GS1-124K5.12	-4.68	7.4e-06	0.00603	-0.35	-0.39	Aortic root size;	chr7:66517644	chr7:66554588~66576923:-
TGCT	cis	rs5769707	0.967	rs2187891	ENSG00000235111.1	RP1-29C18.8	-4.68	7.41e-06	0.00604	-0.31	-0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49612657~49615716:-
TGCT	cis	rs801193	1	rs10252765	ENSG00000272831.1	RP11-792A8.4	4.68	7.43e-06	0.00605	0.41	0.39	Aortic root size;	chr7:66763745	chr7:66739829~66740385:-
TGCT	cis	rs7605378	1	rs7605378	ENSG00000232732.8	AC073043.1	-4.68	7.44e-06	0.00605	-0.45	-0.39	Osteoporosis;	chr2:199812203	chr2:199867396~199911159:-
TGCT	cis	rs7605378	1	rs10194076	ENSG00000232732.8	AC073043.1	-4.68	7.44e-06	0.00605	-0.45	-0.39	Osteoporosis;	chr2:199812940	chr2:199867396~199911159:-
TGCT	cis	rs10504229	0.683	rs10504224	ENSG00000253301.4	RP11-513O17.2	4.68	7.44e-06	0.00606	0.59	0.39	Developmental language disorder (linguistic errors);	chr8:57231176	chr8:57142689~57240298:+
TGCT	cis	rs10129255	0.585	rs2008440	ENSG00000211970.3	IGHV4-61	-4.68	7.45e-06	0.00606	-0.41	-0.39	Kawasaki disease;	chr14:106654988	chr14:106639119~106639657:-
TGCT	cis	rs2976388	0.647	rs1048831	ENSG00000253196.1	RP11-706C16.7	4.68	7.46e-06	0.00606	0.39	0.39	Urinary tract infection frequency;	chr8:142700440	chr8:142763116~142766427:+
TGCT	cis	rs10246939	0.543	rs11769089	ENSG00000228775.6	WEE2-AS1	4.68	7.46e-06	0.00607	0.35	0.39	Bitter taste perception;	chr7:141914310	chr7:141704338~141738346:-
TGCT	cis	rs10246939	0.543	rs11765974	ENSG00000228775.6	WEE2-AS1	4.68	7.46e-06	0.00607	0.35	0.39	Bitter taste perception;	chr7:141914390	chr7:141704338~141738346:-
TGCT	cis	rs7605378	0.688	rs769961	ENSG00000232732.8	AC073043.1	-4.68	7.47e-06	0.00607	-0.46	-0.39	Osteoporosis;	chr2:199847418	chr2:199867396~199911159:-
TGCT	cis	rs4660456	0.827	rs617413	ENSG00000237899.1	RP4-739H11.3	4.68	7.47e-06	0.00608	0.51	0.39	Platelet count;	chr1:40669846	chr1:40669089~40687588:-
TGCT	cis	rs10129255	0.5	rs2105989	ENSG00000223648.3	IGHV3-64	4.68	7.49e-06	0.00609	0.32	0.39	Kawasaki disease;	chr14:106682199	chr14:106643132~106658258:-
TGCT	cis	rs507080	0.961	rs600969	ENSG00000255422.1	AP002954.4	-4.68	7.5e-06	0.0061	-0.45	-0.39	Serum metabolite levels;	chr11:118675087	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.922	rs12577485	ENSG00000255422.1	AP002954.4	-4.68	7.5e-06	0.0061	-0.45	-0.39	Serum metabolite levels;	chr11:118676793	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.961	rs1784298	ENSG00000255422.1	AP002954.4	-4.68	7.5e-06	0.0061	-0.45	-0.39	Serum metabolite levels;	chr11:118677956	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.961	rs4938522	ENSG00000255422.1	AP002954.4	-4.68	7.5e-06	0.0061	-0.45	-0.39	Serum metabolite levels;	chr11:118677962	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.961	rs4938523	ENSG00000255422.1	AP002954.4	-4.68	7.5e-06	0.0061	-0.45	-0.39	Serum metabolite levels;	chr11:118678129	chr11:118704607~118750263:+
TGCT	cis	rs507080	1	rs507080	ENSG00000255422.1	AP002954.4	-4.68	7.5e-06	0.0061	-0.45	-0.39	Serum metabolite levels;	chr11:118678873	chr11:118704607~118750263:+
TGCT	cis	rs507080	1	rs659969	ENSG00000255422.1	AP002954.4	-4.68	7.5e-06	0.0061	-0.45	-0.39	Serum metabolite levels;	chr11:118679094	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.961	rs673770	ENSG00000255422.1	AP002954.4	-4.68	7.5e-06	0.0061	-0.45	-0.39	Serum metabolite levels;	chr11:118679892	chr11:118704607~118750263:+
TGCT	cis	rs5769707	0.967	rs5769698	ENSG00000235111.1	RP1-29C18.8	-4.68	7.5e-06	0.0061	-0.32	-0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49612657~49615716:-
TGCT	cis	rs875971	0.755	rs76288834	ENSG00000232559.3	GS1-124K5.12	-4.68	7.51e-06	0.0061	-0.36	-0.39	Aortic root size;	chr7:66604815	chr7:66554588~66576923:-
TGCT	cis	rs6604026	0.624	rs11800409	ENSG00000223787.2	RP4-593M8.1	4.68	7.51e-06	0.0061	0.55	0.39	Multiple sclerosis;	chr1:92715456	chr1:92580476~92580821:-
TGCT	cis	rs4660456	0.83	rs12566786	ENSG00000237899.1	RP4-739H11.3	-4.68	7.51e-06	0.0061	-0.51	-0.39	Platelet count;	chr1:40742709	chr1:40669089~40687588:-
TGCT	cis	rs1823913	0.892	rs35596292	ENSG00000280083.1	RP11-317J9.1	-4.68	7.51e-06	0.0061	-0.33	-0.39	Obesity-related traits;	chr2:191246890	chr2:191154118~191156070:-
TGCT	cis	rs1823913	0.927	rs35530564	ENSG00000280083.1	RP11-317J9.1	-4.68	7.51e-06	0.0061	-0.33	-0.39	Obesity-related traits;	chr2:191247324	chr2:191154118~191156070:-
TGCT	cis	rs875971	0.651	rs2420596	ENSG00000232559.3	GS1-124K5.12	4.68	7.52e-06	0.0061	0.36	0.39	Aortic root size;	chr7:66450996	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.52	rs2420597	ENSG00000232559.3	GS1-124K5.12	4.68	7.52e-06	0.0061	0.36	0.39	Aortic root size;	chr7:66450999	chr7:66554588~66576923:-
TGCT	cis	rs67311347	0.956	rs4974029	ENSG00000223797.4	ENTPD3-AS1	4.68	7.52e-06	0.00611	0.41	0.39	Renal cell carcinoma;	chr3:40479827	chr3:40313802~40453329:-
TGCT	cis	rs2117029	0.619	rs9325145	ENSG00000258017.1	RP11-386G11.10	-4.68	7.52e-06	0.00611	-0.51	-0.39	Intelligence (multi-trait analysis);	chr12:49132101	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.586	rs10783307	ENSG00000258017.1	RP11-386G11.10	-4.68	7.52e-06	0.00611	-0.51	-0.39	Intelligence (multi-trait analysis);	chr12:49135822	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.554	rs12306494	ENSG00000258017.1	RP11-386G11.10	-4.68	7.52e-06	0.00611	-0.51	-0.39	Intelligence (multi-trait analysis);	chr12:49136998	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.586	rs10783308	ENSG00000258017.1	RP11-386G11.10	-4.68	7.52e-06	0.00611	-0.51	-0.39	Intelligence (multi-trait analysis);	chr12:49137675	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.586	rs11168884	ENSG00000258017.1	RP11-386G11.10	-4.68	7.52e-06	0.00611	-0.51	-0.39	Intelligence (multi-trait analysis);	chr12:49146109	chr12:49127782~49147869:+
TGCT	cis	rs11168854	0.719	rs11168890	ENSG00000258017.1	RP11-386G11.10	-4.68	7.52e-06	0.00611	-0.51	-0.39	Body mass index;	chr12:49150130	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.586	rs7954521	ENSG00000258017.1	RP11-386G11.10	-4.68	7.52e-06	0.00611	-0.51	-0.39	Intelligence (multi-trait analysis);	chr12:49151857	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.553	rs2162644	ENSG00000258017.1	RP11-386G11.10	-4.68	7.52e-06	0.00611	-0.51	-0.39	Intelligence (multi-trait analysis);	chr12:49154407	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.586	rs2114846	ENSG00000258017.1	RP11-386G11.10	-4.68	7.52e-06	0.00611	-0.51	-0.39	Intelligence (multi-trait analysis);	chr12:49154493	chr12:49127782~49147869:+
TGCT	cis	rs73198271	0.562	rs17631022	ENSG00000253893.2	FAM85B	4.68	7.53e-06	0.00611	0.63	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8804687	chr8:8167819~8226614:-
TGCT	cis	rs11671005	0.736	rs11668201	ENSG00000232098.3	CTD-2619J13.14	-4.68	7.53e-06	0.00611	-0.45	-0.39	Mean platelet volume;	chr19:58492265	chr19:58404238~58408484:-
TGCT	cis	rs34217772	0.699	rs59416658	ENSG00000258536.1	RP11-1053O12.1	4.68	7.54e-06	0.00612	0.33	0.39	Myopia;	chr14:41844095	chr14:41742639~41742963:+
TGCT	cis	rs1799949	0.773	rs2137990	ENSG00000198496.9	NBR2	4.68	7.54e-06	0.00612	0.54	0.39	Menopause (age at onset);	chr17:43165879	chr17:43125610~43153671:+
TGCT	cis	rs10829156	0.786	rs7093907	ENSG00000240291.1	RP11-499P20.2	4.68	7.54e-06	0.00612	0.36	0.39	Sudden cardiac arrest;	chr10:18587225	chr10:18513115~18545651:-
TGCT	cis	rs728616	0.717	rs17098169	ENSG00000230091.5	TMEM254-AS1	-4.68	7.55e-06	0.00612	-0.74	-0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80056378	chr10:80046860~80078912:-
TGCT	cis	rs1153858	1	rs1613559	ENSG00000259520.4	CTD-2651B20.3	-4.67	7.55e-06	0.00612	-0.33	-0.39	Homoarginine levels;	chr15:45329918	chr15:45251580~45279251:-
TGCT	cis	rs1153858	1	rs1618874	ENSG00000259520.4	CTD-2651B20.3	-4.67	7.55e-06	0.00612	-0.33	-0.39	Homoarginine levels;	chr15:45330588	chr15:45251580~45279251:-
TGCT	cis	rs755249	0.501	rs2455648	ENSG00000182109.6	RP11-69E11.4	4.67	7.55e-06	0.00612	0.39	0.39	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39178040	chr1:39522280~39546187:-
TGCT	cis	rs755249	0.501	rs2484133	ENSG00000182109.6	RP11-69E11.4	4.67	7.55e-06	0.00612	0.39	0.39	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39188322	chr1:39522280~39546187:-
TGCT	cis	rs6700559	0.654	rs12061556	ENSG00000260088.1	RP11-92G12.3	4.67	7.58e-06	0.00614	0.47	0.39	Coronary artery disease;	chr1:200681111	chr1:200669507~200694250:+
TGCT	cis	rs8059260	0.668	rs76212701	ENSG00000274038.1	RP11-66H6.4	-4.67	7.58e-06	0.00614	-0.52	-0.39	Alcohol consumption over the past year;	chr16:11023634	chr16:11056556~11057034:+
TGCT	cis	rs7246967	0.673	rs60675447	ENSG00000269509.1	BNIP3P34	4.67	7.59e-06	0.00614	0.63	0.39	Bronchopulmonary dysplasia;	chr19:22628090	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs56725192	ENSG00000269509.1	BNIP3P34	4.67	7.59e-06	0.00614	0.63	0.39	Bronchopulmonary dysplasia;	chr19:22628136	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs1433085	ENSG00000269509.1	BNIP3P34	4.67	7.59e-06	0.00614	0.63	0.39	Bronchopulmonary dysplasia;	chr19:22628297	chr19:22773853~22774424:+
TGCT	cis	rs875971	0.862	rs1612452	ENSG00000237310.1	GS1-124K5.4	-4.67	7.6e-06	0.00615	-0.42	-0.39	Aortic root size;	chr7:66108909	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs1167390	ENSG00000237310.1	GS1-124K5.4	-4.67	7.6e-06	0.00615	-0.42	-0.39	Aortic root size;	chr7:66110906	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs35034167	ENSG00000237310.1	GS1-124K5.4	-4.67	7.6e-06	0.00615	-0.42	-0.39	Aortic root size;	chr7:66115179	chr7:66493706~66495474:+
TGCT	cis	rs8059260	0.736	rs16957836	ENSG00000274038.1	RP11-66H6.4	-4.67	7.6e-06	0.00615	-0.55	-0.39	Alcohol consumption over the past year;	chr16:10959229	chr16:11056556~11057034:+
TGCT	cis	rs13118159	0.55	rs4974617	ENSG00000254094.1	AC078852.1	-4.67	7.62e-06	0.00617	-0.49	-0.39	Longevity;	chr4:1379870	chr4:1356581~1358075:+
TGCT	cis	rs3096299	0.933	rs3114848	ENSG00000274627.1	RP11-104N10.2	4.67	7.63e-06	0.00617	0.41	0.39	Multiple myeloma (IgH translocation);	chr16:89386363	chr16:89516797~89522217:+
TGCT	cis	rs2976388	0.935	rs2920285	ENSG00000253196.1	RP11-706C16.7	-4.67	7.63e-06	0.00617	-0.4	-0.39	Urinary tract infection frequency;	chr8:142674800	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.935	rs2978978	ENSG00000253196.1	RP11-706C16.7	-4.67	7.63e-06	0.00617	-0.4	-0.39	Urinary tract infection frequency;	chr8:142675112	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.762	rs34635647	ENSG00000253196.1	RP11-706C16.7	-4.67	7.63e-06	0.00617	-0.4	-0.39	Urinary tract infection frequency;	chr8:142675472	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.935	rs2920284	ENSG00000253196.1	RP11-706C16.7	-4.67	7.63e-06	0.00617	-0.4	-0.39	Urinary tract infection frequency;	chr8:142675501	chr8:142763116~142766427:+
TGCT	cis	rs2976388	1	rs2920283	ENSG00000253196.1	RP11-706C16.7	-4.67	7.63e-06	0.00617	-0.4	-0.39	Urinary tract infection frequency;	chr8:142675619	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.935	rs2978979	ENSG00000253196.1	RP11-706C16.7	-4.67	7.63e-06	0.00617	-0.4	-0.39	Urinary tract infection frequency;	chr8:142675868	chr8:142763116~142766427:+
TGCT	cis	rs17826219	0.706	rs28469200	ENSG00000280069.1	CTD-2349P21.3	-4.67	7.63e-06	0.00617	-0.54	-0.39	Body mass index;	chr17:30806554	chr17:30738182~30740275:+
TGCT	cis	rs673078	0.607	rs2036314	ENSG00000275759.1	RP11-131L12.3	-4.67	7.64e-06	0.00618	-0.64	-0.39	Glucose homeostasis traits;	chr12:118367132	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs61943369	ENSG00000275759.1	RP11-131L12.3	-4.67	7.64e-06	0.00618	-0.64	-0.39	Glucose homeostasis traits;	chr12:118368145	chr12:118428281~118428870:+
TGCT	cis	rs5769707	0.967	rs17182154	ENSG00000235111.1	RP1-29C18.8	-4.67	7.65e-06	0.00618	-0.31	-0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49596822	chr22:49612657~49615716:-
TGCT	cis	rs4835473	0.932	rs4835305	ENSG00000251600.4	RP11-673E1.1	-4.67	7.65e-06	0.00618	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143823646	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs11721700	ENSG00000251600.4	RP11-673E1.1	-4.67	7.65e-06	0.00618	-0.39	-0.39	Immature fraction of reticulocytes;	chr4:143824264	chr4:143912331~143982454:+
TGCT	cis	rs7201929	1	rs7499878	ENSG00000259982.1	CDC37P1	-4.67	7.65e-06	0.00618	-0.52	-0.39	QT interval;	chr16:28857143	chr16:28700294~28701540:-
TGCT	cis	rs875971	0.862	rs6971059	ENSG00000232559.3	GS1-124K5.12	-4.67	7.65e-06	0.00618	-0.36	-0.39	Aortic root size;	chr7:66602045	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.789	rs7808013	ENSG00000232559.3	GS1-124K5.12	-4.67	7.65e-06	0.00618	-0.36	-0.39	Aortic root size;	chr7:66606209	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.825	rs7384021	ENSG00000232559.3	GS1-124K5.12	-4.67	7.65e-06	0.00618	-0.36	-0.39	Aortic root size;	chr7:66612917	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.825	rs66981195	ENSG00000232559.3	GS1-124K5.12	-4.67	7.65e-06	0.00618	-0.36	-0.39	Aortic root size;	chr7:66614048	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs3926380	ENSG00000232559.3	GS1-124K5.12	-4.67	7.65e-06	0.00618	-0.36	-0.39	Aortic root size;	chr7:66615658	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.825	rs1860472	ENSG00000232559.3	GS1-124K5.12	-4.67	7.65e-06	0.00618	-0.36	-0.39	Aortic root size;	chr7:66617736	chr7:66554588~66576923:-
TGCT	cis	rs867371	0.502	rs2047679	ENSG00000255769.6	GOLGA2P10	-4.67	7.66e-06	0.00619	-0.37	-0.39	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82472993~82513950:-
TGCT	cis	rs7201929	1	rs12920514	ENSG00000259982.1	CDC37P1	-4.67	7.66e-06	0.00619	-0.55	-0.39	QT interval;	chr16:28824579	chr16:28700294~28701540:-
TGCT	cis	rs12935418	0.83	rs7188549	ENSG00000261061.1	RP11-303E16.2	-4.67	7.67e-06	0.00619	-0.51	-0.39	Mean corpuscular volume;	chr16:81016371	chr16:81030770~81031485:+
TGCT	cis	rs12935418	0.83	rs7195459	ENSG00000261061.1	RP11-303E16.2	-4.67	7.67e-06	0.00619	-0.51	-0.39	Mean corpuscular volume;	chr16:81016376	chr16:81030770~81031485:+
TGCT	cis	rs67311347	1	rs11539046	ENSG00000223797.4	ENTPD3-AS1	-4.67	7.67e-06	0.00619	-0.41	-0.39	Renal cell carcinoma;	chr3:40462318	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs12633431	ENSG00000223797.4	ENTPD3-AS1	-4.67	7.67e-06	0.00619	-0.41	-0.39	Renal cell carcinoma;	chr3:40464249	chr3:40313802~40453329:-
TGCT	cis	rs67311347	0.956	rs6771527	ENSG00000223797.4	ENTPD3-AS1	-4.67	7.67e-06	0.00619	-0.41	-0.39	Renal cell carcinoma;	chr3:40465057	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs7628796	ENSG00000223797.4	ENTPD3-AS1	-4.67	7.67e-06	0.00619	-0.41	-0.39	Renal cell carcinoma;	chr3:40465841	chr3:40313802~40453329:-
TGCT	cis	rs67311347	0.955	rs6782746	ENSG00000223797.4	ENTPD3-AS1	-4.67	7.67e-06	0.00619	-0.41	-0.39	Renal cell carcinoma;	chr3:40469101	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs7628247	ENSG00000223797.4	ENTPD3-AS1	-4.67	7.67e-06	0.00619	-0.41	-0.39	Renal cell carcinoma;	chr3:40471191	chr3:40313802~40453329:-
TGCT	cis	rs67311347	0.91	rs7651204	ENSG00000223797.4	ENTPD3-AS1	-4.67	7.67e-06	0.00619	-0.41	-0.39	Renal cell carcinoma;	chr3:40471344	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs7633809	ENSG00000223797.4	ENTPD3-AS1	-4.67	7.67e-06	0.00619	-0.41	-0.39	Renal cell carcinoma;	chr3:40476246	chr3:40313802~40453329:-
TGCT	cis	rs1865760	0.964	rs9379802	ENSG00000217159.2	LARP1P1	-4.67	7.68e-06	0.0062	-0.44	-0.39	Height;	chr6:25933670	chr6:26164072~26164363:+
TGCT	cis	rs2739330	0.587	rs4820571	ENSG00000218537.1	MIF-AS1	4.67	7.68e-06	0.0062	0.48	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23894426~23898930:-
TGCT	cis	rs11118620	0.853	rs11118622	ENSG00000272823.1	RP11-295M18.6	4.67	7.68e-06	0.00621	0.36	0.39	Heart failure;	chr1:220868833	chr1:220828676~220829211:-
TGCT	cis	rs801193	1	rs4717319	ENSG00000272831.1	RP11-792A8.4	4.67	7.7e-06	0.00622	0.42	0.39	Aortic root size;	chr7:66777606	chr7:66739829~66740385:-
TGCT	cis	rs7714584	1	rs7724036	ENSG00000197083.10	ZNF300P1	-4.67	7.72e-06	0.00623	-0.6	-0.39	Crohn's disease;	chr5:150905246	chr5:150930645~150946289:-
TGCT	cis	rs73198271	0.562	rs17154743	ENSG00000253893.2	FAM85B	4.67	7.72e-06	0.00623	0.63	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793277	chr8:8167819~8226614:-
TGCT	cis	rs786425	0.901	rs11057307	ENSG00000247373.3	RP11-486O12.2	4.67	7.72e-06	0.00623	0.46	0.39	Pubertal anthropometrics;	chr12:123613666	chr12:123575891~123585115:-
TGCT	cis	rs2442825	0.693	rs2258768	ENSG00000206573.7	THUMPD3-AS1	4.67	7.72e-06	0.00623	0.36	0.39	Cerebrospinal fluid clusterin levels;	chr3:9363193	chr3:9349689~9398579:-
TGCT	cis	rs13108904	0.539	rs13135102	ENSG00000253399.1	AC078852.2	-4.67	7.73e-06	0.00623	-0.46	-0.39	Obesity-related traits;	chr4:1337195	chr4:1358479~1359461:+
TGCT	cis	rs13108904	0.517	rs13128825	ENSG00000253399.1	AC078852.2	-4.67	7.73e-06	0.00623	-0.46	-0.39	Obesity-related traits;	chr4:1340219	chr4:1358479~1359461:+
TGCT	cis	rs13108904	0.517	rs13134568	ENSG00000253399.1	AC078852.2	-4.67	7.73e-06	0.00623	-0.46	-0.39	Obesity-related traits;	chr4:1340501	chr4:1358479~1359461:+
TGCT	cis	rs13108904	0.517	rs4974551	ENSG00000253399.1	AC078852.2	-4.67	7.73e-06	0.00623	-0.46	-0.39	Obesity-related traits;	chr4:1342622	chr4:1358479~1359461:+
TGCT	cis	rs13108904	0.539	rs13145722	ENSG00000253399.1	AC078852.2	-4.67	7.73e-06	0.00623	-0.46	-0.39	Obesity-related traits;	chr4:1344634	chr4:1358479~1359461:+
TGCT	cis	rs875971	0.516	rs6945322	ENSG00000272831.1	RP11-792A8.4	4.67	7.73e-06	0.00624	0.4	0.39	Aortic root size;	chr7:65871069	chr7:66739829~66740385:-
TGCT	cis	rs17711722	0.701	rs55773927	ENSG00000272831.1	RP11-792A8.4	4.67	7.73e-06	0.00624	0.4	0.39	Calcium levels;	chr7:65872915	chr7:66739829~66740385:-
TGCT	cis	rs17711722	0.727	rs35850374	ENSG00000272831.1	RP11-792A8.4	4.67	7.73e-06	0.00624	0.4	0.39	Calcium levels;	chr7:65892789	chr7:66739829~66740385:-
TGCT	cis	rs7221109	0.71	rs4890093	ENSG00000278834.1	RP11-458J1.1	4.67	7.73e-06	0.00624	0.28	0.39	Type 1 diabetes;	chr17:40639691	chr17:40648300~40649718:+
TGCT	cis	rs2717559	0.522	rs2572924	ENSG00000253196.1	RP11-706C16.7	4.67	7.74e-06	0.00624	0.41	0.39	Urinary tract infection frequency;	chr8:142787698	chr8:142763116~142766427:+
TGCT	cis	rs875971	0.545	rs1796217	ENSG00000237310.1	GS1-124K5.4	-4.67	7.74e-06	0.00624	-0.46	-0.39	Aortic root size;	chr7:66620931	chr7:66493706~66495474:+
TGCT	cis	rs17301013	0.729	rs12094143	ENSG00000227373.4	RP11-160H22.5	4.67	7.75e-06	0.00625	0.4	0.39	Systemic lupus erythematosus;	chr1:174511986	chr1:174115300~174160004:-
TGCT	cis	rs453301	0.653	rs1045529	ENSG00000254340.1	RP11-10A14.3	-4.67	7.75e-06	0.00625	-0.39	-0.39	Joint mobility (Beighton score);	chr8:9032588	chr8:9141424~9145435:+
TGCT	cis	rs8091660	0.862	rs12607412	ENSG00000278983.1	RP11-426J5.3	4.67	7.75e-06	0.00625	0.46	0.39	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48545949	chr18:48564795~48568342:+
TGCT	cis	rs34779708	0.931	rs13377158	ENSG00000230534.5	RP11-297A16.2	-4.67	7.77e-06	0.00626	-0.46	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35081537	chr10:35098006~35127020:-
TGCT	cis	rs1707322	0.717	rs11211161	ENSG00000280836.1	AL355480.1	-4.67	7.78e-06	0.00627	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45581219~45581321:-
TGCT	cis	rs875971	0.545	rs10950036	ENSG00000237310.1	GS1-124K5.4	4.67	7.78e-06	0.00627	0.46	0.39	Aortic root size;	chr7:66353241	chr7:66493706~66495474:+
TGCT	cis	rs7208859	0.725	rs9891656	ENSG00000266490.1	CTD-2349P21.9	4.67	7.79e-06	0.00628	0.37	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916337	chr17:30792372~30792833:+
TGCT	cis	rs6600671	1	rs2319969	ENSG00000275131.1	CH17-472G23.4	-4.67	7.8e-06	0.00628	-0.26	-0.39	Hip geometry;	chr1:121465481	chr1:120489625~120579190:-
TGCT	cis	rs1865760	0.963	rs9356991	ENSG00000217159.2	LARP1P1	-4.67	7.81e-06	0.00629	-0.45	-0.39	Height;	chr6:25901530	chr6:26164072~26164363:+
TGCT	cis	rs1865760	1	rs7757666	ENSG00000217159.2	LARP1P1	-4.67	7.81e-06	0.00629	-0.45	-0.39	Height;	chr6:25902398	chr6:26164072~26164363:+
TGCT	cis	rs1865760	1	rs6910138	ENSG00000217159.2	LARP1P1	-4.67	7.81e-06	0.00629	-0.45	-0.39	Height;	chr6:25904124	chr6:26164072~26164363:+
TGCT	cis	rs1865760	1	rs6910174	ENSG00000217159.2	LARP1P1	-4.67	7.81e-06	0.00629	-0.45	-0.39	Height;	chr6:25904186	chr6:26164072~26164363:+
TGCT	cis	rs1865760	1	rs7739966	ENSG00000217159.2	LARP1P1	-4.67	7.81e-06	0.00629	-0.45	-0.39	Height;	chr6:25905812	chr6:26164072~26164363:+
TGCT	cis	rs1865760	1	rs56118523	ENSG00000217159.2	LARP1P1	-4.67	7.81e-06	0.00629	-0.45	-0.39	Height;	chr6:25908747	chr6:26164072~26164363:+
TGCT	cis	rs1865760	1	rs12209482	ENSG00000217159.2	LARP1P1	-4.67	7.81e-06	0.00629	-0.45	-0.39	Height;	chr6:25909001	chr6:26164072~26164363:+
TGCT	cis	rs1865760	0.963	rs3846838	ENSG00000217159.2	LARP1P1	-4.67	7.81e-06	0.00629	-0.45	-0.39	Height;	chr6:25911547	chr6:26164072~26164363:+
TGCT	cis	rs1865760	1	rs6905887	ENSG00000217159.2	LARP1P1	-4.67	7.81e-06	0.00629	-0.45	-0.39	Height;	chr6:25911875	chr6:26164072~26164363:+
TGCT	cis	rs1865760	0.964	rs6932113	ENSG00000217159.2	LARP1P1	-4.67	7.81e-06	0.00629	-0.45	-0.39	Height;	chr6:25912870	chr6:26164072~26164363:+
TGCT	cis	rs1865760	1	rs3830057	ENSG00000217159.2	LARP1P1	-4.67	7.83e-06	0.0063	-0.45	-0.39	Height;	chr6:25918282	chr6:26164072~26164363:+
TGCT	cis	rs1865760	1	rs3752421	ENSG00000217159.2	LARP1P1	-4.67	7.83e-06	0.0063	-0.45	-0.39	Height;	chr6:25918460	chr6:26164072~26164363:+
TGCT	cis	rs6964833	0.554	rs2527380	ENSG00000123965.13	PMS2P5	-4.67	7.83e-06	0.0063	-0.45	-0.39	Menarche (age at onset);	chr7:74690372	chr7:74894116~74897835:+
TGCT	cis	rs875971	0.54	rs4717275	ENSG00000272831.1	RP11-792A8.4	-4.67	7.83e-06	0.0063	-0.4	-0.39	Aortic root size;	chr7:65800193	chr7:66739829~66740385:-
TGCT	cis	rs17711722	0.701	rs4467826	ENSG00000272831.1	RP11-792A8.4	4.67	7.83e-06	0.0063	0.4	0.39	Calcium levels;	chr7:65903721	chr7:66739829~66740385:-
TGCT	cis	rs1010254	0.51	rs17543712	ENSG00000253921.1	CTB-113P19.3	-4.67	7.84e-06	0.00631	-0.47	-0.39	Optic nerve measurement (cup area);	chr5:152335965	chr5:151753992~151767247:+
TGCT	cis	rs2177312	0.83	rs1523160	ENSG00000251129.1	RP11-734I18.1	-4.67	7.86e-06	0.00632	-0.45	-0.39	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31966116	chr4:31997397~32155406:+
TGCT	cis	rs12439619	0.846	rs62011975	ENSG00000255769.6	GOLGA2P10	-4.67	7.86e-06	0.00632	-0.46	-0.39	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472993~82513950:-
TGCT	cis	rs12439619	0.846	rs62012003	ENSG00000255769.6	GOLGA2P10	-4.67	7.86e-06	0.00632	-0.46	-0.39	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472993~82513950:-
TGCT	cis	rs12439619	0.846	rs62012004	ENSG00000255769.6	GOLGA2P10	-4.67	7.86e-06	0.00632	-0.46	-0.39	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472993~82513950:-
TGCT	cis	rs4835473	0.715	rs1849124	ENSG00000251600.4	RP11-673E1.1	4.67	7.86e-06	0.00632	0.41	0.39	Immature fraction of reticulocytes;	chr4:143978494	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.689	rs1849123	ENSG00000251600.4	RP11-673E1.1	4.67	7.86e-06	0.00632	0.41	0.39	Immature fraction of reticulocytes;	chr4:143978495	chr4:143912331~143982454:+
TGCT	cis	rs2976388	0.647	rs2585154	ENSG00000253196.1	RP11-706C16.7	4.67	7.86e-06	0.00632	0.38	0.39	Urinary tract infection frequency;	chr8:142702067	chr8:142763116~142766427:+
TGCT	cis	rs875971	0.798	rs12698522	ENSG00000237310.1	GS1-124K5.4	4.66	7.87e-06	0.00632	0.41	0.39	Aortic root size;	chr7:66502354	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.83	rs28714531	ENSG00000237310.1	GS1-124K5.4	4.66	7.87e-06	0.00632	0.41	0.39	Aortic root size;	chr7:66503250	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs12698526	ENSG00000237310.1	GS1-124K5.4	4.66	7.87e-06	0.00632	0.41	0.39	Aortic root size;	chr7:66504118	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs13232191	ENSG00000237310.1	GS1-124K5.4	4.66	7.87e-06	0.00632	0.41	0.39	Aortic root size;	chr7:66521661	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs35378740	ENSG00000237310.1	GS1-124K5.4	4.66	7.87e-06	0.00632	0.41	0.39	Aortic root size;	chr7:66522725	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs10950043	ENSG00000237310.1	GS1-124K5.4	4.66	7.87e-06	0.00632	0.41	0.39	Aortic root size;	chr7:66523623	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs17747530	ENSG00000237310.1	GS1-124K5.4	4.66	7.87e-06	0.00632	0.41	0.39	Aortic root size;	chr7:66529742	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs13226170	ENSG00000237310.1	GS1-124K5.4	4.66	7.87e-06	0.00632	0.41	0.39	Aortic root size;	chr7:66534311	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs2420611	ENSG00000237310.1	GS1-124K5.4	4.66	7.87e-06	0.00632	0.41	0.39	Aortic root size;	chr7:66534333	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.767	rs61348003	ENSG00000237310.1	GS1-124K5.4	4.66	7.87e-06	0.00632	0.41	0.39	Aortic root size;	chr7:66540947	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.861	rs801215	ENSG00000237310.1	GS1-124K5.4	-4.66	7.87e-06	0.00632	-0.41	-0.39	Aortic root size;	chr7:66546951	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs13536	ENSG00000237310.1	GS1-124K5.4	-4.66	7.87e-06	0.00632	-0.41	-0.39	Aortic root size;	chr7:66554203	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs801209	ENSG00000237310.1	GS1-124K5.4	-4.66	7.87e-06	0.00632	-0.41	-0.39	Aortic root size;	chr7:66554403	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs801206	ENSG00000237310.1	GS1-124K5.4	-4.66	7.87e-06	0.00632	-0.41	-0.39	Aortic root size;	chr7:66556979	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs801204	ENSG00000237310.1	GS1-124K5.4	-4.66	7.87e-06	0.00632	-0.41	-0.39	Aortic root size;	chr7:66557934	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs801203	ENSG00000237310.1	GS1-124K5.4	-4.66	7.87e-06	0.00632	-0.41	-0.39	Aortic root size;	chr7:66558025	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.825	rs801202	ENSG00000237310.1	GS1-124K5.4	-4.66	7.87e-06	0.00632	-0.41	-0.39	Aortic root size;	chr7:66558942	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs801195	ENSG00000237310.1	GS1-124K5.4	-4.66	7.87e-06	0.00632	-0.41	-0.39	Aortic root size;	chr7:66561128	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs801194	ENSG00000237310.1	GS1-124K5.4	-4.66	7.87e-06	0.00632	-0.41	-0.39	Aortic root size;	chr7:66563508	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs2024192	ENSG00000237310.1	GS1-124K5.4	-4.66	7.87e-06	0.00632	-0.41	-0.39	Aortic root size;	chr7:66576460	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs6955837	ENSG00000237310.1	GS1-124K5.4	-4.66	7.87e-06	0.00632	-0.41	-0.39	Aortic root size;	chr7:66578155	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.825	rs10281499	ENSG00000237310.1	GS1-124K5.4	-4.66	7.87e-06	0.00632	-0.41	-0.39	Aortic root size;	chr7:66583979	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs4718377	ENSG00000237310.1	GS1-124K5.4	-4.66	7.87e-06	0.00632	-0.41	-0.39	Aortic root size;	chr7:66584691	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs10278014	ENSG00000237310.1	GS1-124K5.4	-4.66	7.87e-06	0.00632	-0.41	-0.39	Aortic root size;	chr7:66586277	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs1968126	ENSG00000237310.1	GS1-124K5.4	-4.66	7.87e-06	0.00632	-0.41	-0.39	Aortic root size;	chr7:66592017	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs6460306	ENSG00000237310.1	GS1-124K5.4	-4.66	7.87e-06	0.00632	-0.41	-0.39	Aortic root size;	chr7:66595806	chr7:66493706~66495474:+
TGCT	cis	rs34779708	0.966	rs10508816	ENSG00000230534.5	RP11-297A16.2	4.66	7.88e-06	0.00633	0.45	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35171048	chr10:35098006~35127020:-
TGCT	cis	rs34779708	1	rs34779708	ENSG00000230534.5	RP11-297A16.2	4.66	7.88e-06	0.00633	0.45	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35177257	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs12762493	ENSG00000230534.5	RP11-297A16.2	4.66	7.88e-06	0.00633	0.45	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35182945	chr10:35098006~35127020:-
TGCT	cis	rs1707322	0.721	rs4660314	ENSG00000280836.1	AL355480.1	-4.66	7.88e-06	0.00633	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.686	rs61784833	ENSG00000280836.1	AL355480.1	-4.66	7.88e-06	0.00633	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs7519900	ENSG00000280836.1	AL355480.1	-4.66	7.88e-06	0.00633	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45581219~45581321:-
TGCT	cis	rs4927850	0.752	rs7618864	ENSG00000242086.7	LINC00969	4.66	7.89e-06	0.00634	0.43	0.39	Pancreatic cancer;	chr3:196022690	chr3:195658062~195739964:+
TGCT	cis	rs867186	1	rs6060230	ENSG00000126005.14	MMP24-AS1	4.66	7.9e-06	0.00634	0.51	0.39	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35101505	chr20:35216462~35278131:-
TGCT	cis	rs867186	1	rs17092297	ENSG00000126005.14	MMP24-AS1	4.66	7.9e-06	0.00634	0.51	0.39	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35115331	chr20:35216462~35278131:-
TGCT	cis	rs867186	1	rs6060222	ENSG00000126005.14	MMP24-AS1	-4.66	7.9e-06	0.00634	-0.51	-0.39	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35094767	chr20:35216462~35278131:-
TGCT	cis	rs867186	1	rs7261312	ENSG00000126005.14	MMP24-AS1	-4.66	7.9e-06	0.00634	-0.51	-0.39	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35097106	chr20:35216462~35278131:-
TGCT	cis	rs867186	0.688	rs6060225	ENSG00000126005.14	MMP24-AS1	-4.66	7.9e-06	0.00634	-0.51	-0.39	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35098601	chr20:35216462~35278131:-
TGCT	cis	rs867186	1	rs7270326	ENSG00000126005.14	MMP24-AS1	-4.66	7.9e-06	0.00634	-0.51	-0.39	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35105779	chr20:35216462~35278131:-
TGCT	cis	rs867186	0.92	rs6060242	ENSG00000126005.14	MMP24-AS1	-4.66	7.9e-06	0.00634	-0.51	-0.39	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35110213	chr20:35216462~35278131:-
TGCT	cis	rs9755467	0.705	rs4974433	ENSG00000221413.1	AC023593.1	4.66	7.9e-06	0.00634	0.6	0.39	Educational attainment (years of education);	chr3:127454317	chr3:127664704~127664810:+
TGCT	cis	rs9755467	0.705	rs4974434	ENSG00000221413.1	AC023593.1	4.66	7.9e-06	0.00634	0.6	0.39	Educational attainment (years of education);	chr3:127454369	chr3:127664704~127664810:+
TGCT	cis	rs3096299	0.933	rs3096297	ENSG00000274627.1	RP11-104N10.2	4.66	7.91e-06	0.00635	0.4	0.39	Multiple myeloma (IgH translocation);	chr16:89386747	chr16:89516797~89522217:+
TGCT	cis	rs12891047	0.744	rs8017007	ENSG00000258759.1	RP11-1012A1.7	-4.66	7.92e-06	0.00635	-0.32	-0.39	Amyotrophic lateral sclerosis (sporadic);	chr14:67886188	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.78	rs1015023	ENSG00000258759.1	RP11-1012A1.7	-4.66	7.92e-06	0.00635	-0.32	-0.39	Amyotrophic lateral sclerosis (sporadic);	chr14:67895514	chr14:67799004~67799609:+
TGCT	cis	rs3096299	0.874	rs3102342	ENSG00000274627.1	RP11-104N10.2	4.66	7.93e-06	0.00636	0.4	0.39	Multiple myeloma (IgH translocation);	chr16:89385167	chr16:89516797~89522217:+
TGCT	cis	rs10504229	0.871	rs10504227	ENSG00000253301.4	RP11-513O17.2	4.66	7.96e-06	0.00637	0.5	0.39	Developmental language disorder (linguistic errors);	chr8:57249446	chr8:57142689~57240298:+
TGCT	cis	rs7795991	0.667	rs12154701	ENSG00000224330.1	AC005019.3	4.66	7.97e-06	0.00637	0.42	0.39	Type 2 diabetes;	chr7:13847383	chr7:13854355~13859025:-
TGCT	cis	rs7927592	0.513	rs556442	ENSG00000212093.1	AP000807.1	-4.66	7.97e-06	0.00637	-0.38	-0.39	Total body bone mineral density;	chr11:68425222	chr11:68506083~68506166:-
TGCT	cis	rs1891275	0.515	rs10881957	ENSG00000228701.1	TNKS2-AS1	-4.66	7.97e-06	0.00637	-0.42	-0.39	Intelligence (multi-trait analysis);	chr10:91742119	chr10:91782839~91798291:-
TGCT	cis	rs9400467	0.506	rs12197149	ENSG00000272356.1	RP5-1112D6.8	-4.66	7.97e-06	0.00637	-0.44	-0.39	Amino acid levels;Blood metabolite levels;	chr6:111334864	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs12207774	ENSG00000272356.1	RP5-1112D6.8	-4.66	7.97e-06	0.00637	-0.44	-0.39	Amino acid levels;Blood metabolite levels;	chr6:111336373	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs12198556	ENSG00000272356.1	RP5-1112D6.8	-4.66	7.97e-06	0.00637	-0.44	-0.39	Amino acid levels;Blood metabolite levels;	chr6:111341135	chr6:111309203~111313517:+
TGCT	cis	rs6568686	0.627	rs17539951	ENSG00000272356.1	RP5-1112D6.8	-4.66	7.97e-06	0.00637	-0.44	-0.39	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111343766	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs12209969	ENSG00000272356.1	RP5-1112D6.8	-4.66	7.97e-06	0.00637	-0.44	-0.39	Amino acid levels;Blood metabolite levels;	chr6:111346964	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs17539875	ENSG00000272356.1	RP5-1112D6.8	-4.66	7.97e-06	0.00637	-0.44	-0.39	Amino acid levels;Blood metabolite levels;	chr6:111353147	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs12199656	ENSG00000272356.1	RP5-1112D6.8	-4.66	7.97e-06	0.00637	-0.44	-0.39	Amino acid levels;Blood metabolite levels;	chr6:111353940	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs12203741	ENSG00000272356.1	RP5-1112D6.8	-4.66	7.97e-06	0.00637	-0.44	-0.39	Amino acid levels;Blood metabolite levels;	chr6:111356341	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs77549436	ENSG00000272356.1	RP5-1112D6.8	-4.66	7.97e-06	0.00637	-0.44	-0.39	Amino acid levels;Blood metabolite levels;	chr6:111369527	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs76813116	ENSG00000272356.1	RP5-1112D6.8	-4.66	7.97e-06	0.00637	-0.44	-0.39	Amino acid levels;Blood metabolite levels;	chr6:111369530	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs12190135	ENSG00000272356.1	RP5-1112D6.8	-4.66	7.97e-06	0.00637	-0.44	-0.39	Amino acid levels;Blood metabolite levels;	chr6:111377001	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs12200758	ENSG00000272356.1	RP5-1112D6.8	-4.66	7.97e-06	0.00637	-0.44	-0.39	Amino acid levels;Blood metabolite levels;	chr6:111389641	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs75819068	ENSG00000272356.1	RP5-1112D6.8	-4.66	7.97e-06	0.00637	-0.44	-0.39	Amino acid levels;Blood metabolite levels;	chr6:111401284	chr6:111309203~111313517:+
TGCT	cis	rs2019137	0.539	rs4849181	ENSG00000189223.12	PAX8-AS1	-4.66	7.97e-06	0.00637	-0.52	-0.39	Lymphocyte counts;	chr2:113234393	chr2:113211522~113276581:+
TGCT	cis	rs673078	0.571	rs17440823	ENSG00000275759.1	RP11-131L12.3	-4.66	7.98e-06	0.00638	-0.72	-0.39	Glucose homeostasis traits;	chr12:118353023	chr12:118428281~118428870:+
TGCT	cis	rs7208859	0.573	rs8070182	ENSG00000263531.1	RP13-753N3.1	4.66	7.99e-06	0.00638	0.71	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30863921~30864940:-
TGCT	cis	rs7829975	0.536	rs2980439	ENSG00000253981.4	ALG1L13P	4.66	7.99e-06	0.00638	0.41	0.39	Mood instability;	chr8:8237348	chr8:8236003~8244667:-
TGCT	cis	rs847851	0.617	rs9380478	ENSG00000186328.4	RP11-140K17.2	4.66	7.99e-06	0.00638	0.56	0.39	Colonoscopy-negative controls vs population controls;	chr6:34993034	chr6:34715613~34715940:+
TGCT	cis	rs847851	0.569	rs3800439	ENSG00000186328.4	RP11-140K17.2	4.66	7.99e-06	0.00638	0.56	0.39	Colonoscopy-negative controls vs population controls;	chr6:34993629	chr6:34715613~34715940:+
TGCT	cis	rs847851	0.617	rs73403805	ENSG00000186328.4	RP11-140K17.2	4.66	7.99e-06	0.00638	0.56	0.39	Colonoscopy-negative controls vs population controls;	chr6:34996947	chr6:34715613~34715940:+
TGCT	cis	rs36052053	0.522	rs75670734	ENSG00000219700.1	PTCHD3P3	4.66	7.99e-06	0.00638	0.79	0.39	Red cell distribution width;	chr6:109311974	chr6:109288571~109290503:-
TGCT	cis	rs36052053	0.522	rs111774344	ENSG00000219700.1	PTCHD3P3	4.66	7.99e-06	0.00638	0.79	0.39	Red cell distribution width;	chr6:109314650	chr6:109288571~109290503:-
TGCT	cis	rs36052053	0.522	rs61734155	ENSG00000219700.1	PTCHD3P3	4.66	7.99e-06	0.00638	0.79	0.39	Red cell distribution width;	chr6:109315328	chr6:109288571~109290503:-
TGCT	cis	rs16975963	0.644	rs12151280	ENSG00000276846.1	CTD-3220F14.3	-4.66	8e-06	0.00638	-0.37	-0.39	Longevity;	chr19:37576988	chr19:37314868~37315620:-
TGCT	cis	rs1707322	0.716	rs6694889	ENSG00000280836.1	AL355480.1	-4.66	8.01e-06	0.00638	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.752	rs4607935	ENSG00000280836.1	AL355480.1	-4.66	8.01e-06	0.00638	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.752	rs3811436	ENSG00000280836.1	AL355480.1	-4.66	8.01e-06	0.00638	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs4415615	ENSG00000280836.1	AL355480.1	-4.66	8.01e-06	0.00638	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.752	rs7529699	ENSG00000280836.1	AL355480.1	-4.66	8.01e-06	0.00638	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.752	rs10430105	ENSG00000280836.1	AL355480.1	-4.66	8.01e-06	0.00638	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr1:45581219~45581321:-
TGCT	cis	rs11231017	0.507	rs10897266	ENSG00000254454.2	RCC2P6	-4.66	8.01e-06	0.00638	-0.26	-0.39	HIV-1 viral setpoint;	chr11:62387640	chr11:62371146~62373168:+
TGCT	cis	rs911555	0.755	rs2756135	ENSG00000244691.1	RPL10AP1	4.66	8.03e-06	0.00638	0.51	0.39	Intelligence (multi-trait analysis);	chr14:103496242	chr14:103412119~103412761:-
TGCT	cis	rs17826219	0.5	rs2874724	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Body mass index;	chr17:30745415	chr17:30738182~30740275:+
TGCT	cis	rs17826219	0.568	rs9898097	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Body mass index;	chr17:30745654	chr17:30738182~30740275:+
TGCT	cis	rs17826219	0.5	rs9891256	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Body mass index;	chr17:30745674	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs9911490	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs7503542	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs7503335	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.573	rs11656278	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.573	rs56031503	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs6505207	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.573	rs7223803	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30738182~30740275:+
TGCT	cis	rs17826219	0.568	rs2626985	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Body mass index;	chr17:30750419	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs55814012	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30738182~30740275:+
TGCT	cis	rs17826219	0.5	rs2449749	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Body mass index;	chr17:30751280	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs9894709	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs9896603	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs7219361	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs7219712	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.573	rs8078656	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs8080882	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs9898084	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs28556733	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30738182~30740275:+
TGCT	cis	rs17826219	0.5	rs28452421	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Body mass index;	chr17:30756962	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs28433704	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.573	rs28779471	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30738182~30740275:+
TGCT	cis	rs17826219	0.5	rs61685770	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Body mass index;	chr17:30758695	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs57486336	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30738182~30740275:+
TGCT	cis	rs17826219	0.706	rs55764512	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Body mass index;	chr17:30758740	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.524	rs73988172	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs12103440	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs12103508	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.524	rs11653605	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs11657777	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs73269913	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs7217984	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs55811708	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.562	rs8078897	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs8075163	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30738182~30740275:+
TGCT	cis	rs17826219	0.706	rs8075107	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Body mass index;	chr17:30779631	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs7223209	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs7223404	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs9916725	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs9916727	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs9914499	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs73269945	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs9897728	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs9890558	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs9912283	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs12006	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs3752021	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs3752020	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs9890855	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs9893422	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs9891166	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs73269974	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs34756112	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.573	rs60724269	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs76633166	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs1061346	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs1061343	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs1061342	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs55938328	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs73269988	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs55961983	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.573	rs7222803	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.673	rs9899525	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30738182~30740275:+
TGCT	cis	rs17826219	0.568	rs7213925	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Body mass index;	chr17:30794616	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.524	rs11653098	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs11658945	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs11657990	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs9911784	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs9911997	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs9890862	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs78071511	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs11650982	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs2035494	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs9915546	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs9915566	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.573	rs8064686	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs11657369	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs8075341	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs73271842	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.673	rs9895815	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.573	rs7214313	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.673	rs8077116	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.524	rs28760584	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30738182~30740275:+
TGCT	cis	rs17826219	0.706	rs73271850	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Body mass index;	chr17:30815122	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs7208088	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs7212991	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs7208441	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs28627615	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs9912440	ENSG00000280069.1	CTD-2349P21.3	-4.66	8.03e-06	0.00638	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30738182~30740275:+
TGCT	cis	rs4660456	0.869	rs616954	ENSG00000237899.1	RP4-739H11.3	4.66	8.03e-06	0.00639	0.51	0.39	Platelet count;	chr1:40669947	chr1:40669089~40687588:-
TGCT	cis	rs34217772	0.6	rs17181825	ENSG00000258536.1	RP11-1053O12.1	4.66	8.04e-06	0.00639	0.35	0.39	Myopia;	chr14:41925993	chr14:41742639~41742963:+
TGCT	cis	rs3096299	0.967	rs7205785	ENSG00000274627.1	RP11-104N10.2	4.66	8.04e-06	0.00639	0.41	0.39	Multiple myeloma (IgH translocation);	chr16:89392576	chr16:89516797~89522217:+
TGCT	cis	rs2117029	0.586	rs10875928	ENSG00000258017.1	RP11-386G11.10	-4.66	8.04e-06	0.00639	-0.51	-0.39	Intelligence (multi-trait analysis);	chr12:49162520	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.586	rs6580701	ENSG00000258017.1	RP11-386G11.10	-4.66	8.04e-06	0.00639	-0.51	-0.39	Intelligence (multi-trait analysis);	chr12:49163482	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.554	rs2334931	ENSG00000258017.1	RP11-386G11.10	-4.66	8.04e-06	0.00639	-0.51	-0.39	Intelligence (multi-trait analysis);	chr12:49174130	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.586	rs10875929	ENSG00000258017.1	RP11-386G11.10	-4.66	8.04e-06	0.00639	-0.51	-0.39	Intelligence (multi-trait analysis);	chr12:49174605	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.554	rs2334930	ENSG00000258017.1	RP11-386G11.10	-4.66	8.04e-06	0.00639	-0.51	-0.39	Intelligence (multi-trait analysis);	chr12:49175528	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.586	rs11168904	ENSG00000258017.1	RP11-386G11.10	-4.66	8.04e-06	0.00639	-0.51	-0.39	Intelligence (multi-trait analysis);	chr12:49177234	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.586	rs10875931	ENSG00000258017.1	RP11-386G11.10	-4.66	8.04e-06	0.00639	-0.51	-0.39	Intelligence (multi-trait analysis);	chr12:49179513	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.554	rs7954530	ENSG00000258017.1	RP11-386G11.10	-4.66	8.04e-06	0.00639	-0.51	-0.39	Intelligence (multi-trait analysis);	chr12:49179742	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.586	rs7957998	ENSG00000258017.1	RP11-386G11.10	-4.66	8.04e-06	0.00639	-0.51	-0.39	Intelligence (multi-trait analysis);	chr12:49180240	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.553	rs11168909	ENSG00000258017.1	RP11-386G11.10	-4.66	8.04e-06	0.00639	-0.51	-0.39	Intelligence (multi-trait analysis);	chr12:49183092	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.521	rs1056875	ENSG00000258017.1	RP11-386G11.10	-4.66	8.04e-06	0.00639	-0.51	-0.39	Intelligence (multi-trait analysis);	chr12:49186397	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.586	rs1874908	ENSG00000258017.1	RP11-386G11.10	-4.66	8.04e-06	0.00639	-0.51	-0.39	Intelligence (multi-trait analysis);	chr12:49190247	chr12:49127782~49147869:+
TGCT	cis	rs10875746	0.68	rs4760610	ENSG00000240399.1	RP1-228P16.1	-4.66	8.04e-06	0.00639	-0.46	-0.39	Longevity (90 years and older);	chr12:48024442	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.768	rs10875724	ENSG00000240399.1	RP1-228P16.1	-4.66	8.04e-06	0.00639	-0.46	-0.39	Longevity (90 years and older);	chr12:48026470	chr12:48054813~48055591:-
TGCT	cis	rs875971	0.862	rs7786892	ENSG00000237310.1	GS1-124K5.4	-4.66	8.04e-06	0.00639	-0.42	-0.39	Aortic root size;	chr7:66163889	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs2420174	ENSG00000237310.1	GS1-124K5.4	-4.66	8.04e-06	0.00639	-0.42	-0.39	Aortic root size;	chr7:66180374	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs2420173	ENSG00000237310.1	GS1-124K5.4	-4.66	8.04e-06	0.00639	-0.42	-0.39	Aortic root size;	chr7:66180412	chr7:66493706~66495474:+
TGCT	cis	rs2709736	0.5	rs204591	ENSG00000232790.2	LINC01162	-4.66	8.04e-06	0.00639	-0.3	-0.39	Bipolar I disorder;	chr7:20869992	chr7:20835431~21023148:+
TGCT	cis	rs2709736	0.5	rs204592	ENSG00000232790.2	LINC01162	-4.66	8.04e-06	0.00639	-0.3	-0.39	Bipolar I disorder;	chr7:20870003	chr7:20835431~21023148:+
TGCT	cis	rs2709736	0.532	rs204593	ENSG00000232790.2	LINC01162	-4.66	8.04e-06	0.00639	-0.3	-0.39	Bipolar I disorder;	chr7:20870047	chr7:20835431~21023148:+
TGCT	cis	rs67311347	0.911	rs9849224	ENSG00000223797.4	ENTPD3-AS1	4.66	8.04e-06	0.00639	0.39	0.39	Renal cell carcinoma;	chr3:40351071	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs2168111	ENSG00000223797.4	ENTPD3-AS1	4.66	8.04e-06	0.00639	0.39	0.39	Renal cell carcinoma;	chr3:40353834	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs9834052	ENSG00000223797.4	ENTPD3-AS1	4.66	8.04e-06	0.00639	0.39	0.39	Renal cell carcinoma;	chr3:40357569	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs6599094	ENSG00000223797.4	ENTPD3-AS1	4.66	8.04e-06	0.00639	0.39	0.39	Renal cell carcinoma;	chr3:40358102	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs7612015	ENSG00000223797.4	ENTPD3-AS1	4.66	8.04e-06	0.00639	0.39	0.39	Renal cell carcinoma;	chr3:40358483	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs10510708	ENSG00000223797.4	ENTPD3-AS1	4.66	8.04e-06	0.00639	0.39	0.39	Renal cell carcinoma;	chr3:40363279	chr3:40313802~40453329:-
TGCT	cis	rs2136613	0.563	rs1509957	ENSG00000238280.1	RP11-436D10.3	-4.66	8.05e-06	0.00639	-0.43	-0.39	Selective IgA deficiency;	chr10:62850958	chr10:62793562~62805887:-
TGCT	cis	rs761746	0.577	rs5994431	ENSG00000236132.1	CTA-440B3.1	4.66	8.05e-06	0.00639	0.49	0.39	Intelligence;	chr22:31814314	chr22:31816379~31817491:-
TGCT	cis	rs761746	0.577	rs5998136	ENSG00000236132.1	CTA-440B3.1	-4.66	8.05e-06	0.00639	-0.49	-0.39	Intelligence;	chr22:31828687	chr22:31816379~31817491:-
TGCT	cis	rs2439831	0.717	rs2470132	ENSG00000205771.5	CATSPER2P1	-4.66	8.05e-06	0.00639	-0.64	-0.39	Lung cancer in ever smokers;	chr15:43543283	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.867	rs2251844	ENSG00000205771.5	CATSPER2P1	-4.66	8.05e-06	0.00639	-0.64	-0.39	Lung cancer in ever smokers;	chr15:43544280	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.867	rs2255051	ENSG00000205771.5	CATSPER2P1	-4.66	8.05e-06	0.00639	-0.64	-0.39	Lung cancer in ever smokers;	chr15:43553963	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.867	rs2255042	ENSG00000205771.5	CATSPER2P1	4.66	8.05e-06	0.00639	0.64	0.39	Lung cancer in ever smokers;	chr15:43542120	chr15:43726918~43747094:-
TGCT	cis	rs673078	0.607	rs17441172	ENSG00000275759.1	RP11-131L12.3	4.66	8.12e-06	0.00644	0.76	0.39	Glucose homeostasis traits;	chr12:118430456	chr12:118428281~118428870:+
TGCT	cis	rs4835473	0.897	rs6537172	ENSG00000251600.4	RP11-673E1.1	4.66	8.12e-06	0.00644	0.4	0.39	Immature fraction of reticulocytes;	chr4:143710612	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.714	rs10013005	ENSG00000251600.4	RP11-673E1.1	4.66	8.12e-06	0.00644	0.4	0.39	Immature fraction of reticulocytes;	chr4:143711351	chr4:143912331~143982454:+
TGCT	cis	rs3096299	0.933	rs28608022	ENSG00000274627.1	RP11-104N10.2	4.66	8.13e-06	0.00645	0.4	0.39	Multiple myeloma (IgH translocation);	chr16:89387884	chr16:89516797~89522217:+
TGCT	cis	rs7208859	0.673	rs56846352	ENSG00000266490.1	CTD-2349P21.9	4.66	8.14e-06	0.00645	0.41	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs7211776	ENSG00000266490.1	CTD-2349P21.9	4.66	8.14e-06	0.00645	0.41	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs9912122	ENSG00000266490.1	CTD-2349P21.9	4.66	8.14e-06	0.00645	0.41	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30792372~30792833:+
TGCT	cis	rs73607972	1	rs73607972	ENSG00000279344.1	RP11-44F14.7	4.66	8.14e-06	0.00645	0.58	0.39	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53634741	chr16:53478957~53481550:-
TGCT	cis	rs1962636	1	rs1962636	ENSG00000260306.1	RP11-645C24.5	-4.66	8.14e-06	0.00645	-0.37	-0.39	Schizophrenia;	chr16:22053074	chr16:21794095~21795759:-
TGCT	cis	rs2709736	0.596	rs2539961	ENSG00000232790.2	LINC01162	4.66	8.15e-06	0.00646	0.31	0.39	Bipolar I disorder;	chr7:20882998	chr7:20835431~21023148:+
TGCT	cis	rs2976388	0.935	rs2978980	ENSG00000253196.1	RP11-706C16.7	-4.66	8.15e-06	0.00646	-0.4	-0.39	Urinary tract infection frequency;	chr8:142676290	chr8:142763116~142766427:+
TGCT	cis	rs2976388	1	rs2920282	ENSG00000253196.1	RP11-706C16.7	-4.66	8.15e-06	0.00646	-0.4	-0.39	Urinary tract infection frequency;	chr8:142676345	chr8:142763116~142766427:+
TGCT	cis	rs11673344	0.868	rs1047333	ENSG00000226686.6	LINC01535	4.66	8.17e-06	0.00648	0.45	0.39	Obesity-related traits;	chr19:37151263	chr19:37251912~37265535:+
TGCT	cis	rs875971	0.862	rs7783779	ENSG00000237310.1	GS1-124K5.4	-4.66	8.18e-06	0.00648	-0.41	-0.39	Aortic root size;	chr7:66331639	chr7:66493706~66495474:+
TGCT	cis	rs2665103	0.589	rs3858953	ENSG00000255769.6	GOLGA2P10	-4.66	8.18e-06	0.00648	-0.38	-0.39	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82472993~82513950:-
TGCT	cis	rs3096299	0.967	rs16965692	ENSG00000274627.1	RP11-104N10.2	4.66	8.18e-06	0.00648	0.41	0.39	Multiple myeloma (IgH translocation);	chr16:89405074	chr16:89516797~89522217:+
TGCT	cis	rs73198271	0.562	rs76702427	ENSG00000253893.2	FAM85B	4.66	8.19e-06	0.00648	0.63	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802631	chr8:8167819~8226614:-
TGCT	cis	rs73198271	0.562	rs73519953	ENSG00000253893.2	FAM85B	4.66	8.19e-06	0.00648	0.63	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802768	chr8:8167819~8226614:-
TGCT	cis	rs7826238	0.623	rs2976893	ENSG00000173295.6	FAM86B3P	-4.66	8.19e-06	0.00649	-0.43	-0.39	Systolic blood pressure;	chr8:8480709	chr8:8228595~8244865:+
TGCT	cis	rs875971	0.558	rs4433015	ENSG00000237310.1	GS1-124K5.4	-4.65	8.2e-06	0.00649	-0.44	-0.39	Aortic root size;	chr7:66174736	chr7:66493706~66495474:+
TGCT	cis	rs9326248	1	rs10790175	ENSG00000280143.1	AP000892.6	4.65	8.21e-06	0.0065	0.49	0.39	Blood protein levels;	chr11:117164013	chr11:117204967~117210292:+
TGCT	cis	rs111332265	1	rs111332265	ENSG00000197083.10	ZNF300P1	4.65	8.21e-06	0.0065	0.78	0.39	Tumor necrosis factor alpha levels;	chr5:151013545	chr5:150930645~150946289:-
TGCT	cis	rs9987353	0.522	rs2929466	ENSG00000173295.6	FAM86B3P	-4.65	8.22e-06	0.0065	-0.41	-0.39	Recombination measurement;	chr8:9206389	chr8:8228595~8244865:+
TGCT	cis	rs877819	0.583	rs2940712	ENSG00000228403.1	RP11-563N6.6	-4.65	8.22e-06	0.0065	-0.41	-0.39	Systemic lupus erythematosus;	chr10:48848403	chr10:48878022~48878649:+
TGCT	cis	rs1075265	0.584	rs34769118	ENSG00000233266.1	HMGB1P31	4.65	8.24e-06	0.00652	0.43	0.39	Chronotype;Morning vs. evening chronotype;	chr2:54102173	chr2:54051334~54051760:+
TGCT	cis	rs2882667	0.537	rs7701116	ENSG00000253404.1	AC034243.1	4.65	8.25e-06	0.00652	0.43	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070389	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.537	rs13181793	ENSG00000253404.1	AC034243.1	4.65	8.25e-06	0.00652	0.43	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073267	chr5:138744434~138753309:-
TGCT	cis	rs2882667	0.537	rs11743534	ENSG00000253404.1	AC034243.1	4.65	8.25e-06	0.00652	0.43	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073318	chr5:138744434~138753309:-
TGCT	cis	rs2033711	0.87	rs7259841	ENSG00000269473.1	CTD-2619J13.19	4.65	8.25e-06	0.00652	0.31	0.39	Uric acid clearance;	chr19:58439756	chr19:58440448~58445849:+
TGCT	cis	rs2033711	0.87	rs11084545	ENSG00000269473.1	CTD-2619J13.19	4.65	8.25e-06	0.00652	0.31	0.39	Uric acid clearance;	chr19:58440326	chr19:58440448~58445849:+
TGCT	cis	rs881375	0.967	rs1548783	ENSG00000226752.6	PSMD5-AS1	-4.65	8.25e-06	0.00653	-0.46	-0.39	Rheumatoid arthritis;	chr9:120896361	chr9:120824828~120854385:+
TGCT	cis	rs786425	0.966	rs6488883	ENSG00000247373.3	RP11-486O12.2	4.65	8.26e-06	0.00653	0.46	0.39	Pubertal anthropometrics;	chr12:123616800	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.966	rs7134896	ENSG00000247373.3	RP11-486O12.2	4.65	8.26e-06	0.00653	0.46	0.39	Pubertal anthropometrics;	chr12:123617311	chr12:123575891~123585115:-
TGCT	cis	rs2665103	0.61	rs1972460	ENSG00000255769.6	GOLGA2P10	-4.65	8.26e-06	0.00653	-0.36	-0.39	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82472993~82513950:-
TGCT	cis	rs2980439	0.846	rs2980437	ENSG00000253893.2	FAM85B	4.65	8.26e-06	0.00653	0.48	0.39	Neuroticism;	chr8:8237241	chr8:8167819~8226614:-
TGCT	cis	rs7201929	1	rs7201929	ENSG00000259982.1	CDC37P1	4.65	8.27e-06	0.00654	0.51	0.39	QT interval;	chr16:28860645	chr16:28700294~28701540:-
TGCT	cis	rs9987353	0.519	rs2929465	ENSG00000173295.6	FAM86B3P	-4.65	8.27e-06	0.00654	-0.42	-0.39	Recombination measurement;	chr8:9206492	chr8:8228595~8244865:+
TGCT	cis	rs3096299	0.9	rs4785666	ENSG00000274627.1	RP11-104N10.2	4.65	8.27e-06	0.00654	0.41	0.39	Multiple myeloma (IgH translocation);	chr16:89396363	chr16:89516797~89522217:+
TGCT	cis	rs3096299	0.934	rs9927904	ENSG00000274627.1	RP11-104N10.2	4.65	8.27e-06	0.00654	0.41	0.39	Multiple myeloma (IgH translocation);	chr16:89396439	chr16:89516797~89522217:+
TGCT	cis	rs7208859	0.673	rs216410	ENSG00000266490.1	CTD-2349P21.9	-4.65	8.28e-06	0.00655	-0.44	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576813	chr17:30792372~30792833:+
TGCT	cis	rs875971	0.545	rs4718325	ENSG00000237310.1	GS1-124K5.4	4.65	8.29e-06	0.00655	0.47	0.39	Aortic root size;	chr7:66215323	chr7:66493706~66495474:+
TGCT	cis	rs10504229	1	rs73609760	ENSG00000253301.4	RP11-513O17.2	4.65	8.29e-06	0.00655	0.49	0.39	Developmental language disorder (linguistic errors);	chr8:57279611	chr8:57142689~57240298:+
TGCT	cis	rs12891047	0.752	rs28855496	ENSG00000258759.1	RP11-1012A1.7	-4.65	8.29e-06	0.00655	-0.32	-0.39	Amyotrophic lateral sclerosis (sporadic);	chr14:67904400	chr14:67799004~67799609:+
TGCT	cis	rs12891047	0.779	rs4902533	ENSG00000258759.1	RP11-1012A1.7	-4.65	8.29e-06	0.00655	-0.32	-0.39	Amyotrophic lateral sclerosis (sporadic);	chr14:67905439	chr14:67799004~67799609:+
TGCT	cis	rs11662586	0.517	rs7228070	ENSG00000261126.6	RP11-795F19.1	4.65	8.3e-06	0.00656	0.34	0.39	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr18:79938967	chr18:80046900~80095482:+
TGCT	cis	rs453301	0.686	rs6601280	ENSG00000173295.6	FAM86B3P	4.65	8.3e-06	0.00656	0.47	0.39	Joint mobility (Beighton score);	chr8:9051726	chr8:8228595~8244865:+
TGCT	cis	rs13118159	0.55	rs10016557	ENSG00000254094.1	AC078852.1	4.65	8.31e-06	0.00656	0.46	0.39	Longevity;	chr4:1369840	chr4:1356581~1358075:+
TGCT	cis	rs2033711	0.783	rs11671113	ENSG00000269473.1	CTD-2619J13.19	4.65	8.32e-06	0.00657	0.31	0.39	Uric acid clearance;	chr19:58446720	chr19:58440448~58445849:+
TGCT	cis	rs755249	0.501	rs1889830	ENSG00000182109.6	RP11-69E11.4	-4.65	8.34e-06	0.00658	-0.39	-0.39	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39264500	chr1:39522280~39546187:-
TGCT	cis	rs13108904	0.539	rs11247997	ENSG00000253399.1	AC078852.2	-4.65	8.34e-06	0.00659	-0.46	-0.39	Obesity-related traits;	chr4:1367269	chr4:1358479~1359461:+
TGCT	cis	rs2581828	0.656	rs2336723	ENSG00000242142.1	SERBP1P3	4.65	8.35e-06	0.00659	0.35	0.39	Crohn's disease;	chr3:53072031	chr3:53064283~53065091:-
TGCT	cis	rs17711722	1	rs17711722	ENSG00000272831.1	RP11-792A8.4	-4.65	8.36e-06	0.0066	-0.4	-0.39	Calcium levels;	chr7:65806210	chr7:66739829~66740385:-
TGCT	cis	rs17711722	0.675	rs6947132	ENSG00000272831.1	RP11-792A8.4	-4.65	8.36e-06	0.0066	-0.4	-0.39	Calcium levels;	chr7:65808508	chr7:66739829~66740385:-
TGCT	cis	rs8105895	0.935	rs28635943	ENSG00000269742.1	BNIP3P29	4.65	8.36e-06	0.0066	0.68	0.39	Body mass index (change over time);	chr19:22085910	chr19:22065828~22066398:-
TGCT	cis	rs34779708	0.931	rs59418206	ENSG00000230534.5	RP11-297A16.2	4.65	8.36e-06	0.0066	0.45	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35042696	chr10:35098006~35127020:-
TGCT	cis	rs904251	0.523	rs9349039	ENSG00000279942.1	RP1-153P14.7	-4.65	8.36e-06	0.0066	-0.4	-0.39	Cognitive performance;	chr6:37512616	chr6:37567716~37571460:+
TGCT	cis	rs904251	0.523	rs9366935	ENSG00000279942.1	RP1-153P14.7	-4.65	8.36e-06	0.0066	-0.4	-0.39	Cognitive performance;	chr6:37512628	chr6:37567716~37571460:+
TGCT	cis	rs1075265	0.669	rs805317	ENSG00000233266.1	HMGB1P31	4.65	8.36e-06	0.0066	0.39	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53907867	chr2:54051334~54051760:+
TGCT	cis	rs1075265	0.692	rs805318	ENSG00000233266.1	HMGB1P31	4.65	8.36e-06	0.0066	0.39	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53907915	chr2:54051334~54051760:+
TGCT	cis	rs911555	0.692	rs60235428	ENSG00000244691.1	RPL10AP1	4.65	8.38e-06	0.00661	0.52	0.39	Intelligence (multi-trait analysis);	chr14:103438013	chr14:103412119~103412761:-
TGCT	cis	rs911555	0.755	rs8016676	ENSG00000244691.1	RPL10AP1	4.65	8.38e-06	0.00661	0.52	0.39	Intelligence (multi-trait analysis);	chr14:103438505	chr14:103412119~103412761:-
TGCT	cis	rs911555	0.723	rs4906324	ENSG00000244691.1	RPL10AP1	4.65	8.38e-06	0.00661	0.52	0.39	Intelligence (multi-trait analysis);	chr14:103456762	chr14:103412119~103412761:-
TGCT	cis	rs911555	0.723	rs2273701	ENSG00000244691.1	RPL10AP1	4.65	8.38e-06	0.00661	0.52	0.39	Intelligence (multi-trait analysis);	chr14:103456888	chr14:103412119~103412761:-
TGCT	cis	rs911555	0.723	rs12894652	ENSG00000244691.1	RPL10AP1	4.65	8.38e-06	0.00661	0.52	0.39	Intelligence (multi-trait analysis);	chr14:103459687	chr14:103412119~103412761:-
TGCT	cis	rs911555	0.755	rs12436729	ENSG00000244691.1	RPL10AP1	4.65	8.38e-06	0.00661	0.52	0.39	Intelligence (multi-trait analysis);	chr14:103463552	chr14:103412119~103412761:-
TGCT	cis	rs911555	0.755	rs12432803	ENSG00000244691.1	RPL10AP1	4.65	8.38e-06	0.00661	0.52	0.39	Intelligence (multi-trait analysis);	chr14:103463695	chr14:103412119~103412761:-
TGCT	cis	rs911555	0.755	rs1116095	ENSG00000244691.1	RPL10AP1	4.65	8.38e-06	0.00661	0.52	0.39	Intelligence (multi-trait analysis);	chr14:103465542	chr14:103412119~103412761:-
TGCT	cis	rs911555	0.755	rs8010247	ENSG00000244691.1	RPL10AP1	4.65	8.38e-06	0.00661	0.52	0.39	Intelligence (multi-trait analysis);	chr14:103467219	chr14:103412119~103412761:-
TGCT	cis	rs911555	0.755	rs4906329	ENSG00000244691.1	RPL10AP1	4.65	8.38e-06	0.00661	0.52	0.39	Intelligence (multi-trait analysis);	chr14:103476332	chr14:103412119~103412761:-
TGCT	cis	rs911555	0.755	rs55742283	ENSG00000244691.1	RPL10AP1	4.65	8.38e-06	0.00661	0.52	0.39	Intelligence (multi-trait analysis);	chr14:103476628	chr14:103412119~103412761:-
TGCT	cis	rs911555	0.755	rs8014800	ENSG00000244691.1	RPL10AP1	4.65	8.38e-06	0.00661	0.52	0.39	Intelligence (multi-trait analysis);	chr14:103479965	chr14:103412119~103412761:-
TGCT	cis	rs911555	0.755	rs12435516	ENSG00000244691.1	RPL10AP1	4.65	8.38e-06	0.00661	0.52	0.39	Intelligence (multi-trait analysis);	chr14:103488067	chr14:103412119~103412761:-
TGCT	cis	rs801193	1	rs2420824	ENSG00000237310.1	GS1-124K5.4	-4.65	8.39e-06	0.00661	-0.43	-0.39	Aortic root size;	chr7:66666129	chr7:66493706~66495474:+
TGCT	cis	rs1355223	0.573	rs1148930	ENSG00000271369.1	RP11-350D17.3	4.65	8.39e-06	0.00662	0.38	0.39	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34710678	chr11:34709600~34710161:+
TGCT	cis	rs10759883	0.539	rs10117340	ENSG00000175611.10	LINC00476	-4.65	8.41e-06	0.00663	-0.34	-0.39	Nicotine dependence;	chr9:96032530	chr9:95759231~95875977:-
TGCT	cis	rs2288884	0.636	rs8101936	ENSG00000269235.1	ZNF350-AS1	4.65	8.41e-06	0.00663	0.47	0.39	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52073226	chr19:51949134~51981367:+
TGCT	cis	rs2288884	0.636	rs8105801	ENSG00000269235.1	ZNF350-AS1	4.65	8.41e-06	0.00663	0.47	0.39	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52074095	chr19:51949134~51981367:+
TGCT	cis	rs9322193	0.884	rs1125	ENSG00000216906.2	RP11-350J20.9	4.65	8.41e-06	0.00663	0.44	0.39	Lung cancer;	chr6:149658280	chr6:149904243~149906418:+
TGCT	cis	rs10875746	0.768	rs12305182	ENSG00000240399.1	RP1-228P16.1	-4.65	8.41e-06	0.00663	-0.45	-0.39	Longevity (90 years and older);	chr12:48027624	chr12:48054813~48055591:-
TGCT	cis	rs67311347	1	rs28491638	ENSG00000223797.4	ENTPD3-AS1	4.65	8.43e-06	0.00664	0.42	0.39	Renal cell carcinoma;	chr3:40454772	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs28536038	ENSG00000223797.4	ENTPD3-AS1	4.65	8.43e-06	0.00664	0.42	0.39	Renal cell carcinoma;	chr3:40454891	chr3:40313802~40453329:-
TGCT	cis	rs7208859	0.673	rs3816780	ENSG00000280069.1	CTD-2349P21.3	-4.65	8.43e-06	0.00665	-0.55	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30738182~30740275:+
TGCT	cis	rs10256972	0.514	rs2140578	ENSG00000229043.2	AC091729.9	-4.65	8.44e-06	0.00665	-0.39	-0.39	Endometriosis;Longevity;	chr7:1174367	chr7:1160374~1165267:+
TGCT	cis	rs9309473	0.95	rs7596773	ENSG00000163016.8	ALMS1P	4.65	8.44e-06	0.00665	0.36	0.39	Metabolite levels;	chr2:73618873	chr2:73644919~73685576:+
TGCT	cis	rs17826219	0.706	rs609472	ENSG00000266490.1	CTD-2349P21.9	4.65	8.46e-06	0.00667	0.42	0.39	Body mass index;	chr17:30624409	chr17:30792372~30792833:+
TGCT	cis	rs34217772	0.699	rs12432215	ENSG00000258536.1	RP11-1053O12.1	4.65	8.47e-06	0.00667	0.32	0.39	Myopia;	chr14:41843280	chr14:41742639~41742963:+
TGCT	cis	rs12682352	0.602	rs4841044	ENSG00000253893.2	FAM85B	4.65	8.47e-06	0.00667	0.49	0.39	Neuroticism;	chr8:8807430	chr8:8167819~8226614:-
TGCT	cis	rs67311347	1	rs11720360	ENSG00000223797.4	ENTPD3-AS1	4.65	8.48e-06	0.00668	0.41	0.39	Renal cell carcinoma;	chr3:40406906	chr3:40313802~40453329:-
TGCT	cis	rs2463822	1	rs2513744	ENSG00000254454.2	RCC2P6	-4.65	8.48e-06	0.00668	-0.43	-0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62310313	chr11:62371146~62373168:+
TGCT	cis	rs1865760	1	rs3799371	ENSG00000217159.2	LARP1P1	4.65	8.49e-06	0.00669	0.45	0.39	Height;	chr6:25912588	chr6:26164072~26164363:+
TGCT	cis	rs2665103	0.715	rs16973457	ENSG00000278603.1	RP13-608F4.5	4.65	8.49e-06	0.00669	0.51	0.39	Intelligence (multi-trait analysis);	chr15:82271650	chr15:82472203~82472426:+
TGCT	cis	rs2188561	0.708	rs9718496	ENSG00000241764.3	AC002467.7	4.65	8.49e-06	0.00669	0.36	0.39	Alcohol consumption;	chr7:107730187	chr7:107742817~107744581:-
TGCT	cis	rs507080	0.922	rs533646	ENSG00000255239.1	AP002954.6	4.65	8.5e-06	0.00669	0.5	0.39	Serum metabolite levels;	chr11:118696037	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.922	rs642662	ENSG00000255239.1	AP002954.6	4.65	8.5e-06	0.00669	0.5	0.39	Serum metabolite levels;	chr11:118696311	chr11:118688039~118690600:-
TGCT	cis	rs6700559	0.74	rs4387211	ENSG00000260088.1	RP11-92G12.3	-4.65	8.5e-06	0.0067	-0.46	-0.39	Coronary artery disease;	chr1:200676810	chr1:200669507~200694250:+
TGCT	cis	rs11763147	1	rs11763147	ENSG00000237310.1	GS1-124K5.4	-4.65	8.51e-06	0.0067	-0.42	-0.39	Corneal structure;	chr7:65861834	chr7:66493706~66495474:+
TGCT	cis	rs4268898	0.722	rs11680491	ENSG00000223754.1	AC008073.9	-4.65	8.52e-06	0.00671	-0.42	-0.39	Asthma;	chr2:24193423	chr2:24199839~24201698:-
TGCT	cis	rs904251	0.523	rs9369005	ENSG00000204110.6	RP1-153P14.8	-4.65	8.52e-06	0.00671	-0.41	-0.39	Cognitive performance;	chr6:37515333	chr6:37507348~37535616:+
TGCT	cis	rs9987353	0.544	rs2929469	ENSG00000173295.6	FAM86B3P	4.65	8.53e-06	0.00671	0.42	0.39	Recombination measurement;	chr8:9205146	chr8:8228595~8244865:+
TGCT	cis	rs2976388	0.609	rs2244152	ENSG00000253196.1	RP11-706C16.7	4.65	8.53e-06	0.00671	0.38	0.39	Urinary tract infection frequency;	chr8:142703467	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.609	rs2585153	ENSG00000253196.1	RP11-706C16.7	4.65	8.53e-06	0.00671	0.38	0.39	Urinary tract infection frequency;	chr8:142703927	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.609	rs2572899	ENSG00000253196.1	RP11-706C16.7	4.65	8.53e-06	0.00671	0.38	0.39	Urinary tract infection frequency;	chr8:142704131	chr8:142763116~142766427:+
TGCT	cis	rs17826219	0.5	rs117560728	ENSG00000266490.1	CTD-2349P21.9	4.65	8.53e-06	0.00671	0.48	0.39	Body mass index;	chr17:30743920	chr17:30792372~30792833:+
TGCT	cis	rs786425	0.901	rs11057307	ENSG00000278112.1	RP11-972P1.11	4.65	8.53e-06	0.00672	0.43	0.38	Pubertal anthropometrics;	chr12:123613666	chr12:123519390~123519856:-
TGCT	cis	rs17826219	0.636	rs4055314	ENSG00000280069.1	CTD-2349P21.3	-4.65	8.54e-06	0.00672	-0.54	-0.38	Body mass index;	chr17:30752751	chr17:30738182~30740275:+
TGCT	cis	rs17826219	0.636	rs79565452	ENSG00000280069.1	CTD-2349P21.3	-4.65	8.54e-06	0.00672	-0.54	-0.38	Body mass index;	chr17:30815823	chr17:30738182~30740275:+
TGCT	cis	rs2439831	0.85	rs8032649	ENSG00000205771.5	CATSPER2P1	4.64	8.54e-06	0.00672	0.62	0.38	Lung cancer in ever smokers;	chr15:43842724	chr15:43726918~43747094:-
TGCT	cis	rs875971	0.66	rs2013222	ENSG00000236529.1	RP13-254B10.1	-4.64	8.54e-06	0.00672	-0.29	-0.38	Aortic root size;	chr7:66570949	chr7:65840212~65840596:+
TGCT	cis	rs2919917	0.628	rs7823970	ENSG00000254352.1	RP11-578O24.2	4.64	8.55e-06	0.00673	0.46	0.38	Lymphocyte counts;	chr8:78681364	chr8:78723796~78724136:-
TGCT	cis	rs2919917	0.616	rs7823723	ENSG00000254352.1	RP11-578O24.2	4.64	8.55e-06	0.00673	0.46	0.38	Lymphocyte counts;	chr8:78681390	chr8:78723796~78724136:-
TGCT	cis	rs2709736	0.571	rs2709719	ENSG00000232790.2	LINC01162	4.64	8.57e-06	0.00673	0.31	0.38	Bipolar I disorder;	chr7:20879243	chr7:20835431~21023148:+
TGCT	cis	rs2709736	0.596	rs2539960	ENSG00000232790.2	LINC01162	4.64	8.57e-06	0.00673	0.31	0.38	Bipolar I disorder;	chr7:20880964	chr7:20835431~21023148:+
TGCT	cis	rs4835473	0.831	rs1912743	ENSG00000251600.4	RP11-673E1.1	4.64	8.57e-06	0.00673	0.4	0.38	Immature fraction of reticulocytes;	chr4:143993705	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.614	rs4487293	ENSG00000251600.4	RP11-673E1.1	4.64	8.57e-06	0.00673	0.4	0.38	Immature fraction of reticulocytes;	chr4:143993880	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.742	rs6537238	ENSG00000251600.4	RP11-673E1.1	4.64	8.57e-06	0.00673	0.4	0.38	Immature fraction of reticulocytes;	chr4:143996463	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1473055	ENSG00000251600.4	RP11-673E1.1	4.64	8.57e-06	0.00673	0.4	0.38	Immature fraction of reticulocytes;	chr4:143997714	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs4835126	ENSG00000251600.4	RP11-673E1.1	4.64	8.57e-06	0.00673	0.4	0.38	Immature fraction of reticulocytes;	chr4:143997740	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.699	rs4835127	ENSG00000251600.4	RP11-673E1.1	4.64	8.57e-06	0.00673	0.4	0.38	Immature fraction of reticulocytes;	chr4:143997972	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs10025455	ENSG00000251600.4	RP11-673E1.1	-4.64	8.57e-06	0.00673	-0.4	-0.38	Immature fraction of reticulocytes;	chr4:143998417	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.722	rs7666296	ENSG00000251600.4	RP11-673E1.1	-4.64	8.57e-06	0.00673	-0.4	-0.38	Immature fraction of reticulocytes;	chr4:143999004	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.618	rs7666297	ENSG00000251600.4	RP11-673E1.1	-4.64	8.57e-06	0.00673	-0.4	-0.38	Immature fraction of reticulocytes;	chr4:143999005	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.868	rs7683365	ENSG00000251600.4	RP11-673E1.1	-4.64	8.57e-06	0.00673	-0.4	-0.38	Immature fraction of reticulocytes;	chr4:143999443	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.722	rs7662277	ENSG00000251600.4	RP11-673E1.1	-4.64	8.57e-06	0.00673	-0.4	-0.38	Immature fraction of reticulocytes;	chr4:143999485	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.618	rs12499907	ENSG00000251600.4	RP11-673E1.1	-4.64	8.57e-06	0.00673	-0.4	-0.38	Immature fraction of reticulocytes;	chr4:143999748	chr4:143912331~143982454:+
TGCT	cis	rs6017291	1	rs67398314	ENSG00000223891.4	OSER1-AS1	4.64	8.57e-06	0.00673	0.58	0.38	Cognitive performance;	chr20:44231401	chr20:44210960~44226027:+
TGCT	cis	rs6017291	1	rs35133353	ENSG00000223891.4	OSER1-AS1	4.64	8.57e-06	0.00673	0.58	0.38	Cognitive performance;	chr20:44231948	chr20:44210960~44226027:+
TGCT	cis	rs6017291	1	rs66626476	ENSG00000223891.4	OSER1-AS1	4.64	8.57e-06	0.00673	0.58	0.38	Cognitive performance;	chr20:44231978	chr20:44210960~44226027:+
TGCT	cis	rs6017291	1	rs34155184	ENSG00000223891.4	OSER1-AS1	4.64	8.57e-06	0.00673	0.58	0.38	Cognitive performance;	chr20:44233450	chr20:44210960~44226027:+
TGCT	cis	rs6017291	1	rs35060279	ENSG00000223891.4	OSER1-AS1	4.64	8.57e-06	0.00673	0.58	0.38	Cognitive performance;	chr20:44233732	chr20:44210960~44226027:+
TGCT	cis	rs6017291	1	rs66620958	ENSG00000223891.4	OSER1-AS1	4.64	8.57e-06	0.00673	0.58	0.38	Cognitive performance;	chr20:44233736	chr20:44210960~44226027:+
TGCT	cis	rs6017291	1	rs34748169	ENSG00000223891.4	OSER1-AS1	4.64	8.57e-06	0.00673	0.58	0.38	Cognitive performance;	chr20:44234865	chr20:44210960~44226027:+
TGCT	cis	rs796364	1	rs796364	ENSG00000232732.8	AC073043.1	-4.64	8.59e-06	0.00675	-0.55	-0.38	Schizophrenia;	chr2:199851396	chr2:199867396~199911159:-
TGCT	cis	rs786425	0.966	rs3748269	ENSG00000247373.3	RP11-486O12.2	4.64	8.6e-06	0.00675	0.46	0.38	Pubertal anthropometrics;	chr12:123615378	chr12:123575891~123585115:-
TGCT	cis	rs875971	0.66	rs801193	ENSG00000237310.1	GS1-124K5.4	-4.64	8.64e-06	0.00677	-0.44	-0.38	Aortic root size;	chr7:66565625	chr7:66493706~66495474:+
TGCT	cis	rs4660456	0.913	rs34212676	ENSG00000237899.1	RP4-739H11.3	-4.64	8.64e-06	0.00677	-0.51	-0.38	Platelet count;	chr1:40766522	chr1:40669089~40687588:-
TGCT	cis	rs4834770	0.792	rs7676969	ENSG00000245958.5	RP11-33B1.1	-4.64	8.65e-06	0.00677	-0.39	-0.38	Blood protein levels;	chr4:119252569	chr4:119454791~119552025:+
TGCT	cis	rs4834770	0.685	rs4496567	ENSG00000245958.5	RP11-33B1.1	-4.64	8.65e-06	0.00677	-0.39	-0.38	Blood protein levels;	chr4:119254470	chr4:119454791~119552025:+
TGCT	cis	rs4660456	0.913	rs3767951	ENSG00000237899.1	RP4-739H11.3	-4.64	8.65e-06	0.00677	-0.51	-0.38	Platelet count;	chr1:40767359	chr1:40669089~40687588:-
TGCT	cis	rs8062405	0.755	rs17707300	ENSG00000259982.1	CDC37P1	4.64	8.65e-06	0.00677	0.54	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28700294~28701540:-
TGCT	cis	rs9584850	0.834	rs745638	ENSG00000231194.1	FARP1-AS1	-4.64	8.65e-06	0.00678	-0.51	-0.38	Neuroticism;	chr13:98467053	chr13:98435405~98435840:-
TGCT	cis	rs2745572	0.688	rs2816294	ENSG00000272279.1	RP11-157J24.2	4.64	8.65e-06	0.00678	0.45	0.38	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1538546	chr6:1528364~1528911:-
TGCT	cis	rs67311347	1	rs9835219	ENSG00000223797.4	ENTPD3-AS1	4.64	8.66e-06	0.00678	0.4	0.38	Renal cell carcinoma;	chr3:40382602	chr3:40313802~40453329:-
TGCT	cis	rs12891047	0.78	rs11624166	ENSG00000258759.1	RP11-1012A1.7	4.64	8.66e-06	0.00678	0.32	0.38	Amyotrophic lateral sclerosis (sporadic);	chr14:67859818	chr14:67799004~67799609:+
TGCT	cis	rs1815787	1	rs1815787	ENSG00000254851.1	RP11-109L13.1	-4.64	8.67e-06	0.00679	-0.76	-0.38	Subjective well-being;	chr11:117050681	chr11:117135528~117138582:+
TGCT	cis	rs9309473	0.948	rs13392691	ENSG00000163016.8	ALMS1P	4.64	8.68e-06	0.00679	0.35	0.38	Metabolite levels;	chr2:73521853	chr2:73644919~73685576:+
TGCT	cis	rs9462027	0.628	rs2814971	ENSG00000186328.4	RP11-140K17.2	-4.64	8.68e-06	0.0068	-0.36	-0.38	Systemic lupus erythematosus;	chr6:34746432	chr6:34715613~34715940:+
TGCT	cis	rs1618992	0.791	rs2655364	ENSG00000265994.1	RP11-510D21.1	-4.64	8.7e-06	0.00681	-0.39	-0.38	Gut microbiome composition (summer and winter);	chr18:28649375	chr18:28785068~28789260:+
TGCT	cis	rs9987353	0.519	rs13276350	ENSG00000173295.6	FAM86B3P	-4.64	8.7e-06	0.00681	-0.42	-0.38	Recombination measurement;	chr8:9205647	chr8:8228595~8244865:+
TGCT	cis	rs73086581	0.838	rs11907416	ENSG00000229539.1	RP11-119B16.2	4.64	8.7e-06	0.00681	0.57	0.38	Response to antidepressants in depression;	chr20:4024972	chr20:3888239~3888868:-
TGCT	cis	rs801193	1	rs2659909	ENSG00000237310.1	GS1-124K5.4	4.64	8.7e-06	0.00681	0.43	0.38	Aortic root size;	chr7:66695292	chr7:66493706~66495474:+
TGCT	cis	rs1023500	0.552	rs5758566	ENSG00000270083.1	RP1-257I20.14	4.64	8.7e-06	0.00681	0.39	0.38	Schizophrenia;	chr22:42058350	chr22:42089630~42090028:-
TGCT	cis	rs4713118	0.662	rs9393881	ENSG00000219392.1	RP1-265C24.5	-4.64	8.71e-06	0.00681	-0.49	-0.38	Parkinson's disease;	chr6:28055973	chr6:28115628~28116551:+
TGCT	cis	rs2581828	0.656	rs2581800	ENSG00000242142.1	SERBP1P3	4.64	8.71e-06	0.00681	0.36	0.38	Crohn's disease;	chr3:53075336	chr3:53064283~53065091:-
TGCT	cis	rs8059260	0.541	rs6498167	ENSG00000274038.1	RP11-66H6.4	-4.64	8.71e-06	0.00682	-0.55	-0.38	Alcohol consumption over the past year;	chr16:11127727	chr16:11056556~11057034:+
TGCT	cis	rs4713118	0.662	rs149969	ENSG00000219891.2	ZSCAN12P1	4.64	8.72e-06	0.00682	0.44	0.38	Parkinson's disease;	chr6:28009959	chr6:28091154~28093664:+
TGCT	cis	rs2442825	0.693	rs2648536	ENSG00000206573.7	THUMPD3-AS1	4.64	8.72e-06	0.00682	0.36	0.38	Cerebrospinal fluid clusterin levels;	chr3:9365338	chr3:9349689~9398579:-
TGCT	cis	rs1799949	0.929	rs799906	ENSG00000198496.9	NBR2	-4.64	8.72e-06	0.00682	-0.54	-0.38	Menopause (age at onset);	chr17:43126099	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.965	rs799908	ENSG00000198496.9	NBR2	-4.64	8.72e-06	0.00682	-0.54	-0.38	Menopause (age at onset);	chr17:43126899	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.93	rs1554063	ENSG00000198496.9	NBR2	-4.64	8.72e-06	0.00682	-0.54	-0.38	Menopause (age at onset);	chr17:43135128	chr17:43125610~43153671:+
TGCT	cis	rs2976388	0.609	rs2164308	ENSG00000253196.1	RP11-706C16.7	-4.64	8.73e-06	0.00683	-0.37	-0.38	Urinary tract infection frequency;	chr8:142704241	chr8:142763116~142766427:+
TGCT	cis	rs11157436	0.697	rs4334205	ENSG00000211813.2	TRAV34	-4.64	8.73e-06	0.00683	-0.39	-0.38	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22155699	chr14:22207522~22208129:+
TGCT	cis	rs3096299	0.967	rs2965827	ENSG00000274627.1	RP11-104N10.2	-4.64	8.73e-06	0.00683	-0.41	-0.38	Multiple myeloma (IgH translocation);	chr16:89390942	chr16:89516797~89522217:+
TGCT	cis	rs6604026	0.624	rs35038369	ENSG00000223787.2	RP4-593M8.1	4.64	8.73e-06	0.00683	0.55	0.38	Multiple sclerosis;	chr1:92765411	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.624	rs11585590	ENSG00000223787.2	RP4-593M8.1	4.64	8.73e-06	0.00683	0.55	0.38	Multiple sclerosis;	chr1:92766823	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.624	rs35705463	ENSG00000223787.2	RP4-593M8.1	4.64	8.73e-06	0.00683	0.55	0.38	Multiple sclerosis;	chr1:92767766	chr1:92580476~92580821:-
TGCT	cis	rs7208859	0.623	rs170051	ENSG00000266490.1	CTD-2349P21.9	4.64	8.75e-06	0.00684	0.44	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs216434	ENSG00000266490.1	CTD-2349P21.9	4.64	8.75e-06	0.00684	0.44	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs216436	ENSG00000266490.1	CTD-2349P21.9	4.64	8.75e-06	0.00684	0.44	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30792372~30792833:+
TGCT	cis	rs853679	0.628	rs9368560	ENSG00000219392.1	RP1-265C24.5	-4.64	8.75e-06	0.00684	-0.52	-0.38	Depression;	chr6:28192182	chr6:28115628~28116551:+
TGCT	cis	rs1823913	0.599	rs17511445	ENSG00000227542.1	AC092614.2	-4.64	8.75e-06	0.00684	-0.41	-0.38	Obesity-related traits;	chr2:191279831	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs13002286	ENSG00000227542.1	AC092614.2	-4.64	8.75e-06	0.00684	-0.41	-0.38	Obesity-related traits;	chr2:191285626	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs17346475	ENSG00000227542.1	AC092614.2	-4.64	8.75e-06	0.00684	-0.41	-0.38	Obesity-related traits;	chr2:191288488	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs56328712	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191273807	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs55862924	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191273809	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.561	rs60479498	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191275197	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs12989203	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191276617	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs17511410	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191278043	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs34262638	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191279442	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs34100174	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191283579	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs55786000	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191284500	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs13001899	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191285442	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs17346412	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191285902	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs17412239	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191285937	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs35098152	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191286658	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs35150635	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191287303	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs2168166	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191288063	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs2124093	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191288280	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.622	rs55787447	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191288596	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs13027086	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191294058	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs2067610	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191299251	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs1454754	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191303562	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs13010441	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191303903	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs12988037	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191306419	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs55685315	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191306451	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs13015653	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191306813	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs12994212	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191306910	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs12994236	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191306991	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs35495506	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191307551	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs34691559	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191307688	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.561	rs55790432	ENSG00000227542.1	AC092614.2	4.64	8.75e-06	0.00684	0.41	0.38	Obesity-related traits;	chr2:191307722	chr2:191229165~191246172:-
TGCT	cis	rs8105895	0.935	rs1560716	ENSG00000269742.1	BNIP3P29	4.64	8.75e-06	0.00684	0.73	0.38	Body mass index (change over time);	chr19:22123099	chr19:22065828~22066398:-
TGCT	cis	rs7208859	0.673	rs423151	ENSG00000280069.1	CTD-2349P21.3	-4.64	8.78e-06	0.00685	-0.49	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30738182~30740275:+
TGCT	cis	rs7617773	0.851	rs13068288	ENSG00000229759.1	MRPS18AP1	4.64	8.79e-06	0.00686	0.34	0.38	Coronary artery disease;	chr3:48290261	chr3:48256350~48256938:-
TGCT	cis	rs6782228	0.606	rs10048945	ENSG00000242551.2	POU5F1P6	-4.64	8.79e-06	0.00686	-0.46	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128690837	chr3:128674735~128677005:-
TGCT	cis	rs5742933	0.803	rs1233302	ENSG00000273240.1	RP11-455J20.3	-4.64	8.79e-06	0.00686	-0.36	-0.38	Ferritin levels;	chr2:189804154	chr2:189763859~189764456:-
TGCT	cis	rs9462027	0.628	rs9469914	ENSG00000186328.4	RP11-140K17.2	4.64	8.81e-06	0.00687	0.36	0.38	Systemic lupus erythematosus;	chr6:34859916	chr6:34715613~34715940:+
TGCT	cis	rs67311347	0.956	rs12633446	ENSG00000223797.4	ENTPD3-AS1	-4.64	8.81e-06	0.00687	-0.4	-0.38	Renal cell carcinoma;	chr3:40464170	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs7617989	ENSG00000223797.4	ENTPD3-AS1	-4.64	8.81e-06	0.00687	-0.4	-0.38	Renal cell carcinoma;	chr3:40470972	chr3:40313802~40453329:-
TGCT	cis	rs6981523	0.553	rs11783890	ENSG00000255310.2	AF131215.2	-4.64	8.83e-06	0.00689	-0.32	-0.38	Neuroticism;	chr8:11198879	chr8:11107788~11109726:-
TGCT	cis	rs10504229	0.871	rs16921952	ENSG00000253301.4	RP11-513O17.2	4.64	8.83e-06	0.00689	0.49	0.38	Developmental language disorder (linguistic errors);	chr8:57250758	chr8:57142689~57240298:+
TGCT	cis	rs3091242	0.933	rs10903129	ENSG00000224183.1	SDHDP6	-4.64	8.84e-06	0.00689	-0.39	-0.38	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25294164~25294643:-
TGCT	cis	rs4660456	0.913	rs6667368	ENSG00000237899.1	RP4-739H11.3	4.64	8.87e-06	0.00691	0.53	0.38	Platelet count;	chr1:40694887	chr1:40669089~40687588:-
TGCT	cis	rs4835473	0.897	rs2219912	ENSG00000251600.4	RP11-673E1.1	4.64	8.89e-06	0.00693	0.39	0.38	Immature fraction of reticulocytes;	chr4:143707909	chr4:143912331~143982454:+
TGCT	cis	rs9462027	0.628	rs9469917	ENSG00000186328.4	RP11-140K17.2	4.64	8.9e-06	0.00693	0.37	0.38	Systemic lupus erythematosus;	chr6:34863592	chr6:34715613~34715940:+
TGCT	cis	rs7208859	0.524	rs77498725	ENSG00000266490.1	CTD-2349P21.9	4.64	8.9e-06	0.00693	0.44	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.573	rs73267865	ENSG00000266490.1	CTD-2349P21.9	4.64	8.9e-06	0.00693	0.44	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30792372~30792833:+
TGCT	cis	rs17826219	0.706	rs57698184	ENSG00000266490.1	CTD-2349P21.9	4.64	8.9e-06	0.00693	0.44	0.38	Body mass index;	chr17:30737900	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.524	rs59923796	ENSG00000266490.1	CTD-2349P21.9	4.64	8.9e-06	0.00693	0.44	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30792372~30792833:+
TGCT	cis	rs17826219	0.5	rs57005940	ENSG00000266490.1	CTD-2349P21.9	4.64	8.9e-06	0.00693	0.44	0.38	Body mass index;	chr17:30739311	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.573	rs73267872	ENSG00000266490.1	CTD-2349P21.9	4.64	8.9e-06	0.00693	0.44	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30792372~30792833:+
TGCT	cis	rs17826219	0.706	rs9893922	ENSG00000266490.1	CTD-2349P21.9	4.64	8.9e-06	0.00693	0.44	0.38	Body mass index;	chr17:30741407	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs56812022	ENSG00000266490.1	CTD-2349P21.9	4.64	8.9e-06	0.00693	0.44	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.524	rs57670615	ENSG00000266490.1	CTD-2349P21.9	4.64	8.9e-06	0.00693	0.44	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30792372~30792833:+
TGCT	cis	rs11671005	0.735	rs1122955	ENSG00000232098.3	CTD-2619J13.14	-4.64	8.9e-06	0.00693	-0.43	-0.38	Mean platelet volume;	chr19:58434836	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.735	rs11668814	ENSG00000232098.3	CTD-2619J13.14	-4.64	8.9e-06	0.00693	-0.43	-0.38	Mean platelet volume;	chr19:58435466	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.735	rs45617039	ENSG00000232098.3	CTD-2619J13.14	-4.64	8.9e-06	0.00693	-0.43	-0.38	Mean platelet volume;	chr19:58439729	chr19:58404238~58408484:-
TGCT	cis	rs9880211	0.8	rs9865995	ENSG00000239213.4	NCK1-AS1	4.64	8.9e-06	0.00693	0.42	0.38	Height;Body mass index;	chr3:136794508	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.8	rs9871184	ENSG00000239213.4	NCK1-AS1	4.64	8.9e-06	0.00693	0.42	0.38	Height;Body mass index;	chr3:136795468	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.8	rs115050567	ENSG00000239213.4	NCK1-AS1	4.64	8.9e-06	0.00693	0.42	0.38	Height;Body mass index;	chr3:136796817	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.8	rs9858560	ENSG00000239213.4	NCK1-AS1	4.64	8.9e-06	0.00693	0.42	0.38	Height;Body mass index;	chr3:136798312	chr3:136841726~136862054:-
TGCT	cis	rs2524005	1	rs2524005	ENSG00000235821.1	IFITM4P	-4.63	8.91e-06	0.00694	-0.49	-0.38	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29750729~29751148:-
TGCT	cis	rs17373728	0.71	rs12544686	ENSG00000249395.2	CASC9	4.63	8.93e-06	0.00695	0.48	0.38	Diabetic kidney disease;	chr8:75305839	chr8:75223404~75324741:-
TGCT	cis	rs2919917	0.628	rs6997255	ENSG00000254352.1	RP11-578O24.2	4.63	8.93e-06	0.00695	0.46	0.38	Lymphocyte counts;	chr8:78694850	chr8:78723796~78724136:-
TGCT	cis	rs2919917	0.628	rs7017898	ENSG00000254352.1	RP11-578O24.2	4.63	8.93e-06	0.00695	0.46	0.38	Lymphocyte counts;	chr8:78697147	chr8:78723796~78724136:-
TGCT	cis	rs2919917	0.628	rs7010299	ENSG00000254352.1	RP11-578O24.2	4.63	8.93e-06	0.00695	0.46	0.38	Lymphocyte counts;	chr8:78707786	chr8:78723796~78724136:-
TGCT	cis	rs2919917	0.628	rs2625663	ENSG00000254352.1	RP11-578O24.2	4.63	8.93e-06	0.00695	0.46	0.38	Lymphocyte counts;	chr8:78718106	chr8:78723796~78724136:-
TGCT	cis	rs3809863	0.602	rs11650072	ENSG00000228782.6	CTD-2026D20.3	4.63	8.94e-06	0.00695	0.48	0.38	Glaucoma (primary open-angle);	chr17:47316299	chr17:47450568~47492492:-
TGCT	cis	rs7246967	0.542	rs56355379	ENSG00000269509.1	BNIP3P34	4.63	8.95e-06	0.00696	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22717653	chr19:22773853~22774424:+
TGCT	cis	rs10875746	0.859	rs12305647	ENSG00000240399.1	RP1-228P16.1	-4.63	8.96e-06	0.00697	-0.44	-0.38	Longevity (90 years and older);	chr12:48189178	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.859	rs12305511	ENSG00000240399.1	RP1-228P16.1	4.63	8.96e-06	0.00697	0.44	0.38	Longevity (90 years and older);	chr12:48188933	chr12:48054813~48055591:-
TGCT	cis	rs2033711	0.936	rs882609	ENSG00000269473.1	CTD-2619J13.19	4.63	8.97e-06	0.00697	0.33	0.38	Uric acid clearance;	chr19:58480112	chr19:58440448~58445849:+
TGCT	cis	rs853679	0.55	rs1233701	ENSG00000187763.3	OR2B7P	-4.63	8.97e-06	0.00698	-0.37	-0.38	Depression;	chr6:28200948	chr6:28046434~28047367:+
TGCT	cis	rs7301826	0.934	rs10848212	ENSG00000256299.1	RP11-989F5.3	4.63	8.98e-06	0.00698	0.41	0.38	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810821~130812622:-
TGCT	cis	rs7621331	0.684	rs66626713	ENSG00000239213.4	NCK1-AS1	4.63	8.99e-06	0.00698	0.37	0.38	Waist circumference adjusted for body mass index;	chr3:135940152	chr3:136841726~136862054:-
TGCT	cis	rs972540	0.889	rs62195877	ENSG00000279220.1	GPR1-AS	4.63	8.99e-06	0.00698	0.4	0.38	Body mass index;	chr2:206360734	chr2:206203376~206266243:+
TGCT	cis	rs972540	0.889	rs62195878	ENSG00000279220.1	GPR1-AS	4.63	8.99e-06	0.00698	0.4	0.38	Body mass index;	chr2:206364230	chr2:206203376~206266243:+
TGCT	cis	rs972540	0.924	rs62195879	ENSG00000279220.1	GPR1-AS	4.63	8.99e-06	0.00698	0.4	0.38	Body mass index;	chr2:206365180	chr2:206203376~206266243:+
TGCT	cis	rs972540	0.924	rs62195880	ENSG00000279220.1	GPR1-AS	4.63	8.99e-06	0.00698	0.4	0.38	Body mass index;	chr2:206365205	chr2:206203376~206266243:+
TGCT	cis	rs7246967	0.673	rs4933026	ENSG00000269509.1	BNIP3P34	4.63	8.99e-06	0.00699	0.61	0.38	Bronchopulmonary dysplasia;	chr19:22691690	chr19:22773853~22774424:+
TGCT	cis	rs9309473	0.861	rs6546857	ENSG00000163016.8	ALMS1P	4.63	8.99e-06	0.00699	0.36	0.38	Metabolite levels;	chr2:73610828	chr2:73644919~73685576:+
TGCT	cis	rs3742264	0.961	rs11620308	ENSG00000235903.6	CPB2-AS1	-4.63	9e-06	0.00699	-0.47	-0.38	Blood protein levels;	chr13:46075588	chr13:46052806~46113332:+
TGCT	cis	rs10504229	0.679	rs17800895	ENSG00000253301.4	RP11-513O17.2	4.63	9e-06	0.007	0.62	0.38	Developmental language disorder (linguistic errors);	chr8:57137526	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.679	rs17801003	ENSG00000253301.4	RP11-513O17.2	4.63	9e-06	0.007	0.62	0.38	Developmental language disorder (linguistic errors);	chr8:57138371	chr8:57142689~57240298:+
TGCT	cis	rs7605378	1	rs7577763	ENSG00000232732.8	AC073043.1	-4.63	9e-06	0.007	-0.45	-0.38	Osteoporosis;	chr2:199817030	chr2:199867396~199911159:-
TGCT	cis	rs7605378	1	rs2577852	ENSG00000232732.8	AC073043.1	-4.63	9e-06	0.007	-0.45	-0.38	Osteoporosis;	chr2:199822525	chr2:199867396~199911159:-
TGCT	cis	rs7605378	0.964	rs2689763	ENSG00000232732.8	AC073043.1	-4.63	9e-06	0.007	-0.45	-0.38	Osteoporosis;	chr2:199824832	chr2:199867396~199911159:-
TGCT	cis	rs7605378	1	rs796363	ENSG00000232732.8	AC073043.1	-4.63	9e-06	0.007	-0.45	-0.38	Osteoporosis;	chr2:199828945	chr2:199867396~199911159:-
TGCT	cis	rs2439831	0.557	rs13329084	ENSG00000205771.5	CATSPER2P1	4.63	9.01e-06	0.007	0.63	0.38	Lung cancer in ever smokers;	chr15:43858865	chr15:43726918~43747094:-
TGCT	cis	rs2980439	0.783	rs2948305	ENSG00000253981.4	ALG1L13P	4.63	9.02e-06	0.00701	0.4	0.38	Neuroticism;	chr8:8241055	chr8:8236003~8244667:-
TGCT	cis	rs796364	0.865	rs769948	ENSG00000232732.8	AC073043.1	-4.63	9.03e-06	0.00701	-0.55	-0.38	Schizophrenia;	chr2:199863752	chr2:199867396~199911159:-
TGCT	cis	rs796364	1	rs769949	ENSG00000232732.8	AC073043.1	-4.63	9.03e-06	0.00701	-0.55	-0.38	Schizophrenia;	chr2:199864835	chr2:199867396~199911159:-
TGCT	cis	rs796364	1	rs769950	ENSG00000232732.8	AC073043.1	-4.63	9.03e-06	0.00701	-0.55	-0.38	Schizophrenia;	chr2:199865305	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.951	rs769952	ENSG00000232732.8	AC073043.1	-4.63	9.03e-06	0.00701	-0.55	-0.38	Schizophrenia;	chr2:199869645	chr2:199867396~199911159:-
TGCT	cis	rs796364	1	rs281785	ENSG00000232732.8	AC073043.1	-4.63	9.03e-06	0.00701	-0.55	-0.38	Schizophrenia;	chr2:199884843	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.906	rs281784	ENSG00000232732.8	AC073043.1	-4.63	9.03e-06	0.00701	-0.55	-0.38	Schizophrenia;	chr2:199885026	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.95	rs188146	ENSG00000232732.8	AC073043.1	-4.63	9.03e-06	0.00701	-0.55	-0.38	Schizophrenia;	chr2:199885721	chr2:199867396~199911159:-
TGCT	cis	rs796364	1	rs281783	ENSG00000232732.8	AC073043.1	-4.63	9.03e-06	0.00701	-0.55	-0.38	Schizophrenia;	chr2:199886859	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.95	rs56155997	ENSG00000232732.8	AC073043.1	4.63	9.03e-06	0.00701	0.55	0.38	Schizophrenia;	chr2:199903768	chr2:199867396~199911159:-
TGCT	cis	rs796364	1	rs35594306	ENSG00000232732.8	AC073043.1	4.63	9.03e-06	0.00701	0.55	0.38	Schizophrenia;	chr2:199910402	chr2:199867396~199911159:-
TGCT	cis	rs796364	1	rs35220450	ENSG00000232732.8	AC073043.1	4.63	9.03e-06	0.00701	0.55	0.38	Schizophrenia;	chr2:199916014	chr2:199867396~199911159:-
TGCT	cis	rs796364	1	rs11680723	ENSG00000232732.8	AC073043.1	4.63	9.03e-06	0.00701	0.55	0.38	Schizophrenia;	chr2:199946234	chr2:199867396~199911159:-
TGCT	cis	rs62355901	0.609	rs66893416	ENSG00000271828.1	CTD-2310F14.1	4.63	9.05e-06	0.00702	0.47	0.38	Breast cancer;	chr5:56755769	chr5:56927874~56929573:+
TGCT	cis	rs17361889	0.634	rs1527210	ENSG00000224683.1	RPL36AP29	4.63	9.05e-06	0.00703	0.4	0.38	Pediatric bone mineral content (hip);	chr7:16236056	chr7:16208945~16209265:+
TGCT	cis	rs9462027	0.606	rs205260	ENSG00000186328.4	RP11-140K17.2	4.63	9.05e-06	0.00703	0.36	0.38	Systemic lupus erythematosus;	chr6:34596181	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.606	rs205258	ENSG00000186328.4	RP11-140K17.2	4.63	9.05e-06	0.00703	0.36	0.38	Systemic lupus erythematosus;	chr6:34596466	chr6:34715613~34715940:+
TGCT	cis	rs4835473	0.766	rs6537222	ENSG00000251600.4	RP11-673E1.1	4.63	9.06e-06	0.00703	0.4	0.38	Immature fraction of reticulocytes;	chr4:143971459	chr4:143912331~143982454:+
TGCT	cis	rs7826238	0.601	rs2976907	ENSG00000173295.6	FAM86B3P	4.63	9.06e-06	0.00703	0.44	0.38	Systolic blood pressure;	chr8:8487658	chr8:8228595~8244865:+
TGCT	cis	rs7826238	0.601	rs2979206	ENSG00000173295.6	FAM86B3P	4.63	9.06e-06	0.00703	0.44	0.38	Systolic blood pressure;	chr8:8488071	chr8:8228595~8244865:+
TGCT	cis	rs2709736	0.563	rs204582	ENSG00000232790.2	LINC01162	4.63	9.06e-06	0.00703	0.3	0.38	Bipolar I disorder;	chr7:20862151	chr7:20835431~21023148:+
TGCT	cis	rs11822910	1	rs2439448	ENSG00000265566.2	RN7SL605P	4.63	9.06e-06	0.00703	0.47	0.38	Platelet distribution width;	chr11:57431738	chr11:57528085~57528365:-
TGCT	cis	rs4835473	0.932	rs35055653	ENSG00000251600.4	RP11-673E1.1	-4.63	9.07e-06	0.00704	-0.41	-0.38	Immature fraction of reticulocytes;	chr4:143754836	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs35017645	ENSG00000251600.4	RP11-673E1.1	-4.63	9.07e-06	0.00704	-0.41	-0.38	Immature fraction of reticulocytes;	chr4:143760196	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs7697916	ENSG00000251600.4	RP11-673E1.1	-4.63	9.07e-06	0.00704	-0.41	-0.38	Immature fraction of reticulocytes;	chr4:143765628	chr4:143912331~143982454:+
TGCT	cis	rs9880211	0.752	rs9847427	ENSG00000239213.4	NCK1-AS1	4.63	9.1e-06	0.00705	0.42	0.38	Height;Body mass index;	chr3:136632708	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.752	rs9881831	ENSG00000239213.4	NCK1-AS1	4.63	9.1e-06	0.00705	0.42	0.38	Height;Body mass index;	chr3:136670876	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.8	rs9873536	ENSG00000239213.4	NCK1-AS1	4.63	9.1e-06	0.00705	0.42	0.38	Height;Body mass index;	chr3:136755425	chr3:136841726~136862054:-
TGCT	cis	rs67311347	1	rs73080137	ENSG00000223797.4	ENTPD3-AS1	4.63	9.11e-06	0.00706	0.41	0.38	Renal cell carcinoma;	chr3:40474921	chr3:40313802~40453329:-
TGCT	cis	rs7923609	0.902	rs10733793	ENSG00000232075.1	MRPL35P2	-4.63	9.11e-06	0.00706	-0.37	-0.38	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63564049	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.902	rs10822182	ENSG00000232075.1	MRPL35P2	-4.63	9.11e-06	0.00706	-0.37	-0.38	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63565718	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.902	rs4633333	ENSG00000232075.1	MRPL35P2	-4.63	9.11e-06	0.00706	-0.37	-0.38	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568779	chr10:63634317~63634827:-
TGCT	cis	rs853679	0.55	rs1237875	ENSG00000219392.1	RP1-265C24.5	4.63	9.11e-06	0.00706	0.51	0.38	Depression;	chr6:28205232	chr6:28115628~28116551:+
TGCT	cis	rs62355902	1	rs62355902	ENSG00000271828.1	CTD-2310F14.1	4.63	9.12e-06	0.00707	0.47	0.38	Breast cancer;Breast cancer (estrogen-receptor negative);	chr5:56757896	chr5:56927874~56929573:+
TGCT	cis	rs2742234	0.541	rs7073849	ENSG00000273008.1	RP11-351D16.3	4.63	9.13e-06	0.00707	0.53	0.38	Hirschsprung disease;	chr10:43245026	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.541	rs7098236	ENSG00000273008.1	RP11-351D16.3	4.63	9.13e-06	0.00707	0.53	0.38	Hirschsprung disease;	chr10:43245060	chr10:43136824~43138334:-
TGCT	cis	rs1864400	0.69	rs7098237	ENSG00000273008.1	RP11-351D16.3	4.63	9.13e-06	0.00707	0.53	0.38	Hirschsprung disease;	chr10:43245065	chr10:43136824~43138334:-
TGCT	cis	rs5758659	1	rs134902	ENSG00000270083.1	RP1-257I20.14	4.63	9.13e-06	0.00707	0.38	0.38	Cognitive function;	chr22:42287991	chr22:42089630~42090028:-
TGCT	cis	rs9322193	0.962	rs35443312	ENSG00000216906.2	RP11-350J20.9	4.63	9.13e-06	0.00707	0.43	0.38	Lung cancer;	chr6:149670625	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs35031906	ENSG00000216906.2	RP11-350J20.9	4.63	9.13e-06	0.00707	0.43	0.38	Lung cancer;	chr6:149677438	chr6:149904243~149906418:+
TGCT	cis	rs10504229	0.639	rs11781834	ENSG00000253301.4	RP11-513O17.2	4.63	9.14e-06	0.00708	0.56	0.38	Developmental language disorder (linguistic errors);	chr8:57220863	chr8:57142689~57240298:+
TGCT	cis	rs2717559	0.542	rs2717560	ENSG00000253196.1	RP11-706C16.7	-4.63	9.15e-06	0.00709	-0.4	-0.38	Urinary tract infection frequency;	chr8:142800254	chr8:142763116~142766427:+
TGCT	cis	rs1865760	0.929	rs1816546	ENSG00000217159.2	LARP1P1	-4.63	9.16e-06	0.0071	-0.45	-0.38	Height;	chr6:25938024	chr6:26164072~26164363:+
TGCT	cis	rs1865760	0.786	rs1436308	ENSG00000217159.2	LARP1P1	-4.63	9.16e-06	0.0071	-0.45	-0.38	Height;	chr6:25939339	chr6:26164072~26164363:+
TGCT	cis	rs1865760	0.929	rs1436307	ENSG00000217159.2	LARP1P1	-4.63	9.16e-06	0.0071	-0.45	-0.38	Height;	chr6:25939495	chr6:26164072~26164363:+
TGCT	cis	rs1865760	0.892	rs9379806	ENSG00000217159.2	LARP1P1	-4.63	9.16e-06	0.0071	-0.45	-0.38	Height;	chr6:25940730	chr6:26164072~26164363:+
TGCT	cis	rs7181230	0.885	rs17723133	ENSG00000275636.1	RP11-521C20.5	-4.63	9.18e-06	0.0071	-0.47	-0.38	Dehydroepiandrosterone sulphate levels;	chr15:40073217	chr15:40078892~40079347:+
TGCT	cis	rs867371	1	rs7166570	ENSG00000255769.6	GOLGA2P10	-4.63	9.19e-06	0.00711	-0.41	-0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82472993~82513950:-
TGCT	cis	rs867371	1	rs1846911	ENSG00000255769.6	GOLGA2P10	-4.63	9.19e-06	0.00711	-0.41	-0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82472993~82513950:-
TGCT	cis	rs875971	0.502	rs1796227	ENSG00000237310.1	GS1-124K5.4	-4.63	9.19e-06	0.00711	-0.46	-0.38	Aortic root size;	chr7:66622032	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs1796219	ENSG00000237310.1	GS1-124K5.4	-4.63	9.19e-06	0.00711	-0.46	-0.38	Aortic root size;	chr7:66645977	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.502	rs6460311	ENSG00000237310.1	GS1-124K5.4	-4.63	9.19e-06	0.00711	-0.46	-0.38	Aortic root size;	chr7:66646886	chr7:66493706~66495474:+
TGCT	cis	rs17826219	0.562	rs719600	ENSG00000263531.1	RP13-753N3.1	-4.63	9.19e-06	0.00712	-0.66	-0.38	Body mass index;	chr17:30404244	chr17:30863921~30864940:-
TGCT	cis	rs2717559	0.522	rs2572922	ENSG00000253196.1	RP11-706C16.7	4.63	9.2e-06	0.00712	0.4	0.38	Urinary tract infection frequency;	chr8:142790236	chr8:142763116~142766427:+
TGCT	cis	rs2717559	0.522	rs2949872	ENSG00000253196.1	RP11-706C16.7	4.63	9.2e-06	0.00712	0.4	0.38	Urinary tract infection frequency;	chr8:142791488	chr8:142763116~142766427:+
TGCT	cis	rs2717559	0.522	rs2572918	ENSG00000253196.1	RP11-706C16.7	4.63	9.2e-06	0.00712	0.4	0.38	Urinary tract infection frequency;	chr8:142794305	chr8:142763116~142766427:+
TGCT	cis	rs2717559	0.522	rs2585159	ENSG00000253196.1	RP11-706C16.7	4.63	9.2e-06	0.00712	0.4	0.38	Urinary tract infection frequency;	chr8:142794401	chr8:142763116~142766427:+
TGCT	cis	rs2717559	0.522	rs2585158	ENSG00000253196.1	RP11-706C16.7	4.63	9.2e-06	0.00712	0.4	0.38	Urinary tract infection frequency;	chr8:142794416	chr8:142763116~142766427:+
TGCT	cis	rs2177312	0.83	rs1523156	ENSG00000251129.1	RP11-734I18.1	-4.63	9.21e-06	0.00712	-0.44	-0.38	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31970819	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.83	rs1523141	ENSG00000251129.1	RP11-734I18.1	-4.63	9.21e-06	0.00712	-0.44	-0.38	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31974255	chr4:31997397~32155406:+
TGCT	cis	rs72772090	0.539	rs11739020	ENSG00000248734.2	CTD-2260A17.1	4.63	9.21e-06	0.00712	0.48	0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778134	chr5:96784777~96785999:+
TGCT	cis	rs853679	0.55	rs34477097	ENSG00000219392.1	RP1-265C24.5	-4.63	9.21e-06	0.00712	-0.5	-0.38	Depression;	chr6:28229408	chr6:28115628~28116551:+
TGCT	cis	rs7208859	0.673	rs450585	ENSG00000263531.1	RP13-753N3.1	4.63	9.21e-06	0.00713	0.67	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30863921~30864940:-
TGCT	cis	rs875971	0.545	rs11767262	ENSG00000237310.1	GS1-124K5.4	4.63	9.22e-06	0.00713	0.45	0.38	Aortic root size;	chr7:66302237	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs66594357	ENSG00000237310.1	GS1-124K5.4	4.63	9.22e-06	0.00713	0.45	0.38	Aortic root size;	chr7:66327797	chr7:66493706~66495474:+
TGCT	cis	rs9326248	0.817	rs1242127	ENSG00000280143.1	AP000892.6	-4.63	9.24e-06	0.00714	-0.48	-0.38	Blood protein levels;	chr11:117205848	chr11:117204967~117210292:+
TGCT	cis	rs2717559	0.522	rs35816096	ENSG00000253196.1	RP11-706C16.7	-4.63	9.24e-06	0.00714	-0.4	-0.38	Urinary tract infection frequency;	chr8:142803522	chr8:142763116~142766427:+
TGCT	cis	rs2739330	0.685	rs4822453	ENSG00000235689.1	AP000351.13	4.63	9.25e-06	0.00715	0.37	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:24006305~24008258:-
TGCT	cis	rs9462027	0.628	rs6921363	ENSG00000186328.4	RP11-140K17.2	4.63	9.26e-06	0.00715	0.36	0.38	Systemic lupus erythematosus;	chr6:34803043	chr6:34715613~34715940:+
TGCT	cis	rs524281	0.506	rs560393	ENSG00000255320.1	RP11-755F10.1	4.63	9.27e-06	0.00716	0.47	0.38	Electroencephalogram traits;	chr11:66238006	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.506	rs2298466	ENSG00000255320.1	RP11-755F10.1	4.63	9.27e-06	0.00716	0.47	0.38	Electroencephalogram traits;	chr11:66243809	chr11:66244840~66246239:-
TGCT	cis	rs1823913	0.637	rs11688994	ENSG00000227542.1	AC092614.2	4.63	9.27e-06	0.00716	0.41	0.38	Obesity-related traits;	chr2:191266242	chr2:191229165~191246172:-
TGCT	cis	rs17507216	0.667	rs13379724	ENSG00000278603.1	RP13-608F4.5	4.63	9.27e-06	0.00716	0.56	0.38	Excessive daytime sleepiness;	chr15:82619892	chr15:82472203~82472426:+
TGCT	cis	rs4835473	0.897	rs7657088	ENSG00000251600.4	RP11-673E1.1	-4.62	9.28e-06	0.00717	-0.4	-0.38	Immature fraction of reticulocytes;	chr4:143701877	chr4:143912331~143982454:+
TGCT	cis	rs875971	0.862	rs6944374	ENSG00000232559.3	GS1-124K5.12	-4.62	9.28e-06	0.00717	-0.35	-0.38	Aortic root size;	chr7:66221942	chr7:66554588~66576923:-
TGCT	cis	rs10875746	0.768	rs4760609	ENSG00000240399.1	RP1-228P16.1	4.62	9.28e-06	0.00717	0.43	0.38	Longevity (90 years and older);	chr12:48021974	chr12:48054813~48055591:-
TGCT	cis	rs4713118	0.662	rs9380046	ENSG00000219891.2	ZSCAN12P1	4.62	9.29e-06	0.00718	0.48	0.38	Parkinson's disease;	chr6:28062721	chr6:28091154~28093664:+
TGCT	cis	rs1075265	0.692	rs805358	ENSG00000233266.1	HMGB1P31	4.62	9.29e-06	0.00718	0.38	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53934885	chr2:54051334~54051760:+
TGCT	cis	rs6782228	0.675	rs9813845	ENSG00000242551.2	POU5F1P6	-4.62	9.3e-06	0.00718	-0.46	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128680780	chr3:128674735~128677005:-
TGCT	cis	rs10875746	0.768	rs4760676	ENSG00000240399.1	RP1-228P16.1	-4.62	9.3e-06	0.00719	-0.45	-0.38	Longevity (90 years and older);	chr12:48027880	chr12:48054813~48055591:-
TGCT	cis	rs599083	0.829	rs23691	ENSG00000212093.1	AP000807.1	-4.62	9.31e-06	0.00719	-0.38	-0.38	Bone mineral density (spine);	chr11:68411200	chr11:68506083~68506166:-
TGCT	cis	rs6604026	0.624	rs35311203	ENSG00000223787.2	RP4-593M8.1	4.62	9.31e-06	0.00719	0.55	0.38	Multiple sclerosis;	chr1:92712910	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.59	rs12749480	ENSG00000223787.2	RP4-593M8.1	4.62	9.31e-06	0.00719	0.55	0.38	Multiple sclerosis;	chr1:92714968	chr1:92580476~92580821:-
TGCT	cis	rs7829975	0.777	rs486781	ENSG00000173295.6	FAM86B3P	-4.62	9.34e-06	0.00721	-0.47	-0.38	Mood instability;	chr8:8782230	chr8:8228595~8244865:+
TGCT	cis	rs853679	0.628	rs9368560	ENSG00000219891.2	ZSCAN12P1	4.62	9.34e-06	0.00721	0.51	0.38	Depression;	chr6:28192182	chr6:28091154~28093664:+
TGCT	cis	rs10829156	0.679	rs4747352	ENSG00000240291.1	RP11-499P20.2	4.62	9.34e-06	0.00721	0.35	0.38	Sudden cardiac arrest;	chr10:18539734	chr10:18513115~18545651:-
TGCT	cis	rs67311347	0.956	rs7640228	ENSG00000223797.4	ENTPD3-AS1	-4.62	9.36e-06	0.00722	-0.4	-0.38	Renal cell carcinoma;	chr3:40474699	chr3:40313802~40453329:-
TGCT	cis	rs10829156	0.732	rs7075678	ENSG00000240291.1	RP11-499P20.2	4.62	9.36e-06	0.00722	0.35	0.38	Sudden cardiac arrest;	chr10:18585174	chr10:18513115~18545651:-
TGCT	cis	rs1134634	1	rs1134634	ENSG00000273133.1	RP11-799M12.2	4.62	9.36e-06	0.00722	0.47	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15601446	chr4:15563698~15564253:-
TGCT	cis	rs853679	0.599	rs156743	ENSG00000219891.2	ZSCAN12P1	4.62	9.37e-06	0.00723	0.63	0.38	Depression;	chr6:27999311	chr6:28091154~28093664:+
TGCT	cis	rs875971	0.825	rs1129531	ENSG00000237310.1	GS1-124K5.4	-4.62	9.37e-06	0.00723	-0.42	-0.38	Aortic root size;	chr7:66154117	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs73142233	ENSG00000237310.1	GS1-124K5.4	4.62	9.38e-06	0.00724	0.46	0.38	Aortic root size;	chr7:66221293	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs73142245	ENSG00000237310.1	GS1-124K5.4	4.62	9.38e-06	0.00724	0.46	0.38	Aortic root size;	chr7:66226662	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs73142265	ENSG00000237310.1	GS1-124K5.4	4.62	9.38e-06	0.00724	0.46	0.38	Aortic root size;	chr7:66234510	chr7:66493706~66495474:+
TGCT	cis	rs2764208	0.599	rs9368828	ENSG00000186328.4	RP11-140K17.2	-4.62	9.39e-06	0.00724	-0.37	-0.38	Systemic lupus erythematosus;	chr6:34693672	chr6:34715613~34715940:+
TGCT	cis	rs9755467	0.861	rs56046336	ENSG00000221413.1	AC023593.1	4.62	9.4e-06	0.00725	0.59	0.38	Educational attainment (years of education);	chr3:127447760	chr3:127664704~127664810:+
TGCT	cis	rs9326248	0.911	rs11216284	ENSG00000280143.1	AP000892.6	4.62	9.4e-06	0.00725	0.53	0.38	Blood protein levels;	chr11:117132344	chr11:117204967~117210292:+
TGCT	cis	rs2442825	0.693	rs2728949	ENSG00000206573.7	THUMPD3-AS1	4.62	9.41e-06	0.00725	0.35	0.38	Cerebrospinal fluid clusterin levels;	chr3:9364977	chr3:9349689~9398579:-
TGCT	cis	rs2442825	0.693	rs1054975	ENSG00000206573.7	THUMPD3-AS1	4.62	9.41e-06	0.00725	0.35	0.38	Cerebrospinal fluid clusterin levels;	chr3:9365152	chr3:9349689~9398579:-
TGCT	cis	rs2442825	0.693	rs2648535	ENSG00000206573.7	THUMPD3-AS1	4.62	9.41e-06	0.00725	0.35	0.38	Cerebrospinal fluid clusterin levels;	chr3:9366759	chr3:9349689~9398579:-
TGCT	cis	rs2442825	0.693	rs2648523	ENSG00000206573.7	THUMPD3-AS1	4.62	9.41e-06	0.00725	0.35	0.38	Cerebrospinal fluid clusterin levels;	chr3:9370654	chr3:9349689~9398579:-
TGCT	cis	rs875971	0.66	rs10263935	ENSG00000237310.1	GS1-124K5.4	4.62	9.43e-06	0.00727	0.43	0.38	Aortic root size;	chr7:66631041	chr7:66493706~66495474:+
TGCT	cis	rs2033711	0.87	rs11669741	ENSG00000268912.1	CTD-2619J13.17	4.62	9.44e-06	0.00727	0.34	0.38	Uric acid clearance;	chr19:58449114	chr19:58428632~58431148:-
TGCT	cis	rs7306456	0.623	rs10902513	ENSG00000256576.2	RP13-977J11.2	4.62	9.45e-06	0.00728	0.4	0.38	Anti-saccade response;	chr12:132208942	chr12:132186735~132189695:-
TGCT	cis	rs72819454	0.522	rs56149148	ENSG00000266852.2	MIR4482	4.62	9.45e-06	0.00728	0.66	0.38	Interleukin-9 levels;	chr10:103748413	chr10:104268336~104268405:-
TGCT	cis	rs507080	0.922	rs525485	ENSG00000255239.1	AP002954.6	4.62	9.45e-06	0.00728	0.49	0.38	Serum metabolite levels;	chr11:118685045	chr11:118688039~118690600:-
TGCT	cis	rs4660456	0.913	rs3767950	ENSG00000237899.1	RP4-739H11.3	-4.62	9.45e-06	0.00728	-0.51	-0.38	Platelet count;	chr1:40767541	chr1:40669089~40687588:-
TGCT	cis	rs4660456	0.913	rs3754179	ENSG00000237899.1	RP4-739H11.3	-4.62	9.45e-06	0.00728	-0.51	-0.38	Platelet count;	chr1:40768464	chr1:40669089~40687588:-
TGCT	cis	rs1555322	0.505	rs2254207	ENSG00000126005.14	MMP24-AS1	-4.62	9.47e-06	0.00729	-0.47	-0.38	Attention deficit hyperactivity disorder;	chr20:35269908	chr20:35216462~35278131:-
TGCT	cis	rs67311347	1	rs112619360	ENSG00000223797.4	ENTPD3-AS1	4.62	9.48e-06	0.00729	0.41	0.38	Renal cell carcinoma;	chr3:40391154	chr3:40313802~40453329:-
TGCT	cis	rs9400467	0.506	rs12215396	ENSG00000272356.1	RP5-1112D6.8	-4.62	9.48e-06	0.00729	-0.45	-0.38	Amino acid levels;Blood metabolite levels;	chr6:111251192	chr6:111309203~111313517:+
TGCT	cis	rs9309473	0.948	rs11884776	ENSG00000163016.8	ALMS1P	4.62	9.51e-06	0.00732	0.34	0.38	Metabolite levels;	chr2:73519796	chr2:73644919~73685576:+
TGCT	cis	rs7208859	0.673	rs216424	ENSG00000263531.1	RP13-753N3.1	4.62	9.52e-06	0.00733	0.68	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30863921~30864940:-
TGCT	cis	rs11671005	0.735	rs34188294	ENSG00000268912.1	CTD-2619J13.17	-4.62	9.53e-06	0.00733	-0.47	-0.38	Mean platelet volume;	chr19:58408190	chr19:58428632~58431148:-
TGCT	cis	rs1891275	0.515	rs4244930	ENSG00000228701.1	TNKS2-AS1	-4.62	9.54e-06	0.00733	-0.43	-0.38	Intelligence (multi-trait analysis);	chr10:91707092	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.515	rs11186666	ENSG00000228701.1	TNKS2-AS1	-4.62	9.54e-06	0.00733	-0.43	-0.38	Intelligence (multi-trait analysis);	chr10:91718162	chr10:91782839~91798291:-
TGCT	cis	rs34779708	0.931	rs11010130	ENSG00000230534.5	RP11-297A16.2	4.62	9.54e-06	0.00734	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35224379	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.897	rs11010131	ENSG00000230534.5	RP11-297A16.2	4.62	9.54e-06	0.00734	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35224388	chr10:35098006~35127020:-
TGCT	cis	rs17711722	0.74	rs7809991	ENSG00000272831.1	RP11-792A8.4	4.62	9.56e-06	0.00735	0.4	0.38	Calcium levels;	chr7:65941231	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.522	rs6960048	ENSG00000272831.1	RP11-792A8.4	4.62	9.56e-06	0.00735	0.4	0.38	Aortic root size;	chr7:65943052	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.522	rs10807697	ENSG00000272831.1	RP11-792A8.4	4.62	9.56e-06	0.00735	0.4	0.38	Aortic root size;	chr7:65951183	chr7:66739829~66740385:-
TGCT	cis	rs5758511	0.689	rs56906457	ENSG00000182057.4	OGFRP1	-4.62	9.57e-06	0.00735	-0.38	-0.38	Birth weight;	chr22:42232329	chr22:42269753~42275196:+
TGCT	cis	rs67311347	0.91	rs7617361	ENSG00000223797.4	ENTPD3-AS1	4.62	9.57e-06	0.00735	0.39	0.38	Renal cell carcinoma;	chr3:40331768	chr3:40313802~40453329:-
TGCT	cis	rs73198271	0.562	rs2048420	ENSG00000253893.2	FAM85B	4.62	9.58e-06	0.00736	0.63	0.38	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8810093	chr8:8167819~8226614:-
TGCT	cis	rs7714584	1	rs73268545	ENSG00000197083.10	ZNF300P1	4.62	9.58e-06	0.00736	1.08	0.38	Crohn's disease;	chr5:150955720	chr5:150930645~150946289:-
TGCT	cis	rs4835473	0.897	rs2590034	ENSG00000251600.4	RP11-673E1.1	4.62	9.59e-06	0.00737	0.39	0.38	Immature fraction of reticulocytes;	chr4:143926778	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs10027246	ENSG00000251600.4	RP11-673E1.1	-4.62	9.59e-06	0.00737	-0.39	-0.38	Immature fraction of reticulocytes;	chr4:143935069	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.808	rs11725413	ENSG00000251600.4	RP11-673E1.1	-4.62	9.59e-06	0.00737	-0.39	-0.38	Immature fraction of reticulocytes;	chr4:143943366	chr4:143912331~143982454:+
TGCT	cis	rs321358	0.895	rs7131434	ENSG00000271584.1	RP11-89C3.4	4.62	9.59e-06	0.00737	0.49	0.38	Body mass index;	chr11:111085693	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.895	rs73015175	ENSG00000271584.1	RP11-89C3.4	4.62	9.59e-06	0.00737	0.49	0.38	Body mass index;	chr11:111088593	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.895	rs17536143	ENSG00000271584.1	RP11-89C3.4	4.62	9.59e-06	0.00737	0.49	0.38	Body mass index;	chr11:111088619	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.895	rs17457658	ENSG00000271584.1	RP11-89C3.4	4.62	9.59e-06	0.00737	0.49	0.38	Body mass index;	chr11:111089448	chr11:111091932~111097357:-
TGCT	cis	rs321358	0.895	rs12419745	ENSG00000271584.1	RP11-89C3.4	4.62	9.59e-06	0.00737	0.49	0.38	Body mass index;	chr11:111090741	chr11:111091932~111097357:-
TGCT	cis	rs2709736	0.571	rs2539955	ENSG00000232790.2	LINC01162	4.62	9.59e-06	0.00737	0.31	0.38	Bipolar I disorder;	chr7:20879136	chr7:20835431~21023148:+
TGCT	cis	rs853679	0.55	rs1233699	ENSG00000187763.3	OR2B7P	4.62	9.6e-06	0.00737	0.38	0.38	Depression;	chr6:28201380	chr6:28046434~28047367:+
TGCT	cis	rs1707322	0.65	rs4553239	ENSG00000280836.1	AL355480.1	-4.62	9.61e-06	0.00738	-0.52	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr1:45581219~45581321:-
TGCT	cis	rs2188561	0.697	rs6947099	ENSG00000241764.3	AC002467.7	4.62	9.61e-06	0.00738	0.36	0.38	Alcohol consumption;	chr7:107720471	chr7:107742817~107744581:-
TGCT	cis	rs2188561	0.697	rs13242107	ENSG00000241764.3	AC002467.7	4.62	9.61e-06	0.00738	0.36	0.38	Alcohol consumption;	chr7:107734800	chr7:107742817~107744581:-
TGCT	cis	rs2188561	0.697	rs34986332	ENSG00000241764.3	AC002467.7	4.62	9.61e-06	0.00738	0.36	0.38	Alcohol consumption;	chr7:107739010	chr7:107742817~107744581:-
TGCT	cis	rs2188561	0.638	rs28690459	ENSG00000241764.3	AC002467.7	4.62	9.61e-06	0.00738	0.36	0.38	Alcohol consumption;	chr7:107740258	chr7:107742817~107744581:-
TGCT	cis	rs2188561	0.638	rs3735609	ENSG00000241764.3	AC002467.7	4.62	9.61e-06	0.00738	0.36	0.38	Alcohol consumption;	chr7:107743299	chr7:107742817~107744581:-
TGCT	cis	rs2188561	0.697	rs3735607	ENSG00000241764.3	AC002467.7	4.62	9.61e-06	0.00738	0.36	0.38	Alcohol consumption;	chr7:107743833	chr7:107742817~107744581:-
TGCT	cis	rs2188561	0.697	rs10808154	ENSG00000241764.3	AC002467.7	4.62	9.61e-06	0.00738	0.36	0.38	Alcohol consumption;	chr7:107745951	chr7:107742817~107744581:-
TGCT	cis	rs875971	0.862	rs6460307	ENSG00000237310.1	GS1-124K5.4	4.62	9.61e-06	0.00738	0.39	0.38	Aortic root size;	chr7:66595884	chr7:66493706~66495474:+
TGCT	cis	rs4853012	0.941	rs4852329	ENSG00000217702.2	RP11-287D1.4	4.62	9.62e-06	0.00738	0.57	0.38	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74130583~74135395:+
TGCT	cis	rs7923609	0.905	rs7092784	ENSG00000232075.1	MRPL35P2	-4.62	9.62e-06	0.00738	-0.37	-0.38	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63454989	chr10:63634317~63634827:-
TGCT	cis	rs4835473	0.897	rs1450246	ENSG00000251600.4	RP11-673E1.1	4.62	9.64e-06	0.00739	0.4	0.38	Immature fraction of reticulocytes;	chr4:143702954	chr4:143912331~143982454:+
TGCT	cis	rs8105895	0.799	rs6511327	ENSG00000269742.1	BNIP3P29	4.62	9.65e-06	0.0074	0.71	0.38	Body mass index (change over time);	chr19:22104097	chr19:22065828~22066398:-
TGCT	cis	rs34779708	0.931	rs4934709	ENSG00000230534.5	RP11-297A16.2	-4.61	9.66e-06	0.00741	-0.46	-0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35050396	chr10:35098006~35127020:-
TGCT	cis	rs13118159	0.55	rs4974614	ENSG00000254094.1	AC078852.1	-4.61	9.68e-06	0.00742	-0.48	-0.38	Longevity;	chr4:1379701	chr4:1356581~1358075:+
TGCT	cis	rs10875746	0.729	rs1990028	ENSG00000240399.1	RP1-228P16.1	-4.61	9.68e-06	0.00742	-0.44	-0.38	Longevity (90 years and older);	chr12:48014230	chr12:48054813~48055591:-
TGCT	cis	rs1497406	0.744	rs4537547	ENSG00000235084.3	CHCHD2P6	-4.61	9.68e-06	0.00743	-0.44	-0.38	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);	chr1:16184303	chr1:15604597~15605043:+
TGCT	cis	rs1075265	0.584	rs1559037	ENSG00000233266.1	HMGB1P31	4.61	9.68e-06	0.00743	0.42	0.38	Chronotype;Morning vs. evening chronotype;	chr2:54051448	chr2:54051334~54051760:+
TGCT	cis	rs1075265	0.584	rs7590846	ENSG00000233266.1	HMGB1P31	4.61	9.68e-06	0.00743	0.42	0.38	Chronotype;Morning vs. evening chronotype;	chr2:54051530	chr2:54051334~54051760:+
TGCT	cis	rs13108904	0.539	rs13141992	ENSG00000253399.1	AC078852.2	-4.61	9.69e-06	0.00743	-0.46	-0.38	Obesity-related traits;	chr4:1346977	chr4:1358479~1359461:+
TGCT	cis	rs13108904	0.539	rs13140926	ENSG00000253399.1	AC078852.2	-4.61	9.69e-06	0.00743	-0.46	-0.38	Obesity-related traits;	chr4:1347151	chr4:1358479~1359461:+
TGCT	cis	rs2015599	0.623	rs2288128	ENSG00000275476.1	RP11-996F15.4	4.61	9.7e-06	0.00744	0.41	0.38	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29277397~29277882:-
TGCT	cis	rs2015599	0.584	rs2288129	ENSG00000275476.1	RP11-996F15.4	4.61	9.7e-06	0.00744	0.41	0.38	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29277397~29277882:-
TGCT	cis	rs7201929	1	rs8061877	ENSG00000259982.1	CDC37P1	-4.61	9.72e-06	0.00745	-0.52	-0.38	QT interval;	chr16:28845498	chr16:28700294~28701540:-
TGCT	cis	rs10504229	0.871	rs60342323	ENSG00000253301.4	RP11-513O17.2	4.61	9.72e-06	0.00745	0.51	0.38	Developmental language disorder (linguistic errors);	chr8:57242340	chr8:57142689~57240298:+
TGCT	cis	rs911555	0.755	rs8014013	ENSG00000244691.1	RPL10AP1	4.61	9.73e-06	0.00745	0.52	0.38	Intelligence (multi-trait analysis);	chr14:103471035	chr14:103412119~103412761:-
TGCT	cis	rs72819454	0.522	rs56136023	ENSG00000266852.2	MIR4482	4.61	9.74e-06	0.00745	0.61	0.38	Interleukin-9 levels;	chr10:103722722	chr10:104268336~104268405:-
TGCT	cis	rs875971	0.862	rs2909688	ENSG00000232559.3	GS1-124K5.12	4.61	9.74e-06	0.00746	0.35	0.38	Aortic root size;	chr7:66376625	chr7:66554588~66576923:-
TGCT	cis	rs2919917	0.628	rs10113703	ENSG00000254352.1	RP11-578O24.2	4.61	9.76e-06	0.00747	0.46	0.38	Lymphocyte counts;	chr8:78688404	chr8:78723796~78724136:-
TGCT	cis	rs1618992	0.729	rs7231726	ENSG00000265994.1	RP11-510D21.1	4.61	9.78e-06	0.00748	0.39	0.38	Gut microbiome composition (summer and winter);	chr18:28590508	chr18:28785068~28789260:+
TGCT	cis	rs4237845	1	rs4237845	ENSG00000257159.1	RP11-58A17.3	-4.61	9.78e-06	0.00748	-0.45	-0.38	Intelligence (multi-trait analysis);	chr12:57908653	chr12:57967058~57968399:+
TGCT	cis	rs1891275	0.515	rs7092745	ENSG00000228701.1	TNKS2-AS1	-4.61	9.79e-06	0.00749	-0.43	-0.38	Intelligence (multi-trait analysis);	chr10:91724063	chr10:91782839~91798291:-
TGCT	cis	rs1891275	0.515	rs1418161	ENSG00000228701.1	TNKS2-AS1	-4.61	9.79e-06	0.00749	-0.43	-0.38	Intelligence (multi-trait analysis);	chr10:91724898	chr10:91782839~91798291:-
TGCT	cis	rs2439831	0.702	rs28699233	ENSG00000205771.5	CATSPER2P1	-4.61	9.79e-06	0.00749	-0.68	-0.38	Lung cancer in ever smokers;	chr15:43830668	chr15:43726918~43747094:-
TGCT	cis	rs17826219	0.636	rs12946563	ENSG00000280069.1	CTD-2349P21.3	-4.61	9.8e-06	0.00749	-0.54	-0.38	Body mass index;	chr17:30776148	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs8081299	ENSG00000280069.1	CTD-2349P21.3	-4.61	9.8e-06	0.00749	-0.54	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs8068645	ENSG00000280069.1	CTD-2349P21.3	-4.61	9.8e-06	0.00749	-0.54	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30738182~30740275:+
TGCT	cis	rs13118159	0.527	rs6599308	ENSG00000254094.1	AC078852.1	-4.61	9.8e-06	0.0075	-0.5	-0.38	Longevity;	chr4:1393992	chr4:1356581~1358075:+
TGCT	cis	rs507080	0.845	rs667982	ENSG00000255239.1	AP002954.6	4.61	9.83e-06	0.00751	0.5	0.38	Serum metabolite levels;	chr11:118692058	chr11:118688039~118690600:-
TGCT	cis	rs875971	0.767	rs12668005	ENSG00000237310.1	GS1-124K5.4	4.61	9.83e-06	0.00752	0.4	0.38	Aortic root size;	chr7:66444034	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs11765791	ENSG00000237310.1	GS1-124K5.4	4.61	9.83e-06	0.00752	0.4	0.38	Aortic root size;	chr7:66471587	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.522	rs7784623	ENSG00000272831.1	RP11-792A8.4	4.61	9.84e-06	0.00752	0.4	0.38	Aortic root size;	chr7:65930047	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.522	rs34973832	ENSG00000272831.1	RP11-792A8.4	4.61	9.84e-06	0.00752	0.4	0.38	Aortic root size;	chr7:65931217	chr7:66739829~66740385:-
TGCT	cis	rs10504229	1	rs59275611	ENSG00000253301.4	RP11-513O17.2	4.61	9.85e-06	0.00753	0.5	0.38	Developmental language disorder (linguistic errors);	chr8:57282632	chr8:57142689~57240298:+
TGCT	cis	rs3742264	0.961	rs11620307	ENSG00000235903.6	CPB2-AS1	-4.61	9.86e-06	0.00753	-0.47	-0.38	Blood protein levels;	chr13:46075586	chr13:46052806~46113332:+
TGCT	cis	rs3742264	1	rs9534311	ENSG00000235903.6	CPB2-AS1	-4.61	9.86e-06	0.00753	-0.47	-0.38	Blood protein levels;	chr13:46075986	chr13:46052806~46113332:+
TGCT	cis	rs4237845	0.967	rs4553410	ENSG00000257159.1	RP11-58A17.3	4.61	9.86e-06	0.00754	0.46	0.38	Intelligence (multi-trait analysis);	chr12:57907428	chr12:57967058~57968399:+
TGCT	cis	rs11671005	0.779	rs3794971	ENSG00000268912.1	CTD-2619J13.17	-4.61	9.87e-06	0.00754	-0.49	-0.38	Mean platelet volume;	chr19:58474499	chr19:58428632~58431148:-
TGCT	cis	rs8059260	0.668	rs74423828	ENSG00000274038.1	RP11-66H6.4	-4.61	9.89e-06	0.00755	-0.55	-0.38	Alcohol consumption over the past year;	chr16:10975574	chr16:11056556~11057034:+
TGCT	cis	rs4563143	0.577	rs73025093	ENSG00000267243.4	AC005307.3	-4.61	9.89e-06	0.00756	-0.47	-0.38	Methadone dose in opioid dependence;	chr19:28763711	chr19:28435388~28727777:-
TGCT	cis	rs67311347	1	rs9968170	ENSG00000223797.4	ENTPD3-AS1	-4.61	9.89e-06	0.00756	-0.41	-0.38	Renal cell carcinoma;	chr3:40452783	chr3:40313802~40453329:-
TGCT	cis	rs9322193	0.961	rs9027	ENSG00000216906.2	RP11-350J20.9	4.61	9.89e-06	0.00756	0.42	0.38	Lung cancer;	chr6:149594921	chr6:149904243~149906418:+
TGCT	cis	rs9322193	1	rs9322193	ENSG00000216906.2	RP11-350J20.9	4.61	9.89e-06	0.00756	0.42	0.38	Lung cancer;	chr6:149598007	chr6:149904243~149906418:+
TGCT	cis	rs7605378	1	rs769958	ENSG00000232732.8	AC073043.1	-4.61	9.89e-06	0.00756	-0.45	-0.38	Osteoporosis;	chr2:199831178	chr2:199867396~199911159:-
TGCT	cis	rs5742933	0.75	rs10197331	ENSG00000273240.1	RP11-455J20.3	4.61	9.9e-06	0.00756	0.36	0.38	Ferritin levels;	chr2:189768112	chr2:189763859~189764456:-
TGCT	cis	rs2288884	0.636	rs1560690	ENSG00000269235.1	ZNF350-AS1	4.61	9.92e-06	0.00757	0.46	0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52075094	chr19:51949134~51981367:+
TGCT	cis	rs1707322	0.721	rs12069121	ENSG00000280836.1	AL355480.1	-4.61	9.93e-06	0.00758	-0.51	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr1:45581219~45581321:-
TGCT	cis	rs7208859	0.673	rs1347360	ENSG00000266490.1	CTD-2349P21.9	4.61	9.94e-06	0.00759	0.42	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30792372~30792833:+
TGCT	cis	rs8072100	0.676	rs9905308	ENSG00000228782.6	CTD-2026D20.3	4.61	9.94e-06	0.00759	0.48	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47332020	chr17:47450568~47492492:-
TGCT	cis	rs6604026	0.624	rs111281067	ENSG00000223787.2	RP4-593M8.1	4.61	9.95e-06	0.0076	0.56	0.38	Multiple sclerosis;	chr1:92790096	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.589	rs34250288	ENSG00000223787.2	RP4-593M8.1	4.61	9.95e-06	0.0076	0.56	0.38	Multiple sclerosis;	chr1:92792062	chr1:92580476~92580821:-
TGCT	cis	rs73198271	0.562	rs17698256	ENSG00000253893.2	FAM85B	4.61	9.95e-06	0.0076	0.6	0.38	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802103	chr8:8167819~8226614:-
TGCT	cis	rs73198271	0.562	rs79296712	ENSG00000253893.2	FAM85B	4.61	9.95e-06	0.0076	0.6	0.38	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802468	chr8:8167819~8226614:-
TGCT	cis	rs651907	0.535	rs17347156	ENSG00000244119.1	PDCL3P4	4.61	9.97e-06	0.00761	0.28	0.38	Colorectal cancer;	chr3:101785830	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.535	rs58658478	ENSG00000244119.1	PDCL3P4	4.61	9.97e-06	0.00761	0.28	0.38	Colorectal cancer;	chr3:101792823	chr3:101712472~101713191:+
TGCT	cis	rs875971	0.522	rs1880556	ENSG00000237310.1	GS1-124K5.4	4.61	9.97e-06	0.00761	0.42	0.38	Aortic root size;	chr7:65967557	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.522	rs781144	ENSG00000237310.1	GS1-124K5.4	4.61	9.97e-06	0.00761	0.42	0.38	Aortic root size;	chr7:65975357	chr7:66493706~66495474:+
TGCT	cis	rs7829975	0.502	rs7820738	ENSG00000173295.6	FAM86B3P	-4.61	9.97e-06	0.00761	-0.44	-0.38	Mood instability;	chr8:8845097	chr8:8228595~8244865:+
TGCT	cis	rs875971	0.628	rs6974355	ENSG00000237310.1	GS1-124K5.4	4.61	9.98e-06	0.00762	0.44	0.38	Aortic root size;	chr7:66376994	chr7:66493706~66495474:+
TGCT	cis	rs867371	1	rs7181655	ENSG00000255769.6	GOLGA2P10	-4.61	9.98e-06	0.00762	-0.41	-0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82472993~82513950:-
TGCT	cis	rs867371	1	rs7180584	ENSG00000255769.6	GOLGA2P10	-4.61	9.98e-06	0.00762	-0.41	-0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82472993~82513950:-
TGCT	cis	rs867371	1	rs6495642	ENSG00000255769.6	GOLGA2P10	-4.61	9.98e-06	0.00762	-0.41	-0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82472993~82513950:-
TGCT	cis	rs867371	1	rs8037224	ENSG00000255769.6	GOLGA2P10	-4.61	9.98e-06	0.00762	-0.41	-0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82472993~82513950:-
TGCT	cis	rs10256972	0.552	rs2960830	ENSG00000226291.1	AC091729.8	-4.61	1e-05	0.00763	-0.4	-0.38	Endometriosis;Longevity;	chr7:1161005	chr7:1080863~1082178:+
TGCT	cis	rs10256972	0.552	rs2960831	ENSG00000226291.1	AC091729.8	-4.61	1e-05	0.00763	-0.4	-0.38	Endometriosis;Longevity;	chr7:1161556	chr7:1080863~1082178:+
TGCT	cis	rs4380275	0.782	rs11691064	ENSG00000223751.1	AC116609.2	4.61	1e-05	0.00763	0.4	0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:755718	chr2:742488~747767:+
TGCT	cis	rs4380275	0.809	rs6753699	ENSG00000223751.1	AC116609.2	4.61	1e-05	0.00763	0.4	0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:766081	chr2:742488~747767:+
TGCT	cis	rs4380275	0.782	rs60367761	ENSG00000223751.1	AC116609.2	4.61	1e-05	0.00763	0.4	0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:766414	chr2:742488~747767:+
TGCT	cis	rs8059260	0.668	rs7198089	ENSG00000274038.1	RP11-66H6.4	-4.61	1e-05	0.00764	-0.53	-0.38	Alcohol consumption over the past year;	chr16:11027199	chr16:11056556~11057034:+
TGCT	cis	rs2188561	0.697	rs66560125	ENSG00000241764.3	AC002467.7	4.61	1e-05	0.00764	0.36	0.38	Alcohol consumption;	chr7:107729589	chr7:107742817~107744581:-
TGCT	cis	rs73198271	0.562	rs17631052	ENSG00000253893.2	FAM85B	4.61	1e-05	0.00765	0.62	0.38	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8806277	chr8:8167819~8226614:-
TGCT	cis	rs7208859	0.673	rs1347359	ENSG00000263531.1	RP13-753N3.1	4.61	1e-05	0.00765	0.67	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.562	rs216408	ENSG00000263531.1	RP13-753N3.1	-4.61	1e-05	0.00765	-0.67	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30863921~30864940:-
TGCT	cis	rs889312	0.504	rs62355900	ENSG00000271828.1	CTD-2310F14.1	4.61	1e-05	0.00765	0.47	0.38	Breast cancer (early onset);Breast cancer;	chr5:56756868	chr5:56927874~56929573:+
TGCT	cis	rs4835473	0.932	rs11734290	ENSG00000251600.4	RP11-673E1.1	-4.61	1e-05	0.00765	-0.4	-0.38	Immature fraction of reticulocytes;	chr4:143823636	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs11734383	ENSG00000251600.4	RP11-673E1.1	-4.61	1e-05	0.00765	-0.4	-0.38	Immature fraction of reticulocytes;	chr4:143824093	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.868	rs11735295	ENSG00000251600.4	RP11-673E1.1	-4.61	1e-05	0.00765	-0.4	-0.38	Immature fraction of reticulocytes;	chr4:143824150	chr4:143912331~143982454:+
TGCT	cis	rs131777	0.526	rs86337	ENSG00000205559.3	CHKB-AS1	-4.61	1e-05	0.00765	-0.44	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50582239	chr22:50583026~50583877:+
TGCT	cis	rs2286503	0.78	rs12113458	ENSG00000234286.1	AC006026.13	4.61	1e-05	0.00765	0.46	0.38	Fibrinogen;	chr7:22816009	chr7:23680195~23680786:-
TGCT	cis	rs7819412	0.54	rs11777355	ENSG00000255310.2	AF131215.2	-4.61	1.01e-05	0.00766	-0.33	-0.38	Triglycerides;	chr8:11187180	chr8:11107788~11109726:-
TGCT	cis	rs6981523	0.5	rs4412337	ENSG00000255310.2	AF131215.2	4.61	1.01e-05	0.00766	0.33	0.38	Neuroticism;	chr8:11214511	chr8:11107788~11109726:-
TGCT	cis	rs9309473	0.748	rs2421552	ENSG00000163016.8	ALMS1P	4.61	1.01e-05	0.00766	0.35	0.38	Metabolite levels;	chr2:73531676	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.948	rs10199224	ENSG00000163016.8	ALMS1P	4.61	1.01e-05	0.00766	0.35	0.38	Metabolite levels;	chr2:73534319	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.948	rs13391552	ENSG00000163016.8	ALMS1P	4.61	1.01e-05	0.00766	0.35	0.38	Metabolite levels;	chr2:73591809	chr2:73644919~73685576:+
TGCT	cis	rs4268898	0.795	rs12470303	ENSG00000223754.1	AC008073.9	4.61	1.01e-05	0.00766	0.42	0.38	Asthma;	chr2:24397014	chr2:24199839~24201698:-
TGCT	cis	rs2439831	0.867	rs496584	ENSG00000205771.5	CATSPER2P1	-4.61	1.01e-05	0.00766	-0.62	-0.38	Lung cancer in ever smokers;	chr15:43539725	chr15:43726918~43747094:-
TGCT	cis	rs2581828	0.656	rs2564921	ENSG00000242142.1	SERBP1P3	-4.6	1.01e-05	0.00766	-0.34	-0.38	Crohn's disease;	chr3:53091569	chr3:53064283~53065091:-
TGCT	cis	rs7208859	0.623	rs7214570	ENSG00000280069.1	CTD-2349P21.3	-4.6	1.01e-05	0.00766	-0.5	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30738182~30740275:+
TGCT	cis	rs6600671	1	rs1986111	ENSG00000275131.1	CH17-472G23.4	-4.6	1.01e-05	0.00766	-0.24	-0.38	Hip geometry;	chr1:121462934	chr1:120489625~120579190:-
TGCT	cis	rs7246967	0.673	rs937078	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22628865	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs12978794	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22629332	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs4932782	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22629999	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs4933017	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22630178	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs66866654	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22630937	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs73028776	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22630938	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.551	rs56968124	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22631647	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.551	rs57775631	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22631659	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs2361021	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22633522	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs2361022	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22633731	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs2361023	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22634065	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs118059742	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22636644	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs56663398	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22637398	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs35731237	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22637708	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs12979173	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22637879	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs12979848	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22637996	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.551	rs6511367	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22638468	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs7250964	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22639692	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs7250343	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22640043	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs35007247	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22640121	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs34682021	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22643926	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.551	rs34897132	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22644089	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs60021625	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22646752	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs28787949	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22647554	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs67631531	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22647664	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.541	rs74169641	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22647774	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs56271774	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22648525	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs4414616	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22649609	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs4627499	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22649831	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs1835993	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22650235	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.551	rs1835994	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22650243	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs12984634	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22650942	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs12984903	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22651079	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs2099341	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22651558	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs2361245	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22651728	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs2082445	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22651785	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs7250285	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22654306	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs66620859	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22654428	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs3951783	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22656462	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs2885221	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22656585	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs2885222	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22657142	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs2915932	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22660899	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs11881740	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22661042	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs62118823	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22661264	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs73020703	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22661537	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.551	rs7248993	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22666350	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs12980342	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22666555	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs3951784	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22669124	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs3951785	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22669126	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.551	rs7250608	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22670254	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs7250620	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22670324	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs4244915	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22671336	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs8104052	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22675002	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.551	rs75360744	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22675154	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs12975767	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22680007	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.604	rs12975793	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22680042	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs57013651	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22680225	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs12979264	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22682332	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs34795935	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22682386	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs7252925	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22683006	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs7253063	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22683095	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs7254097	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22683098	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs3902164	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22683479	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs6511374	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22683568	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs8103875	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22684060	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs4933024	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22684261	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs8104327	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22684357	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs8104564	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22684405	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs8107724	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22684612	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs12973264	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22684947	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs597906	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22685403	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs35335083	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22686790	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs8102172	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22687217	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs8102006	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22687301	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs3853652	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22689111	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs3853653	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22689130	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs55932152	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22690626	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs4932784	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22691449	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs73022711	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22692602	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs73022713	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22693420	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs57027767	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22693733	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs62120313	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22694381	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs7248107	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22695727	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.551	rs8102812	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22696441	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs8106180	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22696558	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs8106215	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22696644	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs16994997	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22696808	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs34806882	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22697302	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs57736314	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22697470	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.604	rs58536761	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22697529	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs3853649	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22697658	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs3853650	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22697688	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs3844578	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22697808	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.551	rs3925175	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22698156	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.551	rs7257333	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22698347	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs34342502	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22698626	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs7245540	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22698702	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs7246424	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22699383	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs7249685	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22699577	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs7249003	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22705132	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs12971914	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22706096	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs8105441	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22708664	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.551	rs8112442	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22710567	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs73022763	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22711414	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs3931771	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22714018	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.604	rs8107322	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22714630	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs7247191	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22716783	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs34425596	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22716977	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs34376806	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22718059	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs16999571	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22721962	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs36029703	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22723386	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.551	rs7249473	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22723892	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.551	rs16998998	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22728314	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs9677019	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22729857	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs2112610	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22734049	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs34676724	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22735671	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs16999580	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22740685	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs55684269	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22741745	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs34003335	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22742800	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs12974988	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22743163	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs2194112	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22743387	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.551	rs34907478	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22746029	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs12985495	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22747576	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs8103430	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22748696	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs34174596	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22750717	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.551	rs8103204	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22753715	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs59621958	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22757857	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.604	rs58653025	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22758815	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs16999598	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22760323	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs34671960	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22765891	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs34726149	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22769309	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs12985825	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22770649	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs62120125	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22772297	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs2194113	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22775273	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs62120457	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22775717	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs55744741	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22777171	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs4933036	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22780267	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs35061555	ENSG00000269509.1	BNIP3P34	4.6	1.01e-05	0.00766	0.6	0.38	Bronchopulmonary dysplasia;	chr19:22780964	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs16999519	ENSG00000269509.1	BNIP3P34	-4.6	1.01e-05	0.00766	-0.6	-0.38	Bronchopulmonary dysplasia;	chr19:22631274	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs4933027	ENSG00000269509.1	BNIP3P34	-4.6	1.01e-05	0.00766	-0.6	-0.38	Bronchopulmonary dysplasia;	chr19:22721170	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.541	rs16999009	ENSG00000269509.1	BNIP3P34	-4.6	1.01e-05	0.00766	-0.6	-0.38	Bronchopulmonary dysplasia;	chr19:22726856	chr19:22773853~22774424:+
TGCT	cis	rs12022452	0.591	rs11208356	ENSG00000238287.1	RP11-656D10.3	-4.6	1.01e-05	0.00766	-0.49	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40541259	chr1:40493157~40508661:-
TGCT	cis	rs2742234	0.59	rs2742237	ENSG00000273008.1	RP11-351D16.3	-4.6	1.01e-05	0.00767	-0.51	-0.38	Hirschsprung disease;	chr10:43125875	chr10:43136824~43138334:-
TGCT	cis	rs1864400	0.696	rs2742239	ENSG00000273008.1	RP11-351D16.3	-4.6	1.01e-05	0.00767	-0.51	-0.38	Hirschsprung disease;	chr10:43126264	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.59	rs2075912	ENSG00000273008.1	RP11-351D16.3	-4.6	1.01e-05	0.00767	-0.51	-0.38	Hirschsprung disease;	chr10:43126769	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.578	rs2742241	ENSG00000273008.1	RP11-351D16.3	-4.6	1.01e-05	0.00767	-0.51	-0.38	Hirschsprung disease;	chr10:43129775	chr10:43136824~43138334:-
TGCT	cis	rs1864400	0.645	rs2249005	ENSG00000273008.1	RP11-351D16.3	-4.6	1.01e-05	0.00767	-0.51	-0.38	Hirschsprung disease;	chr10:43131832	chr10:43136824~43138334:-
TGCT	cis	rs853679	0.55	rs1225598	ENSG00000187763.3	OR2B7P	4.6	1.01e-05	0.00767	0.38	0.38	Depression;	chr6:28193021	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.55	rs1150689	ENSG00000187763.3	OR2B7P	4.6	1.01e-05	0.00767	0.38	0.38	Depression;	chr6:28197321	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.55	rs1225599	ENSG00000187763.3	OR2B7P	4.6	1.01e-05	0.00767	0.38	0.38	Depression;	chr6:28197412	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.574	rs1233705	ENSG00000187763.3	OR2B7P	4.6	1.01e-05	0.00767	0.38	0.38	Depression;	chr6:28198669	chr6:28046434~28047367:+
TGCT	cis	rs1010254	0.51	rs80091187	ENSG00000253921.1	CTB-113P19.3	-4.6	1.01e-05	0.00767	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152315294	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.51	rs1363419	ENSG00000253921.1	CTB-113P19.3	-4.6	1.01e-05	0.00767	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152316850	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.51	rs17446143	ENSG00000253921.1	CTB-113P19.3	-4.6	1.01e-05	0.00767	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152318089	chr5:151753992~151767247:+
TGCT	cis	rs1865760	0.928	rs9295673	ENSG00000217159.2	LARP1P1	-4.6	1.01e-05	0.00767	-0.45	-0.38	Height;	chr6:25911866	chr6:26164072~26164363:+
TGCT	cis	rs12439619	0.739	rs4778988	ENSG00000278603.1	RP13-608F4.5	4.6	1.02e-05	0.00769	0.5	0.38	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472203~82472426:+
TGCT	cis	rs786425	0.509	rs56176939	ENSG00000278112.1	RP11-972P1.11	4.6	1.02e-05	0.00769	0.43	0.38	Pubertal anthropometrics;	chr12:123700282	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.833	rs2222061	ENSG00000278112.1	RP11-972P1.11	4.6	1.02e-05	0.00769	0.43	0.38	Pubertal anthropometrics;	chr12:123710382	chr12:123519390~123519856:-
TGCT	cis	rs4835473	0.831	rs1579816	ENSG00000251600.4	RP11-673E1.1	4.6	1.02e-05	0.00769	0.4	0.38	Immature fraction of reticulocytes;	chr4:143866772	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs4240334	ENSG00000251600.4	RP11-673E1.1	4.6	1.02e-05	0.00769	0.4	0.38	Immature fraction of reticulocytes;	chr4:143871352	chr4:143912331~143982454:+
TGCT	cis	rs2136613	0.533	rs10761665	ENSG00000238280.1	RP11-436D10.3	-4.6	1.02e-05	0.00769	-0.43	-0.38	Selective IgA deficiency;	chr10:62848538	chr10:62793562~62805887:-
TGCT	cis	rs728616	0.764	rs61859016	ENSG00000230091.5	TMEM254-AS1	4.6	1.02e-05	0.0077	0.7	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80092744	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs61859022	ENSG00000230091.5	TMEM254-AS1	4.6	1.02e-05	0.0077	0.7	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80101043	chr10:80046860~80078912:-
TGCT	cis	rs1618992	0.729	rs1039557	ENSG00000265994.1	RP11-510D21.1	-4.6	1.02e-05	0.0077	-0.4	-0.38	Gut microbiome composition (summer and winter);	chr18:28616031	chr18:28785068~28789260:+
TGCT	cis	rs6600671	1	rs1832558	ENSG00000275131.1	CH17-472G23.4	-4.6	1.02e-05	0.0077	-0.24	-0.38	Hip geometry;	chr1:121435521	chr1:120489625~120579190:-
TGCT	cis	rs6600671	0.967	rs11249349	ENSG00000275131.1	CH17-472G23.4	-4.6	1.02e-05	0.0077	-0.24	-0.38	Hip geometry;	chr1:121437310	chr1:120489625~120579190:-
TGCT	cis	rs6600671	1	rs2185281	ENSG00000275131.1	CH17-472G23.4	-4.6	1.02e-05	0.0077	-0.24	-0.38	Hip geometry;	chr1:121438132	chr1:120489625~120579190:-
TGCT	cis	rs9650657	0.589	rs6985109	ENSG00000255310.2	AF131215.2	4.6	1.02e-05	0.0077	0.31	0.38	Neuroticism;	chr8:10904075	chr8:11107788~11109726:-
TGCT	cis	rs728616	0.717	rs111403425	ENSG00000230091.5	TMEM254-AS1	4.6	1.02e-05	0.00771	0.7	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80060786	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs78131725	ENSG00000230091.5	TMEM254-AS1	4.6	1.02e-05	0.00771	0.7	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80061163	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs12411407	ENSG00000230091.5	TMEM254-AS1	4.6	1.02e-05	0.00771	0.7	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80068475	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs61859008	ENSG00000230091.5	TMEM254-AS1	4.6	1.02e-05	0.00771	0.7	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80071955	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs56235549	ENSG00000230091.5	TMEM254-AS1	4.6	1.02e-05	0.00771	0.7	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80075192	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs17098720	ENSG00000230091.5	TMEM254-AS1	4.6	1.02e-05	0.00771	0.7	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80080480	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.717	rs12414332	ENSG00000230091.5	TMEM254-AS1	4.6	1.02e-05	0.00771	0.7	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80081199	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs57257258	ENSG00000230091.5	TMEM254-AS1	4.6	1.02e-05	0.00771	0.7	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80084264	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs17606361	ENSG00000230091.5	TMEM254-AS1	4.6	1.02e-05	0.00771	0.7	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80085655	chr10:80046860~80078912:-
TGCT	cis	rs728616	1	rs728616	ENSG00000230091.5	TMEM254-AS1	4.6	1.02e-05	0.00771	0.7	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80088158	chr10:80046860~80078912:-
TGCT	cis	rs728616	1	rs728615	ENSG00000230091.5	TMEM254-AS1	4.6	1.02e-05	0.00771	0.7	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80088333	chr10:80046860~80078912:-
TGCT	cis	rs875971	0.862	rs3893216	ENSG00000232559.3	GS1-124K5.12	-4.6	1.02e-05	0.00771	-0.35	-0.38	Aortic root size;	chr7:66325720	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs6958294	ENSG00000232559.3	GS1-124K5.12	-4.6	1.02e-05	0.00771	-0.35	-0.38	Aortic root size;	chr7:66329809	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs2088655	ENSG00000232559.3	GS1-124K5.12	-4.6	1.02e-05	0.00771	-0.35	-0.38	Aortic root size;	chr7:66330724	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.895	rs10447522	ENSG00000232559.3	GS1-124K5.12	-4.6	1.02e-05	0.00771	-0.35	-0.38	Aortic root size;	chr7:66331087	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs2088653	ENSG00000232559.3	GS1-124K5.12	-4.6	1.02e-05	0.00771	-0.35	-0.38	Aortic root size;	chr7:66343621	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs6460293	ENSG00000232559.3	GS1-124K5.12	-4.6	1.02e-05	0.00771	-0.35	-0.38	Aortic root size;	chr7:66345205	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs778736	ENSG00000232559.3	GS1-124K5.12	4.6	1.02e-05	0.00771	0.35	0.38	Aortic root size;	chr7:66348861	chr7:66554588~66576923:-
TGCT	cis	rs2117029	0.782	rs6580699	ENSG00000258017.1	RP11-386G11.10	4.6	1.02e-05	0.00772	0.45	0.38	Intelligence (multi-trait analysis);	chr12:49085029	chr12:49127782~49147869:+
TGCT	cis	rs1519814	0.668	rs7836786	ENSG00000254343.2	RP11-760H22.2	-4.6	1.02e-05	0.00772	-0.63	-0.38	Breast cancer;	chr8:119994587	chr8:120052180~120056201:+
TGCT	cis	rs2976388	0.692	rs2585175	ENSG00000253196.1	RP11-706C16.7	4.6	1.02e-05	0.00772	0.39	0.38	Urinary tract infection frequency;	chr8:142699871	chr8:142763116~142766427:+
TGCT	cis	rs875971	0.756	rs4718328	ENSG00000232559.3	GS1-124K5.12	-4.6	1.02e-05	0.00772	-0.36	-0.38	Aortic root size;	chr7:66228350	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs4718330	ENSG00000232559.3	GS1-124K5.12	-4.6	1.02e-05	0.00772	-0.36	-0.38	Aortic root size;	chr7:66250256	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs949930	ENSG00000232559.3	GS1-124K5.12	-4.6	1.02e-05	0.00772	-0.36	-0.38	Aortic root size;	chr7:66301835	chr7:66554588~66576923:-
TGCT	cis	rs10829156	0.57	rs7904365	ENSG00000240291.1	RP11-499P20.2	4.6	1.03e-05	0.00774	0.35	0.38	Sudden cardiac arrest;	chr10:18542375	chr10:18513115~18545651:-
TGCT	cis	rs1972460	0.506	rs62012050	ENSG00000278603.1	RP13-608F4.5	4.6	1.03e-05	0.00774	0.5	0.38	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472203~82472426:+
TGCT	cis	rs12439619	1	rs35152457	ENSG00000278603.1	RP13-608F4.5	4.6	1.03e-05	0.00774	0.5	0.38	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472203~82472426:+
TGCT	cis	rs3742264	0.961	rs9534308	ENSG00000235903.6	CPB2-AS1	-4.6	1.03e-05	0.00774	-0.45	-0.38	Blood protein levels;	chr13:46071726	chr13:46052806~46113332:+
TGCT	cis	rs3742264	1	rs1409434	ENSG00000235903.6	CPB2-AS1	-4.6	1.03e-05	0.00774	-0.45	-0.38	Blood protein levels;	chr13:46072309	chr13:46052806~46113332:+
TGCT	cis	rs3742264	0.961	rs9534309	ENSG00000235903.6	CPB2-AS1	-4.6	1.03e-05	0.00774	-0.45	-0.38	Blood protein levels;	chr13:46073402	chr13:46052806~46113332:+
TGCT	cis	rs3742264	1	rs3742264	ENSG00000235903.6	CPB2-AS1	-4.6	1.03e-05	0.00774	-0.45	-0.38	Blood protein levels;	chr13:46073959	chr13:46052806~46113332:+
TGCT	cis	rs3742264	0.961	rs1326400	ENSG00000235903.6	CPB2-AS1	-4.6	1.03e-05	0.00774	-0.45	-0.38	Blood protein levels;	chr13:46074388	chr13:46052806~46113332:+
TGCT	cis	rs3742264	1	rs1326399	ENSG00000235903.6	CPB2-AS1	-4.6	1.03e-05	0.00774	-0.45	-0.38	Blood protein levels;	chr13:46074472	chr13:46052806~46113332:+
TGCT	cis	rs3742264	1	rs9534310	ENSG00000235903.6	CPB2-AS1	-4.6	1.03e-05	0.00774	-0.45	-0.38	Blood protein levels;	chr13:46074840	chr13:46052806~46113332:+
TGCT	cis	rs12745968	0.589	rs4484938	ENSG00000223787.2	RP4-593M8.1	-4.6	1.03e-05	0.00776	-0.49	-0.38	Bipolar disorder and schizophrenia;	chr1:92490264	chr1:92580476~92580821:-
TGCT	cis	rs13118159	0.509	rs4974554	ENSG00000254094.1	AC078852.1	-4.6	1.03e-05	0.00776	-0.46	-0.38	Longevity;	chr4:1363179	chr4:1356581~1358075:+
TGCT	cis	rs13118159	0.509	rs4974556	ENSG00000254094.1	AC078852.1	-4.6	1.03e-05	0.00776	-0.46	-0.38	Longevity;	chr4:1364353	chr4:1356581~1358075:+
TGCT	cis	rs13118159	0.55	rs4974611	ENSG00000254094.1	AC078852.1	-4.6	1.03e-05	0.00776	-0.46	-0.38	Longevity;	chr4:1364661	chr4:1356581~1358075:+
TGCT	cis	rs11662586	0.517	rs7230837	ENSG00000261126.6	RP11-795F19.1	4.6	1.03e-05	0.00776	0.32	0.38	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr18:79935384	chr18:80046900~80095482:+
TGCT	cis	rs131777	0.532	rs131747	ENSG00000205559.3	CHKB-AS1	-4.6	1.03e-05	0.00776	-0.42	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586645	chr22:50583026~50583877:+
TGCT	cis	rs7829975	0.871	rs572307	ENSG00000173295.6	FAM86B3P	-4.6	1.03e-05	0.00777	-0.47	-0.38	Mood instability;	chr8:8721301	chr8:8228595~8244865:+
TGCT	cis	rs904251	0.965	rs1317563	ENSG00000279942.1	RP1-153P14.7	-4.6	1.03e-05	0.00777	-0.43	-0.38	Cognitive performance;	chr6:37484078	chr6:37567716~37571460:+
TGCT	cis	rs875971	0.862	rs10282433	ENSG00000237310.1	GS1-124K5.4	-4.6	1.03e-05	0.00777	-0.42	-0.38	Aortic root size;	chr7:66256452	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs10276077	ENSG00000237310.1	GS1-124K5.4	-4.6	1.03e-05	0.00777	-0.42	-0.38	Aortic root size;	chr7:66263424	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.825	rs4587224	ENSG00000237310.1	GS1-124K5.4	-4.6	1.03e-05	0.00777	-0.42	-0.38	Aortic root size;	chr7:66271195	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.792	rs6971752	ENSG00000237310.1	GS1-124K5.4	-4.6	1.03e-05	0.00777	-0.42	-0.38	Aortic root size;	chr7:66272999	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs10950033	ENSG00000237310.1	GS1-124K5.4	-4.6	1.03e-05	0.00777	-0.42	-0.38	Aortic root size;	chr7:66274686	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs11760844	ENSG00000237310.1	GS1-124K5.4	-4.6	1.03e-05	0.00777	-0.42	-0.38	Aortic root size;	chr7:66274896	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs4149461	ENSG00000237310.1	GS1-124K5.4	-4.6	1.03e-05	0.00777	-0.42	-0.38	Aortic root size;	chr7:66279745	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs12537823	ENSG00000237310.1	GS1-124K5.4	4.6	1.03e-05	0.00777	0.42	0.38	Aortic root size;	chr7:66255897	chr7:66493706~66495474:+
TGCT	cis	rs3096299	0.9	rs4785663	ENSG00000274627.1	RP11-104N10.2	4.6	1.03e-05	0.00777	0.4	0.38	Multiple myeloma (IgH translocation);	chr16:89368480	chr16:89516797~89522217:+
TGCT	cis	rs8072100	0.869	rs4439799	ENSG00000228782.6	CTD-2026D20.3	4.6	1.03e-05	0.00778	0.44	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47704233	chr17:47450568~47492492:-
TGCT	cis	rs6604026	0.557	rs72724515	ENSG00000223787.2	RP4-593M8.1	4.6	1.03e-05	0.00778	0.55	0.38	Multiple sclerosis;	chr1:92585519	chr1:92580476~92580821:-
TGCT	cis	rs1075265	0.584	rs11896781	ENSG00000233266.1	HMGB1P31	4.6	1.03e-05	0.00779	0.43	0.38	Chronotype;Morning vs. evening chronotype;	chr2:54096987	chr2:54051334~54051760:+
TGCT	cis	rs1075265	0.547	rs10865279	ENSG00000233266.1	HMGB1P31	4.6	1.03e-05	0.00779	0.43	0.38	Chronotype;Morning vs. evening chronotype;	chr2:54097564	chr2:54051334~54051760:+
TGCT	cis	rs2333021	0.649	rs12884588	ENSG00000259015.1	RP11-109N23.6	4.6	1.04e-05	0.00779	0.22	0.38	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73007111	chr14:72960595~72961993:+
TGCT	cis	rs875971	0.862	rs2909688	ENSG00000237310.1	GS1-124K5.4	4.6	1.04e-05	0.00779	0.41	0.38	Aortic root size;	chr7:66376625	chr7:66493706~66495474:+
TGCT	cis	rs3096299	0.967	rs2965935	ENSG00000274627.1	RP11-104N10.2	-4.6	1.04e-05	0.0078	-0.39	-0.38	Multiple myeloma (IgH translocation);	chr16:89414866	chr16:89516797~89522217:+
TGCT	cis	rs7208859	0.623	rs1054397	ENSG00000280069.1	CTD-2349P21.3	-4.6	1.04e-05	0.0078	-0.53	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30738182~30740275:+
TGCT	cis	rs10170266	1	rs10170266	ENSG00000279220.1	GPR1-AS	-4.6	1.04e-05	0.0078	-0.32	-0.38	Reticulocyte fraction of red cells;	chr2:206080351	chr2:206203376~206266243:+
TGCT	cis	rs2976388	0.647	rs2585174	ENSG00000253196.1	RP11-706C16.7	4.6	1.04e-05	0.0078	0.38	0.38	Urinary tract infection frequency;	chr8:142700626	chr8:142763116~142766427:+
TGCT	cis	rs13118159	0.509	rs7688922	ENSG00000254094.1	AC078852.1	-4.6	1.04e-05	0.0078	-0.46	-0.38	Longevity;	chr4:1367223	chr4:1356581~1358075:+
TGCT	cis	rs13118159	0.55	rs4974612	ENSG00000254094.1	AC078852.1	-4.6	1.04e-05	0.0078	-0.46	-0.38	Longevity;	chr4:1370755	chr4:1356581~1358075:+
TGCT	cis	rs11673344	0.864	rs8110696	ENSG00000226686.6	LINC01535	4.6	1.04e-05	0.00781	0.45	0.38	Obesity-related traits;	chr19:37009449	chr19:37251912~37265535:+
TGCT	cis	rs73198271	0.562	rs35432123	ENSG00000253893.2	FAM85B	4.6	1.04e-05	0.00781	0.62	0.38	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8813508	chr8:8167819~8226614:-
TGCT	cis	rs73198271	0.531	rs112930476	ENSG00000253893.2	FAM85B	4.6	1.04e-05	0.00781	0.62	0.38	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8814041	chr8:8167819~8226614:-
TGCT	cis	rs9322193	0.962	rs3763162	ENSG00000216906.2	RP11-350J20.9	-4.6	1.04e-05	0.00781	-0.43	-0.38	Lung cancer;	chr6:149819674	chr6:149904243~149906418:+
TGCT	cis	rs875971	0.66	rs2013222	ENSG00000237310.1	GS1-124K5.4	-4.6	1.04e-05	0.00782	-0.43	-0.38	Aortic root size;	chr7:66570949	chr7:66493706~66495474:+
TGCT	cis	rs9462027	0.607	rs205259	ENSG00000186328.4	RP11-140K17.2	4.6	1.04e-05	0.00782	0.36	0.38	Systemic lupus erythematosus;	chr6:34596289	chr6:34715613~34715940:+
TGCT	cis	rs7688540	0.511	rs10003260	ENSG00000275426.1	CH17-262A2.1	4.6	1.04e-05	0.00783	0.78	0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:191053	chr4:149738~150317:+
TGCT	cis	rs10504229	0.639	rs35527749	ENSG00000253301.4	RP11-513O17.2	4.6	1.04e-05	0.00783	0.6	0.38	Developmental language disorder (linguistic errors);	chr8:57215518	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs79262965	ENSG00000253301.4	RP11-513O17.2	4.6	1.04e-05	0.00783	0.6	0.38	Developmental language disorder (linguistic errors);	chr8:57217267	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs11774645	ENSG00000253301.4	RP11-513O17.2	4.6	1.04e-05	0.00783	0.6	0.38	Developmental language disorder (linguistic errors);	chr8:57220362	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs11774697	ENSG00000253301.4	RP11-513O17.2	4.6	1.04e-05	0.00783	0.6	0.38	Developmental language disorder (linguistic errors);	chr8:57220560	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs11775568	ENSG00000253301.4	RP11-513O17.2	4.6	1.04e-05	0.00783	0.6	0.38	Developmental language disorder (linguistic errors);	chr8:57221203	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs72650847	ENSG00000253301.4	RP11-513O17.2	4.6	1.04e-05	0.00783	0.6	0.38	Developmental language disorder (linguistic errors);	chr8:57224266	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs59528137	ENSG00000253301.4	RP11-513O17.2	4.6	1.04e-05	0.00783	0.6	0.38	Developmental language disorder (linguistic errors);	chr8:57226006	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs11774847	ENSG00000253301.4	RP11-513O17.2	4.6	1.04e-05	0.00783	0.6	0.38	Developmental language disorder (linguistic errors);	chr8:57228216	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.639	rs2291764	ENSG00000253301.4	RP11-513O17.2	4.6	1.04e-05	0.00783	0.6	0.38	Developmental language disorder (linguistic errors);	chr8:57230384	chr8:57142689~57240298:+
TGCT	cis	rs2136613	0.533	rs1412554	ENSG00000238280.1	RP11-436D10.3	4.6	1.05e-05	0.00785	0.43	0.38	Selective IgA deficiency;	chr10:62850180	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs10761668	ENSG00000238280.1	RP11-436D10.3	-4.6	1.05e-05	0.00785	-0.43	-0.38	Selective IgA deficiency;	chr10:62849983	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs10740090	ENSG00000238280.1	RP11-436D10.3	-4.6	1.05e-05	0.00785	-0.43	-0.38	Selective IgA deficiency;	chr10:62850027	chr10:62793562~62805887:-
TGCT	cis	rs6604026	0.555	rs34812295	ENSG00000223787.2	RP4-593M8.1	4.6	1.05e-05	0.00785	0.55	0.38	Multiple sclerosis;	chr1:92606712	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.555	rs11805007	ENSG00000223787.2	RP4-593M8.1	4.6	1.05e-05	0.00785	0.55	0.38	Multiple sclerosis;	chr1:92616633	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.555	rs56044027	ENSG00000223787.2	RP4-593M8.1	4.6	1.05e-05	0.00785	0.55	0.38	Multiple sclerosis;	chr1:92617137	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.555	rs3790450	ENSG00000223787.2	RP4-593M8.1	4.6	1.05e-05	0.00785	0.55	0.38	Multiple sclerosis;	chr1:92625508	chr1:92580476~92580821:-
TGCT	cis	rs4238585	0.947	rs9935994	ENSG00000261195.1	CTD-2380F24.1	4.6	1.05e-05	0.00785	0.57	0.38	Body mass index;	chr16:20244274	chr16:19761172~19766099:-
TGCT	cis	rs72819454	0.522	rs7098795	ENSG00000266852.2	MIR4482	4.6	1.05e-05	0.00786	0.67	0.38	Interleukin-9 levels;	chr10:103750028	chr10:104268336~104268405:-
TGCT	cis	rs72819454	0.522	rs17812914	ENSG00000266852.2	MIR4482	4.6	1.05e-05	0.00786	0.67	0.38	Interleukin-9 levels;	chr10:103750487	chr10:104268336~104268405:-
TGCT	cis	rs72819454	0.522	rs56270609	ENSG00000266852.2	MIR4482	4.6	1.05e-05	0.00786	0.67	0.38	Interleukin-9 levels;	chr10:103754270	chr10:104268336~104268405:-
TGCT	cis	rs72819454	0.522	rs11814652	ENSG00000266852.2	MIR4482	4.6	1.05e-05	0.00786	0.67	0.38	Interleukin-9 levels;	chr10:103754653	chr10:104268336~104268405:-
TGCT	cis	rs1010254	0.51	rs1035401	ENSG00000253921.1	CTB-113P19.3	-4.6	1.05e-05	0.00786	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152330117	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.51	rs2112538	ENSG00000253921.1	CTB-113P19.3	-4.6	1.05e-05	0.00786	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152331831	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.51	rs17113105	ENSG00000253921.1	CTB-113P19.3	-4.6	1.05e-05	0.00786	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152332726	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.51	rs2348648	ENSG00000253921.1	CTB-113P19.3	-4.6	1.05e-05	0.00786	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152335009	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.51	rs72808305	ENSG00000253921.1	CTB-113P19.3	-4.6	1.05e-05	0.00786	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152339960	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.559	rs72808307	ENSG00000253921.1	CTB-113P19.3	-4.6	1.05e-05	0.00786	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152349046	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.559	rs114133296	ENSG00000253921.1	CTB-113P19.3	-4.6	1.05e-05	0.00786	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152350694	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.559	rs114626875	ENSG00000253921.1	CTB-113P19.3	-4.6	1.05e-05	0.00786	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152361378	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.559	rs55920366	ENSG00000253921.1	CTB-113P19.3	-4.6	1.05e-05	0.00786	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152361476	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.559	rs72808322	ENSG00000253921.1	CTB-113P19.3	-4.6	1.05e-05	0.00786	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152363175	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.559	rs72808324	ENSG00000253921.1	CTB-113P19.3	-4.6	1.05e-05	0.00786	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152363434	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.559	rs114309942	ENSG00000253921.1	CTB-113P19.3	-4.6	1.05e-05	0.00786	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152364354	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.559	rs1592896	ENSG00000253921.1	CTB-113P19.3	-4.6	1.05e-05	0.00786	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152366524	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.559	rs72808328	ENSG00000253921.1	CTB-113P19.3	-4.6	1.05e-05	0.00786	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152366749	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.559	rs72808330	ENSG00000253921.1	CTB-113P19.3	-4.6	1.05e-05	0.00786	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152367008	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.559	rs991637	ENSG00000253921.1	CTB-113P19.3	-4.6	1.05e-05	0.00786	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152369247	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.559	rs991635	ENSG00000253921.1	CTB-113P19.3	-4.6	1.05e-05	0.00786	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152369360	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.559	rs115672114	ENSG00000253921.1	CTB-113P19.3	-4.6	1.05e-05	0.00786	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152370213	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.559	rs56261934	ENSG00000253921.1	CTB-113P19.3	-4.6	1.05e-05	0.00786	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152370870	chr5:151753992~151767247:+
TGCT	cis	rs875971	0.862	rs1875057	ENSG00000232559.3	GS1-124K5.12	-4.6	1.05e-05	0.00786	-0.36	-0.38	Aortic root size;	chr7:66266868	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs6960446	ENSG00000232559.3	GS1-124K5.12	-4.6	1.05e-05	0.00786	-0.36	-0.38	Aortic root size;	chr7:66268272	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.789	rs10260426	ENSG00000232559.3	GS1-124K5.12	-4.6	1.05e-05	0.00786	-0.36	-0.38	Aortic root size;	chr7:66271055	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs7796162	ENSG00000232559.3	GS1-124K5.12	-4.6	1.05e-05	0.00786	-0.36	-0.38	Aortic root size;	chr7:66280771	chr7:66554588~66576923:-
TGCT	cis	rs67311347	1	rs1119179	ENSG00000223797.4	ENTPD3-AS1	-4.6	1.05e-05	0.00786	-0.4	-0.38	Renal cell carcinoma;	chr3:40383438	chr3:40313802~40453329:-
TGCT	cis	rs9880211	0.528	rs75685279	ENSG00000239213.4	NCK1-AS1	4.6	1.05e-05	0.00786	0.41	0.38	Height;Body mass index;	chr3:136715991	chr3:136841726~136862054:-
TGCT	cis	rs7567389	0.704	rs4662714	ENSG00000236682.1	AC068282.3	4.59	1.05e-05	0.00787	0.5	0.38	Self-rated health;	chr2:127237637	chr2:127389130~127400580:+
TGCT	cis	rs62388641	0.547	rs4513844	ENSG00000272279.1	RP11-157J24.2	-4.59	1.05e-05	0.00787	-0.39	-0.38	Daytime sleep phenotypes;	chr6:1551747	chr6:1528364~1528911:-
TGCT	cis	rs1865760	0.929	rs9358896	ENSG00000217159.2	LARP1P1	-4.59	1.05e-05	0.00787	-0.44	-0.38	Height;	chr6:25942969	chr6:26164072~26164363:+
TGCT	cis	rs2717559	0.522	rs60714144	ENSG00000253196.1	RP11-706C16.7	4.59	1.05e-05	0.00787	0.4	0.38	Urinary tract infection frequency;	chr8:142785741	chr8:142763116~142766427:+
TGCT	cis	rs9425766	0.692	rs4652294	ENSG00000227373.4	RP11-160H22.5	4.59	1.05e-05	0.00788	0.4	0.38	Life satisfaction;	chr1:174272027	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.679	rs6670617	ENSG00000227373.4	RP11-160H22.5	4.59	1.05e-05	0.00788	0.4	0.38	Life satisfaction;	chr1:174277574	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.679	rs4650990	ENSG00000227373.4	RP11-160H22.5	4.59	1.05e-05	0.00788	0.4	0.38	Life satisfaction;	chr1:174289943	chr1:174115300~174160004:-
TGCT	cis	rs4660456	0.913	rs2223486	ENSG00000237899.1	RP4-739H11.3	-4.59	1.05e-05	0.00788	-0.5	-0.38	Platelet count;	chr1:40693557	chr1:40669089~40687588:-
TGCT	cis	rs796364	1	rs11895190	ENSG00000232732.8	AC073043.1	4.59	1.05e-05	0.00788	0.55	0.38	Schizophrenia;	chr2:199973890	chr2:199867396~199911159:-
TGCT	cis	rs7208859	0.673	rs9907197	ENSG00000263531.1	RP13-753N3.1	4.59	1.05e-05	0.00789	0.68	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs9915963	ENSG00000263531.1	RP13-753N3.1	4.59	1.05e-05	0.00789	0.68	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30863921~30864940:-
TGCT	cis	rs904251	0.507	rs11756941	ENSG00000279942.1	RP1-153P14.7	-4.59	1.05e-05	0.00789	-0.49	-0.38	Cognitive performance;	chr6:37448443	chr6:37567716~37571460:+
TGCT	cis	rs3096299	0.9	rs3114867	ENSG00000274627.1	RP11-104N10.2	4.59	1.05e-05	0.00789	0.39	0.38	Multiple myeloma (IgH translocation);	chr16:89362559	chr16:89516797~89522217:+
TGCT	cis	rs11671005	0.737	rs11673101	ENSG00000232098.3	CTD-2619J13.14	-4.59	1.05e-05	0.0079	-0.49	-0.38	Mean platelet volume;	chr19:58483686	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.696	rs73066211	ENSG00000232098.3	CTD-2619J13.14	-4.59	1.05e-05	0.0079	-0.49	-0.38	Mean platelet volume;	chr19:58485712	chr19:58404238~58408484:-
TGCT	cis	rs13118159	0.573	rs7664763	ENSG00000254094.1	AC078852.1	-4.59	1.05e-05	0.0079	-0.46	-0.38	Longevity;	chr4:1358517	chr4:1356581~1358075:+
TGCT	cis	rs11671005	0.779	rs3794970	ENSG00000232098.3	CTD-2619J13.14	4.59	1.06e-05	0.00791	0.45	0.38	Mean platelet volume;	chr19:58474893	chr19:58404238~58408484:-
TGCT	cis	rs9322193	0.962	rs9688750	ENSG00000216906.2	RP11-350J20.9	4.59	1.06e-05	0.00793	0.42	0.38	Lung cancer;	chr6:149657633	chr6:149904243~149906418:+
TGCT	cis	rs884366	0.964	rs4946953	ENSG00000203799.9	CCDC162P	-4.59	1.06e-05	0.00793	-0.4	-0.38	HDL cholesterol;HDL cholesterol levels;	chr6:109262428	chr6:109285485~109355063:+
TGCT	cis	rs11118620	0.535	rs1389750	ENSG00000238078.1	LINC01352	4.59	1.06e-05	0.00793	0.35	0.38	Heart failure;	chr1:220866829	chr1:220829255~220832429:+
TGCT	cis	rs4925386	1	rs1889201	ENSG00000273619.1	RP5-908M14.9	4.59	1.06e-05	0.00794	0.42	0.38	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62348019	chr20:62386303~62386970:-
TGCT	cis	rs12439619	0.693	rs28689861	ENSG00000255769.6	GOLGA2P10	-4.59	1.06e-05	0.00795	-0.44	-0.38	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472993~82513950:-
TGCT	cis	rs12143943	0.966	rs3795567	ENSG00000176754.11	LINC00303	4.59	1.06e-05	0.00795	0.35	0.38	Cognitive performance;	chr1:204616610	chr1:204032447~204041265:-
TGCT	cis	rs2117029	0.782	rs6580698	ENSG00000258017.1	RP11-386G11.10	-4.59	1.06e-05	0.00795	-0.46	-0.38	Intelligence (multi-trait analysis);	chr12:49084875	chr12:49127782~49147869:+
TGCT	cis	rs9400467	0.506	rs77097930	ENSG00000272356.1	RP5-1112D6.8	-4.59	1.06e-05	0.00795	-0.44	-0.38	Amino acid levels;Blood metabolite levels;	chr6:111294276	chr6:111309203~111313517:+
TGCT	cis	rs10246939	0.505	rs13236432	ENSG00000228775.6	WEE2-AS1	4.59	1.06e-05	0.00796	0.35	0.38	Bitter taste perception;	chr7:141850980	chr7:141704338~141738346:-
TGCT	cis	rs10246939	0.505	rs10952508	ENSG00000228775.6	WEE2-AS1	4.59	1.06e-05	0.00796	0.35	0.38	Bitter taste perception;	chr7:141879415	chr7:141704338~141738346:-
TGCT	cis	rs10246939	0.543	rs12538701	ENSG00000228775.6	WEE2-AS1	4.59	1.06e-05	0.00796	0.35	0.38	Bitter taste perception;	chr7:141893634	chr7:141704338~141738346:-
TGCT	cis	rs2136613	0.533	rs7093716	ENSG00000238280.1	RP11-436D10.3	-4.59	1.06e-05	0.00796	-0.43	-0.38	Selective IgA deficiency;	chr10:62847717	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs7097383	ENSG00000238280.1	RP11-436D10.3	-4.59	1.06e-05	0.00796	-0.43	-0.38	Selective IgA deficiency;	chr10:62848279	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs10740088	ENSG00000238280.1	RP11-436D10.3	-4.59	1.06e-05	0.00796	-0.43	-0.38	Selective IgA deficiency;	chr10:62849651	chr10:62793562~62805887:-
TGCT	cis	rs2136613	0.533	rs10740089	ENSG00000238280.1	RP11-436D10.3	-4.59	1.06e-05	0.00796	-0.43	-0.38	Selective IgA deficiency;	chr10:62849674	chr10:62793562~62805887:-
TGCT	cis	rs12497850	0.644	rs11928552	ENSG00000226913.1	BSN-AS2	-4.59	1.07e-05	0.00798	-0.31	-0.38	Parkinson's disease;	chr3:48702450	chr3:49549306~49554366:-
TGCT	cis	rs17711722	0.523	rs313812	ENSG00000226824.5	RP4-756H11.3	4.59	1.07e-05	0.008	0.41	0.38	Calcium levels;	chr7:66040056	chr7:66654538~66669855:+
TGCT	cis	rs786425	0.966	rs4040225	ENSG00000278112.1	RP11-972P1.11	4.59	1.07e-05	0.008	0.43	0.38	Pubertal anthropometrics;	chr12:123612126	chr12:123519390~123519856:-
TGCT	cis	rs875971	0.83	rs4718358	ENSG00000237310.1	GS1-124K5.4	4.59	1.07e-05	0.008	0.42	0.38	Aortic root size;	chr7:66508681	chr7:66493706~66495474:+
TGCT	cis	rs1010254	0.51	rs72808338	ENSG00000213433.5	RPLP1P6	-4.59	1.07e-05	0.00801	-0.49	-0.38	Optic nerve measurement (cup area);	chr5:152375900	chr5:151765859~151766378:-
TGCT	cis	rs7829975	0.582	rs6982832	ENSG00000173295.6	FAM86B3P	-4.59	1.07e-05	0.00802	-0.44	-0.38	Mood instability;	chr8:8934707	chr8:8228595~8244865:+
TGCT	cis	rs7829975	0.582	rs6983150	ENSG00000173295.6	FAM86B3P	-4.59	1.07e-05	0.00802	-0.44	-0.38	Mood instability;	chr8:8934916	chr8:8228595~8244865:+
TGCT	cis	rs1799949	0.965	rs4239149	ENSG00000198496.9	NBR2	4.59	1.07e-05	0.00802	0.53	0.38	Menopause (age at onset);	chr17:43176078	chr17:43125610~43153671:+
TGCT	cis	rs9660180	1	rs3737628	ENSG00000268575.1	RP1-283E3.8	-4.59	1.08e-05	0.00803	-0.3	-0.38	Body mass index;	chr1:1791493	chr1:1702736~1737688:-
TGCT	cis	rs73198271	0.562	rs3827810	ENSG00000253893.2	FAM85B	4.59	1.08e-05	0.00804	0.6	0.38	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8801530	chr8:8167819~8226614:-
TGCT	cis	rs1012068	0.624	rs4820997	ENSG00000236132.1	CTA-440B3.1	-4.59	1.08e-05	0.00804	-0.45	-0.38	Chronic hepatitis C infection;	chr22:31928154	chr22:31816379~31817491:-
TGCT	cis	rs9462027	0.628	rs9296131	ENSG00000186328.4	RP11-140K17.2	4.59	1.08e-05	0.00805	0.36	0.38	Systemic lupus erythematosus;	chr6:34808584	chr6:34715613~34715940:+
TGCT	cis	rs1528149	0.521	rs11766276	ENSG00000224683.1	RPL36AP29	-4.59	1.08e-05	0.00805	-0.42	-0.38	Sitting height ratio;	chr7:16060963	chr7:16208945~16209265:+
TGCT	cis	rs7923609	0.578	rs10761789	ENSG00000232075.1	MRPL35P2	-4.59	1.08e-05	0.00806	-0.36	-0.38	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63636804	chr10:63634317~63634827:-
TGCT	cis	rs7208859	0.623	rs11657662	ENSG00000266490.1	CTD-2349P21.9	-4.59	1.08e-05	0.00806	-0.43	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs11658022	ENSG00000266490.1	CTD-2349P21.9	4.59	1.08e-05	0.00806	0.43	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs3794796	ENSG00000266490.1	CTD-2349P21.9	4.59	1.08e-05	0.00806	0.43	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.573	rs11654035	ENSG00000266490.1	CTD-2349P21.9	4.59	1.08e-05	0.00806	0.43	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30792372~30792833:+
TGCT	cis	rs13118159	0.509	rs10023473	ENSG00000254094.1	AC078852.1	-4.59	1.08e-05	0.00808	-0.48	-0.38	Longevity;	chr4:1381497	chr4:1356581~1358075:+
TGCT	cis	rs1799949	0.965	rs799910	ENSG00000198496.9	NBR2	-4.59	1.08e-05	0.00808	-0.53	-0.38	Menopause (age at onset);	chr17:43127544	chr17:43125610~43153671:+
TGCT	cis	rs867371	0.502	rs3759800	ENSG00000255769.6	GOLGA2P10	4.59	1.08e-05	0.00808	0.37	0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82472993~82513950:-
TGCT	cis	rs6568686	0.576	rs12201640	ENSG00000272356.1	RP5-1112D6.8	-4.59	1.08e-05	0.00808	-0.44	-0.38	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111297115	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs12215049	ENSG00000272356.1	RP5-1112D6.8	-4.59	1.08e-05	0.00808	-0.44	-0.38	Amino acid levels;Blood metabolite levels;	chr6:111297181	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs12205046	ENSG00000272356.1	RP5-1112D6.8	-4.59	1.08e-05	0.00808	-0.44	-0.38	Amino acid levels;Blood metabolite levels;	chr6:111298417	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs1061388	ENSG00000272356.1	RP5-1112D6.8	-4.59	1.08e-05	0.00808	-0.44	-0.38	Amino acid levels;Blood metabolite levels;	chr6:111299091	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs12200641	ENSG00000272356.1	RP5-1112D6.8	-4.59	1.08e-05	0.00808	-0.44	-0.38	Amino acid levels;Blood metabolite levels;	chr6:111301555	chr6:111309203~111313517:+
TGCT	cis	rs6568686	0.627	rs117205661	ENSG00000272356.1	RP5-1112D6.8	-4.59	1.08e-05	0.00808	-0.44	-0.38	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111303354	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs118071464	ENSG00000272356.1	RP5-1112D6.8	-4.59	1.08e-05	0.00808	-0.44	-0.38	Amino acid levels;Blood metabolite levels;	chr6:111305469	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs3204954	ENSG00000272356.1	RP5-1112D6.8	-4.59	1.08e-05	0.00808	-0.44	-0.38	Amino acid levels;Blood metabolite levels;	chr6:111307394	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs3204953	ENSG00000272356.1	RP5-1112D6.8	-4.59	1.08e-05	0.00808	-0.44	-0.38	Amino acid levels;Blood metabolite levels;	chr6:111307423	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs10485124	ENSG00000272356.1	RP5-1112D6.8	-4.59	1.08e-05	0.00808	-0.44	-0.38	Amino acid levels;Blood metabolite levels;	chr6:111310704	chr6:111309203~111313517:+
TGCT	cis	rs8105895	0.935	rs7252547	ENSG00000269742.1	BNIP3P29	4.59	1.08e-05	0.00809	0.72	0.38	Body mass index (change over time);	chr19:22122679	chr19:22065828~22066398:-
TGCT	cis	rs10504229	0.906	rs2270609	ENSG00000253301.4	RP11-513O17.2	4.59	1.08e-05	0.00809	0.51	0.38	Developmental language disorder (linguistic errors);	chr8:57282125	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.906	rs2270608	ENSG00000253301.4	RP11-513O17.2	4.59	1.08e-05	0.00809	0.51	0.38	Developmental language disorder (linguistic errors);	chr8:57282129	chr8:57142689~57240298:+
TGCT	cis	rs796364	0.951	rs12996313	ENSG00000232732.8	AC073043.1	4.59	1.08e-05	0.00809	0.5	0.38	Schizophrenia;	chr2:200133193	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.951	rs13029537	ENSG00000232732.8	AC073043.1	4.59	1.08e-05	0.00809	0.5	0.38	Schizophrenia;	chr2:200134227	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.951	rs12613687	ENSG00000232732.8	AC073043.1	4.59	1.08e-05	0.00809	0.5	0.38	Schizophrenia;	chr2:200134533	chr2:199867396~199911159:-
TGCT	cis	rs34779708	0.966	rs17591163	ENSG00000230534.5	RP11-297A16.2	4.59	1.09e-05	0.00809	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35176351	chr10:35098006~35127020:-
TGCT	cis	rs10246939	0.505	rs12703409	ENSG00000228775.6	WEE2-AS1	4.59	1.09e-05	0.00809	0.36	0.38	Bitter taste perception;	chr7:141812058	chr7:141704338~141738346:-
TGCT	cis	rs911555	0.755	rs11620897	ENSG00000244691.1	RPL10AP1	-4.59	1.09e-05	0.00809	-0.51	-0.38	Intelligence (multi-trait analysis);	chr14:103478524	chr14:103412119~103412761:-
TGCT	cis	rs911555	0.755	rs11627446	ENSG00000244691.1	RPL10AP1	-4.59	1.09e-05	0.00809	-0.51	-0.38	Intelligence (multi-trait analysis);	chr14:103480113	chr14:103412119~103412761:-
TGCT	cis	rs911555	0.755	rs4143998	ENSG00000244691.1	RPL10AP1	-4.59	1.09e-05	0.00809	-0.51	-0.38	Intelligence (multi-trait analysis);	chr14:103488910	chr14:103412119~103412761:-
TGCT	cis	rs911555	0.755	rs1138400	ENSG00000244691.1	RPL10AP1	-4.59	1.09e-05	0.00809	-0.51	-0.38	Intelligence (multi-trait analysis);	chr14:103490496	chr14:103412119~103412761:-
TGCT	cis	rs911555	0.755	rs7147664	ENSG00000244691.1	RPL10AP1	-4.59	1.09e-05	0.00809	-0.51	-0.38	Intelligence (multi-trait analysis);	chr14:103497083	chr14:103412119~103412761:-
TGCT	cis	rs786425	0.677	rs10846537	ENSG00000247373.3	RP11-486O12.2	4.59	1.09e-05	0.00809	0.47	0.38	Pubertal anthropometrics;	chr12:123653799	chr12:123575891~123585115:-
TGCT	cis	rs2742234	0.541	rs1317214	ENSG00000273008.1	RP11-351D16.3	4.59	1.09e-05	0.00809	0.53	0.38	Hirschsprung disease;	chr10:43238083	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.541	rs871763	ENSG00000273008.1	RP11-351D16.3	4.59	1.09e-05	0.00809	0.53	0.38	Hirschsprung disease;	chr10:43238740	chr10:43136824~43138334:-
TGCT	cis	rs875971	0.929	rs4122249	ENSG00000237310.1	GS1-124K5.4	4.59	1.09e-05	0.0081	0.42	0.38	Aortic root size;	chr7:66455949	chr7:66493706~66495474:+
TGCT	cis	rs1012068	0.662	rs4820994	ENSG00000236132.1	CTA-440B3.1	-4.59	1.09e-05	0.00811	-0.44	-0.38	Chronic hepatitis C infection;	chr22:31915633	chr22:31816379~31817491:-
TGCT	cis	rs36093924	0.646	rs4822069	ENSG00000182057.4	OGFRP1	-4.59	1.09e-05	0.00811	-0.27	-0.38	Intelligence;	chr22:41955477	chr22:42269753~42275196:+
TGCT	cis	rs11671005	0.779	rs55875034	ENSG00000232098.3	CTD-2619J13.14	-4.59	1.09e-05	0.00811	-0.47	-0.38	Mean platelet volume;	chr19:58472191	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.779	rs11670125	ENSG00000232098.3	CTD-2619J13.14	-4.59	1.09e-05	0.00811	-0.47	-0.38	Mean platelet volume;	chr19:58476023	chr19:58404238~58408484:-
TGCT	cis	rs9462027	0.539	rs2814963	ENSG00000186328.4	RP11-140K17.2	4.59	1.09e-05	0.00811	0.36	0.38	Systemic lupus erythematosus;	chr6:34741131	chr6:34715613~34715940:+
TGCT	cis	rs9326248	0.53	rs72645460	ENSG00000254851.1	RP11-109L13.1	4.59	1.09e-05	0.00813	0.69	0.38	Blood protein levels;	chr11:116900659	chr11:117135528~117138582:+
TGCT	cis	rs2980439	0.87	rs2945230	ENSG00000254340.1	RP11-10A14.3	4.58	1.09e-05	0.00813	0.4	0.38	Neuroticism;	chr8:8252414	chr8:9141424~9145435:+
TGCT	cis	rs801193	1	rs2659915	ENSG00000237310.1	GS1-124K5.4	4.58	1.09e-05	0.00814	0.41	0.38	Aortic root size;	chr7:66688114	chr7:66493706~66495474:+
TGCT	cis	rs5758659	0.737	rs10854749	ENSG00000270083.1	RP1-257I20.14	4.58	1.09e-05	0.00814	0.35	0.38	Cognitive function;	chr22:42051337	chr22:42089630~42090028:-
TGCT	cis	rs9987353	0.519	rs11779181	ENSG00000173295.6	FAM86B3P	4.58	1.09e-05	0.00814	0.41	0.38	Recombination measurement;	chr8:9205517	chr8:8228595~8244865:+
TGCT	cis	rs8113308	0.515	rs73066986	ENSG00000269235.1	ZNF350-AS1	4.58	1.1e-05	0.00815	0.85	0.38	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51962805	chr19:51949134~51981367:+
TGCT	cis	rs8113308	0.515	rs4986770	ENSG00000269235.1	ZNF350-AS1	4.58	1.1e-05	0.00815	0.85	0.38	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51964781	chr19:51949134~51981367:+
TGCT	cis	rs7829975	1	rs7829975	ENSG00000173295.6	FAM86B3P	-4.58	1.1e-05	0.00815	-0.47	-0.38	Mood instability;	chr8:8690607	chr8:8228595~8244865:+
TGCT	cis	rs728616	0.867	rs73297466	ENSG00000230091.5	TMEM254-AS1	4.58	1.1e-05	0.00815	0.71	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80127178	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs61859980	ENSG00000230091.5	TMEM254-AS1	4.58	1.1e-05	0.00815	0.71	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80128938	chr10:80046860~80078912:-
TGCT	cis	rs2408955	0.504	rs11168441	ENSG00000258273.1	RP11-370I10.4	-4.58	1.1e-05	0.00815	-0.44	-0.38	Glycated hemoglobin levels;	chr12:48182271	chr12:48333755~48333901:-
TGCT	cis	rs875971	0.756	rs2901210	ENSG00000237310.1	GS1-124K5.4	-4.58	1.1e-05	0.00816	-0.4	-0.38	Aortic root size;	chr7:66552518	chr7:66493706~66495474:+
TGCT	cis	rs67311347	0.956	rs11714871	ENSG00000223797.4	ENTPD3-AS1	4.58	1.1e-05	0.00817	0.39	0.38	Renal cell carcinoma;	chr3:40387447	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs2305521	ENSG00000223797.4	ENTPD3-AS1	4.58	1.1e-05	0.00817	0.39	0.38	Renal cell carcinoma;	chr3:40387692	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs2305522	ENSG00000223797.4	ENTPD3-AS1	4.58	1.1e-05	0.00817	0.39	0.38	Renal cell carcinoma;	chr3:40387867	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs7636719	ENSG00000223797.4	ENTPD3-AS1	4.58	1.1e-05	0.00817	0.39	0.38	Renal cell carcinoma;	chr3:40390593	chr3:40313802~40453329:-
TGCT	cis	rs1618992	0.791	rs1504109	ENSG00000265994.1	RP11-510D21.1	4.58	1.1e-05	0.00817	0.38	0.38	Gut microbiome composition (summer and winter);	chr18:28641733	chr18:28785068~28789260:+
TGCT	cis	rs34217772	0.64	rs58844543	ENSG00000258536.1	RP11-1053O12.1	4.58	1.1e-05	0.00817	0.31	0.38	Myopia;	chr14:41725427	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.581	rs61990346	ENSG00000258536.1	RP11-1053O12.1	4.58	1.1e-05	0.00817	0.31	0.38	Myopia;	chr14:41728950	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.64	rs58373729	ENSG00000258536.1	RP11-1053O12.1	4.58	1.1e-05	0.00817	0.31	0.38	Myopia;	chr14:41729765	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.64	rs1597050	ENSG00000258536.1	RP11-1053O12.1	4.58	1.1e-05	0.00817	0.31	0.38	Myopia;	chr14:41731692	chr14:41742639~41742963:+
TGCT	cis	rs875971	0.66	rs10215132	ENSG00000272831.1	RP11-792A8.4	-4.58	1.1e-05	0.00818	-0.41	-0.38	Aortic root size;	chr7:66589419	chr7:66739829~66740385:-
TGCT	cis	rs6700559	0.716	rs12140579	ENSG00000260088.1	RP11-92G12.3	4.58	1.1e-05	0.00818	0.47	0.38	Coronary artery disease;	chr1:200655368	chr1:200669507~200694250:+
TGCT	cis	rs904251	0.58	rs62408367	ENSG00000279942.1	RP1-153P14.7	-4.58	1.1e-05	0.00819	-0.4	-0.38	Cognitive performance;	chr6:37477037	chr6:37567716~37571460:+
TGCT	cis	rs875971	0.597	rs11763224	ENSG00000237310.1	GS1-124K5.4	4.58	1.1e-05	0.0082	0.46	0.38	Aortic root size;	chr7:66518628	chr7:66493706~66495474:+
TGCT	cis	rs367615	0.552	rs2963022	ENSG00000249476.1	CTD-2587M2.1	-4.58	1.1e-05	0.00821	-0.4	-0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109391484	chr5:109237120~109326369:-
TGCT	cis	rs367615	0.552	rs2963023	ENSG00000249476.1	CTD-2587M2.1	-4.58	1.1e-05	0.00821	-0.4	-0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109394369	chr5:109237120~109326369:-
TGCT	cis	rs875971	0.522	rs4718285	ENSG00000272831.1	RP11-792A8.4	4.58	1.11e-05	0.00821	0.39	0.38	Aortic root size;	chr7:65827018	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.522	rs4718286	ENSG00000272831.1	RP11-792A8.4	4.58	1.11e-05	0.00821	0.39	0.38	Aortic root size;	chr7:65827777	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.522	rs4502988	ENSG00000272831.1	RP11-792A8.4	4.58	1.11e-05	0.00821	0.39	0.38	Aortic root size;	chr7:65832759	chr7:66739829~66740385:-
TGCT	cis	rs17711722	0.585	rs6942660	ENSG00000272831.1	RP11-792A8.4	4.58	1.11e-05	0.00821	0.39	0.38	Calcium levels;	chr7:65837419	chr7:66739829~66740385:-
TGCT	cis	rs17711722	0.64	rs13237956	ENSG00000272831.1	RP11-792A8.4	4.58	1.11e-05	0.00821	0.39	0.38	Calcium levels;	chr7:65853042	chr7:66739829~66740385:-
TGCT	cis	rs1555322	0.53	rs2425043	ENSG00000126005.14	MMP24-AS1	-4.58	1.11e-05	0.00821	-0.46	-0.38	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35216462~35278131:-
TGCT	cis	rs10759883	0.525	rs1556026	ENSG00000175611.10	LINC00476	4.58	1.11e-05	0.00822	0.33	0.38	Nicotine dependence;	chr9:96046454	chr9:95759231~95875977:-
TGCT	cis	rs875971	0.66	rs6460308	ENSG00000272831.1	RP11-792A8.4	-4.58	1.11e-05	0.00822	-0.41	-0.38	Aortic root size;	chr7:66619753	chr7:66739829~66740385:-
TGCT	cis	rs9462027	0.628	rs9469899	ENSG00000186328.4	RP11-140K17.2	4.58	1.11e-05	0.00822	0.37	0.38	Systemic lupus erythematosus;	chr6:34825347	chr6:34715613~34715940:+
TGCT	cis	rs2439831	0.867	rs2260160	ENSG00000205771.5	CATSPER2P1	-4.58	1.11e-05	0.00822	-0.65	-0.38	Lung cancer in ever smokers;	chr15:43603445	chr15:43726918~43747094:-
TGCT	cis	rs62296447	0.514	rs12646839	ENSG00000248515.1	RP11-608O21.1	-4.58	1.11e-05	0.00823	-0.38	-0.38	Schizophrenia;	chr4:19494936	chr4:19455436~19909692:+
TGCT	cis	rs453301	0.509	rs7000323	ENSG00000254367.4	RP11-211C9.1	4.58	1.11e-05	0.00824	0.28	0.38	Joint mobility (Beighton score);	chr8:8934763	chr8:8723693~8782479:-
TGCT	cis	rs507080	0.883	rs656575	ENSG00000255422.1	AP002954.4	-4.58	1.11e-05	0.00825	-0.45	-0.38	Serum metabolite levels;	chr11:118679199	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.961	rs656505	ENSG00000255422.1	AP002954.4	-4.58	1.11e-05	0.00825	-0.45	-0.38	Serum metabolite levels;	chr11:118679245	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.961	rs660489	ENSG00000255422.1	AP002954.4	-4.58	1.11e-05	0.00825	-0.45	-0.38	Serum metabolite levels;	chr11:118679255	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.961	rs543327	ENSG00000255422.1	AP002954.4	-4.58	1.11e-05	0.00825	-0.45	-0.38	Serum metabolite levels;	chr11:118679276	chr11:118704607~118750263:+
TGCT	cis	rs11123170	0.529	rs35606997	ENSG00000189223.12	PAX8-AS1	-4.58	1.11e-05	0.00825	-0.62	-0.38	Renal function-related traits (BUN);	chr2:113215773	chr2:113211522~113276581:+
TGCT	cis	rs7829975	0.536	rs2980439	ENSG00000254340.1	RP11-10A14.3	4.58	1.11e-05	0.00825	0.39	0.38	Mood instability;	chr8:8237348	chr8:9141424~9145435:+
TGCT	cis	rs2919917	0.628	rs9643739	ENSG00000254352.1	RP11-578O24.2	4.58	1.11e-05	0.00826	0.46	0.38	Lymphocyte counts;	chr8:78679535	chr8:78723796~78724136:-
TGCT	cis	rs2919917	0.628	rs2170732	ENSG00000254352.1	RP11-578O24.2	4.58	1.11e-05	0.00826	0.46	0.38	Lymphocyte counts;	chr8:78684261	chr8:78723796~78724136:-
TGCT	cis	rs2919917	0.628	rs6990105	ENSG00000254352.1	RP11-578O24.2	4.58	1.11e-05	0.00826	0.46	0.38	Lymphocyte counts;	chr8:78689652	chr8:78723796~78724136:-
TGCT	cis	rs911555	0.755	rs9671414	ENSG00000244691.1	RPL10AP1	4.58	1.12e-05	0.00827	0.53	0.38	Intelligence (multi-trait analysis);	chr14:103500962	chr14:103412119~103412761:-
TGCT	cis	rs2742234	0.59	rs2505553	ENSG00000273008.1	RP11-351D16.3	-4.58	1.12e-05	0.00828	-0.52	-0.38	Hirschsprung disease;	chr10:43185803	chr10:43136824~43138334:-
TGCT	cis	rs801193	1	rs2659915	ENSG00000272831.1	RP11-792A8.4	4.58	1.12e-05	0.00828	0.38	0.38	Aortic root size;	chr7:66688114	chr7:66739829~66740385:-
TGCT	cis	rs4713118	0.621	rs9295755	ENSG00000219891.2	ZSCAN12P1	-4.58	1.12e-05	0.00828	-0.47	-0.38	Parkinson's disease;	chr6:28065396	chr6:28091154~28093664:+
TGCT	cis	rs10129255	0.528	rs8008320	ENSG00000211970.3	IGHV4-61	-4.58	1.12e-05	0.00828	-0.41	-0.38	Kawasaki disease;	chr14:106652124	chr14:106639119~106639657:-
TGCT	cis	rs10129255	0.53	rs8008811	ENSG00000211970.3	IGHV4-61	-4.58	1.12e-05	0.00828	-0.41	-0.38	Kawasaki disease;	chr14:106652273	chr14:106639119~106639657:-
TGCT	cis	rs10129255	0.542	rs8009795	ENSG00000211970.3	IGHV4-61	-4.58	1.12e-05	0.00828	-0.41	-0.38	Kawasaki disease;	chr14:106652287	chr14:106639119~106639657:-
TGCT	cis	rs10129255	0.528	rs8008831	ENSG00000211970.3	IGHV4-61	-4.58	1.12e-05	0.00828	-0.41	-0.38	Kawasaki disease;	chr14:106652290	chr14:106639119~106639657:-
TGCT	cis	rs10129255	0.584	rs11161001	ENSG00000211970.3	IGHV4-61	-4.58	1.12e-05	0.00828	-0.41	-0.38	Kawasaki disease;	chr14:106652664	chr14:106639119~106639657:-
TGCT	cis	rs10129255	0.507	rs58656539	ENSG00000211970.3	IGHV4-61	-4.58	1.12e-05	0.00828	-0.41	-0.38	Kawasaki disease;	chr14:106653262	chr14:106639119~106639657:-
TGCT	cis	rs10129255	0.544	rs61997583	ENSG00000211970.3	IGHV4-61	-4.58	1.12e-05	0.00828	-0.41	-0.38	Kawasaki disease;	chr14:106654351	chr14:106639119~106639657:-
TGCT	cis	rs12439619	0.508	rs8023960	ENSG00000278603.1	RP13-608F4.5	4.58	1.12e-05	0.00828	0.5	0.38	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472203~82472426:+
TGCT	cis	rs6604026	0.624	rs35526187	ENSG00000223787.2	RP4-593M8.1	4.58	1.12e-05	0.00829	0.54	0.38	Multiple sclerosis;	chr1:92732610	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.624	rs11805698	ENSG00000223787.2	RP4-593M8.1	4.58	1.12e-05	0.00829	0.54	0.38	Multiple sclerosis;	chr1:92737695	chr1:92580476~92580821:-
TGCT	cis	rs9660180	1	rs9660180	ENSG00000268575.1	RP1-283E3.8	-4.58	1.12e-05	0.0083	-0.31	-0.38	Body mass index;	chr1:1791592	chr1:1702736~1737688:-
TGCT	cis	rs853679	1	rs11965538	ENSG00000216901.1	AL022393.7	4.58	1.12e-05	0.00832	0.62	0.38	Depression;	chr6:28272137	chr6:28176188~28176674:+
TGCT	cis	rs853679	0.882	rs2743555	ENSG00000216901.1	AL022393.7	4.58	1.12e-05	0.00832	0.62	0.38	Depression;	chr6:28273304	chr6:28176188~28176674:+
TGCT	cis	rs847851	1	rs847846	ENSG00000186328.4	RP11-140K17.2	-4.58	1.12e-05	0.00833	-0.4	-0.38	Colonoscopy-negative controls vs population controls;	chr6:34957594	chr6:34715613~34715940:+
TGCT	cis	rs2015599	0.623	rs12581107	ENSG00000275476.1	RP11-996F15.4	-4.58	1.12e-05	0.00833	-0.43	-0.38	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29277397~29277882:-
TGCT	cis	rs2976388	1	rs2976388	ENSG00000253196.1	RP11-706C16.7	-4.58	1.13e-05	0.00834	-0.39	-0.38	Urinary tract infection frequency;	chr8:142678838	chr8:142763116~142766427:+
TGCT	cis	rs34779708	0.931	rs12771399	ENSG00000230534.5	RP11-297A16.2	4.58	1.13e-05	0.00835	0.44	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35163449	chr10:35098006~35127020:-
TGCT	cis	rs8091660	1	rs8091660	ENSG00000278983.1	RP11-426J5.3	4.58	1.13e-05	0.00836	0.46	0.38	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48561565	chr18:48564795~48568342:+
TGCT	cis	rs9807989	0.507	rs1420097	ENSG00000234389.1	AC007278.3	-4.58	1.13e-05	0.00836	-0.28	-0.38	Asthma;	chr2:102392894	chr2:102438713~102440475:+
TGCT	cis	rs7208859	0.524	rs60114476	ENSG00000280069.1	CTD-2349P21.3	-4.58	1.13e-05	0.00836	-0.54	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30738182~30740275:+
TGCT	cis	rs2117029	0.619	rs10747562	ENSG00000258017.1	RP11-386G11.10	-4.58	1.13e-05	0.00836	-0.5	-0.38	Intelligence (multi-trait analysis);	chr12:49111401	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.619	rs11168862	ENSG00000258017.1	RP11-386G11.10	-4.58	1.13e-05	0.00836	-0.5	-0.38	Intelligence (multi-trait analysis);	chr12:49112175	chr12:49127782~49147869:+
TGCT	cis	rs7208859	0.673	rs216440	ENSG00000280069.1	CTD-2349P21.3	-4.58	1.13e-05	0.00837	-0.5	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30601291	chr17:30738182~30740275:+
TGCT	cis	rs17826219	0.561	rs562840	ENSG00000280069.1	CTD-2349P21.3	-4.58	1.13e-05	0.00837	-0.5	-0.38	Body mass index;	chr17:30622372	chr17:30738182~30740275:+
TGCT	cis	rs875971	0.66	rs12698534	ENSG00000272831.1	RP11-792A8.4	4.58	1.13e-05	0.00839	0.41	0.38	Aortic root size;	chr7:66521858	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.66	rs62465434	ENSG00000272831.1	RP11-792A8.4	4.58	1.13e-05	0.00839	0.41	0.38	Aortic root size;	chr7:66540165	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.66	rs13224319	ENSG00000272831.1	RP11-792A8.4	4.58	1.13e-05	0.00839	0.41	0.38	Aortic root size;	chr7:66542376	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.66	rs801217	ENSG00000272831.1	RP11-792A8.4	-4.58	1.13e-05	0.00839	-0.41	-0.38	Aortic root size;	chr7:66545590	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.638	rs801216	ENSG00000272831.1	RP11-792A8.4	-4.58	1.13e-05	0.00839	-0.41	-0.38	Aortic root size;	chr7:66546680	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.66	rs801211	ENSG00000272831.1	RP11-792A8.4	-4.58	1.13e-05	0.00839	-0.41	-0.38	Aortic root size;	chr7:66550702	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.638	rs801205	ENSG00000272831.1	RP11-792A8.4	-4.58	1.13e-05	0.00839	-0.41	-0.38	Aortic root size;	chr7:66557157	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.617	rs810400	ENSG00000272831.1	RP11-792A8.4	-4.58	1.13e-05	0.00839	-0.41	-0.38	Aortic root size;	chr7:66557902	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.638	rs3898855	ENSG00000272831.1	RP11-792A8.4	-4.58	1.13e-05	0.00839	-0.41	-0.38	Aortic root size;	chr7:66571411	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.638	rs10278816	ENSG00000272831.1	RP11-792A8.4	-4.58	1.13e-05	0.00839	-0.41	-0.38	Aortic root size;	chr7:66572000	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.66	rs10281080	ENSG00000272831.1	RP11-792A8.4	-4.58	1.13e-05	0.00839	-0.41	-0.38	Aortic root size;	chr7:66577454	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.66	rs10950044	ENSG00000272831.1	RP11-792A8.4	-4.58	1.13e-05	0.00839	-0.41	-0.38	Aortic root size;	chr7:66577989	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.638	rs10249404	ENSG00000272831.1	RP11-792A8.4	-4.58	1.13e-05	0.00839	-0.41	-0.38	Aortic root size;	chr7:66581737	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.619	rs10278371	ENSG00000272831.1	RP11-792A8.4	-4.58	1.13e-05	0.00839	-0.41	-0.38	Aortic root size;	chr7:66586553	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.522	rs1968127	ENSG00000272831.1	RP11-792A8.4	-4.58	1.13e-05	0.00839	-0.41	-0.38	Aortic root size;	chr7:66591816	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.66	rs79009421	ENSG00000272831.1	RP11-792A8.4	-4.58	1.13e-05	0.00839	-0.41	-0.38	Aortic root size;	chr7:66603522	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.66	rs7807930	ENSG00000272831.1	RP11-792A8.4	-4.58	1.13e-05	0.00839	-0.41	-0.38	Aortic root size;	chr7:66622178	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.66	rs7807944	ENSG00000272831.1	RP11-792A8.4	-4.58	1.13e-05	0.00839	-0.41	-0.38	Aortic root size;	chr7:66622208	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.638	rs35986979	ENSG00000272831.1	RP11-792A8.4	-4.58	1.13e-05	0.00839	-0.41	-0.38	Aortic root size;	chr7:66624003	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.642	rs35526611	ENSG00000272831.1	RP11-792A8.4	-4.58	1.13e-05	0.00839	-0.41	-0.38	Aortic root size;	chr7:66629021	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.66	rs3764903	ENSG00000272831.1	RP11-792A8.4	-4.58	1.13e-05	0.00839	-0.41	-0.38	Aortic root size;	chr7:66633495	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.66	rs1860470	ENSG00000272831.1	RP11-792A8.4	-4.58	1.13e-05	0.00839	-0.41	-0.38	Aortic root size;	chr7:66638707	chr7:66739829~66740385:-
TGCT	cis	rs10504229	0.679	rs11781858	ENSG00000253301.4	RP11-513O17.2	4.58	1.14e-05	0.00839	0.62	0.38	Developmental language disorder (linguistic errors);	chr8:57125847	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.679	rs11786328	ENSG00000253301.4	RP11-513O17.2	4.58	1.14e-05	0.00839	0.62	0.38	Developmental language disorder (linguistic errors);	chr8:57126710	chr8:57142689~57240298:+
TGCT	cis	rs6504663	1	rs6504661	ENSG00000275897.1	RP11-94C24.13	-4.58	1.14e-05	0.00839	-0.55	-0.38	Visceral fat;	chr17:50502765	chr17:50475819~50478391:+
TGCT	cis	rs9660180	0.967	rs12034740	ENSG00000268575.1	RP1-283E3.8	-4.58	1.14e-05	0.00839	-0.31	-0.38	Body mass index;	chr1:1797530	chr1:1702736~1737688:-
TGCT	cis	rs2919917	0.628	rs6981103	ENSG00000254352.1	RP11-578O24.2	4.58	1.14e-05	0.00839	0.46	0.38	Lymphocyte counts;	chr8:78691702	chr8:78723796~78724136:-
TGCT	cis	rs3742264	0.848	rs9567615	ENSG00000235903.6	CPB2-AS1	-4.58	1.14e-05	0.0084	-0.46	-0.38	Blood protein levels;	chr13:46076945	chr13:46052806~46113332:+
TGCT	cis	rs3742264	0.848	rs9567616	ENSG00000235903.6	CPB2-AS1	-4.58	1.14e-05	0.0084	-0.46	-0.38	Blood protein levels;	chr13:46076956	chr13:46052806~46113332:+
TGCT	cis	rs3742264	0.848	rs9567617	ENSG00000235903.6	CPB2-AS1	-4.58	1.14e-05	0.0084	-0.46	-0.38	Blood protein levels;	chr13:46076973	chr13:46052806~46113332:+
TGCT	cis	rs2919917	0.628	rs10109359	ENSG00000254352.1	RP11-578O24.2	4.58	1.14e-05	0.0084	0.46	0.38	Lymphocyte counts;	chr8:78694369	chr8:78723796~78724136:-
TGCT	cis	rs62355901	1	rs62355901	ENSG00000271828.1	CTD-2310F14.1	4.58	1.14e-05	0.0084	0.47	0.38	Breast cancer;	chr5:56757708	chr5:56927874~56929573:+
TGCT	cis	rs875971	0.577	rs35072105	ENSG00000237310.1	GS1-124K5.4	-4.58	1.14e-05	0.0084	-0.43	-0.38	Aortic root size;	chr7:66144830	chr7:66493706~66495474:+
TGCT	cis	rs1823913	0.562	rs17347499	ENSG00000227542.1	AC092614.2	4.58	1.14e-05	0.0084	0.41	0.38	Obesity-related traits;	chr2:191301116	chr2:191229165~191246172:-
TGCT	cis	rs34779708	0.931	rs17591135	ENSG00000230534.5	RP11-297A16.2	4.57	1.14e-05	0.0084	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35176262	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs55724039	ENSG00000230534.5	RP11-297A16.2	4.57	1.14e-05	0.0084	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35176469	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs12769484	ENSG00000230534.5	RP11-297A16.2	4.57	1.14e-05	0.0084	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35176818	chr10:35098006~35127020:-
TGCT	cis	rs2117029	0.638	rs7296288	ENSG00000258017.1	RP11-386G11.10	-4.57	1.14e-05	0.00841	-0.46	-0.38	Intelligence (multi-trait analysis);	chr12:49086185	chr12:49127782~49147869:+
TGCT	cis	rs853679	0.599	rs156743	ENSG00000216901.1	AL022393.7	4.57	1.14e-05	0.00842	0.65	0.38	Depression;	chr6:27999311	chr6:28176188~28176674:+
TGCT	cis	rs9880211	0.948	rs9872178	ENSG00000239213.4	NCK1-AS1	4.57	1.14e-05	0.00843	0.41	0.38	Height;Body mass index;	chr3:136267596	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs12695645	ENSG00000239213.4	NCK1-AS1	4.57	1.14e-05	0.00843	0.41	0.38	Height;Body mass index;	chr3:136272039	chr3:136841726~136862054:-
TGCT	cis	rs2980439	0.818	rs2948294	ENSG00000253893.2	FAM85B	-4.57	1.14e-05	0.00844	-0.49	-0.38	Neuroticism;	chr8:8237439	chr8:8167819~8226614:-
TGCT	cis	rs2980439	0.783	rs2955587	ENSG00000253893.2	FAM85B	-4.57	1.14e-05	0.00844	-0.49	-0.38	Neuroticism;	chr8:8240557	chr8:8167819~8226614:-
TGCT	cis	rs1865760	1	rs9348698	ENSG00000217159.2	LARP1P1	-4.57	1.15e-05	0.00844	-0.44	-0.38	Height;	chr6:25929461	chr6:26164072~26164363:+
TGCT	cis	rs1865760	1	rs9393675	ENSG00000217159.2	LARP1P1	-4.57	1.15e-05	0.00844	-0.44	-0.38	Height;	chr6:25929888	chr6:26164072~26164363:+
TGCT	cis	rs2177312	0.761	rs1523157	ENSG00000251129.1	RP11-734I18.1	-4.57	1.15e-05	0.00844	-0.44	-0.38	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31970612	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.83	rs1357462	ENSG00000251129.1	RP11-734I18.1	-4.57	1.15e-05	0.00844	-0.44	-0.38	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31979347	chr4:31997397~32155406:+
TGCT	cis	rs4834770	1	rs4834770	ENSG00000245958.5	RP11-33B1.1	-4.57	1.15e-05	0.00845	-0.37	-0.38	Blood protein levels;	chr4:119320694	chr4:119454791~119552025:+
TGCT	cis	rs4834770	1	rs6823963	ENSG00000245958.5	RP11-33B1.1	-4.57	1.15e-05	0.00845	-0.37	-0.38	Blood protein levels;	chr4:119321009	chr4:119454791~119552025:+
TGCT	cis	rs4834770	1	rs4834771	ENSG00000245958.5	RP11-33B1.1	-4.57	1.15e-05	0.00845	-0.37	-0.38	Blood protein levels;	chr4:119321617	chr4:119454791~119552025:+
TGCT	cis	rs4834770	1	rs1397613	ENSG00000245958.5	RP11-33B1.1	-4.57	1.15e-05	0.00845	-0.37	-0.38	Blood protein levels;	chr4:119321774	chr4:119454791~119552025:+
TGCT	cis	rs4834770	1	rs6857641	ENSG00000245958.5	RP11-33B1.1	-4.57	1.15e-05	0.00845	-0.37	-0.38	Blood protein levels;	chr4:119322356	chr4:119454791~119552025:+
TGCT	cis	rs4834770	1	rs2282688	ENSG00000245958.5	RP11-33B1.1	-4.57	1.15e-05	0.00845	-0.37	-0.38	Blood protein levels;	chr4:119322567	chr4:119454791~119552025:+
TGCT	cis	rs4834770	1	rs10034579	ENSG00000245958.5	RP11-33B1.1	-4.57	1.15e-05	0.00845	-0.37	-0.38	Blood protein levels;	chr4:119322874	chr4:119454791~119552025:+
TGCT	cis	rs4835473	0.9	rs3856989	ENSG00000251600.4	RP11-673E1.1	4.57	1.15e-05	0.00845	0.39	0.38	Immature fraction of reticulocytes;	chr4:143921752	chr4:143912331~143982454:+
TGCT	cis	rs4268898	0.697	rs6714652	ENSG00000223754.1	AC008073.9	-4.57	1.15e-05	0.00847	-0.43	-0.38	Asthma;	chr2:24160189	chr2:24199839~24201698:-
TGCT	cis	rs4268898	0.722	rs2288072	ENSG00000223754.1	AC008073.9	-4.57	1.15e-05	0.00847	-0.43	-0.38	Asthma;	chr2:24167648	chr2:24199839~24201698:-
TGCT	cis	rs950027	1	rs950027	ENSG00000259520.4	CTD-2651B20.3	4.57	1.15e-05	0.00847	0.27	0.38	Response to fenofibrate (adiponectin levels);	chr15:45508837	chr15:45251580~45279251:-
TGCT	cis	rs877819	0.583	rs1904600	ENSG00000228403.1	RP11-563N6.6	-4.57	1.15e-05	0.0085	-0.41	-0.38	Systemic lupus erythematosus;	chr10:48859171	chr10:48878022~48878649:+
TGCT	cis	rs2919917	0.628	rs11776243	ENSG00000254352.1	RP11-578O24.2	4.57	1.16e-05	0.0085	0.46	0.38	Lymphocyte counts;	chr8:78648848	chr8:78723796~78724136:-
TGCT	cis	rs2919917	0.628	rs10110524	ENSG00000254352.1	RP11-578O24.2	4.57	1.16e-05	0.0085	0.46	0.38	Lymphocyte counts;	chr8:78648871	chr8:78723796~78724136:-
TGCT	cis	rs786425	1	rs786425	ENSG00000278112.1	RP11-972P1.11	-4.57	1.16e-05	0.00851	-0.42	-0.38	Pubertal anthropometrics;	chr12:123600955	chr12:123519390~123519856:-
TGCT	cis	rs673078	0.607	rs7312555	ENSG00000275759.1	RP11-131L12.3	-4.57	1.16e-05	0.00851	-0.72	-0.38	Glucose homeostasis traits;	chr12:118414120	chr12:118428281~118428870:+
TGCT	cis	rs7829975	0.6	rs1719381	ENSG00000173295.6	FAM86B3P	-4.57	1.16e-05	0.00851	-0.46	-0.38	Mood instability;	chr8:8744834	chr8:8228595~8244865:+
TGCT	cis	rs7829975	0.559	rs4841025	ENSG00000173295.6	FAM86B3P	-4.57	1.16e-05	0.00851	-0.46	-0.38	Mood instability;	chr8:8745650	chr8:8228595~8244865:+
TGCT	cis	rs8113308	1	rs7246064	ENSG00000269235.1	ZNF350-AS1	4.57	1.16e-05	0.00852	0.59	0.38	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939009	chr19:51949134~51981367:+
TGCT	cis	rs8113308	1	rs6509600	ENSG00000269235.1	ZNF350-AS1	4.57	1.16e-05	0.00852	0.59	0.38	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939336	chr19:51949134~51981367:+
TGCT	cis	rs8113308	1	rs8113308	ENSG00000269235.1	ZNF350-AS1	4.57	1.16e-05	0.00852	0.59	0.38	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942133	chr19:51949134~51981367:+
TGCT	cis	rs8113308	1	rs8105440	ENSG00000269235.1	ZNF350-AS1	4.57	1.16e-05	0.00852	0.59	0.38	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51948647	chr19:51949134~51981367:+
TGCT	cis	rs867371	1	rs7173339	ENSG00000255769.6	GOLGA2P10	-4.57	1.16e-05	0.00852	-0.41	-0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82472993~82513950:-
TGCT	cis	rs6600671	1	rs4844380	ENSG00000275131.1	CH17-472G23.4	-4.57	1.16e-05	0.00853	-0.24	-0.38	Hip geometry;	chr1:121451764	chr1:120489625~120579190:-
TGCT	cis	rs7829975	0.617	rs4841071	ENSG00000254340.1	RP11-10A14.3	4.57	1.16e-05	0.00853	0.37	0.38	Mood instability;	chr8:8933634	chr8:9141424~9145435:+
TGCT	cis	rs7208859	0.623	rs11651857	ENSG00000280069.1	CTD-2349P21.3	-4.57	1.16e-05	0.00853	-0.54	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs216439	ENSG00000280069.1	CTD-2349P21.3	-4.57	1.16e-05	0.00853	-0.54	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.573	rs216442	ENSG00000280069.1	CTD-2349P21.3	-4.57	1.16e-05	0.00853	-0.54	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs216445	ENSG00000280069.1	CTD-2349P21.3	-4.57	1.16e-05	0.00853	-0.54	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs216446	ENSG00000280069.1	CTD-2349P21.3	-4.57	1.16e-05	0.00853	-0.54	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs79607958	ENSG00000280069.1	CTD-2349P21.3	-4.57	1.16e-05	0.00853	-0.54	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs75136574	ENSG00000280069.1	CTD-2349P21.3	-4.57	1.16e-05	0.00853	-0.54	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs77544470	ENSG00000280069.1	CTD-2349P21.3	-4.57	1.16e-05	0.00853	-0.54	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs609063	ENSG00000280069.1	CTD-2349P21.3	-4.57	1.16e-05	0.00853	-0.54	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs383436	ENSG00000280069.1	CTD-2349P21.3	-4.57	1.16e-05	0.00853	-0.54	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30738182~30740275:+
TGCT	cis	rs17826219	0.714	rs11650821	ENSG00000280069.1	CTD-2349P21.3	-4.57	1.16e-05	0.00853	-0.54	-0.38	Body mass index;	chr17:30641132	chr17:30738182~30740275:+
TGCT	cis	rs73198271	0.562	rs112717383	ENSG00000253893.2	FAM85B	4.57	1.16e-05	0.00854	0.62	0.38	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8805706	chr8:8167819~8226614:-
TGCT	cis	rs875971	0.666	rs13242072	ENSG00000236529.1	RP13-254B10.1	-4.57	1.16e-05	0.00855	-0.29	-0.38	Aortic root size;	chr7:66301001	chr7:65840212~65840596:+
TGCT	cis	rs2739330	0.731	rs5751792	ENSG00000235689.1	AP000351.13	4.57	1.16e-05	0.00855	0.37	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:24006305~24008258:-
TGCT	cis	rs7115242	0.8	rs7931770	ENSG00000254851.1	RP11-109L13.1	-4.57	1.16e-05	0.00856	-0.65	-0.38	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116995574	chr11:117135528~117138582:+
TGCT	cis	rs753274	0.623	rs56174157	ENSG00000267147.2	CTC-548K16.1	-4.57	1.17e-05	0.00857	-0.47	-0.38	Tumor necrosis factor beta levels;	chr19:14304147	chr19:14333743~14343916:+
TGCT	cis	rs5769707	0.521	rs5769719	ENSG00000235111.1	RP1-29C18.8	-4.57	1.17e-05	0.00857	-0.36	-0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49668453	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.521	rs5769720	ENSG00000235111.1	RP1-29C18.8	-4.57	1.17e-05	0.00857	-0.36	-0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49668485	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.521	rs5770633	ENSG00000235111.1	RP1-29C18.8	-4.57	1.17e-05	0.00857	-0.36	-0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49668779	chr22:49612657~49615716:-
TGCT	cis	rs904251	0.861	rs1757183	ENSG00000204110.6	RP1-153P14.8	4.57	1.17e-05	0.00858	0.43	0.38	Cognitive performance;	chr6:37517014	chr6:37507348~37535616:+
TGCT	cis	rs17826219	0.561	rs11655876	ENSG00000263531.1	RP13-753N3.1	4.57	1.17e-05	0.00859	0.68	0.38	Body mass index;	chr17:30690132	chr17:30863921~30864940:-
TGCT	cis	rs1865760	0.964	rs9295677	ENSG00000217159.2	LARP1P1	-4.57	1.17e-05	0.0086	-0.44	-0.38	Height;	chr6:25933484	chr6:26164072~26164363:+
TGCT	cis	rs1023500	0.596	rs5758562	ENSG00000270083.1	RP1-257I20.14	4.57	1.17e-05	0.0086	0.38	0.38	Schizophrenia;	chr22:42052234	chr22:42089630~42090028:-
TGCT	cis	rs1023500	0.596	rs5751209	ENSG00000270083.1	RP1-257I20.14	4.57	1.17e-05	0.0086	0.38	0.38	Schizophrenia;	chr22:42055599	chr22:42089630~42090028:-
TGCT	cis	rs8072100	0.846	rs6503796	ENSG00000228782.6	CTD-2026D20.3	4.57	1.17e-05	0.0086	0.47	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47687883	chr17:47450568~47492492:-
TGCT	cis	rs9462027	0.628	rs7752522	ENSG00000186328.4	RP11-140K17.2	4.57	1.17e-05	0.00861	0.36	0.38	Systemic lupus erythematosus;	chr6:34792806	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs998278	ENSG00000186328.4	RP11-140K17.2	4.57	1.17e-05	0.00861	0.36	0.38	Systemic lupus erythematosus;	chr6:34797807	chr6:34715613~34715940:+
TGCT	cis	rs3743162	0.553	rs4842994	ENSG00000225151.9	GOLGA2P7	4.57	1.17e-05	0.00861	0.48	0.38	Alzheimer's disease (age of onset);	chr15:84872568	chr15:84199311~84230136:-
TGCT	cis	rs8108269	1	rs8108269	ENSG00000241226.3	RN7SL836P	4.57	1.17e-05	0.00861	0.4	0.38	Type 2 diabetes;	chr19:45655255	chr19:45651510~45651805:+
TGCT	cis	rs875971	0.545	rs6970498	ENSG00000237310.1	GS1-124K5.4	4.57	1.17e-05	0.00862	0.46	0.38	Aortic root size;	chr7:66275908	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs6979636	ENSG00000237310.1	GS1-124K5.4	4.57	1.17e-05	0.00862	0.46	0.38	Aortic root size;	chr7:66276638	chr7:66493706~66495474:+
TGCT	cis	rs2919917	0.628	rs1351742	ENSG00000254352.1	RP11-578O24.2	4.57	1.17e-05	0.00862	0.45	0.38	Lymphocyte counts;	chr8:78655823	chr8:78723796~78724136:-
TGCT	cis	rs2919917	0.666	rs982032	ENSG00000254352.1	RP11-578O24.2	4.57	1.17e-05	0.00862	0.45	0.38	Lymphocyte counts;	chr8:78655825	chr8:78723796~78724136:-
TGCT	cis	rs507080	0.883	rs558593	ENSG00000255239.1	AP002954.6	4.57	1.18e-05	0.00863	0.49	0.38	Serum metabolite levels;	chr11:118691811	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.922	rs582630	ENSG00000255239.1	AP002954.6	4.57	1.18e-05	0.00863	0.49	0.38	Serum metabolite levels;	chr11:118692090	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.883	rs527475	ENSG00000255239.1	AP002954.6	4.57	1.18e-05	0.00863	0.49	0.38	Serum metabolite levels;	chr11:118692530	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.922	rs585039	ENSG00000255239.1	AP002954.6	4.57	1.18e-05	0.00863	0.49	0.38	Serum metabolite levels;	chr11:118692672	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.922	rs508640	ENSG00000255239.1	AP002954.6	4.57	1.18e-05	0.00863	0.49	0.38	Serum metabolite levels;	chr11:118693704	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.922	rs471227	ENSG00000255239.1	AP002954.6	4.57	1.18e-05	0.00863	0.49	0.38	Serum metabolite levels;	chr11:118693892	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.922	rs516153	ENSG00000255239.1	AP002954.6	4.57	1.18e-05	0.00863	0.49	0.38	Serum metabolite levels;	chr11:118694053	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.922	rs518028	ENSG00000255239.1	AP002954.6	4.57	1.18e-05	0.00863	0.49	0.38	Serum metabolite levels;	chr11:118694273	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.922	rs519982	ENSG00000255239.1	AP002954.6	4.57	1.18e-05	0.00863	0.49	0.38	Serum metabolite levels;	chr11:118694522	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.922	rs478371	ENSG00000255239.1	AP002954.6	4.57	1.18e-05	0.00863	0.49	0.38	Serum metabolite levels;	chr11:118694627	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.922	rs502601	ENSG00000255239.1	AP002954.6	4.57	1.18e-05	0.00863	0.49	0.38	Serum metabolite levels;	chr11:118694970	chr11:118688039~118690600:-
TGCT	cis	rs34779708	0.771	rs12098283	ENSG00000230534.5	RP11-297A16.2	4.57	1.18e-05	0.00864	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35189187	chr10:35098006~35127020:-
TGCT	cis	rs35160687	0.814	rs1863063	ENSG00000273080.1	RP11-301O19.1	4.57	1.18e-05	0.00864	0.43	0.38	Night sleep phenotypes;	chr2:86291126	chr2:86195590~86196049:+
TGCT	cis	rs1707322	0.721	rs10890341	ENSG00000280836.1	AL355480.1	-4.57	1.18e-05	0.00866	-0.51	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr1:45581219~45581321:-
TGCT	cis	rs507080	0.922	rs7114458	ENSG00000255239.1	AP002954.6	4.57	1.18e-05	0.00866	0.49	0.38	Serum metabolite levels;	chr11:118695466	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.922	rs7114216	ENSG00000255239.1	AP002954.6	4.57	1.18e-05	0.00866	0.49	0.38	Serum metabolite levels;	chr11:118695525	chr11:118688039~118690600:-
TGCT	cis	rs877819	0.5	rs11101517	ENSG00000228403.1	RP11-563N6.6	-4.57	1.18e-05	0.00867	-0.41	-0.38	Systemic lupus erythematosus;	chr10:48823456	chr10:48878022~48878649:+
TGCT	cis	rs7201929	0.801	rs9933198	ENSG00000259982.1	CDC37P1	-4.57	1.19e-05	0.00868	-0.51	-0.38	QT interval;	chr16:28877088	chr16:28700294~28701540:-
TGCT	cis	rs10504229	0.636	rs77691549	ENSG00000253301.4	RP11-513O17.2	4.57	1.19e-05	0.00868	0.61	0.38	Developmental language disorder (linguistic errors);	chr8:57142567	chr8:57142689~57240298:+
TGCT	cis	rs651907	0.535	rs1460097	ENSG00000244119.1	PDCL3P4	4.56	1.19e-05	0.00871	0.27	0.38	Colorectal cancer;	chr3:101778725	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.535	rs17412601	ENSG00000244119.1	PDCL3P4	4.56	1.19e-05	0.00871	0.27	0.38	Colorectal cancer;	chr3:101780431	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.535	rs13094753	ENSG00000244119.1	PDCL3P4	4.56	1.19e-05	0.00871	0.27	0.38	Colorectal cancer;	chr3:101806238	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.535	rs11716558	ENSG00000244119.1	PDCL3P4	4.56	1.19e-05	0.00871	0.27	0.38	Colorectal cancer;	chr3:101809637	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.535	rs12633089	ENSG00000244119.1	PDCL3P4	4.56	1.19e-05	0.00871	0.27	0.38	Colorectal cancer;	chr3:101809919	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.535	rs11707250	ENSG00000244119.1	PDCL3P4	-4.56	1.19e-05	0.00871	-0.27	-0.38	Colorectal cancer;	chr3:101790527	chr3:101712472~101713191:+
TGCT	cis	rs10504229	0.683	rs72649192	ENSG00000253301.4	RP11-513O17.2	4.56	1.19e-05	0.00871	0.6	0.38	Developmental language disorder (linguistic errors);	chr8:57197931	chr8:57142689~57240298:+
TGCT	cis	rs11671005	0.737	rs11671033	ENSG00000232098.3	CTD-2619J13.14	-4.56	1.19e-05	0.00871	-0.46	-0.38	Mean platelet volume;	chr19:58452302	chr19:58404238~58408484:-
TGCT	cis	rs72772090	0.539	rs10515248	ENSG00000248734.2	CTD-2260A17.1	-4.56	1.19e-05	0.00871	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776301	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs56213813	ENSG00000248734.2	CTD-2260A17.1	-4.56	1.19e-05	0.00871	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776580	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.52	rs56325109	ENSG00000248734.2	CTD-2260A17.1	-4.56	1.19e-05	0.00871	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776591	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs11747148	ENSG00000248734.2	CTD-2260A17.1	-4.56	1.19e-05	0.00871	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777159	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs11747179	ENSG00000248734.2	CTD-2260A17.1	-4.56	1.19e-05	0.00871	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777265	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs11738115	ENSG00000248734.2	CTD-2260A17.1	4.56	1.19e-05	0.00871	0.49	0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777368	chr5:96784777~96785999:+
TGCT	cis	rs3742264	1	rs9534313	ENSG00000235903.6	CPB2-AS1	-4.56	1.19e-05	0.00872	-0.46	-0.38	Blood protein levels;	chr13:46076411	chr13:46052806~46113332:+
TGCT	cis	rs3742264	1	rs8181800	ENSG00000235903.6	CPB2-AS1	-4.56	1.19e-05	0.00872	-0.46	-0.38	Blood protein levels;	chr13:46076559	chr13:46052806~46113332:+
TGCT	cis	rs3742264	1	rs17844052	ENSG00000235903.6	CPB2-AS1	-4.56	1.19e-05	0.00872	-0.46	-0.38	Blood protein levels;	chr13:46076653	chr13:46052806~46113332:+
TGCT	cis	rs3742264	0.922	rs4942473	ENSG00000235903.6	CPB2-AS1	-4.56	1.19e-05	0.00872	-0.46	-0.38	Blood protein levels;	chr13:46077173	chr13:46052806~46113332:+
TGCT	cis	rs3742264	0.961	rs4942474	ENSG00000235903.6	CPB2-AS1	-4.56	1.19e-05	0.00872	-0.46	-0.38	Blood protein levels;	chr13:46077209	chr13:46052806~46113332:+
TGCT	cis	rs3742264	0.922	rs4942475	ENSG00000235903.6	CPB2-AS1	-4.56	1.19e-05	0.00872	-0.46	-0.38	Blood protein levels;	chr13:46077386	chr13:46052806~46113332:+
TGCT	cis	rs3742264	0.885	rs4942476	ENSG00000235903.6	CPB2-AS1	-4.56	1.19e-05	0.00872	-0.46	-0.38	Blood protein levels;	chr13:46077491	chr13:46052806~46113332:+
TGCT	cis	rs3742264	0.922	rs4942477	ENSG00000235903.6	CPB2-AS1	-4.56	1.19e-05	0.00872	-0.46	-0.38	Blood protein levels;	chr13:46077628	chr13:46052806~46113332:+
TGCT	cis	rs2286503	0.78	rs2240727	ENSG00000234286.1	AC006026.13	4.56	1.19e-05	0.00872	0.46	0.38	Fibrinogen;	chr7:22812893	chr7:23680195~23680786:-
TGCT	cis	rs2286503	0.78	rs2286506	ENSG00000234286.1	AC006026.13	4.56	1.19e-05	0.00872	0.46	0.38	Fibrinogen;	chr7:22815196	chr7:23680195~23680786:-
TGCT	cis	rs2286503	0.752	rs2286504	ENSG00000234286.1	AC006026.13	4.56	1.19e-05	0.00872	0.46	0.38	Fibrinogen;	chr7:22815228	chr7:23680195~23680786:-
TGCT	cis	rs10504229	0.954	rs903717	ENSG00000253301.4	RP11-513O17.2	4.56	1.19e-05	0.00873	0.45	0.38	Developmental language disorder (linguistic errors);	chr8:57255297	chr8:57142689~57240298:+
TGCT	cis	rs786425	0.966	rs7302183	ENSG00000278112.1	RP11-972P1.11	4.56	1.19e-05	0.00874	0.43	0.38	Pubertal anthropometrics;	chr12:123619913	chr12:123519390~123519856:-
TGCT	cis	rs877819	0.583	rs2620890	ENSG00000228403.1	RP11-563N6.6	-4.56	1.2e-05	0.00876	-0.41	-0.38	Systemic lupus erythematosus;	chr10:48851723	chr10:48878022~48878649:+
TGCT	cis	rs877819	0.583	rs2889699	ENSG00000228403.1	RP11-563N6.6	-4.56	1.2e-05	0.00876	-0.41	-0.38	Systemic lupus erythematosus;	chr10:48854659	chr10:48878022~48878649:+
TGCT	cis	rs2919917	0.554	rs2086755	ENSG00000254352.1	RP11-578O24.2	4.56	1.2e-05	0.00876	0.46	0.38	Lymphocyte counts;	chr8:78701809	chr8:78723796~78724136:-
TGCT	cis	rs1707322	0.827	rs12125508	ENSG00000280836.1	AL355480.1	-4.56	1.2e-05	0.00877	-0.5	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.789	rs10789473	ENSG00000280836.1	AL355480.1	-4.56	1.2e-05	0.00877	-0.5	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr1:45581219~45581321:-
TGCT	cis	rs7208859	0.778	rs6505219	ENSG00000263531.1	RP13-753N3.1	4.56	1.2e-05	0.00877	0.58	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30938603	chr17:30863921~30864940:-
TGCT	cis	rs1799949	0.965	rs8176198	ENSG00000198496.9	NBR2	-4.56	1.2e-05	0.00878	-0.55	-0.38	Menopause (age at onset);	chr17:43078520	chr17:43125610~43153671:+
TGCT	cis	rs3742264	1	rs9562633	ENSG00000235903.6	CPB2-AS1	-4.56	1.2e-05	0.00878	-0.45	-0.38	Blood protein levels;	chr13:46068624	chr13:46052806~46113332:+
TGCT	cis	rs3742264	1	rs9567610	ENSG00000235903.6	CPB2-AS1	-4.56	1.2e-05	0.00878	-0.45	-0.38	Blood protein levels;	chr13:46068632	chr13:46052806~46113332:+
TGCT	cis	rs3742264	1	rs9562635	ENSG00000235903.6	CPB2-AS1	-4.56	1.2e-05	0.00878	-0.45	-0.38	Blood protein levels;	chr13:46068857	chr13:46052806~46113332:+
TGCT	cis	rs3742264	1	rs9562636	ENSG00000235903.6	CPB2-AS1	-4.56	1.2e-05	0.00878	-0.45	-0.38	Blood protein levels;	chr13:46068889	chr13:46052806~46113332:+
TGCT	cis	rs3742264	1	rs7990092	ENSG00000235903.6	CPB2-AS1	-4.56	1.2e-05	0.00878	-0.45	-0.38	Blood protein levels;	chr13:46069154	chr13:46052806~46113332:+
TGCT	cis	rs3742264	1	rs7988836	ENSG00000235903.6	CPB2-AS1	-4.56	1.2e-05	0.00878	-0.45	-0.38	Blood protein levels;	chr13:46069238	chr13:46052806~46113332:+
TGCT	cis	rs3742264	1	rs7993537	ENSG00000235903.6	CPB2-AS1	-4.56	1.2e-05	0.00878	-0.45	-0.38	Blood protein levels;	chr13:46069426	chr13:46052806~46113332:+
TGCT	cis	rs3742264	1	rs7993567	ENSG00000235903.6	CPB2-AS1	-4.56	1.2e-05	0.00878	-0.45	-0.38	Blood protein levels;	chr13:46069471	chr13:46052806~46113332:+
TGCT	cis	rs3742264	1	rs7995615	ENSG00000235903.6	CPB2-AS1	-4.56	1.2e-05	0.00878	-0.45	-0.38	Blood protein levels;	chr13:46069673	chr13:46052806~46113332:+
TGCT	cis	rs8111998	0.826	rs8108776	ENSG00000269332.4	GOLGA2P9	4.56	1.2e-05	0.00878	0.65	0.38	Corneal structure;	chr19:22582582	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.826	rs6511364	ENSG00000269332.4	GOLGA2P9	4.56	1.2e-05	0.00878	0.65	0.38	Corneal structure;	chr19:22583006	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.826	rs10418805	ENSG00000269332.4	GOLGA2P9	4.56	1.2e-05	0.00878	0.65	0.38	Corneal structure;	chr19:22583189	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.625	rs7255845	ENSG00000269332.4	GOLGA2P9	4.56	1.2e-05	0.00878	0.65	0.38	Corneal structure;	chr19:22583249	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.826	rs59838183	ENSG00000269332.4	GOLGA2P9	4.56	1.2e-05	0.00878	0.65	0.38	Corneal structure;	chr19:22583632	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.826	rs59427371	ENSG00000269332.4	GOLGA2P9	4.56	1.2e-05	0.00878	0.65	0.38	Corneal structure;	chr19:22583660	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.826	rs4932774	ENSG00000269332.4	GOLGA2P9	4.56	1.2e-05	0.00878	0.65	0.38	Corneal structure;	chr19:22583791	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.826	rs4932775	ENSG00000269332.4	GOLGA2P9	4.56	1.2e-05	0.00878	0.65	0.38	Corneal structure;	chr19:22583849	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.826	rs4932776	ENSG00000269332.4	GOLGA2P9	4.56	1.2e-05	0.00878	0.65	0.38	Corneal structure;	chr19:22583895	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.826	rs4932777	ENSG00000269332.4	GOLGA2P9	4.56	1.2e-05	0.00878	0.65	0.38	Corneal structure;	chr19:22583962	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.826	rs4932778	ENSG00000269332.4	GOLGA2P9	4.56	1.2e-05	0.00878	0.65	0.38	Corneal structure;	chr19:22584169	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.826	rs10420648	ENSG00000269332.4	GOLGA2P9	4.56	1.2e-05	0.00878	0.65	0.38	Corneal structure;	chr19:22585017	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.826	rs10421310	ENSG00000269332.4	GOLGA2P9	4.56	1.2e-05	0.00878	0.65	0.38	Corneal structure;	chr19:22585267	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.826	rs10421335	ENSG00000269332.4	GOLGA2P9	4.56	1.2e-05	0.00878	0.65	0.38	Corneal structure;	chr19:22585303	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.702	rs16999400	ENSG00000269332.4	GOLGA2P9	4.56	1.2e-05	0.00878	0.65	0.38	Corneal structure;	chr19:22585806	chr19:22596257~22603550:+
TGCT	cis	rs7617773	0.539	rs12486944	ENSG00000229759.1	MRPS18AP1	4.56	1.2e-05	0.00879	0.31	0.38	Coronary artery disease;	chr3:48348526	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.539	rs12486935	ENSG00000229759.1	MRPS18AP1	4.56	1.2e-05	0.00879	0.31	0.38	Coronary artery disease;	chr3:48348674	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.563	rs62263035	ENSG00000229759.1	MRPS18AP1	4.56	1.2e-05	0.00879	0.31	0.38	Coronary artery disease;	chr3:48350079	chr3:48256350~48256938:-
TGCT	cis	rs1707322	0.752	rs61784793	ENSG00000280836.1	AL355480.1	-4.56	1.2e-05	0.0088	-0.51	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.648	rs4439382	ENSG00000280836.1	AL355480.1	-4.56	1.2e-05	0.0088	-0.51	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr1:45581219~45581321:-
TGCT	cis	rs9400467	0.506	rs12209435	ENSG00000272356.1	RP5-1112D6.8	-4.56	1.21e-05	0.0088	-0.44	-0.38	Amino acid levels;Blood metabolite levels;	chr6:111321834	chr6:111309203~111313517:+
TGCT	cis	rs875971	0.577	rs34888281	ENSG00000237310.1	GS1-124K5.4	-4.56	1.21e-05	0.0088	-0.43	-0.38	Aortic root size;	chr7:66120784	chr7:66493706~66495474:+
TGCT	cis	rs9425766	0.523	rs6668959	ENSG00000227373.4	RP11-160H22.5	4.56	1.21e-05	0.0088	0.41	0.38	Life satisfaction;	chr1:174088488	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.665	rs7553788	ENSG00000227373.4	RP11-160H22.5	4.56	1.21e-05	0.0088	0.41	0.38	Life satisfaction;	chr1:174093773	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.655	rs4652169	ENSG00000227373.4	RP11-160H22.5	4.56	1.21e-05	0.0088	0.41	0.38	Life satisfaction;	chr1:174095343	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.679	rs6682017	ENSG00000227373.4	RP11-160H22.5	4.56	1.21e-05	0.0088	0.41	0.38	Life satisfaction;	chr1:174097809	chr1:174115300~174160004:-
TGCT	cis	rs34779708	0.966	rs11010129	ENSG00000230534.5	RP11-297A16.2	4.56	1.21e-05	0.00881	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35221894	chr10:35098006~35127020:-
TGCT	cis	rs9322193	0.923	rs12175504	ENSG00000216906.2	RP11-350J20.9	4.56	1.21e-05	0.00881	0.42	0.38	Lung cancer;	chr6:149664079	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs62439843	ENSG00000216906.2	RP11-350J20.9	4.56	1.21e-05	0.00881	0.42	0.38	Lung cancer;	chr6:149676521	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs7753812	ENSG00000216906.2	RP11-350J20.9	4.56	1.21e-05	0.00881	0.42	0.38	Lung cancer;	chr6:149690150	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs12195866	ENSG00000216906.2	RP11-350J20.9	4.56	1.21e-05	0.00881	0.42	0.38	Lung cancer;	chr6:149693334	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9285524	ENSG00000216906.2	RP11-350J20.9	4.56	1.21e-05	0.00881	0.42	0.38	Lung cancer;	chr6:149694122	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs10872645	ENSG00000216906.2	RP11-350J20.9	4.56	1.21e-05	0.00881	0.42	0.38	Lung cancer;	chr6:149742840	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs12211511	ENSG00000216906.2	RP11-350J20.9	4.56	1.21e-05	0.00881	0.42	0.38	Lung cancer;	chr6:149745206	chr6:149904243~149906418:+
TGCT	cis	rs4835473	0.932	rs9308176	ENSG00000251600.4	RP11-673E1.1	-4.56	1.21e-05	0.00883	-0.4	-0.38	Immature fraction of reticulocytes;	chr4:144072718	chr4:143912331~143982454:+
TGCT	cis	rs1372520	0.684	rs356191	ENSG00000247775.2	SNCA-AS1	-4.56	1.21e-05	0.00883	-0.37	-0.38	Neuroticism;	chr4:89766969	chr4:89836408~89841978:+
TGCT	cis	rs1372520	0.684	rs356188	ENSG00000247775.2	SNCA-AS1	-4.56	1.21e-05	0.00883	-0.37	-0.38	Neuroticism;	chr4:89770386	chr4:89836408~89841978:+
TGCT	cis	rs1372520	0.684	rs356162	ENSG00000247775.2	SNCA-AS1	-4.56	1.21e-05	0.00883	-0.37	-0.38	Neuroticism;	chr4:89776006	chr4:89836408~89841978:+
TGCT	cis	rs1372520	0.684	rs184810	ENSG00000247775.2	SNCA-AS1	-4.56	1.21e-05	0.00883	-0.37	-0.38	Neuroticism;	chr4:89776828	chr4:89836408~89841978:+
TGCT	cis	rs807029	0.533	rs67813203	ENSG00000272572.1	RP11-179B2.2	-4.56	1.21e-05	0.00883	-0.33	-0.38	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100978794	chr10:100911103~100912739:-
TGCT	cis	rs807029	0.533	rs67692077	ENSG00000272572.1	RP11-179B2.2	-4.56	1.21e-05	0.00883	-0.33	-0.38	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100980514	chr10:100911103~100912739:-
TGCT	cis	rs807029	0.533	rs12571302	ENSG00000272572.1	RP11-179B2.2	-4.56	1.21e-05	0.00883	-0.33	-0.38	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100983006	chr10:100911103~100912739:-
TGCT	cis	rs807029	0.533	rs2295716	ENSG00000272572.1	RP11-179B2.2	-4.56	1.21e-05	0.00883	-0.33	-0.38	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100984457	chr10:100911103~100912739:-
TGCT	cis	rs807029	0.533	rs722435	ENSG00000272572.1	RP11-179B2.2	-4.56	1.21e-05	0.00883	-0.33	-0.38	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100985305	chr10:100911103~100912739:-
TGCT	cis	rs807029	0.533	rs2863095	ENSG00000272572.1	RP11-179B2.2	-4.56	1.21e-05	0.00883	-0.33	-0.38	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100986746	chr10:100911103~100912739:-
TGCT	cis	rs807029	0.533	rs3740485	ENSG00000272572.1	RP11-179B2.2	-4.56	1.21e-05	0.00883	-0.33	-0.38	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100990864	chr10:100911103~100912739:-
TGCT	cis	rs807029	0.533	rs3740486	ENSG00000272572.1	RP11-179B2.2	-4.56	1.21e-05	0.00883	-0.33	-0.38	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100990866	chr10:100911103~100912739:-
TGCT	cis	rs807029	0.533	rs3740487	ENSG00000272572.1	RP11-179B2.2	-4.56	1.21e-05	0.00883	-0.33	-0.38	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100991026	chr10:100911103~100912739:-
TGCT	cis	rs73607972	0.66	rs9923447	ENSG00000275191.1	RP11-36I17.2	-4.56	1.21e-05	0.00884	-0.42	-0.38	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53609191	chr16:53628256~53628816:-
TGCT	cis	rs2717559	0.542	rs11774823	ENSG00000253196.1	RP11-706C16.7	-4.56	1.21e-05	0.00885	-0.39	-0.38	Urinary tract infection frequency;	chr8:142806152	chr8:142763116~142766427:+
TGCT	cis	rs2717559	0.542	rs11777634	ENSG00000253196.1	RP11-706C16.7	-4.56	1.21e-05	0.00885	-0.39	-0.38	Urinary tract infection frequency;	chr8:142806541	chr8:142763116~142766427:+
TGCT	cis	rs34779708	0.966	rs1148245	ENSG00000230534.5	RP11-297A16.2	4.56	1.21e-05	0.00885	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35222966	chr10:35098006~35127020:-
TGCT	cis	rs9425766	0.655	rs2145376	ENSG00000227373.4	RP11-160H22.5	4.56	1.22e-05	0.00886	0.41	0.38	Life satisfaction;	chr1:174098911	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.679	rs6663794	ENSG00000227373.4	RP11-160H22.5	4.56	1.22e-05	0.00886	0.41	0.38	Life satisfaction;	chr1:174099791	chr1:174115300~174160004:-
TGCT	cis	rs9425766	0.679	rs6691711	ENSG00000227373.4	RP11-160H22.5	4.56	1.22e-05	0.00886	0.41	0.38	Life satisfaction;	chr1:174100283	chr1:174115300~174160004:-
TGCT	cis	rs786425	0.966	rs3748269	ENSG00000278112.1	RP11-972P1.11	4.56	1.22e-05	0.00887	0.43	0.38	Pubertal anthropometrics;	chr12:123615378	chr12:123519390~123519856:-
TGCT	cis	rs7829975	0.606	rs7837026	ENSG00000254340.1	RP11-10A14.3	-4.56	1.22e-05	0.00888	-0.4	-0.38	Mood instability;	chr8:8944182	chr8:9141424~9145435:+
TGCT	cis	rs10246939	0.543	rs10952509	ENSG00000228775.6	WEE2-AS1	4.56	1.22e-05	0.00888	0.35	0.38	Bitter taste perception;	chr7:141890884	chr7:141704338~141738346:-
TGCT	cis	rs5769707	0.933	rs2157444	ENSG00000235111.1	RP1-29C18.8	-4.56	1.22e-05	0.00888	-0.31	-0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49612657~49615716:-
TGCT	cis	rs763121	0.815	rs9306328	ENSG00000273076.1	RP3-508I15.22	4.56	1.22e-05	0.00888	0.41	0.38	Menopause (age at onset);	chr22:38632908	chr22:38743495~38743910:+
TGCT	cis	rs2019137	0.868	rs3748916	ENSG00000189223.12	PAX8-AS1	4.56	1.22e-05	0.00889	0.47	0.38	Lymphocyte counts;	chr2:113226456	chr2:113211522~113276581:+
TGCT	cis	rs2188561	0.697	rs739518	ENSG00000241764.3	AC002467.7	4.56	1.22e-05	0.00889	0.35	0.38	Alcohol consumption;	chr7:107743682	chr7:107742817~107744581:-
TGCT	cis	rs1618992	0.818	rs11083296	ENSG00000265994.1	RP11-510D21.1	4.56	1.22e-05	0.00889	0.38	0.38	Gut microbiome composition (summer and winter);	chr18:28642046	chr18:28785068~28789260:+
TGCT	cis	rs1618992	0.74	rs12605271	ENSG00000265994.1	RP11-510D21.1	4.56	1.22e-05	0.00889	0.38	0.38	Gut microbiome composition (summer and winter);	chr18:28642388	chr18:28785068~28789260:+
TGCT	cis	rs1618992	0.791	rs28866230	ENSG00000265994.1	RP11-510D21.1	4.56	1.22e-05	0.00889	0.38	0.38	Gut microbiome composition (summer and winter);	chr18:28642970	chr18:28785068~28789260:+
TGCT	cis	rs1618992	0.721	rs8098398	ENSG00000265994.1	RP11-510D21.1	4.56	1.22e-05	0.00889	0.38	0.38	Gut microbiome composition (summer and winter);	chr18:28643781	chr18:28785068~28789260:+
TGCT	cis	rs1618992	0.791	rs11874898	ENSG00000265994.1	RP11-510D21.1	4.56	1.22e-05	0.00889	0.38	0.38	Gut microbiome composition (summer and winter);	chr18:28643876	chr18:28785068~28789260:+
TGCT	cis	rs1618992	0.765	rs56057525	ENSG00000265994.1	RP11-510D21.1	4.56	1.22e-05	0.00889	0.38	0.38	Gut microbiome composition (summer and winter);	chr18:28644061	chr18:28785068~28789260:+
TGCT	cis	rs1618992	0.791	rs56183213	ENSG00000265994.1	RP11-510D21.1	4.56	1.22e-05	0.00889	0.38	0.38	Gut microbiome composition (summer and winter);	chr18:28644152	chr18:28785068~28789260:+
TGCT	cis	rs9309473	0.95	rs11126412	ENSG00000163016.8	ALMS1P	4.56	1.22e-05	0.00891	0.35	0.38	Metabolite levels;	chr2:73660507	chr2:73644919~73685576:+
TGCT	cis	rs6604026	0.555	rs12743520	ENSG00000223787.2	RP4-593M8.1	4.56	1.22e-05	0.00891	0.55	0.38	Multiple sclerosis;	chr1:92571555	chr1:92580476~92580821:-
TGCT	cis	rs1891275	0.515	rs7911755	ENSG00000228701.1	TNKS2-AS1	-4.56	1.22e-05	0.00892	-0.43	-0.38	Intelligence (multi-trait analysis);	chr10:91730060	chr10:91782839~91798291:-
TGCT	cis	rs17507216	0.518	rs1877240	ENSG00000255769.6	GOLGA2P10	-4.56	1.23e-05	0.00893	-0.49	-0.38	Excessive daytime sleepiness;	chr15:82770126	chr15:82472993~82513950:-
TGCT	cis	rs4380275	0.782	rs4854276	ENSG00000223751.1	AC116609.2	4.56	1.23e-05	0.00893	0.39	0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:764357	chr2:742488~747767:+
TGCT	cis	rs7923609	1	rs1935	ENSG00000232075.1	MRPL35P2	-4.56	1.23e-05	0.00893	-0.37	-0.38	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63168063	chr10:63634317~63634827:-
TGCT	cis	rs6604026	0.624	rs34202284	ENSG00000223787.2	RP4-593M8.1	-4.56	1.23e-05	0.00894	-0.52	-0.38	Multiple sclerosis;	chr1:92694445	chr1:92580476~92580821:-
TGCT	cis	rs4835473	0.932	rs7693772	ENSG00000251600.4	RP11-673E1.1	4.56	1.23e-05	0.00894	0.4	0.38	Immature fraction of reticulocytes;	chr4:143965614	chr4:143912331~143982454:+
TGCT	cis	rs1618992	0.678	rs6508551	ENSG00000265994.1	RP11-510D21.1	4.56	1.23e-05	0.00895	0.38	0.38	Gut microbiome composition (summer and winter);	chr18:28567270	chr18:28785068~28789260:+
TGCT	cis	rs7208859	0.725	rs9897673	ENSG00000266490.1	CTD-2349P21.9	4.56	1.23e-05	0.00895	0.38	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916348	chr17:30792372~30792833:+
TGCT	cis	rs67311347	1	rs2276868	ENSG00000223797.4	ENTPD3-AS1	-4.56	1.23e-05	0.00895	-0.39	-0.38	Renal cell carcinoma;	chr3:40457354	chr3:40313802~40453329:-
TGCT	cis	rs10504229	0.683	rs57866073	ENSG00000253301.4	RP11-513O17.2	4.55	1.24e-05	0.00899	0.58	0.38	Developmental language disorder (linguistic errors);	chr8:57226579	chr8:57142689~57240298:+
TGCT	cis	rs786425	0.932	rs786443	ENSG00000247373.3	RP11-486O12.2	-4.55	1.24e-05	0.009	-0.45	-0.38	Pubertal anthropometrics;	chr12:123579344	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.868	rs786447	ENSG00000247373.3	RP11-486O12.2	-4.55	1.24e-05	0.009	-0.45	-0.38	Pubertal anthropometrics;	chr12:123585120	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.932	rs786448	ENSG00000247373.3	RP11-486O12.2	-4.55	1.24e-05	0.009	-0.45	-0.38	Pubertal anthropometrics;	chr12:123585667	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.966	rs786449	ENSG00000247373.3	RP11-486O12.2	-4.55	1.24e-05	0.009	-0.45	-0.38	Pubertal anthropometrics;	chr12:123587181	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.966	rs6551	ENSG00000247373.3	RP11-486O12.2	-4.55	1.24e-05	0.009	-0.45	-0.38	Pubertal anthropometrics;	chr12:123597693	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.966	rs786422	ENSG00000247373.3	RP11-486O12.2	-4.55	1.24e-05	0.009	-0.45	-0.38	Pubertal anthropometrics;	chr12:123599015	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.838	rs1543075	ENSG00000247373.3	RP11-486O12.2	-4.55	1.24e-05	0.009	-0.45	-0.38	Pubertal anthropometrics;	chr12:123601901	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.966	rs4456350	ENSG00000247373.3	RP11-486O12.2	4.55	1.24e-05	0.009	0.45	0.38	Pubertal anthropometrics;	chr12:123573942	chr12:123575891~123585115:-
TGCT	cis	rs875971	0.929	rs778712	ENSG00000237310.1	GS1-124K5.4	4.55	1.24e-05	0.00901	0.41	0.38	Aortic root size;	chr7:66384991	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs778710	ENSG00000237310.1	GS1-124K5.4	4.55	1.24e-05	0.00901	0.41	0.38	Aortic root size;	chr7:66389847	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.964	rs778708	ENSG00000237310.1	GS1-124K5.4	4.55	1.24e-05	0.00901	0.41	0.38	Aortic root size;	chr7:66391332	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs778696	ENSG00000237310.1	GS1-124K5.4	4.55	1.24e-05	0.00901	0.41	0.38	Aortic root size;	chr7:66405826	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs778694	ENSG00000237310.1	GS1-124K5.4	4.55	1.24e-05	0.00901	0.41	0.38	Aortic root size;	chr7:66406571	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs4718344	ENSG00000237310.1	GS1-124K5.4	4.55	1.24e-05	0.00901	0.41	0.38	Aortic root size;	chr7:66409394	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.737	rs7803424	ENSG00000237310.1	GS1-124K5.4	4.55	1.24e-05	0.00901	0.41	0.38	Aortic root size;	chr7:66415618	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.83	rs7799834	ENSG00000237310.1	GS1-124K5.4	4.55	1.24e-05	0.00901	0.41	0.38	Aortic root size;	chr7:66415707	chr7:66493706~66495474:+
TGCT	cis	rs6604026	0.555	rs1333743	ENSG00000223787.2	RP4-593M8.1	4.55	1.24e-05	0.00901	0.55	0.38	Multiple sclerosis;	chr1:92600617	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.555	rs11808092	ENSG00000223787.2	RP4-593M8.1	4.55	1.24e-05	0.00901	0.55	0.38	Multiple sclerosis;	chr1:92607671	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.555	rs34734076	ENSG00000223787.2	RP4-593M8.1	4.55	1.24e-05	0.00901	0.55	0.38	Multiple sclerosis;	chr1:92613901	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.555	rs11807962	ENSG00000223787.2	RP4-593M8.1	4.55	1.24e-05	0.00901	0.55	0.38	Multiple sclerosis;	chr1:92614721	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.555	rs34221961	ENSG00000223787.2	RP4-593M8.1	4.55	1.24e-05	0.00901	0.55	0.38	Multiple sclerosis;	chr1:92615337	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.555	rs11589122	ENSG00000223787.2	RP4-593M8.1	4.55	1.24e-05	0.00901	0.55	0.38	Multiple sclerosis;	chr1:92618346	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.555	rs4642892	ENSG00000223787.2	RP4-593M8.1	4.55	1.24e-05	0.00901	0.55	0.38	Multiple sclerosis;	chr1:92628570	chr1:92580476~92580821:-
TGCT	cis	rs853679	0.55	rs1150692	ENSG00000187763.3	OR2B7P	4.55	1.24e-05	0.00903	0.38	0.38	Depression;	chr6:28206179	chr6:28046434~28047367:+
TGCT	cis	rs3743162	0.553	rs12900463	ENSG00000225151.9	GOLGA2P7	-4.55	1.25e-05	0.00904	-0.47	-0.38	Alzheimer's disease (age of onset);	chr15:84872155	chr15:84199311~84230136:-
TGCT	cis	rs3743162	0.553	rs12915656	ENSG00000225151.9	GOLGA2P7	-4.55	1.25e-05	0.00904	-0.47	-0.38	Alzheimer's disease (age of onset);	chr15:84872349	chr15:84199311~84230136:-
TGCT	cis	rs17154702	0.51	rs7831224	ENSG00000253893.2	FAM85B	4.55	1.25e-05	0.00906	0.59	0.38	Neurocognitive impairment in HIV-1 infection (continuous);	chr8:8799137	chr8:8167819~8226614:-
TGCT	cis	rs520525	0.963	rs501680	ENSG00000271811.1	RP1-79C4.4	4.55	1.25e-05	0.00906	0.31	0.38	Atrial fibrillation;	chr1:170656726	chr1:170667381~170669425:+
TGCT	cis	rs4423214	0.802	rs2276358	ENSG00000254682.1	RP11-660L16.2	-4.55	1.25e-05	0.00907	-0.58	-0.38	Vitamin D levels;	chr11:71473452	chr11:71448674~71452157:+
TGCT	cis	rs7923609	0.811	rs10822181	ENSG00000232075.1	MRPL35P2	4.55	1.25e-05	0.00907	0.37	0.38	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63565366	chr10:63634317~63634827:-
TGCT	cis	rs453301	0.574	rs10081437	ENSG00000254340.1	RP11-10A14.3	-4.55	1.25e-05	0.00908	-0.4	-0.38	Joint mobility (Beighton score);	chr8:9091469	chr8:9141424~9145435:+
TGCT	cis	rs1707322	0.682	rs12041197	ENSG00000280836.1	AL355480.1	-4.55	1.25e-05	0.00908	-0.51	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.752	rs11211146	ENSG00000280836.1	AL355480.1	-4.55	1.25e-05	0.00908	-0.51	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.752	rs11211147	ENSG00000280836.1	AL355480.1	-4.55	1.25e-05	0.00908	-0.51	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.752	rs11211152	ENSG00000280836.1	AL355480.1	-4.55	1.25e-05	0.00908	-0.51	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.681	rs12048866	ENSG00000280836.1	AL355480.1	-4.55	1.25e-05	0.00908	-0.51	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.752	rs12024590	ENSG00000280836.1	AL355480.1	-4.55	1.25e-05	0.00908	-0.51	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.752	rs12027622	ENSG00000280836.1	AL355480.1	-4.55	1.25e-05	0.00908	-0.51	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.716	rs6699444	ENSG00000280836.1	AL355480.1	-4.55	1.25e-05	0.00908	-0.51	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr1:45581219~45581321:-
TGCT	cis	rs2463822	1	rs115395195	ENSG00000254454.2	RCC2P6	4.55	1.25e-05	0.00908	0.41	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62332881	chr11:62371146~62373168:+
TGCT	cis	rs2463822	1	rs118049526	ENSG00000254454.2	RCC2P6	4.55	1.25e-05	0.00908	0.41	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62340036	chr11:62371146~62373168:+
TGCT	cis	rs2463822	1	rs2463822	ENSG00000254454.2	RCC2P6	-4.55	1.25e-05	0.00908	-0.41	-0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62335948	chr11:62371146~62373168:+
TGCT	cis	rs2463822	1	rs951677	ENSG00000254454.2	RCC2P6	-4.55	1.25e-05	0.00908	-0.41	-0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62339777	chr11:62371146~62373168:+
TGCT	cis	rs1010254	0.543	rs113559777	ENSG00000213433.5	RPLP1P6	-4.55	1.25e-05	0.00908	-0.44	-0.38	Optic nerve measurement (cup area);	chr5:152437084	chr5:151765859~151766378:-
TGCT	cis	rs7617773	0.539	rs13094496	ENSG00000229759.1	MRPS18AP1	4.55	1.25e-05	0.00909	0.31	0.38	Coronary artery disease;	chr3:48345560	chr3:48256350~48256938:-
TGCT	cis	rs2919917	0.628	rs1036751	ENSG00000254352.1	RP11-578O24.2	-4.55	1.26e-05	0.00909	-0.46	-0.38	Lymphocyte counts;	chr8:78729671	chr8:78723796~78724136:-
TGCT	cis	rs2919917	0.628	rs12544041	ENSG00000254352.1	RP11-578O24.2	-4.55	1.26e-05	0.00909	-0.46	-0.38	Lymphocyte counts;	chr8:78731404	chr8:78723796~78724136:-
TGCT	cis	rs2919917	0.628	rs2583759	ENSG00000254352.1	RP11-578O24.2	-4.55	1.26e-05	0.00909	-0.46	-0.38	Lymphocyte counts;	chr8:78732729	chr8:78723796~78724136:-
TGCT	cis	rs2919917	0.628	rs894222	ENSG00000254352.1	RP11-578O24.2	-4.55	1.26e-05	0.00909	-0.46	-0.38	Lymphocyte counts;	chr8:78737034	chr8:78723796~78724136:-
TGCT	cis	rs2919917	0.628	rs2583778	ENSG00000254352.1	RP11-578O24.2	-4.55	1.26e-05	0.00909	-0.46	-0.38	Lymphocyte counts;	chr8:78738906	chr8:78723796~78724136:-
TGCT	cis	rs1618992	0.791	rs2847398	ENSG00000265994.1	RP11-510D21.1	4.55	1.26e-05	0.00909	0.38	0.38	Gut microbiome composition (summer and winter);	chr18:28642597	chr18:28785068~28789260:+
TGCT	cis	rs4660214	0.724	rs7554301	ENSG00000182109.6	RP11-69E11.4	-4.55	1.26e-05	0.00909	-0.38	-0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39177792	chr1:39522280~39546187:-
TGCT	cis	rs875971	0.545	rs2707851	ENSG00000237310.1	GS1-124K5.4	-4.55	1.26e-05	0.0091	-0.45	-0.38	Aortic root size;	chr7:66624178	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs1796226	ENSG00000237310.1	GS1-124K5.4	4.55	1.26e-05	0.0091	0.45	0.38	Aortic root size;	chr7:66622723	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs10263690	ENSG00000237310.1	GS1-124K5.4	-4.55	1.26e-05	0.0091	-0.41	-0.38	Aortic root size;	chr7:66301466	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs10250544	ENSG00000237310.1	GS1-124K5.4	-4.55	1.26e-05	0.0091	-0.41	-0.38	Aortic root size;	chr7:66301574	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.895	rs12531677	ENSG00000237310.1	GS1-124K5.4	-4.55	1.26e-05	0.0091	-0.41	-0.38	Aortic root size;	chr7:66304099	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs7798630	ENSG00000237310.1	GS1-124K5.4	-4.55	1.26e-05	0.0091	-0.41	-0.38	Aortic root size;	chr7:66306492	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs11984115	ENSG00000237310.1	GS1-124K5.4	-4.55	1.26e-05	0.0091	-0.41	-0.38	Aortic root size;	chr7:66308872	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.755	rs10228885	ENSG00000237310.1	GS1-124K5.4	-4.55	1.26e-05	0.0091	-0.41	-0.38	Aortic root size;	chr7:66315542	chr7:66493706~66495474:+
TGCT	cis	rs1372520	1	rs1372520	ENSG00000247775.2	SNCA-AS1	4.55	1.26e-05	0.0091	0.39	0.38	Neuroticism;	chr4:89836354	chr4:89836408~89841978:+
TGCT	cis	rs761746	0.584	rs62238892	ENSG00000236132.1	CTA-440B3.1	-4.55	1.26e-05	0.0091	-0.49	-0.38	Intelligence;	chr22:31765563	chr22:31816379~31817491:-
TGCT	cis	rs761746	0.579	rs5998121	ENSG00000236132.1	CTA-440B3.1	-4.55	1.26e-05	0.0091	-0.49	-0.38	Intelligence;	chr22:31776381	chr22:31816379~31817491:-
TGCT	cis	rs761746	0.543	rs5998122	ENSG00000236132.1	CTA-440B3.1	-4.55	1.26e-05	0.0091	-0.49	-0.38	Intelligence;	chr22:31777067	chr22:31816379~31817491:-
TGCT	cis	rs761746	0.579	rs5998126	ENSG00000236132.1	CTA-440B3.1	-4.55	1.26e-05	0.0091	-0.49	-0.38	Intelligence;	chr22:31782416	chr22:31816379~31817491:-
TGCT	cis	rs761746	0.614	rs2108108	ENSG00000236132.1	CTA-440B3.1	-4.55	1.26e-05	0.0091	-0.49	-0.38	Intelligence;	chr22:31785951	chr22:31816379~31817491:-
TGCT	cis	rs761746	0.614	rs8141214	ENSG00000236132.1	CTA-440B3.1	-4.55	1.26e-05	0.0091	-0.49	-0.38	Intelligence;	chr22:31800195	chr22:31816379~31817491:-
TGCT	cis	rs2980439	0.818	rs2948300	ENSG00000253893.2	FAM85B	-4.55	1.26e-05	0.0091	-0.49	-0.38	Neuroticism;	chr8:8248986	chr8:8167819~8226614:-
TGCT	cis	rs9462027	0.539	rs9469883	ENSG00000186328.4	RP11-140K17.2	4.55	1.26e-05	0.0091	0.36	0.38	Systemic lupus erythematosus;	chr6:34790850	chr6:34715613~34715940:+
TGCT	cis	rs847851	0.63	rs9462021	ENSG00000186328.4	RP11-140K17.2	4.55	1.26e-05	0.0091	0.36	0.38	Colonoscopy-negative controls vs population controls;	chr6:34790863	chr6:34715613~34715940:+
TGCT	cis	rs559928	1	rs641168	ENSG00000236935.1	AP003774.1	-4.55	1.26e-05	0.0091	-0.4	-0.38	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64378817	chr11:64325050~64329504:-
TGCT	cis	rs2439831	0.867	rs486301	ENSG00000205771.5	CATSPER2P1	-4.55	1.26e-05	0.0091	-0.63	-0.38	Lung cancer in ever smokers;	chr15:43544751	chr15:43726918~43747094:-
TGCT	cis	rs7923609	0.578	rs10740138	ENSG00000232075.1	MRPL35P2	-4.55	1.26e-05	0.00911	-0.36	-0.38	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63635373	chr10:63634317~63634827:-
TGCT	cis	rs16852403	0.548	rs623225	ENSG00000224687.1	RASAL2-AS1	-4.55	1.26e-05	0.00912	-0.51	-0.38	Childhood ear infection;	chr1:178242187	chr1:178091508~178093984:-
TGCT	cis	rs16852403	0.548	rs543452	ENSG00000224687.1	RASAL2-AS1	-4.55	1.26e-05	0.00912	-0.51	-0.38	Childhood ear infection;	chr1:178251743	chr1:178091508~178093984:-
TGCT	cis	rs16852403	0.548	rs482269	ENSG00000224687.1	RASAL2-AS1	-4.55	1.26e-05	0.00912	-0.51	-0.38	Childhood ear infection;	chr1:178257489	chr1:178091508~178093984:-
TGCT	cis	rs10246939	0.505	rs34726057	ENSG00000228775.6	WEE2-AS1	4.55	1.26e-05	0.00913	0.35	0.38	Bitter taste perception;	chr7:141832117	chr7:141704338~141738346:-
TGCT	cis	rs10246939	0.505	rs9640203	ENSG00000228775.6	WEE2-AS1	4.55	1.26e-05	0.00913	0.35	0.38	Bitter taste perception;	chr7:141844295	chr7:141704338~141738346:-
TGCT	cis	rs72772090	0.539	rs72773942	ENSG00000248734.2	CTD-2260A17.1	-4.55	1.26e-05	0.00913	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96787663	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs11743410	ENSG00000248734.2	CTD-2260A17.1	-4.55	1.26e-05	0.00913	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96788750	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs11746534	ENSG00000248734.2	CTD-2260A17.1	-4.55	1.26e-05	0.00913	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789104	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs55773007	ENSG00000248734.2	CTD-2260A17.1	-4.55	1.26e-05	0.00913	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789215	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs111886458	ENSG00000248734.2	CTD-2260A17.1	-4.55	1.26e-05	0.00913	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789344	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs10515249	ENSG00000248734.2	CTD-2260A17.1	-4.55	1.26e-05	0.00913	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789556	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs72773947	ENSG00000248734.2	CTD-2260A17.1	-4.55	1.26e-05	0.00913	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789830	chr5:96784777~96785999:+
TGCT	cis	rs875971	0.862	rs2901152	ENSG00000232559.3	GS1-124K5.12	-4.55	1.26e-05	0.00913	-0.35	-0.38	Aortic root size;	chr7:66300017	chr7:66554588~66576923:-
TGCT	cis	rs1618992	0.791	rs1941319	ENSG00000265994.1	RP11-510D21.1	4.55	1.26e-05	0.00913	0.38	0.38	Gut microbiome composition (summer and winter);	chr18:28647095	chr18:28785068~28789260:+
TGCT	cis	rs7246967	0.673	rs34126042	ENSG00000269509.1	BNIP3P34	4.55	1.26e-05	0.00914	0.59	0.38	Bronchopulmonary dysplasia;	chr19:22726416	chr19:22773853~22774424:+
TGCT	cis	rs7829975	0.714	rs7823757	ENSG00000173295.6	FAM86B3P	4.55	1.27e-05	0.00914	0.45	0.38	Mood instability;	chr8:8812667	chr8:8228595~8244865:+
TGCT	cis	rs7829975	0.714	rs60315134	ENSG00000173295.6	FAM86B3P	4.55	1.27e-05	0.00914	0.45	0.38	Mood instability;	chr8:8813089	chr8:8228595~8244865:+
TGCT	cis	rs728616	0.867	rs726289	ENSG00000230091.5	TMEM254-AS1	4.55	1.27e-05	0.00915	0.67	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79947195	chr10:80046860~80078912:-
TGCT	cis	rs3931020	0.508	rs11485298	ENSG00000272864.1	RP11-17E13.2	-4.55	1.27e-05	0.00915	-0.43	-0.38	Resistin levels;	chr1:74752068	chr1:74698769~74699333:-
TGCT	cis	rs3931020	0.508	rs4145871	ENSG00000272864.1	RP11-17E13.2	-4.55	1.27e-05	0.00915	-0.43	-0.38	Resistin levels;	chr1:74753020	chr1:74698769~74699333:-
TGCT	cis	rs9462027	0.628	rs7774697	ENSG00000186328.4	RP11-140K17.2	-4.55	1.27e-05	0.00915	-0.36	-0.38	Systemic lupus erythematosus;	chr6:34823250	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs2814967	ENSG00000186328.4	RP11-140K17.2	4.55	1.27e-05	0.00915	0.36	0.38	Systemic lupus erythematosus;	chr6:34745061	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs2764206	ENSG00000186328.4	RP11-140K17.2	4.55	1.27e-05	0.00915	0.36	0.38	Systemic lupus erythematosus;	chr6:34745123	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs2764207	ENSG00000186328.4	RP11-140K17.2	4.55	1.27e-05	0.00915	0.36	0.38	Systemic lupus erythematosus;	chr6:34745221	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs2814968	ENSG00000186328.4	RP11-140K17.2	4.55	1.27e-05	0.00915	0.36	0.38	Systemic lupus erythematosus;	chr6:34745361	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs2814969	ENSG00000186328.4	RP11-140K17.2	4.55	1.27e-05	0.00915	0.36	0.38	Systemic lupus erythematosus;	chr6:34745622	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs2814970	ENSG00000186328.4	RP11-140K17.2	4.55	1.27e-05	0.00915	0.36	0.38	Systemic lupus erythematosus;	chr6:34745723	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs2764208	ENSG00000186328.4	RP11-140K17.2	4.55	1.27e-05	0.00915	0.36	0.38	Systemic lupus erythematosus;	chr6:34746545	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.583	rs7755982	ENSG00000186328.4	RP11-140K17.2	4.55	1.27e-05	0.00915	0.36	0.38	Systemic lupus erythematosus;	chr6:34747520	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.606	rs7756009	ENSG00000186328.4	RP11-140K17.2	4.55	1.27e-05	0.00915	0.36	0.38	Systemic lupus erythematosus;	chr6:34747618	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.583	rs912716	ENSG00000186328.4	RP11-140K17.2	4.55	1.27e-05	0.00915	0.36	0.38	Systemic lupus erythematosus;	chr6:34747984	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs3734268	ENSG00000186328.4	RP11-140K17.2	4.55	1.27e-05	0.00915	0.36	0.38	Systemic lupus erythematosus;	chr6:34748251	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs9462009	ENSG00000186328.4	RP11-140K17.2	4.55	1.27e-05	0.00915	0.36	0.38	Systemic lupus erythematosus;	chr6:34748553	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs9462010	ENSG00000186328.4	RP11-140K17.2	4.55	1.27e-05	0.00915	0.36	0.38	Systemic lupus erythematosus;	chr6:34748828	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs9296127	ENSG00000186328.4	RP11-140K17.2	4.55	1.27e-05	0.00915	0.36	0.38	Systemic lupus erythematosus;	chr6:34751851	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.651	rs7752390	ENSG00000186328.4	RP11-140K17.2	4.55	1.27e-05	0.00915	0.36	0.38	Systemic lupus erythematosus;	chr6:34822847	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs6937132	ENSG00000186328.4	RP11-140K17.2	4.55	1.27e-05	0.00915	0.36	0.38	Systemic lupus erythematosus;	chr6:34831444	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs6937314	ENSG00000186328.4	RP11-140K17.2	4.55	1.27e-05	0.00915	0.36	0.38	Systemic lupus erythematosus;	chr6:34831531	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs7739003	ENSG00000186328.4	RP11-140K17.2	4.55	1.27e-05	0.00915	0.36	0.38	Systemic lupus erythematosus;	chr6:34832552	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs6925623	ENSG00000186328.4	RP11-140K17.2	4.55	1.27e-05	0.00915	0.36	0.38	Systemic lupus erythematosus;	chr6:34833119	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.606	rs6906129	ENSG00000186328.4	RP11-140K17.2	4.55	1.27e-05	0.00915	0.36	0.38	Systemic lupus erythematosus;	chr6:34833383	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.675	rs34657938	ENSG00000186328.4	RP11-140K17.2	4.55	1.27e-05	0.00915	0.36	0.38	Systemic lupus erythematosus;	chr6:34833854	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.606	rs4624858	ENSG00000186328.4	RP11-140K17.2	4.55	1.27e-05	0.00915	0.36	0.38	Systemic lupus erythematosus;	chr6:34834524	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs2296360	ENSG00000186328.4	RP11-140K17.2	4.55	1.27e-05	0.00915	0.36	0.38	Systemic lupus erythematosus;	chr6:34835781	chr6:34715613~34715940:+
TGCT	cis	rs6510489	1	rs6510489	ENSG00000267439.1	AC002398.11	4.55	1.27e-05	0.00916	0.48	0.38	Bipolar disorder;	chr19:35482387	chr19:35747057~35753415:-
TGCT	cis	rs2283792	0.624	rs2876981	ENSG00000228050.1	TOP3BP1	4.55	1.27e-05	0.00916	0.47	0.38	Multiple sclerosis;	chr22:21851322	chr22:22223187~22224566:-
TGCT	cis	rs2236295	1	rs2236295	ENSG00000238280.1	RP11-436D10.3	-4.55	1.27e-05	0.00916	-0.51	-0.38	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62805132	chr10:62793562~62805887:-
TGCT	cis	rs11123170	0.65	rs2289897	ENSG00000189223.12	PAX8-AS1	-4.55	1.27e-05	0.00916	-0.64	-0.38	Renal function-related traits (BUN);	chr2:113219877	chr2:113211522~113276581:+
TGCT	cis	rs2880765	0.525	rs35899940	ENSG00000259295.5	CSPG4P12	4.55	1.27e-05	0.00916	0.48	0.38	Coronary artery disease;	chr15:85510466	chr15:85191438~85213905:+
TGCT	cis	rs7829975	0.774	rs13259216	ENSG00000173295.6	FAM86B3P	4.55	1.27e-05	0.00916	0.45	0.38	Mood instability;	chr8:8816091	chr8:8228595~8244865:+
TGCT	cis	rs1618992	0.791	rs2655359	ENSG00000265994.1	RP11-510D21.1	4.55	1.27e-05	0.00916	0.38	0.38	Gut microbiome composition (summer and winter);	chr18:28651539	chr18:28785068~28789260:+
TGCT	cis	rs875971	0.862	rs4236208	ENSG00000237310.1	GS1-124K5.4	-4.55	1.27e-05	0.00917	-0.41	-0.38	Aortic root size;	chr7:66284091	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs10261398	ENSG00000237310.1	GS1-124K5.4	-4.55	1.27e-05	0.00917	-0.41	-0.38	Aortic root size;	chr7:66285177	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs10224872	ENSG00000237310.1	GS1-124K5.4	-4.55	1.27e-05	0.00917	-0.41	-0.38	Aortic root size;	chr7:66294786	chr7:66493706~66495474:+
TGCT	cis	rs77669868	0.568	rs3825045	ENSG00000256452.1	RP11-667M19.10	-4.55	1.27e-05	0.00918	-0.4	-0.38	Monocyte percentage of white cells;	chr11:114202478	chr11:113818077~113822458:+
TGCT	cis	rs8111998	0.826	rs60316370	ENSG00000269332.4	GOLGA2P9	4.55	1.27e-05	0.00918	0.65	0.38	Corneal structure;	chr19:22581941	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.826	rs16999362	ENSG00000269332.4	GOLGA2P9	4.55	1.27e-05	0.00918	0.65	0.38	Corneal structure;	chr19:22582023	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.625	rs57665772	ENSG00000269332.4	GOLGA2P9	4.55	1.27e-05	0.00918	0.65	0.38	Corneal structure;	chr19:22582075	chr19:22596257~22603550:+
TGCT	cis	rs877819	0.583	rs2620880	ENSG00000228403.1	RP11-563N6.6	4.55	1.27e-05	0.00918	0.39	0.38	Systemic lupus erythematosus;	chr10:48877383	chr10:48878022~48878649:+
TGCT	cis	rs1823913	0.637	rs12992372	ENSG00000227542.1	AC092614.2	4.55	1.27e-05	0.00919	0.41	0.38	Obesity-related traits;	chr2:191289251	chr2:191229165~191246172:-
TGCT	cis	rs875971	0.79	rs10257911	ENSG00000232559.3	GS1-124K5.12	-4.55	1.27e-05	0.0092	-0.36	-0.38	Aortic root size;	chr7:66278783	chr7:66554588~66576923:-
TGCT	cis	rs13068223	0.607	rs184695	ENSG00000243926.1	TIPARP-AS1	-4.55	1.28e-05	0.0092	-0.41	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr3:156679600	chr3:156671862~156674378:-
TGCT	cis	rs72772090	0.539	rs11750464	ENSG00000248734.2	CTD-2260A17.1	4.55	1.28e-05	0.0092	0.52	0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777327	chr5:96784777~96785999:+
TGCT	cis	rs9322193	0.962	rs9322220	ENSG00000216906.2	RP11-350J20.9	4.55	1.28e-05	0.00921	0.42	0.38	Lung cancer;	chr6:149782897	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs10214845	ENSG00000216906.2	RP11-350J20.9	4.55	1.28e-05	0.00921	0.42	0.38	Lung cancer;	chr6:149783124	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs9767122	ENSG00000216906.2	RP11-350J20.9	4.55	1.28e-05	0.00921	0.42	0.38	Lung cancer;	chr6:149783553	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs1413654	ENSG00000216906.2	RP11-350J20.9	4.55	1.28e-05	0.00921	0.42	0.38	Lung cancer;	chr6:149783956	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.683	rs113281309	ENSG00000216906.2	RP11-350J20.9	4.55	1.28e-05	0.00921	0.42	0.38	Lung cancer;	chr6:149787289	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs9688809	ENSG00000216906.2	RP11-350J20.9	4.55	1.28e-05	0.00921	0.42	0.38	Lung cancer;	chr6:149787920	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs9689242	ENSG00000216906.2	RP11-350J20.9	4.55	1.28e-05	0.00921	0.42	0.38	Lung cancer;	chr6:149787970	chr6:149904243~149906418:+
TGCT	cis	rs9322193	1	rs9767077	ENSG00000216906.2	RP11-350J20.9	4.55	1.28e-05	0.00921	0.42	0.38	Lung cancer;	chr6:149788479	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9688938	ENSG00000216906.2	RP11-350J20.9	4.55	1.28e-05	0.00921	0.42	0.38	Lung cancer;	chr6:149788941	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs9688940	ENSG00000216906.2	RP11-350J20.9	4.55	1.28e-05	0.00921	0.42	0.38	Lung cancer;	chr6:149788977	chr6:149904243~149906418:+
TGCT	cis	rs7208859	0.614	rs216412	ENSG00000263531.1	RP13-753N3.1	-4.55	1.28e-05	0.00921	-0.66	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30863921~30864940:-
TGCT	cis	rs10829156	0.898	rs6482565	ENSG00000240291.1	RP11-499P20.2	4.55	1.28e-05	0.00921	0.33	0.38	Sudden cardiac arrest;	chr10:18611664	chr10:18513115~18545651:-
TGCT	cis	rs1799949	0.929	rs799905	ENSG00000198496.9	NBR2	-4.55	1.28e-05	0.00921	-0.52	-0.38	Menopause (age at onset);	chr17:43125170	chr17:43125610~43153671:+
TGCT	cis	rs34217772	0.581	rs34665916	ENSG00000258536.1	RP11-1053O12.1	4.55	1.28e-05	0.00923	0.32	0.38	Myopia;	chr14:41832583	chr14:41742639~41742963:+
TGCT	cis	rs1707322	0.717	rs1135812	ENSG00000280836.1	AL355480.1	-4.55	1.29e-05	0.00925	-0.51	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45581219~45581321:-
TGCT	cis	rs7208859	0.623	rs11651857	ENSG00000266490.1	CTD-2349P21.9	4.55	1.29e-05	0.00925	0.43	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs216439	ENSG00000266490.1	CTD-2349P21.9	4.55	1.29e-05	0.00925	0.43	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.573	rs216442	ENSG00000266490.1	CTD-2349P21.9	4.55	1.29e-05	0.00925	0.43	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs216445	ENSG00000266490.1	CTD-2349P21.9	4.55	1.29e-05	0.00925	0.43	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs216446	ENSG00000266490.1	CTD-2349P21.9	4.55	1.29e-05	0.00925	0.43	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs79607958	ENSG00000266490.1	CTD-2349P21.9	4.55	1.29e-05	0.00925	0.43	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs75136574	ENSG00000266490.1	CTD-2349P21.9	4.55	1.29e-05	0.00925	0.43	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs77544470	ENSG00000266490.1	CTD-2349P21.9	4.55	1.29e-05	0.00925	0.43	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs609063	ENSG00000266490.1	CTD-2349P21.9	4.55	1.29e-05	0.00925	0.43	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs383436	ENSG00000266490.1	CTD-2349P21.9	4.55	1.29e-05	0.00925	0.43	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30792372~30792833:+
TGCT	cis	rs17826219	0.714	rs11650821	ENSG00000266490.1	CTD-2349P21.9	4.55	1.29e-05	0.00925	0.43	0.38	Body mass index;	chr17:30641132	chr17:30792372~30792833:+
TGCT	cis	rs8111998	0.793	rs10411767	ENSG00000269332.4	GOLGA2P9	4.54	1.29e-05	0.00926	0.69	0.38	Corneal structure;	chr19:22575081	chr19:22596257~22603550:+
TGCT	cis	rs10044254	1	rs10044254	ENSG00000246214.1	RP11-260E18.1	4.54	1.29e-05	0.00926	0.59	0.38	Asthma (corticosteroid response);	chr5:15783487	chr5:16615926~16629969:+
TGCT	cis	rs11671005	0.693	rs11084542	ENSG00000232098.3	CTD-2619J13.14	-4.54	1.29e-05	0.00927	-0.42	-0.38	Mean platelet volume;	chr19:58420732	chr19:58404238~58408484:-
TGCT	cis	rs453301	0.522	rs1964356	ENSG00000173295.6	FAM86B3P	4.54	1.29e-05	0.00928	0.44	0.38	Joint mobility (Beighton score);	chr8:8995760	chr8:8228595~8244865:+
TGCT	cis	rs651907	0.535	rs4342086	ENSG00000244119.1	PDCL3P4	4.54	1.29e-05	0.00929	0.27	0.38	Colorectal cancer;	chr3:101784921	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.513	rs34963630	ENSG00000244119.1	PDCL3P4	4.54	1.29e-05	0.00929	0.27	0.38	Colorectal cancer;	chr3:101785973	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.535	rs11717638	ENSG00000244119.1	PDCL3P4	4.54	1.29e-05	0.00929	0.27	0.38	Colorectal cancer;	chr3:101786624	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.535	rs34263427	ENSG00000244119.1	PDCL3P4	4.54	1.29e-05	0.00929	0.27	0.38	Colorectal cancer;	chr3:101788961	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.535	rs61396602	ENSG00000244119.1	PDCL3P4	4.54	1.29e-05	0.00929	0.27	0.38	Colorectal cancer;	chr3:101790202	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.514	rs11706494	ENSG00000244119.1	PDCL3P4	4.54	1.29e-05	0.00929	0.27	0.38	Colorectal cancer;	chr3:101790631	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.535	rs34063583	ENSG00000244119.1	PDCL3P4	4.54	1.29e-05	0.00929	0.27	0.38	Colorectal cancer;	chr3:101791104	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.535	rs34161138	ENSG00000244119.1	PDCL3P4	4.54	1.29e-05	0.00929	0.27	0.38	Colorectal cancer;	chr3:101791544	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.535	rs34648996	ENSG00000244119.1	PDCL3P4	4.54	1.29e-05	0.00929	0.27	0.38	Colorectal cancer;	chr3:101792358	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.535	rs11714444	ENSG00000244119.1	PDCL3P4	4.54	1.29e-05	0.00929	0.27	0.38	Colorectal cancer;	chr3:101794838	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.535	rs12631513	ENSG00000244119.1	PDCL3P4	4.54	1.29e-05	0.00929	0.27	0.38	Colorectal cancer;	chr3:101798632	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.535	rs13094911	ENSG00000244119.1	PDCL3P4	4.54	1.29e-05	0.00929	0.27	0.38	Colorectal cancer;	chr3:101800177	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.535	rs11712309	ENSG00000244119.1	PDCL3P4	4.54	1.29e-05	0.00929	0.27	0.38	Colorectal cancer;	chr3:101800253	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.535	rs35799195	ENSG00000244119.1	PDCL3P4	4.54	1.29e-05	0.00929	0.27	0.38	Colorectal cancer;	chr3:101803083	chr3:101712472~101713191:+
TGCT	cis	rs1707322	0.721	rs6699418	ENSG00000280836.1	AL355480.1	-4.54	1.29e-05	0.0093	-0.51	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs4431884	ENSG00000280836.1	AL355480.1	-4.54	1.29e-05	0.0093	-0.51	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.65	rs4660879	ENSG00000280836.1	AL355480.1	-4.54	1.29e-05	0.0093	-0.51	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs10789468	ENSG00000280836.1	AL355480.1	-4.54	1.29e-05	0.0093	-0.51	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs6429574	ENSG00000280836.1	AL355480.1	-4.54	1.29e-05	0.0093	-0.51	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45581219~45581321:-
TGCT	cis	rs7208859	0.524	rs8069400	ENSG00000280069.1	CTD-2349P21.3	-4.54	1.29e-05	0.0093	-0.54	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.673	rs216418	ENSG00000263531.1	RP13-753N3.1	4.54	1.29e-05	0.0093	0.66	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30609519	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs216420	ENSG00000263531.1	RP13-753N3.1	4.54	1.29e-05	0.0093	0.66	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs216423	ENSG00000263531.1	RP13-753N3.1	4.54	1.29e-05	0.0093	0.66	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30863921~30864940:-
TGCT	cis	rs875971	0.545	rs73378304	ENSG00000237310.1	GS1-124K5.4	4.54	1.29e-05	0.0093	0.45	0.38	Aortic root size;	chr7:66175760	chr7:66493706~66495474:+
TGCT	cis	rs9462027	0.527	rs6939600	ENSG00000186328.4	RP11-140K17.2	4.54	1.29e-05	0.0093	0.36	0.38	Systemic lupus erythematosus;	chr6:34854399	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.527	rs11755393	ENSG00000186328.4	RP11-140K17.2	4.54	1.29e-05	0.0093	0.36	0.38	Systemic lupus erythematosus;	chr6:34856859	chr6:34715613~34715940:+
TGCT	cis	rs2015599	0.623	rs10843385	ENSG00000275476.1	RP11-996F15.4	-4.54	1.29e-05	0.0093	-0.41	-0.38	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29277397~29277882:-
TGCT	cis	rs2015599	0.601	rs17715086	ENSG00000275476.1	RP11-996F15.4	-4.54	1.29e-05	0.0093	-0.41	-0.38	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29277397~29277882:-
TGCT	cis	rs2717559	0.542	rs10956986	ENSG00000253196.1	RP11-706C16.7	-4.54	1.29e-05	0.0093	-0.4	-0.38	Urinary tract infection frequency;	chr8:142805185	chr8:142763116~142766427:+
TGCT	cis	rs2463822	0.858	rs2513077	ENSG00000254454.2	RCC2P6	4.54	1.3e-05	0.00931	0.39	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62338453	chr11:62371146~62373168:+
TGCT	cis	rs12682352	0.579	rs7006589	ENSG00000253893.2	FAM85B	-4.54	1.3e-05	0.00931	-0.48	-0.38	Neuroticism;	chr8:8810976	chr8:8167819~8226614:-
TGCT	cis	rs7829975	0.582	rs448231	ENSG00000254340.1	RP11-10A14.3	-4.54	1.3e-05	0.00932	-0.36	-0.38	Mood instability;	chr8:8932549	chr8:9141424~9145435:+
TGCT	cis	rs10716631	1	rs10716631	ENSG00000261338.2	RP11-378A13.1	4.54	1.3e-05	0.00933	0.31	0.38	Plateletcrit;High light scatter reticulocyte percentage of red cells;	chr2:218273447	chr2:218255319~218257366:+
TGCT	cis	rs3931020	0.508	rs2345436	ENSG00000272864.1	RP11-17E13.2	-4.54	1.3e-05	0.00934	-0.42	-0.38	Resistin levels;	chr1:74733056	chr1:74698769~74699333:-
TGCT	cis	rs3931020	0.508	rs28568334	ENSG00000272864.1	RP11-17E13.2	-4.54	1.3e-05	0.00934	-0.42	-0.38	Resistin levels;	chr1:74733615	chr1:74698769~74699333:-
TGCT	cis	rs1757171	0.542	rs3818985	ENSG00000204110.6	RP1-153P14.8	-4.54	1.3e-05	0.00934	-0.41	-0.38	Cognitive performance;	chr6:37516438	chr6:37507348~37535616:+
TGCT	cis	rs875971	0.862	rs709596	ENSG00000232559.3	GS1-124K5.12	4.54	1.3e-05	0.00934	0.35	0.38	Aortic root size;	chr7:66360926	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.895	rs3857684	ENSG00000237310.1	GS1-124K5.4	4.54	1.3e-05	0.00934	0.41	0.38	Aortic root size;	chr7:66473171	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs12533997	ENSG00000237310.1	GS1-124K5.4	4.54	1.3e-05	0.00934	0.41	0.38	Aortic root size;	chr7:66500390	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.964	rs60193905	ENSG00000237310.1	GS1-124K5.4	4.54	1.3e-05	0.00934	0.41	0.38	Aortic root size;	chr7:66506273	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.929	rs10950041	ENSG00000237310.1	GS1-124K5.4	4.54	1.3e-05	0.00934	0.41	0.38	Aortic root size;	chr7:66508888	chr7:66493706~66495474:+
TGCT	cis	rs2980439	0.818	rs2948300	ENSG00000253981.4	ALG1L13P	4.54	1.3e-05	0.00935	0.4	0.38	Neuroticism;	chr8:8248986	chr8:8236003~8244667:-
TGCT	cis	rs67311347	0.955	rs2123999	ENSG00000223797.4	ENTPD3-AS1	4.54	1.3e-05	0.00935	0.39	0.38	Renal cell carcinoma;	chr3:40337247	chr3:40313802~40453329:-
TGCT	cis	rs10504229	0.683	rs6999131	ENSG00000253301.4	RP11-513O17.2	4.54	1.3e-05	0.00935	0.59	0.38	Developmental language disorder (linguistic errors);	chr8:57214493	chr8:57142689~57240298:+
TGCT	cis	rs9400467	0.506	rs17678681	ENSG00000272356.1	RP5-1112D6.8	-4.54	1.3e-05	0.00935	-0.44	-0.38	Amino acid levels;Blood metabolite levels;	chr6:111260835	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs12203093	ENSG00000272356.1	RP5-1112D6.8	-4.54	1.3e-05	0.00935	-0.44	-0.38	Amino acid levels;Blood metabolite levels;	chr6:111264179	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs10456872	ENSG00000272356.1	RP5-1112D6.8	-4.54	1.3e-05	0.00935	-0.44	-0.38	Amino acid levels;Blood metabolite levels;	chr6:111265464	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs12199233	ENSG00000272356.1	RP5-1112D6.8	-4.54	1.3e-05	0.00935	-0.44	-0.38	Amino acid levels;Blood metabolite levels;	chr6:111271114	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs11153281	ENSG00000272356.1	RP5-1112D6.8	-4.54	1.3e-05	0.00935	-0.44	-0.38	Amino acid levels;Blood metabolite levels;	chr6:111273391	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs79788276	ENSG00000272356.1	RP5-1112D6.8	-4.54	1.3e-05	0.00935	-0.44	-0.38	Amino acid levels;Blood metabolite levels;	chr6:111278011	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs78051065	ENSG00000272356.1	RP5-1112D6.8	-4.54	1.3e-05	0.00935	-0.44	-0.38	Amino acid levels;Blood metabolite levels;	chr6:111279203	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs76110409	ENSG00000272356.1	RP5-1112D6.8	-4.54	1.3e-05	0.00935	-0.44	-0.38	Amino acid levels;Blood metabolite levels;	chr6:111281929	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs10457237	ENSG00000272356.1	RP5-1112D6.8	-4.54	1.3e-05	0.00935	-0.44	-0.38	Amino acid levels;Blood metabolite levels;	chr6:111284923	chr6:111309203~111313517:+
TGCT	cis	rs67311347	1	rs7642906	ENSG00000223797.4	ENTPD3-AS1	-4.54	1.3e-05	0.00935	-0.4	-0.38	Renal cell carcinoma;	chr3:40451142	chr3:40313802~40453329:-
TGCT	cis	rs11671005	0.779	rs3794971	ENSG00000232098.3	CTD-2619J13.14	-4.54	1.31e-05	0.00935	-0.46	-0.38	Mean platelet volume;	chr19:58474499	chr19:58404238~58408484:-
TGCT	cis	rs11083241	0.698	rs2034108	ENSG00000227279.1	AC015933.2	-4.54	1.31e-05	0.00936	-0.41	-0.38	Intelligence (multi-trait analysis);	chr18:27970785	chr18:27954519~27963687:+
TGCT	cis	rs2919917	0.578	rs11783804	ENSG00000254352.1	RP11-578O24.2	4.54	1.31e-05	0.00937	0.44	0.38	Lymphocyte counts;	chr8:78652776	chr8:78723796~78724136:-
TGCT	cis	rs2919917	0.628	rs10111658	ENSG00000254352.1	RP11-578O24.2	4.54	1.31e-05	0.00937	0.44	0.38	Lymphocyte counts;	chr8:78652834	chr8:78723796~78724136:-
TGCT	cis	rs2919917	0.59	rs10098472	ENSG00000254352.1	RP11-578O24.2	4.54	1.31e-05	0.00937	0.44	0.38	Lymphocyte counts;	chr8:78652955	chr8:78723796~78724136:-
TGCT	cis	rs2919917	0.628	rs13251931	ENSG00000254352.1	RP11-578O24.2	4.54	1.31e-05	0.00937	0.44	0.38	Lymphocyte counts;	chr8:78653990	chr8:78723796~78724136:-
TGCT	cis	rs1010254	0.51	rs17543421	ENSG00000253921.1	CTB-113P19.3	-4.54	1.31e-05	0.00937	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152321789	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.51	rs72806379	ENSG00000253921.1	CTB-113P19.3	-4.54	1.31e-05	0.00937	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152322381	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.51	rs72806384	ENSG00000253921.1	CTB-113P19.3	-4.54	1.31e-05	0.00937	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152324397	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.51	rs72806385	ENSG00000253921.1	CTB-113P19.3	-4.54	1.31e-05	0.00937	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152324446	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.51	rs72806389	ENSG00000253921.1	CTB-113P19.3	-4.54	1.31e-05	0.00937	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152325372	chr5:151753992~151767247:+
TGCT	cis	rs1372520	0.808	rs1372518	ENSG00000247775.2	SNCA-AS1	4.54	1.31e-05	0.00937	0.38	0.38	Neuroticism;	chr4:89836143	chr4:89836408~89841978:+
TGCT	cis	rs1372520	0.935	rs1372519	ENSG00000247775.2	SNCA-AS1	4.54	1.31e-05	0.00937	0.38	0.38	Neuroticism;	chr4:89836158	chr4:89836408~89841978:+
TGCT	cis	rs10504229	0.683	rs2318144	ENSG00000253301.4	RP11-513O17.2	4.54	1.31e-05	0.00939	0.59	0.38	Developmental language disorder (linguistic errors);	chr8:57202184	chr8:57142689~57240298:+
TGCT	cis	rs7208859	0.623	rs7220289	ENSG00000280069.1	CTD-2349P21.3	-4.54	1.31e-05	0.00939	-0.54	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30738182~30740275:+
TGCT	cis	rs1075265	0.669	rs805330	ENSG00000233266.1	HMGB1P31	4.54	1.31e-05	0.00939	0.38	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53921194	chr2:54051334~54051760:+
TGCT	cis	rs11671005	0.779	rs35631681	ENSG00000268912.1	CTD-2619J13.17	-4.54	1.31e-05	0.00939	-0.5	-0.38	Mean platelet volume;	chr19:58488473	chr19:58428632~58431148:-
TGCT	cis	rs875971	0.666	rs13242072	ENSG00000237310.1	GS1-124K5.4	-4.54	1.31e-05	0.00939	-0.43	-0.38	Aortic root size;	chr7:66301001	chr7:66493706~66495474:+
TGCT	cis	rs4660456	0.913	rs2744808	ENSG00000237899.1	RP4-739H11.3	-4.54	1.31e-05	0.00939	-0.49	-0.38	Platelet count;	chr1:40712271	chr1:40669089~40687588:-
TGCT	cis	rs73198271	0.531	rs3827812	ENSG00000253893.2	FAM85B	4.54	1.31e-05	0.00939	0.59	0.38	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8797388	chr8:8167819~8226614:-
TGCT	cis	rs73198271	0.531	rs3748142	ENSG00000253893.2	FAM85B	4.54	1.31e-05	0.00939	0.59	0.38	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8797845	chr8:8167819~8226614:-
TGCT	cis	rs73198271	0.531	rs17630714	ENSG00000253893.2	FAM85B	4.54	1.31e-05	0.00939	0.59	0.38	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8800171	chr8:8167819~8226614:-
TGCT	cis	rs73198271	0.562	rs75525911	ENSG00000253893.2	FAM85B	4.54	1.31e-05	0.00939	0.59	0.38	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8801849	chr8:8167819~8226614:-
TGCT	cis	rs5742933	0.857	rs1233284	ENSG00000273240.1	RP11-455J20.3	-4.54	1.31e-05	0.0094	-0.35	-0.38	Ferritin levels;	chr2:189825045	chr2:189763859~189764456:-
TGCT	cis	rs5742933	0.817	rs1233288	ENSG00000273240.1	RP11-455J20.3	-4.54	1.31e-05	0.0094	-0.35	-0.38	Ferritin levels;	chr2:189825999	chr2:189763859~189764456:-
TGCT	cis	rs7208859	0.623	rs73269916	ENSG00000280069.1	CTD-2349P21.3	-4.54	1.31e-05	0.0094	-0.54	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30738182~30740275:+
TGCT	cis	rs12745968	0.653	rs6604008	ENSG00000223787.2	RP4-593M8.1	-4.54	1.31e-05	0.0094	-0.49	-0.38	Bipolar disorder and schizophrenia;	chr1:92711884	chr1:92580476~92580821:-
TGCT	cis	rs2944755	0.723	rs13274041	ENSG00000279766.1	RP11-642A1.2	-4.54	1.31e-05	0.0094	-0.37	-0.38	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140577816	chr8:140572142~140572812:-
TGCT	cis	rs2944755	0.723	rs13274321	ENSG00000279766.1	RP11-642A1.2	-4.54	1.31e-05	0.0094	-0.37	-0.38	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140578107	chr8:140572142~140572812:-
TGCT	cis	rs2944755	0.723	rs13273553	ENSG00000279766.1	RP11-642A1.2	-4.54	1.31e-05	0.0094	-0.37	-0.38	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140578166	chr8:140572142~140572812:-
TGCT	cis	rs2944755	0.686	rs11997913	ENSG00000279766.1	RP11-642A1.2	-4.54	1.31e-05	0.0094	-0.37	-0.38	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140578561	chr8:140572142~140572812:-
TGCT	cis	rs10504229	0.679	rs72649132	ENSG00000253301.4	RP11-513O17.2	4.54	1.32e-05	0.00942	0.61	0.38	Developmental language disorder (linguistic errors);	chr8:57142056	chr8:57142689~57240298:+
TGCT	cis	rs12682352	0.602	rs11783966	ENSG00000253893.2	FAM85B	4.54	1.32e-05	0.00942	0.49	0.38	Neuroticism;	chr8:8807637	chr8:8167819~8226614:-
TGCT	cis	rs1023500	0.596	rs133350	ENSG00000270083.1	RP1-257I20.14	4.54	1.32e-05	0.00943	0.37	0.38	Schizophrenia;	chr22:42033045	chr22:42089630~42090028:-
TGCT	cis	rs1023500	0.596	rs5751204	ENSG00000270083.1	RP1-257I20.14	4.54	1.32e-05	0.00943	0.37	0.38	Schizophrenia;	chr22:42037797	chr22:42089630~42090028:-
TGCT	cis	rs34779708	0.966	rs1213392	ENSG00000230534.5	RP11-297A16.2	4.54	1.32e-05	0.00943	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35141357	chr10:35098006~35127020:-
TGCT	cis	rs10504229	0.679	rs72649109	ENSG00000253301.4	RP11-513O17.2	4.54	1.32e-05	0.00943	0.6	0.38	Developmental language disorder (linguistic errors);	chr8:57118715	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.679	rs72649115	ENSG00000253301.4	RP11-513O17.2	4.54	1.32e-05	0.00943	0.6	0.38	Developmental language disorder (linguistic errors);	chr8:57125072	chr8:57142689~57240298:+
TGCT	cis	rs7567389	0.74	rs1604817	ENSG00000236682.1	AC068282.3	4.54	1.32e-05	0.00944	0.5	0.38	Self-rated health;	chr2:127242345	chr2:127389130~127400580:+
TGCT	cis	rs4794202	0.523	rs11871969	ENSG00000264920.1	RP11-6N17.4	-4.54	1.32e-05	0.00945	-0.43	-0.38	Alzheimer's disease (cognitive decline);	chr17:47915256	chr17:47891255~47895812:-
TGCT	cis	rs453301	0.653	rs7005133	ENSG00000254340.1	RP11-10A14.3	4.54	1.32e-05	0.00945	0.38	0.38	Joint mobility (Beighton score);	chr8:9043712	chr8:9141424~9145435:+
TGCT	cis	rs6604026	0.522	rs12756786	ENSG00000223787.2	RP4-593M8.1	4.54	1.32e-05	0.00946	0.55	0.38	Multiple sclerosis;	chr1:92579398	chr1:92580476~92580821:-
TGCT	cis	rs728616	1	rs56317427	ENSG00000230091.5	TMEM254-AS1	4.54	1.32e-05	0.00947	0.69	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80102178	chr10:80046860~80078912:-
TGCT	cis	rs17767294	0.572	rs11965137	ENSG00000187763.3	OR2B7P	4.54	1.32e-05	0.00947	0.64	0.38	Parkinson's disease;	chr6:27656970	chr6:28046434~28047367:+
TGCT	cis	rs7829975	0.517	rs12542733	ENSG00000253893.2	FAM85B	4.54	1.33e-05	0.00948	0.5	0.38	Mood instability;	chr8:8967348	chr8:8167819~8226614:-
TGCT	cis	rs2463822	1	rs2463825	ENSG00000254454.2	RCC2P6	-4.54	1.33e-05	0.00948	-0.4	-0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62327021	chr11:62371146~62373168:+
TGCT	cis	rs2463822	0.764	rs7125402	ENSG00000254454.2	RCC2P6	-4.54	1.33e-05	0.00948	-0.4	-0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62329787	chr11:62371146~62373168:+
TGCT	cis	rs2463822	1	rs2513071	ENSG00000254454.2	RCC2P6	-4.54	1.33e-05	0.00948	-0.4	-0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62330915	chr11:62371146~62373168:+
TGCT	cis	rs2463822	1	rs2513747	ENSG00000254454.2	RCC2P6	-4.54	1.33e-05	0.00948	-0.4	-0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62331263	chr11:62371146~62373168:+
TGCT	cis	rs2463822	1	rs2513074	ENSG00000254454.2	RCC2P6	-4.54	1.33e-05	0.00948	-0.4	-0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62333408	chr11:62371146~62373168:+
TGCT	cis	rs2463822	0.925	rs2513075	ENSG00000254454.2	RCC2P6	-4.54	1.33e-05	0.00948	-0.4	-0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62334936	chr11:62371146~62373168:+
TGCT	cis	rs2463822	1	rs2513076	ENSG00000254454.2	RCC2P6	-4.54	1.33e-05	0.00948	-0.4	-0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62336239	chr11:62371146~62373168:+
TGCT	cis	rs2463822	1	rs2246920	ENSG00000254454.2	RCC2P6	-4.54	1.33e-05	0.00948	-0.4	-0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62337465	chr11:62371146~62373168:+
TGCT	cis	rs2463822	1	rs2513749	ENSG00000254454.2	RCC2P6	-4.54	1.33e-05	0.00948	-0.4	-0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62337919	chr11:62371146~62373168:+
TGCT	cis	rs2463822	1	rs2513052	ENSG00000254454.2	RCC2P6	-4.54	1.33e-05	0.00948	-0.4	-0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62340776	chr11:62371146~62373168:+
TGCT	cis	rs753274	0.65	rs28850626	ENSG00000267147.2	CTC-548K16.1	-4.54	1.33e-05	0.00948	-0.46	-0.38	Tumor necrosis factor beta levels;	chr19:14310287	chr19:14333743~14343916:+
TGCT	cis	rs17826219	0.562	rs719600	ENSG00000280069.1	CTD-2349P21.3	4.54	1.33e-05	0.00949	0.49	0.38	Body mass index;	chr17:30404244	chr17:30738182~30740275:+
TGCT	cis	rs9309473	1	rs9309473	ENSG00000163016.8	ALMS1P	4.54	1.33e-05	0.0095	0.35	0.38	Metabolite levels;	chr2:73516855	chr2:73644919~73685576:+
TGCT	cis	rs1528149	0.78	rs28422957	ENSG00000224683.1	RPL36AP29	4.54	1.33e-05	0.00951	0.45	0.38	Sitting height ratio;	chr7:16059895	chr7:16208945~16209265:+
TGCT	cis	rs9807989	0.507	rs2058659	ENSG00000234389.1	AC007278.3	-4.54	1.33e-05	0.00951	-0.28	-0.38	Asthma;	chr2:102438096	chr2:102438713~102440475:+
TGCT	cis	rs1010254	0.51	rs72806396	ENSG00000253921.1	CTB-113P19.3	-4.54	1.33e-05	0.00952	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152328764	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.51	rs72806402	ENSG00000253921.1	CTB-113P19.3	-4.54	1.33e-05	0.00952	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152332964	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.51	rs72808303	ENSG00000253921.1	CTB-113P19.3	-4.54	1.33e-05	0.00952	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152338488	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.559	rs72808320	ENSG00000253921.1	CTB-113P19.3	-4.54	1.33e-05	0.00952	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152362297	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.559	rs55693068	ENSG00000253921.1	CTB-113P19.3	-4.54	1.33e-05	0.00952	-0.47	-0.38	Optic nerve measurement (cup area);	chr5:152370878	chr5:151753992~151767247:+
TGCT	cis	rs728616	0.867	rs61859977	ENSG00000230091.5	TMEM254-AS1	4.54	1.33e-05	0.00953	0.69	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80123933	chr10:80046860~80078912:-
TGCT	cis	rs1497406	0.744	rs12057175	ENSG00000235084.3	CHCHD2P6	4.54	1.34e-05	0.00953	0.43	0.38	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);	chr1:16181880	chr1:15604597~15605043:+
TGCT	cis	rs1497406	0.744	rs12057222	ENSG00000235084.3	CHCHD2P6	4.54	1.34e-05	0.00953	0.43	0.38	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);	chr1:16182039	chr1:15604597~15605043:+
TGCT	cis	rs9462027	0.651	rs13220394	ENSG00000186328.4	RP11-140K17.2	4.54	1.34e-05	0.00954	0.36	0.38	Systemic lupus erythematosus;	chr6:34842395	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs6919654	ENSG00000186328.4	RP11-140K17.2	4.54	1.34e-05	0.00954	0.36	0.38	Systemic lupus erythematosus;	chr6:34842962	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs6924898	ENSG00000186328.4	RP11-140K17.2	4.54	1.34e-05	0.00954	0.36	0.38	Systemic lupus erythematosus;	chr6:34843422	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.651	rs7748203	ENSG00000186328.4	RP11-140K17.2	4.54	1.34e-05	0.00954	0.36	0.38	Systemic lupus erythematosus;	chr6:34844277	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs9469909	ENSG00000186328.4	RP11-140K17.2	4.54	1.34e-05	0.00954	0.36	0.38	Systemic lupus erythematosus;	chr6:34845300	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs6457795	ENSG00000186328.4	RP11-140K17.2	4.54	1.34e-05	0.00954	0.36	0.38	Systemic lupus erythematosus;	chr6:34851589	chr6:34715613~34715940:+
TGCT	cis	rs875971	0.825	rs6951503	ENSG00000232559.3	GS1-124K5.12	-4.54	1.34e-05	0.00955	-0.36	-0.38	Aortic root size;	chr7:66253949	chr7:66554588~66576923:-
TGCT	cis	rs7829975	0.711	rs12682352	ENSG00000253893.2	FAM85B	-4.54	1.34e-05	0.00955	-0.49	-0.38	Mood instability;	chr8:8788736	chr8:8167819~8226614:-
TGCT	cis	rs9918079	0.56	rs6449153	ENSG00000273133.1	RP11-799M12.2	-4.54	1.34e-05	0.00956	-0.58	-0.38	Obesity-related traits;	chr4:15629593	chr4:15563698~15564253:-
TGCT	cis	rs6782228	0.675	rs2253151	ENSG00000242551.2	POU5F1P6	-4.54	1.34e-05	0.00956	-0.46	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611294	chr3:128674735~128677005:-
TGCT	cis	rs755249	0.545	rs12037073	ENSG00000182109.6	RP11-69E11.4	-4.53	1.34e-05	0.00957	-0.36	-0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39581225	chr1:39522280~39546187:-
TGCT	cis	rs755249	0.565	rs4660846	ENSG00000182109.6	RP11-69E11.4	-4.53	1.34e-05	0.00957	-0.36	-0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583839	chr1:39522280~39546187:-
TGCT	cis	rs755249	0.565	rs7539279	ENSG00000182109.6	RP11-69E11.4	-4.53	1.34e-05	0.00957	-0.36	-0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39584896	chr1:39522280~39546187:-
TGCT	cis	rs7208859	0.623	rs7214570	ENSG00000266490.1	CTD-2349P21.9	4.53	1.34e-05	0.00957	0.4	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30792372~30792833:+
TGCT	cis	rs7927592	0.513	rs3853616	ENSG00000212093.1	AP000807.1	4.53	1.34e-05	0.00957	0.36	0.38	Total body bone mineral density;	chr11:68430784	chr11:68506083~68506166:-
TGCT	cis	rs875971	0.964	rs1643388	ENSG00000237310.1	GS1-124K5.4	4.53	1.34e-05	0.00957	0.41	0.38	Aortic root size;	chr7:66379575	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs778722	ENSG00000237310.1	GS1-124K5.4	4.53	1.34e-05	0.00957	0.41	0.38	Aortic root size;	chr7:66379841	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.964	rs778721	ENSG00000237310.1	GS1-124K5.4	4.53	1.34e-05	0.00957	0.41	0.38	Aortic root size;	chr7:66380410	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs778706	ENSG00000237310.1	GS1-124K5.4	4.53	1.34e-05	0.00957	0.41	0.38	Aortic root size;	chr7:66395437	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.895	rs778700	ENSG00000237310.1	GS1-124K5.4	4.53	1.34e-05	0.00957	0.41	0.38	Aortic root size;	chr7:66401463	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs778699	ENSG00000237310.1	GS1-124K5.4	4.53	1.34e-05	0.00957	0.41	0.38	Aortic root size;	chr7:66403303	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.929	rs778692	ENSG00000237310.1	GS1-124K5.4	4.53	1.34e-05	0.00957	0.41	0.38	Aortic root size;	chr7:66407462	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs4718343	ENSG00000237310.1	GS1-124K5.4	4.53	1.34e-05	0.00957	0.41	0.38	Aortic root size;	chr7:66409301	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs1968225	ENSG00000237310.1	GS1-124K5.4	4.53	1.34e-05	0.00957	0.41	0.38	Aortic root size;	chr7:66409786	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs6460295	ENSG00000237310.1	GS1-124K5.4	4.53	1.34e-05	0.00957	0.41	0.38	Aortic root size;	chr7:66417741	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.964	rs6978721	ENSG00000237310.1	GS1-124K5.4	4.53	1.34e-05	0.00957	0.41	0.38	Aortic root size;	chr7:66418217	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs6979382	ENSG00000237310.1	GS1-124K5.4	4.53	1.34e-05	0.00957	0.41	0.38	Aortic root size;	chr7:66421388	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs6961990	ENSG00000237310.1	GS1-124K5.4	4.53	1.34e-05	0.00957	0.41	0.38	Aortic root size;	chr7:66423583	chr7:66493706~66495474:+
TGCT	cis	rs9462027	0.628	rs6905393	ENSG00000186328.4	RP11-140K17.2	4.53	1.34e-05	0.00958	0.36	0.38	Systemic lupus erythematosus;	chr6:34808849	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs4601124	ENSG00000186328.4	RP11-140K17.2	4.53	1.34e-05	0.00958	0.36	0.38	Systemic lupus erythematosus;	chr6:34809133	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs34141614	ENSG00000186328.4	RP11-140K17.2	4.53	1.34e-05	0.00958	0.36	0.38	Systemic lupus erythematosus;	chr6:34809254	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs66506671	ENSG00000186328.4	RP11-140K17.2	4.53	1.34e-05	0.00958	0.36	0.38	Systemic lupus erythematosus;	chr6:34809372	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.675	rs9296132	ENSG00000186328.4	RP11-140K17.2	4.53	1.34e-05	0.00958	0.36	0.38	Systemic lupus erythematosus;	chr6:34809754	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs2038839	ENSG00000186328.4	RP11-140K17.2	4.53	1.34e-05	0.00958	0.36	0.38	Systemic lupus erythematosus;	chr6:34810014	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.606	rs2395606	ENSG00000186328.4	RP11-140K17.2	4.53	1.34e-05	0.00958	0.36	0.38	Systemic lupus erythematosus;	chr6:34810709	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs7739771	ENSG00000186328.4	RP11-140K17.2	4.53	1.34e-05	0.00958	0.36	0.38	Systemic lupus erythematosus;	chr6:34812024	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs10947532	ENSG00000186328.4	RP11-140K17.2	4.53	1.34e-05	0.00958	0.36	0.38	Systemic lupus erythematosus;	chr6:34812538	chr6:34715613~34715940:+
TGCT	cis	rs9309473	1	rs6710438	ENSG00000163016.8	ALMS1P	-4.53	1.34e-05	0.00958	-0.35	-0.38	Metabolite levels;	chr2:73592981	chr2:73644919~73685576:+
TGCT	cis	rs6600671	0.934	rs12060031	ENSG00000275131.1	CH17-472G23.4	4.53	1.34e-05	0.00958	0.25	0.38	Hip geometry;	chr1:121501652	chr1:120489625~120579190:-
TGCT	cis	rs6600671	0.934	rs11249431	ENSG00000275131.1	CH17-472G23.4	4.53	1.34e-05	0.00958	0.25	0.38	Hip geometry;	chr1:121544405	chr1:120489625~120579190:-
TGCT	cis	rs72772090	0.539	rs11741100	ENSG00000248734.2	CTD-2260A17.1	-4.53	1.34e-05	0.00958	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777541	chr5:96784777~96785999:+
TGCT	cis	rs673078	0.607	rs7967900	ENSG00000275759.1	RP11-131L12.3	4.53	1.34e-05	0.00959	0.67	0.38	Glucose homeostasis traits;	chr12:118381902	chr12:118428281~118428870:+
TGCT	cis	rs6981523	0.553	rs11783045	ENSG00000255310.2	AF131215.2	-4.53	1.35e-05	0.00961	-0.31	-0.38	Neuroticism;	chr8:11198666	chr8:11107788~11109726:-
TGCT	cis	rs4423214	0.84	rs1792233	ENSG00000254682.1	RP11-660L16.2	-4.53	1.35e-05	0.00962	-0.57	-0.38	Vitamin D levels;	chr11:71471133	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.84	rs1790339	ENSG00000254682.1	RP11-660L16.2	-4.53	1.35e-05	0.00962	-0.57	-0.38	Vitamin D levels;	chr11:71471715	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.84	rs4435028	ENSG00000254682.1	RP11-660L16.2	-4.53	1.35e-05	0.00962	-0.57	-0.38	Vitamin D levels;	chr11:71472644	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.802	rs4616066	ENSG00000254682.1	RP11-660L16.2	-4.53	1.35e-05	0.00962	-0.57	-0.38	Vitamin D levels;	chr11:71472800	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.802	rs4402322	ENSG00000254682.1	RP11-660L16.2	-4.53	1.35e-05	0.00962	-0.57	-0.38	Vitamin D levels;	chr11:71472969	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.84	rs1123007	ENSG00000254682.1	RP11-660L16.2	-4.53	1.35e-05	0.00962	-0.57	-0.38	Vitamin D levels;	chr11:71474311	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.84	rs3794057	ENSG00000254682.1	RP11-660L16.2	-4.53	1.35e-05	0.00962	-0.57	-0.38	Vitamin D levels;	chr11:71475698	chr11:71448674~71452157:+
TGCT	cis	rs4423214	0.84	rs2017686	ENSG00000254682.1	RP11-660L16.2	-4.53	1.35e-05	0.00962	-0.57	-0.38	Vitamin D levels;	chr11:71476015	chr11:71448674~71452157:+
TGCT	cis	rs9326248	0.861	rs4938353	ENSG00000280143.1	AP000892.6	4.53	1.35e-05	0.00962	0.53	0.38	Blood protein levels;	chr11:117175481	chr11:117204967~117210292:+
TGCT	cis	rs9880211	1	rs6805316	ENSG00000239213.4	NCK1-AS1	4.53	1.35e-05	0.00962	0.41	0.38	Height;Body mass index;	chr3:136233270	chr3:136841726~136862054:-
TGCT	cis	rs728616	0.867	rs118134654	ENSG00000230091.5	TMEM254-AS1	4.53	1.35e-05	0.00963	0.71	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79984625	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs61860034	ENSG00000230091.5	TMEM254-AS1	4.53	1.35e-05	0.00963	0.71	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172092	chr10:80046860~80078912:-
TGCT	cis	rs16852403	0.548	rs316280	ENSG00000224687.1	RASAL2-AS1	4.53	1.35e-05	0.00963	0.51	0.38	Childhood ear infection;	chr1:178188950	chr1:178091508~178093984:-
TGCT	cis	rs992157	1	rs2292553	ENSG00000261338.2	RP11-378A13.1	4.53	1.35e-05	0.00964	0.3	0.38	Colorectal cancer;	chr2:218282080	chr2:218255319~218257366:+
TGCT	cis	rs4853012	0.941	rs78128123	ENSG00000217702.2	RP11-287D1.4	4.53	1.35e-05	0.00964	0.57	0.38	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74130583~74135395:+
TGCT	cis	rs10504229	0.683	rs7464038	ENSG00000253301.4	RP11-513O17.2	4.53	1.35e-05	0.00964	0.59	0.38	Developmental language disorder (linguistic errors);	chr8:57199349	chr8:57142689~57240298:+
TGCT	cis	rs11157436	1	rs12587166	ENSG00000211813.2	TRAV34	4.53	1.35e-05	0.00964	0.41	0.38	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22165492	chr14:22207522~22208129:+
TGCT	cis	rs72772090	0.539	rs114006288	ENSG00000248734.2	CTD-2260A17.1	-4.53	1.35e-05	0.00964	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782300	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs72773932	ENSG00000248734.2	CTD-2260A17.1	-4.53	1.35e-05	0.00964	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782444	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs11750934	ENSG00000248734.2	CTD-2260A17.1	-4.53	1.35e-05	0.00964	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782783	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs11738810	ENSG00000248734.2	CTD-2260A17.1	-4.53	1.35e-05	0.00964	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96783351	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs11748519	ENSG00000248734.2	CTD-2260A17.1	-4.53	1.35e-05	0.00964	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96783624	chr5:96784777~96785999:+
TGCT	cis	rs507080	0.845	rs613377	ENSG00000255239.1	AP002954.6	4.53	1.36e-05	0.00965	0.49	0.38	Serum metabolite levels;	chr11:118685375	chr11:118688039~118690600:-
TGCT	cis	rs6600671	1	rs10794671	ENSG00000275131.1	CH17-472G23.4	-4.53	1.36e-05	0.00965	-0.24	-0.38	Hip geometry;	chr1:121426382	chr1:120489625~120579190:-
TGCT	cis	rs6600671	1	rs1856572	ENSG00000275131.1	CH17-472G23.4	-4.53	1.36e-05	0.00965	-0.24	-0.38	Hip geometry;	chr1:121427719	chr1:120489625~120579190:-
TGCT	cis	rs12550646	0.6	rs10110994	ENSG00000253943.1	KRT18P37	4.53	1.36e-05	0.00966	0.42	0.38	Reticulocyte fraction of red cells;Reticulocyte count;	chr8:41813985	chr8:41511240~41512521:+
TGCT	cis	rs6474412	1	rs4950	ENSG00000255101.1	RP11-412B14.1	4.53	1.36e-05	0.00966	0.37	0.38	Smoking behavior;	chr8:42697490	chr8:42705583~42721946:-
TGCT	cis	rs2919917	0.628	rs13265305	ENSG00000254352.1	RP11-578O24.2	4.53	1.36e-05	0.00967	0.44	0.38	Lymphocyte counts;	chr8:78656575	chr8:78723796~78724136:-
TGCT	cis	rs2919917	0.628	rs2887482	ENSG00000254352.1	RP11-578O24.2	4.53	1.36e-05	0.00967	0.44	0.38	Lymphocyte counts;	chr8:78659633	chr8:78723796~78724136:-
TGCT	cis	rs2919917	0.628	rs1905364	ENSG00000254352.1	RP11-578O24.2	4.53	1.36e-05	0.00967	0.44	0.38	Lymphocyte counts;	chr8:78660244	chr8:78723796~78724136:-
TGCT	cis	rs875971	0.545	rs6460281	ENSG00000237310.1	GS1-124K5.4	4.53	1.36e-05	0.00967	0.45	0.38	Aortic root size;	chr7:66216128	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs17138156	ENSG00000237310.1	GS1-124K5.4	4.53	1.36e-05	0.00967	0.45	0.38	Aortic root size;	chr7:66249708	chr7:66493706~66495474:+
TGCT	cis	rs1823913	0.599	rs17412635	ENSG00000227542.1	AC092614.2	-4.53	1.36e-05	0.00967	-0.4	-0.38	Obesity-related traits;	chr2:191294834	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs13382985	ENSG00000227542.1	AC092614.2	-4.53	1.36e-05	0.00967	-0.4	-0.38	Obesity-related traits;	chr2:191306335	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs10497713	ENSG00000227542.1	AC092614.2	4.53	1.36e-05	0.00967	0.4	0.38	Obesity-related traits;	chr2:191279312	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs58106487	ENSG00000227542.1	AC092614.2	4.53	1.36e-05	0.00967	0.4	0.38	Obesity-related traits;	chr2:191292404	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs67781530	ENSG00000227542.1	AC092614.2	4.53	1.36e-05	0.00967	0.4	0.38	Obesity-related traits;	chr2:191295608	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs67342262	ENSG00000227542.1	AC092614.2	4.53	1.36e-05	0.00967	0.4	0.38	Obesity-related traits;	chr2:191295612	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs1378162	ENSG00000227542.1	AC092614.2	4.53	1.36e-05	0.00967	0.4	0.38	Obesity-related traits;	chr2:191298523	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.526	rs36028476	ENSG00000227542.1	AC092614.2	4.53	1.36e-05	0.00967	0.4	0.38	Obesity-related traits;	chr2:191300595	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs2124095	ENSG00000227542.1	AC092614.2	4.53	1.36e-05	0.00967	0.4	0.38	Obesity-related traits;	chr2:191301728	chr2:191229165~191246172:-
TGCT	cis	rs853679	0.55	rs1233707	ENSG00000187763.3	OR2B7P	4.53	1.36e-05	0.00968	0.37	0.38	Depression;	chr6:28205175	chr6:28046434~28047367:+
TGCT	cis	rs494459	0.838	rs632124	ENSG00000255422.1	AP002954.4	-4.53	1.36e-05	0.00969	-0.4	-0.38	Height;	chr11:118742526	chr11:118704607~118750263:+
TGCT	cis	rs494459	0.838	rs607125	ENSG00000255422.1	AP002954.4	-4.53	1.36e-05	0.00969	-0.4	-0.38	Height;	chr11:118746590	chr11:118704607~118750263:+
TGCT	cis	rs2463822	1	rs1881534	ENSG00000254454.2	RCC2P6	-4.53	1.36e-05	0.00969	-0.41	-0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62317611	chr11:62371146~62373168:+
TGCT	cis	rs911555	0.617	rs7156036	ENSG00000244691.1	RPL10AP1	4.53	1.36e-05	0.0097	0.51	0.38	Intelligence (multi-trait analysis);	chr14:103441805	chr14:103412119~103412761:-
TGCT	cis	rs911555	0.723	rs6575991	ENSG00000244691.1	RPL10AP1	4.53	1.36e-05	0.0097	0.51	0.38	Intelligence (multi-trait analysis);	chr14:103442096	chr14:103412119~103412761:-
TGCT	cis	rs911555	0.692	rs7146215	ENSG00000244691.1	RPL10AP1	4.53	1.36e-05	0.0097	0.51	0.38	Intelligence (multi-trait analysis);	chr14:103449571	chr14:103412119~103412761:-
TGCT	cis	rs2709736	0.596	rs2058075	ENSG00000232790.2	LINC01162	-4.53	1.36e-05	0.0097	-0.3	-0.38	Bipolar I disorder;	chr7:20856698	chr7:20835431~21023148:+
TGCT	cis	rs9549367	0.713	rs2146750	ENSG00000269125.1	RP11-98F14.11	4.53	1.36e-05	0.0097	0.47	0.38	Platelet distribution width;	chr13:113168216	chr13:113165002~113165183:-
TGCT	cis	rs9462027	0.54	rs4282407	ENSG00000186328.4	RP11-140K17.2	4.53	1.37e-05	0.00972	0.36	0.38	Systemic lupus erythematosus;	chr6:34862385	chr6:34715613~34715940:+
TGCT	cis	rs7208859	0.573	rs8078182	ENSG00000280069.1	CTD-2349P21.3	-4.53	1.37e-05	0.00972	-0.52	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30738182~30740275:+
TGCT	cis	rs2581828	0.656	rs2581787	ENSG00000242142.1	SERBP1P3	4.53	1.37e-05	0.00973	0.34	0.38	Crohn's disease;	chr3:53093661	chr3:53064283~53065091:-
TGCT	cis	rs801193	0.967	rs2707841	ENSG00000272831.1	RP11-792A8.4	4.53	1.37e-05	0.00973	0.4	0.38	Aortic root size;	chr7:66692033	chr7:66739829~66740385:-
TGCT	cis	rs801193	1	rs4717310	ENSG00000272831.1	RP11-792A8.4	4.53	1.37e-05	0.00973	0.4	0.38	Aortic root size;	chr7:66696020	chr7:66739829~66740385:-
TGCT	cis	rs801193	1	rs7785213	ENSG00000272831.1	RP11-792A8.4	-4.53	1.37e-05	0.00973	-0.4	-0.38	Aortic root size;	chr7:66673991	chr7:66739829~66740385:-
TGCT	cis	rs801193	0.935	rs3800820	ENSG00000272831.1	RP11-792A8.4	-4.53	1.37e-05	0.00973	-0.4	-0.38	Aortic root size;	chr7:66682191	chr7:66739829~66740385:-
TGCT	cis	rs801193	1	rs2003301	ENSG00000272831.1	RP11-792A8.4	-4.53	1.37e-05	0.00973	-0.4	-0.38	Aortic root size;	chr7:66682669	chr7:66739829~66740385:-
TGCT	cis	rs11640533	0.901	rs2908792	ENSG00000262714.1	RP11-44F14.8	-4.53	1.37e-05	0.00974	-0.43	-0.38	Intelligence (multi-trait analysis);	chr16:53378507	chr16:53386944~53389085:+
TGCT	cis	rs11157436	0.958	rs764160	ENSG00000211813.2	TRAV34	4.53	1.37e-05	0.00975	0.39	0.38	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231098	chr14:22207522~22208129:+
TGCT	cis	rs2033711	0.84	rs4801590	ENSG00000268912.1	CTD-2619J13.17	-4.53	1.37e-05	0.00976	-0.33	-0.38	Uric acid clearance;	chr19:58450446	chr19:58428632~58431148:-
TGCT	cis	rs10504229	0.639	rs55687236	ENSG00000253301.4	RP11-513O17.2	4.53	1.37e-05	0.00977	0.6	0.38	Developmental language disorder (linguistic errors);	chr8:57193297	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs17194792	ENSG00000253301.4	RP11-513O17.2	4.53	1.37e-05	0.00977	0.6	0.38	Developmental language disorder (linguistic errors);	chr8:57194636	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs79284841	ENSG00000253301.4	RP11-513O17.2	4.53	1.37e-05	0.00977	0.6	0.38	Developmental language disorder (linguistic errors);	chr8:57195052	chr8:57142689~57240298:+
TGCT	cis	rs11920570	0.526	rs3828362	ENSG00000272758.4	RP11-299J3.8	4.53	1.38e-05	0.00977	0.37	0.38	Resting heart rate;	chr3:122412930	chr3:122416207~122443180:+
TGCT	cis	rs2919917	0.628	rs1021157	ENSG00000254352.1	RP11-578O24.2	4.53	1.38e-05	0.00978	0.44	0.38	Lymphocyte counts;	chr8:78662938	chr8:78723796~78724136:-
TGCT	cis	rs2919917	0.628	rs979564	ENSG00000254352.1	RP11-578O24.2	4.53	1.38e-05	0.00978	0.44	0.38	Lymphocyte counts;	chr8:78663924	chr8:78723796~78724136:-
TGCT	cis	rs1865760	0.964	rs3799373	ENSG00000217159.2	LARP1P1	-4.53	1.38e-05	0.00979	-0.44	-0.38	Height;	chr6:25928945	chr6:26164072~26164363:+
TGCT	cis	rs2709736	0.562	rs10252529	ENSG00000232790.2	LINC01162	-4.53	1.38e-05	0.00979	-0.3	-0.38	Bipolar I disorder;	chr7:20858243	chr7:20835431~21023148:+
TGCT	cis	rs2709736	0.5	rs204575	ENSG00000232790.2	LINC01162	-4.53	1.38e-05	0.00979	-0.3	-0.38	Bipolar I disorder;	chr7:20858290	chr7:20835431~21023148:+
TGCT	cis	rs786425	0.707	rs1969272	ENSG00000278112.1	RP11-972P1.11	4.53	1.38e-05	0.00979	0.42	0.38	Pubertal anthropometrics;	chr12:123685746	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.866	rs7302449	ENSG00000278112.1	RP11-972P1.11	4.53	1.38e-05	0.00979	0.42	0.38	Pubertal anthropometrics;	chr12:123688199	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.576	rs10846541	ENSG00000278112.1	RP11-972P1.11	4.53	1.38e-05	0.00979	0.42	0.38	Pubertal anthropometrics;	chr12:123691739	chr12:123519390~123519856:-
TGCT	cis	rs786425	0.866	rs7137946	ENSG00000278112.1	RP11-972P1.11	4.53	1.38e-05	0.00979	0.42	0.38	Pubertal anthropometrics;	chr12:123692742	chr12:123519390~123519856:-
TGCT	cis	rs8105895	0.935	rs62112918	ENSG00000269742.1	BNIP3P29	4.53	1.38e-05	0.00979	0.69	0.38	Body mass index (change over time);	chr19:22044277	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.877	rs62112919	ENSG00000269742.1	BNIP3P29	4.53	1.38e-05	0.00979	0.69	0.38	Body mass index (change over time);	chr19:22044343	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs62112920	ENSG00000269742.1	BNIP3P29	4.53	1.38e-05	0.00979	0.69	0.38	Body mass index (change over time);	chr19:22044347	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs62112921	ENSG00000269742.1	BNIP3P29	4.53	1.38e-05	0.00979	0.69	0.38	Body mass index (change over time);	chr19:22044775	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.799	rs62112922	ENSG00000269742.1	BNIP3P29	4.53	1.38e-05	0.00979	0.69	0.38	Body mass index (change over time);	chr19:22045538	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs75025987	ENSG00000269742.1	BNIP3P29	4.53	1.38e-05	0.00979	0.69	0.38	Body mass index (change over time);	chr19:22047867	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs8110289	ENSG00000269742.1	BNIP3P29	4.53	1.38e-05	0.00979	0.69	0.38	Body mass index (change over time);	chr19:22056915	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.736	rs2359835	ENSG00000269742.1	BNIP3P29	4.53	1.38e-05	0.00979	0.69	0.38	Body mass index (change over time);	chr19:22059888	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.733	rs62110979	ENSG00000269742.1	BNIP3P29	4.53	1.38e-05	0.00979	0.69	0.38	Body mass index (change over time);	chr19:22062350	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs7252220	ENSG00000269742.1	BNIP3P29	4.53	1.38e-05	0.00979	0.69	0.38	Body mass index (change over time);	chr19:22062762	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs62110981	ENSG00000269742.1	BNIP3P29	4.53	1.38e-05	0.00979	0.69	0.38	Body mass index (change over time);	chr19:22063211	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs62110985	ENSG00000269742.1	BNIP3P29	4.53	1.38e-05	0.00979	0.69	0.38	Body mass index (change over time);	chr19:22073275	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs62110986	ENSG00000269742.1	BNIP3P29	4.53	1.38e-05	0.00979	0.69	0.38	Body mass index (change over time);	chr19:22073969	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs62110987	ENSG00000269742.1	BNIP3P29	4.53	1.38e-05	0.00979	0.69	0.38	Body mass index (change over time);	chr19:22074493	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs62110988	ENSG00000269742.1	BNIP3P29	4.53	1.38e-05	0.00979	0.69	0.38	Body mass index (change over time);	chr19:22077154	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs62110989	ENSG00000269742.1	BNIP3P29	4.53	1.38e-05	0.00979	0.69	0.38	Body mass index (change over time);	chr19:22077497	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs62110992	ENSG00000269742.1	BNIP3P29	4.53	1.38e-05	0.00979	0.69	0.38	Body mass index (change over time);	chr19:22078714	chr19:22065828~22066398:-
TGCT	cis	rs673078	0.607	rs61943393	ENSG00000275759.1	RP11-131L12.3	-4.53	1.38e-05	0.00981	-0.71	-0.38	Glucose homeostasis traits;	chr12:118383650	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs73205576	ENSG00000275759.1	RP11-131L12.3	-4.53	1.38e-05	0.00981	-0.71	-0.38	Glucose homeostasis traits;	chr12:118384268	chr12:118428281~118428870:+
TGCT	cis	rs6568686	0.527	rs174408	ENSG00000272356.1	RP5-1112D6.8	-4.53	1.38e-05	0.00981	-0.45	-0.38	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111611146	chr6:111309203~111313517:+
TGCT	cis	rs6568686	0.527	rs174409	ENSG00000272356.1	RP5-1112D6.8	-4.53	1.38e-05	0.00981	-0.45	-0.38	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111611181	chr6:111309203~111313517:+
TGCT	cis	rs2944755	0.723	rs13250299	ENSG00000279766.1	RP11-642A1.2	-4.53	1.38e-05	0.00982	-0.37	-0.38	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140579485	chr8:140572142~140572812:-
TGCT	cis	rs801193	1	rs7782320	ENSG00000272831.1	RP11-792A8.4	4.53	1.39e-05	0.00983	0.4	0.38	Aortic root size;	chr7:66712111	chr7:66739829~66740385:-
TGCT	cis	rs1061377	1	rs9996285	ENSG00000249685.1	RP11-360F5.3	4.53	1.39e-05	0.00983	0.36	0.38	Uric acid levels;	chr4:39130556	chr4:39133913~39135608:+
TGCT	cis	rs4835473	0.932	rs1849115	ENSG00000251600.4	RP11-673E1.1	4.53	1.39e-05	0.00984	0.4	0.38	Immature fraction of reticulocytes;	chr4:143989687	chr4:143912331~143982454:+
TGCT	cis	rs62038064	1	rs2174403	ENSG00000278058.1	RP11-70D24.2	4.53	1.39e-05	0.00984	0.31	0.38	Post bronchodilator FEV1/FVC ratio;	chr16:78895561	chr16:79605802~79606605:+
TGCT	cis	rs867371	1	rs867370	ENSG00000255769.6	GOLGA2P10	4.53	1.39e-05	0.00984	0.41	0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82145921	chr15:82472993~82513950:-
TGCT	cis	rs867371	1	rs867371	ENSG00000255769.6	GOLGA2P10	4.53	1.39e-05	0.00984	0.41	0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82146005	chr15:82472993~82513950:-
TGCT	cis	rs17373728	0.739	rs6472896	ENSG00000249395.2	CASC9	4.53	1.39e-05	0.00985	0.47	0.38	Diabetic kidney disease;	chr8:75278080	chr8:75223404~75324741:-
TGCT	cis	rs4308124	0.708	rs28766030	ENSG00000227992.1	AC108463.2	-4.53	1.39e-05	0.00985	-0.4	-0.38	Vitiligo;	chr2:111204852	chr2:111203964~111206215:-
TGCT	cis	rs4308124	0.708	rs28871990	ENSG00000227992.1	AC108463.2	-4.53	1.39e-05	0.00985	-0.4	-0.38	Vitiligo;	chr2:111204864	chr2:111203964~111206215:-
TGCT	cis	rs4308124	0.679	rs7600458	ENSG00000227992.1	AC108463.2	-4.53	1.39e-05	0.00985	-0.4	-0.38	Vitiligo;	chr2:111206013	chr2:111203964~111206215:-
TGCT	cis	rs853679	0.599	rs149990	ENSG00000216901.1	AL022393.7	4.53	1.39e-05	0.00985	0.65	0.38	Depression;	chr6:28030480	chr6:28176188~28176674:+
TGCT	cis	rs853679	0.599	rs149943	ENSG00000216901.1	AL022393.7	4.53	1.39e-05	0.00985	0.65	0.38	Depression;	chr6:28034610	chr6:28176188~28176674:+
TGCT	cis	rs599083	0.53	rs667126	ENSG00000212093.1	AP000807.1	-4.53	1.39e-05	0.00986	-0.38	-0.38	Bone mineral density (spine);	chr11:68410260	chr11:68506083~68506166:-
TGCT	cis	rs2280018	0.609	rs2941253	ENSG00000250251.5	PKD1P6	4.53	1.39e-05	0.00986	0.28	0.38	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15079889	chr16:15125242~15154564:-
TGCT	cis	rs10504229	0.871	rs56372514	ENSG00000253301.4	RP11-513O17.2	4.53	1.39e-05	0.00987	0.49	0.38	Developmental language disorder (linguistic errors);	chr8:57244607	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.871	rs10504226	ENSG00000253301.4	RP11-513O17.2	4.53	1.39e-05	0.00987	0.49	0.38	Developmental language disorder (linguistic errors);	chr8:57246724	chr8:57142689~57240298:+
TGCT	cis	rs4835473	0.897	rs7695328	ENSG00000251600.4	RP11-673E1.1	4.53	1.39e-05	0.00988	0.39	0.38	Immature fraction of reticulocytes;	chr4:143703768	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.864	rs57137521	ENSG00000251600.4	RP11-673E1.1	-4.53	1.39e-05	0.00988	-0.39	-0.38	Immature fraction of reticulocytes;	chr4:143704045	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs55945293	ENSG00000251600.4	RP11-673E1.1	-4.53	1.39e-05	0.00988	-0.39	-0.38	Immature fraction of reticulocytes;	chr4:143704766	chr4:143912331~143982454:+
TGCT	cis	rs6017291	1	rs35101355	ENSG00000223891.4	OSER1-AS1	4.53	1.39e-05	0.00988	0.56	0.38	Cognitive performance;	chr20:44292767	chr20:44210960~44226027:+
TGCT	cis	rs875971	0.825	rs1000464	ENSG00000232559.3	GS1-124K5.12	-4.53	1.4e-05	0.00988	-0.35	-0.38	Aortic root size;	chr7:66312922	chr7:66554588~66576923:-
TGCT	cis	rs7829975	0.714	rs4840362	ENSG00000173295.6	FAM86B3P	-4.52	1.4e-05	0.00989	-0.46	-0.38	Mood instability;	chr8:8812572	chr8:8228595~8244865:+
TGCT	cis	rs7795991	0.607	rs4236281	ENSG00000224330.1	AC005019.3	-4.52	1.4e-05	0.0099	-0.4	-0.38	Type 2 diabetes;	chr7:13865817	chr7:13854355~13859025:-
TGCT	cis	rs72772090	0.539	rs55996659	ENSG00000248734.2	CTD-2260A17.1	-4.52	1.4e-05	0.0099	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778446	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs17481759	ENSG00000248734.2	CTD-2260A17.1	-4.52	1.4e-05	0.0099	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778991	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs111237997	ENSG00000248734.2	CTD-2260A17.1	-4.52	1.4e-05	0.0099	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779249	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs3335	ENSG00000248734.2	CTD-2260A17.1	-4.52	1.4e-05	0.0099	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779366	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs3334	ENSG00000248734.2	CTD-2260A17.1	-4.52	1.4e-05	0.0099	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779381	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs3333	ENSG00000248734.2	CTD-2260A17.1	-4.52	1.4e-05	0.0099	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779407	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs11749811	ENSG00000248734.2	CTD-2260A17.1	-4.52	1.4e-05	0.0099	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780221	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs67140788	ENSG00000248734.2	CTD-2260A17.1	-4.52	1.4e-05	0.0099	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780582	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs72773922	ENSG00000248734.2	CTD-2260A17.1	-4.52	1.4e-05	0.0099	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780956	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs17481856	ENSG00000248734.2	CTD-2260A17.1	-4.52	1.4e-05	0.0099	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96781104	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs72773923	ENSG00000248734.2	CTD-2260A17.1	-4.52	1.4e-05	0.0099	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96781875	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs116360011	ENSG00000248734.2	CTD-2260A17.1	-4.52	1.4e-05	0.0099	-0.49	-0.38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782093	chr5:96784777~96785999:+
TGCT	cis	rs1891275	0.515	rs1592051	ENSG00000228701.1	TNKS2-AS1	4.52	1.4e-05	0.0099	0.42	0.38	Intelligence (multi-trait analysis);	chr10:91782429	chr10:91782839~91798291:-
TGCT	cis	rs875971	0.895	rs12698520	ENSG00000237310.1	GS1-124K5.4	4.52	1.4e-05	0.00991	0.41	0.38	Aortic root size;	chr7:66453720	chr7:66493706~66495474:+
TGCT	cis	rs7208859	0.623	rs7220999	ENSG00000266490.1	CTD-2349P21.9	4.52	1.4e-05	0.00991	0.43	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs55638872	ENSG00000266490.1	CTD-2349P21.9	4.52	1.4e-05	0.00991	0.43	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs9899268	ENSG00000266490.1	CTD-2349P21.9	4.52	1.4e-05	0.00991	0.43	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30792372~30792833:+
TGCT	cis	rs2333021	0.649	rs8022992	ENSG00000259015.1	RP11-109N23.6	4.52	1.4e-05	0.00991	0.22	0.38	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73005615	chr14:72960595~72961993:+
TGCT	cis	rs1618992	0.729	rs8092832	ENSG00000265994.1	RP11-510D21.1	4.52	1.4e-05	0.00992	0.38	0.38	Gut microbiome composition (summer and winter);	chr18:28579296	chr18:28785068~28789260:+
TGCT	cis	rs7208859	0.673	rs73263981	ENSG00000263531.1	RP13-753N3.1	4.52	1.4e-05	0.00992	0.67	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.524	rs73263982	ENSG00000263531.1	RP13-753N3.1	4.52	1.4e-05	0.00992	0.67	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.623	rs216433	ENSG00000263531.1	RP13-753N3.1	4.52	1.4e-05	0.00992	0.67	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs216435	ENSG00000263531.1	RP13-753N3.1	4.52	1.4e-05	0.00992	0.67	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30863921~30864940:-
TGCT	cis	rs4713118	0.662	rs149969	ENSG00000219392.1	RP1-265C24.5	-4.52	1.4e-05	0.00993	-0.45	-0.38	Parkinson's disease;	chr6:28009959	chr6:28115628~28116551:+
TGCT	cis	rs7208859	0.673	rs216440	ENSG00000266490.1	CTD-2349P21.9	4.52	1.4e-05	0.00993	0.4	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30601291	chr17:30792372~30792833:+
TGCT	cis	rs17826219	0.561	rs562840	ENSG00000266490.1	CTD-2349P21.9	4.52	1.4e-05	0.00993	0.4	0.38	Body mass index;	chr17:30622372	chr17:30792372~30792833:+
TGCT	cis	rs901683	1	rs12779976	ENSG00000264204.2	AGAP7P	4.52	1.41e-05	0.00994	0.82	0.38	Mean corpuscular volume;Red blood cell traits;	chr10:45547484	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs9422440	ENSG00000264204.2	AGAP7P	-4.52	1.41e-05	0.00994	-0.82	-0.38	Mean corpuscular volume;Red blood cell traits;	chr10:45549677	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs9422650	ENSG00000264204.2	AGAP7P	-4.52	1.41e-05	0.00994	-0.82	-0.38	Mean corpuscular volume;Red blood cell traits;	chr10:45550313	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs78363416	ENSG00000264204.2	AGAP7P	-4.52	1.41e-05	0.00994	-0.82	-0.38	Mean corpuscular volume;Red blood cell traits;	chr10:45550686	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs34138033	ENSG00000264204.2	AGAP7P	-4.52	1.41e-05	0.00994	-0.82	-0.38	Mean corpuscular volume;Red blood cell traits;	chr10:45551064	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35036712	ENSG00000264204.2	AGAP7P	-4.52	1.41e-05	0.00994	-0.82	-0.38	Mean corpuscular volume;Red blood cell traits;	chr10:45551262	chr10:46109621~46131358:+
TGCT	cis	rs6600671	1	rs1591882	ENSG00000275131.1	CH17-472G23.4	-4.52	1.41e-05	0.00994	-0.24	-0.38	Hip geometry;	chr1:121441455	chr1:120489625~120579190:-
TGCT	cis	rs10504229	1	rs10504229	ENSG00000253301.4	RP11-513O17.2	4.52	1.41e-05	0.00994	0.5	0.38	Developmental language disorder (linguistic errors);	chr8:57283936	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs59708460	ENSG00000253301.4	RP11-513O17.2	4.52	1.41e-05	0.00994	0.5	0.38	Developmental language disorder (linguistic errors);	chr8:57283967	chr8:57142689~57240298:+
TGCT	cis	rs11129295	0.618	rs9823274	ENSG00000224237.1	MINOS1P3	4.52	1.41e-05	0.00994	0.41	0.38	Multiple sclerosis;	chr3:27771175	chr3:27214816~27215018:-
TGCT	cis	rs73198271	0.563	rs3748143	ENSG00000253893.2	FAM85B	-4.52	1.41e-05	0.00995	-0.59	-0.38	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8797727	chr8:8167819~8226614:-
TGCT	cis	rs17711722	0.528	rs73138179	ENSG00000236529.1	RP13-254B10.1	4.52	1.41e-05	0.00995	0.27	0.38	Calcium levels;	chr7:65829495	chr7:65840212~65840596:+
TGCT	cis	rs875971	0.964	rs6978429	ENSG00000237310.1	GS1-124K5.4	4.52	1.41e-05	0.00996	0.41	0.38	Aortic root size;	chr7:66494889	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.929	rs12535036	ENSG00000237310.1	GS1-124K5.4	4.52	1.41e-05	0.00996	0.41	0.38	Aortic root size;	chr7:66499076	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs12532998	ENSG00000237310.1	GS1-124K5.4	4.52	1.41e-05	0.00996	0.41	0.38	Aortic root size;	chr7:66502472	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs12698523	ENSG00000237310.1	GS1-124K5.4	4.52	1.41e-05	0.00996	0.41	0.38	Aortic root size;	chr7:66503126	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs6970030	ENSG00000237310.1	GS1-124K5.4	4.52	1.41e-05	0.00996	0.41	0.38	Aortic root size;	chr7:66503692	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.928	rs6970357	ENSG00000237310.1	GS1-124K5.4	4.52	1.41e-05	0.00996	0.41	0.38	Aortic root size;	chr7:66503891	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs3735148	ENSG00000237310.1	GS1-124K5.4	4.52	1.41e-05	0.00996	0.41	0.38	Aortic root size;	chr7:66506022	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.929	rs6970860	ENSG00000237310.1	GS1-124K5.4	4.52	1.41e-05	0.00996	0.41	0.38	Aortic root size;	chr7:66511647	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs6957199	ENSG00000237310.1	GS1-124K5.4	4.52	1.41e-05	0.00996	0.41	0.38	Aortic root size;	chr7:66513532	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs6958271	ENSG00000237310.1	GS1-124K5.4	4.52	1.41e-05	0.00996	0.41	0.38	Aortic root size;	chr7:66514344	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs6958277	ENSG00000237310.1	GS1-124K5.4	4.52	1.41e-05	0.00996	0.41	0.38	Aortic root size;	chr7:66514362	chr7:66493706~66495474:+
TGCT	cis	rs67311347	1	rs6795475	ENSG00000223797.4	ENTPD3-AS1	4.52	1.41e-05	0.00996	0.39	0.38	Renal cell carcinoma;	chr3:40447790	chr3:40313802~40453329:-
TGCT	cis	rs2742234	0.541	rs11528481	ENSG00000273008.1	RP11-351D16.3	4.52	1.41e-05	0.00999	0.54	0.38	Hirschsprung disease;	chr10:43242319	chr10:43136824~43138334:-
TGCT	cis	rs753274	0.65	rs10403233	ENSG00000267147.2	CTC-548K16.1	-4.52	1.42e-05	0.01	-0.46	-0.38	Tumor necrosis factor beta levels;	chr19:14309013	chr19:14333743~14343916:+
TGCT	cis	rs753274	0.65	rs28825416	ENSG00000267147.2	CTC-548K16.1	-4.52	1.42e-05	0.01	-0.46	-0.38	Tumor necrosis factor beta levels;	chr19:14309282	chr19:14333743~14343916:+
TGCT	cis	rs13108904	0.65	rs3796618	ENSG00000253399.1	AC078852.2	-4.52	1.42e-05	0.01	-0.42	-0.38	Obesity-related traits;	chr4:1355814	chr4:1358479~1359461:+
TGCT	cis	rs11671005	0.735	rs34873624	ENSG00000232098.3	CTD-2619J13.14	-4.52	1.42e-05	0.01	-0.42	-0.38	Mean platelet volume;	chr19:58432035	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.693	rs34230465	ENSG00000232098.3	CTD-2619J13.14	-4.52	1.42e-05	0.01	-0.42	-0.38	Mean platelet volume;	chr19:58432209	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.735	rs3764529	ENSG00000232098.3	CTD-2619J13.14	-4.52	1.42e-05	0.01	-0.42	-0.38	Mean platelet volume;	chr19:58433722	chr19:58404238~58408484:-
TGCT	cis	rs6604026	0.59	rs11809055	ENSG00000223787.2	RP4-593M8.1	4.52	1.42e-05	0.01	0.55	0.38	Multiple sclerosis;	chr1:92675107	chr1:92580476~92580821:-
TGCT	cis	rs755249	0.565	rs2695324	ENSG00000182109.6	RP11-69E11.4	4.52	1.42e-05	0.01	0.36	0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39587969	chr1:39522280~39546187:-
TGCT	cis	rs1891275	0.515	rs6583784	ENSG00000228701.1	TNKS2-AS1	4.52	1.42e-05	0.01	0.42	0.38	Intelligence (multi-trait analysis);	chr10:91731819	chr10:91782839~91798291:-
TGCT	cis	rs34217772	0.525	rs7359059	ENSG00000258536.1	RP11-1053O12.1	4.52	1.42e-05	0.01	0.31	0.38	Myopia;	chr14:41947575	chr14:41742639~41742963:+
TGCT	cis	rs8105895	0.935	rs7252380	ENSG00000269742.1	BNIP3P29	4.52	1.42e-05	0.01	0.69	0.38	Body mass index (change over time);	chr19:22062913	chr19:22065828~22066398:-
TGCT	cis	rs11671005	0.779	rs35631681	ENSG00000232098.3	CTD-2619J13.14	-4.52	1.42e-05	0.01	-0.47	-0.38	Mean platelet volume;	chr19:58488473	chr19:58404238~58408484:-
TGCT	cis	rs5769707	0.967	rs739241	ENSG00000235111.1	RP1-29C18.8	-4.52	1.42e-05	0.01	-0.3	-0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49659273	chr22:49612657~49615716:-
TGCT	cis	rs5769707	0.967	rs12485195	ENSG00000235111.1	RP1-29C18.8	-4.52	1.42e-05	0.01	-0.3	-0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49660223	chr22:49612657~49615716:-
TGCT	cis	rs972540	0.889	rs1026119	ENSG00000279220.1	GPR1-AS	4.52	1.42e-05	0.01	0.38	0.38	Body mass index;	chr2:206362150	chr2:206203376~206266243:+
TGCT	cis	rs1577917	0.545	rs1832070	ENSG00000203875.9	SNHG5	4.52	1.42e-05	0.01	0.5	0.38	Response to antipsychotic treatment;	chr6:85773454	chr6:85660950~85678736:-
TGCT	cis	rs1577917	0.545	rs9344548	ENSG00000203875.9	SNHG5	4.52	1.42e-05	0.01	0.5	0.38	Response to antipsychotic treatment;	chr6:85777619	chr6:85660950~85678736:-
TGCT	cis	rs867371	1	rs1392976	ENSG00000255769.6	GOLGA2P10	4.52	1.43e-05	0.01	0.4	0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82472993~82513950:-
TGCT	cis	rs11671005	0.693	rs11669665	ENSG00000232098.3	CTD-2619J13.14	-4.52	1.43e-05	0.01	-0.42	-0.38	Mean platelet volume;	chr19:58420518	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.735	rs11084543	ENSG00000232098.3	CTD-2619J13.14	-4.52	1.43e-05	0.01	-0.42	-0.38	Mean platelet volume;	chr19:58421334	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.735	rs11881000	ENSG00000232098.3	CTD-2619J13.14	-4.52	1.43e-05	0.01	-0.42	-0.38	Mean platelet volume;	chr19:58421421	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.695	rs11673069	ENSG00000232098.3	CTD-2619J13.14	-4.52	1.43e-05	0.01	-0.42	-0.38	Mean platelet volume;	chr19:58423551	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.735	rs12981875	ENSG00000232098.3	CTD-2619J13.14	-4.52	1.43e-05	0.01	-0.42	-0.38	Mean platelet volume;	chr19:58423763	chr19:58404238~58408484:-
TGCT	cis	rs4713118	0.662	rs464312	ENSG00000216901.1	AL022393.7	4.52	1.43e-05	0.01	0.47	0.38	Parkinson's disease;	chr6:27999813	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.662	rs469228	ENSG00000216901.1	AL022393.7	4.52	1.43e-05	0.01	0.47	0.38	Parkinson's disease;	chr6:28002926	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.54	rs469227	ENSG00000216901.1	AL022393.7	4.52	1.43e-05	0.01	0.47	0.38	Parkinson's disease;	chr6:28002927	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.662	rs149948	ENSG00000216901.1	AL022393.7	4.52	1.43e-05	0.01	0.47	0.38	Parkinson's disease;	chr6:28007039	chr6:28176188~28176674:+
TGCT	cis	rs755249	0.565	rs9729677	ENSG00000182109.6	RP11-69E11.4	-4.52	1.43e-05	0.01	-0.36	-0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39587137	chr1:39522280~39546187:-
TGCT	cis	rs1823913	0.599	rs13035132	ENSG00000227542.1	AC092614.2	4.52	1.43e-05	0.01	0.4	0.38	Obesity-related traits;	chr2:191265275	chr2:191229165~191246172:-
TGCT	cis	rs12745968	0.652	rs4970702	ENSG00000223787.2	RP4-593M8.1	-4.52	1.43e-05	0.01	-0.51	-0.38	Bipolar disorder and schizophrenia;	chr1:92479437	chr1:92580476~92580821:-
TGCT	cis	rs17301013	0.507	rs72713512	ENSG00000227373.4	RP11-160H22.5	4.52	1.43e-05	0.01	0.41	0.38	Systemic lupus erythematosus;	chr1:174283505	chr1:174115300~174160004:-
TGCT	cis	rs17507216	0.667	rs72753916	ENSG00000278603.1	RP13-608F4.5	4.52	1.43e-05	0.0101	0.56	0.38	Excessive daytime sleepiness;	chr15:82684001	chr15:82472203~82472426:+
TGCT	cis	rs7923609	0.811	rs12245367	ENSG00000232075.1	MRPL35P2	4.52	1.43e-05	0.0101	0.37	0.38	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63561704	chr10:63634317~63634827:-
TGCT	cis	rs4835473	0.639	rs28674022	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143966409	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.864	rs28423022	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143966416	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.864	rs35888177	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143966863	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs10033382	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143967103	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs11931330	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143970808	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.549	rs11940719	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143970855	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.83	rs7692672	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143971048	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs6537223	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143971541	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.615	rs6857432	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143971912	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.742	rs1838519	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143972242	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.831	rs4452380	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143972856	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.798	rs34353812	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143973949	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.831	rs10428468	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143974104	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.75	rs57610804	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143974341	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs13148097	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143976238	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs28377887	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143977075	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs6826862	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143978180	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.663	rs4835115	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143979308	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.864	rs4257604	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143980261	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs35599924	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143980602	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs4516663	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143980791	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.8	rs2089839	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143980955	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs4835118	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143981994	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs4835471	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143982153	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs4835119	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143982210	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs4835120	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143982370	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs4835472	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143982398	chr4:143912331~143982454:+
TGCT	cis	rs4835473	1	rs4835473	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143982419	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs4835474	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143982444	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs6847869	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143982881	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs6846984	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143983098	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs34617134	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143983606	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.736	rs11724009	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143984291	chr4:143912331~143982454:+
TGCT	cis	rs4323050	0.514	rs28647406	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	High light scatter reticulocyte percentage of red cells;	chr4:143984437	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.604	rs11938387	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143984476	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.798	rs11100829	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143984761	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1511425	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143985122	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1849120	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143985337	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs4835476	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143985517	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1828502	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143985797	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs7668698	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143986333	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs6537231	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143986489	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1877234	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143986774	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs6852502	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143987174	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs4260486	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143987556	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs4287958	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143987719	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs4125545	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143988650	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs12649594	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143989307	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.864	rs13101482	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143989463	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.864	rs13135472	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143989465	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1849118	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143989822	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.663	rs1511423	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143990136	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.639	rs5029916	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143990684	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1988206	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143991344	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.831	rs4323050	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143992106	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs4423826	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143992165	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1849128	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143992582	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.715	rs4538428	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143992751	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.771	rs2175452	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143992887	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.8	rs2175451	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	Immature fraction of reticulocytes;	chr4:143992964	chr4:143912331~143982454:+
TGCT	cis	rs4323050	0.51	rs4254715	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	High light scatter reticulocyte percentage of red cells;	chr4:143993140	chr4:143912331~143982454:+
TGCT	cis	rs4323050	0.51	rs4273414	ENSG00000251600.4	RP11-673E1.1	4.52	1.44e-05	0.0101	0.39	0.38	High light scatter reticulocyte percentage of red cells;	chr4:143993142	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs36018946	ENSG00000251600.4	RP11-673E1.1	-4.52	1.44e-05	0.0101	-0.39	-0.38	Immature fraction of reticulocytes;	chr4:143980942	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.9	rs13101531	ENSG00000251600.4	RP11-673E1.1	-4.52	1.44e-05	0.0101	-0.39	-0.38	Immature fraction of reticulocytes;	chr4:143982197	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs28668841	ENSG00000251600.4	RP11-673E1.1	-4.52	1.44e-05	0.0101	-0.39	-0.38	Immature fraction of reticulocytes;	chr4:143982530	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs1877235	ENSG00000251600.4	RP11-673E1.1	-4.52	1.44e-05	0.0101	-0.39	-0.38	Immature fraction of reticulocytes;	chr4:143986961	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.868	rs1828503	ENSG00000251600.4	RP11-673E1.1	-4.52	1.44e-05	0.0101	-0.39	-0.38	Immature fraction of reticulocytes;	chr4:143993354	chr4:143912331~143982454:+
TGCT	cis	rs4988958	0.565	rs885088	ENSG00000234389.1	AC007278.3	4.52	1.44e-05	0.0101	0.28	0.38	Asthma (childhood onset);	chr2:102422584	chr2:102438713~102440475:+
TGCT	cis	rs11118620	0.535	rs1389750	ENSG00000257551.1	HLX-AS1	4.52	1.44e-05	0.0101	0.36	0.38	Heart failure;	chr1:220866829	chr1:220832763~220880140:-
TGCT	cis	rs2709736	0.596	rs204594	ENSG00000232790.2	LINC01162	-4.52	1.44e-05	0.0101	-0.29	-0.38	Bipolar I disorder;	chr7:20871593	chr7:20835431~21023148:+
TGCT	cis	rs2717559	0.542	rs2717590	ENSG00000253196.1	RP11-706C16.7	-4.52	1.44e-05	0.0101	-0.38	-0.38	Urinary tract infection frequency;	chr8:142819296	chr8:142763116~142766427:+
TGCT	cis	rs7246967	0.551	rs35740274	ENSG00000269509.1	BNIP3P34	4.52	1.44e-05	0.0101	0.59	0.38	Bronchopulmonary dysplasia;	chr19:22648611	chr19:22773853~22774424:+
TGCT	cis	rs3824488	0.541	rs79667894	ENSG00000228142.2	RP11-180I4.2	4.52	1.44e-05	0.0101	0.84	0.38	Neuroticism;	chr9:95437744	chr9:95650154~95715718:+
TGCT	cis	rs2463822	1	rs1406384	ENSG00000254454.2	RCC2P6	4.52	1.44e-05	0.0101	0.4	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62316058	chr11:62371146~62373168:+
TGCT	cis	rs4308124	0.708	rs56693625	ENSG00000227992.1	AC108463.2	-4.52	1.44e-05	0.0101	-0.4	-0.38	Vitiligo;	chr2:111207578	chr2:111203964~111206215:-
TGCT	cis	rs4308124	0.708	rs61358692	ENSG00000227992.1	AC108463.2	-4.52	1.44e-05	0.0101	-0.4	-0.38	Vitiligo;	chr2:111207582	chr2:111203964~111206215:-
TGCT	cis	rs651907	0.535	rs2290859	ENSG00000244119.1	PDCL3P4	4.52	1.44e-05	0.0101	0.27	0.38	Colorectal cancer;	chr3:101806781	chr3:101712472~101713191:+
TGCT	cis	rs1618992	0.791	rs7231009	ENSG00000265994.1	RP11-510D21.1	4.52	1.44e-05	0.0101	0.38	0.38	Gut microbiome composition (summer and winter);	chr18:28638813	chr18:28785068~28789260:+
TGCT	cis	rs1618992	0.791	rs1394191	ENSG00000265994.1	RP11-510D21.1	4.52	1.44e-05	0.0101	0.38	0.38	Gut microbiome composition (summer and winter);	chr18:28639996	chr18:28785068~28789260:+
TGCT	cis	rs7819412	0.645	rs4841508	ENSG00000269918.1	AF131215.9	-4.52	1.44e-05	0.0101	-0.39	-0.38	Triglycerides;	chr8:11207494	chr8:11104691~11106704:-
TGCT	cis	rs34779708	0.966	rs113170867	ENSG00000230534.5	RP11-297A16.2	4.52	1.45e-05	0.0102	0.44	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35161219	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.966	rs12782948	ENSG00000230534.5	RP11-297A16.2	4.52	1.45e-05	0.0102	0.44	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35161679	chr10:35098006~35127020:-
TGCT	cis	rs34779708	0.931	rs35126129	ENSG00000230534.5	RP11-297A16.2	4.52	1.45e-05	0.0102	0.44	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35163213	chr10:35098006~35127020:-
TGCT	cis	rs9326248	1	rs4938344	ENSG00000280143.1	AP000892.6	4.52	1.45e-05	0.0102	0.52	0.38	Blood protein levels;	chr11:117133033	chr11:117204967~117210292:+
TGCT	cis	rs2439831	0.85	rs28413881	ENSG00000205771.5	CATSPER2P1	-4.52	1.45e-05	0.0102	-0.63	-0.38	Lung cancer in ever smokers;	chr15:43881901	chr15:43726918~43747094:-
TGCT	cis	rs6981523	0.532	rs1987190	ENSG00000269918.1	AF131215.9	-4.52	1.45e-05	0.0102	-0.38	-0.38	Neuroticism;	chr8:11196005	chr8:11104691~11106704:-
TGCT	cis	rs2980439	0.807	rs2980438	ENSG00000254340.1	RP11-10A14.3	4.51	1.45e-05	0.0102	0.38	0.38	Neuroticism;	chr8:8237303	chr8:9141424~9145435:+
TGCT	cis	rs10256972	0.684	rs4724039	ENSG00000226291.1	AC091729.8	-4.51	1.45e-05	0.0102	-0.4	-0.38	Endometriosis;Longevity;	chr7:1071997	chr7:1080863~1082178:+
TGCT	cis	rs2033711	0.87	rs1051500	ENSG00000269473.1	CTD-2619J13.19	4.51	1.46e-05	0.0102	0.3	0.38	Uric acid clearance;	chr19:58433035	chr19:58440448~58445849:+
TGCT	cis	rs7829975	0.517	rs12542733	ENSG00000173295.6	FAM86B3P	-4.51	1.46e-05	0.0102	-0.46	-0.38	Mood instability;	chr8:8967348	chr8:8228595~8244865:+
TGCT	cis	rs875971	0.825	rs59466412	ENSG00000232559.3	GS1-124K5.12	-4.51	1.46e-05	0.0102	-0.35	-0.38	Aortic root size;	chr7:66100371	chr7:66554588~66576923:-
TGCT	cis	rs884366	1	rs4946955	ENSG00000203799.9	CCDC162P	-4.51	1.46e-05	0.0102	-0.4	-0.38	HDL cholesterol;HDL cholesterol levels;	chr6:109318507	chr6:109285485~109355063:+
TGCT	cis	rs12022452	0.591	rs16827359	ENSG00000238287.1	RP11-656D10.3	4.51	1.46e-05	0.0102	0.45	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40535766	chr1:40493157~40508661:-
TGCT	cis	rs1618992	0.74	rs1394189	ENSG00000265994.1	RP11-510D21.1	4.51	1.46e-05	0.0102	0.37	0.38	Gut microbiome composition (summer and winter);	chr18:28640240	chr18:28785068~28789260:+
TGCT	cis	rs1618992	0.791	rs2847397	ENSG00000265994.1	RP11-510D21.1	4.51	1.46e-05	0.0102	0.37	0.38	Gut microbiome composition (summer and winter);	chr18:28640679	chr18:28785068~28789260:+
TGCT	cis	rs1618992	0.791	rs1857704	ENSG00000265994.1	RP11-510D21.1	4.51	1.46e-05	0.0102	0.37	0.38	Gut microbiome composition (summer and winter);	chr18:28641018	chr18:28785068~28789260:+
TGCT	cis	rs1618992	0.765	rs1857703	ENSG00000265994.1	RP11-510D21.1	4.51	1.46e-05	0.0102	0.37	0.38	Gut microbiome composition (summer and winter);	chr18:28641041	chr18:28785068~28789260:+
TGCT	cis	rs17711722	0.523	rs365896	ENSG00000226824.5	RP4-756H11.3	4.51	1.46e-05	0.0102	0.4	0.38	Calcium levels;	chr7:66045710	chr7:66654538~66669855:+
TGCT	cis	rs4835473	0.897	rs11728121	ENSG00000251600.4	RP11-673E1.1	4.51	1.46e-05	0.0102	0.4	0.38	Immature fraction of reticulocytes;	chr4:143707079	chr4:143912331~143982454:+
TGCT	cis	rs11673344	0.636	rs7255595	ENSG00000226686.6	LINC01535	4.51	1.46e-05	0.0102	0.43	0.38	Obesity-related traits;	chr19:36896260	chr19:37251912~37265535:+
TGCT	cis	rs755249	0.508	rs12023553	ENSG00000182109.6	RP11-69E11.4	-4.51	1.46e-05	0.0102	-0.38	-0.38	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39205820	chr1:39522280~39546187:-
TGCT	cis	rs5758659	0.845	rs5758645	ENSG00000270083.1	RP1-257I20.14	4.51	1.46e-05	0.0102	0.37	0.38	Cognitive function;	chr22:42202945	chr22:42089630~42090028:-
TGCT	cis	rs2188561	0.697	rs4730258	ENSG00000241764.3	AC002467.7	4.51	1.46e-05	0.0102	0.35	0.38	Alcohol consumption;	chr7:107755787	chr7:107742817~107744581:-
TGCT	cis	rs3105593	1	rs934624	ENSG00000273674.3	CTD-2378E12.1	4.51	1.46e-05	0.0102	0.4	0.38	QT interval;	chr15:50676709	chr15:50839875~50908599:-
TGCT	cis	rs10246939	0.505	rs892354	ENSG00000228775.6	WEE2-AS1	4.51	1.47e-05	0.0103	0.35	0.38	Bitter taste perception;	chr7:141844934	chr7:141704338~141738346:-
TGCT	cis	rs507080	0.961	rs543413	ENSG00000255422.1	AP002954.4	-4.51	1.47e-05	0.0103	-0.44	-0.38	Serum metabolite levels;	chr11:118679308	chr11:118704607~118750263:+
TGCT	cis	rs875971	0.862	rs778734	ENSG00000232559.3	GS1-124K5.12	4.51	1.47e-05	0.0103	0.35	0.38	Aortic root size;	chr7:66349862	chr7:66554588~66576923:-
TGCT	cis	rs2463822	0.844	rs7104149	ENSG00000254454.2	RCC2P6	4.51	1.47e-05	0.0103	0.41	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62404155	chr11:62371146~62373168:+
TGCT	cis	rs7208859	0.573	rs216443	ENSG00000280069.1	CTD-2349P21.3	-4.51	1.47e-05	0.0103	-0.53	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30738182~30740275:+
TGCT	cis	rs1823913	0.576	rs13011608	ENSG00000227542.1	AC092614.2	4.51	1.47e-05	0.0103	0.4	0.38	Obesity-related traits;	chr2:191267097	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs7598639	ENSG00000227542.1	AC092614.2	4.51	1.47e-05	0.0103	0.4	0.38	Obesity-related traits;	chr2:191267958	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs13399251	ENSG00000227542.1	AC092614.2	4.51	1.47e-05	0.0103	0.4	0.38	Obesity-related traits;	chr2:191268758	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs35892286	ENSG00000227542.1	AC092614.2	4.51	1.47e-05	0.0103	0.4	0.38	Obesity-related traits;	chr2:191269010	chr2:191229165~191246172:-
TGCT	cis	rs2288073	1	rs6708328	ENSG00000223754.1	AC008073.9	4.51	1.47e-05	0.0103	0.45	0.38	Venous thromboembolism (SNP x SNP interaction);	chr2:24189544	chr2:24199839~24201698:-
TGCT	cis	rs1618992	0.729	rs8088603	ENSG00000265994.1	RP11-510D21.1	4.51	1.47e-05	0.0103	0.38	0.38	Gut microbiome composition (summer and winter);	chr18:28608088	chr18:28785068~28789260:+
TGCT	cis	rs1010254	0.764	rs11953436	ENSG00000213433.5	RPLP1P6	-4.51	1.48e-05	0.0103	-0.39	-0.38	Optic nerve measurement (cup area);	chr5:152410070	chr5:151765859~151766378:-
TGCT	cis	rs796364	0.806	rs11679676	ENSG00000232732.8	AC073043.1	4.51	1.48e-05	0.0103	0.57	0.38	Schizophrenia;	chr2:200176258	chr2:199867396~199911159:-
TGCT	cis	rs12439619	0.53	rs7162177	ENSG00000278603.1	RP13-608F4.5	4.51	1.48e-05	0.0103	0.49	0.38	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82472203~82472426:+
TGCT	cis	rs12439619	0.508	rs8042665	ENSG00000278603.1	RP13-608F4.5	4.51	1.48e-05	0.0103	0.49	0.38	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82472203~82472426:+
TGCT	cis	rs10759883	0.563	rs625105	ENSG00000175611.10	LINC00476	4.51	1.48e-05	0.0103	0.33	0.38	Nicotine dependence;	chr9:96007466	chr9:95759231~95875977:-
TGCT	cis	rs6017291	1	rs13045630	ENSG00000223891.4	OSER1-AS1	4.51	1.48e-05	0.0103	0.56	0.38	Cognitive performance;	chr20:44232987	chr20:44210960~44226027:+
TGCT	cis	rs6017291	1	rs13037106	ENSG00000223891.4	OSER1-AS1	4.51	1.48e-05	0.0103	0.56	0.38	Cognitive performance;	chr20:44232991	chr20:44210960~44226027:+
TGCT	cis	rs9462027	0.54	rs9469867	ENSG00000186328.4	RP11-140K17.2	4.51	1.48e-05	0.0103	0.36	0.38	Systemic lupus erythematosus;	chr6:34774672	chr6:34715613~34715940:+
TGCT	cis	rs847851	0.612	rs7768189	ENSG00000186328.4	RP11-140K17.2	4.51	1.48e-05	0.0103	0.36	0.38	Colonoscopy-negative controls vs population controls;	chr6:34774673	chr6:34715613~34715940:+
TGCT	cis	rs9322193	0.923	rs9479810	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149751359	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs12175575	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149763351	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs4869966	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149763714	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs1112730	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149766383	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs1112729	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149766491	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs10452626	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149767481	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs62441303	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149767547	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs9765929	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149769680	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs3805748	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149772542	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.736	rs10457851	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149775216	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.886	rs10872652	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149775303	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.886	rs12525871	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149775882	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.886	rs17672976	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149776207	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs2184369	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149776681	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs2342861	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149777561	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.926	rs2342860	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149777641	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs10872653	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149778907	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs9505974	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149779294	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs11155683	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149779341	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.926	rs9689036	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149780563	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.923	rs9372044	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149780867	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs11155685	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149781649	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs9322218	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149782183	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs9322219	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149782263	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs9689447	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149789350	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.632	rs3828700	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149791033	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.736	rs3828701	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149791063	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.736	rs3805750	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149791065	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.926	rs3805751	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149791193	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs9689269	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149791861	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs62441335	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149792658	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs13215691	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149792666	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs4816	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149793609	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs3805753	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149795662	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.926	rs952166	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149798774	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs952165	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149798900	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs10872656	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149799444	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.926	rs9285525	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149801253	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs9322223	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149801509	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs9688412	ENSG00000216906.2	RP11-350J20.9	-4.51	1.48e-05	0.0103	-0.42	-0.38	Lung cancer;	chr6:149803147	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.884	rs2342858	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149805967	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.962	rs6914319	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149806304	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.884	rs2095375	ENSG00000216906.2	RP11-350J20.9	4.51	1.48e-05	0.0103	0.42	0.38	Lung cancer;	chr6:149807037	chr6:149904243~149906418:+
TGCT	cis	rs6600671	0.966	rs6600664	ENSG00000275131.1	CH17-472G23.4	-4.51	1.48e-05	0.0103	-0.24	-0.38	Hip geometry;	chr1:121480638	chr1:120489625~120579190:-
TGCT	cis	rs6600671	0.932	rs6600663	ENSG00000275131.1	CH17-472G23.4	-4.51	1.48e-05	0.0103	-0.24	-0.38	Hip geometry;	chr1:121480639	chr1:120489625~120579190:-
TGCT	cis	rs801193	0.591	rs4506088	ENSG00000237310.1	GS1-124K5.4	-4.51	1.48e-05	0.0103	-0.4	-0.38	Aortic root size;	chr7:66670470	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.569	rs2659908	ENSG00000237310.1	GS1-124K5.4	4.51	1.48e-05	0.0103	0.4	0.38	Aortic root size;	chr7:66695835	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.569	rs2659907	ENSG00000237310.1	GS1-124K5.4	4.51	1.48e-05	0.0103	0.4	0.38	Aortic root size;	chr7:66699045	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.569	rs7782587	ENSG00000237310.1	GS1-124K5.4	4.51	1.48e-05	0.0103	0.4	0.38	Aortic root size;	chr7:66701485	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.569	rs4717315	ENSG00000237310.1	GS1-124K5.4	4.51	1.48e-05	0.0103	0.4	0.38	Aortic root size;	chr7:66713338	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.527	rs2707837	ENSG00000237310.1	GS1-124K5.4	4.51	1.48e-05	0.0103	0.4	0.38	Aortic root size;	chr7:66716086	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.569	rs2707824	ENSG00000237310.1	GS1-124K5.4	4.51	1.48e-05	0.0103	0.4	0.38	Aortic root size;	chr7:66724256	chr7:66493706~66495474:+
TGCT	cis	rs807029	0.533	rs3824783	ENSG00000272572.1	RP11-179B2.2	-4.51	1.49e-05	0.0104	-0.33	-0.38	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100991094	chr10:100911103~100912739:-
TGCT	cis	rs9462027	0.628	rs7756405	ENSG00000186328.4	RP11-140K17.2	4.51	1.49e-05	0.0104	0.35	0.38	Systemic lupus erythematosus;	chr6:34754882	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.606	rs7341253	ENSG00000186328.4	RP11-140K17.2	4.51	1.49e-05	0.0104	0.35	0.38	Systemic lupus erythematosus;	chr6:34759061	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.63	rs7341267	ENSG00000186328.4	RP11-140K17.2	4.51	1.49e-05	0.0104	0.35	0.38	Systemic lupus erythematosus;	chr6:34759254	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.606	rs7759227	ENSG00000186328.4	RP11-140K17.2	4.51	1.49e-05	0.0104	0.35	0.38	Systemic lupus erythematosus;	chr6:34760453	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.583	rs9469862	ENSG00000186328.4	RP11-140K17.2	4.51	1.49e-05	0.0104	0.35	0.38	Systemic lupus erythematosus;	chr6:34762071	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs28675115	ENSG00000186328.4	RP11-140K17.2	4.51	1.49e-05	0.0104	0.35	0.38	Systemic lupus erythematosus;	chr6:34764737	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.727	rs3798352	ENSG00000186328.4	RP11-140K17.2	4.51	1.49e-05	0.0104	0.35	0.38	Systemic lupus erythematosus;	chr6:34767032	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.651	rs6940395	ENSG00000186328.4	RP11-140K17.2	4.51	1.49e-05	0.0104	0.35	0.38	Systemic lupus erythematosus;	chr6:34768776	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs7741437	ENSG00000186328.4	RP11-140K17.2	4.51	1.49e-05	0.0104	0.35	0.38	Systemic lupus erythematosus;	chr6:34769776	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.606	rs2038841	ENSG00000186328.4	RP11-140K17.2	4.51	1.49e-05	0.0104	0.35	0.38	Systemic lupus erythematosus;	chr6:34770426	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs9469863	ENSG00000186328.4	RP11-140K17.2	4.51	1.49e-05	0.0104	0.35	0.38	Systemic lupus erythematosus;	chr6:34771872	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs9462015	ENSG00000186328.4	RP11-140K17.2	4.51	1.49e-05	0.0104	0.35	0.38	Systemic lupus erythematosus;	chr6:34771949	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.651	rs1543559	ENSG00000186328.4	RP11-140K17.2	4.51	1.49e-05	0.0104	0.35	0.38	Systemic lupus erythematosus;	chr6:34816327	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs1543558	ENSG00000186328.4	RP11-140K17.2	4.51	1.49e-05	0.0104	0.35	0.38	Systemic lupus erythematosus;	chr6:34816594	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs7776219	ENSG00000186328.4	RP11-140K17.2	4.51	1.49e-05	0.0104	0.35	0.38	Systemic lupus erythematosus;	chr6:34816890	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs1125341	ENSG00000186328.4	RP11-140K17.2	4.51	1.49e-05	0.0104	0.35	0.38	Systemic lupus erythematosus;	chr6:34818528	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs1125340	ENSG00000186328.4	RP11-140K17.2	4.51	1.49e-05	0.0104	0.35	0.38	Systemic lupus erythematosus;	chr6:34818631	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs2395604	ENSG00000186328.4	RP11-140K17.2	4.51	1.49e-05	0.0104	0.35	0.38	Systemic lupus erythematosus;	chr6:34820199	chr6:34715613~34715940:+
TGCT	cis	rs875971	1	rs6460296	ENSG00000237310.1	GS1-124K5.4	4.51	1.49e-05	0.0104	0.41	0.38	Aortic root size;	chr7:66430152	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.895	rs4718349	ENSG00000237310.1	GS1-124K5.4	4.51	1.49e-05	0.0104	0.41	0.38	Aortic root size;	chr7:66444024	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs2042133	ENSG00000237310.1	GS1-124K5.4	4.51	1.49e-05	0.0104	0.41	0.38	Aortic root size;	chr7:66466935	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.964	rs2161065	ENSG00000237310.1	GS1-124K5.4	4.51	1.49e-05	0.0104	0.41	0.38	Aortic root size;	chr7:66467918	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs12698521	ENSG00000237310.1	GS1-124K5.4	4.51	1.49e-05	0.0104	0.41	0.38	Aortic root size;	chr7:66474502	chr7:66493706~66495474:+
TGCT	cis	rs1823913	0.599	rs1378156	ENSG00000227542.1	AC092614.2	-4.51	1.49e-05	0.0104	-0.4	-0.38	Obesity-related traits;	chr2:191272466	chr2:191229165~191246172:-
TGCT	cis	rs875971	0.54	rs35510581	ENSG00000237310.1	GS1-124K5.4	-4.51	1.49e-05	0.0104	-0.42	-0.38	Aortic root size;	chr7:66113790	chr7:66493706~66495474:+
TGCT	cis	rs4691139	0.903	rs13127188	ENSG00000236941.6	RP11-366M4.8	4.51	1.49e-05	0.0104	0.29	0.38	Ovarian cancer in BRCA1 mutation carriers;	chr4:164997524	chr4:164948079~164949438:+
TGCT	cis	rs4691139	0.903	rs6835415	ENSG00000236941.6	RP11-366M4.8	4.51	1.49e-05	0.0104	0.29	0.38	Ovarian cancer in BRCA1 mutation carriers;	chr4:164998932	chr4:164948079~164949438:+
TGCT	cis	rs4691139	0.903	rs6812591	ENSG00000236941.6	RP11-366M4.8	4.51	1.49e-05	0.0104	0.29	0.38	Ovarian cancer in BRCA1 mutation carriers;	chr4:164999023	chr4:164948079~164949438:+
TGCT	cis	rs4691139	0.903	rs6812776	ENSG00000236941.6	RP11-366M4.8	4.51	1.49e-05	0.0104	0.29	0.38	Ovarian cancer in BRCA1 mutation carriers;	chr4:164999097	chr4:164948079~164949438:+
TGCT	cis	rs34779708	0.966	rs4934737	ENSG00000230534.5	RP11-297A16.2	4.51	1.49e-05	0.0104	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35223871	chr10:35098006~35127020:-
TGCT	cis	rs12022452	0.591	rs6672398	ENSG00000238287.1	RP11-656D10.3	-4.51	1.49e-05	0.0104	-0.49	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536505	chr1:40493157~40508661:-
TGCT	cis	rs67311347	1	rs4973878	ENSG00000223797.4	ENTPD3-AS1	4.51	1.49e-05	0.0104	0.38	0.38	Renal cell carcinoma;	chr3:40366074	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs4246666	ENSG00000223797.4	ENTPD3-AS1	4.51	1.49e-05	0.0104	0.38	0.38	Renal cell carcinoma;	chr3:40366179	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs2887995	ENSG00000223797.4	ENTPD3-AS1	4.51	1.49e-05	0.0104	0.38	0.38	Renal cell carcinoma;	chr3:40367538	chr3:40313802~40453329:-
TGCT	cis	rs67311347	0.955	rs11719205	ENSG00000223797.4	ENTPD3-AS1	4.51	1.49e-05	0.0104	0.38	0.38	Renal cell carcinoma;	chr3:40375767	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs9829800	ENSG00000223797.4	ENTPD3-AS1	4.51	1.49e-05	0.0104	0.38	0.38	Renal cell carcinoma;	chr3:40402436	chr3:40313802~40453329:-
TGCT	cis	rs67311347	0.955	rs6599100	ENSG00000223797.4	ENTPD3-AS1	4.51	1.49e-05	0.0104	0.38	0.38	Renal cell carcinoma;	chr3:40405871	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs4973997	ENSG00000223797.4	ENTPD3-AS1	4.51	1.49e-05	0.0104	0.38	0.38	Renal cell carcinoma;	chr3:40418654	chr3:40313802~40453329:-
TGCT	cis	rs67311347	0.955	rs4973999	ENSG00000223797.4	ENTPD3-AS1	4.51	1.49e-05	0.0104	0.38	0.38	Renal cell carcinoma;	chr3:40418892	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs13324109	ENSG00000223797.4	ENTPD3-AS1	4.51	1.49e-05	0.0104	0.38	0.38	Renal cell carcinoma;	chr3:40419276	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs1466236	ENSG00000223797.4	ENTPD3-AS1	4.51	1.49e-05	0.0104	0.38	0.38	Renal cell carcinoma;	chr3:40420671	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs951560	ENSG00000223797.4	ENTPD3-AS1	4.51	1.49e-05	0.0104	0.38	0.38	Renal cell carcinoma;	chr3:40421980	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs7648952	ENSG00000223797.4	ENTPD3-AS1	-4.51	1.49e-05	0.0104	-0.38	-0.38	Renal cell carcinoma;	chr3:40415547	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs9848083	ENSG00000223797.4	ENTPD3-AS1	-4.51	1.49e-05	0.0104	-0.38	-0.38	Renal cell carcinoma;	chr3:40425488	chr3:40313802~40453329:-
TGCT	cis	rs6981523	0.553	rs2409730	ENSG00000255310.2	AF131215.2	-4.51	1.49e-05	0.0104	-0.32	-0.38	Neuroticism;	chr8:11203129	chr8:11107788~11109726:-
TGCT	cis	rs2177312	0.593	rs55818328	ENSG00000251129.1	RP11-734I18.1	-4.51	1.5e-05	0.0104	-0.43	-0.38	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31960881	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.514	rs11730254	ENSG00000251129.1	RP11-734I18.1	-4.51	1.5e-05	0.0104	-0.43	-0.38	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31961483	chr4:31997397~32155406:+
TGCT	cis	rs7829975	0.54	rs2976909	ENSG00000254340.1	RP11-10A14.3	-4.51	1.5e-05	0.0104	-0.35	-0.38	Mood instability;	chr8:8489180	chr8:9141424~9145435:+
TGCT	cis	rs875971	0.545	rs17138149	ENSG00000237310.1	GS1-124K5.4	4.51	1.5e-05	0.0104	0.44	0.38	Aortic root size;	chr7:66228193	chr7:66493706~66495474:+
TGCT	cis	rs6844153	0.68	rs6833053	ENSG00000240005.4	RP11-293A21.1	-4.51	1.5e-05	0.0104	-0.45	-0.38	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26870838	chr4:26859806~26860599:-
TGCT	cis	rs4713118	0.662	rs149901	ENSG00000216901.1	AL022393.7	4.51	1.5e-05	0.0104	0.47	0.38	Parkinson's disease;	chr6:27997725	chr6:28176188~28176674:+
TGCT	cis	rs507080	0.845	rs481903	ENSG00000255239.1	AP002954.6	4.51	1.5e-05	0.0105	0.5	0.38	Serum metabolite levels;	chr11:118697024	chr11:118688039~118690600:-
TGCT	cis	rs11123170	0.529	rs1015755	ENSG00000189223.12	PAX8-AS1	-4.51	1.51e-05	0.0105	-0.65	-0.38	Renal function-related traits (BUN);	chr2:113210730	chr2:113211522~113276581:+
TGCT	cis	rs9462027	0.585	rs2814976	ENSG00000186328.4	RP11-140K17.2	4.51	1.51e-05	0.0105	0.35	0.38	Systemic lupus erythematosus;	chr6:34608460	chr6:34715613~34715940:+
TGCT	cis	rs875971	0.862	rs3893216	ENSG00000237310.1	GS1-124K5.4	-4.51	1.51e-05	0.0105	-0.4	-0.38	Aortic root size;	chr7:66325720	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs6958294	ENSG00000237310.1	GS1-124K5.4	-4.51	1.51e-05	0.0105	-0.4	-0.38	Aortic root size;	chr7:66329809	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs2088655	ENSG00000237310.1	GS1-124K5.4	-4.51	1.51e-05	0.0105	-0.4	-0.38	Aortic root size;	chr7:66330724	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.895	rs10447522	ENSG00000237310.1	GS1-124K5.4	-4.51	1.51e-05	0.0105	-0.4	-0.38	Aortic root size;	chr7:66331087	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs2088653	ENSG00000237310.1	GS1-124K5.4	-4.51	1.51e-05	0.0105	-0.4	-0.38	Aortic root size;	chr7:66343621	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs6460293	ENSG00000237310.1	GS1-124K5.4	-4.51	1.51e-05	0.0105	-0.4	-0.38	Aortic root size;	chr7:66345205	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs778736	ENSG00000237310.1	GS1-124K5.4	4.51	1.51e-05	0.0105	0.4	0.38	Aortic root size;	chr7:66348861	chr7:66493706~66495474:+
TGCT	cis	rs8091660	0.929	rs4939780	ENSG00000278983.1	RP11-426J5.3	4.51	1.51e-05	0.0105	0.45	0.38	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568873	chr18:48564795~48568342:+
TGCT	cis	rs10751647	0.804	rs3809112	ENSG00000251661.3	RP11-326C3.11	-4.51	1.51e-05	0.0105	-0.32	-0.38	Monocyte count;	chr11:307036	chr11:318640~325631:+
TGCT	cis	rs875971	0.862	rs880166	ENSG00000232559.3	GS1-124K5.12	-4.51	1.51e-05	0.0105	-0.35	-0.38	Aortic root size;	chr7:66205775	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.928	rs2036263	ENSG00000232559.3	GS1-124K5.12	-4.51	1.51e-05	0.0105	-0.35	-0.38	Aortic root size;	chr7:66335210	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs10240949	ENSG00000232559.3	GS1-124K5.12	-4.51	1.51e-05	0.0105	-0.35	-0.38	Aortic root size;	chr7:66339430	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs7782704	ENSG00000232559.3	GS1-124K5.12	-4.51	1.51e-05	0.0105	-0.35	-0.38	Aortic root size;	chr7:66340379	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs6460290	ENSG00000232559.3	GS1-124K5.12	-4.51	1.51e-05	0.0105	-0.35	-0.38	Aortic root size;	chr7:66344119	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs6959268	ENSG00000232559.3	GS1-124K5.12	-4.51	1.51e-05	0.0105	-0.35	-0.38	Aortic root size;	chr7:66347979	chr7:66554588~66576923:-
TGCT	cis	rs11123170	0.529	rs1015753	ENSG00000189223.12	PAX8-AS1	-4.51	1.51e-05	0.0105	-0.63	-0.38	Renal function-related traits (BUN);	chr2:113211226	chr2:113211522~113276581:+
TGCT	cis	rs507080	0.922	rs546890	ENSG00000255239.1	AP002954.6	4.51	1.51e-05	0.0105	0.48	0.38	Serum metabolite levels;	chr11:118686489	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.922	rs555356	ENSG00000255239.1	AP002954.6	4.51	1.51e-05	0.0105	0.48	0.38	Serum metabolite levels;	chr11:118687369	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.883	rs693306	ENSG00000255239.1	AP002954.6	4.51	1.51e-05	0.0105	0.48	0.38	Serum metabolite levels;	chr11:118687624	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.922	rs558907	ENSG00000255239.1	AP002954.6	4.51	1.51e-05	0.0105	0.48	0.38	Serum metabolite levels;	chr11:118687746	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.922	rs561845	ENSG00000255239.1	AP002954.6	4.51	1.51e-05	0.0105	0.48	0.38	Serum metabolite levels;	chr11:118688118	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.922	rs638805	ENSG00000255239.1	AP002954.6	4.51	1.51e-05	0.0105	0.48	0.38	Serum metabolite levels;	chr11:118688180	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.845	rs510408	ENSG00000255239.1	AP002954.6	4.51	1.51e-05	0.0105	0.48	0.38	Serum metabolite levels;	chr11:118688192	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.845	rs509641	ENSG00000255239.1	AP002954.6	4.51	1.51e-05	0.0105	0.48	0.38	Serum metabolite levels;	chr11:118688243	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.883	rs563549	ENSG00000255239.1	AP002954.6	4.51	1.51e-05	0.0105	0.48	0.38	Serum metabolite levels;	chr11:118688244	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.885	rs533144	ENSG00000255239.1	AP002954.6	4.51	1.51e-05	0.0105	0.48	0.38	Serum metabolite levels;	chr11:118688538	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.885	rs7926959	ENSG00000255239.1	AP002954.6	4.51	1.51e-05	0.0105	0.48	0.38	Serum metabolite levels;	chr11:118689157	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.663	rs7926970	ENSG00000255239.1	AP002954.6	4.51	1.51e-05	0.0105	0.48	0.38	Serum metabolite levels;	chr11:118689172	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.885	rs4938530	ENSG00000255239.1	AP002954.6	4.51	1.51e-05	0.0105	0.48	0.38	Serum metabolite levels;	chr11:118689861	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.883	rs12798453	ENSG00000255239.1	AP002954.6	4.51	1.51e-05	0.0105	0.48	0.38	Serum metabolite levels;	chr11:118690701	chr11:118688039~118690600:-
TGCT	cis	rs1707322	0.826	rs10890349	ENSG00000280836.1	AL355480.1	-4.51	1.51e-05	0.0105	-0.49	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.758	rs10789474	ENSG00000280836.1	AL355480.1	-4.51	1.51e-05	0.0105	-0.49	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr1:45581219~45581321:-
TGCT	cis	rs2980439	0.818	rs2945249	ENSG00000254340.1	RP11-10A14.3	4.51	1.51e-05	0.0105	0.38	0.38	Neuroticism;	chr8:8237204	chr8:9141424~9145435:+
TGCT	cis	rs899997	1	rs7182567	ENSG00000261143.1	ADAMTS7P3	4.5	1.51e-05	0.0105	0.45	0.38	Coronary artery disease or large artery stroke;	chr15:78752712	chr15:77976042~77993057:+
TGCT	cis	rs875971	0.862	rs778724	ENSG00000232559.3	GS1-124K5.12	4.5	1.52e-05	0.0105	0.35	0.38	Aortic root size;	chr7:66364304	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs778686	ENSG00000232559.3	GS1-124K5.12	4.5	1.52e-05	0.0105	0.35	0.38	Aortic root size;	chr7:66370923	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.767	rs1643394	ENSG00000232559.3	GS1-124K5.12	4.5	1.52e-05	0.0105	0.35	0.38	Aortic root size;	chr7:66371107	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs778684	ENSG00000232559.3	GS1-124K5.12	4.5	1.52e-05	0.0105	0.35	0.38	Aortic root size;	chr7:66371416	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs778680	ENSG00000232559.3	GS1-124K5.12	4.5	1.52e-05	0.0105	0.35	0.38	Aortic root size;	chr7:66375427	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs11769079	ENSG00000232559.3	GS1-124K5.12	4.5	1.52e-05	0.0105	0.35	0.38	Aortic root size;	chr7:66377141	chr7:66554588~66576923:-
TGCT	cis	rs67311347	1	rs9842564	ENSG00000223797.4	ENTPD3-AS1	-4.5	1.52e-05	0.0105	-0.41	-0.37	Renal cell carcinoma;	chr3:40364319	chr3:40313802~40453329:-
TGCT	cis	rs17695224	0.565	rs28800315	ENSG00000269483.1	AC006272.1	4.5	1.52e-05	0.0105	0.38	0.37	HDL cholesterol;HDL cholesterol levels;	chr19:51805837	chr19:51839924~51843324:-
TGCT	cis	rs67340775	0.541	rs200979	ENSG00000187763.3	OR2B7P	4.5	1.52e-05	0.0105	0.44	0.37	Lung cancer in ever smokers;	chr6:27884579	chr6:28046434~28047367:+
TGCT	cis	rs67340775	0.541	rs169287	ENSG00000187763.3	OR2B7P	4.5	1.52e-05	0.0105	0.44	0.37	Lung cancer in ever smokers;	chr6:27886982	chr6:28046434~28047367:+
TGCT	cis	rs67340775	0.541	rs200975	ENSG00000187763.3	OR2B7P	4.5	1.52e-05	0.0105	0.44	0.37	Lung cancer in ever smokers;	chr6:27887847	chr6:28046434~28047367:+
TGCT	cis	rs67340775	0.541	rs200974	ENSG00000187763.3	OR2B7P	4.5	1.52e-05	0.0105	0.44	0.37	Lung cancer in ever smokers;	chr6:27888067	chr6:28046434~28047367:+
TGCT	cis	rs10504229	0.683	rs17802743	ENSG00000253301.4	RP11-513O17.2	4.5	1.52e-05	0.0105	0.6	0.37	Developmental language disorder (linguistic errors);	chr8:57193338	chr8:57142689~57240298:+
TGCT	cis	rs9309473	1	rs7572722	ENSG00000163016.8	ALMS1P	4.5	1.52e-05	0.0105	0.34	0.37	Metabolite levels;	chr2:73497548	chr2:73644919~73685576:+
TGCT	cis	rs6844153	0.752	rs58968032	ENSG00000240005.4	RP11-293A21.1	-4.5	1.52e-05	0.0106	-0.45	-0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884674	chr4:26859806~26860599:-
TGCT	cis	rs1010254	0.51	rs72806368	ENSG00000253921.1	CTB-113P19.3	-4.5	1.52e-05	0.0106	-0.47	-0.37	Optic nerve measurement (cup area);	chr5:152313181	chr5:151753992~151767247:+
TGCT	cis	rs4242434	0.757	rs4872531	ENSG00000254064.1	CTD-2530N21.4	4.5	1.52e-05	0.0106	0.22	0.37	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22672182	chr8:22254576~22275162:-
TGCT	cis	rs3824488	0.541	rs57247461	ENSG00000228142.2	RP11-180I4.2	4.5	1.53e-05	0.0106	0.86	0.37	Neuroticism;	chr9:95430315	chr9:95650154~95715718:+
TGCT	cis	rs3824488	0.541	rs79180263	ENSG00000228142.2	RP11-180I4.2	4.5	1.53e-05	0.0106	0.86	0.37	Neuroticism;	chr9:95431709	chr9:95650154~95715718:+
TGCT	cis	rs3824488	0.541	rs80321314	ENSG00000228142.2	RP11-180I4.2	4.5	1.53e-05	0.0106	0.86	0.37	Neuroticism;	chr9:95432479	chr9:95650154~95715718:+
TGCT	cis	rs3824488	0.541	rs76014677	ENSG00000228142.2	RP11-180I4.2	4.5	1.53e-05	0.0106	0.86	0.37	Neuroticism;	chr9:95433488	chr9:95650154~95715718:+
TGCT	cis	rs3824488	0.541	rs77806505	ENSG00000228142.2	RP11-180I4.2	4.5	1.53e-05	0.0106	0.86	0.37	Neuroticism;	chr9:95434361	chr9:95650154~95715718:+
TGCT	cis	rs3824488	0.599	rs113502615	ENSG00000228142.2	RP11-180I4.2	4.5	1.53e-05	0.0106	0.86	0.37	Neuroticism;	chr9:95437049	chr9:95650154~95715718:+
TGCT	cis	rs9400467	0.506	rs12192718	ENSG00000272356.1	RP5-1112D6.8	-4.5	1.53e-05	0.0106	-0.44	-0.37	Amino acid levels;Blood metabolite levels;	chr6:111247948	chr6:111309203~111313517:+
TGCT	cis	rs7923609	0.812	rs10761753	ENSG00000232075.1	MRPL35P2	-4.5	1.53e-05	0.0106	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63402143	chr10:63634317~63634827:-
TGCT	cis	rs1865760	1	rs9467636	ENSG00000217159.2	LARP1P1	-4.5	1.53e-05	0.0106	-0.44	-0.37	Height;	chr6:25919321	chr6:26164072~26164363:+
TGCT	cis	rs1865760	1	rs9358893	ENSG00000217159.2	LARP1P1	-4.5	1.53e-05	0.0106	-0.44	-0.37	Height;	chr6:25921533	chr6:26164072~26164363:+
TGCT	cis	rs1865760	1	rs3799372	ENSG00000217159.2	LARP1P1	-4.5	1.53e-05	0.0106	-0.44	-0.37	Height;	chr6:25922083	chr6:26164072~26164363:+
TGCT	cis	rs1865760	0.963	rs1540273	ENSG00000217159.2	LARP1P1	-4.5	1.53e-05	0.0106	-0.44	-0.37	Height;	chr6:25923930	chr6:26164072~26164363:+
TGCT	cis	rs1865760	1	rs9358895	ENSG00000217159.2	LARP1P1	-4.5	1.53e-05	0.0106	-0.44	-0.37	Height;	chr6:25924427	chr6:26164072~26164363:+
TGCT	cis	rs1865760	1	rs7770139	ENSG00000217159.2	LARP1P1	-4.5	1.53e-05	0.0106	-0.44	-0.37	Height;	chr6:25925595	chr6:26164072~26164363:+
TGCT	cis	rs2742234	0.59	rs2565201	ENSG00000273008.1	RP11-351D16.3	-4.5	1.53e-05	0.0106	-0.5	-0.37	Hirschsprung disease;	chr10:43123036	chr10:43136824~43138334:-
TGCT	cis	rs7567389	0.744	rs6430934	ENSG00000236682.1	AC068282.3	4.5	1.53e-05	0.0106	0.49	0.37	Self-rated health;	chr2:127243257	chr2:127389130~127400580:+
TGCT	cis	rs12439619	0.693	rs8034801	ENSG00000255769.6	GOLGA2P10	-4.5	1.53e-05	0.0106	-0.43	-0.37	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472993~82513950:-
TGCT	cis	rs1707322	0.752	rs6678444	ENSG00000280836.1	AL355480.1	-4.5	1.53e-05	0.0106	-0.5	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.752	rs7541962	ENSG00000280836.1	AL355480.1	-4.5	1.53e-05	0.0106	-0.5	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45581219~45581321:-
TGCT	cis	rs4691139	1	rs9917978	ENSG00000236941.6	RP11-366M4.8	4.5	1.53e-05	0.0106	0.28	0.37	Ovarian cancer in BRCA1 mutation carriers;	chr4:164963991	chr4:164948079~164949438:+
TGCT	cis	rs4691139	1	rs13134489	ENSG00000236941.6	RP11-366M4.8	4.5	1.53e-05	0.0106	0.28	0.37	Ovarian cancer in BRCA1 mutation carriers;	chr4:164968285	chr4:164948079~164949438:+
TGCT	cis	rs4691139	1	rs10007789	ENSG00000236941.6	RP11-366M4.8	4.5	1.53e-05	0.0106	0.28	0.37	Ovarian cancer in BRCA1 mutation carriers;	chr4:164969225	chr4:164948079~164949438:+
TGCT	cis	rs875971	0.862	rs4718319	ENSG00000237310.1	GS1-124K5.4	-4.5	1.53e-05	0.0106	-0.41	-0.37	Aortic root size;	chr7:66187797	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.723	rs28391294	ENSG00000237310.1	GS1-124K5.4	-4.5	1.53e-05	0.0106	-0.41	-0.37	Aortic root size;	chr7:66189328	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.83	rs6967708	ENSG00000237310.1	GS1-124K5.4	-4.5	1.53e-05	0.0106	-0.41	-0.37	Aortic root size;	chr7:66192326	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.895	rs7782806	ENSG00000237310.1	GS1-124K5.4	-4.5	1.53e-05	0.0106	-0.41	-0.37	Aortic root size;	chr7:66192910	chr7:66493706~66495474:+
TGCT	cis	rs2944755	0.686	rs7824304	ENSG00000279766.1	RP11-642A1.2	-4.5	1.53e-05	0.0106	-0.37	-0.37	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140573918	chr8:140572142~140572812:-
TGCT	cis	rs1823913	0.599	rs1823912	ENSG00000227542.1	AC092614.2	4.5	1.53e-05	0.0106	0.4	0.37	Obesity-related traits;	chr2:191266388	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.599	rs1378155	ENSG00000227542.1	AC092614.2	4.5	1.53e-05	0.0106	0.4	0.37	Obesity-related traits;	chr2:191266610	chr2:191229165~191246172:-
TGCT	cis	rs12216499	0.515	rs12195377	ENSG00000188451.8	SRP72P2	4.5	1.54e-05	0.0106	0.49	0.37	Bladder cancer (smoking interaction);	chr6:158957884	chr6:158237336~158242797:-
TGCT	cis	rs12216499	0.515	rs75612314	ENSG00000188451.8	SRP72P2	4.5	1.54e-05	0.0106	0.49	0.37	Bladder cancer (smoking interaction);	chr6:158963084	chr6:158237336~158242797:-
TGCT	cis	rs17507216	0.628	rs17158396	ENSG00000278603.1	RP13-608F4.5	4.5	1.54e-05	0.0106	0.55	0.37	Excessive daytime sleepiness;	chr15:82615688	chr15:82472203~82472426:+
TGCT	cis	rs4835473	0.932	rs1597445	ENSG00000251600.4	RP11-673E1.1	-4.5	1.54e-05	0.0106	-0.39	-0.37	Immature fraction of reticulocytes;	chr4:143768543	chr4:143912331~143982454:+
TGCT	cis	rs13118159	0.509	rs1882098	ENSG00000254094.1	AC078852.1	-4.5	1.54e-05	0.0106	-0.45	-0.37	Longevity;	chr4:1358643	chr4:1356581~1358075:+
TGCT	cis	rs13118159	0.55	rs2878607	ENSG00000254094.1	AC078852.1	-4.5	1.54e-05	0.0106	-0.45	-0.37	Longevity;	chr4:1359522	chr4:1356581~1358075:+
TGCT	cis	rs9807989	0.507	rs2287033	ENSG00000234389.1	AC007278.3	-4.5	1.54e-05	0.0106	-0.28	-0.37	Asthma;	chr2:102394777	chr2:102438713~102440475:+
TGCT	cis	rs2255336	0.817	rs10743889	ENSG00000245648.1	RP11-277P12.20	4.5	1.54e-05	0.0106	0.37	0.37	Blood protein levels;	chr12:10368790	chr12:10363769~10398506:+
TGCT	cis	rs1823913	0.637	rs6722183	ENSG00000227542.1	AC092614.2	-4.5	1.54e-05	0.0106	-0.4	-0.37	Obesity-related traits;	chr2:191333203	chr2:191229165~191246172:-
TGCT	cis	rs8105895	0.867	rs116220423	ENSG00000269742.1	BNIP3P29	4.5	1.54e-05	0.0107	0.68	0.37	Body mass index (change over time);	chr19:22054239	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs16998834	ENSG00000269742.1	BNIP3P29	4.5	1.54e-05	0.0107	0.68	0.37	Body mass index (change over time);	chr19:22084235	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs62110993	ENSG00000269742.1	BNIP3P29	4.5	1.54e-05	0.0107	0.68	0.37	Body mass index (change over time);	chr19:22085458	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs62111027	ENSG00000269742.1	BNIP3P29	4.5	1.54e-05	0.0107	0.68	0.37	Body mass index (change over time);	chr19:22086217	chr19:22065828~22066398:-
TGCT	cis	rs875971	0.545	rs316328	ENSG00000237310.1	GS1-124K5.4	-4.5	1.54e-05	0.0107	-0.43	-0.37	Aortic root size;	chr7:66143851	chr7:66493706~66495474:+
TGCT	cis	rs453301	0.598	rs2921383	ENSG00000254340.1	RP11-10A14.3	4.5	1.55e-05	0.0107	0.38	0.37	Joint mobility (Beighton score);	chr8:9034711	chr8:9141424~9145435:+
TGCT	cis	rs9462027	0.628	rs9469857	ENSG00000186328.4	RP11-140K17.2	4.5	1.55e-05	0.0107	0.34	0.37	Systemic lupus erythematosus;	chr6:34752016	chr6:34715613~34715940:+
TGCT	cis	rs6981523	0.553	rs11989369	ENSG00000255310.2	AF131215.2	4.5	1.55e-05	0.0107	0.31	0.37	Neuroticism;	chr8:11197876	chr8:11107788~11109726:-
TGCT	cis	rs9462027	0.628	rs9469892	ENSG00000186328.4	RP11-140K17.2	4.5	1.55e-05	0.0107	0.35	0.37	Systemic lupus erythematosus;	chr6:34801324	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs9462023	ENSG00000186328.4	RP11-140K17.2	4.5	1.55e-05	0.0107	0.35	0.37	Systemic lupus erythematosus;	chr6:34801633	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.561	rs3798348	ENSG00000186328.4	RP11-140K17.2	4.5	1.55e-05	0.0107	0.35	0.37	Systemic lupus erythematosus;	chr6:34804115	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.606	rs3777752	ENSG00000186328.4	RP11-140K17.2	4.5	1.55e-05	0.0107	0.35	0.37	Systemic lupus erythematosus;	chr6:34804435	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.606	rs9462024	ENSG00000186328.4	RP11-140K17.2	4.5	1.55e-05	0.0107	0.35	0.37	Systemic lupus erythematosus;	chr6:34805016	chr6:34715613~34715940:+
TGCT	cis	rs6474412	0.7	rs7017612	ENSG00000255101.1	RP11-412B14.1	-4.5	1.55e-05	0.0107	-0.38	-0.37	Smoking behavior;	chr8:42744102	chr8:42705583~42721946:-
TGCT	cis	rs1799949	0.965	rs799912	ENSG00000198496.9	NBR2	-4.5	1.55e-05	0.0107	-0.52	-0.37	Menopause (age at onset);	chr17:43105117	chr17:43125610~43153671:+
TGCT	cis	rs3096299	0.967	rs28689480	ENSG00000274627.1	RP11-104N10.2	4.5	1.55e-05	0.0107	0.39	0.37	Multiple myeloma (IgH translocation);	chr16:89393685	chr16:89516797~89522217:+
TGCT	cis	rs8040855	0.599	rs4643289	ENSG00000259295.5	CSPG4P12	-4.5	1.55e-05	0.0107	-0.51	-0.37	Bulimia nervosa;	chr15:85183483	chr15:85191438~85213905:+
TGCT	cis	rs2333021	0.649	rs12888375	ENSG00000259015.1	RP11-109N23.6	4.5	1.55e-05	0.0107	0.22	0.37	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73003877	chr14:72960595~72961993:+
TGCT	cis	rs2333021	0.649	rs8022470	ENSG00000259015.1	RP11-109N23.6	4.5	1.55e-05	0.0107	0.22	0.37	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73005293	chr14:72960595~72961993:+
TGCT	cis	rs77669868	0.703	rs61904685	ENSG00000256452.1	RP11-667M19.10	-4.5	1.56e-05	0.0107	-0.39	-0.37	Monocyte percentage of white cells;	chr11:114201937	chr11:113818077~113822458:+
TGCT	cis	rs10612751	1	rs10612751	ENSG00000277863.1	RP11-282A11.4	4.5	1.56e-05	0.0108	0.43	0.37	Lobe attachment (rater-scored or self-reported);	chr13:106993686	chr13:106903150~106904099:-
TGCT	cis	rs2463822	0.748	rs2513053	ENSG00000254454.2	RCC2P6	-4.5	1.56e-05	0.0108	-0.4	-0.37	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62342001	chr11:62371146~62373168:+
TGCT	cis	rs1823913	0.637	rs1470962	ENSG00000227542.1	AC092614.2	-4.5	1.56e-05	0.0108	-0.4	-0.37	Obesity-related traits;	chr2:191270271	chr2:191229165~191246172:-
TGCT	cis	rs875971	0.862	rs2460432	ENSG00000237310.1	GS1-124K5.4	-4.5	1.56e-05	0.0108	-0.41	-0.37	Aortic root size;	chr7:66089398	chr7:66493706~66495474:+
TGCT	cis	rs7005380	0.581	rs4871793	ENSG00000254343.2	RP11-760H22.2	4.5	1.56e-05	0.0108	0.53	0.37	Interstitial lung disease;	chr8:119929288	chr8:120052180~120056201:+
TGCT	cis	rs9309473	1	rs6736866	ENSG00000163016.8	ALMS1P	4.5	1.56e-05	0.0108	0.34	0.37	Metabolite levels;	chr2:73434858	chr2:73644919~73685576:+
TGCT	cis	rs853679	0.599	rs149990	ENSG00000219891.2	ZSCAN12P1	4.5	1.56e-05	0.0108	0.62	0.37	Depression;	chr6:28030480	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.599	rs149943	ENSG00000219891.2	ZSCAN12P1	4.5	1.56e-05	0.0108	0.62	0.37	Depression;	chr6:28034610	chr6:28091154~28093664:+
TGCT	cis	rs1023500	0.551	rs2301521	ENSG00000270083.1	RP1-257I20.14	4.5	1.56e-05	0.0108	0.37	0.37	Schizophrenia;	chr22:42027106	chr22:42089630~42090028:-
TGCT	cis	rs875971	0.964	rs11765965	ENSG00000237310.1	GS1-124K5.4	4.5	1.56e-05	0.0108	0.42	0.37	Aortic root size;	chr7:66377234	chr7:66493706~66495474:+
TGCT	cis	rs9309473	1	rs10187192	ENSG00000163016.8	ALMS1P	4.5	1.56e-05	0.0108	0.34	0.37	Metabolite levels;	chr2:73486373	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.948	rs10183818	ENSG00000163016.8	ALMS1P	4.5	1.56e-05	0.0108	0.34	0.37	Metabolite levels;	chr2:73487429	chr2:73644919~73685576:+
TGCT	cis	rs801193	1	rs10234018	ENSG00000237310.1	GS1-124K5.4	-4.5	1.57e-05	0.0108	-0.43	-0.37	Aortic root size;	chr7:66681297	chr7:66493706~66495474:+
TGCT	cis	rs1355223	0.557	rs7936076	ENSG00000271369.1	RP11-350D17.3	-4.5	1.57e-05	0.0108	-0.37	-0.37	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34703125	chr11:34709600~34710161:+
TGCT	cis	rs3020736	0.5	rs6002597	ENSG00000270083.1	RP1-257I20.14	-4.5	1.57e-05	0.0108	-0.39	-0.37	Autism spectrum disorder or schizophrenia;	chr22:42092156	chr22:42089630~42090028:-
TGCT	cis	rs3020736	0.5	rs7292241	ENSG00000270083.1	RP1-257I20.14	-4.5	1.57e-05	0.0108	-0.39	-0.37	Autism spectrum disorder or schizophrenia;	chr22:42096059	chr22:42089630~42090028:-
TGCT	cis	rs3020736	0.5	rs6002603	ENSG00000270083.1	RP1-257I20.14	-4.5	1.57e-05	0.0108	-0.39	-0.37	Autism spectrum disorder or schizophrenia;	chr22:42096358	chr22:42089630~42090028:-
TGCT	cis	rs3020736	0.5	rs5996111	ENSG00000270083.1	RP1-257I20.14	-4.5	1.57e-05	0.0108	-0.39	-0.37	Autism spectrum disorder or schizophrenia;	chr22:42097898	chr22:42089630~42090028:-
TGCT	cis	rs4660214	0.724	rs2484751	ENSG00000182109.6	RP11-69E11.4	-4.5	1.57e-05	0.0108	-0.38	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282867	chr1:39522280~39546187:-
TGCT	cis	rs755249	0.501	rs2484749	ENSG00000182109.6	RP11-69E11.4	-4.5	1.57e-05	0.0108	-0.38	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39293283	chr1:39522280~39546187:-
TGCT	cis	rs1618992	0.791	rs987124	ENSG00000265994.1	RP11-510D21.1	-4.5	1.57e-05	0.0108	-0.37	-0.37	Gut microbiome composition (summer and winter);	chr18:28637387	chr18:28785068~28789260:+
TGCT	cis	rs2033711	0.837	rs3764535	ENSG00000269473.1	CTD-2619J13.19	4.5	1.57e-05	0.0108	0.3	0.37	Uric acid clearance;	chr19:58417685	chr19:58440448~58445849:+
TGCT	cis	rs2033711	0.84	rs3764533	ENSG00000269473.1	CTD-2619J13.19	4.5	1.57e-05	0.0108	0.3	0.37	Uric acid clearance;	chr19:58417827	chr19:58440448~58445849:+
TGCT	cis	rs10829156	0.66	rs4338439	ENSG00000240291.1	RP11-499P20.2	4.5	1.57e-05	0.0109	0.34	0.37	Sudden cardiac arrest;	chr10:18594220	chr10:18513115~18545651:-
TGCT	cis	rs10829156	0.741	rs9731044	ENSG00000240291.1	RP11-499P20.2	4.5	1.57e-05	0.0109	0.34	0.37	Sudden cardiac arrest;	chr10:18605356	chr10:18513115~18545651:-
TGCT	cis	rs10829156	0.538	rs61840846	ENSG00000240291.1	RP11-499P20.2	4.5	1.57e-05	0.0109	0.34	0.37	Sudden cardiac arrest;	chr10:18606393	chr10:18513115~18545651:-
TGCT	cis	rs559928	1	rs7105178	ENSG00000236935.1	AP003774.1	-4.5	1.57e-05	0.0109	-0.39	-0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64377637	chr11:64325050~64329504:-
TGCT	cis	rs1519814	0.654	rs2139438	ENSG00000254343.2	RP11-760H22.2	-4.5	1.57e-05	0.0109	-0.61	-0.37	Breast cancer;	chr8:119995478	chr8:120052180~120056201:+
TGCT	cis	rs728616	0.867	rs61860044	ENSG00000230091.5	TMEM254-AS1	4.5	1.58e-05	0.0109	0.7	0.37	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186782	chr10:80046860~80078912:-
TGCT	cis	rs10826995	0.961	rs72778402	ENSG00000239731.3	RN7SL825P	-4.5	1.58e-05	0.0109	-0.38	-0.37	Pulse pressure;	chr10:31960645	chr10:31992087~31992381:-
TGCT	cis	rs10826995	0.961	rs6481765	ENSG00000239731.3	RN7SL825P	-4.5	1.58e-05	0.0109	-0.38	-0.37	Pulse pressure;	chr10:31961907	chr10:31992087~31992381:-
TGCT	cis	rs9462027	0.628	rs9462019	ENSG00000186328.4	RP11-140K17.2	4.49	1.58e-05	0.0109	0.35	0.37	Systemic lupus erythematosus;	chr6:34780953	chr6:34715613~34715940:+
TGCT	cis	rs72615157	0.628	rs7801070	ENSG00000242294.5	STAG3L5P	4.49	1.58e-05	0.0109	0.34	0.37	Lung function (FEV1/FVC);	chr7:100249524	chr7:100336079~100351900:+
TGCT	cis	rs72615157	0.645	rs11771660	ENSG00000242294.5	STAG3L5P	4.49	1.58e-05	0.0109	0.34	0.37	Lung function (FEV1/FVC);	chr7:100253646	chr7:100336079~100351900:+
TGCT	cis	rs4660214	0.724	rs10888683	ENSG00000182109.6	RP11-69E11.4	4.49	1.58e-05	0.0109	0.38	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39157997	chr1:39522280~39546187:-
TGCT	cis	rs9959491	0.56	rs4800823	ENSG00000227279.1	AC015933.2	-4.49	1.58e-05	0.0109	-0.4	-0.37	Breast cancer;	chr18:27809350	chr18:27954519~27963687:+
TGCT	cis	rs6591341	0.515	rs599301	ENSG00000212093.1	AP000807.1	4.49	1.58e-05	0.0109	0.37	0.37	Lean body mass;	chr11:68422477	chr11:68506083~68506166:-
TGCT	cis	rs2919917	0.628	rs4739135	ENSG00000254352.1	RP11-578O24.2	4.49	1.58e-05	0.0109	0.44	0.37	Lymphocyte counts;	chr8:78656057	chr8:78723796~78724136:-
TGCT	cis	rs7714584	1	rs59980321	ENSG00000197083.10	ZNF300P1	4.49	1.58e-05	0.0109	0.63	0.37	Crohn's disease;	chr5:150862251	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs7709650	ENSG00000197083.10	ZNF300P1	4.49	1.58e-05	0.0109	0.63	0.37	Crohn's disease;	chr5:150867123	chr5:150930645~150946289:-
TGCT	cis	rs11671005	0.57	rs73062110	ENSG00000232098.3	CTD-2619J13.14	-4.49	1.59e-05	0.0109	-0.41	-0.37	Mean platelet volume;	chr19:58425275	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.735	rs11668420	ENSG00000232098.3	CTD-2619J13.14	-4.49	1.59e-05	0.0109	-0.41	-0.37	Mean platelet volume;	chr19:58426469	chr19:58404238~58408484:-
TGCT	cis	rs35424364	1	rs35424364	ENSG00000203799.9	CCDC162P	-4.49	1.59e-05	0.0109	-0.56	-0.37	Obstructive sleep apnea trait (average respiratory event duration);	chr6:109322402	chr6:109285485~109355063:+
TGCT	cis	rs875971	0.862	rs12537823	ENSG00000232559.3	GS1-124K5.12	4.49	1.59e-05	0.0109	0.35	0.37	Aortic root size;	chr7:66255897	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs10282433	ENSG00000232559.3	GS1-124K5.12	-4.49	1.59e-05	0.0109	-0.35	-0.37	Aortic root size;	chr7:66256452	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs10276077	ENSG00000232559.3	GS1-124K5.12	-4.49	1.59e-05	0.0109	-0.35	-0.37	Aortic root size;	chr7:66263424	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.825	rs4587224	ENSG00000232559.3	GS1-124K5.12	-4.49	1.59e-05	0.0109	-0.35	-0.37	Aortic root size;	chr7:66271195	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.792	rs6971752	ENSG00000232559.3	GS1-124K5.12	-4.49	1.59e-05	0.0109	-0.35	-0.37	Aortic root size;	chr7:66272999	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs10950033	ENSG00000232559.3	GS1-124K5.12	-4.49	1.59e-05	0.0109	-0.35	-0.37	Aortic root size;	chr7:66274686	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs11760844	ENSG00000232559.3	GS1-124K5.12	-4.49	1.59e-05	0.0109	-0.35	-0.37	Aortic root size;	chr7:66274896	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs4149461	ENSG00000232559.3	GS1-124K5.12	-4.49	1.59e-05	0.0109	-0.35	-0.37	Aortic root size;	chr7:66279745	chr7:66554588~66576923:-
TGCT	cis	rs12682352	0.652	rs1567398	ENSG00000254340.1	RP11-10A14.3	-4.49	1.59e-05	0.0109	-0.37	-0.37	Neuroticism;	chr8:8869294	chr8:9141424~9145435:+
TGCT	cis	rs7923609	0.783	rs4746203	ENSG00000232075.1	MRPL35P2	4.49	1.59e-05	0.0109	0.36	0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63564237	chr10:63634317~63634827:-
TGCT	cis	rs7429990	0.932	rs11130155	ENSG00000229759.1	MRPS18AP1	-4.49	1.59e-05	0.0109	-0.31	-0.37	Educational attainment (years of education);	chr3:48098938	chr3:48256350~48256938:-
TGCT	cis	rs9309473	0.95	rs11689588	ENSG00000163016.8	ALMS1P	4.49	1.59e-05	0.0109	0.34	0.37	Metabolite levels;	chr2:73546564	chr2:73644919~73685576:+
TGCT	cis	rs2439831	0.85	rs7183809	ENSG00000205771.5	CATSPER2P1	-4.49	1.59e-05	0.0109	-0.63	-0.37	Lung cancer in ever smokers;	chr15:43828670	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs3759790	ENSG00000205771.5	CATSPER2P1	-4.49	1.59e-05	0.0109	-0.63	-0.37	Lung cancer in ever smokers;	chr15:43828832	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs28524541	ENSG00000205771.5	CATSPER2P1	-4.49	1.59e-05	0.0109	-0.63	-0.37	Lung cancer in ever smokers;	chr15:43832633	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs28564774	ENSG00000205771.5	CATSPER2P1	-4.49	1.59e-05	0.0109	-0.63	-0.37	Lung cancer in ever smokers;	chr15:43833277	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs28513374	ENSG00000205771.5	CATSPER2P1	-4.49	1.59e-05	0.0109	-0.63	-0.37	Lung cancer in ever smokers;	chr15:43833297	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs12441984	ENSG00000205771.5	CATSPER2P1	-4.49	1.59e-05	0.0109	-0.63	-0.37	Lung cancer in ever smokers;	chr15:43834087	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs7169322	ENSG00000205771.5	CATSPER2P1	-4.49	1.59e-05	0.0109	-0.63	-0.37	Lung cancer in ever smokers;	chr15:43838816	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs28707214	ENSG00000205771.5	CATSPER2P1	-4.49	1.59e-05	0.0109	-0.63	-0.37	Lung cancer in ever smokers;	chr15:43839425	chr15:43726918~43747094:-
TGCT	cis	rs3760776	0.522	rs78060698	ENSG00000266941.1	AC104532.3	4.49	1.59e-05	0.0109	1.02	0.37	Vitamin B12 levels;Tumor biomarkers;N-glycan levels;	chr19:5832762	chr19:5899895~5901511:+
TGCT	cis	rs7819412	0.818	rs11989439	ENSG00000269918.1	AF131215.9	-4.49	1.59e-05	0.0109	-0.37	-0.37	Triglycerides;	chr8:11198088	chr8:11104691~11106704:-
TGCT	cis	rs6600671	1	rs7532615	ENSG00000275131.1	CH17-472G23.4	4.49	1.59e-05	0.011	0.24	0.37	Hip geometry;	chr1:121430980	chr1:120489625~120579190:-
TGCT	cis	rs559928	1	rs471584	ENSG00000236935.1	AP003774.1	-4.49	1.59e-05	0.011	-0.38	-0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64381780	chr11:64325050~64329504:-
TGCT	cis	rs559928	0.947	rs10792430	ENSG00000236935.1	AP003774.1	4.49	1.59e-05	0.011	0.38	0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64379642	chr11:64325050~64329504:-
TGCT	cis	rs559928	1	rs11601872	ENSG00000236935.1	AP003774.1	4.49	1.59e-05	0.011	0.38	0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64380155	chr11:64325050~64329504:-
TGCT	cis	rs507080	0.961	rs607527	ENSG00000255422.1	AP002954.4	4.49	1.59e-05	0.011	0.43	0.37	Serum metabolite levels;	chr11:118667478	chr11:118704607~118750263:+
TGCT	cis	rs7208859	0.573	rs73267829	ENSG00000266490.1	CTD-2349P21.9	4.49	1.59e-05	0.011	0.43	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30792372~30792833:+
TGCT	cis	rs2333021	0.689	rs2998006	ENSG00000259015.1	RP11-109N23.6	-4.49	1.6e-05	0.011	-0.21	-0.37	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72962406	chr14:72960595~72961993:+
TGCT	cis	rs2333021	0.689	rs8010674	ENSG00000259015.1	RP11-109N23.6	-4.49	1.6e-05	0.011	-0.21	-0.37	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72962458	chr14:72960595~72961993:+
TGCT	cis	rs2333021	0.689	rs2535901	ENSG00000259015.1	RP11-109N23.6	-4.49	1.6e-05	0.011	-0.21	-0.37	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72965734	chr14:72960595~72961993:+
TGCT	cis	rs2333021	0.689	rs2535897	ENSG00000259015.1	RP11-109N23.6	-4.49	1.6e-05	0.011	-0.21	-0.37	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72967514	chr14:72960595~72961993:+
TGCT	cis	rs10246939	0.511	rs62475469	ENSG00000228775.6	WEE2-AS1	4.49	1.6e-05	0.011	0.33	0.37	Bitter taste perception;	chr7:141864846	chr7:141704338~141738346:-
TGCT	cis	rs17826219	0.568	rs11658027	ENSG00000280069.1	CTD-2349P21.3	4.49	1.6e-05	0.011	0.54	0.37	Body mass index;	chr17:30767864	chr17:30738182~30740275:+
TGCT	cis	rs11123170	0.503	rs28679654	ENSG00000189223.12	PAX8-AS1	-4.49	1.6e-05	0.011	-0.64	-0.37	Renal function-related traits (BUN);	chr2:113210040	chr2:113211522~113276581:+
TGCT	cis	rs875971	0.862	rs10274883	ENSG00000237310.1	GS1-124K5.4	-4.49	1.6e-05	0.011	-0.4	-0.37	Aortic root size;	chr7:66651104	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.569	rs881285	ENSG00000237310.1	GS1-124K5.4	-4.49	1.6e-05	0.011	-0.4	-0.37	Aortic root size;	chr7:66654433	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.569	rs3846973	ENSG00000237310.1	GS1-124K5.4	-4.49	1.6e-05	0.011	-0.4	-0.37	Aortic root size;	chr7:66655048	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.569	rs2013908	ENSG00000237310.1	GS1-124K5.4	-4.49	1.6e-05	0.011	-0.4	-0.37	Aortic root size;	chr7:66656082	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.569	rs13242290	ENSG00000237310.1	GS1-124K5.4	-4.49	1.6e-05	0.011	-0.4	-0.37	Aortic root size;	chr7:66656898	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.548	rs2109297	ENSG00000237310.1	GS1-124K5.4	-4.49	1.6e-05	0.011	-0.4	-0.37	Aortic root size;	chr7:66657397	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.569	rs6978178	ENSG00000237310.1	GS1-124K5.4	-4.49	1.6e-05	0.011	-0.4	-0.37	Aortic root size;	chr7:66658097	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.591	rs721717	ENSG00000237310.1	GS1-124K5.4	-4.49	1.6e-05	0.011	-0.4	-0.37	Aortic root size;	chr7:66665305	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.569	rs6951302	ENSG00000237310.1	GS1-124K5.4	-4.49	1.6e-05	0.011	-0.4	-0.37	Aortic root size;	chr7:66667525	chr7:66493706~66495474:+
TGCT	cis	rs2337406	1	rs7145100	ENSG00000274576.2	IGHV2-70	-4.49	1.6e-05	0.011	-0.57	-0.37	Alzheimer's disease (late onset);	chr14:106704673	chr14:106770577~106771020:-
TGCT	cis	rs10826995	0.961	rs78862806	ENSG00000239731.3	RN7SL825P	-4.49	1.6e-05	0.011	-0.37	-0.37	Pulse pressure;	chr10:31978567	chr10:31992087~31992381:-
TGCT	cis	rs10826995	0.961	rs78360411	ENSG00000239731.3	RN7SL825P	-4.49	1.6e-05	0.011	-0.37	-0.37	Pulse pressure;	chr10:31978578	chr10:31992087~31992381:-
TGCT	cis	rs786425	0.835	rs7966867	ENSG00000247373.3	RP11-486O12.2	-4.49	1.61e-05	0.011	-0.44	-0.37	Pubertal anthropometrics;	chr12:123694870	chr12:123575891~123585115:-
TGCT	cis	rs10256972	0.732	rs1574108	ENSG00000226291.1	AC091729.8	-4.49	1.61e-05	0.011	-0.4	-0.37	Endometriosis;Longevity;	chr7:1066169	chr7:1080863~1082178:+
TGCT	cis	rs9660180	0.967	rs6603802	ENSG00000231050.1	RP1-140A9.1	4.49	1.61e-05	0.011	0.34	0.37	Body mass index;	chr1:1881082	chr1:1891471~1892658:+
TGCT	cis	rs4835473	0.897	rs7682204	ENSG00000251600.4	RP11-673E1.1	4.49	1.61e-05	0.011	0.39	0.37	Immature fraction of reticulocytes;	chr4:143966306	chr4:143912331~143982454:+
TGCT	cis	rs732716	0.785	rs34080966	ENSG00000267769.1	CTB-50L17.9	4.49	1.61e-05	0.011	0.43	0.37	Mean corpuscular volume;	chr19:4417848	chr19:4454014~4455286:+
TGCT	cis	rs875971	0.862	rs6971059	ENSG00000237310.1	GS1-124K5.4	-4.49	1.61e-05	0.0111	-0.4	-0.37	Aortic root size;	chr7:66602045	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.789	rs7808013	ENSG00000237310.1	GS1-124K5.4	-4.49	1.61e-05	0.0111	-0.4	-0.37	Aortic root size;	chr7:66606209	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.825	rs7384021	ENSG00000237310.1	GS1-124K5.4	-4.49	1.61e-05	0.0111	-0.4	-0.37	Aortic root size;	chr7:66612917	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.825	rs66981195	ENSG00000237310.1	GS1-124K5.4	-4.49	1.61e-05	0.0111	-0.4	-0.37	Aortic root size;	chr7:66614048	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs3926380	ENSG00000237310.1	GS1-124K5.4	-4.49	1.61e-05	0.0111	-0.4	-0.37	Aortic root size;	chr7:66615658	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.825	rs1860472	ENSG00000237310.1	GS1-124K5.4	-4.49	1.61e-05	0.0111	-0.4	-0.37	Aortic root size;	chr7:66617736	chr7:66493706~66495474:+
TGCT	cis	rs2980439	0.517	rs793753	ENSG00000254340.1	RP11-10A14.3	-4.49	1.61e-05	0.0111	-0.4	-0.37	Neuroticism;	chr8:8247837	chr8:9141424~9145435:+
TGCT	cis	rs7829975	0.714	rs11784052	ENSG00000173295.6	FAM86B3P	4.49	1.61e-05	0.0111	0.44	0.37	Mood instability;	chr8:8814452	chr8:8228595~8244865:+
TGCT	cis	rs34779708	0.897	rs7900480	ENSG00000230534.5	RP11-297A16.2	-4.49	1.61e-05	0.0111	-0.44	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35049771	chr10:35098006~35127020:-
TGCT	cis	rs12439619	0.705	rs4778665	ENSG00000255769.6	GOLGA2P10	-4.49	1.61e-05	0.0111	-0.47	-0.37	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472993~82513950:-
TGCT	cis	rs10829156	1	rs10829157	ENSG00000240291.1	RP11-499P20.2	4.49	1.61e-05	0.0111	0.34	0.37	Sudden cardiac arrest;	chr10:18662534	chr10:18513115~18545651:-
TGCT	cis	rs7923609	0.811	rs7899657	ENSG00000232075.1	MRPL35P2	4.49	1.61e-05	0.0111	0.36	0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63563505	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.811	rs4746204	ENSG00000232075.1	MRPL35P2	4.49	1.61e-05	0.0111	0.36	0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568758	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.783	rs7907451	ENSG00000232075.1	MRPL35P2	4.49	1.61e-05	0.0111	0.36	0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568980	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.783	rs7100409	ENSG00000232075.1	MRPL35P2	4.49	1.61e-05	0.0111	0.36	0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63570435	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.703	rs7100413	ENSG00000232075.1	MRPL35P2	4.49	1.61e-05	0.0111	0.36	0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63570448	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.811	rs3847325	ENSG00000232075.1	MRPL35P2	4.49	1.61e-05	0.0111	0.36	0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63571751	chr10:63634317~63634827:-
TGCT	cis	rs2742234	0.541	rs10899786	ENSG00000273008.1	RP11-351D16.3	4.49	1.61e-05	0.0111	0.52	0.37	Hirschsprung disease;	chr10:43249135	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.541	rs61845684	ENSG00000273008.1	RP11-351D16.3	4.49	1.61e-05	0.0111	0.52	0.37	Hirschsprung disease;	chr10:43249535	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.541	rs10793426	ENSG00000273008.1	RP11-351D16.3	4.49	1.61e-05	0.0111	0.52	0.37	Hirschsprung disease;	chr10:43249832	chr10:43136824~43138334:-
TGCT	cis	rs12745968	0.653	rs11164810	ENSG00000223787.2	RP4-593M8.1	-4.49	1.62e-05	0.0111	-0.5	-0.37	Bipolar disorder and schizophrenia;	chr1:92779423	chr1:92580476~92580821:-
TGCT	cis	rs73198271	0.562	rs76960788	ENSG00000253893.2	FAM85B	4.49	1.62e-05	0.0111	0.61	0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8816539	chr8:8167819~8226614:-
TGCT	cis	rs73198271	0.562	rs55961293	ENSG00000253893.2	FAM85B	4.49	1.62e-05	0.0111	0.61	0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8817968	chr8:8167819~8226614:-
TGCT	cis	rs73198271	0.562	rs55657655	ENSG00000253893.2	FAM85B	4.49	1.62e-05	0.0111	0.61	0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8817981	chr8:8167819~8226614:-
TGCT	cis	rs875971	1	rs2077593	ENSG00000237310.1	GS1-124K5.4	4.49	1.62e-05	0.0111	0.41	0.37	Aortic root size;	chr7:66427543	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs4717292	ENSG00000237310.1	GS1-124K5.4	4.49	1.62e-05	0.0111	0.41	0.37	Aortic root size;	chr7:66430611	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs2420591	ENSG00000237310.1	GS1-124K5.4	4.49	1.62e-05	0.0111	0.41	0.37	Aortic root size;	chr7:66447394	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.895	rs10755833	ENSG00000237310.1	GS1-124K5.4	4.49	1.62e-05	0.0111	0.41	0.37	Aortic root size;	chr7:66448930	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.964	rs12668936	ENSG00000237310.1	GS1-124K5.4	4.49	1.62e-05	0.0111	0.41	0.37	Aortic root size;	chr7:66449417	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.895	rs7788984	ENSG00000237310.1	GS1-124K5.4	4.49	1.62e-05	0.0111	0.41	0.37	Aortic root size;	chr7:66450629	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.895	rs1833495	ENSG00000237310.1	GS1-124K5.4	4.49	1.62e-05	0.0111	0.41	0.37	Aortic root size;	chr7:66456608	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.964	rs6945019	ENSG00000237310.1	GS1-124K5.4	4.49	1.62e-05	0.0111	0.41	0.37	Aortic root size;	chr7:66457471	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.964	rs6945032	ENSG00000237310.1	GS1-124K5.4	4.49	1.62e-05	0.0111	0.41	0.37	Aortic root size;	chr7:66457499	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.929	rs12673810	ENSG00000237310.1	GS1-124K5.4	4.49	1.62e-05	0.0111	0.41	0.37	Aortic root size;	chr7:66458866	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs35149210	ENSG00000237310.1	GS1-124K5.4	4.49	1.62e-05	0.0111	0.41	0.37	Aortic root size;	chr7:66464938	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.929	rs34406470	ENSG00000237310.1	GS1-124K5.4	4.49	1.62e-05	0.0111	0.41	0.37	Aortic root size;	chr7:66464969	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs6961155	ENSG00000237310.1	GS1-124K5.4	4.49	1.62e-05	0.0111	0.41	0.37	Aortic root size;	chr7:66468308	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs7789768	ENSG00000237310.1	GS1-124K5.4	4.49	1.62e-05	0.0111	0.41	0.37	Aortic root size;	chr7:66473993	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs1363055	ENSG00000237310.1	GS1-124K5.4	4.49	1.62e-05	0.0111	0.41	0.37	Aortic root size;	chr7:66478288	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.964	rs9691480	ENSG00000237310.1	GS1-124K5.4	4.49	1.62e-05	0.0111	0.41	0.37	Aortic root size;	chr7:66479319	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs7789554	ENSG00000237310.1	GS1-124K5.4	4.49	1.62e-05	0.0111	0.41	0.37	Aortic root size;	chr7:66481051	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs4717300	ENSG00000237310.1	GS1-124K5.4	4.49	1.62e-05	0.0111	0.41	0.37	Aortic root size;	chr7:66482393	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.895	rs1974769	ENSG00000237310.1	GS1-124K5.4	4.49	1.62e-05	0.0111	0.41	0.37	Aortic root size;	chr7:66485627	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.895	rs6460300	ENSG00000237310.1	GS1-124K5.4	4.49	1.62e-05	0.0111	0.41	0.37	Aortic root size;	chr7:66487937	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs7803416	ENSG00000237310.1	GS1-124K5.4	4.49	1.62e-05	0.0111	0.41	0.37	Aortic root size;	chr7:66489212	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs1981798	ENSG00000237310.1	GS1-124K5.4	4.49	1.62e-05	0.0111	0.41	0.37	Aortic root size;	chr7:66489916	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs1981799	ENSG00000237310.1	GS1-124K5.4	4.49	1.62e-05	0.0111	0.41	0.37	Aortic root size;	chr7:66490572	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.964	rs2277911	ENSG00000237310.1	GS1-124K5.4	4.49	1.62e-05	0.0111	0.41	0.37	Aortic root size;	chr7:66493638	chr7:66493706~66495474:+
TGCT	cis	rs7923609	0.811	rs3847326	ENSG00000232075.1	MRPL35P2	4.49	1.62e-05	0.0111	0.36	0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63572099	chr10:63634317~63634827:-
TGCT	cis	rs4925166	1	rs4925166	ENSG00000273018.4	CTD-2303H24.2	-4.49	1.62e-05	0.0111	-0.4	-0.37	Multiple sclerosis;	chr17:18307496	chr17:18511221~18551705:-
TGCT	cis	rs7208859	0.623	rs7220999	ENSG00000280069.1	CTD-2349P21.3	-4.49	1.62e-05	0.0111	-0.53	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs55638872	ENSG00000280069.1	CTD-2349P21.3	-4.49	1.62e-05	0.0111	-0.53	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs9899268	ENSG00000280069.1	CTD-2349P21.3	-4.49	1.62e-05	0.0111	-0.53	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30738182~30740275:+
TGCT	cis	rs1799955	0.935	rs9634672	ENSG00000215515.2	IFIT1P1	-4.49	1.62e-05	0.0111	-0.52	-0.37	LDL cholesterol levels;	chr13:32369919	chr13:32384660~32386108:+
TGCT	cis	rs1799955	0.935	rs9567609	ENSG00000215515.2	IFIT1P1	-4.49	1.62e-05	0.0111	-0.52	-0.37	LDL cholesterol levels;	chr13:32371580	chr13:32384660~32386108:+
TGCT	cis	rs4660214	0.724	rs10788933	ENSG00000182109.6	RP11-69E11.4	-4.49	1.62e-05	0.0111	-0.38	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39229483	chr1:39522280~39546187:-
TGCT	cis	rs4835473	0.808	rs6836630	ENSG00000251600.4	RP11-673E1.1	-4.49	1.62e-05	0.0111	-0.39	-0.37	Immature fraction of reticulocytes;	chr4:143801068	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs13101541	ENSG00000251600.4	RP11-673E1.1	-4.49	1.62e-05	0.0111	-0.39	-0.37	Immature fraction of reticulocytes;	chr4:143806590	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs17695238	ENSG00000251600.4	RP11-673E1.1	-4.49	1.62e-05	0.0111	-0.39	-0.37	Immature fraction of reticulocytes;	chr4:143820720	chr4:143912331~143982454:+
TGCT	cis	rs11671005	0.735	rs3826684	ENSG00000232098.3	CTD-2619J13.14	-4.49	1.62e-05	0.0111	-0.42	-0.37	Mean platelet volume;	chr19:58407338	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.735	rs3826683	ENSG00000232098.3	CTD-2619J13.14	-4.49	1.62e-05	0.0111	-0.42	-0.37	Mean platelet volume;	chr19:58407366	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.735	rs3826682	ENSG00000232098.3	CTD-2619J13.14	-4.49	1.62e-05	0.0111	-0.42	-0.37	Mean platelet volume;	chr19:58407381	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.735	rs3826681	ENSG00000232098.3	CTD-2619J13.14	-4.49	1.62e-05	0.0111	-0.42	-0.37	Mean platelet volume;	chr19:58407397	chr19:58404238~58408484:-
TGCT	cis	rs1618992	0.678	rs3942830	ENSG00000265994.1	RP11-510D21.1	4.49	1.62e-05	0.0111	0.38	0.37	Gut microbiome composition (summer and winter);	chr18:28555081	chr18:28785068~28789260:+
TGCT	cis	rs2919009	0.607	rs12250320	ENSG00000271670.1	RP11-95I16.4	4.49	1.62e-05	0.0111	0.45	0.37	Obesity-related traits;	chr10:120959795	chr10:120879256~120880667:-
TGCT	cis	rs77669868	0.64	rs2073848	ENSG00000256452.1	RP11-667M19.10	-4.49	1.62e-05	0.0111	-0.37	-0.37	Monocyte percentage of white cells;	chr11:114181182	chr11:113818077~113822458:+
TGCT	cis	rs10971721	0.584	rs10971938	ENSG00000230074.1	RP11-195F19.9	4.49	1.63e-05	0.0111	0.53	0.37	Body mass index;	chr9:34120722	chr9:34665665~34681298:+
TGCT	cis	rs875971	0.862	rs1167408	ENSG00000237310.1	GS1-124K5.4	-4.49	1.63e-05	0.0111	-0.41	-0.37	Aortic root size;	chr7:66091121	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.83	rs1167406	ENSG00000237310.1	GS1-124K5.4	-4.49	1.63e-05	0.0111	-0.41	-0.37	Aortic root size;	chr7:66091949	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs709609	ENSG00000237310.1	GS1-124K5.4	-4.49	1.63e-05	0.0111	-0.41	-0.37	Aortic root size;	chr7:66095574	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs1167399	ENSG00000237310.1	GS1-124K5.4	-4.49	1.63e-05	0.0111	-0.41	-0.37	Aortic root size;	chr7:66096890	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs57866200	ENSG00000237310.1	GS1-124K5.4	-4.49	1.63e-05	0.0111	-0.41	-0.37	Aortic root size;	chr7:66100405	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.522	rs709604	ENSG00000272831.1	RP11-792A8.4	-4.49	1.63e-05	0.0111	-0.39	-0.37	Aortic root size;	chr7:66032447	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.505	rs1723275	ENSG00000272831.1	RP11-792A8.4	-4.49	1.63e-05	0.0111	-0.39	-0.37	Aortic root size;	chr7:66039646	chr7:66739829~66740385:-
TGCT	cis	rs559928	1	rs72926046	ENSG00000236935.1	AP003774.1	4.49	1.63e-05	0.0111	0.38	0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64375915	chr11:64325050~64329504:-
TGCT	cis	rs559928	1	rs72926050	ENSG00000236935.1	AP003774.1	4.49	1.63e-05	0.0111	0.38	0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64376102	chr11:64325050~64329504:-
TGCT	cis	rs559928	0.947	rs12417275	ENSG00000236935.1	AP003774.1	4.49	1.63e-05	0.0111	0.38	0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64376302	chr11:64325050~64329504:-
TGCT	cis	rs3096299	0.9	rs744327	ENSG00000274627.1	RP11-104N10.2	4.49	1.63e-05	0.0111	0.39	0.37	Multiple myeloma (IgH translocation);	chr16:89372862	chr16:89516797~89522217:+
TGCT	cis	rs1618992	0.74	rs2174268	ENSG00000265994.1	RP11-510D21.1	4.49	1.63e-05	0.0111	0.38	0.37	Gut microbiome composition (summer and winter);	chr18:28608240	chr18:28785068~28789260:+
TGCT	cis	rs875971	0.545	rs2420456	ENSG00000237310.1	GS1-124K5.4	4.49	1.63e-05	0.0112	0.45	0.37	Aortic root size;	chr7:66280619	chr7:66493706~66495474:+
TGCT	cis	rs6017291	1	rs35687465	ENSG00000223891.4	OSER1-AS1	4.49	1.64e-05	0.0112	0.57	0.37	Cognitive performance;	chr20:44250711	chr20:44210960~44226027:+
TGCT	cis	rs6017291	1	rs35781708	ENSG00000223891.4	OSER1-AS1	4.49	1.64e-05	0.0112	0.57	0.37	Cognitive performance;	chr20:44250969	chr20:44210960~44226027:+
TGCT	cis	rs6017291	0.793	rs2017384	ENSG00000223891.4	OSER1-AS1	4.49	1.64e-05	0.0112	0.57	0.37	Cognitive performance;	chr20:44256438	chr20:44210960~44226027:+
TGCT	cis	rs6017291	1	rs2143641	ENSG00000223891.4	OSER1-AS1	4.49	1.64e-05	0.0112	0.57	0.37	Cognitive performance;	chr20:44261379	chr20:44210960~44226027:+
TGCT	cis	rs6017291	1	rs4366964	ENSG00000223891.4	OSER1-AS1	4.49	1.64e-05	0.0112	0.57	0.37	Cognitive performance;	chr20:44267266	chr20:44210960~44226027:+
TGCT	cis	rs1519814	0.654	rs6469882	ENSG00000254343.2	RP11-760H22.2	-4.49	1.64e-05	0.0112	-0.61	-0.37	Breast cancer;	chr8:119998232	chr8:120052180~120056201:+
TGCT	cis	rs1519814	0.581	rs1879150	ENSG00000254343.2	RP11-760H22.2	-4.49	1.64e-05	0.0112	-0.61	-0.37	Breast cancer;	chr8:119998994	chr8:120052180~120056201:+
TGCT	cis	rs1519814	0.616	rs2326428	ENSG00000254343.2	RP11-760H22.2	-4.49	1.64e-05	0.0112	-0.61	-0.37	Breast cancer;	chr8:119999124	chr8:120052180~120056201:+
TGCT	cis	rs1519814	0.616	rs28885745	ENSG00000254343.2	RP11-760H22.2	-4.49	1.64e-05	0.0112	-0.61	-0.37	Breast cancer;	chr8:120000219	chr8:120052180~120056201:+
TGCT	cis	rs1519814	0.654	rs11986190	ENSG00000254343.2	RP11-760H22.2	-4.49	1.64e-05	0.0112	-0.61	-0.37	Breast cancer;	chr8:120001086	chr8:120052180~120056201:+
TGCT	cis	rs7246967	0.673	rs59567211	ENSG00000269509.1	BNIP3P34	4.49	1.64e-05	0.0112	0.59	0.37	Bronchopulmonary dysplasia;	chr19:22647080	chr19:22773853~22774424:+
TGCT	cis	rs4713118	0.662	rs149946	ENSG00000219891.2	ZSCAN12P1	-4.48	1.64e-05	0.0112	-0.45	-0.37	Parkinson's disease;	chr6:28002253	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.662	rs156744	ENSG00000219891.2	ZSCAN12P1	4.48	1.64e-05	0.0112	0.45	0.37	Parkinson's disease;	chr6:27999496	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.662	rs149947	ENSG00000219891.2	ZSCAN12P1	4.48	1.64e-05	0.0112	0.45	0.37	Parkinson's disease;	chr6:28004655	chr6:28091154~28093664:+
TGCT	cis	rs4834770	0.765	rs1511016	ENSG00000245958.5	RP11-33B1.1	-4.48	1.64e-05	0.0112	-0.38	-0.37	Blood protein levels;	chr4:119249200	chr4:119454791~119552025:+
TGCT	cis	rs7615952	0.932	rs13325495	ENSG00000171084.14	FAM86JP	4.48	1.64e-05	0.0112	0.68	0.37	Blood pressure (smoking interaction);	chr3:125918573	chr3:125916620~125930024:+
TGCT	cis	rs72772090	0.539	rs11747896	ENSG00000248734.2	CTD-2260A17.1	4.48	1.64e-05	0.0112	0.48	0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777693	chr5:96784777~96785999:+
TGCT	cis	rs7182621	0.846	rs12915935	ENSG00000259363.4	CTD-2054N24.2	-4.48	1.64e-05	0.0112	-0.34	-0.37	Colonoscopy-negative controls vs population controls;	chr15:99871875	chr15:99807023~99877148:+
TGCT	cis	rs12143943	0.774	rs6594014	ENSG00000176754.11	LINC00303	4.48	1.64e-05	0.0112	0.33	0.37	Cognitive performance;	chr1:204480306	chr1:204032447~204041265:-
TGCT	cis	rs73086581	0.524	rs2253977	ENSG00000229539.1	RP11-119B16.2	-4.48	1.64e-05	0.0112	-0.46	-0.37	Response to antidepressants in depression;	chr20:3958493	chr20:3888239~3888868:-
TGCT	cis	rs1577917	0.545	rs1335443	ENSG00000203875.9	SNHG5	-4.48	1.64e-05	0.0112	-0.49	-0.37	Response to antipsychotic treatment;	chr6:85769019	chr6:85660950~85678736:-
TGCT	cis	rs2033711	0.84	rs4801590	ENSG00000269473.1	CTD-2619J13.19	4.48	1.65e-05	0.0112	0.3	0.37	Uric acid clearance;	chr19:58450446	chr19:58440448~58445849:+
TGCT	cis	rs4660214	0.666	rs7554206	ENSG00000182109.6	RP11-69E11.4	-4.48	1.65e-05	0.0113	-0.37	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39463568	chr1:39522280~39546187:-
TGCT	cis	rs10829156	0.898	rs7923072	ENSG00000240291.1	RP11-499P20.2	4.48	1.65e-05	0.0113	0.33	0.37	Sudden cardiac arrest;	chr10:18649305	chr10:18513115~18545651:-
TGCT	cis	rs875971	0.895	rs6460278	ENSG00000232559.3	GS1-124K5.12	-4.48	1.65e-05	0.0113	-0.35	-0.37	Aortic root size;	chr7:66197749	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs6460279	ENSG00000232559.3	GS1-124K5.12	-4.48	1.65e-05	0.0113	-0.35	-0.37	Aortic root size;	chr7:66197774	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs28491091	ENSG00000232559.3	GS1-124K5.12	-4.48	1.65e-05	0.0113	-0.35	-0.37	Aortic root size;	chr7:66204077	chr7:66554588~66576923:-
TGCT	cis	rs2980439	0.818	rs2948294	ENSG00000253981.4	ALG1L13P	4.48	1.65e-05	0.0113	0.39	0.37	Neuroticism;	chr8:8237439	chr8:8236003~8244667:-
TGCT	cis	rs2980439	0.783	rs2955587	ENSG00000253981.4	ALG1L13P	4.48	1.65e-05	0.0113	0.39	0.37	Neuroticism;	chr8:8240557	chr8:8236003~8244667:-
TGCT	cis	rs875971	0.502	rs2465121	ENSG00000237310.1	GS1-124K5.4	-4.48	1.65e-05	0.0113	-0.46	-0.37	Aortic root size;	chr7:66156017	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.502	rs11769702	ENSG00000237310.1	GS1-124K5.4	4.48	1.65e-05	0.0113	0.46	0.37	Aortic root size;	chr7:66255529	chr7:66493706~66495474:+
TGCT	cis	rs8111998	0.826	rs10420442	ENSG00000269332.4	GOLGA2P9	4.48	1.65e-05	0.0113	0.67	0.37	Corneal structure;	chr19:22584928	chr19:22596257~22603550:+
TGCT	cis	rs5769707	0.777	rs8141219	ENSG00000235111.1	RP1-29C18.8	-4.48	1.65e-05	0.0113	-0.34	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49650898	chr22:49612657~49615716:-
TGCT	cis	rs5742933	0.857	rs1233272	ENSG00000273240.1	RP11-455J20.3	-4.48	1.65e-05	0.0113	-0.35	-0.37	Ferritin levels;	chr2:189814968	chr2:189763859~189764456:-
TGCT	cis	rs875971	0.862	rs1167408	ENSG00000232559.3	GS1-124K5.12	-4.48	1.65e-05	0.0113	-0.35	-0.37	Aortic root size;	chr7:66091121	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.83	rs1167406	ENSG00000232559.3	GS1-124K5.12	-4.48	1.65e-05	0.0113	-0.35	-0.37	Aortic root size;	chr7:66091949	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs709609	ENSG00000232559.3	GS1-124K5.12	-4.48	1.65e-05	0.0113	-0.35	-0.37	Aortic root size;	chr7:66095574	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs1167399	ENSG00000232559.3	GS1-124K5.12	-4.48	1.65e-05	0.0113	-0.35	-0.37	Aortic root size;	chr7:66096890	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs57866200	ENSG00000232559.3	GS1-124K5.12	-4.48	1.65e-05	0.0113	-0.35	-0.37	Aortic root size;	chr7:66100405	chr7:66554588~66576923:-
TGCT	cis	rs12143943	0.966	rs2369246	ENSG00000176754.11	LINC00303	4.48	1.65e-05	0.0113	0.34	0.37	Cognitive performance;	chr1:204598634	chr1:204032447~204041265:-
TGCT	cis	rs2581828	0.965	rs2564961	ENSG00000242142.1	SERBP1P3	4.48	1.65e-05	0.0113	0.35	0.37	Crohn's disease;	chr3:53102445	chr3:53064283~53065091:-
TGCT	cis	rs9462027	0.628	rs1998702	ENSG00000186328.4	RP11-140K17.2	4.48	1.66e-05	0.0113	0.35	0.37	Systemic lupus erythematosus;	chr6:34774140	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs6906759	ENSG00000186328.4	RP11-140K17.2	4.48	1.66e-05	0.0113	0.35	0.37	Systemic lupus erythematosus;	chr6:34775213	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.63	rs9469871	ENSG00000186328.4	RP11-140K17.2	4.48	1.66e-05	0.0113	0.35	0.37	Systemic lupus erythematosus;	chr6:34777230	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs11759151	ENSG00000186328.4	RP11-140K17.2	4.48	1.66e-05	0.0113	0.35	0.37	Systemic lupus erythematosus;	chr6:34779826	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs6899938	ENSG00000186328.4	RP11-140K17.2	4.48	1.66e-05	0.0113	0.35	0.37	Systemic lupus erythematosus;	chr6:34781336	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs9462020	ENSG00000186328.4	RP11-140K17.2	4.48	1.66e-05	0.0113	0.35	0.37	Systemic lupus erythematosus;	chr6:34783488	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs58671447	ENSG00000186328.4	RP11-140K17.2	4.48	1.66e-05	0.0113	0.35	0.37	Systemic lupus erythematosus;	chr6:34784574	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs9689820	ENSG00000186328.4	RP11-140K17.2	4.48	1.66e-05	0.0113	0.35	0.37	Systemic lupus erythematosus;	chr6:34785186	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.651	rs34493158	ENSG00000186328.4	RP11-140K17.2	4.48	1.66e-05	0.0113	0.35	0.37	Systemic lupus erythematosus;	chr6:34785562	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.651	rs9469884	ENSG00000186328.4	RP11-140K17.2	4.48	1.66e-05	0.0113	0.35	0.37	Systemic lupus erythematosus;	chr6:34790926	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.651	rs9469885	ENSG00000186328.4	RP11-140K17.2	4.48	1.66e-05	0.0113	0.35	0.37	Systemic lupus erythematosus;	chr6:34790939	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs9469887	ENSG00000186328.4	RP11-140K17.2	4.48	1.66e-05	0.0113	0.35	0.37	Systemic lupus erythematosus;	chr6:34791163	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.588	rs13215181	ENSG00000186328.4	RP11-140K17.2	4.48	1.66e-05	0.0113	0.35	0.37	Systemic lupus erythematosus;	chr6:34792104	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.506	rs6934662	ENSG00000186328.4	RP11-140K17.2	4.48	1.66e-05	0.0113	0.35	0.37	Systemic lupus erythematosus;	chr6:34792107	chr6:34715613~34715940:+
TGCT	cis	rs2764208	0.576	rs6457791	ENSG00000186328.4	RP11-140K17.2	4.48	1.66e-05	0.0113	0.35	0.37	Systemic lupus erythematosus;	chr6:34792177	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs7769961	ENSG00000186328.4	RP11-140K17.2	4.48	1.66e-05	0.0113	0.35	0.37	Systemic lupus erythematosus;	chr6:34792385	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.651	rs7769820	ENSG00000186328.4	RP11-140K17.2	4.48	1.66e-05	0.0113	0.35	0.37	Systemic lupus erythematosus;	chr6:34792451	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs7752060	ENSG00000186328.4	RP11-140K17.2	4.48	1.66e-05	0.0113	0.35	0.37	Systemic lupus erythematosus;	chr6:34792548	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs11757370	ENSG00000186328.4	RP11-140K17.2	4.48	1.66e-05	0.0113	0.35	0.37	Systemic lupus erythematosus;	chr6:34792959	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.583	rs11755420	ENSG00000186328.4	RP11-140K17.2	4.48	1.66e-05	0.0113	0.35	0.37	Systemic lupus erythematosus;	chr6:34793179	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.583	rs9462022	ENSG00000186328.4	RP11-140K17.2	4.48	1.66e-05	0.0113	0.35	0.37	Systemic lupus erythematosus;	chr6:34793907	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs6942040	ENSG00000186328.4	RP11-140K17.2	4.48	1.66e-05	0.0113	0.35	0.37	Systemic lupus erythematosus;	chr6:34794032	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs9469889	ENSG00000186328.4	RP11-140K17.2	4.48	1.66e-05	0.0113	0.35	0.37	Systemic lupus erythematosus;	chr6:34796123	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs9469891	ENSG00000186328.4	RP11-140K17.2	4.48	1.66e-05	0.0113	0.35	0.37	Systemic lupus erythematosus;	chr6:34799619	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs9469894	ENSG00000186328.4	RP11-140K17.2	4.48	1.66e-05	0.0113	0.35	0.37	Systemic lupus erythematosus;	chr6:34806948	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs10947531	ENSG00000186328.4	RP11-140K17.2	-4.48	1.66e-05	0.0113	-0.35	-0.37	Systemic lupus erythematosus;	chr6:34797341	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs9296129	ENSG00000186328.4	RP11-140K17.2	-4.48	1.66e-05	0.0113	-0.35	-0.37	Systemic lupus erythematosus;	chr6:34806637	chr6:34715613~34715940:+
TGCT	cis	rs7923609	0.578	rs3858121	ENSG00000232075.1	MRPL35P2	-4.48	1.66e-05	0.0113	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63640237	chr10:63634317~63634827:-
TGCT	cis	rs3096299	0.869	rs748941	ENSG00000274627.1	RP11-104N10.2	4.48	1.66e-05	0.0113	0.39	0.37	Multiple myeloma (IgH translocation);	chr16:89374346	chr16:89516797~89522217:+
TGCT	cis	rs10759883	0.539	rs2296858	ENSG00000175611.10	LINC00476	4.48	1.66e-05	0.0113	0.33	0.37	Nicotine dependence;	chr9:96041126	chr9:95759231~95875977:-
TGCT	cis	rs6474412	0.833	rs10958725	ENSG00000255101.1	RP11-412B14.1	4.48	1.66e-05	0.0113	0.37	0.37	Smoking behavior;	chr8:42669441	chr8:42705583~42721946:-
TGCT	cis	rs6474412	0.957	rs1979140	ENSG00000255101.1	RP11-412B14.1	4.48	1.66e-05	0.0113	0.37	0.37	Smoking behavior;	chr8:42675693	chr8:42705583~42721946:-
TGCT	cis	rs9400467	0.506	rs12195578	ENSG00000272356.1	RP5-1112D6.8	-4.48	1.66e-05	0.0113	-0.43	-0.37	Amino acid levels;Blood metabolite levels;	chr6:111293583	chr6:111309203~111313517:+
TGCT	cis	rs786425	0.689	rs2222060	ENSG00000247373.3	RP11-486O12.2	4.48	1.66e-05	0.0113	0.49	0.37	Pubertal anthropometrics;	chr12:123709891	chr12:123575891~123585115:-
TGCT	cis	rs1023500	0.551	rs133379	ENSG00000270083.1	RP1-257I20.14	4.48	1.66e-05	0.0113	0.37	0.37	Schizophrenia;	chr22:42072531	chr22:42089630~42090028:-
TGCT	cis	rs2742234	0.541	rs12220534	ENSG00000273008.1	RP11-351D16.3	-4.48	1.66e-05	0.0113	-0.5	-0.37	Hirschsprung disease;	chr10:43238858	chr10:43136824~43138334:-
TGCT	cis	rs8062405	0.757	rs2411453	ENSG00000259982.1	CDC37P1	-4.48	1.66e-05	0.0113	-0.43	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28700294~28701540:-
TGCT	cis	rs1010254	0.51	rs723427	ENSG00000253921.1	CTB-113P19.3	-4.48	1.66e-05	0.0113	-0.47	-0.37	Optic nerve measurement (cup area);	chr5:152316208	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.51	rs2881985	ENSG00000253921.1	CTB-113P19.3	4.48	1.66e-05	0.0113	0.47	0.37	Optic nerve measurement (cup area);	chr5:152320768	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.51	rs56019388	ENSG00000253921.1	CTB-113P19.3	-4.48	1.66e-05	0.0113	-0.47	-0.37	Optic nerve measurement (cup area);	chr5:152326664	chr5:151753992~151767247:+
TGCT	cis	rs5742933	0.817	rs7591929	ENSG00000273240.1	RP11-455J20.3	4.48	1.66e-05	0.0113	0.35	0.37	Ferritin levels;	chr2:189778531	chr2:189763859~189764456:-
TGCT	cis	rs992157	1	rs736730	ENSG00000261338.2	RP11-378A13.1	4.48	1.67e-05	0.0113	0.3	0.37	Colorectal cancer;	chr2:218255532	chr2:218255319~218257366:+
TGCT	cis	rs992157	1	rs736731	ENSG00000261338.2	RP11-378A13.1	4.48	1.67e-05	0.0113	0.3	0.37	Colorectal cancer;	chr2:218255865	chr2:218255319~218257366:+
TGCT	cis	rs992157	1	rs10932766	ENSG00000261338.2	RP11-378A13.1	4.48	1.67e-05	0.0113	0.3	0.37	Colorectal cancer;	chr2:218257367	chr2:218255319~218257366:+
TGCT	cis	rs992157	1	rs3731859	ENSG00000261338.2	RP11-378A13.1	4.48	1.67e-05	0.0113	0.3	0.37	Colorectal cancer;	chr2:218259499	chr2:218255319~218257366:+
TGCT	cis	rs992157	1	rs13003334	ENSG00000261338.2	RP11-378A13.1	4.48	1.67e-05	0.0113	0.3	0.37	Colorectal cancer;	chr2:218260198	chr2:218255319~218257366:+
TGCT	cis	rs992157	1	rs11554825	ENSG00000261338.2	RP11-378A13.1	4.48	1.67e-05	0.0113	0.3	0.37	Colorectal cancer;	chr2:218261086	chr2:218255319~218257366:+
TGCT	cis	rs992157	1	rs4791	ENSG00000261338.2	RP11-378A13.1	4.48	1.67e-05	0.0113	0.3	0.37	Colorectal cancer;	chr2:218274217	chr2:218255319~218257366:+
TGCT	cis	rs7429990	0.932	rs13085054	ENSG00000229759.1	MRPS18AP1	-4.48	1.67e-05	0.0113	-0.31	-0.37	Educational attainment (years of education);	chr3:48092647	chr3:48256350~48256938:-
TGCT	cis	rs7429990	0.87	rs13089844	ENSG00000229759.1	MRPS18AP1	-4.48	1.67e-05	0.0113	-0.31	-0.37	Educational attainment (years of education);	chr3:48098741	chr3:48256350~48256938:-
TGCT	cis	rs7429990	0.932	rs12493348	ENSG00000229759.1	MRPS18AP1	-4.48	1.67e-05	0.0113	-0.31	-0.37	Educational attainment (years of education);	chr3:48102048	chr3:48256350~48256938:-
TGCT	cis	rs2745572	0.752	rs7739648	ENSG00000272279.1	RP11-157J24.2	4.48	1.67e-05	0.0113	0.43	0.37	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1540248	chr6:1528364~1528911:-
TGCT	cis	rs1555322	0.53	rs2297789	ENSG00000126005.14	MMP24-AS1	-4.48	1.67e-05	0.0114	-0.45	-0.37	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35216462~35278131:-
TGCT	cis	rs2742234	0.541	rs10899782	ENSG00000273008.1	RP11-351D16.3	4.48	1.67e-05	0.0114	0.52	0.37	Hirschsprung disease;	chr10:43240913	chr10:43136824~43138334:-
TGCT	cis	rs801193	0.901	rs4273746	ENSG00000236529.1	RP13-254B10.1	-4.48	1.67e-05	0.0114	-0.29	-0.37	Aortic root size;	chr7:66836124	chr7:65840212~65840596:+
TGCT	cis	rs8108269	0.911	rs10415769	ENSG00000241226.3	RN7SL836P	-4.48	1.67e-05	0.0114	-0.39	-0.37	Type 2 diabetes;	chr19:45655385	chr19:45651510~45651805:+
TGCT	cis	rs8108269	0.956	rs10420680	ENSG00000241226.3	RN7SL836P	-4.48	1.67e-05	0.0114	-0.39	-0.37	Type 2 diabetes;	chr19:45655570	chr19:45651510~45651805:+
TGCT	cis	rs8108269	1	rs10421259	ENSG00000241226.3	RN7SL836P	-4.48	1.67e-05	0.0114	-0.39	-0.37	Type 2 diabetes;	chr19:45655602	chr19:45651510~45651805:+
TGCT	cis	rs8108269	0.868	rs10421566	ENSG00000241226.3	RN7SL836P	-4.48	1.67e-05	0.0114	-0.39	-0.37	Type 2 diabetes;	chr19:45655865	chr19:45651510~45651805:+
TGCT	cis	rs8108269	1	rs7258890	ENSG00000241226.3	RN7SL836P	-4.48	1.67e-05	0.0114	-0.39	-0.37	Type 2 diabetes;	chr19:45656351	chr19:45651510~45651805:+
TGCT	cis	rs2439831	0.85	rs2228368	ENSG00000205771.5	CATSPER2P1	-4.48	1.67e-05	0.0114	-0.61	-0.37	Lung cancer in ever smokers;	chr15:43809812	chr15:43726918~43747094:-
TGCT	cis	rs7829975	0.714	rs11777085	ENSG00000173295.6	FAM86B3P	4.48	1.67e-05	0.0114	0.44	0.37	Mood instability;	chr8:8814919	chr8:8228595~8244865:+
TGCT	cis	rs1355223	0.573	rs1097403	ENSG00000271369.1	RP11-350D17.3	4.48	1.67e-05	0.0114	0.37	0.37	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34708536	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.573	rs2084970	ENSG00000271369.1	RP11-350D17.3	-4.48	1.67e-05	0.0114	-0.37	-0.37	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34702182	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.573	rs1901830	ENSG00000271369.1	RP11-350D17.3	-4.48	1.67e-05	0.0114	-0.37	-0.37	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34703481	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.533	rs1597960	ENSG00000271369.1	RP11-350D17.3	-4.48	1.67e-05	0.0114	-0.37	-0.37	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34705422	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.573	rs1597961	ENSG00000271369.1	RP11-350D17.3	-4.48	1.67e-05	0.0114	-0.37	-0.37	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34705567	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.573	rs7127169	ENSG00000271369.1	RP11-350D17.3	-4.48	1.67e-05	0.0114	-0.37	-0.37	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34706299	chr11:34709600~34710161:+
TGCT	cis	rs9844666	0.532	rs7625040	ENSG00000239213.4	NCK1-AS1	4.48	1.67e-05	0.0114	0.37	0.37	Height;	chr3:135943623	chr3:136841726~136862054:-
TGCT	cis	rs10504229	1	rs79311869	ENSG00000253301.4	RP11-513O17.2	4.48	1.67e-05	0.0114	0.5	0.37	Developmental language disorder (linguistic errors);	chr8:57282987	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs76270388	ENSG00000253301.4	RP11-513O17.2	4.48	1.67e-05	0.0114	0.5	0.37	Developmental language disorder (linguistic errors);	chr8:57283046	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs73591706	ENSG00000253301.4	RP11-513O17.2	4.48	1.67e-05	0.0114	0.5	0.37	Developmental language disorder (linguistic errors);	chr8:57283074	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs67096506	ENSG00000253301.4	RP11-513O17.2	4.48	1.67e-05	0.0114	0.5	0.37	Developmental language disorder (linguistic errors);	chr8:57283096	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs59843034	ENSG00000253301.4	RP11-513O17.2	4.48	1.67e-05	0.0114	0.5	0.37	Developmental language disorder (linguistic errors);	chr8:57283197	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.861	rs60346509	ENSG00000253301.4	RP11-513O17.2	4.48	1.67e-05	0.0114	0.5	0.37	Developmental language disorder (linguistic errors);	chr8:57283491	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.861	rs57314710	ENSG00000253301.4	RP11-513O17.2	4.48	1.67e-05	0.0114	0.5	0.37	Developmental language disorder (linguistic errors);	chr8:57283492	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs68114352	ENSG00000253301.4	RP11-513O17.2	4.48	1.67e-05	0.0114	0.5	0.37	Developmental language disorder (linguistic errors);	chr8:57283522	chr8:57142689~57240298:+
TGCT	cis	rs1823913	0.599	rs13427761	ENSG00000227542.1	AC092614.2	-4.48	1.68e-05	0.0114	-0.4	-0.37	Obesity-related traits;	chr2:191269256	chr2:191229165~191246172:-
TGCT	cis	rs11168854	0.595	rs11168857	ENSG00000258017.1	RP11-386G11.10	-4.48	1.68e-05	0.0114	-0.49	-0.37	Body mass index;	chr12:49096526	chr12:49127782~49147869:+
TGCT	cis	rs4268898	0.722	rs35520052	ENSG00000223754.1	AC008073.9	-4.48	1.68e-05	0.0114	-0.4	-0.37	Asthma;	chr2:24192408	chr2:24199839~24201698:-
TGCT	cis	rs4268898	0.722	rs12185638	ENSG00000223754.1	AC008073.9	-4.48	1.68e-05	0.0114	-0.42	-0.37	Asthma;	chr2:24159160	chr2:24199839~24201698:-
TGCT	cis	rs4268898	0.722	rs4665253	ENSG00000223754.1	AC008073.9	-4.48	1.68e-05	0.0114	-0.42	-0.37	Asthma;	chr2:24159676	chr2:24199839~24201698:-
TGCT	cis	rs4268898	0.722	rs6723257	ENSG00000223754.1	AC008073.9	-4.48	1.68e-05	0.0114	-0.42	-0.37	Asthma;	chr2:24168260	chr2:24199839~24201698:-
TGCT	cis	rs753274	0.65	rs72998945	ENSG00000267147.2	CTC-548K16.1	-4.48	1.68e-05	0.0114	-0.46	-0.37	Tumor necrosis factor beta levels;	chr19:14307629	chr19:14333743~14343916:+
TGCT	cis	rs753274	0.65	rs7257738	ENSG00000267147.2	CTC-548K16.1	-4.48	1.68e-05	0.0114	-0.46	-0.37	Tumor necrosis factor beta levels;	chr19:14308109	chr19:14333743~14343916:+
TGCT	cis	rs34779708	0.966	rs12257770	ENSG00000230534.5	RP11-297A16.2	4.48	1.68e-05	0.0114	0.44	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35228306	chr10:35098006~35127020:-
TGCT	cis	rs7044106	0.762	rs3903886	ENSG00000238181.2	AHCYP2	4.48	1.68e-05	0.0114	0.39	0.37	Hip circumference adjusted for BMI;	chr9:120621368	chr9:120720673~120721972:+
TGCT	cis	rs875971	0.502	rs2946580	ENSG00000237310.1	GS1-124K5.4	-4.48	1.68e-05	0.0114	-0.46	-0.37	Aortic root size;	chr7:66066855	chr7:66493706~66495474:+
TGCT	cis	rs987724	0.512	rs9842198	ENSG00000240875.4	LINC00886	-4.48	1.68e-05	0.0114	-0.3	-0.37	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156821415	chr3:156747346~156817062:-
TGCT	cis	rs7829975	0.567	rs6601273	ENSG00000173295.6	FAM86B3P	-4.48	1.68e-05	0.0114	-0.44	-0.37	Mood instability;	chr8:8939009	chr8:8228595~8244865:+
TGCT	cis	rs7829975	0.606	rs7819827	ENSG00000173295.6	FAM86B3P	-4.48	1.68e-05	0.0114	-0.44	-0.37	Mood instability;	chr8:8939545	chr8:8228595~8244865:+
TGCT	cis	rs7829975	0.509	rs7838674	ENSG00000173295.6	FAM86B3P	-4.48	1.68e-05	0.0114	-0.44	-0.37	Mood instability;	chr8:8939563	chr8:8228595~8244865:+
TGCT	cis	rs7829975	0.573	rs7842359	ENSG00000173295.6	FAM86B3P	-4.48	1.68e-05	0.0114	-0.44	-0.37	Mood instability;	chr8:8939568	chr8:8228595~8244865:+
TGCT	cis	rs10256972	0.539	rs2949174	ENSG00000229043.2	AC091729.9	-4.48	1.68e-05	0.0114	-0.37	-0.37	Endometriosis;Longevity;	chr7:1174287	chr7:1160374~1165267:+
TGCT	cis	rs4713118	0.662	rs149970	ENSG00000216901.1	AL022393.7	4.48	1.69e-05	0.0115	0.45	0.37	Parkinson's disease;	chr6:28012442	chr6:28176188~28176674:+
TGCT	cis	rs11671005	0.779	rs55875034	ENSG00000268912.1	CTD-2619J13.17	-4.48	1.69e-05	0.0115	-0.49	-0.37	Mean platelet volume;	chr19:58472191	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.779	rs11670125	ENSG00000268912.1	CTD-2619J13.17	-4.48	1.69e-05	0.0115	-0.49	-0.37	Mean platelet volume;	chr19:58476023	chr19:58428632~58431148:-
TGCT	cis	rs10829156	0.607	rs7908550	ENSG00000240291.1	RP11-499P20.2	4.48	1.69e-05	0.0115	0.35	0.37	Sudden cardiac arrest;	chr10:18573282	chr10:18513115~18545651:-
TGCT	cis	rs2944755	0.723	rs11996672	ENSG00000279766.1	RP11-642A1.2	-4.48	1.69e-05	0.0115	-0.36	-0.37	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140576900	chr8:140572142~140572812:-
TGCT	cis	rs651907	0.535	rs35810977	ENSG00000244119.1	PDCL3P4	4.48	1.69e-05	0.0115	0.27	0.37	Colorectal cancer;	chr3:101812536	chr3:101712472~101713191:+
TGCT	cis	rs867371	0.929	rs7176075	ENSG00000255769.6	GOLGA2P10	-4.48	1.7e-05	0.0115	-0.4	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82472993~82513950:-
TGCT	cis	rs867371	1	rs8041868	ENSG00000255769.6	GOLGA2P10	-4.48	1.7e-05	0.0115	-0.4	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82472993~82513950:-
TGCT	cis	rs867371	1	rs8041924	ENSG00000255769.6	GOLGA2P10	-4.48	1.7e-05	0.0115	-0.4	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82472993~82513950:-
TGCT	cis	rs867371	1	rs2088858	ENSG00000255769.6	GOLGA2P10	-4.48	1.7e-05	0.0115	-0.4	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82472993~82513950:-
TGCT	cis	rs867371	1	rs4778982	ENSG00000255769.6	GOLGA2P10	-4.48	1.7e-05	0.0115	-0.4	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82472993~82513950:-
TGCT	cis	rs867371	1	rs2867579	ENSG00000255769.6	GOLGA2P10	-4.48	1.7e-05	0.0115	-0.4	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82472993~82513950:-
TGCT	cis	rs867371	1	rs881308	ENSG00000255769.6	GOLGA2P10	-4.48	1.7e-05	0.0115	-0.4	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82472993~82513950:-
TGCT	cis	rs867371	0.964	rs7169961	ENSG00000255769.6	GOLGA2P10	-4.48	1.7e-05	0.0115	-0.4	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82472993~82513950:-
TGCT	cis	rs867371	1	rs6495643	ENSG00000255769.6	GOLGA2P10	-4.48	1.7e-05	0.0115	-0.4	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82472993~82513950:-
TGCT	cis	rs10504229	0.593	rs17192845	ENSG00000253301.4	RP11-513O17.2	4.48	1.7e-05	0.0115	0.6	0.37	Developmental language disorder (linguistic errors);	chr8:57140780	chr8:57142689~57240298:+
TGCT	cis	rs786425	0.682	rs11611354	ENSG00000247373.3	RP11-486O12.2	4.48	1.7e-05	0.0115	0.47	0.37	Pubertal anthropometrics;	chr12:123669092	chr12:123575891~123585115:-
TGCT	cis	rs12143943	0.966	rs11240762	ENSG00000176754.11	LINC00303	4.48	1.7e-05	0.0115	0.32	0.37	Cognitive performance;	chr1:204597871	chr1:204032447~204041265:-
TGCT	cis	rs7804306	0.522	rs2882015	ENSG00000233264.2	AC006042.8	4.48	1.7e-05	0.0115	0.59	0.37	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8029247	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.579	rs13245462	ENSG00000233264.2	AC006042.8	4.48	1.7e-05	0.0115	0.59	0.37	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8034978	chr7:7980312~7982228:+
TGCT	cis	rs7804306	0.522	rs34261596	ENSG00000233264.2	AC006042.8	4.48	1.7e-05	0.0115	0.59	0.37	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8036054	chr7:7980312~7982228:+
TGCT	cis	rs10938353	0.638	rs6813425	ENSG00000273369.1	RP11-700J17.1	4.48	1.7e-05	0.0115	0.55	0.37	Body mass index;	chr4:44659503	chr4:44693946~44694386:-
TGCT	cis	rs10938353	0.68	rs72624165	ENSG00000273369.1	RP11-700J17.1	4.48	1.7e-05	0.0115	0.55	0.37	Body mass index;	chr4:44662457	chr4:44693946~44694386:-
TGCT	cis	rs8108269	1	rs10403962	ENSG00000241226.3	RN7SL836P	-4.48	1.7e-05	0.0115	-0.4	-0.37	Type 2 diabetes;	chr19:45657380	chr19:45651510~45651805:+
TGCT	cis	rs8108269	1	rs10404142	ENSG00000241226.3	RN7SL836P	-4.48	1.7e-05	0.0115	-0.4	-0.37	Type 2 diabetes;	chr19:45657440	chr19:45651510~45651805:+
TGCT	cis	rs8108269	0.911	rs10404527	ENSG00000241226.3	RN7SL836P	-4.48	1.7e-05	0.0115	-0.4	-0.37	Type 2 diabetes;	chr19:45657445	chr19:45651510~45651805:+
TGCT	cis	rs8108269	1	rs10409882	ENSG00000241226.3	RN7SL836P	-4.48	1.7e-05	0.0115	-0.4	-0.37	Type 2 diabetes;	chr19:45657677	chr19:45651510~45651805:+
TGCT	cis	rs8108269	1	rs8104845	ENSG00000241226.3	RN7SL836P	-4.48	1.7e-05	0.0115	-0.4	-0.37	Type 2 diabetes;	chr19:45658068	chr19:45651510~45651805:+
TGCT	cis	rs10829156	0.898	rs7095666	ENSG00000240291.1	RP11-499P20.2	-4.48	1.7e-05	0.0115	-0.33	-0.37	Sudden cardiac arrest;	chr10:18650538	chr10:18513115~18545651:-
TGCT	cis	rs796364	0.951	rs10931888	ENSG00000232732.8	AC073043.1	4.48	1.7e-05	0.0115	0.5	0.37	Schizophrenia;	chr2:200158229	chr2:199867396~199911159:-
TGCT	cis	rs9326248	0.953	rs488962	ENSG00000280143.1	AP000892.6	-4.48	1.7e-05	0.0116	-0.5	-0.37	Blood protein levels;	chr11:117201809	chr11:117204967~117210292:+
TGCT	cis	rs9462027	0.651	rs9469870	ENSG00000186328.4	RP11-140K17.2	4.48	1.71e-05	0.0116	0.35	0.37	Systemic lupus erythematosus;	chr6:34776572	chr6:34715613~34715940:+
TGCT	cis	rs11640533	0.901	rs2908790	ENSG00000262714.1	RP11-44F14.8	-4.47	1.71e-05	0.0116	-0.43	-0.37	Intelligence (multi-trait analysis);	chr16:53378249	chr16:53386944~53389085:+
TGCT	cis	rs1528149	0.504	rs10950600	ENSG00000224683.1	RPL36AP29	-4.47	1.71e-05	0.0116	-0.41	-0.37	Sitting height ratio;	chr7:16063823	chr7:16208945~16209265:+
TGCT	cis	rs1528149	0.521	rs6959719	ENSG00000224683.1	RPL36AP29	4.47	1.71e-05	0.0116	0.41	0.37	Sitting height ratio;	chr7:16064461	chr7:16208945~16209265:+
TGCT	cis	rs6782228	0.606	rs6775270	ENSG00000242551.2	POU5F1P6	-4.47	1.71e-05	0.0116	-0.45	-0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128684655	chr3:128674735~128677005:-
TGCT	cis	rs6782228	0.606	rs4857861	ENSG00000242551.2	POU5F1P6	-4.47	1.71e-05	0.0116	-0.45	-0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687924	chr3:128674735~128677005:-
TGCT	cis	rs6782228	0.606	rs4857919	ENSG00000242551.2	POU5F1P6	-4.47	1.71e-05	0.0116	-0.45	-0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128688652	chr3:128674735~128677005:-
TGCT	cis	rs453301	0.686	rs6601280	ENSG00000254340.1	RP11-10A14.3	4.47	1.71e-05	0.0116	0.38	0.37	Joint mobility (Beighton score);	chr8:9051726	chr8:9141424~9145435:+
TGCT	cis	rs8108269	0.868	rs10422601	ENSG00000241226.3	RN7SL836P	-4.47	1.71e-05	0.0116	-0.39	-0.37	Type 2 diabetes;	chr19:45656156	chr19:45651510~45651805:+
TGCT	cis	rs796364	0.806	rs11691873	ENSG00000232732.8	AC073043.1	4.47	1.71e-05	0.0116	0.53	0.37	Schizophrenia;	chr2:200101614	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs10931887	ENSG00000232732.8	AC073043.1	4.47	1.71e-05	0.0116	0.53	0.37	Schizophrenia;	chr2:200104182	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.76	rs11690371	ENSG00000232732.8	AC073043.1	4.47	1.71e-05	0.0116	0.53	0.37	Schizophrenia;	chr2:200124893	chr2:199867396~199911159:-
TGCT	cis	rs10826995	0.961	rs211271	ENSG00000239731.3	RN7SL825P	-4.47	1.72e-05	0.0116	-0.38	-0.37	Pulse pressure;	chr10:31986389	chr10:31992087~31992381:-
TGCT	cis	rs6604026	0.503	rs4847311	ENSG00000223787.2	RP4-593M8.1	-4.47	1.72e-05	0.0116	-0.49	-0.37	Multiple sclerosis;	chr1:92758297	chr1:92580476~92580821:-
TGCT	cis	rs904251	0.772	rs1224127	ENSG00000279942.1	RP1-153P14.7	-4.47	1.72e-05	0.0116	-0.47	-0.37	Cognitive performance;	chr6:37449780	chr6:37567716~37571460:+
TGCT	cis	rs4660214	0.666	rs10493087	ENSG00000182109.6	RP11-69E11.4	-4.47	1.72e-05	0.0117	-0.39	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39251584	chr1:39522280~39546187:-
TGCT	cis	rs4660214	0.666	rs11205828	ENSG00000182109.6	RP11-69E11.4	-4.47	1.72e-05	0.0117	-0.39	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39253674	chr1:39522280~39546187:-
TGCT	cis	rs801193	1	rs10252765	ENSG00000237310.1	GS1-124K5.4	4.47	1.72e-05	0.0117	0.42	0.37	Aortic root size;	chr7:66763745	chr7:66493706~66495474:+
TGCT	cis	rs1010254	0.51	rs72806351	ENSG00000253921.1	CTB-113P19.3	-4.47	1.72e-05	0.0117	-0.46	-0.37	Optic nerve measurement (cup area);	chr5:152301549	chr5:151753992~151767247:+
TGCT	cis	rs1010254	0.51	rs72806363	ENSG00000253921.1	CTB-113P19.3	-4.47	1.72e-05	0.0117	-0.46	-0.37	Optic nerve measurement (cup area);	chr5:152307408	chr5:151753992~151767247:+
TGCT	cis	rs67311347	1	rs13073003	ENSG00000223797.4	ENTPD3-AS1	-4.47	1.72e-05	0.0117	-0.39	-0.37	Renal cell carcinoma;	chr3:40462835	chr3:40313802~40453329:-
TGCT	cis	rs67311347	0.876	rs13068097	ENSG00000223797.4	ENTPD3-AS1	-4.47	1.72e-05	0.0117	-0.39	-0.37	Renal cell carcinoma;	chr3:40462933	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs6801185	ENSG00000223797.4	ENTPD3-AS1	-4.47	1.72e-05	0.0117	-0.39	-0.37	Renal cell carcinoma;	chr3:40463569	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs13095055	ENSG00000223797.4	ENTPD3-AS1	-4.47	1.72e-05	0.0117	-0.39	-0.37	Renal cell carcinoma;	chr3:40464175	chr3:40313802~40453329:-
TGCT	cis	rs67311347	0.956	rs9822870	ENSG00000223797.4	ENTPD3-AS1	-4.47	1.72e-05	0.0117	-0.39	-0.37	Renal cell carcinoma;	chr3:40473399	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs9882171	ENSG00000223797.4	ENTPD3-AS1	4.47	1.72e-05	0.0117	0.39	0.37	Renal cell carcinoma;	chr3:40477330	chr3:40313802~40453329:-
TGCT	cis	rs2177312	0.767	rs1523149	ENSG00000251129.1	RP11-734I18.1	-4.47	1.72e-05	0.0117	-0.43	-0.37	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31962066	chr4:31997397~32155406:+
TGCT	cis	rs9309473	1	rs7564890	ENSG00000163016.8	ALMS1P	4.47	1.72e-05	0.0117	0.34	0.37	Metabolite levels;	chr2:73414725	chr2:73644919~73685576:+
TGCT	cis	rs4691139	0.967	rs4588418	ENSG00000236941.6	RP11-366M4.8	4.47	1.73e-05	0.0117	0.28	0.37	Ovarian cancer in BRCA1 mutation carriers;	chr4:164981136	chr4:164948079~164949438:+
TGCT	cis	rs4691139	1	rs7692919	ENSG00000236941.6	RP11-366M4.8	4.47	1.73e-05	0.0117	0.28	0.37	Ovarian cancer in BRCA1 mutation carriers;	chr4:164981629	chr4:164948079~164949438:+
TGCT	cis	rs4691139	1	rs1914859	ENSG00000236941.6	RP11-366M4.8	4.47	1.73e-05	0.0117	0.28	0.37	Ovarian cancer in BRCA1 mutation carriers;	chr4:164984989	chr4:164948079~164949438:+
TGCT	cis	rs4691139	1	rs6855591	ENSG00000236941.6	RP11-366M4.8	4.47	1.73e-05	0.0117	0.28	0.37	Ovarian cancer in BRCA1 mutation carriers;	chr4:164985571	chr4:164948079~164949438:+
TGCT	cis	rs4691139	1	rs12498808	ENSG00000236941.6	RP11-366M4.8	4.47	1.73e-05	0.0117	0.28	0.37	Ovarian cancer in BRCA1 mutation carriers;	chr4:164985753	chr4:164948079~164949438:+
TGCT	cis	rs2439831	0.85	rs68079546	ENSG00000205771.5	CATSPER2P1	-4.47	1.73e-05	0.0117	-0.63	-0.37	Lung cancer in ever smokers;	chr15:43844759	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs56909447	ENSG00000205771.5	CATSPER2P1	-4.47	1.73e-05	0.0117	-0.63	-0.37	Lung cancer in ever smokers;	chr15:43845420	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs28476182	ENSG00000205771.5	CATSPER2P1	-4.47	1.73e-05	0.0117	-0.63	-0.37	Lung cancer in ever smokers;	chr15:43847445	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs28696802	ENSG00000205771.5	CATSPER2P1	-4.47	1.73e-05	0.0117	-0.63	-0.37	Lung cancer in ever smokers;	chr15:43848197	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs28413704	ENSG00000205771.5	CATSPER2P1	-4.47	1.73e-05	0.0117	-0.63	-0.37	Lung cancer in ever smokers;	chr15:43856229	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs16977798	ENSG00000205771.5	CATSPER2P1	-4.47	1.73e-05	0.0117	-0.63	-0.37	Lung cancer in ever smokers;	chr15:43859750	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.702	rs9989313	ENSG00000205771.5	CATSPER2P1	-4.47	1.73e-05	0.0117	-0.63	-0.37	Lung cancer in ever smokers;	chr15:43860619	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs28858500	ENSG00000205771.5	CATSPER2P1	-4.47	1.73e-05	0.0117	-0.63	-0.37	Lung cancer in ever smokers;	chr15:43864744	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs61390361	ENSG00000205771.5	CATSPER2P1	-4.47	1.73e-05	0.0117	-0.63	-0.37	Lung cancer in ever smokers;	chr15:43867644	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs11856795	ENSG00000205771.5	CATSPER2P1	-4.47	1.73e-05	0.0117	-0.63	-0.37	Lung cancer in ever smokers;	chr15:43868384	chr15:43726918~43747094:-
TGCT	cis	rs2033711	0.87	rs1465789	ENSG00000269473.1	CTD-2619J13.19	4.47	1.73e-05	0.0117	0.3	0.37	Uric acid clearance;	chr19:58434689	chr19:58440448~58445849:+
TGCT	cis	rs11671005	0.735	rs56292587	ENSG00000232098.3	CTD-2619J13.14	-4.47	1.73e-05	0.0117	-0.42	-0.37	Mean platelet volume;	chr19:58407699	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.735	rs56290606	ENSG00000232098.3	CTD-2619J13.14	-4.47	1.73e-05	0.0117	-0.42	-0.37	Mean platelet volume;	chr19:58407953	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.651	rs11878203	ENSG00000232098.3	CTD-2619J13.14	-4.47	1.73e-05	0.0117	-0.42	-0.37	Mean platelet volume;	chr19:58408683	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.735	rs11878198	ENSG00000232098.3	CTD-2619J13.14	-4.47	1.73e-05	0.0117	-0.42	-0.37	Mean platelet volume;	chr19:58408935	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.735	rs11666716	ENSG00000232098.3	CTD-2619J13.14	-4.47	1.73e-05	0.0117	-0.42	-0.37	Mean platelet volume;	chr19:58409585	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.735	rs34511020	ENSG00000232098.3	CTD-2619J13.14	-4.47	1.73e-05	0.0117	-0.42	-0.37	Mean platelet volume;	chr19:58409929	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.735	rs11666303	ENSG00000232098.3	CTD-2619J13.14	-4.47	1.73e-05	0.0117	-0.42	-0.37	Mean platelet volume;	chr19:58411135	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.735	rs34152946	ENSG00000232098.3	CTD-2619J13.14	-4.47	1.73e-05	0.0117	-0.42	-0.37	Mean platelet volume;	chr19:58411896	chr19:58404238~58408484:-
TGCT	cis	rs7829975	0.807	rs519019	ENSG00000173295.6	FAM86B3P	-4.47	1.73e-05	0.0117	-0.46	-0.37	Mood instability;	chr8:8737594	chr8:8228595~8244865:+
TGCT	cis	rs8059260	0.866	rs12922318	ENSG00000274038.1	RP11-66H6.4	-4.47	1.73e-05	0.0117	-0.42	-0.37	Alcohol consumption over the past year;	chr16:10946769	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.668	rs75637865	ENSG00000274038.1	RP11-66H6.4	-4.47	1.73e-05	0.0117	-0.53	-0.37	Alcohol consumption over the past year;	chr16:10982439	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.736	rs7202408	ENSG00000274038.1	RP11-66H6.4	-4.47	1.73e-05	0.0117	-0.53	-0.37	Alcohol consumption over the past year;	chr16:10984758	chr16:11056556~11057034:+
TGCT	cis	rs1707322	0.686	rs1084086	ENSG00000280836.1	AL355480.1	4.47	1.74e-05	0.0117	0.54	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45581219~45581321:-
TGCT	cis	rs7819412	0.502	rs11777918	ENSG00000255310.2	AF131215.2	4.47	1.74e-05	0.0117	0.32	0.37	Triglycerides;	chr8:11179410	chr8:11107788~11109726:-
TGCT	cis	rs75422866	0.867	rs73111258	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47597313	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs117388682	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47599713	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs79113930	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47600628	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs35044089	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47610881	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs78912815	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47612065	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs73113117	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47617299	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs73113139	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47622826	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs73113143	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47623060	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.717	rs73113159	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47631318	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.717	rs73113161	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47632361	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs117022227	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47633282	chr12:47731908~47732351:+
TGCT	cis	rs75422866	1	rs73102120	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47637280	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs73102125	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47637869	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs12426849	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47638975	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs117950951	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47639794	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs7954764	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47641136	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs12422974	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47644559	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs73102127	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47645341	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs73102140	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47647497	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs73102148	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47648013	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs73102151	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47648023	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs75568526	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47649718	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs116302411	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47649788	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs73102166	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47653769	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs73102168	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47654010	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs73102171	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47656077	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs76100981	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47660092	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs73102188	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47662993	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs73102195	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47666309	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs73102201	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47669269	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs73104103	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47669604	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs73104104	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47671986	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs73104111	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47673994	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs73104115	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47684843	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs73104116	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47685023	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs73104138	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47692302	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.717	rs73104143	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47693449	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs73104144	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47694390	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs73104148	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47696732	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs73104152	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47699091	chr12:47731908~47732351:+
TGCT	cis	rs75422866	0.867	rs73104155	ENSG00000274902.1	RP1-197B17.4	4.47	1.74e-05	0.0117	0.7	0.37	Pneumonia;	chr12:47700790	chr12:47731908~47732351:+
TGCT	cis	rs7684253	0.587	rs4339274	ENSG00000269949.1	RP11-738E22.3	4.47	1.74e-05	0.0117	0.38	0.37	Migraine;	chr4:56881468	chr4:56960927~56961373:-
TGCT	cis	rs8108269	0.956	rs8107527	ENSG00000241226.3	RN7SL836P	-4.47	1.74e-05	0.0117	-0.39	-0.37	Type 2 diabetes;	chr19:45655159	chr19:45651510~45651805:+
TGCT	cis	rs8108269	1	rs8107236	ENSG00000241226.3	RN7SL836P	-4.47	1.74e-05	0.0117	-0.39	-0.37	Type 2 diabetes;	chr19:45655178	chr19:45651510~45651805:+
TGCT	cis	rs11157436	1	rs11157436	ENSG00000211813.2	TRAV34	-4.47	1.74e-05	0.0117	-0.4	-0.37	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22168978	chr14:22207522~22208129:+
TGCT	cis	rs4691139	0.901	rs9762579	ENSG00000236941.6	RP11-366M4.8	4.47	1.74e-05	0.0117	0.29	0.37	Ovarian cancer in BRCA1 mutation carriers;	chr4:164956838	chr4:164948079~164949438:+
TGCT	cis	rs12745968	0.532	rs10874724	ENSG00000223787.2	RP4-593M8.1	-4.47	1.74e-05	0.0117	-0.5	-0.37	Bipolar disorder and schizophrenia;	chr1:92622626	chr1:92580476~92580821:-
TGCT	cis	rs12745968	0.589	rs10874725	ENSG00000223787.2	RP4-593M8.1	-4.47	1.74e-05	0.0117	-0.5	-0.37	Bipolar disorder and schizophrenia;	chr1:92625293	chr1:92580476~92580821:-
TGCT	cis	rs786425	0.682	rs7302788	ENSG00000247373.3	RP11-486O12.2	4.47	1.74e-05	0.0117	0.47	0.37	Pubertal anthropometrics;	chr12:123682474	chr12:123575891~123585115:-
TGCT	cis	rs10971721	0.658	rs55656643	ENSG00000230074.1	RP11-195F19.9	-4.47	1.74e-05	0.0117	-0.54	-0.37	Body mass index;	chr9:34058497	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.543	rs72729378	ENSG00000230074.1	RP11-195F19.9	-4.47	1.74e-05	0.0117	-0.54	-0.37	Body mass index;	chr9:34059927	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.631	rs117965906	ENSG00000230074.1	RP11-195F19.9	-4.47	1.74e-05	0.0117	-0.54	-0.37	Body mass index;	chr9:34063843	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.631	rs55943129	ENSG00000230074.1	RP11-195F19.9	-4.47	1.74e-05	0.0117	-0.54	-0.37	Body mass index;	chr9:34064796	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.631	rs72729385	ENSG00000230074.1	RP11-195F19.9	-4.47	1.74e-05	0.0117	-0.54	-0.37	Body mass index;	chr9:34065401	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.631	rs10971882	ENSG00000230074.1	RP11-195F19.9	-4.47	1.74e-05	0.0117	-0.54	-0.37	Body mass index;	chr9:34066186	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.631	rs10971883	ENSG00000230074.1	RP11-195F19.9	-4.47	1.74e-05	0.0117	-0.54	-0.37	Body mass index;	chr9:34066487	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.631	rs56278960	ENSG00000230074.1	RP11-195F19.9	-4.47	1.74e-05	0.0117	-0.54	-0.37	Body mass index;	chr9:34073416	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.631	rs10971891	ENSG00000230074.1	RP11-195F19.9	-4.47	1.74e-05	0.0117	-0.54	-0.37	Body mass index;	chr9:34076593	chr9:34665665~34681298:+
TGCT	cis	rs10826995	0.922	rs112978277	ENSG00000239731.3	RN7SL825P	-4.47	1.74e-05	0.0117	-0.37	-0.37	Pulse pressure;	chr10:31901178	chr10:31992087~31992381:-
TGCT	cis	rs1010254	0.51	rs72806361	ENSG00000253921.1	CTB-113P19.3	-4.47	1.74e-05	0.0117	-0.47	-0.37	Optic nerve measurement (cup area);	chr5:152305599	chr5:151753992~151767247:+
TGCT	cis	rs10256972	0.732	rs12701856	ENSG00000226291.1	AC091729.8	-4.47	1.74e-05	0.0117	-0.4	-0.37	Endometriosis;Longevity;	chr7:1068071	chr7:1080863~1082178:+
TGCT	cis	rs2717559	0.522	rs2585160	ENSG00000253196.1	RP11-706C16.7	4.47	1.75e-05	0.0118	0.38	0.37	Urinary tract infection frequency;	chr8:142793788	chr8:142763116~142766427:+
TGCT	cis	rs9322193	0.847	rs868375	ENSG00000231760.4	RP11-350J20.5	4.47	1.75e-05	0.0118	0.46	0.37	Lung cancer;	chr6:149844905	chr6:149796151~149826294:-
TGCT	cis	rs10826995	0.961	rs11595082	ENSG00000239731.3	RN7SL825P	-4.47	1.75e-05	0.0118	-0.37	-0.37	Pulse pressure;	chr10:31885166	chr10:31992087~31992381:-
TGCT	cis	rs10875976	0.507	rs4898539	ENSG00000242041.1	RP11-70F11.2	4.47	1.75e-05	0.0118	0.33	0.37	Obesity;	chr12:49858127	chr12:49863173~49863503:+
TGCT	cis	rs875971	0.522	rs2949690	ENSG00000272831.1	RP11-792A8.4	-4.47	1.75e-05	0.0118	-0.39	-0.37	Aortic root size;	chr7:66018255	chr7:66739829~66740385:-
TGCT	cis	rs9400467	0.506	rs12214933	ENSG00000272356.1	RP5-1112D6.8	-4.47	1.75e-05	0.0118	-0.44	-0.37	Amino acid levels;Blood metabolite levels;	chr6:111236803	chr6:111309203~111313517:+
TGCT	cis	rs9309473	1	rs6755217	ENSG00000163016.8	ALMS1P	4.47	1.75e-05	0.0118	0.34	0.37	Metabolite levels;	chr2:73414157	chr2:73644919~73685576:+
TGCT	cis	rs7829975	0.742	rs1533058	ENSG00000254340.1	RP11-10A14.3	4.47	1.75e-05	0.0118	0.37	0.37	Mood instability;	chr8:8827680	chr8:9141424~9145435:+
TGCT	cis	rs10256972	0.758	rs11979275	ENSG00000226291.1	AC091729.8	-4.47	1.75e-05	0.0118	-0.4	-0.37	Endometriosis;Longevity;	chr7:1029699	chr7:1080863~1082178:+
TGCT	cis	rs10256972	0.758	rs11980081	ENSG00000226291.1	AC091729.8	-4.47	1.75e-05	0.0118	-0.4	-0.37	Endometriosis;Longevity;	chr7:1029736	chr7:1080863~1082178:+
TGCT	cis	rs10256972	0.758	rs4723649	ENSG00000226291.1	AC091729.8	-4.47	1.75e-05	0.0118	-0.4	-0.37	Endometriosis;Longevity;	chr7:1032269	chr7:1080863~1082178:+
TGCT	cis	rs10256972	0.721	rs4720249	ENSG00000226291.1	AC091729.8	-4.47	1.75e-05	0.0118	-0.4	-0.37	Endometriosis;Longevity;	chr7:1032927	chr7:1080863~1082178:+
TGCT	cis	rs34217772	0.699	rs12435301	ENSG00000258536.1	RP11-1053O12.1	4.47	1.75e-05	0.0118	0.31	0.37	Myopia;	chr14:41829190	chr14:41742639~41742963:+
TGCT	cis	rs904251	0.704	rs2776873	ENSG00000204110.6	RP1-153P14.8	-4.47	1.75e-05	0.0118	-0.46	-0.37	Cognitive performance;	chr6:37515366	chr6:37507348~37535616:+
TGCT	cis	rs73086581	0.617	rs2300213	ENSG00000229539.1	RP11-119B16.2	-4.47	1.76e-05	0.0118	-0.49	-0.37	Response to antidepressants in depression;	chr20:4006076	chr20:3888239~3888868:-
TGCT	cis	rs1823913	0.637	rs4853584	ENSG00000227542.1	AC092614.2	-4.47	1.76e-05	0.0118	-0.4	-0.37	Obesity-related traits;	chr2:191310596	chr2:191229165~191246172:-
TGCT	cis	rs12143943	0.866	rs10458588	ENSG00000176754.11	LINC00303	4.47	1.76e-05	0.0118	0.35	0.37	Cognitive performance;	chr1:204536359	chr1:204032447~204041265:-
TGCT	cis	rs12143943	0.866	rs4252713	ENSG00000176754.11	LINC00303	4.47	1.76e-05	0.0118	0.35	0.37	Cognitive performance;	chr1:204541400	chr1:204032447~204041265:-
TGCT	cis	rs732716	0.719	rs56088814	ENSG00000267769.1	CTB-50L17.9	-4.47	1.76e-05	0.0119	-0.42	-0.37	Mean corpuscular volume;	chr19:4422181	chr19:4454014~4455286:+
TGCT	cis	rs17711722	0.727	rs2658585	ENSG00000272831.1	RP11-792A8.4	4.47	1.76e-05	0.0119	0.39	0.37	Calcium levels;	chr7:65996954	chr7:66739829~66740385:-
TGCT	cis	rs2087017	0.747	rs9817063	ENSG00000273394.1	RP11-255E6.6	4.47	1.76e-05	0.0119	0.31	0.37	Personality dimensions;	chr3:114128261	chr3:113947005~113947570:-
TGCT	cis	rs2087017	0.747	rs7632193	ENSG00000273394.1	RP11-255E6.6	4.47	1.76e-05	0.0119	0.31	0.37	Personality dimensions;	chr3:114129346	chr3:113947005~113947570:-
TGCT	cis	rs2087017	0.68	rs9845417	ENSG00000273394.1	RP11-255E6.6	4.47	1.76e-05	0.0119	0.31	0.37	Personality dimensions;	chr3:114130264	chr3:113947005~113947570:-
TGCT	cis	rs997154	1	rs997154	ENSG00000279656.1	RP11-298I3.6	-4.47	1.77e-05	0.0119	-0.66	-0.37	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22995273	chr14:23023083~23024217:-
TGCT	cis	rs1823913	0.599	rs34840299	ENSG00000227542.1	AC092614.2	4.47	1.77e-05	0.0119	0.4	0.37	Obesity-related traits;	chr2:191280379	chr2:191229165~191246172:-
TGCT	cis	rs651907	0.514	rs34301719	ENSG00000244119.1	PDCL3P4	4.47	1.77e-05	0.0119	0.28	0.37	Colorectal cancer;	chr3:101699149	chr3:101712472~101713191:+
TGCT	cis	rs753274	0.65	rs28497965	ENSG00000267147.2	CTC-548K16.1	-4.47	1.77e-05	0.0119	-0.46	-0.37	Tumor necrosis factor beta levels;	chr19:14306590	chr19:14333743~14343916:+
TGCT	cis	rs2764208	0.77	rs112283401	ENSG00000186328.4	RP11-140K17.2	4.47	1.77e-05	0.0119	0.36	0.37	Systemic lupus erythematosus;	chr6:34829979	chr6:34715613~34715940:+
TGCT	cis	rs786425	0.899	rs908373	ENSG00000247373.3	RP11-486O12.2	4.47	1.77e-05	0.0119	0.45	0.37	Pubertal anthropometrics;	chr12:123628772	chr12:123575891~123585115:-
TGCT	cis	rs2019137	0.901	rs4849176	ENSG00000189223.12	PAX8-AS1	4.47	1.77e-05	0.0119	0.46	0.37	Lymphocyte counts;	chr2:113220359	chr2:113211522~113276581:+
TGCT	cis	rs34375054	0.553	rs12580221	ENSG00000279233.1	RP11-158L12.4	4.47	1.77e-05	0.0119	0.39	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125136520	chr12:125138245~125141711:+
TGCT	cis	rs1618992	0.729	rs28664001	ENSG00000265994.1	RP11-510D21.1	4.47	1.77e-05	0.0119	0.38	0.37	Gut microbiome composition (summer and winter);	chr18:28604455	chr18:28785068~28789260:+
TGCT	cis	rs6568686	0.527	rs174407	ENSG00000272356.1	RP5-1112D6.8	-4.47	1.77e-05	0.0119	-0.44	-0.37	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111610484	chr6:111309203~111313517:+
TGCT	cis	rs9322193	0.923	rs12174035	ENSG00000216906.2	RP11-350J20.9	4.47	1.77e-05	0.0119	0.42	0.37	Lung cancer;	chr6:149763311	chr6:149904243~149906418:+
TGCT	cis	rs9959491	0.56	rs11873565	ENSG00000227279.1	AC015933.2	4.47	1.77e-05	0.0119	0.41	0.37	Breast cancer;	chr18:27810954	chr18:27954519~27963687:+
TGCT	cis	rs9322193	0.516	rs1999632	ENSG00000216906.2	RP11-350J20.9	4.47	1.78e-05	0.0119	0.49	0.37	Lung cancer;	chr6:149866737	chr6:149904243~149906418:+
TGCT	cis	rs2717559	0.522	rs10956987	ENSG00000253196.1	RP11-706C16.7	-4.46	1.78e-05	0.012	-0.39	-0.37	Urinary tract infection frequency;	chr8:142805197	chr8:142763116~142766427:+
TGCT	cis	rs7824557	0.564	rs13260727	ENSG00000255310.2	AF131215.2	4.46	1.78e-05	0.012	0.29	0.37	Retinal vascular caliber;	chr8:11375351	chr8:11107788~11109726:-
TGCT	cis	rs10971721	0.584	rs10971900	ENSG00000230074.1	RP11-195F19.9	-4.46	1.78e-05	0.012	-0.55	-0.37	Body mass index;	chr9:34085079	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.584	rs10971901	ENSG00000230074.1	RP11-195F19.9	-4.46	1.78e-05	0.012	-0.55	-0.37	Body mass index;	chr9:34085149	chr9:34665665~34681298:+
TGCT	cis	rs1519814	0.696	rs7386139	ENSG00000254343.2	RP11-760H22.2	-4.46	1.78e-05	0.012	-0.61	-0.37	Breast cancer;	chr8:120015180	chr8:120052180~120056201:+
TGCT	cis	rs9755467	0.665	rs59008549	ENSG00000221413.1	AC023593.1	4.46	1.79e-05	0.012	0.58	0.37	Educational attainment (years of education);	chr3:127472592	chr3:127664704~127664810:+
TGCT	cis	rs9755467	0.665	rs67235138	ENSG00000221413.1	AC023593.1	4.46	1.79e-05	0.012	0.58	0.37	Educational attainment (years of education);	chr3:127473009	chr3:127664704~127664810:+
TGCT	cis	rs899997	0.954	rs4887091	ENSG00000261143.1	ADAMTS7P3	4.46	1.79e-05	0.012	0.44	0.37	Coronary artery disease or large artery stroke;	chr15:78751238	chr15:77976042~77993057:+
TGCT	cis	rs899997	1	rs11632672	ENSG00000261143.1	ADAMTS7P3	4.46	1.79e-05	0.012	0.44	0.37	Coronary artery disease or large artery stroke;	chr15:78751988	chr15:77976042~77993057:+
TGCT	cis	rs899997	1	rs7182993	ENSG00000261143.1	ADAMTS7P3	4.46	1.79e-05	0.012	0.44	0.37	Coronary artery disease or large artery stroke;	chr15:78752672	chr15:77976042~77993057:+
TGCT	cis	rs899997	1	rs7182694	ENSG00000261143.1	ADAMTS7P3	4.46	1.79e-05	0.012	0.44	0.37	Coronary artery disease or large artery stroke;	chr15:78752688	chr15:77976042~77993057:+
TGCT	cis	rs9660180	0.967	rs61422524	ENSG00000231050.1	RP1-140A9.1	4.46	1.79e-05	0.012	0.34	0.37	Body mass index;	chr1:1836126	chr1:1891471~1892658:+
TGCT	cis	rs10044254	1	rs34352554	ENSG00000246214.1	RP11-260E18.1	-4.46	1.79e-05	0.012	-0.62	-0.37	Asthma (corticosteroid response);	chr5:15786690	chr5:16615926~16629969:+
TGCT	cis	rs7208859	0.573	rs8078182	ENSG00000266490.1	CTD-2349P21.9	4.46	1.79e-05	0.012	0.42	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30792372~30792833:+
TGCT	cis	rs10246939	0.505	rs6967189	ENSG00000228775.6	WEE2-AS1	4.46	1.79e-05	0.012	0.35	0.37	Bitter taste perception;	chr7:141826220	chr7:141704338~141738346:-
TGCT	cis	rs12550646	0.652	rs12680139	ENSG00000253943.1	KRT18P37	4.46	1.8e-05	0.0121	0.41	0.37	Reticulocyte fraction of red cells;Reticulocyte count;	chr8:41808837	chr8:41511240~41512521:+
TGCT	cis	rs2739330	0.76	rs5751761	ENSG00000235689.1	AP000351.13	-4.46	1.8e-05	0.0121	-0.35	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:24006305~24008258:-
TGCT	cis	rs7617773	0.539	rs13082217	ENSG00000229759.1	MRPS18AP1	4.46	1.8e-05	0.0121	0.3	0.37	Coronary artery disease;	chr3:48341774	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.539	rs11706939	ENSG00000229759.1	MRPS18AP1	4.46	1.8e-05	0.0121	0.3	0.37	Coronary artery disease;	chr3:48342502	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.539	rs11130165	ENSG00000229759.1	MRPS18AP1	4.46	1.8e-05	0.0121	0.3	0.37	Coronary artery disease;	chr3:48343231	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.539	rs1471217	ENSG00000229759.1	MRPS18AP1	4.46	1.8e-05	0.0121	0.3	0.37	Coronary artery disease;	chr3:48343405	chr3:48256350~48256938:-
TGCT	cis	rs4835473	0.8	rs1849117	ENSG00000251600.4	RP11-673E1.1	4.46	1.81e-05	0.0121	0.39	0.37	Immature fraction of reticulocytes;	chr4:143989791	chr4:143912331~143982454:+
TGCT	cis	rs12745968	0.589	rs3936944	ENSG00000223787.2	RP4-593M8.1	-4.46	1.81e-05	0.0121	-0.49	-0.37	Bipolar disorder and schizophrenia;	chr1:92641401	chr1:92580476~92580821:-
TGCT	cis	rs9807989	0.507	rs2293224	ENSG00000234389.1	AC007278.3	4.46	1.81e-05	0.0121	0.28	0.37	Asthma;	chr2:102419319	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs6743516	ENSG00000234389.1	AC007278.3	4.46	1.81e-05	0.0121	0.28	0.37	Asthma;	chr2:102419875	chr2:102438713~102440475:+
TGCT	cis	rs4988958	0.565	rs1420100	ENSG00000234389.1	AC007278.3	4.46	1.81e-05	0.0121	0.28	0.37	Asthma (childhood onset);	chr2:102420542	chr2:102438713~102440475:+
TGCT	cis	rs4988958	0.527	rs3771155	ENSG00000234389.1	AC007278.3	4.46	1.81e-05	0.0121	0.28	0.37	Asthma (childhood onset);	chr2:102421366	chr2:102438713~102440475:+
TGCT	cis	rs4988958	0.565	rs10206291	ENSG00000234389.1	AC007278.3	4.46	1.81e-05	0.0121	0.28	0.37	Asthma (childhood onset);	chr2:102422403	chr2:102438713~102440475:+
TGCT	cis	rs9309473	1	rs6705489	ENSG00000163016.8	ALMS1P	4.46	1.81e-05	0.0121	0.34	0.37	Metabolite levels;	chr2:73421683	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs10190219	ENSG00000163016.8	ALMS1P	4.46	1.81e-05	0.0121	0.34	0.37	Metabolite levels;	chr2:73431203	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs13398956	ENSG00000163016.8	ALMS1P	4.46	1.81e-05	0.0121	0.34	0.37	Metabolite levels;	chr2:73493131	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs56154726	ENSG00000163016.8	ALMS1P	4.46	1.81e-05	0.0121	0.34	0.37	Metabolite levels;	chr2:73494640	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.95	rs10178678	ENSG00000163016.8	ALMS1P	4.46	1.81e-05	0.0121	0.34	0.37	Metabolite levels;	chr2:73535109	chr2:73644919~73685576:+
TGCT	cis	rs8050896	1	rs7205730	ENSG00000259847.1	RP11-95H3.1	-4.46	1.81e-05	0.0121	-0.58	-0.37	Response to antipsychotic treatment;	chr16:66127140	chr16:65141756~65176713:-
TGCT	cis	rs8050896	1	rs6499064	ENSG00000259847.1	RP11-95H3.1	-4.46	1.81e-05	0.0121	-0.58	-0.37	Response to antipsychotic treatment;	chr16:66127526	chr16:65141756~65176713:-
TGCT	cis	rs11671005	0.695	rs8106061	ENSG00000232098.3	CTD-2619J13.14	-4.46	1.81e-05	0.0121	-0.42	-0.37	Mean platelet volume;	chr19:58406623	chr19:58404238~58408484:-
TGCT	cis	rs9309473	1	rs7594511	ENSG00000163016.8	ALMS1P	4.46	1.81e-05	0.0121	0.34	0.37	Metabolite levels;	chr2:73454512	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs62151652	ENSG00000163016.8	ALMS1P	4.46	1.81e-05	0.0121	0.34	0.37	Metabolite levels;	chr2:73473004	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs13421462	ENSG00000163016.8	ALMS1P	4.46	1.81e-05	0.0121	0.34	0.37	Metabolite levels;	chr2:73492748	chr2:73644919~73685576:+
TGCT	cis	rs875971	0.54	rs1723268	ENSG00000272831.1	RP11-792A8.4	4.46	1.81e-05	0.0121	0.39	0.37	Aortic root size;	chr7:66008093	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.522	rs1701760	ENSG00000272831.1	RP11-792A8.4	4.46	1.81e-05	0.0121	0.39	0.37	Aortic root size;	chr7:66008701	chr7:66739829~66740385:-
TGCT	cis	rs9807989	0.524	rs4851576	ENSG00000234389.1	AC007278.3	4.46	1.81e-05	0.0121	0.28	0.37	Asthma;	chr2:102412435	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs4851577	ENSG00000234389.1	AC007278.3	4.46	1.81e-05	0.0121	0.28	0.37	Asthma;	chr2:102412461	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs4851579	ENSG00000234389.1	AC007278.3	4.46	1.81e-05	0.0121	0.28	0.37	Asthma;	chr2:102412524	chr2:102438713~102440475:+
TGCT	cis	rs875971	0.545	rs12670811	ENSG00000237310.1	GS1-124K5.4	4.46	1.81e-05	0.0121	0.44	0.37	Aortic root size;	chr7:66358032	chr7:66493706~66495474:+
TGCT	cis	rs7429990	0.901	rs6442102	ENSG00000229759.1	MRPS18AP1	-4.46	1.81e-05	0.0121	-0.32	-0.37	Educational attainment (years of education);	chr3:48111072	chr3:48256350~48256938:-
TGCT	cis	rs7429990	0.803	rs11714518	ENSG00000229759.1	MRPS18AP1	-4.46	1.81e-05	0.0121	-0.32	-0.37	Educational attainment (years of education);	chr3:48115145	chr3:48256350~48256938:-
TGCT	cis	rs7429990	0.896	rs7427648	ENSG00000229759.1	MRPS18AP1	-4.46	1.81e-05	0.0121	-0.32	-0.37	Educational attainment (years of education);	chr3:48116749	chr3:48256350~48256938:-
TGCT	cis	rs4835473	0.932	rs62337619	ENSG00000251600.4	RP11-673E1.1	-4.46	1.81e-05	0.0121	-0.4	-0.37	Immature fraction of reticulocytes;	chr4:143742083	chr4:143912331~143982454:+
TGCT	cis	rs904251	0.523	rs914348	ENSG00000204110.6	RP1-153P14.8	-4.46	1.82e-05	0.0122	-0.39	-0.37	Cognitive performance;	chr6:37516953	chr6:37507348~37535616:+
TGCT	cis	rs1010254	0.559	rs72808310	ENSG00000253921.1	CTB-113P19.3	-4.46	1.82e-05	0.0122	-0.45	-0.37	Optic nerve measurement (cup area);	chr5:152350746	chr5:151753992~151767247:+
TGCT	cis	rs9807989	0.507	rs11465721	ENSG00000234389.1	AC007278.3	4.46	1.82e-05	0.0122	0.28	0.37	Asthma;	chr2:102446780	chr2:102438713~102440475:+
TGCT	cis	rs904251	0.523	rs10947675	ENSG00000204110.6	RP1-153P14.8	-4.46	1.82e-05	0.0122	-0.4	-0.37	Cognitive performance;	chr6:37512196	chr6:37507348~37535616:+
TGCT	cis	rs13108904	0.518	rs4974602	ENSG00000253399.1	AC078852.2	-4.46	1.83e-05	0.0122	-0.45	-0.37	Obesity-related traits;	chr4:1348603	chr4:1358479~1359461:+
TGCT	cis	rs13108904	0.56	rs11247994	ENSG00000253399.1	AC078852.2	-4.46	1.83e-05	0.0122	-0.45	-0.37	Obesity-related traits;	chr4:1349932	chr4:1358479~1359461:+
TGCT	cis	rs5769707	0.749	rs7286706	ENSG00000235111.1	RP1-29C18.8	-4.46	1.83e-05	0.0122	-0.3	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49664698	chr22:49612657~49615716:-
TGCT	cis	rs67311347	1	rs66841330	ENSG00000223797.4	ENTPD3-AS1	4.46	1.83e-05	0.0122	0.42	0.37	Renal cell carcinoma;	chr3:40489632	chr3:40313802~40453329:-
TGCT	cis	rs7684253	0.548	rs13106200	ENSG00000269949.1	RP11-738E22.3	-4.46	1.83e-05	0.0122	-0.35	-0.37	Migraine;	chr4:56852029	chr4:56960927~56961373:-
TGCT	cis	rs9807989	0.507	rs4851004	ENSG00000234389.1	AC007278.3	-4.46	1.83e-05	0.0122	-0.28	-0.37	Asthma;	chr2:102393077	chr2:102438713~102440475:+
TGCT	cis	rs4988958	0.565	rs6732138	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma (childhood onset);	chr2:102393202	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs1420096	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma;	chr2:102394452	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs1420094	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma;	chr2:102399227	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs4851571	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma;	chr2:102402540	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs4851572	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma;	chr2:102402571	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs1035129	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma;	chr2:102403325	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.524	rs2110662	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma;	chr2:102403679	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.524	rs7594402	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma;	chr2:102404807	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs6710034	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma;	chr2:102407218	chr2:102438713~102440475:+
TGCT	cis	rs4988958	0.584	rs7589142	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma (childhood onset);	chr2:102408200	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.524	rs6543126	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma;	chr2:102410644	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs10203558	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma;	chr2:102411180	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs10200952	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma;	chr2:102411191	chr2:102438713~102440475:+
TGCT	cis	rs4988958	0.548	rs6543127	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma (childhood onset);	chr2:102411841	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs1592459	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma;	chr2:102415109	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs1592458	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma;	chr2:102415289	chr2:102438713~102440475:+
TGCT	cis	rs4988958	0.565	rs1035125	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma (childhood onset);	chr2:102417379	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs2160201	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma;	chr2:102417501	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs1833174	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma;	chr2:102418383	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs1420105	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma;	chr2:102418659	chr2:102438713~102440475:+
TGCT	cis	rs4988958	0.565	rs3771154	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma (childhood onset);	chr2:102422900	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.524	rs6759479	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma;	chr2:102423587	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs6543133	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma;	chr2:102423717	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs3755266	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma;	chr2:102426252	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs2110659	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma;	chr2:102427407	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs7605284	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma;	chr2:102427715	chr2:102438713~102440475:+
TGCT	cis	rs4988958	0.584	rs12712149	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma (childhood onset);	chr2:102428733	chr2:102438713~102440475:+
TGCT	cis	rs4988958	0.584	rs7559845	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma (childhood onset);	chr2:102429754	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs6755905	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma;	chr2:102431747	chr2:102438713~102440475:+
TGCT	cis	rs4988958	0.527	rs6756161	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma (childhood onset);	chr2:102431957	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs6726985	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma;	chr2:102432120	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs2310300	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma;	chr2:102432614	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs7581119	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma;	chr2:102433405	chr2:102438713~102440475:+
TGCT	cis	rs4988958	0.565	rs3755265	ENSG00000234389.1	AC007278.3	4.46	1.83e-05	0.0122	0.28	0.37	Asthma (childhood onset);	chr2:102436356	chr2:102438713~102440475:+
TGCT	cis	rs72615157	0.645	rs76281814	ENSG00000242294.5	STAG3L5P	4.46	1.83e-05	0.0122	0.34	0.37	Lung function (FEV1/FVC);	chr7:100248791	chr7:100336079~100351900:+
TGCT	cis	rs72615157	0.595	rs112241539	ENSG00000242294.5	STAG3L5P	4.46	1.83e-05	0.0122	0.34	0.37	Lung function (FEV1/FVC);	chr7:100249614	chr7:100336079~100351900:+
TGCT	cis	rs72615157	0.561	rs113401658	ENSG00000242294.5	STAG3L5P	4.46	1.83e-05	0.0122	0.34	0.37	Lung function (FEV1/FVC);	chr7:100260882	chr7:100336079~100351900:+
TGCT	cis	rs72615157	0.561	rs113844570	ENSG00000242294.5	STAG3L5P	4.46	1.83e-05	0.0122	0.34	0.37	Lung function (FEV1/FVC);	chr7:100276155	chr7:100336079~100351900:+
TGCT	cis	rs853679	0.55	rs6901017	ENSG00000187763.3	OR2B7P	4.46	1.83e-05	0.0123	0.37	0.37	Depression;	chr6:28184805	chr6:28046434~28047367:+
TGCT	cis	rs4308124	0.708	rs6749633	ENSG00000227992.1	AC108463.2	4.46	1.84e-05	0.0123	0.39	0.37	Vitiligo;	chr2:111230439	chr2:111203964~111206215:-
TGCT	cis	rs172166	0.694	rs203884	ENSG00000219891.2	ZSCAN12P1	4.46	1.84e-05	0.0123	0.43	0.37	Cardiac Troponin-T levels;	chr6:28109596	chr6:28091154~28093664:+
TGCT	cis	rs7246967	0.611	rs73030508	ENSG00000269509.1	BNIP3P34	4.46	1.84e-05	0.0123	0.58	0.37	Bronchopulmonary dysplasia;	chr19:22643230	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs73030511	ENSG00000269509.1	BNIP3P34	4.46	1.84e-05	0.0123	0.58	0.37	Bronchopulmonary dysplasia;	chr19:22643232	chr19:22773853~22774424:+
TGCT	cis	rs911555	0.723	rs12436956	ENSG00000244691.1	RPL10AP1	4.46	1.84e-05	0.0123	0.51	0.37	Intelligence (multi-trait analysis);	chr14:103386270	chr14:103412119~103412761:-
TGCT	cis	rs10504229	0.683	rs7820559	ENSG00000253301.4	RP11-513O17.2	4.46	1.84e-05	0.0123	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57230103	chr8:57142689~57240298:+
TGCT	cis	rs73607972	0.877	rs67786703	ENSG00000275191.1	RP11-36I17.2	-4.46	1.84e-05	0.0123	-0.45	-0.37	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53572427	chr16:53628256~53628816:-
TGCT	cis	rs6568686	0.527	rs174406	ENSG00000272356.1	RP5-1112D6.8	-4.46	1.84e-05	0.0123	-0.44	-0.37	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111610125	chr6:111309203~111313517:+
TGCT	cis	rs10829156	0.732	rs1917823	ENSG00000240291.1	RP11-499P20.2	4.46	1.85e-05	0.0123	0.35	0.37	Sudden cardiac arrest;	chr10:18528184	chr10:18513115~18545651:-
TGCT	cis	rs8113308	0.572	rs7259556	ENSG00000269235.1	ZNF350-AS1	4.46	1.85e-05	0.0123	0.81	0.37	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51980967	chr19:51949134~51981367:+
TGCT	cis	rs8113308	0.572	rs7260510	ENSG00000269235.1	ZNF350-AS1	4.46	1.85e-05	0.0123	0.81	0.37	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51980968	chr19:51949134~51981367:+
TGCT	cis	rs67311347	0.955	rs11717036	ENSG00000223797.4	ENTPD3-AS1	-4.46	1.85e-05	0.0123	-0.38	-0.37	Renal cell carcinoma;	chr3:40338087	chr3:40313802~40453329:-
TGCT	cis	rs2412819	0.52	rs17727763	ENSG00000205771.5	CATSPER2P1	-4.46	1.85e-05	0.0123	-0.59	-0.37	Lung cancer;	chr15:43623873	chr15:43726918~43747094:-
TGCT	cis	rs796364	0.76	rs2881594	ENSG00000232732.8	AC073043.1	4.46	1.85e-05	0.0123	0.54	0.37	Schizophrenia;	chr2:200161460	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs11674293	ENSG00000232732.8	AC073043.1	4.46	1.85e-05	0.0123	0.54	0.37	Schizophrenia;	chr2:200162020	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.76	rs55906940	ENSG00000232732.8	AC073043.1	4.46	1.85e-05	0.0123	0.54	0.37	Schizophrenia;	chr2:200184663	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.715	rs11688872	ENSG00000232732.8	AC073043.1	4.46	1.85e-05	0.0123	0.54	0.37	Schizophrenia;	chr2:200187695	chr2:199867396~199911159:-
TGCT	cis	rs2739330	0.791	rs4822458	ENSG00000272787.1	KB-226F1.2	-4.45	1.85e-05	0.0123	-0.42	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23969211~23969873:+
TGCT	cis	rs2333021	0.649	rs12897762	ENSG00000259015.1	RP11-109N23.6	4.45	1.85e-05	0.0124	0.22	0.37	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73016212	chr14:72960595~72961993:+
TGCT	cis	rs2333021	0.611	rs12883199	ENSG00000259015.1	RP11-109N23.6	4.45	1.85e-05	0.0124	0.22	0.37	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73016459	chr14:72960595~72961993:+
TGCT	cis	rs2333021	0.562	rs12882235	ENSG00000259015.1	RP11-109N23.6	4.45	1.85e-05	0.0124	0.22	0.37	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73016574	chr14:72960595~72961993:+
TGCT	cis	rs12143943	0.934	rs1563827	ENSG00000176754.11	LINC00303	4.45	1.85e-05	0.0124	0.34	0.37	Cognitive performance;	chr1:204610011	chr1:204032447~204041265:-
TGCT	cis	rs7615952	0.551	rs6438945	ENSG00000171084.14	FAM86JP	4.45	1.85e-05	0.0124	0.66	0.37	Blood pressure (smoking interaction);	chr3:125915630	chr3:125916620~125930024:+
TGCT	cis	rs1823913	0.637	rs4853569	ENSG00000227542.1	AC092614.2	-4.45	1.85e-05	0.0124	-0.4	-0.37	Obesity-related traits;	chr2:191266970	chr2:191229165~191246172:-
TGCT	cis	rs7617773	0.539	rs17593974	ENSG00000229759.1	MRPS18AP1	4.45	1.86e-05	0.0124	0.3	0.37	Coronary artery disease;	chr3:48345844	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.514	rs11130166	ENSG00000229759.1	MRPS18AP1	4.45	1.86e-05	0.0124	0.3	0.37	Coronary artery disease;	chr3:48346566	chr3:48256350~48256938:-
TGCT	cis	rs755249	0.501	rs661316	ENSG00000182109.6	RP11-69E11.4	4.45	1.86e-05	0.0124	0.38	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39165625	chr1:39522280~39546187:-
TGCT	cis	rs11671005	0.735	rs12986387	ENSG00000232098.3	CTD-2619J13.14	-4.45	1.86e-05	0.0124	-0.42	-0.37	Mean platelet volume;	chr19:58415848	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.735	rs11667723	ENSG00000232098.3	CTD-2619J13.14	-4.45	1.86e-05	0.0124	-0.42	-0.37	Mean platelet volume;	chr19:58416122	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.693	rs11668757	ENSG00000232098.3	CTD-2619J13.14	-4.45	1.86e-05	0.0124	-0.42	-0.37	Mean platelet volume;	chr19:58416932	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.735	rs11668789	ENSG00000232098.3	CTD-2619J13.14	-4.45	1.86e-05	0.0124	-0.42	-0.37	Mean platelet volume;	chr19:58416942	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.735	rs35652377	ENSG00000232098.3	CTD-2619J13.14	-4.45	1.86e-05	0.0124	-0.42	-0.37	Mean platelet volume;	chr19:58417833	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.735	rs3764532	ENSG00000232098.3	CTD-2619J13.14	-4.45	1.86e-05	0.0124	-0.42	-0.37	Mean platelet volume;	chr19:58417855	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.735	rs3088284	ENSG00000232098.3	CTD-2619J13.14	-4.45	1.86e-05	0.0124	-0.42	-0.37	Mean platelet volume;	chr19:58418060	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.735	rs12981649	ENSG00000232098.3	CTD-2619J13.14	-4.45	1.86e-05	0.0124	-0.42	-0.37	Mean platelet volume;	chr19:58418676	chr19:58404238~58408484:-
TGCT	cis	rs2188561	0.697	rs2237679	ENSG00000241764.3	AC002467.7	4.45	1.86e-05	0.0124	0.35	0.37	Alcohol consumption;	chr7:107693581	chr7:107742817~107744581:-
TGCT	cis	rs2188561	0.697	rs2072064	ENSG00000241764.3	AC002467.7	4.45	1.86e-05	0.0124	0.35	0.37	Alcohol consumption;	chr7:107694068	chr7:107742817~107744581:-
TGCT	cis	rs2463822	0.858	rs2513037	ENSG00000254454.2	RCC2P6	4.45	1.86e-05	0.0124	0.39	0.37	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62317350	chr11:62371146~62373168:+
TGCT	cis	rs2483374	0.587	rs1029114	ENSG00000253771.4	TPTE2P1	-4.45	1.86e-05	0.0124	-0.36	-0.37	Obesity-related traits;	chr13:24916298	chr13:24924677~24968487:-
TGCT	cis	rs10829156	0.786	rs7077786	ENSG00000240291.1	RP11-499P20.2	4.45	1.86e-05	0.0124	0.34	0.37	Sudden cardiac arrest;	chr10:18603453	chr10:18513115~18545651:-
TGCT	cis	rs875971	0.54	rs736270	ENSG00000272831.1	RP11-792A8.4	4.45	1.86e-05	0.0124	0.39	0.37	Aortic root size;	chr7:65963835	chr7:66739829~66740385:-
TGCT	cis	rs9400467	0.506	rs12192147	ENSG00000272356.1	RP5-1112D6.8	-4.45	1.86e-05	0.0124	-0.42	-0.37	Amino acid levels;Blood metabolite levels;	chr6:111326854	chr6:111309203~111313517:+
TGCT	cis	rs1707322	0.662	rs11211160	ENSG00000280836.1	AL355480.1	-4.45	1.86e-05	0.0124	-0.5	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr1:45581219~45581321:-
TGCT	cis	rs10826995	0.961	rs11594899	ENSG00000239731.3	RN7SL825P	-4.45	1.86e-05	0.0124	-0.37	-0.37	Pulse pressure;	chr10:31850998	chr10:31992087~31992381:-
TGCT	cis	rs867371	1	rs1501372	ENSG00000255769.6	GOLGA2P10	-4.45	1.87e-05	0.0124	-0.4	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82472993~82513950:-
TGCT	cis	rs901683	0.557	rs34663276	ENSG00000264204.2	AGAP7P	-4.45	1.87e-05	0.0124	-0.79	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45475912	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs34661476	ENSG00000264204.2	AGAP7P	-4.45	1.87e-05	0.0124	-0.79	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45475965	chr10:46109621~46131358:+
TGCT	cis	rs796364	0.616	rs2689765	ENSG00000232732.8	AC073043.1	-4.45	1.87e-05	0.0125	-0.57	-0.37	Schizophrenia;	chr2:199831629	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.616	rs6710393	ENSG00000232732.8	AC073043.1	-4.45	1.87e-05	0.0125	-0.57	-0.37	Schizophrenia;	chr2:199832523	chr2:199867396~199911159:-
TGCT	cis	rs7923609	0.967	rs7912893	ENSG00000232075.1	MRPL35P2	-4.45	1.87e-05	0.0125	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63402240	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.967	rs7896783	ENSG00000232075.1	MRPL35P2	-4.45	1.87e-05	0.0125	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63402393	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.934	rs10761756	ENSG00000232075.1	MRPL35P2	-4.45	1.87e-05	0.0125	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63412568	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.967	rs10761758	ENSG00000232075.1	MRPL35P2	-4.45	1.87e-05	0.0125	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63412987	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.967	rs7909269	ENSG00000232075.1	MRPL35P2	-4.45	1.87e-05	0.0125	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63418006	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.967	rs10761762	ENSG00000232075.1	MRPL35P2	-4.45	1.87e-05	0.0125	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63424957	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.934	rs10761763	ENSG00000232075.1	MRPL35P2	-4.45	1.87e-05	0.0125	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63428558	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.967	rs10761766	ENSG00000232075.1	MRPL35P2	-4.45	1.87e-05	0.0125	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63430567	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.967	rs3740331	ENSG00000232075.1	MRPL35P2	-4.45	1.87e-05	0.0125	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63432528	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.967	rs3956912	ENSG00000232075.1	MRPL35P2	-4.45	1.87e-05	0.0125	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63446121	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.967	rs10509186	ENSG00000232075.1	MRPL35P2	-4.45	1.87e-05	0.0125	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63447258	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.967	rs7085621	ENSG00000232075.1	MRPL35P2	-4.45	1.87e-05	0.0125	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63449166	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.936	rs10740125	ENSG00000232075.1	MRPL35P2	-4.45	1.87e-05	0.0125	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63449849	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.967	rs10740126	ENSG00000232075.1	MRPL35P2	-4.45	1.87e-05	0.0125	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63451175	chr10:63634317~63634827:-
TGCT	cis	rs1707322	0.752	rs4586014	ENSG00000280836.1	AL355480.1	-4.45	1.87e-05	0.0125	-0.5	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr1:45581219~45581321:-
TGCT	cis	rs2117029	0.555	rs7958241	ENSG00000258017.1	RP11-386G11.10	4.45	1.87e-05	0.0125	0.49	0.37	Intelligence (multi-trait analysis);	chr12:49115479	chr12:49127782~49147869:+
TGCT	cis	rs992157	0.731	rs1399132	ENSG00000261338.2	RP11-378A13.1	4.45	1.87e-05	0.0125	0.31	0.37	Colorectal cancer;	chr2:218295047	chr2:218255319~218257366:+
TGCT	cis	rs992157	0.796	rs55680399	ENSG00000261338.2	RP11-378A13.1	4.45	1.87e-05	0.0125	0.31	0.37	Colorectal cancer;	chr2:218295898	chr2:218255319~218257366:+
TGCT	cis	rs901683	1	rs34731408	ENSG00000264204.2	AGAP7P	-4.45	1.88e-05	0.0125	-0.78	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45465572	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs17157832	ENSG00000264204.2	AGAP7P	-4.45	1.88e-05	0.0125	-0.78	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45466313	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs17157836	ENSG00000264204.2	AGAP7P	-4.45	1.88e-05	0.0125	-0.78	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45468138	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs17157839	ENSG00000264204.2	AGAP7P	-4.45	1.88e-05	0.0125	-0.78	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45468329	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71494785	ENSG00000264204.2	AGAP7P	-4.45	1.88e-05	0.0125	-0.78	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45469105	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs901682	ENSG00000264204.2	AGAP7P	-4.45	1.88e-05	0.0125	-0.78	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45470413	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs901683	ENSG00000264204.2	AGAP7P	-4.45	1.88e-05	0.0125	-0.78	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45470974	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71494786	ENSG00000264204.2	AGAP7P	-4.45	1.88e-05	0.0125	-0.78	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45474669	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs34771643	ENSG00000264204.2	AGAP7P	-4.45	1.88e-05	0.0125	-0.78	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45475184	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs34937315	ENSG00000264204.2	AGAP7P	-4.45	1.88e-05	0.0125	-0.78	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45475269	chr10:46109621~46131358:+
TGCT	cis	rs901683	0.85	rs34081552	ENSG00000264204.2	AGAP7P	-4.45	1.88e-05	0.0125	-0.78	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45475708	chr10:46109621~46131358:+
TGCT	cis	rs992157	0.965	rs13419763	ENSG00000261338.2	RP11-378A13.1	4.45	1.88e-05	0.0125	0.31	0.37	Colorectal cancer;	chr2:218270227	chr2:218255319~218257366:+
TGCT	cis	rs6782228	0.527	rs7426806	ENSG00000242551.2	POU5F1P6	-4.45	1.88e-05	0.0125	-0.45	-0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694087	chr3:128674735~128677005:-
TGCT	cis	rs6782228	0.527	rs6767383	ENSG00000242551.2	POU5F1P6	-4.45	1.88e-05	0.0125	-0.45	-0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694744	chr3:128674735~128677005:-
TGCT	cis	rs6782228	0.509	rs6780447	ENSG00000242551.2	POU5F1P6	-4.45	1.88e-05	0.0125	-0.45	-0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694965	chr3:128674735~128677005:-
TGCT	cis	rs6782228	0.585	rs6774515	ENSG00000242551.2	POU5F1P6	-4.45	1.88e-05	0.0125	-0.45	-0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128697035	chr3:128674735~128677005:-
TGCT	cis	rs6782228	0.565	rs12695509	ENSG00000242551.2	POU5F1P6	-4.45	1.88e-05	0.0125	-0.45	-0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128698201	chr3:128674735~128677005:-
TGCT	cis	rs875971	0.522	rs2008188	ENSG00000272831.1	RP11-792A8.4	4.45	1.88e-05	0.0125	0.39	0.37	Aortic root size;	chr7:65964026	chr7:66739829~66740385:-
TGCT	cis	rs17711722	0.727	rs1880555	ENSG00000272831.1	RP11-792A8.4	4.45	1.88e-05	0.0125	0.39	0.37	Calcium levels;	chr7:65967580	chr7:66739829~66740385:-
TGCT	cis	rs17711722	0.701	rs781143	ENSG00000272831.1	RP11-792A8.4	4.45	1.88e-05	0.0125	0.39	0.37	Calcium levels;	chr7:65974892	chr7:66739829~66740385:-
TGCT	cis	rs17711722	0.701	rs781145	ENSG00000272831.1	RP11-792A8.4	4.45	1.88e-05	0.0125	0.39	0.37	Calcium levels;	chr7:65975383	chr7:66739829~66740385:-
TGCT	cis	rs877819	0.583	rs2663020	ENSG00000228403.1	RP11-563N6.6	-4.45	1.88e-05	0.0125	-0.39	-0.37	Systemic lupus erythematosus;	chr10:48868229	chr10:48878022~48878649:+
TGCT	cis	rs2708377	0.932	rs2257110	ENSG00000256019.1	TAS2R63P	4.45	1.88e-05	0.0125	0.49	0.37	Bitter taste perception;	chr12:11049923	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.929	rs1817043	ENSG00000256019.1	TAS2R63P	4.45	1.88e-05	0.0125	0.49	0.37	Bitter taste perception;	chr12:11063253	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.929	rs2255418	ENSG00000256019.1	TAS2R63P	4.45	1.88e-05	0.0125	0.49	0.37	Bitter taste perception;	chr12:11064373	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.929	rs2599415	ENSG00000256019.1	TAS2R63P	4.45	1.88e-05	0.0125	0.49	0.37	Bitter taste perception;	chr12:11064638	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.86	rs2597975	ENSG00000256019.1	TAS2R63P	4.45	1.88e-05	0.0125	0.49	0.37	Bitter taste perception;	chr12:11100198	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.929	rs2597974	ENSG00000256019.1	TAS2R63P	4.45	1.88e-05	0.0125	0.49	0.37	Bitter taste perception;	chr12:11100246	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.929	rs2600340	ENSG00000256019.1	TAS2R63P	4.45	1.88e-05	0.0125	0.49	0.37	Bitter taste perception;	chr12:11108990	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.86	rs2600347	ENSG00000256019.1	TAS2R63P	4.45	1.88e-05	0.0125	0.49	0.37	Bitter taste perception;	chr12:11115281	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.929	rs2708334	ENSG00000256019.1	TAS2R63P	4.45	1.88e-05	0.0125	0.49	0.37	Bitter taste perception;	chr12:11117069	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.86	rs2708336	ENSG00000256019.1	TAS2R63P	4.45	1.88e-05	0.0125	0.49	0.37	Bitter taste perception;	chr12:11120807	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.658	rs2708347	ENSG00000256019.1	TAS2R63P	4.45	1.88e-05	0.0125	0.49	0.37	Bitter taste perception;	chr12:11128893	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.858	rs2599399	ENSG00000256019.1	TAS2R63P	4.45	1.88e-05	0.0125	0.49	0.37	Bitter taste perception;	chr12:11130564	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.799	rs977474	ENSG00000256019.1	TAS2R63P	4.45	1.88e-05	0.0125	0.49	0.37	Bitter taste perception;	chr12:11132173	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.929	rs61931269	ENSG00000256019.1	TAS2R63P	4.45	1.88e-05	0.0125	0.49	0.37	Bitter taste perception;	chr12:11143819	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.929	rs7487324	ENSG00000256019.1	TAS2R63P	4.45	1.88e-05	0.0125	0.49	0.37	Bitter taste perception;	chr12:11146619	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.929	rs61931280	ENSG00000256019.1	TAS2R63P	4.45	1.88e-05	0.0125	0.49	0.37	Bitter taste perception;	chr12:11147656	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.929	rs61928567	ENSG00000256019.1	TAS2R63P	4.45	1.88e-05	0.0125	0.49	0.37	Bitter taste perception;	chr12:11151814	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.86	rs7962445	ENSG00000256019.1	TAS2R63P	4.45	1.88e-05	0.0125	0.49	0.37	Bitter taste perception;	chr12:11153245	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.858	rs4763632	ENSG00000256019.1	TAS2R63P	4.45	1.88e-05	0.0125	0.49	0.37	Bitter taste perception;	chr12:11154679	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.929	rs4763634	ENSG00000256019.1	TAS2R63P	4.45	1.88e-05	0.0125	0.49	0.37	Bitter taste perception;	chr12:11155016	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.86	rs35318883	ENSG00000256019.1	TAS2R63P	4.45	1.88e-05	0.0125	0.49	0.37	Bitter taste perception;	chr12:11157151	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.929	rs7298947	ENSG00000256019.1	TAS2R63P	4.45	1.88e-05	0.0125	0.49	0.37	Bitter taste perception;	chr12:11158560	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.799	rs7296270	ENSG00000256019.1	TAS2R63P	4.45	1.88e-05	0.0125	0.49	0.37	Bitter taste perception;	chr12:11158991	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.799	rs61928604	ENSG00000256019.1	TAS2R63P	4.45	1.88e-05	0.0125	0.49	0.37	Bitter taste perception;	chr12:11159348	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.929	rs7973298	ENSG00000256019.1	TAS2R63P	4.45	1.88e-05	0.0125	0.49	0.37	Bitter taste perception;	chr12:11161287	chr12:11048332~11049256:-
TGCT	cis	rs17507216	0.958	rs28648832	ENSG00000255769.6	GOLGA2P10	-4.45	1.88e-05	0.0125	-0.45	-0.37	Excessive daytime sleepiness;	chr15:82567642	chr15:82472993~82513950:-
TGCT	cis	rs7795991	0.534	rs6962343	ENSG00000224330.1	AC005019.3	-4.45	1.88e-05	0.0125	-0.4	-0.37	Type 2 diabetes;	chr7:13871123	chr7:13854355~13859025:-
TGCT	cis	rs67311347	1	rs9332450	ENSG00000223797.4	ENTPD3-AS1	-4.45	1.89e-05	0.0125	-0.39	-0.37	Renal cell carcinoma;	chr3:40416550	chr3:40313802~40453329:-
TGCT	cis	rs1023500	0.551	rs2854837	ENSG00000270083.1	RP1-257I20.14	4.45	1.89e-05	0.0125	0.37	0.37	Schizophrenia;	chr22:42062477	chr22:42089630~42090028:-
TGCT	cis	rs9911578	0.805	rs1811202	ENSG00000265148.4	BZRAP1-AS1	4.45	1.89e-05	0.0126	0.24	0.37	Intelligence (multi-trait analysis);	chr17:58377074	chr17:58325450~58415766:+
TGCT	cis	rs875971	0.862	rs4236208	ENSG00000232559.3	GS1-124K5.12	-4.45	1.89e-05	0.0126	-0.35	-0.37	Aortic root size;	chr7:66284091	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs10261398	ENSG00000232559.3	GS1-124K5.12	-4.45	1.89e-05	0.0126	-0.35	-0.37	Aortic root size;	chr7:66285177	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs10224872	ENSG00000232559.3	GS1-124K5.12	-4.45	1.89e-05	0.0126	-0.35	-0.37	Aortic root size;	chr7:66294786	chr7:66554588~66576923:-
TGCT	cis	rs7826238	0.543	rs2976908	ENSG00000173295.6	FAM86B3P	4.45	1.89e-05	0.0126	0.44	0.37	Systolic blood pressure;	chr8:8488264	chr8:8228595~8244865:+
TGCT	cis	rs7208859	0.673	rs216418	ENSG00000280069.1	CTD-2349P21.3	-4.45	1.89e-05	0.0126	-0.49	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30609519	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.673	rs216420	ENSG00000280069.1	CTD-2349P21.3	-4.45	1.89e-05	0.0126	-0.49	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs216423	ENSG00000280069.1	CTD-2349P21.3	-4.45	1.89e-05	0.0126	-0.49	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30738182~30740275:+
TGCT	cis	rs8059260	0.604	rs2160042	ENSG00000274038.1	RP11-66H6.4	-4.45	1.89e-05	0.0126	-0.55	-0.37	Alcohol consumption over the past year;	chr16:11064375	chr16:11056556~11057034:+
TGCT	cis	rs8070740	0.838	rs57745425	ENSG00000262227.1	RP5-1050D4.5	-4.45	1.89e-05	0.0126	-0.35	-0.37	Menopause (age at onset);	chr17:5424208	chr17:4987706~4988446:+
TGCT	cis	rs2919917	0.628	rs9298314	ENSG00000254352.1	RP11-578O24.2	4.45	1.89e-05	0.0126	0.43	0.37	Lymphocyte counts;	chr8:78660874	chr8:78723796~78724136:-
TGCT	cis	rs10504229	0.683	rs7817188	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57216990	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs7835498	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57217221	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs7816733	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57217296	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs72650839	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57217470	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs113492050	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57217487	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs56208052	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57217648	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.679	rs11783963	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57217937	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.679	rs11783965	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57217951	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.679	rs7839948	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57218048	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs7843919	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57218233	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs7822631	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57218357	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.679	rs11783444	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57218708	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs11786523	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57218760	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs11786527	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57218785	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs11784908	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57218913	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs11787247	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57218969	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.679	rs56040464	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57219044	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs56204590	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57219083	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs55807014	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57219242	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs55714371	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57219287	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.638	rs7826839	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57219516	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs7827881	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57219578	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs7827014	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57219671	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs11774585	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57220126	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs11785258	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57220334	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs11785260	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57220347	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs11781690	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57220372	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs11786043	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57220615	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs11786074	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57220973	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs11786843	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57221070	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs11775506	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57221080	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs11786845	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57221083	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs62621195	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57221405	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs61364624	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57221780	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs59679713	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57221811	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.724	rs58715581	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57222009	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs61306359	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57222087	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs58438731	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57222231	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs56192850	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57222797	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs55637580	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57222860	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs55868006	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57223144	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs56741275	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57223549	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.679	rs75402323	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57223668	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.679	rs7813252	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57223830	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs7838958	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57224409	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs55986917	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57224651	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs56408763	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57224717	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs58883273	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57225716	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs61201557	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57225811	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.645	rs56670121	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57226313	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs67077711	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57227210	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs67035623	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57227404	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs67048677	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57227464	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs67492041	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57227518	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs10504221	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57227697	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs72650849	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57227764	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs10504223	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57228385	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs1495866	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57228569	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs1495865	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57228601	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs56196593	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57229339	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs66893068	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57231679	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs949856	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57231937	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs10504225	ENSG00000253301.4	RP11-513O17.2	4.45	1.9e-05	0.0126	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57232562	chr8:57142689~57240298:+
TGCT	cis	rs12682352	0.602	rs6988939	ENSG00000253893.2	FAM85B	-4.45	1.9e-05	0.0126	-0.48	-0.37	Neuroticism;	chr8:8809406	chr8:8167819~8226614:-
TGCT	cis	rs12682352	0.602	rs6993494	ENSG00000253893.2	FAM85B	-4.45	1.9e-05	0.0126	-0.48	-0.37	Neuroticism;	chr8:8809934	chr8:8167819~8226614:-
TGCT	cis	rs13118159	0.556	rs4974615	ENSG00000254094.1	AC078852.1	4.45	1.9e-05	0.0126	0.44	0.37	Longevity;	chr4:1379763	chr4:1356581~1358075:+
TGCT	cis	rs9322193	0.923	rs9322197	ENSG00000216906.2	RP11-350J20.9	4.45	1.9e-05	0.0126	0.42	0.37	Lung cancer;	chr6:149622577	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.884	rs9688858	ENSG00000216906.2	RP11-350J20.9	4.45	1.9e-05	0.0126	0.42	0.37	Lung cancer;	chr6:149637911	chr6:149904243~149906418:+
TGCT	cis	rs7201929	1	rs11644151	ENSG00000259982.1	CDC37P1	-4.45	1.9e-05	0.0126	-0.5	-0.37	QT interval;	chr16:28884339	chr16:28700294~28701540:-
TGCT	cis	rs9918079	0.542	rs7688984	ENSG00000273133.1	RP11-799M12.2	-4.45	1.91e-05	0.0126	-0.56	-0.37	Obesity-related traits;	chr4:15655630	chr4:15563698~15564253:-
TGCT	cis	rs7829975	0.681	rs2271342	ENSG00000253893.2	FAM85B	-4.45	1.91e-05	0.0126	-0.48	-0.37	Mood instability;	chr8:8786428	chr8:8167819~8226614:-
TGCT	cis	rs7829975	0.591	rs12677543	ENSG00000253893.2	FAM85B	-4.45	1.91e-05	0.0126	-0.48	-0.37	Mood instability;	chr8:8786764	chr8:8167819~8226614:-
TGCT	cis	rs992157	0.932	rs1870125	ENSG00000261338.2	RP11-378A13.1	4.45	1.91e-05	0.0126	0.31	0.37	Colorectal cancer;	chr2:218323178	chr2:218255319~218257366:+
TGCT	cis	rs8072100	0.967	rs11871606	ENSG00000228782.6	CTD-2026D20.3	-4.45	1.91e-05	0.0126	-0.44	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655408	chr17:47450568~47492492:-
TGCT	cis	rs4794202	0.717	rs6503897	ENSG00000264920.1	RP11-6N17.4	4.45	1.91e-05	0.0126	0.42	0.37	Alzheimer's disease (cognitive decline);	chr17:47879683	chr17:47891255~47895812:-
TGCT	cis	rs10256972	0.721	rs2030959	ENSG00000226291.1	AC091729.8	-4.45	1.91e-05	0.0127	-0.4	-0.37	Endometriosis;Longevity;	chr7:1036270	chr7:1080863~1082178:+
TGCT	cis	rs12143943	0.866	rs35666383	ENSG00000176754.11	LINC00303	4.45	1.91e-05	0.0127	0.35	0.37	Cognitive performance;	chr1:204523656	chr1:204032447~204041265:-
TGCT	cis	rs12143943	0.866	rs3789051	ENSG00000176754.11	LINC00303	4.45	1.91e-05	0.0127	0.35	0.37	Cognitive performance;	chr1:204525308	chr1:204032447~204041265:-
TGCT	cis	rs12143943	0.866	rs3789052	ENSG00000176754.11	LINC00303	-4.45	1.91e-05	0.0127	-0.35	-0.37	Cognitive performance;	chr1:204525155	chr1:204032447~204041265:-
TGCT	cis	rs7208859	0.673	rs450585	ENSG00000280069.1	CTD-2349P21.3	-4.45	1.91e-05	0.0127	-0.48	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30738182~30740275:+
TGCT	cis	rs7588746	0.868	rs12104649	ENSG00000232732.8	AC073043.1	4.45	1.91e-05	0.0127	0.49	0.37	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:200264109	chr2:199867396~199911159:-
TGCT	cis	rs7429990	0.932	rs12486714	ENSG00000229759.1	MRPS18AP1	-4.45	1.91e-05	0.0127	-0.32	-0.37	Educational attainment (years of education);	chr3:48107210	chr3:48256350~48256938:-
TGCT	cis	rs7429990	0.932	rs2361684	ENSG00000229759.1	MRPS18AP1	-4.45	1.91e-05	0.0127	-0.32	-0.37	Educational attainment (years of education);	chr3:48111128	chr3:48256350~48256938:-
TGCT	cis	rs5758511	0.68	rs5758698	ENSG00000182057.4	OGFRP1	-4.45	1.91e-05	0.0127	-0.35	-0.37	Birth weight;	chr22:42288812	chr22:42269753~42275196:+
TGCT	cis	rs651907	0.557	rs34947019	ENSG00000244119.1	PDCL3P4	4.45	1.92e-05	0.0127	0.27	0.37	Colorectal cancer;	chr3:101813391	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.535	rs34743741	ENSG00000244119.1	PDCL3P4	4.45	1.92e-05	0.0127	0.27	0.37	Colorectal cancer;	chr3:101813604	chr3:101712472~101713191:+
TGCT	cis	rs651907	0.535	rs13084113	ENSG00000244119.1	PDCL3P4	4.45	1.92e-05	0.0127	0.27	0.37	Colorectal cancer;	chr3:101815195	chr3:101712472~101713191:+
TGCT	cis	rs853679	0.506	rs1150693	ENSG00000187763.3	OR2B7P	4.45	1.92e-05	0.0127	0.37	0.37	Depression;	chr6:28206812	chr6:28046434~28047367:+
TGCT	cis	rs72772090	0.539	rs11740375	ENSG00000248734.2	CTD-2260A17.1	-4.45	1.92e-05	0.0127	-0.46	-0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777193	chr5:96784777~96785999:+
TGCT	cis	rs801193	0.967	rs2707853	ENSG00000272831.1	RP11-792A8.4	4.45	1.92e-05	0.0127	0.4	0.37	Aortic root size;	chr7:66749023	chr7:66739829~66740385:-
TGCT	cis	rs801193	1	rs2659889	ENSG00000272831.1	RP11-792A8.4	4.45	1.92e-05	0.0127	0.4	0.37	Aortic root size;	chr7:66752125	chr7:66739829~66740385:-
TGCT	cis	rs786425	0.899	rs1515814	ENSG00000278112.1	RP11-972P1.11	4.45	1.92e-05	0.0127	0.41	0.37	Pubertal anthropometrics;	chr12:123624152	chr12:123519390~123519856:-
TGCT	cis	rs380904	0.552	rs10099003	ENSG00000254859.1	RP11-661A12.5	-4.45	1.92e-05	0.0127	-0.53	-0.37	Venous thromboembolism (SNP x SNP interaction);	chr8:143563290	chr8:143541973~143549729:-
TGCT	cis	rs17711722	0.653	rs2460421	ENSG00000237310.1	GS1-124K5.4	-4.45	1.92e-05	0.0127	-0.4	-0.37	Calcium levels;	chr7:66026136	chr7:66493706~66495474:+
TGCT	cis	rs2033711	0.87	rs7409473	ENSG00000269473.1	CTD-2619J13.19	4.45	1.92e-05	0.0127	0.3	0.37	Uric acid clearance;	chr19:58427798	chr19:58440448~58445849:+
TGCT	cis	rs2033711	0.87	rs7408188	ENSG00000269473.1	CTD-2619J13.19	4.45	1.92e-05	0.0127	0.3	0.37	Uric acid clearance;	chr19:58428022	chr19:58440448~58445849:+
TGCT	cis	rs7927592	0.513	rs901823	ENSG00000212093.1	AP000807.1	4.45	1.92e-05	0.0127	0.37	0.37	Total body bone mineral density;	chr11:68438110	chr11:68506083~68506166:-
TGCT	cis	rs9322193	0.926	rs9766562	ENSG00000216906.2	RP11-350J20.9	4.45	1.92e-05	0.0127	0.41	0.37	Lung cancer;	chr6:149788709	chr6:149904243~149906418:+
TGCT	cis	rs12891047	0.738	rs12432558	ENSG00000258759.1	RP11-1012A1.7	4.45	1.93e-05	0.0127	0.29	0.37	Amyotrophic lateral sclerosis (sporadic);	chr14:67891622	chr14:67799004~67799609:+
TGCT	cis	rs875971	0.862	rs6952182	ENSG00000237310.1	GS1-124K5.4	-4.44	1.93e-05	0.0127	-0.4	-0.37	Aortic root size;	chr7:66218330	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs6964437	ENSG00000237310.1	GS1-124K5.4	-4.44	1.93e-05	0.0127	-0.4	-0.37	Aortic root size;	chr7:66221457	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs6460282	ENSG00000237310.1	GS1-124K5.4	-4.44	1.93e-05	0.0127	-0.4	-0.37	Aortic root size;	chr7:66226259	chr7:66493706~66495474:+
TGCT	cis	rs28580297	1	rs28580297	ENSG00000225892.3	RP11-384K6.2	-4.44	1.93e-05	0.0128	-0.38	-0.37	Body mass index;	chr4:118506802	chr4:118632274~118634759:+
TGCT	cis	rs786425	0.682	rs11612479	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123670979	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.717	rs12817757	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123671940	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.601	rs7138209	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123672505	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs12822546	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123672700	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs7975119	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123673127	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs7975233	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123673198	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs7978447	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123673533	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs7953596	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123673903	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs7953599	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123673908	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs7963498	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123673955	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.74	rs7133543	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123674864	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs7302649	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123675219	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs34534928	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123676287	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs12820195	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123677500	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs7973695	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123677930	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs7959553	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123678158	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.711	rs66690784	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123681130	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.711	rs7963968	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123681494	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.628	rs118004082	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123684693	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.655	rs114208992	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123684695	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs35416308	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123684914	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs7309528	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123687111	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.69	rs6488892	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123687279	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs6488893	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123687356	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs12829984	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123687760	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs7135660	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123689687	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.654	rs7307343	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123689818	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.654	rs7310918	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123690109	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs11833604	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123691925	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs35946281	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123692469	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.655	rs12821242	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123693782	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.711	rs12831081	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123695192	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs7298440	ENSG00000247373.3	RP11-486O12.2	4.44	1.93e-05	0.0128	0.47	0.37	Pubertal anthropometrics;	chr12:123696502	chr12:123575891~123585115:-
TGCT	cis	rs9807989	0.507	rs2041739	ENSG00000234389.1	AC007278.3	-4.44	1.94e-05	0.0128	-0.27	-0.37	Asthma;	chr2:102377873	chr2:102438713~102440475:+
TGCT	cis	rs2333021	0.689	rs12878701	ENSG00000259015.1	RP11-109N23.6	4.44	1.94e-05	0.0128	0.21	0.37	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72976068	chr14:72960595~72961993:+
TGCT	cis	rs2033711	0.84	rs10423138	ENSG00000269473.1	CTD-2619J13.19	4.44	1.94e-05	0.0128	0.3	0.37	Uric acid clearance;	chr19:58416935	chr19:58440448~58445849:+
TGCT	cis	rs2033711	0.87	rs3764534	ENSG00000269473.1	CTD-2619J13.19	4.44	1.94e-05	0.0128	0.3	0.37	Uric acid clearance;	chr19:58417769	chr19:58440448~58445849:+
TGCT	cis	rs3742264	1	rs9567614	ENSG00000235903.6	CPB2-AS1	-4.44	1.94e-05	0.0128	-0.44	-0.37	Blood protein levels;	chr13:46075318	chr13:46052806~46113332:+
TGCT	cis	rs877819	0.583	rs2620894	ENSG00000228403.1	RP11-563N6.6	-4.44	1.94e-05	0.0128	-0.39	-0.37	Systemic lupus erythematosus;	chr10:48858616	chr10:48878022~48878649:+
TGCT	cis	rs8059260	0.736	rs2302558	ENSG00000274038.1	RP11-66H6.4	-4.44	1.94e-05	0.0128	-0.52	-0.37	Alcohol consumption over the past year;	chr16:10969154	chr16:11056556~11057034:+
TGCT	cis	rs875971	0.825	rs59466412	ENSG00000237310.1	GS1-124K5.4	-4.44	1.94e-05	0.0128	-0.41	-0.37	Aortic root size;	chr7:66100371	chr7:66493706~66495474:+
TGCT	cis	rs2177312	0.83	rs1581454	ENSG00000251129.1	RP11-734I18.1	-4.44	1.94e-05	0.0128	-0.42	-0.37	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31948437	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.767	rs1581455	ENSG00000251129.1	RP11-734I18.1	-4.44	1.94e-05	0.0128	-0.42	-0.37	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31948491	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.794	rs1523169	ENSG00000251129.1	RP11-734I18.1	-4.44	1.94e-05	0.0128	-0.42	-0.37	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31948572	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.868	rs1523170	ENSG00000251129.1	RP11-734I18.1	-4.44	1.94e-05	0.0128	-0.42	-0.37	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31948957	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.868	rs1523171	ENSG00000251129.1	RP11-734I18.1	-4.44	1.94e-05	0.0128	-0.42	-0.37	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31948967	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.868	rs1523172	ENSG00000251129.1	RP11-734I18.1	-4.44	1.94e-05	0.0128	-0.42	-0.37	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31949082	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.868	rs1996882	ENSG00000251129.1	RP11-734I18.1	-4.44	1.94e-05	0.0128	-0.42	-0.37	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31949355	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.83	rs1523173	ENSG00000251129.1	RP11-734I18.1	-4.44	1.94e-05	0.0128	-0.42	-0.37	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31949737	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.767	rs1523174	ENSG00000251129.1	RP11-734I18.1	-4.44	1.94e-05	0.0128	-0.42	-0.37	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31949952	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.868	rs1357464	ENSG00000251129.1	RP11-734I18.1	-4.44	1.94e-05	0.0128	-0.42	-0.37	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31951995	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.868	rs1357463	ENSG00000251129.1	RP11-734I18.1	-4.44	1.94e-05	0.0128	-0.42	-0.37	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31953425	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.868	rs6553978	ENSG00000251129.1	RP11-734I18.1	-4.44	1.94e-05	0.0128	-0.42	-0.37	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31954999	chr4:31997397~32155406:+
TGCT	cis	rs904251	0.828	rs1757178	ENSG00000204110.6	RP1-153P14.8	4.44	1.94e-05	0.0128	0.44	0.37	Cognitive performance;	chr6:37518534	chr6:37507348~37535616:+
TGCT	cis	rs4835473	0.742	rs7654409	ENSG00000251600.4	RP11-673E1.1	4.44	1.94e-05	0.0128	0.39	0.37	Immature fraction of reticulocytes;	chr4:143956842	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.708	rs7655939	ENSG00000251600.4	RP11-673E1.1	4.44	1.94e-05	0.0128	0.39	0.37	Immature fraction of reticulocytes;	chr4:143956889	chr4:143912331~143982454:+
TGCT	cis	rs4308124	0.708	rs67816163	ENSG00000227992.1	AC108463.2	-4.44	1.95e-05	0.0128	-0.39	-0.37	Vitiligo;	chr2:111205733	chr2:111203964~111206215:-
TGCT	cis	rs67311347	1	rs7642552	ENSG00000223797.4	ENTPD3-AS1	4.44	1.95e-05	0.0128	0.39	0.37	Renal cell carcinoma;	chr3:40383325	chr3:40313802~40453329:-
TGCT	cis	rs801193	1	rs17566701	ENSG00000236529.1	RP13-254B10.1	4.44	1.95e-05	0.0128	0.28	0.37	Aortic root size;	chr7:66728196	chr7:65840212~65840596:+
TGCT	cis	rs10885997	0.678	rs7072157	ENSG00000277879.1	RP11-129M16.4	-4.44	1.95e-05	0.0128	-0.33	-0.37	Phospholipid levels (plasma);	chr10:116635866	chr10:117267116~117268668:-
TGCT	cis	rs11669181	1	rs11669181	ENSG00000267147.2	CTC-548K16.1	4.44	1.95e-05	0.0129	0.44	0.37	Conotruncal heart defects (maternal effects);	chr19:14334326	chr19:14333743~14343916:+
TGCT	cis	rs4853012	0.775	rs12465641	ENSG00000217702.2	RP11-287D1.4	-4.44	1.95e-05	0.0129	-0.59	-0.37	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74130583~74135395:+
TGCT	cis	rs2177312	0.574	rs1523140	ENSG00000251129.1	RP11-734I18.1	-4.44	1.95e-05	0.0129	-0.37	-0.37	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31982809	chr4:31997397~32155406:+
TGCT	cis	rs7605378	1	rs769954	ENSG00000232732.8	AC073043.1	4.44	1.95e-05	0.0129	0.43	0.37	Osteoporosis;	chr2:199827436	chr2:199867396~199911159:-
TGCT	cis	rs7819412	0.521	rs10100660	ENSG00000255310.2	AF131215.2	-4.44	1.96e-05	0.0129	-0.32	-0.37	Triglycerides;	chr8:11181376	chr8:11107788~11109726:-
TGCT	cis	rs7819412	0.521	rs10110684	ENSG00000255310.2	AF131215.2	-4.44	1.96e-05	0.0129	-0.32	-0.37	Triglycerides;	chr8:11181650	chr8:11107788~11109726:-
TGCT	cis	rs7819412	0.54	rs2409725	ENSG00000255310.2	AF131215.2	-4.44	1.96e-05	0.0129	-0.32	-0.37	Triglycerides;	chr8:11184152	chr8:11107788~11109726:-
TGCT	cis	rs7819412	0.54	rs2409726	ENSG00000255310.2	AF131215.2	-4.44	1.96e-05	0.0129	-0.32	-0.37	Triglycerides;	chr8:11185629	chr8:11107788~11109726:-
TGCT	cis	rs875971	0.571	rs160641	ENSG00000237310.1	GS1-124K5.4	-4.44	1.96e-05	0.0129	-0.45	-0.37	Aortic root size;	chr7:66112359	chr7:66493706~66495474:+
TGCT	cis	rs7615952	0.932	rs13065725	ENSG00000171084.14	FAM86JP	4.44	1.96e-05	0.0129	0.66	0.37	Blood pressure (smoking interaction);	chr3:125913446	chr3:125916620~125930024:+
TGCT	cis	rs853679	0.55	rs1233701	ENSG00000219891.2	ZSCAN12P1	-4.44	1.96e-05	0.0129	-0.47	-0.37	Depression;	chr6:28200948	chr6:28091154~28093664:+
TGCT	cis	rs904251	0.802	rs2646933	ENSG00000279942.1	RP1-153P14.7	-4.44	1.96e-05	0.0129	-0.47	-0.37	Cognitive performance;	chr6:37434294	chr6:37567716~37571460:+
TGCT	cis	rs9309473	0.95	rs6745480	ENSG00000163016.8	ALMS1P	4.44	1.96e-05	0.0129	0.33	0.37	Metabolite levels;	chr2:73612928	chr2:73644919~73685576:+
TGCT	cis	rs2742234	0.59	rs2503863	ENSG00000273008.1	RP11-351D16.3	-4.44	1.96e-05	0.0129	-0.48	-0.37	Hirschsprung disease;	chr10:43171950	chr10:43136824~43138334:-
TGCT	cis	rs875971	0.545	rs1638735	ENSG00000237310.1	GS1-124K5.4	4.44	1.97e-05	0.0129	0.43	0.37	Aortic root size;	chr7:66630751	chr7:66493706~66495474:+
TGCT	cis	rs4815617	1	rs4815617	ENSG00000275491.1	RP5-1009E24.8	-4.44	1.97e-05	0.0129	-0.57	-0.37	Asthma;	chr20:3846662	chr20:3808357~3812434:+
TGCT	cis	rs11763147	1	rs11763147	ENSG00000272831.1	RP11-792A8.4	-4.44	1.97e-05	0.013	-0.38	-0.37	Corneal structure;	chr7:65861834	chr7:66739829~66740385:-
TGCT	cis	rs3809863	0.602	rs6504833	ENSG00000228782.6	CTD-2026D20.3	4.44	1.97e-05	0.013	0.48	0.37	Glaucoma (primary open-angle);	chr17:47318721	chr17:47450568~47492492:-
TGCT	cis	rs8105895	0.935	rs62111038	ENSG00000269742.1	BNIP3P29	4.44	1.97e-05	0.013	0.69	0.37	Body mass index (change over time);	chr19:22103812	chr19:22065828~22066398:-
TGCT	cis	rs1061377	0.674	rs34506243	ENSG00000249207.1	RP11-360F5.1	-4.44	1.97e-05	0.013	-0.39	-0.37	Uric acid levels;	chr4:39082702	chr4:39112677~39126818:-
TGCT	cis	rs1150668	0.799	rs9301	ENSG00000204709.4	LINC01556	4.44	1.97e-05	0.013	0.4	0.37	Pubertal anthropometrics;	chr6:28324929	chr6:28943877~28944537:+
TGCT	cis	rs1150668	0.799	rs853684	ENSG00000204709.4	LINC01556	4.44	1.97e-05	0.013	0.4	0.37	Pubertal anthropometrics;	chr6:28326773	chr6:28943877~28944537:+
TGCT	cis	rs7927592	0.513	rs689075	ENSG00000212093.1	AP000807.1	4.44	1.97e-05	0.013	0.37	0.37	Total body bone mineral density;	chr11:68426964	chr11:68506083~68506166:-
TGCT	cis	rs525592	1	rs525592	ENSG00000212093.1	AP000807.1	4.44	1.97e-05	0.013	0.37	0.37	Bone mineral density;	chr11:68427636	chr11:68506083~68506166:-
TGCT	cis	rs7201929	1	rs12920514	ENSG00000251417.2	RP11-1348G14.4	4.44	1.98e-05	0.013	0.43	0.37	QT interval;	chr16:28824579	chr16:28802743~28817828:+
TGCT	cis	rs853679	0.55	rs9295762	ENSG00000219891.2	ZSCAN12P1	-4.44	1.98e-05	0.013	-0.45	-0.37	Depression;	chr6:28187640	chr6:28091154~28093664:+
TGCT	cis	rs494459	0.838	rs581045	ENSG00000255422.1	AP002954.4	-4.44	1.98e-05	0.013	-0.39	-0.37	Height;	chr11:118761813	chr11:118704607~118750263:+
TGCT	cis	rs9308062	1	rs9308062	ENSG00000273449.1	RP11-218F10.3	-4.44	1.98e-05	0.013	-0.41	-0.37	Small cell lung carcinoma;	chr4:163517048	chr4:163529771~163530697:+
TGCT	cis	rs1075232	0.655	rs77987193	ENSG00000215302.7	CTD-3092A11.1	-4.44	1.98e-05	0.013	-0.71	-0.37	Survival in colorectal cancer (non-distant metastatic);	chr15:31296055	chr15:30470779~30507623:+
TGCT	cis	rs4660456	0.913	rs545218	ENSG00000237899.1	RP4-739H11.3	4.44	1.98e-05	0.013	0.5	0.37	Platelet count;	chr1:40675313	chr1:40669089~40687588:-
TGCT	cis	rs801193	1	rs2707845	ENSG00000272831.1	RP11-792A8.4	4.44	1.98e-05	0.013	0.4	0.37	Aortic root size;	chr7:66733811	chr7:66739829~66740385:-
TGCT	cis	rs801193	1	rs2707850	ENSG00000272831.1	RP11-792A8.4	4.44	1.98e-05	0.013	0.4	0.37	Aortic root size;	chr7:66738883	chr7:66739829~66740385:-
TGCT	cis	rs801193	0.967	rs1110414	ENSG00000272831.1	RP11-792A8.4	4.44	1.98e-05	0.013	0.4	0.37	Aortic root size;	chr7:66740595	chr7:66739829~66740385:-
TGCT	cis	rs801193	1	rs7783924	ENSG00000272831.1	RP11-792A8.4	4.44	1.98e-05	0.013	0.4	0.37	Aortic root size;	chr7:66744070	chr7:66739829~66740385:-
TGCT	cis	rs801193	1	rs7789184	ENSG00000272831.1	RP11-792A8.4	4.44	1.98e-05	0.013	0.4	0.37	Aortic root size;	chr7:66745208	chr7:66739829~66740385:-
TGCT	cis	rs801193	1	rs2707854	ENSG00000272831.1	RP11-792A8.4	4.44	1.98e-05	0.013	0.4	0.37	Aortic root size;	chr7:66747610	chr7:66739829~66740385:-
TGCT	cis	rs8072100	0.967	rs4794001	ENSG00000228782.6	CTD-2026D20.3	4.44	1.98e-05	0.013	0.44	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47643483	chr17:47450568~47492492:-
TGCT	cis	rs2177312	0.868	rs4280779	ENSG00000251129.1	RP11-734I18.1	-4.44	1.98e-05	0.013	-0.42	-0.37	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31959890	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.761	rs13128834	ENSG00000251129.1	RP11-734I18.1	-4.44	1.98e-05	0.013	-0.42	-0.37	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31960440	chr4:31997397~32155406:+
TGCT	cis	rs507080	0.733	rs673547	ENSG00000255239.1	AP002954.6	4.44	1.98e-05	0.013	0.49	0.37	Serum metabolite levels;	chr11:118702630	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.733	rs517445	ENSG00000255239.1	AP002954.6	4.44	1.98e-05	0.013	0.49	0.37	Serum metabolite levels;	chr11:118702826	chr11:118688039~118690600:-
TGCT	cis	rs1972460	0.506	rs62012050	ENSG00000255769.6	GOLGA2P10	-4.44	1.98e-05	0.0131	-0.37	-0.37	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472993~82513950:-
TGCT	cis	rs12439619	1	rs35152457	ENSG00000255769.6	GOLGA2P10	-4.44	1.98e-05	0.0131	-0.37	-0.37	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472993~82513950:-
TGCT	cis	rs7795991	0.558	rs62452257	ENSG00000224330.1	AC005019.3	-4.44	1.98e-05	0.0131	-0.41	-0.37	Type 2 diabetes;	chr7:13868678	chr7:13854355~13859025:-
TGCT	cis	rs7795991	0.558	rs58975419	ENSG00000224330.1	AC005019.3	-4.44	1.98e-05	0.0131	-0.41	-0.37	Type 2 diabetes;	chr7:13869220	chr7:13854355~13859025:-
TGCT	cis	rs9755467	0.861	rs78035593	ENSG00000221413.1	AC023593.1	4.44	1.99e-05	0.0131	0.58	0.37	Educational attainment (years of education);	chr3:127443706	chr3:127664704~127664810:+
TGCT	cis	rs875971	0.619	rs2302918	ENSG00000272831.1	RP11-792A8.4	4.44	2e-05	0.0131	0.4	0.37	Aortic root size;	chr7:66535945	chr7:66739829~66740385:-
TGCT	cis	rs1707322	0.752	rs6703748	ENSG00000280836.1	AL355480.1	-4.44	2e-05	0.0131	-0.5	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45581219~45581321:-
TGCT	cis	rs2033711	0.905	rs1077420	ENSG00000269473.1	CTD-2619J13.19	4.44	2e-05	0.0131	0.3	0.37	Uric acid clearance;	chr19:58457508	chr19:58440448~58445849:+
TGCT	cis	rs36093924	0.586	rs6002561	ENSG00000182057.4	OGFRP1	-4.44	2e-05	0.0131	-0.27	-0.37	Intelligence;	chr22:41963200	chr22:42269753~42275196:+
TGCT	cis	rs67311347	1	rs73080138	ENSG00000223797.4	ENTPD3-AS1	4.43	2.01e-05	0.0132	0.39	0.37	Renal cell carcinoma;	chr3:40474926	chr3:40313802~40453329:-
TGCT	cis	rs5758511	0.68	rs5758692	ENSG00000182057.4	OGFRP1	-4.43	2.01e-05	0.0132	-0.35	-0.37	Birth weight;	chr22:42273023	chr22:42269753~42275196:+
TGCT	cis	rs911555	0.755	rs8018400	ENSG00000244691.1	RPL10AP1	4.43	2.01e-05	0.0132	0.5	0.37	Intelligence (multi-trait analysis);	chr14:103434748	chr14:103412119~103412761:-
TGCT	cis	rs7824557	0.688	rs2572397	ENSG00000269918.1	AF131215.9	4.43	2.01e-05	0.0132	0.36	0.37	Retinal vascular caliber;	chr8:11318894	chr8:11104691~11106704:-
TGCT	cis	rs7824557	0.724	rs2251473	ENSG00000269918.1	AF131215.9	4.43	2.01e-05	0.0132	0.36	0.37	Retinal vascular caliber;	chr8:11319617	chr8:11104691~11106704:-
TGCT	cis	rs7824557	0.724	rs2572398	ENSG00000269918.1	AF131215.9	4.43	2.01e-05	0.0132	0.36	0.37	Retinal vascular caliber;	chr8:11320584	chr8:11104691~11106704:-
TGCT	cis	rs8062405	0.789	rs28676837	ENSG00000259982.1	CDC37P1	-4.43	2.02e-05	0.0132	-0.45	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615742	chr16:28700294~28701540:-
TGCT	cis	rs8059260	0.736	rs80079627	ENSG00000274038.1	RP11-66H6.4	-4.43	2.02e-05	0.0132	-0.53	-0.37	Alcohol consumption over the past year;	chr16:10948741	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.736	rs77920180	ENSG00000274038.1	RP11-66H6.4	-4.43	2.02e-05	0.0132	-0.53	-0.37	Alcohol consumption over the past year;	chr16:10949041	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.736	rs7195509	ENSG00000274038.1	RP11-66H6.4	-4.43	2.02e-05	0.0132	-0.53	-0.37	Alcohol consumption over the past year;	chr16:10951572	chr16:11056556~11057034:+
TGCT	cis	rs786425	0.801	rs12813346	ENSG00000278112.1	RP11-972P1.11	4.43	2.02e-05	0.0132	0.42	0.37	Pubertal anthropometrics;	chr12:123716567	chr12:123519390~123519856:-
TGCT	cis	rs9807989	0.507	rs13021177	ENSG00000234389.1	AC007278.3	4.43	2.02e-05	0.0132	0.27	0.37	Asthma;	chr2:102440033	chr2:102438713~102440475:+
TGCT	cis	rs453301	0.624	rs4841083	ENSG00000254340.1	RP11-10A14.3	4.43	2.02e-05	0.0132	0.38	0.37	Joint mobility (Beighton score);	chr8:9012918	chr8:9141424~9145435:+
TGCT	cis	rs453301	0.624	rs2979256	ENSG00000254340.1	RP11-10A14.3	4.43	2.02e-05	0.0132	0.38	0.37	Joint mobility (Beighton score);	chr8:9014200	chr8:9141424~9145435:+
TGCT	cis	rs11822910	0.815	rs12422015	ENSG00000265566.2	RN7SL605P	4.43	2.02e-05	0.0133	0.46	0.37	Platelet distribution width;	chr11:57426180	chr11:57528085~57528365:-
TGCT	cis	rs651907	0.535	rs11711903	ENSG00000244119.1	PDCL3P4	4.43	2.02e-05	0.0133	0.26	0.37	Colorectal cancer;	chr3:101781904	chr3:101712472~101713191:+
TGCT	cis	rs12745968	0.589	rs12025792	ENSG00000223787.2	RP4-593M8.1	-4.43	2.03e-05	0.0133	-0.49	-0.37	Bipolar disorder and schizophrenia;	chr1:92641851	chr1:92580476~92580821:-
TGCT	cis	rs11231017	1	rs11231015	ENSG00000254454.2	RCC2P6	-4.43	2.03e-05	0.0133	-0.29	-0.37	HIV-1 viral setpoint;	chr11:62293697	chr11:62371146~62373168:+
TGCT	cis	rs11231017	1	rs11231016	ENSG00000254454.2	RCC2P6	-4.43	2.03e-05	0.0133	-0.29	-0.37	HIV-1 viral setpoint;	chr11:62293698	chr11:62371146~62373168:+
TGCT	cis	rs11231017	1	rs11231017	ENSG00000254454.2	RCC2P6	-4.43	2.03e-05	0.0133	-0.29	-0.37	HIV-1 viral setpoint;	chr11:62293877	chr11:62371146~62373168:+
TGCT	cis	rs11168618	0.605	rs2731102	ENSG00000240399.1	RP1-228P16.1	-4.43	2.03e-05	0.0133	-0.34	-0.37	Adiponectin levels;	chr12:48490752	chr12:48054813~48055591:-
TGCT	cis	rs847851	1	rs2473615	ENSG00000186328.4	RP11-140K17.2	4.43	2.03e-05	0.0133	0.38	0.37	Colonoscopy-negative controls vs population controls;	chr6:34926133	chr6:34715613~34715940:+
TGCT	cis	rs2945232	1	rs2945232	ENSG00000254340.1	RP11-10A14.3	4.43	2.03e-05	0.0133	0.38	0.37	Schizophrenia;	chr8:8240516	chr8:9141424~9145435:+
TGCT	cis	rs9326248	0.813	rs588534	ENSG00000280143.1	AP000892.6	4.43	2.03e-05	0.0133	0.53	0.37	Blood protein levels;	chr11:117197788	chr11:117204967~117210292:+
TGCT	cis	rs801193	0.967	rs2420827	ENSG00000236529.1	RP13-254B10.1	-4.43	2.03e-05	0.0133	-0.28	-0.37	Aortic root size;	chr7:66682114	chr7:65840212~65840596:+
TGCT	cis	rs801193	0.967	rs3800823	ENSG00000236529.1	RP13-254B10.1	-4.43	2.03e-05	0.0133	-0.28	-0.37	Aortic root size;	chr7:66682123	chr7:65840212~65840596:+
TGCT	cis	rs10826995	0.961	rs11008713	ENSG00000239731.3	RN7SL825P	-4.43	2.03e-05	0.0133	-0.37	-0.37	Pulse pressure;	chr10:31976644	chr10:31992087~31992381:-
TGCT	cis	rs10826995	0.961	rs72780012	ENSG00000239731.3	RN7SL825P	-4.43	2.03e-05	0.0133	-0.37	-0.37	Pulse pressure;	chr10:31980657	chr10:31992087~31992381:-
TGCT	cis	rs10826995	0.961	rs12261222	ENSG00000239731.3	RN7SL825P	-4.43	2.03e-05	0.0133	-0.37	-0.37	Pulse pressure;	chr10:31981900	chr10:31992087~31992381:-
TGCT	cis	rs10826995	0.961	rs11818697	ENSG00000239731.3	RN7SL825P	-4.43	2.03e-05	0.0133	-0.37	-0.37	Pulse pressure;	chr10:31984349	chr10:31992087~31992381:-
TGCT	cis	rs899997	0.953	rs11633519	ENSG00000261143.1	ADAMTS7P3	4.43	2.03e-05	0.0133	0.45	0.37	Coronary artery disease or large artery stroke;	chr15:78707210	chr15:77976042~77993057:+
TGCT	cis	rs4242434	0.892	rs4872527	ENSG00000254064.1	CTD-2530N21.4	-4.43	2.03e-05	0.0133	-0.23	-0.37	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22638535	chr8:22254576~22275162:-
TGCT	cis	rs4242434	1	rs4242434	ENSG00000254064.1	CTD-2530N21.4	-4.43	2.03e-05	0.0133	-0.23	-0.37	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22644317	chr8:22254576~22275162:-
TGCT	cis	rs4660456	0.913	rs4660449	ENSG00000237899.1	RP4-739H11.3	4.43	2.03e-05	0.0133	0.48	0.37	Platelet count;	chr1:40739780	chr1:40669089~40687588:-
TGCT	cis	rs9309473	0.904	rs78450880	ENSG00000163016.8	ALMS1P	4.43	2.03e-05	0.0133	0.34	0.37	Metabolite levels;	chr2:73594254	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.904	rs79145598	ENSG00000163016.8	ALMS1P	4.43	2.03e-05	0.0133	0.34	0.37	Metabolite levels;	chr2:73594255	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.904	rs62149783	ENSG00000163016.8	ALMS1P	4.43	2.03e-05	0.0133	0.34	0.37	Metabolite levels;	chr2:73594257	chr2:73644919~73685576:+
TGCT	cis	rs7829975	0.572	rs28730413	ENSG00000254340.1	RP11-10A14.3	-4.43	2.03e-05	0.0133	-0.36	-0.37	Mood instability;	chr8:8937937	chr8:9141424~9145435:+
TGCT	cis	rs9309473	1	rs10179134	ENSG00000163016.8	ALMS1P	4.43	2.04e-05	0.0133	0.34	0.37	Metabolite levels;	chr2:73410391	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs6755241	ENSG00000163016.8	ALMS1P	4.43	2.04e-05	0.0133	0.34	0.37	Metabolite levels;	chr2:73414236	chr2:73644919~73685576:+
TGCT	cis	rs7824557	0.688	rs2572397	ENSG00000255310.2	AF131215.2	4.43	2.04e-05	0.0134	0.29	0.37	Retinal vascular caliber;	chr8:11318894	chr8:11107788~11109726:-
TGCT	cis	rs7824557	0.724	rs2251473	ENSG00000255310.2	AF131215.2	4.43	2.04e-05	0.0134	0.29	0.37	Retinal vascular caliber;	chr8:11319617	chr8:11107788~11109726:-
TGCT	cis	rs7824557	0.724	rs2572398	ENSG00000255310.2	AF131215.2	4.43	2.04e-05	0.0134	0.29	0.37	Retinal vascular caliber;	chr8:11320584	chr8:11107788~11109726:-
TGCT	cis	rs801193	0.569	rs11772819	ENSG00000237310.1	GS1-124K5.4	4.43	2.04e-05	0.0134	0.4	0.37	Aortic root size;	chr7:66752983	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.569	rs7800620	ENSG00000237310.1	GS1-124K5.4	4.43	2.04e-05	0.0134	0.4	0.37	Aortic root size;	chr7:66758701	chr7:66493706~66495474:+
TGCT	cis	rs10826995	0.883	rs113059026	ENSG00000239731.3	RN7SL825P	-4.43	2.04e-05	0.0134	-0.36	-0.37	Pulse pressure;	chr10:31869550	chr10:31992087~31992381:-
TGCT	cis	rs10826995	0.885	rs7906054	ENSG00000239731.3	RN7SL825P	-4.43	2.04e-05	0.0134	-0.36	-0.37	Pulse pressure;	chr10:31872382	chr10:31992087~31992381:-
TGCT	cis	rs1519814	0.659	rs7829279	ENSG00000254343.2	RP11-760H22.2	-4.43	2.04e-05	0.0134	-0.6	-0.37	Breast cancer;	chr8:120011275	chr8:120052180~120056201:+
TGCT	cis	rs1519814	0.659	rs7387672	ENSG00000254343.2	RP11-760H22.2	-4.43	2.04e-05	0.0134	-0.6	-0.37	Breast cancer;	chr8:120012272	chr8:120052180~120056201:+
TGCT	cis	rs1075232	1	rs67634762	ENSG00000215302.7	CTD-3092A11.1	-4.43	2.05e-05	0.0134	-0.68	-0.37	Survival in colorectal cancer (non-distant metastatic);	chr15:31455852	chr15:30470779~30507623:+
TGCT	cis	rs17507216	0.628	rs8028130	ENSG00000255769.6	GOLGA2P10	-4.43	2.05e-05	0.0134	-0.47	-0.37	Excessive daytime sleepiness;	chr15:82734974	chr15:82472993~82513950:-
TGCT	cis	rs2286503	0.752	rs6461669	ENSG00000234286.1	AC006026.13	4.43	2.05e-05	0.0134	0.44	0.37	Fibrinogen;	chr7:22818447	chr7:23680195~23680786:-
TGCT	cis	rs10504229	1	rs66479724	ENSG00000253301.4	RP11-513O17.2	4.43	2.06e-05	0.0134	0.47	0.37	Developmental language disorder (linguistic errors);	chr8:57275750	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs72652905	ENSG00000253301.4	RP11-513O17.2	4.43	2.06e-05	0.0134	0.47	0.37	Developmental language disorder (linguistic errors);	chr8:57275796	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs72652906	ENSG00000253301.4	RP11-513O17.2	4.43	2.06e-05	0.0134	0.47	0.37	Developmental language disorder (linguistic errors);	chr8:57275801	chr8:57142689~57240298:+
TGCT	cis	rs12143943	0.835	rs4951383	ENSG00000176754.11	LINC00303	4.43	2.06e-05	0.0135	0.33	0.37	Cognitive performance;	chr1:204483150	chr1:204032447~204041265:-
TGCT	cis	rs12143943	0.835	rs12402641	ENSG00000176754.11	LINC00303	4.43	2.06e-05	0.0135	0.33	0.37	Cognitive performance;	chr1:204483651	chr1:204032447~204041265:-
TGCT	cis	rs12143943	0.802	rs12117054	ENSG00000176754.11	LINC00303	4.43	2.06e-05	0.0135	0.33	0.37	Cognitive performance;	chr1:204485613	chr1:204032447~204041265:-
TGCT	cis	rs7819412	0.521	rs9329238	ENSG00000255310.2	AF131215.2	-4.43	2.06e-05	0.0135	-0.32	-0.37	Triglycerides;	chr8:11176228	chr8:11107788~11109726:-
TGCT	cis	rs992157	0.798	rs4996257	ENSG00000261338.2	RP11-378A13.1	4.43	2.06e-05	0.0135	0.31	0.37	Colorectal cancer;	chr2:218298113	chr2:218255319~218257366:+
TGCT	cis	rs3742264	1	rs9316180	ENSG00000235903.6	CPB2-AS1	4.43	2.06e-05	0.0135	0.43	0.37	Blood protein levels;	chr13:46067550	chr13:46052806~46113332:+
TGCT	cis	rs6568686	0.73	rs56300817	ENSG00000272356.1	RP5-1112D6.8	-4.43	2.06e-05	0.0135	-0.41	-0.37	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111463827	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs12208482	ENSG00000272356.1	RP5-1112D6.8	-4.43	2.06e-05	0.0135	-0.41	-0.37	Amino acid levels;Blood metabolite levels;	chr6:111472443	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs80354920	ENSG00000272356.1	RP5-1112D6.8	-4.43	2.06e-05	0.0135	-0.41	-0.37	Amino acid levels;Blood metabolite levels;	chr6:111473279	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs17510381	ENSG00000272356.1	RP5-1112D6.8	-4.43	2.06e-05	0.0135	-0.41	-0.37	Amino acid levels;Blood metabolite levels;	chr6:111473455	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.568	rs12213391	ENSG00000272356.1	RP5-1112D6.8	-4.43	2.06e-05	0.0135	-0.41	-0.37	Amino acid levels;Blood metabolite levels;	chr6:111479365	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs74510204	ENSG00000272356.1	RP5-1112D6.8	-4.43	2.06e-05	0.0135	-0.41	-0.37	Amino acid levels;Blood metabolite levels;	chr6:111482594	chr6:111309203~111313517:+
TGCT	cis	rs8072100	0.967	rs11079784	ENSG00000228782.6	CTD-2026D20.3	-4.43	2.06e-05	0.0135	-0.44	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47624914	chr17:47450568~47492492:-
TGCT	cis	rs7615952	0.932	rs9841157	ENSG00000171084.14	FAM86JP	4.43	2.06e-05	0.0135	0.67	0.37	Blood pressure (smoking interaction);	chr3:125916812	chr3:125916620~125930024:+
TGCT	cis	rs7615952	0.551	rs12695470	ENSG00000171084.14	FAM86JP	4.43	2.06e-05	0.0135	0.67	0.37	Blood pressure (smoking interaction);	chr3:125916875	chr3:125916620~125930024:+
TGCT	cis	rs1012068	0.686	rs4820996	ENSG00000236132.1	CTA-440B3.1	-4.43	2.07e-05	0.0135	-0.43	-0.37	Chronic hepatitis C infection;	chr22:31928044	chr22:31816379~31817491:-
TGCT	cis	rs2033711	0.783	rs11671113	ENSG00000268912.1	CTD-2619J13.17	-4.43	2.07e-05	0.0135	-0.33	-0.37	Uric acid clearance;	chr19:58446720	chr19:58428632~58431148:-
TGCT	cis	rs6604026	0.555	rs36114576	ENSG00000223787.2	RP4-593M8.1	4.43	2.07e-05	0.0135	0.55	0.37	Multiple sclerosis;	chr1:92671999	chr1:92580476~92580821:-
TGCT	cis	rs8105895	0.935	rs1560717	ENSG00000269742.1	BNIP3P29	4.43	2.07e-05	0.0135	0.68	0.37	Body mass index (change over time);	chr19:22109445	chr19:22065828~22066398:-
TGCT	cis	rs1799949	0.602	rs8176257	ENSG00000198496.9	NBR2	-4.43	2.07e-05	0.0135	-0.63	-0.37	Menopause (age at onset);	chr17:43064188	chr17:43125610~43153671:+
TGCT	cis	rs11231017	1	rs61893566	ENSG00000254454.2	RCC2P6	-4.43	2.07e-05	0.0135	-0.29	-0.37	HIV-1 viral setpoint;	chr11:62292961	chr11:62371146~62373168:+
TGCT	cis	rs11742741	0.652	rs66527927	ENSG00000248874.4	C5orf17	-4.43	2.07e-05	0.0136	-0.44	-0.37	Educational attainment;	chr5:24226579	chr5:23951348~24178263:+
TGCT	cis	rs7605378	1	rs769957	ENSG00000232732.8	AC073043.1	-4.43	2.08e-05	0.0136	-0.44	-0.37	Osteoporosis;	chr2:199830801	chr2:199867396~199911159:-
TGCT	cis	rs2980439	0.783	rs2948305	ENSG00000254340.1	RP11-10A14.3	4.43	2.08e-05	0.0136	0.38	0.37	Neuroticism;	chr8:8241055	chr8:9141424~9145435:+
TGCT	cis	rs2487032	0.573	rs2164560	ENSG00000226334.1	RP11-217B7.2	-4.43	2.08e-05	0.0136	-0.37	-0.37	Glaucoma (high intraocular pressure);	chr9:104945072	chr9:104927553~104928892:+
TGCT	cis	rs453301	0.574	rs10081437	ENSG00000173295.6	FAM86B3P	-4.43	2.08e-05	0.0136	-0.47	-0.37	Joint mobility (Beighton score);	chr8:9091469	chr8:8228595~8244865:+
TGCT	cis	rs9867325	0.895	rs9879531	ENSG00000239213.4	NCK1-AS1	4.43	2.08e-05	0.0136	0.39	0.37	Body mass index;	chr3:136920133	chr3:136841726~136862054:-
TGCT	cis	rs8059260	0.877	rs111352543	ENSG00000274038.1	RP11-66H6.4	4.43	2.08e-05	0.0136	0.43	0.37	Alcohol consumption over the past year;	chr16:10949603	chr16:11056556~11057034:+
TGCT	cis	rs8072100	0.967	rs4239162	ENSG00000228782.6	CTD-2026D20.3	4.43	2.08e-05	0.0136	0.44	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678444	chr17:47450568~47492492:-
TGCT	cis	rs8072100	0.967	rs4239163	ENSG00000228782.6	CTD-2026D20.3	4.43	2.08e-05	0.0136	0.44	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678588	chr17:47450568~47492492:-
TGCT	cis	rs992157	1	rs4674280	ENSG00000261338.2	RP11-378A13.1	-4.43	2.08e-05	0.0136	-0.3	-0.37	Colorectal cancer;	chr2:218276735	chr2:218255319~218257366:+
TGCT	cis	rs2333021	0.649	rs12893375	ENSG00000259015.1	RP11-109N23.6	4.43	2.08e-05	0.0136	0.21	0.37	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72990559	chr14:72960595~72961993:+
TGCT	cis	rs2333021	0.624	rs56282258	ENSG00000259015.1	RP11-109N23.6	4.43	2.08e-05	0.0136	0.21	0.37	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72992221	chr14:72960595~72961993:+
TGCT	cis	rs2333021	0.649	rs2333016	ENSG00000259015.1	RP11-109N23.6	4.43	2.08e-05	0.0136	0.21	0.37	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72993209	chr14:72960595~72961993:+
TGCT	cis	rs2333021	0.649	rs12881153	ENSG00000259015.1	RP11-109N23.6	4.43	2.08e-05	0.0136	0.21	0.37	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72993647	chr14:72960595~72961993:+
TGCT	cis	rs2333021	0.649	rs34158414	ENSG00000259015.1	RP11-109N23.6	4.43	2.08e-05	0.0136	0.21	0.37	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72995629	chr14:72960595~72961993:+
TGCT	cis	rs2333021	0.649	rs9888613	ENSG00000259015.1	RP11-109N23.6	4.43	2.08e-05	0.0136	0.21	0.37	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72995635	chr14:72960595~72961993:+
TGCT	cis	rs2333021	0.624	rs9888617	ENSG00000259015.1	RP11-109N23.6	4.43	2.08e-05	0.0136	0.21	0.37	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72996154	chr14:72960595~72961993:+
TGCT	cis	rs2333021	0.649	rs9888558	ENSG00000259015.1	RP11-109N23.6	4.43	2.08e-05	0.0136	0.21	0.37	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72997435	chr14:72960595~72961993:+
TGCT	cis	rs2333021	0.649	rs997667	ENSG00000259015.1	RP11-109N23.6	4.43	2.08e-05	0.0136	0.21	0.37	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72998295	chr14:72960595~72961993:+
TGCT	cis	rs1823913	0.614	rs4853576	ENSG00000227542.1	AC092614.2	-4.42	2.09e-05	0.0136	-0.4	-0.37	Obesity-related traits;	chr2:191296618	chr2:191229165~191246172:-
TGCT	cis	rs2117029	0.555	rs2279596	ENSG00000258017.1	RP11-386G11.10	-4.42	2.09e-05	0.0136	-0.48	-0.37	Intelligence (multi-trait analysis);	chr12:49104968	chr12:49127782~49147869:+
TGCT	cis	rs1555322	0.53	rs2425044	ENSG00000126005.14	MMP24-AS1	-4.42	2.09e-05	0.0136	-0.45	-0.37	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35216462~35278131:-
TGCT	cis	rs875971	0.52	rs12666485	ENSG00000222364.1	RNU6-96P	-4.42	2.09e-05	0.0136	-0.47	-0.37	Aortic root size;	chr7:66160135	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.545	rs67688847	ENSG00000222364.1	RNU6-96P	-4.42	2.09e-05	0.0136	-0.47	-0.37	Aortic root size;	chr7:66161064	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.545	rs7787063	ENSG00000222364.1	RNU6-96P	-4.42	2.09e-05	0.0136	-0.47	-0.37	Aortic root size;	chr7:66164012	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.545	rs12673308	ENSG00000222364.1	RNU6-96P	-4.42	2.09e-05	0.0136	-0.47	-0.37	Aortic root size;	chr7:66166374	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.545	rs67397473	ENSG00000222364.1	RNU6-96P	-4.42	2.09e-05	0.0136	-0.47	-0.37	Aortic root size;	chr7:66168318	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.545	rs10950027	ENSG00000222364.1	RNU6-96P	-4.42	2.09e-05	0.0136	-0.47	-0.37	Aortic root size;	chr7:66169164	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.545	rs73376401	ENSG00000222364.1	RNU6-96P	-4.42	2.09e-05	0.0136	-0.47	-0.37	Aortic root size;	chr7:66174841	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.545	rs6460276	ENSG00000222364.1	RNU6-96P	-4.42	2.09e-05	0.0136	-0.47	-0.37	Aortic root size;	chr7:66182290	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.545	rs67775320	ENSG00000222364.1	RNU6-96P	-4.42	2.09e-05	0.0136	-0.47	-0.37	Aortic root size;	chr7:66193792	chr7:66395191~66395286:+
TGCT	cis	rs11671005	0.735	rs11667591	ENSG00000232098.3	CTD-2619J13.14	-4.42	2.09e-05	0.0136	-0.41	-0.37	Mean platelet volume;	chr19:58426270	chr19:58404238~58408484:-
TGCT	cis	rs11671005	0.735	rs11670871	ENSG00000232098.3	CTD-2619J13.14	4.42	2.09e-05	0.0136	0.41	0.37	Mean platelet volume;	chr19:58429147	chr19:58404238~58408484:-
TGCT	cis	rs1075232	0.655	rs28451043	ENSG00000215302.7	CTD-3092A11.1	-4.42	2.09e-05	0.0136	-0.71	-0.37	Survival in colorectal cancer (non-distant metastatic);	chr15:31295359	chr15:30470779~30507623:+
TGCT	cis	rs2709736	0.967	rs2709721	ENSG00000232790.2	LINC01162	-4.42	2.09e-05	0.0136	-0.27	-0.37	Bipolar I disorder;	chr7:20826478	chr7:20835431~21023148:+
TGCT	cis	rs867371	1	rs11855089	ENSG00000255769.6	GOLGA2P10	-4.42	2.09e-05	0.0136	-0.4	-0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82472993~82513950:-
TGCT	cis	rs867371	1	rs1174543	ENSG00000255769.6	GOLGA2P10	4.42	2.09e-05	0.0136	0.4	0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82472993~82513950:-
TGCT	cis	rs2333021	0.689	rs10142131	ENSG00000259015.1	RP11-109N23.6	4.42	2.09e-05	0.0136	0.21	0.37	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73000966	chr14:72960595~72961993:+
TGCT	cis	rs2880765	0.506	rs719138	ENSG00000259295.5	CSPG4P12	4.42	2.09e-05	0.0136	0.48	0.37	Coronary artery disease;	chr15:85511831	chr15:85191438~85213905:+
TGCT	cis	rs1707322	0.685	rs56177313	ENSG00000280836.1	AL355480.1	-4.42	2.09e-05	0.0137	-0.48	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs11211178	ENSG00000280836.1	AL355480.1	-4.42	2.09e-05	0.0137	-0.48	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45581219~45581321:-
TGCT	cis	rs904251	0.772	rs1812186	ENSG00000279942.1	RP1-153P14.7	-4.42	2.1e-05	0.0137	-0.46	-0.37	Cognitive performance;	chr6:37498140	chr6:37567716~37571460:+
TGCT	cis	rs9959491	0.56	rs11083228	ENSG00000227279.1	AC015933.2	4.42	2.1e-05	0.0137	0.4	0.37	Breast cancer;	chr18:27808336	chr18:27954519~27963687:+
TGCT	cis	rs12143943	0.966	rs2169136	ENSG00000176754.11	LINC00303	4.42	2.1e-05	0.0137	0.33	0.37	Cognitive performance;	chr1:204595109	chr1:204032447~204041265:-
TGCT	cis	rs7829975	0.714	rs59046059	ENSG00000173295.6	FAM86B3P	4.42	2.1e-05	0.0137	0.45	0.37	Mood instability;	chr8:8813226	chr8:8228595~8244865:+
TGCT	cis	rs4835473	0.864	rs56084830	ENSG00000251600.4	RP11-673E1.1	-4.42	2.1e-05	0.0137	-0.37	-0.37	Immature fraction of reticulocytes;	chr4:143791943	chr4:143912331~143982454:+
TGCT	cis	rs11671005	0.737	rs11673101	ENSG00000268912.1	CTD-2619J13.17	-4.42	2.1e-05	0.0137	-0.5	-0.37	Mean platelet volume;	chr19:58483686	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.696	rs73066211	ENSG00000268912.1	CTD-2619J13.17	-4.42	2.1e-05	0.0137	-0.5	-0.37	Mean platelet volume;	chr19:58485712	chr19:58428632~58431148:-
TGCT	cis	rs13256369	0.774	rs13260303	ENSG00000173295.6	FAM86B3P	4.42	2.11e-05	0.0137	0.52	0.37	Obesity-related traits;	chr8:8729832	chr8:8228595~8244865:+
TGCT	cis	rs73086581	0.645	rs2103659	ENSG00000229539.1	RP11-119B16.2	-4.42	2.11e-05	0.0137	-0.46	-0.37	Response to antidepressants in depression;	chr20:4001925	chr20:3888239~3888868:-
TGCT	cis	rs453301	0.592	rs4841084	ENSG00000254340.1	RP11-10A14.3	4.42	2.11e-05	0.0137	0.38	0.37	Joint mobility (Beighton score);	chr8:9026395	chr8:9141424~9145435:+
TGCT	cis	rs453301	0.653	rs2956244	ENSG00000254340.1	RP11-10A14.3	4.42	2.11e-05	0.0137	0.38	0.37	Joint mobility (Beighton score);	chr8:9027656	chr8:9141424~9145435:+
TGCT	cis	rs8059260	0.541	rs35126143	ENSG00000274038.1	RP11-66H6.4	-4.42	2.11e-05	0.0137	-0.56	-0.37	Alcohol consumption over the past year;	chr16:11070455	chr16:11056556~11057034:+
TGCT	cis	rs4713118	0.868	rs35069907	ENSG00000272009.1	RP1-313I6.12	-4.42	2.11e-05	0.0138	-0.46	-0.37	Parkinson's disease;	chr6:27778913	chr6:28078792~28081130:-
TGCT	cis	rs853679	0.599	rs202906	ENSG00000216901.1	AL022393.7	-4.42	2.11e-05	0.0138	-0.63	-0.37	Depression;	chr6:28043874	chr6:28176188~28176674:+
TGCT	cis	rs853679	0.599	rs149949	ENSG00000216901.1	AL022393.7	4.42	2.11e-05	0.0138	0.63	0.37	Depression;	chr6:28043738	chr6:28176188~28176674:+
TGCT	cis	rs7246967	0.611	rs62118770	ENSG00000269509.1	BNIP3P34	4.42	2.12e-05	0.0138	0.59	0.37	Bronchopulmonary dysplasia;	chr19:22641227	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs62118771	ENSG00000269509.1	BNIP3P34	4.42	2.12e-05	0.0138	0.59	0.37	Bronchopulmonary dysplasia;	chr19:22641496	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs62118780	ENSG00000269509.1	BNIP3P34	4.42	2.12e-05	0.0138	0.59	0.37	Bronchopulmonary dysplasia;	chr19:22648312	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs4933019	ENSG00000269509.1	BNIP3P34	4.42	2.12e-05	0.0138	0.59	0.37	Bronchopulmonary dysplasia;	chr19:22649184	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs35355374	ENSG00000269509.1	BNIP3P34	4.42	2.12e-05	0.0138	0.59	0.37	Bronchopulmonary dysplasia;	chr19:22654899	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.551	rs34563787	ENSG00000269509.1	BNIP3P34	4.42	2.12e-05	0.0138	0.59	0.37	Bronchopulmonary dysplasia;	chr19:22654934	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs12983761	ENSG00000269509.1	BNIP3P34	4.42	2.12e-05	0.0138	0.59	0.37	Bronchopulmonary dysplasia;	chr19:22657795	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs8108452	ENSG00000269509.1	BNIP3P34	4.42	2.12e-05	0.0138	0.59	0.37	Bronchopulmonary dysplasia;	chr19:22670816	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs12973627	ENSG00000269509.1	BNIP3P34	4.42	2.12e-05	0.0138	0.59	0.37	Bronchopulmonary dysplasia;	chr19:22684903	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.551	rs12974117	ENSG00000269509.1	BNIP3P34	4.42	2.12e-05	0.0138	0.59	0.37	Bronchopulmonary dysplasia;	chr19:22685074	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs62120304	ENSG00000269509.1	BNIP3P34	4.42	2.12e-05	0.0138	0.59	0.37	Bronchopulmonary dysplasia;	chr19:22689466	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs73022717	ENSG00000269509.1	BNIP3P34	4.42	2.12e-05	0.0138	0.59	0.37	Bronchopulmonary dysplasia;	chr19:22694257	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs8102927	ENSG00000269509.1	BNIP3P34	4.42	2.12e-05	0.0138	0.59	0.37	Bronchopulmonary dysplasia;	chr19:22696554	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs74664155	ENSG00000269509.1	BNIP3P34	4.42	2.12e-05	0.0138	0.59	0.37	Bronchopulmonary dysplasia;	chr19:22697530	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.551	rs59127381	ENSG00000269509.1	BNIP3P34	4.42	2.12e-05	0.0138	0.59	0.37	Bronchopulmonary dysplasia;	chr19:22702233	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.551	rs73022749	ENSG00000269509.1	BNIP3P34	4.42	2.12e-05	0.0138	0.59	0.37	Bronchopulmonary dysplasia;	chr19:22704458	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs67531478	ENSG00000269509.1	BNIP3P34	4.42	2.12e-05	0.0138	0.59	0.37	Bronchopulmonary dysplasia;	chr19:22706702	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.604	rs8112577	ENSG00000269509.1	BNIP3P34	4.42	2.12e-05	0.0138	0.59	0.37	Bronchopulmonary dysplasia;	chr19:22710669	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs4446014	ENSG00000269509.1	BNIP3P34	4.42	2.12e-05	0.0138	0.59	0.37	Bronchopulmonary dysplasia;	chr19:22714956	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.604	rs8111899	ENSG00000269509.1	BNIP3P34	4.42	2.12e-05	0.0138	0.59	0.37	Bronchopulmonary dysplasia;	chr19:22716069	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.611	rs56276210	ENSG00000269509.1	BNIP3P34	4.42	2.12e-05	0.0138	0.59	0.37	Bronchopulmonary dysplasia;	chr19:22716841	chr19:22773853~22774424:+
TGCT	cis	rs12130219	0.5	rs4845743	ENSG00000237975.5	FLG-AS1	-4.42	2.12e-05	0.0138	-0.4	-0.37	Inflammatory skin disease;	chr1:152211673	chr1:152168125~152445456:+
TGCT	cis	rs7829975	0.509	rs2945269	ENSG00000254340.1	RP11-10A14.3	4.42	2.13e-05	0.0138	0.37	0.37	Mood instability;	chr8:8258056	chr8:9141424~9145435:+
TGCT	cis	rs875971	0.964	rs778723	ENSG00000237310.1	GS1-124K5.4	4.42	2.13e-05	0.0138	0.41	0.37	Aortic root size;	chr7:66364510	chr7:66493706~66495474:+
TGCT	cis	rs9309473	1	rs11893881	ENSG00000163016.8	ALMS1P	4.42	2.13e-05	0.0138	0.33	0.37	Metabolite levels;	chr2:73597246	chr2:73644919~73685576:+
TGCT	cis	rs877819	0.583	rs2663050	ENSG00000228403.1	RP11-563N6.6	-4.42	2.13e-05	0.0139	-0.39	-0.37	Systemic lupus erythematosus;	chr10:48862280	chr10:48878022~48878649:+
TGCT	cis	rs877819	0.583	rs2940729	ENSG00000228403.1	RP11-563N6.6	-4.42	2.13e-05	0.0139	-0.39	-0.37	Systemic lupus erythematosus;	chr10:48866159	chr10:48878022~48878649:+
TGCT	cis	rs877819	0.583	rs2663019	ENSG00000228403.1	RP11-563N6.6	-4.42	2.13e-05	0.0139	-0.39	-0.37	Systemic lupus erythematosus;	chr10:48867416	chr10:48878022~48878649:+
TGCT	cis	rs875971	0.862	rs1875057	ENSG00000237310.1	GS1-124K5.4	-4.42	2.13e-05	0.0139	-0.4	-0.37	Aortic root size;	chr7:66266868	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs6960446	ENSG00000237310.1	GS1-124K5.4	-4.42	2.13e-05	0.0139	-0.4	-0.37	Aortic root size;	chr7:66268272	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.789	rs10260426	ENSG00000237310.1	GS1-124K5.4	-4.42	2.13e-05	0.0139	-0.4	-0.37	Aortic root size;	chr7:66271055	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs7796162	ENSG00000237310.1	GS1-124K5.4	-4.42	2.13e-05	0.0139	-0.4	-0.37	Aortic root size;	chr7:66280771	chr7:66493706~66495474:+
TGCT	cis	rs1023500	0.506	rs6002625	ENSG00000270083.1	RP1-257I20.14	-4.42	2.13e-05	0.0139	-0.37	-0.37	Schizophrenia;	chr22:42121685	chr22:42089630~42090028:-
TGCT	cis	rs2732480	1	rs2732480	ENSG00000258273.1	RP11-370I10.4	4.42	2.14e-05	0.0139	0.41	0.37	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342520	chr12:48333755~48333901:-
TGCT	cis	rs7833986	0.501	rs2668007	ENSG00000253603.1	CTA-397H3.3	4.42	2.14e-05	0.0139	0.61	0.37	Height;	chr8:56031552	chr8:56074592~56075274:+
TGCT	cis	rs4713118	0.662	rs175954	ENSG00000187763.3	OR2B7P	4.42	2.14e-05	0.0139	0.37	0.37	Parkinson's disease;	chr6:28043807	chr6:28046434~28047367:+
TGCT	cis	rs2408955	0.521	rs11168437	ENSG00000258273.1	RP11-370I10.4	-4.42	2.14e-05	0.0139	-0.43	-0.37	Glycated hemoglobin levels;	chr12:48172373	chr12:48333755~48333901:-
TGCT	cis	rs9309473	0.95	rs73947808	ENSG00000163016.8	ALMS1P	4.42	2.14e-05	0.0139	0.34	0.37	Metabolite levels;	chr2:73494123	chr2:73644919~73685576:+
TGCT	cis	rs4713118	0.614	rs9380007	ENSG00000216901.1	AL022393.7	4.42	2.14e-05	0.0139	0.42	0.37	Parkinson's disease;	chr6:27692729	chr6:28176188~28176674:+
TGCT	cis	rs12745968	0.652	rs4970700	ENSG00000223787.2	RP4-593M8.1	4.42	2.14e-05	0.0139	0.48	0.37	Bipolar disorder and schizophrenia;	chr1:92509936	chr1:92580476~92580821:-
TGCT	cis	rs801193	0.569	rs2659893	ENSG00000237310.1	GS1-124K5.4	4.42	2.14e-05	0.0139	0.4	0.37	Aortic root size;	chr7:66735006	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.569	rs2659892	ENSG00000237310.1	GS1-124K5.4	4.42	2.14e-05	0.0139	0.4	0.37	Aortic root size;	chr7:66735318	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.548	rs2659891	ENSG00000237310.1	GS1-124K5.4	4.42	2.14e-05	0.0139	0.4	0.37	Aortic root size;	chr7:66736127	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.569	rs2707847	ENSG00000237310.1	GS1-124K5.4	4.42	2.14e-05	0.0139	0.4	0.37	Aortic root size;	chr7:66737884	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.548	rs7805152	ENSG00000237310.1	GS1-124K5.4	4.42	2.14e-05	0.0139	0.4	0.37	Aortic root size;	chr7:66744266	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.569	rs11761542	ENSG00000237310.1	GS1-124K5.4	4.42	2.14e-05	0.0139	0.4	0.37	Aortic root size;	chr7:66753209	chr7:66493706~66495474:+
TGCT	cis	rs4660456	0.913	rs2361651	ENSG00000237899.1	RP4-739H11.3	4.42	2.15e-05	0.0139	0.5	0.37	Platelet count;	chr1:40764542	chr1:40669089~40687588:-
TGCT	cis	rs7829975	0.606	rs7837026	ENSG00000173295.6	FAM86B3P	-4.42	2.15e-05	0.0139	-0.46	-0.37	Mood instability;	chr8:8944182	chr8:8228595~8244865:+
TGCT	cis	rs8105895	0.935	rs62111032	ENSG00000269742.1	BNIP3P29	4.42	2.15e-05	0.0139	0.68	0.37	Body mass index (change over time);	chr19:22098547	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs959908	ENSG00000269742.1	BNIP3P29	4.42	2.15e-05	0.0139	0.68	0.37	Body mass index (change over time);	chr19:22099091	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.867	rs12151358	ENSG00000269742.1	BNIP3P29	4.42	2.15e-05	0.0139	0.68	0.37	Body mass index (change over time);	chr19:22099806	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs62111034	ENSG00000269742.1	BNIP3P29	4.42	2.15e-05	0.0139	0.68	0.37	Body mass index (change over time);	chr19:22101918	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.867	rs62111037	ENSG00000269742.1	BNIP3P29	4.42	2.15e-05	0.0139	0.68	0.37	Body mass index (change over time);	chr19:22103761	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs7254050	ENSG00000269742.1	BNIP3P29	4.42	2.15e-05	0.0139	0.68	0.37	Body mass index (change over time);	chr19:22103939	chr19:22065828~22066398:-
TGCT	cis	rs7255436	0.965	rs7254882	ENSG00000269386.4	RAB11B-AS1	4.42	2.15e-05	0.0139	0.38	0.37	HDL cholesterol;	chr19:8388938	chr19:8374373~8390685:-
TGCT	cis	rs12745968	0.589	rs3936945	ENSG00000223787.2	RP4-593M8.1	-4.42	2.15e-05	0.014	-0.49	-0.37	Bipolar disorder and schizophrenia;	chr1:92641314	chr1:92580476~92580821:-
TGCT	cis	rs801193	1	rs2707856	ENSG00000272831.1	RP11-792A8.4	4.42	2.15e-05	0.014	0.4	0.37	Aortic root size;	chr7:66746023	chr7:66739829~66740385:-
TGCT	cis	rs7104764	0.778	rs7930823	ENSG00000277290.1	RP11-326C3.16	4.42	2.16e-05	0.014	0.33	0.37	Menarche (age at onset);	chr11:206767	chr11:243099~243483:-
TGCT	cis	rs1012068	0.581	rs5753817	ENSG00000236132.1	CTA-440B3.1	-4.42	2.16e-05	0.014	-0.43	-0.37	Chronic hepatitis C infection;	chr22:31917741	chr22:31816379~31817491:-
TGCT	cis	rs1012068	0.541	rs11703587	ENSG00000236132.1	CTA-440B3.1	-4.42	2.16e-05	0.014	-0.43	-0.37	Chronic hepatitis C infection;	chr22:31926428	chr22:31816379~31817491:-
TGCT	cis	rs13108904	0.539	rs13141169	ENSG00000253399.1	AC078852.2	-4.42	2.16e-05	0.014	-0.44	-0.37	Obesity-related traits;	chr4:1346565	chr4:1358479~1359461:+
TGCT	cis	rs10504229	0.683	rs16921843	ENSG00000253301.4	RP11-513O17.2	4.42	2.16e-05	0.014	0.55	0.37	Developmental language disorder (linguistic errors);	chr8:57200779	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs56211106	ENSG00000253301.4	RP11-513O17.2	4.42	2.16e-05	0.014	0.55	0.37	Developmental language disorder (linguistic errors);	chr8:57200938	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.639	rs17331850	ENSG00000253301.4	RP11-513O17.2	4.42	2.16e-05	0.014	0.55	0.37	Developmental language disorder (linguistic errors);	chr8:57200979	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs6995355	ENSG00000253301.4	RP11-513O17.2	4.42	2.16e-05	0.014	0.55	0.37	Developmental language disorder (linguistic errors);	chr8:57201311	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.679	rs6995378	ENSG00000253301.4	RP11-513O17.2	4.42	2.16e-05	0.014	0.55	0.37	Developmental language disorder (linguistic errors);	chr8:57201374	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.638	rs6981055	ENSG00000253301.4	RP11-513O17.2	4.42	2.16e-05	0.014	0.55	0.37	Developmental language disorder (linguistic errors);	chr8:57201382	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.645	rs6995814	ENSG00000253301.4	RP11-513O17.2	4.42	2.16e-05	0.014	0.55	0.37	Developmental language disorder (linguistic errors);	chr8:57201600	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs7000349	ENSG00000253301.4	RP11-513O17.2	4.42	2.16e-05	0.014	0.55	0.37	Developmental language disorder (linguistic errors);	chr8:57202010	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs2873638	ENSG00000253301.4	RP11-513O17.2	4.42	2.16e-05	0.014	0.55	0.37	Developmental language disorder (linguistic errors);	chr8:57202034	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs2318143	ENSG00000253301.4	RP11-513O17.2	4.42	2.16e-05	0.014	0.55	0.37	Developmental language disorder (linguistic errors);	chr8:57202101	chr8:57142689~57240298:+
TGCT	cis	rs8108269	0.955	rs55872740	ENSG00000241226.3	RN7SL836P	-4.42	2.16e-05	0.014	-0.39	-0.37	Type 2 diabetes;	chr19:45657065	chr19:45651510~45651805:+
TGCT	cis	rs4691139	0.873	rs12509081	ENSG00000236941.6	RP11-366M4.8	4.42	2.17e-05	0.014	0.27	0.37	Ovarian cancer in BRCA1 mutation carriers;	chr4:164971812	chr4:164948079~164949438:+
TGCT	cis	rs9880211	0.519	rs10512981	ENSG00000239213.4	NCK1-AS1	4.42	2.17e-05	0.014	0.37	0.37	Height;Body mass index;	chr3:135930468	chr3:136841726~136862054:-
TGCT	cis	rs7621331	0.747	rs7640153	ENSG00000239213.4	NCK1-AS1	4.42	2.17e-05	0.014	0.37	0.37	Waist circumference adjusted for body mass index;	chr3:135931218	chr3:136841726~136862054:-
TGCT	cis	rs9844666	0.532	rs7638129	ENSG00000239213.4	NCK1-AS1	4.42	2.17e-05	0.014	0.37	0.37	Height;	chr3:135931799	chr3:136841726~136862054:-
TGCT	cis	rs9844666	0.512	rs2204259	ENSG00000239213.4	NCK1-AS1	4.42	2.17e-05	0.014	0.37	0.37	Height;	chr3:135934430	chr3:136841726~136862054:-
TGCT	cis	rs9844666	0.512	rs66544356	ENSG00000239213.4	NCK1-AS1	4.42	2.17e-05	0.014	0.37	0.37	Height;	chr3:135935625	chr3:136841726~136862054:-
TGCT	cis	rs4423214	0.84	rs1792231	ENSG00000254682.1	RP11-660L16.2	-4.42	2.17e-05	0.014	-0.57	-0.37	Vitamin D levels;	chr11:71471635	chr11:71448674~71452157:+
TGCT	cis	rs34779708	0.832	rs6481946	ENSG00000230534.5	RP11-297A16.2	4.42	2.17e-05	0.014	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35240186	chr10:35098006~35127020:-
TGCT	cis	rs1355223	0.573	rs7125773	ENSG00000271369.1	RP11-350D17.3	-4.42	2.17e-05	0.014	-0.37	-0.37	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34702026	chr11:34709600~34710161:+
TGCT	cis	rs520525	1	rs520525	ENSG00000271811.1	RP1-79C4.4	4.42	2.17e-05	0.014	0.3	0.37	Atrial fibrillation;	chr1:170669192	chr1:170667381~170669425:+
TGCT	cis	rs10129255	0.5	rs9324092	ENSG00000223648.3	IGHV3-64	-4.42	2.17e-05	0.014	-0.32	-0.37	Kawasaki disease;	chr14:106683806	chr14:106643132~106658258:-
TGCT	cis	rs72819454	0.522	rs55921327	ENSG00000266852.2	MIR4482	4.42	2.17e-05	0.0141	0.64	0.37	Interleukin-9 levels;	chr10:103756584	chr10:104268336~104268405:-
TGCT	cis	rs4660456	1	rs4660456	ENSG00000237899.1	RP4-739H11.3	-4.41	2.17e-05	0.0141	-0.5	-0.37	Platelet count;	chr1:40773839	chr1:40669089~40687588:-
TGCT	cis	rs2742234	0.59	rs2503864	ENSG00000273008.1	RP11-351D16.3	-4.41	2.17e-05	0.0141	-0.48	-0.37	Hirschsprung disease;	chr10:43171319	chr10:43136824~43138334:-
TGCT	cis	rs972540	1	rs61570189	ENSG00000279220.1	GPR1-AS	4.41	2.17e-05	0.0141	0.37	0.37	Body mass index;	chr2:206399831	chr2:206203376~206266243:+
TGCT	cis	rs796364	0.806	rs74706215	ENSG00000232732.8	AC073043.1	4.41	2.18e-05	0.0141	0.54	0.37	Schizophrenia;	chr2:200076644	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs56216998	ENSG00000232732.8	AC073043.1	4.41	2.18e-05	0.0141	0.54	0.37	Schizophrenia;	chr2:200079610	chr2:199867396~199911159:-
TGCT	cis	rs7201929	1	rs8061877	ENSG00000251417.2	RP11-1348G14.4	4.41	2.18e-05	0.0141	0.4	0.37	QT interval;	chr16:28845498	chr16:28802743~28817828:+
TGCT	cis	rs367615	0.552	rs3828603	ENSG00000249476.1	CTD-2587M2.1	-4.41	2.18e-05	0.0141	-0.39	-0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109376367	chr5:109237120~109326369:-
TGCT	cis	rs10504229	0.635	rs72649130	ENSG00000253301.4	RP11-513O17.2	4.41	2.18e-05	0.0141	0.59	0.37	Developmental language disorder (linguistic errors);	chr8:57141251	chr8:57142689~57240298:+
TGCT	cis	rs2944755	0.723	rs9694342	ENSG00000279766.1	RP11-642A1.2	-4.41	2.18e-05	0.0141	-0.36	-0.37	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140577305	chr8:140572142~140572812:-
TGCT	cis	rs17507216	1	rs17356118	ENSG00000255769.6	GOLGA2P10	-4.41	2.18e-05	0.0141	-0.45	-0.37	Excessive daytime sleepiness;	chr15:82569149	chr15:82472993~82513950:-
TGCT	cis	rs4660456	0.956	rs4660457	ENSG00000237899.1	RP4-739H11.3	-4.41	2.18e-05	0.0141	-0.5	-0.37	Platelet count;	chr1:40774121	chr1:40669089~40687588:-
TGCT	cis	rs17711722	0.565	rs73372653	ENSG00000226824.5	RP4-756H11.3	-4.41	2.18e-05	0.0141	-0.4	-0.37	Calcium levels;	chr7:65977808	chr7:66654538~66669855:+
TGCT	cis	rs507080	0.733	rs489126	ENSG00000255239.1	AP002954.6	4.41	2.19e-05	0.0141	0.49	0.37	Serum metabolite levels;	chr11:118702038	chr11:118688039~118690600:-
TGCT	cis	rs8059260	0.542	rs80000109	ENSG00000274038.1	RP11-66H6.4	-4.41	2.19e-05	0.0141	-0.53	-0.37	Alcohol consumption over the past year;	chr16:11031457	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.542	rs11860777	ENSG00000274038.1	RP11-66H6.4	-4.41	2.19e-05	0.0141	-0.53	-0.37	Alcohol consumption over the past year;	chr16:11033718	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.542	rs11860851	ENSG00000274038.1	RP11-66H6.4	-4.41	2.19e-05	0.0141	-0.53	-0.37	Alcohol consumption over the past year;	chr16:11033893	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.542	rs16957948	ENSG00000274038.1	RP11-66H6.4	-4.41	2.19e-05	0.0141	-0.53	-0.37	Alcohol consumption over the past year;	chr16:11034208	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.542	rs7184915	ENSG00000274038.1	RP11-66H6.4	-4.41	2.19e-05	0.0141	-0.53	-0.37	Alcohol consumption over the past year;	chr16:11034509	chr16:11056556~11057034:+
TGCT	cis	rs11822910	0.737	rs2729389	ENSG00000265566.2	RN7SL605P	-4.41	2.19e-05	0.0141	-0.43	-0.37	Platelet distribution width;	chr11:57444173	chr11:57528085~57528365:-
TGCT	cis	rs7923609	0.869	rs9971352	ENSG00000232075.1	MRPL35P2	-4.41	2.19e-05	0.0142	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63505348	chr10:63634317~63634827:-
TGCT	cis	rs728616	0.867	rs17883671	ENSG00000230091.5	TMEM254-AS1	4.41	2.19e-05	0.0142	0.7	0.37	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79935437	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs17885031	ENSG00000230091.5	TMEM254-AS1	4.41	2.19e-05	0.0142	0.7	0.37	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79936335	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs3088308	ENSG00000230091.5	TMEM254-AS1	4.41	2.19e-05	0.0142	0.7	0.37	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79938112	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs17879726	ENSG00000230091.5	TMEM254-AS1	4.41	2.19e-05	0.0142	0.7	0.37	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79938967	chr10:80046860~80078912:-
TGCT	cis	rs10759883	0.563	rs690286	ENSG00000175611.10	LINC00476	4.41	2.19e-05	0.0142	0.33	0.37	Nicotine dependence;	chr9:96034685	chr9:95759231~95875977:-
TGCT	cis	rs7829975	0.714	rs11784052	ENSG00000254340.1	RP11-10A14.3	4.41	2.2e-05	0.0142	0.37	0.37	Mood instability;	chr8:8814452	chr8:9141424~9145435:+
TGCT	cis	rs7246967	0.611	rs12978511	ENSG00000269509.1	BNIP3P34	4.41	2.2e-05	0.0142	0.58	0.37	Bronchopulmonary dysplasia;	chr19:22636414	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs12978964	ENSG00000269509.1	BNIP3P34	4.41	2.2e-05	0.0142	0.58	0.37	Bronchopulmonary dysplasia;	chr19:22636442	chr19:22773853~22774424:+
TGCT	cis	rs11086243	0.935	rs6066638	ENSG00000235621.7	LINC00494	-4.41	2.2e-05	0.0142	-0.33	-0.37	Nephrotic syndrome (acquired);	chr20:48135716	chr20:48359950~48370629:+
TGCT	cis	rs875971	0.862	rs2460432	ENSG00000232559.3	GS1-124K5.12	-4.41	2.2e-05	0.0142	-0.35	-0.37	Aortic root size;	chr7:66089398	chr7:66554588~66576923:-
TGCT	cis	rs1061377	0.748	rs4974933	ENSG00000249685.1	RP11-360F5.3	4.41	2.2e-05	0.0142	0.34	0.37	Uric acid levels;	chr4:39105636	chr4:39133913~39135608:+
TGCT	cis	rs6600671	0.902	rs2222371	ENSG00000275131.1	CH17-472G23.4	4.41	2.2e-05	0.0142	0.25	0.37	Hip geometry;	chr1:121547320	chr1:120489625~120579190:-
TGCT	cis	rs2976388	0.934	rs2920279	ENSG00000253196.1	RP11-706C16.7	-4.41	2.2e-05	0.0142	-0.38	-0.37	Urinary tract infection frequency;	chr8:142680717	chr8:142763116~142766427:+
TGCT	cis	rs10256972	0.514	rs2140578	ENSG00000226291.1	AC091729.8	-4.41	2.2e-05	0.0142	-0.4	-0.37	Endometriosis;Longevity;	chr7:1174367	chr7:1080863~1082178:+
TGCT	cis	rs2280018	0.526	rs2966128	ENSG00000260735.1	RP11-72I8.1	-4.41	2.2e-05	0.0142	-0.51	-0.37	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15094411~15109197:+
TGCT	cis	rs2280018	0.526	rs2966129	ENSG00000260735.1	RP11-72I8.1	4.41	2.2e-05	0.0142	0.51	0.37	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15094411~15109197:+
TGCT	cis	rs901683	0.85	rs12765244	ENSG00000264204.2	AGAP7P	-4.41	2.2e-05	0.0142	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45536593	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71496612	ENSG00000264204.2	AGAP7P	-4.41	2.2e-05	0.0142	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45537057	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71496613	ENSG00000264204.2	AGAP7P	-4.41	2.2e-05	0.0142	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45537125	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs17157898	ENSG00000264204.2	AGAP7P	-4.41	2.2e-05	0.0142	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45541761	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs36054203	ENSG00000264204.2	AGAP7P	-4.41	2.2e-05	0.0142	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45542413	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs12776291	ENSG00000264204.2	AGAP7P	-4.41	2.2e-05	0.0142	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45543059	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs12781506	ENSG00000264204.2	AGAP7P	-4.41	2.2e-05	0.0142	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45543254	chr10:46109621~46131358:+
TGCT	cis	rs901683	0.85	rs12774453	ENSG00000264204.2	AGAP7P	-4.41	2.2e-05	0.0142	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45543473	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs34309840	ENSG00000264204.2	AGAP7P	-4.41	2.2e-05	0.0142	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45543913	chr10:46109621~46131358:+
TGCT	cis	rs901683	0.85	rs36109121	ENSG00000264204.2	AGAP7P	-4.41	2.2e-05	0.0142	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45544063	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35034867	ENSG00000264204.2	AGAP7P	-4.41	2.2e-05	0.0142	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45544117	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs75595592	ENSG00000264204.2	AGAP7P	-4.41	2.2e-05	0.0142	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45544482	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs9422439	ENSG00000264204.2	AGAP7P	-4.41	2.2e-05	0.0142	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45545025	chr10:46109621~46131358:+
TGCT	cis	rs1012068	0.662	rs5753816	ENSG00000236132.1	CTA-440B3.1	-4.41	2.2e-05	0.0142	-0.43	-0.37	Chronic hepatitis C infection;	chr22:31916856	chr22:31816379~31817491:-
TGCT	cis	rs2117029	0.561	rs7957983	ENSG00000258017.1	RP11-386G11.10	-4.41	2.21e-05	0.0142	-0.48	-0.37	Intelligence (multi-trait analysis);	chr12:49115204	chr12:49127782~49147869:+
TGCT	cis	rs2117029	0.587	rs7958572	ENSG00000258017.1	RP11-386G11.10	-4.41	2.21e-05	0.0142	-0.48	-0.37	Intelligence (multi-trait analysis);	chr12:49115658	chr12:49127782~49147869:+
TGCT	cis	rs796364	0.806	rs74724807	ENSG00000232732.8	AC073043.1	4.41	2.21e-05	0.0142	0.51	0.37	Schizophrenia;	chr2:200140386	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs74266489	ENSG00000232732.8	AC073043.1	4.41	2.21e-05	0.0142	0.51	0.37	Schizophrenia;	chr2:200141009	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs74266490	ENSG00000232732.8	AC073043.1	4.41	2.21e-05	0.0142	0.51	0.37	Schizophrenia;	chr2:200141272	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs115717210	ENSG00000232732.8	AC073043.1	4.41	2.21e-05	0.0142	0.51	0.37	Schizophrenia;	chr2:200141524	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs77853713	ENSG00000232732.8	AC073043.1	4.41	2.21e-05	0.0142	0.51	0.37	Schizophrenia;	chr2:200142157	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs12616905	ENSG00000232732.8	AC073043.1	4.41	2.21e-05	0.0142	0.51	0.37	Schizophrenia;	chr2:200143041	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs11684895	ENSG00000232732.8	AC073043.1	4.41	2.21e-05	0.0142	0.51	0.37	Schizophrenia;	chr2:200144303	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs11684942	ENSG00000232732.8	AC073043.1	4.41	2.21e-05	0.0142	0.51	0.37	Schizophrenia;	chr2:200144413	chr2:199867396~199911159:-
TGCT	cis	rs67311347	1	rs6599102	ENSG00000223797.4	ENTPD3-AS1	4.41	2.21e-05	0.0142	0.39	0.37	Renal cell carcinoma;	chr3:40426915	chr3:40313802~40453329:-
TGCT	cis	rs67311347	0.911	rs6773917	ENSG00000223797.4	ENTPD3-AS1	4.41	2.21e-05	0.0142	0.39	0.37	Renal cell carcinoma;	chr3:40427763	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs9874006	ENSG00000223797.4	ENTPD3-AS1	4.41	2.21e-05	0.0142	0.39	0.37	Renal cell carcinoma;	chr3:40430105	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs56992941	ENSG00000223797.4	ENTPD3-AS1	4.41	2.21e-05	0.0142	0.39	0.37	Renal cell carcinoma;	chr3:40430943	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs4974017	ENSG00000223797.4	ENTPD3-AS1	4.41	2.21e-05	0.0142	0.39	0.37	Renal cell carcinoma;	chr3:40432028	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs12638199	ENSG00000223797.4	ENTPD3-AS1	4.41	2.21e-05	0.0142	0.39	0.37	Renal cell carcinoma;	chr3:40433794	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs34762643	ENSG00000223797.4	ENTPD3-AS1	4.41	2.21e-05	0.0142	0.39	0.37	Renal cell carcinoma;	chr3:40433942	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs9841335	ENSG00000223797.4	ENTPD3-AS1	4.41	2.21e-05	0.0142	0.39	0.37	Renal cell carcinoma;	chr3:40434367	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs6762997	ENSG00000223797.4	ENTPD3-AS1	4.41	2.21e-05	0.0142	0.39	0.37	Renal cell carcinoma;	chr3:40436660	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs977652	ENSG00000223797.4	ENTPD3-AS1	4.41	2.21e-05	0.0142	0.39	0.37	Renal cell carcinoma;	chr3:40437678	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs28434528	ENSG00000223797.4	ENTPD3-AS1	4.41	2.21e-05	0.0142	0.39	0.37	Renal cell carcinoma;	chr3:40443402	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs11716675	ENSG00000223797.4	ENTPD3-AS1	4.41	2.21e-05	0.0142	0.39	0.37	Renal cell carcinoma;	chr3:40443789	chr3:40313802~40453329:-
TGCT	cis	rs796364	0.806	rs79897806	ENSG00000232732.8	AC073043.1	4.41	2.21e-05	0.0142	0.54	0.37	Schizophrenia;	chr2:200209245	chr2:199867396~199911159:-
TGCT	cis	rs904251	0.797	rs1776460	ENSG00000204110.6	RP1-153P14.8	-4.41	2.21e-05	0.0142	-0.42	-0.37	Cognitive performance;	chr6:37517708	chr6:37507348~37535616:+
TGCT	cis	rs1497406	0.744	rs4661718	ENSG00000235084.3	CHCHD2P6	4.41	2.21e-05	0.0142	0.43	0.37	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);	chr1:16179413	chr1:15604597~15605043:+
TGCT	cis	rs1387259	0.759	rs7960122	ENSG00000258273.1	RP11-370I10.4	4.41	2.21e-05	0.0142	0.45	0.37	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48383217	chr12:48333755~48333901:-
TGCT	cis	rs4835473	0.8	rs1849122	ENSG00000251600.4	RP11-673E1.1	4.41	2.21e-05	0.0142	0.39	0.37	Immature fraction of reticulocytes;	chr4:143978699	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.771	rs4443231	ENSG00000251600.4	RP11-673E1.1	4.41	2.21e-05	0.0142	0.39	0.37	Immature fraction of reticulocytes;	chr4:143979501	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.771	rs4261935	ENSG00000251600.4	RP11-673E1.1	4.41	2.21e-05	0.0142	0.39	0.37	Immature fraction of reticulocytes;	chr4:143979751	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.524	rs4404495	ENSG00000251600.4	RP11-673E1.1	4.41	2.21e-05	0.0142	0.39	0.37	Immature fraction of reticulocytes;	chr4:143979791	chr4:143912331~143982454:+
TGCT	cis	rs74054849	0.571	rs4645995	ENSG00000235084.3	CHCHD2P6	4.41	2.21e-05	0.0142	0.7	0.37	Alcoholic chronic pancreatitis;	chr1:15522508	chr1:15604597~15605043:+
TGCT	cis	rs7208859	0.623	rs56325146	ENSG00000280069.1	CTD-2349P21.3	-4.41	2.21e-05	0.0142	-0.46	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30738182~30740275:+
TGCT	cis	rs7555523	0.83	rs6426936	ENSG00000224358.1	RP11-466F5.8	4.41	2.21e-05	0.0143	0.62	0.37	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165715470	chr1:165768929~165775176:+
TGCT	cis	rs7831492	0.548	rs10089438	ENSG00000253943.1	KRT18P37	4.41	2.22e-05	0.0143	0.4	0.37	Colorectal cancer;	chr8:41806628	chr8:41511240~41512521:+
TGCT	cis	rs904251	0.861	rs914349	ENSG00000204110.6	RP1-153P14.8	-4.41	2.22e-05	0.0143	-0.42	-0.37	Cognitive performance;	chr6:37516939	chr6:37507348~37535616:+
TGCT	cis	rs7615952	0.673	rs7632557	ENSG00000171084.14	FAM86JP	4.41	2.22e-05	0.0143	0.65	0.37	Blood pressure (smoking interaction);	chr3:125916038	chr3:125916620~125930024:+
TGCT	cis	rs2745572	0.688	rs2317961	ENSG00000272279.1	RP11-157J24.2	4.41	2.22e-05	0.0143	0.42	0.37	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1532881	chr6:1528364~1528911:-
TGCT	cis	rs7182621	0.512	rs12903892	ENSG00000259363.4	CTD-2054N24.2	-4.41	2.22e-05	0.0143	-0.38	-0.37	Colonoscopy-negative controls vs population controls;	chr15:99869662	chr15:99807023~99877148:+
TGCT	cis	rs5769707	0.777	rs739243	ENSG00000235111.1	RP1-29C18.8	-4.41	2.22e-05	0.0143	-0.3	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49663563	chr22:49612657~49615716:-
TGCT	cis	rs4713118	0.868	rs10484401	ENSG00000272009.1	RP1-313I6.12	4.41	2.23e-05	0.0143	0.46	0.37	Parkinson's disease;	chr6:27778811	chr6:28078792~28081130:-
TGCT	cis	rs2976388	1	rs2294008	ENSG00000253196.1	RP11-706C16.7	-4.41	2.23e-05	0.0144	-0.38	-0.37	Urinary tract infection frequency;	chr8:142680513	chr8:142763116~142766427:+
TGCT	cis	rs801193	0.569	rs13226966	ENSG00000237310.1	GS1-124K5.4	4.41	2.23e-05	0.0144	0.4	0.37	Aortic root size;	chr7:66768636	chr7:66493706~66495474:+
TGCT	cis	rs1823913	0.599	rs4146103	ENSG00000227542.1	AC092614.2	4.41	2.23e-05	0.0144	0.39	0.37	Obesity-related traits;	chr2:191272000	chr2:191229165~191246172:-
TGCT	cis	rs9322193	1	rs9377229	ENSG00000216906.2	RP11-350J20.9	4.41	2.23e-05	0.0144	0.41	0.37	Lung cancer;	chr6:149607655	chr6:149904243~149906418:+
TGCT	cis	rs12682352	0.652	rs3789843	ENSG00000254340.1	RP11-10A14.3	4.41	2.24e-05	0.0144	0.37	0.37	Neuroticism;	chr8:8866747	chr8:9141424~9145435:+
TGCT	cis	rs12682352	0.652	rs3827806	ENSG00000254340.1	RP11-10A14.3	4.41	2.24e-05	0.0144	0.37	0.37	Neuroticism;	chr8:8866766	chr8:9141424~9145435:+
TGCT	cis	rs16852403	0.548	rs7547504	ENSG00000224687.1	RASAL2-AS1	4.41	2.24e-05	0.0144	0.49	0.37	Childhood ear infection;	chr1:178232177	chr1:178091508~178093984:-
TGCT	cis	rs16852403	0.548	rs3748788	ENSG00000224687.1	RASAL2-AS1	4.41	2.24e-05	0.0144	0.49	0.37	Childhood ear infection;	chr1:178233672	chr1:178091508~178093984:-
TGCT	cis	rs16852403	0.548	rs1412784	ENSG00000224687.1	RASAL2-AS1	4.41	2.24e-05	0.0144	0.49	0.37	Childhood ear infection;	chr1:178237529	chr1:178091508~178093984:-
TGCT	cis	rs16852403	0.548	rs1018706	ENSG00000224687.1	RASAL2-AS1	4.41	2.24e-05	0.0144	0.49	0.37	Childhood ear infection;	chr1:178240760	chr1:178091508~178093984:-
TGCT	cis	rs16852403	0.519	rs10913523	ENSG00000224687.1	RASAL2-AS1	4.41	2.24e-05	0.0144	0.49	0.37	Childhood ear infection;	chr1:178250865	chr1:178091508~178093984:-
TGCT	cis	rs16852403	0.548	rs10913524	ENSG00000224687.1	RASAL2-AS1	4.41	2.24e-05	0.0144	0.49	0.37	Childhood ear infection;	chr1:178251972	chr1:178091508~178093984:-
TGCT	cis	rs16852403	0.581	rs10913525	ENSG00000224687.1	RASAL2-AS1	4.41	2.24e-05	0.0144	0.49	0.37	Childhood ear infection;	chr1:178254298	chr1:178091508~178093984:-
TGCT	cis	rs16852403	0.548	rs10798602	ENSG00000224687.1	RASAL2-AS1	4.41	2.24e-05	0.0144	0.49	0.37	Childhood ear infection;	chr1:178257304	chr1:178091508~178093984:-
TGCT	cis	rs10504229	0.683	rs17194995	ENSG00000253301.4	RP11-513O17.2	-4.41	2.24e-05	0.0144	-0.58	-0.37	Developmental language disorder (linguistic errors);	chr8:57196661	chr8:57142689~57240298:+
TGCT	cis	rs801193	0.875	rs13227951	ENSG00000236529.1	RP13-254B10.1	-4.41	2.24e-05	0.0144	-0.28	-0.37	Aortic root size;	chr7:66748121	chr7:65840212~65840596:+
TGCT	cis	rs8177876	0.658	rs12456	ENSG00000261061.1	RP11-303E16.2	-4.41	2.24e-05	0.0144	-0.68	-0.37	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81031454	chr16:81030770~81031485:+
TGCT	cis	rs2439831	0.85	rs694985	ENSG00000205771.5	CATSPER2P1	-4.41	2.24e-05	0.0144	-0.59	-0.37	Lung cancer in ever smokers;	chr15:43521189	chr15:43726918~43747094:-
TGCT	cis	rs599083	0.53	rs491347	ENSG00000212093.1	AP000807.1	-4.41	2.24e-05	0.0144	-0.39	-0.37	Bone mineral density (spine);	chr11:68402220	chr11:68506083~68506166:-
TGCT	cis	rs599083	0.569	rs685095	ENSG00000212093.1	AP000807.1	-4.41	2.24e-05	0.0144	-0.39	-0.37	Bone mineral density (spine);	chr11:68402908	chr11:68506083~68506166:-
TGCT	cis	rs599083	0.53	rs686921	ENSG00000212093.1	AP000807.1	-4.41	2.24e-05	0.0144	-0.39	-0.37	Bone mineral density (spine);	chr11:68403365	chr11:68506083~68506166:-
TGCT	cis	rs599083	0.53	rs2508834	ENSG00000212093.1	AP000807.1	-4.41	2.24e-05	0.0144	-0.39	-0.37	Bone mineral density (spine);	chr11:68407886	chr11:68506083~68506166:-
TGCT	cis	rs17361889	0.613	rs4721484	ENSG00000224683.1	RPL36AP29	4.41	2.24e-05	0.0144	0.39	0.37	Pediatric bone mineral content (hip);	chr7:16242778	chr7:16208945~16209265:+
TGCT	cis	rs1555322	0.53	rs6060347	ENSG00000126005.14	MMP24-AS1	-4.41	2.25e-05	0.0144	-0.45	-0.37	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35216462~35278131:-
TGCT	cis	rs2581828	0.931	rs2336722	ENSG00000242142.1	SERBP1P3	4.41	2.25e-05	0.0144	0.34	0.37	Crohn's disease;	chr3:53105961	chr3:53064283~53065091:-
TGCT	cis	rs4927850	0.501	rs9881504	ENSG00000242086.7	LINC00969	4.41	2.25e-05	0.0144	0.41	0.37	Pancreatic cancer;	chr3:195929743	chr3:195658062~195739964:+
TGCT	cis	rs7246967	0.544	rs420861	ENSG00000269509.1	BNIP3P34	4.41	2.25e-05	0.0145	0.49	0.37	Bronchopulmonary dysplasia;	chr19:22823102	chr19:22773853~22774424:+
TGCT	cis	rs7937890	0.706	rs7115393	ENSG00000254418.1	RP11-21L19.1	-4.41	2.25e-05	0.0145	-0.36	-0.37	Mitochondrial DNA levels;	chr11:14246832	chr11:14262846~14273691:-
TGCT	cis	rs7829975	0.714	rs11777085	ENSG00000254340.1	RP11-10A14.3	4.41	2.25e-05	0.0145	0.37	0.37	Mood instability;	chr8:8814919	chr8:9141424~9145435:+
TGCT	cis	rs755249	0.546	rs7533743	ENSG00000182109.6	RP11-69E11.4	-4.41	2.25e-05	0.0145	-0.38	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39491497	chr1:39522280~39546187:-
TGCT	cis	rs755249	0.565	rs7555699	ENSG00000182109.6	RP11-69E11.4	-4.41	2.25e-05	0.0145	-0.38	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39491629	chr1:39522280~39546187:-
TGCT	cis	rs755249	0.614	rs10888798	ENSG00000182109.6	RP11-69E11.4	-4.41	2.25e-05	0.0145	-0.38	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39492408	chr1:39522280~39546187:-
TGCT	cis	rs755249	0.565	rs1809697	ENSG00000182109.6	RP11-69E11.4	-4.41	2.25e-05	0.0145	-0.38	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39493413	chr1:39522280~39546187:-
TGCT	cis	rs4242434	0.854	rs3735893	ENSG00000254064.1	CTD-2530N21.4	-4.41	2.26e-05	0.0145	-0.21	-0.37	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22595191	chr8:22254576~22275162:-
TGCT	cis	rs847845	0.841	rs2395601	ENSG00000186328.4	RP11-140K17.2	4.41	2.26e-05	0.0145	0.52	0.37	Non-small cell lung cancer;	chr6:35009445	chr6:34715613~34715940:+
TGCT	cis	rs2976388	1	rs2294010	ENSG00000253196.1	RP11-706C16.7	-4.4	2.26e-05	0.0145	-0.38	-0.37	Urinary tract infection frequency;	chr8:142681012	chr8:142763116~142766427:+
TGCT	cis	rs2976388	1	rs2920298	ENSG00000253196.1	RP11-706C16.7	-4.4	2.26e-05	0.0145	-0.38	-0.37	Urinary tract infection frequency;	chr8:142681625	chr8:142763116~142766427:+
TGCT	cis	rs2976388	1	rs2920297	ENSG00000253196.1	RP11-706C16.7	-4.4	2.26e-05	0.0145	-0.38	-0.37	Urinary tract infection frequency;	chr8:142681665	chr8:142763116~142766427:+
TGCT	cis	rs2976388	1	rs2920296	ENSG00000253196.1	RP11-706C16.7	-4.4	2.26e-05	0.0145	-0.38	-0.37	Urinary tract infection frequency;	chr8:142681691	chr8:142763116~142766427:+
TGCT	cis	rs2976388	1	rs2978982	ENSG00000253196.1	RP11-706C16.7	-4.4	2.26e-05	0.0145	-0.38	-0.37	Urinary tract infection frequency;	chr8:142682072	chr8:142763116~142766427:+
TGCT	cis	rs2976388	1	rs1045531	ENSG00000253196.1	RP11-706C16.7	-4.4	2.26e-05	0.0145	-0.38	-0.37	Urinary tract infection frequency;	chr8:142682129	chr8:142763116~142766427:+
TGCT	cis	rs2976388	1	rs2976394	ENSG00000253196.1	RP11-706C16.7	-4.4	2.26e-05	0.0145	-0.38	-0.37	Urinary tract infection frequency;	chr8:142682204	chr8:142763116~142766427:+
TGCT	cis	rs2976388	1	rs10216533	ENSG00000253196.1	RP11-706C16.7	-4.4	2.26e-05	0.0145	-0.38	-0.37	Urinary tract infection frequency;	chr8:142682272	chr8:142763116~142766427:+
TGCT	cis	rs2976388	0.967	rs2976395	ENSG00000253196.1	RP11-706C16.7	-4.4	2.26e-05	0.0145	-0.38	-0.37	Urinary tract infection frequency;	chr8:142682332	chr8:142763116~142766427:+
TGCT	cis	rs2976388	1	rs1045547	ENSG00000253196.1	RP11-706C16.7	-4.4	2.26e-05	0.0145	-0.38	-0.37	Urinary tract infection frequency;	chr8:142682339	chr8:142763116~142766427:+
TGCT	cis	rs2976388	1	rs1045605	ENSG00000253196.1	RP11-706C16.7	-4.4	2.26e-05	0.0145	-0.38	-0.37	Urinary tract infection frequency;	chr8:142682683	chr8:142763116~142766427:+
TGCT	cis	rs2976388	1	rs2976398	ENSG00000253196.1	RP11-706C16.7	-4.4	2.26e-05	0.0145	-0.38	-0.37	Urinary tract infection frequency;	chr8:142683461	chr8:142763116~142766427:+
TGCT	cis	rs2976388	1	rs2920294	ENSG00000253196.1	RP11-706C16.7	-4.4	2.26e-05	0.0145	-0.38	-0.37	Urinary tract infection frequency;	chr8:142683908	chr8:142763116~142766427:+
TGCT	cis	rs2976388	1	rs2920293	ENSG00000253196.1	RP11-706C16.7	-4.4	2.26e-05	0.0145	-0.38	-0.37	Urinary tract infection frequency;	chr8:142683996	chr8:142763116~142766427:+
TGCT	cis	rs2976388	1	rs2920292	ENSG00000253196.1	RP11-706C16.7	-4.4	2.26e-05	0.0145	-0.38	-0.37	Urinary tract infection frequency;	chr8:142684281	chr8:142763116~142766427:+
TGCT	cis	rs9880211	0.948	rs9857966	ENSG00000239213.4	NCK1-AS1	4.4	2.27e-05	0.0145	0.4	0.37	Height;Body mass index;	chr3:136560548	chr3:136841726~136862054:-
TGCT	cis	rs12682352	0.602	rs1473029	ENSG00000253893.2	FAM85B	-4.4	2.27e-05	0.0145	-0.48	-0.37	Neuroticism;	chr8:8811407	chr8:8167819~8226614:-
TGCT	cis	rs10504229	0.639	rs2318145	ENSG00000253301.4	RP11-513O17.2	4.4	2.27e-05	0.0146	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57202308	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.639	rs2318146	ENSG00000253301.4	RP11-513O17.2	4.4	2.27e-05	0.0146	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57202314	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs2318148	ENSG00000253301.4	RP11-513O17.2	4.4	2.27e-05	0.0146	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57202396	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs6999984	ENSG00000253301.4	RP11-513O17.2	4.4	2.27e-05	0.0146	0.54	0.37	Developmental language disorder (linguistic errors);	chr8:57202520	chr8:57142689~57240298:+
TGCT	cis	rs494459	0.838	rs555639	ENSG00000255422.1	AP002954.4	4.4	2.27e-05	0.0146	0.39	0.37	Height;	chr11:118758322	chr11:118704607~118750263:+
TGCT	cis	rs2177312	0.868	rs1523176	ENSG00000251129.1	RP11-734I18.1	4.4	2.27e-05	0.0146	0.43	0.37	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31950414	chr4:31997397~32155406:+
TGCT	cis	rs877819	0.583	rs2663029	ENSG00000228403.1	RP11-563N6.6	4.4	2.28e-05	0.0146	0.37	0.37	Systemic lupus erythematosus;	chr10:48878956	chr10:48878022~48878649:+
TGCT	cis	rs950169	0.545	rs4354897	ENSG00000225151.9	GOLGA2P7	-4.4	2.28e-05	0.0146	-0.43	-0.37	Schizophrenia;	chr15:83976219	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.579	rs881983	ENSG00000225151.9	GOLGA2P7	-4.4	2.28e-05	0.0146	-0.43	-0.37	Schizophrenia;	chr15:83978556	chr15:84199311~84230136:-
TGCT	cis	rs6017291	1	rs66585887	ENSG00000223891.4	OSER1-AS1	4.4	2.28e-05	0.0146	0.55	0.37	Cognitive performance;	chr20:44238703	chr20:44210960~44226027:+
TGCT	cis	rs6017291	0.793	rs74173196	ENSG00000223891.4	OSER1-AS1	4.4	2.28e-05	0.0146	0.55	0.37	Cognitive performance;	chr20:44240017	chr20:44210960~44226027:+
TGCT	cis	rs6017291	1	rs73107727	ENSG00000223891.4	OSER1-AS1	4.4	2.28e-05	0.0146	0.55	0.37	Cognitive performance;	chr20:44240299	chr20:44210960~44226027:+
TGCT	cis	rs6017291	1	rs67768154	ENSG00000223891.4	OSER1-AS1	4.4	2.28e-05	0.0146	0.55	0.37	Cognitive performance;	chr20:44240327	chr20:44210960~44226027:+
TGCT	cis	rs599083	0.59	rs661988	ENSG00000212093.1	AP000807.1	4.4	2.28e-05	0.0146	0.42	0.37	Bone mineral density (spine);	chr11:68421783	chr11:68506083~68506166:-
TGCT	cis	rs10129255	0.828	rs10140989	ENSG00000211970.3	IGHV4-61	-4.4	2.28e-05	0.0146	-0.4	-0.37	Kawasaki disease;	chr14:106668657	chr14:106639119~106639657:-
TGCT	cis	rs4713118	0.621	rs9295756	ENSG00000219891.2	ZSCAN12P1	4.4	2.28e-05	0.0146	0.47	0.37	Parkinson's disease;	chr6:28065618	chr6:28091154~28093664:+
TGCT	cis	rs904251	0.62	rs883372	ENSG00000279942.1	RP1-153P14.7	-4.4	2.28e-05	0.0146	-0.47	-0.37	Cognitive performance;	chr6:37509829	chr6:37567716~37571460:+
TGCT	cis	rs3742264	1	rs9534312	ENSG00000235903.6	CPB2-AS1	-4.4	2.28e-05	0.0146	-0.45	-0.37	Blood protein levels;	chr13:46076084	chr13:46052806~46113332:+
TGCT	cis	rs8072100	0.967	rs7219303	ENSG00000228782.6	CTD-2026D20.3	-4.4	2.28e-05	0.0146	-0.44	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47660335	chr17:47450568~47492492:-
TGCT	cis	rs4308124	0.708	rs6727313	ENSG00000227992.1	AC108463.2	-4.4	2.28e-05	0.0146	-0.39	-0.37	Vitiligo;	chr2:111213963	chr2:111203964~111206215:-
TGCT	cis	rs4308124	0.708	rs10178095	ENSG00000227992.1	AC108463.2	-4.4	2.28e-05	0.0146	-0.39	-0.37	Vitiligo;	chr2:111214939	chr2:111203964~111206215:-
TGCT	cis	rs4308124	0.708	rs7585313	ENSG00000227992.1	AC108463.2	-4.4	2.28e-05	0.0146	-0.39	-0.37	Vitiligo;	chr2:111217626	chr2:111203964~111206215:-
TGCT	cis	rs494459	0.688	rs1048040	ENSG00000255422.1	AP002954.4	-4.4	2.29e-05	0.0147	-0.38	-0.37	Height;	chr11:118747911	chr11:118704607~118750263:+
TGCT	cis	rs494459	0.838	rs488219	ENSG00000255422.1	AP002954.4	-4.4	2.29e-05	0.0147	-0.38	-0.37	Height;	chr11:118749988	chr11:118704607~118750263:+
TGCT	cis	rs494459	0.838	rs1784543	ENSG00000255422.1	AP002954.4	-4.4	2.29e-05	0.0147	-0.38	-0.37	Height;	chr11:118760944	chr11:118704607~118750263:+
TGCT	cis	rs494459	0.657	rs614554	ENSG00000255422.1	AP002954.4	-4.4	2.29e-05	0.0147	-0.38	-0.37	Height;	chr11:118764443	chr11:118704607~118750263:+
TGCT	cis	rs3742264	1	rs9534305	ENSG00000235903.6	CPB2-AS1	-4.4	2.29e-05	0.0147	-0.44	-0.37	Blood protein levels;	chr13:46068021	chr13:46052806~46113332:+
TGCT	cis	rs1865760	0.927	rs6915834	ENSG00000217159.2	LARP1P1	-4.4	2.29e-05	0.0147	-0.42	-0.37	Height;	chr6:25935199	chr6:26164072~26164363:+
TGCT	cis	rs1865760	0.892	rs2328903	ENSG00000217159.2	LARP1P1	-4.4	2.29e-05	0.0147	-0.42	-0.37	Height;	chr6:25935537	chr6:26164072~26164363:+
TGCT	cis	rs1865760	0.892	rs6456705	ENSG00000217159.2	LARP1P1	-4.4	2.29e-05	0.0147	-0.42	-0.37	Height;	chr6:25935828	chr6:26164072~26164363:+
TGCT	cis	rs2725220	0.967	rs2728108	ENSG00000202000.1	RNU1-36P	-4.4	2.29e-05	0.0147	-0.31	-0.37	Renal function-related traits (urea);	chr4:88040584	chr4:88000237~88000401:+
TGCT	cis	rs6604026	0.555	rs1415296	ENSG00000223787.2	RP4-593M8.1	-4.4	2.29e-05	0.0147	-0.52	-0.37	Multiple sclerosis;	chr1:92624919	chr1:92580476~92580821:-
TGCT	cis	rs875971	1	rs778726	ENSG00000237310.1	GS1-124K5.4	4.4	2.29e-05	0.0147	0.41	0.37	Aortic root size;	chr7:66363744	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.767	rs1695815	ENSG00000237310.1	GS1-124K5.4	4.4	2.29e-05	0.0147	0.41	0.37	Aortic root size;	chr7:66366357	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs778685	ENSG00000237310.1	GS1-124K5.4	4.4	2.29e-05	0.0147	0.41	0.37	Aortic root size;	chr7:66371189	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.929	rs778682	ENSG00000237310.1	GS1-124K5.4	4.4	2.29e-05	0.0147	0.41	0.37	Aortic root size;	chr7:66372947	chr7:66493706~66495474:+
TGCT	cis	rs1372520	0.873	rs2583990	ENSG00000247775.2	SNCA-AS1	4.4	2.29e-05	0.0147	0.36	0.37	Neuroticism;	chr4:89850348	chr4:89836408~89841978:+
TGCT	cis	rs801193	1	rs2055682	ENSG00000236529.1	RP13-254B10.1	4.4	2.29e-05	0.0147	0.28	0.37	Aortic root size;	chr7:66795302	chr7:65840212~65840596:+
TGCT	cis	rs6782228	0.565	rs11719239	ENSG00000242551.2	POU5F1P6	-4.4	2.29e-05	0.0147	-0.45	-0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700211	chr3:128674735~128677005:-
TGCT	cis	rs6782228	0.606	rs2001950	ENSG00000242551.2	POU5F1P6	-4.4	2.29e-05	0.0147	-0.45	-0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700913	chr3:128674735~128677005:-
TGCT	cis	rs2286503	0.78	rs1304431	ENSG00000234286.1	AC006026.13	4.4	2.3e-05	0.0147	0.44	0.37	Fibrinogen;	chr7:22825793	chr7:23680195~23680786:-
TGCT	cis	rs4835473	0.897	rs28701142	ENSG00000251600.4	RP11-673E1.1	4.4	2.3e-05	0.0147	0.39	0.37	Immature fraction of reticulocytes;	chr4:143945730	chr4:143912331~143982454:+
TGCT	cis	rs1012068	0.662	rs11703779	ENSG00000236132.1	CTA-440B3.1	-4.4	2.3e-05	0.0147	-0.43	-0.37	Chronic hepatitis C infection;	chr22:31926398	chr22:31816379~31817491:-
TGCT	cis	rs1934620	0.51	rs12029230	ENSG00000227591.4	RP1-28O10.1	4.4	2.3e-05	0.0147	0.73	0.37	Smooth-surface caries;	chr1:210719979	chr1:209661364~209724125:-
TGCT	cis	rs10170266	0.875	rs1093548	ENSG00000279220.1	GPR1-AS	4.4	2.3e-05	0.0147	0.3	0.37	Reticulocyte fraction of red cells;	chr2:206015941	chr2:206203376~206266243:+
TGCT	cis	rs10170266	0.875	rs817997	ENSG00000279220.1	GPR1-AS	4.4	2.3e-05	0.0147	0.3	0.37	Reticulocyte fraction of red cells;	chr2:206018245	chr2:206203376~206266243:+
TGCT	cis	rs10170266	0.875	rs818000	ENSG00000279220.1	GPR1-AS	4.4	2.3e-05	0.0147	0.3	0.37	Reticulocyte fraction of red cells;	chr2:206021329	chr2:206203376~206266243:+
TGCT	cis	rs796364	1	rs1658807	ENSG00000232732.8	AC073043.1	-4.4	2.31e-05	0.0148	-0.53	-0.37	Schizophrenia;	chr2:199902789	chr2:199867396~199911159:-
TGCT	cis	rs1707322	0.821	rs10749857	ENSG00000280836.1	AL355480.1	-4.4	2.31e-05	0.0148	-0.49	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr1:45581219~45581321:-
TGCT	cis	rs131777	0.577	rs131748	ENSG00000205559.3	CHKB-AS1	4.4	2.31e-05	0.0148	0.4	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586408	chr22:50583026~50583877:+
TGCT	cis	rs2976388	1	rs2976392	ENSG00000253196.1	RP11-706C16.7	-4.4	2.31e-05	0.0148	-0.38	-0.37	Urinary tract infection frequency;	chr8:142681514	chr8:142763116~142766427:+
TGCT	cis	rs559928	0.948	rs1198984	ENSG00000236935.1	AP003774.1	-4.4	2.31e-05	0.0148	-0.38	-0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64380948	chr11:64325050~64329504:-
TGCT	cis	rs9425766	0.679	rs4650945	ENSG00000227373.4	RP11-160H22.5	-4.4	2.31e-05	0.0148	-0.4	-0.37	Life satisfaction;	chr1:174114966	chr1:174115300~174160004:-
TGCT	cis	rs2555155	0.697	rs10839566	ENSG00000254595.1	CTD-2010I16.1	4.4	2.31e-05	0.0148	0.33	0.37	DNA methylation (variation);	chr11:6463257	chr11:6488186~6489377:-
TGCT	cis	rs904251	0.737	rs914347	ENSG00000204110.6	RP1-153P14.8	-4.4	2.31e-05	0.0148	-0.42	-0.37	Cognitive performance;	chr6:37517194	chr6:37507348~37535616:+
TGCT	cis	rs67311347	1	rs72861689	ENSG00000223797.4	ENTPD3-AS1	4.4	2.31e-05	0.0148	0.38	0.37	Renal cell carcinoma;	chr3:40394399	chr3:40313802~40453329:-
TGCT	cis	rs3742264	1	rs9567613	ENSG00000235903.6	CPB2-AS1	4.4	2.32e-05	0.0148	0.44	0.37	Blood protein levels;	chr13:46075263	chr13:46052806~46113332:+
TGCT	cis	rs17373728	0.739	rs7835101	ENSG00000249395.2	CASC9	4.4	2.32e-05	0.0148	0.46	0.37	Diabetic kidney disease;	chr8:75256950	chr8:75223404~75324741:-
TGCT	cis	rs10129255	0.872	rs8015406	ENSG00000211970.3	IGHV4-61	-4.4	2.32e-05	0.0148	-0.39	-0.37	Kawasaki disease;	chr14:106670611	chr14:106639119~106639657:-
TGCT	cis	rs321358	0.79	rs728059	ENSG00000271584.1	RP11-89C3.4	4.4	2.32e-05	0.0148	0.48	0.37	Body mass index;	chr11:111074331	chr11:111091932~111097357:-
TGCT	cis	rs9650657	0.562	rs10090444	ENSG00000255310.2	AF131215.2	4.4	2.32e-05	0.0148	0.3	0.37	Neuroticism;	chr8:10887959	chr8:11107788~11109726:-
TGCT	cis	rs9650657	0.589	rs10107145	ENSG00000255310.2	AF131215.2	-4.4	2.32e-05	0.0148	-0.3	-0.37	Neuroticism;	chr8:10900703	chr8:11107788~11109726:-
TGCT	cis	rs875971	0.571	rs160647	ENSG00000237310.1	GS1-124K5.4	-4.4	2.32e-05	0.0148	-0.46	-0.37	Aortic root size;	chr7:66089365	chr7:66493706~66495474:+
TGCT	cis	rs507080	0.769	rs570836	ENSG00000255239.1	AP002954.6	4.4	2.32e-05	0.0149	0.47	0.37	Serum metabolite levels;	chr11:118641444	chr11:118688039~118690600:-
TGCT	cis	rs11148252	0.5	rs342768	ENSG00000278238.1	RP11-245D16.4	-4.4	2.33e-05	0.0149	-0.27	-0.37	Lewy body disease;	chr13:52634747	chr13:52454775~52455331:-
TGCT	cis	rs16975963	0.644	rs73035164	ENSG00000276846.1	CTD-3220F14.3	-4.4	2.33e-05	0.0149	-0.35	-0.37	Longevity;	chr19:37655819	chr19:37314868~37315620:-
TGCT	cis	rs7005380	0.581	rs4871795	ENSG00000254343.2	RP11-760H22.2	-4.4	2.33e-05	0.0149	-0.52	-0.37	Interstitial lung disease;	chr8:119929425	chr8:120052180~120056201:+
TGCT	cis	rs12682352	0.65	rs13265731	ENSG00000253893.2	FAM85B	-4.4	2.33e-05	0.0149	-0.48	-0.37	Neuroticism;	chr8:8815810	chr8:8167819~8226614:-
TGCT	cis	rs12682352	0.602	rs13260419	ENSG00000253893.2	FAM85B	-4.4	2.33e-05	0.0149	-0.48	-0.37	Neuroticism;	chr8:8817666	chr8:8167819~8226614:-
TGCT	cis	rs6940638	0.744	rs858964	ENSG00000187763.3	OR2B7P	-4.4	2.33e-05	0.0149	-0.34	-0.37	Intelligence (multi-trait analysis);	chr6:27174835	chr6:28046434~28047367:+
TGCT	cis	rs2242073	0.733	rs10206080	ENSG00000232799.1	CRYGFP	-4.4	2.33e-05	0.0149	-0.56	-0.37	Attention deficit hyperactivity disorder;	chr2:208159471	chr2:209145241~209147687:+
TGCT	cis	rs728616	0.867	rs12414877	ENSG00000230091.5	TMEM254-AS1	4.4	2.33e-05	0.0149	0.65	0.37	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80020952	chr10:80046860~80078912:-
TGCT	cis	rs13068223	0.584	rs344018	ENSG00000243926.1	TIPARP-AS1	-4.4	2.33e-05	0.0149	-0.4	-0.37	Age-related hearing impairment (SNP x SNP interaction);	chr3:156698204	chr3:156671862~156674378:-
TGCT	cis	rs7255436	0.965	rs11666233	ENSG00000269386.4	RAB11B-AS1	4.4	2.33e-05	0.0149	0.38	0.37	HDL cholesterol;	chr19:8387161	chr19:8374373~8390685:-
TGCT	cis	rs4713118	0.662	rs149900	ENSG00000219392.1	RP1-265C24.5	-4.4	2.33e-05	0.0149	-0.49	-0.37	Parkinson's disease;	chr6:28046819	chr6:28115628~28116551:+
TGCT	cis	rs2976388	0.967	rs2976393	ENSG00000253196.1	RP11-706C16.7	-4.4	2.34e-05	0.0149	-0.38	-0.37	Urinary tract infection frequency;	chr8:142682200	chr8:142763116~142766427:+
TGCT	cis	rs9462027	0.651	rs4259246	ENSG00000186328.4	RP11-140K17.2	4.4	2.34e-05	0.0149	0.35	0.37	Systemic lupus erythematosus;	chr6:34836170	chr6:34715613~34715940:+
TGCT	cis	rs2739330	0.761	rs5760176	ENSG00000235689.1	AP000351.13	-4.4	2.34e-05	0.0149	-0.35	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:24006305~24008258:-
TGCT	cis	rs7027203	0.576	rs7855940	ENSG00000231990.1	RP11-53B5.1	4.4	2.34e-05	0.0149	0.29	0.37	DNA methylation (variation);	chr9:93773684	chr9:93857083~93858333:+
TGCT	cis	rs2033711	0.936	rs3794968	ENSG00000269473.1	CTD-2619J13.19	4.4	2.34e-05	0.0149	0.31	0.37	Uric acid clearance;	chr19:58475432	chr19:58440448~58445849:+
TGCT	cis	rs9309473	0.898	rs10185080	ENSG00000163016.8	ALMS1P	4.4	2.34e-05	0.0149	0.33	0.37	Metabolite levels;	chr2:73570380	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.898	rs10197755	ENSG00000163016.8	ALMS1P	4.4	2.34e-05	0.0149	0.33	0.37	Metabolite levels;	chr2:73570496	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.898	rs28879089	ENSG00000163016.8	ALMS1P	4.4	2.34e-05	0.0149	0.33	0.37	Metabolite levels;	chr2:73585759	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.948	rs7603647	ENSG00000163016.8	ALMS1P	4.4	2.34e-05	0.0149	0.33	0.37	Metabolite levels;	chr2:73590111	chr2:73644919~73685576:+
TGCT	cis	rs10504229	0.817	rs35207430	ENSG00000253301.4	RP11-513O17.2	4.4	2.34e-05	0.015	0.47	0.37	Developmental language disorder (linguistic errors);	chr8:57255055	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.906	rs7842855	ENSG00000253301.4	RP11-513O17.2	4.4	2.34e-05	0.015	0.47	0.37	Developmental language disorder (linguistic errors);	chr8:57255159	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.906	rs7842482	ENSG00000253301.4	RP11-513O17.2	4.4	2.34e-05	0.015	0.47	0.37	Developmental language disorder (linguistic errors);	chr8:57255161	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.906	rs903718	ENSG00000253301.4	RP11-513O17.2	4.4	2.34e-05	0.015	0.47	0.37	Developmental language disorder (linguistic errors);	chr8:57255167	chr8:57142689~57240298:+
TGCT	cis	rs9462027	0.883	rs6941110	ENSG00000186328.4	RP11-140K17.2	4.4	2.34e-05	0.015	0.36	0.37	Systemic lupus erythematosus;	chr6:34823557	chr6:34715613~34715940:+
TGCT	cis	rs2242073	0.668	rs111279488	ENSG00000232799.1	CRYGFP	-4.4	2.35e-05	0.015	-0.56	-0.37	Attention deficit hyperactivity disorder;	chr2:208161298	chr2:209145241~209147687:+
TGCT	cis	rs7829975	0.871	rs7829826	ENSG00000173295.6	FAM86B3P	-4.4	2.35e-05	0.015	-0.46	-0.37	Mood instability;	chr8:8720610	chr8:8228595~8244865:+
TGCT	cis	rs7927592	0.546	rs638076	ENSG00000212093.1	AP000807.1	4.4	2.35e-05	0.015	0.35	0.37	Total body bone mineral density;	chr11:68435112	chr11:68506083~68506166:-
TGCT	cis	rs10938353	0.731	rs73191022	ENSG00000273369.1	RP11-700J17.1	4.4	2.35e-05	0.015	0.61	0.37	Body mass index;	chr4:44616645	chr4:44693946~44694386:-
TGCT	cis	rs13118159	0.836	rs2293630	ENSG00000254094.1	AC078852.1	-4.4	2.35e-05	0.015	-0.43	-0.37	Longevity;	chr4:1348733	chr4:1356581~1358075:+
TGCT	cis	rs9326248	0.53	rs579890	ENSG00000254851.1	RP11-109L13.1	-4.4	2.35e-05	0.015	-0.68	-0.37	Blood protein levels;	chr11:116928247	chr11:117135528~117138582:+
TGCT	cis	rs9755467	0.821	rs75930501	ENSG00000221413.1	AC023593.1	4.39	2.35e-05	0.015	0.58	0.37	Educational attainment (years of education);	chr3:127443502	chr3:127664704~127664810:+
TGCT	cis	rs72772090	0.539	rs11135480	ENSG00000248734.2	CTD-2260A17.1	-4.39	2.35e-05	0.015	-0.48	-0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96774878	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs13601	ENSG00000248734.2	CTD-2260A17.1	-4.39	2.35e-05	0.015	-0.48	-0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96774892	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs56120748	ENSG00000248734.2	CTD-2260A17.1	-4.39	2.35e-05	0.015	-0.48	-0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96774918	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs72773917	ENSG00000248734.2	CTD-2260A17.1	-4.39	2.35e-05	0.015	-0.48	-0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96775598	chr5:96784777~96785999:+
TGCT	cis	rs4713118	0.621	rs9295755	ENSG00000187763.3	OR2B7P	-4.39	2.35e-05	0.015	-0.35	-0.37	Parkinson's disease;	chr6:28065396	chr6:28046434~28047367:+
TGCT	cis	rs12550646	0.652	rs10090395	ENSG00000253943.1	KRT18P37	-4.39	2.35e-05	0.015	-0.4	-0.37	Reticulocyte fraction of red cells;Reticulocyte count;	chr8:41809356	chr8:41511240~41512521:+
TGCT	cis	rs10875746	0.859	rs4760695	ENSG00000240399.1	RP1-228P16.1	-4.39	2.36e-05	0.0151	-0.42	-0.37	Longevity (90 years and older);	chr12:48198065	chr12:48054813~48055591:-
TGCT	cis	rs10875746	0.859	rs4760622	ENSG00000240399.1	RP1-228P16.1	-4.39	2.36e-05	0.0151	-0.42	-0.37	Longevity (90 years and older);	chr12:48198177	chr12:48054813~48055591:-
TGCT	cis	rs3091242	0.933	rs34933589	ENSG00000224183.1	SDHDP6	4.39	2.36e-05	0.0151	0.39	0.37	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25294164~25294643:-
TGCT	cis	rs12022452	0.506	rs12569328	ENSG00000238287.1	RP11-656D10.3	-4.39	2.36e-05	0.0151	-0.48	-0.37	Age-related hearing impairment (SNP x SNP interaction);	chr1:40553549	chr1:40493157~40508661:-
TGCT	cis	rs8059260	0.736	rs16957835	ENSG00000274038.1	RP11-66H6.4	-4.39	2.36e-05	0.0151	-0.52	-0.37	Alcohol consumption over the past year;	chr16:10958198	chr16:11056556~11057034:+
TGCT	cis	rs875971	0.545	rs10950029	ENSG00000237310.1	GS1-124K5.4	4.39	2.36e-05	0.0151	0.43	0.37	Aortic root size;	chr7:66169334	chr7:66493706~66495474:+
TGCT	cis	rs7684253	0.526	rs34112167	ENSG00000269949.1	RP11-738E22.3	-4.39	2.36e-05	0.0151	-0.35	-0.37	Migraine;	chr4:56853383	chr4:56960927~56961373:-
TGCT	cis	rs9807989	0.507	rs3732124	ENSG00000234389.1	AC007278.3	-4.39	2.37e-05	0.0151	-0.27	-0.37	Asthma;	chr2:102401592	chr2:102438713~102440475:+
TGCT	cis	rs9918079	0.56	rs4698406	ENSG00000273133.1	RP11-799M12.2	-4.39	2.37e-05	0.0151	-0.57	-0.37	Obesity-related traits;	chr4:15638994	chr4:15563698~15564253:-
TGCT	cis	rs2665103	0.715	rs7403041	ENSG00000278603.1	RP13-608F4.5	-4.39	2.37e-05	0.0151	-0.49	-0.37	Intelligence (multi-trait analysis);	chr15:82287841	chr15:82472203~82472426:+
TGCT	cis	rs9733	0.818	rs7520022	ENSG00000236713.1	RP11-363I22.3	4.39	2.37e-05	0.0151	0.27	0.37	Tonsillectomy;	chr1:150686697	chr1:150780272~150780644:+
TGCT	cis	rs875971	1	rs7792762	ENSG00000237310.1	GS1-124K5.4	4.39	2.37e-05	0.0151	0.4	0.37	Aortic root size;	chr7:66539151	chr7:66493706~66495474:+
TGCT	cis	rs8177876	0.658	rs77874075	ENSG00000261838.4	RP11-303E16.6	4.39	2.37e-05	0.0151	0.85	0.37	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81032734	chr16:81069854~81076598:+
TGCT	cis	rs8059260	0.673	rs7188928	ENSG00000274038.1	RP11-66H6.4	-4.39	2.37e-05	0.0151	-0.52	-0.37	Alcohol consumption over the past year;	chr16:10964896	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.551	rs7187539	ENSG00000274038.1	RP11-66H6.4	-4.39	2.37e-05	0.0151	-0.52	-0.37	Alcohol consumption over the past year;	chr16:10964900	chr16:11056556~11057034:+
TGCT	cis	rs10129255	0.5	rs4774008	ENSG00000223648.3	IGHV3-64	4.39	2.37e-05	0.0151	0.31	0.37	Kawasaki disease;	chr14:106681273	chr14:106643132~106658258:-
TGCT	cis	rs72772090	0.539	rs2042386	ENSG00000248734.2	CTD-2260A17.1	-4.39	2.38e-05	0.0151	-0.47	-0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96821080	chr5:96784777~96785999:+
TGCT	cis	rs8105895	0.935	rs62111028	ENSG00000269742.1	BNIP3P29	4.39	2.38e-05	0.0151	0.68	0.37	Body mass index (change over time);	chr19:22089595	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.733	rs62111029	ENSG00000269742.1	BNIP3P29	4.39	2.38e-05	0.0151	0.68	0.37	Body mass index (change over time);	chr19:22093799	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs62111030	ENSG00000269742.1	BNIP3P29	4.39	2.38e-05	0.0151	0.68	0.37	Body mass index (change over time);	chr19:22096573	chr19:22065828~22066398:-
TGCT	cis	rs17695224	0.565	rs7253182	ENSG00000269483.1	AC006272.1	4.39	2.38e-05	0.0151	0.37	0.37	HDL cholesterol;HDL cholesterol levels;	chr19:51808838	chr19:51839924~51843324:-
TGCT	cis	rs728616	0.867	rs41297151	ENSG00000230091.5	TMEM254-AS1	4.39	2.38e-05	0.0151	0.67	0.37	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80047411	chr10:80046860~80078912:-
TGCT	cis	rs2033711	0.87	rs6510152	ENSG00000269473.1	CTD-2619J13.19	4.39	2.38e-05	0.0152	0.3	0.37	Uric acid clearance;	chr19:58441952	chr19:58440448~58445849:+
TGCT	cis	rs6604026	0.695	rs11164801	ENSG00000223787.2	RP4-593M8.1	4.39	2.38e-05	0.0152	0.52	0.37	Multiple sclerosis;	chr1:92737621	chr1:92580476~92580821:-
TGCT	cis	rs4691139	0.903	rs13127378	ENSG00000236941.6	RP11-366M4.8	4.39	2.38e-05	0.0152	0.28	0.37	Ovarian cancer in BRCA1 mutation carriers;	chr4:164997485	chr4:164948079~164949438:+
TGCT	cis	rs4835473	0.868	rs4350958	ENSG00000251600.4	RP11-673E1.1	4.39	2.39e-05	0.0152	0.41	0.37	Immature fraction of reticulocytes;	chr4:143744656	chr4:143912331~143982454:+
TGCT	cis	rs4820803	0.806	rs9537	ENSG00000226471.5	CTA-292E10.6	-4.39	2.39e-05	0.0152	-0.45	-0.37	Breast cancer;	chr22:29259427	chr22:28800683~28848559:+
TGCT	cis	rs7208859	0.573	rs79505916	ENSG00000280069.1	CTD-2349P21.3	-4.39	2.39e-05	0.0152	-0.52	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30738182~30740275:+
TGCT	cis	rs7923609	0.936	rs10761779	ENSG00000232075.1	MRPL35P2	-4.39	2.39e-05	0.0152	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63515167	chr10:63634317~63634827:-
TGCT	cis	rs507080	0.733	rs611733	ENSG00000255239.1	AP002954.6	4.39	2.39e-05	0.0152	0.49	0.37	Serum metabolite levels;	chr11:118702051	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.733	rs552079	ENSG00000255239.1	AP002954.6	4.39	2.39e-05	0.0152	0.49	0.37	Serum metabolite levels;	chr11:118702313	chr11:118688039~118690600:-
TGCT	cis	rs12745968	0.561	rs10874726	ENSG00000223787.2	RP4-593M8.1	-4.39	2.39e-05	0.0152	-0.49	-0.37	Bipolar disorder and schizophrenia;	chr1:92637542	chr1:92580476~92580821:-
TGCT	cis	rs12745968	0.589	rs10874727	ENSG00000223787.2	RP4-593M8.1	-4.39	2.39e-05	0.0152	-0.49	-0.37	Bipolar disorder and schizophrenia;	chr1:92637595	chr1:92580476~92580821:-
TGCT	cis	rs12745968	0.589	rs10782937	ENSG00000223787.2	RP4-593M8.1	-4.39	2.39e-05	0.0152	-0.49	-0.37	Bipolar disorder and schizophrenia;	chr1:92637644	chr1:92580476~92580821:-
TGCT	cis	rs2013441	1	rs11871827	ENSG00000230528.6	NOS2P3	4.39	2.39e-05	0.0152	0.36	0.37	Obesity-related traits;	chr17:20312592	chr17:20436337~20447249:+
TGCT	cis	rs7208859	0.673	rs216411	ENSG00000263531.1	RP13-753N3.1	-4.39	2.39e-05	0.0152	-0.67	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576475	chr17:30863921~30864940:-
TGCT	cis	rs796364	0.76	rs1569178	ENSG00000232732.8	AC073043.1	4.39	2.39e-05	0.0152	0.52	0.37	Schizophrenia;	chr2:200159789	chr2:199867396~199911159:-
TGCT	cis	rs5769707	0.521	rs739244	ENSG00000235111.1	RP1-29C18.8	-4.39	2.39e-05	0.0152	-0.35	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49666510	chr22:49612657~49615716:-
TGCT	cis	rs1823913	0.637	rs4853573	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191295866	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.614	rs4853466	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191295943	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs4853574	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191296113	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs4853575	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191296149	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs4853577	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191297118	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs4853579	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191297413	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs12622194	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191298680	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs13019567	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191298736	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs1947456	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191298759	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.614	rs11693878	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191299399	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs10931494	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191299442	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs10931495	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191299447	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs12623156	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191299661	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs1349938	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191299970	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.592	rs1349939	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191300079	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs4853581	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191301533	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.614	rs7565987	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191301815	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.614	rs1973067	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191302021	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs1973068	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191302227	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs7569231	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191302373	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs6434461	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191302661	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.614	rs6434462	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191302705	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs6750360	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191303089	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs11677694	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191303203	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.571	rs6737307	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191303247	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs4853582	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191303483	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs35200176	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191303534	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs17348013	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191303726	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs4853583	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191304648	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs10931497	ENSG00000227542.1	AC092614.2	-4.39	2.39e-05	0.0152	-0.39	-0.37	Obesity-related traits;	chr2:191306254	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs4853578	ENSG00000227542.1	AC092614.2	4.39	2.39e-05	0.0152	0.39	0.37	Obesity-related traits;	chr2:191297215	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs979967	ENSG00000227542.1	AC092614.2	4.39	2.39e-05	0.0152	0.39	0.37	Obesity-related traits;	chr2:191304695	chr2:191229165~191246172:-
TGCT	cis	rs7829975	0.711	rs4481596	ENSG00000254340.1	RP11-10A14.3	4.39	2.39e-05	0.0152	0.37	0.37	Mood instability;	chr8:8846820	chr8:9141424~9145435:+
TGCT	cis	rs786425	0.899	rs908373	ENSG00000278112.1	RP11-972P1.11	4.39	2.39e-05	0.0152	0.42	0.37	Pubertal anthropometrics;	chr12:123628772	chr12:123519390~123519856:-
TGCT	cis	rs77505915	0.512	rs12921808	ENSG00000261783.1	RP11-252K23.2	4.39	2.39e-05	0.0152	0.57	0.37	Migraine;	chr16:75350086	chr16:75379818~75381260:-
TGCT	cis	rs728616	0.867	rs56000427	ENSG00000230091.5	TMEM254-AS1	4.39	2.4e-05	0.0152	0.69	0.37	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80227190	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.717	rs116884206	ENSG00000230091.5	TMEM254-AS1	4.39	2.4e-05	0.0152	0.69	0.37	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80230790	chr10:80046860~80078912:-
TGCT	cis	rs9462027	0.583	rs9469902	ENSG00000186328.4	RP11-140K17.2	4.39	2.4e-05	0.0152	0.35	0.37	Systemic lupus erythematosus;	chr6:34825991	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs7745097	ENSG00000186328.4	RP11-140K17.2	4.39	2.4e-05	0.0152	0.35	0.37	Systemic lupus erythematosus;	chr6:34826657	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.606	rs7768759	ENSG00000186328.4	RP11-140K17.2	4.39	2.4e-05	0.0152	0.35	0.37	Systemic lupus erythematosus;	chr6:34827908	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs9462026	ENSG00000186328.4	RP11-140K17.2	4.39	2.4e-05	0.0152	0.35	0.37	Systemic lupus erythematosus;	chr6:34829256	chr6:34715613~34715940:+
TGCT	cis	rs847851	0.63	rs9469905	ENSG00000186328.4	RP11-140K17.2	4.39	2.4e-05	0.0152	0.35	0.37	Colonoscopy-negative controls vs population controls;	chr6:34829970	chr6:34715613~34715940:+
TGCT	cis	rs4660214	0.666	rs7553009	ENSG00000182109.6	RP11-69E11.4	-4.39	2.4e-05	0.0152	-0.38	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39247441	chr1:39522280~39546187:-
TGCT	cis	rs11054731	0.774	rs7962366	ENSG00000247498.8	RP11-392P7.6	-4.39	2.4e-05	0.0152	-0.35	-0.37	Coronary artery calcification;	chr12:12286128	chr12:12927726~12984645:+
TGCT	cis	rs875971	0.545	rs4441996	ENSG00000237310.1	GS1-124K5.4	-4.39	2.4e-05	0.0152	-0.45	-0.37	Aortic root size;	chr7:66123233	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs10950025	ENSG00000237310.1	GS1-124K5.4	4.39	2.4e-05	0.0152	0.45	0.37	Aortic root size;	chr7:66158946	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs1547529	ENSG00000237310.1	GS1-124K5.4	4.39	2.4e-05	0.0152	0.45	0.37	Aortic root size;	chr7:66258859	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs316324	ENSG00000237310.1	GS1-124K5.4	-4.39	2.4e-05	0.0152	-0.45	-0.37	Aortic root size;	chr7:66145627	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs316323	ENSG00000237310.1	GS1-124K5.4	-4.39	2.4e-05	0.0152	-0.45	-0.37	Aortic root size;	chr7:66146002	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs316316	ENSG00000237310.1	GS1-124K5.4	-4.39	2.4e-05	0.0152	-0.45	-0.37	Aortic root size;	chr7:66149270	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs2460427	ENSG00000237310.1	GS1-124K5.4	-4.39	2.4e-05	0.0152	-0.45	-0.37	Aortic root size;	chr7:66154218	chr7:66493706~66495474:+
TGCT	cis	rs904251	0.523	rs2776874	ENSG00000204110.6	RP1-153P14.8	-4.39	2.4e-05	0.0152	-0.36	-0.37	Cognitive performance;	chr6:37515421	chr6:37507348~37535616:+
TGCT	cis	rs728616	1	rs12414891	ENSG00000230091.5	TMEM254-AS1	4.39	2.4e-05	0.0153	0.72	0.37	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79930629	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.717	rs12415523	ENSG00000230091.5	TMEM254-AS1	4.39	2.4e-05	0.0153	0.72	0.37	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79932220	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.764	rs75385771	ENSG00000230091.5	TMEM254-AS1	4.39	2.4e-05	0.0153	0.72	0.37	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79933023	chr10:80046860~80078912:-
TGCT	cis	rs7927592	0.513	rs7950129	ENSG00000212093.1	AP000807.1	4.39	2.4e-05	0.0153	0.35	0.37	Total body bone mineral density;	chr11:68435435	chr11:68506083~68506166:-
TGCT	cis	rs7927592	0.513	rs653056	ENSG00000212093.1	AP000807.1	4.39	2.4e-05	0.0153	0.35	0.37	Total body bone mineral density;	chr11:68436157	chr11:68506083~68506166:-
TGCT	cis	rs9807989	0.507	rs6734762	ENSG00000234389.1	AC007278.3	4.39	2.4e-05	0.0153	0.27	0.37	Asthma;	chr2:102446466	chr2:102438713~102440475:+
TGCT	cis	rs9309473	0.95	rs6546854	ENSG00000163016.8	ALMS1P	4.39	2.4e-05	0.0153	0.34	0.37	Metabolite levels;	chr2:73606907	chr2:73644919~73685576:+
TGCT	cis	rs8049040	0.967	rs8050135	ENSG00000260886.1	TAT-AS1	4.39	2.41e-05	0.0153	0.37	0.37	Blood protein levels;	chr16:71438668	chr16:71565789~71578187:+
TGCT	cis	rs9880211	1	rs6768743	ENSG00000239213.4	NCK1-AS1	-4.39	2.41e-05	0.0153	-0.38	-0.37	Height;Body mass index;	chr3:136486165	chr3:136841726~136862054:-
TGCT	cis	rs884366	1	rs4946956	ENSG00000203799.9	CCDC162P	-4.39	2.41e-05	0.0153	-0.38	-0.37	HDL cholesterol;HDL cholesterol levels;	chr6:109319912	chr6:109285485~109355063:+
TGCT	cis	rs884366	1	rs4946957	ENSG00000203799.9	CCDC162P	-4.39	2.41e-05	0.0153	-0.38	-0.37	HDL cholesterol;HDL cholesterol levels;	chr6:109320208	chr6:109285485~109355063:+
TGCT	cis	rs710913	0.774	rs2695319	ENSG00000182109.6	RP11-69E11.4	4.39	2.41e-05	0.0153	0.36	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39591028	chr1:39522280~39546187:-
TGCT	cis	rs2976388	0.967	rs2585183	ENSG00000253196.1	RP11-706C16.7	-4.39	2.42e-05	0.0153	-0.38	-0.37	Urinary tract infection frequency;	chr8:142684641	chr8:142763116~142766427:+
TGCT	cis	rs1823913	0.599	rs6736071	ENSG00000227542.1	AC092614.2	-4.39	2.42e-05	0.0154	-0.39	-0.37	Obesity-related traits;	chr2:191287265	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs12624271	ENSG00000227542.1	AC092614.2	-4.39	2.42e-05	0.0154	-0.39	-0.37	Obesity-related traits;	chr2:191288586	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs11686185	ENSG00000227542.1	AC092614.2	-4.39	2.42e-05	0.0154	-0.39	-0.37	Obesity-related traits;	chr2:191289282	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs4853465	ENSG00000227542.1	AC092614.2	-4.39	2.42e-05	0.0154	-0.39	-0.37	Obesity-related traits;	chr2:191294768	chr2:191229165~191246172:-
TGCT	cis	rs6604026	0.656	rs12745968	ENSG00000223787.2	RP4-593M8.1	-4.39	2.42e-05	0.0154	-0.44	-0.37	Multiple sclerosis;	chr1:92936280	chr1:92580476~92580821:-
TGCT	cis	rs763121	0.962	rs909564	ENSG00000273076.1	RP3-508I15.22	4.39	2.42e-05	0.0154	0.4	0.37	Menopause (age at onset);	chr22:38730503	chr22:38743495~38743910:+
TGCT	cis	rs763121	0.925	rs9835	ENSG00000273076.1	RP3-508I15.22	4.39	2.42e-05	0.0154	0.4	0.37	Menopause (age at onset);	chr22:38734966	chr22:38743495~38743910:+
TGCT	cis	rs875971	0.66	rs10272357	ENSG00000237310.1	GS1-124K5.4	-4.39	2.42e-05	0.0154	-0.42	-0.37	Aortic root size;	chr7:66598087	chr7:66493706~66495474:+
TGCT	cis	rs494459	0.838	rs567680	ENSG00000255422.1	AP002954.4	-4.39	2.43e-05	0.0154	-0.39	-0.37	Height;	chr11:118737823	chr11:118704607~118750263:+
TGCT	cis	rs494459	0.838	rs566733	ENSG00000255422.1	AP002954.4	-4.39	2.43e-05	0.0154	-0.39	-0.37	Height;	chr11:118737916	chr11:118704607~118750263:+
TGCT	cis	rs2033711	0.902	rs4801589	ENSG00000268912.1	CTD-2619J13.17	-4.39	2.43e-05	0.0154	-0.33	-0.37	Uric acid clearance;	chr19:58442031	chr19:58428632~58431148:-
TGCT	cis	rs34375054	0.525	rs7133006	ENSG00000279233.1	RP11-158L12.4	4.39	2.43e-05	0.0154	0.38	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125121577	chr12:125138245~125141711:+
TGCT	cis	rs34375054	0.525	rs7133864	ENSG00000279233.1	RP11-158L12.4	4.39	2.43e-05	0.0154	0.38	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125121634	chr12:125138245~125141711:+
TGCT	cis	rs10246939	0.544	rs6957037	ENSG00000228775.6	WEE2-AS1	4.39	2.43e-05	0.0154	0.33	0.37	Bitter taste perception;	chr7:141865557	chr7:141704338~141738346:-
TGCT	cis	rs10246939	0.544	rs2163953	ENSG00000228775.6	WEE2-AS1	4.39	2.43e-05	0.0154	0.33	0.37	Bitter taste perception;	chr7:141867769	chr7:141704338~141738346:-
TGCT	cis	rs10246939	0.544	rs6959360	ENSG00000228775.6	WEE2-AS1	4.39	2.43e-05	0.0154	0.33	0.37	Bitter taste perception;	chr7:141869806	chr7:141704338~141738346:-
TGCT	cis	rs7396835	0.5	rs5092	ENSG00000254851.1	RP11-109L13.1	-4.39	2.44e-05	0.0154	-0.52	-0.37	Quantitative traits;	chr11:116822748	chr11:117135528~117138582:+
TGCT	cis	rs9880211	0.898	rs9866840	ENSG00000239213.4	NCK1-AS1	4.39	2.44e-05	0.0155	0.38	0.37	Height;Body mass index;	chr3:136310416	chr3:136841726~136862054:-
TGCT	cis	rs4308124	0.708	rs6716091	ENSG00000227992.1	AC108463.2	-4.39	2.45e-05	0.0155	-0.39	-0.37	Vitiligo;	chr2:111233556	chr2:111203964~111206215:-
TGCT	cis	rs1823913	0.614	rs12616167	ENSG00000227542.1	AC092614.2	-4.39	2.45e-05	0.0155	-0.4	-0.37	Obesity-related traits;	chr2:191311274	chr2:191229165~191246172:-
TGCT	cis	rs2177312	0.574	rs6553981	ENSG00000251129.1	RP11-734I18.1	-4.39	2.45e-05	0.0155	-0.36	-0.37	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31976790	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.574	rs1554554	ENSG00000251129.1	RP11-734I18.1	-4.39	2.45e-05	0.0155	-0.36	-0.37	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31977641	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.574	rs6850529	ENSG00000251129.1	RP11-734I18.1	-4.39	2.45e-05	0.0155	-0.36	-0.37	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31979087	chr4:31997397~32155406:+
TGCT	cis	rs9880211	0.898	rs34031772	ENSG00000239213.4	NCK1-AS1	4.38	2.45e-05	0.0155	0.38	0.37	Height;Body mass index;	chr3:136299299	chr3:136841726~136862054:-
TGCT	cis	rs1707322	0.721	rs11211181	ENSG00000280836.1	AL355480.1	-4.38	2.45e-05	0.0155	-0.49	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45581219~45581321:-
TGCT	cis	rs9959491	0.56	rs1806401	ENSG00000227279.1	AC015933.2	4.38	2.45e-05	0.0155	0.4	0.37	Breast cancer;	chr18:27809125	chr18:27954519~27963687:+
TGCT	cis	rs9959491	0.56	rs4800822	ENSG00000227279.1	AC015933.2	4.38	2.45e-05	0.0155	0.4	0.37	Breast cancer;	chr18:27809160	chr18:27954519~27963687:+
TGCT	cis	rs2412819	0.571	rs2930531	ENSG00000205771.5	CATSPER2P1	4.38	2.45e-05	0.0155	0.61	0.37	Lung cancer;	chr15:43829372	chr15:43726918~43747094:-
TGCT	cis	rs875971	0.505	rs6955582	ENSG00000272831.1	RP11-792A8.4	4.38	2.45e-05	0.0155	0.38	0.37	Aortic root size;	chr7:65966699	chr7:66739829~66740385:-
TGCT	cis	rs4308124	0.708	rs6747657	ENSG00000227992.1	AC108463.2	-4.38	2.45e-05	0.0155	-0.38	-0.37	Vitiligo;	chr2:111245586	chr2:111203964~111206215:-
TGCT	cis	rs2015599	0.514	rs10843376	ENSG00000257176.2	RP11-996F15.2	4.38	2.45e-05	0.0155	0.39	0.37	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29280418~29317848:-
TGCT	cis	rs884366	1	rs884366	ENSG00000203799.9	CCDC162P	-4.38	2.45e-05	0.0155	-0.39	-0.37	HDL cholesterol;HDL cholesterol levels;	chr6:109252892	chr6:109285485~109355063:+
TGCT	cis	rs12745968	0.62	rs11164607	ENSG00000223787.2	RP4-593M8.1	-4.38	2.45e-05	0.0155	-0.48	-0.37	Bipolar disorder and schizophrenia;	chr1:92481581	chr1:92580476~92580821:-
TGCT	cis	rs875971	0.545	rs7783889	ENSG00000237310.1	GS1-124K5.4	4.38	2.45e-05	0.0155	0.44	0.37	Aortic root size;	chr7:66283366	chr7:66493706~66495474:+
TGCT	cis	rs7927592	0.513	rs531163	ENSG00000212093.1	AP000807.1	4.38	2.45e-05	0.0155	0.36	0.37	Total body bone mineral density;	chr11:68427028	chr11:68506083~68506166:-
TGCT	cis	rs2921073	0.604	rs2979140	ENSG00000253981.4	ALG1L13P	4.38	2.45e-05	0.0155	0.38	0.37	Parkinson's disease;	chr8:8409692	chr8:8236003~8244667:-
TGCT	cis	rs875971	0.825	rs28480509	ENSG00000237310.1	GS1-124K5.4	-4.38	2.46e-05	0.0156	-0.4	-0.37	Aortic root size;	chr7:66634237	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs9791712	ENSG00000237310.1	GS1-124K5.4	-4.38	2.46e-05	0.0156	-0.4	-0.37	Aortic root size;	chr7:66640176	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs9791713	ENSG00000237310.1	GS1-124K5.4	-4.38	2.46e-05	0.0156	-0.4	-0.37	Aortic root size;	chr7:66640211	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs1860469	ENSG00000237310.1	GS1-124K5.4	-4.38	2.46e-05	0.0156	-0.4	-0.37	Aortic root size;	chr7:66641888	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs4718383	ENSG00000237310.1	GS1-124K5.4	-4.38	2.46e-05	0.0156	-0.4	-0.37	Aortic root size;	chr7:66643422	chr7:66493706~66495474:+
TGCT	cis	rs1823913	0.637	rs897197	ENSG00000227542.1	AC092614.2	-4.38	2.46e-05	0.0156	-0.39	-0.37	Obesity-related traits;	chr2:191281456	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs2883912	ENSG00000227542.1	AC092614.2	-4.38	2.46e-05	0.0156	-0.39	-0.37	Obesity-related traits;	chr2:191284290	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.637	rs921737	ENSG00000227542.1	AC092614.2	-4.38	2.46e-05	0.0156	-0.39	-0.37	Obesity-related traits;	chr2:191286097	chr2:191229165~191246172:-
TGCT	cis	rs6940638	0.688	rs2022272	ENSG00000187763.3	OR2B7P	4.38	2.46e-05	0.0156	0.33	0.37	Intelligence (multi-trait analysis);	chr6:27135801	chr6:28046434~28047367:+
TGCT	cis	rs5758659	0.504	rs133367	ENSG00000270083.1	RP1-257I20.14	-4.38	2.46e-05	0.0156	-0.36	-0.37	Cognitive function;	chr22:42067362	chr22:42089630~42090028:-
TGCT	cis	rs9880211	1	rs9826454	ENSG00000239213.4	NCK1-AS1	4.38	2.46e-05	0.0156	0.41	0.37	Height;Body mass index;	chr3:136234378	chr3:136841726~136862054:-
TGCT	cis	rs1707322	1	rs6677777	ENSG00000280836.1	AL355480.1	-4.38	2.46e-05	0.0156	-0.48	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46010164	chr1:45581219~45581321:-
TGCT	cis	rs3096299	0.748	rs3102339	ENSG00000274627.1	RP11-104N10.2	4.38	2.46e-05	0.0156	0.38	0.37	Multiple myeloma (IgH translocation);	chr16:89376303	chr16:89516797~89522217:+
TGCT	cis	rs659580	1	rs659580	ENSG00000271811.1	RP1-79C4.4	-4.38	2.46e-05	0.0156	-0.33	-0.37	Response to angiotensin II receptor blocker therapy;Lobe attachment (rater-scored or self-reported);	chr1:170664755	chr1:170667381~170669425:+
TGCT	cis	rs73607972	0.593	rs4784321	ENSG00000275191.1	RP11-36I17.2	-4.38	2.47e-05	0.0156	-0.4	-0.37	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53602497	chr16:53628256~53628816:-
TGCT	cis	rs904251	0.605	rs4257849	ENSG00000279942.1	RP1-153P14.7	-4.38	2.47e-05	0.0156	-0.47	-0.37	Cognitive performance;	chr6:37443193	chr6:37567716~37571460:+
TGCT	cis	rs904251	0.686	rs1224128	ENSG00000279942.1	RP1-153P14.7	-4.38	2.47e-05	0.0156	-0.47	-0.37	Cognitive performance;	chr6:37447900	chr6:37567716~37571460:+
TGCT	cis	rs4660214	0.666	rs1537818	ENSG00000182109.6	RP11-69E11.4	-4.38	2.47e-05	0.0156	-0.36	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39181366	chr1:39522280~39546187:-
TGCT	cis	rs2239557	0.529	rs2041185	ENSG00000259065.1	RP5-1021I20.1	4.38	2.47e-05	0.0156	0.34	0.37	Common traits (Other);	chr14:73815387	chr14:73787360~73803270:+
TGCT	cis	rs4713118	0.588	rs200994	ENSG00000187763.3	OR2B7P	-4.38	2.47e-05	0.0156	-0.36	-0.37	Parkinson's disease;	chr6:27846035	chr6:28046434~28047367:+
TGCT	cis	rs9584850	0.794	rs72655609	ENSG00000231194.1	FARP1-AS1	4.38	2.47e-05	0.0156	0.49	0.37	Neuroticism;	chr13:98476368	chr13:98435405~98435840:-
TGCT	cis	rs73086581	0.568	rs6084541	ENSG00000229539.1	RP11-119B16.2	-4.38	2.47e-05	0.0156	-0.45	-0.37	Response to antidepressants in depression;	chr20:3982084	chr20:3888239~3888868:-
TGCT	cis	rs7246967	0.736	rs436595	ENSG00000269509.1	BNIP3P34	4.38	2.47e-05	0.0156	0.58	0.37	Bronchopulmonary dysplasia;	chr19:22810243	chr19:22773853~22774424:+
TGCT	cis	rs72819454	0.522	rs12414928	ENSG00000266852.2	MIR4482	4.38	2.47e-05	0.0156	0.63	0.37	Interleukin-9 levels;	chr10:103741689	chr10:104268336~104268405:-
TGCT	cis	rs10759883	0.539	rs689744	ENSG00000175611.10	LINC00476	4.38	2.48e-05	0.0157	0.33	0.37	Nicotine dependence;	chr9:96040417	chr9:95759231~95875977:-
TGCT	cis	rs172166	0.637	rs1233708	ENSG00000219392.1	RP1-265C24.5	-4.38	2.48e-05	0.0157	-0.43	-0.37	Cardiac Troponin-T levels;	chr6:28205441	chr6:28115628~28116551:+
TGCT	cis	rs34217772	0.739	rs17181741	ENSG00000258536.1	RP11-1053O12.1	4.38	2.48e-05	0.0157	0.31	0.37	Myopia;	chr14:41839275	chr14:41742639~41742963:+
TGCT	cis	rs728616	0.867	rs28365998	ENSG00000230091.5	TMEM254-AS1	4.38	2.48e-05	0.0157	0.7	0.37	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80205680	chr10:80046860~80078912:-
TGCT	cis	rs10129255	0.912	rs730099	ENSG00000211970.3	IGHV4-61	-4.38	2.48e-05	0.0157	-0.4	-0.37	Kawasaki disease;	chr14:106711838	chr14:106639119~106639657:-
TGCT	cis	rs10129255	0.957	rs3814926	ENSG00000211970.3	IGHV4-61	-4.38	2.48e-05	0.0157	-0.4	-0.37	Kawasaki disease;	chr14:106712246	chr14:106639119~106639657:-
TGCT	cis	rs9807989	0.507	rs4479442	ENSG00000234389.1	AC007278.3	4.38	2.48e-05	0.0157	0.28	0.37	Asthma;	chr2:102437614	chr2:102438713~102440475:+
TGCT	cis	rs1707322	0.963	rs12145287	ENSG00000280836.1	AL355480.1	-4.38	2.48e-05	0.0157	-0.49	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr1:45581219~45581321:-
TGCT	cis	rs8059260	0.668	rs7206753	ENSG00000274038.1	RP11-66H6.4	-4.38	2.48e-05	0.0157	-0.51	-0.37	Alcohol consumption over the past year;	chr16:10974987	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.736	rs7192695	ENSG00000274038.1	RP11-66H6.4	-4.38	2.48e-05	0.0157	-0.51	-0.37	Alcohol consumption over the past year;	chr16:11005395	chr16:11056556~11057034:+
TGCT	cis	rs10829156	0.66	rs7910506	ENSG00000240291.1	RP11-499P20.2	-4.38	2.48e-05	0.0157	-0.31	-0.37	Sudden cardiac arrest;	chr10:18518128	chr10:18513115~18545651:-
TGCT	cis	rs877819	0.583	rs2663049	ENSG00000228403.1	RP11-563N6.6	-4.38	2.49e-05	0.0157	-0.39	-0.37	Systemic lupus erythematosus;	chr10:48858716	chr10:48878022~48878649:+
TGCT	cis	rs11722228	0.508	rs2241472	ENSG00000261490.1	RP11-448G15.3	4.38	2.49e-05	0.0157	0.35	0.37	Urate levels;Serum uric acid levels;Gout;	chr4:10084278	chr4:10068089~10073019:-
TGCT	cis	rs3096299	0.679	rs3096322	ENSG00000274627.1	RP11-104N10.2	-4.38	2.49e-05	0.0157	-0.38	-0.37	Multiple myeloma (IgH translocation);	chr16:89374715	chr16:89516797~89522217:+
TGCT	cis	rs507080	0.922	rs558781	ENSG00000255239.1	AP002954.6	4.38	2.49e-05	0.0157	0.48	0.37	Serum metabolite levels;	chr11:118693688	chr11:118688039~118690600:-
TGCT	cis	rs1823913	0.637	rs6741454	ENSG00000227542.1	AC092614.2	-4.38	2.49e-05	0.0157	-0.39	-0.37	Obesity-related traits;	chr2:191269520	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.614	rs6755243	ENSG00000227542.1	AC092614.2	-4.38	2.49e-05	0.0157	-0.39	-0.37	Obesity-related traits;	chr2:191269810	chr2:191229165~191246172:-
TGCT	cis	rs2177312	0.868	rs1523175	ENSG00000251129.1	RP11-734I18.1	-4.38	2.49e-05	0.0157	-0.42	-0.37	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31950071	chr4:31997397~32155406:+
TGCT	cis	rs6474412	1	rs7816726	ENSG00000255101.1	RP11-412B14.1	4.38	2.49e-05	0.0158	0.36	0.37	Smoking behavior;	chr8:42680294	chr8:42705583~42721946:-
TGCT	cis	rs807029	0.72	rs14177	ENSG00000272572.1	RP11-179B2.2	-4.38	2.5e-05	0.0158	-0.3	-0.37	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101007398	chr10:100911103~100912739:-
TGCT	cis	rs4242434	0.787	rs1545837	ENSG00000254064.1	CTD-2530N21.4	-4.38	2.5e-05	0.0158	-0.21	-0.37	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22620294	chr8:22254576~22275162:-
TGCT	cis	rs7246967	0.673	rs6511383	ENSG00000269509.1	BNIP3P34	4.38	2.5e-05	0.0158	0.55	0.37	Bronchopulmonary dysplasia;	chr19:22774098	chr19:22773853~22774424:+
TGCT	cis	rs3749237	0.595	rs2878298	ENSG00000226913.1	BSN-AS2	-4.38	2.5e-05	0.0158	-0.28	-0.37	Resting heart rate;	chr3:49368647	chr3:49549306~49554366:-
TGCT	cis	rs7923609	1	rs4379723	ENSG00000232075.1	MRPL35P2	-4.38	2.5e-05	0.0158	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63203689	chr10:63634317~63634827:-
TGCT	cis	rs2283792	0.646	rs7292584	ENSG00000228050.1	TOP3BP1	4.38	2.5e-05	0.0158	0.47	0.37	Multiple sclerosis;	chr22:21768458	chr22:22223187~22224566:-
TGCT	cis	rs2283792	0.646	rs9610317	ENSG00000228050.1	TOP3BP1	4.38	2.5e-05	0.0158	0.47	0.37	Multiple sclerosis;	chr22:21785601	chr22:22223187~22224566:-
TGCT	cis	rs10256972	0.758	rs9801444	ENSG00000226291.1	AC091729.8	4.38	2.5e-05	0.0158	0.39	0.37	Endometriosis;Longevity;	chr7:1040808	chr7:1080863~1082178:+
TGCT	cis	rs875971	0.83	rs12673450	ENSG00000232559.3	GS1-124K5.12	4.38	2.5e-05	0.0158	0.34	0.37	Aortic root size;	chr7:66544233	chr7:66554588~66576923:-
TGCT	cis	rs877819	0.697	rs7915025	ENSG00000228403.1	RP11-563N6.6	-4.38	2.5e-05	0.0158	-0.4	-0.37	Systemic lupus erythematosus;	chr10:48843200	chr10:48878022~48878649:+
TGCT	cis	rs2117029	0.555	rs10747561	ENSG00000258017.1	RP11-386G11.10	-4.38	2.51e-05	0.0158	-0.48	-0.37	Intelligence (multi-trait analysis);	chr12:49106726	chr12:49127782~49147869:+
TGCT	cis	rs4835473	0.932	rs1849112	ENSG00000251600.4	RP11-673E1.1	4.38	2.51e-05	0.0158	0.39	0.37	Immature fraction of reticulocytes;	chr4:143962502	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.831	rs4125544	ENSG00000251600.4	RP11-673E1.1	4.38	2.51e-05	0.0158	0.39	0.37	Immature fraction of reticulocytes;	chr4:143962542	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.864	rs12507633	ENSG00000251600.4	RP11-673E1.1	4.38	2.51e-05	0.0158	0.39	0.37	Immature fraction of reticulocytes;	chr4:143962730	chr4:143912331~143982454:+
TGCT	cis	rs9326248	0.773	rs1060211	ENSG00000280143.1	AP000892.6	4.38	2.51e-05	0.0158	0.53	0.37	Blood protein levels;	chr11:117169081	chr11:117204967~117210292:+
TGCT	cis	rs3931020	0.548	rs969435	ENSG00000272864.1	RP11-17E13.2	4.38	2.51e-05	0.0158	0.4	0.37	Resistin levels;	chr1:74808182	chr1:74698769~74699333:-
TGCT	cis	rs884366	1	rs12191774	ENSG00000243587.6	C6orf183	-4.38	2.51e-05	0.0158	-0.37	-0.37	HDL cholesterol;HDL cholesterol levels;	chr6:109327150	chr6:109165833~109271014:+
TGCT	cis	rs7335046	0.611	rs2892976	ENSG00000234005.3	GAPDHP22	4.38	2.51e-05	0.0159	0.35	0.37	Basal cell carcinoma;	chr13:99406307	chr13:99190579~99190991:-
TGCT	cis	rs10819861	0.967	rs10989287	ENSG00000175611.10	LINC00476	4.38	2.52e-05	0.0159	0.31	0.37	Electrocardiographic traits;	chr9:96105566	chr9:95759231~95875977:-
TGCT	cis	rs12745968	0.586	rs2065915	ENSG00000223787.2	RP4-593M8.1	-4.38	2.52e-05	0.0159	-0.48	-0.37	Bipolar disorder and schizophrenia;	chr1:92735925	chr1:92580476~92580821:-
TGCT	cis	rs12745968	0.718	rs10782941	ENSG00000223787.2	RP4-593M8.1	-4.38	2.52e-05	0.0159	-0.48	-0.37	Bipolar disorder and schizophrenia;	chr1:92744283	chr1:92580476~92580821:-
TGCT	cis	rs6782228	0.606	rs7613073	ENSG00000242551.2	POU5F1P6	-4.38	2.52e-05	0.0159	-0.44	-0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669660	chr3:128674735~128677005:-
TGCT	cis	rs761746	0.577	rs131244	ENSG00000236132.1	CTA-440B3.1	-4.38	2.52e-05	0.0159	-0.49	-0.37	Intelligence;	chr22:31730577	chr22:31816379~31817491:-
TGCT	cis	rs761746	0.577	rs131245	ENSG00000236132.1	CTA-440B3.1	-4.38	2.52e-05	0.0159	-0.49	-0.37	Intelligence;	chr22:31730777	chr22:31816379~31817491:-
TGCT	cis	rs761746	0.614	rs131250	ENSG00000236132.1	CTA-440B3.1	-4.38	2.52e-05	0.0159	-0.49	-0.37	Intelligence;	chr22:31733617	chr22:31816379~31817491:-
TGCT	cis	rs761746	0.579	rs131253	ENSG00000236132.1	CTA-440B3.1	-4.38	2.52e-05	0.0159	-0.49	-0.37	Intelligence;	chr22:31734696	chr22:31816379~31817491:-
TGCT	cis	rs761746	0.614	rs5994427	ENSG00000236132.1	CTA-440B3.1	-4.38	2.52e-05	0.0159	-0.49	-0.37	Intelligence;	chr22:31736590	chr22:31816379~31817491:-
TGCT	cis	rs7208859	0.524	rs77498725	ENSG00000280069.1	CTD-2349P21.3	-4.38	2.52e-05	0.0159	-0.52	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.573	rs73267865	ENSG00000280069.1	CTD-2349P21.3	-4.38	2.52e-05	0.0159	-0.52	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30738182~30740275:+
TGCT	cis	rs17826219	0.706	rs57698184	ENSG00000280069.1	CTD-2349P21.3	-4.38	2.52e-05	0.0159	-0.52	-0.37	Body mass index;	chr17:30737900	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.524	rs59923796	ENSG00000280069.1	CTD-2349P21.3	-4.38	2.52e-05	0.0159	-0.52	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30738182~30740275:+
TGCT	cis	rs17826219	0.5	rs57005940	ENSG00000280069.1	CTD-2349P21.3	-4.38	2.52e-05	0.0159	-0.52	-0.37	Body mass index;	chr17:30739311	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.573	rs73267872	ENSG00000280069.1	CTD-2349P21.3	-4.38	2.52e-05	0.0159	-0.52	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30738182~30740275:+
TGCT	cis	rs17826219	0.706	rs9893922	ENSG00000280069.1	CTD-2349P21.3	-4.38	2.52e-05	0.0159	-0.52	-0.37	Body mass index;	chr17:30741407	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs56812022	ENSG00000280069.1	CTD-2349P21.3	-4.38	2.52e-05	0.0159	-0.52	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.524	rs57670615	ENSG00000280069.1	CTD-2349P21.3	-4.38	2.52e-05	0.0159	-0.52	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30738182~30740275:+
TGCT	cis	rs77669868	0.929	rs3782007	ENSG00000256452.1	RP11-667M19.10	4.38	2.52e-05	0.0159	0.32	0.37	Monocyte percentage of white cells;	chr11:114195716	chr11:113818077~113822458:+
TGCT	cis	rs4242434	0.757	rs7005025	ENSG00000254064.1	CTD-2530N21.4	-4.38	2.52e-05	0.0159	-0.21	-0.37	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22662302	chr8:22254576~22275162:-
TGCT	cis	rs8105895	0.935	rs988211	ENSG00000269742.1	BNIP3P29	4.38	2.53e-05	0.0159	0.68	0.37	Body mass index (change over time);	chr19:22119734	chr19:22065828~22066398:-
TGCT	cis	rs8062405	0.789	rs1968752	ENSG00000259982.1	CDC37P1	4.38	2.53e-05	0.0159	0.44	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28700294~28701540:-
TGCT	cis	rs10129255	0.5	rs8011115	ENSG00000223648.3	IGHV3-64	4.38	2.53e-05	0.0159	0.32	0.37	Kawasaki disease;	chr14:106786292	chr14:106643132~106658258:-
TGCT	cis	rs1023500	0.573	rs133381	ENSG00000270083.1	RP1-257I20.14	4.38	2.53e-05	0.0159	0.38	0.37	Schizophrenia;	chr22:42074604	chr22:42089630~42090028:-
TGCT	cis	rs1372520	0.935	rs1442152	ENSG00000247775.2	SNCA-AS1	4.38	2.53e-05	0.0159	0.35	0.37	Neuroticism;	chr4:89854498	chr4:89836408~89841978:+
TGCT	cis	rs1372520	0.873	rs2736989	ENSG00000247775.2	SNCA-AS1	4.38	2.53e-05	0.0159	0.35	0.37	Neuroticism;	chr4:89855106	chr4:89836408~89841978:+
TGCT	cis	rs875971	1	rs7781698	ENSG00000237310.1	GS1-124K5.4	4.38	2.53e-05	0.016	0.4	0.37	Aortic root size;	chr7:66431325	chr7:66493706~66495474:+
TGCT	cis	rs1450985	0.808	rs35370588	ENSG00000239653.1	PSMD6-AS2	4.38	2.53e-05	0.016	0.34	0.37	Breast cancer;	chr3:64036642	chr3:64004022~64012148:+
TGCT	cis	rs9558942	0.852	rs9558940	ENSG00000277863.1	RP11-282A11.4	4.38	2.54e-05	0.016	0.41	0.37	Obesity-related traits;	chr13:107030291	chr13:106903150~106904099:-
TGCT	cis	rs12745968	0.589	rs722356	ENSG00000223787.2	RP4-593M8.1	-4.38	2.54e-05	0.016	-0.46	-0.37	Bipolar disorder and schizophrenia;	chr1:92516848	chr1:92580476~92580821:-
TGCT	cis	rs7923609	0.934	rs10761771	ENSG00000232075.1	MRPL35P2	-4.38	2.54e-05	0.016	-0.35	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63470404	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.869	rs10733792	ENSG00000232075.1	MRPL35P2	-4.38	2.54e-05	0.016	-0.35	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63472779	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.838	rs7909960	ENSG00000232075.1	MRPL35P2	-4.38	2.54e-05	0.016	-0.35	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63479417	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.967	rs7915779	ENSG00000232075.1	MRPL35P2	-4.38	2.54e-05	0.016	-0.35	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63484484	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.967	rs2393977	ENSG00000232075.1	MRPL35P2	-4.38	2.54e-05	0.016	-0.35	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63487849	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.905	rs10740129	ENSG00000232075.1	MRPL35P2	-4.38	2.54e-05	0.016	-0.35	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63491048	chr10:63634317~63634827:-
TGCT	cis	rs34524635	1	rs34524635	ENSG00000232075.1	MRPL35P2	-4.38	2.54e-05	0.016	-0.35	-0.37	Vascular endothelial growth factor levels;	chr10:63501417	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.967	rs10509189	ENSG00000232075.1	MRPL35P2	-4.38	2.54e-05	0.016	-0.35	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63504366	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.967	rs4486511	ENSG00000232075.1	MRPL35P2	-4.38	2.54e-05	0.016	-0.35	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63504506	chr10:63634317~63634827:-
TGCT	cis	rs7819412	0.74	rs7844536	ENSG00000255310.2	AF131215.2	-4.38	2.54e-05	0.016	-0.3	-0.37	Triglycerides;	chr8:11176519	chr8:11107788~11109726:-
TGCT	cis	rs3749237	0.595	rs17595772	ENSG00000226913.1	BSN-AS2	-4.38	2.54e-05	0.016	-0.28	-0.37	Resting heart rate;	chr3:49372271	chr3:49549306~49554366:-
TGCT	cis	rs3749237	0.595	rs7621003	ENSG00000226913.1	BSN-AS2	-4.38	2.54e-05	0.016	-0.28	-0.37	Resting heart rate;	chr3:49373971	chr3:49549306~49554366:-
TGCT	cis	rs3749237	0.555	rs2117939	ENSG00000226913.1	BSN-AS2	-4.38	2.54e-05	0.016	-0.28	-0.37	Resting heart rate;	chr3:49377746	chr3:49549306~49554366:-
TGCT	cis	rs3749237	0.595	rs4955412	ENSG00000226913.1	BSN-AS2	-4.38	2.54e-05	0.016	-0.28	-0.37	Resting heart rate;	chr3:49380735	chr3:49549306~49554366:-
TGCT	cis	rs3749237	0.595	rs6797765	ENSG00000226913.1	BSN-AS2	-4.38	2.54e-05	0.016	-0.28	-0.37	Resting heart rate;	chr3:49386543	chr3:49549306~49554366:-
TGCT	cis	rs3749237	0.557	rs7631908	ENSG00000226913.1	BSN-AS2	-4.38	2.54e-05	0.016	-0.28	-0.37	Resting heart rate;	chr3:49388274	chr3:49549306~49554366:-
TGCT	cis	rs3749237	0.615	rs55957735	ENSG00000226913.1	BSN-AS2	-4.38	2.54e-05	0.016	-0.28	-0.37	Resting heart rate;	chr3:49400725	chr3:49549306~49554366:-
TGCT	cis	rs9309473	0.948	rs7607892	ENSG00000163016.8	ALMS1P	4.38	2.54e-05	0.016	0.34	0.37	Metabolite levels;	chr2:73591580	chr2:73644919~73685576:+
TGCT	cis	rs1618992	0.791	rs1910556	ENSG00000265994.1	RP11-510D21.1	4.38	2.54e-05	0.016	0.37	0.37	Gut microbiome composition (summer and winter);	chr18:28643385	chr18:28785068~28789260:+
TGCT	cis	rs16852403	0.517	rs7531227	ENSG00000224687.1	RASAL2-AS1	4.38	2.54e-05	0.016	0.49	0.37	Childhood ear infection;	chr1:178263334	chr1:178091508~178093984:-
TGCT	cis	rs16852403	0.517	rs11584886	ENSG00000224687.1	RASAL2-AS1	4.38	2.54e-05	0.016	0.49	0.37	Childhood ear infection;	chr1:178274227	chr1:178091508~178093984:-
TGCT	cis	rs16852403	0.517	rs2902217	ENSG00000224687.1	RASAL2-AS1	4.38	2.54e-05	0.016	0.49	0.37	Childhood ear infection;	chr1:178279027	chr1:178091508~178093984:-
TGCT	cis	rs16852403	0.517	rs12733805	ENSG00000224687.1	RASAL2-AS1	4.38	2.54e-05	0.016	0.49	0.37	Childhood ear infection;	chr1:178280718	chr1:178091508~178093984:-
TGCT	cis	rs17507216	0.56	rs28493687	ENSG00000278603.1	RP13-608F4.5	4.38	2.54e-05	0.016	0.48	0.37	Excessive daytime sleepiness;	chr15:82560062	chr15:82472203~82472426:+
TGCT	cis	rs13118159	0.527	rs6599309	ENSG00000254094.1	AC078852.1	-4.38	2.55e-05	0.016	-0.47	-0.37	Longevity;	chr4:1394327	chr4:1356581~1358075:+
TGCT	cis	rs13118159	0.527	rs9328733	ENSG00000254094.1	AC078852.1	-4.38	2.55e-05	0.016	-0.47	-0.37	Longevity;	chr4:1394795	chr4:1356581~1358075:+
TGCT	cis	rs16975963	0.644	rs35205379	ENSG00000276846.1	CTD-3220F14.3	4.38	2.55e-05	0.016	0.34	0.37	Longevity;	chr19:37685941	chr19:37314868~37315620:-
TGCT	cis	rs2278034	0.516	rs9829709	ENSG00000207650.1	MIR570	4.38	2.55e-05	0.016	0.4	0.37	Bronchopulmonary dysplasia;	chr3:195889802	chr3:195699401~195699497:+
TGCT	cis	rs11671005	0.572	rs11669127	ENSG00000232098.3	CTD-2619J13.14	4.38	2.55e-05	0.016	0.42	0.37	Mean platelet volume;	chr19:58492463	chr19:58404238~58408484:-
TGCT	cis	rs8072100	0.875	rs7208530	ENSG00000228782.6	CTD-2026D20.3	4.37	2.55e-05	0.016	0.43	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47466741	chr17:47450568~47492492:-
TGCT	cis	rs8072100	0.875	rs12451409	ENSG00000228782.6	CTD-2026D20.3	4.37	2.55e-05	0.016	0.43	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47467490	chr17:47450568~47492492:-
TGCT	cis	rs7923609	1	rs10822149	ENSG00000232075.1	MRPL35P2	-4.37	2.55e-05	0.016	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63227652	chr10:63634317~63634827:-
TGCT	cis	rs7923609	1	rs10761727	ENSG00000232075.1	MRPL35P2	-4.37	2.55e-05	0.016	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63235733	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.967	rs10761729	ENSG00000232075.1	MRPL35P2	-4.37	2.55e-05	0.016	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63235844	chr10:63634317~63634827:-
TGCT	cis	rs7923609	1	rs4399232	ENSG00000232075.1	MRPL35P2	-4.37	2.55e-05	0.016	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63239730	chr10:63634317~63634827:-
TGCT	cis	rs9400467	0.506	rs12200610	ENSG00000272356.1	RP5-1112D6.8	-4.37	2.55e-05	0.016	-0.41	-0.37	Amino acid levels;Blood metabolite levels;	chr6:111342364	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs12198788	ENSG00000272356.1	RP5-1112D6.8	-4.37	2.55e-05	0.016	-0.41	-0.37	Amino acid levels;Blood metabolite levels;	chr6:111365588	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.537	rs3218591	ENSG00000272356.1	RP5-1112D6.8	-4.37	2.55e-05	0.016	-0.41	-0.37	Amino acid levels;Blood metabolite levels;	chr6:111374926	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs12191195	ENSG00000272356.1	RP5-1112D6.8	-4.37	2.55e-05	0.016	-0.41	-0.37	Amino acid levels;Blood metabolite levels;	chr6:111391515	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs78344470	ENSG00000272356.1	RP5-1112D6.8	-4.37	2.55e-05	0.016	-0.41	-0.37	Amino acid levels;Blood metabolite levels;	chr6:111440580	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs10457238	ENSG00000272356.1	RP5-1112D6.8	-4.37	2.55e-05	0.016	-0.41	-0.37	Amino acid levels;Blood metabolite levels;	chr6:111441390	chr6:111309203~111313517:+
TGCT	cis	rs6568686	0.627	rs12207339	ENSG00000272356.1	RP5-1112D6.8	-4.37	2.55e-05	0.016	-0.41	-0.37	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111445809	chr6:111309203~111313517:+
TGCT	cis	rs6568686	0.627	rs12207557	ENSG00000272356.1	RP5-1112D6.8	-4.37	2.55e-05	0.016	-0.41	-0.37	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111446256	chr6:111309203~111313517:+
TGCT	cis	rs6568686	0.627	rs12191726	ENSG00000272356.1	RP5-1112D6.8	-4.37	2.55e-05	0.016	-0.41	-0.37	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111448321	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs17751426	ENSG00000272356.1	RP5-1112D6.8	-4.37	2.55e-05	0.016	-0.41	-0.37	Amino acid levels;Blood metabolite levels;	chr6:111451020	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs74529244	ENSG00000272356.1	RP5-1112D6.8	-4.37	2.55e-05	0.016	-0.41	-0.37	Amino acid levels;Blood metabolite levels;	chr6:111454155	chr6:111309203~111313517:+
TGCT	cis	rs6568686	0.627	rs113922733	ENSG00000272356.1	RP5-1112D6.8	-4.37	2.55e-05	0.016	-0.41	-0.37	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111458245	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs79720667	ENSG00000272356.1	RP5-1112D6.8	-4.37	2.55e-05	0.016	-0.41	-0.37	Amino acid levels;Blood metabolite levels;	chr6:111458630	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs12192837	ENSG00000272356.1	RP5-1112D6.8	-4.37	2.55e-05	0.016	-0.41	-0.37	Amino acid levels;Blood metabolite levels;	chr6:111463037	chr6:111309203~111313517:+
TGCT	cis	rs7927592	0.513	rs630225	ENSG00000212093.1	AP000807.1	4.37	2.56e-05	0.0161	0.36	0.37	Total body bone mineral density;	chr11:68427143	chr11:68506083~68506166:-
TGCT	cis	rs755249	0.508	rs6703800	ENSG00000182109.6	RP11-69E11.4	-4.37	2.56e-05	0.0161	-0.37	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39160970	chr1:39522280~39546187:-
TGCT	cis	rs875971	0.545	rs4441996	ENSG00000222364.1	RNU6-96P	4.37	2.56e-05	0.0161	0.46	0.37	Aortic root size;	chr7:66123233	chr7:66395191~66395286:+
TGCT	cis	rs1061377	0.608	rs35168672	ENSG00000249207.1	RP11-360F5.1	-4.37	2.56e-05	0.0161	-0.38	-0.37	Uric acid levels;	chr4:39078902	chr4:39112677~39126818:-
TGCT	cis	rs763121	0.925	rs5757251	ENSG00000273076.1	RP3-508I15.22	4.37	2.56e-05	0.0161	0.39	0.37	Menopause (age at onset);	chr22:38704123	chr22:38743495~38743910:+
TGCT	cis	rs7923609	1	rs7070296	ENSG00000232075.1	MRPL35P2	-4.37	2.56e-05	0.0161	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63310678	chr10:63634317~63634827:-
TGCT	cis	rs786425	0.682	rs7307008	ENSG00000247373.3	RP11-486O12.2	-4.37	2.56e-05	0.0161	-0.47	-0.37	Pubertal anthropometrics;	chr12:123675474	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs7968029	ENSG00000247373.3	RP11-486O12.2	4.37	2.56e-05	0.0161	0.47	0.37	Pubertal anthropometrics;	chr12:123697573	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.637	rs7308234	ENSG00000247373.3	RP11-486O12.2	4.37	2.56e-05	0.0161	0.47	0.37	Pubertal anthropometrics;	chr12:123699257	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs11613632	ENSG00000247373.3	RP11-486O12.2	4.37	2.56e-05	0.0161	0.47	0.37	Pubertal anthropometrics;	chr12:123699518	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.575	rs73219037	ENSG00000247373.3	RP11-486O12.2	4.37	2.56e-05	0.0161	0.47	0.37	Pubertal anthropometrics;	chr12:123699935	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs7398152	ENSG00000247373.3	RP11-486O12.2	4.37	2.56e-05	0.0161	0.47	0.37	Pubertal anthropometrics;	chr12:123700092	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.655	rs7973155	ENSG00000247373.3	RP11-486O12.2	4.37	2.56e-05	0.0161	0.47	0.37	Pubertal anthropometrics;	chr12:123701401	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.655	rs11612030	ENSG00000247373.3	RP11-486O12.2	4.37	2.56e-05	0.0161	0.47	0.37	Pubertal anthropometrics;	chr12:123703517	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs12827074	ENSG00000247373.3	RP11-486O12.2	4.37	2.56e-05	0.0161	0.47	0.37	Pubertal anthropometrics;	chr12:123706289	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.655	rs7398298	ENSG00000247373.3	RP11-486O12.2	4.37	2.56e-05	0.0161	0.47	0.37	Pubertal anthropometrics;	chr12:123708181	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.654	rs7305838	ENSG00000247373.3	RP11-486O12.2	4.37	2.56e-05	0.0161	0.47	0.37	Pubertal anthropometrics;	chr12:123708924	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs7399224	ENSG00000247373.3	RP11-486O12.2	4.37	2.56e-05	0.0161	0.47	0.37	Pubertal anthropometrics;	chr12:123711309	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.74	rs7397160	ENSG00000247373.3	RP11-486O12.2	4.37	2.56e-05	0.0161	0.47	0.37	Pubertal anthropometrics;	chr12:123711672	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.601	rs67178535	ENSG00000247373.3	RP11-486O12.2	4.37	2.56e-05	0.0161	0.47	0.37	Pubertal anthropometrics;	chr12:123711752	chr12:123575891~123585115:-
TGCT	cis	rs901683	1	rs115391636	ENSG00000264204.2	AGAP7P	-4.37	2.56e-05	0.0161	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45516597	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35750365	ENSG00000264204.2	AGAP7P	-4.37	2.56e-05	0.0161	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45517695	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs12781186	ENSG00000264204.2	AGAP7P	-4.37	2.56e-05	0.0161	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45517990	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs12779198	ENSG00000264204.2	AGAP7P	-4.37	2.56e-05	0.0161	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45518099	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs12762495	ENSG00000264204.2	AGAP7P	-4.37	2.56e-05	0.0161	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45518167	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs17157880	ENSG00000264204.2	AGAP7P	-4.37	2.56e-05	0.0161	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45519040	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35131026	ENSG00000264204.2	AGAP7P	-4.37	2.56e-05	0.0161	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45519311	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs17157884	ENSG00000264204.2	AGAP7P	-4.37	2.56e-05	0.0161	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45520494	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71496608	ENSG00000264204.2	AGAP7P	-4.37	2.56e-05	0.0161	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45521684	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs78913745	ENSG00000264204.2	AGAP7P	-4.37	2.56e-05	0.0161	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45524463	chr10:46109621~46131358:+
TGCT	cis	rs901683	0.867	rs17157885	ENSG00000264204.2	AGAP7P	-4.37	2.56e-05	0.0161	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45524646	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs17157887	ENSG00000264204.2	AGAP7P	-4.37	2.56e-05	0.0161	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45524900	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71496609	ENSG00000264204.2	AGAP7P	-4.37	2.56e-05	0.0161	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45525583	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71496611	ENSG00000264204.2	AGAP7P	-4.37	2.56e-05	0.0161	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45526284	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs36070535	ENSG00000264204.2	AGAP7P	-4.37	2.56e-05	0.0161	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45526790	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs12764693	ENSG00000264204.2	AGAP7P	-4.37	2.56e-05	0.0161	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45527879	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35902429	ENSG00000264204.2	AGAP7P	-4.37	2.56e-05	0.0161	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45528887	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs34897497	ENSG00000264204.2	AGAP7P	-4.37	2.56e-05	0.0161	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45529229	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs12775527	ENSG00000264204.2	AGAP7P	-4.37	2.56e-05	0.0161	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45529542	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs76805415	ENSG00000264204.2	AGAP7P	-4.37	2.56e-05	0.0161	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45530715	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs34195613	ENSG00000264204.2	AGAP7P	-4.37	2.56e-05	0.0161	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45534926	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35824277	ENSG00000264204.2	AGAP7P	-4.37	2.56e-05	0.0161	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45535029	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs9422651	ENSG00000264204.2	AGAP7P	-4.37	2.56e-05	0.0161	-0.82	-0.37	Mean corpuscular volume;Red blood cell traits;	chr10:45552008	chr10:46109621~46131358:+
TGCT	cis	rs8105895	0.935	rs62112362	ENSG00000269742.1	BNIP3P29	4.37	2.57e-05	0.0161	0.67	0.37	Body mass index (change over time);	chr19:22110311	chr19:22065828~22066398:-
TGCT	cis	rs8105895	0.935	rs62112364	ENSG00000269742.1	BNIP3P29	4.37	2.57e-05	0.0161	0.67	0.37	Body mass index (change over time);	chr19:22112101	chr19:22065828~22066398:-
TGCT	cis	rs7615952	0.866	rs13063119	ENSG00000171084.14	FAM86JP	4.37	2.57e-05	0.0161	0.63	0.37	Blood pressure (smoking interaction);	chr3:125925004	chr3:125916620~125930024:+
TGCT	cis	rs7615952	0.736	rs13063122	ENSG00000171084.14	FAM86JP	4.37	2.57e-05	0.0161	0.63	0.37	Blood pressure (smoking interaction);	chr3:125925017	chr3:125916620~125930024:+
TGCT	cis	rs10938353	0.68	rs1371240	ENSG00000273369.1	RP11-700J17.1	4.37	2.57e-05	0.0161	0.55	0.37	Body mass index;	chr4:44621681	chr4:44693946~44694386:-
TGCT	cis	rs12550646	0.652	rs13438989	ENSG00000253943.1	KRT18P37	4.37	2.57e-05	0.0161	0.42	0.37	Reticulocyte fraction of red cells;Reticulocyte count;	chr8:41828327	chr8:41511240~41512521:+
TGCT	cis	rs453301	0.624	rs330049	ENSG00000254340.1	RP11-10A14.3	4.37	2.57e-05	0.0161	0.34	0.37	Joint mobility (Beighton score);	chr8:9229789	chr8:9141424~9145435:+
TGCT	cis	rs7923609	0.87	rs10822156	ENSG00000232075.1	MRPL35P2	-4.37	2.57e-05	0.0161	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63320967	chr10:63634317~63634827:-
TGCT	cis	rs7923609	1	rs10761742	ENSG00000232075.1	MRPL35P2	-4.37	2.57e-05	0.0161	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63325288	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.902	rs10822158	ENSG00000232075.1	MRPL35P2	-4.37	2.57e-05	0.0161	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63334623	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.846	rs10740115	ENSG00000232075.1	MRPL35P2	-4.37	2.57e-05	0.0161	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63335230	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.846	rs10740116	ENSG00000232075.1	MRPL35P2	-4.37	2.57e-05	0.0161	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63335232	chr10:63634317~63634827:-
TGCT	cis	rs5758659	0.729	rs134866	ENSG00000182057.4	OGFRP1	4.37	2.57e-05	0.0161	0.27	0.37	Cognitive function;	chr22:42254657	chr22:42269753~42275196:+
TGCT	cis	rs5758659	0.679	rs134870	ENSG00000182057.4	OGFRP1	4.37	2.57e-05	0.0161	0.27	0.37	Cognitive function;	chr22:42256311	chr22:42269753~42275196:+
TGCT	cis	rs904251	0.686	rs931649	ENSG00000279942.1	RP1-153P14.7	-4.37	2.57e-05	0.0161	-0.47	-0.37	Cognitive performance;	chr6:37498303	chr6:37567716~37571460:+
TGCT	cis	rs559928	1	rs72926038	ENSG00000236935.1	AP003774.1	4.37	2.58e-05	0.0162	0.37	0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64374919	chr11:64325050~64329504:-
TGCT	cis	rs559928	0.947	rs56339474	ENSG00000236935.1	AP003774.1	4.37	2.58e-05	0.0162	0.37	0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64375006	chr11:64325050~64329504:-
TGCT	cis	rs17373728	0.71	rs2221810	ENSG00000249395.2	CASC9	4.37	2.58e-05	0.0162	0.45	0.37	Diabetic kidney disease;	chr8:75309233	chr8:75223404~75324741:-
TGCT	cis	rs4273100	0.646	rs1472932	ENSG00000262319.1	CTC-457L16.2	4.37	2.58e-05	0.0162	0.46	0.37	Schizophrenia;	chr17:19317353	chr17:19141017~19143689:-
TGCT	cis	rs559928	1	rs72924202	ENSG00000236935.1	AP003774.1	4.37	2.58e-05	0.0162	0.38	0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64365756	chr11:64325050~64329504:-
TGCT	cis	rs12022452	0.544	rs11208423	ENSG00000238287.1	RP11-656D10.3	-4.37	2.58e-05	0.0162	-0.46	-0.37	Age-related hearing impairment (SNP x SNP interaction);	chr1:40563942	chr1:40493157~40508661:-
TGCT	cis	rs9309473	0.898	rs10201159	ENSG00000163016.8	ALMS1P	4.37	2.58e-05	0.0162	0.33	0.37	Metabolite levels;	chr2:73631838	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.847	rs4547554	ENSG00000163016.8	ALMS1P	4.37	2.58e-05	0.0162	0.33	0.37	Metabolite levels;	chr2:73640735	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.847	rs13538	ENSG00000163016.8	ALMS1P	4.37	2.58e-05	0.0162	0.33	0.37	Metabolite levels;	chr2:73641201	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.95	rs13431529	ENSG00000163016.8	ALMS1P	4.37	2.58e-05	0.0162	0.33	0.37	Metabolite levels;	chr2:73648914	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.95	rs10189885	ENSG00000163016.8	ALMS1P	4.37	2.58e-05	0.0162	0.33	0.37	Metabolite levels;	chr2:73649928	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.95	rs13408433	ENSG00000163016.8	ALMS1P	4.37	2.58e-05	0.0162	0.33	0.37	Metabolite levels;	chr2:73655945	chr2:73644919~73685576:+
TGCT	cis	rs4691139	1	rs9991678	ENSG00000236941.6	RP11-366M4.8	4.37	2.58e-05	0.0162	0.28	0.37	Ovarian cancer in BRCA1 mutation carriers;	chr4:164963887	chr4:164948079~164949438:+
TGCT	cis	rs4835473	0.897	rs13144504	ENSG00000251600.4	RP11-673E1.1	-4.37	2.58e-05	0.0162	-0.38	-0.37	Immature fraction of reticulocytes;	chr4:143707402	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs28825455	ENSG00000251600.4	RP11-673E1.1	4.37	2.58e-05	0.0162	0.38	0.37	Immature fraction of reticulocytes;	chr4:143707593	chr4:143912331~143982454:+
TGCT	cis	rs875971	1	rs9986696	ENSG00000237310.1	GS1-124K5.4	-4.37	2.59e-05	0.0162	-0.41	-0.37	Aortic root size;	chr7:66239589	chr7:66493706~66495474:+
TGCT	cis	rs7826238	0.509	rs2948288	ENSG00000254340.1	RP11-10A14.3	4.37	2.59e-05	0.0162	0.37	0.37	Systolic blood pressure;	chr8:8257782	chr8:9141424~9145435:+
TGCT	cis	rs7714584	1	rs13361189	ENSG00000197083.10	ZNF300P1	4.37	2.59e-05	0.0162	0.63	0.37	Crohn's disease;	chr5:150843825	chr5:150930645~150946289:-
TGCT	cis	rs13118159	0.573	rs4974618	ENSG00000254094.1	AC078852.1	-4.37	2.59e-05	0.0162	-0.45	-0.37	Longevity;	chr4:1379875	chr4:1356581~1358075:+
TGCT	cis	rs7396835	1	rs7396835	ENSG00000254851.1	RP11-109L13.1	-4.37	2.59e-05	0.0162	-0.55	-0.37	Quantitative traits;	chr11:116813312	chr11:117135528~117138582:+
TGCT	cis	rs2505998	0.912	rs2505994	ENSG00000273008.1	RP11-351D16.3	4.37	2.59e-05	0.0162	0.44	0.37	Hirschsprung disease;	chr10:43073439	chr10:43136824~43138334:-
TGCT	cis	rs1823913	0.637	rs2356354	ENSG00000227542.1	AC092614.2	-4.37	2.6e-05	0.0162	-0.39	-0.37	Obesity-related traits;	chr2:191270970	chr2:191229165~191246172:-
TGCT	cis	rs34217772	0.64	rs61990337	ENSG00000258536.1	RP11-1053O12.1	4.37	2.6e-05	0.0163	0.3	0.37	Myopia;	chr14:41715214	chr14:41742639~41742963:+
TGCT	cis	rs1823913	0.614	rs6434459	ENSG00000227542.1	AC092614.2	-4.37	2.6e-05	0.0163	-0.39	-0.37	Obesity-related traits;	chr2:191300886	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.592	rs7588555	ENSG00000227542.1	AC092614.2	-4.37	2.6e-05	0.0163	-0.39	-0.37	Obesity-related traits;	chr2:191300912	chr2:191229165~191246172:-
TGCT	cis	rs13108904	0.604	rs13103860	ENSG00000253399.1	AC078852.2	-4.37	2.6e-05	0.0163	-0.43	-0.37	Obesity-related traits;	chr4:1326332	chr4:1358479~1359461:+
TGCT	cis	rs1497406	0.773	rs7538833	ENSG00000235084.3	CHCHD2P6	4.37	2.6e-05	0.0163	0.43	0.37	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);	chr1:16177886	chr1:15604597~15605043:+
TGCT	cis	rs755249	0.501	rs2490945	ENSG00000182109.6	RP11-69E11.4	4.37	2.6e-05	0.0163	0.37	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371672	chr1:39522280~39546187:-
TGCT	cis	rs755249	0.501	rs621807	ENSG00000182109.6	RP11-69E11.4	4.37	2.6e-05	0.0163	0.37	0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39376771	chr1:39522280~39546187:-
TGCT	cis	rs34217772	0.739	rs12878452	ENSG00000258536.1	RP11-1053O12.1	-4.37	2.6e-05	0.0163	-0.33	-0.37	Myopia;	chr14:41842228	chr14:41742639~41742963:+
TGCT	cis	rs904251	0.861	rs1757180	ENSG00000204110.6	RP1-153P14.8	-4.37	2.6e-05	0.0163	-0.43	-0.37	Cognitive performance;	chr6:37518369	chr6:37507348~37535616:+
TGCT	cis	rs1153858	0.848	rs9806699	ENSG00000259520.4	CTD-2651B20.3	-4.37	2.61e-05	0.0163	-0.31	-0.37	Homoarginine levels;	chr15:45448194	chr15:45251580~45279251:-
TGCT	cis	rs875971	0.545	rs73376394	ENSG00000237310.1	GS1-124K5.4	4.37	2.61e-05	0.0163	0.45	0.37	Aortic root size;	chr7:66172694	chr7:66493706~66495474:+
TGCT	cis	rs4660214	0.694	rs16866216	ENSG00000182109.6	RP11-69E11.4	-4.37	2.61e-05	0.0163	-0.38	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39208916	chr1:39522280~39546187:-
TGCT	cis	rs7923609	1	rs10761723	ENSG00000232075.1	MRPL35P2	-4.37	2.61e-05	0.0163	-0.36	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63195821	chr10:63634317~63634827:-
TGCT	cis	rs1823913	0.927	rs13013390	ENSG00000280083.1	RP11-317J9.1	-4.37	2.62e-05	0.0163	-0.31	-0.37	Obesity-related traits;	chr2:191262001	chr2:191154118~191156070:-
TGCT	cis	rs5758511	0.633	rs5758689	ENSG00000182057.4	OGFRP1	-4.37	2.62e-05	0.0163	-0.35	-0.37	Birth weight;	chr22:42268966	chr22:42269753~42275196:+
TGCT	cis	rs5758511	0.689	rs5758691	ENSG00000182057.4	OGFRP1	-4.37	2.62e-05	0.0163	-0.35	-0.37	Birth weight;	chr22:42272498	chr22:42269753~42275196:+
TGCT	cis	rs5758511	0.634	rs1001587	ENSG00000182057.4	OGFRP1	-4.37	2.62e-05	0.0163	-0.35	-0.37	Birth weight;	chr22:42274105	chr22:42269753~42275196:+
TGCT	cis	rs5758511	0.68	rs1001586	ENSG00000182057.4	OGFRP1	-4.37	2.62e-05	0.0163	-0.35	-0.37	Birth weight;	chr22:42274287	chr22:42269753~42275196:+
TGCT	cis	rs5758511	0.68	rs739147	ENSG00000182057.4	OGFRP1	-4.37	2.62e-05	0.0163	-0.35	-0.37	Birth weight;	chr22:42275060	chr22:42269753~42275196:+
TGCT	cis	rs5758659	0.512	rs4822072	ENSG00000182057.4	OGFRP1	4.37	2.62e-05	0.0164	0.25	0.37	Cognitive function;	chr22:41964829	chr22:42269753~42275196:+
TGCT	cis	rs453301	0.653	rs11784393	ENSG00000254340.1	RP11-10A14.3	4.37	2.62e-05	0.0164	0.37	0.37	Joint mobility (Beighton score);	chr8:9045624	chr8:9141424~9145435:+
TGCT	cis	rs2153535	0.58	rs6597318	ENSG00000230939.1	RP11-314C16.1	-4.37	2.63e-05	0.0164	-0.36	-0.37	Motion sickness;	chr6:8437056	chr6:8784178~8785445:+
TGCT	cis	rs17507216	1	rs17507216	ENSG00000255769.6	GOLGA2P10	4.37	2.63e-05	0.0164	0.44	0.37	Excessive daytime sleepiness;	chr15:82558175	chr15:82472993~82513950:-
TGCT	cis	rs748404	0.666	rs8027748	ENSG00000205771.5	CATSPER2P1	-4.37	2.63e-05	0.0164	-0.53	-0.37	Lung cancer;	chr15:43447622	chr15:43726918~43747094:-
TGCT	cis	rs7182621	0.512	rs71403471	ENSG00000259363.4	CTD-2054N24.2	-4.37	2.63e-05	0.0164	-0.37	-0.37	Colonoscopy-negative controls vs population controls;	chr15:99870656	chr15:99807023~99877148:+
TGCT	cis	rs4713118	0.662	rs149901	ENSG00000219392.1	RP1-265C24.5	-4.37	2.63e-05	0.0164	-0.45	-0.37	Parkinson's disease;	chr6:27997725	chr6:28115628~28116551:+
TGCT	cis	rs2945232	1	rs2945232	ENSG00000253981.4	ALG1L13P	4.37	2.63e-05	0.0164	0.39	0.37	Schizophrenia;	chr8:8240516	chr8:8236003~8244667:-
TGCT	cis	rs875971	0.862	rs2901152	ENSG00000237310.1	GS1-124K5.4	-4.37	2.63e-05	0.0164	-0.4	-0.37	Aortic root size;	chr7:66300017	chr7:66493706~66495474:+
TGCT	cis	rs3742264	1	rs9534307	ENSG00000235903.6	CPB2-AS1	-4.37	2.63e-05	0.0164	-0.44	-0.37	Blood protein levels;	chr13:46069995	chr13:46052806~46113332:+
TGCT	cis	rs11723261	0.621	rs7440274	ENSG00000275426.1	CH17-262A2.1	-4.37	2.63e-05	0.0164	-0.64	-0.37	Immune response to smallpox vaccine (IL-6);	chr4:161923	chr4:149738~150317:+
TGCT	cis	rs67311347	1	rs7625736	ENSG00000223797.4	ENTPD3-AS1	-4.37	2.63e-05	0.0164	-0.37	-0.37	Renal cell carcinoma;	chr3:40399854	chr3:40313802~40453329:-
TGCT	cis	rs67311347	0.956	rs13066971	ENSG00000223797.4	ENTPD3-AS1	-4.37	2.63e-05	0.0164	-0.37	-0.37	Renal cell carcinoma;	chr3:40421019	chr3:40313802~40453329:-
TGCT	cis	rs853679	0.527	rs9461443	ENSG00000219392.1	RP1-265C24.5	-4.37	2.64e-05	0.0165	-0.48	-0.37	Depression;	chr6:28226851	chr6:28115628~28116551:+
TGCT	cis	rs507080	0.501	rs516503	ENSG00000255422.1	AP002954.4	-4.37	2.64e-05	0.0165	-0.39	-0.37	Serum metabolite levels;	chr11:118709639	chr11:118704607~118750263:+
TGCT	cis	rs10256972	0.539	rs2949174	ENSG00000226291.1	AC091729.8	-4.37	2.64e-05	0.0165	-0.39	-0.37	Endometriosis;Longevity;	chr7:1174287	chr7:1080863~1082178:+
TGCT	cis	rs10129255	0.5	rs2027903	ENSG00000280411.1	IGHV1-69-2	-4.37	2.64e-05	0.0165	-0.37	-0.37	Kawasaki disease;	chr14:106807047	chr14:106762092~106762588:-
TGCT	cis	rs10129255	0.518	rs28378320	ENSG00000280411.1	IGHV1-69-2	-4.37	2.64e-05	0.0165	-0.37	-0.37	Kawasaki disease;	chr14:106808609	chr14:106762092~106762588:-
TGCT	cis	rs8072100	0.837	rs62074055	ENSG00000228782.6	CTD-2026D20.3	4.37	2.64e-05	0.0165	0.41	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694567	chr17:47450568~47492492:-
TGCT	cis	rs9400467	0.506	rs12196873	ENSG00000272356.1	RP5-1112D6.8	4.37	2.65e-05	0.0165	0.42	0.36	Amino acid levels;Blood metabolite levels;	chr6:111276855	chr6:111309203~111313517:+
TGCT	cis	rs728616	0.614	rs1998374	ENSG00000230091.5	TMEM254-AS1	4.36	2.65e-05	0.0165	0.52	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79942966	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.614	rs10887199	ENSG00000230091.5	TMEM254-AS1	4.36	2.65e-05	0.0165	0.52	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79943078	chr10:80046860~80078912:-
TGCT	cis	rs853679	0.55	rs1233704	ENSG00000187763.3	OR2B7P	-4.36	2.65e-05	0.0165	-0.37	-0.36	Depression;	chr6:28199145	chr6:28046434~28047367:+
TGCT	cis	rs1519814	0.654	rs6469888	ENSG00000254343.2	RP11-760H22.2	-4.36	2.66e-05	0.0165	-0.59	-0.36	Breast cancer;	chr8:120005936	chr8:120052180~120056201:+
TGCT	cis	rs7246967	0.932	rs62120780	ENSG00000268541.1	VN1R88P	-4.36	2.66e-05	0.0166	-0.41	-0.36	Bronchopulmonary dysplasia;	chr19:22860912	chr19:22861303~22861594:+
TGCT	cis	rs763121	0.962	rs138703	ENSG00000273076.1	RP3-508I15.22	4.36	2.66e-05	0.0166	0.39	0.36	Menopause (age at onset);	chr22:38736743	chr22:38743495~38743910:+
TGCT	cis	rs4691139	1	rs4691139	ENSG00000236941.6	RP11-366M4.8	4.36	2.66e-05	0.0166	0.27	0.36	Ovarian cancer in BRCA1 mutation carriers;	chr4:164987569	chr4:164948079~164949438:+
TGCT	cis	rs5758511	0.68	rs5758699	ENSG00000182057.4	OGFRP1	-4.36	2.66e-05	0.0166	-0.35	-0.36	Birth weight;	chr22:42292028	chr22:42269753~42275196:+
TGCT	cis	rs12143943	0.966	rs4950953	ENSG00000176754.11	LINC00303	4.36	2.66e-05	0.0166	0.32	0.36	Cognitive performance;	chr1:204606353	chr1:204032447~204041265:-
TGCT	cis	rs4691139	1	rs6536882	ENSG00000236941.6	RP11-366M4.8	4.36	2.66e-05	0.0166	0.27	0.36	Ovarian cancer in BRCA1 mutation carriers;	chr4:164979528	chr4:164948079~164949438:+
TGCT	cis	rs4691139	1	rs6536883	ENSG00000236941.6	RP11-366M4.8	4.36	2.66e-05	0.0166	0.27	0.36	Ovarian cancer in BRCA1 mutation carriers;	chr4:164979552	chr4:164948079~164949438:+
TGCT	cis	rs1012068	0.686	rs5998176	ENSG00000236132.1	CTA-440B3.1	-4.36	2.66e-05	0.0166	-0.43	-0.36	Chronic hepatitis C infection;	chr22:31922107	chr22:31816379~31817491:-
TGCT	cis	rs10256972	0.9	rs7812072	ENSG00000226291.1	AC091729.8	-4.36	2.67e-05	0.0166	-0.38	-0.36	Endometriosis;Longevity;	chr7:1014226	chr7:1080863~1082178:+
TGCT	cis	rs7615952	0.8	rs12489350	ENSG00000171084.14	FAM86JP	4.36	2.67e-05	0.0166	0.63	0.36	Blood pressure (smoking interaction);	chr3:125925273	chr3:125916620~125930024:+
TGCT	cis	rs6782228	0.606	rs4634140	ENSG00000242551.2	POU5F1P6	4.36	2.67e-05	0.0166	0.44	0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705613	chr3:128674735~128677005:-
TGCT	cis	rs16852403	0.502	rs6682970	ENSG00000224687.1	RASAL2-AS1	4.36	2.67e-05	0.0166	0.49	0.36	Childhood ear infection;	chr1:178201385	chr1:178091508~178093984:-
TGCT	cis	rs16852403	0.548	rs28760457	ENSG00000224687.1	RASAL2-AS1	4.36	2.67e-05	0.0166	0.49	0.36	Childhood ear infection;	chr1:178205350	chr1:178091508~178093984:-
TGCT	cis	rs16852403	0.548	rs6685012	ENSG00000224687.1	RASAL2-AS1	4.36	2.67e-05	0.0166	0.49	0.36	Childhood ear infection;	chr1:178206166	chr1:178091508~178093984:-
TGCT	cis	rs16852403	0.517	rs12047029	ENSG00000224687.1	RASAL2-AS1	4.36	2.67e-05	0.0166	0.49	0.36	Childhood ear infection;	chr1:178210582	chr1:178091508~178093984:-
TGCT	cis	rs16852403	0.501	rs2862318	ENSG00000224687.1	RASAL2-AS1	4.36	2.67e-05	0.0166	0.49	0.36	Childhood ear infection;	chr1:178210992	chr1:178091508~178093984:-
TGCT	cis	rs16852403	0.548	rs10798600	ENSG00000224687.1	RASAL2-AS1	4.36	2.67e-05	0.0166	0.49	0.36	Childhood ear infection;	chr1:178211584	chr1:178091508~178093984:-
TGCT	cis	rs16852403	0.548	rs12410235	ENSG00000224687.1	RASAL2-AS1	4.36	2.67e-05	0.0166	0.49	0.36	Childhood ear infection;	chr1:178215647	chr1:178091508~178093984:-
TGCT	cis	rs16852403	0.548	rs10798601	ENSG00000224687.1	RASAL2-AS1	4.36	2.67e-05	0.0166	0.49	0.36	Childhood ear infection;	chr1:178217746	chr1:178091508~178093984:-
TGCT	cis	rs16852403	0.548	rs2225586	ENSG00000224687.1	RASAL2-AS1	4.36	2.67e-05	0.0166	0.49	0.36	Childhood ear infection;	chr1:178234997	chr1:178091508~178093984:-
TGCT	cis	rs2019137	0.836	rs4848318	ENSG00000189223.12	PAX8-AS1	4.36	2.67e-05	0.0166	0.45	0.36	Lymphocyte counts;	chr2:113196375	chr2:113211522~113276581:+
TGCT	cis	rs2019137	0.936	rs2241978	ENSG00000189223.12	PAX8-AS1	4.36	2.67e-05	0.0166	0.45	0.36	Lymphocyte counts;	chr2:113196429	chr2:113211522~113276581:+
TGCT	cis	rs2019137	0.905	rs2276561	ENSG00000189223.12	PAX8-AS1	4.36	2.67e-05	0.0166	0.45	0.36	Lymphocyte counts;	chr2:113198794	chr2:113211522~113276581:+
TGCT	cis	rs2019137	0.936	rs2305133	ENSG00000189223.12	PAX8-AS1	4.36	2.67e-05	0.0166	0.45	0.36	Lymphocyte counts;	chr2:113199244	chr2:113211522~113276581:+
TGCT	cis	rs2019137	0.936	rs12612729	ENSG00000189223.12	PAX8-AS1	4.36	2.67e-05	0.0166	0.45	0.36	Lymphocyte counts;	chr2:113199471	chr2:113211522~113276581:+
TGCT	cis	rs2019137	0.936	rs731834	ENSG00000189223.12	PAX8-AS1	4.36	2.67e-05	0.0166	0.45	0.36	Lymphocyte counts;	chr2:113199621	chr2:113211522~113276581:+
TGCT	cis	rs2019137	0.936	rs3811059	ENSG00000189223.12	PAX8-AS1	4.36	2.67e-05	0.0166	0.45	0.36	Lymphocyte counts;	chr2:113204494	chr2:113211522~113276581:+
TGCT	cis	rs2019137	0.936	rs12620738	ENSG00000189223.12	PAX8-AS1	4.36	2.67e-05	0.0166	0.45	0.36	Lymphocyte counts;	chr2:113206162	chr2:113211522~113276581:+
TGCT	cis	rs728616	0.867	rs723191	ENSG00000230091.5	TMEM254-AS1	4.36	2.67e-05	0.0166	0.7	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948164	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs723193	ENSG00000230091.5	TMEM254-AS1	4.36	2.67e-05	0.0166	0.7	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948399	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs1923534	ENSG00000230091.5	TMEM254-AS1	4.36	2.67e-05	0.0166	0.7	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79950729	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs12414096	ENSG00000230091.5	TMEM254-AS1	4.36	2.67e-05	0.0166	0.7	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953873	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.557	rs17107449	ENSG00000230091.5	TMEM254-AS1	4.36	2.67e-05	0.0166	0.7	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955940	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs76239460	ENSG00000230091.5	TMEM254-AS1	4.36	2.67e-05	0.0166	0.7	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963471	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs61860400	ENSG00000230091.5	TMEM254-AS1	4.36	2.67e-05	0.0166	0.7	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963671	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs61860412	ENSG00000230091.5	TMEM254-AS1	4.36	2.67e-05	0.0166	0.7	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968730	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs12412257	ENSG00000230091.5	TMEM254-AS1	4.36	2.67e-05	0.0166	0.7	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79969847	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs117139504	ENSG00000230091.5	TMEM254-AS1	4.36	2.67e-05	0.0166	0.7	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79974451	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs61860417	ENSG00000230091.5	TMEM254-AS1	4.36	2.67e-05	0.0166	0.7	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79974971	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs12412226	ENSG00000230091.5	TMEM254-AS1	4.36	2.67e-05	0.0166	0.7	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79975532	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs4387301	ENSG00000230091.5	TMEM254-AS1	4.36	2.67e-05	0.0166	0.7	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79976643	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.764	rs117833443	ENSG00000230091.5	TMEM254-AS1	4.36	2.67e-05	0.0166	0.7	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79978380	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs116994688	ENSG00000230091.5	TMEM254-AS1	4.36	2.67e-05	0.0166	0.7	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79978381	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs61860420	ENSG00000230091.5	TMEM254-AS1	4.36	2.67e-05	0.0166	0.7	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79979623	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs75447386	ENSG00000230091.5	TMEM254-AS1	4.36	2.67e-05	0.0166	0.7	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79979891	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs4520539	ENSG00000230091.5	TMEM254-AS1	4.36	2.67e-05	0.0166	0.7	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79980773	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs61860421	ENSG00000230091.5	TMEM254-AS1	4.36	2.67e-05	0.0166	0.7	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79983643	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.702	rs78734698	ENSG00000230091.5	TMEM254-AS1	4.36	2.67e-05	0.0166	0.7	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79996693	chr10:80046860~80078912:-
TGCT	cis	rs875971	0.545	rs73376394	ENSG00000222364.1	RNU6-96P	-4.36	2.67e-05	0.0166	-0.47	-0.36	Aortic root size;	chr7:66172694	chr7:66395191~66395286:+
TGCT	cis	rs901683	1	rs34574958	ENSG00000264204.2	AGAP7P	-4.36	2.68e-05	0.0166	-0.85	-0.36	Mean corpuscular volume;Red blood cell traits;	chr10:45591592	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs12779005	ENSG00000264204.2	AGAP7P	-4.36	2.68e-05	0.0166	-0.85	-0.36	Mean corpuscular volume;Red blood cell traits;	chr10:45591926	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs34539215	ENSG00000264204.2	AGAP7P	-4.36	2.68e-05	0.0166	-0.85	-0.36	Mean corpuscular volume;Red blood cell traits;	chr10:45591930	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs78766622	ENSG00000264204.2	AGAP7P	-4.36	2.68e-05	0.0166	-0.85	-0.36	Mean corpuscular volume;Red blood cell traits;	chr10:45592071	chr10:46109621~46131358:+
TGCT	cis	rs2019137	0.936	rs3828188	ENSG00000189223.12	PAX8-AS1	4.36	2.68e-05	0.0166	0.45	0.36	Lymphocyte counts;	chr2:113196670	chr2:113211522~113276581:+
TGCT	cis	rs2019137	0.936	rs3828189	ENSG00000189223.12	PAX8-AS1	4.36	2.68e-05	0.0166	0.45	0.36	Lymphocyte counts;	chr2:113196919	chr2:113211522~113276581:+
TGCT	cis	rs796364	0.806	rs79053279	ENSG00000232732.8	AC073043.1	4.36	2.68e-05	0.0166	0.53	0.36	Schizophrenia;	chr2:200192720	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.76	rs74993507	ENSG00000232732.8	AC073043.1	4.36	2.68e-05	0.0166	0.53	0.36	Schizophrenia;	chr2:200203961	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs112486506	ENSG00000232732.8	AC073043.1	4.36	2.68e-05	0.0166	0.53	0.36	Schizophrenia;	chr2:200209224	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs10445791	ENSG00000232732.8	AC073043.1	4.36	2.68e-05	0.0166	0.53	0.36	Schizophrenia;	chr2:200213584	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs10445792	ENSG00000232732.8	AC073043.1	4.36	2.68e-05	0.0166	0.53	0.36	Schizophrenia;	chr2:200214098	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs79725795	ENSG00000232732.8	AC073043.1	4.36	2.68e-05	0.0166	0.53	0.36	Schizophrenia;	chr2:200218811	chr2:199867396~199911159:-
TGCT	cis	rs10170266	0.875	rs6747107	ENSG00000279220.1	GPR1-AS	4.36	2.68e-05	0.0167	0.3	0.36	Reticulocyte fraction of red cells;	chr2:206022465	chr2:206203376~206266243:+
TGCT	cis	rs10170266	0.875	rs6759124	ENSG00000279220.1	GPR1-AS	4.36	2.68e-05	0.0167	0.3	0.36	Reticulocyte fraction of red cells;	chr2:206025090	chr2:206203376~206266243:+
TGCT	cis	rs2019137	0.936	rs4849169	ENSG00000189223.12	PAX8-AS1	4.36	2.68e-05	0.0167	0.45	0.36	Lymphocyte counts;	chr2:113196080	chr2:113211522~113276581:+
TGCT	cis	rs6474412	0.957	rs4236926	ENSG00000255101.1	RP11-412B14.1	4.36	2.69e-05	0.0167	0.36	0.36	Smoking behavior;	chr8:42722916	chr8:42705583~42721946:-
TGCT	cis	rs6474412	0.912	rs16891561	ENSG00000255101.1	RP11-412B14.1	4.36	2.69e-05	0.0167	0.36	0.36	Smoking behavior;	chr8:42724596	chr8:42705583~42721946:-
TGCT	cis	rs4691139	1	rs7693977	ENSG00000236941.6	RP11-366M4.8	4.36	2.69e-05	0.0167	0.27	0.36	Ovarian cancer in BRCA1 mutation carriers;	chr4:164981898	chr4:164948079~164949438:+
TGCT	cis	rs2581828	0.965	rs2581830	ENSG00000242142.1	SERBP1P3	4.36	2.69e-05	0.0167	0.34	0.36	Crohn's disease;	chr3:53100082	chr3:53064283~53065091:-
TGCT	cis	rs2581828	0.965	rs35783750	ENSG00000242142.1	SERBP1P3	4.36	2.69e-05	0.0167	0.34	0.36	Crohn's disease;	chr3:53100847	chr3:53064283~53065091:-
TGCT	cis	rs2581828	0.965	rs34454739	ENSG00000242142.1	SERBP1P3	4.36	2.69e-05	0.0167	0.34	0.36	Crohn's disease;	chr3:53100955	chr3:53064283~53065091:-
TGCT	cis	rs2581828	0.965	rs4337632	ENSG00000242142.1	SERBP1P3	4.36	2.69e-05	0.0167	0.34	0.36	Crohn's disease;	chr3:53103295	chr3:53064283~53065091:-
TGCT	cis	rs2177312	0.794	rs1523161	ENSG00000251129.1	RP11-734I18.1	-4.36	2.69e-05	0.0167	-0.41	-0.36	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31953016	chr4:31997397~32155406:+
TGCT	cis	rs6782228	0.628	rs7641584	ENSG00000242551.2	POU5F1P6	-4.36	2.7e-05	0.0167	-0.44	-0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128673787	chr3:128674735~128677005:-
TGCT	cis	rs1823913	0.599	rs6732976	ENSG00000227542.1	AC092614.2	-4.36	2.7e-05	0.0167	-0.39	-0.36	Obesity-related traits;	chr2:191281004	chr2:191229165~191246172:-
TGCT	cis	rs6604026	0.59	rs11810217	ENSG00000223787.2	RP4-593M8.1	4.36	2.7e-05	0.0167	0.51	0.36	Multiple sclerosis;	chr1:92682820	chr1:92580476~92580821:-
TGCT	cis	rs11810217	0.718	rs114225281	ENSG00000223787.2	RP4-593M8.1	4.36	2.7e-05	0.0167	0.51	0.36	Multiple sclerosis;	chr1:92685669	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.59	rs111807611	ENSG00000223787.2	RP4-593M8.1	4.36	2.7e-05	0.0167	0.51	0.36	Multiple sclerosis;	chr1:92687707	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.59	rs2051841	ENSG00000223787.2	RP4-593M8.1	4.36	2.7e-05	0.0167	0.51	0.36	Multiple sclerosis;	chr1:92690638	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.59	rs11577426	ENSG00000223787.2	RP4-593M8.1	4.36	2.7e-05	0.0167	0.51	0.36	Multiple sclerosis;	chr1:92694681	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.624	rs12756698	ENSG00000223787.2	RP4-593M8.1	4.36	2.7e-05	0.0167	0.51	0.36	Multiple sclerosis;	chr1:92697243	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.624	rs11803097	ENSG00000223787.2	RP4-593M8.1	4.36	2.7e-05	0.0167	0.51	0.36	Multiple sclerosis;	chr1:92705932	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.59	rs12749786	ENSG00000223787.2	RP4-593M8.1	4.36	2.7e-05	0.0167	0.51	0.36	Multiple sclerosis;	chr1:92706367	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.624	rs72724586	ENSG00000223787.2	RP4-593M8.1	4.36	2.7e-05	0.0167	0.51	0.36	Multiple sclerosis;	chr1:92707620	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.624	rs34305407	ENSG00000223787.2	RP4-593M8.1	4.36	2.7e-05	0.0167	0.51	0.36	Multiple sclerosis;	chr1:92708658	chr1:92580476~92580821:-
TGCT	cis	rs412000	0.56	rs4793583	ENSG00000265148.4	BZRAP1-AS1	4.36	2.7e-05	0.0168	0.23	0.36	Primary tooth development (time to first tooth eruption);	chr17:58374046	chr17:58325450~58415766:+
TGCT	cis	rs35000415	0.688	rs35429892	ENSG00000242078.1	RP11-738B7.1	4.36	2.7e-05	0.0168	0.56	0.36	Systemic lupus erythematosus;	chr7:129073576	chr7:129783370~129785185:-
TGCT	cis	rs35000415	0.688	rs13241591	ENSG00000242078.1	RP11-738B7.1	4.36	2.7e-05	0.0168	0.56	0.36	Systemic lupus erythematosus;	chr7:129074692	chr7:129783370~129785185:-
TGCT	cis	rs35000415	0.688	rs13229034	ENSG00000242078.1	RP11-738B7.1	4.36	2.7e-05	0.0168	0.56	0.36	Systemic lupus erythematosus;	chr7:129074789	chr7:129783370~129785185:-
TGCT	cis	rs7923609	0.967	rs7082470	ENSG00000232075.1	MRPL35P2	-4.36	2.7e-05	0.0168	-0.35	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63517266	chr10:63634317~63634827:-
TGCT	cis	rs2033711	0.87	rs4801583	ENSG00000269473.1	CTD-2619J13.19	4.36	2.71e-05	0.0168	0.29	0.36	Uric acid clearance;	chr19:58407038	chr19:58440448~58445849:+
TGCT	cis	rs796364	0.539	rs6738494	ENSG00000232732.8	AC073043.1	-4.36	2.71e-05	0.0168	-0.56	-0.36	Schizophrenia;	chr2:199832335	chr2:199867396~199911159:-
TGCT	cis	rs72772090	0.539	rs10515247	ENSG00000248734.2	CTD-2260A17.1	-4.36	2.71e-05	0.0168	-0.48	-0.36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776022	chr5:96784777~96785999:+
TGCT	cis	rs10759883	0.539	rs10115110	ENSG00000175611.10	LINC00476	4.36	2.71e-05	0.0168	0.32	0.36	Nicotine dependence;	chr9:96033023	chr9:95759231~95875977:-
TGCT	cis	rs508487	0.537	rs5072	ENSG00000254851.1	RP11-109L13.1	-4.36	2.72e-05	0.0168	-0.71	-0.36	Cardiovascular disease risk factors;Triglyceride levels;	chr11:116836867	chr11:117135528~117138582:+
TGCT	cis	rs10504229	1	rs59797486	ENSG00000253301.4	RP11-513O17.2	4.36	2.72e-05	0.0168	0.45	0.36	Developmental language disorder (linguistic errors);	chr8:57261876	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.906	rs61638902	ENSG00000253301.4	RP11-513O17.2	4.36	2.72e-05	0.0168	0.45	0.36	Developmental language disorder (linguistic errors);	chr8:57280952	chr8:57142689~57240298:+
TGCT	cis	rs10875976	1	rs66908137	ENSG00000257253.2	RP11-70F11.7	4.36	2.72e-05	0.0168	0.3	0.36	Obesity;	chr12:49825706	chr12:49861207~49865802:+
TGCT	cis	rs2177312	0.794	rs7659098	ENSG00000251129.1	RP11-734I18.1	-4.36	2.72e-05	0.0169	-0.41	-0.36	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31957567	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.868	rs1608334	ENSG00000251129.1	RP11-734I18.1	-4.36	2.72e-05	0.0169	-0.41	-0.36	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31957762	chr4:31997397~32155406:+
TGCT	cis	rs2976388	1	rs2920295	ENSG00000253196.1	RP11-706C16.7	-4.36	2.72e-05	0.0169	-0.38	-0.36	Urinary tract infection frequency;	chr8:142683519	chr8:142763116~142766427:+
TGCT	cis	rs1891275	0.515	rs7092884	ENSG00000228701.1	TNKS2-AS1	4.36	2.73e-05	0.0169	0.41	0.36	Intelligence (multi-trait analysis);	chr10:91724115	chr10:91782839~91798291:-
TGCT	cis	rs4242434	0.854	rs3064	ENSG00000254064.1	CTD-2530N21.4	4.36	2.73e-05	0.0169	0.22	0.36	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22594175	chr8:22254576~22275162:-
TGCT	cis	rs11673344	0.932	rs76350084	ENSG00000226686.6	LINC01535	4.36	2.73e-05	0.0169	0.42	0.36	Obesity-related traits;	chr19:37187917	chr19:37251912~37265535:+
TGCT	cis	rs7181230	0.885	rs28736699	ENSG00000275636.1	RP11-521C20.5	4.36	2.74e-05	0.0169	0.46	0.36	Dehydroepiandrosterone sulphate levels;	chr15:40055234	chr15:40078892~40079347:+
TGCT	cis	rs7181230	0.885	rs4924413	ENSG00000275636.1	RP11-521C20.5	4.36	2.74e-05	0.0169	0.46	0.36	Dehydroepiandrosterone sulphate levels;	chr15:40056496	chr15:40078892~40079347:+
TGCT	cis	rs7181230	0.885	rs749748	ENSG00000275636.1	RP11-521C20.5	4.36	2.74e-05	0.0169	0.46	0.36	Dehydroepiandrosterone sulphate levels;	chr15:40057708	chr15:40078892~40079347:+
TGCT	cis	rs17826219	0.706	rs8075357	ENSG00000280069.1	CTD-2349P21.3	-4.36	2.74e-05	0.0169	-0.51	-0.36	Body mass index;	chr17:30730179	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs59447372	ENSG00000280069.1	CTD-2349P21.3	-4.36	2.74e-05	0.0169	-0.51	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30738182~30740275:+
TGCT	cis	rs17826219	0.706	rs61643715	ENSG00000280069.1	CTD-2349P21.3	-4.36	2.74e-05	0.0169	-0.51	-0.36	Body mass index;	chr17:30730744	chr17:30738182~30740275:+
TGCT	cis	rs17826219	0.636	rs8080829	ENSG00000280069.1	CTD-2349P21.3	-4.36	2.74e-05	0.0169	-0.51	-0.36	Body mass index;	chr17:30731712	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs8079891	ENSG00000280069.1	CTD-2349P21.3	-4.36	2.74e-05	0.0169	-0.51	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs73267858	ENSG00000280069.1	CTD-2349P21.3	-4.36	2.74e-05	0.0169	-0.51	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs56018041	ENSG00000280069.1	CTD-2349P21.3	-4.36	2.74e-05	0.0169	-0.51	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs56095789	ENSG00000280069.1	CTD-2349P21.3	-4.36	2.74e-05	0.0169	-0.51	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs11656844	ENSG00000280069.1	CTD-2349P21.3	-4.36	2.74e-05	0.0169	-0.51	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs11652533	ENSG00000280069.1	CTD-2349P21.3	-4.36	2.74e-05	0.0169	-0.51	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs11652631	ENSG00000280069.1	CTD-2349P21.3	-4.36	2.74e-05	0.0169	-0.51	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30738182~30740275:+
TGCT	cis	rs875971	0.965	rs697968	ENSG00000237310.1	GS1-124K5.4	-4.36	2.74e-05	0.0169	-0.4	-0.36	Aortic root size;	chr7:66070046	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs1167411	ENSG00000237310.1	GS1-124K5.4	-4.36	2.74e-05	0.0169	-0.4	-0.36	Aortic root size;	chr7:66074277	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs1183245	ENSG00000237310.1	GS1-124K5.4	-4.36	2.74e-05	0.0169	-0.4	-0.36	Aortic root size;	chr7:66076198	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs1144895	ENSG00000237310.1	GS1-124K5.4	-4.36	2.74e-05	0.0169	-0.4	-0.36	Aortic root size;	chr7:66076320	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs1144894	ENSG00000237310.1	GS1-124K5.4	-4.36	2.74e-05	0.0169	-0.4	-0.36	Aortic root size;	chr7:66077907	chr7:66493706~66495474:+
TGCT	cis	rs4973397	0.765	rs13030174	ENSG00000183022.5	TPM3P8	4.36	2.74e-05	0.017	0.52	0.36	Anti-saccade response;	chr2:231406573	chr2:230573167~230573809:-
TGCT	cis	rs786425	0.707	rs34996665	ENSG00000247373.3	RP11-486O12.2	4.36	2.74e-05	0.017	0.45	0.36	Pubertal anthropometrics;	chr12:123650109	chr12:123575891~123585115:-
TGCT	cis	rs950169	0.614	rs12911536	ENSG00000225151.9	GOLGA2P7	-4.36	2.74e-05	0.017	-0.42	-0.36	Schizophrenia;	chr15:84004278	chr15:84199311~84230136:-
TGCT	cis	rs875971	0.545	rs221986	ENSG00000237310.1	GS1-124K5.4	-4.36	2.75e-05	0.017	-0.44	-0.36	Aortic root size;	chr7:66105323	chr7:66493706~66495474:+
TGCT	cis	rs72819454	0.522	rs56309638	ENSG00000266852.2	MIR4482	4.36	2.75e-05	0.017	0.63	0.36	Interleukin-9 levels;	chr10:103760600	chr10:104268336~104268405:-
TGCT	cis	rs72819454	0.522	rs56275413	ENSG00000266852.2	MIR4482	4.36	2.75e-05	0.017	0.63	0.36	Interleukin-9 levels;	chr10:103760666	chr10:104268336~104268405:-
TGCT	cis	rs2033711	0.905	rs893186	ENSG00000269473.1	CTD-2619J13.19	4.36	2.75e-05	0.017	0.3	0.36	Uric acid clearance;	chr19:58457812	chr19:58440448~58445849:+
TGCT	cis	rs10875976	0.74	rs1031476	ENSG00000257253.2	RP11-70F11.7	4.36	2.75e-05	0.017	0.33	0.36	Obesity;	chr12:49824650	chr12:49861207~49865802:+
TGCT	cis	rs8072100	0.902	rs12051716	ENSG00000228782.6	CTD-2026D20.3	-4.36	2.75e-05	0.017	-0.44	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505029	chr17:47450568~47492492:-
TGCT	cis	rs13118159	0.714	rs6843025	ENSG00000254094.1	AC078852.1	-4.36	2.75e-05	0.017	-0.43	-0.36	Longevity;	chr4:1340630	chr4:1356581~1358075:+
TGCT	cis	rs13118159	0.771	rs13117476	ENSG00000254094.1	AC078852.1	-4.36	2.75e-05	0.017	-0.43	-0.36	Longevity;	chr4:1340933	chr4:1356581~1358075:+
TGCT	cis	rs4835473	0.897	rs1545437	ENSG00000251600.4	RP11-673E1.1	-4.36	2.75e-05	0.017	-0.39	-0.36	Immature fraction of reticulocytes;	chr4:143696689	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.864	rs61427459	ENSG00000251600.4	RP11-673E1.1	-4.36	2.75e-05	0.017	-0.39	-0.36	Immature fraction of reticulocytes;	chr4:143699605	chr4:143912331~143982454:+
TGCT	cis	rs1707322	0.685	rs28617418	ENSG00000280836.1	AL355480.1	-4.36	2.76e-05	0.017	-0.48	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.682	rs28490344	ENSG00000280836.1	AL355480.1	-4.36	2.76e-05	0.017	-0.48	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs28501477	ENSG00000280836.1	AL355480.1	-4.36	2.76e-05	0.017	-0.48	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs28641748	ENSG00000280836.1	AL355480.1	-4.36	2.76e-05	0.017	-0.48	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs6697821	ENSG00000280836.1	AL355480.1	-4.36	2.76e-05	0.017	-0.48	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs4330955	ENSG00000280836.1	AL355480.1	-4.36	2.76e-05	0.017	-0.48	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.691	rs11211174	ENSG00000280836.1	AL355480.1	-4.36	2.76e-05	0.017	-0.48	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.691	rs12031182	ENSG00000280836.1	AL355480.1	-4.36	2.76e-05	0.017	-0.48	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs10430123	ENSG00000280836.1	AL355480.1	-4.36	2.76e-05	0.017	-0.48	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45581219~45581321:-
TGCT	cis	rs2980439	0.818	rs2948294	ENSG00000254340.1	RP11-10A14.3	4.35	2.76e-05	0.017	0.37	0.36	Neuroticism;	chr8:8237439	chr8:9141424~9145435:+
TGCT	cis	rs2980439	0.783	rs2955587	ENSG00000254340.1	RP11-10A14.3	4.35	2.76e-05	0.017	0.37	0.36	Neuroticism;	chr8:8240557	chr8:9141424~9145435:+
TGCT	cis	rs10504229	0.683	rs16921808	ENSG00000253301.4	RP11-513O17.2	4.35	2.76e-05	0.017	0.58	0.36	Developmental language disorder (linguistic errors);	chr8:57193490	chr8:57142689~57240298:+
TGCT	cis	rs7829975	0.623	rs10092965	ENSG00000254340.1	RP11-10A14.3	4.35	2.76e-05	0.017	0.37	0.36	Mood instability;	chr8:8515975	chr8:9141424~9145435:+
TGCT	cis	rs7829975	0.623	rs7010753	ENSG00000254340.1	RP11-10A14.3	4.35	2.76e-05	0.017	0.37	0.36	Mood instability;	chr8:8516446	chr8:9141424~9145435:+
TGCT	cis	rs2665103	0.589	rs2134046	ENSG00000255769.6	GOLGA2P10	-4.35	2.76e-05	0.0171	-0.36	-0.36	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82472993~82513950:-
TGCT	cis	rs4660214	0.568	rs6692769	ENSG00000182109.6	RP11-69E11.4	-4.35	2.76e-05	0.0171	-0.37	-0.36	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39217503	chr1:39522280~39546187:-
TGCT	cis	rs8072100	0.817	rs11869940	ENSG00000228782.6	CTD-2026D20.3	-4.35	2.76e-05	0.0171	-0.44	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47501069	chr17:47450568~47492492:-
TGCT	cis	rs8072100	0.967	rs62076549	ENSG00000228782.6	CTD-2026D20.3	-4.35	2.76e-05	0.0171	-0.44	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47502189	chr17:47450568~47492492:-
TGCT	cis	rs8072100	0.967	rs7221548	ENSG00000228782.6	CTD-2026D20.3	-4.35	2.76e-05	0.0171	-0.44	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505586	chr17:47450568~47492492:-
TGCT	cis	rs8111998	0.826	rs28838101	ENSG00000269332.4	GOLGA2P9	4.35	2.76e-05	0.0171	0.63	0.36	Corneal structure;	chr19:22577843	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.826	rs28839261	ENSG00000269332.4	GOLGA2P9	4.35	2.76e-05	0.0171	0.63	0.36	Corneal structure;	chr19:22578107	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.826	rs56759565	ENSG00000269332.4	GOLGA2P9	4.35	2.76e-05	0.0171	0.63	0.36	Corneal structure;	chr19:22578137	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.625	rs60300487	ENSG00000269332.4	GOLGA2P9	4.35	2.76e-05	0.0171	0.63	0.36	Corneal structure;	chr19:22578273	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.826	rs73924274	ENSG00000269332.4	GOLGA2P9	4.35	2.76e-05	0.0171	0.63	0.36	Corneal structure;	chr19:22578318	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.826	rs73924275	ENSG00000269332.4	GOLGA2P9	4.35	2.76e-05	0.0171	0.63	0.36	Corneal structure;	chr19:22578320	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.625	rs77271158	ENSG00000269332.4	GOLGA2P9	4.35	2.76e-05	0.0171	0.63	0.36	Corneal structure;	chr19:22578375	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.826	rs73924276	ENSG00000269332.4	GOLGA2P9	4.35	2.76e-05	0.0171	0.63	0.36	Corneal structure;	chr19:22578508	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.826	rs112535874	ENSG00000269332.4	GOLGA2P9	4.35	2.76e-05	0.0171	0.63	0.36	Corneal structure;	chr19:22578616	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.826	rs28750772	ENSG00000269332.4	GOLGA2P9	4.35	2.76e-05	0.0171	0.63	0.36	Corneal structure;	chr19:22578852	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.536	rs8110837	ENSG00000269332.4	GOLGA2P9	4.35	2.76e-05	0.0171	0.63	0.36	Corneal structure;	chr19:22579673	chr19:22596257~22603550:+
TGCT	cis	rs8111998	0.826	rs7247524	ENSG00000269332.4	GOLGA2P9	4.35	2.76e-05	0.0171	0.63	0.36	Corneal structure;	chr19:22581411	chr19:22596257~22603550:+
TGCT	cis	rs2976388	0.967	rs2976397	ENSG00000253196.1	RP11-706C16.7	-4.35	2.77e-05	0.0171	-0.38	-0.36	Urinary tract infection frequency;	chr8:142683195	chr8:142763116~142766427:+
TGCT	cis	rs2283792	0.646	rs9610271	ENSG00000228050.1	TOP3BP1	4.35	2.77e-05	0.0171	0.46	0.36	Multiple sclerosis;	chr22:21758238	chr22:22223187~22224566:-
TGCT	cis	rs4811196	1	rs6096486	ENSG00000277829.1	RP5-1054A22.4	-4.35	2.77e-05	0.0171	-0.4	-0.36	Bone mineral density;	chr20:37844050	chr20:38233251~38233799:-
TGCT	cis	rs6474412	1	rs7842601	ENSG00000255101.1	RP11-412B14.1	4.35	2.77e-05	0.0171	0.38	0.36	Smoking behavior;	chr8:42681912	chr8:42705583~42721946:-
TGCT	cis	rs884366	0.964	rs4945826	ENSG00000203799.9	CCDC162P	-4.35	2.77e-05	0.0171	-0.39	-0.36	HDL cholesterol;HDL cholesterol levels;	chr6:109253867	chr6:109285485~109355063:+
TGCT	cis	rs877819	0.697	rs7915340	ENSG00000228403.1	RP11-563N6.6	-4.35	2.77e-05	0.0171	-0.4	-0.36	Systemic lupus erythematosus;	chr10:48840495	chr10:48878022~48878649:+
TGCT	cis	rs786425	0.835	rs7966867	ENSG00000278112.1	RP11-972P1.11	-4.35	2.77e-05	0.0171	-0.4	-0.36	Pubertal anthropometrics;	chr12:123694870	chr12:123519390~123519856:-
TGCT	cis	rs12967678	1	rs12967678	ENSG00000260302.1	RP11-973H7.1	4.35	2.78e-05	0.0171	0.62	0.36	Selective IgA deficiency;	chr18:12805389	chr18:12774651~12775923:-
TGCT	cis	rs10504229	0.906	rs56130194	ENSG00000253301.4	RP11-513O17.2	4.35	2.78e-05	0.0171	0.49	0.36	Developmental language disorder (linguistic errors);	chr8:57284502	chr8:57142689~57240298:+
TGCT	cis	rs8105895	1	rs62112917	ENSG00000269742.1	BNIP3P29	4.35	2.78e-05	0.0171	0.67	0.36	Body mass index (change over time);	chr19:22043778	chr19:22065828~22066398:-
TGCT	cis	rs1450985	0.741	rs55969752	ENSG00000239653.1	PSMD6-AS2	4.35	2.79e-05	0.0172	0.34	0.36	Breast cancer;	chr3:64046101	chr3:64004022~64012148:+
TGCT	cis	rs9844666	0.532	rs9857579	ENSG00000239213.4	NCK1-AS1	4.35	2.79e-05	0.0172	0.36	0.36	Height;	chr3:135937654	chr3:136841726~136862054:-
TGCT	cis	rs9844666	0.512	rs9819707	ENSG00000239213.4	NCK1-AS1	4.35	2.79e-05	0.0172	0.36	0.36	Height;	chr3:135937664	chr3:136841726~136862054:-
TGCT	cis	rs9844666	0.512	rs9820057	ENSG00000239213.4	NCK1-AS1	4.35	2.79e-05	0.0172	0.36	0.36	Height;	chr3:135937896	chr3:136841726~136862054:-
TGCT	cis	rs9844666	0.512	rs7623721	ENSG00000239213.4	NCK1-AS1	4.35	2.79e-05	0.0172	0.36	0.36	Height;	chr3:135938572	chr3:136841726~136862054:-
TGCT	cis	rs9844666	0.512	rs34485548	ENSG00000239213.4	NCK1-AS1	4.35	2.79e-05	0.0172	0.36	0.36	Height;	chr3:135939473	chr3:136841726~136862054:-
TGCT	cis	rs9844666	0.532	rs12330820	ENSG00000239213.4	NCK1-AS1	4.35	2.79e-05	0.0172	0.36	0.36	Height;	chr3:135940543	chr3:136841726~136862054:-
TGCT	cis	rs9844666	0.512	rs35896773	ENSG00000239213.4	NCK1-AS1	4.35	2.79e-05	0.0172	0.36	0.36	Height;	chr3:135940724	chr3:136841726~136862054:-
TGCT	cis	rs7567389	1	rs7567389	ENSG00000236682.1	AC068282.3	4.35	2.79e-05	0.0172	0.47	0.36	Self-rated health;	chr2:127225069	chr2:127389130~127400580:+
TGCT	cis	rs10504229	1	rs67546820	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57256008	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs1961778	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57256197	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs949848	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57256566	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs17216620	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57256853	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs17216648	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57256870	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs57941207	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57257262	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs58382845	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57257292	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs60231757	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57257378	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs77857677	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57257572	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs75037501	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57257577	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs77823122	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57257602	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs73607863	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57257619	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs77120900	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57257809	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs112272435	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57257812	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs115548028	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57258113	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs17216711	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57258297	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.953	rs17805380	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57258569	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.861	rs57942497	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57258680	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.953	rs75253516	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57258988	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.953	rs78089850	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57258998	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs74546828	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57259119	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.906	rs58559296	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57259155	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.953	rs57131327	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57259336	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs57261109	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57259593	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.906	rs58251024	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57259700	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.861	rs59873610	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57259731	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.906	rs17805439	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57259841	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.906	rs73607868	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57259923	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.906	rs73607869	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57260106	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.953	rs75545548	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57260257	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.953	rs116564484	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57260259	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs66936919	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57260309	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs73607871	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57260448	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.906	rs7003276	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57260530	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.906	rs7003285	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57260549	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs58053450	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57260789	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs73607874	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57260874	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs73607875	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57260963	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs113379801	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57261127	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs60454728	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57261222	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.953	rs66676208	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57261307	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs61212428	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57261404	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs60651159	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57261515	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs66796009	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57261970	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs67039591	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57261994	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.953	rs66509078	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57262175	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs67243305	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57262399	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs72650885	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57262572	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.953	rs67677367	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57262705	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.911	rs77203035	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57262899	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs56740825	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57263058	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs67237174	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57263217	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs67236942	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57263966	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs67388517	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57264058	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.906	rs59336968	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57264298	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs57624567	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57264436	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs57186557	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57264718	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs6987435	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57264775	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs72650887	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57264784	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs67705655	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57265129	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs67913746	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57265266	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs67895971	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57265435	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs56350499	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57265580	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs56255635	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57265705	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs6989060	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57266430	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs7007805	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57266768	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs17805549	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57267094	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.953	rs72650891	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57267138	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs72650892	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57267155	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.906	rs72650894	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57267175	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs66672857	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57267258	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs17216957	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57267334	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs17805602	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57267356	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs66870803	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57267463	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs17217033	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57267502	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs56344560	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57268067	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs55944282	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57268262	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs17217082	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57268359	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.906	rs6990615	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57270397	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.861	rs6990617	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57270401	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.861	rs6990796	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57270538	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.953	rs6990806	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57270554	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.953	rs6991035	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57270815	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs56168206	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57271926	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.906	rs56138544	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57271999	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs34616626	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57272091	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.861	rs116964504	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57272795	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs117231141	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57272906	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs67630725	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57273021	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.906	rs111838497	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57273061	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs72650900	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57273116	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs17816781	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57273602	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs59549824	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57273646	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs59071610	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57273742	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.906	rs66480865	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57274541	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.953	rs67886764	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57274558	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.953	rs66815941	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57274747	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs66495524	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57274806	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs67188507	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57274933	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs67344620	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57274978	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs66886949	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57275054	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs66477954	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57275251	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs66731170	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57275336	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs68112919	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57275688	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs58947041	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57276375	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs73609747	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57276545	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs58371676	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57276823	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs59383954	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57277130	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.953	rs59265461	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57277142	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs66840104	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57277442	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs9650139	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57277949	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.906	rs116341227	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57277973	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.953	rs115634610	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57277974	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.906	rs112793785	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57277978	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs3814486	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57278667	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs68076606	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57278712	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.906	rs113745779	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57278742	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.953	rs72652908	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57278765	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.861	rs67042991	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57279190	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs67105789	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57279443	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.953	rs75585481	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57279643	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs61998258	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57279725	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs61998259	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57279731	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs61733801	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57279954	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs73609762	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57280136	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs73609764	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57280412	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs76023408	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57280786	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.906	rs67389108	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57281159	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.773	rs1874373	ENSG00000253301.4	RP11-513O17.2	4.35	2.79e-05	0.0172	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57281864	chr8:57142689~57240298:+
TGCT	cis	rs3105593	0.965	rs62017203	ENSG00000273674.3	CTD-2378E12.1	4.35	2.79e-05	0.0172	0.39	0.36	QT interval;	chr15:50658393	chr15:50839875~50908599:-
TGCT	cis	rs7937890	0.668	rs12361851	ENSG00000254418.1	RP11-21L19.1	-4.35	2.8e-05	0.0172	-0.35	-0.36	Mitochondrial DNA levels;	chr11:14246122	chr11:14262846~14273691:-
TGCT	cis	rs1062753	0.527	rs2187959	ENSG00000182057.4	OGFRP1	-4.35	2.8e-05	0.0172	-0.27	-0.36	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41951840	chr22:42269753~42275196:+
TGCT	cis	rs1062753	0.527	rs6519296	ENSG00000182057.4	OGFRP1	-4.35	2.8e-05	0.0172	-0.27	-0.36	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41952598	chr22:42269753~42275196:+
TGCT	cis	rs4794202	0.7	rs11649750	ENSG00000264920.1	RP11-6N17.4	-4.35	2.8e-05	0.0172	-0.45	-0.36	Alzheimer's disease (cognitive decline);	chr17:47872656	chr17:47891255~47895812:-
TGCT	cis	rs4660214	0.666	rs950805	ENSG00000182109.6	RP11-69E11.4	-4.35	2.8e-05	0.0172	-0.37	-0.36	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39239786	chr1:39522280~39546187:-
TGCT	cis	rs728616	0.867	rs4633405	ENSG00000230091.5	TMEM254-AS1	4.35	2.8e-05	0.0172	0.68	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80167690	chr10:80046860~80078912:-
TGCT	cis	rs367615	0.552	rs2963024	ENSG00000249476.1	CTD-2587M2.1	-4.35	2.8e-05	0.0172	-0.39	-0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109395072	chr5:109237120~109326369:-
TGCT	cis	rs4835473	0.868	rs1822841	ENSG00000251600.4	RP11-673E1.1	4.35	2.8e-05	0.0172	0.38	0.36	Immature fraction of reticulocytes;	chr4:143921485	chr4:143912331~143982454:+
TGCT	cis	rs2412819	0.545	rs35822148	ENSG00000205771.5	CATSPER2P1	-4.35	2.81e-05	0.0172	-0.59	-0.36	Lung cancer;	chr15:43808084	chr15:43726918~43747094:-
TGCT	cis	rs875971	1	rs6963646	ENSG00000237310.1	GS1-124K5.4	-4.35	2.81e-05	0.0173	-0.4	-0.36	Aortic root size;	chr7:66220780	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.965	rs28682868	ENSG00000237310.1	GS1-124K5.4	-4.35	2.81e-05	0.0173	-0.4	-0.36	Aortic root size;	chr7:66224822	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.898	rs6977501	ENSG00000237310.1	GS1-124K5.4	-4.35	2.81e-05	0.0173	-0.4	-0.36	Aortic root size;	chr7:66228355	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.965	rs6971509	ENSG00000237310.1	GS1-124K5.4	-4.35	2.81e-05	0.0173	-0.4	-0.36	Aortic root size;	chr7:66249983	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs937495	ENSG00000237310.1	GS1-124K5.4	-4.35	2.81e-05	0.0173	-0.4	-0.36	Aortic root size;	chr7:66314811	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs4718319	ENSG00000232559.3	GS1-124K5.12	-4.35	2.81e-05	0.0173	-0.34	-0.36	Aortic root size;	chr7:66187797	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.723	rs28391294	ENSG00000232559.3	GS1-124K5.12	-4.35	2.81e-05	0.0173	-0.34	-0.36	Aortic root size;	chr7:66189328	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.83	rs6967708	ENSG00000232559.3	GS1-124K5.12	-4.35	2.81e-05	0.0173	-0.34	-0.36	Aortic root size;	chr7:66192326	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.895	rs7782806	ENSG00000232559.3	GS1-124K5.12	-4.35	2.81e-05	0.0173	-0.34	-0.36	Aortic root size;	chr7:66192910	chr7:66554588~66576923:-
TGCT	cis	rs9400467	0.537	rs449308	ENSG00000272356.1	RP5-1112D6.8	4.35	2.82e-05	0.0173	0.43	0.36	Amino acid levels;Blood metabolite levels;	chr6:111159192	chr6:111309203~111313517:+
TGCT	cis	rs4811196	1	rs2281146	ENSG00000277829.1	RP5-1054A22.4	4.35	2.82e-05	0.0173	0.43	0.36	Bone mineral density;	chr20:37806455	chr20:38233251~38233799:-
TGCT	cis	rs4811196	0.912	rs6021024	ENSG00000277829.1	RP5-1054A22.4	-4.35	2.82e-05	0.0173	-0.43	-0.36	Bone mineral density;	chr20:37803792	chr20:38233251~38233799:-
TGCT	cis	rs5758511	0.633	rs5751258	ENSG00000182057.4	OGFRP1	-4.35	2.82e-05	0.0173	-0.34	-0.36	Birth weight;	chr22:42267865	chr22:42269753~42275196:+
TGCT	cis	rs8072100	0.817	rs7213086	ENSG00000228782.6	CTD-2026D20.3	4.35	2.83e-05	0.0173	0.45	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47674944	chr17:47450568~47492492:-
TGCT	cis	rs7603514	0.585	rs6758395	ENSG00000279220.1	GPR1-AS	4.35	2.83e-05	0.0173	0.35	0.36	Obesity (extreme);	chr2:206213576	chr2:206203376~206266243:+
TGCT	cis	rs853679	0.599	rs188015	ENSG00000219891.2	ZSCAN12P1	4.35	2.83e-05	0.0174	0.65	0.36	Depression;	chr6:27909668	chr6:28091154~28093664:+
TGCT	cis	rs1707322	0.721	rs4559551	ENSG00000280836.1	AL355480.1	-4.35	2.83e-05	0.0174	-0.48	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45581219~45581321:-
TGCT	cis	rs9462027	0.606	rs2235569	ENSG00000186328.4	RP11-140K17.2	4.35	2.83e-05	0.0174	0.34	0.36	Systemic lupus erythematosus;	chr6:34602293	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.561	rs2235568	ENSG00000186328.4	RP11-140K17.2	4.35	2.83e-05	0.0174	0.34	0.36	Systemic lupus erythematosus;	chr6:34602317	chr6:34715613~34715940:+
TGCT	cis	rs1577917	0.545	rs7755958	ENSG00000203875.9	SNHG5	4.35	2.84e-05	0.0174	0.48	0.36	Response to antipsychotic treatment;	chr6:85778793	chr6:85660950~85678736:-
TGCT	cis	rs7824557	0.564	rs55758514	ENSG00000255310.2	AF131215.2	-4.35	2.84e-05	0.0174	-0.29	-0.36	Retinal vascular caliber;	chr8:11372750	chr8:11107788~11109726:-
TGCT	cis	rs1528149	0.576	rs10277151	ENSG00000224683.1	RPL36AP29	4.35	2.84e-05	0.0174	0.39	0.36	Sitting height ratio;	chr7:16075788	chr7:16208945~16209265:+
TGCT	cis	rs7246967	0.544	rs400275	ENSG00000269509.1	BNIP3P34	4.35	2.84e-05	0.0174	0.49	0.36	Bronchopulmonary dysplasia;	chr19:22833054	chr19:22773853~22774424:+
TGCT	cis	rs12549025	0.782	rs11781222	ENSG00000253390.1	CTC-756D1.2	-4.35	2.84e-05	0.0174	-0.45	-0.36	Reticulocyte fraction of red cells;	chr8:23532058	chr8:23458601~23484971:+
TGCT	cis	rs10826995	0.961	rs7077016	ENSG00000239731.3	RN7SL825P	-4.35	2.84e-05	0.0174	-0.35	-0.36	Pulse pressure;	chr10:31871591	chr10:31992087~31992381:-
TGCT	cis	rs9322193	0.566	rs9397070	ENSG00000216906.2	RP11-350J20.9	-4.35	2.85e-05	0.0175	-0.47	-0.36	Lung cancer;	chr6:149922073	chr6:149904243~149906418:+
TGCT	cis	rs875971	0.793	rs460678	ENSG00000237310.1	GS1-124K5.4	4.35	2.85e-05	0.0175	0.39	0.36	Aortic root size;	chr7:66062213	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.964	rs160635	ENSG00000237310.1	GS1-124K5.4	4.35	2.85e-05	0.0175	0.39	0.36	Aortic root size;	chr7:66063931	chr7:66493706~66495474:+
TGCT	cis	rs7923609	0.936	rs10761778	ENSG00000232075.1	MRPL35P2	-4.35	2.85e-05	0.0175	-0.35	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63514022	chr10:63634317~63634827:-
TGCT	cis	rs7829975	0.711	rs4481596	ENSG00000253893.2	FAM85B	-4.35	2.85e-05	0.0175	-0.46	-0.36	Mood instability;	chr8:8846820	chr8:8167819~8226614:-
TGCT	cis	rs5758511	0.68	rs5758688	ENSG00000182057.4	OGFRP1	-4.35	2.85e-05	0.0175	-0.35	-0.36	Birth weight;	chr22:42266495	chr22:42269753~42275196:+
TGCT	cis	rs12143943	0.934	rs12567161	ENSG00000176754.11	LINC00303	4.35	2.85e-05	0.0175	0.33	0.36	Cognitive performance;	chr1:204608704	chr1:204032447~204041265:-
TGCT	cis	rs453301	0.653	rs7016139	ENSG00000254340.1	RP11-10A14.3	-4.35	2.85e-05	0.0175	-0.36	-0.36	Joint mobility (Beighton score);	chr8:9037960	chr8:9141424~9145435:+
TGCT	cis	rs4713118	0.868	rs760587	ENSG00000272009.1	RP1-313I6.12	-4.35	2.85e-05	0.0175	-0.45	-0.36	Parkinson's disease;	chr6:27772521	chr6:28078792~28081130:-
TGCT	cis	rs9880211	0.8	rs34324561	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136382400	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs9880211	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136388707	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs28634226	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136411040	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs9841529	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136418441	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.948	rs34282798	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136424515	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs34757183	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136424826	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.948	rs13316214	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136439379	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs9823373	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136448185	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs28718456	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136485164	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs9818056	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136491232	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs35899944	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136510215	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs9878078	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136518731	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs13092193	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136521524	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs6771002	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136522186	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs9828088	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136528948	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs9869630	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136529177	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs28811905	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136533210	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs12695649	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136553074	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs6774964	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136556740	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs6775314	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136557106	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs28641809	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136571647	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs13071220	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136595277	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.848	rs71336069	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136633024	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs28750366	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136642213	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs4038586	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136644449	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs6767889	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136646613	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.898	rs35304385	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136667411	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.904	rs9857833	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136685625	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.846	rs73230043	ENSG00000239213.4	NCK1-AS1	4.35	2.85e-05	0.0175	0.38	0.36	Height;Body mass index;	chr3:136688317	chr3:136841726~136862054:-
TGCT	cis	rs6597981	0.592	rs10902218	ENSG00000255284.1	AP006621.5	-4.35	2.86e-05	0.0175	-0.29	-0.36	Breast cancer;	chr11:743813	chr11:777578~784297:+
TGCT	cis	rs875971	0.545	rs73378304	ENSG00000222364.1	RNU6-96P	-4.35	2.86e-05	0.0175	-0.45	-0.36	Aortic root size;	chr7:66175760	chr7:66395191~66395286:+
TGCT	cis	rs9326248	0.53	rs2513095	ENSG00000254851.1	RP11-109L13.1	-4.35	2.86e-05	0.0175	-0.62	-0.36	Blood protein levels;	chr11:116935553	chr11:117135528~117138582:+
TGCT	cis	rs9326248	0.53	rs510988	ENSG00000254851.1	RP11-109L13.1	-4.35	2.86e-05	0.0175	-0.62	-0.36	Blood protein levels;	chr11:116943088	chr11:117135528~117138582:+
TGCT	cis	rs7115242	0.669	rs1241658	ENSG00000254851.1	RP11-109L13.1	-4.35	2.86e-05	0.0175	-0.62	-0.36	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116948901	chr11:117135528~117138582:+
TGCT	cis	rs9326248	0.53	rs511676	ENSG00000254851.1	RP11-109L13.1	-4.35	2.86e-05	0.0175	-0.62	-0.36	Blood protein levels;	chr11:116954168	chr11:117135528~117138582:+
TGCT	cis	rs67311347	1	rs4973898	ENSG00000223797.4	ENTPD3-AS1	-4.35	2.86e-05	0.0175	-0.37	-0.36	Renal cell carcinoma;	chr3:40418041	chr3:40313802~40453329:-
TGCT	cis	rs4835473	0.897	rs1391189	ENSG00000251600.4	RP11-673E1.1	-4.35	2.86e-05	0.0175	-0.37	-0.36	Immature fraction of reticulocytes;	chr4:143690951	chr4:143912331~143982454:+
TGCT	cis	rs7137828	0.837	rs653178	ENSG00000226469.1	ADAM1B	-4.35	2.86e-05	0.0175	-0.32	-0.36	Coronary artery disease;Glaucoma (primary open-angle);Allergic disease (asthma, hay fever or eczema);	chr12:111569952	chr12:111927018~111929017:+
TGCT	cis	rs28595532	0.545	rs55699931	ENSG00000225892.3	RP11-384K6.2	-4.35	2.86e-05	0.0175	-0.45	-0.36	Cannabis dependence symptom count;	chr4:118328680	chr4:118632274~118634759:+
TGCT	cis	rs28595532	0.545	rs13132957	ENSG00000225892.3	RP11-384K6.2	-4.35	2.86e-05	0.0175	-0.45	-0.36	Cannabis dependence symptom count;	chr4:118329686	chr4:118632274~118634759:+
TGCT	cis	rs28595532	0.545	rs17594782	ENSG00000225892.3	RP11-384K6.2	-4.35	2.86e-05	0.0175	-0.45	-0.36	Cannabis dependence symptom count;	chr4:118329722	chr4:118632274~118634759:+
TGCT	cis	rs28595532	0.545	rs13101451	ENSG00000225892.3	RP11-384K6.2	-4.35	2.86e-05	0.0175	-0.45	-0.36	Cannabis dependence symptom count;	chr4:118332272	chr4:118632274~118634759:+
TGCT	cis	rs28595532	0.545	rs13144171	ENSG00000225892.3	RP11-384K6.2	-4.35	2.86e-05	0.0175	-0.45	-0.36	Cannabis dependence symptom count;	chr4:118336303	chr4:118632274~118634759:+
TGCT	cis	rs28595532	0.545	rs17516512	ENSG00000225892.3	RP11-384K6.2	-4.35	2.86e-05	0.0175	-0.45	-0.36	Cannabis dependence symptom count;	chr4:118337336	chr4:118632274~118634759:+
TGCT	cis	rs28595532	0.545	rs17516526	ENSG00000225892.3	RP11-384K6.2	-4.35	2.86e-05	0.0175	-0.45	-0.36	Cannabis dependence symptom count;	chr4:118338044	chr4:118632274~118634759:+
TGCT	cis	rs28595532	0.545	rs72677057	ENSG00000225892.3	RP11-384K6.2	-4.35	2.86e-05	0.0175	-0.45	-0.36	Cannabis dependence symptom count;	chr4:118343007	chr4:118632274~118634759:+
TGCT	cis	rs1355223	0.573	rs286865	ENSG00000271369.1	RP11-350D17.3	4.35	2.86e-05	0.0175	0.35	0.36	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34698369	chr11:34709600~34710161:+
TGCT	cis	rs6759004	1	rs6759004	ENSG00000183308.6	AC005037.3	4.35	2.86e-05	0.0175	0.59	0.36	Triptolide cytotoxicity;	chr2:201139953	chr2:200963263~201009102:+
TGCT	cis	rs875971	1	rs7792762	ENSG00000232559.3	GS1-124K5.12	4.35	2.86e-05	0.0175	0.34	0.36	Aortic root size;	chr7:66539151	chr7:66554588~66576923:-
TGCT	cis	rs7829975	0.623	rs10087493	ENSG00000254340.1	RP11-10A14.3	-4.35	2.86e-05	0.0175	-0.37	-0.36	Mood instability;	chr8:8516047	chr8:9141424~9145435:+
TGCT	cis	rs67311347	0.713	rs73073505	ENSG00000223797.4	ENTPD3-AS1	4.35	2.87e-05	0.0176	0.37	0.36	Renal cell carcinoma;	chr3:40269202	chr3:40313802~40453329:-
TGCT	cis	rs12439619	0.739	rs4778988	ENSG00000255769.6	GOLGA2P10	-4.34	2.87e-05	0.0176	-0.37	-0.36	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472993~82513950:-
TGCT	cis	rs507080	0.771	rs687664	ENSG00000255239.1	AP002954.6	4.34	2.87e-05	0.0176	0.48	0.36	Serum metabolite levels;	chr11:118703476	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.771	rs523715	ENSG00000255239.1	AP002954.6	4.34	2.87e-05	0.0176	0.48	0.36	Serum metabolite levels;	chr11:118703479	chr11:118688039~118690600:-
TGCT	cis	rs853679	0.506	rs1150693	ENSG00000219891.2	ZSCAN12P1	4.34	2.88e-05	0.0176	0.47	0.36	Depression;	chr6:28206812	chr6:28091154~28093664:+
TGCT	cis	rs801193	0.569	rs10950050	ENSG00000232559.3	GS1-124K5.12	4.34	2.88e-05	0.0176	0.32	0.36	Aortic root size;	chr7:66774601	chr7:66554588~66576923:-
TGCT	cis	rs2280018	0.538	rs7404526	ENSG00000250251.5	PKD1P6	4.34	2.88e-05	0.0176	0.28	0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035305	chr16:15125242~15154564:-
TGCT	cis	rs507080	0.733	rs601318	ENSG00000255422.1	AP002954.4	-4.34	2.88e-05	0.0176	-0.42	-0.36	Serum metabolite levels;	chr11:118648845	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.697	rs653008	ENSG00000255422.1	AP002954.4	-4.34	2.88e-05	0.0176	-0.42	-0.36	Serum metabolite levels;	chr11:118649775	chr11:118704607~118750263:+
TGCT	cis	rs11640533	0.901	rs11862250	ENSG00000262714.1	RP11-44F14.8	-4.34	2.88e-05	0.0176	-0.42	-0.36	Intelligence (multi-trait analysis);	chr16:53381126	chr16:53386944~53389085:+
TGCT	cis	rs10129255	1	rs8010605	ENSG00000211970.3	IGHV4-61	-4.34	2.88e-05	0.0176	-0.38	-0.36	Kawasaki disease;	chr14:106678742	chr14:106639119~106639657:-
TGCT	cis	rs2177312	0.767	rs1403534	ENSG00000251129.1	RP11-734I18.1	-4.34	2.88e-05	0.0176	-0.44	-0.36	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31956250	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.718	rs1403533	ENSG00000251129.1	RP11-734I18.1	-4.34	2.88e-05	0.0176	-0.44	-0.36	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31956333	chr4:31997397~32155406:+
TGCT	cis	rs2033711	0.87	rs7259841	ENSG00000268912.1	CTD-2619J13.17	-4.34	2.89e-05	0.0177	-0.32	-0.36	Uric acid clearance;	chr19:58439756	chr19:58428632~58431148:-
TGCT	cis	rs2033711	0.87	rs11084545	ENSG00000268912.1	CTD-2619J13.17	-4.34	2.89e-05	0.0177	-0.32	-0.36	Uric acid clearance;	chr19:58440326	chr19:58428632~58431148:-
TGCT	cis	rs13118159	0.899	rs3796613	ENSG00000254094.1	AC078852.1	-4.34	2.89e-05	0.0177	-0.42	-0.36	Longevity;	chr4:1359533	chr4:1356581~1358075:+
TGCT	cis	rs7208859	0.573	rs73267873	ENSG00000280069.1	CTD-2349P21.3	-4.34	2.89e-05	0.0177	-0.51	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30738182~30740275:+
TGCT	cis	rs17826219	0.561	rs4085382	ENSG00000280069.1	CTD-2349P21.3	-4.34	2.89e-05	0.0177	-0.51	-0.36	Body mass index;	chr17:30744184	chr17:30738182~30740275:+
TGCT	cis	rs520525	0.963	rs600093	ENSG00000271811.1	RP1-79C4.4	4.34	2.9e-05	0.0177	0.29	0.36	Atrial fibrillation;	chr1:170660697	chr1:170667381~170669425:+
TGCT	cis	rs10829156	0.738	rs4748502	ENSG00000240291.1	RP11-499P20.2	4.34	2.9e-05	0.0177	0.33	0.36	Sudden cardiac arrest;	chr10:18647032	chr10:18513115~18545651:-
TGCT	cis	rs67311347	1	rs7641495	ENSG00000223797.4	ENTPD3-AS1	-4.34	2.9e-05	0.0177	-0.39	-0.36	Renal cell carcinoma;	chr3:40453199	chr3:40313802~40453329:-
TGCT	cis	rs8105895	0.935	rs8110975	ENSG00000269742.1	BNIP3P29	4.34	2.9e-05	0.0177	0.66	0.36	Body mass index (change over time);	chr19:22057431	chr19:22065828~22066398:-
TGCT	cis	rs1707322	0.647	rs6686944	ENSG00000280836.1	AL355480.1	-4.34	2.9e-05	0.0177	-0.48	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45581219~45581321:-
TGCT	cis	rs1555322	0.53	rs2250205	ENSG00000126005.14	MMP24-AS1	-4.34	2.9e-05	0.0177	-0.45	-0.36	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35216462~35278131:-
TGCT	cis	rs8070740	0.891	rs2285747	ENSG00000262227.1	RP5-1050D4.5	-4.34	2.9e-05	0.0177	-0.31	-0.36	Menopause (age at onset);	chr17:5433817	chr17:4987706~4988446:+
TGCT	cis	rs867371	0.502	rs1846908	ENSG00000255769.6	GOLGA2P10	-4.34	2.9e-05	0.0177	-0.35	-0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82472993~82513950:-
TGCT	cis	rs2665103	0.655	rs1501367	ENSG00000255769.6	GOLGA2P10	-4.34	2.9e-05	0.0177	-0.35	-0.36	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82472993~82513950:-
TGCT	cis	rs7976269	0.537	rs4471475	ENSG00000275476.1	RP11-996F15.4	-4.34	2.9e-05	0.0177	-0.37	-0.36	Male-pattern baldness;	chr12:29022461	chr12:29277397~29277882:-
TGCT	cis	rs1075265	0.626	rs805412	ENSG00000233266.1	HMGB1P31	4.34	2.91e-05	0.0177	0.38	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53893683	chr2:54051334~54051760:+
TGCT	cis	rs9952991	0.941	rs1893217	ENSG00000260302.1	RP11-973H7.1	4.34	2.91e-05	0.0177	0.56	0.36	Inflammatory skin disease;	chr18:12809341	chr18:12774651~12775923:-
TGCT	cis	rs6810295	0.652	rs6774204	ENSG00000237433.1	AC097639.8	4.34	2.91e-05	0.0178	0.44	0.36	Body mass index (education interaction);	chr3:31926194	chr3:32190747~32191627:+
TGCT	cis	rs12745968	0.652	rs11164601	ENSG00000223787.2	RP4-593M8.1	-4.34	2.91e-05	0.0178	-0.49	-0.36	Bipolar disorder and schizophrenia;	chr1:92479950	chr1:92580476~92580821:-
TGCT	cis	rs12022452	0.506	rs11208363	ENSG00000238287.1	RP11-656D10.3	-4.34	2.92e-05	0.0178	-0.48	-0.36	Age-related hearing impairment (SNP x SNP interaction);	chr1:40544782	chr1:40493157~40508661:-
TGCT	cis	rs875971	1	rs875971	ENSG00000237310.1	GS1-124K5.4	-4.34	2.92e-05	0.0178	-0.4	-0.36	Aortic root size;	chr7:66152608	chr7:66493706~66495474:+
TGCT	cis	rs67311347	1	rs11129876	ENSG00000223797.4	ENTPD3-AS1	-4.34	2.92e-05	0.0178	-0.37	-0.36	Renal cell carcinoma;	chr3:40360145	chr3:40313802~40453329:-
TGCT	cis	rs875971	0.545	rs316305	ENSG00000237310.1	GS1-124K5.4	-4.34	2.92e-05	0.0178	-0.44	-0.36	Aortic root size;	chr7:66152984	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs316306	ENSG00000237310.1	GS1-124K5.4	-4.34	2.92e-05	0.0178	-0.44	-0.36	Aortic root size;	chr7:66153687	chr7:66493706~66495474:+
TGCT	cis	rs1867631	1	rs10889640	ENSG00000223263.1	RNU6-387P	-4.34	2.92e-05	0.0178	-0.41	-0.36	Menopause (age at onset);	chr1:66662168	chr1:67417214~67417318:+
TGCT	cis	rs10891354	0.547	rs10502156	ENSG00000176343.5	RPL37AP8	-4.34	2.92e-05	0.0178	-0.41	-0.36	Schizophrenia;	chr11:112394949	chr11:111889199~111889474:-
TGCT	cis	rs4835473	0.897	rs6537167	ENSG00000251600.4	RP11-673E1.1	4.34	2.92e-05	0.0178	0.36	0.36	Immature fraction of reticulocytes;	chr4:143691323	chr4:143912331~143982454:+
TGCT	cis	rs9309473	0.95	rs2947860	ENSG00000163016.8	ALMS1P	4.34	2.92e-05	0.0178	0.33	0.36	Metabolite levels;	chr2:73628259	chr2:73644919~73685576:+
TGCT	cis	rs875971	0.964	rs778735	ENSG00000237310.1	GS1-124K5.4	4.34	2.93e-05	0.0178	0.4	0.36	Aortic root size;	chr7:66349822	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs709595	ENSG00000237310.1	GS1-124K5.4	4.34	2.93e-05	0.0178	0.4	0.36	Aortic root size;	chr7:66352346	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs811880	ENSG00000237310.1	GS1-124K5.4	4.34	2.93e-05	0.0178	0.4	0.36	Aortic root size;	chr7:66353659	chr7:66493706~66495474:+
TGCT	cis	rs904251	0.797	rs1757181	ENSG00000204110.6	RP1-153P14.8	4.34	2.93e-05	0.0178	0.42	0.36	Cognitive performance;	chr6:37517952	chr6:37507348~37535616:+
TGCT	cis	rs9309473	1	rs11674602	ENSG00000163016.8	ALMS1P	4.34	2.93e-05	0.0178	0.33	0.36	Metabolite levels;	chr2:73496058	chr2:73644919~73685576:+
TGCT	cis	rs1618992	0.791	rs6508558	ENSG00000265994.1	RP11-510D21.1	-4.34	2.93e-05	0.0178	-0.36	-0.36	Gut microbiome composition (summer and winter);	chr18:28648523	chr18:28785068~28789260:+
TGCT	cis	rs875971	0.545	rs7783889	ENSG00000222364.1	RNU6-96P	-4.34	2.93e-05	0.0178	-0.45	-0.36	Aortic root size;	chr7:66283366	chr7:66395191~66395286:+
TGCT	cis	rs10504229	1	rs55787104	ENSG00000253301.4	RP11-513O17.2	4.34	2.93e-05	0.0179	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57265960	chr8:57142689~57240298:+
TGCT	cis	rs1865760	1	rs2071301	ENSG00000217159.2	LARP1P1	-4.34	2.93e-05	0.0179	-0.43	-0.36	Height;	chr6:25914035	chr6:26164072~26164363:+
TGCT	cis	rs2919917	0.628	rs2717540	ENSG00000254352.1	RP11-578O24.2	4.34	2.94e-05	0.0179	0.44	0.36	Lymphocyte counts;	chr8:78710128	chr8:78723796~78724136:-
TGCT	cis	rs9558942	1	rs1927754	ENSG00000277863.1	RP11-282A11.4	-4.34	2.94e-05	0.0179	-0.42	-0.36	Obesity-related traits;	chr13:107051597	chr13:106903150~106904099:-
TGCT	cis	rs9952991	0.941	rs60735058	ENSG00000260302.1	RP11-973H7.1	4.34	2.94e-05	0.0179	0.56	0.36	Inflammatory skin disease;	chr18:12795471	chr18:12774651~12775923:-
TGCT	cis	rs2732480	0.967	rs2732469	ENSG00000258273.1	RP11-370I10.4	-4.34	2.94e-05	0.0179	-0.41	-0.36	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48319149	chr12:48333755~48333901:-
TGCT	cis	rs7714584	1	rs3900064	ENSG00000197083.10	ZNF300P1	-4.34	2.94e-05	0.0179	-0.61	-0.36	Crohn's disease;	chr5:150884852	chr5:150930645~150946289:-
TGCT	cis	rs4760786	0.607	rs1707498	ENSG00000257454.1	CTD-2021H9.2	4.34	2.94e-05	0.0179	0.43	0.36	Monobrow;	chr12:71084846	chr12:71034122~71104526:-
TGCT	cis	rs853679	1	rs1419183	ENSG00000216901.1	AL022393.7	4.34	2.94e-05	0.0179	0.59	0.36	Depression;	chr6:28275017	chr6:28176188~28176674:+
TGCT	cis	rs13118159	0.55	rs28614045	ENSG00000254094.1	AC078852.1	-4.34	2.94e-05	0.0179	-0.45	-0.36	Longevity;	chr4:1380907	chr4:1356581~1358075:+
TGCT	cis	rs4835473	0.932	rs4585249	ENSG00000251600.4	RP11-673E1.1	-4.34	2.94e-05	0.0179	-0.39	-0.36	Immature fraction of reticulocytes;	chr4:143981173	chr4:143912331~143982454:+
TGCT	cis	rs7824557	0.614	rs7816606	ENSG00000255020.1	AF131216.5	4.34	2.94e-05	0.0179	0.25	0.36	Retinal vascular caliber;	chr8:11348093	chr8:11345748~11347502:-
TGCT	cis	rs12022452	0.506	rs6673386	ENSG00000238287.1	RP11-656D10.3	-4.34	2.94e-05	0.0179	-0.48	-0.36	Age-related hearing impairment (SNP x SNP interaction);	chr1:40546207	chr1:40493157~40508661:-
TGCT	cis	rs12022452	0.506	rs61779163	ENSG00000238287.1	RP11-656D10.3	-4.34	2.94e-05	0.0179	-0.48	-0.36	Age-related hearing impairment (SNP x SNP interaction);	chr1:40549751	chr1:40493157~40508661:-
TGCT	cis	rs2976388	1	rs2976396	ENSG00000253196.1	RP11-706C16.7	4.34	2.95e-05	0.0179	0.38	0.36	Urinary tract infection frequency;	chr8:142682583	chr8:142763116~142766427:+
TGCT	cis	rs875971	0.79	rs10257911	ENSG00000237310.1	GS1-124K5.4	-4.34	2.95e-05	0.0179	-0.4	-0.36	Aortic root size;	chr7:66278783	chr7:66493706~66495474:+
TGCT	cis	rs1519814	0.624	rs2176749	ENSG00000254343.2	RP11-760H22.2	-4.34	2.95e-05	0.0179	-0.59	-0.36	Breast cancer;	chr8:120020195	chr8:120052180~120056201:+
TGCT	cis	rs1519814	0.696	rs7813264	ENSG00000254343.2	RP11-760H22.2	-4.34	2.95e-05	0.0179	-0.59	-0.36	Breast cancer;	chr8:120020514	chr8:120052180~120056201:+
TGCT	cis	rs1519814	0.659	rs7817075	ENSG00000254343.2	RP11-760H22.2	-4.34	2.95e-05	0.0179	-0.59	-0.36	Breast cancer;	chr8:120020607	chr8:120052180~120056201:+
TGCT	cis	rs1519814	0.696	rs7821842	ENSG00000254343.2	RP11-760H22.2	-4.34	2.95e-05	0.0179	-0.59	-0.36	Breast cancer;	chr8:120021743	chr8:120052180~120056201:+
TGCT	cis	rs1519814	0.696	rs7832657	ENSG00000254343.2	RP11-760H22.2	-4.34	2.95e-05	0.0179	-0.59	-0.36	Breast cancer;	chr8:120024393	chr8:120052180~120056201:+
TGCT	cis	rs1519814	0.696	rs2875927	ENSG00000254343.2	RP11-760H22.2	-4.34	2.95e-05	0.0179	-0.59	-0.36	Breast cancer;	chr8:120024602	chr8:120052180~120056201:+
TGCT	cis	rs2581828	1	rs2581828	ENSG00000242142.1	SERBP1P3	4.34	2.95e-05	0.0179	0.34	0.36	Crohn's disease;	chr3:53099133	chr3:53064283~53065091:-
TGCT	cis	rs875971	0.66	rs2013222	ENSG00000272831.1	RP11-792A8.4	-4.34	2.95e-05	0.0179	-0.38	-0.36	Aortic root size;	chr7:66570949	chr7:66739829~66740385:-
TGCT	cis	rs9755467	0.665	rs57706556	ENSG00000221413.1	AC023593.1	4.34	2.95e-05	0.0179	0.56	0.36	Educational attainment (years of education);	chr3:127462736	chr3:127664704~127664810:+
TGCT	cis	rs7621331	0.817	rs1403769	ENSG00000239213.4	NCK1-AS1	4.34	2.96e-05	0.018	0.37	0.36	Waist circumference adjusted for body mass index;	chr3:135949506	chr3:136841726~136862054:-
TGCT	cis	rs5758659	1	rs134882	ENSG00000270083.1	RP1-257I20.14	4.34	2.96e-05	0.018	0.36	0.36	Cognitive function;	chr22:42274959	chr22:42089630~42090028:-
TGCT	cis	rs62025270	0.688	rs55738258	ENSG00000259416.2	RP11-158M2.5	-4.34	2.96e-05	0.018	-0.44	-0.36	Idiopathic pulmonary fibrosis;	chr15:85773000	chr15:85754941~85756237:-
TGCT	cis	rs62025270	0.688	rs55957626	ENSG00000259416.2	RP11-158M2.5	-4.34	2.96e-05	0.018	-0.44	-0.36	Idiopathic pulmonary fibrosis;	chr15:85773486	chr15:85754941~85756237:-
TGCT	cis	rs62025270	0.688	rs62025297	ENSG00000259416.2	RP11-158M2.5	-4.34	2.96e-05	0.018	-0.44	-0.36	Idiopathic pulmonary fibrosis;	chr15:85773708	chr15:85754941~85756237:-
TGCT	cis	rs62025270	0.688	rs62025298	ENSG00000259416.2	RP11-158M2.5	-4.34	2.96e-05	0.018	-0.44	-0.36	Idiopathic pulmonary fibrosis;	chr15:85773921	chr15:85754941~85756237:-
TGCT	cis	rs1618992	0.791	rs2655344	ENSG00000265994.1	RP11-510D21.1	4.34	2.96e-05	0.018	0.36	0.36	Gut microbiome composition (summer and winter);	chr18:28639828	chr18:28785068~28789260:+
TGCT	cis	rs1618992	0.791	rs1394190	ENSG00000265994.1	RP11-510D21.1	4.34	2.96e-05	0.018	0.36	0.36	Gut microbiome composition (summer and winter);	chr18:28640013	chr18:28785068~28789260:+
TGCT	cis	rs4660214	0.666	rs7538300	ENSG00000182109.6	RP11-69E11.4	-4.34	2.96e-05	0.018	-0.36	-0.36	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39187092	chr1:39522280~39546187:-
TGCT	cis	rs4660214	0.666	rs11205739	ENSG00000182109.6	RP11-69E11.4	-4.34	2.96e-05	0.018	-0.36	-0.36	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39190729	chr1:39522280~39546187:-
TGCT	cis	rs2919917	0.59	rs2919919	ENSG00000254352.1	RP11-578O24.2	-4.34	2.96e-05	0.018	-0.45	-0.36	Lymphocyte counts;	chr8:78745274	chr8:78723796~78724136:-
TGCT	cis	rs755249	0.508	rs10888688	ENSG00000182109.6	RP11-69E11.4	-4.34	2.96e-05	0.018	-0.37	-0.36	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39171633	chr1:39522280~39546187:-
TGCT	cis	rs7615952	0.932	rs13321217	ENSG00000171084.14	FAM86JP	4.34	2.96e-05	0.018	0.59	0.36	Blood pressure (smoking interaction);	chr3:125912928	chr3:125916620~125930024:+
TGCT	cis	rs904251	0.772	rs1812186	ENSG00000204110.6	RP1-153P14.8	-4.34	2.97e-05	0.018	-0.47	-0.36	Cognitive performance;	chr6:37498140	chr6:37507348~37535616:+
TGCT	cis	rs10246939	0.543	rs11765575	ENSG00000228775.6	WEE2-AS1	4.34	2.97e-05	0.018	0.32	0.36	Bitter taste perception;	chr7:141838168	chr7:141704338~141738346:-
TGCT	cis	rs1555322	0.505	rs639763	ENSG00000126005.14	MMP24-AS1	-4.34	2.98e-05	0.0181	-0.45	-0.36	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35216462~35278131:-
TGCT	cis	rs17507216	0.718	rs4779033	ENSG00000255769.6	GOLGA2P10	4.34	2.98e-05	0.0181	0.46	0.36	Excessive daytime sleepiness;	chr15:82576634	chr15:82472993~82513950:-
TGCT	cis	rs755249	0.565	rs12138051	ENSG00000182109.6	RP11-69E11.4	-4.34	2.98e-05	0.0181	-0.36	-0.36	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39482552	chr1:39522280~39546187:-
TGCT	cis	rs755249	0.564	rs6691194	ENSG00000182109.6	RP11-69E11.4	-4.34	2.98e-05	0.0181	-0.36	-0.36	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39483069	chr1:39522280~39546187:-
TGCT	cis	rs13118159	0.742	rs34947293	ENSG00000254094.1	AC078852.1	-4.34	2.98e-05	0.0181	-0.43	-0.36	Longevity;	chr4:1341246	chr4:1356581~1358075:+
TGCT	cis	rs3742264	1	rs9534302	ENSG00000235903.6	CPB2-AS1	-4.33	2.99e-05	0.0181	-0.43	-0.36	Blood protein levels;	chr13:46065920	chr13:46052806~46113332:+
TGCT	cis	rs3742264	1	rs9534303	ENSG00000235903.6	CPB2-AS1	-4.33	2.99e-05	0.0181	-0.43	-0.36	Blood protein levels;	chr13:46066007	chr13:46052806~46113332:+
TGCT	cis	rs3742264	0.961	rs9534304	ENSG00000235903.6	CPB2-AS1	-4.33	2.99e-05	0.0181	-0.43	-0.36	Blood protein levels;	chr13:46066467	chr13:46052806~46113332:+
TGCT	cis	rs3742264	0.922	rs7336360	ENSG00000235903.6	CPB2-AS1	-4.33	2.99e-05	0.0181	-0.43	-0.36	Blood protein levels;	chr13:46066946	chr13:46052806~46113332:+
TGCT	cis	rs3742264	1	rs9526136	ENSG00000235903.6	CPB2-AS1	-4.33	2.99e-05	0.0181	-0.43	-0.36	Blood protein levels;	chr13:46067012	chr13:46052806~46113332:+
TGCT	cis	rs3742264	1	rs9526137	ENSG00000235903.6	CPB2-AS1	-4.33	2.99e-05	0.0181	-0.43	-0.36	Blood protein levels;	chr13:46067114	chr13:46052806~46113332:+
TGCT	cis	rs2177312	0.868	rs11734946	ENSG00000251129.1	RP11-734I18.1	-4.33	2.99e-05	0.0181	-0.43	-0.36	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31942218	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.868	rs1523164	ENSG00000251129.1	RP11-734I18.1	-4.33	2.99e-05	0.0181	-0.43	-0.36	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31943592	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.794	rs1523165	ENSG00000251129.1	RP11-734I18.1	-4.33	2.99e-05	0.0181	-0.43	-0.36	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31943836	chr4:31997397~32155406:+
TGCT	cis	rs10504229	0.906	rs28447218	ENSG00000253301.4	RP11-513O17.2	4.33	2.99e-05	0.0181	0.45	0.36	Developmental language disorder (linguistic errors);	chr8:57258254	chr8:57142689~57240298:+
TGCT	cis	rs17410015	0.516	rs6577211	ENSG00000225169.1	BRI3P1	4.33	2.99e-05	0.0181	0.85	0.36	Response to antipsychotic treatment;	chr1:100827335	chr1:100213293~100213670:+
TGCT	cis	rs4835473	0.669	rs56112476	ENSG00000251600.4	RP11-673E1.1	-4.33	2.99e-05	0.0181	-0.38	-0.36	Immature fraction of reticulocytes;	chr4:143948716	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs13103072	ENSG00000251600.4	RP11-673E1.1	-4.33	2.99e-05	0.0181	-0.38	-0.36	Immature fraction of reticulocytes;	chr4:143952116	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.864	rs28609839	ENSG00000251600.4	RP11-673E1.1	-4.33	2.99e-05	0.0181	-0.38	-0.36	Immature fraction of reticulocytes;	chr4:143954160	chr4:143912331~143982454:+
TGCT	cis	rs9322193	0.962	rs2065664	ENSG00000216906.2	RP11-350J20.9	4.33	3e-05	0.0182	0.37	0.36	Lung cancer;	chr6:149762485	chr6:149904243~149906418:+
TGCT	cis	rs2136613	0.533	rs1509956	ENSG00000238280.1	RP11-436D10.3	-4.33	3e-05	0.0182	-0.41	-0.36	Selective IgA deficiency;	chr10:62843574	chr10:62793562~62805887:-
TGCT	cis	rs3105593	1	rs62017210	ENSG00000273674.3	CTD-2378E12.1	4.33	3.01e-05	0.0182	0.39	0.36	QT interval;	chr15:50668423	chr15:50839875~50908599:-
TGCT	cis	rs7429990	0.932	rs11720151	ENSG00000229759.1	MRPS18AP1	-4.33	3.01e-05	0.0182	-0.31	-0.36	Educational attainment (years of education);	chr3:48099144	chr3:48256350~48256938:-
TGCT	cis	rs10504229	1	rs79561699	ENSG00000253301.4	RP11-513O17.2	4.33	3.01e-05	0.0182	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57258042	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs78953746	ENSG00000253301.4	RP11-513O17.2	4.33	3.01e-05	0.0182	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57258049	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.906	rs113823909	ENSG00000253301.4	RP11-513O17.2	4.33	3.01e-05	0.0182	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57258076	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.817	rs114173899	ENSG00000253301.4	RP11-513O17.2	4.33	3.01e-05	0.0182	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57258081	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.861	rs114700910	ENSG00000253301.4	RP11-513O17.2	4.33	3.01e-05	0.0182	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57258083	chr8:57142689~57240298:+
TGCT	cis	rs12143943	0.866	rs4252726	ENSG00000176754.11	LINC00303	4.33	3.02e-05	0.0183	0.34	0.36	Cognitive performance;	chr1:204544274	chr1:204032447~204041265:-
TGCT	cis	rs9462027	0.585	rs2814974	ENSG00000186328.4	RP11-140K17.2	4.33	3.02e-05	0.0183	0.34	0.36	Systemic lupus erythematosus;	chr6:34604251	chr6:34715613~34715940:+
TGCT	cis	rs5758511	0.633	rs5758690	ENSG00000182057.4	OGFRP1	-4.33	3.02e-05	0.0183	-0.35	-0.36	Birth weight;	chr22:42272289	chr22:42269753~42275196:+
TGCT	cis	rs72772090	0.539	rs72773989	ENSG00000248734.2	CTD-2260A17.1	-4.33	3.02e-05	0.0183	-0.46	-0.36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96827910	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs11748328	ENSG00000248734.2	CTD-2260A17.1	-4.33	3.02e-05	0.0183	-0.46	-0.36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96834213	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs35898772	ENSG00000248734.2	CTD-2260A17.1	-4.33	3.02e-05	0.0183	-0.46	-0.36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96843982	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs17405676	ENSG00000248734.2	CTD-2260A17.1	-4.33	3.02e-05	0.0183	-0.46	-0.36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96846912	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs72775809	ENSG00000248734.2	CTD-2260A17.1	-4.33	3.02e-05	0.0183	-0.46	-0.36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96847853	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs72775810	ENSG00000248734.2	CTD-2260A17.1	-4.33	3.02e-05	0.0183	-0.46	-0.36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96849604	chr5:96784777~96785999:+
TGCT	cis	rs11822910	0.654	rs2439450	ENSG00000265566.2	RN7SL605P	4.33	3.02e-05	0.0183	0.46	0.36	Platelet distribution width;	chr11:57445588	chr11:57528085~57528365:-
TGCT	cis	rs12682352	0.602	rs28399241	ENSG00000253893.2	FAM85B	-4.33	3.02e-05	0.0183	-0.47	-0.36	Neuroticism;	chr8:8805705	chr8:8167819~8226614:-
TGCT	cis	rs10129255	0.5	rs8021941	ENSG00000223648.3	IGHV3-64	4.33	3.02e-05	0.0183	0.31	0.36	Kawasaki disease;	chr14:106781490	chr14:106643132~106658258:-
TGCT	cis	rs10129255	0.5	rs10142931	ENSG00000223648.3	IGHV3-64	4.33	3.02e-05	0.0183	0.31	0.36	Kawasaki disease;	chr14:106782288	chr14:106643132~106658258:-
TGCT	cis	rs2980439	0.783	rs2948305	ENSG00000253893.2	FAM85B	-4.33	3.02e-05	0.0183	-0.47	-0.36	Neuroticism;	chr8:8241055	chr8:8167819~8226614:-
TGCT	cis	rs12760731	0.92	rs12750502	ENSG00000224687.1	RASAL2-AS1	4.33	3.02e-05	0.0183	0.57	0.36	Obesity-related traits;	chr1:178518089	chr1:178091508~178093984:-
TGCT	cis	rs4835473	0.932	rs4305468	ENSG00000251600.4	RP11-673E1.1	-4.33	3.02e-05	0.0183	-0.38	-0.36	Immature fraction of reticulocytes;	chr4:143987315	chr4:143912331~143982454:+
TGCT	cis	rs3956705	1	rs12701265	ENSG00000205763.12	RP9P	4.33	3.03e-05	0.0183	0.2	0.36	Red cell distribution width;	chr7:32931624	chr7:32916815~32943176:-
TGCT	cis	rs3956705	1	rs35500246	ENSG00000205763.12	RP9P	4.33	3.03e-05	0.0183	0.2	0.36	Red cell distribution width;	chr7:32932161	chr7:32916815~32943176:-
TGCT	cis	rs34217772	0.552	rs7147055	ENSG00000258536.1	RP11-1053O12.1	4.33	3.03e-05	0.0183	0.32	0.36	Myopia;	chr14:41947705	chr14:41742639~41742963:+
TGCT	cis	rs7985	0.595	rs2032576	ENSG00000244625.4	MIATNB	4.33	3.03e-05	0.0183	0.42	0.36	Electroencephalogram traits;	chr22:26693692	chr22:26672767~26780207:+
TGCT	cis	rs875971	0.83	rs12673450	ENSG00000237310.1	GS1-124K5.4	4.33	3.03e-05	0.0183	0.39	0.36	Aortic root size;	chr7:66544233	chr7:66493706~66495474:+
TGCT	cis	rs7181230	0.885	rs4497657	ENSG00000275636.1	RP11-521C20.5	4.33	3.03e-05	0.0184	0.45	0.36	Dehydroepiandrosterone sulphate levels;	chr15:40067232	chr15:40078892~40079347:+
TGCT	cis	rs786425	0.966	rs7302183	ENSG00000247373.3	RP11-486O12.2	4.33	3.04e-05	0.0184	0.44	0.36	Pubertal anthropometrics;	chr12:123619913	chr12:123575891~123585115:-
TGCT	cis	rs1823913	0.66	rs1454752	ENSG00000227542.1	AC092614.2	-4.33	3.04e-05	0.0184	-0.4	-0.36	Obesity-related traits;	chr2:191298668	chr2:191229165~191246172:-
TGCT	cis	rs7310615	1	rs7310615	ENSG00000226469.1	ADAM1B	4.33	3.04e-05	0.0184	0.32	0.36	Fibrinogen levels;	chr12:111427245	chr12:111927018~111929017:+
TGCT	cis	rs2439831	1	rs1814538	ENSG00000205771.5	CATSPER2P1	4.33	3.04e-05	0.0184	0.55	0.36	Lung cancer in ever smokers;	chr15:43467576	chr15:43726918~43747094:-
TGCT	cis	rs9309473	0.95	rs10206899	ENSG00000163016.8	ALMS1P	4.33	3.04e-05	0.0184	0.33	0.36	Metabolite levels;	chr2:73673773	chr2:73644919~73685576:+
TGCT	cis	rs6981523	0.553	rs11989369	ENSG00000269918.1	AF131215.9	4.33	3.04e-05	0.0184	0.37	0.36	Neuroticism;	chr8:11197876	chr8:11104691~11106704:-
TGCT	cis	rs1519814	0.696	rs7012522	ENSG00000254343.2	RP11-760H22.2	-4.33	3.04e-05	0.0184	-0.59	-0.36	Breast cancer;	chr8:120025805	chr8:120052180~120056201:+
TGCT	cis	rs1519814	0.702	rs7846263	ENSG00000254343.2	RP11-760H22.2	-4.33	3.04e-05	0.0184	-0.59	-0.36	Breast cancer;	chr8:120026797	chr8:120052180~120056201:+
TGCT	cis	rs1510272	0.515	rs2089735	ENSG00000243926.1	TIPARP-AS1	-4.33	3.05e-05	0.0184	-0.45	-0.36	Testicular germ cell tumor;	chr3:156624763	chr3:156671862~156674378:-
TGCT	cis	rs12143943	0.966	rs4951410	ENSG00000176754.11	LINC00303	4.33	3.05e-05	0.0184	0.33	0.36	Cognitive performance;	chr1:204594689	chr1:204032447~204041265:-
TGCT	cis	rs17711722	0.565	rs4275112	ENSG00000226824.5	RP4-756H11.3	4.33	3.05e-05	0.0184	0.39	0.36	Calcium levels;	chr7:65733651	chr7:66654538~66669855:+
TGCT	cis	rs950169	0.512	rs4374136	ENSG00000225151.9	GOLGA2P7	-4.33	3.05e-05	0.0184	-0.47	-0.36	Schizophrenia;	chr15:83976255	chr15:84199311~84230136:-
TGCT	cis	rs7829975	0.846	rs7005216	ENSG00000253893.2	FAM85B	4.33	3.05e-05	0.0184	0.49	0.36	Mood instability;	chr8:8689600	chr8:8167819~8226614:-
TGCT	cis	rs9558942	0.961	rs4771548	ENSG00000277863.1	RP11-282A11.4	-4.33	3.05e-05	0.0184	-0.41	-0.36	Obesity-related traits;	chr13:107045348	chr13:106903150~106904099:-
TGCT	cis	rs10971721	0.543	rs68113313	ENSG00000230074.1	RP11-195F19.9	-4.33	3.05e-05	0.0184	-0.53	-0.36	Body mass index;	chr9:34059988	chr9:34665665~34681298:+
TGCT	cis	rs1707322	0.827	rs6683274	ENSG00000280836.1	AL355480.1	-4.33	3.05e-05	0.0184	-0.49	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45581219~45581321:-
TGCT	cis	rs867371	0.656	rs2665103	ENSG00000276710.3	CSPG4P8	4.33	3.06e-05	0.0184	0.34	0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:82459472~82477258:+
TGCT	cis	rs4713118	0.662	rs464312	ENSG00000219392.1	RP1-265C24.5	-4.33	3.06e-05	0.0185	-0.45	-0.36	Parkinson's disease;	chr6:27999813	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.662	rs469228	ENSG00000219392.1	RP1-265C24.5	-4.33	3.06e-05	0.0185	-0.45	-0.36	Parkinson's disease;	chr6:28002926	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.54	rs469227	ENSG00000219392.1	RP1-265C24.5	-4.33	3.06e-05	0.0185	-0.45	-0.36	Parkinson's disease;	chr6:28002927	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.662	rs149948	ENSG00000219392.1	RP1-265C24.5	-4.33	3.06e-05	0.0185	-0.45	-0.36	Parkinson's disease;	chr6:28007039	chr6:28115628~28116551:+
TGCT	cis	rs72819454	0.522	rs55760245	ENSG00000266852.2	MIR4482	4.33	3.06e-05	0.0185	0.63	0.36	Interleukin-9 levels;	chr10:103763262	chr10:104268336~104268405:-
TGCT	cis	rs72819454	0.522	rs56178332	ENSG00000266852.2	MIR4482	4.33	3.06e-05	0.0185	0.63	0.36	Interleukin-9 levels;	chr10:103763409	chr10:104268336~104268405:-
TGCT	cis	rs1010254	0.51	rs1363418	ENSG00000253921.1	CTB-113P19.3	4.33	3.06e-05	0.0185	0.49	0.36	Optic nerve measurement (cup area);	chr5:152320273	chr5:151753992~151767247:+
TGCT	cis	rs2278034	0.502	rs3747672	ENSG00000207650.1	MIR570	4.33	3.06e-05	0.0185	0.4	0.36	Bronchopulmonary dysplasia;	chr3:195885163	chr3:195699401~195699497:+
TGCT	cis	rs7208859	0.623	rs426434	ENSG00000266490.1	CTD-2349P21.9	4.33	3.06e-05	0.0185	0.41	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30792372~30792833:+
TGCT	cis	rs10759883	0.539	rs7847393	ENSG00000175611.10	LINC00476	4.33	3.06e-05	0.0185	0.32	0.36	Nicotine dependence;	chr9:96033431	chr9:95759231~95875977:-
TGCT	cis	rs891378	0.793	rs12021745	ENSG00000274245.1	RP11-357P18.2	4.33	3.07e-05	0.0185	0.5	0.36	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207293254	chr1:207372559~207373252:+
TGCT	cis	rs877819	0.697	rs10776651	ENSG00000228403.1	RP11-563N6.6	-4.33	3.07e-05	0.0185	-0.4	-0.36	Systemic lupus erythematosus;	chr10:48876481	chr10:48878022~48878649:+
TGCT	cis	rs1707322	0.717	rs12023439	ENSG00000280836.1	AL355480.1	-4.33	3.07e-05	0.0185	-0.49	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs11211149	ENSG00000280836.1	AL355480.1	-4.33	3.07e-05	0.0185	-0.49	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr1:45581219~45581321:-
TGCT	cis	rs9807989	0.507	rs6745614	ENSG00000234389.1	AC007278.3	4.33	3.07e-05	0.0185	0.27	0.36	Asthma;	chr2:102374753	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs10208196	ENSG00000234389.1	AC007278.3	4.33	3.07e-05	0.0185	0.27	0.36	Asthma;	chr2:102379885	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs7584093	ENSG00000234389.1	AC007278.3	4.33	3.07e-05	0.0185	0.27	0.36	Asthma;	chr2:102381261	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs3213732	ENSG00000234389.1	AC007278.3	4.33	3.07e-05	0.0185	0.27	0.36	Asthma;	chr2:102381819	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs10204757	ENSG00000234389.1	AC007278.3	4.33	3.07e-05	0.0185	0.27	0.36	Asthma;	chr2:102382514	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.524	rs7591246	ENSG00000234389.1	AC007278.3	4.33	3.07e-05	0.0185	0.27	0.36	Asthma;	chr2:102382943	chr2:102438713~102440475:+
TGCT	cis	rs4988958	0.565	rs6760621	ENSG00000234389.1	AC007278.3	4.33	3.07e-05	0.0185	0.27	0.36	Asthma (childhood onset);	chr2:102383492	chr2:102438713~102440475:+
TGCT	cis	rs4988958	0.527	rs11465641	ENSG00000234389.1	AC007278.3	4.33	3.07e-05	0.0185	0.27	0.36	Asthma (childhood onset);	chr2:102384408	chr2:102438713~102440475:+
TGCT	cis	rs4988958	0.525	rs3771159	ENSG00000234389.1	AC007278.3	4.33	3.07e-05	0.0185	0.27	0.36	Asthma (childhood onset);	chr2:102388498	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.501	rs11903946	ENSG00000234389.1	AC007278.3	4.33	3.07e-05	0.0185	0.27	0.36	Asthma;	chr2:102388870	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs6706002	ENSG00000234389.1	AC007278.3	4.33	3.07e-05	0.0185	0.27	0.36	Asthma;	chr2:102389644	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs6749014	ENSG00000234389.1	AC007278.3	4.33	3.07e-05	0.0185	0.27	0.36	Asthma;	chr2:102389988	chr2:102438713~102440475:+
TGCT	cis	rs4988958	0.565	rs12712146	ENSG00000234389.1	AC007278.3	4.33	3.07e-05	0.0185	0.27	0.36	Asthma (childhood onset);	chr2:102392254	chr2:102438713~102440475:+
TGCT	cis	rs9807989	0.507	rs10439410	ENSG00000234389.1	AC007278.3	-4.33	3.07e-05	0.0185	-0.27	-0.36	Asthma;	chr2:102374328	chr2:102438713~102440475:+
TGCT	cis	rs9462027	0.675	rs7755926	ENSG00000186328.4	RP11-140K17.2	4.33	3.07e-05	0.0185	0.34	0.36	Systemic lupus erythematosus;	chr6:34754797	chr6:34715613~34715940:+
TGCT	cis	rs9462027	0.628	rs9469859	ENSG00000186328.4	RP11-140K17.2	4.33	3.07e-05	0.0185	0.34	0.36	Systemic lupus erythematosus;	chr6:34755125	chr6:34715613~34715940:+
TGCT	cis	rs3809863	0.646	rs9899121	ENSG00000228782.6	CTD-2026D20.3	4.33	3.07e-05	0.0185	0.47	0.36	Glaucoma (primary open-angle);	chr17:47317778	chr17:47450568~47492492:-
TGCT	cis	rs12745968	0.619	rs10874738	ENSG00000223787.2	RP4-593M8.1	-4.33	3.07e-05	0.0185	-0.48	-0.36	Bipolar disorder and schizophrenia;	chr1:92758662	chr1:92580476~92580821:-
TGCT	cis	rs12745968	0.685	rs11164807	ENSG00000223787.2	RP4-593M8.1	-4.33	3.07e-05	0.0185	-0.48	-0.36	Bipolar disorder and schizophrenia;	chr1:92768538	chr1:92580476~92580821:-
TGCT	cis	rs12745968	0.589	rs10782936	ENSG00000223787.2	RP4-593M8.1	-4.33	3.07e-05	0.0185	-0.47	-0.36	Bipolar disorder and schizophrenia;	chr1:92576349	chr1:92580476~92580821:-
TGCT	cis	rs673078	0.607	rs11068919	ENSG00000275759.1	RP11-131L12.3	-4.33	3.07e-05	0.0185	-0.6	-0.36	Glucose homeostasis traits;	chr12:118354925	chr12:118428281~118428870:+
TGCT	cis	rs17507216	0.958	rs72751643	ENSG00000255769.6	GOLGA2P10	-4.33	3.08e-05	0.0185	-0.44	-0.36	Excessive daytime sleepiness;	chr15:82559444	chr15:82472993~82513950:-
TGCT	cis	rs7246967	0.608	rs396440	ENSG00000269509.1	BNIP3P34	4.33	3.08e-05	0.0186	0.48	0.36	Bronchopulmonary dysplasia;	chr19:22820164	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.608	rs433579	ENSG00000269509.1	BNIP3P34	4.33	3.08e-05	0.0186	0.48	0.36	Bronchopulmonary dysplasia;	chr19:22820325	chr19:22773853~22774424:+
TGCT	cis	rs755249	0.565	rs7539261	ENSG00000182109.6	RP11-69E11.4	-4.33	3.08e-05	0.0186	-0.34	-0.36	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39584831	chr1:39522280~39546187:-
TGCT	cis	rs728616	0.867	rs56008106	ENSG00000230091.5	TMEM254-AS1	4.33	3.08e-05	0.0186	0.69	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80194020	chr10:80046860~80078912:-
TGCT	cis	rs10504229	0.871	rs56048296	ENSG00000253301.4	RP11-513O17.2	4.33	3.08e-05	0.0186	0.45	0.36	Developmental language disorder (linguistic errors);	chr8:57251222	chr8:57142689~57240298:+
TGCT	cis	rs950169	0.579	rs62027818	ENSG00000225151.9	GOLGA2P7	-4.33	3.08e-05	0.0186	-0.42	-0.36	Schizophrenia;	chr15:83992393	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.579	rs12912716	ENSG00000225151.9	GOLGA2P7	-4.33	3.08e-05	0.0186	-0.42	-0.36	Schizophrenia;	chr15:83995511	chr15:84199311~84230136:-
TGCT	cis	rs950169	0.579	rs12913054	ENSG00000225151.9	GOLGA2P7	-4.33	3.08e-05	0.0186	-0.42	-0.36	Schizophrenia;	chr15:83995704	chr15:84199311~84230136:-
TGCT	cis	rs2742234	0.955	rs1800861	ENSG00000273008.1	RP11-351D16.3	-4.33	3.08e-05	0.0186	-0.4	-0.36	Hirschsprung disease;	chr10:43118395	chr10:43136824~43138334:-
TGCT	cis	rs13118159	0.55	rs13123016	ENSG00000254094.1	AC078852.1	-4.33	3.09e-05	0.0186	-0.44	-0.36	Longevity;	chr4:1347101	chr4:1356581~1358075:+
TGCT	cis	rs1153858	0.945	rs16943246	ENSG00000259520.4	CTD-2651B20.3	-4.33	3.09e-05	0.0186	-0.32	-0.36	Homoarginine levels;	chr15:45428399	chr15:45251580~45279251:-
TGCT	cis	rs2581828	0.965	rs2581829	ENSG00000242142.1	SERBP1P3	-4.33	3.09e-05	0.0186	-0.33	-0.36	Crohn's disease;	chr3:53099510	chr3:53064283~53065091:-
TGCT	cis	rs7523273	0.512	rs2761435	ENSG00000203709.8	C1orf132	4.33	3.09e-05	0.0186	0.3	0.36	Schizophrenia;	chr1:207745121	chr1:207801518~207869150:-
TGCT	cis	rs7923609	0.934	rs7923544	ENSG00000232075.1	MRPL35P2	-4.33	3.09e-05	0.0186	-0.36	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63422496	chr10:63634317~63634827:-
TGCT	cis	rs7829975	0.774	rs13259216	ENSG00000254340.1	RP11-10A14.3	4.33	3.1e-05	0.0187	0.37	0.36	Mood instability;	chr8:8816091	chr8:9141424~9145435:+
TGCT	cis	rs453301	0.624	rs2288671	ENSG00000254340.1	RP11-10A14.3	4.32	3.11e-05	0.0187	0.37	0.36	Joint mobility (Beighton score);	chr8:9003384	chr8:9141424~9145435:+
TGCT	cis	rs901683	1	rs71496610	ENSG00000264204.2	AGAP7P	-4.32	3.11e-05	0.0187	-0.81	-0.36	Mean corpuscular volume;Red blood cell traits;	chr10:45526198	chr10:46109621~46131358:+
TGCT	cis	rs881375	0.934	rs1468671	ENSG00000226752.6	PSMD5-AS1	-4.32	3.11e-05	0.0187	-0.42	-0.36	Rheumatoid arthritis;	chr9:120895224	chr9:120824828~120854385:+
TGCT	cis	rs34375054	0.525	rs7133614	ENSG00000279233.1	RP11-158L12.4	4.32	3.11e-05	0.0187	0.38	0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125121411	chr12:125138245~125141711:+
TGCT	cis	rs786425	0.71	rs11057326	ENSG00000247373.3	RP11-486O12.2	4.32	3.11e-05	0.0187	0.45	0.36	Pubertal anthropometrics;	chr12:123663931	chr12:123575891~123585115:-
TGCT	cis	rs9297994	0.594	rs10106272	ENSG00000242970.2	AC068522.4	-4.32	3.11e-05	0.0187	-0.45	-0.36	LDL cholesterol;	chr8:58506292	chr8:58588420~58588764:-
TGCT	cis	rs9297994	0.556	rs10087310	ENSG00000242970.2	AC068522.4	-4.32	3.11e-05	0.0187	-0.45	-0.36	LDL cholesterol;	chr8:58512520	chr8:58588420~58588764:-
TGCT	cis	rs13118159	0.55	rs1137789	ENSG00000254094.1	AC078852.1	-4.32	3.11e-05	0.0187	-0.44	-0.36	Longevity;	chr4:1388010	chr4:1356581~1358075:+
TGCT	cis	rs1012068	0.581	rs5749339	ENSG00000236132.1	CTA-440B3.1	4.32	3.12e-05	0.0187	0.42	0.36	Chronic hepatitis C infection;	chr22:31919749	chr22:31816379~31817491:-
TGCT	cis	rs10822145	1	rs10822145	ENSG00000232075.1	MRPL35P2	-4.32	3.12e-05	0.0187	-0.35	-0.36	Triglycerides;	chr10:63174788	chr10:63634317~63634827:-
TGCT	cis	rs875971	0.965	rs9969301	ENSG00000237310.1	GS1-124K5.4	-4.32	3.12e-05	0.0188	-0.4	-0.36	Aortic root size;	chr7:66316668	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.867	rs1002053	ENSG00000237310.1	GS1-124K5.4	-4.32	3.12e-05	0.0188	-0.4	-0.36	Aortic root size;	chr7:66333558	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs2036264	ENSG00000237310.1	GS1-124K5.4	-4.32	3.12e-05	0.0188	-0.4	-0.36	Aortic root size;	chr7:66334917	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs7783613	ENSG00000237310.1	GS1-124K5.4	-4.32	3.12e-05	0.0188	-0.4	-0.36	Aortic root size;	chr7:66340274	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs6460292	ENSG00000237310.1	GS1-124K5.4	-4.32	3.12e-05	0.0188	-0.4	-0.36	Aortic root size;	chr7:66345088	chr7:66493706~66495474:+
TGCT	cis	rs7923609	0.967	rs10740134	ENSG00000232075.1	MRPL35P2	-4.32	3.12e-05	0.0188	-0.35	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63555673	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.967	rs2393986	ENSG00000232075.1	MRPL35P2	-4.32	3.12e-05	0.0188	-0.35	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63560246	chr10:63634317~63634827:-
TGCT	cis	rs5758511	0.68	rs58654759	ENSG00000182057.4	OGFRP1	-4.32	3.12e-05	0.0188	-0.35	-0.36	Birth weight;	chr22:42246570	chr22:42269753~42275196:+
TGCT	cis	rs5758511	0.68	rs5758682	ENSG00000182057.4	OGFRP1	-4.32	3.12e-05	0.0188	-0.35	-0.36	Birth weight;	chr22:42249196	chr22:42269753~42275196:+
TGCT	cis	rs5758511	0.68	rs5758684	ENSG00000182057.4	OGFRP1	-4.32	3.12e-05	0.0188	-0.35	-0.36	Birth weight;	chr22:42253503	chr22:42269753~42275196:+
TGCT	cis	rs10771431	0.967	rs7137443	ENSG00000111788.10	RP11-22B23.1	4.32	3.12e-05	0.0188	0.32	0.36	Breast size;	chr12:9219433	chr12:9277235~9313241:+
TGCT	cis	rs507080	0.769	rs7389	ENSG00000255239.1	AP002954.6	-4.32	3.12e-05	0.0188	-0.46	-0.36	Serum metabolite levels;	chr11:118657756	chr11:118688039~118690600:-
TGCT	cis	rs710913	0.531	rs1180331	ENSG00000182109.6	RP11-69E11.4	-4.32	3.13e-05	0.0188	-0.35	-0.36	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546512	chr1:39522280~39546187:-
TGCT	cis	rs599083	0.53	rs546803	ENSG00000212093.1	AP000807.1	-4.32	3.13e-05	0.0188	-0.39	-0.36	Bone mineral density (spine);	chr11:68418924	chr11:68506083~68506166:-
TGCT	cis	rs904251	0.797	rs1757177	ENSG00000204110.6	RP1-153P14.8	-4.32	3.14e-05	0.0189	-0.44	-0.36	Cognitive performance;	chr6:37518594	chr6:37507348~37535616:+
TGCT	cis	rs875971	0.545	rs313830	ENSG00000237310.1	GS1-124K5.4	-4.32	3.14e-05	0.0189	-0.45	-0.36	Aortic root size;	chr7:66086944	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs313828	ENSG00000237310.1	GS1-124K5.4	-4.32	3.14e-05	0.0189	-0.45	-0.36	Aortic root size;	chr7:66087627	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.52	rs160645	ENSG00000237310.1	GS1-124K5.4	-4.32	3.14e-05	0.0189	-0.45	-0.36	Aortic root size;	chr7:66091320	chr7:66493706~66495474:+
TGCT	cis	rs904251	0.772	rs2776906	ENSG00000279942.1	RP1-153P14.7	-4.32	3.14e-05	0.0189	-0.45	-0.36	Cognitive performance;	chr6:37463981	chr6:37567716~37571460:+
TGCT	cis	rs3809863	0.602	rs7225700	ENSG00000228782.6	CTD-2026D20.3	4.32	3.14e-05	0.0189	0.47	0.36	Glaucoma (primary open-angle);	chr17:47314438	chr17:47450568~47492492:-
TGCT	cis	rs3809863	0.602	rs2317677	ENSG00000228782.6	CTD-2026D20.3	4.32	3.14e-05	0.0189	0.47	0.36	Glaucoma (primary open-angle);	chr17:47316041	chr17:47450568~47492492:-
TGCT	cis	rs11722228	0.508	rs3756227	ENSG00000261490.1	RP11-448G15.3	4.32	3.14e-05	0.0189	0.34	0.36	Urate levels;Serum uric acid levels;Gout;	chr4:10086371	chr4:10068089~10073019:-
TGCT	cis	rs11651753	0.613	rs3096	ENSG00000264920.1	RP11-6N17.4	-4.32	3.14e-05	0.0189	-0.35	-0.36	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47952066	chr17:47891255~47895812:-
TGCT	cis	rs11722228	0.549	rs56146302	ENSG00000261490.1	RP11-448G15.3	4.32	3.15e-05	0.0189	0.35	0.36	Urate levels;Serum uric acid levels;Gout;	chr4:10079428	chr4:10068089~10073019:-
TGCT	cis	rs11722228	0.549	rs55848383	ENSG00000261490.1	RP11-448G15.3	4.32	3.15e-05	0.0189	0.35	0.36	Urate levels;Serum uric acid levels;Gout;	chr4:10079493	chr4:10068089~10073019:-
TGCT	cis	rs9880211	1	rs17200216	ENSG00000239213.4	NCK1-AS1	4.32	3.15e-05	0.0189	0.38	0.36	Height;Body mass index;	chr3:136348390	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs9837158	ENSG00000239213.4	NCK1-AS1	4.32	3.15e-05	0.0189	0.38	0.36	Height;Body mass index;	chr3:136354321	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs17364492	ENSG00000239213.4	NCK1-AS1	-4.32	3.15e-05	0.0189	-0.38	-0.36	Height;Body mass index;	chr3:136485595	chr3:136841726~136862054:-
TGCT	cis	rs728616	0.85	rs3889823	ENSG00000230091.5	TMEM254-AS1	4.32	3.15e-05	0.0189	0.69	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80158606	chr10:80046860~80078912:-
TGCT	cis	rs2286503	0.78	rs929464	ENSG00000234286.1	AC006026.13	4.32	3.16e-05	0.0189	0.43	0.36	Fibrinogen;	chr7:22835151	chr7:23680195~23680786:-
TGCT	cis	rs453301	0.598	rs1025395	ENSG00000254340.1	RP11-10A14.3	4.32	3.16e-05	0.019	0.37	0.36	Joint mobility (Beighton score);	chr8:8979093	chr8:9141424~9145435:+
TGCT	cis	rs10504229	1	rs1390411	ENSG00000253301.4	RP11-513O17.2	4.32	3.16e-05	0.019	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57281587	chr8:57142689~57240298:+
TGCT	cis	rs807029	0.72	rs701836	ENSG00000272572.1	RP11-179B2.2	-4.32	3.16e-05	0.019	-0.3	-0.36	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101007360	chr10:100911103~100912739:-
TGCT	cis	rs12745968	0.629	rs2145824	ENSG00000223787.2	RP4-593M8.1	-4.32	3.17e-05	0.019	-0.47	-0.36	Bipolar disorder and schizophrenia;	chr1:92734844	chr1:92580476~92580821:-
TGCT	cis	rs7829975	0.714	rs7823757	ENSG00000254340.1	RP11-10A14.3	4.32	3.17e-05	0.019	0.37	0.36	Mood instability;	chr8:8812667	chr8:9141424~9145435:+
TGCT	cis	rs7829975	0.714	rs60315134	ENSG00000254340.1	RP11-10A14.3	4.32	3.17e-05	0.019	0.37	0.36	Mood instability;	chr8:8813089	chr8:9141424~9145435:+
TGCT	cis	rs875971	0.545	rs10950025	ENSG00000222364.1	RNU6-96P	-4.32	3.17e-05	0.019	-0.46	-0.36	Aortic root size;	chr7:66158946	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.545	rs1547529	ENSG00000222364.1	RNU6-96P	-4.32	3.17e-05	0.019	-0.46	-0.36	Aortic root size;	chr7:66258859	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.545	rs316324	ENSG00000222364.1	RNU6-96P	4.32	3.17e-05	0.019	0.46	0.36	Aortic root size;	chr7:66145627	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.545	rs316323	ENSG00000222364.1	RNU6-96P	4.32	3.17e-05	0.019	0.46	0.36	Aortic root size;	chr7:66146002	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.545	rs316316	ENSG00000222364.1	RNU6-96P	4.32	3.17e-05	0.019	0.46	0.36	Aortic root size;	chr7:66149270	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.545	rs2460427	ENSG00000222364.1	RNU6-96P	4.32	3.17e-05	0.019	0.46	0.36	Aortic root size;	chr7:66154218	chr7:66395191~66395286:+
TGCT	cis	rs7824557	0.564	rs13260727	ENSG00000269918.1	AF131215.9	4.32	3.17e-05	0.019	0.34	0.36	Retinal vascular caliber;	chr8:11375351	chr8:11104691~11106704:-
TGCT	cis	rs507080	0.922	rs625513	ENSG00000255239.1	AP002954.6	4.32	3.17e-05	0.019	0.47	0.36	Serum metabolite levels;	chr11:118685010	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.922	rs514143	ENSG00000255239.1	AP002954.6	4.32	3.17e-05	0.019	0.47	0.36	Serum metabolite levels;	chr11:118687740	chr11:118688039~118690600:-
TGCT	cis	rs4811196	1	rs4811144	ENSG00000277829.1	RP5-1054A22.4	-4.32	3.18e-05	0.019	-0.42	-0.36	Bone mineral density;	chr20:37813412	chr20:38233251~38233799:-
TGCT	cis	rs1519814	0.659	rs6469891	ENSG00000254343.2	RP11-760H22.2	-4.32	3.18e-05	0.019	-0.59	-0.36	Breast cancer;	chr8:120025178	chr8:120052180~120056201:+
TGCT	cis	rs7923609	1	rs10822163	ENSG00000232075.1	MRPL35P2	-4.32	3.18e-05	0.0191	-0.35	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63364338	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.967	rs6479896	ENSG00000232075.1	MRPL35P2	-4.32	3.18e-05	0.0191	-0.35	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63367072	chr10:63634317~63634827:-
TGCT	cis	rs1707322	1	rs10890382	ENSG00000280836.1	AL355480.1	-4.32	3.18e-05	0.0191	-0.48	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs4660335	ENSG00000280836.1	AL355480.1	-4.32	3.18e-05	0.0191	-0.48	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr1:45581219~45581321:-
TGCT	cis	rs3105593	1	rs62017206	ENSG00000273674.3	CTD-2378E12.1	4.32	3.18e-05	0.0191	0.39	0.36	QT interval;	chr15:50663429	chr15:50839875~50908599:-
TGCT	cis	rs3105593	1	rs8036588	ENSG00000273674.3	CTD-2378E12.1	4.32	3.18e-05	0.0191	0.39	0.36	QT interval;	chr15:50664637	chr15:50839875~50908599:-
TGCT	cis	rs3105593	1	rs7167138	ENSG00000273674.3	CTD-2378E12.1	4.32	3.18e-05	0.0191	0.39	0.36	QT interval;	chr15:50666801	chr15:50839875~50908599:-
TGCT	cis	rs3105593	1	rs11070805	ENSG00000273674.3	CTD-2378E12.1	4.32	3.18e-05	0.0191	0.39	0.36	QT interval;	chr15:50671995	chr15:50839875~50908599:-
TGCT	cis	rs3105593	1	rs28817917	ENSG00000273674.3	CTD-2378E12.1	4.32	3.18e-05	0.0191	0.39	0.36	QT interval;	chr15:50673649	chr15:50839875~50908599:-
TGCT	cis	rs3105593	1	rs56069965	ENSG00000273674.3	CTD-2378E12.1	4.32	3.18e-05	0.0191	0.39	0.36	QT interval;	chr15:50674776	chr15:50839875~50908599:-
TGCT	cis	rs3105593	1	rs934625	ENSG00000273674.3	CTD-2378E12.1	4.32	3.18e-05	0.0191	0.39	0.36	QT interval;	chr15:50676559	chr15:50839875~50908599:-
TGCT	cis	rs3105593	1	rs12591751	ENSG00000273674.3	CTD-2378E12.1	4.32	3.18e-05	0.0191	0.39	0.36	QT interval;	chr15:50680300	chr15:50839875~50908599:-
TGCT	cis	rs3105593	1	rs11070807	ENSG00000273674.3	CTD-2378E12.1	4.32	3.18e-05	0.0191	0.39	0.36	QT interval;	chr15:50682308	chr15:50839875~50908599:-
TGCT	cis	rs3105593	1	rs56015123	ENSG00000273674.3	CTD-2378E12.1	4.32	3.18e-05	0.0191	0.39	0.36	QT interval;	chr15:50685031	chr15:50839875~50908599:-
TGCT	cis	rs10504229	1	rs17217047	ENSG00000253301.4	RP11-513O17.2	4.32	3.18e-05	0.0191	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57267737	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs17805656	ENSG00000253301.4	RP11-513O17.2	4.32	3.18e-05	0.0191	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57267759	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs67384205	ENSG00000253301.4	RP11-513O17.2	4.32	3.18e-05	0.0191	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57267789	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs67594249	ENSG00000253301.4	RP11-513O17.2	4.32	3.18e-05	0.0191	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57267962	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs72650899	ENSG00000253301.4	RP11-513O17.2	4.32	3.18e-05	0.0191	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57267966	chr8:57142689~57240298:+
TGCT	cis	rs2283792	0.74	rs11912377	ENSG00000228050.1	TOP3BP1	4.32	3.19e-05	0.0191	0.43	0.36	Multiple sclerosis;	chr22:21864332	chr22:22223187~22224566:-
TGCT	cis	rs1061377	0.71	rs12503506	ENSG00000249207.1	RP11-360F5.1	-4.32	3.19e-05	0.0191	-0.38	-0.36	Uric acid levels;	chr4:39082553	chr4:39112677~39126818:-
TGCT	cis	rs673078	0.607	rs55929628	ENSG00000275759.1	RP11-131L12.3	-4.32	3.19e-05	0.0191	-0.67	-0.36	Glucose homeostasis traits;	chr12:118371332	chr12:118428281~118428870:+
TGCT	cis	rs9400467	0.506	rs17756732	ENSG00000272356.1	RP5-1112D6.8	-4.32	3.19e-05	0.0191	-0.43	-0.36	Amino acid levels;Blood metabolite levels;	chr6:111258951	chr6:111309203~111313517:+
TGCT	cis	rs9326248	0.53	rs562179	ENSG00000254851.1	RP11-109L13.1	-4.32	3.19e-05	0.0191	-0.62	-0.36	Blood protein levels;	chr11:116934488	chr11:117135528~117138582:+
TGCT	cis	rs2117029	1	rs11168839	ENSG00000258017.1	RP11-386G11.10	4.32	3.2e-05	0.0192	0.43	0.36	Intelligence (multi-trait analysis);	chr12:49063852	chr12:49127782~49147869:+
TGCT	cis	rs867371	1	rs13380319	ENSG00000255769.6	GOLGA2P10	-4.32	3.2e-05	0.0192	-0.39	-0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82472993~82513950:-
TGCT	cis	rs2439831	0.85	rs8023458	ENSG00000205771.5	CATSPER2P1	-4.32	3.2e-05	0.0192	-0.62	-0.36	Lung cancer in ever smokers;	chr15:43788741	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs16963953	ENSG00000205771.5	CATSPER2P1	-4.32	3.2e-05	0.0192	-0.62	-0.36	Lung cancer in ever smokers;	chr15:43789521	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.702	rs3759791	ENSG00000205771.5	CATSPER2P1	-4.32	3.2e-05	0.0192	-0.62	-0.36	Lung cancer in ever smokers;	chr15:43798600	chr15:43726918~43747094:-
TGCT	cis	rs9322193	0.576	rs7452592	ENSG00000216906.2	RP11-350J20.9	4.32	3.2e-05	0.0192	0.49	0.36	Lung cancer;	chr6:149875445	chr6:149904243~149906418:+
TGCT	cis	rs6474412	0.871	rs11783507	ENSG00000255101.1	RP11-412B14.1	4.32	3.2e-05	0.0192	0.37	0.36	Smoking behavior;	chr8:42679252	chr8:42705583~42721946:-
TGCT	cis	rs6474412	1	rs10958726	ENSG00000255101.1	RP11-412B14.1	4.32	3.2e-05	0.0192	0.37	0.36	Smoking behavior;	chr8:42680766	chr8:42705583~42721946:-
TGCT	cis	rs17826219	0.561	rs11655876	ENSG00000280069.1	CTD-2349P21.3	-4.32	3.21e-05	0.0192	-0.49	-0.36	Body mass index;	chr17:30690132	chr17:30738182~30740275:+
TGCT	cis	rs6125961	0.714	rs6122894	ENSG00000224397.4	LINC01272	-4.32	3.21e-05	0.0192	-0.53	-0.36	Granulocyte percentage of myeloid white cells;Monocyte count;	chr20:50246554	chr20:50267486~50279795:+
TGCT	cis	rs365032	0.584	rs4809256	ENSG00000203900.2	RP11-261N11.8	-4.32	3.21e-05	0.0192	-0.42	-0.36	Restless legs syndrome;	chr20:64150729	chr20:63359988~63371177:+
TGCT	cis	rs10504229	0.906	rs114810777	ENSG00000253301.4	RP11-513O17.2	4.32	3.22e-05	0.0192	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57272739	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.815	rs75577263	ENSG00000253301.4	RP11-513O17.2	4.32	3.22e-05	0.0192	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57275875	chr8:57142689~57240298:+
TGCT	cis	rs6782228	0.606	rs6807019	ENSG00000242551.2	POU5F1P6	-4.32	3.22e-05	0.0193	-0.44	-0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687091	chr3:128674735~128677005:-
TGCT	cis	rs10504229	1	rs111915672	ENSG00000253301.4	RP11-513O17.2	4.32	3.22e-05	0.0193	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57279106	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.906	rs113857287	ENSG00000253301.4	RP11-513O17.2	4.32	3.22e-05	0.0193	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57279124	chr8:57142689~57240298:+
TGCT	cis	rs6604026	0.59	rs12743005	ENSG00000223787.2	RP4-593M8.1	4.32	3.22e-05	0.0193	0.52	0.36	Multiple sclerosis;	chr1:92727181	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.624	rs34761380	ENSG00000223787.2	RP4-593M8.1	4.32	3.22e-05	0.0193	0.52	0.36	Multiple sclerosis;	chr1:92731928	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.59	rs35241270	ENSG00000223787.2	RP4-593M8.1	4.32	3.22e-05	0.0193	0.52	0.36	Multiple sclerosis;	chr1:92739957	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.624	rs12746893	ENSG00000223787.2	RP4-593M8.1	4.32	3.22e-05	0.0193	0.52	0.36	Multiple sclerosis;	chr1:92745319	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.624	rs11164803	ENSG00000223787.2	RP4-593M8.1	4.32	3.22e-05	0.0193	0.52	0.36	Multiple sclerosis;	chr1:92746363	chr1:92580476~92580821:-
TGCT	cis	rs9462027	0.628	rs9469886	ENSG00000186328.4	RP11-140K17.2	4.32	3.22e-05	0.0193	0.34	0.36	Systemic lupus erythematosus;	chr6:34791047	chr6:34715613~34715940:+
TGCT	cis	rs875971	0.545	rs1638735	ENSG00000222364.1	RNU6-96P	-4.32	3.22e-05	0.0193	-0.44	-0.36	Aortic root size;	chr7:66630751	chr7:66395191~66395286:+
TGCT	cis	rs7403037	0.527	rs8026962	ENSG00000259905.4	PWRN1	4.32	3.23e-05	0.0193	0.38	0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24537677	chr15:24493137~24652130:+
TGCT	cis	rs6717918	0.561	rs2633260	ENSG00000231494.1	AC104634.3	-4.32	3.23e-05	0.0193	-0.46	-0.36	Height;	chr2:232268100	chr2:231559903~231560364:+
TGCT	cis	rs11671005	0.735	rs11084544	ENSG00000232098.3	CTD-2619J13.14	-4.32	3.23e-05	0.0193	-0.4	-0.36	Mean platelet volume;	chr19:58428760	chr19:58404238~58408484:-
TGCT	cis	rs577676	0.524	rs601938	ENSG00000271811.1	RP1-79C4.4	4.31	3.23e-05	0.0193	0.29	0.36	Prevalent atrial fibrillation;	chr1:170661118	chr1:170667381~170669425:+
TGCT	cis	rs7714584	1	rs77698001	ENSG00000197083.10	ZNF300P1	4.31	3.23e-05	0.0193	0.6	0.36	Crohn's disease;	chr5:150870805	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs10463307	ENSG00000197083.10	ZNF300P1	4.31	3.23e-05	0.0193	0.6	0.36	Crohn's disease;	chr5:150875058	chr5:150930645~150946289:-
TGCT	cis	rs9921222	0.5	rs11645742	ENSG00000268836.1	LA16c-OS12.2	4.31	3.23e-05	0.0193	0.39	0.36	Bone mineral density (spine);Bone mineral density;	chr16:317516	chr16:185748~186294:-
TGCT	cis	rs728616	0.614	rs2181204	ENSG00000230091.5	TMEM254-AS1	4.31	3.24e-05	0.0193	0.52	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79944756	chr10:80046860~80078912:-
TGCT	cis	rs34375054	0.525	rs7136220	ENSG00000279233.1	RP11-158L12.4	4.31	3.24e-05	0.0193	0.38	0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125118138	chr12:125138245~125141711:+
TGCT	cis	rs13118159	0.55	rs28522910	ENSG00000254094.1	AC078852.1	-4.31	3.24e-05	0.0194	-0.44	-0.36	Longevity;	chr4:1380986	chr4:1356581~1358075:+
TGCT	cis	rs875971	0.825	rs28480509	ENSG00000232559.3	GS1-124K5.12	-4.31	3.24e-05	0.0194	-0.34	-0.36	Aortic root size;	chr7:66634237	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs9791712	ENSG00000232559.3	GS1-124K5.12	-4.31	3.24e-05	0.0194	-0.34	-0.36	Aortic root size;	chr7:66640176	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs9791713	ENSG00000232559.3	GS1-124K5.12	-4.31	3.24e-05	0.0194	-0.34	-0.36	Aortic root size;	chr7:66640211	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs1860469	ENSG00000232559.3	GS1-124K5.12	-4.31	3.24e-05	0.0194	-0.34	-0.36	Aortic root size;	chr7:66641888	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs4718383	ENSG00000232559.3	GS1-124K5.12	-4.31	3.24e-05	0.0194	-0.34	-0.36	Aortic root size;	chr7:66643422	chr7:66554588~66576923:-
TGCT	cis	rs2439831	0.85	rs7169988	ENSG00000205771.5	CATSPER2P1	-4.31	3.24e-05	0.0194	-0.62	-0.36	Lung cancer in ever smokers;	chr15:43768237	chr15:43726918~43747094:-
TGCT	cis	rs1867631	1	rs10789212	ENSG00000223263.1	RNU6-387P	-4.31	3.25e-05	0.0194	-0.41	-0.36	Menopause (age at onset);	chr1:66662472	chr1:67417214~67417318:+
TGCT	cis	rs1867631	1	rs10789213	ENSG00000223263.1	RNU6-387P	-4.31	3.25e-05	0.0194	-0.41	-0.36	Menopause (age at onset);	chr1:66662518	chr1:67417214~67417318:+
TGCT	cis	rs673078	0.607	rs61944661	ENSG00000275759.1	RP11-131L12.3	-4.31	3.25e-05	0.0194	-0.65	-0.36	Glucose homeostasis traits;	chr12:118445514	chr12:118428281~118428870:+
TGCT	cis	rs867371	0.502	rs28610286	ENSG00000255769.6	GOLGA2P10	-4.31	3.25e-05	0.0194	-0.35	-0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82472993~82513950:-
TGCT	cis	rs1823913	0.637	rs4613316	ENSG00000227542.1	AC092614.2	4.31	3.25e-05	0.0194	0.39	0.36	Obesity-related traits;	chr2:191326074	chr2:191229165~191246172:-
TGCT	cis	rs2153535	0.58	rs915350	ENSG00000230939.1	RP11-314C16.1	-4.31	3.25e-05	0.0194	-0.35	-0.36	Motion sickness;	chr6:8443253	chr6:8784178~8785445:+
TGCT	cis	rs8059260	1	rs8059260	ENSG00000274038.1	RP11-66H6.4	-4.31	3.25e-05	0.0194	-0.48	-0.36	Alcohol consumption over the past year;	chr16:10966294	chr16:11056556~11057034:+
TGCT	cis	rs7208859	0.623	rs80355557	ENSG00000280069.1	CTD-2349P21.3	-4.31	3.26e-05	0.0194	-0.45	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs9911173	ENSG00000280069.1	CTD-2349P21.3	-4.31	3.26e-05	0.0194	-0.45	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.673	rs73271887	ENSG00000280069.1	CTD-2349P21.3	-4.31	3.26e-05	0.0194	-0.45	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.673	rs9898858	ENSG00000280069.1	CTD-2349P21.3	-4.31	3.26e-05	0.0194	-0.45	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.673	rs55658077	ENSG00000280069.1	CTD-2349P21.3	-4.31	3.26e-05	0.0194	-0.45	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs9899692	ENSG00000280069.1	CTD-2349P21.3	-4.31	3.26e-05	0.0194	-0.45	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs9906957	ENSG00000280069.1	CTD-2349P21.3	-4.31	3.26e-05	0.0194	-0.45	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.673	rs9915139	ENSG00000280069.1	CTD-2349P21.3	-4.31	3.26e-05	0.0194	-0.45	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30738182~30740275:+
TGCT	cis	rs2019137	1	rs2019137	ENSG00000189223.12	PAX8-AS1	4.31	3.26e-05	0.0194	0.45	0.36	Lymphocyte counts;	chr2:113216055	chr2:113211522~113276581:+
TGCT	cis	rs2019137	0.967	rs895412	ENSG00000189223.12	PAX8-AS1	4.31	3.26e-05	0.0194	0.45	0.36	Lymphocyte counts;	chr2:113216387	chr2:113211522~113276581:+
TGCT	cis	rs1387259	0.619	rs7134565	ENSG00000258273.1	RP11-370I10.4	4.31	3.26e-05	0.0194	0.42	0.36	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48236241	chr12:48333755~48333901:-
TGCT	cis	rs1387259	0.619	rs2130095	ENSG00000258273.1	RP11-370I10.4	4.31	3.26e-05	0.0194	0.42	0.36	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48244972	chr12:48333755~48333901:-
TGCT	cis	rs1387259	0.64	rs10783243	ENSG00000258273.1	RP11-370I10.4	4.31	3.26e-05	0.0194	0.42	0.36	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48259220	chr12:48333755~48333901:-
TGCT	cis	rs5758511	0.68	rs56111723	ENSG00000182057.4	OGFRP1	-4.31	3.26e-05	0.0195	-0.34	-0.36	Birth weight;	chr22:42268877	chr22:42269753~42275196:+
TGCT	cis	rs34779708	0.771	rs3867218	ENSG00000230534.5	RP11-297A16.2	4.31	3.26e-05	0.0195	0.44	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35238615	chr10:35098006~35127020:-
TGCT	cis	rs728616	0.867	rs61860039	ENSG00000230091.5	TMEM254-AS1	4.31	3.26e-05	0.0195	0.67	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80180150	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs61860041	ENSG00000230091.5	TMEM254-AS1	4.31	3.26e-05	0.0195	0.67	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80184575	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs61860042	ENSG00000230091.5	TMEM254-AS1	4.31	3.26e-05	0.0195	0.67	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186482	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs61860043	ENSG00000230091.5	TMEM254-AS1	4.31	3.26e-05	0.0195	0.67	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186642	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs12415870	ENSG00000230091.5	TMEM254-AS1	4.31	3.26e-05	0.0195	0.67	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80189714	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs12414521	ENSG00000230091.5	TMEM254-AS1	4.31	3.26e-05	0.0195	0.67	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80189778	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs55666905	ENSG00000230091.5	TMEM254-AS1	4.31	3.26e-05	0.0195	0.67	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80193883	chr10:80046860~80078912:-
TGCT	cis	rs651386	0.529	rs576736	ENSG00000271811.1	RP1-79C4.4	4.31	3.26e-05	0.0195	0.27	0.36	Atrial fibrillation;	chr1:170618074	chr1:170667381~170669425:+
TGCT	cis	rs9533975	0.521	rs7326813	ENSG00000235097.1	LINC00330	4.31	3.27e-05	0.0195	0.32	0.36	Subjective well-being;Life satisfaction;	chr13:44749242	chr13:44799503~44809630:-
TGCT	cis	rs9533975	0.521	rs1570472	ENSG00000235097.1	LINC00330	4.31	3.27e-05	0.0195	0.32	0.36	Subjective well-being;Life satisfaction;	chr13:44750220	chr13:44799503~44809630:-
TGCT	cis	rs172166	0.543	rs1150691	ENSG00000204709.4	LINC01556	4.31	3.27e-05	0.0195	0.4	0.36	Cardiac Troponin-T levels;	chr6:28200255	chr6:28943877~28944537:+
TGCT	cis	rs7621331	0.817	rs1568349	ENSG00000239213.4	NCK1-AS1	4.31	3.27e-05	0.0195	0.36	0.36	Waist circumference adjusted for body mass index;	chr3:135929379	chr3:136841726~136862054:-
TGCT	cis	rs7335046	0.572	rs4772195	ENSG00000234005.3	GAPDHP22	-4.31	3.27e-05	0.0195	-0.35	-0.36	Basal cell carcinoma;	chr13:99406443	chr13:99190579~99190991:-
TGCT	cis	rs7923609	1	rs4310508	ENSG00000232075.1	MRPL35P2	-4.31	3.28e-05	0.0195	-0.35	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63378813	chr10:63634317~63634827:-
TGCT	cis	rs7923609	1	rs7910927	ENSG00000232075.1	MRPL35P2	-4.31	3.28e-05	0.0195	-0.35	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63379150	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.967	rs10761751	ENSG00000232075.1	MRPL35P2	-4.31	3.28e-05	0.0195	-0.35	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63395125	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.967	rs10761752	ENSG00000232075.1	MRPL35P2	-4.31	3.28e-05	0.0195	-0.35	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63400561	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.967	rs7095571	ENSG00000232075.1	MRPL35P2	-4.31	3.28e-05	0.0195	-0.35	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63391199	chr10:63634317~63634827:-
TGCT	cis	rs2188561	0.697	rs7787927	ENSG00000241764.3	AC002467.7	4.31	3.28e-05	0.0195	0.34	0.36	Alcohol consumption;	chr7:107763915	chr7:107742817~107744581:-
TGCT	cis	rs4713118	0.662	rs149961	ENSG00000187763.3	OR2B7P	4.31	3.28e-05	0.0195	0.35	0.36	Parkinson's disease;	chr6:28047791	chr6:28046434~28047367:+
TGCT	cis	rs4713118	0.629	rs149899	ENSG00000187763.3	OR2B7P	4.31	3.28e-05	0.0195	0.35	0.36	Parkinson's disease;	chr6:28052201	chr6:28046434~28047367:+
TGCT	cis	rs4713118	0.629	rs172165	ENSG00000187763.3	OR2B7P	4.31	3.28e-05	0.0195	0.35	0.36	Parkinson's disease;	chr6:28053036	chr6:28046434~28047367:+
TGCT	cis	rs4713118	0.597	rs172166	ENSG00000187763.3	OR2B7P	4.31	3.28e-05	0.0195	0.35	0.36	Parkinson's disease;	chr6:28053042	chr6:28046434~28047367:+
TGCT	cis	rs4713118	0.629	rs203889	ENSG00000187763.3	OR2B7P	4.31	3.28e-05	0.0195	0.35	0.36	Parkinson's disease;	chr6:28053997	chr6:28046434~28047367:+
TGCT	cis	rs4713118	0.629	rs203890	ENSG00000187763.3	OR2B7P	4.31	3.28e-05	0.0195	0.35	0.36	Parkinson's disease;	chr6:28054470	chr6:28046434~28047367:+
TGCT	cis	rs4713118	0.662	rs9357060	ENSG00000187763.3	OR2B7P	4.31	3.28e-05	0.0195	0.35	0.36	Parkinson's disease;	chr6:28056708	chr6:28046434~28047367:+
TGCT	cis	rs4713118	0.662	rs9468271	ENSG00000187763.3	OR2B7P	4.31	3.28e-05	0.0195	0.35	0.36	Parkinson's disease;	chr6:28056792	chr6:28046434~28047367:+
TGCT	cis	rs4713118	0.662	rs9380045	ENSG00000187763.3	OR2B7P	4.31	3.28e-05	0.0195	0.35	0.36	Parkinson's disease;	chr6:28057501	chr6:28046434~28047367:+
TGCT	cis	rs4713118	0.616	rs9348789	ENSG00000187763.3	OR2B7P	4.31	3.28e-05	0.0195	0.35	0.36	Parkinson's disease;	chr6:28057708	chr6:28046434~28047367:+
TGCT	cis	rs4713118	0.662	rs9468274	ENSG00000187763.3	OR2B7P	4.31	3.28e-05	0.0195	0.35	0.36	Parkinson's disease;	chr6:28058299	chr6:28046434~28047367:+
TGCT	cis	rs4713118	0.662	rs9468275	ENSG00000187763.3	OR2B7P	4.31	3.28e-05	0.0195	0.35	0.36	Parkinson's disease;	chr6:28058358	chr6:28046434~28047367:+
TGCT	cis	rs4713118	0.662	rs9468276	ENSG00000187763.3	OR2B7P	4.31	3.28e-05	0.0195	0.35	0.36	Parkinson's disease;	chr6:28059910	chr6:28046434~28047367:+
TGCT	cis	rs4713118	0.662	rs9468277	ENSG00000187763.3	OR2B7P	4.31	3.28e-05	0.0195	0.35	0.36	Parkinson's disease;	chr6:28060612	chr6:28046434~28047367:+
TGCT	cis	rs4713118	0.662	rs9468278	ENSG00000187763.3	OR2B7P	4.31	3.28e-05	0.0195	0.35	0.36	Parkinson's disease;	chr6:28060704	chr6:28046434~28047367:+
TGCT	cis	rs4713118	0.662	rs13218430	ENSG00000187763.3	OR2B7P	4.31	3.28e-05	0.0195	0.35	0.36	Parkinson's disease;	chr6:28062059	chr6:28046434~28047367:+
TGCT	cis	rs10504229	0.817	rs60646469	ENSG00000253301.4	RP11-513O17.2	4.31	3.28e-05	0.0196	0.48	0.36	Developmental language disorder (linguistic errors);	chr8:57282789	chr8:57142689~57240298:+
TGCT	cis	rs1707322	1	rs11211232	ENSG00000280836.1	AL355480.1	-4.31	3.28e-05	0.0196	-0.49	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr1:45581219~45581321:-
TGCT	cis	rs728616	0.717	rs12412999	ENSG00000230091.5	TMEM254-AS1	4.31	3.28e-05	0.0196	0.69	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80248385	chr10:80046860~80078912:-
TGCT	cis	rs4308124	0.708	rs10179596	ENSG00000227992.1	AC108463.2	-4.31	3.28e-05	0.0196	-0.38	-0.36	Vitiligo;	chr2:111212803	chr2:111203964~111206215:-
TGCT	cis	rs10504229	0.679	rs16921688	ENSG00000253301.4	RP11-513O17.2	4.31	3.28e-05	0.0196	0.58	0.36	Developmental language disorder (linguistic errors);	chr8:57142100	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.639	rs112926738	ENSG00000253301.4	RP11-513O17.2	4.31	3.28e-05	0.0196	0.58	0.36	Developmental language disorder (linguistic errors);	chr8:57142380	chr8:57142689~57240298:+
TGCT	cis	rs6782228	0.675	rs9841987	ENSG00000242551.2	POU5F1P6	-4.31	3.29e-05	0.0196	-0.44	-0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128666299	chr3:128674735~128677005:-
TGCT	cis	rs6782228	0.675	rs56141228	ENSG00000242551.2	POU5F1P6	-4.31	3.29e-05	0.0196	-0.44	-0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128667199	chr3:128674735~128677005:-
TGCT	cis	rs6782228	0.651	rs9852825	ENSG00000242551.2	POU5F1P6	-4.31	3.29e-05	0.0196	-0.44	-0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128668514	chr3:128674735~128677005:-
TGCT	cis	rs6782228	0.651	rs9289332	ENSG00000242551.2	POU5F1P6	-4.31	3.29e-05	0.0196	-0.44	-0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669041	chr3:128674735~128677005:-
TGCT	cis	rs5760092	0.572	rs738806	ENSG00000225282.1	AP000350.6	4.31	3.29e-05	0.0196	0.47	0.36	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23926900~23929574:+
TGCT	cis	rs12554020	0.792	rs11975	ENSG00000227603.1	RP11-165J3.6	4.31	3.29e-05	0.0196	0.59	0.36	Schizophrenia;	chr9:93565409	chr9:93435332~93437121:-
TGCT	cis	rs12554020	0.892	rs12341488	ENSG00000227603.1	RP11-165J3.6	4.31	3.29e-05	0.0196	0.59	0.36	Schizophrenia;	chr9:93568889	chr9:93435332~93437121:-
TGCT	cis	rs1864400	0.605	rs12360493	ENSG00000273008.1	RP11-351D16.3	4.31	3.29e-05	0.0196	0.48	0.36	Hirschsprung disease;	chr10:43223165	chr10:43136824~43138334:-
TGCT	cis	rs801193	0.591	rs9986881	ENSG00000237310.1	GS1-124K5.4	4.31	3.29e-05	0.0196	0.39	0.36	Aortic root size;	chr7:66708053	chr7:66493706~66495474:+
TGCT	cis	rs73086581	1	rs17215340	ENSG00000229539.1	RP11-119B16.2	-4.31	3.29e-05	0.0196	-0.53	-0.36	Response to antidepressants in depression;	chr20:3989526	chr20:3888239~3888868:-
TGCT	cis	rs13068223	0.669	rs168247	ENSG00000243926.1	TIPARP-AS1	-4.31	3.29e-05	0.0196	-0.39	-0.36	Age-related hearing impairment (SNP x SNP interaction);	chr3:156722397	chr3:156671862~156674378:-
TGCT	cis	rs4242434	0.927	rs13264187	ENSG00000254064.1	CTD-2530N21.4	-4.31	3.29e-05	0.0196	-0.22	-0.36	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22648585	chr8:22254576~22275162:-
TGCT	cis	rs2243480	1	rs160633	ENSG00000164669.11	INTS4P1	4.31	3.3e-05	0.0196	0.55	0.36	Diabetic kidney disease;	chr7:66063241	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs160655	ENSG00000164669.11	INTS4P1	4.31	3.3e-05	0.0196	0.55	0.36	Diabetic kidney disease;	chr7:66068227	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs160652	ENSG00000164669.11	INTS4P1	4.31	3.3e-05	0.0196	0.55	0.36	Diabetic kidney disease;	chr7:66073444	chr7:65141225~65234216:+
TGCT	cis	rs2243480	0.803	rs160649	ENSG00000164669.11	INTS4P1	4.31	3.3e-05	0.0196	0.55	0.36	Diabetic kidney disease;	chr7:66078212	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs160648	ENSG00000164669.11	INTS4P1	4.31	3.3e-05	0.0196	0.55	0.36	Diabetic kidney disease;	chr7:66078397	chr7:65141225~65234216:+
TGCT	cis	rs9309473	1	rs6711033	ENSG00000163016.8	ALMS1P	4.31	3.3e-05	0.0196	0.33	0.36	Metabolite levels;	chr2:73519516	chr2:73644919~73685576:+
TGCT	cis	rs507080	0.733	rs4486664	ENSG00000255239.1	AP002954.6	4.31	3.3e-05	0.0196	0.48	0.36	Serum metabolite levels;	chr11:118698358	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.733	rs7108144	ENSG00000255239.1	AP002954.6	4.31	3.3e-05	0.0196	0.48	0.36	Serum metabolite levels;	chr11:118698985	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.663	rs523793	ENSG00000255239.1	AP002954.6	4.31	3.3e-05	0.0196	0.48	0.36	Serum metabolite levels;	chr11:118699988	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.736	rs659564	ENSG00000255239.1	AP002954.6	4.31	3.3e-05	0.0196	0.48	0.36	Serum metabolite levels;	chr11:118700205	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.736	rs642224	ENSG00000255239.1	AP002954.6	4.31	3.3e-05	0.0196	0.48	0.36	Serum metabolite levels;	chr11:118700210	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.733	rs541631	ENSG00000255239.1	AP002954.6	4.31	3.3e-05	0.0196	0.48	0.36	Serum metabolite levels;	chr11:118700314	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.736	rs658676	ENSG00000255239.1	AP002954.6	4.31	3.3e-05	0.0196	0.48	0.36	Serum metabolite levels;	chr11:118700414	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.733	rs488141	ENSG00000255239.1	AP002954.6	4.31	3.3e-05	0.0196	0.48	0.36	Serum metabolite levels;	chr11:118700459	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.733	rs657769	ENSG00000255239.1	AP002954.6	4.31	3.3e-05	0.0196	0.48	0.36	Serum metabolite levels;	chr11:118700607	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.733	rs544452	ENSG00000255239.1	AP002954.6	4.31	3.3e-05	0.0196	0.48	0.36	Serum metabolite levels;	chr11:118700648	chr11:118688039~118690600:-
TGCT	cis	rs7829975	0.711	rs4841051	ENSG00000173295.6	FAM86B3P	-4.31	3.3e-05	0.0196	-0.43	-0.36	Mood instability;	chr8:8828136	chr8:8228595~8244865:+
TGCT	cis	rs853679	0.506	rs1150693	ENSG00000216901.1	AL022393.7	4.31	3.3e-05	0.0196	0.49	0.36	Depression;	chr6:28206812	chr6:28176188~28176674:+
TGCT	cis	rs801193	1	rs2420824	ENSG00000272831.1	RP11-792A8.4	-4.31	3.31e-05	0.0197	-0.38	-0.36	Aortic root size;	chr7:66666129	chr7:66739829~66740385:-
TGCT	cis	rs17783634	0.509	rs11775489	ENSG00000255310.2	AF131215.2	-4.31	3.31e-05	0.0197	-0.31	-0.36	Subjective well-being;	chr8:11179334	chr8:11107788~11109726:-
TGCT	cis	rs3808502	0.527	rs4410870	ENSG00000255310.2	AF131215.2	-4.31	3.31e-05	0.0197	-0.3	-0.36	Neuroticism;	chr8:11298611	chr8:11107788~11109726:-
TGCT	cis	rs17826219	0.706	rs609472	ENSG00000263531.1	RP13-753N3.1	4.31	3.31e-05	0.0197	0.65	0.36	Body mass index;	chr17:30624409	chr17:30863921~30864940:-
TGCT	cis	rs6510489	1	rs11880364	ENSG00000267439.1	AC002398.11	4.31	3.32e-05	0.0197	0.48	0.36	Bipolar disorder;	chr19:35497892	chr19:35747057~35753415:-
TGCT	cis	rs4380275	0.782	rs4468850	ENSG00000272342.1	RP13-539J13.1	4.31	3.32e-05	0.0197	0.45	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:749467	chr2:739588~740164:-
TGCT	cis	rs11168351	0.517	rs10875754	ENSG00000258273.1	RP11-370I10.4	-4.31	3.32e-05	0.0197	-0.44	-0.36	Bipolar disorder and schizophrenia;	chr12:48164139	chr12:48333755~48333901:-
TGCT	cis	rs9326248	0.861	rs7931335	ENSG00000280143.1	AP000892.6	4.31	3.33e-05	0.0198	0.52	0.36	Blood protein levels;	chr11:117166089	chr11:117204967~117210292:+
TGCT	cis	rs875971	0.66	rs801193	ENSG00000272831.1	RP11-792A8.4	-4.31	3.33e-05	0.0198	-0.39	-0.36	Aortic root size;	chr7:66565625	chr7:66739829~66740385:-
TGCT	cis	rs2297363	1	rs3777411	ENSG00000213073.4	RP11-288H12.3	-4.31	3.33e-05	0.0198	-0.34	-0.36	Total cholesterol levels;Blood protein levels;	chr6:160055913	chr6:160093082~160096212:+
TGCT	cis	rs1799955	0.935	rs3764791	ENSG00000215515.2	IFIT1P1	-4.31	3.33e-05	0.0198	-0.5	-0.36	LDL cholesterol levels;	chr13:32376974	chr13:32384660~32386108:+
TGCT	cis	rs1799955	0.935	rs3764792	ENSG00000215515.2	IFIT1P1	-4.31	3.33e-05	0.0198	-0.5	-0.36	LDL cholesterol levels;	chr13:32376978	chr13:32384660~32386108:+
TGCT	cis	rs1799955	0.935	rs9567623	ENSG00000215515.2	IFIT1P1	-4.31	3.33e-05	0.0198	-0.5	-0.36	LDL cholesterol levels;	chr13:32377317	chr13:32384660~32386108:+
TGCT	cis	rs4973397	0.765	rs2290130	ENSG00000183022.5	TPM3P8	4.31	3.33e-05	0.0198	0.51	0.36	Anti-saccade response;	chr2:231398416	chr2:230573167~230573809:-
TGCT	cis	rs4973397	0.765	rs10445830	ENSG00000183022.5	TPM3P8	4.31	3.33e-05	0.0198	0.51	0.36	Anti-saccade response;	chr2:231399262	chr2:230573167~230573809:-
TGCT	cis	rs12216499	0.591	rs10945583	ENSG00000188451.8	SRP72P2	4.31	3.33e-05	0.0198	0.46	0.36	Bladder cancer (smoking interaction);	chr6:158960100	chr6:158237336~158242797:-
TGCT	cis	rs875971	1	rs4718357	ENSG00000237310.1	GS1-124K5.4	4.31	3.33e-05	0.0198	0.4	0.36	Aortic root size;	chr7:66495891	chr7:66493706~66495474:+
TGCT	cis	rs853679	0.55	rs1233707	ENSG00000219891.2	ZSCAN12P1	4.31	3.33e-05	0.0198	0.46	0.36	Depression;	chr6:28205175	chr6:28091154~28093664:+
TGCT	cis	rs7246967	0.673	rs8103012	ENSG00000198153.8	ZNF849P	4.31	3.33e-05	0.0198	0.61	0.36	Bronchopulmonary dysplasia;	chr19:22696483	chr19:22685167~22686732:+
TGCT	cis	rs2439831	0.85	rs60883262	ENSG00000205771.5	CATSPER2P1	-4.31	3.33e-05	0.0198	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43784305	chr15:43726918~43747094:-
TGCT	cis	rs2739330	0.892	rs5751776	ENSG00000250470.1	AP000351.3	4.31	3.33e-05	0.0198	0.37	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23976904~23977585:-
TGCT	cis	rs1707322	0.752	rs11211145	ENSG00000280836.1	AL355480.1	-4.31	3.33e-05	0.0198	-0.49	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45581219~45581321:-
TGCT	cis	rs10129255	0.913	rs28861466	ENSG00000211970.3	IGHV4-61	-4.31	3.33e-05	0.0198	-0.39	-0.36	Kawasaki disease;	chr14:106718572	chr14:106639119~106639657:-
TGCT	cis	rs10129255	0.913	rs10140943	ENSG00000211970.3	IGHV4-61	-4.31	3.33e-05	0.0198	-0.39	-0.36	Kawasaki disease;	chr14:106767441	chr14:106639119~106639657:-
TGCT	cis	rs801193	0.66	rs1962050	ENSG00000237310.1	GS1-124K5.4	-4.31	3.33e-05	0.0198	-0.39	-0.36	Aortic root size;	chr7:66775021	chr7:66493706~66495474:+
TGCT	cis	rs1372520	0.532	rs2583972	ENSG00000247775.2	SNCA-AS1	4.31	3.34e-05	0.0198	0.36	0.36	Neuroticism;	chr4:89826260	chr4:89836408~89841978:+
TGCT	cis	rs1023500	0.573	rs13057094	ENSG00000270083.1	RP1-257I20.14	4.31	3.34e-05	0.0198	0.36	0.36	Schizophrenia;	chr22:42074313	chr22:42089630~42090028:-
TGCT	cis	rs10826995	0.961	rs7894229	ENSG00000239731.3	RN7SL825P	-4.31	3.34e-05	0.0198	-0.36	-0.36	Pulse pressure;	chr10:31952401	chr10:31992087~31992381:-
TGCT	cis	rs10826995	0.922	rs72778399	ENSG00000239731.3	RN7SL825P	-4.31	3.34e-05	0.0198	-0.36	-0.36	Pulse pressure;	chr10:31955907	chr10:31992087~31992381:-
TGCT	cis	rs875971	0.571	rs160641	ENSG00000222364.1	RNU6-96P	4.31	3.34e-05	0.0198	0.46	0.36	Aortic root size;	chr7:66112359	chr7:66395191~66395286:+
TGCT	cis	rs7714584	1	rs1428555	ENSG00000197083.10	ZNF300P1	-4.31	3.34e-05	0.0198	-0.59	-0.36	Crohn's disease;	chr5:150877829	chr5:150930645~150946289:-
TGCT	cis	rs7182621	0.512	rs34151878	ENSG00000259363.4	CTD-2054N24.2	-4.31	3.34e-05	0.0198	-0.37	-0.36	Colonoscopy-negative controls vs population controls;	chr15:99869179	chr15:99807023~99877148:+
TGCT	cis	rs72615157	0.612	rs7786505	ENSG00000242294.5	STAG3L5P	4.31	3.35e-05	0.0199	0.32	0.36	Lung function (FEV1/FVC);	chr7:100219962	chr7:100336079~100351900:+
TGCT	cis	rs72615157	0.613	rs56089143	ENSG00000242294.5	STAG3L5P	4.31	3.35e-05	0.0199	0.32	0.36	Lung function (FEV1/FVC);	chr7:100222221	chr7:100336079~100351900:+
TGCT	cis	rs72615157	0.664	rs6953580	ENSG00000242294.5	STAG3L5P	4.31	3.35e-05	0.0199	0.32	0.36	Lung function (FEV1/FVC);	chr7:100227652	chr7:100336079~100351900:+
TGCT	cis	rs17608059	0.634	rs10852819	ENSG00000141028.6	CDRT15P1	-4.31	3.35e-05	0.0199	-0.41	-0.36	Temperament;	chr17:14018109	chr17:14024514~14025488:+
TGCT	cis	rs28735056	0.591	rs2277724	ENSG00000261126.6	RP11-795F19.1	-4.31	3.35e-05	0.0199	-0.3	-0.36	Schizophrenia;	chr18:79934294	chr18:80046900~80095482:+
TGCT	cis	rs2439831	0.85	rs28504496	ENSG00000205771.5	CATSPER2P1	-4.31	3.35e-05	0.0199	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43724685	chr15:43726918~43747094:-
TGCT	cis	rs853679	1	rs6901575	ENSG00000216901.1	AL022393.7	4.31	3.35e-05	0.0199	0.59	0.36	Depression;	chr6:28283207	chr6:28176188~28176674:+
TGCT	cis	rs7208859	0.623	rs122898	ENSG00000263603.1	CTD-2349P21.5	4.31	3.35e-05	0.0199	0.5	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30729469~30731202:+
TGCT	cis	rs7826238	0.72	rs12546760	ENSG00000254340.1	RP11-10A14.3	-4.31	3.36e-05	0.0199	-0.35	-0.36	Systolic blood pressure;	chr8:8517326	chr8:9141424~9145435:+
TGCT	cis	rs2013441	1	rs17686798	ENSG00000230528.6	NOS2P3	4.3	3.36e-05	0.0199	0.35	0.36	Obesity-related traits;	chr17:20125857	chr17:20436337~20447249:+
TGCT	cis	rs786425	0.933	rs786423	ENSG00000247373.3	RP11-486O12.2	-4.3	3.36e-05	0.0199	-0.42	-0.36	Pubertal anthropometrics;	chr12:123599351	chr12:123575891~123585115:-
TGCT	cis	rs1010254	0.559	rs17447016	ENSG00000253921.1	CTB-113P19.3	-4.3	3.36e-05	0.0199	-0.47	-0.36	Optic nerve measurement (cup area);	chr5:152357998	chr5:151753992~151767247:+
TGCT	cis	rs2439831	0.85	rs16965120	ENSG00000205771.5	CATSPER2P1	-4.3	3.36e-05	0.0199	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43808144	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs3825783	ENSG00000205771.5	CATSPER2P1	-4.3	3.36e-05	0.0199	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43810111	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs3736180	ENSG00000205771.5	CATSPER2P1	-4.3	3.36e-05	0.0199	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43814426	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs28684672	ENSG00000205771.5	CATSPER2P1	-4.3	3.36e-05	0.0199	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43815464	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs12440573	ENSG00000205771.5	CATSPER2P1	-4.3	3.36e-05	0.0199	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43816799	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs28590651	ENSG00000205771.5	CATSPER2P1	-4.3	3.36e-05	0.0199	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43820818	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs3816792	ENSG00000205771.5	CATSPER2P1	4.3	3.36e-05	0.0199	0.61	0.36	Lung cancer in ever smokers;	chr15:43824788	chr15:43726918~43747094:-
TGCT	cis	rs10971721	0.749	rs72725371	ENSG00000230074.1	RP11-195F19.9	-4.3	3.36e-05	0.0199	-0.54	-0.36	Body mass index;	chr9:33825013	chr9:34665665~34681298:+
TGCT	cis	rs1707322	0.685	rs11211177	ENSG00000280836.1	AL355480.1	-4.3	3.36e-05	0.0199	-0.46	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45581219~45581321:-
TGCT	cis	rs67311347	1	rs1466237	ENSG00000223797.4	ENTPD3-AS1	4.3	3.37e-05	0.02	0.37	0.36	Renal cell carcinoma;	chr3:40420535	chr3:40313802~40453329:-
TGCT	cis	rs7829975	0.606	rs6422352	ENSG00000254340.1	RP11-10A14.3	-4.3	3.37e-05	0.02	-0.36	-0.36	Mood instability;	chr8:8936683	chr8:9141424~9145435:+
TGCT	cis	rs7829975	0.606	rs891570	ENSG00000254340.1	RP11-10A14.3	-4.3	3.37e-05	0.02	-0.36	-0.36	Mood instability;	chr8:8936944	chr8:9141424~9145435:+
TGCT	cis	rs2919917	1	rs1466526	ENSG00000254352.1	RP11-578O24.2	-4.3	3.37e-05	0.02	-0.42	-0.36	Lymphocyte counts;	chr8:78643239	chr8:78723796~78724136:-
TGCT	cis	rs13118159	0.55	rs2336081	ENSG00000254094.1	AC078852.1	4.3	3.37e-05	0.02	0.42	0.36	Longevity;	chr4:1356534	chr4:1356581~1358075:+
TGCT	cis	rs4811196	1	rs4811148	ENSG00000277829.1	RP5-1054A22.4	-4.3	3.37e-05	0.02	-0.43	-0.36	Bone mineral density;	chr20:37815339	chr20:38233251~38233799:-
TGCT	cis	rs1010254	0.51	rs72791425	ENSG00000213433.5	RPLP1P6	-4.3	3.37e-05	0.02	-0.46	-0.36	Optic nerve measurement (cup area);	chr5:152391085	chr5:151765859~151766378:-
TGCT	cis	rs992157	0.798	rs7557709	ENSG00000261338.2	RP11-378A13.1	4.3	3.37e-05	0.02	0.31	0.36	Colorectal cancer;	chr2:218302806	chr2:218255319~218257366:+
TGCT	cis	rs520525	0.963	rs627848	ENSG00000271811.1	RP1-79C4.4	4.3	3.37e-05	0.02	0.29	0.36	Atrial fibrillation;	chr1:170662279	chr1:170667381~170669425:+
TGCT	cis	rs7829975	0.742	rs1533058	ENSG00000173295.6	FAM86B3P	4.3	3.37e-05	0.02	0.42	0.36	Mood instability;	chr8:8827680	chr8:8228595~8244865:+
TGCT	cis	rs7829975	0.806	rs2428	ENSG00000173295.6	FAM86B3P	4.3	3.38e-05	0.02	0.45	0.36	Mood instability;	chr8:8783635	chr8:8228595~8244865:+
TGCT	cis	rs9959491	0.518	rs4800825	ENSG00000227279.1	AC015933.2	4.3	3.38e-05	0.02	0.39	0.36	Breast cancer;	chr18:27812252	chr18:27954519~27963687:+
TGCT	cis	rs9959491	0.517	rs4337378	ENSG00000227279.1	AC015933.2	4.3	3.38e-05	0.02	0.39	0.36	Breast cancer;	chr18:27813353	chr18:27954519~27963687:+
TGCT	cis	rs2665103	0.61	rs56398167	ENSG00000255769.6	GOLGA2P10	-4.3	3.38e-05	0.02	-0.35	-0.36	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82472993~82513950:-
TGCT	cis	rs10246939	0.519	rs12534927	ENSG00000228775.6	WEE2-AS1	4.3	3.38e-05	0.02	0.32	0.36	Bitter taste perception;	chr7:141873255	chr7:141704338~141738346:-
TGCT	cis	rs10246939	0.544	rs12668089	ENSG00000228775.6	WEE2-AS1	4.3	3.38e-05	0.02	0.32	0.36	Bitter taste perception;	chr7:141875111	chr7:141704338~141738346:-
TGCT	cis	rs10246939	0.544	rs12668693	ENSG00000228775.6	WEE2-AS1	4.3	3.38e-05	0.02	0.32	0.36	Bitter taste perception;	chr7:141876000	chr7:141704338~141738346:-
TGCT	cis	rs10246939	0.519	rs2082551	ENSG00000228775.6	WEE2-AS1	4.3	3.38e-05	0.02	0.32	0.36	Bitter taste perception;	chr7:141877386	chr7:141704338~141738346:-
TGCT	cis	rs10246939	0.544	rs13235900	ENSG00000228775.6	WEE2-AS1	4.3	3.38e-05	0.02	0.32	0.36	Bitter taste perception;	chr7:141884384	chr7:141704338~141738346:-
TGCT	cis	rs10246939	0.544	rs1980369	ENSG00000228775.6	WEE2-AS1	4.3	3.38e-05	0.02	0.32	0.36	Bitter taste perception;	chr7:141885366	chr7:141704338~141738346:-
TGCT	cis	rs801193	1	rs2659915	ENSG00000236529.1	RP13-254B10.1	4.3	3.38e-05	0.02	0.26	0.36	Aortic root size;	chr7:66688114	chr7:65840212~65840596:+
TGCT	cis	rs4380275	0.782	rs4854369	ENSG00000272342.1	RP13-539J13.1	4.3	3.38e-05	0.02	0.45	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:752530	chr2:739588~740164:-
TGCT	cis	rs2742234	0.614	rs3026750	ENSG00000273008.1	RP11-351D16.3	-4.3	3.38e-05	0.02	-0.4	-0.36	Hirschsprung disease;	chr10:43112308	chr10:43136824~43138334:-
TGCT	cis	rs16852403	0.517	rs1319918	ENSG00000224687.1	RASAL2-AS1	4.3	3.38e-05	0.02	0.48	0.36	Childhood ear infection;	chr1:178274389	chr1:178091508~178093984:-
TGCT	cis	rs1707322	0.752	rs28550303	ENSG00000280836.1	AL355480.1	-4.3	3.38e-05	0.02	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.716	rs28375469	ENSG00000280836.1	AL355480.1	-4.3	3.38e-05	0.02	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.752	rs28545085	ENSG00000280836.1	AL355480.1	-4.3	3.38e-05	0.02	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.752	rs28507722	ENSG00000280836.1	AL355480.1	-4.3	3.38e-05	0.02	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.717	rs28396194	ENSG00000280836.1	AL355480.1	-4.3	3.38e-05	0.02	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.717	rs28752166	ENSG00000280836.1	AL355480.1	-4.3	3.38e-05	0.02	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45581219~45581321:-
TGCT	cis	rs7005380	0.733	rs2037346	ENSG00000254343.2	RP11-760H22.2	4.3	3.39e-05	0.0201	0.45	0.36	Interstitial lung disease;	chr8:119923212	chr8:120052180~120056201:+
TGCT	cis	rs10256972	0.713	rs10435026	ENSG00000226291.1	AC091729.8	-4.3	3.39e-05	0.0201	-0.38	-0.36	Endometriosis;Longevity;	chr7:1026312	chr7:1080863~1082178:+
TGCT	cis	rs2242073	0.733	rs62194804	ENSG00000232799.1	CRYGFP	-4.3	3.39e-05	0.0201	-0.55	-0.36	Attention deficit hyperactivity disorder;	chr2:208162056	chr2:209145241~209147687:+
TGCT	cis	rs5758511	0.68	rs5758651	ENSG00000182057.4	OGFRP1	-4.3	3.39e-05	0.0201	-0.35	-0.36	Birth weight;	chr22:42213142	chr22:42269753~42275196:+
TGCT	cis	rs5758511	0.68	rs5758652	ENSG00000182057.4	OGFRP1	-4.3	3.39e-05	0.0201	-0.35	-0.36	Birth weight;	chr22:42216402	chr22:42269753~42275196:+
TGCT	cis	rs5758511	0.68	rs1033459	ENSG00000182057.4	OGFRP1	-4.3	3.39e-05	0.0201	-0.35	-0.36	Birth weight;	chr22:42223061	chr22:42269753~42275196:+
TGCT	cis	rs5758511	0.68	rs1033460	ENSG00000182057.4	OGFRP1	-4.3	3.39e-05	0.0201	-0.35	-0.36	Birth weight;	chr22:42223302	chr22:42269753~42275196:+
TGCT	cis	rs5758511	0.679	rs55867855	ENSG00000182057.4	OGFRP1	-4.3	3.39e-05	0.0201	-0.35	-0.36	Birth weight;	chr22:42227252	chr22:42269753~42275196:+
TGCT	cis	rs5758511	0.68	rs17002902	ENSG00000182057.4	OGFRP1	-4.3	3.39e-05	0.0201	-0.35	-0.36	Birth weight;	chr22:42229503	chr22:42269753~42275196:+
TGCT	cis	rs5758511	0.68	rs5758662	ENSG00000182057.4	OGFRP1	-4.3	3.39e-05	0.0201	-0.35	-0.36	Birth weight;	chr22:42232082	chr22:42269753~42275196:+
TGCT	cis	rs5758511	0.68	rs5758667	ENSG00000182057.4	OGFRP1	-4.3	3.39e-05	0.0201	-0.35	-0.36	Birth weight;	chr22:42237198	chr22:42269753~42275196:+
TGCT	cis	rs9425766	0.631	rs10158289	ENSG00000227373.4	RP11-160H22.5	4.3	3.4e-05	0.0201	0.4	0.36	Life satisfaction;	chr1:174081529	chr1:174115300~174160004:-
TGCT	cis	rs7786765	0.511	rs3802052	ENSG00000234695.1	AC002076.10	4.3	3.4e-05	0.0201	0.42	0.36	Body mass index;	chr7:93462173	chr7:93890913~93893601:+
TGCT	cis	rs2439831	0.85	rs10438303	ENSG00000205771.5	CATSPER2P1	-4.3	3.41e-05	0.0201	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43724219	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs12441127	ENSG00000205771.5	CATSPER2P1	-4.3	3.41e-05	0.0201	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43728977	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.702	rs7171750	ENSG00000205771.5	CATSPER2P1	-4.3	3.41e-05	0.0201	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43733660	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs11070408	ENSG00000205771.5	CATSPER2P1	-4.3	3.41e-05	0.0201	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43742590	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs16950562	ENSG00000205771.5	CATSPER2P1	-4.3	3.41e-05	0.0201	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43744166	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs28718261	ENSG00000205771.5	CATSPER2P1	-4.3	3.41e-05	0.0201	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43751595	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs28595038	ENSG00000205771.5	CATSPER2P1	-4.3	3.41e-05	0.0201	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43752661	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs10163054	ENSG00000205771.5	CATSPER2P1	-4.3	3.41e-05	0.0201	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43755440	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs7168158	ENSG00000205771.5	CATSPER2P1	-4.3	3.41e-05	0.0201	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43758178	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs7174208	ENSG00000205771.5	CATSPER2P1	-4.3	3.41e-05	0.0201	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43760484	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs12101756	ENSG00000205771.5	CATSPER2P1	-4.3	3.41e-05	0.0201	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43761689	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs12442129	ENSG00000205771.5	CATSPER2P1	-4.3	3.41e-05	0.0201	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43763658	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.702	rs7175032	ENSG00000205771.5	CATSPER2P1	-4.3	3.41e-05	0.0201	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43768038	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs12441861	ENSG00000205771.5	CATSPER2P1	-4.3	3.41e-05	0.0201	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43768685	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs3862142	ENSG00000205771.5	CATSPER2P1	-4.3	3.41e-05	0.0201	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43772608	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.702	rs2788	ENSG00000205771.5	CATSPER2P1	-4.3	3.41e-05	0.0201	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43772688	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs28891769	ENSG00000205771.5	CATSPER2P1	-4.3	3.41e-05	0.0201	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43780662	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs28578398	ENSG00000205771.5	CATSPER2P1	-4.3	3.41e-05	0.0201	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43782848	chr15:43726918~43747094:-
TGCT	cis	rs904251	0.772	rs756202	ENSG00000279942.1	RP1-153P14.7	-4.3	3.41e-05	0.0201	-0.44	-0.36	Cognitive performance;	chr6:37492574	chr6:37567716~37571460:+
TGCT	cis	rs7824557	0.564	rs34964435	ENSG00000255310.2	AF131215.2	-4.3	3.41e-05	0.0202	-0.29	-0.36	Retinal vascular caliber;	chr8:11372697	chr8:11107788~11109726:-
TGCT	cis	rs10170266	0.875	rs818015	ENSG00000279220.1	GPR1-AS	4.3	3.41e-05	0.0202	0.29	0.36	Reticulocyte fraction of red cells;	chr2:206038792	chr2:206203376~206266243:+
TGCT	cis	rs10170266	0.875	rs2616352	ENSG00000279220.1	GPR1-AS	4.3	3.41e-05	0.0202	0.29	0.36	Reticulocyte fraction of red cells;	chr2:206044265	chr2:206203376~206266243:+
TGCT	cis	rs10170266	0.875	rs818007	ENSG00000279220.1	GPR1-AS	4.3	3.41e-05	0.0202	0.29	0.36	Reticulocyte fraction of red cells;	chr2:206053380	chr2:206203376~206266243:+
TGCT	cis	rs10170266	0.841	rs10211492	ENSG00000279220.1	GPR1-AS	-4.3	3.41e-05	0.0202	-0.29	-0.36	Reticulocyte fraction of red cells;	chr2:206066154	chr2:206203376~206266243:+
TGCT	cis	rs10170266	0.875	rs10932144	ENSG00000279220.1	GPR1-AS	-4.3	3.41e-05	0.0202	-0.29	-0.36	Reticulocyte fraction of red cells;	chr2:206067716	chr2:206203376~206266243:+
TGCT	cis	rs507080	0.961	rs642530	ENSG00000255239.1	AP002954.6	4.3	3.41e-05	0.0202	0.44	0.36	Serum metabolite levels;	chr11:118680047	chr11:118688039~118690600:-
TGCT	cis	rs524281	0.506	rs512421	ENSG00000255320.1	RP11-755F10.1	4.3	3.41e-05	0.0202	0.44	0.36	Electroencephalogram traits;	chr11:66217697	chr11:66244840~66246239:-
TGCT	cis	rs1823913	0.614	rs4853463	ENSG00000227542.1	AC092614.2	-4.3	3.42e-05	0.0202	-0.39	-0.36	Obesity-related traits;	chr2:191278699	chr2:191229165~191246172:-
TGCT	cis	rs7208859	0.623	rs3752019	ENSG00000280069.1	CTD-2349P21.3	-4.3	3.42e-05	0.0202	-0.45	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs73271869	ENSG00000280069.1	CTD-2349P21.3	-4.3	3.42e-05	0.0202	-0.45	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs73271872	ENSG00000280069.1	CTD-2349P21.3	-4.3	3.42e-05	0.0202	-0.45	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs55724095	ENSG00000280069.1	CTD-2349P21.3	-4.3	3.42e-05	0.0202	-0.45	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.673	rs56146117	ENSG00000280069.1	CTD-2349P21.3	-4.3	3.42e-05	0.0202	-0.45	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30738182~30740275:+
TGCT	cis	rs17826219	0.568	rs9903854	ENSG00000280069.1	CTD-2349P21.3	-4.3	3.42e-05	0.0202	-0.45	-0.36	Body mass index;	chr17:30826980	chr17:30738182~30740275:+
TGCT	cis	rs17826219	0.568	rs9907834	ENSG00000280069.1	CTD-2349P21.3	-4.3	3.42e-05	0.0202	-0.45	-0.36	Body mass index;	chr17:30826995	chr17:30738182~30740275:+
TGCT	cis	rs780096	0.778	rs780094	ENSG00000234072.1	AC074117.10	4.3	3.42e-05	0.0202	0.29	0.36	Total body bone mineral density;	chr2:27518370	chr2:27356246~27367622:+
TGCT	cis	rs1355223	0.583	rs2956074	ENSG00000271369.1	RP11-350D17.3	4.3	3.42e-05	0.0202	0.35	0.36	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34843333	chr11:34709600~34710161:+
TGCT	cis	rs1355223	0.583	rs2941044	ENSG00000271369.1	RP11-350D17.3	4.3	3.42e-05	0.0202	0.35	0.36	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34845897	chr11:34709600~34710161:+
TGCT	cis	rs2439831	0.85	rs7179388	ENSG00000205771.5	CATSPER2P1	-4.3	3.42e-05	0.0202	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43831747	chr15:43726918~43747094:-
TGCT	cis	rs17711722	0.522	rs4642526	ENSG00000226824.5	RP4-756H11.3	-4.3	3.43e-05	0.0202	-0.39	-0.36	Calcium levels;	chr7:65751755	chr7:66654538~66669855:+
TGCT	cis	rs10504229	0.679	rs111843870	ENSG00000253301.4	RP11-513O17.2	4.3	3.43e-05	0.0202	0.54	0.36	Developmental language disorder (linguistic errors);	chr8:57214239	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.724	rs72650827	ENSG00000253301.4	RP11-513O17.2	4.3	3.43e-05	0.0202	0.54	0.36	Developmental language disorder (linguistic errors);	chr8:57214325	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs6980540	ENSG00000253301.4	RP11-513O17.2	4.3	3.43e-05	0.0202	0.54	0.36	Developmental language disorder (linguistic errors);	chr8:57214463	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs6984765	ENSG00000253301.4	RP11-513O17.2	4.3	3.43e-05	0.0202	0.54	0.36	Developmental language disorder (linguistic errors);	chr8:57214565	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs6980850	ENSG00000253301.4	RP11-513O17.2	4.3	3.43e-05	0.0202	0.54	0.36	Developmental language disorder (linguistic errors);	chr8:57214645	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs6999351	ENSG00000253301.4	RP11-513O17.2	4.3	3.43e-05	0.0202	0.54	0.36	Developmental language disorder (linguistic errors);	chr8:57214668	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs66730544	ENSG00000253301.4	RP11-513O17.2	4.3	3.43e-05	0.0202	0.54	0.36	Developmental language disorder (linguistic errors);	chr8:57214721	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.61	rs6999661	ENSG00000253301.4	RP11-513O17.2	4.3	3.43e-05	0.0202	0.54	0.36	Developmental language disorder (linguistic errors);	chr8:57214832	chr8:57142689~57240298:+
TGCT	cis	rs7684253	0.548	rs922570	ENSG00000269949.1	RP11-738E22.3	-4.3	3.43e-05	0.0202	-0.34	-0.36	Migraine;	chr4:56851192	chr4:56960927~56961373:-
TGCT	cis	rs7684253	0.548	rs13108002	ENSG00000269949.1	RP11-738E22.3	-4.3	3.43e-05	0.0202	-0.34	-0.36	Migraine;	chr4:56852087	chr4:56960927~56961373:-
TGCT	cis	rs9952991	0.883	rs11663253	ENSG00000260302.1	RP11-973H7.1	4.3	3.43e-05	0.0202	0.56	0.36	Inflammatory skin disease;	chr18:12789557	chr18:12774651~12775923:-
TGCT	cis	rs5758511	0.68	rs1107554	ENSG00000182057.4	OGFRP1	-4.3	3.43e-05	0.0202	-0.34	-0.36	Birth weight;	chr22:42271588	chr22:42269753~42275196:+
TGCT	cis	rs10971721	0.584	rs56145814	ENSG00000230074.1	RP11-195F19.9	-4.3	3.43e-05	0.0203	-0.51	-0.36	Body mass index;	chr9:34088953	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.584	rs12375716	ENSG00000230074.1	RP11-195F19.9	-4.3	3.43e-05	0.0203	-0.51	-0.36	Body mass index;	chr9:34100034	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.584	rs12379730	ENSG00000230074.1	RP11-195F19.9	-4.3	3.43e-05	0.0203	-0.51	-0.36	Body mass index;	chr9:34100072	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.584	rs55672700	ENSG00000230074.1	RP11-195F19.9	-4.3	3.43e-05	0.0203	-0.51	-0.36	Body mass index;	chr9:34102723	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.584	rs1378	ENSG00000230074.1	RP11-195F19.9	-4.3	3.43e-05	0.0203	-0.51	-0.36	Body mass index;	chr9:34107506	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.584	rs72731212	ENSG00000230074.1	RP11-195F19.9	-4.3	3.43e-05	0.0203	-0.51	-0.36	Body mass index;	chr9:34109710	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.584	rs12376939	ENSG00000230074.1	RP11-195F19.9	-4.3	3.43e-05	0.0203	-0.51	-0.36	Body mass index;	chr9:34110139	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.584	rs72731214	ENSG00000230074.1	RP11-195F19.9	-4.3	3.43e-05	0.0203	-0.51	-0.36	Body mass index;	chr9:34113019	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.584	rs117997985	ENSG00000230074.1	RP11-195F19.9	-4.3	3.43e-05	0.0203	-0.51	-0.36	Body mass index;	chr9:34113176	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.584	rs72731216	ENSG00000230074.1	RP11-195F19.9	-4.3	3.43e-05	0.0203	-0.51	-0.36	Body mass index;	chr9:34115066	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.584	rs10971933	ENSG00000230074.1	RP11-195F19.9	-4.3	3.43e-05	0.0203	-0.51	-0.36	Body mass index;	chr9:34117073	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.584	rs10971935	ENSG00000230074.1	RP11-195F19.9	-4.3	3.43e-05	0.0203	-0.51	-0.36	Body mass index;	chr9:34118147	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.584	rs10971936	ENSG00000230074.1	RP11-195F19.9	-4.3	3.43e-05	0.0203	-0.51	-0.36	Body mass index;	chr9:34118988	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.584	rs72731217	ENSG00000230074.1	RP11-195F19.9	-4.3	3.43e-05	0.0203	-0.51	-0.36	Body mass index;	chr9:34119555	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.584	rs72731218	ENSG00000230074.1	RP11-195F19.9	-4.3	3.43e-05	0.0203	-0.51	-0.36	Body mass index;	chr9:34119678	chr9:34665665~34681298:+
TGCT	cis	rs34779708	0.832	rs12764283	ENSG00000230534.5	RP11-297A16.2	4.3	3.44e-05	0.0203	0.45	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35241532	chr10:35098006~35127020:-
TGCT	cis	rs4660214	0.666	rs2275187	ENSG00000182109.6	RP11-69E11.4	-4.3	3.44e-05	0.0203	-0.36	-0.36	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39297570	chr1:39522280~39546187:-
TGCT	cis	rs6782228	0.675	rs4443194	ENSG00000242551.2	POU5F1P6	-4.3	3.44e-05	0.0203	-0.44	-0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664603	chr3:128674735~128677005:-
TGCT	cis	rs16928809	0.929	rs450244	ENSG00000183562.3	CTC-343N3.1	-4.3	3.44e-05	0.0203	-0.5	-0.36	Bilirubin levels;	chr11:2919262	chr11:2989863~2991344:+
TGCT	cis	rs4927850	0.723	rs7630825	ENSG00000242086.7	LINC00969	4.3	3.45e-05	0.0203	0.41	0.36	Pancreatic cancer;	chr3:196026869	chr3:195658062~195739964:+
TGCT	cis	rs801193	0.875	rs13227951	ENSG00000237310.1	GS1-124K5.4	-4.3	3.45e-05	0.0203	-0.4	-0.36	Aortic root size;	chr7:66748121	chr7:66493706~66495474:+
TGCT	cis	rs4238585	0.947	rs12598578	ENSG00000261195.1	CTD-2380F24.1	-4.3	3.45e-05	0.0203	-0.55	-0.36	Body mass index;	chr16:20243154	chr16:19761172~19766099:-
TGCT	cis	rs4238585	0.947	rs13339519	ENSG00000261195.1	CTD-2380F24.1	-4.3	3.45e-05	0.0203	-0.55	-0.36	Body mass index;	chr16:20245570	chr16:19761172~19766099:-
TGCT	cis	rs10875976	0.905	rs55758326	ENSG00000257253.2	RP11-70F11.7	4.3	3.45e-05	0.0203	0.29	0.36	Obesity;	chr12:49823448	chr12:49861207~49865802:+
TGCT	cis	rs901683	1	rs17157919	ENSG00000264204.2	AGAP7P	4.3	3.45e-05	0.0203	0.76	0.36	Mean corpuscular volume;Red blood cell traits;	chr10:45548644	chr10:46109621~46131358:+
TGCT	cis	rs7246967	0.608	rs2569728	ENSG00000269509.1	BNIP3P34	4.3	3.46e-05	0.0204	0.48	0.36	Bronchopulmonary dysplasia;	chr19:22831202	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.608	rs453175	ENSG00000269509.1	BNIP3P34	4.3	3.46e-05	0.0204	0.48	0.36	Bronchopulmonary dysplasia;	chr19:22831285	chr19:22773853~22774424:+
TGCT	cis	rs7208859	0.673	rs216410	ENSG00000280069.1	CTD-2349P21.3	4.3	3.46e-05	0.0204	0.51	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576813	chr17:30738182~30740275:+
TGCT	cis	rs4835473	0.897	rs2089835	ENSG00000251600.4	RP11-673E1.1	4.3	3.46e-05	0.0204	0.38	0.36	Immature fraction of reticulocytes;	chr4:143965127	chr4:143912331~143982454:+
TGCT	cis	rs1707322	0.752	rs12062535	ENSG00000280836.1	AL355480.1	-4.3	3.46e-05	0.0204	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45581219~45581321:-
TGCT	cis	rs453301	0.653	rs1562211	ENSG00000254340.1	RP11-10A14.3	-4.3	3.47e-05	0.0204	-0.36	-0.36	Joint mobility (Beighton score);	chr8:9044914	chr8:9141424~9145435:+
TGCT	cis	rs1707322	0.785	rs10890348	ENSG00000280836.1	AL355480.1	-4.3	3.47e-05	0.0204	-0.48	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr1:45581219~45581321:-
TGCT	cis	rs3096299	0.802	rs3102336	ENSG00000274627.1	RP11-104N10.2	4.3	3.47e-05	0.0204	0.38	0.36	Multiple myeloma (IgH translocation);	chr16:89375598	chr16:89516797~89522217:+
TGCT	cis	rs10019835	0.947	rs17033385	ENSG00000260244.1	RP11-588K22.2	4.3	3.47e-05	0.0204	0.29	0.36	Diabetic kidney disease;	chr4:155712118	chr4:155734448~155737062:+
TGCT	cis	rs8081395	0.836	rs2063353	ENSG00000266992.1	DHX40P1	-4.3	3.47e-05	0.0204	-0.38	-0.36	White blood cell count;	chr17:59811831	chr17:59976009~60002384:-
TGCT	cis	rs875971	1	rs55962648	ENSG00000237310.1	GS1-124K5.4	-4.3	3.47e-05	0.0204	-0.4	-0.36	Aortic root size;	chr7:66160764	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs11971949	ENSG00000237310.1	GS1-124K5.4	-4.3	3.47e-05	0.0204	-0.4	-0.36	Aortic root size;	chr7:66161027	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs2420168	ENSG00000237310.1	GS1-124K5.4	-4.3	3.47e-05	0.0204	-0.4	-0.36	Aortic root size;	chr7:66165644	chr7:66493706~66495474:+
TGCT	cis	rs9844666	0.512	rs9813082	ENSG00000239213.4	NCK1-AS1	4.3	3.48e-05	0.0205	0.35	0.36	Height;	chr3:135918615	chr3:136841726~136862054:-
TGCT	cis	rs1061377	1	rs1061377	ENSG00000249685.1	RP11-360F5.3	4.3	3.48e-05	0.0205	0.34	0.36	Uric acid levels;	chr4:39123130	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs1982009	ENSG00000249685.1	RP11-360F5.3	4.3	3.48e-05	0.0205	0.34	0.36	Uric acid levels;	chr4:39123253	chr4:39133913~39135608:+
TGCT	cis	rs1061377	0.965	rs1138494	ENSG00000249685.1	RP11-360F5.3	4.3	3.48e-05	0.0205	0.34	0.36	Uric acid levels;	chr4:39123315	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs13109200	ENSG00000249685.1	RP11-360F5.3	4.3	3.48e-05	0.0205	0.34	0.36	Uric acid levels;	chr4:39124396	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs2890659	ENSG00000249685.1	RP11-360F5.3	4.3	3.48e-05	0.0205	0.34	0.36	Uric acid levels;	chr4:39125401	chr4:39133913~39135608:+
TGCT	cis	rs1061377	0.965	rs1046655	ENSG00000249685.1	RP11-360F5.3	4.3	3.48e-05	0.0205	0.34	0.36	Uric acid levels;	chr4:39126127	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs7694760	ENSG00000249685.1	RP11-360F5.3	4.3	3.48e-05	0.0205	0.34	0.36	Uric acid levels;	chr4:39126481	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs35116118	ENSG00000249685.1	RP11-360F5.3	4.3	3.48e-05	0.0205	0.34	0.36	Uric acid levels;	chr4:39127293	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs34771104	ENSG00000249685.1	RP11-360F5.3	4.3	3.48e-05	0.0205	0.34	0.36	Uric acid levels;	chr4:39127432	chr4:39133913~39135608:+
TGCT	cis	rs1061377	0.932	rs35464499	ENSG00000249685.1	RP11-360F5.3	4.3	3.48e-05	0.0205	0.34	0.36	Uric acid levels;	chr4:39127670	chr4:39133913~39135608:+
TGCT	cis	rs1061377	0.965	rs11728058	ENSG00000249685.1	RP11-360F5.3	4.3	3.48e-05	0.0205	0.34	0.36	Uric acid levels;	chr4:39128224	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs13144374	ENSG00000249685.1	RP11-360F5.3	4.3	3.48e-05	0.0205	0.34	0.36	Uric acid levels;	chr4:39128859	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs17508864	ENSG00000249685.1	RP11-360F5.3	4.3	3.48e-05	0.0205	0.34	0.36	Uric acid levels;	chr4:39129025	chr4:39133913~39135608:+
TGCT	cis	rs1519814	0.696	rs4871031	ENSG00000254343.2	RP11-760H22.2	-4.3	3.48e-05	0.0205	-0.59	-0.36	Breast cancer;	chr8:120019538	chr8:120052180~120056201:+
TGCT	cis	rs867371	0.502	rs8025964	ENSG00000255769.6	GOLGA2P10	-4.3	3.48e-05	0.0205	-0.36	-0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82472993~82513950:-
TGCT	cis	rs5758511	0.68	rs5751243	ENSG00000182057.4	OGFRP1	-4.3	3.48e-05	0.0205	-0.35	-0.36	Birth weight;	chr22:42221171	chr22:42269753~42275196:+
TGCT	cis	rs5758511	0.637	rs5751244	ENSG00000182057.4	OGFRP1	-4.3	3.48e-05	0.0205	-0.35	-0.36	Birth weight;	chr22:42221405	chr22:42269753~42275196:+
TGCT	cis	rs367615	0.552	rs2115511	ENSG00000249476.1	CTD-2587M2.1	-4.3	3.49e-05	0.0205	-0.37	-0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109389702	chr5:109237120~109326369:-
TGCT	cis	rs367615	0.552	rs2963025	ENSG00000249476.1	CTD-2587M2.1	-4.3	3.49e-05	0.0205	-0.37	-0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109397555	chr5:109237120~109326369:-
TGCT	cis	rs367615	0.552	rs2416210	ENSG00000249476.1	CTD-2587M2.1	-4.3	3.49e-05	0.0205	-0.37	-0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109405436	chr5:109237120~109326369:-
TGCT	cis	rs12230172	0.809	rs11180710	ENSG00000271142.1	YWHAQP7	4.29	3.49e-05	0.0205	0.37	0.36	Glioma;Non-glioblastoma glioma;	chr12:75844626	chr12:76619386~76620043:+
TGCT	cis	rs11662586	0.517	rs11663082	ENSG00000261126.6	RP11-795F19.1	4.29	3.49e-05	0.0205	0.32	0.36	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr18:79953494	chr18:80046900~80095482:+
TGCT	cis	rs11662586	0.517	rs11662894	ENSG00000261126.6	RP11-795F19.1	4.29	3.49e-05	0.0205	0.32	0.36	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr18:79953591	chr18:80046900~80095482:+
TGCT	cis	rs2976388	1	rs1045574	ENSG00000253196.1	RP11-706C16.7	-4.29	3.5e-05	0.0206	-0.38	-0.36	Urinary tract infection frequency;	chr8:142682540	chr8:142763116~142766427:+
TGCT	cis	rs7181230	0.885	rs8026641	ENSG00000275636.1	RP11-521C20.5	-4.29	3.5e-05	0.0206	-0.45	-0.36	Dehydroepiandrosterone sulphate levels;	chr15:40046660	chr15:40078892~40079347:+
TGCT	cis	rs11231017	1	rs11602307	ENSG00000254454.2	RCC2P6	-4.29	3.5e-05	0.0206	-0.28	-0.36	HIV-1 viral setpoint;	chr11:62293074	chr11:62371146~62373168:+
TGCT	cis	rs786425	0.677	rs11834141	ENSG00000247373.3	RP11-486O12.2	4.29	3.5e-05	0.0206	0.45	0.36	Pubertal anthropometrics;	chr12:123666149	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.59	rs7296804	ENSG00000247373.3	RP11-486O12.2	4.29	3.5e-05	0.0206	0.45	0.36	Pubertal anthropometrics;	chr12:123669316	chr12:123575891~123585115:-
TGCT	cis	rs7208859	0.573	rs73267829	ENSG00000280069.1	CTD-2349P21.3	-4.29	3.5e-05	0.0206	-0.51	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30738182~30740275:+
TGCT	cis	rs7824557	0.564	rs13268126	ENSG00000255310.2	AF131215.2	-4.29	3.5e-05	0.0206	-0.29	-0.36	Retinal vascular caliber;	chr8:11373065	chr8:11107788~11109726:-
TGCT	cis	rs2980436	1	rs2980436	ENSG00000253893.2	FAM85B	4.29	3.5e-05	0.0206	0.46	0.36	Schizophrenia;	chr8:8234503	chr8:8167819~8226614:-
TGCT	cis	rs9880211	0.948	rs17298525	ENSG00000239213.4	NCK1-AS1	4.29	3.5e-05	0.0206	0.38	0.36	Height;Body mass index;	chr3:136474183	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs67949818	ENSG00000239213.4	NCK1-AS1	4.29	3.5e-05	0.0206	0.38	0.36	Height;Body mass index;	chr3:136494136	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.948	rs9813691	ENSG00000239213.4	NCK1-AS1	4.29	3.5e-05	0.0206	0.38	0.36	Height;Body mass index;	chr3:136541880	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs9883189	ENSG00000239213.4	NCK1-AS1	4.29	3.5e-05	0.0206	0.38	0.36	Height;Body mass index;	chr3:136570624	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.898	rs28877020	ENSG00000239213.4	NCK1-AS1	4.29	3.5e-05	0.0206	0.38	0.36	Height;Body mass index;	chr3:136676874	chr3:136841726~136862054:-
TGCT	cis	rs1355223	0.583	rs2915178	ENSG00000271369.1	RP11-350D17.3	4.29	3.51e-05	0.0206	0.36	0.36	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34856504	chr11:34709600~34710161:+
TGCT	cis	rs7831492	0.548	rs10958699	ENSG00000253943.1	KRT18P37	4.29	3.51e-05	0.0206	0.39	0.36	Colorectal cancer;	chr8:41790840	chr8:41511240~41512521:+
TGCT	cis	rs3779195	0.929	rs10953259	ENSG00000272950.1	RP11-307C18.1	-4.29	3.51e-05	0.0206	-0.43	-0.36	Sex hormone-binding globulin levels;	chr7:98383795	chr7:98322853~98323430:+
TGCT	cis	rs801193	1	rs2659909	ENSG00000272831.1	RP11-792A8.4	4.29	3.51e-05	0.0206	0.38	0.36	Aortic root size;	chr7:66695292	chr7:66739829~66740385:-
TGCT	cis	rs1075265	0.633	rs7591431	ENSG00000233266.1	HMGB1P31	4.29	3.52e-05	0.0206	0.4	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53995028	chr2:54051334~54051760:+
TGCT	cis	rs9309473	0.948	rs6719753	ENSG00000163016.8	ALMS1P	4.29	3.52e-05	0.0207	0.32	0.36	Metabolite levels;	chr2:73521927	chr2:73644919~73685576:+
TGCT	cis	rs1707322	1	rs6672115	ENSG00000280836.1	AL355480.1	-4.29	3.52e-05	0.0207	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs12097761	ENSG00000280836.1	AL355480.1	-4.29	3.52e-05	0.0207	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs4606257	ENSG00000280836.1	AL355480.1	-4.29	3.52e-05	0.0207	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.963	rs6429581	ENSG00000280836.1	AL355480.1	-4.29	3.52e-05	0.0207	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.963	rs10789478	ENSG00000280836.1	AL355480.1	-4.29	3.52e-05	0.0207	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs10789479	ENSG00000280836.1	AL355480.1	-4.29	3.52e-05	0.0207	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr1:45581219~45581321:-
TGCT	cis	rs9326248	1	rs7107152	ENSG00000280143.1	AP000892.6	-4.29	3.52e-05	0.0207	-0.44	-0.36	Blood protein levels;	chr11:117185364	chr11:117204967~117210292:+
TGCT	cis	rs75422866	0.867	rs73104112	ENSG00000257433.4	RP1-197B17.3	4.29	3.52e-05	0.0207	0.64	0.36	Pneumonia;	chr12:47680969	chr12:47706085~47742294:+
TGCT	cis	rs755249	0.588	rs2275767	ENSG00000182109.6	RP11-69E11.4	-4.29	3.52e-05	0.0207	-0.36	-0.36	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479625	chr1:39522280~39546187:-
TGCT	cis	rs12554020	0.786	rs6479495	ENSG00000227603.1	RP11-165J3.6	4.29	3.53e-05	0.0207	0.6	0.36	Schizophrenia;	chr9:93572320	chr9:93435332~93437121:-
TGCT	cis	rs10759883	0.627	rs10739622	ENSG00000175611.10	LINC00476	4.29	3.53e-05	0.0207	0.34	0.36	Nicotine dependence;	chr9:95852889	chr9:95759231~95875977:-
TGCT	cis	rs10759883	0.627	rs10760269	ENSG00000175611.10	LINC00476	4.29	3.53e-05	0.0207	0.34	0.36	Nicotine dependence;	chr9:95852897	chr9:95759231~95875977:-
TGCT	cis	rs10256972	0.758	rs2280724	ENSG00000226291.1	AC091729.8	-4.29	3.53e-05	0.0207	-0.37	-0.36	Endometriosis;Longevity;	chr7:1025084	chr7:1080863~1082178:+
TGCT	cis	rs453301	0.522	rs2929309	ENSG00000254340.1	RP11-10A14.3	-4.29	3.53e-05	0.0207	-0.34	-0.36	Joint mobility (Beighton score);	chr8:9226261	chr8:9141424~9145435:+
TGCT	cis	rs10170266	0.875	rs2909111	ENSG00000279220.1	GPR1-AS	4.29	3.53e-05	0.0207	0.29	0.36	Reticulocyte fraction of red cells;	chr2:206046504	chr2:206203376~206266243:+
TGCT	cis	rs12682352	0.715	rs332039	ENSG00000254340.1	RP11-10A14.3	4.29	3.54e-05	0.0207	0.36	0.36	Neuroticism;	chr8:8866141	chr8:9141424~9145435:+
TGCT	cis	rs2742234	0.955	rs2075910	ENSG00000273008.1	RP11-351D16.3	-4.29	3.54e-05	0.0208	-0.4	-0.36	Hirschsprung disease;	chr10:43118782	chr10:43136824~43138334:-
TGCT	cis	rs7208859	0.524	rs8065744	ENSG00000280069.1	CTD-2349P21.3	-4.29	3.54e-05	0.0208	-0.51	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30738182~30740275:+
TGCT	cis	rs17826219	0.706	rs8071236	ENSG00000280069.1	CTD-2349P21.3	-4.29	3.54e-05	0.0208	-0.51	-0.36	Body mass index;	chr17:30772984	chr17:30738182~30740275:+
TGCT	cis	rs17826219	0.636	rs2449770	ENSG00000280069.1	CTD-2349P21.3	-4.29	3.54e-05	0.0208	-0.51	-0.36	Body mass index;	chr17:30774046	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.524	rs59913838	ENSG00000280069.1	CTD-2349P21.3	-4.29	3.54e-05	0.0208	-0.51	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs56163556	ENSG00000280069.1	CTD-2349P21.3	-4.29	3.54e-05	0.0208	-0.51	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs8067035	ENSG00000280069.1	CTD-2349P21.3	-4.29	3.54e-05	0.0208	-0.51	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs8067338	ENSG00000280069.1	CTD-2349P21.3	-4.29	3.54e-05	0.0208	-0.51	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.573	rs4055105	ENSG00000280069.1	CTD-2349P21.3	-4.29	3.54e-05	0.0208	-0.51	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30738182~30740275:+
TGCT	cis	rs748404	0.697	rs493444	ENSG00000205771.5	CATSPER2P1	-4.29	3.55e-05	0.0208	-0.41	-0.36	Lung cancer;	chr15:43274272	chr15:43726918~43747094:-
TGCT	cis	rs728616	0.867	rs61858980	ENSG00000230091.5	TMEM254-AS1	4.29	3.56e-05	0.0208	0.65	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80056862	chr10:80046860~80078912:-
TGCT	cis	rs12143943	0.934	rs12027855	ENSG00000176754.11	LINC00303	4.29	3.56e-05	0.0208	0.33	0.36	Cognitive performance;	chr1:204626416	chr1:204032447~204041265:-
TGCT	cis	rs17507216	0.56	rs2871011	ENSG00000278603.1	RP13-608F4.5	4.29	3.56e-05	0.0209	0.47	0.36	Excessive daytime sleepiness;	chr15:82560792	chr15:82472203~82472426:+
TGCT	cis	rs7927592	0.513	rs608343	ENSG00000212093.1	AP000807.1	4.29	3.57e-05	0.0209	0.35	0.36	Total body bone mineral density;	chr11:68429362	chr11:68506083~68506166:-
TGCT	cis	rs7927592	0.513	rs607887	ENSG00000212093.1	AP000807.1	4.29	3.57e-05	0.0209	0.35	0.36	Total body bone mineral density;	chr11:68429493	chr11:68506083~68506166:-
TGCT	cis	rs853679	0.55	rs1237875	ENSG00000187763.3	OR2B7P	-4.29	3.57e-05	0.0209	-0.36	-0.36	Depression;	chr6:28205232	chr6:28046434~28047367:+
TGCT	cis	rs891378	0.785	rs55957981	ENSG00000274245.1	RP11-357P18.2	-4.29	3.57e-05	0.0209	-0.44	-0.36	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207205594	chr1:207372559~207373252:+
TGCT	cis	rs891378	0.785	rs6540876	ENSG00000274245.1	RP11-357P18.2	-4.29	3.57e-05	0.0209	-0.44	-0.36	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207222873	chr1:207372559~207373252:+
TGCT	cis	rs728616	0.867	rs2152550	ENSG00000230091.5	TMEM254-AS1	4.29	3.57e-05	0.0209	0.65	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80058753	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs56271768	ENSG00000230091.5	TMEM254-AS1	4.29	3.57e-05	0.0209	0.65	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80077295	chr10:80046860~80078912:-
TGCT	cis	rs7829975	0.606	rs6601274	ENSG00000173295.6	FAM86B3P	-4.29	3.57e-05	0.0209	-0.44	-0.36	Mood instability;	chr8:8941549	chr8:8228595~8244865:+
TGCT	cis	rs11722228	0.549	rs73212828	ENSG00000261490.1	RP11-448G15.3	4.29	3.57e-05	0.0209	0.35	0.36	Urate levels;Serum uric acid levels;Gout;	chr4:10077132	chr4:10068089~10073019:-
TGCT	cis	rs11722228	0.549	rs73212830	ENSG00000261490.1	RP11-448G15.3	4.29	3.57e-05	0.0209	0.35	0.36	Urate levels;Serum uric acid levels;Gout;	chr4:10077135	chr4:10068089~10073019:-
TGCT	cis	rs7829975	0.606	rs6601274	ENSG00000254340.1	RP11-10A14.3	-4.29	3.57e-05	0.0209	-0.37	-0.36	Mood instability;	chr8:8941549	chr8:9141424~9145435:+
TGCT	cis	rs16975963	0.545	rs12461753	ENSG00000276846.1	CTD-3220F14.3	-4.29	3.58e-05	0.0209	-0.34	-0.36	Longevity;	chr19:37711614	chr19:37314868~37315620:-
TGCT	cis	rs801193	1	rs2659909	ENSG00000236529.1	RP13-254B10.1	4.29	3.58e-05	0.0209	0.27	0.36	Aortic root size;	chr7:66695292	chr7:65840212~65840596:+
TGCT	cis	rs5758511	0.689	rs17002947	ENSG00000182057.4	OGFRP1	4.29	3.58e-05	0.0209	0.37	0.36	Birth weight;	chr22:42292526	chr22:42269753~42275196:+
TGCT	cis	rs599083	0.53	rs576118	ENSG00000212093.1	AP000807.1	-4.29	3.58e-05	0.0209	-0.38	-0.36	Bone mineral density (spine);	chr11:68410240	chr11:68506083~68506166:-
TGCT	cis	rs67311347	1	rs962847	ENSG00000223797.4	ENTPD3-AS1	-4.29	3.58e-05	0.0209	-0.39	-0.36	Renal cell carcinoma;	chr3:40453665	chr3:40313802~40453329:-
TGCT	cis	rs67311347	1	rs1454497	ENSG00000223797.4	ENTPD3-AS1	-4.29	3.58e-05	0.0209	-0.39	-0.36	Renal cell carcinoma;	chr3:40454835	chr3:40313802~40453329:-
TGCT	cis	rs4713118	0.614	rs9468209	ENSG00000216901.1	AL022393.7	4.29	3.58e-05	0.0209	0.39	0.36	Parkinson's disease;	chr6:27726642	chr6:28176188~28176674:+
TGCT	cis	rs12935418	0.523	rs2549840	ENSG00000261061.1	RP11-303E16.2	4.29	3.58e-05	0.0209	0.4	0.36	Mean corpuscular volume;	chr16:80989817	chr16:81030770~81031485:+
TGCT	cis	rs901683	1	rs17157825	ENSG00000264204.2	AGAP7P	-4.29	3.58e-05	0.0209	-0.9	-0.36	Mean corpuscular volume;Red blood cell traits;	chr10:45463228	chr10:46109621~46131358:+
TGCT	cis	rs901683	0.85	rs76491632	ENSG00000264204.2	AGAP7P	-4.29	3.58e-05	0.0209	-0.9	-0.36	Mean corpuscular volume;Red blood cell traits;	chr10:45471150	chr10:46109621~46131358:+
TGCT	cis	rs901683	0.702	rs77676696	ENSG00000264204.2	AGAP7P	-4.29	3.58e-05	0.0209	-0.9	-0.36	Mean corpuscular volume;Red blood cell traits;	chr10:45471810	chr10:46109621~46131358:+
TGCT	cis	rs2742234	1	rs2742234	ENSG00000273008.1	RP11-351D16.3	4.29	3.58e-05	0.021	0.39	0.36	Hirschsprung disease;	chr10:43117161	chr10:43136824~43138334:-
TGCT	cis	rs34057264	1	rs34057264	ENSG00000253390.1	CTC-756D1.2	-4.29	3.58e-05	0.021	-0.44	-0.36	Mean corpuscular hemoglobin;Hemoglobin concentration;	chr8:23515274	chr8:23458601~23484971:+
TGCT	cis	rs7824557	0.564	rs6601584	ENSG00000255310.2	AF131215.2	-4.29	3.59e-05	0.021	-0.29	-0.36	Retinal vascular caliber;	chr8:11374834	chr8:11107788~11109726:-
TGCT	cis	rs9880211	0.821	rs9832813	ENSG00000239213.4	NCK1-AS1	4.29	3.59e-05	0.021	0.35	0.36	Height;Body mass index;	chr3:136346723	chr3:136841726~136862054:-
TGCT	cis	rs875971	0.545	rs10261710	ENSG00000237310.1	GS1-124K5.4	4.29	3.59e-05	0.021	0.44	0.36	Aortic root size;	chr7:66249202	chr7:66493706~66495474:+
TGCT	cis	rs1519814	0.696	rs2139439	ENSG00000254343.2	RP11-760H22.2	-4.29	3.59e-05	0.021	-0.57	-0.36	Breast cancer;	chr8:120024852	chr8:120052180~120056201:+
TGCT	cis	rs9859260	0.689	rs3817672	ENSG00000231464.1	AC024937.4	4.29	3.59e-05	0.021	0.37	0.36	Mean corpuscular volume;	chr3:196073940	chr3:195996738~195998233:+
TGCT	cis	rs875971	1	rs11974219	ENSG00000237310.1	GS1-124K5.4	-4.29	3.59e-05	0.021	-0.4	-0.36	Aortic root size;	chr7:66182423	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs11974264	ENSG00000237310.1	GS1-124K5.4	-4.29	3.59e-05	0.021	-0.4	-0.36	Aortic root size;	chr7:66182595	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs1540651	ENSG00000237310.1	GS1-124K5.4	-4.29	3.59e-05	0.021	-0.4	-0.36	Aortic root size;	chr7:66185134	chr7:66493706~66495474:+
TGCT	cis	rs11722779	0.869	rs223350	ENSG00000230069.3	LRRC37A15P	-4.29	3.59e-05	0.021	-0.32	-0.36	Schizophrenia;	chr4:102856899	chr4:102727274~102730721:-
TGCT	cis	rs5758511	0.68	rs5758686	ENSG00000182057.4	OGFRP1	-4.29	3.59e-05	0.021	-0.35	-0.36	Birth weight;	chr22:42259371	chr22:42269753~42275196:+
TGCT	cis	rs5758511	0.68	rs5758681	ENSG00000182057.4	OGFRP1	-4.29	3.6e-05	0.021	-0.35	-0.36	Birth weight;	chr22:42249085	chr22:42269753~42275196:+
TGCT	cis	rs5758511	0.68	rs34107327	ENSG00000182057.4	OGFRP1	-4.29	3.6e-05	0.021	-0.35	-0.36	Birth weight;	chr22:42252347	chr22:42269753~42275196:+
TGCT	cis	rs6921919	0.887	rs7766356	ENSG00000216901.1	AL022393.7	4.29	3.6e-05	0.021	0.49	0.36	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28176188~28176674:+
TGCT	cis	rs494459	0.964	rs576283	ENSG00000255422.1	AP002954.4	-4.29	3.6e-05	0.021	-0.39	-0.36	Height;	chr11:118703185	chr11:118704607~118750263:+
TGCT	cis	rs494459	0.929	rs627391	ENSG00000255422.1	AP002954.4	-4.29	3.6e-05	0.021	-0.39	-0.36	Height;	chr11:118703207	chr11:118704607~118750263:+
TGCT	cis	rs507080	0.524	rs524409	ENSG00000255422.1	AP002954.4	-4.29	3.6e-05	0.021	-0.39	-0.36	Serum metabolite levels;	chr11:118703602	chr11:118704607~118750263:+
TGCT	cis	rs8187707	1	rs17216177	ENSG00000235823.1	OLMALINC	4.29	3.6e-05	0.021	0.66	0.36	Carboplatin disposition in epthelial ovarian cancer;	chr10:99843765	chr10:100373615~100383368:+
TGCT	cis	rs992157	0.767	rs2382822	ENSG00000261338.2	RP11-378A13.1	-4.29	3.6e-05	0.021	-0.31	-0.36	Colorectal cancer;	chr2:218308604	chr2:218255319~218257366:+
TGCT	cis	rs72627509	0.951	rs6554401	ENSG00000269949.1	RP11-738E22.3	4.29	3.6e-05	0.021	0.41	0.36	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56959170	chr4:56960927~56961373:-
TGCT	cis	rs8040855	0.658	rs3862411	ENSG00000259295.5	CSPG4P12	4.29	3.6e-05	0.021	0.46	0.36	Bulimia nervosa;	chr15:85007770	chr15:85191438~85213905:+
TGCT	cis	rs507080	0.733	rs601318	ENSG00000255239.1	AP002954.6	4.29	3.6e-05	0.021	0.46	0.36	Serum metabolite levels;	chr11:118648845	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.697	rs653008	ENSG00000255239.1	AP002954.6	4.29	3.6e-05	0.021	0.46	0.36	Serum metabolite levels;	chr11:118649775	chr11:118688039~118690600:-
TGCT	cis	rs3931020	0.688	rs525487	ENSG00000272864.1	RP11-17E13.2	4.29	3.61e-05	0.0211	0.42	0.36	Resistin levels;	chr1:74751736	chr1:74698769~74699333:-
TGCT	cis	rs992157	0.932	rs4672884	ENSG00000261338.2	RP11-378A13.1	-4.29	3.61e-05	0.0211	-0.29	-0.36	Colorectal cancer;	chr2:218317758	chr2:218255319~218257366:+
TGCT	cis	rs9880211	0.898	rs6770476	ENSG00000239213.4	NCK1-AS1	4.29	3.61e-05	0.0211	0.36	0.36	Height;Body mass index;	chr3:136355078	chr3:136841726~136862054:-
TGCT	cis	rs17507216	0.628	rs4513065	ENSG00000255769.6	GOLGA2P10	-4.29	3.61e-05	0.0211	-0.47	-0.36	Excessive daytime sleepiness;	chr15:82712096	chr15:82472993~82513950:-
TGCT	cis	rs5742933	1	rs2289404	ENSG00000273240.1	RP11-455J20.3	-4.29	3.62e-05	0.0211	-0.37	-0.36	Ferritin levels;	chr2:189771288	chr2:189763859~189764456:-
TGCT	cis	rs5742933	1	rs12622902	ENSG00000273240.1	RP11-455J20.3	-4.29	3.62e-05	0.0211	-0.37	-0.36	Ferritin levels;	chr2:189776263	chr2:189763859~189764456:-
TGCT	cis	rs5742933	1	rs12619808	ENSG00000273240.1	RP11-455J20.3	-4.29	3.62e-05	0.0211	-0.37	-0.36	Ferritin levels;	chr2:189776458	chr2:189763859~189764456:-
TGCT	cis	rs7829975	0.84	rs555617	ENSG00000173295.6	FAM86B3P	-4.29	3.62e-05	0.0211	-0.44	-0.36	Mood instability;	chr8:8735335	chr8:8228595~8244865:+
TGCT	cis	rs2333021	0.624	rs12050080	ENSG00000259015.1	RP11-109N23.6	4.29	3.62e-05	0.0211	0.21	0.36	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73012645	chr14:72960595~72961993:+
TGCT	cis	rs875971	0.52	rs12666485	ENSG00000237310.1	GS1-124K5.4	4.29	3.62e-05	0.0211	0.44	0.36	Aortic root size;	chr7:66160135	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs67688847	ENSG00000237310.1	GS1-124K5.4	4.29	3.62e-05	0.0211	0.44	0.36	Aortic root size;	chr7:66161064	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs7787063	ENSG00000237310.1	GS1-124K5.4	4.29	3.62e-05	0.0211	0.44	0.36	Aortic root size;	chr7:66164012	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs12673308	ENSG00000237310.1	GS1-124K5.4	4.29	3.62e-05	0.0211	0.44	0.36	Aortic root size;	chr7:66166374	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs67397473	ENSG00000237310.1	GS1-124K5.4	4.29	3.62e-05	0.0211	0.44	0.36	Aortic root size;	chr7:66168318	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs10950027	ENSG00000237310.1	GS1-124K5.4	4.29	3.62e-05	0.0211	0.44	0.36	Aortic root size;	chr7:66169164	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs73376401	ENSG00000237310.1	GS1-124K5.4	4.29	3.62e-05	0.0211	0.44	0.36	Aortic root size;	chr7:66174841	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs6460276	ENSG00000237310.1	GS1-124K5.4	4.29	3.62e-05	0.0211	0.44	0.36	Aortic root size;	chr7:66182290	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.545	rs67775320	ENSG00000237310.1	GS1-124K5.4	4.29	3.62e-05	0.0211	0.44	0.36	Aortic root size;	chr7:66193792	chr7:66493706~66495474:+
TGCT	cis	rs9595066	1	rs66786230	ENSG00000227258.4	SMIM2-AS1	4.29	3.62e-05	0.0211	0.55	0.36	Schizophrenia;	chr13:44137489	chr13:44110451~44240517:+
TGCT	cis	rs12130219	0.5	rs1552991	ENSG00000237975.5	FLG-AS1	-4.29	3.63e-05	0.0212	-0.39	-0.36	Inflammatory skin disease;	chr1:152193402	chr1:152168125~152445456:+
TGCT	cis	rs55879323	1	rs55879323	ENSG00000237975.5	FLG-AS1	-4.29	3.63e-05	0.0212	-0.39	-0.36	Inflammatory skin disease;	chr1:152196264	chr1:152168125~152445456:+
TGCT	cis	rs12130219	0.5	rs4845737	ENSG00000237975.5	FLG-AS1	-4.29	3.63e-05	0.0212	-0.39	-0.36	Inflammatory skin disease;	chr1:152205063	chr1:152168125~152445456:+
TGCT	cis	rs1010254	0.527	rs72804360	ENSG00000213433.5	RPLP1P6	-4.28	3.64e-05	0.0212	-0.47	-0.36	Optic nerve measurement (cup area);	chr5:152277496	chr5:151765859~151766378:-
TGCT	cis	rs12549025	0.677	rs62503282	ENSG00000253390.1	CTC-756D1.2	-4.28	3.64e-05	0.0212	-0.44	-0.36	Reticulocyte fraction of red cells;	chr8:23529679	chr8:23458601~23484971:+
TGCT	cis	rs875971	1	rs6946143	ENSG00000237310.1	GS1-124K5.4	4.28	3.64e-05	0.0212	0.38	0.36	Aortic root size;	chr7:66114735	chr7:66493706~66495474:+
TGCT	cis	rs12745968	0.718	rs911523	ENSG00000223787.2	RP4-593M8.1	-4.28	3.64e-05	0.0212	-0.46	-0.36	Bipolar disorder and schizophrenia;	chr1:92696163	chr1:92580476~92580821:-
TGCT	cis	rs4242434	0.927	rs57594397	ENSG00000254064.1	CTD-2530N21.4	-4.28	3.64e-05	0.0212	-0.22	-0.36	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22618144	chr8:22254576~22275162:-
TGCT	cis	rs12554020	0.892	rs7870210	ENSG00000227603.1	RP11-165J3.6	4.28	3.64e-05	0.0212	0.59	0.36	Schizophrenia;	chr9:93569534	chr9:93435332~93437121:-
TGCT	cis	rs12554020	0.892	rs7860098	ENSG00000227603.1	RP11-165J3.6	4.28	3.64e-05	0.0212	0.59	0.36	Schizophrenia;	chr9:93569562	chr9:93435332~93437121:-
TGCT	cis	rs12554020	0.786	rs7857183	ENSG00000227603.1	RP11-165J3.6	4.28	3.64e-05	0.0212	0.59	0.36	Schizophrenia;	chr9:93569762	chr9:93435332~93437121:-
TGCT	cis	rs12554020	0.786	rs60076242	ENSG00000227603.1	RP11-165J3.6	4.28	3.64e-05	0.0212	0.59	0.36	Schizophrenia;	chr9:93571634	chr9:93435332~93437121:-
TGCT	cis	rs12554020	0.786	rs10429558	ENSG00000227603.1	RP11-165J3.6	4.28	3.64e-05	0.0212	0.59	0.36	Schizophrenia;	chr9:93574508	chr9:93435332~93437121:-
TGCT	cis	rs9952991	0.941	rs8096138	ENSG00000260302.1	RP11-973H7.1	4.28	3.65e-05	0.0213	0.56	0.36	Inflammatory skin disease;	chr18:12808141	chr18:12774651~12775923:-
TGCT	cis	rs10504229	0.683	rs16921831	ENSG00000253301.4	RP11-513O17.2	4.28	3.65e-05	0.0213	0.54	0.36	Developmental language disorder (linguistic errors);	chr8:57198583	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.724	rs16922734	ENSG00000253301.4	RP11-513O17.2	4.28	3.65e-05	0.0213	0.54	0.36	Developmental language disorder (linguistic errors);	chr8:57198633	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs7460059	ENSG00000253301.4	RP11-513O17.2	4.28	3.65e-05	0.0213	0.54	0.36	Developmental language disorder (linguistic errors);	chr8:57199002	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs7459925	ENSG00000253301.4	RP11-513O17.2	4.28	3.65e-05	0.0213	0.54	0.36	Developmental language disorder (linguistic errors);	chr8:57199212	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs7459958	ENSG00000253301.4	RP11-513O17.2	4.28	3.65e-05	0.0213	0.54	0.36	Developmental language disorder (linguistic errors);	chr8:57199346	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs7463453	ENSG00000253301.4	RP11-513O17.2	4.28	3.65e-05	0.0213	0.54	0.36	Developmental language disorder (linguistic errors);	chr8:57199494	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs2088217	ENSG00000253301.4	RP11-513O17.2	4.28	3.65e-05	0.0213	0.54	0.36	Developmental language disorder (linguistic errors);	chr8:57200565	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs2101864	ENSG00000253301.4	RP11-513O17.2	4.28	3.65e-05	0.0213	0.54	0.36	Developmental language disorder (linguistic errors);	chr8:57200667	chr8:57142689~57240298:+
TGCT	cis	rs11671104	0.536	rs2035765	ENSG00000269332.4	GOLGA2P9	4.28	3.65e-05	0.0213	0.49	0.36	Colorectal cancer (diet interaction);	chr19:22597071	chr19:22596257~22603550:+
TGCT	cis	rs11671104	0.536	rs4933010	ENSG00000269332.4	GOLGA2P9	4.28	3.65e-05	0.0213	0.49	0.36	Colorectal cancer (diet interaction);	chr19:22597525	chr19:22596257~22603550:+
TGCT	cis	rs11671104	0.536	rs4933011	ENSG00000269332.4	GOLGA2P9	4.28	3.65e-05	0.0213	0.49	0.36	Colorectal cancer (diet interaction);	chr19:22597641	chr19:22596257~22603550:+
TGCT	cis	rs2439831	0.702	rs16977724	ENSG00000205771.5	CATSPER2P1	-4.28	3.65e-05	0.0213	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43859101	chr15:43726918~43747094:-
TGCT	cis	rs62355901	0.545	rs58774999	ENSG00000271828.1	CTD-2310F14.1	4.28	3.65e-05	0.0213	0.5	0.36	Breast cancer;	chr5:56798018	chr5:56927874~56929573:+
TGCT	cis	rs62355901	0.545	rs62355938	ENSG00000271828.1	CTD-2310F14.1	4.28	3.65e-05	0.0213	0.5	0.36	Breast cancer;	chr5:56798887	chr5:56927874~56929573:+
TGCT	cis	rs62355900	0.627	rs1862620	ENSG00000271828.1	CTD-2310F14.1	4.28	3.65e-05	0.0213	0.5	0.36	Endometriosis;	chr5:56802543	chr5:56927874~56929573:+
TGCT	cis	rs1555322	0.53	rs2425042	ENSG00000126005.14	MMP24-AS1	-4.28	3.66e-05	0.0213	-0.44	-0.36	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35216462~35278131:-
TGCT	cis	rs1555322	0.53	rs7004	ENSG00000126005.14	MMP24-AS1	-4.28	3.66e-05	0.0213	-0.44	-0.36	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35216462~35278131:-
TGCT	cis	rs56205728	0.606	rs3784398	ENSG00000273855.1	RP11-133K1.12	4.28	3.66e-05	0.0213	0.4	0.36	Schizophrenia;	chr15:40304665	chr15:40285468~40285909:-
TGCT	cis	rs1707322	0.721	rs10890346	ENSG00000280836.1	AL355480.1	4.28	3.66e-05	0.0213	0.46	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45581219~45581321:-
TGCT	cis	rs16975963	0.644	rs11666738	ENSG00000276846.1	CTD-3220F14.3	-4.28	3.66e-05	0.0213	-0.34	-0.36	Longevity;	chr19:37639418	chr19:37314868~37315620:-
TGCT	cis	rs9309473	1	rs13428235	ENSG00000163016.8	ALMS1P	4.28	3.66e-05	0.0213	0.32	0.36	Metabolite levels;	chr2:73406302	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs7580825	ENSG00000163016.8	ALMS1P	4.28	3.66e-05	0.0213	0.32	0.36	Metabolite levels;	chr2:73408020	chr2:73644919~73685576:+
TGCT	cis	rs17213965	0.561	rs9929598	ENSG00000263335.1	AF001548.5	-4.28	3.67e-05	0.0214	-0.49	-0.36	Waist-hip ratio;	chr16:15786153	chr16:15726674~15732993:+
TGCT	cis	rs9921222	0.5	rs8046256	ENSG00000268836.1	LA16c-OS12.2	4.28	3.67e-05	0.0214	0.39	0.36	Bone mineral density (spine);Bone mineral density;	chr16:343948	chr16:185748~186294:-
TGCT	cis	rs875971	0.66	rs10272357	ENSG00000272831.1	RP11-792A8.4	-4.28	3.67e-05	0.0214	-0.38	-0.36	Aortic root size;	chr7:66598087	chr7:66739829~66740385:-
TGCT	cis	rs4713118	0.662	rs464312	ENSG00000219891.2	ZSCAN12P1	4.28	3.67e-05	0.0214	0.43	0.36	Parkinson's disease;	chr6:27999813	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.662	rs469228	ENSG00000219891.2	ZSCAN12P1	4.28	3.67e-05	0.0214	0.43	0.36	Parkinson's disease;	chr6:28002926	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.54	rs469227	ENSG00000219891.2	ZSCAN12P1	4.28	3.67e-05	0.0214	0.43	0.36	Parkinson's disease;	chr6:28002927	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.662	rs149948	ENSG00000219891.2	ZSCAN12P1	4.28	3.67e-05	0.0214	0.43	0.36	Parkinson's disease;	chr6:28007039	chr6:28091154~28093664:+
TGCT	cis	rs5769707	0.749	rs8137251	ENSG00000235111.1	RP1-29C18.8	-4.28	3.67e-05	0.0214	-0.32	-0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49643021	chr22:49612657~49615716:-
TGCT	cis	rs755249	0.565	rs722357	ENSG00000182109.6	RP11-69E11.4	-4.28	3.68e-05	0.0214	-0.36	-0.36	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479096	chr1:39522280~39546187:-
TGCT	cis	rs11673344	0.966	rs56330606	ENSG00000226686.6	LINC01535	4.28	3.68e-05	0.0214	0.41	0.36	Obesity-related traits;	chr19:37183051	chr19:37251912~37265535:+
TGCT	cis	rs10740039	0.583	rs1904404	ENSG00000254271.1	RP11-131N11.4	-4.28	3.68e-05	0.0214	-0.38	-0.36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60742428	chr10:60734342~60741828:+
TGCT	cis	rs5758659	0.716	rs86669	ENSG00000182057.4	OGFRP1	4.28	3.68e-05	0.0214	0.27	0.36	Cognitive function;	chr22:42284794	chr22:42269753~42275196:+
TGCT	cis	rs2015599	0.645	rs12578931	ENSG00000275476.1	RP11-996F15.4	-4.28	3.68e-05	0.0214	-0.41	-0.36	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29277397~29277882:-
TGCT	cis	rs2015599	0.623	rs4931174	ENSG00000275476.1	RP11-996F15.4	-4.28	3.68e-05	0.0214	-0.41	-0.36	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29277397~29277882:-
TGCT	cis	rs11139399	0.613	rs10867803	ENSG00000233926.1	RP11-154D17.1	-4.28	3.68e-05	0.0214	-0.41	-0.36	Hippocampal atrophy;	chr9:81726032	chr9:81689713~81776900:+
TGCT	cis	rs7208859	0.623	rs8082537	ENSG00000280069.1	CTD-2349P21.3	-4.28	3.69e-05	0.0215	-0.49	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30738182~30740275:+
TGCT	cis	rs9481169	0.557	rs33980500	ENSG00000255389.1	C6orf3	-4.28	3.69e-05	0.0215	-0.64	-0.36	Inflammatory skin disease;	chr6:111592059	chr6:111599875~111602295:+
TGCT	cis	rs7208859	0.573	rs8070182	ENSG00000266490.1	CTD-2349P21.9	4.28	3.69e-05	0.0215	0.4	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30792372~30792833:+
TGCT	cis	rs8059260	1	rs6498138	ENSG00000274038.1	RP11-66H6.4	4.28	3.69e-05	0.0215	0.48	0.36	Alcohol consumption over the past year;	chr16:10951421	chr16:11056556~11057034:+
TGCT	cis	rs8059260	1	rs7205474	ENSG00000274038.1	RP11-66H6.4	-4.28	3.69e-05	0.0215	-0.48	-0.36	Alcohol consumption over the past year;	chr16:10949556	chr16:11056556~11057034:+
TGCT	cis	rs8059260	0.877	rs111352543	ENSG00000274038.1	RP11-66H6.4	-4.28	3.69e-05	0.0215	-0.48	-0.36	Alcohol consumption over the past year;	chr16:10949603	chr16:11056556~11057034:+
TGCT	cis	rs8059260	1	rs8057540	ENSG00000274038.1	RP11-66H6.4	-4.28	3.69e-05	0.0215	-0.48	-0.36	Alcohol consumption over the past year;	chr16:10951985	chr16:11056556~11057034:+
TGCT	cis	rs8059260	1	rs6498139	ENSG00000274038.1	RP11-66H6.4	-4.28	3.69e-05	0.0215	-0.48	-0.36	Alcohol consumption over the past year;	chr16:10954066	chr16:11056556~11057034:+
TGCT	cis	rs8059260	1	rs7185978	ENSG00000274038.1	RP11-66H6.4	-4.28	3.69e-05	0.0215	-0.48	-0.36	Alcohol consumption over the past year;	chr16:10954417	chr16:11056556~11057034:+
TGCT	cis	rs227275	0.525	rs223462	ENSG00000230069.3	LRRC37A15P	-4.28	3.69e-05	0.0215	-0.31	-0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102780661	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs223459	ENSG00000230069.3	LRRC37A15P	-4.28	3.69e-05	0.0215	-0.31	-0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102788229	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.588	rs223458	ENSG00000230069.3	LRRC37A15P	-4.28	3.69e-05	0.0215	-0.31	-0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102788414	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs223445	ENSG00000230069.3	LRRC37A15P	-4.28	3.69e-05	0.0215	-0.31	-0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793337	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs223443	ENSG00000230069.3	LRRC37A15P	-4.28	3.69e-05	0.0215	-0.31	-0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.536	rs223437	ENSG00000230069.3	LRRC37A15P	-4.28	3.69e-05	0.0215	-0.31	-0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798736	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs223435	ENSG00000230069.3	LRRC37A15P	-4.28	3.69e-05	0.0215	-0.31	-0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799826	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.556	rs223426	ENSG00000230069.3	LRRC37A15P	-4.28	3.69e-05	0.0215	-0.31	-0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102801330	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.554	rs223425	ENSG00000230069.3	LRRC37A15P	-4.28	3.69e-05	0.0215	-0.31	-0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102802836	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs223451	ENSG00000230069.3	LRRC37A15P	-4.28	3.7e-05	0.0215	-0.31	-0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791032	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs223450	ENSG00000230069.3	LRRC37A15P	-4.28	3.7e-05	0.0215	-0.31	-0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791052	chr4:102727274~102730721:-
TGCT	cis	rs8072100	0.967	rs4794058	ENSG00000228782.6	CTD-2026D20.3	-4.28	3.7e-05	0.0215	-0.43	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47519732	chr17:47450568~47492492:-
TGCT	cis	rs8072100	0.87	rs10432035	ENSG00000228782.6	CTD-2026D20.3	-4.28	3.7e-05	0.0215	-0.43	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47547547	chr17:47450568~47492492:-
TGCT	cis	rs7208859	0.623	rs11657662	ENSG00000280069.1	CTD-2349P21.3	4.28	3.7e-05	0.0215	0.51	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs11658022	ENSG00000280069.1	CTD-2349P21.3	-4.28	3.7e-05	0.0215	-0.51	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs3794796	ENSG00000280069.1	CTD-2349P21.3	-4.28	3.7e-05	0.0215	-0.51	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.573	rs11654035	ENSG00000280069.1	CTD-2349P21.3	-4.28	3.7e-05	0.0215	-0.51	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30738182~30740275:+
TGCT	cis	rs9921222	0.5	rs11648673	ENSG00000268836.1	LA16c-OS12.2	4.28	3.7e-05	0.0215	0.38	0.36	Bone mineral density (spine);Bone mineral density;	chr16:327794	chr16:185748~186294:-
TGCT	cis	rs13068223	0.716	rs344067	ENSG00000243926.1	TIPARP-AS1	-4.28	3.7e-05	0.0215	-0.38	-0.36	Age-related hearing impairment (SNP x SNP interaction);	chr3:156723825	chr3:156671862~156674378:-
TGCT	cis	rs1061377	0.748	rs13117988	ENSG00000249207.1	RP11-360F5.1	-4.28	3.7e-05	0.0215	-0.38	-0.36	Uric acid levels;	chr4:39092219	chr4:39112677~39126818:-
TGCT	cis	rs1061377	0.748	rs35904472	ENSG00000249207.1	RP11-360F5.1	-4.28	3.7e-05	0.0215	-0.38	-0.36	Uric acid levels;	chr4:39094901	chr4:39112677~39126818:-
TGCT	cis	rs1061377	0.748	rs10856841	ENSG00000249207.1	RP11-360F5.1	-4.28	3.7e-05	0.0215	-0.38	-0.36	Uric acid levels;	chr4:39095240	chr4:39112677~39126818:-
TGCT	cis	rs1061377	0.748	rs12642261	ENSG00000249207.1	RP11-360F5.1	-4.28	3.7e-05	0.0215	-0.38	-0.36	Uric acid levels;	chr4:39096278	chr4:39112677~39126818:-
TGCT	cis	rs4713118	0.662	rs149946	ENSG00000216901.1	AL022393.7	-4.28	3.71e-05	0.0215	-0.46	-0.36	Parkinson's disease;	chr6:28002253	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.662	rs156744	ENSG00000216901.1	AL022393.7	4.28	3.71e-05	0.0215	0.46	0.36	Parkinson's disease;	chr6:27999496	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.662	rs149947	ENSG00000216901.1	AL022393.7	4.28	3.71e-05	0.0215	0.46	0.36	Parkinson's disease;	chr6:28004655	chr6:28176188~28176674:+
TGCT	cis	rs3096299	0.679	rs3102338	ENSG00000274627.1	RP11-104N10.2	4.28	3.71e-05	0.0215	0.38	0.36	Multiple myeloma (IgH translocation);	chr16:89375842	chr16:89516797~89522217:+
TGCT	cis	rs2463822	0.92	rs7924998	ENSG00000254454.2	RCC2P6	4.28	3.71e-05	0.0215	0.42	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr11:62306508	chr11:62371146~62373168:+
TGCT	cis	rs9326248	0.813	rs474488	ENSG00000280143.1	AP000892.6	4.28	3.71e-05	0.0215	0.53	0.36	Blood protein levels;	chr11:117198261	chr11:117204967~117210292:+
TGCT	cis	rs10178409	1	rs10178409	ENSG00000163016.8	ALMS1P	4.28	3.71e-05	0.0216	0.33	0.36	Urinary metabolites;	chr2:73628380	chr2:73644919~73685576:+
TGCT	cis	rs7714584	1	rs2115069	ENSG00000197083.10	ZNF300P1	4.28	3.71e-05	0.0216	0.58	0.36	Crohn's disease;	chr5:150872803	chr5:150930645~150946289:-
TGCT	cis	rs7246967	0.608	rs437859	ENSG00000269509.1	BNIP3P34	-4.28	3.71e-05	0.0216	-0.48	-0.36	Bronchopulmonary dysplasia;	chr19:22824547	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.544	rs403717	ENSG00000269509.1	BNIP3P34	4.28	3.71e-05	0.0216	0.48	0.36	Bronchopulmonary dysplasia;	chr19:22826001	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.544	rs391308	ENSG00000269509.1	BNIP3P34	4.28	3.71e-05	0.0216	0.48	0.36	Bronchopulmonary dysplasia;	chr19:22826758	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.608	rs428613	ENSG00000269509.1	BNIP3P34	4.28	3.71e-05	0.0216	0.48	0.36	Bronchopulmonary dysplasia;	chr19:22827117	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.608	rs370734	ENSG00000269509.1	BNIP3P34	4.28	3.71e-05	0.0216	0.48	0.36	Bronchopulmonary dysplasia;	chr19:22829784	chr19:22773853~22774424:+
TGCT	cis	rs7829975	0.811	rs7011229	ENSG00000173295.6	FAM86B3P	-4.28	3.71e-05	0.0216	-0.44	-0.36	Mood instability;	chr8:8685814	chr8:8228595~8244865:+
TGCT	cis	rs10759883	0.563	rs10819720	ENSG00000175611.10	LINC00476	4.28	3.71e-05	0.0216	0.32	0.36	Nicotine dependence;	chr9:96021506	chr9:95759231~95875977:-
TGCT	cis	rs7819412	0.522	rs4642600	ENSG00000255310.2	AF131215.2	-4.28	3.72e-05	0.0216	-0.31	-0.36	Triglycerides;	chr8:11155515	chr8:11107788~11109726:-
TGCT	cis	rs7714584	1	rs1428551	ENSG00000197083.10	ZNF300P1	4.28	3.72e-05	0.0216	0.58	0.36	Crohn's disease;	chr5:150880270	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs1816256	ENSG00000197083.10	ZNF300P1	4.28	3.72e-05	0.0216	0.58	0.36	Crohn's disease;	chr5:150893291	chr5:150930645~150946289:-
TGCT	cis	rs853679	0.545	rs35949109	ENSG00000216901.1	AL022393.7	4.28	3.72e-05	0.0216	0.62	0.36	Depression;	chr6:28058148	chr6:28176188~28176674:+
TGCT	cis	rs2288884	0.581	rs9636144	ENSG00000269235.1	ZNF350-AS1	4.28	3.72e-05	0.0216	0.45	0.36	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52057881	chr19:51949134~51981367:+
TGCT	cis	rs2288884	0.636	rs73066154	ENSG00000269235.1	ZNF350-AS1	4.28	3.72e-05	0.0216	0.45	0.36	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52060240	chr19:51949134~51981367:+
TGCT	cis	rs10938353	0.68	rs1491313	ENSG00000273369.1	RP11-700J17.1	4.28	3.72e-05	0.0216	0.54	0.36	Body mass index;	chr4:44783372	chr4:44693946~44694386:-
TGCT	cis	rs10946737	0.756	rs7768143	ENSG00000220517.2	ASS1P1	4.28	3.72e-05	0.0216	0.35	0.36	Liver injury in anti-tuberculosis drug treatment;	chr6:24986986	chr6:25023247~25024483:-
TGCT	cis	rs7181230	0.885	rs2412478	ENSG00000275636.1	RP11-521C20.5	4.28	3.72e-05	0.0216	0.45	0.36	Dehydroepiandrosterone sulphate levels;	chr15:40068971	chr15:40078892~40079347:+
TGCT	cis	rs8072100	0.967	rs4289035	ENSG00000228782.6	CTD-2026D20.3	4.28	3.73e-05	0.0216	0.42	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47629845	chr17:47450568~47492492:-
TGCT	cis	rs7829975	0.742	rs882462	ENSG00000254340.1	RP11-10A14.3	4.28	3.73e-05	0.0216	0.36	0.36	Mood instability;	chr8:8821020	chr8:9141424~9145435:+
TGCT	cis	rs7829975	0.744	rs2409092	ENSG00000254340.1	RP11-10A14.3	4.28	3.73e-05	0.0216	0.36	0.36	Mood instability;	chr8:8824682	chr8:9141424~9145435:+
TGCT	cis	rs4242434	0.757	rs2280104	ENSG00000254064.1	CTD-2530N21.4	-4.28	3.73e-05	0.0217	-0.21	-0.36	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22668467	chr8:22254576~22275162:-
TGCT	cis	rs992157	0.775	rs1877714	ENSG00000261338.2	RP11-378A13.1	-4.28	3.73e-05	0.0217	-0.31	-0.36	Colorectal cancer;	chr2:218270205	chr2:218255319~218257366:+
TGCT	cis	rs10504229	1	rs112284078	ENSG00000253301.4	RP11-513O17.2	4.28	3.74e-05	0.0217	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57279081	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs76944716	ENSG00000253301.4	RP11-513O17.2	4.28	3.74e-05	0.0217	0.46	0.36	Developmental language disorder (linguistic errors);	chr8:57279084	chr8:57142689~57240298:+
TGCT	cis	rs7829975	0.774	rs35431455	ENSG00000254340.1	RP11-10A14.3	4.28	3.74e-05	0.0217	0.36	0.36	Mood instability;	chr8:8816226	chr8:9141424~9145435:+
TGCT	cis	rs875971	1	rs709597	ENSG00000237310.1	GS1-124K5.4	-4.28	3.75e-05	0.0217	-0.4	-0.36	Aortic root size;	chr7:66360996	chr7:66493706~66495474:+
TGCT	cis	rs17711722	0.522	rs62469933	ENSG00000226824.5	RP4-756H11.3	-4.28	3.75e-05	0.0217	-0.39	-0.36	Calcium levels;	chr7:65800652	chr7:66654538~66669855:+
TGCT	cis	rs7923609	0.846	rs7075901	ENSG00000232075.1	MRPL35P2	-4.28	3.75e-05	0.0217	-0.35	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63521234	chr10:63634317~63634827:-
TGCT	cis	rs12143943	0.902	rs7541449	ENSG00000176754.11	LINC00303	4.28	3.75e-05	0.0217	0.33	0.36	Cognitive performance;	chr1:204609180	chr1:204032447~204041265:-
TGCT	cis	rs11822910	0.737	rs2584858	ENSG00000265566.2	RN7SL605P	4.28	3.75e-05	0.0218	0.42	0.36	Platelet distribution width;	chr11:57439604	chr11:57528085~57528365:-
TGCT	cis	rs7181230	1	rs9972424	ENSG00000275636.1	RP11-521C20.5	4.28	3.75e-05	0.0218	0.41	0.36	Dehydroepiandrosterone sulphate levels;	chr15:40073650	chr15:40078892~40079347:+
TGCT	cis	rs7795991	0.5	rs17167587	ENSG00000224330.1	AC005019.3	4.28	3.75e-05	0.0218	0.4	0.36	Type 2 diabetes;	chr7:13852565	chr7:13854355~13859025:-
TGCT	cis	rs11086243	0.935	rs6090807	ENSG00000235621.7	LINC00494	4.28	3.76e-05	0.0218	0.33	0.36	Nephrotic syndrome (acquired);	chr20:48134671	chr20:48359950~48370629:+
TGCT	cis	rs911555	0.755	rs17841064	ENSG00000244691.1	RPL10AP1	-4.28	3.76e-05	0.0218	-0.48	-0.36	Intelligence (multi-trait analysis);	chr14:103434272	chr14:103412119~103412761:-
TGCT	cis	rs904251	0.861	rs1776456	ENSG00000204110.6	RP1-153P14.8	-4.28	3.76e-05	0.0218	-0.42	-0.36	Cognitive performance;	chr6:37516922	chr6:37507348~37535616:+
TGCT	cis	rs9326248	0.53	rs2513093	ENSG00000254851.1	RP11-109L13.1	-4.28	3.76e-05	0.0218	-0.61	-0.36	Blood protein levels;	chr11:116935971	chr11:117135528~117138582:+
TGCT	cis	rs2188561	1	rs2712207	ENSG00000241764.3	AC002467.7	4.28	3.77e-05	0.0218	0.36	0.36	Alcohol consumption;	chr7:107711672	chr7:107742817~107744581:-
TGCT	cis	rs2243480	1	rs34702770	ENSG00000164669.11	INTS4P1	4.28	3.77e-05	0.0219	0.58	0.36	Diabetic kidney disease;	chr7:65879836	chr7:65141225~65234216:+
TGCT	cis	rs1150668	0.83	rs2023493	ENSG00000204709.4	LINC01556	4.28	3.77e-05	0.0219	0.4	0.36	Pubertal anthropometrics;	chr6:28432385	chr6:28943877~28944537:+
TGCT	cis	rs453301	0.512	rs2921381	ENSG00000254340.1	RP11-10A14.3	4.28	3.78e-05	0.0219	0.36	0.36	Joint mobility (Beighton score);	chr8:9037891	chr8:9141424~9145435:+
TGCT	cis	rs9457247	1	rs386548	ENSG00000265828.1	MIR3939	4.27	3.78e-05	0.0219	0.33	0.36	Crohn's disease;	chr6:166972045	chr6:166997807~166997912:-
TGCT	cis	rs786425	0.899	rs1515814	ENSG00000247373.3	RP11-486O12.2	4.27	3.78e-05	0.0219	0.42	0.36	Pubertal anthropometrics;	chr12:123624152	chr12:123575891~123585115:-
TGCT	cis	rs11742741	0.69	rs35311965	ENSG00000248874.4	C5orf17	-4.27	3.78e-05	0.0219	-0.42	-0.36	Educational attainment;	chr5:24176027	chr5:23951348~24178263:+
TGCT	cis	rs5758511	0.689	rs55906806	ENSG00000182057.4	OGFRP1	-4.27	3.78e-05	0.0219	-0.38	-0.36	Birth weight;	chr22:42248465	chr22:42269753~42275196:+
TGCT	cis	rs2283792	0.691	rs11913721	ENSG00000228050.1	TOP3BP1	4.27	3.78e-05	0.0219	0.43	0.36	Multiple sclerosis;	chr22:21855846	chr22:22223187~22224566:-
TGCT	cis	rs3105593	1	rs2011064	ENSG00000273674.3	CTD-2378E12.1	4.27	3.79e-05	0.0219	0.41	0.36	QT interval;	chr15:50665428	chr15:50839875~50908599:-
TGCT	cis	rs67311347	0.911	rs6775936	ENSG00000223797.4	ENTPD3-AS1	4.27	3.79e-05	0.0219	0.37	0.36	Renal cell carcinoma;	chr3:40335908	chr3:40313802~40453329:-
TGCT	cis	rs11074306	0.563	rs3930739	ENSG00000232394.1	AC090696.2	-4.27	3.79e-05	0.0219	-0.32	-0.36	Uveal melanoma;	chr15:27795196	chr15:27775621~27776798:+
TGCT	cis	rs9595066	0.941	rs9533777	ENSG00000227258.4	SMIM2-AS1	-4.27	3.79e-05	0.022	-0.47	-0.36	Schizophrenia;	chr13:44134584	chr13:44110451~44240517:+
TGCT	cis	rs365032	0.584	rs4809257	ENSG00000203900.2	RP11-261N11.8	-4.27	3.8e-05	0.022	-0.42	-0.36	Restless legs syndrome;	chr20:64151888	chr20:63359988~63371177:+
TGCT	cis	rs365032	0.549	rs4809416	ENSG00000203900.2	RP11-261N11.8	-4.27	3.8e-05	0.022	-0.42	-0.36	Restless legs syndrome;	chr20:64152060	chr20:63359988~63371177:+
TGCT	cis	rs3931020	0.657	rs7522428	ENSG00000272864.1	RP11-17E13.2	-4.27	3.8e-05	0.022	-0.43	-0.36	Resistin levels;	chr1:74712676	chr1:74698769~74699333:-
TGCT	cis	rs4713118	0.662	rs156744	ENSG00000219392.1	RP1-265C24.5	-4.27	3.8e-05	0.022	-0.45	-0.36	Parkinson's disease;	chr6:27999496	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.662	rs149947	ENSG00000219392.1	RP1-265C24.5	-4.27	3.8e-05	0.022	-0.45	-0.36	Parkinson's disease;	chr6:28004655	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.662	rs149946	ENSG00000219392.1	RP1-265C24.5	4.27	3.8e-05	0.022	0.45	0.36	Parkinson's disease;	chr6:28002253	chr6:28115628~28116551:+
TGCT	cis	rs801193	1	rs2420824	ENSG00000236529.1	RP13-254B10.1	-4.27	3.8e-05	0.022	-0.27	-0.36	Aortic root size;	chr7:66666129	chr7:65840212~65840596:+
TGCT	cis	rs7603514	0.626	rs6730407	ENSG00000279220.1	GPR1-AS	-4.27	3.8e-05	0.022	-0.34	-0.36	Obesity (extreme);	chr2:206213809	chr2:206203376~206266243:+
TGCT	cis	rs875971	0.862	rs10274883	ENSG00000232559.3	GS1-124K5.12	-4.27	3.8e-05	0.022	-0.33	-0.36	Aortic root size;	chr7:66651104	chr7:66554588~66576923:-
TGCT	cis	rs801193	0.569	rs881285	ENSG00000232559.3	GS1-124K5.12	-4.27	3.8e-05	0.022	-0.33	-0.36	Aortic root size;	chr7:66654433	chr7:66554588~66576923:-
TGCT	cis	rs801193	0.569	rs3846973	ENSG00000232559.3	GS1-124K5.12	-4.27	3.8e-05	0.022	-0.33	-0.36	Aortic root size;	chr7:66655048	chr7:66554588~66576923:-
TGCT	cis	rs801193	0.569	rs2013908	ENSG00000232559.3	GS1-124K5.12	-4.27	3.8e-05	0.022	-0.33	-0.36	Aortic root size;	chr7:66656082	chr7:66554588~66576923:-
TGCT	cis	rs801193	0.569	rs13242290	ENSG00000232559.3	GS1-124K5.12	-4.27	3.8e-05	0.022	-0.33	-0.36	Aortic root size;	chr7:66656898	chr7:66554588~66576923:-
TGCT	cis	rs801193	0.548	rs2109297	ENSG00000232559.3	GS1-124K5.12	-4.27	3.8e-05	0.022	-0.33	-0.36	Aortic root size;	chr7:66657397	chr7:66554588~66576923:-
TGCT	cis	rs801193	0.569	rs6978178	ENSG00000232559.3	GS1-124K5.12	-4.27	3.8e-05	0.022	-0.33	-0.36	Aortic root size;	chr7:66658097	chr7:66554588~66576923:-
TGCT	cis	rs801193	0.591	rs721717	ENSG00000232559.3	GS1-124K5.12	-4.27	3.8e-05	0.022	-0.33	-0.36	Aortic root size;	chr7:66665305	chr7:66554588~66576923:-
TGCT	cis	rs801193	0.569	rs6951302	ENSG00000232559.3	GS1-124K5.12	-4.27	3.8e-05	0.022	-0.33	-0.36	Aortic root size;	chr7:66667525	chr7:66554588~66576923:-
TGCT	cis	rs1707322	0.752	rs4660880	ENSG00000280836.1	AL355480.1	-4.27	3.8e-05	0.022	-0.49	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45581219~45581321:-
TGCT	cis	rs6782228	0.675	rs4857918	ENSG00000242551.2	POU5F1P6	-4.27	3.81e-05	0.022	-0.43	-0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128665117	chr3:128674735~128677005:-
TGCT	cis	rs5758659	0.633	rs762995	ENSG00000182057.4	OGFRP1	4.27	3.81e-05	0.0221	0.26	0.36	Cognitive function;	chr22:42276118	chr22:42269753~42275196:+
TGCT	cis	rs12210905	0.8	rs11758585	ENSG00000187763.3	OR2B7P	4.27	3.81e-05	0.0221	0.5	0.36	Hip circumference adjusted for BMI;	chr6:27222475	chr6:28046434~28047367:+
TGCT	cis	rs12210905	0.858	rs11758615	ENSG00000187763.3	OR2B7P	4.27	3.81e-05	0.0221	0.5	0.36	Hip circumference adjusted for BMI;	chr6:27224603	chr6:28046434~28047367:+
TGCT	cis	rs17293817	0.647	rs2255595	ENSG00000229869.1	RP11-363N22.2	-4.27	3.81e-05	0.0221	-0.46	-0.36	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:1413348	chr10:933026~942743:+
TGCT	cis	rs673078	0.607	rs8467	ENSG00000275759.1	RP11-131L12.3	-4.27	3.82e-05	0.0221	-0.66	-0.36	Glucose homeostasis traits;	chr12:118417479	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs7295288	ENSG00000275759.1	RP11-131L12.3	-4.27	3.82e-05	0.0221	-0.66	-0.36	Glucose homeostasis traits;	chr12:118418008	chr12:118428281~118428870:+
TGCT	cis	rs875971	0.929	rs4122249	ENSG00000232559.3	GS1-124K5.12	4.27	3.83e-05	0.0221	0.34	0.36	Aortic root size;	chr7:66455949	chr7:66554588~66576923:-
TGCT	cis	rs7674212	0.507	rs223471	ENSG00000230069.3	LRRC37A15P	-4.27	3.83e-05	0.0221	-0.35	-0.36	Type 2 diabetes;	chr4:102777629	chr4:102727274~102730721:-
TGCT	cis	rs6940638	0.688	rs9379960	ENSG00000187763.3	OR2B7P	4.27	3.83e-05	0.0222	0.32	0.36	Intelligence (multi-trait analysis);	chr6:27153546	chr6:28046434~28047367:+
TGCT	cis	rs911555	0.755	rs34411783	ENSG00000244691.1	RPL10AP1	4.27	3.83e-05	0.0222	0.49	0.36	Intelligence (multi-trait analysis);	chr14:103434302	chr14:103412119~103412761:-
TGCT	cis	rs875971	0.862	rs6944374	ENSG00000237310.1	GS1-124K5.4	-4.27	3.83e-05	0.0222	-0.38	-0.36	Aortic root size;	chr7:66221942	chr7:66493706~66495474:+
TGCT	cis	rs2333021	0.62	rs2002033	ENSG00000259015.1	RP11-109N23.6	-4.27	3.84e-05	0.0222	-0.2	-0.36	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72968648	chr14:72960595~72961993:+
TGCT	cis	rs8059260	0.935	rs9928255	ENSG00000274038.1	RP11-66H6.4	-4.27	3.84e-05	0.0222	-0.39	-0.36	Alcohol consumption over the past year;	chr16:11027408	chr16:11056556~11057034:+
TGCT	cis	rs11083241	0.698	rs1220157	ENSG00000227279.1	AC015933.2	4.27	3.84e-05	0.0222	0.38	0.36	Intelligence (multi-trait analysis);	chr18:27971994	chr18:27954519~27963687:+
TGCT	cis	rs507080	0.769	rs527290	ENSG00000255239.1	AP002954.6	4.27	3.84e-05	0.0222	0.45	0.36	Serum metabolite levels;	chr11:118644898	chr11:118688039~118690600:-
TGCT	cis	rs4238585	0.947	rs8057825	ENSG00000261195.1	CTD-2380F24.1	-4.27	3.84e-05	0.0222	-0.55	-0.36	Body mass index;	chr16:20246387	chr16:19761172~19766099:-
TGCT	cis	rs992157	0.932	rs10194082	ENSG00000261338.2	RP11-378A13.1	4.27	3.85e-05	0.0222	0.29	0.36	Colorectal cancer;	chr2:218323854	chr2:218255319~218257366:+
TGCT	cis	rs992157	0.932	rs1473901	ENSG00000261338.2	RP11-378A13.1	4.27	3.85e-05	0.0222	0.29	0.36	Colorectal cancer;	chr2:218324115	chr2:218255319~218257366:+
TGCT	cis	rs1799949	0.965	rs799917	ENSG00000198496.9	NBR2	-4.27	3.85e-05	0.0222	-0.49	-0.36	Menopause (age at onset);	chr17:43092919	chr17:43125610~43153671:+
TGCT	cis	rs6604026	0.778	rs11810111	ENSG00000223787.2	RP4-593M8.1	4.27	3.85e-05	0.0222	0.53	0.36	Multiple sclerosis;	chr1:92813212	chr1:92580476~92580821:-
TGCT	cis	rs9309473	1	rs7598419	ENSG00000163016.8	ALMS1P	4.27	3.85e-05	0.0222	0.33	0.36	Metabolite levels;	chr2:73571096	chr2:73644919~73685576:+
TGCT	cis	rs34779708	0.931	rs11010077	ENSG00000230534.5	RP11-297A16.2	-4.27	3.85e-05	0.0222	-0.42	-0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35039160	chr10:35098006~35127020:-
TGCT	cis	rs1865760	0.929	rs2876693	ENSG00000217159.2	LARP1P1	-4.27	3.85e-05	0.0223	-0.41	-0.36	Height;	chr6:25954206	chr6:26164072~26164363:+
TGCT	cis	rs1865760	0.929	rs12195653	ENSG00000217159.2	LARP1P1	-4.27	3.85e-05	0.0223	-0.41	-0.36	Height;	chr6:25958393	chr6:26164072~26164363:+
TGCT	cis	rs7976269	0.609	rs1344855	ENSG00000275476.1	RP11-996F15.4	4.27	3.86e-05	0.0223	0.37	0.36	Male-pattern baldness;	chr12:29065605	chr12:29277397~29277882:-
TGCT	cis	rs17711722	0.565	rs4717276	ENSG00000226824.5	RP4-756H11.3	-4.27	3.86e-05	0.0223	-0.39	-0.36	Calcium levels;	chr7:65829754	chr7:66654538~66669855:+
TGCT	cis	rs453301	0.686	rs2409120	ENSG00000254340.1	RP11-10A14.3	-4.27	3.86e-05	0.0223	-0.38	-0.36	Joint mobility (Beighton score);	chr8:9025061	chr8:9141424~9145435:+
TGCT	cis	rs1150668	0.764	rs9368565	ENSG00000204709.4	LINC01556	-4.27	3.86e-05	0.0223	-0.39	-0.36	Pubertal anthropometrics;	chr6:28377433	chr6:28943877~28944537:+
TGCT	cis	rs12216499	0.591	rs12198180	ENSG00000188451.8	SRP72P2	4.27	3.86e-05	0.0223	0.46	0.36	Bladder cancer (smoking interaction);	chr6:158939454	chr6:158237336~158242797:-
TGCT	cis	rs786425	0.77	rs71458814	ENSG00000247373.3	RP11-486O12.2	4.27	3.87e-05	0.0223	0.46	0.36	Pubertal anthropometrics;	chr12:123712344	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs1139320	ENSG00000247373.3	RP11-486O12.2	4.27	3.87e-05	0.0223	0.46	0.36	Pubertal anthropometrics;	chr12:123712552	chr12:123575891~123585115:-
TGCT	cis	rs1061377	1	rs1897136	ENSG00000249685.1	RP11-360F5.3	4.27	3.87e-05	0.0223	0.33	0.36	Uric acid levels;	chr4:39131242	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs1897137	ENSG00000249685.1	RP11-360F5.3	4.27	3.87e-05	0.0223	0.33	0.36	Uric acid levels;	chr4:39131387	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs35437629	ENSG00000249685.1	RP11-360F5.3	4.27	3.87e-05	0.0223	0.33	0.36	Uric acid levels;	chr4:39131712	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs7657926	ENSG00000249685.1	RP11-360F5.3	4.27	3.87e-05	0.0223	0.33	0.36	Uric acid levels;	chr4:39132443	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs7681116	ENSG00000249685.1	RP11-360F5.3	4.27	3.87e-05	0.0223	0.33	0.36	Uric acid levels;	chr4:39133015	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs11096982	ENSG00000249685.1	RP11-360F5.3	4.27	3.87e-05	0.0223	0.33	0.36	Uric acid levels;	chr4:39133247	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs11727875	ENSG00000249685.1	RP11-360F5.3	4.27	3.87e-05	0.0223	0.33	0.36	Uric acid levels;	chr4:39133699	chr4:39133913~39135608:+
TGCT	cis	rs1061377	0.965	rs10018622	ENSG00000249685.1	RP11-360F5.3	4.27	3.87e-05	0.0223	0.33	0.36	Uric acid levels;	chr4:39133944	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs28607301	ENSG00000249685.1	RP11-360F5.3	4.27	3.87e-05	0.0223	0.33	0.36	Uric acid levels;	chr4:39136460	chr4:39133913~39135608:+
TGCT	cis	rs1061377	1	rs36090629	ENSG00000249685.1	RP11-360F5.3	4.27	3.87e-05	0.0223	0.33	0.36	Uric acid levels;	chr4:39137195	chr4:39133913~39135608:+
TGCT	cis	rs1061377	0.87	rs73238544	ENSG00000249685.1	RP11-360F5.3	4.27	3.87e-05	0.0223	0.33	0.36	Uric acid levels;	chr4:39137343	chr4:39133913~39135608:+
TGCT	cis	rs11779860	0.736	rs7004748	ENSG00000245970.2	KB-1208A12.3	4.27	3.87e-05	0.0223	0.4	0.36	QT interval;	chr8:97836138	chr8:98041726~98044121:+
TGCT	cis	rs1061377	0.585	rs3733271	ENSG00000249207.1	RP11-360F5.1	-4.27	3.87e-05	0.0223	-0.37	-0.36	Uric acid levels;	chr4:39047948	chr4:39112677~39126818:-
TGCT	cis	rs1061377	0.585	rs12648581	ENSG00000249207.1	RP11-360F5.1	-4.27	3.87e-05	0.0223	-0.37	-0.36	Uric acid levels;	chr4:39054024	chr4:39112677~39126818:-
TGCT	cis	rs8028182	0.525	rs9920028	ENSG00000260269.4	CTD-2323K18.1	-4.27	3.88e-05	0.0223	-0.44	-0.36	Sudden cardiac arrest;	chr15:75635376	chr15:75527150~75601205:-
TGCT	cis	rs875971	0.929	rs778712	ENSG00000232559.3	GS1-124K5.12	4.27	3.88e-05	0.0223	0.34	0.36	Aortic root size;	chr7:66384991	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs778710	ENSG00000232559.3	GS1-124K5.12	4.27	3.88e-05	0.0223	0.34	0.36	Aortic root size;	chr7:66389847	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.964	rs778708	ENSG00000232559.3	GS1-124K5.12	4.27	3.88e-05	0.0223	0.34	0.36	Aortic root size;	chr7:66391332	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs778696	ENSG00000232559.3	GS1-124K5.12	4.27	3.88e-05	0.0223	0.34	0.36	Aortic root size;	chr7:66405826	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs778694	ENSG00000232559.3	GS1-124K5.12	4.27	3.88e-05	0.0223	0.34	0.36	Aortic root size;	chr7:66406571	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs4718344	ENSG00000232559.3	GS1-124K5.12	4.27	3.88e-05	0.0223	0.34	0.36	Aortic root size;	chr7:66409394	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.737	rs7803424	ENSG00000232559.3	GS1-124K5.12	4.27	3.88e-05	0.0223	0.34	0.36	Aortic root size;	chr7:66415618	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.83	rs7799834	ENSG00000232559.3	GS1-124K5.12	4.27	3.88e-05	0.0223	0.34	0.36	Aortic root size;	chr7:66415707	chr7:66554588~66576923:-
TGCT	cis	rs507080	0.697	rs656287	ENSG00000255239.1	AP002954.6	4.27	3.88e-05	0.0223	0.48	0.36	Serum metabolite levels;	chr11:118701081	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.733	rs570949	ENSG00000255239.1	AP002954.6	4.27	3.88e-05	0.0223	0.48	0.36	Serum metabolite levels;	chr11:118701202	chr11:118688039~118690600:-
TGCT	cis	rs10759883	0.58	rs10818738	ENSG00000175611.10	LINC00476	4.27	3.88e-05	0.0224	0.35	0.36	Nicotine dependence;	chr9:95846938	chr9:95759231~95875977:-
TGCT	cis	rs10759883	0.627	rs12343734	ENSG00000175611.10	LINC00476	4.27	3.88e-05	0.0224	0.35	0.36	Nicotine dependence;	chr9:95847873	chr9:95759231~95875977:-
TGCT	cis	rs10759883	0.627	rs10818746	ENSG00000175611.10	LINC00476	4.27	3.88e-05	0.0224	0.35	0.36	Nicotine dependence;	chr9:95848031	chr9:95759231~95875977:-
TGCT	cis	rs10759883	0.627	rs10985769	ENSG00000175611.10	LINC00476	4.27	3.88e-05	0.0224	0.35	0.36	Nicotine dependence;	chr9:95848094	chr9:95759231~95875977:-
TGCT	cis	rs12760731	0.92	rs12747346	ENSG00000224687.1	RASAL2-AS1	4.27	3.88e-05	0.0224	0.56	0.36	Obesity-related traits;	chr1:178519674	chr1:178091508~178093984:-
TGCT	cis	rs10971721	0.822	rs7856487	ENSG00000230074.1	RP11-195F19.9	-4.27	3.89e-05	0.0224	-0.53	-0.36	Body mass index;	chr9:33870942	chr9:34665665~34681298:+
TGCT	cis	rs12210905	1	rs12191280	ENSG00000187763.3	OR2B7P	4.27	3.89e-05	0.0224	0.5	0.36	Hip circumference adjusted for BMI;	chr6:27215538	chr6:28046434~28047367:+
TGCT	cis	rs12210905	0.687	rs12204768	ENSG00000187763.3	OR2B7P	4.27	3.89e-05	0.0224	0.5	0.36	Hip circumference adjusted for BMI;	chr6:27215784	chr6:28046434~28047367:+
TGCT	cis	rs12210905	0.858	rs3800306	ENSG00000187763.3	OR2B7P	4.27	3.89e-05	0.0224	0.5	0.36	Hip circumference adjusted for BMI;	chr6:27217947	chr6:28046434~28047367:+
TGCT	cis	rs12210905	0.858	rs2023467	ENSG00000187763.3	OR2B7P	4.27	3.89e-05	0.0224	0.5	0.36	Hip circumference adjusted for BMI;	chr6:27219224	chr6:28046434~28047367:+
TGCT	cis	rs12210905	0.858	rs12200798	ENSG00000187763.3	OR2B7P	4.27	3.89e-05	0.0224	0.5	0.36	Hip circumference adjusted for BMI;	chr6:27220688	chr6:28046434~28047367:+
TGCT	cis	rs7829975	0.684	rs474892	ENSG00000173295.6	FAM86B3P	-4.27	3.89e-05	0.0224	-0.44	-0.36	Mood instability;	chr8:8739221	chr8:8228595~8244865:+
TGCT	cis	rs7757969	1	rs7752077	ENSG00000227012.2	RP1-97J1.2	-4.27	3.89e-05	0.0224	-0.64	-0.36	Schizophrenia;	chr6:111825904	chr6:111900489~111901851:-
TGCT	cis	rs9368849	0.527	rs9366881	ENSG00000186328.4	RP11-140K17.2	-4.27	3.89e-05	0.0224	-0.49	-0.36	Airway responsiveness in chronic obstructive pulmonary disease;	chr6:35182300	chr6:34715613~34715940:+
TGCT	cis	rs2005	0.502	rs12189669	ENSG00000186328.4	RP11-140K17.2	-4.27	3.89e-05	0.0224	-0.49	-0.36	Obesity-related traits;	chr6:35183023	chr6:34715613~34715940:+
TGCT	cis	rs2011503	0.883	rs17216041	ENSG00000275540.1	CTC-559E9.12	4.27	3.9e-05	0.0224	0.57	0.36	Bipolar disorder;	chr19:19255834	chr19:19740884~19750127:+
TGCT	cis	rs10256972	0.721	rs6975972	ENSG00000226291.1	AC091729.8	-4.27	3.9e-05	0.0224	-0.39	-0.36	Endometriosis;Longevity;	chr7:1030832	chr7:1080863~1082178:+
TGCT	cis	rs12745968	0.653	rs10874736	ENSG00000223787.2	RP4-593M8.1	-4.27	3.9e-05	0.0224	-0.47	-0.36	Bipolar disorder and schizophrenia;	chr1:92714639	chr1:92580476~92580821:-
TGCT	cis	rs34375054	0.553	rs12581512	ENSG00000279233.1	RP11-158L12.4	4.27	3.9e-05	0.0225	0.38	0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125137716	chr12:125138245~125141711:+
TGCT	cis	rs2709736	0.967	rs2529760	ENSG00000232790.2	LINC01162	-4.27	3.9e-05	0.0225	-0.26	-0.36	Bipolar I disorder;	chr7:20818328	chr7:20835431~21023148:+
TGCT	cis	rs2709736	0.933	rs2709744	ENSG00000232790.2	LINC01162	-4.27	3.9e-05	0.0225	-0.26	-0.36	Bipolar I disorder;	chr7:20818700	chr7:20835431~21023148:+
TGCT	cis	rs1707322	0.691	rs61784803	ENSG00000280836.1	AL355480.1	4.27	3.91e-05	0.0225	0.47	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.663	rs3935296	ENSG00000280836.1	AL355480.1	4.27	3.91e-05	0.0225	0.47	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs11211163	ENSG00000280836.1	AL355480.1	-4.27	3.91e-05	0.0225	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs12037803	ENSG00000280836.1	AL355480.1	-4.27	3.91e-05	0.0225	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs10789470	ENSG00000280836.1	AL355480.1	-4.27	3.91e-05	0.0225	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs61784796	ENSG00000280836.1	AL355480.1	-4.27	3.91e-05	0.0225	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs10749856	ENSG00000280836.1	AL355480.1	-4.27	3.91e-05	0.0225	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs10890344	ENSG00000280836.1	AL355480.1	-4.27	3.91e-05	0.0225	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs4564187	ENSG00000280836.1	AL355480.1	-4.27	3.91e-05	0.0225	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.752	rs28438704	ENSG00000280836.1	AL355480.1	-4.27	3.91e-05	0.0225	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs28442079	ENSG00000280836.1	AL355480.1	-4.27	3.91e-05	0.0225	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs28817701	ENSG00000280836.1	AL355480.1	-4.27	3.91e-05	0.0225	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.691	rs28495425	ENSG00000280836.1	AL355480.1	-4.27	3.91e-05	0.0225	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45581219~45581321:-
TGCT	cis	rs5758511	0.68	rs5758657	ENSG00000182057.4	OGFRP1	-4.27	3.91e-05	0.0225	-0.35	-0.36	Birth weight;	chr22:42222663	chr22:42269753~42275196:+
TGCT	cis	rs786425	0.682	rs12828408	ENSG00000247373.3	RP11-486O12.2	4.27	3.91e-05	0.0225	0.46	0.36	Pubertal anthropometrics;	chr12:123714171	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs3817309	ENSG00000247373.3	RP11-486O12.2	4.27	3.91e-05	0.0225	0.46	0.36	Pubertal anthropometrics;	chr12:123714174	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs66471742	ENSG00000247373.3	RP11-486O12.2	4.27	3.91e-05	0.0225	0.46	0.36	Pubertal anthropometrics;	chr12:123714459	chr12:123575891~123585115:-
TGCT	cis	rs786425	0.682	rs7135267	ENSG00000247373.3	RP11-486O12.2	4.27	3.91e-05	0.0225	0.46	0.36	Pubertal anthropometrics;	chr12:123714573	chr12:123575891~123585115:-
TGCT	cis	rs9326248	0.768	rs4936366	ENSG00000280143.1	AP000892.6	4.27	3.92e-05	0.0225	0.53	0.36	Blood protein levels;	chr11:117156169	chr11:117204967~117210292:+
TGCT	cis	rs9326248	0.861	rs4938352	ENSG00000280143.1	AP000892.6	4.27	3.92e-05	0.0225	0.53	0.36	Blood protein levels;	chr11:117156765	chr11:117204967~117210292:+
TGCT	cis	rs12216499	0.591	rs10455834	ENSG00000188451.8	SRP72P2	-4.27	3.92e-05	0.0225	-0.46	-0.36	Bladder cancer (smoking interaction);	chr6:158971253	chr6:158237336~158242797:-
TGCT	cis	rs12216499	0.591	rs12190139	ENSG00000188451.8	SRP72P2	-4.27	3.92e-05	0.0225	-0.46	-0.36	Bladder cancer (smoking interaction);	chr6:158993071	chr6:158237336~158242797:-
TGCT	cis	rs12216499	0.591	rs16889309	ENSG00000188451.8	SRP72P2	4.27	3.92e-05	0.0225	0.46	0.36	Bladder cancer (smoking interaction);	chr6:158981413	chr6:158237336~158242797:-
TGCT	cis	rs12216499	0.591	rs12204311	ENSG00000188451.8	SRP72P2	4.27	3.92e-05	0.0225	0.46	0.36	Bladder cancer (smoking interaction);	chr6:158982906	chr6:158237336~158242797:-
TGCT	cis	rs12216499	0.591	rs2143651	ENSG00000188451.8	SRP72P2	4.27	3.92e-05	0.0225	0.46	0.36	Bladder cancer (smoking interaction);	chr6:158983830	chr6:158237336~158242797:-
TGCT	cis	rs12216499	0.636	rs34582178	ENSG00000188451.8	SRP72P2	4.27	3.92e-05	0.0225	0.46	0.36	Bladder cancer (smoking interaction);	chr6:158986414	chr6:158237336~158242797:-
TGCT	cis	rs12216499	0.591	rs12524644	ENSG00000188451.8	SRP72P2	4.27	3.92e-05	0.0225	0.46	0.36	Bladder cancer (smoking interaction);	chr6:158987170	chr6:158237336~158242797:-
TGCT	cis	rs12216499	0.591	rs4709255	ENSG00000188451.8	SRP72P2	4.27	3.92e-05	0.0225	0.46	0.36	Bladder cancer (smoking interaction);	chr6:158988009	chr6:158237336~158242797:-
TGCT	cis	rs12216499	0.591	rs12190703	ENSG00000188451.8	SRP72P2	4.27	3.92e-05	0.0225	0.46	0.36	Bladder cancer (smoking interaction);	chr6:158989799	chr6:158237336~158242797:-
TGCT	cis	rs12216499	0.591	rs4709257	ENSG00000188451.8	SRP72P2	4.27	3.92e-05	0.0225	0.46	0.36	Bladder cancer (smoking interaction);	chr6:158990885	chr6:158237336~158242797:-
TGCT	cis	rs12216499	0.591	rs12202116	ENSG00000188451.8	SRP72P2	4.27	3.92e-05	0.0225	0.46	0.36	Bladder cancer (smoking interaction);	chr6:158992153	chr6:158237336~158242797:-
TGCT	cis	rs4660214	0.666	rs4617393	ENSG00000182109.6	RP11-69E11.4	-4.27	3.92e-05	0.0225	-0.36	-0.36	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39474551	chr1:39522280~39546187:-
TGCT	cis	rs728616	0.867	rs41302709	ENSG00000230091.5	TMEM254-AS1	4.27	3.92e-05	0.0225	0.6	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80047522	chr10:80046860~80078912:-
TGCT	cis	rs67311347	1	rs7631893	ENSG00000223797.4	ENTPD3-AS1	4.27	3.92e-05	0.0225	0.38	0.36	Renal cell carcinoma;	chr3:40399378	chr3:40313802~40453329:-
TGCT	cis	rs73607972	0.877	rs66646415	ENSG00000275191.1	RP11-36I17.2	-4.26	3.93e-05	0.0226	-0.43	-0.36	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53572317	chr16:53628256~53628816:-
TGCT	cis	rs853679	0.55	rs6901017	ENSG00000219891.2	ZSCAN12P1	4.26	3.93e-05	0.0226	0.46	0.36	Depression;	chr6:28184805	chr6:28091154~28093664:+
TGCT	cis	rs7181230	0.885	rs35781999	ENSG00000275636.1	RP11-521C20.5	4.26	3.93e-05	0.0226	0.45	0.36	Dehydroepiandrosterone sulphate levels;	chr15:40063205	chr15:40078892~40079347:+
TGCT	cis	rs7937890	0.874	rs2303972	ENSG00000254418.1	RP11-21L19.1	-4.26	3.93e-05	0.0226	-0.32	-0.36	Mitochondrial DNA levels;	chr11:14281736	chr11:14262846~14273691:-
TGCT	cis	rs4713118	0.55	rs9368527	ENSG00000216901.1	AL022393.7	4.26	3.93e-05	0.0226	0.4	0.36	Parkinson's disease;	chr6:27711666	chr6:28176188~28176674:+
TGCT	cis	rs8059260	0.932	rs7186166	ENSG00000274038.1	RP11-66H6.4	-4.26	3.93e-05	0.0226	-0.4	-0.36	Alcohol consumption over the past year;	chr16:11011577	chr16:11056556~11057034:+
TGCT	cis	rs4713118	0.662	rs149970	ENSG00000219392.1	RP1-265C24.5	-4.26	3.94e-05	0.0226	-0.42	-0.36	Parkinson's disease;	chr6:28012442	chr6:28115628~28116551:+
TGCT	cis	rs9326248	0.53	rs473188	ENSG00000254851.1	RP11-109L13.1	-4.26	3.94e-05	0.0226	-0.61	-0.36	Blood protein levels;	chr11:116941313	chr11:117135528~117138582:+
TGCT	cis	rs16928809	0.929	rs440150	ENSG00000183562.3	CTC-343N3.1	-4.26	3.94e-05	0.0226	-0.49	-0.36	Bilirubin levels;	chr11:2915427	chr11:2989863~2991344:+
TGCT	cis	rs11651753	0.636	rs4793731	ENSG00000264920.1	RP11-6N17.4	-4.26	3.94e-05	0.0226	-0.34	-0.36	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47956327	chr17:47891255~47895812:-
TGCT	cis	rs11651753	0.636	rs4793733	ENSG00000264920.1	RP11-6N17.4	-4.26	3.94e-05	0.0226	-0.34	-0.36	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47956616	chr17:47891255~47895812:-
TGCT	cis	rs11651753	0.636	rs35280206	ENSG00000264920.1	RP11-6N17.4	-4.26	3.94e-05	0.0226	-0.34	-0.36	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47957645	chr17:47891255~47895812:-
TGCT	cis	rs853679	0.527	rs9461443	ENSG00000187763.3	OR2B7P	4.26	3.94e-05	0.0227	0.35	0.36	Depression;	chr6:28226851	chr6:28046434~28047367:+
TGCT	cis	rs2177312	0.83	rs2030586	ENSG00000251129.1	RP11-734I18.1	-4.26	3.95e-05	0.0227	-0.44	-0.36	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31936771	chr4:31997397~32155406:+
TGCT	cis	rs8049040	1	rs7197127	ENSG00000260886.1	TAT-AS1	4.26	3.95e-05	0.0227	0.35	0.36	Blood protein levels;	chr16:71439933	chr16:71565789~71578187:+
TGCT	cis	rs4713118	0.513	rs6915987	ENSG00000216901.1	AL022393.7	-4.26	3.95e-05	0.0227	-0.41	-0.36	Parkinson's disease;	chr6:27547997	chr6:28176188~28176674:+
TGCT	cis	rs2188561	0.673	rs2712218	ENSG00000241764.3	AC002467.7	4.26	3.96e-05	0.0227	0.36	0.36	Alcohol consumption;	chr7:107716314	chr7:107742817~107744581:-
TGCT	cis	rs2236295	0.597	rs7477765	ENSG00000238280.1	RP11-436D10.3	-4.26	3.96e-05	0.0227	-0.45	-0.36	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62831984	chr10:62793562~62805887:-
TGCT	cis	rs7829975	0.774	rs35431455	ENSG00000173295.6	FAM86B3P	4.26	3.96e-05	0.0227	0.43	0.36	Mood instability;	chr8:8816226	chr8:8228595~8244865:+
TGCT	cis	rs7829975	0.617	rs4841072	ENSG00000173295.6	FAM86B3P	-4.26	3.96e-05	0.0227	-0.42	-0.36	Mood instability;	chr8:8933743	chr8:8228595~8244865:+
TGCT	cis	rs7829975	0.582	rs6982832	ENSG00000254340.1	RP11-10A14.3	-4.26	3.96e-05	0.0227	-0.35	-0.36	Mood instability;	chr8:8934707	chr8:9141424~9145435:+
TGCT	cis	rs7829975	0.582	rs6983150	ENSG00000254340.1	RP11-10A14.3	-4.26	3.96e-05	0.0227	-0.35	-0.36	Mood instability;	chr8:8934916	chr8:9141424~9145435:+
TGCT	cis	rs9595066	1	rs7981575	ENSG00000227258.4	SMIM2-AS1	4.26	3.96e-05	0.0227	0.53	0.36	Schizophrenia;	chr13:44136811	chr13:44110451~44240517:+
TGCT	cis	rs867371	1	rs13380317	ENSG00000255769.6	GOLGA2P10	4.26	3.97e-05	0.0228	0.36	0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82472993~82513950:-
TGCT	cis	rs1075265	0.626	rs805320	ENSG00000233266.1	HMGB1P31	4.26	3.97e-05	0.0228	0.36	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53911305	chr2:54051334~54051760:+
TGCT	cis	rs3931020	0.688	rs405445	ENSG00000272864.1	RP11-17E13.2	4.26	3.97e-05	0.0228	0.43	0.36	Resistin levels;	chr1:74755466	chr1:74698769~74699333:-
TGCT	cis	rs4713118	0.662	rs9393881	ENSG00000187763.3	OR2B7P	4.26	3.97e-05	0.0228	0.34	0.36	Parkinson's disease;	chr6:28055973	chr6:28046434~28047367:+
TGCT	cis	rs30380	0.734	rs27044	ENSG00000248734.2	CTD-2260A17.1	4.26	3.98e-05	0.0228	0.3	0.36	Cerebrospinal fluid biomarker levels;	chr5:96783148	chr5:96784777~96785999:+
TGCT	cis	rs30380	0.69	rs27432	ENSG00000248734.2	CTD-2260A17.1	4.26	3.98e-05	0.0228	0.3	0.36	Cerebrospinal fluid biomarker levels;	chr5:96783569	chr5:96784777~96785999:+
TGCT	cis	rs39841	1	rs39841	ENSG00000248734.2	CTD-2260A17.1	4.26	3.98e-05	0.0228	0.3	0.36	Inflammatory skin disease;	chr5:96784466	chr5:96784777~96785999:+
TGCT	cis	rs30380	0.734	rs30376	ENSG00000248734.2	CTD-2260A17.1	4.26	3.98e-05	0.0228	0.3	0.36	Cerebrospinal fluid biomarker levels;	chr5:96784555	chr5:96784777~96785999:+
TGCT	cis	rs7829975	0.533	rs7820146	ENSG00000173295.6	FAM86B3P	4.26	3.98e-05	0.0228	0.43	0.36	Mood instability;	chr8:8842247	chr8:8228595~8244865:+
TGCT	cis	rs7829975	0.606	rs7833171	ENSG00000173295.6	FAM86B3P	4.26	3.98e-05	0.0228	0.43	0.36	Mood instability;	chr8:8842251	chr8:8228595~8244865:+
TGCT	cis	rs1150668	0.796	rs1052215	ENSG00000204709.4	LINC01556	-4.26	3.98e-05	0.0228	-0.39	-0.36	Pubertal anthropometrics;	chr6:28380381	chr6:28943877~28944537:+
TGCT	cis	rs7208859	0.673	rs216410	ENSG00000263531.1	RP13-753N3.1	-4.26	3.98e-05	0.0228	-0.67	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576813	chr17:30863921~30864940:-
TGCT	cis	rs875971	1	rs10244498	ENSG00000237310.1	GS1-124K5.4	4.26	3.98e-05	0.0229	0.4	0.36	Aortic root size;	chr7:66651069	chr7:66493706~66495474:+
TGCT	cis	rs1010254	0.959	rs13357566	ENSG00000213433.5	RPLP1P6	-4.26	3.99e-05	0.0229	-0.37	-0.36	Optic nerve measurement (cup area);	chr5:152316605	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.959	rs2348646	ENSG00000213433.5	RPLP1P6	-4.26	3.99e-05	0.0229	-0.37	-0.36	Optic nerve measurement (cup area);	chr5:152317313	chr5:151765859~151766378:-
TGCT	cis	rs875971	1	rs3981131	ENSG00000237310.1	GS1-124K5.4	4.26	3.99e-05	0.0229	0.38	0.36	Aortic root size;	chr7:66486690	chr7:66493706~66495474:+
TGCT	cis	rs2882667	0.537	rs7704790	ENSG00000253404.1	AC034243.1	4.26	3.99e-05	0.0229	0.41	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr5:139074407	chr5:138744434~138753309:-
TGCT	cis	rs1707322	0.964	rs7512395	ENSG00000280836.1	AL355480.1	-4.26	3.99e-05	0.0229	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs12124847	ENSG00000280836.1	AL355480.1	-4.26	3.99e-05	0.0229	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs4074225	ENSG00000280836.1	AL355480.1	-4.26	3.99e-05	0.0229	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.963	rs10890373	ENSG00000280836.1	AL355480.1	-4.26	3.99e-05	0.0229	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs4134387	ENSG00000280836.1	AL355480.1	-4.26	3.99e-05	0.0229	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs10890376	ENSG00000280836.1	AL355480.1	-4.26	3.99e-05	0.0229	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs10789485	ENSG00000280836.1	AL355480.1	-4.26	3.99e-05	0.0229	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr1:45581219~45581321:-
TGCT	cis	rs10875976	0.967	rs4898532	ENSG00000257253.2	RP11-70F11.7	4.26	4e-05	0.0229	0.3	0.36	Obesity;	chr12:49829796	chr12:49861207~49865802:+
TGCT	cis	rs10971721	0.908	rs10971722	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33828166	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs10971723	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33829604	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.908	rs12376055	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33831957	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.908	rs55684780	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33833210	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.908	rs10971728	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33834635	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.642	rs114466241	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33835731	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.731	rs12378261	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33837174	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72725374	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33840651	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.749	rs72725375	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33840706	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72725376	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33841931	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72725377	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33842228	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72725378	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33842896	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs12380143	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33847588	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72725381	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33851167	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs10971735	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33851801	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.642	rs10971736	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33854376	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.749	rs10971741	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33856869	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs56253239	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33860068	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs115554740	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33860888	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72725387	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33863673	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.731	rs72725388	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33864624	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs117687546	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33864931	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs56370320	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33865630	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs56172788	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33865752	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.731	rs10971750	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33869783	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs10971753	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33870438	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs10971754	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33871714	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs10971755	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33872007	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72725398	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33875920	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs10971758	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33876071	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.731	rs72725402	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33878358	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.731	rs72727303	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33878378	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs10971763	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33879779	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs10971764	ENSG00000230074.1	RP11-195F19.9	-4.26	4e-05	0.0229	-0.53	-0.36	Body mass index;	chr9:33880102	chr9:34665665~34681298:+
TGCT	cis	rs847851	1	rs4646949	ENSG00000186328.4	RP11-140K17.2	4.26	4e-05	0.0229	0.39	0.36	Colonoscopy-negative controls vs population controls;	chr6:34877672	chr6:34715613~34715940:+
TGCT	cis	rs17826219	0.568	rs11658027	ENSG00000266490.1	CTD-2349P21.9	-4.26	4e-05	0.0229	-0.42	-0.36	Body mass index;	chr17:30767864	chr17:30792372~30792833:+
TGCT	cis	rs16975963	0.644	rs2290999	ENSG00000276846.1	CTD-3220F14.3	-4.26	4e-05	0.0229	-0.34	-0.36	Longevity;	chr19:37647986	chr19:37314868~37315620:-
TGCT	cis	rs2581828	0.931	rs2564942	ENSG00000242142.1	SERBP1P3	4.26	4.01e-05	0.0229	0.33	0.36	Crohn's disease;	chr3:53105490	chr3:53064283~53065091:-
TGCT	cis	rs2581828	0.931	rs2581774	ENSG00000242142.1	SERBP1P3	4.26	4.01e-05	0.0229	0.33	0.36	Crohn's disease;	chr3:53105491	chr3:53064283~53065091:-
TGCT	cis	rs7804306	0.522	rs11981425	ENSG00000233264.2	AC006042.8	4.26	4.01e-05	0.023	0.52	0.36	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8045298	chr7:7980312~7982228:+
TGCT	cis	rs763121	0.815	rs4821799	ENSG00000273076.1	RP3-508I15.22	4.26	4.01e-05	0.023	0.39	0.36	Menopause (age at onset);	chr22:38625321	chr22:38743495~38743910:+
TGCT	cis	rs11772815	1	rs4722787	ENSG00000233830.2	EIF4HP1	-4.26	4.02e-05	0.023	-0.38	-0.36	Folding of antihelix;	chr7:28367205	chr7:27458163~27458849:-
TGCT	cis	rs4835473	0.932	rs3872	ENSG00000251600.4	RP11-673E1.1	4.26	4.02e-05	0.023	0.38	0.36	Immature fraction of reticulocytes;	chr4:143968788	chr4:143912331~143982454:+
TGCT	cis	rs2739330	0.703	rs5760112	ENSG00000235689.1	AP000351.13	4.26	4.02e-05	0.023	0.34	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:24006305~24008258:-
TGCT	cis	rs1275600	0.638	rs12310593	ENSG00000271142.1	YWHAQP7	4.26	4.02e-05	0.023	0.36	0.36	Non-glioblastoma glioma;	chr12:75859139	chr12:76619386~76620043:+
TGCT	cis	rs786425	0.966	rs4040225	ENSG00000247373.3	RP11-486O12.2	4.26	4.02e-05	0.023	0.42	0.36	Pubertal anthropometrics;	chr12:123612126	chr12:123575891~123585115:-
TGCT	cis	rs10759883	0.627	rs12000073	ENSG00000175611.10	LINC00476	4.26	4.03e-05	0.023	0.34	0.36	Nicotine dependence;	chr9:95853844	chr9:95759231~95875977:-
TGCT	cis	rs7208859	0.573	rs55661352	ENSG00000280069.1	CTD-2349P21.3	-4.26	4.03e-05	0.023	-0.5	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30738182~30740275:+
TGCT	cis	rs12216499	0.551	rs77993394	ENSG00000188451.8	SRP72P2	4.26	4.03e-05	0.023	0.46	0.36	Bladder cancer (smoking interaction);	chr6:158936189	chr6:158237336~158242797:-
TGCT	cis	rs12216499	0.551	rs12526611	ENSG00000188451.8	SRP72P2	4.26	4.03e-05	0.023	0.46	0.36	Bladder cancer (smoking interaction);	chr6:158937074	chr6:158237336~158242797:-
TGCT	cis	rs12216499	0.591	rs4612195	ENSG00000188451.8	SRP72P2	4.26	4.03e-05	0.023	0.46	0.36	Bladder cancer (smoking interaction);	chr6:158937676	chr6:158237336~158242797:-
TGCT	cis	rs12216499	0.591	rs4515409	ENSG00000188451.8	SRP72P2	4.26	4.03e-05	0.023	0.46	0.36	Bladder cancer (smoking interaction);	chr6:158955000	chr6:158237336~158242797:-
TGCT	cis	rs12216499	0.591	rs34075942	ENSG00000188451.8	SRP72P2	4.26	4.03e-05	0.023	0.46	0.36	Bladder cancer (smoking interaction);	chr6:158955424	chr6:158237336~158242797:-
TGCT	cis	rs12216499	0.591	rs12199481	ENSG00000188451.8	SRP72P2	4.26	4.03e-05	0.023	0.46	0.36	Bladder cancer (smoking interaction);	chr6:158960460	chr6:158237336~158242797:-
TGCT	cis	rs12216499	0.591	rs12192650	ENSG00000188451.8	SRP72P2	4.26	4.03e-05	0.023	0.46	0.36	Bladder cancer (smoking interaction);	chr6:158960661	chr6:158237336~158242797:-
TGCT	cis	rs12216499	0.591	rs80335337	ENSG00000188451.8	SRP72P2	4.26	4.03e-05	0.023	0.46	0.36	Bladder cancer (smoking interaction);	chr6:158962222	chr6:158237336~158242797:-
TGCT	cis	rs12216499	0.591	rs10945584	ENSG00000188451.8	SRP72P2	4.26	4.03e-05	0.023	0.46	0.36	Bladder cancer (smoking interaction);	chr6:158965815	chr6:158237336~158242797:-
TGCT	cis	rs12216499	0.591	rs10755566	ENSG00000188451.8	SRP72P2	4.26	4.03e-05	0.023	0.46	0.36	Bladder cancer (smoking interaction);	chr6:158969639	chr6:158237336~158242797:-
TGCT	cis	rs12216499	0.591	rs10945585	ENSG00000188451.8	SRP72P2	4.26	4.03e-05	0.023	0.46	0.36	Bladder cancer (smoking interaction);	chr6:158970083	chr6:158237336~158242797:-
TGCT	cis	rs12216499	0.591	rs3756988	ENSG00000188451.8	SRP72P2	4.26	4.03e-05	0.023	0.46	0.36	Bladder cancer (smoking interaction);	chr6:158977601	chr6:158237336~158242797:-
TGCT	cis	rs12216499	0.591	rs12190523	ENSG00000188451.8	SRP72P2	4.26	4.03e-05	0.023	0.46	0.36	Bladder cancer (smoking interaction);	chr6:158980457	chr6:158237336~158242797:-
TGCT	cis	rs12216499	0.591	rs12216267	ENSG00000188451.8	SRP72P2	-4.26	4.03e-05	0.023	-0.46	-0.36	Bladder cancer (smoking interaction);	chr6:158959582	chr6:158237336~158242797:-
TGCT	cis	rs12216499	0.591	rs3756987	ENSG00000188451.8	SRP72P2	-4.26	4.03e-05	0.023	-0.46	-0.36	Bladder cancer (smoking interaction);	chr6:158977668	chr6:158237336~158242797:-
TGCT	cis	rs875971	0.965	rs7794930	ENSG00000237310.1	GS1-124K5.4	-4.26	4.03e-05	0.0231	-0.4	-0.36	Aortic root size;	chr7:66313559	chr7:66493706~66495474:+
TGCT	cis	rs9880211	0.898	rs1052620	ENSG00000239213.4	NCK1-AS1	4.26	4.04e-05	0.0231	0.38	0.36	Height;Body mass index;	chr3:136855679	chr3:136841726~136862054:-
TGCT	cis	rs9867325	1	rs9867325	ENSG00000239213.4	NCK1-AS1	4.26	4.04e-05	0.0231	0.38	0.36	Body mass index;	chr3:136900067	chr3:136841726~136862054:-
TGCT	cis	rs9867325	1	rs9840500	ENSG00000239213.4	NCK1-AS1	4.26	4.04e-05	0.0231	0.38	0.36	Body mass index;	chr3:136902496	chr3:136841726~136862054:-
TGCT	cis	rs5742933	1	rs1966729	ENSG00000273240.1	RP11-455J20.3	-4.26	4.04e-05	0.0231	-0.37	-0.36	Ferritin levels;	chr2:189721105	chr2:189763859~189764456:-
TGCT	cis	rs5742933	0.842	rs1225101	ENSG00000273240.1	RP11-455J20.3	-4.26	4.04e-05	0.0231	-0.37	-0.36	Ferritin levels;	chr2:189740695	chr2:189763859~189764456:-
TGCT	cis	rs9297994	0.556	rs10097590	ENSG00000242970.2	AC068522.4	-4.26	4.04e-05	0.0231	-0.46	-0.36	LDL cholesterol;	chr8:58519918	chr8:58588420~58588764:-
TGCT	cis	rs9297994	0.556	rs10110065	ENSG00000242970.2	AC068522.4	-4.26	4.04e-05	0.0231	-0.46	-0.36	LDL cholesterol;	chr8:58523662	chr8:58588420~58588764:-
TGCT	cis	rs9297994	0.556	rs72647424	ENSG00000242970.2	AC068522.4	-4.26	4.04e-05	0.0231	-0.46	-0.36	LDL cholesterol;	chr8:58524096	chr8:58588420~58588764:-
TGCT	cis	rs9297994	0.556	rs72647425	ENSG00000242970.2	AC068522.4	-4.26	4.04e-05	0.0231	-0.46	-0.36	LDL cholesterol;	chr8:58525976	chr8:58588420~58588764:-
TGCT	cis	rs9297994	0.556	rs11775194	ENSG00000242970.2	AC068522.4	-4.26	4.04e-05	0.0231	-0.46	-0.36	LDL cholesterol;	chr8:58527218	chr8:58588420~58588764:-
TGCT	cis	rs3931020	0.657	rs10890142	ENSG00000272864.1	RP11-17E13.2	-4.26	4.04e-05	0.0231	-0.43	-0.36	Resistin levels;	chr1:74713445	chr1:74698769~74699333:-
TGCT	cis	rs7208859	0.673	rs999798	ENSG00000280069.1	CTD-2349P21.3	-4.26	4.04e-05	0.0231	-0.44	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30738182~30740275:+
TGCT	cis	rs9309473	0.95	rs6740766	ENSG00000163016.8	ALMS1P	4.26	4.05e-05	0.0231	0.33	0.36	Metabolite levels;	chr2:73553786	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs13431267	ENSG00000163016.8	ALMS1P	4.26	4.05e-05	0.0231	0.33	0.36	Metabolite levels;	chr2:73555073	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs10207220	ENSG00000163016.8	ALMS1P	4.26	4.05e-05	0.0231	0.33	0.36	Metabolite levels;	chr2:73557919	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.95	rs10169213	ENSG00000163016.8	ALMS1P	4.26	4.05e-05	0.0231	0.33	0.36	Metabolite levels;	chr2:73560107	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.95	rs6735946	ENSG00000163016.8	ALMS1P	4.26	4.05e-05	0.0231	0.33	0.36	Metabolite levels;	chr2:73562931	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.95	rs17009149	ENSG00000163016.8	ALMS1P	4.26	4.05e-05	0.0231	0.33	0.36	Metabolite levels;	chr2:73563241	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.95	rs10198549	ENSG00000163016.8	ALMS1P	4.26	4.05e-05	0.0231	0.33	0.36	Metabolite levels;	chr2:73567277	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs9653557	ENSG00000163016.8	ALMS1P	4.26	4.05e-05	0.0231	0.33	0.36	Metabolite levels;	chr2:73568835	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.848	rs17009159	ENSG00000163016.8	ALMS1P	4.26	4.05e-05	0.0231	0.33	0.36	Metabolite levels;	chr2:73570635	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs7583255	ENSG00000163016.8	ALMS1P	4.26	4.05e-05	0.0231	0.33	0.36	Metabolite levels;	chr2:73570869	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs7586463	ENSG00000163016.8	ALMS1P	4.26	4.05e-05	0.0231	0.33	0.36	Metabolite levels;	chr2:73571349	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs1114380	ENSG00000163016.8	ALMS1P	4.26	4.05e-05	0.0231	0.33	0.36	Metabolite levels;	chr2:73577581	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs10169714	ENSG00000163016.8	ALMS1P	4.26	4.05e-05	0.0231	0.33	0.36	Metabolite levels;	chr2:73581646	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs6745368	ENSG00000163016.8	ALMS1P	4.26	4.05e-05	0.0231	0.33	0.36	Metabolite levels;	chr2:73582847	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs7558944	ENSG00000163016.8	ALMS1P	4.26	4.05e-05	0.0231	0.33	0.36	Metabolite levels;	chr2:73583782	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs13432605	ENSG00000163016.8	ALMS1P	4.26	4.05e-05	0.0231	0.33	0.36	Metabolite levels;	chr2:73583854	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.848	rs9750915	ENSG00000163016.8	ALMS1P	4.26	4.05e-05	0.0231	0.33	0.36	Metabolite levels;	chr2:73584753	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.948	rs10173534	ENSG00000163016.8	ALMS1P	4.26	4.05e-05	0.0231	0.33	0.36	Metabolite levels;	chr2:73586305	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs7582606	ENSG00000163016.8	ALMS1P	4.26	4.05e-05	0.0231	0.33	0.36	Metabolite levels;	chr2:73586818	chr2:73644919~73685576:+
TGCT	cis	rs4242434	0.757	rs2280104	ENSG00000253200.1	RP11-582J16.5	4.26	4.05e-05	0.0231	0.2	0.36	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22668467	chr8:22613908~22616657:-
TGCT	cis	rs8059260	0.696	rs2110354	ENSG00000274038.1	RP11-66H6.4	-4.26	4.05e-05	0.0231	-0.38	-0.36	Alcohol consumption over the past year;	chr16:11013635	chr16:11056556~11057034:+
TGCT	cis	rs875971	1	rs1544549	ENSG00000237310.1	GS1-124K5.4	-4.26	4.06e-05	0.0232	-0.39	-0.36	Aortic root size;	chr7:66625676	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs2420820	ENSG00000237310.1	GS1-124K5.4	-4.26	4.06e-05	0.0232	-0.39	-0.36	Aortic root size;	chr7:66626920	chr7:66493706~66495474:+
TGCT	cis	rs1010254	0.764	rs73282722	ENSG00000213433.5	RPLP1P6	-4.26	4.06e-05	0.0232	-0.37	-0.36	Optic nerve measurement (cup area);	chr5:152409077	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.764	rs9687964	ENSG00000213433.5	RPLP1P6	-4.26	4.06e-05	0.0232	-0.37	-0.36	Optic nerve measurement (cup area);	chr5:152412408	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.764	rs9688095	ENSG00000213433.5	RPLP1P6	-4.26	4.06e-05	0.0232	-0.37	-0.36	Optic nerve measurement (cup area);	chr5:152412514	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.723	rs2098636	ENSG00000213433.5	RPLP1P6	-4.26	4.06e-05	0.0232	-0.37	-0.36	Optic nerve measurement (cup area);	chr5:152412712	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.764	rs1422369	ENSG00000213433.5	RPLP1P6	-4.26	4.06e-05	0.0232	-0.37	-0.36	Optic nerve measurement (cup area);	chr5:152413049	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.764	rs1422370	ENSG00000213433.5	RPLP1P6	-4.26	4.06e-05	0.0232	-0.37	-0.36	Optic nerve measurement (cup area);	chr5:152413161	chr5:151765859~151766378:-
TGCT	cis	rs10256972	0.758	rs7799391	ENSG00000226291.1	AC091729.8	-4.26	4.06e-05	0.0232	-0.38	-0.36	Endometriosis;Longevity;	chr7:1042930	chr7:1080863~1082178:+
TGCT	cis	rs75422866	0.867	rs73111258	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47597313	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs117388682	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47599713	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs79113930	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47600628	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs35044089	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47610881	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs78912815	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47612065	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs73113117	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47617299	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs73113139	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47622826	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs73113143	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47623060	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.717	rs73113159	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47631318	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.717	rs73113161	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47632361	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs117022227	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47633282	chr12:47728151~47730598:-
TGCT	cis	rs75422866	1	rs73102120	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47637280	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs73102125	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47637869	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs12426849	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47638975	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs117950951	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47639794	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs7954764	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47641136	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs12422974	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47644559	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs73102127	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47645341	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs73102140	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47647497	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs73102148	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47648013	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs73102151	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47648023	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs75568526	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47649718	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs116302411	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47649788	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs73102166	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47653769	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs73102168	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47654010	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs73102171	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47656077	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs76100981	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47660092	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs73102188	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47662993	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs73102195	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47666309	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs73102201	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47669269	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs73104103	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47669604	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs73104104	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47671986	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs73104111	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47673994	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs73104115	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47684843	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs73104116	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47685023	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs73104138	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47692302	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.717	rs73104143	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47693449	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs73104144	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47694390	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs73104148	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47696732	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs73104152	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47699091	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs73104155	ENSG00000280054.1	RP1-197B17.7	4.26	4.06e-05	0.0232	0.67	0.36	Pneumonia;	chr12:47700790	chr12:47728151~47730598:-
TGCT	cis	rs11139399	0.613	rs7023303	ENSG00000233926.1	RP11-154D17.1	-4.26	4.07e-05	0.0232	-0.41	-0.36	Hippocampal atrophy;	chr9:81721395	chr9:81689713~81776900:+
TGCT	cis	rs10129255	1	rs11627342	ENSG00000211970.3	IGHV4-61	-4.26	4.07e-05	0.0232	-0.38	-0.36	Kawasaki disease;	chr14:106675823	chr14:106639119~106639657:-
TGCT	cis	rs7829975	0.667	rs1877119	ENSG00000173295.6	FAM86B3P	4.26	4.07e-05	0.0232	0.44	0.36	Mood instability;	chr8:8849687	chr8:8228595~8244865:+
TGCT	cis	rs11123170	0.543	rs4849178	ENSG00000189223.12	PAX8-AS1	-4.26	4.07e-05	0.0232	-0.58	-0.36	Renal function-related traits (BUN);	chr2:113225031	chr2:113211522~113276581:+
TGCT	cis	rs891378	0.651	rs7546693	ENSG00000274245.1	RP11-357P18.2	-4.26	4.07e-05	0.0232	-0.45	-0.36	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207192864	chr1:207372559~207373252:+
TGCT	cis	rs8072100	0.817	rs6505049	ENSG00000228782.6	CTD-2026D20.3	-4.26	4.07e-05	0.0232	-0.44	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47598415	chr17:47450568~47492492:-
TGCT	cis	rs3931020	0.688	rs1051122	ENSG00000272864.1	RP11-17E13.2	-4.26	4.07e-05	0.0232	-0.42	-0.36	Resistin levels;	chr1:74724768	chr1:74698769~74699333:-
TGCT	cis	rs3931020	0.688	rs968358	ENSG00000272864.1	RP11-17E13.2	-4.26	4.07e-05	0.0232	-0.42	-0.36	Resistin levels;	chr1:74728305	chr1:74698769~74699333:-
TGCT	cis	rs4713118	0.662	rs9380046	ENSG00000187763.3	OR2B7P	4.26	4.07e-05	0.0232	0.35	0.36	Parkinson's disease;	chr6:28062721	chr6:28046434~28047367:+
TGCT	cis	rs1964356	0.967	rs2953802	ENSG00000173295.6	FAM86B3P	4.26	4.07e-05	0.0232	0.43	0.36	Mean corpuscular volume;	chr8:8994371	chr8:8228595~8244865:+
TGCT	cis	rs11121022	1	rs11121022	ENSG00000269925.1	RP3-467L1.6	-4.26	4.08e-05	0.0232	-0.37	-0.36	Morning vs. evening chronotype;	chr1:7776599	chr1:7776383~7776775:+
TGCT	cis	rs11673344	0.8	rs8108214	ENSG00000226686.6	LINC01535	-4.26	4.08e-05	0.0232	-0.41	-0.36	Obesity-related traits;	chr19:37025184	chr19:37251912~37265535:+
TGCT	cis	rs12745968	0.56	rs1325434	ENSG00000223787.2	RP4-593M8.1	-4.26	4.08e-05	0.0232	-0.46	-0.36	Bipolar disorder and schizophrenia;	chr1:92495775	chr1:92580476~92580821:-
TGCT	cis	rs12745968	0.589	rs912796	ENSG00000223787.2	RP4-593M8.1	-4.26	4.08e-05	0.0232	-0.46	-0.36	Bipolar disorder and schizophrenia;	chr1:92495853	chr1:92580476~92580821:-
TGCT	cis	rs12143943	0.835	rs12730457	ENSG00000176754.11	LINC00303	4.26	4.08e-05	0.0232	0.33	0.36	Cognitive performance;	chr1:204579004	chr1:204032447~204041265:-
TGCT	cis	rs6474412	0.843	rs1530848	ENSG00000255101.1	RP11-412B14.1	4.26	4.08e-05	0.0232	0.34	0.36	Smoking behavior;	chr8:42697765	chr8:42705583~42721946:-
TGCT	cis	rs9322193	0.607	rs9371228	ENSG00000216906.2	RP11-350J20.9	-4.25	4.09e-05	0.0233	-0.46	-0.36	Lung cancer;	chr6:149921977	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.566	rs4870118	ENSG00000216906.2	RP11-350J20.9	-4.25	4.09e-05	0.0233	-0.46	-0.36	Lung cancer;	chr6:149923877	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.566	rs4869767	ENSG00000216906.2	RP11-350J20.9	-4.25	4.09e-05	0.0233	-0.46	-0.36	Lung cancer;	chr6:149923974	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.566	rs4869768	ENSG00000216906.2	RP11-350J20.9	-4.25	4.09e-05	0.0233	-0.46	-0.36	Lung cancer;	chr6:149924067	chr6:149904243~149906418:+
TGCT	cis	rs2739330	0.587	rs4820571	ENSG00000272787.1	KB-226F1.2	-4.25	4.09e-05	0.0233	-0.4	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23969211~23969873:+
TGCT	cis	rs867186	0.925	rs6120843	ENSG00000126005.14	MMP24-AS1	-4.25	4.09e-05	0.0233	-0.46	-0.36	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35131190	chr20:35216462~35278131:-
TGCT	cis	rs867186	0.92	rs56289894	ENSG00000126005.14	MMP24-AS1	-4.25	4.09e-05	0.0233	-0.46	-0.36	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35131597	chr20:35216462~35278131:-
TGCT	cis	rs867186	0.925	rs1033797	ENSG00000126005.14	MMP24-AS1	-4.25	4.09e-05	0.0233	-0.46	-0.36	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35131884	chr20:35216462~35278131:-
TGCT	cis	rs867186	0.925	rs6120844	ENSG00000126005.14	MMP24-AS1	-4.25	4.09e-05	0.0233	-0.46	-0.36	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35132437	chr20:35216462~35278131:-
TGCT	cis	rs7829975	0.542	rs7844374	ENSG00000173295.6	FAM86B3P	-4.25	4.09e-05	0.0233	-0.44	-0.36	Mood instability;	chr8:8941174	chr8:8228595~8244865:+
TGCT	cis	rs801193	1	rs13239306	ENSG00000237310.1	GS1-124K5.4	-4.25	4.1e-05	0.0233	-0.41	-0.36	Aortic root size;	chr7:66671030	chr7:66493706~66495474:+
TGCT	cis	rs10504229	0.569	rs75466737	ENSG00000253301.4	RP11-513O17.2	4.25	4.1e-05	0.0234	0.58	0.36	Developmental language disorder (linguistic errors);	chr8:57142475	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.636	rs115738451	ENSG00000253301.4	RP11-513O17.2	4.25	4.1e-05	0.0234	0.58	0.36	Developmental language disorder (linguistic errors);	chr8:57142574	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.636	rs77290284	ENSG00000253301.4	RP11-513O17.2	4.25	4.1e-05	0.0234	0.58	0.36	Developmental language disorder (linguistic errors);	chr8:57142710	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.636	rs117439064	ENSG00000253301.4	RP11-513O17.2	4.25	4.1e-05	0.0234	0.58	0.36	Developmental language disorder (linguistic errors);	chr8:57142720	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.679	rs17193048	ENSG00000253301.4	RP11-513O17.2	4.25	4.1e-05	0.0234	0.58	0.36	Developmental language disorder (linguistic errors);	chr8:57142833	chr8:57142689~57240298:+
TGCT	cis	rs11673344	0.931	rs73622783	ENSG00000226686.6	LINC01535	4.25	4.11e-05	0.0234	0.4	0.36	Obesity-related traits;	chr19:37165155	chr19:37251912~37265535:+
TGCT	cis	rs11722228	0.522	rs73212817	ENSG00000261490.1	RP11-448G15.3	4.25	4.11e-05	0.0234	0.35	0.36	Urate levels;Serum uric acid levels;Gout;	chr4:10062387	chr4:10068089~10073019:-
TGCT	cis	rs801193	0.636	rs10233806	ENSG00000237310.1	GS1-124K5.4	-4.25	4.11e-05	0.0234	-0.4	-0.36	Aortic root size;	chr7:66653261	chr7:66493706~66495474:+
TGCT	cis	rs1707322	0.752	rs6662164	ENSG00000280836.1	AL355480.1	-4.25	4.11e-05	0.0234	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr1:45581219~45581321:-
TGCT	cis	rs4660214	0.666	rs6698791	ENSG00000182109.6	RP11-69E11.4	-4.25	4.11e-05	0.0234	-0.36	-0.36	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39469104	chr1:39522280~39546187:-
TGCT	cis	rs4660214	0.666	rs10888788	ENSG00000182109.6	RP11-69E11.4	-4.25	4.11e-05	0.0234	-0.36	-0.36	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39472024	chr1:39522280~39546187:-
TGCT	cis	rs801193	0.66	rs2659914	ENSG00000237310.1	GS1-124K5.4	4.25	4.12e-05	0.0234	0.4	0.36	Aortic root size;	chr7:66691927	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.636	rs2659895	ENSG00000237310.1	GS1-124K5.4	4.25	4.12e-05	0.0234	0.4	0.36	Aortic root size;	chr7:66731484	chr7:66493706~66495474:+
TGCT	cis	rs1372520	0.564	rs2737011	ENSG00000247775.2	SNCA-AS1	4.25	4.12e-05	0.0234	0.35	0.36	Neuroticism;	chr4:89825068	chr4:89836408~89841978:+
TGCT	cis	rs1372520	0.623	rs2583975	ENSG00000247775.2	SNCA-AS1	4.25	4.12e-05	0.0234	0.35	0.36	Neuroticism;	chr4:89827337	chr4:89836408~89841978:+
TGCT	cis	rs1159268	0.521	rs61822531	ENSG00000223842.1	RP11-135J2.3	-4.25	4.12e-05	0.0234	-0.38	-0.36	Acne (severe);	chr1:218669969	chr1:219222248~219225497:-
TGCT	cis	rs1159268	0.514	rs4846277	ENSG00000223842.1	RP11-135J2.3	-4.25	4.12e-05	0.0234	-0.38	-0.36	Acne (severe);	chr1:218669994	chr1:219222248~219225497:-
TGCT	cis	rs911555	0.755	rs2273702	ENSG00000244691.1	RPL10AP1	4.25	4.12e-05	0.0234	0.48	0.36	Intelligence (multi-trait analysis);	chr14:103451845	chr14:103412119~103412761:-
TGCT	cis	rs11673344	0.864	rs7247589	ENSG00000226686.6	LINC01535	4.25	4.12e-05	0.0234	0.41	0.36	Obesity-related traits;	chr19:37019879	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.864	rs7256213	ENSG00000226686.6	LINC01535	4.25	4.12e-05	0.0234	0.41	0.36	Obesity-related traits;	chr19:37020589	chr19:37251912~37265535:+
TGCT	cis	rs4853012	0.838	rs6707729	ENSG00000257800.1	FNBP1P1	4.25	4.13e-05	0.0235	0.39	0.36	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74120680~74123218:+
TGCT	cis	rs867186	0.614	rs73902680	ENSG00000126005.14	MMP24-AS1	-4.25	4.13e-05	0.0235	-0.65	-0.36	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34706140	chr20:35216462~35278131:-
TGCT	cis	rs17711722	0.522	rs6957759	ENSG00000226824.5	RP4-756H11.3	-4.25	4.13e-05	0.0235	-0.39	-0.36	Calcium levels;	chr7:65806798	chr7:66654538~66669855:+
TGCT	cis	rs16852403	0.517	rs12032786	ENSG00000224687.1	RASAL2-AS1	4.25	4.13e-05	0.0235	0.48	0.36	Childhood ear infection;	chr1:178267041	chr1:178091508~178093984:-
TGCT	cis	rs8072100	0.967	rs11656855	ENSG00000228782.6	CTD-2026D20.3	-4.25	4.13e-05	0.0235	-0.42	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47637289	chr17:47450568~47492492:-
TGCT	cis	rs5758511	0.68	rs5758687	ENSG00000182057.4	OGFRP1	-4.25	4.14e-05	0.0235	-0.35	-0.36	Birth weight;	chr22:42260582	chr22:42269753~42275196:+
TGCT	cis	rs12745968	0.652	rs7546197	ENSG00000223787.2	RP4-593M8.1	-4.25	4.15e-05	0.0236	-0.46	-0.36	Bipolar disorder and schizophrenia;	chr1:92690382	chr1:92580476~92580821:-
TGCT	cis	rs10504229	0.639	rs16921812	ENSG00000253301.4	RP11-513O17.2	4.25	4.15e-05	0.0236	0.54	0.36	Developmental language disorder (linguistic errors);	chr8:57194178	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs2005392	ENSG00000253301.4	RP11-513O17.2	4.25	4.15e-05	0.0236	0.54	0.36	Developmental language disorder (linguistic errors);	chr8:57194337	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs16921814	ENSG00000253301.4	RP11-513O17.2	4.25	4.15e-05	0.0236	0.54	0.36	Developmental language disorder (linguistic errors);	chr8:57194862	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs16921817	ENSG00000253301.4	RP11-513O17.2	4.25	4.15e-05	0.0236	0.54	0.36	Developmental language disorder (linguistic errors);	chr8:57195004	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.724	rs73603871	ENSG00000253301.4	RP11-513O17.2	4.25	4.15e-05	0.0236	0.54	0.36	Developmental language disorder (linguistic errors);	chr8:57195053	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs16921819	ENSG00000253301.4	RP11-513O17.2	4.25	4.15e-05	0.0236	0.54	0.36	Developmental language disorder (linguistic errors);	chr8:57195377	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs72649187	ENSG00000253301.4	RP11-513O17.2	4.25	4.15e-05	0.0236	0.54	0.36	Developmental language disorder (linguistic errors);	chr8:57195761	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs73603874	ENSG00000253301.4	RP11-513O17.2	4.25	4.15e-05	0.0236	0.54	0.36	Developmental language disorder (linguistic errors);	chr8:57195781	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs73603877	ENSG00000253301.4	RP11-513O17.2	4.25	4.15e-05	0.0236	0.54	0.36	Developmental language disorder (linguistic errors);	chr8:57195869	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs16921823	ENSG00000253301.4	RP11-513O17.2	4.25	4.15e-05	0.0236	0.54	0.36	Developmental language disorder (linguistic errors);	chr8:57196053	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs72649188	ENSG00000253301.4	RP11-513O17.2	4.25	4.15e-05	0.0236	0.54	0.36	Developmental language disorder (linguistic errors);	chr8:57196270	chr8:57142689~57240298:+
TGCT	cis	rs12549025	0.782	rs3736030	ENSG00000253390.1	CTC-756D1.2	-4.25	4.15e-05	0.0236	-0.44	-0.36	Reticulocyte fraction of red cells;	chr8:23535220	chr8:23458601~23484971:+
TGCT	cis	rs7246967	0.673	rs4933026	ENSG00000198153.8	ZNF849P	4.25	4.15e-05	0.0236	0.59	0.36	Bronchopulmonary dysplasia;	chr19:22691690	chr19:22685167~22686732:+
TGCT	cis	rs875971	1	rs2087647	ENSG00000237310.1	GS1-124K5.4	-4.25	4.16e-05	0.0236	-0.39	-0.36	Aortic root size;	chr7:66128201	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs6958484	ENSG00000237310.1	GS1-124K5.4	-4.25	4.16e-05	0.0236	-0.39	-0.36	Aortic root size;	chr7:66134459	chr7:66493706~66495474:+
TGCT	cis	rs2188561	0.697	rs3735606	ENSG00000241764.3	AC002467.7	4.25	4.16e-05	0.0236	0.34	0.36	Alcohol consumption;	chr7:107743864	chr7:107742817~107744581:-
TGCT	cis	rs2739330	0.828	rs5760102	ENSG00000250470.1	AP000351.3	4.25	4.16e-05	0.0236	0.37	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23976904~23977585:-
TGCT	cis	rs1061377	0.748	rs11096977	ENSG00000249685.1	RP11-360F5.3	4.25	4.16e-05	0.0236	0.32	0.36	Uric acid levels;	chr4:39106186	chr4:39133913~39135608:+
TGCT	cis	rs1061377	0.748	rs6810770	ENSG00000249685.1	RP11-360F5.3	4.25	4.16e-05	0.0236	0.32	0.36	Uric acid levels;	chr4:39106545	chr4:39133913~39135608:+
TGCT	cis	rs1061377	0.748	rs6812316	ENSG00000249685.1	RP11-360F5.3	4.25	4.16e-05	0.0236	0.32	0.36	Uric acid levels;	chr4:39106617	chr4:39133913~39135608:+
TGCT	cis	rs1799949	1	rs8077486	ENSG00000198496.9	NBR2	-4.25	4.16e-05	0.0236	-0.51	-0.36	Menopause (age at onset);	chr17:43060788	chr17:43125610~43153671:+
TGCT	cis	rs16975963	0.843	rs1056405	ENSG00000276846.1	CTD-3220F14.3	-4.25	4.17e-05	0.0237	-0.37	-0.36	Longevity;	chr19:37822381	chr19:37314868~37315620:-
TGCT	cis	rs16975963	0.793	rs12460735	ENSG00000276846.1	CTD-3220F14.3	-4.25	4.17e-05	0.0237	-0.37	-0.36	Longevity;	chr19:37822910	chr19:37314868~37315620:-
TGCT	cis	rs16975963	0.843	rs2382624	ENSG00000276846.1	CTD-3220F14.3	-4.25	4.17e-05	0.0237	-0.37	-0.36	Longevity;	chr19:37928385	chr19:37314868~37315620:-
TGCT	cis	rs16975963	0.843	rs77895245	ENSG00000276846.1	CTD-3220F14.3	-4.25	4.17e-05	0.0237	-0.37	-0.36	Longevity;	chr19:37929140	chr19:37314868~37315620:-
TGCT	cis	rs16975963	0.843	rs73029180	ENSG00000276846.1	CTD-3220F14.3	-4.25	4.17e-05	0.0237	-0.37	-0.36	Longevity;	chr19:37929766	chr19:37314868~37315620:-
TGCT	cis	rs16975963	0.843	rs11083442	ENSG00000276846.1	CTD-3220F14.3	-4.25	4.17e-05	0.0237	-0.37	-0.36	Longevity;	chr19:37936888	chr19:37314868~37315620:-
TGCT	cis	rs16975963	0.843	rs73031215	ENSG00000276846.1	CTD-3220F14.3	-4.25	4.17e-05	0.0237	-0.37	-0.36	Longevity;	chr19:37942915	chr19:37314868~37315620:-
TGCT	cis	rs16975963	0.843	rs11672257	ENSG00000276846.1	CTD-3220F14.3	-4.25	4.17e-05	0.0237	-0.37	-0.36	Longevity;	chr19:37948722	chr19:37314868~37315620:-
TGCT	cis	rs2708377	0.929	rs2600337	ENSG00000256019.1	TAS2R63P	4.25	4.18e-05	0.0237	0.48	0.36	Bitter taste perception;	chr12:11140531	chr12:11048332~11049256:-
TGCT	cis	rs1707322	0.821	rs11211182	ENSG00000280836.1	AL355480.1	-4.25	4.18e-05	0.0237	-0.49	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45581219~45581321:-
TGCT	cis	rs56205728	0.606	rs3784397	ENSG00000273855.1	RP11-133K1.12	4.25	4.18e-05	0.0237	0.39	0.36	Schizophrenia;	chr15:40304643	chr15:40285468~40285909:-
TGCT	cis	rs2439831	0.85	rs12442297	ENSG00000205771.5	CATSPER2P1	-4.25	4.18e-05	0.0237	-0.6	-0.36	Lung cancer in ever smokers;	chr15:43876272	chr15:43726918~43747094:-
TGCT	cis	rs801193	0.591	rs4506088	ENSG00000232559.3	GS1-124K5.12	-4.25	4.19e-05	0.0237	-0.33	-0.36	Aortic root size;	chr7:66670470	chr7:66554588~66576923:-
TGCT	cis	rs801193	0.569	rs2659908	ENSG00000232559.3	GS1-124K5.12	4.25	4.19e-05	0.0237	0.33	0.36	Aortic root size;	chr7:66695835	chr7:66554588~66576923:-
TGCT	cis	rs801193	0.569	rs2659907	ENSG00000232559.3	GS1-124K5.12	4.25	4.19e-05	0.0237	0.33	0.36	Aortic root size;	chr7:66699045	chr7:66554588~66576923:-
TGCT	cis	rs801193	0.569	rs7782587	ENSG00000232559.3	GS1-124K5.12	4.25	4.19e-05	0.0237	0.33	0.36	Aortic root size;	chr7:66701485	chr7:66554588~66576923:-
TGCT	cis	rs801193	0.569	rs4717315	ENSG00000232559.3	GS1-124K5.12	4.25	4.19e-05	0.0237	0.33	0.36	Aortic root size;	chr7:66713338	chr7:66554588~66576923:-
TGCT	cis	rs801193	0.527	rs2707837	ENSG00000232559.3	GS1-124K5.12	4.25	4.19e-05	0.0237	0.33	0.36	Aortic root size;	chr7:66716086	chr7:66554588~66576923:-
TGCT	cis	rs801193	0.569	rs2707824	ENSG00000232559.3	GS1-124K5.12	4.25	4.19e-05	0.0237	0.33	0.36	Aortic root size;	chr7:66724256	chr7:66554588~66576923:-
TGCT	cis	rs1061377	0.748	rs12506723	ENSG00000249685.1	RP11-360F5.3	4.25	4.19e-05	0.0238	0.33	0.36	Uric acid levels;	chr4:39103152	chr4:39133913~39135608:+
TGCT	cis	rs1061377	0.748	rs1964345	ENSG00000249685.1	RP11-360F5.3	4.25	4.19e-05	0.0238	0.33	0.36	Uric acid levels;	chr4:39104793	chr4:39133913~39135608:+
TGCT	cis	rs1061377	0.748	rs1964347	ENSG00000249685.1	RP11-360F5.3	4.25	4.19e-05	0.0238	0.33	0.36	Uric acid levels;	chr4:39104956	chr4:39133913~39135608:+
TGCT	cis	rs1061377	0.748	rs1036033	ENSG00000249685.1	RP11-360F5.3	4.25	4.19e-05	0.0238	0.33	0.36	Uric acid levels;	chr4:39105295	chr4:39133913~39135608:+
TGCT	cis	rs1061377	0.748	rs1036034	ENSG00000249685.1	RP11-360F5.3	4.25	4.19e-05	0.0238	0.33	0.36	Uric acid levels;	chr4:39105299	chr4:39133913~39135608:+
TGCT	cis	rs2976388	1	rs2572910	ENSG00000253196.1	RP11-706C16.7	-4.25	4.19e-05	0.0238	-0.37	-0.36	Urinary tract infection frequency;	chr8:142688717	chr8:142763116~142766427:+
TGCT	cis	rs2976388	1	rs2585179	ENSG00000253196.1	RP11-706C16.7	-4.25	4.19e-05	0.0238	-0.37	-0.36	Urinary tract infection frequency;	chr8:142692775	chr8:142763116~142766427:+
TGCT	cis	rs2976388	1	rs2717562	ENSG00000253196.1	RP11-706C16.7	-4.25	4.19e-05	0.0238	-0.37	-0.36	Urinary tract infection frequency;	chr8:142695250	chr8:142763116~142766427:+
TGCT	cis	rs10256972	1	rs10256972	ENSG00000226291.1	AC091729.8	4.25	4.19e-05	0.0238	0.37	0.36	Endometriosis;Longevity;	chr7:999367	chr7:1080863~1082178:+
TGCT	cis	rs520525	0.963	rs663887	ENSG00000271811.1	RP1-79C4.4	4.25	4.2e-05	0.0238	0.28	0.36	Atrial fibrillation;	chr1:170657812	chr1:170667381~170669425:+
TGCT	cis	rs520525	0.963	rs524877	ENSG00000271811.1	RP1-79C4.4	4.25	4.2e-05	0.0238	0.28	0.36	Atrial fibrillation;	chr1:170659294	chr1:170667381~170669425:+
TGCT	cis	rs3096299	0.933	rs889576	ENSG00000274627.1	RP11-104N10.2	-4.25	4.2e-05	0.0238	-0.36	-0.36	Multiple myeloma (IgH translocation);	chr16:89363245	chr16:89516797~89522217:+
TGCT	cis	rs7005380	0.62	rs7387264	ENSG00000254343.2	RP11-760H22.2	4.25	4.2e-05	0.0238	0.47	0.36	Interstitial lung disease;	chr8:119913758	chr8:120052180~120056201:+
TGCT	cis	rs8072100	0.967	rs8078880	ENSG00000228782.6	CTD-2026D20.3	-4.25	4.2e-05	0.0238	-0.42	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599160	chr17:47450568~47492492:-
TGCT	cis	rs8072100	0.935	rs12943464	ENSG00000228782.6	CTD-2026D20.3	-4.25	4.2e-05	0.0238	-0.42	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47612985	chr17:47450568~47492492:-
TGCT	cis	rs8072100	0.935	rs4793978	ENSG00000228782.6	CTD-2026D20.3	-4.25	4.2e-05	0.0238	-0.42	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47620809	chr17:47450568~47492492:-
TGCT	cis	rs7647973	0.506	rs11920251	ENSG00000226913.1	BSN-AS2	-4.25	4.2e-05	0.0238	-0.28	-0.36	Menarche (age at onset);	chr3:49319238	chr3:49549306~49554366:-
TGCT	cis	rs10826995	0.961	rs7905471	ENSG00000239731.3	RN7SL825P	-4.25	4.21e-05	0.0238	-0.35	-0.36	Pulse pressure;	chr10:31805076	chr10:31992087~31992381:-
TGCT	cis	rs10826995	0.922	rs72786794	ENSG00000239731.3	RN7SL825P	-4.25	4.21e-05	0.0238	-0.35	-0.36	Pulse pressure;	chr10:31816790	chr10:31992087~31992381:-
TGCT	cis	rs10826995	0.961	rs72771468	ENSG00000239731.3	RN7SL825P	-4.25	4.21e-05	0.0238	-0.35	-0.36	Pulse pressure;	chr10:31819989	chr10:31992087~31992381:-
TGCT	cis	rs10826995	0.883	rs7913503	ENSG00000239731.3	RN7SL825P	-4.25	4.21e-05	0.0238	-0.35	-0.36	Pulse pressure;	chr10:31821427	chr10:31992087~31992381:-
TGCT	cis	rs10826995	0.961	rs7899891	ENSG00000239731.3	RN7SL825P	-4.25	4.21e-05	0.0238	-0.35	-0.36	Pulse pressure;	chr10:31825388	chr10:31992087~31992381:-
TGCT	cis	rs10826995	0.961	rs59453288	ENSG00000239731.3	RN7SL825P	-4.25	4.21e-05	0.0238	-0.35	-0.36	Pulse pressure;	chr10:31834627	chr10:31992087~31992381:-
TGCT	cis	rs10826995	0.922	rs2013220	ENSG00000239731.3	RN7SL825P	-4.25	4.21e-05	0.0238	-0.35	-0.36	Pulse pressure;	chr10:31835236	chr10:31992087~31992381:-
TGCT	cis	rs10826995	0.922	rs11591529	ENSG00000239731.3	RN7SL825P	-4.25	4.21e-05	0.0238	-0.35	-0.36	Pulse pressure;	chr10:31840215	chr10:31992087~31992381:-
TGCT	cis	rs10826995	0.922	rs56408600	ENSG00000239731.3	RN7SL825P	-4.25	4.21e-05	0.0238	-0.35	-0.36	Pulse pressure;	chr10:31848791	chr10:31992087~31992381:-
TGCT	cis	rs1519814	0.696	rs7821583	ENSG00000254343.2	RP11-760H22.2	-4.25	4.21e-05	0.0238	-0.58	-0.36	Breast cancer;	chr8:120021623	chr8:120052180~120056201:+
TGCT	cis	rs1519814	0.696	rs7822000	ENSG00000254343.2	RP11-760H22.2	-4.25	4.21e-05	0.0238	-0.58	-0.36	Breast cancer;	chr8:120021873	chr8:120052180~120056201:+
TGCT	cis	rs1519814	0.696	rs2326430	ENSG00000254343.2	RP11-760H22.2	-4.25	4.21e-05	0.0238	-0.58	-0.36	Breast cancer;	chr8:120024659	chr8:120052180~120056201:+
TGCT	cis	rs10129255	0.5	rs2078686	ENSG00000223648.3	IGHV3-64	4.25	4.21e-05	0.0238	0.3	0.36	Kawasaki disease;	chr14:106703345	chr14:106643132~106658258:-
TGCT	cis	rs875971	1	rs6961717	ENSG00000237310.1	GS1-124K5.4	-4.25	4.21e-05	0.0238	-0.39	-0.36	Aortic root size;	chr7:66122550	chr7:66493706~66495474:+
TGCT	cis	rs34375054	0.735	rs34961756	ENSG00000279233.1	RP11-158L12.4	4.25	4.21e-05	0.0238	0.36	0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125144052	chr12:125138245~125141711:+
TGCT	cis	rs2948294	0.588	rs4840913	ENSG00000253981.4	ALG1L13P	4.25	4.21e-05	0.0239	0.38	0.36	Red cell distribution width;	chr8:8259384	chr8:8236003~8244667:-
TGCT	cis	rs10256972	0.933	rs35696159	ENSG00000226291.1	AC091729.8	-4.25	4.21e-05	0.0239	-0.37	-0.36	Endometriosis;Longevity;	chr7:1007558	chr7:1080863~1082178:+
TGCT	cis	rs7824557	0.544	rs1865521	ENSG00000255020.1	AF131216.5	4.25	4.22e-05	0.0239	0.24	0.36	Retinal vascular caliber;	chr8:11373740	chr8:11345748~11347502:-
TGCT	cis	rs8105895	0.935	rs62111039	ENSG00000269742.1	BNIP3P29	4.25	4.22e-05	0.0239	0.67	0.36	Body mass index (change over time);	chr19:22104534	chr19:22065828~22066398:-
TGCT	cis	rs3742264	1	rs9316179	ENSG00000235903.6	CPB2-AS1	4.25	4.22e-05	0.0239	0.42	0.36	Blood protein levels;	chr13:46067331	chr13:46052806~46113332:+
TGCT	cis	rs7829975	0.536	rs2980439	ENSG00000253893.2	FAM85B	-4.25	4.22e-05	0.0239	-0.47	-0.36	Mood instability;	chr8:8237348	chr8:8167819~8226614:-
TGCT	cis	rs9322193	0.566	rs3922947	ENSG00000216906.2	RP11-350J20.9	-4.25	4.22e-05	0.0239	-0.45	-0.36	Lung cancer;	chr6:149924856	chr6:149904243~149906418:+
TGCT	cis	rs4268898	0.722	rs7563958	ENSG00000223754.1	AC008073.9	-4.25	4.22e-05	0.0239	-0.39	-0.36	Asthma;	chr2:24199512	chr2:24199839~24201698:-
TGCT	cis	rs2833693	0.572	rs4817477	ENSG00000261610.1	AP000265.1	4.25	4.23e-05	0.0239	0.43	0.36	Temperament;	chr21:32213799	chr21:32259804~32261585:-
TGCT	cis	rs9660180	1	rs9660180	ENSG00000231050.1	RP1-140A9.1	4.25	4.23e-05	0.0239	0.32	0.36	Body mass index;	chr1:1791592	chr1:1891471~1892658:+
TGCT	cis	rs7917772	0.56	rs10786697	ENSG00000273108.1	RP11-416N2.4	-4.25	4.23e-05	0.0239	-0.34	-0.36	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102618806	chr10:103608619~103610050:+
TGCT	cis	rs7208859	0.623	rs9914242	ENSG00000266490.1	CTD-2349P21.9	4.25	4.23e-05	0.0239	0.38	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30792372~30792833:+
TGCT	cis	rs12143943	0.934	rs868097	ENSG00000176754.11	LINC00303	4.25	4.23e-05	0.0239	0.33	0.36	Cognitive performance;	chr1:204611011	chr1:204032447~204041265:-
TGCT	cis	rs4835473	0.897	rs36083752	ENSG00000251600.4	RP11-673E1.1	-4.25	4.24e-05	0.024	-0.38	-0.36	Immature fraction of reticulocytes;	chr4:143693377	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs35162238	ENSG00000251600.4	RP11-673E1.1	-4.25	4.24e-05	0.024	-0.38	-0.36	Immature fraction of reticulocytes;	chr4:143693518	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs11100802	ENSG00000251600.4	RP11-673E1.1	-4.25	4.24e-05	0.024	-0.38	-0.36	Immature fraction of reticulocytes;	chr4:143700046	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.863	rs7696828	ENSG00000251600.4	RP11-673E1.1	4.25	4.24e-05	0.024	0.38	0.36	Immature fraction of reticulocytes;	chr4:143700846	chr4:143912331~143982454:+
TGCT	cis	rs227275	0.554	rs223467	ENSG00000230069.3	LRRC37A15P	-4.25	4.24e-05	0.024	-0.32	-0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102779721	chr4:102727274~102730721:-
TGCT	cis	rs7757969	0.536	rs1327202	ENSG00000227012.2	RP1-97J1.2	-4.25	4.24e-05	0.024	-0.72	-0.36	Schizophrenia;	chr6:111831212	chr6:111900489~111901851:-
TGCT	cis	rs7714584	1	rs12054923	ENSG00000197083.10	ZNF300P1	4.25	4.24e-05	0.024	0.58	0.36	Crohn's disease;	chr5:150869497	chr5:150930645~150946289:-
TGCT	cis	rs2188561	0.697	rs13224313	ENSG00000241764.3	AC002467.7	4.25	4.24e-05	0.024	0.33	0.36	Alcohol consumption;	chr7:107741907	chr7:107742817~107744581:-
TGCT	cis	rs957448	1	rs72674866	ENSG00000253175.1	RP11-267M23.6	4.25	4.24e-05	0.024	0.47	0.36	Nonsyndromic cleft lip with cleft palate;	chr8:94564619	chr8:94565036~94565715:+
TGCT	cis	rs957448	1	rs55897841	ENSG00000253175.1	RP11-267M23.6	4.25	4.24e-05	0.024	0.47	0.36	Nonsyndromic cleft lip with cleft palate;	chr8:94565042	chr8:94565036~94565715:+
TGCT	cis	rs957448	0.948	rs72674867	ENSG00000253175.1	RP11-267M23.6	4.25	4.24e-05	0.024	0.47	0.36	Nonsyndromic cleft lip with cleft palate;	chr8:94565973	chr8:94565036~94565715:+
TGCT	cis	rs4713118	0.662	rs149900	ENSG00000187763.3	OR2B7P	4.25	4.24e-05	0.024	0.35	0.36	Parkinson's disease;	chr6:28046819	chr6:28046434~28047367:+
TGCT	cis	rs992157	0.798	rs12053514	ENSG00000261338.2	RP11-378A13.1	-4.25	4.24e-05	0.024	-0.31	-0.36	Colorectal cancer;	chr2:218303242	chr2:218255319~218257366:+
TGCT	cis	rs7208859	0.562	rs11650923	ENSG00000280069.1	CTD-2349P21.3	-4.24	4.25e-05	0.024	-0.5	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs56378576	ENSG00000280069.1	CTD-2349P21.3	-4.24	4.25e-05	0.024	-0.5	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.623	rs35916850	ENSG00000280069.1	CTD-2349P21.3	-4.24	4.25e-05	0.024	-0.5	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30738182~30740275:+
TGCT	cis	rs73607972	0.935	rs4617860	ENSG00000275191.1	RP11-36I17.2	-4.24	4.25e-05	0.024	-0.45	-0.36	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53690608	chr16:53628256~53628816:-
TGCT	cis	rs73607972	0.935	rs35089292	ENSG00000275191.1	RP11-36I17.2	-4.24	4.25e-05	0.024	-0.45	-0.36	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53692910	chr16:53628256~53628816:-
TGCT	cis	rs73607972	0.935	rs73609954	ENSG00000275191.1	RP11-36I17.2	-4.24	4.25e-05	0.024	-0.45	-0.36	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53693937	chr16:53628256~53628816:-
TGCT	cis	rs73607972	0.935	rs4591140	ENSG00000275191.1	RP11-36I17.2	-4.24	4.25e-05	0.024	-0.45	-0.36	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53699775	chr16:53628256~53628816:-
TGCT	cis	rs8072100	0.875	rs9635762	ENSG00000228782.6	CTD-2026D20.3	-4.24	4.25e-05	0.024	-0.42	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47571080	chr17:47450568~47492492:-
TGCT	cis	rs8072100	0.967	rs4793842	ENSG00000228782.6	CTD-2026D20.3	-4.24	4.25e-05	0.024	-0.42	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47594140	chr17:47450568~47492492:-
TGCT	cis	rs8072100	0.967	rs8075411	ENSG00000228782.6	CTD-2026D20.3	-4.24	4.25e-05	0.024	-0.42	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599394	chr17:47450568~47492492:-
TGCT	cis	rs8072100	0.701	rs10163469	ENSG00000228782.6	CTD-2026D20.3	-4.24	4.25e-05	0.024	-0.42	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47610401	chr17:47450568~47492492:-
TGCT	cis	rs8072100	0.967	rs3760370	ENSG00000228782.6	CTD-2026D20.3	-4.24	4.25e-05	0.024	-0.42	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618466	chr17:47450568~47492492:-
TGCT	cis	rs7829975	0.633	rs2979181	ENSG00000254340.1	RP11-10A14.3	4.24	4.26e-05	0.0241	0.35	0.36	Mood instability;	chr8:8465578	chr8:9141424~9145435:+
TGCT	cis	rs1618992	0.607	rs2655354	ENSG00000265994.1	RP11-510D21.1	4.24	4.26e-05	0.0241	0.36	0.36	Gut microbiome composition (summer and winter);	chr18:28612173	chr18:28785068~28789260:+
TGCT	cis	rs6604026	0.555	rs67646822	ENSG00000223787.2	RP4-593M8.1	4.24	4.27e-05	0.0241	0.52	0.36	Multiple sclerosis;	chr1:92643406	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.661	rs72724555	ENSG00000223787.2	RP4-593M8.1	4.24	4.27e-05	0.0241	0.52	0.36	Multiple sclerosis;	chr1:92645318	chr1:92580476~92580821:-
TGCT	cis	rs6504663	0.558	rs11871603	ENSG00000275897.1	RP11-94C24.13	4.24	4.27e-05	0.0241	0.52	0.36	Visceral fat;	chr17:50481676	chr17:50475819~50478391:+
TGCT	cis	rs12210905	0.858	rs858992	ENSG00000187763.3	OR2B7P	-4.24	4.27e-05	0.0241	-0.5	-0.36	Hip circumference adjusted for BMI;	chr6:27213048	chr6:28046434~28047367:+
TGCT	cis	rs2276314	0.532	rs11081927	ENSG00000278986.1	RP11-723J4.3	-4.24	4.27e-05	0.0241	-0.36	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36034319	chr18:35972151~35973916:+
TGCT	cis	rs796364	1	rs71424239	ENSG00000232732.8	AC073043.1	4.24	4.27e-05	0.0241	0.51	0.36	Schizophrenia;	chr2:199860750	chr2:199867396~199911159:-
TGCT	cis	rs796364	1	rs11694369	ENSG00000232732.8	AC073043.1	4.24	4.27e-05	0.0241	0.51	0.36	Schizophrenia;	chr2:199876997	chr2:199867396~199911159:-
TGCT	cis	rs12439619	1	rs12439619	ENSG00000276710.3	CSPG4P8	-4.24	4.28e-05	0.0241	-0.31	-0.36	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82459472~82477258:+
TGCT	cis	rs2283792	0.715	rs56036797	ENSG00000228050.1	TOP3BP1	4.24	4.28e-05	0.0241	0.43	0.36	Multiple sclerosis;	chr22:21860875	chr22:22223187~22224566:-
TGCT	cis	rs2742234	0.915	rs2742233	ENSG00000273008.1	RP11-351D16.3	-4.24	4.28e-05	0.0241	-0.39	-0.36	Hirschsprung disease;	chr10:43115110	chr10:43136824~43138334:-
TGCT	cis	rs9309473	1	rs6546836	ENSG00000163016.8	ALMS1P	4.24	4.28e-05	0.0242	0.32	0.36	Metabolite levels;	chr2:73450706	chr2:73644919~73685576:+
TGCT	cis	rs7684253	0.548	rs62308071	ENSG00000269949.1	RP11-738E22.3	-4.24	4.29e-05	0.0242	-0.34	-0.36	Migraine;	chr4:56850720	chr4:56960927~56961373:-
TGCT	cis	rs2725220	0.936	rs2725216	ENSG00000202000.1	RNU1-36P	4.24	4.29e-05	0.0242	0.3	0.36	Renal function-related traits (urea);	chr4:88039427	chr4:88000237~88000401:+
TGCT	cis	rs7005380	0.556	rs62528692	ENSG00000254343.2	RP11-760H22.2	-4.24	4.29e-05	0.0242	-0.52	-0.36	Interstitial lung disease;	chr8:119932967	chr8:120052180~120056201:+
TGCT	cis	rs2280018	0.581	rs7404524	ENSG00000250251.5	PKD1P6	4.24	4.29e-05	0.0242	0.27	0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035301	chr16:15125242~15154564:-
TGCT	cis	rs9309473	0.948	rs10170849	ENSG00000163016.8	ALMS1P	4.24	4.31e-05	0.0243	0.32	0.36	Metabolite levels;	chr2:73520805	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.948	rs7566385	ENSG00000163016.8	ALMS1P	4.24	4.31e-05	0.0243	0.32	0.36	Metabolite levels;	chr2:73529690	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs3738848	ENSG00000163016.8	ALMS1P	4.24	4.31e-05	0.0243	0.32	0.36	Metabolite levels;	chr2:73534754	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs10496193	ENSG00000163016.8	ALMS1P	4.24	4.31e-05	0.0243	0.32	0.36	Metabolite levels;	chr2:73546376	chr2:73644919~73685576:+
TGCT	cis	rs875971	0.597	rs11771318	ENSG00000237310.1	GS1-124K5.4	-4.24	4.31e-05	0.0243	-0.39	-0.36	Aortic root size;	chr7:66597493	chr7:66493706~66495474:+
TGCT	cis	rs6604026	0.885	rs17614449	ENSG00000223787.2	RP4-593M8.1	4.24	4.31e-05	0.0243	0.51	0.36	Multiple sclerosis;	chr1:92810377	chr1:92580476~92580821:-
TGCT	cis	rs9660180	0.967	rs12034740	ENSG00000231050.1	RP1-140A9.1	4.24	4.31e-05	0.0243	0.32	0.36	Body mass index;	chr1:1797530	chr1:1891471~1892658:+
TGCT	cis	rs10971721	0.822	rs72725392	ENSG00000230074.1	RP11-195F19.9	-4.24	4.31e-05	0.0243	-0.52	-0.36	Body mass index;	chr9:33867780	chr9:34665665~34681298:+
TGCT	cis	rs786425	0.682	rs7979528	ENSG00000247373.3	RP11-486O12.2	4.24	4.32e-05	0.0243	0.45	0.36	Pubertal anthropometrics;	chr12:123697273	chr12:123575891~123585115:-
TGCT	cis	rs4835473	0.897	rs6537171	ENSG00000251600.4	RP11-673E1.1	4.24	4.32e-05	0.0243	0.37	0.36	Immature fraction of reticulocytes;	chr4:143709222	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs6832722	ENSG00000251600.4	RP11-673E1.1	4.24	4.32e-05	0.0243	0.37	0.36	Immature fraction of reticulocytes;	chr4:143709430	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs6832749	ENSG00000251600.4	RP11-673E1.1	4.24	4.32e-05	0.0243	0.37	0.36	Immature fraction of reticulocytes;	chr4:143709473	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs6831477	ENSG00000251600.4	RP11-673E1.1	4.24	4.32e-05	0.0243	0.37	0.36	Immature fraction of reticulocytes;	chr4:143709487	chr4:143912331~143982454:+
TGCT	cis	rs1372520	0.766	rs2583961	ENSG00000247775.2	SNCA-AS1	4.24	4.32e-05	0.0243	0.35	0.36	Neuroticism;	chr4:89858607	chr4:89836408~89841978:+
TGCT	cis	rs1372520	0.873	rs2737026	ENSG00000247775.2	SNCA-AS1	4.24	4.32e-05	0.0243	0.35	0.36	Neuroticism;	chr4:89858672	chr4:89836408~89841978:+
TGCT	cis	rs2288884	0.636	rs11669439	ENSG00000269235.1	ZNF350-AS1	4.24	4.32e-05	0.0243	0.44	0.36	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52069047	chr19:51949134~51981367:+
TGCT	cis	rs11673344	0.931	rs1234251	ENSG00000226686.6	LINC01535	4.24	4.32e-05	0.0243	0.4	0.36	Obesity-related traits;	chr19:37180354	chr19:37251912~37265535:+
TGCT	cis	rs34375054	0.525	rs7398636	ENSG00000279233.1	RP11-158L12.4	4.24	4.32e-05	0.0243	0.38	0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125114058	chr12:125138245~125141711:+
TGCT	cis	rs8070740	0.838	rs1050456	ENSG00000262227.1	RP5-1050D4.5	-4.24	4.32e-05	0.0243	-0.31	-0.36	Menopause (age at onset);	chr17:5432868	chr17:4987706~4988446:+
TGCT	cis	rs8070740	0.838	rs1050461	ENSG00000262227.1	RP5-1050D4.5	-4.24	4.32e-05	0.0243	-0.31	-0.36	Menopause (age at onset);	chr17:5432890	chr17:4987706~4988446:+
TGCT	cis	rs8070740	0.891	rs4790264	ENSG00000262227.1	RP5-1050D4.5	-4.24	4.32e-05	0.0243	-0.31	-0.36	Menopause (age at onset);	chr17:5433471	chr17:4987706~4988446:+
TGCT	cis	rs732716	0.785	rs11667543	ENSG00000267769.1	CTB-50L17.9	-4.24	4.32e-05	0.0243	-0.42	-0.36	Mean corpuscular volume;	chr19:4374853	chr19:4454014~4455286:+
TGCT	cis	rs7824557	0.564	rs7828263	ENSG00000255310.2	AF131215.2	-4.24	4.32e-05	0.0244	-0.29	-0.36	Retinal vascular caliber;	chr8:11374377	chr8:11107788~11109726:-
TGCT	cis	rs9309473	1	rs13384952	ENSG00000163016.8	ALMS1P	-4.24	4.32e-05	0.0244	-0.37	-0.36	Metabolite levels;	chr2:73496832	chr2:73644919~73685576:+
TGCT	cis	rs4814920	0.756	rs1543472	ENSG00000275142.1	RP5-999L4.2	4.24	4.33e-05	0.0244	0.51	0.36	Bipolar disorder (body mass index interaction);	chr20:19867383	chr20:19871891~19872284:+
TGCT	cis	rs67311347	0.713	rs4974018	ENSG00000223797.4	ENTPD3-AS1	4.24	4.34e-05	0.0244	0.35	0.36	Renal cell carcinoma;	chr3:40265928	chr3:40313802~40453329:-
TGCT	cis	rs67311347	0.713	rs9861194	ENSG00000223797.4	ENTPD3-AS1	4.24	4.34e-05	0.0244	0.35	0.36	Renal cell carcinoma;	chr3:40267734	chr3:40313802~40453329:-
TGCT	cis	rs3020264	1	rs3020264	ENSG00000271743.1	CTD-2541M15.3	4.24	4.34e-05	0.0244	0.36	0.36	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6631056	chr8:6615604~6617198:-
TGCT	cis	rs2179367	0.959	rs9373589	ENSG00000216906.2	RP11-350J20.9	4.24	4.34e-05	0.0244	0.37	0.36	Dupuytren's disease;	chr6:149386152	chr6:149904243~149906418:+
TGCT	cis	rs11742741	0.714	rs61442687	ENSG00000248874.4	C5orf17	-4.24	4.34e-05	0.0244	-0.42	-0.36	Educational attainment;	chr5:24189306	chr5:23951348~24178263:+
TGCT	cis	rs6940638	0.956	rs10946899	ENSG00000187763.3	OR2B7P	4.24	4.34e-05	0.0244	0.33	0.36	Intelligence (multi-trait analysis);	chr6:27055915	chr6:28046434~28047367:+
TGCT	cis	rs732716	0.74	rs62129356	ENSG00000267769.1	CTB-50L17.9	-4.24	4.35e-05	0.0245	-0.41	-0.36	Mean corpuscular volume;	chr19:4400317	chr19:4454014~4455286:+
TGCT	cis	rs2033711	0.811	rs9304814	ENSG00000268912.1	CTD-2619J13.17	-4.24	4.35e-05	0.0245	-0.32	-0.36	Uric acid clearance;	chr19:58440444	chr19:58428632~58431148:-
TGCT	cis	rs3105593	1	rs17645826	ENSG00000273674.3	CTD-2378E12.1	4.24	4.35e-05	0.0245	0.38	0.36	QT interval;	chr15:50657944	chr15:50839875~50908599:-
TGCT	cis	rs3105593	1	rs56080544	ENSG00000273674.3	CTD-2378E12.1	4.24	4.35e-05	0.0245	0.38	0.36	QT interval;	chr15:50658773	chr15:50839875~50908599:-
TGCT	cis	rs9880211	0.948	rs9844666	ENSG00000239213.4	NCK1-AS1	4.24	4.35e-05	0.0245	0.4	0.36	Height;Body mass index;	chr3:136255374	chr3:136841726~136862054:-
TGCT	cis	rs904251	0.772	rs10692	ENSG00000279942.1	RP1-153P14.7	-4.24	4.35e-05	0.0245	-0.44	-0.36	Cognitive performance;	chr6:37483138	chr6:37567716~37571460:+
TGCT	cis	rs1150668	0.796	rs1005125	ENSG00000204709.4	LINC01556	4.24	4.35e-05	0.0245	0.39	0.36	Pubertal anthropometrics;	chr6:28399578	chr6:28943877~28944537:+
TGCT	cis	rs875971	0.545	rs2420456	ENSG00000222364.1	RNU6-96P	-4.24	4.35e-05	0.0245	-0.44	-0.36	Aortic root size;	chr7:66280619	chr7:66395191~66395286:+
TGCT	cis	rs3931020	0.53	rs12125889	ENSG00000272864.1	RP11-17E13.2	-4.24	4.36e-05	0.0245	-0.4	-0.36	Resistin levels;	chr1:74776287	chr1:74698769~74699333:-
TGCT	cis	rs12022452	0.822	rs6600343	ENSG00000238287.1	RP11-656D10.3	-4.24	4.36e-05	0.0245	-0.47	-0.36	Age-related hearing impairment (SNP x SNP interaction);	chr1:40562538	chr1:40493157~40508661:-
TGCT	cis	rs6844153	1	rs74895929	ENSG00000240005.4	RP11-293A21.1	-4.24	4.36e-05	0.0245	-0.43	-0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26846035	chr4:26859806~26860599:-
TGCT	cis	rs7255436	0.928	rs7250870	ENSG00000269386.4	RAB11B-AS1	4.24	4.36e-05	0.0245	0.37	0.36	HDL cholesterol;	chr19:8388798	chr19:8374373~8390685:-
TGCT	cis	rs7714584	1	rs1896708	ENSG00000197083.10	ZNF300P1	4.24	4.37e-05	0.0246	0.58	0.36	Crohn's disease;	chr5:150865514	chr5:150930645~150946289:-
TGCT	cis	rs992157	0.932	rs10203039	ENSG00000261338.2	RP11-378A13.1	4.24	4.37e-05	0.0246	0.29	0.36	Colorectal cancer;	chr2:218322644	chr2:218255319~218257366:+
TGCT	cis	rs4660214	0.724	rs12117785	ENSG00000182109.6	RP11-69E11.4	-4.24	4.37e-05	0.0246	-0.36	-0.36	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39162739	chr1:39522280~39546187:-
TGCT	cis	rs7255436	0.965	rs62117510	ENSG00000269386.4	RAB11B-AS1	4.24	4.38e-05	0.0246	0.37	0.36	HDL cholesterol;	chr19:8387729	chr19:8374373~8390685:-
TGCT	cis	rs7255436	0.965	rs28729307	ENSG00000269386.4	RAB11B-AS1	4.24	4.38e-05	0.0246	0.37	0.36	HDL cholesterol;	chr19:8387858	chr19:8374373~8390685:-
TGCT	cis	rs7255436	0.894	rs10413136	ENSG00000269386.4	RAB11B-AS1	4.24	4.38e-05	0.0246	0.37	0.36	HDL cholesterol;	chr19:8387995	chr19:8374373~8390685:-
TGCT	cis	rs1707322	1	rs34444543	ENSG00000280836.1	AL355480.1	-4.24	4.38e-05	0.0246	-0.46	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr1:45581219~45581321:-
TGCT	cis	rs7829975	0.564	rs2921060	ENSG00000254340.1	RP11-10A14.3	-4.24	4.38e-05	0.0246	-0.34	-0.36	Mood instability;	chr8:8460307	chr8:9141424~9145435:+
TGCT	cis	rs62025270	0.688	rs62025272	ENSG00000259416.2	RP11-158M2.5	-4.24	4.38e-05	0.0246	-0.43	-0.36	Idiopathic pulmonary fibrosis;	chr15:85770391	chr15:85754941~85756237:-
TGCT	cis	rs62025270	0.688	rs56388190	ENSG00000259416.2	RP11-158M2.5	-4.24	4.38e-05	0.0246	-0.43	-0.36	Idiopathic pulmonary fibrosis;	chr15:85771665	chr15:85754941~85756237:-
TGCT	cis	rs792448	0.798	rs7521853	ENSG00000201544.1	SNORA16B	4.24	4.38e-05	0.0246	0.36	0.36	White blood cell count (basophil);	chr1:212330862	chr1:212352816~212352950:+
TGCT	cis	rs801193	0.613	rs2659900	ENSG00000237310.1	GS1-124K5.4	4.24	4.39e-05	0.0246	0.4	0.36	Aortic root size;	chr7:66719456	chr7:66493706~66495474:+
TGCT	cis	rs8081395	0.801	rs2665405	ENSG00000266992.1	DHX40P1	-4.24	4.39e-05	0.0246	-0.38	-0.36	White blood cell count;	chr17:59797931	chr17:59976009~60002384:-
TGCT	cis	rs9322193	0.607	rs6557165	ENSG00000216906.2	RP11-350J20.9	-4.24	4.39e-05	0.0247	-0.46	-0.36	Lung cancer;	chr6:149906883	chr6:149904243~149906418:+
TGCT	cis	rs1707322	0.927	rs6690386	ENSG00000280836.1	AL355480.1	-4.24	4.39e-05	0.0247	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.963	rs4630155	ENSG00000280836.1	AL355480.1	-4.24	4.39e-05	0.0247	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.963	rs12076580	ENSG00000280836.1	AL355480.1	-4.24	4.39e-05	0.0247	-0.47	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr1:45581219~45581321:-
TGCT	cis	rs28735056	0.563	rs55642704	ENSG00000261126.6	RP11-795F19.1	-4.24	4.4e-05	0.0247	-0.3	-0.36	Schizophrenia;	chr18:79928124	chr18:80046900~80095482:+
TGCT	cis	rs10129255	0.5	rs4600373	ENSG00000223648.3	IGHV3-64	4.24	4.4e-05	0.0247	0.3	0.36	Kawasaki disease;	chr14:106704809	chr14:106643132~106658258:-
TGCT	cis	rs7617773	0.539	rs13069884	ENSG00000229759.1	MRPS18AP1	4.24	4.4e-05	0.0247	0.29	0.36	Coronary artery disease;	chr3:48339658	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.539	rs2017859	ENSG00000229759.1	MRPS18AP1	4.24	4.4e-05	0.0247	0.29	0.36	Coronary artery disease;	chr3:48340771	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.539	rs2017858	ENSG00000229759.1	MRPS18AP1	4.24	4.4e-05	0.0247	0.29	0.36	Coronary artery disease;	chr3:48340792	chr3:48256350~48256938:-
TGCT	cis	rs7617773	0.501	rs12185901	ENSG00000229759.1	MRPS18AP1	4.24	4.4e-05	0.0247	0.29	0.36	Coronary artery disease;	chr3:48341429	chr3:48256350~48256938:-
TGCT	cis	rs7829975	0.714	rs4840362	ENSG00000254340.1	RP11-10A14.3	-4.24	4.4e-05	0.0247	-0.36	-0.36	Mood instability;	chr8:8812572	chr8:9141424~9145435:+
TGCT	cis	rs73607972	0.696	rs7201237	ENSG00000279344.1	RP11-44F14.7	4.24	4.4e-05	0.0247	0.41	0.36	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53526005	chr16:53478957~53481550:-
TGCT	cis	rs728616	0.867	rs7906286	ENSG00000230091.5	TMEM254-AS1	4.24	4.4e-05	0.0247	0.59	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80074279	chr10:80046860~80078912:-
TGCT	cis	rs34217772	0.511	rs4904915	ENSG00000258536.1	RP11-1053O12.1	-4.24	4.4e-05	0.0247	-0.28	-0.36	Myopia;	chr14:41861994	chr14:41742639~41742963:+
TGCT	cis	rs11651753	0.636	rs4794332	ENSG00000264920.1	RP11-6N17.4	-4.24	4.4e-05	0.0247	-0.34	-0.36	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47963201	chr17:47891255~47895812:-
TGCT	cis	rs9309473	0.861	rs6546856	ENSG00000163016.8	ALMS1P	4.24	4.41e-05	0.0247	0.33	0.36	Metabolite levels;	chr2:73610624	chr2:73644919~73685576:+
TGCT	cis	rs11722228	0.522	rs73212880	ENSG00000261490.1	RP11-448G15.3	4.24	4.41e-05	0.0247	0.34	0.36	Urate levels;Serum uric acid levels;Gout;	chr4:10114068	chr4:10068089~10073019:-
TGCT	cis	rs12908161	0.959	rs17534709	ENSG00000259728.4	LINC00933	4.24	4.41e-05	0.0247	0.41	0.36	Schizophrenia;	chr15:84771166	chr15:84570649~84580175:+
TGCT	cis	rs801193	0.591	rs2707839	ENSG00000237310.1	GS1-124K5.4	4.24	4.41e-05	0.0247	0.4	0.36	Aortic root size;	chr7:66728097	chr7:66493706~66495474:+
TGCT	cis	rs2742234	0.955	rs1272142	ENSG00000273008.1	RP11-351D16.3	-4.24	4.41e-05	0.0247	-0.4	-0.36	Hirschsprung disease;	chr10:43200036	chr10:43136824~43138334:-
TGCT	cis	rs12745968	0.653	rs6604013	ENSG00000223787.2	RP4-593M8.1	-4.24	4.41e-05	0.0248	-0.46	-0.36	Bipolar disorder and schizophrenia;	chr1:92726577	chr1:92580476~92580821:-
TGCT	cis	rs12745968	0.653	rs2107519	ENSG00000223787.2	RP4-593M8.1	-4.24	4.41e-05	0.0248	-0.46	-0.36	Bipolar disorder and schizophrenia;	chr1:92727313	chr1:92580476~92580821:-
TGCT	cis	rs12745968	0.653	rs4847301	ENSG00000223787.2	RP4-593M8.1	-4.24	4.41e-05	0.0248	-0.46	-0.36	Bipolar disorder and schizophrenia;	chr1:92735367	chr1:92580476~92580821:-
TGCT	cis	rs12745968	0.624	rs6675753	ENSG00000223787.2	RP4-593M8.1	-4.24	4.41e-05	0.0248	-0.46	-0.36	Bipolar disorder and schizophrenia;	chr1:92750039	chr1:92580476~92580821:-
TGCT	cis	rs12745968	0.595	rs6604014	ENSG00000223787.2	RP4-593M8.1	-4.24	4.41e-05	0.0248	-0.46	-0.36	Bipolar disorder and schizophrenia;	chr1:92750161	chr1:92580476~92580821:-
TGCT	cis	rs12745968	0.561	rs4847306	ENSG00000223787.2	RP4-593M8.1	-4.24	4.41e-05	0.0248	-0.46	-0.36	Bipolar disorder and schizophrenia;	chr1:92751415	chr1:92580476~92580821:-
TGCT	cis	rs12745968	0.59	rs2391195	ENSG00000223787.2	RP4-593M8.1	-4.24	4.41e-05	0.0248	-0.46	-0.36	Bipolar disorder and schizophrenia;	chr1:92753126	chr1:92580476~92580821:-
TGCT	cis	rs12745968	0.59	rs1337107	ENSG00000223787.2	RP4-593M8.1	-4.24	4.41e-05	0.0248	-0.46	-0.36	Bipolar disorder and schizophrenia;	chr1:92753219	chr1:92580476~92580821:-
TGCT	cis	rs12745968	0.62	rs6666831	ENSG00000223787.2	RP4-593M8.1	-4.24	4.41e-05	0.0248	-0.46	-0.36	Bipolar disorder and schizophrenia;	chr1:92757240	chr1:92580476~92580821:-
TGCT	cis	rs11722228	0.522	rs73212808	ENSG00000261490.1	RP11-448G15.3	4.23	4.42e-05	0.0248	0.34	0.36	Urate levels;Serum uric acid levels;Gout;	chr4:10053815	chr4:10068089~10073019:-
TGCT	cis	rs875971	0.895	rs3857684	ENSG00000232559.3	GS1-124K5.12	4.23	4.42e-05	0.0248	0.34	0.36	Aortic root size;	chr7:66473171	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs12533997	ENSG00000232559.3	GS1-124K5.12	4.23	4.42e-05	0.0248	0.34	0.36	Aortic root size;	chr7:66500390	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.964	rs60193905	ENSG00000232559.3	GS1-124K5.12	4.23	4.42e-05	0.0248	0.34	0.36	Aortic root size;	chr7:66506273	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.929	rs10950041	ENSG00000232559.3	GS1-124K5.12	4.23	4.42e-05	0.0248	0.34	0.36	Aortic root size;	chr7:66508888	chr7:66554588~66576923:-
TGCT	cis	rs10971721	0.822	rs12377078	ENSG00000230074.1	RP11-195F19.9	4.23	4.42e-05	0.0248	0.53	0.36	Body mass index;	chr9:33934823	chr9:34665665~34681298:+
TGCT	cis	rs12143943	0.866	rs12032618	ENSG00000176754.11	LINC00303	4.23	4.42e-05	0.0248	0.33	0.36	Cognitive performance;	chr1:204563531	chr1:204032447~204041265:-
TGCT	cis	rs12143943	0.834	rs34812029	ENSG00000176754.11	LINC00303	4.23	4.42e-05	0.0248	0.33	0.36	Cognitive performance;	chr1:204577859	chr1:204032447~204041265:-
TGCT	cis	rs1707322	1	rs11211190	ENSG00000280836.1	AL355480.1	-4.23	4.43e-05	0.0248	-0.46	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800583	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs4390216	ENSG00000280836.1	AL355480.1	-4.23	4.43e-05	0.0248	-0.46	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr1:45581219~45581321:-
TGCT	cis	rs875971	1	rs1544549	ENSG00000232559.3	GS1-124K5.12	-4.23	4.43e-05	0.0248	-0.34	-0.36	Aortic root size;	chr7:66625676	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs2420820	ENSG00000232559.3	GS1-124K5.12	-4.23	4.43e-05	0.0248	-0.34	-0.36	Aortic root size;	chr7:66626920	chr7:66554588~66576923:-
TGCT	cis	rs7115242	0.8	rs493134	ENSG00000254851.1	RP11-109L13.1	-4.23	4.43e-05	0.0248	-0.6	-0.36	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116962963	chr11:117135528~117138582:+
TGCT	cis	rs853679	0.517	rs9380052	ENSG00000272009.1	RP1-313I6.12	-4.23	4.43e-05	0.0248	-0.47	-0.36	Depression;	chr6:28096845	chr6:28078792~28081130:-
TGCT	cis	rs875971	0.545	rs73136346	ENSG00000237310.1	GS1-124K5.4	-4.23	4.43e-05	0.0248	-0.44	-0.36	Aortic root size;	chr7:66101095	chr7:66493706~66495474:+
TGCT	cis	rs7729723	0.935	rs10075580	ENSG00000250159.5	RP11-381K20.2	-4.23	4.43e-05	0.0249	-0.38	-0.36	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);	chr5:138482920	chr5:137814333~137889336:-
TGCT	cis	rs3020264	0.669	rs7005662	ENSG00000271743.1	CTD-2541M15.3	4.23	4.43e-05	0.0249	0.35	0.36	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6619105	chr8:6615604~6617198:-
TGCT	cis	rs34421088	0.623	rs4841515	ENSG00000254936.4	AF131215.3	-4.23	4.44e-05	0.0249	-0.39	-0.36	Neuroticism;	chr8:11239657	chr8:11123381~11126064:-
TGCT	cis	rs7255436	1	rs7255436	ENSG00000269386.4	RAB11B-AS1	4.23	4.45e-05	0.0249	0.37	0.36	HDL cholesterol;	chr19:8368312	chr19:8374373~8390685:-
TGCT	cis	rs7255436	0.931	rs7249520	ENSG00000269386.4	RAB11B-AS1	4.23	4.45e-05	0.0249	0.37	0.36	HDL cholesterol;	chr19:8381172	chr19:8374373~8390685:-
TGCT	cis	rs7255436	0.965	rs7249624	ENSG00000269386.4	RAB11B-AS1	4.23	4.45e-05	0.0249	0.37	0.36	HDL cholesterol;	chr19:8381251	chr19:8374373~8390685:-
TGCT	cis	rs11671005	0.735	rs11671591	ENSG00000232098.3	CTD-2619J13.14	4.23	4.45e-05	0.0249	0.4	0.36	Mean platelet volume;	chr19:58406970	chr19:58404238~58408484:-
TGCT	cis	rs10129255	0.536	rs3944157	ENSG00000280411.1	IGHV1-69-2	-4.23	4.45e-05	0.0249	-0.36	-0.36	Kawasaki disease;	chr14:106682286	chr14:106762092~106762588:-
TGCT	cis	rs10129255	0.556	rs9324093	ENSG00000280411.1	IGHV1-69-2	-4.23	4.45e-05	0.0249	-0.36	-0.36	Kawasaki disease;	chr14:106683893	chr14:106762092~106762588:-
TGCT	cis	rs507080	0.501	rs626645	ENSG00000255422.1	AP002954.4	-4.23	4.45e-05	0.0249	-0.38	-0.36	Serum metabolite levels;	chr11:118704471	chr11:118704607~118750263:+
TGCT	cis	rs11673344	0.864	rs8106386	ENSG00000226686.6	LINC01535	-4.23	4.45e-05	0.0249	-0.41	-0.36	Obesity-related traits;	chr19:37012997	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.864	rs55792845	ENSG00000226686.6	LINC01535	4.23	4.45e-05	0.0249	0.41	0.36	Obesity-related traits;	chr19:37007783	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.864	rs56208574	ENSG00000226686.6	LINC01535	4.23	4.45e-05	0.0249	0.41	0.36	Obesity-related traits;	chr19:37007843	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.864	rs8107192	ENSG00000226686.6	LINC01535	4.23	4.45e-05	0.0249	0.41	0.36	Obesity-related traits;	chr19:37008725	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.864	rs79927931	ENSG00000226686.6	LINC01535	4.23	4.45e-05	0.0249	0.41	0.36	Obesity-related traits;	chr19:37012241	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.864	rs11670216	ENSG00000226686.6	LINC01535	4.23	4.45e-05	0.0249	0.41	0.36	Obesity-related traits;	chr19:37012526	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.864	rs8104919	ENSG00000226686.6	LINC01535	4.23	4.45e-05	0.0249	0.41	0.36	Obesity-related traits;	chr19:37012881	chr19:37251912~37265535:+
TGCT	cis	rs5758511	0.596	rs55644935	ENSG00000182057.4	OGFRP1	-4.23	4.45e-05	0.0249	-0.33	-0.36	Birth weight;	chr22:42270063	chr22:42269753~42275196:+
TGCT	cis	rs12143943	0.966	rs898385	ENSG00000176754.11	LINC00303	4.23	4.45e-05	0.025	0.32	0.36	Cognitive performance;	chr1:204610732	chr1:204032447~204041265:-
TGCT	cis	rs7255436	0.965	rs11668346	ENSG00000269386.4	RAB11B-AS1	4.23	4.46e-05	0.025	0.37	0.36	HDL cholesterol;	chr19:8385970	chr19:8374373~8390685:-
TGCT	cis	rs7255436	0.965	rs12981318	ENSG00000269386.4	RAB11B-AS1	4.23	4.46e-05	0.025	0.37	0.36	HDL cholesterol;	chr19:8386546	chr19:8374373~8390685:-
TGCT	cis	rs7255436	0.965	rs7351098	ENSG00000269386.4	RAB11B-AS1	4.23	4.46e-05	0.025	0.37	0.36	HDL cholesterol;	chr19:8386787	chr19:8374373~8390685:-
TGCT	cis	rs7255436	0.965	rs11666003	ENSG00000269386.4	RAB11B-AS1	4.23	4.46e-05	0.025	0.37	0.36	HDL cholesterol;	chr19:8387218	chr19:8374373~8390685:-
TGCT	cis	rs7819412	0.654	rs34741518	ENSG00000255310.2	AF131215.2	-4.23	4.46e-05	0.025	-0.3	-0.36	Triglycerides;	chr8:10919350	chr8:11107788~11109726:-
TGCT	cis	rs904251	0.686	rs2776911	ENSG00000279942.1	RP1-153P14.7	-4.23	4.46e-05	0.025	-0.45	-0.36	Cognitive performance;	chr6:37472174	chr6:37567716~37571460:+
TGCT	cis	rs11166629	1	rs3739423	ENSG00000272456.1	CTD-2342N23.3	4.23	4.46e-05	0.025	0.39	0.36	Smoking quantity;	chr8:134602462	chr8:134722947~134723949:+
TGCT	cis	rs11166629	1	rs7003870	ENSG00000272456.1	CTD-2342N23.3	4.23	4.46e-05	0.025	0.39	0.36	Smoking quantity;	chr8:134604343	chr8:134722947~134723949:+
TGCT	cis	rs673078	0.607	rs1060964	ENSG00000275759.1	RP11-131L12.3	-4.23	4.46e-05	0.025	-0.66	-0.36	Glucose homeostasis traits;	chr12:118414906	chr12:118428281~118428870:+
TGCT	cis	rs5758511	0.68	rs1107553	ENSG00000182057.4	OGFRP1	-4.23	4.46e-05	0.025	-0.35	-0.36	Birth weight;	chr22:42271467	chr22:42269753~42275196:+
TGCT	cis	rs2708377	0.789	rs115164039	ENSG00000256019.1	TAS2R63P	-4.23	4.47e-05	0.025	-0.48	-0.36	Bitter taste perception;	chr12:11096794	chr12:11048332~11049256:-
TGCT	cis	rs7255436	0.83	rs4350678	ENSG00000269386.4	RAB11B-AS1	4.23	4.47e-05	0.025	0.37	0.36	HDL cholesterol;	chr19:8382482	chr19:8374373~8390685:-
TGCT	cis	rs17507216	0.591	rs7163848	ENSG00000276710.3	CSPG4P8	-4.23	4.47e-05	0.025	-0.39	-0.36	Excessive daytime sleepiness;	chr15:82729563	chr15:82459472~82477258:+
TGCT	cis	rs34421088	0.623	rs2572433	ENSG00000254936.4	AF131215.3	4.23	4.48e-05	0.0251	0.38	0.36	Neuroticism;	chr8:11243532	chr8:11123381~11126064:-
TGCT	cis	rs10504229	0.679	rs17804870	ENSG00000253301.4	RP11-513O17.2	4.23	4.48e-05	0.0251	0.59	0.36	Developmental language disorder (linguistic errors);	chr8:57245512	chr8:57142689~57240298:+
TGCT	cis	rs763121	0.962	rs138711	ENSG00000273076.1	RP3-508I15.22	4.23	4.48e-05	0.0251	0.54	0.36	Menopause (age at onset);	chr22:38743908	chr22:38743495~38743910:+
TGCT	cis	rs10946737	0.829	rs7753740	ENSG00000220517.2	ASS1P1	4.23	4.49e-05	0.0251	0.36	0.36	Liver injury in anti-tuberculosis drug treatment;	chr6:25002205	chr6:25023247~25024483:-
TGCT	cis	rs11231017	1	rs11231018	ENSG00000254454.2	RCC2P6	4.23	4.49e-05	0.0251	0.27	0.36	HIV-1 viral setpoint;	chr11:62295037	chr11:62371146~62373168:+
TGCT	cis	rs10759883	0.627	rs10818574	ENSG00000175611.10	LINC00476	4.23	4.49e-05	0.0251	0.36	0.36	Nicotine dependence;	chr9:95836685	chr9:95759231~95875977:-
TGCT	cis	rs992157	0.698	rs6746089	ENSG00000261338.2	RP11-378A13.1	4.23	4.49e-05	0.0251	0.31	0.36	Colorectal cancer;	chr2:218305654	chr2:218255319~218257366:+
TGCT	cis	rs8059260	0.668	rs74737820	ENSG00000274038.1	RP11-66H6.4	-4.23	4.5e-05	0.0251	-0.53	-0.36	Alcohol consumption over the past year;	chr16:10972240	chr16:11056556~11057034:+
TGCT	cis	rs992157	0.767	rs2014615	ENSG00000261338.2	RP11-378A13.1	4.23	4.5e-05	0.0252	0.31	0.36	Colorectal cancer;	chr2:218306468	chr2:218255319~218257366:+
TGCT	cis	rs2033711	0.755	rs4801587	ENSG00000269473.1	CTD-2619J13.19	4.23	4.5e-05	0.0252	0.28	0.36	Uric acid clearance;	chr19:58425312	chr19:58440448~58445849:+
TGCT	cis	rs875971	0.964	rs1643388	ENSG00000232559.3	GS1-124K5.12	4.23	4.51e-05	0.0252	0.34	0.36	Aortic root size;	chr7:66379575	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs778722	ENSG00000232559.3	GS1-124K5.12	4.23	4.51e-05	0.0252	0.34	0.36	Aortic root size;	chr7:66379841	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.964	rs778721	ENSG00000232559.3	GS1-124K5.12	4.23	4.51e-05	0.0252	0.34	0.36	Aortic root size;	chr7:66380410	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs778706	ENSG00000232559.3	GS1-124K5.12	4.23	4.51e-05	0.0252	0.34	0.36	Aortic root size;	chr7:66395437	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.895	rs778700	ENSG00000232559.3	GS1-124K5.12	4.23	4.51e-05	0.0252	0.34	0.36	Aortic root size;	chr7:66401463	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs778699	ENSG00000232559.3	GS1-124K5.12	4.23	4.51e-05	0.0252	0.34	0.36	Aortic root size;	chr7:66403303	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.929	rs778692	ENSG00000232559.3	GS1-124K5.12	4.23	4.51e-05	0.0252	0.34	0.36	Aortic root size;	chr7:66407462	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs4718343	ENSG00000232559.3	GS1-124K5.12	4.23	4.51e-05	0.0252	0.34	0.36	Aortic root size;	chr7:66409301	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs1968225	ENSG00000232559.3	GS1-124K5.12	4.23	4.51e-05	0.0252	0.34	0.36	Aortic root size;	chr7:66409786	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs6460295	ENSG00000232559.3	GS1-124K5.12	4.23	4.51e-05	0.0252	0.34	0.36	Aortic root size;	chr7:66417741	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.964	rs6978721	ENSG00000232559.3	GS1-124K5.12	4.23	4.51e-05	0.0252	0.34	0.36	Aortic root size;	chr7:66418217	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs6979382	ENSG00000232559.3	GS1-124K5.12	4.23	4.51e-05	0.0252	0.34	0.36	Aortic root size;	chr7:66421388	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs6961990	ENSG00000232559.3	GS1-124K5.12	4.23	4.51e-05	0.0252	0.34	0.36	Aortic root size;	chr7:66423583	chr7:66554588~66576923:-
TGCT	cis	rs77204473	0.744	rs6589606	ENSG00000254851.1	RP11-109L13.1	4.23	4.51e-05	0.0252	0.84	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117222170	chr11:117135528~117138582:+
TGCT	cis	rs875971	1	rs4718307	ENSG00000237310.1	GS1-124K5.4	-4.23	4.51e-05	0.0252	-0.39	-0.36	Aortic root size;	chr7:66146001	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs7801282	ENSG00000237310.1	GS1-124K5.4	-4.23	4.51e-05	0.0252	-0.39	-0.36	Aortic root size;	chr7:66148700	chr7:66493706~66495474:+
TGCT	cis	rs2033711	0.936	rs7257999	ENSG00000269473.1	CTD-2619J13.19	4.23	4.51e-05	0.0252	0.3	0.36	Uric acid clearance;	chr19:58453493	chr19:58440448~58445849:+
TGCT	cis	rs7208859	0.623	rs56325146	ENSG00000266490.1	CTD-2349P21.9	4.23	4.51e-05	0.0252	0.36	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30792372~30792833:+
TGCT	cis	rs9326248	0.727	rs4938347	ENSG00000280143.1	AP000892.6	4.23	4.52e-05	0.0252	0.52	0.36	Blood protein levels;	chr11:117151043	chr11:117204967~117210292:+
TGCT	cis	rs10504229	0.6	rs6987243	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57202847	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.596	rs6991216	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57203027	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.596	rs7004566	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57203043	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.639	rs72650811	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57203102	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.636	rs77753517	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57203338	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs55645894	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57203586	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.609	rs56289889	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57203717	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.639	rs66667899	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57204506	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.639	rs67996345	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57204568	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs73605816	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57204608	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.639	rs67002486	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57204659	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.595	rs77615399	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57204835	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.595	rs76447299	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57204836	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.595	rs36081958	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57204946	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.595	rs79077737	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57204961	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.595	rs116490935	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57204972	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs77548248	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57204983	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs34804288	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57205011	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs35840293	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57205075	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs34859456	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57205163	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs35889486	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57205190	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs35244711	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57205203	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs903706	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57215575	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.645	rs35142596	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57215592	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.654	rs903705	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57215626	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.562	rs2014516	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57215729	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs903702	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57215998	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs56058640	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57216303	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs55660024	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57216384	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.545	rs56394419	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57216423	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs882429	ENSG00000253301.4	RP11-513O17.2	4.23	4.52e-05	0.0252	0.52	0.36	Developmental language disorder (linguistic errors);	chr8:57216733	chr8:57142689~57240298:+
TGCT	cis	rs2333021	0.649	rs12891315	ENSG00000259015.1	RP11-109N23.6	4.23	4.52e-05	0.0253	0.21	0.36	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73002646	chr14:72960595~72961993:+
TGCT	cis	rs8091660	0.929	rs2175564	ENSG00000278983.1	RP11-426J5.3	4.23	4.53e-05	0.0253	0.43	0.35	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48570838	chr18:48564795~48568342:+
TGCT	cis	rs17826219	0.568	rs11658027	ENSG00000263603.1	CTD-2349P21.5	4.23	4.53e-05	0.0253	0.52	0.35	Body mass index;	chr17:30767864	chr17:30729469~30731202:+
TGCT	cis	rs9313772	0.928	rs7700842	ENSG00000253519.1	AC106801.1	-4.23	4.54e-05	0.0253	-0.32	-0.35	Blood pressure;	chr5:158397175	chr5:157565964~157569098:+
TGCT	cis	rs9313772	0.928	rs7701003	ENSG00000253519.1	AC106801.1	-4.23	4.54e-05	0.0253	-0.32	-0.35	Blood pressure;	chr5:158397473	chr5:157565964~157569098:+
TGCT	cis	rs4835473	0.932	rs11100824	ENSG00000251600.4	RP11-673E1.1	4.23	4.54e-05	0.0253	0.38	0.35	Immature fraction of reticulocytes;	chr4:143964845	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.592	rs11100825	ENSG00000251600.4	RP11-673E1.1	4.23	4.54e-05	0.0253	0.38	0.35	Immature fraction of reticulocytes;	chr4:143964903	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.864	rs2089837	ENSG00000251600.4	RP11-673E1.1	4.23	4.54e-05	0.0253	0.38	0.35	Immature fraction of reticulocytes;	chr4:143965038	chr4:143912331~143982454:+
TGCT	cis	rs2033711	0.87	rs4801270	ENSG00000269473.1	CTD-2619J13.19	4.23	4.54e-05	0.0253	0.28	0.35	Uric acid clearance;	chr19:58421395	chr19:58440448~58445849:+
TGCT	cis	rs2033711	0.728	rs4801586	ENSG00000269473.1	CTD-2619J13.19	4.23	4.54e-05	0.0253	0.28	0.35	Uric acid clearance;	chr19:58423161	chr19:58440448~58445849:+
TGCT	cis	rs2285002	0.516	rs1695751	ENSG00000276116.2	FUT8-AS1	4.23	4.54e-05	0.0254	0.37	0.35	Red cell distribution width;	chr14:64823248	chr14:65411170~65412690:-
TGCT	cis	rs7160336	0.555	rs8021337	ENSG00000259065.1	RP5-1021I20.1	-4.23	4.55e-05	0.0254	-0.34	-0.35	Blood protein levels;	chr14:74184738	chr14:73787360~73803270:+
TGCT	cis	rs6604026	0.555	rs68160001	ENSG00000223787.2	RP4-593M8.1	4.23	4.55e-05	0.0254	0.52	0.35	Multiple sclerosis;	chr1:92668018	chr1:92580476~92580821:-
TGCT	cis	rs520525	0.963	rs552277	ENSG00000271811.1	RP1-79C4.4	4.23	4.55e-05	0.0254	0.28	0.35	Atrial fibrillation;	chr1:170658653	chr1:170667381~170669425:+
TGCT	cis	rs7005380	0.62	rs6987580	ENSG00000254343.2	RP11-760H22.2	-4.23	4.55e-05	0.0254	-0.47	-0.35	Interstitial lung disease;	chr8:119898140	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.6	rs4871772	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119895655	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.6	rs4871773	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119895671	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs4871012	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119895734	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs4871013	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119895750	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.579	rs7465181	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119896349	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs7462250	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119896367	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs7459671	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119896646	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs13281299	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119897253	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs7832923	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119897540	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs6469861	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119897673	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs6469862	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119897796	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs6469863	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119897910	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs6469864	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119897985	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs6469865	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119897995	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs6988011	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119898298	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.6	rs35272074	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119898543	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.6	rs10103660	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119898547	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs6993375	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119899390	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.6	rs6993797	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119899405	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs6989741	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119899914	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.6	rs13257252	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119899993	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs10093230	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119900606	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs9649947	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119901117	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs13279398	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119902030	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs13277947	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119902192	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.6	rs13277992	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119902287	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs13253140	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119902668	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.6	rs11777705	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119902992	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs12681402	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119903622	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs7461290	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119904154	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.58	rs4073560	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119905148	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs7462302	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119905531	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs7002839	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119906508	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs7006905	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119906683	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.58	rs13265546	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119907735	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.6	rs13267896	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119908414	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs13275524	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119908701	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.6	rs6469867	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119909172	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.58	rs6469868	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119909601	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.606	rs6469869	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119909696	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs6469870	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119909773	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs6469871	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119909839	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.6	rs6469872	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119910007	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.6	rs7015470	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119910101	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs6995139	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119910157	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs10217077	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119910943	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs10217083	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119911045	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs939242	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119912030	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.6	rs939241	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119912297	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs10216503	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119912843	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.62	rs7824545	ENSG00000254343.2	RP11-760H22.2	4.23	4.55e-05	0.0254	0.47	0.35	Interstitial lung disease;	chr8:119913381	chr8:120052180~120056201:+
TGCT	cis	rs10504229	0.683	rs6982990	ENSG00000253301.4	RP11-513O17.2	-4.23	4.55e-05	0.0254	-0.5	-0.35	Developmental language disorder (linguistic errors);	chr8:57202716	chr8:57142689~57240298:+
TGCT	cis	rs11139399	0.613	rs10867801	ENSG00000233926.1	RP11-154D17.1	-4.23	4.56e-05	0.0254	-0.4	-0.35	Hippocampal atrophy;	chr9:81723673	chr9:81689713~81776900:+
TGCT	cis	rs875971	0.545	rs4718348	ENSG00000237310.1	GS1-124K5.4	4.23	4.56e-05	0.0254	0.43	0.35	Aortic root size;	chr7:66441589	chr7:66493706~66495474:+
TGCT	cis	rs3758911	0.964	rs10789601	ENSG00000255353.1	RP11-382M14.1	-4.23	4.56e-05	0.0254	-0.39	-0.35	Coronary artery disease;	chr11:107310693	chr11:107176286~107177530:+
TGCT	cis	rs1355223	0.573	rs1361646	ENSG00000271369.1	RP11-350D17.3	-4.23	4.56e-05	0.0254	-0.34	-0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34724813	chr11:34709600~34710161:+
TGCT	cis	rs56205728	0.606	rs2898991	ENSG00000273855.1	RP11-133K1.12	4.23	4.56e-05	0.0254	0.39	0.35	Schizophrenia;	chr15:40304367	chr15:40285468~40285909:-
TGCT	cis	rs7829975	0.711	rs1039916	ENSG00000173295.6	FAM86B3P	4.23	4.57e-05	0.0254	0.43	0.35	Mood instability;	chr8:8828344	chr8:8228595~8244865:+
TGCT	cis	rs7182621	0.639	rs34701806	ENSG00000259363.4	CTD-2054N24.2	-4.23	4.57e-05	0.0254	-0.36	-0.35	Colonoscopy-negative controls vs population controls;	chr15:99872953	chr15:99807023~99877148:+
TGCT	cis	rs7182621	0.639	rs12906050	ENSG00000259363.4	CTD-2054N24.2	-4.23	4.57e-05	0.0254	-0.36	-0.35	Colonoscopy-negative controls vs population controls;	chr15:99873384	chr15:99807023~99877148:+
TGCT	cis	rs7182621	0.639	rs35248328	ENSG00000259363.4	CTD-2054N24.2	-4.23	4.57e-05	0.0254	-0.36	-0.35	Colonoscopy-negative controls vs population controls;	chr15:99873399	chr15:99807023~99877148:+
TGCT	cis	rs172166	0.694	rs1225716	ENSG00000219392.1	RP1-265C24.5	-4.23	4.57e-05	0.0254	-0.44	-0.35	Cardiac Troponin-T levels;	chr6:28145968	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.512	rs2622319	ENSG00000219392.1	RP1-265C24.5	-4.23	4.57e-05	0.0254	-0.44	-0.35	Parkinson's disease;	chr6:28152623	chr6:28115628~28116551:+
TGCT	cis	rs172166	0.694	rs1150666	ENSG00000219392.1	RP1-265C24.5	-4.23	4.57e-05	0.0254	-0.44	-0.35	Cardiac Troponin-T levels;	chr6:28156150	chr6:28115628~28116551:+
TGCT	cis	rs172166	0.694	rs9295760	ENSG00000219392.1	RP1-265C24.5	-4.23	4.57e-05	0.0254	-0.44	-0.35	Cardiac Troponin-T levels;	chr6:28179607	chr6:28115628~28116551:+
TGCT	cis	rs12550646	0.612	rs13439740	ENSG00000253943.1	KRT18P37	4.23	4.57e-05	0.0254	0.41	0.35	Reticulocyte fraction of red cells;Reticulocyte count;	chr8:41828499	chr8:41511240~41512521:+
TGCT	cis	rs12550646	0.625	rs1549064	ENSG00000253943.1	KRT18P37	4.23	4.58e-05	0.0254	0.39	0.35	Reticulocyte fraction of red cells;Reticulocyte count;	chr8:41826970	chr8:41511240~41512521:+
TGCT	cis	rs17507216	1	rs17158413	ENSG00000255769.6	GOLGA2P10	-4.23	4.58e-05	0.0255	-0.43	-0.35	Excessive daytime sleepiness;	chr15:82566658	chr15:82472993~82513950:-
TGCT	cis	rs9400467	0.537	rs1891387	ENSG00000272356.1	RP5-1112D6.8	-4.23	4.58e-05	0.0255	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111141087	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.537	rs12215291	ENSG00000272356.1	RP5-1112D6.8	-4.23	4.58e-05	0.0255	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111142317	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.537	rs1150081	ENSG00000272356.1	RP5-1112D6.8	-4.23	4.58e-05	0.0255	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111157813	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.537	rs584937	ENSG00000272356.1	RP5-1112D6.8	-4.23	4.58e-05	0.0255	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111160374	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.537	rs354533	ENSG00000272356.1	RP5-1112D6.8	-4.23	4.58e-05	0.0255	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111165901	chr6:111309203~111313517:+
TGCT	cis	rs786425	1	rs786425	ENSG00000247373.3	RP11-486O12.2	-4.23	4.58e-05	0.0255	-0.42	-0.35	Pubertal anthropometrics;	chr12:123600955	chr12:123575891~123585115:-
TGCT	cis	rs11168854	0.93	rs10783302	ENSG00000258017.1	RP11-386G11.10	4.23	4.58e-05	0.0255	0.45	0.35	Body mass index;	chr12:49104347	chr12:49127782~49147869:+
TGCT	cis	rs853679	1	rs10456362	ENSG00000219392.1	RP1-265C24.5	4.23	4.58e-05	0.0255	0.53	0.35	Depression;	chr6:28254038	chr6:28115628~28116551:+
TGCT	cis	rs2033711	0.783	rs8113810	ENSG00000269473.1	CTD-2619J13.19	4.23	4.59e-05	0.0255	0.28	0.35	Uric acid clearance;	chr19:58420739	chr19:58440448~58445849:+
TGCT	cis	rs7615952	0.688	rs7624806	ENSG00000171084.14	FAM86JP	4.22	4.6e-05	0.0255	0.63	0.35	Blood pressure (smoking interaction);	chr3:125880231	chr3:125916620~125930024:+
TGCT	cis	rs62296447	0.514	rs6858545	ENSG00000248515.1	RP11-608O21.1	-4.22	4.6e-05	0.0255	-0.36	-0.35	Schizophrenia;	chr4:19417747	chr4:19455436~19909692:+
TGCT	cis	rs7819412	0.521	rs2409720	ENSG00000255310.2	AF131215.2	-4.22	4.6e-05	0.0255	-0.3	-0.35	Triglycerides;	chr8:11180394	chr8:11107788~11109726:-
TGCT	cis	rs11722228	0.521	rs56403947	ENSG00000261490.1	RP11-448G15.3	4.22	4.6e-05	0.0255	0.34	0.35	Urate levels;Serum uric acid levels;Gout;	chr4:10110905	chr4:10068089~10073019:-
TGCT	cis	rs11722228	0.522	rs2241468	ENSG00000261490.1	RP11-448G15.3	4.22	4.6e-05	0.0255	0.34	0.35	Urate levels;Serum uric acid levels;Gout;	chr4:10112281	chr4:10068089~10073019:-
TGCT	cis	rs172166	0.694	rs203876	ENSG00000219392.1	RP1-265C24.5	-4.22	4.6e-05	0.0256	-0.44	-0.35	Cardiac Troponin-T levels;	chr6:28078895	chr6:28115628~28116551:+
TGCT	cis	rs172166	0.694	rs203877	ENSG00000219392.1	RP1-265C24.5	-4.22	4.6e-05	0.0256	-0.44	-0.35	Cardiac Troponin-T levels;	chr6:28080846	chr6:28115628~28116551:+
TGCT	cis	rs172166	0.694	rs203893	ENSG00000219392.1	RP1-265C24.5	-4.22	4.6e-05	0.0256	-0.44	-0.35	Cardiac Troponin-T levels;	chr6:28094288	chr6:28115628~28116551:+
TGCT	cis	rs172166	0.652	rs476167	ENSG00000219392.1	RP1-265C24.5	-4.22	4.6e-05	0.0256	-0.44	-0.35	Cardiac Troponin-T levels;	chr6:28098110	chr6:28115628~28116551:+
TGCT	cis	rs172166	0.694	rs203892	ENSG00000219392.1	RP1-265C24.5	-4.22	4.6e-05	0.0256	-0.44	-0.35	Cardiac Troponin-T levels;	chr6:28099418	chr6:28115628~28116551:+
TGCT	cis	rs172166	0.694	rs188105	ENSG00000219392.1	RP1-265C24.5	-4.22	4.6e-05	0.0256	-0.44	-0.35	Cardiac Troponin-T levels;	chr6:28103615	chr6:28115628~28116551:+
TGCT	cis	rs7246967	0.932	rs1478457	ENSG00000268541.1	VN1R88P	-4.22	4.6e-05	0.0256	-0.43	-0.35	Bronchopulmonary dysplasia;	chr19:22882467	chr19:22861303~22861594:+
TGCT	cis	rs7824557	0.872	rs2572417	ENSG00000255052.4	FAM66D	4.22	4.61e-05	0.0256	0.36	0.35	Retinal vascular caliber;	chr8:11253953	chr8:12115782~12177550:+
TGCT	cis	rs10504229	0.683	rs6998040	ENSG00000253301.4	RP11-513O17.2	-4.22	4.62e-05	0.0256	-0.51	-0.35	Developmental language disorder (linguistic errors);	chr8:57197596	chr8:57142689~57240298:+
TGCT	cis	rs4835473	0.864	rs1597446	ENSG00000251600.4	RP11-673E1.1	4.22	4.62e-05	0.0256	0.37	0.35	Immature fraction of reticulocytes;	chr4:143708338	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.835	rs1450247	ENSG00000251600.4	RP11-673E1.1	4.22	4.62e-05	0.0256	0.37	0.35	Immature fraction of reticulocytes;	chr4:143708529	chr4:143912331~143982454:+
TGCT	cis	rs11123170	0.529	rs112692022	ENSG00000189223.12	PAX8-AS1	-4.22	4.62e-05	0.0257	-0.59	-0.35	Renal function-related traits (BUN);	chr2:113212605	chr2:113211522~113276581:+
TGCT	cis	rs1387259	0.57	rs12368659	ENSG00000258273.1	RP11-370I10.4	-4.22	4.62e-05	0.0257	-0.4	-0.35	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48333755~48333901:-
TGCT	cis	rs6604026	0.589	rs12738833	ENSG00000223787.2	RP4-593M8.1	4.22	4.62e-05	0.0257	0.52	0.35	Multiple sclerosis;	chr1:92653561	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.589	rs11578098	ENSG00000223787.2	RP4-593M8.1	4.22	4.62e-05	0.0257	0.52	0.35	Multiple sclerosis;	chr1:92653853	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.589	rs11800771	ENSG00000223787.2	RP4-593M8.1	4.22	4.62e-05	0.0257	0.52	0.35	Multiple sclerosis;	chr1:92661552	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.589	rs11800848	ENSG00000223787.2	RP4-593M8.1	4.22	4.62e-05	0.0257	0.52	0.35	Multiple sclerosis;	chr1:92662370	chr1:92580476~92580821:-
TGCT	cis	rs1799949	0.965	rs7212284	ENSG00000198496.9	NBR2	-4.22	4.63e-05	0.0257	-0.51	-0.35	Menopause (age at onset);	chr17:43053924	chr17:43125610~43153671:+
TGCT	cis	rs4273100	0.607	rs8072587	ENSG00000262319.1	CTC-457L16.2	4.22	4.63e-05	0.0257	0.46	0.35	Schizophrenia;	chr17:19307760	chr17:19141017~19143689:-
TGCT	cis	rs4273100	0.646	rs11652784	ENSG00000262319.1	CTC-457L16.2	4.22	4.63e-05	0.0257	0.46	0.35	Schizophrenia;	chr17:19313948	chr17:19141017~19143689:-
TGCT	cis	rs1799949	0.965	rs7223952	ENSG00000198496.9	NBR2	-4.22	4.63e-05	0.0257	-0.51	-0.35	Menopause (age at onset);	chr17:43042868	chr17:43125610~43153671:+
TGCT	cis	rs3931020	0.671	rs1327088	ENSG00000272864.1	RP11-17E13.2	-4.22	4.64e-05	0.0257	-0.39	-0.35	Resistin levels;	chr1:74789807	chr1:74698769~74699333:-
TGCT	cis	rs10504229	0.953	rs57669205	ENSG00000253301.4	RP11-513O17.2	4.22	4.64e-05	0.0257	0.45	0.35	Developmental language disorder (linguistic errors);	chr8:57259694	chr8:57142689~57240298:+
TGCT	cis	rs4713118	0.662	rs156744	ENSG00000187763.3	OR2B7P	4.22	4.64e-05	0.0257	0.33	0.35	Parkinson's disease;	chr6:27999496	chr6:28046434~28047367:+
TGCT	cis	rs4713118	0.662	rs149946	ENSG00000187763.3	OR2B7P	-4.22	4.64e-05	0.0257	-0.33	-0.35	Parkinson's disease;	chr6:28002253	chr6:28046434~28047367:+
TGCT	cis	rs4713118	0.662	rs149947	ENSG00000187763.3	OR2B7P	4.22	4.64e-05	0.0257	0.33	0.35	Parkinson's disease;	chr6:28004655	chr6:28046434~28047367:+
TGCT	cis	rs7923609	1	rs7923609	ENSG00000232075.1	MRPL35P2	-4.22	4.65e-05	0.0258	-0.35	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63374062	chr10:63634317~63634827:-
TGCT	cis	rs9309473	1	rs6753344	ENSG00000163016.8	ALMS1P	-4.22	4.65e-05	0.0258	-0.32	-0.35	Metabolite levels;	chr2:73426010	chr2:73644919~73685576:+
TGCT	cis	rs673078	0.607	rs7958551	ENSG00000275759.1	RP11-131L12.3	-4.22	4.65e-05	0.0258	-0.64	-0.35	Glucose homeostasis traits;	chr12:118442585	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs7958652	ENSG00000275759.1	RP11-131L12.3	-4.22	4.65e-05	0.0258	-0.64	-0.35	Glucose homeostasis traits;	chr12:118442630	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs111607725	ENSG00000275759.1	RP11-131L12.3	-4.22	4.65e-05	0.0258	-0.64	-0.35	Glucose homeostasis traits;	chr12:118442957	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs73207573	ENSG00000275759.1	RP11-131L12.3	-4.22	4.65e-05	0.0258	-0.64	-0.35	Glucose homeostasis traits;	chr12:118444664	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs76809232	ENSG00000275759.1	RP11-131L12.3	-4.22	4.65e-05	0.0258	-0.64	-0.35	Glucose homeostasis traits;	chr12:118444979	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs61944660	ENSG00000275759.1	RP11-131L12.3	-4.22	4.65e-05	0.0258	-0.64	-0.35	Glucose homeostasis traits;	chr12:118445326	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs61944662	ENSG00000275759.1	RP11-131L12.3	-4.22	4.65e-05	0.0258	-0.64	-0.35	Glucose homeostasis traits;	chr12:118445520	chr12:118428281~118428870:+
TGCT	cis	rs9650657	0.589	rs6985109	ENSG00000269918.1	AF131215.9	4.22	4.65e-05	0.0258	0.35	0.35	Neuroticism;	chr8:10904075	chr8:11104691~11106704:-
TGCT	cis	rs807029	0.577	rs701834	ENSG00000272572.1	RP11-179B2.2	-4.22	4.66e-05	0.0258	-0.31	-0.35	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101002044	chr10:100911103~100912739:-
TGCT	cis	rs4268898	0.662	rs55661701	ENSG00000223754.1	AC008073.9	4.22	4.66e-05	0.0258	0.49	0.35	Asthma;	chr2:24177900	chr2:24199839~24201698:-
TGCT	cis	rs11148252	0.508	rs6561671	ENSG00000278238.1	RP11-245D16.4	-4.22	4.66e-05	0.0258	-0.26	-0.35	Lewy body disease;	chr13:52608179	chr13:52454775~52455331:-
TGCT	cis	rs1210638	0.706	rs2518798	ENSG00000237517.7	DGCR5	-4.22	4.66e-05	0.0258	-0.33	-0.35	Response to serotonin reuptake inhibitors in major depressive disorder;	chr22:18982890	chr22:18970514~19031242:+
TGCT	cis	rs2033711	0.87	rs11669741	ENSG00000269473.1	CTD-2619J13.19	-4.22	4.66e-05	0.0258	-0.28	-0.35	Uric acid clearance;	chr19:58449114	chr19:58440448~58445849:+
TGCT	cis	rs10511112	0.867	rs56327659	ENSG00000242781.1	RP11-47P18.2	-4.22	4.66e-05	0.0259	-0.51	-0.35	Migraine;	chr3:80311514	chr3:80764897~80789354:+
TGCT	cis	rs7923609	0.936	rs10822160	ENSG00000232075.1	MRPL35P2	-4.22	4.66e-05	0.0259	-0.35	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63353036	chr10:63634317~63634827:-
TGCT	cis	rs7923609	1	rs10822161	ENSG00000232075.1	MRPL35P2	-4.22	4.66e-05	0.0259	-0.35	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63358443	chr10:63634317~63634827:-
TGCT	cis	rs8141529	0.702	rs5762870	ENSG00000226471.5	CTA-292E10.6	-4.22	4.67e-05	0.0259	-0.37	-0.35	Lymphocyte counts;	chr22:28865171	chr22:28800683~28848559:+
TGCT	cis	rs987724	0.592	rs1430411	ENSG00000240875.4	LINC00886	-4.22	4.67e-05	0.0259	-0.29	-0.35	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156807607	chr3:156747346~156817062:-
TGCT	cis	rs9313772	0.928	rs1958603	ENSG00000253519.1	AC106801.1	-4.22	4.67e-05	0.0259	-0.32	-0.35	Blood pressure;	chr5:158395106	chr5:157565964~157569098:+
TGCT	cis	rs1250259	0.519	rs10172425	ENSG00000225166.1	AC012462.2	-4.22	4.67e-05	0.0259	-0.34	-0.35	Coronary artery disease;Pulse pressure;	chr2:215403632	chr2:215453707~215463871:+
TGCT	cis	rs11772815	1	rs11772490	ENSG00000233830.2	EIF4HP1	-4.22	4.67e-05	0.0259	-0.38	-0.35	Folding of antihelix;	chr7:28347372	chr7:27458163~27458849:-
TGCT	cis	rs8070740	0.838	rs1050390	ENSG00000262227.1	RP5-1050D4.5	-4.22	4.67e-05	0.0259	-0.31	-0.35	Menopause (age at onset);	chr17:5432738	chr17:4987706~4988446:+
TGCT	cis	rs17410015	0.764	rs17449778	ENSG00000225169.1	BRI3P1	4.22	4.67e-05	0.0259	0.77	0.35	Response to antipsychotic treatment;	chr1:101051935	chr1:100213293~100213670:+
TGCT	cis	rs34375054	0.738	rs10846834	ENSG00000279233.1	RP11-158L12.4	4.22	4.68e-05	0.0259	0.36	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125141024	chr12:125138245~125141711:+
TGCT	cis	rs4713118	0.662	rs149900	ENSG00000216901.1	AL022393.7	4.22	4.68e-05	0.0259	0.48	0.35	Parkinson's disease;	chr6:28046819	chr6:28176188~28176674:+
TGCT	cis	rs17410015	0.764	rs17610195	ENSG00000225169.1	BRI3P1	4.22	4.68e-05	0.0259	0.7	0.35	Response to antipsychotic treatment;	chr1:100962908	chr1:100213293~100213670:+
TGCT	cis	rs4835473	0.864	rs2323418	ENSG00000251600.4	RP11-673E1.1	4.22	4.69e-05	0.026	0.38	0.35	Immature fraction of reticulocytes;	chr4:143969141	chr4:143912331~143982454:+
TGCT	cis	rs10504229	0.817	rs55891651	ENSG00000253301.4	RP11-513O17.2	4.22	4.69e-05	0.026	0.44	0.35	Developmental language disorder (linguistic errors);	chr8:57255041	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.817	rs55949560	ENSG00000253301.4	RP11-513O17.2	4.22	4.69e-05	0.026	0.44	0.35	Developmental language disorder (linguistic errors);	chr8:57255044	chr8:57142689~57240298:+
TGCT	cis	rs10504229	1	rs57378064	ENSG00000253301.4	RP11-513O17.2	4.22	4.69e-05	0.026	0.44	0.35	Developmental language disorder (linguistic errors);	chr8:57257285	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.906	rs7846666	ENSG00000253301.4	RP11-513O17.2	4.22	4.69e-05	0.026	0.44	0.35	Developmental language disorder (linguistic errors);	chr8:57259743	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.953	rs59034808	ENSG00000253301.4	RP11-513O17.2	4.22	4.69e-05	0.026	0.44	0.35	Developmental language disorder (linguistic errors);	chr8:57272778	chr8:57142689~57240298:+
TGCT	cis	rs7615952	0.932	rs13314869	ENSG00000171084.14	FAM86JP	4.22	4.69e-05	0.026	0.61	0.35	Blood pressure (smoking interaction);	chr3:125925826	chr3:125916620~125930024:+
TGCT	cis	rs7615952	0.741	rs13314845	ENSG00000171084.14	FAM86JP	4.22	4.69e-05	0.026	0.61	0.35	Blood pressure (smoking interaction);	chr3:125925939	chr3:125916620~125930024:+
TGCT	cis	rs7615952	0.733	rs13314847	ENSG00000171084.14	FAM86JP	4.22	4.69e-05	0.026	0.61	0.35	Blood pressure (smoking interaction);	chr3:125925945	chr3:125916620~125930024:+
TGCT	cis	rs7615952	0.932	rs13086087	ENSG00000171084.14	FAM86JP	4.22	4.69e-05	0.026	0.61	0.35	Blood pressure (smoking interaction);	chr3:125927438	chr3:125916620~125930024:+
TGCT	cis	rs7615952	0.8	rs13086460	ENSG00000171084.14	FAM86JP	4.22	4.69e-05	0.026	0.61	0.35	Blood pressure (smoking interaction);	chr3:125927574	chr3:125916620~125930024:+
TGCT	cis	rs1023500	0.573	rs133380	ENSG00000270083.1	RP1-257I20.14	4.22	4.7e-05	0.026	0.37	0.35	Schizophrenia;	chr22:42072906	chr22:42089630~42090028:-
TGCT	cis	rs10875746	0.859	rs11168371	ENSG00000240399.1	RP1-228P16.1	-4.22	4.7e-05	0.026	-0.42	-0.35	Longevity (90 years and older);	chr12:48043903	chr12:48054813~48055591:-
TGCT	cis	rs7829975	0.626	rs332040	ENSG00000254340.1	RP11-10A14.3	4.22	4.7e-05	0.026	0.35	0.35	Mood instability;	chr8:8872978	chr8:9141424~9145435:+
TGCT	cis	rs12143943	0.966	rs3789047	ENSG00000176754.11	LINC00303	4.22	4.7e-05	0.026	0.33	0.35	Cognitive performance;	chr1:204617056	chr1:204032447~204041265:-
TGCT	cis	rs4273100	0.688	rs12939947	ENSG00000262319.1	CTC-457L16.2	-4.22	4.7e-05	0.026	-0.46	-0.35	Schizophrenia;	chr17:19301218	chr17:19141017~19143689:-
TGCT	cis	rs11086243	0.935	rs1133029	ENSG00000235621.7	LINC00494	4.22	4.71e-05	0.0261	0.32	0.35	Nephrotic syndrome (acquired);	chr20:48135884	chr20:48359950~48370629:+
TGCT	cis	rs10504229	0.817	rs10504230	ENSG00000253301.4	RP11-513O17.2	-4.22	4.71e-05	0.0261	-0.47	-0.35	Developmental language disorder (linguistic errors);	chr8:57284591	chr8:57142689~57240298:+
TGCT	cis	rs4713118	0.826	rs2893929	ENSG00000272009.1	RP1-313I6.12	-4.22	4.71e-05	0.0261	-0.43	-0.35	Parkinson's disease;	chr6:27770953	chr6:28078792~28081130:-
TGCT	cis	rs4713118	0.666	rs4140646	ENSG00000272009.1	RP1-313I6.12	-4.22	4.71e-05	0.0261	-0.43	-0.35	Parkinson's disease;	chr6:27771022	chr6:28078792~28081130:-
TGCT	cis	rs4713118	0.666	rs2893930	ENSG00000272009.1	RP1-313I6.12	-4.22	4.71e-05	0.0261	-0.43	-0.35	Parkinson's disease;	chr6:27771027	chr6:28078792~28081130:-
TGCT	cis	rs453301	0.624	rs6987558	ENSG00000254340.1	RP11-10A14.3	4.22	4.71e-05	0.0261	0.36	0.35	Joint mobility (Beighton score);	chr8:9005011	chr8:9141424~9145435:+
TGCT	cis	rs9309473	1	rs7607014	ENSG00000163016.8	ALMS1P	-4.22	4.71e-05	0.0261	-0.32	-0.35	Metabolite levels;	chr2:73503047	chr2:73644919~73685576:+
TGCT	cis	rs9660180	0.967	rs2272908	ENSG00000231050.1	RP1-140A9.1	-4.22	4.72e-05	0.0261	-0.32	-0.35	Body mass index;	chr1:1790040	chr1:1891471~1892658:+
TGCT	cis	rs10829156	0.898	rs4748504	ENSG00000240291.1	RP11-499P20.2	4.22	4.72e-05	0.0261	0.32	0.35	Sudden cardiac arrest;	chr10:18651868	chr10:18513115~18545651:-
TGCT	cis	rs7208859	0.673	rs3816780	ENSG00000263603.1	CTD-2349P21.5	-4.22	4.72e-05	0.0261	-0.5	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30729469~30731202:+
TGCT	cis	rs17826219	0.706	rs609472	ENSG00000280069.1	CTD-2349P21.3	-4.22	4.73e-05	0.0261	-0.48	-0.35	Body mass index;	chr17:30624409	chr17:30738182~30740275:+
TGCT	cis	rs807029	0.758	rs807027	ENSG00000272572.1	RP11-179B2.2	-4.22	4.73e-05	0.0262	-0.29	-0.35	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101004850	chr10:100911103~100912739:-
TGCT	cis	rs2439831	0.867	rs2245715	ENSG00000205771.5	CATSPER2P1	-4.22	4.73e-05	0.0262	-0.59	-0.35	Lung cancer in ever smokers;	chr15:43525854	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.867	rs2255440	ENSG00000205771.5	CATSPER2P1	-4.22	4.73e-05	0.0262	-0.59	-0.35	Lung cancer in ever smokers;	chr15:43538269	chr15:43726918~43747094:-
TGCT	cis	rs4713118	0.621	rs4713132	ENSG00000187763.3	OR2B7P	4.22	4.73e-05	0.0262	0.35	0.35	Parkinson's disease;	chr6:28066257	chr6:28046434~28047367:+
TGCT	cis	rs4713118	0.621	rs4713133	ENSG00000187763.3	OR2B7P	4.22	4.73e-05	0.0262	0.35	0.35	Parkinson's disease;	chr6:28066263	chr6:28046434~28047367:+
TGCT	cis	rs4713118	0.621	rs4713134	ENSG00000187763.3	OR2B7P	4.22	4.73e-05	0.0262	0.35	0.35	Parkinson's disease;	chr6:28066343	chr6:28046434~28047367:+
TGCT	cis	rs2717559	0.542	rs2717586	ENSG00000253196.1	RP11-706C16.7	4.22	4.74e-05	0.0262	0.36	0.35	Urinary tract infection frequency;	chr8:142816466	chr8:142763116~142766427:+
TGCT	cis	rs2177312	0.868	rs1523168	ENSG00000251129.1	RP11-734I18.1	-4.22	4.75e-05	0.0262	-0.4	-0.35	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31944658	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.868	rs10029983	ENSG00000251129.1	RP11-734I18.1	-4.22	4.75e-05	0.0262	-0.4	-0.35	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31945451	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.868	rs10005394	ENSG00000251129.1	RP11-734I18.1	-4.22	4.75e-05	0.0262	-0.4	-0.35	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31945452	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.868	rs10007897	ENSG00000251129.1	RP11-734I18.1	-4.22	4.75e-05	0.0262	-0.4	-0.35	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31945840	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.868	rs7441108	ENSG00000251129.1	RP11-734I18.1	-4.22	4.75e-05	0.0262	-0.4	-0.35	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31946705	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.868	rs2177311	ENSG00000251129.1	RP11-734I18.1	-4.22	4.75e-05	0.0262	-0.4	-0.35	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31946793	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.868	rs2404292	ENSG00000251129.1	RP11-734I18.1	-4.22	4.75e-05	0.0262	-0.4	-0.35	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31946860	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.868	rs1916300	ENSG00000251129.1	RP11-734I18.1	-4.22	4.75e-05	0.0262	-0.4	-0.35	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31947056	chr4:31997397~32155406:+
TGCT	cis	rs2177312	1	rs2177312	ENSG00000251129.1	RP11-734I18.1	-4.22	4.75e-05	0.0262	-0.4	-0.35	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31947421	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.83	rs1533925	ENSG00000251129.1	RP11-734I18.1	-4.22	4.75e-05	0.0262	-0.4	-0.35	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31947689	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.868	rs4600961	ENSG00000251129.1	RP11-734I18.1	4.22	4.75e-05	0.0262	0.4	0.35	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31947858	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.868	rs1357466	ENSG00000251129.1	RP11-734I18.1	-4.22	4.75e-05	0.0262	-0.4	-0.35	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31948068	chr4:31997397~32155406:+
TGCT	cis	rs875971	0.789	rs28815324	ENSG00000222364.1	RNU6-96P	4.22	4.75e-05	0.0262	0.46	0.35	Aortic root size;	chr7:66100789	chr7:66395191~66395286:+
TGCT	cis	rs10740039	0.583	rs2127350	ENSG00000254271.1	RP11-131N11.4	-4.22	4.75e-05	0.0262	-0.37	-0.35	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741079	chr10:60734342~60741828:+
TGCT	cis	rs10740039	0.583	rs2127351	ENSG00000254271.1	RP11-131N11.4	-4.22	4.75e-05	0.0262	-0.37	-0.35	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741425	chr10:60734342~60741828:+
TGCT	cis	rs10740039	0.583	rs1904401	ENSG00000254271.1	RP11-131N11.4	-4.22	4.75e-05	0.0262	-0.37	-0.35	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741809	chr10:60734342~60741828:+
TGCT	cis	rs10740039	0.583	rs2127352	ENSG00000254271.1	RP11-131N11.4	-4.22	4.75e-05	0.0262	-0.37	-0.35	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60742129	chr10:60734342~60741828:+
TGCT	cis	rs10129255	0.872	rs1858683	ENSG00000211970.3	IGHV4-61	-4.22	4.75e-05	0.0262	-0.38	-0.35	Kawasaki disease;	chr14:106670217	chr14:106639119~106639657:-
TGCT	cis	rs11671005	0.735	rs12977592	ENSG00000232098.3	CTD-2619J13.14	-4.22	4.76e-05	0.0263	-0.37	-0.35	Mean platelet volume;	chr19:58449689	chr19:58404238~58408484:-
TGCT	cis	rs4713118	0.629	rs203887	ENSG00000216901.1	AL022393.7	4.22	4.76e-05	0.0263	0.47	0.35	Parkinson's disease;	chr6:28053491	chr6:28176188~28176674:+
TGCT	cis	rs34091987	0.622	rs2193052	ENSG00000256124.4	LINC01152	-4.22	4.76e-05	0.0263	-0.33	-0.35	Nose size;	chr17:72029996	chr17:72030291~72041297:+
TGCT	cis	rs72634501	0.568	rs590214	ENSG00000182109.6	RP11-69E11.4	4.22	4.77e-05	0.0263	0.36	0.35	HDL cholesterol;	chr1:39146821	chr1:39522280~39546187:-
TGCT	cis	rs10129255	0.517	rs11625572	ENSG00000253755.1	IGHGP	-4.22	4.77e-05	0.0263	-0.33	-0.35	Kawasaki disease;	chr14:106656426	chr14:105664633~105669843:-
TGCT	cis	rs2243480	1	rs13220979	ENSG00000164669.11	INTS4P1	4.21	4.77e-05	0.0263	0.58	0.35	Diabetic kidney disease;	chr7:65898217	chr7:65141225~65234216:+
TGCT	cis	rs10938353	0.731	rs17600732	ENSG00000273369.1	RP11-700J17.1	-4.21	4.77e-05	0.0264	-0.59	-0.35	Body mass index;	chr4:44619710	chr4:44693946~44694386:-
TGCT	cis	rs875971	0.83	rs427973	ENSG00000237310.1	GS1-124K5.4	4.21	4.77e-05	0.0264	0.39	0.35	Aortic root size;	chr7:66061661	chr7:66493706~66495474:+
TGCT	cis	rs10875976	1	rs55677077	ENSG00000242041.1	RP11-70F11.2	4.21	4.77e-05	0.0264	0.31	0.35	Obesity;	chr12:49825725	chr12:49863173~49863503:+
TGCT	cis	rs2709736	1	rs2709736	ENSG00000232790.2	LINC01162	4.21	4.78e-05	0.0264	0.25	0.35	Bipolar I disorder;	chr7:20822683	chr7:20835431~21023148:+
TGCT	cis	rs7923609	0.902	rs7897379	ENSG00000232075.1	MRPL35P2	-4.21	4.78e-05	0.0264	-0.34	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63541965	chr10:63634317~63634827:-
TGCT	cis	rs891378	1	rs10864167	ENSG00000274245.1	RP11-357P18.2	-4.21	4.79e-05	0.0264	-0.45	-0.35	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207248227	chr1:207372559~207373252:+
TGCT	cis	rs786425	0.966	rs786444	ENSG00000278112.1	RP11-972P1.11	4.21	4.79e-05	0.0264	0.39	0.35	Pubertal anthropometrics;	chr12:123580869	chr12:123519390~123519856:-
TGCT	cis	rs6474412	1	rs6997909	ENSG00000255101.1	RP11-412B14.1	4.21	4.79e-05	0.0264	0.34	0.35	Smoking behavior;	chr8:42705106	chr8:42705583~42721946:-
TGCT	cis	rs6474412	0.957	rs6474414	ENSG00000255101.1	RP11-412B14.1	4.21	4.79e-05	0.0264	0.34	0.35	Smoking behavior;	chr8:42705193	chr8:42705583~42721946:-
TGCT	cis	rs6474412	1	rs6474415	ENSG00000255101.1	RP11-412B14.1	4.21	4.79e-05	0.0264	0.34	0.35	Smoking behavior;	chr8:42707795	chr8:42705583~42721946:-
TGCT	cis	rs7824557	0.583	rs4448232	ENSG00000255020.1	AF131216.5	4.21	4.79e-05	0.0264	0.24	0.35	Retinal vascular caliber;	chr8:11373845	chr8:11345748~11347502:-
TGCT	cis	rs3931020	0.688	rs277374	ENSG00000272864.1	RP11-17E13.2	4.21	4.8e-05	0.0264	0.42	0.35	Resistin levels;	chr1:74734802	chr1:74698769~74699333:-
TGCT	cis	rs2980439	0.517	rs793753	ENSG00000173295.6	FAM86B3P	-4.21	4.8e-05	0.0264	-0.45	-0.35	Neuroticism;	chr8:8247837	chr8:8228595~8244865:+
TGCT	cis	rs10170266	0.875	rs818018	ENSG00000279220.1	GPR1-AS	4.21	4.8e-05	0.0265	0.29	0.35	Reticulocyte fraction of red cells;	chr2:206037365	chr2:206203376~206266243:+
TGCT	cis	rs1707322	0.716	rs10890342	ENSG00000280836.1	AL355480.1	-4.21	4.8e-05	0.0265	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.752	rs6658700	ENSG00000280836.1	AL355480.1	-4.21	4.8e-05	0.0265	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.752	rs12047629	ENSG00000280836.1	AL355480.1	-4.21	4.8e-05	0.0265	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.752	rs11211169	ENSG00000280836.1	AL355480.1	-4.21	4.8e-05	0.0265	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45581219~45581321:-
TGCT	cis	rs10891354	0.547	rs10789877	ENSG00000176343.5	RPL37AP8	4.21	4.8e-05	0.0265	0.4	0.35	Schizophrenia;	chr11:112395279	chr11:111889199~111889474:-
TGCT	cis	rs10891354	0.547	rs10891356	ENSG00000176343.5	RPL37AP8	4.21	4.8e-05	0.0265	0.4	0.35	Schizophrenia;	chr11:112395380	chr11:111889199~111889474:-
TGCT	cis	rs10891354	0.547	rs10891357	ENSG00000176343.5	RPL37AP8	4.21	4.8e-05	0.0265	0.4	0.35	Schizophrenia;	chr11:112395406	chr11:111889199~111889474:-
TGCT	cis	rs10891354	0.547	rs4936060	ENSG00000176343.5	RPL37AP8	4.21	4.8e-05	0.0265	0.4	0.35	Schizophrenia;	chr11:112395927	chr11:111889199~111889474:-
TGCT	cis	rs10891354	0.547	rs4937367	ENSG00000176343.5	RPL37AP8	4.21	4.8e-05	0.0265	0.4	0.35	Schizophrenia;	chr11:112396836	chr11:111889199~111889474:-
TGCT	cis	rs4925166	1	rs4925166	ENSG00000186831.10	KRT17P2	-4.21	4.8e-05	0.0265	-0.4	-0.35	Multiple sclerosis;	chr17:18307496	chr17:18426861~18431848:+
TGCT	cis	rs10129255	0.585	rs2008440	ENSG00000253755.1	IGHGP	-4.21	4.8e-05	0.0265	-0.34	-0.35	Kawasaki disease;	chr14:106654988	chr14:105664633~105669843:-
TGCT	cis	rs9309473	1	rs6715819	ENSG00000163016.8	ALMS1P	4.21	4.8e-05	0.0265	0.33	0.35	Metabolite levels;	chr2:73545182	chr2:73644919~73685576:+
TGCT	cis	rs496547	0.588	rs473298	ENSG00000255239.1	AP002954.6	4.21	4.8e-05	0.0265	0.4	0.35	Hip minimal joint space width;	chr11:118808678	chr11:118688039~118690600:-
TGCT	cis	rs4713118	0.629	rs203888	ENSG00000187763.3	OR2B7P	4.21	4.8e-05	0.0265	0.34	0.35	Parkinson's disease;	chr6:28053811	chr6:28046434~28047367:+
TGCT	cis	rs4660214	0.614	rs11205802	ENSG00000182109.6	RP11-69E11.4	-4.21	4.81e-05	0.0265	-0.36	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39233442	chr1:39522280~39546187:-
TGCT	cis	rs4660214	0.614	rs10888715	ENSG00000182109.6	RP11-69E11.4	-4.21	4.81e-05	0.0265	-0.36	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39233572	chr1:39522280~39546187:-
TGCT	cis	rs35424364	1	rs35424364	ENSG00000243587.6	C6orf183	-4.21	4.81e-05	0.0265	-0.51	-0.35	Obstructive sleep apnea trait (average respiratory event duration);	chr6:109322402	chr6:109165833~109271014:+
TGCT	cis	rs9400467	0.537	rs73530951	ENSG00000272356.1	RP5-1112D6.8	-4.21	4.81e-05	0.0265	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111163611	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.537	rs73530952	ENSG00000272356.1	RP5-1112D6.8	-4.21	4.81e-05	0.0265	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111165039	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.537	rs12202411	ENSG00000272356.1	RP5-1112D6.8	-4.21	4.81e-05	0.0265	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111167315	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.568	rs12204075	ENSG00000272356.1	RP5-1112D6.8	-4.21	4.81e-05	0.0265	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111167856	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs12192617	ENSG00000272356.1	RP5-1112D6.8	-4.21	4.81e-05	0.0265	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111169072	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.537	rs55643604	ENSG00000272356.1	RP5-1112D6.8	-4.21	4.81e-05	0.0265	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111169445	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.537	rs12197886	ENSG00000272356.1	RP5-1112D6.8	-4.21	4.81e-05	0.0265	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111170202	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.537	rs56272203	ENSG00000272356.1	RP5-1112D6.8	-4.21	4.81e-05	0.0265	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111171233	chr6:111309203~111313517:+
TGCT	cis	rs901683	0.764	rs2279434	ENSG00000264204.2	AGAP7P	-4.21	4.81e-05	0.0265	-0.76	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45459616	chr10:46109621~46131358:+
TGCT	cis	rs16975963	0.639	rs112997435	ENSG00000276846.1	CTD-3220F14.3	-4.21	4.81e-05	0.0265	-0.33	-0.35	Longevity;	chr19:37713730	chr19:37314868~37315620:-
TGCT	cis	rs7824557	0.606	rs2736273	ENSG00000255020.1	AF131216.5	4.21	4.82e-05	0.0266	0.25	0.35	Retinal vascular caliber;	chr8:11342429	chr8:11345748~11347502:-
TGCT	cis	rs7923609	0.934	rs2893919	ENSG00000232075.1	MRPL35P2	-4.21	4.82e-05	0.0266	-0.34	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63375018	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.967	rs2393966	ENSG00000232075.1	MRPL35P2	-4.21	4.82e-05	0.0266	-0.34	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63375054	chr10:63634317~63634827:-
TGCT	cis	rs9987353	0.62	rs34455383	ENSG00000173295.6	FAM86B3P	-4.21	4.83e-05	0.0266	-0.4	-0.35	Recombination measurement;	chr8:9208948	chr8:8228595~8244865:+
TGCT	cis	rs801193	0.66	rs2659897	ENSG00000237310.1	GS1-124K5.4	-4.21	4.83e-05	0.0266	-0.4	-0.35	Aortic root size;	chr7:66722728	chr7:66493706~66495474:+
TGCT	cis	rs10946737	0.756	rs4712870	ENSG00000220517.2	ASS1P1	4.21	4.83e-05	0.0266	0.34	0.35	Liver injury in anti-tuberculosis drug treatment;	chr6:24988673	chr6:25023247~25024483:-
TGCT	cis	rs10946737	0.756	rs12192232	ENSG00000220517.2	ASS1P1	4.21	4.83e-05	0.0266	0.34	0.35	Liver injury in anti-tuberculosis drug treatment;	chr6:24989777	chr6:25023247~25024483:-
TGCT	cis	rs673078	0.66	rs17512574	ENSG00000275759.1	RP11-131L12.3	-4.21	4.83e-05	0.0266	-0.63	-0.35	Glucose homeostasis traits;	chr12:118350198	chr12:118428281~118428870:+
TGCT	cis	rs7923609	1	rs12355784	ENSG00000232075.1	MRPL35P2	-4.21	4.83e-05	0.0266	-0.34	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63361805	chr10:63634317~63634827:-
TGCT	cis	rs853679	0.55	rs1225598	ENSG00000219891.2	ZSCAN12P1	4.21	4.84e-05	0.0266	0.46	0.35	Depression;	chr6:28193021	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.55	rs1150689	ENSG00000219891.2	ZSCAN12P1	4.21	4.84e-05	0.0266	0.46	0.35	Depression;	chr6:28197321	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.55	rs1225599	ENSG00000219891.2	ZSCAN12P1	4.21	4.84e-05	0.0266	0.46	0.35	Depression;	chr6:28197412	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.574	rs1233705	ENSG00000219891.2	ZSCAN12P1	4.21	4.84e-05	0.0266	0.46	0.35	Depression;	chr6:28198669	chr6:28091154~28093664:+
TGCT	cis	rs673078	0.607	rs6490177	ENSG00000275759.1	RP11-131L12.3	-4.21	4.84e-05	0.0266	-0.59	-0.35	Glucose homeostasis traits;	chr12:118358280	chr12:118428281~118428870:+
TGCT	cis	rs73607972	0.74	rs66961852	ENSG00000275191.1	RP11-36I17.2	-4.21	4.84e-05	0.0266	-0.45	-0.35	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53587476	chr16:53628256~53628816:-
TGCT	cis	rs6568686	0.53	rs56340018	ENSG00000272356.1	RP5-1112D6.8	-4.21	4.84e-05	0.0267	-0.42	-0.35	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111620092	chr6:111309203~111313517:+
TGCT	cis	rs2019137	0.936	rs902696	ENSG00000189223.12	PAX8-AS1	-4.21	4.84e-05	0.0267	-0.43	-0.35	Lymphocyte counts;	chr2:113197302	chr2:113211522~113276581:+
TGCT	cis	rs13118159	0.801	rs7664474	ENSG00000254094.1	AC078852.1	-4.21	4.84e-05	0.0267	-0.42	-0.35	Longevity;	chr4:1335328	chr4:1356581~1358075:+
TGCT	cis	rs13118159	0.801	rs1128427	ENSG00000254094.1	AC078852.1	-4.21	4.84e-05	0.0267	-0.42	-0.35	Longevity;	chr4:1336971	chr4:1356581~1358075:+
TGCT	cis	rs4660214	0.666	rs11205696	ENSG00000182109.6	RP11-69E11.4	-4.21	4.85e-05	0.0267	-0.35	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39155880	chr1:39522280~39546187:-
TGCT	cis	rs4660214	0.666	rs6600290	ENSG00000182109.6	RP11-69E11.4	-4.21	4.85e-05	0.0267	-0.35	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39157151	chr1:39522280~39546187:-
TGCT	cis	rs4660214	0.666	rs10888682	ENSG00000182109.6	RP11-69E11.4	-4.21	4.85e-05	0.0267	-0.35	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39157635	chr1:39522280~39546187:-
TGCT	cis	rs4660214	0.666	rs11205698	ENSG00000182109.6	RP11-69E11.4	-4.21	4.85e-05	0.0267	-0.35	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39158708	chr1:39522280~39546187:-
TGCT	cis	rs875971	0.895	rs6460278	ENSG00000237310.1	GS1-124K5.4	-4.21	4.85e-05	0.0267	-0.39	-0.35	Aortic root size;	chr7:66197749	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs6460279	ENSG00000237310.1	GS1-124K5.4	-4.21	4.85e-05	0.0267	-0.39	-0.35	Aortic root size;	chr7:66197774	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.862	rs28491091	ENSG00000237310.1	GS1-124K5.4	-4.21	4.85e-05	0.0267	-0.39	-0.35	Aortic root size;	chr7:66204077	chr7:66493706~66495474:+
TGCT	cis	rs8111998	0.826	rs10426000	ENSG00000269332.4	GOLGA2P9	4.21	4.85e-05	0.0267	0.62	0.35	Corneal structure;	chr19:22576890	chr19:22596257~22603550:+
TGCT	cis	rs10740039	0.549	rs9414741	ENSG00000254271.1	RP11-131N11.4	-4.21	4.85e-05	0.0267	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60738510	chr10:60734342~60741828:+
TGCT	cis	rs10740039	0.583	rs1904399	ENSG00000254271.1	RP11-131N11.4	-4.21	4.85e-05	0.0267	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739240	chr10:60734342~60741828:+
TGCT	cis	rs10740039	0.583	rs1904400	ENSG00000254271.1	RP11-131N11.4	-4.21	4.85e-05	0.0267	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739361	chr10:60734342~60741828:+
TGCT	cis	rs10740039	0.515	rs9414742	ENSG00000254271.1	RP11-131N11.4	-4.21	4.85e-05	0.0267	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739769	chr10:60734342~60741828:+
TGCT	cis	rs10740039	0.583	rs9415609	ENSG00000254271.1	RP11-131N11.4	-4.21	4.85e-05	0.0267	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739832	chr10:60734342~60741828:+
TGCT	cis	rs10740039	0.583	rs4948263	ENSG00000254271.1	RP11-131N11.4	-4.21	4.85e-05	0.0267	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740132	chr10:60734342~60741828:+
TGCT	cis	rs10740039	0.583	rs4948264	ENSG00000254271.1	RP11-131N11.4	-4.21	4.85e-05	0.0267	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740484	chr10:60734342~60741828:+
TGCT	cis	rs10740039	0.583	rs4948265	ENSG00000254271.1	RP11-131N11.4	-4.21	4.85e-05	0.0267	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740495	chr10:60734342~60741828:+
TGCT	cis	rs10740039	0.583	rs7917700	ENSG00000254271.1	RP11-131N11.4	-4.21	4.85e-05	0.0267	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740596	chr10:60734342~60741828:+
TGCT	cis	rs10740039	0.583	rs2127348	ENSG00000254271.1	RP11-131N11.4	-4.21	4.85e-05	0.0267	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740945	chr10:60734342~60741828:+
TGCT	cis	rs10740039	0.583	rs2127349	ENSG00000254271.1	RP11-131N11.4	-4.21	4.85e-05	0.0267	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740947	chr10:60734342~60741828:+
TGCT	cis	rs7819412	0.522	rs11776603	ENSG00000255310.2	AF131215.2	-4.21	4.85e-05	0.0267	-0.3	-0.35	Triglycerides;	chr8:11162803	chr8:11107788~11109726:-
TGCT	cis	rs5758659	0.652	rs6519301	ENSG00000182057.4	OGFRP1	4.21	4.85e-05	0.0267	0.26	0.35	Cognitive function;	chr22:41989963	chr22:42269753~42275196:+
TGCT	cis	rs11822910	0.911	rs11828218	ENSG00000265566.2	RN7SL605P	4.21	4.85e-05	0.0267	0.43	0.35	Platelet distribution width;	chr11:57428750	chr11:57528085~57528365:-
TGCT	cis	rs728616	0.717	rs61860016	ENSG00000230091.5	TMEM254-AS1	4.21	4.85e-05	0.0267	0.62	0.35	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80156133	chr10:80046860~80078912:-
TGCT	cis	rs2708377	0.79	rs73051387	ENSG00000256019.1	TAS2R63P	-4.21	4.86e-05	0.0267	-0.47	-0.35	Bitter taste perception;	chr12:11161864	chr12:11048332~11049256:-
TGCT	cis	rs2278034	0.578	rs881753	ENSG00000207650.1	MIR570	-4.21	4.86e-05	0.0267	-0.39	-0.35	Bronchopulmonary dysplasia;	chr3:195879899	chr3:195699401~195699497:+
TGCT	cis	rs7829975	0.782	rs6990746	ENSG00000173295.6	FAM86B3P	-4.21	4.87e-05	0.0268	-0.44	-0.35	Mood instability;	chr8:8690301	chr8:8228595~8244865:+
TGCT	cis	rs7829975	0.66	rs10093926	ENSG00000173295.6	FAM86B3P	-4.21	4.87e-05	0.0268	-0.44	-0.35	Mood instability;	chr8:8691510	chr8:8228595~8244865:+
TGCT	cis	rs7208859	0.673	rs999797	ENSG00000266490.1	CTD-2349P21.9	4.21	4.87e-05	0.0268	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30792372~30792833:+
TGCT	cis	rs875971	1	rs6460296	ENSG00000232559.3	GS1-124K5.12	4.21	4.87e-05	0.0268	0.33	0.35	Aortic root size;	chr7:66430152	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.895	rs4718349	ENSG00000232559.3	GS1-124K5.12	4.21	4.87e-05	0.0268	0.33	0.35	Aortic root size;	chr7:66444024	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs2042133	ENSG00000232559.3	GS1-124K5.12	4.21	4.87e-05	0.0268	0.33	0.35	Aortic root size;	chr7:66466935	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.964	rs2161065	ENSG00000232559.3	GS1-124K5.12	4.21	4.87e-05	0.0268	0.33	0.35	Aortic root size;	chr7:66467918	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs12698521	ENSG00000232559.3	GS1-124K5.12	4.21	4.87e-05	0.0268	0.33	0.35	Aortic root size;	chr7:66474502	chr7:66554588~66576923:-
TGCT	cis	rs8059260	0.542	rs7196077	ENSG00000274038.1	RP11-66H6.4	-4.21	4.87e-05	0.0268	-0.52	-0.35	Alcohol consumption over the past year;	chr16:11033198	chr16:11056556~11057034:+
TGCT	cis	rs9959491	0.539	rs35557236	ENSG00000227279.1	AC015933.2	-4.21	4.87e-05	0.0268	-0.38	-0.35	Breast cancer;	chr18:27804790	chr18:27954519~27963687:+
TGCT	cis	rs875971	1	rs6945843	ENSG00000237310.1	GS1-124K5.4	-4.21	4.88e-05	0.0268	-0.4	-0.35	Aortic root size;	chr7:66269796	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.965	rs10267430	ENSG00000237310.1	GS1-124K5.4	-4.21	4.88e-05	0.0268	-0.4	-0.35	Aortic root size;	chr7:66278036	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs10257427	ENSG00000237310.1	GS1-124K5.4	-4.21	4.88e-05	0.0268	-0.4	-0.35	Aortic root size;	chr7:66278221	chr7:66493706~66495474:+
TGCT	cis	rs2505998	0.833	rs2505533	ENSG00000273008.1	RP11-351D16.3	-4.21	4.88e-05	0.0268	-0.41	-0.35	Hirschsprung disease;	chr10:43099005	chr10:43136824~43138334:-
TGCT	cis	rs853679	0.55	rs34477097	ENSG00000187763.3	OR2B7P	4.21	4.88e-05	0.0268	0.35	0.35	Depression;	chr6:28229408	chr6:28046434~28047367:+
TGCT	cis	rs1010254	0.51	rs72808338	ENSG00000253921.1	CTB-113P19.3	-4.21	4.88e-05	0.0268	-0.46	-0.35	Optic nerve measurement (cup area);	chr5:152375900	chr5:151753992~151767247:+
TGCT	cis	rs12935418	0.672	rs2549879	ENSG00000261061.1	RP11-303E16.2	4.21	4.89e-05	0.0269	0.39	0.35	Mean corpuscular volume;	chr16:81012496	chr16:81030770~81031485:+
TGCT	cis	rs12935418	0.672	rs1453327	ENSG00000261061.1	RP11-303E16.2	4.21	4.89e-05	0.0269	0.39	0.35	Mean corpuscular volume;	chr16:81014959	chr16:81030770~81031485:+
TGCT	cis	rs6844153	0.941	rs75656258	ENSG00000240005.4	RP11-293A21.1	-4.21	4.89e-05	0.0269	-0.43	-0.35	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26843577	chr4:26859806~26860599:-
TGCT	cis	rs1707322	0.721	rs7520123	ENSG00000280836.1	AL355480.1	-4.21	4.89e-05	0.0269	-0.48	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr1:45581219~45581321:-
TGCT	cis	rs4713118	0.662	rs9393881	ENSG00000216901.1	AL022393.7	4.21	4.89e-05	0.0269	0.46	0.35	Parkinson's disease;	chr6:28055973	chr6:28176188~28176674:+
TGCT	cis	rs34091987	0.582	rs2193053	ENSG00000256124.4	LINC01152	-4.21	4.89e-05	0.0269	-0.33	-0.35	Nose size;	chr17:72029790	chr17:72030291~72041297:+
TGCT	cis	rs7824557	0.628	rs11777746	ENSG00000255020.1	AF131216.5	4.21	4.89e-05	0.0269	0.25	0.35	Retinal vascular caliber;	chr8:11347246	chr8:11345748~11347502:-
TGCT	cis	rs1707322	1	rs10890350	ENSG00000280836.1	AL355480.1	-4.21	4.89e-05	0.0269	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796706	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.964	rs10437063	ENSG00000280836.1	AL355480.1	-4.21	4.89e-05	0.0269	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs6676982	ENSG00000280836.1	AL355480.1	-4.21	4.89e-05	0.0269	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs6429580	ENSG00000280836.1	AL355480.1	-4.21	4.89e-05	0.0269	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809976	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.927	rs11211194	ENSG00000280836.1	AL355480.1	-4.21	4.89e-05	0.0269	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45816412	chr1:45581219~45581321:-
TGCT	cis	rs796364	0.951	rs2881593	ENSG00000232732.8	AC073043.1	4.21	4.9e-05	0.0269	0.43	0.35	Schizophrenia;	chr2:200135624	chr2:199867396~199911159:-
TGCT	cis	rs11139399	0.613	rs1471723	ENSG00000233926.1	RP11-154D17.1	-4.21	4.9e-05	0.0269	-0.4	-0.35	Hippocampal atrophy;	chr9:81722132	chr9:81689713~81776900:+
TGCT	cis	rs7246967	0.673	rs407989	ENSG00000269509.1	BNIP3P34	-4.21	4.9e-05	0.0269	-0.56	-0.35	Bronchopulmonary dysplasia;	chr19:22808784	chr19:22773853~22774424:+
TGCT	cis	rs17608059	0.611	rs62052300	ENSG00000141028.6	CDRT15P1	-4.21	4.91e-05	0.0269	-0.4	-0.35	Temperament;	chr17:14013482	chr17:14024514~14025488:+
TGCT	cis	rs786425	0.966	rs786444	ENSG00000247373.3	RP11-486O12.2	4.21	4.91e-05	0.027	0.41	0.35	Pubertal anthropometrics;	chr12:123580869	chr12:123575891~123585115:-
TGCT	cis	rs796364	0.616	rs7574313	ENSG00000232732.8	AC073043.1	-4.21	4.91e-05	0.027	-0.54	-0.35	Schizophrenia;	chr2:199816317	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.616	rs2689762	ENSG00000232732.8	AC073043.1	-4.21	4.91e-05	0.027	-0.54	-0.35	Schizophrenia;	chr2:199822481	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.616	rs2103094	ENSG00000232732.8	AC073043.1	-4.21	4.91e-05	0.027	-0.54	-0.35	Schizophrenia;	chr2:199823231	chr2:199867396~199911159:-
TGCT	cis	rs1372520	0.564	rs356186	ENSG00000247775.2	SNCA-AS1	4.21	4.92e-05	0.027	0.35	0.35	Neuroticism;	chr4:89784213	chr4:89836408~89841978:+
TGCT	cis	rs2033711	0.811	rs9304814	ENSG00000269473.1	CTD-2619J13.19	4.21	4.92e-05	0.027	0.29	0.35	Uric acid clearance;	chr19:58440444	chr19:58440448~58445849:+
TGCT	cis	rs2015599	0.525	rs10771514	ENSG00000275476.1	RP11-996F15.4	4.21	4.92e-05	0.027	0.37	0.35	Platelet count;Mean platelet volume;	chr12:29315751	chr12:29277397~29277882:-
TGCT	cis	rs2015599	0.525	rs7298031	ENSG00000275476.1	RP11-996F15.4	4.21	4.92e-05	0.027	0.37	0.35	Platelet count;Mean platelet volume;	chr12:29317333	chr12:29277397~29277882:-
TGCT	cis	rs2015599	0.525	rs2016832	ENSG00000275476.1	RP11-996F15.4	4.21	4.92e-05	0.027	0.37	0.35	Platelet count;Mean platelet volume;	chr12:29318199	chr12:29277397~29277882:-
TGCT	cis	rs3105593	1	rs2115671	ENSG00000273674.3	CTD-2378E12.1	4.21	4.92e-05	0.027	0.38	0.35	QT interval;	chr15:50664235	chr15:50839875~50908599:-
TGCT	cis	rs9641123	0.551	rs17787723	ENSG00000234695.1	AC002076.10	4.21	4.93e-05	0.0271	0.42	0.35	Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index;Lean body mass;	chr7:93469341	chr7:93890913~93893601:+
TGCT	cis	rs1061377	1	rs13182	ENSG00000249685.1	RP11-360F5.3	4.21	4.93e-05	0.0271	0.33	0.35	Uric acid levels;	chr4:39121293	chr4:39133913~39135608:+
TGCT	cis	rs801193	0.66	rs1016265	ENSG00000237310.1	GS1-124K5.4	4.21	4.93e-05	0.0271	0.4	0.35	Aortic root size;	chr7:66749580	chr7:66493706~66495474:+
TGCT	cis	rs801193	0.66	rs4610622	ENSG00000237310.1	GS1-124K5.4	4.21	4.93e-05	0.0271	0.4	0.35	Aortic root size;	chr7:66759510	chr7:66493706~66495474:+
TGCT	cis	rs853679	0.517	rs9283884	ENSG00000219891.2	ZSCAN12P1	-4.21	4.93e-05	0.0271	-0.45	-0.35	Depression;	chr6:28167882	chr6:28091154~28093664:+
TGCT	cis	rs899997	1	rs11072800	ENSG00000261143.1	ADAMTS7P3	-4.21	4.94e-05	0.0271	-0.38	-0.35	Coronary artery disease or large artery stroke;	chr15:78753515	chr15:77976042~77993057:+
TGCT	cis	rs875971	0.83	rs4718358	ENSG00000232559.3	GS1-124K5.12	4.21	4.94e-05	0.0271	0.33	0.35	Aortic root size;	chr7:66508681	chr7:66554588~66576923:-
TGCT	cis	rs847845	0.841	rs2030611	ENSG00000186328.4	RP11-140K17.2	-4.21	4.95e-05	0.0271	-0.54	-0.35	Non-small cell lung cancer;	chr6:34989029	chr6:34715613~34715940:+
TGCT	cis	rs9400467	0.537	rs12213248	ENSG00000272356.1	RP5-1112D6.8	-4.21	4.95e-05	0.0271	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111178191	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.537	rs9647629	ENSG00000272356.1	RP5-1112D6.8	-4.21	4.95e-05	0.0271	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111180281	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.537	rs73530977	ENSG00000272356.1	RP5-1112D6.8	-4.21	4.95e-05	0.0271	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111183616	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.537	rs17663278	ENSG00000272356.1	RP5-1112D6.8	-4.21	4.95e-05	0.0271	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111183678	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.537	rs12214550	ENSG00000272356.1	RP5-1112D6.8	-4.21	4.95e-05	0.0271	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111184296	chr6:111309203~111313517:+
TGCT	cis	rs13118159	0.767	rs2141656	ENSG00000254094.1	AC078852.1	-4.21	4.95e-05	0.0272	-0.41	-0.35	Longevity;	chr4:1323404	chr4:1356581~1358075:+
TGCT	cis	rs11722228	0.508	rs9732	ENSG00000261490.1	RP11-448G15.3	4.21	4.96e-05	0.0272	0.33	0.35	Urate levels;Serum uric acid levels;Gout;	chr4:10075034	chr4:10068089~10073019:-
TGCT	cis	rs10129255	0.912	rs61996059	ENSG00000211970.3	IGHV4-61	-4.21	4.96e-05	0.0272	-0.39	-0.35	Kawasaki disease;	chr14:106716897	chr14:106639119~106639657:-
TGCT	cis	rs1618992	0.729	rs1039556	ENSG00000265994.1	RP11-510D21.1	4.2	4.97e-05	0.0272	0.37	0.35	Gut microbiome composition (summer and winter);	chr18:28616008	chr18:28785068~28789260:+
TGCT	cis	rs3931020	0.688	rs277396	ENSG00000272864.1	RP11-17E13.2	4.2	4.97e-05	0.0272	0.42	0.35	Resistin levels;	chr1:74747964	chr1:74698769~74699333:-
TGCT	cis	rs9880211	0.948	rs34913797	ENSG00000239213.4	NCK1-AS1	4.2	4.97e-05	0.0272	0.38	0.35	Height;Body mass index;	chr3:136408728	chr3:136841726~136862054:-
TGCT	cis	rs9880211	1	rs9812579	ENSG00000239213.4	NCK1-AS1	4.2	4.97e-05	0.0272	0.38	0.35	Height;Body mass index;	chr3:136432408	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.948	rs1604793	ENSG00000239213.4	NCK1-AS1	4.2	4.97e-05	0.0272	0.38	0.35	Height;Body mass index;	chr3:136462228	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.948	rs13321721	ENSG00000239213.4	NCK1-AS1	4.2	4.97e-05	0.0272	0.38	0.35	Height;Body mass index;	chr3:136490708	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.948	rs34135127	ENSG00000239213.4	NCK1-AS1	4.2	4.97e-05	0.0272	0.38	0.35	Height;Body mass index;	chr3:136507656	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.948	rs13326151	ENSG00000239213.4	NCK1-AS1	4.2	4.97e-05	0.0272	0.38	0.35	Height;Body mass index;	chr3:136542902	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.948	rs6806123	ENSG00000239213.4	NCK1-AS1	4.2	4.97e-05	0.0272	0.38	0.35	Height;Body mass index;	chr3:136586634	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.898	rs13434116	ENSG00000239213.4	NCK1-AS1	4.2	4.97e-05	0.0272	0.38	0.35	Height;Body mass index;	chr3:136634232	chr3:136841726~136862054:-
TGCT	cis	rs2739330	0.796	rs5760097	ENSG00000250470.1	AP000351.3	4.2	4.97e-05	0.0272	0.36	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23976904~23977585:-
TGCT	cis	rs2739330	0.828	rs4822451	ENSG00000250470.1	AP000351.3	4.2	4.97e-05	0.0272	0.36	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23976904~23977585:-
TGCT	cis	rs2739330	0.828	rs5760098	ENSG00000250470.1	AP000351.3	4.2	4.97e-05	0.0272	0.36	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23976904~23977585:-
TGCT	cis	rs2739330	0.828	rs5760099	ENSG00000250470.1	AP000351.3	4.2	4.97e-05	0.0272	0.36	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23976904~23977585:-
TGCT	cis	rs11722228	0.522	rs12504600	ENSG00000261490.1	RP11-448G15.3	4.2	4.98e-05	0.0273	0.34	0.35	Urate levels;Serum uric acid levels;Gout;	chr4:10065514	chr4:10068089~10073019:-
TGCT	cis	rs2297363	1	rs2282140	ENSG00000213073.4	RP11-288H12.3	-4.2	4.98e-05	0.0273	-0.34	-0.35	Total cholesterol levels;Blood protein levels;	chr6:160073489	chr6:160093082~160096212:+
TGCT	cis	rs2297363	1	rs3777404	ENSG00000213073.4	RP11-288H12.3	-4.2	4.98e-05	0.0273	-0.34	-0.35	Total cholesterol levels;Blood protein levels;	chr6:160077017	chr6:160093082~160096212:+
TGCT	cis	rs4713118	0.662	rs149969	ENSG00000216901.1	AL022393.7	4.2	4.98e-05	0.0273	0.43	0.35	Parkinson's disease;	chr6:28009959	chr6:28176188~28176674:+
TGCT	cis	rs3749237	0.595	rs1568661	ENSG00000226913.1	BSN-AS2	-4.2	4.99e-05	0.0273	-0.27	-0.35	Resting heart rate;	chr3:49483525	chr3:49549306~49554366:-
TGCT	cis	rs9807989	0.507	rs6758936	ENSG00000234389.1	AC007278.3	-4.2	4.99e-05	0.0273	-0.26	-0.35	Asthma;	chr2:102374909	chr2:102438713~102440475:+
TGCT	cis	rs853679	0.55	rs1233707	ENSG00000216901.1	AL022393.7	4.2	4.99e-05	0.0273	0.48	0.35	Depression;	chr6:28205175	chr6:28176188~28176674:+
TGCT	cis	rs7534537	0.624	rs7534329	ENSG00000237379.1	CBX1P3	-4.2	4.99e-05	0.0273	-0.7	-0.35	Palmitoleic acid (16:1n-7) levels;	chr1:204340510	chr1:203954640~203955780:+
TGCT	cis	rs2337406	1	rs11845269	ENSG00000274576.2	IGHV2-70	-4.2	4.99e-05	0.0273	-0.53	-0.35	Alzheimer's disease (late onset);	chr14:106683851	chr14:106770577~106771020:-
TGCT	cis	rs4660214	0.724	rs11205695	ENSG00000182109.6	RP11-69E11.4	-4.2	4.99e-05	0.0273	-0.36	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39155285	chr1:39522280~39546187:-
TGCT	cis	rs11779860	1	rs11779860	ENSG00000245970.2	KB-1208A12.3	-4.2	5e-05	0.0273	-0.4	-0.35	QT interval;	chr8:97838102	chr8:98041726~98044121:+
TGCT	cis	rs10491083	0.661	rs4796538	ENSG00000279296.1	RP11-609D21.3	-4.2	5e-05	0.0273	-0.67	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:6666073	chr17:6772831~6776116:-
TGCT	cis	rs7923609	0.967	rs7920058	ENSG00000232075.1	MRPL35P2	-4.2	5e-05	0.0274	-0.34	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63534164	chr10:63634317~63634827:-
TGCT	cis	rs732716	0.785	rs11666453	ENSG00000267769.1	CTB-50L17.9	-4.2	5.01e-05	0.0274	-0.42	-0.35	Mean corpuscular volume;	chr19:4368800	chr19:4454014~4455286:+
TGCT	cis	rs860295	0.54	rs6670493	ENSG00000246203.2	RP11-29H23.5	4.2	5.02e-05	0.0274	0.31	0.35	Body mass index;	chr1:155987112	chr1:155614726~155660245:-
TGCT	cis	rs860295	0.54	rs4661218	ENSG00000246203.2	RP11-29H23.5	4.2	5.02e-05	0.0274	0.31	0.35	Body mass index;	chr1:155990394	chr1:155614726~155660245:-
TGCT	cis	rs1153858	0.945	rs1974981	ENSG00000259520.4	CTD-2651B20.3	4.2	5.02e-05	0.0274	0.3	0.35	Homoarginine levels;	chr15:45436925	chr15:45251580~45279251:-
TGCT	cis	rs1153858	0.887	rs28569043	ENSG00000259520.4	CTD-2651B20.3	-4.2	5.02e-05	0.0274	-0.3	-0.35	Homoarginine levels;	chr15:45438728	chr15:45251580~45279251:-
TGCT	cis	rs9660180	0.967	rs6603803	ENSG00000231050.1	RP1-140A9.1	4.2	5.02e-05	0.0274	0.32	0.35	Body mass index;	chr1:1881249	chr1:1891471~1892658:+
TGCT	cis	rs796364	0.57	rs4673491	ENSG00000232732.8	AC073043.1	-4.2	5.02e-05	0.0274	-0.54	-0.35	Schizophrenia;	chr2:199804385	chr2:199867396~199911159:-
TGCT	cis	rs10483853	0.525	rs10138789	ENSG00000258695.2	RP3-414A15.2	-4.2	5.03e-05	0.0275	-0.43	-0.35	Coronary artery calcification;	chr14:73497574	chr14:73522878~73530610:+
TGCT	cis	rs4242434	0.889	rs11785755	ENSG00000254064.1	CTD-2530N21.4	-4.2	5.03e-05	0.0275	-0.21	-0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22595710	chr8:22254576~22275162:-
TGCT	cis	rs7615952	0.866	rs1976459	ENSG00000171084.14	FAM86JP	4.2	5.03e-05	0.0275	0.61	0.35	Blood pressure (smoking interaction);	chr3:125928643	chr3:125916620~125930024:+
TGCT	cis	rs7615952	0.932	rs1976458	ENSG00000171084.14	FAM86JP	4.2	5.03e-05	0.0275	0.61	0.35	Blood pressure (smoking interaction);	chr3:125928669	chr3:125916620~125930024:+
TGCT	cis	rs7615952	0.673	rs3811677	ENSG00000171084.14	FAM86JP	4.2	5.03e-05	0.0275	0.61	0.35	Blood pressure (smoking interaction);	chr3:125929237	chr3:125916620~125930024:+
TGCT	cis	rs7615952	0.932	rs3811679	ENSG00000171084.14	FAM86JP	4.2	5.03e-05	0.0275	0.61	0.35	Blood pressure (smoking interaction);	chr3:125929440	chr3:125916620~125930024:+
TGCT	cis	rs1563304	1	rs1563304	ENSG00000262539.1	RP11-259G18.3	4.2	5.04e-05	0.0275	0.67	0.35	Neuroticism;	chr17:46797087	chr17:46259551~46260606:-
TGCT	cis	rs6005807	0.843	rs9625467	ENSG00000272858.1	CTA-292E10.8	-4.2	5.04e-05	0.0275	-0.53	-0.35	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28395876	chr22:28814914~28815662:+
TGCT	cis	rs6005807	0.843	rs738200	ENSG00000272858.1	CTA-292E10.8	-4.2	5.04e-05	0.0275	-0.53	-0.35	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28396899	chr22:28814914~28815662:+
TGCT	cis	rs7923609	0.934	rs10822153	ENSG00000232075.1	MRPL35P2	-4.2	5.04e-05	0.0275	-0.35	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63297053	chr10:63634317~63634827:-
TGCT	cis	rs4268898	0.735	rs34125395	ENSG00000223754.1	AC008073.9	-4.2	5.04e-05	0.0275	-0.38	-0.35	Asthma;	chr2:24335373	chr2:24199839~24201698:-
TGCT	cis	rs4268898	0.76	rs7597919	ENSG00000223754.1	AC008073.9	-4.2	5.04e-05	0.0275	-0.38	-0.35	Asthma;	chr2:24340777	chr2:24199839~24201698:-
TGCT	cis	rs4268898	0.76	rs55863105	ENSG00000223754.1	AC008073.9	-4.2	5.04e-05	0.0275	-0.38	-0.35	Asthma;	chr2:24347826	chr2:24199839~24201698:-
TGCT	cis	rs1062753	0.527	rs62240998	ENSG00000182057.4	OGFRP1	-4.2	5.04e-05	0.0275	-0.26	-0.35	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41958697	chr22:42269753~42275196:+
TGCT	cis	rs2297363	1	rs13207901	ENSG00000213073.4	RP11-288H12.3	-4.2	5.05e-05	0.0276	-0.34	-0.35	Total cholesterol levels;Blood protein levels;	chr6:160081428	chr6:160093082~160096212:+
TGCT	cis	rs2297363	1	rs16888669	ENSG00000213073.4	RP11-288H12.3	-4.2	5.05e-05	0.0276	-0.34	-0.35	Total cholesterol levels;Blood protein levels;	chr6:160082862	chr6:160093082~160096212:+
TGCT	cis	rs2297363	1	rs2297363	ENSG00000213073.4	RP11-288H12.3	-4.2	5.05e-05	0.0276	-0.34	-0.35	Total cholesterol levels;Blood protein levels;	chr6:160085430	chr6:160093082~160096212:+
TGCT	cis	rs2297363	0.841	rs13220323	ENSG00000213073.4	RP11-288H12.3	-4.2	5.05e-05	0.0276	-0.34	-0.35	Total cholesterol levels;Blood protein levels;	chr6:160085723	chr6:160093082~160096212:+
TGCT	cis	rs8177876	0.658	rs2278022	ENSG00000261838.4	RP11-303E16.6	4.2	5.05e-05	0.0276	0.84	0.35	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81043216	chr16:81069854~81076598:+
TGCT	cis	rs10129255	0.5	rs10150118	ENSG00000223648.3	IGHV3-64	4.2	5.05e-05	0.0276	0.3	0.35	Kawasaki disease;	chr14:106707871	chr14:106643132~106658258:-
TGCT	cis	rs73086581	0.592	rs6037702	ENSG00000229539.1	RP11-119B16.2	-4.2	5.05e-05	0.0276	-0.46	-0.35	Response to antidepressants in depression;	chr20:3955745	chr20:3888239~3888868:-
TGCT	cis	rs10129255	0.528	rs8008320	ENSG00000253755.1	IGHGP	-4.2	5.05e-05	0.0276	-0.34	-0.35	Kawasaki disease;	chr14:106652124	chr14:105664633~105669843:-
TGCT	cis	rs10129255	0.53	rs8008811	ENSG00000253755.1	IGHGP	-4.2	5.05e-05	0.0276	-0.34	-0.35	Kawasaki disease;	chr14:106652273	chr14:105664633~105669843:-
TGCT	cis	rs10129255	0.542	rs8009795	ENSG00000253755.1	IGHGP	-4.2	5.05e-05	0.0276	-0.34	-0.35	Kawasaki disease;	chr14:106652287	chr14:105664633~105669843:-
TGCT	cis	rs10129255	0.528	rs8008831	ENSG00000253755.1	IGHGP	-4.2	5.05e-05	0.0276	-0.34	-0.35	Kawasaki disease;	chr14:106652290	chr14:105664633~105669843:-
TGCT	cis	rs10129255	0.584	rs11161001	ENSG00000253755.1	IGHGP	-4.2	5.05e-05	0.0276	-0.34	-0.35	Kawasaki disease;	chr14:106652664	chr14:105664633~105669843:-
TGCT	cis	rs10129255	0.507	rs58656539	ENSG00000253755.1	IGHGP	-4.2	5.05e-05	0.0276	-0.34	-0.35	Kawasaki disease;	chr14:106653262	chr14:105664633~105669843:-
TGCT	cis	rs10129255	0.544	rs61997583	ENSG00000253755.1	IGHGP	-4.2	5.05e-05	0.0276	-0.34	-0.35	Kawasaki disease;	chr14:106654351	chr14:105664633~105669843:-
TGCT	cis	rs853679	0.517	rs6932109	ENSG00000219891.2	ZSCAN12P1	-4.2	5.06e-05	0.0276	-0.46	-0.35	Depression;	chr6:28110525	chr6:28091154~28093664:+
TGCT	cis	rs10740039	0.583	rs9415612	ENSG00000254271.1	RP11-131N11.4	-4.2	5.06e-05	0.0276	-0.37	-0.35	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60746638	chr10:60734342~60741828:+
TGCT	cis	rs10761750	1	rs10761750	ENSG00000232075.1	MRPL35P2	-4.2	5.06e-05	0.0276	-0.35	-0.35	Vascular endothelial growth factor levels;	chr10:63368859	chr10:63634317~63634827:-
TGCT	cis	rs875971	0.545	rs13311962	ENSG00000237310.1	GS1-124K5.4	-4.2	5.06e-05	0.0276	-0.42	-0.35	Aortic root size;	chr7:66603142	chr7:66493706~66495474:+
TGCT	cis	rs9462027	0.561	rs2814972	ENSG00000186328.4	RP11-140K17.2	4.2	5.07e-05	0.0276	0.34	0.35	Systemic lupus erythematosus;	chr6:34599198	chr6:34715613~34715940:+
TGCT	cis	rs9309473	0.95	rs6726694	ENSG00000163016.8	ALMS1P	4.2	5.07e-05	0.0276	0.31	0.35	Metabolite levels;	chr2:73620103	chr2:73644919~73685576:+
TGCT	cis	rs1555322	0.505	rs591590	ENSG00000126005.14	MMP24-AS1	4.2	5.07e-05	0.0277	0.43	0.35	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35216462~35278131:-
TGCT	cis	rs7923609	0.936	rs4405189	ENSG00000232075.1	MRPL35P2	-4.2	5.07e-05	0.0277	-0.35	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63254175	chr10:63634317~63634827:-
TGCT	cis	rs7208859	0.623	rs122898	ENSG00000266490.1	CTD-2349P21.9	-4.2	5.07e-05	0.0277	-0.4	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30792372~30792833:+
TGCT	cis	rs7819412	0.54	rs11777355	ENSG00000269918.1	AF131215.9	-4.2	5.07e-05	0.0277	-0.37	-0.35	Triglycerides;	chr8:11187180	chr8:11104691~11106704:-
TGCT	cis	rs1865760	0.929	rs9467646	ENSG00000217159.2	LARP1P1	-4.2	5.08e-05	0.0277	-0.41	-0.35	Height;	chr6:25957180	chr6:26164072~26164363:+
TGCT	cis	rs1707322	0.752	rs28719889	ENSG00000280836.1	AL355480.1	-4.2	5.08e-05	0.0277	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.752	rs28812624	ENSG00000280836.1	AL355480.1	-4.2	5.08e-05	0.0277	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.752	rs28568986	ENSG00000280836.1	AL355480.1	-4.2	5.08e-05	0.0277	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.717	rs10890345	ENSG00000280836.1	AL355480.1	-4.2	5.08e-05	0.0277	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.721	rs10789471	ENSG00000280836.1	AL355480.1	-4.2	5.08e-05	0.0277	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45581219~45581321:-
TGCT	cis	rs6474412	1	rs1901281	ENSG00000255101.1	RP11-412B14.1	4.2	5.08e-05	0.0277	0.35	0.35	Smoking behavior;	chr8:42691745	chr8:42705583~42721946:-
TGCT	cis	rs7923609	0.967	rs7085018	ENSG00000232075.1	MRPL35P2	-4.2	5.08e-05	0.0277	-0.34	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63526907	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.841	rs7920036	ENSG00000232075.1	MRPL35P2	-4.2	5.08e-05	0.0277	-0.34	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63534100	chr10:63634317~63634827:-
TGCT	cis	rs28735056	0.563	rs12968139	ENSG00000261126.6	RP11-795F19.1	-4.2	5.08e-05	0.0277	-0.3	-0.35	Schizophrenia;	chr18:79925520	chr18:80046900~80095482:+
TGCT	cis	rs28735056	0.592	rs12455965	ENSG00000261126.6	RP11-795F19.1	-4.2	5.08e-05	0.0277	-0.3	-0.35	Schizophrenia;	chr18:79928830	chr18:80046900~80095482:+
TGCT	cis	rs1061377	0.608	rs35168672	ENSG00000249685.1	RP11-360F5.3	4.2	5.09e-05	0.0277	0.32	0.35	Uric acid levels;	chr4:39078902	chr4:39133913~39135608:+
TGCT	cis	rs6981523	0.5	rs4412337	ENSG00000269918.1	AF131215.9	4.2	5.09e-05	0.0278	0.38	0.35	Neuroticism;	chr8:11214511	chr8:11104691~11106704:-
TGCT	cis	rs6604026	0.589	rs67026262	ENSG00000223787.2	RP4-593M8.1	4.2	5.1e-05	0.0278	0.52	0.35	Multiple sclerosis;	chr1:92646070	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.589	rs67876779	ENSG00000223787.2	RP4-593M8.1	4.2	5.1e-05	0.0278	0.52	0.35	Multiple sclerosis;	chr1:92646308	chr1:92580476~92580821:-
TGCT	cis	rs4853012	0.838	rs4452177	ENSG00000257800.1	FNBP1P1	4.2	5.1e-05	0.0278	0.38	0.35	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74120680~74123218:+
TGCT	cis	rs4853012	0.838	rs60705299	ENSG00000257800.1	FNBP1P1	4.2	5.1e-05	0.0278	0.38	0.35	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74120680~74123218:+
TGCT	cis	rs4242434	0.787	rs1545837	ENSG00000253200.1	RP11-582J16.5	4.2	5.11e-05	0.0278	0.2	0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22620294	chr8:22613908~22616657:-
TGCT	cis	rs12745968	0.589	rs10747446	ENSG00000223787.2	RP4-593M8.1	-4.2	5.11e-05	0.0278	-0.48	-0.35	Bipolar disorder and schizophrenia;	chr1:92642845	chr1:92580476~92580821:-
TGCT	cis	rs10466239	0.73	rs12221341	ENSG00000230555.2	RP11-517P14.2	4.2	5.11e-05	0.0278	0.46	0.35	Telomere length;	chr10:43361882	chr10:43420738~43422100:+
TGCT	cis	rs1250259	0.519	rs2372544	ENSG00000225166.1	AC012462.2	-4.2	5.11e-05	0.0278	-0.34	-0.35	Coronary artery disease;Pulse pressure;	chr2:215399547	chr2:215453707~215463871:+
TGCT	cis	rs507080	0.769	rs11603616	ENSG00000255239.1	AP002954.6	4.2	5.11e-05	0.0278	0.45	0.35	Serum metabolite levels;	chr11:118625350	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.769	rs483283	ENSG00000255239.1	AP002954.6	4.2	5.11e-05	0.0278	0.45	0.35	Serum metabolite levels;	chr11:118635684	chr11:118688039~118690600:-
TGCT	cis	rs9733	0.687	rs11204735	ENSG00000236713.1	RP11-363I22.3	4.2	5.12e-05	0.0278	0.27	0.35	Tonsillectomy;	chr1:150869191	chr1:150780272~150780644:+
TGCT	cis	rs9733	0.744	rs12758227	ENSG00000236713.1	RP11-363I22.3	4.2	5.12e-05	0.0278	0.27	0.35	Tonsillectomy;	chr1:150872107	chr1:150780272~150780644:+
TGCT	cis	rs9733	0.744	rs11204737	ENSG00000236713.1	RP11-363I22.3	4.2	5.12e-05	0.0278	0.27	0.35	Tonsillectomy;	chr1:150875171	chr1:150780272~150780644:+
TGCT	cis	rs9733	0.818	rs6694531	ENSG00000236713.1	RP11-363I22.3	4.2	5.12e-05	0.0278	0.26	0.35	Tonsillectomy;	chr1:150711036	chr1:150780272~150780644:+
TGCT	cis	rs9733	0.818	rs10888388	ENSG00000236713.1	RP11-363I22.3	4.2	5.12e-05	0.0278	0.26	0.35	Tonsillectomy;	chr1:150714820	chr1:150780272~150780644:+
TGCT	cis	rs9733	0.818	rs12130363	ENSG00000236713.1	RP11-363I22.3	4.2	5.12e-05	0.0278	0.26	0.35	Tonsillectomy;	chr1:150716120	chr1:150780272~150780644:+
TGCT	cis	rs112158604	1	rs112158604	ENSG00000236713.1	RP11-363I22.3	4.2	5.12e-05	0.0278	0.26	0.35	Lymphocyte counts;	chr1:150724325	chr1:150780272~150780644:+
TGCT	cis	rs12143943	0.834	rs10900598	ENSG00000176754.11	LINC00303	4.2	5.12e-05	0.0278	0.33	0.35	Cognitive performance;	chr1:204556440	chr1:204032447~204041265:-
TGCT	cis	rs2555155	0.633	rs2723663	ENSG00000254595.1	CTD-2010I16.1	4.2	5.12e-05	0.0279	0.31	0.35	DNA methylation (variation);	chr11:6462280	chr11:6488186~6489377:-
TGCT	cis	rs12900463	0.752	rs12904777	ENSG00000225151.9	GOLGA2P7	-4.2	5.13e-05	0.0279	-0.42	-0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84872514	chr15:84199311~84230136:-
TGCT	cis	rs10759883	0.563	rs624075	ENSG00000175611.10	LINC00476	4.2	5.13e-05	0.0279	0.32	0.35	Nicotine dependence;	chr9:95902665	chr9:95759231~95875977:-
TGCT	cis	rs10759883	0.563	rs1327997	ENSG00000175611.10	LINC00476	4.2	5.13e-05	0.0279	0.32	0.35	Nicotine dependence;	chr9:95913600	chr9:95759231~95875977:-
TGCT	cis	rs10759883	0.563	rs1327996	ENSG00000175611.10	LINC00476	4.2	5.13e-05	0.0279	0.32	0.35	Nicotine dependence;	chr9:95913710	chr9:95759231~95875977:-
TGCT	cis	rs10759883	0.563	rs617187	ENSG00000175611.10	LINC00476	4.2	5.13e-05	0.0279	0.32	0.35	Nicotine dependence;	chr9:95917359	chr9:95759231~95875977:-
TGCT	cis	rs10759883	0.563	rs689619	ENSG00000175611.10	LINC00476	4.2	5.13e-05	0.0279	0.32	0.35	Nicotine dependence;	chr9:95921689	chr9:95759231~95875977:-
TGCT	cis	rs10759883	0.563	rs10512245	ENSG00000175611.10	LINC00476	4.2	5.13e-05	0.0279	0.32	0.35	Nicotine dependence;	chr9:95929529	chr9:95759231~95875977:-
TGCT	cis	rs4242434	0.892	rs11776549	ENSG00000254064.1	CTD-2530N21.4	-4.2	5.14e-05	0.0279	-0.22	-0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22635611	chr8:22254576~22275162:-
TGCT	cis	rs7208859	0.623	rs73269923	ENSG00000280069.1	CTD-2349P21.3	-4.2	5.14e-05	0.0279	-0.5	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30738182~30740275:+
TGCT	cis	rs2019137	0.967	rs902695	ENSG00000189223.12	PAX8-AS1	4.2	5.14e-05	0.0279	0.44	0.35	Lymphocyte counts;	chr2:113197497	chr2:113211522~113276581:+
TGCT	cis	rs801193	0.66	rs10950049	ENSG00000237310.1	GS1-124K5.4	4.2	5.14e-05	0.0279	0.4	0.35	Aortic root size;	chr7:66765873	chr7:66493706~66495474:+
TGCT	cis	rs10819861	1	rs10819861	ENSG00000175611.10	LINC00476	-4.2	5.14e-05	0.0279	-0.3	-0.35	Electrocardiographic traits;	chr9:96105531	chr9:95759231~95875977:-
TGCT	cis	rs891378	0.755	rs7411168	ENSG00000274245.1	RP11-357P18.2	-4.2	5.14e-05	0.0279	-0.44	-0.35	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207201970	chr1:207372559~207373252:+
TGCT	cis	rs891378	0.755	rs6703809	ENSG00000274245.1	RP11-357P18.2	-4.2	5.14e-05	0.0279	-0.44	-0.35	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207228650	chr1:207372559~207373252:+
TGCT	cis	rs891378	0.675	rs6700746	ENSG00000274245.1	RP11-357P18.2	-4.2	5.14e-05	0.0279	-0.44	-0.35	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207228666	chr1:207372559~207373252:+
TGCT	cis	rs891378	0.785	rs10864144	ENSG00000274245.1	RP11-357P18.2	-4.2	5.14e-05	0.0279	-0.44	-0.35	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207229508	chr1:207372559~207373252:+
TGCT	cis	rs891378	0.785	rs60673767	ENSG00000274245.1	RP11-357P18.2	-4.2	5.14e-05	0.0279	-0.44	-0.35	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207230859	chr1:207372559~207373252:+
TGCT	cis	rs891378	0.655	rs1019829	ENSG00000274245.1	RP11-357P18.2	-4.2	5.14e-05	0.0279	-0.44	-0.35	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207231786	chr1:207372559~207373252:+
TGCT	cis	rs891378	0.785	rs11120485	ENSG00000274245.1	RP11-357P18.2	-4.2	5.14e-05	0.0279	-0.44	-0.35	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207232482	chr1:207372559~207373252:+
TGCT	cis	rs891378	0.727	rs11120492	ENSG00000274245.1	RP11-357P18.2	-4.2	5.14e-05	0.0279	-0.44	-0.35	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207234553	chr1:207372559~207373252:+
TGCT	cis	rs1382167	0.636	rs1841916	ENSG00000225542.1	ZNF385D-AS1	-4.2	5.14e-05	0.0279	-0.34	-0.35	Airway wall thickness;	chr3:21573781	chr3:21542816~21579959:+
TGCT	cis	rs4242434	0.927	rs2272718	ENSG00000254064.1	CTD-2530N21.4	-4.2	5.15e-05	0.028	-0.22	-0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22599875	chr8:22254576~22275162:-
TGCT	cis	rs4242434	0.927	rs746011	ENSG00000254064.1	CTD-2530N21.4	-4.2	5.15e-05	0.028	-0.22	-0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22600291	chr8:22254576~22275162:-
TGCT	cis	rs10504229	0.906	rs7006539	ENSG00000253301.4	RP11-513O17.2	4.2	5.15e-05	0.028	0.45	0.35	Developmental language disorder (linguistic errors);	chr8:57266240	chr8:57142689~57240298:+
TGCT	cis	rs875971	0.964	rs6978429	ENSG00000232559.3	GS1-124K5.12	4.2	5.15e-05	0.028	0.33	0.35	Aortic root size;	chr7:66494889	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.929	rs12535036	ENSG00000232559.3	GS1-124K5.12	4.2	5.15e-05	0.028	0.33	0.35	Aortic root size;	chr7:66499076	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs12532998	ENSG00000232559.3	GS1-124K5.12	4.2	5.15e-05	0.028	0.33	0.35	Aortic root size;	chr7:66502472	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs12698523	ENSG00000232559.3	GS1-124K5.12	4.2	5.15e-05	0.028	0.33	0.35	Aortic root size;	chr7:66503126	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs6970030	ENSG00000232559.3	GS1-124K5.12	4.2	5.15e-05	0.028	0.33	0.35	Aortic root size;	chr7:66503692	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.928	rs6970357	ENSG00000232559.3	GS1-124K5.12	4.2	5.15e-05	0.028	0.33	0.35	Aortic root size;	chr7:66503891	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs3735148	ENSG00000232559.3	GS1-124K5.12	4.2	5.15e-05	0.028	0.33	0.35	Aortic root size;	chr7:66506022	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.929	rs6970860	ENSG00000232559.3	GS1-124K5.12	4.2	5.15e-05	0.028	0.33	0.35	Aortic root size;	chr7:66511647	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs6957199	ENSG00000232559.3	GS1-124K5.12	4.2	5.15e-05	0.028	0.33	0.35	Aortic root size;	chr7:66513532	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs6958271	ENSG00000232559.3	GS1-124K5.12	4.2	5.15e-05	0.028	0.33	0.35	Aortic root size;	chr7:66514344	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs6958277	ENSG00000232559.3	GS1-124K5.12	4.2	5.15e-05	0.028	0.33	0.35	Aortic root size;	chr7:66514362	chr7:66554588~66576923:-
TGCT	cis	rs6940638	0.688	rs6456766	ENSG00000187763.3	OR2B7P	4.2	5.15e-05	0.028	0.32	0.35	Intelligence (multi-trait analysis);	chr6:27051796	chr6:28046434~28047367:+
TGCT	cis	rs7773456	0.533	rs9350190	ENSG00000228412.5	RP4-625H18.2	-4.2	5.15e-05	0.028	-0.39	-0.35	Lupus nephritis in systemic lupus erythematosus;	chr6:19811429	chr6:19802164~19804752:-
TGCT	cis	rs7773456	0.533	rs9368127	ENSG00000228412.5	RP4-625H18.2	-4.2	5.15e-05	0.028	-0.39	-0.35	Lupus nephritis in systemic lupus erythematosus;	chr6:19811760	chr6:19802164~19804752:-
TGCT	cis	rs7181230	1	rs28620926	ENSG00000275636.1	RP11-521C20.5	4.2	5.15e-05	0.028	0.4	0.35	Dehydroepiandrosterone sulphate levels;	chr15:40064970	chr15:40078892~40079347:+
TGCT	cis	rs853679	0.55	rs1150692	ENSG00000216901.1	AL022393.7	4.19	5.15e-05	0.028	0.48	0.35	Depression;	chr6:28206179	chr6:28176188~28176674:+
TGCT	cis	rs2439831	0.702	rs2467402	ENSG00000205771.5	CATSPER2P1	4.19	5.15e-05	0.028	0.56	0.35	Lung cancer in ever smokers;	chr15:43732292	chr15:43726918~43747094:-
TGCT	cis	rs2337406	1	rs7145172	ENSG00000274576.2	IGHV2-70	-4.19	5.16e-05	0.028	-0.52	-0.35	Alzheimer's disease (late onset);	chr14:106704924	chr14:106770577~106771020:-
TGCT	cis	rs2337406	1	rs1858677	ENSG00000274576.2	IGHV2-70	-4.19	5.16e-05	0.028	-0.52	-0.35	Alzheimer's disease (late onset);	chr14:106706828	chr14:106770577~106771020:-
TGCT	cis	rs8049040	1	rs8049040	ENSG00000260886.1	TAT-AS1	4.19	5.16e-05	0.028	0.34	0.35	Blood protein levels;	chr16:71438801	chr16:71565789~71578187:+
TGCT	cis	rs4660214	0.666	rs7414381	ENSG00000182109.6	RP11-69E11.4	-4.19	5.16e-05	0.028	-0.36	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39275848	chr1:39522280~39546187:-
TGCT	cis	rs4660214	0.666	rs3116387	ENSG00000182109.6	RP11-69E11.4	-4.19	5.16e-05	0.028	-0.36	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39277197	chr1:39522280~39546187:-
TGCT	cis	rs4660214	0.614	rs1537815	ENSG00000182109.6	RP11-69E11.4	-4.19	5.16e-05	0.028	-0.36	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39278946	chr1:39522280~39546187:-
TGCT	cis	rs4660214	0.789	rs1984142	ENSG00000182109.6	RP11-69E11.4	-4.19	5.16e-05	0.028	-0.36	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39279936	chr1:39522280~39546187:-
TGCT	cis	rs4660214	0.614	rs6688708	ENSG00000182109.6	RP11-69E11.4	-4.19	5.16e-05	0.028	-0.36	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39293321	chr1:39522280~39546187:-
TGCT	cis	rs4713118	0.621	rs4713132	ENSG00000219891.2	ZSCAN12P1	4.19	5.16e-05	0.028	0.45	0.35	Parkinson's disease;	chr6:28066257	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.621	rs4713133	ENSG00000219891.2	ZSCAN12P1	4.19	5.16e-05	0.028	0.45	0.35	Parkinson's disease;	chr6:28066263	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.621	rs4713134	ENSG00000219891.2	ZSCAN12P1	4.19	5.16e-05	0.028	0.45	0.35	Parkinson's disease;	chr6:28066343	chr6:28091154~28093664:+
TGCT	cis	rs35612822	0.866	rs10207455	ENSG00000235042.1	AC098820.2	4.19	5.16e-05	0.028	0.37	0.35	Kidney disease (early stage) in type 1 diabetes;	chr2:216460888	chr2:216385288~216412696:-
TGCT	cis	rs7829975	0.606	rs10112585	ENSG00000254340.1	RP11-10A14.3	-4.19	5.16e-05	0.028	-0.35	-0.35	Mood instability;	chr8:8937520	chr8:9141424~9145435:+
TGCT	cis	rs7829975	0.572	rs7005000	ENSG00000254340.1	RP11-10A14.3	-4.19	5.16e-05	0.028	-0.35	-0.35	Mood instability;	chr8:8939092	chr8:9141424~9145435:+
TGCT	cis	rs9326248	0.652	rs7128382	ENSG00000280143.1	AP000892.6	4.19	5.17e-05	0.028	0.52	0.35	Blood protein levels;	chr11:117152771	chr11:117204967~117210292:+
TGCT	cis	rs6568686	0.577	rs383515	ENSG00000272356.1	RP5-1112D6.8	-4.19	5.17e-05	0.028	-0.41	-0.35	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111595465	chr6:111309203~111313517:+
TGCT	cis	rs9368849	0.548	rs10484578	ENSG00000186328.4	RP11-140K17.2	-4.19	5.17e-05	0.0281	-0.35	-0.35	Airway responsiveness in chronic obstructive pulmonary disease;	chr6:35278542	chr6:34715613~34715940:+
TGCT	cis	rs10740039	0.583	rs9415611	ENSG00000254271.1	RP11-131N11.4	-4.19	5.17e-05	0.0281	-0.37	-0.35	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60743440	chr10:60734342~60741828:+
TGCT	cis	rs10504229	0.636	rs72649133	ENSG00000253301.4	RP11-513O17.2	4.19	5.18e-05	0.0281	0.57	0.35	Developmental language disorder (linguistic errors);	chr8:57142122	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.689	rs17801390	ENSG00000253301.4	RP11-513O17.2	4.19	5.18e-05	0.0281	0.57	0.35	Developmental language disorder (linguistic errors);	chr8:57142209	chr8:57142689~57240298:+
TGCT	cis	rs4268898	0.76	rs4665675	ENSG00000223754.1	AC008073.9	4.19	5.19e-05	0.0281	0.41	0.35	Asthma;	chr2:24245263	chr2:24199839~24201698:-
TGCT	cis	rs2739330	0.929	rs5751777	ENSG00000250470.1	AP000351.3	4.19	5.19e-05	0.0281	0.36	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23976904~23977585:-
TGCT	cis	rs4927850	0.666	rs4927853	ENSG00000207650.1	MIR570	4.19	5.19e-05	0.0281	0.5	0.35	Pancreatic cancer;	chr3:196025182	chr3:195699401~195699497:+
TGCT	cis	rs728616	0.867	rs7080405	ENSG00000230091.5	TMEM254-AS1	4.19	5.19e-05	0.0282	0.62	0.35	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80142187	chr10:80046860~80078912:-
TGCT	cis	rs9302065	0.565	rs2992908	ENSG00000223298.1	RNY3P8	4.19	5.19e-05	0.0282	0.28	0.35	Blood metabolite levels;	chr13:95308346	chr13:95310830~95310955:-
TGCT	cis	rs9302065	0.565	rs2993584	ENSG00000223298.1	RNY3P8	4.19	5.19e-05	0.0282	0.28	0.35	Blood metabolite levels;	chr13:95309424	chr13:95310830~95310955:-
TGCT	cis	rs9302065	0.565	rs2993585	ENSG00000223298.1	RNY3P8	4.19	5.19e-05	0.0282	0.28	0.35	Blood metabolite levels;	chr13:95309712	chr13:95310830~95310955:-
TGCT	cis	rs9302065	0.565	rs2992910	ENSG00000223298.1	RNY3P8	4.19	5.19e-05	0.0282	0.28	0.35	Blood metabolite levels;	chr13:95309962	chr13:95310830~95310955:-
TGCT	cis	rs9302065	0.565	rs2993586	ENSG00000223298.1	RNY3P8	4.19	5.19e-05	0.0282	0.28	0.35	Blood metabolite levels;	chr13:95310324	chr13:95310830~95310955:-
TGCT	cis	rs2013441	1	rs11654025	ENSG00000230528.6	NOS2P3	4.19	5.2e-05	0.0282	0.35	0.35	Obesity-related traits;	chr17:20294847	chr17:20436337~20447249:+
TGCT	cis	rs2439831	0.85	rs67541383	ENSG00000205771.5	CATSPER2P1	-4.19	5.2e-05	0.0282	-0.62	-0.35	Lung cancer in ever smokers;	chr15:43880350	chr15:43726918~43747094:-
TGCT	cis	rs801193	0.66	rs974239	ENSG00000237310.1	GS1-124K5.4	4.19	5.2e-05	0.0282	0.4	0.35	Aortic root size;	chr7:66748504	chr7:66493706~66495474:+
TGCT	cis	rs7208859	0.673	rs9895684	ENSG00000266490.1	CTD-2349P21.9	4.19	5.2e-05	0.0282	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30792372~30792833:+
TGCT	cis	rs4238585	0.947	rs7188545	ENSG00000261195.1	CTD-2380F24.1	-4.19	5.21e-05	0.0282	-0.54	-0.35	Body mass index;	chr16:20247882	chr16:19761172~19766099:-
TGCT	cis	rs6741892	0.793	rs17576472	ENSG00000225402.1	AC010878.3	4.19	5.21e-05	0.0282	0.89	0.35	5-HTT brain serotonin transporter levels;	chr2:38675880	chr2:37816915~37817961:+
TGCT	cis	rs7621331	0.714	rs7626676	ENSG00000239213.4	NCK1-AS1	4.19	5.22e-05	0.0282	0.35	0.35	Waist circumference adjusted for body mass index;	chr3:135931908	chr3:136841726~136862054:-
TGCT	cis	rs847845	0.841	rs9784889	ENSG00000186328.4	RP11-140K17.2	-4.19	5.22e-05	0.0283	-0.53	-0.35	Non-small cell lung cancer;	chr6:34998270	chr6:34715613~34715940:+
TGCT	cis	rs875971	1	rs7781698	ENSG00000232559.3	GS1-124K5.12	4.19	5.23e-05	0.0283	0.33	0.35	Aortic root size;	chr7:66431325	chr7:66554588~66576923:-
TGCT	cis	rs4963124	0.886	rs10902216	ENSG00000279672.1	CMB9-55F22.1	4.19	5.23e-05	0.0283	0.45	0.35	Proteinuria and chronic kidney disease;	chr11:739392	chr11:779617~780755:+
TGCT	cis	rs3749237	0.595	rs4855877	ENSG00000226913.1	BSN-AS2	-4.19	5.23e-05	0.0283	-0.27	-0.35	Resting heart rate;	chr3:49411094	chr3:49549306~49554366:-
TGCT	cis	rs2015599	0.623	rs3782510	ENSG00000275476.1	RP11-996F15.4	4.19	5.23e-05	0.0283	0.37	0.35	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29277397~29277882:-
TGCT	cis	rs1061377	0.748	rs11096977	ENSG00000249207.1	RP11-360F5.1	-4.19	5.23e-05	0.0283	-0.37	-0.35	Uric acid levels;	chr4:39106186	chr4:39112677~39126818:-
TGCT	cis	rs1061377	0.748	rs6810770	ENSG00000249207.1	RP11-360F5.1	-4.19	5.23e-05	0.0283	-0.37	-0.35	Uric acid levels;	chr4:39106545	chr4:39112677~39126818:-
TGCT	cis	rs1061377	0.748	rs6812316	ENSG00000249207.1	RP11-360F5.1	-4.19	5.23e-05	0.0283	-0.37	-0.35	Uric acid levels;	chr4:39106617	chr4:39112677~39126818:-
TGCT	cis	rs9309473	0.95	rs6546860	ENSG00000163016.8	ALMS1P	4.19	5.24e-05	0.0283	0.32	0.35	Metabolite levels;	chr2:73617122	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.95	rs13427832	ENSG00000163016.8	ALMS1P	4.19	5.24e-05	0.0283	0.32	0.35	Metabolite levels;	chr2:73617691	chr2:73644919~73685576:+
TGCT	cis	rs2283792	0.765	rs9610338	ENSG00000228050.1	TOP3BP1	-4.19	5.24e-05	0.0283	-0.43	-0.35	Multiple sclerosis;	chr22:21797532	chr22:22223187~22224566:-
TGCT	cis	rs1061377	0.748	rs12506723	ENSG00000249207.1	RP11-360F5.1	-4.19	5.25e-05	0.0284	-0.37	-0.35	Uric acid levels;	chr4:39103152	chr4:39112677~39126818:-
TGCT	cis	rs1061377	0.748	rs1964345	ENSG00000249207.1	RP11-360F5.1	-4.19	5.25e-05	0.0284	-0.37	-0.35	Uric acid levels;	chr4:39104793	chr4:39112677~39126818:-
TGCT	cis	rs1061377	0.748	rs1964347	ENSG00000249207.1	RP11-360F5.1	-4.19	5.25e-05	0.0284	-0.37	-0.35	Uric acid levels;	chr4:39104956	chr4:39112677~39126818:-
TGCT	cis	rs1061377	0.748	rs1036033	ENSG00000249207.1	RP11-360F5.1	-4.19	5.25e-05	0.0284	-0.37	-0.35	Uric acid levels;	chr4:39105295	chr4:39112677~39126818:-
TGCT	cis	rs1061377	0.748	rs1036034	ENSG00000249207.1	RP11-360F5.1	-4.19	5.25e-05	0.0284	-0.37	-0.35	Uric acid levels;	chr4:39105299	chr4:39112677~39126818:-
TGCT	cis	rs853679	0.513	rs9468296	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28145952	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs4711164	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28147378	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs4711165	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28147406	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs4713148	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28148143	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9348794	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28149979	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9468297	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28151096	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9295758	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28152885	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs17774663	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28153120	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9468298	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28154567	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9295759	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28156691	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9348796	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28158424	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs11552219	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28159056	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9380058	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28159666	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9393896	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28159925	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9393897	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28159932	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9357065	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28161802	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9357066	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28162053	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9393898	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28162598	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9368556	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28163375	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9368557	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28163759	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9380059	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28164580	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9380060	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28164825	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs35227624	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28164948	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9380061	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28165025	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9368558	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28165528	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.587	rs9393899	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Parkinson's disease;	chr6:28165750	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs4713150	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28168434	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.527	rs4713151	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Parkinson's disease;	chr6:28168578	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9393901	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28169019	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs3173443	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28169249	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs4713152	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28169676	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9348797	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28169755	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9380062	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28169791	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.542	rs9380063	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28170075	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs12332979	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28173770	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs67878650	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28174809	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.569	rs9348798	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28175233	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9380065	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28176973	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9295761	ENSG00000219891.2	ZSCAN12P1	4.19	5.25e-05	0.0284	0.46	0.35	Depression;	chr6:28180209	chr6:28091154~28093664:+
TGCT	cis	rs1150668	0.745	rs213238	ENSG00000204709.4	LINC01556	4.19	5.26e-05	0.0284	0.39	0.35	Pubertal anthropometrics;	chr6:28354216	chr6:28943877~28944537:+
TGCT	cis	rs2742234	0.911	rs3004214	ENSG00000273008.1	RP11-351D16.3	-4.19	5.26e-05	0.0284	-0.4	-0.35	Hirschsprung disease;	chr10:43136250	chr10:43136824~43138334:-
TGCT	cis	rs9733	0.818	rs4970926	ENSG00000236713.1	RP11-363I22.3	4.19	5.26e-05	0.0284	0.26	0.35	Tonsillectomy;	chr1:150701208	chr1:150780272~150780644:+
TGCT	cis	rs9733	0.818	rs12403609	ENSG00000236713.1	RP11-363I22.3	4.19	5.26e-05	0.0284	0.26	0.35	Tonsillectomy;	chr1:150704009	chr1:150780272~150780644:+
TGCT	cis	rs4242434	0.854	rs11782130	ENSG00000254064.1	CTD-2530N21.4	-4.19	5.26e-05	0.0284	-0.21	-0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22594844	chr8:22254576~22275162:-
TGCT	cis	rs599083	0.53	rs583545	ENSG00000212093.1	AP000807.1	-4.19	5.26e-05	0.0284	-0.37	-0.35	Bone mineral density (spine);	chr11:68411167	chr11:68506083~68506166:-
TGCT	cis	rs599083	0.53	rs689179	ENSG00000212093.1	AP000807.1	-4.19	5.26e-05	0.0284	-0.37	-0.35	Bone mineral density (spine);	chr11:68411698	chr11:68506083~68506166:-
TGCT	cis	rs599083	0.53	rs640569	ENSG00000212093.1	AP000807.1	-4.19	5.26e-05	0.0284	-0.37	-0.35	Bone mineral density (spine);	chr11:68417352	chr11:68506083~68506166:-
TGCT	cis	rs599083	0.53	rs2472415	ENSG00000212093.1	AP000807.1	-4.19	5.26e-05	0.0284	-0.37	-0.35	Bone mineral density (spine);	chr11:68418148	chr11:68506083~68506166:-
TGCT	cis	rs8141529	0.732	rs5762788	ENSG00000226471.5	CTA-292E10.6	-4.19	5.27e-05	0.0284	-0.37	-0.35	Lymphocyte counts;	chr22:28778782	chr22:28800683~28848559:+
TGCT	cis	rs72843506	0.656	rs74333705	ENSG00000261033.1	RP11-209D14.2	4.19	5.27e-05	0.0284	0.52	0.35	Schizophrenia;	chr17:20097448	chr17:20008051~20009234:-
TGCT	cis	rs10971721	1	rs10971721	ENSG00000230074.1	RP11-195F19.9	-4.19	5.27e-05	0.0285	-0.52	-0.35	Body mass index;	chr9:33827696	chr9:34665665~34681298:+
TGCT	cis	rs10759883	0.651	rs816670	ENSG00000175611.10	LINC00476	-4.19	5.27e-05	0.0285	-0.33	-0.35	Nicotine dependence;	chr9:95813152	chr9:95759231~95875977:-
TGCT	cis	rs1563304	1	rs1563304	ENSG00000214401.4	KANSL1-AS1	4.19	5.27e-05	0.0285	0.61	0.35	Neuroticism;	chr17:46797087	chr17:46193576~46196723:+
TGCT	cis	rs10829156	0.755	rs10732437	ENSG00000240291.1	RP11-499P20.2	4.19	5.27e-05	0.0285	0.32	0.35	Sudden cardiac arrest;	chr10:18626973	chr10:18513115~18545651:-
TGCT	cis	rs172166	0.61	rs276369	ENSG00000204709.4	LINC01556	4.19	5.28e-05	0.0285	0.39	0.35	Cardiac Troponin-T levels;	chr6:27951465	chr6:28943877~28944537:+
TGCT	cis	rs5742933	0.597	rs7568449	ENSG00000273240.1	RP11-455J20.3	4.19	5.28e-05	0.0285	0.36	0.35	Ferritin levels;	chr2:189656328	chr2:189763859~189764456:-
TGCT	cis	rs7829975	0.593	rs2921061	ENSG00000254340.1	RP11-10A14.3	4.19	5.28e-05	0.0285	0.35	0.35	Mood instability;	chr8:8460105	chr8:9141424~9145435:+
TGCT	cis	rs4691139	0.903	rs6812176	ENSG00000236941.6	RP11-366M4.8	4.19	5.28e-05	0.0285	0.28	0.35	Ovarian cancer in BRCA1 mutation carriers;	chr4:164998820	chr4:164948079~164949438:+
TGCT	cis	rs1850744	1	rs10939507	ENSG00000251624.1	UNC93B7	4.19	5.28e-05	0.0285	0.81	0.35	Economic and political preferences;	chr4:9767199	chr4:9493736~9498066:+
TGCT	cis	rs7208859	0.673	rs9907197	ENSG00000280069.1	CTD-2349P21.3	-4.19	5.29e-05	0.0285	-0.47	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30738182~30740275:+
TGCT	cis	rs7208859	0.673	rs9915963	ENSG00000280069.1	CTD-2349P21.3	-4.19	5.29e-05	0.0285	-0.47	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30738182~30740275:+
TGCT	cis	rs2243480	1	rs34815098	ENSG00000164669.11	INTS4P1	4.19	5.3e-05	0.0286	0.58	0.35	Diabetic kidney disease;	chr7:65827267	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs4548056	ENSG00000164669.11	INTS4P1	4.19	5.3e-05	0.0286	0.58	0.35	Diabetic kidney disease;	chr7:65833886	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs7456042	ENSG00000164669.11	INTS4P1	4.19	5.3e-05	0.0286	0.58	0.35	Diabetic kidney disease;	chr7:65834791	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs35735127	ENSG00000164669.11	INTS4P1	4.19	5.3e-05	0.0286	0.58	0.35	Diabetic kidney disease;	chr7:65835436	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs34703416	ENSG00000164669.11	INTS4P1	4.19	5.3e-05	0.0286	0.58	0.35	Diabetic kidney disease;	chr7:65835655	chr7:65141225~65234216:+
TGCT	cis	rs2243480	0.901	rs35256305	ENSG00000164669.11	INTS4P1	4.19	5.3e-05	0.0286	0.58	0.35	Diabetic kidney disease;	chr7:65841418	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs73142121	ENSG00000164669.11	INTS4P1	4.19	5.3e-05	0.0286	0.58	0.35	Diabetic kidney disease;	chr7:65846219	chr7:65141225~65234216:+
TGCT	cis	rs2243480	0.803	rs34004500	ENSG00000164669.11	INTS4P1	4.19	5.3e-05	0.0286	0.58	0.35	Diabetic kidney disease;	chr7:65847191	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs35825738	ENSG00000164669.11	INTS4P1	4.19	5.3e-05	0.0286	0.58	0.35	Diabetic kidney disease;	chr7:65853040	chr7:65141225~65234216:+
TGCT	cis	rs2243480	0.803	rs35480979	ENSG00000164669.11	INTS4P1	4.19	5.3e-05	0.0286	0.58	0.35	Diabetic kidney disease;	chr7:65892097	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs34637256	ENSG00000164669.11	INTS4P1	4.19	5.3e-05	0.0286	0.58	0.35	Diabetic kidney disease;	chr7:65895144	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs35391607	ENSG00000164669.11	INTS4P1	4.19	5.3e-05	0.0286	0.58	0.35	Diabetic kidney disease;	chr7:65895842	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs34974928	ENSG00000164669.11	INTS4P1	4.19	5.3e-05	0.0286	0.58	0.35	Diabetic kidney disease;	chr7:65899019	chr7:65141225~65234216:+
TGCT	cis	rs35486314	1	rs35486314	ENSG00000236713.1	RP11-363I22.3	4.19	5.3e-05	0.0286	0.27	0.35	Monocyte chemoattractant protein-1 levels;	chr1:150929385	chr1:150780272~150780644:+
TGCT	cis	rs2348418	0.765	rs6487665	ENSG00000273989.1	RP11-425D17.2	-4.19	5.3e-05	0.0286	-0.31	-0.35	Lung function (FEV1);Lung function (FVC);	chr12:28177726	chr12:28236227~28236828:+
TGCT	cis	rs9660180	0.934	rs12729990	ENSG00000231050.1	RP1-140A9.1	4.19	5.3e-05	0.0286	0.32	0.35	Body mass index;	chr1:1880596	chr1:1891471~1892658:+
TGCT	cis	rs61931739	0.613	rs1817500	ENSG00000259937.2	RP11-438D14.2	4.19	5.31e-05	0.0286	0.29	0.35	Morning vs. evening chronotype;	chr12:33526874	chr12:33404872~33405896:-
TGCT	cis	rs4242434	0.757	rs7005025	ENSG00000253200.1	RP11-582J16.5	4.19	5.31e-05	0.0286	0.2	0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22662302	chr8:22613908~22616657:-
TGCT	cis	rs875971	0.66	rs10263935	ENSG00000236529.1	RP13-254B10.1	4.19	5.31e-05	0.0286	0.27	0.35	Aortic root size;	chr7:66631041	chr7:65840212~65840596:+
TGCT	cis	rs11098499	1	rs1011054	ENSG00000260091.1	RP11-33B1.4	4.19	5.31e-05	0.0286	0.21	0.35	Corneal astigmatism;	chr4:119281232	chr4:119409333~119410233:+
TGCT	cis	rs10971721	0.822	rs12376145	ENSG00000230074.1	RP11-195F19.9	-4.19	5.32e-05	0.0286	-0.52	-0.35	Body mass index;	chr9:34050408	chr9:34665665~34681298:+
TGCT	cis	rs732716	0.785	rs11085073	ENSG00000267980.1	AC007292.6	4.19	5.32e-05	0.0287	0.38	0.35	Mean corpuscular volume;	chr19:4375165	chr19:4363789~4364640:+
TGCT	cis	rs9807989	0.507	rs6710528	ENSG00000234389.1	AC007278.3	-4.19	5.32e-05	0.0287	-0.26	-0.35	Asthma;	chr2:102399682	chr2:102438713~102440475:+
TGCT	cis	rs11168618	0.967	rs1895996	ENSG00000240399.1	RP1-228P16.1	4.19	5.32e-05	0.0287	0.34	0.35	Adiponectin levels;	chr12:48561788	chr12:48054813~48055591:-
TGCT	cis	rs7923609	1	rs2393969	ENSG00000232075.1	MRPL35P2	-4.19	5.33e-05	0.0287	-0.34	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63380680	chr10:63634317~63634827:-
TGCT	cis	rs2739330	0.76	rs1002286	ENSG00000235689.1	AP000351.13	-4.19	5.33e-05	0.0287	-0.34	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:24006305~24008258:-
TGCT	cis	rs7605378	0.658	rs4673507	ENSG00000232732.8	AC073043.1	-4.19	5.33e-05	0.0287	-0.42	-0.35	Osteoporosis;	chr2:199845444	chr2:199867396~199911159:-
TGCT	cis	rs11139399	0.552	rs10867800	ENSG00000233926.1	RP11-154D17.1	-4.19	5.34e-05	0.0287	-0.4	-0.35	Hippocampal atrophy;	chr9:81722438	chr9:81689713~81776900:+
TGCT	cis	rs4242434	0.927	rs2291231	ENSG00000254064.1	CTD-2530N21.4	-4.19	5.34e-05	0.0287	-0.21	-0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22606399	chr8:22254576~22275162:-
TGCT	cis	rs4242434	0.892	rs34269854	ENSG00000254064.1	CTD-2530N21.4	-4.19	5.34e-05	0.0287	-0.21	-0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22607647	chr8:22254576~22275162:-
TGCT	cis	rs875971	0.564	rs313804	ENSG00000237310.1	GS1-124K5.4	4.19	5.34e-05	0.0287	0.38	0.35	Aortic root size;	chr7:66049635	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.662	rs448725	ENSG00000237310.1	GS1-124K5.4	4.19	5.34e-05	0.0287	0.38	0.35	Aortic root size;	chr7:66049641	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.658	rs432667	ENSG00000237310.1	GS1-124K5.4	4.19	5.34e-05	0.0287	0.38	0.35	Aortic root size;	chr7:66049646	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.8	rs427557	ENSG00000237310.1	GS1-124K5.4	4.19	5.34e-05	0.0287	0.38	0.35	Aortic root size;	chr7:66054263	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.83	rs587360	ENSG00000237310.1	GS1-124K5.4	4.19	5.34e-05	0.0287	0.38	0.35	Aortic root size;	chr7:66057711	chr7:66493706~66495474:+
TGCT	cis	rs9322193	0.607	rs6925151	ENSG00000216906.2	RP11-350J20.9	4.19	5.34e-05	0.0288	0.45	0.35	Lung cancer;	chr6:149889587	chr6:149904243~149906418:+
TGCT	cis	rs6565180	0.889	rs8051096	ENSG00000183604.13	SMG1P5	-4.19	5.35e-05	0.0288	-0.25	-0.35	Tonsillectomy;	chr16:30336410	chr16:30267553~30335374:-
TGCT	cis	rs55726902	0.506	rs1006476	ENSG00000276691.1	RP5-1057I20.5	4.19	5.35e-05	0.0288	0.49	0.35	Allergic disease (asthma, hay fever or eczema);	chr12:47785564	chr12:47788426~47788971:+
TGCT	cis	rs7005380	0.556	rs6996081	ENSG00000254343.2	RP11-760H22.2	4.19	5.35e-05	0.0288	0.5	0.35	Interstitial lung disease;	chr8:119934865	chr8:120052180~120056201:+
TGCT	cis	rs11231017	1	rs11231019	ENSG00000254454.2	RCC2P6	-4.19	5.35e-05	0.0288	-0.27	-0.35	HIV-1 viral setpoint;	chr11:62295397	chr11:62371146~62373168:+
TGCT	cis	rs11722228	0.508	rs2241473	ENSG00000261490.1	RP11-448G15.3	4.18	5.36e-05	0.0288	0.33	0.35	Urate levels;Serum uric acid levels;Gout;	chr4:10084325	chr4:10068089~10073019:-
TGCT	cis	rs172166	0.694	rs1225716	ENSG00000219891.2	ZSCAN12P1	4.18	5.36e-05	0.0288	0.42	0.35	Cardiac Troponin-T levels;	chr6:28145968	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.512	rs2622319	ENSG00000219891.2	ZSCAN12P1	4.18	5.36e-05	0.0288	0.42	0.35	Parkinson's disease;	chr6:28152623	chr6:28091154~28093664:+
TGCT	cis	rs172166	0.694	rs1150666	ENSG00000219891.2	ZSCAN12P1	4.18	5.36e-05	0.0288	0.42	0.35	Cardiac Troponin-T levels;	chr6:28156150	chr6:28091154~28093664:+
TGCT	cis	rs172166	0.694	rs9295760	ENSG00000219891.2	ZSCAN12P1	4.18	5.36e-05	0.0288	0.42	0.35	Cardiac Troponin-T levels;	chr6:28179607	chr6:28091154~28093664:+
TGCT	cis	rs853356	0.843	rs4441955	ENSG00000234261.2	RP11-146I2.1	4.18	5.36e-05	0.0288	0.35	0.35	Height;	chr6:14182494	chr6:14661829~15090003:-
TGCT	cis	rs7301826	0.504	rs11061164	ENSG00000256299.1	RP11-989F5.3	-4.18	5.36e-05	0.0288	-0.37	-0.35	Plasma plasminogen activator levels;	chr12:130839724	chr12:130810821~130812622:-
TGCT	cis	rs7181230	0.885	rs28444847	ENSG00000275636.1	RP11-521C20.5	4.18	5.36e-05	0.0288	0.44	0.35	Dehydroepiandrosterone sulphate levels;	chr15:40064403	chr15:40078892~40079347:+
TGCT	cis	rs755249	0.701	rs1180342	ENSG00000182109.6	RP11-69E11.4	-4.18	5.36e-05	0.0288	-0.34	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527206	chr1:39522280~39546187:-
TGCT	cis	rs34421088	0.576	rs2572432	ENSG00000254936.4	AF131215.3	-4.18	5.37e-05	0.0288	-0.38	-0.35	Neuroticism;	chr8:11244214	chr8:11123381~11126064:-
TGCT	cis	rs7829975	0.846	rs11779061	ENSG00000173295.6	FAM86B3P	-4.18	5.37e-05	0.0288	-0.43	-0.35	Mood instability;	chr8:8691922	chr8:8228595~8244865:+
TGCT	cis	rs7826238	0.539	rs2945891	ENSG00000253893.2	FAM85B	-4.18	5.37e-05	0.0288	-0.46	-0.35	Systolic blood pressure;	chr8:8297953	chr8:8167819~8226614:-
TGCT	cis	rs10875976	1	rs55677077	ENSG00000257253.2	RP11-70F11.7	4.18	5.37e-05	0.0289	0.29	0.35	Obesity;	chr12:49825725	chr12:49861207~49865802:+
TGCT	cis	rs651907	0.557	rs17347644	ENSG00000244119.1	PDCL3P4	4.18	5.38e-05	0.0289	0.25	0.35	Colorectal cancer;	chr3:101828889	chr3:101712472~101713191:+
TGCT	cis	rs2739330	0.76	rs5751760	ENSG00000235689.1	AP000351.13	4.18	5.38e-05	0.0289	0.34	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:24006305~24008258:-
TGCT	cis	rs673078	0.66	rs17619932	ENSG00000275759.1	RP11-131L12.3	-4.18	5.38e-05	0.0289	-0.59	-0.35	Glucose homeostasis traits;	chr12:118352228	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.66	rs11068917	ENSG00000275759.1	RP11-131L12.3	-4.18	5.38e-05	0.0289	-0.59	-0.35	Glucose homeostasis traits;	chr12:118353315	chr12:118428281~118428870:+
TGCT	cis	rs62025270	0.688	rs17577869	ENSG00000259416.2	RP11-158M2.5	-4.18	5.38e-05	0.0289	-0.42	-0.35	Idiopathic pulmonary fibrosis;	chr15:85771142	chr15:85754941~85756237:-
TGCT	cis	rs453301	0.653	rs7005133	ENSG00000253893.2	FAM85B	-4.18	5.39e-05	0.0289	-0.46	-0.35	Joint mobility (Beighton score);	chr8:9043712	chr8:8167819~8226614:-
TGCT	cis	rs34375054	0.738	rs10773145	ENSG00000279233.1	RP11-158L12.4	-4.18	5.39e-05	0.0289	-0.36	-0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125141057	chr12:125138245~125141711:+
TGCT	cis	rs2652822	0.504	rs4619348	ENSG00000259498.1	RP11-244F12.3	4.18	5.39e-05	0.0289	0.33	0.35	Metabolic traits;	chr15:63067365	chr15:63046034~63049387:-
TGCT	cis	rs6474412	0.957	rs9643891	ENSG00000255101.1	RP11-412B14.1	4.18	5.4e-05	0.029	0.34	0.35	Smoking behavior;	chr8:42701454	chr8:42705583~42721946:-
TGCT	cis	rs6474412	0.957	rs9643853	ENSG00000255101.1	RP11-412B14.1	4.18	5.4e-05	0.029	0.34	0.35	Smoking behavior;	chr8:42701509	chr8:42705583~42721946:-
TGCT	cis	rs13118159	0.836	rs2276903	ENSG00000253399.1	AC078852.2	-4.18	5.41e-05	0.029	-0.42	-0.35	Longevity;	chr4:1349617	chr4:1358479~1359461:+
TGCT	cis	rs2283792	0.765	rs2283793	ENSG00000228050.1	TOP3BP1	4.18	5.41e-05	0.029	0.43	0.35	Multiple sclerosis;	chr22:21827189	chr22:22223187~22224566:-
TGCT	cis	rs2283792	0.765	rs5999752	ENSG00000228050.1	TOP3BP1	4.18	5.41e-05	0.029	0.43	0.35	Multiple sclerosis;	chr22:21833894	chr22:22223187~22224566:-
TGCT	cis	rs172166	0.637	rs1225592	ENSG00000219891.2	ZSCAN12P1	4.18	5.42e-05	0.029	0.42	0.35	Cardiac Troponin-T levels;	chr6:28182464	chr6:28091154~28093664:+
TGCT	cis	rs172166	0.637	rs1225595	ENSG00000219891.2	ZSCAN12P1	4.18	5.42e-05	0.029	0.42	0.35	Cardiac Troponin-T levels;	chr6:28183562	chr6:28091154~28093664:+
TGCT	cis	rs172166	0.637	rs1233691	ENSG00000219891.2	ZSCAN12P1	4.18	5.42e-05	0.029	0.42	0.35	Cardiac Troponin-T levels;	chr6:28186119	chr6:28091154~28093664:+
TGCT	cis	rs2297363	1	rs1130861	ENSG00000213073.4	RP11-288H12.3	-4.18	5.42e-05	0.0291	-0.34	-0.35	Total cholesterol levels;Blood protein levels;	chr6:160090322	chr6:160093082~160096212:+
TGCT	cis	rs6474412	1	rs13280604	ENSG00000255101.1	RP11-412B14.1	4.18	5.42e-05	0.0291	0.35	0.35	Smoking behavior;	chr8:42704443	chr8:42705583~42721946:-
TGCT	cis	rs875971	0.545	rs316305	ENSG00000222364.1	RNU6-96P	4.18	5.42e-05	0.0291	0.45	0.35	Aortic root size;	chr7:66152984	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.545	rs316306	ENSG00000222364.1	RNU6-96P	4.18	5.42e-05	0.0291	0.45	0.35	Aortic root size;	chr7:66153687	chr7:66395191~66395286:+
TGCT	cis	rs4273100	0.688	rs4924980	ENSG00000262319.1	CTC-457L16.2	4.18	5.43e-05	0.0291	0.46	0.35	Schizophrenia;	chr17:19301550	chr17:19141017~19143689:-
TGCT	cis	rs4242434	0.889	rs11783129	ENSG00000254064.1	CTD-2530N21.4	-4.18	5.43e-05	0.0291	-0.21	-0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22595913	chr8:22254576~22275162:-
TGCT	cis	rs4242434	0.927	rs13271626	ENSG00000254064.1	CTD-2530N21.4	-4.18	5.43e-05	0.0291	-0.21	-0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22610247	chr8:22254576~22275162:-
TGCT	cis	rs4242434	0.927	rs720746	ENSG00000254064.1	CTD-2530N21.4	-4.18	5.43e-05	0.0291	-0.21	-0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22613886	chr8:22254576~22275162:-
TGCT	cis	rs4242434	0.927	rs3736147	ENSG00000254064.1	CTD-2530N21.4	4.18	5.43e-05	0.0291	0.21	0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22614311	chr8:22254576~22275162:-
TGCT	cis	rs4242434	0.927	rs11781149	ENSG00000254064.1	CTD-2530N21.4	-4.18	5.43e-05	0.0291	-0.21	-0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22615645	chr8:22254576~22275162:-
TGCT	cis	rs2015599	0.525	rs10743656	ENSG00000275476.1	RP11-996F15.4	4.18	5.44e-05	0.0291	0.37	0.35	Platelet count;Mean platelet volume;	chr12:29332516	chr12:29277397~29277882:-
TGCT	cis	rs904251	0.647	rs2776908	ENSG00000279942.1	RP1-153P14.7	-4.18	5.44e-05	0.0291	-0.45	-0.35	Cognitive performance;	chr6:37467081	chr6:37567716~37571460:+
TGCT	cis	rs7208859	0.623	rs9895785	ENSG00000263603.1	CTD-2349P21.5	4.18	5.44e-05	0.0291	0.5	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30729469~30731202:+
TGCT	cis	rs2283792	0.74	rs2283791	ENSG00000228050.1	TOP3BP1	4.18	5.44e-05	0.0291	0.44	0.35	Multiple sclerosis;	chr22:21776656	chr22:22223187~22224566:-
TGCT	cis	rs7005380	0.556	rs6995862	ENSG00000254343.2	RP11-760H22.2	-4.18	5.44e-05	0.0291	-0.53	-0.35	Interstitial lung disease;	chr8:119934609	chr8:120052180~120056201:+
TGCT	cis	rs2188561	1	rs2188561	ENSG00000241764.3	AC002467.7	4.18	5.44e-05	0.0291	0.35	0.35	Alcohol consumption;	chr7:107695613	chr7:107742817~107744581:-
TGCT	cis	rs2188561	1	rs2712208	ENSG00000241764.3	AC002467.7	4.18	5.44e-05	0.0291	0.35	0.35	Alcohol consumption;	chr7:107703317	chr7:107742817~107744581:-
TGCT	cis	rs901683	0.85	rs112297763	ENSG00000264204.2	AGAP7P	-4.18	5.45e-05	0.0292	-0.76	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45573988	chr10:46109621~46131358:+
TGCT	cis	rs7396835	0.866	rs6589571	ENSG00000254851.1	RP11-109L13.1	-4.18	5.46e-05	0.0292	-0.65	-0.35	Quantitative traits;	chr11:116809702	chr11:117135528~117138582:+
TGCT	cis	rs7403037	0.55	rs34469274	ENSG00000259905.4	PWRN1	4.18	5.46e-05	0.0292	0.47	0.35	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24362112	chr15:24493137~24652130:+
TGCT	cis	rs10129255	0.536	rs8004835	ENSG00000280411.1	IGHV1-69-2	-4.18	5.46e-05	0.0292	-0.36	-0.35	Kawasaki disease;	chr14:106686361	chr14:106762092~106762588:-
TGCT	cis	rs7208859	0.623	rs170051	ENSG00000263603.1	CTD-2349P21.5	-4.18	5.46e-05	0.0292	-0.51	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs216434	ENSG00000263603.1	CTD-2349P21.5	-4.18	5.46e-05	0.0292	-0.51	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs216436	ENSG00000263603.1	CTD-2349P21.5	-4.18	5.46e-05	0.0292	-0.51	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30729469~30731202:+
TGCT	cis	rs7181230	1	rs11638521	ENSG00000275636.1	RP11-521C20.5	-4.18	5.47e-05	0.0292	-0.4	-0.35	Dehydroepiandrosterone sulphate levels;	chr15:40068113	chr15:40078892~40079347:+
TGCT	cis	rs7819412	0.715	rs35223712	ENSG00000269918.1	AF131215.9	-4.18	5.47e-05	0.0293	-0.37	-0.35	Triglycerides;	chr8:11186417	chr8:11104691~11106704:-
TGCT	cis	rs7429990	0.932	rs936428	ENSG00000229759.1	MRPS18AP1	-4.18	5.47e-05	0.0293	-0.3	-0.35	Educational attainment (years of education);	chr3:48125791	chr3:48256350~48256938:-
TGCT	cis	rs950169	0.579	rs11633088	ENSG00000225151.9	GOLGA2P7	4.18	5.47e-05	0.0293	0.41	0.35	Schizophrenia;	chr15:84003429	chr15:84199311~84230136:-
TGCT	cis	rs1519814	0.654	rs1543201	ENSG00000254343.2	RP11-760H22.2	4.18	5.48e-05	0.0293	0.59	0.35	Breast cancer;	chr8:120006649	chr8:120052180~120056201:+
TGCT	cis	rs453301	0.598	rs10104303	ENSG00000254340.1	RP11-10A14.3	4.18	5.48e-05	0.0293	0.35	0.35	Joint mobility (Beighton score);	chr8:8977018	chr8:9141424~9145435:+
TGCT	cis	rs796364	0.806	rs76112266	ENSG00000232732.8	AC073043.1	4.18	5.49e-05	0.0293	0.51	0.35	Schizophrenia;	chr2:200222434	chr2:199867396~199911159:-
TGCT	cis	rs904251	0.523	rs1776455	ENSG00000204110.6	RP1-153P14.8	-4.18	5.49e-05	0.0294	-0.35	-0.35	Cognitive performance;	chr6:37515147	chr6:37507348~37535616:+
TGCT	cis	rs8072100	0.764	rs4794371	ENSG00000228782.6	CTD-2026D20.3	-4.18	5.5e-05	0.0294	-0.41	-0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47550327	chr17:47450568~47492492:-
TGCT	cis	rs748404	0.697	rs546170	ENSG00000205771.5	CATSPER2P1	-4.18	5.51e-05	0.0294	-0.4	-0.35	Lung cancer;	chr15:43272651	chr15:43726918~43747094:-
TGCT	cis	rs3742264	1	rs11618062	ENSG00000235903.6	CPB2-AS1	4.18	5.51e-05	0.0294	0.42	0.35	Blood protein levels;	chr13:46075433	chr13:46052806~46113332:+
TGCT	cis	rs72819454	0.522	rs55908118	ENSG00000266852.2	MIR4482	4.18	5.51e-05	0.0294	0.6	0.35	Interleukin-9 levels;	chr10:103774251	chr10:104268336~104268405:-
TGCT	cis	rs10129255	0.5	rs1024350	ENSG00000223648.3	IGHV3-64	4.18	5.51e-05	0.0294	0.3	0.35	Kawasaki disease;	chr14:106685105	chr14:106643132~106658258:-
TGCT	cis	rs10129255	0.518	rs7143784	ENSG00000223648.3	IGHV3-64	4.18	5.51e-05	0.0294	0.3	0.35	Kawasaki disease;	chr14:106687277	chr14:106643132~106658258:-
TGCT	cis	rs11671005	0.572	rs11669127	ENSG00000268912.1	CTD-2619J13.17	4.18	5.51e-05	0.0294	0.42	0.35	Mean platelet volume;	chr19:58492463	chr19:58428632~58431148:-
TGCT	cis	rs7829975	1	rs7829975	ENSG00000253893.2	FAM85B	4.18	5.51e-05	0.0294	0.46	0.35	Mood instability;	chr8:8690607	chr8:8167819~8226614:-
TGCT	cis	rs7976269	0.583	rs4931131	ENSG00000275476.1	RP11-996F15.4	-4.18	5.51e-05	0.0294	-0.36	-0.35	Male-pattern baldness;	chr12:29015898	chr12:29277397~29277882:-
TGCT	cis	rs5742933	1	rs5742998	ENSG00000273240.1	RP11-455J20.3	-4.18	5.51e-05	0.0294	-0.36	-0.35	Ferritin levels;	chr2:189799626	chr2:189763859~189764456:-
TGCT	cis	rs12908161	0.683	rs12903256	ENSG00000225151.9	GOLGA2P7	-4.18	5.51e-05	0.0294	-0.37	-0.35	Schizophrenia;	chr15:84764910	chr15:84199311~84230136:-
TGCT	cis	rs904251	0.772	rs2252920	ENSG00000279942.1	RP1-153P14.7	-4.18	5.51e-05	0.0295	-0.45	-0.35	Cognitive performance;	chr6:37450551	chr6:37567716~37571460:+
TGCT	cis	rs1010254	0.959	rs4958300	ENSG00000213433.5	RPLP1P6	-4.18	5.52e-05	0.0295	-0.36	-0.35	Optic nerve measurement (cup area);	chr5:152336518	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.917	rs68155174	ENSG00000213433.5	RPLP1P6	-4.18	5.52e-05	0.0295	-0.36	-0.35	Optic nerve measurement (cup area);	chr5:152338357	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.959	rs11959224	ENSG00000213433.5	RPLP1P6	-4.18	5.52e-05	0.0295	-0.36	-0.35	Optic nerve measurement (cup area);	chr5:152339182	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.959	rs6876461	ENSG00000213433.5	RPLP1P6	-4.18	5.52e-05	0.0295	-0.36	-0.35	Optic nerve measurement (cup area);	chr5:152339830	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.959	rs4958529	ENSG00000213433.5	RPLP1P6	-4.18	5.52e-05	0.0295	-0.36	-0.35	Optic nerve measurement (cup area);	chr5:152348330	chr5:151765859~151766378:-
TGCT	cis	rs1010254	1	rs7703937	ENSG00000213433.5	RPLP1P6	-4.18	5.52e-05	0.0295	-0.36	-0.35	Optic nerve measurement (cup area);	chr5:152349893	chr5:151765859~151766378:-
TGCT	cis	rs1010254	1	rs17446828	ENSG00000213433.5	RPLP1P6	-4.18	5.52e-05	0.0295	-0.36	-0.35	Optic nerve measurement (cup area);	chr5:152351446	chr5:151765859~151766378:-
TGCT	cis	rs1010254	1	rs56221251	ENSG00000213433.5	RPLP1P6	-4.18	5.52e-05	0.0295	-0.36	-0.35	Optic nerve measurement (cup area);	chr5:152353458	chr5:151765859~151766378:-
TGCT	cis	rs1010254	1	rs17113145	ENSG00000213433.5	RPLP1P6	-4.18	5.52e-05	0.0295	-0.36	-0.35	Optic nerve measurement (cup area);	chr5:152353495	chr5:151765859~151766378:-
TGCT	cis	rs1010254	1	rs6870097	ENSG00000213433.5	RPLP1P6	-4.18	5.52e-05	0.0295	-0.36	-0.35	Optic nerve measurement (cup area);	chr5:152354910	chr5:151765859~151766378:-
TGCT	cis	rs1010254	1	rs6896780	ENSG00000213433.5	RPLP1P6	-4.18	5.52e-05	0.0295	-0.36	-0.35	Optic nerve measurement (cup area);	chr5:152355563	chr5:151765859~151766378:-
TGCT	cis	rs854624	0.892	rs1734954	ENSG00000267369.1	RP11-1094M14.8	4.18	5.52e-05	0.0295	0.47	0.35	Blood protein levels;	chr17:36010848	chr17:35498218~35499175:+
TGCT	cis	rs4691139	1	rs12512283	ENSG00000236941.6	RP11-366M4.8	4.18	5.52e-05	0.0295	0.27	0.35	Ovarian cancer in BRCA1 mutation carriers;	chr4:164987775	chr4:164948079~164949438:+
TGCT	cis	rs7403037	0.526	rs28545658	ENSG00000259905.4	PWRN1	4.18	5.53e-05	0.0295	0.38	0.35	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24553856	chr15:24493137~24652130:+
TGCT	cis	rs9880772	0.747	rs7621606	ENSG00000224237.1	MINOS1P3	-4.18	5.53e-05	0.0295	-0.36	-0.35	Chronic lymphocytic leukemia;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);	chr3:27778292	chr3:27214816~27215018:-
TGCT	cis	rs9959491	0.56	rs35383685	ENSG00000227279.1	AC015933.2	4.18	5.53e-05	0.0295	0.38	0.35	Breast cancer;	chr18:27803521	chr18:27954519~27963687:+
TGCT	cis	rs9959491	0.581	rs1893947	ENSG00000227279.1	AC015933.2	4.18	5.53e-05	0.0295	0.38	0.35	Breast cancer;	chr18:27803988	chr18:27954519~27963687:+
TGCT	cis	rs9959491	0.56	rs4275930	ENSG00000227279.1	AC015933.2	4.18	5.53e-05	0.0295	0.38	0.35	Breast cancer;	chr18:27805091	chr18:27954519~27963687:+
TGCT	cis	rs9959491	0.56	rs4506992	ENSG00000227279.1	AC015933.2	4.18	5.53e-05	0.0295	0.38	0.35	Breast cancer;	chr18:27805257	chr18:27954519~27963687:+
TGCT	cis	rs9959491	0.56	rs4508491	ENSG00000227279.1	AC015933.2	4.18	5.53e-05	0.0295	0.38	0.35	Breast cancer;	chr18:27805796	chr18:27954519~27963687:+
TGCT	cis	rs875971	1	rs10215948	ENSG00000237310.1	GS1-124K5.4	-4.18	5.53e-05	0.0295	-0.39	-0.35	Aortic root size;	chr7:66282799	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.838	rs2173570	ENSG00000237310.1	GS1-124K5.4	-4.18	5.53e-05	0.0295	-0.39	-0.35	Aortic root size;	chr7:66297976	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.964	rs55748098	ENSG00000237310.1	GS1-124K5.4	-4.18	5.53e-05	0.0295	-0.39	-0.35	Aortic root size;	chr7:66298631	chr7:66493706~66495474:+
TGCT	cis	rs7208859	0.623	rs3752019	ENSG00000266490.1	CTD-2349P21.9	4.18	5.53e-05	0.0295	0.36	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs73271869	ENSG00000266490.1	CTD-2349P21.9	4.18	5.53e-05	0.0295	0.36	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs73271872	ENSG00000266490.1	CTD-2349P21.9	4.18	5.53e-05	0.0295	0.36	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs55724095	ENSG00000266490.1	CTD-2349P21.9	4.18	5.53e-05	0.0295	0.36	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs56146117	ENSG00000266490.1	CTD-2349P21.9	4.18	5.53e-05	0.0295	0.36	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30792372~30792833:+
TGCT	cis	rs17826219	0.568	rs9903854	ENSG00000266490.1	CTD-2349P21.9	4.18	5.53e-05	0.0295	0.36	0.35	Body mass index;	chr17:30826980	chr17:30792372~30792833:+
TGCT	cis	rs17826219	0.568	rs9907834	ENSG00000266490.1	CTD-2349P21.9	4.18	5.53e-05	0.0295	0.36	0.35	Body mass index;	chr17:30826995	chr17:30792372~30792833:+
TGCT	cis	rs4691139	1	rs6821283	ENSG00000236941.6	RP11-366M4.8	4.18	5.53e-05	0.0295	0.27	0.35	Ovarian cancer in BRCA1 mutation carriers;	chr4:164980493	chr4:164948079~164949438:+
TGCT	cis	rs7674212	0.531	rs10006474	ENSG00000251288.2	RP11-10L12.2	-4.18	5.54e-05	0.0295	-0.47	-0.35	Type 2 diabetes;	chr4:103006890	chr4:102751401~102752641:+
TGCT	cis	rs11673344	0.864	rs1879497	ENSG00000226686.6	LINC01535	4.18	5.54e-05	0.0295	0.41	0.35	Obesity-related traits;	chr19:37141975	chr19:37251912~37265535:+
TGCT	cis	rs11715604	1	rs11715604	ENSG00000239213.4	NCK1-AS1	-4.18	5.54e-05	0.0296	-0.46	-0.35	B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);	chr3:136870707	chr3:136841726~136862054:-
TGCT	cis	rs2015599	0.525	rs7959145	ENSG00000275476.1	RP11-996F15.4	4.18	5.54e-05	0.0296	0.37	0.35	Platelet count;Mean platelet volume;	chr12:29330850	chr12:29277397~29277882:-
TGCT	cis	rs2015599	0.525	rs7961943	ENSG00000275476.1	RP11-996F15.4	4.18	5.54e-05	0.0296	0.37	0.35	Platelet count;Mean platelet volume;	chr12:29331146	chr12:29277397~29277882:-
TGCT	cis	rs10826995	0.883	rs11813229	ENSG00000239731.3	RN7SL825P	-4.18	5.54e-05	0.0296	-0.35	-0.35	Pulse pressure;	chr10:31915853	chr10:31992087~31992381:-
TGCT	cis	rs10826995	0.961	rs11594848	ENSG00000239731.3	RN7SL825P	-4.18	5.54e-05	0.0296	-0.35	-0.35	Pulse pressure;	chr10:31919901	chr10:31992087~31992381:-
TGCT	cis	rs853356	1	rs853380	ENSG00000234261.2	RP11-146I2.1	4.18	5.55e-05	0.0296	0.34	0.35	Height;	chr6:14178667	chr6:14661829~15090003:-
TGCT	cis	rs853356	0.947	rs853382	ENSG00000234261.2	RP11-146I2.1	4.18	5.55e-05	0.0296	0.34	0.35	Height;	chr6:14179545	chr6:14661829~15090003:-
TGCT	cis	rs761746	0.577	rs2012150	ENSG00000236132.1	CTA-440B3.1	-4.18	5.56e-05	0.0296	-0.45	-0.35	Intelligence;	chr22:31820153	chr22:31816379~31817491:-
TGCT	cis	rs7819412	0.715	rs2409727	ENSG00000269918.1	AF131215.9	-4.18	5.56e-05	0.0296	-0.36	-0.35	Triglycerides;	chr8:11185727	chr8:11104691~11106704:-
TGCT	cis	rs1250248	0.536	rs1053238	ENSG00000225166.1	AC012462.2	-4.18	5.56e-05	0.0296	-0.34	-0.35	Total cholesterol levels;	chr2:215404486	chr2:215453707~215463871:+
TGCT	cis	rs12550646	0.6	rs10089948	ENSG00000253943.1	KRT18P37	-4.18	5.56e-05	0.0296	-0.39	-0.35	Reticulocyte fraction of red cells;Reticulocyte count;	chr8:41814935	chr8:41511240~41512521:+
TGCT	cis	rs11723261	0.582	rs4582104	ENSG00000275426.1	CH17-262A2.1	4.18	5.56e-05	0.0297	0.59	0.35	Immune response to smallpox vaccine (IL-6);	chr4:143160	chr4:149738~150317:+
TGCT	cis	rs13118159	0.505	rs1250128	ENSG00000254094.1	AC078852.1	4.18	5.56e-05	0.0297	0.43	0.35	Longevity;	chr4:1263523	chr4:1356581~1358075:+
TGCT	cis	rs453301	0.658	rs9650616	ENSG00000254340.1	RP11-10A14.3	-4.18	5.56e-05	0.0297	-0.38	-0.35	Joint mobility (Beighton score);	chr8:9011689	chr8:9141424~9145435:+
TGCT	cis	rs453301	0.686	rs28665409	ENSG00000254340.1	RP11-10A14.3	-4.18	5.56e-05	0.0297	-0.38	-0.35	Joint mobility (Beighton score);	chr8:9011767	chr8:9141424~9145435:+
TGCT	cis	rs875971	0.789	rs28815324	ENSG00000237310.1	GS1-124K5.4	-4.18	5.56e-05	0.0297	-0.44	-0.35	Aortic root size;	chr7:66100789	chr7:66493706~66495474:+
TGCT	cis	rs6928977	0.66	rs2614263	ENSG00000234084.1	RP3-388E23.2	4.17	5.57e-05	0.0297	0.34	0.35	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135459579	chr6:135301568~135307158:+
TGCT	cis	rs6928977	0.66	rs9373131	ENSG00000234084.1	RP3-388E23.2	4.17	5.57e-05	0.0297	0.34	0.35	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135478786	chr6:135301568~135307158:+
TGCT	cis	rs2980439	0.517	rs712253	ENSG00000173295.6	FAM86B3P	-4.17	5.57e-05	0.0297	-0.45	-0.35	Neuroticism;	chr8:8246260	chr8:8228595~8244865:+
TGCT	cis	rs2980439	0.517	rs17594065	ENSG00000173295.6	FAM86B3P	-4.17	5.57e-05	0.0297	-0.45	-0.35	Neuroticism;	chr8:8247883	chr8:8228595~8244865:+
TGCT	cis	rs10891354	0.547	rs7942468	ENSG00000176343.5	RPL37AP8	4.17	5.58e-05	0.0297	0.43	0.35	Schizophrenia;	chr11:112394629	chr11:111889199~111889474:-
TGCT	cis	rs1010254	0.764	rs1363427	ENSG00000213433.5	RPLP1P6	-4.17	5.59e-05	0.0298	-0.36	-0.35	Optic nerve measurement (cup area);	chr5:152414036	chr5:151765859~151766378:-
TGCT	cis	rs1150668	0.83	rs213240	ENSG00000204709.4	LINC01556	4.17	5.59e-05	0.0298	0.38	0.35	Pubertal anthropometrics;	chr6:28348098	chr6:28943877~28944537:+
TGCT	cis	rs8070740	0.838	rs8072363	ENSG00000262227.1	RP5-1050D4.5	-4.17	5.59e-05	0.0298	-0.31	-0.35	Menopause (age at onset);	chr17:5432432	chr17:4987706~4988446:+
TGCT	cis	rs6700559	0.545	rs12744758	ENSG00000260088.1	RP11-92G12.3	4.17	5.59e-05	0.0298	0.44	0.35	Coronary artery disease;	chr1:200624010	chr1:200669507~200694250:+
TGCT	cis	rs2439831	0.85	rs7181039	ENSG00000205771.5	CATSPER2P1	-4.17	5.59e-05	0.0298	-0.58	-0.35	Lung cancer in ever smokers;	chr15:43886914	chr15:43726918~43747094:-
TGCT	cis	rs62296447	0.514	rs4697123	ENSG00000248515.1	RP11-608O21.1	-4.17	5.59e-05	0.0298	-0.36	-0.35	Schizophrenia;	chr4:19440656	chr4:19455436~19909692:+
TGCT	cis	rs17608059	0.545	rs9944522	ENSG00000141028.6	CDRT15P1	-4.17	5.6e-05	0.0298	-0.39	-0.35	Temperament;	chr17:14015466	chr17:14024514~14025488:+
TGCT	cis	rs12745968	0.594	rs10735781	ENSG00000223787.2	RP4-593M8.1	-4.17	5.6e-05	0.0298	-0.49	-0.35	Bipolar disorder and schizophrenia;	chr1:92655550	chr1:92580476~92580821:-
TGCT	cis	rs34375054	0.525	rs10846829	ENSG00000279233.1	RP11-158L12.4	4.17	5.6e-05	0.0298	0.38	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125110512	chr12:125138245~125141711:+
TGCT	cis	rs732716	0.785	rs62130979	ENSG00000267769.1	CTB-50L17.9	-4.17	5.61e-05	0.0298	-0.41	-0.35	Mean corpuscular volume;	chr19:4432447	chr19:4454014~4455286:+
TGCT	cis	rs732716	0.819	rs12459919	ENSG00000267769.1	CTB-50L17.9	-4.17	5.61e-05	0.0298	-0.41	-0.35	Mean corpuscular volume;	chr19:4434506	chr19:4454014~4455286:+
TGCT	cis	rs172166	0.637	rs1233708	ENSG00000219891.2	ZSCAN12P1	4.17	5.61e-05	0.0299	0.4	0.35	Cardiac Troponin-T levels;	chr6:28205441	chr6:28091154~28093664:+
TGCT	cis	rs11673344	0.832	rs8104296	ENSG00000226686.6	LINC01535	4.17	5.61e-05	0.0299	0.41	0.35	Obesity-related traits;	chr19:37025634	chr19:37251912~37265535:+
TGCT	cis	rs2153535	0.58	rs2225766	ENSG00000230939.1	RP11-314C16.1	-4.17	5.61e-05	0.0299	-0.34	-0.35	Motion sickness;	chr6:8481600	chr6:8784178~8785445:+
TGCT	cis	rs12497850	1	rs1352420	ENSG00000226913.1	BSN-AS2	-4.17	5.61e-05	0.0299	-0.28	-0.35	Parkinson's disease;	chr3:48719858	chr3:49549306~49554366:-
TGCT	cis	rs9131	1	rs9131	ENSG00000249920.2	HNRNPA1P55	4.17	5.61e-05	0.0299	0.43	0.35	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr4:74097332	chr4:73938604~73939558:-
TGCT	cis	rs10759883	0.563	rs689761	ENSG00000175611.10	LINC00476	-4.17	5.62e-05	0.0299	-0.34	-0.35	Nicotine dependence;	chr9:95970902	chr9:95759231~95875977:-
TGCT	cis	rs9733	0.818	rs4970924	ENSG00000236713.1	RP11-363I22.3	4.17	5.62e-05	0.0299	0.26	0.35	Tonsillectomy;	chr1:150660603	chr1:150780272~150780644:+
TGCT	cis	rs9733	0.818	rs11204702	ENSG00000236713.1	RP11-363I22.3	4.17	5.62e-05	0.0299	0.26	0.35	Tonsillectomy;	chr1:150691031	chr1:150780272~150780644:+
TGCT	cis	rs7819412	0.521	rs4451268	ENSG00000255310.2	AF131215.2	-4.17	5.63e-05	0.0299	-0.3	-0.35	Triglycerides;	chr8:11177350	chr8:11107788~11109726:-
TGCT	cis	rs10829156	0.947	rs10764661	ENSG00000240291.1	RP11-499P20.2	4.17	5.63e-05	0.03	0.33	0.35	Sudden cardiac arrest;	chr10:18659018	chr10:18513115~18545651:-
TGCT	cis	rs6981523	0.553	rs11783045	ENSG00000269918.1	AF131215.9	-4.17	5.63e-05	0.03	-0.35	-0.35	Neuroticism;	chr8:11198666	chr8:11104691~11106704:-
TGCT	cis	rs867186	0.92	rs17092456	ENSG00000126005.14	MMP24-AS1	-4.17	5.63e-05	0.03	-0.47	-0.35	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35208389	chr20:35216462~35278131:-
TGCT	cis	rs2177312	0.868	rs6821341	ENSG00000251129.1	RP11-734I18.1	-4.17	5.64e-05	0.03	-0.43	-0.35	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31939414	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.868	rs4435785	ENSG00000251129.1	RP11-734I18.1	-4.17	5.64e-05	0.03	-0.43	-0.35	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31940998	chr4:31997397~32155406:+
TGCT	cis	rs10740039	0.583	rs2170005	ENSG00000254271.1	RP11-131N11.4	4.17	5.64e-05	0.03	0.37	0.35	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740842	chr10:60734342~60741828:+
TGCT	cis	rs9796	0.775	rs57393155	ENSG00000259838.1	TCEB1P2	4.17	5.64e-05	0.03	0.44	0.35	Menopause (age at onset);	chr15:41134053	chr15:41557027~41557435:+
TGCT	cis	rs4919669	0.668	rs17114810	ENSG00000273108.1	RP11-416N2.4	-4.17	5.65e-05	0.03	-0.5	-0.35	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102631788	chr10:103608619~103610050:+
TGCT	cis	rs4919669	0.719	rs11818043	ENSG00000273108.1	RP11-416N2.4	-4.17	5.65e-05	0.03	-0.5	-0.35	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102631870	chr10:103608619~103610050:+
TGCT	cis	rs7927592	0.673	rs10791986	ENSG00000212093.1	AP000807.1	-4.17	5.65e-05	0.03	-0.37	-0.35	Total body bone mineral density;	chr11:68642696	chr11:68506083~68506166:-
TGCT	cis	rs2708377	0.656	rs116607079	ENSG00000256019.1	TAS2R63P	-4.17	5.65e-05	0.03	-0.47	-0.35	Bitter taste perception;	chr12:11109445	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.929	rs73066828	ENSG00000256019.1	TAS2R63P	-4.17	5.65e-05	0.03	-0.47	-0.35	Bitter taste perception;	chr12:11118055	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.656	rs73066852	ENSG00000256019.1	TAS2R63P	-4.17	5.65e-05	0.03	-0.47	-0.35	Bitter taste perception;	chr12:11123942	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.858	rs117212341	ENSG00000256019.1	TAS2R63P	-4.17	5.65e-05	0.03	-0.47	-0.35	Bitter taste perception;	chr12:11129957	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.858	rs68045377	ENSG00000256019.1	TAS2R63P	-4.17	5.65e-05	0.03	-0.47	-0.35	Bitter taste perception;	chr12:11141853	chr12:11048332~11049256:-
TGCT	cis	rs2708377	0.858	rs115781584	ENSG00000256019.1	TAS2R63P	-4.17	5.65e-05	0.03	-0.47	-0.35	Bitter taste perception;	chr12:11151961	chr12:11048332~11049256:-
TGCT	cis	rs6741892	0.793	rs34391548	ENSG00000225402.1	AC010878.3	4.17	5.65e-05	0.03	0.89	0.35	5-HTT brain serotonin transporter levels;	chr2:38679344	chr2:37816915~37817961:+
TGCT	cis	rs6741892	1	rs12712612	ENSG00000225402.1	AC010878.3	4.17	5.65e-05	0.03	0.89	0.35	5-HTT brain serotonin transporter levels;	chr2:38680463	chr2:37816915~37817961:+
TGCT	cis	rs228614	0.51	rs3774987	ENSG00000230069.3	LRRC37A15P	-4.17	5.65e-05	0.03	-0.31	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799709	chr4:102727274~102730721:-
TGCT	cis	rs1075232	0.826	rs16956738	ENSG00000215302.7	CTD-3092A11.1	4.17	5.65e-05	0.03	0.63	0.35	Survival in colorectal cancer (non-distant metastatic);	chr15:31444028	chr15:30470779~30507623:+
TGCT	cis	rs4919669	0.668	rs10786700	ENSG00000273108.1	RP11-416N2.4	-4.17	5.65e-05	0.03	-0.5	-0.35	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102627978	chr10:103608619~103610050:+
TGCT	cis	rs4919669	0.623	rs2298278	ENSG00000273108.1	RP11-416N2.4	-4.17	5.65e-05	0.03	-0.5	-0.35	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102630546	chr10:103608619~103610050:+
TGCT	cis	rs667920	0.512	rs13071085	ENSG00000239213.4	NCK1-AS1	-4.17	5.65e-05	0.03	-0.44	-0.35	Coronary artery disease;	chr3:136296081	chr3:136841726~136862054:-
TGCT	cis	rs9322193	0.884	rs2064521	ENSG00000216906.2	RP11-350J20.9	-4.17	5.66e-05	0.0301	-0.46	-0.35	Lung cancer;	chr6:149625336	chr6:149904243~149906418:+
TGCT	cis	rs7005380	0.733	rs56864850	ENSG00000254343.2	RP11-760H22.2	-4.17	5.66e-05	0.0301	-0.45	-0.35	Interstitial lung disease;	chr8:119931204	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.785	rs55892034	ENSG00000254343.2	RP11-760H22.2	-4.17	5.66e-05	0.0301	-0.45	-0.35	Interstitial lung disease;	chr8:119931267	chr8:120052180~120056201:+
TGCT	cis	rs11157436	1	rs72638482	ENSG00000211813.2	TRAV34	4.17	5.66e-05	0.0301	0.38	0.35	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22153322	chr14:22207522~22208129:+
TGCT	cis	rs7688540	0.771	rs77234191	ENSG00000275426.1	CH17-262A2.1	4.17	5.67e-05	0.0301	0.71	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:264505	chr4:149738~150317:+
TGCT	cis	rs804292	0.763	rs8191514	ENSG00000255394.4	C8orf49	-4.17	5.67e-05	0.0301	-0.4	-0.35	Nicotine use;Alcohol dependence;	chr8:11769604	chr8:11761256~11763223:+
TGCT	cis	rs12745968	0.62	rs7514156	ENSG00000223787.2	RP4-593M8.1	-4.17	5.67e-05	0.0301	-0.45	-0.35	Bipolar disorder and schizophrenia;	chr1:92504652	chr1:92580476~92580821:-
TGCT	cis	rs12745968	0.532	rs4970704	ENSG00000223787.2	RP4-593M8.1	-4.17	5.67e-05	0.0301	-0.45	-0.35	Bipolar disorder and schizophrenia;	chr1:92506145	chr1:92580476~92580821:-
TGCT	cis	rs12745968	0.589	rs3903212	ENSG00000223787.2	RP4-593M8.1	-4.17	5.67e-05	0.0301	-0.45	-0.35	Bipolar disorder and schizophrenia;	chr1:92518498	chr1:92580476~92580821:-
TGCT	cis	rs12745968	0.589	rs4970707	ENSG00000223787.2	RP4-593M8.1	-4.17	5.67e-05	0.0301	-0.45	-0.35	Bipolar disorder and schizophrenia;	chr1:92520889	chr1:92580476~92580821:-
TGCT	cis	rs801193	0.569	rs13226966	ENSG00000232559.3	GS1-124K5.12	4.17	5.67e-05	0.0301	0.33	0.35	Aortic root size;	chr7:66768636	chr7:66554588~66576923:-
TGCT	cis	rs997781	0.67	rs2302134	ENSG00000267009.5	RP11-120M18.2	4.17	5.68e-05	0.0302	0.45	0.35	MGMT methylation in smokers;	chr17:69085689	chr17:68413623~68524949:+
TGCT	cis	rs9309473	1	rs3813227	ENSG00000163016.8	ALMS1P	-4.17	5.68e-05	0.0302	-0.32	-0.35	Metabolite levels;	chr2:73424839	chr2:73644919~73685576:+
TGCT	cis	rs7829975	0.811	rs7011229	ENSG00000253893.2	FAM85B	4.17	5.68e-05	0.0302	0.46	0.35	Mood instability;	chr8:8685814	chr8:8167819~8226614:-
TGCT	cis	rs72627509	0.951	rs72627508	ENSG00000269949.1	RP11-738E22.3	4.17	5.68e-05	0.0302	0.4	0.35	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56965398	chr4:56960927~56961373:-
TGCT	cis	rs7246967	0.608	rs2569725	ENSG00000269509.1	BNIP3P34	4.17	5.68e-05	0.0302	0.48	0.35	Bronchopulmonary dysplasia;	chr19:22833208	chr19:22773853~22774424:+
TGCT	cis	rs6782228	0.606	rs2811489	ENSG00000242551.2	POU5F1P6	4.17	5.68e-05	0.0302	0.43	0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128618528	chr3:128674735~128677005:-
TGCT	cis	rs6782228	0.606	rs58977394	ENSG00000242551.2	POU5F1P6	-4.17	5.68e-05	0.0302	-0.43	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619074	chr3:128674735~128677005:-
TGCT	cis	rs6782228	0.606	rs2712381	ENSG00000242551.2	POU5F1P6	-4.17	5.68e-05	0.0302	-0.43	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619757	chr3:128674735~128677005:-
TGCT	cis	rs4660214	0.666	rs2275188	ENSG00000182109.6	RP11-69E11.4	-4.17	5.68e-05	0.0302	-0.36	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39283249	chr1:39522280~39546187:-
TGCT	cis	rs4660214	0.666	rs2275186	ENSG00000182109.6	RP11-69E11.4	-4.17	5.68e-05	0.0302	-0.36	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300383	chr1:39522280~39546187:-
TGCT	cis	rs12497850	1	rs12493578	ENSG00000226913.1	BSN-AS2	4.17	5.69e-05	0.0302	0.28	0.35	Parkinson's disease;	chr3:48692683	chr3:49549306~49554366:-
TGCT	cis	rs10829156	0.732	rs10828834	ENSG00000240291.1	RP11-499P20.2	4.17	5.69e-05	0.0302	0.32	0.35	Sudden cardiac arrest;	chr10:18523505	chr10:18513115~18545651:-
TGCT	cis	rs10829156	0.732	rs7100884	ENSG00000240291.1	RP11-499P20.2	4.17	5.69e-05	0.0302	0.32	0.35	Sudden cardiac arrest;	chr10:18523768	chr10:18513115~18545651:-
TGCT	cis	rs72843506	0.586	rs75721433	ENSG00000261033.1	RP11-209D14.2	4.17	5.69e-05	0.0302	0.52	0.35	Schizophrenia;	chr17:19978747	chr17:20008051~20009234:-
TGCT	cis	rs2015599	0.549	rs7956305	ENSG00000275476.1	RP11-996F15.4	4.17	5.69e-05	0.0302	0.36	0.35	Platelet count;Mean platelet volume;	chr12:29308639	chr12:29277397~29277882:-
TGCT	cis	rs2015599	0.543	rs6487807	ENSG00000275476.1	RP11-996F15.4	4.17	5.69e-05	0.0302	0.36	0.35	Platelet count;Mean platelet volume;	chr12:29309291	chr12:29277397~29277882:-
TGCT	cis	rs8072100	0.764	rs2644349	ENSG00000228782.6	CTD-2026D20.3	-4.17	5.69e-05	0.0302	-0.42	-0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47564377	chr17:47450568~47492492:-
TGCT	cis	rs224278	0.51	rs1888967	ENSG00000238280.1	RP11-436D10.3	-4.17	5.7e-05	0.0302	-0.43	-0.35	Ewing sarcoma;	chr10:62819700	chr10:62793562~62805887:-
TGCT	cis	rs875971	1	rs2077593	ENSG00000232559.3	GS1-124K5.12	4.17	5.7e-05	0.0302	0.33	0.35	Aortic root size;	chr7:66427543	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs4717292	ENSG00000232559.3	GS1-124K5.12	4.17	5.7e-05	0.0302	0.33	0.35	Aortic root size;	chr7:66430611	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs2420591	ENSG00000232559.3	GS1-124K5.12	4.17	5.7e-05	0.0302	0.33	0.35	Aortic root size;	chr7:66447394	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.895	rs10755833	ENSG00000232559.3	GS1-124K5.12	4.17	5.7e-05	0.0302	0.33	0.35	Aortic root size;	chr7:66448930	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.964	rs12668936	ENSG00000232559.3	GS1-124K5.12	4.17	5.7e-05	0.0302	0.33	0.35	Aortic root size;	chr7:66449417	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.895	rs7788984	ENSG00000232559.3	GS1-124K5.12	4.17	5.7e-05	0.0302	0.33	0.35	Aortic root size;	chr7:66450629	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.895	rs1833495	ENSG00000232559.3	GS1-124K5.12	4.17	5.7e-05	0.0302	0.33	0.35	Aortic root size;	chr7:66456608	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.964	rs6945019	ENSG00000232559.3	GS1-124K5.12	4.17	5.7e-05	0.0302	0.33	0.35	Aortic root size;	chr7:66457471	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.964	rs6945032	ENSG00000232559.3	GS1-124K5.12	4.17	5.7e-05	0.0302	0.33	0.35	Aortic root size;	chr7:66457499	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.929	rs12673810	ENSG00000232559.3	GS1-124K5.12	4.17	5.7e-05	0.0302	0.33	0.35	Aortic root size;	chr7:66458866	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs35149210	ENSG00000232559.3	GS1-124K5.12	4.17	5.7e-05	0.0302	0.33	0.35	Aortic root size;	chr7:66464938	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.929	rs34406470	ENSG00000232559.3	GS1-124K5.12	4.17	5.7e-05	0.0302	0.33	0.35	Aortic root size;	chr7:66464969	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs6961155	ENSG00000232559.3	GS1-124K5.12	4.17	5.7e-05	0.0302	0.33	0.35	Aortic root size;	chr7:66468308	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs7789768	ENSG00000232559.3	GS1-124K5.12	4.17	5.7e-05	0.0302	0.33	0.35	Aortic root size;	chr7:66473993	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs1363055	ENSG00000232559.3	GS1-124K5.12	4.17	5.7e-05	0.0302	0.33	0.35	Aortic root size;	chr7:66478288	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.964	rs9691480	ENSG00000232559.3	GS1-124K5.12	4.17	5.7e-05	0.0302	0.33	0.35	Aortic root size;	chr7:66479319	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs7789554	ENSG00000232559.3	GS1-124K5.12	4.17	5.7e-05	0.0302	0.33	0.35	Aortic root size;	chr7:66481051	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs4717300	ENSG00000232559.3	GS1-124K5.12	4.17	5.7e-05	0.0302	0.33	0.35	Aortic root size;	chr7:66482393	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.895	rs1974769	ENSG00000232559.3	GS1-124K5.12	4.17	5.7e-05	0.0302	0.33	0.35	Aortic root size;	chr7:66485627	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.895	rs6460300	ENSG00000232559.3	GS1-124K5.12	4.17	5.7e-05	0.0302	0.33	0.35	Aortic root size;	chr7:66487937	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs7803416	ENSG00000232559.3	GS1-124K5.12	4.17	5.7e-05	0.0302	0.33	0.35	Aortic root size;	chr7:66489212	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs1981798	ENSG00000232559.3	GS1-124K5.12	4.17	5.7e-05	0.0302	0.33	0.35	Aortic root size;	chr7:66489916	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.862	rs1981799	ENSG00000232559.3	GS1-124K5.12	4.17	5.7e-05	0.0302	0.33	0.35	Aortic root size;	chr7:66490572	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.964	rs2277911	ENSG00000232559.3	GS1-124K5.12	4.17	5.7e-05	0.0302	0.33	0.35	Aortic root size;	chr7:66493638	chr7:66554588~66576923:-
TGCT	cis	rs10129255	0.536	rs10139058	ENSG00000280411.1	IGHV1-69-2	-4.17	5.7e-05	0.0302	-0.36	-0.35	Kawasaki disease;	chr14:106685899	chr14:106762092~106762588:-
TGCT	cis	rs6474412	1	rs9792277	ENSG00000255101.1	RP11-412B14.1	4.17	5.7e-05	0.0302	0.36	0.35	Smoking behavior;	chr8:42690684	chr8:42705583~42721946:-
TGCT	cis	rs6474412	1	rs1451239	ENSG00000255101.1	RP11-412B14.1	4.17	5.7e-05	0.0302	0.36	0.35	Smoking behavior;	chr8:42691399	chr8:42705583~42721946:-
TGCT	cis	rs6474412	1	rs1451240	ENSG00000255101.1	RP11-412B14.1	4.17	5.7e-05	0.0302	0.36	0.35	Smoking behavior;	chr8:42691568	chr8:42705583~42721946:-
TGCT	cis	rs6474412	1	rs4736835	ENSG00000255101.1	RP11-412B14.1	4.17	5.7e-05	0.0302	0.36	0.35	Smoking behavior;	chr8:42691890	chr8:42705583~42721946:-
TGCT	cis	rs853679	0.55	rs1150692	ENSG00000219891.2	ZSCAN12P1	4.17	5.71e-05	0.0303	0.45	0.35	Depression;	chr6:28206179	chr6:28091154~28093664:+
TGCT	cis	rs748404	0.697	rs505249	ENSG00000205771.5	CATSPER2P1	-4.17	5.71e-05	0.0303	-0.39	-0.35	Lung cancer;	chr15:43267762	chr15:43726918~43747094:-
TGCT	cis	rs875971	1	rs1167612	ENSG00000232559.3	GS1-124K5.12	-4.17	5.72e-05	0.0303	-0.33	-0.35	Aortic root size;	chr7:66102989	chr7:66554588~66576923:-
TGCT	cis	rs732716	0.785	rs56272533	ENSG00000267769.1	CTB-50L17.9	-4.17	5.72e-05	0.0303	-0.41	-0.35	Mean corpuscular volume;	chr19:4420045	chr19:4454014~4455286:+
TGCT	cis	rs9755467	0.904	rs11720209	ENSG00000221413.1	AC023593.1	4.17	5.73e-05	0.0303	0.56	0.35	Educational attainment (years of education);	chr3:127442794	chr3:127664704~127664810:+
TGCT	cis	rs9755467	0.904	rs11720236	ENSG00000221413.1	AC023593.1	4.17	5.73e-05	0.0303	0.56	0.35	Educational attainment (years of education);	chr3:127442846	chr3:127664704~127664810:+
TGCT	cis	rs9755467	0.904	rs11709100	ENSG00000221413.1	AC023593.1	4.17	5.73e-05	0.0303	0.56	0.35	Educational attainment (years of education);	chr3:127443197	chr3:127664704~127664810:+
TGCT	cis	rs7429990	0.901	rs7374482	ENSG00000229759.1	MRPS18AP1	-4.17	5.73e-05	0.0303	-0.3	-0.35	Educational attainment (years of education);	chr3:48126900	chr3:48256350~48256938:-
TGCT	cis	rs875971	0.895	rs12698520	ENSG00000232559.3	GS1-124K5.12	4.17	5.73e-05	0.0303	0.33	0.35	Aortic root size;	chr7:66453720	chr7:66554588~66576923:-
TGCT	cis	rs453301	0.624	rs2979265	ENSG00000254340.1	RP11-10A14.3	4.17	5.74e-05	0.0304	0.35	0.35	Joint mobility (Beighton score);	chr8:9001207	chr8:9141424~9145435:+
TGCT	cis	rs9309473	0.95	rs7567585	ENSG00000163016.8	ALMS1P	4.17	5.74e-05	0.0304	0.31	0.35	Metabolite levels;	chr2:73524839	chr2:73644919~73685576:+
TGCT	cis	rs7829975	0.755	rs3789849	ENSG00000254340.1	RP11-10A14.3	4.17	5.74e-05	0.0304	0.35	0.35	Mood instability;	chr8:8829544	chr8:9141424~9145435:+
TGCT	cis	rs9329221	0.651	rs2975648	ENSG00000253678.1	RP11-981G7.3	-4.17	5.74e-05	0.0304	-0.33	-0.35	Neuroticism;	chr8:10278466	chr8:10477491~10479375:-
TGCT	cis	rs2439831	0.85	rs2277531	ENSG00000205771.5	CATSPER2P1	-4.17	5.75e-05	0.0305	-0.6	-0.35	Lung cancer in ever smokers;	chr15:43776871	chr15:43726918~43747094:-
TGCT	cis	rs7396835	0.537	rs10892035	ENSG00000254851.1	RP11-109L13.1	-4.17	5.75e-05	0.0305	-0.49	-0.35	Quantitative traits;	chr11:116824222	chr11:117135528~117138582:+
TGCT	cis	rs7523273	0.564	rs1977268	ENSG00000203709.8	C1orf132	4.17	5.75e-05	0.0305	0.27	0.35	Schizophrenia;	chr1:207707691	chr1:207801518~207869150:-
TGCT	cis	rs3011225	0.697	rs3791050	ENSG00000230615.5	RP5-1198O20.4	4.17	5.75e-05	0.0305	0.45	0.35	Amyotrophic lateral sclerosis (age of onset);	chr1:43786875	chr1:44030443~44115913:+
TGCT	cis	rs7829975	0.846	rs1879957	ENSG00000173295.6	FAM86B3P	-4.17	5.76e-05	0.0305	-0.43	-0.35	Mood instability;	chr8:8687298	chr8:8228595~8244865:+
TGCT	cis	rs7824557	0.778	rs3808502	ENSG00000269918.1	AF131215.9	4.17	5.76e-05	0.0305	0.33	0.35	Retinal vascular caliber;	chr8:11321949	chr8:11104691~11106704:-
TGCT	cis	rs7976269	0.583	rs7955393	ENSG00000275476.1	RP11-996F15.4	-4.17	5.76e-05	0.0305	-0.35	-0.35	Male-pattern baldness;	chr12:29065773	chr12:29277397~29277882:-
TGCT	cis	rs6956675	0.534	rs7780975	ENSG00000227148.1	RP11-196D18.1	4.17	5.76e-05	0.0305	0.42	0.35	Obesity-related traits;	chr7:63192065	chr7:63044827~63054431:-
TGCT	cis	rs7181230	1	rs28587891	ENSG00000275636.1	RP11-521C20.5	4.17	5.76e-05	0.0305	0.4	0.35	Dehydroepiandrosterone sulphate levels;	chr15:40072905	chr15:40078892~40079347:+
TGCT	cis	rs853679	0.55	rs1225598	ENSG00000216901.1	AL022393.7	4.17	5.76e-05	0.0305	0.48	0.35	Depression;	chr6:28193021	chr6:28176188~28176674:+
TGCT	cis	rs853679	0.55	rs1150689	ENSG00000216901.1	AL022393.7	4.17	5.76e-05	0.0305	0.48	0.35	Depression;	chr6:28197321	chr6:28176188~28176674:+
TGCT	cis	rs853679	0.55	rs1225599	ENSG00000216901.1	AL022393.7	4.17	5.76e-05	0.0305	0.48	0.35	Depression;	chr6:28197412	chr6:28176188~28176674:+
TGCT	cis	rs853679	0.574	rs1233705	ENSG00000216901.1	AL022393.7	4.17	5.76e-05	0.0305	0.48	0.35	Depression;	chr6:28198669	chr6:28176188~28176674:+
TGCT	cis	rs2439831	0.85	rs9944216	ENSG00000205771.5	CATSPER2P1	4.17	5.77e-05	0.0305	0.6	0.35	Lung cancer in ever smokers;	chr15:43868575	chr15:43726918~43747094:-
TGCT	cis	rs4973397	0.765	rs13025087	ENSG00000183022.5	TPM3P8	-4.17	5.77e-05	0.0305	-0.48	-0.35	Anti-saccade response;	chr2:231400203	chr2:230573167~230573809:-
TGCT	cis	rs2944755	0.58	rs13251004	ENSG00000279766.1	RP11-642A1.2	-4.17	5.78e-05	0.0305	-0.34	-0.35	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140576027	chr8:140572142~140572812:-
TGCT	cis	rs9309473	0.898	rs6546851	ENSG00000163016.8	ALMS1P	4.17	5.78e-05	0.0306	0.32	0.35	Metabolite levels;	chr2:73606156	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.948	rs2421577	ENSG00000163016.8	ALMS1P	4.17	5.78e-05	0.0306	0.32	0.35	Metabolite levels;	chr2:73613871	chr2:73644919~73685576:+
TGCT	cis	rs853679	0.517	rs1340004	ENSG00000187763.3	OR2B7P	4.17	5.78e-05	0.0306	0.37	0.35	Depression;	chr6:28135913	chr6:28046434~28047367:+
TGCT	cis	rs7824557	0.778	rs3808502	ENSG00000255310.2	AF131215.2	4.17	5.78e-05	0.0306	0.27	0.35	Retinal vascular caliber;	chr8:11321949	chr8:11107788~11109726:-
TGCT	cis	rs9733	0.791	rs11800059	ENSG00000236713.1	RP11-363I22.3	4.16	5.79e-05	0.0306	0.26	0.35	Tonsillectomy;	chr1:150678699	chr1:150780272~150780644:+
TGCT	cis	rs9733	0.818	rs11204695	ENSG00000236713.1	RP11-363I22.3	4.16	5.79e-05	0.0306	0.26	0.35	Tonsillectomy;	chr1:150684535	chr1:150780272~150780644:+
TGCT	cis	rs34091987	0.83	rs34619180	ENSG00000256124.4	LINC01152	-4.16	5.79e-05	0.0306	-0.38	-0.35	Nose size;	chr17:72035184	chr17:72030291~72041297:+
TGCT	cis	rs8072100	0.935	rs8070759	ENSG00000228782.6	CTD-2026D20.3	-4.16	5.79e-05	0.0306	-0.42	-0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47561394	chr17:47450568~47492492:-
TGCT	cis	rs10129255	0.784	rs7147210	ENSG00000211970.3	IGHV4-61	-4.16	5.8e-05	0.0306	-0.38	-0.35	Kawasaki disease;	chr14:106705271	chr14:106639119~106639657:-
TGCT	cis	rs10129255	0.826	rs7150693	ENSG00000211970.3	IGHV4-61	-4.16	5.8e-05	0.0306	-0.38	-0.35	Kawasaki disease;	chr14:106705382	chr14:106639119~106639657:-
TGCT	cis	rs10129255	0.869	rs7150549	ENSG00000211970.3	IGHV4-61	-4.16	5.8e-05	0.0306	-0.38	-0.35	Kawasaki disease;	chr14:106705441	chr14:106639119~106639657:-
TGCT	cis	rs10129255	0.917	rs7142373	ENSG00000211970.3	IGHV4-61	-4.16	5.8e-05	0.0306	-0.38	-0.35	Kawasaki disease;	chr14:106708947	chr14:106639119~106639657:-
TGCT	cis	rs10129255	0.834	rs10139893	ENSG00000211970.3	IGHV4-61	-4.16	5.8e-05	0.0306	-0.38	-0.35	Kawasaki disease;	chr14:106711377	chr14:106639119~106639657:-
TGCT	cis	rs1010254	0.51	rs72806368	ENSG00000213433.5	RPLP1P6	-4.16	5.8e-05	0.0307	-0.43	-0.35	Optic nerve measurement (cup area);	chr5:152313181	chr5:151765859~151766378:-
TGCT	cis	rs1707322	0.963	rs4508055	ENSG00000280836.1	AL355480.1	-4.16	5.81e-05	0.0307	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr1:45581219~45581321:-
TGCT	cis	rs9952991	0.941	rs45450798	ENSG00000260302.1	RP11-973H7.1	4.16	5.81e-05	0.0307	0.55	0.35	Inflammatory skin disease;	chr18:12792941	chr18:12774651~12775923:-
TGCT	cis	rs1707322	0.963	rs34907901	ENSG00000280836.1	AL355480.1	-4.16	5.81e-05	0.0307	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45939542	chr1:45581219~45581321:-
TGCT	cis	rs73607972	0.877	rs4290466	ENSG00000275191.1	RP11-36I17.2	4.16	5.82e-05	0.0308	0.44	0.35	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53658122	chr16:53628256~53628816:-
TGCT	cis	rs797680	0.586	rs2281525	ENSG00000223745.6	RP4-717I23.3	4.16	5.82e-05	0.0308	0.29	0.35	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93129749	chr1:93262186~93346025:-
TGCT	cis	rs9487094	0.677	rs4428538	ENSG00000219700.1	PTCHD3P3	4.16	5.83e-05	0.0308	0.49	0.35	Height;	chr6:109409645	chr6:109288571~109290503:-
TGCT	cis	rs7919656	0.662	rs2928404	ENSG00000228403.1	RP11-563N6.6	-4.16	5.83e-05	0.0308	-0.37	-0.35	Clinically amyopathic dermatomyositis;	chr10:48870956	chr10:48878022~48878649:+
TGCT	cis	rs228614	0.51	rs223463	ENSG00000230069.3	LRRC37A15P	-4.16	5.83e-05	0.0308	-0.31	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780620	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs223455	ENSG00000230069.3	LRRC37A15P	-4.16	5.83e-05	0.0308	-0.31	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789026	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.556	rs223449	ENSG00000230069.3	LRRC37A15P	-4.16	5.83e-05	0.0308	-0.31	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102791180	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs223447	ENSG00000230069.3	LRRC37A15P	-4.16	5.83e-05	0.0308	-0.31	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102792202	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs223446	ENSG00000230069.3	LRRC37A15P	-4.16	5.83e-05	0.0308	-0.31	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793025	chr4:102727274~102730721:-
TGCT	cis	rs13068223	0.568	rs7636965	ENSG00000243926.1	TIPARP-AS1	4.16	5.83e-05	0.0308	0.39	0.35	Age-related hearing impairment (SNP x SNP interaction);	chr3:156700615	chr3:156671862~156674378:-
TGCT	cis	rs5758511	0.68	rs739146	ENSG00000182057.4	OGFRP1	-4.16	5.83e-05	0.0308	-0.34	-0.35	Birth weight;	chr22:42264408	chr22:42269753~42275196:+
TGCT	cis	rs904251	0.861	rs1757171	ENSG00000204110.6	RP1-153P14.8	-4.16	5.84e-05	0.0308	-0.41	-0.35	Cognitive performance;	chr6:37519268	chr6:37507348~37535616:+
TGCT	cis	rs13118159	0.899	rs3796613	ENSG00000253399.1	AC078852.2	-4.16	5.85e-05	0.0309	-0.42	-0.35	Longevity;	chr4:1359533	chr4:1358479~1359461:+
TGCT	cis	rs7829975	0.846	rs6601724	ENSG00000253893.2	FAM85B	4.16	5.85e-05	0.0309	0.45	0.35	Mood instability;	chr8:8687362	chr8:8167819~8226614:-
TGCT	cis	rs2005	0.582	rs3800404	ENSG00000186328.4	RP11-140K17.2	-4.16	5.85e-05	0.0309	-0.5	-0.35	Obesity-related traits;	chr6:35170093	chr6:34715613~34715940:+
TGCT	cis	rs877819	0.697	rs6537581	ENSG00000228403.1	RP11-563N6.6	-4.16	5.86e-05	0.0309	-0.38	-0.35	Systemic lupus erythematosus;	chr10:48838075	chr10:48878022~48878649:+
TGCT	cis	rs877819	0.697	rs7101184	ENSG00000228403.1	RP11-563N6.6	-4.16	5.86e-05	0.0309	-0.38	-0.35	Systemic lupus erythematosus;	chr10:48838278	chr10:48878022~48878649:+
TGCT	cis	rs877819	0.697	rs7074067	ENSG00000228403.1	RP11-563N6.6	-4.16	5.86e-05	0.0309	-0.38	-0.35	Systemic lupus erythematosus;	chr10:48838279	chr10:48878022~48878649:+
TGCT	cis	rs877819	0.697	rs6537582	ENSG00000228403.1	RP11-563N6.6	-4.16	5.86e-05	0.0309	-0.38	-0.35	Systemic lupus erythematosus;	chr10:48838600	chr10:48878022~48878649:+
TGCT	cis	rs877819	0.697	rs10776650	ENSG00000228403.1	RP11-563N6.6	-4.16	5.86e-05	0.0309	-0.38	-0.35	Systemic lupus erythematosus;	chr10:48839229	chr10:48878022~48878649:+
TGCT	cis	rs10504229	0.683	rs16921829	ENSG00000253301.4	RP11-513O17.2	4.16	5.86e-05	0.0309	0.52	0.35	Developmental language disorder (linguistic errors);	chr8:57198391	chr8:57142689~57240298:+
TGCT	cis	rs11779860	0.656	rs7818662	ENSG00000245970.2	KB-1208A12.3	-4.16	5.86e-05	0.0309	-0.37	-0.35	QT interval;	chr8:97815408	chr8:98041726~98044121:+
TGCT	cis	rs10938353	0.731	rs17600700	ENSG00000273369.1	RP11-700J17.1	4.16	5.86e-05	0.0309	0.58	0.35	Body mass index;	chr4:44613435	chr4:44693946~44694386:-
TGCT	cis	rs1061377	0.621	rs11096974	ENSG00000249207.1	RP11-360F5.1	-4.16	5.87e-05	0.0309	-0.37	-0.35	Uric acid levels;	chr4:39062039	chr4:39112677~39126818:-
TGCT	cis	rs4760786	0.607	rs1796330	ENSG00000257454.1	CTD-2021H9.2	4.16	5.87e-05	0.031	0.41	0.35	Monobrow;	chr12:71129173	chr12:71034122~71104526:-
TGCT	cis	rs6474412	1	rs13273442	ENSG00000255101.1	RP11-412B14.1	4.16	5.87e-05	0.031	0.36	0.35	Smoking behavior;	chr8:42688874	chr8:42705583~42721946:-
TGCT	cis	rs6474412	0.957	rs13254578	ENSG00000255101.1	RP11-412B14.1	4.16	5.87e-05	0.031	0.36	0.35	Smoking behavior;	chr8:42690703	chr8:42705583~42721946:-
TGCT	cis	rs853679	0.55	rs1233701	ENSG00000216901.1	AL022393.7	-4.16	5.87e-05	0.031	-0.46	-0.35	Depression;	chr6:28200948	chr6:28176188~28176674:+
TGCT	cis	rs73086581	0.891	rs73084555	ENSG00000229539.1	RP11-119B16.2	4.16	5.87e-05	0.031	0.57	0.35	Response to antidepressants in depression;	chr20:3913153	chr20:3888239~3888868:-
TGCT	cis	rs66823261	0.778	rs2906332	ENSG00000253166.2	RP11-585F1.6	-4.16	5.87e-05	0.031	-0.48	-0.35	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:244943	chr8:202660~202897:-
TGCT	cis	rs732716	0.785	rs55660045	ENSG00000267769.1	CTB-50L17.9	-4.16	5.87e-05	0.031	-0.41	-0.35	Mean corpuscular volume;	chr19:4425308	chr19:4454014~4455286:+
TGCT	cis	rs1061377	0.76	rs7678457	ENSG00000249685.1	RP11-360F5.3	4.16	5.88e-05	0.031	0.33	0.35	Uric acid levels;	chr4:39136041	chr4:39133913~39135608:+
TGCT	cis	rs7208859	0.673	rs3764420	ENSG00000266490.1	CTD-2349P21.9	4.16	5.89e-05	0.031	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30792372~30792833:+
TGCT	cis	rs1497406	0.744	rs7538966	ENSG00000235084.3	CHCHD2P6	4.16	5.89e-05	0.031	0.41	0.35	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);	chr1:16178054	chr1:15604597~15605043:+
TGCT	cis	rs11671005	0.779	rs731259	ENSG00000268912.1	CTD-2619J13.17	-4.16	5.89e-05	0.0311	-0.48	-0.35	Mean platelet volume;	chr19:58478057	chr19:58428632~58431148:-
TGCT	cis	rs6700559	0.565	rs12728040	ENSG00000260088.1	RP11-92G12.3	4.16	5.89e-05	0.0311	0.44	0.35	Coronary artery disease;	chr1:200626751	chr1:200669507~200694250:+
TGCT	cis	rs11651753	0.636	rs12602494	ENSG00000264920.1	RP11-6N17.4	-4.16	5.9e-05	0.0311	-0.34	-0.35	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47960241	chr17:47891255~47895812:-
TGCT	cis	rs8059260	0.935	rs7203687	ENSG00000274038.1	RP11-66H6.4	-4.16	5.9e-05	0.0311	-0.38	-0.35	Alcohol consumption over the past year;	chr16:11013063	chr16:11056556~11057034:+
TGCT	cis	rs4242434	0.672	rs2404654	ENSG00000253200.1	RP11-582J16.5	4.16	5.91e-05	0.0311	0.19	0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22627436	chr8:22613908~22616657:-
TGCT	cis	rs1850744	0.826	rs7661082	ENSG00000251624.1	UNC93B7	4.16	5.91e-05	0.0311	0.72	0.35	Economic and political preferences;	chr4:9754041	chr4:9493736~9498066:+
TGCT	cis	rs7795991	0.5	rs34863470	ENSG00000224330.1	AC005019.3	-4.16	5.92e-05	0.0312	-0.39	-0.35	Type 2 diabetes;	chr7:13848006	chr7:13854355~13859025:-
TGCT	cis	rs7208859	0.614	rs216474	ENSG00000263531.1	RP13-753N3.1	-4.16	5.92e-05	0.0312	-0.61	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30538073	chr17:30863921~30864940:-
TGCT	cis	rs1250259	0.542	rs13306359	ENSG00000225166.1	AC012462.2	-4.16	5.93e-05	0.0312	-0.34	-0.35	Coronary artery disease;Pulse pressure;	chr2:215404372	chr2:215453707~215463871:+
TGCT	cis	rs1250259	0.542	rs7589580	ENSG00000225166.1	AC012462.2	-4.16	5.93e-05	0.0312	-0.34	-0.35	Coronary artery disease;Pulse pressure;	chr2:215404531	chr2:215453707~215463871:+
TGCT	cis	rs12549025	0.729	rs11784090	ENSG00000253390.1	CTC-756D1.2	-4.16	5.93e-05	0.0312	-0.43	-0.35	Reticulocyte fraction of red cells;	chr8:23519648	chr8:23458601~23484971:+
TGCT	cis	rs7824557	0.547	rs2409745	ENSG00000269918.1	AF131215.9	4.16	5.93e-05	0.0312	0.35	0.35	Retinal vascular caliber;	chr8:11219126	chr8:11104691~11106704:-
TGCT	cis	rs4238585	0.947	rs8045740	ENSG00000261195.1	CTD-2380F24.1	-4.16	5.94e-05	0.0312	-0.54	-0.35	Body mass index;	chr16:20251454	chr16:19761172~19766099:-
TGCT	cis	rs889312	0.532	rs16886181	ENSG00000271828.1	CTD-2310F14.1	4.16	5.94e-05	0.0313	0.47	0.35	Breast cancer (early onset);Breast cancer;	chr5:56733416	chr5:56927874~56929573:+
TGCT	cis	rs957448	1	rs28817653	ENSG00000253175.1	RP11-267M23.6	4.16	5.94e-05	0.0313	0.45	0.35	Nonsyndromic cleft lip with cleft palate;	chr8:94557822	chr8:94565036~94565715:+
TGCT	cis	rs2708377	0.789	rs3911150	ENSG00000256019.1	TAS2R63P	4.16	5.95e-05	0.0313	0.46	0.35	Bitter taste perception;	chr12:11049649	chr12:11048332~11049256:-
TGCT	cis	rs732716	0.785	rs9973266	ENSG00000267769.1	CTB-50L17.9	-4.16	5.96e-05	0.0313	-0.41	-0.35	Mean corpuscular volume;	chr19:4392718	chr19:4454014~4455286:+
TGCT	cis	rs116095464	0.558	rs12173015	ENSG00000250848.1	CTD-2083E4.5	4.16	5.96e-05	0.0313	0.38	0.35	Breast cancer;	chr5:269852	chr5:288833~290321:-
TGCT	cis	rs755249	0.501	rs4660669	ENSG00000182109.6	RP11-69E11.4	-4.16	5.96e-05	0.0314	-0.36	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39341786	chr1:39522280~39546187:-
TGCT	cis	rs8141529	0.753	rs5752813	ENSG00000226471.5	CTA-292E10.6	-4.16	5.97e-05	0.0314	-0.37	-0.35	Lymphocyte counts;	chr22:28830582	chr22:28800683~28848559:+
TGCT	cis	rs4242434	0.672	rs10099266	ENSG00000253200.1	RP11-582J16.5	4.16	5.97e-05	0.0314	0.19	0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22626755	chr8:22613908~22616657:-
TGCT	cis	rs4242434	0.672	rs10110443	ENSG00000253200.1	RP11-582J16.5	4.16	5.97e-05	0.0314	0.19	0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22626783	chr8:22613908~22616657:-
TGCT	cis	rs34217772	0.513	rs10872958	ENSG00000258536.1	RP11-1053O12.1	-4.16	5.97e-05	0.0314	-0.28	-0.35	Myopia;	chr14:41870258	chr14:41742639~41742963:+
TGCT	cis	rs3931020	0.626	rs277402	ENSG00000272864.1	RP11-17E13.2	4.16	5.97e-05	0.0314	0.42	0.35	Resistin levels;	chr1:74722637	chr1:74698769~74699333:-
TGCT	cis	rs7729723	0.869	rs10793824	ENSG00000250159.5	RP11-381K20.2	-4.16	5.97e-05	0.0314	-0.38	-0.35	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);	chr5:138489144	chr5:137814333~137889336:-
TGCT	cis	rs62025270	1	rs62025270	ENSG00000259416.2	RP11-158M2.5	-4.16	5.97e-05	0.0314	-0.42	-0.35	Idiopathic pulmonary fibrosis;	chr15:85756967	chr15:85754941~85756237:-
TGCT	cis	rs11779860	0.708	rs7014909	ENSG00000245970.2	KB-1208A12.3	-4.16	5.98e-05	0.0314	-0.39	-0.35	QT interval;	chr8:97837699	chr8:98041726~98044121:+
TGCT	cis	rs77204473	0.549	rs12280210	ENSG00000254851.1	RP11-109L13.1	4.16	5.98e-05	0.0314	0.69	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069733	chr11:117135528~117138582:+
TGCT	cis	rs4691139	0.658	rs4691142	ENSG00000250227.1	TRIM60P14	4.16	5.99e-05	0.0314	0.38	0.35	Ovarian cancer in BRCA1 mutation carriers;	chr4:165005634	chr4:164915565~164916983:+
TGCT	cis	rs4718428	1	rs4718428	ENSG00000272831.1	RP11-792A8.4	4.16	5.99e-05	0.0314	0.4	0.35	Corneal structure;	chr7:66956459	chr7:66739829~66740385:-
TGCT	cis	rs884366	1	rs4946955	ENSG00000243587.6	C6orf183	-4.16	5.99e-05	0.0314	-0.36	-0.35	HDL cholesterol;HDL cholesterol levels;	chr6:109318507	chr6:109165833~109271014:+
TGCT	cis	rs10129255	0.5	rs10143242	ENSG00000223648.3	IGHV3-64	4.16	5.99e-05	0.0314	0.29	0.35	Kawasaki disease;	chr14:106681814	chr14:106643132~106658258:-
TGCT	cis	rs528418	1	rs480259	ENSG00000270638.1	RP3-466P17.1	4.16	5.99e-05	0.0314	0.39	0.35	Methadone dose in opioid dependence;	chr6:145268927	chr6:145735570~145737218:+
TGCT	cis	rs9733	0.744	rs11204725	ENSG00000236713.1	RP11-363I22.3	4.16	5.99e-05	0.0314	0.26	0.35	Tonsillectomy;	chr1:150770224	chr1:150780272~150780644:+
TGCT	cis	rs9733	0.744	rs12125650	ENSG00000236713.1	RP11-363I22.3	4.16	5.99e-05	0.0314	0.26	0.35	Tonsillectomy;	chr1:150787698	chr1:150780272~150780644:+
TGCT	cis	rs9733	0.688	rs12725667	ENSG00000236713.1	RP11-363I22.3	4.16	5.99e-05	0.0314	0.26	0.35	Tonsillectomy;	chr1:150793594	chr1:150780272~150780644:+
TGCT	cis	rs2709736	0.935	rs6965781	ENSG00000232790.2	LINC01162	-4.16	6e-05	0.0315	-0.25	-0.35	Bipolar I disorder;	chr7:20823369	chr7:20835431~21023148:+
TGCT	cis	rs10759883	0.627	rs690528	ENSG00000175611.10	LINC00476	4.16	6.01e-05	0.0315	0.31	0.35	Nicotine dependence;	chr9:95876006	chr9:95759231~95875977:-
TGCT	cis	rs10759883	0.627	rs689697	ENSG00000175611.10	LINC00476	4.16	6.01e-05	0.0315	0.31	0.35	Nicotine dependence;	chr9:95876560	chr9:95759231~95875977:-
TGCT	cis	rs875971	0.522	rs1617484	ENSG00000237310.1	GS1-124K5.4	4.16	6.01e-05	0.0315	0.39	0.35	Aortic root size;	chr7:65998108	chr7:66493706~66495474:+
TGCT	cis	rs911555	0.713	rs1107070	ENSG00000244691.1	RPL10AP1	4.16	6.01e-05	0.0315	0.47	0.35	Intelligence (multi-trait analysis);	chr14:103504171	chr14:103412119~103412761:-
TGCT	cis	rs9326248	0.813	rs4938350	ENSG00000280143.1	AP000892.6	4.16	6.01e-05	0.0315	0.51	0.35	Blood protein levels;	chr11:117151560	chr11:117204967~117210292:+
TGCT	cis	rs7684253	0.55	rs4566710	ENSG00000269949.1	RP11-738E22.3	-4.15	6.01e-05	0.0315	-0.35	-0.35	Migraine;	chr4:56879297	chr4:56960927~56961373:-
TGCT	cis	rs62388641	0.547	rs2317966	ENSG00000272279.1	RP11-157J24.2	-4.15	6.02e-05	0.0316	-0.35	-0.35	Daytime sleep phenotypes;	chr6:1550651	chr6:1528364~1528911:-
TGCT	cis	rs12922040	0.701	rs12149912	ENSG00000263335.1	AF001548.5	-4.15	6.03e-05	0.0316	-0.44	-0.35	Serum uric acid levels in response to allopurinol in gout;	chr16:15774798	chr16:15726674~15732993:+
TGCT	cis	rs228614	0.51	rs223434	ENSG00000230069.3	LRRC37A15P	-4.15	6.03e-05	0.0316	-0.31	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799902	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.536	rs223418	ENSG00000230069.3	LRRC37A15P	-4.15	6.03e-05	0.0316	-0.31	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102809336	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs223415	ENSG00000230069.3	LRRC37A15P	-4.15	6.03e-05	0.0316	-0.31	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102811016	chr4:102727274~102730721:-
TGCT	cis	rs17826219	0.706	rs9905827	ENSG00000266490.1	CTD-2349P21.9	4.15	6.03e-05	0.0316	0.37	0.35	Body mass index;	chr17:30865150	chr17:30792372~30792833:+
TGCT	cis	rs7937890	0.904	rs7484197	ENSG00000254418.1	RP11-21L19.1	4.15	6.03e-05	0.0316	0.32	0.35	Mitochondrial DNA levels;	chr11:14262108	chr11:14262846~14273691:-
TGCT	cis	rs1010254	0.959	rs67575700	ENSG00000213433.5	RPLP1P6	-4.15	6.03e-05	0.0316	-0.36	-0.35	Optic nerve measurement (cup area);	chr5:152315464	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.879	rs66579862	ENSG00000213433.5	RPLP1P6	-4.15	6.03e-05	0.0316	-0.36	-0.35	Optic nerve measurement (cup area);	chr5:152319054	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.959	rs7722129	ENSG00000213433.5	RPLP1P6	-4.15	6.03e-05	0.0316	-0.36	-0.35	Optic nerve measurement (cup area);	chr5:152319904	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.797	rs28625684	ENSG00000213433.5	RPLP1P6	-4.15	6.03e-05	0.0316	-0.36	-0.35	Optic nerve measurement (cup area);	chr5:152322293	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.959	rs67427655	ENSG00000213433.5	RPLP1P6	-4.15	6.03e-05	0.0316	-0.36	-0.35	Optic nerve measurement (cup area);	chr5:152323077	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.959	rs7737302	ENSG00000213433.5	RPLP1P6	-4.15	6.03e-05	0.0316	-0.36	-0.35	Optic nerve measurement (cup area);	chr5:152328458	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.959	rs7704063	ENSG00000213433.5	RPLP1P6	-4.15	6.03e-05	0.0316	-0.36	-0.35	Optic nerve measurement (cup area);	chr5:152329074	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.959	rs1035400	ENSG00000213433.5	RPLP1P6	-4.15	6.03e-05	0.0316	-0.36	-0.35	Optic nerve measurement (cup area);	chr5:152330339	chr5:151765859~151766378:-
TGCT	cis	rs1010254	1	rs17113138	ENSG00000213433.5	RPLP1P6	-4.15	6.03e-05	0.0316	-0.36	-0.35	Optic nerve measurement (cup area);	chr5:152351716	chr5:151765859~151766378:-
TGCT	cis	rs7829975	0.806	rs2428	ENSG00000253893.2	FAM85B	-4.15	6.03e-05	0.0316	-0.47	-0.35	Mood instability;	chr8:8783635	chr8:8167819~8226614:-
TGCT	cis	rs111315781	1	rs111315781	ENSG00000183308.6	AC005037.3	4.15	6.03e-05	0.0316	0.58	0.35	Triptolide cytotoxicity;	chr2:200874001	chr2:200963263~201009102:+
TGCT	cis	rs7919656	0.662	rs2663069	ENSG00000228403.1	RP11-563N6.6	-4.15	6.03e-05	0.0316	-0.37	-0.35	Clinically amyopathic dermatomyositis;	chr10:48873077	chr10:48878022~48878649:+
TGCT	cis	rs4268898	0.735	rs12469585	ENSG00000223754.1	AC008073.9	-4.15	6.04e-05	0.0316	-0.37	-0.35	Asthma;	chr2:24266185	chr2:24199839~24201698:-
TGCT	cis	rs7824557	0.675	rs2736265	ENSG00000255020.1	AF131216.5	4.15	6.04e-05	0.0317	0.24	0.35	Retinal vascular caliber;	chr8:11329165	chr8:11345748~11347502:-
TGCT	cis	rs6005807	0.777	rs12168708	ENSG00000272858.1	CTA-292E10.8	-4.15	6.05e-05	0.0317	-0.53	-0.35	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28344774	chr22:28814914~28815662:+
TGCT	cis	rs7829975	0.774	rs11775523	ENSG00000254340.1	RP11-10A14.3	4.15	6.05e-05	0.0317	0.35	0.35	Mood instability;	chr8:8821666	chr8:9141424~9145435:+
TGCT	cis	rs7829975	0.774	rs1039915	ENSG00000254340.1	RP11-10A14.3	4.15	6.05e-05	0.0317	0.35	0.35	Mood instability;	chr8:8822104	chr8:9141424~9145435:+
TGCT	cis	rs7829975	0.774	rs57312668	ENSG00000254340.1	RP11-10A14.3	4.15	6.05e-05	0.0317	0.35	0.35	Mood instability;	chr8:8822967	chr8:9141424~9145435:+
TGCT	cis	rs1250259	0.519	rs34255697	ENSG00000225166.1	AC012462.2	-4.15	6.06e-05	0.0317	-0.34	-0.35	Coronary artery disease;Pulse pressure;	chr2:215401502	chr2:215453707~215463871:+
TGCT	cis	rs4835473	0.591	rs6822129	ENSG00000251600.4	RP11-673E1.1	-4.15	6.06e-05	0.0317	-0.38	-0.35	Immature fraction of reticulocytes;	chr4:144058755	chr4:143912331~143982454:+
TGCT	cis	rs10129255	0.5	rs2105991	ENSG00000223648.3	IGHV3-64	4.15	6.06e-05	0.0317	0.3	0.35	Kawasaki disease;	chr14:106682022	chr14:106643132~106658258:-
TGCT	cis	rs4718428	1	rs1830070	ENSG00000272831.1	RP11-792A8.4	4.15	6.06e-05	0.0317	0.4	0.35	Corneal structure;	chr7:66884684	chr7:66739829~66740385:-
TGCT	cis	rs67311347	0.866	rs2371183	ENSG00000223797.4	ENTPD3-AS1	-4.15	6.06e-05	0.0317	-0.36	-0.35	Renal cell carcinoma;	chr3:40292756	chr3:40313802~40453329:-
TGCT	cis	rs748404	0.589	rs62020616	ENSG00000205771.5	CATSPER2P1	-4.15	6.06e-05	0.0317	-0.51	-0.35	Lung cancer;	chr15:43558554	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.626	rs60367691	ENSG00000205771.5	CATSPER2P1	-4.15	6.06e-05	0.0317	-0.51	-0.35	Lung cancer;	chr15:43559201	chr15:43726918~43747094:-
TGCT	cis	rs2505998	0.833	rs1864403	ENSG00000273008.1	RP11-351D16.3	4.15	6.07e-05	0.0317	0.4	0.35	Hirschsprung disease;	chr10:43109502	chr10:43136824~43138334:-
TGCT	cis	rs13108904	0.934	rs35201724	ENSG00000253399.1	AC078852.2	-4.15	6.07e-05	0.0317	-0.41	-0.35	Obesity-related traits;	chr4:1316929	chr4:1358479~1359461:+
TGCT	cis	rs875971	0.545	rs316328	ENSG00000222364.1	RNU6-96P	4.15	6.07e-05	0.0317	0.41	0.35	Aortic root size;	chr7:66143851	chr7:66395191~66395286:+
TGCT	cis	rs228614	0.51	rs223452	ENSG00000230069.3	LRRC37A15P	-4.15	6.07e-05	0.0317	-0.31	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102790277	chr4:102727274~102730721:-
TGCT	cis	rs4238585	1	rs6497451	ENSG00000261195.1	CTD-2380F24.1	-4.15	6.07e-05	0.0317	-0.54	-0.35	Body mass index;	chr16:20237144	chr16:19761172~19766099:-
TGCT	cis	rs2833693	0.615	rs9974274	ENSG00000261610.1	AP000265.1	4.15	6.08e-05	0.0317	0.42	0.35	Temperament;	chr21:32196563	chr21:32259804~32261585:-
TGCT	cis	rs2153535	0.58	rs6920779	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8437391	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs7743418	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8437895	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs4960411	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8437998	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs4960412	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8438028	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs4960413	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8438233	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.601	rs4960414	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8438308	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.542	rs9393012	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8439576	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.542	rs6912740	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8439726	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.542	rs6905925	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8439797	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.541	rs6905934	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8439810	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs2327050	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8440397	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs4404802	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8441819	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs5001130	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8442065	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1932275	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8442100	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1932276	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8442360	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs915352	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8442533	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs915351	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8442560	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.541	rs945304	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8442659	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs2327053	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8442894	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.601	rs2327054	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8442897	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.623	rs2327055	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8442912	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs2327056	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8443072	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs2327057	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8443086	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs3938660	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8443102	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1889715	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8443242	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1577466	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8443959	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1577467	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8444008	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1577468	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8444033	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.601	rs1855765	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8444092	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9406143	ENSG00000230939.1	RP11-314C16.1	-4.15	6.08e-05	0.0317	-0.34	-0.35	Motion sickness;	chr6:8444350	chr6:8784178~8785445:+
TGCT	cis	rs1250259	0.519	rs6435906	ENSG00000225166.1	AC012462.2	-4.15	6.08e-05	0.0317	-0.34	-0.35	Coronary artery disease;Pulse pressure;	chr2:215404917	chr2:215453707~215463871:+
TGCT	cis	rs9322193	0.566	rs6912330	ENSG00000216906.2	RP11-350J20.9	-4.15	6.08e-05	0.0317	-0.45	-0.35	Lung cancer;	chr6:149908811	chr6:149904243~149906418:+
TGCT	cis	rs7523273	0.564	rs1570565	ENSG00000203709.8	C1orf132	4.15	6.08e-05	0.0317	0.27	0.35	Schizophrenia;	chr1:207707911	chr1:207801518~207869150:-
TGCT	cis	rs7523273	0.505	rs35438924	ENSG00000203709.8	C1orf132	4.15	6.08e-05	0.0317	0.27	0.35	Schizophrenia;	chr1:207708144	chr1:207801518~207869150:-
TGCT	cis	rs7523273	0.505	rs34277355	ENSG00000203709.8	C1orf132	4.15	6.08e-05	0.0317	0.27	0.35	Schizophrenia;	chr1:207708146	chr1:207801518~207869150:-
TGCT	cis	rs7523273	0.564	rs7543097	ENSG00000203709.8	C1orf132	4.15	6.08e-05	0.0317	0.27	0.35	Schizophrenia;	chr1:207709247	chr1:207801518~207869150:-
TGCT	cis	rs6700559	0.692	rs12126676	ENSG00000260088.1	RP11-92G12.3	4.15	6.08e-05	0.0317	0.45	0.35	Coronary artery disease;	chr1:200631692	chr1:200669507~200694250:+
TGCT	cis	rs8141529	0.719	rs6005916	ENSG00000226471.5	CTA-292E10.6	-4.15	6.08e-05	0.0317	-0.37	-0.35	Lymphocyte counts;	chr22:28837354	chr22:28800683~28848559:+
TGCT	cis	rs853356	1	rs853350	ENSG00000234261.2	RP11-146I2.1	4.15	6.08e-05	0.0317	0.33	0.35	Height;	chr6:14168749	chr6:14661829~15090003:-
TGCT	cis	rs853356	1	rs853352	ENSG00000234261.2	RP11-146I2.1	4.15	6.08e-05	0.0317	0.33	0.35	Height;	chr6:14169485	chr6:14661829~15090003:-
TGCT	cis	rs2739330	0.828	rs5751770	ENSG00000250470.1	AP000351.3	4.15	6.08e-05	0.0317	0.36	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23976904~23977585:-
TGCT	cis	rs891378	0.785	rs10158940	ENSG00000274245.1	RP11-357P18.2	-4.15	6.09e-05	0.0318	-0.44	-0.35	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207191575	chr1:207372559~207373252:+
TGCT	cis	rs891378	0.755	rs10157327	ENSG00000274245.1	RP11-357P18.2	-4.15	6.09e-05	0.0318	-0.44	-0.35	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207191756	chr1:207372559~207373252:+
TGCT	cis	rs2153535	0.563	rs1796688	ENSG00000230939.1	RP11-314C16.1	-4.15	6.09e-05	0.0318	-0.35	-0.35	Motion sickness;	chr6:8536190	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.526	rs1796689	ENSG00000230939.1	RP11-314C16.1	-4.15	6.09e-05	0.0318	-0.35	-0.35	Motion sickness;	chr6:8536200	chr6:8784178~8785445:+
TGCT	cis	rs2019137	0.539	rs4849181	ENSG00000274877.1	RP11-65I12.1	-4.15	6.1e-05	0.0318	-0.35	-0.35	Lymphocyte counts;	chr2:113234393	chr2:113237595~113240825:+
TGCT	cis	rs11673344	0.764	rs10424584	ENSG00000226686.6	LINC01535	4.15	6.1e-05	0.0318	0.4	0.35	Obesity-related traits;	chr19:36975986	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.764	rs10403679	ENSG00000226686.6	LINC01535	4.15	6.1e-05	0.0318	0.4	0.35	Obesity-related traits;	chr19:36980810	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.764	rs13345491	ENSG00000226686.6	LINC01535	4.15	6.1e-05	0.0318	0.4	0.35	Obesity-related traits;	chr19:36982197	chr19:37251912~37265535:+
TGCT	cis	rs786425	0.866	rs7139193	ENSG00000278112.1	RP11-972P1.11	4.15	6.11e-05	0.0319	0.4	0.35	Pubertal anthropometrics;	chr12:123686629	chr12:123519390~123519856:-
TGCT	cis	rs10129255	0.53	rs11624912	ENSG00000223648.3	IGHV3-64	4.15	6.12e-05	0.0319	0.29	0.35	Kawasaki disease;	chr14:106673891	chr14:106643132~106658258:-
TGCT	cis	rs4273100	0.688	rs4924967	ENSG00000262319.1	CTC-457L16.2	-4.15	6.12e-05	0.0319	-0.46	-0.35	Schizophrenia;	chr17:19268883	chr17:19141017~19143689:-
TGCT	cis	rs4273100	0.688	rs28760541	ENSG00000262319.1	CTC-457L16.2	-4.15	6.12e-05	0.0319	-0.46	-0.35	Schizophrenia;	chr17:19269192	chr17:19141017~19143689:-
TGCT	cis	rs4273100	0.605	rs28591622	ENSG00000262319.1	CTC-457L16.2	-4.15	6.12e-05	0.0319	-0.46	-0.35	Schizophrenia;	chr17:19272004	chr17:19141017~19143689:-
TGCT	cis	rs62012628	0.527	rs12437868	ENSG00000261143.1	ADAMTS7P3	-4.15	6.12e-05	0.0319	-0.34	-0.35	Diastolic blood pressure;	chr15:78796118	chr15:77976042~77993057:+
TGCT	cis	rs7923609	0.871	rs12245149	ENSG00000232075.1	MRPL35P2	4.15	6.13e-05	0.0319	0.34	0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63561387	chr10:63634317~63634827:-
TGCT	cis	rs17711722	0.523	rs365896	ENSG00000237310.1	GS1-124K5.4	-4.15	6.13e-05	0.0319	-0.37	-0.35	Calcium levels;	chr7:66045710	chr7:66493706~66495474:+
TGCT	cis	rs10129255	1	rs9324091	ENSG00000211970.3	IGHV4-61	-4.15	6.13e-05	0.032	-0.37	-0.35	Kawasaki disease;	chr14:106676625	chr14:106639119~106639657:-
TGCT	cis	rs10129255	1	rs61997605	ENSG00000211970.3	IGHV4-61	-4.15	6.13e-05	0.032	-0.37	-0.35	Kawasaki disease;	chr14:106678368	chr14:106639119~106639657:-
TGCT	cis	rs10129255	1	rs8012033	ENSG00000211970.3	IGHV4-61	-4.15	6.13e-05	0.032	-0.37	-0.35	Kawasaki disease;	chr14:106678854	chr14:106639119~106639657:-
TGCT	cis	rs10129255	0.912	rs8011090	ENSG00000211970.3	IGHV4-61	-4.15	6.13e-05	0.032	-0.37	-0.35	Kawasaki disease;	chr14:106678896	chr14:106639119~106639657:-
TGCT	cis	rs10129255	0.912	rs67410411	ENSG00000211970.3	IGHV4-61	-4.15	6.13e-05	0.032	-0.37	-0.35	Kawasaki disease;	chr14:106680324	chr14:106639119~106639657:-
TGCT	cis	rs494459	0.838	rs2510897	ENSG00000255422.1	AP002954.4	-4.15	6.13e-05	0.032	-0.37	-0.35	Height;	chr11:118773873	chr11:118704607~118750263:+
TGCT	cis	rs7189233	0.531	rs4281707	ENSG00000279344.1	RP11-44F14.7	4.15	6.14e-05	0.032	0.38	0.35	Intelligence (multi-trait analysis);	chr16:53468034	chr16:53478957~53481550:-
TGCT	cis	rs2280018	0.526	rs2941257	ENSG00000260735.1	RP11-72I8.1	-4.15	6.14e-05	0.032	-0.45	-0.35	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15094411~15109197:+
TGCT	cis	rs8141529	0.719	rs5762825	ENSG00000226471.5	CTA-292E10.6	-4.15	6.15e-05	0.032	-0.37	-0.35	Lymphocyte counts;	chr22:28827654	chr22:28800683~28848559:+
TGCT	cis	rs8141529	0.764	rs5752809	ENSG00000226471.5	CTA-292E10.6	-4.15	6.15e-05	0.032	-0.37	-0.35	Lymphocyte counts;	chr22:28829512	chr22:28800683~28848559:+
TGCT	cis	rs8141529	0.764	rs5752812	ENSG00000226471.5	CTA-292E10.6	-4.15	6.15e-05	0.032	-0.37	-0.35	Lymphocyte counts;	chr22:28829615	chr22:28800683~28848559:+
TGCT	cis	rs12549025	0.685	rs36104352	ENSG00000253390.1	CTC-756D1.2	-4.15	6.15e-05	0.032	-0.47	-0.35	Reticulocyte fraction of red cells;	chr8:23520091	chr8:23458601~23484971:+
TGCT	cis	rs748404	0.697	rs1095389	ENSG00000205771.5	CATSPER2P1	-4.15	6.16e-05	0.0321	-0.4	-0.35	Lung cancer;	chr15:43274473	chr15:43726918~43747094:-
TGCT	cis	rs7819412	0.668	rs2409721	ENSG00000269918.1	AF131215.9	-4.15	6.16e-05	0.0321	-0.36	-0.35	Triglycerides;	chr8:11180735	chr8:11104691~11106704:-
TGCT	cis	rs2153535	0.563	rs1737584	ENSG00000230939.1	RP11-314C16.1	-4.15	6.16e-05	0.0321	-0.34	-0.35	Motion sickness;	chr6:8536509	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.505	rs1737583	ENSG00000230939.1	RP11-314C16.1	-4.15	6.16e-05	0.0321	-0.34	-0.35	Motion sickness;	chr6:8536579	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.563	rs3117071	ENSG00000230939.1	RP11-314C16.1	-4.15	6.16e-05	0.0321	-0.34	-0.35	Motion sickness;	chr6:8537675	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.526	rs9406179	ENSG00000230939.1	RP11-314C16.1	-4.15	6.16e-05	0.0321	-0.34	-0.35	Motion sickness;	chr6:8537991	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.601	rs9379224	ENSG00000230939.1	RP11-314C16.1	-4.15	6.16e-05	0.0321	-0.34	-0.35	Motion sickness;	chr6:8538180	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.601	rs9505472	ENSG00000230939.1	RP11-314C16.1	-4.15	6.16e-05	0.0321	-0.34	-0.35	Motion sickness;	chr6:8538532	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.601	rs9505473	ENSG00000230939.1	RP11-314C16.1	-4.15	6.16e-05	0.0321	-0.34	-0.35	Motion sickness;	chr6:8538544	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.601	rs1737581	ENSG00000230939.1	RP11-314C16.1	-4.15	6.16e-05	0.0321	-0.34	-0.35	Motion sickness;	chr6:8538905	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.601	rs2015281	ENSG00000230939.1	RP11-314C16.1	-4.15	6.16e-05	0.0321	-0.34	-0.35	Motion sickness;	chr6:8539440	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.601	rs9505474	ENSG00000230939.1	RP11-314C16.1	-4.15	6.16e-05	0.0321	-0.34	-0.35	Motion sickness;	chr6:8539561	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.601	rs2327091	ENSG00000230939.1	RP11-314C16.1	-4.15	6.16e-05	0.0321	-0.34	-0.35	Motion sickness;	chr6:8540136	chr6:8784178~8785445:+
TGCT	cis	rs7824557	0.843	rs2572418	ENSG00000255052.4	FAM66D	4.15	6.16e-05	0.0321	0.36	0.35	Retinal vascular caliber;	chr8:11255580	chr8:12115782~12177550:+
TGCT	cis	rs7923609	0.841	rs10740131	ENSG00000232075.1	MRPL35P2	-4.15	6.16e-05	0.0321	-0.33	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63511728	chr10:63634317~63634827:-
TGCT	cis	rs875971	1	rs1565531	ENSG00000237310.1	GS1-124K5.4	-4.15	6.16e-05	0.0321	-0.39	-0.35	Aortic root size;	chr7:66198126	chr7:66493706~66495474:+
TGCT	cis	rs2439831	0.681	rs526450	ENSG00000205771.5	CATSPER2P1	-4.15	6.17e-05	0.0321	-0.59	-0.35	Lung cancer in ever smokers;	chr15:43307127	chr15:43726918~43747094:-
TGCT	cis	rs73607972	0.877	rs8055188	ENSG00000275191.1	RP11-36I17.2	4.15	6.17e-05	0.0321	0.44	0.35	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53655975	chr16:53628256~53628816:-
TGCT	cis	rs4718428	1	rs12534637	ENSG00000272831.1	RP11-792A8.4	4.15	6.17e-05	0.0321	0.4	0.35	Corneal structure;	chr7:66862667	chr7:66739829~66740385:-
TGCT	cis	rs667920	0.557	rs35849216	ENSG00000239213.4	NCK1-AS1	-4.15	6.17e-05	0.0321	-0.46	-0.35	Coronary artery disease;	chr3:136608727	chr3:136841726~136862054:-
TGCT	cis	rs853679	0.55	rs6901017	ENSG00000216901.1	AL022393.7	4.15	6.18e-05	0.0321	0.48	0.35	Depression;	chr6:28184805	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.662	rs149901	ENSG00000219891.2	ZSCAN12P1	4.15	6.18e-05	0.0321	0.42	0.35	Parkinson's disease;	chr6:27997725	chr6:28091154~28093664:+
TGCT	cis	rs7824557	0.603	rs11250130	ENSG00000255020.1	AF131216.5	-4.15	6.18e-05	0.0322	-0.24	-0.35	Retinal vascular caliber;	chr8:11356946	chr8:11345748~11347502:-
TGCT	cis	rs7976269	0.515	rs9300183	ENSG00000275476.1	RP11-996F15.4	-4.15	6.18e-05	0.0322	-0.36	-0.35	Male-pattern baldness;	chr12:29002316	chr12:29277397~29277882:-
TGCT	cis	rs11673344	0.931	rs7256746	ENSG00000226686.6	LINC01535	4.15	6.18e-05	0.0322	0.4	0.35	Obesity-related traits;	chr19:37175073	chr19:37251912~37265535:+
TGCT	cis	rs72819454	0.522	rs9665617	ENSG00000266852.2	MIR4482	4.15	6.18e-05	0.0322	0.6	0.35	Interleukin-9 levels;	chr10:103764487	chr10:104268336~104268405:-
TGCT	cis	rs72819454	0.522	rs9665618	ENSG00000266852.2	MIR4482	4.15	6.18e-05	0.0322	0.6	0.35	Interleukin-9 levels;	chr10:103764550	chr10:104268336~104268405:-
TGCT	cis	rs72819454	0.522	rs56030972	ENSG00000266852.2	MIR4482	4.15	6.18e-05	0.0322	0.6	0.35	Interleukin-9 levels;	chr10:103765222	chr10:104268336~104268405:-
TGCT	cis	rs72819454	0.579	rs112836951	ENSG00000266852.2	MIR4482	4.15	6.18e-05	0.0322	0.6	0.35	Interleukin-9 levels;	chr10:103773143	chr10:104268336~104268405:-
TGCT	cis	rs4788815	0.691	rs4788808	ENSG00000260886.1	TAT-AS1	4.15	6.18e-05	0.0322	0.32	0.35	Metabolite levels;	chr16:71581710	chr16:71565789~71578187:+
TGCT	cis	rs1250248	0.512	rs6744921	ENSG00000225166.1	AC012462.2	-4.15	6.19e-05	0.0322	-0.34	-0.35	Total cholesterol levels;	chr2:215402013	chr2:215453707~215463871:+
TGCT	cis	rs11772815	1	rs12700878	ENSG00000233830.2	EIF4HP1	4.15	6.19e-05	0.0322	0.38	0.35	Folding of antihelix;	chr7:28351208	chr7:27458163~27458849:-
TGCT	cis	rs11772815	0.93	rs12700883	ENSG00000233830.2	EIF4HP1	4.15	6.19e-05	0.0322	0.38	0.35	Folding of antihelix;	chr7:28351844	chr7:27458163~27458849:-
TGCT	cis	rs11772815	1	rs2191826	ENSG00000233830.2	EIF4HP1	4.15	6.19e-05	0.0322	0.38	0.35	Folding of antihelix;	chr7:28352958	chr7:27458163~27458849:-
TGCT	cis	rs11772815	0.965	rs1541510	ENSG00000233830.2	EIF4HP1	4.15	6.19e-05	0.0322	0.38	0.35	Folding of antihelix;	chr7:28353937	chr7:27458163~27458849:-
TGCT	cis	rs11673344	0.864	rs11667146	ENSG00000226686.6	LINC01535	4.15	6.19e-05	0.0322	0.41	0.35	Obesity-related traits;	chr19:37004493	chr19:37251912~37265535:+
TGCT	cis	rs992157	0.798	rs7587220	ENSG00000261338.2	RP11-378A13.1	-4.15	6.19e-05	0.0322	-0.31	-0.35	Colorectal cancer;	chr2:218296141	chr2:218255319~218257366:+
TGCT	cis	rs992157	0.798	rs4674284	ENSG00000261338.2	RP11-378A13.1	-4.15	6.19e-05	0.0322	-0.31	-0.35	Colorectal cancer;	chr2:218296518	chr2:218255319~218257366:+
TGCT	cis	rs35000415	0.745	rs117944677	ENSG00000242078.1	RP11-738B7.1	4.15	6.2e-05	0.0323	0.56	0.35	Systemic lupus erythematosus;	chr7:129058131	chr7:129783370~129785185:-
TGCT	cis	rs35000415	0.745	rs117473643	ENSG00000242078.1	RP11-738B7.1	4.15	6.2e-05	0.0323	0.56	0.35	Systemic lupus erythematosus;	chr7:129058132	chr7:129783370~129785185:-
TGCT	cis	rs35000415	0.873	rs34748780	ENSG00000242078.1	RP11-738B7.1	4.15	6.2e-05	0.0323	0.56	0.35	Systemic lupus erythematosus;	chr7:129060099	chr7:129783370~129785185:-
TGCT	cis	rs35000415	0.873	rs13246321	ENSG00000242078.1	RP11-738B7.1	4.15	6.2e-05	0.0323	0.56	0.35	Systemic lupus erythematosus;	chr7:129061277	chr7:129783370~129785185:-
TGCT	cis	rs228614	0.51	rs223470	ENSG00000230069.3	LRRC37A15P	-4.15	6.21e-05	0.0323	-0.31	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102778004	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs223468	ENSG00000230069.3	LRRC37A15P	-4.15	6.21e-05	0.0323	-0.31	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102779265	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.554	rs223466	ENSG00000230069.3	LRRC37A15P	-4.15	6.21e-05	0.0323	-0.31	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102780039	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs223465	ENSG00000230069.3	LRRC37A15P	-4.15	6.21e-05	0.0323	-0.31	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780174	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs223464	ENSG00000230069.3	LRRC37A15P	-4.15	6.21e-05	0.0323	-0.31	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780603	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.525	rs223461	ENSG00000230069.3	LRRC37A15P	-4.15	6.21e-05	0.0323	-0.31	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102782372	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.531	rs223460	ENSG00000230069.3	LRRC37A15P	-4.15	6.21e-05	0.0323	-0.31	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102782903	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.554	rs223457	ENSG00000230069.3	LRRC37A15P	-4.15	6.21e-05	0.0323	-0.31	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102788506	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs223453	ENSG00000230069.3	LRRC37A15P	-4.15	6.21e-05	0.0323	-0.31	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789895	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.554	rs150895	ENSG00000230069.3	LRRC37A15P	-4.15	6.21e-05	0.0323	-0.31	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102791432	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.586	rs223448	ENSG00000230069.3	LRRC37A15P	-4.15	6.21e-05	0.0323	-0.31	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102792189	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.554	rs223442	ENSG00000230069.3	LRRC37A15P	-4.15	6.21e-05	0.0323	-0.31	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102793960	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.554	rs223441	ENSG00000230069.3	LRRC37A15P	-4.15	6.21e-05	0.0323	-0.31	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102794228	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.554	rs223439	ENSG00000230069.3	LRRC37A15P	-4.15	6.21e-05	0.0323	-0.31	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102798377	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.554	rs223436	ENSG00000230069.3	LRRC37A15P	-4.15	6.21e-05	0.0323	-0.31	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102798749	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs65671	ENSG00000230069.3	LRRC37A15P	-4.15	6.21e-05	0.0323	-0.31	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102801081	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.554	rs223424	ENSG00000230069.3	LRRC37A15P	-4.15	6.21e-05	0.0323	-0.31	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102804177	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.524	rs223423	ENSG00000230069.3	LRRC37A15P	-4.15	6.21e-05	0.0323	-0.31	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102804737	chr4:102727274~102730721:-
TGCT	cis	rs2243480	1	rs160646	ENSG00000164669.11	INTS4P1	4.15	6.21e-05	0.0323	0.53	0.35	Diabetic kidney disease;	chr7:66091293	chr7:65141225~65234216:+
TGCT	cis	rs6968802	1	rs6968802	ENSG00000233264.2	AC006042.8	4.15	6.21e-05	0.0323	0.56	0.35	Granulocyte percentage of myeloid white cells;	chr7:8016446	chr7:7980312~7982228:+
TGCT	cis	rs10504229	1	rs17805326	ENSG00000253301.4	RP11-513O17.2	4.15	6.22e-05	0.0323	0.46	0.35	Developmental language disorder (linguistic errors);	chr8:57256974	chr8:57142689~57240298:+
TGCT	cis	rs72843506	0.656	rs73981807	ENSG00000261033.1	RP11-209D14.2	4.15	6.22e-05	0.0323	0.5	0.35	Schizophrenia;	chr17:20092917	chr17:20008051~20009234:-
TGCT	cis	rs34375054	0.738	rs3751181	ENSG00000279233.1	RP11-158L12.4	4.15	6.23e-05	0.0324	0.36	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125141989	chr12:125138245~125141711:+
TGCT	cis	rs6782228	0.606	rs1127030	ENSG00000242551.2	POU5F1P6	-4.15	6.23e-05	0.0324	-0.43	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128620110	chr3:128674735~128677005:-
TGCT	cis	rs6782228	0.606	rs2712419	ENSG00000242551.2	POU5F1P6	-4.15	6.23e-05	0.0324	-0.43	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128622053	chr3:128674735~128677005:-
TGCT	cis	rs6782228	0.606	rs2712417	ENSG00000242551.2	POU5F1P6	-4.15	6.23e-05	0.0324	-0.43	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128626336	chr3:128674735~128677005:-
TGCT	cis	rs6782228	0.527	rs2712371	ENSG00000242551.2	POU5F1P6	-4.15	6.23e-05	0.0324	-0.43	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128627371	chr3:128674735~128677005:-
TGCT	cis	rs2709736	1	rs6947890	ENSG00000232790.2	LINC01162	-4.15	6.23e-05	0.0324	-0.25	-0.35	Bipolar I disorder;	chr7:20823534	chr7:20835431~21023148:+
TGCT	cis	rs801193	0.569	rs11772819	ENSG00000232559.3	GS1-124K5.12	4.15	6.23e-05	0.0324	0.32	0.35	Aortic root size;	chr7:66752983	chr7:66554588~66576923:-
TGCT	cis	rs801193	0.569	rs7800620	ENSG00000232559.3	GS1-124K5.12	4.15	6.23e-05	0.0324	0.32	0.35	Aortic root size;	chr7:66758701	chr7:66554588~66576923:-
TGCT	cis	rs7819412	0.56	rs3021497	ENSG00000255310.2	AF131215.2	-4.15	6.24e-05	0.0324	-0.3	-0.35	Triglycerides;	chr8:11138579	chr8:11107788~11109726:-
TGCT	cis	rs10129255	0.536	rs17113249	ENSG00000223648.3	IGHV3-64	4.15	6.24e-05	0.0324	0.29	0.35	Kawasaki disease;	chr14:106678273	chr14:106643132~106658258:-
TGCT	cis	rs57502260	0.764	rs7105218	ENSG00000212093.1	AP000807.1	4.15	6.24e-05	0.0324	0.43	0.35	Total body bone mineral density (age 45-60);	chr11:68454993	chr11:68506083~68506166:-
TGCT	cis	rs507080	0.501	rs637563	ENSG00000255422.1	AP002954.4	-4.15	6.24e-05	0.0324	-0.38	-0.35	Serum metabolite levels;	chr11:118704770	chr11:118704607~118750263:+
TGCT	cis	rs11139399	0.613	rs10780529	ENSG00000233926.1	RP11-154D17.1	-4.15	6.24e-05	0.0324	-0.4	-0.35	Hippocampal atrophy;	chr9:81723515	chr9:81689713~81776900:+
TGCT	cis	rs11139399	0.566	rs7859813	ENSG00000233926.1	RP11-154D17.1	-4.15	6.24e-05	0.0324	-0.4	-0.35	Hippocampal atrophy;	chr9:81723526	chr9:81689713~81776900:+
TGCT	cis	rs12143943	0.966	rs3789046	ENSG00000176754.11	LINC00303	4.15	6.24e-05	0.0324	0.32	0.35	Cognitive performance;	chr1:204617677	chr1:204032447~204041265:-
TGCT	cis	rs12143943	0.966	rs3747632	ENSG00000176754.11	LINC00303	4.15	6.24e-05	0.0324	0.32	0.35	Cognitive performance;	chr1:204618112	chr1:204032447~204041265:-
TGCT	cis	rs12549025	0.536	rs35742726	ENSG00000253390.1	CTC-756D1.2	-4.15	6.25e-05	0.0324	-0.39	-0.35	Reticulocyte fraction of red cells;	chr8:23509429	chr8:23458601~23484971:+
TGCT	cis	rs4242434	0.927	rs11778693	ENSG00000254064.1	CTD-2530N21.4	-4.14	6.25e-05	0.0324	-0.21	-0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22605339	chr8:22254576~22275162:-
TGCT	cis	rs4242434	0.927	rs7843828	ENSG00000254064.1	CTD-2530N21.4	-4.14	6.25e-05	0.0324	-0.21	-0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22606110	chr8:22254576~22275162:-
TGCT	cis	rs4242434	0.927	rs2291232	ENSG00000254064.1	CTD-2530N21.4	-4.14	6.25e-05	0.0324	-0.21	-0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22606551	chr8:22254576~22275162:-
TGCT	cis	rs4242434	0.927	rs34027561	ENSG00000254064.1	CTD-2530N21.4	-4.14	6.25e-05	0.0324	-0.21	-0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22607872	chr8:22254576~22275162:-
TGCT	cis	rs4242434	0.927	rs11136092	ENSG00000254064.1	CTD-2530N21.4	-4.14	6.25e-05	0.0324	-0.21	-0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22608975	chr8:22254576~22275162:-
TGCT	cis	rs8081395	0.801	rs2777895	ENSG00000266992.1	DHX40P1	-4.14	6.26e-05	0.0325	-0.37	-0.35	White blood cell count;	chr17:59802249	chr17:59976009~60002384:-
TGCT	cis	rs8081395	0.769	rs12449331	ENSG00000266992.1	DHX40P1	-4.14	6.26e-05	0.0325	-0.37	-0.35	White blood cell count;	chr17:59806285	chr17:59976009~60002384:-
TGCT	cis	rs73607972	0.877	rs1477199	ENSG00000279344.1	RP11-44F14.7	4.14	6.26e-05	0.0325	0.48	0.35	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53678223	chr16:53478957~53481550:-
TGCT	cis	rs748404	0.666	rs12906481	ENSG00000205771.5	CATSPER2P1	-4.14	6.26e-05	0.0325	-0.52	-0.35	Lung cancer;	chr15:43467356	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.666	rs35958032	ENSG00000205771.5	CATSPER2P1	-4.14	6.26e-05	0.0325	-0.52	-0.35	Lung cancer;	chr15:43494397	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.55	rs12912505	ENSG00000205771.5	CATSPER2P1	-4.14	6.26e-05	0.0325	-0.52	-0.35	Lung cancer;	chr15:43525206	chr15:43726918~43747094:-
TGCT	cis	rs10938353	0.773	rs73191016	ENSG00000273369.1	RP11-700J17.1	4.14	6.26e-05	0.0325	0.58	0.35	Body mass index;	chr4:44613093	chr4:44693946~44694386:-
TGCT	cis	rs67311347	1	rs897117	ENSG00000223797.4	ENTPD3-AS1	-4.14	6.26e-05	0.0325	-0.36	-0.35	Renal cell carcinoma;	chr3:40395803	chr3:40313802~40453329:-
TGCT	cis	rs1426063	0.614	rs17266308	ENSG00000260265.1	RP11-44F21.5	-4.14	6.27e-05	0.0325	-0.46	-0.35	QT interval;	chr4:75137695	chr4:75081702~75084717:-
TGCT	cis	rs11157436	1	rs2293731	ENSG00000211813.2	TRAV34	4.14	6.27e-05	0.0325	0.38	0.35	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22148880	chr14:22207522~22208129:+
TGCT	cis	rs72843506	0.656	rs77314146	ENSG00000261033.1	RP11-209D14.2	4.14	6.27e-05	0.0325	0.51	0.35	Schizophrenia;	chr17:20003827	chr17:20008051~20009234:-
TGCT	cis	rs1010254	0.51	rs72806361	ENSG00000213433.5	RPLP1P6	-4.14	6.27e-05	0.0325	-0.43	-0.35	Optic nerve measurement (cup area);	chr5:152305599	chr5:151765859~151766378:-
TGCT	cis	rs12216499	0.591	rs12665751	ENSG00000188451.8	SRP72P2	4.14	6.27e-05	0.0325	0.45	0.35	Bladder cancer (smoking interaction);	chr6:158994702	chr6:158237336~158242797:-
TGCT	cis	rs2709736	0.967	rs4721954	ENSG00000232790.2	LINC01162	-4.14	6.27e-05	0.0325	-0.25	-0.35	Bipolar I disorder;	chr7:20823247	chr7:20835431~21023148:+
TGCT	cis	rs6940638	0.688	rs7744759	ENSG00000187763.3	OR2B7P	4.14	6.28e-05	0.0325	0.32	0.35	Intelligence (multi-trait analysis);	chr6:27152047	chr6:28046434~28047367:+
TGCT	cis	rs2283792	0.765	rs9610328	ENSG00000228050.1	TOP3BP1	4.14	6.28e-05	0.0325	0.43	0.35	Multiple sclerosis;	chr22:21793085	chr22:22223187~22224566:-
TGCT	cis	rs2283792	0.765	rs6518968	ENSG00000228050.1	TOP3BP1	4.14	6.28e-05	0.0325	0.43	0.35	Multiple sclerosis;	chr22:21793327	chr22:22223187~22224566:-
TGCT	cis	rs2283792	0.765	rs7290469	ENSG00000228050.1	TOP3BP1	4.14	6.28e-05	0.0325	0.43	0.35	Multiple sclerosis;	chr22:21796693	chr22:22223187~22224566:-
TGCT	cis	rs875971	1	rs1167612	ENSG00000237310.1	GS1-124K5.4	-4.14	6.28e-05	0.0325	-0.38	-0.35	Aortic root size;	chr7:66102989	chr7:66493706~66495474:+
TGCT	cis	rs1823913	0.637	rs10931493	ENSG00000227542.1	AC092614.2	4.14	6.28e-05	0.0325	0.37	0.35	Obesity-related traits;	chr2:191288142	chr2:191229165~191246172:-
TGCT	cis	rs12745968	0.623	rs4294424	ENSG00000223787.2	RP4-593M8.1	-4.14	6.29e-05	0.0326	-0.47	-0.35	Bipolar disorder and schizophrenia;	chr1:92673817	chr1:92580476~92580821:-
TGCT	cis	rs9400467	0.537	rs12212282	ENSG00000272356.1	RP5-1112D6.8	-4.14	6.3e-05	0.0326	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111203635	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.506	rs12207199	ENSG00000272356.1	RP5-1112D6.8	-4.14	6.3e-05	0.0326	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111204703	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.537	rs12191266	ENSG00000272356.1	RP5-1112D6.8	-4.14	6.3e-05	0.0326	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111206838	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.537	rs78080415	ENSG00000272356.1	RP5-1112D6.8	-4.14	6.3e-05	0.0326	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111215813	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.537	rs12210707	ENSG00000272356.1	RP5-1112D6.8	-4.14	6.3e-05	0.0326	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111217184	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.537	rs17606481	ENSG00000272356.1	RP5-1112D6.8	-4.14	6.3e-05	0.0326	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111221185	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.537	rs12213673	ENSG00000272356.1	RP5-1112D6.8	-4.14	6.3e-05	0.0326	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111223636	chr6:111309203~111313517:+
TGCT	cis	rs9400467	0.537	rs17606672	ENSG00000272356.1	RP5-1112D6.8	-4.14	6.3e-05	0.0326	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111225630	chr6:111309203~111313517:+
TGCT	cis	rs9880211	0.613	rs6786582	ENSG00000239213.4	NCK1-AS1	-4.14	6.3e-05	0.0326	-0.34	-0.35	Height;Body mass index;	chr3:136180142	chr3:136841726~136862054:-
TGCT	cis	rs2709736	1	rs10224799	ENSG00000232790.2	LINC01162	-4.14	6.3e-05	0.0326	-0.25	-0.35	Bipolar I disorder;	chr7:20816270	chr7:20835431~21023148:+
TGCT	cis	rs7674212	0.507	rs223471	ENSG00000251288.2	RP11-10L12.2	-4.14	6.3e-05	0.0326	-0.47	-0.35	Type 2 diabetes;	chr4:102777629	chr4:102751401~102752641:+
TGCT	cis	rs796364	0.951	rs7565005	ENSG00000232732.8	AC073043.1	4.14	6.31e-05	0.0327	0.44	0.35	Schizophrenia;	chr2:200148554	chr2:199867396~199911159:-
TGCT	cis	rs12439619	0.705	rs17354185	ENSG00000255769.6	GOLGA2P10	4.14	6.31e-05	0.0327	0.48	0.35	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472993~82513950:-
TGCT	cis	rs17665889	0.51	rs72907895	ENSG00000225791.5	TRAM2-AS1	-4.14	6.31e-05	0.0327	-0.43	-0.35	Cannabis dependence symptom count;	chr6:51584795	chr6:52577307~52583993:+
TGCT	cis	rs17665889	0.51	rs6909067	ENSG00000225791.5	TRAM2-AS1	-4.14	6.31e-05	0.0327	-0.43	-0.35	Cannabis dependence symptom count;	chr6:51585327	chr6:52577307~52583993:+
TGCT	cis	rs17665889	0.51	rs9357699	ENSG00000225791.5	TRAM2-AS1	-4.14	6.31e-05	0.0327	-0.43	-0.35	Cannabis dependence symptom count;	chr6:51586108	chr6:52577307~52583993:+
TGCT	cis	rs17665889	0.51	rs72909903	ENSG00000225791.5	TRAM2-AS1	-4.14	6.31e-05	0.0327	-0.43	-0.35	Cannabis dependence symptom count;	chr6:51594812	chr6:52577307~52583993:+
TGCT	cis	rs7208859	0.673	rs11657270	ENSG00000266490.1	CTD-2349P21.9	4.14	6.31e-05	0.0327	0.36	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30792372~30792833:+
TGCT	cis	rs7829975	0.846	rs6601724	ENSG00000173295.6	FAM86B3P	-4.14	6.32e-05	0.0327	-0.42	-0.35	Mood instability;	chr8:8687362	chr8:8228595~8244865:+
TGCT	cis	rs9309473	1	rs7584575	ENSG00000163016.8	ALMS1P	4.14	6.32e-05	0.0327	0.31	0.35	Metabolite levels;	chr2:73439274	chr2:73644919~73685576:+
TGCT	cis	rs7208859	0.673	rs56846352	ENSG00000263531.1	RP13-753N3.1	4.14	6.32e-05	0.0327	0.62	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs7211776	ENSG00000263531.1	RP13-753N3.1	4.14	6.32e-05	0.0327	0.62	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs9912122	ENSG00000263531.1	RP13-753N3.1	4.14	6.32e-05	0.0327	0.62	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30863921~30864940:-
TGCT	cis	rs4835473	0.897	rs35140014	ENSG00000251600.4	RP11-673E1.1	4.14	6.33e-05	0.0328	0.37	0.35	Immature fraction of reticulocytes;	chr4:143964292	chr4:143912331~143982454:+
TGCT	cis	rs10759883	0.627	rs12349742	ENSG00000175611.10	LINC00476	4.14	6.33e-05	0.0328	0.33	0.35	Nicotine dependence;	chr9:95857698	chr9:95759231~95875977:-
TGCT	cis	rs10759883	0.58	rs2026031	ENSG00000175611.10	LINC00476	4.14	6.33e-05	0.0328	0.33	0.35	Nicotine dependence;	chr9:95859068	chr9:95759231~95875977:-
TGCT	cis	rs7824557	0.564	rs35009431	ENSG00000255310.2	AF131215.2	-4.14	6.34e-05	0.0328	-0.28	-0.35	Retinal vascular caliber;	chr8:11375279	chr8:11107788~11109726:-
TGCT	cis	rs2243480	1	rs313832	ENSG00000164669.11	INTS4P1	4.14	6.34e-05	0.0328	0.53	0.35	Diabetic kidney disease;	chr7:66085904	chr7:65141225~65234216:+
TGCT	cis	rs755249	0.508	rs586057	ENSG00000182109.6	RP11-69E11.4	4.14	6.34e-05	0.0328	0.35	0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39393122	chr1:39522280~39546187:-
TGCT	cis	rs755249	0.508	rs624971	ENSG00000182109.6	RP11-69E11.4	4.14	6.34e-05	0.0328	0.35	0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39393275	chr1:39522280~39546187:-
TGCT	cis	rs9880211	1	rs9809988	ENSG00000239213.4	NCK1-AS1	4.14	6.34e-05	0.0328	0.37	0.35	Height;Body mass index;	chr3:136803379	chr3:136841726~136862054:-
TGCT	cis	rs8093502	0.543	rs2367994	ENSG00000261780.2	CTD-2354A18.1	4.14	6.34e-05	0.0328	0.37	0.35	Smoking initiation;	chr18:72550886	chr18:73324941~73349878:+
TGCT	cis	rs7917772	0.582	rs7087984	ENSG00000273108.1	RP11-416N2.4	-4.14	6.34e-05	0.0328	-0.33	-0.35	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102620929	chr10:103608619~103610050:+
TGCT	cis	rs10129255	0.5	rs2187989	ENSG00000223648.3	IGHV3-64	4.14	6.34e-05	0.0328	0.3	0.35	Kawasaki disease;	chr14:106714972	chr14:106643132~106658258:-
TGCT	cis	rs73607972	0.935	rs16952396	ENSG00000275191.1	RP11-36I17.2	-4.14	6.35e-05	0.0328	-0.42	-0.35	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53616751	chr16:53628256~53628816:-
TGCT	cis	rs10759883	0.563	rs689710	ENSG00000175611.10	LINC00476	4.14	6.35e-05	0.0328	0.32	0.35	Nicotine dependence;	chr9:95908339	chr9:95759231~95875977:-
TGCT	cis	rs72843506	0.656	rs79773274	ENSG00000261033.1	RP11-209D14.2	4.14	6.35e-05	0.0328	0.51	0.35	Schizophrenia;	chr17:20002618	chr17:20008051~20009234:-
TGCT	cis	rs7208859	0.673	rs11651802	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs17826219	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs61223749	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs3764421	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs11651858	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs36056619	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs9909497	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs11080135	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs9894876	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs73277967	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs60020217	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.573	rs73277974	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs73277978	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs11657391	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs58089675	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs73263755	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs9899349	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs11652358	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs11656845	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs9891179	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs9891413	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs73263776	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs11650271	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs73263785	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs78799101	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs55904046	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs9889968	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs61348930	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.614	rs28758251	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs9899943	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs11080138	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs73265612	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs2433	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs11658435	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs73265624	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs2269915	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs2269916	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs11649765	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs12103759	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs59029591	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs73265633	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs9913782	ENSG00000266490.1	CTD-2349P21.9	4.14	6.36e-05	0.0328	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30792372~30792833:+
TGCT	cis	rs9322193	1	rs9377229	ENSG00000231760.4	RP11-350J20.5	4.14	6.36e-05	0.0329	0.42	0.35	Lung cancer;	chr6:149607655	chr6:149796151~149826294:-
TGCT	cis	rs7829975	0.593	rs2921051	ENSG00000254340.1	RP11-10A14.3	4.14	6.36e-05	0.0329	0.34	0.35	Mood instability;	chr8:8462594	chr8:9141424~9145435:+
TGCT	cis	rs7523273	0.565	rs2796232	ENSG00000203709.8	C1orf132	-4.14	6.36e-05	0.0329	-0.27	-0.35	Schizophrenia;	chr1:207727023	chr1:207801518~207869150:-
TGCT	cis	rs6510489	1	rs7976	ENSG00000267439.1	AC002398.11	4.14	6.36e-05	0.0329	0.48	0.35	Bipolar disorder;	chr19:35487397	chr19:35747057~35753415:-
TGCT	cis	rs7005380	0.556	rs12548248	ENSG00000254343.2	RP11-760H22.2	4.14	6.37e-05	0.0329	0.5	0.35	Interstitial lung disease;	chr8:119920081	chr8:120052180~120056201:+
TGCT	cis	rs11074306	0.561	rs4778192	ENSG00000232394.1	AC090696.2	-4.14	6.37e-05	0.0329	-0.33	-0.35	Uveal melanoma;	chr15:27834915	chr15:27775621~27776798:+
TGCT	cis	rs7208859	0.673	rs2470251	ENSG00000263531.1	RP13-753N3.1	4.14	6.37e-05	0.0329	0.62	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.673	rs11652370	ENSG00000263531.1	RP13-753N3.1	4.14	6.37e-05	0.0329	0.62	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30863921~30864940:-
TGCT	cis	rs891378	0.755	rs1019830	ENSG00000274245.1	RP11-357P18.2	-4.14	6.38e-05	0.0329	-0.43	-0.35	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236817	chr1:207372559~207373252:+
TGCT	cis	rs904251	0.772	rs1812186	ENSG00000227920.2	RP1-153P14.5	-4.14	6.38e-05	0.0329	-0.44	-0.35	Cognitive performance;	chr6:37498140	chr6:37545145~37550860:+
TGCT	cis	rs875971	1	rs6946143	ENSG00000232559.3	GS1-124K5.12	4.14	6.38e-05	0.0329	0.31	0.35	Aortic root size;	chr7:66114735	chr7:66554588~66576923:-
TGCT	cis	rs853679	0.55	rs9295762	ENSG00000187763.3	OR2B7P	-4.14	6.38e-05	0.0329	-0.33	-0.35	Depression;	chr6:28187640	chr6:28046434~28047367:+
TGCT	cis	rs10129255	0.5	rs8004923	ENSG00000223648.3	IGHV3-64	4.14	6.39e-05	0.033	0.3	0.35	Kawasaki disease;	chr14:106785926	chr14:106643132~106658258:-
TGCT	cis	rs10129255	0.5	rs6576232	ENSG00000223648.3	IGHV3-64	4.14	6.39e-05	0.033	0.3	0.35	Kawasaki disease;	chr14:106787090	chr14:106643132~106658258:-
TGCT	cis	rs10129255	0.5	rs10131875	ENSG00000223648.3	IGHV3-64	4.14	6.39e-05	0.033	0.3	0.35	Kawasaki disease;	chr14:106792798	chr14:106643132~106658258:-
TGCT	cis	rs10129255	0.5	rs11628999	ENSG00000223648.3	IGHV3-64	4.14	6.39e-05	0.033	0.3	0.35	Kawasaki disease;	chr14:106800208	chr14:106643132~106658258:-
TGCT	cis	rs8141529	0.764	rs5762854	ENSG00000226471.5	CTA-292E10.6	-4.14	6.39e-05	0.033	-0.37	-0.35	Lymphocyte counts;	chr22:28850290	chr22:28800683~28848559:+
TGCT	cis	rs875971	1	rs4718357	ENSG00000232559.3	GS1-124K5.12	4.14	6.4e-05	0.033	0.33	0.35	Aortic root size;	chr7:66495891	chr7:66554588~66576923:-
TGCT	cis	rs9487094	0.645	rs34292461	ENSG00000219700.1	PTCHD3P3	4.14	6.4e-05	0.033	0.49	0.35	Height;	chr6:109352277	chr6:109288571~109290503:-
TGCT	cis	rs748404	0.697	rs513970	ENSG00000205771.5	CATSPER2P1	-4.14	6.41e-05	0.033	-0.41	-0.35	Lung cancer;	chr15:43287368	chr15:43726918~43747094:-
TGCT	cis	rs11047510	0.824	rs57785077	ENSG00000255753.1	RP11-22B23.2	4.14	6.41e-05	0.0331	0.44	0.35	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr12:8848014	chr12:9314402~9316173:-
TGCT	cis	rs9733	0.65	rs11204668	ENSG00000236713.1	RP11-363I22.3	4.14	6.41e-05	0.0331	0.28	0.35	Tonsillectomy;	chr1:150571210	chr1:150780272~150780644:+
TGCT	cis	rs9733	0.65	rs12406712	ENSG00000236713.1	RP11-363I22.3	4.14	6.41e-05	0.0331	0.28	0.35	Tonsillectomy;	chr1:150572608	chr1:150780272~150780644:+
TGCT	cis	rs10210955	0.546	rs10048703	ENSG00000204588.5	LINC01123	4.14	6.41e-05	0.0331	0.35	0.35	Lymphocyte percentage of white cells;	chr2:110832983	chr2:109987063~109996140:+
TGCT	cis	rs7831492	0.517	rs11995974	ENSG00000253943.1	KRT18P37	4.14	6.41e-05	0.0331	0.38	0.35	Colorectal cancer;	chr8:41789165	chr8:41511240~41512521:+
TGCT	cis	rs7647973	0.58	rs4955432	ENSG00000226913.1	BSN-AS2	-4.14	6.41e-05	0.0331	-0.28	-0.35	Menarche (age at onset);	chr3:49229339	chr3:49549306~49554366:-
TGCT	cis	rs7647973	0.6	rs11920267	ENSG00000226913.1	BSN-AS2	-4.14	6.41e-05	0.0331	-0.28	-0.35	Menarche (age at onset);	chr3:49238531	chr3:49549306~49554366:-
TGCT	cis	rs9326248	0.861	rs7120309	ENSG00000280143.1	AP000892.6	4.14	6.41e-05	0.0331	0.5	0.35	Blood protein levels;	chr11:117172100	chr11:117204967~117210292:+
TGCT	cis	rs9326248	0.861	rs7120449	ENSG00000280143.1	AP000892.6	4.14	6.41e-05	0.0331	0.5	0.35	Blood protein levels;	chr11:117172183	chr11:117204967~117210292:+
TGCT	cis	rs10129255	0.536	rs6576201	ENSG00000223648.3	IGHV3-64	-4.14	6.41e-05	0.0331	-0.29	-0.35	Kawasaki disease;	chr14:106683696	chr14:106643132~106658258:-
TGCT	cis	rs7795991	0.558	rs10281330	ENSG00000224330.1	AC005019.3	4.14	6.42e-05	0.0331	0.39	0.35	Type 2 diabetes;	chr7:13871408	chr7:13854355~13859025:-
TGCT	cis	rs12497850	0.863	rs4974084	ENSG00000226913.1	BSN-AS2	-4.14	6.42e-05	0.0331	-0.29	-0.35	Parkinson's disease;	chr3:48901647	chr3:49549306~49554366:-
TGCT	cis	rs2439831	0.85	rs3742982	ENSG00000205771.5	CATSPER2P1	-4.14	6.42e-05	0.0331	-0.58	-0.35	Lung cancer in ever smokers;	chr15:43884483	chr15:43726918~43747094:-
TGCT	cis	rs875971	0.825	rs6951503	ENSG00000237310.1	GS1-124K5.4	-4.14	6.42e-05	0.0331	-0.38	-0.35	Aortic root size;	chr7:66253949	chr7:66493706~66495474:+
TGCT	cis	rs728616	0.614	rs10887218	ENSG00000230091.5	TMEM254-AS1	4.14	6.42e-05	0.0331	0.53	0.35	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79951268	chr10:80046860~80078912:-
TGCT	cis	rs2408955	0.515	rs10875742	ENSG00000240399.1	RP1-228P16.1	-4.14	6.43e-05	0.0331	-0.34	-0.35	Glycated hemoglobin levels;	chr12:48099591	chr12:48054813~48055591:-
TGCT	cis	rs853356	0.947	rs853383	ENSG00000234261.2	RP11-146I2.1	4.14	6.43e-05	0.0332	0.34	0.35	Height;	chr6:14180474	chr6:14661829~15090003:-
TGCT	cis	rs853356	1	rs853385	ENSG00000234261.2	RP11-146I2.1	4.14	6.43e-05	0.0332	0.34	0.35	Height;	chr6:14182510	chr6:14661829~15090003:-
TGCT	cis	rs853679	0.517	rs17711344	ENSG00000187763.3	OR2B7P	-4.14	6.44e-05	0.0332	-0.34	-0.35	Depression;	chr6:28109824	chr6:28046434~28047367:+
TGCT	cis	rs11742741	0.572	rs4701425	ENSG00000248874.4	C5orf17	-4.14	6.44e-05	0.0332	-0.42	-0.35	Educational attainment;	chr5:24172342	chr5:23951348~24178263:+
TGCT	cis	rs11673344	0.704	rs1667384	ENSG00000226686.6	LINC01535	4.14	6.44e-05	0.0332	0.39	0.35	Obesity-related traits;	chr19:36925852	chr19:37251912~37265535:+
TGCT	cis	rs847851	0.958	rs847850	ENSG00000186328.4	RP11-140K17.2	4.14	6.44e-05	0.0332	0.36	0.35	Colonoscopy-negative controls vs population controls;	chr6:34937191	chr6:34715613~34715940:+
TGCT	cis	rs847851	0.834	rs2504164	ENSG00000186328.4	RP11-140K17.2	4.14	6.44e-05	0.0332	0.36	0.35	Colonoscopy-negative controls vs population controls;	chr6:34946601	chr6:34715613~34715940:+
TGCT	cis	rs901683	1	rs9422657	ENSG00000264204.2	AGAP7P	-4.14	6.44e-05	0.0332	-0.78	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45557613	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs36074276	ENSG00000264204.2	AGAP7P	-4.14	6.44e-05	0.0332	-0.78	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45560293	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs77651228	ENSG00000264204.2	AGAP7P	-4.14	6.44e-05	0.0332	-0.78	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45560681	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs9422658	ENSG00000264204.2	AGAP7P	-4.14	6.44e-05	0.0332	-0.78	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45564219	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs34011467	ENSG00000264204.2	AGAP7P	-4.14	6.44e-05	0.0332	-0.78	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45564310	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35934513	ENSG00000264204.2	AGAP7P	-4.14	6.44e-05	0.0332	-0.78	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45564333	chr10:46109621~46131358:+
TGCT	cis	rs901683	0.85	rs12778143	ENSG00000264204.2	AGAP7P	-4.14	6.44e-05	0.0332	-0.78	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45568092	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs12776336	ENSG00000264204.2	AGAP7P	-4.14	6.44e-05	0.0332	-0.78	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45568463	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs12779204	ENSG00000264204.2	AGAP7P	-4.14	6.44e-05	0.0332	-0.78	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45568807	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs34670342	ENSG00000264204.2	AGAP7P	-4.14	6.44e-05	0.0332	-0.78	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45570714	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71496619	ENSG00000264204.2	AGAP7P	-4.14	6.44e-05	0.0332	-0.78	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45572647	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs33997730	ENSG00000264204.2	AGAP7P	-4.14	6.44e-05	0.0332	-0.78	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45572665	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs113862353	ENSG00000264204.2	AGAP7P	-4.14	6.44e-05	0.0332	-0.78	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45573138	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35001302	ENSG00000264204.2	AGAP7P	-4.14	6.44e-05	0.0332	-0.78	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45573488	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35585999	ENSG00000264204.2	AGAP7P	-4.14	6.44e-05	0.0332	-0.78	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45574711	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35639934	ENSG00000264204.2	AGAP7P	-4.14	6.44e-05	0.0332	-0.78	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45575179	chr10:46109621~46131358:+
TGCT	cis	rs901683	0.702	rs34176769	ENSG00000264204.2	AGAP7P	-4.14	6.44e-05	0.0332	-0.78	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45575579	chr10:46109621~46131358:+
TGCT	cis	rs901683	0.85	rs35150810	ENSG00000264204.2	AGAP7P	-4.14	6.44e-05	0.0332	-0.78	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45575694	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs74411575	ENSG00000264204.2	AGAP7P	-4.14	6.44e-05	0.0332	-0.78	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45576519	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs79752400	ENSG00000264204.2	AGAP7P	-4.14	6.44e-05	0.0332	-0.78	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45576640	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs34383275	ENSG00000264204.2	AGAP7P	-4.14	6.44e-05	0.0332	-0.78	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45577429	chr10:46109621~46131358:+
TGCT	cis	rs9844666	0.512	rs9819440	ENSG00000239213.4	NCK1-AS1	-4.14	6.44e-05	0.0332	-0.34	-0.35	Height;	chr3:135944640	chr3:136841726~136862054:-
TGCT	cis	rs7181230	0.922	rs4924410	ENSG00000275636.1	RP11-521C20.5	-4.14	6.44e-05	0.0332	-0.45	-0.35	Dehydroepiandrosterone sulphate levels;	chr15:40047293	chr15:40078892~40079347:+
TGCT	cis	rs7005380	0.561	rs7818471	ENSG00000254343.2	RP11-760H22.2	4.14	6.46e-05	0.0332	0.47	0.35	Interstitial lung disease;	chr8:119897596	chr8:120052180~120056201:+
TGCT	cis	rs12935418	0.616	rs12444054	ENSG00000261061.1	RP11-303E16.2	-4.14	6.46e-05	0.0332	-0.41	-0.35	Mean corpuscular volume;	chr16:80930320	chr16:81030770~81031485:+
TGCT	cis	rs786425	0.771	rs7135624	ENSG00000247373.3	RP11-486O12.2	4.14	6.46e-05	0.0332	0.41	0.35	Pubertal anthropometrics;	chr12:123663284	chr12:123575891~123585115:-
TGCT	cis	rs2709736	0.9	rs2709742	ENSG00000232790.2	LINC01162	-4.14	6.46e-05	0.0332	-0.26	-0.35	Bipolar I disorder;	chr7:20832721	chr7:20835431~21023148:+
TGCT	cis	rs11671005	0.736	rs11668201	ENSG00000268912.1	CTD-2619J13.17	-4.14	6.47e-05	0.0333	-0.42	-0.35	Mean platelet volume;	chr19:58492265	chr19:58428632~58431148:-
TGCT	cis	rs847851	1	rs4646926	ENSG00000186328.4	RP11-140K17.2	4.14	6.47e-05	0.0333	0.36	0.35	Colonoscopy-negative controls vs population controls;	chr6:34884476	chr6:34715613~34715940:+
TGCT	cis	rs847851	1	rs57951780	ENSG00000186328.4	RP11-140K17.2	4.14	6.47e-05	0.0333	0.36	0.35	Colonoscopy-negative controls vs population controls;	chr6:34885114	chr6:34715613~34715940:+
TGCT	cis	rs380904	0.517	rs11775744	ENSG00000254859.1	RP11-661A12.5	-4.14	6.47e-05	0.0333	-0.54	-0.35	Venous thromboembolism (SNP x SNP interaction);	chr8:143567022	chr8:143541973~143549729:-
TGCT	cis	rs7829975	0.714	rs12544992	ENSG00000173295.6	FAM86B3P	4.14	6.47e-05	0.0333	0.43	0.35	Mood instability;	chr8:8804171	chr8:8228595~8244865:+
TGCT	cis	rs7637701	0.818	rs11717133	ENSG00000240875.4	LINC00886	-4.14	6.47e-05	0.0333	-0.28	-0.35	Breast cancer;	chr3:156816792	chr3:156747346~156817062:-
TGCT	cis	rs8141529	0.778	rs763073	ENSG00000272858.1	CTA-292E10.8	-4.14	6.47e-05	0.0333	-0.35	-0.35	Lymphocyte counts;	chr22:28819554	chr22:28814914~28815662:+
TGCT	cis	rs7829975	0.742	rs1533059	ENSG00000253893.2	FAM85B	4.14	6.48e-05	0.0333	0.44	0.35	Mood instability;	chr8:8827443	chr8:8167819~8226614:-
TGCT	cis	rs397969	0.646	rs1638528	ENSG00000266126.1	RP11-209D14.4	4.14	6.48e-05	0.0333	0.51	0.35	Platelet count;	chr17:19934616	chr17:19929372~19929737:-
TGCT	cis	rs4268898	0.662	rs714531	ENSG00000223754.1	AC008073.9	4.14	6.48e-05	0.0333	0.48	0.35	Asthma;	chr2:24177008	chr2:24199839~24201698:-
TGCT	cis	rs4268898	0.662	rs58971404	ENSG00000223754.1	AC008073.9	4.14	6.48e-05	0.0333	0.48	0.35	Asthma;	chr2:24180884	chr2:24199839~24201698:-
TGCT	cis	rs4268898	0.662	rs59996104	ENSG00000223754.1	AC008073.9	4.14	6.48e-05	0.0333	0.48	0.35	Asthma;	chr2:24181195	chr2:24199839~24201698:-
TGCT	cis	rs4268898	0.662	rs56006260	ENSG00000223754.1	AC008073.9	4.14	6.48e-05	0.0333	0.48	0.35	Asthma;	chr2:24187034	chr2:24199839~24201698:-
TGCT	cis	rs4919669	0.777	rs5011218	ENSG00000273108.1	RP11-416N2.4	-4.14	6.48e-05	0.0333	-0.53	-0.35	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102641461	chr10:103608619~103610050:+
TGCT	cis	rs4919669	0.668	rs4146429	ENSG00000273108.1	RP11-416N2.4	-4.14	6.48e-05	0.0333	-0.53	-0.35	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102641875	chr10:103608619~103610050:+
TGCT	cis	rs4919669	0.668	rs4146428	ENSG00000273108.1	RP11-416N2.4	-4.14	6.48e-05	0.0333	-0.53	-0.35	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102641964	chr10:103608619~103610050:+
TGCT	cis	rs4919669	0.668	rs11191359	ENSG00000273108.1	RP11-416N2.4	-4.14	6.49e-05	0.0333	-0.53	-0.35	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102641729	chr10:103608619~103610050:+
TGCT	cis	rs2442825	0.54	rs35728233	ENSG00000206573.7	THUMPD3-AS1	-4.14	6.49e-05	0.0333	-0.34	-0.35	Cerebrospinal fluid clusterin levels;	chr3:9387510	chr3:9349689~9398579:-
TGCT	cis	rs10129255	0.5	rs2105991	ENSG00000280411.1	IGHV1-69-2	-4.13	6.49e-05	0.0334	-0.35	-0.35	Kawasaki disease;	chr14:106682022	chr14:106762092~106762588:-
TGCT	cis	rs4242434	0.927	rs35952885	ENSG00000254064.1	CTD-2530N21.4	-4.13	6.49e-05	0.0334	-0.21	-0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22634109	chr8:22254576~22275162:-
TGCT	cis	rs34217772	0.64	rs4904888	ENSG00000258536.1	RP11-1053O12.1	-4.13	6.5e-05	0.0334	-0.3	-0.35	Myopia;	chr14:41858325	chr14:41742639~41742963:+
TGCT	cis	rs2273156	1	rs17102904	ENSG00000226677.3	IGBP1P1	4.13	6.5e-05	0.0334	0.46	0.35	Immunoglobulin light chain (AL) amyloidosis;	chr14:34971843	chr14:34939324~34940332:+
TGCT	cis	rs8050896	1	rs8051967	ENSG00000259847.1	RP11-95H3.1	-4.13	6.51e-05	0.0334	-0.5	-0.35	Response to antipsychotic treatment;	chr16:66125186	chr16:65141756~65176713:-
TGCT	cis	rs3931020	0.688	rs455032	ENSG00000272864.1	RP11-17E13.2	4.13	6.51e-05	0.0334	0.41	0.35	Resistin levels;	chr1:74730804	chr1:74698769~74699333:-
TGCT	cis	rs2283792	0.715	rs56227348	ENSG00000228050.1	TOP3BP1	4.13	6.51e-05	0.0334	0.42	0.35	Multiple sclerosis;	chr22:21791443	chr22:22223187~22224566:-
TGCT	cis	rs987724	0.571	rs7641929	ENSG00000240875.4	LINC00886	-4.13	6.52e-05	0.0334	-0.28	-0.35	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156811605	chr3:156747346~156817062:-
TGCT	cis	rs987724	0.531	rs12492804	ENSG00000240875.4	LINC00886	-4.13	6.52e-05	0.0334	-0.28	-0.35	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156814356	chr3:156747346~156817062:-
TGCT	cis	rs987724	0.592	rs12497539	ENSG00000240875.4	LINC00886	-4.13	6.52e-05	0.0334	-0.28	-0.35	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156816148	chr3:156747346~156817062:-
TGCT	cis	rs987724	0.571	rs59717073	ENSG00000240875.4	LINC00886	-4.13	6.52e-05	0.0334	-0.28	-0.35	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156816456	chr3:156747346~156817062:-
TGCT	cis	rs748404	0.666	rs72709850	ENSG00000205771.5	CATSPER2P1	-4.13	6.52e-05	0.0335	-0.5	-0.35	Lung cancer;	chr15:43462486	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.666	rs34633582	ENSG00000205771.5	CATSPER2P1	-4.13	6.52e-05	0.0335	-0.5	-0.35	Lung cancer;	chr15:43462683	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.666	rs12905220	ENSG00000205771.5	CATSPER2P1	-4.13	6.52e-05	0.0335	-0.5	-0.35	Lung cancer;	chr15:43465641	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.666	rs36078097	ENSG00000205771.5	CATSPER2P1	-4.13	6.52e-05	0.0335	-0.5	-0.35	Lung cancer;	chr15:43466209	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.666	rs7181783	ENSG00000205771.5	CATSPER2P1	-4.13	6.52e-05	0.0335	-0.5	-0.35	Lung cancer;	chr15:43469723	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.666	rs35903301	ENSG00000205771.5	CATSPER2P1	-4.13	6.52e-05	0.0335	-0.5	-0.35	Lung cancer;	chr15:43472332	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.666	rs34002293	ENSG00000205771.5	CATSPER2P1	-4.13	6.52e-05	0.0335	-0.5	-0.35	Lung cancer;	chr15:43472401	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.666	rs34181131	ENSG00000205771.5	CATSPER2P1	-4.13	6.52e-05	0.0335	-0.5	-0.35	Lung cancer;	chr15:43478527	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.666	rs7173383	ENSG00000205771.5	CATSPER2P1	-4.13	6.52e-05	0.0335	-0.5	-0.35	Lung cancer;	chr15:43480838	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.666	rs55801120	ENSG00000205771.5	CATSPER2P1	-4.13	6.52e-05	0.0335	-0.5	-0.35	Lung cancer;	chr15:43495042	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.666	rs12911740	ENSG00000205771.5	CATSPER2P1	-4.13	6.52e-05	0.0335	-0.5	-0.35	Lung cancer;	chr15:43498254	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.589	rs3862138	ENSG00000205771.5	CATSPER2P1	-4.13	6.52e-05	0.0335	-0.5	-0.35	Lung cancer;	chr15:43523801	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.589	rs62020612	ENSG00000205771.5	CATSPER2P1	-4.13	6.52e-05	0.0335	-0.5	-0.35	Lung cancer;	chr15:43525881	chr15:43726918~43747094:-
TGCT	cis	rs8141529	0.764	rs8137969	ENSG00000226471.5	CTA-292E10.6	-4.13	6.52e-05	0.0335	-0.37	-0.35	Lymphocyte counts;	chr22:28832496	chr22:28800683~28848559:+
TGCT	cis	rs1012068	0.686	rs5753818	ENSG00000236132.1	CTA-440B3.1	4.13	6.53e-05	0.0335	0.41	0.35	Chronic hepatitis C infection;	chr22:31917947	chr22:31816379~31817491:-
TGCT	cis	rs2742234	1	rs1864399	ENSG00000273008.1	RP11-351D16.3	-4.13	6.53e-05	0.0335	-0.38	-0.35	Hirschsprung disease;	chr10:43115007	chr10:43136824~43138334:-
TGCT	cis	rs77204473	0.744	rs2046149	ENSG00000254851.1	RP11-109L13.1	4.13	6.53e-05	0.0335	0.83	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117183993	chr11:117135528~117138582:+
TGCT	cis	rs77204473	0.744	rs11606672	ENSG00000254851.1	RP11-109L13.1	4.13	6.53e-05	0.0335	0.83	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117185343	chr11:117135528~117138582:+
TGCT	cis	rs77204473	0.744	rs2306472	ENSG00000254851.1	RP11-109L13.1	4.13	6.53e-05	0.0335	0.83	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117187346	chr11:117135528~117138582:+
TGCT	cis	rs77204473	0.744	rs3213459	ENSG00000254851.1	RP11-109L13.1	4.13	6.53e-05	0.0335	0.83	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117191773	chr11:117135528~117138582:+
TGCT	cis	rs77204473	0.744	rs2301174	ENSG00000254851.1	RP11-109L13.1	4.13	6.53e-05	0.0335	0.83	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117192993	chr11:117135528~117138582:+
TGCT	cis	rs77204473	0.744	rs3781985	ENSG00000254851.1	RP11-109L13.1	4.13	6.53e-05	0.0335	0.83	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194350	chr11:117135528~117138582:+
TGCT	cis	rs77204473	0.744	rs11606480	ENSG00000254851.1	RP11-109L13.1	4.13	6.53e-05	0.0335	0.83	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194817	chr11:117135528~117138582:+
TGCT	cis	rs77204473	0.744	rs2269399	ENSG00000254851.1	RP11-109L13.1	4.13	6.53e-05	0.0335	0.83	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117195637	chr11:117135528~117138582:+
TGCT	cis	rs77204473	0.744	rs2239678	ENSG00000254851.1	RP11-109L13.1	4.13	6.53e-05	0.0335	0.83	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117199880	chr11:117135528~117138582:+
TGCT	cis	rs77204473	0.744	rs2170317	ENSG00000254851.1	RP11-109L13.1	4.13	6.53e-05	0.0335	0.83	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117200024	chr11:117135528~117138582:+
TGCT	cis	rs6782228	0.509	rs2811495	ENSG00000242551.2	POU5F1P6	-4.13	6.53e-05	0.0335	-0.43	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641114	chr3:128674735~128677005:-
TGCT	cis	rs6782228	0.565	rs2811496	ENSG00000242551.2	POU5F1P6	-4.13	6.53e-05	0.0335	-0.43	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641115	chr3:128674735~128677005:-
TGCT	cis	rs5758659	0.716	rs2143138	ENSG00000182057.4	OGFRP1	4.13	6.53e-05	0.0335	0.26	0.35	Cognitive function;	chr22:42222334	chr22:42269753~42275196:+
TGCT	cis	rs2087017	0.903	rs3732790	ENSG00000273394.1	RP11-255E6.6	4.13	6.54e-05	0.0335	0.3	0.35	Personality dimensions;	chr3:114128436	chr3:113947005~113947570:-
TGCT	cis	rs453301	0.506	rs686189	ENSG00000173295.6	FAM86B3P	-4.13	6.54e-05	0.0335	-0.4	-0.35	Joint mobility (Beighton score);	chr8:8766127	chr8:8228595~8244865:+
TGCT	cis	rs9322193	0.962	rs3763162	ENSG00000231760.4	RP11-350J20.5	-4.13	6.54e-05	0.0335	-0.42	-0.35	Lung cancer;	chr6:149819674	chr6:149796151~149826294:-
TGCT	cis	rs2709736	0.504	rs9691964	ENSG00000232790.2	LINC01162	-4.13	6.54e-05	0.0335	-0.3	-0.35	Bipolar I disorder;	chr7:20832249	chr7:20835431~21023148:+
TGCT	cis	rs2709736	0.504	rs9691976	ENSG00000232790.2	LINC01162	-4.13	6.54e-05	0.0335	-0.3	-0.35	Bipolar I disorder;	chr7:20832479	chr7:20835431~21023148:+
TGCT	cis	rs2709736	0.504	rs2709743	ENSG00000232790.2	LINC01162	4.13	6.54e-05	0.0335	0.3	0.35	Bipolar I disorder;	chr7:20832584	chr7:20835431~21023148:+
TGCT	cis	rs8141529	0.732	rs5997408	ENSG00000226471.5	CTA-292E10.6	-4.13	6.54e-05	0.0335	-0.37	-0.35	Lymphocyte counts;	chr22:28811927	chr22:28800683~28848559:+
TGCT	cis	rs8141529	0.778	rs7287806	ENSG00000226471.5	CTA-292E10.6	-4.13	6.54e-05	0.0335	-0.37	-0.35	Lymphocyte counts;	chr22:28817023	chr22:28800683~28848559:+
TGCT	cis	rs115344852	0.575	rs1015811	ENSG00000216901.1	AL022393.7	4.13	6.54e-05	0.0335	0.43	0.35	Epithelial ovarian cancer;	chr6:28480309	chr6:28176188~28176674:+
TGCT	cis	rs2153535	0.504	rs5001323	ENSG00000230939.1	RP11-314C16.1	-4.13	6.55e-05	0.0336	-0.33	-0.35	Motion sickness;	chr6:8451372	chr6:8784178~8785445:+
TGCT	cis	rs2725236	0.638	rs67543560	ENSG00000202000.1	RNU1-36P	4.13	6.55e-05	0.0336	0.34	0.35	Caffeine consumption;	chr4:88010369	chr4:88000237~88000401:+
TGCT	cis	rs11673344	0.864	rs55921822	ENSG00000226686.6	LINC01535	4.13	6.55e-05	0.0336	0.41	0.35	Obesity-related traits;	chr19:37005910	chr19:37251912~37265535:+
TGCT	cis	rs901683	1	rs71496620	ENSG00000264204.2	AGAP7P	-4.13	6.56e-05	0.0336	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45578881	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs78661209	ENSG00000264204.2	AGAP7P	-4.13	6.56e-05	0.0336	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45579491	chr10:46109621~46131358:+
TGCT	cis	rs8141529	0.764	rs5762824	ENSG00000226471.5	CTA-292E10.6	-4.13	6.56e-05	0.0336	-0.37	-0.35	Lymphocyte counts;	chr22:28826942	chr22:28800683~28848559:+
TGCT	cis	rs8141529	0.764	rs5752807	ENSG00000226471.5	CTA-292E10.6	-4.13	6.56e-05	0.0336	-0.37	-0.35	Lymphocyte counts;	chr22:28827181	chr22:28800683~28848559:+
TGCT	cis	rs4713118	0.911	rs9461406	ENSG00000272009.1	RP1-313I6.12	4.13	6.56e-05	0.0336	0.41	0.35	Parkinson's disease;	chr6:27751985	chr6:28078792~28081130:-
TGCT	cis	rs9309473	1	rs10189574	ENSG00000163016.8	ALMS1P	4.13	6.56e-05	0.0336	0.31	0.35	Metabolite levels;	chr2:73471391	chr2:73644919~73685576:+
TGCT	cis	rs4242434	0.699	rs878051	ENSG00000253200.1	RP11-582J16.5	4.13	6.57e-05	0.0337	0.19	0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22626323	chr8:22613908~22616657:-
TGCT	cis	rs4242434	0.699	rs878053	ENSG00000253200.1	RP11-582J16.5	4.13	6.57e-05	0.0337	0.19	0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22626336	chr8:22613908~22616657:-
TGCT	cis	rs1629083	0.738	rs619250	ENSG00000255114.1	RP11-110I1.6	4.13	6.57e-05	0.0337	0.29	0.35	Lung cancer;	chr11:118193867	chr11:119044188~119045493:+
TGCT	cis	rs728616	0.867	rs56365235	ENSG00000230091.5	TMEM254-AS1	4.13	6.57e-05	0.0337	0.6	0.35	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80134983	chr10:80046860~80078912:-
TGCT	cis	rs11971779	0.68	rs6965212	ENSG00000252332.1	RNU6-911P	-4.13	6.58e-05	0.0337	-0.4	-0.35	Diisocyanate-induced asthma;	chr7:139341719	chr7:139448740~139448843:+
TGCT	cis	rs728616	0.867	rs1537835	ENSG00000230091.5	TMEM254-AS1	4.13	6.58e-05	0.0337	0.57	0.35	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80070396	chr10:80046860~80078912:-
TGCT	cis	rs62025270	0.806	rs62025266	ENSG00000259416.2	RP11-158M2.5	-4.13	6.58e-05	0.0337	-0.42	-0.35	Idiopathic pulmonary fibrosis;	chr15:85755217	chr15:85754941~85756237:-
TGCT	cis	rs62025270	0.848	rs62025269	ENSG00000259416.2	RP11-158M2.5	-4.13	6.58e-05	0.0337	-0.42	-0.35	Idiopathic pulmonary fibrosis;	chr15:85756859	chr15:85754941~85756237:-
TGCT	cis	rs6890270	1	rs6890270	ENSG00000271828.1	CTD-2310F14.1	4.13	6.58e-05	0.0337	0.42	0.35	Breast cancer;	chr5:56964779	chr5:56927874~56929573:+
TGCT	cis	rs6940638	0.688	rs9295730	ENSG00000187763.3	OR2B7P	4.13	6.58e-05	0.0337	0.32	0.35	Intelligence (multi-trait analysis);	chr6:27161027	chr6:28046434~28047367:+
TGCT	cis	rs6940638	0.688	rs1028308	ENSG00000187763.3	OR2B7P	4.13	6.58e-05	0.0337	0.32	0.35	Intelligence (multi-trait analysis);	chr6:27161978	chr6:28046434~28047367:+
TGCT	cis	rs4131099	0.793	rs11644493	ENSG00000261393.1	RP11-21B23.1	-4.13	6.59e-05	0.0337	-0.49	-0.35	Personality dimensions;	chr16:51337168	chr16:50368580~50371480:+
TGCT	cis	rs4835473	0.932	rs4835455	ENSG00000251600.4	RP11-673E1.1	4.13	6.59e-05	0.0338	0.36	0.35	Immature fraction of reticulocytes;	chr4:143962290	chr4:143912331~143982454:+
TGCT	cis	rs728616	0.614	rs3934643	ENSG00000230091.5	TMEM254-AS1	4.13	6.6e-05	0.0338	0.53	0.35	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79977061	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.764	rs11201025	ENSG00000230091.5	TMEM254-AS1	4.13	6.6e-05	0.0338	0.53	0.35	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79982402	chr10:80046860~80078912:-
TGCT	cis	rs884366	0.964	rs11153164	ENSG00000203799.9	CCDC162P	-4.13	6.6e-05	0.0338	-0.38	-0.35	HDL cholesterol;HDL cholesterol levels;	chr6:109275106	chr6:109285485~109355063:+
TGCT	cis	rs4242434	0.927	rs57594397	ENSG00000253200.1	RP11-582J16.5	4.13	6.6e-05	0.0338	0.2	0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22618144	chr8:22613908~22616657:-
TGCT	cis	rs10044254	0.724	rs4702108	ENSG00000246214.1	RP11-260E18.1	-4.13	6.6e-05	0.0338	-0.45	-0.35	Asthma (corticosteroid response);	chr5:15780267	chr5:16615926~16629969:+
TGCT	cis	rs1150668	0.768	rs1150716	ENSG00000204709.4	LINC01556	4.13	6.6e-05	0.0338	0.37	0.35	Pubertal anthropometrics;	chr6:28294921	chr6:28943877~28944537:+
TGCT	cis	rs1150668	0.799	rs2142730	ENSG00000204709.4	LINC01556	4.13	6.6e-05	0.0338	0.37	0.35	Pubertal anthropometrics;	chr6:28298372	chr6:28943877~28944537:+
TGCT	cis	rs10971721	0.584	rs72731221	ENSG00000230074.1	RP11-195F19.9	-4.13	6.61e-05	0.0338	-0.51	-0.35	Body mass index;	chr9:34122376	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.584	rs72731222	ENSG00000230074.1	RP11-195F19.9	-4.13	6.61e-05	0.0338	-0.51	-0.35	Body mass index;	chr9:34122864	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.584	rs72731224	ENSG00000230074.1	RP11-195F19.9	-4.13	6.61e-05	0.0338	-0.51	-0.35	Body mass index;	chr9:34122888	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.584	rs10971939	ENSG00000230074.1	RP11-195F19.9	-4.13	6.61e-05	0.0338	-0.51	-0.35	Body mass index;	chr9:34123437	chr9:34665665~34681298:+
TGCT	cis	rs9399135	0.743	rs7745098	ENSG00000232876.1	CTA-212D2.2	-4.13	6.61e-05	0.0338	-0.31	-0.35	Red blood cell count;	chr6:135093866	chr6:135055033~135060550:+
TGCT	cis	rs7674212	0.507	rs223413	ENSG00000251288.2	RP11-10L12.2	4.13	6.62e-05	0.0339	0.48	0.35	Type 2 diabetes;	chr4:102811709	chr4:102751401~102752641:+
TGCT	cis	rs9987353	0.544	rs2929470	ENSG00000173295.6	FAM86B3P	-4.13	6.62e-05	0.0339	-0.37	-0.35	Recombination measurement;	chr8:9204980	chr8:8228595~8244865:+
TGCT	cis	rs12554020	0.892	rs6479494	ENSG00000227603.1	RP11-165J3.6	-4.13	6.62e-05	0.0339	-0.57	-0.35	Schizophrenia;	chr9:93568217	chr9:93435332~93437121:-
TGCT	cis	rs901683	1	rs77649955	ENSG00000264204.2	AGAP7P	-4.13	6.62e-05	0.0339	-0.77	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45555241	chr10:46109621~46131358:+
TGCT	cis	rs901683	0.85	rs74874679	ENSG00000264204.2	AGAP7P	-4.13	6.62e-05	0.0339	-0.77	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45555285	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs9422654	ENSG00000264204.2	AGAP7P	-4.13	6.62e-05	0.0339	-0.77	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45555953	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs9422655	ENSG00000264204.2	AGAP7P	-4.13	6.62e-05	0.0339	-0.77	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45555960	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs17451208	ENSG00000264204.2	AGAP7P	-4.13	6.62e-05	0.0339	-0.77	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45556457	chr10:46109621~46131358:+
TGCT	cis	rs853679	0.517	rs16893666	ENSG00000219891.2	ZSCAN12P1	-4.13	6.62e-05	0.0339	-0.44	-0.35	Depression;	chr6:28086929	chr6:28091154~28093664:+
TGCT	cis	rs4268898	0.76	rs11676939	ENSG00000223754.1	AC008073.9	-4.13	6.63e-05	0.0339	-0.37	-0.35	Asthma;	chr2:24256188	chr2:24199839~24201698:-
TGCT	cis	rs2348418	0.733	rs12425200	ENSG00000273989.1	RP11-425D17.2	-4.13	6.63e-05	0.0339	-0.33	-0.35	Lung function (FEV1);Lung function (FVC);	chr12:28237896	chr12:28236227~28236828:+
TGCT	cis	rs2153535	0.542	rs915354	ENSG00000230939.1	RP11-314C16.1	-4.13	6.63e-05	0.0339	-0.34	-0.35	Motion sickness;	chr6:8440124	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.542	rs915353	ENSG00000230939.1	RP11-314C16.1	-4.13	6.63e-05	0.0339	-0.34	-0.35	Motion sickness;	chr6:8440137	chr6:8784178~8785445:+
TGCT	cis	rs72772090	0.539	rs11750671	ENSG00000248734.2	CTD-2260A17.1	-4.13	6.63e-05	0.0339	-0.42	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96852779	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs72775817	ENSG00000248734.2	CTD-2260A17.1	-4.13	6.63e-05	0.0339	-0.42	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96855006	chr5:96784777~96785999:+
TGCT	cis	rs72772090	0.539	rs72775818	ENSG00000248734.2	CTD-2260A17.1	-4.13	6.63e-05	0.0339	-0.42	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96857512	chr5:96784777~96785999:+
TGCT	cis	rs13118159	0.872	rs1882105	ENSG00000254094.1	AC078852.1	-4.13	6.63e-05	0.0339	-0.39	-0.35	Longevity;	chr4:1352168	chr4:1356581~1358075:+
TGCT	cis	rs5769707	0.732	rs135865	ENSG00000235111.1	RP1-29C18.8	-4.13	6.64e-05	0.0339	-0.31	-0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49612657~49615716:-
TGCT	cis	rs380904	0.519	rs12541790	ENSG00000254859.1	RP11-661A12.5	-4.13	6.64e-05	0.0339	-0.55	-0.35	Venous thromboembolism (SNP x SNP interaction);	chr8:143561151	chr8:143541973~143549729:-
TGCT	cis	rs380904	0.519	rs1377663	ENSG00000254859.1	RP11-661A12.5	-4.13	6.64e-05	0.0339	-0.55	-0.35	Venous thromboembolism (SNP x SNP interaction);	chr8:143562617	chr8:143541973~143549729:-
TGCT	cis	rs1799949	0.965	rs8071278	ENSG00000198496.9	NBR2	-4.13	6.64e-05	0.0339	-0.49	-0.35	Menopause (age at onset);	chr17:43041893	chr17:43125610~43153671:+
TGCT	cis	rs4713118	0.588	rs200994	ENSG00000216901.1	AL022393.7	-4.13	6.64e-05	0.034	-0.46	-0.35	Parkinson's disease;	chr6:27846035	chr6:28176188~28176674:+
TGCT	cis	rs891378	0.727	rs7513914	ENSG00000274245.1	RP11-357P18.2	-4.13	6.65e-05	0.034	-0.43	-0.35	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236087	chr1:207372559~207373252:+
TGCT	cis	rs891378	0.785	rs1896956	ENSG00000274245.1	RP11-357P18.2	-4.13	6.65e-05	0.034	-0.43	-0.35	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236302	chr1:207372559~207373252:+
TGCT	cis	rs7937890	0.904	rs11023169	ENSG00000254418.1	RP11-21L19.1	-4.13	6.65e-05	0.034	-0.31	-0.35	Mitochondrial DNA levels;	chr11:14269439	chr11:14262846~14273691:-
TGCT	cis	rs7937890	0.904	rs67623158	ENSG00000254418.1	RP11-21L19.1	-4.13	6.65e-05	0.034	-0.31	-0.35	Mitochondrial DNA levels;	chr11:14273650	chr11:14262846~14273691:-
TGCT	cis	rs7688540	0.771	rs11248009	ENSG00000275426.1	CH17-262A2.1	4.13	6.65e-05	0.034	0.7	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:226360	chr4:149738~150317:+
TGCT	cis	rs5742933	1	rs1898560	ENSG00000273240.1	RP11-455J20.3	-4.13	6.65e-05	0.034	-0.36	-0.35	Ferritin levels;	chr2:189747601	chr2:189763859~189764456:-
TGCT	cis	rs6510489	1	rs10421540	ENSG00000267439.1	AC002398.11	4.13	6.65e-05	0.034	0.47	0.35	Bipolar disorder;	chr19:35480325	chr19:35747057~35753415:-
TGCT	cis	rs1618992	0.703	rs6508556	ENSG00000265994.1	RP11-510D21.1	4.13	6.66e-05	0.034	0.36	0.35	Gut microbiome composition (summer and winter);	chr18:28612490	chr18:28785068~28789260:+
TGCT	cis	rs1618992	0.703	rs62086868	ENSG00000265994.1	RP11-510D21.1	4.13	6.66e-05	0.034	0.36	0.35	Gut microbiome composition (summer and winter);	chr18:28614901	chr18:28785068~28789260:+
TGCT	cis	rs3931020	0.688	rs452242	ENSG00000272864.1	RP11-17E13.2	4.13	6.66e-05	0.034	0.41	0.35	Resistin levels;	chr1:74759941	chr1:74698769~74699333:-
TGCT	cis	rs11083241	0.78	rs1785613	ENSG00000227279.1	AC015933.2	4.13	6.66e-05	0.034	0.37	0.35	Intelligence (multi-trait analysis);	chr18:27965642	chr18:27954519~27963687:+
TGCT	cis	rs72843506	0.586	rs75128113	ENSG00000261033.1	RP11-209D14.2	4.13	6.67e-05	0.0341	0.51	0.35	Schizophrenia;	chr17:20000172	chr17:20008051~20009234:-
TGCT	cis	rs17608059	0.566	rs6502327	ENSG00000141028.6	CDRT15P1	-4.13	6.67e-05	0.0341	-0.39	-0.35	Temperament;	chr17:14042870	chr17:14024514~14025488:+
TGCT	cis	rs367615	0.552	rs10042721	ENSG00000249476.1	CTD-2587M2.1	-4.13	6.67e-05	0.0341	-0.37	-0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109378269	chr5:109237120~109326369:-
TGCT	cis	rs877819	0.697	rs7912174	ENSG00000228403.1	RP11-563N6.6	4.13	6.68e-05	0.0341	0.37	0.35	Systemic lupus erythematosus;	chr10:48837426	chr10:48878022~48878649:+
TGCT	cis	rs10971721	0.731	rs12377117	ENSG00000230074.1	RP11-195F19.9	-4.13	6.68e-05	0.0341	-0.52	-0.35	Body mass index;	chr9:33806586	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.73	rs72725361	ENSG00000230074.1	RP11-195F19.9	-4.13	6.68e-05	0.0341	-0.52	-0.35	Body mass index;	chr9:33806615	chr9:34665665~34681298:+
TGCT	cis	rs7688540	0.771	rs11723615	ENSG00000275426.1	CH17-262A2.1	4.13	6.68e-05	0.0341	0.66	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283194	chr4:149738~150317:+
TGCT	cis	rs4713118	0.662	rs9380046	ENSG00000216901.1	AL022393.7	4.13	6.68e-05	0.0341	0.46	0.35	Parkinson's disease;	chr6:28062721	chr6:28176188~28176674:+
TGCT	cis	rs12216499	0.591	rs2179700	ENSG00000188451.8	SRP72P2	4.13	6.68e-05	0.0341	0.45	0.35	Bladder cancer (smoking interaction);	chr6:158983258	chr6:158237336~158242797:-
TGCT	cis	rs8059260	0.799	rs7194545	ENSG00000274038.1	RP11-66H6.4	-4.13	6.69e-05	0.0341	-0.39	-0.35	Alcohol consumption over the past year;	chr16:11030439	chr16:11056556~11057034:+
TGCT	cis	rs17695224	0.545	rs4802872	ENSG00000269483.1	AC006272.1	4.13	6.69e-05	0.0341	0.35	0.35	HDL cholesterol;HDL cholesterol levels;	chr19:51817790	chr19:51839924~51843324:-
TGCT	cis	rs7826238	0.566	rs2945886	ENSG00000253893.2	FAM85B	-4.13	6.69e-05	0.0341	-0.45	-0.35	Systolic blood pressure;	chr8:8290748	chr8:8167819~8226614:-
TGCT	cis	rs2153535	0.58	rs4639392	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8446314	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1832100	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8446723	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs2327058	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8446785	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.601	rs2327059	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8446838	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs2327060	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8446878	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs2327061	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8446998	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs7453115	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8447028	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs2184582	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8447560	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs2184583	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8447575	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs6929206	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8447728	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs6910742	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8448095	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9505446	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8448458	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1335633	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8448567	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1115079	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8449382	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1115078	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8449405	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs6597322	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8449719	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs962590	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8450666	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs5001324	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8451371	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs5001322	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8451375	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs969422	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8451547	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs969421	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8451716	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.601	rs969420	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8451733	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs7741456	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8452191	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs7742689	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8452200	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs7767756	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8453195	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs7767780	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8453229	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs7767926	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8453324	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs7748455	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8453392	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs2327062	ENSG00000230939.1	RP11-314C16.1	-4.13	6.69e-05	0.0341	-0.33	-0.35	Motion sickness;	chr6:8453625	chr6:8784178~8785445:+
TGCT	cis	rs943437	0.687	rs1409838	ENSG00000227012.2	RP1-97J1.2	-4.13	6.69e-05	0.0341	-0.55	-0.35	Parkinson's disease;	chr6:111984329	chr6:111900489~111901851:-
TGCT	cis	rs9880211	0.699	rs9809269	ENSG00000239213.4	NCK1-AS1	4.13	6.69e-05	0.0341	0.4	0.35	Height;Body mass index;	chr3:136711064	chr3:136841726~136862054:-
TGCT	cis	rs5758659	0.652	rs133303	ENSG00000182057.4	OGFRP1	4.13	6.69e-05	0.0341	0.25	0.35	Cognitive function;	chr22:41999238	chr22:42269753~42275196:+
TGCT	cis	rs792448	0.66	rs12035647	ENSG00000201544.1	SNORA16B	4.13	6.69e-05	0.0341	0.35	0.35	White blood cell count (basophil);	chr1:212313969	chr1:212352816~212352950:+
TGCT	cis	rs2980439	0.525	rs2945238	ENSG00000253893.2	FAM85B	-4.13	6.69e-05	0.0341	-0.45	-0.35	Neuroticism;	chr8:8312614	chr8:8167819~8226614:-
TGCT	cis	rs694739	0.536	rs671976	ENSG00000236935.1	AP003774.1	4.13	6.7e-05	0.0342	0.25	0.35	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64278557	chr11:64325050~64329504:-
TGCT	cis	rs10256972	0.786	rs3735686	ENSG00000226291.1	AC091729.8	-4.13	6.7e-05	0.0342	-0.37	-0.35	Endometriosis;Longevity;	chr7:1022891	chr7:1080863~1082178:+
TGCT	cis	rs2739330	0.731	rs2000468	ENSG00000235689.1	AP000351.13	4.13	6.71e-05	0.0342	0.33	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:24006305~24008258:-
TGCT	cis	rs35955747	0.738	rs2012451	ENSG00000236132.1	CTA-440B3.1	4.13	6.72e-05	0.0342	0.33	0.35	Neutrophil count;Sum basophil neutrophil counts;	chr22:31448387	chr22:31816379~31817491:-
TGCT	cis	rs17711722	0.503	rs453835	ENSG00000237310.1	GS1-124K5.4	-4.13	6.72e-05	0.0343	-0.36	-0.35	Calcium levels;	chr7:66046172	chr7:66493706~66495474:+
TGCT	cis	rs796364	0.57	rs35733345	ENSG00000232732.8	AC073043.1	4.13	6.72e-05	0.0343	0.54	0.35	Schizophrenia;	chr2:199782810	chr2:199867396~199911159:-
TGCT	cis	rs11230394	0.595	rs4939446	ENSG00000255947.1	RP11-855O10.3	4.13	6.72e-05	0.0343	0.3	0.35	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);	chr11:60697688	chr11:61654665~61655702:-
TGCT	cis	rs5758659	1	rs134873	ENSG00000182057.4	OGFRP1	4.13	6.72e-05	0.0343	0.26	0.35	Cognitive function;	chr22:42261560	chr22:42269753~42275196:+
TGCT	cis	rs5758659	0.904	rs134877	ENSG00000182057.4	OGFRP1	4.13	6.72e-05	0.0343	0.26	0.35	Cognitive function;	chr22:42266365	chr22:42269753~42275196:+
TGCT	cis	rs7208859	0.673	rs79541516	ENSG00000266490.1	CTD-2349P21.9	4.13	6.73e-05	0.0343	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30792372~30792833:+
TGCT	cis	rs2153535	0.505	rs9405395	ENSG00000230939.1	RP11-314C16.1	-4.13	6.73e-05	0.0343	-0.33	-0.35	Motion sickness;	chr6:8468389	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9392223	ENSG00000230939.1	RP11-314C16.1	-4.13	6.73e-05	0.0343	-0.33	-0.35	Motion sickness;	chr6:8468417	chr6:8784178~8785445:+
TGCT	cis	rs9309473	1	rs11899740	ENSG00000163016.8	ALMS1P	4.13	6.73e-05	0.0343	0.32	0.35	Metabolite levels;	chr2:73404084	chr2:73644919~73685576:+
TGCT	cis	rs4268898	0.76	rs11125535	ENSG00000223754.1	AC008073.9	-4.13	6.74e-05	0.0343	-0.38	-0.35	Asthma;	chr2:24305245	chr2:24199839~24201698:-
TGCT	cis	rs10759883	0.627	rs816684	ENSG00000175611.10	LINC00476	-4.13	6.74e-05	0.0343	-0.33	-0.35	Nicotine dependence;	chr9:95822707	chr9:95759231~95875977:-
TGCT	cis	rs10759883	0.627	rs816683	ENSG00000175611.10	LINC00476	-4.13	6.74e-05	0.0343	-0.33	-0.35	Nicotine dependence;	chr9:95822819	chr9:95759231~95875977:-
TGCT	cis	rs2739330	0.828	rs4820572	ENSG00000250470.1	AP000351.3	4.13	6.74e-05	0.0343	0.36	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23976904~23977585:-
TGCT	cis	rs10938353	0.678	rs60018658	ENSG00000273369.1	RP11-700J17.1	4.13	6.74e-05	0.0343	0.5	0.35	Body mass index;	chr4:44800149	chr4:44693946~44694386:-
TGCT	cis	rs1150668	0.796	rs2531832	ENSG00000204709.4	LINC01556	4.12	6.75e-05	0.0344	0.38	0.35	Pubertal anthropometrics;	chr6:28421445	chr6:28943877~28944537:+
TGCT	cis	rs10971721	0.822	rs72727332	ENSG00000230074.1	RP11-195F19.9	-4.12	6.75e-05	0.0344	-0.52	-0.35	Body mass index;	chr9:33929479	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72727335	ENSG00000230074.1	RP11-195F19.9	-4.12	6.75e-05	0.0344	-0.52	-0.35	Body mass index;	chr9:33931720	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72727336	ENSG00000230074.1	RP11-195F19.9	-4.12	6.75e-05	0.0344	-0.52	-0.35	Body mass index;	chr9:33931795	chr9:34665665~34681298:+
TGCT	cis	rs786425	0.804	rs11057320	ENSG00000278112.1	RP11-972P1.11	4.12	6.75e-05	0.0344	0.39	0.35	Pubertal anthropometrics;	chr12:123656815	chr12:123519390~123519856:-
TGCT	cis	rs4713118	0.696	rs2394002	ENSG00000187763.3	OR2B7P	4.12	6.75e-05	0.0344	0.32	0.35	Parkinson's disease;	chr6:27780236	chr6:28046434~28047367:+
TGCT	cis	rs8050896	1	rs16969792	ENSG00000259847.1	RP11-95H3.1	-4.12	6.75e-05	0.0344	-0.52	-0.35	Response to antipsychotic treatment;	chr16:66125508	chr16:65141756~65176713:-
TGCT	cis	rs507080	0.501	rs494459	ENSG00000255422.1	AP002954.4	4.12	6.75e-05	0.0344	0.37	0.35	Serum metabolite levels;	chr11:118703966	chr11:118704607~118750263:+
TGCT	cis	rs524281	0.682	rs34274349	ENSG00000255320.1	RP11-755F10.1	-4.12	6.76e-05	0.0344	-0.54	-0.35	Electroencephalogram traits;	chr11:66030595	chr11:66244840~66246239:-
TGCT	cis	rs524281	0.731	rs730787	ENSG00000255320.1	RP11-755F10.1	-4.12	6.76e-05	0.0344	-0.54	-0.35	Electroencephalogram traits;	chr11:66031488	chr11:66244840~66246239:-
TGCT	cis	rs8072100	0.967	rs8072644	ENSG00000228782.6	CTD-2026D20.3	-4.12	6.76e-05	0.0344	-0.41	-0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575998	chr17:47450568~47492492:-
TGCT	cis	rs7824557	0.564	rs11781637	ENSG00000255020.1	AF131216.5	-4.12	6.76e-05	0.0344	-0.24	-0.35	Retinal vascular caliber;	chr8:11357463	chr8:11345748~11347502:-
TGCT	cis	rs8141529	0.732	rs3788409	ENSG00000226471.5	CTA-292E10.6	-4.12	6.76e-05	0.0344	-0.37	-0.35	Lymphocyte counts;	chr22:28802163	chr22:28800683~28848559:+
TGCT	cis	rs8141529	0.732	rs5762815	ENSG00000226471.5	CTA-292E10.6	-4.12	6.76e-05	0.0344	-0.37	-0.35	Lymphocyte counts;	chr22:28809088	chr22:28800683~28848559:+
TGCT	cis	rs1010254	1	rs6870816	ENSG00000213433.5	RPLP1P6	-4.12	6.76e-05	0.0344	-0.36	-0.35	Optic nerve measurement (cup area);	chr5:152355140	chr5:151765859~151766378:-
TGCT	cis	rs7923609	0.74	rs10761784	ENSG00000232075.1	MRPL35P2	-4.12	6.76e-05	0.0344	-0.34	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63548990	chr10:63634317~63634827:-
TGCT	cis	rs11858159	0.871	rs11858315	ENSG00000259905.4	PWRN1	4.12	6.77e-05	0.0345	0.35	0.35	Platelet thrombus formation;	chr15:24556575	chr15:24493137~24652130:+
TGCT	cis	rs7246657	0.941	rs12982333	ENSG00000226686.6	LINC01535	-4.12	6.78e-05	0.0345	-0.55	-0.35	Coronary artery calcification;	chr19:37303822	chr19:37251912~37265535:+
TGCT	cis	rs7246657	1	rs10426297	ENSG00000226686.6	LINC01535	-4.12	6.78e-05	0.0345	-0.55	-0.35	Coronary artery calcification;	chr19:37307471	chr19:37251912~37265535:+
TGCT	cis	rs7246657	1	rs1823061	ENSG00000226686.6	LINC01535	-4.12	6.78e-05	0.0345	-0.55	-0.35	Coronary artery calcification;	chr19:37309724	chr19:37251912~37265535:+
TGCT	cis	rs10511112	0.867	rs2880027	ENSG00000242781.1	RP11-47P18.2	-4.12	6.78e-05	0.0345	-0.49	-0.35	Migraine;	chr3:80251438	chr3:80764897~80789354:+
TGCT	cis	rs17608059	0.566	rs17676459	ENSG00000141028.6	CDRT15P1	-4.12	6.78e-05	0.0345	-0.39	-0.35	Temperament;	chr17:14007198	chr17:14024514~14025488:+
TGCT	cis	rs7829975	0.617	rs4841072	ENSG00000254340.1	RP11-10A14.3	-4.12	6.78e-05	0.0345	-0.34	-0.35	Mood instability;	chr8:8933743	chr8:9141424~9145435:+
TGCT	cis	rs796364	0.616	rs6718118	ENSG00000232732.8	AC073043.1	4.12	6.78e-05	0.0345	0.53	0.35	Schizophrenia;	chr2:199827129	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.616	rs769956	ENSG00000232732.8	AC073043.1	4.12	6.78e-05	0.0345	0.53	0.35	Schizophrenia;	chr2:199828997	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.616	rs7589545	ENSG00000232732.8	AC073043.1	-4.12	6.78e-05	0.0345	-0.53	-0.35	Schizophrenia;	chr2:199811379	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.616	rs2030653	ENSG00000232732.8	AC073043.1	-4.12	6.78e-05	0.0345	-0.53	-0.35	Schizophrenia;	chr2:199812902	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.577	rs7574287	ENSG00000232732.8	AC073043.1	-4.12	6.78e-05	0.0345	-0.53	-0.35	Schizophrenia;	chr2:199816276	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.616	rs2140486	ENSG00000232732.8	AC073043.1	-4.12	6.78e-05	0.0345	-0.53	-0.35	Schizophrenia;	chr2:199825379	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.616	rs769955	ENSG00000232732.8	AC073043.1	-4.12	6.78e-05	0.0345	-0.53	-0.35	Schizophrenia;	chr2:199827872	chr2:199867396~199911159:-
TGCT	cis	rs10504229	1	rs58608483	ENSG00000253301.4	RP11-513O17.2	4.12	6.79e-05	0.0345	0.43	0.35	Developmental language disorder (linguistic errors);	chr8:57282710	chr8:57142689~57240298:+
TGCT	cis	rs3750965	0.575	rs3892895	ENSG00000260808.1	CTD-2007L18.5	4.12	6.79e-05	0.0345	0.27	0.35	Hair color;	chr11:69117287	chr11:68612899~68616711:-
TGCT	cis	rs6981523	0.553	rs11783890	ENSG00000269918.1	AF131215.9	-4.12	6.8e-05	0.0346	-0.35	-0.35	Neuroticism;	chr8:11198879	chr8:11104691~11106704:-
TGCT	cis	rs12745968	0.623	rs4847432	ENSG00000223787.2	RP4-593M8.1	-4.12	6.8e-05	0.0346	-0.46	-0.35	Bipolar disorder and schizophrenia;	chr1:92653327	chr1:92580476~92580821:-
TGCT	cis	rs12745968	0.653	rs11164791	ENSG00000223787.2	RP4-593M8.1	-4.12	6.8e-05	0.0346	-0.46	-0.35	Bipolar disorder and schizophrenia;	chr1:92654077	chr1:92580476~92580821:-
TGCT	cis	rs12745968	0.623	rs10874732	ENSG00000223787.2	RP4-593M8.1	-4.12	6.8e-05	0.0346	-0.46	-0.35	Bipolar disorder and schizophrenia;	chr1:92658002	chr1:92580476~92580821:-
TGCT	cis	rs12745968	0.623	rs10874733	ENSG00000223787.2	RP4-593M8.1	-4.12	6.8e-05	0.0346	-0.46	-0.35	Bipolar disorder and schizophrenia;	chr1:92658176	chr1:92580476~92580821:-
TGCT	cis	rs12745968	0.589	rs7530780	ENSG00000223787.2	RP4-593M8.1	-4.12	6.8e-05	0.0346	-0.46	-0.35	Bipolar disorder and schizophrenia;	chr1:92664711	chr1:92580476~92580821:-
TGCT	cis	rs6700559	0.703	rs10919993	ENSG00000260088.1	RP11-92G12.3	4.12	6.8e-05	0.0346	0.44	0.35	Coronary artery disease;	chr1:200658184	chr1:200669507~200694250:+
TGCT	cis	rs6604026	0.848	rs2893226	ENSG00000223787.2	RP4-593M8.1	4.12	6.81e-05	0.0346	0.48	0.35	Multiple sclerosis;	chr1:92822880	chr1:92580476~92580821:-
TGCT	cis	rs2505998	0.833	rs2251674	ENSG00000273008.1	RP11-351D16.3	4.12	6.81e-05	0.0346	0.41	0.35	Hirschsprung disease;	chr10:43109944	chr10:43136824~43138334:-
TGCT	cis	rs6568686	0.577	rs174391	ENSG00000272356.1	RP5-1112D6.8	-4.12	6.81e-05	0.0346	-0.4	-0.35	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111596745	chr6:111309203~111313517:+
TGCT	cis	rs1707322	0.721	rs11211166	ENSG00000280836.1	AL355480.1	-4.12	6.82e-05	0.0347	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45581219~45581321:-
TGCT	cis	rs7208859	0.623	rs80355557	ENSG00000266490.1	CTD-2349P21.9	4.12	6.82e-05	0.0347	0.35	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs9911173	ENSG00000266490.1	CTD-2349P21.9	4.12	6.82e-05	0.0347	0.35	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs73271887	ENSG00000266490.1	CTD-2349P21.9	4.12	6.82e-05	0.0347	0.35	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs9898858	ENSG00000266490.1	CTD-2349P21.9	4.12	6.82e-05	0.0347	0.35	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs55658077	ENSG00000266490.1	CTD-2349P21.9	4.12	6.82e-05	0.0347	0.35	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs9899692	ENSG00000266490.1	CTD-2349P21.9	4.12	6.82e-05	0.0347	0.35	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs9906957	ENSG00000266490.1	CTD-2349P21.9	4.12	6.82e-05	0.0347	0.35	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.673	rs9915139	ENSG00000266490.1	CTD-2349P21.9	4.12	6.82e-05	0.0347	0.35	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30792372~30792833:+
TGCT	cis	rs10129255	0.518	rs12590732	ENSG00000280411.1	IGHV1-69-2	4.12	6.82e-05	0.0347	0.35	0.35	Kawasaki disease;	chr14:106779612	chr14:106762092~106762588:-
TGCT	cis	rs10938353	0.68	rs66691259	ENSG00000273369.1	RP11-700J17.1	4.12	6.82e-05	0.0347	0.52	0.35	Body mass index;	chr4:44705036	chr4:44693946~44694386:-
TGCT	cis	rs957448	1	rs72674861	ENSG00000253175.1	RP11-267M23.6	4.12	6.83e-05	0.0347	0.45	0.35	Nonsyndromic cleft lip with cleft palate;	chr8:94550051	chr8:94565036~94565715:+
TGCT	cis	rs957448	1	rs60655325	ENSG00000253175.1	RP11-267M23.6	4.12	6.83e-05	0.0347	0.45	0.35	Nonsyndromic cleft lip with cleft palate;	chr8:94552606	chr8:94565036~94565715:+
TGCT	cis	rs957448	1	rs16916881	ENSG00000253175.1	RP11-267M23.6	4.12	6.83e-05	0.0347	0.45	0.35	Nonsyndromic cleft lip with cleft palate;	chr8:94554042	chr8:94565036~94565715:+
TGCT	cis	rs2505998	0.833	rs1864405	ENSG00000273008.1	RP11-351D16.3	-4.12	6.84e-05	0.0347	-0.4	-0.35	Hirschsprung disease;	chr10:43108700	chr10:43136824~43138334:-
TGCT	cis	rs2505998	0.833	rs1864404	ENSG00000273008.1	RP11-351D16.3	-4.12	6.84e-05	0.0347	-0.4	-0.35	Hirschsprung disease;	chr10:43108942	chr10:43136824~43138334:-
TGCT	cis	rs3749237	0.615	rs6792911	ENSG00000226913.1	BSN-AS2	-4.12	6.84e-05	0.0347	-0.26	-0.35	Resting heart rate;	chr3:49392423	chr3:49549306~49554366:-
TGCT	cis	rs11671104	0.609	rs7256630	ENSG00000269332.4	GOLGA2P9	4.12	6.84e-05	0.0347	0.48	0.35	Colorectal cancer (diet interaction);	chr19:22606461	chr19:22596257~22603550:+
TGCT	cis	rs2833693	0.572	rs9982765	ENSG00000261610.1	AP000265.1	4.12	6.84e-05	0.0348	0.41	0.35	Temperament;	chr21:32204315	chr21:32259804~32261585:-
TGCT	cis	rs73607972	0.935	rs73603987	ENSG00000275191.1	RP11-36I17.2	-4.12	6.84e-05	0.0348	-0.46	-0.35	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53577714	chr16:53628256~53628816:-
TGCT	cis	rs73607972	0.799	rs112105499	ENSG00000275191.1	RP11-36I17.2	-4.12	6.84e-05	0.0348	-0.46	-0.35	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53577948	chr16:53628256~53628816:-
TGCT	cis	rs2739330	0.76	rs5760095	ENSG00000235689.1	AP000351.13	4.12	6.84e-05	0.0348	0.33	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:24006305~24008258:-
TGCT	cis	rs2505998	0.719	rs10900296	ENSG00000273008.1	RP11-351D16.3	-4.12	6.84e-05	0.0348	-0.39	-0.35	Hirschsprung disease;	chr10:43077059	chr10:43136824~43138334:-
TGCT	cis	rs11722228	0.549	rs73212863	ENSG00000261490.1	RP11-448G15.3	4.12	6.84e-05	0.0348	0.35	0.35	Urate levels;Serum uric acid levels;Gout;	chr4:10102549	chr4:10068089~10073019:-
TGCT	cis	rs11722228	0.508	rs73212864	ENSG00000261490.1	RP11-448G15.3	4.12	6.84e-05	0.0348	0.35	0.35	Urate levels;Serum uric acid levels;Gout;	chr4:10102567	chr4:10068089~10073019:-
TGCT	cis	rs9322193	0.923	rs9371207	ENSG00000231760.4	RP11-350J20.5	4.12	6.84e-05	0.0348	0.44	0.35	Lung cancer;	chr6:149858087	chr6:149796151~149826294:-
TGCT	cis	rs9322193	0.923	rs2880436	ENSG00000231760.4	RP11-350J20.5	4.12	6.84e-05	0.0348	0.44	0.35	Lung cancer;	chr6:149859123	chr6:149796151~149826294:-
TGCT	cis	rs7824557	0.606	rs2736264	ENSG00000255020.1	AF131216.5	4.12	6.85e-05	0.0348	0.24	0.35	Retinal vascular caliber;	chr8:11329130	chr8:11345748~11347502:-
TGCT	cis	rs507080	0.922	rs4936433	ENSG00000255422.1	AP002954.4	4.12	6.85e-05	0.0348	0.45	0.35	Serum metabolite levels;	chr11:118681711	chr11:118704607~118750263:+
TGCT	cis	rs7824557	0.651	rs6601582	ENSG00000255020.1	AF131216.5	4.12	6.85e-05	0.0348	0.24	0.35	Retinal vascular caliber;	chr8:11349858	chr8:11345748~11347502:-
TGCT	cis	rs2033711	0.87	rs1051500	ENSG00000268912.1	CTD-2619J13.17	-4.12	6.85e-05	0.0348	-0.31	-0.35	Uric acid clearance;	chr19:58433035	chr19:58428632~58431148:-
TGCT	cis	rs10129255	0.5	rs7159033	ENSG00000223648.3	IGHV3-64	4.12	6.85e-05	0.0348	0.3	0.35	Kawasaki disease;	chr14:106701709	chr14:106643132~106658258:-
TGCT	cis	rs7647973	0.6	rs12631989	ENSG00000226913.1	BSN-AS2	-4.12	6.85e-05	0.0348	-0.27	-0.35	Menarche (age at onset);	chr3:49236563	chr3:49549306~49554366:-
TGCT	cis	rs7647973	0.6	rs13064780	ENSG00000226913.1	BSN-AS2	-4.12	6.85e-05	0.0348	-0.27	-0.35	Menarche (age at onset);	chr3:49237393	chr3:49549306~49554366:-
TGCT	cis	rs7647973	0.58	rs35218722	ENSG00000226913.1	BSN-AS2	-4.12	6.85e-05	0.0348	-0.27	-0.35	Menarche (age at onset);	chr3:49238372	chr3:49549306~49554366:-
TGCT	cis	rs7647973	0.6	rs35174559	ENSG00000226913.1	BSN-AS2	-4.12	6.85e-05	0.0348	-0.27	-0.35	Menarche (age at onset);	chr3:49250326	chr3:49549306~49554366:-
TGCT	cis	rs7647973	0.56	rs7638154	ENSG00000226913.1	BSN-AS2	-4.12	6.85e-05	0.0348	-0.27	-0.35	Menarche (age at onset);	chr3:49261942	chr3:49549306~49554366:-
TGCT	cis	rs6940638	0.688	rs9348750	ENSG00000187763.3	OR2B7P	4.12	6.86e-05	0.0348	0.32	0.35	Intelligence (multi-trait analysis);	chr6:27090166	chr6:28046434~28047367:+
TGCT	cis	rs6940638	0.715	rs9348751	ENSG00000187763.3	OR2B7P	4.12	6.86e-05	0.0348	0.32	0.35	Intelligence (multi-trait analysis);	chr6:27099411	chr6:28046434~28047367:+
TGCT	cis	rs6940638	0.688	rs6921388	ENSG00000187763.3	OR2B7P	4.12	6.86e-05	0.0348	0.32	0.35	Intelligence (multi-trait analysis);	chr6:27112426	chr6:28046434~28047367:+
TGCT	cis	rs7829975	0.564	rs2921057	ENSG00000254340.1	RP11-10A14.3	4.12	6.86e-05	0.0348	0.35	0.35	Mood instability;	chr8:8461157	chr8:9141424~9145435:+
TGCT	cis	rs2159292	0.59	rs8069599	ENSG00000261433.1	CTC-297N7.1	4.12	6.86e-05	0.0348	0.66	0.35	Schizophrenia;	chr17:11253405	chr17:10658542~10659082:-
TGCT	cis	rs875971	0.545	rs73136346	ENSG00000222364.1	RNU6-96P	4.12	6.86e-05	0.0348	0.45	0.35	Aortic root size;	chr7:66101095	chr7:66395191~66395286:+
TGCT	cis	rs7605378	0.752	rs769960	ENSG00000232732.8	AC073043.1	4.12	6.86e-05	0.0348	0.41	0.35	Osteoporosis;	chr2:199845983	chr2:199867396~199911159:-
TGCT	cis	rs9558942	0.961	rs4640043	ENSG00000277863.1	RP11-282A11.4	-4.12	6.86e-05	0.0348	-0.4	-0.35	Obesity-related traits;	chr13:107059568	chr13:106903150~106904099:-
TGCT	cis	rs9558942	0.961	rs4771549	ENSG00000277863.1	RP11-282A11.4	-4.12	6.86e-05	0.0348	-0.4	-0.35	Obesity-related traits;	chr13:107059881	chr13:106903150~106904099:-
TGCT	cis	rs6471717	0.509	rs12680996	ENSG00000242970.2	AC068522.4	-4.12	6.87e-05	0.0349	-0.4	-0.35	Gallstone disease;	chr8:58542776	chr8:58588420~58588764:-
TGCT	cis	rs9660180	0.967	rs9660106	ENSG00000231050.1	RP1-140A9.1	4.12	6.87e-05	0.0349	0.32	0.35	Body mass index;	chr1:1866508	chr1:1891471~1892658:+
TGCT	cis	rs9660180	0.967	rs11260623	ENSG00000231050.1	RP1-140A9.1	4.12	6.87e-05	0.0349	0.32	0.35	Body mass index;	chr1:1850017	chr1:1891471~1892658:+
TGCT	cis	rs8081395	0.836	rs2150879	ENSG00000266992.1	DHX40P1	-4.12	6.88e-05	0.0349	-0.37	-0.35	White blood cell count;	chr17:59781849	chr17:59976009~60002384:-
TGCT	cis	rs1012068	0.686	rs5994451	ENSG00000236132.1	CTA-440B3.1	-4.12	6.88e-05	0.0349	-0.41	-0.35	Chronic hepatitis C infection;	chr22:31927525	chr22:31816379~31817491:-
TGCT	cis	rs7005380	0.733	rs6469878	ENSG00000254343.2	RP11-760H22.2	-4.12	6.88e-05	0.0349	-0.44	-0.35	Interstitial lung disease;	chr8:119926208	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.733	rs10808505	ENSG00000254343.2	RP11-760H22.2	-4.12	6.88e-05	0.0349	-0.44	-0.35	Interstitial lung disease;	chr8:119927966	chr8:120052180~120056201:+
TGCT	cis	rs1707322	1	rs10890365	ENSG00000280836.1	AL355480.1	-4.12	6.88e-05	0.0349	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893676	chr1:45581219~45581321:-
TGCT	cis	rs8081395	0.801	rs12938273	ENSG00000266992.1	DHX40P1	-4.12	6.88e-05	0.0349	-0.37	-0.35	White blood cell count;	chr17:59824291	chr17:59976009~60002384:-
TGCT	cis	rs10946737	0.867	rs10946739	ENSG00000220517.2	ASS1P1	4.12	6.88e-05	0.0349	0.34	0.35	Liver injury in anti-tuberculosis drug treatment;	chr6:24992899	chr6:25023247~25024483:-
TGCT	cis	rs7208859	0.573	rs8070182	ENSG00000263603.1	CTD-2349P21.5	-4.12	6.88e-05	0.0349	-0.48	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30729469~30731202:+
TGCT	cis	rs9733	0.744	rs12568757	ENSG00000236713.1	RP11-363I22.3	4.12	6.9e-05	0.035	0.26	0.35	Tonsillectomy;	chr1:150757317	chr1:150780272~150780644:+
TGCT	cis	rs2066819	0.792	rs1274496	ENSG00000257303.1	RP11-977G19.11	-4.12	6.9e-05	0.035	-0.6	-0.35	Psoriasis vulgaris;	chr12:56231909	chr12:56300142~56314808:+
TGCT	cis	rs7523273	0.565	rs2796250	ENSG00000203709.8	C1orf132	-4.12	6.91e-05	0.035	-0.27	-0.35	Schizophrenia;	chr1:207730309	chr1:207801518~207869150:-
TGCT	cis	rs7523273	0.565	rs2796251	ENSG00000203709.8	C1orf132	-4.12	6.91e-05	0.035	-0.27	-0.35	Schizophrenia;	chr1:207730343	chr1:207801518~207869150:-
TGCT	cis	rs875971	1	rs875971	ENSG00000232559.3	GS1-124K5.12	-4.12	6.92e-05	0.0351	-0.33	-0.35	Aortic root size;	chr7:66152608	chr7:66554588~66576923:-
TGCT	cis	rs801193	0.613	rs2016325	ENSG00000272831.1	RP11-792A8.4	-4.12	6.93e-05	0.0351	-0.35	-0.35	Aortic root size;	chr7:66858513	chr7:66739829~66740385:-
TGCT	cis	rs7923609	0.776	rs10761785	ENSG00000232075.1	MRPL35P2	-4.12	6.93e-05	0.0351	-0.33	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63559006	chr10:63634317~63634827:-
TGCT	cis	rs4660214	0.666	rs1984143	ENSG00000182109.6	RP11-69E11.4	-4.12	6.93e-05	0.0351	-0.36	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39290645	chr1:39522280~39546187:-
TGCT	cis	rs4660214	0.666	rs12025847	ENSG00000182109.6	RP11-69E11.4	-4.12	6.93e-05	0.0351	-0.36	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300977	chr1:39522280~39546187:-
TGCT	cis	rs13118159	0.527	rs1250119	ENSG00000254094.1	AC078852.1	4.12	6.93e-05	0.0351	0.43	0.35	Longevity;	chr4:1267548	chr4:1356581~1358075:+
TGCT	cis	rs9322193	0.607	rs7764677	ENSG00000216906.2	RP11-350J20.9	4.12	6.93e-05	0.0351	0.44	0.35	Lung cancer;	chr6:149906197	chr6:149904243~149906418:+
TGCT	cis	rs9457247	0.935	rs1187529	ENSG00000265828.1	MIR3939	4.12	6.94e-05	0.0351	0.33	0.35	Crohn's disease;	chr6:166963205	chr6:166997807~166997912:-
TGCT	cis	rs7775554	0.874	rs1757815	ENSG00000219240.2	RP11-63K6.5	4.12	6.94e-05	0.0352	0.29	0.35	Blood metabolite levels;	chr6:89169577	chr6:89886156~89887848:+
TGCT	cis	rs9733	0.65	rs6698495	ENSG00000236713.1	RP11-363I22.3	4.12	6.94e-05	0.0352	0.27	0.35	Tonsillectomy;	chr1:150592000	chr1:150780272~150780644:+
TGCT	cis	rs2243480	0.522	rs778717	ENSG00000226824.5	RP4-756H11.3	-4.12	6.95e-05	0.0352	-0.66	-0.35	Diabetic kidney disease;	chr7:66383164	chr7:66654538~66669855:+
TGCT	cis	rs2709736	0.869	rs10229390	ENSG00000232790.2	LINC01162	-4.12	6.95e-05	0.0352	-0.25	-0.35	Bipolar I disorder;	chr7:20817716	chr7:20835431~21023148:+
TGCT	cis	rs6669072	1	rs6676886	ENSG00000231613.1	RP5-943J3.1	-4.12	6.95e-05	0.0352	-0.34	-0.35	Cognitive function;	chr1:90778786	chr1:89788914~89790492:+
TGCT	cis	rs901683	1	rs71494787	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45476799	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71494788	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45476877	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71494789	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45477033	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71494790	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45477163	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35464392	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45477432	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs34566829	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45478150	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35349326	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45478176	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35424022	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45481092	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs34285816	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45481403	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs12779281	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45481999	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71499565	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45482267	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71494791	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45482883	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71494792	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45487601	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35632234	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45487931	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs36070902	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45488529	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs12773263	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45488898	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71494793	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45489644	chr10:46109621~46131358:+
TGCT	cis	rs901683	0.85	rs71494794	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45489836	chr10:46109621~46131358:+
TGCT	cis	rs901683	0.85	rs71515355	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45489908	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs34415465	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45490132	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs12768131	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45491000	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs12763205	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45491047	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35187216	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45491172	chr10:46109621~46131358:+
TGCT	cis	rs901683	0.681	rs71494795	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45492297	chr10:46109621~46131358:+
TGCT	cis	rs901683	0.702	rs34019727	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45492303	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs75712637	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45492744	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs78220003	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45492900	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs34268168	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45493078	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35303148	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45493806	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs12774690	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45494297	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs12764652	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45496530	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs12778980	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45498763	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs34081402	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45498979	chr10:46109621~46131358:+
TGCT	cis	rs901683	0.85	rs35081812	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45500341	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71499566	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45500567	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71494797	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45502010	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35326978	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45502264	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs34879733	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45502313	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35918870	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45502830	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71494798	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45503532	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35394192	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45505313	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs12764485	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45507139	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71494799	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45507408	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71494800	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45507506	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs12773463	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45508183	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35172875	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45508712	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71494802	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45510176	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71496603	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45510201	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35294227	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45511350	chr10:46109621~46131358:+
TGCT	cis	rs35993099	1	rs35993099	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular hemoglobin;Red blood cell count;	chr10:45511519	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71496605	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45514370	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71496606	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45514650	chr10:46109621~46131358:+
TGCT	cis	rs901683	0.85	rs71496607	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45514868	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35504302	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45515057	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs12766550	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45515907	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs12772485	ENSG00000264204.2	AGAP7P	-4.12	6.95e-05	0.0352	-0.81	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45515973	chr10:46109621~46131358:+
TGCT	cis	rs1519814	0.702	rs4871032	ENSG00000254343.2	RP11-760H22.2	4.12	6.96e-05	0.0352	0.55	0.35	Breast cancer;	chr8:120029835	chr8:120052180~120056201:+
TGCT	cis	rs17608059	0.518	rs4792436	ENSG00000141028.6	CDRT15P1	4.12	6.96e-05	0.0352	0.38	0.35	Temperament;	chr17:14068990	chr17:14024514~14025488:+
TGCT	cis	rs11651753	0.613	rs4793732	ENSG00000264920.1	RP11-6N17.4	-4.12	6.96e-05	0.0352	-0.35	-0.35	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47956488	chr17:47891255~47895812:-
TGCT	cis	rs10971721	0.584	rs55857848	ENSG00000230074.1	RP11-195F19.9	-4.12	6.97e-05	0.0352	-0.5	-0.35	Body mass index;	chr9:34121512	chr9:34665665~34681298:+
TGCT	cis	rs6782228	0.606	rs2811488	ENSG00000242551.2	POU5F1P6	-4.12	6.97e-05	0.0352	-0.43	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617674	chr3:128674735~128677005:-
TGCT	cis	rs901683	1	rs35968565	ENSG00000264204.2	AGAP7P	-4.12	6.97e-05	0.0352	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45580748	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs75820736	ENSG00000264204.2	AGAP7P	-4.12	6.97e-05	0.0352	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45580788	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71496621	ENSG00000264204.2	AGAP7P	-4.12	6.97e-05	0.0352	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45580900	chr10:46109621~46131358:+
TGCT	cis	rs2337406	1	rs78631692	ENSG00000274576.2	IGHV2-70	-4.12	6.98e-05	0.0353	-0.52	-0.35	Alzheimer's disease (late onset);	chr14:106709371	chr14:106770577~106771020:-
TGCT	cis	rs7775554	1	rs7775554	ENSG00000219240.2	RP11-63K6.5	4.12	6.99e-05	0.0353	0.28	0.35	Blood metabolite levels;	chr6:89169449	chr6:89886156~89887848:+
TGCT	cis	rs6782228	0.585	rs2712392	ENSG00000242551.2	POU5F1P6	-4.12	6.99e-05	0.0353	-0.42	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705414	chr3:128674735~128677005:-
TGCT	cis	rs673078	0.562	rs56347775	ENSG00000275759.1	RP11-131L12.3	-4.12	6.99e-05	0.0353	-0.62	-0.35	Glucose homeostasis traits;	chr12:118438002	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs61943451	ENSG00000275759.1	RP11-131L12.3	-4.12	6.99e-05	0.0353	-0.62	-0.35	Glucose homeostasis traits;	chr12:118438929	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.518	rs61943452	ENSG00000275759.1	RP11-131L12.3	-4.12	6.99e-05	0.0353	-0.62	-0.35	Glucose homeostasis traits;	chr12:118438990	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs61943454	ENSG00000275759.1	RP11-131L12.3	-4.12	6.99e-05	0.0353	-0.62	-0.35	Glucose homeostasis traits;	chr12:118439140	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.517	rs61943455	ENSG00000275759.1	RP11-131L12.3	-4.12	6.99e-05	0.0353	-0.62	-0.35	Glucose homeostasis traits;	chr12:118439414	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs73207566	ENSG00000275759.1	RP11-131L12.3	-4.12	6.99e-05	0.0353	-0.62	-0.35	Glucose homeostasis traits;	chr12:118439471	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs2393416	ENSG00000275759.1	RP11-131L12.3	-4.12	6.99e-05	0.0353	-0.62	-0.35	Glucose homeostasis traits;	chr12:118439968	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.56	rs4406856	ENSG00000275759.1	RP11-131L12.3	-4.12	6.99e-05	0.0353	-0.62	-0.35	Glucose homeostasis traits;	chr12:118440094	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs4457791	ENSG00000275759.1	RP11-131L12.3	-4.12	6.99e-05	0.0353	-0.62	-0.35	Glucose homeostasis traits;	chr12:118440144	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs61943456	ENSG00000275759.1	RP11-131L12.3	-4.12	6.99e-05	0.0353	-0.62	-0.35	Glucose homeostasis traits;	chr12:118440326	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs17513006	ENSG00000275759.1	RP11-131L12.3	-4.12	6.99e-05	0.0353	-0.62	-0.35	Glucose homeostasis traits;	chr12:118440383	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.56	rs61943457	ENSG00000275759.1	RP11-131L12.3	-4.12	6.99e-05	0.0353	-0.62	-0.35	Glucose homeostasis traits;	chr12:118440487	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.562	rs55883417	ENSG00000275759.1	RP11-131L12.3	-4.12	6.99e-05	0.0353	-0.62	-0.35	Glucose homeostasis traits;	chr12:118440801	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs55842338	ENSG00000275759.1	RP11-131L12.3	-4.12	6.99e-05	0.0353	-0.62	-0.35	Glucose homeostasis traits;	chr12:118441259	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.518	rs17441251	ENSG00000275759.1	RP11-131L12.3	-4.12	6.99e-05	0.0353	-0.62	-0.35	Glucose homeostasis traits;	chr12:118441361	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs17513013	ENSG00000275759.1	RP11-131L12.3	-4.12	6.99e-05	0.0353	-0.62	-0.35	Glucose homeostasis traits;	chr12:118442070	chr12:118428281~118428870:+
TGCT	cis	rs2029362	0.611	rs10767665	ENSG00000245573.6	BDNF-AS	4.12	7e-05	0.0354	0.27	0.35	Total body bone mineral density;	chr11:27712311	chr11:27506838~27698174:+
TGCT	cis	rs11671005	0.779	rs731259	ENSG00000232098.3	CTD-2619J13.14	-4.12	7.01e-05	0.0354	-0.45	-0.35	Mean platelet volume;	chr19:58478057	chr19:58404238~58408484:-
TGCT	cis	rs853679	0.55	rs1233699	ENSG00000219891.2	ZSCAN12P1	4.11	7.01e-05	0.0354	0.44	0.35	Depression;	chr6:28201380	chr6:28091154~28093664:+
TGCT	cis	rs1799955	1	rs1799955	ENSG00000215515.2	IFIT1P1	-4.11	7.01e-05	0.0354	-0.48	-0.35	LDL cholesterol levels;	chr13:32355095	chr13:32384660~32386108:+
TGCT	cis	rs1799955	1	rs9567600	ENSG00000215515.2	IFIT1P1	-4.11	7.01e-05	0.0354	-0.48	-0.35	LDL cholesterol levels;	chr13:32359789	chr13:32384660~32386108:+
TGCT	cis	rs1799955	1	rs11571717	ENSG00000215515.2	IFIT1P1	-4.11	7.01e-05	0.0354	-0.48	-0.35	LDL cholesterol levels;	chr13:32360774	chr13:32384660~32386108:+
TGCT	cis	rs17665889	0.51	rs9395700	ENSG00000225791.5	TRAM2-AS1	4.11	7.01e-05	0.0354	0.43	0.35	Cannabis dependence symptom count;	chr6:51620911	chr6:52577307~52583993:+
TGCT	cis	rs12908161	0.96	rs11633450	ENSG00000259728.4	LINC00933	4.11	7.01e-05	0.0354	0.42	0.35	Schizophrenia;	chr15:84764056	chr15:84570649~84580175:+
TGCT	cis	rs801193	0.569	rs2659893	ENSG00000232559.3	GS1-124K5.12	4.11	7.02e-05	0.0354	0.32	0.35	Aortic root size;	chr7:66735006	chr7:66554588~66576923:-
TGCT	cis	rs801193	0.569	rs2659892	ENSG00000232559.3	GS1-124K5.12	4.11	7.02e-05	0.0354	0.32	0.35	Aortic root size;	chr7:66735318	chr7:66554588~66576923:-
TGCT	cis	rs801193	0.548	rs2659891	ENSG00000232559.3	GS1-124K5.12	4.11	7.02e-05	0.0354	0.32	0.35	Aortic root size;	chr7:66736127	chr7:66554588~66576923:-
TGCT	cis	rs801193	0.569	rs2707847	ENSG00000232559.3	GS1-124K5.12	4.11	7.02e-05	0.0354	0.32	0.35	Aortic root size;	chr7:66737884	chr7:66554588~66576923:-
TGCT	cis	rs801193	0.548	rs7805152	ENSG00000232559.3	GS1-124K5.12	4.11	7.02e-05	0.0354	0.32	0.35	Aortic root size;	chr7:66744266	chr7:66554588~66576923:-
TGCT	cis	rs801193	0.569	rs11761542	ENSG00000232559.3	GS1-124K5.12	4.11	7.02e-05	0.0354	0.32	0.35	Aortic root size;	chr7:66753209	chr7:66554588~66576923:-
TGCT	cis	rs72843506	0.586	rs76886618	ENSG00000261033.1	RP11-209D14.2	4.11	7.03e-05	0.0355	0.5	0.35	Schizophrenia;	chr17:19975483	chr17:20008051~20009234:-
TGCT	cis	rs72843506	0.586	rs74811834	ENSG00000261033.1	RP11-209D14.2	4.11	7.03e-05	0.0355	0.5	0.35	Schizophrenia;	chr17:19982271	chr17:20008051~20009234:-
TGCT	cis	rs72843506	0.52	rs78178505	ENSG00000261033.1	RP11-209D14.2	4.11	7.03e-05	0.0355	0.5	0.35	Schizophrenia;	chr17:19984410	chr17:20008051~20009234:-
TGCT	cis	rs875971	1	rs2087647	ENSG00000232559.3	GS1-124K5.12	-4.11	7.03e-05	0.0355	-0.33	-0.35	Aortic root size;	chr7:66128201	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs6958484	ENSG00000232559.3	GS1-124K5.12	-4.11	7.03e-05	0.0355	-0.33	-0.35	Aortic root size;	chr7:66134459	chr7:66554588~66576923:-
TGCT	cis	rs1799949	0.965	rs8176310	ENSG00000198496.9	NBR2	-4.11	7.03e-05	0.0355	-0.49	-0.35	Menopause (age at onset);	chr17:43047896	chr17:43125610~43153671:+
TGCT	cis	rs1799949	0.965	rs8070179	ENSG00000198496.9	NBR2	-4.11	7.03e-05	0.0355	-0.49	-0.35	Menopause (age at onset);	chr17:43050671	chr17:43125610~43153671:+
TGCT	cis	rs1707322	1	rs4660906	ENSG00000280836.1	AL355480.1	-4.11	7.03e-05	0.0355	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46005188	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs3922887	ENSG00000280836.1	AL355480.1	-4.11	7.03e-05	0.0355	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008130	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs3922886	ENSG00000280836.1	AL355480.1	-4.11	7.03e-05	0.0355	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008230	chr1:45581219~45581321:-
TGCT	cis	rs7688540	0.771	rs61794996	ENSG00000275426.1	CH17-262A2.1	4.11	7.03e-05	0.0355	0.69	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:215539	chr4:149738~150317:+
TGCT	cis	rs67340775	0.541	rs200965	ENSG00000187763.3	OR2B7P	4.11	7.03e-05	0.0355	0.4	0.35	Lung cancer in ever smokers;	chr6:27898606	chr6:28046434~28047367:+
TGCT	cis	rs4380275	0.782	rs4335978	ENSG00000272342.1	RP13-539J13.1	4.11	7.03e-05	0.0355	0.44	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:750078	chr2:739588~740164:-
TGCT	cis	rs67311347	0.866	rs11712426	ENSG00000223797.4	ENTPD3-AS1	4.11	7.04e-05	0.0355	0.36	0.35	Renal cell carcinoma;	chr3:40288831	chr3:40313802~40453329:-
TGCT	cis	rs10129255	0.576	rs2157616	ENSG00000280411.1	IGHV1-69-2	-4.11	7.05e-05	0.0355	-0.35	-0.35	Kawasaki disease;	chr14:106767802	chr14:106762092~106762588:-
TGCT	cis	rs10256972	0.967	rs7799110	ENSG00000226291.1	AC091729.8	-4.11	7.05e-05	0.0355	-0.36	-0.35	Endometriosis;Longevity;	chr7:999429	chr7:1080863~1082178:+
TGCT	cis	rs10256972	0.869	rs4720158	ENSG00000226291.1	AC091729.8	-4.11	7.05e-05	0.0355	-0.36	-0.35	Endometriosis;Longevity;	chr7:1000689	chr7:1080863~1082178:+
TGCT	cis	rs9309473	0.95	rs6756885	ENSG00000163016.8	ALMS1P	4.11	7.05e-05	0.0355	0.31	0.35	Metabolite levels;	chr2:73578045	chr2:73644919~73685576:+
TGCT	cis	rs10504229	0.639	rs56066782	ENSG00000253301.4	RP11-513O17.2	4.11	7.05e-05	0.0356	0.53	0.35	Developmental language disorder (linguistic errors);	chr8:57193298	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs16921807	ENSG00000253301.4	RP11-513O17.2	4.11	7.05e-05	0.0356	0.53	0.35	Developmental language disorder (linguistic errors);	chr8:57193408	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs56235637	ENSG00000253301.4	RP11-513O17.2	4.11	7.05e-05	0.0356	0.53	0.35	Developmental language disorder (linguistic errors);	chr8:57193449	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs16921810	ENSG00000253301.4	RP11-513O17.2	4.11	7.05e-05	0.0356	0.53	0.35	Developmental language disorder (linguistic errors);	chr8:57193508	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.679	rs16920056	ENSG00000253301.4	RP11-513O17.2	4.11	7.05e-05	0.0356	0.53	0.35	Developmental language disorder (linguistic errors);	chr8:57193659	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs55881798	ENSG00000253301.4	RP11-513O17.2	4.11	7.05e-05	0.0356	0.53	0.35	Developmental language disorder (linguistic errors);	chr8:57193847	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.639	rs56825757	ENSG00000253301.4	RP11-513O17.2	4.11	7.05e-05	0.0356	0.53	0.35	Developmental language disorder (linguistic errors);	chr8:57193910	chr8:57142689~57240298:+
TGCT	cis	rs10504229	0.683	rs61241336	ENSG00000253301.4	RP11-513O17.2	4.11	7.05e-05	0.0356	0.53	0.35	Developmental language disorder (linguistic errors);	chr8:57194026	chr8:57142689~57240298:+
TGCT	cis	rs7824557	0.606	rs1047950	ENSG00000255020.1	AF131216.5	4.11	7.06e-05	0.0356	0.24	0.35	Retinal vascular caliber;	chr8:11327587	chr8:11345748~11347502:-
TGCT	cis	rs7824557	0.569	rs35418978	ENSG00000255020.1	AF131216.5	4.11	7.06e-05	0.0356	0.24	0.35	Retinal vascular caliber;	chr8:11328944	chr8:11345748~11347502:-
TGCT	cis	rs875971	0.522	rs1880556	ENSG00000272831.1	RP11-792A8.4	4.11	7.06e-05	0.0356	0.36	0.35	Aortic root size;	chr7:65967557	chr7:66739829~66740385:-
TGCT	cis	rs875971	0.522	rs781144	ENSG00000272831.1	RP11-792A8.4	4.11	7.06e-05	0.0356	0.36	0.35	Aortic root size;	chr7:65975357	chr7:66739829~66740385:-
TGCT	cis	rs993925	0.534	rs6694661	ENSG00000223842.1	RP11-135J2.3	-4.11	7.06e-05	0.0356	-0.37	-0.35	Pulmonary function;	chr1:218669862	chr1:219222248~219225497:-
TGCT	cis	rs9796	0.774	rs28866311	ENSG00000259838.1	TCEB1P2	4.11	7.06e-05	0.0356	0.44	0.35	Menopause (age at onset);	chr15:41149997	chr15:41557027~41557435:+
TGCT	cis	rs748404	0.666	rs10518812	ENSG00000205771.5	CATSPER2P1	4.11	7.06e-05	0.0356	0.5	0.35	Lung cancer;	chr15:43360739	chr15:43726918~43747094:-
TGCT	cis	rs6604026	0.59	rs35612297	ENSG00000223787.2	RP4-593M8.1	4.11	7.06e-05	0.0356	0.48	0.35	Multiple sclerosis;	chr1:92688538	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.59	rs72724574	ENSG00000223787.2	RP4-593M8.1	4.11	7.06e-05	0.0356	0.48	0.35	Multiple sclerosis;	chr1:92692547	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.624	rs12731107	ENSG00000223787.2	RP4-593M8.1	4.11	7.06e-05	0.0356	0.48	0.35	Multiple sclerosis;	chr1:92701772	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.624	rs72724587	ENSG00000223787.2	RP4-593M8.1	4.11	7.06e-05	0.0356	0.48	0.35	Multiple sclerosis;	chr1:92707653	chr1:92580476~92580821:-
TGCT	cis	rs9660180	0.967	rs10907191	ENSG00000231050.1	RP1-140A9.1	4.11	7.07e-05	0.0356	0.32	0.35	Body mass index;	chr1:1843381	chr1:1891471~1892658:+
TGCT	cis	rs11121022	0.965	rs11121021	ENSG00000269925.1	RP3-467L1.6	-4.11	7.07e-05	0.0356	-0.36	-0.35	Morning vs. evening chronotype;	chr1:7775639	chr1:7776383~7776775:+
TGCT	cis	rs4713118	0.662	rs149970	ENSG00000219891.2	ZSCAN12P1	4.11	7.08e-05	0.0357	0.39	0.35	Parkinson's disease;	chr6:28012442	chr6:28091154~28093664:+
TGCT	cis	rs7181230	0.885	rs28826672	ENSG00000275636.1	RP11-521C20.5	4.11	7.08e-05	0.0357	0.44	0.35	Dehydroepiandrosterone sulphate levels;	chr15:40068165	chr15:40078892~40079347:+
TGCT	cis	rs2033711	0.84	rs10423138	ENSG00000268912.1	CTD-2619J13.17	-4.11	7.08e-05	0.0357	-0.3	-0.35	Uric acid clearance;	chr19:58416935	chr19:58428632~58431148:-
TGCT	cis	rs2033711	0.87	rs3764534	ENSG00000268912.1	CTD-2619J13.17	-4.11	7.08e-05	0.0357	-0.3	-0.35	Uric acid clearance;	chr19:58417769	chr19:58428632~58431148:-
TGCT	cis	rs1150668	0.796	rs1124132	ENSG00000204709.4	LINC01556	4.11	7.09e-05	0.0357	0.38	0.35	Pubertal anthropometrics;	chr6:28412544	chr6:28943877~28944537:+
TGCT	cis	rs2439831	1	rs2584726	ENSG00000205771.5	CATSPER2P1	-4.11	7.09e-05	0.0357	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43423184	chr15:43726918~43747094:-
TGCT	cis	rs2439831	1	rs565007	ENSG00000205771.5	CATSPER2P1	-4.11	7.09e-05	0.0357	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43424443	chr15:43726918~43747094:-
TGCT	cis	rs2439831	1	rs550239	ENSG00000205771.5	CATSPER2P1	-4.11	7.09e-05	0.0357	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43427999	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.85	rs558656	ENSG00000205771.5	CATSPER2P1	-4.11	7.09e-05	0.0357	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43431316	chr15:43726918~43747094:-
TGCT	cis	rs2439831	1	rs690002	ENSG00000205771.5	CATSPER2P1	-4.11	7.09e-05	0.0357	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43437151	chr15:43726918~43747094:-
TGCT	cis	rs2439831	1	rs537115	ENSG00000205771.5	CATSPER2P1	-4.11	7.09e-05	0.0357	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43437750	chr15:43726918~43747094:-
TGCT	cis	rs2439831	1	rs2245908	ENSG00000205771.5	CATSPER2P1	-4.11	7.09e-05	0.0357	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43439256	chr15:43726918~43747094:-
TGCT	cis	rs2439831	1	rs471229	ENSG00000205771.5	CATSPER2P1	-4.11	7.09e-05	0.0357	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43441796	chr15:43726918~43747094:-
TGCT	cis	rs2439831	1	rs2439841	ENSG00000205771.5	CATSPER2P1	-4.11	7.09e-05	0.0357	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43442551	chr15:43726918~43747094:-
TGCT	cis	rs2439831	1	rs2444029	ENSG00000205771.5	CATSPER2P1	-4.11	7.09e-05	0.0357	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43445286	chr15:43726918~43747094:-
TGCT	cis	rs2439831	1	rs2467739	ENSG00000205771.5	CATSPER2P1	-4.11	7.09e-05	0.0357	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43447998	chr15:43726918~43747094:-
TGCT	cis	rs2439831	1	rs28666488	ENSG00000205771.5	CATSPER2P1	-4.11	7.09e-05	0.0357	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43448892	chr15:43726918~43747094:-
TGCT	cis	rs2439831	1	rs2245790	ENSG00000205771.5	CATSPER2P1	-4.11	7.09e-05	0.0357	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43452259	chr15:43726918~43747094:-
TGCT	cis	rs2439831	1	rs2467740	ENSG00000205771.5	CATSPER2P1	-4.11	7.09e-05	0.0357	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43454594	chr15:43726918~43747094:-
TGCT	cis	rs2439831	1	rs690436	ENSG00000205771.5	CATSPER2P1	-4.11	7.09e-05	0.0357	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43469007	chr15:43726918~43747094:-
TGCT	cis	rs2439831	1	rs561863	ENSG00000205771.5	CATSPER2P1	-4.11	7.09e-05	0.0357	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43469154	chr15:43726918~43747094:-
TGCT	cis	rs2439831	1	rs689596	ENSG00000205771.5	CATSPER2P1	-4.11	7.09e-05	0.0357	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43469519	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.867	rs689616	ENSG00000205771.5	CATSPER2P1	-4.11	7.09e-05	0.0357	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43469703	chr15:43726918~43747094:-
TGCT	cis	rs2439831	1	rs689647	ENSG00000205771.5	CATSPER2P1	-4.11	7.09e-05	0.0357	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43469998	chr15:43726918~43747094:-
TGCT	cis	rs2439831	1	rs2264239	ENSG00000205771.5	CATSPER2P1	-4.11	7.09e-05	0.0357	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43473335	chr15:43726918~43747094:-
TGCT	cis	rs2439831	1	rs2251538	ENSG00000205771.5	CATSPER2P1	-4.11	7.09e-05	0.0357	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43475011	chr15:43726918~43747094:-
TGCT	cis	rs1707322	0.721	rs11211165	ENSG00000280836.1	AL355480.1	-4.11	7.1e-05	0.0357	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45581219~45581321:-
TGCT	cis	rs4919669	0.668	rs74558061	ENSG00000273108.1	RP11-416N2.4	-4.11	7.1e-05	0.0357	-0.49	-0.35	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102624580	chr10:103608619~103610050:+
TGCT	cis	rs2243480	1	rs410128	ENSG00000226824.5	RP4-756H11.3	-4.11	7.1e-05	0.0357	-0.62	-0.35	Diabetic kidney disease;	chr7:66138186	chr7:66654538~66669855:+
TGCT	cis	rs5758659	0.904	rs5758653	ENSG00000270083.1	RP1-257I20.14	4.11	7.1e-05	0.0357	0.34	0.35	Cognitive function;	chr22:42217479	chr22:42089630~42090028:-
TGCT	cis	rs172166	0.694	rs203876	ENSG00000219891.2	ZSCAN12P1	4.11	7.11e-05	0.0358	0.42	0.35	Cardiac Troponin-T levels;	chr6:28078895	chr6:28091154~28093664:+
TGCT	cis	rs172166	0.694	rs203877	ENSG00000219891.2	ZSCAN12P1	4.11	7.11e-05	0.0358	0.42	0.35	Cardiac Troponin-T levels;	chr6:28080846	chr6:28091154~28093664:+
TGCT	cis	rs172166	0.694	rs203893	ENSG00000219891.2	ZSCAN12P1	4.11	7.11e-05	0.0358	0.42	0.35	Cardiac Troponin-T levels;	chr6:28094288	chr6:28091154~28093664:+
TGCT	cis	rs172166	0.652	rs476167	ENSG00000219891.2	ZSCAN12P1	4.11	7.11e-05	0.0358	0.42	0.35	Cardiac Troponin-T levels;	chr6:28098110	chr6:28091154~28093664:+
TGCT	cis	rs172166	0.694	rs203892	ENSG00000219891.2	ZSCAN12P1	4.11	7.11e-05	0.0358	0.42	0.35	Cardiac Troponin-T levels;	chr6:28099418	chr6:28091154~28093664:+
TGCT	cis	rs172166	0.694	rs188105	ENSG00000219891.2	ZSCAN12P1	4.11	7.11e-05	0.0358	0.42	0.35	Cardiac Troponin-T levels;	chr6:28103615	chr6:28091154~28093664:+
TGCT	cis	rs7829975	0.714	rs6994038	ENSG00000173295.6	FAM86B3P	4.11	7.11e-05	0.0358	0.42	0.35	Mood instability;	chr8:8803028	chr8:8228595~8244865:+
TGCT	cis	rs7674212	0.507	rs10516495	ENSG00000230069.3	LRRC37A15P	-4.11	7.11e-05	0.0358	-0.33	-0.35	Type 2 diabetes;	chr4:102978933	chr4:102727274~102730721:-
TGCT	cis	rs7829975	0.572	rs28446104	ENSG00000254340.1	RP11-10A14.3	-4.11	7.11e-05	0.0358	-0.35	-0.35	Mood instability;	chr8:8938391	chr8:9141424~9145435:+
TGCT	cis	rs2276314	0.553	rs1789501	ENSG00000278986.1	RP11-723J4.3	4.11	7.11e-05	0.0358	0.36	0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:36037097	chr18:35972151~35973916:+
TGCT	cis	rs2919009	0.607	rs11199682	ENSG00000271670.1	RP11-95I16.4	4.11	7.11e-05	0.0358	0.44	0.35	Obesity-related traits;	chr10:120958339	chr10:120879256~120880667:-
TGCT	cis	rs2919009	0.607	rs12265028	ENSG00000271670.1	RP11-95I16.4	4.11	7.11e-05	0.0358	0.44	0.35	Obesity-related traits;	chr10:120959561	chr10:120879256~120880667:-
TGCT	cis	rs9733	0.715	rs7534124	ENSG00000236713.1	RP11-363I22.3	4.11	7.12e-05	0.0358	0.26	0.35	Tonsillectomy;	chr1:150766597	chr1:150780272~150780644:+
TGCT	cis	rs992157	0.73	rs4280446	ENSG00000261338.2	RP11-378A13.1	4.11	7.12e-05	0.0358	0.3	0.35	Colorectal cancer;	chr2:218319998	chr2:218255319~218257366:+
TGCT	cis	rs1150668	0.83	rs2859365	ENSG00000204709.4	LINC01556	-4.11	7.12e-05	0.0358	-0.38	-0.35	Pubertal anthropometrics;	chr6:28423688	chr6:28943877~28944537:+
TGCT	cis	rs4131099	0.793	rs16949691	ENSG00000261393.1	RP11-21B23.1	-4.11	7.12e-05	0.0358	-0.49	-0.35	Personality dimensions;	chr16:51329349	chr16:50368580~50371480:+
TGCT	cis	rs2286503	0.752	rs59538378	ENSG00000234286.1	AC006026.13	4.11	7.12e-05	0.0358	0.41	0.35	Fibrinogen;	chr7:22837478	chr7:23680195~23680786:-
TGCT	cis	rs992157	1	rs2168704	ENSG00000261338.2	RP11-378A13.1	4.11	7.13e-05	0.0358	0.28	0.35	Colorectal cancer;	chr2:218277769	chr2:218255319~218257366:+
TGCT	cis	rs992157	1	rs13429408	ENSG00000261338.2	RP11-378A13.1	4.11	7.13e-05	0.0358	0.28	0.35	Colorectal cancer;	chr2:218278137	chr2:218255319~218257366:+
TGCT	cis	rs992157	0.965	rs62182826	ENSG00000261338.2	RP11-378A13.1	4.11	7.13e-05	0.0358	0.28	0.35	Colorectal cancer;	chr2:218284000	chr2:218255319~218257366:+
TGCT	cis	rs5758659	1	rs134902	ENSG00000182057.4	OGFRP1	4.11	7.13e-05	0.0358	0.26	0.35	Cognitive function;	chr22:42287991	chr22:42269753~42275196:+
TGCT	cis	rs2280018	0.526	rs1510148	ENSG00000260735.1	RP11-72I8.1	-4.11	7.13e-05	0.0358	-0.45	-0.35	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15094411~15109197:+
TGCT	cis	rs7246657	0.941	rs10418729	ENSG00000226686.6	LINC01535	-4.11	7.14e-05	0.0359	-0.53	-0.35	Coronary artery calcification;	chr19:37246163	chr19:37251912~37265535:+
TGCT	cis	rs4925386	0.625	rs3810550	ENSG00000273619.1	RP5-908M14.9	-4.11	7.14e-05	0.0359	-0.43	-0.35	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62337061	chr20:62386303~62386970:-
TGCT	cis	rs7523273	0.606	rs2761430	ENSG00000203709.8	C1orf132	4.11	7.14e-05	0.0359	0.3	0.35	Schizophrenia;	chr1:207739063	chr1:207801518~207869150:-
TGCT	cis	rs9660180	0.967	rs6664664	ENSG00000231050.1	RP1-140A9.1	4.11	7.14e-05	0.0359	0.32	0.35	Body mass index;	chr1:1819825	chr1:1891471~1892658:+
TGCT	cis	rs1707322	0.752	rs11211171	ENSG00000280836.1	AL355480.1	-4.11	7.14e-05	0.0359	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.752	rs28623463	ENSG00000280836.1	AL355480.1	-4.11	7.14e-05	0.0359	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.716	rs28370457	ENSG00000280836.1	AL355480.1	-4.11	7.14e-05	0.0359	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.752	rs28890893	ENSG00000280836.1	AL355480.1	-4.11	7.14e-05	0.0359	-0.46	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45581219~45581321:-
TGCT	cis	rs853679	0.517	rs12174753	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28074687	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.517	rs55747925	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28076559	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.517	rs56310871	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28076704	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.517	rs34716816	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28078391	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.517	rs9393884	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28079011	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.517	rs9380049	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28080757	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.517	rs9380050	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28080760	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.517	rs9393885	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28082231	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.517	rs9393886	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28082261	chr6:28046434~28047367:+
TGCT	cis	rs4713118	0.515	rs9368549	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Parkinson's disease;	chr6:28082269	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.517	rs56364346	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28082984	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.517	rs9357061	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28083994	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.517	rs9368550	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28084025	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.542	rs2295594	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28085319	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.517	rs2273564	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28089816	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.517	rs1853097	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28090857	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.517	rs9393887	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28091242	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.517	rs9393888	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28091439	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.517	rs9357063	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28092227	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.517	rs3823180	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28093966	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.517	rs9368551	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28094014	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.517	rs9393890	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28096077	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.517	rs9366715	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28096855	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.598	rs9380054	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28099759	chr6:28046434~28047367:+
TGCT	cis	rs4713118	0.547	rs2116981	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Parkinson's disease;	chr6:28100173	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.517	rs9368552	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28100648	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.517	rs2281588	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28104824	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.542	rs34131763	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28107222	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.517	rs35193936	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28108492	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.517	rs36078605	ENSG00000187763.3	OR2B7P	4.11	7.14e-05	0.0359	0.35	0.35	Depression;	chr6:28110254	chr6:28046434~28047367:+
TGCT	cis	rs2283792	0.765	rs9607285	ENSG00000228050.1	TOP3BP1	4.11	7.14e-05	0.0359	0.42	0.35	Multiple sclerosis;	chr22:21808704	chr22:22223187~22224566:-
TGCT	cis	rs10759883	0.549	rs816680	ENSG00000175611.10	LINC00476	-4.11	7.14e-05	0.0359	-0.32	-0.35	Nicotine dependence;	chr9:95804111	chr9:95759231~95875977:-
TGCT	cis	rs35000415	0.938	rs13239597	ENSG00000242078.1	RP11-738B7.1	4.11	7.15e-05	0.0359	0.55	0.35	Systemic lupus erythematosus;	chr7:129055929	chr7:129783370~129785185:-
TGCT	cis	rs7005380	0.733	rs4871787	ENSG00000254343.2	RP11-760H22.2	-4.11	7.16e-05	0.0359	-0.44	-0.35	Interstitial lung disease;	chr8:119924178	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.746	rs1464276	ENSG00000254343.2	RP11-760H22.2	-4.11	7.16e-05	0.0359	-0.44	-0.35	Interstitial lung disease;	chr8:119924801	chr8:120052180~120056201:+
TGCT	cis	rs10971721	0.822	rs10971794	ENSG00000230074.1	RP11-195F19.9	-4.11	7.16e-05	0.0359	-0.52	-0.35	Body mass index;	chr9:33924314	chr9:34665665~34681298:+
TGCT	cis	rs748404	0.65	rs556851	ENSG00000205771.5	CATSPER2P1	-4.11	7.16e-05	0.0359	-0.41	-0.35	Lung cancer;	chr15:43279021	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.697	rs567357	ENSG00000205771.5	CATSPER2P1	-4.11	7.16e-05	0.0359	-0.41	-0.35	Lung cancer;	chr15:43279192	chr15:43726918~43747094:-
TGCT	cis	rs4660214	0.639	rs6699928	ENSG00000182109.6	RP11-69E11.4	-4.11	7.16e-05	0.0359	-0.36	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39267827	chr1:39522280~39546187:-
TGCT	cis	rs4660214	0.666	rs11205839	ENSG00000182109.6	RP11-69E11.4	-4.11	7.16e-05	0.0359	-0.36	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39268061	chr1:39522280~39546187:-
TGCT	cis	rs875971	1	rs6961717	ENSG00000232559.3	GS1-124K5.12	-4.11	7.16e-05	0.0359	-0.33	-0.35	Aortic root size;	chr7:66122550	chr7:66554588~66576923:-
TGCT	cis	rs7208859	0.673	rs1347360	ENSG00000263603.1	CTD-2349P21.5	-4.11	7.16e-05	0.0359	-0.48	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30729469~30731202:+
TGCT	cis	rs2029362	0.611	rs10835215	ENSG00000245573.6	BDNF-AS	4.11	7.16e-05	0.036	0.27	0.35	Total body bone mineral density;	chr11:27718402	chr11:27506838~27698174:+
TGCT	cis	rs453301	0.686	rs6748	ENSG00000254340.1	RP11-10A14.3	-4.11	7.17e-05	0.036	-0.36	-0.35	Joint mobility (Beighton score);	chr8:9033292	chr8:9141424~9145435:+
TGCT	cis	rs1045529	0.524	rs34251783	ENSG00000254340.1	RP11-10A14.3	-4.11	7.17e-05	0.036	-0.36	-0.35	Myopia (pathological);Myopia;	chr8:9033866	chr8:9141424~9145435:+
TGCT	cis	rs453301	0.686	rs11785634	ENSG00000254340.1	RP11-10A14.3	-4.11	7.17e-05	0.036	-0.36	-0.35	Joint mobility (Beighton score);	chr8:9035087	chr8:9141424~9145435:+
TGCT	cis	rs453301	0.719	rs34004903	ENSG00000254340.1	RP11-10A14.3	-4.11	7.17e-05	0.036	-0.36	-0.35	Joint mobility (Beighton score);	chr8:9035094	chr8:9141424~9145435:+
TGCT	cis	rs453301	0.686	rs6987107	ENSG00000254340.1	RP11-10A14.3	-4.11	7.17e-05	0.036	-0.36	-0.35	Joint mobility (Beighton score);	chr8:9036071	chr8:9141424~9145435:+
TGCT	cis	rs10510102	0.935	rs11200260	ENSG00000276742.1	RP11-500G22.4	4.11	7.17e-05	0.036	0.57	0.35	Breast cancer;	chr10:121920169	chr10:121956782~121957098:+
TGCT	cis	rs2337406	0.85	rs1858678	ENSG00000274576.2	IGHV2-70	-4.11	7.17e-05	0.036	-0.54	-0.35	Alzheimer's disease (late onset);	chr14:106706790	chr14:106770577~106771020:-
TGCT	cis	rs748404	0.666	rs12906017	ENSG00000205771.5	CATSPER2P1	-4.11	7.18e-05	0.036	-0.52	-0.35	Lung cancer;	chr15:43504710	chr15:43726918~43747094:-
TGCT	cis	rs4713118	0.868	rs7756968	ENSG00000272009.1	RP1-313I6.12	-4.11	7.18e-05	0.036	-0.42	-0.35	Parkinson's disease;	chr6:27767175	chr6:28078792~28081130:-
TGCT	cis	rs7515577	0.588	rs35846792	ENSG00000223787.2	RP4-593M8.1	4.11	7.18e-05	0.036	0.83	0.35	Cholesterol, total;	chr1:92505756	chr1:92580476~92580821:-
TGCT	cis	rs7515577	0.588	rs17371561	ENSG00000223787.2	RP4-593M8.1	4.11	7.18e-05	0.036	0.83	0.35	Cholesterol, total;	chr1:92515682	chr1:92580476~92580821:-
TGCT	cis	rs7515577	0.541	rs75911573	ENSG00000223787.2	RP4-593M8.1	4.11	7.18e-05	0.036	0.83	0.35	Cholesterol, total;	chr1:92560205	chr1:92580476~92580821:-
TGCT	cis	rs7515577	0.588	rs17380378	ENSG00000223787.2	RP4-593M8.1	4.11	7.18e-05	0.036	0.83	0.35	Cholesterol, total;	chr1:92580420	chr1:92580476~92580821:-
TGCT	cis	rs2709736	0.503	rs10234049	ENSG00000232790.2	LINC01162	-4.11	7.19e-05	0.036	-0.3	-0.35	Bipolar I disorder;	chr7:20813016	chr7:20835431~21023148:+
TGCT	cis	rs11074306	0.561	rs924314	ENSG00000232394.1	AC090696.2	-4.11	7.19e-05	0.036	-0.32	-0.35	Uveal melanoma;	chr15:27809200	chr15:27775621~27776798:+
TGCT	cis	rs10938353	0.68	rs12645110	ENSG00000273369.1	RP11-700J17.1	4.11	7.2e-05	0.0361	0.51	0.35	Body mass index;	chr4:44667706	chr4:44693946~44694386:-
TGCT	cis	rs10938353	0.638	rs61549581	ENSG00000273369.1	RP11-700J17.1	4.11	7.2e-05	0.0361	0.51	0.35	Body mass index;	chr4:44692702	chr4:44693946~44694386:-
TGCT	cis	rs9952991	0.941	rs888270	ENSG00000260302.1	RP11-973H7.1	4.11	7.2e-05	0.0361	0.53	0.35	Inflammatory skin disease;	chr18:12774895	chr18:12774651~12775923:-
TGCT	cis	rs4237845	0.591	rs4760344	ENSG00000257159.1	RP11-58A17.3	4.11	7.2e-05	0.0361	0.47	0.35	Intelligence (multi-trait analysis);	chr12:57927000	chr12:57967058~57968399:+
TGCT	cis	rs10946737	0.782	rs2894032	ENSG00000220517.2	ASS1P1	-4.11	7.21e-05	0.0361	-0.34	-0.35	Liver injury in anti-tuberculosis drug treatment;	chr6:24985248	chr6:25023247~25024483:-
TGCT	cis	rs2033711	0.87	rs7409473	ENSG00000268912.1	CTD-2619J13.17	-4.11	7.21e-05	0.0361	-0.3	-0.35	Uric acid clearance;	chr19:58427798	chr19:58428632~58431148:-
TGCT	cis	rs2033711	0.87	rs7408188	ENSG00000268912.1	CTD-2619J13.17	-4.11	7.21e-05	0.0361	-0.3	-0.35	Uric acid clearance;	chr19:58428022	chr19:58428632~58431148:-
TGCT	cis	rs728616	0.867	rs61859763	ENSG00000230091.5	TMEM254-AS1	4.11	7.21e-05	0.0361	0.7	0.35	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79911859	chr10:80046860~80078912:-
TGCT	cis	rs7917772	0.582	rs10786695	ENSG00000273108.1	RP11-416N2.4	-4.11	7.21e-05	0.0361	-0.33	-0.35	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102608999	chr10:103608619~103610050:+
TGCT	cis	rs7917772	0.582	rs11191352	ENSG00000273108.1	RP11-416N2.4	-4.11	7.21e-05	0.0361	-0.33	-0.35	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102612487	chr10:103608619~103610050:+
TGCT	cis	rs7917772	0.582	rs10883753	ENSG00000273108.1	RP11-416N2.4	-4.11	7.21e-05	0.0361	-0.33	-0.35	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102612684	chr10:103608619~103610050:+
TGCT	cis	rs7917772	0.604	rs7908249	ENSG00000273108.1	RP11-416N2.4	-4.11	7.21e-05	0.0361	-0.33	-0.35	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102613543	chr10:103608619~103610050:+
TGCT	cis	rs7917772	0.56	rs7912339	ENSG00000273108.1	RP11-416N2.4	-4.11	7.21e-05	0.0361	-0.33	-0.35	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102614001	chr10:103608619~103610050:+
TGCT	cis	rs7917772	0.628	rs4604806	ENSG00000273108.1	RP11-416N2.4	-4.11	7.21e-05	0.0361	-0.33	-0.35	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102614147	chr10:103608619~103610050:+
TGCT	cis	rs7917772	0.51	rs2001389	ENSG00000273108.1	RP11-416N2.4	-4.11	7.21e-05	0.0361	-0.33	-0.35	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102615501	chr10:103608619~103610050:+
TGCT	cis	rs7917772	0.582	rs10786696	ENSG00000273108.1	RP11-416N2.4	-4.11	7.21e-05	0.0361	-0.33	-0.35	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102618377	chr10:103608619~103610050:+
TGCT	cis	rs7917772	0.582	rs10786698	ENSG00000273108.1	RP11-416N2.4	-4.11	7.21e-05	0.0361	-0.33	-0.35	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102618993	chr10:103608619~103610050:+
TGCT	cis	rs7917772	0.582	rs7907417	ENSG00000273108.1	RP11-416N2.4	4.11	7.21e-05	0.0361	0.33	0.35	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102610905	chr10:103608619~103610050:+
TGCT	cis	rs10256972	0.552	rs7805591	ENSG00000229043.2	AC091729.9	-4.11	7.21e-05	0.0362	-0.34	-0.35	Endometriosis;Longevity;	chr7:1171109	chr7:1160374~1165267:+
TGCT	cis	rs2725220	1	rs2725220	ENSG00000202000.1	RNU1-36P	4.11	7.21e-05	0.0362	0.3	0.35	Renal function-related traits (urea);	chr4:88038770	chr4:88000237~88000401:+
TGCT	cis	rs6600671	1	rs6600671	ENSG00000275131.1	CH17-472G23.4	4.11	7.21e-05	0.0362	0.23	0.35	Hip geometry;	chr1:121458637	chr1:120489625~120579190:-
TGCT	cis	rs2188561	0.697	rs7782475	ENSG00000241764.3	AC002467.7	-4.11	7.21e-05	0.0362	-0.33	-0.35	Alcohol consumption;	chr7:107745806	chr7:107742817~107744581:-
TGCT	cis	rs875971	0.755	rs76288834	ENSG00000237310.1	GS1-124K5.4	-4.11	7.22e-05	0.0362	-0.37	-0.35	Aortic root size;	chr7:66604815	chr7:66493706~66495474:+
TGCT	cis	rs786425	0.933	rs786423	ENSG00000278112.1	RP11-972P1.11	-4.11	7.22e-05	0.0362	-0.38	-0.35	Pubertal anthropometrics;	chr12:123599351	chr12:123519390~123519856:-
TGCT	cis	rs7208859	0.524	rs8069400	ENSG00000263603.1	CTD-2349P21.5	-4.11	7.23e-05	0.0362	-0.5	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30729469~30731202:+
TGCT	cis	rs524281	0.731	rs12576969	ENSG00000255320.1	RP11-755F10.1	-4.11	7.23e-05	0.0362	-0.57	-0.35	Electroencephalogram traits;	chr11:66035007	chr11:66244840~66246239:-
TGCT	cis	rs507080	0.769	rs2077173	ENSG00000255239.1	AP002954.6	4.11	7.24e-05	0.0363	0.45	0.35	Serum metabolite levels;	chr11:118621876	chr11:118688039~118690600:-
TGCT	cis	rs5758659	0.622	rs6519298	ENSG00000182057.4	OGFRP1	4.11	7.24e-05	0.0363	0.25	0.35	Cognitive function;	chr22:41968993	chr22:42269753~42275196:+
TGCT	cis	rs6600671	1	rs4844607	ENSG00000275131.1	CH17-472G23.4	4.11	7.25e-05	0.0363	0.22	0.35	Hip geometry;	chr1:121442201	chr1:120489625~120579190:-
TGCT	cis	rs6741892	1	rs28716236	ENSG00000225402.1	AC010878.3	4.11	7.25e-05	0.0363	0.86	0.35	5-HTT brain serotonin transporter levels;	chr2:38672086	chr2:37816915~37817961:+
TGCT	cis	rs7246967	0.8	rs8111895	ENSG00000269509.1	BNIP3P34	4.11	7.25e-05	0.0363	0.64	0.35	Bronchopulmonary dysplasia;	chr19:22890403	chr19:22773853~22774424:+
TGCT	cis	rs2029362	0.513	rs10767667	ENSG00000245573.6	BDNF-AS	4.11	7.26e-05	0.0363	0.27	0.35	Total body bone mineral density;	chr11:27725002	chr11:27506838~27698174:+
TGCT	cis	rs2029362	0.513	rs7931247	ENSG00000245573.6	BDNF-AS	4.11	7.26e-05	0.0363	0.27	0.35	Total body bone mineral density;	chr11:27725444	chr11:27506838~27698174:+
TGCT	cis	rs4242434	0.757	rs4872531	ENSG00000253200.1	RP11-582J16.5	-4.11	7.26e-05	0.0364	-0.19	-0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22672182	chr8:22613908~22616657:-
TGCT	cis	rs12143943	0.934	rs4951406	ENSG00000176754.11	LINC00303	4.11	7.26e-05	0.0364	0.32	0.35	Cognitive performance;	chr1:204585475	chr1:204032447~204041265:-
TGCT	cis	rs12143943	0.966	rs12135707	ENSG00000176754.11	LINC00303	4.11	7.26e-05	0.0364	0.32	0.35	Cognitive performance;	chr1:204587095	chr1:204032447~204041265:-
TGCT	cis	rs12143943	0.966	rs6669246	ENSG00000176754.11	LINC00303	4.11	7.26e-05	0.0364	0.32	0.35	Cognitive performance;	chr1:204588433	chr1:204032447~204041265:-
TGCT	cis	rs10759883	0.563	rs690063	ENSG00000175611.10	LINC00476	4.11	7.26e-05	0.0364	0.31	0.35	Nicotine dependence;	chr9:95931019	chr9:95759231~95875977:-
TGCT	cis	rs3105593	1	rs3131573	ENSG00000273674.3	CTD-2378E12.1	4.11	7.26e-05	0.0364	0.36	0.35	QT interval;	chr15:50577404	chr15:50839875~50908599:-
TGCT	cis	rs875971	0.545	rs221986	ENSG00000222364.1	RNU6-96P	4.11	7.27e-05	0.0364	0.44	0.35	Aortic root size;	chr7:66105323	chr7:66395191~66395286:+
TGCT	cis	rs2283792	0.765	rs2266969	ENSG00000228050.1	TOP3BP1	4.11	7.27e-05	0.0364	0.42	0.35	Multiple sclerosis;	chr22:21819618	chr22:22223187~22224566:-
TGCT	cis	rs2283792	0.765	rs9610374	ENSG00000228050.1	TOP3BP1	4.11	7.27e-05	0.0364	0.42	0.35	Multiple sclerosis;	chr22:21832514	chr22:22223187~22224566:-
TGCT	cis	rs453301	0.568	rs13281377	ENSG00000173295.6	FAM86B3P	4.11	7.27e-05	0.0364	0.42	0.35	Joint mobility (Beighton score);	chr8:8954054	chr8:8228595~8244865:+
TGCT	cis	rs853679	0.517	rs12174753	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28074687	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs55747925	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28076559	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs56310871	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28076704	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs34716816	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28078391	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9393884	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28079011	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9380049	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28080757	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9380050	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28080760	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9393885	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28082231	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9393886	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28082261	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.515	rs9368549	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Parkinson's disease;	chr6:28082269	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs56364346	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28082984	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9357061	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28083994	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9368550	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28084025	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.542	rs2295594	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28085319	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs2273564	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28089816	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs1853097	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28090857	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9393887	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28091242	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9393888	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28091439	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9357063	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28092227	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs3823180	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28093966	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9368551	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28094014	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9393890	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28096077	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9366715	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28096855	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.598	rs9380054	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28099759	chr6:28091154~28093664:+
TGCT	cis	rs4713118	0.547	rs2116981	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Parkinson's disease;	chr6:28100173	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs9368552	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28100648	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs2281588	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28104824	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.542	rs34131763	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28107222	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs35193936	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28108492	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs36078605	ENSG00000219891.2	ZSCAN12P1	4.11	7.27e-05	0.0364	0.45	0.35	Depression;	chr6:28110254	chr6:28091154~28093664:+
TGCT	cis	rs2297363	1	rs3777399	ENSG00000213073.4	RP11-288H12.3	-4.11	7.28e-05	0.0364	-0.33	-0.35	Total cholesterol levels;Blood protein levels;	chr6:160092761	chr6:160093082~160096212:+
TGCT	cis	rs9400467	0.537	rs12202418	ENSG00000272356.1	RP5-1112D6.8	-4.11	7.28e-05	0.0364	-0.41	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111130264	chr6:111309203~111313517:+
TGCT	cis	rs992157	0.737	rs3731860	ENSG00000261338.2	RP11-378A13.1	-4.1	7.28e-05	0.0364	-0.3	-0.35	Colorectal cancer;	chr2:218292256	chr2:218255319~218257366:+
TGCT	cis	rs11123170	0.543	rs12472361	ENSG00000189223.12	PAX8-AS1	-4.1	7.28e-05	0.0364	-0.59	-0.35	Renal function-related traits (BUN);	chr2:113223068	chr2:113211522~113276581:+
TGCT	cis	rs11123170	0.543	rs4849180	ENSG00000189223.12	PAX8-AS1	-4.1	7.28e-05	0.0364	-0.59	-0.35	Renal function-related traits (BUN);	chr2:113227609	chr2:113211522~113276581:+
TGCT	cis	rs11123170	0.543	rs35222158	ENSG00000189223.12	PAX8-AS1	-4.1	7.28e-05	0.0364	-0.59	-0.35	Renal function-related traits (BUN);	chr2:113229052	chr2:113211522~113276581:+
TGCT	cis	rs11123170	0.543	rs2863242	ENSG00000189223.12	PAX8-AS1	-4.1	7.28e-05	0.0364	-0.59	-0.35	Renal function-related traits (BUN);	chr2:113231659	chr2:113211522~113276581:+
TGCT	cis	rs7829975	0.606	rs10112585	ENSG00000253893.2	FAM85B	4.1	7.28e-05	0.0364	0.44	0.35	Mood instability;	chr8:8937520	chr8:8167819~8226614:-
TGCT	cis	rs7829975	0.572	rs7005000	ENSG00000253893.2	FAM85B	4.1	7.28e-05	0.0364	0.44	0.35	Mood instability;	chr8:8939092	chr8:8167819~8226614:-
TGCT	cis	rs867371	0.762	rs12905578	ENSG00000255769.6	GOLGA2P10	4.1	7.29e-05	0.0364	0.37	0.35	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82472993~82513950:-
TGCT	cis	rs453301	0.686	rs4840389	ENSG00000254340.1	RP11-10A14.3	-4.1	7.29e-05	0.0364	-0.37	-0.35	Joint mobility (Beighton score);	chr8:9026993	chr8:9141424~9145435:+
TGCT	cis	rs453301	0.658	rs13271797	ENSG00000254340.1	RP11-10A14.3	-4.1	7.29e-05	0.0364	-0.37	-0.35	Joint mobility (Beighton score);	chr8:9028444	chr8:9141424~9145435:+
TGCT	cis	rs7824557	0.545	rs34482136	ENSG00000255310.2	AF131215.2	-4.1	7.29e-05	0.0365	-0.28	-0.35	Retinal vascular caliber;	chr8:11370376	chr8:11107788~11109726:-
TGCT	cis	rs9650315	0.53	rs35399441	ENSG00000253603.1	CTA-397H3.3	4.1	7.3e-05	0.0365	0.47	0.35	Height;	chr8:56176872	chr8:56074592~56075274:+
TGCT	cis	rs9650315	0.53	rs68005065	ENSG00000253603.1	CTA-397H3.3	4.1	7.3e-05	0.0365	0.47	0.35	Height;	chr8:56177749	chr8:56074592~56075274:+
TGCT	cis	rs7674212	0.507	rs10516495	ENSG00000251288.2	RP11-10L12.2	-4.1	7.3e-05	0.0365	-0.46	-0.35	Type 2 diabetes;	chr4:102978933	chr4:102751401~102752641:+
TGCT	cis	rs853679	0.55	rs1237875	ENSG00000216901.1	AL022393.7	-4.1	7.3e-05	0.0365	-0.47	-0.35	Depression;	chr6:28205232	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.621	rs9295756	ENSG00000187763.3	OR2B7P	4.1	7.3e-05	0.0365	0.34	0.35	Parkinson's disease;	chr6:28065618	chr6:28046434~28047367:+
TGCT	cis	rs786425	0.804	rs10846535	ENSG00000278112.1	RP11-972P1.11	4.1	7.3e-05	0.0365	0.39	0.35	Pubertal anthropometrics;	chr12:123645841	chr12:123519390~123519856:-
TGCT	cis	rs11651753	0.805	rs55822955	ENSG00000264920.1	RP11-6N17.4	-4.1	7.3e-05	0.0365	-0.33	-0.35	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47884447	chr17:47891255~47895812:-
TGCT	cis	rs507080	0.769	rs745663	ENSG00000255239.1	AP002954.6	4.1	7.31e-05	0.0365	0.44	0.35	Serum metabolite levels;	chr11:118658886	chr11:118688039~118690600:-
TGCT	cis	rs10504229	0.683	rs16921937	ENSG00000253301.4	RP11-513O17.2	4.1	7.31e-05	0.0365	0.51	0.35	Developmental language disorder (linguistic errors);	chr8:57232451	chr8:57142689~57240298:+
TGCT	cis	rs5758659	0.652	rs133322	ENSG00000182057.4	OGFRP1	4.1	7.31e-05	0.0365	0.25	0.35	Cognitive function;	chr22:42009655	chr22:42269753~42275196:+
TGCT	cis	rs6887276	0.934	rs1105315	ENSG00000245937.6	LINC01184	4.1	7.32e-05	0.0365	0.2	0.35	Height;	chr5:128108629	chr5:127940426~128083172:-
TGCT	cis	rs9733	0.65	rs12125672	ENSG00000236713.1	RP11-363I22.3	4.1	7.32e-05	0.0366	0.27	0.35	Tonsillectomy;	chr1:150581994	chr1:150780272~150780644:+
TGCT	cis	rs9733	0.65	rs61820165	ENSG00000236713.1	RP11-363I22.3	4.1	7.32e-05	0.0366	0.27	0.35	Tonsillectomy;	chr1:150583511	chr1:150780272~150780644:+
TGCT	cis	rs6568686	0.527	rs174396	ENSG00000272356.1	RP5-1112D6.8	-4.1	7.32e-05	0.0366	-0.4	-0.35	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111598131	chr6:111309203~111313517:+
TGCT	cis	rs7824557	0.628	rs2572387	ENSG00000255020.1	AF131216.5	4.1	7.32e-05	0.0366	0.24	0.35	Retinal vascular caliber;	chr8:11346656	chr8:11345748~11347502:-
TGCT	cis	rs6479901	0.512	rs11817169	ENSG00000232075.1	MRPL35P2	4.1	7.33e-05	0.0366	0.5	0.35	Intelligence (multi-trait analysis);	chr10:63596549	chr10:63634317~63634827:-
TGCT	cis	rs6782228	0.675	rs6806687	ENSG00000242551.2	POU5F1P6	4.1	7.34e-05	0.0366	0.41	0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128674735~128677005:-
TGCT	cis	rs6741892	0.793	rs13005073	ENSG00000225402.1	AC010878.3	4.1	7.34e-05	0.0366	0.86	0.35	5-HTT brain serotonin transporter levels;	chr2:38676757	chr2:37816915~37817961:+
TGCT	cis	rs7923609	0.967	rs3999089	ENSG00000232075.1	MRPL35P2	4.1	7.34e-05	0.0366	0.34	0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63444048	chr10:63634317~63634827:-
TGCT	cis	rs9309473	1	rs10175180	ENSG00000163016.8	ALMS1P	4.1	7.34e-05	0.0366	0.31	0.35	Metabolite levels;	chr2:73445995	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs10496191	ENSG00000163016.8	ALMS1P	4.1	7.34e-05	0.0366	0.31	0.35	Metabolite levels;	chr2:73446670	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs6546837	ENSG00000163016.8	ALMS1P	4.1	7.34e-05	0.0366	0.31	0.35	Metabolite levels;	chr2:73450771	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs6546838	ENSG00000163016.8	ALMS1P	4.1	7.34e-05	0.0366	0.31	0.35	Metabolite levels;	chr2:73452153	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs6724782	ENSG00000163016.8	ALMS1P	4.1	7.34e-05	0.0366	0.31	0.35	Metabolite levels;	chr2:73452863	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs6546839	ENSG00000163016.8	ALMS1P	4.1	7.34e-05	0.0366	0.31	0.35	Metabolite levels;	chr2:73453381	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs6756987	ENSG00000163016.8	ALMS1P	4.1	7.34e-05	0.0366	0.31	0.35	Metabolite levels;	chr2:73459950	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.898	rs9807961	ENSG00000163016.8	ALMS1P	4.1	7.34e-05	0.0366	0.31	0.35	Metabolite levels;	chr2:73466916	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs10186501	ENSG00000163016.8	ALMS1P	4.1	7.34e-05	0.0366	0.31	0.35	Metabolite levels;	chr2:73470717	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs2140195	ENSG00000163016.8	ALMS1P	4.1	7.34e-05	0.0366	0.31	0.35	Metabolite levels;	chr2:73475217	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs10187416	ENSG00000163016.8	ALMS1P	4.1	7.34e-05	0.0366	0.31	0.35	Metabolite levels;	chr2:73486614	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.95	rs10207264	ENSG00000163016.8	ALMS1P	4.1	7.34e-05	0.0366	0.31	0.35	Metabolite levels;	chr2:73486970	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs2056486	ENSG00000163016.8	ALMS1P	4.1	7.34e-05	0.0366	0.31	0.35	Metabolite levels;	chr2:73490440	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs10193972	ENSG00000163016.8	ALMS1P	4.1	7.34e-05	0.0366	0.31	0.35	Metabolite levels;	chr2:73490529	chr2:73644919~73685576:+
TGCT	cis	rs2505998	0.787	rs28502801	ENSG00000273008.1	RP11-351D16.3	-4.1	7.35e-05	0.0366	-0.39	-0.35	Hirschsprung disease;	chr10:43088591	chr10:43136824~43138334:-
TGCT	cis	rs10971721	0.822	rs10971802	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33933284	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs10971803	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33933289	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs41314578	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33933943	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs56274755	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33934273	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs118115128	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33935451	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72727340	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33936736	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72727341	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33936878	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72727342	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33938084	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs117733169	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33938101	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72727344	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33939122	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs10971807	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33939557	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72727345	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33940200	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72727346	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33940420	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72727350	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33944732	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72727351	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33950434	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72727353	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33950824	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs10971817	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33951886	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.731	rs10971819	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33954149	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72727362	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33957324	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72727367	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33965180	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72727369	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33965777	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs307673	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33968821	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs10971826	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33972035	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs10971827	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33972469	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs10971828	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33973417	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72727378	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33975792	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72727389	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33987030	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72727399	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33997271	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs10971838	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33997948	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.686	rs10971839	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:33998410	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72729305	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:34000293	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72729316	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:34008175	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs10971845	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:34009879	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs10971847	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:34011460	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs10971848	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:34012504	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs10971850	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:34013910	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.731	rs10814061	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:34014032	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs12380173	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:34018500	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs12377970	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:34021269	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.731	rs10971857	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:34021621	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.908	rs72729329	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:34022884	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.908	rs10971858	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:34023693	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72729341	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:34031693	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72729344	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:34034032	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72729357	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:34041170	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs117703548	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:34041199	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs10971867	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:34046758	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72729361	ENSG00000230074.1	RP11-195F19.9	-4.1	7.35e-05	0.0366	-0.52	-0.35	Body mass index;	chr9:34047525	chr9:34665665~34681298:+
TGCT	cis	rs3105593	1	rs3131589	ENSG00000273674.3	CTD-2378E12.1	4.1	7.35e-05	0.0367	0.37	0.35	QT interval;	chr15:50548856	chr15:50839875~50908599:-
TGCT	cis	rs10759883	0.627	rs596413	ENSG00000175611.10	LINC00476	4.1	7.35e-05	0.0367	0.31	0.35	Nicotine dependence;	chr9:95871561	chr9:95759231~95875977:-
TGCT	cis	rs34217772	0.83	rs61291604	ENSG00000258536.1	RP11-1053O12.1	4.1	7.35e-05	0.0367	0.32	0.35	Myopia;	chr14:41742495	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.771	rs59496647	ENSG00000258536.1	RP11-1053O12.1	4.1	7.35e-05	0.0367	0.32	0.35	Myopia;	chr14:41742704	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.83	rs58922111	ENSG00000258536.1	RP11-1053O12.1	4.1	7.35e-05	0.0367	0.32	0.35	Myopia;	chr14:41742813	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.83	rs60296848	ENSG00000258536.1	RP11-1053O12.1	4.1	7.35e-05	0.0367	0.32	0.35	Myopia;	chr14:41742909	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.83	rs57774630	ENSG00000258536.1	RP11-1053O12.1	4.1	7.35e-05	0.0367	0.32	0.35	Myopia;	chr14:41742930	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.83	rs56084127	ENSG00000258536.1	RP11-1053O12.1	4.1	7.35e-05	0.0367	0.32	0.35	Myopia;	chr14:41743146	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.83	rs61992395	ENSG00000258536.1	RP11-1053O12.1	4.1	7.35e-05	0.0367	0.32	0.35	Myopia;	chr14:41743612	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.83	rs61992396	ENSG00000258536.1	RP11-1053O12.1	4.1	7.35e-05	0.0367	0.32	0.35	Myopia;	chr14:41743794	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.83	rs61992397	ENSG00000258536.1	RP11-1053O12.1	4.1	7.35e-05	0.0367	0.32	0.35	Myopia;	chr14:41744059	chr14:41742639~41742963:+
TGCT	cis	rs853679	0.517	rs3734573	ENSG00000187763.3	OR2B7P	4.1	7.35e-05	0.0367	0.35	0.35	Depression;	chr6:28091659	chr6:28046434~28047367:+
TGCT	cis	rs732716	0.785	rs56033249	ENSG00000267769.1	CTB-50L17.9	-4.1	7.36e-05	0.0367	-0.41	-0.35	Mean corpuscular volume;	chr19:4369450	chr19:4454014~4455286:+
TGCT	cis	rs8028182	0.501	rs7166281	ENSG00000260269.4	CTD-2323K18.1	4.1	7.37e-05	0.0367	0.41	0.35	Sudden cardiac arrest;	chr15:75635851	chr15:75527150~75601205:-
TGCT	cis	rs9309473	1	rs1534471	ENSG00000163016.8	ALMS1P	4.1	7.37e-05	0.0367	0.31	0.35	Metabolite levels;	chr2:73420380	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs1881245	ENSG00000163016.8	ALMS1P	4.1	7.37e-05	0.0367	0.31	0.35	Metabolite levels;	chr2:73422800	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs6740223	ENSG00000163016.8	ALMS1P	4.1	7.37e-05	0.0367	0.31	0.35	Metabolite levels;	chr2:73426204	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs6707722	ENSG00000163016.8	ALMS1P	4.1	7.37e-05	0.0367	0.31	0.35	Metabolite levels;	chr2:73427235	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.948	rs2421550	ENSG00000163016.8	ALMS1P	4.1	7.37e-05	0.0367	0.31	0.35	Metabolite levels;	chr2:73431558	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs6546835	ENSG00000163016.8	ALMS1P	4.1	7.37e-05	0.0367	0.31	0.35	Metabolite levels;	chr2:73437587	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs2901438	ENSG00000163016.8	ALMS1P	4.1	7.37e-05	0.0367	0.31	0.35	Metabolite levels;	chr2:73438528	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs11901272	ENSG00000163016.8	ALMS1P	4.1	7.37e-05	0.0367	0.31	0.35	Metabolite levels;	chr2:73493317	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs58603761	ENSG00000163016.8	ALMS1P	4.1	7.37e-05	0.0367	0.31	0.35	Metabolite levels;	chr2:73499478	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.95	rs1052162	ENSG00000163016.8	ALMS1P	-4.1	7.37e-05	0.0367	-0.31	-0.35	Metabolite levels;	chr2:73602245	chr2:73644919~73685576:+
TGCT	cis	rs4691139	1	rs10517825	ENSG00000236941.6	RP11-366M4.8	-4.1	7.37e-05	0.0367	-0.27	-0.35	Ovarian cancer in BRCA1 mutation carriers;	chr4:164972334	chr4:164948079~164949438:+
TGCT	cis	rs17695224	0.5	rs55899451	ENSG00000269483.1	AC006272.1	4.1	7.38e-05	0.0367	0.36	0.35	HDL cholesterol;HDL cholesterol levels;	chr19:51818058	chr19:51839924~51843324:-
TGCT	cis	rs17695224	0.545	rs55883913	ENSG00000269483.1	AC006272.1	4.1	7.38e-05	0.0367	0.36	0.35	HDL cholesterol;HDL cholesterol levels;	chr19:51818071	chr19:51839924~51843324:-
TGCT	cis	rs17695224	0.5	rs55843033	ENSG00000269483.1	AC006272.1	4.1	7.38e-05	0.0367	0.36	0.35	HDL cholesterol;HDL cholesterol levels;	chr19:51818280	chr19:51839924~51843324:-
TGCT	cis	rs2236295	0.618	rs224285	ENSG00000238280.1	RP11-436D10.3	4.1	7.38e-05	0.0367	0.44	0.35	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62825050	chr10:62793562~62805887:-
TGCT	cis	rs1609391	0.543	rs2117009	ENSG00000239213.4	NCK1-AS1	-4.1	7.38e-05	0.0367	-0.31	-0.35	Neuroticism;	chr3:136914729	chr3:136841726~136862054:-
TGCT	cis	rs7829975	0.846	rs1879957	ENSG00000253893.2	FAM85B	4.1	7.38e-05	0.0368	0.46	0.35	Mood instability;	chr8:8687298	chr8:8167819~8226614:-
TGCT	cis	rs11779860	0.708	rs17827449	ENSG00000245970.2	KB-1208A12.3	-4.1	7.38e-05	0.0368	-0.38	-0.35	QT interval;	chr8:97836481	chr8:98041726~98044121:+
TGCT	cis	rs11779860	0.708	rs10504980	ENSG00000245970.2	KB-1208A12.3	-4.1	7.38e-05	0.0368	-0.38	-0.35	QT interval;	chr8:97836681	chr8:98041726~98044121:+
TGCT	cis	rs10129255	1	rs10134517	ENSG00000211970.3	IGHV4-61	-4.1	7.39e-05	0.0368	-0.37	-0.35	Kawasaki disease;	chr14:106718498	chr14:106639119~106639657:-
TGCT	cis	rs4713118	0.866	rs9468217	ENSG00000272009.1	RP1-313I6.12	-4.1	7.39e-05	0.0368	-0.41	-0.35	Parkinson's disease;	chr6:27758688	chr6:28078792~28081130:-
TGCT	cis	rs4713118	0.911	rs9295746	ENSG00000272009.1	RP1-313I6.12	-4.1	7.39e-05	0.0368	-0.41	-0.35	Parkinson's disease;	chr6:27762285	chr6:28078792~28081130:-
TGCT	cis	rs4713118	0.868	rs9468220	ENSG00000272009.1	RP1-313I6.12	4.1	7.39e-05	0.0368	0.41	0.35	Parkinson's disease;	chr6:27765197	chr6:28078792~28081130:-
TGCT	cis	rs5758659	0.569	rs133294	ENSG00000182057.4	OGFRP1	4.1	7.39e-05	0.0368	0.25	0.35	Cognitive function;	chr22:41986801	chr22:42269753~42275196:+
TGCT	cis	rs5758659	0.652	rs133300	ENSG00000182057.4	OGFRP1	4.1	7.39e-05	0.0368	0.25	0.35	Cognitive function;	chr22:41993835	chr22:42269753~42275196:+
TGCT	cis	rs5758659	0.623	rs133328	ENSG00000182057.4	OGFRP1	4.1	7.39e-05	0.0368	0.25	0.35	Cognitive function;	chr22:42012075	chr22:42269753~42275196:+
TGCT	cis	rs2153535	0.541	rs4637688	ENSG00000230939.1	RP11-314C16.1	-4.1	7.4e-05	0.0368	-0.33	-0.35	Motion sickness;	chr6:8446268	chr6:8784178~8785445:+
TGCT	cis	rs10759883	0.627	rs689804	ENSG00000175611.10	LINC00476	4.1	7.4e-05	0.0368	0.31	0.35	Nicotine dependence;	chr9:95868574	chr9:95759231~95875977:-
TGCT	cis	rs10129255	0.518	rs2006284	ENSG00000223648.3	IGHV3-64	4.1	7.4e-05	0.0368	0.29	0.35	Kawasaki disease;	chr14:106676185	chr14:106643132~106658258:-
TGCT	cis	rs1010254	0.51	rs2881985	ENSG00000213433.5	RPLP1P6	4.1	7.4e-05	0.0368	0.42	0.35	Optic nerve measurement (cup area);	chr5:152320768	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.51	rs723427	ENSG00000213433.5	RPLP1P6	-4.1	7.4e-05	0.0368	-0.42	-0.35	Optic nerve measurement (cup area);	chr5:152316208	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.51	rs56019388	ENSG00000213433.5	RPLP1P6	-4.1	7.4e-05	0.0368	-0.42	-0.35	Optic nerve measurement (cup area);	chr5:152326664	chr5:151765859~151766378:-
TGCT	cis	rs5758659	0.594	rs739292	ENSG00000182057.4	OGFRP1	4.1	7.4e-05	0.0368	0.25	0.35	Cognitive function;	chr22:41972853	chr22:42269753~42275196:+
TGCT	cis	rs34375054	0.525	rs1080910	ENSG00000279233.1	RP11-158L12.4	4.1	7.4e-05	0.0368	0.37	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125123946	chr12:125138245~125141711:+
TGCT	cis	rs75422866	0.867	rs7303895	ENSG00000280054.1	RP1-197B17.7	4.1	7.41e-05	0.0368	0.61	0.35	Pneumonia;	chr12:47683290	chr12:47728151~47730598:-
TGCT	cis	rs75422866	0.867	rs7304743	ENSG00000280054.1	RP1-197B17.7	-4.1	7.41e-05	0.0368	-0.61	-0.35	Pneumonia;	chr12:47683658	chr12:47728151~47730598:-
TGCT	cis	rs651907	0.557	rs3094296	ENSG00000244119.1	PDCL3P4	4.1	7.41e-05	0.0368	0.26	0.35	Colorectal cancer;	chr3:101681323	chr3:101712472~101713191:+
TGCT	cis	rs10971721	0.822	rs10971866	ENSG00000230074.1	RP11-195F19.9	-4.1	7.41e-05	0.0369	-0.51	-0.35	Body mass index;	chr9:34043163	chr9:34665665~34681298:+
TGCT	cis	rs7208859	0.614	rs216477	ENSG00000263531.1	RP13-753N3.1	-4.1	7.41e-05	0.0369	-0.59	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30539726	chr17:30863921~30864940:-
TGCT	cis	rs1010254	0.51	rs72806396	ENSG00000213433.5	RPLP1P6	-4.1	7.42e-05	0.0369	-0.42	-0.35	Optic nerve measurement (cup area);	chr5:152328764	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.51	rs72806402	ENSG00000213433.5	RPLP1P6	-4.1	7.42e-05	0.0369	-0.42	-0.35	Optic nerve measurement (cup area);	chr5:152332964	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.51	rs72808303	ENSG00000213433.5	RPLP1P6	-4.1	7.42e-05	0.0369	-0.42	-0.35	Optic nerve measurement (cup area);	chr5:152338488	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.559	rs72808320	ENSG00000213433.5	RPLP1P6	-4.1	7.42e-05	0.0369	-0.42	-0.35	Optic nerve measurement (cup area);	chr5:152362297	chr5:151765859~151766378:-
TGCT	cis	rs1010254	0.559	rs55693068	ENSG00000213433.5	RPLP1P6	-4.1	7.42e-05	0.0369	-0.42	-0.35	Optic nerve measurement (cup area);	chr5:152370878	chr5:151765859~151766378:-
TGCT	cis	rs901683	1	rs12766764	ENSG00000264204.2	AGAP7P	-4.1	7.42e-05	0.0369	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45584065	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs12761573	ENSG00000264204.2	AGAP7P	-4.1	7.42e-05	0.0369	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45584069	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35070150	ENSG00000264204.2	AGAP7P	-4.1	7.42e-05	0.0369	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45584385	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs76469200	ENSG00000264204.2	AGAP7P	-4.1	7.42e-05	0.0369	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45584585	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs79490183	ENSG00000264204.2	AGAP7P	-4.1	7.42e-05	0.0369	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45584793	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs34793991	ENSG00000264204.2	AGAP7P	-4.1	7.42e-05	0.0369	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45585142	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35183191	ENSG00000264204.2	AGAP7P	-4.1	7.42e-05	0.0369	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45585169	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs34163035	ENSG00000264204.2	AGAP7P	-4.1	7.42e-05	0.0369	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45585271	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs12779637	ENSG00000264204.2	AGAP7P	-4.1	7.42e-05	0.0369	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45585648	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs12772102	ENSG00000264204.2	AGAP7P	-4.1	7.42e-05	0.0369	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45585653	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35183751	ENSG00000264204.2	AGAP7P	-4.1	7.42e-05	0.0369	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45585910	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71496622	ENSG00000264204.2	AGAP7P	-4.1	7.42e-05	0.0369	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45586140	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs34516867	ENSG00000264204.2	AGAP7P	-4.1	7.42e-05	0.0369	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45586289	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35049879	ENSG00000264204.2	AGAP7P	-4.1	7.42e-05	0.0369	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45586296	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs36102549	ENSG00000264204.2	AGAP7P	-4.1	7.42e-05	0.0369	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45586595	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs36052429	ENSG00000264204.2	AGAP7P	-4.1	7.42e-05	0.0369	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45586897	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs4442500	ENSG00000264204.2	AGAP7P	-4.1	7.42e-05	0.0369	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45587050	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35916836	ENSG00000264204.2	AGAP7P	-4.1	7.42e-05	0.0369	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45587068	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs12763285	ENSG00000264204.2	AGAP7P	-4.1	7.42e-05	0.0369	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45587421	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71499567	ENSG00000264204.2	AGAP7P	-4.1	7.42e-05	0.0369	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45588508	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35506889	ENSG00000264204.2	AGAP7P	-4.1	7.42e-05	0.0369	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45589189	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71496623	ENSG00000264204.2	AGAP7P	-4.1	7.42e-05	0.0369	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45590418	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs71496624	ENSG00000264204.2	AGAP7P	-4.1	7.42e-05	0.0369	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45590501	chr10:46109621~46131358:+
TGCT	cis	rs901683	0.867	rs34144887	ENSG00000264204.2	AGAP7P	-4.1	7.42e-05	0.0369	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45590945	chr10:46109621~46131358:+
TGCT	cis	rs901683	0.867	rs71496625	ENSG00000264204.2	AGAP7P	-4.1	7.42e-05	0.0369	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45591201	chr10:46109621~46131358:+
TGCT	cis	rs901683	0.867	rs35003524	ENSG00000264204.2	AGAP7P	-4.1	7.42e-05	0.0369	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45591333	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs36100685	ENSG00000264204.2	AGAP7P	-4.1	7.42e-05	0.0369	-0.8	-0.35	Mean corpuscular volume;Red blood cell traits;	chr10:45591406	chr10:46109621~46131358:+
TGCT	cis	rs4238585	0.947	rs12596903	ENSG00000261195.1	CTD-2380F24.1	-4.1	7.42e-05	0.0369	-0.51	-0.35	Body mass index;	chr16:20243553	chr16:19761172~19766099:-
TGCT	cis	rs4713118	0.513	rs1225591	ENSG00000219392.1	RP1-265C24.5	-4.1	7.42e-05	0.0369	-0.44	-0.35	Parkinson's disease;	chr6:28180974	chr6:28115628~28116551:+
TGCT	cis	rs11671005	0.735	rs34188294	ENSG00000232098.3	CTD-2619J13.14	-4.1	7.43e-05	0.0369	-0.4	-0.35	Mean platelet volume;	chr19:58408190	chr19:58404238~58408484:-
TGCT	cis	rs6669072	0.967	rs4101233	ENSG00000231613.1	RP5-943J3.1	4.1	7.43e-05	0.0369	0.34	0.35	Cognitive function;	chr1:90773216	chr1:89788914~89790492:+
TGCT	cis	rs7201929	1	rs7499878	ENSG00000251417.2	RP11-1348G14.4	4.1	7.44e-05	0.0369	0.37	0.35	QT interval;	chr16:28857143	chr16:28802743~28817828:+
TGCT	cis	rs748404	0.666	rs60018990	ENSG00000205771.5	CATSPER2P1	-4.1	7.44e-05	0.0369	-0.5	-0.35	Lung cancer;	chr15:43504606	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.666	rs7177146	ENSG00000205771.5	CATSPER2P1	-4.1	7.44e-05	0.0369	-0.5	-0.35	Lung cancer;	chr15:43506110	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.666	rs72709879	ENSG00000205771.5	CATSPER2P1	-4.1	7.44e-05	0.0369	-0.5	-0.35	Lung cancer;	chr15:43507777	chr15:43726918~43747094:-
TGCT	cis	rs3779195	0.929	rs1635612	ENSG00000272950.1	RP11-307C18.1	4.1	7.44e-05	0.0369	0.42	0.35	Sex hormone-binding globulin levels;	chr7:98385737	chr7:98322853~98323430:+
TGCT	cis	rs453301	0.686	rs10217044	ENSG00000254340.1	RP11-10A14.3	-4.1	7.44e-05	0.0369	-0.36	-0.35	Joint mobility (Beighton score);	chr8:9037242	chr8:9141424~9145435:+
TGCT	cis	rs12745968	0.624	rs1059268	ENSG00000223787.2	RP4-593M8.1	-4.1	7.44e-05	0.0369	-0.46	-0.35	Bipolar disorder and schizophrenia;	chr1:92509687	chr1:92580476~92580821:-
TGCT	cis	rs12745968	0.589	rs1059267	ENSG00000223787.2	RP4-593M8.1	-4.1	7.44e-05	0.0369	-0.46	-0.35	Bipolar disorder and schizophrenia;	chr1:92509705	chr1:92580476~92580821:-
TGCT	cis	rs12745968	0.623	rs1886684	ENSG00000223787.2	RP4-593M8.1	-4.1	7.44e-05	0.0369	-0.46	-0.35	Bipolar disorder and schizophrenia;	chr1:92510381	chr1:92580476~92580821:-
TGCT	cis	rs520525	0.927	rs1234282	ENSG00000271811.1	RP1-79C4.4	4.1	7.45e-05	0.037	0.27	0.35	Atrial fibrillation;	chr1:170650183	chr1:170667381~170669425:+
TGCT	cis	rs36052053	0.522	rs76576241	ENSG00000219700.1	PTCHD3P3	4.1	7.45e-05	0.037	0.71	0.35	Red cell distribution width;	chr6:109306348	chr6:109288571~109290503:-
TGCT	cis	rs36052053	0.522	rs56150455	ENSG00000219700.1	PTCHD3P3	4.1	7.45e-05	0.037	0.71	0.35	Red cell distribution width;	chr6:109307939	chr6:109288571~109290503:-
TGCT	cis	rs36052053	0.522	rs74997551	ENSG00000219700.1	PTCHD3P3	4.1	7.45e-05	0.037	0.71	0.35	Red cell distribution width;	chr6:109308440	chr6:109288571~109290503:-
TGCT	cis	rs875971	0.545	rs13311962	ENSG00000222364.1	RNU6-96P	4.1	7.45e-05	0.037	0.43	0.35	Aortic root size;	chr7:66603142	chr7:66395191~66395286:+
TGCT	cis	rs2337406	0.925	rs11851094	ENSG00000274576.2	IGHV2-70	-4.1	7.45e-05	0.037	-0.53	-0.35	Alzheimer's disease (late onset);	chr14:106688967	chr14:106770577~106771020:-
TGCT	cis	rs2337406	1	rs17113276	ENSG00000274576.2	IGHV2-70	4.1	7.45e-05	0.037	0.53	0.35	Alzheimer's disease (late onset);	chr14:106683485	chr14:106770577~106771020:-
TGCT	cis	rs6510489	1	rs17638216	ENSG00000267439.1	AC002398.11	4.1	7.45e-05	0.037	0.47	0.35	Bipolar disorder;	chr19:35487556	chr19:35747057~35753415:-
TGCT	cis	rs6510489	1	rs62111717	ENSG00000267439.1	AC002398.11	4.1	7.45e-05	0.037	0.47	0.35	Bipolar disorder;	chr19:35487665	chr19:35747057~35753415:-
TGCT	cis	rs10129255	0.957	rs4387509	ENSG00000211970.3	IGHV4-61	-4.1	7.45e-05	0.037	-0.38	-0.35	Kawasaki disease;	chr14:106704386	chr14:106639119~106639657:-
TGCT	cis	rs4713118	0.868	rs742047	ENSG00000272009.1	RP1-313I6.12	-4.1	7.46e-05	0.037	-0.42	-0.35	Parkinson's disease;	chr6:27771601	chr6:28078792~28081130:-
TGCT	cis	rs9326248	0.813	rs7115562	ENSG00000280143.1	AP000892.6	4.1	7.46e-05	0.037	0.5	0.35	Blood protein levels;	chr11:117149754	chr11:117204967~117210292:+
TGCT	cis	rs12468226	1	rs13426118	ENSG00000236047.1	AC073410.1	-4.1	7.47e-05	0.037	-0.42	-0.35	Urate levels;	chr2:202390762	chr2:202520401~202520989:+
TGCT	cis	rs9951698	0.678	rs578208	ENSG00000266969.1	RP11-773H22.4	-4.1	7.47e-05	0.0371	-0.42	-0.35	Intelligence (multi-trait analysis);	chr18:13068133	chr18:12984694~12991173:-
TGCT	cis	rs4268898	0.722	rs7564420	ENSG00000242628.4	AC009228.1	4.1	7.48e-05	0.0371	0.34	0.35	Asthma;	chr2:24191133	chr2:24214381~24221516:+
TGCT	cis	rs1618992	0.729	rs766641	ENSG00000265994.1	RP11-510D21.1	4.1	7.48e-05	0.0371	0.36	0.35	Gut microbiome composition (summer and winter);	chr18:28618628	chr18:28785068~28789260:+
TGCT	cis	rs34217772	0.539	rs4904914	ENSG00000258536.1	RP11-1053O12.1	4.1	7.48e-05	0.0371	0.27	0.35	Myopia;	chr14:41861702	chr14:41742639~41742963:+
TGCT	cis	rs2709736	0.9	rs2709741	ENSG00000232790.2	LINC01162	-4.1	7.48e-05	0.0371	-0.25	-0.35	Bipolar I disorder;	chr7:20833235	chr7:20835431~21023148:+
TGCT	cis	rs4242434	0.927	rs2291234	ENSG00000254064.1	CTD-2530N21.4	-4.1	7.49e-05	0.0371	-0.21	-0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22606877	chr8:22254576~22275162:-
TGCT	cis	rs4242434	0.927	rs7843616	ENSG00000254064.1	CTD-2530N21.4	-4.1	7.49e-05	0.0371	-0.21	-0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22609028	chr8:22254576~22275162:-
TGCT	cis	rs5758659	0.967	rs5751250	ENSG00000270083.1	RP1-257I20.14	4.1	7.49e-05	0.0371	0.34	0.35	Cognitive function;	chr22:42243639	chr22:42089630~42090028:-
TGCT	cis	rs11772815	1	rs7789122	ENSG00000233830.2	EIF4HP1	4.1	7.5e-05	0.0372	0.37	0.35	Folding of antihelix;	chr7:28363294	chr7:27458163~27458849:-
TGCT	cis	rs4660214	0.756	rs11205823	ENSG00000182109.6	RP11-69E11.4	-4.1	7.5e-05	0.0372	-0.36	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39248566	chr1:39522280~39546187:-
TGCT	cis	rs367615	0.506	rs246102	ENSG00000249476.1	CTD-2587M2.1	-4.1	7.51e-05	0.0372	-0.36	-0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109363994	chr5:109237120~109326369:-
TGCT	cis	rs73607972	0.935	rs4783818	ENSG00000279344.1	RP11-44F14.7	4.1	7.51e-05	0.0372	0.48	0.35	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53704371	chr16:53478957~53481550:-
TGCT	cis	rs891378	0.876	rs1367067	ENSG00000274245.1	RP11-357P18.2	4.1	7.51e-05	0.0372	0.48	0.35	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207269019	chr1:207372559~207373252:+
TGCT	cis	rs9309473	1	rs13383871	ENSG00000163016.8	ALMS1P	4.1	7.51e-05	0.0372	0.32	0.35	Metabolite levels;	chr2:73404651	chr2:73644919~73685576:+
TGCT	cis	rs10829156	0.629	rs7069955	ENSG00000240291.1	RP11-499P20.2	4.1	7.51e-05	0.0372	0.35	0.35	Sudden cardiac arrest;	chr10:18688210	chr10:18513115~18545651:-
TGCT	cis	rs10971721	0.822	rs12376664	ENSG00000230074.1	RP11-195F19.9	-4.1	7.51e-05	0.0372	-0.52	-0.35	Body mass index;	chr9:33808705	chr9:34665665~34681298:+
TGCT	cis	rs453301	0.522	rs2929455	ENSG00000254340.1	RP11-10A14.3	-4.1	7.52e-05	0.0372	-0.33	-0.35	Joint mobility (Beighton score);	chr8:9225923	chr8:9141424~9145435:+
TGCT	cis	rs8041943	0.744	rs8031905	ENSG00000177699.4	RP11-16K12.1	-4.1	7.52e-05	0.0373	-0.29	-0.35	Bone mineral density (spine) and age at menarche;	chr15:79614759	chr15:78978889~78985926:+
TGCT	cis	rs10504229	0.906	rs2270607	ENSG00000253301.4	RP11-513O17.2	4.1	7.53e-05	0.0373	0.43	0.35	Developmental language disorder (linguistic errors);	chr8:57282140	chr8:57142689~57240298:+
TGCT	cis	rs17507216	1	rs3850610	ENSG00000255769.6	GOLGA2P10	4.1	7.53e-05	0.0373	0.41	0.35	Excessive daytime sleepiness;	chr15:82552642	chr15:82472993~82513950:-
TGCT	cis	rs997781	0.525	rs1024598	ENSG00000267009.5	RP11-120M18.2	4.1	7.53e-05	0.0373	0.44	0.35	MGMT methylation in smokers;	chr17:69179527	chr17:68413623~68524949:+
TGCT	cis	rs453301	0.686	rs3989373	ENSG00000254340.1	RP11-10A14.3	-4.1	7.53e-05	0.0373	-0.35	-0.35	Joint mobility (Beighton score);	chr8:9053798	chr8:9141424~9145435:+
TGCT	cis	rs507080	0.883	rs656575	ENSG00000255239.1	AP002954.6	4.1	7.53e-05	0.0373	0.45	0.35	Serum metabolite levels;	chr11:118679199	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.961	rs656505	ENSG00000255239.1	AP002954.6	4.1	7.53e-05	0.0373	0.45	0.35	Serum metabolite levels;	chr11:118679245	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.961	rs660489	ENSG00000255239.1	AP002954.6	4.1	7.53e-05	0.0373	0.45	0.35	Serum metabolite levels;	chr11:118679255	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.961	rs543327	ENSG00000255239.1	AP002954.6	4.1	7.53e-05	0.0373	0.45	0.35	Serum metabolite levels;	chr11:118679276	chr11:118688039~118690600:-
TGCT	cis	rs7923609	0.935	rs10995477	ENSG00000232075.1	MRPL35P2	-4.1	7.54e-05	0.0373	-0.34	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63250912	chr10:63634317~63634827:-
TGCT	cis	rs7923609	1	rs4400684	ENSG00000232075.1	MRPL35P2	-4.1	7.54e-05	0.0373	-0.34	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63252927	chr10:63634317~63634827:-
TGCT	cis	rs7923609	0.967	rs4454603	ENSG00000232075.1	MRPL35P2	-4.1	7.54e-05	0.0373	-0.34	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63252990	chr10:63634317~63634827:-
TGCT	cis	rs7923609	1	rs4595427	ENSG00000232075.1	MRPL35P2	-4.1	7.54e-05	0.0373	-0.34	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63253184	chr10:63634317~63634827:-
TGCT	cis	rs62012628	0.527	rs12438008	ENSG00000261143.1	ADAMTS7P3	-4.1	7.54e-05	0.0373	-0.33	-0.35	Diastolic blood pressure;	chr15:78792338	chr15:77976042~77993057:+
TGCT	cis	rs1061377	0.585	rs1367296	ENSG00000249207.1	RP11-360F5.1	-4.1	7.54e-05	0.0373	-0.36	-0.35	Uric acid levels;	chr4:39066895	chr4:39112677~39126818:-
TGCT	cis	rs6568686	0.577	rs174394	ENSG00000272356.1	RP5-1112D6.8	-4.1	7.54e-05	0.0373	-0.39	-0.35	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111597796	chr6:111309203~111313517:+
TGCT	cis	rs6568686	0.577	rs174395	ENSG00000272356.1	RP5-1112D6.8	-4.1	7.54e-05	0.0373	-0.39	-0.35	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111597804	chr6:111309203~111313517:+
TGCT	cis	rs1707322	0.964	rs7546237	ENSG00000280836.1	AL355480.1	-4.1	7.54e-05	0.0373	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.964	rs6697830	ENSG00000280836.1	AL355480.1	-4.1	7.54e-05	0.0373	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45824805	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs12060274	ENSG00000280836.1	AL355480.1	-4.1	7.54e-05	0.0373	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825390	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.963	rs11211202	ENSG00000280836.1	AL355480.1	-4.1	7.54e-05	0.0373	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs4660889	ENSG00000280836.1	AL355480.1	-4.1	7.54e-05	0.0373	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs10890353	ENSG00000280836.1	AL355480.1	-4.1	7.54e-05	0.0373	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45832711	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs10890355	ENSG00000280836.1	AL355480.1	-4.1	7.54e-05	0.0373	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs11211204	ENSG00000280836.1	AL355480.1	-4.1	7.54e-05	0.0373	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.964	rs10890358	ENSG00000280836.1	AL355480.1	-4.1	7.54e-05	0.0373	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853353	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs7547189	ENSG00000280836.1	AL355480.1	-4.1	7.54e-05	0.0373	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853842	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs7547284	ENSG00000280836.1	AL355480.1	-4.1	7.54e-05	0.0373	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853893	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs11211205	ENSG00000280836.1	AL355480.1	-4.1	7.54e-05	0.0373	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45856202	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs6675222	ENSG00000280836.1	AL355480.1	-4.1	7.54e-05	0.0373	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45860904	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs4660895	ENSG00000280836.1	AL355480.1	-4.1	7.54e-05	0.0373	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864067	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs7531911	ENSG00000280836.1	AL355480.1	-4.1	7.54e-05	0.0373	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864751	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs4660318	ENSG00000280836.1	AL355480.1	-4.1	7.54e-05	0.0373	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45869204	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs10890359	ENSG00000280836.1	AL355480.1	-4.1	7.54e-05	0.0373	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45870963	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs10890360	ENSG00000280836.1	AL355480.1	-4.1	7.54e-05	0.0373	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45872772	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs6682683	ENSG00000280836.1	AL355480.1	-4.1	7.54e-05	0.0373	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45876665	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs11211217	ENSG00000280836.1	AL355480.1	-4.1	7.54e-05	0.0373	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45882557	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs7553924	ENSG00000280836.1	AL355480.1	-4.1	7.54e-05	0.0373	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs4641257	ENSG00000280836.1	AL355480.1	-4.1	7.54e-05	0.0373	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs6693336	ENSG00000280836.1	AL355480.1	-4.1	7.54e-05	0.0373	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr1:45581219~45581321:-
TGCT	cis	rs7824557	0.606	rs2736270	ENSG00000255020.1	AF131216.5	4.1	7.55e-05	0.0373	0.24	0.35	Retinal vascular caliber;	chr8:11335084	chr8:11345748~11347502:-
TGCT	cis	rs7621025	0.505	rs13063893	ENSG00000239213.4	NCK1-AS1	-4.1	7.55e-05	0.0373	-0.46	-0.35	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136668796	chr3:136841726~136862054:-
TGCT	cis	rs7621025	0.505	rs34613715	ENSG00000239213.4	NCK1-AS1	-4.1	7.55e-05	0.0373	-0.46	-0.35	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136736165	chr3:136841726~136862054:-
TGCT	cis	rs7621025	0.505	rs34281413	ENSG00000239213.4	NCK1-AS1	-4.1	7.55e-05	0.0373	-0.46	-0.35	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136743018	chr3:136841726~136862054:-
TGCT	cis	rs11742741	0.676	rs13155915	ENSG00000248874.4	C5orf17	-4.1	7.56e-05	0.0374	-0.41	-0.35	Educational attainment;	chr5:24191881	chr5:23951348~24178263:+
TGCT	cis	rs11742741	0.702	rs13154927	ENSG00000248874.4	C5orf17	-4.1	7.56e-05	0.0374	-0.41	-0.35	Educational attainment;	chr5:24191972	chr5:23951348~24178263:+
TGCT	cis	rs11742741	0.676	rs34323137	ENSG00000248874.4	C5orf17	-4.1	7.56e-05	0.0374	-0.41	-0.35	Educational attainment;	chr5:24196120	chr5:23951348~24178263:+
TGCT	cis	rs11742741	0.676	rs34415514	ENSG00000248874.4	C5orf17	-4.1	7.56e-05	0.0374	-0.41	-0.35	Educational attainment;	chr5:24196173	chr5:23951348~24178263:+
TGCT	cis	rs11742741	0.676	rs62347896	ENSG00000248874.4	C5orf17	-4.1	7.56e-05	0.0374	-0.41	-0.35	Educational attainment;	chr5:24204990	chr5:23951348~24178263:+
TGCT	cis	rs11742741	0.702	rs3924719	ENSG00000248874.4	C5orf17	-4.1	7.56e-05	0.0374	-0.41	-0.35	Educational attainment;	chr5:24206968	chr5:23951348~24178263:+
TGCT	cis	rs11742741	0.64	rs62347897	ENSG00000248874.4	C5orf17	-4.1	7.56e-05	0.0374	-0.41	-0.35	Educational attainment;	chr5:24214756	chr5:23951348~24178263:+
TGCT	cis	rs911555	0.928	rs911554	ENSG00000244691.1	RPL10AP1	4.09	7.56e-05	0.0374	0.46	0.35	Intelligence (multi-trait analysis);	chr14:103533034	chr14:103412119~103412761:-
TGCT	cis	rs10771431	0.81	rs10771418	ENSG00000111788.10	RP11-22B23.1	4.09	7.57e-05	0.0374	0.31	0.35	Breast size;	chr12:9206399	chr12:9277235~9313241:+
TGCT	cis	rs453301	0.538	rs7830804	ENSG00000173295.6	FAM86B3P	-4.09	7.57e-05	0.0374	-0.44	-0.35	Joint mobility (Beighton score);	chr8:9113252	chr8:8228595~8244865:+
TGCT	cis	rs12760731	0.92	rs74226628	ENSG00000224687.1	RASAL2-AS1	4.09	7.57e-05	0.0374	0.6	0.35	Obesity-related traits;	chr1:178515459	chr1:178091508~178093984:-
TGCT	cis	rs11054731	0.807	rs4763795	ENSG00000247498.8	RP11-392P7.6	-4.09	7.57e-05	0.0374	-0.33	-0.35	Coronary artery calcification;	chr12:12284548	chr12:12927726~12984645:+
TGCT	cis	rs80262450	1	rs80262450	ENSG00000260302.1	RP11-973H7.1	4.09	7.57e-05	0.0374	0.63	0.35	Inflammatory bowel disease;Crohn's disease;	chr18:12818923	chr18:12774651~12775923:-
TGCT	cis	rs992157	0.798	rs10193383	ENSG00000261338.2	RP11-378A13.1	4.09	7.57e-05	0.0374	0.3	0.35	Colorectal cancer;	chr2:218292969	chr2:218255319~218257366:+
TGCT	cis	rs992157	0.798	rs10206064	ENSG00000261338.2	RP11-378A13.1	4.09	7.57e-05	0.0374	0.3	0.35	Colorectal cancer;	chr2:218293236	chr2:218255319~218257366:+
TGCT	cis	rs992157	0.7	rs10165153	ENSG00000261338.2	RP11-378A13.1	4.09	7.57e-05	0.0374	0.3	0.35	Colorectal cancer;	chr2:218294906	chr2:218255319~218257366:+
TGCT	cis	rs4273100	0.607	rs1043809	ENSG00000262319.1	CTC-457L16.2	4.09	7.57e-05	0.0374	0.44	0.35	Schizophrenia;	chr17:19336119	chr17:19141017~19143689:-
TGCT	cis	rs4273100	0.688	rs4143829	ENSG00000262319.1	CTC-457L16.2	4.09	7.57e-05	0.0374	0.44	0.35	Schizophrenia;	chr17:19338192	chr17:19141017~19143689:-
TGCT	cis	rs4273100	0.646	rs4924987	ENSG00000262319.1	CTC-457L16.2	4.09	7.57e-05	0.0374	0.44	0.35	Schizophrenia;	chr17:19343762	chr17:19141017~19143689:-
TGCT	cis	rs13118159	0.801	rs13147602	ENSG00000254094.1	AC078852.1	-4.09	7.57e-05	0.0374	-0.39	-0.35	Longevity;	chr4:1338387	chr4:1356581~1358075:+
TGCT	cis	rs1865760	0.929	rs9461224	ENSG00000217159.2	LARP1P1	-4.09	7.58e-05	0.0374	-0.46	-0.35	Height;	chr6:25936174	chr6:26164072~26164363:+
TGCT	cis	rs847851	1	rs1535001	ENSG00000186328.4	RP11-140K17.2	4.09	7.58e-05	0.0374	0.36	0.35	Colonoscopy-negative controls vs population controls;	chr6:34959503	chr6:34715613~34715940:+
TGCT	cis	rs847851	1	rs847859	ENSG00000186328.4	RP11-140K17.2	4.09	7.58e-05	0.0374	0.36	0.35	Colonoscopy-negative controls vs population controls;	chr6:34969695	chr6:34715613~34715940:+
TGCT	cis	rs884366	1	rs6903519	ENSG00000203799.9	CCDC162P	4.09	7.59e-05	0.0375	0.36	0.35	HDL cholesterol;HDL cholesterol levels;	chr6:109310112	chr6:109285485~109355063:+
TGCT	cis	rs7614311	0.636	rs56165216	ENSG00000239653.1	PSMD6-AS2	4.09	7.59e-05	0.0375	0.49	0.35	Lung function (FVC);Lung function (FEV1);	chr3:63930944	chr3:64004022~64012148:+
TGCT	cis	rs3105593	1	rs3109879	ENSG00000273674.3	CTD-2378E12.1	4.09	7.6e-05	0.0375	0.37	0.35	QT interval;	chr15:50545421	chr15:50839875~50908599:-
TGCT	cis	rs3105593	1	rs3109880	ENSG00000273674.3	CTD-2378E12.1	4.09	7.6e-05	0.0375	0.37	0.35	QT interval;	chr15:50545615	chr15:50839875~50908599:-
TGCT	cis	rs3105593	1	rs3109881	ENSG00000273674.3	CTD-2378E12.1	4.09	7.6e-05	0.0375	0.37	0.35	QT interval;	chr15:50547075	chr15:50839875~50908599:-
TGCT	cis	rs3105593	1	rs3131590	ENSG00000273674.3	CTD-2378E12.1	4.09	7.6e-05	0.0375	0.37	0.35	QT interval;	chr15:50548758	chr15:50839875~50908599:-
TGCT	cis	rs11722779	0.815	rs223347	ENSG00000230069.3	LRRC37A15P	-4.09	7.6e-05	0.0375	-0.31	-0.35	Schizophrenia;	chr4:102858815	chr4:102727274~102730721:-
TGCT	cis	rs11722779	0.873	rs223346	ENSG00000230069.3	LRRC37A15P	-4.09	7.6e-05	0.0375	-0.31	-0.35	Schizophrenia;	chr4:102859339	chr4:102727274~102730721:-
TGCT	cis	rs4242434	0.927	rs3736147	ENSG00000253200.1	RP11-582J16.5	-4.09	7.61e-05	0.0376	-0.2	-0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22614311	chr8:22613908~22616657:-
TGCT	cis	rs4242434	0.927	rs13271626	ENSG00000253200.1	RP11-582J16.5	4.09	7.61e-05	0.0376	0.2	0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22610247	chr8:22613908~22616657:-
TGCT	cis	rs4242434	0.927	rs720746	ENSG00000253200.1	RP11-582J16.5	4.09	7.61e-05	0.0376	0.2	0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22613886	chr8:22613908~22616657:-
TGCT	cis	rs4242434	0.927	rs11781149	ENSG00000253200.1	RP11-582J16.5	4.09	7.61e-05	0.0376	0.2	0.35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22615645	chr8:22613908~22616657:-
TGCT	cis	rs5758659	0.692	rs5751251	ENSG00000182057.4	OGFRP1	4.09	7.62e-05	0.0376	0.26	0.34	Cognitive function;	chr22:42244600	chr22:42269753~42275196:+
TGCT	cis	rs9400467	0.506	rs12215189	ENSG00000272356.1	RP5-1112D6.8	-4.09	7.62e-05	0.0376	-0.42	-0.34	Amino acid levels;Blood metabolite levels;	chr6:111324799	chr6:111309203~111313517:+
TGCT	cis	rs62025270	0.632	rs62022920	ENSG00000259416.2	RP11-158M2.5	-4.09	7.62e-05	0.0376	-0.41	-0.34	Idiopathic pulmonary fibrosis;	chr15:85680159	chr15:85754941~85756237:-
TGCT	cis	rs3758911	0.796	rs10890720	ENSG00000255353.1	RP11-382M14.1	4.09	7.62e-05	0.0376	0.41	0.34	Coronary artery disease;	chr11:107335292	chr11:107176286~107177530:+
TGCT	cis	rs2013441	1	rs2703817	ENSG00000230528.6	NOS2P3	4.09	7.62e-05	0.0376	0.34	0.34	Obesity-related traits;	chr17:20216364	chr17:20436337~20447249:+
TGCT	cis	rs2029362	0.66	rs2049046	ENSG00000245573.6	BDNF-AS	4.09	7.63e-05	0.0376	0.27	0.34	Total body bone mineral density;	chr11:27702228	chr11:27506838~27698174:+
TGCT	cis	rs911555	0.926	rs2756121	ENSG00000244691.1	RPL10AP1	4.09	7.63e-05	0.0377	0.47	0.34	Intelligence (multi-trait analysis);	chr14:103523244	chr14:103412119~103412761:-
TGCT	cis	rs2617170	0.845	rs1049174	ENSG00000245648.1	RP11-277P12.20	4.09	7.64e-05	0.0377	0.3	0.34	Behcet's disease;	chr12:10372766	chr12:10363769~10398506:+
TGCT	cis	rs62025270	0.848	rs2554	ENSG00000259416.2	RP11-158M2.5	-4.09	7.64e-05	0.0377	-0.42	-0.34	Idiopathic pulmonary fibrosis;	chr15:85759412	chr15:85754941~85756237:-
TGCT	cis	rs62025270	0.747	rs17639314	ENSG00000259416.2	RP11-158M2.5	-4.09	7.64e-05	0.0377	-0.42	-0.34	Idiopathic pulmonary fibrosis;	chr15:85766678	chr15:85754941~85756237:-
TGCT	cis	rs2337406	1	rs4774173	ENSG00000274576.2	IGHV2-70	-4.09	7.64e-05	0.0377	-0.54	-0.34	Alzheimer's disease (late onset);	chr14:106682029	chr14:106770577~106771020:-
TGCT	cis	rs227275	0.524	rs223337	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.543	rs223330	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102872502	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs223329	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873031	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs223324	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102876177	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.554	rs223314	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102884642	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs223313	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102886563	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs7254	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888488	chr4:102727274~102730721:-
TGCT	cis	rs11722779	0.566	rs6822658	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Schizophrenia;	chr4:102891964	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs6823625	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892437	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs6846762	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892577	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs4699032	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892724	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs6830407	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102895366	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.556	rs4235407	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102897427	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs4699033	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102897577	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.556	rs6815526	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102899729	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.556	rs28367331	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102900734	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.556	rs6824070	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102901676	chr4:102727274~102730721:-
TGCT	cis	rs11722779	0.935	rs6856176	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Schizophrenia;	chr4:102902574	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.556	rs11722779	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102906331	chr4:102727274~102730721:-
TGCT	cis	rs11722779	0.838	rs4533776	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Schizophrenia;	chr4:102912732	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.514	rs59550147	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.525	rs13113923	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102918936	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.525	rs3974608	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102727274~102730721:-
TGCT	cis	rs11722779	0.844	rs3974602	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Schizophrenia;	chr4:102928840	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.525	rs10028116	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.554	rs9307281	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102727274~102730721:-
TGCT	cis	rs11722779	0.903	rs6533037	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Schizophrenia;	chr4:102935865	chr4:102727274~102730721:-
TGCT	cis	rs11722779	0.903	rs4530634	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Schizophrenia;	chr4:102937924	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.525	rs7676943	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102938135	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.525	rs6419160	ENSG00000230069.3	LRRC37A15P	-4.09	7.64e-05	0.0377	-0.3	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102938648	chr4:102727274~102730721:-
TGCT	cis	rs17665889	0.51	rs9395698	ENSG00000225791.5	TRAM2-AS1	-4.09	7.64e-05	0.0377	-0.43	-0.34	Cannabis dependence symptom count;	chr6:51614725	chr6:52577307~52583993:+
TGCT	cis	rs227275	0.554	rs223334	ENSG00000230069.3	LRRC37A15P	4.09	7.64e-05	0.0377	0.3	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102727274~102730721:-
TGCT	cis	rs786425	0.77	rs7958693	ENSG00000280328.1	RP11-972P1.7	4.09	7.64e-05	0.0377	0.28	0.34	Pubertal anthropometrics;	chr12:123678203	chr12:123472200~123476093:-
TGCT	cis	rs12143943	0.934	rs1870551	ENSG00000176754.11	LINC00303	4.09	7.64e-05	0.0377	0.32	0.34	Cognitive performance;	chr1:204611886	chr1:204032447~204041265:-
TGCT	cis	rs7005380	0.733	rs10107579	ENSG00000254343.2	RP11-760H22.2	-4.09	7.65e-05	0.0377	-0.44	-0.34	Interstitial lung disease;	chr8:119922329	chr8:120052180~120056201:+
TGCT	cis	rs11722228	0.508	rs3796826	ENSG00000261490.1	RP11-448G15.3	4.09	7.66e-05	0.0378	0.34	0.34	Urate levels;Serum uric acid levels;Gout;	chr4:10091104	chr4:10068089~10073019:-
TGCT	cis	rs11722228	0.508	rs3796825	ENSG00000261490.1	RP11-448G15.3	4.09	7.66e-05	0.0378	0.34	0.34	Urate levels;Serum uric acid levels;Gout;	chr4:10091255	chr4:10068089~10073019:-
TGCT	cis	rs11722228	0.508	rs3822246	ENSG00000261490.1	RP11-448G15.3	4.09	7.66e-05	0.0378	0.34	0.34	Urate levels;Serum uric acid levels;Gout;	chr4:10093074	chr4:10068089~10073019:-
TGCT	cis	rs453301	0.653	rs1562211	ENSG00000253893.2	FAM85B	4.09	7.66e-05	0.0378	0.44	0.34	Joint mobility (Beighton score);	chr8:9044914	chr8:8167819~8226614:-
TGCT	cis	rs901683	1	rs34618850	ENSG00000264204.2	AGAP7P	-4.09	7.67e-05	0.0378	-0.82	-0.34	Mean corpuscular volume;Red blood cell traits;	chr10:45592415	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35670420	ENSG00000264204.2	AGAP7P	-4.09	7.67e-05	0.0378	-0.82	-0.34	Mean corpuscular volume;Red blood cell traits;	chr10:45592604	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs36053776	ENSG00000264204.2	AGAP7P	-4.09	7.67e-05	0.0378	-0.82	-0.34	Mean corpuscular volume;Red blood cell traits;	chr10:45592697	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35713143	ENSG00000264204.2	AGAP7P	-4.09	7.67e-05	0.0378	-0.82	-0.34	Mean corpuscular volume;Red blood cell traits;	chr10:45592711	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35626777	ENSG00000264204.2	AGAP7P	-4.09	7.67e-05	0.0378	-0.82	-0.34	Mean corpuscular volume;Red blood cell traits;	chr10:45592719	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs35047800	ENSG00000264204.2	AGAP7P	-4.09	7.67e-05	0.0378	-0.82	-0.34	Mean corpuscular volume;Red blood cell traits;	chr10:45593599	chr10:46109621~46131358:+
TGCT	cis	rs2243480	1	rs313831	ENSG00000164669.11	INTS4P1	4.09	7.67e-05	0.0378	0.52	0.34	Diabetic kidney disease;	chr7:66086239	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs465359	ENSG00000164669.11	INTS4P1	4.09	7.67e-05	0.0378	0.52	0.34	Diabetic kidney disease;	chr7:66093177	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs462853	ENSG00000164669.11	INTS4P1	4.09	7.67e-05	0.0378	0.52	0.34	Diabetic kidney disease;	chr7:66093180	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs160644	ENSG00000164669.11	INTS4P1	4.09	7.67e-05	0.0378	0.52	0.34	Diabetic kidney disease;	chr7:66093199	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs160642	ENSG00000164669.11	INTS4P1	4.09	7.67e-05	0.0378	0.52	0.34	Diabetic kidney disease;	chr7:66093386	chr7:65141225~65234216:+
TGCT	cis	rs2243480	0.614	rs34032527	ENSG00000164669.11	INTS4P1	4.09	7.67e-05	0.0378	0.52	0.34	Diabetic kidney disease;	chr7:66100154	chr7:65141225~65234216:+
TGCT	cis	rs957448	1	rs1055800	ENSG00000253175.1	RP11-267M23.6	-4.09	7.68e-05	0.0378	-0.43	-0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94510810	chr8:94565036~94565715:+
TGCT	cis	rs7208859	0.51	rs216402	ENSG00000263603.1	CTD-2349P21.5	-4.09	7.68e-05	0.0378	-0.5	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30729469~30731202:+
TGCT	cis	rs7829975	0.742	rs12547493	ENSG00000173295.6	FAM86B3P	-4.09	7.68e-05	0.0378	-0.41	-0.34	Mood instability;	chr8:8804024	chr8:8228595~8244865:+
TGCT	cis	rs4671458	0.656	rs72806010	ENSG00000260101.1	RP11-568N6.1	4.09	7.68e-05	0.0378	0.31	0.34	Subjective well-being;	chr2:63526668	chr2:64522187~64524093:-
TGCT	cis	rs4671458	0.656	rs12470478	ENSG00000260101.1	RP11-568N6.1	4.09	7.68e-05	0.0378	0.31	0.34	Subjective well-being;	chr2:63542174	chr2:64522187~64524093:-
TGCT	cis	rs5758659	1	rs134869	ENSG00000270083.1	RP1-257I20.14	4.09	7.68e-05	0.0378	0.34	0.34	Cognitive function;	chr22:42256068	chr22:42089630~42090028:-
TGCT	cis	rs4794202	0.618	rs4794224	ENSG00000264920.1	RP11-6N17.4	-4.09	7.69e-05	0.0379	-0.38	-0.34	Alzheimer's disease (cognitive decline);	chr17:47880097	chr17:47891255~47895812:-
TGCT	cis	rs7523273	0.586	rs2761425	ENSG00000203709.8	C1orf132	-4.09	7.69e-05	0.0379	-0.26	-0.34	Schizophrenia;	chr1:207720688	chr1:207801518~207869150:-
TGCT	cis	rs7829975	0.777	rs486781	ENSG00000253893.2	FAM85B	4.09	7.7e-05	0.0379	0.45	0.34	Mood instability;	chr8:8782230	chr8:8167819~8226614:-
TGCT	cis	rs11166629	1	rs4909330	ENSG00000272456.1	CTD-2342N23.3	4.09	7.7e-05	0.0379	0.39	0.34	Smoking quantity;	chr8:134632126	chr8:134722947~134723949:+
TGCT	cis	rs11166629	1	rs4909331	ENSG00000272456.1	CTD-2342N23.3	4.09	7.7e-05	0.0379	0.39	0.34	Smoking quantity;	chr8:134632297	chr8:134722947~134723949:+
TGCT	cis	rs1707322	1	rs4539075	ENSG00000280836.1	AL355480.1	-4.09	7.71e-05	0.0379	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr1:45581219~45581321:-
TGCT	cis	rs807029	0.577	rs3740489	ENSG00000272572.1	RP11-179B2.2	-4.09	7.71e-05	0.038	-0.29	-0.34	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100994481	chr10:100911103~100912739:-
TGCT	cis	rs7824557	0.606	rs1435277	ENSG00000255020.1	AF131216.5	4.09	7.71e-05	0.038	0.24	0.34	Retinal vascular caliber;	chr8:11339461	chr8:11345748~11347502:-
TGCT	cis	rs7824557	0.564	rs7839307	ENSG00000255020.1	AF131216.5	4.09	7.71e-05	0.038	0.24	0.34	Retinal vascular caliber;	chr8:11341283	chr8:11345748~11347502:-
TGCT	cis	rs453301	0.506	rs476845	ENSG00000173295.6	FAM86B3P	-4.09	7.72e-05	0.038	-0.39	-0.34	Joint mobility (Beighton score);	chr8:8765367	chr8:8228595~8244865:+
TGCT	cis	rs507080	0.961	rs642497	ENSG00000255239.1	AP002954.6	4.09	7.73e-05	0.038	0.45	0.34	Serum metabolite levels;	chr11:118680075	chr11:118688039~118690600:-
TGCT	cis	rs2739330	0.828	rs4820572	ENSG00000235689.1	AP000351.13	4.09	7.73e-05	0.038	0.35	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:24006305~24008258:-
TGCT	cis	rs9322193	0.886	rs4870055	ENSG00000231760.4	RP11-350J20.5	4.09	7.73e-05	0.038	0.41	0.34	Lung cancer;	chr6:149848433	chr6:149796151~149826294:-
TGCT	cis	rs2153535	0.58	rs7766852	ENSG00000230939.1	RP11-314C16.1	-4.09	7.74e-05	0.0381	-0.33	-0.34	Motion sickness;	chr6:8472184	chr6:8784178~8785445:+
TGCT	cis	rs17826219	0.568	rs59858012	ENSG00000263531.1	RP13-753N3.1	4.09	7.74e-05	0.0381	0.73	0.34	Body mass index;	chr17:30751564	chr17:30863921~30864940:-
TGCT	cis	rs10891354	0.547	rs10891360	ENSG00000176343.5	RPL37AP8	4.09	7.74e-05	0.0381	0.38	0.34	Schizophrenia;	chr11:112399728	chr11:111889199~111889474:-
TGCT	cis	rs10891354	0.547	rs10891361	ENSG00000176343.5	RPL37AP8	4.09	7.74e-05	0.0381	0.38	0.34	Schizophrenia;	chr11:112399751	chr11:111889199~111889474:-
TGCT	cis	rs2408955	0.522	rs3997	ENSG00000258273.1	RP11-370I10.4	4.09	7.75e-05	0.0381	0.41	0.34	Glycated hemoglobin levels;	chr12:48087804	chr12:48333755~48333901:-
TGCT	cis	rs7121756	1	rs7121756	ENSG00000255303.1	OR5BA1P	4.09	7.75e-05	0.0381	0.43	0.34	Fractures (vertebral);	chr11:57980425	chr11:57866298~57867279:-
TGCT	cis	rs7121756	1	rs7122921	ENSG00000255303.1	OR5BA1P	4.09	7.75e-05	0.0381	0.43	0.34	Fractures (vertebral);	chr11:57980660	chr11:57866298~57867279:-
TGCT	cis	rs9951698	0.703	rs11663049	ENSG00000266969.1	RP11-773H22.4	4.09	7.75e-05	0.0381	0.42	0.34	Intelligence (multi-trait analysis);	chr18:12991394	chr18:12984694~12991173:-
TGCT	cis	rs755249	0.51	rs582883	ENSG00000182109.6	RP11-69E11.4	4.09	7.76e-05	0.0381	0.35	0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39369868	chr1:39522280~39546187:-
TGCT	cis	rs4835473	0.863	rs13146607	ENSG00000251600.4	RP11-673E1.1	-4.09	7.76e-05	0.0382	-0.37	-0.34	Immature fraction of reticulocytes;	chr4:143687283	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.863	rs11735239	ENSG00000251600.4	RP11-673E1.1	-4.09	7.76e-05	0.0382	-0.37	-0.34	Immature fraction of reticulocytes;	chr4:143689372	chr4:143912331~143982454:+
TGCT	cis	rs11603023	0.625	rs633683	ENSG00000255422.1	AP002954.4	-4.09	7.76e-05	0.0382	-0.37	-0.34	Cholesterol, total;	chr11:118634025	chr11:118704607~118750263:+
TGCT	cis	rs11673344	0.704	rs1644710	ENSG00000226686.6	LINC01535	4.09	7.76e-05	0.0382	0.39	0.34	Obesity-related traits;	chr19:36926160	chr19:37251912~37265535:+
TGCT	cis	rs10129255	0.518	rs10150460	ENSG00000280411.1	IGHV1-69-2	4.09	7.77e-05	0.0382	0.34	0.34	Kawasaki disease;	chr14:106677179	chr14:106762092~106762588:-
TGCT	cis	rs2739330	0.828	rs5760102	ENSG00000235689.1	AP000351.13	4.09	7.77e-05	0.0382	0.35	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:24006305~24008258:-
TGCT	cis	rs12908161	0.853	rs12912342	ENSG00000225151.9	GOLGA2P7	-4.09	7.77e-05	0.0382	-0.35	-0.34	Schizophrenia;	chr15:84704985	chr15:84199311~84230136:-
TGCT	cis	rs7829975	0.606	rs6601274	ENSG00000253893.2	FAM85B	4.09	7.77e-05	0.0382	0.46	0.34	Mood instability;	chr8:8941549	chr8:8167819~8226614:-
TGCT	cis	rs4380275	0.782	rs11691064	ENSG00000272342.1	RP13-539J13.1	4.09	7.78e-05	0.0382	0.44	0.34	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:755718	chr2:739588~740164:-
TGCT	cis	rs4380275	0.809	rs6753699	ENSG00000272342.1	RP13-539J13.1	4.09	7.78e-05	0.0382	0.44	0.34	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:766081	chr2:739588~740164:-
TGCT	cis	rs4380275	0.782	rs60367761	ENSG00000272342.1	RP13-539J13.1	4.09	7.78e-05	0.0382	0.44	0.34	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:766414	chr2:739588~740164:-
TGCT	cis	rs1930961	0.85	rs5996945	ENSG00000271138.1	IGLVIVOR22-1	4.09	7.78e-05	0.0382	0.49	0.34	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25437306~25437823:-
TGCT	cis	rs34217772	0.539	rs966489	ENSG00000258536.1	RP11-1053O12.1	-4.09	7.78e-05	0.0382	-0.28	-0.34	Myopia;	chr14:41858628	chr14:41742639~41742963:+
TGCT	cis	rs9844666	0.512	rs9849088	ENSG00000239213.4	NCK1-AS1	4.09	7.78e-05	0.0382	0.34	0.34	Height;	chr3:135925060	chr3:136841726~136862054:-
TGCT	cis	rs9844666	0.512	rs56807950	ENSG00000239213.4	NCK1-AS1	4.09	7.78e-05	0.0382	0.34	0.34	Height;	chr3:135925531	chr3:136841726~136862054:-
TGCT	cis	rs9844666	0.512	rs59063369	ENSG00000239213.4	NCK1-AS1	4.09	7.78e-05	0.0382	0.34	0.34	Height;	chr3:135925636	chr3:136841726~136862054:-
TGCT	cis	rs7137828	0.901	rs3184504	ENSG00000226469.1	ADAM1B	4.09	7.78e-05	0.0382	0.31	0.34	Coronary artery disease;Glaucoma (primary open-angle);Allergic disease (asthma, hay fever or eczema);	chr12:111446804	chr12:111927018~111929017:+
TGCT	cis	rs875971	0.83	rs427575	ENSG00000237310.1	GS1-124K5.4	4.09	7.78e-05	0.0382	0.38	0.34	Aortic root size;	chr7:66054232	chr7:66493706~66495474:+
TGCT	cis	rs786425	0.804	rs10846535	ENSG00000247373.3	RP11-486O12.2	4.09	7.79e-05	0.0383	0.41	0.34	Pubertal anthropometrics;	chr12:123645841	chr12:123575891~123585115:-
TGCT	cis	rs1150668	0.796	rs2247002	ENSG00000204709.4	LINC01556	4.09	7.79e-05	0.0383	0.39	0.34	Pubertal anthropometrics;	chr6:28430174	chr6:28943877~28944537:+
TGCT	cis	rs2285002	0.516	rs114813	ENSG00000276116.2	FUT8-AS1	4.09	7.79e-05	0.0383	0.37	0.34	Red cell distribution width;	chr14:64827358	chr14:65411170~65412690:-
TGCT	cis	rs733592	0.507	rs7299704	ENSG00000258273.1	RP11-370I10.4	-4.09	7.79e-05	0.0383	-0.42	-0.34	Plateletcrit;	chr12:48050705	chr12:48333755~48333901:-
TGCT	cis	rs807029	0.577	rs3740488	ENSG00000272572.1	RP11-179B2.2	-4.09	7.79e-05	0.0383	-0.29	-0.34	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100994276	chr10:100911103~100912739:-
TGCT	cis	rs11822910	1	rs11822910	ENSG00000265566.2	RN7SL605P	4.09	7.8e-05	0.0383	0.47	0.34	Platelet distribution width;	chr11:57428444	chr11:57528085~57528365:-
TGCT	cis	rs11822910	1	rs4477456	ENSG00000265566.2	RN7SL605P	4.09	7.8e-05	0.0383	0.47	0.34	Platelet distribution width;	chr11:57430308	chr11:57528085~57528365:-
TGCT	cis	rs7572644	1	rs7572644	ENSG00000270210.1	RP11-373D23.3	-4.09	7.8e-05	0.0383	-0.38	-0.34	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28097166	chr2:28425945~28426719:+
TGCT	cis	rs10971721	0.822	rs72725368	ENSG00000230074.1	RP11-195F19.9	-4.09	7.8e-05	0.0383	-0.51	-0.34	Body mass index;	chr9:33815457	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72725370	ENSG00000230074.1	RP11-195F19.9	-4.09	7.8e-05	0.0383	-0.51	-0.34	Body mass index;	chr9:33818459	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.554	rs10971712	ENSG00000230074.1	RP11-195F19.9	-4.09	7.8e-05	0.0383	-0.51	-0.34	Body mass index;	chr9:33820940	chr9:34665665~34681298:+
TGCT	cis	rs7246967	0.611	rs12978511	ENSG00000198153.8	ZNF849P	4.09	7.81e-05	0.0383	0.57	0.34	Bronchopulmonary dysplasia;	chr19:22636414	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs12978964	ENSG00000198153.8	ZNF849P	4.09	7.81e-05	0.0383	0.57	0.34	Bronchopulmonary dysplasia;	chr19:22636442	chr19:22685167~22686732:+
TGCT	cis	rs9951698	0.678	rs1787004	ENSG00000266969.1	RP11-773H22.4	-4.09	7.82e-05	0.0384	-0.42	-0.34	Intelligence (multi-trait analysis);	chr18:13131396	chr18:12984694~12991173:-
TGCT	cis	rs2006771	0.618	rs470072	ENSG00000236132.1	CTA-440B3.1	-4.09	7.82e-05	0.0384	-0.36	-0.34	Nonsyndromic cleft lip with cleft palate;	chr22:31867145	chr22:31816379~31817491:-
TGCT	cis	rs10256972	0.577	rs6962809	ENSG00000229043.2	AC091729.9	-4.09	7.82e-05	0.0384	-0.33	-0.34	Endometriosis;Longevity;	chr7:1169253	chr7:1160374~1165267:+
TGCT	cis	rs10829156	0.796	rs6482567	ENSG00000240291.1	RP11-499P20.2	4.09	7.82e-05	0.0384	0.32	0.34	Sudden cardiac arrest;	chr10:18625860	chr10:18513115~18545651:-
TGCT	cis	rs10829156	0.898	rs10741120	ENSG00000240291.1	RP11-499P20.2	4.09	7.82e-05	0.0384	0.32	0.34	Sudden cardiac arrest;	chr10:18641063	chr10:18513115~18545651:-
TGCT	cis	rs10256972	0.552	rs2960830	ENSG00000229043.2	AC091729.9	-4.09	7.82e-05	0.0384	-0.33	-0.34	Endometriosis;Longevity;	chr7:1161005	chr7:1160374~1165267:+
TGCT	cis	rs10256972	0.552	rs2960831	ENSG00000229043.2	AC091729.9	-4.09	7.82e-05	0.0384	-0.33	-0.34	Endometriosis;Longevity;	chr7:1161556	chr7:1160374~1165267:+
TGCT	cis	rs7621025	0.542	rs71336078	ENSG00000239213.4	NCK1-AS1	-4.09	7.82e-05	0.0384	-0.45	-0.34	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136770760	chr3:136841726~136862054:-
TGCT	cis	rs875971	0.66	rs801192	ENSG00000236529.1	RP13-254B10.1	-4.09	7.82e-05	0.0384	-0.27	-0.34	Aortic root size;	chr7:66566965	chr7:65840212~65840596:+
TGCT	cis	rs875971	0.66	rs801190	ENSG00000236529.1	RP13-254B10.1	-4.09	7.82e-05	0.0384	-0.27	-0.34	Aortic root size;	chr7:66568046	chr7:65840212~65840596:+
TGCT	cis	rs875971	0.66	rs3857686	ENSG00000236529.1	RP13-254B10.1	-4.09	7.82e-05	0.0384	-0.27	-0.34	Aortic root size;	chr7:66571204	chr7:65840212~65840596:+
TGCT	cis	rs875971	0.638	rs6460305	ENSG00000236529.1	RP13-254B10.1	-4.09	7.82e-05	0.0384	-0.27	-0.34	Aortic root size;	chr7:66595421	chr7:65840212~65840596:+
TGCT	cis	rs875971	0.638	rs6960778	ENSG00000236529.1	RP13-254B10.1	-4.09	7.82e-05	0.0384	-0.27	-0.34	Aortic root size;	chr7:66606610	chr7:65840212~65840596:+
TGCT	cis	rs875971	0.66	rs1860468	ENSG00000236529.1	RP13-254B10.1	-4.09	7.82e-05	0.0384	-0.27	-0.34	Aortic root size;	chr7:66642265	chr7:65840212~65840596:+
TGCT	cis	rs875971	0.619	rs12533585	ENSG00000236529.1	RP13-254B10.1	4.09	7.82e-05	0.0384	0.27	0.34	Aortic root size;	chr7:66519618	chr7:65840212~65840596:+
TGCT	cis	rs875971	0.66	rs28698552	ENSG00000236529.1	RP13-254B10.1	4.09	7.82e-05	0.0384	0.27	0.34	Aortic root size;	chr7:66540031	chr7:65840212~65840596:+
TGCT	cis	rs792448	0.743	rs3767863	ENSG00000201544.1	SNORA16B	4.09	7.83e-05	0.0384	0.35	0.34	White blood cell count (basophil);	chr1:212364365	chr1:212352816~212352950:+
TGCT	cis	rs12745968	0.652	rs6603986	ENSG00000223787.2	RP4-593M8.1	-4.09	7.83e-05	0.0384	-0.46	-0.34	Bipolar disorder and schizophrenia;	chr1:92551664	chr1:92580476~92580821:-
TGCT	cis	rs792448	0.701	rs1774247	ENSG00000201544.1	SNORA16B	4.09	7.83e-05	0.0384	0.35	0.34	White blood cell count (basophil);	chr1:212376015	chr1:212352816~212352950:+
TGCT	cis	rs7824557	0.564	rs55758514	ENSG00000269918.1	AF131215.9	-4.09	7.84e-05	0.0384	-0.34	-0.34	Retinal vascular caliber;	chr8:11372750	chr8:11104691~11106704:-
TGCT	cis	rs11157436	0.918	rs1983519	ENSG00000211813.2	TRAV34	4.09	7.84e-05	0.0385	0.37	0.34	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150310	chr14:22207522~22208129:+
TGCT	cis	rs12760731	0.92	rs16852934	ENSG00000224687.1	RASAL2-AS1	4.09	7.84e-05	0.0385	0.52	0.34	Obesity-related traits;	chr1:178510155	chr1:178091508~178093984:-
TGCT	cis	rs12760731	0.92	rs9658883	ENSG00000224687.1	RASAL2-AS1	4.09	7.84e-05	0.0385	0.52	0.34	Obesity-related traits;	chr1:178511180	chr1:178091508~178093984:-
TGCT	cis	rs12760731	0.92	rs6695982	ENSG00000224687.1	RASAL2-AS1	4.09	7.84e-05	0.0385	0.52	0.34	Obesity-related traits;	chr1:178511598	chr1:178091508~178093984:-
TGCT	cis	rs6993244	1	rs6993244	ENSG00000254340.1	RP11-10A14.3	4.09	7.85e-05	0.0385	0.34	0.34	Mean corpuscular hemoglobin;	chr8:9005549	chr8:9141424~9145435:+
TGCT	cis	rs9487094	0.645	rs1322818	ENSG00000219700.1	PTCHD3P3	4.08	7.86e-05	0.0385	0.47	0.34	Height;	chr6:109369898	chr6:109288571~109290503:-
TGCT	cis	rs10129255	0.869	rs10136183	ENSG00000211970.3	IGHV4-61	-4.08	7.87e-05	0.0385	-0.38	-0.34	Kawasaki disease;	chr14:106710236	chr14:106639119~106639657:-
TGCT	cis	rs875971	0.545	rs1796226	ENSG00000222364.1	RNU6-96P	-4.08	7.87e-05	0.0386	-0.43	-0.34	Aortic root size;	chr7:66622723	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.545	rs2707851	ENSG00000222364.1	RNU6-96P	4.08	7.87e-05	0.0386	0.43	0.34	Aortic root size;	chr7:66624178	chr7:66395191~66395286:+
TGCT	cis	rs172166	0.637	rs1225597	ENSG00000219392.1	RP1-265C24.5	-4.08	7.88e-05	0.0386	-0.42	-0.34	Cardiac Troponin-T levels;	chr6:28194309	chr6:28115628~28116551:+
TGCT	cis	rs1867631	1	rs1867631	ENSG00000223263.1	RNU6-387P	-4.08	7.88e-05	0.0386	-0.38	-0.34	Menopause (age at onset);	chr1:66580443	chr1:67417214~67417318:+
TGCT	cis	rs9660180	1	rs3737628	ENSG00000231050.1	RP1-140A9.1	4.08	7.88e-05	0.0386	0.3	0.34	Body mass index;	chr1:1791493	chr1:1891471~1892658:+
TGCT	cis	rs2337406	0.706	rs74090742	ENSG00000274576.2	IGHV2-70	-4.08	7.89e-05	0.0386	-0.51	-0.34	Alzheimer's disease (late onset);	chr14:106696601	chr14:106770577~106771020:-
TGCT	cis	rs2337406	1	rs61268362	ENSG00000274576.2	IGHV2-70	-4.08	7.89e-05	0.0386	-0.51	-0.34	Alzheimer's disease (late onset);	chr14:106697010	chr14:106770577~106771020:-
TGCT	cis	rs2337406	0.85	rs8014460	ENSG00000274576.2	IGHV2-70	-4.08	7.89e-05	0.0386	-0.51	-0.34	Alzheimer's disease (late onset);	chr14:106697140	chr14:106770577~106771020:-
TGCT	cis	rs10483853	0.689	rs11623977	ENSG00000258695.2	RP3-414A15.2	-4.08	7.89e-05	0.0386	-0.43	-0.34	Coronary artery calcification;	chr14:73370662	chr14:73522878~73530610:+
TGCT	cis	rs10483853	0.54	rs2108552	ENSG00000258695.2	RP3-414A15.2	-4.08	7.89e-05	0.0386	-0.43	-0.34	Coronary artery calcification;	chr14:73410218	chr14:73522878~73530610:+
TGCT	cis	rs34792	0.554	rs2067063	ENSG00000260872.1	RP11-680G24.5	-4.08	7.9e-05	0.0387	-0.4	-0.34	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15515106	chr16:15018106~15020488:-
TGCT	cis	rs2919009	0.551	rs7080781	ENSG00000271670.1	RP11-95I16.4	4.08	7.9e-05	0.0387	0.43	0.34	Obesity-related traits;	chr10:120962171	chr10:120879256~120880667:-
TGCT	cis	rs7246967	0.736	rs423687	ENSG00000269509.1	BNIP3P34	4.08	7.9e-05	0.0387	0.5	0.34	Bronchopulmonary dysplasia;	chr19:22817943	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.673	rs368144	ENSG00000269509.1	BNIP3P34	4.08	7.9e-05	0.0387	0.5	0.34	Bronchopulmonary dysplasia;	chr19:22817985	chr19:22773853~22774424:+
TGCT	cis	rs7246967	0.736	rs386119	ENSG00000269509.1	BNIP3P34	4.08	7.9e-05	0.0387	0.5	0.34	Bronchopulmonary dysplasia;	chr19:22818016	chr19:22773853~22774424:+
TGCT	cis	rs6669072	1	rs6669072	ENSG00000231613.1	RP5-943J3.1	4.08	7.9e-05	0.0387	0.35	0.34	Cognitive function;	chr1:90781788	chr1:89788914~89790492:+
TGCT	cis	rs6669072	1	rs10922923	ENSG00000231613.1	RP5-943J3.1	4.08	7.9e-05	0.0387	0.35	0.34	Cognitive function;	chr1:90782472	chr1:89788914~89790492:+
TGCT	cis	rs72627509	0.951	rs17087335	ENSG00000269949.1	RP11-738E22.3	4.08	7.91e-05	0.0387	0.4	0.34	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56972417	chr4:56960927~56961373:-
TGCT	cis	rs2965260	0.621	rs117943561	ENSG00000269288.1	CTD-2245F17.6	4.08	7.91e-05	0.0387	0.46	0.34	IgG glycosylation;	chr19:53261469	chr19:53240675~53241913:+
TGCT	cis	rs2965260	0.621	rs17305073	ENSG00000269288.1	CTD-2245F17.6	4.08	7.91e-05	0.0387	0.46	0.34	IgG glycosylation;	chr19:53264900	chr19:53240675~53241913:+
TGCT	cis	rs1707322	1	rs12077974	ENSG00000280836.1	AL355480.1	-4.08	7.91e-05	0.0387	-0.46	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45918469	chr1:45581219~45581321:-
TGCT	cis	rs5742933	1	rs3791773	ENSG00000273240.1	RP11-455J20.3	-4.08	7.91e-05	0.0387	-0.36	-0.34	Ferritin levels;	chr2:189817906	chr2:189763859~189764456:-
TGCT	cis	rs6887276	0.934	rs10067555	ENSG00000245937.6	LINC01184	4.08	7.91e-05	0.0387	0.2	0.34	Height;	chr5:128091841	chr5:127940426~128083172:-
TGCT	cis	rs6887276	0.934	rs10039525	ENSG00000245937.6	LINC01184	4.08	7.91e-05	0.0387	0.2	0.34	Height;	chr5:128118028	chr5:127940426~128083172:-
TGCT	cis	rs6887276	0.934	rs809841	ENSG00000245937.6	LINC01184	4.08	7.91e-05	0.0387	0.2	0.34	Height;	chr5:128124390	chr5:127940426~128083172:-
TGCT	cis	rs4927850	0.521	rs4927679	ENSG00000207650.1	MIR570	-4.08	7.92e-05	0.0388	-0.43	-0.34	Pancreatic cancer;	chr3:195931489	chr3:195699401~195699497:+
TGCT	cis	rs67311347	0.824	rs59922539	ENSG00000223797.4	ENTPD3-AS1	4.08	7.92e-05	0.0388	0.35	0.34	Renal cell carcinoma;	chr3:40295619	chr3:40313802~40453329:-
TGCT	cis	rs67311347	0.822	rs9826847	ENSG00000223797.4	ENTPD3-AS1	4.08	7.92e-05	0.0388	0.35	0.34	Renal cell carcinoma;	chr3:40303821	chr3:40313802~40453329:-
TGCT	cis	rs6940638	0.688	rs7764984	ENSG00000187763.3	OR2B7P	4.08	7.93e-05	0.0388	0.33	0.34	Intelligence (multi-trait analysis);	chr6:27066402	chr6:28046434~28047367:+
TGCT	cis	rs11231017	0.967	rs4477443	ENSG00000254454.2	RCC2P6	-4.08	7.94e-05	0.0388	-0.27	-0.34	HIV-1 viral setpoint;	chr11:62297369	chr11:62371146~62373168:+
TGCT	cis	rs11231017	1	rs4280004	ENSG00000254454.2	RCC2P6	-4.08	7.94e-05	0.0388	-0.27	-0.34	HIV-1 viral setpoint;	chr11:62297372	chr11:62371146~62373168:+
TGCT	cis	rs876347	0.509	rs10983944	ENSG00000234782.3	TPT1P9	-4.08	7.94e-05	0.0388	-0.43	-0.34	Response to antipsychotic therapy (extrapyramidal side effects);	chr9:118248691	chr9:118082869~118083382:-
TGCT	cis	rs7246967	0.542	rs56355379	ENSG00000198153.8	ZNF849P	4.08	7.94e-05	0.0388	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22717653	chr19:22685167~22686732:+
TGCT	cis	rs10511112	0.867	rs12634294	ENSG00000242781.1	RP11-47P18.2	-4.08	7.94e-05	0.0389	-0.46	-0.34	Migraine;	chr3:80245951	chr3:80764897~80789354:+
TGCT	cis	rs9400467	0.537	rs12214886	ENSG00000272356.1	RP5-1112D6.8	-4.08	7.95e-05	0.0389	-0.41	-0.34	Amino acid levels;Blood metabolite levels;	chr6:111178878	chr6:111309203~111313517:+
TGCT	cis	rs875971	0.651	rs313829	ENSG00000164669.11	INTS4P1	4.08	7.96e-05	0.0389	0.37	0.34	Aortic root size;	chr7:66087510	chr7:65141225~65234216:+
TGCT	cis	rs10129255	0.528	rs17113214	ENSG00000211970.3	IGHV4-61	-4.08	7.96e-05	0.0389	-0.37	-0.34	Kawasaki disease;	chr14:106651954	chr14:106639119~106639657:-
TGCT	cis	rs10129255	0.613	rs11161000	ENSG00000211970.3	IGHV4-61	-4.08	7.96e-05	0.0389	-0.37	-0.34	Kawasaki disease;	chr14:106652584	chr14:106639119~106639657:-
TGCT	cis	rs227275	0.554	rs223454	ENSG00000230069.3	LRRC37A15P	-4.08	7.96e-05	0.0389	-0.3	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102789773	chr4:102727274~102730721:-
TGCT	cis	rs17608059	0.566	rs5005684	ENSG00000141028.6	CDRT15P1	-4.08	7.96e-05	0.0389	-0.39	-0.34	Temperament;	chr17:14007316	chr17:14024514~14025488:+
TGCT	cis	rs847851	1	rs847851	ENSG00000186328.4	RP11-140K17.2	-4.08	7.96e-05	0.0389	-0.36	-0.34	Colonoscopy-negative controls vs population controls;	chr6:34936807	chr6:34715613~34715940:+
TGCT	cis	rs847851	0.958	rs7753949	ENSG00000186328.4	RP11-140K17.2	4.08	7.96e-05	0.0389	0.36	0.34	Colonoscopy-negative controls vs population controls;	chr6:34914617	chr6:34715613~34715940:+
TGCT	cis	rs507080	0.961	rs543413	ENSG00000255239.1	AP002954.6	4.08	7.96e-05	0.0389	0.45	0.34	Serum metabolite levels;	chr11:118679308	chr11:118688039~118690600:-
TGCT	cis	rs10129255	1	rs10129255	ENSG00000211970.3	IGHV4-61	4.08	7.97e-05	0.0389	0.36	0.34	Kawasaki disease;	chr14:106767970	chr14:106639119~106639657:-
TGCT	cis	rs12760731	0.623	rs10913556	ENSG00000224687.1	RASAL2-AS1	4.08	7.97e-05	0.039	0.52	0.34	Obesity-related traits;	chr1:178467543	chr1:178091508~178093984:-
TGCT	cis	rs11168351	0.833	rs6580652	ENSG00000258273.1	RP11-370I10.4	4.08	7.97e-05	0.039	0.4	0.34	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48333755~48333901:-
TGCT	cis	rs2408955	0.522	rs4760679	ENSG00000258273.1	RP11-370I10.4	4.08	7.97e-05	0.039	0.4	0.34	Glycated hemoglobin levels;	chr12:48067852	chr12:48333755~48333901:-
TGCT	cis	rs2408955	0.561	rs9971924	ENSG00000258273.1	RP11-370I10.4	4.08	7.97e-05	0.039	0.4	0.34	Glycated hemoglobin levels;	chr12:48086049	chr12:48333755~48333901:-
TGCT	cis	rs2408955	0.522	rs7139330	ENSG00000258273.1	RP11-370I10.4	4.08	7.97e-05	0.039	0.4	0.34	Glycated hemoglobin levels;	chr12:48089701	chr12:48333755~48333901:-
TGCT	cis	rs2408955	0.522	rs2051851	ENSG00000258273.1	RP11-370I10.4	4.08	7.97e-05	0.039	0.4	0.34	Glycated hemoglobin levels;	chr12:48092157	chr12:48333755~48333901:-
TGCT	cis	rs2408955	0.522	rs973398	ENSG00000258273.1	RP11-370I10.4	4.08	7.97e-05	0.039	0.4	0.34	Glycated hemoglobin levels;	chr12:48097265	chr12:48333755~48333901:-
TGCT	cis	rs11168351	0.864	rs12228750	ENSG00000258273.1	RP11-370I10.4	4.08	7.97e-05	0.039	0.4	0.34	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48333755~48333901:-
TGCT	cis	rs11168351	0.864	rs10875743	ENSG00000258273.1	RP11-370I10.4	4.08	7.97e-05	0.039	0.4	0.34	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48333755~48333901:-
TGCT	cis	rs2408955	0.568	rs12099462	ENSG00000258273.1	RP11-370I10.4	4.08	7.97e-05	0.039	0.4	0.34	Glycated hemoglobin levels;	chr12:48109321	chr12:48333755~48333901:-
TGCT	cis	rs2408955	0.521	rs10875749	ENSG00000258273.1	RP11-370I10.4	4.08	7.97e-05	0.039	0.4	0.34	Glycated hemoglobin levels;	chr12:48138134	chr12:48333755~48333901:-
TGCT	cis	rs2408955	0.541	rs11168428	ENSG00000258273.1	RP11-370I10.4	4.08	7.97e-05	0.039	0.4	0.34	Glycated hemoglobin levels;	chr12:48153345	chr12:48333755~48333901:-
TGCT	cis	rs2408955	0.501	rs8716	ENSG00000258273.1	RP11-370I10.4	-4.08	7.97e-05	0.039	-0.4	-0.34	Glycated hemoglobin levels;	chr12:48145699	chr12:48333755~48333901:-
TGCT	cis	rs2408955	0.521	rs7301003	ENSG00000258273.1	RP11-370I10.4	-4.08	7.97e-05	0.039	-0.4	-0.34	Glycated hemoglobin levels;	chr12:48156444	chr12:48333755~48333901:-
TGCT	cis	rs1563304	1	rs1563304	ENSG00000262500.1	RP11-259G18.2	4.08	7.97e-05	0.039	0.59	0.34	Neuroticism;	chr17:46797087	chr17:46243606~46245044:+
TGCT	cis	rs62025270	0.522	rs16943120	ENSG00000259416.2	RP11-158M2.5	-4.08	7.98e-05	0.039	-0.41	-0.34	Idiopathic pulmonary fibrosis;	chr15:85683066	chr15:85754941~85756237:-
TGCT	cis	rs9309473	0.95	rs1918863	ENSG00000163016.8	ALMS1P	4.08	7.98e-05	0.039	0.31	0.34	Metabolite levels;	chr2:73417353	chr2:73644919~73685576:+
TGCT	cis	rs4973397	0.774	rs12998237	ENSG00000183022.5	TPM3P8	4.08	7.98e-05	0.039	0.48	0.34	Anti-saccade response;	chr2:231411940	chr2:230573167~230573809:-
TGCT	cis	rs2505998	0.833	rs2565203	ENSG00000273008.1	RP11-351D16.3	-4.08	7.98e-05	0.039	-0.4	-0.34	Hirschsprung disease;	chr10:43108287	chr10:43136824~43138334:-
TGCT	cis	rs6741892	1	rs4670885	ENSG00000225402.1	AC010878.3	4.08	7.98e-05	0.039	0.87	0.34	5-HTT brain serotonin transporter levels;	chr2:38683260	chr2:37816915~37817961:+
TGCT	cis	rs2015599	0.623	rs3782505	ENSG00000275476.1	RP11-996F15.4	4.08	7.99e-05	0.039	0.37	0.34	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29277397~29277882:-
TGCT	cis	rs9297994	0.556	rs10100873	ENSG00000242970.2	AC068522.4	-4.08	7.99e-05	0.039	-0.42	-0.34	LDL cholesterol;	chr8:58552244	chr8:58588420~58588764:-
TGCT	cis	rs1850744	1	rs1850744	ENSG00000251624.1	UNC93B7	4.08	7.99e-05	0.039	0.7	0.34	Economic and political preferences;	chr4:9789088	chr4:9493736~9498066:+
TGCT	cis	rs1850744	1	rs2867388	ENSG00000251624.1	UNC93B7	4.08	7.99e-05	0.039	0.7	0.34	Economic and political preferences;	chr4:9794871	chr4:9493736~9498066:+
TGCT	cis	rs1850744	1	rs2280208	ENSG00000251624.1	UNC93B7	4.08	7.99e-05	0.039	0.7	0.34	Economic and political preferences;	chr4:9798419	chr4:9493736~9498066:+
TGCT	cis	rs915071	0.686	rs8009524	ENSG00000202402.1	Y_RNA	4.08	8e-05	0.0391	0.22	0.34	Bipolar disorder and schizophrenia;	chr14:31991193	chr14:31244761~31244861:+
TGCT	cis	rs748404	0.697	rs473554	ENSG00000205771.5	CATSPER2P1	-4.08	8.01e-05	0.0391	-0.41	-0.34	Lung cancer;	chr15:43276009	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.697	rs530683	ENSG00000205771.5	CATSPER2P1	4.08	8.01e-05	0.0391	0.41	0.34	Lung cancer;	chr15:43276801	chr15:43726918~43747094:-
TGCT	cis	rs2273156	0.57	rs11156875	ENSG00000226677.3	IGBP1P1	-4.08	8.02e-05	0.0391	-0.47	-0.34	Immunoglobulin light chain (AL) amyloidosis;	chr14:35150610	chr14:34939324~34940332:+
TGCT	cis	rs10129255	0.957	rs8005468	ENSG00000211970.3	IGHV4-61	-4.08	8.02e-05	0.0391	-0.37	-0.34	Kawasaki disease;	chr14:106686431	chr14:106639119~106639657:-
TGCT	cis	rs10129255	0.957	rs1024349	ENSG00000211970.3	IGHV4-61	-4.08	8.02e-05	0.0391	-0.37	-0.34	Kawasaki disease;	chr14:106689997	chr14:106639119~106639657:-
TGCT	cis	rs10129255	0.957	rs2013423	ENSG00000211970.3	IGHV4-61	-4.08	8.02e-05	0.0391	-0.37	-0.34	Kawasaki disease;	chr14:106690675	chr14:106639119~106639657:-
TGCT	cis	rs10129255	0.957	rs56134540	ENSG00000211970.3	IGHV4-61	-4.08	8.02e-05	0.0391	-0.37	-0.34	Kawasaki disease;	chr14:106691290	chr14:106639119~106639657:-
TGCT	cis	rs4242434	0.927	rs10099846	ENSG00000254064.1	CTD-2530N21.4	4.08	8.02e-05	0.0391	0.21	0.34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22676665	chr8:22254576~22275162:-
TGCT	cis	rs34217772	0.783	rs61992398	ENSG00000258536.1	RP11-1053O12.1	4.08	8.04e-05	0.0392	0.32	0.34	Myopia;	chr14:41744578	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.83	rs61992399	ENSG00000258536.1	RP11-1053O12.1	4.08	8.04e-05	0.0392	0.32	0.34	Myopia;	chr14:41744786	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.83	rs61992400	ENSG00000258536.1	RP11-1053O12.1	4.08	8.04e-05	0.0392	0.32	0.34	Myopia;	chr14:41744838	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.83	rs58644188	ENSG00000258536.1	RP11-1053O12.1	4.08	8.04e-05	0.0392	0.32	0.34	Myopia;	chr14:41745351	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.771	rs57676929	ENSG00000258536.1	RP11-1053O12.1	4.08	8.04e-05	0.0392	0.32	0.34	Myopia;	chr14:41745826	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.83	rs55718011	ENSG00000258536.1	RP11-1053O12.1	4.08	8.04e-05	0.0392	0.32	0.34	Myopia;	chr14:41746496	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.83	rs60081458	ENSG00000258536.1	RP11-1053O12.1	4.08	8.04e-05	0.0392	0.32	0.34	Myopia;	chr14:41746599	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.83	rs57130262	ENSG00000258536.1	RP11-1053O12.1	4.08	8.04e-05	0.0392	0.32	0.34	Myopia;	chr14:41746601	chr14:41742639~41742963:+
TGCT	cis	rs172166	0.561	rs149976	ENSG00000204709.4	LINC01556	-4.08	8.04e-05	0.0392	-0.37	-0.34	Cardiac Troponin-T levels;	chr6:28019998	chr6:28943877~28944537:+
TGCT	cis	rs12439619	0.508	rs8032033	ENSG00000278603.1	RP13-608F4.5	4.08	8.04e-05	0.0392	0.44	0.34	Intelligence (multi-trait analysis);	chr15:82165555	chr15:82472203~82472426:+
TGCT	cis	rs4713118	0.662	rs175954	ENSG00000216901.1	AL022393.7	4.08	8.04e-05	0.0392	0.46	0.34	Parkinson's disease;	chr6:28043807	chr6:28176188~28176674:+
TGCT	cis	rs6604026	0.656	rs2255723	ENSG00000223787.2	RP4-593M8.1	4.08	8.05e-05	0.0393	0.44	0.34	Multiple sclerosis;	chr1:92902752	chr1:92580476~92580821:-
TGCT	cis	rs8141529	0.778	rs763073	ENSG00000226471.5	CTA-292E10.6	-4.08	8.06e-05	0.0393	-0.36	-0.34	Lymphocyte counts;	chr22:28819554	chr22:28800683~28848559:+
TGCT	cis	rs10754283	0.871	rs72712569	ENSG00000231613.1	RP5-943J3.1	-4.08	8.07e-05	0.0393	-0.35	-0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89660098	chr1:89788914~89790492:+
TGCT	cis	rs9584850	0.54	rs61969407	ENSG00000231194.1	FARP1-AS1	4.08	8.07e-05	0.0393	0.51	0.34	Neuroticism;	chr13:98466906	chr13:98435405~98435840:-
TGCT	cis	rs34217772	0.883	rs61992380	ENSG00000258536.1	RP11-1053O12.1	4.08	8.07e-05	0.0393	0.32	0.34	Myopia;	chr14:41739054	chr14:41742639~41742963:+
TGCT	cis	rs34217772	0.771	rs58694176	ENSG00000258536.1	RP11-1053O12.1	4.08	8.07e-05	0.0393	0.32	0.34	Myopia;	chr14:41740295	chr14:41742639~41742963:+
TGCT	cis	rs13068223	0.819	rs8792	ENSG00000243926.1	TIPARP-AS1	-4.08	8.08e-05	0.0394	-0.34	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747639	chr3:156671862~156674378:-
TGCT	cis	rs17826219	0.706	rs2322197	ENSG00000263603.1	CTD-2349P21.5	-4.08	8.08e-05	0.0394	-0.48	-0.34	Body mass index;	chr17:30778787	chr17:30729469~30731202:+
TGCT	cis	rs10511112	0.764	rs60035901	ENSG00000242781.1	RP11-47P18.2	-4.08	8.08e-05	0.0394	-0.49	-0.34	Migraine;	chr3:80325020	chr3:80764897~80789354:+
TGCT	cis	rs62355901	0.505	rs72758017	ENSG00000271828.1	CTD-2310F14.1	4.08	8.09e-05	0.0394	0.52	0.34	Breast cancer;	chr5:56797732	chr5:56927874~56929573:+
TGCT	cis	rs2742234	0.541	rs10793427	ENSG00000273008.1	RP11-351D16.3	4.08	8.09e-05	0.0394	0.47	0.34	Hirschsprung disease;	chr10:43251995	chr10:43136824~43138334:-
TGCT	cis	rs172166	0.637	rs1071893	ENSG00000219891.2	ZSCAN12P1	4.08	8.09e-05	0.0394	0.41	0.34	Cardiac Troponin-T levels;	chr6:28199857	chr6:28091154~28093664:+
TGCT	cis	rs1150668	0.796	rs728122	ENSG00000204709.4	LINC01556	4.08	8.09e-05	0.0394	0.39	0.34	Pubertal anthropometrics;	chr6:28431347	chr6:28943877~28944537:+
TGCT	cis	rs7591472	1	rs7591472	ENSG00000183308.6	AC005037.3	4.08	8.09e-05	0.0394	0.51	0.34	Triptolide cytotoxicity;	chr2:201025028	chr2:200963263~201009102:+
TGCT	cis	rs11772815	1	rs11772815	ENSG00000233830.2	EIF4HP1	4.08	8.1e-05	0.0394	0.37	0.34	Folding of antihelix;	chr7:28351428	chr7:27458163~27458849:-
TGCT	cis	rs763121	0.925	rs1056661	ENSG00000273076.1	RP3-508I15.22	4.08	8.1e-05	0.0394	0.37	0.34	Menopause (age at onset);	chr22:38684240	chr22:38743495~38743910:+
TGCT	cis	rs5758659	1	rs5758660	ENSG00000182057.4	OGFRP1	4.08	8.1e-05	0.0394	0.26	0.34	Cognitive function;	chr22:42227712	chr22:42269753~42275196:+
TGCT	cis	rs34217772	0.699	rs2415690	ENSG00000258536.1	RP11-1053O12.1	4.08	8.1e-05	0.0394	0.29	0.34	Myopia;	chr14:41843671	chr14:41742639~41742963:+
TGCT	cis	rs2015599	0.549	rs7134796	ENSG00000275476.1	RP11-996F15.4	4.08	8.1e-05	0.0394	0.36	0.34	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29277397~29277882:-
TGCT	cis	rs904251	0.772	rs10692	ENSG00000227920.2	RP1-153P14.5	-4.08	8.11e-05	0.0395	-0.43	-0.34	Cognitive performance;	chr6:37483138	chr6:37545145~37550860:+
TGCT	cis	rs7208859	0.524	rs8069400	ENSG00000266490.1	CTD-2349P21.9	4.08	8.11e-05	0.0395	0.4	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30792372~30792833:+
TGCT	cis	rs7819412	0.654	rs6987059	ENSG00000269918.1	AF131215.9	-4.08	8.11e-05	0.0395	-0.36	-0.34	Triglycerides;	chr8:11213548	chr8:11104691~11106704:-
TGCT	cis	rs10466239	0.73	rs2245413	ENSG00000230555.2	RP11-517P14.2	-4.08	8.11e-05	0.0395	-0.45	-0.34	Telomere length;	chr10:43355120	chr10:43420738~43422100:+
TGCT	cis	rs5758659	0.716	rs5758661	ENSG00000182057.4	OGFRP1	4.08	8.11e-05	0.0395	0.25	0.34	Cognitive function;	chr22:42228439	chr22:42269753~42275196:+
TGCT	cis	rs3020264	0.566	rs2911968	ENSG00000271743.1	CTD-2541M15.3	4.08	8.11e-05	0.0395	0.3	0.34	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6630984	chr8:6615604~6617198:-
TGCT	cis	rs1707322	0.896	rs946528	ENSG00000280836.1	AL355480.1	4.08	8.12e-05	0.0395	0.44	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019890	chr1:45581219~45581321:-
TGCT	cis	rs755249	0.588	rs6665948	ENSG00000182109.6	RP11-69E11.4	-4.08	8.13e-05	0.0395	-0.35	-0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39478508	chr1:39522280~39546187:-
TGCT	cis	rs4718428	0.924	rs6971897	ENSG00000226824.5	RP4-756H11.3	-4.08	8.13e-05	0.0395	-0.42	-0.34	Corneal structure;	chr7:66947787	chr7:66654538~66669855:+
TGCT	cis	rs9844666	0.512	rs9864656	ENSG00000239213.4	NCK1-AS1	-4.08	8.13e-05	0.0396	-0.34	-0.34	Height;	chr3:135924696	chr3:136841726~136862054:-
TGCT	cis	rs34421088	0.562	rs920050	ENSG00000254936.4	AF131215.3	-4.08	8.13e-05	0.0396	-0.37	-0.34	Neuroticism;	chr8:11250959	chr8:11123381~11126064:-
TGCT	cis	rs524281	0.731	rs10896075	ENSG00000255320.1	RP11-755F10.1	-4.08	8.14e-05	0.0396	-0.54	-0.34	Electroencephalogram traits;	chr11:66024742	chr11:66244840~66246239:-
TGCT	cis	rs67340775	0.541	rs200968	ENSG00000187763.3	OR2B7P	4.08	8.14e-05	0.0396	0.39	0.34	Lung cancer in ever smokers;	chr6:27891790	chr6:28046434~28047367:+
TGCT	cis	rs67340775	0.541	rs200966	ENSG00000187763.3	OR2B7P	4.08	8.14e-05	0.0396	0.39	0.34	Lung cancer in ever smokers;	chr6:27894374	chr6:28046434~28047367:+
TGCT	cis	rs792448	0.743	rs351380	ENSG00000201544.1	SNORA16B	4.08	8.14e-05	0.0396	0.35	0.34	White blood cell count (basophil);	chr1:212309510	chr1:212352816~212352950:+
TGCT	cis	rs853679	0.628	rs9368560	ENSG00000216901.1	AL022393.7	4.08	8.15e-05	0.0396	0.48	0.34	Depression;	chr6:28192182	chr6:28176188~28176674:+
TGCT	cis	rs7208859	0.673	rs9911989	ENSG00000266490.1	CTD-2349P21.9	-4.08	8.15e-05	0.0396	-0.36	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30792372~30792833:+
TGCT	cis	rs227275	0.555	rs223403	ENSG00000230069.3	LRRC37A15P	-4.08	8.15e-05	0.0396	-0.3	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102817086	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.555	rs223402	ENSG00000230069.3	LRRC37A15P	-4.08	8.15e-05	0.0396	-0.3	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102817198	chr4:102727274~102730721:-
TGCT	cis	rs904251	0.772	rs1224127	ENSG00000227920.2	RP1-153P14.5	-4.07	8.16e-05	0.0396	-0.43	-0.34	Cognitive performance;	chr6:37449780	chr6:37545145~37550860:+
TGCT	cis	rs796364	0.806	rs55985986	ENSG00000232732.8	AC073043.1	4.07	8.16e-05	0.0397	0.51	0.34	Schizophrenia;	chr2:200256264	chr2:199867396~199911159:-
TGCT	cis	rs758324	0.773	rs2404777	ENSG00000233006.5	AC034220.3	4.07	8.16e-05	0.0397	0.26	0.34	Alzheimer's disease in APOE e4- carriers;	chr5:131837110	chr5:132311285~132369916:-
TGCT	cis	rs758324	0.773	rs10069521	ENSG00000233006.5	AC034220.3	4.07	8.16e-05	0.0397	0.26	0.34	Alzheimer's disease in APOE e4- carriers;	chr5:131838522	chr5:132311285~132369916:-
TGCT	cis	rs453301	0.624	rs7014430	ENSG00000253893.2	FAM85B	-4.07	8.16e-05	0.0397	-0.46	-0.34	Joint mobility (Beighton score);	chr8:8970227	chr8:8167819~8226614:-
TGCT	cis	rs10759883	0.627	rs13294931	ENSG00000175611.10	LINC00476	-4.07	8.17e-05	0.0397	-0.39	-0.34	Nicotine dependence;	chr9:95833220	chr9:95759231~95875977:-
TGCT	cis	rs7819412	0.765	rs17783634	ENSG00000269918.1	AF131215.9	-4.07	8.18e-05	0.0397	-0.33	-0.34	Triglycerides;	chr8:11196588	chr8:11104691~11106704:-
TGCT	cis	rs4919669	0.668	rs10883760	ENSG00000273108.1	RP11-416N2.4	-4.07	8.18e-05	0.0397	-0.54	-0.34	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102659708	chr10:103608619~103610050:+
TGCT	cis	rs4919669	0.668	rs10883761	ENSG00000273108.1	RP11-416N2.4	-4.07	8.18e-05	0.0397	-0.54	-0.34	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102660261	chr10:103608619~103610050:+
TGCT	cis	rs7829975	0.846	rs11779061	ENSG00000253893.2	FAM85B	4.07	8.18e-05	0.0397	0.45	0.34	Mood instability;	chr8:8691922	chr8:8167819~8226614:-
TGCT	cis	rs4691139	0.557	rs4485779	ENSG00000250227.1	TRIM60P14	4.07	8.19e-05	0.0398	0.38	0.34	Ovarian cancer in BRCA1 mutation carriers;	chr4:165002877	chr4:164915565~164916983:+
TGCT	cis	rs72634501	0.517	rs10788925	ENSG00000182109.6	RP11-69E11.4	-4.07	8.2e-05	0.0398	-0.35	-0.34	HDL cholesterol;	chr1:39128430	chr1:39522280~39546187:-
TGCT	cis	rs11673344	0.764	rs16971873	ENSG00000226686.6	LINC01535	4.07	8.2e-05	0.0398	0.39	0.34	Obesity-related traits;	chr19:36978521	chr19:37251912~37265535:+
TGCT	cis	rs2439831	0.867	rs2614811	ENSG00000205771.5	CATSPER2P1	-4.07	8.2e-05	0.0398	-0.59	-0.34	Lung cancer in ever smokers;	chr15:43621289	chr15:43726918~43747094:-
TGCT	cis	rs6487679	1	rs1017302	ENSG00000111788.10	RP11-22B23.1	4.07	8.21e-05	0.0398	0.35	0.34	Non-alcoholic fatty liver disease histology (AST);	chr12:9214806	chr12:9277235~9313241:+
TGCT	cis	rs6487679	1	rs10734765	ENSG00000111788.10	RP11-22B23.1	4.07	8.21e-05	0.0398	0.35	0.34	Non-alcoholic fatty liver disease histology (AST);	chr12:9216789	chr12:9277235~9313241:+
TGCT	cis	rs6487679	1	rs6487679	ENSG00000111788.10	RP11-22B23.1	4.07	8.21e-05	0.0398	0.35	0.34	Non-alcoholic fatty liver disease histology (AST);	chr12:9218736	chr12:9277235~9313241:+
TGCT	cis	rs853679	0.513	rs13437444	ENSG00000187763.3	OR2B7P	4.07	8.21e-05	0.0398	0.39	0.34	Depression;	chr6:28103220	chr6:28046434~28047367:+
TGCT	cis	rs10129255	0.518	rs10136903	ENSG00000280411.1	IGHV1-69-2	-4.07	8.21e-05	0.0398	-0.35	-0.34	Kawasaki disease;	chr14:106778866	chr14:106762092~106762588:-
TGCT	cis	rs6952407	1	rs6952407	ENSG00000236529.1	RP13-254B10.1	-4.07	8.22e-05	0.0399	-0.27	-0.34	Cotinine glucuronidation;	chr7:66580525	chr7:65840212~65840596:+
TGCT	cis	rs1867631	1	rs10889636	ENSG00000223263.1	RNU6-387P	4.07	8.22e-05	0.0399	0.38	0.34	Menopause (age at onset);	chr1:66624241	chr1:67417214~67417318:+
TGCT	cis	rs10129255	0.5	rs988134	ENSG00000280411.1	IGHV1-69-2	-4.07	8.22e-05	0.0399	-0.34	-0.34	Kawasaki disease;	chr14:106776698	chr14:106762092~106762588:-
TGCT	cis	rs10129255	0.5	rs988133	ENSG00000280411.1	IGHV1-69-2	-4.07	8.22e-05	0.0399	-0.34	-0.34	Kawasaki disease;	chr14:106776724	chr14:106762092~106762588:-
TGCT	cis	rs10129255	0.518	rs8009594	ENSG00000280411.1	IGHV1-69-2	-4.07	8.22e-05	0.0399	-0.34	-0.34	Kawasaki disease;	chr14:106777494	chr14:106762092~106762588:-
TGCT	cis	rs10129255	0.518	rs8009612	ENSG00000280411.1	IGHV1-69-2	-4.07	8.22e-05	0.0399	-0.34	-0.34	Kawasaki disease;	chr14:106777510	chr14:106762092~106762588:-
TGCT	cis	rs10129255	0.5	rs6576230	ENSG00000280411.1	IGHV1-69-2	-4.07	8.22e-05	0.0399	-0.34	-0.34	Kawasaki disease;	chr14:106778539	chr14:106762092~106762588:-
TGCT	cis	rs10129255	0.518	rs11847766	ENSG00000280411.1	IGHV1-69-2	-4.07	8.22e-05	0.0399	-0.34	-0.34	Kawasaki disease;	chr14:106779186	chr14:106762092~106762588:-
TGCT	cis	rs7829975	0.511	rs2976902	ENSG00000254340.1	RP11-10A14.3	4.07	8.22e-05	0.0399	0.33	0.34	Mood instability;	chr8:8483595	chr8:9141424~9145435:+
TGCT	cis	rs7829975	0.511	rs2976906	ENSG00000254340.1	RP11-10A14.3	4.07	8.22e-05	0.0399	0.33	0.34	Mood instability;	chr8:8484905	chr8:9141424~9145435:+
TGCT	cis	rs12891047	0.78	rs1950769	ENSG00000258759.1	RP11-1012A1.7	-4.07	8.23e-05	0.0399	-0.29	-0.34	Amyotrophic lateral sclerosis (sporadic);	chr14:67887825	chr14:67799004~67799609:+
TGCT	cis	rs7208859	0.623	rs1054400	ENSG00000263603.1	CTD-2349P21.5	-4.07	8.23e-05	0.0399	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30729469~30731202:+
TGCT	cis	rs7819412	0.505	rs17782554	ENSG00000255310.2	AF131215.2	-4.07	8.23e-05	0.0399	-0.28	-0.34	Triglycerides;	chr8:11164596	chr8:11107788~11109726:-
TGCT	cis	rs13108904	0.604	rs11946375	ENSG00000253399.1	AC078852.2	-4.07	8.24e-05	0.0399	-0.37	-0.34	Obesity-related traits;	chr4:1319700	chr4:1358479~1359461:+
TGCT	cis	rs4380275	0.782	rs4854276	ENSG00000272342.1	RP13-539J13.1	4.07	8.24e-05	0.04	0.44	0.34	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:764357	chr2:739588~740164:-
TGCT	cis	rs17301853	0.915	rs7545388	ENSG00000227373.4	RP11-160H22.5	4.07	8.24e-05	0.04	0.55	0.34	Migraine without aura;Migraine - clinic-based;	chr1:174296285	chr1:174115300~174160004:-
TGCT	cis	rs17301853	0.908	rs78683861	ENSG00000227373.4	RP11-160H22.5	4.07	8.24e-05	0.04	0.55	0.34	Migraine without aura;Migraine - clinic-based;	chr1:174333802	chr1:174115300~174160004:-
TGCT	cis	rs17301853	1	rs17301125	ENSG00000227373.4	RP11-160H22.5	4.07	8.24e-05	0.04	0.55	0.34	Migraine without aura;Migraine - clinic-based;	chr1:174374755	chr1:174115300~174160004:-
TGCT	cis	rs17301853	1	rs78326521	ENSG00000227373.4	RP11-160H22.5	4.07	8.24e-05	0.04	0.55	0.34	Migraine without aura;Migraine - clinic-based;	chr1:174377714	chr1:174115300~174160004:-
TGCT	cis	rs786425	0.804	rs11057320	ENSG00000247373.3	RP11-486O12.2	4.07	8.24e-05	0.04	0.41	0.34	Pubertal anthropometrics;	chr12:123656815	chr12:123575891~123585115:-
TGCT	cis	rs17507216	0.518	rs1877240	ENSG00000278603.1	RP13-608F4.5	4.07	8.24e-05	0.04	0.58	0.34	Excessive daytime sleepiness;	chr15:82770126	chr15:82472203~82472426:+
TGCT	cis	rs755249	0.51	rs613511	ENSG00000182109.6	RP11-69E11.4	4.07	8.24e-05	0.04	0.35	0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367801	chr1:39522280~39546187:-
TGCT	cis	rs4660214	0.666	rs629093	ENSG00000182109.6	RP11-69E11.4	4.07	8.24e-05	0.04	0.35	0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367831	chr1:39522280~39546187:-
TGCT	cis	rs4660214	0.666	rs2490946	ENSG00000182109.6	RP11-69E11.4	4.07	8.24e-05	0.04	0.35	0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371955	chr1:39522280~39546187:-
TGCT	cis	rs4660214	0.666	rs663449	ENSG00000182109.6	RP11-69E11.4	4.07	8.24e-05	0.04	0.35	0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39378286	chr1:39522280~39546187:-
TGCT	cis	rs755249	0.51	rs1184716	ENSG00000182109.6	RP11-69E11.4	4.07	8.24e-05	0.04	0.35	0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380817	chr1:39522280~39546187:-
TGCT	cis	rs10483853	0.767	rs12590879	ENSG00000258695.2	RP3-414A15.2	-4.07	8.25e-05	0.04	-0.41	-0.34	Coronary artery calcification;	chr14:73338201	chr14:73522878~73530610:+
TGCT	cis	rs9921222	0.521	rs11649255	ENSG00000268836.1	LA16c-OS12.2	4.07	8.26e-05	0.04	0.35	0.34	Bone mineral density (spine);Bone mineral density;	chr16:307140	chr16:185748~186294:-
TGCT	cis	rs875971	0.545	rs1796217	ENSG00000222364.1	RNU6-96P	4.07	8.26e-05	0.04	0.43	0.34	Aortic root size;	chr7:66620931	chr7:66395191~66395286:+
TGCT	cis	rs792448	0.743	rs351393	ENSG00000201544.1	SNORA16B	-4.07	8.26e-05	0.0401	-0.34	-0.34	White blood cell count (basophil);	chr1:212303177	chr1:212352816~212352950:+
TGCT	cis	rs9880211	1	rs9828976	ENSG00000239213.4	NCK1-AS1	4.07	8.27e-05	0.0401	0.37	0.34	Height;Body mass index;	chr3:136817993	chr3:136841726~136862054:-
TGCT	cis	rs5758659	0.967	rs5758670	ENSG00000270083.1	RP1-257I20.14	4.07	8.27e-05	0.0401	0.34	0.34	Cognitive function;	chr22:42240681	chr22:42089630~42090028:-
TGCT	cis	rs7949030	0.62	rs2428551	ENSG00000269176.2	RP11-727F15.12	-4.07	8.28e-05	0.0401	-0.29	-0.34	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62562286	chr11:62786023~62786785:-
TGCT	cis	rs10129255	0.5	rs7159033	ENSG00000280411.1	IGHV1-69-2	-4.07	8.28e-05	0.0401	-0.34	-0.34	Kawasaki disease;	chr14:106701709	chr14:106762092~106762588:-
TGCT	cis	rs10466239	0.73	rs2946992	ENSG00000230555.2	RP11-517P14.2	-4.07	8.29e-05	0.0401	-0.46	-0.34	Telomere length;	chr10:43358831	chr10:43420738~43422100:+
TGCT	cis	rs228614	0.51	rs223392	ENSG00000230069.3	LRRC37A15P	-4.07	8.29e-05	0.0401	-0.3	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102824599	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs223353	ENSG00000230069.3	LRRC37A15P	-4.07	8.29e-05	0.0401	-0.3	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102854547	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs223352	ENSG00000230069.3	LRRC37A15P	-4.07	8.29e-05	0.0401	-0.3	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102855710	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs223349	ENSG00000230069.3	LRRC37A15P	-4.07	8.29e-05	0.0401	-0.3	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102857277	chr4:102727274~102730721:-
TGCT	cis	rs728616	0.614	rs726014	ENSG00000230091.5	TMEM254-AS1	4.07	8.29e-05	0.0401	0.52	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948988	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.614	rs59169164	ENSG00000230091.5	TMEM254-AS1	4.07	8.29e-05	0.0401	0.52	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952159	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.614	rs1885552	ENSG00000230091.5	TMEM254-AS1	4.07	8.29e-05	0.0401	0.52	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952336	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.614	rs1885551	ENSG00000230091.5	TMEM254-AS1	4.07	8.29e-05	0.0401	0.52	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952597	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.614	rs12253608	ENSG00000230091.5	TMEM254-AS1	4.07	8.29e-05	0.0401	0.52	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952727	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.764	rs1885549	ENSG00000230091.5	TMEM254-AS1	4.07	8.29e-05	0.0401	0.52	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952794	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.614	rs12245076	ENSG00000230091.5	TMEM254-AS1	4.07	8.29e-05	0.0401	0.52	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953675	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.614	rs10788319	ENSG00000230091.5	TMEM254-AS1	4.07	8.29e-05	0.0401	0.52	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953754	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.614	rs11200859	ENSG00000230091.5	TMEM254-AS1	4.07	8.29e-05	0.0401	0.52	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953805	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.614	rs10887229	ENSG00000230091.5	TMEM254-AS1	4.07	8.29e-05	0.0401	0.52	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954018	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.614	rs10788321	ENSG00000230091.5	TMEM254-AS1	4.07	8.29e-05	0.0401	0.52	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954039	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.614	rs61858839	ENSG00000230091.5	TMEM254-AS1	4.07	8.29e-05	0.0401	0.52	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954162	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.614	rs61858841	ENSG00000230091.5	TMEM254-AS1	4.07	8.29e-05	0.0401	0.52	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954420	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.614	rs61858842	ENSG00000230091.5	TMEM254-AS1	4.07	8.29e-05	0.0401	0.52	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955283	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.614	rs10887233	ENSG00000230091.5	TMEM254-AS1	4.07	8.29e-05	0.0401	0.52	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955596	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.614	rs10887234	ENSG00000230091.5	TMEM254-AS1	4.07	8.29e-05	0.0401	0.52	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955666	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.614	rs10887235	ENSG00000230091.5	TMEM254-AS1	4.07	8.29e-05	0.0401	0.52	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955890	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.614	rs2146192	ENSG00000230091.5	TMEM254-AS1	4.07	8.29e-05	0.0401	0.52	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955982	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.614	rs2146191	ENSG00000230091.5	TMEM254-AS1	4.07	8.29e-05	0.0401	0.52	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955998	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.614	rs10887243	ENSG00000230091.5	TMEM254-AS1	4.07	8.29e-05	0.0401	0.52	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79957339	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.614	rs10887244	ENSG00000230091.5	TMEM254-AS1	4.07	8.29e-05	0.0401	0.52	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79957352	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.541	rs61860401	ENSG00000230091.5	TMEM254-AS1	4.07	8.29e-05	0.0401	0.52	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963766	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.614	rs55768100	ENSG00000230091.5	TMEM254-AS1	4.07	8.29e-05	0.0401	0.52	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79964721	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.614	rs58606426	ENSG00000230091.5	TMEM254-AS1	4.07	8.29e-05	0.0401	0.52	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968556	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.614	rs57966752	ENSG00000230091.5	TMEM254-AS1	4.07	8.29e-05	0.0401	0.52	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968557	chr10:80046860~80078912:-
TGCT	cis	rs853679	0.55	rs1233704	ENSG00000216901.1	AL022393.7	-4.07	8.29e-05	0.0401	-0.47	-0.34	Depression;	chr6:28199145	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.513	rs149878	ENSG00000187763.3	OR2B7P	4.07	8.3e-05	0.0402	0.31	0.34	Parkinson's disease;	chr6:27910960	chr6:28046434~28047367:+
TGCT	cis	rs7187423	0.677	rs11646264	ENSG00000261291.1	RP11-295M3.2	4.07	8.3e-05	0.0402	0.91	0.34	Allergic rhinitis;	chr16:53998602	chr16:53168522~53169450:+
TGCT	cis	rs7187423	0.677	rs11642317	ENSG00000261291.1	RP11-295M3.2	4.07	8.3e-05	0.0402	0.91	0.34	Allergic rhinitis;	chr16:53999212	chr16:53168522~53169450:+
TGCT	cis	rs1850744	0.826	rs9291607	ENSG00000251624.1	UNC93B7	-4.07	8.31e-05	0.0402	-0.59	-0.34	Economic and political preferences;	chr4:9707174	chr4:9493736~9498066:+
TGCT	cis	rs12497850	1	rs4858828	ENSG00000226913.1	BSN-AS2	-4.07	8.31e-05	0.0402	-0.27	-0.34	Parkinson's disease;	chr3:48687378	chr3:49549306~49554366:-
TGCT	cis	rs12497850	0.863	rs4858799	ENSG00000226913.1	BSN-AS2	-4.07	8.31e-05	0.0402	-0.27	-0.34	Parkinson's disease;	chr3:48690771	chr3:49549306~49554366:-
TGCT	cis	rs12497850	1	rs10865952	ENSG00000226913.1	BSN-AS2	-4.07	8.31e-05	0.0402	-0.27	-0.34	Parkinson's disease;	chr3:48707051	chr3:49549306~49554366:-
TGCT	cis	rs12497850	1	rs12497850	ENSG00000226913.1	BSN-AS2	-4.07	8.31e-05	0.0402	-0.27	-0.34	Parkinson's disease;	chr3:48711556	chr3:49549306~49554366:-
TGCT	cis	rs12497850	1	rs6788650	ENSG00000226913.1	BSN-AS2	-4.07	8.31e-05	0.0402	-0.27	-0.34	Parkinson's disease;	chr3:48712110	chr3:49549306~49554366:-
TGCT	cis	rs748404	0.666	rs34591748	ENSG00000205771.5	CATSPER2P1	-4.07	8.31e-05	0.0402	-0.5	-0.34	Lung cancer;	chr15:43334917	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.666	rs35326382	ENSG00000205771.5	CATSPER2P1	-4.07	8.31e-05	0.0402	-0.5	-0.34	Lung cancer;	chr15:43338686	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.666	rs34515241	ENSG00000205771.5	CATSPER2P1	-4.07	8.31e-05	0.0402	-0.5	-0.34	Lung cancer;	chr15:43342011	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.626	rs35992154	ENSG00000205771.5	CATSPER2P1	-4.07	8.31e-05	0.0402	-0.5	-0.34	Lung cancer;	chr15:43345669	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.666	rs17780417	ENSG00000205771.5	CATSPER2P1	-4.07	8.31e-05	0.0402	-0.5	-0.34	Lung cancer;	chr15:43347264	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.666	rs7181634	ENSG00000205771.5	CATSPER2P1	-4.07	8.31e-05	0.0402	-0.5	-0.34	Lung cancer;	chr15:43351703	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.626	rs72707530	ENSG00000205771.5	CATSPER2P1	-4.07	8.31e-05	0.0402	-0.5	-0.34	Lung cancer;	chr15:43353622	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.666	rs7183708	ENSG00000205771.5	CATSPER2P1	-4.07	8.31e-05	0.0402	-0.5	-0.34	Lung cancer;	chr15:43355226	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.666	rs55748552	ENSG00000205771.5	CATSPER2P1	-4.07	8.31e-05	0.0402	-0.5	-0.34	Lung cancer;	chr15:43359428	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.63	rs35278805	ENSG00000205771.5	CATSPER2P1	-4.07	8.31e-05	0.0402	-0.5	-0.34	Lung cancer;	chr15:43361124	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.666	rs35160541	ENSG00000205771.5	CATSPER2P1	-4.07	8.31e-05	0.0402	-0.5	-0.34	Lung cancer;	chr15:43365601	chr15:43726918~43747094:-
TGCT	cis	rs1850744	0.702	rs7666466	ENSG00000250884.1	OR7E85P	4.07	8.32e-05	0.0402	0.68	0.34	Economic and political preferences;	chr4:9627879	chr4:9483718~9484702:+
TGCT	cis	rs1850744	0.609	rs11729458	ENSG00000250884.1	OR7E85P	4.07	8.32e-05	0.0402	0.68	0.34	Economic and political preferences;	chr4:9628447	chr4:9483718~9484702:+
TGCT	cis	rs1850744	0.609	rs11939928	ENSG00000250884.1	OR7E85P	4.07	8.32e-05	0.0402	0.68	0.34	Economic and political preferences;	chr4:9628867	chr4:9483718~9484702:+
TGCT	cis	rs1850744	0.826	rs11933525	ENSG00000250884.1	OR7E85P	4.07	8.32e-05	0.0402	0.68	0.34	Economic and political preferences;	chr4:9628880	chr4:9483718~9484702:+
TGCT	cis	rs10129255	0.5	rs4774189	ENSG00000223648.3	IGHV3-64	4.07	8.32e-05	0.0402	0.29	0.34	Kawasaki disease;	chr14:106768275	chr14:106643132~106658258:-
TGCT	cis	rs1964356	0.967	rs17701675	ENSG00000173295.6	FAM86B3P	-4.07	8.32e-05	0.0402	-0.41	-0.34	Mean corpuscular volume;	chr8:8993123	chr8:8228595~8244865:+
TGCT	cis	rs1850744	0.536	rs10014408	ENSG00000251624.1	UNC93B7	4.07	8.32e-05	0.0402	0.67	0.34	Economic and political preferences;	chr4:9693521	chr4:9493736~9498066:+
TGCT	cis	rs7829975	0.511	rs2980426	ENSG00000253893.2	FAM85B	-4.07	8.32e-05	0.0403	-0.45	-0.34	Mood instability;	chr8:8288087	chr8:8167819~8226614:-
TGCT	cis	rs2733954	0.707	rs9931892	ENSG00000270184.1	RP11-568J23.5	-4.07	8.33e-05	0.0403	-0.25	-0.34	Leprosy;	chr16:85791923	chr16:85784382~85787617:+
TGCT	cis	rs748404	0.697	rs1814323	ENSG00000205771.5	CATSPER2P1	4.07	8.33e-05	0.0403	0.39	0.34	Lung cancer;	chr15:43271039	chr15:43726918~43747094:-
TGCT	cis	rs1976403	0.659	rs10799701	ENSG00000227001.3	NBPF2P	4.07	8.34e-05	0.0403	0.29	0.34	Liver enzyme levels (alkaline phosphatase);	chr1:21494497	chr1:21424625~21427967:-
TGCT	cis	rs875971	1	rs6956179	ENSG00000237310.1	GS1-124K5.4	-4.07	8.34e-05	0.0403	-0.37	-0.34	Aortic root size;	chr7:66341672	chr7:66493706~66495474:+
TGCT	cis	rs7829975	0.711	rs4841051	ENSG00000254340.1	RP11-10A14.3	-4.07	8.34e-05	0.0403	-0.35	-0.34	Mood instability;	chr8:8828136	chr8:9141424~9145435:+
TGCT	cis	rs875971	1	rs4718307	ENSG00000232559.3	GS1-124K5.12	-4.07	8.35e-05	0.0403	-0.32	-0.34	Aortic root size;	chr7:66146001	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs7801282	ENSG00000232559.3	GS1-124K5.12	-4.07	8.35e-05	0.0403	-0.32	-0.34	Aortic root size;	chr7:66148700	chr7:66554588~66576923:-
TGCT	cis	rs4150161	0.656	rs77958073	ENSG00000278214.1	RP11-442O1.4	4.07	8.35e-05	0.0403	0.84	0.34	Systolic blood pressure response to hydrochlorothiazide in hypertension;	chr16:84190016	chr16:85137150~85149443:+
TGCT	cis	rs7829975	0.542	rs7844374	ENSG00000254340.1	RP11-10A14.3	-4.07	8.35e-05	0.0404	-0.35	-0.34	Mood instability;	chr8:8941174	chr8:9141424~9145435:+
TGCT	cis	rs875971	0.545	rs17138149	ENSG00000222364.1	RNU6-96P	-4.07	8.35e-05	0.0404	-0.42	-0.34	Aortic root size;	chr7:66228193	chr7:66395191~66395286:+
TGCT	cis	rs11168618	0.81	rs11168595	ENSG00000240399.1	RP1-228P16.1	4.07	8.36e-05	0.0404	0.32	0.34	Adiponectin levels;	chr12:48474428	chr12:48054813~48055591:-
TGCT	cis	rs11168618	0.743	rs12815151	ENSG00000240399.1	RP1-228P16.1	4.07	8.36e-05	0.0404	0.32	0.34	Adiponectin levels;	chr12:48481053	chr12:48054813~48055591:-
TGCT	cis	rs2153535	0.58	rs4451187	ENSG00000230939.1	RP11-314C16.1	-4.07	8.37e-05	0.0405	-0.33	-0.34	Motion sickness;	chr6:8473677	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.504	rs4493781	ENSG00000230939.1	RP11-314C16.1	-4.07	8.37e-05	0.0405	-0.33	-0.34	Motion sickness;	chr6:8473708	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.541	rs5026687	ENSG00000230939.1	RP11-314C16.1	-4.07	8.37e-05	0.0405	-0.33	-0.34	Motion sickness;	chr6:8473724	chr6:8784178~8785445:+
TGCT	cis	rs1972460	0.506	rs62012050	ENSG00000276710.3	CSPG4P8	-4.07	8.38e-05	0.0405	-0.31	-0.34	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82459472~82477258:+
TGCT	cis	rs12439619	1	rs35152457	ENSG00000276710.3	CSPG4P8	-4.07	8.38e-05	0.0405	-0.31	-0.34	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82459472~82477258:+
TGCT	cis	rs792448	0.743	rs7519959	ENSG00000201544.1	SNORA16B	4.07	8.38e-05	0.0405	0.34	0.34	White blood cell count (basophil);	chr1:212325310	chr1:212352816~212352950:+
TGCT	cis	rs792448	0.743	rs4951589	ENSG00000201544.1	SNORA16B	4.07	8.38e-05	0.0405	0.34	0.34	White blood cell count (basophil);	chr1:212327351	chr1:212352816~212352950:+
TGCT	cis	rs1707322	1	rs34694458	ENSG00000280836.1	AL355480.1	-4.07	8.38e-05	0.0405	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867024	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs10158032	ENSG00000280836.1	AL355480.1	-4.07	8.38e-05	0.0405	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867029	chr1:45581219~45581321:-
TGCT	cis	rs7829975	0.714	rs4840362	ENSG00000253893.2	FAM85B	4.07	8.38e-05	0.0405	0.45	0.34	Mood instability;	chr8:8812572	chr8:8167819~8226614:-
TGCT	cis	rs13204927	1	rs13204927	ENSG00000219700.1	PTCHD3P3	4.07	8.38e-05	0.0405	0.5	0.34	Mean corpuscular hemoglobin;	chr6:109281587	chr6:109288571~109290503:-
TGCT	cis	rs7246967	0.932	rs4932800	ENSG00000268541.1	VN1R88P	-4.07	8.39e-05	0.0405	-0.4	-0.34	Bronchopulmonary dysplasia;	chr19:22868846	chr19:22861303~22861594:+
TGCT	cis	rs7246967	0.932	rs4932801	ENSG00000268541.1	VN1R88P	-4.07	8.39e-05	0.0405	-0.4	-0.34	Bronchopulmonary dysplasia;	chr19:22868851	chr19:22861303~22861594:+
TGCT	cis	rs7829975	0.572	rs28730413	ENSG00000253893.2	FAM85B	4.07	8.39e-05	0.0405	0.43	0.34	Mood instability;	chr8:8937937	chr8:8167819~8226614:-
TGCT	cis	rs8059260	0.668	rs6498152	ENSG00000274038.1	RP11-66H6.4	-4.07	8.39e-05	0.0405	-0.38	-0.34	Alcohol consumption over the past year;	chr16:11030590	chr16:11056556~11057034:+
TGCT	cis	rs10129255	0.957	rs17113284	ENSG00000211970.3	IGHV4-61	4.07	8.4e-05	0.0405	0.37	0.34	Kawasaki disease;	chr14:106684476	chr14:106639119~106639657:-
TGCT	cis	rs667920	0.5	rs34738913	ENSG00000239213.4	NCK1-AS1	-4.07	8.4e-05	0.0405	-0.47	-0.34	Coronary artery disease;	chr3:136719042	chr3:136841726~136862054:-
TGCT	cis	rs7684253	0.587	rs2002154	ENSG00000269949.1	RP11-738E22.3	-4.07	8.4e-05	0.0405	-0.34	-0.34	Migraine;	chr4:56879851	chr4:56960927~56961373:-
TGCT	cis	rs7684253	0.587	rs7670313	ENSG00000269949.1	RP11-738E22.3	-4.07	8.4e-05	0.0405	-0.34	-0.34	Migraine;	chr4:56880007	chr4:56960927~56961373:-
TGCT	cis	rs7684253	0.587	rs2170074	ENSG00000269949.1	RP11-738E22.3	-4.07	8.4e-05	0.0405	-0.34	-0.34	Migraine;	chr4:56880190	chr4:56960927~56961373:-
TGCT	cis	rs7684253	0.587	rs2170073	ENSG00000269949.1	RP11-738E22.3	-4.07	8.4e-05	0.0405	-0.34	-0.34	Migraine;	chr4:56880659	chr4:56960927~56961373:-
TGCT	cis	rs11722228	0.521	rs12501336	ENSG00000261490.1	RP11-448G15.3	4.07	8.4e-05	0.0406	0.3	0.34	Urate levels;Serum uric acid levels;Gout;	chr4:10135727	chr4:10068089~10073019:-
TGCT	cis	rs7824557	0.564	rs6601584	ENSG00000269918.1	AF131215.9	-4.07	8.41e-05	0.0406	-0.34	-0.34	Retinal vascular caliber;	chr8:11374834	chr8:11104691~11106704:-
TGCT	cis	rs786425	0.833	rs7313628	ENSG00000278112.1	RP11-972P1.11	4.07	8.41e-05	0.0406	0.38	0.34	Pubertal anthropometrics;	chr12:123622468	chr12:123519390~123519856:-
TGCT	cis	rs1497406	0.744	rs12562207	ENSG00000235084.3	CHCHD2P6	4.07	8.42e-05	0.0406	0.4	0.34	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);	chr1:16181564	chr1:15604597~15605043:+
TGCT	cis	rs1497406	0.744	rs1007887	ENSG00000235084.3	CHCHD2P6	4.07	8.42e-05	0.0406	0.4	0.34	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);	chr1:16182534	chr1:15604597~15605043:+
TGCT	cis	rs4820539	0.934	rs3788348	ENSG00000218537.1	MIF-AS1	4.07	8.42e-05	0.0406	0.43	0.34	Bone mineral density;	chr22:23125759	chr22:23894426~23898930:-
TGCT	cis	rs4820539	0.932	rs3788349	ENSG00000218537.1	MIF-AS1	4.07	8.42e-05	0.0406	0.43	0.34	Bone mineral density;	chr22:23125763	chr22:23894426~23898930:-
TGCT	cis	rs4820539	1	rs3827316	ENSG00000218537.1	MIF-AS1	4.07	8.42e-05	0.0406	0.43	0.34	Bone mineral density;	chr22:23126351	chr22:23894426~23898930:-
TGCT	cis	rs34421088	0.576	rs2736369	ENSG00000254936.4	AF131215.3	-4.07	8.42e-05	0.0406	-0.37	-0.34	Neuroticism;	chr8:11243889	chr8:11123381~11126064:-
TGCT	cis	rs8050896	1	rs7199238	ENSG00000259847.1	RP11-95H3.1	-4.07	8.42e-05	0.0406	-0.5	-0.34	Response to antipsychotic treatment;	chr16:66124251	chr16:65141756~65176713:-
TGCT	cis	rs8050896	1	rs7198326	ENSG00000259847.1	RP11-95H3.1	-4.07	8.42e-05	0.0406	-0.5	-0.34	Response to antipsychotic treatment;	chr16:66124311	chr16:65141756~65176713:-
TGCT	cis	rs3743162	0.644	rs4842996	ENSG00000225151.9	GOLGA2P7	4.07	8.43e-05	0.0407	0.43	0.34	Alzheimer's disease (age of onset);	chr15:84876267	chr15:84199311~84230136:-
TGCT	cis	rs722611	0.614	rs7781003	ENSG00000230751.1	AC007036.4	-4.07	8.43e-05	0.0407	-0.35	-0.34	Methadone dose in opioid dependence;	chr7:29477034	chr7:30140870~30141417:+
TGCT	cis	rs35612822	0.65	rs6743973	ENSG00000235042.1	AC098820.2	-4.07	8.46e-05	0.0408	-0.35	-0.34	Kidney disease (early stage) in type 1 diabetes;	chr2:216405370	chr2:216385288~216412696:-
TGCT	cis	rs7829975	0.774	rs11249893	ENSG00000254340.1	RP11-10A14.3	4.07	8.46e-05	0.0408	0.34	0.34	Mood instability;	chr8:8843341	chr8:9141424~9145435:+
TGCT	cis	rs5758659	1	rs5751255	ENSG00000270083.1	RP1-257I20.14	4.07	8.46e-05	0.0408	0.34	0.34	Cognitive function;	chr22:42252402	chr22:42089630~42090028:-
TGCT	cis	rs2505998	0.833	rs2742243	ENSG00000273008.1	RP11-351D16.3	-4.07	8.47e-05	0.0408	-0.39	-0.34	Hirschsprung disease;	chr10:43106301	chr10:43136824~43138334:-
TGCT	cis	rs2505998	0.833	rs2565204	ENSG00000273008.1	RP11-351D16.3	-4.07	8.47e-05	0.0408	-0.39	-0.34	Hirschsprung disease;	chr10:43107725	chr10:43136824~43138334:-
TGCT	cis	rs2505998	0.833	rs2742244	ENSG00000273008.1	RP11-351D16.3	-4.07	8.47e-05	0.0408	-0.39	-0.34	Hirschsprung disease;	chr10:43108144	chr10:43136824~43138334:-
TGCT	cis	rs6956675	0.534	rs1879840	ENSG00000227148.1	RP11-196D18.1	-4.06	8.47e-05	0.0408	-0.42	-0.34	Obesity-related traits;	chr7:63192929	chr7:63044827~63054431:-
TGCT	cis	rs1555322	0.53	rs2425053	ENSG00000126005.14	MMP24-AS1	-4.06	8.47e-05	0.0408	-0.42	-0.34	Attention deficit hyperactivity disorder;	chr20:35294017	chr20:35216462~35278131:-
TGCT	cis	rs1707322	0.752	rs11488313	ENSG00000280836.1	AL355480.1	-4.06	8.48e-05	0.0408	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45581219~45581321:-
TGCT	cis	rs10129255	0.5	rs7161740	ENSG00000280411.1	IGHV1-69-2	-4.06	8.48e-05	0.0409	-0.34	-0.34	Kawasaki disease;	chr14:106776119	chr14:106762092~106762588:-
TGCT	cis	rs10129255	0.556	rs6576222	ENSG00000280411.1	IGHV1-69-2	-4.06	8.48e-05	0.0409	-0.34	-0.34	Kawasaki disease;	chr14:106776442	chr14:106762092~106762588:-
TGCT	cis	rs10129255	0.536	rs6576223	ENSG00000280411.1	IGHV1-69-2	-4.06	8.48e-05	0.0409	-0.34	-0.34	Kawasaki disease;	chr14:106776448	chr14:106762092~106762588:-
TGCT	cis	rs11671005	0.651	rs35117909	ENSG00000252334.1	RNU6-1337P	4.06	8.48e-05	0.0409	0.5	0.34	Mean platelet volume;	chr19:58401539	chr19:58483749~58483843:-
TGCT	cis	rs11671005	0.693	rs34023391	ENSG00000252334.1	RNU6-1337P	4.06	8.48e-05	0.0409	0.5	0.34	Mean platelet volume;	chr19:58402001	chr19:58483749~58483843:-
TGCT	cis	rs11671005	0.693	rs11666928	ENSG00000252334.1	RNU6-1337P	4.06	8.48e-05	0.0409	0.5	0.34	Mean platelet volume;	chr19:58402864	chr19:58483749~58483843:-
TGCT	cis	rs7824557	0.564	rs13268126	ENSG00000269918.1	AF131215.9	-4.06	8.48e-05	0.0409	-0.34	-0.34	Retinal vascular caliber;	chr8:11373065	chr8:11104691~11106704:-
TGCT	cis	rs1150668	0.796	rs2531825	ENSG00000204709.4	LINC01556	4.06	8.49e-05	0.0409	0.38	0.34	Pubertal anthropometrics;	chr6:28381487	chr6:28943877~28944537:+
TGCT	cis	rs12497850	1	rs4858831	ENSG00000226913.1	BSN-AS2	-4.06	8.49e-05	0.0409	-0.27	-0.34	Parkinson's disease;	chr3:48698125	chr3:49549306~49554366:-
TGCT	cis	rs2316527	1	rs7780428	ENSG00000228806.1	AC092628.3	4.06	8.49e-05	0.0409	0.37	0.34	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr7:154834150	chr7:155106400~155106651:+
TGCT	cis	rs7824557	0.872	rs1347410	ENSG00000255052.4	FAM66D	4.06	8.49e-05	0.0409	0.35	0.34	Retinal vascular caliber;	chr8:11253733	chr8:12115782~12177550:+
TGCT	cis	rs10129255	0.83	rs61997609	ENSG00000211970.3	IGHV4-61	-4.06	8.5e-05	0.0409	-0.37	-0.34	Kawasaki disease;	chr14:106692376	chr14:106639119~106639657:-
TGCT	cis	rs4713118	0.662	rs149961	ENSG00000216901.1	AL022393.7	4.06	8.5e-05	0.0409	0.45	0.34	Parkinson's disease;	chr6:28047791	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.629	rs149899	ENSG00000216901.1	AL022393.7	4.06	8.5e-05	0.0409	0.45	0.34	Parkinson's disease;	chr6:28052201	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.629	rs172165	ENSG00000216901.1	AL022393.7	4.06	8.5e-05	0.0409	0.45	0.34	Parkinson's disease;	chr6:28053036	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.597	rs172166	ENSG00000216901.1	AL022393.7	4.06	8.5e-05	0.0409	0.45	0.34	Parkinson's disease;	chr6:28053042	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.629	rs203889	ENSG00000216901.1	AL022393.7	4.06	8.5e-05	0.0409	0.45	0.34	Parkinson's disease;	chr6:28053997	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.629	rs203890	ENSG00000216901.1	AL022393.7	4.06	8.5e-05	0.0409	0.45	0.34	Parkinson's disease;	chr6:28054470	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.662	rs9357060	ENSG00000216901.1	AL022393.7	4.06	8.5e-05	0.0409	0.45	0.34	Parkinson's disease;	chr6:28056708	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.662	rs9468271	ENSG00000216901.1	AL022393.7	4.06	8.5e-05	0.0409	0.45	0.34	Parkinson's disease;	chr6:28056792	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.662	rs9380045	ENSG00000216901.1	AL022393.7	4.06	8.5e-05	0.0409	0.45	0.34	Parkinson's disease;	chr6:28057501	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.616	rs9348789	ENSG00000216901.1	AL022393.7	4.06	8.5e-05	0.0409	0.45	0.34	Parkinson's disease;	chr6:28057708	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.662	rs9468274	ENSG00000216901.1	AL022393.7	4.06	8.5e-05	0.0409	0.45	0.34	Parkinson's disease;	chr6:28058299	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.662	rs9468275	ENSG00000216901.1	AL022393.7	4.06	8.5e-05	0.0409	0.45	0.34	Parkinson's disease;	chr6:28058358	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.662	rs9468276	ENSG00000216901.1	AL022393.7	4.06	8.5e-05	0.0409	0.45	0.34	Parkinson's disease;	chr6:28059910	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.662	rs9468277	ENSG00000216901.1	AL022393.7	4.06	8.5e-05	0.0409	0.45	0.34	Parkinson's disease;	chr6:28060612	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.662	rs9468278	ENSG00000216901.1	AL022393.7	4.06	8.5e-05	0.0409	0.45	0.34	Parkinson's disease;	chr6:28060704	chr6:28176188~28176674:+
TGCT	cis	rs4713118	0.662	rs13218430	ENSG00000216901.1	AL022393.7	4.06	8.5e-05	0.0409	0.45	0.34	Parkinson's disease;	chr6:28062059	chr6:28176188~28176674:+
TGCT	cis	rs17507216	0.718	rs7161977	ENSG00000255769.6	GOLGA2P10	-4.06	8.5e-05	0.0409	-0.45	-0.34	Excessive daytime sleepiness;	chr15:82646782	chr15:82472993~82513950:-
TGCT	cis	rs12143943	0.866	rs12030639	ENSG00000176754.11	LINC00303	4.06	8.5e-05	0.0409	0.31	0.34	Cognitive performance;	chr1:204561796	chr1:204032447~204041265:-
TGCT	cis	rs2153535	0.58	rs6905237	ENSG00000230939.1	RP11-314C16.1	-4.06	8.5e-05	0.0409	-0.33	-0.34	Motion sickness;	chr6:8471557	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs6905242	ENSG00000230939.1	RP11-314C16.1	-4.06	8.5e-05	0.0409	-0.33	-0.34	Motion sickness;	chr6:8471566	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.542	rs4440510	ENSG00000230939.1	RP11-314C16.1	-4.06	8.5e-05	0.0409	-0.33	-0.34	Motion sickness;	chr6:8471585	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.541	rs1414347	ENSG00000230939.1	RP11-314C16.1	-4.06	8.5e-05	0.0409	-0.33	-0.34	Motion sickness;	chr6:8471598	chr6:8784178~8785445:+
TGCT	cis	rs2439831	0.717	rs2447198	ENSG00000205771.5	CATSPER2P1	-4.06	8.5e-05	0.0409	-0.61	-0.34	Lung cancer in ever smokers;	chr15:43602920	chr15:43726918~43747094:-
TGCT	cis	rs10129255	0.719	rs7156660	ENSG00000211970.3	IGHV4-61	-4.06	8.51e-05	0.041	-0.36	-0.34	Kawasaki disease;	chr14:106673171	chr14:106639119~106639657:-
TGCT	cis	rs1372520	0.873	rs983361	ENSG00000247775.2	SNCA-AS1	4.06	8.51e-05	0.041	0.33	0.34	Neuroticism;	chr4:89840793	chr4:89836408~89841978:+
TGCT	cis	rs11168618	0.875	rs7972785	ENSG00000240399.1	RP1-228P16.1	4.06	8.52e-05	0.041	0.32	0.34	Adiponectin levels;	chr12:48483273	chr12:48054813~48055591:-
TGCT	cis	rs2243480	1	rs11538349	ENSG00000164669.11	INTS4P1	4.06	8.52e-05	0.041	0.54	0.34	Diabetic kidney disease;	chr7:65956884	chr7:65141225~65234216:+
TGCT	cis	rs758324	0.812	rs4705839	ENSG00000233006.5	AC034220.3	4.06	8.52e-05	0.041	0.26	0.34	Alzheimer's disease in APOE e4- carriers;	chr5:131839565	chr5:132311285~132369916:-
TGCT	cis	rs758324	0.812	rs2088718	ENSG00000233006.5	AC034220.3	4.06	8.52e-05	0.041	0.26	0.34	Alzheimer's disease in APOE e4- carriers;	chr5:131843496	chr5:132311285~132369916:-
TGCT	cis	rs2243480	0.522	rs73150635	ENSG00000226824.5	RP4-756H11.3	-4.06	8.52e-05	0.041	-0.65	-0.34	Diabetic kidney disease;	chr7:66507503	chr7:66654538~66669855:+
TGCT	cis	rs6782228	0.606	rs2811500	ENSG00000242551.2	POU5F1P6	-4.06	8.52e-05	0.041	-0.42	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128647413	chr3:128674735~128677005:-
TGCT	cis	rs7133214	0.51	rs4931479	ENSG00000278733.1	RP11-425D17.1	-4.06	8.52e-05	0.041	-0.38	-0.34	Gut microbiota (functional units);	chr12:27795682	chr12:28185625~28186190:-
TGCT	cis	rs10826995	0.961	rs72778378	ENSG00000239731.3	RN7SL825P	-4.06	8.53e-05	0.041	-0.35	-0.34	Pulse pressure;	chr10:31926641	chr10:31992087~31992381:-
TGCT	cis	rs17301853	1	rs75402546	ENSG00000227373.4	RP11-160H22.5	4.06	8.54e-05	0.0411	0.55	0.34	Migraine without aura;Migraine - clinic-based;	chr1:174172092	chr1:174115300~174160004:-
TGCT	cis	rs847845	1	rs847845	ENSG00000186328.4	RP11-140K17.2	-4.06	8.54e-05	0.0411	-0.47	-0.34	Non-small cell lung cancer;	chr6:34956087	chr6:34715613~34715940:+
TGCT	cis	rs12497850	1	rs4858798	ENSG00000226913.1	BSN-AS2	-4.06	8.54e-05	0.0411	-0.27	-0.34	Parkinson's disease;	chr3:48689679	chr3:49549306~49554366:-
TGCT	cis	rs11673344	0.832	rs11084871	ENSG00000226686.6	LINC01535	4.06	8.54e-05	0.0411	0.4	0.34	Obesity-related traits;	chr19:37042023	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.832	rs77772684	ENSG00000226686.6	LINC01535	4.06	8.54e-05	0.0411	0.4	0.34	Obesity-related traits;	chr19:37055838	chr19:37251912~37265535:+
TGCT	cis	rs860295	0.54	rs928596	ENSG00000246203.2	RP11-29H23.5	4.06	8.54e-05	0.0411	0.31	0.34	Body mass index;	chr1:155978084	chr1:155614726~155660245:-
TGCT	cis	rs2739330	0.828	rs2877178	ENSG00000250470.1	AP000351.3	4.06	8.55e-05	0.0411	0.35	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23976904~23977585:-
TGCT	cis	rs2739330	0.828	rs2154593	ENSG00000250470.1	AP000351.3	4.06	8.55e-05	0.0411	0.35	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23976904~23977585:-
TGCT	cis	rs10129255	0.5	rs8022547	ENSG00000280411.1	IGHV1-69-2	-4.06	8.55e-05	0.0411	-0.34	-0.34	Kawasaki disease;	chr14:106781985	chr14:106762092~106762588:-
TGCT	cis	rs10129255	0.5	rs8006888	ENSG00000280411.1	IGHV1-69-2	-4.06	8.55e-05	0.0411	-0.34	-0.34	Kawasaki disease;	chr14:106782219	chr14:106762092~106762588:-
TGCT	cis	rs10129255	0.536	rs10142951	ENSG00000280411.1	IGHV1-69-2	-4.06	8.55e-05	0.0411	-0.34	-0.34	Kawasaki disease;	chr14:106782337	chr14:106762092~106762588:-
TGCT	cis	rs10129255	0.5	rs34326748	ENSG00000280411.1	IGHV1-69-2	-4.06	8.55e-05	0.0411	-0.34	-0.34	Kawasaki disease;	chr14:106782523	chr14:106762092~106762588:-
TGCT	cis	rs10129255	0.5	rs10143385	ENSG00000280411.1	IGHV1-69-2	-4.06	8.55e-05	0.0411	-0.34	-0.34	Kawasaki disease;	chr14:106782559	chr14:106762092~106762588:-
TGCT	cis	rs10129255	0.5	rs59939897	ENSG00000280411.1	IGHV1-69-2	-4.06	8.55e-05	0.0411	-0.34	-0.34	Kawasaki disease;	chr14:106783414	chr14:106762092~106762588:-
TGCT	cis	rs10129255	0.5	rs6576231	ENSG00000280411.1	IGHV1-69-2	-4.06	8.55e-05	0.0411	-0.34	-0.34	Kawasaki disease;	chr14:106783693	chr14:106762092~106762588:-
TGCT	cis	rs10129255	0.5	rs8014529	ENSG00000280411.1	IGHV1-69-2	-4.06	8.55e-05	0.0411	-0.34	-0.34	Kawasaki disease;	chr14:106784065	chr14:106762092~106762588:-
TGCT	cis	rs10129255	0.5	rs12101190	ENSG00000280411.1	IGHV1-69-2	-4.06	8.55e-05	0.0411	-0.34	-0.34	Kawasaki disease;	chr14:106784149	chr14:106762092~106762588:-
TGCT	cis	rs10129255	0.518	rs8004895	ENSG00000280411.1	IGHV1-69-2	-4.06	8.55e-05	0.0411	-0.34	-0.34	Kawasaki disease;	chr14:106785139	chr14:106762092~106762588:-
TGCT	cis	rs6604026	0.555	rs11591094	ENSG00000223787.2	RP4-593M8.1	4.06	8.55e-05	0.0411	0.5	0.34	Multiple sclerosis;	chr1:92649899	chr1:92580476~92580821:-
TGCT	cis	rs763567	0.605	rs619456	ENSG00000271811.1	RP1-79C4.4	-4.06	8.56e-05	0.0411	-0.26	-0.34	Tonsillectomy;	chr1:170616691	chr1:170667381~170669425:+
TGCT	cis	rs1707322	0.721	rs10430124	ENSG00000280836.1	AL355480.1	-4.06	8.56e-05	0.0412	-0.48	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr1:45581219~45581321:-
TGCT	cis	rs11722228	0.549	rs3796818	ENSG00000261490.1	RP11-448G15.3	4.06	8.56e-05	0.0412	0.34	0.34	Urate levels;Serum uric acid levels;Gout;	chr4:10096352	chr4:10068089~10073019:-
TGCT	cis	rs11722228	0.549	rs41268389	ENSG00000261490.1	RP11-448G15.3	4.06	8.56e-05	0.0412	0.34	0.34	Urate levels;Serum uric acid levels;Gout;	chr4:10097653	chr4:10068089~10073019:-
TGCT	cis	rs11722228	0.521	rs62288520	ENSG00000261490.1	RP11-448G15.3	4.06	8.56e-05	0.0412	0.34	0.34	Urate levels;Serum uric acid levels;Gout;	chr4:10098050	chr4:10068089~10073019:-
TGCT	cis	rs11722228	0.549	rs62288521	ENSG00000261490.1	RP11-448G15.3	4.06	8.56e-05	0.0412	0.34	0.34	Urate levels;Serum uric acid levels;Gout;	chr4:10098148	chr4:10068089~10073019:-
TGCT	cis	rs5742933	0.597	rs6756913	ENSG00000273240.1	RP11-455J20.3	4.06	8.56e-05	0.0412	0.35	0.34	Ferritin levels;	chr2:189641040	chr2:189763859~189764456:-
TGCT	cis	rs12549025	0.536	rs9644075	ENSG00000253390.1	CTC-756D1.2	-4.06	8.56e-05	0.0412	-0.37	-0.34	Reticulocyte fraction of red cells;	chr8:23502448	chr8:23458601~23484971:+
TGCT	cis	rs993925	0.517	rs6684868	ENSG00000223842.1	RP11-135J2.3	4.06	8.57e-05	0.0412	0.36	0.34	Pulmonary function;	chr1:218674648	chr1:219222248~219225497:-
TGCT	cis	rs4908769	0.55	rs2029706	ENSG00000270282.1	RP5-1115A15.2	4.06	8.57e-05	0.0412	0.44	0.34	Allergy;	chr1:8807242	chr1:8512653~8513021:+
TGCT	cis	rs10938353	0.638	rs11732880	ENSG00000273369.1	RP11-700J17.1	-4.06	8.57e-05	0.0412	-0.5	-0.34	Body mass index;	chr4:44673497	chr4:44693946~44694386:-
TGCT	cis	rs9322193	0.566	rs12528243	ENSG00000216906.2	RP11-350J20.9	4.06	8.57e-05	0.0412	0.44	0.34	Lung cancer;	chr6:149898491	chr6:149904243~149906418:+
TGCT	cis	rs4713118	0.621	rs9368548	ENSG00000187763.3	OR2B7P	4.06	8.57e-05	0.0412	0.34	0.34	Parkinson's disease;	chr6:28066959	chr6:28046434~28047367:+
TGCT	cis	rs9733	0.744	rs2039590	ENSG00000236713.1	RP11-363I22.3	4.06	8.57e-05	0.0412	0.26	0.34	Tonsillectomy;	chr1:150840839	chr1:150780272~150780644:+
TGCT	cis	rs9733	0.791	rs11204693	ENSG00000236713.1	RP11-363I22.3	4.06	8.58e-05	0.0412	0.25	0.34	Tonsillectomy;	chr1:150675511	chr1:150780272~150780644:+
TGCT	cis	rs67311347	0.866	rs1454491	ENSG00000223797.4	ENTPD3-AS1	4.06	8.58e-05	0.0412	0.35	0.34	Renal cell carcinoma;	chr3:40311156	chr3:40313802~40453329:-
TGCT	cis	rs1062753	0.527	rs6002560	ENSG00000182057.4	OGFRP1	4.06	8.58e-05	0.0412	0.25	0.34	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41960882	chr22:42269753~42275196:+
TGCT	cis	rs875971	0.862	rs6460302	ENSG00000232559.3	GS1-124K5.12	4.06	8.59e-05	0.0413	0.33	0.34	Aortic root size;	chr7:66495270	chr7:66554588~66576923:-
TGCT	cis	rs7873102	0.967	rs7025303	ENSG00000232454.2	RP11-3J10.7	-4.06	8.59e-05	0.0413	-0.36	-0.34	Brain structure;	chr9:38040098	chr9:37836044~37836394:+
TGCT	cis	rs7829975	0.593	rs2979241	ENSG00000254340.1	RP11-10A14.3	4.06	8.59e-05	0.0413	0.33	0.34	Mood instability;	chr8:8445843	chr8:9141424~9145435:+
TGCT	cis	rs4242434	0.927	rs3735901	ENSG00000254064.1	CTD-2530N21.4	-4.06	8.59e-05	0.0413	-0.21	-0.34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22604861	chr8:22254576~22275162:-
TGCT	cis	rs7181230	0.813	rs4924417	ENSG00000275636.1	RP11-521C20.5	4.06	8.6e-05	0.0413	0.43	0.34	Dehydroepiandrosterone sulphate levels;	chr15:40074738	chr15:40078892~40079347:+
TGCT	cis	rs1707322	1	rs7532204	ENSG00000280836.1	AL355480.1	4.06	8.61e-05	0.0413	0.44	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019403	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.835	rs946525	ENSG00000280836.1	AL355480.1	4.06	8.61e-05	0.0413	0.44	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021605	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs946524	ENSG00000280836.1	AL355480.1	4.06	8.61e-05	0.0413	0.44	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021888	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs4660336	ENSG00000280836.1	AL355480.1	4.06	8.61e-05	0.0413	0.44	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46022304	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs785478	ENSG00000280836.1	AL355480.1	4.06	8.61e-05	0.0413	0.44	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46025963	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs11211219	ENSG00000280836.1	AL355480.1	-4.06	8.61e-05	0.0413	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs11211222	ENSG00000280836.1	AL355480.1	-4.06	8.61e-05	0.0413	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.928	rs7527244	ENSG00000280836.1	AL355480.1	-4.06	8.61e-05	0.0413	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45903100	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs4524994	ENSG00000280836.1	AL355480.1	-4.06	8.61e-05	0.0413	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45904591	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.963	rs9787412	ENSG00000280836.1	AL355480.1	-4.06	8.61e-05	0.0413	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs4660896	ENSG00000280836.1	AL355480.1	-4.06	8.61e-05	0.0413	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.928	rs10732844	ENSG00000280836.1	AL355480.1	-4.06	8.61e-05	0.0413	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs12133129	ENSG00000280836.1	AL355480.1	-4.06	8.61e-05	0.0413	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.963	rs4553121	ENSG00000280836.1	AL355480.1	-4.06	8.61e-05	0.0413	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.963	rs6690652	ENSG00000280836.1	AL355480.1	-4.06	8.61e-05	0.0413	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs6695421	ENSG00000280836.1	AL355480.1	-4.06	8.61e-05	0.0413	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs11211223	ENSG00000280836.1	AL355480.1	-4.06	8.61e-05	0.0413	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914933	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs6687301	ENSG00000280836.1	AL355480.1	-4.06	8.61e-05	0.0413	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs6657720	ENSG00000280836.1	AL355480.1	-4.06	8.61e-05	0.0413	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs7519181	ENSG00000280836.1	AL355480.1	-4.06	8.61e-05	0.0413	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs7526369	ENSG00000280836.1	AL355480.1	-4.06	8.61e-05	0.0413	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.963	rs10890371	ENSG00000280836.1	AL355480.1	-4.06	8.61e-05	0.0413	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs10890372	ENSG00000280836.1	AL355480.1	-4.06	8.61e-05	0.0413	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.928	rs6681068	ENSG00000280836.1	AL355480.1	-4.06	8.61e-05	0.0413	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs11211228	ENSG00000280836.1	AL355480.1	-4.06	8.61e-05	0.0413	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.963	rs11211229	ENSG00000280836.1	AL355480.1	-4.06	8.61e-05	0.0413	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs9803784	ENSG00000280836.1	AL355480.1	-4.06	8.61e-05	0.0413	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.963	rs12022335	ENSG00000280836.1	AL355480.1	-4.06	8.61e-05	0.0413	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs10890375	ENSG00000280836.1	AL355480.1	-4.06	8.61e-05	0.0413	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs10890377	ENSG00000280836.1	AL355480.1	-4.06	8.61e-05	0.0413	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr1:45581219~45581321:-
TGCT	cis	rs1707322	0.963	rs10789484	ENSG00000280836.1	AL355480.1	-4.06	8.61e-05	0.0413	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr1:45581219~45581321:-
TGCT	cis	rs1707322	1	rs11211248	ENSG00000280836.1	AL355480.1	-4.06	8.61e-05	0.0413	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46011172	chr1:45581219~45581321:-
TGCT	cis	rs853679	0.517	rs16893666	ENSG00000187763.3	OR2B7P	-4.06	8.62e-05	0.0414	-0.33	-0.34	Depression;	chr6:28086929	chr6:28046434~28047367:+
TGCT	cis	rs7403037	0.583	rs35463340	ENSG00000259905.4	PWRN1	4.06	8.64e-05	0.0414	0.45	0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24581313	chr15:24493137~24652130:+
TGCT	cis	rs7702057	0.53	rs1567332	ENSG00000197575.6	RPS17P2	-4.06	8.64e-05	0.0414	-0.56	-0.34	Amyotrophic lateral sclerosis;	chr5:116078690	chr5:116716243~116716650:+
TGCT	cis	rs4973397	0.81	rs12999051	ENSG00000183022.5	TPM3P8	4.06	8.65e-05	0.0415	0.47	0.34	Anti-saccade response;	chr2:231412281	chr2:230573167~230573809:-
TGCT	cis	rs6981523	0.553	rs2409730	ENSG00000269918.1	AF131215.9	-4.06	8.65e-05	0.0415	-0.36	-0.34	Neuroticism;	chr8:11203129	chr8:11104691~11106704:-
TGCT	cis	rs7714584	1	rs17111376	ENSG00000197083.10	ZNF300P1	4.06	8.66e-05	0.0415	0.54	0.34	Crohn's disease;	chr5:150847337	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs10065172	ENSG00000197083.10	ZNF300P1	4.06	8.66e-05	0.0415	0.54	0.34	Crohn's disease;	chr5:150848436	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs7705542	ENSG00000197083.10	ZNF300P1	4.06	8.66e-05	0.0415	0.54	0.34	Crohn's disease;	chr5:150848756	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs11749391	ENSG00000197083.10	ZNF300P1	4.06	8.66e-05	0.0415	0.54	0.34	Crohn's disease;	chr5:150849504	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs10078968	ENSG00000197083.10	ZNF300P1	4.06	8.66e-05	0.0415	0.54	0.34	Crohn's disease;	chr5:150864711	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs1896709	ENSG00000197083.10	ZNF300P1	4.06	8.66e-05	0.0415	0.54	0.34	Crohn's disease;	chr5:150865470	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs6862814	ENSG00000197083.10	ZNF300P1	4.06	8.66e-05	0.0415	0.54	0.34	Crohn's disease;	chr5:150865697	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs7709388	ENSG00000197083.10	ZNF300P1	4.06	8.66e-05	0.0415	0.54	0.34	Crohn's disease;	chr5:150866977	chr5:150930645~150946289:-
TGCT	cis	rs7714584	0.793	rs7709721	ENSG00000197083.10	ZNF300P1	4.06	8.66e-05	0.0415	0.54	0.34	Crohn's disease;	chr5:150867296	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs11950957	ENSG00000197083.10	ZNF300P1	4.06	8.66e-05	0.0415	0.54	0.34	Crohn's disease;	chr5:150874352	chr5:150930645~150946289:-
TGCT	cis	rs7714584	0.793	rs11958146	ENSG00000197083.10	ZNF300P1	4.06	8.66e-05	0.0415	0.54	0.34	Crohn's disease;	chr5:150874596	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs11951694	ENSG00000197083.10	ZNF300P1	4.06	8.66e-05	0.0415	0.54	0.34	Crohn's disease;	chr5:150874776	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs11955172	ENSG00000197083.10	ZNF300P1	4.06	8.66e-05	0.0415	0.54	0.34	Crohn's disease;	chr5:150874816	chr5:150930645~150946289:-
TGCT	cis	rs7714584	0.793	rs11955174	ENSG00000197083.10	ZNF300P1	4.06	8.66e-05	0.0415	0.54	0.34	Crohn's disease;	chr5:150874829	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs10061105	ENSG00000197083.10	ZNF300P1	4.06	8.66e-05	0.0415	0.54	0.34	Crohn's disease;	chr5:150875623	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs6579803	ENSG00000197083.10	ZNF300P1	4.06	8.66e-05	0.0415	0.54	0.34	Crohn's disease;	chr5:150875997	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs6579804	ENSG00000197083.10	ZNF300P1	4.06	8.66e-05	0.0415	0.54	0.34	Crohn's disease;	chr5:150876369	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs7734778	ENSG00000197083.10	ZNF300P1	4.06	8.66e-05	0.0415	0.54	0.34	Crohn's disease;	chr5:150876994	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs7734928	ENSG00000197083.10	ZNF300P1	4.06	8.66e-05	0.0415	0.54	0.34	Crohn's disease;	chr5:150877051	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs10463240	ENSG00000197083.10	ZNF300P1	4.06	8.66e-05	0.0415	0.54	0.34	Crohn's disease;	chr5:150877291	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs9324660	ENSG00000197083.10	ZNF300P1	4.06	8.66e-05	0.0415	0.54	0.34	Crohn's disease;	chr5:150877492	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs1428554	ENSG00000197083.10	ZNF300P1	4.06	8.66e-05	0.0415	0.54	0.34	Crohn's disease;	chr5:150878054	chr5:150930645~150946289:-
TGCT	cis	rs115344852	0.598	rs2531815	ENSG00000216901.1	AL022393.7	4.06	8.67e-05	0.0415	0.41	0.34	Epithelial ovarian cancer;	chr6:28468283	chr6:28176188~28176674:+
TGCT	cis	rs792448	0.743	rs3767861	ENSG00000201544.1	SNORA16B	4.06	8.67e-05	0.0415	0.34	0.34	White blood cell count (basophil);	chr1:212364211	chr1:212352816~212352950:+
TGCT	cis	rs792448	0.743	rs3767862	ENSG00000201544.1	SNORA16B	4.06	8.67e-05	0.0415	0.34	0.34	White blood cell count (basophil);	chr1:212364360	chr1:212352816~212352950:+
TGCT	cis	rs792448	0.701	rs3099112	ENSG00000201544.1	SNORA16B	4.06	8.67e-05	0.0415	0.34	0.34	White blood cell count (basophil);	chr1:212369068	chr1:212352816~212352950:+
TGCT	cis	rs847845	0.841	rs7740148	ENSG00000186328.4	RP11-140K17.2	-4.06	8.67e-05	0.0415	-0.53	-0.34	Non-small cell lung cancer;	chr6:34987926	chr6:34715613~34715940:+
TGCT	cis	rs2153535	0.563	rs1737586	ENSG00000230939.1	RP11-314C16.1	-4.06	8.67e-05	0.0415	-0.34	-0.34	Motion sickness;	chr6:8535664	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.547	rs9505475	ENSG00000230939.1	RP11-314C16.1	-4.06	8.67e-05	0.0415	-0.34	-0.34	Motion sickness;	chr6:8542657	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.601	rs6906170	ENSG00000230939.1	RP11-314C16.1	-4.06	8.67e-05	0.0415	-0.34	-0.34	Motion sickness;	chr6:8542895	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.601	rs330105	ENSG00000230939.1	RP11-314C16.1	-4.06	8.67e-05	0.0415	-0.34	-0.34	Motion sickness;	chr6:8543748	chr6:8784178~8785445:+
TGCT	cis	rs10740039	0.583	rs2127353	ENSG00000254271.1	RP11-131N11.4	-4.06	8.67e-05	0.0415	-0.36	-0.34	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60750206	chr10:60734342~60741828:+
TGCT	cis	rs524281	0.731	rs10791838	ENSG00000255320.1	RP11-755F10.1	4.06	8.68e-05	0.0416	0.54	0.34	Electroencephalogram traits;	chr11:66022383	chr11:66244840~66246239:-
TGCT	cis	rs7182621	0.639	rs1561048	ENSG00000259363.4	CTD-2054N24.2	-4.06	8.68e-05	0.0416	-0.34	-0.34	Colonoscopy-negative controls vs population controls;	chr15:99875369	chr15:99807023~99877148:+
TGCT	cis	rs7246657	0.882	rs10412043	ENSG00000266916.4	ZNF793-AS1	-4.06	8.69e-05	0.0416	-0.32	-0.34	Coronary artery calcification;	chr19:37335724	chr19:37497159~37507046:-
TGCT	cis	rs6782228	0.606	rs7627549	ENSG00000242551.2	POU5F1P6	-4.06	8.69e-05	0.0416	-0.42	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128634236	chr3:128674735~128677005:-
TGCT	cis	rs6782228	0.585	rs2811492	ENSG00000242551.2	POU5F1P6	-4.06	8.69e-05	0.0416	-0.42	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128637436	chr3:128674735~128677005:-
TGCT	cis	rs6782228	0.606	rs1697	ENSG00000242551.2	POU5F1P6	-4.06	8.69e-05	0.0416	-0.42	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128638009	chr3:128674735~128677005:-
TGCT	cis	rs6782228	0.606	rs6439135	ENSG00000242551.2	POU5F1P6	-4.06	8.69e-05	0.0416	-0.42	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128639790	chr3:128674735~128677005:-
TGCT	cis	rs6782228	0.585	rs3122175	ENSG00000242551.2	POU5F1P6	-4.06	8.69e-05	0.0416	-0.42	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642433	chr3:128674735~128677005:-
TGCT	cis	rs6782228	0.606	rs7650156	ENSG00000242551.2	POU5F1P6	-4.06	8.69e-05	0.0416	-0.42	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642712	chr3:128674735~128677005:-
TGCT	cis	rs6782228	0.606	rs2811497	ENSG00000242551.2	POU5F1P6	-4.06	8.69e-05	0.0416	-0.42	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128644489	chr3:128674735~128677005:-
TGCT	cis	rs7819412	0.511	rs2409797	ENSG00000255556.2	RP11-351I21.6	-4.06	8.7e-05	0.0416	-0.36	-0.34	Triglycerides;	chr8:11576271	chr8:12378679~12380265:-
TGCT	cis	rs6547631	0.592	rs13408224	ENSG00000229648.1	AC016753.7	4.06	8.7e-05	0.0416	0.4	0.34	Blood protein levels;	chr2:85696813	chr2:85490930~85491780:-
TGCT	cis	rs9660180	0.935	rs9786942	ENSG00000231050.1	RP1-140A9.1	4.06	8.7e-05	0.0416	0.31	0.34	Body mass index;	chr1:1827774	chr1:1891471~1892658:+
TGCT	cis	rs9660180	0.934	rs34849348	ENSG00000231050.1	RP1-140A9.1	4.06	8.7e-05	0.0416	0.31	0.34	Body mass index;	chr1:1831318	chr1:1891471~1892658:+
TGCT	cis	rs4273100	0.688	rs28582509	ENSG00000262319.1	CTC-457L16.2	-4.06	8.7e-05	0.0416	-0.45	-0.34	Schizophrenia;	chr17:19261866	chr17:19141017~19143689:-
TGCT	cis	rs7688540	0.771	rs61794997	ENSG00000275426.1	CH17-262A2.1	4.06	8.71e-05	0.0416	0.69	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:228314	chr4:149738~150317:+
TGCT	cis	rs7688540	0.771	rs11724417	ENSG00000275426.1	CH17-262A2.1	4.06	8.71e-05	0.0416	0.69	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:229563	chr4:149738~150317:+
TGCT	cis	rs7688540	0.771	rs11724176	ENSG00000275426.1	CH17-262A2.1	4.06	8.71e-05	0.0416	0.69	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231112	chr4:149738~150317:+
TGCT	cis	rs7688540	0.723	rs1986386	ENSG00000275426.1	CH17-262A2.1	4.06	8.71e-05	0.0416	0.69	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235020	chr4:149738~150317:+
TGCT	cis	rs7688540	0.723	rs61794999	ENSG00000275426.1	CH17-262A2.1	4.06	8.71e-05	0.0416	0.69	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238578	chr4:149738~150317:+
TGCT	cis	rs7688540	0.609	rs77700883	ENSG00000275426.1	CH17-262A2.1	4.06	8.71e-05	0.0416	0.69	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238743	chr4:149738~150317:+
TGCT	cis	rs7688540	0.609	rs78896226	ENSG00000275426.1	CH17-262A2.1	4.06	8.71e-05	0.0416	0.69	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238744	chr4:149738~150317:+
TGCT	cis	rs7688540	0.623	rs11735968	ENSG00000275426.1	CH17-262A2.1	4.06	8.71e-05	0.0416	0.69	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245031	chr4:149738~150317:+
TGCT	cis	rs7688540	0.771	rs7686546	ENSG00000275426.1	CH17-262A2.1	4.06	8.71e-05	0.0416	0.69	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246825	chr4:149738~150317:+
TGCT	cis	rs7688540	0.771	rs61795001	ENSG00000275426.1	CH17-262A2.1	4.06	8.71e-05	0.0416	0.69	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248268	chr4:149738~150317:+
TGCT	cis	rs7688540	0.771	rs61795002	ENSG00000275426.1	CH17-262A2.1	4.06	8.71e-05	0.0416	0.69	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249008	chr4:149738~150317:+
TGCT	cis	rs7688540	0.771	rs6599318	ENSG00000275426.1	CH17-262A2.1	4.06	8.71e-05	0.0416	0.69	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:250179	chr4:149738~150317:+
TGCT	cis	rs7688540	0.771	rs4582105	ENSG00000275426.1	CH17-262A2.1	4.06	8.71e-05	0.0416	0.69	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:252553	chr4:149738~150317:+
TGCT	cis	rs7688540	0.771	rs74984113	ENSG00000275426.1	CH17-262A2.1	4.06	8.71e-05	0.0416	0.69	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:256733	chr4:149738~150317:+
TGCT	cis	rs7688540	0.771	rs17164747	ENSG00000275426.1	CH17-262A2.1	4.06	8.71e-05	0.0416	0.69	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266798	chr4:149738~150317:+
TGCT	cis	rs7688540	0.771	rs79366248	ENSG00000275426.1	CH17-262A2.1	4.06	8.71e-05	0.0416	0.69	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:272870	chr4:149738~150317:+
TGCT	cis	rs7688540	0.771	rs78343340	ENSG00000275426.1	CH17-262A2.1	4.06	8.71e-05	0.0416	0.69	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:273648	chr4:149738~150317:+
TGCT	cis	rs7688540	0.771	rs11729365	ENSG00000275426.1	CH17-262A2.1	4.06	8.71e-05	0.0416	0.69	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278735	chr4:149738~150317:+
TGCT	cis	rs7688540	0.771	rs11722521	ENSG00000275426.1	CH17-262A2.1	4.06	8.71e-05	0.0416	0.69	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:282976	chr4:149738~150317:+
TGCT	cis	rs7688540	0.771	rs7665727	ENSG00000275426.1	CH17-262A2.1	4.06	8.71e-05	0.0416	0.69	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283268	chr4:149738~150317:+
TGCT	cis	rs7688540	0.771	rs11722197	ENSG00000275426.1	CH17-262A2.1	4.06	8.71e-05	0.0416	0.69	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287918	chr4:149738~150317:+
TGCT	cis	rs7688540	0.771	rs11723261	ENSG00000275426.1	CH17-262A2.1	4.06	8.71e-05	0.0416	0.69	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288710	chr4:149738~150317:+
TGCT	cis	rs7688540	0.771	rs4129956	ENSG00000275426.1	CH17-262A2.1	4.06	8.71e-05	0.0416	0.69	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:308219	chr4:149738~150317:+
TGCT	cis	rs7688540	0.723	rs17521834	ENSG00000275426.1	CH17-262A2.1	-4.06	8.71e-05	0.0416	-0.69	-0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231660	chr4:149738~150317:+
TGCT	cis	rs9532669	0.926	rs4941995	ENSG00000176268.5	CYCSP34	4.06	8.71e-05	0.0416	0.36	0.34	Cervical cancer;	chr13:40850117	chr13:40863599~40863902:-
TGCT	cis	rs9532669	0.926	rs9315789	ENSG00000176268.5	CYCSP34	4.06	8.71e-05	0.0416	0.36	0.34	Cervical cancer;	chr13:40852898	chr13:40863599~40863902:-
TGCT	cis	rs9532669	0.857	rs7327018	ENSG00000176268.5	CYCSP34	4.06	8.71e-05	0.0416	0.36	0.34	Cervical cancer;	chr13:40856376	chr13:40863599~40863902:-
TGCT	cis	rs9532669	0.926	rs7327315	ENSG00000176268.5	CYCSP34	4.06	8.71e-05	0.0416	0.36	0.34	Cervical cancer;	chr13:40856383	chr13:40863599~40863902:-
TGCT	cis	rs9532669	0.926	rs7327059	ENSG00000176268.5	CYCSP34	4.06	8.71e-05	0.0416	0.36	0.34	Cervical cancer;	chr13:40856458	chr13:40863599~40863902:-
TGCT	cis	rs9532669	0.926	rs9594433	ENSG00000176268.5	CYCSP34	4.06	8.71e-05	0.0416	0.36	0.34	Cervical cancer;	chr13:40856935	chr13:40863599~40863902:-
TGCT	cis	rs9532669	0.926	rs9525403	ENSG00000176268.5	CYCSP34	4.06	8.71e-05	0.0416	0.36	0.34	Cervical cancer;	chr13:40858292	chr13:40863599~40863902:-
TGCT	cis	rs9532669	0.926	rs7318768	ENSG00000176268.5	CYCSP34	4.06	8.71e-05	0.0416	0.36	0.34	Cervical cancer;	chr13:40859140	chr13:40863599~40863902:-
TGCT	cis	rs9532669	0.824	rs4941998	ENSG00000176268.5	CYCSP34	4.06	8.71e-05	0.0416	0.36	0.34	Cervical cancer;	chr13:40859901	chr13:40863599~40863902:-
TGCT	cis	rs9532669	0.926	rs4942000	ENSG00000176268.5	CYCSP34	4.06	8.71e-05	0.0416	0.36	0.34	Cervical cancer;	chr13:40859979	chr13:40863599~40863902:-
TGCT	cis	rs2243480	1	rs2462569	ENSG00000164669.11	INTS4P1	-4.06	8.71e-05	0.0416	-0.56	-0.34	Diabetic kidney disease;	chr7:66009859	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs1039664	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:65984729	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs73150014	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:65985932	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs1964692	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:65989196	chr7:65141225~65234216:+
TGCT	cis	rs2243480	0.901	rs2456483	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:65996588	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs1701750	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66002158	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs1723270	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66004843	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs1701758	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66005214	chr7:65141225~65234216:+
TGCT	cis	rs2243480	0.901	rs1701759	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66005945	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs1723269	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66007799	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs1723267	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66008327	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs781157	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66013324	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs781156	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66014154	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs781150	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66015986	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs781149	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66016297	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs451396	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66019087	chr7:65141225~65234216:+
TGCT	cis	rs2243480	0.901	rs58207111	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66021736	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs1167613	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66022452	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs1715235	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66023407	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs313798	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66028044	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs313799	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66029343	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs35396113	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66030474	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs313807	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66034494	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs313809	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66034996	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs313814	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66038306	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs427044	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66043558	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs437889	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66044247	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs402418	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66044482	chr7:65141225~65234216:+
TGCT	cis	rs2243480	0.803	rs423187	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66044512	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs431318	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66046610	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs313803	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66049744	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs313802	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66051386	chr7:65141225~65234216:+
TGCT	cis	rs2243480	0.803	rs403089	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66052736	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs458291	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66055492	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs466983	ENSG00000164669.11	INTS4P1	4.06	8.71e-05	0.0416	0.56	0.34	Diabetic kidney disease;	chr7:66055509	chr7:65141225~65234216:+
TGCT	cis	rs1930961	0.702	rs8141065	ENSG00000271138.1	IGLVIVOR22-1	4.06	8.71e-05	0.0416	0.5	0.34	Bipolar disorder with mood-incongruent psychosis;	chr22:25489221	chr22:25437306~25437823:-
TGCT	cis	rs2011503	0.882	rs10401714	ENSG00000275540.1	CTC-559E9.12	4.06	8.72e-05	0.0416	0.54	0.34	Bipolar disorder;	chr19:19252821	chr19:19740884~19750127:+
TGCT	cis	rs2011503	0.882	rs4808933	ENSG00000275540.1	CTC-559E9.12	4.06	8.72e-05	0.0416	0.54	0.34	Bipolar disorder;	chr19:19253003	chr19:19740884~19750127:+
TGCT	cis	rs2011503	0.882	rs72999030	ENSG00000275540.1	CTC-559E9.12	4.06	8.72e-05	0.0416	0.54	0.34	Bipolar disorder;	chr19:19253431	chr19:19740884~19750127:+
TGCT	cis	rs2011503	0.882	rs10407933	ENSG00000275540.1	CTC-559E9.12	4.06	8.72e-05	0.0416	0.54	0.34	Bipolar disorder;	chr19:19253510	chr19:19740884~19750127:+
TGCT	cis	rs9309473	0.615	rs74523560	ENSG00000163016.8	ALMS1P	4.06	8.73e-05	0.0416	0.35	0.34	Metabolite levels;	chr2:73537058	chr2:73644919~73685576:+
TGCT	cis	rs3020264	0.962	rs1974946	ENSG00000271743.1	CTD-2541M15.3	-4.06	8.73e-05	0.0416	-0.34	-0.34	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6631266	chr8:6615604~6617198:-
TGCT	cis	rs9952991	0.941	rs2014857	ENSG00000260302.1	RP11-973H7.1	-4.06	8.73e-05	0.0416	-0.51	-0.34	Inflammatory skin disease;	chr18:12774327	chr18:12774651~12775923:-
TGCT	cis	rs9952991	0.883	rs2847260	ENSG00000260302.1	RP11-973H7.1	-4.06	8.73e-05	0.0416	-0.51	-0.34	Inflammatory skin disease;	chr18:12775592	chr18:12774651~12775923:-
TGCT	cis	rs9952991	0.883	rs2542147	ENSG00000260302.1	RP11-973H7.1	-4.06	8.73e-05	0.0416	-0.51	-0.34	Inflammatory skin disease;	chr18:12775852	chr18:12774651~12775923:-
TGCT	cis	rs9952991	0.883	rs2542148	ENSG00000260302.1	RP11-973H7.1	-4.06	8.73e-05	0.0416	-0.51	-0.34	Inflammatory skin disease;	chr18:12777574	chr18:12774651~12775923:-
TGCT	cis	rs9952991	0.941	rs9952749	ENSG00000260302.1	RP11-973H7.1	-4.06	8.73e-05	0.0416	-0.51	-0.34	Inflammatory skin disease;	chr18:12780457	chr18:12774651~12775923:-
TGCT	cis	rs9952991	0.943	rs9952753	ENSG00000260302.1	RP11-973H7.1	-4.06	8.73e-05	0.0416	-0.51	-0.34	Inflammatory skin disease;	chr18:12780464	chr18:12774651~12775923:-
TGCT	cis	rs9952991	0.883	rs2847293	ENSG00000260302.1	RP11-973H7.1	-4.06	8.73e-05	0.0416	-0.51	-0.34	Inflammatory skin disease;	chr18:12782449	chr18:12774651~12775923:-
TGCT	cis	rs786425	0.771	rs7135624	ENSG00000278112.1	RP11-972P1.11	4.06	8.73e-05	0.0416	0.38	0.34	Pubertal anthropometrics;	chr12:123663284	chr12:123519390~123519856:-
TGCT	cis	rs11858159	0.729	rs7183482	ENSG00000259905.4	PWRN1	4.06	8.74e-05	0.0416	0.37	0.34	Platelet thrombus formation;	chr15:24554391	chr15:24493137~24652130:+
TGCT	cis	rs11858159	0.902	rs71404365	ENSG00000259905.4	PWRN1	4.06	8.74e-05	0.0416	0.37	0.34	Platelet thrombus formation;	chr15:24554393	chr15:24493137~24652130:+
TGCT	cis	rs11858159	0.902	rs7182166	ENSG00000259905.4	PWRN1	4.06	8.74e-05	0.0416	0.37	0.34	Platelet thrombus formation;	chr15:24554398	chr15:24493137~24652130:+
TGCT	cis	rs7246967	0.673	rs16999519	ENSG00000198153.8	ZNF849P	-4.06	8.74e-05	0.0416	-0.56	-0.34	Bronchopulmonary dysplasia;	chr19:22631274	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs4933027	ENSG00000198153.8	ZNF849P	-4.06	8.74e-05	0.0416	-0.56	-0.34	Bronchopulmonary dysplasia;	chr19:22721170	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.541	rs16999009	ENSG00000198153.8	ZNF849P	-4.06	8.74e-05	0.0416	-0.56	-0.34	Bronchopulmonary dysplasia;	chr19:22726856	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs937078	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22628865	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs12978794	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22629332	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs4932782	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22629999	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs4933017	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22630178	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs66866654	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22630937	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs73028776	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22630938	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.551	rs56968124	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22631647	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.551	rs57775631	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22631659	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs2361021	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22633522	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs2361022	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22633731	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs2361023	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22634065	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs118059742	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22636644	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs56663398	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22637398	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs35731237	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22637708	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs12979173	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22637879	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs12979848	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22637996	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.551	rs6511367	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22638468	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs7250964	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22639692	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs7250343	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22640043	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs35007247	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22640121	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs34682021	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22643926	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.551	rs34897132	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22644089	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs60021625	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22646752	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs28787949	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22647554	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs67631531	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22647664	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.541	rs74169641	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22647774	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs56271774	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22648525	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs4414616	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22649609	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs4627499	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22649831	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs1835993	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22650235	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.551	rs1835994	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22650243	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs12984634	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22650942	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs12984903	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22651079	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs2099341	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22651558	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs2361245	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22651728	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs2082445	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22651785	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs7250285	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22654306	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs66620859	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22654428	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs3951783	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22656462	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs2885221	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22656585	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs2885222	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22657142	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs2915932	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22660899	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs11881740	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22661042	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs62118823	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22661264	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs73020703	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22661537	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.551	rs7248993	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22666350	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs12980342	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22666555	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs3951784	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22669124	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs3951785	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22669126	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.551	rs7250608	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22670254	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs7250620	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22670324	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs4244915	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22671336	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs8104052	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22675002	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.551	rs75360744	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22675154	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs12975767	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22680007	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.604	rs12975793	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22680042	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs57013651	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22680225	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs12979264	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22682332	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs34795935	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22682386	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs7252925	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22683006	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs7253063	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22683095	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs7254097	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22683098	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs3902164	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22683479	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs6511374	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22683568	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs8103875	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22684060	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs4933024	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22684261	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs8104327	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22684357	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs8104564	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22684405	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs8107724	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22684612	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs12973264	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22684947	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs597906	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22685403	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs35335083	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22686790	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs8102172	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22687217	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs8102006	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22687301	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs3853652	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22689111	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs3853653	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22689130	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs55932152	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22690626	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs4932784	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22691449	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs73022711	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22692602	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs73022713	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22693420	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs57027767	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22693733	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs62120313	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22694381	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs7248107	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22695727	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.551	rs8102812	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22696441	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs8106180	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22696558	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs8106215	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22696644	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs16994997	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22696808	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs34806882	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22697302	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs57736314	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22697470	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.604	rs58536761	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22697529	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs3853649	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22697658	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs3853650	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22697688	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs3844578	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22697808	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.551	rs3925175	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22698156	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.551	rs7257333	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22698347	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs34342502	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22698626	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs7245540	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22698702	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs7246424	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22699383	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs7249685	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22699577	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs7249003	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22705132	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs12971914	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22706096	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs8105441	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22708664	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.551	rs8112442	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22710567	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs73022763	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22711414	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs3931771	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22714018	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.604	rs8107322	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22714630	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs7247191	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22716783	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs34425596	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22716977	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs34376806	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22718059	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs16999571	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22721962	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs36029703	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22723386	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.551	rs7249473	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22723892	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.551	rs16998998	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22728314	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs9677019	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22729857	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs2112610	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22734049	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs34676724	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22735671	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs16999580	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22740685	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs55684269	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22741745	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs34003335	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22742800	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs12974988	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22743163	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs2194112	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22743387	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.551	rs34907478	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22746029	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs12985495	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22747576	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs8103430	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22748696	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs34174596	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22750717	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.551	rs8103204	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22753715	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs59621958	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22757857	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.604	rs58653025	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22758815	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs16999598	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22760323	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs34671960	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22765891	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs34726149	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22769309	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs12985825	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22770649	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs62120125	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22772297	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs2194113	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22775273	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs62120457	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22775717	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs55744741	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22777171	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs4933036	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22780267	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs35061555	ENSG00000198153.8	ZNF849P	4.06	8.74e-05	0.0416	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22780964	chr19:22685167~22686732:+
TGCT	cis	rs5742933	1	rs5743052	ENSG00000273240.1	RP11-455J20.3	-4.06	8.74e-05	0.0416	-0.36	-0.34	Ferritin levels;	chr2:189824558	chr2:189763859~189764456:-
TGCT	cis	rs7555523	0.779	rs2790049	ENSG00000224358.1	RP11-466F5.8	-4.06	8.75e-05	0.0416	-0.59	-0.34	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165774286	chr1:165768929~165775176:+
TGCT	cis	rs12935418	0.672	rs9925780	ENSG00000261061.1	RP11-303E16.2	-4.06	8.75e-05	0.0416	-0.39	-0.34	Mean corpuscular volume;	chr16:81011571	chr16:81030770~81031485:+
TGCT	cis	rs3931020	0.688	rs277375	ENSG00000272864.1	RP11-17E13.2	-4.06	8.75e-05	0.0416	-0.4	-0.34	Resistin levels;	chr1:74738459	chr1:74698769~74699333:-
TGCT	cis	rs9646096	1	rs75753776	ENSG00000279511.1	RP11-676B18.1	4.06	8.75e-05	0.0416	0.66	0.34	Age-related macular degeneration;	chr13:37487164	chr13:37142967~37146718:-
TGCT	cis	rs9646096	1	rs9646095	ENSG00000279511.1	RP11-676B18.1	4.06	8.75e-05	0.0416	0.66	0.34	Age-related macular degeneration;	chr13:37488621	chr13:37142967~37146718:-
TGCT	cis	rs9646096	1	rs76045829	ENSG00000279511.1	RP11-676B18.1	4.06	8.75e-05	0.0416	0.66	0.34	Age-related macular degeneration;	chr13:37489416	chr13:37142967~37146718:-
TGCT	cis	rs9646096	1	rs9547903	ENSG00000279511.1	RP11-676B18.1	4.06	8.75e-05	0.0416	0.66	0.34	Age-related macular degeneration;	chr13:37489741	chr13:37142967~37146718:-
TGCT	cis	rs7829975	0.742	rs1533059	ENSG00000254340.1	RP11-10A14.3	-4.06	8.75e-05	0.0416	-0.34	-0.34	Mood instability;	chr8:8827443	chr8:9141424~9145435:+
TGCT	cis	rs73198271	0.74	rs964771	ENSG00000253893.2	FAM85B	-4.06	8.75e-05	0.0416	-0.5	-0.34	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793429	chr8:8167819~8226614:-
TGCT	cis	rs7588746	0.571	rs4673891	ENSG00000232732.8	AC073043.1	4.06	8.76e-05	0.0417	0.47	0.34	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:200291639	chr2:199867396~199911159:-
TGCT	cis	rs2316527	1	rs61242046	ENSG00000228806.1	AC092628.3	4.06	8.76e-05	0.0417	0.37	0.34	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr7:154833929	chr7:155106400~155106651:+
TGCT	cis	rs2316527	1	rs1997094	ENSG00000228806.1	AC092628.3	4.06	8.76e-05	0.0417	0.37	0.34	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr7:154835432	chr7:155106400~155106651:+
TGCT	cis	rs2316527	1	rs1997093	ENSG00000228806.1	AC092628.3	4.06	8.76e-05	0.0417	0.37	0.34	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr7:154835499	chr7:155106400~155106651:+
TGCT	cis	rs6732189	0.559	rs584526	ENSG00000279844.1	RP11-20F18.1	-4.06	8.76e-05	0.0417	-0.32	-0.34	Educational attainment;	chr2:160747318	chr2:160849313~160850676:-
TGCT	cis	rs4273100	0.688	rs1467028	ENSG00000262319.1	CTC-457L16.2	-4.06	8.78e-05	0.0417	-0.45	-0.34	Schizophrenia;	chr17:19271561	chr17:19141017~19143689:-
TGCT	cis	rs7786765	0.509	rs10277001	ENSG00000234695.1	AC002076.10	4.06	8.78e-05	0.0417	0.4	0.34	Body mass index;	chr7:93475134	chr7:93890913~93893601:+
TGCT	cis	rs7780752	0.502	rs3802046	ENSG00000234695.1	AC002076.10	4.06	8.78e-05	0.0417	0.4	0.34	Birth weight;	chr7:93476427	chr7:93890913~93893601:+
TGCT	cis	rs9640161	0.702	rs1962004	ENSG00000261305.1	RP4-584D14.7	4.06	8.78e-05	0.0418	0.44	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150323292	chr7:150341771~150342607:+
TGCT	cis	rs1519814	0.654	rs1401810	ENSG00000254343.2	RP11-760H22.2	-4.06	8.79e-05	0.0418	-0.55	-0.34	Breast cancer;	chr8:120003581	chr8:120052180~120056201:+
TGCT	cis	rs7819412	0.634	rs4841485	ENSG00000255310.2	AF131215.2	4.06	8.79e-05	0.0418	0.26	0.34	Triglycerides;	chr8:11052426	chr8:11107788~11109726:-
TGCT	cis	rs957448	1	rs7829886	ENSG00000253175.1	RP11-267M23.6	4.06	8.79e-05	0.0418	0.45	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94485160	chr8:94565036~94565715:+
TGCT	cis	rs957448	1	rs12543207	ENSG00000253175.1	RP11-267M23.6	4.06	8.79e-05	0.0418	0.45	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94485202	chr8:94565036~94565715:+
TGCT	cis	rs969348	0.505	rs2867430	ENSG00000259594.4	CTD-2034I4.2	4.06	8.8e-05	0.0418	0.44	0.34	Paclitaxel disposition in epithelial ovarian cancer;	chr15:81611321	chr15:81554003~81696780:+
TGCT	cis	rs6547631	0.622	rs1866141	ENSG00000229648.1	AC016753.7	4.05	8.8e-05	0.0418	0.41	0.34	Blood protein levels;	chr2:85698263	chr2:85490930~85491780:-
TGCT	cis	rs35955747	0.633	rs7287937	ENSG00000236132.1	CTA-440B3.1	4.05	8.81e-05	0.0419	0.33	0.34	Neutrophil count;Sum basophil neutrophil counts;	chr22:31624759	chr22:31816379~31817491:-
TGCT	cis	rs10759883	0.563	rs12348051	ENSG00000175611.10	LINC00476	4.05	8.81e-05	0.0419	0.31	0.34	Nicotine dependence;	chr9:95905928	chr9:95759231~95875977:-
TGCT	cis	rs17445774	1	rs1509833	ENSG00000232732.8	AC073043.1	-4.05	8.81e-05	0.0419	-0.48	-0.34	LDL cholesterol to HDL cholesterol ratio;	chr2:200000502	chr2:199867396~199911159:-
TGCT	cis	rs853356	0.947	rs853384	ENSG00000234261.2	RP11-146I2.1	4.05	8.82e-05	0.0419	0.33	0.34	Height;	chr6:14182074	chr6:14661829~15090003:-
TGCT	cis	rs7246657	0.943	rs4803229	ENSG00000266916.4	ZNF793-AS1	-4.05	8.82e-05	0.0419	-0.31	-0.34	Coronary artery calcification;	chr19:37373780	chr19:37497159~37507046:-
TGCT	cis	rs7246657	0.943	rs1559229	ENSG00000266916.4	ZNF793-AS1	-4.05	8.82e-05	0.0419	-0.31	-0.34	Coronary artery calcification;	chr19:37385295	chr19:37497159~37507046:-
TGCT	cis	rs7246657	0.882	rs6508719	ENSG00000266916.4	ZNF793-AS1	-4.05	8.82e-05	0.0419	-0.31	-0.34	Coronary artery calcification;	chr19:37386517	chr19:37497159~37507046:-
TGCT	cis	rs7246657	0.943	rs4452075	ENSG00000266916.4	ZNF793-AS1	-4.05	8.82e-05	0.0419	-0.31	-0.34	Coronary artery calcification;	chr19:37388687	chr19:37497159~37507046:-
TGCT	cis	rs3749237	0.595	rs4855873	ENSG00000226913.1	BSN-AS2	-4.05	8.82e-05	0.0419	-0.26	-0.34	Resting heart rate;	chr3:49421681	chr3:49549306~49554366:-
TGCT	cis	rs3749237	0.595	rs1464566	ENSG00000226913.1	BSN-AS2	-4.05	8.82e-05	0.0419	-0.26	-0.34	Resting heart rate;	chr3:49421943	chr3:49549306~49554366:-
TGCT	cis	rs3749237	0.537	rs4459909	ENSG00000226913.1	BSN-AS2	-4.05	8.82e-05	0.0419	-0.26	-0.34	Resting heart rate;	chr3:49431784	chr3:49549306~49554366:-
TGCT	cis	rs3749237	0.595	rs11130196	ENSG00000226913.1	BSN-AS2	-4.05	8.82e-05	0.0419	-0.26	-0.34	Resting heart rate;	chr3:49452716	chr3:49549306~49554366:-
TGCT	cis	rs3749237	0.595	rs4855839	ENSG00000226913.1	BSN-AS2	-4.05	8.82e-05	0.0419	-0.26	-0.34	Resting heart rate;	chr3:49470414	chr3:49549306~49554366:-
TGCT	cis	rs3749237	0.595	rs35701831	ENSG00000226913.1	BSN-AS2	-4.05	8.82e-05	0.0419	-0.26	-0.34	Resting heart rate;	chr3:49477567	chr3:49549306~49554366:-
TGCT	cis	rs3749237	0.595	rs4855864	ENSG00000226913.1	BSN-AS2	-4.05	8.82e-05	0.0419	-0.26	-0.34	Resting heart rate;	chr3:49484541	chr3:49549306~49554366:-
TGCT	cis	rs3749237	0.595	rs11130199	ENSG00000226913.1	BSN-AS2	-4.05	8.82e-05	0.0419	-0.26	-0.34	Resting heart rate;	chr3:49501366	chr3:49549306~49554366:-
TGCT	cis	rs2283792	0.765	rs9607241	ENSG00000228050.1	TOP3BP1	4.05	8.82e-05	0.0419	0.42	0.34	Multiple sclerosis;	chr22:21750584	chr22:22223187~22224566:-
TGCT	cis	rs227275	0.554	rs223390	ENSG00000230069.3	LRRC37A15P	-4.05	8.82e-05	0.0419	-0.3	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102827640	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.51	rs50034	ENSG00000230069.3	LRRC37A15P	-4.05	8.82e-05	0.0419	-0.3	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102832214	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.556	rs223380	ENSG00000230069.3	LRRC37A15P	-4.05	8.82e-05	0.0419	-0.3	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102833343	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.556	rs223379	ENSG00000230069.3	LRRC37A15P	-4.05	8.82e-05	0.0419	-0.3	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102833434	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.536	rs223375	ENSG00000230069.3	LRRC37A15P	-4.05	8.82e-05	0.0419	-0.3	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102836484	chr4:102727274~102730721:-
TGCT	cis	rs7917772	0.555	rs2244524	ENSG00000273108.1	RP11-416N2.4	-4.05	8.83e-05	0.0419	-0.33	-0.34	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102727217	chr10:103608619~103610050:+
TGCT	cis	rs34779708	0.733	rs60616028	ENSG00000230534.5	RP11-297A16.2	4.05	8.83e-05	0.0419	0.43	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35254874	chr10:35098006~35127020:-
TGCT	cis	rs10129255	0.744	rs28517388	ENSG00000211970.3	IGHV4-61	-4.05	8.83e-05	0.0419	-0.38	-0.34	Kawasaki disease;	chr14:106704323	chr14:106639119~106639657:-
TGCT	cis	rs2177312	0.553	rs9994107	ENSG00000251129.1	RP11-734I18.1	-4.05	8.83e-05	0.042	-0.34	-0.34	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31969061	chr4:31997397~32155406:+
TGCT	cis	rs2177312	0.62	rs6553980	ENSG00000251129.1	RP11-734I18.1	-4.05	8.83e-05	0.042	-0.34	-0.34	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31975116	chr4:31997397~32155406:+
TGCT	cis	rs11640436	0.565	rs2162957	ENSG00000226348.1	VN2R10P	-4.05	8.84e-05	0.042	-0.38	-0.34	Lobe attachment (rater-scored or self-reported);	chr16:77263296	chr16:77220406~77221258:+
TGCT	cis	rs507080	0.961	rs600969	ENSG00000255239.1	AP002954.6	4.05	8.84e-05	0.042	0.44	0.34	Serum metabolite levels;	chr11:118675087	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.922	rs12577485	ENSG00000255239.1	AP002954.6	4.05	8.84e-05	0.042	0.44	0.34	Serum metabolite levels;	chr11:118676793	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.961	rs1784298	ENSG00000255239.1	AP002954.6	4.05	8.84e-05	0.042	0.44	0.34	Serum metabolite levels;	chr11:118677956	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.961	rs4938522	ENSG00000255239.1	AP002954.6	4.05	8.84e-05	0.042	0.44	0.34	Serum metabolite levels;	chr11:118677962	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.961	rs4938523	ENSG00000255239.1	AP002954.6	4.05	8.84e-05	0.042	0.44	0.34	Serum metabolite levels;	chr11:118678129	chr11:118688039~118690600:-
TGCT	cis	rs507080	1	rs507080	ENSG00000255239.1	AP002954.6	4.05	8.84e-05	0.042	0.44	0.34	Serum metabolite levels;	chr11:118678873	chr11:118688039~118690600:-
TGCT	cis	rs507080	1	rs659969	ENSG00000255239.1	AP002954.6	4.05	8.84e-05	0.042	0.44	0.34	Serum metabolite levels;	chr11:118679094	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.961	rs673770	ENSG00000255239.1	AP002954.6	4.05	8.84e-05	0.042	0.44	0.34	Serum metabolite levels;	chr11:118679892	chr11:118688039~118690600:-
TGCT	cis	rs748404	0.666	rs12907870	ENSG00000205771.5	CATSPER2P1	-4.05	8.84e-05	0.042	-0.5	-0.34	Lung cancer;	chr15:43453971	chr15:43726918~43747094:-
TGCT	cis	rs7829975	0.688	rs7837587	ENSG00000254340.1	RP11-10A14.3	4.05	8.85e-05	0.042	0.34	0.34	Mood instability;	chr8:8521482	chr8:9141424~9145435:+
TGCT	cis	rs7829975	0.688	rs7826654	ENSG00000254340.1	RP11-10A14.3	4.05	8.85e-05	0.042	0.34	0.34	Mood instability;	chr8:8521596	chr8:9141424~9145435:+
TGCT	cis	rs7829975	0.688	rs7826660	ENSG00000254340.1	RP11-10A14.3	4.05	8.85e-05	0.042	0.34	0.34	Mood instability;	chr8:8521597	chr8:9141424~9145435:+
TGCT	cis	rs7829975	0.688	rs6601703	ENSG00000254340.1	RP11-10A14.3	4.05	8.85e-05	0.042	0.34	0.34	Mood instability;	chr8:8522714	chr8:9141424~9145435:+
TGCT	cis	rs9650657	0.537	rs4841457	ENSG00000255310.2	AF131215.2	-4.05	8.85e-05	0.042	-0.29	-0.34	Neuroticism;	chr8:10916001	chr8:11107788~11109726:-
TGCT	cis	rs4242434	0.927	rs2291234	ENSG00000253200.1	RP11-582J16.5	4.05	8.85e-05	0.042	0.19	0.34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22606877	chr8:22613908~22616657:-
TGCT	cis	rs4242434	0.927	rs7843616	ENSG00000253200.1	RP11-582J16.5	4.05	8.85e-05	0.042	0.19	0.34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22609028	chr8:22613908~22616657:-
TGCT	cis	rs10129255	0.5	rs8021941	ENSG00000280411.1	IGHV1-69-2	-4.05	8.85e-05	0.042	-0.34	-0.34	Kawasaki disease;	chr14:106781490	chr14:106762092~106762588:-
TGCT	cis	rs10129255	0.5	rs10142931	ENSG00000280411.1	IGHV1-69-2	-4.05	8.85e-05	0.042	-0.34	-0.34	Kawasaki disease;	chr14:106782288	chr14:106762092~106762588:-
TGCT	cis	rs453301	0.686	rs28482034	ENSG00000254340.1	RP11-10A14.3	-4.05	8.86e-05	0.0421	-0.37	-0.34	Joint mobility (Beighton score);	chr8:9012154	chr8:9141424~9145435:+
TGCT	cis	rs453301	0.686	rs11785819	ENSG00000254340.1	RP11-10A14.3	-4.05	8.86e-05	0.0421	-0.37	-0.34	Joint mobility (Beighton score);	chr8:9012868	chr8:9141424~9145435:+
TGCT	cis	rs453301	0.686	rs7017868	ENSG00000254340.1	RP11-10A14.3	-4.05	8.86e-05	0.0421	-0.37	-0.34	Joint mobility (Beighton score);	chr8:9015783	chr8:9141424~9145435:+
TGCT	cis	rs453301	0.686	rs3895823	ENSG00000254340.1	RP11-10A14.3	-4.05	8.86e-05	0.0421	-0.37	-0.34	Joint mobility (Beighton score);	chr8:9016136	chr8:9141424~9145435:+
TGCT	cis	rs3796352	1	rs17052727	ENSG00000242142.1	SERBP1P3	-4.05	8.86e-05	0.0421	-0.54	-0.34	Immune reponse to smallpox (secreted IL-2);	chr3:53036898	chr3:53064283~53065091:-
TGCT	cis	rs796364	0.694	rs1653299	ENSG00000232732.8	AC073043.1	-4.05	8.86e-05	0.0421	-0.44	-0.34	Schizophrenia;	chr2:200210888	chr2:199867396~199911159:-
TGCT	cis	rs7115242	0.702	rs672058	ENSG00000254851.1	RP11-109L13.1	-4.05	8.87e-05	0.0421	-0.54	-0.34	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116893305	chr11:117135528~117138582:+
TGCT	cis	rs2483374	0.557	rs2018248	ENSG00000253771.4	TPTE2P1	4.05	8.87e-05	0.0421	0.32	0.34	Obesity-related traits;	chr13:24857428	chr13:24924677~24968487:-
TGCT	cis	rs115344852	0.598	rs2191035	ENSG00000216901.1	AL022393.7	4.05	8.87e-05	0.0421	0.41	0.34	Epithelial ovarian cancer;	chr6:28467166	chr6:28176188~28176674:+
TGCT	cis	rs4242434	0.597	rs1877675	ENSG00000253200.1	RP11-582J16.5	-4.05	8.88e-05	0.0421	-0.19	-0.34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22676434	chr8:22613908~22616657:-
TGCT	cis	rs8141529	0.778	rs9625566	ENSG00000226471.5	CTA-292E10.6	-4.05	8.88e-05	0.0421	-0.36	-0.34	Lymphocyte counts;	chr22:28766518	chr22:28800683~28848559:+
TGCT	cis	rs10256972	0.621	rs2280725	ENSG00000226291.1	AC091729.8	-4.05	8.89e-05	0.0421	-0.37	-0.34	Endometriosis;Longevity;	chr7:1047790	chr7:1080863~1082178:+
TGCT	cis	rs10256972	0.621	rs10951594	ENSG00000226291.1	AC091729.8	-4.05	8.89e-05	0.0421	-0.37	-0.34	Endometriosis;Longevity;	chr7:1048971	chr7:1080863~1082178:+
TGCT	cis	rs4820539	1	rs3788347	ENSG00000218537.1	MIF-AS1	4.05	8.89e-05	0.0422	0.43	0.34	Bone mineral density;	chr22:23125617	chr22:23894426~23898930:-
TGCT	cis	rs7208859	0.623	rs11651857	ENSG00000263603.1	CTD-2349P21.5	-4.05	8.89e-05	0.0422	-0.49	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs216439	ENSG00000263603.1	CTD-2349P21.5	-4.05	8.89e-05	0.0422	-0.49	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.573	rs216442	ENSG00000263603.1	CTD-2349P21.5	-4.05	8.89e-05	0.0422	-0.49	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs216445	ENSG00000263603.1	CTD-2349P21.5	-4.05	8.89e-05	0.0422	-0.49	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs216446	ENSG00000263603.1	CTD-2349P21.5	-4.05	8.89e-05	0.0422	-0.49	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs79607958	ENSG00000263603.1	CTD-2349P21.5	-4.05	8.89e-05	0.0422	-0.49	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs75136574	ENSG00000263603.1	CTD-2349P21.5	-4.05	8.89e-05	0.0422	-0.49	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs77544470	ENSG00000263603.1	CTD-2349P21.5	-4.05	8.89e-05	0.0422	-0.49	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs609063	ENSG00000263603.1	CTD-2349P21.5	-4.05	8.89e-05	0.0422	-0.49	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs383436	ENSG00000263603.1	CTD-2349P21.5	-4.05	8.89e-05	0.0422	-0.49	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30729469~30731202:+
TGCT	cis	rs17826219	0.714	rs11650821	ENSG00000263603.1	CTD-2349P21.5	-4.05	8.89e-05	0.0422	-0.49	-0.34	Body mass index;	chr17:30641132	chr17:30729469~30731202:+
TGCT	cis	rs10759883	0.587	rs6478977	ENSG00000175611.10	LINC00476	-4.05	8.9e-05	0.0422	-0.31	-0.34	Nicotine dependence;	chr9:95797994	chr9:95759231~95875977:-
TGCT	cis	rs10759883	0.612	rs816675	ENSG00000175611.10	LINC00476	-4.05	8.9e-05	0.0422	-0.31	-0.34	Nicotine dependence;	chr9:95806799	chr9:95759231~95875977:-
TGCT	cis	rs10759883	0.627	rs816674	ENSG00000175611.10	LINC00476	-4.05	8.9e-05	0.0422	-0.31	-0.34	Nicotine dependence;	chr9:95807835	chr9:95759231~95875977:-
TGCT	cis	rs10759883	0.627	rs816673	ENSG00000175611.10	LINC00476	-4.05	8.9e-05	0.0422	-0.31	-0.34	Nicotine dependence;	chr9:95811134	chr9:95759231~95875977:-
TGCT	cis	rs2720460	0.502	rs223374	ENSG00000251288.2	RP11-10L12.2	-4.05	8.9e-05	0.0422	-0.45	-0.34	Testicular germ cell tumor;	chr4:102837144	chr4:102751401~102752641:+
TGCT	cis	rs7829975	0.688	rs7827182	ENSG00000254340.1	RP11-10A14.3	4.05	8.9e-05	0.0422	0.34	0.34	Mood instability;	chr8:8522961	chr8:9141424~9145435:+
TGCT	cis	rs7829975	0.688	rs7817376	ENSG00000254340.1	RP11-10A14.3	-4.05	8.9e-05	0.0422	-0.34	-0.34	Mood instability;	chr8:8523020	chr8:9141424~9145435:+
TGCT	cis	rs1618992	0.729	rs1504119	ENSG00000265994.1	RP11-510D21.1	4.05	8.92e-05	0.0422	0.35	0.34	Gut microbiome composition (summer and winter);	chr18:28612915	chr18:28785068~28789260:+
TGCT	cis	rs1618992	0.729	rs2655353	ENSG00000265994.1	RP11-510D21.1	4.05	8.92e-05	0.0422	0.35	0.34	Gut microbiome composition (summer and winter);	chr18:28614996	chr18:28785068~28789260:+
TGCT	cis	rs2408955	0.542	rs7975632	ENSG00000258273.1	RP11-370I10.4	-4.05	8.92e-05	0.0422	-0.41	-0.34	Glycated hemoglobin levels;	chr12:48049265	chr12:48333755~48333901:-
TGCT	cis	rs17507216	0.518	rs1877240	ENSG00000276710.3	CSPG4P8	-4.05	8.92e-05	0.0422	-0.39	-0.34	Excessive daytime sleepiness;	chr15:82770126	chr15:82459472~82477258:+
TGCT	cis	rs41271473	0.5	rs4606285	ENSG00000236975.1	RP5-1065P14.2	-4.05	8.92e-05	0.0422	-0.31	-0.34	Chronic lymphocytic leukemia;	chr1:228751797	chr1:229092815~229094905:-
TGCT	cis	rs6547631	0.622	rs34943381	ENSG00000229648.1	AC016753.7	4.05	8.92e-05	0.0423	0.4	0.34	Blood protein levels;	chr2:85696874	chr2:85490930~85491780:-
TGCT	cis	rs5758659	1	rs5758659	ENSG00000182057.4	OGFRP1	4.05	8.93e-05	0.0423	0.26	0.34	Cognitive function;	chr22:42225997	chr22:42269753~42275196:+
TGCT	cis	rs6782228	0.509	rs4481172	ENSG00000242551.2	POU5F1P6	-4.05	8.94e-05	0.0423	-0.42	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128653814	chr3:128674735~128677005:-
TGCT	cis	rs5758511	0.689	rs17478227	ENSG00000182057.4	OGFRP1	4.05	8.94e-05	0.0423	0.34	0.34	Birth weight;	chr22:42258321	chr22:42269753~42275196:+
TGCT	cis	rs4242434	0.927	rs10095121	ENSG00000254064.1	CTD-2530N21.4	-4.05	8.94e-05	0.0423	-0.21	-0.34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22680913	chr8:22254576~22275162:-
TGCT	cis	rs4835473	0.897	rs7687317	ENSG00000251600.4	RP11-673E1.1	4.05	8.94e-05	0.0423	0.37	0.34	Immature fraction of reticulocytes;	chr4:143709010	chr4:143912331~143982454:+
TGCT	cis	rs34091987	0.83	rs12453158	ENSG00000256124.4	LINC01152	-4.05	8.95e-05	0.0423	-0.37	-0.34	Nose size;	chr17:72032367	chr17:72030291~72041297:+
TGCT	cis	rs72615157	0.634	rs11762932	ENSG00000242294.5	STAG3L5P	-4.05	8.95e-05	0.0423	-0.3	-0.34	Lung function (FEV1/FVC);	chr7:100195043	chr7:100336079~100351900:+
TGCT	cis	rs904251	0.861	rs2776875	ENSG00000204110.6	RP1-153P14.8	-4.05	8.95e-05	0.0423	-0.4	-0.34	Cognitive performance;	chr6:37519020	chr6:37507348~37535616:+
TGCT	cis	rs904251	0.861	rs1757173	ENSG00000204110.6	RP1-153P14.8	-4.05	8.95e-05	0.0423	-0.4	-0.34	Cognitive performance;	chr6:37519176	chr6:37507348~37535616:+
TGCT	cis	rs904251	0.861	rs1757169	ENSG00000204110.6	RP1-153P14.8	-4.05	8.95e-05	0.0423	-0.4	-0.34	Cognitive performance;	chr6:37519300	chr6:37507348~37535616:+
TGCT	cis	rs11168618	0.74	rs7312017	ENSG00000240399.1	RP1-228P16.1	4.05	8.95e-05	0.0424	0.31	0.34	Adiponectin levels;	chr12:48560442	chr12:48054813~48055591:-
TGCT	cis	rs4718428	1	rs4718428	ENSG00000226824.5	RP4-756H11.3	-4.05	8.96e-05	0.0424	-0.42	-0.34	Corneal structure;	chr7:66956459	chr7:66654538~66669855:+
TGCT	cis	rs8041943	0.9	rs3848182	ENSG00000177699.4	RP11-16K12.1	-4.05	8.96e-05	0.0424	-0.26	-0.34	Bone mineral density (spine) and age at menarche;	chr15:79626369	chr15:78978889~78985926:+
TGCT	cis	rs763121	0.962	rs6001193	ENSG00000273076.1	RP3-508I15.22	4.05	8.96e-05	0.0424	0.37	0.34	Menopause (age at onset);	chr22:38678732	chr22:38743495~38743910:+
TGCT	cis	rs12935418	0.672	rs12448656	ENSG00000261061.1	RP11-303E16.2	-4.05	8.96e-05	0.0424	-0.38	-0.34	Mean corpuscular volume;	chr16:81008876	chr16:81030770~81031485:+
TGCT	cis	rs11123170	0.543	rs2166421	ENSG00000189223.12	PAX8-AS1	-4.05	8.96e-05	0.0424	-0.59	-0.34	Renal function-related traits (BUN);	chr2:113232665	chr2:113211522~113276581:+
TGCT	cis	rs9322193	0.607	rs9322229	ENSG00000216906.2	RP11-350J20.9	4.05	8.97e-05	0.0424	0.41	0.34	Lung cancer;	chr6:149908949	chr6:149904243~149906418:+
TGCT	cis	rs796364	0.806	rs10931889	ENSG00000232732.8	AC073043.1	4.05	8.97e-05	0.0424	0.51	0.34	Schizophrenia;	chr2:200237177	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.806	rs10931890	ENSG00000232732.8	AC073043.1	4.05	8.97e-05	0.0424	0.51	0.34	Schizophrenia;	chr2:200237332	chr2:199867396~199911159:-
TGCT	cis	rs877819	0.549	rs7900483	ENSG00000228403.1	RP11-563N6.6	-4.05	8.97e-05	0.0424	-0.35	-0.34	Systemic lupus erythematosus;	chr10:48890430	chr10:48878022~48878649:+
TGCT	cis	rs3931020	0.657	rs277368	ENSG00000272864.1	RP11-17E13.2	4.05	8.97e-05	0.0424	0.4	0.34	Resistin levels;	chr1:74764922	chr1:74698769~74699333:-
TGCT	cis	rs3931020	0.657	rs277369	ENSG00000272864.1	RP11-17E13.2	4.05	8.97e-05	0.0424	0.4	0.34	Resistin levels;	chr1:74768977	chr1:74698769~74699333:-
TGCT	cis	rs853679	0.517	rs9380052	ENSG00000219891.2	ZSCAN12P1	4.05	8.97e-05	0.0424	0.45	0.34	Depression;	chr6:28096845	chr6:28091154~28093664:+
TGCT	cis	rs992157	0.764	rs2382827	ENSG00000261338.2	RP11-378A13.1	4.05	8.98e-05	0.0424	0.29	0.34	Colorectal cancer;	chr2:218319664	chr2:218255319~218257366:+
TGCT	cis	rs992157	0.764	rs2891076	ENSG00000261338.2	RP11-378A13.1	4.05	8.98e-05	0.0424	0.29	0.34	Colorectal cancer;	chr2:218319675	chr2:218255319~218257366:+
TGCT	cis	rs992157	0.764	rs2891077	ENSG00000261338.2	RP11-378A13.1	4.05	8.98e-05	0.0424	0.29	0.34	Colorectal cancer;	chr2:218319707	chr2:218255319~218257366:+
TGCT	cis	rs992157	0.73	rs2891078	ENSG00000261338.2	RP11-378A13.1	4.05	8.98e-05	0.0424	0.29	0.34	Colorectal cancer;	chr2:218319709	chr2:218255319~218257366:+
TGCT	cis	rs2483374	0.557	rs4770754	ENSG00000253771.4	TPTE2P1	4.05	8.98e-05	0.0424	0.32	0.34	Obesity-related traits;	chr13:24896389	chr13:24924677~24968487:-
TGCT	cis	rs7182621	0.639	rs35049216	ENSG00000259363.4	CTD-2054N24.2	-4.05	8.98e-05	0.0424	-0.34	-0.34	Colonoscopy-negative controls vs population controls;	chr15:99872562	chr15:99807023~99877148:+
TGCT	cis	rs7182621	0.639	rs12906068	ENSG00000259363.4	CTD-2054N24.2	-4.05	8.98e-05	0.0424	-0.34	-0.34	Colonoscopy-negative controls vs population controls;	chr15:99873422	chr15:99807023~99877148:+
TGCT	cis	rs7005380	1	rs7005380	ENSG00000254343.2	RP11-760H22.2	-4.05	8.98e-05	0.0424	-0.46	-0.34	Interstitial lung disease;	chr8:119941633	chr8:120052180~120056201:+
TGCT	cis	rs4835473	0.932	rs7667092	ENSG00000251600.4	RP11-673E1.1	4.05	8.98e-05	0.0425	0.36	0.34	Immature fraction of reticulocytes;	chr4:143968604	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs3874	ENSG00000251600.4	RP11-673E1.1	4.05	8.98e-05	0.0425	0.36	0.34	Immature fraction of reticulocytes;	chr4:143968795	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.932	rs2323417	ENSG00000251600.4	RP11-673E1.1	4.05	8.98e-05	0.0425	0.36	0.34	Immature fraction of reticulocytes;	chr4:143969108	chr4:143912331~143982454:+
TGCT	cis	rs763121	0.813	rs2179143	ENSG00000273076.1	RP3-508I15.22	4.05	8.98e-05	0.0425	0.37	0.34	Menopause (age at onset);	chr22:38641979	chr22:38743495~38743910:+
TGCT	cis	rs901683	1	rs9422652	ENSG00000264204.2	AGAP7P	-4.05	8.99e-05	0.0425	-0.78	-0.34	Mean corpuscular volume;Red blood cell traits;	chr10:45552486	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs9422441	ENSG00000264204.2	AGAP7P	-4.05	8.99e-05	0.0425	-0.78	-0.34	Mean corpuscular volume;Red blood cell traits;	chr10:45552605	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs9422442	ENSG00000264204.2	AGAP7P	-4.05	8.99e-05	0.0425	-0.78	-0.34	Mean corpuscular volume;Red blood cell traits;	chr10:45552630	chr10:46109621~46131358:+
TGCT	cis	rs901683	1	rs17157928	ENSG00000264204.2	AGAP7P	-4.05	8.99e-05	0.0425	-0.78	-0.34	Mean corpuscular volume;Red blood cell traits;	chr10:45552781	chr10:46109621~46131358:+
TGCT	cis	rs4888378	0.576	rs8050367	ENSG00000261783.1	RP11-252K23.2	4.05	8.99e-05	0.0425	0.56	0.34	Coronary artery disease;	chr16:75279360	chr16:75379818~75381260:-
TGCT	cis	rs9309473	1	rs7604682	ENSG00000163016.8	ALMS1P	4.05	8.99e-05	0.0425	0.3	0.34	Metabolite levels;	chr2:73560899	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.898	rs10170786	ENSG00000163016.8	ALMS1P	4.05	8.99e-05	0.0425	0.3	0.34	Metabolite levels;	chr2:73585861	chr2:73644919~73685576:+
TGCT	cis	rs9309473	1	rs11903916	ENSG00000163016.8	ALMS1P	4.05	8.99e-05	0.0425	0.3	0.34	Metabolite levels;	chr2:73588201	chr2:73644919~73685576:+
TGCT	cis	rs7777677	0.925	rs6969951	ENSG00000244273.1	PGBD4P1	4.05	8.99e-05	0.0425	0.4	0.34	Alcoholic chronic pancreatitis;	chr7:142661753	chr7:142722358~142722764:+
TGCT	cis	rs10938353	0.68	rs66829609	ENSG00000273369.1	RP11-700J17.1	4.05	9e-05	0.0425	0.52	0.34	Body mass index;	chr4:44769814	chr4:44693946~44694386:-
TGCT	cis	rs7403037	0.617	rs35110243	ENSG00000259905.4	PWRN1	4.05	9e-05	0.0425	0.45	0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24581421	chr15:24493137~24652130:+
TGCT	cis	rs875971	0.545	rs6460281	ENSG00000222364.1	RNU6-96P	-4.05	9e-05	0.0425	-0.43	-0.34	Aortic root size;	chr7:66216128	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.545	rs17138156	ENSG00000222364.1	RNU6-96P	-4.05	9e-05	0.0425	-0.43	-0.34	Aortic root size;	chr7:66249708	chr7:66395191~66395286:+
TGCT	cis	rs494459	0.733	rs556437	ENSG00000255422.1	AP002954.4	-4.05	9e-05	0.0425	-0.37	-0.34	Height;	chr11:118835044	chr11:118704607~118750263:+
TGCT	cis	rs7182621	0.639	rs1561047	ENSG00000259363.4	CTD-2054N24.2	-4.05	9e-05	0.0425	-0.35	-0.34	Colonoscopy-negative controls vs population controls;	chr15:99874606	chr15:99807023~99877148:+
TGCT	cis	rs4973397	0.81	rs12993290	ENSG00000183022.5	TPM3P8	4.05	9.01e-05	0.0425	0.48	0.34	Anti-saccade response;	chr2:231414976	chr2:230573167~230573809:-
TGCT	cis	rs17608059	0.71	rs8080167	ENSG00000141028.6	CDRT15P1	-4.05	9.01e-05	0.0426	-0.38	-0.34	Temperament;	chr17:14046511	chr17:14024514~14025488:+
TGCT	cis	rs17608059	0.679	rs9898056	ENSG00000141028.6	CDRT15P1	-4.05	9.01e-05	0.0426	-0.38	-0.34	Temperament;	chr17:14048649	chr17:14024514~14025488:+
TGCT	cis	rs7819412	0.511	rs10108511	ENSG00000255556.2	RP11-351I21.6	-4.05	9.01e-05	0.0426	-0.36	-0.34	Triglycerides;	chr8:11578007	chr8:12378679~12380265:-
TGCT	cis	rs2243480	1	rs4718269	ENSG00000226824.5	RP4-756H11.3	4.05	9.02e-05	0.0426	0.61	0.34	Diabetic kidney disease;	chr7:65735810	chr7:66654538~66669855:+
TGCT	cis	rs2243480	1	rs4718270	ENSG00000226824.5	RP4-756H11.3	-4.05	9.02e-05	0.0426	-0.61	-0.34	Diabetic kidney disease;	chr7:65737415	chr7:66654538~66669855:+
TGCT	cis	rs2243480	0.901	rs2900904	ENSG00000226824.5	RP4-756H11.3	-4.05	9.02e-05	0.0426	-0.61	-0.34	Diabetic kidney disease;	chr7:65739282	chr7:66654538~66669855:+
TGCT	cis	rs2243480	1	rs6460260	ENSG00000226824.5	RP4-756H11.3	4.05	9.02e-05	0.0426	0.61	0.34	Diabetic kidney disease;	chr7:65750468	chr7:66654538~66669855:+
TGCT	cis	rs2243480	1	rs6460261	ENSG00000226824.5	RP4-756H11.3	4.05	9.02e-05	0.0426	0.61	0.34	Diabetic kidney disease;	chr7:65750593	chr7:66654538~66669855:+
TGCT	cis	rs2243480	0.908	rs4718273	ENSG00000226824.5	RP4-756H11.3	4.05	9.02e-05	0.0426	0.61	0.34	Diabetic kidney disease;	chr7:65751112	chr7:66654538~66669855:+
TGCT	cis	rs7829975	0.714	rs59046059	ENSG00000254340.1	RP11-10A14.3	4.05	9.02e-05	0.0426	0.35	0.34	Mood instability;	chr8:8813226	chr8:9141424~9145435:+
TGCT	cis	rs2015599	0.623	rs7964831	ENSG00000257176.2	RP11-996F15.2	-4.05	9.02e-05	0.0426	-0.34	-0.34	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29280418~29317848:-
TGCT	cis	rs11168618	0.846	rs11168599	ENSG00000240399.1	RP1-228P16.1	4.05	9.03e-05	0.0426	0.33	0.34	Adiponectin levels;	chr12:48486168	chr12:48054813~48055591:-
TGCT	cis	rs2243480	0.803	rs36127118	ENSG00000164669.11	INTS4P1	4.05	9.03e-05	0.0426	0.52	0.34	Diabetic kidney disease;	chr7:66100518	chr7:65141225~65234216:+
TGCT	cis	rs28599928	1	rs28599928	ENSG00000227370.1	RP4-669P10.19	-4.05	9.03e-05	0.0426	-0.72	-0.34	Breast cancer;	chr22:43072659	chr22:42132543~42132998:+
TGCT	cis	rs4835473	0.83	rs75309663	ENSG00000251600.4	RP11-673E1.1	-4.05	9.03e-05	0.0426	-0.36	-0.34	Immature fraction of reticulocytes;	chr4:143675647	chr4:143912331~143982454:+
TGCT	cis	rs4986172	0.726	rs12946454	ENSG00000267288.2	RP13-890H12.2	-4.05	9.04e-05	0.0426	-0.4	-0.34	Height;	chr17:45130754	chr17:45168800~45171584:-
TGCT	cis	rs7917772	0.56	rs35095897	ENSG00000273108.1	RP11-416N2.4	4.05	9.04e-05	0.0427	0.32	0.34	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102618002	chr10:103608619~103610050:+
TGCT	cis	rs10875976	1	rs4898534	ENSG00000257253.2	RP11-70F11.7	-4.05	9.04e-05	0.0427	-0.28	-0.34	Obesity;	chr12:49837242	chr12:49861207~49865802:+
TGCT	cis	rs10875976	1	rs11169170	ENSG00000257253.2	RP11-70F11.7	4.05	9.04e-05	0.0427	0.28	0.34	Obesity;	chr12:49829230	chr12:49861207~49865802:+
TGCT	cis	rs10875976	1	rs10875976	ENSG00000257253.2	RP11-70F11.7	4.05	9.04e-05	0.0427	0.28	0.34	Obesity;	chr12:49832684	chr12:49861207~49865802:+
TGCT	cis	rs10875976	1	rs7973894	ENSG00000257253.2	RP11-70F11.7	4.05	9.04e-05	0.0427	0.28	0.34	Obesity;	chr12:49839473	chr12:49861207~49865802:+
TGCT	cis	rs7829975	0.653	rs13259070	ENSG00000173295.6	FAM86B3P	4.05	9.05e-05	0.0427	0.41	0.34	Mood instability;	chr8:8833277	chr8:8228595~8244865:+
TGCT	cis	rs7829975	0.533	rs13274028	ENSG00000173295.6	FAM86B3P	4.05	9.05e-05	0.0427	0.4	0.34	Mood instability;	chr8:8871683	chr8:8228595~8244865:+
TGCT	cis	rs748404	0.65	rs518234	ENSG00000205771.5	CATSPER2P1	-4.05	9.05e-05	0.0427	-0.4	-0.34	Lung cancer;	chr15:43281223	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.65	rs518261	ENSG00000205771.5	CATSPER2P1	-4.05	9.05e-05	0.0427	-0.4	-0.34	Lung cancer;	chr15:43281231	chr15:43726918~43747094:-
TGCT	cis	rs12549025	0.536	rs9644077	ENSG00000253390.1	CTC-756D1.2	-4.05	9.05e-05	0.0427	-0.38	-0.34	Reticulocyte fraction of red cells;	chr8:23502819	chr8:23458601~23484971:+
TGCT	cis	rs11168618	0.904	rs12371700	ENSG00000240399.1	RP1-228P16.1	-4.05	9.05e-05	0.0427	-0.33	-0.34	Adiponectin levels;	chr12:48525430	chr12:48054813~48055591:-
TGCT	cis	rs3812049	0.826	rs17764730	ENSG00000245937.6	LINC01184	4.05	9.06e-05	0.0427	0.23	0.34	Lymphocyte counts;Red cell distribution width;	chr5:128021834	chr5:127940426~128083172:-
TGCT	cis	rs6568686	0.577	rs174400	ENSG00000272356.1	RP5-1112D6.8	-4.05	9.06e-05	0.0427	-0.39	-0.34	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111601776	chr6:111309203~111313517:+
TGCT	cis	rs5758659	0.652	rs133326	ENSG00000182057.4	OGFRP1	4.05	9.06e-05	0.0427	0.25	0.34	Cognitive function;	chr22:42010881	chr22:42269753~42275196:+
TGCT	cis	rs5758659	0.652	rs133336	ENSG00000182057.4	OGFRP1	4.05	9.06e-05	0.0427	0.25	0.34	Cognitive function;	chr22:42020299	chr22:42269753~42275196:+
TGCT	cis	rs5758659	0.652	rs133340	ENSG00000182057.4	OGFRP1	-4.05	9.06e-05	0.0427	-0.25	-0.34	Cognitive function;	chr22:42021683	chr22:42269753~42275196:+
TGCT	cis	rs4919669	0.668	rs4919666	ENSG00000273108.1	RP11-416N2.4	-4.05	9.06e-05	0.0427	-0.47	-0.34	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102624272	chr10:103608619~103610050:+
TGCT	cis	rs4919669	0.668	rs7086898	ENSG00000273108.1	RP11-416N2.4	-4.05	9.06e-05	0.0427	-0.47	-0.34	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102626395	chr10:103608619~103610050:+
TGCT	cis	rs4919669	0.719	rs17114803	ENSG00000273108.1	RP11-416N2.4	-4.05	9.06e-05	0.0427	-0.47	-0.34	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102627177	chr10:103608619~103610050:+
TGCT	cis	rs7819412	0.74	rs11250119	ENSG00000269918.1	AF131215.9	-4.05	9.06e-05	0.0428	-0.34	-0.34	Triglycerides;	chr8:11179525	chr8:11104691~11106704:-
TGCT	cis	rs5758659	1	rs134873	ENSG00000270083.1	RP1-257I20.14	4.05	9.07e-05	0.0428	0.34	0.34	Cognitive function;	chr22:42261560	chr22:42089630~42090028:-
TGCT	cis	rs5758659	0.904	rs134877	ENSG00000270083.1	RP1-257I20.14	4.05	9.07e-05	0.0428	0.34	0.34	Cognitive function;	chr22:42266365	chr22:42089630~42090028:-
TGCT	cis	rs2337406	0.777	rs17112822	ENSG00000274576.2	IGHV2-70	-4.05	9.07e-05	0.0428	-0.53	-0.34	Alzheimer's disease (late onset);	chr14:106713390	chr14:106770577~106771020:-
TGCT	cis	rs6844153	1	rs74642474	ENSG00000240005.4	RP11-293A21.1	-4.05	9.07e-05	0.0428	-0.44	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26854979	chr4:26859806~26860599:-
TGCT	cis	rs2013441	1	rs1992562	ENSG00000230528.6	NOS2P3	4.05	9.07e-05	0.0428	0.34	0.34	Obesity-related traits;	chr17:20315480	chr17:20436337~20447249:+
TGCT	cis	rs4718428	0.576	rs12698546	ENSG00000272831.1	RP11-792A8.4	4.05	9.08e-05	0.0428	0.42	0.34	Corneal structure;	chr7:66801919	chr7:66739829~66740385:-
TGCT	cis	rs13053817	0.898	rs35847236	ENSG00000225465.8	RFPL1S	-4.05	9.08e-05	0.0428	-0.46	-0.34	Carotid atherosclerosis in HIV infection;	chr22:29470605	chr22:29436534~29478175:-
TGCT	cis	rs6741892	1	rs13010022	ENSG00000225402.1	AC010878.3	4.05	9.09e-05	0.0428	0.87	0.34	5-HTT brain serotonin transporter levels;	chr2:38682564	chr2:37816915~37817961:+
TGCT	cis	rs6741892	1	rs17576507	ENSG00000225402.1	AC010878.3	4.05	9.09e-05	0.0428	0.87	0.34	5-HTT brain serotonin transporter levels;	chr2:38682989	chr2:37816915~37817961:+
TGCT	cis	rs6741892	0.59	rs12469534	ENSG00000225402.1	AC010878.3	4.05	9.09e-05	0.0428	0.87	0.34	5-HTT brain serotonin transporter levels;	chr2:38684887	chr2:37816915~37817961:+
TGCT	cis	rs2524005	1	rs2524005	ENSG00000176998.4	HCG4	-4.05	9.09e-05	0.0428	-0.41	-0.34	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29791753~29792750:-
TGCT	cis	rs35955747	0.689	rs5997988	ENSG00000236132.1	CTA-440B3.1	4.05	9.09e-05	0.0429	0.34	0.34	Neutrophil count;Sum basophil neutrophil counts;	chr22:31442099	chr22:31816379~31817491:-
TGCT	cis	rs10129255	0.5	rs1024350	ENSG00000280411.1	IGHV1-69-2	-4.05	9.09e-05	0.0429	-0.34	-0.34	Kawasaki disease;	chr14:106685105	chr14:106762092~106762588:-
TGCT	cis	rs10129255	0.518	rs7143784	ENSG00000280411.1	IGHV1-69-2	-4.05	9.09e-05	0.0429	-0.34	-0.34	Kawasaki disease;	chr14:106687277	chr14:106762092~106762588:-
TGCT	cis	rs875971	1	rs11974219	ENSG00000232559.3	GS1-124K5.12	-4.05	9.1e-05	0.0429	-0.33	-0.34	Aortic root size;	chr7:66182423	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs11974264	ENSG00000232559.3	GS1-124K5.12	-4.05	9.1e-05	0.0429	-0.33	-0.34	Aortic root size;	chr7:66182595	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs1540651	ENSG00000232559.3	GS1-124K5.12	-4.05	9.1e-05	0.0429	-0.33	-0.34	Aortic root size;	chr7:66185134	chr7:66554588~66576923:-
TGCT	cis	rs875971	0.502	rs2946580	ENSG00000222364.1	RNU6-96P	4.05	9.1e-05	0.0429	0.44	0.34	Aortic root size;	chr7:66066855	chr7:66395191~66395286:+
TGCT	cis	rs7246967	0.673	rs59567211	ENSG00000198153.8	ZNF849P	4.05	9.1e-05	0.0429	0.55	0.34	Bronchopulmonary dysplasia;	chr19:22647080	chr19:22685167~22686732:+
TGCT	cis	rs4654899	0.772	rs10916892	ENSG00000236073.2	RP11-487E1.2	-4.05	9.11e-05	0.0429	-0.37	-0.34	Superior frontal gyrus grey matter volume;	chr1:20874832	chr1:21073639~21073753:-
TGCT	cis	rs10256972	0.967	rs1881122	ENSG00000226291.1	AC091729.8	-4.05	9.12e-05	0.0429	-0.35	-0.34	Endometriosis;Longevity;	chr7:1001310	chr7:1080863~1082178:+
TGCT	cis	rs4266144	0.563	rs61124401	ENSG00000244515.1	KRT18P34	-4.05	9.12e-05	0.0429	-0.37	-0.34	Coronary artery disease;	chr3:157123130	chr3:157162663~157163932:-
TGCT	cis	rs2739330	0.796	rs5760097	ENSG00000235689.1	AP000351.13	4.05	9.12e-05	0.0429	0.34	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:24006305~24008258:-
TGCT	cis	rs2739330	0.828	rs4822451	ENSG00000235689.1	AP000351.13	4.05	9.12e-05	0.0429	0.34	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:24006305~24008258:-
TGCT	cis	rs2739330	0.828	rs5760098	ENSG00000235689.1	AP000351.13	4.05	9.12e-05	0.0429	0.34	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:24006305~24008258:-
TGCT	cis	rs2739330	0.828	rs5760099	ENSG00000235689.1	AP000351.13	4.05	9.12e-05	0.0429	0.34	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:24006305~24008258:-
TGCT	cis	rs2243480	1	rs4718334	ENSG00000222364.1	RNU6-96P	4.05	9.12e-05	0.0429	0.64	0.34	Diabetic kidney disease;	chr7:66324467	chr7:66395191~66395286:+
TGCT	cis	rs2316527	1	rs79697169	ENSG00000228806.1	AC092628.3	4.05	9.12e-05	0.0429	0.37	0.34	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr7:154836611	chr7:155106400~155106651:+
TGCT	cis	rs10971721	0.731	rs72727392	ENSG00000230074.1	RP11-195F19.9	-4.05	9.12e-05	0.0429	-0.52	-0.34	Body mass index;	chr9:33988921	chr9:34665665~34681298:+
TGCT	cis	rs1618992	0.729	rs1995494	ENSG00000265994.1	RP11-510D21.1	4.05	9.12e-05	0.0429	0.35	0.34	Gut microbiome composition (summer and winter);	chr18:28619397	chr18:28785068~28789260:+
TGCT	cis	rs733592	0.723	rs10875766	ENSG00000275228.1	RP11-370I10.10	-4.05	9.13e-05	0.0429	-0.4	-0.34	Plateletcrit;	chr12:48199797	chr12:48327942~48328472:-
TGCT	cis	rs7208859	0.614	rs7216394	ENSG00000263531.1	RP13-753N3.1	-4.05	9.13e-05	0.043	-0.59	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30498738	chr17:30863921~30864940:-
TGCT	cis	rs7208859	0.614	rs4794874	ENSG00000263531.1	RP13-753N3.1	-4.05	9.13e-05	0.043	-0.59	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30514300	chr17:30863921~30864940:-
TGCT	cis	rs2316527	1	rs61027511	ENSG00000228806.1	AC092628.3	4.05	9.13e-05	0.043	0.37	0.34	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr7:154832623	chr7:155106400~155106651:+
TGCT	cis	rs875971	0.597	rs11771318	ENSG00000272831.1	RP11-792A8.4	-4.05	9.13e-05	0.043	-0.35	-0.34	Aortic root size;	chr7:66597493	chr7:66739829~66740385:-
TGCT	cis	rs6750795	0.502	rs11685196	ENSG00000181798.2	LINC00471	-4.04	9.14e-05	0.043	-0.3	-0.34	Height;	chr2:231516587	chr2:231508426~231514339:-
TGCT	cis	rs2833693	0.572	rs11088213	ENSG00000261610.1	AP000265.1	4.04	9.14e-05	0.043	0.41	0.34	Temperament;	chr21:32241398	chr21:32259804~32261585:-
TGCT	cis	rs228614	0.51	rs223410	ENSG00000230069.3	LRRC37A15P	-4.04	9.14e-05	0.043	-0.3	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102813568	chr4:102727274~102730721:-
TGCT	cis	rs4927850	0.501	rs9881504	ENSG00000231464.1	AC024937.4	4.04	9.14e-05	0.043	0.34	0.34	Pancreatic cancer;	chr3:195929743	chr3:195996738~195998233:+
TGCT	cis	rs2285002	0.516	rs438035	ENSG00000276116.2	FUT8-AS1	4.04	9.14e-05	0.043	0.4	0.34	Red cell distribution width;	chr14:64835260	chr14:65411170~65412690:-
TGCT	cis	rs5758659	0.652	rs5751195	ENSG00000182057.4	OGFRP1	4.04	9.14e-05	0.043	0.25	0.34	Cognitive function;	chr22:41983997	chr22:42269753~42275196:+
TGCT	cis	rs5758659	0.569	rs133293	ENSG00000182057.4	OGFRP1	4.04	9.14e-05	0.043	0.25	0.34	Cognitive function;	chr22:41986793	chr22:42269753~42275196:+
TGCT	cis	rs5758659	0.652	rs133301	ENSG00000182057.4	OGFRP1	4.04	9.14e-05	0.043	0.25	0.34	Cognitive function;	chr22:41994089	chr22:42269753~42275196:+
TGCT	cis	rs5758659	0.652	rs133305	ENSG00000182057.4	OGFRP1	4.04	9.14e-05	0.043	0.25	0.34	Cognitive function;	chr22:41999956	chr22:42269753~42275196:+
TGCT	cis	rs5758659	0.682	rs133306	ENSG00000182057.4	OGFRP1	4.04	9.14e-05	0.043	0.25	0.34	Cognitive function;	chr22:42000146	chr22:42269753~42275196:+
TGCT	cis	rs5758659	0.519	rs133307	ENSG00000182057.4	OGFRP1	4.04	9.14e-05	0.043	0.25	0.34	Cognitive function;	chr22:42000564	chr22:42269753~42275196:+
TGCT	cis	rs5758659	0.652	rs5758537	ENSG00000182057.4	OGFRP1	4.04	9.14e-05	0.043	0.25	0.34	Cognitive function;	chr22:42001038	chr22:42269753~42275196:+
TGCT	cis	rs5758659	0.622	rs129856	ENSG00000182057.4	OGFRP1	4.04	9.14e-05	0.043	0.25	0.34	Cognitive function;	chr22:42003392	chr22:42269753~42275196:+
TGCT	cis	rs5758659	0.652	rs129857	ENSG00000182057.4	OGFRP1	-4.04	9.14e-05	0.043	-0.25	-0.34	Cognitive function;	chr22:42003682	chr22:42269753~42275196:+
TGCT	cis	rs5758659	0.652	rs133313	ENSG00000182057.4	OGFRP1	4.04	9.14e-05	0.043	0.25	0.34	Cognitive function;	chr22:42005745	chr22:42269753~42275196:+
TGCT	cis	rs5758659	0.652	rs133314	ENSG00000182057.4	OGFRP1	4.04	9.14e-05	0.043	0.25	0.34	Cognitive function;	chr22:42005837	chr22:42269753~42275196:+
TGCT	cis	rs5758659	0.652	rs133321	ENSG00000182057.4	OGFRP1	4.04	9.14e-05	0.043	0.25	0.34	Cognitive function;	chr22:42009318	chr22:42269753~42275196:+
TGCT	cis	rs5758659	0.652	rs133323	ENSG00000182057.4	OGFRP1	4.04	9.14e-05	0.043	0.25	0.34	Cognitive function;	chr22:42009918	chr22:42269753~42275196:+
TGCT	cis	rs5758659	0.652	rs133324	ENSG00000182057.4	OGFRP1	4.04	9.14e-05	0.043	0.25	0.34	Cognitive function;	chr22:42010367	chr22:42269753~42275196:+
TGCT	cis	rs5758659	0.652	rs133327	ENSG00000182057.4	OGFRP1	4.04	9.14e-05	0.043	0.25	0.34	Cognitive function;	chr22:42011685	chr22:42269753~42275196:+
TGCT	cis	rs5758659	0.652	rs133330	ENSG00000182057.4	OGFRP1	4.04	9.14e-05	0.043	0.25	0.34	Cognitive function;	chr22:42013452	chr22:42269753~42275196:+
TGCT	cis	rs2153535	0.58	rs4960433	ENSG00000230939.1	RP11-314C16.1	-4.04	9.15e-05	0.043	-0.33	-0.34	Motion sickness;	chr6:8523464	chr6:8784178~8785445:+
TGCT	cis	rs2348418	0.733	rs7137557	ENSG00000273989.1	RP11-425D17.2	-4.04	9.15e-05	0.043	-0.33	-0.34	Lung function (FEV1);Lung function (FVC);	chr12:28221259	chr12:28236227~28236828:+
TGCT	cis	rs67311347	0.503	rs11719968	ENSG00000223797.4	ENTPD3-AS1	4.04	9.15e-05	0.043	0.34	0.34	Renal cell carcinoma;	chr3:40200109	chr3:40313802~40453329:-
TGCT	cis	rs10971721	0.584	rs10971940	ENSG00000230074.1	RP11-195F19.9	-4.04	9.15e-05	0.043	-0.5	-0.34	Body mass index;	chr9:34127213	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.584	rs72731226	ENSG00000230074.1	RP11-195F19.9	-4.04	9.15e-05	0.043	-0.5	-0.34	Body mass index;	chr9:34128832	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.584	rs10971944	ENSG00000230074.1	RP11-195F19.9	-4.04	9.15e-05	0.043	-0.5	-0.34	Body mass index;	chr9:34129008	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.631	rs10971945	ENSG00000230074.1	RP11-195F19.9	-4.04	9.15e-05	0.043	-0.5	-0.34	Body mass index;	chr9:34129397	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.631	rs74450404	ENSG00000230074.1	RP11-195F19.9	-4.04	9.15e-05	0.043	-0.5	-0.34	Body mass index;	chr9:34134666	chr9:34665665~34681298:+
TGCT	cis	rs1912483	0.505	rs11079772	ENSG00000228782.6	CTD-2026D20.3	-4.04	9.15e-05	0.043	-0.43	-0.34	Coronary artery disease;	chr17:47316373	chr17:47450568~47492492:-
TGCT	cis	rs7208859	0.614	rs73265646	ENSG00000266490.1	CTD-2349P21.9	4.04	9.15e-05	0.043	0.36	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30792372~30792833:+
TGCT	cis	rs7208859	0.623	rs58908911	ENSG00000266490.1	CTD-2349P21.9	4.04	9.15e-05	0.043	0.36	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30792372~30792833:+
TGCT	cis	rs2581828	0.896	rs12637287	ENSG00000242142.1	SERBP1P3	4.04	9.16e-05	0.0431	0.32	0.34	Crohn's disease;	chr3:53105425	chr3:53064283~53065091:-
TGCT	cis	rs11098499	0.863	rs6534139	ENSG00000260091.1	RP11-33B1.4	4.04	9.16e-05	0.0431	0.21	0.34	Corneal astigmatism;	chr4:119528301	chr4:119409333~119410233:+
TGCT	cis	rs7523273	0.565	rs1998539	ENSG00000203709.8	C1orf132	4.04	9.17e-05	0.0431	0.27	0.34	Schizophrenia;	chr1:207713251	chr1:207801518~207869150:-
TGCT	cis	rs4760786	0.607	rs1798097	ENSG00000257454.1	CTD-2021H9.2	4.04	9.18e-05	0.0431	0.4	0.34	Monobrow;	chr12:71125820	chr12:71034122~71104526:-
TGCT	cis	rs904251	0.704	rs2776873	ENSG00000227920.2	RP1-153P14.5	-4.04	9.18e-05	0.0431	-0.41	-0.34	Cognitive performance;	chr6:37515366	chr6:37545145~37550860:+
TGCT	cis	rs8077577	0.747	rs11078415	ENSG00000186831.10	KRT17P2	-4.04	9.18e-05	0.0432	-0.48	-0.34	Obesity-related traits;	chr17:18352184	chr17:18426861~18431848:+
TGCT	cis	rs5758659	0.7	rs739294	ENSG00000182057.4	OGFRP1	4.04	9.18e-05	0.0432	0.24	0.34	Cognitive function;	chr22:41985722	chr22:42269753~42275196:+
TGCT	cis	rs4835473	0.932	rs10025527	ENSG00000251600.4	RP11-673E1.1	4.04	9.2e-05	0.0432	0.37	0.34	Immature fraction of reticulocytes;	chr4:143968391	chr4:143912331~143982454:+
TGCT	cis	rs4660214	0.666	rs598415	ENSG00000182109.6	RP11-69E11.4	4.04	9.21e-05	0.0433	0.35	0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39366735	chr1:39522280~39546187:-
TGCT	cis	rs853679	0.517	rs6932109	ENSG00000187763.3	OR2B7P	-4.04	9.22e-05	0.0433	-0.34	-0.34	Depression;	chr6:28110525	chr6:28046434~28047367:+
TGCT	cis	rs4242434	0.854	rs13258100	ENSG00000254064.1	CTD-2530N21.4	-4.04	9.22e-05	0.0433	-0.2	-0.34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22593603	chr8:22254576~22275162:-
TGCT	cis	rs6604026	0.922	rs35183060	ENSG00000223787.2	RP4-593M8.1	-4.04	9.23e-05	0.0434	-0.44	-0.34	Multiple sclerosis;	chr1:92881371	chr1:92580476~92580821:-
TGCT	cis	rs1850744	1	rs1533615	ENSG00000251624.1	UNC93B7	-4.04	9.25e-05	0.0434	-0.64	-0.34	Economic and political preferences;	chr4:9802900	chr4:9493736~9498066:+
TGCT	cis	rs7786765	0.511	rs1108233	ENSG00000234695.1	AC002076.10	-4.04	9.25e-05	0.0434	-0.39	-0.34	Body mass index;	chr7:93461926	chr7:93890913~93893601:+
TGCT	cis	rs17507216	0.718	rs28587782	ENSG00000255769.6	GOLGA2P10	-4.04	9.25e-05	0.0434	-0.45	-0.34	Excessive daytime sleepiness;	chr15:82576881	chr15:82472993~82513950:-
TGCT	cis	rs17507216	0.718	rs72751657	ENSG00000255769.6	GOLGA2P10	-4.04	9.25e-05	0.0434	-0.45	-0.34	Excessive daytime sleepiness;	chr15:82581259	chr15:82472993~82513950:-
TGCT	cis	rs17507216	0.718	rs72751662	ENSG00000255769.6	GOLGA2P10	-4.04	9.25e-05	0.0434	-0.45	-0.34	Excessive daytime sleepiness;	chr15:82594705	chr15:82472993~82513950:-
TGCT	cis	rs17507216	0.718	rs72751675	ENSG00000255769.6	GOLGA2P10	-4.04	9.25e-05	0.0434	-0.45	-0.34	Excessive daytime sleepiness;	chr15:82630452	chr15:82472993~82513950:-
TGCT	cis	rs17507216	0.718	rs7165690	ENSG00000255769.6	GOLGA2P10	-4.04	9.25e-05	0.0434	-0.45	-0.34	Excessive daytime sleepiness;	chr15:82654804	chr15:82472993~82513950:-
TGCT	cis	rs8141529	0.673	rs132548	ENSG00000226471.5	CTA-292E10.6	4.04	9.25e-05	0.0434	0.38	0.34	Lymphocyte counts;	chr22:28921571	chr22:28800683~28848559:+
TGCT	cis	rs228614	0.51	rs223405	ENSG00000230069.3	LRRC37A15P	-4.04	9.25e-05	0.0434	-0.3	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102815894	chr4:102727274~102730721:-
TGCT	cis	rs7246967	0.866	rs12981220	ENSG00000268541.1	VN1R88P	4.04	9.27e-05	0.0434	0.38	0.34	Bronchopulmonary dysplasia;	chr19:22838598	chr19:22861303~22861594:+
TGCT	cis	rs7829975	0.564	rs2976855	ENSG00000254340.1	RP11-10A14.3	4.04	9.27e-05	0.0434	0.33	0.34	Mood instability;	chr8:8444284	chr8:9141424~9145435:+
TGCT	cis	rs1865760	0.865	rs1541987	ENSG00000217159.2	LARP1P1	4.04	9.27e-05	0.0434	0.39	0.34	Height;	chr6:25950169	chr6:26164072~26164363:+
TGCT	cis	rs6510489	1	rs10410228	ENSG00000267439.1	AC002398.11	4.04	9.27e-05	0.0434	0.47	0.34	Bipolar disorder;	chr19:35488794	chr19:35747057~35753415:-
TGCT	cis	rs2273156	0.57	rs28399702	ENSG00000226677.3	IGBP1P1	-4.04	9.27e-05	0.0434	-0.46	-0.34	Immunoglobulin light chain (AL) amyloidosis;	chr14:35156011	chr14:34939324~34940332:+
TGCT	cis	rs2153535	0.623	rs2152346	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8454419	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs6921036	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8455167	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.562	rs6901765	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8455203	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.601	rs9502715	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8455476	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs6926759	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8455943	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs6912193	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8456073	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs6912374	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8456190	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.541	rs6908504	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8456545	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs7755284	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8457246	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs7769020	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8457491	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9392220	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8457713	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9379206	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8457788	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.541	rs9379207	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8457953	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9393016	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8458340	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs4960421	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8459059	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs4960422	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8459076	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs7742794	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8459490	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9505448	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8459571	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1832101	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8459944	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1119690	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8460427	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1119689	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8460521	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1119688	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8460617	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs6597325	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8460820	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs6918391	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8460945	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.521	rs6939827	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8461127	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.541	rs6923558	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8461234	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9379210	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8461695	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9393019	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8461858	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1577470	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8462193	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9378551	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8463511	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9378552	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8463515	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.562	rs9379211	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8463694	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9406158	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8463919	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1319169	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8464223	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs965706	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8464475	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1335636	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8464814	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1335637	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8464868	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs986060	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8465195	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9393021	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8465890	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9406161	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8465911	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9406162	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8465963	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9405390	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8465976	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9405391	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8466315	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9393022	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8466355	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9406163	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8466409	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.504	rs9405393	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8467199	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.541	rs9392222	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8467416	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.541	rs6932434	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8467446	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1034273	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8467912	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs2184584	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8468174	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.541	rs9328471	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8468609	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.541	rs7774752	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8468745	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1034272	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8469102	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9505450	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8469669	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.601	rs9505451	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8469717	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9393023	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8469761	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9406164	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8469815	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs7341201	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8470037	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs7341206	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8470256	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs7341381	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8470304	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs7341382	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8470316	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs7341383	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8470401	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.504	rs9328472	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8470615	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1414344	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8471132	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1414345	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8471304	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1414346	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8471341	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1414348	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8471707	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1414349	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8472057	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1414350	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8472098	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.526	rs7748404	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8472267	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9392224	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8472381	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.542	rs9378553	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8472399	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.601	rs1855768	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8472736	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1855769	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8472862	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1932279	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8473420	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1932280	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8473421	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1932281	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8473532	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs6900007	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8473802	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs2184585	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8473935	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs2184586	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8473949	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs2152347	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8474048	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs2152348	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8474068	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9379213	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8474712	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs6902001	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8476822	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs4960423	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8476977	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1932282	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8477097	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1932283	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8477428	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1932284	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8477461	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1932285	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8477486	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs7775909	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8477545	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9505454	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8478299	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9505455	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8478389	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.541	rs9505456	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8478768	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9505457	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8478909	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9505458	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8478982	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9379215	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8480992	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9379216	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8481002	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs7450817	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8481188	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.56	rs2210798	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8481289	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs2225765	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8481552	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs6597326	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8481786	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs6597327	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8481924	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs7763190	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8483964	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.546	rs1335640	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8485092	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.541	rs1414352	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8485314	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.541	rs1414353	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8485409	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1577471	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8485672	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1577472	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8485982	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.542	rs1120393	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8486657	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1120392	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8486820	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1335641	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8487627	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1335643	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8487788	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.525	rs1335644	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8487808	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9378554	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8488235	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.563	rs4428546	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8490143	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9393025	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8490385	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1414340	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8490906	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1335628	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8491509	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.505	rs1335629	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8491630	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs6597330	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8491843	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs763376	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8492543	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs6941771	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8494219	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs6937186	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8494260	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs7743995	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8495979	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs2143357	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8496963	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9406167	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8502619	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs4140586	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8502959	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.601	rs4140585	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8503065	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs6597332	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8504515	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs6597334	ENSG00000230939.1	RP11-314C16.1	-4.04	9.27e-05	0.0434	-0.33	-0.34	Motion sickness;	chr6:8504546	chr6:8784178~8785445:+
TGCT	cis	rs4820539	0.966	rs2267005	ENSG00000218537.1	MIF-AS1	4.04	9.27e-05	0.0434	0.41	0.34	Bone mineral density;	chr22:23119536	chr22:23894426~23898930:-
TGCT	cis	rs1250259	0.542	rs2372545	ENSG00000225166.1	AC012462.2	-4.04	9.28e-05	0.0434	-0.33	-0.34	Coronary artery disease;Pulse pressure;	chr2:215408902	chr2:215453707~215463871:+
TGCT	cis	rs4242434	0.597	rs11985023	ENSG00000253200.1	RP11-582J16.5	-4.04	9.28e-05	0.0434	-0.19	-0.34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22673950	chr8:22613908~22616657:-
TGCT	cis	rs733592	0.56	rs2158515	ENSG00000258273.1	RP11-370I10.4	4.04	9.28e-05	0.0434	0.42	0.34	Plateletcrit;	chr12:48113885	chr12:48333755~48333901:-
TGCT	cis	rs2408955	0.522	rs11168408	ENSG00000258273.1	RP11-370I10.4	4.04	9.28e-05	0.0435	0.4	0.34	Glycated hemoglobin levels;	chr12:48104544	chr12:48333755~48333901:-
TGCT	cis	rs748404	0.697	rs546722	ENSG00000205771.5	CATSPER2P1	-4.04	9.28e-05	0.0435	-0.4	-0.34	Lung cancer;	chr15:43288621	chr15:43726918~43747094:-
TGCT	cis	rs7027203	0.576	rs7851269	ENSG00000231990.1	RP11-53B5.1	-4.04	9.29e-05	0.0435	-0.28	-0.34	DNA methylation (variation);	chr9:93778248	chr9:93857083~93858333:+
TGCT	cis	rs3096299	0.582	rs12935119	ENSG00000274627.1	RP11-104N10.2	4.04	9.29e-05	0.0435	0.36	0.34	Multiple myeloma (IgH translocation);	chr16:89476466	chr16:89516797~89522217:+
TGCT	cis	rs11054731	0.744	rs10845507	ENSG00000247498.8	RP11-392P7.6	4.04	9.29e-05	0.0435	0.33	0.34	Coronary artery calcification;	chr12:12285969	chr12:12927726~12984645:+
TGCT	cis	rs228614	0.536	rs223420	ENSG00000230069.3	LRRC37A15P	-4.04	9.29e-05	0.0435	-0.3	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102806853	chr4:102727274~102730721:-
TGCT	cis	rs228614	0.536	rs223419	ENSG00000230069.3	LRRC37A15P	-4.04	9.29e-05	0.0435	-0.3	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102808586	chr4:102727274~102730721:-
TGCT	cis	rs7601234	0.64	rs2551809	ENSG00000229066.1	AC096649.3	-4.04	9.31e-05	0.0436	-0.23	-0.34	Amyotrophic lateral sclerosis (sporadic);	chr2:176112145	chr2:175257250~175454640:+
TGCT	cis	rs733592	0.524	rs10875744	ENSG00000258273.1	RP11-370I10.4	-4.04	9.31e-05	0.0436	-0.42	-0.34	Plateletcrit;	chr12:48104657	chr12:48333755~48333901:-
TGCT	cis	rs733592	0.524	rs10875741	ENSG00000258273.1	RP11-370I10.4	4.04	9.31e-05	0.0436	0.42	0.34	Plateletcrit;	chr12:48099139	chr12:48333755~48333901:-
TGCT	cis	rs733592	0.507	rs7304428	ENSG00000258273.1	RP11-370I10.4	4.04	9.31e-05	0.0436	0.42	0.34	Plateletcrit;	chr12:48100492	chr12:48333755~48333901:-
TGCT	cis	rs10826995	0.922	rs16932785	ENSG00000239731.3	RN7SL825P	-4.04	9.31e-05	0.0436	-0.35	-0.34	Pulse pressure;	chr10:31925194	chr10:31992087~31992381:-
TGCT	cis	rs10826995	0.961	rs11599690	ENSG00000239731.3	RN7SL825P	-4.04	9.31e-05	0.0436	-0.35	-0.34	Pulse pressure;	chr10:31929671	chr10:31992087~31992381:-
TGCT	cis	rs901683	1	rs10508896	ENSG00000264204.2	AGAP7P	-4.04	9.31e-05	0.0436	-0.78	-0.34	Mean corpuscular volume;Red blood cell traits;	chr10:45535195	chr10:46109621~46131358:+
TGCT	cis	rs875971	1	rs55962648	ENSG00000232559.3	GS1-124K5.12	-4.04	9.31e-05	0.0436	-0.33	-0.34	Aortic root size;	chr7:66160764	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs11971949	ENSG00000232559.3	GS1-124K5.12	-4.04	9.31e-05	0.0436	-0.33	-0.34	Aortic root size;	chr7:66161027	chr7:66554588~66576923:-
TGCT	cis	rs875971	1	rs2420168	ENSG00000232559.3	GS1-124K5.12	-4.04	9.31e-05	0.0436	-0.33	-0.34	Aortic root size;	chr7:66165644	chr7:66554588~66576923:-
TGCT	cis	rs35851103	0.6	rs4841662	ENSG00000255556.2	RP11-351I21.6	-4.04	9.31e-05	0.0436	-0.33	-0.34	Neuroticism;	chr8:11986249	chr8:12378679~12380265:-
TGCT	cis	rs2285002	0.516	rs229619	ENSG00000276116.2	FUT8-AS1	4.04	9.32e-05	0.0436	0.37	0.34	Red cell distribution width;	chr14:64823528	chr14:65411170~65412690:-
TGCT	cis	rs2285002	0.516	rs229618	ENSG00000276116.2	FUT8-AS1	4.04	9.32e-05	0.0436	0.37	0.34	Red cell distribution width;	chr14:64823543	chr14:65411170~65412690:-
TGCT	cis	rs11168618	0.715	rs35367885	ENSG00000240399.1	RP1-228P16.1	4.04	9.32e-05	0.0436	0.33	0.34	Adiponectin levels;	chr12:48525877	chr12:48054813~48055591:-
TGCT	cis	rs3956705	0.866	rs71532543	ENSG00000205763.12	RP9P	4.04	9.33e-05	0.0436	0.19	0.34	Red cell distribution width;	chr7:32959298	chr7:32916815~32943176:-
TGCT	cis	rs2439831	0.867	rs2447196	ENSG00000205771.5	CATSPER2P1	4.04	9.33e-05	0.0436	0.56	0.34	Lung cancer in ever smokers;	chr15:43601620	chr15:43726918~43747094:-
TGCT	cis	rs935334	0.542	rs2543380	ENSG00000258454.1	RP11-361H10.3	4.04	9.33e-05	0.0436	0.43	0.34	Blood pressure;	chr14:76153403	chr14:76235817~76263474:+
TGCT	cis	rs4760786	0.607	rs1580713	ENSG00000257454.1	CTD-2021H9.2	4.04	9.33e-05	0.0436	0.4	0.34	Monobrow;	chr12:71106386	chr12:71034122~71104526:-
TGCT	cis	rs4760786	0.607	rs1796329	ENSG00000257454.1	CTD-2021H9.2	4.04	9.33e-05	0.0436	0.4	0.34	Monobrow;	chr12:71116056	chr12:71034122~71104526:-
TGCT	cis	rs786425	0.682	rs34586028	ENSG00000247373.3	RP11-486O12.2	4.04	9.34e-05	0.0437	0.43	0.34	Pubertal anthropometrics;	chr12:123702535	chr12:123575891~123585115:-
TGCT	cis	rs11168618	0.626	rs2731107	ENSG00000240399.1	RP1-228P16.1	-4.04	9.34e-05	0.0437	-0.31	-0.34	Adiponectin levels;	chr12:48493376	chr12:48054813~48055591:-
TGCT	cis	rs875971	1	rs2220626	ENSG00000237310.1	GS1-124K5.4	-4.04	9.34e-05	0.0437	-0.38	-0.34	Aortic root size;	chr7:66081075	chr7:66493706~66495474:+
TGCT	cis	rs875971	0.964	rs697969	ENSG00000237310.1	GS1-124K5.4	-4.04	9.34e-05	0.0437	-0.38	-0.34	Aortic root size;	chr7:66093491	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs697970	ENSG00000237310.1	GS1-124K5.4	-4.04	9.34e-05	0.0437	-0.38	-0.34	Aortic root size;	chr7:66095065	chr7:66493706~66495474:+
TGCT	cis	rs875971	1	rs1182882	ENSG00000237310.1	GS1-124K5.4	-4.04	9.34e-05	0.0437	-0.38	-0.34	Aortic root size;	chr7:66097076	chr7:66493706~66495474:+
TGCT	cis	rs7829975	0.777	rs560544	ENSG00000253893.2	FAM85B	4.04	9.36e-05	0.0437	0.45	0.34	Mood instability;	chr8:8779919	chr8:8167819~8226614:-
TGCT	cis	rs2237579	0.935	rs3802050	ENSG00000234695.1	AC002076.10	4.04	9.36e-05	0.0437	0.4	0.34	Body mass index;	chr7:93464505	chr7:93890913~93893601:+
TGCT	cis	rs7780752	0.502	rs10250228	ENSG00000234695.1	AC002076.10	4.04	9.36e-05	0.0437	0.4	0.34	Birth weight;	chr7:93471768	chr7:93890913~93893601:+
TGCT	cis	rs7786765	0.509	rs10247699	ENSG00000234695.1	AC002076.10	4.04	9.36e-05	0.0437	0.4	0.34	Body mass index;	chr7:93474989	chr7:93890913~93893601:+
TGCT	cis	rs1867631	0.876	rs10889637	ENSG00000223263.1	RNU6-387P	-4.04	9.36e-05	0.0437	-0.38	-0.34	Menopause (age at onset);	chr1:66631782	chr1:67417214~67417318:+
TGCT	cis	rs2439831	1	rs690316	ENSG00000205771.5	CATSPER2P1	-4.04	9.37e-05	0.0438	-0.55	-0.34	Lung cancer in ever smokers;	chr15:43445682	chr15:43726918~43747094:-
TGCT	cis	rs7523273	0.606	rs2796263	ENSG00000203709.8	C1orf132	4.04	9.37e-05	0.0438	0.29	0.34	Schizophrenia;	chr1:207742633	chr1:207801518~207869150:-
TGCT	cis	rs7523273	0.606	rs1830764	ENSG00000203709.8	C1orf132	4.04	9.37e-05	0.0438	0.29	0.34	Schizophrenia;	chr1:207743707	chr1:207801518~207869150:-
TGCT	cis	rs7523273	0.606	rs2761433	ENSG00000203709.8	C1orf132	4.04	9.37e-05	0.0438	0.29	0.34	Schizophrenia;	chr1:207744016	chr1:207801518~207869150:-
TGCT	cis	rs13108904	0.901	rs1316394	ENSG00000253399.1	AC078852.2	-4.04	9.37e-05	0.0438	-0.39	-0.34	Obesity-related traits;	chr4:1322032	chr4:1358479~1359461:+
TGCT	cis	rs13108904	0.934	rs13115173	ENSG00000253399.1	AC078852.2	-4.04	9.37e-05	0.0438	-0.39	-0.34	Obesity-related traits;	chr4:1323036	chr4:1358479~1359461:+
TGCT	cis	rs13108904	0.901	rs1316393	ENSG00000253399.1	AC078852.2	4.04	9.37e-05	0.0438	0.39	0.34	Obesity-related traits;	chr4:1321831	chr4:1358479~1359461:+
TGCT	cis	rs2439831	1	rs2439831	ENSG00000205771.5	CATSPER2P1	-4.04	9.37e-05	0.0438	-0.56	-0.34	Lung cancer in ever smokers;	chr15:43492277	chr15:43726918~43747094:-
TGCT	cis	rs2725236	0.638	rs13104358	ENSG00000202000.1	RNU1-36P	4.04	9.37e-05	0.0438	0.33	0.34	Caffeine consumption;	chr4:88007045	chr4:88000237~88000401:+
TGCT	cis	rs2725236	0.638	rs13110188	ENSG00000202000.1	RNU1-36P	4.04	9.37e-05	0.0438	0.33	0.34	Caffeine consumption;	chr4:88007247	chr4:88000237~88000401:+
TGCT	cis	rs1850744	0.702	rs7434744	ENSG00000250884.1	OR7E85P	4.04	9.37e-05	0.0438	0.65	0.34	Economic and political preferences;	chr4:9671064	chr4:9483718~9484702:+
TGCT	cis	rs755249	0.883	rs12035330	ENSG00000182109.6	RP11-69E11.4	4.04	9.38e-05	0.0438	0.33	0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39535388	chr1:39522280~39546187:-
TGCT	cis	rs73607972	0.696	rs7197014	ENSG00000279344.1	RP11-44F14.7	4.04	9.4e-05	0.0439	0.4	0.34	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53525165	chr16:53478957~53481550:-
TGCT	cis	rs7824557	0.564	rs34964435	ENSG00000269918.1	AF131215.9	-4.04	9.4e-05	0.0439	-0.33	-0.34	Retinal vascular caliber;	chr8:11372697	chr8:11104691~11106704:-
TGCT	cis	rs76878669	0.793	rs10791867	ENSG00000254756.1	RP11-867G23.12	4.04	9.4e-05	0.0439	0.4	0.34	Educational attainment (years of education);	chr11:66313740	chr11:66334494~66339875:+
TGCT	cis	rs227275	0.554	rs223363	ENSG00000230069.3	LRRC37A15P	-4.04	9.41e-05	0.0439	-0.3	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102846182	chr4:102727274~102730721:-
TGCT	cis	rs9880211	0.898	rs73231903	ENSG00000239213.4	NCK1-AS1	4.04	9.41e-05	0.0439	0.36	0.34	Height;Body mass index;	chr3:136842783	chr3:136841726~136862054:-
TGCT	cis	rs2243480	0.901	rs2949697	ENSG00000164669.11	INTS4P1	4.04	9.41e-05	0.0439	0.56	0.34	Diabetic kidney disease;	chr7:65999249	chr7:65141225~65234216:+
TGCT	cis	rs62038064	0.675	rs10492909	ENSG00000278058.1	RP11-70D24.2	4.04	9.42e-05	0.0439	0.24	0.34	Post bronchodilator FEV1/FVC ratio;	chr16:78889177	chr16:79605802~79606605:+
TGCT	cis	rs12497850	0.764	rs6784111	ENSG00000226913.1	BSN-AS2	-4.04	9.42e-05	0.0439	-0.28	-0.34	Parkinson's disease;	chr3:49141413	chr3:49549306~49554366:-
TGCT	cis	rs12497850	0.864	rs12493001	ENSG00000226913.1	BSN-AS2	-4.04	9.42e-05	0.0439	-0.28	-0.34	Parkinson's disease;	chr3:49144452	chr3:49549306~49554366:-
TGCT	cis	rs12497850	0.829	rs12636030	ENSG00000226913.1	BSN-AS2	-4.04	9.42e-05	0.0439	-0.28	-0.34	Parkinson's disease;	chr3:49144804	chr3:49549306~49554366:-
TGCT	cis	rs748404	0.666	rs34178146	ENSG00000205771.5	CATSPER2P1	-4.04	9.43e-05	0.044	-0.5	-0.34	Lung cancer;	chr15:43384406	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.626	rs62021176	ENSG00000205771.5	CATSPER2P1	-4.04	9.43e-05	0.044	-0.5	-0.34	Lung cancer;	chr15:43388014	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.666	rs35158584	ENSG00000205771.5	CATSPER2P1	-4.04	9.43e-05	0.044	-0.5	-0.34	Lung cancer;	chr15:43392876	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.666	rs16957680	ENSG00000205771.5	CATSPER2P1	-4.04	9.43e-05	0.044	-0.5	-0.34	Lung cancer;	chr15:43396207	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.666	rs7180812	ENSG00000205771.5	CATSPER2P1	-4.04	9.43e-05	0.044	-0.5	-0.34	Lung cancer;	chr15:43403033	chr15:43726918~43747094:-
TGCT	cis	rs12025262	0.546	rs10754539	ENSG00000227671.4	RP11-488L18.4	-4.04	9.43e-05	0.044	-0.18	-0.34	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr1:247202128	chr1:247189851~247210856:-
TGCT	cis	rs1707322	1	rs4660334	ENSG00000280836.1	AL355480.1	-4.04	9.43e-05	0.044	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45996454	chr1:45581219~45581321:-
TGCT	cis	rs3808502	0.527	rs4410870	ENSG00000269918.1	AF131215.9	-4.04	9.43e-05	0.044	-0.35	-0.34	Neuroticism;	chr8:11298611	chr8:11104691~11106704:-
TGCT	cis	rs4835473	0.797	rs34585546	ENSG00000251600.4	RP11-673E1.1	-4.04	9.44e-05	0.044	-0.36	-0.34	Immature fraction of reticulocytes;	chr4:143680693	chr4:143912331~143982454:+
TGCT	cis	rs10129255	0.5	rs4774189	ENSG00000280411.1	IGHV1-69-2	-4.04	9.44e-05	0.044	-0.34	-0.34	Kawasaki disease;	chr14:106768275	chr14:106762092~106762588:-
TGCT	cis	rs35851103	0.507	rs6601649	ENSG00000255052.4	FAM66D	4.04	9.45e-05	0.044	0.34	0.34	Neuroticism;	chr8:11999808	chr8:12115782~12177550:+
TGCT	cis	rs7819412	0.634	rs6987767	ENSG00000255310.2	AF131215.2	4.04	9.45e-05	0.044	0.26	0.34	Triglycerides;	chr8:11052556	chr8:11107788~11109726:-
TGCT	cis	rs2153535	0.601	rs9502719	ENSG00000230939.1	RP11-314C16.1	-4.04	9.45e-05	0.044	-0.33	-0.34	Motion sickness;	chr6:8540799	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.547	rs9502720	ENSG00000230939.1	RP11-314C16.1	-4.04	9.45e-05	0.044	-0.33	-0.34	Motion sickness;	chr6:8541129	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.584	rs9502721	ENSG00000230939.1	RP11-314C16.1	-4.04	9.45e-05	0.044	-0.33	-0.34	Motion sickness;	chr6:8541146	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.607	rs9502722	ENSG00000230939.1	RP11-314C16.1	-4.04	9.45e-05	0.044	-0.33	-0.34	Motion sickness;	chr6:8541250	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.584	rs9502723	ENSG00000230939.1	RP11-314C16.1	-4.04	9.45e-05	0.044	-0.33	-0.34	Motion sickness;	chr6:8541271	chr6:8784178~8785445:+
TGCT	cis	rs12288023	0.555	rs4930497	ENSG00000255318.1	RP11-655M14.13	-4.04	9.46e-05	0.0441	-0.61	-0.34	Serum metabolite levels;	chr11:67708130	chr11:67618279~67627304:-
TGCT	cis	rs7246967	0.673	rs60675447	ENSG00000198153.8	ZNF849P	4.04	9.46e-05	0.0441	0.58	0.34	Bronchopulmonary dysplasia;	chr19:22628090	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs56725192	ENSG00000198153.8	ZNF849P	4.04	9.46e-05	0.0441	0.58	0.34	Bronchopulmonary dysplasia;	chr19:22628136	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs1433085	ENSG00000198153.8	ZNF849P	4.04	9.46e-05	0.0441	0.58	0.34	Bronchopulmonary dysplasia;	chr19:22628297	chr19:22685167~22686732:+
TGCT	cis	rs1382167	0.714	rs3860580	ENSG00000225542.1	ZNF385D-AS1	-4.04	9.46e-05	0.0441	-0.32	-0.34	Airway wall thickness;	chr3:21571084	chr3:21542816~21579959:+
TGCT	cis	rs1382167	0.777	rs1457586	ENSG00000225542.1	ZNF385D-AS1	-4.04	9.46e-05	0.0441	-0.32	-0.34	Airway wall thickness;	chr3:21572093	chr3:21542816~21579959:+
TGCT	cis	rs1382167	0.777	rs6785919	ENSG00000225542.1	ZNF385D-AS1	-4.04	9.46e-05	0.0441	-0.32	-0.34	Airway wall thickness;	chr3:21574209	chr3:21542816~21579959:+
TGCT	cis	rs7714584	1	rs7715981	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150878545	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs7736554	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150878746	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs7736873	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150878920	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs7716903	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150879012	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs10041072	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150880080	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs1428552	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150880269	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs10463310	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150881343	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs60134818	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150881481	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs73284126	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150881745	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs7732643	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150881874	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs7732945	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150882039	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs1820682	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150882580	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs2344181	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150883012	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs4560537	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150883024	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs11746108	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150885060	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs11739619	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150885100	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs11167519	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150885845	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs11167520	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150886077	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs73284141	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150886524	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs3906527	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150886830	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs2345001	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150886956	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs3906528	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150887156	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs2344180	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150887795	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs2880791	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150887814	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs3857422	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150889047	chr5:150930645~150946289:-
TGCT	cis	rs7714584	0.59	rs4352593	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150889770	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs7709464	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150889879	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs10053750	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150890489	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs7714415	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150890730	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs7714584	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150890858	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs6579806	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150891522	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs4958848	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150891560	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs1863998	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150892191	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs11167521	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150892223	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs10057988	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150892500	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs10052606	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150892655	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs57001853	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150892890	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs2217266	ENSG00000197083.10	ZNF300P1	4.04	9.46e-05	0.0441	0.54	0.34	Crohn's disease;	chr5:150893059	chr5:150930645~150946289:-
TGCT	cis	rs7714584	1	rs11747270	ENSG00000197083.10	ZNF300P1	-4.04	9.46e-05	0.0441	-0.54	-0.34	Crohn's disease;	chr5:150879305	chr5:150930645~150946289:-
TGCT	cis	rs16975963	0.644	rs11666662	ENSG00000276846.1	CTD-3220F14.3	4.04	9.46e-05	0.0441	0.34	0.34	Longevity;	chr19:37663801	chr19:37314868~37315620:-
TGCT	cis	rs7927592	0.871	rs113020558	ENSG00000212093.1	AP000807.1	4.04	9.47e-05	0.0441	0.39	0.34	Total body bone mineral density;	chr11:68529364	chr11:68506083~68506166:-
TGCT	cis	rs7927592	0.913	rs6591340	ENSG00000212093.1	AP000807.1	4.04	9.47e-05	0.0441	0.39	0.34	Total body bone mineral density;	chr11:68530168	chr11:68506083~68506166:-
TGCT	cis	rs34375054	0.66	rs12303416	ENSG00000279233.1	RP11-158L12.4	4.04	9.47e-05	0.0441	0.36	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125108812	chr12:125138245~125141711:+
TGCT	cis	rs2505998	0.868	rs2505991	ENSG00000273008.1	RP11-351D16.3	-4.04	9.47e-05	0.0441	-0.41	-0.34	Hirschsprung disease;	chr10:43070912	chr10:43136824~43138334:-
TGCT	cis	rs11157436	0.602	rs11157438	ENSG00000211813.2	TRAV34	4.04	9.48e-05	0.0441	0.35	0.34	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22169147	chr14:22207522~22208129:+
TGCT	cis	rs9880211	0.613	rs6799056	ENSG00000239213.4	NCK1-AS1	4.04	9.48e-05	0.0441	0.35	0.34	Height;Body mass index;	chr3:136083508	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.644	rs6799320	ENSG00000239213.4	NCK1-AS1	4.04	9.48e-05	0.0441	0.35	0.34	Height;Body mass index;	chr3:136083597	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.613	rs9653930	ENSG00000239213.4	NCK1-AS1	4.04	9.48e-05	0.0441	0.35	0.34	Height;Body mass index;	chr3:136091472	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.583	rs9870122	ENSG00000239213.4	NCK1-AS1	4.04	9.48e-05	0.0441	0.35	0.34	Height;Body mass index;	chr3:136101423	chr3:136841726~136862054:-
TGCT	cis	rs10170266	0.685	rs818014	ENSG00000279220.1	GPR1-AS	4.04	9.48e-05	0.0441	0.27	0.34	Reticulocyte fraction of red cells;	chr2:206039337	chr2:206203376~206266243:+
TGCT	cis	rs7819412	0.715	rs35223712	ENSG00000255310.2	AF131215.2	-4.03	9.48e-05	0.0441	-0.29	-0.34	Triglycerides;	chr8:11186417	chr8:11107788~11109726:-
TGCT	cis	rs847845	0.841	rs7751820	ENSG00000186328.4	RP11-140K17.2	-4.03	9.49e-05	0.0441	-0.5	-0.34	Non-small cell lung cancer;	chr6:35007151	chr6:34715613~34715940:+
TGCT	cis	rs847845	0.841	rs10947535	ENSG00000186328.4	RP11-140K17.2	-4.03	9.49e-05	0.0441	-0.5	-0.34	Non-small cell lung cancer;	chr6:35008192	chr6:34715613~34715940:+
TGCT	cis	rs904251	0.766	rs1757175	ENSG00000204110.6	RP1-153P14.8	-4.03	9.5e-05	0.0442	-0.4	-0.34	Cognitive performance;	chr6:37518918	chr6:37507348~37535616:+
TGCT	cis	rs904251	0.828	rs1757174	ENSG00000204110.6	RP1-153P14.8	-4.03	9.5e-05	0.0442	-0.4	-0.34	Cognitive performance;	chr6:37518919	chr6:37507348~37535616:+
TGCT	cis	rs1707322	0.752	rs11211173	ENSG00000280836.1	AL355480.1	-4.03	9.5e-05	0.0442	-0.45	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45581219~45581321:-
TGCT	cis	rs72627509	0.904	rs3796529	ENSG00000269949.1	RP11-738E22.3	4.03	9.51e-05	0.0442	0.39	0.34	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56931248	chr4:56960927~56961373:-
TGCT	cis	rs10891354	0.547	rs4937368	ENSG00000176343.5	RPL37AP8	4.03	9.51e-05	0.0442	0.39	0.34	Schizophrenia;	chr11:112396968	chr11:111889199~111889474:-
TGCT	cis	rs10759883	0.563	rs686048	ENSG00000175611.10	LINC00476	4.03	9.52e-05	0.0443	0.32	0.34	Nicotine dependence;	chr9:95967100	chr9:95759231~95875977:-
TGCT	cis	rs10759883	0.539	rs649819	ENSG00000175611.10	LINC00476	4.03	9.52e-05	0.0443	0.32	0.34	Nicotine dependence;	chr9:95969323	chr9:95759231~95875977:-
TGCT	cis	rs62355900	0.627	rs59715006	ENSG00000271828.1	CTD-2310F14.1	4.03	9.52e-05	0.0443	0.47	0.34	Endometriosis;	chr5:56899820	chr5:56927874~56929573:+
TGCT	cis	rs62355900	0.627	rs61663138	ENSG00000271828.1	CTD-2310F14.1	4.03	9.52e-05	0.0443	0.47	0.34	Endometriosis;	chr5:56899946	chr5:56927874~56929573:+
TGCT	cis	rs13118159	0.641	rs4974598	ENSG00000254094.1	AC078852.1	-4.03	9.53e-05	0.0443	-0.39	-0.34	Longevity;	chr4:1319432	chr4:1356581~1358075:+
TGCT	cis	rs2177312	0.714	rs4379100	ENSG00000251129.1	RP11-734I18.1	-4.03	9.54e-05	0.0443	-0.44	-0.34	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31940956	chr4:31997397~32155406:+
TGCT	cis	rs796364	0.951	rs11680258	ENSG00000232732.8	AC073043.1	4.03	9.54e-05	0.0443	0.43	0.34	Schizophrenia;	chr2:200132253	chr2:199867396~199911159:-
TGCT	cis	rs796364	0.951	rs7608668	ENSG00000232732.8	AC073043.1	4.03	9.54e-05	0.0443	0.43	0.34	Schizophrenia;	chr2:200135294	chr2:199867396~199911159:-
TGCT	cis	rs17665889	0.51	rs2397052	ENSG00000225791.5	TRAM2-AS1	-4.03	9.54e-05	0.0444	-0.43	-0.34	Cannabis dependence symptom count;	chr6:51577747	chr6:52577307~52583993:+
TGCT	cis	rs10170266	0.74	rs1209370	ENSG00000279220.1	GPR1-AS	4.03	9.54e-05	0.0444	0.27	0.34	Reticulocyte fraction of red cells;	chr2:206007877	chr2:206203376~206266243:+
TGCT	cis	rs10170266	0.875	rs817991	ENSG00000279220.1	GPR1-AS	4.03	9.54e-05	0.0444	0.27	0.34	Reticulocyte fraction of red cells;	chr2:206009615	chr2:206203376~206266243:+
TGCT	cis	rs10170266	0.875	rs817992	ENSG00000279220.1	GPR1-AS	4.03	9.54e-05	0.0444	0.27	0.34	Reticulocyte fraction of red cells;	chr2:206011535	chr2:206203376~206266243:+
TGCT	cis	rs2725236	0.647	rs2728105	ENSG00000202000.1	RNU1-36P	-4.03	9.54e-05	0.0444	-0.3	-0.34	Caffeine consumption;	chr4:88050915	chr4:88000237~88000401:+
TGCT	cis	rs4835473	0.897	rs7681914	ENSG00000251600.4	RP11-673E1.1	4.03	9.55e-05	0.0444	0.36	0.34	Immature fraction of reticulocytes;	chr4:143708838	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.864	rs7682096	ENSG00000251600.4	RP11-673E1.1	4.03	9.55e-05	0.0444	0.36	0.34	Immature fraction of reticulocytes;	chr4:143708892	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.897	rs7682128	ENSG00000251600.4	RP11-673E1.1	4.03	9.55e-05	0.0444	0.36	0.34	Immature fraction of reticulocytes;	chr4:143708950	chr4:143912331~143982454:+
TGCT	cis	rs11214589	0.651	rs12360992	ENSG00000270179.1	RP11-159N11.4	-4.03	9.56e-05	0.0444	-0.25	-0.34	Neuroticism;	chr11:113392178	chr11:113368478~113369117:+
TGCT	cis	rs5742933	1	rs1550388	ENSG00000273240.1	RP11-455J20.3	4.03	9.56e-05	0.0444	0.35	0.34	Ferritin levels;	chr2:189739054	chr2:189763859~189764456:-
TGCT	cis	rs7181230	0.885	rs9919974	ENSG00000275636.1	RP11-521C20.5	4.03	9.56e-05	0.0444	0.44	0.34	Dehydroepiandrosterone sulphate levels;	chr15:40045261	chr15:40078892~40079347:+
TGCT	cis	rs10971721	0.822	rs10971818	ENSG00000230074.1	RP11-195F19.9	4.03	9.56e-05	0.0444	0.48	0.34	Body mass index;	chr9:33952155	chr9:34665665~34681298:+
TGCT	cis	rs12760731	0.92	rs61109337	ENSG00000224687.1	RASAL2-AS1	4.03	9.56e-05	0.0445	0.54	0.34	Obesity-related traits;	chr1:178515539	chr1:178091508~178093984:-
TGCT	cis	rs11129295	0.618	rs17020287	ENSG00000224237.1	MINOS1P3	4.03	9.57e-05	0.0445	0.38	0.34	Multiple sclerosis;	chr3:27760388	chr3:27214816~27215018:-
TGCT	cis	rs11129295	0.618	rs17020288	ENSG00000224237.1	MINOS1P3	4.03	9.57e-05	0.0445	0.38	0.34	Multiple sclerosis;	chr3:27760468	chr3:27214816~27215018:-
TGCT	cis	rs6005807	0.688	rs17413405	ENSG00000272858.1	CTA-292E10.8	-4.03	9.57e-05	0.0445	-0.7	-0.34	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28454628	chr22:28814914~28815662:+
TGCT	cis	rs875971	0.545	rs12671152	ENSG00000237310.1	GS1-124K5.4	4.03	9.58e-05	0.0445	0.41	0.34	Aortic root size;	chr7:66311140	chr7:66493706~66495474:+
TGCT	cis	rs16975963	0.843	rs73025630	ENSG00000276846.1	CTD-3220F14.3	-4.03	9.58e-05	0.0445	-0.35	-0.34	Longevity;	chr19:37860644	chr19:37314868~37315620:-
TGCT	cis	rs16975963	0.793	rs73027418	ENSG00000276846.1	CTD-3220F14.3	-4.03	9.58e-05	0.0445	-0.35	-0.34	Longevity;	chr19:37870380	chr19:37314868~37315620:-
TGCT	cis	rs16975963	0.843	rs113690074	ENSG00000276846.1	CTD-3220F14.3	-4.03	9.58e-05	0.0445	-0.35	-0.34	Longevity;	chr19:37884753	chr19:37314868~37315620:-
TGCT	cis	rs16975963	0.843	rs75802547	ENSG00000276846.1	CTD-3220F14.3	-4.03	9.58e-05	0.0445	-0.35	-0.34	Longevity;	chr19:37902681	chr19:37314868~37315620:-
TGCT	cis	rs7819412	0.715	rs2409727	ENSG00000255310.2	AF131215.2	-4.03	9.59e-05	0.0445	-0.29	-0.34	Triglycerides;	chr8:11185727	chr8:11107788~11109726:-
TGCT	cis	rs6604026	0.656	rs17380908	ENSG00000223787.2	RP4-593M8.1	4.03	9.6e-05	0.0446	0.42	0.34	Multiple sclerosis;	chr1:92936994	chr1:92580476~92580821:-
TGCT	cis	rs507080	0.769	rs571001	ENSG00000255239.1	AP002954.6	4.03	9.6e-05	0.0446	0.44	0.34	Serum metabolite levels;	chr11:118629457	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.769	rs570952	ENSG00000255239.1	AP002954.6	4.03	9.6e-05	0.0446	0.44	0.34	Serum metabolite levels;	chr11:118629477	chr11:118688039~118690600:-
TGCT	cis	rs507080	0.769	rs645637	ENSG00000255239.1	AP002954.6	4.03	9.6e-05	0.0446	0.44	0.34	Serum metabolite levels;	chr11:118634373	chr11:118688039~118690600:-
TGCT	cis	rs2709736	0.526	rs10256428	ENSG00000232790.2	LINC01162	-4.03	9.6e-05	0.0446	-0.29	-0.34	Bipolar I disorder;	chr7:20828902	chr7:20835431~21023148:+
TGCT	cis	rs2709736	0.548	rs10272835	ENSG00000232790.2	LINC01162	-4.03	9.6e-05	0.0446	-0.29	-0.34	Bipolar I disorder;	chr7:20829620	chr7:20835431~21023148:+
TGCT	cis	rs8049040	0.967	rs8044168	ENSG00000260886.1	TAT-AS1	4.03	9.6e-05	0.0446	0.35	0.34	Blood protein levels;	chr16:71473080	chr16:71565789~71578187:+
TGCT	cis	rs13118159	0.742	rs7679860	ENSG00000254094.1	AC078852.1	-4.03	9.61e-05	0.0446	-0.39	-0.34	Longevity;	chr4:1340199	chr4:1356581~1358075:+
TGCT	cis	rs56318008	0.773	rs2268177	ENSG00000218510.5	LINC00339	4.03	9.63e-05	0.0447	0.55	0.34	Total body bone mineral density;Gestational age at birth (maternal effect);	chr1:22088917	chr1:22025188~22031223:+
TGCT	cis	rs4713118	0.869	rs4713121	ENSG00000272009.1	RP1-313I6.12	-4.03	9.64e-05	0.0447	-0.41	-0.34	Parkinson's disease;	chr6:27754285	chr6:28078792~28081130:-
TGCT	cis	rs7674212	0.556	rs223401	ENSG00000230069.3	LRRC37A15P	-4.03	9.64e-05	0.0447	-0.32	-0.34	Type 2 diabetes;	chr4:102817815	chr4:102727274~102730721:-
TGCT	cis	rs11168618	0.686	rs11168574	ENSG00000240399.1	RP1-228P16.1	4.03	9.64e-05	0.0447	0.32	0.34	Adiponectin levels;	chr12:48445186	chr12:48054813~48055591:-
TGCT	cis	rs11168618	0.81	rs35338015	ENSG00000240399.1	RP1-228P16.1	4.03	9.64e-05	0.0447	0.32	0.34	Adiponectin levels;	chr12:48445618	chr12:48054813~48055591:-
TGCT	cis	rs11168618	0.81	rs6580671	ENSG00000240399.1	RP1-228P16.1	4.03	9.64e-05	0.0447	0.32	0.34	Adiponectin levels;	chr12:48447274	chr12:48054813~48055591:-
TGCT	cis	rs11168618	0.846	rs11168577	ENSG00000240399.1	RP1-228P16.1	4.03	9.64e-05	0.0447	0.32	0.34	Adiponectin levels;	chr12:48448809	chr12:48054813~48055591:-
TGCT	cis	rs7537765	1	rs17037429	ENSG00000230337.1	RP4-635E18.6	4.03	9.64e-05	0.0447	0.37	0.34	QRS complex (12-leadsum);	chr1:11813730	chr1:11099675~11102100:+
TGCT	cis	rs10891354	0.526	rs4937366	ENSG00000176343.5	RPL37AP8	4.03	9.64e-05	0.0447	0.38	0.34	Schizophrenia;	chr11:112396025	chr11:111889199~111889474:-
TGCT	cis	rs10891354	0.526	rs10128697	ENSG00000176343.5	RPL37AP8	4.03	9.64e-05	0.0447	0.38	0.34	Schizophrenia;	chr11:112396399	chr11:111889199~111889474:-
TGCT	cis	rs11671005	0.571	rs56243535	ENSG00000268912.1	CTD-2619J13.17	-4.03	9.65e-05	0.0447	-0.41	-0.34	Mean platelet volume;	chr19:58494783	chr19:58428632~58431148:-
TGCT	cis	rs11671005	0.611	rs56026876	ENSG00000268912.1	CTD-2619J13.17	-4.03	9.65e-05	0.0447	-0.41	-0.34	Mean platelet volume;	chr19:58494790	chr19:58428632~58431148:-
TGCT	cis	rs2153535	0.563	rs1796687	ENSG00000230939.1	RP11-314C16.1	-4.03	9.65e-05	0.0448	-0.33	-0.34	Motion sickness;	chr6:8535885	chr6:8784178~8785445:+
TGCT	cis	rs10759883	0.627	rs816672	ENSG00000175611.10	LINC00476	4.03	9.66e-05	0.0448	0.3	0.34	Nicotine dependence;	chr9:95812171	chr9:95759231~95875977:-
TGCT	cis	rs35146811	0.735	rs1043915	ENSG00000281827.1	AC005071.4	-4.03	9.66e-05	0.0448	-0.4	-0.34	Coronary artery disease;	chr7:100202222	chr7:100344375~100344475:-
TGCT	cis	rs12497850	0.864	rs4955410	ENSG00000226913.1	BSN-AS2	-4.03	9.66e-05	0.0448	-0.27	-0.34	Parkinson's disease;	chr3:49143785	chr3:49549306~49554366:-
TGCT	cis	rs12497850	0.765	rs12487580	ENSG00000226913.1	BSN-AS2	-4.03	9.66e-05	0.0448	-0.27	-0.34	Parkinson's disease;	chr3:49145499	chr3:49549306~49554366:-
TGCT	cis	rs12497850	0.797	rs61583136	ENSG00000226913.1	BSN-AS2	-4.03	9.66e-05	0.0448	-0.27	-0.34	Parkinson's disease;	chr3:49151762	chr3:49549306~49554366:-
TGCT	cis	rs3105593	1	rs57002197	ENSG00000273674.3	CTD-2378E12.1	4.03	9.66e-05	0.0448	0.36	0.34	QT interval;	chr15:50581563	chr15:50839875~50908599:-
TGCT	cis	rs3105593	0.965	rs3109891	ENSG00000273674.3	CTD-2378E12.1	4.03	9.66e-05	0.0448	0.36	0.34	QT interval;	chr15:50582767	chr15:50839875~50908599:-
TGCT	cis	rs3105593	1	rs3131596	ENSG00000273674.3	CTD-2378E12.1	4.03	9.66e-05	0.0448	0.36	0.34	QT interval;	chr15:50585378	chr15:50839875~50908599:-
TGCT	cis	rs3105593	1	rs3131582	ENSG00000273674.3	CTD-2378E12.1	4.03	9.66e-05	0.0448	0.36	0.34	QT interval;	chr15:50587473	chr15:50839875~50908599:-
TGCT	cis	rs3105593	1	rs3848130	ENSG00000273674.3	CTD-2378E12.1	4.03	9.66e-05	0.0448	0.36	0.34	QT interval;	chr15:50599914	chr15:50839875~50908599:-
TGCT	cis	rs3105593	1	rs4509958	ENSG00000273674.3	CTD-2378E12.1	4.03	9.66e-05	0.0448	0.36	0.34	QT interval;	chr15:50601978	chr15:50839875~50908599:-
TGCT	cis	rs3105593	1	rs12439744	ENSG00000273674.3	CTD-2378E12.1	4.03	9.66e-05	0.0448	0.36	0.34	QT interval;	chr15:50607014	chr15:50839875~50908599:-
TGCT	cis	rs7829975	0.902	rs777707	ENSG00000254340.1	RP11-10A14.3	4.03	9.66e-05	0.0448	0.34	0.34	Mood instability;	chr8:8726834	chr8:9141424~9145435:+
TGCT	cis	rs496547	0.686	rs477014	ENSG00000255239.1	AP002954.6	4.03	9.66e-05	0.0448	0.39	0.34	Hip minimal joint space width;	chr11:118808277	chr11:118688039~118690600:-
TGCT	cis	rs496547	0.557	rs516719	ENSG00000255239.1	AP002954.6	4.03	9.66e-05	0.0448	0.39	0.34	Hip minimal joint space width;	chr11:118808736	chr11:118688039~118690600:-
TGCT	cis	rs9322193	0.607	rs12210822	ENSG00000216906.2	RP11-350J20.9	4.03	9.66e-05	0.0448	0.44	0.34	Lung cancer;	chr6:149905356	chr6:149904243~149906418:+
TGCT	cis	rs62025270	0.632	rs74025655	ENSG00000259416.2	RP11-158M2.5	-4.03	9.67e-05	0.0448	-0.41	-0.34	Idiopathic pulmonary fibrosis;	chr15:85674319	chr15:85754941~85756237:-
TGCT	cis	rs62025270	0.632	rs62022918	ENSG00000259416.2	RP11-158M2.5	-4.03	9.67e-05	0.0448	-0.41	-0.34	Idiopathic pulmonary fibrosis;	chr15:85675053	chr15:85754941~85756237:-
TGCT	cis	rs62025270	0.632	rs62022919	ENSG00000259416.2	RP11-158M2.5	-4.03	9.67e-05	0.0448	-0.41	-0.34	Idiopathic pulmonary fibrosis;	chr15:85675079	chr15:85754941~85756237:-
TGCT	cis	rs62025270	0.632	rs17636096	ENSG00000259416.2	RP11-158M2.5	-4.03	9.67e-05	0.0448	-0.41	-0.34	Idiopathic pulmonary fibrosis;	chr15:85675503	chr15:85754941~85756237:-
TGCT	cis	rs113835537	0.529	rs11227515	ENSG00000255517.5	CTD-3074O7.5	-4.03	9.68e-05	0.0448	-0.36	-0.34	Airway imaging phenotypes;	chr11:66519912	chr11:66473490~66480233:-
TGCT	cis	rs17301013	0.606	rs12076453	ENSG00000227373.4	RP11-160H22.5	4.03	9.68e-05	0.0448	0.53	0.34	Systemic lupus erythematosus;	chr1:174230438	chr1:174115300~174160004:-
TGCT	cis	rs1850744	0.702	rs10939428	ENSG00000250884.1	OR7E85P	4.03	9.68e-05	0.0448	0.68	0.34	Economic and political preferences;	chr4:9628417	chr4:9483718~9484702:+
TGCT	cis	rs1850744	0.702	rs6836184	ENSG00000250884.1	OR7E85P	4.03	9.68e-05	0.0448	0.68	0.34	Economic and political preferences;	chr4:9632087	chr4:9483718~9484702:+
TGCT	cis	rs1850744	0.536	rs6843869	ENSG00000250884.1	OR7E85P	4.03	9.68e-05	0.0448	0.68	0.34	Economic and political preferences;	chr4:9632827	chr4:9483718~9484702:+
TGCT	cis	rs1823913	0.503	rs34716486	ENSG00000227542.1	AC092614.2	4.03	9.69e-05	0.0449	0.35	0.34	Obesity-related traits;	chr2:191343335	chr2:191229165~191246172:-
TGCT	cis	rs1823913	0.503	rs35868016	ENSG00000227542.1	AC092614.2	4.03	9.69e-05	0.0449	0.35	0.34	Obesity-related traits;	chr2:191344082	chr2:191229165~191246172:-
TGCT	cis	rs2337406	1	rs2157618	ENSG00000274576.2	IGHV2-70	-4.03	9.69e-05	0.0449	-0.51	-0.34	Alzheimer's disease (late onset);	chr14:106711313	chr14:106770577~106771020:-
TGCT	cis	rs62355901	0.545	rs16886263	ENSG00000271828.1	CTD-2310F14.1	-4.03	9.7e-05	0.0449	-0.47	-0.34	Breast cancer;	chr5:56769680	chr5:56927874~56929573:+
TGCT	cis	rs9322193	0.607	rs915140	ENSG00000216906.2	RP11-350J20.9	4.03	9.7e-05	0.0449	0.44	0.34	Lung cancer;	chr6:149899674	chr6:149904243~149906418:+
TGCT	cis	rs9322193	0.607	rs12209310	ENSG00000216906.2	RP11-350J20.9	4.03	9.7e-05	0.0449	0.44	0.34	Lung cancer;	chr6:149904882	chr6:149904243~149906418:+
TGCT	cis	rs763121	0.853	rs1569492	ENSG00000273076.1	RP3-508I15.22	-4.03	9.71e-05	0.0449	-0.36	-0.34	Menopause (age at onset);	chr22:38579506	chr22:38743495~38743910:+
TGCT	cis	rs763567	0.626	rs1234230	ENSG00000271811.1	RP1-79C4.4	-4.03	9.71e-05	0.0449	-0.26	-0.34	Tonsillectomy;	chr1:170602702	chr1:170667381~170669425:+
TGCT	cis	rs10129255	0.5	rs7157975	ENSG00000280411.1	IGHV1-69-2	-4.03	9.72e-05	0.045	-0.35	-0.34	Kawasaki disease;	chr14:106804049	chr14:106762092~106762588:-
TGCT	cis	rs172166	0.637	rs1071893	ENSG00000219392.1	RP1-265C24.5	-4.03	9.73e-05	0.045	-0.41	-0.34	Cardiac Troponin-T levels;	chr6:28199857	chr6:28115628~28116551:+
TGCT	cis	rs7674212	0.556	rs223401	ENSG00000251288.2	RP11-10L12.2	-4.03	9.73e-05	0.045	-0.45	-0.34	Type 2 diabetes;	chr4:102817815	chr4:102751401~102752641:+
TGCT	cis	rs10946737	0.867	rs12194111	ENSG00000220517.2	ASS1P1	4.03	9.73e-05	0.045	0.33	0.34	Liver injury in anti-tuberculosis drug treatment;	chr6:24990890	chr6:25023247~25024483:-
TGCT	cis	rs2505998	0.871	rs2505990	ENSG00000273008.1	RP11-351D16.3	-4.03	9.74e-05	0.045	-0.42	-0.34	Hirschsprung disease;	chr10:43069900	chr10:43136824~43138334:-
TGCT	cis	rs62355900	0.627	rs62358073	ENSG00000271828.1	CTD-2310F14.1	4.03	9.74e-05	0.045	0.48	0.34	Endometriosis;	chr5:56831013	chr5:56927874~56929573:+
TGCT	cis	rs13068223	0.74	rs344028	ENSG00000243926.1	TIPARP-AS1	4.03	9.75e-05	0.0451	0.35	0.34	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747980	chr3:156671862~156674378:-
TGCT	cis	rs9755467	0.904	rs6767638	ENSG00000221413.1	AC023593.1	4.03	9.75e-05	0.0451	0.51	0.34	Educational attainment (years of education);	chr3:127440356	chr3:127664704~127664810:+
TGCT	cis	rs9755467	0.904	rs55767110	ENSG00000221413.1	AC023593.1	4.03	9.75e-05	0.0451	0.51	0.34	Educational attainment (years of education);	chr3:127441139	chr3:127664704~127664810:+
TGCT	cis	rs9755467	0.904	rs9647321	ENSG00000221413.1	AC023593.1	4.03	9.75e-05	0.0451	0.51	0.34	Educational attainment (years of education);	chr3:127441440	chr3:127664704~127664810:+
TGCT	cis	rs9755467	0.904	rs11927562	ENSG00000221413.1	AC023593.1	4.03	9.75e-05	0.0451	0.51	0.34	Educational attainment (years of education);	chr3:127441876	chr3:127664704~127664810:+
TGCT	cis	rs2739330	0.892	rs4822455	ENSG00000250470.1	AP000351.3	4.03	9.76e-05	0.0451	0.34	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23976904~23977585:-
TGCT	cis	rs4713118	0.699	rs573179	ENSG00000187763.3	OR2B7P	4.03	9.76e-05	0.0451	0.34	0.34	Parkinson's disease;	chr6:27881898	chr6:28046434~28047367:+
TGCT	cis	rs4713118	0.699	rs200978	ENSG00000187763.3	OR2B7P	4.03	9.76e-05	0.0451	0.34	0.34	Parkinson's disease;	chr6:27885390	chr6:28046434~28047367:+
TGCT	cis	rs9326248	0.906	rs171052	ENSG00000280143.1	AP000892.6	-4.03	9.77e-05	0.0451	-0.46	-0.34	Blood protein levels;	chr11:117211047	chr11:117204967~117210292:+
TGCT	cis	rs11214589	0.651	rs17600713	ENSG00000270179.1	RP11-159N11.4	-4.03	9.78e-05	0.0452	-0.25	-0.34	Neuroticism;	chr11:113389225	chr11:113368478~113369117:+
TGCT	cis	rs6782228	0.606	rs6787559	ENSG00000242551.2	POU5F1P6	-4.03	9.79e-05	0.0452	-0.41	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662243	chr3:128674735~128677005:-
TGCT	cis	rs6782228	0.606	rs2001703	ENSG00000242551.2	POU5F1P6	-4.03	9.79e-05	0.0452	-0.41	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664254	chr3:128674735~128677005:-
TGCT	cis	rs7824557	0.614	rs2736277	ENSG00000255310.2	AF131215.2	-4.03	9.79e-05	0.0452	-0.26	-0.34	Retinal vascular caliber;	chr8:11361384	chr8:11107788~11109726:-
TGCT	cis	rs2742234	0.955	rs2503865	ENSG00000273008.1	RP11-351D16.3	-4.03	9.8e-05	0.0453	-0.38	-0.34	Hirschsprung disease;	chr10:43164088	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.955	rs2435385	ENSG00000273008.1	RP11-351D16.3	-4.03	9.8e-05	0.0453	-0.38	-0.34	Hirschsprung disease;	chr10:43170302	chr10:43136824~43138334:-
TGCT	cis	rs9657451	0.556	rs9324463	ENSG00000253988.1	RP11-489O18.1	4.03	9.8e-05	0.0453	0.45	0.34	Cognitive performance;	chr8:137870903	chr8:138063268~138073240:+
TGCT	cis	rs5758659	0.935	rs134879	ENSG00000270083.1	RP1-257I20.14	4.03	9.8e-05	0.0453	0.33	0.34	Cognitive function;	chr22:42268195	chr22:42089630~42090028:-
TGCT	cis	rs7786765	0.511	rs2074121	ENSG00000234695.1	AC002076.10	4.03	9.8e-05	0.0453	0.39	0.34	Body mass index;	chr7:93479771	chr7:93890913~93893601:+
TGCT	cis	rs867371	0.502	rs7176926	ENSG00000276710.3	CSPG4P8	-4.03	9.81e-05	0.0453	-0.29	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82459472~82477258:+
TGCT	cis	rs2665103	0.632	rs3902959	ENSG00000276710.3	CSPG4P8	-4.03	9.81e-05	0.0453	-0.29	-0.34	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82459472~82477258:+
TGCT	cis	rs4713118	0.629	rs203888	ENSG00000216901.1	AL022393.7	4.03	9.81e-05	0.0453	0.44	0.34	Parkinson's disease;	chr6:28053811	chr6:28176188~28176674:+
TGCT	cis	rs11166629	1	rs4909332	ENSG00000272456.1	CTD-2342N23.3	4.03	9.82e-05	0.0453	0.38	0.34	Smoking quantity;	chr8:134634097	chr8:134722947~134723949:+
TGCT	cis	rs4908769	0.775	rs4995074	ENSG00000270282.1	RP5-1115A15.2	4.03	9.82e-05	0.0453	0.41	0.34	Allergy;	chr1:8475104	chr1:8512653~8513021:+
TGCT	cis	rs4908769	0.775	rs12759741	ENSG00000270282.1	RP5-1115A15.2	4.03	9.82e-05	0.0453	0.41	0.34	Allergy;	chr1:8499600	chr1:8512653~8513021:+
TGCT	cis	rs4908769	0.735	rs6577497	ENSG00000270282.1	RP5-1115A15.2	4.03	9.82e-05	0.0453	0.41	0.34	Allergy;	chr1:8545608	chr1:8512653~8513021:+
TGCT	cis	rs741668	0.641	rs9562637	ENSG00000235903.6	CPB2-AS1	-4.03	9.82e-05	0.0453	-0.38	-0.34	Cerebrospinal fluid clusterin levels;	chr13:46071410	chr13:46052806~46113332:+
TGCT	cis	rs11751618	1	rs3846772	ENSG00000203875.9	SNHG5	-4.03	9.82e-05	0.0453	-0.52	-0.34	Gut microbiome composition (winter);	chr6:86527531	chr6:85660950~85678736:-
TGCT	cis	rs2153535	0.58	rs7745043	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8513274	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9406170	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8513920	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9378556	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8514462	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9379222	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8514555	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9406171	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8515129	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9406172	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8515231	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.601	rs9393030	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8516256	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9406174	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8516531	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.54	rs9378557	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8517148	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs2143356	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8517442	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs2143355	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8517623	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs2143354	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8517674	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs2327067	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8518249	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.541	rs9328477	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8518876	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9328478	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8518950	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9328479	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8519413	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9505467	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8519986	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1360054	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8520144	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9328483	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8521062	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9393033	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8521213	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.541	rs6938688	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8521396	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9328484	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8524610	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1410766	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8525127	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs7743686	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8525878	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1328862	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8526448	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.601	rs718504	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8527279	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs6597335	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8527481	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9328486	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8527775	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs2183112	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8527979	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.601	rs9328487	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8529145	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9328488	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8529178	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.601	rs1928183	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8529785	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.601	rs2143353	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8529878	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.601	rs2143352	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8530015	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.601	rs7775274	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8530070	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.601	rs7741024	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8530080	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs6421948	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8530787	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs6597337	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8531419	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs6421949	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8531536	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs1928184	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8531875	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.623	rs6597338	ENSG00000230939.1	RP11-314C16.1	-4.03	9.82e-05	0.0453	-0.33	-0.34	Motion sickness;	chr6:8533275	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.563	rs6942177	ENSG00000230939.1	RP11-314C16.1	4.03	9.82e-05	0.0453	0.33	0.34	Motion sickness;	chr6:8534227	chr6:8784178~8785445:+
TGCT	cis	rs11858159	0.934	rs7182190	ENSG00000259905.4	PWRN1	4.03	9.82e-05	0.0453	0.35	0.34	Platelet thrombus formation;	chr15:24554442	chr15:24493137~24652130:+
TGCT	cis	rs9309473	1	rs7576245	ENSG00000163016.8	ALMS1P	4.03	9.83e-05	0.0453	0.31	0.34	Metabolite levels;	chr2:73602551	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.95	rs6546849	ENSG00000163016.8	ALMS1P	4.03	9.83e-05	0.0453	0.31	0.34	Metabolite levels;	chr2:73603910	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.851	rs6546850	ENSG00000163016.8	ALMS1P	4.03	9.83e-05	0.0453	0.31	0.34	Metabolite levels;	chr2:73604020	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.898	rs6546852	ENSG00000163016.8	ALMS1P	4.03	9.83e-05	0.0453	0.31	0.34	Metabolite levels;	chr2:73606304	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.95	rs6546853	ENSG00000163016.8	ALMS1P	4.03	9.83e-05	0.0453	0.31	0.34	Metabolite levels;	chr2:73606612	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.95	rs6546858	ENSG00000163016.8	ALMS1P	4.03	9.83e-05	0.0453	0.31	0.34	Metabolite levels;	chr2:73611486	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.95	rs6546859	ENSG00000163016.8	ALMS1P	4.03	9.83e-05	0.0453	0.31	0.34	Metabolite levels;	chr2:73614928	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.95	rs7566364	ENSG00000163016.8	ALMS1P	4.03	9.83e-05	0.0453	0.31	0.34	Metabolite levels;	chr2:73615762	chr2:73644919~73685576:+
TGCT	cis	rs6694270	0.913	rs3935030	ENSG00000270728.1	RP4-657E11.10	-4.03	9.84e-05	0.0454	-0.23	-0.34	Drug-induced liver injury (nitrofurantoin);	chr1:18790462	chr1:19297080~19297903:+
TGCT	cis	rs748404	0.706	rs57728767	ENSG00000205771.5	CATSPER2P1	-4.03	9.84e-05	0.0454	-0.51	-0.34	Lung cancer;	chr15:43473639	chr15:43726918~43747094:-
TGCT	cis	rs228614	0.51	rs223412	ENSG00000230069.3	LRRC37A15P	-4.03	9.84e-05	0.0454	-0.3	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102812443	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.554	rs223409	ENSG00000230069.3	LRRC37A15P	-4.03	9.84e-05	0.0454	-0.3	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102815023	chr4:102727274~102730721:-
TGCT	cis	rs853679	0.517	rs9380052	ENSG00000187763.3	OR2B7P	4.03	9.84e-05	0.0454	0.34	0.34	Depression;	chr6:28096845	chr6:28046434~28047367:+
TGCT	cis	rs7829975	0.606	rs11776838	ENSG00000253893.2	FAM85B	4.03	9.84e-05	0.0454	0.43	0.34	Mood instability;	chr8:8937291	chr8:8167819~8226614:-
TGCT	cis	rs10411161	0.671	rs10412377	ENSG00000269483.1	AC006272.1	-4.03	9.85e-05	0.0454	-0.46	-0.34	Breast cancer;	chr19:51847419	chr19:51839924~51843324:-
TGCT	cis	rs10891354	0.547	rs11214190	ENSG00000176343.5	RPL37AP8	4.02	9.85e-05	0.0454	0.38	0.34	Schizophrenia;	chr11:112397656	chr11:111889199~111889474:-
TGCT	cis	rs7555523	0.887	rs4657476	ENSG00000224358.1	RP11-466F5.8	4.02	9.86e-05	0.0454	0.56	0.34	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165763424	chr1:165768929~165775176:+
TGCT	cis	rs2709736	0.634	rs28827829	ENSG00000232790.2	LINC01162	-4.02	9.86e-05	0.0454	-0.26	-0.34	Bipolar I disorder;	chr7:20822133	chr7:20835431~21023148:+
TGCT	cis	rs6568686	0.578	rs56103131	ENSG00000272356.1	RP5-1112D6.8	-4.02	9.86e-05	0.0454	-0.42	-0.34	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111614545	chr6:111309203~111313517:+
TGCT	cis	rs6568686	0.53	rs76540042	ENSG00000272356.1	RP5-1112D6.8	-4.02	9.86e-05	0.0454	-0.42	-0.34	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111616177	chr6:111309203~111313517:+
TGCT	cis	rs11139399	0.65	rs4434691	ENSG00000233926.1	RP11-154D17.1	4.02	9.87e-05	0.0455	0.39	0.34	Hippocampal atrophy;	chr9:81733847	chr9:81689713~81776900:+
TGCT	cis	rs7829975	0.582	rs448231	ENSG00000253893.2	FAM85B	4.02	9.88e-05	0.0455	0.41	0.34	Mood instability;	chr8:8932549	chr8:8167819~8226614:-
TGCT	cis	rs4654899	0.714	rs12401630	ENSG00000236073.2	RP11-487E1.2	-4.02	9.88e-05	0.0455	-0.31	-0.34	Superior frontal gyrus grey matter volume;	chr1:21168556	chr1:21073639~21073753:-
TGCT	cis	rs9733	0.68	rs3738484	ENSG00000236713.1	RP11-363I22.3	4.02	9.88e-05	0.0455	0.26	0.34	Tonsillectomy;	chr1:150579854	chr1:150780272~150780644:+
TGCT	cis	rs9733	0.65	rs3738485	ENSG00000236713.1	RP11-363I22.3	4.02	9.88e-05	0.0455	0.26	0.34	Tonsillectomy;	chr1:150579916	chr1:150780272~150780644:+
TGCT	cis	rs9733	0.65	rs9803935	ENSG00000236713.1	RP11-363I22.3	4.02	9.88e-05	0.0455	0.26	0.34	Tonsillectomy;	chr1:150580146	chr1:150780272~150780644:+
TGCT	cis	rs1355223	0.583	rs2941041	ENSG00000271369.1	RP11-350D17.3	4.02	9.88e-05	0.0455	0.34	0.34	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34853187	chr11:34709600~34710161:+
TGCT	cis	rs3824488	0.541	rs60608001	ENSG00000228142.2	RP11-180I4.2	4.02	9.88e-05	0.0455	0.72	0.34	Neuroticism;	chr9:95438662	chr9:95650154~95715718:+
TGCT	cis	rs3749237	0.576	rs62259939	ENSG00000226913.1	BSN-AS2	-4.02	9.89e-05	0.0455	-0.26	-0.34	Resting heart rate;	chr3:49348614	chr3:49549306~49554366:-
TGCT	cis	rs35146811	0.7	rs866500	ENSG00000281827.1	AC005071.4	4.02	9.89e-05	0.0455	0.41	0.34	Coronary artery disease;	chr7:100242838	chr7:100344375~100344475:-
TGCT	cis	rs8077577	0.671	rs4500798	ENSG00000186831.10	KRT17P2	-4.02	9.89e-05	0.0455	-0.48	-0.34	Obesity-related traits;	chr17:18351765	chr17:18426861~18431848:+
TGCT	cis	rs453301	0.686	rs7814328	ENSG00000254340.1	RP11-10A14.3	-4.02	9.91e-05	0.0456	-0.36	-0.34	Joint mobility (Beighton score);	chr8:9018719	chr8:9141424~9145435:+
TGCT	cis	rs875971	0.502	rs11769702	ENSG00000222364.1	RNU6-96P	-4.02	9.91e-05	0.0456	-0.43	-0.34	Aortic root size;	chr7:66255529	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.502	rs2465121	ENSG00000222364.1	RNU6-96P	4.02	9.91e-05	0.0456	0.43	0.34	Aortic root size;	chr7:66156017	chr7:66395191~66395286:+
TGCT	cis	rs10483853	0.731	rs10162414	ENSG00000258695.2	RP3-414A15.2	4.02	9.91e-05	0.0456	0.4	0.34	Coronary artery calcification;	chr14:73296524	chr14:73522878~73530610:+
TGCT	cis	rs7829975	0.686	rs907180	ENSG00000173295.6	FAM86B3P	4.02	9.91e-05	0.0456	0.4	0.34	Mood instability;	chr8:8845317	chr8:8228595~8244865:+
TGCT	cis	rs9532669	0.7	rs9525406	ENSG00000176268.5	CYCSP34	4.02	9.91e-05	0.0456	0.36	0.34	Cervical cancer;	chr13:40860812	chr13:40863599~40863902:-
TGCT	cis	rs4242434	0.854	rs4872007	ENSG00000254064.1	CTD-2530N21.4	4.02	9.92e-05	0.0456	0.21	0.34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22681366	chr8:22254576~22275162:-
TGCT	cis	rs4919669	0.668	rs10883757	ENSG00000273108.1	RP11-416N2.4	-4.02	9.93e-05	0.0457	-0.5	-0.34	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102640376	chr10:103608619~103610050:+
TGCT	cis	rs2243480	1	rs937108	ENSG00000164669.11	INTS4P1	4.02	9.95e-05	0.0458	0.54	0.34	Diabetic kidney disease;	chr7:65963465	chr7:65141225~65234216:+
TGCT	cis	rs853679	0.55	rs9295762	ENSG00000216901.1	AL022393.7	-4.02	9.96e-05	0.0458	-0.44	-0.34	Depression;	chr6:28187640	chr6:28176188~28176674:+
TGCT	cis	rs2243480	1	rs67728539	ENSG00000164669.11	INTS4P1	4.02	9.96e-05	0.0458	0.55	0.34	Diabetic kidney disease;	chr7:65913137	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs34136756	ENSG00000164669.11	INTS4P1	4.02	9.96e-05	0.0458	0.55	0.34	Diabetic kidney disease;	chr7:65916269	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs78803505	ENSG00000164669.11	INTS4P1	4.02	9.96e-05	0.0458	0.55	0.34	Diabetic kidney disease;	chr7:65917585	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs34933526	ENSG00000164669.11	INTS4P1	4.02	9.96e-05	0.0458	0.55	0.34	Diabetic kidney disease;	chr7:65918212	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs34577383	ENSG00000164669.11	INTS4P1	4.02	9.96e-05	0.0458	0.55	0.34	Diabetic kidney disease;	chr7:65920739	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs6949812	ENSG00000164669.11	INTS4P1	4.02	9.96e-05	0.0458	0.55	0.34	Diabetic kidney disease;	chr7:65922114	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs55895244	ENSG00000164669.11	INTS4P1	4.02	9.96e-05	0.0458	0.55	0.34	Diabetic kidney disease;	chr7:65922691	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs6970243	ENSG00000164669.11	INTS4P1	4.02	9.96e-05	0.0458	0.55	0.34	Diabetic kidney disease;	chr7:65923503	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs7794661	ENSG00000164669.11	INTS4P1	4.02	9.96e-05	0.0458	0.55	0.34	Diabetic kidney disease;	chr7:65924743	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs7795242	ENSG00000164669.11	INTS4P1	4.02	9.96e-05	0.0458	0.55	0.34	Diabetic kidney disease;	chr7:65925107	chr7:65141225~65234216:+
TGCT	cis	rs2243480	0.708	rs35310401	ENSG00000164669.11	INTS4P1	4.02	9.96e-05	0.0458	0.55	0.34	Diabetic kidney disease;	chr7:65925372	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs35058610	ENSG00000164669.11	INTS4P1	4.02	9.96e-05	0.0458	0.55	0.34	Diabetic kidney disease;	chr7:65925938	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs2177703	ENSG00000164669.11	INTS4P1	4.02	9.96e-05	0.0458	0.55	0.34	Diabetic kidney disease;	chr7:65926730	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs35432774	ENSG00000164669.11	INTS4P1	4.02	9.96e-05	0.0458	0.55	0.34	Diabetic kidney disease;	chr7:65928032	chr7:65141225~65234216:+
TGCT	cis	rs2243480	0.831	rs7806717	ENSG00000164669.11	INTS4P1	-4.02	9.96e-05	0.0458	-0.55	-0.34	Diabetic kidney disease;	chr7:65928187	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs56985706	ENSG00000164669.11	INTS4P1	4.02	9.96e-05	0.0458	0.55	0.34	Diabetic kidney disease;	chr7:65929575	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs60683927	ENSG00000164669.11	INTS4P1	4.02	9.96e-05	0.0458	0.55	0.34	Diabetic kidney disease;	chr7:65929781	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs58062456	ENSG00000164669.11	INTS4P1	4.02	9.96e-05	0.0458	0.55	0.34	Diabetic kidney disease;	chr7:65929865	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs34529418	ENSG00000164669.11	INTS4P1	4.02	9.96e-05	0.0458	0.55	0.34	Diabetic kidney disease;	chr7:65938222	chr7:65141225~65234216:+
TGCT	cis	rs36052053	0.522	rs74690263	ENSG00000219700.1	PTCHD3P3	4.02	9.97e-05	0.0458	0.71	0.34	Red cell distribution width;	chr6:109310308	chr6:109288571~109290503:-
TGCT	cis	rs321358	0.895	rs17536059	ENSG00000271584.1	RP11-89C3.4	-4.02	9.97e-05	0.0458	-0.43	-0.34	Body mass index;	chr11:111086611	chr11:111091932~111097357:-
TGCT	cis	rs17826219	0.636	rs12946563	ENSG00000263603.1	CTD-2349P21.5	-4.02	9.97e-05	0.0458	-0.48	-0.34	Body mass index;	chr17:30776148	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs8081299	ENSG00000263603.1	CTD-2349P21.5	-4.02	9.97e-05	0.0458	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs8068645	ENSG00000263603.1	CTD-2349P21.5	-4.02	9.97e-05	0.0458	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30729469~30731202:+
TGCT	cis	rs4820539	0.934	rs3788351	ENSG00000218537.1	MIF-AS1	4.02	9.98e-05	0.0458	0.43	0.34	Bone mineral density;	chr22:23126994	chr22:23894426~23898930:-
TGCT	cis	rs7948471	1	rs7938426	ENSG00000167355.6	AC104389.28	4.02	9.99e-05	0.0459	0.3	0.34	Sickle cell anemia (haemolysis);	chr11:5450602	chr11:5304976~5505652:-
TGCT	cis	rs2153535	0.58	rs4587214	ENSG00000230939.1	RP11-314C16.1	-4.02	9.99e-05	0.0459	-0.32	-0.34	Motion sickness;	chr6:8453886	chr6:8784178~8785445:+
TGCT	cis	rs10971721	0.818	rs10971708	ENSG00000230074.1	RP11-195F19.9	-4.02	1e-04	0.0459	-0.51	-0.34	Body mass index;	chr9:33803273	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs12376279	ENSG00000230074.1	RP11-195F19.9	-4.02	1e-04	0.0459	-0.51	-0.34	Body mass index;	chr9:33804256	chr9:34665665~34681298:+
TGCT	cis	rs7819412	0.74	rs7844536	ENSG00000269918.1	AF131215.9	-4.02	1e-04	0.0459	-0.35	-0.34	Triglycerides;	chr8:11176519	chr8:11104691~11106704:-
TGCT	cis	rs2709736	0.933	rs10274248	ENSG00000232790.2	LINC01162	-4.02	1e-04	0.0459	-0.25	-0.34	Bipolar I disorder;	chr7:20826702	chr7:20835431~21023148:+
TGCT	cis	rs10129255	0.589	rs78599641	ENSG00000253755.1	IGHGP	-4.02	1e-04	0.0459	-0.32	-0.34	Kawasaki disease;	chr14:106637576	chr14:105664633~105669843:-
TGCT	cis	rs853679	0.55	rs1237875	ENSG00000219891.2	ZSCAN12P1	-4.02	1e-04	0.046	-0.44	-0.34	Depression;	chr6:28205232	chr6:28091154~28093664:+
TGCT	cis	rs12760731	0.92	rs12096233	ENSG00000224687.1	RASAL2-AS1	4.02	1e-04	0.046	0.49	0.34	Obesity-related traits;	chr1:178513747	chr1:178091508~178093984:-
TGCT	cis	rs4713118	0.513	rs156739	ENSG00000219392.1	RP1-265C24.5	-4.02	1e-04	0.046	-0.43	-0.34	Parkinson's disease;	chr6:28045632	chr6:28115628~28116551:+
TGCT	cis	rs227275	0.554	rs223422	ENSG00000230069.3	LRRC37A15P	-4.02	1e-04	0.046	-0.3	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102805616	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.554	rs223421	ENSG00000230069.3	LRRC37A15P	-4.02	1e-04	0.046	-0.3	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102805861	chr4:102727274~102730721:-
TGCT	cis	rs11722779	0.81	rs223417	ENSG00000230069.3	LRRC37A15P	-4.02	1e-04	0.046	-0.3	-0.34	Schizophrenia;	chr4:102810568	chr4:102727274~102730721:-
TGCT	cis	rs11722779	0.805	rs223416	ENSG00000230069.3	LRRC37A15P	-4.02	1e-04	0.046	-0.3	-0.34	Schizophrenia;	chr4:102810580	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.554	rs149576	ENSG00000230069.3	LRRC37A15P	-4.02	1e-04	0.046	-0.3	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102811411	chr4:102727274~102730721:-
TGCT	cis	rs227275	0.524	rs150894	ENSG00000230069.3	LRRC37A15P	-4.02	1e-04	0.046	-0.3	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102811541	chr4:102727274~102730721:-
TGCT	cis	rs11722779	0.692	rs223414	ENSG00000230069.3	LRRC37A15P	-4.02	1e-04	0.046	-0.3	-0.34	Schizophrenia;	chr4:102811688	chr4:102727274~102730721:-
TGCT	cis	rs796364	0.512	rs1653290	ENSG00000232732.8	AC073043.1	-4.02	1e-04	0.046	-0.47	-0.34	Schizophrenia;	chr2:200213442	chr2:199867396~199911159:-
TGCT	cis	rs7702057	0.53	rs1567330	ENSG00000197575.6	RPS17P2	-4.02	1e-04	0.046	-0.56	-0.34	Amyotrophic lateral sclerosis;	chr5:116077348	chr5:116716243~116716650:+
TGCT	cis	rs7702057	0.53	rs3946989	ENSG00000197575.6	RPS17P2	-4.02	1e-04	0.046	-0.56	-0.34	Amyotrophic lateral sclerosis;	chr5:116078431	chr5:116716243~116716650:+
TGCT	cis	rs7702057	0.53	rs1567331	ENSG00000197575.6	RPS17P2	-4.02	1e-04	0.046	-0.56	-0.34	Amyotrophic lateral sclerosis;	chr5:116078627	chr5:116716243~116716650:+
TGCT	cis	rs1832007	0.529	rs17306779	ENSG00000224034.1	RP11-445P17.8	4.02	0.000101	0.0461	0.39	0.34	Triglyceride levels;Triglycerides;	chr10:5200201	chr10:5266033~5271236:-
TGCT	cis	rs9952991	0.941	rs34920518	ENSG00000260302.1	RP11-973H7.1	4.02	0.000101	0.0461	0.52	0.34	Inflammatory skin disease;	chr18:12783087	chr18:12774651~12775923:-
TGCT	cis	rs853679	0.517	rs9393895	ENSG00000219891.2	ZSCAN12P1	4.02	0.000101	0.0461	0.45	0.34	Depression;	chr6:28159843	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.513	rs13437444	ENSG00000219392.1	RP1-265C24.5	-4.02	0.000101	0.0461	-0.51	-0.34	Depression;	chr6:28103220	chr6:28115628~28116551:+
TGCT	cis	rs17507216	0.628	rs28607761	ENSG00000255769.6	GOLGA2P10	-4.02	0.000101	0.0461	-0.44	-0.34	Excessive daytime sleepiness;	chr15:82715317	chr15:82472993~82513950:-
TGCT	cis	rs507080	0.961	rs34413584	ENSG00000255239.1	AP002954.6	4.02	0.000101	0.0462	0.44	0.34	Serum metabolite levels;	chr11:118675072	chr11:118688039~118690600:-
TGCT	cis	rs11168618	0.846	rs11168580	ENSG00000240399.1	RP1-228P16.1	4.02	0.000101	0.0462	0.32	0.34	Adiponectin levels;	chr12:48456641	chr12:48054813~48055591:-
TGCT	cis	rs62025270	0.747	rs12324721	ENSG00000259416.2	RP11-158M2.5	-4.02	0.000101	0.0462	-0.41	-0.34	Idiopathic pulmonary fibrosis;	chr15:85767741	chr15:85754941~85756237:-
TGCT	cis	rs891378	0.837	rs11120688	ENSG00000274245.1	RP11-357P18.2	4.02	0.000101	0.0462	0.47	0.34	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207312770	chr1:207372559~207373252:+
TGCT	cis	rs62355900	0.627	rs62355943	ENSG00000271828.1	CTD-2310F14.1	4.02	0.000101	0.0462	0.48	0.34	Endometriosis;	chr5:56814472	chr5:56927874~56929573:+
TGCT	cis	rs62355900	0.627	rs72758038	ENSG00000271828.1	CTD-2310F14.1	4.02	0.000101	0.0462	0.48	0.34	Endometriosis;	chr5:56814857	chr5:56927874~56929573:+
TGCT	cis	rs62355900	0.627	rs60985357	ENSG00000271828.1	CTD-2310F14.1	4.02	0.000101	0.0462	0.48	0.34	Endometriosis;	chr5:56827875	chr5:56927874~56929573:+
TGCT	cis	rs62355900	0.627	rs16886383	ENSG00000271828.1	CTD-2310F14.1	4.02	0.000101	0.0462	0.48	0.34	Endometriosis;	chr5:56829869	chr5:56927874~56929573:+
TGCT	cis	rs62355900	0.627	rs726501	ENSG00000271828.1	CTD-2310F14.1	4.02	0.000101	0.0462	0.48	0.34	Endometriosis;	chr5:56832039	chr5:56927874~56929573:+
TGCT	cis	rs62355900	0.627	rs58292679	ENSG00000271828.1	CTD-2310F14.1	4.02	0.000101	0.0462	0.48	0.34	Endometriosis;	chr5:56839989	chr5:56927874~56929573:+
TGCT	cis	rs62355900	0.627	rs16886400	ENSG00000271828.1	CTD-2310F14.1	4.02	0.000101	0.0462	0.48	0.34	Endometriosis;	chr5:56841605	chr5:56927874~56929573:+
TGCT	cis	rs62355900	0.627	rs61141156	ENSG00000271828.1	CTD-2310F14.1	4.02	0.000101	0.0462	0.48	0.34	Endometriosis;	chr5:56842951	chr5:56927874~56929573:+
TGCT	cis	rs62355900	0.627	rs58151318	ENSG00000271828.1	CTD-2310F14.1	4.02	0.000101	0.0462	0.48	0.34	Endometriosis;	chr5:56843355	chr5:56927874~56929573:+
TGCT	cis	rs62355900	0.627	rs16886407	ENSG00000271828.1	CTD-2310F14.1	4.02	0.000101	0.0462	0.48	0.34	Endometriosis;	chr5:56845540	chr5:56927874~56929573:+
TGCT	cis	rs62355900	0.627	rs16886419	ENSG00000271828.1	CTD-2310F14.1	4.02	0.000101	0.0462	0.48	0.34	Endometriosis;	chr5:56847034	chr5:56927874~56929573:+
TGCT	cis	rs62355901	0.545	rs1862621	ENSG00000271828.1	CTD-2310F14.1	4.02	0.000101	0.0462	0.48	0.34	Breast cancer;	chr5:56847332	chr5:56927874~56929573:+
TGCT	cis	rs62355900	0.627	rs62358076	ENSG00000271828.1	CTD-2310F14.1	4.02	0.000101	0.0462	0.48	0.34	Endometriosis;	chr5:56848189	chr5:56927874~56929573:+
TGCT	cis	rs62355900	0.627	rs16886424	ENSG00000271828.1	CTD-2310F14.1	4.02	0.000101	0.0462	0.48	0.34	Endometriosis;	chr5:56850866	chr5:56927874~56929573:+
TGCT	cis	rs62355900	0.627	rs16886429	ENSG00000271828.1	CTD-2310F14.1	4.02	0.000101	0.0462	0.48	0.34	Endometriosis;	chr5:56857265	chr5:56927874~56929573:+
TGCT	cis	rs62355900	0.627	rs62358104	ENSG00000271828.1	CTD-2310F14.1	4.02	0.000101	0.0462	0.48	0.34	Endometriosis;	chr5:56863344	chr5:56927874~56929573:+
TGCT	cis	rs62355900	0.627	rs61243567	ENSG00000271828.1	CTD-2310F14.1	4.02	0.000101	0.0462	0.48	0.34	Endometriosis;	chr5:56867986	chr5:56927874~56929573:+
TGCT	cis	rs62355900	0.627	rs72758096	ENSG00000271828.1	CTD-2310F14.1	4.02	0.000101	0.0462	0.48	0.34	Endometriosis;	chr5:56870367	chr5:56927874~56929573:+
TGCT	cis	rs62355900	0.627	rs16886449	ENSG00000271828.1	CTD-2310F14.1	4.02	0.000101	0.0462	0.48	0.34	Endometriosis;	chr5:56880479	chr5:56927874~56929573:+
TGCT	cis	rs62355900	0.627	rs895380	ENSG00000271828.1	CTD-2310F14.1	4.02	0.000101	0.0462	0.48	0.34	Endometriosis;	chr5:56881321	chr5:56927874~56929573:+
TGCT	cis	rs62355900	0.627	rs16886463	ENSG00000271828.1	CTD-2310F14.1	4.02	0.000101	0.0462	0.48	0.34	Endometriosis;	chr5:56883514	chr5:56927874~56929573:+
TGCT	cis	rs62355900	0.627	rs62358106	ENSG00000271828.1	CTD-2310F14.1	4.02	0.000101	0.0462	0.48	0.34	Endometriosis;	chr5:56885542	chr5:56927874~56929573:+
TGCT	cis	rs62355900	0.627	rs3817119	ENSG00000271828.1	CTD-2310F14.1	4.02	0.000101	0.0462	0.48	0.34	Endometriosis;	chr5:56887916	chr5:56927874~56929573:+
TGCT	cis	rs12210905	0.858	rs3800305	ENSG00000187763.3	OR2B7P	4.02	0.000101	0.0462	0.45	0.34	Hip circumference adjusted for BMI;	chr6:27217797	chr6:28046434~28047367:+
TGCT	cis	rs7005380	0.581	rs9649949	ENSG00000254343.2	RP11-760H22.2	4.02	0.000101	0.0462	0.48	0.34	Interstitial lung disease;	chr8:119901335	chr8:120052180~120056201:+
TGCT	cis	rs2739330	0.828	rs5760108	ENSG00000250470.1	AP000351.3	4.02	0.000101	0.0462	0.35	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23976904~23977585:-
TGCT	cis	rs7829975	0.606	rs11776838	ENSG00000254340.1	RP11-10A14.3	-4.02	0.000101	0.0462	-0.33	-0.34	Mood instability;	chr8:8937291	chr8:9141424~9145435:+
TGCT	cis	rs2337406	1	rs11846866	ENSG00000274576.2	IGHV2-70	-4.02	0.000101	0.0462	-0.49	-0.34	Alzheimer's disease (late onset);	chr14:106703003	chr14:106770577~106771020:-
TGCT	cis	rs6510489	0.961	rs17705450	ENSG00000267439.1	AC002398.11	4.02	0.000101	0.0463	0.46	0.34	Bipolar disorder;	chr19:35484665	chr19:35747057~35753415:-
TGCT	cis	rs67311347	0.635	rs73071706	ENSG00000223797.4	ENTPD3-AS1	4.02	0.000101	0.0463	0.34	0.34	Renal cell carcinoma;	chr3:40246699	chr3:40313802~40453329:-
TGCT	cis	rs67311347	0.668	rs73071710	ENSG00000223797.4	ENTPD3-AS1	4.02	0.000101	0.0463	0.34	0.34	Renal cell carcinoma;	chr3:40247096	chr3:40313802~40453329:-
TGCT	cis	rs728616	0.867	rs77376252	ENSG00000230091.5	TMEM254-AS1	4.02	0.000101	0.0463	0.63	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80049626	chr10:80046860~80078912:-
TGCT	cis	rs9640161	0.789	rs2373751	ENSG00000261305.1	RP4-584D14.7	4.02	0.000101	0.0463	0.44	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150324510	chr7:150341771~150342607:+
TGCT	cis	rs9640161	0.636	rs56190213	ENSG00000261305.1	RP4-584D14.7	4.02	0.000101	0.0463	0.44	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150328631	chr7:150341771~150342607:+
TGCT	cis	rs9640161	0.711	rs55881542	ENSG00000261305.1	RP4-584D14.7	4.02	0.000101	0.0463	0.44	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150328645	chr7:150341771~150342607:+
TGCT	cis	rs2243480	1	rs35542501	ENSG00000164669.11	INTS4P1	4.02	0.000101	0.0463	0.57	0.34	Diabetic kidney disease;	chr7:65966228	chr7:65141225~65234216:+
TGCT	cis	rs2243480	0.711	rs1626926	ENSG00000164669.11	INTS4P1	4.02	0.000101	0.0463	0.57	0.34	Diabetic kidney disease;	chr7:65970805	chr7:65141225~65234216:+
TGCT	cis	rs2243480	0.708	rs781141	ENSG00000164669.11	INTS4P1	4.02	0.000101	0.0463	0.57	0.34	Diabetic kidney disease;	chr7:65973566	chr7:65141225~65234216:+
TGCT	cis	rs2243480	1	rs781142	ENSG00000164669.11	INTS4P1	4.02	0.000101	0.0463	0.57	0.34	Diabetic kidney disease;	chr7:65973791	chr7:65141225~65234216:+
TGCT	cis	rs4660214	0.666	rs587404	ENSG00000182109.6	RP11-69E11.4	4.02	0.000101	0.0463	0.35	0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39442834	chr1:39522280~39546187:-
TGCT	cis	rs10129255	0.5	rs2027903	ENSG00000223648.3	IGHV3-64	4.02	0.000101	0.0463	0.29	0.34	Kawasaki disease;	chr14:106807047	chr14:106643132~106658258:-
TGCT	cis	rs10129255	0.518	rs28378320	ENSG00000223648.3	IGHV3-64	4.02	0.000101	0.0463	0.29	0.34	Kawasaki disease;	chr14:106808609	chr14:106643132~106658258:-
TGCT	cis	rs7403037	0.583	rs12904497	ENSG00000259905.4	PWRN1	-4.02	0.000101	0.0463	-0.44	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24564703	chr15:24493137~24652130:+
TGCT	cis	rs3819817	0.519	rs10859988	ENSG00000258343.1	RP11-536G4.2	4.02	0.000101	0.0463	0.47	0.34	Vitamin D levels;	chr12:95932442	chr12:95795345~95858839:-
TGCT	cis	rs3819817	0.519	rs2060547	ENSG00000258343.1	RP11-536G4.2	4.02	0.000101	0.0463	0.47	0.34	Vitamin D levels;	chr12:95933120	chr12:95795345~95858839:-
TGCT	cis	rs10019835	0.947	rs3796583	ENSG00000260244.1	RP11-588K22.2	4.02	0.000101	0.0463	0.27	0.34	Diabetic kidney disease;	chr4:155721578	chr4:155734448~155737062:+
TGCT	cis	rs7617480	0.519	rs6790914	ENSG00000226913.1	BSN-AS2	-4.02	0.000101	0.0463	-0.28	-0.34	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49168885	chr3:49549306~49554366:-
TGCT	cis	rs2115630	0.641	rs11073613	ENSG00000225151.9	GOLGA2P7	4.02	0.000101	0.0463	0.33	0.34	P wave terminal force;	chr15:84642662	chr15:84199311~84230136:-
TGCT	cis	rs10891354	0.547	rs11214191	ENSG00000176343.5	RPL37AP8	4.02	0.000101	0.0463	0.38	0.34	Schizophrenia;	chr11:112397695	chr11:111889199~111889474:-
TGCT	cis	rs2739330	0.929	rs5751777	ENSG00000235689.1	AP000351.13	4.02	0.000101	0.0463	0.34	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:24006305~24008258:-
TGCT	cis	rs67311347	0.822	rs11709089	ENSG00000223797.4	ENTPD3-AS1	4.02	0.000101	0.0464	0.35	0.34	Renal cell carcinoma;	chr3:40309993	chr3:40313802~40453329:-
TGCT	cis	rs807029	0.717	rs807024	ENSG00000272572.1	RP11-179B2.2	-4.02	0.000101	0.0464	-0.28	-0.34	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101006817	chr10:100911103~100912739:-
TGCT	cis	rs11047510	0.73	rs55906630	ENSG00000255753.1	RP11-22B23.2	4.02	0.000101	0.0464	0.43	0.34	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr12:8846296	chr12:9314402~9316173:-
TGCT	cis	rs7979367	0.695	rs1562936	ENSG00000251536.2	RP11-572C21.1	4.02	0.000102	0.0464	0.37	0.34	Behavioural disinhibition (generation interaction);Illicit drug use;	chr12:129746195	chr12:129852208~129854944:-
TGCT	cis	rs2153535	0.58	rs6938071	ENSG00000230939.1	RP11-314C16.1	-4.02	0.000102	0.0464	-0.32	-0.34	Motion sickness;	chr6:8464612	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs9406159	ENSG00000230939.1	RP11-314C16.1	-4.02	0.000102	0.0464	-0.32	-0.34	Motion sickness;	chr6:8464626	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.601	rs9406160	ENSG00000230939.1	RP11-314C16.1	-4.02	0.000102	0.0464	-0.32	-0.34	Motion sickness;	chr6:8464674	chr6:8784178~8785445:+
TGCT	cis	rs7005380	0.58	rs10110216	ENSG00000254343.2	RP11-760H22.2	4.02	0.000102	0.0465	0.44	0.34	Interstitial lung disease;	chr8:119875307	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.58	rs10110223	ENSG00000254343.2	RP11-760H22.2	4.02	0.000102	0.0465	0.44	0.34	Interstitial lung disease;	chr8:119875326	chr8:120052180~120056201:+
TGCT	cis	rs7005380	0.58	rs11781657	ENSG00000254343.2	RP11-760H22.2	4.02	0.000102	0.0465	0.44	0.34	Interstitial lung disease;	chr8:119877002	chr8:120052180~120056201:+
TGCT	cis	rs2276314	0.512	rs1789506	ENSG00000278986.1	RP11-723J4.3	4.02	0.000102	0.0465	0.34	0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36045407	chr18:35972151~35973916:+
TGCT	cis	rs5758659	1	rs5758659	ENSG00000270083.1	RP1-257I20.14	4.02	0.000102	0.0465	0.34	0.34	Cognitive function;	chr22:42225997	chr22:42089630~42090028:-
TGCT	cis	rs7795991	0.667	rs17167582	ENSG00000224330.1	AC005019.3	-4.02	0.000102	0.0465	-0.36	-0.34	Type 2 diabetes;	chr7:13850781	chr7:13854355~13859025:-
TGCT	cis	rs853356	1	rs853356	ENSG00000234261.2	RP11-146I2.1	4.02	0.000102	0.0465	0.33	0.34	Height;	chr6:14173197	chr6:14661829~15090003:-
TGCT	cis	rs9322193	0.923	rs6913486	ENSG00000231760.4	RP11-350J20.5	-4.02	0.000102	0.0465	-0.43	-0.34	Lung cancer;	chr6:149705060	chr6:149796151~149826294:-
TGCT	cis	rs853679	0.517	rs9380047	ENSG00000187763.3	OR2B7P	4.02	0.000102	0.0465	0.34	0.34	Depression;	chr6:28070115	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.517	rs7755442	ENSG00000187763.3	OR2B7P	4.02	0.000102	0.0465	0.34	0.34	Depression;	chr6:28071237	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.517	rs4713135	ENSG00000187763.3	OR2B7P	4.02	0.000102	0.0465	0.34	0.34	Depression;	chr6:28071808	chr6:28046434~28047367:+
TGCT	cis	rs1345301	1	rs12470560	ENSG00000234389.1	AC007278.3	-4.02	0.000102	0.0465	-0.26	-0.34	Waist circumference;	chr2:102252380	chr2:102438713~102440475:+
TGCT	cis	rs1345301	1	rs12474199	ENSG00000234389.1	AC007278.3	-4.02	0.000102	0.0465	-0.26	-0.34	Waist circumference;	chr2:102252520	chr2:102438713~102440475:+
TGCT	cis	rs4713118	0.621	rs9368548	ENSG00000219891.2	ZSCAN12P1	4.02	0.000102	0.0465	0.43	0.34	Parkinson's disease;	chr6:28066959	chr6:28091154~28093664:+
TGCT	cis	rs1555322	0.53	rs8122819	ENSG00000126005.14	MMP24-AS1	-4.02	0.000102	0.0465	-0.41	-0.34	Attention deficit hyperactivity disorder;	chr20:35293783	chr20:35216462~35278131:-
TGCT	cis	rs2243480	1	rs709607	ENSG00000164669.11	INTS4P1	-4.02	0.000102	0.0465	-0.57	-0.34	Diabetic kidney disease;	chr7:65984554	chr7:65141225~65234216:+
TGCT	cis	rs4242434	0.889	rs4592028	ENSG00000254064.1	CTD-2530N21.4	-4.02	0.000102	0.0466	-0.21	-0.34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22591971	chr8:22254576~22275162:-
TGCT	cis	rs9952991	0.941	rs7237497	ENSG00000260302.1	RP11-973H7.1	-4.02	0.000102	0.0466	-0.5	-0.34	Inflammatory skin disease;	chr18:12777326	chr18:12774651~12775923:-
TGCT	cis	rs9952991	0.882	rs2847274	ENSG00000260302.1	RP11-973H7.1	-4.02	0.000102	0.0466	-0.5	-0.34	Inflammatory skin disease;	chr18:12777604	chr18:12774651~12775923:-
TGCT	cis	rs9952991	0.941	rs2847278	ENSG00000260302.1	RP11-973H7.1	-4.02	0.000102	0.0466	-0.5	-0.34	Inflammatory skin disease;	chr18:12778716	chr18:12774651~12775923:-
TGCT	cis	rs9952991	0.941	rs2542149	ENSG00000260302.1	RP11-973H7.1	-4.02	0.000102	0.0466	-0.5	-0.34	Inflammatory skin disease;	chr18:12779019	chr18:12774651~12775923:-
TGCT	cis	rs9952991	0.941	rs2847280	ENSG00000260302.1	RP11-973H7.1	-4.02	0.000102	0.0466	-0.5	-0.34	Inflammatory skin disease;	chr18:12779343	chr18:12774651~12775923:-
TGCT	cis	rs9952991	0.941	rs2542150	ENSG00000260302.1	RP11-973H7.1	-4.02	0.000102	0.0466	-0.5	-0.34	Inflammatory skin disease;	chr18:12779764	chr18:12774651~12775923:-
TGCT	cis	rs8072100	0.905	rs11651766	ENSG00000228782.6	CTD-2026D20.3	4.02	0.000102	0.0466	0.4	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47497565	chr17:47450568~47492492:-
TGCT	cis	rs8072100	0.905	rs9901869	ENSG00000228782.6	CTD-2026D20.3	4.02	0.000102	0.0466	0.4	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47497840	chr17:47450568~47492492:-
TGCT	cis	rs853679	0.517	rs17711344	ENSG00000219891.2	ZSCAN12P1	-4.02	0.000102	0.0466	-0.43	-0.34	Depression;	chr6:28109824	chr6:28091154~28093664:+
TGCT	cis	rs2243480	0.901	rs313808	ENSG00000164669.11	INTS4P1	4.02	0.000102	0.0466	0.56	0.34	Diabetic kidney disease;	chr7:66034886	chr7:65141225~65234216:+
TGCT	cis	rs4718428	0.96	rs6460317	ENSG00000226824.5	RP4-756H11.3	-4.02	0.000102	0.0466	-0.42	-0.34	Corneal structure;	chr7:66925268	chr7:66654538~66669855:+
TGCT	cis	rs17507216	0.588	rs28864981	ENSG00000255769.6	GOLGA2P10	-4.01	0.000102	0.0467	-0.44	-0.34	Excessive daytime sleepiness;	chr15:82695420	chr15:82472993~82513950:-
TGCT	cis	rs17507216	0.628	rs8032321	ENSG00000255769.6	GOLGA2P10	-4.01	0.000102	0.0467	-0.44	-0.34	Excessive daytime sleepiness;	chr15:82698956	chr15:82472993~82513950:-
TGCT	cis	rs17507216	0.628	rs8040488	ENSG00000255769.6	GOLGA2P10	-4.01	0.000102	0.0467	-0.44	-0.34	Excessive daytime sleepiness;	chr15:82699081	chr15:82472993~82513950:-
TGCT	cis	rs17507216	0.628	rs4627310	ENSG00000255769.6	GOLGA2P10	-4.01	0.000102	0.0467	-0.44	-0.34	Excessive daytime sleepiness;	chr15:82708330	chr15:82472993~82513950:-
TGCT	cis	rs17507216	0.628	rs28371837	ENSG00000255769.6	GOLGA2P10	-4.01	0.000102	0.0467	-0.44	-0.34	Excessive daytime sleepiness;	chr15:82714435	chr15:82472993~82513950:-
TGCT	cis	rs17507216	0.718	rs17158403	ENSG00000255769.6	GOLGA2P10	-4.01	0.000102	0.0467	-0.44	-0.34	Excessive daytime sleepiness;	chr15:82572478	chr15:82472993~82513950:-
TGCT	cis	rs17507216	0.671	rs4779035	ENSG00000255769.6	GOLGA2P10	-4.01	0.000102	0.0467	-0.44	-0.34	Excessive daytime sleepiness;	chr15:82591686	chr15:82472993~82513950:-
TGCT	cis	rs228614	0.51	rs223358	ENSG00000230069.3	LRRC37A15P	-4.01	0.000102	0.0467	-0.29	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102849637	chr4:102727274~102730721:-
TGCT	cis	rs12549025	0.838	rs12549737	ENSG00000253390.1	CTC-756D1.2	-4.01	0.000102	0.0467	-0.42	-0.34	Reticulocyte fraction of red cells;	chr8:23536948	chr8:23458601~23484971:+
TGCT	cis	rs12439619	0.739	rs4778988	ENSG00000276710.3	CSPG4P8	-4.01	0.000102	0.0468	-0.31	-0.34	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82459472~82477258:+
TGCT	cis	rs72843506	0.722	rs74255392	ENSG00000261033.1	RP11-209D14.2	4.01	0.000103	0.0468	0.51	0.34	Schizophrenia;	chr17:20425739	chr17:20008051~20009234:-
TGCT	cis	rs72843506	0.591	rs117720402	ENSG00000261033.1	RP11-209D14.2	4.01	0.000103	0.0468	0.51	0.34	Schizophrenia;	chr17:20444298	chr17:20008051~20009234:-
TGCT	cis	rs8077577	0.747	rs11872031	ENSG00000186831.10	KRT17P2	-4.01	0.000103	0.0468	-0.48	-0.34	Obesity-related traits;	chr17:18247500	chr17:18426861~18431848:+
TGCT	cis	rs1065852	0.648	rs62240863	ENSG00000182057.4	OGFRP1	-4.01	0.000103	0.0468	-0.34	-0.34	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42167523	chr22:42269753~42275196:+
TGCT	cis	rs11118620	0.622	rs11118618	ENSG00000272823.1	RP11-295M18.6	4.01	0.000103	0.0468	0.34	0.34	Heart failure;	chr1:220838204	chr1:220828676~220829211:-
TGCT	cis	rs853679	0.517	rs3734573	ENSG00000219891.2	ZSCAN12P1	4.01	0.000103	0.0468	0.44	0.34	Depression;	chr6:28091659	chr6:28091154~28093664:+
TGCT	cis	rs9309473	0.898	rs10209517	ENSG00000163016.8	ALMS1P	4.01	0.000103	0.0468	0.31	0.34	Metabolite levels;	chr2:73618265	chr2:73644919~73685576:+
TGCT	cis	rs9309473	0.797	rs6723247	ENSG00000163016.8	ALMS1P	4.01	0.000103	0.0468	0.31	0.34	Metabolite levels;	chr2:73619622	chr2:73644919~73685576:+
TGCT	cis	rs2739330	0.753	rs4822452	ENSG00000250470.1	AP000351.3	4.01	0.000103	0.0468	0.35	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23976904~23977585:-
TGCT	cis	rs2153535	0.541	rs9405386	ENSG00000230939.1	RP11-314C16.1	-4.01	0.000103	0.0469	-0.32	-0.34	Motion sickness;	chr6:8457834	chr6:8784178~8785445:+
TGCT	cis	rs2177312	0.868	rs3934117	ENSG00000251129.1	RP11-734I18.1	4.01	0.000103	0.0469	0.41	0.34	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31936498	chr4:31997397~32155406:+
TGCT	cis	rs1497406	0.744	rs924203	ENSG00000235084.3	CHCHD2P6	4.01	0.000103	0.0469	0.4	0.34	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);	chr1:16185044	chr1:15604597~15605043:+
TGCT	cis	rs7246967	0.551	rs35740274	ENSG00000198153.8	ZNF849P	4.01	0.000103	0.0469	0.55	0.34	Bronchopulmonary dysplasia;	chr19:22648611	chr19:22685167~22686732:+
TGCT	cis	rs2029362	0.611	rs7934165	ENSG00000245573.6	BDNF-AS	4.01	0.000103	0.0469	0.26	0.34	Total body bone mineral density;	chr11:27710436	chr11:27506838~27698174:+
TGCT	cis	rs728616	0.867	rs56198874	ENSG00000230091.5	TMEM254-AS1	4.01	0.000103	0.0469	0.66	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79926732	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs12413715	ENSG00000230091.5	TMEM254-AS1	4.01	0.000103	0.0469	0.66	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79927604	chr10:80046860~80078912:-
TGCT	cis	rs728616	0.867	rs17884637	ENSG00000230091.5	TMEM254-AS1	4.01	0.000103	0.0469	0.66	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79928166	chr10:80046860~80078912:-
TGCT	cis	rs17270561	0.583	rs7749149	ENSG00000217159.2	LARP1P1	-4.01	0.000103	0.0469	-0.43	-0.34	Iron status biomarkers;	chr6:25780911	chr6:26164072~26164363:+
TGCT	cis	rs3956705	1	rs2392158	ENSG00000205763.12	RP9P	4.01	0.000103	0.0469	0.19	0.34	Red cell distribution width;	chr7:32940591	chr7:32916815~32943176:-
TGCT	cis	rs3956705	0.966	rs1037324	ENSG00000205763.12	RP9P	4.01	0.000103	0.0469	0.19	0.34	Red cell distribution width;	chr7:32941549	chr7:32916815~32943176:-
TGCT	cis	rs2337406	0.641	rs3814915	ENSG00000274576.2	IGHV2-70	-4.01	0.000103	0.0469	-0.53	-0.34	Alzheimer's disease (late onset);	chr14:106712886	chr14:106770577~106771020:-
TGCT	cis	rs875971	0.545	rs313830	ENSG00000222364.1	RNU6-96P	4.01	0.000103	0.0469	0.43	0.34	Aortic root size;	chr7:66086944	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.545	rs313828	ENSG00000222364.1	RNU6-96P	4.01	0.000103	0.0469	0.43	0.34	Aortic root size;	chr7:66087627	chr7:66395191~66395286:+
TGCT	cis	rs875971	0.52	rs160645	ENSG00000222364.1	RNU6-96P	4.01	0.000103	0.0469	0.43	0.34	Aortic root size;	chr7:66091320	chr7:66395191~66395286:+
TGCT	cis	rs2455601	0.638	rs2568092	ENSG00000254860.4	TMEM9B-AS1	-4.01	0.000103	0.0469	-0.37	-0.34	Schizophrenia;	chr11:8965891	chr11:8964675~8977527:+
TGCT	cis	rs9660180	0.935	rs2180311	ENSG00000231050.1	RP1-140A9.1	4.01	0.000103	0.0469	0.31	0.34	Body mass index;	chr1:1817295	chr1:1891471~1892658:+
TGCT	cis	rs13256369	0.951	rs12679360	ENSG00000173295.6	FAM86B3P	-4.01	0.000103	0.0469	-0.42	-0.34	Obesity-related traits;	chr8:8708759	chr8:8228595~8244865:+
TGCT	cis	rs35000415	0.688	rs59110799	ENSG00000242078.1	RP11-738B7.1	4.01	0.000103	0.047	0.49	0.34	Systemic lupus erythematosus;	chr7:129075953	chr7:129783370~129785185:-
TGCT	cis	rs758324	0.812	rs11242095	ENSG00000233006.5	AC034220.3	4.01	0.000103	0.047	0.26	0.34	Alzheimer's disease in APOE e4- carriers;	chr5:131816882	chr5:132311285~132369916:-
TGCT	cis	rs3750965	0.575	rs3018691	ENSG00000260808.1	CTD-2007L18.5	-4.01	0.000103	0.047	-0.28	-0.34	Hair color;	chr11:69117075	chr11:68612899~68616711:-
TGCT	cis	rs2505998	1	rs2505998	ENSG00000273008.1	RP11-351D16.3	-4.01	0.000103	0.047	-0.38	-0.34	Hirschsprung disease;	chr10:43075477	chr10:43136824~43138334:-
TGCT	cis	rs2505998	0.957	rs2435366	ENSG00000273008.1	RP11-351D16.3	-4.01	0.000103	0.047	-0.38	-0.34	Hirschsprung disease;	chr10:43076540	chr10:43136824~43138334:-
TGCT	cis	rs2153535	0.58	rs7747306	ENSG00000230939.1	RP11-314C16.1	4.01	0.000103	0.047	0.32	0.34	Motion sickness;	chr6:8453430	chr6:8784178~8785445:+
TGCT	cis	rs7829975	0.774	rs11249893	ENSG00000253893.2	FAM85B	-4.01	0.000103	0.047	-0.43	-0.34	Mood instability;	chr8:8843341	chr8:8167819~8226614:-
TGCT	cis	rs2709736	0.652	rs2709716	ENSG00000232790.2	LINC01162	-4.01	0.000103	0.0471	-0.26	-0.34	Bipolar I disorder;	chr7:20843459	chr7:20835431~21023148:+
TGCT	cis	rs116175783	0.557	rs3731768	ENSG00000227403.1	AC009299.3	4.01	0.000103	0.0471	0.52	0.34	Intelligence (multi-trait analysis);	chr2:161250809	chr2:161244739~161249050:+
TGCT	cis	rs11673344	0.832	rs76781063	ENSG00000226686.6	LINC01535	4.01	0.000104	0.0471	0.39	0.34	Obesity-related traits;	chr19:37036040	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.618	rs4420645	ENSG00000226686.6	LINC01535	4.01	0.000104	0.0471	0.39	0.34	Obesity-related traits;	chr19:37054086	chr19:37251912~37265535:+
TGCT	cis	rs11673344	0.832	rs2011475	ENSG00000226686.6	LINC01535	4.01	0.000104	0.0471	0.39	0.34	Obesity-related traits;	chr19:37054712	chr19:37251912~37265535:+
TGCT	cis	rs73607972	0.696	rs9931018	ENSG00000279344.1	RP11-44F14.7	4.01	0.000104	0.0471	0.4	0.34	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53529205	chr16:53478957~53481550:-
TGCT	cis	rs12935418	0.672	rs78895138	ENSG00000261061.1	RP11-303E16.2	-4.01	0.000104	0.0471	-0.38	-0.34	Mean corpuscular volume;	chr16:81014820	chr16:81030770~81031485:+
TGCT	cis	rs10510102	0.872	rs7906271	ENSG00000276742.1	RP11-500G22.4	-4.01	0.000104	0.0471	-0.54	-0.34	Breast cancer;	chr10:121948207	chr10:121956782~121957098:+
TGCT	cis	rs7555523	0.887	rs6696454	ENSG00000224358.1	RP11-466F5.8	-4.01	0.000104	0.0471	-0.57	-0.34	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165738686	chr1:165768929~165775176:+
TGCT	cis	rs7555523	0.943	rs4537525	ENSG00000224358.1	RP11-466F5.8	-4.01	0.000104	0.0471	-0.57	-0.34	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165741852	chr1:165768929~165775176:+
TGCT	cis	rs7555523	0.887	rs4269750	ENSG00000224358.1	RP11-466F5.8	-4.01	0.000104	0.0471	-0.57	-0.34	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165742273	chr1:165768929~165775176:+
TGCT	cis	rs7555523	0.887	rs10918274	ENSG00000224358.1	RP11-466F5.8	-4.01	0.000104	0.0471	-0.57	-0.34	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165745179	chr1:165768929~165775176:+
TGCT	cis	rs7555523	0.779	rs6662839	ENSG00000224358.1	RP11-466F5.8	-4.01	0.000104	0.0471	-0.57	-0.34	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165753409	chr1:165768929~165775176:+
TGCT	cis	rs2179367	0.959	rs544947	ENSG00000216906.2	RP11-350J20.9	4.01	0.000104	0.0471	0.37	0.34	Dupuytren's disease;	chr6:149402412	chr6:149904243~149906418:+
TGCT	cis	rs7615952	1	rs7616044	ENSG00000171084.14	FAM86JP	4.01	0.000104	0.0471	0.58	0.34	Blood pressure (smoking interaction);	chr3:125930511	chr3:125916620~125930024:+
TGCT	cis	rs11722228	0.539	rs62287552	ENSG00000261490.1	RP11-448G15.3	4.01	0.000104	0.0471	0.31	0.34	Urate levels;Serum uric acid levels;Gout;	chr4:10151573	chr4:10068089~10073019:-
TGCT	cis	rs2066819	1	rs808919	ENSG00000257303.1	RP11-977G19.11	-4.01	0.000104	0.0471	-0.53	-0.34	Psoriasis vulgaris;	chr12:56254127	chr12:56300142~56314808:+
TGCT	cis	rs7403037	0.583	rs61993131	ENSG00000259905.4	PWRN1	4.01	0.000104	0.0471	0.44	0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24541287	chr15:24493137~24652130:+
TGCT	cis	rs7403037	0.652	rs61993134	ENSG00000259905.4	PWRN1	4.01	0.000104	0.0471	0.44	0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24544682	chr15:24493137~24652130:+
TGCT	cis	rs4965272	1	rs1600678	ENSG00000189419.6	SPATA41	-4.01	0.000104	0.0471	-0.3	-0.34	Gastroesophageal reflux disease;	chr15:100039245	chr15:100344457~100349655:-
TGCT	cis	rs5758511	0.514	rs2899354	ENSG00000182057.4	OGFRP1	-4.01	0.000104	0.0472	-0.33	-0.34	Birth weight;	chr22:42158403	chr22:42269753~42275196:+
TGCT	cis	rs1930961	0.85	rs5996945	ENSG00000272798.1	CTA-390C10.9	4.01	0.000104	0.0472	0.54	0.34	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25436312~25436915:+
TGCT	cis	rs4965272	0.909	rs12232371	ENSG00000189419.6	SPATA41	-4.01	0.000104	0.0472	-0.3	-0.34	Gastroesophageal reflux disease;	chr15:100037433	chr15:100344457~100349655:-
TGCT	cis	rs7138803	0.508	rs2290442	ENSG00000271547.1	RP11-579D7.8	-4.01	0.000104	0.0472	-0.32	-0.34	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49791551	chr12:48800576~48801086:-
TGCT	cis	rs13068223	0.74	rs343999	ENSG00000243926.1	TIPARP-AS1	-4.01	0.000104	0.0472	-0.35	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr3:156734050	chr3:156671862~156674378:-
TGCT	cis	rs13068223	0.74	rs344003	ENSG00000243926.1	TIPARP-AS1	-4.01	0.000104	0.0472	-0.35	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr3:156739931	chr3:156671862~156674378:-
TGCT	cis	rs13068223	0.792	rs344034	ENSG00000243926.1	TIPARP-AS1	-4.01	0.000104	0.0472	-0.35	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr3:156745215	chr3:156671862~156674378:-
TGCT	cis	rs7523273	0.586	rs2796264	ENSG00000203709.8	C1orf132	4.01	0.000104	0.0472	0.29	0.34	Schizophrenia;	chr1:207746623	chr1:207801518~207869150:-
TGCT	cis	rs6782228	0.527	rs2811491	ENSG00000242551.2	POU5F1P6	-4.01	0.000104	0.0472	-0.42	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128635107	chr3:128674735~128677005:-
TGCT	cis	rs4691139	0.595	rs10000199	ENSG00000250227.1	TRIM60P14	4.01	0.000104	0.0472	0.38	0.34	Ovarian cancer in BRCA1 mutation carriers;	chr4:165001813	chr4:164915565~164916983:+
TGCT	cis	rs4919669	0.668	rs10786701	ENSG00000273108.1	RP11-416N2.4	-4.01	0.000104	0.0472	-0.52	-0.34	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102652551	chr10:103608619~103610050:+
TGCT	cis	rs7702057	0.53	rs6890263	ENSG00000197575.6	RPS17P2	-4.01	0.000104	0.0472	-0.56	-0.34	Amyotrophic lateral sclerosis;	chr5:116079739	chr5:116716243~116716650:+
TGCT	cis	rs6700559	0.565	rs11807125	ENSG00000260088.1	RP11-92G12.3	4.01	0.000104	0.0472	0.42	0.34	Coronary artery disease;	chr1:200623167	chr1:200669507~200694250:+
TGCT	cis	rs453301	0.658	rs9329175	ENSG00000254340.1	RP11-10A14.3	-4.01	0.000104	0.0472	-0.35	-0.34	Joint mobility (Beighton score);	chr8:9009151	chr8:9141424~9145435:+
TGCT	cis	rs34792	0.524	rs34629185	ENSG00000260872.1	RP11-680G24.5	-4.01	0.000104	0.0473	-0.39	-0.34	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15517597	chr16:15018106~15020488:-
TGCT	cis	rs34792	0.525	rs66651392	ENSG00000260872.1	RP11-680G24.5	-4.01	0.000104	0.0473	-0.39	-0.34	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15517735	chr16:15018106~15020488:-
TGCT	cis	rs7246967	0.932	rs62120780	ENSG00000269509.1	BNIP3P34	4.01	0.000104	0.0473	0.44	0.34	Bronchopulmonary dysplasia;	chr19:22860912	chr19:22773853~22774424:+
TGCT	cis	rs35000415	0.938	rs10488631	ENSG00000242078.1	RP11-738B7.1	4.01	0.000104	0.0473	0.54	0.34	Systemic lupus erythematosus;	chr7:128954129	chr7:129783370~129785185:-
TGCT	cis	rs35000415	0.873	rs12539741	ENSG00000242078.1	RP11-738B7.1	4.01	0.000104	0.0473	0.54	0.34	Systemic lupus erythematosus;	chr7:128956751	chr7:129783370~129785185:-
TGCT	cis	rs1707322	1	rs4298677	ENSG00000280836.1	AL355480.1	-4.01	0.000104	0.0473	-0.44	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45840947	chr1:45581219~45581321:-
TGCT	cis	rs2153535	0.542	rs9505465	ENSG00000230939.1	RP11-314C16.1	-4.01	0.000104	0.0473	-0.33	-0.34	Motion sickness;	chr6:8510613	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs718502	ENSG00000230939.1	RP11-314C16.1	-4.01	0.000104	0.0473	-0.33	-0.34	Motion sickness;	chr6:8527167	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs718503	ENSG00000230939.1	RP11-314C16.1	-4.01	0.000104	0.0473	-0.33	-0.34	Motion sickness;	chr6:8527230	chr6:8784178~8785445:+
TGCT	cis	rs2177312	0.868	rs6852058	ENSG00000251129.1	RP11-734I18.1	-4.01	0.000104	0.0473	-0.42	-0.34	Very long-chain saturated fatty acid levels (fatty acid 22:0);	chr4:31934537	chr4:31997397~32155406:+
TGCT	cis	rs2709736	0.545	rs28608742	ENSG00000232790.2	LINC01162	-4.01	0.000104	0.0473	-0.29	-0.34	Bipolar I disorder;	chr7:20822751	chr7:20835431~21023148:+
TGCT	cis	rs73411413	0.661	rs11599981	ENSG00000233930.3	KRTAP5-AS1	-4.01	0.000104	0.0474	-0.37	-0.34	Myringotomy;	chr11:1498833	chr11:1571353~1599184:+
TGCT	cis	rs6940638	0.688	rs9393790	ENSG00000187763.3	OR2B7P	-4.01	0.000104	0.0474	-0.32	-0.34	Intelligence (multi-trait analysis);	chr6:27146273	chr6:28046434~28047367:+
TGCT	cis	rs7829975	0.688	rs6995407	ENSG00000254340.1	RP11-10A14.3	4.01	0.000104	0.0474	0.35	0.34	Mood instability;	chr8:8527137	chr8:9141424~9145435:+
TGCT	cis	rs7208859	0.673	rs9911989	ENSG00000280069.1	CTD-2349P21.3	4.01	0.000104	0.0474	0.44	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30738182~30740275:+
TGCT	cis	rs5758659	1	rs5758660	ENSG00000270083.1	RP1-257I20.14	4.01	0.000104	0.0474	0.33	0.34	Cognitive function;	chr22:42227712	chr22:42089630~42090028:-
TGCT	cis	rs10759883	0.563	rs689738	ENSG00000175611.10	LINC00476	4.01	0.000104	0.0474	0.31	0.34	Nicotine dependence;	chr9:95939738	chr9:95759231~95875977:-
TGCT	cis	rs73607972	0.935	rs4783818	ENSG00000275191.1	RP11-36I17.2	-4.01	0.000104	0.0474	-0.44	-0.34	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53704371	chr16:53628256~53628816:-
TGCT	cis	rs2273788	0.837	rs13297520	ENSG00000204173.9	LRRC37A5P	4.01	0.000105	0.0474	0.39	0.34	Monocyte count;	chr9:111588861	chr9:111602831~111631289:-
TGCT	cis	rs1850744	0.826	rs4554078	ENSG00000250884.1	OR7E85P	4.01	0.000105	0.0474	0.65	0.34	Economic and political preferences;	chr4:9699920	chr4:9483718~9484702:+
TGCT	cis	rs453301	0.5	rs7015336	ENSG00000173295.6	FAM86B3P	4.01	0.000105	0.0474	0.43	0.34	Joint mobility (Beighton score);	chr8:8973210	chr8:8228595~8244865:+
TGCT	cis	rs673078	0.607	rs4254101	ENSG00000275759.1	RP11-131L12.3	-4.01	0.000105	0.0474	-0.61	-0.34	Glucose homeostasis traits;	chr12:118445877	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs4622305	ENSG00000275759.1	RP11-131L12.3	-4.01	0.000105	0.0474	-0.61	-0.34	Glucose homeostasis traits;	chr12:118445912	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs73207575	ENSG00000275759.1	RP11-131L12.3	-4.01	0.000105	0.0474	-0.61	-0.34	Glucose homeostasis traits;	chr12:118446711	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs61944663	ENSG00000275759.1	RP11-131L12.3	-4.01	0.000105	0.0474	-0.61	-0.34	Glucose homeostasis traits;	chr12:118446886	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs73207577	ENSG00000275759.1	RP11-131L12.3	-4.01	0.000105	0.0474	-0.61	-0.34	Glucose homeostasis traits;	chr12:118447012	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs73207579	ENSG00000275759.1	RP11-131L12.3	-4.01	0.000105	0.0474	-0.61	-0.34	Glucose homeostasis traits;	chr12:118447123	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs61944664	ENSG00000275759.1	RP11-131L12.3	-4.01	0.000105	0.0474	-0.61	-0.34	Glucose homeostasis traits;	chr12:118447145	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs7969871	ENSG00000275759.1	RP11-131L12.3	-4.01	0.000105	0.0474	-0.61	-0.34	Glucose homeostasis traits;	chr12:118447331	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.56	rs7970361	ENSG00000275759.1	RP11-131L12.3	-4.01	0.000105	0.0474	-0.61	-0.34	Glucose homeostasis traits;	chr12:118447723	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs61944669	ENSG00000275759.1	RP11-131L12.3	-4.01	0.000105	0.0474	-0.61	-0.34	Glucose homeostasis traits;	chr12:118448530	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.607	rs61944670	ENSG00000275759.1	RP11-131L12.3	-4.01	0.000105	0.0474	-0.61	-0.34	Glucose homeostasis traits;	chr12:118448697	chr12:118428281~118428870:+
TGCT	cis	rs13118159	0.509	rs7688922	ENSG00000253399.1	AC078852.2	-4.01	0.000105	0.0475	-0.42	-0.34	Longevity;	chr4:1367223	chr4:1358479~1359461:+
TGCT	cis	rs13118159	0.55	rs4974612	ENSG00000253399.1	AC078852.2	-4.01	0.000105	0.0475	-0.42	-0.34	Longevity;	chr4:1370755	chr4:1358479~1359461:+
TGCT	cis	rs2179367	0.959	rs521845	ENSG00000216906.2	RP11-350J20.9	-4.01	0.000105	0.0475	-0.36	-0.34	Dupuytren's disease;	chr6:149350562	chr6:149904243~149906418:+
TGCT	cis	rs7955901	0.691	rs10784889	ENSG00000257454.1	CTD-2021H9.2	4.01	0.000105	0.0475	0.39	0.34	Type 2 diabetes;	chr12:71015481	chr12:71034122~71104526:-
TGCT	cis	rs9952991	0.941	rs2542151	ENSG00000260302.1	RP11-973H7.1	-4.01	0.000105	0.0475	-0.5	-0.34	Inflammatory skin disease;	chr18:12779948	chr18:12774651~12775923:-
TGCT	cis	rs4713118	0.824	rs9468223	ENSG00000187763.3	OR2B7P	4.01	0.000105	0.0475	0.31	0.34	Parkinson's disease;	chr6:27772887	chr6:28046434~28047367:+
TGCT	cis	rs4713118	0.866	rs2179094	ENSG00000187763.3	OR2B7P	4.01	0.000105	0.0475	0.31	0.34	Parkinson's disease;	chr6:27774046	chr6:28046434~28047367:+
TGCT	cis	rs35824328	0.571	rs12694326	ENSG00000197585.8	AC107218.3	4.01	0.000105	0.0475	0.48	0.34	HIV-associated neurocognitive disorder (mild neurocognitive disorder);	chr2:214352073	chr2:214250040~214684246:-
TGCT	cis	rs35824328	0.517	rs1912191	ENSG00000197585.8	AC107218.3	4.01	0.000105	0.0475	0.48	0.34	HIV-associated neurocognitive disorder (mild neurocognitive disorder);	chr2:214352818	chr2:214250040~214684246:-
TGCT	cis	rs1912191	0.651	rs1912188	ENSG00000197585.8	AC107218.3	4.01	0.000105	0.0475	0.48	0.34	Post bronchodilator FEV1/FVC ratio in COPD;	chr2:214354143	chr2:214250040~214684246:-
TGCT	cis	rs2283792	0.765	rs9607298	ENSG00000228050.1	TOP3BP1	4.01	0.000105	0.0475	0.41	0.34	Multiple sclerosis;	chr22:21829844	chr22:22223187~22224566:-
TGCT	cis	rs11166629	1	rs966659	ENSG00000272456.1	CTD-2342N23.3	-4.01	0.000105	0.0476	-0.38	-0.34	Smoking quantity;	chr8:134626802	chr8:134722947~134723949:+
TGCT	cis	rs5742933	1	rs6719224	ENSG00000273240.1	RP11-455J20.3	-4.01	0.000105	0.0476	-0.38	-0.34	Ferritin levels;	chr2:189769545	chr2:189763859~189764456:-
TGCT	cis	rs4820539	1	rs885964	ENSG00000218537.1	MIF-AS1	4.01	0.000105	0.0476	0.42	0.34	Bone mineral density;	chr22:23118816	chr22:23894426~23898930:-
TGCT	cis	rs5758659	0.967	rs5751250	ENSG00000182057.4	OGFRP1	4.01	0.000105	0.0476	0.25	0.34	Cognitive function;	chr22:42243639	chr22:42269753~42275196:+
TGCT	cis	rs12745968	0.589	rs7513775	ENSG00000223787.2	RP4-593M8.1	-4.01	0.000105	0.0476	-0.44	-0.34	Bipolar disorder and schizophrenia;	chr1:92538940	chr1:92580476~92580821:-
TGCT	cis	rs7617480	0.61	rs4955420	ENSG00000226913.1	BSN-AS2	-4.01	0.000105	0.0476	-0.27	-0.34	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49171432	chr3:49549306~49554366:-
TGCT	cis	rs7819412	0.668	rs2409721	ENSG00000255310.2	AF131215.2	-4.01	0.000105	0.0477	-0.29	-0.34	Triglycerides;	chr8:11180735	chr8:11107788~11109726:-
TGCT	cis	rs7403037	0.527	rs28499176	ENSG00000259905.4	PWRN1	4.01	0.000105	0.0477	0.36	0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24533837	chr15:24493137~24652130:+
TGCT	cis	rs2505998	0.843	rs2435344	ENSG00000273008.1	RP11-351D16.3	-4.01	0.000105	0.0477	-0.38	-0.34	Hirschsprung disease;	chr10:43090426	chr10:43136824~43138334:-
TGCT	cis	rs2505998	0.833	rs12767776	ENSG00000273008.1	RP11-351D16.3	-4.01	0.000105	0.0477	-0.38	-0.34	Hirschsprung disease;	chr10:43094065	chr10:43136824~43138334:-
TGCT	cis	rs2505998	0.796	rs2505537	ENSG00000273008.1	RP11-351D16.3	-4.01	0.000105	0.0477	-0.38	-0.34	Hirschsprung disease;	chr10:43096710	chr10:43136824~43138334:-
TGCT	cis	rs10885997	0.775	rs10510024	ENSG00000266200.5	PNLIPRP2	4.01	0.000105	0.0477	0.31	0.34	Phospholipid levels (plasma);	chr10:116620441	chr10:116620953~116645143:+
TGCT	cis	rs9313772	0.928	rs10045018	ENSG00000253519.1	AC106801.1	4.01	0.000105	0.0478	0.3	0.34	Blood pressure;	chr5:158391010	chr5:157565964~157569098:+
TGCT	cis	rs9313772	0.928	rs10076730	ENSG00000253519.1	AC106801.1	-4.01	0.000105	0.0478	-0.3	-0.34	Blood pressure;	chr5:158389984	chr5:157565964~157569098:+
TGCT	cis	rs9313772	0.928	rs13178245	ENSG00000253519.1	AC106801.1	-4.01	0.000105	0.0478	-0.3	-0.34	Blood pressure;	chr5:158390285	chr5:157565964~157569098:+
TGCT	cis	rs9313772	0.928	rs11960210	ENSG00000253519.1	AC106801.1	-4.01	0.000105	0.0478	-0.3	-0.34	Blood pressure;	chr5:158390626	chr5:157565964~157569098:+
TGCT	cis	rs1382167	0.568	rs1478068	ENSG00000225542.1	ZNF385D-AS1	-4.01	0.000105	0.0478	-0.32	-0.34	Airway wall thickness;	chr3:21586900	chr3:21542816~21579959:+
TGCT	cis	rs10129255	1	rs11621409	ENSG00000211970.3	IGHV4-61	-4.01	0.000105	0.0478	-0.37	-0.34	Kawasaki disease;	chr14:106695603	chr14:106639119~106639657:-
TGCT	cis	rs9660180	0.836	rs72634845	ENSG00000231050.1	RP1-140A9.1	4.01	0.000105	0.0478	0.3	0.34	Body mass index;	chr1:1773460	chr1:1891471~1892658:+
TGCT	cis	rs9660180	0.868	rs72634846	ENSG00000231050.1	RP1-140A9.1	4.01	0.000105	0.0478	0.3	0.34	Body mass index;	chr1:1773476	chr1:1891471~1892658:+
TGCT	cis	rs9660180	0.839	rs12040826	ENSG00000231050.1	RP1-140A9.1	4.01	0.000105	0.0478	0.3	0.34	Body mass index;	chr1:1773848	chr1:1891471~1892658:+
TGCT	cis	rs9660180	0.967	rs12044597	ENSG00000231050.1	RP1-140A9.1	4.01	0.000105	0.0478	0.3	0.34	Body mass index;	chr1:1777362	chr1:1891471~1892658:+
TGCT	cis	rs792448	0.743	rs7415843	ENSG00000201544.1	SNORA16B	4.01	0.000106	0.0478	0.34	0.34	White blood cell count (basophil);	chr1:212336420	chr1:212352816~212352950:+
TGCT	cis	rs792448	0.743	rs12033246	ENSG00000201544.1	SNORA16B	4.01	0.000106	0.0478	0.34	0.34	White blood cell count (basophil);	chr1:212339906	chr1:212352816~212352950:+
TGCT	cis	rs792448	0.728	rs2252044	ENSG00000201544.1	SNORA16B	4.01	0.000106	0.0478	0.34	0.34	White blood cell count (basophil);	chr1:212342903	chr1:212352816~212352950:+
TGCT	cis	rs792448	0.743	rs10019	ENSG00000201544.1	SNORA16B	4.01	0.000106	0.0478	0.34	0.34	White blood cell count (basophil);	chr1:212361035	chr1:212352816~212352950:+
TGCT	cis	rs3105593	1	rs12442787	ENSG00000273674.3	CTD-2378E12.1	4.01	0.000106	0.0479	0.36	0.34	QT interval;	chr15:50625910	chr15:50839875~50908599:-
TGCT	cis	rs2337406	1	rs17113331	ENSG00000274576.2	IGHV2-70	-4.01	0.000106	0.0479	-0.5	-0.34	Alzheimer's disease (late onset);	chr14:106703843	chr14:106770577~106771020:-
TGCT	cis	rs2337406	0.704	rs1858679	ENSG00000274576.2	IGHV2-70	-4.01	0.000106	0.0479	-0.5	-0.34	Alzheimer's disease (late onset);	chr14:106706726	chr14:106770577~106771020:-
TGCT	cis	rs10129255	0.613	rs36005652	ENSG00000211970.3	IGHV4-61	-4.01	0.000106	0.0479	-0.36	-0.34	Kawasaki disease;	chr14:106651223	chr14:106639119~106639657:-
TGCT	cis	rs10129255	0.53	rs35069612	ENSG00000211970.3	IGHV4-61	-4.01	0.000106	0.0479	-0.36	-0.34	Kawasaki disease;	chr14:106651364	chr14:106639119~106639657:-
TGCT	cis	rs10129255	0.528	rs61997578	ENSG00000211970.3	IGHV4-61	-4.01	0.000106	0.0479	-0.36	-0.34	Kawasaki disease;	chr14:106651717	chr14:106639119~106639657:-
TGCT	cis	rs10129255	0.56	rs61997579	ENSG00000211970.3	IGHV4-61	-4.01	0.000106	0.0479	-0.36	-0.34	Kawasaki disease;	chr14:106651755	chr14:106639119~106639657:-
TGCT	cis	rs10129255	0.557	rs72622064	ENSG00000211970.3	IGHV4-61	-4.01	0.000106	0.0479	-0.36	-0.34	Kawasaki disease;	chr14:106651784	chr14:106639119~106639657:-
TGCT	cis	rs992157	0.835	rs11677953	ENSG00000261338.2	RP11-378A13.1	-4.01	0.000106	0.0479	-0.3	-0.34	Colorectal cancer;	chr2:218256940	chr2:218255319~218257366:+
TGCT	cis	rs992157	0.804	rs6758540	ENSG00000261338.2	RP11-378A13.1	-4.01	0.000106	0.0479	-0.3	-0.34	Colorectal cancer;	chr2:218273902	chr2:218255319~218257366:+
TGCT	cis	rs992157	0.835	rs2292550	ENSG00000261338.2	RP11-378A13.1	-4.01	0.000106	0.0479	-0.3	-0.34	Colorectal cancer;	chr2:218275565	chr2:218255319~218257366:+
TGCT	cis	rs763121	1	rs86796	ENSG00000273076.1	RP3-508I15.22	-4.01	0.000106	0.0479	-0.36	-0.34	Menopause (age at onset);	chr22:38485449	chr22:38743495~38743910:+
TGCT	cis	rs10129255	0.557	rs4043727	ENSG00000211970.3	IGHV4-61	-4.01	0.000106	0.0479	-0.36	-0.34	Kawasaki disease;	chr14:106649820	chr14:106639119~106639657:-
TGCT	cis	rs2739330	0.587	rs4820571	ENSG00000235689.1	AP000351.13	4.01	0.000106	0.048	0.33	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:24006305~24008258:-
TGCT	cis	rs875971	0.571	rs160647	ENSG00000222364.1	RNU6-96P	4.01	0.000106	0.048	0.44	0.34	Aortic root size;	chr7:66089365	chr7:66395191~66395286:+
TGCT	cis	rs2716882	1	rs2716882	ENSG00000262165.1	RP11-81A22.5	-4	0.000106	0.0481	-0.62	-0.34	Gut microbiome composition (summer);	chr17:5679014	chr17:4801159~4807013:-
TGCT	cis	rs9733	0.744	rs2089081	ENSG00000236713.1	RP11-363I22.3	4	0.000106	0.0481	0.26	0.34	Tonsillectomy;	chr1:150827641	chr1:150780272~150780644:+
TGCT	cis	rs67311347	0.866	rs56331709	ENSG00000223797.4	ENTPD3-AS1	4	0.000106	0.0481	0.35	0.34	Renal cell carcinoma;	chr3:40315067	chr3:40313802~40453329:-
TGCT	cis	rs67311347	0.824	rs73073561	ENSG00000223797.4	ENTPD3-AS1	4	0.000106	0.0481	0.35	0.34	Renal cell carcinoma;	chr3:40315807	chr3:40313802~40453329:-
TGCT	cis	rs853679	0.882	rs9380069	ENSG00000219891.2	ZSCAN12P1	4	0.000106	0.0481	0.54	0.34	Depression;	chr6:28235522	chr6:28091154~28093664:+
TGCT	cis	rs7246967	0.673	rs34126042	ENSG00000198153.8	ZNF849P	4	0.000106	0.0481	0.55	0.34	Bronchopulmonary dysplasia;	chr19:22726416	chr19:22685167~22686732:+
TGCT	cis	rs7829975	0.684	rs488904	ENSG00000173295.6	FAM86B3P	-4	0.000106	0.0481	-0.41	-0.34	Mood instability;	chr8:8730061	chr8:8228595~8244865:+
TGCT	cis	rs7246967	0.611	rs62118770	ENSG00000198153.8	ZNF849P	4	0.000106	0.0481	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22641227	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs62118771	ENSG00000198153.8	ZNF849P	4	0.000106	0.0481	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22641496	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs62118780	ENSG00000198153.8	ZNF849P	4	0.000106	0.0481	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22648312	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs4933019	ENSG00000198153.8	ZNF849P	4	0.000106	0.0481	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22649184	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs35355374	ENSG00000198153.8	ZNF849P	4	0.000106	0.0481	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22654899	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.551	rs34563787	ENSG00000198153.8	ZNF849P	4	0.000106	0.0481	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22654934	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs12983761	ENSG00000198153.8	ZNF849P	4	0.000106	0.0481	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22657795	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs8108452	ENSG00000198153.8	ZNF849P	4	0.000106	0.0481	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22670816	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs12973627	ENSG00000198153.8	ZNF849P	4	0.000106	0.0481	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22684903	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.551	rs12974117	ENSG00000198153.8	ZNF849P	4	0.000106	0.0481	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22685074	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs62120304	ENSG00000198153.8	ZNF849P	4	0.000106	0.0481	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22689466	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs73022717	ENSG00000198153.8	ZNF849P	4	0.000106	0.0481	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22694257	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs8102927	ENSG00000198153.8	ZNF849P	4	0.000106	0.0481	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22696554	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs74664155	ENSG00000198153.8	ZNF849P	4	0.000106	0.0481	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22697530	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.551	rs59127381	ENSG00000198153.8	ZNF849P	4	0.000106	0.0481	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22702233	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.551	rs73022749	ENSG00000198153.8	ZNF849P	4	0.000106	0.0481	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22704458	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs67531478	ENSG00000198153.8	ZNF849P	4	0.000106	0.0481	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22706702	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.604	rs8112577	ENSG00000198153.8	ZNF849P	4	0.000106	0.0481	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22710669	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.673	rs4446014	ENSG00000198153.8	ZNF849P	4	0.000106	0.0481	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22714956	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.604	rs8111899	ENSG00000198153.8	ZNF849P	4	0.000106	0.0481	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22716069	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.611	rs56276210	ENSG00000198153.8	ZNF849P	4	0.000106	0.0481	0.56	0.34	Bronchopulmonary dysplasia;	chr19:22716841	chr19:22685167~22686732:+
TGCT	cis	rs4713118	0.739	rs2893931	ENSG00000187763.3	OR2B7P	4	0.000107	0.0481	0.31	0.34	Parkinson's disease;	chr6:27780231	chr6:28046434~28047367:+
TGCT	cis	rs801193	0.875	rs13227951	ENSG00000272831.1	RP11-792A8.4	-4	0.000107	0.0482	-0.35	-0.34	Aortic root size;	chr7:66748121	chr7:66739829~66740385:-
TGCT	cis	rs11772815	1	rs2391663	ENSG00000233830.2	EIF4HP1	4	0.000107	0.0482	0.37	0.34	Folding of antihelix;	chr7:28348518	chr7:27458163~27458849:-
TGCT	cis	rs72627509	1	rs57265257	ENSG00000269949.1	RP11-738E22.3	4	0.000107	0.0482	0.4	0.34	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56973114	chr4:56960927~56961373:-
TGCT	cis	rs7246657	0.943	rs7408563	ENSG00000226686.6	LINC01535	-4	0.000107	0.0482	-0.56	-0.34	Coronary artery calcification;	chr19:37317683	chr19:37251912~37265535:+
TGCT	cis	rs7246657	0.943	rs7258692	ENSG00000226686.6	LINC01535	-4	0.000107	0.0482	-0.56	-0.34	Coronary artery calcification;	chr19:37327927	chr19:37251912~37265535:+
TGCT	cis	rs7005380	0.785	rs7814294	ENSG00000254343.2	RP11-760H22.2	-4	0.000107	0.0482	-0.43	-0.34	Interstitial lung disease;	chr8:119927196	chr8:120052180~120056201:+
TGCT	cis	rs10256972	0.721	rs10435145	ENSG00000226291.1	AC091729.8	-4	0.000107	0.0482	-0.36	-0.34	Endometriosis;Longevity;	chr7:1026352	chr7:1080863~1082178:+
TGCT	cis	rs62246343	0.516	rs2251166	ENSG00000206573.7	THUMPD3-AS1	4	0.000107	0.0482	0.37	0.34	Fibrinogen levels;	chr3:9400053	chr3:9349689~9398579:-
TGCT	cis	rs172166	0.637	rs1225592	ENSG00000219392.1	RP1-265C24.5	-4	0.000107	0.0482	-0.41	-0.34	Cardiac Troponin-T levels;	chr6:28182464	chr6:28115628~28116551:+
TGCT	cis	rs172166	0.637	rs1225595	ENSG00000219392.1	RP1-265C24.5	-4	0.000107	0.0482	-0.41	-0.34	Cardiac Troponin-T levels;	chr6:28183562	chr6:28115628~28116551:+
TGCT	cis	rs172166	0.637	rs1233691	ENSG00000219392.1	RP1-265C24.5	-4	0.000107	0.0482	-0.41	-0.34	Cardiac Troponin-T levels;	chr6:28186119	chr6:28115628~28116551:+
TGCT	cis	rs13108904	0.934	rs13128045	ENSG00000253399.1	AC078852.2	-4	0.000107	0.0483	-0.39	-0.34	Obesity-related traits;	chr4:1311521	chr4:1358479~1359461:+
TGCT	cis	rs35000415	0.688	rs13232316	ENSG00000242078.1	RP11-738B7.1	4	0.000107	0.0483	0.49	0.34	Systemic lupus erythematosus;	chr7:129075245	chr7:129783370~129785185:-
TGCT	cis	rs35000415	0.688	rs13222044	ENSG00000242078.1	RP11-738B7.1	4	0.000107	0.0483	0.49	0.34	Systemic lupus erythematosus;	chr7:129076471	chr7:129783370~129785185:-
TGCT	cis	rs35000415	0.688	rs12536719	ENSG00000242078.1	RP11-738B7.1	4	0.000107	0.0483	0.49	0.34	Systemic lupus erythematosus;	chr7:129077686	chr7:129783370~129785185:-
TGCT	cis	rs35000415	0.688	rs12537284	ENSG00000242078.1	RP11-738B7.1	4	0.000107	0.0483	0.49	0.34	Systemic lupus erythematosus;	chr7:129077852	chr7:129783370~129785185:-
TGCT	cis	rs35000415	0.688	rs34350562	ENSG00000242078.1	RP11-738B7.1	4	0.000107	0.0483	0.49	0.34	Systemic lupus erythematosus;	chr7:129078654	chr7:129783370~129785185:-
TGCT	cis	rs35000415	0.688	rs13237546	ENSG00000242078.1	RP11-738B7.1	4	0.000107	0.0483	0.49	0.34	Systemic lupus erythematosus;	chr7:129080379	chr7:129783370~129785185:-
TGCT	cis	rs35000415	0.566	rs34644138	ENSG00000242078.1	RP11-738B7.1	4	0.000107	0.0483	0.49	0.34	Systemic lupus erythematosus;	chr7:129080913	chr7:129783370~129785185:-
TGCT	cis	rs35000415	0.566	rs35144535	ENSG00000242078.1	RP11-738B7.1	4	0.000107	0.0483	0.49	0.34	Systemic lupus erythematosus;	chr7:129081723	chr7:129783370~129785185:-
TGCT	cis	rs35000415	0.638	rs77508372	ENSG00000242078.1	RP11-738B7.1	4	0.000107	0.0483	0.49	0.34	Systemic lupus erythematosus;	chr7:129081743	chr7:129783370~129785185:-
TGCT	cis	rs35000415	0.683	rs66872377	ENSG00000242078.1	RP11-738B7.1	4	0.000107	0.0483	0.49	0.34	Systemic lupus erythematosus;	chr7:129082118	chr7:129783370~129785185:-
TGCT	cis	rs35000415	0.683	rs71581969	ENSG00000242078.1	RP11-738B7.1	4	0.000107	0.0483	0.49	0.34	Systemic lupus erythematosus;	chr7:129082183	chr7:129783370~129785185:-
TGCT	cis	rs35000415	0.688	rs17340542	ENSG00000242078.1	RP11-738B7.1	-4	0.000107	0.0483	-0.49	-0.34	Systemic lupus erythematosus;	chr7:129079991	chr7:129783370~129785185:-
TGCT	cis	rs9959491	0.56	rs11663001	ENSG00000227279.1	AC015933.2	4	0.000107	0.0483	0.36	0.34	Breast cancer;	chr18:27808664	chr18:27954519~27963687:+
TGCT	cis	rs172166	0.637	rs1225597	ENSG00000219891.2	ZSCAN12P1	4	0.000107	0.0483	0.4	0.34	Cardiac Troponin-T levels;	chr6:28194309	chr6:28091154~28093664:+
TGCT	cis	rs2015599	0.623	rs7358667	ENSG00000275476.1	RP11-996F15.4	4	0.000107	0.0483	0.36	0.34	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29277397~29277882:-
TGCT	cis	rs4242434	0.672	rs4615566	ENSG00000253200.1	RP11-582J16.5	-4	0.000107	0.0483	-0.18	-0.34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22663169	chr8:22613908~22616657:-
TGCT	cis	rs7160336	0.555	rs7147523	ENSG00000259065.1	RP5-1021I20.1	4	0.000107	0.0483	0.32	0.34	Blood protein levels;	chr14:74034747	chr14:73787360~73803270:+
TGCT	cis	rs5742933	1	rs7557519	ENSG00000273240.1	RP11-455J20.3	-4	0.000107	0.0484	-0.34	-0.34	Ferritin levels;	chr2:189718461	chr2:189763859~189764456:-
TGCT	cis	rs2285002	0.516	rs1273204	ENSG00000276116.2	FUT8-AS1	4	0.000107	0.0484	0.38	0.34	Red cell distribution width;	chr14:64829946	chr14:65411170~65412690:-
TGCT	cis	rs6570726	0.526	rs4895674	ENSG00000270638.1	RP3-466P17.1	-4	0.000107	0.0484	-0.26	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145414724	chr6:145735570~145737218:+
TGCT	cis	rs3956705	0.933	rs13311772	ENSG00000205763.12	RP9P	4	0.000107	0.0484	0.19	0.34	Red cell distribution width;	chr7:32960198	chr7:32916815~32943176:-
TGCT	cis	rs2505998	0.833	rs752977	ENSG00000273008.1	RP11-351D16.3	-4	0.000107	0.0484	-0.38	-0.34	Hirschsprung disease;	chr10:43092933	chr10:43136824~43138334:-
TGCT	cis	rs11054731	0.807	rs10431302	ENSG00000247498.8	RP11-392P7.6	-4	0.000107	0.0485	-0.31	-0.34	Coronary artery calcification;	chr12:12276717	chr12:12927726~12984645:+
TGCT	cis	rs9880211	0.613	rs34864445	ENSG00000239213.4	NCK1-AS1	4	0.000108	0.0485	0.35	0.34	Height;Body mass index;	chr3:136104082	chr3:136841726~136862054:-
TGCT	cis	rs9880211	0.613	rs67109185	ENSG00000239213.4	NCK1-AS1	4	0.000108	0.0485	0.35	0.34	Height;Body mass index;	chr3:136108550	chr3:136841726~136862054:-
TGCT	cis	rs453301	0.592	rs4841084	ENSG00000253981.4	ALG1L13P	4	0.000108	0.0485	0.36	0.34	Joint mobility (Beighton score);	chr8:9026395	chr8:8236003~8244667:-
TGCT	cis	rs453301	0.653	rs2956244	ENSG00000253981.4	ALG1L13P	4	0.000108	0.0485	0.36	0.34	Joint mobility (Beighton score);	chr8:9027656	chr8:8236003~8244667:-
TGCT	cis	rs7246967	0.736	rs446058	ENSG00000269509.1	BNIP3P34	4	0.000108	0.0485	0.5	0.34	Bronchopulmonary dysplasia;	chr19:22817259	chr19:22773853~22774424:+
TGCT	cis	rs7829975	0.606	rs6422352	ENSG00000253893.2	FAM85B	4	0.000108	0.0485	0.43	0.34	Mood instability;	chr8:8936683	chr8:8167819~8226614:-
TGCT	cis	rs7829975	0.606	rs891570	ENSG00000253893.2	FAM85B	4	0.000108	0.0485	0.43	0.34	Mood instability;	chr8:8936944	chr8:8167819~8226614:-
TGCT	cis	rs10946737	0.756	rs1410687	ENSG00000220517.2	ASS1P1	4	0.000108	0.0485	0.33	0.34	Liver injury in anti-tuberculosis drug treatment;	chr6:24985935	chr6:25023247~25024483:-
TGCT	cis	rs11673344	0.711	rs112857724	ENSG00000226686.6	LINC01535	4	0.000108	0.0485	0.39	0.34	Obesity-related traits;	chr19:37030176	chr19:37251912~37265535:+
TGCT	cis	rs3749237	0.595	rs17650792	ENSG00000226913.1	BSN-AS2	-4	0.000108	0.0485	-0.26	-0.34	Resting heart rate;	chr3:49352817	chr3:49549306~49554366:-
TGCT	cis	rs1150668	0.796	rs213237	ENSG00000204709.4	LINC01556	4	0.000108	0.0485	0.37	0.34	Pubertal anthropometrics;	chr6:28356161	chr6:28943877~28944537:+
TGCT	cis	rs1150668	0.796	rs213236	ENSG00000204709.4	LINC01556	4	0.000108	0.0485	0.37	0.34	Pubertal anthropometrics;	chr6:28356620	chr6:28943877~28944537:+
TGCT	cis	rs6782228	0.606	rs2811490	ENSG00000242551.2	POU5F1P6	-4	0.000108	0.0485	-0.41	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128632912	chr3:128674735~128677005:-
TGCT	cis	rs7819412	0.502	rs11777918	ENSG00000269918.1	AF131215.9	4	0.000108	0.0485	0.35	0.34	Triglycerides;	chr8:11179410	chr8:11104691~11106704:-
TGCT	cis	rs453301	0.653	rs7853	ENSG00000253893.2	FAM85B	-4	0.000108	0.0486	-0.43	-0.34	Joint mobility (Beighton score);	chr8:9033304	chr8:8167819~8226614:-
TGCT	cis	rs2337406	0.925	rs873533	ENSG00000274576.2	IGHV2-70	-4	0.000108	0.0486	-0.5	-0.34	Alzheimer's disease (late onset);	chr14:106667442	chr14:106770577~106771020:-
TGCT	cis	rs2337406	1	rs11849532	ENSG00000274576.2	IGHV2-70	-4	0.000108	0.0486	-0.5	-0.34	Alzheimer's disease (late onset);	chr14:106669877	chr14:106770577~106771020:-
TGCT	cis	rs2337406	1	rs11850709	ENSG00000274576.2	IGHV2-70	-4	0.000108	0.0486	-0.5	-0.34	Alzheimer's disease (late onset);	chr14:106670844	chr14:106770577~106771020:-
TGCT	cis	rs2337406	1	rs17113257	ENSG00000274576.2	IGHV2-70	-4	0.000108	0.0486	-0.5	-0.34	Alzheimer's disease (late onset);	chr14:106679574	chr14:106770577~106771020:-
TGCT	cis	rs2337406	1	rs1961901	ENSG00000274576.2	IGHV2-70	-4	0.000108	0.0486	-0.5	-0.34	Alzheimer's disease (late onset);	chr14:106680856	chr14:106770577~106771020:-
TGCT	cis	rs2337406	1	rs4774172	ENSG00000274576.2	IGHV2-70	-4	0.000108	0.0486	-0.5	-0.34	Alzheimer's disease (late onset);	chr14:106681320	chr14:106770577~106771020:-
TGCT	cis	rs881375	0.935	rs7034390	ENSG00000226752.6	PSMD5-AS1	-4	0.000108	0.0486	-0.39	-0.34	Rheumatoid arthritis;	chr9:120884210	chr9:120824828~120854385:+
TGCT	cis	rs77204473	0.655	rs11216183	ENSG00000254851.1	RP11-109L13.1	4	0.000108	0.0486	0.7	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116910829	chr11:117135528~117138582:+
TGCT	cis	rs753274	0.65	rs28497965	ENSG00000266913.1	CTC-548K16.2	-4	0.000108	0.0486	-0.47	-0.34	Tumor necrosis factor beta levels;	chr19:14306590	chr19:14305458~14370196:-
TGCT	cis	rs7777677	0.925	rs4726542	ENSG00000244273.1	PGBD4P1	-4	0.000108	0.0486	-0.4	-0.34	Alcoholic chronic pancreatitis;	chr7:142659516	chr7:142722358~142722764:+
TGCT	cis	rs7777677	0.925	rs73543808	ENSG00000244273.1	PGBD4P1	-4	0.000108	0.0486	-0.4	-0.34	Alcoholic chronic pancreatitis;	chr7:142660024	chr7:142722358~142722764:+
TGCT	cis	rs7777677	0.925	rs4726546	ENSG00000244273.1	PGBD4P1	-4	0.000108	0.0486	-0.4	-0.34	Alcoholic chronic pancreatitis;	chr7:142660485	chr7:142722358~142722764:+
TGCT	cis	rs7777677	0.925	rs6960743	ENSG00000244273.1	PGBD4P1	-4	0.000108	0.0486	-0.4	-0.34	Alcoholic chronic pancreatitis;	chr7:142661768	chr7:142722358~142722764:+
TGCT	cis	rs7777677	0.925	rs6956756	ENSG00000244273.1	PGBD4P1	-4	0.000108	0.0486	-0.4	-0.34	Alcoholic chronic pancreatitis;	chr7:142661832	chr7:142722358~142722764:+
TGCT	cis	rs7777677	0.889	rs6975391	ENSG00000244273.1	PGBD4P1	-4	0.000108	0.0486	-0.4	-0.34	Alcoholic chronic pancreatitis;	chr7:142662001	chr7:142722358~142722764:+
TGCT	cis	rs7777677	0.925	rs9655661	ENSG00000244273.1	PGBD4P1	-4	0.000108	0.0486	-0.4	-0.34	Alcoholic chronic pancreatitis;	chr7:142662291	chr7:142722358~142722764:+
TGCT	cis	rs7777677	0.888	rs9655574	ENSG00000244273.1	PGBD4P1	-4	0.000108	0.0486	-0.4	-0.34	Alcoholic chronic pancreatitis;	chr7:142662412	chr7:142722358~142722764:+
TGCT	cis	rs7777677	0.963	rs4726550	ENSG00000244273.1	PGBD4P1	-4	0.000108	0.0486	-0.4	-0.34	Alcoholic chronic pancreatitis;	chr7:142662932	chr7:142722358~142722764:+
TGCT	cis	rs7777677	0.963	rs7796324	ENSG00000244273.1	PGBD4P1	-4	0.000108	0.0486	-0.4	-0.34	Alcoholic chronic pancreatitis;	chr7:142663708	chr7:142722358~142722764:+
TGCT	cis	rs8113308	0.81	rs8104626	ENSG00000269235.1	ZNF350-AS1	4	0.000108	0.0486	0.6	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51977364	chr19:51949134~51981367:+
TGCT	cis	rs8113308	0.748	rs7251478	ENSG00000269235.1	ZNF350-AS1	4	0.000108	0.0486	0.6	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51979258	chr19:51949134~51981367:+
TGCT	cis	rs2505998	0.833	rs1800858	ENSG00000273008.1	RP11-351D16.3	-4	0.000108	0.0486	-0.39	-0.34	Hirschsprung disease;	chr10:43100520	chr10:43136824~43138334:-
TGCT	cis	rs904251	0.772	rs756202	ENSG00000227920.2	RP1-153P14.5	-4	0.000108	0.0486	-0.42	-0.34	Cognitive performance;	chr6:37492574	chr6:37545145~37550860:+
TGCT	cis	rs7246657	0.943	rs7255952	ENSG00000266916.4	ZNF793-AS1	-4	0.000108	0.0486	-0.34	-0.34	Coronary artery calcification;	chr19:37497895	chr19:37497159~37507046:-
TGCT	cis	rs4713118	0.513	rs149897	ENSG00000219392.1	RP1-265C24.5	-4	0.000108	0.0486	-0.44	-0.34	Parkinson's disease;	chr6:28038872	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.513	rs156734	ENSG00000219392.1	RP1-265C24.5	-4	0.000108	0.0486	-0.44	-0.34	Parkinson's disease;	chr6:28039579	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.513	rs202908	ENSG00000219392.1	RP1-265C24.5	-4	0.000108	0.0486	-0.44	-0.34	Parkinson's disease;	chr6:28043773	chr6:28115628~28116551:+
TGCT	cis	rs10971721	0.822	rs10971773	ENSG00000230074.1	RP11-195F19.9	-4	0.000108	0.0486	-0.5	-0.34	Body mass index;	chr9:33898781	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs56160720	ENSG00000230074.1	RP11-195F19.9	-4	0.000108	0.0486	-0.5	-0.34	Body mass index;	chr9:33899827	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs10971774	ENSG00000230074.1	RP11-195F19.9	-4	0.000108	0.0486	-0.5	-0.34	Body mass index;	chr9:33900111	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72727318	ENSG00000230074.1	RP11-195F19.9	-4	0.000108	0.0486	-0.5	-0.34	Body mass index;	chr9:33901802	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.731	rs10971782	ENSG00000230074.1	RP11-195F19.9	-4	0.000108	0.0486	-0.5	-0.34	Body mass index;	chr9:33909466	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.908	rs10971787	ENSG00000230074.1	RP11-195F19.9	-4	0.000108	0.0486	-0.5	-0.34	Body mass index;	chr9:33914414	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs10971788	ENSG00000230074.1	RP11-195F19.9	-4	0.000108	0.0486	-0.5	-0.34	Body mass index;	chr9:33915087	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72727327	ENSG00000230074.1	RP11-195F19.9	-4	0.000108	0.0486	-0.5	-0.34	Body mass index;	chr9:33918818	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs10971791	ENSG00000230074.1	RP11-195F19.9	-4	0.000108	0.0486	-0.5	-0.34	Body mass index;	chr9:33920912	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs10971792	ENSG00000230074.1	RP11-195F19.9	-4	0.000108	0.0486	-0.5	-0.34	Body mass index;	chr9:33920955	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs72727329	ENSG00000230074.1	RP11-195F19.9	-4	0.000108	0.0486	-0.5	-0.34	Body mass index;	chr9:33921666	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs11848	ENSG00000230074.1	RP11-195F19.9	-4	0.000108	0.0486	-0.5	-0.34	Body mass index;	chr9:33921921	chr9:34665665~34681298:+
TGCT	cis	rs10971721	0.822	rs10971793	ENSG00000230074.1	RP11-195F19.9	-4	0.000108	0.0486	-0.5	-0.34	Body mass index;	chr9:33922628	chr9:34665665~34681298:+
TGCT	cis	rs9640161	0.75	rs11769348	ENSG00000261305.1	RP4-584D14.7	-4	0.000108	0.0486	-0.43	-0.34	Blood protein levels;Circulating chemerin levels;	chr7:150329664	chr7:150341771~150342607:+
TGCT	cis	rs453301	0.682	rs2929308	ENSG00000253893.2	FAM85B	4	0.000108	0.0486	0.42	0.34	Joint mobility (Beighton score);	chr8:9226611	chr8:8167819~8226614:-
TGCT	cis	rs7829975	0.755	rs3789849	ENSG00000173295.6	FAM86B3P	4	0.000108	0.0487	0.4	0.34	Mood instability;	chr8:8829544	chr8:8228595~8244865:+
TGCT	cis	rs673078	0.66	rs11068891	ENSG00000275759.1	RP11-131L12.3	4	0.000108	0.0487	0.62	0.34	Glucose homeostasis traits;	chr12:118259814	chr12:118428281~118428870:+
TGCT	cis	rs673078	0.66	rs7974718	ENSG00000275759.1	RP11-131L12.3	-4	0.000108	0.0487	-0.62	-0.34	Glucose homeostasis traits;	chr12:118243258	chr12:118428281~118428870:+
TGCT	cis	rs2455601	0.638	rs11042148	ENSG00000254860.4	TMEM9B-AS1	4	0.000108	0.0487	0.38	0.34	Schizophrenia;	chr11:8987127	chr11:8964675~8977527:+
TGCT	cis	rs1707322	1	rs7539800	ENSG00000280836.1	AL355480.1	4	0.000108	0.0487	0.46	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr1:45581219~45581321:-
TGCT	cis	rs2337406	0.925	rs873533	ENSG00000211974.3	IGHV2-70	-4	0.000108	0.0487	-0.52	-0.34	Alzheimer's disease (late onset);	chr14:106667442	chr14:106723574~106724093:-
TGCT	cis	rs2337406	1	rs11849532	ENSG00000211974.3	IGHV2-70	-4	0.000108	0.0487	-0.52	-0.34	Alzheimer's disease (late onset);	chr14:106669877	chr14:106723574~106724093:-
TGCT	cis	rs2337406	1	rs11850709	ENSG00000211974.3	IGHV2-70	-4	0.000108	0.0487	-0.52	-0.34	Alzheimer's disease (late onset);	chr14:106670844	chr14:106723574~106724093:-
TGCT	cis	rs2337406	1	rs17113257	ENSG00000211974.3	IGHV2-70	-4	0.000108	0.0487	-0.52	-0.34	Alzheimer's disease (late onset);	chr14:106679574	chr14:106723574~106724093:-
TGCT	cis	rs2337406	1	rs1961901	ENSG00000211974.3	IGHV2-70	-4	0.000108	0.0487	-0.52	-0.34	Alzheimer's disease (late onset);	chr14:106680856	chr14:106723574~106724093:-
TGCT	cis	rs2337406	1	rs4774172	ENSG00000211974.3	IGHV2-70	-4	0.000108	0.0487	-0.52	-0.34	Alzheimer's disease (late onset);	chr14:106681320	chr14:106723574~106724093:-
TGCT	cis	rs7819412	0.74	rs28633434	ENSG00000269918.1	AF131215.9	-4	0.000108	0.0488	-0.33	-0.34	Triglycerides;	chr8:11196413	chr8:11104691~11106704:-
TGCT	cis	rs8072100	0.79	rs11656856	ENSG00000228782.6	CTD-2026D20.3	-4	0.000109	0.0488	-0.4	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47637305	chr17:47450568~47492492:-
TGCT	cis	rs77683187	1	rs77683187	ENSG00000254851.1	RP11-109L13.1	4	0.000109	0.0488	0.82	0.34	Breast cancer;	chr11:117214494	chr11:117135528~117138582:+
TGCT	cis	rs7396835	0.551	rs10750098	ENSG00000254851.1	RP11-109L13.1	-4	0.000109	0.0488	-0.57	-0.34	Quantitative traits;	chr11:116834852	chr11:117135528~117138582:+
TGCT	cis	rs911555	0.519	rs8014069	ENSG00000244691.1	RPL10AP1	-4	0.000109	0.0489	-0.51	-0.34	Intelligence (multi-trait analysis);	chr14:103537974	chr14:103412119~103412761:-
TGCT	cis	rs2439831	0.85	rs28509275	ENSG00000205771.5	CATSPER2P1	-4	0.000109	0.0489	-0.64	-0.34	Lung cancer in ever smokers;	chr15:43805907	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.626	rs1814324	ENSG00000205771.5	CATSPER2P1	-4	0.000109	0.0489	-0.5	-0.34	Lung cancer;	chr15:43314951	chr15:43726918~43747094:-
TGCT	cis	rs17213965	0.561	rs9929522	ENSG00000263335.1	AF001548.5	-4	0.000109	0.049	-0.47	-0.34	Waist-hip ratio;	chr16:15785903	chr16:15726674~15732993:+
TGCT	cis	rs9532669	0.89	rs9532593	ENSG00000176268.5	CYCSP34	4	0.000109	0.049	0.35	0.34	Cervical cancer;	chr13:40847717	chr13:40863599~40863902:-
TGCT	cis	rs673078	0.607	rs2393418	ENSG00000275759.1	RP11-131L12.3	-4	0.000109	0.049	-0.61	-0.34	Glucose homeostasis traits;	chr12:118445995	chr12:118428281~118428870:+
TGCT	cis	rs2439831	1	rs2467743	ENSG00000205771.5	CATSPER2P1	-4	0.000109	0.049	-0.55	-0.34	Lung cancer in ever smokers;	chr15:43458148	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.867	rs2245176	ENSG00000205771.5	CATSPER2P1	-4	0.000109	0.049	-0.55	-0.34	Lung cancer in ever smokers;	chr15:43458564	chr15:43726918~43747094:-
TGCT	cis	rs2439831	1	rs2245054	ENSG00000205771.5	CATSPER2P1	-4	0.000109	0.049	-0.55	-0.34	Lung cancer in ever smokers;	chr15:43459711	chr15:43726918~43747094:-
TGCT	cis	rs2439831	0.867	rs2264876	ENSG00000205771.5	CATSPER2P1	-4	0.000109	0.049	-0.55	-0.34	Lung cancer in ever smokers;	chr15:43465221	chr15:43726918~43747094:-
TGCT	cis	rs1010254	0.543	rs113559777	ENSG00000253921.1	CTB-113P19.3	-4	0.000109	0.049	-0.4	-0.34	Optic nerve measurement (cup area);	chr5:152437084	chr5:151753992~151767247:+
TGCT	cis	rs2285002	0.516	rs229616	ENSG00000276116.2	FUT8-AS1	4	0.000109	0.049	0.37	0.34	Red cell distribution width;	chr14:64826838	chr14:65411170~65412690:-
TGCT	cis	rs2285002	0.516	rs229609	ENSG00000276116.2	FUT8-AS1	4	0.000109	0.049	0.37	0.34	Red cell distribution width;	chr14:64833092	chr14:65411170~65412690:-
TGCT	cis	rs4366055	1	rs4366055	ENSG00000253175.1	RP11-267M23.6	4	0.000109	0.049	0.44	0.34	Body mass index;	chr8:94495100	chr8:94565036~94565715:+
TGCT	cis	rs891378	0.785	rs7516640	ENSG00000274245.1	RP11-357P18.2	4	0.000109	0.049	0.41	0.34	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236069	chr1:207372559~207373252:+
TGCT	cis	rs6844153	1	rs7655686	ENSG00000240005.4	RP11-293A21.1	-4	0.000109	0.049	-0.44	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26897955	chr4:26859806~26860599:-
TGCT	cis	rs13118159	0.55	rs10016557	ENSG00000253399.1	AC078852.2	4	0.000109	0.049	0.41	0.34	Longevity;	chr4:1369840	chr4:1358479~1359461:+
TGCT	cis	rs4273100	0.646	rs2296981	ENSG00000262319.1	CTC-457L16.2	4	0.000109	0.049	0.46	0.34	Schizophrenia;	chr17:19310022	chr17:19141017~19143689:-
TGCT	cis	rs4273100	0.646	rs6587216	ENSG00000262319.1	CTC-457L16.2	4	0.000109	0.049	0.46	0.34	Schizophrenia;	chr17:19321084	chr17:19141017~19143689:-
TGCT	cis	rs1555322	0.53	rs6058224	ENSG00000126005.14	MMP24-AS1	-4	0.000109	0.0491	-0.41	-0.34	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35216462~35278131:-
TGCT	cis	rs3105593	1	rs17645649	ENSG00000273674.3	CTD-2378E12.1	4	0.00011	0.0491	0.36	0.34	QT interval;	chr15:50608173	chr15:50839875~50908599:-
TGCT	cis	rs3105593	1	rs11070800	ENSG00000273674.3	CTD-2378E12.1	4	0.00011	0.0491	0.36	0.34	QT interval;	chr15:50615150	chr15:50839875~50908599:-
TGCT	cis	rs3105593	1	rs28494067	ENSG00000273674.3	CTD-2378E12.1	4	0.00011	0.0491	0.36	0.34	QT interval;	chr15:50616075	chr15:50839875~50908599:-
TGCT	cis	rs3105593	1	rs28718130	ENSG00000273674.3	CTD-2378E12.1	4	0.00011	0.0491	0.36	0.34	QT interval;	chr15:50617292	chr15:50839875~50908599:-
TGCT	cis	rs3105593	0.965	rs12442721	ENSG00000273674.3	CTD-2378E12.1	4	0.00011	0.0491	0.36	0.34	QT interval;	chr15:50618616	chr15:50839875~50908599:-
TGCT	cis	rs3105593	0.965	rs8029073	ENSG00000273674.3	CTD-2378E12.1	4	0.00011	0.0491	0.36	0.34	QT interval;	chr15:50620951	chr15:50839875~50908599:-
TGCT	cis	rs3105593	1	rs62017189	ENSG00000273674.3	CTD-2378E12.1	4	0.00011	0.0491	0.36	0.34	QT interval;	chr15:50629835	chr15:50839875~50908599:-
TGCT	cis	rs3105593	1	rs56118429	ENSG00000273674.3	CTD-2378E12.1	4	0.00011	0.0491	0.36	0.34	QT interval;	chr15:50631652	chr15:50839875~50908599:-
TGCT	cis	rs3105593	1	rs2292174	ENSG00000273674.3	CTD-2378E12.1	4	0.00011	0.0491	0.36	0.34	QT interval;	chr15:50632759	chr15:50839875~50908599:-
TGCT	cis	rs3105593	1	rs8023644	ENSG00000273674.3	CTD-2378E12.1	4	0.00011	0.0491	0.36	0.34	QT interval;	chr15:50644926	chr15:50839875~50908599:-
TGCT	cis	rs3105593	1	rs2899462	ENSG00000273674.3	CTD-2378E12.1	4	0.00011	0.0491	0.36	0.34	QT interval;	chr15:50647057	chr15:50839875~50908599:-
TGCT	cis	rs3105593	0.965	rs62017197	ENSG00000273674.3	CTD-2378E12.1	4	0.00011	0.0491	0.36	0.34	QT interval;	chr15:50648294	chr15:50839875~50908599:-
TGCT	cis	rs3105593	0.966	rs2063010	ENSG00000273674.3	CTD-2378E12.1	4	0.00011	0.0491	0.36	0.34	QT interval;	chr15:50648934	chr15:50839875~50908599:-
TGCT	cis	rs3105593	1	rs11634746	ENSG00000273674.3	CTD-2378E12.1	4	0.00011	0.0491	0.36	0.34	QT interval;	chr15:50649299	chr15:50839875~50908599:-
TGCT	cis	rs10129255	0.956	rs10137268	ENSG00000211970.3	IGHV4-61	-4	0.00011	0.0491	-0.37	-0.34	Kawasaki disease;	chr14:106697402	chr14:106639119~106639657:-
TGCT	cis	rs35000415	0.872	rs2070197	ENSG00000242078.1	RP11-738B7.1	4	0.00011	0.0491	0.54	0.34	Systemic lupus erythematosus;	chr7:128948946	chr7:129783370~129785185:-
TGCT	cis	rs10256972	0.577	rs4999286	ENSG00000229043.2	AC091729.9	-4	0.00011	0.0491	-0.33	-0.34	Endometriosis;Longevity;	chr7:1159870	chr7:1160374~1165267:+
TGCT	cis	rs2408955	0.521	rs10875753	ENSG00000258273.1	RP11-370I10.4	-4	0.00011	0.0491	-0.39	-0.34	Glycated hemoglobin levels;	chr12:48163358	chr12:48333755~48333901:-
TGCT	cis	rs2408955	0.5	rs12816820	ENSG00000258273.1	RP11-370I10.4	-4	0.00011	0.0491	-0.39	-0.34	Glycated hemoglobin levels;	chr12:48164542	chr12:48333755~48333901:-
TGCT	cis	rs9400467	0.537	rs12195305	ENSG00000272356.1	RP5-1112D6.8	-4	0.00011	0.0491	-0.41	-0.34	Amino acid levels;Blood metabolite levels;	chr6:111128025	chr6:111309203~111313517:+
TGCT	cis	rs7829975	0.714	rs11777085	ENSG00000253893.2	FAM85B	-4	0.00011	0.0491	-0.43	-0.34	Mood instability;	chr8:8814919	chr8:8167819~8226614:-
TGCT	cis	rs17507216	0.718	rs72753931	ENSG00000255769.6	GOLGA2P10	-4	0.00011	0.0491	-0.44	-0.34	Excessive daytime sleepiness;	chr15:82721485	chr15:82472993~82513950:-
TGCT	cis	rs2153535	0.58	rs6941670	ENSG00000230939.1	RP11-314C16.1	-4	0.00011	0.0491	-0.32	-0.34	Motion sickness;	chr6:8446113	chr6:8784178~8785445:+
TGCT	cis	rs2153535	0.58	rs6921964	ENSG00000230939.1	RP11-314C16.1	-4	0.00011	0.0491	-0.32	-0.34	Motion sickness;	chr6:8446162	chr6:8784178~8785445:+
TGCT	cis	rs748404	0.697	rs554001	ENSG00000205771.5	CATSPER2P1	-4	0.00011	0.0492	-0.38	-0.34	Lung cancer;	chr15:43259721	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.697	rs501884	ENSG00000205771.5	CATSPER2P1	-4	0.00011	0.0492	-0.38	-0.34	Lung cancer;	chr15:43261784	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.697	rs504417	ENSG00000205771.5	CATSPER2P1	-4	0.00011	0.0492	-0.38	-0.34	Lung cancer;	chr15:43262028	chr15:43726918~43747094:-
TGCT	cis	rs748404	0.723	rs560134	ENSG00000205771.5	CATSPER2P1	-4	0.00011	0.0492	-0.38	-0.34	Lung cancer;	chr15:43263501	chr15:43726918~43747094:-
TGCT	cis	rs4713118	0.513	rs149958	ENSG00000219392.1	RP1-265C24.5	-4	0.00011	0.0492	-0.42	-0.34	Parkinson's disease;	chr6:28045839	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.513	rs149959	ENSG00000219392.1	RP1-265C24.5	-4	0.00011	0.0492	-0.42	-0.34	Parkinson's disease;	chr6:28046076	chr6:28115628~28116551:+
TGCT	cis	rs4713118	0.513	rs156738	ENSG00000219392.1	RP1-265C24.5	-4	0.00011	0.0492	-0.42	-0.34	Parkinson's disease;	chr6:28046247	chr6:28115628~28116551:+
TGCT	cis	rs10946737	0.756	rs4712871	ENSG00000220517.2	ASS1P1	4	0.00011	0.0492	0.32	0.34	Liver injury in anti-tuberculosis drug treatment;	chr6:24990377	chr6:25023247~25024483:-
TGCT	cis	rs12497850	0.864	rs6779394	ENSG00000226913.1	BSN-AS2	-4	0.00011	0.0492	-0.27	-0.34	Parkinson's disease;	chr3:49120338	chr3:49549306~49554366:-
TGCT	cis	rs4713118	0.738	rs200465	ENSG00000187763.3	OR2B7P	4	0.00011	0.0492	0.32	0.34	Parkinson's disease;	chr6:27789875	chr6:28046434~28047367:+
TGCT	cis	rs853679	0.517	rs9380047	ENSG00000219891.2	ZSCAN12P1	4	0.00011	0.0492	0.44	0.34	Depression;	chr6:28070115	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs7755442	ENSG00000219891.2	ZSCAN12P1	4	0.00011	0.0492	0.44	0.34	Depression;	chr6:28071237	chr6:28091154~28093664:+
TGCT	cis	rs853679	0.517	rs4713135	ENSG00000219891.2	ZSCAN12P1	4	0.00011	0.0492	0.44	0.34	Depression;	chr6:28071808	chr6:28091154~28093664:+
TGCT	cis	rs10894147	0.608	rs692094	ENSG00000255262.3	TCEB2P2	4	0.00011	0.0492	0.32	0.34	Obesity-related traits;	chr11:129780885	chr11:130032866~130033220:-
TGCT	cis	rs17826219	0.5	rs2874724	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Body mass index;	chr17:30745415	chr17:30729469~30731202:+
TGCT	cis	rs17826219	0.568	rs9898097	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Body mass index;	chr17:30745654	chr17:30729469~30731202:+
TGCT	cis	rs17826219	0.5	rs9891256	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Body mass index;	chr17:30745674	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs9911490	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs7503542	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs7503335	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.573	rs11656278	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.573	rs56031503	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs6505207	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.573	rs7223803	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30729469~30731202:+
TGCT	cis	rs17826219	0.568	rs2626985	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Body mass index;	chr17:30750419	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs55814012	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30729469~30731202:+
TGCT	cis	rs17826219	0.5	rs2449749	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Body mass index;	chr17:30751280	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs9894709	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs9896603	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs7219361	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs7219712	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.573	rs8078656	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs8080882	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs9898084	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs28556733	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30729469~30731202:+
TGCT	cis	rs17826219	0.5	rs28452421	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Body mass index;	chr17:30756962	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs28433704	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.573	rs28779471	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30729469~30731202:+
TGCT	cis	rs17826219	0.5	rs61685770	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Body mass index;	chr17:30758695	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs57486336	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30729469~30731202:+
TGCT	cis	rs17826219	0.706	rs55764512	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Body mass index;	chr17:30758740	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.524	rs73988172	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs12103440	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs12103508	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.524	rs11653605	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs11657777	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs73269913	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs7217984	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs55811708	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.562	rs8078897	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs8075163	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30729469~30731202:+
TGCT	cis	rs17826219	0.706	rs8075107	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Body mass index;	chr17:30779631	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs7223209	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs7223404	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs9916725	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs9916727	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs9914499	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs73269945	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs9897728	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs9890558	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs9912283	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs12006	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs3752021	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs3752020	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs9890855	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs9893422	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs9891166	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs73269974	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs34756112	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.573	rs60724269	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs76633166	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs1061346	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs1061343	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs1061342	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs55938328	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs73269988	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs55961983	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.573	rs7222803	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.673	rs9899525	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30729469~30731202:+
TGCT	cis	rs17826219	0.568	rs7213925	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Body mass index;	chr17:30794616	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.524	rs11653098	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs11658945	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs11657990	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs9911784	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs9911997	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs9890862	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs78071511	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs11650982	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs2035494	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs9915546	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs9915566	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.573	rs8064686	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs11657369	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs8075341	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs73271842	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.673	rs9895815	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.573	rs7214313	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.673	rs8077116	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.524	rs28760584	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30729469~30731202:+
TGCT	cis	rs17826219	0.706	rs73271850	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Body mass index;	chr17:30815122	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs7208088	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs7212991	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs7208441	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs28627615	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30729469~30731202:+
TGCT	cis	rs7208859	0.623	rs9912440	ENSG00000263603.1	CTD-2349P21.5	-4	0.00011	0.0492	-0.48	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30729469~30731202:+
TGCT	cis	rs4242434	0.927	rs11778693	ENSG00000253200.1	RP11-582J16.5	4	0.00011	0.0492	0.19	0.34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22605339	chr8:22613908~22616657:-
TGCT	cis	rs4242434	0.927	rs7843828	ENSG00000253200.1	RP11-582J16.5	4	0.00011	0.0492	0.19	0.34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22606110	chr8:22613908~22616657:-
TGCT	cis	rs4242434	0.927	rs2291232	ENSG00000253200.1	RP11-582J16.5	4	0.00011	0.0492	0.19	0.34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22606551	chr8:22613908~22616657:-
TGCT	cis	rs4242434	0.927	rs34027561	ENSG00000253200.1	RP11-582J16.5	4	0.00011	0.0492	0.19	0.34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22607872	chr8:22613908~22616657:-
TGCT	cis	rs4242434	0.927	rs11136092	ENSG00000253200.1	RP11-582J16.5	4	0.00011	0.0492	0.19	0.34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22608975	chr8:22613908~22616657:-
TGCT	cis	rs507080	0.733	rs4393358	ENSG00000255239.1	AP002954.6	4	0.00011	0.0492	0.44	0.34	Serum metabolite levels;	chr11:118698388	chr11:118688039~118690600:-
TGCT	cis	rs12908161	0.853	rs11633788	ENSG00000225151.9	GOLGA2P7	-4	0.00011	0.0492	-0.35	-0.34	Schizophrenia;	chr15:84761911	chr15:84199311~84230136:-
TGCT	cis	rs4835473	0.897	rs7676614	ENSG00000251600.4	RP11-673E1.1	-4	0.00011	0.0492	-0.36	-0.34	Immature fraction of reticulocytes;	chr4:143695213	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.864	rs7681559	ENSG00000251600.4	RP11-673E1.1	-4	0.00011	0.0492	-0.36	-0.34	Immature fraction of reticulocytes;	chr4:143695248	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.832	rs55935372	ENSG00000251600.4	RP11-673E1.1	-4	0.00011	0.0492	-0.36	-0.34	Immature fraction of reticulocytes;	chr4:143700626	chr4:143912331~143982454:+
TGCT	cis	rs875971	0.54	rs781152	ENSG00000272831.1	RP11-792A8.4	4	0.00011	0.0492	0.35	0.34	Aortic root size;	chr7:66014585	chr7:66739829~66740385:-
TGCT	cis	rs17711722	0.727	rs781151	ENSG00000272831.1	RP11-792A8.4	4	0.00011	0.0492	0.35	0.34	Calcium levels;	chr7:66014891	chr7:66739829~66740385:-
TGCT	cis	rs2483374	0.527	rs9507423	ENSG00000253771.4	TPTE2P1	-4	0.00011	0.0492	-0.31	-0.34	Obesity-related traits;	chr13:24862119	chr13:24924677~24968487:-
TGCT	cis	rs6604026	0.656	rs2481710	ENSG00000223787.2	RP4-593M8.1	-3.99	0.00011	0.0492	-0.41	-0.34	Multiple sclerosis;	chr1:92871937	chr1:92580476~92580821:-
TGCT	cis	rs6604026	0.656	rs2811594	ENSG00000223787.2	RP4-593M8.1	-3.99	0.00011	0.0492	-0.41	-0.34	Multiple sclerosis;	chr1:92877725	chr1:92580476~92580821:-
TGCT	cis	rs73607972	0.935	rs6499628	ENSG00000275191.1	RP11-36I17.2	-3.99	0.00011	0.0492	-0.45	-0.34	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53570265	chr16:53628256~53628816:-
TGCT	cis	rs7615952	0.8	rs11914298	ENSG00000171084.14	FAM86JP	3.99	0.00011	0.0492	0.58	0.34	Blood pressure (smoking interaction);	chr3:125924929	chr3:125916620~125930024:+
TGCT	cis	rs13118159	0.55	rs2336081	ENSG00000253399.1	AC078852.2	3.99	0.00011	0.0492	0.4	0.34	Longevity;	chr4:1356534	chr4:1358479~1359461:+
TGCT	cis	rs6005807	0.764	rs9620817	ENSG00000272858.1	CTA-292E10.8	-3.99	0.00011	0.0493	-0.53	-0.34	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28712568	chr22:28814914~28815662:+
TGCT	cis	rs2159292	0.59	rs9303273	ENSG00000261433.1	CTC-297N7.1	-3.99	0.00011	0.0493	-0.66	-0.34	Schizophrenia;	chr17:11250522	chr17:10658542~10659082:-
TGCT	cis	rs5769707	0.521	rs74351010	ENSG00000188511.11	C22orf34	-3.99	0.00011	0.0493	-0.46	-0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49643172	chr22:49414524~49657542:-
TGCT	cis	rs673078	0.607	rs56080343	ENSG00000275759.1	RP11-131L12.3	-3.99	0.00011	0.0493	-0.55	-0.34	Glucose homeostasis traits;	chr12:118439113	chr12:118428281~118428870:+
TGCT	cis	rs75422866	0.541	rs61918136	ENSG00000274902.1	RP1-197B17.4	3.99	0.00011	0.0493	0.63	0.34	Pneumonia;	chr12:47566798	chr12:47731908~47732351:+
TGCT	cis	rs1881744	0.588	rs78808618	ENSG00000274902.1	RP1-197B17.4	3.99	0.00011	0.0493	0.63	0.34	Metabolite levels (HVA/5-HIAA ratio);	chr12:47567624	chr12:47731908~47732351:+
TGCT	cis	rs1113500	0.541	rs9803640	ENSG00000226822.1	RP11-356N1.2	-3.99	0.000111	0.0493	-0.44	-0.34	Growth-regulated protein alpha levels;	chr1:108033645	chr1:108071482~108074519:+
TGCT	cis	rs2742234	0.955	rs2503849	ENSG00000273008.1	RP11-351D16.3	-3.99	0.000111	0.0493	-0.38	-0.34	Hirschsprung disease;	chr10:43177328	chr10:43136824~43138334:-
TGCT	cis	rs2742234	0.955	rs2435384	ENSG00000273008.1	RP11-351D16.3	-3.99	0.000111	0.0493	-0.38	-0.34	Hirschsprung disease;	chr10:43178283	chr10:43136824~43138334:-
TGCT	cis	rs7824557	0.585	rs2572385	ENSG00000255020.1	AF131216.5	3.99	0.000111	0.0494	0.24	0.34	Retinal vascular caliber;	chr8:11351394	chr8:11345748~11347502:-
TGCT	cis	rs7246967	0.736	rs446058	ENSG00000198153.8	ZNF849P	3.99	0.000111	0.0494	0.51	0.34	Bronchopulmonary dysplasia;	chr19:22817259	chr19:22685167~22686732:+
TGCT	cis	rs12210905	1	rs12196084	ENSG00000187763.3	OR2B7P	3.99	0.000111	0.0494	0.52	0.34	Hip circumference adjusted for BMI;	chr6:27230425	chr6:28046434~28047367:+
TGCT	cis	rs1850744	0.51	rs9995183	ENSG00000250884.1	OR7E85P	3.99	0.000111	0.0494	0.68	0.34	Economic and political preferences;	chr4:9624169	chr4:9483718~9484702:+
TGCT	cis	rs1850744	0.702	rs6837106	ENSG00000250884.1	OR7E85P	3.99	0.000111	0.0494	0.68	0.34	Economic and political preferences;	chr4:9624680	chr4:9483718~9484702:+
TGCT	cis	rs1850744	0.536	rs9998663	ENSG00000250884.1	OR7E85P	3.99	0.000111	0.0494	0.68	0.34	Economic and political preferences;	chr4:9625429	chr4:9483718~9484702:+
TGCT	cis	rs1850744	0.702	rs11939895	ENSG00000250884.1	OR7E85P	3.99	0.000111	0.0494	0.68	0.34	Economic and political preferences;	chr4:9628778	chr4:9483718~9484702:+
TGCT	cis	rs11168618	0.846	rs11168586	ENSG00000240399.1	RP1-228P16.1	3.99	0.000111	0.0494	0.31	0.34	Adiponectin levels;	chr12:48460229	chr12:48054813~48055591:-
TGCT	cis	rs7824557	0.564	rs34389419	ENSG00000255310.2	AF131215.2	-3.99	0.000111	0.0494	-0.27	-0.34	Retinal vascular caliber;	chr8:11371810	chr8:11107788~11109726:-
TGCT	cis	rs496547	0.721	rs2508570	ENSG00000255239.1	AP002954.6	3.99	0.000111	0.0494	0.38	0.34	Hip minimal joint space width;	chr11:118807900	chr11:118688039~118690600:-
TGCT	cis	rs496547	0.686	rs591756	ENSG00000255239.1	AP002954.6	3.99	0.000111	0.0494	0.38	0.34	Hip minimal joint space width;	chr11:118808172	chr11:118688039~118690600:-
TGCT	cis	rs73607972	1	rs73607972	ENSG00000275191.1	RP11-36I17.2	-3.99	0.000111	0.0495	-0.47	-0.34	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53634741	chr16:53628256~53628816:-
TGCT	cis	rs9329221	0.638	rs12543645	ENSG00000255310.2	AF131215.2	-3.99	0.000111	0.0495	-0.27	-0.34	Neuroticism;	chr8:10388815	chr8:11107788~11109726:-
TGCT	cis	rs7819412	0.521	rs10100660	ENSG00000269918.1	AF131215.9	-3.99	0.000111	0.0495	-0.36	-0.34	Triglycerides;	chr8:11181376	chr8:11104691~11106704:-
TGCT	cis	rs7819412	0.521	rs10110684	ENSG00000269918.1	AF131215.9	-3.99	0.000111	0.0495	-0.36	-0.34	Triglycerides;	chr8:11181650	chr8:11104691~11106704:-
TGCT	cis	rs7819412	0.54	rs2409725	ENSG00000269918.1	AF131215.9	-3.99	0.000111	0.0495	-0.36	-0.34	Triglycerides;	chr8:11184152	chr8:11104691~11106704:-
TGCT	cis	rs7819412	0.54	rs2409726	ENSG00000269918.1	AF131215.9	-3.99	0.000111	0.0495	-0.36	-0.34	Triglycerides;	chr8:11185629	chr8:11104691~11106704:-
TGCT	cis	rs17695224	0.5	rs56083320	ENSG00000269483.1	AC006272.1	3.99	0.000111	0.0495	0.35	0.34	HDL cholesterol;HDL cholesterol levels;	chr19:51818005	chr19:51839924~51843324:-
TGCT	cis	rs853679	1	rs6901575	ENSG00000219392.1	RP1-265C24.5	-3.99	0.000111	0.0495	-0.55	-0.34	Depression;	chr6:28283207	chr6:28115628~28116551:+
TGCT	cis	rs8050896	0.793	rs2014885	ENSG00000259847.1	RP11-95H3.1	-3.99	0.000111	0.0495	-0.49	-0.34	Response to antipsychotic treatment;	chr16:66123012	chr16:65141756~65176713:-
TGCT	cis	rs8050896	1	rs8056781	ENSG00000259847.1	RP11-95H3.1	-3.99	0.000111	0.0495	-0.49	-0.34	Response to antipsychotic treatment;	chr16:66123904	chr16:65141756~65176713:-
TGCT	cis	rs8050896	1	rs16969780	ENSG00000259847.1	RP11-95H3.1	-3.99	0.000111	0.0495	-0.49	-0.34	Response to antipsychotic treatment;	chr16:66123985	chr16:65141756~65176713:-
TGCT	cis	rs8050896	1	rs59544104	ENSG00000259847.1	RP11-95H3.1	-3.99	0.000111	0.0495	-0.49	-0.34	Response to antipsychotic treatment;	chr16:66124034	chr16:65141756~65176713:-
TGCT	cis	rs8050896	1	rs7198106	ENSG00000259847.1	RP11-95H3.1	-3.99	0.000111	0.0495	-0.49	-0.34	Response to antipsychotic treatment;	chr16:66124175	chr16:65141756~65176713:-
TGCT	cis	rs875971	0.545	rs10950029	ENSG00000222364.1	RNU6-96P	-3.99	0.000111	0.0495	-0.41	-0.34	Aortic root size;	chr7:66169334	chr7:66395191~66395286:+
TGCT	cis	rs4713118	0.621	rs10484403	ENSG00000219891.2	ZSCAN12P1	3.99	0.000111	0.0495	0.43	0.34	Parkinson's disease;	chr6:28065745	chr6:28091154~28093664:+
TGCT	cis	rs507080	0.501	rs625735	ENSG00000255422.1	AP002954.4	-3.99	0.000111	0.0496	-0.36	-0.34	Serum metabolite levels;	chr11:118704710	chr11:118704607~118750263:+
TGCT	cis	rs12745968	0.587	rs1034218	ENSG00000223787.2	RP4-593M8.1	-3.99	0.000111	0.0496	-0.43	-0.34	Bipolar disorder and schizophrenia;	chr1:92583574	chr1:92580476~92580821:-
TGCT	cis	rs12745968	0.62	rs7535490	ENSG00000223787.2	RP4-593M8.1	-3.99	0.000111	0.0496	-0.43	-0.34	Bipolar disorder and schizophrenia;	chr1:92596292	chr1:92580476~92580821:-
TGCT	cis	rs12745968	0.525	rs6603997	ENSG00000223787.2	RP4-593M8.1	-3.99	0.000111	0.0496	-0.43	-0.34	Bipolar disorder and schizophrenia;	chr1:92597054	chr1:92580476~92580821:-
TGCT	cis	rs7246967	0.608	rs2569728	ENSG00000198153.8	ZNF849P	3.99	0.000111	0.0496	0.47	0.34	Bronchopulmonary dysplasia;	chr19:22831202	chr19:22685167~22686732:+
TGCT	cis	rs7246967	0.608	rs453175	ENSG00000198153.8	ZNF849P	3.99	0.000111	0.0496	0.47	0.34	Bronchopulmonary dysplasia;	chr19:22831285	chr19:22685167~22686732:+
TGCT	cis	rs2013441	1	rs11870147	ENSG00000230528.6	NOS2P3	3.99	0.000111	0.0496	0.34	0.34	Obesity-related traits;	chr17:20312782	chr17:20436337~20447249:+
TGCT	cis	rs891378	0.959	rs1864370	ENSG00000274245.1	RP11-357P18.2	-3.99	0.000111	0.0496	-0.42	-0.34	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207245687	chr1:207372559~207373252:+
TGCT	cis	rs891378	1	rs1429906	ENSG00000274245.1	RP11-357P18.2	-3.99	0.000111	0.0496	-0.42	-0.34	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207246982	chr1:207372559~207373252:+
TGCT	cis	rs947474	0.887	rs10796035	ENSG00000238266.1	LINC00707	3.99	0.000111	0.0496	0.59	0.34	Rheumatoid arthritis;Type 1 diabetes;	chr10:6354661	chr10:6779598~6842906:+
TGCT	cis	rs5758659	1	rs134869	ENSG00000182057.4	OGFRP1	3.99	0.000111	0.0496	0.25	0.34	Cognitive function;	chr22:42256068	chr22:42269753~42275196:+
TGCT	cis	rs7523273	0.565	rs2025374	ENSG00000203709.8	C1orf132	-3.99	0.000111	0.0497	-0.26	-0.34	Schizophrenia;	chr1:207714191	chr1:207801518~207869150:-
TGCT	cis	rs4660214	0.666	rs1775656	ENSG00000182109.6	RP11-69E11.4	3.99	0.000111	0.0497	0.34	0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39445329	chr1:39522280~39546187:-
TGCT	cis	rs7221109	1	rs7221109	ENSG00000278834.1	RP11-458J1.1	3.99	0.000112	0.0497	0.26	0.34	Type 1 diabetes;	chr17:40614034	chr17:40648300~40649718:+
TGCT	cis	rs2283792	0.765	rs9340	ENSG00000228050.1	TOP3BP1	3.99	0.000112	0.0497	0.41	0.34	Multiple sclerosis;	chr22:21761064	chr22:22223187~22224566:-
TGCT	cis	rs2283792	0.765	rs1063311	ENSG00000228050.1	TOP3BP1	3.99	0.000112	0.0497	0.41	0.34	Multiple sclerosis;	chr22:21762178	chr22:22223187~22224566:-
TGCT	cis	rs10129255	0.509	rs756583	ENSG00000280411.1	IGHV1-69-2	-3.99	0.000112	0.0497	-0.34	-0.34	Kawasaki disease;	chr14:106680002	chr14:106762092~106762588:-
TGCT	cis	rs10875976	1	rs66908137	ENSG00000242041.1	RP11-70F11.2	3.99	0.000112	0.0497	0.29	0.34	Obesity;	chr12:49825706	chr12:49863173~49863503:+
TGCT	cis	rs1497406	0.744	rs7538216	ENSG00000235084.3	CHCHD2P6	3.99	0.000112	0.0497	0.4	0.34	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);	chr1:16183176	chr1:15604597~15605043:+
TGCT	cis	rs1497406	0.744	rs10907282	ENSG00000235084.3	CHCHD2P6	3.99	0.000112	0.0497	0.4	0.34	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);	chr1:16183644	chr1:15604597~15605043:+
TGCT	cis	rs72843506	0.656	rs28567541	ENSG00000261033.1	RP11-209D14.2	3.99	0.000112	0.0497	0.48	0.34	Schizophrenia;	chr17:20051789	chr17:20008051~20009234:-
TGCT	cis	rs72843506	0.656	rs80250684	ENSG00000261033.1	RP11-209D14.2	3.99	0.000112	0.0497	0.48	0.34	Schizophrenia;	chr17:20054983	chr17:20008051~20009234:-
TGCT	cis	rs72843506	0.656	rs28622601	ENSG00000261033.1	RP11-209D14.2	3.99	0.000112	0.0497	0.48	0.34	Schizophrenia;	chr17:20055341	chr17:20008051~20009234:-
TGCT	cis	rs72843506	0.586	rs75048432	ENSG00000261033.1	RP11-209D14.2	3.99	0.000112	0.0497	0.48	0.34	Schizophrenia;	chr17:20057571	chr17:20008051~20009234:-
TGCT	cis	rs72843506	0.656	rs16960660	ENSG00000261033.1	RP11-209D14.2	3.99	0.000112	0.0497	0.48	0.34	Schizophrenia;	chr17:20062274	chr17:20008051~20009234:-
TGCT	cis	rs72843506	0.656	rs73984564	ENSG00000261033.1	RP11-209D14.2	3.99	0.000112	0.0497	0.48	0.34	Schizophrenia;	chr17:20068535	chr17:20008051~20009234:-
TGCT	cis	rs72843506	0.656	rs77540008	ENSG00000261033.1	RP11-209D14.2	3.99	0.000112	0.0497	0.48	0.34	Schizophrenia;	chr17:20069886	chr17:20008051~20009234:-
TGCT	cis	rs72843506	0.656	rs13339684	ENSG00000261033.1	RP11-209D14.2	3.99	0.000112	0.0497	0.48	0.34	Schizophrenia;	chr17:20073898	chr17:20008051~20009234:-
TGCT	cis	rs72843506	0.656	rs73984568	ENSG00000261033.1	RP11-209D14.2	3.99	0.000112	0.0497	0.48	0.34	Schizophrenia;	chr17:20074301	chr17:20008051~20009234:-
TGCT	cis	rs4660456	0.529	rs61779237	ENSG00000237899.1	RP4-739H11.3	3.99	0.000112	0.0497	0.41	0.34	Platelet count;	chr1:40685300	chr1:40669089~40687588:-
TGCT	cis	rs7829975	0.742	rs7832968	ENSG00000173295.6	FAM86B3P	3.99	0.000112	0.0497	0.4	0.34	Mood instability;	chr8:8795379	chr8:8228595~8244865:+
TGCT	cis	rs4660456	0.529	rs2769255	ENSG00000238287.1	RP11-656D10.3	-3.99	0.000112	0.0498	-0.36	-0.34	Platelet count;	chr1:40779682	chr1:40493157~40508661:-
TGCT	cis	rs4691139	0.619	rs2139218	ENSG00000250227.1	TRIM60P14	3.99	0.000112	0.0498	0.38	0.34	Ovarian cancer in BRCA1 mutation carriers;	chr4:165001275	chr4:164915565~164916983:+
TGCT	cis	rs2033711	0.783	rs8113810	ENSG00000268912.1	CTD-2619J13.17	-3.99	0.000112	0.0498	-0.29	-0.34	Uric acid clearance;	chr19:58420739	chr19:58428632~58431148:-
TGCT	cis	rs7829975	0.774	rs35039922	ENSG00000254340.1	RP11-10A14.3	3.99	0.000112	0.0498	0.34	0.34	Mood instability;	chr8:8817815	chr8:9141424~9145435:+
TGCT	cis	rs10759883	0.563	rs12345187	ENSG00000175611.10	LINC00476	3.99	0.000112	0.0498	0.3	0.34	Nicotine dependence;	chr9:95906088	chr9:95759231~95875977:-
TGCT	cis	rs4835473	0.897	rs13135627	ENSG00000251600.4	RP11-673E1.1	-3.99	0.000112	0.0498	-0.36	-0.34	Immature fraction of reticulocytes;	chr4:143691099	chr4:143912331~143982454:+
TGCT	cis	rs4835473	0.864	rs57648439	ENSG00000251600.4	RP11-673E1.1	-3.99	0.000112	0.0498	-0.36	-0.34	Immature fraction of reticulocytes;	chr4:143691519	chr4:143912331~143982454:+
TGCT	cis	rs12497850	0.864	rs4279134	ENSG00000226913.1	BSN-AS2	-3.99	0.000112	0.0498	-0.27	-0.34	Parkinson's disease;	chr3:49119243	chr3:49549306~49554366:-
TGCT	cis	rs9660180	0.78	rs12038111	ENSG00000231050.1	RP1-140A9.1	3.99	0.000112	0.0498	0.3	0.34	Body mass index;	chr1:1772410	chr1:1891471~1892658:+
TGCT	cis	rs9660180	0.836	rs12038134	ENSG00000231050.1	RP1-140A9.1	3.99	0.000112	0.0498	0.3	0.34	Body mass index;	chr1:1772426	chr1:1891471~1892658:+
TGCT	cis	rs10129255	0.556	rs8010005	ENSG00000280411.1	IGHV1-69-2	-3.99	0.000112	0.0498	-0.34	-0.34	Kawasaki disease;	chr14:106777987	chr14:106762092~106762588:-
TGCT	cis	rs10129255	0.556	rs6576224	ENSG00000280411.1	IGHV1-69-2	-3.99	0.000112	0.0498	-0.34	-0.34	Kawasaki disease;	chr14:106777997	chr14:106762092~106762588:-
TGCT	cis	rs10129255	0.518	rs8010020	ENSG00000280411.1	IGHV1-69-2	-3.99	0.000112	0.0498	-0.34	-0.34	Kawasaki disease;	chr14:106778016	chr14:106762092~106762588:-
TGCT	cis	rs10129255	0.5	rs6576225	ENSG00000280411.1	IGHV1-69-2	-3.99	0.000112	0.0498	-0.34	-0.34	Kawasaki disease;	chr14:106778120	chr14:106762092~106762588:-
TGCT	cis	rs10129255	0.5	rs6576226	ENSG00000280411.1	IGHV1-69-2	-3.99	0.000112	0.0498	-0.34	-0.34	Kawasaki disease;	chr14:106778135	chr14:106762092~106762588:-
TGCT	cis	rs7555523	0.887	rs7518099	ENSG00000224358.1	RP11-466F5.8	-3.99	0.000112	0.0498	-0.56	-0.34	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165767643	chr1:165768929~165775176:+
TGCT	cis	rs7555523	0.887	rs2790053	ENSG00000224358.1	RP11-466F5.8	-3.99	0.000112	0.0498	-0.56	-0.34	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165768467	chr1:165768929~165775176:+
TGCT	cis	rs7555523	0.778	rs2790052	ENSG00000224358.1	RP11-466F5.8	-3.99	0.000112	0.0498	-0.56	-0.34	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165769226	chr1:165768929~165775176:+
TGCT	cis	rs10504229	1	rs17805332	ENSG00000253301.4	RP11-513O17.2	3.99	0.000112	0.0498	0.43	0.34	Developmental language disorder (linguistic errors);	chr8:57257239	chr8:57142689~57240298:+
TGCT	cis	rs2302464	1	rs6835705	ENSG00000214846.4	RP11-115L11.1	-3.99	0.000112	0.0499	-0.61	-0.34	Cerebrospinal fluid biomarker levels;	chr4:15736747	chr4:15730962~15731627:-
TGCT	cis	rs10129255	0.528	rs17113214	ENSG00000223648.3	IGHV3-64	3.99	0.000112	0.0499	0.34	0.34	Kawasaki disease;	chr14:106651954	chr14:106643132~106658258:-
TGCT	cis	rs10129255	0.613	rs11161000	ENSG00000223648.3	IGHV3-64	3.99	0.000112	0.0499	0.34	0.34	Kawasaki disease;	chr14:106652584	chr14:106643132~106658258:-
TGCT	cis	rs957448	1	rs72674843	ENSG00000253175.1	RP11-267M23.6	3.99	0.000112	0.0499	0.44	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94520772	chr8:94565036~94565715:+
TGCT	cis	rs957448	1	rs957447	ENSG00000253175.1	RP11-267M23.6	3.99	0.000112	0.0499	0.44	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94528995	chr8:94565036~94565715:+
TGCT	cis	rs957448	1	rs957448	ENSG00000253175.1	RP11-267M23.6	3.99	0.000112	0.0499	0.44	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94529074	chr8:94565036~94565715:+
TGCT	cis	rs957448	1	rs72674852	ENSG00000253175.1	RP11-267M23.6	3.99	0.000112	0.0499	0.44	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94536523	chr8:94565036~94565715:+
TGCT	cis	rs957448	1	rs72674855	ENSG00000253175.1	RP11-267M23.6	3.99	0.000112	0.0499	0.44	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94536706	chr8:94565036~94565715:+
TGCT	cis	rs957448	1	rs16916874	ENSG00000253175.1	RP11-267M23.6	3.99	0.000112	0.0499	0.44	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94537749	chr8:94565036~94565715:+
TGCT	cis	rs7403037	0.583	rs34466529	ENSG00000259905.4	PWRN1	3.99	0.000112	0.0499	0.45	0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24554698	chr15:24493137~24652130:+
TGCT	cis	rs7403037	0.571	rs34414719	ENSG00000259905.4	PWRN1	3.99	0.000112	0.0499	0.45	0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24555095	chr15:24493137~24652130:+
TGCT	cis	rs7403037	0.687	rs36080197	ENSG00000259905.4	PWRN1	3.99	0.000112	0.0499	0.45	0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24561951	chr15:24493137~24652130:+
TGCT	cis	rs12682352	0.652	rs3789843	ENSG00000173295.6	FAM86B3P	3.99	0.000112	0.0499	0.41	0.34	Neuroticism;	chr8:8866747	chr8:8228595~8244865:+
TGCT	cis	rs12682352	0.652	rs3827806	ENSG00000173295.6	FAM86B3P	3.99	0.000112	0.0499	0.41	0.34	Neuroticism;	chr8:8866766	chr8:8228595~8244865:+
TGCT	cis	rs877819	0.697	rs7094742	ENSG00000228403.1	RP11-563N6.6	-3.99	0.000112	0.0499	-0.38	-0.34	Systemic lupus erythematosus;	chr10:48849280	chr10:48878022~48878649:+
TGCT	cis	rs17826219	0.706	rs28469200	ENSG00000263603.1	CTD-2349P21.5	-3.99	0.000112	0.05	-0.47	-0.34	Body mass index;	chr17:30806554	chr17:30729469~30731202:+
TGCT	cis	rs1061377	0.585	rs1367296	ENSG00000249685.1	RP11-360F5.3	3.99	0.000112	0.05	0.31	0.34	Uric acid levels;	chr4:39066895	chr4:39133913~39135608:+
TGCT	cis	rs7107174	1	rs2510047	ENSG00000254420.1	RP11-452H21.1	-3.99	0.000112	0.05	-0.41	-0.34	Testicular germ cell tumor;	chr11:78277622	chr11:78324758~78444049:+
TGCT	cis	rs12210905	0.92	rs858995	ENSG00000187763.3	OR2B7P	-3.99	0.000112	0.05	-0.52	-0.34	Hip circumference adjusted for BMI;	chr6:27213922	chr6:28046434~28047367:+
TGCT	cis	rs4660214	0.666	rs1180383	ENSG00000182109.6	RP11-69E11.4	3.99	0.000112	0.05	0.34	0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380595	chr1:39522280~39546187:-
TGCT	trans	rs7949030	0.626	rs72927213	ENSG00000186676.3	EEF1GP1	18.12	1.16e-36	9.89e-28	1.07	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62583726	chr7:125033453~125035301:+
TGCT	trans	rs928391	0.681	rs12145743	ENSG00000227183.3	HDGFP1	18.03	1.88e-36	1.18e-27	1.07	0.85	Platelet count;	chr1:156730859	chrX:131646639~131646890:+
TGCT	trans	rs7949030	0.626	rs11231154	ENSG00000186676.3	EEF1GP1	17.75	7.59e-36	3.3e-27	1.07	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62594821	chr7:125033453~125035301:+
TGCT	trans	rs7949030	0.591	rs11231156	ENSG00000186676.3	EEF1GP1	17.75	7.59e-36	3.3e-27	1.07	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598982	chr7:125033453~125035301:+
TGCT	trans	rs7949030	0.591	rs12049914	ENSG00000186676.3	EEF1GP1	17.75	7.59e-36	3.3e-27	1.07	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601964	chr7:125033453~125035301:+
TGCT	trans	rs7949030	0.591	rs35156678	ENSG00000186676.3	EEF1GP1	17.75	7.59e-36	3.3e-27	1.07	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602409	chr7:125033453~125035301:+
TGCT	trans	rs7949030	0.596	rs71490394	ENSG00000186676.3	EEF1GP1	17.75	7.59e-36	3.3e-27	1.07	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602683	chr7:125033453~125035301:+
TGCT	trans	rs7949030	0.626	rs11231144	ENSG00000186676.3	EEF1GP1	17.7	9.68e-36	4.14e-27	1.08	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62560566	chr7:125033453~125035301:+
TGCT	trans	rs7949030	0.59	rs12225213	ENSG00000186676.3	EEF1GP1	17.69	1.05e-35	4.45e-27	1.07	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62582776	chr7:125033453~125035301:+
TGCT	trans	rs7949030	0.626	rs11231141	ENSG00000186676.3	EEF1GP1	17.61	1.55e-35	6.34e-27	1.07	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62558793	chr7:125033453~125035301:+
TGCT	trans	rs7949030	0.626	rs61296092	ENSG00000186676.3	EEF1GP1	17.4	4.4e-35	1.64e-26	1.07	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62553366	chr7:125033453~125035301:+
TGCT	trans	rs7949030	0.626	rs7943191	ENSG00000186676.3	EEF1GP1	17.27	8.62e-35	3.14e-26	1.06	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561079	chr7:125033453~125035301:+
TGCT	trans	rs7949030	0.626	rs11231145	ENSG00000186676.3	EEF1GP1	17.27	8.62e-35	3.14e-26	1.06	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561382	chr7:125033453~125035301:+
TGCT	trans	rs7949030	0.626	rs71490390	ENSG00000186676.3	EEF1GP1	17.27	8.62e-35	3.14e-26	1.06	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561713	chr7:125033453~125035301:+
TGCT	trans	rs7949030	0.626	rs7124057	ENSG00000186676.3	EEF1GP1	17.27	8.62e-35	3.14e-26	1.06	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62566624	chr7:125033453~125035301:+
TGCT	trans	rs7949030	0.626	rs1061093	ENSG00000186676.3	EEF1GP1	17.27	8.62e-35	3.14e-26	1.06	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62567436	chr7:125033453~125035301:+
TGCT	trans	rs13177918	0.677	rs13161417	ENSG00000213058.3	RP4-765C7.2	17.21	1.19e-34	4.25e-26	1.17	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:178411616~178411972:+
TGCT	trans	rs13177918	0.677	rs13161156	ENSG00000213058.3	RP4-765C7.2	17.21	1.19e-34	4.25e-26	1.17	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:178411616~178411972:+
TGCT	trans	rs7949030	0.653	rs17773169	ENSG00000186676.3	EEF1GP1	17.09	2.16e-34	7.62e-26	1.06	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551058	chr7:125033453~125035301:+
TGCT	trans	rs7949030	0.596	rs11231138	ENSG00000186676.3	EEF1GP1	17.08	2.24e-34	7.79e-26	1.08	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62548723	chr7:125033453~125035301:+
TGCT	trans	rs928391	0.681	rs12161427	ENSG00000227183.3	HDGFP1	16.99	3.52e-34	1.18e-25	1.06	0.84	Platelet count;	chr1:156736030	chrX:131646639~131646890:+
TGCT	trans	rs13177918	0.677	rs13181401	ENSG00000213058.3	RP4-765C7.2	16.98	3.81e-34	1.18e-25	1.17	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:178411616~178411972:+
TGCT	trans	rs13177918	0.677	rs4541646	ENSG00000213058.3	RP4-765C7.2	16.98	3.81e-34	1.18e-25	1.17	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:178411616~178411972:+
TGCT	trans	rs13177918	0.677	rs3900644	ENSG00000213058.3	RP4-765C7.2	16.98	3.81e-34	1.18e-25	1.17	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:178411616~178411972:+
TGCT	trans	rs13177918	0.677	rs2070844	ENSG00000213058.3	RP4-765C7.2	16.98	3.81e-34	1.18e-25	1.17	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:178411616~178411972:+
TGCT	trans	rs13177918	0.629	rs2070842	ENSG00000213058.3	RP4-765C7.2	16.98	3.81e-34	1.18e-25	1.17	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:178411616~178411972:+
TGCT	trans	rs13177918	0.677	rs13171800	ENSG00000213058.3	RP4-765C7.2	16.98	3.81e-34	1.18e-25	1.17	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:178411616~178411972:+
TGCT	trans	rs13177918	0.677	rs2070841	ENSG00000213058.3	RP4-765C7.2	16.98	3.81e-34	1.18e-25	1.17	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:178411616~178411972:+
TGCT	trans	rs13177918	0.677	rs13177951	ENSG00000213058.3	RP4-765C7.2	16.98	3.81e-34	1.18e-25	1.17	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:178411616~178411972:+
TGCT	trans	rs13177918	0.677	rs13177970	ENSG00000213058.3	RP4-765C7.2	16.98	3.81e-34	1.18e-25	1.17	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:178411616~178411972:+
TGCT	trans	rs13177918	0.677	rs13164105	ENSG00000213058.3	RP4-765C7.2	16.98	3.81e-34	1.18e-25	1.17	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:178411616~178411972:+
TGCT	trans	rs928391	0.681	rs11264535	ENSG00000227183.3	HDGFP1	16.85	7.48e-34	2.28e-25	1.05	0.83	Platelet count;	chr1:156752632	chrX:131646639~131646890:+
TGCT	trans	rs13177918	0.677	rs57890152	ENSG00000213058.3	RP4-765C7.2	16.85	7.56e-34	2.28e-25	1.17	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:178411616~178411972:+
TGCT	trans	rs13177918	0.677	rs13160685	ENSG00000213058.3	RP4-765C7.2	16.85	7.56e-34	2.28e-25	1.17	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:178411616~178411972:+
TGCT	trans	rs13177918	0.677	rs13161099	ENSG00000213058.3	RP4-765C7.2	16.85	7.56e-34	2.28e-25	1.17	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:178411616~178411972:+
TGCT	trans	rs13177918	0.629	rs13161261	ENSG00000213058.3	RP4-765C7.2	16.85	7.56e-34	2.28e-25	1.17	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:178411616~178411972:+
TGCT	trans	rs13177918	0.677	rs2073472	ENSG00000213058.3	RP4-765C7.2	16.83	8.03e-34	2.4e-25	1.17	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:178411616~178411972:+
TGCT	trans	rs13177918	0.677	rs3797622	ENSG00000213058.3	RP4-765C7.2	16.83	8.33e-34	2.47e-25	1.16	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:178411616~178411972:+
TGCT	trans	rs7949030	0.62	rs2428551	ENSG00000186676.3	EEF1GP1	16.83	8.34e-34	2.47e-25	1.03	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62562286	chr7:125033453~125035301:+
TGCT	trans	rs7949030	0.591	rs35880596	ENSG00000186676.3	EEF1GP1	16.81	9.23e-34	2.72e-25	1.05	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602412	chr7:125033453~125035301:+
TGCT	trans	rs13177918	0.677	rs4841	ENSG00000213058.3	RP4-765C7.2	16.73	1.33e-33	3.9e-25	1.16	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:178411616~178411972:+
TGCT	trans	rs13177918	0.677	rs13183077	ENSG00000213058.3	RP4-765C7.2	16.73	1.33e-33	3.9e-25	1.16	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:178411616~178411972:+
TGCT	trans	rs7949030	0.626	rs7930896	ENSG00000186676.3	EEF1GP1	16.71	1.5e-33	4.36e-25	1.05	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62557800	chr7:125033453~125035301:+
TGCT	trans	rs13177918	0.677	rs3857421	ENSG00000213058.3	RP4-765C7.2	-16.68	1.81e-33	5.14e-25	-1.12	-0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:178411616~178411972:+
TGCT	trans	rs7949030	0.688	rs11231155	ENSG00000186676.3	EEF1GP1	16.68	1.81e-33	5.14e-25	1.03	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598147	chr7:125033453~125035301:+
TGCT	trans	rs9611565	0.685	rs169363	ENSG00000268568.1	AC007228.9	16.68	1.82e-33	5.14e-25	1.14	0.83	Vitiligo;	chr22:41457113	chr19:56672574~56673901:-
TGCT	trans	rs13177918	0.686	rs12654827	ENSG00000213058.3	RP4-765C7.2	16.64	2.19e-33	6.15e-25	1.17	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:178411616~178411972:+
TGCT	trans	rs7949030	0.622	rs34894392	ENSG00000186676.3	EEF1GP1	16.53	3.81e-33	1.05e-24	1.03	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62607349	chr7:125033453~125035301:+
TGCT	trans	rs7949030	0.653	rs2516634	ENSG00000186676.3	EEF1GP1	-16.5	4.44e-33	1.22e-24	-1.03	-0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599714	chr7:125033453~125035301:+
TGCT	trans	rs9611565	0.694	rs79008	ENSG00000268568.1	AC007228.9	-16.49	4.66e-33	1.28e-24	-1.13	-0.83	Vitiligo;	chr22:41454496	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.694	rs106860	ENSG00000268568.1	AC007228.9	-16.48	4.87e-33	1.3e-24	-1.13	-0.83	Vitiligo;	chr22:41444403	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.694	rs202656	ENSG00000268568.1	AC007228.9	16.48	4.87e-33	1.3e-24	1.13	0.83	Vitiligo;	chr22:41446199	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.649	rs202657	ENSG00000268568.1	AC007228.9	16.48	4.87e-33	1.3e-24	1.13	0.83	Vitiligo;	chr22:41448782	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.694	rs5751107	ENSG00000268568.1	AC007228.9	16.48	4.87e-33	1.3e-24	1.13	0.83	Vitiligo;	chr22:41461808	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.649	rs5751108	ENSG00000268568.1	AC007228.9	16.48	4.87e-33	1.3e-24	1.13	0.83	Vitiligo;	chr22:41462031	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.694	rs202639	ENSG00000268568.1	AC007228.9	16.42	6.91e-33	1.81e-24	1.13	0.83	Vitiligo;	chr22:41460133	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.694	rs5758365	ENSG00000268568.1	AC007228.9	16.42	6.91e-33	1.81e-24	1.13	0.83	Vitiligo;	chr22:41462653	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.649	rs79009	ENSG00000268568.1	AC007228.9	16.42	6.91e-33	1.81e-24	1.13	0.83	Vitiligo;	chr22:41464860	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.694	rs202622	ENSG00000268568.1	AC007228.9	16.27	1.49e-32	3.76e-24	1.13	0.83	Vitiligo;	chr22:41429338	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.649	rs202625	ENSG00000268568.1	AC007228.9	16.27	1.49e-32	3.76e-24	1.13	0.83	Vitiligo;	chr22:41431078	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.694	rs7285041	ENSG00000268568.1	AC007228.9	16.27	1.49e-32	3.76e-24	1.13	0.83	Vitiligo;	chr22:41433145	chr19:56672574~56673901:-
TGCT	trans	rs12291225	0.679	rs11605531	ENSG00000236360.2	RP11-334A14.2	16.11	3.45e-32	7.94e-24	0.99	0.82	Sense of smell;	chr11:14270048	chr1:52993201~52993702:-
TGCT	trans	rs12291225	0.639	rs61883858	ENSG00000236360.2	RP11-334A14.2	16.11	3.45e-32	7.94e-24	0.99	0.82	Sense of smell;	chr11:14273162	chr1:52993201~52993702:-
TGCT	trans	rs12291225	0.679	rs11023170	ENSG00000236360.2	RP11-334A14.2	16.11	3.45e-32	7.94e-24	0.99	0.82	Sense of smell;	chr11:14273363	chr1:52993201~52993702:-
TGCT	trans	rs12291225	0.679	rs11023172	ENSG00000236360.2	RP11-334A14.2	16.11	3.45e-32	7.94e-24	0.99	0.82	Sense of smell;	chr11:14273821	chr1:52993201~52993702:-
TGCT	trans	rs12291225	0.679	rs4757245	ENSG00000236360.2	RP11-334A14.2	16.11	3.45e-32	7.94e-24	0.99	0.82	Sense of smell;	chr11:14276326	chr1:52993201~52993702:-
TGCT	trans	rs12291225	0.637	rs8570	ENSG00000236360.2	RP11-334A14.2	16.11	3.45e-32	7.94e-24	0.99	0.82	Sense of smell;	chr11:14279213	chr1:52993201~52993702:-
TGCT	trans	rs12291225	0.753	rs1431374	ENSG00000236360.2	RP11-334A14.2	16.11	3.45e-32	7.94e-24	0.99	0.82	Sense of smell;	chr11:14282429	chr1:52993201~52993702:-
TGCT	trans	rs12291225	0.679	rs7934671	ENSG00000236360.2	RP11-334A14.2	16.11	3.45e-32	7.94e-24	0.99	0.82	Sense of smell;	chr11:14283555	chr1:52993201~52993702:-
TGCT	trans	rs12291225	0.679	rs11023178	ENSG00000236360.2	RP11-334A14.2	16.11	3.45e-32	7.94e-24	0.99	0.82	Sense of smell;	chr11:14288736	chr1:52993201~52993702:-
TGCT	trans	rs12291225	0.679	rs34238445	ENSG00000236360.2	RP11-334A14.2	16.11	3.45e-32	7.94e-24	0.99	0.82	Sense of smell;	chr11:14294369	chr1:52993201~52993702:-
TGCT	trans	rs9611565	0.84	rs3788584	ENSG00000268568.1	AC007228.9	-16.1	3.67e-32	8.41e-24	-1.1	-0.82	Vitiligo;	chr22:41383069	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.694	rs202665	ENSG00000268568.1	AC007228.9	16.04	4.9e-32	1.12e-23	1.1	0.82	Vitiligo;	chr22:41418397	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.649	rs202666	ENSG00000268568.1	AC007228.9	16.04	4.9e-32	1.12e-23	1.1	0.82	Vitiligo;	chr22:41418715	chr19:56672574~56673901:-
TGCT	trans	rs12291225	0.679	rs10832240	ENSG00000236360.2	RP11-334A14.2	16.02	5.53e-32	1.26e-23	0.99	0.82	Sense of smell;	chr11:14283198	chr1:52993201~52993702:-
TGCT	trans	rs12291225	0.645	rs3763950	ENSG00000236360.2	RP11-334A14.2	16.02	5.62e-32	1.27e-23	1	0.82	Sense of smell;	chr11:14256503	chr1:52993201~52993702:-
TGCT	trans	rs12291225	0.679	rs4756786	ENSG00000236360.2	RP11-334A14.2	16.02	5.62e-32	1.27e-23	1	0.82	Sense of smell;	chr11:14264354	chr1:52993201~52993702:-
TGCT	trans	rs9611565	0.84	rs4822025	ENSG00000268568.1	AC007228.9	-16	6.05e-32	1.36e-23	-1.09	-0.82	Vitiligo;	chr22:41380642	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.84	rs2234052	ENSG00000268568.1	AC007228.9	-15.99	6.39e-32	1.41e-23	-1.1	-0.82	Vitiligo;	chr22:41381237	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.527	rs2234053	ENSG00000268568.1	AC007228.9	-15.99	6.39e-32	1.41e-23	-1.1	-0.82	Vitiligo;	chr22:41381311	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.84	rs9607799	ENSG00000268568.1	AC007228.9	-15.99	6.39e-32	1.41e-23	-1.1	-0.82	Vitiligo;	chr22:41381554	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.802	rs2234058	ENSG00000268568.1	AC007228.9	-15.99	6.39e-32	1.41e-23	-1.1	-0.82	Vitiligo;	chr22:41381879	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.84	rs2234059	ENSG00000268568.1	AC007228.9	-15.99	6.39e-32	1.41e-23	-1.1	-0.82	Vitiligo;	chr22:41381909	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.694	rs202628	ENSG00000268568.1	AC007228.9	-15.97	6.94e-32	1.46e-23	-1.12	-0.82	Vitiligo;	chr22:41453509	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.694	rs202641	ENSG00000268568.1	AC007228.9	15.97	6.94e-32	1.46e-23	1.12	0.82	Vitiligo;	chr22:41437112	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.649	rs79005	ENSG00000268568.1	AC007228.9	15.97	6.94e-32	1.46e-23	1.12	0.82	Vitiligo;	chr22:41439540	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.608	rs202652	ENSG00000268568.1	AC007228.9	15.97	6.94e-32	1.46e-23	1.12	0.82	Vitiligo;	chr22:41442788	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs202653	ENSG00000268568.1	AC007228.9	15.97	6.94e-32	1.46e-23	1.12	0.82	Vitiligo;	chr22:41444154	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.649	rs202655	ENSG00000268568.1	AC007228.9	15.97	6.94e-32	1.46e-23	1.12	0.82	Vitiligo;	chr22:41445560	chr19:56672574~56673901:-
TGCT	trans	rs727563	0.58	rs202626	ENSG00000268568.1	AC007228.9	15.97	6.94e-32	1.46e-23	1.12	0.82	Crohn's disease;Inflammatory bowel disease;	chr22:41451186	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.532	rs202627	ENSG00000268568.1	AC007228.9	15.97	6.94e-32	1.46e-23	1.12	0.82	Vitiligo;	chr22:41451363	chr19:56672574~56673901:-
TGCT	trans	rs202629	1	rs202629	ENSG00000268568.1	AC007228.9	15.97	6.94e-32	1.46e-23	1.12	0.82	Cannabis dependence symptom count;	chr22:41453971	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.694	rs19573	ENSG00000268568.1	AC007228.9	15.97	7.11e-32	1.48e-23	1.13	0.82	Vitiligo;	chr22:41469805	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.694	rs79011	ENSG00000268568.1	AC007228.9	15.97	7.11e-32	1.48e-23	1.13	0.82	Vitiligo;	chr22:41470934	chr19:56672574~56673901:-
TGCT	trans	rs12291225	0.679	rs11369	ENSG00000236360.2	RP11-334A14.2	15.97	7.3e-32	1.51e-23	0.99	0.82	Sense of smell;	chr11:14266550	chr1:52993201~52993702:-
TGCT	trans	rs12291225	0.679	rs11238	ENSG00000236360.2	RP11-334A14.2	-15.97	7.3e-32	1.51e-23	-0.99	-0.82	Sense of smell;	chr11:14266582	chr1:52993201~52993702:-
TGCT	trans	rs9611565	0.729	rs132902	ENSG00000268568.1	AC007228.9	-15.95	7.86e-32	1.61e-23	-1.1	-0.82	Vitiligo;	chr22:41401754	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.694	rs202664	ENSG00000268568.1	AC007228.9	15.95	7.86e-32	1.61e-23	1.1	0.82	Vitiligo;	chr22:41417882	chr19:56672574~56673901:-
TGCT	trans	rs7949030	0.725	rs12808829	ENSG00000186676.3	EEF1GP1	15.91	9.88e-32	2.02e-23	1.03	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62611188	chr7:125033453~125035301:+
TGCT	trans	rs9611565	0.649	rs5758344	ENSG00000268568.1	AC007228.9	15.87	1.19e-31	2.32e-23	1.12	0.82	Vitiligo;	chr22:41421681	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.694	rs2142505	ENSG00000268568.1	AC007228.9	15.87	1.19e-31	2.32e-23	1.12	0.82	Vitiligo;	chr22:41424537	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.694	rs5758347	ENSG00000268568.1	AC007228.9	15.87	1.19e-31	2.32e-23	1.12	0.82	Vitiligo;	chr22:41425015	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.694	rs202613	ENSG00000268568.1	AC007228.9	15.87	1.19e-31	2.32e-23	1.12	0.82	Vitiligo;	chr22:41425989	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.649	rs202614	ENSG00000268568.1	AC007228.9	15.87	1.19e-31	2.32e-23	1.12	0.82	Vitiligo;	chr22:41426146	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.694	rs202616	ENSG00000268568.1	AC007228.9	15.87	1.19e-31	2.32e-23	1.12	0.82	Vitiligo;	chr22:41426217	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.569	rs188057	ENSG00000268568.1	AC007228.9	15.87	1.19e-31	2.32e-23	1.12	0.82	Vitiligo;	chr22:41426301	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.694	rs202618	ENSG00000268568.1	AC007228.9	15.87	1.19e-31	2.32e-23	1.12	0.82	Vitiligo;	chr22:41426852	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.729	rs2413646	ENSG00000268568.1	AC007228.9	-15.83	1.45e-31	2.73e-23	-1.14	-0.82	Vitiligo;	chr22:41510321	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.694	rs202631	ENSG00000268568.1	AC007228.9	15.73	2.57e-31	4.75e-23	1.12	0.82	Vitiligo;	chr22:41467419	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs169361	ENSG00000268568.1	AC007228.9	15.63	4.19e-31	7.72e-23	1.14	0.81	Vitiligo;	chr22:41481985	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.765	rs767593	ENSG00000268568.1	AC007228.9	-15.61	4.69e-31	8.59e-23	-1.11	-0.81	Vitiligo;	chr22:41383967	chr19:56672574~56673901:-
TGCT	trans	rs7949030	0.695	rs11231161	ENSG00000186676.3	EEF1GP1	15.61	4.73e-31	8.65e-23	1.01	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62610749	chr7:125033453~125035301:+
TGCT	trans	rs7949030	0.688	rs2849031	ENSG00000186676.3	EEF1GP1	-15.59	5.21e-31	9.47e-23	-1.01	-0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598193	chr7:125033453~125035301:+
TGCT	trans	rs7949030	0.653	rs2849030	ENSG00000186676.3	EEF1GP1	-15.59	5.21e-31	9.47e-23	-1.01	-0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599514	chr7:125033453~125035301:+
TGCT	trans	rs9611565	0.694	rs5758368	ENSG00000268568.1	AC007228.9	-15.57	5.86e-31	1.06e-22	-1.08	-0.81	Vitiligo;	chr22:41466284	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.649	rs202645	ENSG00000268568.1	AC007228.9	15.54	6.72e-31	1.21e-22	1.12	0.81	Vitiligo;	chr22:41402516	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.729	rs4822027	ENSG00000268568.1	AC007228.9	-15.54	6.72e-31	1.21e-22	-1.12	-0.81	Vitiligo;	chr22:41390223	chr19:56672574~56673901:-
TGCT	trans	rs7949030	0.765	rs11553576	ENSG00000186676.3	EEF1GP1	15.53	7.16e-31	1.28e-22	1.01	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62611329	chr7:125033453~125035301:+
TGCT	trans	rs9611565	0.729	rs73176686	ENSG00000268568.1	AC007228.9	-15.5	8.28e-31	1.47e-22	-1.11	-0.81	Vitiligo;	chr22:41386115	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.729	rs73176689	ENSG00000268568.1	AC007228.9	-15.5	8.28e-31	1.47e-22	-1.11	-0.81	Vitiligo;	chr22:41386629	chr19:56672574~56673901:-
TGCT	trans	rs13253073	0.723	rs4626565	ENSG00000260318.1	COX6CP1	15.45	1.1e-30	1.88e-22	1.38	0.81	Glucose homeostasis traits;	chr8:99878314	chr16:11903923~11904137:-
TGCT	trans	rs13253073	0.723	rs7844439	ENSG00000260318.1	COX6CP1	15.45	1.1e-30	1.88e-22	1.38	0.81	Glucose homeostasis traits;	chr8:99878567	chr16:11903923~11904137:-
TGCT	trans	rs13253073	0.723	rs4510829	ENSG00000260318.1	COX6CP1	15.45	1.1e-30	1.88e-22	1.38	0.81	Glucose homeostasis traits;	chr8:99878982	chr16:11903923~11904137:-
TGCT	trans	rs13253073	0.723	rs1135382	ENSG00000260318.1	COX6CP1	15.45	1.1e-30	1.88e-22	1.38	0.81	Glucose homeostasis traits;	chr8:99879402	chr16:11903923~11904137:-
TGCT	trans	rs13253073	0.723	rs7828241	ENSG00000260318.1	COX6CP1	15.45	1.1e-30	1.88e-22	1.38	0.81	Glucose homeostasis traits;	chr8:99880417	chr16:11903923~11904137:-
TGCT	trans	rs13253073	0.723	rs7812991	ENSG00000260318.1	COX6CP1	15.45	1.1e-30	1.88e-22	1.38	0.81	Glucose homeostasis traits;	chr8:99884095	chr16:11903923~11904137:-
TGCT	trans	rs13253073	0.723	rs12548840	ENSG00000260318.1	COX6CP1	15.45	1.1e-30	1.88e-22	1.38	0.81	Glucose homeostasis traits;	chr8:99885580	chr16:11903923~11904137:-
TGCT	trans	rs13253073	0.723	rs1130569	ENSG00000260318.1	COX6CP1	15.45	1.1e-30	1.88e-22	1.38	0.81	Glucose homeostasis traits;	chr8:99887565	chr16:11903923~11904137:-
TGCT	trans	rs13253073	0.723	rs35429753	ENSG00000260318.1	COX6CP1	15.45	1.1e-30	1.88e-22	1.38	0.81	Glucose homeostasis traits;	chr8:99891015	chr16:11903923~11904137:-
TGCT	trans	rs13253073	0.723	rs1130474	ENSG00000260318.1	COX6CP1	15.45	1.1e-30	1.88e-22	1.38	0.81	Glucose homeostasis traits;	chr8:99892049	chr16:11903923~11904137:-
TGCT	trans	rs9611565	0.592	rs5751101	ENSG00000268568.1	AC007228.9	15.37	1.72e-30	2.92e-22	1.07	0.81	Vitiligo;	chr22:41432107	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.918	rs9611566	ENSG00000268568.1	AC007228.9	15.29	2.64e-30	4.46e-22	1.06	0.81	Vitiligo;	chr22:41372621	chr19:56672574~56673901:-
TGCT	trans	rs3749237	0.576	rs4241406	ENSG00000197582.5	GPX1P1	15.28	2.73e-30	4.61e-22	0.99	0.81	Resting heart rate;	chr3:49562993	chrX:13378735~13379340:-
TGCT	trans	rs13253073	0.723	rs7157	ENSG00000260318.1	COX6CP1	15.25	3.12e-30	5.18e-22	1.41	0.81	Glucose homeostasis traits;	chr8:99877449	chr16:11903923~11904137:-
TGCT	trans	rs13253073	0.723	rs7813557	ENSG00000260318.1	COX6CP1	15.25	3.12e-30	5.18e-22	1.41	0.81	Glucose homeostasis traits;	chr8:99878665	chr16:11903923~11904137:-
TGCT	trans	rs13253073	0.76	rs62534633	ENSG00000260318.1	COX6CP1	15.25	3.12e-30	5.18e-22	1.41	0.81	Glucose homeostasis traits;	chr8:99884533	chr16:11903923~11904137:-
TGCT	trans	rs13253073	0.723	rs12548542	ENSG00000260318.1	COX6CP1	15.25	3.12e-30	5.18e-22	1.41	0.81	Glucose homeostasis traits;	chr8:99890167	chr16:11903923~11904137:-
TGCT	trans	rs9611565	0.729	rs2413647	ENSG00000268568.1	AC007228.9	-15.24	3.32e-30	5.47e-22	-1.11	-0.81	Vitiligo;	chr22:41511144	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs9611602	ENSG00000268568.1	AC007228.9	-15.24	3.32e-30	5.47e-22	-1.11	-0.81	Vitiligo;	chr22:41512401	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs1569516	ENSG00000268568.1	AC007228.9	-15.24	3.32e-30	5.47e-22	-1.11	-0.81	Vitiligo;	chr22:41514240	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.694	rs202637	ENSG00000268568.1	AC007228.9	15.24	3.43e-30	5.64e-22	1.15	0.81	Vitiligo;	chr22:41457924	chr19:56672574~56673901:-
TGCT	trans	rs3749237	0.595	rs1464568	ENSG00000197582.5	GPX1P1	15.08	7.85e-30	1.25e-21	0.96	0.8	Resting heart rate;	chr3:49420833	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.595	rs12489092	ENSG00000197582.5	GPX1P1	15.08	7.85e-30	1.25e-21	0.96	0.8	Resting heart rate;	chr3:49513481	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.555	rs7637665	ENSG00000197582.5	GPX1P1	15.08	7.85e-30	1.25e-21	0.96	0.8	Resting heart rate;	chr3:49514862	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.595	rs3870337	ENSG00000197582.5	GPX1P1	15.08	7.85e-30	1.25e-21	0.96	0.8	Resting heart rate;	chr3:49519662	chrX:13378735~13379340:-
TGCT	trans	rs13177918	0.677	rs3857421	ENSG00000224114.1	RP11-343H5.4	-15.02	1.08e-29	1.7e-21	-1.07	-0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:206695837~206696269:-
TGCT	trans	rs3749237	0.595	rs3870338	ENSG00000197582.5	GPX1P1	15.02	1.09e-29	1.71e-21	0.94	0.8	Resting heart rate;	chr3:49519618	chrX:13378735~13379340:-
TGCT	trans	rs9611565	0.918	rs4822024	ENSG00000268568.1	AC007228.9	-14.97	1.42e-29	2.23e-21	-1.1	-0.8	Vitiligo;	chr22:41361643	chr19:56672574~56673901:-
TGCT	trans	rs13177918	0.626	rs3819332	ENSG00000213058.3	RP4-765C7.2	14.97	1.45e-29	2.27e-21	1.1	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:178411616~178411972:+
TGCT	trans	rs13177918	0.626	rs13170300	ENSG00000213058.3	RP4-765C7.2	14.97	1.45e-29	2.27e-21	1.1	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:178411616~178411972:+
TGCT	trans	rs13177918	0.626	rs13175436	ENSG00000213058.3	RP4-765C7.2	14.97	1.46e-29	2.28e-21	1.1	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:178411616~178411972:+
TGCT	trans	rs13177918	0.603	rs13175992	ENSG00000213058.3	RP4-765C7.2	14.97	1.46e-29	2.28e-21	1.1	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:178411616~178411972:+
TGCT	trans	rs13253073	0.657	rs35135010	ENSG00000260318.1	COX6CP1	14.94	1.64e-29	2.54e-21	1.38	0.8	Glucose homeostasis traits;	chr8:99864209	chr16:11903923~11904137:-
TGCT	trans	rs13253073	0.723	rs34830464	ENSG00000260318.1	COX6CP1	14.94	1.64e-29	2.54e-21	1.38	0.8	Glucose homeostasis traits;	chr8:99866638	chr16:11903923~11904137:-
TGCT	trans	rs9611565	0.918	rs9538	ENSG00000268568.1	AC007228.9	-14.88	2.34e-29	3.59e-21	-1.09	-0.8	Vitiligo;	chr22:41359853	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.918	rs9611561	ENSG00000268568.1	AC007228.9	-14.88	2.34e-29	3.59e-21	-1.09	-0.8	Vitiligo;	chr22:41361230	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.918	rs9611562	ENSG00000268568.1	AC007228.9	-14.88	2.34e-29	3.59e-21	-1.09	-0.8	Vitiligo;	chr22:41364168	chr19:56672574~56673901:-
TGCT	trans	rs13177918	0.75	rs58256223	ENSG00000213058.3	RP4-765C7.2	14.85	2.7e-29	4.12e-21	1.11	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:178411616~178411972:+
TGCT	trans	rs13253073	0.723	rs12546882	ENSG00000260318.1	COX6CP1	14.78	3.96e-29	5.98e-21	1.4	0.8	Glucose homeostasis traits;	chr8:99869919	chr16:11903923~11904137:-
TGCT	trans	rs9611565	0.838	rs4239894	ENSG00000268568.1	AC007228.9	-14.77	4.22e-29	6.36e-21	-1.08	-0.8	Vitiligo;	chr22:41349544	chr19:56672574~56673901:-
TGCT	trans	rs5758343	1	rs5758343	ENSG00000268568.1	AC007228.9	14.69	6.33e-29	9.38e-21	1.11	0.8	Allergic disease (asthma, hay fever or eczema);	chr22:41420648	chr19:56672574~56673901:-
TGCT	trans	rs13177918	0.557	rs12520101	ENSG00000213058.3	RP4-765C7.2	14.64	8.59e-29	1.26e-20	1.13	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:178411616~178411972:+
TGCT	trans	rs3749237	0.595	rs4855877	ENSG00000197582.5	GPX1P1	14.62	9.39e-29	1.37e-20	0.95	0.8	Resting heart rate;	chr3:49411094	chrX:13378735~13379340:-
TGCT	trans	rs9611565	0.605	rs202638	ENSG00000268568.1	AC007228.9	14.61	9.93e-29	1.44e-20	1.06	0.8	Vitiligo;	chr22:41459454	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.918	rs7290404	ENSG00000268568.1	AC007228.9	-14.59	1.13e-28	1.63e-20	-1.08	-0.79	Vitiligo;	chr22:41353792	chr19:56672574~56673901:-
TGCT	trans	rs3749237	0.595	rs4855873	ENSG00000197582.5	GPX1P1	14.57	1.2e-28	1.68e-20	0.96	0.79	Resting heart rate;	chr3:49421681	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.595	rs1464566	ENSG00000197582.5	GPX1P1	14.57	1.2e-28	1.68e-20	0.96	0.79	Resting heart rate;	chr3:49421943	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.537	rs4459909	ENSG00000197582.5	GPX1P1	14.57	1.2e-28	1.68e-20	0.96	0.79	Resting heart rate;	chr3:49431784	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.595	rs11130196	ENSG00000197582.5	GPX1P1	14.57	1.2e-28	1.68e-20	0.96	0.79	Resting heart rate;	chr3:49452716	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.595	rs4855839	ENSG00000197582.5	GPX1P1	14.57	1.2e-28	1.68e-20	0.96	0.79	Resting heart rate;	chr3:49470414	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.595	rs35701831	ENSG00000197582.5	GPX1P1	14.57	1.2e-28	1.68e-20	0.96	0.79	Resting heart rate;	chr3:49477567	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.595	rs4855864	ENSG00000197582.5	GPX1P1	14.57	1.2e-28	1.68e-20	0.96	0.79	Resting heart rate;	chr3:49484541	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.595	rs11130199	ENSG00000197582.5	GPX1P1	14.57	1.2e-28	1.68e-20	0.96	0.79	Resting heart rate;	chr3:49501366	chrX:13378735~13379340:-
TGCT	trans	rs916888	0.773	rs199447	ENSG00000263503.1	RP11-707O23.5	14.56	1.31e-28	1.82e-20	1.23	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45600869~45602340:-
TGCT	trans	rs916888	0.773	rs199445	ENSG00000263503.1	RP11-707O23.5	14.56	1.31e-28	1.82e-20	1.23	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45600869~45602340:-
TGCT	trans	rs916888	0.773	rs199443	ENSG00000263503.1	RP11-707O23.5	14.56	1.31e-28	1.82e-20	1.23	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45600869~45602340:-
TGCT	trans	rs916888	0.773	rs199534	ENSG00000263503.1	RP11-707O23.5	14.56	1.31e-28	1.82e-20	1.23	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45600869~45602340:-
TGCT	trans	rs13177918	0.626	rs67026795	ENSG00000213058.3	RP4-765C7.2	14.54	1.44e-28	2e-20	1.1	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:178411616~178411972:+
TGCT	trans	rs13177918	0.603	rs10447222	ENSG00000213058.3	RP4-765C7.2	14.54	1.44e-28	2e-20	1.1	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:178411616~178411972:+
TGCT	trans	rs13253073	0.723	rs7831963	ENSG00000260318.1	COX6CP1	14.54	1.47e-28	2.01e-20	1.38	0.79	Glucose homeostasis traits;	chr8:99853014	chr16:11903923~11904137:-
TGCT	trans	rs13253073	0.723	rs7832488	ENSG00000260318.1	COX6CP1	14.54	1.47e-28	2.01e-20	1.38	0.79	Glucose homeostasis traits;	chr8:99853185	chr16:11903923~11904137:-
TGCT	trans	rs13253073	0.723	rs6468695	ENSG00000260318.1	COX6CP1	14.54	1.47e-28	2.01e-20	1.38	0.79	Glucose homeostasis traits;	chr8:99857123	chr16:11903923~11904137:-
TGCT	trans	rs13253073	0.723	rs6468696	ENSG00000260318.1	COX6CP1	14.54	1.47e-28	2.01e-20	1.38	0.79	Glucose homeostasis traits;	chr8:99857130	chr16:11903923~11904137:-
TGCT	trans	rs13253073	0.723	rs12548344	ENSG00000260318.1	COX6CP1	14.54	1.47e-28	2.01e-20	1.38	0.79	Glucose homeostasis traits;	chr8:99868676	chr16:11903923~11904137:-
TGCT	trans	rs13253073	0.723	rs7009713	ENSG00000260318.1	COX6CP1	14.54	1.47e-28	2.01e-20	1.38	0.79	Glucose homeostasis traits;	chr8:99869626	chr16:11903923~11904137:-
TGCT	trans	rs9611565	0.918	rs28638318	ENSG00000268568.1	AC007228.9	-14.5	1.74e-28	2.38e-20	-1.08	-0.79	Vitiligo;	chr22:41357055	chr19:56672574~56673901:-
TGCT	trans	rs13177918	0.677	rs3797622	ENSG00000224114.1	RP11-343H5.4	14.48	1.95e-28	2.66e-20	1.09	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:206695837~206696269:-
TGCT	trans	rs916888	0.773	rs199533	ENSG00000263503.1	RP11-707O23.5	14.48	2.03e-28	2.76e-20	1.23	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45600869~45602340:-
TGCT	trans	rs9611565	0.729	rs137831	ENSG00000268568.1	AC007228.9	-14.48	2.04e-28	2.77e-20	-1.04	-0.79	Vitiligo;	chr22:41507809	chr19:56672574~56673901:-
TGCT	trans	rs916888	0.773	rs9896243	ENSG00000263503.1	RP11-707O23.5	14.47	2.14e-28	2.88e-20	1.2	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45600869~45602340:-
TGCT	trans	rs13177918	0.75	rs59354956	ENSG00000213058.3	RP4-765C7.2	14.42	2.75e-28	3.59e-20	1.1	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:178411616~178411972:+
TGCT	trans	rs3749237	0.595	rs1568661	ENSG00000197582.5	GPX1P1	14.4	3.05e-28	3.93e-20	0.95	0.79	Resting heart rate;	chr3:49483525	chrX:13378735~13379340:-
TGCT	trans	rs916888	0.773	rs199448	ENSG00000263503.1	RP11-707O23.5	14.38	3.36e-28	4.31e-20	1.18	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45600869~45602340:-
TGCT	trans	rs13253073	0.723	rs7840626	ENSG00000260318.1	COX6CP1	14.35	4.03e-28	5.14e-20	1.41	0.79	Glucose homeostasis traits;	chr8:99867598	chr16:11903923~11904137:-
TGCT	trans	rs13177918	0.677	rs4841	ENSG00000224114.1	RP11-343H5.4	14.33	4.45e-28	5.6e-20	1.09	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:206695837~206696269:-
TGCT	trans	rs13177918	0.677	rs13183077	ENSG00000224114.1	RP11-343H5.4	14.33	4.45e-28	5.6e-20	1.09	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:206695837~206696269:-
TGCT	trans	rs13177918	0.677	rs13181401	ENSG00000224114.1	RP11-343H5.4	14.33	4.53e-28	5.6e-20	1.08	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:206695837~206696269:-
TGCT	trans	rs13177918	0.677	rs4541646	ENSG00000224114.1	RP11-343H5.4	14.33	4.53e-28	5.6e-20	1.08	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:206695837~206696269:-
TGCT	trans	rs13177918	0.677	rs3900644	ENSG00000224114.1	RP11-343H5.4	14.33	4.53e-28	5.6e-20	1.08	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:206695837~206696269:-
TGCT	trans	rs13177918	0.677	rs2070844	ENSG00000224114.1	RP11-343H5.4	14.33	4.53e-28	5.6e-20	1.08	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:206695837~206696269:-
TGCT	trans	rs13177918	0.629	rs2070842	ENSG00000224114.1	RP11-343H5.4	14.33	4.53e-28	5.6e-20	1.08	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:206695837~206696269:-
TGCT	trans	rs13177918	0.677	rs13171800	ENSG00000224114.1	RP11-343H5.4	14.33	4.53e-28	5.6e-20	1.08	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:206695837~206696269:-
TGCT	trans	rs13177918	0.677	rs2070841	ENSG00000224114.1	RP11-343H5.4	14.33	4.53e-28	5.6e-20	1.08	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:206695837~206696269:-
TGCT	trans	rs13177918	0.677	rs13177951	ENSG00000224114.1	RP11-343H5.4	14.33	4.53e-28	5.6e-20	1.08	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:206695837~206696269:-
TGCT	trans	rs13177918	0.677	rs13177970	ENSG00000224114.1	RP11-343H5.4	14.33	4.53e-28	5.6e-20	1.08	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:206695837~206696269:-
TGCT	trans	rs13177918	0.677	rs13164105	ENSG00000224114.1	RP11-343H5.4	14.33	4.53e-28	5.6e-20	1.08	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:206695837~206696269:-
TGCT	trans	rs6477998	0.58	rs9299214	ENSG00000238072.1	RP11-305M3.2	14.28	5.8e-28	7.01e-20	0.97	0.79	Hematology traits;	chr9:113273416	chr7:129410113~129410370:-
TGCT	trans	rs13177918	0.677	rs13161417	ENSG00000239528.1	RPS14P8	14.25	6.93e-28	8.24e-20	1.09	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr5:116562562~116562930:+
TGCT	trans	rs13177918	0.677	rs13161156	ENSG00000239528.1	RPS14P8	14.25	6.93e-28	8.24e-20	1.09	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr5:116562562~116562930:+
TGCT	trans	rs13177918	0.578	rs35919198	ENSG00000213058.3	RP4-765C7.2	14.23	7.87e-28	9.34e-20	1.09	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr1:178411616~178411972:+
TGCT	trans	rs916888	0.687	rs199456	ENSG00000263503.1	RP11-707O23.5	14.22	8.31e-28	9.84e-20	1.22	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45600869~45602340:-
TGCT	trans	rs13177918	0.677	rs13181401	ENSG00000239528.1	RPS14P8	14.2	8.91e-28	1.03e-19	1.08	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr5:116562562~116562930:+
TGCT	trans	rs13177918	0.677	rs4541646	ENSG00000239528.1	RPS14P8	14.2	8.91e-28	1.03e-19	1.08	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr5:116562562~116562930:+
TGCT	trans	rs13177918	0.677	rs3900644	ENSG00000239528.1	RPS14P8	14.2	8.91e-28	1.03e-19	1.08	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr5:116562562~116562930:+
TGCT	trans	rs13177918	0.677	rs2070844	ENSG00000239528.1	RPS14P8	14.2	8.91e-28	1.03e-19	1.08	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr5:116562562~116562930:+
TGCT	trans	rs13177918	0.629	rs2070842	ENSG00000239528.1	RPS14P8	14.2	8.91e-28	1.03e-19	1.08	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr5:116562562~116562930:+
TGCT	trans	rs13177918	0.677	rs13171800	ENSG00000239528.1	RPS14P8	14.2	8.91e-28	1.03e-19	1.08	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr5:116562562~116562930:+
TGCT	trans	rs13177918	0.677	rs2070841	ENSG00000239528.1	RPS14P8	14.2	8.91e-28	1.03e-19	1.08	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr5:116562562~116562930:+
TGCT	trans	rs13177918	0.677	rs13177951	ENSG00000239528.1	RPS14P8	14.2	8.91e-28	1.03e-19	1.08	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr5:116562562~116562930:+
TGCT	trans	rs13177918	0.677	rs13177970	ENSG00000239528.1	RPS14P8	14.2	8.91e-28	1.03e-19	1.08	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr5:116562562~116562930:+
TGCT	trans	rs13177918	0.677	rs13164105	ENSG00000239528.1	RPS14P8	14.2	8.91e-28	1.03e-19	1.08	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr5:116562562~116562930:+
TGCT	trans	rs9611565	0.918	rs4820438	ENSG00000268568.1	AC007228.9	-14.2	9.01e-28	1.04e-19	-1.05	-0.79	Vitiligo;	chr22:41371131	chr19:56672574~56673901:-
TGCT	trans	rs13253073	0.662	rs34513504	ENSG00000260318.1	COX6CP1	14.2	9.22e-28	1.06e-19	1.39	0.79	Glucose homeostasis traits;	chr8:99848918	chr16:11903923~11904137:-
TGCT	trans	rs13177918	0.677	rs13161417	ENSG00000224114.1	RP11-343H5.4	14.19	9.49e-28	1.09e-19	1.08	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:206695837~206696269:-
TGCT	trans	rs13177918	0.677	rs13161156	ENSG00000224114.1	RP11-343H5.4	14.19	9.49e-28	1.09e-19	1.08	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:206695837~206696269:-
TGCT	trans	rs13177918	0.677	rs57890152	ENSG00000239528.1	RPS14P8	14.17	1.06e-27	1.21e-19	1.09	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr5:116562562~116562930:+
TGCT	trans	rs13177918	0.677	rs13160685	ENSG00000239528.1	RPS14P8	14.17	1.06e-27	1.21e-19	1.09	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr5:116562562~116562930:+
TGCT	trans	rs13177918	0.677	rs13161099	ENSG00000239528.1	RPS14P8	14.17	1.06e-27	1.21e-19	1.09	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr5:116562562~116562930:+
TGCT	trans	rs13177918	0.629	rs13161261	ENSG00000239528.1	RPS14P8	14.17	1.06e-27	1.21e-19	1.09	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr5:116562562~116562930:+
TGCT	trans	rs13253073	0.723	rs62534626	ENSG00000260318.1	COX6CP1	14.15	1.19e-27	1.35e-19	1.41	0.79	Glucose homeostasis traits;	chr8:99866119	chr16:11903923~11904137:-
TGCT	trans	rs13177918	0.677	rs57890152	ENSG00000224114.1	RP11-343H5.4	14.15	1.21e-27	1.36e-19	1.08	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:206695837~206696269:-
TGCT	trans	rs13177918	0.677	rs13160685	ENSG00000224114.1	RP11-343H5.4	14.15	1.21e-27	1.36e-19	1.08	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:206695837~206696269:-
TGCT	trans	rs13177918	0.677	rs13161099	ENSG00000224114.1	RP11-343H5.4	14.15	1.21e-27	1.36e-19	1.08	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:206695837~206696269:-
TGCT	trans	rs13177918	0.629	rs13161261	ENSG00000224114.1	RP11-343H5.4	14.15	1.21e-27	1.36e-19	1.08	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:206695837~206696269:-
TGCT	trans	rs13177918	0.677	rs2073472	ENSG00000224114.1	RP11-343H5.4	14.1	1.58e-27	1.77e-19	1.08	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:206695837~206696269:-
TGCT	trans	rs13177918	0.677	rs3857421	ENSG00000239528.1	RPS14P8	-14.07	1.8e-27	2.01e-19	-1.05	-0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr5:116562562~116562930:+
TGCT	trans	rs3749237	0.595	rs6784820	ENSG00000197582.5	GPX1P1	-14.06	1.99e-27	2.21e-19	-0.92	-0.78	Resting heart rate;	chr3:49413431	chrX:13378735~13379340:-
TGCT	trans	rs12291225	0.679	rs1043237	ENSG00000236360.2	RP11-334A14.2	14.05	2.08e-27	2.31e-19	0.95	0.78	Sense of smell;	chr11:14267507	chr1:52993201~52993702:-
TGCT	trans	rs13177918	0.677	rs4841	ENSG00000239528.1	RPS14P8	14	2.65e-27	2.92e-19	1.08	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr5:116562562~116562930:+
TGCT	trans	rs13177918	0.677	rs13183077	ENSG00000239528.1	RPS14P8	14	2.65e-27	2.92e-19	1.08	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr5:116562562~116562930:+
TGCT	trans	rs13177918	0.677	rs3797622	ENSG00000239528.1	RPS14P8	14	2.68e-27	2.95e-19	1.08	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr5:116562562~116562930:+
TGCT	trans	rs13177918	0.686	rs12654827	ENSG00000239528.1	RPS14P8	14	2.7e-27	2.96e-19	1.08	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr5:116562562~116562930:+
TGCT	trans	rs916888	0.779	rs199528	ENSG00000263503.1	RP11-707O23.5	14	2.72e-27	2.96e-19	1.17	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45600869~45602340:-
TGCT	trans	rs916888	0.821	rs199525	ENSG00000263503.1	RP11-707O23.5	14	2.72e-27	2.96e-19	1.17	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45600869~45602340:-
TGCT	trans	rs13177918	0.686	rs12654827	ENSG00000224114.1	RP11-343H5.4	14	2.72e-27	2.96e-19	1.08	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:206695837~206696269:-
TGCT	trans	rs3749237	0.595	rs11130192	ENSG00000197582.5	GPX1P1	13.99	2.89e-27	3e-19	0.93	0.78	Resting heart rate;	chr3:49429773	chrX:13378735~13379340:-
TGCT	trans	rs13096760	1	rs13096760	ENSG00000197582.5	GPX1P1	13.99	2.89e-27	3e-19	0.93	0.78	Intelligence (multi-trait analysis);	chr3:49439373	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.595	rs885592	ENSG00000197582.5	GPX1P1	13.99	2.89e-27	3e-19	0.93	0.78	Resting heart rate;	chr3:49460450	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.595	rs10865955	ENSG00000197582.5	GPX1P1	13.99	2.89e-27	3e-19	0.93	0.78	Resting heart rate;	chr3:49462396	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.636	rs1568662	ENSG00000197582.5	GPX1P1	13.99	2.89e-27	3e-19	0.93	0.78	Resting heart rate;	chr3:49483830	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.595	rs3924462	ENSG00000197582.5	GPX1P1	13.99	2.89e-27	3e-19	0.93	0.78	Resting heart rate;	chr3:49486803	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.595	rs4855861	ENSG00000197582.5	GPX1P1	13.99	2.89e-27	3e-19	0.93	0.78	Resting heart rate;	chr3:49488529	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.595	rs4855859	ENSG00000197582.5	GPX1P1	13.99	2.89e-27	3e-19	0.93	0.78	Resting heart rate;	chr3:49488867	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.595	rs7643845	ENSG00000197582.5	GPX1P1	13.99	2.89e-27	3e-19	0.93	0.78	Resting heart rate;	chr3:49493278	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.595	rs7637999	ENSG00000197582.5	GPX1P1	13.99	2.89e-27	3e-19	0.93	0.78	Resting heart rate;	chr3:49497682	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.576	rs3877784	ENSG00000197582.5	GPX1P1	13.99	2.89e-27	3e-19	0.93	0.78	Resting heart rate;	chr3:49501984	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.595	rs11720264	ENSG00000197582.5	GPX1P1	13.99	2.89e-27	3e-19	0.93	0.78	Resting heart rate;	chr3:49542914	chrX:13378735~13379340:-
TGCT	trans	rs13177918	0.677	rs2073472	ENSG00000239528.1	RPS14P8	13.96	3.36e-27	3.46e-19	1.08	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr5:116562562~116562930:+
TGCT	trans	rs13253073	0.8	rs7015733	ENSG00000260318.1	COX6CP1	13.88	5.15e-27	5.26e-19	1.27	0.78	Glucose homeostasis traits;	chr8:99899353	chr16:11903923~11904137:-
TGCT	trans	rs916888	0.773	rs199457	ENSG00000263503.1	RP11-707O23.5	13.84	6.48e-27	6.57e-19	1.22	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45600869~45602340:-
TGCT	trans	rs7554547	0.667	rs4846072	ENSG00000261819.1	RP11-680G24.4	13.79	8.31e-27	8.32e-19	0.94	0.78	Nonsyndromic cleft lip with cleft palate;	chr1:11890334	chr16:14988259~14990160:-
TGCT	trans	rs9611565	0.659	rs9611603	ENSG00000268568.1	AC007228.9	-13.79	8.32e-27	8.32e-19	-1.06	-0.78	Vitiligo;	chr22:41516746	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs11090049	ENSG00000268568.1	AC007228.9	-13.79	8.32e-27	8.32e-19	-1.06	-0.78	Vitiligo;	chr22:41519325	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs9611604	ENSG00000268568.1	AC007228.9	-13.79	8.32e-27	8.32e-19	-1.06	-0.78	Vitiligo;	chr22:41519997	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs12484694	ENSG00000268568.1	AC007228.9	-13.79	8.32e-27	8.32e-19	-1.06	-0.78	Vitiligo;	chr22:41523326	chr19:56672574~56673901:-
TGCT	trans	rs916888	0.773	rs199451	ENSG00000263503.1	RP11-707O23.5	13.79	8.57e-27	8.57e-19	1.2	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45600869~45602340:-
TGCT	trans	rs13177918	0.626	rs3819332	ENSG00000224114.1	RP11-343H5.4	13.77	9.47e-27	9.36e-19	1.05	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:206695837~206696269:-
TGCT	trans	rs13177918	0.626	rs13170300	ENSG00000224114.1	RP11-343H5.4	13.77	9.47e-27	9.36e-19	1.05	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:206695837~206696269:-
TGCT	trans	rs13177918	0.75	rs58256223	ENSG00000224114.1	RP11-343H5.4	13.74	1.14e-26	1.12e-18	1.06	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:206695837~206696269:-
TGCT	trans	rs928391	0.681	rs9427242	ENSG00000227183.3	HDGFP1	-13.71	1.29e-26	1.26e-18	-0.93	-0.78	Platelet count;	chr1:156755209	chrX:131646639~131646890:+
TGCT	trans	rs3749237	0.615	rs11130202	ENSG00000197582.5	GPX1P1	13.71	1.34e-26	1.31e-18	0.93	0.78	Resting heart rate;	chr3:49529282	chrX:13378735~13379340:-
TGCT	trans	rs9611565	0.659	rs4822035	ENSG00000268568.1	AC007228.9	13.69	1.47e-26	1.44e-18	1.05	0.78	Vitiligo;	chr22:41539908	chr19:56672574~56673901:-
TGCT	trans	rs7554547	0.667	rs2336377	ENSG00000261819.1	RP11-680G24.4	-13.67	1.65e-26	1.6e-18	-0.94	-0.78	Nonsyndromic cleft lip with cleft palate;	chr1:11889913	chr16:14988259~14990160:-
TGCT	trans	rs3749237	0.595	rs17595772	ENSG00000197582.5	GPX1P1	13.64	1.93e-26	1.83e-18	0.93	0.77	Resting heart rate;	chr3:49372271	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.595	rs7621003	ENSG00000197582.5	GPX1P1	13.64	1.93e-26	1.83e-18	0.93	0.77	Resting heart rate;	chr3:49373971	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.555	rs2117939	ENSG00000197582.5	GPX1P1	13.64	1.93e-26	1.83e-18	0.93	0.77	Resting heart rate;	chr3:49377746	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.595	rs4955412	ENSG00000197582.5	GPX1P1	13.64	1.93e-26	1.83e-18	0.93	0.77	Resting heart rate;	chr3:49380735	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.595	rs6797765	ENSG00000197582.5	GPX1P1	13.64	1.93e-26	1.83e-18	0.93	0.77	Resting heart rate;	chr3:49386543	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.557	rs7631908	ENSG00000197582.5	GPX1P1	13.64	1.93e-26	1.83e-18	0.93	0.77	Resting heart rate;	chr3:49388274	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.615	rs55957735	ENSG00000197582.5	GPX1P1	13.64	1.93e-26	1.83e-18	0.93	0.77	Resting heart rate;	chr3:49400725	chrX:13378735~13379340:-
TGCT	trans	rs916888	0.773	rs199535	ENSG00000263503.1	RP11-707O23.5	13.64	1.93e-26	1.83e-18	1.2	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45600869~45602340:-
TGCT	trans	rs13177918	0.626	rs13175436	ENSG00000224114.1	RP11-343H5.4	13.64	1.93e-26	1.83e-18	1.05	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:206695837~206696269:-
TGCT	trans	rs13177918	0.603	rs13175992	ENSG00000224114.1	RP11-343H5.4	13.64	1.93e-26	1.83e-18	1.05	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:206695837~206696269:-
TGCT	trans	rs13253073	0.723	rs13274441	ENSG00000260318.1	COX6CP1	13.64	1.98e-26	1.87e-18	1.39	0.77	Glucose homeostasis traits;	chr8:99861038	chr16:11903923~11904137:-
TGCT	trans	rs3749237	0.595	rs2878298	ENSG00000197582.5	GPX1P1	13.63	2.04e-26	1.92e-18	0.93	0.77	Resting heart rate;	chr3:49368647	chrX:13378735~13379340:-
TGCT	trans	rs9611565	0.579	rs73178621	ENSG00000268568.1	AC007228.9	-13.6	2.46e-26	2.21e-18	-1.05	-0.77	Vitiligo;	chr22:41525661	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs17367849	ENSG00000268568.1	AC007228.9	-13.6	2.46e-26	2.21e-18	-1.05	-0.77	Vitiligo;	chr22:41527640	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs1810461	ENSG00000268568.1	AC007228.9	-13.6	2.46e-26	2.21e-18	-1.05	-0.77	Vitiligo;	chr22:41531816	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.625	rs73178625	ENSG00000268568.1	AC007228.9	-13.6	2.46e-26	2.21e-18	-1.05	-0.77	Vitiligo;	chr22:41532316	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs73178626	ENSG00000268568.1	AC007228.9	-13.6	2.46e-26	2.21e-18	-1.05	-0.77	Vitiligo;	chr22:41532367	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs4822034	ENSG00000268568.1	AC007228.9	-13.6	2.46e-26	2.21e-18	-1.05	-0.77	Vitiligo;	chr22:41535006	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.625	rs9611606	ENSG00000268568.1	AC007228.9	-13.6	2.46e-26	2.21e-18	-1.05	-0.77	Vitiligo;	chr22:41535070	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs116959331	ENSG00000268568.1	AC007228.9	-13.6	2.46e-26	2.21e-18	-1.05	-0.77	Vitiligo;	chr22:41536770	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs56319767	ENSG00000268568.1	AC007228.9	-13.6	2.46e-26	2.21e-18	-1.05	-0.77	Vitiligo;	chr22:41537833	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs73178632	ENSG00000268568.1	AC007228.9	-13.6	2.46e-26	2.21e-18	-1.05	-0.77	Vitiligo;	chr22:41538569	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs28530678	ENSG00000268568.1	AC007228.9	-13.6	2.46e-26	2.21e-18	-1.05	-0.77	Vitiligo;	chr22:41538957	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs12483998	ENSG00000268568.1	AC007228.9	-13.6	2.46e-26	2.21e-18	-1.05	-0.77	Vitiligo;	chr22:41539358	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs4822036	ENSG00000268568.1	AC007228.9	-13.6	2.46e-26	2.21e-18	-1.05	-0.77	Vitiligo;	chr22:41540015	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs12483786	ENSG00000268568.1	AC007228.9	-13.6	2.46e-26	2.21e-18	-1.05	-0.77	Vitiligo;	chr22:41542532	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs12484228	ENSG00000268568.1	AC007228.9	-13.6	2.46e-26	2.21e-18	-1.05	-0.77	Vitiligo;	chr22:41543735	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs28623192	ENSG00000268568.1	AC007228.9	-13.6	2.46e-26	2.21e-18	-1.05	-0.77	Vitiligo;	chr22:41544520	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs9607812	ENSG00000268568.1	AC007228.9	-13.6	2.46e-26	2.21e-18	-1.05	-0.77	Vitiligo;	chr22:41545239	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs9607813	ENSG00000268568.1	AC007228.9	-13.6	2.46e-26	2.21e-18	-1.05	-0.77	Vitiligo;	chr22:41545475	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.527	rs73178638	ENSG00000268568.1	AC007228.9	-13.6	2.46e-26	2.21e-18	-1.05	-0.77	Vitiligo;	chr22:41546900	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs4822037	ENSG00000268568.1	AC007228.9	-13.6	2.46e-26	2.21e-18	-1.05	-0.77	Vitiligo;	chr22:41549109	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs9611609	ENSG00000268568.1	AC007228.9	-13.6	2.46e-26	2.21e-18	-1.05	-0.77	Vitiligo;	chr22:41549353	chr19:56672574~56673901:-
TGCT	trans	rs12291225	0.585	rs4517475	ENSG00000236360.2	RP11-334A14.2	13.58	2.75e-26	2.47e-18	0.95	0.77	Sense of smell;	chr11:14364599	chr1:52993201~52993702:-
TGCT	trans	rs9611565	0.765	rs132905	ENSG00000268568.1	AC007228.9	13.57	2.83e-26	2.47e-18	1	0.77	Vitiligo;	chr22:41403102	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.765	rs132909	ENSG00000268568.1	AC007228.9	13.57	2.83e-26	2.47e-18	1	0.77	Vitiligo;	chr22:41406027	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.681	rs5751094	ENSG00000268568.1	AC007228.9	13.57	2.83e-26	2.47e-18	1	0.77	Vitiligo;	chr22:41407275	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.765	rs132914	ENSG00000268568.1	AC007228.9	13.57	2.83e-26	2.47e-18	1	0.77	Vitiligo;	chr22:41409745	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.765	rs132915	ENSG00000268568.1	AC007228.9	13.57	2.83e-26	2.47e-18	1	0.77	Vitiligo;	chr22:41409778	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.722	rs202635	ENSG00000268568.1	AC007228.9	13.57	2.83e-26	2.47e-18	1	0.77	Vitiligo;	chr22:41413633	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.765	rs132920	ENSG00000268568.1	AC007228.9	13.57	2.83e-26	2.47e-18	1	0.77	Vitiligo;	chr22:41414166	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.765	rs202659	ENSG00000268568.1	AC007228.9	13.57	2.83e-26	2.47e-18	1	0.77	Vitiligo;	chr22:41415616	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.765	rs202663	ENSG00000268568.1	AC007228.9	13.57	2.83e-26	2.47e-18	1	0.77	Vitiligo;	chr22:41416815	chr19:56672574~56673901:-
TGCT	trans	rs13177918	0.75	rs59354956	ENSG00000224114.1	RP11-343H5.4	13.56	2.95e-26	2.57e-18	1.06	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:206695837~206696269:-
TGCT	trans	rs3749237	0.595	rs1464567	ENSG00000197582.5	GPX1P1	-13.56	2.99e-26	2.6e-18	-0.93	-0.77	Resting heart rate;	chr3:49421819	chrX:13378735~13379340:-
TGCT	trans	rs9611565	0.681	rs132918	ENSG00000268568.1	AC007228.9	13.56	3.03e-26	2.61e-18	1	0.77	Vitiligo;	chr22:41412346	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.765	rs132921	ENSG00000268568.1	AC007228.9	13.56	3.03e-26	2.61e-18	1	0.77	Vitiligo;	chr22:41416040	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.625	rs2076199	ENSG00000268568.1	AC007228.9	-13.54	3.26e-26	2.8e-18	-1	-0.77	Vitiligo;	chr22:41507739	chr19:56672574~56673901:-
TGCT	trans	rs13177918	0.626	rs67026795	ENSG00000224114.1	RP11-343H5.4	13.5	4.21e-26	3.6e-18	1.05	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:206695837~206696269:-
TGCT	trans	rs13177918	0.603	rs10447222	ENSG00000224114.1	RP11-343H5.4	13.5	4.21e-26	3.6e-18	1.05	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:206695837~206696269:-
TGCT	trans	rs7949030	1	rs7949030	ENSG00000186676.3	EEF1GP1	13.48	4.7e-26	4.01e-18	0.93	0.77	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62627409	chr7:125033453~125035301:+
TGCT	trans	rs916888	0.821	rs199514	ENSG00000263503.1	RP11-707O23.5	-13.45	5.45e-26	4.6e-18	-1.17	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45600869~45602340:-
TGCT	trans	rs916888	0.697	rs199516	ENSG00000263503.1	RP11-707O23.5	-13.44	5.9e-26	4.96e-18	-1.16	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45600869~45602340:-
TGCT	trans	rs9611565	0.877	rs3817999	ENSG00000268568.1	AC007228.9	13.44	5.9e-26	4.96e-18	0.99	0.77	Vitiligo;	chr22:41351713	chr19:56672574~56673901:-
TGCT	trans	rs12291225	0.546	rs12291662	ENSG00000236360.2	RP11-334A14.2	13.38	8.02e-26	6.55e-18	0.93	0.77	Sense of smell;	chr11:14321403	chr1:52993201~52993702:-
TGCT	trans	rs12291225	0.545	rs11023187	ENSG00000236360.2	RP11-334A14.2	13.38	8.02e-26	6.55e-18	0.93	0.77	Sense of smell;	chr11:14324013	chr1:52993201~52993702:-
TGCT	trans	rs12291225	0.546	rs12795545	ENSG00000236360.2	RP11-334A14.2	13.38	8.02e-26	6.55e-18	0.93	0.77	Sense of smell;	chr11:14334018	chr1:52993201~52993702:-
TGCT	trans	rs12291225	0.585	rs10832242	ENSG00000236360.2	RP11-334A14.2	-13.38	8.02e-26	6.55e-18	-0.93	-0.77	Sense of smell;	chr11:14318958	chr1:52993201~52993702:-
TGCT	trans	rs13253073	0.662	rs4434590	ENSG00000260318.1	COX6CP1	13.37	8.55e-26	6.96e-18	1.33	0.77	Glucose homeostasis traits;	chr8:99848429	chr16:11903923~11904137:-
TGCT	trans	rs12291225	0.546	rs11023199	ENSG00000236360.2	RP11-334A14.2	13.34	9.79e-26	7.93e-18	0.95	0.77	Sense of smell;	chr11:14372712	chr1:52993201~52993702:-
TGCT	trans	rs13177918	0.578	rs35919198	ENSG00000224114.1	RP11-343H5.4	13.29	1.31e-25	1.05e-17	1.04	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr1:206695837~206696269:-
TGCT	trans	rs9611565	0.659	rs9611610	ENSG00000268568.1	AC007228.9	-13.28	1.37e-25	1.1e-17	-1.04	-0.77	Vitiligo;	chr22:41553255	chr19:56672574~56673901:-
TGCT	trans	rs12291225	0.585	rs11023194	ENSG00000236360.2	RP11-334A14.2	13.25	1.62e-25	1.29e-17	0.93	0.77	Sense of smell;	chr11:14348223	chr1:52993201~52993702:-
TGCT	trans	rs13177918	0.626	rs3819332	ENSG00000239528.1	RPS14P8	13.25	1.63e-25	1.29e-17	1.04	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr5:116562562~116562930:+
TGCT	trans	rs13177918	0.626	rs13170300	ENSG00000239528.1	RPS14P8	13.25	1.63e-25	1.29e-17	1.04	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr5:116562562~116562930:+
TGCT	trans	rs9611565	0.729	rs12165508	ENSG00000268568.1	AC007228.9	13.23	1.8e-25	1.42e-17	0.99	0.77	Vitiligo;	chr22:41423956	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.729	rs169362	ENSG00000268568.1	AC007228.9	13.23	1.8e-25	1.42e-17	0.99	0.77	Vitiligo;	chr22:41431585	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.729	rs202654	ENSG00000268568.1	AC007228.9	13.23	1.8e-25	1.42e-17	0.99	0.77	Vitiligo;	chr22:41445030	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.729	rs505533	ENSG00000268568.1	AC007228.9	13.23	1.8e-25	1.42e-17	0.99	0.77	Vitiligo;	chr22:41468212	chr19:56672574~56673901:-
TGCT	trans	rs7554547	0.63	rs4845889	ENSG00000261819.1	RP11-680G24.4	13.23	1.86e-25	1.46e-17	0.92	0.77	Nonsyndromic cleft lip with cleft palate;	chr1:11911288	chr16:14988259~14990160:-
TGCT	trans	rs7554547	0.667	rs7525521	ENSG00000261819.1	RP11-680G24.4	13.23	1.86e-25	1.46e-17	0.92	0.77	Nonsyndromic cleft lip with cleft palate;	chr1:11915109	chr16:14988259~14990160:-
TGCT	trans	rs9611565	0.643	rs202634	ENSG00000268568.1	AC007228.9	13.21	2.04e-25	1.59e-17	1.01	0.76	Vitiligo;	chr22:41413619	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.694	rs202617	ENSG00000268568.1	AC007228.9	13.2	2.12e-25	1.65e-17	1.21	0.76	Vitiligo;	chr22:41426789	chr19:56672574~56673901:-
TGCT	trans	rs13177918	0.626	rs13175436	ENSG00000239528.1	RPS14P8	13.19	2.31e-25	1.79e-17	1.03	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr5:116562562~116562930:+
TGCT	trans	rs13177918	0.603	rs13175992	ENSG00000239528.1	RPS14P8	13.19	2.31e-25	1.79e-17	1.03	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr5:116562562~116562930:+
TGCT	trans	rs6477998	0.603	rs10117451	ENSG00000238072.1	RP11-305M3.2	13.19	2.34e-25	1.8e-17	0.92	0.76	Hematology traits;	chr9:113273610	chr7:129410113~129410370:-
TGCT	trans	rs13177918	0.578	rs35919198	ENSG00000239528.1	RPS14P8	13.18	2.38e-25	1.84e-17	1.04	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr5:116562562~116562930:+
TGCT	trans	rs12291225	0.585	rs10832246	ENSG00000236360.2	RP11-334A14.2	13.15	2.82e-25	2.15e-17	0.93	0.76	Sense of smell;	chr11:14359282	chr1:52993201~52993702:-
TGCT	trans	rs12291225	0.585	rs11023197	ENSG00000236360.2	RP11-334A14.2	13.15	2.82e-25	2.15e-17	0.93	0.76	Sense of smell;	chr11:14359452	chr1:52993201~52993702:-
TGCT	trans	rs9611565	0.765	rs727563	ENSG00000268568.1	AC007228.9	13.15	2.82e-25	2.15e-17	1	0.76	Vitiligo;	chr22:41471373	chr19:56672574~56673901:-
TGCT	trans	rs13177918	0.626	rs67026795	ENSG00000239528.1	RPS14P8	13.15	2.83e-25	2.16e-17	1.04	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr5:116562562~116562930:+
TGCT	trans	rs13177918	0.603	rs10447222	ENSG00000239528.1	RPS14P8	13.15	2.83e-25	2.16e-17	1.04	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr5:116562562~116562930:+
TGCT	trans	rs9611565	0.659	rs9607815	ENSG00000268568.1	AC007228.9	-13.15	2.88e-25	2.18e-17	-1.03	-0.76	Vitiligo;	chr22:41554667	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs73178641	ENSG00000268568.1	AC007228.9	-13.15	2.88e-25	2.18e-17	-1.03	-0.76	Vitiligo;	chr22:41556071	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs12484175	ENSG00000268568.1	AC007228.9	-13.15	2.88e-25	2.18e-17	-1.03	-0.76	Vitiligo;	chr22:41557735	chr19:56672574~56673901:-
TGCT	trans	rs3749237	0.615	rs6792911	ENSG00000197582.5	GPX1P1	13.15	2.9e-25	2.19e-17	0.9	0.76	Resting heart rate;	chr3:49392423	chrX:13378735~13379340:-
TGCT	trans	rs9611565	0.765	rs132907	ENSG00000268568.1	AC007228.9	13.15	2.95e-25	2.21e-17	1.01	0.76	Vitiligo;	chr22:41405264	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.681	rs6002372	ENSG00000268568.1	AC007228.9	13.15	2.95e-25	2.21e-17	1.01	0.76	Vitiligo;	chr22:41405295	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.765	rs132908	ENSG00000268568.1	AC007228.9	13.15	2.95e-25	2.21e-17	1.01	0.76	Vitiligo;	chr22:41405791	chr19:56672574~56673901:-
TGCT	trans	rs916888	0.821	rs199512	ENSG00000263503.1	RP11-707O23.5	-13.13	3.14e-25	2.32e-17	-1.16	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45600869~45602340:-
TGCT	trans	rs916888	0.821	rs199509	ENSG00000263503.1	RP11-707O23.5	-13.13	3.14e-25	2.32e-17	-1.16	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45600869~45602340:-
TGCT	trans	rs916888	0.821	rs199507	ENSG00000263503.1	RP11-707O23.5	-13.13	3.14e-25	2.32e-17	-1.16	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45600869~45602340:-
TGCT	trans	rs916888	0.821	rs199506	ENSG00000263503.1	RP11-707O23.5	-13.13	3.14e-25	2.32e-17	-1.16	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45600869~45602340:-
TGCT	trans	rs916888	0.821	rs415430	ENSG00000263503.1	RP11-707O23.5	-13.13	3.14e-25	2.32e-17	-1.16	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45600869~45602340:-
TGCT	trans	rs916888	0.779	rs430685	ENSG00000263503.1	RP11-707O23.5	-13.13	3.14e-25	2.32e-17	-1.16	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45600869~45602340:-
TGCT	trans	rs916888	0.821	rs199505	ENSG00000263503.1	RP11-707O23.5	-13.13	3.14e-25	2.32e-17	-1.16	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45600869~45602340:-
TGCT	trans	rs916888	0.821	rs70602	ENSG00000263503.1	RP11-707O23.5	-13.13	3.14e-25	2.32e-17	-1.16	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45600869~45602340:-
TGCT	trans	rs916888	0.821	rs70600	ENSG00000263503.1	RP11-707O23.5	13.13	3.14e-25	2.32e-17	1.16	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45600869~45602340:-
TGCT	trans	rs9611565	0.694	rs9607816	ENSG00000268568.1	AC007228.9	-13.12	3.44e-25	2.54e-17	-1.03	-0.76	Vitiligo;	chr22:41554893	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs56364401	ENSG00000268568.1	AC007228.9	-13.12	3.44e-25	2.54e-17	-1.03	-0.76	Vitiligo;	chr22:41555239	chr19:56672574~56673901:-
TGCT	trans	rs12709013	0.646	rs8046154	ENSG00000230849.2	GOT2P2	-13.11	3.5e-25	2.57e-17	-0.92	-0.76	Blood metabolite ratios;	chr16:58773978	chr1:173141100~173142350:-
TGCT	trans	rs9611565	0.659	rs17367716	ENSG00000268568.1	AC007228.9	-13.11	3.63e-25	2.67e-17	-1.03	-0.76	Vitiligo;	chr22:41517840	chr19:56672574~56673901:-
TGCT	trans	rs916888	0.773	rs199533	ENSG00000264070.1	DND1P1	13.1	3.69e-25	2.71e-17	1.38	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45585871~45586929:+
TGCT	trans	rs916888	0.773	rs199447	ENSG00000264070.1	DND1P1	13.1	3.72e-25	2.72e-17	1.37	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45585871~45586929:+
TGCT	trans	rs916888	0.773	rs199445	ENSG00000264070.1	DND1P1	13.1	3.72e-25	2.72e-17	1.37	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45585871~45586929:+
TGCT	trans	rs916888	0.773	rs199443	ENSG00000264070.1	DND1P1	13.1	3.72e-25	2.72e-17	1.37	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45585871~45586929:+
TGCT	trans	rs916888	0.773	rs199534	ENSG00000264070.1	DND1P1	13.1	3.72e-25	2.72e-17	1.37	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45585871~45586929:+
TGCT	trans	rs12291225	0.585	rs12270374	ENSG00000236360.2	RP11-334A14.2	13.1	3.86e-25	2.82e-17	0.92	0.76	Sense of smell;	chr11:14353533	chr1:52993201~52993702:-
TGCT	trans	rs9611565	0.918	rs73176685	ENSG00000268568.1	AC007228.9	-13.06	4.81e-25	3.44e-17	-1	-0.76	Vitiligo;	chr22:41385090	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.918	rs6002351	ENSG00000268568.1	AC007228.9	-13.05	4.86e-25	3.46e-17	-0.99	-0.76	Vitiligo;	chr22:41361219	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.879	rs5758311	ENSG00000268568.1	AC007228.9	-13.05	4.86e-25	3.46e-17	-0.99	-0.76	Vitiligo;	chr22:41363371	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.879	rs4820437	ENSG00000268568.1	AC007228.9	-13.05	4.86e-25	3.46e-17	-0.99	-0.76	Vitiligo;	chr22:41365286	chr19:56672574~56673901:-
TGCT	trans	rs13177918	0.75	rs58256223	ENSG00000239528.1	RPS14P8	13.02	5.84e-25	4.13e-17	1.04	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr5:116562562~116562930:+
TGCT	trans	rs3749237	0.595	rs17650792	ENSG00000197582.5	GPX1P1	13.02	5.94e-25	4.2e-17	0.92	0.76	Resting heart rate;	chr3:49352817	chrX:13378735~13379340:-
TGCT	trans	rs9611565	0.802	rs9611571	ENSG00000268568.1	AC007228.9	-13.01	6.14e-25	4.3e-17	-1	-0.76	Vitiligo;	chr22:41388863	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.802	rs73176692	ENSG00000268568.1	AC007228.9	-13.01	6.14e-25	4.3e-17	-1	-0.76	Vitiligo;	chr22:41389731	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.802	rs73176694	ENSG00000268568.1	AC007228.9	-13.01	6.14e-25	4.3e-17	-1	-0.76	Vitiligo;	chr22:41390784	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.802	rs4822028	ENSG00000268568.1	AC007228.9	-13.01	6.14e-25	4.3e-17	-1	-0.76	Vitiligo;	chr22:41393404	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.802	rs9611577	ENSG00000268568.1	AC007228.9	-13.01	6.14e-25	4.3e-17	-1	-0.76	Vitiligo;	chr22:41397086	chr19:56672574~56673901:-
TGCT	trans	rs916888	0.821	rs199504	ENSG00000263503.1	RP11-707O23.5	-12.98	7.39e-25	5.17e-17	-1.15	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45600869~45602340:-
TGCT	trans	rs3749237	0.595	rs1050088	ENSG00000197582.5	GPX1P1	-12.94	8.91e-25	6.21e-17	-0.9	-0.76	Resting heart rate;	chr3:49533449	chrX:13378735~13379340:-
TGCT	trans	rs9611565	0.765	rs9607800	ENSG00000268568.1	AC007228.9	-12.94	9.17e-25	6.37e-17	-0.99	-0.76	Vitiligo;	chr22:41388558	chr19:56672574~56673901:-
TGCT	trans	rs12291225	0.585	rs34171876	ENSG00000236360.2	RP11-334A14.2	12.92	1.03e-24	7.1e-17	0.93	0.76	Sense of smell;	chr11:14332411	chr1:52993201~52993702:-
TGCT	trans	rs9611565	0.921	rs4822021	ENSG00000268568.1	AC007228.9	-12.91	1.09e-24	7.5e-17	-1	-0.76	Vitiligo;	chr22:41330049	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.921	rs8137373	ENSG00000268568.1	AC007228.9	12.91	1.09e-24	7.5e-17	1	0.76	Vitiligo;	chr22:41333212	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.879	rs5758307	ENSG00000268568.1	AC007228.9	-12.9	1.13e-24	7.76e-17	-0.99	-0.76	Vitiligo;	chr22:41354215	chr19:56672574~56673901:-
TGCT	trans	rs12709013	0.636	rs1646284	ENSG00000230849.2	GOT2P2	12.88	1.31e-24	9.01e-17	0.94	0.76	Blood metabolite ratios;	chr16:58752093	chr1:173141100~173142350:-
TGCT	trans	rs916888	0.779	rs199528	ENSG00000264070.1	DND1P1	12.87	1.38e-24	9.42e-17	1.32	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45585871~45586929:+
TGCT	trans	rs916888	0.821	rs199525	ENSG00000264070.1	DND1P1	12.87	1.38e-24	9.42e-17	1.32	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45585871~45586929:+
TGCT	trans	rs941207	0.724	rs4788	ENSG00000121089.4	NACA3P	12.86	1.45e-24	9.88e-17	1.01	0.76	Platelet count;	chr12:56712876	chr4:164943290~164943937:+
TGCT	trans	rs916888	0.738	rs199515	ENSG00000263503.1	RP11-707O23.5	-12.85	1.53e-24	1.04e-16	-1.17	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45600869~45602340:-
TGCT	trans	rs13177918	0.75	rs59354956	ENSG00000239528.1	RPS14P8	12.81	1.86e-24	1.25e-16	1.04	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr5:116562562~116562930:+
TGCT	trans	rs9611565	0.592	rs5758405	ENSG00000268568.1	AC007228.9	12.79	2.11e-24	1.4e-16	1.01	0.75	Vitiligo;	chr22:41680377	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.592	rs5758406	ENSG00000268568.1	AC007228.9	12.79	2.11e-24	1.4e-16	1.01	0.75	Vitiligo;	chr22:41680637	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.5	rs10775759	ENSG00000268568.1	AC007228.9	12.79	2.11e-24	1.4e-16	1.01	0.75	Vitiligo;	chr22:41692154	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.546	rs739134	ENSG00000268568.1	AC007228.9	12.79	2.11e-24	1.4e-16	1.01	0.75	Vitiligo;	chr22:41693619	chr19:56672574~56673901:-
TGCT	trans	rs6477998	0.58	rs10981715	ENSG00000238072.1	RP11-305M3.2	12.73	2.9e-24	1.9e-16	0.97	0.75	Hematology traits;	chr9:113287218	chr7:129410113~129410370:-
TGCT	trans	rs9611565	0.592	rs8779	ENSG00000268568.1	AC007228.9	12.72	3.06e-24	1.97e-16	1.04	0.75	Vitiligo;	chr22:41674272	chr19:56672574~56673901:-
TGCT	trans	rs727563	0.594	rs132807	ENSG00000268568.1	AC007228.9	12.72	3.06e-24	1.97e-16	1.04	0.75	Crohn's disease;Inflammatory bowel disease;	chr22:41675580	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.592	rs1811113	ENSG00000268568.1	AC007228.9	12.72	3.06e-24	1.97e-16	1.04	0.75	Vitiligo;	chr22:41677130	chr19:56672574~56673901:-
TGCT	trans	rs727563	0.594	rs5758408	ENSG00000268568.1	AC007228.9	12.72	3.06e-24	1.97e-16	1.04	0.75	Crohn's disease;Inflammatory bowel disease;	chr22:41681733	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.559	rs5758412	ENSG00000268568.1	AC007228.9	12.72	3.06e-24	1.97e-16	1.04	0.75	Vitiligo;	chr22:41684799	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.559	rs13056262	ENSG00000268568.1	AC007228.9	12.72	3.06e-24	1.97e-16	1.04	0.75	Vitiligo;	chr22:41685917	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.513	rs739135	ENSG00000268568.1	AC007228.9	12.72	3.06e-24	1.97e-16	1.04	0.75	Vitiligo;	chr22:41694065	chr19:56672574~56673901:-
TGCT	trans	rs727563	0.636	rs2187795	ENSG00000268568.1	AC007228.9	12.72	3.06e-24	1.97e-16	1.04	0.75	Crohn's disease;Inflammatory bowel disease;	chr22:41696221	chr19:56672574~56673901:-
TGCT	trans	rs4822044	0.68	rs8138780	ENSG00000268568.1	AC007228.9	12.72	3.06e-24	1.97e-16	1.04	0.75	Cannabis dependence symptom count;	chr22:41701458	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.918	rs2281333	ENSG00000268568.1	AC007228.9	-12.72	3.18e-24	2.05e-16	-0.97	-0.75	Vitiligo;	chr22:41353626	chr19:56672574~56673901:-
TGCT	trans	rs916888	0.773	rs199448	ENSG00000264070.1	DND1P1	12.71	3.25e-24	2.09e-16	1.31	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45585871~45586929:+
TGCT	trans	rs9611565	0.921	rs6002333	ENSG00000268568.1	AC007228.9	-12.7	3.53e-24	2.26e-16	-0.97	-0.75	Vitiligo;	chr22:41323465	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.921	rs3927	ENSG00000268568.1	AC007228.9	-12.7	3.56e-24	2.27e-16	-0.97	-0.75	Vitiligo;	chr22:41326860	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.659	rs1810460	ENSG00000268568.1	AC007228.9	-12.68	3.88e-24	2.46e-16	-1	-0.75	Vitiligo;	chr22:41531696	chr19:56672574~56673901:-
TGCT	trans	rs916888	0.773	rs9896243	ENSG00000264070.1	DND1P1	12.68	3.89e-24	2.46e-16	1.33	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45585871~45586929:+
TGCT	trans	rs9611565	0.729	rs203319	ENSG00000268568.1	AC007228.9	-12.68	3.89e-24	2.46e-16	-0.96	-0.75	Vitiligo;	chr22:41518589	chr19:56672574~56673901:-
TGCT	trans	rs941207	0.756	rs7313074	ENSG00000121089.4	NACA3P	-12.68	3.9e-24	2.46e-16	-1.01	-0.75	Platelet count;	chr12:56760705	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.756	rs2958149	ENSG00000121089.4	NACA3P	12.68	3.9e-24	2.46e-16	1.01	0.75	Platelet count;	chr12:56716008	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.756	rs2926743	ENSG00000121089.4	NACA3P	12.68	3.9e-24	2.46e-16	1.01	0.75	Platelet count;	chr12:56720316	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.724	rs1979325	ENSG00000121089.4	NACA3P	12.68	3.9e-24	2.46e-16	1.01	0.75	Platelet count;	chr12:56728152	chr4:164943290~164943937:+
TGCT	trans	rs9611565	0.592	rs6519270	ENSG00000268568.1	AC007228.9	12.68	3.94e-24	2.48e-16	1	0.75	Vitiligo;	chr22:41682662	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.546	rs5758426	ENSG00000268568.1	AC007228.9	12.68	3.94e-24	2.48e-16	1	0.75	Vitiligo;	chr22:41702759	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.608	rs2003816	ENSG00000268568.1	AC007228.9	12.66	4.28e-24	2.68e-16	1	0.75	Vitiligo;	chr22:41699136	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.694	rs11090056	ENSG00000268568.1	AC007228.9	12.66	4.28e-24	2.68e-16	1	0.75	Vitiligo;	chr22:41699900	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.649	rs2064189	ENSG00000268568.1	AC007228.9	12.66	4.39e-24	2.73e-16	1.01	0.75	Vitiligo;	chr22:41731995	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.694	rs5758411	ENSG00000268568.1	AC007228.9	12.66	4.4e-24	2.73e-16	0.99	0.75	Vitiligo;	chr22:41683730	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.644	rs2413652	ENSG00000268568.1	AC007228.9	12.66	4.4e-24	2.73e-16	0.99	0.75	Vitiligo;	chr22:41701234	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.559	rs132761	ENSG00000268568.1	AC007228.9	12.64	4.93e-24	3.03e-16	1.03	0.75	Vitiligo;	chr22:41608367	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.559	rs132765	ENSG00000268568.1	AC007228.9	12.64	4.93e-24	3.03e-16	1.03	0.75	Vitiligo;	chr22:41612064	chr19:56672574~56673901:-
TGCT	trans	rs4822044	0.56	rs7284839	ENSG00000268568.1	AC007228.9	12.64	4.93e-24	3.03e-16	1.03	0.75	Cannabis dependence symptom count;	chr22:41614898	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.559	rs132768	ENSG00000268568.1	AC007228.9	12.64	4.93e-24	3.03e-16	1.03	0.75	Vitiligo;	chr22:41617519	chr19:56672574~56673901:-
TGCT	trans	rs727563	0.555	rs5751136	ENSG00000268568.1	AC007228.9	12.64	4.96e-24	3.05e-16	1.03	0.75	Crohn's disease;Inflammatory bowel disease;	chr22:41679577	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.694	rs9611591	ENSG00000268568.1	AC007228.9	12.63	5.26e-24	3.23e-16	0.97	0.75	Vitiligo;	chr22:41434208	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.592	rs5758427	ENSG00000268568.1	AC007228.9	12.62	5.4e-24	3.29e-16	1	0.75	Vitiligo;	chr22:41703684	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.546	rs5758430	ENSG00000268568.1	AC007228.9	12.62	5.4e-24	3.29e-16	1	0.75	Vitiligo;	chr22:41713840	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.546	rs5758431	ENSG00000268568.1	AC007228.9	12.62	5.4e-24	3.29e-16	1	0.75	Vitiligo;	chr22:41713913	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.546	rs2092274	ENSG00000268568.1	AC007228.9	12.62	5.4e-24	3.29e-16	1	0.75	Vitiligo;	chr22:41727733	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.765	rs28604950	ENSG00000268568.1	AC007228.9	-12.61	5.61e-24	3.42e-16	-1.01	-0.75	Vitiligo;	chr22:41389808	chr19:56672574~56673901:-
TGCT	trans	rs12709013	0.576	rs2432622	ENSG00000230849.2	GOT2P2	12.59	6.23e-24	3.78e-16	0.93	0.75	Blood metabolite ratios;	chr16:58749681	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs1646281	ENSG00000230849.2	GOT2P2	12.58	6.6e-24	3.97e-16	0.92	0.75	Blood metabolite ratios;	chr16:58750512	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.613	rs1618602	ENSG00000230849.2	GOT2P2	12.58	6.6e-24	3.97e-16	0.92	0.75	Blood metabolite ratios;	chr16:58756080	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.613	rs8049462	ENSG00000230849.2	GOT2P2	12.58	6.6e-24	3.97e-16	0.92	0.75	Blood metabolite ratios;	chr16:58757654	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.66	rs257629	ENSG00000230849.2	GOT2P2	12.58	6.6e-24	3.97e-16	0.92	0.75	Blood metabolite ratios;	chr16:58758044	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs8045466	ENSG00000230849.2	GOT2P2	12.58	6.6e-24	3.97e-16	0.92	0.75	Blood metabolite ratios;	chr16:58765113	chr1:173141100~173142350:-
TGCT	trans	rs9611565	0.918	rs12484074	ENSG00000268568.1	AC007228.9	-12.56	7.52e-24	4.52e-16	-1.08	-0.75	Vitiligo;	chr22:41356743	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.592	rs5751139	ENSG00000268568.1	AC007228.9	12.53	8.73e-24	5.12e-16	1.02	0.75	Vitiligo;	chr22:41703977	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.559	rs5758428	ENSG00000268568.1	AC007228.9	12.53	8.73e-24	5.12e-16	1.02	0.75	Vitiligo;	chr22:41710212	chr19:56672574~56673901:-
TGCT	trans	rs727563	0.636	rs2413653	ENSG00000268568.1	AC007228.9	12.53	8.73e-24	5.12e-16	1.02	0.75	Crohn's disease;Inflammatory bowel disease;	chr22:41710992	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.546	rs739129	ENSG00000268568.1	AC007228.9	12.53	8.73e-24	5.12e-16	1.02	0.75	Vitiligo;	chr22:41722245	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.546	rs739132	ENSG00000268568.1	AC007228.9	12.53	8.73e-24	5.12e-16	1.02	0.75	Vitiligo;	chr22:41727095	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs5758436	ENSG00000268568.1	AC007228.9	12.53	8.73e-24	5.12e-16	1.02	0.75	Vitiligo;	chr22:41728261	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs7291736	ENSG00000268568.1	AC007228.9	12.53	8.73e-24	5.12e-16	1.02	0.75	Vitiligo;	chr22:41728870	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.559	rs739136	ENSG00000268568.1	AC007228.9	-12.53	8.73e-24	5.12e-16	-1.02	-0.75	Vitiligo;	chr22:41704271	chr19:56672574~56673901:-
TGCT	trans	rs9611565	1	rs1109151	ENSG00000268568.1	AC007228.9	-12.53	9.08e-24	5.28e-16	-0.97	-0.75	Vitiligo;	chr22:41356940	chr19:56672574~56673901:-
TGCT	trans	rs916888	0.61	rs199529	ENSG00000263503.1	RP11-707O23.5	12.51	1.01e-23	5.82e-16	1.13	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45600869~45602340:-
TGCT	trans	rs12709013	0.536	rs1646260	ENSG00000230849.2	GOT2P2	12.5	1.03e-23	5.93e-16	0.92	0.75	Blood metabolite ratios;	chr16:58734951	chr1:173141100~173142350:-
TGCT	trans	rs13253073	0.545	rs13265660	ENSG00000260318.1	COX6CP1	12.5	1.05e-23	6.04e-16	1.35	0.75	Glucose homeostasis traits;	chr8:99815931	chr16:11903923~11904137:-
TGCT	trans	rs9611565	0.649	rs5751144	ENSG00000268568.1	AC007228.9	-12.5	1.06e-23	6.04e-16	-0.99	-0.75	Vitiligo;	chr22:41732093	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.573	rs9306355	ENSG00000268568.1	AC007228.9	12.5	1.06e-23	6.04e-16	0.99	0.75	Vitiligo;	chr22:41715892	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.649	rs5758434	ENSG00000268568.1	AC007228.9	12.5	1.06e-23	6.04e-16	0.99	0.75	Vitiligo;	chr22:41720159	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.5	rs2011053	ENSG00000268568.1	AC007228.9	12.5	1.06e-23	6.04e-16	0.99	0.75	Vitiligo;	chr22:41725274	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.649	rs738422	ENSG00000268568.1	AC007228.9	12.5	1.06e-23	6.04e-16	0.99	0.75	Vitiligo;	chr22:41727395	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.607	rs132792	ENSG00000268568.1	AC007228.9	12.5	1.07e-23	6.12e-16	0.98	0.75	Vitiligo;	chr22:41666818	chr19:56672574~56673901:-
TGCT	trans	rs916888	0.687	rs199456	ENSG00000264070.1	DND1P1	12.48	1.19e-23	6.77e-16	1.35	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45585871~45586929:+
TGCT	trans	rs916888	0.773	rs199535	ENSG00000264070.1	DND1P1	12.46	1.35e-23	7.66e-16	1.34	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45585871~45586929:+
TGCT	trans	rs12709013	0.613	rs4238801	ENSG00000230849.2	GOT2P2	12.44	1.46e-23	8.24e-16	0.92	0.75	Blood metabolite ratios;	chr16:58738275	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs4575523	ENSG00000230849.2	GOT2P2	12.44	1.46e-23	8.24e-16	0.92	0.75	Blood metabolite ratios;	chr16:58738559	chr1:173141100~173142350:-
TGCT	trans	rs9611565	0.921	rs761366	ENSG00000268568.1	AC007228.9	-12.44	1.49e-23	8.4e-16	-0.96	-0.75	Vitiligo;	chr22:41348018	chr19:56672574~56673901:-
TGCT	trans	rs13253073	0.545	rs13260744	ENSG00000260318.1	COX6CP1	12.42	1.66e-23	9.26e-16	1.36	0.74	Glucose homeostasis traits;	chr8:99819032	chr16:11903923~11904137:-
TGCT	trans	rs12709013	0.591	rs30838	ENSG00000230849.2	GOT2P2	12.41	1.72e-23	9.6e-16	0.91	0.74	Blood metabolite ratios;	chr16:58711513	chr1:173141100~173142350:-
TGCT	trans	rs916888	0.773	rs199457	ENSG00000264070.1	DND1P1	12.4	1.89e-23	1.05e-15	1.35	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45585871~45586929:+
TGCT	trans	rs9611565	0.57	rs12159188	ENSG00000268568.1	AC007228.9	12.36	2.35e-23	1.29e-15	0.98	0.74	Vitiligo;	chr22:41725121	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.694	rs5758389	ENSG00000268568.1	AC007228.9	-12.34	2.54e-23	1.4e-15	-0.95	-0.74	Vitiligo;	chr22:41545745	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.545	rs5758432	ENSG00000268568.1	AC007228.9	12.33	2.72e-23	1.5e-15	1.01	0.74	Vitiligo;	chr22:41715689	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.625	rs12483991	ENSG00000268568.1	AC007228.9	-12.32	2.86e-23	1.57e-15	-0.95	-0.74	Vitiligo;	chr22:41539281	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs132767	ENSG00000268568.1	AC007228.9	-12.3	3.26e-23	1.78e-15	-1.01	-0.74	Vitiligo;	chr22:41613516	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.592	rs5751129	ENSG00000268568.1	AC007228.9	12.29	3.49e-23	1.88e-15	0.98	0.74	Vitiligo;	chr22:41619761	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs5758439	ENSG00000268568.1	AC007228.9	12.28	3.62e-23	1.93e-15	1.04	0.74	Vitiligo;	chr22:41735758	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs5751145	ENSG00000268568.1	AC007228.9	12.28	3.62e-23	1.93e-15	1.04	0.74	Vitiligo;	chr22:41737548	chr19:56672574~56673901:-
TGCT	trans	rs727563	0.635	rs5758444	ENSG00000268568.1	AC007228.9	12.28	3.62e-23	1.93e-15	1.04	0.74	Crohn's disease;Inflammatory bowel disease;	chr22:41737917	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs768414	ENSG00000268568.1	AC007228.9	12.28	3.62e-23	1.93e-15	1.04	0.74	Vitiligo;	chr22:41739747	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs8141103	ENSG00000268568.1	AC007228.9	12.28	3.62e-23	1.93e-15	1.04	0.74	Vitiligo;	chr22:41740926	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs5751147	ENSG00000268568.1	AC007228.9	12.28	3.62e-23	1.93e-15	1.04	0.74	Vitiligo;	chr22:41743050	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs5751148	ENSG00000268568.1	AC007228.9	12.28	3.62e-23	1.93e-15	1.04	0.74	Vitiligo;	chr22:41743074	chr19:56672574~56673901:-
TGCT	trans	rs727563	0.635	rs5751149	ENSG00000268568.1	AC007228.9	12.28	3.62e-23	1.93e-15	1.04	0.74	Crohn's disease;Inflammatory bowel disease;	chr22:41743497	chr19:56672574~56673901:-
TGCT	trans	rs4822044	0.617	rs13054514	ENSG00000268568.1	AC007228.9	12.23	4.63e-23	2.43e-15	1	0.74	Cannabis dependence symptom count;	chr22:41734379	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.568	rs5758441	ENSG00000268568.1	AC007228.9	12.23	4.63e-23	2.43e-15	1	0.74	Vitiligo;	chr22:41736884	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.649	rs5758442	ENSG00000268568.1	AC007228.9	12.23	4.63e-23	2.43e-15	1	0.74	Vitiligo;	chr22:41737056	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.58	rs5758449	ENSG00000268568.1	AC007228.9	12.23	4.63e-23	2.43e-15	1	0.74	Vitiligo;	chr22:41744156	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.559	rs5758397	ENSG00000268568.1	AC007228.9	12.23	4.73e-23	2.48e-15	1.02	0.74	Vitiligo;	chr22:41623247	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.559	rs132771	ENSG00000268568.1	AC007228.9	12.23	4.73e-23	2.48e-15	1.02	0.74	Vitiligo;	chr22:41629346	chr19:56672574~56673901:-
TGCT	trans	rs727563	0.52	rs132773	ENSG00000268568.1	AC007228.9	12.23	4.73e-23	2.48e-15	1.02	0.74	Crohn's disease;Inflammatory bowel disease;	chr22:41635764	chr19:56672574~56673901:-
TGCT	trans	rs916888	0.697	rs199516	ENSG00000264070.1	DND1P1	-12.18	6.21e-23	3.23e-15	-1.3	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45585871~45586929:+
TGCT	trans	rs3749237	0.576	rs62259939	ENSG00000197582.5	GPX1P1	12.18	6.27e-23	3.25e-15	0.89	0.74	Resting heart rate;	chr3:49348614	chrX:13378735~13379340:-
TGCT	trans	rs9611565	0.546	rs132793	ENSG00000268568.1	AC007228.9	12.18	6.31e-23	3.27e-15	1.01	0.74	Vitiligo;	chr22:41667677	chr19:56672574~56673901:-
TGCT	trans	rs6477998	0.58	rs4979231	ENSG00000238072.1	RP11-305M3.2	12.17	6.74e-23	3.49e-15	0.93	0.74	Hematology traits;	chr9:113286475	chr7:129410113~129410370:-
TGCT	trans	rs916888	0.773	rs538628	ENSG00000263503.1	RP11-707O23.5	12.15	7.26e-23	3.75e-15	1.17	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45600869~45602340:-
TGCT	trans	rs916888	0.773	rs169201	ENSG00000263503.1	RP11-707O23.5	12.15	7.26e-23	3.75e-15	1.17	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45600869~45602340:-
TGCT	trans	rs916888	0.773	rs199439	ENSG00000263503.1	RP11-707O23.5	12.15	7.26e-23	3.75e-15	1.17	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45600869~45602340:-
TGCT	trans	rs916888	0.821	rs199514	ENSG00000264070.1	DND1P1	-12.14	7.98e-23	4.11e-15	-1.31	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45585871~45586929:+
TGCT	trans	rs13177918	0.557	rs12520101	ENSG00000239528.1	RPS14P8	12.13	8.23e-23	4.24e-15	1.03	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr5:116562562~116562930:+
TGCT	trans	rs916888	0.773	rs1378358	ENSG00000263503.1	RP11-707O23.5	12.09	1.03e-22	5.26e-15	1.17	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45600869~45602340:-
TGCT	trans	rs727563	0.593	rs132770	ENSG00000268568.1	AC007228.9	12.07	1.17e-22	5.98e-15	1.01	0.73	Crohn's disease;Inflammatory bowel disease;	chr22:41621260	chr19:56672574~56673901:-
TGCT	trans	rs4822044	0.561	rs132781	ENSG00000268568.1	AC007228.9	12.07	1.18e-22	5.98e-15	1.02	0.73	Cannabis dependence symptom count;	chr22:41650118	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs132784	ENSG00000268568.1	AC007228.9	12.07	1.18e-22	5.98e-15	1.02	0.73	Vitiligo;	chr22:41656359	chr19:56672574~56673901:-
TGCT	trans	rs916888	0.773	rs199451	ENSG00000264070.1	DND1P1	12.06	1.21e-22	6.15e-15	1.32	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45585871~45586929:+
TGCT	trans	rs9611565	0.802	rs132916	ENSG00000268568.1	AC007228.9	12.06	1.23e-22	6.23e-15	0.94	0.73	Vitiligo;	chr22:41410764	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.592	rs9611612	ENSG00000268568.1	AC007228.9	-12.06	1.23e-22	6.24e-15	-1	-0.73	Vitiligo;	chr22:41565185	chr19:56672574~56673901:-
TGCT	trans	rs12709013	0.591	rs30841	ENSG00000230849.2	GOT2P2	12.05	1.3e-22	6.57e-15	0.91	0.73	Blood metabolite ratios;	chr16:58709819	chr1:173141100~173142350:-
TGCT	trans	rs6477998	0.58	rs12343629	ENSG00000238072.1	RP11-305M3.2	12.04	1.35e-22	6.85e-15	0.96	0.73	Hematology traits;	chr9:113279301	chr7:129410113~129410370:-
TGCT	trans	rs9611565	0.568	rs2413656	ENSG00000268568.1	AC007228.9	12.03	1.42e-22	7.17e-15	0.99	0.73	Vitiligo;	chr22:41733353	chr19:56672574~56673901:-
TGCT	trans	rs12709013	0.591	rs30842	ENSG00000230849.2	GOT2P2	-11.99	1.76e-22	8.87e-15	-0.91	-0.73	Blood metabolite ratios;	chr16:58709550	chr1:173141100~173142350:-
TGCT	trans	rs9611565	0.559	rs6002408	ENSG00000268568.1	AC007228.9	-11.98	1.88e-22	9.45e-15	-1	-0.73	Vitiligo;	chr22:41571866	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.729	rs203320	ENSG00000268568.1	AC007228.9	-11.98	1.95e-22	9.72e-15	-0.92	-0.73	Vitiligo;	chr22:41517473	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs139566	ENSG00000268568.1	AC007228.9	-11.97	2.02e-22	1e-14	-1.02	-0.73	Vitiligo;	chr22:41803273	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs139562	ENSG00000268568.1	AC007228.9	-11.97	2.07e-22	1.02e-14	-1.02	-0.73	Vitiligo;	chr22:41800680	chr19:56672574~56673901:-
TGCT	trans	rs6477998	0.58	rs10759638	ENSG00000238072.1	RP11-305M3.2	-11.95	2.27e-22	1.12e-14	-0.95	-0.73	Hematology traits;	chr9:113280212	chr7:129410113~129410370:-
TGCT	trans	rs13177918	0.557	rs12520101	ENSG00000224114.1	RP11-343H5.4	11.94	2.38e-22	1.18e-14	1.03	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:206695837~206696269:-
TGCT	trans	rs9611565	0.592	rs9611613	ENSG00000268568.1	AC007228.9	-11.93	2.57e-22	1.26e-14	-0.99	-0.73	Vitiligo;	chr22:41565827	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.559	rs12483860	ENSG00000268568.1	AC007228.9	-11.93	2.57e-22	1.26e-14	-0.99	-0.73	Vitiligo;	chr22:41565912	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.592	rs12484254	ENSG00000268568.1	AC007228.9	-11.93	2.57e-22	1.26e-14	-0.99	-0.73	Vitiligo;	chr22:41565999	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.559	rs7290990	ENSG00000268568.1	AC007228.9	-11.93	2.57e-22	1.26e-14	-0.99	-0.73	Vitiligo;	chr22:41568353	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.559	rs7290991	ENSG00000268568.1	AC007228.9	-11.93	2.57e-22	1.26e-14	-0.99	-0.73	Vitiligo;	chr22:41568357	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.592	rs5996037	ENSG00000268568.1	AC007228.9	-11.93	2.57e-22	1.26e-14	-0.99	-0.73	Vitiligo;	chr22:41569288	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.592	rs5996038	ENSG00000268568.1	AC007228.9	-11.93	2.57e-22	1.26e-14	-0.99	-0.73	Vitiligo;	chr22:41569296	chr19:56672574~56673901:-
TGCT	trans	rs13177918	0.603	rs2748241	ENSG00000224114.1	RP11-343H5.4	11.93	2.59e-22	1.27e-14	0.94	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:206695837~206696269:-
TGCT	trans	rs727563	0.569	rs73178647	ENSG00000268568.1	AC007228.9	-11.91	2.91e-22	1.41e-14	-1.03	-0.73	Crohn's disease;Inflammatory bowel disease;	chr22:41568164	chr19:56672574~56673901:-
TGCT	trans	rs916888	0.821	rs70600	ENSG00000264070.1	DND1P1	11.89	3.11e-22	1.5e-14	1.29	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45585871~45586929:+
TGCT	trans	rs916888	0.821	rs199512	ENSG00000264070.1	DND1P1	-11.89	3.11e-22	1.5e-14	-1.29	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45585871~45586929:+
TGCT	trans	rs916888	0.821	rs199509	ENSG00000264070.1	DND1P1	-11.89	3.11e-22	1.5e-14	-1.29	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45585871~45586929:+
TGCT	trans	rs916888	0.821	rs199507	ENSG00000264070.1	DND1P1	-11.89	3.11e-22	1.5e-14	-1.29	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45585871~45586929:+
TGCT	trans	rs916888	0.821	rs199506	ENSG00000264070.1	DND1P1	-11.89	3.11e-22	1.5e-14	-1.29	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45585871~45586929:+
TGCT	trans	rs916888	0.821	rs415430	ENSG00000264070.1	DND1P1	-11.89	3.11e-22	1.5e-14	-1.29	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45585871~45586929:+
TGCT	trans	rs916888	0.779	rs430685	ENSG00000264070.1	DND1P1	-11.89	3.11e-22	1.5e-14	-1.29	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45585871~45586929:+
TGCT	trans	rs916888	0.821	rs199505	ENSG00000264070.1	DND1P1	-11.89	3.11e-22	1.5e-14	-1.29	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45585871~45586929:+
TGCT	trans	rs916888	0.821	rs70602	ENSG00000264070.1	DND1P1	-11.89	3.11e-22	1.5e-14	-1.29	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45585871~45586929:+
TGCT	trans	rs727563	0.608	rs2076200	ENSG00000268568.1	AC007228.9	-11.82	4.77e-22	2.26e-14	-1.03	-0.73	Crohn's disease;Inflammatory bowel disease;	chr22:41589952	chr19:56672574~56673901:-
TGCT	trans	rs727563	0.552	rs4822045	ENSG00000268568.1	AC007228.9	-11.82	4.77e-22	2.26e-14	-1.03	-0.73	Crohn's disease;Inflammatory bowel disease;	chr22:41589954	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.559	rs9611619	ENSG00000268568.1	AC007228.9	-11.82	4.77e-22	2.26e-14	-1.03	-0.73	Vitiligo;	chr22:41590710	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.592	rs4822046	ENSG00000268568.1	AC007228.9	-11.82	4.77e-22	2.26e-14	-1.03	-0.73	Vitiligo;	chr22:41591539	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.559	rs4822048	ENSG00000268568.1	AC007228.9	-11.82	4.77e-22	2.26e-14	-1.03	-0.73	Vitiligo;	chr22:41592221	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.559	rs4822049	ENSG00000268568.1	AC007228.9	-11.82	4.77e-22	2.26e-14	-1.03	-0.73	Vitiligo;	chr22:41597492	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.694	rs4822032	ENSG00000268568.1	AC007228.9	-11.81	5.03e-22	2.38e-14	-0.92	-0.73	Vitiligo;	chr22:41529531	chr19:56672574~56673901:-
TGCT	trans	rs727563	0.635	rs5751141	ENSG00000268568.1	AC007228.9	11.8	5.18e-22	2.45e-14	1	0.73	Crohn's disease;Inflammatory bowel disease;	chr22:41711741	chr19:56672574~56673901:-
TGCT	trans	rs6477998	0.58	rs11552582	ENSG00000238072.1	RP11-305M3.2	11.8	5.21e-22	2.46e-14	0.94	0.73	Hematology traits;	chr9:113282718	chr7:129410113~129410370:-
TGCT	trans	rs9611565	1	rs9611565	ENSG00000268568.1	AC007228.9	-11.79	5.49e-22	2.58e-14	-0.93	-0.73	Vitiligo;	chr22:41371482	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.592	rs80477	ENSG00000268568.1	AC007228.9	11.77	6.2e-22	2.9e-14	0.98	0.73	Vitiligo;	chr22:41605179	chr19:56672574~56673901:-
TGCT	trans	rs941207	0.756	rs7978685	ENSG00000121089.4	NACA3P	11.76	6.66e-22	3.12e-14	1.01	0.73	Platelet count;	chr12:56709370	chr4:164943290~164943937:+
TGCT	trans	rs9611565	0.592	rs4481089	ENSG00000268568.1	AC007228.9	-11.75	6.78e-22	3.16e-14	-0.98	-0.73	Vitiligo;	chr22:41584888	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.592	rs5996039	ENSG00000268568.1	AC007228.9	-11.75	6.78e-22	3.16e-14	-0.98	-0.73	Vitiligo;	chr22:41585953	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.592	rs57102627	ENSG00000268568.1	AC007228.9	-11.75	6.78e-22	3.16e-14	-0.98	-0.73	Vitiligo;	chr22:41591623	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.592	rs28750375	ENSG00000268568.1	AC007228.9	-11.75	6.78e-22	3.16e-14	-0.98	-0.73	Vitiligo;	chr22:41594640	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.559	rs8139993	ENSG00000268568.1	AC007228.9	-11.75	6.78e-22	3.16e-14	-0.98	-0.73	Vitiligo;	chr22:41599331	chr19:56672574~56673901:-
TGCT	trans	rs916888	0.821	rs199513	ENSG00000263503.1	RP11-707O23.5	-11.75	6.91e-22	3.22e-14	-1.05	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45600869~45602340:-
TGCT	trans	rs9611565	0.765	rs132906	ENSG00000268568.1	AC007228.9	11.74	7.39e-22	3.44e-14	0.92	0.73	Vitiligo;	chr22:41403763	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.592	rs12484467	ENSG00000268568.1	AC007228.9	-11.72	8.11e-22	3.77e-14	-1.02	-0.73	Vitiligo;	chr22:41561606	chr19:56672574~56673901:-
TGCT	trans	rs12709013	0.591	rs30840	ENSG00000230849.2	GOT2P2	11.72	8.14e-22	3.78e-14	0.9	0.72	Blood metabolite ratios;	chr16:58710165	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.569	rs30837	ENSG00000230849.2	GOT2P2	11.72	8.14e-22	3.78e-14	0.9	0.72	Blood metabolite ratios;	chr16:58711942	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.591	rs30834	ENSG00000230849.2	GOT2P2	11.72	8.43e-22	3.91e-14	0.9	0.72	Blood metabolite ratios;	chr16:58715394	chr1:173141100~173142350:-
TGCT	trans	rs6477998	0.58	rs3750533	ENSG00000238072.1	RP11-305M3.2	11.68	1.01e-21	4.65e-14	0.95	0.72	Hematology traits;	chr9:113297941	chr7:129410113~129410370:-
TGCT	trans	rs916888	0.821	rs199504	ENSG00000264070.1	DND1P1	-11.66	1.17e-21	5.39e-14	-1.28	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45585871~45586929:+
TGCT	trans	rs9611565	0.512	rs4820446	ENSG00000268568.1	AC007228.9	-11.65	1.18e-21	5.44e-14	-0.99	-0.72	Vitiligo;	chr22:41819680	chr19:56672574~56673901:-
TGCT	trans	rs941207	0.756	rs7315472	ENSG00000121089.4	NACA3P	-11.64	1.27e-21	5.79e-14	-0.99	-0.72	Platelet count;	chr12:56648276	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.756	rs67046307	ENSG00000121089.4	NACA3P	-11.64	1.27e-21	5.79e-14	-0.99	-0.72	Platelet count;	chr12:56651152	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.756	rs10876915	ENSG00000121089.4	NACA3P	-11.64	1.27e-21	5.79e-14	-0.99	-0.72	Platelet count;	chr12:56655280	chr4:164943290~164943937:+
TGCT	trans	rs6477998	0.557	rs3750534	ENSG00000238072.1	RP11-305M3.2	11.62	1.4e-21	6.37e-14	0.92	0.72	Hematology traits;	chr9:113297844	chr7:129410113~129410370:-
TGCT	trans	rs6477998	0.58	rs3750532	ENSG00000238072.1	RP11-305M3.2	11.62	1.4e-21	6.37e-14	0.92	0.72	Hematology traits;	chr9:113298207	chr7:129410113~129410370:-
TGCT	trans	rs916888	0.61	rs199529	ENSG00000264070.1	DND1P1	11.62	1.48e-21	6.68e-14	1.28	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45585871~45586929:+
TGCT	trans	rs9611565	0.512	rs2050031	ENSG00000268568.1	AC007228.9	11.59	1.66e-21	7.39e-14	1	0.72	Vitiligo;	chr22:41756262	chr19:56672574~56673901:-
TGCT	trans	rs5751150	1	rs5751150	ENSG00000268568.1	AC007228.9	11.59	1.66e-21	7.39e-14	1	0.72	Cannabis dependence symptom count;	chr22:41757288	chr19:56672574~56673901:-
TGCT	trans	rs727563	0.562	rs5758458	ENSG00000268568.1	AC007228.9	11.59	1.66e-21	7.39e-14	1	0.72	Crohn's disease;Inflammatory bowel disease;	chr22:41758128	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs2899347	ENSG00000268568.1	AC007228.9	11.59	1.66e-21	7.39e-14	1	0.72	Vitiligo;	chr22:41762200	chr19:56672574~56673901:-
TGCT	trans	rs727563	0.635	rs713988	ENSG00000268568.1	AC007228.9	11.59	1.66e-21	7.39e-14	1	0.72	Crohn's disease;Inflammatory bowel disease;	chr22:41763068	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs4820444	ENSG00000268568.1	AC007228.9	11.59	1.66e-21	7.39e-14	1	0.72	Vitiligo;	chr22:41806602	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs4512	ENSG00000268568.1	AC007228.9	-11.59	1.66e-21	7.39e-14	-1	-0.72	Vitiligo;	chr22:41810080	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs9611672	ENSG00000268568.1	AC007228.9	-11.59	1.66e-21	7.39e-14	-1	-0.72	Vitiligo;	chr22:41813918	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs139571	ENSG00000268568.1	AC007228.9	-11.59	1.66e-21	7.39e-14	-1	-0.72	Vitiligo;	chr22:41818234	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs139572	ENSG00000268568.1	AC007228.9	-11.59	1.66e-21	7.39e-14	-1	-0.72	Vitiligo;	chr22:41818528	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs139573	ENSG00000268568.1	AC007228.9	-11.59	1.66e-21	7.39e-14	-1	-0.72	Vitiligo;	chr22:41818781	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.592	rs4822040	ENSG00000268568.1	AC007228.9	-11.59	1.71e-21	7.59e-14	-0.96	-0.72	Vitiligo;	chr22:41567549	chr19:56672574~56673901:-
TGCT	trans	rs941207	0.789	rs2958145	ENSG00000121089.4	NACA3P	-11.58	1.83e-21	8.08e-14	-0.99	-0.72	Platelet count;	chr12:56662290	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.756	rs2958153	ENSG00000121089.4	NACA3P	11.58	1.83e-21	8.08e-14	0.99	0.72	Platelet count;	chr12:56687733	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.756	rs1465081	ENSG00000121089.4	NACA3P	-11.56	1.99e-21	8.75e-14	-1	-0.72	Platelet count;	chr12:56656390	chr4:164943290~164943937:+
TGCT	trans	rs6477998	0.58	rs4979233	ENSG00000238072.1	RP11-305M3.2	11.52	2.46e-21	1.07e-13	0.93	0.72	Hematology traits;	chr9:113295501	chr7:129410113~129410370:-
TGCT	trans	rs916888	0.738	rs199515	ENSG00000264070.1	DND1P1	-11.49	2.98e-21	1.3e-13	-1.29	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45585871~45586929:+
TGCT	trans	rs13177918	0.559	rs12109637	ENSG00000224114.1	RP11-343H5.4	11.45	3.63e-21	1.55e-13	0.94	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:206695837~206696269:-
TGCT	trans	rs9611565	0.532	rs4401299	ENSG00000268568.1	AC007228.9	11.42	4.39e-21	1.86e-13	0.96	0.72	Vitiligo;	chr22:41760513	chr19:56672574~56673901:-
TGCT	trans	rs6477998	0.557	rs11789755	ENSG00000238072.1	RP11-305M3.2	11.4	4.92e-21	2.08e-13	0.92	0.72	Hematology traits;	chr9:113292796	chr7:129410113~129410370:-
TGCT	trans	rs941207	0.756	rs2950394	ENSG00000121089.4	NACA3P	-11.39	5.08e-21	2.15e-13	-0.98	-0.72	Platelet count;	chr12:56644548	chr4:164943290~164943937:+
TGCT	trans	rs9611565	0.512	rs4822052	ENSG00000268568.1	AC007228.9	-11.36	6.09e-21	2.57e-13	-0.94	-0.71	Vitiligo;	chr22:41797737	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.592	rs4822044	ENSG00000268568.1	AC007228.9	-11.35	6.56e-21	2.76e-13	-1.01	-0.71	Vitiligo;	chr22:41583664	chr19:56672574~56673901:-
TGCT	trans	rs727563	0.648	rs6002406	ENSG00000268568.1	AC007228.9	-11.33	7.51e-21	3.15e-13	-1	-0.71	Crohn's disease;Inflammatory bowel disease;	chr22:41569233	chr19:56672574~56673901:-
TGCT	trans	rs13177918	0.603	rs2748241	ENSG00000213058.3	RP4-765C7.2	11.32	7.9e-21	3.31e-13	0.93	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:178411616~178411972:+
TGCT	trans	rs9611565	0.571	rs2050032	ENSG00000268568.1	AC007228.9	11.3	8.48e-21	3.55e-13	0.97	0.71	Vitiligo;	chr22:41756425	chr19:56672574~56673901:-
TGCT	trans	rs916888	0.821	rs199513	ENSG00000264070.1	DND1P1	-11.3	8.57e-21	3.59e-13	-1.21	-0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45585871~45586929:+
TGCT	trans	rs13177918	0.559	rs10447224	ENSG00000224114.1	RP11-343H5.4	11.27	1.02e-20	4.24e-13	0.94	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:206695837~206696269:-
TGCT	trans	rs13177918	0.559	rs10447225	ENSG00000224114.1	RP11-343H5.4	11.27	1.02e-20	4.24e-13	0.94	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:206695837~206696269:-
TGCT	trans	rs61990749	0.597	rs2267761	ENSG00000235400.1	RP4-641G12.4	-11.27	1.02e-20	4.24e-13	-1.2	-0.71	Fibroblast growth factor basic levels;	chr14:77681506	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.544	rs7151211	ENSG00000235400.1	RP4-641G12.4	-11.27	1.02e-20	4.24e-13	-1.2	-0.71	Fibroblast growth factor basic levels;	chr14:77685558	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs72685264	ENSG00000235400.1	RP4-641G12.4	-11.27	1.02e-20	4.24e-13	-1.2	-0.71	Fibroblast growth factor basic levels;	chr14:77686655	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs7147516	ENSG00000235400.1	RP4-641G12.4	-11.27	1.02e-20	4.24e-13	-1.2	-0.71	Fibroblast growth factor basic levels;	chr14:77687637	chr1:78749073~78750659:+
TGCT	trans	rs12709013	0.636	rs1646268	ENSG00000230849.2	GOT2P2	11.27	1.02e-20	4.24e-13	0.83	0.71	Blood metabolite ratios;	chr16:58743292	chr1:173141100~173142350:-
TGCT	trans	rs9611565	0.592	rs4822038	ENSG00000268568.1	AC007228.9	-11.25	1.15e-20	4.77e-13	-1	-0.71	Vitiligo;	chr22:41562491	chr19:56672574~56673901:-
TGCT	trans	rs13253073	1	rs4409375	ENSG00000260318.1	COX6CP1	11.24	1.19e-20	4.92e-13	1.25	0.71	Glucose homeostasis traits;	chr8:99877759	chr16:11903923~11904137:-
TGCT	trans	rs12709013	0.597	rs1657171	ENSG00000230849.2	GOT2P2	11.22	1.34e-20	5.53e-13	0.84	0.71	Blood metabolite ratios;	chr16:58752083	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs1646285	ENSG00000230849.2	GOT2P2	11.22	1.34e-20	5.53e-13	0.84	0.71	Blood metabolite ratios;	chr16:58752102	chr1:173141100~173142350:-
TGCT	trans	rs13253073	1	rs35935983	ENSG00000260318.1	COX6CP1	11.22	1.39e-20	5.73e-13	1.27	0.71	Glucose homeostasis traits;	chr8:99888966	chr16:11903923~11904137:-
TGCT	trans	rs12709013	0.636	rs1646256	ENSG00000230849.2	GOT2P2	11.21	1.44e-20	5.91e-13	0.86	0.71	Blood metabolite ratios;	chr16:58712114	chr1:173141100~173142350:-
TGCT	trans	rs9611565	0.921	rs2143695	ENSG00000268568.1	AC007228.9	-11.17	1.75e-20	7.16e-13	-0.87	-0.71	Vitiligo;	chr22:41332616	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.649	rs139559	ENSG00000268568.1	AC007228.9	-11.17	1.77e-20	7.26e-13	-0.93	-0.71	Vitiligo;	chr22:41795632	chr19:56672574~56673901:-
TGCT	trans	rs7121616	0.563	rs1461494	ENSG00000234176.1	HSPA8P1	11.17	1.82e-20	7.43e-13	0.96	0.71	Breast cancer;	chr11:123055777	chrX:121203182~121205014:-
TGCT	trans	rs9611565	0.649	rs139553	ENSG00000268568.1	AC007228.9	11.14	2.1e-20	8.52e-13	0.95	0.71	Vitiligo;	chr22:41791195	chr19:56672574~56673901:-
TGCT	trans	rs61990749	0.597	rs2267758	ENSG00000235400.1	RP4-641G12.4	-11.12	2.31e-20	9.16e-13	-1.19	-0.71	Fibroblast growth factor basic levels;	chr14:77681086	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs2299930	ENSG00000235400.1	RP4-641G12.4	-11.12	2.31e-20	9.16e-13	-1.19	-0.71	Fibroblast growth factor basic levels;	chr14:77697379	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs176943	ENSG00000235400.1	RP4-641G12.4	-11.12	2.31e-20	9.16e-13	-1.19	-0.71	Fibroblast growth factor basic levels;	chr14:77709454	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs176955	ENSG00000235400.1	RP4-641G12.4	11.12	2.31e-20	9.16e-13	1.19	0.71	Fibroblast growth factor basic levels;	chr14:77714877	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.544	rs176962	ENSG00000235400.1	RP4-641G12.4	11.12	2.31e-20	9.16e-13	1.19	0.71	Fibroblast growth factor basic levels;	chr14:77719167	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs176971	ENSG00000235400.1	RP4-641G12.4	11.12	2.31e-20	9.16e-13	1.19	0.71	Fibroblast growth factor basic levels;	chr14:77725256	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs6574391	ENSG00000235400.1	RP4-641G12.4	11.12	2.31e-20	9.16e-13	1.19	0.71	Fibroblast growth factor basic levels;	chr14:77741778	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.544	rs8003979	ENSG00000235400.1	RP4-641G12.4	11.12	2.31e-20	9.16e-13	1.19	0.71	Fibroblast growth factor basic levels;	chr14:77744947	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs8016416	ENSG00000235400.1	RP4-641G12.4	11.12	2.31e-20	9.16e-13	1.19	0.71	Fibroblast growth factor basic levels;	chr14:77746757	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs2032781	ENSG00000235400.1	RP4-641G12.4	11.12	2.31e-20	9.16e-13	1.19	0.71	Fibroblast growth factor basic levels;	chr14:77748532	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.686	rs11159288	ENSG00000235400.1	RP4-641G12.4	11.12	2.31e-20	9.16e-13	1.19	0.71	Fibroblast growth factor basic levels;	chr14:77750629	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs3783980	ENSG00000235400.1	RP4-641G12.4	11.12	2.31e-20	9.16e-13	1.19	0.71	Fibroblast growth factor basic levels;	chr14:77753464	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs8016447	ENSG00000235400.1	RP4-641G12.4	11.12	2.31e-20	9.16e-13	1.19	0.71	Fibroblast growth factor basic levels;	chr14:77755725	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs1477262	ENSG00000235400.1	RP4-641G12.4	11.12	2.31e-20	9.16e-13	1.19	0.71	Fibroblast growth factor basic levels;	chr14:77760310	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs2112136	ENSG00000235400.1	RP4-641G12.4	11.12	2.31e-20	9.16e-13	1.19	0.71	Fibroblast growth factor basic levels;	chr14:77782609	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs4903643	ENSG00000235400.1	RP4-641G12.4	11.12	2.31e-20	9.16e-13	1.19	0.71	Fibroblast growth factor basic levels;	chr14:77788448	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs1477260	ENSG00000235400.1	RP4-641G12.4	11.12	2.31e-20	9.16e-13	1.19	0.71	Fibroblast growth factor basic levels;	chr14:77790475	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs1008988	ENSG00000235400.1	RP4-641G12.4	11.12	2.31e-20	9.16e-13	1.19	0.71	Fibroblast growth factor basic levels;	chr14:77794452	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs6574402	ENSG00000235400.1	RP4-641G12.4	11.12	2.31e-20	9.16e-13	1.19	0.71	Fibroblast growth factor basic levels;	chr14:77801607	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.5	rs8011337	ENSG00000235400.1	RP4-641G12.4	11.12	2.31e-20	9.16e-13	1.19	0.71	Fibroblast growth factor basic levels;	chr14:77806283	chr1:78749073~78750659:+
TGCT	trans	rs727563	0.638	rs5996058	ENSG00000268568.1	AC007228.9	11.11	2.53e-20	1e-12	0.97	0.71	Crohn's disease;Inflammatory bowel disease;	chr22:41745448	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.921	rs5758297	ENSG00000268568.1	AC007228.9	-11.08	3.01e-20	1.18e-12	-0.87	-0.71	Vitiligo;	chr22:41324693	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.921	rs5751077	ENSG00000268568.1	AC007228.9	-11.08	3.01e-20	1.18e-12	-0.87	-0.71	Vitiligo;	chr22:41324724	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.879	rs2235845	ENSG00000268568.1	AC007228.9	-11.08	3.01e-20	1.18e-12	-0.87	-0.71	Vitiligo;	chr22:41333290	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.921	rs5751080	ENSG00000268568.1	AC007228.9	-11.05	3.45e-20	1.34e-12	-0.87	-0.7	Vitiligo;	chr22:41340263	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.921	rs2235846	ENSG00000268568.1	AC007228.9	-11.05	3.45e-20	1.34e-12	-0.87	-0.7	Vitiligo;	chr22:41345038	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.921	rs5751081	ENSG00000268568.1	AC007228.9	-11.05	3.45e-20	1.34e-12	-0.87	-0.7	Vitiligo;	chr22:41346784	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.921	rs2281332	ENSG00000268568.1	AC007228.9	-11.05	3.45e-20	1.34e-12	-0.87	-0.7	Vitiligo;	chr22:41350208	chr19:56672574~56673901:-
TGCT	trans	rs916888	0.773	rs538628	ENSG00000264070.1	DND1P1	11.03	3.98e-20	1.55e-12	1.31	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45585871~45586929:+
TGCT	trans	rs916888	0.773	rs169201	ENSG00000264070.1	DND1P1	11.03	3.98e-20	1.55e-12	1.31	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45585871~45586929:+
TGCT	trans	rs916888	0.773	rs199439	ENSG00000264070.1	DND1P1	11.03	3.98e-20	1.55e-12	1.31	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45585871~45586929:+
TGCT	trans	rs916888	0.773	rs1378358	ENSG00000264070.1	DND1P1	11.02	4.18e-20	1.62e-12	1.31	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45585871~45586929:+
TGCT	trans	rs941207	0.855	rs2256341	ENSG00000121089.4	NACA3P	-11.01	4.4e-20	1.7e-12	-0.98	-0.7	Platelet count;	chr12:56599930	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.805	rs2958139	ENSG00000121089.4	NACA3P	-11.01	4.4e-20	1.7e-12	-0.98	-0.7	Platelet count;	chr12:56610884	chr4:164943290~164943937:+
TGCT	trans	rs12709013	0.574	rs839418	ENSG00000230849.2	GOT2P2	10.99	5e-20	1.93e-12	0.88	0.7	Blood metabolite ratios;	chr16:58705426	chr1:173141100~173142350:-
TGCT	trans	rs6477998	0.58	rs7027833	ENSG00000238072.1	RP11-305M3.2	10.99	5.05e-20	1.95e-12	0.86	0.7	Hematology traits;	chr9:113301377	chr7:129410113~129410370:-
TGCT	trans	rs61990749	0.597	rs1006039	ENSG00000235400.1	RP4-641G12.4	-10.98	5.29e-20	2.04e-12	-1.16	-0.7	Fibroblast growth factor basic levels;	chr14:77796853	chr1:78749073~78750659:+
TGCT	trans	rs9611565	0.649	rs139540	ENSG00000268568.1	AC007228.9	-10.97	5.5e-20	2.12e-12	-0.94	-0.7	Vitiligo;	chr22:41782036	chr19:56672574~56673901:-
TGCT	trans	rs12709013	0.597	rs11076259	ENSG00000230849.2	GOT2P2	10.96	5.95e-20	2.25e-12	0.82	0.7	Blood metabolite ratios;	chr16:58749860	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs12325516	ENSG00000230849.2	GOT2P2	10.96	5.95e-20	2.25e-12	0.82	0.7	Blood metabolite ratios;	chr16:58749899	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs11076260	ENSG00000230849.2	GOT2P2	10.96	5.95e-20	2.25e-12	0.82	0.7	Blood metabolite ratios;	chr16:58749942	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs1646278	ENSG00000230849.2	GOT2P2	10.96	5.95e-20	2.25e-12	0.82	0.7	Blood metabolite ratios;	chr16:58750084	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs1646279	ENSG00000230849.2	GOT2P2	10.96	5.95e-20	2.25e-12	0.82	0.7	Blood metabolite ratios;	chr16:58750235	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs1646280	ENSG00000230849.2	GOT2P2	10.96	5.95e-20	2.25e-12	0.82	0.7	Blood metabolite ratios;	chr16:58750420	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.597	rs1646286	ENSG00000230849.2	GOT2P2	10.96	5.95e-20	2.25e-12	0.82	0.7	Blood metabolite ratios;	chr16:58752651	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs1624301	ENSG00000230849.2	GOT2P2	10.96	5.95e-20	2.25e-12	0.82	0.7	Blood metabolite ratios;	chr16:58753491	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs1626006	ENSG00000230849.2	GOT2P2	10.96	5.95e-20	2.25e-12	0.82	0.7	Blood metabolite ratios;	chr16:58753691	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.684	rs1646287	ENSG00000230849.2	GOT2P2	10.96	5.95e-20	2.25e-12	0.82	0.7	Blood metabolite ratios;	chr16:58753774	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.671	rs1369933	ENSG00000230849.2	GOT2P2	10.96	5.95e-20	2.25e-12	0.82	0.7	Blood metabolite ratios;	chr16:58753927	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs1369934	ENSG00000230849.2	GOT2P2	10.96	5.95e-20	2.25e-12	0.82	0.7	Blood metabolite ratios;	chr16:58754124	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.613	rs1646288	ENSG00000230849.2	GOT2P2	10.96	5.95e-20	2.25e-12	0.82	0.7	Blood metabolite ratios;	chr16:58755576	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.561	rs727484	ENSG00000230849.2	GOT2P2	10.96	5.95e-20	2.25e-12	0.82	0.7	Blood metabolite ratios;	chr16:58756568	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs257628	ENSG00000230849.2	GOT2P2	10.96	5.95e-20	2.25e-12	0.82	0.7	Blood metabolite ratios;	chr16:58758924	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs257627	ENSG00000230849.2	GOT2P2	10.96	5.95e-20	2.25e-12	0.82	0.7	Blood metabolite ratios;	chr16:58758956	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs191783	ENSG00000230849.2	GOT2P2	10.96	5.95e-20	2.25e-12	0.82	0.7	Blood metabolite ratios;	chr16:58759994	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs257624	ENSG00000230849.2	GOT2P2	10.96	5.95e-20	2.25e-12	0.82	0.7	Blood metabolite ratios;	chr16:58760994	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs8060717	ENSG00000230849.2	GOT2P2	10.96	5.95e-20	2.25e-12	0.82	0.7	Blood metabolite ratios;	chr16:58765574	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.559	rs8060721	ENSG00000230849.2	GOT2P2	10.96	5.95e-20	2.25e-12	0.82	0.7	Blood metabolite ratios;	chr16:58765581	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs8044542	ENSG00000230849.2	GOT2P2	10.96	5.95e-20	2.25e-12	0.82	0.7	Blood metabolite ratios;	chr16:58765620	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.601	rs2432621	ENSG00000230849.2	GOT2P2	10.96	5.99e-20	2.27e-12	0.83	0.7	Blood metabolite ratios;	chr16:58749676	chr1:173141100~173142350:-
TGCT	trans	rs61990749	0.597	rs176946	ENSG00000235400.1	RP4-641G12.4	10.95	6.1e-20	2.31e-12	1.15	0.7	Fibroblast growth factor basic levels;	chr14:77712096	chr1:78749073~78750659:+
TGCT	trans	rs12709013	0.535	rs9924136	ENSG00000230849.2	GOT2P2	10.94	6.49e-20	2.43e-12	0.89	0.7	Blood metabolite ratios;	chr16:58779573	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.574	rs35321124	ENSG00000230849.2	GOT2P2	10.94	6.49e-20	2.43e-12	0.89	0.7	Blood metabolite ratios;	chr16:58786561	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs1657164	ENSG00000230849.2	GOT2P2	10.94	6.61e-20	2.47e-12	0.82	0.7	Blood metabolite ratios;	chr16:58747949	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.537	rs1657167	ENSG00000230849.2	GOT2P2	10.94	6.61e-20	2.47e-12	0.82	0.7	Blood metabolite ratios;	chr16:58748955	chr1:173141100~173142350:-
TGCT	trans	rs61990749	0.597	rs9323650	ENSG00000235400.1	RP4-641G12.4	10.93	6.84e-20	2.55e-12	1.18	0.7	Fibroblast growth factor basic levels;	chr14:77683993	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs2364584	ENSG00000235400.1	RP4-641G12.4	-10.93	6.98e-20	2.6e-12	-1.19	-0.7	Fibroblast growth factor basic levels;	chr14:77685943	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs10136053	ENSG00000235400.1	RP4-641G12.4	-10.93	6.98e-20	2.6e-12	-1.19	-0.7	Fibroblast growth factor basic levels;	chr14:77688862	chr1:78749073~78750659:+
TGCT	trans	rs12709013	0.591	rs6499980	ENSG00000230849.2	GOT2P2	10.93	6.99e-20	2.6e-12	0.88	0.7	Blood metabolite ratios;	chr16:58787972	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.591	rs899375	ENSG00000230849.2	GOT2P2	10.93	6.99e-20	2.6e-12	0.88	0.7	Blood metabolite ratios;	chr16:58792325	chr1:173141100~173142350:-
TGCT	trans	rs9611565	0.504	rs5758452	ENSG00000268568.1	AC007228.9	10.92	7.27e-20	2.68e-12	0.92	0.7	Vitiligo;	chr22:41748923	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.649	rs9623450	ENSG00000268568.1	AC007228.9	10.92	7.27e-20	2.68e-12	0.92	0.7	Vitiligo;	chr22:41779227	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.568	rs5751159	ENSG00000268568.1	AC007228.9	10.92	7.27e-20	2.68e-12	0.92	0.7	Vitiligo;	chr22:41779361	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.649	rs5758466	ENSG00000268568.1	AC007228.9	10.92	7.27e-20	2.68e-12	0.92	0.7	Vitiligo;	chr22:41780055	chr19:56672574~56673901:-
TGCT	trans	rs727563	0.638	rs4820443	ENSG00000268568.1	AC007228.9	-10.92	7.4e-20	2.71e-12	-0.95	-0.7	Crohn's disease;Inflammatory bowel disease;	chr22:41797909	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs139560	ENSG00000268568.1	AC007228.9	-10.92	7.4e-20	2.71e-12	-0.95	-0.7	Vitiligo;	chr22:41798958	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs9607842	ENSG00000268568.1	AC007228.9	-10.92	7.48e-20	2.74e-12	-0.95	-0.7	Vitiligo;	chr22:41796718	chr19:56672574~56673901:-
TGCT	trans	rs12709013	0.613	rs1657178	ENSG00000230849.2	GOT2P2	10.91	7.63e-20	2.77e-12	0.82	0.7	Blood metabolite ratios;	chr16:58735300	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.585	rs7188608	ENSG00000230849.2	GOT2P2	10.91	7.63e-20	2.77e-12	0.82	0.7	Blood metabolite ratios;	chr16:58736236	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs1657176	ENSG00000230849.2	GOT2P2	10.91	7.63e-20	2.77e-12	0.82	0.7	Blood metabolite ratios;	chr16:58736833	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs1646282	ENSG00000230849.2	GOT2P2	10.91	7.63e-20	2.77e-12	0.82	0.7	Blood metabolite ratios;	chr16:58741296	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs4784977	ENSG00000230849.2	GOT2P2	10.91	7.63e-20	2.77e-12	0.82	0.7	Blood metabolite ratios;	chr16:58742120	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs1657161	ENSG00000230849.2	GOT2P2	10.91	7.63e-20	2.77e-12	0.82	0.7	Blood metabolite ratios;	chr16:58743234	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs1646269	ENSG00000230849.2	GOT2P2	10.91	7.63e-20	2.77e-12	0.82	0.7	Blood metabolite ratios;	chr16:58743412	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs4538000	ENSG00000230849.2	GOT2P2	10.91	7.63e-20	2.77e-12	0.82	0.7	Blood metabolite ratios;	chr16:58744506	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs1646272	ENSG00000230849.2	GOT2P2	10.91	7.63e-20	2.77e-12	0.82	0.7	Blood metabolite ratios;	chr16:58746508	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.66	rs1657163	ENSG00000230849.2	GOT2P2	10.91	7.63e-20	2.77e-12	0.82	0.7	Blood metabolite ratios;	chr16:58746688	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.597	rs1616072	ENSG00000230849.2	GOT2P2	10.91	7.63e-20	2.77e-12	0.82	0.7	Blood metabolite ratios;	chr16:58747194	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs2575374	ENSG00000230849.2	GOT2P2	10.91	7.63e-20	2.77e-12	0.82	0.7	Blood metabolite ratios;	chr16:58747494	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs72792430	ENSG00000230849.2	GOT2P2	-10.91	7.63e-20	2.77e-12	-0.82	-0.7	Blood metabolite ratios;	chr16:58746990	chr1:173141100~173142350:-
TGCT	trans	rs9611565	0.649	rs6002480	ENSG00000268568.1	AC007228.9	-10.9	8.31e-20	3.01e-12	-0.92	-0.7	Vitiligo;	chr22:41780913	chr19:56672574~56673901:-
TGCT	trans	rs12709013	0.636	rs8054414	ENSG00000230849.2	GOT2P2	10.89	8.72e-20	3.14e-12	0.82	0.7	Blood metabolite ratios;	chr16:58749772	chr1:173141100~173142350:-
TGCT	trans	rs13177918	0.559	rs12109637	ENSG00000213058.3	RP4-765C7.2	10.88	8.89e-20	3.19e-12	0.93	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:178411616~178411972:+
TGCT	trans	rs12709013	0.514	rs8062639	ENSG00000230849.2	GOT2P2	10.88	9.12e-20	3.26e-12	0.88	0.7	Blood metabolite ratios;	chr16:58800264	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.591	rs4410065	ENSG00000230849.2	GOT2P2	10.88	9.12e-20	3.26e-12	0.88	0.7	Blood metabolite ratios;	chr16:58800968	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.591	rs2406234	ENSG00000230849.2	GOT2P2	10.88	9.12e-20	3.26e-12	0.88	0.7	Blood metabolite ratios;	chr16:58801840	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.613	rs6499984	ENSG00000230849.2	GOT2P2	10.87	9.39e-20	3.36e-12	0.88	0.7	Blood metabolite ratios;	chr16:58810209	chr1:173141100~173142350:-
TGCT	trans	rs9611565	0.503	rs5751156	ENSG00000268568.1	AC007228.9	10.85	1.09e-19	3.86e-12	0.95	0.7	Vitiligo;	chr22:41774021	chr19:56672574~56673901:-
TGCT	trans	rs7121616	0.576	rs4802	ENSG00000234176.1	HSPA8P1	10.83	1.2e-19	4.24e-12	0.96	0.7	Breast cancer;	chr11:123057914	chrX:121203182~121205014:-
TGCT	trans	rs9611565	0.512	rs715498	ENSG00000268568.1	AC007228.9	10.82	1.25e-19	4.35e-12	0.95	0.7	Vitiligo;	chr22:41752463	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs1534932	ENSG00000268568.1	AC007228.9	10.82	1.25e-19	4.35e-12	0.95	0.7	Vitiligo;	chr22:41754142	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs2050033	ENSG00000268568.1	AC007228.9	10.82	1.25e-19	4.35e-12	0.95	0.7	Vitiligo;	chr22:41763225	chr19:56672574~56673901:-
TGCT	trans	rs727563	0.593	rs5758461	ENSG00000268568.1	AC007228.9	10.82	1.25e-19	4.35e-12	0.95	0.7	Crohn's disease;Inflammatory bowel disease;	chr22:41766185	chr19:56672574~56673901:-
TGCT	trans	rs727563	0.635	rs2899348	ENSG00000268568.1	AC007228.9	10.82	1.25e-19	4.35e-12	0.95	0.7	Crohn's disease;Inflammatory bowel disease;	chr22:41768512	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs2899349	ENSG00000268568.1	AC007228.9	10.82	1.25e-19	4.35e-12	0.95	0.7	Vitiligo;	chr22:41768656	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs1983576	ENSG00000268568.1	AC007228.9	10.82	1.25e-19	4.35e-12	0.95	0.7	Vitiligo;	chr22:41770482	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.503	rs5996062	ENSG00000268568.1	AC007228.9	10.82	1.25e-19	4.35e-12	0.95	0.7	Vitiligo;	chr22:41771460	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs6002474	ENSG00000268568.1	AC007228.9	10.82	1.25e-19	4.35e-12	0.95	0.7	Vitiligo;	chr22:41772177	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs5996063	ENSG00000268568.1	AC007228.9	10.82	1.25e-19	4.35e-12	0.95	0.7	Vitiligo;	chr22:41772763	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs6519289	ENSG00000268568.1	AC007228.9	10.82	1.25e-19	4.35e-12	0.95	0.7	Vitiligo;	chr22:41774428	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs5758465	ENSG00000268568.1	AC007228.9	10.82	1.25e-19	4.35e-12	0.95	0.7	Vitiligo;	chr22:41779310	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.559	rs5751160	ENSG00000268568.1	AC007228.9	10.82	1.25e-19	4.35e-12	0.95	0.7	Vitiligo;	chr22:41779691	chr19:56672574~56673901:-
TGCT	trans	rs13177918	0.559	rs10447224	ENSG00000213058.3	RP4-765C7.2	10.82	1.26e-19	4.39e-12	0.93	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:178411616~178411972:+
TGCT	trans	rs13177918	0.559	rs10447225	ENSG00000213058.3	RP4-765C7.2	10.82	1.26e-19	4.39e-12	0.93	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:178411616~178411972:+
TGCT	trans	rs12709013	0.591	rs2086206	ENSG00000230849.2	GOT2P2	10.82	1.3e-19	4.52e-12	0.88	0.7	Blood metabolite ratios;	chr16:58802094	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.536	rs9930758	ENSG00000230849.2	GOT2P2	10.82	1.3e-19	4.52e-12	0.88	0.7	Blood metabolite ratios;	chr16:58803167	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.591	rs9932967	ENSG00000230849.2	GOT2P2	10.82	1.3e-19	4.52e-12	0.88	0.7	Blood metabolite ratios;	chr16:58805583	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs967852	ENSG00000230849.2	GOT2P2	10.82	1.3e-19	4.52e-12	0.88	0.7	Blood metabolite ratios;	chr16:58807313	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.591	rs7184377	ENSG00000230849.2	GOT2P2	10.82	1.3e-19	4.52e-12	0.88	0.7	Blood metabolite ratios;	chr16:58808765	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.574	rs9302706	ENSG00000230849.2	GOT2P2	10.82	1.3e-19	4.52e-12	0.88	0.7	Blood metabolite ratios;	chr16:58812060	chr1:173141100~173142350:-
TGCT	trans	rs9611565	0.512	rs139561	ENSG00000268568.1	AC007228.9	10.82	1.31e-19	4.55e-12	0.93	0.7	Vitiligo;	chr22:41799406	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs964899	ENSG00000268568.1	AC007228.9	10.81	1.36e-19	4.74e-12	0.95	0.7	Vitiligo;	chr22:41746382	chr19:56672574~56673901:-
TGCT	trans	rs9611565	1	rs5758314	ENSG00000268568.1	AC007228.9	-10.8	1.42e-19	4.94e-12	-0.88	-0.7	Vitiligo;	chr22:41366519	chr19:56672574~56673901:-
TGCT	trans	rs61990749	0.597	rs117131659	ENSG00000235400.1	RP4-641G12.4	-10.79	1.51e-19	5.21e-12	-1.19	-0.7	Fibroblast growth factor basic levels;	chr14:77664783	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs11624101	ENSG00000235400.1	RP4-641G12.4	-10.79	1.51e-19	5.21e-12	-1.19	-0.7	Fibroblast growth factor basic levels;	chr14:77671716	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs1048147	ENSG00000235400.1	RP4-641G12.4	-10.79	1.51e-19	5.21e-12	-1.19	-0.7	Fibroblast growth factor basic levels;	chr14:77673645	chr1:78749073~78750659:+
TGCT	trans	rs12709013	0.591	rs4784986	ENSG00000230849.2	GOT2P2	10.78	1.59e-19	5.46e-12	0.86	0.7	Blood metabolite ratios;	chr16:58803007	chr1:173141100~173142350:-
TGCT	trans	rs9611565	0.512	rs964898	ENSG00000268568.1	AC007228.9	-10.78	1.6e-19	5.49e-12	-0.95	-0.7	Vitiligo;	chr22:41746302	chr19:56672574~56673901:-
TGCT	trans	rs61990749	0.597	rs176952	ENSG00000235400.1	RP4-641G12.4	10.78	1.62e-19	5.54e-12	1.18	0.7	Fibroblast growth factor basic levels;	chr14:77714393	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.544	rs2544566	ENSG00000235400.1	RP4-641G12.4	10.78	1.62e-19	5.54e-12	1.18	0.7	Fibroblast growth factor basic levels;	chr14:77715395	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.544	rs2544567	ENSG00000235400.1	RP4-641G12.4	10.78	1.62e-19	5.54e-12	1.18	0.7	Fibroblast growth factor basic levels;	chr14:77715396	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs13379065	ENSG00000235400.1	RP4-641G12.4	-10.78	1.62e-19	5.54e-12	-1.18	-0.7	Fibroblast growth factor basic levels;	chr14:77674952	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs17106157	ENSG00000235400.1	RP4-641G12.4	-10.78	1.62e-19	5.54e-12	-1.18	-0.7	Fibroblast growth factor basic levels;	chr14:77680535	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs2267759	ENSG00000235400.1	RP4-641G12.4	-10.78	1.62e-19	5.54e-12	-1.18	-0.7	Fibroblast growth factor basic levels;	chr14:77681272	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs28534379	ENSG00000235400.1	RP4-641G12.4	-10.78	1.62e-19	5.54e-12	-1.18	-0.7	Fibroblast growth factor basic levels;	chr14:77705797	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs176944	ENSG00000235400.1	RP4-641G12.4	-10.78	1.62e-19	5.54e-12	-1.18	-0.7	Fibroblast growth factor basic levels;	chr14:77709868	chr1:78749073~78750659:+
TGCT	trans	rs9611565	0.649	rs2413659	ENSG00000268568.1	AC007228.9	10.76	1.76e-19	5.96e-12	0.92	0.69	Vitiligo;	chr22:41768858	chr19:56672574~56673901:-
TGCT	trans	rs6477998	0.535	rs3750535	ENSG00000238072.1	RP11-305M3.2	10.76	1.82e-19	6.18e-12	0.87	0.69	Hematology traits;	chr9:113297453	chr7:129410113~129410370:-
TGCT	trans	rs9611565	0.512	rs5758450	ENSG00000268568.1	AC007228.9	10.75	1.9e-19	6.42e-12	0.95	0.69	Vitiligo;	chr22:41745636	chr19:56672574~56673901:-
TGCT	trans	rs13177918	0.559	rs12109637	ENSG00000239528.1	RPS14P8	10.75	1.9e-19	6.43e-12	0.91	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr5:116562562~116562930:+
TGCT	trans	rs12709013	0.561	rs1657174	ENSG00000230849.2	GOT2P2	10.73	2.13e-19	7.19e-12	0.82	0.69	Blood metabolite ratios;	chr16:58755139	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.636	rs10852565	ENSG00000230849.2	GOT2P2	10.73	2.15e-19	7.28e-12	0.81	0.69	Blood metabolite ratios;	chr16:58771277	chr1:173141100~173142350:-
TGCT	trans	rs13177918	0.559	rs10447224	ENSG00000239528.1	RPS14P8	10.72	2.2e-19	7.44e-12	0.92	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr5:116562562~116562930:+
TGCT	trans	rs13177918	0.559	rs10447225	ENSG00000239528.1	RPS14P8	10.72	2.2e-19	7.44e-12	0.92	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr5:116562562~116562930:+
TGCT	trans	rs12709013	0.636	rs1865836	ENSG00000230849.2	GOT2P2	10.69	2.63e-19	8.8e-12	0.8	0.69	Blood metabolite ratios;	chr16:58768143	chr1:173141100~173142350:-
TGCT	trans	rs13253073	1	rs4480092	ENSG00000260318.1	COX6CP1	10.66	3.22e-19	1.06e-11	1.25	0.69	Glucose homeostasis traits;	chr8:99873372	chr16:11903923~11904137:-
TGCT	trans	rs13253073	1	rs13252579	ENSG00000260318.1	COX6CP1	10.65	3.26e-19	1.07e-11	1.25	0.69	Glucose homeostasis traits;	chr8:99885073	chr16:11903923~11904137:-
TGCT	trans	rs13253073	1	rs13253073	ENSG00000260318.1	COX6CP1	10.65	3.26e-19	1.07e-11	1.25	0.69	Glucose homeostasis traits;	chr8:99885155	chr16:11903923~11904137:-
TGCT	trans	rs13253073	1	rs13259066	ENSG00000260318.1	COX6CP1	10.65	3.26e-19	1.07e-11	1.25	0.69	Glucose homeostasis traits;	chr8:99889455	chr16:11903923~11904137:-
TGCT	trans	rs13253073	1	rs12544943	ENSG00000260318.1	COX6CP1	10.65	3.26e-19	1.07e-11	1.25	0.69	Glucose homeostasis traits;	chr8:99891662	chr16:11903923~11904137:-
TGCT	trans	rs13253073	1	rs34029308	ENSG00000260318.1	COX6CP1	10.65	3.26e-19	1.07e-11	1.25	0.69	Glucose homeostasis traits;	chr8:99892425	chr16:11903923~11904137:-
TGCT	trans	rs9611565	0.649	rs4822050	ENSG00000268568.1	AC007228.9	-10.65	3.37e-19	1.1e-11	-0.89	-0.69	Vitiligo;	chr22:41781449	chr19:56672574~56673901:-
TGCT	trans	rs12709013	0.636	rs6499976	ENSG00000230849.2	GOT2P2	10.63	3.7e-19	1.21e-11	0.79	0.69	Blood metabolite ratios;	chr16:58770330	chr1:173141100~173142350:-
TGCT	trans	rs7121616	0.576	rs4936767	ENSG00000234176.1	HSPA8P1	10.61	4.05e-19	1.32e-11	0.92	0.69	Breast cancer;	chr11:123047451	chrX:121203182~121205014:-
TGCT	trans	rs9611565	0.512	rs45500192	ENSG00000268568.1	AC007228.9	-10.61	4.15e-19	1.35e-11	-0.94	-0.69	Vitiligo;	chr22:41781895	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs9607841	ENSG00000268568.1	AC007228.9	-10.61	4.15e-19	1.35e-11	-0.94	-0.69	Vitiligo;	chr22:41790834	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.512	rs9611667	ENSG00000268568.1	AC007228.9	-10.61	4.15e-19	1.35e-11	-0.94	-0.69	Vitiligo;	chr22:41791011	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.572	rs139569	ENSG00000268568.1	AC007228.9	-10.61	4.2e-19	1.36e-11	-0.91	-0.69	Vitiligo;	chr22:41815137	chr19:56672574~56673901:-
TGCT	trans	rs7121616	0.562	rs7131452	ENSG00000234176.1	HSPA8P1	10.6	4.32e-19	1.4e-11	0.96	0.69	Breast cancer;	chr11:123065314	chrX:121203182~121205014:-
TGCT	trans	rs12709013	0.621	rs6499974	ENSG00000230849.2	GOT2P2	10.59	4.53e-19	1.47e-11	0.79	0.69	Blood metabolite ratios;	chr16:58769642	chr1:173141100~173142350:-
TGCT	trans	rs727563	0.565	rs132774	ENSG00000268568.1	AC007228.9	-10.58	4.92e-19	1.59e-11	-0.91	-0.69	Crohn's disease;Inflammatory bowel disease;	chr22:41635949	chr19:56672574~56673901:-
TGCT	trans	rs12709013	0.597	rs8051078	ENSG00000230849.2	GOT2P2	10.57	5.25e-19	1.69e-11	0.79	0.69	Blood metabolite ratios;	chr16:58774200	chr1:173141100~173142350:-
TGCT	trans	rs941207	1	rs941207	ENSG00000121089.4	NACA3P	-10.56	5.63e-19	1.81e-11	-0.96	-0.69	Platelet count;	chr12:56629500	chr4:164943290~164943937:+
TGCT	trans	rs12709013	0.636	rs9937713	ENSG00000230849.2	GOT2P2	10.55	5.93e-19	1.9e-11	0.79	0.69	Blood metabolite ratios;	chr16:58771921	chr1:173141100~173142350:-
TGCT	trans	rs61990749	0.597	rs10148373	ENSG00000235400.1	RP4-641G12.4	10.52	6.9e-19	2.21e-11	1.18	0.69	Fibroblast growth factor basic levels;	chr14:77813856	chr1:78749073~78750659:+
TGCT	trans	rs9611565	1	rs5751086	ENSG00000268568.1	AC007228.9	-10.5	7.9e-19	2.51e-11	-0.85	-0.69	Vitiligo;	chr22:41372858	chr19:56672574~56673901:-
TGCT	trans	rs12709013	0.636	rs4499224	ENSG00000230849.2	GOT2P2	10.49	8.3e-19	2.63e-11	0.79	0.69	Blood metabolite ratios;	chr16:58770364	chr1:173141100~173142350:-
TGCT	trans	rs61990749	0.597	rs59848135	ENSG00000235400.1	RP4-641G12.4	-10.49	8.33e-19	2.64e-11	-1.18	-0.69	Fibroblast growth factor basic levels;	chr14:77662657	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs11623088	ENSG00000235400.1	RP4-641G12.4	-10.46	9.48e-19	2.99e-11	-1.17	-0.68	Fibroblast growth factor basic levels;	chr14:77671392	chr1:78749073~78750659:+
TGCT	trans	rs7943191	0.81	rs7942154	ENSG00000186676.3	EEF1GP1	10.46	9.8e-19	3.09e-11	0.94	0.68	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569691	chr7:125033453~125035301:+
TGCT	trans	rs12709013	0.636	rs1595180	ENSG00000230849.2	GOT2P2	10.45	1.02e-18	3.21e-11	0.78	0.68	Blood metabolite ratios;	chr16:58770545	chr1:173141100~173142350:-
TGCT	trans	rs13253073	1	rs10955222	ENSG00000260318.1	COX6CP1	-10.45	1.04e-18	3.26e-11	-1.19	-0.68	Glucose homeostasis traits;	chr8:99875122	chr16:11903923~11904137:-
TGCT	trans	rs6477998	0.58	rs2296073	ENSG00000238072.1	RP11-305M3.2	10.41	1.24e-18	3.79e-11	0.82	0.68	Hematology traits;	chr9:113299348	chr7:129410113~129410370:-
TGCT	trans	rs7949030	0.626	rs35587183	ENSG00000186676.3	EEF1GP1	10.41	1.27e-18	3.88e-11	0.96	0.68	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551184	chr7:125033453~125035301:+
TGCT	trans	rs61990749	0.544	rs11628888	ENSG00000235400.1	RP4-641G12.4	-10.4	1.34e-18	4.1e-11	-1.15	-0.68	Fibroblast growth factor basic levels;	chr14:77695163	chr1:78749073~78750659:+
TGCT	trans	rs2950393	0.509	rs10459247	ENSG00000121089.4	NACA3P	-10.39	1.39e-18	4.24e-11	-0.91	-0.68	Platelet distribution width;	chr12:56777732	chr4:164943290~164943937:+
TGCT	trans	rs7949030	0.523	rs12223627	ENSG00000186676.3	EEF1GP1	10.37	1.6e-18	4.85e-11	0.95	0.68	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601085	chr7:125033453~125035301:+
TGCT	trans	rs7943191	0.768	rs34065644	ENSG00000186676.3	EEF1GP1	10.37	1.6e-18	4.85e-11	0.95	0.68	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62604466	chr7:125033453~125035301:+
TGCT	trans	rs877636	0.692	rs10876870	ENSG00000235459.5	RPS26P31	-10.37	1.62e-18	4.91e-11	-0.77	-0.68	Cognitive function;	chr12:56084218	chr7:122681315~122681662:+
TGCT	trans	rs877636	0.692	rs7971751	ENSG00000235459.5	RPS26P31	-10.37	1.62e-18	4.91e-11	-0.77	-0.68	Cognitive function;	chr12:56084874	chr7:122681315~122681662:+
TGCT	trans	rs9611565	0.625	rs9607819	ENSG00000268568.1	AC007228.9	-10.35	1.79e-18	5.39e-11	-0.94	-0.68	Vitiligo;	chr22:41562858	chr19:56672574~56673901:-
TGCT	trans	rs941207	0.756	rs2950388	ENSG00000121089.4	NACA3P	-10.32	2.12e-18	6.36e-11	-0.95	-0.68	Platelet count;	chr12:56639569	chr4:164943290~164943937:+
TGCT	trans	rs61990749	0.597	rs9788540	ENSG00000235400.1	RP4-641G12.4	-10.32	2.16e-18	6.47e-11	-1.17	-0.68	Fibroblast growth factor basic levels;	chr14:77665829	chr1:78749073~78750659:+
TGCT	trans	rs941207	0.756	rs9634246	ENSG00000121089.4	NACA3P	-10.31	2.19e-18	6.56e-11	-0.95	-0.68	Platelet count;	chr12:56640604	chr4:164943290~164943937:+
TGCT	trans	rs7943191	0.805	rs12226821	ENSG00000186676.3	EEF1GP1	10.3	2.38e-18	7.11e-11	0.95	0.68	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62601546	chr7:125033453~125035301:+
TGCT	trans	rs61990749	0.597	rs176980	ENSG00000235400.1	RP4-641G12.4	-10.29	2.43e-18	7.22e-11	-1.15	-0.68	Fibroblast growth factor basic levels;	chr14:77732106	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.544	rs176979	ENSG00000235400.1	RP4-641G12.4	10.29	2.43e-18	7.22e-11	1.15	0.68	Fibroblast growth factor basic levels;	chr14:77731729	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs12887282	ENSG00000235400.1	RP4-641G12.4	10.29	2.43e-18	7.22e-11	1.15	0.68	Fibroblast growth factor basic levels;	chr14:77734242	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs12887606	ENSG00000235400.1	RP4-641G12.4	10.29	2.43e-18	7.22e-11	1.15	0.68	Fibroblast growth factor basic levels;	chr14:77734277	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs8003691	ENSG00000235400.1	RP4-641G12.4	10.29	2.43e-18	7.22e-11	1.15	0.68	Fibroblast growth factor basic levels;	chr14:77744882	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs2267768	ENSG00000235400.1	RP4-641G12.4	10.29	2.43e-18	7.22e-11	1.15	0.68	Fibroblast growth factor basic levels;	chr14:77749671	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs1549119	ENSG00000235400.1	RP4-641G12.4	10.29	2.43e-18	7.22e-11	1.15	0.68	Fibroblast growth factor basic levels;	chr14:77753469	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs1978416	ENSG00000235400.1	RP4-641G12.4	10.29	2.43e-18	7.22e-11	1.15	0.68	Fibroblast growth factor basic levels;	chr14:77761558	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.544	rs3759728	ENSG00000235400.1	RP4-641G12.4	10.29	2.43e-18	7.22e-11	1.15	0.68	Fibroblast growth factor basic levels;	chr14:77763816	chr1:78749073~78750659:+
TGCT	trans	rs7554547	0.871	rs6661289	ENSG00000261819.1	RP11-680G24.4	10.29	2.56e-18	7.56e-11	0.79	0.68	Nonsyndromic cleft lip with cleft palate;	chr1:11882724	chr16:14988259~14990160:-
TGCT	trans	rs7949030	0.596	rs11231137	ENSG00000186676.3	EEF1GP1	10.24	3.3e-18	9.36e-11	0.96	0.68	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62548227	chr7:125033453~125035301:+
TGCT	trans	rs877636	0.692	rs11171739	ENSG00000235459.5	RPS26P31	10.22	3.6e-18	1.02e-10	0.75	0.68	Cognitive function;	chr12:56076841	chr7:122681315~122681662:+
TGCT	trans	rs13253073	1	rs6468694	ENSG00000260318.1	COX6CP1	10.21	3.87e-18	1.09e-10	1.25	0.68	Glucose homeostasis traits;	chr8:99853608	chr16:11903923~11904137:-
TGCT	trans	rs13253073	1	rs6986006	ENSG00000260318.1	COX6CP1	10.21	3.87e-18	1.09e-10	1.25	0.68	Glucose homeostasis traits;	chr8:99857251	chr16:11903923~11904137:-
TGCT	trans	rs13253073	1	rs12541837	ENSG00000260318.1	COX6CP1	-10.21	3.87e-18	1.09e-10	-1.25	-0.68	Glucose homeostasis traits;	chr8:99869645	chr16:11903923~11904137:-
TGCT	trans	rs7554547	0.695	rs198384	ENSG00000261819.1	RP11-680G24.4	10.19	4.29e-18	1.2e-10	0.83	0.68	Nonsyndromic cleft lip with cleft palate;	chr1:11874321	chr16:14988259~14990160:-
TGCT	trans	rs13253073	1	rs13273257	ENSG00000260318.1	COX6CP1	10.18	4.58e-18	1.28e-10	1.24	0.67	Glucose homeostasis traits;	chr8:99852468	chr16:11903923~11904137:-
TGCT	trans	rs916888	0.773	rs199447	ENSG00000214425.5	LRRC37A4P	-10.15	5.39e-18	1.5e-10	-0.9	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45506741~45550335:-
TGCT	trans	rs916888	0.773	rs199445	ENSG00000214425.5	LRRC37A4P	-10.15	5.39e-18	1.5e-10	-0.9	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45506741~45550335:-
TGCT	trans	rs916888	0.773	rs199443	ENSG00000214425.5	LRRC37A4P	-10.15	5.39e-18	1.5e-10	-0.9	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45506741~45550335:-
TGCT	trans	rs916888	0.773	rs199534	ENSG00000214425.5	LRRC37A4P	-10.15	5.39e-18	1.5e-10	-0.9	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45506741~45550335:-
TGCT	trans	rs877636	0.692	rs2271194	ENSG00000235459.5	RPS26P31	-10.11	6.88e-18	1.9e-10	-0.76	-0.67	Cognitive function;	chr12:56083910	chr7:122681315~122681662:+
TGCT	trans	rs916888	0.773	rs199535	ENSG00000214425.5	LRRC37A4P	-10.09	7.57e-18	2.09e-10	-0.9	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45506741~45550335:-
TGCT	trans	rs7121616	0.576	rs11218967	ENSG00000234176.1	HSPA8P1	10.07	8.79e-18	2.41e-10	0.95	0.67	Breast cancer;	chr11:123087551	chrX:121203182~121205014:-
TGCT	trans	rs877636	1	rs877636	ENSG00000235459.5	RPS26P31	-10.06	9.04e-18	2.47e-10	-0.84	-0.67	Cognitive function;	chr12:56086799	chr7:122681315~122681662:+
TGCT	trans	rs7943191	0.81	rs7942991	ENSG00000186676.3	EEF1GP1	-10.06	9.15e-18	2.5e-10	-0.92	-0.67	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569731	chr7:125033453~125035301:+
TGCT	trans	rs916888	0.773	rs199533	ENSG00000214425.5	LRRC37A4P	-10.05	9.69e-18	2.63e-10	-0.91	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45506741~45550335:-
TGCT	trans	rs928391	1	rs12043405	ENSG00000227183.3	HDGFP1	10.03	1.05e-17	2.71e-10	0.92	0.67	Platelet count;	chr1:156784508	chrX:131646639~131646890:+
TGCT	trans	rs916888	0.773	rs199448	ENSG00000214425.5	LRRC37A4P	-10.03	1.06e-17	2.72e-10	-0.87	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45506741~45550335:-
TGCT	trans	rs916888	0.773	rs9896243	ENSG00000214425.5	LRRC37A4P	-10.03	1.08e-17	2.78e-10	-0.88	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45506741~45550335:-
TGCT	trans	rs13253073	0.883	rs2305290	ENSG00000260318.1	COX6CP1	10.03	1.09e-17	2.81e-10	1.23	0.67	Glucose homeostasis traits;	chr8:99819066	chr16:11903923~11904137:-
TGCT	trans	rs928391	0.947	rs11264549	ENSG00000227183.3	HDGFP1	10.02	1.11e-17	2.84e-10	0.93	0.67	Platelet count;	chr1:156781017	chrX:131646639~131646890:+
TGCT	trans	rs928391	1	rs12134991	ENSG00000227183.3	HDGFP1	10.02	1.11e-17	2.84e-10	0.93	0.67	Platelet count;	chr1:156781285	chrX:131646639~131646890:+
TGCT	trans	rs928391	1	rs2274501	ENSG00000227183.3	HDGFP1	10.02	1.11e-17	2.84e-10	0.93	0.67	Platelet count;	chr1:156782460	chrX:131646639~131646890:+
TGCT	trans	rs7121616	0.563	rs4936770	ENSG00000234176.1	HSPA8P1	9.98	1.45e-17	3.68e-10	0.93	0.67	Breast cancer;	chr11:123058167	chrX:121203182~121205014:-
TGCT	trans	rs928391	1	rs2644615	ENSG00000227183.3	HDGFP1	9.97	1.49e-17	3.78e-10	0.9	0.67	Platelet count;	chr1:156791826	chrX:131646639~131646890:+
TGCT	trans	rs9611565	0.614	rs4822053	ENSG00000268568.1	AC007228.9	-9.97	1.53e-17	3.88e-10	-0.87	-0.67	Vitiligo;	chr22:41816932	chr19:56672574~56673901:-
TGCT	trans	rs61990749	0.597	rs12896026	ENSG00000235400.1	RP4-641G12.4	9.96	1.59e-17	4.01e-10	1.13	0.67	Fibroblast growth factor basic levels;	chr14:77778093	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.544	rs12435761	ENSG00000235400.1	RP4-641G12.4	9.96	1.59e-17	4.01e-10	1.13	0.67	Fibroblast growth factor basic levels;	chr14:77779734	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs759808	ENSG00000235400.1	RP4-641G12.4	9.96	1.59e-17	4.01e-10	1.13	0.67	Fibroblast growth factor basic levels;	chr14:77784502	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs717683	ENSG00000235400.1	RP4-641G12.4	9.96	1.59e-17	4.01e-10	1.13	0.67	Fibroblast growth factor basic levels;	chr14:77789110	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.544	rs1477259	ENSG00000235400.1	RP4-641G12.4	9.96	1.59e-17	4.01e-10	1.13	0.67	Fibroblast growth factor basic levels;	chr14:77789795	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.597	rs4632066	ENSG00000235400.1	RP4-641G12.4	-9.96	1.59e-17	4.01e-10	-1.13	-0.67	Fibroblast growth factor basic levels;	chr14:77780939	chr1:78749073~78750659:+
TGCT	trans	rs9611565	0.649	rs126092	ENSG00000268568.1	AC007228.9	9.96	1.61e-17	4.04e-10	0.92	0.67	Vitiligo;	chr22:41782437	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.571	rs7364123	ENSG00000268568.1	AC007228.9	-9.93	1.89e-17	4.69e-10	-0.89	-0.67	Vitiligo;	chr22:41820322	chr19:56672574~56673901:-
TGCT	trans	rs928391	0.895	rs12042999	ENSG00000227183.3	HDGFP1	9.92	1.96e-17	4.86e-10	0.93	0.67	Platelet count;	chr1:156768636	chrX:131646639~131646890:+
TGCT	trans	rs928391	0.895	rs11264547	ENSG00000227183.3	HDGFP1	9.92	1.96e-17	4.86e-10	0.93	0.67	Platelet count;	chr1:156776326	chrX:131646639~131646890:+
TGCT	trans	rs928391	1	rs61816272	ENSG00000227183.3	HDGFP1	9.91	2.13e-17	5.26e-10	0.93	0.66	Platelet count;	chr1:156778073	chrX:131646639~131646890:+
TGCT	trans	rs928391	1	rs3765787	ENSG00000227183.3	HDGFP1	-9.91	2.14e-17	5.26e-10	-0.91	-0.66	Platelet count;	chr1:156784673	chrX:131646639~131646890:+
TGCT	trans	rs877636	0.692	rs11171739	ENSG00000243403.1	RP11-330L19.1	9.9	2.16e-17	5.32e-10	0.73	0.66	Cognitive function;	chr12:56076841	chr15:64592979~64593326:+
TGCT	trans	rs9611565	0.512	rs5758464	ENSG00000268568.1	AC007228.9	9.9	2.18e-17	5.38e-10	1.15	0.66	Vitiligo;	chr22:41775296	chr19:56672574~56673901:-
TGCT	trans	rs13253073	0.525	rs35509895	ENSG00000260318.1	COX6CP1	9.9	2.21e-17	5.44e-10	1.3	0.66	Glucose homeostasis traits;	chr8:99872093	chr16:11903923~11904137:-
TGCT	trans	rs916888	0.773	rs199451	ENSG00000214425.5	LRRC37A4P	-9.87	2.61e-17	6.32e-10	-0.89	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45506741~45550335:-
TGCT	trans	rs916888	0.687	rs199456	ENSG00000214425.5	LRRC37A4P	-9.84	3.1e-17	7.47e-10	-0.89	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45506741~45550335:-
TGCT	trans	rs7949030	0.504	rs2516633	ENSG00000186676.3	EEF1GP1	-9.81	3.61e-17	8.64e-10	-0.9	-0.66	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62604301	chr7:125033453~125035301:+
TGCT	trans	rs7554547	0.871	rs11588551	ENSG00000261819.1	RP11-680G24.4	-9.79	4.19e-17	9.97e-10	-0.75	-0.66	Nonsyndromic cleft lip with cleft palate;	chr1:11881879	chr16:14988259~14990160:-
TGCT	trans	rs13253073	0.545	rs35769167	ENSG00000260318.1	COX6CP1	9.76	4.7e-17	1.11e-09	1.3	0.66	Glucose homeostasis traits;	chr8:99872095	chr16:11903923~11904137:-
TGCT	trans	rs7121616	0.595	rs7949414	ENSG00000234176.1	HSPA8P1	9.76	4.94e-17	1.17e-09	0.97	0.66	Breast cancer;	chr11:123072787	chrX:121203182~121205014:-
TGCT	trans	rs4822044	0.568	rs1883370	ENSG00000268568.1	AC007228.9	9.75	5.25e-17	1.24e-09	0.9	0.66	Cannabis dependence symptom count;	chr22:41747736	chr19:56672574~56673901:-
TGCT	trans	rs13253073	0.825	rs6984511	ENSG00000260318.1	COX6CP1	9.74	5.29e-17	1.25e-09	1.31	0.66	Glucose homeostasis traits;	chr8:99869513	chr16:11903923~11904137:-
TGCT	trans	rs9611519	0.732	rs1883826	ENSG00000268568.1	AC007228.9	-9.73	5.57e-17	1.31e-09	-0.81	-0.66	Neuroticism;	chr22:41307424	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.525	rs9611549	ENSG00000268568.1	AC007228.9	-9.73	5.57e-17	1.31e-09	-0.81	-0.66	Vitiligo;	chr22:41309905	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.506	rs2024566	ENSG00000268568.1	AC007228.9	-9.73	5.74e-17	1.35e-09	-0.81	-0.66	Vitiligo;	chr22:41301334	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.506	rs2024567	ENSG00000268568.1	AC007228.9	-9.73	5.74e-17	1.35e-09	-0.81	-0.66	Vitiligo;	chr22:41303202	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.506	rs4822020	ENSG00000268568.1	AC007228.9	-9.73	5.74e-17	1.35e-09	-0.81	-0.66	Vitiligo;	chr22:41304199	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.506	rs1984839	ENSG00000268568.1	AC007228.9	-9.73	5.76e-17	1.35e-09	-0.81	-0.66	Vitiligo;	chr22:41289933	chr19:56672574~56673901:-
TGCT	trans	rs61990749	0.597	rs7142390	ENSG00000235400.1	RP4-641G12.4	9.73	5.8e-17	1.36e-09	1.16	0.66	Fibroblast growth factor basic levels;	chr14:77766537	chr1:78749073~78750659:+
TGCT	trans	rs9611519	0.78	rs1535048	ENSG00000268568.1	AC007228.9	-9.72	6.13e-17	1.43e-09	-0.8	-0.66	Neuroticism;	chr22:41288089	chr19:56672574~56673901:-
TGCT	trans	rs9611519	0.78	rs9611546	ENSG00000268568.1	AC007228.9	-9.7	6.79e-17	1.58e-09	-0.8	-0.66	Neuroticism;	chr22:41302538	chr19:56672574~56673901:-
TGCT	trans	rs928391	1	rs2777929	ENSG00000227183.3	HDGFP1	9.67	8.1e-17	1.88e-09	0.89	0.66	Platelet count;	chr1:156797879	chrX:131646639~131646890:+
TGCT	trans	rs928391	1	rs2768767	ENSG00000227183.3	HDGFP1	9.66	8.61e-17	1.99e-09	0.89	0.66	Platelet count;	chr1:156797933	chrX:131646639~131646890:+
TGCT	trans	rs877636	0.669	rs7297175	ENSG00000243403.1	RP11-330L19.1	-9.65	8.91e-17	2.05e-09	-0.73	-0.65	Cognitive function;	chr12:56080024	chr15:64592979~64593326:+
TGCT	trans	rs9611565	0.525	rs9611548	ENSG00000268568.1	AC007228.9	-9.65	9.13e-17	2.09e-09	-0.78	-0.65	Vitiligo;	chr22:41308139	chr19:56672574~56673901:-
TGCT	trans	rs9611519	0.78	rs9611542	ENSG00000268568.1	AC007228.9	-9.64	9.2e-17	2.11e-09	-0.78	-0.65	Neuroticism;	chr22:41281313	chr19:56672574~56673901:-
TGCT	trans	rs877636	0.692	rs10876870	ENSG00000243403.1	RP11-330L19.1	-9.64	9.57e-17	2.19e-09	-0.74	-0.65	Cognitive function;	chr12:56084218	chr15:64592979~64593326:+
TGCT	trans	rs877636	0.692	rs7971751	ENSG00000243403.1	RP11-330L19.1	-9.64	9.57e-17	2.19e-09	-0.74	-0.65	Cognitive function;	chr12:56084874	chr15:64592979~64593326:+
TGCT	trans	rs916888	0.773	rs538628	ENSG00000214425.5	LRRC37A4P	-9.63	9.93e-17	2.27e-09	-0.9	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45506741~45550335:-
TGCT	trans	rs916888	0.773	rs169201	ENSG00000214425.5	LRRC37A4P	-9.63	9.93e-17	2.27e-09	-0.9	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45506741~45550335:-
TGCT	trans	rs916888	0.773	rs199439	ENSG00000214425.5	LRRC37A4P	-9.63	9.93e-17	2.27e-09	-0.9	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45506741~45550335:-
TGCT	trans	rs877636	0.669	rs7297175	ENSG00000235459.5	RPS26P31	-9.63	9.99e-17	2.29e-09	-0.74	-0.65	Cognitive function;	chr12:56080024	chr7:122681315~122681662:+
TGCT	trans	rs877636	0.692	rs2271194	ENSG00000243403.1	RP11-330L19.1	-9.62	1.06e-16	2.42e-09	-0.73	-0.65	Cognitive function;	chr12:56083910	chr15:64592979~64593326:+
TGCT	trans	rs13177918	0.603	rs2748241	ENSG00000239528.1	RPS14P8	9.56	1.51e-16	3.31e-09	0.84	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr5:116562562~116562930:+
TGCT	trans	rs916888	0.647	rs199524	ENSG00000263503.1	RP11-707O23.5	-9.52	1.85e-16	3.97e-09	-0.86	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45600869~45602340:-
TGCT	trans	rs916888	0.647	rs199523	ENSG00000263503.1	RP11-707O23.5	-9.52	1.85e-16	3.97e-09	-0.86	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45600869~45602340:-
TGCT	trans	rs7554547	0.716	rs34954501	ENSG00000261819.1	RP11-680G24.4	9.51	1.97e-16	4.22e-09	0.78	0.65	Nonsyndromic cleft lip with cleft palate;	chr1:11878146	chr16:14988259~14990160:-
TGCT	trans	rs916888	0.773	rs199457	ENSG00000214425.5	LRRC37A4P	-9.5	2.08e-16	4.44e-09	-0.88	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45506741~45550335:-
TGCT	trans	rs928391	1	rs10157555	ENSG00000227183.3	HDGFP1	-9.5	2.1e-16	4.49e-09	-0.87	-0.65	Platelet count;	chr1:156802060	chrX:131646639~131646890:+
TGCT	trans	rs928391	1	rs12129173	ENSG00000227183.3	HDGFP1	9.49	2.16e-16	4.61e-09	0.88	0.65	Platelet count;	chr1:156803833	chrX:131646639~131646890:+
TGCT	trans	rs916888	0.773	rs1378358	ENSG00000214425.5	LRRC37A4P	-9.48	2.33e-16	4.95e-09	-0.9	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45506741~45550335:-
TGCT	trans	rs877636	1	rs2292239	ENSG00000235459.5	RPS26P31	9.4	3.61e-16	7.55e-09	0.8	0.64	Cognitive function;	chr12:56088396	chr7:122681315~122681662:+
TGCT	trans	rs12291225	0.535	rs16930126	ENSG00000236360.2	RP11-334A14.2	-9.39	3.82e-16	7.96e-09	-0.76	-0.64	Sense of smell;	chr11:14383437	chr1:52993201~52993702:-
TGCT	trans	rs61990749	0.597	rs10142722	ENSG00000235400.1	RP4-641G12.4	9.38	4.08e-16	8.5e-09	1.12	0.64	Fibroblast growth factor basic levels;	chr14:77809206	chr1:78749073~78750659:+
TGCT	trans	rs916888	0.647	rs199449	ENSG00000263503.1	RP11-707O23.5	9.34	5.03e-16	1.03e-08	0.87	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45600869~45602340:-
TGCT	trans	rs12291225	0.535	rs11023203	ENSG00000236360.2	RP11-334A14.2	9.33	5.22e-16	1.07e-08	0.75	0.64	Sense of smell;	chr11:14388269	chr1:52993201~52993702:-
TGCT	trans	rs877636	1	rs4759229	ENSG00000235459.5	RPS26P31	-9.32	5.6e-16	1.14e-08	-0.79	-0.64	Cognitive function;	chr12:56080696	chr7:122681315~122681662:+
TGCT	trans	rs877636	0.859	rs3741499	ENSG00000235459.5	RPS26P31	-9.32	5.73e-16	1.17e-08	-0.79	-0.64	Cognitive function;	chr12:56080595	chr7:122681315~122681662:+
TGCT	trans	rs916888	0.61	rs199442	ENSG00000263503.1	RP11-707O23.5	9.27	7.45e-16	1.5e-08	0.86	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45600869~45602340:-
TGCT	trans	rs928391	1	rs928391	ENSG00000227183.3	HDGFP1	9.26	7.68e-16	1.54e-08	0.87	0.64	Platelet count;	chr1:156806925	chrX:131646639~131646890:+
TGCT	trans	rs928391	1	rs2644606	ENSG00000227183.3	HDGFP1	9.26	7.68e-16	1.54e-08	0.87	0.64	Platelet count;	chr1:156808053	chrX:131646639~131646890:+
TGCT	trans	rs13190036	1	rs13157667	ENSG00000217325.2	PRELID1P1	-9.25	8.15e-16	1.63e-08	-0.85	-0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177186876	chr6:126643488~126644390:+
TGCT	trans	rs13190036	1	rs13167431	ENSG00000217325.2	PRELID1P1	-9.25	8.15e-16	1.63e-08	-0.85	-0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177194074	chr6:126643488~126644390:+
TGCT	trans	rs13190036	1	rs35535623	ENSG00000217325.2	PRELID1P1	-9.25	8.15e-16	1.63e-08	-0.85	-0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177202295	chr6:126643488~126644390:+
TGCT	trans	rs928391	0.948	rs2735657	ENSG00000227183.3	HDGFP1	9.25	8.3e-16	1.66e-08	0.84	0.64	Platelet count;	chr1:156810514	chrX:131646639~131646890:+
TGCT	trans	rs13190036	1	rs59737888	ENSG00000217325.2	PRELID1P1	-9.24	8.62e-16	1.71e-08	-0.85	-0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177160374	chr6:126643488~126644390:+
TGCT	trans	rs12291225	0.535	rs10832248	ENSG00000236360.2	RP11-334A14.2	9.24	8.79e-16	1.74e-08	0.74	0.64	Sense of smell;	chr11:14391541	chr1:52993201~52993702:-
TGCT	trans	rs941207	0.542	rs11171978	ENSG00000121089.4	NACA3P	9.23	9.02e-16	1.79e-08	0.83	0.64	Platelet count;	chr12:56800015	chr4:164943290~164943937:+
TGCT	trans	rs916888	0.779	rs199528	ENSG00000214425.5	LRRC37A4P	-9.23	9.04e-16	1.79e-08	-0.83	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45506741~45550335:-
TGCT	trans	rs916888	0.821	rs199525	ENSG00000214425.5	LRRC37A4P	-9.23	9.04e-16	1.79e-08	-0.83	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45506741~45550335:-
TGCT	trans	rs928391	1	rs928392	ENSG00000227183.3	HDGFP1	9.23	9.36e-16	1.85e-08	0.86	0.64	Platelet count;	chr1:156801024	chrX:131646639~131646890:+
TGCT	trans	rs7121616	0.595	rs7941144	ENSG00000234176.1	HSPA8P1	9.22	9.7e-16	1.92e-08	0.88	0.64	Breast cancer;	chr11:123079805	chrX:121203182~121205014:-
TGCT	trans	rs916888	0.61	rs199444	ENSG00000263503.1	RP11-707O23.5	9.21	1.02e-15	2.01e-08	0.86	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45600869~45602340:-
TGCT	trans	rs13253073	0.941	rs4076509	ENSG00000260318.1	COX6CP1	9.21	1.03e-15	2.04e-08	1.15	0.64	Glucose homeostasis traits;	chr8:99842928	chr16:11903923~11904137:-
TGCT	trans	rs13253073	0.941	rs12548827	ENSG00000260318.1	COX6CP1	9.2	1.08e-15	2.14e-08	1.16	0.64	Glucose homeostasis traits;	chr8:99841495	chr16:11903923~11904137:-
TGCT	trans	rs6477998	0.535	rs10981712	ENSG00000238072.1	RP11-305M3.2	9.2	1.11e-15	2.18e-08	0.82	0.64	Hematology traits;	chr9:113283846	chr7:129410113~129410370:-
TGCT	trans	rs9611519	0.754	rs4820435	ENSG00000268568.1	AC007228.9	-9.19	1.16e-15	2.27e-08	-0.76	-0.64	Neuroticism;	chr22:41256842	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.506	rs7364221	ENSG00000268568.1	AC007228.9	-9.19	1.16e-15	2.28e-08	-0.77	-0.64	Vitiligo;	chr22:41254186	chr19:56672574~56673901:-
TGCT	trans	rs13190036	0.901	rs55741473	ENSG00000217325.2	PRELID1P1	-9.18	1.21e-15	2.37e-08	-0.84	-0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147218	chr6:126643488~126644390:+
TGCT	trans	rs13190036	1	rs34446750	ENSG00000217325.2	PRELID1P1	-9.18	1.21e-15	2.37e-08	-0.84	-0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177168079	chr6:126643488~126644390:+
TGCT	trans	rs12709013	0.755	rs1424245	ENSG00000230849.2	GOT2P2	9.17	1.3e-15	2.53e-08	0.75	0.64	Blood metabolite ratios;	chr16:58729926	chr1:173141100~173142350:-
TGCT	trans	rs9611519	0.857	rs4820434	ENSG00000268568.1	AC007228.9	-9.15	1.4e-15	2.72e-08	-0.76	-0.64	Neuroticism;	chr22:41241115	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.506	rs1883825	ENSG00000268568.1	AC007228.9	-9.14	1.52e-15	2.94e-08	-0.77	-0.63	Vitiligo;	chr22:41307404	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.525	rs1883827	ENSG00000268568.1	AC007228.9	-9.14	1.52e-15	2.94e-08	-0.77	-0.63	Vitiligo;	chr22:41307575	chr19:56672574~56673901:-
TGCT	trans	rs9611565	0.569	rs6002328	ENSG00000268568.1	AC007228.9	-9.14	1.52e-15	2.94e-08	-0.77	-0.63	Vitiligo;	chr22:41314030	chr19:56672574~56673901:-
TGCT	trans	rs916888	0.697	rs199516	ENSG00000214425.5	LRRC37A4P	9.11	1.8e-15	3.46e-08	0.83	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45506741~45550335:-
TGCT	trans	rs13190036	1	rs71601343	ENSG00000217325.2	PRELID1P1	-9.1	1.84e-15	3.54e-08	-0.84	-0.63	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177205106	chr6:126643488~126644390:+
TGCT	trans	rs13190036	1	rs71601344	ENSG00000217325.2	PRELID1P1	-9.1	1.84e-15	3.54e-08	-0.84	-0.63	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206492	chr6:126643488~126644390:+
TGCT	trans	rs13190036	1	rs3733875	ENSG00000217325.2	PRELID1P1	-9.1	1.84e-15	3.54e-08	-0.84	-0.63	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210239	chr6:126643488~126644390:+
TGCT	trans	rs55665837	0.583	rs78843135	ENSG00000236360.2	RP11-334A14.2	9.1	1.85e-15	3.56e-08	0.73	0.63	Vitamin D levels;	chr11:14389708	chr1:52993201~52993702:-
TGCT	trans	rs928391	1	rs2768766	ENSG00000227183.3	HDGFP1	9.1	1.87e-15	3.6e-08	0.86	0.63	Platelet count;	chr1:156805842	chrX:131646639~131646890:+
TGCT	trans	rs7554547	0.69	rs61402980	ENSG00000261819.1	RP11-680G24.4	9.1	1.9e-15	3.65e-08	0.79	0.63	Nonsyndromic cleft lip with cleft palate;	chr1:11876432	chr16:14988259~14990160:-
TGCT	trans	rs7554547	0.69	rs7364817	ENSG00000261819.1	RP11-680G24.4	9.1	1.9e-15	3.65e-08	0.79	0.63	Nonsyndromic cleft lip with cleft palate;	chr1:11877060	chr16:14988259~14990160:-
TGCT	trans	rs7312770	0.637	rs705699	ENSG00000235459.5	RPS26P31	9.09	1.96e-15	3.76e-08	0.74	0.63	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr7:122681315~122681662:+
TGCT	trans	rs13253073	0.765	rs35615286	ENSG00000260318.1	COX6CP1	9.07	2.18e-15	4.17e-08	1.14	0.63	Glucose homeostasis traits;	chr8:99834866	chr16:11903923~11904137:-
TGCT	trans	rs7312770	0.637	rs705700	ENSG00000235459.5	RPS26P31	9.07	2.2e-15	4.2e-08	0.74	0.63	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr7:122681315~122681662:+
TGCT	trans	rs9611519	0.78	rs3171692	ENSG00000268568.1	AC007228.9	-9.06	2.34e-15	4.45e-08	-0.76	-0.63	Neuroticism;	chr22:41246208	chr19:56672574~56673901:-
TGCT	trans	rs13253073	0.883	rs12545602	ENSG00000260318.1	COX6CP1	9.03	2.73e-15	5.18e-08	1.15	0.63	Glucose homeostasis traits;	chr8:99834612	chr16:11903923~11904137:-
TGCT	trans	rs877636	0.692	rs10876870	ENSG00000225071.1	GS1-184P14.2	-9.03	2.79e-15	5.29e-08	-0.68	-0.63	Cognitive function;	chr12:56084218	chrX:24429573~24429920:-
TGCT	trans	rs877636	0.692	rs7971751	ENSG00000225071.1	GS1-184P14.2	-9.03	2.79e-15	5.29e-08	-0.68	-0.63	Cognitive function;	chr12:56084874	chrX:24429573~24429920:-
TGCT	trans	rs7554547	0.69	rs4846066	ENSG00000261819.1	RP11-680G24.4	9.02	2.96e-15	5.61e-08	0.79	0.63	Nonsyndromic cleft lip with cleft palate;	chr1:11877993	chr16:14988259~14990160:-
TGCT	trans	rs916888	0.821	rs199514	ENSG00000214425.5	LRRC37A4P	9.01	3.08e-15	5.83e-08	0.83	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45506741~45550335:-
TGCT	trans	rs13190036	1	rs6889220	ENSG00000217325.2	PRELID1P1	9.01	3.1e-15	5.85e-08	0.85	0.63	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266887	chr6:126643488~126644390:+
TGCT	trans	rs1816752	0.805	rs61614647	ENSG00000237917.1	PARP4P1	9	3.19e-15	6.02e-08	0.76	0.63	Obesity-related traits;	chr13:24441829	chrY:26594851~26634652:-
TGCT	trans	rs12291225	0.535	rs12806025	ENSG00000236360.2	RP11-334A14.2	9	3.32e-15	6.26e-08	0.73	0.63	Sense of smell;	chr11:14392271	chr1:52993201~52993702:-
TGCT	trans	rs55665837	0.524	rs2882128	ENSG00000236360.2	RP11-334A14.2	9	3.32e-15	6.26e-08	0.73	0.63	Vitamin D levels;	chr11:14393088	chr1:52993201~52993702:-
TGCT	trans	rs9611519	0.808	rs5751074	ENSG00000268568.1	AC007228.9	-8.99	3.47e-15	6.54e-08	-0.75	-0.63	Neuroticism;	chr22:41269718	chr19:56672574~56673901:-
TGCT	trans	rs9611519	0.78	rs9611527	ENSG00000268568.1	AC007228.9	-8.97	3.79e-15	7.12e-08	-0.75	-0.63	Neuroticism;	chr22:41248424	chr19:56672574~56673901:-
TGCT	trans	rs877636	0.692	rs2271194	ENSG00000225071.1	GS1-184P14.2	-8.97	3.81e-15	7.16e-08	-0.67	-0.63	Cognitive function;	chr12:56083910	chrX:24429573~24429920:-
TGCT	trans	rs13190036	1	rs7714695	ENSG00000217325.2	PRELID1P1	-8.96	3.98e-15	7.47e-08	-0.84	-0.63	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177130444	chr6:126643488~126644390:+
TGCT	trans	rs7554547	0.69	rs10864544	ENSG00000261819.1	RP11-680G24.4	8.96	4.02e-15	7.55e-08	0.78	0.63	Nonsyndromic cleft lip with cleft palate;	chr1:11875666	chr16:14988259~14990160:-
TGCT	trans	rs7554547	0.775	rs61359664	ENSG00000261819.1	RP11-680G24.4	8.95	4.38e-15	8.21e-08	0.77	0.63	Nonsyndromic cleft lip with cleft palate;	chr1:11878283	chr16:14988259~14990160:-
TGCT	trans	rs7554547	0.644	rs57077193	ENSG00000261819.1	RP11-680G24.4	8.93	4.92e-15	9.17e-08	0.78	0.63	Nonsyndromic cleft lip with cleft palate;	chr1:11878154	chr16:14988259~14990160:-
TGCT	trans	rs916888	0.61	rs199529	ENSG00000214425.5	LRRC37A4P	-8.93	4.93e-15	9.18e-08	-0.82	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45506741~45550335:-
TGCT	trans	rs7312770	0.612	rs773114	ENSG00000235459.5	RPS26P31	8.92	4.98e-15	9.27e-08	0.73	0.63	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr7:122681315~122681662:+
TGCT	trans	rs877636	0.692	rs11171739	ENSG00000225071.1	GS1-184P14.2	8.91	5.29e-15	9.83e-08	0.66	0.62	Cognitive function;	chr12:56076841	chrX:24429573~24429920:-
TGCT	trans	rs1816752	0.806	rs3816218	ENSG00000237917.1	PARP4P1	8.9	5.66e-15	1.05e-07	0.76	0.62	Obesity-related traits;	chr13:24443033	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.666	rs7994022	ENSG00000237917.1	PARP4P1	8.9	5.66e-15	1.05e-07	0.76	0.62	Obesity-related traits;	chr13:24443092	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.776	rs7998843	ENSG00000237917.1	PARP4P1	8.9	5.66e-15	1.05e-07	0.76	0.62	Obesity-related traits;	chr13:24443147	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.712	rs6490932	ENSG00000237917.1	PARP4P1	8.9	5.66e-15	1.05e-07	0.76	0.62	Obesity-related traits;	chr13:24443313	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.713	rs7336357	ENSG00000237917.1	PARP4P1	8.9	5.66e-15	1.05e-07	0.76	0.62	Obesity-related traits;	chr13:24443452	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.683	rs7330532	ENSG00000237917.1	PARP4P1	8.9	5.66e-15	1.05e-07	0.76	0.62	Obesity-related traits;	chr13:24443453	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.59	rs61947036	ENSG00000237917.1	PARP4P1	8.9	5.66e-15	1.05e-07	0.76	0.62	Obesity-related traits;	chr13:24443544	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.776	rs9511268	ENSG00000237917.1	PARP4P1	8.9	5.66e-15	1.05e-07	0.76	0.62	Obesity-related traits;	chr13:24444182	chrY:26594851~26634652:-
TGCT	trans	rs12709013	0.635	rs6993	ENSG00000230849.2	GOT2P2	8.89	5.85e-15	1.08e-07	0.79	0.62	Blood metabolite ratios;	chr16:58707463	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.66	rs30839	ENSG00000230849.2	GOT2P2	8.89	6.05e-15	1.12e-07	0.75	0.62	Blood metabolite ratios;	chr16:58711437	chr1:173141100~173142350:-
TGCT	trans	rs7554547	0.69	rs4846065	ENSG00000261819.1	RP11-680G24.4	8.89	6.13e-15	1.13e-07	0.78	0.62	Nonsyndromic cleft lip with cleft palate;	chr1:11877306	chr16:14988259~14990160:-
TGCT	trans	rs9611519	0.78	rs5751072	ENSG00000268568.1	AC007228.9	-8.88	6.17e-15	1.14e-07	-0.74	-0.62	Neuroticism;	chr22:41260505	chr19:56672574~56673901:-
TGCT	trans	rs2950393	0.804	rs1466382	ENSG00000121089.4	NACA3P	-8.88	6.36e-15	1.17e-07	-0.78	-0.62	Platelet distribution width;	chr12:56723050	chr4:164943290~164943937:+
TGCT	trans	rs916888	0.61	rs199436	ENSG00000263503.1	RP11-707O23.5	-8.88	6.39e-15	1.18e-07	-0.8	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45600869~45602340:-
TGCT	trans	rs9611519	0.78	rs1983631	ENSG00000268568.1	AC007228.9	-8.88	6.4e-15	1.18e-07	-0.75	-0.62	Neuroticism;	chr22:41248070	chr19:56672574~56673901:-
TGCT	trans	rs9611519	0.78	rs5751071	ENSG00000268568.1	AC007228.9	-8.86	7.04e-15	1.29e-07	-0.74	-0.62	Neuroticism;	chr22:41260328	chr19:56672574~56673901:-
TGCT	trans	rs7554547	0.778	rs2008113	ENSG00000261819.1	RP11-680G24.4	-8.86	7.22e-15	1.32e-07	-0.73	-0.62	Nonsyndromic cleft lip with cleft palate;	chr1:11878809	chr16:14988259~14990160:-
TGCT	trans	rs13190036	0.892	rs71601339	ENSG00000217325.2	PRELID1P1	-8.85	7.36e-15	1.35e-07	-0.83	-0.62	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117495	chr6:126643488~126644390:+
TGCT	trans	rs55665837	0.559	rs9667144	ENSG00000236360.2	RP11-334A14.2	-8.83	8.3e-15	1.52e-07	-0.72	-0.62	Vitamin D levels;	chr11:14399555	chr1:52993201~52993702:-
TGCT	trans	rs13190036	1	rs13177748	ENSG00000217325.2	PRELID1P1	-8.81	9.31e-15	1.7e-07	-0.84	-0.62	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177216953	chr6:126643488~126644390:+
TGCT	trans	rs13190036	1	rs34832871	ENSG00000217325.2	PRELID1P1	-8.81	9.31e-15	1.7e-07	-0.84	-0.62	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228928	chr6:126643488~126644390:+
TGCT	trans	rs9611519	0.78	rs2235850	ENSG00000268568.1	AC007228.9	-8.81	9.43e-15	1.72e-07	-0.73	-0.62	Neuroticism;	chr22:41261622	chr19:56672574~56673901:-
TGCT	trans	rs9611519	0.761	rs35445172	ENSG00000268568.1	AC007228.9	-8.81	9.43e-15	1.72e-07	-0.73	-0.62	Neuroticism;	chr22:41264297	chr19:56672574~56673901:-
TGCT	trans	rs916888	0.61	rs199453	ENSG00000263503.1	RP11-707O23.5	8.8	9.97e-15	1.81e-07	0.82	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45600869~45602340:-
TGCT	trans	rs916888	0.61	rs199452	ENSG00000263503.1	RP11-707O23.5	8.8	9.97e-15	1.81e-07	0.82	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45600869~45602340:-
TGCT	trans	rs9611519	0.78	rs2284079	ENSG00000268568.1	AC007228.9	-8.79	1.05e-14	1.9e-07	-0.73	-0.62	Neuroticism;	chr22:41262628	chr19:56672574~56673901:-
TGCT	trans	rs7554547	0.667	rs59952418	ENSG00000261819.1	RP11-680G24.4	8.79	1.05e-14	1.91e-07	0.78	0.62	Nonsyndromic cleft lip with cleft palate;	chr1:11878153	chr16:14988259~14990160:-
TGCT	trans	rs13190036	1	rs28580074	ENSG00000217325.2	PRELID1P1	8.78	1.09e-14	1.97e-07	0.87	0.62	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177294197	chr6:126643488~126644390:+
TGCT	trans	rs916888	0.821	rs70600	ENSG00000214425.5	LRRC37A4P	-8.78	1.1e-14	1.98e-07	-0.82	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45506741~45550335:-
TGCT	trans	rs916888	0.821	rs199512	ENSG00000214425.5	LRRC37A4P	8.78	1.1e-14	1.98e-07	0.82	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45506741~45550335:-
TGCT	trans	rs916888	0.821	rs199509	ENSG00000214425.5	LRRC37A4P	8.78	1.1e-14	1.98e-07	0.82	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45506741~45550335:-
TGCT	trans	rs916888	0.821	rs199507	ENSG00000214425.5	LRRC37A4P	8.78	1.1e-14	1.98e-07	0.82	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45506741~45550335:-
TGCT	trans	rs916888	0.821	rs199506	ENSG00000214425.5	LRRC37A4P	8.78	1.1e-14	1.98e-07	0.82	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45506741~45550335:-
TGCT	trans	rs916888	0.821	rs415430	ENSG00000214425.5	LRRC37A4P	8.78	1.1e-14	1.98e-07	0.82	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45506741~45550335:-
TGCT	trans	rs916888	0.779	rs430685	ENSG00000214425.5	LRRC37A4P	8.78	1.1e-14	1.98e-07	0.82	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45506741~45550335:-
TGCT	trans	rs916888	0.821	rs199505	ENSG00000214425.5	LRRC37A4P	8.78	1.1e-14	1.98e-07	0.82	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45506741~45550335:-
TGCT	trans	rs916888	0.821	rs70602	ENSG00000214425.5	LRRC37A4P	8.78	1.1e-14	1.98e-07	0.82	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45506741~45550335:-
TGCT	trans	rs7121616	0.92	rs7109445	ENSG00000234176.1	HSPA8P1	8.78	1.11e-14	1.99e-07	0.77	0.62	Breast cancer;	chr11:123094779	chrX:121203182~121205014:-
TGCT	trans	rs916888	0.821	rs199504	ENSG00000214425.5	LRRC37A4P	8.78	1.12e-14	2.01e-07	0.82	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45506741~45550335:-
TGCT	trans	rs877636	1	rs877636	ENSG00000243403.1	RP11-330L19.1	-8.78	1.12e-14	2.02e-07	-0.77	-0.62	Cognitive function;	chr12:56086799	chr15:64592979~64593326:+
TGCT	trans	rs13190036	1	rs4976682	ENSG00000217325.2	PRELID1P1	8.77	1.15e-14	2.06e-07	0.86	0.62	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177299001	chr6:126643488~126644390:+
TGCT	trans	rs13190036	0.901	rs28563911	ENSG00000217325.2	PRELID1P1	8.77	1.15e-14	2.06e-07	0.87	0.62	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177287942	chr6:126643488~126644390:+
TGCT	trans	rs916888	0.647	rs199449	ENSG00000264070.1	DND1P1	8.76	1.23e-14	2.2e-07	0.97	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45585871~45586929:+
TGCT	trans	rs12709013	0.636	rs30835	ENSG00000230849.2	GOT2P2	8.75	1.27e-14	2.28e-07	0.73	0.62	Blood metabolite ratios;	chr16:58714117	chr1:173141100~173142350:-
TGCT	trans	rs916888	0.61	rs199454	ENSG00000263503.1	RP11-707O23.5	-8.73	1.45e-14	2.58e-07	-0.82	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45600869~45602340:-
TGCT	trans	rs877636	1	rs705696	ENSG00000235459.5	RPS26P31	8.72	1.54e-14	2.75e-07	0.79	0.62	Cognitive function;	chr12:56086864	chr7:122681315~122681662:+
TGCT	trans	rs6477998	0.535	rs4979232	ENSG00000238072.1	RP11-305M3.2	-8.72	1.55e-14	2.77e-07	-0.79	-0.62	Hematology traits;	chr9:113286594	chr7:129410113~129410370:-
TGCT	trans	rs916888	0.61	rs199446	ENSG00000263503.1	RP11-707O23.5	-8.7	1.74e-14	3.08e-07	-0.82	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45600869~45602340:-
TGCT	trans	rs916888	0.61	rs199536	ENSG00000263503.1	RP11-707O23.5	-8.7	1.74e-14	3.08e-07	-0.82	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45600869~45602340:-
TGCT	trans	rs55665837	0.559	rs11023210	ENSG00000236360.2	RP11-334A14.2	-8.68	1.92e-14	3.39e-07	-0.71	-0.61	Vitamin D levels;	chr11:14401216	chr1:52993201~52993702:-
TGCT	trans	rs55665837	0.559	rs11023209	ENSG00000236360.2	RP11-334A14.2	8.68	1.92e-14	3.4e-07	0.71	0.61	Vitamin D levels;	chr11:14401054	chr1:52993201~52993702:-
TGCT	trans	rs916888	0.738	rs199515	ENSG00000214425.5	LRRC37A4P	8.67	1.95e-14	3.46e-07	0.82	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45506741~45550335:-
TGCT	trans	rs941207	0.542	rs4277148	ENSG00000121089.4	NACA3P	-8.67	1.99e-14	3.49e-07	-0.81	-0.61	Platelet count;	chr12:56787071	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.542	rs12370142	ENSG00000121089.4	NACA3P	-8.67	1.99e-14	3.49e-07	-0.81	-0.61	Platelet count;	chr12:56790801	chr4:164943290~164943937:+
TGCT	trans	rs12367822	0.956	rs9706160	ENSG00000121089.4	NACA3P	-8.67	1.99e-14	3.49e-07	-0.81	-0.61	Platelet aggregation;	chr12:56791119	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.542	rs2888095	ENSG00000121089.4	NACA3P	-8.67	1.99e-14	3.49e-07	-0.81	-0.61	Platelet count;	chr12:56793689	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.542	rs2888096	ENSG00000121089.4	NACA3P	-8.67	1.99e-14	3.49e-07	-0.81	-0.61	Platelet count;	chr12:56793851	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.542	rs6581106	ENSG00000121089.4	NACA3P	-8.67	1.99e-14	3.49e-07	-0.81	-0.61	Platelet count;	chr12:56796759	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.542	rs7311381	ENSG00000121089.4	NACA3P	-8.67	1.99e-14	3.49e-07	-0.81	-0.61	Platelet count;	chr12:56800286	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.542	rs2126068	ENSG00000121089.4	NACA3P	-8.67	1.99e-14	3.49e-07	-0.81	-0.61	Platelet count;	chr12:56804716	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.542	rs67808059	ENSG00000121089.4	NACA3P	-8.67	1.99e-14	3.49e-07	-0.81	-0.61	Platelet count;	chr12:56805228	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.542	rs11171980	ENSG00000121089.4	NACA3P	-8.67	1.99e-14	3.49e-07	-0.81	-0.61	Platelet count;	chr12:56806397	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.542	rs12366897	ENSG00000121089.4	NACA3P	-8.67	1.99e-14	3.49e-07	-0.81	-0.61	Platelet count;	chr12:56808329	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.542	rs12367312	ENSG00000121089.4	NACA3P	-8.67	1.99e-14	3.49e-07	-0.81	-0.61	Platelet count;	chr12:56809369	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.542	rs12367339	ENSG00000121089.4	NACA3P	-8.67	1.99e-14	3.49e-07	-0.81	-0.61	Platelet count;	chr12:56809521	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.542	rs12367822	ENSG00000121089.4	NACA3P	-8.67	1.99e-14	3.49e-07	-0.81	-0.61	Platelet count;	chr12:56810376	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.542	rs11171983	ENSG00000121089.4	NACA3P	-8.67	1.99e-14	3.49e-07	-0.81	-0.61	Platelet count;	chr12:56814461	chr4:164943290~164943937:+
TGCT	trans	rs1816752	0.774	rs55888616	ENSG00000237917.1	PARP4P1	8.66	2.11e-14	3.7e-07	0.75	0.61	Obesity-related traits;	chr13:24441954	chrY:26594851~26634652:-
TGCT	trans	rs916888	0.647	rs199524	ENSG00000264070.1	DND1P1	-8.65	2.28e-14	3.99e-07	-0.95	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45585871~45586929:+
TGCT	trans	rs916888	0.647	rs199523	ENSG00000264070.1	DND1P1	-8.65	2.28e-14	3.99e-07	-0.95	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45585871~45586929:+
TGCT	trans	rs13190036	0.901	rs28684504	ENSG00000217325.2	PRELID1P1	8.64	2.31e-14	4.04e-07	0.83	0.61	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177300437	chr6:126643488~126644390:+
TGCT	trans	rs916888	0.61	rs199444	ENSG00000264070.1	DND1P1	8.64	2.38e-14	4.16e-07	0.97	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45585871~45586929:+
TGCT	trans	rs13190036	0.901	rs28715668	ENSG00000217325.2	PRELID1P1	8.64	2.42e-14	4.23e-07	0.86	0.61	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272267	chr6:126643488~126644390:+
TGCT	trans	rs7554547	0.69	rs9661078	ENSG00000261819.1	RP11-680G24.4	8.63	2.53e-14	4.43e-07	0.77	0.61	Nonsyndromic cleft lip with cleft palate;	chr1:11876267	chr16:14988259~14990160:-
TGCT	trans	rs1816752	0.905	rs7571	ENSG00000237917.1	PARP4P1	8.62	2.56e-14	4.47e-07	0.72	0.61	Obesity-related traits;	chr13:24426479	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.905	rs9511266	ENSG00000237917.1	PARP4P1	8.62	2.61e-14	4.53e-07	0.72	0.61	Obesity-related traits;	chr13:24438366	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.817	rs7985394	ENSG00000237917.1	PARP4P1	8.62	2.61e-14	4.53e-07	0.72	0.61	Obesity-related traits;	chr13:24438714	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.789	rs7986037	ENSG00000237917.1	PARP4P1	8.62	2.61e-14	4.53e-07	0.72	0.61	Obesity-related traits;	chr13:24438715	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.905	rs7995909	ENSG00000237917.1	PARP4P1	8.62	2.61e-14	4.53e-07	0.72	0.61	Obesity-related traits;	chr13:24439159	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.905	rs6490927	ENSG00000237917.1	PARP4P1	8.62	2.61e-14	4.53e-07	0.72	0.61	Obesity-related traits;	chr13:24439802	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.905	rs6490928	ENSG00000237917.1	PARP4P1	8.62	2.61e-14	4.53e-07	0.72	0.61	Obesity-related traits;	chr13:24439921	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.905	rs6490929	ENSG00000237917.1	PARP4P1	8.62	2.61e-14	4.53e-07	0.72	0.61	Obesity-related traits;	chr13:24440114	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.87	rs3825449	ENSG00000237917.1	PARP4P1	8.62	2.61e-14	4.53e-07	0.72	0.61	Obesity-related traits;	chr13:24440303	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.87	rs7998797	ENSG00000237917.1	PARP4P1	8.62	2.61e-14	4.53e-07	0.72	0.61	Obesity-related traits;	chr13:24440850	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.87	rs7981337	ENSG00000237917.1	PARP4P1	8.62	2.61e-14	4.53e-07	0.72	0.61	Obesity-related traits;	chr13:24440915	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.87	rs7981480	ENSG00000237917.1	PARP4P1	8.62	2.61e-14	4.53e-07	0.72	0.61	Obesity-related traits;	chr13:24440966	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.837	rs4769355	ENSG00000237917.1	PARP4P1	8.62	2.61e-14	4.53e-07	0.72	0.61	Obesity-related traits;	chr13:24441059	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.905	rs4770680	ENSG00000237917.1	PARP4P1	8.62	2.61e-14	4.53e-07	0.72	0.61	Obesity-related traits;	chr13:24441110	chrY:26594851~26634652:-
TGCT	trans	rs941207	0.542	rs6581107	ENSG00000121089.4	NACA3P	-8.61	2.75e-14	4.76e-07	-0.8	-0.61	Platelet count;	chr12:56801197	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.542	rs1870674	ENSG00000121089.4	NACA3P	-8.61	2.75e-14	4.76e-07	-0.8	-0.61	Platelet count;	chr12:56805721	chr4:164943290~164943937:+
TGCT	trans	rs1707322	0.686	rs2050376	ENSG00000255397.1	AC022182.2	-8.61	2.77e-14	4.79e-07	-0.79	-0.61	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr8:60937705~60939871:-
TGCT	trans	rs2950393	0.895	rs2926740	ENSG00000121089.4	NACA3P	8.61	2.77e-14	4.79e-07	0.78	0.61	Platelet distribution width;	chr12:56666751	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.526	rs7303216	ENSG00000121089.4	NACA3P	8.61	2.77e-14	4.79e-07	0.78	0.61	Platelet count;	chr12:56680909	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.507	rs7297289	ENSG00000121089.4	NACA3P	8.61	2.77e-14	4.79e-07	0.78	0.61	Platelet count;	chr12:56682703	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.526	rs4759028	ENSG00000121089.4	NACA3P	8.61	2.77e-14	4.79e-07	0.78	0.61	Platelet count;	chr12:56686399	chr4:164943290~164943937:+
TGCT	trans	rs2950393	0.927	rs11171914	ENSG00000121089.4	NACA3P	-8.59	3.11e-14	5.33e-07	-0.77	-0.61	Platelet distribution width;	chr12:56649462	chr4:164943290~164943937:+
TGCT	trans	rs13190036	1	rs13185316	ENSG00000217325.2	PRELID1P1	-8.58	3.29e-14	5.62e-07	-0.83	-0.61	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177213339	chr6:126643488~126644390:+
TGCT	trans	rs7647973	0.506	rs11920251	ENSG00000197582.5	GPX1P1	8.58	3.29e-14	5.63e-07	0.77	0.61	Menarche (age at onset);	chr3:49319238	chrX:13378735~13379340:-
TGCT	trans	rs2950393	0.804	rs1026565	ENSG00000121089.4	NACA3P	8.58	3.31e-14	5.65e-07	0.75	0.61	Platelet distribution width;	chr12:56744044	chr4:164943290~164943937:+
TGCT	trans	rs1816752	0.87	rs9511261	ENSG00000237917.1	PARP4P1	8.57	3.46e-14	5.9e-07	0.71	0.61	Obesity-related traits;	chr13:24437880	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.905	rs9511262	ENSG00000237917.1	PARP4P1	8.57	3.46e-14	5.9e-07	0.71	0.61	Obesity-related traits;	chr13:24437885	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.87	rs7320102	ENSG00000237917.1	PARP4P1	8.55	3.78e-14	6.43e-07	0.71	0.61	Obesity-related traits;	chr13:24437435	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.905	rs7339140	ENSG00000237917.1	PARP4P1	8.55	3.78e-14	6.43e-07	0.71	0.61	Obesity-related traits;	chr13:24437764	chrY:26594851~26634652:-
TGCT	trans	rs9899728	0.764	rs7219493	ENSG00000234925.2	ATP5HP4	8.55	3.81e-14	6.47e-07	0.93	0.61	Alzheimer's disease or small vessel stroke;	chr17:75048093	chr12:68642519~68642993:-
TGCT	trans	rs9899728	0.665	rs2307008	ENSG00000234925.2	ATP5HP4	8.55	3.87e-14	6.58e-07	0.93	0.61	Alzheimer's disease or small vessel stroke;	chr17:75046587	chr12:68642519~68642993:-
TGCT	trans	rs13253073	0.55	rs6468697	ENSG00000260318.1	COX6CP1	8.54	3.98e-14	6.75e-07	0.89	0.61	Glucose homeostasis traits;	chr8:99858154	chr16:11903923~11904137:-
TGCT	trans	rs916888	0.61	rs199442	ENSG00000264070.1	DND1P1	8.54	4.01e-14	6.79e-07	0.96	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45585871~45586929:+
TGCT	trans	rs1816752	0.875	rs1050110	ENSG00000237917.1	PARP4P1	8.54	4.11e-14	6.95e-07	0.72	0.61	Obesity-related traits;	chr13:24435347	chrY:26594851~26634652:-
TGCT	trans	rs9611519	0.78	rs9611528	ENSG00000268568.1	AC007228.9	-8.53	4.36e-14	7.36e-07	-0.72	-0.61	Neuroticism;	chr22:41252498	chr19:56672574~56673901:-
TGCT	trans	rs55665837	0.524	rs61884009	ENSG00000236360.2	RP11-334A14.2	8.52	4.41e-14	7.45e-07	0.7	0.61	Vitamin D levels;	chr11:14404916	chr1:52993201~52993702:-
TGCT	trans	rs916888	0.647	rs199449	ENSG00000214425.5	LRRC37A4P	-8.52	4.46e-14	7.53e-07	-0.71	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45506741~45550335:-
TGCT	trans	rs877636	0.669	rs7297175	ENSG00000225071.1	GS1-184P14.2	-8.52	4.51e-14	7.61e-07	-0.65	-0.61	Cognitive function;	chr12:56080024	chrX:24429573~24429920:-
TGCT	trans	rs1816752	0.905	rs1050112	ENSG00000237917.1	PARP4P1	8.52	4.53e-14	7.63e-07	0.72	0.61	Obesity-related traits;	chr13:24435159	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.905	rs13428	ENSG00000237917.1	PARP4P1	8.52	4.53e-14	7.63e-07	0.72	0.61	Obesity-related traits;	chr13:24435303	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.87	rs8000215	ENSG00000237917.1	PARP4P1	8.52	4.53e-14	7.63e-07	0.72	0.61	Obesity-related traits;	chr13:24435648	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.905	rs11839006	ENSG00000237917.1	PARP4P1	8.52	4.53e-14	7.63e-07	0.72	0.61	Obesity-related traits;	chr13:24435893	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.87	rs2033955	ENSG00000237917.1	PARP4P1	8.52	4.53e-14	7.63e-07	0.72	0.61	Obesity-related traits;	chr13:24436406	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.87	rs2033954	ENSG00000237917.1	PARP4P1	8.52	4.53e-14	7.63e-07	0.72	0.61	Obesity-related traits;	chr13:24436429	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.905	rs9511260	ENSG00000237917.1	PARP4P1	8.52	4.53e-14	7.63e-07	0.72	0.61	Obesity-related traits;	chr13:24437038	chrY:26594851~26634652:-
TGCT	trans	rs7312770	0.637	rs705700	ENSG00000243403.1	RP11-330L19.1	8.51	4.66e-14	7.84e-07	0.71	0.61	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr15:64592979~64593326:+
TGCT	trans	rs13177918	0.798	rs13182116	ENSG00000224114.1	RP11-343H5.4	-8.51	4.66e-14	7.84e-07	-0.89	-0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:206695837~206696269:-
TGCT	trans	rs616147	0.627	rs816487	ENSG00000183298.5	RP11-556K13.1	-8.5	5.06e-14	8.46e-07	-0.81	-0.61	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39445999	chr1:101786340~101787219:-
TGCT	trans	rs1816752	0.87	rs73469543	ENSG00000237917.1	PARP4P1	8.5	5.13e-14	8.58e-07	0.71	0.61	Obesity-related traits;	chr13:24424832	chrY:26594851~26634652:-
TGCT	trans	rs616147	0.616	rs1768234	ENSG00000183298.5	RP11-556K13.1	-8.49	5.31e-14	8.84e-07	-0.81	-0.61	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39459821	chr1:101786340~101787219:-
TGCT	trans	rs941207	0.526	rs11171916	ENSG00000121089.4	NACA3P	-8.49	5.36e-14	8.93e-07	-0.77	-0.61	Platelet count;	chr12:56653236	chr4:164943290~164943937:+
TGCT	trans	rs12497850	0.627	rs4974078	ENSG00000197582.5	GPX1P1	8.49	5.38e-14	8.96e-07	0.67	0.61	Parkinson's disease;	chr3:48971953	chrX:13378735~13379340:-
TGCT	trans	rs1816752	0.638	rs9578730	ENSG00000237917.1	PARP4P1	8.49	5.38e-14	8.96e-07	0.71	0.61	Obesity-related traits;	chr13:24425545	chrY:26594851~26634652:-
TGCT	trans	rs616147	0.655	rs1707981	ENSG00000183298.5	RP11-556K13.1	-8.48	5.66e-14	9.39e-07	-0.81	-0.61	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461015	chr1:101786340~101787219:-
TGCT	trans	rs616147	0.72	rs1768209	ENSG00000183298.5	RP11-556K13.1	-8.48	5.66e-14	9.39e-07	-0.81	-0.61	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461184	chr1:101786340~101787219:-
TGCT	trans	rs616147	0.72	rs2965067	ENSG00000183298.5	RP11-556K13.1	-8.48	5.66e-14	9.39e-07	-0.81	-0.61	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461546	chr1:101786340~101787219:-
TGCT	trans	rs8010715	0.816	rs11574503	ENSG00000248988.1	RP11-815N9.2	-8.47	5.8e-14	9.62e-07	-0.77	-0.61	IgG glycosylation;	chr14:24132109	chr4:159007119~159007835:+
TGCT	trans	rs2950393	0.857	rs1563896	ENSG00000121089.4	NACA3P	8.47	5.84e-14	9.68e-07	0.77	0.61	Platelet distribution width;	chr12:56699312	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.542	rs1813109	ENSG00000121089.4	NACA3P	-8.47	5.84e-14	9.68e-07	-0.8	-0.61	Platelet count;	chr12:56798079	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.542	rs7315786	ENSG00000121089.4	NACA3P	-8.47	5.84e-14	9.68e-07	-0.8	-0.61	Platelet count;	chr12:56801595	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.542	rs1903370	ENSG00000121089.4	NACA3P	-8.47	5.84e-14	9.68e-07	-0.8	-0.61	Platelet count;	chr12:56812900	chr4:164943290~164943937:+
TGCT	trans	rs916888	0.61	rs199444	ENSG00000214425.5	LRRC37A4P	-8.47	5.95e-14	9.86e-07	-0.71	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45506741~45550335:-
TGCT	trans	rs2657294	0.62	rs7903537	ENSG00000172974.11	AC007318.5	8.47	5.96e-14	9.86e-07	0.74	0.61	Pneumonia;	chr10:75087732	chr2:65205108~65205988:+
TGCT	trans	rs2657294	0.62	rs2395136	ENSG00000172974.11	AC007318.5	8.47	5.96e-14	9.86e-07	0.74	0.61	Pneumonia;	chr10:75088213	chr2:65205108~65205988:+
TGCT	trans	rs941207	0.526	rs2950390	ENSG00000121089.4	NACA3P	8.46	6.31e-14	1.03e-06	0.76	0.6	Platelet count;	chr12:56661507	chr4:164943290~164943937:+
TGCT	trans	rs2950393	0.895	rs2958154	ENSG00000121089.4	NACA3P	-8.46	6.31e-14	1.03e-06	-0.76	-0.6	Platelet distribution width;	chr12:56671929	chr4:164943290~164943937:+
TGCT	trans	rs61990749	0.571	rs2364841	ENSG00000235400.1	RP4-641G12.4	8.45	6.52e-14	1.06e-06	1.08	0.6	Fibroblast growth factor basic levels;	chr14:77817693	chr1:78749073~78750659:+
TGCT	trans	rs6477998	0.535	rs10817475	ENSG00000238072.1	RP11-305M3.2	8.45	6.77e-14	1.1e-06	0.81	0.6	Hematology traits;	chr9:113296774	chr7:129410113~129410370:-
TGCT	trans	rs6477998	0.9	rs7850357	ENSG00000238072.1	RP11-305M3.2	8.44	6.85e-14	1.11e-06	0.72	0.6	Hematology traits;	chr9:113222319	chr7:129410113~129410370:-
TGCT	trans	rs6477998	0.874	rs10739390	ENSG00000238072.1	RP11-305M3.2	8.44	6.85e-14	1.11e-06	0.72	0.6	Hematology traits;	chr9:113226209	chr7:129410113~129410370:-
TGCT	trans	rs877636	1	rs4759229	ENSG00000243403.1	RP11-330L19.1	-8.44	6.98e-14	1.13e-06	-0.74	-0.6	Cognitive function;	chr12:56080696	chr15:64592979~64593326:+
TGCT	trans	rs7554547	0.667	rs12065911	ENSG00000261819.1	RP11-680G24.4	8.43	7.37e-14	1.19e-06	0.82	0.6	Nonsyndromic cleft lip with cleft palate;	chr1:11908323	chr16:14988259~14990160:-
TGCT	trans	rs2657294	0.62	rs2395132	ENSG00000172974.11	AC007318.5	8.43	7.47e-14	1.21e-06	0.7	0.6	Pneumonia;	chr10:75080840	chr2:65205108~65205988:+
TGCT	trans	rs7312770	0.612	rs1873914	ENSG00000235459.5	RPS26P31	8.43	7.47e-14	1.21e-06	0.7	0.6	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr7:122681315~122681662:+
TGCT	trans	rs7554547	0.714	rs4845890	ENSG00000261819.1	RP11-680G24.4	8.43	7.51e-14	1.22e-06	0.81	0.6	Nonsyndromic cleft lip with cleft palate;	chr1:11912612	chr16:14988259~14990160:-
TGCT	trans	rs3749237	1	rs11130214	ENSG00000197582.5	GPX1P1	-8.42	8.02e-14	1.29e-06	-0.81	-0.6	Resting heart rate;	chr3:49698313	chrX:13378735~13379340:-
TGCT	trans	rs3749237	1	rs2291542	ENSG00000197582.5	GPX1P1	8.41	8.43e-14	1.36e-06	0.83	0.6	Resting heart rate;	chr3:49714152	chrX:13378735~13379340:-
TGCT	trans	rs916888	0.531	rs183211	ENSG00000263503.1	RP11-707O23.5	8.4	8.69e-14	1.4e-06	0.79	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45600869~45602340:-
TGCT	trans	rs3749237	1	rs11710675	ENSG00000197582.5	GPX1P1	8.39	9.07e-14	1.46e-06	0.82	0.6	Resting heart rate;	chr3:49714467	chrX:13378735~13379340:-
TGCT	trans	rs7554547	0.714	rs926269	ENSG00000261819.1	RP11-680G24.4	8.39	9.19e-14	1.47e-06	0.82	0.6	Nonsyndromic cleft lip with cleft palate;	chr1:11909691	chr16:14988259~14990160:-
TGCT	trans	rs877636	0.859	rs3741499	ENSG00000243403.1	RP11-330L19.1	-8.38	9.85e-14	1.58e-06	-0.74	-0.6	Cognitive function;	chr12:56080595	chr15:64592979~64593326:+
TGCT	trans	rs13190036	1	rs625882	ENSG00000217325.2	PRELID1P1	-8.37	1.01e-13	1.61e-06	-0.79	-0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177108030	chr6:126643488~126644390:+
TGCT	trans	rs13190036	1	rs17078781	ENSG00000217325.2	PRELID1P1	-8.37	1.01e-13	1.62e-06	-0.81	-0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117227	chr6:126643488~126644390:+
TGCT	trans	rs941207	0.542	rs6581102	ENSG00000121089.4	NACA3P	-8.37	1.03e-13	1.64e-06	-0.79	-0.6	Platelet count;	chr12:56790632	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.542	rs6581103	ENSG00000121089.4	NACA3P	-8.37	1.03e-13	1.64e-06	-0.79	-0.6	Platelet count;	chr12:56790641	chr4:164943290~164943937:+
TGCT	trans	rs916888	0.61	rs199442	ENSG00000214425.5	LRRC37A4P	-8.37	1.03e-13	1.65e-06	-0.7	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45506741~45550335:-
TGCT	trans	rs1816752	1	rs9511265	ENSG00000237917.1	PARP4P1	8.36	1.06e-13	1.69e-06	0.72	0.6	Obesity-related traits;	chr13:24438221	chrY:26594851~26634652:-
TGCT	trans	rs7312770	0.637	rs705699	ENSG00000243403.1	RP11-330L19.1	8.36	1.06e-13	1.69e-06	0.7	0.6	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr15:64592979~64593326:+
TGCT	trans	rs13190036	1	rs628506	ENSG00000217325.2	PRELID1P1	-8.36	1.09e-13	1.74e-06	-0.79	-0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107422	chr6:126643488~126644390:+
TGCT	trans	rs9899728	0.764	rs9660	ENSG00000234925.2	ATP5HP4	8.34	1.18e-13	1.87e-06	0.92	0.6	Alzheimer's disease or small vessel stroke;	chr17:75042651	chr12:68642519~68642993:-
TGCT	trans	rs9611519	0.78	rs2235849	ENSG00000268568.1	AC007228.9	-8.34	1.21e-13	1.92e-06	-0.71	-0.6	Neuroticism;	chr22:41257536	chr19:56672574~56673901:-
TGCT	trans	rs2950393	0.804	rs1131514	ENSG00000121089.4	NACA3P	-8.33	1.29e-13	2.04e-06	-0.7	-0.6	Platelet distribution width;	chr12:56739356	chr4:164943290~164943937:+
TGCT	trans	rs13190036	0.901	rs6556309	ENSG00000217325.2	PRELID1P1	8.33	1.29e-13	2.05e-06	0.77	0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266834	chr6:126643488~126644390:+
TGCT	trans	rs2950393	0.804	rs2290894	ENSG00000121089.4	NACA3P	8.31	1.4e-13	2.22e-06	0.75	0.6	Platelet distribution width;	chr12:56714911	chr4:164943290~164943937:+
TGCT	trans	rs2950393	0.777	rs2926747	ENSG00000121089.4	NACA3P	8.31	1.4e-13	2.22e-06	0.75	0.6	Platelet distribution width;	chr12:56716147	chr4:164943290~164943937:+
TGCT	trans	rs2950393	0.804	rs3214051	ENSG00000121089.4	NACA3P	8.31	1.4e-13	2.22e-06	0.75	0.6	Platelet distribution width;	chr12:56725452	chr4:164943290~164943937:+
TGCT	trans	rs6477998	0.934	rs4979223	ENSG00000238072.1	RP11-305M3.2	8.3	1.47e-13	2.33e-06	0.71	0.6	Hematology traits;	chr9:113219836	chr7:129410113~129410370:-
TGCT	trans	rs916888	0.61	rs199530	ENSG00000263503.1	RP11-707O23.5	-8.3	1.51e-13	2.39e-06	-0.78	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45600869~45602340:-
TGCT	trans	rs6477998	0.513	rs10981720	ENSG00000238072.1	RP11-305M3.2	8.3	1.52e-13	2.39e-06	0.81	0.6	Hematology traits;	chr9:113293831	chr7:129410113~129410370:-
TGCT	trans	rs6477998	0.903	rs4979226	ENSG00000238072.1	RP11-305M3.2	8.3	1.52e-13	2.41e-06	0.71	0.6	Hematology traits;	chr9:113239516	chr7:129410113~129410370:-
TGCT	trans	rs9611519	0.929	rs9611465	ENSG00000268568.1	AC007228.9	-8.3	1.54e-13	2.42e-06	-0.75	-0.6	Neuroticism;	chr22:41030135	chr19:56672574~56673901:-
TGCT	trans	rs9611519	0.929	rs9611466	ENSG00000268568.1	AC007228.9	-8.3	1.54e-13	2.42e-06	-0.75	-0.6	Neuroticism;	chr22:41030295	chr19:56672574~56673901:-
TGCT	trans	rs9611519	0.929	rs12484477	ENSG00000268568.1	AC007228.9	-8.3	1.54e-13	2.42e-06	-0.75	-0.6	Neuroticism;	chr22:41033080	chr19:56672574~56673901:-
TGCT	trans	rs9611519	0.929	rs4820423	ENSG00000268568.1	AC007228.9	-8.3	1.54e-13	2.42e-06	-0.75	-0.6	Neuroticism;	chr22:41034334	chr19:56672574~56673901:-
TGCT	trans	rs9611519	0.929	rs9611469	ENSG00000268568.1	AC007228.9	-8.3	1.54e-13	2.42e-06	-0.75	-0.6	Neuroticism;	chr22:41037315	chr19:56672574~56673901:-
TGCT	trans	rs9611519	0.929	rs73174657	ENSG00000268568.1	AC007228.9	-8.3	1.54e-13	2.42e-06	-0.75	-0.6	Neuroticism;	chr22:41038154	chr19:56672574~56673901:-
TGCT	trans	rs9611519	0.929	rs9611474	ENSG00000268568.1	AC007228.9	-8.3	1.54e-13	2.42e-06	-0.75	-0.6	Neuroticism;	chr22:41038854	chr19:56672574~56673901:-
TGCT	trans	rs9611519	0.929	rs926914	ENSG00000268568.1	AC007228.9	-8.29	1.57e-13	2.46e-06	-0.74	-0.6	Neuroticism;	chr22:41022150	chr19:56672574~56673901:-
TGCT	trans	rs7554547	0.714	rs2878679	ENSG00000261819.1	RP11-680G24.4	8.29	1.57e-13	2.48e-06	0.81	0.6	Nonsyndromic cleft lip with cleft palate;	chr1:11915586	chr16:14988259~14990160:-
TGCT	trans	rs941207	0.542	rs11171979	ENSG00000121089.4	NACA3P	-8.29	1.58e-13	2.49e-06	-0.76	-0.6	Platelet count;	chr12:56802199	chr4:164943290~164943937:+
TGCT	trans	rs7312770	0.637	rs705700	ENSG00000225071.1	GS1-184P14.2	8.29	1.59e-13	2.51e-06	0.67	0.6	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chrX:24429573~24429920:-
TGCT	trans	rs916888	0.61	rs142167	ENSG00000263503.1	RP11-707O23.5	-8.29	1.6e-13	2.52e-06	-0.8	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45600869~45602340:-
TGCT	trans	rs7554547	0.905	rs4993564	ENSG00000261819.1	RP11-680G24.4	8.28	1.69e-13	2.65e-06	0.75	0.6	Nonsyndromic cleft lip with cleft palate;	chr1:11909934	chr16:14988259~14990160:-
TGCT	trans	rs7647973	0.621	rs3774800	ENSG00000197582.5	GPX1P1	-8.27	1.79e-13	2.8e-06	-0.76	-0.6	Menarche (age at onset);	chr3:49297335	chrX:13378735~13379340:-
TGCT	trans	rs1816752	1	rs7999554	ENSG00000237917.1	PARP4P1	8.26	1.83e-13	2.86e-06	0.71	0.6	Obesity-related traits;	chr13:24435631	chrY:26594851~26634652:-
TGCT	trans	rs7312770	0.637	rs705699	ENSG00000225071.1	GS1-184P14.2	8.26	1.89e-13	2.96e-06	0.67	0.6	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chrX:24429573~24429920:-
TGCT	trans	rs13190036	0.551	rs1052432	ENSG00000217325.2	PRELID1P1	-8.25	2e-13	3.13e-06	-0.76	-0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177137188	chr6:126643488~126644390:+
TGCT	trans	rs2657294	0.62	rs7475340	ENSG00000172974.11	AC007318.5	8.24	2.03e-13	3.16e-06	0.69	0.6	Pneumonia;	chr10:75079597	chr2:65205108~65205988:+
TGCT	trans	rs877636	1	rs877636	ENSG00000225071.1	GS1-184P14.2	-8.24	2.04e-13	3.18e-06	-0.71	-0.59	Cognitive function;	chr12:56086799	chrX:24429573~24429920:-
TGCT	trans	rs916888	0.61	rs199436	ENSG00000214425.5	LRRC37A4P	8.24	2.04e-13	3.19e-06	0.66	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45506741~45550335:-
TGCT	trans	rs916888	0.61	rs199453	ENSG00000214425.5	LRRC37A4P	-8.24	2.07e-13	3.22e-06	-0.68	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45506741~45550335:-
TGCT	trans	rs916888	0.61	rs199452	ENSG00000214425.5	LRRC37A4P	-8.24	2.07e-13	3.22e-06	-0.68	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45506741~45550335:-
TGCT	trans	rs916888	0.61	rs199453	ENSG00000264070.1	DND1P1	8.24	2.08e-13	3.24e-06	0.92	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45585871~45586929:+
TGCT	trans	rs916888	0.61	rs199452	ENSG00000264070.1	DND1P1	8.24	2.08e-13	3.24e-06	0.92	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45585871~45586929:+
TGCT	trans	rs12291225	0.883	rs1864658	ENSG00000236360.2	RP11-334A14.2	-8.24	2.1e-13	3.27e-06	-0.72	-0.59	Sense of smell;	chr11:14234898	chr1:52993201~52993702:-
TGCT	trans	rs2950393	0.777	rs7966391	ENSG00000121089.4	NACA3P	8.22	2.25e-13	3.49e-06	0.74	0.59	Platelet distribution width;	chr12:56745272	chr4:164943290~164943937:+
TGCT	trans	rs7554547	0.667	rs11121839	ENSG00000261819.1	RP11-680G24.4	8.22	2.35e-13	3.66e-06	0.81	0.59	Nonsyndromic cleft lip with cleft palate;	chr1:11908280	chr16:14988259~14990160:-
TGCT	trans	rs916888	0.61	rs142167	ENSG00000214425.5	LRRC37A4P	8.21	2.39e-13	3.7e-06	0.69	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45506741~45550335:-
TGCT	trans	rs1816752	0.905	rs9511264	ENSG00000237917.1	PARP4P1	-8.21	2.42e-13	3.75e-06	-0.69	-0.59	Obesity-related traits;	chr13:24438079	chrY:26594851~26634652:-
TGCT	trans	rs916888	0.61	rs199436	ENSG00000264070.1	DND1P1	-8.19	2.66e-13	4.12e-06	-0.89	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45585871~45586929:+
TGCT	trans	rs916888	0.647	rs199524	ENSG00000214425.5	LRRC37A4P	8.19	2.72e-13	4.2e-06	0.68	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45506741~45550335:-
TGCT	trans	rs916888	0.647	rs199523	ENSG00000214425.5	LRRC37A4P	8.19	2.72e-13	4.2e-06	0.68	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45506741~45550335:-
TGCT	trans	rs877636	1	rs2292239	ENSG00000243403.1	RP11-330L19.1	8.17	2.97e-13	4.59e-06	0.73	0.59	Cognitive function;	chr12:56088396	chr15:64592979~64593326:+
TGCT	trans	rs13190036	0.792	rs6874206	ENSG00000217325.2	PRELID1P1	-8.16	3.21e-13	4.93e-06	-0.76	-0.59	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177223970	chr6:126643488~126644390:+
TGCT	trans	rs13190036	0.901	rs10072499	ENSG00000217325.2	PRELID1P1	-8.16	3.21e-13	4.93e-06	-0.76	-0.59	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228236	chr6:126643488~126644390:+
TGCT	trans	rs8010715	0.564	rs10146643	ENSG00000248988.1	RP11-815N9.2	8.16	3.21e-13	4.93e-06	0.76	0.59	IgG glycosylation;	chr14:24120261	chr4:159007119~159007835:+
TGCT	trans	rs1707322	0.686	rs1541131	ENSG00000255397.1	AC022182.2	8.16	3.22e-13	4.95e-06	0.76	0.59	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr8:60937705~60939871:-
TGCT	trans	rs13190036	1	rs6880798	ENSG00000217325.2	PRELID1P1	8.15	3.31e-13	5.07e-06	0.84	0.59	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177277456	chr6:126643488~126644390:+
TGCT	trans	rs8010715	0.771	rs2277481	ENSG00000248988.1	RP11-815N9.2	8.15	3.34e-13	5.11e-06	0.75	0.59	IgG glycosylation;	chr14:24118336	chr4:159007119~159007835:+
TGCT	trans	rs1707322	0.686	rs2991986	ENSG00000255397.1	AC022182.2	8.15	3.35e-13	5.12e-06	0.78	0.59	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr8:60937705~60939871:-
TGCT	trans	rs13190036	1	rs655623	ENSG00000217325.2	PRELID1P1	8.15	3.37e-13	5.15e-06	0.8	0.59	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107515	chr6:126643488~126644390:+
TGCT	trans	rs1707322	0.686	rs1547924	ENSG00000255397.1	AC022182.2	-8.15	3.37e-13	5.15e-06	-0.77	-0.59	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.686	rs3014251	ENSG00000255397.1	AC022182.2	8.15	3.37e-13	5.15e-06	0.77	0.59	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.686	rs2230658	ENSG00000255397.1	AC022182.2	8.15	3.37e-13	5.15e-06	0.77	0.59	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.686	rs2230659	ENSG00000255397.1	AC022182.2	8.15	3.37e-13	5.15e-06	0.77	0.59	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.686	rs2991987	ENSG00000255397.1	AC022182.2	8.15	3.37e-13	5.15e-06	0.77	0.59	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr8:60937705~60939871:-
TGCT	trans	rs7312770	0.612	rs773114	ENSG00000243403.1	RP11-330L19.1	8.14	3.5e-13	5.34e-06	0.68	0.59	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr15:64592979~64593326:+
TGCT	trans	rs7312770	1	rs7312770	ENSG00000235459.5	RPS26P31	-8.14	3.55e-13	5.42e-06	-0.63	-0.59	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr7:122681315~122681662:+
TGCT	trans	rs916888	0.61	rs199454	ENSG00000214425.5	LRRC37A4P	8.14	3.56e-13	5.43e-06	0.68	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45506741~45550335:-
TGCT	trans	rs9611519	0.894	rs9611486	ENSG00000268568.1	AC007228.9	-8.13	3.72e-13	5.66e-06	-0.72	-0.59	Neuroticism;	chr22:41062780	chr19:56672574~56673901:-
TGCT	trans	rs9611519	0.894	rs13053242	ENSG00000268568.1	AC007228.9	-8.13	3.72e-13	5.66e-06	-0.72	-0.59	Neuroticism;	chr22:41063482	chr19:56672574~56673901:-
TGCT	trans	rs916888	0.779	rs199498	ENSG00000263503.1	RP11-707O23.5	8.11	4.25e-13	6.45e-06	0.83	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45600869~45602340:-
TGCT	trans	rs12709013	0.729	rs1657179	ENSG00000230849.2	GOT2P2	8.1	4.4e-13	6.65e-06	0.7	0.59	Blood metabolite ratios;	chr16:58735115	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.792	rs1473206	ENSG00000230849.2	GOT2P2	8.1	4.4e-13	6.65e-06	0.7	0.59	Blood metabolite ratios;	chr16:58737529	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.792	rs1473205	ENSG00000230849.2	GOT2P2	8.1	4.4e-13	6.65e-06	0.7	0.59	Blood metabolite ratios;	chr16:58737547	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.694	rs1616798	ENSG00000230849.2	GOT2P2	8.1	4.4e-13	6.65e-06	0.7	0.59	Blood metabolite ratios;	chr16:58739433	chr1:173141100~173142350:-
TGCT	trans	rs1816752	1	rs9507341	ENSG00000237917.1	PARP4P1	-8.09	4.67e-13	7.02e-06	-0.69	-0.59	Obesity-related traits;	chr13:24432440	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.935	rs4770676	ENSG00000237917.1	PARP4P1	8.09	4.67e-13	7.02e-06	0.69	0.59	Obesity-related traits;	chr13:24429745	chrY:26594851~26634652:-
TGCT	trans	rs1816752	1	rs7326932	ENSG00000237917.1	PARP4P1	8.09	4.67e-13	7.02e-06	0.69	0.59	Obesity-related traits;	chr13:24430355	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.87	rs9581025	ENSG00000237917.1	PARP4P1	8.08	4.77e-13	7.17e-06	0.68	0.59	Obesity-related traits;	chr13:24423687	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.87	rs9581027	ENSG00000237917.1	PARP4P1	8.08	4.77e-13	7.17e-06	0.68	0.59	Obesity-related traits;	chr13:24423790	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.87	rs9318529	ENSG00000237917.1	PARP4P1	8.08	4.77e-13	7.17e-06	0.68	0.59	Obesity-related traits;	chr13:24424190	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.905	rs9511249	ENSG00000237917.1	PARP4P1	8.08	4.77e-13	7.17e-06	0.68	0.59	Obesity-related traits;	chr13:24425457	chrY:26594851~26634652:-
TGCT	trans	rs2731664	0.756	rs4976695	ENSG00000215571.5	GRK6P1	8.08	4.99e-13	7.48e-06	0.72	0.59	Intelligence (multi-trait analysis);	chr5:177435962	chr13:21319156~21320866:+
TGCT	trans	rs2731664	0.792	rs179809	ENSG00000215571.5	GRK6P1	8.08	4.99e-13	7.48e-06	0.72	0.59	Intelligence (multi-trait analysis);	chr5:177438328	chr13:21319156~21320866:+
TGCT	trans	rs9611519	0.894	rs9611488	ENSG00000268568.1	AC007228.9	-8.08	5.02e-13	7.52e-06	-0.71	-0.59	Neuroticism;	chr22:41066588	chr19:56672574~56673901:-
TGCT	trans	rs1816752	0.905	rs9581026	ENSG00000237917.1	PARP4P1	8.07	5.11e-13	7.64e-06	0.68	0.59	Obesity-related traits;	chr13:24423788	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.905	rs7991450	ENSG00000237917.1	PARP4P1	8.07	5.16e-13	7.7e-06	0.67	0.59	Obesity-related traits;	chr13:24425898	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.774	rs7986162	ENSG00000237917.1	PARP4P1	8.07	5.16e-13	7.7e-06	0.67	0.59	Obesity-related traits;	chr13:24425941	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.905	rs4769352	ENSG00000237917.1	PARP4P1	8.07	5.16e-13	7.7e-06	0.67	0.59	Obesity-related traits;	chr13:24426237	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.805	rs4769353	ENSG00000237917.1	PARP4P1	8.07	5.16e-13	7.7e-06	0.67	0.59	Obesity-related traits;	chr13:24426318	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.837	rs7324645	ENSG00000237917.1	PARP4P1	8.07	5.16e-13	7.7e-06	0.67	0.59	Obesity-related traits;	chr13:24426717	chrY:26594851~26634652:-
TGCT	trans	rs916888	0.61	rs199446	ENSG00000214425.5	LRRC37A4P	8.07	5.23e-13	7.79e-06	0.68	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45506741~45550335:-
TGCT	trans	rs916888	0.61	rs199536	ENSG00000214425.5	LRRC37A4P	8.07	5.23e-13	7.79e-06	0.68	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45506741~45550335:-
TGCT	trans	rs1816752	0.905	rs7317850	ENSG00000237917.1	PARP4P1	8.06	5.39e-13	8.02e-06	0.69	0.59	Obesity-related traits;	chr13:24419899	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.719	rs11841989	ENSG00000237917.1	PARP4P1	8.05	5.69e-13	8.45e-06	0.69	0.59	Obesity-related traits;	chr13:24423560	chrY:26594851~26634652:-
TGCT	trans	rs7554547	0.69	rs4846064	ENSG00000261819.1	RP11-680G24.4	8.05	5.71e-13	8.46e-06	0.71	0.59	Nonsyndromic cleft lip with cleft palate;	chr1:11874785	chr16:14988259~14990160:-
TGCT	trans	rs7121616	0.961	rs11218976	ENSG00000234176.1	HSPA8P1	8.05	5.88e-13	8.7e-06	0.74	0.59	Breast cancer;	chr11:123090950	chrX:121203182~121205014:-
TGCT	trans	rs1816752	0.905	rs9511242	ENSG00000237917.1	PARP4P1	8.05	5.9e-13	8.73e-06	0.7	0.59	Obesity-related traits;	chr13:24419261	chrY:26594851~26634652:-
TGCT	trans	rs8010715	0.816	rs762093	ENSG00000248988.1	RP11-815N9.2	8.04	6.2e-13	9.15e-06	0.73	0.59	IgG glycosylation;	chr14:24122709	chr4:159007119~159007835:+
TGCT	trans	rs8010715	0.785	rs2877611	ENSG00000248988.1	RP11-815N9.2	8.04	6.2e-13	9.15e-06	0.73	0.59	IgG glycosylation;	chr14:24126221	chr4:159007119~159007835:+
TGCT	trans	rs8010715	0.816	rs7153156	ENSG00000248988.1	RP11-815N9.2	8.04	6.2e-13	9.15e-06	0.73	0.59	IgG glycosylation;	chr14:24129637	chr4:159007119~159007835:+
TGCT	trans	rs8010715	0.816	rs6573572	ENSG00000248988.1	RP11-815N9.2	8.04	6.2e-13	9.15e-06	0.73	0.59	IgG glycosylation;	chr14:24130021	chr4:159007119~159007835:+
TGCT	trans	rs8010715	0.816	rs8015168	ENSG00000248988.1	RP11-815N9.2	8.04	6.2e-13	9.15e-06	0.73	0.59	IgG glycosylation;	chr14:24130663	chr4:159007119~159007835:+
TGCT	trans	rs8010715	0.816	rs6573565	ENSG00000248988.1	RP11-815N9.2	-8.04	6.2e-13	9.15e-06	-0.73	-0.59	IgG glycosylation;	chr14:24125524	chr4:159007119~159007835:+
TGCT	trans	rs7554547	0.791	rs6665662	ENSG00000261819.1	RP11-680G24.4	8.03	6.28e-13	9.24e-06	0.75	0.59	Nonsyndromic cleft lip with cleft palate;	chr1:11891804	chr16:14988259~14990160:-
TGCT	trans	rs7554547	0.791	rs34117126	ENSG00000261819.1	RP11-680G24.4	8.03	6.28e-13	9.24e-06	0.75	0.59	Nonsyndromic cleft lip with cleft palate;	chr1:11892138	chr16:14988259~14990160:-
TGCT	trans	rs7554547	0.791	rs17037520	ENSG00000261819.1	RP11-680G24.4	8.03	6.28e-13	9.24e-06	0.75	0.59	Nonsyndromic cleft lip with cleft palate;	chr1:11892349	chr16:14988259~14990160:-
TGCT	trans	rs7554547	0.791	rs12749498	ENSG00000261819.1	RP11-680G24.4	8.03	6.28e-13	9.24e-06	0.75	0.59	Nonsyndromic cleft lip with cleft palate;	chr1:11892570	chr16:14988259~14990160:-
TGCT	trans	rs7554547	0.791	rs12036266	ENSG00000261819.1	RP11-680G24.4	8.03	6.28e-13	9.24e-06	0.75	0.59	Nonsyndromic cleft lip with cleft palate;	chr1:11893257	chr16:14988259~14990160:-
TGCT	trans	rs7554547	0.791	rs2065611	ENSG00000261819.1	RP11-680G24.4	8.03	6.28e-13	9.24e-06	0.75	0.59	Nonsyndromic cleft lip with cleft palate;	chr1:11893469	chr16:14988259~14990160:-
TGCT	trans	rs7554547	0.791	rs4492637	ENSG00000261819.1	RP11-680G24.4	8.03	6.28e-13	9.24e-06	0.75	0.59	Nonsyndromic cleft lip with cleft palate;	chr1:11895787	chr16:14988259~14990160:-
TGCT	trans	rs7554547	0.791	rs4846074	ENSG00000261819.1	RP11-680G24.4	8.03	6.28e-13	9.24e-06	0.75	0.59	Nonsyndromic cleft lip with cleft palate;	chr1:11896172	chr16:14988259~14990160:-
TGCT	trans	rs7554547	0.791	rs4846076	ENSG00000261819.1	RP11-680G24.4	8.03	6.28e-13	9.24e-06	0.75	0.59	Nonsyndromic cleft lip with cleft palate;	chr1:11896708	chr16:14988259~14990160:-
TGCT	trans	rs2657294	0.62	rs9783273	ENSG00000172974.11	AC007318.5	8.03	6.37e-13	9.37e-06	0.69	0.58	Pneumonia;	chr10:75081982	chr2:65205108~65205988:+
TGCT	trans	rs2657294	0.62	rs4746259	ENSG00000172974.11	AC007318.5	8.03	6.37e-13	9.37e-06	0.69	0.58	Pneumonia;	chr10:75082310	chr2:65205108~65205988:+
TGCT	trans	rs10940346	0.936	rs303219	ENSG00000231752.4	EMBP1	8.03	6.47e-13	9.5e-06	0.63	0.58	Schizophrenia;	chr5:50407795	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.846	rs2663076	ENSG00000231752.4	EMBP1	8.03	6.47e-13	9.5e-06	0.63	0.58	Schizophrenia;	chr5:50430593	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.934	rs303231	ENSG00000231752.4	EMBP1	8.03	6.47e-13	9.5e-06	0.63	0.58	Schizophrenia;	chr5:50447369	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.935	rs2353959	ENSG00000231752.4	EMBP1	-8.03	6.47e-13	9.5e-06	-0.63	-0.58	Schizophrenia;	chr5:50473217	chr1:121519112~121571892:+
TGCT	trans	rs7312770	0.612	rs773114	ENSG00000225071.1	GS1-184P14.2	8.03	6.53e-13	9.58e-06	0.65	0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chrX:24429573~24429920:-
TGCT	trans	rs10940346	0.934	rs2353960	ENSG00000231752.4	EMBP1	-8.03	6.56e-13	9.61e-06	-0.63	-0.58	Schizophrenia;	chr5:50481153	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.935	rs4971258	ENSG00000231752.4	EMBP1	-8.03	6.56e-13	9.61e-06	-0.63	-0.58	Schizophrenia;	chr5:50498560	chr1:121519112~121571892:+
TGCT	trans	rs9611519	0.929	rs4820425	ENSG00000268568.1	AC007228.9	-8.02	6.69e-13	9.79e-06	-0.74	-0.58	Neuroticism;	chr22:41035338	chr19:56672574~56673901:-
TGCT	trans	rs7312770	1	rs7312770	ENSG00000243403.1	RP11-330L19.1	-8.02	6.89e-13	1.01e-05	-0.62	-0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr15:64592979~64593326:+
TGCT	trans	rs916888	0.531	rs183211	ENSG00000214425.5	LRRC37A4P	-8.01	7.02e-13	1.03e-05	-0.67	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45506741~45550335:-
TGCT	trans	rs7554547	0.69	rs12087996	ENSG00000261819.1	RP11-680G24.4	8.01	7.12e-13	1.04e-05	0.81	0.58	Nonsyndromic cleft lip with cleft palate;	chr1:11897152	chr16:14988259~14990160:-
TGCT	trans	rs616147	0.548	rs2370965	ENSG00000183298.5	RP11-556K13.1	-8.01	7.16e-13	1.04e-05	-0.75	-0.58	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39448996	chr1:101786340~101787219:-
TGCT	trans	rs13190036	0.901	rs4631	ENSG00000217325.2	PRELID1P1	8.01	7.18e-13	1.05e-05	0.84	0.58	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177306115	chr6:126643488~126644390:+
TGCT	trans	rs2731664	0.792	rs335452	ENSG00000215571.5	GRK6P1	8.01	7.18e-13	1.05e-05	0.69	0.58	Intelligence (multi-trait analysis);	chr5:177452670	chr13:21319156~21320866:+
TGCT	trans	rs2731664	0.792	rs385981	ENSG00000215571.5	GRK6P1	8.01	7.18e-13	1.05e-05	0.69	0.58	Intelligence (multi-trait analysis);	chr5:177459538	chr13:21319156~21320866:+
TGCT	trans	rs2731664	0.792	rs465670	ENSG00000215571.5	GRK6P1	8	7.5e-13	1.09e-05	0.69	0.58	Intelligence (multi-trait analysis);	chr5:177450623	chr13:21319156~21320866:+
TGCT	trans	rs9611519	0.828	rs28814423	ENSG00000268568.1	AC007228.9	-8	7.53e-13	1.09e-05	-0.71	-0.58	Neuroticism;	chr22:41056297	chr19:56672574~56673901:-
TGCT	trans	rs1707322	0.721	rs10430124	ENSG00000255397.1	AC022182.2	-8	7.59e-13	1.1e-05	-0.78	-0.58	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr8:60937705~60939871:-
TGCT	trans	rs877636	0.692	rs11171739	ENSG00000212994.5	RPS26P6	7.99	7.75e-13	1.13e-05	0.6	0.58	Cognitive function;	chr12:56076841	chr8:100895771~100896118:+
TGCT	trans	rs916888	0.61	rs199438	ENSG00000214425.5	LRRC37A4P	-7.99	8.01e-13	1.16e-05	-0.67	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45506741~45550335:-
TGCT	trans	rs7554547	0.791	rs2064614	ENSG00000261819.1	RP11-680G24.4	7.99	8.03e-13	1.16e-05	0.75	0.58	Nonsyndromic cleft lip with cleft palate;	chr1:11893883	chr16:14988259~14990160:-
TGCT	trans	rs616147	0.627	rs816510	ENSG00000183298.5	RP11-556K13.1	-7.99	8.04e-13	1.16e-05	-0.75	-0.58	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39430804	chr1:101786340~101787219:-
TGCT	trans	rs877636	1	rs4759229	ENSG00000225071.1	GS1-184P14.2	-7.98	8.2e-13	1.18e-05	-0.69	-0.58	Cognitive function;	chr12:56080696	chrX:24429573~24429920:-
TGCT	trans	rs13190036	1	rs13175695	ENSG00000217325.2	PRELID1P1	7.98	8.24e-13	1.19e-05	0.78	0.58	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272810	chr6:126643488~126644390:+
TGCT	trans	rs2950393	0.804	rs7980317	ENSG00000121089.4	NACA3P	7.98	8.34e-13	1.2e-05	0.72	0.58	Platelet distribution width;	chr12:56764399	chr4:164943290~164943937:+
TGCT	trans	rs2950393	0.804	rs898609	ENSG00000121089.4	NACA3P	7.98	8.36e-13	1.2e-05	0.72	0.58	Platelet distribution width;	chr12:56713026	chr4:164943290~164943937:+
TGCT	trans	rs2950393	0.804	rs4902	ENSG00000121089.4	NACA3P	7.98	8.36e-13	1.2e-05	0.72	0.58	Platelet distribution width;	chr12:56714419	chr4:164943290~164943937:+
TGCT	trans	rs2950393	0.804	rs2926748	ENSG00000121089.4	NACA3P	7.98	8.36e-13	1.2e-05	0.72	0.58	Platelet distribution width;	chr12:56715628	chr4:164943290~164943937:+
TGCT	trans	rs2950393	0.804	rs2035081	ENSG00000121089.4	NACA3P	7.98	8.36e-13	1.2e-05	0.72	0.58	Platelet distribution width;	chr12:56732095	chr4:164943290~164943937:+
TGCT	trans	rs2950393	0.804	rs10783796	ENSG00000121089.4	NACA3P	7.98	8.36e-13	1.2e-05	0.72	0.58	Platelet distribution width;	chr12:56733387	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.762	rs10450	ENSG00000121089.4	NACA3P	7.98	8.45e-13	1.22e-05	0.71	0.58	Platelet count;	chr12:56590822	chr4:164943290~164943937:+
TGCT	trans	rs7554547	0.765	rs2050270	ENSG00000261819.1	RP11-680G24.4	7.97	8.72e-13	1.25e-05	0.76	0.58	Nonsyndromic cleft lip with cleft palate;	chr1:11886399	chr16:14988259~14990160:-
TGCT	trans	rs7554547	0.739	rs2050269	ENSG00000261819.1	RP11-680G24.4	7.97	8.72e-13	1.25e-05	0.76	0.58	Nonsyndromic cleft lip with cleft palate;	chr1:11886432	chr16:14988259~14990160:-
TGCT	trans	rs7554547	0.765	rs2050268	ENSG00000261819.1	RP11-680G24.4	7.97	8.72e-13	1.25e-05	0.76	0.58	Nonsyndromic cleft lip with cleft palate;	chr1:11886487	chr16:14988259~14990160:-
TGCT	trans	rs7554547	0.765	rs2050267	ENSG00000261819.1	RP11-680G24.4	7.97	8.72e-13	1.25e-05	0.76	0.58	Nonsyndromic cleft lip with cleft palate;	chr1:11886516	chr16:14988259~14990160:-
TGCT	trans	rs2950393	0.804	rs2958127	ENSG00000121089.4	NACA3P	7.97	8.84e-13	1.27e-05	0.7	0.58	Platelet distribution width;	chr12:56720523	chr4:164943290~164943937:+
TGCT	trans	rs2731664	0.792	rs335432	ENSG00000215571.5	GRK6P1	7.97	8.86e-13	1.27e-05	0.71	0.58	Intelligence (multi-trait analysis);	chr5:177439257	chr13:21319156~21320866:+
TGCT	trans	rs941207	0.542	rs10876928	ENSG00000121089.4	NACA3P	-7.97	9.04e-13	1.29e-05	-0.74	-0.58	Platelet count;	chr12:56813646	chr4:164943290~164943937:+
TGCT	trans	rs1816752	0.633	rs9578729	ENSG00000237917.1	PARP4P1	7.97	9.06e-13	1.29e-05	0.68	0.58	Obesity-related traits;	chr13:24425106	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.87	rs9581029	ENSG00000237917.1	PARP4P1	7.97	9.06e-13	1.29e-05	0.68	0.58	Obesity-related traits;	chr13:24425147	chrY:26594851~26634652:-
TGCT	trans	rs616147	0.671	rs674192	ENSG00000183298.5	RP11-556K13.1	-7.97	9.06e-13	1.29e-05	-0.75	-0.58	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458653	chr1:101786340~101787219:-
TGCT	trans	rs616147	0.671	rs675595	ENSG00000183298.5	RP11-556K13.1	-7.97	9.06e-13	1.29e-05	-0.75	-0.58	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458987	chr1:101786340~101787219:-
TGCT	trans	rs877636	0.702	rs61937249	ENSG00000235459.5	RPS26P31	7.96	9.34e-13	1.33e-05	0.73	0.58	Cognitive function;	chr12:55988132	chr7:122681315~122681662:+
TGCT	trans	rs1707322	0.717	rs1972410	ENSG00000255397.1	AC022182.2	-7.96	9.51e-13	1.36e-05	-0.79	-0.58	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr8:60937705~60939871:-
TGCT	trans	rs916888	0.61	rs199454	ENSG00000264070.1	DND1P1	-7.96	9.51e-13	1.36e-05	-0.9	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45585871~45586929:+
TGCT	trans	rs7554547	0.667	rs4304595	ENSG00000261819.1	RP11-680G24.4	7.96	9.54e-13	1.36e-05	0.8	0.58	Nonsyndromic cleft lip with cleft palate;	chr1:11886332	chr16:14988259~14990160:-
TGCT	trans	rs2950393	0.804	rs2926752	ENSG00000121089.4	NACA3P	7.95	9.58e-13	1.37e-05	0.74	0.58	Platelet distribution width;	chr12:56710144	chr4:164943290~164943937:+
TGCT	trans	rs2950393	0.777	rs2958148	ENSG00000121089.4	NACA3P	7.95	9.58e-13	1.37e-05	0.74	0.58	Platelet distribution width;	chr12:56710153	chr4:164943290~164943937:+
TGCT	trans	rs9611519	0.929	rs73174660	ENSG00000268568.1	AC007228.9	-7.95	9.75e-13	1.39e-05	-0.71	-0.58	Neuroticism;	chr22:41041300	chr19:56672574~56673901:-
TGCT	trans	rs9611519	0.929	rs12484971	ENSG00000268568.1	AC007228.9	-7.95	9.75e-13	1.39e-05	-0.71	-0.58	Neuroticism;	chr22:41043300	chr19:56672574~56673901:-
TGCT	trans	rs9611519	0.929	rs13055800	ENSG00000268568.1	AC007228.9	-7.95	9.75e-13	1.39e-05	-0.71	-0.58	Neuroticism;	chr22:41044420	chr19:56672574~56673901:-
TGCT	trans	rs9611519	0.929	rs4821991	ENSG00000268568.1	AC007228.9	-7.95	9.75e-13	1.39e-05	-0.71	-0.58	Neuroticism;	chr22:41044679	chr19:56672574~56673901:-
TGCT	trans	rs10242455	0.702	rs917152	ENSG00000228834.1	RP11-249L21.4	7.94	1.01e-12	1.44e-05	1.51	0.58	Blood metabolite levels;	chr7:99406874	chr6:108907615~108907873:-
TGCT	trans	rs877636	0.74	rs772920	ENSG00000235459.5	RPS26P31	7.94	1.03e-12	1.45e-05	0.73	0.58	Cognitive function;	chr12:55996580	chr7:122681315~122681662:+
TGCT	trans	rs2950393	0.929	rs2958155	ENSG00000121089.4	NACA3P	7.94	1.03e-12	1.46e-05	0.75	0.58	Platelet distribution width;	chr12:56670761	chr4:164943290~164943937:+
TGCT	trans	rs2950393	0.929	rs7980835	ENSG00000121089.4	NACA3P	7.94	1.03e-12	1.46e-05	0.75	0.58	Platelet distribution width;	chr12:56676847	chr4:164943290~164943937:+
TGCT	trans	rs2950393	0.929	rs10747769	ENSG00000121089.4	NACA3P	7.94	1.03e-12	1.46e-05	0.75	0.58	Platelet distribution width;	chr12:56677056	chr4:164943290~164943937:+
TGCT	trans	rs1707322	0.686	rs1250	ENSG00000255397.1	AC022182.2	-7.94	1.05e-12	1.48e-05	-0.76	-0.58	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr8:60937705~60939871:-
TGCT	trans	rs74781061	1	rs6495116	ENSG00000227288.3	RP5-837I24.1	7.93	1.08e-12	1.5e-05	0.64	0.58	Endometriosis;	chr15:74593607	chr1:81501794~81503468:+
TGCT	trans	rs2731664	0.756	rs2545796	ENSG00000215571.5	GRK6P1	7.93	1.1e-12	1.52e-05	0.69	0.58	Intelligence (multi-trait analysis);	chr5:177437268	chr13:21319156~21320866:+
TGCT	trans	rs2731664	0.792	rs652242	ENSG00000215571.5	GRK6P1	7.93	1.1e-12	1.52e-05	0.69	0.58	Intelligence (multi-trait analysis);	chr5:177446009	chr13:21319156~21320866:+
TGCT	trans	rs7647973	0.516	rs4955418	ENSG00000197582.5	GPX1P1	7.93	1.11e-12	1.53e-05	0.73	0.58	Menarche (age at onset);	chr3:49163194	chrX:13378735~13379340:-
TGCT	trans	rs7647973	0.516	rs4499638	ENSG00000197582.5	GPX1P1	7.93	1.11e-12	1.53e-05	0.73	0.58	Menarche (age at onset);	chr3:49165349	chrX:13378735~13379340:-
TGCT	trans	rs616147	0.627	rs9871799	ENSG00000183298.5	RP11-556K13.1	7.93	1.12e-12	1.54e-05	0.74	0.58	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr1:101786340~101787219:-
TGCT	trans	rs1707322	0.686	rs3014242	ENSG00000255397.1	AC022182.2	7.92	1.13e-12	1.55e-05	0.76	0.58	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.686	rs3014239	ENSG00000255397.1	AC022182.2	7.92	1.13e-12	1.55e-05	0.76	0.58	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.686	rs3014236	ENSG00000255397.1	AC022182.2	7.92	1.13e-12	1.55e-05	0.76	0.58	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr8:60937705~60939871:-
TGCT	trans	rs2731664	0.792	rs2544809	ENSG00000215571.5	GRK6P1	7.92	1.15e-12	1.59e-05	0.68	0.58	Intelligence (multi-trait analysis);	chr5:177458498	chr13:21319156~21320866:+
TGCT	trans	rs877636	0.74	rs705702	ENSG00000235459.5	RPS26P31	-7.92	1.15e-12	1.59e-05	-0.72	-0.58	Cognitive function;	chr12:55996852	chr7:122681315~122681662:+
TGCT	trans	rs12291225	0.877	rs11023160	ENSG00000236360.2	RP11-334A14.2	7.92	1.15e-12	1.59e-05	0.81	0.58	Sense of smell;	chr11:14242679	chr1:52993201~52993702:-
TGCT	trans	rs6477998	0.868	rs10513189	ENSG00000238072.1	RP11-305M3.2	7.92	1.16e-12	1.6e-05	0.68	0.58	Hematology traits;	chr9:113227941	chr7:129410113~129410370:-
TGCT	trans	rs1816752	0.819	rs7985478	ENSG00000237917.1	PARP4P1	7.92	1.17e-12	1.61e-05	0.7	0.58	Obesity-related traits;	chr13:24417135	chrY:26594851~26634652:-
TGCT	trans	rs877636	0.702	rs773110	ENSG00000235459.5	RPS26P31	7.92	1.17e-12	1.61e-05	0.72	0.58	Cognitive function;	chr12:55981353	chr7:122681315~122681662:+
TGCT	trans	rs877636	0.702	rs773111	ENSG00000235459.5	RPS26P31	7.92	1.17e-12	1.61e-05	0.72	0.58	Cognitive function;	chr12:55981956	chr7:122681315~122681662:+
TGCT	trans	rs877636	0.702	rs773112	ENSG00000235459.5	RPS26P31	7.92	1.17e-12	1.61e-05	0.72	0.58	Cognitive function;	chr12:55982097	chr7:122681315~122681662:+
TGCT	trans	rs916888	0.61	rs199438	ENSG00000263503.1	RP11-707O23.5	7.91	1.21e-12	1.66e-05	0.77	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45600869~45602340:-
TGCT	trans	rs877636	0.74	rs705698	ENSG00000235459.5	RPS26P31	7.91	1.23e-12	1.69e-05	0.73	0.58	Cognitive function;	chr12:55990903	chr7:122681315~122681662:+
TGCT	trans	rs2950393	0.804	rs898611	ENSG00000121089.4	NACA3P	-7.9	1.26e-12	1.72e-05	-0.7	-0.58	Platelet distribution width;	chr12:56769532	chr4:164943290~164943937:+
TGCT	trans	rs10242455	0.702	rs17161726	ENSG00000228834.1	RP11-249L21.4	7.9	1.27e-12	1.75e-05	1.3	0.58	Blood metabolite levels;	chr7:99410772	chr6:108907615~108907873:-
TGCT	trans	rs2950393	0.804	rs7967600	ENSG00000121089.4	NACA3P	7.9	1.3e-12	1.77e-05	0.72	0.58	Platelet distribution width;	chr12:56768208	chr4:164943290~164943937:+
TGCT	trans	rs941207	0.526	rs2950393	ENSG00000121089.4	NACA3P	-7.9	1.31e-12	1.79e-05	-0.75	-0.58	Platelet count;	chr12:56642239	chr4:164943290~164943937:+
TGCT	trans	rs2950393	0.804	rs2958130	ENSG00000121089.4	NACA3P	7.89	1.33e-12	1.82e-05	0.72	0.58	Platelet distribution width;	chr12:56746722	chr4:164943290~164943937:+
TGCT	trans	rs2950393	0.804	rs2958132	ENSG00000121089.4	NACA3P	7.89	1.33e-12	1.82e-05	0.72	0.58	Platelet distribution width;	chr12:56750749	chr4:164943290~164943937:+
TGCT	trans	rs2731664	0.792	rs2731662	ENSG00000215571.5	GRK6P1	-7.89	1.36e-12	1.86e-05	-0.67	-0.58	Intelligence (multi-trait analysis);	chr5:177445493	chr13:21319156~21320866:+
TGCT	trans	rs2731664	0.792	rs335466	ENSG00000215571.5	GRK6P1	7.89	1.39e-12	1.89e-05	0.68	0.58	Intelligence (multi-trait analysis);	chr5:177462529	chr13:21319156~21320866:+
TGCT	trans	rs10242455	0.702	rs73397447	ENSG00000228834.1	RP11-249L21.4	7.88	1.39e-12	1.89e-05	1.52	0.58	Blood metabolite levels;	chr7:99413326	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs73397481	ENSG00000228834.1	RP11-249L21.4	7.88	1.39e-12	1.89e-05	1.52	0.58	Blood metabolite levels;	chr7:99432485	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.557	rs34943973	ENSG00000228834.1	RP11-249L21.4	7.88	1.39e-12	1.89e-05	1.52	0.58	Blood metabolite levels;	chr7:99434894	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.557	rs2404487	ENSG00000228834.1	RP11-249L21.4	7.88	1.39e-12	1.89e-05	1.52	0.58	Blood metabolite levels;	chr7:99440434	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs73711280	ENSG00000228834.1	RP11-249L21.4	7.88	1.39e-12	1.89e-05	1.52	0.58	Blood metabolite levels;	chr7:99441981	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs73397499	ENSG00000228834.1	RP11-249L21.4	7.88	1.39e-12	1.89e-05	1.52	0.58	Blood metabolite levels;	chr7:99442004	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs45448997	ENSG00000228834.1	RP11-249L21.4	7.88	1.39e-12	1.89e-05	1.52	0.58	Blood metabolite levels;	chr7:99443975	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs112475236	ENSG00000228834.1	RP11-249L21.4	7.88	1.39e-12	1.89e-05	1.52	0.58	Blood metabolite levels;	chr7:99447056	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.557	rs45492501	ENSG00000228834.1	RP11-249L21.4	7.88	1.39e-12	1.89e-05	1.52	0.58	Blood metabolite levels;	chr7:99449407	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.557	rs45529541	ENSG00000228834.1	RP11-249L21.4	7.88	1.39e-12	1.89e-05	1.52	0.58	Blood metabolite levels;	chr7:99450520	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs3823813	ENSG00000228834.1	RP11-249L21.4	7.88	1.39e-12	1.89e-05	1.52	0.58	Blood metabolite levels;	chr7:99451766	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs17854665	ENSG00000228834.1	RP11-249L21.4	7.88	1.39e-12	1.89e-05	1.52	0.58	Blood metabolite levels;	chr7:99452416	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs45441991	ENSG00000228834.1	RP11-249L21.4	7.88	1.39e-12	1.89e-05	1.52	0.58	Blood metabolite levels;	chr7:99453364	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs45461000	ENSG00000228834.1	RP11-249L21.4	7.88	1.39e-12	1.89e-05	1.52	0.58	Blood metabolite levels;	chr7:99455087	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs78080383	ENSG00000228834.1	RP11-249L21.4	7.88	1.39e-12	1.89e-05	1.52	0.58	Blood metabolite levels;	chr7:99466842	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs73711293	ENSG00000228834.1	RP11-249L21.4	7.88	1.39e-12	1.89e-05	1.52	0.58	Blood metabolite levels;	chr7:99483972	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs73711294	ENSG00000228834.1	RP11-249L21.4	7.88	1.39e-12	1.89e-05	1.52	0.58	Blood metabolite levels;	chr7:99491091	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs73403247	ENSG00000228834.1	RP11-249L21.4	7.88	1.39e-12	1.89e-05	1.52	0.58	Blood metabolite levels;	chr7:99491107	chr6:108907615~108907873:-
TGCT	trans	rs2209875	0.588	rs7469084	ENSG00000234819.1	RP11-336N8.4	7.88	1.4e-12	1.89e-05	0.61	0.58	Pelvic organ prolapse (moderate/severe);	chr9:89366248	chr9:78219120~78219357:+
TGCT	trans	rs9611519	1	rs9611519	ENSG00000268568.1	AC007228.9	-7.88	1.4e-12	1.89e-05	-0.69	-0.58	Neuroticism;	chr22:41217184	chr19:56672574~56673901:-
TGCT	trans	rs9611519	1	rs9611520	ENSG00000268568.1	AC007228.9	-7.88	1.4e-12	1.89e-05	-0.69	-0.58	Neuroticism;	chr22:41217299	chr19:56672574~56673901:-
TGCT	trans	rs3749237	1	rs11130216	ENSG00000197582.5	GPX1P1	7.88	1.41e-12	1.91e-05	0.78	0.58	Resting heart rate;	chr3:49698739	chrX:13378735~13379340:-
TGCT	trans	rs3749237	1	rs6804655	ENSG00000197582.5	GPX1P1	7.88	1.41e-12	1.91e-05	0.78	0.58	Resting heart rate;	chr3:49701512	chrX:13378735~13379340:-
TGCT	trans	rs3749237	1	rs4768	ENSG00000197582.5	GPX1P1	7.88	1.41e-12	1.91e-05	0.78	0.58	Resting heart rate;	chr3:49721331	chrX:13378735~13379340:-
TGCT	trans	rs7647973	0.516	rs4536858	ENSG00000197582.5	GPX1P1	7.88	1.41e-12	1.91e-05	0.72	0.58	Menarche (age at onset);	chr3:49155648	chrX:13378735~13379340:-
TGCT	trans	rs7647973	0.516	rs12490393	ENSG00000197582.5	GPX1P1	7.88	1.41e-12	1.91e-05	0.72	0.58	Menarche (age at onset);	chr3:49158699	chrX:13378735~13379340:-
TGCT	trans	rs7647973	0.58	rs12637576	ENSG00000197582.5	GPX1P1	7.88	1.42e-12	1.92e-05	0.73	0.58	Menarche (age at onset);	chr3:49199901	chrX:13378735~13379340:-
TGCT	trans	rs2950393	0.804	rs7295862	ENSG00000121089.4	NACA3P	-7.88	1.43e-12	1.94e-05	-0.71	-0.58	Platelet distribution width;	chr12:56775374	chr4:164943290~164943937:+
TGCT	trans	rs7312770	1	rs7312770	ENSG00000212994.5	RPS26P6	-7.88	1.46e-12	1.97e-05	-0.58	-0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:100895771~100896118:+
TGCT	trans	rs7554547	0.667	rs12567187	ENSG00000261819.1	RP11-680G24.4	7.87	1.49e-12	2.01e-05	0.8	0.58	Nonsyndromic cleft lip with cleft palate;	chr1:11896095	chr16:14988259~14990160:-
TGCT	trans	rs13358908	0.715	rs10053628	ENSG00000231752.4	EMBP1	-7.87	1.5e-12	2.03e-05	-0.61	-0.58	Schizophrenia;	chr5:46383233	chr1:121519112~121571892:+
TGCT	trans	rs13177918	0.798	rs13182116	ENSG00000239528.1	RPS14P8	-7.86	1.6e-12	2.13e-05	-0.84	-0.58	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr5:116562562~116562930:+
TGCT	trans	rs7554547	0.765	rs4845886	ENSG00000261819.1	RP11-680G24.4	7.86	1.63e-12	2.16e-05	0.75	0.58	Nonsyndromic cleft lip with cleft palate;	chr1:11888603	chr16:14988259~14990160:-
TGCT	trans	rs7554547	0.791	rs4846069	ENSG00000261819.1	RP11-680G24.4	7.86	1.63e-12	2.16e-05	0.75	0.58	Nonsyndromic cleft lip with cleft palate;	chr1:11888974	chr16:14988259~14990160:-
TGCT	trans	rs7554547	0.791	rs11121837	ENSG00000261819.1	RP11-680G24.4	7.86	1.63e-12	2.16e-05	0.75	0.58	Nonsyndromic cleft lip with cleft palate;	chr1:11889414	chr16:14988259~14990160:-
TGCT	trans	rs7554547	0.765	rs4846070	ENSG00000261819.1	RP11-680G24.4	7.86	1.63e-12	2.16e-05	0.75	0.58	Nonsyndromic cleft lip with cleft palate;	chr1:11889464	chr16:14988259~14990160:-
TGCT	trans	rs7554547	0.739	rs61527718	ENSG00000261819.1	RP11-680G24.4	7.86	1.63e-12	2.16e-05	0.75	0.58	Nonsyndromic cleft lip with cleft palate;	chr1:11889583	chr16:14988259~14990160:-
TGCT	trans	rs7554547	0.714	rs4846071	ENSG00000261819.1	RP11-680G24.4	7.86	1.63e-12	2.16e-05	0.75	0.58	Nonsyndromic cleft lip with cleft palate;	chr1:11889612	chr16:14988259~14990160:-
TGCT	trans	rs7554547	0.69	rs7516708	ENSG00000261819.1	RP11-680G24.4	7.86	1.63e-12	2.16e-05	0.75	0.58	Nonsyndromic cleft lip with cleft palate;	chr1:11890148	chr16:14988259~14990160:-
TGCT	trans	rs7554547	0.739	rs4846073	ENSG00000261819.1	RP11-680G24.4	7.86	1.63e-12	2.16e-05	0.75	0.58	Nonsyndromic cleft lip with cleft palate;	chr1:11890521	chr16:14988259~14990160:-
TGCT	trans	rs7554547	0.791	rs57678332	ENSG00000261819.1	RP11-680G24.4	7.86	1.63e-12	2.16e-05	0.75	0.58	Nonsyndromic cleft lip with cleft palate;	chr1:11890834	chr16:14988259~14990160:-
TGCT	trans	rs7554547	0.765	rs57176983	ENSG00000261819.1	RP11-680G24.4	7.86	1.63e-12	2.16e-05	0.75	0.58	Nonsyndromic cleft lip with cleft palate;	chr1:11891041	chr16:14988259~14990160:-
TGCT	trans	rs7554547	0.791	rs1321072	ENSG00000261819.1	RP11-680G24.4	7.86	1.63e-12	2.16e-05	0.75	0.58	Nonsyndromic cleft lip with cleft palate;	chr1:11891261	chr16:14988259~14990160:-
TGCT	trans	rs877636	0.702	rs773109	ENSG00000235459.5	RPS26P31	7.85	1.64e-12	2.18e-05	0.72	0.58	Cognitive function;	chr12:55980911	chr7:122681315~122681662:+
TGCT	trans	rs2950393	0.929	rs10876916	ENSG00000121089.4	NACA3P	7.85	1.65e-12	2.19e-05	0.75	0.58	Platelet distribution width;	chr12:56692728	chr4:164943290~164943937:+
TGCT	trans	rs2950393	0.794	rs1563897	ENSG00000121089.4	NACA3P	7.85	1.65e-12	2.19e-05	0.75	0.58	Platelet distribution width;	chr12:56699316	chr4:164943290~164943937:+
TGCT	trans	rs916888	0.61	rs199446	ENSG00000264070.1	DND1P1	-7.85	1.67e-12	2.22e-05	-0.89	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45585871~45586929:+
TGCT	trans	rs916888	0.61	rs199536	ENSG00000264070.1	DND1P1	-7.85	1.67e-12	2.22e-05	-0.89	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45585871~45586929:+
TGCT	trans	rs1707322	0.721	rs4660883	ENSG00000255397.1	AC022182.2	-7.85	1.68e-12	2.23e-05	-0.72	-0.58	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr8:60937705~60939871:-
TGCT	trans	rs9611519	0.929	rs11090039	ENSG00000268568.1	AC007228.9	-7.85	1.71e-12	2.27e-05	-0.68	-0.58	Neuroticism;	chr22:41100796	chr19:56672574~56673901:-
TGCT	trans	rs877636	0.692	rs2271194	ENSG00000223416.3	RPS26P15	-7.84	1.74e-12	2.3e-05	-0.62	-0.58	Cognitive function;	chr12:56083910	chr1:58056133~58056480:-
TGCT	trans	rs8081395	0.707	rs1024637	ENSG00000187870.7	RNFT1P3	-7.84	1.76e-12	2.32e-05	-0.66	-0.58	White blood cell count;	chr17:59961532	chr17:20743333~20754501:-
TGCT	trans	rs10242455	0.702	rs28377312	ENSG00000228834.1	RP11-249L21.4	7.84	1.77e-12	2.34e-05	1.52	0.58	Blood metabolite levels;	chr7:99386590	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs1045012	ENSG00000228834.1	RP11-249L21.4	7.84	1.77e-12	2.34e-05	1.52	0.58	Blood metabolite levels;	chr7:99386731	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs10251282	ENSG00000228834.1	RP11-249L21.4	7.84	1.77e-12	2.34e-05	1.52	0.58	Blood metabolite levels;	chr7:99392613	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs28460612	ENSG00000228834.1	RP11-249L21.4	7.84	1.77e-12	2.34e-05	1.52	0.58	Blood metabolite levels;	chr7:99395582	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs115279860	ENSG00000228834.1	RP11-249L21.4	7.84	1.77e-12	2.34e-05	1.52	0.58	Blood metabolite levels;	chr7:99396869	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs28753399	ENSG00000228834.1	RP11-249L21.4	7.84	1.77e-12	2.34e-05	1.52	0.58	Blood metabolite levels;	chr7:99399636	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs28668326	ENSG00000228834.1	RP11-249L21.4	7.84	1.77e-12	2.34e-05	1.52	0.58	Blood metabolite levels;	chr7:99400530	chr6:108907615~108907873:-
TGCT	trans	rs10940346	0.557	rs2168922	ENSG00000231752.4	EMBP1	-7.84	1.81e-12	2.38e-05	-0.6	-0.58	Schizophrenia;	chr5:50151950	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.721	rs60147402	ENSG00000231752.4	EMBP1	-7.84	1.81e-12	2.38e-05	-0.6	-0.58	Schizophrenia;	chr5:50230794	chr1:121519112~121571892:+
TGCT	trans	rs10037055	0.685	rs10039241	ENSG00000217325.2	PRELID1P1	-7.83	1.83e-12	2.41e-05	-0.7	-0.58	Migraine without aura;	chr5:177151071	chr6:126643488~126644390:+
TGCT	trans	rs877636	0.692	rs10876870	ENSG00000223416.3	RPS26P15	-7.83	1.84e-12	2.42e-05	-0.63	-0.58	Cognitive function;	chr12:56084218	chr1:58056133~58056480:-
TGCT	trans	rs877636	0.692	rs7971751	ENSG00000223416.3	RPS26P15	-7.83	1.84e-12	2.42e-05	-0.63	-0.58	Cognitive function;	chr12:56084874	chr1:58056133~58056480:-
TGCT	trans	rs10242455	0.702	rs3528	ENSG00000228834.1	RP11-249L21.4	7.83	1.88e-12	2.47e-05	1.52	0.58	Blood metabolite levels;	chr7:99458317	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs55927283	ENSG00000228834.1	RP11-249L21.4	7.83	1.88e-12	2.47e-05	1.52	0.58	Blood metabolite levels;	chr7:99459568	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs73401510	ENSG00000228834.1	RP11-249L21.4	7.83	1.88e-12	2.47e-05	1.52	0.58	Blood metabolite levels;	chr7:99468189	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.557	rs73401516	ENSG00000228834.1	RP11-249L21.4	7.83	1.88e-12	2.47e-05	1.52	0.58	Blood metabolite levels;	chr7:99470728	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs59240302	ENSG00000228834.1	RP11-249L21.4	7.83	1.88e-12	2.47e-05	1.52	0.58	Blood metabolite levels;	chr7:99475368	chr6:108907615~108907873:-
TGCT	trans	rs13190036	0.551	rs7710269	ENSG00000217325.2	PRELID1P1	-7.83	1.88e-12	2.47e-05	-0.7	-0.58	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177187528	chr6:126643488~126644390:+
TGCT	trans	rs8081395	0.741	rs180519	ENSG00000187870.7	RNFT1P3	7.83	1.89e-12	2.48e-05	0.68	0.58	White blood cell count;	chr17:59938910	chr17:20743333~20754501:-
TGCT	trans	rs8081395	0.711	rs11368	ENSG00000187870.7	RNFT1P3	7.83	1.89e-12	2.48e-05	0.68	0.58	White blood cell count;	chr17:59954051	chr17:20743333~20754501:-
TGCT	trans	rs2731664	0.756	rs335433	ENSG00000215571.5	GRK6P1	7.82	1.97e-12	2.58e-05	0.68	0.57	Intelligence (multi-trait analysis);	chr5:177440206	chr13:21319156~21320866:+
TGCT	trans	rs2731664	0.819	rs449351	ENSG00000215571.5	GRK6P1	7.82	1.97e-12	2.58e-05	0.68	0.57	Intelligence (multi-trait analysis);	chr5:177445590	chr13:21319156~21320866:+
TGCT	trans	rs916888	0.61	rs199530	ENSG00000264070.1	DND1P1	-7.82	2.01e-12	2.62e-05	-0.88	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45585871~45586929:+
TGCT	trans	rs7554547	0.69	rs6669571	ENSG00000261819.1	RP11-680G24.4	7.81	2.03e-12	2.65e-05	0.79	0.57	Nonsyndromic cleft lip with cleft palate;	chr1:11887253	chr16:14988259~14990160:-
TGCT	trans	rs7554547	0.69	rs1474576	ENSG00000261819.1	RP11-680G24.4	7.81	2.03e-12	2.65e-05	0.79	0.57	Nonsyndromic cleft lip with cleft palate;	chr1:11887572	chr16:14988259~14990160:-
TGCT	trans	rs7554547	0.69	rs1474577	ENSG00000261819.1	RP11-680G24.4	7.81	2.03e-12	2.65e-05	0.79	0.57	Nonsyndromic cleft lip with cleft palate;	chr1:11887712	chr16:14988259~14990160:-
TGCT	trans	rs916888	0.531	rs183211	ENSG00000264070.1	DND1P1	7.81	2.03e-12	2.65e-05	0.88	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45585871~45586929:+
TGCT	trans	rs877636	0.859	rs3741499	ENSG00000225071.1	GS1-184P14.2	-7.81	2.04e-12	2.66e-05	-0.68	-0.57	Cognitive function;	chr12:56080595	chrX:24429573~24429920:-
TGCT	trans	rs2950393	0.804	rs11171951	ENSG00000121089.4	NACA3P	7.81	2.08e-12	2.7e-05	0.71	0.57	Platelet distribution width;	chr12:56718853	chr4:164943290~164943937:+
TGCT	trans	rs877636	1	rs705696	ENSG00000243403.1	RP11-330L19.1	7.81	2.09e-12	2.72e-05	0.73	0.57	Cognitive function;	chr12:56086864	chr15:64592979~64593326:+
TGCT	trans	rs916888	0.61	rs142167	ENSG00000264070.1	DND1P1	-7.81	2.12e-12	2.76e-05	-0.9	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45585871~45586929:+
TGCT	trans	rs10940346	1	rs7712749	ENSG00000231752.4	EMBP1	7.8	2.14e-12	2.79e-05	0.62	0.57	Schizophrenia;	chr5:50400441	chr1:121519112~121571892:+
TGCT	trans	rs13190036	0.551	rs11955537	ENSG00000217325.2	PRELID1P1	-7.8	2.16e-12	2.81e-05	-0.7	-0.57	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147087	chr6:126643488~126644390:+
TGCT	trans	rs616147	0.85	rs631312	ENSG00000183298.5	RP11-556K13.1	-7.8	2.16e-12	2.81e-05	-0.81	-0.57	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39467477	chr1:101786340~101787219:-
TGCT	trans	rs10940346	1	rs2668024	ENSG00000231752.4	EMBP1	-7.8	2.17e-12	2.82e-05	-0.6	-0.57	Schizophrenia;	chr5:50414421	chr1:121519112~121571892:+
TGCT	trans	rs877636	0.692	rs2271194	ENSG00000212994.5	RPS26P6	-7.8	2.21e-12	2.86e-05	-0.6	-0.57	Cognitive function;	chr12:56083910	chr8:100895771~100896118:+
TGCT	trans	rs2731664	0.792	rs1130857	ENSG00000215571.5	GRK6P1	7.8	2.22e-12	2.88e-05	0.68	0.57	Intelligence (multi-trait analysis);	chr5:177436518	chr13:21319156~21320866:+
TGCT	trans	rs7554547	0.765	rs34175640	ENSG00000261819.1	RP11-680G24.4	-7.79	2.27e-12	2.94e-05	-0.74	-0.57	Nonsyndromic cleft lip with cleft palate;	chr1:11892155	chr16:14988259~14990160:-
TGCT	trans	rs9611519	0.964	rs20551	ENSG00000268568.1	AC007228.9	-7.79	2.31e-12	3e-05	-0.67	-0.57	Neuroticism;	chr22:41152004	chr19:56672574~56673901:-
TGCT	trans	rs877636	0.702	rs773108	ENSG00000235459.5	RPS26P31	7.79	2.35e-12	3.04e-05	0.72	0.57	Cognitive function;	chr12:55976127	chr7:122681315~122681662:+
TGCT	trans	rs4276421	0.716	rs12656601	ENSG00000231752.4	EMBP1	7.78	2.46e-12	3.18e-05	0.6	0.57	P wave duration;	chr5:46124483	chr1:121519112~121571892:+
TGCT	trans	rs941207	0.526	rs12229457	ENSG00000121089.4	NACA3P	-7.78	2.48e-12	3.2e-05	-0.74	-0.57	Platelet count;	chr12:56639896	chr4:164943290~164943937:+
TGCT	trans	rs74781061	0.858	rs58473469	ENSG00000227288.3	RP5-837I24.1	7.77	2.63e-12	3.39e-05	0.66	0.57	Endometriosis;	chr15:74592722	chr1:81501794~81503468:+
TGCT	trans	rs7312770	0.612	rs1873914	ENSG00000243403.1	RP11-330L19.1	7.76	2.66e-12	3.44e-05	0.66	0.57	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr15:64592979~64593326:+
TGCT	trans	rs13190036	1	rs351862	ENSG00000217325.2	PRELID1P1	-7.76	2.68e-12	3.45e-05	-0.79	-0.57	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177114369	chr6:126643488~126644390:+
TGCT	trans	rs2731664	0.792	rs335434	ENSG00000215571.5	GRK6P1	7.76	2.77e-12	3.56e-05	0.68	0.57	Intelligence (multi-trait analysis);	chr5:177440275	chr13:21319156~21320866:+
TGCT	trans	rs877636	0.669	rs7297175	ENSG00000212994.5	RPS26P6	-7.75	2.82e-12	3.62e-05	-0.6	-0.57	Cognitive function;	chr12:56080024	chr8:100895771~100896118:+
TGCT	trans	rs1707322	0.506	rs2991983	ENSG00000255397.1	AC022182.2	7.75	2.82e-12	3.63e-05	0.75	0.57	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.717	rs3014249	ENSG00000255397.1	AC022182.2	7.75	2.82e-12	3.63e-05	0.75	0.57	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.717	rs2253862	ENSG00000255397.1	AC022182.2	7.75	2.82e-12	3.63e-05	0.75	0.57	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.717	rs2991988	ENSG00000255397.1	AC022182.2	7.75	2.82e-12	3.63e-05	0.75	0.57	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.717	rs2991989	ENSG00000255397.1	AC022182.2	7.75	2.82e-12	3.63e-05	0.75	0.57	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr8:60937705~60939871:-
TGCT	trans	rs13177918	0.798	rs13182116	ENSG00000213058.3	RP4-765C7.2	-7.75	2.89e-12	3.71e-05	-0.85	-0.57	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:178411616~178411972:+
TGCT	trans	rs2731664	0.765	rs2630766	ENSG00000215571.5	GRK6P1	7.74	2.95e-12	3.78e-05	0.66	0.57	Intelligence (multi-trait analysis);	chr5:177447940	chr13:21319156~21320866:+
TGCT	trans	rs2731664	0.792	rs466256	ENSG00000215571.5	GRK6P1	7.74	2.95e-12	3.78e-05	0.66	0.57	Intelligence (multi-trait analysis);	chr5:177448955	chr13:21319156~21320866:+
TGCT	trans	rs2731664	0.792	rs2630765	ENSG00000215571.5	GRK6P1	7.74	2.95e-12	3.78e-05	0.66	0.57	Intelligence (multi-trait analysis);	chr5:177449824	chr13:21319156~21320866:+
TGCT	trans	rs877636	0.692	rs10876870	ENSG00000212994.5	RPS26P6	-7.74	3.01e-12	3.86e-05	-0.61	-0.57	Cognitive function;	chr12:56084218	chr8:100895771~100896118:+
TGCT	trans	rs877636	0.692	rs7971751	ENSG00000212994.5	RPS26P6	-7.74	3.01e-12	3.86e-05	-0.61	-0.57	Cognitive function;	chr12:56084874	chr8:100895771~100896118:+
TGCT	trans	rs7937890	0.9	rs7118682	ENSG00000236360.2	RP11-334A14.2	-7.74	3.05e-12	3.91e-05	-0.64	-0.57	Mitochondrial DNA levels;	chr11:14253004	chr1:52993201~52993702:-
TGCT	trans	rs2731664	0.792	rs335468	ENSG00000215571.5	GRK6P1	-7.73	3.14e-12	4.02e-05	-0.68	-0.57	Intelligence (multi-trait analysis);	chr5:177465348	chr13:21319156~21320866:+
TGCT	trans	rs6477998	0.903	rs7041615	ENSG00000238072.1	RP11-305M3.2	7.73	3.17e-12	4.05e-05	0.66	0.57	Hematology traits;	chr9:113244747	chr7:129410113~129410370:-
TGCT	trans	rs616147	1	rs616147	ENSG00000183298.5	RP11-556K13.1	-7.73	3.18e-12	4.06e-05	-0.82	-0.57	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39492990	chr1:101786340~101787219:-
TGCT	trans	rs1816752	0.719	rs11843470	ENSG00000237917.1	PARP4P1	7.72	3.34e-12	4.25e-05	0.66	0.57	Obesity-related traits;	chr13:24423561	chrY:26594851~26634652:-
TGCT	trans	rs4240897	0.835	rs4845891	ENSG00000261819.1	RP11-680G24.4	7.72	3.34e-12	4.26e-05	0.71	0.57	Tuberculosis;	chr1:11982449	chr16:14988259~14990160:-
TGCT	trans	rs9611519	0.828	rs4822008	ENSG00000268568.1	AC007228.9	-7.72	3.37e-12	4.3e-05	-0.68	-0.57	Neuroticism;	chr22:41143202	chr19:56672574~56673901:-
TGCT	trans	rs13358908	0.652	rs8185385	ENSG00000231752.4	EMBP1	-7.71	3.44e-12	4.39e-05	-0.6	-0.57	Schizophrenia;	chr5:46318532	chr1:121519112~121571892:+
TGCT	trans	rs2731664	0.792	rs2545795	ENSG00000215571.5	GRK6P1	7.71	3.47e-12	4.41e-05	0.65	0.57	Intelligence (multi-trait analysis);	chr5:177460105	chr13:21319156~21320866:+
TGCT	trans	rs8010715	0.816	rs1134340	ENSG00000248988.1	RP11-815N9.2	7.71	3.47e-12	4.41e-05	0.71	0.57	IgG glycosylation;	chr14:24125004	chr4:159007119~159007835:+
TGCT	trans	rs8010715	0.816	rs6573573	ENSG00000248988.1	RP11-815N9.2	7.71	3.47e-12	4.41e-05	0.71	0.57	IgG glycosylation;	chr14:24130048	chr4:159007119~159007835:+
TGCT	trans	rs8081395	0.737	rs4968401	ENSG00000187870.7	RNFT1P3	-7.71	3.53e-12	4.49e-05	-0.66	-0.57	White blood cell count;	chr17:59963369	chr17:20743333~20754501:-
TGCT	trans	rs2731664	0.792	rs2630767	ENSG00000215571.5	GRK6P1	7.71	3.57e-12	4.54e-05	0.66	0.57	Intelligence (multi-trait analysis);	chr5:177443699	chr13:21319156~21320866:+
TGCT	trans	rs13190036	0.515	rs2878686	ENSG00000217325.2	PRELID1P1	-7.7	3.71e-12	4.71e-05	-0.7	-0.57	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206748	chr6:126643488~126644390:+
TGCT	trans	rs8081395	0.741	rs1292051	ENSG00000187870.7	RNFT1P3	7.7	3.77e-12	4.78e-05	0.66	0.57	White blood cell count;	chr17:59886562	chr17:20743333~20754501:-
TGCT	trans	rs2731664	0.792	rs335435	ENSG00000215571.5	GRK6P1	7.69	3.88e-12	4.91e-05	0.66	0.57	Intelligence (multi-trait analysis);	chr5:177440942	chr13:21319156~21320866:+
TGCT	trans	rs13358908	0.631	rs6882540	ENSG00000231752.4	EMBP1	-7.69	3.88e-12	4.91e-05	-0.59	-0.57	Schizophrenia;	chr5:46345971	chr1:121519112~121571892:+
TGCT	trans	rs13190036	0.551	rs28932178	ENSG00000217325.2	PRELID1P1	-7.69	3.89e-12	4.93e-05	-0.74	-0.57	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210575	chr6:126643488~126644390:+
TGCT	trans	rs8010715	0.816	rs2332224	ENSG00000248988.1	RP11-815N9.2	7.69	3.99e-12	5.04e-05	0.72	0.57	IgG glycosylation;	chr14:24129335	chr4:159007119~159007835:+
TGCT	trans	rs7554547	0.69	rs7524721	ENSG00000261819.1	RP11-680G24.4	7.69	4.02e-12	5.07e-05	0.8	0.57	Nonsyndromic cleft lip with cleft palate;	chr1:11890119	chr16:14988259~14990160:-
TGCT	trans	rs1707322	0.686	rs2275085	ENSG00000255397.1	AC022182.2	7.68	4.08e-12	5.15e-05	0.75	0.57	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr8:60937705~60939871:-
TGCT	trans	rs616147	1	rs1768208	ENSG00000183298.5	RP11-556K13.1	-7.68	4.11e-12	5.19e-05	-0.83	-0.57	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39481512	chr1:101786340~101787219:-
TGCT	trans	rs4240897	0.935	rs4846082	ENSG00000261819.1	RP11-680G24.4	7.68	4.12e-12	5.2e-05	0.72	0.57	Tuberculosis;	chr1:11982386	chr16:14988259~14990160:-
TGCT	trans	rs10037055	0.636	rs13166688	ENSG00000217325.2	PRELID1P1	-7.68	4.15e-12	5.23e-05	-0.69	-0.57	Migraine without aura;	chr5:177156965	chr6:126643488~126644390:+
TGCT	trans	rs10940346	1	rs4865674	ENSG00000231752.4	EMBP1	-7.68	4.15e-12	5.23e-05	-0.59	-0.57	Schizophrenia;	chr5:50277531	chr1:121519112~121571892:+
TGCT	trans	rs7312770	0.612	rs1873914	ENSG00000225071.1	GS1-184P14.2	7.68	4.16e-12	5.25e-05	0.63	0.57	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chrX:24429573~24429920:-
TGCT	trans	rs1816752	0.819	rs6490917	ENSG00000237917.1	PARP4P1	7.67	4.25e-12	5.36e-05	0.67	0.57	Obesity-related traits;	chr13:24423119	chrY:26594851~26634652:-
TGCT	trans	rs9611519	1	rs5758267	ENSG00000268568.1	AC007228.9	7.67	4.42e-12	5.57e-05	0.67	0.57	Neuroticism;	chr22:41223346	chr19:56672574~56673901:-
TGCT	trans	rs9611519	0.964	rs5995992	ENSG00000268568.1	AC007228.9	-7.67	4.43e-12	5.58e-05	-0.67	-0.57	Neuroticism;	chr22:41091214	chr19:56672574~56673901:-
TGCT	trans	rs74781061	0.929	rs9635320	ENSG00000227288.3	RP5-837I24.1	7.67	4.44e-12	5.58e-05	0.63	0.57	Endometriosis;	chr15:74592750	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs7176095	ENSG00000227288.3	RP5-837I24.1	7.67	4.44e-12	5.58e-05	0.63	0.57	Endometriosis;	chr15:74594070	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs11072494	ENSG00000227288.3	RP5-837I24.1	7.67	4.44e-12	5.58e-05	0.63	0.57	Endometriosis;	chr15:74596822	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs11072495	ENSG00000227288.3	RP5-837I24.1	7.67	4.44e-12	5.58e-05	0.63	0.57	Endometriosis;	chr15:74598790	chr1:81501794~81503468:+
TGCT	trans	rs1816752	0.905	rs3818938	ENSG00000237917.1	PARP4P1	7.66	4.57e-12	5.74e-05	0.67	0.57	Obesity-related traits;	chr13:24454945	chrY:26594851~26634652:-
TGCT	trans	rs9611519	0.964	rs2092563	ENSG00000268568.1	AC007228.9	-7.66	4.6e-12	5.77e-05	-0.68	-0.57	Neuroticism;	chr22:41196673	chr19:56672574~56673901:-
TGCT	trans	rs7121616	1	rs7121616	ENSG00000234176.1	HSPA8P1	7.66	4.6e-12	5.77e-05	0.74	0.57	Breast cancer;	chr11:123095918	chrX:121203182~121205014:-
TGCT	trans	rs7121616	0.96	rs7122306	ENSG00000234176.1	HSPA8P1	7.66	4.6e-12	5.77e-05	0.74	0.57	Breast cancer;	chr11:123096254	chrX:121203182~121205014:-
TGCT	trans	rs9611519	0.894	rs4821990	ENSG00000268568.1	AC007228.9	-7.66	4.61e-12	5.78e-05	-0.68	-0.57	Neuroticism;	chr22:41042706	chr19:56672574~56673901:-
TGCT	trans	rs2731664	0.792	rs2630764	ENSG00000215571.5	GRK6P1	7.66	4.69e-12	5.87e-05	0.65	0.57	Intelligence (multi-trait analysis);	chr5:177453084	chr13:21319156~21320866:+
TGCT	trans	rs1707322	0.656	rs3014210	ENSG00000255397.1	AC022182.2	7.66	4.71e-12	5.89e-05	0.75	0.57	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr8:60937705~60939871:-
TGCT	trans	rs10940346	1	rs555458	ENSG00000231752.4	EMBP1	-7.66	4.71e-12	5.89e-05	-0.59	-0.57	Schizophrenia;	chr5:50262772	chr1:121519112~121571892:+
TGCT	trans	rs10940346	1	rs510897	ENSG00000231752.4	EMBP1	-7.66	4.71e-12	5.89e-05	-0.59	-0.57	Schizophrenia;	chr5:50263017	chr1:121519112~121571892:+
TGCT	trans	rs10940346	1	rs507396	ENSG00000231752.4	EMBP1	-7.66	4.71e-12	5.89e-05	-0.59	-0.57	Schizophrenia;	chr5:50263374	chr1:121519112~121571892:+
TGCT	trans	rs10940346	1	rs11960661	ENSG00000231752.4	EMBP1	-7.66	4.71e-12	5.89e-05	-0.59	-0.57	Schizophrenia;	chr5:50266528	chr1:121519112~121571892:+
TGCT	trans	rs10940346	1	rs489407	ENSG00000231752.4	EMBP1	-7.66	4.71e-12	5.89e-05	-0.59	-0.57	Schizophrenia;	chr5:50266701	chr1:121519112~121571892:+
TGCT	trans	rs10940346	1	rs491470	ENSG00000231752.4	EMBP1	-7.66	4.71e-12	5.89e-05	-0.59	-0.57	Schizophrenia;	chr5:50266988	chr1:121519112~121571892:+
TGCT	trans	rs7647973	0.58	rs4955432	ENSG00000197582.5	GPX1P1	7.65	4.75e-12	5.93e-05	0.71	0.57	Menarche (age at onset);	chr3:49229339	chrX:13378735~13379340:-
TGCT	trans	rs7647973	0.6	rs11920267	ENSG00000197582.5	GPX1P1	7.65	4.75e-12	5.93e-05	0.71	0.57	Menarche (age at onset);	chr3:49238531	chrX:13378735~13379340:-
TGCT	trans	rs9611519	0.964	rs4820428	ENSG00000268568.1	AC007228.9	7.65	4.8e-12	5.99e-05	0.67	0.57	Neuroticism;	chr22:41141585	chr19:56672574~56673901:-
TGCT	trans	rs9611519	1	rs9611505	ENSG00000268568.1	AC007228.9	-7.65	4.8e-12	5.99e-05	-0.67	-0.57	Neuroticism;	chr22:41144275	chr19:56672574~56673901:-
TGCT	trans	rs9611519	1	rs2057070	ENSG00000268568.1	AC007228.9	-7.65	4.88e-12	6.08e-05	-0.67	-0.57	Neuroticism;	chr22:41168283	chr19:56672574~56673901:-
TGCT	trans	rs9611519	0.929	rs9611509	ENSG00000268568.1	AC007228.9	-7.65	4.88e-12	6.08e-05	-0.67	-0.57	Neuroticism;	chr22:41169823	chr19:56672574~56673901:-
TGCT	trans	rs9611519	1	rs9611510	ENSG00000268568.1	AC007228.9	-7.65	4.88e-12	6.08e-05	-0.67	-0.57	Neuroticism;	chr22:41173120	chr19:56672574~56673901:-
TGCT	trans	rs916888	0.61	rs199530	ENSG00000214425.5	LRRC37A4P	7.64	4.98e-12	6.21e-05	0.64	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45506741~45550335:-
TGCT	trans	rs74781061	0.929	rs59946128	ENSG00000227288.3	RP5-837I24.1	7.64	5.13e-12	6.39e-05	0.62	0.57	Endometriosis;	chr15:74493006	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs60777494	ENSG00000227288.3	RP5-837I24.1	7.64	5.13e-12	6.39e-05	0.62	0.57	Endometriosis;	chr15:74493007	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs57271230	ENSG00000227288.3	RP5-837I24.1	7.64	5.13e-12	6.39e-05	0.62	0.57	Endometriosis;	chr15:74493018	chr1:81501794~81503468:+
TGCT	trans	rs10940346	1	rs13360100	ENSG00000231752.4	EMBP1	-7.64	5.15e-12	6.41e-05	-0.59	-0.57	Schizophrenia;	chr5:50323389	chr1:121519112~121571892:+
TGCT	trans	rs941207	0.507	rs73337030	ENSG00000121089.4	NACA3P	-7.63	5.43e-12	6.73e-05	-0.74	-0.57	Platelet count;	chr12:56652410	chr4:164943290~164943937:+
TGCT	trans	rs12291225	0.877	rs2303974	ENSG00000236360.2	RP11-334A14.2	7.62	5.53e-12	6.85e-05	0.79	0.56	Sense of smell;	chr11:14243433	chr1:52993201~52993702:-
TGCT	trans	rs1816752	0.905	rs4770666	ENSG00000237917.1	PARP4P1	7.62	5.6e-12	6.93e-05	0.67	0.56	Obesity-related traits;	chr13:24414891	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.905	rs7400631	ENSG00000237917.1	PARP4P1	7.62	5.6e-12	6.93e-05	0.67	0.56	Obesity-related traits;	chr13:24415927	chrY:26594851~26634652:-
TGCT	trans	rs10940346	1	rs1328254	ENSG00000231752.4	EMBP1	-7.62	5.61e-12	6.93e-05	-0.59	-0.56	Schizophrenia;	chr5:50265025	chr1:121519112~121571892:+
TGCT	trans	rs1816752	0.837	rs9318530	ENSG00000237917.1	PARP4P1	-7.62	5.61e-12	6.94e-05	-0.66	-0.56	Obesity-related traits;	chr13:24424419	chrY:26594851~26634652:-
TGCT	trans	rs877636	1	rs2292239	ENSG00000225071.1	GS1-184P14.2	7.62	5.62e-12	6.95e-05	0.67	0.56	Cognitive function;	chr12:56088396	chrX:24429573~24429920:-
TGCT	trans	rs1816752	0.819	rs4770665	ENSG00000237917.1	PARP4P1	7.62	5.67e-12	7e-05	0.67	0.56	Obesity-related traits;	chr13:24414810	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.749	rs77832754	ENSG00000237917.1	PARP4P1	7.62	5.67e-12	7e-05	0.67	0.56	Obesity-related traits;	chr13:24416016	chrY:26594851~26634652:-
TGCT	trans	rs7554547	0.69	rs6667637	ENSG00000261819.1	RP11-680G24.4	7.62	5.82e-12	7.18e-05	0.78	0.56	Nonsyndromic cleft lip with cleft palate;	chr1:11887900	chr16:14988259~14990160:-
TGCT	trans	rs1816752	0.712	rs2862898	ENSG00000237917.1	PARP4P1	7.61	5.9e-12	7.27e-05	0.68	0.56	Obesity-related traits;	chr13:24414323	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.652	rs2902356	ENSG00000237917.1	PARP4P1	7.61	5.9e-12	7.27e-05	0.68	0.56	Obesity-related traits;	chr13:24414333	chrY:26594851~26634652:-
TGCT	trans	rs10940346	1	rs12514818	ENSG00000231752.4	EMBP1	-7.61	5.9e-12	7.27e-05	-0.59	-0.56	Schizophrenia;	chr5:50349925	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.684	rs8185217	ENSG00000231752.4	EMBP1	7.61	5.91e-12	7.27e-05	0.59	0.56	P wave duration;	chr5:46169215	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.657	rs10941759	ENSG00000231752.4	EMBP1	-7.61	5.92e-12	7.27e-05	-0.59	-0.56	P wave duration;	chr5:46266862	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.657	rs10941760	ENSG00000231752.4	EMBP1	-7.61	5.92e-12	7.27e-05	-0.59	-0.56	P wave duration;	chr5:46267360	chr1:121519112~121571892:+
TGCT	trans	rs9611519	1	rs6002271	ENSG00000268568.1	AC007228.9	-7.61	5.98e-12	7.27e-05	-0.67	-0.56	Neuroticism;	chr22:41170591	chr19:56672574~56673901:-
TGCT	trans	rs4276421	0.684	rs8185055	ENSG00000231752.4	EMBP1	-7.61	6e-12	7.27e-05	-0.59	-0.56	P wave duration;	chr5:46262149	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.587	rs4975957	ENSG00000231752.4	EMBP1	-7.61	6e-12	7.27e-05	-0.59	-0.56	P wave duration;	chr5:46265200	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.609	rs4975911	ENSG00000231752.4	EMBP1	-7.61	6e-12	7.27e-05	-0.59	-0.56	P wave duration;	chr5:46297143	chr1:121519112~121571892:+
TGCT	trans	rs13358908	0.596	rs9717195	ENSG00000231752.4	EMBP1	-7.61	6e-12	7.27e-05	-0.59	-0.56	Schizophrenia;	chr5:46302679	chr1:121519112~121571892:+
TGCT	trans	rs13358908	0.715	rs8185301	ENSG00000231752.4	EMBP1	-7.61	6e-12	7.27e-05	-0.59	-0.56	Schizophrenia;	chr5:46312149	chr1:121519112~121571892:+
TGCT	trans	rs13358908	0.652	rs7293494	ENSG00000231752.4	EMBP1	-7.61	6e-12	7.27e-05	-0.59	-0.56	Schizophrenia;	chr5:46313550	chr1:121519112~121571892:+
TGCT	trans	rs13358908	0.595	rs4975942	ENSG00000231752.4	EMBP1	-7.61	6e-12	7.27e-05	-0.59	-0.56	Schizophrenia;	chr5:46371833	chr1:121519112~121571892:+
TGCT	trans	rs13358908	0.599	rs34899679	ENSG00000231752.4	EMBP1	-7.61	6e-12	7.27e-05	-0.59	-0.56	Schizophrenia;	chr5:46372360	chr1:121519112~121571892:+
TGCT	trans	rs13358908	0.632	rs35088345	ENSG00000231752.4	EMBP1	-7.61	6e-12	7.27e-05	-0.59	-0.56	Schizophrenia;	chr5:46372364	chr1:121519112~121571892:+
TGCT	trans	rs13358908	0.712	rs28873151	ENSG00000231752.4	EMBP1	-7.61	6e-12	7.27e-05	-0.59	-0.56	Schizophrenia;	chr5:46378558	chr1:121519112~121571892:+
TGCT	trans	rs13358908	0.621	rs28847123	ENSG00000231752.4	EMBP1	-7.61	6e-12	7.27e-05	-0.59	-0.56	Schizophrenia;	chr5:46378829	chr1:121519112~121571892:+
TGCT	trans	rs13358908	0.593	rs28855077	ENSG00000231752.4	EMBP1	-7.61	6e-12	7.27e-05	-0.59	-0.56	Schizophrenia;	chr5:46378855	chr1:121519112~121571892:+
TGCT	trans	rs13358908	0.715	rs12522625	ENSG00000231752.4	EMBP1	-7.61	6e-12	7.27e-05	-0.59	-0.56	Schizophrenia;	chr5:46389266	chr1:121519112~121571892:+
TGCT	trans	rs13358908	0.712	rs10941823	ENSG00000231752.4	EMBP1	-7.61	6e-12	7.27e-05	-0.59	-0.56	Schizophrenia;	chr5:46389481	chr1:121519112~121571892:+
TGCT	trans	rs13358908	0.622	rs12652607	ENSG00000231752.4	EMBP1	-7.61	6e-12	7.27e-05	-0.59	-0.56	Schizophrenia;	chr5:46392338	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.652	rs8185226	ENSG00000231752.4	EMBP1	7.61	6e-12	7.27e-05	0.59	0.56	P wave duration;	chr5:46160685	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.656	rs8185376	ENSG00000231752.4	EMBP1	7.61	6e-12	7.27e-05	0.59	0.56	P wave duration;	chr5:46165191	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.625	rs61187820	ENSG00000231752.4	EMBP1	7.61	6e-12	7.27e-05	0.59	0.56	P wave duration;	chr5:46199336	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.688	rs8188050	ENSG00000231752.4	EMBP1	7.61	6e-12	7.27e-05	0.59	0.56	P wave duration;	chr5:46201372	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.656	rs13188786	ENSG00000231752.4	EMBP1	7.61	6e-12	7.27e-05	0.59	0.56	P wave duration;	chr5:46201856	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.688	rs10064792	ENSG00000231752.4	EMBP1	7.61	6e-12	7.27e-05	0.59	0.56	P wave duration;	chr5:46202002	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.597	rs10072776	ENSG00000231752.4	EMBP1	7.61	6e-12	7.27e-05	0.59	0.56	P wave duration;	chr5:46202178	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.656	rs7293337	ENSG00000231752.4	EMBP1	7.61	6e-12	7.27e-05	0.59	0.56	P wave duration;	chr5:46203395	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.688	rs13168431	ENSG00000231752.4	EMBP1	7.61	6e-12	7.27e-05	0.59	0.56	P wave duration;	chr5:46205598	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.656	rs11960110	ENSG00000231752.4	EMBP1	7.61	6e-12	7.27e-05	0.59	0.56	P wave duration;	chr5:46210055	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.537	rs13166566	ENSG00000231752.4	EMBP1	7.61	6e-12	7.27e-05	0.59	0.56	P wave duration;	chr5:46210486	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.656	rs13172097	ENSG00000231752.4	EMBP1	7.61	6e-12	7.27e-05	0.59	0.56	P wave duration;	chr5:46211694	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.657	rs8188296	ENSG00000231752.4	EMBP1	7.61	6e-12	7.27e-05	0.59	0.56	P wave duration;	chr5:46221948	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.656	rs10064681	ENSG00000231752.4	EMBP1	7.61	6e-12	7.27e-05	0.59	0.56	P wave duration;	chr5:46222829	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.623	rs12109835	ENSG00000231752.4	EMBP1	7.61	6e-12	7.27e-05	0.59	0.56	P wave duration;	chr5:46222967	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.688	rs12697543	ENSG00000231752.4	EMBP1	7.61	6e-12	7.27e-05	0.59	0.56	P wave duration;	chr5:46235824	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.688	rs8185185	ENSG00000231752.4	EMBP1	7.61	6.02e-12	7.3e-05	0.59	0.56	P wave duration;	chr5:46214358	chr1:121519112~121571892:+
TGCT	trans	rs12709013	0.792	rs12325054	ENSG00000230849.2	GOT2P2	7.61	6.03e-12	7.31e-05	0.69	0.56	Blood metabolite ratios;	chr16:58749804	chr1:173141100~173142350:-
TGCT	trans	rs10940346	0.902	rs4865727	ENSG00000231752.4	EMBP1	-7.61	6.04e-12	7.31e-05	-0.59	-0.56	Schizophrenia;	chr5:50145945	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.714	rs12523073	ENSG00000231752.4	EMBP1	-7.61	6.04e-12	7.31e-05	-0.59	-0.56	Schizophrenia;	chr5:50153697	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.584	rs496108	ENSG00000231752.4	EMBP1	-7.61	6.04e-12	7.31e-05	-0.59	-0.56	Schizophrenia;	chr5:50236794	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.744	rs498951	ENSG00000231752.4	EMBP1	-7.61	6.04e-12	7.31e-05	-0.59	-0.56	Schizophrenia;	chr5:50238681	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.653	rs72768421	ENSG00000231752.4	EMBP1	-7.61	6.04e-12	7.31e-05	-0.59	-0.56	Schizophrenia;	chr5:50246898	chr1:121519112~121571892:+
TGCT	trans	rs13358908	0.602	rs4975977	ENSG00000231752.4	EMBP1	-7.61	6.05e-12	7.31e-05	-0.59	-0.56	Schizophrenia;	chr5:46307988	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.846	rs8188203	ENSG00000231752.4	EMBP1	-7.61	6.1e-12	7.36e-05	-0.59	-0.56	Schizophrenia;	chr5:50161448	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.905	rs10053631	ENSG00000231752.4	EMBP1	-7.61	6.1e-12	7.36e-05	-0.59	-0.56	Schizophrenia;	chr5:50164086	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.728	rs10053639	ENSG00000231752.4	EMBP1	-7.61	6.1e-12	7.36e-05	-0.59	-0.56	Schizophrenia;	chr5:50164113	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.688	rs10040808	ENSG00000231752.4	EMBP1	7.61	6.12e-12	7.38e-05	0.59	0.56	P wave duration;	chr5:46123599	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.684	rs8175395	ENSG00000231752.4	EMBP1	7.61	6.12e-12	7.38e-05	0.59	0.56	P wave duration;	chr5:46125498	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.716	rs13156708	ENSG00000231752.4	EMBP1	7.61	6.12e-12	7.38e-05	0.59	0.56	P wave duration;	chr5:46128924	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.744	rs13157345	ENSG00000231752.4	EMBP1	7.61	6.12e-12	7.38e-05	0.59	0.56	P wave duration;	chr5:46129304	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.805	rs7293302	ENSG00000231752.4	EMBP1	7.61	6.12e-12	7.38e-05	0.59	0.56	P wave duration;	chr5:46131077	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.657	rs13186103	ENSG00000231752.4	EMBP1	7.61	6.12e-12	7.38e-05	0.59	0.56	P wave duration;	chr5:46131553	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.688	rs8188054	ENSG00000231752.4	EMBP1	7.61	6.12e-12	7.38e-05	0.59	0.56	P wave duration;	chr5:46215556	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.688	rs10061101	ENSG00000231752.4	EMBP1	7.61	6.12e-12	7.38e-05	0.59	0.56	P wave duration;	chr5:46217831	chr1:121519112~121571892:+
TGCT	trans	rs74781061	0.86	rs2289187	ENSG00000227288.3	RP5-837I24.1	7.6	6.36e-12	7.56e-05	0.61	0.56	Endometriosis;	chr15:74452058	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.86	rs7163775	ENSG00000227288.3	RP5-837I24.1	7.6	6.36e-12	7.56e-05	0.61	0.56	Endometriosis;	chr15:74452760	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.86	rs7166701	ENSG00000227288.3	RP5-837I24.1	7.6	6.36e-12	7.56e-05	0.61	0.56	Endometriosis;	chr15:74456674	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.86	rs77655065	ENSG00000227288.3	RP5-837I24.1	7.6	6.36e-12	7.56e-05	0.61	0.56	Endometriosis;	chr15:74462699	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.858	rs12592493	ENSG00000227288.3	RP5-837I24.1	7.6	6.36e-12	7.56e-05	0.61	0.56	Endometriosis;	chr15:74466999	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.86	rs4077703	ENSG00000227288.3	RP5-837I24.1	7.6	6.36e-12	7.56e-05	0.61	0.56	Endometriosis;	chr15:74469821	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.86	rs6495103	ENSG00000227288.3	RP5-837I24.1	7.6	6.36e-12	7.56e-05	0.61	0.56	Endometriosis;	chr15:74470507	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs8029099	ENSG00000227288.3	RP5-837I24.1	7.6	6.36e-12	7.56e-05	0.61	0.56	Endometriosis;	chr15:74474429	chr1:81501794~81503468:+
TGCT	trans	rs916888	0.821	rs199513	ENSG00000214425.5	LRRC37A4P	7.6	6.42e-12	7.62e-05	0.71	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45506741~45550335:-
TGCT	trans	rs7554547	0.667	rs6666533	ENSG00000261819.1	RP11-680G24.4	7.6	6.47e-12	7.69e-05	0.78	0.56	Nonsyndromic cleft lip with cleft palate;	chr1:11889068	chr16:14988259~14990160:-
TGCT	trans	rs8081395	0.741	rs180532	ENSG00000187870.7	RNFT1P3	7.59	6.49e-12	7.71e-05	0.65	0.56	White blood cell count;	chr17:59925936	chr17:20743333~20754501:-
TGCT	trans	rs8081395	0.741	rs180530	ENSG00000187870.7	RNFT1P3	7.59	6.49e-12	7.71e-05	0.65	0.56	White blood cell count;	chr17:59926233	chr17:20743333~20754501:-
TGCT	trans	rs8081395	0.741	rs2645462	ENSG00000187870.7	RNFT1P3	7.59	6.52e-12	7.73e-05	0.65	0.56	White blood cell count;	chr17:59906198	chr17:20743333~20754501:-
TGCT	trans	rs8081395	0.711	rs1292034	ENSG00000187870.7	RNFT1P3	7.59	6.52e-12	7.73e-05	0.65	0.56	White blood cell count;	chr17:59912499	chr17:20743333~20754501:-
TGCT	trans	rs8081395	0.801	rs2645479	ENSG00000187870.7	RNFT1P3	7.59	6.53e-12	7.75e-05	0.66	0.56	White blood cell count;	chr17:59843171	chr17:20743333~20754501:-
TGCT	trans	rs1816752	0.819	rs4770664	ENSG00000237917.1	PARP4P1	7.59	6.63e-12	7.85e-05	0.67	0.56	Obesity-related traits;	chr13:24414695	chrY:26594851~26634652:-
TGCT	trans	rs1707322	0.685	rs56177313	ENSG00000255397.1	AC022182.2	-7.59	6.65e-12	7.87e-05	-0.69	-0.56	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs11211178	ENSG00000255397.1	AC022182.2	-7.59	6.65e-12	7.87e-05	-0.69	-0.56	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr8:60937705~60939871:-
TGCT	trans	rs616147	0.627	rs9871799	ENSG00000214263.2	RPSAP53	7.59	6.73e-12	7.95e-05	0.7	0.56	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr13:67266845~67267706:-
TGCT	trans	rs9611519	0.894	rs4821998	ENSG00000268568.1	AC007228.9	-7.59	6.8e-12	8.03e-05	-0.68	-0.56	Neuroticism;	chr22:41072269	chr19:56672574~56673901:-
TGCT	trans	rs9611519	0.894	rs8136923	ENSG00000268568.1	AC007228.9	-7.59	6.8e-12	8.03e-05	-0.68	-0.56	Neuroticism;	chr22:41074518	chr19:56672574~56673901:-
TGCT	trans	rs11332131	1	rs11332131	ENSG00000187870.7	RNFT1P3	7.58	6.93e-12	8.18e-05	0.65	0.56	Platelet distribution width;	chr17:59849031	chr17:20743333~20754501:-
TGCT	trans	rs4276421	0.684	rs10072945	ENSG00000231752.4	EMBP1	7.58	6.98e-12	8.23e-05	0.6	0.56	P wave duration;	chr5:46151307	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.716	rs13155082	ENSG00000231752.4	EMBP1	7.58	6.98e-12	8.23e-05	0.6	0.56	P wave duration;	chr5:46155135	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.578	rs8185314	ENSG00000231752.4	EMBP1	-7.58	7.03e-12	8.28e-05	-0.59	-0.56	P wave duration;	chr5:46299648	chr1:121519112~121571892:+
TGCT	trans	rs7937890	0.904	rs11023169	ENSG00000236360.2	RP11-334A14.2	-7.58	7.18e-12	8.44e-05	-0.61	-0.56	Mitochondrial DNA levels;	chr11:14269439	chr1:52993201~52993702:-
TGCT	trans	rs7937890	0.904	rs67623158	ENSG00000236360.2	RP11-334A14.2	-7.58	7.18e-12	8.44e-05	-0.61	-0.56	Mitochondrial DNA levels;	chr11:14273650	chr1:52993201~52993702:-
TGCT	trans	rs10940346	0.846	rs13356208	ENSG00000231752.4	EMBP1	-7.57	7.31e-12	8.59e-05	-0.59	-0.56	Schizophrenia;	chr5:50197970	chr1:121519112~121571892:+
TGCT	trans	rs4240897	0.935	rs1474868	ENSG00000261819.1	RP11-680G24.4	-7.56	7.61e-12	8.93e-05	-0.7	-0.56	Tuberculosis;	chr1:11984107	chr16:14988259~14990160:-
TGCT	trans	rs9611519	0.894	rs9623320	ENSG00000268568.1	AC007228.9	-7.56	7.66e-12	8.99e-05	-0.67	-0.56	Neuroticism;	chr22:41082478	chr19:56672574~56673901:-
TGCT	trans	rs10242455	0.702	rs76635566	ENSG00000228834.1	RP11-249L21.4	7.56	7.69e-12	9.02e-05	1.53	0.56	Blood metabolite levels;	chr7:99374103	chr6:108907615~108907873:-
TGCT	trans	rs1707322	0.656	rs9429172	ENSG00000255397.1	AC022182.2	7.56	7.77e-12	9.1e-05	0.74	0.56	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr8:60937705~60939871:-
TGCT	trans	rs2950393	0.777	rs12828563	ENSG00000121089.4	NACA3P	7.56	7.98e-12	9.32e-05	0.71	0.56	Platelet distribution width;	chr12:56709378	chr4:164943290~164943937:+
TGCT	trans	rs8081395	0.576	rs1292032	ENSG00000187870.7	RNFT1P3	7.55	8.09e-12	9.44e-05	0.63	0.56	White blood cell count;	chr17:59914982	chr17:20743333~20754501:-
TGCT	trans	rs10940346	1	rs2036901	ENSG00000231752.4	EMBP1	7.55	8.41e-12	9.8e-05	0.61	0.56	Schizophrenia;	chr5:50401306	chr1:121519112~121571892:+
TGCT	trans	rs74781061	0.929	rs8041807	ENSG00000227288.3	RP5-837I24.1	7.54	8.43e-12	9.81e-05	0.62	0.56	Endometriosis;	chr15:74534590	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs8027066	ENSG00000227288.3	RP5-837I24.1	7.54	8.43e-12	9.81e-05	0.62	0.56	Endometriosis;	chr15:74535682	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs12594447	ENSG00000227288.3	RP5-837I24.1	7.54	8.43e-12	9.81e-05	0.62	0.56	Endometriosis;	chr15:74536392	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs1821848	ENSG00000227288.3	RP5-837I24.1	7.54	8.43e-12	9.81e-05	0.62	0.56	Endometriosis;	chr15:74541443	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs8043032	ENSG00000227288.3	RP5-837I24.1	7.54	8.43e-12	9.81e-05	0.62	0.56	Endometriosis;	chr15:74543975	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs2415242	ENSG00000227288.3	RP5-837I24.1	7.54	8.43e-12	9.81e-05	0.62	0.56	Endometriosis;	chr15:74546765	chr1:81501794~81503468:+
TGCT	trans	rs1816752	0.633	rs8002387	ENSG00000237917.1	PARP4P1	7.54	8.5e-12	9.88e-05	0.67	0.56	Obesity-related traits;	chr13:24416306	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.905	rs8002215	ENSG00000237917.1	PARP4P1	7.54	8.65e-12	0.000101	0.67	0.56	Obesity-related traits;	chr13:24416229	chrY:26594851~26634652:-
TGCT	trans	rs1707322	0.717	rs3014246	ENSG00000255397.1	AC022182.2	7.54	8.82e-12	0.000102	0.74	0.56	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.717	rs3014245	ENSG00000255397.1	AC022182.2	7.54	8.82e-12	0.000102	0.74	0.56	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.655	rs3014240	ENSG00000255397.1	AC022182.2	7.54	8.82e-12	0.000102	0.74	0.56	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.717	rs3014237	ENSG00000255397.1	AC022182.2	7.54	8.82e-12	0.000102	0.74	0.56	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.686	rs3014235	ENSG00000255397.1	AC022182.2	7.54	8.82e-12	0.000102	0.74	0.56	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.717	rs1135850	ENSG00000255397.1	AC022182.2	-7.54	8.82e-12	0.000102	-0.74	-0.56	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr8:60937705~60939871:-
TGCT	trans	rs916888	0.61	rs199438	ENSG00000264070.1	DND1P1	7.54	8.87e-12	0.000103	0.87	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45585871~45586929:+
TGCT	trans	rs10940346	0.694	rs2219454	ENSG00000231752.4	EMBP1	-7.53	8.89e-12	0.000103	-0.6	-0.56	Schizophrenia;	chr5:50212798	chr1:121519112~121571892:+
TGCT	trans	rs2950393	0.726	rs10459246	ENSG00000121089.4	NACA3P	-7.53	8.9e-12	0.000103	-0.69	-0.56	Platelet distribution width;	chr12:56776034	chr4:164943290~164943937:+
TGCT	trans	rs10940346	0.967	rs2353437	ENSG00000231752.4	EMBP1	7.53	9.24e-12	0.000107	0.61	0.56	Schizophrenia;	chr5:50452078	chr1:121519112~121571892:+
TGCT	trans	rs12709013	0.792	rs1615326	ENSG00000230849.2	GOT2P2	7.53	9.29e-12	0.000107	0.68	0.56	Blood metabolite ratios;	chr16:58747148	chr1:173141100~173142350:-
TGCT	trans	rs4240897	0.935	rs3766744	ENSG00000261819.1	RP11-680G24.4	7.53	9.33e-12	0.000108	0.71	0.56	Tuberculosis;	chr1:11983660	chr16:14988259~14990160:-
TGCT	trans	rs1816752	0.905	rs7995492	ENSG00000237917.1	PARP4P1	7.52	9.43e-12	0.000109	0.64	0.56	Obesity-related traits;	chr13:24438885	chrY:26594851~26634652:-
TGCT	trans	rs9611519	0.929	rs71327107	ENSG00000268568.1	AC007228.9	-7.52	9.53e-12	0.00011	-0.7	-0.56	Neuroticism;	chr22:41022225	chr19:56672574~56673901:-
TGCT	trans	rs9611519	0.828	rs9611460	ENSG00000268568.1	AC007228.9	-7.52	9.53e-12	0.00011	-0.7	-0.56	Neuroticism;	chr22:41022293	chr19:56672574~56673901:-
TGCT	trans	rs10940346	0.967	rs13154223	ENSG00000231752.4	EMBP1	7.52	9.73e-12	0.000111	0.61	0.56	Schizophrenia;	chr5:50403152	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.967	rs62365887	ENSG00000231752.4	EMBP1	7.52	9.73e-12	0.000111	0.61	0.56	Schizophrenia;	chr5:50408254	chr1:121519112~121571892:+
TGCT	trans	rs10940346	1	rs34044167	ENSG00000231752.4	EMBP1	7.52	9.73e-12	0.000111	0.61	0.56	Schizophrenia;	chr5:50410136	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.875	rs13159506	ENSG00000231752.4	EMBP1	7.52	9.73e-12	0.000111	0.61	0.56	Schizophrenia;	chr5:50415061	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.967	rs13173678	ENSG00000231752.4	EMBP1	7.52	9.73e-12	0.000111	0.61	0.56	Schizophrenia;	chr5:50422314	chr1:121519112~121571892:+
TGCT	trans	rs10940346	1	rs6450108	ENSG00000231752.4	EMBP1	7.52	9.73e-12	0.000111	0.61	0.56	Schizophrenia;	chr5:50434427	chr1:121519112~121571892:+
TGCT	trans	rs10940346	1	rs28445612	ENSG00000231752.4	EMBP1	7.52	9.73e-12	0.000111	0.61	0.56	Schizophrenia;	chr5:50439676	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.967	rs2353436	ENSG00000231752.4	EMBP1	7.52	9.73e-12	0.000111	0.61	0.56	Schizophrenia;	chr5:50445695	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.967	rs1849200	ENSG00000231752.4	EMBP1	7.52	9.73e-12	0.000111	0.61	0.56	Schizophrenia;	chr5:50448053	chr1:121519112~121571892:+
TGCT	trans	rs10940346	1	rs6899048	ENSG00000231752.4	EMBP1	7.52	9.73e-12	0.000111	0.61	0.56	Schizophrenia;	chr5:50451256	chr1:121519112~121571892:+
TGCT	trans	rs10940346	1	rs2102454	ENSG00000231752.4	EMBP1	7.52	9.73e-12	0.000111	0.61	0.56	Schizophrenia;	chr5:50452446	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.875	rs13172257	ENSG00000231752.4	EMBP1	7.52	9.73e-12	0.000111	0.61	0.56	Schizophrenia;	chr5:50462916	chr1:121519112~121571892:+
TGCT	trans	rs10940346	1	rs10074196	ENSG00000231752.4	EMBP1	7.52	9.73e-12	0.000111	0.61	0.56	Schizophrenia;	chr5:50464713	chr1:121519112~121571892:+
TGCT	trans	rs10940346	1	rs13186891	ENSG00000231752.4	EMBP1	7.52	9.73e-12	0.000111	0.61	0.56	Schizophrenia;	chr5:50467244	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.967	rs6450134	ENSG00000231752.4	EMBP1	-7.52	9.73e-12	0.000111	-0.61	-0.56	Schizophrenia;	chr5:50471121	chr1:121519112~121571892:+
TGCT	trans	rs10940346	1	rs7380816	ENSG00000231752.4	EMBP1	-7.52	9.73e-12	0.000111	-0.61	-0.56	Schizophrenia;	chr5:50472059	chr1:121519112~121571892:+
TGCT	trans	rs10940346	1	rs2016360	ENSG00000231752.4	EMBP1	-7.51	9.9e-12	0.000113	-0.61	-0.56	Schizophrenia;	chr5:50491064	chr1:121519112~121571892:+
TGCT	trans	rs10940346	1	rs7378983	ENSG00000231752.4	EMBP1	-7.51	9.9e-12	0.000113	-0.61	-0.56	Schizophrenia;	chr5:50491889	chr1:121519112~121571892:+
TGCT	trans	rs74781061	1	rs74781061	ENSG00000227288.3	RP5-837I24.1	7.51	9.97e-12	0.000113	0.58	0.56	Endometriosis;	chr15:74595855	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.86	rs8033841	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74471540	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs4324083	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74479139	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs117379081	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74480106	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.79	rs6495105	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74480512	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.858	rs12592906	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74481811	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs79600239	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74481987	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs4886599	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74484442	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs16969247	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74486541	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs11855521	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74488038	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs55662551	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74488745	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.858	rs79923136	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74492219	chr1:81501794~81503468:+
TGCT	trans	rs74781061	1	rs11072488	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74494017	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs12439505	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74494021	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.858	rs35752918	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74494240	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs79534854	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74494257	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.858	rs4278699	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74500057	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs8038730	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74501003	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs7178219	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74502552	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs6495109	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74504720	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs8037436	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74506167	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.932	rs11857328	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74510550	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs4887155	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74512119	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs11072490	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74515169	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs1821847	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74516873	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs7173006	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74517792	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs78796673	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74520186	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs4261483	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74520993	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs8041030	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74525726	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs8028163	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74530360	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs11072492	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74531782	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs7177407	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74551444	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs8028430	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74553404	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs12442097	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74554792	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs8029215	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74561147	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.858	rs8023865	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74561263	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs12439113	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74563806	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs8043082	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74564896	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs8026923	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74565721	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs7171838	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74571778	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs4887159	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74573541	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs8025976	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74577697	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs6495115	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74578122	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs8025915	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74578188	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.858	rs4887162	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74580159	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs4887163	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74580405	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs4886601	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74591510	chr1:81501794~81503468:+
TGCT	trans	rs74781061	1	rs4887166	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74605257	chr1:81501794~81503468:+
TGCT	trans	rs74781061	1	rs6495117	ENSG00000227288.3	RP5-837I24.1	7.51	1e-11	0.000113	0.61	0.56	Endometriosis;	chr15:74607159	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs16969612	ENSG00000227288.3	RP5-837I24.1	-7.51	1e-11	0.000113	-0.61	-0.56	Endometriosis;	chr15:74514096	chr1:81501794~81503468:+
TGCT	trans	rs10242455	0.702	rs45451992	ENSG00000228834.1	RP11-249L21.4	7.51	1.01e-11	0.000113	1.48	0.56	Blood metabolite levels;	chr7:99443793	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs79285548	ENSG00000228834.1	RP11-249L21.4	7.51	1.01e-11	0.000113	1.48	0.56	Blood metabolite levels;	chr7:99460773	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs79878591	ENSG00000228834.1	RP11-249L21.4	7.51	1.01e-11	0.000113	1.48	0.56	Blood metabolite levels;	chr7:99485305	chr6:108907615~108907873:-
TGCT	trans	rs916888	0.779	rs199498	ENSG00000264070.1	DND1P1	7.51	1.01e-11	0.000113	0.92	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45585871~45586929:+
TGCT	trans	rs12709013	0.792	rs1646270	ENSG00000230849.2	GOT2P2	7.51	1.01e-11	0.000114	0.69	0.56	Blood metabolite ratios;	chr16:58745823	chr1:173141100~173142350:-
TGCT	trans	rs7312770	0.637	rs705700	ENSG00000212994.5	RPS26P6	7.51	1.02e-11	0.000115	0.61	0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr8:100895771~100896118:+
TGCT	trans	rs3749237	1	rs3749237	ENSG00000197582.5	GPX1P1	7.5	1.06e-11	0.000119	0.75	0.56	Resting heart rate;	chr3:49732599	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.964	rs11714957	ENSG00000197582.5	GPX1P1	7.5	1.06e-11	0.000119	0.75	0.56	Resting heart rate;	chr3:49738745	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.964	rs7431078	ENSG00000197582.5	GPX1P1	7.5	1.06e-11	0.000119	0.75	0.56	Resting heart rate;	chr3:49770757	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.964	rs35210174	ENSG00000197582.5	GPX1P1	7.5	1.06e-11	0.000119	0.75	0.56	Resting heart rate;	chr3:49775173	chrX:13378735~13379340:-
TGCT	trans	rs8081395	0.801	rs2665404	ENSG00000187870.7	RNFT1P3	7.5	1.07e-11	0.000119	0.64	0.56	White blood cell count;	chr17:59798035	chr17:20743333~20754501:-
TGCT	trans	rs2731664	0.792	rs163199	ENSG00000215571.5	GRK6P1	7.5	1.08e-11	0.000121	0.65	0.56	Intelligence (multi-trait analysis);	chr5:177463066	chr13:21319156~21320866:+
TGCT	trans	rs8081395	0.741	rs180520	ENSG00000187870.7	RNFT1P3	7.5	1.08e-11	0.000121	0.64	0.56	White blood cell count;	chr17:59937788	chr17:20743333~20754501:-
TGCT	trans	rs9467773	0.62	rs2451738	ENSG00000242375.1	RP11-498P14.3	-7.49	1.11e-11	0.000124	-0.64	-0.56	Intelligence (multi-trait analysis);	chr6:26618231	chr9:97195351~97197687:-
TGCT	trans	rs5022636	0.564	rs2275900	ENSG00000180764.13	PIPSL	7.49	1.14e-11	0.000127	0.69	0.56	Gut microbiota (functional units);	chr1:151265746	chr10:93958191~93961540:-
TGCT	trans	rs5022636	0.594	rs10888408	ENSG00000180764.13	PIPSL	7.49	1.14e-11	0.000127	0.69	0.56	Gut microbiota (functional units);	chr1:151267094	chr10:93958191~93961540:-
TGCT	trans	rs3749237	0.964	rs34522271	ENSG00000197582.5	GPX1P1	7.48	1.16e-11	0.000129	0.75	0.56	Resting heart rate;	chr3:49771084	chrX:13378735~13379340:-
TGCT	trans	rs4240897	0.935	rs2236055	ENSG00000261819.1	RP11-680G24.4	7.48	1.16e-11	0.00013	0.68	0.56	Tuberculosis;	chr1:11982204	chr16:14988259~14990160:-
TGCT	trans	rs4276421	0.695	rs8185255	ENSG00000231752.4	EMBP1	-7.48	1.2e-11	0.000133	-0.58	-0.56	P wave duration;	chr5:46263336	chr1:121519112~121571892:+
TGCT	trans	rs74781061	0.932	rs11629946	ENSG00000227288.3	RP5-837I24.1	-7.48	1.2e-11	0.000134	-0.57	-0.56	Endometriosis;	chr15:74579550	chr1:81501794~81503468:+
TGCT	trans	rs4276421	0.777	rs8185098	ENSG00000231752.4	EMBP1	7.48	1.21e-11	0.000134	0.58	0.56	P wave duration;	chr5:46125388	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.688	rs10038249	ENSG00000231752.4	EMBP1	7.48	1.21e-11	0.000134	0.58	0.56	P wave duration;	chr5:46160595	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.688	rs10941746	ENSG00000231752.4	EMBP1	7.48	1.21e-11	0.000134	0.58	0.56	P wave duration;	chr5:46202737	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.716	rs34186279	ENSG00000231752.4	EMBP1	7.48	1.21e-11	0.000134	0.58	0.56	P wave duration;	chr5:46221966	chr1:121519112~121571892:+
TGCT	trans	rs13190036	0.579	rs13159114	ENSG00000217325.2	PRELID1P1	7.48	1.21e-11	0.000135	0.86	0.56	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177234807	chr6:126643488~126644390:+
TGCT	trans	rs10242455	0.702	rs75944999	ENSG00000228834.1	RP11-249L21.4	7.47	1.25e-11	0.000136	1.48	0.56	Blood metabolite levels;	chr7:99398101	chr6:108907615~108907873:-
TGCT	trans	rs7312770	0.612	rs773114	ENSG00000212994.5	RPS26P6	7.47	1.25e-11	0.000136	0.61	0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:100895771~100896118:+
TGCT	trans	rs1707322	0.721	rs56255771	ENSG00000255397.1	AC022182.2	-7.47	1.26e-11	0.000137	-0.7	-0.56	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr8:60937705~60939871:-
TGCT	trans	rs9467773	1	rs9986382	ENSG00000242375.1	RP11-498P14.3	7.46	1.3e-11	0.000141	0.62	0.56	Intelligence (multi-trait analysis);	chr6:26550391	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs12526680	ENSG00000242375.1	RP11-498P14.3	7.46	1.3e-11	0.000141	0.62	0.56	Intelligence (multi-trait analysis);	chr6:26550726	chr9:97195351~97197687:-
TGCT	trans	rs3749237	0.964	rs11717463	ENSG00000197582.5	GPX1P1	7.46	1.31e-11	0.000142	0.78	0.56	Resting heart rate;	chr3:49771548	chrX:13378735~13379340:-
TGCT	trans	rs4276421	0.63	rs10054134	ENSG00000231752.4	EMBP1	-7.46	1.34e-11	0.000145	-0.58	-0.56	P wave duration;	chr5:46292175	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.574	rs80150384	ENSG00000231752.4	EMBP1	-7.46	1.34e-11	0.000145	-0.58	-0.56	P wave duration;	chr5:46296183	chr1:121519112~121571892:+
TGCT	trans	rs74781061	0.86	rs4887147	ENSG00000227288.3	RP5-837I24.1	7.46	1.35e-11	0.000145	0.6	0.56	Endometriosis;	chr15:74443863	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.86	rs4887150	ENSG00000227288.3	RP5-837I24.1	7.46	1.35e-11	0.000145	0.6	0.56	Endometriosis;	chr15:74444683	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.86	rs4887151	ENSG00000227288.3	RP5-837I24.1	7.46	1.35e-11	0.000145	0.6	0.56	Endometriosis;	chr15:74445126	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.932	rs11854461	ENSG00000227288.3	RP5-837I24.1	7.46	1.35e-11	0.000145	0.6	0.56	Endometriosis;	chr15:74447400	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.789	rs2289188	ENSG00000227288.3	RP5-837I24.1	7.46	1.35e-11	0.000145	0.6	0.56	Endometriosis;	chr15:74450127	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.86	rs6495101	ENSG00000227288.3	RP5-837I24.1	7.46	1.35e-11	0.000145	0.6	0.56	Endometriosis;	chr15:74450411	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.789	rs12440654	ENSG00000227288.3	RP5-837I24.1	7.46	1.35e-11	0.000145	0.6	0.56	Endometriosis;	chr15:74453008	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.86	rs7169985	ENSG00000227288.3	RP5-837I24.1	7.46	1.35e-11	0.000145	0.6	0.56	Endometriosis;	chr15:74453437	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.86	rs8037211	ENSG00000227288.3	RP5-837I24.1	7.46	1.35e-11	0.000145	0.6	0.56	Endometriosis;	chr15:74455061	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.789	rs11852291	ENSG00000227288.3	RP5-837I24.1	7.46	1.35e-11	0.000145	0.6	0.56	Endometriosis;	chr15:74457624	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.86	rs4887152	ENSG00000227288.3	RP5-837I24.1	7.46	1.35e-11	0.000145	0.6	0.56	Endometriosis;	chr15:74464013	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.86	rs4544202	ENSG00000227288.3	RP5-837I24.1	7.46	1.35e-11	0.000145	0.6	0.56	Endometriosis;	chr15:74468654	chr1:81501794~81503468:+
TGCT	trans	rs1707322	0.686	rs1084086	ENSG00000255397.1	AC022182.2	7.46	1.35e-11	0.000145	0.76	0.56	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr8:60937705~60939871:-
TGCT	trans	rs10940346	0.875	rs10076490	ENSG00000231752.4	EMBP1	7.45	1.35e-11	0.000145	0.58	0.56	Schizophrenia;	chr5:50389037	chr1:121519112~121571892:+
TGCT	trans	rs9467773	0.967	rs6941022	ENSG00000242375.1	RP11-498P14.3	7.45	1.36e-11	0.000146	0.62	0.56	Intelligence (multi-trait analysis);	chr6:26553303	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs2224380	ENSG00000242375.1	RP11-498P14.3	7.45	1.36e-11	0.000146	0.62	0.56	Intelligence (multi-trait analysis);	chr6:26553715	chr9:97195351~97197687:-
TGCT	trans	rs941207	0.514	rs6581105	ENSG00000121089.4	NACA3P	-7.45	1.38e-11	0.000148	-0.76	-0.56	Platelet count;	chr12:56792184	chr4:164943290~164943937:+
TGCT	trans	rs10940346	1	rs492337	ENSG00000231752.4	EMBP1	-7.45	1.38e-11	0.000148	-0.58	-0.56	Schizophrenia;	chr5:50274706	chr1:121519112~121571892:+
TGCT	trans	rs1707322	0.682	rs12037459	ENSG00000255397.1	AC022182.2	-7.45	1.38e-11	0.000148	-0.75	-0.56	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr8:60937705~60939871:-
TGCT	trans	rs10940346	1	rs1328253	ENSG00000231752.4	EMBP1	-7.45	1.38e-11	0.000148	-0.58	-0.56	Schizophrenia;	chr5:50286916	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.967	rs6449782	ENSG00000231752.4	EMBP1	-7.45	1.39e-11	0.000148	-0.58	-0.56	Schizophrenia;	chr5:50291694	chr1:121519112~121571892:+
TGCT	trans	rs10940346	1	rs4865522	ENSG00000231752.4	EMBP1	-7.45	1.39e-11	0.000149	-0.58	-0.56	Schizophrenia;	chr5:50303674	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.967	rs10068272	ENSG00000231752.4	EMBP1	-7.45	1.39e-11	0.000149	-0.58	-0.56	Schizophrenia;	chr5:50313688	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.967	rs10940129	ENSG00000231752.4	EMBP1	-7.45	1.39e-11	0.000149	-0.58	-0.56	Schizophrenia;	chr5:50315257	chr1:121519112~121571892:+
TGCT	trans	rs9467773	1	rs9467791	ENSG00000242375.1	RP11-498P14.3	-7.44	1.43e-11	0.000153	-0.62	-0.56	Intelligence (multi-trait analysis);	chr6:26562258	chr9:97195351~97197687:-
TGCT	trans	rs1707322	0.686	rs2991977	ENSG00000255397.1	AC022182.2	7.44	1.44e-11	0.000154	0.74	0.56	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.656	rs2991981	ENSG00000255397.1	AC022182.2	7.44	1.44e-11	0.000154	0.74	0.56	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr8:60937705~60939871:-
TGCT	trans	rs12709013	0.792	rs1657165	ENSG00000230849.2	GOT2P2	7.44	1.46e-11	0.000156	0.68	0.56	Blood metabolite ratios;	chr16:58747980	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.818	rs1646273	ENSG00000230849.2	GOT2P2	7.44	1.46e-11	0.000156	0.68	0.56	Blood metabolite ratios;	chr16:58748318	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.792	rs1646276	ENSG00000230849.2	GOT2P2	7.44	1.5e-11	0.000159	0.68	0.56	Blood metabolite ratios;	chr16:58749654	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.792	rs12325510	ENSG00000230849.2	GOT2P2	7.44	1.5e-11	0.000159	0.68	0.56	Blood metabolite ratios;	chr16:58749707	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.792	rs1646277	ENSG00000230849.2	GOT2P2	7.44	1.5e-11	0.000159	0.68	0.56	Blood metabolite ratios;	chr16:58750037	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.792	rs1646289	ENSG00000230849.2	GOT2P2	7.43	1.51e-11	0.000159	0.68	0.56	Blood metabolite ratios;	chr16:58755689	chr1:173141100~173142350:-
TGCT	trans	rs7312770	0.637	rs705699	ENSG00000223416.3	RPS26P15	7.43	1.53e-11	0.000162	0.63	0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr1:58056133~58056480:-
TGCT	trans	rs10940346	0.967	rs2271236	ENSG00000231752.4	EMBP1	7.43	1.53e-11	0.000162	0.61	0.56	Schizophrenia;	chr5:50405921	chr1:121519112~121571892:+
TGCT	trans	rs877636	0.692	rs11171739	ENSG00000234513.1	AC073072.7	7.43	1.56e-11	0.000166	0.6	0.55	Cognitive function;	chr12:56076841	chr7:22773646~22773993:-
TGCT	trans	rs9467773	1	rs9461271	ENSG00000242375.1	RP11-498P14.3	7.43	1.57e-11	0.000166	0.62	0.55	Intelligence (multi-trait analysis);	chr6:26554740	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs6930120	ENSG00000242375.1	RP11-498P14.3	7.43	1.57e-11	0.000166	0.62	0.55	Intelligence (multi-trait analysis);	chr6:26555256	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs9467787	ENSG00000242375.1	RP11-498P14.3	7.43	1.57e-11	0.000166	0.62	0.55	Intelligence (multi-trait analysis);	chr6:26556541	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs767471	ENSG00000242375.1	RP11-498P14.3	7.43	1.57e-11	0.000166	0.62	0.55	Intelligence (multi-trait analysis);	chr6:26557626	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.967	rs7753565	ENSG00000242375.1	RP11-498P14.3	7.43	1.57e-11	0.000166	0.62	0.55	Intelligence (multi-trait analysis);	chr6:26559784	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs6940188	ENSG00000242375.1	RP11-498P14.3	7.43	1.57e-11	0.000166	0.62	0.55	Intelligence (multi-trait analysis);	chr6:26561801	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs6940053	ENSG00000242375.1	RP11-498P14.3	7.43	1.57e-11	0.000166	0.62	0.55	Intelligence (multi-trait analysis);	chr6:26561894	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs10214634	ENSG00000242375.1	RP11-498P14.3	7.43	1.57e-11	0.000166	0.62	0.55	Intelligence (multi-trait analysis);	chr6:26564354	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.873	rs9295698	ENSG00000242375.1	RP11-498P14.3	7.43	1.57e-11	0.000166	0.62	0.55	Intelligence (multi-trait analysis);	chr6:26565871	chr9:97195351~97197687:-
TGCT	trans	rs10242455	0.702	rs6956305	ENSG00000228834.1	RP11-249L21.4	7.42	1.58e-11	0.000167	1.53	0.55	Blood metabolite levels;	chr7:99643687	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs73713580	ENSG00000228834.1	RP11-249L21.4	7.42	1.58e-11	0.000167	1.53	0.55	Blood metabolite levels;	chr7:99643987	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs6976017	ENSG00000228834.1	RP11-249L21.4	7.42	1.58e-11	0.000167	1.53	0.55	Blood metabolite levels;	chr7:99652376	chr6:108907615~108907873:-
TGCT	trans	rs7312770	0.637	rs705699	ENSG00000212994.5	RPS26P6	7.42	1.59e-11	0.000168	0.61	0.55	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr8:100895771~100896118:+
TGCT	trans	rs1707322	0.686	rs11211179	ENSG00000255397.1	AC022182.2	-7.42	1.63e-11	0.000172	-0.69	-0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs10157795	ENSG00000255397.1	AC022182.2	-7.42	1.63e-11	0.000172	-0.69	-0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr8:60937705~60939871:-
TGCT	trans	rs9611519	0.507	rs12484525	ENSG00000268568.1	AC007228.9	-7.42	1.65e-11	0.000174	-0.64	-0.55	Neuroticism;	chr22:41047873	chr19:56672574~56673901:-
TGCT	trans	rs13190036	0.551	rs9313751	ENSG00000217325.2	PRELID1P1	-7.41	1.69e-11	0.000177	-0.69	-0.55	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177217174	chr6:126643488~126644390:+
TGCT	trans	rs12709013	0.792	rs1657170	ENSG00000230849.2	GOT2P2	7.41	1.69e-11	0.000178	0.69	0.55	Blood metabolite ratios;	chr16:58752082	chr1:173141100~173142350:-
TGCT	trans	rs9611519	0.531	rs1967708	ENSG00000268568.1	AC007228.9	-7.41	1.71e-11	0.000179	-0.64	-0.55	Neuroticism;	chr22:41048440	chr19:56672574~56673901:-
TGCT	trans	rs10940346	1	rs6874697	ENSG00000231752.4	EMBP1	7.41	1.72e-11	0.00018	0.58	0.55	Schizophrenia;	chr5:50344307	chr1:121519112~121571892:+
TGCT	trans	rs10940346	1	rs2137132	ENSG00000231752.4	EMBP1	7.41	1.72e-11	0.00018	0.58	0.55	Schizophrenia;	chr5:50353988	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.967	rs1995795	ENSG00000231752.4	EMBP1	7.41	1.72e-11	0.00018	0.58	0.55	Schizophrenia;	chr5:50356233	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.967	rs6874829	ENSG00000231752.4	EMBP1	7.41	1.72e-11	0.00018	0.58	0.55	Schizophrenia;	chr5:50357573	chr1:121519112~121571892:+
TGCT	trans	rs10940346	1	rs7721808	ENSG00000231752.4	EMBP1	7.41	1.72e-11	0.00018	0.58	0.55	Schizophrenia;	chr5:50363136	chr1:121519112~121571892:+
TGCT	trans	rs10940346	1	rs1812994	ENSG00000231752.4	EMBP1	7.41	1.72e-11	0.00018	0.58	0.55	Schizophrenia;	chr5:50364397	chr1:121519112~121571892:+
TGCT	trans	rs10940346	1	rs13185587	ENSG00000231752.4	EMBP1	7.41	1.72e-11	0.00018	0.58	0.55	Schizophrenia;	chr5:50365409	chr1:121519112~121571892:+
TGCT	trans	rs10940346	1	rs3849670	ENSG00000231752.4	EMBP1	7.41	1.72e-11	0.00018	0.58	0.55	Schizophrenia;	chr5:50365641	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.905	rs4030569	ENSG00000231752.4	EMBP1	7.41	1.72e-11	0.00018	0.58	0.55	Schizophrenia;	chr5:50371779	chr1:121519112~121571892:+
TGCT	trans	rs10940346	1	rs4030570	ENSG00000231752.4	EMBP1	7.41	1.72e-11	0.00018	0.58	0.55	Schizophrenia;	chr5:50371829	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.936	rs10940171	ENSG00000231752.4	EMBP1	7.41	1.72e-11	0.00018	0.58	0.55	Schizophrenia;	chr5:50324613	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.936	rs7705285	ENSG00000231752.4	EMBP1	7.41	1.72e-11	0.00018	0.58	0.55	Schizophrenia;	chr5:50325579	chr1:121519112~121571892:+
TGCT	trans	rs10940346	1	rs35250488	ENSG00000231752.4	EMBP1	7.41	1.72e-11	0.00018	0.58	0.55	Schizophrenia;	chr5:50331004	chr1:121519112~121571892:+
TGCT	trans	rs10940346	1	rs10040323	ENSG00000231752.4	EMBP1	7.41	1.72e-11	0.00018	0.58	0.55	Schizophrenia;	chr5:50336779	chr1:121519112~121571892:+
TGCT	trans	rs10940346	1	rs2055909	ENSG00000231752.4	EMBP1	7.41	1.72e-11	0.00018	0.58	0.55	Schizophrenia;	chr5:50337474	chr1:121519112~121571892:+
TGCT	trans	rs10242455	0.702	rs41385645	ENSG00000228834.1	RP11-249L21.4	7.41	1.75e-11	0.000183	1.32	0.55	Blood metabolite levels;	chr7:99376415	chr6:108907615~108907873:-
TGCT	trans	rs10940346	0.537	rs8188099	ENSG00000231752.4	EMBP1	-7.4	1.76e-11	0.000184	-0.58	-0.55	Schizophrenia;	chr5:50183445	chr1:121519112~121571892:+
TGCT	trans	rs9611519	1	rs5751069	ENSG00000268568.1	AC007228.9	-7.4	1.8e-11	0.000188	-0.65	-0.55	Neuroticism;	chr22:41231771	chr19:56672574~56673901:-
TGCT	trans	rs7647973	0.58	rs11130184	ENSG00000197582.5	GPX1P1	7.4	1.82e-11	0.000189	0.68	0.55	Menarche (age at onset);	chr3:49192497	chrX:13378735~13379340:-
TGCT	trans	rs7647973	0.58	rs11716334	ENSG00000197582.5	GPX1P1	7.4	1.82e-11	0.000189	0.68	0.55	Menarche (age at onset);	chr3:49192663	chrX:13378735~13379340:-
TGCT	trans	rs7647973	0.58	rs2334958	ENSG00000197582.5	GPX1P1	7.4	1.82e-11	0.000189	0.68	0.55	Menarche (age at onset);	chr3:49214931	chrX:13378735~13379340:-
TGCT	trans	rs7647973	0.58	rs2117938	ENSG00000197582.5	GPX1P1	-7.4	1.82e-11	0.000189	-0.68	-0.55	Menarche (age at onset);	chr3:49226417	chrX:13378735~13379340:-
TGCT	trans	rs7647973	0.516	rs4955419	ENSG00000197582.5	GPX1P1	7.4	1.84e-11	0.000191	0.68	0.55	Menarche (age at onset);	chr3:49163259	chrX:13378735~13379340:-
TGCT	trans	rs10242455	0.702	rs6977165	ENSG00000228834.1	RP11-249L21.4	7.39	1.86e-11	0.000193	1.53	0.55	Blood metabolite levels;	chr7:99671774	chr6:108907615~108907873:-
TGCT	trans	rs12709013	0.792	rs62066815	ENSG00000230849.2	GOT2P2	7.39	1.87e-11	0.000193	0.68	0.55	Blood metabolite ratios;	chr16:58751577	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.766	rs1657175	ENSG00000230849.2	GOT2P2	7.39	1.87e-11	0.000193	0.68	0.55	Blood metabolite ratios;	chr16:58755527	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.792	rs1646290	ENSG00000230849.2	GOT2P2	7.39	1.87e-11	0.000193	0.68	0.55	Blood metabolite ratios;	chr16:58755807	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.792	rs1364346	ENSG00000230849.2	GOT2P2	7.39	1.87e-11	0.000193	0.68	0.55	Blood metabolite ratios;	chr16:58756420	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.792	rs257626	ENSG00000230849.2	GOT2P2	7.39	1.87e-11	0.000193	0.68	0.55	Blood metabolite ratios;	chr16:58759574	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.792	rs257625	ENSG00000230849.2	GOT2P2	7.39	1.87e-11	0.000193	0.68	0.55	Blood metabolite ratios;	chr16:58759978	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.792	rs1646262	ENSG00000230849.2	GOT2P2	7.39	1.87e-11	0.000193	0.68	0.55	Blood metabolite ratios;	chr16:58760593	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.792	rs257623	ENSG00000230849.2	GOT2P2	7.39	1.87e-11	0.000193	0.68	0.55	Blood metabolite ratios;	chr16:58761247	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.693	rs1627257	ENSG00000230849.2	GOT2P2	7.39	1.87e-11	0.000193	0.68	0.55	Blood metabolite ratios;	chr16:58763764	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.755	rs1628029	ENSG00000230849.2	GOT2P2	7.39	1.87e-11	0.000193	0.68	0.55	Blood metabolite ratios;	chr16:58763846	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.792	rs12935488	ENSG00000230849.2	GOT2P2	7.39	1.87e-11	0.000193	0.68	0.55	Blood metabolite ratios;	chr16:58766320	chr1:173141100~173142350:-
TGCT	trans	rs7647973	0.58	rs12629759	ENSG00000197582.5	GPX1P1	7.39	1.87e-11	0.000194	0.68	0.55	Menarche (age at onset);	chr3:49199961	chrX:13378735~13379340:-
TGCT	trans	rs9611519	0.78	rs2235852	ENSG00000268568.1	AC007228.9	-7.39	1.89e-11	0.000196	-0.86	-0.55	Neuroticism;	chr22:41265150	chr19:56672574~56673901:-
TGCT	trans	rs10940346	0.967	rs4030572	ENSG00000231752.4	EMBP1	7.39	1.9e-11	0.000196	0.58	0.55	Schizophrenia;	chr5:50375897	chr1:121519112~121571892:+
TGCT	trans	rs7312770	1	rs7312770	ENSG00000225071.1	GS1-184P14.2	-7.39	1.92e-11	0.000198	-0.56	-0.55	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chrX:24429573~24429920:-
TGCT	trans	rs877636	0.692	rs11171739	ENSG00000243538.1	CTB-55B8.1	7.38	1.96e-11	0.000202	0.62	0.55	Cognitive function;	chr12:56076841	chr5:16902294~16902641:-
TGCT	trans	rs74781061	0.929	rs79600165	ENSG00000227288.3	RP5-837I24.1	7.38	2.02e-11	0.000208	0.61	0.55	Endometriosis;	chr15:74648650	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs9672559	ENSG00000227288.3	RP5-837I24.1	7.38	2.02e-11	0.000208	0.61	0.55	Endometriosis;	chr15:74698995	chr1:81501794~81503468:+
TGCT	trans	rs9611519	1	rs4820433	ENSG00000268568.1	AC007228.9	-7.37	2.09e-11	0.000214	-0.64	-0.55	Neuroticism;	chr22:41211061	chr19:56672574~56673901:-
TGCT	trans	rs9611519	1	rs3818003	ENSG00000268568.1	AC007228.9	-7.37	2.09e-11	0.000214	-0.64	-0.55	Neuroticism;	chr22:41213686	chr19:56672574~56673901:-
TGCT	trans	rs9611519	1	rs2273085	ENSG00000268568.1	AC007228.9	-7.37	2.09e-11	0.000214	-0.64	-0.55	Neuroticism;	chr22:41219372	chr19:56672574~56673901:-
TGCT	trans	rs9611519	1	rs5758264	ENSG00000268568.1	AC007228.9	-7.37	2.09e-11	0.000214	-0.64	-0.55	Neuroticism;	chr22:41220280	chr19:56672574~56673901:-
TGCT	trans	rs3749237	0.964	rs2234385	ENSG00000197582.5	GPX1P1	7.37	2.09e-11	0.000215	0.73	0.55	Resting heart rate;	chr3:49808608	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.964	rs1799843	ENSG00000197582.5	GPX1P1	7.37	2.09e-11	0.000215	0.73	0.55	Resting heart rate;	chr3:49812290	chrX:13378735~13379340:-
TGCT	trans	rs3749237	1	rs11717256	ENSG00000197582.5	GPX1P1	7.37	2.09e-11	0.000215	0.73	0.55	Resting heart rate;	chr3:49831087	chrX:13378735~13379340:-
TGCT	trans	rs1707322	0.682	rs3014241	ENSG00000255397.1	AC022182.2	7.37	2.09e-11	0.000215	0.74	0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr8:60937705~60939871:-
TGCT	trans	rs55665837	0.778	rs11023212	ENSG00000236360.2	RP11-334A14.2	7.37	2.1e-11	0.000215	0.63	0.55	Vitamin D levels;	chr11:14410163	chr1:52993201~52993702:-
TGCT	trans	rs13190036	0.551	rs11957608	ENSG00000217325.2	PRELID1P1	-7.36	2.19e-11	0.000224	-0.68	-0.55	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228344	chr6:126643488~126644390:+
TGCT	trans	rs2209875	0.519	rs13283164	ENSG00000234819.1	RP11-336N8.4	7.36	2.19e-11	0.000224	0.6	0.55	Pelvic organ prolapse (moderate/severe);	chr9:89364523	chr9:78219120~78219357:+
TGCT	trans	rs13358908	1	rs13358908	ENSG00000231752.4	EMBP1	-7.36	2.19e-11	0.000224	-0.6	-0.55	Schizophrenia;	chr5:46349602	chr1:121519112~121571892:+
TGCT	trans	rs13253073	0.556	rs35194538	ENSG00000260318.1	COX6CP1	7.36	2.22e-11	0.000227	1.12	0.55	Glucose homeostasis traits;	chr8:99397627	chr16:11903923~11904137:-
TGCT	trans	rs4276421	0.714	rs8185016	ENSG00000231752.4	EMBP1	7.36	2.23e-11	0.000227	0.58	0.55	P wave duration;	chr5:46121704	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.713	rs8188193	ENSG00000231752.4	EMBP1	7.36	2.23e-11	0.000227	0.58	0.55	P wave duration;	chr5:46122428	chr1:121519112~121571892:+
TGCT	trans	rs7200543	1	rs16966953	ENSG00000250569.1	NTAN1P2	7.36	2.26e-11	0.00023	0.69	0.55	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15041997	chr8:86481754~86483002:-
TGCT	trans	rs7200543	1	rs35574015	ENSG00000250569.1	NTAN1P2	7.36	2.26e-11	0.00023	0.69	0.55	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15052204	chr8:86481754~86483002:-
TGCT	trans	rs7647973	0.516	rs4308307	ENSG00000197582.5	GPX1P1	7.36	2.26e-11	0.00023	0.68	0.55	Menarche (age at onset);	chr3:49155783	chrX:13378735~13379340:-
TGCT	trans	rs1816752	0.783	rs7317439	ENSG00000237917.1	PARP4P1	7.35	2.3e-11	0.000234	0.66	0.55	Obesity-related traits;	chr13:24410939	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.819	rs7317504	ENSG00000237917.1	PARP4P1	7.35	2.3e-11	0.000234	0.66	0.55	Obesity-related traits;	chr13:24411287	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.783	rs7317712	ENSG00000237917.1	PARP4P1	7.35	2.3e-11	0.000234	0.66	0.55	Obesity-related traits;	chr13:24411365	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.783	rs7139527	ENSG00000237917.1	PARP4P1	7.35	2.3e-11	0.000234	0.66	0.55	Obesity-related traits;	chr13:24411374	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.819	rs9511240	ENSG00000237917.1	PARP4P1	7.35	2.3e-11	0.000234	0.66	0.55	Obesity-related traits;	chr13:24411768	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.819	rs7988388	ENSG00000237917.1	PARP4P1	7.35	2.3e-11	0.000234	0.66	0.55	Obesity-related traits;	chr13:24412675	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.875	rs7993132	ENSG00000237917.1	PARP4P1	7.35	2.3e-11	0.000234	0.66	0.55	Obesity-related traits;	chr13:24412903	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.792	rs7330956	ENSG00000237917.1	PARP4P1	7.35	2.3e-11	0.000234	0.66	0.55	Obesity-related traits;	chr13:24413174	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.777	rs6490915	ENSG00000237917.1	PARP4P1	7.35	2.3e-11	0.000234	0.66	0.55	Obesity-related traits;	chr13:24413724	chrY:26594851~26634652:-
TGCT	trans	rs2950393	0.787	rs4759254	ENSG00000121089.4	NACA3P	7.35	2.32e-11	0.000235	0.7	0.55	Platelet distribution width;	chr12:56702890	chr4:164943290~164943937:+
TGCT	trans	rs1816752	0.837	rs7139748	ENSG00000237917.1	PARP4P1	7.35	2.34e-11	0.000237	0.66	0.55	Obesity-related traits;	chr13:24411531	chrY:26594851~26634652:-
TGCT	trans	rs77688320	0.517	rs10497868	ENSG00000235105.1	RP11-329A14.1	-7.35	2.34e-11	0.000237	-0.54	-0.55	Breast cancer;	chr2:201439317	chr1:48435967~48437223:+
TGCT	trans	rs2950393	0.895	rs2958123	ENSG00000121089.4	NACA3P	7.35	2.35e-11	0.000237	0.7	0.55	Platelet distribution width;	chr12:56668441	chr4:164943290~164943937:+
TGCT	trans	rs2950393	0.857	rs9989034	ENSG00000121089.4	NACA3P	7.35	2.35e-11	0.000237	0.7	0.55	Platelet distribution width;	chr12:56674508	chr4:164943290~164943937:+
TGCT	trans	rs2950393	0.929	rs2290893	ENSG00000121089.4	NACA3P	7.35	2.35e-11	0.000237	0.7	0.55	Platelet distribution width;	chr12:56684836	chr4:164943290~164943937:+
TGCT	trans	rs7200543	1	rs16966952	ENSG00000250569.1	NTAN1P2	7.35	2.36e-11	0.000238	0.67	0.55	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15042086	chr8:86481754~86483002:-
TGCT	trans	rs10940346	0.934	rs2353222	ENSG00000231752.4	EMBP1	-7.34	2.4e-11	0.000241	-0.58	-0.55	Schizophrenia;	chr5:50174249	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.716	rs8188088	ENSG00000231752.4	EMBP1	-7.34	2.4e-11	0.000241	-0.58	-0.55	Schizophrenia;	chr5:50215591	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.818	rs472278	ENSG00000231752.4	EMBP1	-7.34	2.4e-11	0.000241	-0.58	-0.55	Schizophrenia;	chr5:50215972	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.653	rs4371800	ENSG00000231752.4	EMBP1	-7.34	2.4e-11	0.000241	-0.58	-0.55	Schizophrenia;	chr5:50225349	chr1:121519112~121571892:+
TGCT	trans	rs7200543	0.961	rs1741	ENSG00000250569.1	NTAN1P2	7.34	2.5e-11	0.00025	0.69	0.55	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036494	chr8:86481754~86483002:-
TGCT	trans	rs7200543	1	rs1121	ENSG00000250569.1	NTAN1P2	7.34	2.5e-11	0.00025	0.69	0.55	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037219	chr8:86481754~86483002:-
TGCT	trans	rs7200543	1	rs4985154	ENSG00000250569.1	NTAN1P2	7.34	2.5e-11	0.00025	0.69	0.55	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037785	chr8:86481754~86483002:-
TGCT	trans	rs1816752	1	rs1816752	ENSG00000237917.1	PARP4P1	7.34	2.51e-11	0.000251	0.66	0.55	Obesity-related traits;	chr13:24406811	chrY:26594851~26634652:-
TGCT	trans	rs877636	0.692	rs10876870	ENSG00000243538.1	CTB-55B8.1	-7.33	2.58e-11	0.000257	-0.63	-0.55	Cognitive function;	chr12:56084218	chr5:16902294~16902641:-
TGCT	trans	rs877636	0.692	rs7971751	ENSG00000243538.1	CTB-55B8.1	-7.33	2.58e-11	0.000257	-0.63	-0.55	Cognitive function;	chr12:56084874	chr5:16902294~16902641:-
TGCT	trans	rs7312770	0.637	rs705700	ENSG00000223416.3	RPS26P15	7.32	2.68e-11	0.000267	0.62	0.55	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr1:58056133~58056480:-
TGCT	trans	rs74781061	0.929	rs11072493	ENSG00000227288.3	RP5-837I24.1	7.31	2.83e-11	0.000281	0.57	0.55	Endometriosis;	chr15:74536881	chr1:81501794~81503468:+
TGCT	trans	rs13190036	1	rs13190036	ENSG00000217325.2	PRELID1P1	7.31	2.9e-11	0.000288	0.82	0.55	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177310719	chr6:126643488~126644390:+
TGCT	trans	rs74781061	0.929	rs6495118	ENSG00000227288.3	RP5-837I24.1	7.31	2.92e-11	0.000289	0.6	0.55	Endometriosis;	chr15:74619671	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.872	rs4886598	ENSG00000227288.3	RP5-837I24.1	7.3	2.96e-11	0.000293	0.56	0.55	Endometriosis;	chr15:74484441	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.872	rs6495106	ENSG00000227288.3	RP5-837I24.1	7.3	2.96e-11	0.000293	0.56	0.55	Endometriosis;	chr15:74487006	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.932	rs7176491	ENSG00000227288.3	RP5-837I24.1	7.3	2.96e-11	0.000293	0.56	0.55	Endometriosis;	chr15:74514875	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.932	rs61168092	ENSG00000227288.3	RP5-837I24.1	7.3	2.96e-11	0.000293	0.56	0.55	Endometriosis;	chr15:74517619	chr1:81501794~81503468:+
TGCT	trans	rs74781061	1	rs8040745	ENSG00000227288.3	RP5-837I24.1	7.3	2.96e-11	0.000293	0.56	0.55	Endometriosis;	chr15:74525791	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.932	rs7178568	ENSG00000227288.3	RP5-837I24.1	7.3	2.96e-11	0.000293	0.56	0.55	Endometriosis;	chr15:74559075	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.932	rs8023479	ENSG00000227288.3	RP5-837I24.1	7.3	2.96e-11	0.000293	0.56	0.55	Endometriosis;	chr15:74561337	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.932	rs12437519	ENSG00000227288.3	RP5-837I24.1	7.3	2.96e-11	0.000293	0.56	0.55	Endometriosis;	chr15:74562109	chr1:81501794~81503468:+
TGCT	trans	rs13253073	0.556	rs13279371	ENSG00000260318.1	COX6CP1	7.3	3e-11	0.000296	1.12	0.55	Glucose homeostasis traits;	chr8:99407006	chr16:11903923~11904137:-
TGCT	trans	rs10940346	0.728	rs12655271	ENSG00000231752.4	EMBP1	-7.3	3.03e-11	0.000299	-0.59	-0.55	Schizophrenia;	chr5:50212921	chr1:121519112~121571892:+
TGCT	trans	rs10716881	1	rs10716881	ENSG00000121089.4	NACA3P	-7.3	3.04e-11	3e-04	-0.69	-0.55	High light scatter reticulocyte count;	chr12:56644387	chr4:164943290~164943937:+
TGCT	trans	rs10242455	0.571	rs13438288	ENSG00000228834.1	RP11-249L21.4	7.3	3.09e-11	0.000305	1.41	0.55	Blood metabolite levels;	chr7:99318791	chr6:108907615~108907873:-
TGCT	trans	rs9611519	0.964	rs2179744	ENSG00000268568.1	AC007228.9	-7.3	3.09e-11	0.000305	-0.64	-0.55	Neuroticism;	chr22:41225710	chr19:56672574~56673901:-
TGCT	trans	rs9611519	1	rs5758268	ENSG00000268568.1	AC007228.9	-7.3	3.09e-11	0.000305	-0.64	-0.55	Neuroticism;	chr22:41226415	chr19:56672574~56673901:-
TGCT	trans	rs12709013	0.792	rs12926512	ENSG00000230849.2	GOT2P2	7.29	3.12e-11	0.000308	0.66	0.55	Blood metabolite ratios;	chr16:58768317	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.792	rs12595974	ENSG00000230849.2	GOT2P2	7.29	3.12e-11	0.000308	0.66	0.55	Blood metabolite ratios;	chr16:58769132	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.792	rs1836877	ENSG00000230849.2	GOT2P2	7.29	3.12e-11	0.000308	0.66	0.55	Blood metabolite ratios;	chr16:58769821	chr1:173141100~173142350:-
TGCT	trans	rs3749237	0.964	rs62260719	ENSG00000197582.5	GPX1P1	7.29	3.24e-11	0.000317	0.73	0.55	Resting heart rate;	chr3:49814986	chrX:13378735~13379340:-
TGCT	trans	rs1707322	0.685	rs28617418	ENSG00000255397.1	AC022182.2	-7.28	3.3e-11	0.000322	-0.68	-0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.682	rs28490344	ENSG00000255397.1	AC022182.2	-7.28	3.3e-11	0.000322	-0.68	-0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs28501477	ENSG00000255397.1	AC022182.2	-7.28	3.3e-11	0.000322	-0.68	-0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs28641748	ENSG00000255397.1	AC022182.2	-7.28	3.3e-11	0.000322	-0.68	-0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs6697821	ENSG00000255397.1	AC022182.2	-7.28	3.3e-11	0.000322	-0.68	-0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs4330955	ENSG00000255397.1	AC022182.2	-7.28	3.3e-11	0.000322	-0.68	-0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.691	rs11211174	ENSG00000255397.1	AC022182.2	-7.28	3.3e-11	0.000322	-0.68	-0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.691	rs12031182	ENSG00000255397.1	AC022182.2	-7.28	3.3e-11	0.000322	-0.68	-0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs10430123	ENSG00000255397.1	AC022182.2	-7.28	3.3e-11	0.000322	-0.68	-0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr8:60937705~60939871:-
TGCT	trans	rs13190036	0.681	rs28461408	ENSG00000217325.2	PRELID1P1	7.28	3.33e-11	0.000325	0.84	0.55	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177235292	chr6:126643488~126644390:+
TGCT	trans	rs9467773	1	rs6922824	ENSG00000242375.1	RP11-498P14.3	-7.28	3.34e-11	0.000326	-0.6	-0.55	Intelligence (multi-trait analysis);	chr6:26553587	chr9:97195351~97197687:-
TGCT	trans	rs4276421	0.684	rs11958686	ENSG00000231752.4	EMBP1	7.28	3.35e-11	0.000326	0.57	0.55	P wave duration;	chr5:46173456	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.688	rs11950077	ENSG00000231752.4	EMBP1	7.28	3.35e-11	0.000326	0.57	0.55	P wave duration;	chr5:46179798	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.654	rs8185114	ENSG00000231752.4	EMBP1	7.28	3.35e-11	0.000326	0.57	0.55	P wave duration;	chr5:46181843	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.652	rs8188276	ENSG00000231752.4	EMBP1	7.28	3.35e-11	0.000326	0.57	0.55	P wave duration;	chr5:46182731	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.656	rs8185101	ENSG00000231752.4	EMBP1	7.28	3.35e-11	0.000326	0.57	0.55	P wave duration;	chr5:46183248	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.656	rs13188002	ENSG00000231752.4	EMBP1	7.28	3.35e-11	0.000326	0.57	0.55	P wave duration;	chr5:46184203	chr1:121519112~121571892:+
TGCT	trans	rs9467773	1	rs9357010	ENSG00000242375.1	RP11-498P14.3	7.28	3.35e-11	0.000326	0.6	0.55	Intelligence (multi-trait analysis);	chr6:26527717	chr9:97195351~97197687:-
TGCT	trans	rs4276421	0.623	rs8188231	ENSG00000231752.4	EMBP1	7.28	3.37e-11	0.000328	0.57	0.55	P wave duration;	chr5:46186924	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.684	rs8188258	ENSG00000231752.4	EMBP1	7.28	3.37e-11	0.000328	0.57	0.55	P wave duration;	chr5:46187284	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.688	rs10065920	ENSG00000231752.4	EMBP1	7.28	3.37e-11	0.000328	0.57	0.55	P wave duration;	chr5:46190593	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.688	rs8188292	ENSG00000231752.4	EMBP1	7.28	3.37e-11	0.000328	0.57	0.55	P wave duration;	chr5:46191402	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.684	rs10064829	ENSG00000231752.4	EMBP1	7.28	3.37e-11	0.000328	0.57	0.55	P wave duration;	chr5:46192959	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.657	rs8175415	ENSG00000231752.4	EMBP1	7.28	3.37e-11	0.000328	0.57	0.55	P wave duration;	chr5:46193360	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.657	rs8188010	ENSG00000231752.4	EMBP1	7.28	3.37e-11	0.000328	0.57	0.55	P wave duration;	chr5:46194057	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.633	rs62370770	ENSG00000231752.4	EMBP1	7.28	3.37e-11	0.000328	0.57	0.55	P wave duration;	chr5:46195784	chr1:121519112~121571892:+
TGCT	trans	rs8081395	0.836	rs1295926	ENSG00000187870.7	RNFT1P3	-7.28	3.4e-11	0.000329	-0.63	-0.55	White blood cell count;	chr17:59832012	chr17:20743333~20754501:-
TGCT	trans	rs1816752	0.748	rs6490912	ENSG00000237917.1	PARP4P1	7.27	3.47e-11	0.000336	0.65	0.55	Obesity-related traits;	chr13:24408941	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.819	rs1981276	ENSG00000237917.1	PARP4P1	7.27	3.47e-11	0.000336	0.65	0.55	Obesity-related traits;	chr13:24409361	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.837	rs57052031	ENSG00000237917.1	PARP4P1	7.27	3.47e-11	0.000336	0.65	0.55	Obesity-related traits;	chr13:24409730	chrY:26594851~26634652:-
TGCT	trans	rs2731664	0.792	rs335467	ENSG00000215571.5	GRK6P1	7.27	3.51e-11	0.00034	0.65	0.55	Intelligence (multi-trait analysis);	chr5:177463641	chr13:21319156~21320866:+
TGCT	trans	rs61990749	0.511	rs2052444	ENSG00000235400.1	RP4-641G12.4	7.27	3.55e-11	0.000343	0.98	0.55	Fibroblast growth factor basic levels;	chr14:77846575	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.511	rs724263	ENSG00000235400.1	RP4-641G12.4	7.27	3.55e-11	0.000343	0.98	0.55	Fibroblast growth factor basic levels;	chr14:77855531	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.511	rs10130790	ENSG00000235400.1	RP4-641G12.4	7.27	3.55e-11	0.000343	0.98	0.55	Fibroblast growth factor basic levels;	chr14:77857849	chr1:78749073~78750659:+
TGCT	trans	rs61990749	0.511	rs10146144	ENSG00000235400.1	RP4-641G12.4	7.27	3.55e-11	0.000343	0.98	0.55	Fibroblast growth factor basic levels;	chr14:77858957	chr1:78749073~78750659:+
TGCT	trans	rs1816752	0.819	rs7400583	ENSG00000237917.1	PARP4P1	7.27	3.6e-11	0.000347	0.66	0.55	Obesity-related traits;	chr13:24415916	chrY:26594851~26634652:-
TGCT	trans	rs1707322	0.752	rs11488313	ENSG00000255397.1	AC022182.2	-7.27	3.61e-11	0.000348	-0.67	-0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs4559551	ENSG00000255397.1	AC022182.2	-7.26	3.65e-11	0.000352	-0.68	-0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr8:60937705~60939871:-
TGCT	trans	rs9611519	0.929	rs2064560	ENSG00000268568.1	AC007228.9	-7.26	3.66e-11	0.000352	-0.66	-0.55	Neuroticism;	chr22:41134036	chr19:56672574~56673901:-
TGCT	trans	rs9467773	1	rs4871	ENSG00000242375.1	RP11-498P14.3	7.26	3.7e-11	0.000355	0.61	0.55	Intelligence (multi-trait analysis);	chr6:26545404	chr9:97195351~97197687:-
TGCT	trans	rs1707322	0.721	rs11211163	ENSG00000255397.1	AC022182.2	-7.26	3.7e-11	0.000355	-0.68	-0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs12037803	ENSG00000255397.1	AC022182.2	-7.26	3.7e-11	0.000355	-0.68	-0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs10789470	ENSG00000255397.1	AC022182.2	-7.26	3.7e-11	0.000355	-0.68	-0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs61784796	ENSG00000255397.1	AC022182.2	-7.26	3.7e-11	0.000355	-0.68	-0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs10749856	ENSG00000255397.1	AC022182.2	-7.26	3.7e-11	0.000355	-0.68	-0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs10890344	ENSG00000255397.1	AC022182.2	-7.26	3.7e-11	0.000355	-0.68	-0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs4564187	ENSG00000255397.1	AC022182.2	-7.26	3.7e-11	0.000355	-0.68	-0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.752	rs28438704	ENSG00000255397.1	AC022182.2	-7.26	3.7e-11	0.000355	-0.68	-0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs28442079	ENSG00000255397.1	AC022182.2	-7.26	3.7e-11	0.000355	-0.68	-0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs28817701	ENSG00000255397.1	AC022182.2	-7.26	3.7e-11	0.000355	-0.68	-0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.691	rs28495425	ENSG00000255397.1	AC022182.2	-7.26	3.7e-11	0.000355	-0.68	-0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.691	rs61784803	ENSG00000255397.1	AC022182.2	7.26	3.7e-11	0.000355	0.68	0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.663	rs3935296	ENSG00000255397.1	AC022182.2	7.26	3.7e-11	0.000355	0.68	0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr8:60937705~60939871:-
TGCT	trans	rs8081395	0.741	rs1292053	ENSG00000187870.7	RNFT1P3	-7.26	3.75e-11	0.000359	-0.62	-0.55	White blood cell count;	chr17:59886176	chr17:20743333~20754501:-
TGCT	trans	rs10940346	0.846	rs8175378	ENSG00000231752.4	EMBP1	-7.26	3.75e-11	0.000359	-0.58	-0.55	Schizophrenia;	chr5:50182876	chr1:121519112~121571892:+
TGCT	trans	rs7937890	1	rs7937890	ENSG00000236360.2	RP11-334A14.2	7.26	3.76e-11	0.00036	0.63	0.55	Mitochondrial DNA levels;	chr11:14374939	chr1:52993201~52993702:-
TGCT	trans	rs74781061	0.929	rs4887153	ENSG00000227288.3	RP5-837I24.1	7.25	3.83e-11	0.000367	0.61	0.55	Endometriosis;	chr15:74484701	chr1:81501794~81503468:+
TGCT	trans	rs7647973	0.58	rs7652746	ENSG00000197582.5	GPX1P1	-7.25	3.85e-11	0.000369	-0.66	-0.55	Menarche (age at onset);	chr3:49224874	chrX:13378735~13379340:-
TGCT	trans	rs1816752	0.905	rs1348110	ENSG00000237917.1	PARP4P1	7.25	3.86e-11	0.00037	0.64	0.55	Obesity-related traits;	chr13:24406537	chrY:26594851~26634652:-
TGCT	trans	rs61990749	0.571	rs4448861	ENSG00000235400.1	RP4-641G12.4	7.25	3.87e-11	0.00037	1.01	0.55	Fibroblast growth factor basic levels;	chr14:77841392	chr1:78749073~78750659:+
TGCT	trans	rs10242455	0.571	rs117370443	ENSG00000228834.1	RP11-249L21.4	7.25	3.91e-11	0.000373	1.4	0.55	Blood metabolite levels;	chr7:99377635	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs74552228	ENSG00000228834.1	RP11-249L21.4	7.25	3.91e-11	0.000373	1.4	0.55	Blood metabolite levels;	chr7:99379423	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs17161700	ENSG00000228834.1	RP11-249L21.4	7.25	3.91e-11	0.000373	1.4	0.55	Blood metabolite levels;	chr7:99379444	chr6:108907615~108907873:-
TGCT	trans	rs4276421	0.774	rs10042199	ENSG00000231752.4	EMBP1	-7.25	3.95e-11	0.000375	-0.58	-0.55	P wave duration;	chr5:46103946	chr1:121519112~121571892:+
TGCT	trans	rs877636	0.692	rs11171739	ENSG00000223416.3	RPS26P15	7.25	3.95e-11	0.000376	0.58	0.55	Cognitive function;	chr12:56076841	chr1:58056133~58056480:-
TGCT	trans	rs8081395	0.775	rs2645482	ENSG00000187870.7	RNFT1P3	7.25	3.96e-11	0.000376	0.64	0.55	White blood cell count;	chr17:59865754	chr17:20743333~20754501:-
TGCT	trans	rs8081395	0.805	rs2645485	ENSG00000187870.7	RNFT1P3	7.25	3.96e-11	0.000376	0.64	0.55	White blood cell count;	chr17:59866920	chr17:20743333~20754501:-
TGCT	trans	rs877636	0.692	rs2271194	ENSG00000243538.1	CTB-55B8.1	-7.25	3.96e-11	0.000377	-0.62	-0.55	Cognitive function;	chr12:56083910	chr5:16902294~16902641:-
TGCT	trans	rs1707322	0.682	rs28508523	ENSG00000255397.1	AC022182.2	-7.25	3.99e-11	0.000378	-0.68	-0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.691	rs11211175	ENSG00000255397.1	AC022182.2	-7.25	3.99e-11	0.000378	-0.68	-0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr8:60937705~60939871:-
TGCT	trans	rs8081395	0.805	rs1295927	ENSG00000187870.7	RNFT1P3	7.25	4e-11	0.000379	0.63	0.55	White blood cell count;	chr17:59852174	chr17:20743333~20754501:-
TGCT	trans	rs7200543	0.961	rs3803573	ENSG00000250569.1	NTAN1P2	7.25	4.03e-11	0.000382	0.68	0.55	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044556	chr8:86481754~86483002:-
TGCT	trans	rs7312770	0.612	rs773114	ENSG00000223416.3	RPS26P15	7.24	4.03e-11	0.000382	0.61	0.55	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr1:58056133~58056480:-
TGCT	trans	rs941207	0.507	rs1107479	ENSG00000121089.4	NACA3P	-7.24	4.04e-11	0.000382	-0.72	-0.55	Platelet count;	chr12:56636902	chr4:164943290~164943937:+
TGCT	trans	rs9467773	0.844	rs2393669	ENSG00000242375.1	RP11-498P14.3	7.24	4.04e-11	0.000382	0.61	0.55	Intelligence (multi-trait analysis);	chr6:26503645	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs9461259	ENSG00000242375.1	RP11-498P14.3	7.24	4.04e-11	0.000382	0.61	0.55	Intelligence (multi-trait analysis);	chr6:26504607	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs9467774	ENSG00000242375.1	RP11-498P14.3	7.24	4.04e-11	0.000382	0.61	0.55	Intelligence (multi-trait analysis);	chr6:26504808	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs3736781	ENSG00000242375.1	RP11-498P14.3	7.24	4.04e-11	0.000382	0.61	0.55	Intelligence (multi-trait analysis);	chr6:26505134	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs3736782	ENSG00000242375.1	RP11-498P14.3	7.24	4.04e-11	0.000382	0.61	0.55	Intelligence (multi-trait analysis);	chr6:26505175	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs2208331	ENSG00000242375.1	RP11-498P14.3	7.24	4.04e-11	0.000382	0.61	0.55	Intelligence (multi-trait analysis);	chr6:26507091	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs9393728	ENSG00000242375.1	RP11-498P14.3	7.24	4.04e-11	0.000382	0.61	0.55	Intelligence (multi-trait analysis);	chr6:26509102	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs1056667	ENSG00000242375.1	RP11-498P14.3	7.24	4.04e-11	0.000382	0.61	0.55	Intelligence (multi-trait analysis);	chr6:26510336	chr9:97195351~97197687:-
TGCT	trans	rs1707322	0.717	rs1547925	ENSG00000255397.1	AC022182.2	7.24	4.11e-11	0.000388	0.71	0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr8:60937705~60939871:-
TGCT	trans	rs7937890	0.874	rs2303972	ENSG00000236360.2	RP11-334A14.2	-7.24	4.13e-11	0.00039	-0.59	-0.55	Mitochondrial DNA levels;	chr11:14281736	chr1:52993201~52993702:-
TGCT	trans	rs3749237	0.964	rs2352967	ENSG00000197582.5	GPX1P1	7.24	4.13e-11	0.00039	0.72	0.55	Resting heart rate;	chr3:49834208	chrX:13378735~13379340:-
TGCT	trans	rs9467773	1	rs1321480	ENSG00000242375.1	RP11-498P14.3	7.24	4.17e-11	0.000394	0.61	0.55	Intelligence (multi-trait analysis);	chr6:26532514	chr9:97195351~97197687:-
TGCT	trans	rs10940346	1	rs6450164	ENSG00000231752.4	EMBP1	-7.24	4.18e-11	0.000395	-0.6	-0.54	Schizophrenia;	chr5:50502814	chr1:121519112~121571892:+
TGCT	trans	rs10940346	1	rs1962832	ENSG00000231752.4	EMBP1	-7.24	4.18e-11	0.000395	-0.6	-0.54	Schizophrenia;	chr5:50502962	chr1:121519112~121571892:+
TGCT	trans	rs9467773	0.967	rs9295694	ENSG00000242375.1	RP11-498P14.3	7.24	4.23e-11	0.000397	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26512766	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.967	rs9467775	ENSG00000242375.1	RP11-498P14.3	7.24	4.23e-11	0.000397	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26513207	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs9393729	ENSG00000242375.1	RP11-498P14.3	7.24	4.23e-11	0.000397	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26513938	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.967	rs6456732	ENSG00000242375.1	RP11-498P14.3	7.24	4.23e-11	0.000397	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26514217	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs4713006	ENSG00000242375.1	RP11-498P14.3	7.24	4.23e-11	0.000397	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26519644	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.967	rs1535276	ENSG00000242375.1	RP11-498P14.3	7.24	4.23e-11	0.000397	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26520713	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.967	rs6924865	ENSG00000242375.1	RP11-498P14.3	7.24	4.23e-11	0.000397	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26521125	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs6925703	ENSG00000242375.1	RP11-498P14.3	7.24	4.23e-11	0.000397	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26521361	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs6910899	ENSG00000242375.1	RP11-498P14.3	7.24	4.23e-11	0.000397	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26524111	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.967	rs9461267	ENSG00000242375.1	RP11-498P14.3	7.24	4.23e-11	0.000397	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26525227	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.967	rs1056347	ENSG00000242375.1	RP11-498P14.3	7.24	4.23e-11	0.000397	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26527296	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs9393731	ENSG00000242375.1	RP11-498P14.3	7.24	4.23e-11	0.000397	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26529146	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs11756120	ENSG00000242375.1	RP11-498P14.3	7.24	4.23e-11	0.000397	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26529580	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs9393732	ENSG00000242375.1	RP11-498P14.3	7.24	4.23e-11	0.000397	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26530670	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.967	rs9358954	ENSG00000242375.1	RP11-498P14.3	7.24	4.23e-11	0.000397	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26530950	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs28558133	ENSG00000242375.1	RP11-498P14.3	7.24	4.23e-11	0.000397	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26531205	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs10946834	ENSG00000242375.1	RP11-498P14.3	7.24	4.23e-11	0.000397	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26533436	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs10946835	ENSG00000242375.1	RP11-498P14.3	7.24	4.23e-11	0.000397	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26533529	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs9467778	ENSG00000242375.1	RP11-498P14.3	7.24	4.23e-11	0.000397	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26534515	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs2393670	ENSG00000242375.1	RP11-498P14.3	7.24	4.23e-11	0.000397	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26535313	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs1321481	ENSG00000242375.1	RP11-498P14.3	7.24	4.23e-11	0.000397	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26537982	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs4713008	ENSG00000242375.1	RP11-498P14.3	7.24	4.23e-11	0.000397	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26538040	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.967	rs6932865	ENSG00000242375.1	RP11-498P14.3	7.24	4.23e-11	0.000397	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26539938	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs6933176	ENSG00000242375.1	RP11-498P14.3	7.24	4.23e-11	0.000397	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26539950	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs9467782	ENSG00000242375.1	RP11-498P14.3	7.24	4.23e-11	0.000397	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26542545	chr9:97195351~97197687:-
TGCT	trans	rs8081395	0.836	rs1292061	ENSG00000187870.7	RNFT1P3	-7.23	4.26e-11	4e-04	-0.63	-0.54	White blood cell count;	chr17:59833869	chr17:20743333~20754501:-
TGCT	trans	rs74781061	0.789	rs1078011	ENSG00000227288.3	RP5-837I24.1	7.23	4.35e-11	0.000408	0.59	0.54	Endometriosis;	chr15:74442521	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.86	rs3985310	ENSG00000227288.3	RP5-837I24.1	7.23	4.35e-11	0.000408	0.59	0.54	Endometriosis;	chr15:74442826	chr1:81501794~81503468:+
TGCT	trans	rs77688320	0.517	rs2270315	ENSG00000235105.1	RP11-329A14.1	7.23	4.41e-11	0.000413	0.53	0.54	Breast cancer;	chr2:201452542	chr1:48435967~48437223:+
TGCT	trans	rs77688320	0.517	rs2287054	ENSG00000235105.1	RP11-329A14.1	7.23	4.41e-11	0.000413	0.53	0.54	Breast cancer;	chr2:201454315	chr1:48435967~48437223:+
TGCT	trans	rs77688320	0.5	rs10931948	ENSG00000235105.1	RP11-329A14.1	7.23	4.41e-11	0.000413	0.53	0.54	Breast cancer;	chr2:201459199	chr1:48435967~48437223:+
TGCT	trans	rs77688320	0.535	rs6435084	ENSG00000235105.1	RP11-329A14.1	7.23	4.41e-11	0.000413	0.53	0.54	Breast cancer;	chr2:201461274	chr1:48435967~48437223:+
TGCT	trans	rs877636	0.669	rs7297175	ENSG00000223416.3	RPS26P15	-7.23	4.44e-11	0.000415	-0.59	-0.54	Cognitive function;	chr12:56080024	chr1:58056133~58056480:-
TGCT	trans	rs2950393	0.929	rs7973157	ENSG00000121089.4	NACA3P	-7.22	4.5e-11	0.000421	-0.69	-0.54	Platelet distribution width;	chr12:56655409	chr4:164943290~164943937:+
TGCT	trans	rs7200543	1	rs1135999	ENSG00000250569.1	NTAN1P2	7.22	4.52e-11	0.000423	0.68	0.54	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038105	chr8:86481754~86483002:-
TGCT	trans	rs7200543	1	rs1136001	ENSG00000250569.1	NTAN1P2	7.22	4.52e-11	0.000423	0.68	0.54	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038117	chr8:86481754~86483002:-
TGCT	trans	rs7200543	1	rs2740	ENSG00000250569.1	NTAN1P2	7.22	4.52e-11	0.000423	0.68	0.54	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038251	chr8:86481754~86483002:-
TGCT	trans	rs9467773	0.933	rs35355150	ENSG00000242375.1	RP11-498P14.3	7.22	4.54e-11	0.000425	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26525811	chr9:97195351~97197687:-
TGCT	trans	rs1707322	0.721	rs61784800	ENSG00000255397.1	AC022182.2	7.22	4.55e-11	0.000426	0.68	0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs6665808	ENSG00000255397.1	AC022182.2	-7.22	4.55e-11	0.000426	-0.68	-0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs10890346	ENSG00000255397.1	AC022182.2	7.22	4.62e-11	0.000431	0.66	0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr8:60937705~60939871:-
TGCT	trans	rs1816752	0.721	rs7399656	ENSG00000237917.1	PARP4P1	7.22	4.63e-11	0.000432	0.64	0.54	Obesity-related traits;	chr13:24415708	chrY:26594851~26634652:-
TGCT	trans	rs10940346	1	rs11948752	ENSG00000231752.4	EMBP1	-7.22	4.65e-11	0.000433	-0.61	-0.54	Schizophrenia;	chr5:50504082	chr1:121519112~121571892:+
TGCT	trans	rs3749237	1	rs1317140	ENSG00000197582.5	GPX1P1	7.22	4.69e-11	0.000437	0.73	0.54	Resting heart rate;	chr3:49841219	chrX:13378735~13379340:-
TGCT	trans	rs9467773	0.935	rs9461270	ENSG00000242375.1	RP11-498P14.3	7.22	4.7e-11	0.000438	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26543882	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs1884946	ENSG00000242375.1	RP11-498P14.3	7.22	4.7e-11	0.000438	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26545080	chr9:97195351~97197687:-
TGCT	trans	rs7554547	0.667	rs2050266	ENSG00000261819.1	RP11-680G24.4	7.21	4.76e-11	0.000443	0.76	0.54	Nonsyndromic cleft lip with cleft palate;	chr1:11886531	chr16:14988259~14990160:-
TGCT	trans	rs61990749	0.571	rs4903655	ENSG00000235400.1	RP4-641G12.4	7.21	4.86e-11	0.000451	1.01	0.54	Fibroblast growth factor basic levels;	chr14:77839983	chr1:78749073~78750659:+
TGCT	trans	rs1707322	0.627	rs3014213	ENSG00000255397.1	AC022182.2	7.21	4.86e-11	0.000452	0.73	0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.686	rs2152078	ENSG00000255397.1	AC022182.2	7.21	4.86e-11	0.000452	0.73	0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.686	rs2991979	ENSG00000255397.1	AC022182.2	7.21	4.86e-11	0.000452	0.73	0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr8:60937705~60939871:-
TGCT	trans	rs77688320	0.535	rs2540441	ENSG00000235105.1	RP11-329A14.1	-7.21	4.96e-11	0.000459	-0.52	-0.54	Breast cancer;	chr2:201481946	chr1:48435967~48437223:+
TGCT	trans	rs1707322	0.647	rs6686944	ENSG00000255397.1	AC022182.2	-7.2	5.01e-11	0.000464	-0.68	-0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr8:60937705~60939871:-
TGCT	trans	rs7200543	1	rs34614532	ENSG00000250569.1	NTAN1P2	7.2	5.03e-11	0.000466	0.68	0.54	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15039051	chr8:86481754~86483002:-
TGCT	trans	rs7200543	1	rs14347	ENSG00000250569.1	NTAN1P2	7.2	5.03e-11	0.000466	0.68	0.54	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15040032	chr8:86481754~86483002:-
TGCT	trans	rs9467773	0.595	rs12525810	ENSG00000242375.1	RP11-498P14.3	7.2	5.06e-11	0.000468	0.64	0.54	Intelligence (multi-trait analysis);	chr6:26623283	chr9:97195351~97197687:-
TGCT	trans	rs7554547	0.622	rs28455075	ENSG00000261819.1	RP11-680G24.4	7.2	5.1e-11	0.000471	0.8	0.54	Nonsyndromic cleft lip with cleft palate;	chr1:11879663	chr16:14988259~14990160:-
TGCT	trans	rs74781061	0.929	rs76160708	ENSG00000227288.3	RP5-837I24.1	7.2	5.18e-11	0.000478	0.58	0.54	Endometriosis;	chr15:74636901	chr1:81501794~81503468:+
TGCT	trans	rs10242455	0.557	rs59672032	ENSG00000228834.1	RP11-249L21.4	7.19	5.25e-11	0.000485	1.4	0.54	Blood metabolite levels;	chr7:99461074	chr6:108907615~108907873:-
TGCT	trans	rs9611519	0.603	rs9607764	ENSG00000268568.1	AC007228.9	-7.19	5.28e-11	0.000488	-0.63	-0.54	Neuroticism;	chr22:41015800	chr19:56672574~56673901:-
TGCT	trans	rs9467773	0.62	rs2101581	ENSG00000242375.1	RP11-498P14.3	7.19	5.3e-11	0.000489	0.63	0.54	Intelligence (multi-trait analysis);	chr6:26622541	chr9:97195351~97197687:-
TGCT	trans	rs3749237	1	rs2307021	ENSG00000197582.5	GPX1P1	7.19	5.31e-11	0.00049	0.73	0.54	Resting heart rate;	chr3:49728050	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.964	rs13084243	ENSG00000197582.5	GPX1P1	7.19	5.31e-11	0.00049	0.73	0.54	Resting heart rate;	chr3:49784445	chrX:13378735~13379340:-
TGCT	trans	rs3749237	1	rs11920900	ENSG00000197582.5	GPX1P1	7.19	5.31e-11	0.00049	0.73	0.54	Resting heart rate;	chr3:49785591	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.929	rs62260715	ENSG00000197582.5	GPX1P1	7.19	5.31e-11	0.00049	0.73	0.54	Resting heart rate;	chr3:49791893	chrX:13378735~13379340:-
TGCT	trans	rs80033912	0.713	rs7629936	ENSG00000197582.5	GPX1P1	7.19	5.41e-11	0.000498	0.78	0.54	Intelligence (multi-trait analysis);	chr3:49799274	chrX:13378735~13379340:-
TGCT	trans	rs10940346	1	rs6874016	ENSG00000231752.4	EMBP1	-7.19	5.46e-11	0.000503	-0.59	-0.54	Schizophrenia;	chr5:50549640	chr1:121519112~121571892:+
TGCT	trans	rs9611519	0.566	rs4821981	ENSG00000268568.1	AC007228.9	7.18	5.59e-11	0.000514	0.63	0.54	Neuroticism;	chr22:41019640	chr19:56672574~56673901:-
TGCT	trans	rs9611519	0.58	rs8138349	ENSG00000268568.1	AC007228.9	-7.18	5.59e-11	0.000514	-0.63	-0.54	Neuroticism;	chr22:41016719	chr19:56672574~56673901:-
TGCT	trans	rs9611519	0.602	rs8138520	ENSG00000268568.1	AC007228.9	-7.18	5.59e-11	0.000514	-0.63	-0.54	Neuroticism;	chr22:41016924	chr19:56672574~56673901:-
TGCT	trans	rs9611519	0.579	rs8136274	ENSG00000268568.1	AC007228.9	-7.18	5.59e-11	0.000514	-0.63	-0.54	Neuroticism;	chr22:41019307	chr19:56672574~56673901:-
TGCT	trans	rs9611519	0.59	rs4821980	ENSG00000268568.1	AC007228.9	-7.18	5.59e-11	0.000514	-0.63	-0.54	Neuroticism;	chr22:41019475	chr19:56672574~56673901:-
TGCT	trans	rs9467773	0.595	rs13207371	ENSG00000242375.1	RP11-498P14.3	7.18	5.59e-11	0.000514	0.65	0.54	Intelligence (multi-trait analysis);	chr6:26590846	chr9:97195351~97197687:-
TGCT	trans	rs74781061	0.799	rs4372642	ENSG00000227288.3	RP5-837I24.1	7.18	5.65e-11	0.000519	0.55	0.54	Endometriosis;	chr15:74460095	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.86	rs6495102	ENSG00000227288.3	RP5-837I24.1	7.18	5.65e-11	0.000519	0.55	0.54	Endometriosis;	chr15:74470337	chr1:81501794~81503468:+
TGCT	trans	rs1707322	0.752	rs6662164	ENSG00000255397.1	AC022182.2	-7.18	5.68e-11	0.000522	-0.68	-0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr8:60937705~60939871:-
TGCT	trans	rs9611519	0.565	rs8135524	ENSG00000268568.1	AC007228.9	-7.18	5.76e-11	0.000528	-0.64	-0.54	Neuroticism;	chr22:41040438	chr19:56672574~56673901:-
TGCT	trans	rs877636	0.669	rs7297175	ENSG00000243538.1	CTB-55B8.1	-7.17	5.92e-11	0.000543	-0.62	-0.54	Cognitive function;	chr12:56080024	chr5:16902294~16902641:-
TGCT	trans	rs74781061	0.929	rs12441932	ENSG00000227288.3	RP5-837I24.1	7.17	5.93e-11	0.000543	0.61	0.54	Endometriosis;	chr15:74617658	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.929	rs2068982	ENSG00000227288.3	RP5-837I24.1	-7.17	6.04e-11	0.000553	-0.58	-0.54	Endometriosis;	chr15:74623547	chr1:81501794~81503468:+
TGCT	trans	rs1707322	0.752	rs28550303	ENSG00000255397.1	AC022182.2	-7.17	6.07e-11	0.000555	-0.67	-0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.716	rs28375469	ENSG00000255397.1	AC022182.2	-7.17	6.07e-11	0.000555	-0.67	-0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.752	rs28545085	ENSG00000255397.1	AC022182.2	-7.17	6.07e-11	0.000555	-0.67	-0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.752	rs28507722	ENSG00000255397.1	AC022182.2	-7.17	6.07e-11	0.000555	-0.67	-0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.717	rs28396194	ENSG00000255397.1	AC022182.2	-7.17	6.07e-11	0.000555	-0.67	-0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.717	rs28752166	ENSG00000255397.1	AC022182.2	-7.17	6.07e-11	0.000555	-0.67	-0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr8:60937705~60939871:-
TGCT	trans	rs9467773	0.62	rs1027203	ENSG00000242375.1	RP11-498P14.3	7.17	6.09e-11	0.000557	0.64	0.54	Intelligence (multi-trait analysis);	chr6:26639104	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.595	rs2172007	ENSG00000242375.1	RP11-498P14.3	7.17	6.09e-11	0.000557	0.64	0.54	Intelligence (multi-trait analysis);	chr6:26639549	chr9:97195351~97197687:-
TGCT	trans	rs616147	0.816	rs1768190	ENSG00000183298.5	RP11-556K13.1	7.17	6.09e-11	0.000557	0.72	0.54	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39467949	chr1:101786340~101787219:-
TGCT	trans	rs9467773	1	rs2255070	ENSG00000242375.1	RP11-498P14.3	7.16	6.37e-11	0.00058	0.6	0.54	Intelligence (multi-trait analysis);	chr6:26501549	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs9467783	ENSG00000242375.1	RP11-498P14.3	7.16	6.4e-11	0.000583	0.6	0.54	Intelligence (multi-trait analysis);	chr6:26542666	chr9:97195351~97197687:-
TGCT	trans	rs877636	1	rs877636	ENSG00000243538.1	CTB-55B8.1	-7.16	6.41e-11	0.000584	-0.69	-0.54	Cognitive function;	chr12:56086799	chr5:16902294~16902641:-
TGCT	trans	rs7937890	0.904	rs7484197	ENSG00000236360.2	RP11-334A14.2	7.15	6.46e-11	0.000587	0.59	0.54	Mitochondrial DNA levels;	chr11:14262108	chr1:52993201~52993702:-
TGCT	trans	rs9467773	0.62	rs2451731	ENSG00000242375.1	RP11-498P14.3	7.15	6.46e-11	0.000587	0.63	0.54	Intelligence (multi-trait analysis);	chr6:26624594	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.62	rs9295701	ENSG00000242375.1	RP11-498P14.3	7.15	6.46e-11	0.000587	0.63	0.54	Intelligence (multi-trait analysis);	chr6:26627280	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.62	rs2451741	ENSG00000242375.1	RP11-498P14.3	7.15	6.46e-11	0.000587	0.63	0.54	Intelligence (multi-trait analysis);	chr6:26629176	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.62	rs2494700	ENSG00000242375.1	RP11-498P14.3	7.15	6.46e-11	0.000587	0.63	0.54	Intelligence (multi-trait analysis);	chr6:26631078	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.584	rs1021372	ENSG00000242375.1	RP11-498P14.3	7.15	6.46e-11	0.000587	0.63	0.54	Intelligence (multi-trait analysis);	chr6:26632216	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.583	rs1021373	ENSG00000242375.1	RP11-498P14.3	7.15	6.46e-11	0.000587	0.63	0.54	Intelligence (multi-trait analysis);	chr6:26632229	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.62	rs2451744	ENSG00000242375.1	RP11-498P14.3	7.15	6.46e-11	0.000587	0.63	0.54	Intelligence (multi-trait analysis);	chr6:26633235	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.62	rs2494701	ENSG00000242375.1	RP11-498P14.3	7.15	6.46e-11	0.000587	0.63	0.54	Intelligence (multi-trait analysis);	chr6:26634204	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.62	rs1027204	ENSG00000242375.1	RP11-498P14.3	7.15	6.46e-11	0.000587	0.63	0.54	Intelligence (multi-trait analysis);	chr6:26639385	chr9:97195351~97197687:-
TGCT	trans	rs9611519	0.589	rs8138917	ENSG00000268568.1	AC007228.9	-7.15	6.65e-11	0.000603	-0.63	-0.54	Neuroticism;	chr22:41016421	chr19:56672574~56673901:-
TGCT	trans	rs9467773	0.62	rs1490488	ENSG00000242375.1	RP11-498P14.3	7.15	6.74e-11	0.00061	0.63	0.54	Intelligence (multi-trait analysis);	chr6:26614580	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.62	rs2494692	ENSG00000242375.1	RP11-498P14.3	7.15	6.74e-11	0.00061	0.63	0.54	Intelligence (multi-trait analysis);	chr6:26614995	chr9:97195351~97197687:-
TGCT	trans	rs7647973	0.6	rs12631989	ENSG00000197582.5	GPX1P1	7.15	6.74e-11	0.00061	0.67	0.54	Menarche (age at onset);	chr3:49236563	chrX:13378735~13379340:-
TGCT	trans	rs7647973	0.6	rs13064780	ENSG00000197582.5	GPX1P1	7.15	6.74e-11	0.00061	0.67	0.54	Menarche (age at onset);	chr3:49237393	chrX:13378735~13379340:-
TGCT	trans	rs7647973	0.58	rs35218722	ENSG00000197582.5	GPX1P1	7.15	6.74e-11	0.00061	0.67	0.54	Menarche (age at onset);	chr3:49238372	chrX:13378735~13379340:-
TGCT	trans	rs7647973	0.6	rs35174559	ENSG00000197582.5	GPX1P1	7.15	6.74e-11	0.00061	0.67	0.54	Menarche (age at onset);	chr3:49250326	chrX:13378735~13379340:-
TGCT	trans	rs7647973	0.56	rs7638154	ENSG00000197582.5	GPX1P1	7.15	6.74e-11	0.00061	0.67	0.54	Menarche (age at onset);	chr3:49261942	chrX:13378735~13379340:-
TGCT	trans	rs1707322	0.716	rs10890342	ENSG00000255397.1	AC022182.2	-7.14	6.79e-11	0.000614	-0.67	-0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.752	rs6658700	ENSG00000255397.1	AC022182.2	-7.14	6.79e-11	0.000614	-0.67	-0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.752	rs12047629	ENSG00000255397.1	AC022182.2	-7.14	6.79e-11	0.000614	-0.67	-0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.752	rs11211169	ENSG00000255397.1	AC022182.2	-7.14	6.79e-11	0.000614	-0.67	-0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr8:60937705~60939871:-
TGCT	trans	rs10940346	1	rs2883164	ENSG00000231752.4	EMBP1	7.14	6.81e-11	0.000616	0.57	0.54	Schizophrenia;	chr5:50397624	chr1:121519112~121571892:+
TGCT	trans	rs5022636	0.559	rs41302131	ENSG00000180764.13	PIPSL	7.14	6.83e-11	0.000617	0.67	0.54	Gut microbiota (functional units);	chr1:151267532	chr10:93958191~93961540:-
TGCT	trans	rs7811142	0.83	rs6955367	ENSG00000228546.2	CTA-313A17.3	7.14	6.98e-11	0.000629	0.84	0.54	Platelet count;	chr7:100363571	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.83	rs11768967	ENSG00000228546.2	CTA-313A17.3	7.14	6.98e-11	0.000629	0.84	0.54	Platelet count;	chr7:100370021	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.83	rs7792959	ENSG00000228546.2	CTA-313A17.3	7.14	6.98e-11	0.000629	0.84	0.54	Platelet count;	chr7:100374780	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.83	rs6975660	ENSG00000228546.2	CTA-313A17.3	7.14	6.98e-11	0.000629	0.84	0.54	Platelet count;	chr7:100377643	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.83	rs73401443	ENSG00000228546.2	CTA-313A17.3	7.14	6.98e-11	0.000629	0.84	0.54	Platelet count;	chr7:100379959	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.83	rs10085549	ENSG00000228546.2	CTA-313A17.3	7.14	6.98e-11	0.000629	0.84	0.54	Platelet count;	chr7:100385512	chr7:102337316~102339115:+
TGCT	trans	rs9467773	1	rs9467779	ENSG00000242375.1	RP11-498P14.3	-7.14	6.99e-11	0.00063	-0.59	-0.54	Intelligence (multi-trait analysis);	chr6:26536459	chr9:97195351~97197687:-
TGCT	trans	rs4276421	0.688	rs13155792	ENSG00000231752.4	EMBP1	7.14	7.06e-11	0.000636	0.57	0.54	P wave duration;	chr5:46176452	chr1:121519112~121571892:+
TGCT	trans	rs9467773	1	rs9467773	ENSG00000242375.1	RP11-498P14.3	7.13	7.12e-11	0.000641	0.6	0.54	Intelligence (multi-trait analysis);	chr6:26498198	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs6926629	ENSG00000242375.1	RP11-498P14.3	7.13	7.12e-11	0.000641	0.6	0.54	Intelligence (multi-trait analysis);	chr6:26499675	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs6903973	ENSG00000242375.1	RP11-498P14.3	7.13	7.12e-11	0.000641	0.6	0.54	Intelligence (multi-trait analysis);	chr6:26499714	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.62	rs2451737	ENSG00000242375.1	RP11-498P14.3	7.13	7.24e-11	0.00065	0.63	0.54	Intelligence (multi-trait analysis);	chr6:26618813	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.596	rs2494693	ENSG00000242375.1	RP11-498P14.3	7.13	7.24e-11	0.00065	0.63	0.54	Intelligence (multi-trait analysis);	chr6:26618998	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.62	rs2494694	ENSG00000242375.1	RP11-498P14.3	7.13	7.24e-11	0.00065	0.63	0.54	Intelligence (multi-trait analysis);	chr6:26619100	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.595	rs2451736	ENSG00000242375.1	RP11-498P14.3	7.13	7.24e-11	0.00065	0.63	0.54	Intelligence (multi-trait analysis);	chr6:26620316	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.62	rs2494696	ENSG00000242375.1	RP11-498P14.3	7.13	7.24e-11	0.00065	0.63	0.54	Intelligence (multi-trait analysis);	chr6:26620666	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.62	rs9461275	ENSG00000242375.1	RP11-498P14.3	7.13	7.3e-11	0.000655	0.64	0.54	Intelligence (multi-trait analysis);	chr6:26590573	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.62	rs6925087	ENSG00000242375.1	RP11-498P14.3	7.13	7.3e-11	0.000655	0.64	0.54	Intelligence (multi-trait analysis);	chr6:26592625	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.62	rs4368798	ENSG00000242375.1	RP11-498P14.3	7.13	7.3e-11	0.000655	0.64	0.54	Intelligence (multi-trait analysis);	chr6:26593243	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.62	rs9461276	ENSG00000242375.1	RP11-498P14.3	7.13	7.3e-11	0.000655	0.64	0.54	Intelligence (multi-trait analysis);	chr6:26594940	chr9:97195351~97197687:-
TGCT	trans	rs2657294	0.62	rs4746261	ENSG00000172974.11	AC007318.5	-7.12	7.54e-11	0.000675	-0.71	-0.54	Pneumonia;	chr10:75085874	chr2:65205108~65205988:+
TGCT	trans	rs7554547	0.622	rs72864769	ENSG00000261819.1	RP11-680G24.4	7.12	7.7e-11	0.000689	0.78	0.54	Nonsyndromic cleft lip with cleft palate;	chr1:11881264	chr16:14988259~14990160:-
TGCT	trans	rs8081395	0.741	rs1292055	ENSG00000187870.7	RNFT1P3	7.12	7.7e-11	0.000689	0.63	0.54	White blood cell count;	chr17:59881707	chr17:20743333~20754501:-
TGCT	trans	rs1707322	0.685	rs11211177	ENSG00000255397.1	AC022182.2	-7.11	7.89e-11	0.000706	-0.66	-0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr8:60937705~60939871:-
TGCT	trans	rs616147	0.962	rs1513219	ENSG00000183298.5	RP11-556K13.1	7.11	7.99e-11	0.000714	0.73	0.54	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39492268	chr1:101786340~101787219:-
TGCT	trans	rs616147	0.962	rs1708104	ENSG00000183298.5	RP11-556K13.1	-7.11	7.99e-11	0.000714	-0.73	-0.54	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39493251	chr1:101786340~101787219:-
TGCT	trans	rs10940346	1	rs4643959	ENSG00000231752.4	EMBP1	7.11	8.07e-11	0.000721	0.57	0.54	Schizophrenia;	chr5:50391631	chr1:121519112~121571892:+
TGCT	trans	rs9467773	0.549	rs9467805	ENSG00000242375.1	RP11-498P14.3	7.11	8.3e-11	0.000741	0.64	0.54	Intelligence (multi-trait analysis);	chr6:26583138	chr9:97195351~97197687:-
TGCT	trans	rs4276421	0.745	rs10079238	ENSG00000231752.4	EMBP1	-7.1	8.41e-11	0.00075	-0.58	-0.54	P wave duration;	chr5:46066531	chr1:121519112~121571892:+
TGCT	trans	rs61990749	0.571	rs11628049	ENSG00000235400.1	RP4-641G12.4	-7.1	8.52e-11	0.00076	-0.98	-0.54	Fibroblast growth factor basic levels;	chr14:77842108	chr1:78749073~78750659:+
TGCT	trans	rs9467773	0.595	rs7767847	ENSG00000242375.1	RP11-498P14.3	7.1	8.56e-11	0.000762	0.64	0.54	Intelligence (multi-trait analysis);	chr6:26597665	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.62	rs3800303	ENSG00000242375.1	RP11-498P14.3	7.1	8.56e-11	0.000762	0.64	0.54	Intelligence (multi-trait analysis);	chr6:26597960	chr9:97195351~97197687:-
TGCT	trans	rs877636	1	rs705696	ENSG00000225071.1	GS1-184P14.2	7.1	8.58e-11	0.000763	0.65	0.54	Cognitive function;	chr12:56086864	chrX:24429573~24429920:-
TGCT	trans	rs7405404	1	rs8055219	ENSG00000281831.1	HCP5B	7.1	8.72e-11	0.000776	0.68	0.54	Bipolar disorder lithium response (categorical) or schizophrenia;Schizophrenia;	chr16:13659527	chr6:29871895~29873783:-
TGCT	trans	rs4276421	0.661	rs10059426	ENSG00000231752.4	EMBP1	-7.09	8.87e-11	0.000789	-0.57	-0.54	P wave duration;	chr5:46090412	chr1:121519112~121571892:+
TGCT	trans	rs9467773	1	rs9295695	ENSG00000242375.1	RP11-498P14.3	-7.09	8.91e-11	0.000793	-0.6	-0.54	Intelligence (multi-trait analysis);	chr6:26528022	chr9:97195351~97197687:-
TGCT	trans	rs7937890	1	rs2970335	ENSG00000236360.2	RP11-334A14.2	7.09	9.08e-11	0.000806	0.6	0.54	Mitochondrial DNA levels;	chr11:14303855	chr1:52993201~52993702:-
TGCT	trans	rs9467773	0.62	rs2101582	ENSG00000242375.1	RP11-498P14.3	7.08	9.3e-11	0.000826	0.61	0.54	Intelligence (multi-trait analysis);	chr6:26622506	chr9:97195351~97197687:-
TGCT	trans	rs2209875	0.573	rs74703137	ENSG00000234819.1	RP11-336N8.4	7.08	9.31e-11	0.000826	0.57	0.54	Pelvic organ prolapse (moderate/severe);	chr9:89336429	chr9:78219120~78219357:+
TGCT	trans	rs7647973	1	rs9871024	ENSG00000197582.5	GPX1P1	-7.08	9.65e-11	0.000855	-0.73	-0.54	Menarche (age at onset);	chr3:49516808	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs13322887	ENSG00000197582.5	GPX1P1	-7.08	9.65e-11	0.000855	-0.73	-0.54	Menarche (age at onset);	chr3:49518150	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs1982861	ENSG00000197582.5	GPX1P1	7.08	9.65e-11	0.000855	0.73	0.54	Menarche (age at onset);	chr3:49540232	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs10865956	ENSG00000197582.5	GPX1P1	7.08	9.65e-11	0.000855	0.73	0.54	Menarche (age at onset);	chr3:49544126	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs4241407	ENSG00000197582.5	GPX1P1	7.08	9.65e-11	0.000855	0.73	0.54	Menarche (age at onset);	chr3:49562886	chrX:13378735~13379340:-
TGCT	trans	rs9611519	0.58	rs7286603	ENSG00000268568.1	AC007228.9	-7.08	9.66e-11	0.000856	-0.63	-0.54	Neuroticism;	chr22:41044057	chr19:56672574~56673901:-
TGCT	trans	rs9611519	0.558	rs8137906	ENSG00000268568.1	AC007228.9	-7.08	9.66e-11	0.000856	-0.63	-0.54	Neuroticism;	chr22:41046562	chr19:56672574~56673901:-
TGCT	trans	rs3749237	0.964	rs1799845	ENSG00000197582.5	GPX1P1	7.07	9.74e-11	0.000862	0.71	0.54	Resting heart rate;	chr3:49810190	chrX:13378735~13379340:-
TGCT	trans	rs9611519	0.542	rs8139770	ENSG00000268568.1	AC007228.9	-7.07	9.91e-11	0.000877	-0.63	-0.54	Neuroticism;	chr22:41020177	chr19:56672574~56673901:-
TGCT	trans	rs1816752	0.755	rs1981277	ENSG00000237917.1	PARP4P1	7.06	1.02e-10	0.000904	0.63	0.54	Obesity-related traits;	chr13:24409375	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.712	rs9507335	ENSG00000237917.1	PARP4P1	7.06	1.02e-10	0.000904	0.63	0.54	Obesity-related traits;	chr13:24409766	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.774	rs2862895	ENSG00000237917.1	PARP4P1	7.06	1.02e-10	0.000904	0.63	0.54	Obesity-related traits;	chr13:24410328	chrY:26594851~26634652:-
TGCT	trans	rs1816752	0.811	rs9507337	ENSG00000237917.1	PARP4P1	7.06	1.02e-10	0.000904	0.63	0.54	Obesity-related traits;	chr13:24410807	chrY:26594851~26634652:-
TGCT	trans	rs7312770	0.612	rs1873914	ENSG00000212994.5	RPS26P6	7.06	1.03e-10	0.000906	0.58	0.54	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:100895771~100896118:+
TGCT	trans	rs9467773	0.62	rs2504592	ENSG00000242375.1	RP11-498P14.3	7.06	1.03e-10	0.000909	0.64	0.54	Intelligence (multi-trait analysis);	chr6:26640723	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.62	rs2504599	ENSG00000242375.1	RP11-498P14.3	7.06	1.03e-10	0.000909	0.64	0.54	Intelligence (multi-trait analysis);	chr6:26640832	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.62	rs2504540	ENSG00000242375.1	RP11-498P14.3	7.06	1.03e-10	0.000909	0.64	0.54	Intelligence (multi-trait analysis);	chr6:26641398	chr9:97195351~97197687:-
TGCT	trans	rs7811142	0.666	rs28401739	ENSG00000228546.2	CTA-313A17.3	7.06	1.04e-10	0.000919	0.84	0.54	Platelet count;	chr7:100308061	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.775	rs1059129	ENSG00000228546.2	CTA-313A17.3	7.06	1.04e-10	0.000919	0.84	0.54	Platelet count;	chr7:100328899	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.562	rs7786844	ENSG00000228546.2	CTA-313A17.3	7.06	1.04e-10	0.000919	0.84	0.54	Platelet count;	chr7:100336385	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.83	rs6979910	ENSG00000228546.2	CTA-313A17.3	7.06	1.04e-10	0.000919	0.84	0.54	Platelet count;	chr7:100343007	chr7:102337316~102339115:+
TGCT	trans	rs9467773	0.62	rs9467810	ENSG00000242375.1	RP11-498P14.3	7.06	1.05e-10	0.000922	0.64	0.54	Intelligence (multi-trait analysis);	chr6:26608033	chr9:97195351~97197687:-
TGCT	trans	rs7811142	0.72	rs7795656	ENSG00000228546.2	CTA-313A17.3	7.06	1.05e-10	0.000922	0.84	0.54	Platelet count;	chr7:100352674	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.83	rs7792525	ENSG00000228546.2	CTA-313A17.3	7.06	1.05e-10	0.000922	0.84	0.54	Platelet count;	chr7:100374499	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.83	rs6945952	ENSG00000228546.2	CTA-313A17.3	7.06	1.05e-10	0.000922	0.84	0.54	Platelet count;	chr7:100384152	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.83	rs73401451	ENSG00000228546.2	CTA-313A17.3	7.06	1.05e-10	0.000922	0.84	0.54	Platelet count;	chr7:100384272	chr7:102337316~102339115:+
TGCT	trans	rs74781061	0.929	rs6495108	ENSG00000227288.3	RP5-837I24.1	7.06	1.06e-10	0.000929	0.59	0.54	Endometriosis;	chr15:74502186	chr1:81501794~81503468:+
TGCT	trans	rs1707322	1	rs785498	ENSG00000255397.1	AC022182.2	7.05	1.09e-10	0.000956	0.68	0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr8:60937705~60939871:-
TGCT	trans	rs12291225	0.839	rs4757244	ENSG00000236360.2	RP11-334A14.2	-7.05	1.09e-10	0.000956	-0.7	-0.54	Sense of smell;	chr11:14237109	chr1:52993201~52993702:-
TGCT	trans	rs2731664	0.721	rs2450333	ENSG00000215571.5	GRK6P1	7.05	1.09e-10	0.000961	0.63	0.53	Intelligence (multi-trait analysis);	chr5:177472545	chr13:21319156~21320866:+
TGCT	trans	rs2731664	0.792	rs2630763	ENSG00000215571.5	GRK6P1	7.05	1.09e-10	0.000961	0.63	0.53	Intelligence (multi-trait analysis);	chr5:177474004	chr13:21319156~21320866:+
TGCT	trans	rs74781061	0.932	rs74025818	ENSG00000227288.3	RP5-837I24.1	7.05	1.1e-10	0.000969	0.55	0.53	Endometriosis;	chr15:74618287	chr1:81501794~81503468:+
TGCT	trans	rs5022636	0.594	rs7489	ENSG00000180764.13	PIPSL	7.05	1.12e-10	0.00098	0.67	0.53	Gut microbiota (functional units);	chr1:151266575	chr10:93958191~93961540:-
TGCT	trans	rs877636	0.692	rs2271194	ENSG00000234513.1	AC073072.7	-7.04	1.13e-10	0.000992	-0.59	-0.53	Cognitive function;	chr12:56083910	chr7:22773646~22773993:-
TGCT	trans	rs1707322	0.721	rs11211166	ENSG00000255397.1	AC022182.2	-7.04	1.14e-10	0.000999	-0.67	-0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr8:60937705~60939871:-
TGCT	trans	rs4276421	0.745	rs10041478	ENSG00000231752.4	EMBP1	-7.04	1.14e-10	0.001	-0.57	-0.53	P wave duration;	chr5:46103187	chr1:121519112~121571892:+
TGCT	trans	rs74781061	0.932	rs11072496	ENSG00000227288.3	RP5-837I24.1	7.04	1.16e-10	0.00102	0.54	0.53	Endometriosis;	chr15:74628191	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.932	rs7161903	ENSG00000227288.3	RP5-837I24.1	7.04	1.16e-10	0.00102	0.54	0.53	Endometriosis;	chr15:74647929	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.932	rs7497342	ENSG00000227288.3	RP5-837I24.1	7.04	1.16e-10	0.00102	0.54	0.53	Endometriosis;	chr15:74655722	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.932	rs11072497	ENSG00000227288.3	RP5-837I24.1	7.04	1.16e-10	0.00102	0.54	0.53	Endometriosis;	chr15:74659016	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.932	rs11072498	ENSG00000227288.3	RP5-837I24.1	7.04	1.16e-10	0.00102	0.54	0.53	Endometriosis;	chr15:74661846	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.932	rs2415245	ENSG00000227288.3	RP5-837I24.1	7.04	1.16e-10	0.00102	0.54	0.53	Endometriosis;	chr15:74678091	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.932	rs2198843	ENSG00000227288.3	RP5-837I24.1	7.04	1.16e-10	0.00102	0.54	0.53	Endometriosis;	chr15:74708889	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.86	rs1456432	ENSG00000227288.3	RP5-837I24.1	7.04	1.16e-10	0.00102	0.54	0.53	Endometriosis;	chr15:74710710	chr1:81501794~81503468:+
TGCT	trans	rs74781061	0.932	rs6495121	ENSG00000227288.3	RP5-837I24.1	7.04	1.16e-10	0.00102	0.54	0.53	Endometriosis;	chr15:74711167	chr1:81501794~81503468:+
TGCT	trans	rs616147	0.962	rs545397	ENSG00000183298.5	RP11-556K13.1	7.04	1.17e-10	0.00103	0.73	0.53	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39488592	chr1:101786340~101787219:-
TGCT	trans	rs2657294	0.796	rs2657290	ENSG00000172974.11	AC007318.5	7.04	1.18e-10	0.00104	0.64	0.53	Pneumonia;	chr10:75207404	chr2:65205108~65205988:+
TGCT	trans	rs4276421	0.662	rs4367307	ENSG00000231752.4	EMBP1	-7.03	1.19e-10	0.00104	-0.57	-0.53	P wave duration;	chr5:46065857	chr1:121519112~121571892:+
TGCT	trans	rs6477998	0.932	rs4129395	ENSG00000238072.1	RP11-305M3.2	7.03	1.2e-10	0.00105	0.63	0.53	Hematology traits;	chr9:113213109	chr7:129410113~129410370:-
TGCT	trans	rs6477998	0.966	rs7859354	ENSG00000238072.1	RP11-305M3.2	7.03	1.2e-10	0.00105	0.63	0.53	Hematology traits;	chr9:113214165	chr7:129410113~129410370:-
TGCT	trans	rs6477998	1	rs10739388	ENSG00000238072.1	RP11-305M3.2	7.03	1.2e-10	0.00105	0.63	0.53	Hematology traits;	chr9:113214895	chr7:129410113~129410370:-
TGCT	trans	rs1707322	0.721	rs11211165	ENSG00000255397.1	AC022182.2	-7.03	1.23e-10	0.00107	-0.67	-0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr8:60937705~60939871:-
TGCT	trans	rs7312770	0.637	rs705700	ENSG00000243538.1	CTB-55B8.1	7.03	1.23e-10	0.00107	0.63	0.53	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr5:16902294~16902641:-
TGCT	trans	rs7647973	1	rs12583	ENSG00000197582.5	GPX1P1	-7.03	1.24e-10	0.00108	-0.75	-0.53	Menarche (age at onset);	chr3:49534029	chrX:13378735~13379340:-
TGCT	trans	rs4276421	0.774	rs72755668	ENSG00000231752.4	EMBP1	-7.02	1.27e-10	0.00111	-0.56	-0.53	P wave duration;	chr5:46102658	chr1:121519112~121571892:+
TGCT	trans	rs9467773	0.62	rs2504567	ENSG00000242375.1	RP11-498P14.3	7.02	1.31e-10	0.00114	0.64	0.53	Intelligence (multi-trait analysis);	chr6:26662692	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.62	rs2451711	ENSG00000242375.1	RP11-498P14.3	7.02	1.31e-10	0.00114	0.64	0.53	Intelligence (multi-trait analysis);	chr6:26662882	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.62	rs2504565	ENSG00000242375.1	RP11-498P14.3	7.01	1.32e-10	0.00115	0.65	0.53	Intelligence (multi-trait analysis);	chr6:26656662	chr9:97195351~97197687:-
TGCT	trans	rs1707322	0.721	rs11211181	ENSG00000255397.1	AC022182.2	-7.01	1.33e-10	0.00115	-0.67	-0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.717	rs2275086	ENSG00000255397.1	AC022182.2	7.01	1.34e-10	0.00116	0.7	0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr8:60937705~60939871:-
TGCT	trans	rs1816752	0.583	rs6490918	ENSG00000237917.1	PARP4P1	-7.01	1.38e-10	0.00119	-0.63	-0.53	Obesity-related traits;	chr13:24427977	chrY:26594851~26634652:-
TGCT	trans	rs6477998	0.966	rs7851395	ENSG00000238072.1	RP11-305M3.2	7	1.43e-10	0.00123	0.63	0.53	Hematology traits;	chr9:113240184	chr7:129410113~129410370:-
TGCT	trans	rs1707322	0.752	rs11211168	ENSG00000255397.1	AC022182.2	-7	1.44e-10	0.00124	-0.66	-0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr8:60937705~60939871:-
TGCT	trans	rs2731664	0.792	rs337374	ENSG00000215571.5	GRK6P1	-7	1.46e-10	0.00126	-0.63	-0.53	Intelligence (multi-trait analysis);	chr5:177463415	chr13:21319156~21320866:+
TGCT	trans	rs7811142	0.667	rs3873746	ENSG00000228546.2	CTA-313A17.3	6.99	1.47e-10	0.00126	0.84	0.53	Platelet count;	chr7:100337474	chr7:102337316~102339115:+
TGCT	trans	rs55665837	1	rs4412729	ENSG00000236360.2	RP11-334A14.2	6.99	1.5e-10	0.00129	0.65	0.53	Vitamin D levels;	chr11:14417454	chr1:52993201~52993702:-
TGCT	trans	rs7811142	0.779	rs28680963	ENSG00000228546.2	CTA-313A17.3	6.99	1.51e-10	0.0013	0.84	0.53	Platelet count;	chr7:100307852	chr7:102337316~102339115:+
TGCT	trans	rs13014235	0.667	rs2540328	ENSG00000235105.1	RP11-329A14.1	-6.99	1.53e-10	0.00131	-0.52	-0.53	Basal cell carcinoma;	chr2:201384337	chr1:48435967~48437223:+
TGCT	trans	rs77688320	0.509	rs2714487	ENSG00000235105.1	RP11-329A14.1	-6.99	1.53e-10	0.00131	-0.52	-0.53	Breast cancer;	chr2:201384837	chr1:48435967~48437223:+
TGCT	trans	rs77688320	0.553	rs2244438	ENSG00000235105.1	RP11-329A14.1	-6.99	1.53e-10	0.00131	-0.52	-0.53	Breast cancer;	chr2:201387816	chr1:48435967~48437223:+
TGCT	trans	rs77688320	0.553	rs2540330	ENSG00000235105.1	RP11-329A14.1	-6.99	1.53e-10	0.00131	-0.52	-0.53	Breast cancer;	chr2:201388133	chr1:48435967~48437223:+
TGCT	trans	rs77688320	0.553	rs2540331	ENSG00000235105.1	RP11-329A14.1	-6.99	1.53e-10	0.00131	-0.52	-0.53	Breast cancer;	chr2:201388150	chr1:48435967~48437223:+
TGCT	trans	rs5758265	1	rs5758265	ENSG00000268568.1	AC007228.9	-6.99	1.53e-10	0.00131	-0.62	-0.53	Depressive symptoms (multi-trait analysis);	chr22:41221893	chr19:56672574~56673901:-
TGCT	trans	rs616147	0.627	rs816510	ENSG00000214263.2	RPSAP53	-6.99	1.53e-10	0.00131	-0.67	-0.53	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39430804	chr13:67266845~67267706:-
TGCT	trans	rs13190036	0.591	rs78523677	ENSG00000217325.2	PRELID1P1	-6.98	1.55e-10	0.00133	-0.66	-0.53	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177124102	chr6:126643488~126644390:+
TGCT	trans	rs8081395	0.801	rs2665405	ENSG00000187870.7	RNFT1P3	-6.98	1.55e-10	0.00133	-0.6	-0.53	White blood cell count;	chr17:59797931	chr17:20743333~20754501:-
TGCT	trans	rs7647973	1	rs2312462	ENSG00000197582.5	GPX1P1	6.98	1.57e-10	0.00134	0.72	0.53	Menarche (age at onset);	chr3:49563822	chrX:13378735~13379340:-
TGCT	trans	rs12709013	0.792	rs12598527	ENSG00000230849.2	GOT2P2	6.98	1.59e-10	0.00136	0.64	0.53	Blood metabolite ratios;	chr16:58772987	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.792	rs12600201	ENSG00000230849.2	GOT2P2	6.98	1.59e-10	0.00136	0.64	0.53	Blood metabolite ratios;	chr16:58773132	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.792	rs12600206	ENSG00000230849.2	GOT2P2	6.98	1.59e-10	0.00136	0.64	0.53	Blood metabolite ratios;	chr16:58773169	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.792	rs11076263	ENSG00000230849.2	GOT2P2	6.98	1.59e-10	0.00136	0.64	0.53	Blood metabolite ratios;	chr16:58773295	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.792	rs11646756	ENSG00000230849.2	GOT2P2	6.98	1.59e-10	0.00136	0.64	0.53	Blood metabolite ratios;	chr16:58773598	chr1:173141100~173142350:-
TGCT	trans	rs1707322	0.752	rs12062535	ENSG00000255397.1	AC022182.2	-6.98	1.6e-10	0.00137	-0.66	-0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr8:60937705~60939871:-
TGCT	trans	rs2657294	0.796	rs2804534	ENSG00000172974.11	AC007318.5	-6.98	1.6e-10	0.00137	-0.6	-0.53	Pneumonia;	chr10:75208023	chr2:65205108~65205988:+
TGCT	trans	rs9467773	0.596	rs2451750	ENSG00000242375.1	RP11-498P14.3	6.98	1.62e-10	0.00138	0.64	0.53	Intelligence (multi-trait analysis);	chr6:26646351	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.596	rs2451751	ENSG00000242375.1	RP11-498P14.3	6.98	1.62e-10	0.00138	0.64	0.53	Intelligence (multi-trait analysis);	chr6:26646486	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.62	rs2504600	ENSG00000242375.1	RP11-498P14.3	6.98	1.62e-10	0.00138	0.64	0.53	Intelligence (multi-trait analysis);	chr6:26648106	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.62	rs2130657	ENSG00000242375.1	RP11-498P14.3	6.98	1.62e-10	0.00138	0.64	0.53	Intelligence (multi-trait analysis);	chr6:26650598	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.62	rs2498351	ENSG00000242375.1	RP11-498P14.3	6.98	1.62e-10	0.00138	0.64	0.53	Intelligence (multi-trait analysis);	chr6:26659414	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.62	rs2504566	ENSG00000242375.1	RP11-498P14.3	6.98	1.62e-10	0.00138	0.64	0.53	Intelligence (multi-trait analysis);	chr6:26660260	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.62	rs2494716	ENSG00000242375.1	RP11-498P14.3	6.98	1.62e-10	0.00138	0.64	0.53	Intelligence (multi-trait analysis);	chr6:26662508	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.935	rs4573	ENSG00000242375.1	RP11-498P14.3	6.97	1.62e-10	0.00138	0.59	0.53	Intelligence (multi-trait analysis);	chr6:26546580	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.62	rs2504571	ENSG00000242375.1	RP11-498P14.3	6.97	1.64e-10	0.0014	0.63	0.53	Intelligence (multi-trait analysis);	chr6:26643207	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.549	rs9461273	ENSG00000242375.1	RP11-498P14.3	-6.97	1.65e-10	0.00141	-0.63	-0.53	Intelligence (multi-trait analysis);	chr6:26584298	chr9:97195351~97197687:-
TGCT	trans	rs1816752	0.819	rs7316961	ENSG00000237917.1	PARP4P1	6.97	1.69e-10	0.00144	0.63	0.53	Obesity-related traits;	chr13:24411039	chrY:26594851~26634652:-
TGCT	trans	rs9467773	0.935	rs1884947	ENSG00000242375.1	RP11-498P14.3	6.96	1.75e-10	0.00148	0.59	0.53	Intelligence (multi-trait analysis);	chr6:26553045	chr9:97195351~97197687:-
TGCT	trans	rs7647973	0.925	rs7429661	ENSG00000197582.5	GPX1P1	6.96	1.77e-10	0.0015	0.74	0.53	Menarche (age at onset);	chr3:49191367	chrX:13378735~13379340:-
TGCT	trans	rs7811142	0.83	rs118119933	ENSG00000228546.2	CTA-313A17.3	6.96	1.78e-10	0.00151	0.94	0.53	Platelet count;	chr7:100341427	chr7:102337316~102339115:+
TGCT	trans	rs8081395	0.801	rs12938273	ENSG00000187870.7	RNFT1P3	-6.95	1.82e-10	0.00154	-0.61	-0.53	White blood cell count;	chr17:59824291	chr17:20743333~20754501:-
TGCT	trans	rs8081395	0.836	rs2150879	ENSG00000187870.7	RNFT1P3	-6.95	1.82e-10	0.00154	-0.61	-0.53	White blood cell count;	chr17:59781849	chr17:20743333~20754501:-
TGCT	trans	rs9467773	0.935	rs11752946	ENSG00000242375.1	RP11-498P14.3	6.95	1.82e-10	0.00154	0.59	0.53	Intelligence (multi-trait analysis);	chr6:26560136	chr9:97195351~97197687:-
TGCT	trans	rs74781061	0.872	rs3826041	ENSG00000227288.3	RP5-837I24.1	6.95	1.82e-10	0.00154	0.53	0.53	Endometriosis;	chr15:74726549	chr1:81501794~81503468:+
TGCT	trans	rs7200543	1	rs7200543	ENSG00000250569.1	NTAN1P2	-6.95	1.83e-10	0.00155	-0.66	-0.53	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036113	chr8:86481754~86483002:-
TGCT	trans	rs77688320	0.553	rs1558637	ENSG00000235105.1	RP11-329A14.1	-6.95	1.84e-10	0.00156	-0.52	-0.53	Breast cancer;	chr2:201398651	chr1:48435967~48437223:+
TGCT	trans	rs77688320	0.553	rs2714488	ENSG00000235105.1	RP11-329A14.1	-6.95	1.84e-10	0.00156	-0.52	-0.53	Breast cancer;	chr2:201405050	chr1:48435967~48437223:+
TGCT	trans	rs77688320	0.553	rs2249868	ENSG00000235105.1	RP11-329A14.1	-6.95	1.84e-10	0.00156	-0.52	-0.53	Breast cancer;	chr2:201412503	chr1:48435967~48437223:+
TGCT	trans	rs1707322	0.827	rs10890347	ENSG00000255397.1	AC022182.2	6.95	1.85e-10	0.00156	0.62	0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr8:60937705~60939871:-
TGCT	trans	rs7811142	0.83	rs11771936	ENSG00000228546.2	CTA-313A17.3	6.95	1.85e-10	0.00157	0.84	0.53	Platelet count;	chr7:100345660	chr7:102337316~102339115:+
TGCT	trans	rs10242455	0.557	rs73403272	ENSG00000228834.1	RP11-249L21.4	6.95	1.88e-10	0.00159	1.41	0.53	Blood metabolite levels;	chr7:99536585	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs7794068	ENSG00000228834.1	RP11-249L21.4	6.95	1.88e-10	0.00159	1.41	0.53	Blood metabolite levels;	chr7:99549250	chr6:108907615~108907873:-
TGCT	trans	rs4276421	0.695	rs4421114	ENSG00000231752.4	EMBP1	-6.94	1.89e-10	0.00159	-0.56	-0.53	P wave duration;	chr5:46069241	chr1:121519112~121571892:+
TGCT	trans	rs9467773	1	rs10484442	ENSG00000242375.1	RP11-498P14.3	6.94	1.9e-10	0.0016	0.6	0.53	Intelligence (multi-trait analysis);	chr6:26555651	chr9:97195351~97197687:-
TGCT	trans	rs1707322	0.691	rs61784799	ENSG00000255397.1	AC022182.2	6.94	1.9e-10	0.0016	0.66	0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr8:60937705~60939871:-
TGCT	trans	rs10242455	0.702	rs75156180	ENSG00000228834.1	RP11-249L21.4	6.94	1.9e-10	0.0016	1.4	0.53	Blood metabolite levels;	chr7:99366477	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs57832867	ENSG00000228834.1	RP11-249L21.4	6.94	1.9e-10	0.0016	1.4	0.53	Blood metabolite levels;	chr7:99368773	chr6:108907615~108907873:-
TGCT	trans	rs13253073	1	rs12550092	ENSG00000260318.1	COX6CP1	6.94	1.94e-10	0.00163	1.15	0.53	Glucose homeostasis traits;	chr8:99886954	chr16:11903923~11904137:-
TGCT	trans	rs1707322	0.752	rs28719889	ENSG00000255397.1	AC022182.2	-6.94	1.95e-10	0.00164	-0.66	-0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.752	rs28812624	ENSG00000255397.1	AC022182.2	-6.94	1.95e-10	0.00164	-0.66	-0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.752	rs28568986	ENSG00000255397.1	AC022182.2	-6.94	1.95e-10	0.00164	-0.66	-0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.717	rs10890345	ENSG00000255397.1	AC022182.2	-6.94	1.95e-10	0.00164	-0.66	-0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs10789471	ENSG00000255397.1	AC022182.2	-6.94	1.95e-10	0.00164	-0.66	-0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr8:60937705~60939871:-
TGCT	trans	rs4273100	0.646	rs4924990	ENSG00000260350.1	RP11-152P23.2	6.94	1.96e-10	0.00165	0.87	0.53	Schizophrenia;	chr17:19391511	chr16:8847650~8848724:-
TGCT	trans	rs74781061	0.929	rs8029116	ENSG00000227288.3	RP5-837I24.1	6.94	1.98e-10	0.00166	0.69	0.53	Endometriosis;	chr15:74530753	chr1:81501794~81503468:+
TGCT	trans	rs8081395	0.775	rs2526355	ENSG00000187870.7	RNFT1P3	6.93	2e-10	0.00168	0.6	0.53	White blood cell count;	chr17:59875872	chr17:20743333~20754501:-
TGCT	trans	rs1292048	1	rs1292048	ENSG00000187870.7	RNFT1P3	6.93	2e-10	0.00168	0.6	0.53	Red cell distribution width;	chr17:59877710	chr17:20743333~20754501:-
TGCT	trans	rs1707322	0.752	rs11211171	ENSG00000255397.1	AC022182.2	-6.92	2.16e-10	0.0018	-0.66	-0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.752	rs28623463	ENSG00000255397.1	AC022182.2	-6.92	2.16e-10	0.0018	-0.66	-0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.716	rs28370457	ENSG00000255397.1	AC022182.2	-6.92	2.16e-10	0.0018	-0.66	-0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.752	rs28890893	ENSG00000255397.1	AC022182.2	-6.92	2.16e-10	0.0018	-0.66	-0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr8:60937705~60939871:-
TGCT	trans	rs4276421	0.688	rs7713759	ENSG00000231752.4	EMBP1	6.92	2.18e-10	0.00182	0.58	0.53	P wave duration;	chr5:46143447	chr1:121519112~121571892:+
TGCT	trans	rs6132905	0.52	rs2422823	ENSG00000257956.1	NOP56P3	-6.91	2.2e-10	0.00183	-0.73	-0.53	Mumps;	chr20:2665687	chr12:79558782~79559166:+
TGCT	trans	rs2657294	0.796	rs2804535	ENSG00000172974.11	AC007318.5	-6.91	2.2e-10	0.00183	-0.61	-0.53	Pneumonia;	chr10:75212086	chr2:65205108~65205988:+
TGCT	trans	rs2209875	0.549	rs3211707	ENSG00000234819.1	RP11-336N8.4	6.91	2.2e-10	0.00183	0.56	0.53	Pelvic organ prolapse (moderate/severe);	chr9:89318219	chr9:78219120~78219357:+
TGCT	trans	rs7554547	0.791	rs1321073	ENSG00000261819.1	RP11-680G24.4	6.91	2.22e-10	0.00185	0.68	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11891569	chr16:14988259~14990160:-
TGCT	trans	rs7590268	0.666	rs17406625	ENSG00000254966.1	RP11-1081L13.4	-6.91	2.23e-10	0.00185	-0.68	-0.53	Orofacial clefts;	chr2:43446751	chr11:18706537~18740568:+
TGCT	trans	rs61990749	0.511	rs7146020	ENSG00000235400.1	RP4-641G12.4	6.91	2.23e-10	0.00186	0.92	0.53	Fibroblast growth factor basic levels;	chr14:77891976	chr1:78749073~78750659:+
TGCT	trans	rs616147	0.548	rs2370965	ENSG00000214263.2	RPSAP53	-6.91	2.23e-10	0.00186	-0.66	-0.53	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39448996	chr13:67266845~67267706:-
TGCT	trans	rs8081395	0.836	rs2063353	ENSG00000187870.7	RNFT1P3	-6.91	2.24e-10	0.00187	-0.6	-0.53	White blood cell count;	chr17:59811831	chr17:20743333~20754501:-
TGCT	trans	rs7811142	0.83	rs75636500	ENSG00000228546.2	CTA-313A17.3	6.91	2.27e-10	0.00188	0.83	0.53	Platelet count;	chr7:100350034	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.779	rs77370288	ENSG00000228546.2	CTA-313A17.3	6.91	2.27e-10	0.00188	0.83	0.53	Platelet count;	chr7:100350274	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.83	rs7341507	ENSG00000228546.2	CTA-313A17.3	6.91	2.27e-10	0.00188	0.83	0.53	Platelet count;	chr7:100353692	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.83	rs76798830	ENSG00000228546.2	CTA-313A17.3	6.91	2.27e-10	0.00188	0.83	0.53	Platelet count;	chr7:100355205	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.83	rs78256546	ENSG00000228546.2	CTA-313A17.3	6.91	2.27e-10	0.00188	0.83	0.53	Platelet count;	chr7:100355347	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.775	rs6946768	ENSG00000228546.2	CTA-313A17.3	6.91	2.27e-10	0.00188	0.83	0.53	Platelet count;	chr7:100356770	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.83	rs41280971	ENSG00000228546.2	CTA-313A17.3	6.91	2.27e-10	0.00188	0.83	0.53	Platelet count;	chr7:100356834	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.83	rs3087502	ENSG00000228546.2	CTA-313A17.3	6.91	2.27e-10	0.00188	0.83	0.53	Platelet count;	chr7:100357741	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.83	rs61735533	ENSG00000228546.2	CTA-313A17.3	6.91	2.27e-10	0.00188	0.83	0.53	Platelet count;	chr7:100358243	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.83	rs11761426	ENSG00000228546.2	CTA-313A17.3	6.91	2.27e-10	0.00188	0.83	0.53	Platelet count;	chr7:100359270	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.83	rs77861211	ENSG00000228546.2	CTA-313A17.3	6.91	2.27e-10	0.00188	0.83	0.53	Platelet count;	chr7:100364473	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.83	rs11769057	ENSG00000228546.2	CTA-313A17.3	6.91	2.27e-10	0.00188	0.83	0.53	Platelet count;	chr7:100367038	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.83	rs11765869	ENSG00000228546.2	CTA-313A17.3	6.91	2.27e-10	0.00188	0.83	0.53	Platelet count;	chr7:100367166	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.83	rs705866	ENSG00000228546.2	CTA-313A17.3	6.91	2.27e-10	0.00188	0.83	0.53	Platelet count;	chr7:100367662	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.83	rs6965458	ENSG00000228546.2	CTA-313A17.3	6.91	2.27e-10	0.00188	0.83	0.53	Platelet count;	chr7:100375779	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.83	rs73401450	ENSG00000228546.2	CTA-313A17.3	6.91	2.27e-10	0.00188	0.83	0.53	Platelet count;	chr7:100384236	chr7:102337316~102339115:+
TGCT	trans	rs77688320	0.553	rs7582946	ENSG00000235105.1	RP11-329A14.1	6.91	2.28e-10	0.00189	0.52	0.53	Breast cancer;	chr2:201423969	chr1:48435967~48437223:+
TGCT	trans	rs77688320	0.535	rs10186894	ENSG00000235105.1	RP11-329A14.1	6.91	2.28e-10	0.00189	0.52	0.53	Breast cancer;	chr2:201440909	chr1:48435967~48437223:+
TGCT	trans	rs77688320	0.553	rs2540339	ENSG00000235105.1	RP11-329A14.1	-6.91	2.28e-10	0.00189	-0.52	-0.53	Breast cancer;	chr2:201415725	chr1:48435967~48437223:+
TGCT	trans	rs77688320	0.553	rs2540340	ENSG00000235105.1	RP11-329A14.1	-6.91	2.28e-10	0.00189	-0.52	-0.53	Breast cancer;	chr2:201416477	chr1:48435967~48437223:+
TGCT	trans	rs10242455	0.571	rs56167514	ENSG00000228834.1	RP11-249L21.4	6.91	2.29e-10	0.0019	1.41	0.53	Blood metabolite levels;	chr7:99563724	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.571	rs7805661	ENSG00000228834.1	RP11-249L21.4	6.91	2.29e-10	0.0019	1.41	0.53	Blood metabolite levels;	chr7:99573899	chr6:108907615~108907873:-
TGCT	trans	rs7647973	1	rs8897	ENSG00000197582.5	GPX1P1	6.91	2.3e-10	0.0019	0.68	0.53	Menarche (age at onset);	chr3:49422974	chrX:13378735~13379340:-
TGCT	trans	rs7937890	0.967	rs963212	ENSG00000236360.2	RP11-334A14.2	-6.9	2.33e-10	0.00192	-0.59	-0.53	Mitochondrial DNA levels;	chr11:14303186	chr1:52993201~52993702:-
TGCT	trans	rs7937890	1	rs2970334	ENSG00000236360.2	RP11-334A14.2	-6.9	2.33e-10	0.00192	-0.59	-0.53	Mitochondrial DNA levels;	chr11:14307809	chr1:52993201~52993702:-
TGCT	trans	rs2657294	0.73	rs1259505	ENSG00000172974.11	AC007318.5	6.9	2.33e-10	0.00193	0.62	0.53	Pneumonia;	chr10:75237183	chr2:65205108~65205988:+
TGCT	trans	rs7811142	0.775	rs1636980	ENSG00000228546.2	CTA-313A17.3	-6.9	2.34e-10	0.00194	-0.83	-0.53	Platelet count;	chr7:100341241	chr7:102337316~102339115:+
TGCT	trans	rs7312770	0.637	rs705700	ENSG00000234513.1	AC073072.7	6.9	2.39e-10	0.00198	0.61	0.53	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr7:22773646~22773993:-
TGCT	trans	rs13253073	0.544	rs10955223	ENSG00000260318.1	COX6CP1	6.89	2.48e-10	0.00205	0.94	0.53	Glucose homeostasis traits;	chr8:99903454	chr16:11903923~11904137:-
TGCT	trans	rs4276421	0.714	rs4259174	ENSG00000231752.4	EMBP1	-6.89	2.52e-10	0.00208	-0.56	-0.53	P wave duration;	chr5:46074351	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.661	rs4455569	ENSG00000231752.4	EMBP1	-6.89	2.52e-10	0.00208	-0.56	-0.53	P wave duration;	chr5:46081782	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.657	rs4975885	ENSG00000231752.4	EMBP1	-6.89	2.52e-10	0.00208	-0.56	-0.53	P wave duration;	chr5:46083476	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.774	rs11949490	ENSG00000231752.4	EMBP1	-6.89	2.52e-10	0.00208	-0.56	-0.53	P wave duration;	chr5:46085951	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.743	rs4455568	ENSG00000231752.4	EMBP1	6.89	2.52e-10	0.00208	0.56	0.53	P wave duration;	chr5:46079755	chr1:121519112~121571892:+
TGCT	trans	rs1707322	0.721	rs10890343	ENSG00000255397.1	AC022182.2	-6.89	2.54e-10	0.00209	-0.66	-0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr8:60937705~60939871:-
TGCT	trans	rs8081395	0.801	rs2777895	ENSG00000187870.7	RNFT1P3	-6.88	2.59e-10	0.00213	-0.59	-0.53	White blood cell count;	chr17:59802249	chr17:20743333~20754501:-
TGCT	trans	rs8081395	0.769	rs12449331	ENSG00000187870.7	RNFT1P3	-6.88	2.59e-10	0.00213	-0.59	-0.53	White blood cell count;	chr17:59806285	chr17:20743333~20754501:-
TGCT	trans	rs877636	0.692	rs11171739	ENSG00000196933.5	RPS26P11	6.88	2.68e-10	0.0022	0.55	0.53	Cognitive function;	chr12:56076841	chrX:72044545~72044892:+
TGCT	trans	rs10242455	0.702	rs76840929	ENSG00000228834.1	RP11-249L21.4	6.87	2.7e-10	0.00222	1.39	0.53	Blood metabolite levels;	chr7:99348235	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.702	rs116671616	ENSG00000228834.1	RP11-249L21.4	6.87	2.7e-10	0.00222	1.39	0.53	Blood metabolite levels;	chr7:99356935	chr6:108907615~108907873:-
TGCT	trans	rs12709013	0.686	rs151817	ENSG00000230849.2	GOT2P2	-6.87	2.76e-10	0.00226	-0.65	-0.53	Blood metabolite ratios;	chr16:58704014	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.686	rs244919	ENSG00000230849.2	GOT2P2	-6.87	2.76e-10	0.00226	-0.65	-0.53	Blood metabolite ratios;	chr16:58704146	chr1:173141100~173142350:-
TGCT	trans	rs4276421	0.774	rs4302598	ENSG00000231752.4	EMBP1	6.87	2.79e-10	0.00228	0.55	0.52	P wave duration;	chr5:46019065	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.774	rs4499842	ENSG00000231752.4	EMBP1	6.87	2.79e-10	0.00228	0.55	0.52	P wave duration;	chr5:46034390	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.623	rs12654375	ENSG00000231752.4	EMBP1	6.87	2.79e-10	0.00228	0.55	0.52	P wave duration;	chr5:46036452	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.682	rs10054419	ENSG00000231752.4	EMBP1	6.87	2.79e-10	0.00228	0.55	0.52	P wave duration;	chr5:46036863	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.623	rs4409106	ENSG00000231752.4	EMBP1	6.87	2.79e-10	0.00228	0.55	0.52	P wave duration;	chr5:46038004	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.774	rs4370277	ENSG00000231752.4	EMBP1	6.87	2.79e-10	0.00228	0.55	0.52	P wave duration;	chr5:46048566	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.683	rs4484447	ENSG00000231752.4	EMBP1	6.87	2.79e-10	0.00228	0.55	0.52	P wave duration;	chr5:46048757	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.744	rs4431354	ENSG00000231752.4	EMBP1	6.87	2.79e-10	0.00228	0.55	0.52	P wave duration;	chr5:46051284	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.712	rs4389698	ENSG00000231752.4	EMBP1	6.87	2.79e-10	0.00228	0.55	0.52	P wave duration;	chr5:46051566	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.6	rs4426925	ENSG00000231752.4	EMBP1	6.87	2.79e-10	0.00228	0.55	0.52	P wave duration;	chr5:46055499	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.704	rs57407363	ENSG00000231752.4	EMBP1	-6.87	2.79e-10	0.00228	-0.55	-0.52	P wave duration;	chr5:46073845	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.745	rs13354272	ENSG00000231752.4	EMBP1	-6.87	2.79e-10	0.00228	-0.55	-0.52	P wave duration;	chr5:46078020	chr1:121519112~121571892:+
TGCT	trans	rs1707322	0.721	rs7520123	ENSG00000255397.1	AC022182.2	-6.86	2.84e-10	0.00232	-0.68	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr8:60937705~60939871:-
TGCT	trans	rs877636	0.692	rs10876870	ENSG00000234513.1	AC073072.7	-6.86	2.85e-10	0.00233	-0.58	-0.52	Cognitive function;	chr12:56084218	chr7:22773646~22773993:-
TGCT	trans	rs877636	0.692	rs7971751	ENSG00000234513.1	AC073072.7	-6.86	2.85e-10	0.00233	-0.58	-0.52	Cognitive function;	chr12:56084874	chr7:22773646~22773993:-
TGCT	trans	rs4276421	0.715	rs10043248	ENSG00000231752.4	EMBP1	6.86	2.87e-10	0.00234	0.56	0.52	P wave duration;	chr5:46025930	chr1:121519112~121571892:+
TGCT	trans	rs1707322	0.721	rs4660314	ENSG00000255397.1	AC022182.2	-6.86	2.92e-10	0.00238	-0.66	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.686	rs61784833	ENSG00000255397.1	AC022182.2	-6.86	2.92e-10	0.00238	-0.66	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs7519900	ENSG00000255397.1	AC022182.2	-6.86	2.92e-10	0.00238	-0.66	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr8:60937705~60939871:-
TGCT	trans	rs4276421	0.695	rs4498260	ENSG00000231752.4	EMBP1	-6.86	2.93e-10	0.00239	-0.55	-0.52	P wave duration;	chr5:46079235	chr1:121519112~121571892:+
TGCT	trans	rs2657294	0.796	rs1259501	ENSG00000172974.11	AC007318.5	6.86	2.97e-10	0.00242	0.61	0.52	Pneumonia;	chr10:75230427	chr2:65205108~65205988:+
TGCT	trans	rs2731664	0.792	rs335420	ENSG00000215571.5	GRK6P1	-6.85	3.05e-10	0.00249	-0.61	-0.52	Intelligence (multi-trait analysis);	chr5:177471618	chr13:21319156~21320866:+
TGCT	trans	rs877636	0.74	rs705702	ENSG00000225071.1	GS1-184P14.2	-6.84	3.16e-10	0.00257	-0.62	-0.52	Cognitive function;	chr12:55996852	chrX:24429573~24429920:-
TGCT	trans	rs4276421	0.745	rs11957047	ENSG00000231752.4	EMBP1	-6.84	3.16e-10	0.00257	-0.55	-0.52	P wave duration;	chr5:46080090	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.694	rs10941732	ENSG00000231752.4	EMBP1	-6.84	3.16e-10	0.00257	-0.55	-0.52	P wave duration;	chr5:46080260	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.745	rs4441886	ENSG00000231752.4	EMBP1	-6.84	3.24e-10	0.00263	-0.55	-0.52	P wave duration;	chr5:46063034	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.745	rs10941722	ENSG00000231752.4	EMBP1	-6.84	3.24e-10	0.00263	-0.55	-0.52	P wave duration;	chr5:46067527	chr1:121519112~121571892:+
TGCT	trans	rs10242455	0.571	rs11734	ENSG00000228834.1	RP11-249L21.4	-6.84	3.27e-10	0.00265	-1.32	-0.52	Blood metabolite levels;	chr7:99632145	chr6:108907615~108907873:-
TGCT	trans	rs7811142	0.779	rs111312383	ENSG00000228546.2	CTA-313A17.3	6.83	3.31e-10	0.00269	0.83	0.52	Platelet count;	chr7:100307702	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.83	rs1063945	ENSG00000228546.2	CTA-313A17.3	6.83	3.31e-10	0.00269	0.83	0.52	Platelet count;	chr7:100332824	chr7:102337316~102339115:+
TGCT	trans	rs7811142	0.83	rs11761253	ENSG00000228546.2	CTA-313A17.3	6.83	3.31e-10	0.00269	0.83	0.52	Platelet count;	chr7:100341698	chr7:102337316~102339115:+
TGCT	trans	rs916888	0.779	rs199498	ENSG00000214425.5	LRRC37A4P	-6.83	3.34e-10	0.00271	-0.64	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45506741~45550335:-
TGCT	trans	rs1816752	0.74	rs6490924	ENSG00000237917.1	PARP4P1	-6.83	3.35e-10	0.00271	-0.62	-0.52	Obesity-related traits;	chr13:24432914	chrY:26594851~26634652:-
TGCT	trans	rs7200543	1	rs6498540	ENSG00000250569.1	NTAN1P2	6.83	3.35e-10	0.00271	0.66	0.52	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036737	chr8:86481754~86483002:-
TGCT	trans	rs2657294	0.796	rs4746272	ENSG00000172974.11	AC007318.5	6.83	3.38e-10	0.00273	0.61	0.52	Pneumonia;	chr10:75203869	chr2:65205108~65205988:+
TGCT	trans	rs2657294	0.765	rs2804533	ENSG00000172974.11	AC007318.5	6.83	3.38e-10	0.00273	0.61	0.52	Pneumonia;	chr10:75207723	chr2:65205108~65205988:+
TGCT	trans	rs77688320	0.553	rs10804114	ENSG00000235105.1	RP11-329A14.1	6.83	3.42e-10	0.00277	0.52	0.52	Breast cancer;	chr2:201402139	chr1:48435967~48437223:+
TGCT	trans	rs7647973	0.922	rs7620024	ENSG00000197582.5	GPX1P1	-6.83	3.47e-10	0.0028	-0.72	-0.52	Menarche (age at onset);	chr3:49414258	chrX:13378735~13379340:-
TGCT	trans	rs877636	0.669	rs7297175	ENSG00000234513.1	AC073072.7	-6.82	3.52e-10	0.00284	-0.58	-0.52	Cognitive function;	chr12:56080024	chr7:22773646~22773993:-
TGCT	trans	rs7647973	1	rs6446275	ENSG00000197582.5	GPX1P1	-6.82	3.52e-10	0.00284	-0.72	-0.52	Menarche (age at onset);	chr3:49429438	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs62259933	ENSG00000197582.5	GPX1P1	-6.82	3.52e-10	0.00284	-0.72	-0.52	Menarche (age at onset);	chr3:49432270	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs9860055	ENSG00000197582.5	GPX1P1	-6.82	3.52e-10	0.00284	-0.72	-0.52	Menarche (age at onset);	chr3:49469467	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs74471041	ENSG00000197582.5	GPX1P1	-6.82	3.52e-10	0.00284	-0.72	-0.52	Menarche (age at onset);	chr3:49505110	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs7644148	ENSG00000197582.5	GPX1P1	-6.82	3.52e-10	0.00284	-0.72	-0.52	Menarche (age at onset);	chr3:49507808	chrX:13378735~13379340:-
TGCT	trans	rs8081395	0.741	rs1292056	ENSG00000187870.7	RNFT1P3	6.82	3.58e-10	0.00289	0.59	0.52	White blood cell count;	chr17:59881686	chr17:20743333~20754501:-
TGCT	trans	rs4276421	0.774	rs10050829	ENSG00000231752.4	EMBP1	-6.82	3.6e-10	0.0029	-0.55	-0.52	P wave duration;	chr5:46072628	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.688	rs10067655	ENSG00000231752.4	EMBP1	-6.82	3.6e-10	0.0029	-0.55	-0.52	P wave duration;	chr5:46072803	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.774	rs13361118	ENSG00000231752.4	EMBP1	-6.82	3.6e-10	0.0029	-0.55	-0.52	P wave duration;	chr5:46078308	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.774	rs10066479	ENSG00000231752.4	EMBP1	-6.82	3.6e-10	0.0029	-0.55	-0.52	P wave duration;	chr5:46097385	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.774	rs12515804	ENSG00000231752.4	EMBP1	-6.82	3.6e-10	0.0029	-0.55	-0.52	P wave duration;	chr5:46098504	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.807	rs12520938	ENSG00000231752.4	EMBP1	-6.82	3.6e-10	0.0029	-0.55	-0.52	P wave duration;	chr5:46098683	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.807	rs10941740	ENSG00000231752.4	EMBP1	-6.82	3.6e-10	0.0029	-0.55	-0.52	P wave duration;	chr5:46100208	chr1:121519112~121571892:+
TGCT	trans	rs7647973	0.925	rs6446257	ENSG00000197582.5	GPX1P1	-6.82	3.61e-10	0.00291	-0.7	-0.52	Menarche (age at onset);	chr3:49216059	chrX:13378735~13379340:-
TGCT	trans	rs9467773	1	rs1321479	ENSG00000242375.1	RP11-498P14.3	-6.81	3.72e-10	0.00299	-0.57	-0.52	Intelligence (multi-trait analysis);	chr6:26501669	chr9:97195351~97197687:-
TGCT	trans	rs77688320	0.553	rs6722889	ENSG00000235105.1	RP11-329A14.1	-6.81	3.74e-10	0.003	-0.51	-0.52	Breast cancer;	chr2:201439359	chr1:48435967~48437223:+
TGCT	trans	rs77688320	0.553	rs2540449	ENSG00000235105.1	RP11-329A14.1	-6.81	3.74e-10	0.003	-0.51	-0.52	Breast cancer;	chr2:201451036	chr1:48435967~48437223:+
TGCT	trans	rs77688320	0.573	rs2080327	ENSG00000235105.1	RP11-329A14.1	-6.81	3.74e-10	0.003	-0.51	-0.52	Breast cancer;	chr2:201461495	chr1:48435967~48437223:+
TGCT	trans	rs77688320	0.553	rs2243791	ENSG00000235105.1	RP11-329A14.1	-6.81	3.74e-10	0.003	-0.51	-0.52	Breast cancer;	chr2:201478079	chr1:48435967~48437223:+
TGCT	trans	rs77688320	0.529	rs2540438	ENSG00000235105.1	RP11-329A14.1	-6.81	3.74e-10	0.003	-0.51	-0.52	Breast cancer;	chr2:201485833	chr1:48435967~48437223:+
TGCT	trans	rs77688320	0.573	rs2714480	ENSG00000235105.1	RP11-329A14.1	-6.81	3.74e-10	0.003	-0.51	-0.52	Breast cancer;	chr2:201486286	chr1:48435967~48437223:+
TGCT	trans	rs77688320	0.553	rs2540432	ENSG00000235105.1	RP11-329A14.1	-6.81	3.74e-10	0.003	-0.51	-0.52	Breast cancer;	chr2:201500171	chr1:48435967~48437223:+
TGCT	trans	rs77688320	0.553	rs2540430	ENSG00000235105.1	RP11-329A14.1	-6.81	3.74e-10	0.003	-0.51	-0.52	Breast cancer;	chr2:201503791	chr1:48435967~48437223:+
TGCT	trans	rs77688320	0.553	rs2908763	ENSG00000235105.1	RP11-329A14.1	-6.81	3.74e-10	0.003	-0.51	-0.52	Breast cancer;	chr2:201503860	chr1:48435967~48437223:+
TGCT	trans	rs77688320	0.535	rs60148247	ENSG00000235105.1	RP11-329A14.1	-6.81	3.74e-10	0.003	-0.51	-0.52	Breast cancer;	chr2:201513770	chr1:48435967~48437223:+
TGCT	trans	rs77688320	0.553	rs2080324	ENSG00000235105.1	RP11-329A14.1	-6.81	3.74e-10	0.003	-0.51	-0.52	Breast cancer;	chr2:201514089	chr1:48435967~48437223:+
TGCT	trans	rs77688320	0.553	rs2080323	ENSG00000235105.1	RP11-329A14.1	-6.81	3.74e-10	0.003	-0.51	-0.52	Breast cancer;	chr2:201514126	chr1:48435967~48437223:+
TGCT	trans	rs77688320	0.553	rs2080322	ENSG00000235105.1	RP11-329A14.1	-6.81	3.74e-10	0.003	-0.51	-0.52	Breast cancer;	chr2:201514317	chr1:48435967~48437223:+
TGCT	trans	rs77688320	0.553	rs2080320	ENSG00000235105.1	RP11-329A14.1	6.81	3.74e-10	0.003	0.51	0.52	Breast cancer;	chr2:201514450	chr1:48435967~48437223:+
TGCT	trans	rs7312770	0.637	rs705699	ENSG00000243538.1	CTB-55B8.1	6.81	3.76e-10	0.00302	0.62	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr5:16902294~16902641:-
TGCT	trans	rs1707322	0.662	rs11211160	ENSG00000255397.1	AC022182.2	-6.81	3.77e-10	0.00302	-0.66	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.752	rs11211173	ENSG00000255397.1	AC022182.2	-6.81	3.8e-10	0.00305	-0.65	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr8:60937705~60939871:-
TGCT	trans	rs7312770	0.612	rs773114	ENSG00000234513.1	AC073072.7	6.8	3.84e-10	0.00307	0.59	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr7:22773646~22773993:-
TGCT	trans	rs12709013	0.59	rs982848	ENSG00000230849.2	GOT2P2	6.8	3.87e-10	0.0031	0.64	0.52	Blood metabolite ratios;	chr16:58704294	chr1:173141100~173142350:-
TGCT	trans	rs77688320	0.553	rs12473387	ENSG00000235105.1	RP11-329A14.1	6.8	4.01e-10	0.00321	0.52	0.52	Breast cancer;	chr2:201415778	chr1:48435967~48437223:+
TGCT	trans	rs77688320	0.553	rs4507084	ENSG00000235105.1	RP11-329A14.1	6.8	4.01e-10	0.00321	0.52	0.52	Breast cancer;	chr2:201420377	chr1:48435967~48437223:+
TGCT	trans	rs7811142	0.83	rs6948685	ENSG00000228546.2	CTA-313A17.3	6.79	4.07e-10	0.00325	0.82	0.52	Platelet count;	chr7:100372565	chr7:102337316~102339115:+
TGCT	trans	rs7312770	0.612	rs773114	ENSG00000243538.1	CTB-55B8.1	6.79	4.07e-10	0.00325	0.61	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr5:16902294~16902641:-
TGCT	trans	rs616147	0.671	rs674192	ENSG00000214263.2	RPSAP53	-6.79	4.11e-10	0.00328	-0.65	-0.52	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458653	chr13:67266845~67267706:-
TGCT	trans	rs616147	0.671	rs675595	ENSG00000214263.2	RPSAP53	-6.79	4.11e-10	0.00328	-0.65	-0.52	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458987	chr13:67266845~67267706:-
TGCT	trans	rs74781061	0.932	rs2012008	ENSG00000227288.3	RP5-837I24.1	6.78	4.25e-10	0.00339	0.53	0.52	Endometriosis;	chr15:74441827	chr1:81501794~81503468:+
TGCT	trans	rs4276421	0.743	rs10060199	ENSG00000231752.4	EMBP1	6.78	4.33e-10	0.00345	0.55	0.52	P wave duration;	chr5:46064524	chr1:121519112~121571892:+
TGCT	trans	rs7312770	0.637	rs705699	ENSG00000234513.1	AC073072.7	6.77	4.57e-10	0.00363	0.6	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr7:22773646~22773993:-
TGCT	trans	rs7811142	0.72	rs112622797	ENSG00000228546.2	CTA-313A17.3	6.77	4.69e-10	0.00373	0.84	0.52	Platelet count;	chr7:100319793	chr7:102337316~102339115:+
TGCT	trans	rs2209875	0.574	rs2274576	ENSG00000234819.1	RP11-336N8.4	6.76	4.87e-10	0.00386	0.54	0.52	Pelvic organ prolapse (moderate/severe);	chr9:89311531	chr9:78219120~78219357:+
TGCT	trans	rs1707322	0.721	rs10890333	ENSG00000255397.1	AC022182.2	-6.76	4.88e-10	0.00386	-0.66	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs12043945	ENSG00000255397.1	AC022182.2	-6.76	4.88e-10	0.00386	-0.66	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs12091503	ENSG00000255397.1	AC022182.2	-6.76	4.88e-10	0.00386	-0.66	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs10890336	ENSG00000255397.1	AC022182.2	-6.76	4.88e-10	0.00386	-0.66	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs11211151	ENSG00000255397.1	AC022182.2	-6.76	4.88e-10	0.00386	-0.66	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs12045096	ENSG00000255397.1	AC022182.2	-6.76	4.88e-10	0.00386	-0.66	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs4609469	ENSG00000255397.1	AC022182.2	-6.76	4.88e-10	0.00386	-0.66	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs12049027	ENSG00000255397.1	AC022182.2	-6.76	4.88e-10	0.00386	-0.66	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.752	rs10789467	ENSG00000255397.1	AC022182.2	-6.76	4.88e-10	0.00386	-0.66	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs10890337	ENSG00000255397.1	AC022182.2	-6.76	4.88e-10	0.00386	-0.66	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.752	rs3811435	ENSG00000255397.1	AC022182.2	-6.76	4.88e-10	0.00386	-0.66	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs9793568	ENSG00000255397.1	AC022182.2	-6.76	4.88e-10	0.00386	-0.66	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs11211157	ENSG00000255397.1	AC022182.2	-6.76	4.88e-10	0.00386	-0.66	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs11211158	ENSG00000255397.1	AC022182.2	-6.76	4.88e-10	0.00386	-0.66	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs6429575	ENSG00000255397.1	AC022182.2	-6.76	4.88e-10	0.00386	-0.66	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.685	rs6690926	ENSG00000255397.1	AC022182.2	-6.76	4.88e-10	0.00386	-0.66	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.752	rs8179402	ENSG00000255397.1	AC022182.2	-6.76	4.88e-10	0.00386	-0.66	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.752	rs8179296	ENSG00000255397.1	AC022182.2	-6.76	4.88e-10	0.00386	-0.66	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr8:60937705~60939871:-
TGCT	trans	rs877636	1	rs877636	ENSG00000223416.3	RPS26P15	-6.75	4.97e-10	0.00393	-0.63	-0.52	Cognitive function;	chr12:56086799	chr1:58056133~58056480:-
TGCT	trans	rs74781061	0.932	rs4886605	ENSG00000227288.3	RP5-837I24.1	6.75	5.01e-10	0.00396	0.51	0.52	Endometriosis;	chr15:74733647	chr1:81501794~81503468:+
TGCT	trans	rs2657294	0.726	rs4746275	ENSG00000172974.11	AC007318.5	6.75	5.04e-10	0.00398	0.6	0.52	Pneumonia;	chr10:75214940	chr2:65205108~65205988:+
TGCT	trans	rs10242455	0.702	rs76702117	ENSG00000228834.1	RP11-249L21.4	6.75	5.04e-10	0.00398	1.3	0.52	Blood metabolite levels;	chr7:99319156	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.571	rs79694709	ENSG00000228834.1	RP11-249L21.4	6.75	5.09e-10	0.00402	1.31	0.52	Blood metabolite levels;	chr7:99617088	chr6:108907615~108907873:-
TGCT	trans	rs7617480	0.519	rs6790914	ENSG00000197582.5	GPX1P1	6.75	5.19e-10	0.0041	0.67	0.52	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49168885	chrX:13378735~13379340:-
TGCT	trans	rs12709013	0.792	rs7185513	ENSG00000230849.2	GOT2P2	6.74	5.21e-10	0.00411	0.61	0.52	Blood metabolite ratios;	chr16:58794889	chr1:173141100~173142350:-
TGCT	trans	rs1707322	0.721	rs12069121	ENSG00000255397.1	AC022182.2	-6.74	5.46e-10	0.00429	-0.66	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.789	rs7540578	ENSG00000255397.1	AC022182.2	-6.73	5.5e-10	0.00432	-0.64	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr8:60937705~60939871:-
TGCT	trans	rs7312770	0.612	rs1873914	ENSG00000223416.3	RPS26P15	6.73	5.51e-10	0.00432	0.58	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr1:58056133~58056480:-
TGCT	trans	rs1816752	0.669	rs7984513	ENSG00000237917.1	PARP4P1	-6.73	5.61e-10	0.0044	-0.62	-0.52	Obesity-related traits;	chr13:24445117	chrY:26594851~26634652:-
TGCT	trans	rs7590268	0.895	rs10445925	ENSG00000254966.1	RP11-1081L13.4	6.73	5.63e-10	0.00441	0.66	0.52	Orofacial clefts;	chr2:43443005	chr11:18706537~18740568:+
TGCT	trans	rs877636	0.692	rs11171739	ENSG00000227887.1	RPS26P13	6.73	5.63e-10	0.00442	0.58	0.52	Cognitive function;	chr12:56076841	chr1:208697369~208697698:-
TGCT	trans	rs877636	1	rs4759229	ENSG00000243538.1	CTB-55B8.1	-6.72	5.77e-10	0.00452	-0.65	-0.52	Cognitive function;	chr12:56080696	chr5:16902294~16902641:-
TGCT	trans	rs7647973	0.961	rs7626076	ENSG00000197582.5	GPX1P1	6.72	5.81e-10	0.00455	0.73	0.52	Menarche (age at onset);	chr3:49260706	chrX:13378735~13379340:-
TGCT	trans	rs7647973	0.961	rs7619016	ENSG00000197582.5	GPX1P1	6.72	5.81e-10	0.00455	0.73	0.52	Menarche (age at onset);	chr3:49235156	chrX:13378735~13379340:-
TGCT	trans	rs9467773	0.525	rs1535274	ENSG00000242375.1	RP11-498P14.3	6.72	5.84e-10	0.00457	0.57	0.52	Intelligence (multi-trait analysis);	chr6:26520519	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.565	rs6925047	ENSG00000242375.1	RP11-498P14.3	6.72	5.84e-10	0.00457	0.57	0.52	Intelligence (multi-trait analysis);	chr6:26521207	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.565	rs4343916	ENSG00000242375.1	RP11-498P14.3	6.72	5.84e-10	0.00457	0.57	0.52	Intelligence (multi-trait analysis);	chr6:26522447	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.583	rs2498380	ENSG00000242375.1	RP11-498P14.3	-6.72	5.94e-10	0.00464	-0.61	-0.52	Intelligence (multi-trait analysis);	chr6:26643768	chr9:97195351~97197687:-
TGCT	trans	rs4276421	0.7	rs10070274	ENSG00000231752.4	EMBP1	6.72	6.02e-10	0.00471	0.57	0.52	P wave duration;	chr5:46030675	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.682	rs10067983	ENSG00000231752.4	EMBP1	6.71	6.12e-10	0.00478	0.55	0.52	P wave duration;	chr5:46064294	chr1:121519112~121571892:+
TGCT	trans	rs5022636	0.631	rs6587562	ENSG00000180764.13	PIPSL	-6.71	6.13e-10	0.00478	-0.67	-0.52	Gut microbiota (functional units);	chr1:151273765	chr10:93958191~93961540:-
TGCT	trans	rs9899728	0.572	rs9915968	ENSG00000234925.2	ATP5HP4	6.71	6.15e-10	0.0048	0.7	0.52	Alzheimer's disease or small vessel stroke;	chr17:75063521	chr12:68642519~68642993:-
TGCT	trans	rs9899728	0.572	rs4365317	ENSG00000234925.2	ATP5HP4	6.71	6.15e-10	0.0048	0.7	0.52	Alzheimer's disease or small vessel stroke;	chr17:75063725	chr12:68642519~68642993:-
TGCT	trans	rs1707322	1	rs4660905	ENSG00000255397.1	AC022182.2	6.71	6.19e-10	0.00483	0.63	0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995915	chr8:60937705~60939871:-
TGCT	trans	rs9467773	0.935	rs1056668	ENSG00000242375.1	RP11-498P14.3	6.71	6.2e-10	0.00483	0.57	0.52	Intelligence (multi-trait analysis);	chr6:26510377	chr9:97195351~97197687:-
TGCT	trans	rs7121616	0.531	rs10892958	ENSG00000234176.1	HSPA8P1	6.71	6.2e-10	0.00484	0.77	0.52	Breast cancer;	chr11:123061415	chrX:121203182~121205014:-
TGCT	trans	rs2657294	0.73	rs1259508	ENSG00000172974.11	AC007318.5	6.71	6.22e-10	0.00485	0.61	0.52	Pneumonia;	chr10:75238334	chr2:65205108~65205988:+
TGCT	trans	rs9467773	1	rs6456733	ENSG00000242375.1	RP11-498P14.3	6.7	6.4e-10	0.00498	0.58	0.52	Intelligence (multi-trait analysis);	chr6:26566576	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs6456734	ENSG00000242375.1	RP11-498P14.3	6.7	6.4e-10	0.00498	0.58	0.52	Intelligence (multi-trait analysis);	chr6:26566737	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs1535277	ENSG00000242375.1	RP11-498P14.3	6.7	6.4e-10	0.00498	0.58	0.52	Intelligence (multi-trait analysis);	chr6:26567574	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs1884948	ENSG00000242375.1	RP11-498P14.3	6.7	6.4e-10	0.00498	0.58	0.52	Intelligence (multi-trait analysis);	chr6:26567760	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs1884949	ENSG00000242375.1	RP11-498P14.3	6.7	6.4e-10	0.00498	0.58	0.52	Intelligence (multi-trait analysis);	chr6:26567839	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs9467796	ENSG00000242375.1	RP11-498P14.3	6.7	6.4e-10	0.00498	0.58	0.52	Intelligence (multi-trait analysis);	chr6:26568183	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs9467797	ENSG00000242375.1	RP11-498P14.3	6.7	6.4e-10	0.00498	0.58	0.52	Intelligence (multi-trait analysis);	chr6:26568245	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs1078679	ENSG00000242375.1	RP11-498P14.3	6.7	6.4e-10	0.00498	0.58	0.52	Intelligence (multi-trait analysis);	chr6:26568513	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs6932156	ENSG00000242375.1	RP11-498P14.3	6.7	6.4e-10	0.00498	0.58	0.52	Intelligence (multi-trait analysis);	chr6:26571278	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs6924838	ENSG00000242375.1	RP11-498P14.3	6.7	6.4e-10	0.00498	0.58	0.52	Intelligence (multi-trait analysis);	chr6:26571528	chr9:97195351~97197687:-
TGCT	trans	rs9467773	1	rs6925895	ENSG00000242375.1	RP11-498P14.3	6.7	6.4e-10	0.00498	0.58	0.52	Intelligence (multi-trait analysis);	chr6:26571937	chr9:97195351~97197687:-
TGCT	trans	rs9467773	0.62	rs2451732	ENSG00000242375.1	RP11-498P14.3	-6.69	6.76e-10	0.00525	-0.63	-0.52	Intelligence (multi-trait analysis);	chr6:26622676	chr9:97195351~97197687:-
TGCT	trans	rs4276421	0.682	rs12657581	ENSG00000231752.4	EMBP1	6.68	7.06e-10	0.00547	0.54	0.51	P wave duration;	chr5:46080471	chr1:121519112~121571892:+
TGCT	trans	rs7824557	0.688	rs2572397	ENSG00000173295.6	FAM86B3P	6.68	7.34e-10	0.00567	0.61	0.51	Retinal vascular caliber;	chr8:11318894	chr8:8228595~8244865:+
TGCT	trans	rs7824557	0.724	rs2251473	ENSG00000173295.6	FAM86B3P	6.68	7.34e-10	0.00567	0.61	0.51	Retinal vascular caliber;	chr8:11319617	chr8:8228595~8244865:+
TGCT	trans	rs7824557	0.724	rs2572398	ENSG00000173295.6	FAM86B3P	6.68	7.34e-10	0.00567	0.61	0.51	Retinal vascular caliber;	chr8:11320584	chr8:8228595~8244865:+
TGCT	trans	rs1707322	0.752	rs4660880	ENSG00000255397.1	AC022182.2	-6.68	7.34e-10	0.00567	-0.67	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.682	rs10890334	ENSG00000255397.1	AC022182.2	-6.67	7.42e-10	0.00573	-0.66	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.682	rs10890335	ENSG00000255397.1	AC022182.2	-6.67	7.42e-10	0.00573	-0.66	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr8:60937705~60939871:-
TGCT	trans	rs10242455	0.571	rs6955162	ENSG00000228834.1	RP11-249L21.4	6.67	7.65e-10	0.0059	1.4	0.51	Blood metabolite levels;	chr7:99586777	chr6:108907615~108907873:-
TGCT	trans	rs616147	0.627	rs816487	ENSG00000214263.2	RPSAP53	-6.67	7.68e-10	0.00593	-0.67	-0.51	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39445999	chr13:67266845~67267706:-
TGCT	trans	rs1707322	0.963	rs34907901	ENSG00000255397.1	AC022182.2	-6.67	7.76e-10	0.00598	-0.63	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45939542	chr8:60937705~60939871:-
TGCT	trans	rs4276421	0.55	rs34812524	ENSG00000231752.4	EMBP1	6.66	7.82e-10	0.00603	0.55	0.51	P wave duration;	chr5:46054030	chr1:121519112~121571892:+
TGCT	trans	rs13190036	1	rs625882	ENSG00000228305.2	AC016734.2	-6.66	8.08e-10	0.00622	-0.57	-0.51	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177108030	chr2:63622178~63622831:-
TGCT	trans	rs6132905	0.52	rs2422824	ENSG00000257956.1	NOP56P3	6.65	8.21e-10	0.00631	0.71	0.51	Mumps;	chr20:2666724	chr12:79558782~79559166:+
TGCT	trans	rs9467773	0.534	rs34453863	ENSG00000242375.1	RP11-498P14.3	6.65	8.24e-10	0.00633	0.6	0.51	Intelligence (multi-trait analysis);	chr6:26627777	chr9:97195351~97197687:-
TGCT	trans	rs5022636	0.525	rs7539584	ENSG00000180764.13	PIPSL	6.65	8.32e-10	0.00639	0.64	0.51	Gut microbiota (functional units);	chr1:151210477	chr10:93958191~93961540:-
TGCT	trans	rs13190036	1	rs628506	ENSG00000228305.2	AC016734.2	-6.65	8.34e-10	0.0064	-0.57	-0.51	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107422	chr2:63622178~63622831:-
TGCT	trans	rs7647973	1	rs6446262	ENSG00000197582.5	GPX1P1	6.65	8.41e-10	0.00645	0.73	0.51	Menarche (age at onset);	chr3:49363720	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs62259947	ENSG00000197582.5	GPX1P1	-6.65	8.41e-10	0.00645	-0.73	-0.51	Menarche (age at onset);	chr3:49402491	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs73088137	ENSG00000197582.5	GPX1P1	-6.65	8.41e-10	0.00645	-0.73	-0.51	Menarche (age at onset);	chr3:49410990	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs3905330	ENSG00000197582.5	GPX1P1	6.65	8.49e-10	0.00652	0.68	0.51	Menarche (age at onset);	chr3:49513341	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs3866330	ENSG00000197582.5	GPX1P1	6.65	8.49e-10	0.00652	0.68	0.51	Menarche (age at onset);	chr3:49545561	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs11928090	ENSG00000197582.5	GPX1P1	6.65	8.49e-10	0.00652	0.68	0.51	Menarche (age at onset);	chr3:49567471	chrX:13378735~13379340:-
TGCT	trans	rs9467773	0.572	rs13213953	ENSG00000242375.1	RP11-498P14.3	6.65	8.5e-10	0.00652	0.61	0.51	Intelligence (multi-trait analysis);	chr6:26594306	chr9:97195351~97197687:-
TGCT	trans	rs7121616	0.531	rs11218941	ENSG00000234176.1	HSPA8P1	6.65	8.54e-10	0.00655	0.76	0.51	Breast cancer;	chr11:123061701	chrX:121203182~121205014:-
TGCT	trans	rs6477998	1	rs4560868	ENSG00000238072.1	RP11-305M3.2	-6.65	8.58e-10	0.00658	-0.62	-0.51	Hematology traits;	chr9:113223219	chr7:129410113~129410370:-
TGCT	trans	rs1707322	0.716	rs6694889	ENSG00000255397.1	AC022182.2	-6.64	8.64e-10	0.00662	-0.65	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.752	rs4607935	ENSG00000255397.1	AC022182.2	-6.64	8.64e-10	0.00662	-0.65	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.752	rs3811436	ENSG00000255397.1	AC022182.2	-6.64	8.64e-10	0.00662	-0.65	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs4415615	ENSG00000255397.1	AC022182.2	-6.64	8.64e-10	0.00662	-0.65	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.752	rs7529699	ENSG00000255397.1	AC022182.2	-6.64	8.64e-10	0.00662	-0.65	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.752	rs10430105	ENSG00000255397.1	AC022182.2	-6.64	8.64e-10	0.00662	-0.65	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr8:60937705~60939871:-
TGCT	trans	rs7824557	0.734	rs2293856	ENSG00000173295.6	FAM86B3P	6.64	8.67e-10	0.00664	0.6	0.51	Retinal vascular caliber;	chr8:11319938	chr8:8228595~8244865:+
TGCT	trans	rs877636	0.74	rs772920	ENSG00000225071.1	GS1-184P14.2	6.64	8.69e-10	0.00665	0.62	0.51	Cognitive function;	chr12:55996580	chrX:24429573~24429920:-
TGCT	trans	rs4276421	0.659	rs8188026	ENSG00000231752.4	EMBP1	6.64	8.74e-10	0.00669	0.54	0.51	P wave duration;	chr5:46053462	chr1:121519112~121571892:+
TGCT	trans	rs7590268	0.666	rs12471207	ENSG00000254966.1	RP11-1081L13.4	-6.64	8.75e-10	0.0067	-0.65	-0.51	Orofacial clefts;	chr2:43438859	chr11:18706537~18740568:+
TGCT	trans	rs5022636	1	rs4970948	ENSG00000180764.13	PIPSL	6.64	8.85e-10	0.00675	0.63	0.51	Gut microbiota (functional units);	chr1:151318767	chr10:93958191~93961540:-
TGCT	trans	rs5022636	0.964	rs7518924	ENSG00000180764.13	PIPSL	6.64	8.85e-10	0.00675	0.63	0.51	Gut microbiota (functional units);	chr1:151319225	chr10:93958191~93961540:-
TGCT	trans	rs5022636	0.74	rs11204795	ENSG00000180764.13	PIPSL	6.64	9.01e-10	0.00687	0.61	0.51	Gut microbiota (functional units);	chr1:151275522	chr10:93958191~93961540:-
TGCT	trans	rs1707322	0.721	rs6699418	ENSG00000255397.1	AC022182.2	-6.63	9.06e-10	0.0069	-0.65	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs4431884	ENSG00000255397.1	AC022182.2	-6.63	9.06e-10	0.0069	-0.65	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.65	rs4660879	ENSG00000255397.1	AC022182.2	-6.63	9.06e-10	0.0069	-0.65	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs10789468	ENSG00000255397.1	AC022182.2	-6.63	9.06e-10	0.0069	-0.65	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs6429574	ENSG00000255397.1	AC022182.2	-6.63	9.06e-10	0.0069	-0.65	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr8:60937705~60939871:-
TGCT	trans	rs7824557	0.778	rs3808502	ENSG00000173295.6	FAM86B3P	6.63	9.06e-10	0.0069	0.59	0.51	Retinal vascular caliber;	chr8:11321949	chr8:8228595~8244865:+
TGCT	trans	rs13190036	0.551	rs7732930	ENSG00000217325.2	PRELID1P1	-6.63	9.24e-10	0.00702	-0.64	-0.51	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177121593	chr6:126643488~126644390:+
TGCT	trans	rs1707322	0.752	rs4660313	ENSG00000255397.1	AC022182.2	6.62	9.56e-10	0.00725	0.65	0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr8:60937705~60939871:-
TGCT	trans	rs13190036	1	rs655623	ENSG00000228305.2	AC016734.2	6.62	9.58e-10	0.00726	0.58	0.51	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107515	chr2:63622178~63622831:-
TGCT	trans	rs1707322	0.721	rs10890341	ENSG00000255397.1	AC022182.2	-6.62	9.65e-10	0.00731	-0.65	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr8:60937705~60939871:-
TGCT	trans	rs13190036	0.551	rs4976639	ENSG00000217325.2	PRELID1P1	6.62	9.69e-10	0.00734	0.62	0.51	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177123300	chr6:126643488~126644390:+
TGCT	trans	rs1707322	0.752	rs11211145	ENSG00000255397.1	AC022182.2	-6.62	9.87e-10	0.00747	-0.66	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr8:60937705~60939871:-
TGCT	trans	rs7200543	1	rs16966947	ENSG00000250569.1	NTAN1P2	6.61	1.02e-09	0.00769	0.64	0.51	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15047188	chr8:86481754~86483002:-
TGCT	trans	rs941207	0.526	rs2255074	ENSG00000121089.4	NACA3P	-6.61	1.02e-09	0.00773	-0.66	-0.51	Platelet count;	chr12:56636242	chr4:164943290~164943937:+
TGCT	trans	rs877636	0.692	rs11171739	ENSG00000196656.7	AC004057.1	6.61	1.03e-09	0.00776	0.55	0.51	Cognitive function;	chr12:56076841	chr4:113214046~113217170:-
TGCT	trans	rs877636	0.702	rs773109	ENSG00000225071.1	GS1-184P14.2	6.6	1.09e-09	0.00818	0.6	0.51	Cognitive function;	chr12:55980911	chrX:24429573~24429920:-
TGCT	trans	rs5022636	0.594	rs11204791	ENSG00000180764.13	PIPSL	6.6	1.09e-09	0.00819	0.6	0.51	Gut microbiota (functional units);	chr1:151268066	chr10:93958191~93961540:-
TGCT	trans	rs877636	0.702	rs61937249	ENSG00000225071.1	GS1-184P14.2	6.6	1.1e-09	0.00824	0.61	0.51	Cognitive function;	chr12:55988132	chrX:24429573~24429920:-
TGCT	trans	rs7647973	0.961	rs6778080	ENSG00000197582.5	GPX1P1	-6.59	1.11e-09	0.00837	-0.7	-0.51	Menarche (age at onset);	chr3:49279905	chrX:13378735~13379340:-
TGCT	trans	rs877636	0.859	rs3741499	ENSG00000243538.1	CTB-55B8.1	-6.59	1.12e-09	0.00839	-0.64	-0.51	Cognitive function;	chr12:56080595	chr5:16902294~16902641:-
TGCT	trans	rs1707322	0.65	rs4553239	ENSG00000255397.1	AC022182.2	-6.59	1.13e-09	0.00846	-0.65	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr8:60937705~60939871:-
TGCT	trans	rs7200543	1	rs3803575	ENSG00000250569.1	NTAN1P2	6.59	1.16e-09	0.00866	0.64	0.51	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044590	chr8:86481754~86483002:-
TGCT	trans	rs4276421	0.935	rs4473777	ENSG00000231752.4	EMBP1	6.58	1.19e-09	0.0089	0.53	0.51	P wave duration;	chr5:45968760	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.762	rs10043270	ENSG00000231752.4	EMBP1	6.58	1.19e-09	0.00891	0.54	0.51	P wave duration;	chr5:45967846	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.774	rs8188064	ENSG00000231752.4	EMBP1	6.57	1.27e-09	0.00939	0.54	0.51	P wave duration;	chr5:46045249	chr1:121519112~121571892:+
TGCT	trans	rs9467773	0.572	rs62394558	ENSG00000242375.1	RP11-498P14.3	6.56	1.3e-09	0.00961	0.61	0.51	Intelligence (multi-trait analysis);	chr6:26604422	chr9:97195351~97197687:-
TGCT	trans	rs877636	0.669	rs7297175	ENSG00000196656.7	AC004057.1	-6.56	1.32e-09	0.00977	-0.56	-0.51	Cognitive function;	chr12:56080024	chr4:113214046~113217170:-
TGCT	trans	rs5022636	0.927	rs943637	ENSG00000180764.13	PIPSL	6.56	1.34e-09	0.00984	0.63	0.51	Gut microbiota (functional units);	chr1:151310543	chr10:93958191~93961540:-
TGCT	trans	rs4276421	0.967	rs7725171	ENSG00000231752.4	EMBP1	6.56	1.34e-09	0.00984	0.53	0.51	P wave duration;	chr5:45923684	chr1:121519112~121571892:+
TGCT	trans	rs10037055	0.853	rs10035180	ENSG00000217325.2	PRELID1P1	-6.55	1.36e-09	0.01	-0.57	-0.51	Migraine without aura;	chr5:177171501	chr6:126643488~126644390:+
TGCT	trans	rs7647973	1	rs3448	ENSG00000197582.5	GPX1P1	6.55	1.38e-09	0.0101	0.71	0.51	Menarche (age at onset);	chr3:49359318	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs11130190	ENSG00000197582.5	GPX1P1	6.55	1.38e-09	0.0101	0.71	0.51	Menarche (age at onset);	chr3:49364704	chrX:13378735~13379340:-
TGCT	trans	rs4276421	0.816	rs6451835	ENSG00000231752.4	EMBP1	6.55	1.41e-09	0.0103	0.53	0.51	P wave duration;	chr5:45928735	chr1:121519112~121571892:+
TGCT	trans	rs877636	0.74	rs772920	ENSG00000243403.1	RP11-330L19.1	6.54	1.41e-09	0.0104	0.64	0.51	Cognitive function;	chr12:55996580	chr15:64592979~64593326:+
TGCT	trans	rs13253073	0.544	rs13280341	ENSG00000260318.1	COX6CP1	6.54	1.42e-09	0.0104	0.91	0.51	Glucose homeostasis traits;	chr8:99908840	chr16:11903923~11904137:-
TGCT	trans	rs6132905	0.52	rs2422823	ENSG00000235559.1	NOP56P1	-6.54	1.43e-09	0.0105	-0.69	-0.51	Mumps;	chr20:2665687	chr6:28783633~28784004:-
TGCT	trans	rs6477998	0.966	rs10759637	ENSG00000238072.1	RP11-305M3.2	6.54	1.44e-09	0.0105	0.59	0.51	Hematology traits;	chr9:113262744	chr7:129410113~129410370:-
TGCT	trans	rs4276421	0.904	rs4274988	ENSG00000231752.4	EMBP1	6.54	1.45e-09	0.0106	0.53	0.51	P wave duration;	chr5:45926339	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.935	rs7725537	ENSG00000231752.4	EMBP1	6.54	1.45e-09	0.0106	0.53	0.51	P wave duration;	chr5:45927191	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.935	rs6451834	ENSG00000231752.4	EMBP1	6.54	1.45e-09	0.0106	0.53	0.51	P wave duration;	chr5:45927208	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.935	rs35730142	ENSG00000231752.4	EMBP1	6.54	1.45e-09	0.0106	0.53	0.51	P wave duration;	chr5:45927453	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.904	rs6451843	ENSG00000231752.4	EMBP1	6.54	1.48e-09	0.0108	0.53	0.51	P wave duration;	chr5:45946683	chr1:121519112~121571892:+
TGCT	trans	rs74400468	0.529	rs74137928	ENSG00000203414.2	BTBD7P1	6.53	1.49e-09	0.0108	1.15	0.51	Cannabis dependence symptom count;	chr10:42708305	chr10:13156684~13158136:-
TGCT	trans	rs1707322	0.827	rs6694302	ENSG00000255397.1	AC022182.2	-6.53	1.49e-09	0.0108	-0.63	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr8:60937705~60939871:-
TGCT	trans	rs916888	0.779	rs199528	ENSG00000280022.1	RP11-707O23.1	6.53	1.5e-09	0.0109	0.79	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45592621~45593369:+
TGCT	trans	rs916888	0.821	rs199525	ENSG00000280022.1	RP11-707O23.1	6.53	1.5e-09	0.0109	0.79	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45592621~45593369:+
TGCT	trans	rs4276421	0.935	rs4502836	ENSG00000231752.4	EMBP1	6.53	1.5e-09	0.0109	0.53	0.51	P wave duration;	chr5:45956617	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.934	rs7443410	ENSG00000231752.4	EMBP1	6.53	1.5e-09	0.0109	0.53	0.51	P wave duration;	chr5:45960831	chr1:121519112~121571892:+
TGCT	trans	rs916888	0.61	rs199529	ENSG00000280022.1	RP11-707O23.1	6.53	1.51e-09	0.0109	0.8	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45592621~45593369:+
TGCT	trans	rs877636	0.702	rs773110	ENSG00000225071.1	GS1-184P14.2	6.53	1.54e-09	0.0112	0.6	0.51	Cognitive function;	chr12:55981353	chrX:24429573~24429920:-
TGCT	trans	rs877636	0.702	rs773111	ENSG00000225071.1	GS1-184P14.2	6.53	1.54e-09	0.0112	0.6	0.51	Cognitive function;	chr12:55981956	chrX:24429573~24429920:-
TGCT	trans	rs877636	0.702	rs773112	ENSG00000225071.1	GS1-184P14.2	6.53	1.54e-09	0.0112	0.6	0.51	Cognitive function;	chr12:55982097	chrX:24429573~24429920:-
TGCT	trans	rs1707322	0.717	rs1135812	ENSG00000255397.1	AC022182.2	-6.53	1.55e-09	0.0112	-0.65	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr8:60937705~60939871:-
TGCT	trans	rs7121616	1	rs7113273	ENSG00000234176.1	HSPA8P1	-6.53	1.56e-09	0.0113	-0.63	-0.51	Breast cancer;	chr11:123092192	chrX:121203182~121205014:-
TGCT	trans	rs7200543	0.883	rs4985148	ENSG00000250569.1	NTAN1P2	6.52	1.56e-09	0.0113	0.63	0.51	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053931	chr8:86481754~86483002:-
TGCT	trans	rs4276421	0.839	rs7719401	ENSG00000231752.4	EMBP1	6.52	1.56e-09	0.0113	0.52	0.51	P wave duration;	chr5:45938713	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.967	rs35648163	ENSG00000231752.4	EMBP1	6.52	1.56e-09	0.0113	0.52	0.51	P wave duration;	chr5:45945778	chr1:121519112~121571892:+
TGCT	trans	rs877636	0.74	rs705698	ENSG00000225071.1	GS1-184P14.2	6.52	1.56e-09	0.0113	0.6	0.51	Cognitive function;	chr12:55990903	chrX:24429573~24429920:-
TGCT	trans	rs6477998	1	rs7038769	ENSG00000238072.1	RP11-305M3.2	6.52	1.58e-09	0.0114	0.59	0.51	Hematology traits;	chr9:113245303	chr7:129410113~129410370:-
TGCT	trans	rs6477998	1	rs7022397	ENSG00000238072.1	RP11-305M3.2	6.52	1.58e-09	0.0114	0.59	0.51	Hematology traits;	chr9:113245397	chr7:129410113~129410370:-
TGCT	trans	rs7647973	0.925	rs9881860	ENSG00000197582.5	GPX1P1	6.52	1.58e-09	0.0115	0.72	0.51	Menarche (age at onset);	chr3:49315089	chrX:13378735~13379340:-
TGCT	trans	rs7312770	0.612	rs1873914	ENSG00000234513.1	AC073072.7	6.52	1.6e-09	0.0115	0.58	0.51	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr7:22773646~22773993:-
TGCT	trans	rs7647973	1	rs7613491	ENSG00000197582.5	GPX1P1	-6.51	1.64e-09	0.0118	-0.72	-0.5	Menarche (age at onset);	chr3:49471543	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs7647973	ENSG00000197582.5	GPX1P1	-6.51	1.64e-09	0.0118	-0.72	-0.5	Menarche (age at onset);	chr3:49473498	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs6783003	ENSG00000197582.5	GPX1P1	-6.51	1.64e-09	0.0118	-0.72	-0.5	Menarche (age at onset);	chr3:49487345	chrX:13378735~13379340:-
TGCT	trans	rs1707322	0.752	rs6678444	ENSG00000255397.1	AC022182.2	-6.51	1.65e-09	0.0119	-0.64	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.752	rs7541962	ENSG00000255397.1	AC022182.2	-6.51	1.65e-09	0.0119	-0.64	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.717	rs11211161	ENSG00000255397.1	AC022182.2	-6.51	1.66e-09	0.012	-0.65	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr8:60937705~60939871:-
TGCT	trans	rs4276421	0.805	rs13165481	ENSG00000231752.4	EMBP1	6.51	1.67e-09	0.012	0.53	0.5	P wave duration;	chr5:46034214	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.774	rs4601053	ENSG00000231752.4	EMBP1	6.51	1.67e-09	0.012	0.53	0.5	P wave duration;	chr5:46101734	chr1:121519112~121571892:+
TGCT	trans	rs877636	0.702	rs773108	ENSG00000225071.1	GS1-184P14.2	6.51	1.67e-09	0.012	0.61	0.5	Cognitive function;	chr12:55976127	chrX:24429573~24429920:-
TGCT	trans	rs7200543	1	rs6498541	ENSG00000250569.1	NTAN1P2	6.51	1.68e-09	0.012	0.63	0.5	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046800	chr8:86481754~86483002:-
TGCT	trans	rs7200543	1	rs55727637	ENSG00000250569.1	NTAN1P2	6.51	1.68e-09	0.012	0.63	0.5	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15051395	chr8:86481754~86483002:-
TGCT	trans	rs6477998	1	rs10759636	ENSG00000238072.1	RP11-305M3.2	6.5	1.72e-09	0.0123	0.59	0.5	Hematology traits;	chr9:113256497	chr7:129410113~129410370:-
TGCT	trans	rs7312770	0.612	rs773114	ENSG00000196933.5	RPS26P11	6.5	1.73e-09	0.0124	0.56	0.5	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chrX:72044545~72044892:+
TGCT	trans	rs1707322	0.896	rs809774	ENSG00000255397.1	AC022182.2	6.5	1.75e-09	0.0125	0.65	0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr8:60937705~60939871:-
TGCT	trans	rs7590268	0.636	rs12988285	ENSG00000254966.1	RP11-1081L13.4	-6.5	1.78e-09	0.0127	-0.65	-0.5	Orofacial clefts;	chr2:43487967	chr11:18706537~18740568:+
TGCT	trans	rs7590268	0.636	rs17334980	ENSG00000254966.1	RP11-1081L13.4	6.5	1.78e-09	0.0127	0.65	0.5	Orofacial clefts;	chr2:43491454	chr11:18706537~18740568:+
TGCT	trans	rs941207	0.526	rs2242497	ENSG00000121089.4	NACA3P	-6.5	1.8e-09	0.0128	-0.68	-0.5	Platelet count;	chr12:56598846	chr4:164943290~164943937:+
TGCT	trans	rs4276421	0.901	rs10056175	ENSG00000231752.4	EMBP1	6.49	1.81e-09	0.0129	0.52	0.5	P wave duration;	chr5:45934503	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.934	rs6451840	ENSG00000231752.4	EMBP1	6.49	1.81e-09	0.0129	0.52	0.5	P wave duration;	chr5:45935584	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.87	rs6451842	ENSG00000231752.4	EMBP1	6.49	1.81e-09	0.0129	0.52	0.5	P wave duration;	chr5:45936431	chr1:121519112~121571892:+
TGCT	trans	rs12497850	0.864	rs6779394	ENSG00000197582.5	GPX1P1	6.49	1.86e-09	0.0132	0.65	0.5	Parkinson's disease;	chr3:49120338	chrX:13378735~13379340:-
TGCT	trans	rs616147	0.655	rs1707981	ENSG00000214263.2	RPSAP53	-6.49	1.86e-09	0.0132	-0.65	-0.5	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461015	chr13:67266845~67267706:-
TGCT	trans	rs616147	0.72	rs1768209	ENSG00000214263.2	RPSAP53	-6.49	1.86e-09	0.0132	-0.65	-0.5	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461184	chr13:67266845~67267706:-
TGCT	trans	rs616147	0.72	rs2965067	ENSG00000214263.2	RPSAP53	-6.49	1.86e-09	0.0132	-0.65	-0.5	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461546	chr13:67266845~67267706:-
TGCT	trans	rs12709013	0.792	rs62064901	ENSG00000230849.2	GOT2P2	6.49	1.87e-09	0.0133	0.6	0.5	Blood metabolite ratios;	chr16:58776758	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.729	rs34324769	ENSG00000230849.2	GOT2P2	6.49	1.87e-09	0.0133	0.6	0.5	Blood metabolite ratios;	chr16:58778131	chr1:173141100~173142350:-
TGCT	trans	rs12497850	0.764	rs6784111	ENSG00000197582.5	GPX1P1	6.49	1.87e-09	0.0133	0.65	0.5	Parkinson's disease;	chr3:49141413	chrX:13378735~13379340:-
TGCT	trans	rs12497850	0.864	rs12493001	ENSG00000197582.5	GPX1P1	6.49	1.87e-09	0.0133	0.65	0.5	Parkinson's disease;	chr3:49144452	chrX:13378735~13379340:-
TGCT	trans	rs12497850	0.829	rs12636030	ENSG00000197582.5	GPX1P1	6.49	1.87e-09	0.0133	0.65	0.5	Parkinson's disease;	chr3:49144804	chrX:13378735~13379340:-
TGCT	trans	rs616147	0.616	rs1768234	ENSG00000214263.2	RPSAP53	-6.49	1.89e-09	0.0134	-0.65	-0.5	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39459821	chr13:67266845~67267706:-
TGCT	trans	rs4276421	0.744	rs4541667	ENSG00000231752.4	EMBP1	6.48	1.94e-09	0.0137	0.53	0.5	P wave duration;	chr5:46060767	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.502	rs77189370	ENSG00000231752.4	EMBP1	6.48	1.94e-09	0.0137	0.52	0.5	Schizophrenia;	chr5:50334920	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.934	rs6451838	ENSG00000231752.4	EMBP1	6.48	1.96e-09	0.0139	0.52	0.5	P wave duration;	chr5:45935060	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.874	rs7727331	ENSG00000231752.4	EMBP1	6.48	1.96e-09	0.0139	0.52	0.5	P wave duration;	chr5:45945199	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.874	rs34501453	ENSG00000231752.4	EMBP1	6.48	1.96e-09	0.0139	0.52	0.5	P wave duration;	chr5:45947338	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.874	rs4501347	ENSG00000231752.4	EMBP1	6.48	1.96e-09	0.0139	0.52	0.5	P wave duration;	chr5:45974779	chr1:121519112~121571892:+
TGCT	trans	rs877636	0.702	rs773110	ENSG00000243403.1	RP11-330L19.1	6.48	1.96e-09	0.0139	0.62	0.5	Cognitive function;	chr12:55981353	chr15:64592979~64593326:+
TGCT	trans	rs877636	0.702	rs773111	ENSG00000243403.1	RP11-330L19.1	6.48	1.96e-09	0.0139	0.62	0.5	Cognitive function;	chr12:55981956	chr15:64592979~64593326:+
TGCT	trans	rs877636	0.702	rs773112	ENSG00000243403.1	RP11-330L19.1	6.48	1.96e-09	0.0139	0.62	0.5	Cognitive function;	chr12:55982097	chr15:64592979~64593326:+
TGCT	trans	rs7590268	0.609	rs67584485	ENSG00000254966.1	RP11-1081L13.4	-6.48	1.96e-09	0.0139	-0.64	-0.5	Orofacial clefts;	chr2:43535056	chr11:18706537~18740568:+
TGCT	trans	rs877636	1	rs2292239	ENSG00000243538.1	CTB-55B8.1	6.48	1.97e-09	0.0139	0.63	0.5	Cognitive function;	chr12:56088396	chr5:16902294~16902641:-
TGCT	trans	rs7647973	0.961	rs62259943	ENSG00000197582.5	GPX1P1	-6.48	2e-09	0.0141	-0.72	-0.5	Menarche (age at onset);	chr3:49387734	chrX:13378735~13379340:-
TGCT	trans	rs74781061	0.932	rs11629749	ENSG00000227288.3	RP5-837I24.1	6.47	2.02e-09	0.0142	0.51	0.5	Endometriosis;	chr15:74627252	chr1:81501794~81503468:+
TGCT	trans	rs55665837	1	rs12804549	ENSG00000236360.2	RP11-334A14.2	6.47	2.03e-09	0.0143	0.59	0.5	Vitamin D levels;	chr11:14416212	chr1:52993201~52993702:-
TGCT	trans	rs1707322	0.752	rs61784793	ENSG00000255397.1	AC022182.2	-6.47	2.03e-09	0.0143	-0.64	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.648	rs4439382	ENSG00000255397.1	AC022182.2	-6.47	2.03e-09	0.0143	-0.64	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr8:60937705~60939871:-
TGCT	trans	rs7364180	0.515	rs6002503	ENSG00000268568.1	AC007228.9	-6.47	2.06e-09	0.0145	-0.61	-0.5	Alzheimer's disease biomarkers;	chr22:41812668	chr19:56672574~56673901:-
TGCT	trans	rs80033912	0.626	rs71324982	ENSG00000197582.5	GPX1P1	6.47	2.08e-09	0.0146	0.72	0.5	Intelligence (multi-trait analysis);	chr3:49632515	chrX:13378735~13379340:-
TGCT	trans	rs12497850	0.863	rs4974084	ENSG00000197582.5	GPX1P1	6.47	2.09e-09	0.0147	0.66	0.5	Parkinson's disease;	chr3:48901647	chrX:13378735~13379340:-
TGCT	trans	rs4276421	0.805	rs13168838	ENSG00000231752.4	EMBP1	6.46	2.1e-09	0.0148	0.54	0.5	P wave duration;	chr5:46016815	chr1:121519112~121571892:+
TGCT	trans	rs877636	0.74	rs705698	ENSG00000243403.1	RP11-330L19.1	6.46	2.13e-09	0.0149	0.63	0.5	Cognitive function;	chr12:55990903	chr15:64592979~64593326:+
TGCT	trans	rs4276421	0.869	rs10036065	ENSG00000231752.4	EMBP1	-6.46	2.19e-09	0.0153	-0.54	-0.5	P wave duration;	chr5:45701926	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.644	rs62365309	ENSG00000231752.4	EMBP1	-6.45	2.22e-09	0.0154	-0.53	-0.5	Schizophrenia;	chr5:50568902	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.807	rs4865843	ENSG00000231752.4	EMBP1	-6.45	2.22e-09	0.0154	-0.53	-0.5	Schizophrenia;	chr5:50569681	chr1:121519112~121571892:+
TGCT	trans	rs12709013	0.766	rs11648511	ENSG00000230849.2	GOT2P2	6.45	2.23e-09	0.0155	0.6	0.5	Blood metabolite ratios;	chr16:58798171	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.716	rs11647582	ENSG00000230849.2	GOT2P2	6.45	2.23e-09	0.0155	0.6	0.5	Blood metabolite ratios;	chr16:58801474	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.792	rs35684307	ENSG00000230849.2	GOT2P2	6.45	2.23e-09	0.0155	0.6	0.5	Blood metabolite ratios;	chr16:58801651	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.792	rs11644344	ENSG00000230849.2	GOT2P2	6.45	2.23e-09	0.0155	0.6	0.5	Blood metabolite ratios;	chr16:58803080	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.792	rs11649387	ENSG00000230849.2	GOT2P2	6.45	2.23e-09	0.0155	0.6	0.5	Blood metabolite ratios;	chr16:58803176	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.792	rs11649133	ENSG00000230849.2	GOT2P2	6.45	2.23e-09	0.0155	0.6	0.5	Blood metabolite ratios;	chr16:58803275	chr1:173141100~173142350:-
TGCT	trans	rs877636	0.702	rs61937249	ENSG00000243403.1	RP11-330L19.1	6.45	2.24e-09	0.0155	0.63	0.5	Cognitive function;	chr12:55988132	chr15:64592979~64593326:+
TGCT	trans	rs7121616	1	rs7123187	ENSG00000234176.1	HSPA8P1	6.45	2.24e-09	0.0155	0.63	0.5	Breast cancer;	chr11:123090915	chrX:121203182~121205014:-
TGCT	trans	rs7121616	0.774	rs74693612	ENSG00000234176.1	HSPA8P1	6.45	2.24e-09	0.0155	0.63	0.5	Breast cancer;	chr11:123092310	chrX:121203182~121205014:-
TGCT	trans	rs12709013	0.792	rs62064940	ENSG00000230849.2	GOT2P2	6.45	2.27e-09	0.0157	0.6	0.5	Blood metabolite ratios;	chr16:58796560	chr1:173141100~173142350:-
TGCT	trans	rs7555117	0.565	rs7552424	ENSG00000273823.1	AC215219.2	-6.45	2.27e-09	0.0158	-0.58	-0.5	Facial morphology (factor 19);	chr1:60499052	chr12:17484~17551:-
TGCT	trans	rs2731664	0.74	rs2731670	ENSG00000215571.5	GRK6P1	-6.45	2.29e-09	0.0159	-0.56	-0.5	Intelligence (multi-trait analysis);	chr5:177421018	chr13:21319156~21320866:+
TGCT	trans	rs1707322	0.717	rs12023439	ENSG00000255397.1	AC022182.2	-6.45	2.31e-09	0.016	-0.64	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.721	rs11211149	ENSG00000255397.1	AC022182.2	-6.45	2.31e-09	0.016	-0.64	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr8:60937705~60939871:-
TGCT	trans	rs55665837	1	rs3923294	ENSG00000236360.2	RP11-334A14.2	6.45	2.32e-09	0.016	0.6	0.5	Vitamin D levels;	chr11:14419856	chr1:52993201~52993702:-
TGCT	trans	rs5022636	0.896	rs4971032	ENSG00000180764.13	PIPSL	6.44	2.34e-09	0.0162	0.62	0.5	Gut microbiota (functional units);	chr1:151317948	chr10:93958191~93961540:-
TGCT	trans	rs4276421	0.904	rs4489075	ENSG00000231752.4	EMBP1	6.44	2.37e-09	0.0164	0.52	0.5	P wave duration;	chr5:46018903	chr1:121519112~121571892:+
TGCT	trans	rs7647973	1	rs11710434	ENSG00000197582.5	GPX1P1	6.43	2.44e-09	0.0168	0.7	0.5	Menarche (age at onset);	chr3:49308697	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs11720542	ENSG00000197582.5	GPX1P1	6.43	2.44e-09	0.0168	0.7	0.5	Menarche (age at onset);	chr3:49319994	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs13088309	ENSG00000197582.5	GPX1P1	6.43	2.44e-09	0.0168	0.7	0.5	Menarche (age at onset);	chr3:49330884	chrX:13378735~13379340:-
TGCT	trans	rs7647973	0.961	rs4955430	ENSG00000197582.5	GPX1P1	6.43	2.44e-09	0.0168	0.7	0.5	Menarche (age at onset);	chr3:49340655	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs3870341	ENSG00000197582.5	GPX1P1	6.43	2.44e-09	0.0168	0.67	0.5	Menarche (age at onset);	chr3:49547312	chrX:13378735~13379340:-
TGCT	trans	rs8175379	0.521	rs10037109	ENSG00000231752.4	EMBP1	6.43	2.51e-09	0.0172	0.51	0.5	Interleukin-7 levels;	chr5:46328343	chr1:121519112~121571892:+
TGCT	trans	rs55665837	1	rs2305306	ENSG00000236360.2	RP11-334A14.2	6.43	2.54e-09	0.0174	0.58	0.5	Vitamin D levels;	chr11:14513453	chr1:52993201~52993702:-
TGCT	trans	rs7503168	0.558	rs11656872	ENSG00000234130.2	RP13-88F20.1	-6.42	2.6e-09	0.0177	-0.81	-0.5	Plateletcrit;	chr17:35611585	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs71381463	ENSG00000234130.2	RP13-88F20.1	6.42	2.6e-09	0.0177	0.81	0.5	Plateletcrit;	chr17:35610247	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs12936539	ENSG00000234130.2	RP13-88F20.1	6.42	2.6e-09	0.0177	0.81	0.5	Plateletcrit;	chr17:35611677	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs34063751	ENSG00000234130.2	RP13-88F20.1	6.42	2.6e-09	0.0177	0.81	0.5	Plateletcrit;	chr17:35611893	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs11650225	ENSG00000234130.2	RP13-88F20.1	6.42	2.6e-09	0.0177	0.81	0.5	Plateletcrit;	chr17:35613947	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs17669281	ENSG00000234130.2	RP13-88F20.1	6.42	2.6e-09	0.0177	0.81	0.5	Plateletcrit;	chr17:35616776	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs17606150	ENSG00000234130.2	RP13-88F20.1	6.42	2.6e-09	0.0177	0.81	0.5	Plateletcrit;	chr17:35616789	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs12940422	ENSG00000234130.2	RP13-88F20.1	6.42	2.6e-09	0.0177	0.81	0.5	Plateletcrit;	chr17:35620400	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs12949877	ENSG00000234130.2	RP13-88F20.1	6.42	2.6e-09	0.0177	0.81	0.5	Plateletcrit;	chr17:35621517	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs80278654	ENSG00000234130.2	RP13-88F20.1	6.42	2.6e-09	0.0177	0.81	0.5	Plateletcrit;	chr17:35622193	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs11650621	ENSG00000234130.2	RP13-88F20.1	6.42	2.6e-09	0.0177	0.81	0.5	Plateletcrit;	chr17:35631827	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs12947274	ENSG00000234130.2	RP13-88F20.1	6.42	2.6e-09	0.0177	0.81	0.5	Plateletcrit;	chr17:35635146	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs12936693	ENSG00000234130.2	RP13-88F20.1	6.42	2.6e-09	0.0177	0.81	0.5	Plateletcrit;	chr17:35639391	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs71381465	ENSG00000234130.2	RP13-88F20.1	6.42	2.6e-09	0.0177	0.81	0.5	Plateletcrit;	chr17:35647713	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs12943224	ENSG00000234130.2	RP13-88F20.1	6.42	2.6e-09	0.0177	0.81	0.5	Plateletcrit;	chr17:35650519	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs11651380	ENSG00000234130.2	RP13-88F20.1	6.42	2.6e-09	0.0177	0.81	0.5	Plateletcrit;	chr17:35654677	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs11654542	ENSG00000234130.2	RP13-88F20.1	6.42	2.6e-09	0.0177	0.81	0.5	Plateletcrit;	chr17:35662289	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs34874930	ENSG00000234130.2	RP13-88F20.1	6.42	2.6e-09	0.0177	0.81	0.5	Plateletcrit;	chr17:35667961	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs17670584	ENSG00000234130.2	RP13-88F20.1	6.42	2.6e-09	0.0177	0.81	0.5	Plateletcrit;	chr17:35671885	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs17670614	ENSG00000234130.2	RP13-88F20.1	6.42	2.6e-09	0.0177	0.81	0.5	Plateletcrit;	chr17:35672348	chrX:93222220~93225015:-
TGCT	trans	rs7824557	0.606	rs1047950	ENSG00000173295.6	FAM86B3P	6.42	2.6e-09	0.0177	0.6	0.5	Retinal vascular caliber;	chr8:11327587	chr8:8228595~8244865:+
TGCT	trans	rs7824557	0.569	rs35418978	ENSG00000173295.6	FAM86B3P	6.42	2.6e-09	0.0177	0.6	0.5	Retinal vascular caliber;	chr8:11328944	chr8:8228595~8244865:+
TGCT	trans	rs1707322	0.682	rs12041197	ENSG00000255397.1	AC022182.2	-6.42	2.6e-09	0.0177	-0.64	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.752	rs11211146	ENSG00000255397.1	AC022182.2	-6.42	2.6e-09	0.0177	-0.64	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.752	rs11211147	ENSG00000255397.1	AC022182.2	-6.42	2.6e-09	0.0177	-0.64	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.752	rs11211152	ENSG00000255397.1	AC022182.2	-6.42	2.6e-09	0.0177	-0.64	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.681	rs12048866	ENSG00000255397.1	AC022182.2	-6.42	2.6e-09	0.0177	-0.64	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.752	rs12024590	ENSG00000255397.1	AC022182.2	-6.42	2.6e-09	0.0177	-0.64	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.752	rs12027622	ENSG00000255397.1	AC022182.2	-6.42	2.6e-09	0.0177	-0.64	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.716	rs6699444	ENSG00000255397.1	AC022182.2	-6.42	2.6e-09	0.0177	-0.64	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr8:60937705~60939871:-
TGCT	trans	rs12709013	0.766	rs12599331	ENSG00000230849.2	GOT2P2	6.42	2.6e-09	0.0177	0.6	0.5	Blood metabolite ratios;	chr16:58805307	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.792	rs12928733	ENSG00000230849.2	GOT2P2	6.42	2.6e-09	0.0177	0.6	0.5	Blood metabolite ratios;	chr16:58807216	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.792	rs62066381	ENSG00000230849.2	GOT2P2	6.42	2.6e-09	0.0177	0.6	0.5	Blood metabolite ratios;	chr16:58807981	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.792	rs8049572	ENSG00000230849.2	GOT2P2	6.42	2.6e-09	0.0177	0.6	0.5	Blood metabolite ratios;	chr16:58809672	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.766	rs34438483	ENSG00000230849.2	GOT2P2	6.42	2.6e-09	0.0177	0.6	0.5	Blood metabolite ratios;	chr16:58810530	chr1:173141100~173142350:-
TGCT	trans	rs12709013	0.792	rs36098613	ENSG00000230849.2	GOT2P2	6.42	2.6e-09	0.0177	0.6	0.5	Blood metabolite ratios;	chr16:58810562	chr1:173141100~173142350:-
TGCT	trans	rs1707322	0.827	rs12125508	ENSG00000255397.1	AC022182.2	-6.42	2.65e-09	0.018	-0.62	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.789	rs10789473	ENSG00000255397.1	AC022182.2	-6.42	2.65e-09	0.018	-0.62	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr8:60937705~60939871:-
TGCT	trans	rs7364180	0.582	rs139568	ENSG00000268568.1	AC007228.9	6.42	2.65e-09	0.018	0.59	0.5	Alzheimer's disease biomarkers;	chr22:41814981	chr19:56672574~56673901:-
TGCT	trans	rs877636	0.702	rs773109	ENSG00000243403.1	RP11-330L19.1	6.42	2.66e-09	0.0181	0.62	0.5	Cognitive function;	chr12:55980911	chr15:64592979~64593326:+
TGCT	trans	rs7824557	0.606	rs2736264	ENSG00000173295.6	FAM86B3P	6.42	2.67e-09	0.0181	0.6	0.5	Retinal vascular caliber;	chr8:11329130	chr8:8228595~8244865:+
TGCT	trans	rs1795061	0.683	rs1223679	ENSG00000204136.9	GGTA1P	-6.41	2.7e-09	0.0183	-0.38	-0.5	Abdominal aortic aneurysm;	chr1:214219564	chr9:121444991~121500027:-
TGCT	trans	rs7503168	0.558	rs112693485	ENSG00000234130.2	RP13-88F20.1	6.41	2.7e-09	0.0183	0.82	0.5	Plateletcrit;	chr17:35643688	chrX:93222220~93225015:-
TGCT	trans	rs3740713	0.748	rs35292478	ENSG00000235847.2	LDHAP7	6.41	2.72e-09	0.0184	0.8	0.5	Amyotrophic lateral sclerosis (sporadic);	chr11:18408444	chr2:84777259~84778223:-
TGCT	trans	rs475616	0.579	rs11591768	ENSG00000281756.1	C2-AS1	6.41	2.72e-09	0.0184	0.53	0.5	Monocyte count;	chr10:30223318	chr6:31934474~31941724:-
TGCT	trans	rs10940346	1	rs10940346	ENSG00000231752.4	EMBP1	-6.41	2.74e-09	0.0184	-0.66	-0.5	Schizophrenia;	chr5:50510208	chr1:121519112~121571892:+
TGCT	trans	rs877636	0.74	rs705702	ENSG00000243403.1	RP11-330L19.1	-6.41	2.75e-09	0.0185	-0.62	-0.5	Cognitive function;	chr12:55996852	chr15:64592979~64593326:+
TGCT	trans	rs7647973	1	rs940045	ENSG00000197582.5	GPX1P1	6.41	2.77e-09	0.0186	0.68	0.5	Menarche (age at onset);	chr3:49412205	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs1464569	ENSG00000197582.5	GPX1P1	6.41	2.77e-09	0.0186	0.68	0.5	Menarche (age at onset);	chr3:49422917	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs7619789	ENSG00000197582.5	GPX1P1	6.41	2.77e-09	0.0186	0.68	0.5	Menarche (age at onset);	chr3:49438830	chrX:13378735~13379340:-
TGCT	trans	rs7647973	0.922	rs57273516	ENSG00000197582.5	GPX1P1	6.41	2.77e-09	0.0186	0.68	0.5	Menarche (age at onset);	chr3:49445641	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs1009051	ENSG00000197582.5	GPX1P1	6.41	2.77e-09	0.0186	0.68	0.5	Menarche (age at onset);	chr3:49484116	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs3870339	ENSG00000197582.5	GPX1P1	6.41	2.77e-09	0.0186	0.68	0.5	Menarche (age at onset);	chr3:49499430	chrX:13378735~13379340:-
TGCT	trans	rs12220238	1	rs10824106	ENSG00000227311.3	RP1-228H13.1	-6.4	2.83e-09	0.019	-1.01	-0.5	Soluble interleukin-2 receptor subunit alpha;	chr10:74198650	chr1:40333078~40333557:-
TGCT	trans	rs9467773	0.523	rs2498399	ENSG00000242375.1	RP11-498P14.3	6.4	2.87e-09	0.0192	0.62	0.5	Intelligence (multi-trait analysis);	chr6:26795343	chr9:97195351~97197687:-
TGCT	trans	rs7824557	0.767	rs6991606	ENSG00000173295.6	FAM86B3P	6.4	2.96e-09	0.0198	0.58	0.5	Retinal vascular caliber;	chr8:11318650	chr8:8228595~8244865:+
TGCT	trans	rs55665837	1	rs12295888	ENSG00000236360.2	RP11-334A14.2	6.4	2.96e-09	0.0198	0.59	0.5	Vitamin D levels;	chr11:14428985	chr1:52993201~52993702:-
TGCT	trans	rs7200543	0.583	rs4985149	ENSG00000250569.1	NTAN1P2	6.39	2.99e-09	0.02	0.62	0.5	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053481	chr8:86481754~86483002:-
TGCT	trans	rs7590268	0.789	rs58583407	ENSG00000254966.1	RP11-1081L13.4	-6.39	3.01e-09	0.0201	-0.64	-0.5	Orofacial clefts;	chr2:43405198	chr11:18706537~18740568:+
TGCT	trans	rs55665837	1	rs10832254	ENSG00000236360.2	RP11-334A14.2	6.39	3.02e-09	0.0202	0.59	0.5	Vitamin D levels;	chr11:14413152	chr1:52993201~52993702:-
TGCT	trans	rs55665837	1	rs11023214	ENSG00000236360.2	RP11-334A14.2	6.39	3.02e-09	0.0202	0.59	0.5	Vitamin D levels;	chr11:14414713	chr1:52993201~52993702:-
TGCT	trans	rs2657294	0.761	rs1259498	ENSG00000172974.11	AC007318.5	6.39	3.05e-09	0.0203	0.58	0.5	Pneumonia;	chr10:75226983	chr2:65205108~65205988:+
TGCT	trans	rs10940346	0.584	rs7293449	ENSG00000231752.4	EMBP1	-6.39	3.07e-09	0.0204	-0.51	-0.5	Schizophrenia;	chr5:50259959	chr1:121519112~121571892:+
TGCT	trans	rs7405404	1	rs12925872	ENSG00000281831.1	HCP5B	-6.39	3.08e-09	0.0205	-0.6	-0.5	Bipolar disorder lithium response (categorical) or schizophrenia;Schizophrenia;	chr16:13658499	chr6:29871895~29873783:-
TGCT	trans	rs7824557	0.767	rs7837036	ENSG00000173295.6	FAM86B3P	6.39	3.09e-09	0.0206	0.58	0.5	Retinal vascular caliber;	chr8:11317980	chr8:8228595~8244865:+
TGCT	trans	rs7647973	1	rs892974	ENSG00000197582.5	GPX1P1	6.39	3.1e-09	0.0206	0.71	0.5	Menarche (age at onset);	chr3:49361081	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs13096474	ENSG00000197582.5	GPX1P1	-6.38	3.13e-09	0.0208	-0.66	-0.5	Menarche (age at onset);	chr3:49405648	chrX:13378735~13379340:-
TGCT	trans	rs7647973	0.922	rs6809851	ENSG00000197582.5	GPX1P1	6.38	3.15e-09	0.0209	0.7	0.5	Menarche (age at onset);	chr3:49272354	chrX:13378735~13379340:-
TGCT	trans	rs7824557	0.564	rs2043508	ENSG00000173295.6	FAM86B3P	-6.38	3.19e-09	0.0211	-0.6	-0.5	Retinal vascular caliber;	chr8:11369897	chr8:8228595~8244865:+
TGCT	trans	rs7824557	0.564	rs2736288	ENSG00000173295.6	FAM86B3P	-6.38	3.19e-09	0.0211	-0.6	-0.5	Retinal vascular caliber;	chr8:11370591	chr8:8228595~8244865:+
TGCT	trans	rs8026198	0.705	rs4583208	ENSG00000227741.1	RP11-536C5.7	6.38	3.23e-09	0.0214	0.55	0.5	Fibrinogen levels;	chr15:42264559	chr1:160202199~160208869:-
TGCT	trans	rs12709013	0.804	rs8051459	ENSG00000230849.2	GOT2P2	6.38	3.25e-09	0.0215	0.6	0.5	Blood metabolite ratios;	chr16:58783436	chr1:173141100~173142350:-
TGCT	trans	rs10940346	0.601	rs1841104	ENSG00000231752.4	EMBP1	-6.37	3.28e-09	0.0217	-0.53	-0.5	Schizophrenia;	chr5:50263930	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.562	rs549751	ENSG00000231752.4	EMBP1	-6.37	3.3e-09	0.0218	-0.51	-0.5	Schizophrenia;	chr5:50262114	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs1841103	ENSG00000231752.4	EMBP1	-6.37	3.3e-09	0.0218	-0.51	-0.5	Schizophrenia;	chr5:50263913	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.562	rs504773	ENSG00000231752.4	EMBP1	-6.37	3.3e-09	0.0218	-0.51	-0.5	Schizophrenia;	chr5:50264656	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.524	rs1458763	ENSG00000231752.4	EMBP1	-6.37	3.3e-09	0.0218	-0.51	-0.5	Schizophrenia;	chr5:50265531	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs1458765	ENSG00000231752.4	EMBP1	-6.37	3.3e-09	0.0218	-0.51	-0.5	Schizophrenia;	chr5:50266141	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs1458766	ENSG00000231752.4	EMBP1	-6.37	3.3e-09	0.0218	-0.51	-0.5	Schizophrenia;	chr5:50266457	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs514195	ENSG00000231752.4	EMBP1	-6.37	3.3e-09	0.0218	-0.51	-0.5	Schizophrenia;	chr5:50267123	chr1:121519112~121571892:+
TGCT	trans	rs3749237	0.964	rs10865959	ENSG00000197582.5	GPX1P1	6.37	3.31e-09	0.0218	0.69	0.5	Resting heart rate;	chr3:49853569	chrX:13378735~13379340:-
TGCT	trans	rs3749237	0.964	rs2352975	ENSG00000197582.5	GPX1P1	6.37	3.31e-09	0.0218	0.69	0.5	Resting heart rate;	chr3:49854452	chrX:13378735~13379340:-
TGCT	trans	rs1707322	1	rs11211236	ENSG00000255397.1	AC022182.2	-6.37	3.32e-09	0.0218	-0.61	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr8:60937705~60939871:-
TGCT	trans	rs1707322	1	rs4660328	ENSG00000255397.1	AC022182.2	-6.37	3.32e-09	0.0218	-0.61	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.928	rs61785614	ENSG00000255397.1	AC022182.2	-6.37	3.32e-09	0.0218	-0.61	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr8:60937705~60939871:-
TGCT	trans	rs1707322	1	rs9793167	ENSG00000255397.1	AC022182.2	-6.37	3.32e-09	0.0218	-0.61	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr8:60937705~60939871:-
TGCT	trans	rs1707322	1	rs11211237	ENSG00000255397.1	AC022182.2	-6.37	3.32e-09	0.0218	-0.61	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.963	rs11211238	ENSG00000255397.1	AC022182.2	-6.37	3.32e-09	0.0218	-0.61	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr8:60937705~60939871:-
TGCT	trans	rs1707322	1	rs10890380	ENSG00000255397.1	AC022182.2	-6.37	3.32e-09	0.0218	-0.61	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983797	chr8:60937705~60939871:-
TGCT	trans	rs1707322	1	rs4460583	ENSG00000255397.1	AC022182.2	-6.37	3.32e-09	0.0218	-0.61	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.963	rs4459051	ENSG00000255397.1	AC022182.2	-6.37	3.32e-09	0.0218	-0.61	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr8:60937705~60939871:-
TGCT	trans	rs1707322	1	rs11211239	ENSG00000255397.1	AC022182.2	-6.37	3.32e-09	0.0218	-0.61	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr8:60937705~60939871:-
TGCT	trans	rs1707322	1	rs6429588	ENSG00000255397.1	AC022182.2	-6.37	3.32e-09	0.0218	-0.61	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45988386	chr8:60937705~60939871:-
TGCT	trans	rs1707322	1	rs11211243	ENSG00000255397.1	AC022182.2	-6.37	3.32e-09	0.0218	-0.61	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr8:60937705~60939871:-
TGCT	trans	rs1707322	1	rs11211244	ENSG00000255397.1	AC022182.2	-6.37	3.32e-09	0.0218	-0.61	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr8:60937705~60939871:-
TGCT	trans	rs1707322	1	rs4660903	ENSG00000255397.1	AC022182.2	-6.37	3.32e-09	0.0218	-0.61	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr8:60937705~60939871:-
TGCT	trans	rs1707322	1	rs4660331	ENSG00000255397.1	AC022182.2	-6.37	3.32e-09	0.0218	-0.61	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45993111	chr8:60937705~60939871:-
TGCT	trans	rs1707322	1	rs12097799	ENSG00000255397.1	AC022182.2	-6.37	3.32e-09	0.0218	-0.61	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45994214	chr8:60937705~60939871:-
TGCT	trans	rs55665837	1	rs12287715	ENSG00000236360.2	RP11-334A14.2	6.37	3.36e-09	0.0221	0.59	0.5	Vitamin D levels;	chr11:14423029	chr1:52993201~52993702:-
TGCT	trans	rs55665837	0.922	rs12287212	ENSG00000236360.2	RP11-334A14.2	6.37	3.36e-09	0.0221	0.59	0.5	Vitamin D levels;	chr11:14428315	chr1:52993201~52993702:-
TGCT	trans	rs55665837	1	rs12295723	ENSG00000236360.2	RP11-334A14.2	6.37	3.36e-09	0.0221	0.59	0.5	Vitamin D levels;	chr11:14428655	chr1:52993201~52993702:-
TGCT	trans	rs55665837	1	rs12288873	ENSG00000236360.2	RP11-334A14.2	6.37	3.36e-09	0.0221	0.59	0.5	Vitamin D levels;	chr11:14428919	chr1:52993201~52993702:-
TGCT	trans	rs55665837	1	rs34382046	ENSG00000236360.2	RP11-334A14.2	6.37	3.36e-09	0.0221	0.59	0.5	Vitamin D levels;	chr11:14429772	chr1:52993201~52993702:-
TGCT	trans	rs55665837	1	rs7945167	ENSG00000236360.2	RP11-334A14.2	6.37	3.36e-09	0.0221	0.59	0.5	Vitamin D levels;	chr11:14430274	chr1:52993201~52993702:-
TGCT	trans	rs55665837	0.961	rs60622588	ENSG00000236360.2	RP11-334A14.2	6.37	3.36e-09	0.0221	0.59	0.5	Vitamin D levels;	chr11:14435452	chr1:52993201~52993702:-
TGCT	trans	rs55665837	1	rs11023223	ENSG00000236360.2	RP11-334A14.2	6.37	3.36e-09	0.0221	0.59	0.5	Vitamin D levels;	chr11:14435566	chr1:52993201~52993702:-
TGCT	trans	rs12709013	0.792	rs12596434	ENSG00000230849.2	GOT2P2	6.37	3.36e-09	0.0221	0.59	0.5	Blood metabolite ratios;	chr16:58792309	chr1:173141100~173142350:-
TGCT	trans	rs55665837	1	rs11023224	ENSG00000236360.2	RP11-334A14.2	6.37	3.39e-09	0.0222	0.59	0.5	Vitamin D levels;	chr11:14436193	chr1:52993201~52993702:-
TGCT	trans	rs55665837	0.961	rs11023226	ENSG00000236360.2	RP11-334A14.2	6.37	3.39e-09	0.0222	0.59	0.5	Vitamin D levels;	chr11:14437271	chr1:52993201~52993702:-
TGCT	trans	rs55665837	1	rs11023227	ENSG00000236360.2	RP11-334A14.2	6.37	3.39e-09	0.0222	0.59	0.5	Vitamin D levels;	chr11:14437541	chr1:52993201~52993702:-
TGCT	trans	rs55665837	1	rs10832264	ENSG00000236360.2	RP11-334A14.2	6.37	3.39e-09	0.0222	0.59	0.5	Vitamin D levels;	chr11:14438436	chr1:52993201~52993702:-
TGCT	trans	rs55665837	1	rs11023229	ENSG00000236360.2	RP11-334A14.2	6.37	3.39e-09	0.0222	0.59	0.5	Vitamin D levels;	chr11:14439455	chr1:52993201~52993702:-
TGCT	trans	rs5022636	0.821	rs4246525	ENSG00000180764.13	PIPSL	6.36	3.44e-09	0.0225	0.61	0.5	Gut microbiota (functional units);	chr1:151285263	chr10:93958191~93961540:-
TGCT	trans	rs55665837	1	rs11023216	ENSG00000236360.2	RP11-334A14.2	6.36	3.45e-09	0.0226	0.59	0.5	Vitamin D levels;	chr11:14415607	chr1:52993201~52993702:-
TGCT	trans	rs55665837	1	rs10047429	ENSG00000236360.2	RP11-334A14.2	6.36	3.45e-09	0.0226	0.59	0.5	Vitamin D levels;	chr11:14417486	chr1:52993201~52993702:-
TGCT	trans	rs55665837	1	rs10047457	ENSG00000236360.2	RP11-334A14.2	6.36	3.45e-09	0.0226	0.59	0.5	Vitamin D levels;	chr11:14417913	chr1:52993201~52993702:-
TGCT	trans	rs55665837	1	rs12283797	ENSG00000236360.2	RP11-334A14.2	6.36	3.45e-09	0.0226	0.59	0.5	Vitamin D levels;	chr11:14420716	chr1:52993201~52993702:-
TGCT	trans	rs55665837	1	rs10832256	ENSG00000236360.2	RP11-334A14.2	6.36	3.45e-09	0.0226	0.59	0.5	Vitamin D levels;	chr11:14421329	chr1:52993201~52993702:-
TGCT	trans	rs55665837	1	rs10832257	ENSG00000236360.2	RP11-334A14.2	6.36	3.45e-09	0.0226	0.59	0.5	Vitamin D levels;	chr11:14421770	chr1:52993201~52993702:-
TGCT	trans	rs55665837	0.961	rs12795972	ENSG00000236360.2	RP11-334A14.2	6.36	3.45e-09	0.0226	0.59	0.5	Vitamin D levels;	chr11:14422229	chr1:52993201~52993702:-
TGCT	trans	rs3934007	1	rs10160656	ENSG00000231721.5	LINC-PINT	6.36	3.49e-09	0.0228	0.38	0.5	Interferon alpha levels in systemic lupus erythematosus;	chr11:113671546	chr7:130941760~131110176:-
TGCT	trans	rs8175379	0.506	rs10035927	ENSG00000231752.4	EMBP1	-6.36	3.49e-09	0.0228	-0.51	-0.5	Interleukin-7 levels;	chr5:46404107	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.537	rs7293378	ENSG00000231752.4	EMBP1	-6.36	3.49e-09	0.0228	-0.51	-0.5	Schizophrenia;	chr5:50192402	chr1:121519112~121571892:+
TGCT	trans	rs55665837	1	rs11023246	ENSG00000236360.2	RP11-334A14.2	6.36	3.5e-09	0.0228	0.58	0.5	Vitamin D levels;	chr11:14515410	chr1:52993201~52993702:-
TGCT	trans	rs1707322	1	rs4489497	ENSG00000255397.1	AC022182.2	-6.36	3.52e-09	0.0229	-0.62	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr8:60937705~60939871:-
TGCT	trans	rs1707322	1	rs11211235	ENSG00000255397.1	AC022182.2	-6.36	3.52e-09	0.0229	-0.62	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.893	rs9919275	ENSG00000255397.1	AC022182.2	-6.36	3.52e-09	0.0229	-0.62	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr8:60937705~60939871:-
TGCT	trans	rs10940346	0.601	rs4865676	ENSG00000231752.4	EMBP1	6.36	3.56e-09	0.0231	0.52	0.5	Schizophrenia;	chr5:50279343	chr1:121519112~121571892:+
TGCT	trans	rs73990293	0.737	rs4531775	ENSG00000234130.2	RP13-88F20.1	6.36	3.57e-09	0.0231	0.82	0.5	Clopidogrel active metabolite levels;	chr17:35559919	chrX:93222220~93225015:-
TGCT	trans	rs77688320	0.573	rs59674665	ENSG00000235105.1	RP11-329A14.1	-6.36	3.57e-09	0.0231	-0.5	-0.5	Breast cancer;	chr2:201514881	chr1:48435967~48437223:+
TGCT	trans	rs916888	0.697	rs199516	ENSG00000280022.1	RP11-707O23.1	-6.36	3.58e-09	0.0232	-0.78	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45592621~45593369:+
TGCT	trans	rs877636	1	rs877636	ENSG00000212994.5	RPS26P6	-6.36	3.58e-09	0.0232	-0.58	-0.5	Cognitive function;	chr12:56086799	chr8:100895771~100896118:+
TGCT	trans	rs77688320	0.517	rs12991600	ENSG00000235105.1	RP11-329A14.1	6.35	3.63e-09	0.0235	0.49	0.5	Breast cancer;	chr2:201472513	chr1:48435967~48437223:+
TGCT	trans	rs10940346	0.54	rs12521033	ENSG00000231752.4	EMBP1	-6.35	3.64e-09	0.0235	-0.51	-0.5	Schizophrenia;	chr5:50145974	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.519	rs7293422	ENSG00000231752.4	EMBP1	-6.35	3.64e-09	0.0235	-0.51	-0.5	Schizophrenia;	chr5:50146010	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.58	rs12188257	ENSG00000231752.4	EMBP1	-6.35	3.64e-09	0.0235	-0.51	-0.5	Schizophrenia;	chr5:50147242	chr1:121519112~121571892:+
TGCT	trans	rs7647973	1	rs9862534	ENSG00000197582.5	GPX1P1	6.35	3.66e-09	0.0237	0.66	0.5	Menarche (age at onset);	chr3:49560631	chrX:13378735~13379340:-
TGCT	trans	rs7503168	0.643	rs71381467	ENSG00000234130.2	RP13-88F20.1	6.35	3.67e-09	0.0237	0.8	0.5	Plateletcrit;	chr17:35693030	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.643	rs17608253	ENSG00000234130.2	RP13-88F20.1	6.35	3.67e-09	0.0237	0.8	0.5	Plateletcrit;	chr17:35699451	chrX:93222220~93225015:-
TGCT	trans	rs73990293	0.737	rs11657558	ENSG00000234130.2	RP13-88F20.1	6.35	3.67e-09	0.0237	0.8	0.5	Clopidogrel active metabolite levels;	chr17:35702305	chrX:93222220~93225015:-
TGCT	trans	rs7312770	0.637	rs705699	ENSG00000196933.5	RPS26P11	6.35	3.68e-09	0.0238	0.56	0.5	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chrX:72044545~72044892:+
TGCT	trans	rs1707322	1	rs34444543	ENSG00000255397.1	AC022182.2	-6.35	3.69e-09	0.0238	-0.61	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr8:60937705~60939871:-
TGCT	trans	rs7312770	0.612	rs1873914	ENSG00000243538.1	CTB-55B8.1	6.35	3.71e-09	0.024	0.58	0.5	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr5:16902294~16902641:-
TGCT	trans	rs13358908	0.51	rs4975991	ENSG00000231752.4	EMBP1	-6.35	3.73e-09	0.024	-0.51	-0.5	Schizophrenia;	chr5:46328545	chr1:121519112~121571892:+
TGCT	trans	rs55665837	1	rs2305305	ENSG00000236360.2	RP11-334A14.2	6.35	3.74e-09	0.0241	0.58	0.5	Vitamin D levels;	chr11:14519396	chr1:52993201~52993702:-
TGCT	trans	rs1341267	0.529	rs6492721	ENSG00000213513.3	RP13-39P12.2	-6.35	3.75e-09	0.0242	-0.48	-0.5	Triglyceride levels;	chr13:94606690	chr10:77780337~77781876:-
TGCT	trans	rs7503168	0.643	rs17676508	ENSG00000234130.2	RP13-88F20.1	6.34	3.81e-09	0.0245	0.82	0.5	Plateletcrit;	chr17:35693589	chrX:93222220~93225015:-
TGCT	trans	rs73990293	0.531	rs74324437	ENSG00000234130.2	RP13-88F20.1	6.34	3.81e-09	0.0245	0.82	0.5	Clopidogrel active metabolite levels;	chr17:35712668	chrX:93222220~93225015:-
TGCT	trans	rs877636	0.702	rs773108	ENSG00000243403.1	RP11-330L19.1	6.34	3.83e-09	0.0246	0.62	0.49	Cognitive function;	chr12:55976127	chr15:64592979~64593326:+
TGCT	trans	rs7503168	0.558	rs71381460	ENSG00000234130.2	RP13-88F20.1	6.34	3.92e-09	0.0251	0.8	0.49	Plateletcrit;	chr17:35564602	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs11655098	ENSG00000234130.2	RP13-88F20.1	6.34	3.92e-09	0.0251	0.8	0.49	Plateletcrit;	chr17:35567831	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs17638076	ENSG00000234130.2	RP13-88F20.1	6.34	3.92e-09	0.0251	0.8	0.49	Plateletcrit;	chr17:35569254	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs12939138	ENSG00000234130.2	RP13-88F20.1	6.34	3.92e-09	0.0251	0.8	0.49	Plateletcrit;	chr17:35574559	chrX:93222220~93225015:-
TGCT	trans	rs73990293	0.737	rs12951703	ENSG00000234130.2	RP13-88F20.1	6.34	3.92e-09	0.0251	0.8	0.49	Clopidogrel active metabolite levels;	chr17:35586035	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs79468963	ENSG00000234130.2	RP13-88F20.1	6.34	3.92e-09	0.0251	0.8	0.49	Plateletcrit;	chr17:35590408	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs71381461	ENSG00000234130.2	RP13-88F20.1	6.34	3.92e-09	0.0251	0.8	0.49	Plateletcrit;	chr17:35593601	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs34937989	ENSG00000234130.2	RP13-88F20.1	6.34	3.92e-09	0.0251	0.8	0.49	Plateletcrit;	chr17:35594744	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs12945102	ENSG00000234130.2	RP13-88F20.1	6.34	3.92e-09	0.0251	0.8	0.49	Plateletcrit;	chr17:35601894	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs12945980	ENSG00000234130.2	RP13-88F20.1	6.34	3.92e-09	0.0251	0.8	0.49	Plateletcrit;	chr17:35603002	chrX:93222220~93225015:-
TGCT	trans	rs3740713	0.592	rs73434674	ENSG00000235847.2	LDHAP7	6.34	3.94e-09	0.0252	0.82	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18389950	chr2:84777259~84778223:-
TGCT	trans	rs7590268	0.789	rs35071299	ENSG00000254966.1	RP11-1081L13.4	-6.34	3.97e-09	0.0254	-0.64	-0.49	Orofacial clefts;	chr2:43415898	chr11:18706537~18740568:+
TGCT	trans	rs7647973	0.925	rs4955439	ENSG00000197582.5	GPX1P1	-6.34	3.97e-09	0.0254	-0.68	-0.49	Menarche (age at onset);	chr3:49208212	chrX:13378735~13379340:-
TGCT	trans	rs7824557	0.675	rs2736265	ENSG00000173295.6	FAM86B3P	6.33	4.05e-09	0.0258	0.59	0.49	Retinal vascular caliber;	chr8:11329165	chr8:8228595~8244865:+
TGCT	trans	rs7503168	0.558	rs75787089	ENSG00000234130.2	RP13-88F20.1	6.33	4.09e-09	0.026	0.82	0.49	Plateletcrit;	chr17:35598042	chrX:93222220~93225015:-
TGCT	trans	rs7503168	0.558	rs117414856	ENSG00000234130.2	RP13-88F20.1	6.33	4.09e-09	0.026	0.82	0.49	Plateletcrit;	chr17:35604168	chrX:93222220~93225015:-
TGCT	trans	rs1707322	0.827	rs6683274	ENSG00000255397.1	AC022182.2	-6.33	4.1e-09	0.0261	-0.64	-0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr8:60937705~60939871:-
TGCT	trans	rs7200543	1	rs4500751	ENSG00000250569.1	NTAN1P2	6.33	4.12e-09	0.0262	0.64	0.49	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046354	chr8:86481754~86483002:-
TGCT	trans	rs1816752	0.875	rs59531061	ENSG00000237917.1	PARP4P1	6.33	4.14e-09	0.0264	0.58	0.49	Obesity-related traits;	chr13:24507297	chrY:26594851~26634652:-
TGCT	trans	rs8175379	0.575	rs8185283	ENSG00000231752.4	EMBP1	-6.33	4.17e-09	0.0265	-0.51	-0.49	Interleukin-7 levels;	chr5:46337706	chr1:121519112~121571892:+
TGCT	trans	rs8175379	0.515	rs8185067	ENSG00000231752.4	EMBP1	-6.33	4.17e-09	0.0265	-0.51	-0.49	Interleukin-7 levels;	chr5:46337722	chr1:121519112~121571892:+
TGCT	trans	rs1707322	1	rs10789486	ENSG00000255397.1	AC022182.2	-6.32	4.2e-09	0.0267	-0.61	-0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr8:60937705~60939871:-
TGCT	trans	rs1707322	1	rs6661500	ENSG00000255397.1	AC022182.2	-6.32	4.2e-09	0.0267	-0.61	-0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45999990	chr8:60937705~60939871:-
TGCT	trans	rs4727751	0.817	rs12668963	ENSG00000213250.5	RBMS2P1	6.32	4.25e-09	0.0269	0.48	0.49	Schizophrenia;	chr7:78687564	chr12:94423744~94424969:-
TGCT	trans	rs4727751	0.817	rs10262658	ENSG00000213250.5	RBMS2P1	6.32	4.25e-09	0.0269	0.48	0.49	Schizophrenia;	chr7:78687824	chr12:94423744~94424969:-
TGCT	trans	rs7590268	0.666	rs17406472	ENSG00000254966.1	RP11-1081L13.4	-6.32	4.26e-09	0.027	-0.62	-0.49	Orofacial clefts;	chr2:43406707	chr11:18706537~18740568:+
TGCT	trans	rs7590268	0.789	rs17334310	ENSG00000254966.1	RP11-1081L13.4	6.32	4.35e-09	0.0275	0.63	0.49	Orofacial clefts;	chr2:43350476	chr11:18706537~18740568:+
TGCT	trans	rs7590268	0.895	rs6544648	ENSG00000254966.1	RP11-1081L13.4	-6.32	4.35e-09	0.0275	-0.63	-0.49	Orofacial clefts;	chr2:43372919	chr11:18706537~18740568:+
TGCT	trans	rs1707322	0.964	rs785508	ENSG00000255397.1	AC022182.2	6.31	4.41e-09	0.0279	0.62	0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.964	rs785509	ENSG00000255397.1	AC022182.2	6.31	4.41e-09	0.0279	0.62	0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr8:60937705~60939871:-
TGCT	trans	rs7973618	1	rs7973618	ENSG00000121089.4	NACA3P	-6.31	4.43e-09	0.028	-0.65	-0.49	Mean platelet volume;	chr12:56625659	chr4:164943290~164943937:+
TGCT	trans	rs1707322	1	rs4660906	ENSG00000255397.1	AC022182.2	-6.31	4.46e-09	0.0282	-0.6	-0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46005188	chr8:60937705~60939871:-
TGCT	trans	rs1707322	1	rs3922887	ENSG00000255397.1	AC022182.2	-6.31	4.46e-09	0.0282	-0.6	-0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008130	chr8:60937705~60939871:-
TGCT	trans	rs1707322	1	rs3922886	ENSG00000255397.1	AC022182.2	-6.31	4.46e-09	0.0282	-0.6	-0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008230	chr8:60937705~60939871:-
TGCT	trans	rs7312770	0.637	rs705699	ENSG00000227887.1	RPS26P13	6.31	4.54e-09	0.0287	0.59	0.49	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr1:208697369~208697698:-
TGCT	trans	rs7590268	0.943	rs35338810	ENSG00000254966.1	RP11-1081L13.4	-6.31	4.54e-09	0.0287	-0.65	-0.49	Orofacial clefts;	chr2:43321807	chr11:18706537~18740568:+
TGCT	trans	rs7647973	1	rs9842132	ENSG00000197582.5	GPX1P1	-6.31	4.56e-09	0.0287	-0.69	-0.49	Menarche (age at onset);	chr3:49390500	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs6785045	ENSG00000197582.5	GPX1P1	-6.31	4.56e-09	0.0287	-0.69	-0.49	Menarche (age at onset);	chr3:49397810	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs56127630	ENSG00000197582.5	GPX1P1	-6.31	4.56e-09	0.0287	-0.69	-0.49	Menarche (age at onset);	chr3:49400603	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs7648995	ENSG00000197582.5	GPX1P1	-6.31	4.56e-09	0.0287	-0.69	-0.49	Menarche (age at onset);	chr3:49401370	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs2140270	ENSG00000197582.5	GPX1P1	-6.31	4.56e-09	0.0287	-0.69	-0.49	Menarche (age at onset);	chr3:49402007	chrX:13378735~13379340:-
TGCT	trans	rs7647973	1	rs2177268	ENSG00000197582.5	GPX1P1	-6.31	4.56e-09	0.0287	-0.69	-0.49	Menarche (age at onset);	chr3:49402292	chrX:13378735~13379340:-
TGCT	trans	rs1707322	0.752	rs6703748	ENSG00000255397.1	AC022182.2	-6.31	4.57e-09	0.0288	-0.63	-0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr8:60937705~60939871:-
TGCT	trans	rs4276421	0.81	rs13190242	ENSG00000231752.4	EMBP1	6.31	4.57e-09	0.0288	0.52	0.49	P wave duration;	chr5:46054443	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs567248	ENSG00000231752.4	EMBP1	-6.31	4.6e-09	0.029	-0.54	-0.49	Schizophrenia;	chr5:50277650	chr1:121519112~121571892:+
TGCT	trans	rs55665837	1	rs12276938	ENSG00000236360.2	RP11-334A14.2	6.3	4.63e-09	0.0291	0.58	0.49	Vitamin D levels;	chr11:14441942	chr1:52993201~52993702:-
TGCT	trans	rs4276421	0.904	rs10067132	ENSG00000231752.4	EMBP1	6.3	4.64e-09	0.0292	0.52	0.49	P wave duration;	chr5:46027600	chr1:121519112~121571892:+
TGCT	trans	rs6732160	0.593	rs2288630	ENSG00000236165.1	PRADC1P1	6.3	4.64e-09	0.0292	0.56	0.49	Intelligence (multi-trait analysis);	chr2:73230424	chr3:36976316~36976840:+
TGCT	trans	rs877636	1	rs705696	ENSG00000243538.1	CTB-55B8.1	6.3	4.66e-09	0.0293	0.64	0.49	Cognitive function;	chr12:56086864	chr5:16902294~16902641:-
TGCT	trans	rs55665837	1	rs10832268	ENSG00000236360.2	RP11-334A14.2	6.3	4.67e-09	0.0294	0.58	0.49	Vitamin D levels;	chr11:14443522	chr1:52993201~52993702:-
TGCT	trans	rs55665837	1	rs10832269	ENSG00000236360.2	RP11-334A14.2	6.3	4.67e-09	0.0294	0.58	0.49	Vitamin D levels;	chr11:14443523	chr1:52993201~52993702:-
TGCT	trans	rs55665837	1	rs10832271	ENSG00000236360.2	RP11-334A14.2	6.3	4.67e-09	0.0294	0.58	0.49	Vitamin D levels;	chr11:14445373	chr1:52993201~52993702:-
TGCT	trans	rs55665837	1	rs12792120	ENSG00000236360.2	RP11-334A14.2	6.3	4.67e-09	0.0294	0.58	0.49	Vitamin D levels;	chr11:14447897	chr1:52993201~52993702:-
TGCT	trans	rs55665837	1	rs10832275	ENSG00000236360.2	RP11-334A14.2	6.3	4.67e-09	0.0294	0.58	0.49	Vitamin D levels;	chr11:14456678	chr1:52993201~52993702:-
TGCT	trans	rs55665837	0.961	rs12576926	ENSG00000236360.2	RP11-334A14.2	6.3	4.67e-09	0.0294	0.58	0.49	Vitamin D levels;	chr11:14458746	chr1:52993201~52993702:-
TGCT	trans	rs55665837	1	rs55665837	ENSG00000236360.2	RP11-334A14.2	6.3	4.67e-09	0.0294	0.58	0.49	Vitamin D levels;	chr11:14473503	chr1:52993201~52993702:-
TGCT	trans	rs10940346	0.601	rs10940075	ENSG00000231752.4	EMBP1	-6.3	4.69e-09	0.0294	-0.52	-0.49	Schizophrenia;	chr5:50304547	chr1:121519112~121571892:+
TGCT	trans	rs55665837	1	rs11023215	ENSG00000236360.2	RP11-334A14.2	6.3	4.73e-09	0.0297	0.59	0.49	Vitamin D levels;	chr11:14415424	chr1:52993201~52993702:-
TGCT	trans	rs1707322	0.826	rs10890349	ENSG00000255397.1	AC022182.2	-6.3	4.76e-09	0.0299	-0.61	-0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.758	rs10789474	ENSG00000255397.1	AC022182.2	-6.3	4.76e-09	0.0299	-0.61	-0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr8:60937705~60939871:-
TGCT	trans	rs1707322	1	rs4073847	ENSG00000255397.1	AC022182.2	6.3	4.8e-09	0.0301	0.61	0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45997340	chr8:60937705~60939871:-
TGCT	trans	rs916888	0.773	rs199448	ENSG00000280022.1	RP11-707O23.1	6.29	4.86e-09	0.0301	0.77	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45592621~45593369:+
TGCT	trans	rs8175379	0.522	rs8185256	ENSG00000231752.4	EMBP1	-6.29	4.93e-09	0.0301	-0.5	-0.49	Interleukin-7 levels;	chr5:46298301	chr1:121519112~121571892:+
TGCT	trans	rs8175379	0.502	rs8185361	ENSG00000231752.4	EMBP1	-6.29	4.93e-09	0.0301	-0.5	-0.49	Interleukin-7 levels;	chr5:46300238	chr1:121519112~121571892:+
TGCT	trans	rs13358908	0.526	rs4975974	ENSG00000231752.4	EMBP1	-6.29	4.93e-09	0.0301	-0.5	-0.49	Schizophrenia;	chr5:46307464	chr1:121519112~121571892:+
TGCT	trans	rs8175379	0.501	rs12514178	ENSG00000231752.4	EMBP1	-6.29	4.93e-09	0.0301	-0.5	-0.49	Interleukin-7 levels;	chr5:46309072	chr1:121519112~121571892:+
TGCT	trans	rs8175379	0.501	rs8185192	ENSG00000231752.4	EMBP1	-6.29	4.93e-09	0.0301	-0.5	-0.49	Interleukin-7 levels;	chr5:46309722	chr1:121519112~121571892:+
TGCT	trans	rs13358908	0.556	rs55638678	ENSG00000231752.4	EMBP1	-6.29	4.93e-09	0.0301	-0.5	-0.49	Schizophrenia;	chr5:46332618	chr1:121519112~121571892:+
TGCT	trans	rs13358908	0.511	rs34101830	ENSG00000231752.4	EMBP1	-6.29	4.93e-09	0.0301	-0.5	-0.49	Schizophrenia;	chr5:46349001	chr1:121519112~121571892:+
TGCT	trans	rs13358908	0.503	rs10073687	ENSG00000231752.4	EMBP1	-6.29	4.93e-09	0.0301	-0.5	-0.49	Schizophrenia;	chr5:46352187	chr1:121519112~121571892:+
TGCT	trans	rs8175379	0.506	rs8188256	ENSG00000231752.4	EMBP1	-6.29	4.93e-09	0.0301	-0.5	-0.49	Interleukin-7 levels;	chr5:46372404	chr1:121519112~121571892:+
TGCT	trans	rs13358908	0.507	rs12521357	ENSG00000231752.4	EMBP1	-6.29	4.93e-09	0.0301	-0.5	-0.49	Schizophrenia;	chr5:46403146	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.519	rs10940514	ENSG00000231752.4	EMBP1	-6.29	4.93e-09	0.0301	-0.5	-0.49	Schizophrenia;	chr5:50146166	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.58	rs10940533	ENSG00000231752.4	EMBP1	-6.29	4.93e-09	0.0301	-0.5	-0.49	Schizophrenia;	chr5:50146552	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.58	rs9688065	ENSG00000231752.4	EMBP1	-6.29	4.93e-09	0.0301	-0.5	-0.49	Schizophrenia;	chr5:50147444	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.562	rs4379243	ENSG00000231752.4	EMBP1	-6.29	4.93e-09	0.0301	-0.5	-0.49	Schizophrenia;	chr5:50149933	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs13175165	ENSG00000231752.4	EMBP1	-6.29	4.93e-09	0.0301	-0.5	-0.49	Schizophrenia;	chr5:50151463	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs7448495	ENSG00000231752.4	EMBP1	-6.29	4.93e-09	0.0301	-0.51	-0.49	Schizophrenia;	chr5:50300238	chr1:121519112~121571892:+
TGCT	trans	rs7312770	0.612	rs1873914	ENSG00000196933.5	RPS26P11	6.29	4.96e-09	0.0303	0.55	0.49	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chrX:72044545~72044892:+
TGCT	trans	rs916888	0.821	rs199514	ENSG00000280022.1	RP11-707O23.1	-6.29	4.97e-09	0.0303	-0.78	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45592621~45593369:+
TGCT	trans	rs5022636	0.927	rs10888409	ENSG00000180764.13	PIPSL	6.29	4.98e-09	0.0304	0.59	0.49	Gut microbiota (functional units);	chr1:151299306	chr10:93958191~93961540:-
TGCT	trans	rs4276421	0.774	rs8188072	ENSG00000231752.4	EMBP1	6.29	5.02e-09	0.0306	0.52	0.49	P wave duration;	chr5:46061883	chr1:121519112~121571892:+
TGCT	trans	rs7312770	0.637	rs705700	ENSG00000227887.1	RPS26P13	6.29	5.03e-09	0.0307	0.58	0.49	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr1:208697369~208697698:-
TGCT	trans	rs7590268	0.697	rs10495901	ENSG00000254966.1	RP11-1081L13.4	-6.29	5.07e-09	0.0308	-0.63	-0.49	Orofacial clefts;	chr2:43390587	chr11:18706537~18740568:+
TGCT	trans	rs7617480	0.61	rs4955420	ENSG00000197582.5	GPX1P1	6.29	5.07e-09	0.0309	0.63	0.49	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49171432	chrX:13378735~13379340:-
TGCT	trans	rs877636	0.669	rs7297175	ENSG00000196933.5	RPS26P11	-6.28	5.14e-09	0.0313	-0.53	-0.49	Cognitive function;	chr12:56080024	chrX:72044545~72044892:+
TGCT	trans	rs10037055	0.741	rs4976640	ENSG00000217325.2	PRELID1P1	-6.28	5.16e-09	0.0313	-0.56	-0.49	Migraine without aura;	chr5:177125006	chr6:126643488~126644390:+
TGCT	trans	rs877636	1	rs4759229	ENSG00000223416.3	RPS26P15	-6.28	5.28e-09	0.0321	-0.58	-0.49	Cognitive function;	chr12:56080696	chr1:58056133~58056480:-
TGCT	trans	rs7395662	0.864	rs7483617	ENSG00000134612.10	FOLH1B	-6.28	5.31e-09	0.0322	-0.61	-0.49	HDL cholesterol;	chr11:48530107	chr11:89639227~89698718:+
TGCT	trans	rs928391	0.744	rs6700964	ENSG00000227183.3	HDGFP1	-6.28	5.31e-09	0.0322	-0.64	-0.49	Platelet count;	chr1:156790244	chrX:131646639~131646890:+
TGCT	trans	rs1707322	1	rs6671754	ENSG00000255397.1	AC022182.2	-6.28	5.31e-09	0.0322	-0.61	-0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.963	rs6666763	ENSG00000255397.1	AC022182.2	-6.28	5.31e-09	0.0322	-0.61	-0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr8:60937705~60939871:-
TGCT	trans	rs934734	0.532	rs7569113	ENSG00000213326.4	RPS7P11	-6.28	5.32e-09	0.0322	-0.43	-0.49	Rheumatoid arthritis;	chr2:65429907	chr17:46721582~46722167:-
TGCT	trans	rs7312770	0.637	rs705700	ENSG00000196933.5	RPS26P11	6.27	5.36e-09	0.0325	0.55	0.49	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chrX:72044545~72044892:+
TGCT	trans	rs7312770	0.612	rs773114	ENSG00000227887.1	RPS26P13	6.27	5.38e-09	0.0326	0.58	0.49	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr1:208697369~208697698:-
TGCT	trans	rs10940346	0.56	rs7293410	ENSG00000231752.4	EMBP1	-6.27	5.47e-09	0.0331	-0.5	-0.49	Schizophrenia;	chr5:50163036	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.58	rs4865801	ENSG00000231752.4	EMBP1	-6.27	5.47e-09	0.0331	-0.5	-0.49	Schizophrenia;	chr5:50163364	chr1:121519112~121571892:+
TGCT	trans	rs916888	0.687	rs199456	ENSG00000280022.1	RP11-707O23.1	6.27	5.51e-09	0.0333	0.8	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45592621~45593369:+
TGCT	trans	rs5022636	0.594	rs12048670	ENSG00000180764.13	PIPSL	6.27	5.53e-09	0.0334	0.63	0.49	Gut microbiota (functional units);	chr1:151272510	chr10:93958191~93961540:-
TGCT	trans	rs7637404	1	rs4515105	ENSG00000229349.2	ACTG1P9	6.27	5.59e-09	0.0337	0.56	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr3:191270102	chr6:46204729~46207386:+
TGCT	trans	rs10242455	0.702	rs2293256	ENSG00000228834.1	RP11-249L21.4	-6.27	5.6e-09	0.0338	-1.14	-0.49	Blood metabolite levels;	chr7:99460078	chr6:108907615~108907873:-
TGCT	trans	rs6887276	0.677	rs36696	ENSG00000226526.1	RP1-37C10.3	6.26	5.62e-09	0.0339	0.39	0.49	Height;	chr5:128213884	chr1:16978926~17005091:+
TGCT	trans	rs934734	0.532	rs7569257	ENSG00000213326.4	RPS7P11	6.26	5.66e-09	0.0341	0.43	0.49	Rheumatoid arthritis;	chr2:65429842	chr17:46721582~46722167:-
TGCT	trans	rs9467773	0.596	rs3001369	ENSG00000242375.1	RP11-498P14.3	6.26	5.7e-09	0.0343	0.63	0.49	Intelligence (multi-trait analysis);	chr6:26670741	chr9:97195351~97197687:-
TGCT	trans	rs7647973	0.925	rs9834003	ENSG00000197582.5	GPX1P1	6.26	5.8e-09	0.0347	0.66	0.49	Menarche (age at onset);	chr3:49179039	chrX:13378735~13379340:-
TGCT	trans	rs7647973	0.925	rs4955421	ENSG00000197582.5	GPX1P1	6.26	5.8e-09	0.0347	0.66	0.49	Menarche (age at onset);	chr3:49181455	chrX:13378735~13379340:-
TGCT	trans	rs7647973	0.925	rs4955423	ENSG00000197582.5	GPX1P1	6.26	5.8e-09	0.0347	0.66	0.49	Menarche (age at onset);	chr3:49183015	chrX:13378735~13379340:-
TGCT	trans	rs7647973	0.925	rs6446256	ENSG00000197582.5	GPX1P1	6.26	5.8e-09	0.0347	0.66	0.49	Menarche (age at onset);	chr3:49186777	chrX:13378735~13379340:-
TGCT	trans	rs7647973	0.925	rs11130183	ENSG00000197582.5	GPX1P1	6.26	5.8e-09	0.0347	0.66	0.49	Menarche (age at onset);	chr3:49191513	chrX:13378735~13379340:-
TGCT	trans	rs7647973	0.925	rs6808036	ENSG00000197582.5	GPX1P1	6.26	5.8e-09	0.0347	0.66	0.49	Menarche (age at onset);	chr3:49199006	chrX:13378735~13379340:-
TGCT	trans	rs10940346	0.601	rs6892142	ENSG00000231752.4	EMBP1	-6.26	5.84e-09	0.035	-0.53	-0.49	Schizophrenia;	chr5:50276518	chr1:121519112~121571892:+
TGCT	trans	rs7590268	0.789	rs34992473	ENSG00000254966.1	RP11-1081L13.4	-6.26	5.86e-09	0.0351	-0.63	-0.49	Orofacial clefts;	chr2:43413064	chr11:18706537~18740568:+
TGCT	trans	rs916888	0.773	rs199447	ENSG00000280022.1	RP11-707O23.1	6.26	5.89e-09	0.0352	0.79	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45592621~45593369:+
TGCT	trans	rs916888	0.773	rs199445	ENSG00000280022.1	RP11-707O23.1	6.26	5.89e-09	0.0352	0.79	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45592621~45593369:+
TGCT	trans	rs916888	0.773	rs199443	ENSG00000280022.1	RP11-707O23.1	6.26	5.89e-09	0.0352	0.79	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45592621~45593369:+
TGCT	trans	rs916888	0.773	rs199534	ENSG00000280022.1	RP11-707O23.1	6.26	5.89e-09	0.0352	0.79	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45592621~45593369:+
TGCT	trans	rs6132905	0.52	rs2422824	ENSG00000235559.1	NOP56P1	6.25	5.9e-09	0.0353	0.67	0.49	Mumps;	chr20:2666724	chr6:28783633~28784004:-
TGCT	trans	rs10037055	0.853	rs1546363	ENSG00000217325.2	PRELID1P1	-6.25	5.9e-09	0.0353	-0.55	-0.49	Migraine without aura;	chr5:177174030	chr6:126643488~126644390:+
TGCT	trans	rs10037055	0.853	rs10056008	ENSG00000217325.2	PRELID1P1	-6.25	5.9e-09	0.0353	-0.55	-0.49	Migraine without aura;	chr5:177194147	chr6:126643488~126644390:+
TGCT	trans	rs10037055	0.853	rs10476219	ENSG00000217325.2	PRELID1P1	-6.25	5.9e-09	0.0353	-0.55	-0.49	Migraine without aura;	chr5:177201547	chr6:126643488~126644390:+
TGCT	trans	rs1707322	0.752	rs4586014	ENSG00000255397.1	AC022182.2	-6.25	5.92e-09	0.0354	-0.63	-0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.929	rs785513	ENSG00000255397.1	AC022182.2	6.25	6.02e-09	0.036	0.62	0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46072648	chr8:60937705~60939871:-
TGCT	trans	rs12709013	1	rs12709013	ENSG00000230849.2	GOT2P2	-6.25	6.1e-09	0.0364	-0.59	-0.49	Blood metabolite ratios;	chr16:58795886	chr1:173141100~173142350:-
TGCT	trans	rs8175379	0.584	rs8185180	ENSG00000231752.4	EMBP1	-6.24	6.2e-09	0.037	-0.51	-0.49	Interleukin-7 levels;	chr5:46300291	chr1:121519112~121571892:+
TGCT	trans	rs2642660	0.545	rs157352	ENSG00000281827.1	AC005071.4	-6.24	6.23e-09	0.0371	-0.58	-0.49	Airway responsiveness in chronic obstructive pulmonary disease;	chr5:156713994	chr7:100344375~100344475:-
TGCT	trans	rs7576126	1	rs7576126	ENSG00000213326.4	RPS7P11	6.24	6.29e-09	0.0375	0.43	0.49	Severe influenza A (H1N1) infection;	chr2:65431235	chr17:46721582~46722167:-
TGCT	trans	rs1707322	1	rs7527079	ENSG00000255397.1	AC022182.2	-6.24	6.31e-09	0.0376	-0.61	-0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr8:60937705~60939871:-
TGCT	trans	rs1707322	1	rs34446427	ENSG00000255397.1	AC022182.2	-6.24	6.31e-09	0.0376	-0.61	-0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr8:60937705~60939871:-
TGCT	trans	rs1707322	0.963	rs4660900	ENSG00000255397.1	AC022182.2	-6.24	6.31e-09	0.0376	-0.61	-0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr8:60937705~60939871:-
TGCT	trans	rs1707322	1	rs4454479	ENSG00000255397.1	AC022182.2	-6.24	6.31e-09	0.0376	-0.61	-0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr8:60937705~60939871:-
TGCT	trans	rs1707322	1	rs12403666	ENSG00000255397.1	AC022182.2	-6.24	6.31e-09	0.0376	-0.61	-0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45965949	chr8:60937705~60939871:-
TGCT	trans	rs1707322	1	rs12077546	ENSG00000255397.1	AC022182.2	-6.24	6.31e-09	0.0376	-0.61	-0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr8:60937705~60939871:-
TGCT	trans	rs1707322	1	rs12124291	ENSG00000255397.1	AC022182.2	-6.24	6.31e-09	0.0376	-0.61	-0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr8:60937705~60939871:-
TGCT	trans	rs10940346	0.601	rs496230	ENSG00000231752.4	EMBP1	-6.24	6.34e-09	0.0376	-0.51	-0.49	Schizophrenia;	chr5:50275179	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs526329	ENSG00000231752.4	EMBP1	-6.24	6.34e-09	0.0376	-0.51	-0.49	Schizophrenia;	chr5:50276141	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs524184	ENSG00000231752.4	EMBP1	-6.24	6.34e-09	0.0376	-0.51	-0.49	Schizophrenia;	chr5:50276256	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.58	rs6868713	ENSG00000231752.4	EMBP1	-6.24	6.34e-09	0.0376	-0.51	-0.49	Schizophrenia;	chr5:50276741	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.562	rs555704	ENSG00000231752.4	EMBP1	-6.24	6.34e-09	0.0376	-0.51	-0.49	Schizophrenia;	chr5:50277066	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.562	rs563750	ENSG00000231752.4	EMBP1	-6.24	6.34e-09	0.0376	-0.51	-0.49	Schizophrenia;	chr5:50278004	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs4865675	ENSG00000231752.4	EMBP1	-6.24	6.34e-09	0.0376	-0.51	-0.49	Schizophrenia;	chr5:50279300	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs507761	ENSG00000231752.4	EMBP1	-6.24	6.34e-09	0.0376	-0.51	-0.49	Schizophrenia;	chr5:50279558	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs506919	ENSG00000231752.4	EMBP1	-6.24	6.34e-09	0.0376	-0.51	-0.49	Schizophrenia;	chr5:50279635	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs494540	ENSG00000231752.4	EMBP1	-6.24	6.34e-09	0.0376	-0.51	-0.49	Schizophrenia;	chr5:50280228	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.51	rs10038023	ENSG00000231752.4	EMBP1	-6.24	6.34e-09	0.0376	-0.51	-0.49	Schizophrenia;	chr5:50280387	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs471455	ENSG00000231752.4	EMBP1	-6.24	6.34e-09	0.0376	-0.51	-0.49	Schizophrenia;	chr5:50280427	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.904	rs7444405	ENSG00000231752.4	EMBP1	6.24	6.36e-09	0.0378	0.51	0.49	P wave duration;	chr5:45915373	chr1:121519112~121571892:+
TGCT	trans	rs7200543	1	rs72774845	ENSG00000250569.1	NTAN1P2	6.24	6.42e-09	0.038	0.62	0.49	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15054097	chr8:86481754~86483002:-
TGCT	trans	rs928391	0.744	rs11264555	ENSG00000227183.3	HDGFP1	-6.23	6.52e-09	0.0386	-0.64	-0.49	Platelet count;	chr1:156794246	chrX:131646639~131646890:+
TGCT	trans	rs928391	0.744	rs3765783	ENSG00000227183.3	HDGFP1	-6.23	6.52e-09	0.0386	-0.64	-0.49	Platelet count;	chr1:156796181	chrX:131646639~131646890:+
TGCT	trans	rs4276421	1	rs28657933	ENSG00000231752.4	EMBP1	6.23	6.56e-09	0.0388	0.5	0.49	P wave duration;	chr5:45863597	chr1:121519112~121571892:+
TGCT	trans	rs4276421	1	rs10039283	ENSG00000231752.4	EMBP1	6.23	6.56e-09	0.0388	0.5	0.49	P wave duration;	chr5:45864741	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.967	rs4282324	ENSG00000231752.4	EMBP1	6.23	6.56e-09	0.0388	0.5	0.49	P wave duration;	chr5:45865330	chr1:121519112~121571892:+
TGCT	trans	rs4276421	1	rs4331911	ENSG00000231752.4	EMBP1	6.23	6.59e-09	0.039	0.5	0.49	P wave duration;	chr5:45859273	chr1:121519112~121571892:+
TGCT	trans	rs7312770	1	rs7312770	ENSG00000234513.1	AC073072.7	-6.23	6.61e-09	0.0391	-0.51	-0.49	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr7:22773646~22773993:-
TGCT	trans	rs10037055	0.853	rs10077929	ENSG00000217325.2	PRELID1P1	6.23	6.67e-09	0.0394	0.56	0.49	Migraine without aura;	chr5:177270843	chr6:126643488~126644390:+
TGCT	trans	rs10940346	0.601	rs1033109	ENSG00000231752.4	EMBP1	6.23	6.68e-09	0.0394	0.53	0.49	Schizophrenia;	chr5:50327705	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs13360551	ENSG00000231752.4	EMBP1	-6.23	6.68e-09	0.0394	-0.5	-0.49	Schizophrenia;	chr5:50287350	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs1858343	ENSG00000231752.4	EMBP1	-6.23	6.68e-09	0.0394	-0.5	-0.49	Schizophrenia;	chr5:50290180	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.58	rs1858344	ENSG00000231752.4	EMBP1	-6.23	6.68e-09	0.0394	-0.5	-0.49	Schizophrenia;	chr5:50290345	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs4865685	ENSG00000231752.4	EMBP1	-6.23	6.68e-09	0.0394	-0.5	-0.49	Schizophrenia;	chr5:50290682	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs6449779	ENSG00000231752.4	EMBP1	-6.23	6.68e-09	0.0394	-0.5	-0.49	Schizophrenia;	chr5:50290876	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.623	rs4865519	ENSG00000231752.4	EMBP1	-6.23	6.68e-09	0.0394	-0.5	-0.49	Schizophrenia;	chr5:50293002	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs2353221	ENSG00000231752.4	EMBP1	-6.23	6.68e-09	0.0394	-0.5	-0.49	Schizophrenia;	chr5:50299085	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs6449802	ENSG00000231752.4	EMBP1	-6.23	6.68e-09	0.0394	-0.5	-0.49	Schizophrenia;	chr5:50299390	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs7724645	ENSG00000231752.4	EMBP1	-6.23	6.68e-09	0.0394	-0.5	-0.49	Schizophrenia;	chr5:50299846	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs7709906	ENSG00000231752.4	EMBP1	6.23	6.68e-09	0.0394	0.5	0.49	Schizophrenia;	chr5:50299936	chr1:121519112~121571892:+
TGCT	trans	rs916888	0.773	rs199457	ENSG00000280022.1	RP11-707O23.1	6.23	6.71e-09	0.0396	0.8	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45592621~45593369:+
TGCT	trans	rs2657294	0.796	rs1259499	ENSG00000172974.11	AC007318.5	6.23	6.73e-09	0.0397	0.57	0.49	Pneumonia;	chr10:75228308	chr2:65205108~65205988:+
TGCT	trans	rs4276421	1	rs6895191	ENSG00000231752.4	EMBP1	6.23	6.73e-09	0.0397	0.5	0.49	P wave duration;	chr5:45877572	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.935	rs12109652	ENSG00000231752.4	EMBP1	6.23	6.79e-09	0.04	0.5	0.49	P wave duration;	chr5:45878206	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.935	rs6451827	ENSG00000231752.4	EMBP1	6.23	6.79e-09	0.04	0.5	0.49	P wave duration;	chr5:45879496	chr1:121519112~121571892:+
TGCT	trans	rs7647973	1	rs62261249	ENSG00000197582.5	GPX1P1	-6.22	6.82e-09	0.0402	-0.68	-0.49	Menarche (age at onset);	chr3:49556627	chrX:13378735~13379340:-
TGCT	trans	rs4276421	0.635	rs12186454	ENSG00000231752.4	EMBP1	-6.22	6.86e-09	0.0403	-0.55	-0.49	P wave duration;	chr5:46067621	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.623	rs7736990	ENSG00000231752.4	EMBP1	-6.22	6.87e-09	0.0404	-0.5	-0.49	Schizophrenia;	chr5:50300008	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs10079897	ENSG00000231752.4	EMBP1	-6.22	6.87e-09	0.0404	-0.5	-0.49	Schizophrenia;	chr5:50300032	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs2137129	ENSG00000231752.4	EMBP1	-6.22	6.87e-09	0.0404	-0.5	-0.49	Schizophrenia;	chr5:50300962	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.874	rs6451830	ENSG00000231752.4	EMBP1	6.22	6.93e-09	0.0407	0.5	0.49	P wave duration;	chr5:45893354	chr1:121519112~121571892:+
TGCT	trans	rs1286150	0.627	rs1286087	ENSG00000260390.1	RP11-575I8.1	6.22	6.97e-09	0.0409	0.75	0.49	Total body bone mineral density;	chr14:90971026	chr9:27829276~27844481:+
TGCT	trans	rs3767627	0.505	rs12023748	ENSG00000226985.4	LINC01203	-6.22	7.01e-09	0.0412	-0.34	-0.49	Height;	chr1:149969301	chrX:13335241~13373634:+
TGCT	trans	rs3767627	0.505	rs3738320	ENSG00000226985.4	LINC01203	-6.22	7.01e-09	0.0412	-0.34	-0.49	Height;	chr1:150010677	chrX:13335241~13373634:+
TGCT	trans	rs3740713	0.669	rs113003553	ENSG00000235847.2	LDHAP7	6.22	7.14e-09	0.0418	0.81	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18389314	chr2:84777259~84778223:-
TGCT	trans	rs2950393	0.572	rs10783794	ENSG00000121089.4	NACA3P	-6.21	7.18e-09	0.042	-0.62	-0.49	Platelet distribution width;	chr12:56593395	chr4:164943290~164943937:+
TGCT	trans	rs10940346	0.601	rs2005573	ENSG00000231752.4	EMBP1	-6.21	7.2e-09	0.0421	-0.5	-0.49	Schizophrenia;	chr5:50301614	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs2011540	ENSG00000231752.4	EMBP1	-6.21	7.2e-09	0.0421	-0.5	-0.49	Schizophrenia;	chr5:50301634	chr1:121519112~121571892:+
TGCT	trans	rs73108077	0.736	rs7273790	ENSG00000279352.1	RP11-411B10.7	-6.21	7.2e-09	0.0421	-0.81	-0.49	Red blood cell density in sickle cell anemia;	chr20:31312478	chr18:14010054~14010917:+
TGCT	trans	rs55665837	1	rs7121171	ENSG00000236360.2	RP11-334A14.2	6.21	7.2e-09	0.0421	0.58	0.49	Vitamin D levels;	chr11:14424874	chr1:52993201~52993702:-
TGCT	trans	rs877636	0.692	rs2271194	ENSG00000196933.5	RPS26P11	-6.21	7.21e-09	0.0422	-0.52	-0.49	Cognitive function;	chr12:56083910	chrX:72044545~72044892:+
TGCT	trans	rs1707322	0.785	rs10890348	ENSG00000255397.1	AC022182.2	-6.21	7.25e-09	0.0424	-0.62	-0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr8:60937705~60939871:-
TGCT	trans	rs4276421	0.874	rs71618219	ENSG00000231752.4	EMBP1	6.21	7.26e-09	0.0424	0.5	0.49	P wave duration;	chr5:45950598	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.967	rs10062508	ENSG00000231752.4	EMBP1	6.21	7.26e-09	0.0424	0.5	0.49	P wave duration;	chr5:45961764	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.562	rs10051529	ENSG00000231752.4	EMBP1	-6.21	7.26e-09	0.0424	-0.53	-0.49	Schizophrenia;	chr5:50303103	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs10042601	ENSG00000231752.4	EMBP1	-6.21	7.26e-09	0.0424	-0.53	-0.49	Schizophrenia;	chr5:50315248	chr1:121519112~121571892:+
TGCT	trans	rs10037055	0.947	rs10063803	ENSG00000217325.2	PRELID1P1	6.21	7.3e-09	0.0426	0.57	0.49	Migraine without aura;	chr5:177240326	chr6:126643488~126644390:+
TGCT	trans	rs7824557	0.737	rs2293855	ENSG00000173295.6	FAM86B3P	6.21	7.3e-09	0.0426	0.57	0.49	Retinal vascular caliber;	chr8:11319901	chr8:8228595~8244865:+
TGCT	trans	rs7590268	0.697	rs3884504	ENSG00000254966.1	RP11-1081L13.4	-6.21	7.31e-09	0.0426	-0.62	-0.49	Orofacial clefts;	chr2:43468414	chr11:18706537~18740568:+
TGCT	trans	rs4727751	0.749	rs10239001	ENSG00000213250.5	RBMS2P1	6.21	7.35e-09	0.0428	0.47	0.49	Schizophrenia;	chr7:78693771	chr12:94423744~94424969:-
TGCT	trans	rs10940346	0.54	rs34645496	ENSG00000231752.4	EMBP1	6.21	7.37e-09	0.0429	0.53	0.49	Schizophrenia;	chr5:50322419	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs35330444	ENSG00000231752.4	EMBP1	6.21	7.37e-09	0.0429	0.53	0.49	Schizophrenia;	chr5:50322606	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs6875734	ENSG00000231752.4	EMBP1	6.21	7.37e-09	0.0429	0.53	0.49	Schizophrenia;	chr5:50323203	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs6868380	ENSG00000231752.4	EMBP1	6.21	7.37e-09	0.0429	0.53	0.49	Schizophrenia;	chr5:50328473	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.58	rs34185098	ENSG00000231752.4	EMBP1	6.21	7.37e-09	0.0429	0.53	0.49	Schizophrenia;	chr5:50330100	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs13172932	ENSG00000231752.4	EMBP1	6.21	7.37e-09	0.0429	0.53	0.49	Schizophrenia;	chr5:50345364	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs12651834	ENSG00000231752.4	EMBP1	6.21	7.37e-09	0.0429	0.53	0.49	Schizophrenia;	chr5:50351199	chr1:121519112~121571892:+
TGCT	trans	rs1412259	0.865	rs10491860	ENSG00000232936.4	RP11-80H5.2	6.21	7.42e-09	0.0431	0.57	0.49	Response to taxane treatment (docetaxel);	chr9:1449360	chr10:89645282~89650667:+
TGCT	trans	rs10940346	0.58	rs7447926	ENSG00000231752.4	EMBP1	-6.21	7.44e-09	0.0433	-0.5	-0.49	Schizophrenia;	chr5:50310902	chr1:121519112~121571892:+
TGCT	trans	rs7824557	0.767	rs10104728	ENSG00000173295.6	FAM86B3P	6.21	7.44e-09	0.0433	0.56	0.49	Retinal vascular caliber;	chr8:11313791	chr8:8228595~8244865:+
TGCT	trans	rs10940346	0.601	rs12513730	ENSG00000231752.4	EMBP1	-6.2	7.59e-09	0.044	-0.5	-0.49	Schizophrenia;	chr5:50302800	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs4865698	ENSG00000231752.4	EMBP1	-6.2	7.59e-09	0.044	-0.5	-0.49	Schizophrenia;	chr5:50303332	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs4865699	ENSG00000231752.4	EMBP1	-6.2	7.59e-09	0.044	-0.5	-0.49	Schizophrenia;	chr5:50303347	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs4865700	ENSG00000231752.4	EMBP1	-6.2	7.59e-09	0.044	-0.5	-0.49	Schizophrenia;	chr5:50303862	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs13178993	ENSG00000231752.4	EMBP1	-6.2	7.59e-09	0.044	-0.5	-0.49	Schizophrenia;	chr5:50305256	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs1511738	ENSG00000231752.4	EMBP1	-6.2	7.59e-09	0.044	-0.5	-0.49	Schizophrenia;	chr5:50313444	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs10062032	ENSG00000231752.4	EMBP1	-6.2	7.59e-09	0.044	-0.5	-0.49	Schizophrenia;	chr5:50316138	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs10074359	ENSG00000231752.4	EMBP1	-6.2	7.59e-09	0.044	-0.5	-0.49	Schizophrenia;	chr5:50316423	chr1:121519112~121571892:+
TGCT	trans	rs10037055	0.853	rs10036193	ENSG00000217325.2	PRELID1P1	-6.2	7.59e-09	0.044	-0.54	-0.49	Migraine without aura;	chr5:177141519	chr6:126643488~126644390:+
TGCT	trans	rs10037055	0.853	rs9885210	ENSG00000217325.2	PRELID1P1	-6.2	7.59e-09	0.044	-0.54	-0.49	Migraine without aura;	chr5:177142187	chr6:126643488~126644390:+
TGCT	trans	rs10940346	0.601	rs2036902	ENSG00000231752.4	EMBP1	6.2	7.61e-09	0.0441	0.54	0.49	Schizophrenia;	chr5:50401098	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs7717982	ENSG00000231752.4	EMBP1	6.2	7.61e-09	0.0441	0.54	0.49	Schizophrenia;	chr5:50401488	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.81	rs10213756	ENSG00000231752.4	EMBP1	6.2	7.64e-09	0.0443	0.53	0.49	P wave duration;	chr5:45952498	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.556	rs10213679	ENSG00000231752.4	EMBP1	6.2	7.64e-09	0.0443	0.53	0.49	P wave duration;	chr5:45954206	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.904	rs4289566	ENSG00000231752.4	EMBP1	6.2	7.64e-09	0.0443	0.53	0.49	P wave duration;	chr5:45955499	chr1:121519112~121571892:+
TGCT	trans	rs877636	0.692	rs10876870	ENSG00000196933.5	RPS26P11	-6.2	7.72e-09	0.0447	-0.53	-0.49	Cognitive function;	chr12:56084218	chrX:72044545~72044892:+
TGCT	trans	rs877636	0.692	rs7971751	ENSG00000196933.5	RPS26P11	-6.2	7.72e-09	0.0447	-0.53	-0.49	Cognitive function;	chr12:56084874	chrX:72044545~72044892:+
TGCT	trans	rs10940346	0.601	rs1344339	ENSG00000231752.4	EMBP1	-6.2	7.75e-09	0.0448	-0.51	-0.49	Schizophrenia;	chr5:50327987	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.753	rs7443976	ENSG00000231752.4	EMBP1	6.2	7.76e-09	0.0449	0.5	0.49	P wave duration;	chr5:45936323	chr1:121519112~121571892:+
TGCT	trans	rs7555117	0.635	rs61802836	ENSG00000273823.1	AC215219.2	-6.2	7.78e-09	0.045	-0.59	-0.49	Facial morphology (factor 19);	chr1:60518560	chr12:17484~17551:-
TGCT	trans	rs1950832	0.689	rs712405	ENSG00000252768.1	RNU6-856P	6.19	7.9e-09	0.0457	0.54	0.49	Urate levels in obese individuals;	chr14:41645024	chr3:52551846~52551943:-
TGCT	trans	rs1816752	0.875	rs17384871	ENSG00000237917.1	PARP4P1	6.19	7.92e-09	0.0458	0.58	0.49	Obesity-related traits;	chr13:24484959	chrY:26594851~26634652:-
TGCT	trans	rs12149074	0.532	rs6564727	ENSG00000260803.1	Z84812.4	6.19	7.99e-09	0.0459	0.61	0.49	Bipolar disorder and eating disorder;Eating disorder in bipolar disorder;	chr16:80062657	chr16:17514~35195:-
TGCT	trans	rs12959333	0.892	rs12962202	ENSG00000226792.5	LINC00371	6.19	7.99e-09	0.0459	0.88	0.49	Post bronchodilator FEV1;	chr18:35592865	chr13:51082119~51172388:-
TGCT	trans	rs1816752	0.716	rs9553289	ENSG00000237917.1	PARP4P1	-6.19	7.99e-09	0.0459	-0.56	-0.49	Obesity-related traits;	chr13:24400640	chrY:26594851~26634652:-
TGCT	trans	rs7395662	1	rs4881994	ENSG00000134612.10	FOLH1B	-6.19	8e-09	0.0459	-0.6	-0.49	HDL cholesterol;	chr11:48476587	chr11:89639227~89698718:+
TGCT	trans	rs7395662	0.895	rs1945183	ENSG00000134612.10	FOLH1B	-6.19	8e-09	0.0459	-0.6	-0.49	HDL cholesterol;	chr11:48480875	chr11:89639227~89698718:+
TGCT	trans	rs7395662	1	rs10838917	ENSG00000134612.10	FOLH1B	-6.19	8e-09	0.0459	-0.6	-0.49	HDL cholesterol;	chr11:48481575	chr11:89639227~89698718:+
TGCT	trans	rs7395662	0.963	rs11039772	ENSG00000134612.10	FOLH1B	-6.19	8e-09	0.0459	-0.6	-0.49	HDL cholesterol;	chr11:48492340	chr11:89639227~89698718:+
TGCT	trans	rs7395662	0.963	rs11039773	ENSG00000134612.10	FOLH1B	-6.19	8e-09	0.0459	-0.6	-0.49	HDL cholesterol;	chr11:48492379	chr11:89639227~89698718:+
TGCT	trans	rs7395662	0.963	rs11039774	ENSG00000134612.10	FOLH1B	-6.19	8e-09	0.0459	-0.6	-0.49	HDL cholesterol;	chr11:48492407	chr11:89639227~89698718:+
TGCT	trans	rs7395662	1	rs11039777	ENSG00000134612.10	FOLH1B	-6.19	8e-09	0.0459	-0.6	-0.49	HDL cholesterol;	chr11:48495497	chr11:89639227~89698718:+
TGCT	trans	rs7395662	1	rs11039779	ENSG00000134612.10	FOLH1B	-6.19	8e-09	0.0459	-0.6	-0.49	HDL cholesterol;	chr11:48496343	chr11:89639227~89698718:+
TGCT	trans	rs7395662	1	rs10769371	ENSG00000134612.10	FOLH1B	-6.19	8e-09	0.0459	-0.6	-0.49	HDL cholesterol;	chr11:48509632	chr11:89639227~89698718:+
TGCT	trans	rs7395662	0.963	rs4882094	ENSG00000134612.10	FOLH1B	-6.19	8e-09	0.0459	-0.6	-0.49	HDL cholesterol;	chr11:48510908	chr11:89639227~89698718:+
TGCT	trans	rs7395662	1	rs4882096	ENSG00000134612.10	FOLH1B	-6.19	8e-09	0.0459	-0.6	-0.49	HDL cholesterol;	chr11:48512550	chr11:89639227~89698718:+
TGCT	trans	rs7395662	1	rs10838931	ENSG00000134612.10	FOLH1B	-6.19	8e-09	0.0459	-0.6	-0.49	HDL cholesterol;	chr11:48519421	chr11:89639227~89698718:+
TGCT	trans	rs7395662	0.929	rs12366252	ENSG00000134612.10	FOLH1B	-6.19	8e-09	0.0459	-0.6	-0.49	HDL cholesterol;	chr11:48520766	chr11:89639227~89698718:+
TGCT	trans	rs7395662	1	rs7478900	ENSG00000134612.10	FOLH1B	-6.19	8e-09	0.0459	-0.6	-0.49	HDL cholesterol;	chr11:48522451	chr11:89639227~89698718:+
TGCT	trans	rs7395662	1	rs7121460	ENSG00000134612.10	FOLH1B	-6.19	8e-09	0.0459	-0.6	-0.49	HDL cholesterol;	chr11:48523680	chr11:89639227~89698718:+
TGCT	trans	rs7395662	0.963	rs7125110	ENSG00000134612.10	FOLH1B	-6.19	8e-09	0.0459	-0.6	-0.49	HDL cholesterol;	chr11:48523955	chr11:89639227~89698718:+
TGCT	trans	rs7395662	0.963	rs4882002	ENSG00000134612.10	FOLH1B	-6.19	8e-09	0.0459	-0.6	-0.49	HDL cholesterol;	chr11:48525179	chr11:89639227~89698718:+
TGCT	trans	rs7395662	0.929	rs10838934	ENSG00000134612.10	FOLH1B	-6.19	8e-09	0.0459	-0.6	-0.49	HDL cholesterol;	chr11:48525520	chr11:89639227~89698718:+
TGCT	trans	rs7395662	0.89	rs11039806	ENSG00000134612.10	FOLH1B	-6.19	8e-09	0.0459	-0.6	-0.49	HDL cholesterol;	chr11:48526164	chr11:89639227~89698718:+
TGCT	trans	rs7395662	1	rs12365220	ENSG00000134612.10	FOLH1B	-6.19	8e-09	0.0459	-0.6	-0.49	HDL cholesterol;	chr11:48534405	chr11:89639227~89698718:+
TGCT	trans	rs7395662	0.929	rs12363679	ENSG00000134612.10	FOLH1B	-6.19	8e-09	0.0459	-0.6	-0.49	HDL cholesterol;	chr11:48534471	chr11:89639227~89698718:+
TGCT	trans	rs7395662	1	rs10838943	ENSG00000134612.10	FOLH1B	-6.19	8e-09	0.0459	-0.6	-0.49	HDL cholesterol;	chr11:48535890	chr11:89639227~89698718:+
TGCT	trans	rs7395662	0.963	rs4882109	ENSG00000134612.10	FOLH1B	-6.19	8e-09	0.0459	-0.6	-0.49	HDL cholesterol;	chr11:48536133	chr11:89639227~89698718:+
TGCT	trans	rs7395662	1	rs4882111	ENSG00000134612.10	FOLH1B	-6.19	8e-09	0.0459	-0.6	-0.49	HDL cholesterol;	chr11:48536895	chr11:89639227~89698718:+
TGCT	trans	rs7395662	1	rs4882010	ENSG00000134612.10	FOLH1B	-6.19	8e-09	0.0459	-0.6	-0.49	HDL cholesterol;	chr11:48537621	chr11:89639227~89698718:+
TGCT	trans	rs7824557	0.545	rs2572450	ENSG00000173295.6	FAM86B3P	-6.19	8.05e-09	0.0461	-0.58	-0.49	Retinal vascular caliber;	chr8:11372129	chr8:8228595~8244865:+
TGCT	trans	rs4276421	0.967	rs6878425	ENSG00000231752.4	EMBP1	6.19	8.14e-09	0.0464	0.5	0.49	P wave duration;	chr5:45843153	chr1:121519112~121571892:+
TGCT	trans	rs4276421	1	rs13175559	ENSG00000231752.4	EMBP1	6.19	8.14e-09	0.0464	0.5	0.49	P wave duration;	chr5:45854525	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.967	rs4541666	ENSG00000231752.4	EMBP1	6.19	8.14e-09	0.0464	0.5	0.49	P wave duration;	chr5:45857027	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.935	rs6898824	ENSG00000231752.4	EMBP1	-6.19	8.14e-09	0.0464	-0.5	-0.49	P wave duration;	chr5:45842058	chr1:121519112~121571892:+
TGCT	trans	rs55665837	1	rs10832278	ENSG00000236360.2	RP11-334A14.2	6.19	8.14e-09	0.0464	0.56	0.49	Vitamin D levels;	chr11:14475073	chr1:52993201~52993702:-
TGCT	trans	rs10940346	0.601	rs7378969	ENSG00000231752.4	EMBP1	-6.19	8.15e-09	0.0464	-0.54	-0.49	Schizophrenia;	chr5:50471925	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs7712849	ENSG00000231752.4	EMBP1	6.19	8.15e-09	0.0464	0.54	0.49	Schizophrenia;	chr5:50407774	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.58	rs13357429	ENSG00000231752.4	EMBP1	6.19	8.15e-09	0.0464	0.54	0.49	Schizophrenia;	chr5:50413616	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs4495185	ENSG00000231752.4	EMBP1	6.19	8.15e-09	0.0464	0.54	0.49	Schizophrenia;	chr5:50415453	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs6450098	ENSG00000231752.4	EMBP1	6.19	8.15e-09	0.0464	0.54	0.49	Schizophrenia;	chr5:50420076	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs62365896	ENSG00000231752.4	EMBP1	6.19	8.15e-09	0.0464	0.54	0.49	Schizophrenia;	chr5:50422243	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.56	rs6450107	ENSG00000231752.4	EMBP1	6.19	8.15e-09	0.0464	0.54	0.49	Schizophrenia;	chr5:50430069	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.58	rs9292005	ENSG00000231752.4	EMBP1	6.19	8.15e-09	0.0464	0.54	0.49	Schizophrenia;	chr5:50430521	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs62365901	ENSG00000231752.4	EMBP1	6.19	8.15e-09	0.0464	0.54	0.49	Schizophrenia;	chr5:50434497	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs62365902	ENSG00000231752.4	EMBP1	6.19	8.15e-09	0.0464	0.54	0.49	Schizophrenia;	chr5:50434594	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.58	rs58756661	ENSG00000231752.4	EMBP1	6.19	8.15e-09	0.0464	0.54	0.49	Schizophrenia;	chr5:50436837	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.58	rs28528780	ENSG00000231752.4	EMBP1	6.19	8.15e-09	0.0464	0.54	0.49	Schizophrenia;	chr5:50441293	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs28500170	ENSG00000231752.4	EMBP1	6.19	8.15e-09	0.0464	0.54	0.49	Schizophrenia;	chr5:50441594	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.56	rs16879094	ENSG00000231752.4	EMBP1	6.19	8.15e-09	0.0464	0.54	0.49	Schizophrenia;	chr5:50442603	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.58	rs13157992	ENSG00000231752.4	EMBP1	6.19	8.15e-09	0.0464	0.54	0.49	Schizophrenia;	chr5:50444074	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs7720960	ENSG00000231752.4	EMBP1	6.19	8.15e-09	0.0464	0.54	0.49	Schizophrenia;	chr5:50450489	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs6863108	ENSG00000231752.4	EMBP1	6.19	8.15e-09	0.0464	0.54	0.49	Schizophrenia;	chr5:50451450	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.56	rs13180267	ENSG00000231752.4	EMBP1	6.19	8.15e-09	0.0464	0.54	0.49	Schizophrenia;	chr5:50452300	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.541	rs10041893	ENSG00000231752.4	EMBP1	6.19	8.15e-09	0.0464	0.54	0.49	Schizophrenia;	chr5:50460740	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.58	rs10044979	ENSG00000231752.4	EMBP1	6.19	8.15e-09	0.0464	0.54	0.49	Schizophrenia;	chr5:50464074	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs10045034	ENSG00000231752.4	EMBP1	6.19	8.15e-09	0.0464	0.54	0.49	Schizophrenia;	chr5:50464323	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.54	rs59940663	ENSG00000231752.4	EMBP1	6.19	8.15e-09	0.0464	0.54	0.49	Schizophrenia;	chr5:50467345	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs57300567	ENSG00000231752.4	EMBP1	6.19	8.15e-09	0.0464	0.54	0.49	Schizophrenia;	chr5:50467359	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.58	rs34586987	ENSG00000231752.4	EMBP1	6.19	8.15e-09	0.0464	0.54	0.49	Schizophrenia;	chr5:50467574	chr1:121519112~121571892:+
TGCT	trans	rs55665837	1	rs10766182	ENSG00000236360.2	RP11-334A14.2	6.19	8.17e-09	0.0464	0.57	0.49	Vitamin D levels;	chr11:14477990	chr1:52993201~52993702:-
TGCT	trans	rs55665837	0.961	rs11023237	ENSG00000236360.2	RP11-334A14.2	6.19	8.17e-09	0.0464	0.57	0.49	Vitamin D levels;	chr11:14478788	chr1:52993201~52993702:-
TGCT	trans	rs55665837	1	rs10466412	ENSG00000236360.2	RP11-334A14.2	6.19	8.17e-09	0.0464	0.57	0.49	Vitamin D levels;	chr11:14483643	chr1:52993201~52993702:-
TGCT	trans	rs55665837	1	rs12364959	ENSG00000236360.2	RP11-334A14.2	6.19	8.17e-09	0.0464	0.57	0.49	Vitamin D levels;	chr11:14485889	chr1:52993201~52993702:-
TGCT	trans	rs55665837	1	rs34980103	ENSG00000236360.2	RP11-334A14.2	6.19	8.17e-09	0.0464	0.57	0.49	Vitamin D levels;	chr11:14491339	chr1:52993201~52993702:-
TGCT	trans	rs1816752	0.875	rs59686377	ENSG00000237917.1	PARP4P1	6.19	8.19e-09	0.0466	0.57	0.49	Obesity-related traits;	chr13:24475869	chrY:26594851~26634652:-
TGCT	trans	rs10940346	0.562	rs13182357	ENSG00000231752.4	EMBP1	6.19	8.2e-09	0.0466	0.56	0.49	Schizophrenia;	chr5:50404060	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs6860503	ENSG00000231752.4	EMBP1	6.19	8.2e-09	0.0466	0.56	0.49	Schizophrenia;	chr5:50446340	chr1:121519112~121571892:+
TGCT	trans	rs4918072	0.876	rs4918069	ENSG00000213753.9	CENPBD1P1	-6.19	8.22e-09	0.0467	-0.41	-0.49	Coronary artery disease;	chr10:103894633	chr19:58573503~58599801:+
TGCT	trans	rs4918072	0.874	rs3850670	ENSG00000213753.9	CENPBD1P1	-6.19	8.22e-09	0.0467	-0.41	-0.49	Coronary artery disease;	chr10:103899611	chr19:58573503~58599801:+
TGCT	trans	rs4918072	0.917	rs61861158	ENSG00000213753.9	CENPBD1P1	-6.19	8.22e-09	0.0467	-0.41	-0.49	Coronary artery disease;	chr10:103901928	chr19:58573503~58599801:+
TGCT	trans	rs4918072	0.917	rs12571879	ENSG00000213753.9	CENPBD1P1	-6.19	8.22e-09	0.0467	-0.41	-0.49	Coronary artery disease;	chr10:103903588	chr19:58573503~58599801:+
TGCT	trans	rs10242455	0.571	rs45532337	ENSG00000228834.1	RP11-249L21.4	6.18	8.33e-09	0.0472	1.2	0.49	Blood metabolite levels;	chr7:99712696	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.571	rs45527841	ENSG00000228834.1	RP11-249L21.4	6.18	8.33e-09	0.0472	1.2	0.49	Blood metabolite levels;	chr7:99713342	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.571	rs73713594	ENSG00000228834.1	RP11-249L21.4	6.18	8.33e-09	0.0472	1.2	0.49	Blood metabolite levels;	chr7:99728875	chr6:108907615~108907873:-
TGCT	trans	rs10242455	0.571	rs73713595	ENSG00000228834.1	RP11-249L21.4	6.18	8.33e-09	0.0472	1.2	0.49	Blood metabolite levels;	chr7:99729036	chr6:108907615~108907873:-
TGCT	trans	rs10940346	0.601	rs9291925	ENSG00000231752.4	EMBP1	6.18	8.38e-09	0.0474	0.5	0.49	Schizophrenia;	chr5:50320129	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs7722742	ENSG00000231752.4	EMBP1	6.18	8.38e-09	0.0474	0.5	0.49	Schizophrenia;	chr5:50320312	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.562	rs6449961	ENSG00000231752.4	EMBP1	6.18	8.38e-09	0.0474	0.5	0.49	Schizophrenia;	chr5:50320867	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.58	rs6876902	ENSG00000231752.4	EMBP1	6.18	8.38e-09	0.0474	0.5	0.49	Schizophrenia;	chr5:50320934	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.58	rs7705284	ENSG00000231752.4	EMBP1	6.18	8.38e-09	0.0474	0.5	0.49	Schizophrenia;	chr5:50325574	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs10054503	ENSG00000231752.4	EMBP1	6.18	8.38e-09	0.0474	0.5	0.49	Schizophrenia;	chr5:50326746	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.623	rs6863840	ENSG00000231752.4	EMBP1	6.18	8.38e-09	0.0474	0.5	0.49	Schizophrenia;	chr5:50328070	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.58	rs6871761	ENSG00000231752.4	EMBP1	6.18	8.38e-09	0.0474	0.5	0.49	Schizophrenia;	chr5:50328134	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs6877713	ENSG00000231752.4	EMBP1	6.18	8.38e-09	0.0474	0.5	0.49	Schizophrenia;	chr5:50329254	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs4337857	ENSG00000231752.4	EMBP1	6.18	8.38e-09	0.0474	0.5	0.49	Schizophrenia;	chr5:50329735	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.562	rs34601168	ENSG00000231752.4	EMBP1	6.18	8.38e-09	0.0474	0.5	0.49	Schizophrenia;	chr5:50330561	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs35740733	ENSG00000231752.4	EMBP1	6.18	8.38e-09	0.0474	0.5	0.49	Schizophrenia;	chr5:50330771	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.54	rs10039622	ENSG00000231752.4	EMBP1	6.18	8.38e-09	0.0474	0.5	0.49	Schizophrenia;	chr5:50336720	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs10064702	ENSG00000231752.4	EMBP1	6.18	8.38e-09	0.0474	0.5	0.49	Schizophrenia;	chr5:50336928	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs13160697	ENSG00000231752.4	EMBP1	6.18	8.38e-09	0.0474	0.5	0.49	Schizophrenia;	chr5:50339822	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs6861461	ENSG00000231752.4	EMBP1	6.18	8.38e-09	0.0474	0.5	0.49	Schizophrenia;	chr5:50348493	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.58	rs12332500	ENSG00000231752.4	EMBP1	6.18	8.38e-09	0.0474	0.5	0.49	Schizophrenia;	chr5:50349021	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs7710841	ENSG00000231752.4	EMBP1	6.18	8.38e-09	0.0474	0.5	0.49	Schizophrenia;	chr5:50349986	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs7723480	ENSG00000231752.4	EMBP1	6.18	8.38e-09	0.0474	0.5	0.49	Schizophrenia;	chr5:50350324	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs7722623	ENSG00000231752.4	EMBP1	6.18	8.38e-09	0.0474	0.5	0.49	Schizophrenia;	chr5:50350496	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs35815956	ENSG00000231752.4	EMBP1	6.18	8.38e-09	0.0474	0.5	0.49	Schizophrenia;	chr5:50350905	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs10940242	ENSG00000231752.4	EMBP1	6.18	8.38e-09	0.0474	0.5	0.49	Schizophrenia;	chr5:50351018	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.56	rs10039233	ENSG00000231752.4	EMBP1	6.18	8.38e-09	0.0474	0.5	0.49	Schizophrenia;	chr5:50351630	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs1606224	ENSG00000231752.4	EMBP1	-6.18	8.38e-09	0.0474	-0.5	-0.49	Schizophrenia;	chr5:50317405	chr1:121519112~121571892:+
TGCT	trans	rs10940346	0.601	rs7341010	ENSG00000231752.4	EMBP1	-6.18	8.38e-09	0.0474	-0.5	-0.49	Schizophrenia;	chr5:50317811	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.904	rs7716296	ENSG00000231752.4	EMBP1	6.17	8.77e-09	0.0494	0.5	0.48	P wave duration;	chr5:45895783	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.935	rs6882139	ENSG00000231752.4	EMBP1	6.17	8.77e-09	0.0494	0.5	0.48	P wave duration;	chr5:45897149	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.837	rs6451829	ENSG00000231752.4	EMBP1	6.17	8.87e-09	0.0499	0.5	0.48	P wave duration;	chr5:45893260	chr1:121519112~121571892:+
TGCT	trans	rs4276421	0.935	rs35163964	ENSG00000231752.4	EMBP1	6.17	8.87e-09	0.0499	0.5	0.48	P wave duration;	chr5:45904860	chr1:121519112~121571892:+